-DOCSTART- -X- -X- O

Selegiline NNP NNP B-CHEM
- : : O
induced JJ JJ O
postural JJ JJ O
hypotension NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
: : : O
a DT DT O
longitudinal JJ JJ O
study NN NN O
on IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
drug NN NN O
withdrawal NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
United NNP NNP O
Kingdom NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Research NNP NNP O
Group NNP NNP O
( ( ( O
UKPDRG NNP NNP O
) ) ) O
trial NN NN O
found VBD VBD O
an DT DT O
increased JJ JJ O
mortality NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
randomized VBD VBD O
to TO TO O
receive VB VB O
10 CD CD O
mg NN NN O
selegiline NN NN B-CHEM
per IN IN O
day NN NN O
and CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
compared VBN VBN O
with IN IN O
those DT DT O
taking VBG VBG O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
alone RB RB O
. . . O

Recently RB RB O
, , , O
we PRP PRP O
found VBD VBD O
that IN IN O
therapy NN NN O
with IN IN O
selegiline NN NN B-CHEM
and CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
selective JJ JJ O
systolic JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
which WDT WDT O
was VBD VBD O
abolished VBN VBN O
by IN IN O
withdrawal NN NN O
of IN IN O
selegiline NN NN B-CHEM
. . . O

This DT DT O
unwanted JJ JJ O
effect NN NN O
on IN IN O
postural JJ JJ O
blood NN NN O
pressure NN NN O
was VBD VBD O
not RB RB O
the DT DT O
result NN NN O
of IN IN O
underlying VBG VBG O
autonomic JJ JJ O
failure NN NN O
. . . O

The DT DT O
aims NNS NNS O
of IN IN O
this DT DT O
study NN NN O
were VBD VBD O
to TO TO O
confirm VB VB O
our PRP$ PRP$ O
previous JJ JJ O
findings NNS NNS O
in IN IN O
a DT DT O
separate JJ JJ O
cohort NN NN O
of IN IN O
patients NNS NNS O
and CC CC O
to TO TO O
determine VB VB O
the DT DT O
time NN NN O
course NN NN O
of IN IN O
the DT DT O
cardiovascular JJ JJ O
consequences NNS NNS O
of IN IN O
stopping VBG VBG O
selegiline NN NN B-CHEM
in IN IN O
the DT DT O
expectation NN NN O
that IN IN O
this DT DT O
might MD MD O
shed VB VB O
light JJ JJ O
on IN IN O
the DT DT O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
the DT DT O
drug NN NN O
causes NNS NNS O
orthostatic JJ JJ O
hypotension NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
cardiovascular JJ JJ O
responses NNS NNS O
to TO TO O
standing NN NN O
and CC CC O
head NN NN O
- - - O
up RP RP O
tilt NN NN O
were VBD VBD O
studied VBN VBN O
repeatedly RB RB O
in IN IN O
PD NNP NNP O
patients NNS NNS O
receiving VBG VBG O
selegiline NN NN B-CHEM
and CC CC O
as IN IN O
the DT DT O
drug NN NN O
was VBD VBD O
withdrawn VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Head NNP NNP O
- - - O
up RP RP O
tilt NN NN O
caused VBD VBD O
systolic JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
which WDT WDT O
was VBD VBD O
marked VBN VBN O
in IN IN O
six CD CD O
of IN IN O
20 CD CD O
PD NNP NNP O
patients NNS NNS O
on IN IN O
selegiline NN NN B-CHEM
, , , O
one CD CD O
of IN IN O
whom WP WP O
lost VBD VBD O
consciousness NN NN O
with IN IN O
unrecordable JJ JJ O
blood NN NN O
pressures NNS NNS O
. . . O

A DT DT O
lesser JJR JJR O
degree NN NN O
of IN IN O
orthostatic JJ JJ O
hypotension NN NN O
occurred VBD VBD O
with IN IN O
standing NN NN O
. . . O

Orthostatic NNP NNP O
hypotension NN NN O
was VBD VBD O
ameliorated VBN VBN O
4 CD CD O
days NNS NNS O
after IN IN O
withdrawal NN NN O
of IN IN O
selegiline NN NN B-CHEM
and CC CC O
totally RB RB O
abolished JJ JJ O
7 CD CD O
days NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

Stopping NNP NNP O
selegiline NN NN B-CHEM
also RB RB O
significantly RB RB O
reduced VBD VBD O
the DT DT O
supine NN NN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
blood NN NN O
pressures NNS NNS O
consistent JJ JJ O
with IN IN O
a DT DT O
previously RB RB O
undescribed JJ JJ O
supine NN NN O
pressor NN NN O
action NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
study NN NN O
confirms VBZ VBZ O
our PRP$ PRP$ O
previous JJ JJ O
finding VBG VBG O
that IN IN O
selegiline NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
selective JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
. . . O

The DT DT O
possibilities NNS NNS O
that IN IN O
these DT DT O
cardiovascular JJ JJ O
findings NNS NNS O
might MD MD O
be VB VB O
the DT DT O
result NN NN O
of IN IN O
non NN NN O
- - - O
selective JJ JJ O
inhibition NN NN O
of IN IN O
monoamine NN NN O
oxidase NN NN O
or CC CC O
of IN IN O
amphetamine NN NN B-CHEM
and CC CC O
metamphetamine NN NN B-CHEM
are VBP VBP O
discussed VBN VBN O
. . . O

Further RB RB O
studies NNS NNS O
on IN IN O
effects NNS NNS O
of IN IN O
irrigation NN NN O
solutions NNS NNS O
on IN IN O
rat NN NN O
bladders NNS NNS O
. . . O

Further RB RB O
studies NNS NNS O
on IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
certain JJ JJ O
irrigating VBG VBG O
fluids NNS NNS O
on IN IN O
the DT DT O
rat NN NN O
bladder NN NN O
for IN IN O
18 CD CD O
hours NNS NNS O
are VBP VBP O
reported VBN VBN O
. . . O

The DT DT O
results NNS NNS O
have VBP VBP O
shown VBN VBN O
that IN IN O
the DT DT O
degradation NN NN O
product NN NN O
p NN NN B-CHEM
- - - I-CHEM
choloroaniline NN NN I-CHEM
is VBZ VBZ O
not RB RB O
a DT DT O
significant JJ JJ O
factor NN NN O
in IN IN O
chlorhexidine NN NN B-CHEM
- - - I-CHEM
digluconate NN NN I-CHEM
associated VBN VBN O
erosive JJ JJ O
cystitis NNS NNS O
. . . O

A DT DT O
high JJ JJ O
percentage NN NN O
of IN IN O
kanamycin NN NN B-CHEM
- - - O
colistin NN NN B-CHEM
and CC CC O
povidone NN NN B-CHEM
- - - I-CHEM
iodine NN NN I-CHEM
irrigations NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
erosive JJ JJ O
cystitis NNS NNS O
and CC CC O
suggested VBD VBD O
a DT DT O
possible JJ JJ O
complication NN NN O
with IN IN O
human JJ JJ O
usage NN NN O
. . . O

Picloxydine NNP NNP B-CHEM
irrigations NNS NNS O
appeared VBD VBD O
to TO TO O
have VB VB O
a DT DT O
lower JJR JJR O
incidence NN NN O
of IN IN O
erosive JJ JJ O
cystitis NN NN O
but CC CC O
further JJ JJ O
studies NNS NNS O
would MD MD O
have VB VB O
to TO TO O
be VB VB O
performed VBN VBN O
before IN IN O
it PRP PRP O
could MD MD O
be VB VB O
recommended VBN VBN O
for IN IN O
use NN NN O
in IN IN O
urological JJ JJ O
procedures NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
tetrandrine NN NN B-CHEM
and CC CC O
fangchinoline NN NN B-CHEM
on IN IN O
experimental JJ JJ O
thrombosis NNS NNS O
in IN IN O
mice NNS NNS O
and CC CC O
human JJ JJ O
platelet NN NN O
aggregation NN NN O
. . . O

Tetrandrine NNP NNP B-CHEM
( ( ( O
TET NNP NNP B-CHEM
) ) ) O
and CC CC O
fangchinoline NN NN B-CHEM
( ( ( O
FAN NNP NNP B-CHEM
) ) ) O
are VBP VBP O
two CD CD O
naturally RB RB O
occurring VBG VBG O
analogues NNS NNS O
with IN IN O
a DT DT O
bisbenzylisoquinoline NN NN B-CHEM
structure NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
TET NNP NNP B-CHEM
and CC CC O
FAN NNP NNP B-CHEM
on IN IN O
the DT DT O
experimental JJ JJ O
thrombosis NN NN O
induced VBN VBN O
by IN IN O
collagen NN NN O
plus CC CC O
epinephrine NN NN B-CHEM
( ( ( O
EP NNP NNP B-CHEM
) ) ) O
in IN IN O
mice NN NN O
, , , O
and CC CC O
platelet NN NN O
aggregation NN NN O
and CC CC O
blood NN NN O
coagulation NN NN O
in IN IN O
vitro NN NN O
. . . O

In IN IN O
the DT DT O
in IN IN O
vivo NN NN O
study NN NN O
, , , O
the DT DT O
administration NN NN O
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
of IN IN O
TET NNP NNP B-CHEM
and CC CC O
FAN NNP NNP B-CHEM
in IN IN O
mice NN NN O
showed VBD VBD O
the DT DT O
inhibition NN NN O
of IN IN O
thrombosis NNS NNS O
by IN IN O
55 CD CD O
% NN NN O
and CC CC O
35 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
while IN IN O
acetylsalicylic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
ASA NNP NNP B-CHEM
, , , O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
a DT DT O
positive JJ JJ O
control NN NN O
, , , O
showed VBD VBD O
only RB RB O
30 CD CD O
% NN NN O
inhibition NN NN O
. . . O

In IN IN O
the DT DT O
vitro NN NN O
human JJ JJ O
platelet NN NN O
aggregations NNS NNS O
induced VBN VBN O
by IN IN O
the DT DT O
agonists NNS NNS O
used VBN VBN O
in IN IN O
tests NNS NNS O
, , , O
TET NNP NNP B-CHEM
and CC CC O
FAN NNP NNP B-CHEM
showed VBD VBD O
the DT DT O
inhibitions NNS NNS O
dose VBD VBD O
dependently RB RB O
. . . O

In IN IN O
addition NN NN O
, , , O
neither DT DT O
TET NNP NNP B-CHEM
nor CC CC O
FAN NNP NNP B-CHEM
showed VBD VBD O
any DT DT O
anticoagulation NN NN O
activities NNS NNS O
in IN IN O
the DT DT O
measurement NN NN O
of IN IN O
the DT DT O
activated VBN VBN O
partial JJ JJ O
thromboplastin NN NN O
time NN NN O
( ( ( O
APTT NNP NNP O
) ) ) O
, , , O
prothrombin NN NN O
time NN NN O
( ( ( O
PT NNP NNP O
) ) ) O
and CC CC O
thrombin NN NN O
time NN NN O
( ( ( O
TT NNP NNP O
) ) ) O
using VBG VBG O
human JJ JJ O
- - - O
citrated JJ JJ O
plasma NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
antithrombosis NNS NNS O
of IN IN O
TET NNP NNP B-CHEM
and CC CC O
FAN NNP NNP B-CHEM
in IN IN O
mice NNS NNS O
may MD MD O
be VB VB O
mainly RB RB O
related VBN VBN O
to TO TO O
the DT DT O
antiplatelet NN NN O
aggregation NN NN O
activities NNS NNS O
. . . O

Angioedema NNP NNP O
due JJ JJ O
to TO TO O
ACE NNP NNP B-CHEM
inhibitors NNS NNS I-CHEM
: : : O
common JJ JJ O
and CC CC O
inadequately RB RB O
diagnosed VBN VBN O
. . . O

The DT DT O
estimated JJ JJ O
incidence NN NN O
of IN IN O
angioedema NN NN O
during IN IN O
angiotensin NN NN B-CHEM
- - - I-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
( ( ( I-CHEM
ACE NNP NNP I-CHEM
) ) ) I-CHEM
inhibitor NN NN I-CHEM
treatment NN NN O
is VBZ VBZ O
between IN IN O
1 CD CD O
and CC CC O
7 CD CD O
per IN IN O
thousand NN NN O
patients NNS NNS O
. . . O

This DT DT O
potentially RB RB O
serious JJ JJ O
adverse JJ JJ O
effect NN NN O
is VBZ VBZ O
often RB RB O
preceded VBN VBN O
by IN IN O
minor JJ JJ O
manifestations NNS NNS O
that WDT WDT O
may MD MD O
serve VB VB O
as IN IN O
a DT DT O
warning NN NN O
. . . O

Cocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
mood NN NN O
disorder NN NN O
: : : O
prevalence NN NN O
rates NNS NNS O
and CC CC O
psychiatric JJ JJ O
symptoms NNS NNS O
in IN IN O
an DT DT O
outpatient NN NN O
cocaine NN NN B-CHEM
- : : O
dependent JJ JJ O
sample NN NN O
. . . O

This DT DT O
paper NN NN O
attempts NNS NNS O
to TO TO O
examine VB VB O
and CC CC O
compare VB VB O
prevalence NN NN O
rates NNS NNS O
and CC CC O
symptom NN NN O
patterns NNS NNS O
of IN IN O
DSM NNP NNP O
substance NN NN O
- : : O
induced JJ JJ O
and CC CC O
other JJ JJ O
mood NN NN O
disorders NNS NNS O
. . . O

243 CD CD O
cocaine NN NN B-CHEM
- : : O
dependent JJ JJ O
outpatients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
mood NN NN O
disorder NN NN O
( ( ( O
CIMD NNP NNP O
) ) ) O
, , , O
other JJ JJ O
mood NN NN O
disorders NNS NNS O
, , , O
or CC CC O
no DT DT O
mood NN NN O
disorder NN NN O
were VBD VBD O
compared VBN VBN O
on IN IN O
measures NNS NNS O
of IN IN O
psychiatric JJ JJ O
symptoms NNS NNS O
. . . O

The DT DT O
prevalence NN NN O
rate NN NN O
for IN IN O
CIMD NNP NNP O
was VBD VBD O
12 CD CD O
% NN NN O
at IN IN O
baseline NN NN O
. . . O

Introduction NNP NNP O
of IN IN O
the DT DT O
DSM NNP NNP O
- - - O
IV NNP NNP O
diagnosis NN NN O
of IN IN O
CIMD NNP NNP O
did VBD VBD O
not RB RB O
substantially RB RB O
affect VB VB O
rates NNS NNS O
of IN IN O
the DT DT O
other JJ JJ O
depressive JJ JJ O
disorders NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
CIMD NNP NNP O
had VBD VBD O
symptom JJ JJ O
severity NN NN O
levels NNS NNS O
between IN IN O
those DT DT O
of IN IN O
patients NNS NNS O
with IN IN O
and CC CC O
without IN IN O
a DT DT O
mood NN NN O
disorder NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
some DT DT O
validity NN NN O
for IN IN O
the DT DT O
new JJ JJ O
DSM NNP NNP O
- : : O
IV NNP NNP O
diagnosis NN NN O
of IN IN O
CIMD NNP NNP O
, , , O
but CC CC O
also RB RB O
suggest VB VB O
that IN IN O
it PRP PRP O
requires VBZ VBZ O
further JJ JJ O
specification NN NN O
and CC CC O
replication NN NN O
. . . O

Effect NN NN O
of IN IN O
fucoidan NN NN B-CHEM
treatment NN NN O
on IN IN O
collagenase NN NN O
- : : O
induced JJ JJ O
intracerebral JJ JJ O
hemorrhage NN NN O
in IN IN O
rats NNS NNS O
. . . O

Inflammatory NNP NNP O
cells NNS NNS O
are VBP VBP O
postulated VBN VBN O
to TO TO O
mediate VB VB O
some DT DT O
of IN IN O
the DT DT O
brain NN NN O
damage NN NN O
following VBG VBG O
ischemic JJ JJ O
stroke NN NN O
. . . O

Intracerebral NNP NNP O
hemorrhage NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
more JJR JJR O
inflammation NN NN O
than IN IN O
ischemic JJ JJ O
stroke NN NN O
. . . O

We PRP PRP O
tested VBD VBD O
the DT DT O
sulfated JJ JJ O
polysaccharide NN NN O
fucoidan NN NN B-CHEM
, , , O
which WDT WDT O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
reduce VB VB O
inflammatory JJ JJ O
brain NN NN O
damage NN NN O
, , , O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
intracerebral JJ JJ O
hemorrhage NN NN O
induced VBN VBN O
by IN IN O
injection NN NN O
of IN IN O
bacterial JJ JJ O
collagenase NN NN O
into IN IN O
the DT DT O
caudate NN NN O
nucleus NN NN O
. . . O

Rats NNP NNP O
were VBD VBD O
treated VBN VBN O
with IN IN O
seven CD CD O
day NN NN O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
fucoidan NN NN B-CHEM
( ( ( O
30 CD CD O
micrograms NNS NNS O
h NN NN O
- : : O
1 CD CD O
) ) ) O
or CC CC O
vehicle NN NN O
. . . O

The DT DT O
hematoma NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
vivo NN NN O
by IN IN O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
. . . O

Motor NNP NNP O
behavior NN NN O
, , , O
passive JJ JJ O
avoidance NN NN O
, , , O
and CC CC O
skilled JJ JJ O
forelimb NN NN O
function NN NN O
were VBD VBD O
tested VBN VBN O
repeatedly RB RB O
for IN IN O
six CD CD O
weeks NNS NNS O
. . . O

Fucoidan NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
exhibited JJ JJ O
evidence NN NN O
of IN IN O
impaired VBN VBN O
blood NN NN O
clotting NN NN O
and CC CC O
hemodilution NN NN O
, , , O
had VBD VBD O
larger JJR JJR O
hematomas NN NN O
, , , O
and CC CC O
tended VBD VBD O
to TO TO O
have VB VB O
less JJR JJR O
inflammation NN NN O
in IN IN O
the DT DT O
vicinity NN NN O
of IN IN O
the DT DT O
hematoma NN NN O
after IN IN O
three CD CD O
days NNS NNS O
. . . O

They PRP PRP O
showed VBD VBD O
significantly RB RB O
more JJR JJR O
rapid JJ JJ O
improvement NN NN O
of IN IN O
motor NN NN O
function NN NN O
in IN IN O
the DT DT O
first JJ JJ O
week NN NN O
following VBG VBG O
hemorrhage NN NN O
and CC CC O
better JJR JJR O
memory NN NN O
retention NN NN O
in IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
test NN NN O
. . . O

Acute JJ JJ O
white JJ JJ O
matter NN NN O
edema NN NN O
and CC CC O
eventual JJ JJ O
neuronal JJ JJ O
loss NN NN O
in IN IN O
the DT DT O
striatum NN NN O
adjacent JJ JJ O
to TO TO O
the DT DT O
hematoma NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

Investigation NNP NNP O
of IN IN O
more RBR RBR O
specific JJ JJ O
anti NN NN O
- : : O
inflammatory JJ JJ O
agents NNS NNS O
and CC CC O
hemodiluting VBG VBG O
agents NNS NNS O
are VBP VBP O
warranted VBN VBN O
in IN IN O
intracerebral JJ JJ O
hemorrhage NN NN O
. . . O

Recurarization NNP NNP O
in IN IN O
the DT DT O
recovery NN NN O
room NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
recurarization NN NN O
in IN IN O
the DT DT O
recovery NN NN O
room NN NN O
is VBZ VBZ O
reported VBN VBN O
. . . O

Accumulation NNP NNP O
of IN IN O
atracurium NN NN B-CHEM
in IN IN O
the DT DT O
intravenous JJ JJ O
line NN NN O
led VBN VBN O
to TO TO O
recurarization NN NN O
after IN IN O
flushing VBG VBG O
the DT DT O
line NN NN O
in IN IN O
the DT DT O
recovery NN NN O
room NN NN O
. . . O

A DT DT O
respiratory JJ JJ O
arrest NN NN O
with IN IN O
severe JJ JJ O
desaturation NN NN O
and CC CC O
bradycardia NN NN O
occurred VBD VBD O
. . . O

Circumstances NNP NNP O
leading VBG VBG O
to TO TO O
this DT DT O
event NN NN O
and CC CC O
the DT DT O
mechanisms NNS NNS O
enabling VBG VBG O
a DT DT O
neuromuscular JJ JJ O
blockade NN NN O
to TO TO O
occur VB VB O
, , , O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
a DT DT O
small JJ JJ O
dose NN NN O
of IN IN O
relaxant NN NN O
, , , O
are VBP VBP O
discussed VBN VBN O
. . . O

The DT DT O
haemodynamic JJ JJ O
effects NNS NNS O
of IN IN O
propofol NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
ephedrine NN NN B-CHEM
in IN IN O
elderly JJ JJ O
patients NNS NNS O
( ( ( O
ASA NNP NNP O
groups NNS NNS O
3 CD CD O
and CC CC O
4 CD CD O
) ) ) O
. . . O

The DT DT O
marked VBN VBN O
vasodilator NN NN O
and CC CC O
negative JJ JJ O
inotropic JJ JJ O
effects NNS NNS O
of IN IN O
propofol NN NN B-CHEM
are VBP VBP O
disadvantages NNS NNS O
in IN IN O
frail NN NN O
elderly JJ JJ O
patients NNS NNS O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
adding VBG VBG O
different JJ JJ O
doses NNS NNS O
of IN IN O
ephedrine NN NN B-CHEM
to TO TO O
propofol VB VB B-CHEM
in IN IN O
order NN NN O
to TO TO O
obtund VB VB O
the DT DT O
hypotensive JJ JJ O
response NN NN O
. . . O

The DT DT O
haemodynamic JJ JJ O
effects NNS NNS O
of IN IN O
adding VBG VBG O
15 CD CD O
, , , O
20 CD CD O
or CC CC O
25 CD CD O
mg NN NN O
of IN IN O
ephedrine NN NN B-CHEM
to TO TO O
200 CD CD O
mg NN NN O
of IN IN O
propofol NN NN B-CHEM
were VBD VBD O
compared VBN VBN O
to TO TO O
control VB VB O
in IN IN O
40 CD CD O
ASA NNP NNP O
3 CD CD O
/ NN NN O
4 CD CD O
patients NNS NNS O
over IN IN O
60 CD CD O
years NNS NNS O
presenting VBG VBG O
for IN IN O
genito NN NN O
- - - O
urinary JJ JJ O
surgery NN NN O
. . . O

The DT DT O
addition NN NN O
of IN IN O
ephedrine NN NN B-CHEM
to TO TO O
propofol VB VB B-CHEM
appears VBZ VBZ O
to TO TO O
be VB VB O
an DT DT O
effective JJ JJ O
method NN NN O
of IN IN O
obtunding VBG VBG O
the DT DT O
hypotensive JJ JJ O
response NN NN O
to TO TO O
propofol NN NN B-CHEM
at IN IN O
all DT DT O
doses NNS NNS O
used VBN VBN O
in IN IN O
this DT DT O
study NN NN O
. . . O

However RB RB O
, , , O
marked VBD VBD O
tachycardia NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
ephedrine NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
propofol NN NN B-CHEM
occurred VBD VBD O
in IN IN O
the DT DT O
majority NN NN O
of IN IN O
patients NNS NNS O
, , , O
occasionally RB RB O
reaching VBG VBG O
high JJ JJ O
levels NNS NNS O
in IN IN O
individual JJ JJ O
patients NNS NNS O
. . . O

Due JJ JJ O
to TO TO O
the DT DT O
risk NN NN O
of IN IN O
this DT DT O
tachycardia NN NN O
inducing VBG VBG O
myocardial NN NN O
ischemia NN NN O
, , , O
we PRP PRP O
would MD MD O
not RB RB O
recommend VB VB O
the DT DT O
use NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
of IN IN O
any DT DT O
of IN IN O
the DT DT O
ephedrine NN NN B-CHEM
/ NN NN O
propofol NN NN B-CHEM
/ NN NN O
mixtures NNS NNS O
studied VBN VBN O
. . . O

Gemcitabine NNP NNP B-CHEM
plus CC CC O
vinorelbine NN NN B-CHEM
in IN IN O
nonsmall NN NN O
cell NN NN O
lung NN NN O
carcinoma NN NN O
patients NNS NNS O
age NN NN O
70 CD CD O
years NNS NNS O
or CC CC O
older JJR JJR O
or CC CC O
patients NNS NNS O
who WP WP O
cannot NN NN O
receive JJ JJ O
cisplatin NN NN B-CHEM
. . . O

Oncopaz NNP NNP O
Cooperative NNP NNP O
Group NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Although IN IN O
the DT DT O
prevalence NN NN O
of IN IN O
nonsmall NN NN O
cell NN NN O
lung NN NN O
carcinoma NN NN O
( ( ( O
NSCLC NNP NNP O
) ) ) O
is VBZ VBZ O
high JJ JJ O
among IN IN O
elderly JJ JJ O
patients NNS NNS O
, , , O
few JJ JJ O
data NNS NNS O
are VBP VBP O
available JJ JJ O
regarding VBG VBG O
the DT DT O
efficacy NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
chemotherapy NN NN O
in IN IN O
this DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
. . . O

Recent JJ JJ O
reports NNS NNS O
indicate VBP VBP O
that IN IN O
single JJ JJ O
agent NN NN O
therapy NN NN O
with IN IN O
vinorelbine NN NN B-CHEM
( ( ( O
VNB NNP NNP B-CHEM
) ) ) O
or CC CC O
gemcitabine NN NN B-CHEM
( ( ( O
GEM NNP NNP B-CHEM
) ) ) O
may MD MD O
obtain VB VB O
a DT DT O
response NN NN O
rate NN NN O
of IN IN O
20 CD CD O
- : : O
30 CD CD O
% NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
, , , O
with IN IN O
acceptable JJ JJ O
toxicity NN NN O
and CC CC O
improvement NN NN O
in IN IN O
symptoms NNS NNS O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
. . . O

In IN IN O
the DT DT O
current JJ JJ O
study NN NN O
the DT DT O
efficacy NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
the DT DT O
combination NN NN O
of IN IN O
GEM NNP NNP B-CHEM
and CC CC O
VNB NNP NNP B-CHEM
in IN IN O
elderly JJ JJ O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
NSCLC NNP NNP O
or CC CC O
those DT DT O
with IN IN O
some DT DT O
contraindication NN NN O
to TO TO O
receiving VBG VBG O
cisplatin NN NN B-CHEM
were VBD VBD O
assessed VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
Forty CD CD O
- - - O
nine CD CD O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
NSCLC NNP NNP O
were VBD VBD O
included VBN VBN O
, , , O
38 CD CD O
of IN IN O
whom WP WP O
were VBD VBD O
age NN NN O
> NN NN O
/ NN NN O
= SYM SYM O
70 CD CD O
years NNS NNS O
and CC CC O
11 CD CD O
were VBD VBD O
age NN NN O
< NN NN O
70 CD CD O
years NNS NNS O
but CC CC O
who WP WP O
had VBD VBD O
some DT DT O
contraindication NN NN O
to TO TO O
receiving VBG VBG O
cisplatin NN NN B-CHEM
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
evaluable JJ JJ O
for IN IN O
response NN NN O
and CC CC O
toxicity NN NN O
. . . O

Treatment NN NN O
was VBD VBD O
comprised VBN VBN O
of IN IN O
VNB NNP NNP B-CHEM
, , , O
25 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
, , , O
plus CC CC O
GEM NNP NNP B-CHEM
, , , O
1000 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
, , , O
both DT DT O
on IN IN O
Days NNS NNS O
1 CD CD O
, , , O
8 CD CD O
, , , O
and CC CC O
15 CD CD O
every DT DT O
28 CD CD O
days NNS NNS O
. . . O

Patients NNS NNS O
received VBD VBD O
a DT DT O
minimum NN NN O
of IN IN O
three CD CD O
courses NNS NNS O
unless IN IN O
progressive JJ JJ O
disease NN NN O
was VBD VBD O
detected VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
One CD CD O
hundred CD CD O
sixty NN NN O
- : : O
five CD CD O
courses NNS NNS O
were VBD VBD O
administered VBN VBN O
, , , O
with IN IN O
a DT DT O
median NN NN O
of IN IN O
3 CD CD O
. . . O

6 CD CD O
courses NNS NNS O
per IN IN O
patient NN NN O
. . . O

The DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
was VBD VBD O
26 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
15 CD CD O
- : : O
41 CD CD O
% NN NN O
) ) ) O
. . . O

Two CD CD O
patients NNS NNS O
attained VBD VBD O
a DT DT O
complete JJ JJ O
response NN NN O
( ( ( O
4 CD CD O
% NN NN O
) ) ) O
and CC CC O
11 CD CD O
patients NNS NNS O
( ( ( O
22 CD CD O
% NN NN O
) ) ) O
achieved VBD VBD O
a DT DT O
partial JJ JJ O
response NN NN O
. . . O

Eastern NNP NNP O
Cooperative NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
performance NN NN O
status NN NN O
improved VBN VBN O
in IN IN O
35 CD CD O
% NN NN O
of IN IN O
those DT DT O
patients NNS NNS O
with IN IN O
an DT DT O
initial JJ JJ O
value NN NN O
> NN NN O
0 CD CD O
, , , O
whereas IN IN O
relief NN NN O
of IN IN O
at IN IN O
least JJS JJS O
1 CD CD O
symptom NN NN O
without IN IN O
worsening VBG VBG O
of IN IN O
other JJ JJ O
symptoms NNS NNS O
was VBD VBD O
noted VBN VBN O
in IN IN O
27 CD CD O
patients NNS NNS O
( ( ( O
55 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
median JJ JJ O
time NN NN O
to TO TO O
progression NN NN O
was VBD VBD O
16 CD CD O
weeks NNS NNS O
and CC CC O
the DT DT O
1 CD CD O
- : : O
year NN NN O
survival NN NN O
rate NN NN O
was VBD VBD O
33 CD CD O
% NN NN O
. . . O

Toxicity NNP NNP O
was VBD VBD O
mild JJ JJ O
. . . O

Six CD CD O
patients NNS NNS O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
World NNP NNP O
Health NNP NNP O
Organization NNP NNP O
Grade NNP NNP O
3 CD CD O
- : : O
4 CD CD O
neutropenia NN NN O
, , , O
2 CD CD O
patients NNS NNS O
( ( ( O
4 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
Grade NNP NNP O
3 CD CD O
- : : O
4 CD CD O
thrombocytopenia NN NN O
, , , O
and CC CC O
2 CD CD O
patients NNS NNS O
( ( ( O
4 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
Grade NNP NNP O
3 CD CD O
neurotoxicity NN NN O
. . . O

Three CD CD O
patients NNS NNS O
with IN IN O
severe JJ JJ O
neutropenia NN NN O
( ( ( O
6 CD CD O
% NN NN O
) ) ) O
died VBD VBD O
of IN IN O
sepsis NN NN O
. . . O

The DT DT O
median JJ JJ O
age NN NN O
of IN IN O
those DT DT O
patients NNS NNS O
developing VBG VBG O
Grade NNP NNP O
3 CD CD O
- : : O
4 CD CD O
neutropenia NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
remaining VBG VBG O
patients NNS NNS O
( ( ( O
75 CD CD O
years NNS NNS O
vs NN NN O
. . . O
72 CD CD O
years NNS NNS O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
047 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
combination NN NN O
of IN IN O
GEM NNP NNP B-CHEM
and CC CC O
VNB NNP NNP B-CHEM
is VBZ VBZ O
moderately RB RB O
active JJ JJ O
and CC CC O
well RB RB O
tolerated VBN VBN O
except IN IN O
in IN IN O
patients NNS NNS O
age NN NN O
> NN NN O
/ NN NN O
= SYM SYM O
75 CD CD O
years NNS NNS O
. . . O

This DT DT O
age NN NN O
group NN NN O
had VBD VBD O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
myelosuppression NN NN O
. . . O

Therefore RB RB O
the DT DT O
prophylactic JJ JJ O
use NN NN O
of IN IN O
granulocyte NN NN O
- - - O
colony NN NN O
stimulating VBG VBG O
factor NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
with IN IN O
this DT DT O
treatment NN NN O
. . . O

New NNP NNP O
chemotherapy NN NN O
combinations NNS NNS O
with IN IN O
higher JJR JJR O
activity NN NN O
and CC CC O
lower JJR JJR O
toxicity NN NN O
are VBP VBP O
needed VBN VBN O
for IN IN O
elderly JJ JJ O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
NSCLC NNP NNP O
. . . O

A DT DT O
selective JJ JJ O
dopamine NN NN B-CHEM
D4 NNP NNP O
receptor NN NN O
antagonist NN NN O
, , , O
NRA0160 NNP NNP B-CHEM
: : : O
a DT DT O
preclinical JJ JJ O
neuropharmacological JJ JJ O
profile NN NN O
. . . O

NRA0160 NNP NNP B-CHEM
, , , O
5 CD CD B-CHEM
- : : I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
fluorobenzylidene NN NN I-CHEM
) ) ) I-CHEM
piperidin NN NN I-CHEM
- - - I-CHEM
1 CD CD I-CHEM
- - - I-CHEM
yl NN NN I-CHEM
) ) ) I-CHEM
ethyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
fluorophenyl NN NN I-CHEM
) ) ) I-CHEM
thiazole NN NN I-CHEM
- - - I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
carboxamide NN NN I-CHEM
, , , O
has VBZ VBZ O
a DT DT O
high JJ JJ O
affinity NN NN O
for IN IN O
human JJ JJ O
cloned VBN VBN O
dopamine NN NN B-CHEM
D4 NNP NNP O
. . . O
2 CD CD O
, , , O
D4 NNP NNP O
. . . O
4 CD CD O
and CC CC O
D4 NNP NNP O
. . . O
7 CD CD O
receptors NNS NNS O
, , , O
with IN IN O
Ki NNP NNP O
values NNS NNS O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
, , , O
0 CD CD O
. . . O
9 CD CD O
and CC CC O
2 CD CD O
. . . O
7 CD CD O
nM NN NN O
, , , O
respectively RB RB O
. . . O

NRA0160 NNP NNP B-CHEM
is VBZ VBZ O
over IN IN O
20 CD CD O
, , , O
000fold CD CD O
more JJR JJR O
potent NN NN O
at IN IN O
the DT DT O
dopamine NN NN B-CHEM
D4 NNP NNP O
. . . O
2 CD CD O
receptor NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
human NN NN O
cloned VBN VBN O
dopamine NN NN B-CHEM
D2L NNP NNP O
receptor NN NN O
. . . O

NRA0160 NNP NNP B-CHEM
has VBZ VBZ O
negligible JJ JJ O
affinity NN NN O
for IN IN O
the DT DT O
human NN NN O
cloned VBN VBN O
dopamine NN NN B-CHEM
D3 NNP NNP O
receptor NN NN O
( ( ( O
Ki NNP NNP O
= SYM SYM O
39 CD CD O
nM NN NN O
) ) ) O
, , , O
rat NN NN O
serotonin NN NN B-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
) ) ) O
2A CD CD O
receptors NNS NNS O
( ( ( O
Ki NNP NNP O
= SYM SYM O
180 CD CD O
nM NN NN O
) ) ) O
and CC CC O
rat NN NN O
alpha1 NN NN O
adrenoceptor NN NN O
( ( ( O
Ki NNP NNP O
= SYM SYM O
237 CD CD O
nM NN NN O
) ) ) O
. . . O

NRA0160 NNP NNP B-CHEM
and CC CC O
clozapine NN NN B-CHEM
antagonized JJ JJ O
locomotor NN NN O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
methamphetamine NN NN B-CHEM
( ( ( O
MAP NNP NNP B-CHEM
) ) ) O
in IN IN O
mice NN NN O
. . . O

NRA0160 NNP NNP B-CHEM
and CC CC O
clozapine NN NN B-CHEM
antagonized VBN VBN O
MAP NNP NNP B-CHEM
- : : O
induced JJ JJ O
stereotyped JJ JJ O
behavior NN NN O
in IN IN O
mice NNS NNS O
, , , O
although IN IN O
their PRP$ PRP$ O
effects NNS NNS O
did VBD VBD O
not RB RB O
exceed VB VB O
50 CD CD O
% NN NN O
inhibition NN NN O
, , , O
even RB RB O
at IN IN O
the DT DT O
highest JJS JJS O
dose NN NN O
given VBN VBN O
. . . O

NRA0160 NNP NNP B-CHEM
and CC CC O
clozapine NN NN B-CHEM
significantly RB RB O
induced VBD VBD O
catalepsy NN NN O
in IN IN O
rats NNS NNS O
, , , O
although IN IN O
their PRP$ PRP$ O
effects NNS NNS O
did VBD VBD O
not RB RB O
exceed VB VB O
50 CD CD O
% NN NN O
induction NN NN O
even RB RB O
at IN IN O
the DT DT O
highest JJS JJS O
dose NN NN O
given VBN VBN O
. . . O

NRA0160 NNP NNP B-CHEM
and CC CC O
clozapine NN NN B-CHEM
significantly RB RB O
reversed VBD VBD O
the DT DT O
disruption NN NN O
of IN IN O
prepulse NN NN O
inhibition NN NN O
( ( ( O
PPI NNP NNP O
) ) ) O
in IN IN O
rats NNS NNS O
produced VBN VBN O
by IN IN O
apomorphine NN NN B-CHEM
. . . O

NRA0160 NNP NNP B-CHEM
and CC CC O
clozapine NN NN B-CHEM
significantly RB RB O
shortened VBD VBD O
the DT DT O
phencyclidine NN NN B-CHEM
( ( ( O
PCP NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
prolonged JJ JJ O
swimming NN NN O
latency NN NN O
in IN IN O
rats NNS NNS O
in IN IN O
a DT DT O
water NN NN O
maze NN NN O
task NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
NRA0160 NNP NNP B-CHEM
may MD MD O
have VB VB O
unique JJ JJ O
antipsychotic JJ JJ O
activities NNS NNS O
without IN IN O
the DT DT O
liability NN NN O
of IN IN O
motor NN NN O
side NN NN O
effects NNS NNS O
typical JJ JJ O
of IN IN O
classical JJ JJ O
antipsychotics NNS NNS O
. . . O

Warfarin NNP NNP B-CHEM
- : : O
induced JJ JJ O
artery NN NN O
calcification NN NN O
is VBZ VBZ O
accelerated VBN VBN O
by IN IN O
growth NN NN O
and CC CC O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
. . . O

The DT DT O
present JJ JJ O
studies NNS NNS O
demonstrate VBP VBP O
that IN IN O
growth NN NN O
and CC CC O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
treatment NN NN O
enhance NN NN O
the DT DT O
extent NN NN O
of IN IN O
artery NN NN O
calcification NN NN O
in IN IN O
rats NNS NNS O
given VBN VBN O
sufficient JJ JJ O
doses NNS NNS O
of IN IN O
Warfarin NNP NNP B-CHEM
to TO TO O
inhibit NN NN O
gamma NN NN O
- : : O
carboxylation NN NN O
of IN IN O
matrix NN NN O
Gla NNP NNP O
protein NN NN O
, , , O
a DT DT O
calcification NN NN O
inhibitor NN NN O
known VBN VBN O
to TO TO O
be VB VB O
expressed VBN VBN O
by IN IN O
smooth JJ JJ O
muscle NN NN O
cells NNS NNS O
and CC CC O
macrophages NNS NNS O
in IN IN O
the DT DT O
artery NN NN O
wall NN NN O
. . . O

The DT DT O
first JJ JJ O
series NN NN O
of IN IN O
experiments NNS NNS O
examined VBD VBD O
the DT DT O
influence NN NN O
of IN IN O
age NN NN O
and CC CC O
growth NN NN O
status NN NN O
on IN IN O
artery NN NN O
calcification NN NN O
in IN IN O
Warfarin NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
. . . O

Treatment NN NN O
for IN IN O
2 CD CD O
weeks NNS NNS O
with IN IN O
Warfarin NNP NNP B-CHEM
caused VBD VBD O
massive JJ JJ O
focal JJ JJ O
calcification NN NN O
of IN IN O
the DT DT O
artery NN NN O
media NNS NNS O
in IN IN O
20 CD CD O
- : : O
day NN NN O
- : : O
old JJ JJ O
rats NNS NNS O
and CC CC O
less RBR RBR O
extensive JJ JJ O
focal JJ JJ O
calcification NN NN O
in IN IN O
42 CD CD O
- : : O
day NN NN O
- : : O
old JJ JJ O
rats NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
no DT DT O
artery NN NN O
calcification NN NN O
could MD MD O
be VB VB O
detected VBN VBN O
in IN IN O
10 CD CD O
- : : O
month NN NN O
- - - O
old JJ JJ O
adult NN NN O
rats NNS NNS O
even RB RB O
after IN IN O
4 CD CD O
weeks NNS NNS O
of IN IN O
Warfarin NNP NNP B-CHEM
treatment NN NN O
. . . O

To TO TO O
directly RB RB O
examine VB VB O
the DT DT O
importance NN NN O
of IN IN O
growth NN NN O
to TO TO O
Warfarin NNP NNP B-CHEM
- : : O
induced JJ JJ O
artery NN NN O
calcification NN NN O
in IN IN O
animals NNS NNS O
of IN IN O
the DT DT O
same JJ JJ O
age NN NN O
, , , O
20 CD CD O
- : : O
day NN NN O
- : : O
old JJ JJ O
rats NNS NNS O
were VBD VBD O
fed VBN VBN O
for IN IN O
2 CD CD O
weeks NNS NNS O
either CC CC O
an DT DT O
ad NN NN O
libitum NN NN O
diet NN NN O
or CC CC O
a DT DT O
6 CD CD O
- : : O
g SYM SYM O
/ NN NN O
d SYM SYM O
restricted JJ JJ O
diet NN NN O
that WDT WDT O
maintains VBZ VBZ O
weight NN NN O
but CC CC O
prevents NNS NNS O
growth NN NN O
. . . O

Concurrent NNP NNP O
treatment NN NN O
of IN IN O
both DT DT O
dietary JJ JJ O
groups NNS NNS O
with IN IN O
Warfarin NNP NNP B-CHEM
produced VBD VBD O
massive JJ JJ O
focal JJ JJ O
calcification NN NN O
of IN IN O
the DT DT O
artery NN NN O
media NNS NNS O
in IN IN O
the DT DT O
ad NN NN O
libitum NN NN O
- : : O
fed VBN VBN O
rats NNS NNS O
but CC CC O
no DT DT O
detectable JJ JJ O
artery NN NN O
calcification NN NN O
in IN IN O
the DT DT O
restricted JJ JJ O
- - - O
diet NN NN O
, , , O
growth NN NN O
- - - O
inhibited JJ JJ O
group NN NN O
. . . O

Although IN IN O
the DT DT O
explanation NN NN O
for IN IN O
the DT DT O
association NN NN O
between IN IN O
artery NN NN O
calcification NN NN O
and CC CC O
growth NN NN O
status NN NN O
cannot NN NN O
be VB VB O
determined VBN VBN O
from IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
relationship NN NN O
between IN IN O
higher JJR JJR O
serum NN NN O
phosphate NN NN B-CHEM
and CC CC O
susceptibility NN NN O
to TO TO O
artery NN NN O
calcification NN NN O
, , , O
with IN IN O
30 CD CD O
% NN NN O
higher JJR JJR O
levels NNS NNS O
of IN IN O
serum NN NN O
phosphate NN NN B-CHEM
in IN IN O
young JJ JJ O
, , , O
ad NN NN O
libitum NN NN O
- : : O
fed VBN VBN O
rats NNS NNS O
compared VBN VBN O
with IN IN O
either DT DT O
of IN IN O
the DT DT O
groups NNS NNS O
that WDT WDT O
was VBD VBD O
resistant JJ JJ O
to TO TO O
Warfarin NNP NNP B-CHEM
- : : O
induced JJ JJ O
artery NN NN O
calcification NN NN O
, , , O
ie NN NN O
, , , O
the DT DT O
10 CD CD O
- : : O
month NN NN O
- - - O
old JJ JJ O
rats NNS NNS O
and CC CC O
the DT DT O
restricted JJ JJ O
- - - O
diet NN NN O
, , , O
growth NN NN O
- - - O
inhibited JJ JJ O
young JJ JJ O
rats NNS NNS O
. . . O

This DT DT O
observation NN NN O
suggests VBZ VBZ O
that WDT WDT O
increased VBD VBD O
susceptibility NN NN O
to TO TO O
Warfarin NNP NNP B-CHEM
- : : O
induced JJ JJ O
artery NN NN O
calcification NN NN O
could MD MD O
be VB VB O
related VBN VBN O
to TO TO O
higher JJR JJR O
serum NN NN O
phosphate NN NN B-CHEM
levels NNS NNS O
. . . O

The DT DT O
second JJ JJ O
set NN NN O
of IN IN O
experiments NNS NNS O
examined VBD VBD O
the DT DT O
possible JJ JJ O
synergy NN NN O
between IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
and CC CC O
Warfarin NNP NNP B-CHEM
in IN IN O
artery NN NN O
calcification NN NN O
. . . O

High NNP NNP O
doses NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
are VBP VBP O
known VBN VBN O
to TO TO O
cause VB VB O
calcification NN NN O
of IN IN O
the DT DT O
artery NN NN O
media NNS NNS O
in IN IN O
as RB RB O
little JJ JJ O
as IN IN O
3 CD CD O
to TO TO O
4 CD CD O
days NNS NNS O
. . . O

High NNP NNP O
doses NNS NNS O
of IN IN O
the DT DT O
vitamin NN NN B-CHEM
K NNP NNP I-CHEM
antagonist NN NN O
Warfarin NNP NNP B-CHEM
are VBP VBP O
also RB RB O
known VBN VBN O
to TO TO O
cause VB VB O
calcification NN NN O
of IN IN O
the DT DT O
artery NN NN O
media NNS NNS O
, , , O
but CC CC O
at IN IN O
treatment NN NN O
times NNS NNS O
of IN IN O
2 CD CD O
weeks NNS NNS O
or CC CC O
longer RBR RBR O
yet RB RB O
not RB RB O
at IN IN O
1 CD CD O
week NN NN O
. . . O

In IN IN O
the DT DT O
current JJ JJ O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
synergy NN NN O
between IN IN O
these DT DT O
2 CD CD O
treatments NNS NNS O
and CC CC O
found VBD VBD O
that IN IN O
concurrent NN NN O
Warfarin NNP NNP B-CHEM
administration NN NN O
dramatically RB RB O
increased VBD VBD O
the DT DT O
extent NN NN O
of IN IN O
calcification NN NN O
in IN IN O
the DT DT O
media NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
at IN IN O
3 CD CD O
and CC CC O
4 CD CD O
days NNS NNS O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
close JJ JJ O
parallel NN NN O
between IN IN O
the DT DT O
effect NN NN O
of IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
dose NN NN O
on IN IN O
artery NN NN O
calcification NN NN O
and CC CC O
the DT DT O
effect NN NN O
of IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
dose NN NN O
on IN IN O
the DT DT O
elevation NN NN O
of IN IN O
serum NN NN O
calcium NN NN B-CHEM
, , , O
which WDT WDT O
suggests VBZ VBZ O
that IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
may MD MD O
induce VB VB O
artery NN NN O
calcification NN NN O
through IN IN O
its PRP$ PRP$ O
effect NN NN O
on IN IN O
serum NN NN O
calcium NN NN B-CHEM
. . . O

Because IN IN O
Warfarin NNP NNP B-CHEM
treatment NN NN O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
elevation NN NN O
in IN IN O
serum NN NN O
calcium NN NN B-CHEM
produced VBN VBN O
by IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
, , , O
the DT DT O
synergy NN NN O
between IN IN O
Warfarin NNP NNP B-CHEM
and CC CC O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
is VBZ VBZ O
probably RB RB O
best JJS JJS O
explained VBN VBN O
by IN IN O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
Warfarin NNP NNP B-CHEM
inhibits VBZ VBZ O
the DT DT O
activity NN NN O
of IN IN O
matrix NN NN O
Gla NNP NNP O
protein NN NN O
as IN IN O
a DT DT O
calcification NN NN O
inhibitor NN NN O
. . . O

High NNP NNP O
levels NNS NNS O
of IN IN O
matrix NN NN O
Gla NNP NNP O
protein NN NN O
are VBP VBP O
found VBN VBN O
at IN IN O
sites NNS NNS O
of IN IN O
artery NN NN O
calcification NN NN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
plus CC CC O
Warfarin NNP NNP B-CHEM
, , , O
and CC CC O
chemical NN NN O
analysis NN NN O
showed VBD VBD O
that IN IN O
the DT DT O
protein NN NN O
that DT DT O
accumulated VBD VBD O
was VBD VBD O
indeed RB RB O
not RB RB O
gamma VB VB B-CHEM
- - - I-CHEM
carboxylated JJ JJ I-CHEM
. . . O

These DT DT O
observations NNS NNS O
indicate VBP VBP O
that IN IN O
although IN IN O
the DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
carboxyglutamate JJ JJ I-CHEM
residues NNS NNS O
of IN IN O
matrix NN NN O
Gla NNP NNP O
protein NN NN O
are VBP VBP O
apparently RB RB O
required VBN VBN O
for IN IN O
its PRP$ PRP$ O
function NN NN O
as IN IN O
a DT DT O
calcification NN NN O
inhibitor NN NN O
, , , O
they PRP PRP O
are VBP VBP O
not RB RB O
required VBN VBN O
for IN IN O
its PRP$ PRP$ O
accumulation NN NN O
at IN IN O
calcification NN NN O
sites NNS NNS O
. . . O

Test NNP NNP O
conditions NNS NNS O
influence VBP VBP O
the DT DT O
response NN NN O
to TO TO O
a DT DT O
drug NN NN O
challenge NN NN O
in IN IN O
rodents NNS NNS O
. . . O

These DT DT O
studies NNS NNS O
were VBD VBD O
conducted VBN VBN O
to TO TO O
examine VB VB O
the DT DT O
differential JJ JJ O
response NN NN O
to TO TO O
a DT DT O
drug NN NN O
challenge NN NN O
under IN IN O
varied JJ JJ O
experimental JJ JJ O
test NN NN O
conditions NNS NNS O
routinely RB RB O
employed VBN VBN O
to TO TO O
study VB VB O
drug NN NN O
- : : O
induced JJ JJ O
behavioral NN NN O
and CC CC O
neurophysiological JJ JJ O
responses NNS NNS O
in IN IN O
rodents NNS NNS O
. . . O

Apomorphine NNP NNP B-CHEM
, , , O
a DT DT O
nonselective JJ JJ O
dopamine NN NN B-CHEM
agonist NN NN I-CHEM
, , , O
was VBD VBD O
selected VBN VBN O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
biphasic NN NN O
behavioral JJ JJ O
effects NNS NNS O
, , , O
its PRP$ PRP$ O
ability NN NN O
to TO TO O
induce VB VB O
hypothermia NN NN O
, , , O
and CC CC O
to TO TO O
produce VB VB O
distinct JJ JJ O
changes NNS NNS O
to TO TO O
dopamine VB VB B-CHEM
turnover NN NN O
in IN IN O
the DT DT O
rodent NN NN O
brain NN NN O
. . . O

From IN IN O
such JJ JJ O
experiments NNS NNS O
there RB RB O
is VBZ VBZ O
evidence NN NN O
that DT DT O
characterization NN NN O
and CC CC O
detection NN NN O
of IN IN O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
activity NN NN O
in IN IN O
rodents NNS NNS O
critically RB RB O
depends VBZ VBZ O
upon IN IN O
the DT DT O
test NN NN O
conditions NNS NNS O
employed VBN VBN O
. . . O

In IN IN O
rats NNS NNS O
, , , O
detection NN NN O
of IN IN O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
was VBD VBD O
facilitated VBN VBN O
by IN IN O
a DT DT O
period NN NN O
of IN IN O
acclimatization NN NN O
to TO TO O
the DT DT O
test NN NN O
conditions NNS NNS O
. . . O

Moreover RB RB O
, , , O
test NN NN O
conditions NNS NNS O
can MD MD O
impact VB VB O
upon IN IN O
other JJ JJ O
physiological JJ JJ O
responses NNS NNS O
to TO TO O
apomorphine VB VB B-CHEM
such JJ JJ O
as IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hypothermia NN NN O
. . . O

In IN IN O
mice NNS NNS O
, , , O
apomorphine NN NN B-CHEM
produced VBD VBD O
qualitatively RB RB O
different JJ JJ O
responses NNS NNS O
under IN IN O
novel NN NN O
conditions NNS NNS O
when WRB WRB O
compared VBN VBN O
to TO TO O
those DT DT O
behaviors NNS NNS O
elicited VBD VBD O
in IN IN O
the DT DT O
home NN NN O
test NN NN O
cage NN NN O
. . . O

Drug NN NN O
- : : O
induced VBN VBN O
gross NN NN O
activity NN NN O
counts NNS NNS O
were VBD VBD O
increased VBN VBN O
in IN IN O
the DT DT O
novel NN NN O
exploratory NN NN O
box NN NN O
only RB RB O
, , , O
while IN IN O
measures NNS NNS O
of IN IN O
stereotypic JJ JJ O
behavior NN NN O
were VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
. . . O

By IN IN O
contrast NN NN O
, , , O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotion NN NN O
was VBD VBD O
more RBR RBR O
prominent JJ JJ O
in IN IN O
the DT DT O
novel NN NN O
exploratory NN NN O
box NN NN O
. . . O

Dopamine NNP NNP B-CHEM
turnover NN NN O
ratios NNS NNS O
( ( ( O
DOPAC NNP NNP B-CHEM
: : : O
DA NNP NNP B-CHEM
and CC CC O
HVA NNP NNP B-CHEM
: : : O
DA NNP NNP B-CHEM
) ) ) O
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
lower JJR JJR O
in IN IN O
those DT DT O
animals NNS NNS O
exposed VBN VBN O
to TO TO O
the DT DT O
exploratory NN NN O
box NN NN O
when WRB WRB O
compared VBN VBN O
to TO TO O
their PRP$ PRP$ O
home NN NN O
cage NN NN O
counterparts NNS NNS O
. . . O

However RB RB O
, , , O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
reductions NNS NNS O
in IN IN O
striatal JJ JJ O
dopamine NN NN B-CHEM
turnover NN NN O
were VBD VBD O
detected VBN VBN O
in IN IN O
both DT DT O
novel NN NN O
and CC CC O
home NN NN O
cage NN NN O
environments NNS NNS O
. . . O

The DT DT O
implications NNS NNS O
of IN IN O
these DT DT O
findings NNS NNS O
are VBP VBP O
discussed VBN VBN O
with IN IN O
particular JJ JJ O
emphasis NN NN O
upon IN IN O
conducting VBG VBG O
psychopharmacological JJ JJ O
challenge NN NN O
tests NNS NNS O
in IN IN O
rodents NNS NNS O
. . . O

Hemolysis NNP NNP O
of IN IN O
human JJ JJ O
erythrocytes NNS NNS O
induced VBN VBN O
by IN IN O
tamoxifen NN NN B-CHEM
is VBZ VBZ O
related VBN VBN O
to TO TO O
disruption NN NN O
of IN IN O
membrane NN NN O
structure NN NN O
. . . O

Tamoxifen NNP NNP B-CHEM
( ( ( O
TAM NNP NNP B-CHEM
) ) ) O
, , , O
the DT DT O
antiestrogenic JJ JJ O
drug NN NN O
most RBS RBS O
widely RB RB O
prescribed VBN VBN O
in IN IN O
the DT DT O
chemotherapy NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
, , , O
induces VBZ VBZ O
changes NNS NNS O
in IN IN O
normal JJ JJ O
discoid NN NN O
shape NN NN O
of IN IN O
erythrocytes NNS NNS O
and CC CC O
hemolytic JJ JJ O
anemia NN NN O
. . . O

This DT DT O
work NN NN O
evaluates VBZ VBZ O
the DT DT O
effects NNS NNS O
of IN IN O
TAM NNP NNP B-CHEM
on IN IN O
isolated VBN VBN O
human JJ JJ O
erythrocytes NNS NNS O
, , , O
attempting VBG VBG O
to TO TO O
identify VB VB O
the DT DT O
underlying VBG VBG O
mechanisms NNS NNS O
on IN IN O
TAM NNP NNP B-CHEM
- : : O
induced JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
and CC CC O
the DT DT O
involvement NN NN O
of IN IN O
biomembranes NNS NNS O
in IN IN O
its PRP$ PRP$ O
cytostatic JJ JJ O
action NN NN O
mechanisms NNS NNS O
. . . O

TAM NNP NNP B-CHEM
induces NNS NNS O
hemolysis NN NN O
of IN IN O
erythrocytes NNS NNS O
as IN IN O
a DT DT O
function NN NN O
of IN IN O
concentration NN NN O
. . . O

The DT DT O
extension NN NN O
of IN IN O
hemolysis NN NN O
is VBZ VBZ O
variable JJ JJ O
with IN IN O
erythrocyte NN NN O
samples NNS NNS O
, , , O
but CC CC O
12 CD CD O
. . . O
5 CD CD O
microM NN NN O
TAM NNP NNP B-CHEM
induces NNS NNS O
total JJ JJ O
hemolysis NN NN O
of IN IN O
all DT DT O
tested VBN VBN O
suspensions NNS NNS O
. . . O

Despite IN IN O
inducing VBG VBG O
extensive JJ JJ O
erythrocyte NN NN O
lysis NN NN O
, , , O
TAM NNP NNP B-CHEM
does VBZ VBZ O
not RB RB O
shift VB VB O
the DT DT O
osmotic JJ JJ O
fragility NN NN O
curves NNS NNS O
of IN IN O
erythrocytes NNS NNS O
. . . O

The DT DT O
hemolytic JJ JJ O
effect NN NN O
of IN IN O
TAM NNP NNP B-CHEM
is VBZ VBZ O
prevented VBN VBN O
by IN IN O
low JJ JJ O
concentrations NNS NNS O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
tocopherol NN NN I-CHEM
( ( ( O
alpha NN NN B-CHEM
- - - I-CHEM
T NN NN I-CHEM
) ) ) O
and CC CC O
alpha JJ JJ B-CHEM
- - - I-CHEM
tocopherol NN NN I-CHEM
acetate NN NN I-CHEM
( ( ( O
alpha NN NN B-CHEM
- - - I-CHEM
TAc NNP NNP I-CHEM
) ) ) O
( ( ( O
inactivated VBN VBN O
functional JJ JJ O
hydroxyl NN NN B-CHEM
) ) ) O
indicating VBG VBG O
that IN IN O
TAM NNP NNP B-CHEM
- : : O
induced JJ JJ O
hemolysis NN NN O
is VBZ VBZ O
not RB RB O
related VBN VBN O
to TO TO O
oxidative JJ JJ O
membrane NN NN O
damage NN NN O
. . . O

This DT DT O
was VBD VBD O
further RB RB O
evidenced VBN VBN O
by IN IN O
absence NN NN O
of IN IN O
oxygen NN NN B-CHEM
consumption NN NN O
and CC CC O
hemoglobin NN NN O
oxidation NN NN O
both DT DT O
determined VBN VBN O
in IN IN O
parallel JJ JJ O
with IN IN O
TAM NNP NNP B-CHEM
- : : O
induced JJ JJ O
hemolysis NN NN O
. . . O

Furthermore RB RB O
, , , O
it PRP PRP O
was VBD VBD O
observed VBN VBN O
that IN IN O
TAM NNP NNP B-CHEM
inhibits VBZ VBZ O
the DT DT O
peroxidation NN NN O
of IN IN O
human JJ JJ O
erythrocytes NNS NNS O
induced VBN VBN O
by IN IN O
AAPH NNP NNP B-CHEM
, , , O
thus RB RB O
ruling VBG VBG O
out IN IN O
TAM NNP NNP B-CHEM
- : : O
induced JJ JJ O
cell NN NN O
oxidative JJ JJ O
stress NN NN O
. . . O

Hemolysis NNP NNP O
caused VBN VBN O
by IN IN O
TAM NNP NNP B-CHEM
was VBD VBD O
not RB RB O
preceded VBN VBN O
by IN IN O
the DT DT O
leakage NN NN O
of IN IN O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
from IN IN O
the DT DT O
cells NNS NNS O
, , , O
also RB RB O
excluding VBG VBG O
a DT DT O
colloid NN NN O
- - - O
osmotic JJ JJ O
type NN NN O
mechanism NN NN O
of IN IN O
hemolysis NN NN O
, , , O
according VBG VBG O
to TO TO O
the DT DT O
effects NNS NNS O
on IN IN O
osmotic JJ JJ O
fragility NN NN O
curves NNS NNS O
. . . O

However RB RB O
, , , O
TAM NNP NNP B-CHEM
induces NNS NNS O
release NN NN O
of IN IN O
peripheral JJ JJ O
proteins NNS NNS O
of IN IN O
membrane NN NN O
- - - O
cytoskeleton NN NN O
and CC CC O
cytosol NN NN O
proteins NNS NNS O
essentially RB RB O
bound VBN VBN O
to TO TO O
band NN NN O
3 CD CD O
. . . O

Either CC CC O
alpha NN NN B-CHEM
- - - I-CHEM
T NN NN I-CHEM
or CC CC O
alpha NN NN B-CHEM
- - - I-CHEM
TAc NNP NNP I-CHEM
increases NNS NNS O
membrane NN NN O
packing VBG VBG O
and CC CC O
prevents NNS NNS O
TAM NNP NNP B-CHEM
partition NN NN O
into IN IN O
model NN NN O
membranes NNS NNS O
. . . O

These DT DT O
effects NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
protection NN NN O
from IN IN O
hemolysis NN NN O
by IN IN O
tocopherols NNS NNS B-CHEM
is VBZ VBZ O
related VBN VBN O
to TO TO O
a DT DT O
decreased VBD VBD O
TAM NNP NNP B-CHEM
incorporation NN NN O
in IN IN O
condensed JJ JJ O
membranes NNS NNS O
and CC CC O
the DT DT O
structural JJ JJ O
damage NN NN O
of IN IN O
the DT DT O
erythrocyte NN NN O
membrane NN NN O
is VBZ VBZ O
consequently RB RB O
avoided VBN VBN O
. . . O

Therefore RB RB O
, , , O
TAM NNP NNP B-CHEM
- : : O
induced JJ JJ O
hemolysis NN NN O
results NNS NNS O
from IN IN O
a DT DT O
structural JJ JJ O
perturbation NN NN O
of IN IN O
red JJ JJ O
cell NN NN O
membrane NN NN O
, , , O
leading VBG VBG O
to TO TO O
changes NNS NNS O
in IN IN O
the DT DT O
framework NN NN O
of IN IN O
the DT DT O
erythrocyte NN NN O
membrane NN NN O
and CC CC O
its PRP$ PRP$ O
cytoskeleton NN NN O
caused VBN VBN O
by IN IN O
its PRP$ PRP$ O
high JJ JJ O
partition NN NN O
in IN IN O
the DT DT O
membrane NN NN O
. . . O

These DT DT O
defects NNS NNS O
explain VBP VBP O
the DT DT O
abnormal JJ JJ O
erythrocyte NN NN O
shape NN NN O
and CC CC O
decreased VBD VBD O
mechanical JJ JJ O
stability NN NN O
promoted VBN VBN O
by IN IN O
TAM NNP NNP B-CHEM
, , , O
resulting VBG VBG O
in IN IN O
hemolytic JJ JJ O
anemia NN NN O
. . . O

Additionally RB RB O
, , , O
since IN IN O
membrane NN NN O
leakage NN NN O
is VBZ VBZ O
a DT DT O
final JJ JJ O
stage NN NN O
of IN IN O
cytotoxicity NN NN O
, , , O
the DT DT O
disruption NN NN O
of IN IN O
the DT DT O
structural JJ JJ O
characteristics NNS NNS O
of IN IN O
biomembranes NNS NNS O
by IN IN O
TAM NNP NNP B-CHEM
may MD MD O
contribute VB VB O
to TO TO O
the DT DT O
multiple JJ JJ O
mechanisms NNS NNS O
of IN IN O
its PRP$ PRP$ O
anticancer NN NN O
action NN NN O
. . . O

Changes NNS NNS O
of IN IN O
sodium NN NN B-CHEM
and CC CC O
ATP NNP NNP B-CHEM
affinities NNS NNS O
of IN IN O
the DT DT O
cardiac NN NN O
( ( ( O
Na NNP NNP B-CHEM
, , , O
K NNP NNP B-CHEM
) ) ) O
- : : O
ATPase NNP NNP O
during IN IN O
and CC CC O
after IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
deficient NN NN O
hypertension NN NN O
. . . O

In IN IN O
the DT DT O
cardiovascular JJ JJ O
system NN NN O
, , , O
NO DT DT B-CHEM
is VBZ VBZ O
involved VBN VBN O
in IN IN O
the DT DT O
regulation NN NN O
of IN IN O
a DT DT O
variety NN NN O
of IN IN O
functions NNS NNS O
. . . O

Inhibition NNP NNP O
of IN IN O
NO DT DT B-CHEM
synthesis NN NN O
induces NNS NNS O
sustained VBN VBN O
hypertension NN NN O
. . . O

In IN IN O
several JJ JJ O
models NNS NNS O
of IN IN O
hypertension NN NN O
, , , O
elevation NN NN O
of IN IN O
intracellular JJ JJ O
sodium NN NN B-CHEM
level NN NN O
was VBD VBD O
documented VBN VBN O
in IN IN O
cardiac JJ JJ O
tissue NN NN O
. . . O

To TO TO O
assess VB VB O
the DT DT O
molecular JJ JJ O
basis NN NN O
of IN IN O
disturbances NNS NNS O
in IN IN O
transmembraneous JJ JJ O
transport NN NN O
of IN IN O
Na NNP NNP B-CHEM
+ NN NN O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
response NN NN O
of IN IN O
cardiac JJ JJ O
( ( ( O
Na NNP NNP B-CHEM
, , , O
K NNP NNP B-CHEM
) ) ) O
- : : O
ATPase NNP NNP O
to TO TO O
NO UH UH B-CHEM
- - - O
deficient JJ JJ O
hypertension NN NN O
induced VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
NO UH UH B-CHEM
- : : O
synthase NN NN O
inhibition NN NN O
with IN IN O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
N NNP NNP B-CHEM
( ( ( I-CHEM
G NNP NNP I-CHEM
) ) ) I-CHEM
- : : I-CHEM
nitro NN NN I-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
methyl NN NN I-CHEM
ester NN NN I-CHEM
( ( ( O
L NNP NNP B-CHEM
- - - I-CHEM
NAME NN NN I-CHEM
) ) ) O
for IN IN O
4 CD CD O
four CD CD O
weeks NNS NNS O
. . . O

After IN IN O
4 CD CD O
- : : O
week NN NN O
administration NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
NAME NN NN I-CHEM
, , , O
the DT DT O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
SBP NNP NNP O
) ) ) O
increased VBN VBN O
by IN IN O
36 CD CD O
% NN NN O
. . . O

Two CD CD O
weeks NNS NNS O
after IN IN O
terminating VBG VBG O
the DT DT O
treatment NN NN O
, , , O
the DT DT O
SBP NNP NNP O
recovered VBD VBD O
to TO TO O
control VB VB O
value NN NN O
. . . O

When WRB WRB O
activating VBG VBG O
the DT DT O
( ( ( O
Na NNP NNP B-CHEM
, , , O
K NNP NNP B-CHEM
) ) ) O
- : : O
ATPase NNP NNP O
with IN IN O
its PRP$ PRP$ O
substrate NN NN O
ATP NNP NNP B-CHEM
, , , O
no DT DT O
changes NNS NNS O
in IN IN O
Km NN NN O
and CC CC O
Vmax NNP NNP O
values NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
NO UH UH B-CHEM
- - - O
deficient JJ JJ O
rats NNS NNS O
. . . O

During IN IN O
activation NN NN O
with IN IN O
Na NNP NNP B-CHEM
+ NN NN O
, , , O
the DT DT O
Vmax NNP NNP O
remained VBD VBD O
unchanged JJ JJ O
, , , O
however RB RB O
the DT DT O
K NNP NNP B-CHEM
( ( ( O
Na NNP NNP B-CHEM
) ) ) O
increased VBN VBN O
by IN IN O
50 CD CD O
% NN NN O
, , , O
indicating VBG VBG O
a DT DT O
profound JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
affinity NN NN O
of IN IN O
the DT DT O
Na NNP NNP B-CHEM
+ NN NN O
- : : O
binding JJ JJ O
site NN NN O
in IN IN O
NO UH UH B-CHEM
- - - O
deficient JJ JJ O
rats NNS NNS O
. . . O

After IN IN O
recovery NN NN O
from IN IN O
hypertension NN NN O
, , , O
the DT DT O
activity NN NN O
of IN IN O
( ( ( O
Na NNP NNP B-CHEM
, , , O
K NNP NNP B-CHEM
) ) ) O
- : : O
ATPase NNP NNP O
increased VBD VBD O
, , , O
due JJ JJ O
to TO TO O
higher JJR JJR O
affinity NN NN O
of IN IN O
the DT DT O
ATP NNP NNP B-CHEM
- : : O
binding JJ JJ O
site NN NN O
, , , O
as IN IN O
revealed VBN VBN O
from IN IN O
the DT DT O
lowered JJ JJ O
Km NN NN O
value NN NN O
for IN IN O
ATP NNP NNP B-CHEM
. . . O

The DT DT O
K NNP NNP B-CHEM
( ( ( O
Na NNP NNP B-CHEM
) ) ) O
value NN NN O
for IN IN O
Na NNP NNP B-CHEM
+ NN NN O
returned VBD VBD O
to TO TO O
control VB VB O
value NN NN O
. . . O

Inhibition NNP NNP O
of IN IN O
NO UH UH B-CHEM
- - - O
synthase NN NN O
induced VBD VBD O
a DT DT O
reversible JJ JJ O
hypertension NN NN O
accompanied VBN VBN O
by IN IN O
depressed VBN VBN O
Na NNP NNP B-CHEM
+ NN NN O
- : : O
extrusion NN NN O
from IN IN O
cardiac JJ JJ O
cells NNS NNS O
as IN IN O
a DT DT O
consequence NN NN O
of IN IN O
deteriorated VBN VBN O
Na NNP NNP B-CHEM
+ NN NN O
- : : O
binding JJ JJ O
properties NNS NNS O
of IN IN O
the DT DT O
( ( ( O
Na NNP NNP B-CHEM
, , , O
K NNP NNP B-CHEM
) ) ) O
- : : O
ATPase NNP NNP O
. . . O

After IN IN O
recovery NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
to TO TO O
control VB VB O
values NNS NNS O
, , , O
the DT DT O
extrusion NN NN O
of IN IN O
Na NNP NNP B-CHEM
+ NN NN O
from IN IN O
cardiac JJ JJ O
cells NNS NNS O
was VBD VBD O
normalized JJ JJ O
, , , O
as IN IN O
revealed VBN VBN O
by IN IN O
restoration NN NN O
of IN IN O
the DT DT O
( ( ( O
Na NNP NNP B-CHEM
, , , O
K NNP NNP B-CHEM
) ) ) O
- : : O
ATPase NNP NNP O
activity NN NN O
. . . O

Effects NNP NNP O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
pretreatment NN NN O
with IN IN O
isoproterenol NN NN B-CHEM
on IN IN O
bromocriptine NN NN B-CHEM
- : : O
induced JJ JJ O
tachycardia NN NN O
in IN IN O
conscious JJ JJ O
rats NNS NNS O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
that IN IN O
bromocriptine NN NN B-CHEM
- : : O
induced JJ JJ O
tachycardia NN NN O
, , , O
which WDT WDT O
persisted VBD VBD O
after IN IN O
adrenalectomy NN NN O
, , , O
is VBZ VBZ O
( ( ( O
i NNP NNP O
) ) ) O
mediated VBN VBN O
by IN IN O
central JJ JJ O
dopamine NN NN B-CHEM
D2 NN NN O
receptor NN NN O
activation NN NN O
and CC CC O
( ( ( O
ii NN NN O
) ) ) O
reduced VBN VBN O
by IN IN O
5 CD CD O
- : : O
day NN NN O
isoproterenol JJ JJ B-CHEM
pretreatment NN NN O
, , , O
supporting VBG VBG O
therefore RB RB O
the DT DT O
hypothesis NNS NNS O
that IN IN O
this DT DT O
effect NN NN O
is VBZ VBZ O
dependent JJ JJ O
on IN IN O
sympathetic JJ JJ O
outflow NN NN O
to TO TO O
the DT DT O
heart NN NN O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
conducted VBN VBN O
to TO TO O
examine VB VB O
whether IN IN O
prolonged JJ JJ O
pretreatment NN NN O
with IN IN O
isoproterenol NN NN B-CHEM
could MD MD O
abolish VB VB O
bromocriptine NN NN B-CHEM
- : : O
induced JJ JJ O
tachycardia NN NN O
in IN IN O
conscious JJ JJ O
rats NNS NNS O
. . . O

Isoproterenol NNP NNP B-CHEM
pretreatment NN NN O
for IN IN O
15 CD CD O
days NNS NNS O
caused VBD VBD O
cardiac JJ JJ O
hypertrophy NN NN O
without IN IN O
affecting VBG VBG O
baseline NN NN O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
. . . O

In IN IN O
control NN NN O
rats NNS NNS O
, , , O
intravenous JJ JJ O
bromocriptine NN NN B-CHEM
( ( ( O
150 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
induced VBN VBN O
significant JJ JJ O
hypotension NN NN O
and CC CC O
tachycardia NN NN O
. . . O

Bromocriptine NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
was VBD VBD O
unaffected JJ JJ O
by IN IN O
isoproterenol NN NN B-CHEM
pretreatment NN NN O
, , , O
while IN IN O
tachycardia NN NN O
was VBD VBD O
reversed VBN VBN O
to TO TO O
significant JJ JJ O
bradycardia NN NN O
, , , O
an DT DT O
effect NN NN O
that WDT WDT O
was VBD VBD O
partly RB RB O
reduced VBN VBN O
by IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
domperidone NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

Neither DT DT O
cardiac JJ JJ O
vagal NN NN O
nor CC CC O
sympathetic JJ JJ O
tone NN NN O
was VBD VBD O
altered VBN VBN O
by IN IN O
isoproterenol JJ JJ B-CHEM
pretreatment NN NN O
. . . O

In IN IN O
isolated VBN VBN O
perfused JJ JJ O
heart NN NN O
preparations NNS NNS O
from IN IN O
isoproterenol NN NN B-CHEM
- - - O
pretreated JJ JJ O
rats NNS NNS O
, , , O
the DT DT O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
maximal NN NN O
increase NN NN O
in IN IN O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
pressure NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
, , , O
compared VBN VBN O
with IN IN O
saline NN NN O
- - - O
pretreated JJ JJ O
rats NNS NNS O
( ( ( O
the DT DT O
EC50 NNP NNP O
of IN IN O
the DT DT O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
pressure NN NN O
was VBD VBD O
enhanced VBN VBN O
approximately RB RB O
22 CD CD O
- : : O
fold NN NN O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
15 CD CD O
- : : O
day NN NN O
isoproterenol JJ JJ B-CHEM
pretreatment NN NN O
not RB RB O
only RB RB O
abolished VB VB O
but CC CC O
reversed VBN VBN O
bromocriptine NN NN B-CHEM
- - - O
induced JJ JJ O
tachycardia NN NN O
to TO TO O
bradycardia NNS NNS O
, , , O
an DT DT O
effect NN NN O
that WDT WDT O
is VBZ VBZ O
mainly RB RB O
related VBN VBN O
to TO TO O
further JJ JJ O
cardiac JJ JJ O
beta NN NN O
- - - O
adrenoceptor NN NN O
desensitization NN NN O
rather RB RB O
than IN IN O
to TO TO O
impairment NN NN O
of IN IN O
autonomic JJ JJ O
regulation NN NN O
of IN IN O
the DT DT O
heart NN NN O
. . . O

They PRP PRP O
suggest VBP VBP O
that IN IN O
, , , O
in IN IN O
normal JJ JJ O
conscious JJ JJ O
rats NNS NNS O
, , , O
the DT DT O
central JJ JJ O
tachycardia NNS NNS O
of IN IN O
bromocriptine NN NN B-CHEM
appears VBZ VBZ O
to TO TO O
predominate VB VB O
and CC CC O
to TO TO O
mask VB VB O
the DT DT O
bradycardia NN NN O
of IN IN O
this DT DT O
agonist NN NN O
at IN IN O
peripheral JJ JJ O
dopamine NN NN B-CHEM
D2 NN NN O
receptors NNS NNS O
. . . O

A DT DT O
developmental JJ JJ O
analysis NN NN O
of IN IN O
clonidine NN NN B-CHEM
' '' '' O
s VBZ VBZ O
effects NNS NNS O
on IN IN O
cardiac JJ JJ O
rate NN NN O
and CC CC O
ultrasound JJ JJ O
production NN NN O
in IN IN O
infant NN NN O
rats NNS NNS O
. . . O

Under IN IN O
controlled JJ JJ O
conditions NNS NNS O
, , , O
infant NN NN O
rats NNS NNS O
emit NN NN O
ultrasonic JJ JJ O
vocalizations NNS NNS O
during IN IN O
extreme JJ JJ O
cold JJ JJ O
exposure NN NN O
and CC CC O
after IN IN O
administration NN NN O
of IN IN O
the DT DT O
alpha NN NN O
( ( ( O
2 CD CD O
) ) ) O
adrenoceptor NN NN O
agonist NN NN O
, , , O
clonidine NN NN B-CHEM
. . . O

Previous JJ JJ O
investigations NNS NNS O
have VBP VBP O
determined VBN VBN O
that IN IN O
, , , O
in IN IN O
response NN NN O
to TO TO O
clonidine NN NN B-CHEM
, , , O
ultrasound NN NN O
production NN NN O
increases NNS NNS O
through IN IN O
the DT DT O
2nd CD CD O
- : : O
week NN NN O
postpartum NN NN O
and CC CC O
decreases NNS NNS O
thereafter RB RB O
. . . O

Given VBN VBN O
that DT DT O
sympathetic JJ JJ O
neural NN NN O
dominance NN NN O
exhibits VBZ VBZ O
a DT DT O
similar JJ JJ O
developmental NN NN O
pattern NN NN O
, , , O
and CC CC O
given VBN VBN O
that IN IN O
clonidine NN NN B-CHEM
induces NNS NNS O
sympathetic JJ JJ O
withdrawal NN NN O
and CC CC O
bradycardia NN NN O
, , , O
we PRP PRP O
hypothesized VBN VBN O
that IN IN O
clonidine NN NN B-CHEM
' '' '' O
s VBZ VBZ O
developmental NN NN O
effects NNS NNS O
on IN IN O
cardiac JJ JJ O
rate NN NN O
and CC CC O
ultrasound NN NN O
production NN NN O
would MD MD O
mirror VB VB O
each DT DT O
other JJ JJ O
. . . O

Therefore RB RB O
, , , O
in IN IN O
the DT DT O
present JJ JJ O
experiment NN NN O
, , , O
the DT DT O
effects NNS NNS O
of IN IN O
clonidine NN NN B-CHEM
administration NN NN O
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
on IN IN O
cardiac JJ JJ O
rate NN NN O
and CC CC O
ultrasound JJ JJ O
production NN NN O
were VBD VBD O
examined VBN VBN O
in IN IN O
2 CD CD O
- : : O
, , , O
8 CD CD O
- : : O
, , , O
15 CD CD O
- : : O
, , , O
and CC CC O
20 CD CD O
- : : O
day NN NN O
- : : O
old JJ JJ O
rats NNS NNS O
. . . O

Age NNP NNP O
- - - O
related VBN VBN O
changes NNS NNS O
in IN IN O
ultrasound NN NN O
production NN NN O
corresponded VBN VBN O
with IN IN O
changes NNS NNS O
in IN IN O
cardiovascular JJ JJ O
variables NNS NNS O
, , , O
including VBG VBG O
baseline NN NN O
cardiac NN NN O
rate NN NN O
and CC CC O
clonidine NN NN B-CHEM
- - - O
induced JJ JJ O
bradycardia NN NN O
. . . O

This DT DT O
experiment NN NN O
is VBZ VBZ O
discussed VBN VBN O
with IN IN O
regard NN NN O
to TO TO O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
ultrasound NN NN O
production NN NN O
is VBZ VBZ O
the DT DT O
acoustic JJ JJ O
by IN IN O
- - - O
product NN NN O
of IN IN O
a DT DT O
physiological JJ JJ O
maneuver NN NN O
that WDT WDT O
compensates VBZ VBZ O
for IN IN O
clonidine NN NN B-CHEM
' '' '' O
s VBZ VBZ O
detrimental JJ JJ O
effects NNS NNS O
on IN IN O
cardiovascular JJ JJ O
function NN NN O
. . . O

Recurrent NNP NNP O
use NN NN O
of IN IN O
newer NN NN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
and CC CC O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
. . . O

The DT DT O
epidemiological JJ JJ O
studies NNS NNS O
that WDT WDT O
assessed VBD VBD O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
( ( ( O
VTE NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
newer JJR JJR O
oral NN NN B-CHEM
contraceptives NNS NNS I-CHEM
( ( ( O
OC NNP NNP B-CHEM
) ) ) O
did VBD VBD O
not RB RB O
distinguish VB VB O
between IN IN O
patterns NNS NNS O
of IN IN O
OC NNP NNP B-CHEM
use NN NN O
, , , O
namely RB RB O
first JJ JJ O
- - - O
time NN NN O
users NNS NNS O
, , , O
repeaters NNS NNS O
and CC CC O
switchers NNS NNS O
. . . O

Data NNP NNP O
from IN IN O
a DT DT O
Transnational NNP NNP O
case NN NN O
- : : O
control NN NN O
study NN NN O
were VBD VBD O
used VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
risk NN NN O
of IN IN O
VTE NNP NNP O
for IN IN O
the DT DT O
latter JJ JJ O
patterns NNS NNS O
of IN IN O
use NN NN O
, , , O
while IN IN O
accounting VBG VBG O
for IN IN O
duration NN NN O
of IN IN O
use NN NN O
. . . O

Over IN IN O
the DT DT O
period NN NN O
1993 CD CD O
- : : O
1996 CD CD O
, , , O
551 CD CD O
cases NNS NNS O
of IN IN O
VTE NNP NNP O
were VBD VBD O
identified VBN VBN O
in IN IN O
Germany NNP NNP O
and CC CC O
the DT DT O
UK NNP NNP O
along IN IN O
with IN IN O
2066 CD CD O
controls NNS NNS O
. . . O

Totals NNP NNP O
of IN IN O
128 CD CD O
cases NNS NNS O
and CC CC O
650 CD CD O
controls NNS NNS O
were VBD VBD O
analysed VBN VBN O
for IN IN O
repeat NN NN O
use NN NN O
and CC CC O
135 CD CD O
cases NNS NNS O
and CC CC O
622 CD CD O
controls NNS NNS O
for IN IN O
switching VBG VBG O
patterns NNS NNS O
. . . O

The DT DT O
adjusted JJ JJ O
rate NN NN O
ratio NN NN O
of IN IN O
VTE NNP NNP O
for IN IN O
repeat NN NN O
users NNS NNS O
of IN IN O
third JJ JJ O
generation NN NN O
OC NNP NNP B-CHEM
was VBD VBD O
0 CD CD O
. . . O
6 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
3 CD CD O
- : : O
1 CD CD O
. . . O
2 CD CD O
) ) ) O
relative JJ JJ O
to TO TO O
repeat VB VB O
users NNS NNS O
of IN IN O
second JJ JJ O
generation NN NN O
pills NNS NNS O
, , , O
whereas IN IN O
it PRP PRP O
was VBD VBD O
1 CD CD O
. . . O
3 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
7 CD CD O
- : : O
2 CD CD O
. . . O
4 CD CD O
) ) ) O
for IN IN O
switchers NNS NNS O
from IN IN O
second JJ JJ O
to TO TO O
third JJ JJ O
generation NN NN O
pills NNS NNS O
relative JJ JJ O
to TO TO O
switchers NNS NNS O
from IN IN O
third JJ JJ O
to TO TO O
second JJ JJ O
generation NN NN O
pills NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
second JJ JJ O
and CC CC O
third JJ JJ O
generation NN NN O
agents NNS NNS O
are VBP VBP O
associated VBN VBN O
with IN IN O
equivalent JJ JJ O
risks NNS NNS O
of IN IN O
VTE NNP NNP O
when WRB WRB O
the DT DT O
same JJ JJ O
agent NN NN O
is VBZ VBZ O
used VBN VBN O
repeatedly RB RB O
after IN IN O
interruption NN NN O
periods NNS NNS O
or CC CC O
when WRB WRB O
users NNS NNS O
are VBP VBP O
switched VBN VBN O
between IN IN O
the DT DT O
two CD CD O
generations NNS NNS O
of IN IN O
pills NNS NNS O
. . . O

These DT DT O
analyses NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
higher JJR JJR O
risk NN NN O
observed VBD VBD O
for IN IN O
the DT DT O
newer JJR JJR O
OC NNP NNP B-CHEM
in IN IN O
other JJ JJ O
studies NNS NNS O
may MD MD O
be VB VB O
the DT DT O
result NN NN O
of IN IN O
inadequate JJ JJ O
comparisons NNS NNS O
of IN IN O
pill NN NN O
users NNS NNS O
with IN IN O
different JJ JJ O
patterns NNS NNS O
of IN IN O
pill NN NN O
use NN NN O
. . . O

Differential NNP NNP O
effects NNS NNS O
of IN IN O
systemically RB RB O
administered VBN VBN O
ketamine NN NN B-CHEM
and CC CC O
lidocaine NN NN B-CHEM
on IN IN O
dynamic JJ JJ O
and CC CC O
static JJ JJ O
hyperalgesia NN NN O
induced VBN VBN O
by IN IN O
intradermal JJ JJ O
capsaicin NN NN B-CHEM
in IN IN O
humans NNS NNS O
. . . O

We PRP PRP O
have VBP VBP O
examined VBN VBN O
the DT DT O
effect NN NN O
of IN IN O
systemic JJ JJ O
administration NN NN O
of IN IN O
ketamine NN NN B-CHEM
and CC CC O
lidocaine NN NN B-CHEM
on IN IN O
brush NN NN O
- : : O
evoked JJ JJ O
( ( ( O
dynamic JJ JJ O
) ) ) O
pain NN NN O
and CC CC O
punctate JJ JJ O
- - - O
evoked JJ JJ O
( ( ( O
static JJ JJ O
) ) ) O
hyperalgesia NN NN O
induced VBN VBN O
by IN IN O
capsaicin NN NN B-CHEM
. . . O

In IN IN O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
crossover NN NN O
study NN NN O
, , , O
we PRP PRP O
studied VBD VBD O
12 CD CD O
volunteers NNS NNS O
in IN IN O
three CD CD O
experiments NNS NNS O
. . . O

Capsaicin NNP NNP B-CHEM
100 CD CD O
micrograms NNS NNS O
was VBD VBD O
injected VBN VBN O
intradermally RB RB O
on IN IN O
the DT DT O
volar JJ JJ O
forearm NN NN O
followed VBN VBN O
by IN IN O
an DT DT O
i NNP NNP O
. . . O
v NN NN O
. . . O
infusion NN NN O
of IN IN O
ketamine NN NN B-CHEM
( ( ( O
bolus NN NN O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
over IN IN O
10 CD CD O
min NN NN O
followed VBN VBN O
by IN IN O
infusion NN NN O
of IN IN O
7 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
min NN NN O
- : : O
1 CD CD O
) ) ) O
, , , O
lidocaine NN NN B-CHEM
5 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
or CC CC O
saline NN NN O
for IN IN O
50 CD CD O
min NN NN O
. . . O

Infusion NNP NNP O
started VBD VBD O
15 CD CD O
min NN NN O
after IN IN O
injection NN NN O
of IN IN O
capsaicin NN NN B-CHEM
. . . O

The DT DT O
following VBG VBG O
were VBD VBD O
measured VBN VBN O
: : : O
spontaneous JJ JJ O
pain NN NN O
, , , O
pain NN NN O
evoked VBN VBN O
by IN IN O
punctate NN NN O
and CC CC O
brush NN NN O
stimuli NN NN O
( ( ( O
VAS NNP NNP O
) ) ) O
, , , O
and CC CC O
areas NNS NNS O
of IN IN O
brush NN NN O
- - - O
evoked JJ JJ O
and CC CC O
punctate JJ JJ O
- - - O
evoked JJ JJ O
hyperalgesia NN NN O
. . . O

Ketamine NNP NNP B-CHEM
reduced VBD VBD O
both DT DT O
the DT DT O
area NN NN O
of IN IN O
brush NN NN O
- - - O
evoked JJ JJ O
and CC CC O
punctate JJ JJ O
- - - O
evoked JJ JJ O
hyperalgesia NN NN O
significantly RB RB O
and CC CC O
it PRP PRP O
tended VBD VBD O
to TO TO O
reduce VB VB O
brush NN NN O
- - - O
evoked JJ JJ O
pain NN NN O
. . . O

Lidocaine NNP NNP B-CHEM
reduced VBD VBD O
the DT DT O
area NN NN O
of IN IN O
punctate NN NN O
- - - O
evoked JJ JJ O
hyperalgesia NN NN O
significantly RB RB O
. . . O

It PRP PRP O
tended VBD VBD O
to TO TO O
reduce VB VB O
VAS NNP NNP O
scores NNS NNS O
of IN IN O
spontaneous JJ JJ O
pain NN NN O
but CC CC O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
evoked JJ JJ O
pain NN NN O
. . . O

The DT DT O
differential JJ JJ O
effects NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
and CC CC O
lidocaine NN NN B-CHEM
on IN IN O
static JJ JJ O
and CC CC O
dynamic JJ JJ O
hyperalgesia NN NN O
suggest VBP VBP O
that IN IN O
the DT DT O
two CD CD O
types NNS NNS O
of IN IN O
hyperalgesia NN NN O
are VBP VBP O
mediated VBN VBN O
by IN IN O
separate JJ JJ O
mechanisms NNS NNS O
and CC CC O
have VBP VBP O
a DT DT O
distinct JJ JJ O
pharmacology NN NN O
. . . O

Development NNP NNP O
of IN IN O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
aggressive JJ JJ O
behavior NN NN O
: : : O
comparison NN NN O
of IN IN O
adult NN NN O
male NN NN O
and CC CC O
female JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
. . . O

The DT DT O
development NN NN O
of IN IN O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
( ( ( O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
once RB RB O
daily JJ JJ O
) ) ) O
aggressive JJ JJ O
behavior NN NN O
of IN IN O
adult NN NN O
male NN NN O
and CC CC O
female JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
obtained VBN VBN O
from IN IN O
the DT DT O
same JJ JJ O
breeder NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
two CD CD O
consecutive JJ JJ O
sets NNS NNS O
. . . O

In IN IN O
male JJ JJ O
animals NNS NNS O
, , , O
repeated VBN VBN O
apomorphine JJ JJ B-CHEM
treatment NN NN O
induced VBD VBD O
a DT DT O
gradual JJ JJ O
development NN NN O
of IN IN O
aggressive JJ JJ O
behavior NN NN O
as IN IN O
evidenced VBN VBN O
by IN IN O
the DT DT O
increased JJ JJ O
intensity NN NN O
of IN IN O
aggressiveness NN NN O
and CC CC O
shortened VBD VBD O
latency NN NN O
before IN IN O
the DT DT O
first JJ JJ O
attack NN NN O
toward IN IN O
the DT DT O
opponent NN NN O
. . . O

In IN IN O
female JJ JJ O
rats NNS NNS O
, , , O
only RB RB O
a DT DT O
weak JJ JJ O
tendency NN NN O
toward IN IN O
aggressiveness NN NN O
was VBD VBD O
found VBN VBN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
the DT DT O
present JJ JJ O
study NN NN O
demonstrates VBZ VBZ O
gender NN NN O
differences NNS NNS O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
the DT DT O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
aggressive JJ JJ O
behavior NN NN O
and CC CC O
indicates VBZ VBZ O
that IN IN O
the DT DT O
female JJ JJ O
rats NNS NNS O
do VBP VBP O
not RB RB O
fill VB VB O
the DT DT O
validation NN NN O
criteria NNS NNS O
for IN IN O
use NN NN O
in IN IN O
this DT DT O
method NN NN O
. . . O

Intracranial NNP NNP O
aneurysms NNS NNS O
and CC CC O
cocaine NN NN O
abuse NN NN O
: : : O
analysis NN NN O
of IN IN O
prognostic JJ JJ O
indicators NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
outcome NN NN O
of IN IN O
subarachnoid NN NN O
hemorrhage NN NN O
associated VBN VBN O
with IN IN O
cocaine NN NN O
abuse NN NN O
is VBZ VBZ O
reportedly RB RB O
poor JJ JJ O
. . . O

However RB RB O
, , , O
no DT DT O
study NN NN O
in IN IN O
the DT DT O
literature NN NN O
has VBZ VBZ O
reported VBN VBN O
the DT DT O
use NN NN O
of IN IN O
a DT DT O
statistical JJ JJ O
model NN NN O
to TO TO O
analyze VB VB O
the DT DT O
variables NNS NNS O
that WDT WDT O
influence NN NN O
outcome NN NN O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
review NN NN O
of IN IN O
admissions NNS NNS O
during IN IN O
a DT DT O
6 CD CD O
- : : O
year NN NN O
period NN NN O
revealed VBD VBD O
14 CD CD O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
related VBN VBN O
aneurysms NNS NNS O
. . . O

This DT DT O
group NN NN O
was VBD VBD O
compared VBN VBN O
with IN IN O
a DT DT O
control NN NN O
group NN NN O
of IN IN O
135 CD CD O
patients NNS NNS O
with IN IN O
ruptured JJ JJ O
aneurysms NNS NNS O
and CC CC O
no DT DT O
history NN NN O
of IN IN O
cocaine NN NN O
abuse NN NN O
. . . O

Age NNP NNP O
at IN IN O
presentation NN NN O
, , , O
time NN NN O
of IN IN O
ictus NN NN O
after IN IN O
intoxication NN NN O
, , , O
Hunt NNP NNP O
and CC CC O
Hess NNP NNP O
grade NN NN O
of IN IN O
subarachnoid NN NN O
hemorrhage NN NN O
, , , O
size NN NN O
of IN IN O
the DT DT O
aneurysm NN NN O
, , , O
location NN NN O
of IN IN O
the DT DT O
aneurysm NN NN O
, , , O
and CC CC O
the DT DT O
Glasgow NNP NNP O
Outcome NNP NNP O
Scale NNP NNP O
score NN NN O
were VBD VBD O
assessed VBN VBN O
and CC CC O
compared VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
patients NNS NNS O
in IN IN O
the DT DT O
study NN NN O
group NN NN O
were VBD VBD O
significantly RB RB O
younger JJR JJR O
than IN IN O
the DT DT O
patients NNS NNS O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

In IN IN O
patients NNS NNS O
in IN IN O
the DT DT O
study NN NN O
group NN NN O
, , , O
all DT DT O
aneurysms NNS NNS O
were VBD VBD O
located VBN VBN O
in IN IN O
the DT DT O
anterior NN NN O
circulation NN NN O
. . . O

The DT DT O
majority NN NN O
of IN IN O
these DT DT O
aneurysms NNS NNS O
were VBD VBD O
smaller JJR JJR O
than IN IN O
those DT DT O
of IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
08 CD CD O
mm NN NN O
versus CC CC O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
4 CD CD O
mm NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
differences NNS NNS O
in IN IN O
mortality NN NN O
and CC CC O
morbidity NN NN O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
were VBD VBD O
not RB RB O
significant JJ JJ O
. . . O

Hunt NNP NNP O
and CC CC O
Hess NNP NNP O
grade NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
and CC CC O
age NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
007 CD CD O
) ) ) O
were VBD VBD O
significant JJ JJ O
predictors NNS NNS O
of IN IN O
outcome NN NN O
for IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
related VBN VBN O
aneurysms NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Cocaine NNP NNP B-CHEM
use NN NN O
predisposed VBD VBD O
aneurysmal JJ JJ O
rupture NN NN O
at IN IN O
a DT DT O
significantly RB RB O
earlier RBR RBR O
age NN NN O
and CC CC O
in IN IN O
much JJ JJ O
smaller JJR JJR O
aneurysms NN NN O
. . . O

Contrary NNP NNP O
to TO TO O
the DT DT O
published VBN VBN O
literature NN NN O
, , , O
this DT DT O
group NN NN O
did VBD VBD O
reasonably RB RB O
well RB RB O
with IN IN O
aggressive JJ JJ O
management NN NN O
. . . O

Effect NN NN O
of IN IN O
intravenous JJ JJ O
nimodipine NN NN B-CHEM
on IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
outcome NN NN O
after IN IN O
acute JJ JJ O
stroke NN NN O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
PURPOSE NNP NNP O
: : : O
The DT DT O
Intravenous NNP NNP O
Nimodipine NNP NNP B-CHEM
West NNP NNP O
European JJ JJ O
Stroke NNP NNP O
Trial NN NN O
( ( ( O
INWEST NNP NNP O
) ) ) O
found VBD VBD O
a DT DT O
correlation NN NN O
between IN IN O
nimodipine NN NN B-CHEM
- - - O
induced JJ JJ O
reduction NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
and CC CC O
an DT DT O
unfavorable JJ JJ O
outcome NN NN O
in IN IN O
acute JJ JJ O
stroke NN NN O
. . . O

We PRP PRP O
sought VBD VBD O
to TO TO O
confirm VB VB O
this DT DT O
correlation NN NN O
with IN IN O
and CC CC O
without IN IN O
adjustment NN NN O
for IN IN O
prognostic JJ JJ O
variables NNS NNS O
and CC CC O
to TO TO O
investigate VB VB O
outcome NN NN O
in IN IN O
subgroups NNS NNS O
with IN IN O
increasing VBG VBG O
levels NNS NNS O
of IN IN O
BP NNP NNP O
reduction NN NN O
. . . O

METHODS NNP NNP O
: : : O
Patients NNS NNS O
with IN IN O
a DT DT O
clinical JJ JJ O
diagnosis NN NN O
of IN IN O
ischemic JJ JJ O
stroke NN NN O
( ( ( O
within IN IN O
24 CD CD O
hours NNS NNS O
) ) ) O
were VBD VBD O
consecutively RB RB O
allocated VBN VBN O
to TO TO O
receive VB VB O
placebo NN NN O
( ( ( O
n NN NN O
= SYM SYM O
100 CD CD O
) ) ) O
, , , O
1 CD CD O
mg NN NN O
/ NN NN O
h NN NN O
( ( ( O
low JJ JJ O
- - - O
dose NN NN O
) ) ) O
nimodipine NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
101 CD CD O
) ) ) O
, , , O
or CC CC O
2 CD CD O
mg NN NN O
/ NN NN O
h NN NN O
( ( ( O
high JJ JJ O
- - - O
dose NN NN O
) ) ) O
nimodipine NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
94 CD CD O
) ) ) O
. . . O

The DT DT O
correlation NN NN O
between IN IN O
average JJ JJ O
BP NNP NNP O
change NN NN O
during IN IN O
the DT DT O
first JJ JJ O
2 CD CD O
days NNS NNS O
and CC CC O
the DT DT O
outcome NN NN O
at IN IN O
day NN NN O
21 CD CD O
was VBD VBD O
analyzed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Two CD CD O
hundred CD CD O
sixty NN NN O
- : : O
five CD CD O
patients NNS NNS O
were VBD VBD O
included VBN VBN O
in IN IN O
this DT DT O
analysis NN NN O
( ( ( O
n NN NN O
= SYM SYM O
92 CD CD O
, , , O
93 CD CD O
, , , O
and CC CC O
80 CD CD O
for IN IN O
placebo NN NN O
, , , O
low JJ JJ O
dose NN NN O
, , , O
and CC CC O
high JJ JJ O
dose NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

Nimodipine NNP NNP B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
statistically RB RB O
significant JJ JJ O
reduction NN NN O
in IN IN O
systolic JJ JJ O
BP NNP NNP O
( ( ( O
SBP NNP NNP O
) ) ) O
and CC CC O
diastolic JJ JJ O
BP NNP NNP O
( ( ( O
DBP NNP NNP O
) ) ) O
from IN IN O
baseline NN NN O
compared VBN VBN O
with IN IN O
placebo NN NN O
during IN IN O
the DT DT O
first JJ JJ O
few JJ JJ O
days NNS NNS O
. . . O

In IN IN O
multivariate NN NN O
analysis NN NN O
, , , O
a DT DT O
significant JJ JJ O
correlation NN NN O
between IN IN O
DBP NNP NNP O
reduction NN NN O
and CC CC O
worsening VBG VBG O
of IN IN O
the DT DT O
neurological JJ JJ O
score NN NN O
was VBD VBD O
found VBN VBN O
for IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
( ( ( O
beta NN NN O
= SYM SYM O
0 CD CD O
. . . O
49 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
048 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
with IN IN O
a DT DT O
DBP NNP NNP O
reduction NN NN O
of IN IN O
> NN NN O
or CC CC O
= SYM SYM O
20 CD CD O
% NN NN O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
had VBD VBD O
a DT DT O
significantly RB RB O
increased VBN VBN O
adjusted VBN VBN O
OR CC CC O
for IN IN O
the DT DT O
compound NN NN O
outcome NN NN O
variable JJ JJ O
death NN NN O
or CC CC O
dependency NN NN O
( ( ( O
Barthel NNP NNP O
Index NNP NNP O
< NN NN O
60 CD CD O
) ) ) O
( ( ( O
n NN NN O
/ NN NN O
N NNP NNP O
= SYM SYM O
25 CD CD O
/ NN NN O
26 CD CD O
, , , O
OR CC CC O
10 CD CD O
. . . O
16 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
02 CD CD O
to TO TO O
101 CD CD O
. . . O
74 CD CD O
) ) ) O
and CC CC O
death NN NN O
alone RB RB O
( ( ( O
n NN NN O
/ NN NN O
N NNP NNP O
= SYM SYM O
9 CD CD O
/ NN NN O
26 CD CD O
, , , O
OR CC CC O
4 CD CD O
. . . O
336 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
131 CD CD O
16 CD CD O
. . . O
619 CD CD O
) ) ) O
compared VBN VBN O
with IN IN O
all DT DT O
placebo NN NN O
patients NNS NNS O
( ( ( O
n NN NN O
/ NN NN O
N NNP NNP O
= SYM SYM O
62 CD CD O
/ NN NN O
92 CD CD O
and CC CC O
14 CD CD O
/ NN NN O
92 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
correlation NN NN O
between IN IN O
SBP NNP NNP O
change NN NN O
and CC CC O
outcome NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
DBP NNP NNP O
, , , O
but CC CC O
not RB RB O
SBP NNP NNP O
, , , O
reduction NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
neurological JJ JJ O
worsening NN NN O
after IN IN O
the DT DT O
intravenous JJ JJ O
administration NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
nimodipine NN NN B-CHEM
after IN IN O
acute JJ JJ O
stroke NN NN O
. . . O

For IN IN O
low JJ JJ O
- - - O
dose NN NN O
nimodipine NN NN B-CHEM
, , , O
the DT DT O
results NNS NNS O
were VBD VBD O
not RB RB O
conclusive JJ JJ O
. . . O

These DT DT O
results NNS NNS O
do VBP VBP O
not RB RB O
confirm VB VB O
or CC CC O
exclude VB VB O
a DT DT O
neuroprotective JJ JJ O
property NN NN O
of IN IN O
nimodipine NN NN B-CHEM
. . . O

Neonatal NNP NNP O
pyridoxine NN NN B-CHEM
responsive JJ JJ O
convulsions NNS NNS O
due JJ JJ O
to TO TO O
isoniazid VB VB B-CHEM
therapy NN NN O
. . . O

A DT DT O
17 CD CD O
- : : O
day NN NN O
- : : O
old JJ JJ O
infant NN NN O
on IN IN O
isoniazid NN NN B-CHEM
therapy NN NN O
13 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
daily JJ JJ O
from IN IN O
birth NN NN O
because IN IN O
of IN IN O
maternal JJ JJ O
tuberculosis NN NN O
was VBD VBD O
admitted VBN VBN O
after IN IN O
4 CD CD O
days NNS NNS O
of IN IN O
clonic JJ JJ O
fits NNS NNS O
. . . O

No DT DT O
underlying VBG VBG O
infective JJ JJ O
or CC CC O
biochemical JJ JJ O
cause NN NN O
could MD MD O
be VB VB O
found VBN VBN O
. . . O

The DT DT O
fits NNS NNS O
ceased VBN VBN O
within IN IN O
4 CD CD O
hours NNS NNS O
of IN IN O
administering VBG VBG O
intramuscular JJ JJ O
pyridoxine NN NN B-CHEM
, , , O
suggesting VBG VBG O
an DT DT O
aetiology NN NN O
of IN IN O
pyridoxine NN NN B-CHEM
deficiency NN NN O
secondary JJ JJ O
to TO TO O
isoniazid VB VB B-CHEM
medication NN NN O
. . . O

Ketamine NNP NNP B-CHEM
sedation NN NN O
for IN IN O
the DT DT O
reduction NN NN O
of IN IN O
children NNS NNS O
' POS POS O
s VBZ VBZ O
fractures NNS NNS O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
There EX EX O
recently RB RB O
has VBZ VBZ O
been VBN VBN O
a DT DT O
resurgence NN NN O
in IN IN O
the DT DT O
utilization NN NN O
of IN IN O
ketamine NN NN B-CHEM
, , , O
a DT DT O
unique JJ JJ O
anesthetic JJ JJ O
, , , O
for IN IN O
emergency NN NN O
- - - O
department NN NN O
procedures NNS NNS O
requiring VBG VBG O
sedation NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
examine VB VB O
the DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
ketamine NN NN B-CHEM
for IN IN O
sedation NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
children NNS NNS O
' POS POS O
s VBZ VBZ O
fractures NNS NNS O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
. . . O

METHODS NNP NNP O
: : : O
One CD CD O
hundred CD CD O
and CC CC O
fourteen CD CD O
children NNS NNS O
( ( ( O
average JJ JJ O
age NN NN O
, , , O
5 CD CD O
. . . O
3 CD CD O
years NNS NNS O
; : : O
range NN NN O
, , , O
twelve CD CD O
months NNS NNS O
to TO TO O
ten CD CD O
years NNS NNS O
and CC CC O
ten CD CD O
months NNS NNS O
) ) ) O
who WP WP O
underwent VBD VBD O
closed JJ JJ O
reduction NN NN O
of IN IN O
an DT DT O
isolated JJ JJ O
fracture NN NN O
or CC CC O
dislocation NN NN O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
at IN IN O
a DT DT O
level NN NN O
- - - O
I PRP PRP O
trauma NN NN O
center NN NN O
were VBD VBD O
prospectively RB RB O
evaluated VBN VBN O
. . . O

Ketamine NNP NNP B-CHEM
hydrochloride NN NN I-CHEM
was VBD VBD O
administered VBN VBN O
intravenously RB RB O
( ( ( O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
two CD CD O
milligrams NNS NNS O
per IN IN O
kilogram NN NN O
of IN IN O
body NN NN O
weight NN NN O
) ) ) O
in IN IN O
ninety CD CD O
- - - O
nine CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
and CC CC O
intramuscularly RB RB O
( ( ( O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
four CD CD O
milligrams NNS NNS O
per IN IN O
kilogram NN NN O
of IN IN O
body NN NN O
weight NN NN O
) ) ) O
in IN IN O
the DT DT O
other JJ JJ O
fifteen NN NN O
. . . O

A DT DT O
board NN NN O
- - - O
certified JJ JJ O
emergency NN NN O
physician NN NN O
skilled JJ JJ O
in IN IN O
airway NN NN O
management NN NN O
supervised JJ JJ O
administration NN NN O
of IN IN O
the DT DT O
anesthetic JJ JJ O
, , , O
and CC CC O
the DT DT O
patients NNS NNS O
were VBD VBD O
monitored VBN VBN O
by IN IN O
a DT DT O
registered JJ JJ O
nurse NN NN O
. . . O

Any DT DT O
pain NN NN O
during IN IN O
the DT DT O
reduction NN NN O
was VBD VBD O
rated VBN VBN O
by IN IN O
the DT DT O
orthopaedic NN NN O
surgeon NN NN O
treating VBG VBG O
the DT DT O
patient NN NN O
according VBG VBG O
to TO TO O
the DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
of IN IN O
Eastern NNP NNP O
Ontario NNP NNP O
Pain NN NN O
Scale NNP NNP O
( ( ( O
CHEOPS NNP NNP O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
average JJ JJ O
time NN NN O
from IN IN O
intravenous JJ JJ O
administration NN NN O
of IN IN O
ketamine NN NN B-CHEM
to TO TO O
manipulation NN NN O
of IN IN O
the DT DT O
fracture NN NN O
or CC CC O
dislocation NN NN O
was VBD VBD O
one CD CD O
minute NN NN O
and CC CC O
thirty NN NN O
- - - O
six CD CD O
seconds NNS NNS O
( ( ( O
range NN NN O
, , , O
twenty CD CD O
seconds NNS NNS O
to TO TO O
five CD CD O
minutes NNS NNS O
) ) ) O
, , , O
and CC CC O
the DT DT O
average JJ JJ O
time NN NN O
from IN IN O
intramuscular JJ JJ O
administration NN NN O
to TO TO O
manipulation NN NN O
was VBD VBD O
four CD CD O
minutes NNS NNS O
and CC CC O
forty NN NN O
- - - O
two CD CD O
seconds NNS NNS O
( ( ( O
range NN NN O
, , , O
sixty CD CD O
seconds NNS NNS O
to TO TO O
fifteen VB VB O
minutes NNS NNS O
) ) ) O
. . . O

The DT DT O
average JJ JJ O
score NN NN O
according VBG VBG O
to TO TO O
the DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
of IN IN O
Eastern NNP NNP O
Ontario NNP NNP O
Pain NN NN O
Scale NNP NNP O
was VBD VBD O
6 CD CD O
. . . O
4 CD CD O
points NNS NNS O
( ( ( O
range NN NN O
, , , O
5 CD CD O
to TO TO O
10 CD CD O
points NNS NNS O
) ) ) O
, , , O
reflecting VBG VBG O
minimal JJ JJ O
or CC CC O
no DT DT O
pain NN NN O
during IN IN O
fracture NN NN O
reduction NN NN O
. . . O

Adequate NNP NNP O
fracture NN NN O
reduction NN NN O
was VBD VBD O
obtained VBN VBN O
in IN IN O
111 CD CD O
of IN IN O
the DT DT O
children NNS NNS O
. . . O

Ninety CD CD O
- - - O
nine CD CD O
percent NN NN O
( ( ( O
sixty NN NN O
- - - O
eight CD CD O
) ) ) O
of IN IN O
the DT DT O
sixty NN NN O
- - - O
nine CD CD O
parents NNS NNS O
present JJ JJ O
during IN IN O
the DT DT O
reduction NN NN O
were VBD VBD O
pleased VBN VBN O
with IN IN O
the DT DT O
sedation NN NN O
and CC CC O
would MD MD O
allow VB VB O
it PRP PRP O
to TO TO O
be VB VB O
used VBN VBN O
again RB RB O
in IN IN O
a DT DT O
similar JJ JJ O
situation NN NN O
. . . O

Patency NNP NNP O
of IN IN O
the DT DT O
airway NN NN O
and CC CC O
independent JJ JJ O
respiration NN NN O
were VBD VBD O
maintained VBN VBN O
in IN IN O
all DT DT O
of IN IN O
the DT DT O
patients NNS NNS O
. . . O

Blood NNP NNP O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
remained VBD VBD O
stable JJ JJ O
. . . O

Minor NNP NNP O
side NN NN O
effects NNS NNS O
included VBN VBN O
nausea NN NN O
( ( ( O
thirteen NN NN O
patients NNS NNS O
) ) ) O
, , , O
emesis NN NN O
( ( ( O
eight CD CD O
of IN IN O
the DT DT O
thirteen NN NN O
patients NNS NNS O
with IN IN O
nausea NN NN O
) ) ) O
, , , O
clumsiness NN NN O
( ( ( O
evident NN NN O
as IN IN O
ataxic JJ JJ O
movements NNS NNS O
in IN IN O
ten CD CD O
patients NNS NNS O
) ) ) O
, , , O
and CC CC O
dysphoric JJ JJ O
reaction NN NN O
( ( ( O
one CD CD O
patient NN NN O
) ) ) O
. . . O

No DT DT O
long JJ JJ O
- - - O
term NN NN O
sequelae NN NN O
were VBD VBD O
noted VBN VBN O
, , , O
and CC CC O
no DT DT O
patients NNS NNS O
had VBD VBD O
hallucinations NNS NNS O
or CC CC O
nightmares NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Ketamine NNP NNP B-CHEM
reliably RB RB O
, , , O
safely RB RB O
, , , O
and CC CC O
quickly RB RB O
provided VBD VBD O
adequate JJ JJ O
sedation NN NN O
to TO TO O
effectively RB RB O
facilitate VB VB O
the DT DT O
reduction NN NN O
of IN IN O
children NNS NNS O
' POS POS O
s VBZ VBZ O
fractures NNS NNS O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
at IN IN O
our PRP$ PRP$ O
institution NN NN O
. . . O

Ketamine NNP NNP B-CHEM
should MD MD O
only RB RB O
be VB VB O
used VBN VBN O
in IN IN O
an DT DT O
environment NN NN O
such JJ JJ O
as IN IN O
the DT DT O
emergency NN NN O
department NN NN O
, , , O
where WRB WRB O
proper JJ JJ O
one CD CD O
- - - O
on IN IN O
- : : O
one CD CD O
monitoring VBG VBG O
is VBZ VBZ O
used VBN VBN O
and CC CC O
board NN NN O
- - - O
certified JJ JJ O
physicians NNS NNS O
skilled JJ JJ O
in IN IN O
airway NN NN O
management NN NN O
are VBP VBP O
directly RB RB O
involved VBN VBN O
in IN IN O
the DT DT O
care NN NN O
of IN IN O
the DT DT O
patient NN NN O
. . . O

Cyclosporine NNP NNP B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
- - - O
associated VBN VBN O
thrombotic JJ JJ O
microangiopathy NN NN O
. . . O

The DT DT O
development NN NN O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
( ( ( O
TMA NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
well RB RB O
documented VBN VBN O
. . . O

Treatments NNP NNP O
have VBP VBP O
included VBN VBN O
discontinuation NN NN O
or CC CC O
reduction NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
dose NN NN O
with IN IN O
or CC CC O
without IN IN O
concurrent NN NN O
plasma NN NN O
exchange NN NN O
, , , O
plasma NN NN O
infusion NN NN O
, , , O
anticoagulation NN NN O
, , , O
and CC CC O
intravenous JJ JJ O
immunoglobulin NN NN O
G NNP NNP O
infusion NN NN O
. . . O

However RB RB O
, , , O
for IN IN O
recipients NNS NNS O
of IN IN O
organ NN NN O
transplantation NN NN O
, , , O
removing VBG VBG O
the DT DT O
inciting VBG VBG O
agent NN NN O
is VBZ VBZ O
not RB RB O
without IN IN O
the DT DT O
attendant JJ JJ O
risk NN NN O
of IN IN O
precipitating VBG VBG O
acute JJ JJ O
rejection NN NN O
and CC CC O
graft NN NN O
loss NN NN O
. . . O

The DT DT O
last JJ JJ O
decade NN NN O
has VBZ VBZ O
seen VBN VBN O
the DT DT O
emergence NN NN O
of IN IN O
tacrolimus NN NN B-CHEM
as IN IN O
a DT DT O
potent JJ JJ O
immunosuppressive JJ JJ O
agent NN NN O
with IN IN O
mechanisms NNS NNS O
of IN IN O
action NN NN O
virtually RB RB O
identical JJ JJ O
to TO TO O
those DT DT O
of IN IN O
cyclosporine NN NN B-CHEM
. . . O

As IN IN O
a DT DT O
result NN NN O
, , , O
switching VBG VBG O
to TO TO O
tacrolimus NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
be VB VB O
a DT DT O
viable JJ JJ O
therapeutic JJ JJ O
option NN NN O
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
cyclosporine NN NN B-CHEM
- - - O
induced JJ JJ O
TMA NNP NNP O
. . . O

With IN IN O
the DT DT O
more JJR JJR O
widespread JJ JJ O
application NN NN O
of IN IN O
tacrolimus NN NN B-CHEM
in IN IN O
organ NN NN O
transplantation NN NN O
, , , O
tacrolimus NN NN B-CHEM
- - - O
associated VBN VBN O
TMA NNP NNP O
has VBZ VBZ O
also RB RB O
been VBN VBN O
recognized VBN VBN O
. . . O

However RB RB O
, , , O
literature NN NN O
regarding VBG VBG O
the DT DT O
incidence NN NN O
of IN IN O
the DT DT O
recurrence NN NN O
of IN IN O
TMA NNP NNP O
in IN IN O
patients NNS NNS O
exposed VBN VBN O
sequentially RB RB O
to TO TO O
cyclosporine VB VB B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
is VBZ VBZ O
limited VBN VBN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
living VBG VBG O
donor NN NN O
renal JJ JJ O
transplant NN NN O
recipient NN NN O
who WP WP O
developed VBD VBD O
cyclosporine NN NN B-CHEM
- : : O
induced JJ JJ O
TMA NNP NNP O
that WDT WDT O
responded VBD VBD O
to TO TO O
the DT DT O
withdrawal NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
in IN IN O
conjunction NN NN O
with IN IN O
plasmapheresis NN NN O
and CC CC O
fresh JJ JJ O
frozen VBN VBN O
plasma NN NN O
replacement NN NN O
therapy NN NN O
. . . O

Introduction NNP NNP O
of IN IN O
tacrolimus NN NN B-CHEM
as IN IN O
an DT DT O
alternative JJ JJ O
immunosuppressive JJ JJ O
agent NN NN O
resulted VBD VBD O
in IN IN O
the DT DT O
recurrence NN NN O
of IN IN O
TMA NNP NNP O
and CC CC O
the DT DT O
subsequent JJ JJ O
loss NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
allograft NN NN O
. . . O

Patients NNS NNS O
who WP WP O
are VBP VBP O
switched JJ JJ O
from IN IN O
cyclosporine NN NN B-CHEM
to TO TO O
tacrolimus VB VB B-CHEM
or CC CC O
vice NN NN O
versa NN NN O
should MD MD O
be VB VB O
closely RB RB O
monitored VBN VBN O
for IN IN O
the DT DT O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
of IN IN O
recurrent JJ JJ O
TMA NNP NNP O
. . . O

Analgesic NNP NNP O
effect NN NN O
of IN IN O
intravenous JJ JJ O
ketamine NN NN B-CHEM
in IN IN O
cancer NN NN O
patients NNS NNS O
on IN IN O
morphine NN NN B-CHEM
therapy NN NN O
: : : O
a DT DT O
randomized JJ JJ O
, , , O
controlled VBN VBN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
crossover NN NN O
, , , O
double JJ JJ O
- - - O
dose NN NN O
study NN NN O
. . . O

Pain NN NN O
not RB RB O
responsive JJ JJ O
to TO TO O
morphine VB VB B-CHEM
is VBZ VBZ O
often RB RB O
problematic JJ JJ O
. . . O

Animal NNP NNP O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
have VBP VBP O
suggested VBN VBN O
that IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
antagonists NNS NNS O
, , , O
such JJ JJ O
as IN IN O
ketamine NN NN B-CHEM
, , , O
may MD MD O
be VB VB O
effective JJ JJ O
in IN IN O
improving VBG VBG O
opioid NN NN O
analgesia NN NN O
in IN IN O
difficult JJ JJ O
pain NN NN O
syndromes NNS NNS O
, , , O
such JJ JJ O
as IN IN O
neuropathic JJ JJ O
pain NN NN O
. . . O

A DT DT O
slow JJ JJ O
bolus NN NN O
of IN IN O
subhypnotic JJ JJ O
doses NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
or CC CC O
0 CD CD O
. . . O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
given VBN VBN O
to TO TO O
10 CD CD O
cancer NN NN O
patients NNS NNS O
whose WP$ WP$ O
pain NN NN O
was VBD VBD O
unrelieved VBN VBN O
by IN IN O
morphine NN NN B-CHEM
in IN IN O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
crossover NN NN O
, , , O
double JJ JJ O
- - - O
dose NN NN O
study NN NN O
. . . O

Pain NN NN O
intensity NN NN O
on IN IN O
a DT DT O
0 CD CD O
to TO TO O
10 CD CD O
numerical JJ JJ O
scale NN NN O
; : : O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
, , , O
drowsiness JJ JJ O
, , , O
confusion NN NN O
, , , O
and CC CC O
dry JJ JJ O
mouth NN NN O
, , , O
using VBG VBG O
a DT DT O
scale NN NN O
from IN IN O
0 CD CD O
to TO TO O
3 CD CD O
( ( ( O
not RB RB O
at IN IN O
all DT DT O
, , , O
slight JJ JJ O
, , , O
a DT DT O
lot NN NN O
, , , O
awful JJ JJ O
) ) ) O
; : : O
Mini NNP NNP O
- : : O
Mental NNP NNP O
State NNP NNP O
Examination NNP NNP O
( ( ( O
MMSE NNP NNP O
) ) ) O
( ( ( O
0 CD CD O
- : : O
30 CD CD O
) ) ) O
; : : O
and CC CC O
arterial JJ JJ O
pressure NN NN O
were VBD VBD O
recorded VBN VBN O
before IN IN O
administration NN NN O
of IN IN O
drugs NNS NNS O
( ( ( O
T0 NNP NNP O
) ) ) O
and CC CC O
after IN IN O
30 CD CD O
minutes NNS NNS O
( ( ( O
T30 NNP NNP O
) ) ) O
, , , O
60 CD CD O
minutes NNS NNS O
( ( ( O
T60 NNP NNP O
) ) ) O
, , , O
120 CD CD O
minutes NNS NNS O
( ( ( O
T120 NNP NNP O
) ) ) O
, , , O
and CC CC O
180 CD CD O
minutes NNS NNS O
( ( ( O
T180 NNP NNP O
) ) ) O
. . . O

Ketamine NNP NNP B-CHEM
, , , O
but CC CC O
not RB RB O
saline JJ JJ O
solution NN NN O
, , , O
significantly RB RB O
reduced VBD VBD O
the DT DT O
pain NN NN O
intensity NN NN O
in IN IN O
almost RB RB O
all PDT PDT O
the DT DT O
patients NNS NNS O
at IN IN O
both DT DT O
doses NNS NNS O
. . . O

This DT DT O
effect NN NN O
was VBD VBD O
more RBR RBR O
relevant JJ JJ O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
higher JJR JJR O
doses NNS NNS O
. . . O

Hallucinations NNP NNP O
occurred VBD VBD O
in IN IN O
4 CD CD O
patients NNS NNS O
, , , O
and CC CC O
an DT DT O
unpleasant JJ JJ O
sensation NN NN O
( ( ( O
" '' '' O
empty JJ JJ O
head NN NN O
" '' '' O
) ) ) O
was VBD VBD O
also RB RB O
reported VBN VBN O
by IN IN O
2 CD CD O
patients NNS NNS O
. . . O

These DT DT O
episodes NNS NNS O
reversed VBD VBD O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
diazepam NN NN B-CHEM
1 CD CD O
mg NN NN O
intravenously RB RB O
. . . O

Significant JJ JJ O
increases NNS NNS O
in IN IN O
drowsiness NN NN O
were VBD VBD O
reported VBN VBN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
ketamine NN NN B-CHEM
in IN IN O
both DT DT O
groups NNS NNS O
and CC CC O
were VBD VBD O
more RBR RBR O
marked JJ JJ O
with IN IN O
ketamine NN NN B-CHEM
0 CD CD O
. . . O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

A DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
MMSE NNP NNP O
was VBD VBD O
observed VBN VBN O
at IN IN O
T30 NNP NNP O
in IN IN O
patients NNS NNS O
who WP WP O
received VBD VBD O
0 CD CD O
. . . O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
of IN IN O
ketamine NN NN B-CHEM
. . . O

Ketamine NNP NNP B-CHEM
can MD MD O
improve VB VB O
morphine NN NN B-CHEM
analgesia NN NN O
in IN IN O
difficult JJ JJ O
pain NN NN O
syndromes NNS NNS O
, , , O
such JJ JJ O
as IN IN O
neuropathic JJ JJ O
pain NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
occurrence NN NN O
of IN IN O
central JJ JJ O
adverse JJ JJ O
effects NNS NNS O
should MD MD O
be VB VB O
taken VBN VBN O
into IN IN O
account NN NN O
, , , O
especially RB RB O
when WRB WRB O
using VBG VBG O
higher JJR JJR O
doses NNS NNS O
. . . O

This DT DT O
observation NN NN O
should MD MD O
be VB VB O
tested VBN VBN O
in IN IN O
studies NNS NNS O
of IN IN O
prolonged JJ JJ O
ketamine NN NN B-CHEM
administration NN NN O
. . . O

Paclitaxel NNP NNP B-CHEM
, , , O
cisplatin NN NN B-CHEM
, , , O
and CC CC O
gemcitabine NN NN B-CHEM
combination NN NN O
chemotherapy NN NN O
within IN IN O
a DT DT O
multidisciplinary JJ JJ O
therapeutic JJ JJ O
approach NN NN O
in IN IN O
metastatic JJ JJ O
nonsmall NN NN O
cell NN NN O
lung NN NN O
carcinoma NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Cisplatin NNP NNP B-CHEM
- - - O
based JJ JJ O
chemotherapy NN NN O
combinations NNS NNS O
improve VBP VBP O
quality NN NN O
of IN IN O
life NN NN O
and CC CC O
survival NN NN O
in IN IN O
advanced JJ JJ O
nonsmall NN NN O
cell NN NN O
lung NN NN O
carcinoma NN NN O
( ( ( O
NSCLC NNP NNP O
) ) ) O
. . . O

The DT DT O
emergence NN NN O
of IN IN O
new JJ JJ O
active JJ JJ O
drugs NNS NNS O
might MD MD O
translate VB VB O
into IN IN O
more RBR RBR O
effective JJ JJ O
regimens NNS NNS O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
this DT DT O
disease NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
feasibility NN NN O
, , , O
response NN NN O
rate NN NN O
, , , O
and CC CC O
toxicity NN NN O
of IN IN O
a DT DT O
paclitaxel NN NN B-CHEM
, , , O
cisplatin NN NN B-CHEM
, , , O
and CC CC O
gemcitabine NN NN B-CHEM
combination NN NN O
to TO TO O
treat VB VB O
metastatic JJ JJ O
NSCLC NNP NNP O
. . . O

Thirty NNP NNP O
- : : O
five CD CD O
consecutive JJ JJ O
chemotherapy NN NN O
- - - O
naive JJ JJ O
patients NNS NNS O
with IN IN O
Stage NN NN O
IV NNP NNP O
NSCLC NNP NNP O
and CC CC O
an DT DT O
Eastern NNP NNP O
Cooperative NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
performance NN NN O
status NN NN O
of IN IN O
0 CD CD O
- : : O
2 CD CD O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
combination NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
( ( ( O
135 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
given VBN VBN O
intravenously RB RB O
in IN IN O
3 CD CD O
hours NNS NNS O
) ) ) O
on IN IN O
Day NNP NNP O
1 CD CD O
, , , O
cisplatin NN NN B-CHEM
( ( ( O
120 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
given VBN VBN O
intravenously RB RB O
in IN IN O
6 CD CD O
hours NNS NNS O
) ) ) O
on IN IN O
Day NNP NNP O
1 CD CD O
, , , O
and CC CC O
gemcitabine NN NN B-CHEM
( ( ( O
800 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
given VBN VBN O
intravenously RB RB O
in IN IN O
30 CD CD O
minutes NNS NNS O
) ) ) O
on IN IN O
Days NNS NNS O
1 CD CD O
and CC CC O
8 CD CD O
, , , O
every DT DT O
4 CD CD O
weeks NNS NNS O
. . . O

Although IN IN O
responding VBG VBG O
patients NNS NNS O
were VBD VBD O
scheduled VBN VBN O
to TO TO O
receive VB VB O
consolidation NN NN O
radiotherapy NN NN O
and CC CC O
24 CD CD O
patients NNS NNS O
received VBD VBD O
preplanned VBN VBN O
second JJ JJ O
- - - O
line NN NN O
chemotherapy NN NN O
after IN IN O
disease NN NN O
progression NN NN O
, , , O
the DT DT O
response NN NN O
and CC CC O
toxicity NN NN O
rates NNS NNS O
reported VBD VBD O
refer VBP VBP O
only RB RB O
to TO TO O
the DT DT O
chemotherapy NN NN O
regimen NN NN O
given VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
the DT DT O
patients NNS NNS O
were VBD VBD O
examined VBN VBN O
for IN IN O
toxicity NN NN O
; : : O
34 CD CD O
were VBD VBD O
examinable JJ JJ O
for IN IN O
response NN NN O
. . . O

An DT DT O
objective NN NN O
response NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
73 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
, , , O
55 CD CD O
. . . O
6 CD CD O
- : : O
87 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
including VBG VBG O
4 CD CD O
complete JJ JJ O
responses NNS NNS O
( ( ( O
11 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
. . . O

According VBG VBG O
to TO TO O
intention NN NN O
- - - O
to TO TO O
- - - O
treat NN NN O
, , , O
the DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
was VBD VBD O
71 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
53 CD CD O
. . . O
7 CD CD O
- : : O
85 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
. . . O

After IN IN O
154 CD CD O
courses NNS NNS O
of IN IN O
therapy NN NN O
, , , O
the DT DT O
median NN NN O
dose NN NN O
intensity NN NN O
was VBD VBD O
131 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
for IN IN O
paclitaxel NN NN B-CHEM
( ( ( O
97 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
, , , O
117 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
for IN IN O
cisplatin NN NN B-CHEM
( ( ( O
97 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
1378 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
for IN IN O
gemcitabine NN NN B-CHEM
( ( ( O
86 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
. . . O

World NNP NNP O
Health NNP NNP O
Organization NNP NNP O
Grade NNP NNP O
3 CD CD O
- : : O
4 CD CD O
neutropenia NN NN O
and CC CC O
thrombocytopenia NN NN O
occurred VBD VBD O
in IN IN O
39 CD CD O
. . . O
9 CD CD O
% NN NN O
and CC CC O
11 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
respectively RB RB O
. . . O

There EX EX O
was VBD VBD O
one CD CD O
treatment NN NN O
- - - O
related VBN VBN O
death NN NN O
. . . O

Nonhematologic NNP NNP O
toxicities NNS NNS O
were VBD VBD O
mild JJ JJ O
. . . O

After IN IN O
a DT DT O
median NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
22 CD CD O
months NNS NNS O
, , , O
the DT DT O
median JJ JJ O
progression NN NN O
free JJ JJ O
survival NN NN O
rate NN NN O
was VBD VBD O
7 CD CD O
months NNS NNS O
, , , O
and CC CC O
the DT DT O
median JJ JJ O
survival NN NN O
time NN NN O
was VBD VBD O
16 CD CD O
months NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
combination NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
, , , O
cisplatin NN NN B-CHEM
, , , O
and CC CC O
gemcitabine NN NN B-CHEM
is VBZ VBZ O
well RB RB O
tolerated VBN VBN O
and CC CC O
shows VBZ VBZ O
high JJ JJ O
activity NN NN O
in IN IN O
metastatic JJ JJ O
NSCLC NNP NNP O
. . . O

This DT DT O
treatment NN NN O
merits NNS NNS O
further JJ JJ O
comparison NN NN O
with IN IN O
other JJ JJ O
cisplatin NN NN B-CHEM
- - - O
based JJ JJ O
regimens NNS NNS O
. . . O

Serotonergic NNP NNP B-CHEM
antidepressants NNS NNS I-CHEM
and CC CC O
urinary JJ JJ O
incontinence NN NN O
. . . O

Many JJ JJ O
new JJ JJ O
serotonergic JJ JJ B-CHEM
antidepressants NNS NNS I-CHEM
have VBP VBP O
been VBN VBN O
introduced VBN VBN O
over IN IN O
the DT DT O
past JJ JJ O
decade NN NN O
. . . O

Although IN IN O
urinary JJ JJ O
incontinence NN NN O
is VBZ VBZ O
listed VBN VBN O
as IN IN O
one CD CD O
side NN NN O
effect NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
in IN IN O
their PRP$ PRP$ O
package NN NN O
inserts NNS NNS O
there RB RB O
is VBZ VBZ O
only RB RB O
one CD CD O
report NN NN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

This DT DT O
concerns NNS NNS O
2 CD CD O
male JJ JJ O
patients NNS NNS O
who WP WP O
experienced VBD VBD O
incontinence NN NN O
while IN IN O
taking VBG VBG O
venlafaxine NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
present JJ JJ O
paper NN NN O
the DT DT O
authors NNS NNS O
describe VBP VBP O
2 CD CD O
female JJ JJ O
patients NNS NNS O
who WP WP O
developed VBD VBD O
incontinence NN NN O
secondary JJ JJ O
to TO TO O
the DT DT O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
paroxetine NN NN B-CHEM
and CC CC O
sertraline NN NN B-CHEM
, , , O
as RB RB O
well RB RB O
as IN IN O
a DT DT O
third JJ JJ O
who WP WP O
developed VBD VBD O
this DT DT O
side NN NN O
effect NN NN O
on IN IN O
venlafaxine NN NN B-CHEM
. . . O

In IN IN O
2 CD CD O
of IN IN O
the DT DT O
3 CD CD O
cases NNS NNS O
the DT DT O
patients NNS NNS O
were VBD VBD O
also RB RB O
taking VBG VBG O
lithium NN NN B-CHEM
carbonate NN NN I-CHEM
and CC CC O
beta NN NN O
- : : O
blockers NNS NNS O
, , , O
both DT DT O
of IN IN O
which WDT WDT O
could MD MD O
have VB VB O
contributed VBN VBN O
to TO TO O
the DT DT O
incontinence NN NN O
. . . O

Animal NNP NNP O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
incontinence NN NN O
secondary JJ JJ O
to TO TO O
serotonergic JJ JJ B-CHEM
antidepressants NNS NNS I-CHEM
could MD MD O
be VB VB O
mediated VBN VBN O
by IN IN O
the DT DT O
5HT4 CD CD O
receptors NNS NNS O
found VBD VBD O
on IN IN O
the DT DT O
bladder NN NN O
. . . O

Further RB RB O
research NN NN O
is VBZ VBZ O
needed VBN VBN O
to TO TO O
delineate VB VB O
the DT DT O
frequency NN NN O
of IN IN O
this DT DT O
troubling JJ JJ O
side NN NN O
effect NN NN O
and CC CC O
how WRB WRB O
best JJS JJS O
to TO TO O
treat VB VB O
it PRP PRP O
. . . O

Acute JJ JJ O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
: : : O
differential JJ JJ O
sensitivity NN NN O
of IN IN O
six CD CD O
inbred JJ JJ O
mouse NN NN O
strains NNS NNS O
. . . O

Mature NNP NNP O
male JJ JJ O
and CC CC O
female JJ JJ O
mice NN NN O
from IN IN O
six CD CD O
inbred JJ JJ O
stains NNS NNS O
were VBD VBD O
tested VBN VBN O
for IN IN O
susceptibility NN NN O
to TO TO O
behavioral JJ JJ O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
cocaine NN NN B-CHEM
. . . O

Cocaine NNP NNP B-CHEM
was VBD VBD O
injected VBN VBN O
ip NNP NNP O
over IN IN O
a DT DT O
range NN NN O
of IN IN O
doses NNS NNS O
( ( ( O
50 CD CD O
- : : O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
behavior NN NN O
was VBD VBD O
monitored VBN VBN O
for IN IN O
20 CD CD O
minutes NNS NNS O
. . . O

Seizure NNP NNP O
end NN NN O
points NNS NNS O
included VBD VBD O
latency NN NN O
to TO TO O
forelimb VB VB O
or CC CC O
hindlimb NN NN O
clonus NN NN O
, , , O
latency NN NN O
to TO TO O
clonic JJ JJ O
running NN NN O
seizure NN NN O
and CC CC O
latency NN NN O
to TO TO O
jumping VBG VBG O
bouncing VBG VBG O
seizure NN NN O
. . . O

A DT DT O
range NN NN O
of IN IN O
strain JJ JJ O
specific JJ JJ O
sensitivities NNS NNS O
was VBD VBD O
documented VBN VBN O
with IN IN O
A DT DT O
/ NN NN O
J NNP NNP O
and CC CC O
SJL NNP NNP O
mice NN NN O
being VBG VBG O
most RBS RBS O
sensitive JJ JJ O
and CC CC O
C57BL NNP NNP O
/ NN NN O
6J CD CD O
most RBS RBS O
resistant JJ JJ O
. . . O

DBA NNP NNP O
/ NN NN O
2J CD CD O
, , , O
BALB NNP NNP O
/ NN NN O
cByJ NN NN O
and CC CC O
NZW NNP NNP O
/ NN NN O
LacJ NNP NNP O
strains NNS NNS O
exhibited JJ JJ O
intermediate JJ JJ O
sensitivity NN NN O
. . . O

EEG NNP NNP O
recordings NNS NNS O
were VBD VBD O
made VBN VBN O
in IN IN O
SJL NNP NNP O
, , , O
A DT DT O
/ NN NN O
J NNP NNP O
and CC CC O
C57BL NNP NNP O
/ NN NN O
6J CD CD O
mice NN NN O
revealing VBG VBG O
a DT DT O
close JJ JJ O
correspondence NN NN O
between IN IN O
electrical JJ JJ O
activity NN NN O
and CC CC O
behavior NN NN O
. . . O

Additionally RB RB O
, , , O
levels NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
determined VBN VBN O
in IN IN O
hippocampus NN NN O
and CC CC O
cortex NN NN O
were VBD VBD O
not RB RB O
different JJ JJ O
between IN IN O
sensitive JJ JJ O
and CC CC O
resistant JJ JJ O
strains NNS NNS O
. . . O

Additional JJ JJ O
studies NNS NNS O
of IN IN O
these DT DT O
murine NN NN O
strains NNS NNS O
may MD MD O
be VB VB O
useful JJ JJ O
for IN IN O
investigating VBG VBG O
genetic JJ JJ O
influences VBZ VBZ O
on IN IN O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
. . . O

Hypotension NNP NNP O
following VBG VBG O
the DT DT O
initiation NN NN O
of IN IN O
tizanidine NN NN B-CHEM
in IN IN O
a DT DT O
patient NN NN O
treated VBN VBN O
with IN IN O
an DT DT O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
for IN IN O
chronic JJ JJ O
hypertension NN NN O
. . . O

Centrally NNP NNP O
acting VBG VBG O
alpha NN NN O
- : : O
2 CD CD O
adrenergic JJ JJ O
agonists NNS NNS O
are VBP VBP O
one CD CD O
of IN IN O
several JJ JJ O
pharmacologic JJ JJ O
agents NNS NNS O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
spasticity NN NN O
related VBN VBN O
to TO TO O
disorders NNS NNS O
of IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

In IN IN O
addition NN NN O
to TO TO O
their PRP$ PRP$ O
effects NNS NNS O
on IN IN O
spasticity NN NN O
, , , O
certain JJ JJ O
adverse JJ JJ O
cardiorespiratory NN NN O
effects NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

Adults NNS NNS O
chronically RB RB O
treated VBN VBN O
with IN IN O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
inhibitors NNS NNS O
may MD MD O
have VB VB O
a DT DT O
limited JJ JJ O
ability NN NN O
to TO TO O
respond VB VB O
to TO TO O
hypotension NN NN O
when WRB WRB O
the DT DT O
sympathetic JJ JJ O
response NN NN O
is VBZ VBZ O
simultaneously RB RB O
blocked VBN VBN O
. . . O

The DT DT O
authors NNS NNS O
present VBP VBP O
a DT DT O
10 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
chronically RB RB O
treated VBN VBN O
with IN IN O
lisinopril NN NN B-CHEM
, , , O
an DT DT O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
, , , O
to TO TO O
control VB VB O
hypertension NN NN O
who WP WP O
developed VBD VBD O
hypotension NN NN O
following VBG VBG O
the DT DT O
addition NN NN O
of IN IN O
tizanidine NN NN B-CHEM
, , , O
an DT DT O
alpha NN NN O
- - - O
2 CD CD O
agonist NN NN O
, , , O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
spasticity NN NN O
. . . O

The DT DT O
possible JJ JJ O
interaction NN NN O
of IN IN O
tizanidine NN NN B-CHEM
and CC CC O
other JJ JJ O
antihypertensive JJ JJ O
agents NNS NNS O
should MD MD O
be VB VB O
kept VBN VBN O
in IN IN O
mind NN NN O
when WRB WRB O
prescribing VBG VBG O
therapy NN NN O
to TO TO O
treat VB VB O
either CC CC O
hypertension NN NN O
or CC CC O
spasticity NN NN O
in IN IN O
such JJ JJ O
patients NNS NNS O
. . . O

Two CD CD O
mouse NN NN O
lines NNS NNS O
selected VBN VBN O
for IN IN O
differential JJ JJ O
sensitivities NNS NNS O
to TO TO O
beta NN NN B-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
are VBP VBP O
also RB RB O
differentially RB RB O
sensitive JJ JJ O
to TO TO O
various JJ JJ O
pharmacological JJ JJ O
effects NNS NNS O
of IN IN O
other JJ JJ O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
receptor NN NN O
ligands NNS NNS O
. . . O

Two CD CD O
mouse NN NN O
lines NNS NNS O
were VBD VBD O
selectively RB RB O
bred VBN VBN O
according VBG VBG O
to TO TO O
their PRP$ PRP$ O
sensitivity NN NN O
( ( ( O
BS NNP NNP O
line NN NN O
) ) ) O
or CC CC O
resistance NN NN O
( ( ( O
BR NNP NNP O
line NN NN O
) ) ) O
to TO TO O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
i NNP NNP O
. . . O
p NN NN O
. . . O
injection NN NN O
of IN IN O
methyl NN NN B-CHEM
beta NN NN I-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
- - - I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
carboxylate NN NN I-CHEM
( ( ( O
beta NN NN B-CHEM
- - - I-CHEM
CCM NNP NNP I-CHEM
) ) ) O
, , , O
an DT DT O
inverse JJ JJ O
agonist NN NN O
of IN IN O
the DT DT O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
receptor NN NN O
benzodiazepine NN NN B-CHEM
site NN NN O
. . . O

Our PRP$ PRP$ O
aim NN NN O
was VBD VBD O
to TO TO O
characterize VB VB O
both DT DT O
lines NNS NNS O
' POS POS O
sensitivities NNS NNS O
to TO TO O
various JJ JJ O
physiological JJ JJ O
effects NNS NNS O
of IN IN O
other JJ JJ O
ligands NNS NNS O
of IN IN O
the DT DT O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
receptor NN NN O
. . . O

We PRP PRP O
measured VBD VBD O
diazepam NN NN B-CHEM
- : : O
induced JJ JJ O
anxiolysis NN NN O
with IN IN O
the DT DT O
elevated JJ JJ O
plus CC CC O
- - - O
maze NN NN O
test NN NN O
, , , O
diazepam NN NN B-CHEM
- - - O
induced JJ JJ O
sedation NN NN O
by IN IN O
recording VBG VBG O
the DT DT O
vigilance NN NN O
states NNS NNS O
, , , O
and CC CC O
picrotoxin NN NN B-CHEM
- - - O
and CC CC O
pentylenetetrazol NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
after IN IN O
i NNP NNP O
. . . O
p NN NN O
. . . O
injections NNS NNS O
. . . O

Results NNS NNS O
presented VBN VBN O
here RB RB O
show NN NN O
that IN IN O
the DT DT O
differential JJ JJ O
sensitivities NNS NNS O
of IN IN O
BS NNP NNP O
and CC CC O
BR NNP NNP O
lines NNS NNS O
to TO TO O
beta VB VB B-CHEM
- : : I-CHEM
CCM NNP NNP I-CHEM
can MD MD O
be VB VB O
extended VBN VBN O
to TO TO O
diazepam NN NN B-CHEM
, , , O
picrotoxin NN NN B-CHEM
, , , O
and CC CC O
pentylenetetrazol NN NN B-CHEM
, , , O
suggesting VBG VBG O
a DT DT O
genetic JJ JJ O
selection NN NN O
of IN IN O
a DT DT O
general JJ JJ O
sensitivity NN NN O
and CC CC O
resistance NN NN O
to TO TO O
several JJ JJ O
ligands NNS NNS O
of IN IN O
the DT DT O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
receptor NN NN O
. . . O

Propylthiouracil NNP NNP B-CHEM
- : : O
induced VBN VBN O
perinuclear NN NN O
- - - O
staining VBG VBG O
antineutrophil NN NN O
cytoplasmic JJ JJ O
autoantibody NN NN O
- - - O
positive JJ JJ O
vasculitis NN NN O
in IN IN O
conjunction NN NN O
with IN IN O
pericarditis NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
a DT DT O
case NN NN O
of IN IN O
propylthiouracil NN NN B-CHEM
- - - O
induced JJ JJ O
vasculitis NN NN O
manifesting VBG VBG O
with IN IN O
pericarditis NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
present VBP VBP O
the DT DT O
first JJ JJ O
case NN NN O
report NN NN O
of IN IN O
a DT DT O
woman NN NN O
with IN IN O
hyperthyroidism NN NN O
treated VBN VBN O
with IN IN O
propylthiouracil NN NN B-CHEM
in IN IN O
whom WP WP O
a DT DT O
syndrome NN NN O
of IN IN O
pericarditis NNS NNS O
, , , O
fever NN NN O
, , , O
and CC CC O
glomerulonephritis NN NN O
developed VBN VBN O
. . . O

Serologic NNP NNP O
testing NN NN O
and CC CC O
immunologic JJ JJ O
studies NNS NNS O
were VBD VBD O
done VBN VBN O
, , , O
and CC CC O
a DT DT O
pericardial JJ JJ O
biopsy NN NN O
was VBD VBD O
performed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
25 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
Graves NNP NNP O
' POS POS O
disease NN NN O
had VBD VBD O
a DT DT O
febrile JJ JJ O
illness NN NN O
and CC CC O
evidence NN NN O
of IN IN O
pericarditis NNS NNS O
, , , O
which WDT WDT O
was VBD VBD O
confirmed VBN VBN O
by IN IN O
biopsy NN NN O
. . . O

Serologic NNP NNP O
evaluation NN NN O
revealed VBD VBD O
the DT DT O
presence NN NN O
of IN IN O
perinuclear NN NN O
- - - O
staining VBG VBG O
antineutrophil NN NN O
cytoplasmic JJ JJ O
autoantibodies NNS NNS O
( ( ( O
pANCA NN NN O
) ) ) O
against IN IN O
myeloperoxidase NN NN O
( ( ( O
MPO NNP NNP O
) ) ) O
. . . O

Propylthiouracil NNP NNP B-CHEM
therapy NN NN O
was VBD VBD O
withdrawn VBN VBN O
, , , O
and CC CC O
she PRP PRP O
was VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
1 CD CD O
- : : O
month NN NN O
course NN NN O
of IN IN O
prednisone NN NN B-CHEM
, , , O
which WDT WDT O
alleviated VBD VBD O
her PRP$ PRP$ O
symptoms NNS NNS O
. . . O

A DT DT O
literature NN NN O
review NN NN O
revealed VBD VBD O
no DT DT O
prior JJ JJ O
reports NNS NNS O
of IN IN O
pericarditis NN NN O
in IN IN O
anti JJ JJ O
- : : O
MPO NNP NNP O
pANCA NN NN O
- - - O
positive JJ JJ O
vasculitis NN NN O
associated VBN VBN O
with IN IN O
propylthio NN NN B-CHEM
- - - I-CHEM
uracil NN NN I-CHEM
therapy NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Pericarditis NNP NNP O
may MD MD O
be VB VB O
the DT DT O
initial JJ JJ O
manifestation NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
vasculitis NNS NNS O
attributable JJ JJ O
to TO TO O
propylthio VB VB B-CHEM
- : : I-CHEM
uracil NN NN I-CHEM
therapy NN NN O
. . . O

Repeated NNP NNP O
transient JJ JJ O
anuria NNS NNS O
following VBG VBG O
losartan NN NN B-CHEM
administration NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
a DT DT O
solitary JJ JJ O
kidney NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
70 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
hypertensive JJ JJ O
man NN NN O
with IN IN O
a DT DT O
solitary JJ JJ O
kidney NN NN O
and CC CC O
chronic JJ JJ O
renal JJ JJ O
insufficiency NN NN O
who WP WP O
developed VBD VBD O
two CD CD O
episodes NNS NNS O
of IN IN O
transient NN NN O
anuria NN NN O
after IN IN O
losartan NN NN B-CHEM
administration NN NN O
. . . O

He PRP PRP O
was VBD VBD O
hospitalized VBN VBN O
for IN IN O
a DT DT O
myocardial NN NN O
infarction NN NN O
with IN IN O
pulmonary JJ JJ O
edema NN NN O
, , , O
treated VBN VBN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
diuretics NNS NNS O
. . . O

Due JJ JJ O
to TO TO O
severe JJ JJ O
systolic JJ JJ O
dysfunction NN NN O
losartan NN NN B-CHEM
was VBD VBD O
prescribed VBN VBN O
. . . O

Surprisingly RB RB O
, , , O
the DT DT O
first JJ JJ O
dose NN NN O
of IN IN O
50 CD CD O
mg NN NN O
of IN IN O
losartan NN NN B-CHEM
resulted VBD VBD O
in IN IN O
a DT DT O
sudden JJ JJ O
anuria NNS NNS O
, , , O
which WDT WDT O
lasted VBD VBD O
eight CD CD O
hours NNS NNS O
despite IN IN O
high JJ JJ O
- - - O
dose NN NN O
furosemide NN NN B-CHEM
and CC CC O
amine NN NN B-CHEM
infusion NN NN O
. . . O

One CD CD O
week NN NN O
later RB RB O
, , , O
by IN IN O
mistake NN NN O
, , , O
losartan NN NN B-CHEM
was VBD VBD O
prescribed VBN VBN O
again RB RB O
and CC CC O
after IN IN O
the DT DT O
second JJ JJ O
dose NN NN O
of IN IN O
50 CD CD O
mg NN NN O
, , , O
the DT DT O
patient NN NN O
developed VBD VBD O
a DT DT O
second JJ JJ O
episode NN NN O
of IN IN O
transient JJ JJ O
anuria NN NN O
lasting VBG VBG O
10 CD CD O
hours NNS NNS O
. . . O

During IN IN O
these DT DT O
two CD CD O
episodes NNS NNS O
, , , O
his PRP$ PRP$ O
blood NN NN O
pressure NN NN O
diminished VBD VBD O
but CC CC O
no DT DT O
severe JJ JJ O
hypotension NN NN O
was VBD VBD O
noted VBN VBN O
. . . O

Ultimately RB RB O
, , , O
an DT DT O
arteriography NN NN O
showed VBD VBD O
a DT DT O
70 CD CD O
- : : O
80 CD CD O
% NN NN O
renal JJ JJ O
artery NN NN O
stenosis NN NN O
. . . O

In IN IN O
this DT DT O
patient NN NN O
, , , O
renal JJ JJ O
artery NN NN O
stenosis NN NN O
combined VBN VBN O
with IN IN O
heart NN NN O
failure NN NN O
and CC CC O
diuretic JJ JJ O
therapy NN NN O
certainly RB RB O
resulted VBD VBD O
in IN IN O
a DT DT O
strong JJ JJ O
activation NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
( ( ( O
RAS NNP NNP O
) ) ) O
. . . O

Under IN IN O
such JJ JJ O
conditions NNS NNS O
, , , O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
blockade NN NN O
by IN IN O
losartan NN NN B-CHEM
probably RB RB O
induced VBD VBD O
a DT DT O
critical JJ JJ O
fall NN NN O
in IN IN O
glomerular NN NN O
filtration NN NN O
pressure NN NN O
. . . O

This DT DT O
case NN NN O
report NN NN O
highlights NNS NNS O
the DT DT O
fact NN NN O
that IN IN O
the DT DT O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
antagonist NN NN O
losartan NN NN B-CHEM
can MD MD O
cause VB VB O
serious JJ JJ O
unexpected JJ JJ O
complications NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
renovascular NN NN O
disease NN NN O
and CC CC O
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
extreme JJ JJ O
caution NN NN O
in IN IN O
this DT DT O
setting VBG VBG O
. . . O

Calcineurin NNP NNP O
- : : O
inhibitor NN NN O
induced VBD VBD O
pain NN NN O
syndrome NN NN O
( ( ( O
CIPS NNP NNP O
) ) ) O
: : : O
a DT DT O
severe JJ JJ O
disabling VBG VBG O
complication NN NN O
after IN IN O
organ NN NN O
transplantation NN NN O
. . . O

Bone NNP NNP O
pain NN NN O
after IN IN O
transplantation NN NN O
is VBZ VBZ O
a DT DT O
frequent JJ JJ O
complication NN NN O
that WDT WDT O
can MD MD O
be VB VB O
caused VBN VBN O
by IN IN O
several JJ JJ O
diseases NNS NNS O
. . . O

Treatment NN NN O
strategies NNS NNS O
depend VBP VBP O
on IN IN O
the DT DT O
correct JJ JJ O
diagnosis NN NN O
of IN IN O
the DT DT O
pain NN NN O
. . . O

Nine CD CD O
patients NNS NNS O
with IN IN O
severe JJ JJ O
pain NN NN O
in IN IN O
their PRP$ PRP$ O
feet NNS NNS O
, , , O
which WDT WDT O
was VBD VBD O
registered VBN VBN O
after IN IN O
transplantation NN NN O
, , , O
were VBD VBD O
investigated VBN VBN O
. . . O

Bone NNP NNP O
scans NNS NNS O
showed VBD VBD O
an DT DT O
increased JJ JJ O
tracer NN NN O
uptake NN NN O
of IN IN O
the DT DT O
foot NN NN O
bones NNS NNS O
. . . O

Magnetic NNP NNP O
resonance NN NN O
imaging VBG VBG O
demonstrated VBN VBN O
bone NN NN O
marrow NN NN O
oedema NN NN O
in IN IN O
the DT DT O
painful JJ JJ O
bones NNS NNS O
. . . O

Pain NN NN O
was VBD VBD O
not RB RB O
explained VBN VBN O
by IN IN O
other JJ JJ O
diseases NNS NNS O
causing VBG VBG O
foot NN NN O
pain NN NN O
, , , O
like IN IN O
reflex JJ JJ O
sympathetic JJ JJ O
dystrophy NN NN O
, , , O
polyneuropathy NN NN O
, , , O
Morton NNP NNP O
' POS POS O
s VBZ VBZ O
neuralgia NN NN O
, , , O
gout NN NN O
, , , O
osteoporosis NN NN O
, , , O
avascular JJ JJ O
necrosis NN NN O
, , , O
intermittent JJ JJ O
claudication NN NN O
, , , O
orthopaedic JJ JJ O
foot NN NN O
deformities NNS NNS O
, , , O
stress NN NN O
fractures NNS NNS O
, , , O
and CC CC O
hyperparathyroidism NN NN O
. . . O

The DT DT O
reduction NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
- - - O
or CC CC O
tacrolimus NN NN B-CHEM
trough NN NN O
levels NNS NNS O
and CC CC O
the DT DT O
administration NN NN O
of IN IN O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
led VBN VBN O
to TO TO O
relief NN NN O
of IN IN O
pain NN NN O
. . . O

The DT DT O
Calcineurin NNP NNP O
- - - O
inhibitor NN NN O
Induced NNP NNP O
Pain NN NN O
Syndrome NN NN O
( ( ( O
CIPS NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
but CC CC O
severe JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
or CC CC O
tacrolimus NN NN B-CHEM
and CC CC O
is VBZ VBZ O
accurately RB RB O
diagnosed VBN VBN O
by IN IN O
its PRP$ PRP$ O
typical JJ JJ O
presentation NN NN O
, , , O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
and CC CC O
bone NN NN O
scans NNS NNS O
. . . O

Incorrect NNP NNP O
diagnosis NN NN O
of IN IN O
the DT DT O
syndrome NN NN O
will MD MD O
lead VB VB O
to TO TO O
a DT DT O
significant JJ JJ O
reduction NN NN O
of IN IN O
life NN NN O
quality NN NN O
in IN IN O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
CIPS NNP NNP O
. . . O

Brain NNP NNP O
natriuretic JJ JJ O
peptide NN NN O
is VBZ VBZ O
a DT DT O
predictor NN NN O
of IN IN O
anthracycline NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Anthracyclines NNP NNP B-CHEM
are VBP VBP O
effective JJ JJ O
antineoplastic JJ JJ O
drugs NNS NNS O
, , , O
but CC CC O
they PRP PRP O
frequently RB RB O
cause VBP VBP O
dose NN NN O
- - - O
related VBN VBN O
cardiotoxicity NN NN O
. . . O

The DT DT O
cardiotoxicity NN NN O
of IN IN O
conventional JJ JJ O
anthracycline NN NN B-CHEM
therapy NN NN O
highlights NNS NNS O
a DT DT O
need NN NN O
to TO TO O
search NN NN O
for IN IN O
methods NNS NNS O
that WDT WDT O
are VBP VBP O
highly RB RB O
sensitive JJ JJ O
and CC CC O
capable JJ JJ O
of IN IN O
predicting VBG VBG O
cardiac JJ JJ O
dysfunction NN NN O
. . . O

We PRP PRP O
measured VBD VBD O
the DT DT O
plasma NN NN O
level NN NN O
of IN IN O
brain NN NN O
natriuretic JJ JJ O
peptide NN NN O
( ( ( O
BNP NNP NNP O
) ) ) O
to TO TO O
determine VB VB O
whether IN IN O
BNP NNP NNP O
might MD MD O
serve VB VB O
as IN IN O
a DT DT O
simple JJ JJ O
diagnostic JJ JJ O
indicator NN NN O
of IN IN O
anthracycline NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
leukemia NN NN O
treated VBN VBN O
with IN IN O
a DT DT O
daunorubicin NN NN B-CHEM
( ( ( O
DNR NNP NNP B-CHEM
) ) ) O
- : : O
containing VBG VBG O
regimen NNS NNS O
. . . O

Thirteen NNP NNP O
patients NNS NNS O
with IN IN O
acute JJ JJ O
leukemia NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
DNR NNP NNP B-CHEM
- : : O
containing VBG VBG O
regimen NNS NNS O
. . . O

Cardiac NNP NNP O
functions NNS NNS O
were VBD VBD O
evaluated VBN VBN O
with IN IN O
radionuclide NN NN O
angiography NN NN O
before IN IN O
chemotherapies NNS NNS O
. . . O

The DT DT O
plasma NN NN O
levels NNS NNS O
of IN IN O
atrial JJ JJ O
natriuretic JJ JJ O
peptide NN NN O
( ( ( O
ANP NNP NNP O
) ) ) O
and CC CC O
BNP NNP NNP O
were VBD VBD O
measured VBN VBN O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
radionuclide NN NN O
angiography NN NN O
. . . O

Three CD CD O
patients NNS NNS O
developed VBN VBN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
after IN IN O
the DT DT O
completion NN NN O
of IN IN O
chemotherapy NN NN O
. . . O

Five CD CD O
patients NNS NNS O
were VBD VBD O
diagnosed VBN VBN O
as IN IN O
having VBG VBG O
subclinical JJ JJ O
heart NN NN O
failure NN NN O
after IN IN O
the DT DT O
completion NN NN O
of IN IN O
chemotherapy NN NN O
. . . O

The DT DT O
plasma NN NN O
levels NNS NNS O
of IN IN O
BNP NNP NNP O
in IN IN O
all PDT PDT O
the DT DT O
patients NNS NNS O
with IN IN O
clinical JJ JJ O
and CC CC O
subclinical JJ JJ O
heart NN NN O
failure NN NN O
increased VBD VBD O
above IN IN O
the DT DT O
normal JJ JJ O
limit NN NN O
( ( ( O
40 CD CD O
pg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
before IN IN O
the DT DT O
detection NN NN O
of IN IN O
clinical JJ JJ O
or CC CC O
subclinical JJ JJ O
heart NN NN O
failure NN NN O
by IN IN O
radionuclide NN NN O
angiography NN NN O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
BNP NNP NNP O
did VBD VBD O
not RB RB O
increase VB VB O
in IN IN O
the DT DT O
patients NNS NNS O
without IN IN O
heart NN NN O
failure NN NN O
given VBN VBN O
DNR NNP NNP B-CHEM
, , , O
even RB RB O
at IN IN O
more JJR JJR O
than IN IN O
700 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
. . . O

The DT DT O
plasma NN NN O
level NN NN O
of IN IN O
ANP NNP NNP O
did VBD VBD O
not RB RB O
always RB RB O
increase VB VB O
in IN IN O
all PDT PDT O
the DT DT O
patients NNS NNS O
with IN IN O
clinical JJ JJ O
and CC CC O
subclinical JJ JJ O
heart NN NN O
failure NN NN O
. . . O

These DT DT O
preliminary JJ JJ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
BNP NNP NNP O
may MD MD O
be VB VB O
useful JJ JJ O
as IN IN O
an DT DT O
early JJ JJ O
and CC CC O
sensitive JJ JJ O
indicator NN NN O
of IN IN O
anthracycline NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Nephrotoxicity NNP NNP O
of IN IN O
combined VBN VBN O
cephalothin NN NN B-CHEM
- - - O
gentamicin NN NN B-CHEM
regimen NN NN O
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
acute JJ JJ O
tubular JJ JJ O
necrosis NN NN O
, , , O
characterized VBN VBN O
clinically RB RB O
by IN IN O
acute JJ JJ O
oliguric JJ JJ O
renal NN NN O
failure NN NN O
, , , O
while IN IN O
they PRP PRP O
were VBD VBD O
receiving VBG VBG O
a DT DT O
combination NN NN O
of IN IN O
cephalothin NN NN B-CHEM
sodium NN NN I-CHEM
and CC CC O
gentamicin NN NN B-CHEM
sulfate NN NN I-CHEM
therapy NN NN O
. . . O

Patients NNS NNS O
who WP WP O
are VBP VBP O
given VBN VBN O
this DT DT O
drug NN NN O
regimen NN NN O
should MD MD O
be VB VB O
observed VBN VBN O
very RB RB O
carefully RB RB O
for IN IN O
early JJ JJ O
signs NNS NNS O
of IN IN O
nephrotoxicity NN NN O
. . . O

High NNP NNP O
doses NNS NNS O
of IN IN O
this DT DT O
antibiotic JJ JJ O
combination NN NN O
should MD MD O
be VB VB O
avoided VBN VBN O
especially RB RB O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
renal JJ JJ O
insufficiency NN NN O
should MD MD O
not RB RB O
be VB VB O
given VBN VBN O
this DT DT O
regimen NN NN O
. . . O

In IN IN O
vivo NN NN O
protection NN NN O
of IN IN O
dna NN NN O
damage NN NN O
associated VBN VBN O
apoptotic JJ JJ O
and CC CC O
necrotic JJ JJ O
cell NN NN O
deaths NNS NNS O
during IN IN O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
, , , O
amiodarone NN NN B-CHEM
- - - O
induced JJ JJ O
lung NN NN O
toxicity NN NN O
and CC CC O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
by IN IN O
a DT DT O
novel NN NN O
IH636 NNP NNP B-CHEM
grape NN NN I-CHEM
seed NN NN I-CHEM
proanthocyanidin NN NN I-CHEM
extract NN NN I-CHEM
. . . O

Grape NNP NNP B-CHEM
seed NN NN I-CHEM
extract NN NN I-CHEM
, , , O
primarily RB RB O
a DT DT O
mixture NN NN O
of IN IN O
proanthocyanidins NNS NNS B-CHEM
, , , O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
modulate VB VB O
a DT DT O
wide JJ JJ O
- - - O
range NN NN O
of IN IN O
biological JJ JJ O
, , , O
pharmacological JJ JJ O
and CC CC O
toxicological JJ JJ O
effects NNS NNS O
which WDT WDT O
are VBP VBP O
mainly RB RB O
cytoprotective JJ JJ O
. . . O

This DT DT O
study NN NN O
assessed VBD VBD O
the DT DT O
ability NN NN O
of IN IN O
IH636 NNP NNP B-CHEM
grape NN NN I-CHEM
seed NN NN I-CHEM
proanthocyanidin NN NN I-CHEM
extract NN NN I-CHEM
( ( ( O
GSPE NNP NNP B-CHEM
) ) ) O
to TO TO O
prevent VB VB O
acetaminophen NN NN B-CHEM
( ( ( O
AAP NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
nephrotoxicity NN NN O
, , , O
amiodarone NN NN B-CHEM
( ( ( O
AMI NNP NNP B-CHEM
) ) ) O
- : : O
induced VBD VBD O
lung NN NN O
toxicity NN NN O
, , , O
and CC CC O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
in IN IN O
mice NN NN O
. . . O

Experimental NNP NNP O
design NN NN O
consisted VBD VBD O
of IN IN O
four CD CD O
groups NNS NNS O
: : : O
control NN NN O
( ( ( O
vehicle NN NN O
alone RB RB O
) ) ) O
, , , O
GSPE NNP NNP B-CHEM
alone RB RB O
, , , O
drug NN NN O
alone RB RB O
and CC CC O
GSPE NNP NNP B-CHEM
+ NN NN O
drug NN NN O
. . . O

For IN IN O
the DT DT O
cytoprotection NN NN O
study NN NN O
, , , O
animals NNS NNS O
were VBD VBD O
orally RB RB O
gavaged VBN VBN O
100 CD CD O
mg NN NN O
/ NN NN O
Kg NNP NNP O
GSPE NNP NNP B-CHEM
for IN IN O
7 CD CD O
- : : O
10 CD CD O
days NNS NNS O
followed VBN VBN O
by IN IN O
i NNP NNP O
. . . O
p NN NN O
. . . O
injections NNS NNS O
of IN IN O
organ NN NN O
specific JJ JJ O
three CD CD O
drugs NNS NNS O
( ( ( O
AAP NNP NNP B-CHEM
: : : O
500 CD CD O
mg NN NN O
/ NN NN O
Kg NNP NNP O
for IN IN O
24 CD CD O
h NN NN O
; : : O
AMI NNP NNP B-CHEM
: : : O
50 CD CD O
mg NN NN O
/ NN NN O
Kg NNP NNP O
/ NN NN O
day NN NN O
for IN IN O
four CD CD O
days NNS NNS O
; : : O
DOX NNP NNP B-CHEM
: : : O
20 CD CD O
mg NN NN O
/ NN NN O
Kg NNP NNP O
for IN IN O
48 CD CD O
h NN NN O
) ) ) O
. . . O

Parameters NNP NNP O
of IN IN O
study NN NN O
included VBD VBD O
analysis NN NN O
of IN IN O
serum NN NN O
chemistry NN NN O
( ( ( O
ALT NNP NNP O
, , , O
BUN NNP NNP O
and CC CC O
CPK NNP NNP O
) ) ) O
, , , O
and CC CC O
orderly JJ JJ O
fragmentation NN NN O
of IN IN O
genomic JJ JJ O
DNA NNP NNP O
( ( ( O
both DT DT O
endonuclease VB VB O
- - - O
dependent JJ JJ O
and CC CC O
independent JJ JJ O
) ) ) O
in IN IN O
addition NN NN O
to TO TO O
microscopic JJ JJ O
evaluation NN NN O
of IN IN O
damage NN NN O
and CC CC O
/ NN NN O
or CC CC O
protection NN NN O
in IN IN O
corresponding JJ JJ O
PAS NNP NNP O
stained JJ JJ O
tissues NNS NNS O
. . . O

Results NNS NNS O
indicate VBP VBP O
that IN IN O
GSPE NNP NNP B-CHEM
preexposure NN NN O
prior RB RB O
to TO TO O
AAP NNP NNP B-CHEM
, , , O
AMI NNP NNP B-CHEM
and CC CC O
DOX NNP NNP B-CHEM
, , , O
provided VBN VBN O
near IN IN O
complete JJ JJ O
protection NN NN O
in IN IN O
terms NNS NNS O
of IN IN O
serum NN NN O
chemistry NN NN O
changes NNS NNS O
( ( ( O
ALT NNP NNP O
, , , O
BUN NNP NNP O
and CC CC O
CPK NNP NNP O
) ) ) O
, , , O
and CC CC O
significantly RB RB O
reduced VBD VBD O
DNA NNP NNP O
fragmentation NN NN O
. . . O

Histopathological NNP NNP O
examination NN NN O
of IN IN O
kidney NN NN O
, , , O
heart NN NN O
and CC CC O
lung NN NN O
sections NNS NNS O
revealed VBD VBD O
moderate JJ JJ O
to TO TO O
massive JJ JJ O
tissue NN NN O
damage NN NN O
with IN IN O
a DT DT O
variety NN NN O
of IN IN O
morphological JJ JJ O
aberrations NNS NNS O
by IN IN O
all PDT PDT O
the DT DT O
three CD CD O
drugs NNS NNS O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
GSPE NNP NNP B-CHEM
preexposure NN NN O
than IN IN O
in IN IN O
its PRP$ PRP$ O
presence NN NN O
. . . O

GSPE NNP NNP B-CHEM
+ NN NN O
drug NN NN O
exposed VBN VBN O
tissues NNS NNS O
exhibited VBN VBN O
minor JJ JJ O
residual JJ JJ O
damage NN NN O
or CC CC O
near IN IN O
total JJ JJ O
recovery NN NN O
. . . O

Additionally RB RB O
, , , O
histopathological JJ JJ O
alterations NNS NNS O
mirrored VBD VBD O
both DT DT O
serum NN NN O
chemistry NN NN O
changes NNS NNS O
and CC CC O
the DT DT O
pattern NN NN O
of IN IN O
DNA NNP NNP O
fragmentation NN NN O
. . . O

Interestingly RB RB O
, , , O
all PDT PDT O
the DT DT O
drugs NNS NNS O
, , , O
such JJ JJ O
as IN IN O
, , , O
AAP NNP NNP B-CHEM
, , , O
AMI NNP NNP B-CHEM
and CC CC O
DOX NNP NNP B-CHEM
induced VBD VBD O
apoptotic JJ JJ O
death NN NN O
in IN IN O
addition NN NN O
to TO TO O
necrosis NNS NNS O
in IN IN O
the DT DT O
respective JJ JJ O
organs NNS NNS O
which WDT WDT O
was VBD VBD O
very RB RB O
effectively RB RB O
blocked VBN VBN O
by IN IN O
GSPE NNP NNP B-CHEM
. . . O

Since IN IN O
AAP NNP NNP B-CHEM
, , , O
AMI NNP NNP B-CHEM
and CC CC O
DOX NNP NNP B-CHEM
undergo NN NN O
biotransformation NN NN O
and CC CC O
are VBP VBP O
known VBN VBN O
to TO TO O
produce VB VB O
damaging VBG VBG O
radicals NNS NNS O
in IN IN O
vivo NN NN O
, , , O
the DT DT O
protection NN NN O
by IN IN O
GSPE NNP NNP B-CHEM
may MD MD O
be VB VB O
linked VBN VBN O
to TO TO O
both DT DT O
inhibition NN NN O
of IN IN O
metabolism NN NN O
and CC CC O
/ NN NN O
or CC CC O
detoxification NN NN O
of IN IN O
cytotoxic JJ JJ O
radicals NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
its PRP$ PRP$ O
' POS POS O
presumed JJ JJ O
contribution NN NN O
to TO TO O
DNA NNP NNP O
repair NN NN O
may MD MD O
be VB VB O
another DT DT O
important JJ JJ O
attribute NN NN O
, , , O
which WDT WDT O
played VBD VBD O
a DT DT O
role NN NN O
in IN IN O
the DT DT O
chemoprevention NN NN O
process NN NN O
. . . O

Additionally RB RB O
, , , O
this DT DT O
may MD MD O
have VB VB O
been VBN VBN O
the DT DT O
first JJ JJ O
report NN NN O
on IN IN O
AMI NNP NNP B-CHEM
- : : O
induced JJ JJ O
apoptotic JJ JJ O
death NN NN O
in IN IN O
the DT DT O
lung NN NN O
tissue NN NN O
. . . O

Taken VBN VBN O
together RB RB O
, , , O
these DT DT O
events NNS NNS O
undoubtedly RB RB O
establish VB VB O
GSPE NNP NNP B-CHEM
' POS POS O
s VBZ VBZ O
abundant JJ JJ O
bioavailability NN NN O
, , , O
and CC CC O
the DT DT O
power NN NN O
to TO TO O
defend VB VB O
multiple JJ JJ O
target NN NN O
organs NNS NNS O
from IN IN O
toxic JJ JJ O
assaults NNS NNS O
induced VBN VBN O
by IN IN O
structurally RB RB O
diverse JJ JJ O
and CC CC O
functionally RB RB O
different JJ JJ O
entities NNS NNS O
in IN IN O
vivo NN NN O
. . . O

Antidepressant NNP NNP B-CHEM
- : : O
induced VBN VBN O
mania NN NN O
in IN IN O
bipolar NN NN O
patients NNS NNS O
: : : O
identification NN NN O
of IN IN O
risk NN NN O
factors NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Concerns NNS NNS O
about IN IN O
possible JJ JJ O
risks NNS NNS O
of IN IN O
switching VBG VBG O
to TO TO O
mania NN NN O
associated VBN VBN O
with IN IN O
antidepressants NNS NNS B-CHEM
continue VBP VBP O
to TO TO O
interfere VB VB O
with IN IN O
the DT DT O
establishment NN NN O
of IN IN O
an DT DT O
optimal NN NN O
treatment NN NN O
paradigm NN NN O
for IN IN O
bipolar JJ JJ O
depression NN NN O
. . . O

METHOD NNP NNP O
: : : O
The DT DT O
response NN NN O
of IN IN O
44 CD CD O
patients NNS NNS O
meeting NN NN O
DSM NNP NNP O
- : : O
IV NNP NNP O
criteria NNS NNS O
for IN IN O
bipolar JJ JJ O
disorder NN NN O
to TO TO O
naturalistic JJ JJ O
treatment NN NN O
was VBD VBD O
assessed VBN VBN O
for IN IN O
at IN IN O
least JJS JJS O
6 CD CD O
weeks NNS NNS O
using VBG VBG O
the DT DT O
Montgomery NNP NNP O
- - - O
Asberg NNP NNP O
Depression NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
and CC CC O
the DT DT O
Bech NNP NNP O
- - - O
Rafaelson NNP NNP O
Mania NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
. . . O

Patients NNS NNS O
who WP WP O
experienced VBD VBD O
a DT DT O
manic JJ JJ O
or CC CC O
hypomanic JJ JJ O
switch NN NN O
were VBD VBD O
compared VBN VBN O
with IN IN O
those DT DT O
who WP WP O
did VBD VBD O
not RB RB O
on IN IN O
several JJ JJ O
variables NNS NNS O
including VBG VBG O
age NN NN O
, , , O
sex NN NN O
, , , O
diagnosis NN NN O
( ( ( O
DSM NNP NNP O
- : : O
IV NNP NNP O
bipolar NN NN O
I PRP PRP O
vs NNS NNS O
. . . O
bipolar JJ JJ O
II NNP NNP O
) ) ) O
, , , O
number NN NN O
of IN IN O
previous JJ JJ O
manic JJ JJ O
episodes NNS NNS O
, , , O
type NN NN O
of IN IN O
antidepressant NN NN B-CHEM
therapy NN NN O
used VBN VBN O
( ( ( O
electroconvulsive JJ JJ O
therapy NN NN O
vs NNS NNS O
. . . O
antidepressant JJ JJ B-CHEM
drugs NNS NNS O
and CC CC O
, , , O
more RBR RBR O
particularly RB RB O
, , , O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN I-CHEM
inhibitors NNS NNS I-CHEM
[ NN NN O
SSRIs NNP NNP B-CHEM
] NN NN O
) ) ) O
, , , O
use NN NN O
and CC CC O
type NN NN O
of IN IN O
mood NN NN O
stabilizers NNS NNS O
( ( ( O
lithium NN NN B-CHEM
vs NNS NNS O
. . . O
anticonvulsants NNS NNS O
) ) ) O
, , , O
and CC CC O
temperament NN NN O
of IN IN O
the DT DT O
patient NN NN O
, , , O
assessed VBD VBD O
during IN IN O
a DT DT O
normothymic JJ JJ O
period NN NN O
using VBG VBG O
the DT DT O
hyperthymia NN NN O
component NN NN O
of IN IN O
the DT DT O
Semi NNP NNP O
- - - O
structured JJ JJ O
Affective NNP NNP O
Temperament NNP NNP O
Interview NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
Switches NNP NNP O
to TO TO O
hypomania NN NN O
or CC CC O
mania NN NN O
occurred VBD VBD O
in IN IN O
27 CD CD O
% NN NN O
of IN IN O
all DT DT O
patients NNS NNS O
( ( ( O
N NNP NNP O
= SYM SYM O
12 CD CD O
) ) ) O
( ( ( O
and CC CC O
in IN IN O
24 CD CD O
% NN NN O
of IN IN O
the DT DT O
subgroup NN NN O
of IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
SSRIs NNP NNP B-CHEM
[ NN NN O
8 CD CD O
/ NN NN O
33 CD CD O
] NN NN O
) ) ) O
; : : O
16 CD CD O
% NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
7 CD CD O
) ) ) O
experienced VBN VBN O
manic JJ JJ O
episodes NNS NNS O
, , , O
and CC CC O
11 CD CD O
% NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
5 CD CD O
) ) ) O
experienced VBN VBN O
hypomanic JJ JJ O
episodes NNS NNS O
. . . O

Sex NN NN O
, , , O
age NN NN O
, , , O
diagnosis NN NN O
( ( ( O
bipolar NN NN O
I PRP PRP O
vs NNS NNS O
. . . O
bipolar NN NN O
II NNP NNP O
) ) ) O
, , , O
and CC CC O
additional JJ JJ O
treatment NN NN O
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
risk NN NN O
of IN IN O
switching VBG VBG O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
mood NN NN O
switches NNS NNS O
seemed VBD VBD O
not RB RB O
to TO TO O
differ VB VB O
between IN IN O
patients NNS NNS O
receiving VBG VBG O
an DT DT O
anticonvulsant NN NN O
and CC CC O
those DT DT O
receiving VBG VBG O
no DT DT O
mood NN NN O
stabilizer NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
mood NN NN O
switches NNS NNS O
were VBD VBD O
less RBR RBR O
frequent JJ JJ O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
lithium NN NN B-CHEM
( ( ( O
15 CD CD O
% NN NN O
, , , O
4 CD CD O
/ NN NN O
26 CD CD O
) ) ) O
than IN IN O
in IN IN O
patients NNS NNS O
not RB RB O
treated VBN VBN O
with IN IN O
lithium NN NN B-CHEM
( ( ( O
44 CD CD O
% NN NN O
, , , O
8 CD CD O
/ NN NN O
18 CD CD O
; : : O
p NN NN O
= SYM SYM O
. . . O
04 CD CD O
) ) ) O
. . . O

The DT DT O
number NN NN O
of IN IN O
previous JJ JJ O
manic JJ JJ O
episodes NNS NNS O
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
probability NN NN O
of IN IN O
switching VBG VBG O
, , , O
whereas IN IN O
a DT DT O
high JJ JJ O
score NN NN O
on IN IN O
the DT DT O
hyperthymia NN NN O
component NN NN O
of IN IN O
the DT DT O
Semistructured NNP NNP O
Affective NNP NNP O
Temperament NNP NNP O
Interview NNP NNP O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
greater JJR JJR O
risk NN NN O
of IN IN O
switching VBG VBG O
( ( ( O
p NN NN O
= SYM SYM O
. . . O
008 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
frequency NN NN O
of IN IN O
mood NN NN O
switching VBG VBG O
associated VBN VBN O
with IN IN O
acute JJ JJ O
antidepressant NN NN B-CHEM
therapy NN NN O
may MD MD O
be VB VB O
reduced VBN VBN O
by IN IN O
lithium NN NN B-CHEM
treatment NN NN O
. . . O

Particular JJ JJ O
attention NN NN O
should MD MD O
be VB VB O
paid VBN VBN O
to TO TO O
patients NNS NNS O
with IN IN O
a DT DT O
hyperthymic JJ JJ O
temperament NN NN O
, , , O
who WP WP O
have VBP VBP O
a DT DT O
greater JJR JJR O
risk NN NN O
of IN IN O
mood NN NN O
switches NNS NNS O
. . . O

Peritubular NNP NNP O
capillary JJ JJ O
basement NN NN O
membrane NN NN O
reduplication NN NN O
in IN IN O
allografts NNS NNS O
and CC CC O
native JJ JJ O
kidney NN NN O
disease NN NN O
: : : O
a DT DT O
clinicopathologic JJ JJ O
study NN NN O
of IN IN O
278 CD CD O
consecutive JJ JJ O
renal JJ JJ O
specimens NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
An DT DT O
association NN NN O
has VBZ VBZ O
been VBN VBN O
found VBN VBN O
between IN IN O
transplant NN NN O
glomerulopathy NN NN O
( ( ( O
TG NNP NNP O
) ) ) O
and CC CC O
reduplication NN NN O
of IN IN O
peritubular NN NN O
capillary JJ JJ O
basement NN NN O
membranes NNS NNS O
( ( ( O
PTCR NNP NNP O
) ) ) O
. . . O

Although IN IN O
such JJ JJ O
an DT DT O
association NN NN O
is VBZ VBZ O
of IN IN O
practical JJ JJ O
and CC CC O
theoretical JJ JJ O
importance NN NN O
, , , O
only RB RB O
one CD CD O
prospective JJ JJ O
study NN NN O
has VBZ VBZ O
tried VBN VBN O
to TO TO O
confirm VB VB O
it PRP PRP O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
examined VBD VBD O
278 CD CD O
consecutive JJ JJ O
renal NN NN O
specimens NNS NNS O
( ( ( O
from IN IN O
135 CD CD O
transplants NNS NNS O
and CC CC O
143 CD CD O
native JJ JJ O
kidneys NNS NNS O
) ) ) O
for IN IN O
ultrastructural JJ JJ O
evidence NN NN O
of IN IN O
PTCR NNP NNP O
. . . O

In IN IN O
addition NN NN O
to TO TO O
renal JJ JJ O
allografts NNS NNS O
with IN IN O
TG NNP NNP O
, , , O
we PRP PRP O
also RB RB O
examined VBD VBD O
grafts NNS NNS O
with IN IN O
acute JJ JJ O
rejection NN NN O
, , , O
recurrent JJ JJ O
glomerulonephritis NNS NNS O
, , , O
chronic JJ JJ O
allograft NN NN O
nephropathy NN NN O
and CC CC O
stable JJ JJ O
grafts NNS NNS O
( ( ( O
" '' '' O
protocol NN NN O
biopsies NNS NNS O
" '' '' O
) ) ) O
. . . O

Native NNP NNP O
kidney NN NN O
specimens NNS NNS O
included VBD VBD O
a DT DT O
wide JJ JJ O
range NN NN O
of IN IN O
glomerulopathies NNS NNS O
as RB RB O
well RB RB O
as IN IN O
cases NNS NNS O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
, , , O
malignant JJ JJ O
hypertension NN NN O
, , , O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
, , , O
and CC CC O
acute JJ JJ O
tubular JJ JJ O
necrosis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
found VBD VBD O
PTCR NNP NNP O
in IN IN O
14 CD CD O
of IN IN O
15 CD CD O
cases NNS NNS O
of IN IN O
TG NNP NNP O
, , , O
in IN IN O
7 CD CD O
transplant NN NN O
biopsy NN NN O
specimens NNS NNS O
without IN IN O
TG NNP NNP O
, , , O
and CC CC O
in IN IN O
13 CD CD O
of IN IN O
143 CD CD O
native JJ JJ O
kidney NN NN O
biopsy NN NN O
specimens NNS NNS O
. . . O

These DT DT O
13 CD CD O
included VBD VBD O
cases NNS NNS O
of IN IN O
malignant JJ JJ O
hypertension NN NN O
, , , O
thrombotic JJ JJ O
microangiopathy NN NN O
, , , O
lupus NN NN O
nephritis NNS NNS O
, , , O
Henoch NNP NNP O
- : : O
Schonlein NNP NNP O
nephritis NNS NNS O
, , , O
crescentic JJ JJ O
glomerulonephritis NN NN O
, , , O
and CC CC O
cocaine NN NN B-CHEM
- - - O
related VBN VBN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Mild NNP NNP O
PTCR NNP NNP O
in IN IN O
allografts NNS NNS O
without IN IN O
TG NNP NNP O
did VBD VBD O
not RB RB O
predict VB VB O
renal JJ JJ O
failure NN NN O
or CC CC O
significant JJ JJ O
proteinuria NN NN O
after IN IN O
follow VB VB O
- - - O
up RP RP O
periods NNS NNS O
of IN IN O
between IN IN O
3 CD CD O
months NNS NNS O
and CC CC O
1 CD CD O
year NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
We PRP PRP O
conclude VBP VBP O
that IN IN O
in IN IN O
transplants NNS NNS O
, , , O
there EX EX O
is VBZ VBZ O
a DT DT O
strong JJ JJ O
association NN NN O
between IN IN O
well RB RB O
- - - O
developed VBN VBN O
PTCR NNP NNP O
and CC CC O
TG NNP NNP O
, , , O
while IN IN O
the DT DT O
significance NN NN O
of IN IN O
mild JJ JJ O
PTCR NNP NNP O
and CC CC O
its PRP$ PRP$ O
predictive JJ JJ O
value NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
TG NNP NNP O
is VBZ VBZ O
unclear JJ JJ O
. . . O

PTCR NNP NNP O
also RB RB O
occurs VBZ VBZ O
in IN IN O
certain JJ JJ O
native JJ JJ O
kidney NN NN O
diseases NNS NNS O
, , , O
though IN IN O
the DT DT O
association NN NN O
is VBZ VBZ O
not RB RB O
as RB RB O
strong JJ JJ O
as IN IN O
that DT DT O
for IN IN O
TG NNP NNP O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
repeated VBN VBN O
endothelial JJ JJ O
injury NN NN O
, , , O
including VBG VBG O
immunologic JJ JJ O
injury NN NN O
, , , O
may MD MD O
be VB VB O
the DT DT O
cause NN NN O
of IN IN O
this DT DT O
lesion NN NN O
both DT DT O
in IN IN O
allografts NNS NNS O
and CC CC O
native JJ JJ O
kidneys NNS NNS O
. . . O

Caffeine NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
arrhythmia NN NN O
: : : O
an DT DT O
unrecognised JJ JJ O
danger NN NN O
of IN IN O
healthfood NN NN O
products NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
25 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
pre NN NN O
- - - O
existing VBG VBG O
mitral JJ JJ O
valve NN NN O
prolapse NN NN O
who WP WP O
developed VBD VBD O
intractable JJ JJ O
ventricular JJ JJ O
fibrillation NN NN O
after IN IN O
consuming VBG VBG O
a DT DT O
" '' '' O
natural JJ JJ O
energy NN NN O
" '' '' O
guarana NN NN O
health NN NN O
drink NN NN O
containing VBG VBG O
a DT DT O
high JJ JJ O
concentration NN NN O
of IN IN O
caffeine NN NN B-CHEM
. . . O

This DT DT O
case NN NN O
highlights VBZ VBZ O
the DT DT O
need NN NN O
for IN IN O
adequate JJ JJ O
labelling NN NN O
and CC CC O
regulation NN NN O
of IN IN O
such JJ JJ O
products NNS NNS O
. . . O

Conformationally RB RB O
restricted JJ JJ O
analogs NNS NNS O
of IN IN O
BD1008 NNP NNP B-CHEM
and CC CC O
an DT DT O
antisense NN NN O
oligodeoxynucleotide IN IN B-CHEM
targeting VBG VBG O
sigma1 NN NN O
receptors NNS NNS O
produce VBP VBP O
anti JJ JJ O
- : : O
cocaine NN NN B-CHEM
effects NNS NNS O
in IN IN O
mice NN NN O
. . . O

Cocaine NNP NNP B-CHEM
' POS POS O
s VBZ VBZ O
ability NN NN O
to TO TO O
interact VB VB O
with IN IN O
sigma NN NN O
receptors NNS NNS O
suggests VBZ VBZ O
that IN IN O
these DT DT O
proteins NNS NNS O
mediate VBP VBP O
some DT DT O
of IN IN O
its PRP$ PRP$ O
behavioral JJ JJ O
effects NNS NNS O
. . . O

Therefore RB RB O
, , , O
three CD CD O
novel NN NN O
sigma NN NN O
receptor NN NN O
ligands NNS NNS O
with IN IN O
antagonist NN NN O
activity NN NN O
were VBD VBD O
evaluated VBN VBN O
in IN IN O
Swiss NNP NNP O
Webster NNP NNP O
mice NNS NNS O
: : : O
BD1018 NNP NNP B-CHEM
( ( ( O
3S CD CD B-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dichlorophenyl NN NN I-CHEM
) ) ) I-CHEM
ethyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
diazabicyclo NN NN I-CHEM
[ NN NN I-CHEM
4 CD CD I-CHEM
. . . I-CHEM
3 CD CD I-CHEM
. . . I-CHEM
0 CD CD I-CHEM
] NN NN I-CHEM
nonane NN NN I-CHEM
) ) ) O
, , , O
BD1063 NNP NNP B-CHEM
( ( ( O
1 CD CD B-CHEM
- : : I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dichlorophenyl NN NN I-CHEM
) ) ) I-CHEM
ethyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylpiperazine NN NN I-CHEM
) ) ) O
, , , O
and CC CC O
LR132 NNP NNP B-CHEM
( ( ( O
1R CD CD O
, , , O
2S CD CD O
- : : O
( ( ( O
+ NN NN O
) ) ) O
- : : O
cis NN NN O
- - - O
N NNP NNP O
- : : O
[ NN NN O
2 CD CD O
- : : O
( ( ( O
3 CD CD O
, , , O
4 CD CD O
- : : O
dichlorophenyl NN NN O
) ) ) O
ethyl NN NN O
] NN NN O
- : : O
2 CD CD O
- : : O
( ( ( O
1 CD CD O
- : : O
pyrrolidinyl NN NN O
) ) ) O
cyclohexylamine NN NN O
) ) ) O
. . . O

Competition NN NN O
binding JJ JJ O
assays NNS NNS O
demonstrated VBN VBN O
that IN IN O
all DT DT O
three CD CD O
compounds NNS NNS O
have VBP VBP O
high JJ JJ O
affinities NNS NNS O
for IN IN O
sigma1 NN NN O
receptors NNS NNS O
. . . O

The DT DT O
three CD CD O
compounds NNS NNS O
vary JJ JJ O
in IN IN O
their PRP$ PRP$ O
affinities NNS NNS O
for IN IN O
sigma2 NN NN O
receptors NNS NNS O
and CC CC O
exhibit NN NN O
negligible JJ JJ O
affinities NNS NNS O
for IN IN O
dopamine NN NN B-CHEM
, , , O
opioid NN NN O
, , , O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
and CC CC O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
. . . O

In IN IN O
behavioral JJ JJ O
studies NNS NNS O
, , , O
pre NN NN O
- - - O
treatment NN NN O
of IN IN O
mice NNS NNS O
with IN IN O
BD1018 NNP NNP B-CHEM
, , , O
BD1063 NNP NNP B-CHEM
, , , O
or CC CC O
LR132 NNP NNP B-CHEM
significantly RB RB O
attenuated VBD VBD O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
and CC CC O
lethality NN NN O
. . . O

Moreover RB RB O
, , , O
post NN NN O
- - - O
treatment NN NN O
with IN IN O
LR132 NNP NNP B-CHEM
prevented VBD VBD O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
lethality NN NN O
in IN IN O
a DT DT O
significant JJ JJ O
proportion NN NN O
of IN IN O
animals NNS NNS O
. . . O

In IN IN O
contrast NN NN O
to TO TO O
the DT DT O
protection NN NN O
provided VBN VBN O
by IN IN O
the DT DT O
putative JJ JJ O
antagonists NNS NNS O
, , , O
the DT DT O
well RB RB O
- - - O
characterized JJ JJ O
sigma NN NN O
receptor NN NN O
agonist NN NN O
di NN NN B-CHEM
- : : I-CHEM
o NN NN I-CHEM
- : : I-CHEM
tolylguanidine NN NN I-CHEM
( ( ( O
DTG NNP NNP B-CHEM
) ) ) O
and CC CC O
the DT DT O
novel NN NN O
sigma NN NN O
receptor NN NN O
agonist NN NN O
BD1031 NNP NNP B-CHEM
( ( ( O
3R CD CD B-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dichlorophenyl NN NN I-CHEM
) ) ) I-CHEM
ethyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
diazabicyclo NN NN I-CHEM
[ NN NN I-CHEM
4 CD CD I-CHEM
. . . I-CHEM
3 CD CD I-CHEM
. . . I-CHEM
0 CD CD I-CHEM
] NN NN I-CHEM
nonane NN NN I-CHEM
) ) ) O
each DT DT O
worsened VBD VBD O
the DT DT O
behavioral JJ JJ O
toxicity NN NN O
of IN IN O
cocaine NN NN B-CHEM
. . . O

At IN IN O
doses NNS NNS O
where WRB WRB O
alone RB RB O
, , , O
they PRP PRP O
produced VBD VBD O
no DT DT O
significant JJ JJ O
effects NNS NNS O
on IN IN O
locomotion NN NN O
, , , O
BD1018 NNP NNP B-CHEM
, , , O
BD1063 NNP NNP B-CHEM
and CC CC O
LR132 NNP NNP B-CHEM
significantly RB RB O
attenuated VBD VBD O
the DT DT O
locomotor NN NN O
stimulatory JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
. . . O

To TO TO O
further VB VB O
validate NN NN O
the DT DT O
hypothesis NNS NNS O
that IN IN O
the DT DT O
anti JJ JJ O
- - - O
cocaine NN NN B-CHEM
effects NNS NNS O
of IN IN O
the DT DT O
novel NN NN O
ligands NNS NNS O
involved VBN VBN O
antagonism NN NN O
of IN IN O
sigma NN NN O
receptors NNS NNS O
, , , O
an DT DT O
antisense NN NN O
oligodeoxynucleotide NN NN B-CHEM
against IN IN O
sigma1 NN NN O
receptors NNS NNS O
was VBD VBD O
also RB RB O
shown VBN VBN O
to TO TO O
significantly RB RB O
attenuate VB VB O
the DT DT O
convulsive JJ JJ O
and CC CC O
locomotor NN NN O
stimulatory JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
. . . O

Together RB RB O
, , , O
the DT DT O
data NNS NNS O
suggests VBZ VBZ O
that IN IN O
functional JJ JJ O
antagonism NN NN O
of IN IN O
sigma NN NN O
receptors NNS NNS O
is VBZ VBZ O
capable JJ JJ O
of IN IN O
attenuating VBG VBG O
a DT DT O
number NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
behaviors NNS NNS O
. . . O

Ranitidine NNP NNP B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
in IN IN O
a DT DT O
cadaveric JJ JJ O
renal NN NN O
allograft NN NN O
. . . O

Ranitidine NNP NNP B-CHEM
frequently RB RB O
is VBZ VBZ O
used VBN VBN O
for IN IN O
preventing VBG VBG O
peptic JJ JJ O
ulceration NN NN O
after IN IN O
renal JJ JJ O
transplantation NN NN O
. . . O

This DT DT O
drug NN NN O
occasionally RB RB O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
in IN IN O
native JJ JJ O
kidneys NNS NNS O
. . . O

There EX EX O
are VBP VBP O
no DT DT O
similar JJ JJ O
reports NNS NNS O
with IN IN O
renal JJ JJ O
transplantation NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
ranitidine NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
in IN IN O
a DT DT O
recipient NN NN O
of IN IN O
a DT DT O
cadaveric JJ JJ O
renal NN NN O
allograft NN NN O
presenting VBG VBG O
with IN IN O
acute JJ JJ O
allograft NN NN O
dysfunction NN NN O
within IN IN O
48 CD CD O
hours NNS NNS O
of IN IN O
exposure NN NN O
to TO TO O
the DT DT O
drug NN NN O
. . . O

The DT DT O
biopsy NN NN O
specimen NN NN O
showed VBD VBD O
pathognomonic JJ JJ O
features NNS NNS O
, , , O
including VBG VBG O
eosinophilic JJ JJ O
infiltration NN NN O
of IN IN O
the DT DT O
interstitial JJ JJ O
compartment NN NN O
. . . O

Allograft NNP NNP O
function NN NN O
improved VBD VBD O
rapidly RB RB O
and CC CC O
returned VBD VBD O
to TO TO O
baseline VB VB O
after IN IN O
stopping VBG VBG O
the DT DT O
drug NN NN O
. . . O

Liver NNP NNP O
disease NN NN O
caused VBN VBN O
by IN IN O
propylthiouracil NN NN B-CHEM
. . . O

This DT DT O
report NN NN O
presents VBZ VBZ O
the DT DT O
clinical JJ JJ O
, , , O
laboratory NN NN O
, , , O
and CC CC O
light JJ JJ O
and CC CC O
electron NN NN O
microscopic NN NN O
observations NNS NNS O
on IN IN O
a DT DT O
patient NN NN O
with IN IN O
chronic JJ JJ O
active JJ JJ O
( ( ( O
aggressive JJ JJ O
) ) ) O
hepatitis NN NN O
caused VBN VBN O
by IN IN O
the DT DT O
administration NN NN O
of IN IN O
propylthiouracil NN NN B-CHEM
. . . O

This DT DT O
is VBZ VBZ O
an DT DT O
addition NN NN O
to TO TO O
the DT DT O
list NN NN O
of IN IN O
drugs NNS NNS O
that WDT WDT O
must MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
the DT DT O
evaluation NN NN O
of IN IN O
chronic JJ JJ O
liver NN NN O
disease NN NN O
. . . O

Withdrawal NNP NNP O
- : : O
emergent NN NN O
rabbit NN NN O
syndrome NN NN O
during IN IN O
dose NN NN O
reduction NN NN O
of IN IN O
risperidone NN NN B-CHEM
. . . O

Rabbit NNP NNP O
syndrome NN NN O
( ( ( O
RS NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
extrapyramidal NN NN O
side NN NN O
effect NN NN O
caused VBN VBN O
by IN IN O
prolonged JJ JJ O
neuroleptic JJ JJ O
medication NN NN O
. . . O

Here RB RB O
we PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
withdrawal NN NN O
- - - O
emergent NN NN O
RS NNP NNP O
, , , O
which WDT WDT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
of IN IN O
its PRP$ PRP$ O
kind NN NN O
to TO TO O
be VB VB O
reported VBN VBN O
. . . O

The DT DT O
patient NN NN O
developed VBN VBN O
RS NNP NNP O
during IN IN O
dose NN NN O
reduction NN NN O
of IN IN O
risperidone NN NN B-CHEM
. . . O

The DT DT O
symptom NN NN O
was VBD VBD O
treated VBN VBN O
successfully RB RB O
with IN IN O
trihexyphenidyl NN NN B-CHEM
anticholinergic JJ JJ O
therapy NN NN O
. . . O

The DT DT O
underlying VBG VBG O
mechanism NN NN O
of IN IN O
withdrawal NN NN O
- - - O
emergent NN NN O
RS NNP NNP O
in IN IN O
the DT DT O
present JJ JJ O
case NN NN O
may MD MD O
have VB VB O
been VBN VBN O
related VBN VBN O
to TO TO O
the DT DT O
pharmacological JJ JJ O
profile NN NN O
of IN IN O
risperidone NN NN B-CHEM
, , , O
a DT DT O
serotonin NN NN B-CHEM
- - - O
dopamine NN NN B-CHEM
antagonist NN NN O
, , , O
suggesting VBG VBG O
the DT DT O
pathophysiologic JJ JJ O
influence NN NN O
of IN IN O
the DT DT O
serotonin NN NN B-CHEM
system NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
RS NNP NNP O
. . . O

Pharmacokinetic NNP NNP O
/ NN NN O
pharmacodynamic JJ JJ O
assessment NN NN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
E4031 NNP NNP B-CHEM
, , , O
cisapride NN NN B-CHEM
, , , O
terfenadine NN NN B-CHEM
and CC CC O
terodiline NN NN B-CHEM
on IN IN O
monophasic JJ JJ O
action NN NN O
potential JJ JJ O
duration NN NN O
in IN IN O
dog NN NN O
. . . O

1 CD CD O
. . . O

Torsades NNP NNP O
de IN IN O
pointes NNS NNS O
( ( ( O
TDP NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
potentially RB RB O
fatal JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
associated VBN VBN O
with IN IN O
increases NNS NNS O
in IN IN O
QT NNP NNP O
interval NN NN O
and CC CC O
monophasic JJ JJ O
action NN NN O
potential JJ JJ O
duration NN NN O
( ( ( O
MAPD NNP NNP O
) ) ) O
. . . O

TDP NNP NNP O
is VBZ VBZ O
a DT DT O
side NN NN O
- - - O
effect NN NN O
that WDT WDT O
has VBZ VBZ O
led VBN VBN O
to TO TO O
withdrawal NN NN O
of IN IN O
several JJ JJ O
drugs NNS NNS O
from IN IN O
the DT DT O
market NN NN O
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
terfenadine NN NN B-CHEM
and CC CC O
terodiline NN NN B-CHEM
) ) ) O
. . . O

2 CD CD O
. . . O

The DT DT O
potential NN NN O
of IN IN O
compounds NNS NNS O
to TO TO O
cause VB VB O
TDP NNP NNP O
was VBD VBD O
evaluated VBN VBN O
by IN IN O
monitoring VBG VBG O
their PRP$ PRP$ O
effects NNS NNS O
on IN IN O
MAPD NNP NNP O
in IN IN O
dog NN NN O
. . . O

Four CD CD O
compounds NNS NNS O
known VBN VBN O
to TO TO O
increase VB VB O
QT NNP NNP O
interval NN NN O
and CC CC O
cause VB VB O
TDP NNP NNP O
were VBD VBD O
investigated VBN VBN O
: : : O
terfenadine NN NN B-CHEM
, , , O
terodiline NN NN B-CHEM
, , , O
cisapride NN NN B-CHEM
and CC CC O
E4031 NNP NNP B-CHEM
. . . O

On IN IN O
the DT DT O
basis NN NN O
that IN IN O
only RB RB O
free JJ JJ O
drug NN NN O
in IN IN O
the DT DT O
systemic JJ JJ O
circulation NN NN O
will MD MD O
elicit VB VB O
a DT DT O
pharmacological JJ JJ O
response NN NN O
target NN NN O
, , , O
free JJ JJ O
concentrations NNS NNS O
in IN IN O
plasma NN NN O
were VBD VBD O
selected VBN VBN O
to TO TO O
mimic VB VB O
the DT DT O
free JJ JJ O
drug NN NN O
exposures NNS NNS O
in IN IN O
man NN NN O
. . . O

Infusion NNP NNP O
regimens NNS NNS O
were VBD VBD O
designed VBN VBN O
that IN IN O
rapidly RB RB O
achieved VBN VBN O
and CC CC O
maintained VBN VBN O
target NN NN O
- - - O
free JJ JJ O
concentrations NNS NNS O
of IN IN O
these DT DT O
drugs NNS NNS O
in IN IN O
plasma NN NN O
and CC CC O
data NNS NNS O
on IN IN O
the DT DT O
relationship NN NN O
between IN IN O
free JJ JJ O
concentration NN NN O
and CC CC O
changes NNS NNS O
in IN IN O
MAPD NNP NNP O
were VBD VBD O
obtained VBN VBN O
for IN IN O
these DT DT O
compounds NNS NNS O
. . . O

3 CD CD O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
free JJ JJ O
ED50 NNP NNP O
in IN IN O
plasma NN NN O
for IN IN O
terfenadine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
9 CD CD O
nM NN NN O
) ) ) O
, , , O
terodiline NN NN B-CHEM
( ( ( O
76 CD CD O
nM NN NN O
) ) ) O
, , , O
cisapride NN NN B-CHEM
( ( ( O
11 CD CD O
nM NN NN O
) ) ) O
and CC CC O
E4031 NNP NNP B-CHEM
( ( ( O
1 CD CD O
. . . O
9 CD CD O
nM NN NN O
) ) ) O
closely RB RB O
correlate VBP VBP O
with IN IN O
the DT DT O
free JJ JJ O
concentration NN NN O
in IN IN O
man NN NN O
causing VBG VBG O
QT NNP NNP O
effects NNS NNS O
. . . O

For IN IN O
compounds NNS NNS O
that WDT WDT O
have VBP VBP O
shown VBN VBN O
TDP NNP NNP O
in IN IN O
the DT DT O
clinic NN NN O
( ( ( O
terfenadine NN NN B-CHEM
, , , O
terodiline NN NN B-CHEM
, , , O
cisapride NN NN B-CHEM
) ) ) O
there EX EX O
is VBZ VBZ O
little JJ JJ O
differentiation NN NN O
between IN IN O
the DT DT O
dog NN NN O
ED50 NNP NNP O
and CC CC O
the DT DT O
efficacious JJ JJ O
free JJ JJ O
plasma NN NN O
concentrations NNS NNS O
in IN IN O
man NN NN O
( ( ( O
< NN NN O
10 CD CD O
- : : O
fold NN NN O
) ) ) O
reflecting VBG VBG O
their PRP$ PRP$ O
limited JJ JJ O
safety NN NN O
margins NNS NNS O
. . . O

These DT DT O
data NNS NNS O
underline VBP VBP O
the DT DT O
need NN NN O
to TO TO O
maximize VB VB O
the DT DT O
therapeutic JJ JJ O
ratio NN NN O
with IN IN O
respect NN NN O
to TO TO O
TDP NNP NNP O
in IN IN O
potential JJ JJ O
development NN NN O
candidates NNS NNS O
and CC CC O
the DT DT O
importance NN NN O
of IN IN O
using VBG VBG O
free JJ JJ O
drug NN NN O
concentrations NNS NNS O
in IN IN O
pharmacokinetic JJ JJ O
/ NN NN O
pharmacodynamic JJ JJ O
studies NNS NNS O
. . . O

Bladder NNP NNP O
retention NN NN O
of IN IN O
urine NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
continuous JJ JJ O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
fentanyl NN NN B-CHEM
: : : O
2 CD CD O
case NN NN O
reports NNS NNS O
. . . O

Sedation NNP NNP O
has VBZ VBZ O
been VBN VBN O
commonly RB RB O
used VBN VBN O
in IN IN O
the DT DT O
neonate NN NN O
to TO TO O
decrease VB VB O
the DT DT O
stress NN NN O
and CC CC O
pain NN NN O
from IN IN O
the DT DT O
noxious JJ JJ O
stimuli NN NN O
and CC CC O
invasive JJ JJ O
procedures NNS NNS O
in IN IN O
the DT DT O
neonatal JJ JJ O
intensive JJ JJ O
care NN NN O
unit NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
to TO TO O
facilitate VB VB O
synchrony NN NN O
between IN IN O
ventilator NN NN O
and CC CC O
spontaneous JJ JJ O
breaths NNS NNS O
. . . O

Fentanyl NNP NNP B-CHEM
, , , O
an DT DT O
opioid NN NN O
analgesic NN NN O
, , , O
is VBZ VBZ O
frequently RB RB O
used VBN VBN O
in IN IN O
the DT DT O
neonatal JJ JJ O
intensive JJ JJ O
care NN NN O
unit NN NN O
setting VBG VBG O
for IN IN O
these DT DT O
very RB RB O
purposes NNS NNS O
. . . O

Various JJ JJ O
reported VBD VBD O
side NN NN O
effects NNS NNS O
of IN IN O
fentanyl NN NN B-CHEM
administration NN NN O
include VBP VBP O
chest NN NN O
wall NN NN O
rigidity NN NN O
, , , O
hypotension NN NN O
, , , O
respiratory JJ JJ O
depression NN NN O
, , , O
and CC CC O
bradycardia NN NN O
. . . O

Here RB RB O
, , , O
2 CD CD O
cases NNS NNS O
of IN IN O
urinary JJ JJ O
bladder NN NN O
retention NN NN O
leading VBG VBG O
to TO TO O
renal VB VB O
pelvocalyceal NN NN O
dilatation NN NN O
mimicking VBG VBG O
hydronephrosis NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
continuous JJ JJ O
infusion NN NN O
of IN IN O
fentanyl NN NN B-CHEM
are VBP VBP O
reported VBN VBN O
. . . O

Fatal NNP NNP O
myeloencephalopathy NN NN O
due JJ JJ O
to TO TO O
accidental VB VB O
intrathecal JJ JJ O
vincristin NN NN B-CHEM
administration NN NN O
: : : O
a DT DT O
report NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
two CD CD O
fatal JJ JJ O
cases NNS NNS O
of IN IN O
accidental JJ JJ O
intrathecal JJ JJ O
vincristine NN NN B-CHEM
instillation NN NN O
in IN IN O
a DT DT O
5 CD CD O
- : : O
year NN NN O
old JJ JJ O
girl NN NN O
with IN IN O
recurrent JJ JJ O
acute JJ JJ O
lymphoblastic JJ JJ O
leucemia NN NN O
and CC CC O
a DT DT O
57 CD CD O
- : : O
year NN NN O
old JJ JJ O
man NN NN O
with IN IN O
lymphoblastic JJ JJ O
lymphoma NN NN O
. . . O

The DT DT O
girl NN NN O
died VBD VBD O
seven CD CD O
days NNS NNS O
, , , O
the DT DT O
man NN NN O
four CD CD O
weeks NNS NNS O
after IN IN O
intrathecal JJ JJ O
injection NN NN O
of IN IN O
vincristine NN NN B-CHEM
. . . O

Clinically RB RB O
, , , O
the DT DT O
onset NN NN O
was VBD VBD O
characterized VBN VBN O
by IN IN O
the DT DT O
signs NNS NNS O
of IN IN O
opistothonus NN NN O
, , , O
sensory JJ JJ O
and CC CC O
motor NN NN O
dysfunction NN NN O
and CC CC O
ascending VBG VBG O
paralysis NN NN O
. . . O

Histological NNP NNP O
and CC CC O
immunohistochemical JJ JJ O
investigations NNS NNS O
( ( ( O
HE PRP PRP O
- - - O
LFB NNP NNP O
, , , O
CD NNP NNP O
- : : O
68 CD CD O
, , , O
Neurofilament NNP NNP O
) ) ) O
revealed JJ JJ O
degeneration NN NN O
of IN IN O
myelin NN NN O
and CC CC O
axons NNS NNS O
as RB RB O
well RB RB O
as IN IN O
pseudocystic JJ JJ O
transformation NN NN O
in IN IN O
areas NNS NNS O
exposed VBN VBN O
to TO TO O
vincristine NN NN B-CHEM
, , , O
accompanied VBN VBN O
by IN IN O
secondary JJ JJ O
changes NNS NNS O
with IN IN O
numerous JJ JJ O
prominent JJ JJ O
macrophages NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
course NN NN O
and CC CC O
histopathological JJ JJ O
results NNS NNS O
of IN IN O
the DT DT O
two CD CD O
cases NNS NNS O
are VBP VBP O
presented VBN VBN O
. . . O

A DT DT O
review NN NN O
of IN IN O
all DT DT O
reported VBN VBN O
cases NNS NNS O
in IN IN O
the DT DT O
literature NN NN O
is VBZ VBZ O
given VBN VBN O
. . . O

A DT DT O
better JJR JJR O
controlled JJ JJ O
regimen NNS NNS O
for IN IN O
administering VBG VBG O
vincristine NN NN B-CHEM
and CC CC O
intrathecal JJ JJ O
chemotherapy NN NN O
is VBZ VBZ O
recommended VBN VBN O
. . . O

Palpebral NNP NNP O
twitching VBG VBG O
in IN IN O
a DT DT O
depressed JJ JJ O
adolescent NN NN O
on IN IN O
citalopram NN NN B-CHEM
. . . O

Current NNP NNP O
estimates NNS NNS O
suggest VBP VBP O
that IN IN O
between IN IN O
0 CD CD O
. . . O
4 CD CD O
% NN NN O
and CC CC O
8 CD CD O
. . . O
3 CD CD O
% NN NN O
of IN IN O
children NNS NNS O
and CC CC O
adolescents NNS NNS O
are VBP VBP O
affected VBN VBN O
by IN IN O
major JJ JJ O
depression NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
favorable JJ JJ O
response NN NN O
to TO TO O
treatment NN NN O
with IN IN O
citalopram NN NN B-CHEM
by IN IN O
a DT DT O
15 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
with IN IN O
major JJ JJ O
depression NN NN O
who WP WP O
exhibited VBD VBD O
palpebral JJ JJ O
twitching VBG VBG O
during IN IN O
his PRP$ PRP$ O
first JJ JJ O
2 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

This DT DT O
may MD MD O
have VB VB O
been VBN VBN O
a DT DT O
side NN NN O
effect NN NN O
of IN IN O
citalopram NN NN B-CHEM
as IN IN O
it PRP PRP O
remitted VBD VBD O
with IN IN O
redistribution NN NN O
of IN IN O
doses NNS NNS O
. . . O

The DT DT O
3 CD CD O
- : : O
week NN NN O
sulphasalazine NN NN B-CHEM
syndrome NN NN O
strikes NNS NNS O
again RB RB O
. . . O

A DT DT O
34 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
lady NN NN O
developed VBD VBD O
a DT DT O
constellation NN NN O
of IN IN O
dermatitis NNS NNS O
, , , O
fever NN NN O
, , , O
lymphadenopathy JJ JJ O
and CC CC O
hepatitis NN NN O
, , , O
beginning VBG VBG O
on IN IN O
the DT DT O
17th CD CD O
day NN NN O
of IN IN O
a DT DT O
course NN NN O
of IN IN O
oral JJ JJ O
sulphasalazine NN NN B-CHEM
for IN IN O
sero NN NN O
- - - O
negative JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
. . . O

Cervical NNP NNP O
and CC CC O
inguinal JJ JJ O
lymph NN NN O
node NN NN O
biopsies NNS NNS O
showed VBD VBD O
the DT DT O
features NNS NNS O
of IN IN O
severe JJ JJ O
necrotising VBG VBG O
lymphadenitis NN NN O
, , , O
associated VBN VBN O
with IN IN O
erythrophagocytosis NNS NNS O
and CC CC O
prominent JJ JJ O
eosinophilic JJ JJ O
infiltrates NNS NNS O
, , , O
without IN IN O
viral JJ JJ O
inclusion NN NN O
bodies NNS NNS O
, , , O
suggestive NN NN O
of IN IN O
an DT DT O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
. . . O
A DT DT O
week NN NN O
later RB RB O
, , , O
fulminant JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
hepatitis NN NN O
, , , O
associated VBN VBN O
with IN IN O
the DT DT O
presence NN NN O
of IN IN O
anti JJ JJ O
- - - O
nuclear JJ JJ O
autoantibodies NNS NNS O
( ( ( O
but CC CC O
not RB RB O
with IN IN O
other JJ JJ O
markers NNS NNS O
of IN IN O
autoimmunity NN NN O
) ) ) O
, , , O
and CC CC O
accompanied VBN VBN O
by IN IN O
multi NN NN O
- - - O
organ NN NN O
failure NN NN O
and CC CC O
sepsis NN NN O
, , , O
supervened VBD VBD O
. . . O

She PRP PRP O
subsequently RB RB O
died VBD VBD O
some DT DT O
5 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
commencement NN NN O
of IN IN O
her PRP$ PRP$ O
drug NN NN O
therapy NN NN O
. . . O
Post NNP NNP O
- : : O
mortem NN NN O
examination NN NN O
showed VBD VBD O
evidence NN NN O
of IN IN O
massive JJ JJ O
hepatocellular NN NN O
necrosis NN NN O
, , , O
acute JJ JJ O
hypersensitivity NN NN O
myocarditis NN NN O
, , , O
focal JJ JJ O
acute JJ JJ O
tubulo NN NN O
- : : O
interstitial JJ JJ O
nephritis NNS NNS O
and CC CC O
extensive JJ JJ O
bone NN NN O
marrow NN NN O
necrosis NN NN O
, , , O
with IN IN O
no DT DT O
evidence NN NN O
of IN IN O
malignancy NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
thought VBN VBN O
that IN IN O
the DT DT O
clinico NN NN O
- - - O
pathological JJ JJ O
features NNS NNS O
and CC CC O
chronology NN NN O
of IN IN O
this DT DT O
case NN NN O
bore NN NN O
the DT DT O
hallmarks NNS NNS O
of IN IN O
the DT DT O
so RB RB O
- - - O
called VBN VBN O
" '' '' O
3 CD CD O
- : : O
week NN NN O
sulphasalazine NN NN B-CHEM
syndrome NN NN O
" '' '' O
, , , O
a DT DT O
rare JJ JJ O
, , , O
but CC CC O
often RB RB O
fatal JJ JJ O
, , , O
immunoallergic JJ JJ O
reaction NN NN O
to TO TO O
sulphasalazine VB VB B-CHEM
. . . O

Intravenous NNP NNP O
administration NN NN O
of IN IN O
prochlorperazine NN NN B-CHEM
by IN IN O
15 CD CD O
- : : O
minute NN NN O
infusion NN NN O
versus CC CC O
2 CD CD O
- : : O
minute NN NN O
bolus NN NN O
does VBZ VBZ O
not RB RB O
affect VB VB O
the DT DT O
incidence NN NN O
of IN IN O
akathisia NN NN O
: : : O
a DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
controlled VBN VBN O
trial NN NN O
. . . O

STUDY NNP NNP O
OBJECTIVE NNP NNP O
: : : O
We PRP PRP O
sought VBD VBD O
to TO TO O
compare VB VB O
the DT DT O
rate NN NN O
of IN IN O
akathisia NN NN O
after IN IN O
administration NN NN O
of IN IN O
intravenous JJ JJ O
prochlorperazine NN NN B-CHEM
as IN IN O
a DT DT O
2 CD CD O
- : : O
minute NN NN O
bolus NN NN O
or CC CC O
15 CD CD O
- : : O
minute NN NN O
infusion NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
conducted VBD VBD O
a DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
of IN IN O
a DT DT O
central JJ JJ O
- - - O
city NN NN O
teaching NN NN O
hospital NN NN O
. . . O

Patients NNS NNS O
aged VBN VBN O
18 CD CD O
years NNS NNS O
or CC CC O
older JJR JJR O
treated VBN VBN O
with IN IN O
prochlorperazine NN NN B-CHEM
for IN IN O
headache NN NN O
, , , O
nausea NN NN O
, , , O
or CC CC O
vomiting VBG VBG O
were VBD VBD O
eligible JJ JJ O
for IN IN O
inclusion NN NN O
. . . O

Study NNP NNP O
participants NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
10 CD CD O
mg NN NN O
of IN IN O
prochlorperazine NN NN B-CHEM
administered VBN VBN O
intravenously RB RB O
by IN IN O
means NNS NNS O
of IN IN O
2 CD CD O
- : : O
minute NN NN O
push NN NN O
( ( ( O
bolus NN NN O
group NN NN O
) ) ) O
or CC CC O
10 CD CD O
mg NN NN O
diluted VBD VBD O
in IN IN O
50 CD CD O
mL NN NN O
of IN IN O
normal JJ JJ O
saline NN NN O
solution NN NN O
administered VBN VBN O
by IN IN O
means NNS NNS O
of IN IN O
intravenous JJ JJ O
infusion NN NN O
during IN IN O
a DT DT O
15 CD CD O
- : : O
minute NN NN O
period NN NN O
( ( ( O
infusion NN NN O
group NN NN O
) ) ) O
. . . O

The DT DT O
main JJ JJ O
outcome NN NN O
was VBD VBD O
the DT DT O
number NN NN O
of IN IN O
study NN NN O
participants NNS NNS O
experiencing VBG VBG O
akathisia NN NN O
within IN IN O
60 CD CD O
minutes NNS NNS O
of IN IN O
administration NN NN O
. . . O

Akathisia NNP NNP O
was VBD VBD O
defined VBN VBN O
as IN IN O
either DT DT O
a DT DT O
spontaneous JJ JJ O
report NN NN O
of IN IN O
restlessness NNS NNS O
or CC CC O
agitation NN NN O
or CC CC O
a DT DT O
change NN NN O
of IN IN O
2 CD CD O
or CC CC O
more JJR JJR O
in IN IN O
the DT DT O
patient NN NN O
- - - O
reported VBN VBN O
akathisia NN NN O
rating NN NN O
scale NN NN O
and CC CC O
a DT DT O
change NN NN O
of IN IN O
at IN IN O
least JJS JJS O
1 CD CD O
in IN IN O
the DT DT O
investigator NN NN O
- - - O
observed VBN VBN O
akathisia NN NN O
rating NN NN O
scale NN NN O
. . . O

The DT DT O
intensity NN NN O
of IN IN O
headache NN NN O
and CC CC O
nausea NN NN O
was VBD VBD O
measured VBN VBN O
with IN IN O
a DT DT O
100 CD CD O
- : : O
mm NN NN O
visual JJ JJ O
analog NN NN O
scale NN NN O
. . . O

RESULTS NNS NNS O
: : : O
One CD CD O
hundred CD CD O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
. . . O

One CD CD O
study NN NN O
participant NN NN O
was VBD VBD O
excluded VBN VBN O
after IN IN O
protocol NN NN O
violation NN NN O
. . . O

Seventy CD CD O
- - - O
three CD CD O
percent NN NN O
( ( ( O
73 CD CD O
/ NN NN O
99 CD CD O
) ) ) O
of IN IN O
the DT DT O
study NN NN O
participants NNS NNS O
were VBD VBD O
treated VBN VBN O
for IN IN O
headache NN NN O
and CC CC O
70 CD CD O
% NN NN O
( ( ( O
70 CD CD O
/ NN NN O
99 CD CD O
) ) ) O
for IN IN O
nausea NN NN O
. . . O

In IN IN O
the DT DT O
bolus NN NN O
group NN NN O
, , , O
26 CD CD O
. . . O
0 CD CD O
% NN NN O
( ( ( O
13 CD CD O
/ NN NN O
50 CD CD O
) ) ) O
had VBD VBD O
akathisia NN NN O
compared VBN VBN O
with IN IN O
32 CD CD O
. . . O
7 CD CD O
% NN NN O
( ( ( O
16 CD CD O
/ NN NN O
49 CD CD O
) ) ) O
in IN IN O
the DT DT O
infusion NN NN O
group NN NN O
( ( ( O
Delta NNP NNP O
= SYM SYM O
- : : O
6 CD CD O
. . . O
7 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
- : : O
24 CD CD O
. . . O
6 CD CD O
% NN NN O
to TO TO O
11 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
difference NN NN O
between IN IN O
the DT DT O
bolus NN NN O
and CC CC O
infusion NN NN O
groups NNS NNS O
in IN IN O
the DT DT O
percentage NN NN O
of IN IN O
participants NNS NNS O
who WP WP O
saw VBD VBD O
a DT DT O
50 CD CD O
% NN NN O
reduction NN NN O
in IN IN O
their PRP$ PRP$ O
headache NN NN O
intensity NN NN O
within IN IN O
30 CD CD O
minutes NNS NNS O
was VBD VBD O
11 CD CD O
. . . O
8 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
- : : O
9 CD CD O
. . . O
6 CD CD O
% NN NN O
to TO TO O
33 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
difference NN NN O
in IN IN O
the DT DT O
percentage NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
50 CD CD O
% NN NN O
reduction NN NN O
in IN IN O
their PRP$ PRP$ O
nausea NN NN O
was VBD VBD O
12 CD CD O
. . . O
6 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
- : : O
4 CD CD O
. . . O
6 CD CD O
% NN NN O
to TO TO O
29 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
A DT DT O
50 CD CD O
% NN NN O
reduction NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
akathisia NN NN O
when WRB WRB O
prochlorperazine NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
by IN IN O
means NNS NNS O
of IN IN O
15 CD CD O
- : : O
minute NN NN O
intravenous JJ JJ O
infusion NN NN O
versus CC CC O
a DT DT O
2 CD CD O
- : : O
minute NN NN O
intravenous JJ JJ O
push NN NN O
was VBD VBD O
not RB RB O
detected VBN VBN O
. . . O

The DT DT O
efficacy NN NN O
of IN IN O
prochlorperazine NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
headache NN NN O
and CC CC O
nausea NN NN O
likewise NN NN O
did VBD VBD O
not RB RB O
appear VB VB O
to TO TO O
be VB VB O
affected VBN VBN O
by IN IN O
the DT DT O
rate NN NN O
of IN IN O
administration NN NN O
, , , O
although IN IN O
no DT DT O
formal JJ JJ O
statistical JJ JJ O
comparisons NNS NNS O
were VBD VBD O
made VBN VBN O
. . . O

Combined NNP NNP O
antiretroviral JJ JJ O
therapy NN NN O
causes NNS NNS O
cardiomyopathy NN NN O
and CC CC O
elevates NNS NNS O
plasma NN NN O
lactate NN NN B-CHEM
in IN IN O
transgenic JJ JJ O
AIDS NNP NNP O
mice NN NN O
. . . O

Highly RB RB O
active JJ JJ O
antiretroviral NN NN O
therapy NN NN O
( ( ( O
HAART NNP NNP O
) ) ) O
is VBZ VBZ O
implicated VBN VBN O
in IN IN O
cardiomyopathy NN NN O
( ( ( O
CM NNP NNP O
) ) ) O
and CC CC O
in IN IN O
elevated VBD VBD O
plasma NN NN O
lactate NN NN B-CHEM
( ( ( O
LA NNP NNP B-CHEM
) ) ) O
in IN IN O
AIDS NNP NNP O
through IN IN O
mechanisms NNS NNS O
of IN IN O
mitochondrial JJ JJ O
dysfunction NN NN O
. . . O

To TO TO O
determine VB VB O
mitochondrial JJ JJ O
events NNS NNS O
from IN IN O
HAART NNP NNP O
in IN IN O
vivo NN NN O
, , , O
8 CD CD O
- - - O
week NN NN O
- - - O
old JJ JJ O
hemizygous JJ JJ O
transgenic JJ JJ O
AIDS NNP NNP O
mice NN NN O
( ( ( O
NL4 NNP NNP O
- : : O
3Delta CD CD O
gag NN NN O
/ NN NN O
pol NN NN O
; : : O
TG NNP NNP O
) ) ) O
and CC CC O
wild JJ JJ O
- - - O
type NN NN O
FVB NNP NNP O
/ NN NN O
n NN NN O
littermates NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
the DT DT O
HAART NNP NNP O
combination NN NN O
of IN IN O
zidovudine NN NN B-CHEM
, , , O
lamivudine NN NN B-CHEM
, , , O
and CC CC O
indinavir NN NN B-CHEM
or CC CC O
vehicle NN NN O
control NN NN O
for IN IN O
10 CD CD O
days NNS NNS O
or CC CC O
35 CD CD O
days NNS NNS O
. . . O

At IN IN O
termination NN NN O
of IN IN O
the DT DT O
experiments NNS NNS O
, , , O
mice NN NN O
underwent JJ JJ O
echocardiography NN NN O
, , , O
quantitation NN NN O
of IN IN O
abundance NN NN O
of IN IN O
molecular JJ JJ O
markers NNS NNS O
of IN IN O
CM NNP NNP O
( ( ( O
ventricular NN NN O
mRNA NN NN O
encoding VBG VBG O
atrial JJ JJ O
natriuretic JJ JJ O
factor NN NN O
[ NN NN O
ANF NNP NNP O
] NN NN O
and CC CC O
sarcoplasmic JJ JJ O
calcium NN NN B-CHEM
ATPase NNP NNP O
[ NN NN O
SERCA2 NNP NNP O
] NN NN O
) ) ) O
, , , O
and CC CC O
determination NN NN O
of IN IN O
plasma NN NN O
LA NNP NNP B-CHEM
. . . O

Myocardial NNP NNP O
histologic JJ JJ O
features NNS NNS O
were VBD VBD O
analyzed VBN VBN O
semiquantitatively RB RB O
and CC CC O
results NNS NNS O
were VBD VBD O
confirmed VBN VBN O
by IN IN O
transmission NN NN O
electron NN NN O
microscopy NN NN O
. . . O

After IN IN O
35 CD CD O
days NNS NNS O
in IN IN O
the DT DT O
TG NNP NNP O
+ NN NN O
HAART NNP NNP O
cohort NN NN O
, , , O
left VBD VBD O
ventricular NN NN O
mass NN NN O
increased VBD VBD O
160 CD CD O
% NN NN O
by IN IN O
echocardiography NN NN O
. . . O

Molecularly NNP NNP O
, , , O
ANF NNP NNP O
mRNA NN NN O
increased VBD VBD O
250 CD CD O
% NN NN O
and CC CC O
SERCA2 NNP NNP O
mRNA NN NN O
decreased VBD VBD O
57 CD CD O
% NN NN O
. . . O

Biochemically NNP NNP O
, , , O
LA NNP NNP B-CHEM
was VBD VBD O
elevated VBN VBN O
( ( ( O
8 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
0 CD CD O
mM NN NN O
) ) ) O
. . . O

Pathologically NNP NNP O
, , , O
granular JJ JJ O
cytoplasmic JJ JJ O
changes NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
cardiac JJ JJ O
myocytes NNS NNS O
, , , O
indicating VBG VBG O
enlarged JJ JJ O
, , , O
damaged JJ JJ O
mitochondria NN NN O
. . . O

Findings NNS NNS O
were VBD VBD O
confirmed VBN VBN O
ultrastructurally RB RB O
. . . O

No DT DT O
changes NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
other JJ JJ O
cohorts NNS NNS O
. . . O

After IN IN O
10 CD CD O
days NNS NNS O
, , , O
only RB RB O
ANF NNP NNP O
was VBD VBD O
elevated VBN VBN O
, , , O
and CC CC O
only RB RB O
in IN IN O
the DT DT O
TG NNP NNP O
+ NN NN O
HAART NNP NNP O
cohort NN NN O
. . . O

Results NNS NNS O
show VBP VBP O
that IN IN O
cumulative JJ JJ O
HAART NNP NNP O
caused VBD VBD O
mitochondrial JJ JJ O
CM NNP NNP O
with IN IN O
elevated VBD VBD O
LA NNP NNP B-CHEM
in IN IN O
AIDS NNP NNP O
transgenic JJ JJ O
mice NNS NNS O
. . . O

A DT DT O
Phase NNP NNP O
II NNP NNP O
trial NN NN O
of IN IN O
cisplatin NN NN B-CHEM
plus CC CC O
WR NNP NNP B-CHEM
- : : I-CHEM
2721 CD CD I-CHEM
( ( ( O
amifostine NN NN B-CHEM
) ) ) O
for IN IN O
metastatic JJ JJ O
breast NN NN O
carcinoma NN NN O
: : : O
an DT DT O
Eastern NNP NNP O
Cooperative NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
Study NNP NNP O
( ( ( O
E8188 NNP NNP O
) ) ) O
. . . O

BACKGROUND NNP NNP O
: : : O
Cisplatin NNP NNP B-CHEM
has VBZ VBZ O
minimal JJ JJ O
antitumor NN NN O
activity NN NN O
when WRB WRB O
used VBN VBN O
as IN IN O
second JJ JJ O
- - - O
or CC CC O
third JJ JJ O
- - - O
line NN NN O
treatment NN NN O
of IN IN O
metastatic JJ JJ O
breast NN NN O
carcinoma NN NN O
. . . O

Older JJR JJR O
reports NNS NNS O
suggest VBP VBP O
an DT DT O
objective NN NN O
response NN NN O
rate NN NN O
of IN IN O
8 CD CD O
% NN NN O
when WRB WRB O
60 CD CD O
- : : O
120 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
of IN IN O
cisplatin NN NN B-CHEM
is VBZ VBZ O
administered VBN VBN O
every DT DT O
3 CD CD O
- : : O
4 CD CD O
weeks NNS NNS O
. . . O

Although IN IN O
a DT DT O
dose NN NN O
- - - O
response NN NN O
effect NN NN O
has VBZ VBZ O
been VBN VBN O
observed VBN VBN O
with IN IN O
cisplatin NN NN B-CHEM
, , , O
the DT DT O
dose NN NN O
- - - O
limiting VBG VBG O
toxicities NNS NNS O
associated VBN VBN O
with IN IN O
cisplatin NN NN B-CHEM
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
, , , O
nephrotoxicity NN NN O
, , , O
ototoxicity NN NN O
, , , O
and CC CC O
neurotoxicity NN NN O
) ) ) O
have VBP VBP O
limited JJ JJ O
its PRP$ PRP$ O
use NN NN O
as IN IN O
a DT DT O
treatment NN NN O
for IN IN O
breast NN NN O
carcinoma NN NN O
. . . O

WR NNP NNP B-CHEM
- : : I-CHEM
2721 CD CD I-CHEM
or CC CC O
amifostine NN NN B-CHEM
initially RB RB O
was VBD VBD O
developed VBN VBN O
to TO TO O
protect VB VB O
military JJ JJ O
personnel NNS NNS O
in IN IN O
the DT DT O
event NN NN O
of IN IN O
nuclear JJ JJ O
war NN NN O
. . . O

Amifostine NNP NNP B-CHEM
subsequently RB RB O
was VBD VBD O
shown VBN VBN O
to TO TO O
protect VB VB O
normal JJ JJ O
tissues NNS NNS O
from IN IN O
the DT DT O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
alkylating VBG VBG B-CHEM
agents NNS NNS I-CHEM
and CC CC O
cisplatin NN NN B-CHEM
without IN IN O
decreasing VBG VBG O
the DT DT O
antitumor NN NN O
effect NN NN O
of IN IN O
the DT DT O
chemotherapy NN NN O
. . . O

Early JJ JJ O
trials NNS NNS O
of IN IN O
cisplatin NN NN B-CHEM
and CC CC O
amifostine NN NN B-CHEM
also RB RB O
suggested VBD VBD O
that IN IN O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
, , , O
ototoxicity NN NN O
, , , O
and CC CC O
neuropathy NN NN O
were VBD VBD O
reduced VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
Phase NNP NNP O
II NNP NNP O
study NN NN O
of IN IN O
the DT DT O
combination NN NN O
of IN IN O
cisplatin NN NN B-CHEM
plus CC CC O
amifostine NN NN B-CHEM
was VBD VBD O
conducted VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
progressive JJ JJ O
metastatic JJ JJ O
breast NN NN O
carcinoma NN NN O
who WP WP O
had VBD VBD O
received VBN VBN O
one CD CD O
, , , O
but CC CC O
not RB RB O
more JJR JJR O
than IN IN O
one CD CD O
, , , O
chemotherapy NN NN O
regimen NNS NNS O
for IN IN O
metastatic JJ JJ O
disease NN NN O
. . . O

Patients NNS NNS O
received VBD VBD O
amifostine NN NN B-CHEM
, , , O
910 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
intravenously RB RB O
over IN IN O
15 CD CD O
minutes NNS NNS O
. . . O

After IN IN O
completion NN NN O
of IN IN O
the DT DT O
amifostine NN NN B-CHEM
infusion NN NN O
, , , O
cisplatin NN NN B-CHEM
120 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
was VBD VBD O
administered VBN VBN O
over IN IN O
30 CD CD O
minutes NNS NNS O
. . . O

Intravenous NNP NNP O
hydration NN NN O
and CC CC O
mannitol NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
before IN IN O
and CC CC O
after IN IN O
cisplatin NN NN B-CHEM
. . . O

Treatment NN NN O
was VBD VBD O
administered VBN VBN O
every DT DT O
3 CD CD O
weeks NNS NNS O
until IN IN O
disease NN NN O
progression NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Forty CD CD O
- - - O
four CD CD O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
in IN IN O
the DT DT O
study NN NN O
of IN IN O
which WDT WDT O
7 CD CD O
( ( ( O
16 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
ineligible JJ JJ O
. . . O

A DT DT O
median NN NN O
of IN IN O
2 CD CD O
cycles NNS NNS O
of IN IN O
therapy NN NN O
was VBD VBD O
administered VBN VBN O
to TO TO O
the DT DT O
37 CD CD O
eligible JJ JJ O
patients NNS NNS O
. . . O

Six CD CD O
partial JJ JJ O
responses NNS NNS O
were VBD VBD O
observed VBN VBN O
for IN IN O
an DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
of IN IN O
16 CD CD O
% NN NN O
. . . O

Most JJS JJS O
patients NNS NNS O
( ( ( O
57 CD CD O
% NN NN O
) ) ) O
stopped VBD VBD O
treatment NN NN O
because IN IN O
of IN IN O
disease NN NN O
progression NN NN O
. . . O

Neurologic NNP NNP O
toxicity NN NN O
was VBD VBD O
reported VBN VBN O
in IN IN O
52 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Seven CD CD O
different JJ JJ O
life NN NN O
- - - O
threatening NN NN O
toxicities NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
patients NNS NNS O
while IN IN O
receiving VBG VBG O
treatment NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
combination NN NN O
of IN IN O
cisplatin NN NN B-CHEM
and CC CC O
amifostine NN NN B-CHEM
in IN IN O
this DT DT O
study NN NN O
resulted VBD VBD O
in IN IN O
an DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
of IN IN O
16 CD CD O
% NN NN O
. . . O

Neither DT DT O
a DT DT O
tumor NN NN O
- - - O
protective JJ JJ O
effect NN NN O
nor CC CC O
reduced VBN VBN O
toxicity NN NN O
to TO TO O
normal JJ JJ O
tissues NNS NNS O
was VBD VBD O
observed VBN VBN O
with IN IN O
the DT DT O
addition NN NN O
of IN IN O
amifostine NN NN B-CHEM
to TO TO O
cisplatin NN NN B-CHEM
in IN IN O
this DT DT O
trial NN NN O
. . . O

Oral NNP NNP B-CHEM
contraceptives NNS NNS I-CHEM
and CC CC O
the DT DT O
risk NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
An DT DT O
association NN NN O
between IN IN O
the DT DT O
use NN NN O
of IN IN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
and CC CC O
the DT DT O
risk NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
has VBZ VBZ O
been VBN VBN O
found VBN VBN O
in IN IN O
some DT DT O
, , , O
but CC CC O
not RB RB O
all DT DT O
, , , O
studies NNS NNS O
. . . O

We PRP PRP O
investigated VBD VBD O
this DT DT O
association NN NN O
, , , O
according VBG VBG O
to TO TO O
the DT DT O
type NN NN O
of IN IN O
progestagen NN NN B-CHEM
included VBD VBD O
in IN IN O
third JJ JJ O
- - - O
generation NN NN O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
desogestrel NN NN B-CHEM
or CC CC O
gestodene NN NN B-CHEM
) ) ) O
and CC CC O
second JJ JJ O
- - - O
generation NN NN O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
levonorgestrel NN NN B-CHEM
) ) ) O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
, , , O
the DT DT O
dose NN NN O
of IN IN O
estrogen NN NN B-CHEM
, , , O
and CC CC O
the DT DT O
presence NN NN O
or CC CC O
absence NN NN O
of IN IN O
prothrombotic JJ JJ O
mutations NNS NNS O
METHODS NNP NNP O
: : : O
In IN IN O
a DT DT O
nationwide JJ JJ O
, , , O
population NN NN O
- - - O
based JJ JJ O
, , , O
case NN NN O
- - - O
control NN NN O
study NN NN O
, , , O
we PRP PRP O
identified VBD VBD O
and CC CC O
enrolled VBD VBD O
248 CD CD O
women NNS NNS O
18 CD CD O
through IN IN O
49 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
who WP WP O
had VBD VBD O
had VBD VBD O
a DT DT O
first JJ JJ O
myocardial NN NN O
infarction NN NN O
between IN IN O
1990 CD CD O
and CC CC O
1995 CD CD O
and CC CC O
925 CD CD O
control NN NN O
women NNS NNS O
who WP WP O
had VBD VBD O
not RB RB O
had VBD VBD O
a DT DT O
myocardial NN NN O
infarction NN NN O
and CC CC O
who WP WP O
were VBD VBD O
matched VBN VBN O
for IN IN O
age NN NN O
, , , O
calendar NN NN O
year NN NN O
of IN IN O
the DT DT O
index NN NN O
event NN NN O
, , , O
and CC CC O
area NN NN O
of IN IN O
residence NN NN O
. . . O

Subjects NNP NNP O
supplied VBD VBD O
information NN NN O
on IN IN O
oral JJ JJ B-CHEM
- : : I-CHEM
contraceptive JJ JJ I-CHEM
use NN NN O
and CC CC O
major JJ JJ O
cardiovascular JJ JJ O
risk NN NN O
factors NNS NNS O
. . . O

An DT DT O
analysis NN NN O
for IN IN O
factor NN NN O
V NNP NNP O
Leiden NNP NNP O
and CC CC O
the DT DT O
G20210A NNP NNP O
mutation NN NN O
in IN IN O
the DT DT O
prothrombin NN NN O
gene NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
217 CD CD O
patients NNS NNS O
and CC CC O
763 CD CD O
controls NNS NNS O
RESULTS NNS NNS O
: : : O
The DT DT O
odds NNS NNS O
ratio NN NN O
for IN IN O
myocardial NN NN O
infarction NN NN O
among IN IN O
women NNS NNS O
who WP WP O
used VBD VBD O
any DT DT O
type NN NN O
of IN IN O
combined VBN VBN O
oral JJ JJ B-CHEM
contraceptive JJ JJ I-CHEM
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
nonusers NNS NNS O
, , , O
was VBD VBD O
2 CD CD O
. . . O
0 CD CD O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
5 CD CD O
to TO TO O
2 CD CD O
. . . O
8 CD CD O
) ) ) O
. . . O

The DT DT O
adjusted VBN VBN O
odds NN NN O
ratio NN NN O
was VBD VBD O
2 CD CD O
. . . O
5 CD CD O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
5 CD CD O
to TO TO O
4 CD CD O
. . . O
1 CD CD O
) ) ) O
among IN IN O
women NNS NNS O
who WP WP O
used VBD VBD O
second JJ JJ O
- - - O
generation NN NN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
and CC CC O
1 CD CD O
. . . O
3 CD CD O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
0 CD CD O
. . . O
7 CD CD O
to TO TO O
2 CD CD O
. . . O
5 CD CD O
) ) ) O
among IN IN O
those DT DT O
who WP WP O
used VBD VBD O
third JJ JJ O
- - - O
generation NN NN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

Among IN IN O
women NNS NNS O
who WP WP O
used VBD VBD O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
, , , O
the DT DT O
odds NNS NNS O
ratio NN NN O
was VBD VBD O
2 CD CD O
. . . O
1 CD CD O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
5 CD CD O
to TO TO O
3 CD CD O
. . . O
0 CD CD O
) ) ) O
for IN IN O
those DT DT O
without IN IN O
a DT DT O
prothrombotic JJ JJ O
mutation NN NN O
and CC CC O
1 CD CD O
. . . O
9 CD CD O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
0 CD CD O
. . . O
6 CD CD O
to TO TO O
5 CD CD O
. . . O
5 CD CD O
) ) ) O
for IN IN O
those DT DT O
with IN IN O
a DT DT O
mutation NN NN O
CONCLUSIONS NNP NNP O
: : : O
The DT DT O
risk NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
increased VBN VBN O
among IN IN O
women NNS NNS O
who WP WP O
used VBD VBD O
second JJ JJ O
- - - O
generation NN NN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

The DT DT O
results NNS NNS O
with IN IN O
respect NN NN O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
third JJ JJ O
- - - O
generation NN NN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
were VBD VBD O
inconclusive JJ JJ O
but CC CC O
suggested VBN VBN O
that IN IN O
the DT DT O
risk NN NN O
was VBD VBD O
lower JJR JJR O
than IN IN O
the DT DT O
risk NN NN O
associated VBN VBN O
with IN IN O
second JJ JJ O
- - - O
generation NN NN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

The DT DT O
risk NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
similar JJ JJ O
among IN IN O
women NNS NNS O
who WP WP O
used VBD VBD O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
whether IN IN O
or CC CC O
not RB RB O
they PRP PRP O
had VBD VBD O
a DT DT O
prothrombotic JJ JJ O
mutation NN NN O
. . . O

End NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
( ( ( O
ESRD NNP NNP O
) ) ) O
after IN IN O
orthotopic JJ JJ O
liver NN NN O
transplantation NN NN O
( ( ( O
OLTX NNP NNP O
) ) ) O
using VBG VBG O
calcineurin NN NN O
- - - O
based JJ JJ O
immunotherapy NN NN O
: : : O
risk NN NN O
of IN IN O
development NN NN O
and CC CC O
treatment NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
calcineurin NN NN O
inhibitors NNS NNS O
cyclosporine NN NN B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
are VBP VBP O
both DT DT O
known VBN VBN O
to TO TO O
be VB VB O
nephrotoxic JJ JJ O
. . . O

Their PRP$ PRP$ O
use NN NN O
in IN IN O
orthotopic JJ JJ O
liver NN NN O
transplantation NN NN O
( ( ( O
OLTX NNP NNP O
) ) ) O
has VBZ VBZ O
dramatically RB RB O
improved VBN VBN O
success NN NN O
rates NNS NNS O
. . . O

Recently RB RB O
, , , O
however RB RB O
, , , O
we PRP PRP O
have VBP VBP O
had VBN VBN O
an DT DT O
increase NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
are VBP VBP O
presenting VBG VBG O
after IN IN O
OLTX NNP NNP O
with IN IN O
end NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
( ( ( O
ESRD NNP NNP O
) ) ) O
. . . O

This DT DT O
retrospective NN NN O
study NN NN O
examines VBZ VBZ O
the DT DT O
incidence NN NN O
and CC CC O
treatment NN NN O
of IN IN O
ESRD NNP NNP O
and CC CC O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
CRF NNP NNP O
) ) ) O
in IN IN O
OLTX NNP NNP O
patients NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Patients NNS NNS O
receiving VBG VBG O
an DT DT O
OLTX NNP NNP O
only RB RB O
from IN IN O
June NNP NNP O
1985 CD CD O
through IN IN O
December NNP NNP O
of IN IN O
1994 CD CD O
who WP WP O
survived VBD VBD O
6 CD CD O
months NNS NNS O
postoperatively RB RB O
were VBD VBD O
studied VBN VBN O
( ( ( O
n NN NN O
= SYM SYM O
834 CD CD O
) ) ) O
. . . O

Our PRP$ PRP$ O
prospectively RB RB O
collected VBN VBN O
database NN NN O
was VBD VBD O
the DT DT O
source NN NN O
of IN IN O
information NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
divided VBN VBN O
into IN IN O
three CD CD O
groups NNS NNS O
: : : O
Controls NNP NNP O
, , , O
no DT DT O
CRF NNP NNP O
or CC CC O
ESRD NNP NNP O
, , , O
n NN NN O
= SYM SYM O
748 CD CD O
; : : O
CRF NNP NNP O
, , , O
sustained VBD VBD O
serum NN NN O
creatinine NN NN B-CHEM
> NN NN O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
n NN NN O
= SYM SYM O
41 CD CD O
; : : O
and CC CC O
ESRD NNP NNP O
, , , O
n NN NN O
= SYM SYM O
45 CD CD O
. . . O

Groups NNS NNS O
were VBD VBD O
compared VBN VBN O
for IN IN O
preoperative JJ JJ O
laboratory NN NN O
variables NNS NNS O
, , , O
diagnosis NN NN O
, , , O
postoperative JJ JJ O
variables NNS NNS O
, , , O
survival NN NN O
, , , O
type NN NN O
of IN IN O
ESRD NNP NNP O
therapy NN NN O
, , , O
and CC CC O
survival NN NN O
from IN IN O
onset NN NN O
of IN IN O
ESRD NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
At IN IN O
13 CD CD O
years NNS NNS O
after IN IN O
OLTX NNP NNP O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
severe JJ JJ O
renal JJ JJ O
dysfunction NN NN O
was VBD VBD O
18 CD CD O
. . . O
1 CD CD O
% NN NN O
( ( ( O
CRF NNP NNP O
8 CD CD O
. . . O
6 CD CD O
% NN NN O
and CC CC O
ESRD NNP NNP O
9 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
. . . O

Compared VBN VBN O
with IN IN O
control NN NN O
patients NNS NNS O
, , , O
CRF NNP NNP O
and CC CC O
ESRD NNP NNP O
patients NNS NNS O
had VBD VBD O
higher JJR JJR O
preoperative JJ JJ O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
, , , O
a DT DT O
greater JJR JJR O
percentage NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
hepatorenal JJ JJ O
syndrome NN NN O
, , , O
higher JJR JJR O
percentage NN NN O
requirement NN NN O
for IN IN O
dialysis NN NN O
in IN IN O
the DT DT O
first JJ JJ O
3 CD CD O
months NNS NNS O
postoperatively RB RB O
, , , O
and CC CC O
a DT DT O
higher JJR JJR O
1 CD CD O
- : : O
year NN NN O
serum NN NN O
creatinine NN NN B-CHEM
. . . O

Multivariate NNP NNP O
stepwise NN NN O
logistic JJ JJ O
regression NN NN O
analysis NN NN O
using VBG VBG O
preoperative JJ JJ O
and CC CC O
postoperative JJ JJ O
variables NNS NNS O
identified VBN VBN O
that IN IN O
an DT DT O
increase NN NN O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
compared VBN VBN O
with IN IN O
average JJ JJ O
at IN IN O
1 CD CD O
year NN NN O
, , , O
3 CD CD O
months NNS NNS O
, , , O
and CC CC O
4 CD CD O
weeks NNS NNS O
postoperatively RB RB O
were VBD VBD O
independent JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
CRF NNP NNP O
or CC CC O
ESRD NNP NNP O
with IN IN O
odds NNS NNS O
ratios NN NN O
of IN IN O
2 CD CD O
. . . O
6 CD CD O
, , , O
2 CD CD O
. . . O
2 CD CD O
, , , O
and CC CC O
1 CD CD O
. . . O
6 CD CD O
, , , O
respectively RB RB O
. . . O

Overall NNP NNP O
survival NN NN O
from IN IN O
the DT DT O
time NN NN O
of IN IN O
OLTX NNP NNP O
was VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
among IN IN O
groups NNS NNS O
, , , O
but CC CC O
by IN IN O
year NN NN O
13 CD CD O
, , , O
the DT DT O
survival NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
who WP WP O
had VBD VBD O
ESRD NNP NNP O
was VBD VBD O
only RB RB O
28 CD CD O
. . . O
2 CD CD O
% NN NN O
compared VBN VBN O
with IN IN O
54 CD CD O
. . . O
6 CD CD O
% NN NN O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

Patients NNS NNS O
developing VBG VBG O
ESRD NNP NNP O
had VBD VBD O
a DT DT O
6 CD CD O
- : : O
year NN NN O
survival NN NN O
after IN IN O
onset NN NN O
of IN IN O
ESRD NNP NNP O
of IN IN O
27 CD CD O
% NN NN O
for IN IN O
the DT DT O
patients NNS NNS O
receiving VBG VBG O
hemodialysis NN NN O
versus CC CC O
71 CD CD O
. . . O
4 CD CD O
% NN NN O
for IN IN O
the DT DT O
patients NNS NNS O
developing VBG VBG O
ESRD NNP NNP O
who WP WP O
subsequently RB RB O
received VBD VBD O
kidney NN NN O
transplants NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Patients NNS NNS O
who WP WP O
are VBP VBP O
more JJR JJR O
than IN IN O
10 CD CD O
years NNS NNS O
post NN NN O
- - - O
OLTX NNP NNP O
have VBP VBP O
CRF NNP NNP O
and CC CC O
ESRD NNP NNP O
at IN IN O
a DT DT O
high JJ JJ O
rate NN NN O
. . . O

The DT DT O
development NN NN O
of IN IN O
ESRD NNP NNP O
decreases NNS NNS O
survival NN NN O
, , , O
particularly RB RB O
in IN IN O
those DT DT O
patients NNS NNS O
treated VBN VBN O
with IN IN O
dialysis NN NN O
only RB RB O
. . . O

Patients NNS NNS O
who WP WP O
develop VBP VBP O
ESRD NNP NNP O
have VBP VBP O
a DT DT O
higher JJR JJR O
preoperative JJ JJ O
and CC CC O
1 CD CD O
- : : O
year NN NN O
serum NN NN O
creatinine NN NN B-CHEM
and CC CC O
are VBP VBP O
more RBR RBR O
likely JJ JJ O
to TO TO O
have VB VB O
hepatorenal JJ JJ O
syndrome NN NN O
. . . O

However RB RB O
, , , O
an DT DT O
increase NN NN O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
at IN IN O
various JJ JJ O
times NNS NNS O
postoperatively RB RB O
is VBZ VBZ O
more RBR RBR O
predictive JJ JJ O
of IN IN O
the DT DT O
development NN NN O
of IN IN O
CRF NNP NNP O
or CC CC O
ESRD NNP NNP O
. . . O

New NNP NNP O
strategies NNS NNS O
for IN IN O
long JJ JJ O
- - - O
term NN NN O
immunosuppression NN NN O
may MD MD O
be VB VB O
needed VBN VBN O
to TO TO O
decrease VB VB O
this DT DT O
complication NN NN O
. . . O

Epileptic NNP NNP O
seizures NNS NNS O
following VBG VBG O
cortical JJ JJ O
application NN NN O
of IN IN O
fibrin NN NN O
sealants NNS NNS O
containing VBG VBG O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
rats NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Fibrin NNP NNP O
sealants NNS NNS O
( ( ( O
FS NNP NNP O
) ) ) O
derived VBN VBN O
from IN IN O
human JJ JJ O
plasma NN NN O
are VBP VBP O
frequently RB RB O
used VBN VBN O
in IN IN O
neurosurgery NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
increase VB VB O
clot NN NN O
stability NN NN O
, , , O
FS NNP NNP O
typically RB RB O
contain VB VB O
aprotinin NN NN O
, , , O
a DT DT O
natural JJ JJ O
fibrinolysis NN NN O
inhibitor NN NN O
. . . O

Recently RB RB O
, , , O
synthetic JJ JJ O
fibrinolysis NN NN O
inhibitors NNS NNS O
such JJ JJ O
as IN IN O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
tAMCA NN NN B-CHEM
) ) ) O
have VBP VBP O
been VBN VBN O
considered VBN VBN O
as IN IN O
substitutes NNS NNS O
for IN IN O
aprotinin NN NN O
. . . O

However RB RB O
, , , O
tAMCA NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
cause VB VB O
epileptic JJ JJ O
seizures NNS NNS O
. . . O

We PRP PRP O
wanted VBD VBD O
to TO TO O
study VB VB O
whether IN IN O
tAMCA NN NN B-CHEM
retains VBZ VBZ O
its PRP$ PRP$ O
convulsive JJ JJ O
action NN NN O
if IN IN O
incorporated VBN VBN O
into IN IN O
a DT DT O
FS NNP NNP O
. . . O

METHOD NNP NNP O
: : : O
FS NNP NNP O
containing VBG VBG O
aprotinin NN NN O
or CC CC O
different JJ JJ O
concentrations NNS NNS O
of IN IN O
tAMCA NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
- : : O
47 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
were VBD VBD O
applied VBN VBN O
to TO TO O
the DT DT O
pial JJ JJ O
surface NN NN O
of IN IN O
the DT DT O
cortex NN NN O
of IN IN O
anaesthetized JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
response NN NN O
of IN IN O
the DT DT O
animals NNS NNS O
was VBD VBD O
evaluated VBN VBN O
using VBG VBG O
electroencephalography NN NN O
and CC CC O
by IN IN O
monitoring VBG VBG O
the DT DT O
clinical JJ JJ O
behaviour NN NN O
during IN IN O
and CC CC O
after IN IN O
recovery NN NN O
from IN IN O
anaesthesia NN NN O
. . . O

FINDINGS NNS NNS O
: : : O
FS NNP NNP O
containing VBG VBG O
tAMCA NN NN B-CHEM
caused VBD VBD O
paroxysmal JJ JJ O
brain NN NN O
activity NN NN O
which WDT WDT O
was VBD VBD O
associated VBN VBN O
with IN IN O
distinct JJ JJ O
convulsive JJ JJ O
behaviours NNS NNS O
. . . O

The DT DT O
degree NN NN O
of IN IN O
these DT DT O
seizures NNS NNS O
increased VBN VBN O
with IN IN O
increasing JJ JJ O
concentration NN NN O
of IN IN O
tAMCA NN NN B-CHEM
. . . O

Thus RB RB O
, , , O
FS NNP NNP O
containing VBG VBG O
47 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
tAMCA NN NN B-CHEM
evoked VBD VBD O
generalized JJ JJ O
seizures NNS NNS O
in IN IN O
all DT DT O
tested VBN VBN O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
while IN IN O
the DT DT O
lowest JJS JJS O
concentration NN NN O
of IN IN O
tAMCA NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
only RB RB O
evoked JJ JJ O
brief JJ JJ O
episodes NNS NNS O
of IN IN O
jerk NN NN O
- - - O
correlated JJ JJ O
convulsive JJ JJ O
potentials NNS NNS O
in IN IN O
1 CD CD O
of IN IN O
6 CD CD O
rats NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
FS NNP NNP O
containing VBG VBG O
aprotinin NN NN O
did VBD VBD O
not RB RB O
evoke VB VB O
any DT DT O
paroxysmal NN NN O
activity NN NN O
. . . O

INTERPRETATION NN NN O
: : : O
Tranexamic NNP NNP B-CHEM
acid NN NN I-CHEM
retains VBZ VBZ O
its PRP$ PRP$ O
convulsive JJ JJ O
action NN NN O
within IN IN O
FS NNP NNP O
. . . O

Thus RB RB O
, , , O
use NN NN O
of IN IN O
FS NNP NNP O
containing VBG VBG O
tAMCA NN NN B-CHEM
for IN IN O
surgery NN NN O
within IN IN O
or CC CC O
close VB VB O
to TO TO O
the DT DT O
CNS NNP NNP O
may MD MD O
pose VB VB O
a DT DT O
substantial JJ JJ O
risk NN NN O
to TO TO O
the DT DT O
patient NN NN O
. . . O

Sequential NNP NNP O
observations NNS NNS O
of IN IN O
exencephaly NN NN O
and CC CC O
subsequent JJ JJ O
morphological JJ JJ O
changes NNS NNS O
by IN IN O
mouse NN NN O
exo NN NN O
utero NN NN O
development NN NN O
system NN NN O
: : : O
analysis NN NN O
of IN IN O
the DT DT O
mechanism NN NN O
of IN IN O
transformation NN NN O
from IN IN O
exencephaly NN NN O
to TO TO O
anencephaly VB VB O
. . . O

Anencephaly NNP NNP O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
to TO TO O
develop VB VB O
from IN IN O
exencephaly NN NN O
; : : O
however RB RB O
, , , O
there EX EX O
is VBZ VBZ O
little JJ JJ O
direct JJ JJ O
experimental JJ JJ O
evidence NN NN O
to TO TO O
support VB VB O
this DT DT O
, , , O
and CC CC O
the DT DT O
mechanism NN NN O
of IN IN O
transformation NN NN O
remains NNS NNS O
unclear JJ JJ O
. . . O

We PRP PRP O
examined VBD VBD O
this DT DT O
theory NN NN O
using VBG VBG O
the DT DT O
exo NN NN O
utero NN NN O
development NN NN O
system NN NN O
that WDT WDT O
allows VBZ VBZ O
direct JJ JJ O
and CC CC O
sequential JJ JJ O
observations NNS NNS O
of IN IN O
mid JJ JJ O
- - - O
to TO TO O
late JJ JJ O
- - - O
gestation NN NN O
mouse NN NN O
embryos NNS NNS O
. . . O

We PRP PRP O
observed VBD VBD O
the DT DT O
exencephaly NN NN O
induced VBN VBN O
by IN IN O
5 CD CD B-CHEM
- : : I-CHEM
azacytidine NN NN I-CHEM
at IN IN O
embryonic JJ JJ O
day NN NN O
13 CD CD O
. . . O
5 CD CD O
( ( ( O
E13 NNP NNP O
. . . O
5 CD CD O
) ) ) O
, , , O
let VB VB O
the DT DT O
embryos NNS NNS O
develop VBP VBP O
exo NN NN O
utero NN NN O
until IN IN O
E18 NNP NNP O
. . . O
5 CD CD O
, , , O
and CC CC O
re NN NN O
- - - O
observed RP RP O
the DT DT O
same JJ JJ O
embryos NN NN O
at IN IN O
E18 NNP NNP O
. . . O
5 CD CD O
. . . O

We PRP PRP O
confirmed VBD VBD O
several JJ JJ O
cases NNS NNS O
of IN IN O
transformation NN NN O
from IN IN O
exencephaly NN NN O
to TO TO O
anencephaly VB VB O
. . . O

However RB RB O
, , , O
in IN IN O
many JJ JJ O
cases NNS NNS O
, , , O
the DT DT O
exencephalic JJ JJ O
brain NN NN O
tissue NN NN O
was VBD VBD O
preserved VBN VBN O
with IN IN O
more JJR JJR O
or CC CC O
less JJR JJR O
reduction NN NN O
during IN IN O
this DT DT O
period NN NN O
. . . O

To TO TO O
analyze VB VB O
the DT DT O
transformation NN NN O
patterns NNS NNS O
, , , O
we PRP PRP O
classified VBD VBD O
the DT DT O
exencephaly NN NN O
by IN IN O
size NN NN O
and CC CC O
shape NN NN O
of IN IN O
the DT DT O
exencephalic JJ JJ O
tissue NN NN O
into IN IN O
several JJ JJ O
types NNS NNS O
at IN IN O
E13 NNP NNP O
. . . O
5 CD CD O
and CC CC O
E18 NNP NNP O
. . . O
5 CD CD O
. . . O

It PRP PRP O
was VBD VBD O
found VBN VBN O
that IN IN O
the DT DT O
transformation NN NN O
of IN IN O
exencephalic JJ JJ O
tissue NN NN O
was VBD VBD O
not RB RB O
simply RB RB O
size NN NN O
- - - O
dependent NN NN O
, , , O
and CC CC O
all DT DT O
cases NNS NNS O
of IN IN O
anencephaly NN NN O
at IN IN O
E18 NNP NNP O
. . . O
5 CD CD O
resulted VBD VBD O
from IN IN O
embryos NNS NNS O
with IN IN O
a DT DT O
large JJ JJ O
amount NN NN O
of IN IN O
exencephalic JJ JJ O
tissue NN NN O
at IN IN O
E13 NNP NNP O
. . . O
5 CD CD O
. . . O

Microscopic NNP NNP O
observation NN NN O
showed VBD VBD O
the DT DT O
configuration NN NN O
of IN IN O
exencephaly NN NN O
at IN IN O
E13 NNP NNP O
. . . O
5 CD CD O
, , , O
frequent JJ JJ O
hemorrhaging NN NN O
and CC CC O
detachment NN NN O
of IN IN O
the DT DT O
neural NN NN O
plate NN NN O
from IN IN O
surface NN NN O
ectoderm NN NN O
in IN IN O
the DT DT O
exencephalic JJ JJ O
head NN NN O
at IN IN O
E15 NNP NNP O
. . . O
5 CD CD O
, , , O
and CC CC O
multiple JJ JJ O
modes NNS NNS O
of IN IN O
reduction NN NN O
in IN IN O
the DT DT O
exencephalic JJ JJ O
tissue NN NN O
at IN IN O
E18 NNP NNP O
. . . O
5 CD CD O
. . . O

From IN IN O
observations NNS NNS O
of IN IN O
the DT DT O
vasculature NN NN O
, , , O
altered VBN VBN O
distribution NN NN O
patterns NNS NNS O
of IN IN O
vessels NNS NNS O
were VBD VBD O
identified VBN VBN O
in IN IN O
the DT DT O
exencephalic JJ JJ O
head NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
overgrowth NN NN O
of IN IN O
the DT DT O
exencephalic JJ JJ O
neural NN NN O
tissue NN NN O
causes NNS NNS O
the DT DT O
altered VBN VBN O
distribution NN NN O
patterns NNS NNS O
of IN IN O
vessels NNS NNS O
, , , O
subsequent JJ JJ O
peripheral JJ JJ O
circulatory NN NN O
failure NN NN O
and CC CC O
/ NN NN O
or CC CC O
hemorrhaging VBG VBG O
in IN IN O
various JJ JJ O
parts NNS NNS O
of IN IN O
the DT DT O
exencephalic JJ JJ O
head NN NN O
, , , O
leading VBG VBG O
to TO TO O
the DT DT O
multiple JJ JJ O
modes NNS NNS O
of IN IN O
tissue NN NN O
reduction NN NN O
during IN IN O
transformation NN NN O
from IN IN O
exencephaly NN NN O
to TO TO O
anencephaly VB VB O
. . . O

99mTc CD CD B-CHEM
- : : I-CHEM
glucarate NN NN I-CHEM
for IN IN O
detection NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

Infarct NNP NNP O
- : : O
avid JJ JJ O
radiopharmaceuticals NNS NNS O
are VBP VBP O
necessary JJ JJ O
for IN IN O
rapid JJ JJ O
and CC CC O
timely JJ JJ O
diagnosis NN NN O
of IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

The DT DT O
animal NN NN O
model NN NN O
used VBN VBN O
to TO TO O
produce VB VB O
infarction NN NN O
implies NNS NNS O
artery NN NN O
ligation NN NN O
but CC CC O
chemical NN NN O
induction NN NN O
can MD MD O
be VB VB O
easily RB RB O
obtained VBN VBN O
with IN IN O
isoproterenol NN NN B-CHEM
. . . O

A DT DT O
new JJ JJ O
infarct NN NN O
- - - O
avid JJ JJ O
radiopharmaceutical NN NN O
based VBN VBN O
on IN IN O
glucaric JJ JJ B-CHEM
acid NN NN I-CHEM
was VBD VBD O
prepared VBN VBN O
in IN IN O
the DT DT O
hospital NN NN O
radiopharmacy NN NN O
of IN IN O
the DT DT O
INCMNSZ NNP NNP O
. . . O

99mTc CD CD B-CHEM
- : : I-CHEM
glucarate NN NN I-CHEM
was VBD VBD O
easy JJ JJ O
to TO TO O
prepare VB VB O
, , , O
stable JJ JJ O
for IN IN O
96 CD CD O
h NN NN O
and CC CC O
was VBD VBD O
used VBN VBN O
to TO TO O
study VB VB O
its PRP$ PRP$ O
biodistribution NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

Histological NNP NNP O
studies NNS NNS O
demonstrated VBD VBD O
that IN IN O
the DT DT O
rats NNS NNS O
developed VBN VBN O
an DT DT O
infarct NN NN O
18 CD CD O
h NN NN O
after IN IN O
isoproterenol JJ JJ B-CHEM
administration NN NN O
. . . O

The DT DT O
rat NN NN O
biodistribution NN NN O
studies NNS NNS O
showed VBD VBD O
a DT DT O
rapid JJ JJ O
blood NN NN O
clearance NN NN O
via IN IN O
the DT DT O
kidneys NNS NNS O
. . . O

Thirty NNP NNP O
minutes NNS NNS O
after IN IN O
99mTc CD CD B-CHEM
- : : I-CHEM
glucarate NN NN I-CHEM
administration NN NN O
the DT DT O
standardised JJ JJ O
heart NN NN O
uptake NN NN O
value NN NN O
S NNP NNP O
( ( ( O
h NN NN O
) ) ) O
UV NNP NNP O
was VBD VBD O
4 CD CD O
. . . O
7 CD CD O
in IN IN O
infarcted JJ JJ O
rat NN NN O
heart NN NN O
which WDT WDT O
is VBZ VBZ O
six CD CD O
times NNS NNS O
more JJR JJR O
than IN IN O
in IN IN O
normal JJ JJ O
rats NNS NNS O
. . . O

ROIs NNP NNP O
drawn NN NN O
over IN IN O
the DT DT O
gamma NN NN O
camera NN NN O
images NNS NNS O
showed VBD VBD O
a DT DT O
ratio NN NN O
of IN IN O
4 CD CD O
. . . O
4 CD CD O
. . . O

The DT DT O
high JJ JJ O
image NN NN O
quality NN NN O
suggests VBZ VBZ O
that IN IN O
high JJ JJ O
contrast NN NN O
images NNS NNS O
can MD MD O
be VB VB O
obtained VBN VBN O
in IN IN O
humans NNS NNS O
and CC CC O
the DT DT O
96 CD CD O
h NN NN O
stability NN NN O
makes VBZ VBZ O
it PRP PRP O
an DT DT O
ideal JJ JJ O
agent NN NN O
to TO TO O
detect VB VB O
, , , O
in IN IN O
patients NNS NNS O
, , , O
early JJ JJ O
cardiac NN NN O
infarction NN NN O
. . . O

Bupropion NNP NNP B-CHEM
( ( ( O
Zyban NNP NNP B-CHEM
) ) ) O
toxicity NN NN O
. . . O

Bupropion NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
monocyclic JJ JJ O
antidepressant NN NN B-CHEM
structurally RB RB O
related VBN VBN O
to TO TO O
amphetamine NN NN B-CHEM
. . . O

Zyban NNP NNP B-CHEM
, , , O
a DT DT O
sustained JJ JJ O
- - - O
release NN NN O
formulation NN NN O
of IN IN O
bupropion NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
was VBD VBD O
recently RB RB O
released VBN VBN O
in IN IN O
Ireland NNP NNP O
, , , O
as IN IN O
a DT DT O
smoking NN NN O
cessation NN NN O
aid NN NN O
. . . O

In IN IN O
the DT DT O
initial JJ JJ O
6 CD CD O
months NNS NNS O
since IN IN O
it PRP PRP O
' POS POS O
s VBZ VBZ O
introduction NN NN O
, , , O
12 CD CD O
overdose NN NN O
cases NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
to TO TO O
The DT DT O
National NNP NNP O
Poisons NNP NNP O
Information NNP NNP O
Centre NNP NNP O
. . . O

8 CD CD O
patients NNS NNS O
developed VBN VBN O
symptoms NNS NNS O
of IN IN O
toxicity NN NN O
. . . O

Common JJ JJ O
features NNS NNS O
included VBN VBN O
tachycardia NN NN O
, , , O
drowsiness NN NN O
, , , O
hallucinations NNS NNS O
and CC CC O
convulsions NNS NNS O
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
severe JJ JJ O
cardiac JJ JJ O
arrhythmias NN NN O
, , , O
including VBG VBG O
one CD CD O
patient NN NN O
who WP WP O
was VBD VBD O
resuscitated VBN VBN O
following VBG VBG O
a DT DT O
cardiac JJ JJ O
arrest NN NN O
. . . O

All DT DT O
patients NNS NNS O
recovered VBN VBN O
without IN IN O
sequelae NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
31 CD CD O
year NN NN O
old JJ JJ O
female NN NN O
who WP WP O
required VBD VBD O
admission NN NN O
to TO TO O
the DT DT O
Intensive NNP NNP O
Care NNP NNP O
Unit NNP NNP O
for IN IN O
ventilation NN NN O
and CC CC O
full JJ JJ O
supportive JJ JJ O
therapy NN NN O
, , , O
following VBG VBG O
ingestion NN NN O
of IN IN O
13 CD CD O
. . . O
5g CD CD O
bupropion NN NN B-CHEM
. . . O

Recurrent NNP NNP O
seizures NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
diazepam NN NN B-CHEM
and CC CC O
broad JJ JJ O
complex JJ JJ O
tachycardia NN NN O
was VBD VBD O
successfully RB RB O
treated VBN VBN O
with IN IN O
adenosine NN NN B-CHEM
. . . O

Zyban NNP NNP B-CHEM
caused VBD VBD O
significant JJ JJ O
neurological JJ JJ O
and CC CC O
cardiovascular JJ JJ O
toxicity NN NN O
in IN IN O
overdose NN NN O
. . . O

The DT DT O
potential JJ JJ O
toxic JJ JJ O
effects NNS NNS O
should MD MD O
be VB VB O
considered VBN VBN O
when WRB WRB O
prescribing VBG VBG O
it PRP PRP O
as IN IN O
a DT DT O
smoking NN NN O
cessation NN NN O
aid NN NN O
. . . O

GLEPP1 NNP NNP O
receptor NN NN O
tyrosine NN NN B-CHEM
phosphatase NN NN O
( ( ( O
Ptpro NNP NNP O
) ) ) O
in IN IN O
rat NN NN O
PAN NNP NNP B-CHEM
nephrosis NN NN O
. . . O

A DT DT O
marker NN NN O
of IN IN O
acute JJ JJ O
podocyte NN NN O
injury NN NN O
. . . O

Glomerular NNP NNP O
epithelial NN NN O
protein NN NN O
1 CD CD O
( ( ( O
GLEPP1 NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
podocyte NN NN O
receptor NN NN O
membrane NN NN O
protein NN NN O
tyrosine NN NN B-CHEM
phosphatase NN NN O
located VBN VBN O
on IN IN O
the DT DT O
apical JJ JJ O
cell NN NN O
membrane NN NN O
of IN IN O
visceral JJ JJ O
glomerular NN NN O
epithelial NN NN O
cell NN NN O
and CC CC O
foot NN NN O
processes NNS NNS O
. . . O

This DT DT O
receptor NN NN O
plays VBZ VBZ O
a DT DT O
role NN NN O
in IN IN O
regulating VBG VBG O
the DT DT O
structure NN NN O
and CC CC O
function NN NN O
of IN IN O
podocyte NN NN O
foot NN NN O
process NN NN O
. . . O

To TO TO O
better JJR JJR O
understand VB VB O
the DT DT O
utility NN NN O
of IN IN O
GLEPP1 NNP NNP O
as IN IN O
a DT DT O
marker NN NN O
of IN IN O
glomerular NN NN O
injury NN NN O
, , , O
the DT DT O
amount NN NN O
and CC CC O
distribution NN NN O
of IN IN O
GLEPP1 NNP NNP O
protein NN NN O
and CC CC O
mRNA NN NN O
were VBD VBD O
examined VBN VBN O
by IN IN O
immunohistochemistry NN NN O
, , , O
Western JJ JJ O
blot NN NN O
and CC CC O
RNase NNP NNP O
protection NN NN O
assay NN NN O
in IN IN O
a DT DT O
model NN NN O
of IN IN O
podocyte NN NN O
injury NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Puromycin NNP NNP B-CHEM
aminonucleoside NN NN I-CHEM
nephrosis NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
single JJ JJ O
intraperitoneal JJ JJ O
injection NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
, , , O
20 CD CD O
mg NN NN O
/ NN NN O
100g CD CD O
BW NNP NNP O
) ) ) O
. . . O

Tissues NNP NNP O
were VBD VBD O
analyzed VBN VBN O
at IN IN O
0 CD CD O
, , , O
5 CD CD O
, , , O
7 CD CD O
, , , O
11 CD CD O
, , , O
21 CD CD O
, , , O
45 CD CD O
, , , O
80 CD CD O
and CC CC O
126 CD CD O
days NNS NNS O
after IN IN O
PAN NNP NNP B-CHEM
injection NN NN O
so RB RB O
as IN IN O
to TO TO O
include VB VB O
both DT DT O
the DT DT O
acute JJ JJ O
phase NN NN O
of IN IN O
proteinuria NN NN O
associated VBN VBN O
with IN IN O
foot NN NN O
process NN NN O
effacement NN NN O
( ( ( O
days NNS NNS O
5 CD CD O
- : : O
11 CD CD O
) ) ) O
and CC CC O
the DT DT O
chronic JJ JJ O
phase NN NN O
of IN IN O
proteinuria NN NN O
associated VBN VBN O
with IN IN O
glomerulosclerosis NNS NNS O
( ( ( O
days NNS NNS O
45 CD CD O
- : : O
126 CD CD O
) ) ) O
. . . O

At IN IN O
day NN NN O
5 CD CD O
, , , O
GLEPP1 NNP NNP O
protein NN NN O
and CC CC O
mRNA NN NN O
were VBD VBD O
reduced VBN VBN O
from IN IN O
the DT DT O
normal JJ JJ O
range NN NN O
( ( ( O
265 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
79 CD CD O
. . . O
6 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
6 CD CD O
) ) ) O
moles NNS NNS O
/ NN NN O
glomerulus NN NN O
and CC CC O
100 CD CD O
% NN NN O
) ) ) O
to TO TO O
15 CD CD O
% NN NN O
of IN IN O
normal JJ JJ O
( ( ( O
41 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
8 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
6 CD CD O
) ) ) O
moles NNS NNS O
/ NN NN O
glomerulus NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
. . . O

This DT DT O
occurred VBD VBD O
in IN IN O
association NN NN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
urinary JJ JJ O
protein NN NN O
content NN NN O
from IN IN O
1 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
to TO TO O
99 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
61 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

In IN IN O
contrast NN NN O
, , , O
podocalyxin NN NN O
did VBD VBD O
not RB RB O
change VB VB O
significantly RB RB O
at IN IN O
this DT DT O
time NN NN O
. . . O

By IN IN O
day NN NN O
11 CD CD O
, , , O
GLEPP1 NNP NNP O
protein NN NN O
and CC CC O
mRNA NN NN O
had VBD VBD O
begun VBN VBN O
to TO TO O
return VB VB O
towards IN IN O
baseline NN NN O
. . . O

By IN IN O
day NN NN O
45 CD CD O
- : : O
126 CD CD O
, , , O
at IN IN O
a DT DT O
time NN NN O
when WRB WRB O
glomerular NN NN O
scarring NN NN O
was VBD VBD O
present JJ JJ O
, , , O
GLEPP1 NNP NNP O
was VBD VBD O
absent JJ JJ O
from IN IN O
glomerulosclerotic JJ JJ O
areas NNS NNS O
although IN IN O
the DT DT O
total JJ JJ O
glomerular NN NN O
content NN NN O
of IN IN O
GLEPP1 NNP NNP O
was VBD VBD O
not RB RB O
different JJ JJ O
from IN IN O
normal JJ JJ O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
GLEPP1 NNP NNP O
expression NN NN O
, , , O
unlike IN IN O
podocalyxin NN NN O
, , , O
reflects VBZ VBZ O
podocyte NN NN O
injury NN NN O
induced VBN VBN O
by IN IN O
PAN NNP NNP B-CHEM
. . . O

GLEPP1 NNP NNP O
expression NN NN O
may MD MD O
be VB VB O
a DT DT O
useful JJ JJ O
marker NN NN O
of IN IN O
podocyte NN NN O
injury NN NN O
. . . O

Antithymocyte NNP NNP B-CHEM
globulin NN NN I-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
- - - O
induced JJ JJ O
aplastic JJ JJ O
anemia NN NN O
. . . O

A DT DT O
patient NN NN O
who WP WP O
received VBD VBD O
antithymocyte NN NN B-CHEM
globulin NN NN I-CHEM
therapy NN NN O
for IN IN O
aplastic JJ JJ O
anemia NN NN O
due JJ JJ O
to TO TO O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
therapy NN NN O
is VBZ VBZ O
described VBN VBN O
. . . O

Bone NNP NNP O
marrow NN NN O
recovery NN NN O
and CC CC O
peripheral JJ JJ O
blood NN NN O
recovery NN NN O
were VBD VBD O
complete JJ JJ O
1 CD CD O
month NN NN O
and CC CC O
3 CD CD O
months NNS NNS O
, , , O
respectively RB RB O
, , , O
after IN IN O
treatment NN NN O
, , , O
and CC CC O
blood NN NN O
transfusion NN NN O
or CC CC O
other JJ JJ O
therapies NNS NNS O
were VBD VBD O
not RB RB O
necessary JJ JJ O
in IN IN O
a DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
of IN IN O
more JJR JJR O
than IN IN O
2 CD CD O
years NNS NNS O
. . . O

Use NN NN O
of IN IN O
antithymocyte NN NN B-CHEM
globulin NN NN I-CHEM
may MD MD O
be VB VB O
the DT DT O
optimal NN NN O
treatment NN NN O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
- - - O
induced JJ JJ O
aplastic JJ JJ O
anemia NN NN O
. . . O

Metamizol NNP NNP B-CHEM
potentiates NNS NNS O
morphine NN NN B-CHEM
antinociception NN NN O
but CC CC O
not RB RB O
constipation NN NN O
after IN IN O
chronic JJ JJ O
treatment NN NN O
. . . O

This DT DT O
work NN NN O
evaluates VBZ VBZ O
the DT DT O
antinociceptive JJ JJ O
and CC CC O
constipating VBG VBG O
effects NNS NNS O
of IN IN O
the DT DT O
combination NN NN O
of IN IN O
3 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
morphine NN NN B-CHEM
with IN IN O
177 CD CD O
. . . O
8 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
metamizol NN NN B-CHEM
in IN IN O
acutely RB RB O
and CC CC O
chronically RB RB O
treated VBN VBN O
( ( ( O
once RB RB O
a DT DT O
day NN NN O
for IN IN O
12 CD CD O
days NNS NNS O
) ) ) O
rats NNS NNS O
. . . O

On IN IN O
the DT DT O
13th CD CD O
day NN NN O
, , , O
antinociceptive JJ JJ O
effects NNS NNS O
were VBD VBD O
assessed VBN VBN O
using VBG VBG O
a DT DT O
model NN NN O
of IN IN O
inflammatory JJ JJ O
nociception NN NN O
, , , O
pain NN NN O
- - - O
induced JJ JJ O
functional JJ JJ O
impairment NN NN O
model NN NN O
, , , O
and CC CC O
the DT DT O
charcoal NN NN B-CHEM
meal NN NN O
test NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
intestinal JJ JJ O
transit NN NN O
. . . O

Simultaneous NNP NNP O
administration NN NN O
of IN IN O
morphine NN NN B-CHEM
with IN IN O
metamizol NN NN B-CHEM
resulted VBD VBD O
in IN IN O
a DT DT O
markedly RB RB O
antinociceptive JJ JJ O
potentiation NN NN O
and CC CC O
an DT DT O
increasing NN NN O
of IN IN O
the DT DT O
duration NN NN O
of IN IN O
action NN NN O
after IN IN O
a DT DT O
single JJ JJ O
( ( ( O
298 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
vs NNS NNS O
. . . O
139 CD CD O
+ NN NN O
/ NN NN O
- : : O
36 CD CD O
units NNS NNS O
area NN NN O
( ( ( O
ua NN NN O
) ) ) O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
repeated VBN VBN O
administration NN NN O
( ( ( O
280 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
vs NNS NNS O
. . . O
131 CD CD O
+ NN NN O
/ NN NN O
- : : O
22 CD CD O
ua NN NN O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Antinociceptive JJ JJ O
effect NN NN O
of IN IN O
morphine NN NN B-CHEM
was VBD VBD O
reduced VBN VBN O
in IN IN O
chronically RB RB O
treated VBN VBN O
rats NNS NNS O
( ( ( O
39 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
vs NNS NNS O
. . . O
18 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
au NN NN O
) ) ) O
while IN IN O
the DT DT O
combination NN NN O
- - - O
induced JJ JJ O
antinociception NN NN O
was VBD VBD O
remained VBN VBN O
similar JJ JJ O
as IN IN O
an DT DT O
acute JJ JJ O
treatment NN NN O
( ( ( O
298 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
vs NNS NNS O
. . . O
280 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
au NN NN O
) ) ) O
. . . O

Acute JJ JJ O
antinociceptive JJ JJ O
effects NNS NNS O
of IN IN O
the DT DT O
combination NN NN O
were VBD VBD O
partially RB RB O
prevented VBN VBN O
by IN IN O
3 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
naloxone NN NN B-CHEM
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O

( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
suggesting VBG VBG O
the DT DT O
partial JJ JJ O
involvement NN NN O
of IN IN O
the DT DT O
opioidergic JJ JJ O
system NN NN O
in IN IN O
the DT DT O
synergism NN NN O
observed VBD VBD O
. . . O

In IN IN O
independent JJ JJ O
groups NNS NNS O
, , , O
morphine NN NN B-CHEM
inhibited VBD VBD O
the DT DT O
intestinal JJ JJ O
transit NN NN O
in IN IN O
48 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
% NN NN O
and CC CC O
38 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
% NN NN O
after IN IN O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
treatment NN NN O
, , , O
respectively RB RB O
, , , O
suggesting VBG VBG O
that IN IN O
tolerance NN NN O
did VBD VBD O
not RB RB O
develop VB VB O
to TO TO O
the DT DT O
constipating NN NN O
effects NNS NNS O
. . . O

The DT DT O
combination NN NN O
inhibited VBD VBD O
intestinal JJ JJ O
transit NN NN O
similar JJ JJ O
to TO TO O
that DT DT O
produced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
regardless RB RB O
of IN IN O
the DT DT O
time NN NN O
of IN IN O
treatment NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
metamizol NN NN B-CHEM
did VBD VBD O
not RB RB O
potentiate VB VB O
morphine NN NN B-CHEM
- : : O
induced JJ JJ O
constipation NN NN O
. . . O

These DT DT O
findings NNS NNS O
show VBP VBP O
a DT DT O
significant JJ JJ O
interaction NN NN O
between IN IN O
morphine NN NN B-CHEM
and CC CC O
metamizol NN NN B-CHEM
in IN IN O
chronically RB RB O
treated VBN VBN O
rats NNS NNS O
, , , O
suggesting VBG VBG O
that IN IN O
this DT DT O
combination NN NN O
could MD MD O
be VB VB O
useful JJ JJ O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
chronic JJ JJ O
pain NN NN O
. . . O

Ifosfamide NNP NNP B-CHEM
encephalopathy JJ JJ O
presenting VBG VBG O
with IN IN O
asterixis NNS NNS O
. . . O

CNS NNP NNP O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
the DT DT O
antineoplastic JJ JJ O
agent NN NN O
ifosfamide NN NN B-CHEM
( ( ( O
IFX NNP NNP B-CHEM
) ) ) O
are VBP VBP O
frequent JJ JJ O
and CC CC O
include VBP VBP O
a DT DT O
variety NN NN O
of IN IN O
neurological JJ JJ O
symptoms NNS NNS O
that WDT WDT O
can MD MD O
limit VB VB O
drug NN NN O
use NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
51 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
developed VBD VBD O
severe JJ JJ O
, , , O
disabling VBG VBG O
negative JJ JJ O
myoclonus NN NN O
of IN IN O
the DT DT O
upper JJ JJ O
and CC CC O
lower JJR JJR O
extremities NNS NNS O
after IN IN O
the DT DT O
infusion NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
for IN IN O
plasmacytoma NN NN O
. . . O

He PRP PRP O
was VBD VBD O
awake JJ JJ O
, , , O
revealed VBD VBD O
no DT DT O
changes NNS NNS O
of IN IN O
mental JJ JJ O
status NN NN O
and CC CC O
at IN IN O
rest NN NN O
there EX EX O
were VBD VBD O
no DT DT O
further JJ JJ O
motor NN NN O
symptoms NNS NNS O
. . . O

Cranial NNP NNP O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
and CC CC O
extensive JJ JJ O
laboratory NN NN O
studies NNS NNS O
failed VBD VBD O
to TO TO O
reveal VB VB O
structural JJ JJ O
lesions NNS NNS O
of IN IN O
the DT DT O
brain NN NN O
and CC CC O
metabolic JJ JJ O
abnormalities NNS NNS O
. . . O

An DT DT O
electroencephalogram NN NN O
showed VBD VBD O
continuous JJ JJ O
, , , O
generalized JJ JJ O
irregular NN NN O
slowing VBG VBG O
with IN IN O
admixed JJ JJ O
periodic NN NN O
triphasic JJ JJ O
waves NNS NNS O
indicating VBG VBG O
symptomatic JJ JJ O
encephalopathy NN NN O
. . . O

The DT DT O
administration NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
and CC CC O
within IN IN O
12 CD CD O
h NN NN O
the DT DT O
asterixis NN NN O
resolved VBD VBD O
completely RB RB O
. . . O

In IN IN O
the DT DT O
patient NN NN O
described VBD VBD O
, , , O
the DT DT O
presence NN NN O
of IN IN O
asterixis NNS NNS O
during IN IN O
infusion NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
, , , O
normal JJ JJ O
laboratory NN NN O
findings NNS NNS O
and CC CC O
imaging VBG VBG O
studies NNS NNS O
and CC CC O
the DT DT O
resolution NN NN O
of IN IN O
symptoms NNS NNS O
following VBG VBG O
the DT DT O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
suggest VBP VBP O
that IN IN O
negative JJ JJ O
myoclonus NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
IFX NNP NNP B-CHEM
. . . O

Antagonism NNP NNP O
between IN IN O
interleukin NN NN O
3 CD CD O
and CC CC O
erythropoietin NN NN O
in IN IN O
mice NN NN O
with IN IN O
azidothymidine NN NN B-CHEM
- - - O
induced JJ JJ O
anemia NN NN O
and CC CC O
in IN IN O
bone NN NN O
marrow NN NN O
endothelial JJ JJ O
cells NNS NNS O
. . . O

Azidothymidine NNP NNP B-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
anemia NN NN O
in IN IN O
mice NN NN O
can MD MD O
be VB VB O
reversed VBN VBN O
by IN IN O
the DT DT O
administration NN NN O
of IN IN O
IGF NNP NNP O
- - - O
IL NNP NNP O
- : : O
3 CD CD O
( ( ( O
fusion NN NN O
protein NN NN O
of IN IN O
insulin NN NN O
- - - O
like IN IN O
growth NN NN O
factor NN NN O
II NNP NNP O
( ( ( O
IGF NNP NNP O
II NNP NNP O
) ) ) O
and CC CC O
interleukin NN NN O
3 CD CD O
) ) ) O
. . . O

Although IN IN O
interleukin NN NN O
3 CD CD O
( ( ( O
IL NNP NNP O
- - - O
3 CD CD O
) ) ) O
and CC CC O
erythropoietin NN NN O
( ( ( O
EPO NNP NNP O
) ) ) O
are VBP VBP O
known VBN VBN O
to TO TO O
act VB VB O
synergistically RB RB O
on IN IN O
hematopoietic JJ JJ O
cell NN NN O
proliferation NN NN O
in IN IN O
vitro NN NN O
, , , O
injection NN NN O
of IN IN O
IGF NNP NNP O
- - - O
IL NNP NNP O
- : : O
3 CD CD O
and CC CC O
EPO NNP NNP O
in IN IN O
AZT NNP NNP B-CHEM
- - - O
treated JJ JJ O
mice NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
reduction NN NN O
of IN IN O
red JJ JJ O
cells NNS NNS O
and CC CC O
an DT DT O
increase NN NN O
of IN IN O
plasma NN NN O
EPO NNP NNP O
levels NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
animals NNS NNS O
treated VBN VBN O
with IN IN O
IGF NNP NNP O
- : : O
IL NNP NNP O
- : : O
3 CD CD O
or CC CC O
EPO NNP NNP O
alone RB RB O
. . . O

We PRP PRP O
tested VBD VBD O
the DT DT O
hypothesis NNS NNS O
that IN IN O
the DT DT O
antagonistic JJ JJ O
effect NN NN O
of IN IN O
IL NNP NNP O
- : : O
3 CD CD O
and CC CC O
EPO NNP NNP O
on IN IN O
erythroid NN NN O
cells NNS NNS O
may MD MD O
be VB VB O
mediated VBN VBN O
by IN IN O
endothelial JJ JJ O
cells NNS NNS O
. . . O

Bovine NNP NNP O
liver NN NN O
erythroid NN NN O
cells NNS NNS O
were VBD VBD O
cultured JJ JJ O
on IN IN O
monolayers NNS NNS O
of IN IN O
human JJ JJ O
bone NN NN O
marrow NN NN O
endothelial JJ JJ O
cells NNS NNS O
previously RB RB O
treated VBN VBN O
with IN IN O
EPO NNP NNP O
and CC CC O
IGF NNP NNP O
- : : O
IL NNP NNP O
- : : O
3 CD CD O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
of IN IN O
thymidine NN NN B-CHEM
incorporation NN NN O
into IN IN O
both DT DT O
erythroid NN NN O
and CC CC O
endothelial JJ JJ O
cells NNS NNS O
in IN IN O
cultures NNS NNS O
pre NN NN O
- : : O
treated VBN VBN O
with IN IN O
IGF NNP NNP O
- : : O
IL NNP NNP O
- : : O
3 CD CD O
and CC CC O
EPO NNP NNP O
. . . O

Endothelial NNP NNP O
cell NN NN O
culture NN NN O
supernatants NNS NNS O
separated VBN VBN O
by IN IN O
ultrafiltration NN NN O
and CC CC O
ultracentrifugation NN NN O
from IN IN O
cells NNS NNS O
treated VBN VBN O
with IN IN O
EPO NNP NNP O
and CC CC O
IL NNP NNP O
- : : O
3 CD CD O
significantly RB RB O
reduced VBD VBD O
thymidine NN NN B-CHEM
incorporation NN NN O
into IN IN O
erythroid NN NN O
cells NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
identical JJ JJ O
fractions NNS NNS O
obtained VBN VBN O
from IN IN O
the DT DT O
media NNS NNS O
of IN IN O
cells NNS NNS O
cultured JJ JJ O
with IN IN O
EPO NNP NNP O
alone RB RB O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
endothelial JJ JJ O
cells NNS NNS O
treated VBN VBN O
simultaneously RB RB O
with IN IN O
EPO NNP NNP O
and CC CC O
IL NNP NNP O
- : : O
3 CD CD O
have VBP VBP O
a DT DT O
negative JJ JJ O
effect NN NN O
on IN IN O
erythroid NN NN O
cell NN NN O
production NN NN O
. . . O

The DT DT O
relationship NN NN O
between IN IN O
hippocampal JJ JJ O
acetylcholine NN NN B-CHEM
release NN NN O
and CC CC O
cholinergic JJ JJ O
convulsant NN NN O
sensitivity NN NN O
in IN IN O
withdrawal NN NN O
seizure NN NN O
- : : O
prone NN NN O
and CC CC O
withdrawal NN NN O
seizure NN NN O
- : : O
resistant NN NN O
selected VBD VBD O
mouse NN NN O
lines NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
septo NN NN O
- - - O
hippocampal JJ JJ O
cholinergic JJ JJ O
pathway NN NN O
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
in IN IN O
epileptogenesis NN NN O
, , , O
and CC CC O
genetic JJ JJ O
factors NNS NNS O
influence VBP VBP O
the DT DT O
response NN NN O
to TO TO O
cholinergic JJ JJ O
agents NNS NNS O
, , , O
but CC CC O
limited JJ JJ O
data NNS NNS O
are VBP VBP O
available JJ JJ O
on IN IN O
cholinergic JJ JJ O
involvement NN NN O
in IN IN O
alcohol NN NN B-CHEM
withdrawal NN NN O
severity NN NN O
. . . O

Thus RB RB O
, , , O
the DT DT O
relationship NN NN O
between IN IN O
cholinergic JJ JJ O
activity NN NN O
and CC CC O
responsiveness NN NN O
and CC CC O
alcohol NN NN B-CHEM
withdrawal NN NN O
was VBD VBD O
investigated VBN VBN O
in IN IN O
a DT DT O
genetic JJ JJ O
animal NN NN O
model NN NN O
of IN IN O
ethanol NN NN B-CHEM
withdrawal NN NN O
severity NN NN O
. . . O

METHODS NNP NNP O
: : : O
Cholinergic NNP NNP O
convulsant NN NN O
sensitivity NN NN O
was VBD VBD O
examined VBN VBN O
in IN IN O
alcohol NN NN B-CHEM
- - - O
na NN NN O
ve NN NN O
Withdrawal NNP NNP O
Seizure NNP NNP O
- : : O
Prone NNP NNP O
( ( ( O
WSP NNP NNP O
) ) ) O
and CC CC O
- : : O
Resistant NNP NNP O
( ( ( O
WSR NNP NNP O
) ) ) O
mice NN NN O
. . . O

Animals NNS NNS O
were VBD VBD O
administered VBN VBN O
nicotine NN NN B-CHEM
, , , O
carbachol NN NN B-CHEM
, , , O
or CC CC O
neostigmine NN NN B-CHEM
via IN IN O
timed VBN VBN O
tail NN NN O
vein NN NN O
infusion NN NN O
, , , O
and CC CC O
the DT DT O
latencies NNS NNS O
to TO TO O
onset NN NN O
of IN IN O
tremor NN NN O
and CC CC O
clonus NN NN O
were VBD VBD O
recorded VBN VBN O
and CC CC O
converted VBN VBN O
to TO TO O
threshold VB VB O
dose NN NN O
. . . O

We PRP PRP O
also RB RB O
used VBD VBD O
microdialysis NNS NNS O
to TO TO O
measure VB VB O
basal NN NN O
and CC CC O
potassium NN NN B-CHEM
- - - O
stimulated VBN VBN O
acetylcholine NN NN B-CHEM
( ( ( O
ACh NNP NNP B-CHEM
) ) ) O
release NN NN O
in IN IN O
the DT DT O
CA1 NNP NNP O
region NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
. . . O

Potassium NNP NNP B-CHEM
was VBD VBD O
applied VBN VBN O
by IN IN O
reverse NN NN O
dialysis NN NN O
twice RB RB O
, , , O
separated JJ JJ O
by IN IN O
75 CD CD O
min NN NN O
. . . O

Hippocampal NNP NNP O
ACh NNP NNP B-CHEM
also RB RB O
was VBD VBD O
measured VBN VBN O
during IN IN O
testing NN NN O
for IN IN O
handling VBG VBG O
- - - O
induced JJ JJ O
convulsions NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Sensitivity NNP NNP O
to TO TO O
several JJ JJ O
convulsion NN NN O
endpoints NNS NNS O
induced VBN VBN O
by IN IN O
nicotine NN NN B-CHEM
, , , O
carbachol NN NN B-CHEM
, , , O
and CC CC O
neostigmine NN NN B-CHEM
were VBD VBD O
significantly RB RB O
greater JJR JJR O
in IN IN O
WSR NNP NNP O
versus CC CC O
WSP NNP NNP O
mice NN NN O
. . . O

In IN IN O
microdialysis NN NN O
experiments NNS NNS O
, , , O
the DT DT O
lines NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
in IN IN O
basal NN NN O
release NN NN O
of IN IN O
ACh NNP NNP B-CHEM
, , , O
and CC CC O
50 CD CD O
mM NN NN O
KCl NNP NNP B-CHEM
increased VBD VBD O
ACh NNP NNP B-CHEM
output NN NN O
in IN IN O
both DT DT O
lines NNS NNS O
of IN IN O
mice NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
increase NN NN O
in IN IN O
release NN NN O
of IN IN O
ACh NNP NNP B-CHEM
produced VBN VBN O
by IN IN O
the DT DT O
first JJ JJ O
application NN NN O
of IN IN O
KCl NNP NNP B-CHEM
was VBD VBD O
2 CD CD O
- : : O
fold VB VB O
higher JJR JJR O
in IN IN O
WSP NNP NNP O
versus CC CC O
WSR NNP NNP O
mice NN NN O
. . . O

When WRB WRB O
hippocampal JJ JJ O
ACh NNP NNP B-CHEM
was VBD VBD O
measured VBN VBN O
during IN IN O
testing NN NN O
for IN IN O
handling VBG VBG O
- - - O
induced JJ JJ O
convulsions NNS NNS O
, , , O
extracellular NN NN O
ACh NNP NNP B-CHEM
was VBD VBD O
significantly RB RB O
elevated VBD VBD O
( ( ( O
192 CD CD O
% NN NN O
) ) ) O
in IN IN O
WSP NNP NNP O
mice NN NN O
, , , O
but CC CC O
was VBD VBD O
nonsignificantly RB RB O
elevated VBN VBN O
( ( ( O
59 CD CD O
% NN NN O
) ) ) O
in IN IN O
WSR NNP NNP O
mice NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
differences NNS NNS O
in IN IN O
cholinergic JJ JJ O
activity NN NN O
and CC CC O
postsynaptic JJ JJ O
sensitivity NN NN O
to TO TO O
cholinergic JJ JJ O
convulsants NNS NNS O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
ethanol NN NN B-CHEM
withdrawal NN NN O
severity NN NN O
and CC CC O
implicate JJ JJ O
cholinergic JJ JJ O
mechanisms NNS NNS O
in IN IN O
alcohol NN NN B-CHEM
withdrawal NN NN O
. . . O

Specifically RB RB O
, , , O
WSP NNP NNP O
mice NNS NNS O
may MD MD O
have VB VB O
lower JJR JJR O
sensitivity NN NN O
to TO TO O
cholinergic JJ JJ O
convulsants NNS NNS O
compared VBN VBN O
with IN IN O
WSR NNP NNP O
because IN IN O
of IN IN O
postsynaptic JJ JJ O
receptor NN NN O
desensitization NN NN O
brought VBN VBN O
on IN IN O
by IN IN O
higher JJR JJR O
activity NN NN O
of IN IN O
cholinergic JJ JJ O
neurons NNS NNS O
. . . O

Capsaicin NNP NNP B-CHEM
- : : O
induced JJ JJ O
muscle NN NN O
pain NN NN O
alters NNS NNS O
the DT DT O
excitability NN NN O
of IN IN O
the DT DT O
human JJ JJ O
jaw NN NN O
- - - O
stretch NN NN O
reflex NN NN O
. . . O

The DT DT O
pathophysiology NN NN O
of IN IN O
painful JJ JJ O
temporomandibular NN NN O
disorders NNS NNS O
is VBZ VBZ O
not RB RB O
fully RB RB O
understood VBN VBN O
, , , O
but CC CC O
evidence NN NN O
suggests VBZ VBZ O
that IN IN O
muscle NN NN O
pain NN NN O
modulates NNS NNS O
motor NN NN O
function NN NN O
in IN IN O
characteristic JJ JJ O
ways NNS NNS O
. . . O

This DT DT O
study NN NN O
tested VBD VBD O
the DT DT O
hypothesis NNS NNS O
that DT DT O
activation NN NN O
of IN IN O
nociceptive JJ JJ O
muscle NN NN O
afferent NN NN O
fibers NNS NNS O
would MD MD O
be VB VB O
linked VBN VBN O
to TO TO O
an DT DT O
increased JJ JJ O
excitability NN NN O
of IN IN O
the DT DT O
human JJ JJ O
jaw NN NN O
- - - O
stretch NN NN O
reflex NN NN O
and CC CC O
whether IN IN O
this DT DT O
process NN NN O
would MD MD O
be VB VB O
sensitive JJ JJ O
to TO TO O
length NN NN O
and CC CC O
velocity NN NN O
of IN IN O
the DT DT O
stretch NN NN O
. . . O

Capsaicin NNP NNP B-CHEM
( ( ( O
10 CD CD O
micro JJ JJ O
g SYM SYM O
) ) ) O
was VBD VBD O
injected VBN VBN O
into IN IN O
the DT DT O
masseter NN NN O
muscle NN NN O
to TO TO O
induce VB VB O
pain NN NN O
in IN IN O
11 CD CD O
healthy JJ JJ O
volunteers NNS NNS O
. . . O

Short JJ JJ O
- : : O
latency NN NN O
reflex NN NN O
responses NNS NNS O
were VBD VBD O
evoked VBN VBN O
in IN IN O
the DT DT O
masseter NN NN O
and CC CC O
temporalis NNS NNS O
muscles NNS NNS O
by IN IN O
a DT DT O
stretch NN NN O
device NN NN O
with IN IN O
different JJ JJ O
velocities NNS NNS O
and CC CC O
displacements NNS NNS O
before IN IN O
, , , O
during IN IN O
, , , O
and CC CC O
after IN IN O
the DT DT O
pain NN NN O
. . . O

The DT DT O
normalized JJ JJ O
reflex NN NN O
amplitude NN NN O
increased VBN VBN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
velocity NN NN O
at IN IN O
a DT DT O
given VBN VBN O
displacement NN NN O
, , , O
but CC CC O
remained VBD VBD O
constant JJ JJ O
with IN IN O
different JJ JJ O
displacements NNS NNS O
at IN IN O
a DT DT O
given VBN VBN O
velocity NN NN O
. . . O

The DT DT O
normalized JJ JJ O
reflex NN NN O
amplitude NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
during IN IN O
pain NN NN O
, , , O
but CC CC O
only RB RB O
at IN IN O
faster RBR RBR O
stretches NNS NNS O
in IN IN O
the DT DT O
painful JJ JJ O
muscle NN NN O
. . . O

Increased NNP NNP O
sensitivity NN NN O
of IN IN O
the DT DT O
fusimotor NN NN O
system NN NN O
during IN IN O
acute JJ JJ O
muscle NN NN O
pain NN NN O
could MD MD O
be VB VB O
one CD CD O
likely JJ JJ O
mechanism NN NN O
to TO TO O
explain VB VB O
the DT DT O
findings NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
5 CD CD O
- : : O
HT1B NNP NNP O
receptor NN NN O
ligands NNS NNS O
microinjected VBN VBN O
into IN IN O
the DT DT O
accumbal NN NN O
shell NN NN O
or CC CC O
core NN NN O
on IN IN O
the DT DT O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
hyperactivity NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
examine VB VB O
the DT DT O
effect NN NN O
of IN IN O
5 CD CD O
- : : O
HT1B NNP NNP O
receptor NN NN O
ligands NNS NNS O
microinjected VBN VBN O
into IN IN O
the DT DT O
subregions NNS NNS O
of IN IN O
the DT DT O
nucleus NN NN O
accumbens NNS NNS O
( ( ( O
the DT DT O
shell NN NN O
and CC CC O
the DT DT O
core NN NN O
) ) ) O
on IN IN O
the DT DT O
locomotor NN NN O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
cocaine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
implanted VBN VBN O
bilaterally RB RB O
with IN IN O
cannulae NN NN O
into IN IN O
the DT DT O
accumbens NNS NNS O
shell NN NN O
or CC CC O
core NN NN O
, , , O
and CC CC O
then RB RB O
were VBD VBD O
locally RB RB O
injected VBN VBN O
with IN IN O
GR NNP NNP B-CHEM
55562 CD CD I-CHEM
( ( ( O
an DT DT O
antagonist NN NN O
of IN IN O
5 CD CD O
- : : O
HT1B NNP NNP O
receptors NNS NNS O
) ) ) O
or CC CC O
CP NNP NNP B-CHEM
93129 CD CD I-CHEM
( ( ( O
an DT DT O
agonist NN NN O
of IN IN O
5 CD CD O
- : : O
HT1B NNP NNP O
receptors NNS NNS O
) ) ) O
. . . O

Given VBN VBN O
alone RB RB O
to TO TO O
any DT DT O
accumbal JJ JJ O
subregion NN NN O
, , , O
GR NNP NNP B-CHEM
55562 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
- : : O
10 CD CD O
microg NN NN O
/ NN NN O
side NN NN O
) ) ) O
or CC CC O
CP NNP NNP B-CHEM
93129 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
- : : O
10 CD CD O
microg NN NN O
/ NN NN O
side NN NN O
) ) ) O
did VBD VBD O
not RB RB O
change VB VB O
basal NN NN O
locomotor NN NN O
activity NN NN O
. . . O

Systemic NNP NNP O
cocaine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
significantly RB RB O
increased VBD VBD O
the DT DT O
locomotor NN NN O
activity NN NN O
of IN IN O
rats NNS NNS O
. . . O

GR NNP NNP B-CHEM
55562 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
- : : O
10 CD CD O
microg NN NN O
/ NN NN O
side NN NN O
) ) ) O
, , , O
administered VBN VBN O
intra NN NN O
- - - O
accumbens NNS NNS O
shell NN NN O
prior RB RB O
to TO TO O
cocaine VB VB B-CHEM
, , , O
dose VB VB O
- - - O
dependently RB RB O
attenuated VBN VBN O
the DT DT O
psychostimulant NN NN O
- - - O
induced JJ JJ O
locomotor NN NN O
hyperactivity NN NN O
. . . O

Such JJ JJ O
attenuation NN NN O
was VBD VBD O
not RB RB O
found VBN VBN O
in IN IN O
animals NNS NNS O
which WDT WDT O
had VBD VBD O
been VBN VBN O
injected VBN VBN O
with IN IN O
GR NNP NNP B-CHEM
55562 CD CD I-CHEM
into IN IN O
the DT DT O
accumbens NNS NNS O
core NN NN O
. . . O

When WRB WRB O
injected VBN VBN O
into IN IN O
the DT DT O
accumbens NNS NNS O
shell NN NN O
( ( ( O
but CC CC O
not RB RB O
the DT DT O
core NN NN O
) ) ) O
before IN IN O
cocaine NN NN B-CHEM
, , , O
CP NNP NNP B-CHEM
93129 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
- : : O
10 CD CD O
microg NN NN O
/ NN NN O
side NN NN O
) ) ) O
enhanced VBD VBD O
the DT DT O
locomotor NN NN O
response NN NN O
to TO TO O
cocaine NN NN B-CHEM
; : : O
the DT DT O
maximum NN NN O
effect NN NN O
being VBG VBG O
observed VBN VBN O
after IN IN O
10 CD CD O
microg NN NN O
/ NN NN O
side NN NN O
of IN IN O
the DT DT O
agonist NN NN O
. . . O

The DT DT O
later RBR RBR O
enhancement NN NN O
was VBD VBD O
attenuated VBN VBN O
after IN IN O
intra NN NN O
- - - O
accumbens NNS NNS O
shell NN NN O
treatment NN NN O
with IN IN O
GR NNP NNP B-CHEM
55562 CD CD I-CHEM
( ( ( O
1 CD CD O
microg NN NN O
/ NN NN O
side NN NN O
) ) ) O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
cocaine NN NN B-CHEM
induced JJ JJ O
hyperlocomotion NN NN O
is VBZ VBZ O
modified VBN VBN O
by IN IN O
5 CD CD O
- : : O
HT1B NNP NNP O
receptor NN NN O
ligands NNS NNS O
microinjected VBN VBN O
into IN IN O
the DT DT O
accumbens NNS NNS O
shell NN NN O
, , , O
but CC CC O
not RB RB O
core VB VB O
, , , O
this DT DT O
modification NN NN O
consisting VBG VBG O
in IN IN O
inhibitory NN NN O
and CC CC O
facilitatory JJ JJ O
effects NNS NNS O
of IN IN O
the DT DT O
5 CD CD O
- : : O
HT1B NNP NNP O
receptor NN NN O
antagonist NN NN O
( ( ( O
GR NNP NNP B-CHEM
55562 CD CD I-CHEM
) ) ) O
and CC CC O
agonist NN NN O
( ( ( O
CP NNP NNP B-CHEM
93129 CD CD I-CHEM
) ) ) O
, , , O
respectively RB RB O
. . . O

In IN IN O
other JJ JJ O
words NNS NNS O
, , , O
the DT DT O
present JJ JJ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
accumbal NN NN O
shell NN NN O
5 CD CD O
- : : O
HT1B NNP NNP O
receptors NNS NNS O
play VBP VBP O
a DT DT O
permissive JJ JJ O
role NN NN O
in IN IN O
the DT DT O
behavioural NN NN O
response NN NN O
to TO TO O
the DT DT O
psychostimulant NN NN O
. . . O

Cocaine NNP NNP B-CHEM
related VBD VBD O
chest NN NN O
pain NN NN O
: : : O
are VBP VBP O
we PRP PRP O
seeing VBG VBG O
the DT DT O
tip NN NN O
of IN IN O
an DT DT O
iceberg NN NN O
? . . O

The DT DT O
recreational JJ JJ O
use NN NN O
of IN IN O
cocaine NN NN B-CHEM
is VBZ VBZ O
on IN IN O
the DT DT O
increase NN NN O
. . . O

The DT DT O
emergency NN NN O
nurse NN NN O
ought MD MD O
to TO TO O
be VB VB O
familiar JJ JJ O
with IN IN O
some DT DT O
of IN IN O
the DT DT O
cardiovascular JJ JJ O
consequences NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

In IN IN O
particular JJ JJ O
, , , O
the DT DT O
tendency NN NN O
of IN IN O
cocaine NN NN B-CHEM
to TO TO O
produce VB VB O
chest NN NN O
pain NN NN O
ought MD MD O
to TO TO O
be VB VB O
in IN IN O
the DT DT O
mind NN NN O
of IN IN O
the DT DT O
emergency NN NN O
nurse NN NN O
when WRB WRB O
faced VBN VBN O
with IN IN O
a DT DT O
young JJ JJ O
victim NN NN O
of IN IN O
chest NN NN O
pain NN NN O
who WP WP O
is VBZ VBZ O
otherwise RB RB O
at IN IN O
low JJ JJ O
risk NN NN O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
chest NN NN O
pain NN NN O
related VBN VBN O
to TO TO O
cocaine VB VB B-CHEM
use NN NN O
is VBZ VBZ O
discussed VBN VBN O
and CC CC O
treatment NN NN O
dilemmas NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Finally RB RB O
, , , O
moral JJ JJ O
issues NNS NNS O
relating VBG VBG O
to TO TO O
the DT DT O
testing NN NN O
of IN IN O
potential JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
will MD MD O
be VB VB O
addressed VBN VBN O
. . . O

Crossover NNP NNP O
comparison NN NN O
of IN IN O
efficacy NN NN O
and CC CC O
preference NN NN O
for IN IN O
rizatriptan NN NN B-CHEM
10 CD CD O
mg NN NN O
versus CC CC O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
in IN IN O
migraine NN NN O
. . . O

Rizatriptan NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
selective JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
( ( ( O
1B CD CD O
/ NN NN O
1D CD CD O
) ) ) O
receptor NN NN O
agonist NN NN O
with IN IN O
rapid JJ JJ O
oral JJ JJ O
absorption NN NN O
and CC CC O
early JJ JJ O
onset NN NN O
of IN IN O
action NN NN O
in IN IN O
the DT DT O
acute JJ JJ O
treatment NN NN O
of IN IN O
migraine NN NN O
. . . O

This DT DT O
randomized JJ JJ O
double JJ JJ O
- - - O
blind JJ JJ O
crossover NN NN O
outpatient JJ JJ O
study NN NN O
assessed VBD VBD O
the DT DT O
preference NN NN O
for IN IN O
1 CD CD O
rizatriptan NN NN B-CHEM
10 CD CD O
mg NN NN O
tablet NN NN O
to TO TO O
2 CD CD O
ergotamine NN NN B-CHEM
1 CD CD O
mg NN NN O
/ NN NN O
caffeine NN NN B-CHEM
100 CD CD O
mg NN NN O
tablets NNS NNS O
in IN IN O
439 CD CD O
patients NNS NNS O
treating VBG VBG O
a DT DT O
single JJ JJ O
migraine NN NN O
attack NN NN O
with IN IN O
each DT DT O
therapy NN NN O
. . . O

Of IN IN O
patients NNS NNS O
expressing VBG VBG O
a DT DT O
preference NN NN O
( ( ( O
89 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
more JJR JJR O
than IN IN O
twice RB RB O
as IN IN O
many JJ JJ O
preferred VBN VBN O
rizatriptan NN NN B-CHEM
to TO TO O
ergotamine VB VB B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
( ( ( O
69 CD CD O
. . . O
9 CD CD O
vs NNS NNS O
. . . O
30 CD CD O
. . . O
1 CD CD O
% NN NN O
, , , O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Faster NNP NNP O
relief NN NN O
of IN IN O
headache NN NN O
was VBD VBD O
the DT DT O
most RBS RBS O
important JJ JJ O
reason NN NN O
for IN IN O
preference NN NN O
, , , O
cited VBN VBN O
by IN IN O
67 CD CD O
. . . O
3 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
preferring VBG VBG O
rizatriptan NN NN B-CHEM
and CC CC O
54 CD CD O
. . . O
2 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
preferred VBD VBD O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
. . . O

The DT DT O
co NN NN O
- - - O
primary JJ JJ O
endpoint NN NN O
of IN IN O
being VBG VBG O
pain NN NN O
free JJ JJ O
at IN IN O
2 CD CD O
h NN NN O
was VBD VBD O
also RB RB O
in IN IN O
favor NN NN O
of IN IN O
rizatriptan NN NN B-CHEM
. . . O

Forty CD CD O
- - - O
nine CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
were VBD VBD O
pain NN NN O
free JJ JJ O
2 CD CD O
h NN NN O
after IN IN O
rizatriptan NN NN B-CHEM
, , , O
compared VBN VBN O
with IN IN O
24 CD CD O
. . . O
3 CD CD O
% NN NN O
treated VBN VBN O
with IN IN O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
( ( ( O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
rizatriptan NN NN B-CHEM
being VBG VBG O
superior JJ JJ O
within IN IN O
1 CD CD O
h NN NN O
of IN IN O
treatment NN NN O
. . . O

Headache NNP NNP O
relief NN NN O
at IN IN O
2 CD CD O
h NN NN O
was VBD VBD O
75 CD CD O
. . . O
9 CD CD O
% NN NN O
for IN IN O
rizatriptan NN NN B-CHEM
and CC CC O
47 CD CD O
. . . O
3 CD CD O
% NN NN O
for IN IN O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
( ( ( O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
with IN IN O
rizatriptan NN NN B-CHEM
being VBG VBG O
superior JJ JJ O
to TO TO O
ergotamine VB VB B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
within IN IN O
30 CD CD O
min NN NN O
of IN IN O
dosing VBG VBG O
. . . O

Almost RB RB O
36 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
taking VBG VBG O
rizatriptan NN NN B-CHEM
were VBD VBD O
pain NN NN O
free JJ JJ O
at IN IN O
2 CD CD O
h NN NN O
and CC CC O
had VBD VBD O
no DT DT O
recurrence NN NN O
or CC CC O
need NN NN O
for IN IN O
additional JJ JJ O
medication NN NN O
within IN IN O
24 CD CD O
h NN NN O
, , , O
compared VBN VBN O
to TO TO O
20 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
on IN IN O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
( ( ( O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Rizatriptan NNP NNP B-CHEM
was VBD VBD O
also RB RB O
superior JJ JJ O
to TO TO O
ergotamine VB VB B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
in IN IN O
the DT DT O
proportions NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
no DT DT O
nausea NN NN O
, , , O
vomiting VBG VBG O
, , , O
phonophobia NN NN O
or CC CC O
photophobia NN NN O
and CC CC O
for IN IN O
patients NNS NNS O
with IN IN O
normal JJ JJ O
function NN NN O
2 CD CD O
h NN NN O
after IN IN O
drug NN NN O
intake NN NN O
( ( ( O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

More JJR JJR O
patients NNS NNS O
were VBD VBD O
( ( ( O
completely RB RB O
, , , O
very RB RB O
or CC CC O
somewhat RB RB O
) ) ) O
satisfied VBN VBN O
2 CD CD O
h NN NN O
after IN IN O
treatment NN NN O
with IN IN O
rizatriptan NN NN B-CHEM
( ( ( O
69 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
than IN IN O
at IN IN O
2 CD CD O
h NN NN O
after IN IN O
treatment NN NN O
with IN IN O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
( ( ( O
38 CD CD O
. . . O
6 CD CD O
% NN NN O
, , , O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Recurrence NNP NNP O
rates NNS NNS O
were VBD VBD O
31 CD CD O
. . . O
4 CD CD O
% NN NN O
with IN IN O
rizatriptan NN NN B-CHEM
and CC CC O
15 CD CD O
. . . O
3 CD CD O
% NN NN O
with IN IN O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
. . . O

Both DT DT O
active JJ JJ O
treatments NNS NNS O
were VBD VBD O
well RB RB O
tolerated VBN VBN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
events NNS NNS O
( ( ( O
incidence NN NN O
> NN NN O
or CC CC O
= SYM SYM O
5 CD CD O
% NN NN O
in IN IN O
one CD CD O
group NN NN O
) ) ) O
after IN IN O
rizatriptan NN NN B-CHEM
and CC CC O
ergotamine NN NN B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
, , , O
respectively RB RB O
, , , O
were VBD VBD O
dizziness JJ JJ O
( ( ( O
6 CD CD O
. . . O
7 CD CD O
and CC CC O
5 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
, , , O
nausea NN NN O
( ( ( O
4 CD CD O
. . . O
2 CD CD O
and CC CC O
8 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
and CC CC O
somnolence NN NN O
( ( ( O
5 CD CD O
. . . O
5 CD CD O
and CC CC O
2 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

Severe NNP NNP O
ocular JJ JJ O
and CC CC O
orbital JJ JJ O
toxicity NN NN O
after IN IN O
intracarotid NN NN O
injection NN NN O
of IN IN O
carboplatin NN NN B-CHEM
for IN IN O
recurrent JJ JJ O
glioblastomas NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Glioblastoma NNP NNP O
is VBZ VBZ O
a DT DT O
malignant JJ JJ O
tumor NN NN O
that WDT WDT O
occurs VBZ VBZ O
in IN IN O
the DT DT O
cerebrum NN NN O
during IN IN O
adulthood NN NN O
. . . O

With IN IN O
current JJ JJ O
treatment NN NN O
regimens NNS NNS O
including VBG VBG O
combined VBN VBN O
surgery NN NN O
, , , O
radiation NN NN O
and CC CC O
chemotherapy NN NN O
, , , O
the DT DT O
average JJ JJ O
life NN NN O
expectancy NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
is VBZ VBZ O
limited VBN VBN O
to TO TO O
approximately RB RB O
1 CD CD O
year NN NN O
. . . O

Therefore RB RB O
, , , O
patients NNS NNS O
with IN IN O
glioblastoma NN NN O
sometimes RB RB O
have VBP VBP O
intracarotid JJ JJ O
injection NN NN O
of IN IN O
carcinostatics NNS NNS O
added VBD VBD O
to TO TO O
the DT DT O
treatment NN NN O
regimen NNS NNS O
. . . O

Generally RB RB O
, , , O
carboplatin NN NN B-CHEM
is VBZ VBZ O
said VBN VBN O
to TO TO O
have VB VB O
milder NN NN O
side NN NN O
effects NNS NNS O
than IN IN O
cisplatin NN NN B-CHEM
, , , O
whose WP$ WP$ O
ocular JJ JJ O
and CC CC O
orbital JJ JJ O
toxicity NN NN O
are VBP VBP O
well RB RB O
known VBN VBN O
. . . O

However RB RB O
, , , O
we PRP PRP O
experienced VBD VBD O
a DT DT O
case NN NN O
of IN IN O
severe JJ JJ O
ocular NN NN O
and CC CC O
orbital JJ JJ O
toxicity NN NN O
after IN IN O
intracarotid NN NN O
injection NN NN O
of IN IN O
carboplatin NN NN B-CHEM
, , , O
which WDT WDT O
is VBZ VBZ O
infrequently RB RB O
reported VBN VBN O
. . . O

CASE NN NN O
: : : O
A DT DT O
58 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
received VBD VBD O
an DT DT O
intracarotid NN NN O
injection NN NN O
of IN IN O
carboplatin NN NN B-CHEM
for IN IN O
recurrent JJ JJ O
glioblastomas NN NN O
in IN IN O
his PRP$ PRP$ O
left JJ JJ O
temporal JJ JJ O
lobe NN NN O
. . . O

He PRP PRP O
complained VBD VBD O
of IN IN O
pain NN NN O
and CC CC O
visual JJ JJ O
disturbance NN NN O
in IN IN O
the DT DT O
ipsilateral JJ JJ O
eye NN NN O
30 CD CD O
h NN NN O
after IN IN O
the DT DT O
injection NN NN O
. . . O

Various JJ JJ O
ocular JJ JJ O
symptoms NNS NNS O
and CC CC O
findings NNS NNS O
caused VBN VBN O
by IN IN O
carboplatin NN NN B-CHEM
toxicity NN NN O
were VBD VBD O
seen VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
He PRP PRP O
was VBD VBD O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
administration NN NN O
of IN IN O
corticosteroids NNS NNS O
and CC CC O
glycerin NN NN B-CHEM
for IN IN O
6 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
injection NN NN O
. . . O

Although IN IN O
the DT DT O
intraocular JJ JJ O
pressure NN NN O
elevation NN NN O
caused VBN VBN O
by IN IN O
secondary JJ JJ O
acute JJ JJ O
angle NN NN O
- - - O
closure NN NN O
glaucoma NN NN O
decreased VBD VBD O
and CC CC O
ocular JJ JJ O
pain NN NN O
diminished VBN VBN O
, , , O
inexorable JJ JJ O
papilledema NN NN O
and CC CC O
exudative JJ JJ O
retinal NN NN O
detachment NN NN O
continued VBD VBD O
for IN IN O
3 CD CD O
weeks NNS NNS O
. . . O

Finally RB RB O
, , , O
6 CD CD O
weeks NNS NNS O
later RB RB O
, , , O
diffuse NN NN O
chorioretinal JJ JJ O
atrophy NN NN O
with IN IN O
optic JJ JJ O
atrophy NN NN O
occurred VBD VBD O
and CC CC O
the DT DT O
vision NN NN O
in IN IN O
his PRP$ PRP$ O
left JJ JJ O
eye NN NN O
was VBD VBD O
lost VBN VBN O
. . . O

CONCLUSION NNP NNP O
: : : O
When WRB WRB O
performing VBG VBG O
intracarotid NN NN O
injection NN NN O
of IN IN O
carboplatin NN NN B-CHEM
, , , O
we PRP PRP O
must MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
its PRP$ PRP$ O
potentially RB RB O
blinding VBG VBG O
ocular JJ JJ O
toxicity NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
recommended VBN VBN O
that IN IN O
further JJ JJ O
studies NNS NNS O
and CC CC O
investigations NNS NNS O
are VBP VBP O
undertaken VBN VBN O
in IN IN O
the DT DT O
effort NN NN O
to TO TO O
minimize VB VB O
such JJ JJ O
severe JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

Visual NNP NNP O
hallucinations NNS NNS O
associated VBN VBN O
with IN IN O
zonisamide NN NN B-CHEM
. . . O

Zonisamide NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
broad JJ JJ O
- - - O
spectrum NN NN O
antiepileptic JJ JJ O
drug NN NN O
used VBN VBN O
to TO TO O
treat VB VB O
various JJ JJ O
types NNS NNS O
of IN IN O
seizures NNS NNS O
. . . O

Although IN IN O
visual JJ JJ O
hallucinations NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
reported VBN VBN O
as IN IN O
an DT DT O
adverse JJ JJ O
effect NN NN O
of IN IN O
this DT DT O
agent NN NN O
, , , O
we PRP PRP O
describe VBP VBP O
three CD CD O
patients NNS NNS O
who WP WP O
experienced VBD VBD O
complex JJ JJ O
visual JJ JJ O
hallucinations NNS NNS O
and CC CC O
altered VBN VBN O
mental JJ JJ O
status NN NN O
after IN IN O
zonisamide NN NN B-CHEM
treatment NN NN O
was VBD VBD O
begun VBN VBN O
or CC CC O
its PRP$ PRP$ O
dosage NN NN O
increased VBD VBD O
. . . O

All DT DT O
three CD CD O
had VBD VBD O
been VBN VBN O
diagnosed VBN VBN O
earlier RBR RBR O
with IN IN O
epilepsy NN NN O
, , , O
and CC CC O
their PRP$ PRP$ O
electroencephalogram NN NN O
( ( ( O
EEG NNP NNP O
) ) ) O
findings NNS NNS O
were VBD VBD O
abnormal JJ JJ O
. . . O

During IN IN O
monitoring NN NN O
, , , O
visual JJ JJ O
hallucinations NNS NNS O
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
EEG NNP NNP O
readings NNS NNS O
, , , O
nor CC CC O
did VBD VBD O
video NN NN O
recording VBG VBG O
capture NN NN O
any DT DT O
of IN IN O
the DT DT O
described JJ JJ O
events NNS NNS O
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
experienced VBN VBN O
visual JJ JJ O
hallucinations NNS NNS O
before IN IN O
this DT DT O
event NN NN O
. . . O

The DT DT O
only RB RB O
recent JJ JJ O
change NN NN O
in IN IN O
their PRP$ PRP$ O
treatment NN NN O
was VBD VBD O
the DT DT O
introduction NN NN O
or CC CC O
increased VBN VBN O
dosage NN NN O
of IN IN O
zonisamide NN NN B-CHEM
. . . O

With IN IN O
either DT DT O
discontinuation NN NN O
or CC CC O
decreased VBD VBD O
dosage NN NN O
of IN IN O
the DT DT O
drug NN NN O
the DT DT O
symptoms NNS NNS O
disappeared VBD VBD O
and CC CC O
did VBD VBD O
not RB RB O
recur VB VB O
. . . O

Further RB RB O
observations NNS NNS O
and CC CC O
reports NNS NNS O
will MD MD O
help VB VB O
clarify VB VB O
this DT DT O
adverse JJ JJ O
effect NN NN O
. . . O

Until IN IN O
then RB RB O
, , , O
clinicians NNS NNS O
need VBP VBP O
to TO TO O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
possible JJ JJ O
complication NN NN O
associated VBN VBN O
with IN IN O
zonisamide NN NN B-CHEM
. . . O

Anti NNP NNP O
- : : O
epileptic JJ JJ O
drugs NNS NNS O
- : : O
induced VBN VBN O
de IN IN O
novo NN NN O
absence NN NN O
seizures NNS NNS O
. . . O

The DT DT O
authors NNS NNS O
present JJ JJ O
three CD CD O
patients NNS NNS O
with IN IN O
de IN IN O
novo NN NN O
absence NN NN O
epilepsy NN NN O
after IN IN O
administration NN NN O
of IN IN O
carbamazepine NN NN B-CHEM
and CC CC O
vigabatrin NN NN B-CHEM
. . . O

Despite IN IN O
the DT DT O
underlying VBG VBG O
diseases NNS NNS O
, , , O
the DT DT O
prognosis NN NN O
for IN IN O
drug NN NN O
- - - O
induced JJ JJ O
de IN IN O
novo NN NN O
absence NN NN O
seizure NN NN O
is VBZ VBZ O
good JJ JJ O
because IN IN O
it PRP PRP O
subsides NNS NNS O
rapidly RB RB O
after IN IN O
discontinuing VBG VBG O
the DT DT O
use NN NN O
of IN IN O
the DT DT O
offending VBG VBG O
drugs NNS NNS O
. . . O

The DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
- - - O
transmitted JJ JJ O
thalamocortical JJ JJ O
circuitry NN NN O
accounts NNS NNS O
for IN IN O
a DT DT O
major JJ JJ O
part NN NN O
of IN IN O
the DT DT O
underlying VBG VBG O
neurophysiology NN NN O
of IN IN O
the DT DT O
absence NN NN O
epilepsy NN NN O
. . . O

Because IN IN O
drug NN NN O
- - - O
induced JJ JJ O
de IN IN O
novo NN NN O
absence NN NN O
seizure NN NN O
is VBZ VBZ O
rare JJ JJ O
, , , O
pro FW FW O
- - - O
absence NN NN O
drugs NNS NNS O
can MD MD O
only RB RB O
be VB VB O
considered VBN VBN O
a DT DT O
promoting VBG VBG O
factor NN NN O
. . . O

The DT DT O
underlying VBG VBG O
epileptogenecity NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
or CC CC O
the DT DT O
synergistic JJ JJ O
effects NNS NNS O
of IN IN O
the DT DT O
accompanying VBG VBG O
drugs NNS NNS O
is VBZ VBZ O
required VBN VBN O
to TO TO O
trigger VB VB O
the DT DT O
de NN NN O
novo NN NN O
absence NN NN O
seizure NN NN O
. . . O

The DT DT O
possibility NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
aggravation NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
whenever WRB WRB O
an DT DT O
unexpected JJ JJ O
increase NN NN O
in IN IN O
seizure NN NN O
frequency NN NN O
and CC CC O
/ NN NN O
or CC CC O
new JJ JJ O
seizure NN NN O
types NNS NNS O
appear VBP VBP O
following VBG VBG O
a DT DT O
change NN NN O
in IN IN O
drug NN NN O
treatment NN NN O
. . . O

By IN IN O
understanding VBG VBG O
the DT DT O
underlying VBG VBG O
mechanism NN NN O
of IN IN O
absence NN NN O
epilepsy NN NN O
, , , O
we PRP PRP O
can MD MD O
avoid VB VB O
the DT DT O
inappropriate JJ JJ O
use NN NN O
of IN IN O
anticonvulsants NNS NNS O
in IN IN O
children NNS NNS O
with IN IN O
epilepsy NN NN O
and CC CC O
prevent VB VB O
drug NN NN O
- : : O
induced JJ JJ O
absence NN NN O
seizures NNS NNS O
. . . O

Prenatal NNP NNP O
dexamethasone NN NN B-CHEM
programs NNS NNS O
hypertension NN NN O
and CC CC O
renal JJ JJ O
injury NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Dexamethasone NNP NNP O
is VBZ VBZ O
frequently RB RB O
administered VBN VBN O
to TO TO O
the DT DT O
developing VBG VBG O
fetus NN NN O
to TO TO O
accelerate VB VB O
pulmonary JJ JJ O
development NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
if IN IN O
prenatal JJ JJ O
dexamethasone NN NN B-CHEM
programmed VBD VBD O
a DT DT O
progressive JJ JJ O
increase NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
renal JJ JJ O
injury NN NN O
in IN IN O
rats NNS NNS O
. . . O

Pregnant NNP NNP O
rats NNS NNS O
were VBD VBD O
given VBN VBN O
either CC CC O
vehicle NN NN O
or CC CC O
2 CD CD O
daily RB RB O
intraperitoneal NN NN O
injections NNS NNS O
of IN IN O
dexamethasone NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) ) ) O
on IN IN O
gestational JJ JJ O
days NNS NNS O
11 CD CD O
and CC CC O
12 CD CD O
, , , O
13 CD CD O
and CC CC O
14 CD CD O
, , , O
15 CD CD O
and CC CC O
16 CD CD O
, , , O
17 CD CD O
and CC CC O
18 CD CD O
, , , O
or CC CC O
19 CD CD O
and CC CC O
20 CD CD O
. . . O

Offspring NNP NNP O
of IN IN O
rats NNS NNS O
administered VBD VBD O
dexamethasone NN NN B-CHEM
on IN IN O
days NNS NNS O
15 CD CD O
and CC CC O
16 CD CD O
gestation NN NN O
had VBD VBD O
a DT DT O
20 CD CD O
% NN NN O
reduction NN NN O
in IN IN O
glomerular NN NN O
number NN NN O
compared VBN VBN O
with IN IN O
control NN NN O
at IN IN O
6 CD CD O
to TO TO O
9 CD CD O
months NNS NNS O
of IN IN O
age NN NN O
( ( ( O
22 CD CD O
527 CD CD O
+ NN NN O
/ NN NN O
- : : O
509 CD CD O
versus CC CC O
28 CD CD O
050 CD CD O
+ NN NN O
/ NN NN O
- : : O
561 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
which WDT WDT O
was VBD VBD O
comparable JJ JJ O
to TO TO O
the DT DT O
percent NN NN O
reduction NN NN O
in IN IN O
glomeruli NN NN O
measured VBN VBN O
at IN IN O
3 CD CD O
weeks NNS NNS O
of IN IN O
age NN NN O
. . . O

Six CD CD O
- : : O
to TO TO O
9 CD CD O
- : : O
month NN NN O
old JJ JJ O
rats NNS NNS O
receiving VBG VBG O
prenatal JJ JJ O
dexamethasone NN NN B-CHEM
on IN IN O
days NNS NNS O
17 CD CD O
and CC CC O
18 CD CD O
of IN IN O
gestation NN NN O
had VBD VBD O
a DT DT O
17 CD CD O
% NN NN O
reduction NN NN O
in IN IN O
glomeruli NN NN O
( ( ( O
23 CD CD O
380 CD CD O
+ NN NN O
/ NN NN O
- : : O
587 CD CD O
) ) ) O
compared VBN VBN O
with IN IN O
control NN NN O
rats NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Male NNP NNP O
rats NNS NNS O
that WDT WDT O
received VBD VBD O
prenatal JJ JJ O
dexamethasone NN NN B-CHEM
on IN IN O
days NNS NNS O
15 CD CD O
and CC CC O
16 CD CD O
, , , O
17 CD CD O
and CC CC O
18 CD CD O
, , , O
and CC CC O
13 CD CD O
and CC CC O
14 CD CD O
of IN IN O
gestation NN NN O
had VBD VBD O
elevated VBN VBN O
blood NN NN O
pressures NNS NNS O
at IN IN O
6 CD CD O
months NNS NNS O
of IN IN O
age NN NN O
; : : O
the DT DT O
latter JJ JJ O
group NN NN O
did VBD VBD O
not RB RB O
have VB VB O
a DT DT O
reduction NN NN O
in IN IN O
glomerular NN NN O
number NN NN O
. . . O

Adult NNP NNP O
rats NNS NNS O
given VBN VBN O
dexamethasone NN NN B-CHEM
on IN IN O
days NNS NNS O
15 CD CD O
and CC CC O
16 CD CD O
of IN IN O
gestation NN NN O
had VBD VBD O
more JJR JJR O
glomeruli NN NN O
with IN IN O
glomerulosclerosis NN NN O
than IN IN O
control NN NN O
rats NNS NNS O
. . . O

This DT DT O
study NN NN O
shows VBZ VBZ O
that IN IN O
prenatal JJ JJ O
dexamethasone NN NN B-CHEM
in IN IN O
rats NNS NNS O
results NNS NNS O
in IN IN O
a DT DT O
reduction NN NN O
in IN IN O
glomerular NN NN O
number NN NN O
, , , O
glomerulosclerosis NN NN O
, , , O
and CC CC O
hypertension NN NN O
when WRB WRB O
administered VBN VBN O
at IN IN O
specific JJ JJ O
points NNS NNS O
during IN IN O
gestation NN NN O
. . . O

Hypertension NNP NNP O
was VBD VBD O
observed VBN VBN O
in IN IN O
animals NNS NNS O
that WDT WDT O
had VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
glomeruli NN NN O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
a DT DT O
group NN NN O
that WDT WDT O
did VBD VBD O
not RB RB O
have VB VB O
a DT DT O
reduction NN NN O
in IN IN O
glomerular NN NN O
number NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
a DT DT O
reduction NN NN O
in IN IN O
glomerular NN NN O
number NN NN O
is VBZ VBZ O
not RB RB O
the DT DT O
sole JJ JJ O
cause NN NN O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
hypertension NN NN O
. . . O

Kidney NNP NNP O
function NN NN O
and CC CC O
morphology NN NN O
after IN IN O
short JJ JJ O
- - - O
term NN NN O
combination NN NN O
therapy NN NN O
with IN IN O
cyclosporine NN NN B-CHEM
A DT DT I-CHEM
, , , O
tacrolimus NN NN B-CHEM
and CC CC O
sirolimus NN NN B-CHEM
in IN IN O
the DT DT O
rat NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Sirolimus NNP NNP B-CHEM
( ( ( O
SRL NNP NNP B-CHEM
) ) ) O
may MD MD O
supplement VB VB O
calcineurin NN NN O
inhibitors NNS NNS O
in IN IN O
clinical JJ JJ O
organ NN NN O
transplantation NN NN O
. . . O

These DT DT O
are VBP VBP O
nephrotoxic RB RB O
, , , O
but CC CC O
SRL NNP NNP B-CHEM
seems VBZ VBZ O
to TO TO O
act VB VB O
differently RB RB O
displaying VBG VBG O
only RB RB O
minor JJ JJ O
nephrotoxic JJ JJ O
effects NNS NNS O
, , , O
although IN IN O
this DT DT O
question NN NN O
is VBZ VBZ O
still RB RB O
open JJ JJ O
. . . O

In IN IN O
a DT DT O
number NN NN O
of IN IN O
treatment NN NN O
protocols NNS NNS O
where WRB WRB O
SRL NNP NNP B-CHEM
was VBD VBD O
combined VBN VBN O
with IN IN O
a DT DT O
calcineurin NN NN O
inhibitor NN NN O
indications NNS NNS O
of IN IN O
a DT DT O
synergistic JJ JJ O
nephrotoxic JJ JJ O
effect NN NN O
were VBD VBD O
described VBN VBN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
examine VB VB O
further JJ JJ O
the DT DT O
renal JJ JJ O
function NN NN O
, , , O
including VBG VBG O
morphological JJ JJ O
analysis NN NN O
of IN IN O
the DT DT O
kidneys NNS NNS O
of IN IN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
treated VBN VBN O
with IN IN O
either DT DT O
cyclosporine NN NN B-CHEM
A DT DT I-CHEM
( ( ( O
CsA NNP NNP B-CHEM
) ) ) O
, , , O
tacrolimus NN NN B-CHEM
( ( ( O
FK506 NNP NNP B-CHEM
) ) ) O
or CC CC O
SRL NNP NNP B-CHEM
as IN IN O
monotherapies NNS NNS O
or CC CC O
in IN IN O
different JJ JJ O
combinations NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
For IN IN O
a DT DT O
period NN NN O
of IN IN O
2 CD CD O
weeks NNS NNS O
, , , O
CsA NNP NNP B-CHEM
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( ( ( O
given VBN VBN O
orally RB RB O
) ) ) O
, , , O
FK506 NNP NNP B-CHEM
3 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( ( ( O
given VBN VBN O
orally RB RB O
) ) ) O
or CC CC O
SRL NNP NNP B-CHEM
0 CD CD O
. . . O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( ( ( O
given VBN VBN O
intraperitoneally RB RB O
) ) ) O
was VBD VBD O
administered VBN VBN O
once RB RB O
a DT DT O
day NN NN O
as IN IN O
these DT DT O
doses NNS NNS O
have VBP VBP O
earlier RBR RBR O
been VBN VBN O
found VBN VBN O
to TO TO O
achieve VB VB O
a DT DT O
significant JJ JJ O
immunosuppressive JJ JJ O
effect NN NN O
in IN IN O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
. . . O

In IN IN O
the DT DT O
' POS POS O
conscious JJ JJ O
catheterized JJ JJ O
rat NN NN O
' '' '' O
model NN NN O
, , , O
the DT DT O
glomerular NN NN O
filtration NN NN O
rate NN NN O
( ( ( O
GFR NNP NNP O
) ) ) O
was VBD VBD O
measured VBN VBN O
as IN IN O
the DT DT O
clearance NN NN O
of IN IN O
Cr NNP NNP O
( ( ( O
EDTA NNP NNP O
) ) ) O
. . . O

The DT DT O
morphological JJ JJ O
analysis NN NN O
of IN IN O
the DT DT O
kidneys NNS NNS O
included VBD VBD O
a DT DT O
semi NN NN O
- - - O
quantitative JJ JJ O
scoring VBG VBG O
system NN NN O
analysing VBG VBG O
the DT DT O
degree NN NN O
of IN IN O
striped JJ JJ O
fibrosis NNS NNS O
, , , O
subcapsular JJ JJ O
fibrosis NNS NNS O
and CC CC O
the DT DT O
number NN NN O
of IN IN O
basophilic JJ JJ O
tubules NNS NNS O
, , , O
plus CC CC O
an DT DT O
additional JJ JJ O
stereological JJ JJ O
analysis NN NN O
of IN IN O
the DT DT O
total JJ JJ O
grade NN NN O
of IN IN O
fibrosis NNS NNS O
in IN IN O
the DT DT O
cortex NN NN O
stained VBD VBD O
with IN IN O
Sirius NNP NNP O
Red NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
CsA NNP NNP B-CHEM
, , , O
FK506 NNP NNP B-CHEM
and CC CC O
SRL NNP NNP B-CHEM
all DT DT O
significantly RB RB O
decreased VBN VBN O
the DT DT O
GFR NNP NNP O
. . . O

A DT DT O
further JJ JJ O
deterioration NN NN O
was VBD VBD O
seen VBN VBN O
when WRB WRB O
CsA NNP NNP B-CHEM
was VBD VBD O
combined VBN VBN O
with IN IN O
either DT DT O
FK506 NNP NNP B-CHEM
or CC CC O
SRL NNP NNP B-CHEM
, , , O
whereas IN IN O
the DT DT O
GFR NNP NNP O
remained VBD VBD O
unchanged JJ JJ O
in IN IN O
the DT DT O
group NN NN O
treated VBN VBN O
with IN IN O
FK506 NNP NNP B-CHEM
plus CC CC O
SRL NNP NNP B-CHEM
when WRB WRB O
compared VBN VBN O
with IN IN O
treatment NN NN O
with IN IN O
any DT DT O
of IN IN O
the DT DT O
single JJ JJ O
substances NNS NNS O
. . . O

The DT DT O
morphological JJ JJ O
changes NNS NNS O
presented VBN VBN O
a DT DT O
similar JJ JJ O
pattern NN NN O
. . . O

The DT DT O
semi NN NN O
- - - O
quantitative JJ JJ O
scoring NN NN O
was VBD VBD O
significantly RB RB O
worst JJS JJS O
in IN IN O
the DT DT O
group NN NN O
treated VBN VBN O
with IN IN O
CsA NNP NNP B-CHEM
plus CC CC O
SRL NNP NNP B-CHEM
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
compared VBN VBN O
with IN IN O
controls NNS NNS O
) ) ) O
and CC CC O
the DT DT O
analysis NN NN O
of IN IN O
the DT DT O
total JJ JJ O
grade NN NN O
of IN IN O
fibrosis NNS NNS O
also RB RB O
showed VBD VBD O
the DT DT O
highest JJS JJS O
proportion NN NN O
in IN IN O
the DT DT O
same JJ JJ O
group NN NN O
and CC CC O
was VBD VBD O
significantly RB RB O
different JJ JJ O
from IN IN O
controls NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

The DT DT O
FK506 NNP NNP B-CHEM
plus CC CC O
SRL NNP NNP B-CHEM
combination NN NN O
showed VBD VBD O
only RB RB O
a DT DT O
marginally RB RB O
higher JJR JJR O
degree NN NN O
of IN IN O
fibrosis NNS NNS O
as IN IN O
compared VBN VBN O
with IN IN O
controls NNS NNS O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
rat NN NN O
study NN NN O
demonstrated VBD VBD O
a DT DT O
synergistic JJ JJ O
nephrotoxic JJ JJ O
effect NN NN O
of IN IN O
CsA NNP NNP B-CHEM
plus CC CC O
SRL NNP NNP B-CHEM
, , , O
whereas IN IN O
FK506 NNP NNP B-CHEM
plus CC CC O
SRL NNP NNP B-CHEM
was VBD VBD O
better RBR RBR O
tolerated JJ JJ O
. . . O

Evaluation NNP NNP O
of IN IN O
cardiac JJ JJ O
troponin NN NN O
I PRP PRP O
and CC CC O
T NN NN O
levels NNS NNS O
as IN IN O
markers NNS NNS O
of IN IN O
myocardial NN NN O
damage NN NN O
in IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
rats NNS NNS O
, , , O
and CC CC O
their PRP$ PRP$ O
relationship NN NN O
with IN IN O
echocardiographic JJ JJ O
and CC CC O
histological JJ JJ O
findings NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Cardiac NNP NNP O
troponins NNS NNS O
I PRP PRP O
( ( ( O
cTnI NN NN O
) ) ) O
and CC CC O
T NN NN O
( ( ( O
cTnT NN NN O
) ) ) O
have VBP VBP O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
highly RB RB O
sensitive JJ JJ O
and CC CC O
specific JJ JJ O
markers NNS NNS O
of IN IN O
myocardial NN NN O
cell NN NN O
injury NN NN O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
diagnostic JJ JJ O
value NN NN O
of IN IN O
cTnI NN NN O
and CC CC O
cTnT NN NN O
for IN IN O
the DT DT O
diagnosis NN NN O
of IN IN O
myocardial NN NN O
damage NN NN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
, , , O
and CC CC O
we PRP PRP O
examined VBD VBD O
the DT DT O
relationship NN NN O
between IN IN O
serial JJ JJ O
cTnI NN NN O
and CC CC O
cTnT NN NN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
cardiac JJ JJ O
disorders NNS NNS O
monitored VBN VBN O
by IN IN O
echocardiography NN NN O
and CC CC O
histological JJ JJ O
examinations NNS NNS O
in IN IN O
this DT DT O
model NN NN O
. . . O

METHODS NNP NNP O
: : : O
Thirty NNP NNP O
- - - O
five CD CD O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
given VBN VBN O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
DOX NNP NNP B-CHEM
, , , O
i NNP NNP O
. . . O
v NN NN O
. . . O
, , , O
weekly NN NN O
for IN IN O
up IN IN O
to TO TO O
8 CD CD O
weeks NNS NNS O
for IN IN O
a DT DT O
total JJ JJ O
cumulative JJ JJ O
dose NN NN O
of IN IN O
12 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
. . . O

Ten CD CD O
rats NNS NNS O
received VBD VBD O
saline NN NN O
as IN IN O
a DT DT O
control NN NN O
group NN NN O
. . . O

cTnI NN NN O
was VBD VBD O
measured VBN VBN O
with IN IN O
Access NNP NNP O
( ( ( O
R NN NN O
) ) ) O
( ( ( O
ng NN NN O
/ NN NN O
ml NN NN O
) ) ) O
and CC CC O
a DT DT O
research NN NN O
immunoassay NN NN O
( ( ( O
pg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
, , , O
and CC CC O
compared VBD VBD O
with IN IN O
cTnT NN NN O
, , , O
CK NNP NNP O
- : : O
MB NNP NNP O
mass NN NN O
and CC CC O
CK NNP NNP O
. . . O

By IN IN O
using VBG VBG O
transthoracic NN NN O
echocardiography NN NN O
, , , O
anterior NN NN O
and CC CC O
posterior NN NN O
wall NN NN O
thickness NN NN O
, , , O
LV NNP NNP O
diameters NNS NNS O
and CC CC O
LV NNP NNP O
fractional JJ JJ O
shortening VBG VBG O
( ( ( O
FS NNP NNP O
) ) ) O
were VBD VBD O
measured VBN VBN O
in IN IN O
all DT DT O
rats NNS NNS O
before IN IN O
DOX NNP NNP B-CHEM
or CC CC O
saline NN NN O
, , , O
and CC CC O
at IN IN O
weeks NNS NNS O
6 CD CD O
and CC CC O
9 CD CD O
after IN IN O
treatment NN NN O
in IN IN O
all DT DT O
surviving VBG VBG O
rats NNS NNS O
. . . O

Histology NNP NNP O
was VBD VBD O
performed VBN VBN O
in IN IN O
DOX NNP NNP B-CHEM
- : : O
rats NNS NNS O
at IN IN O
6 CD CD O
and CC CC O
9 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
last JJ JJ O
DOX NNP NNP B-CHEM
dose NN NN O
and CC CC O
in IN IN O
all DT DT O
controls NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Eighteen NNP NNP O
of IN IN O
the DT DT O
DOX NNP NNP B-CHEM
rats NNS NNS O
died VBD VBD O
prematurely RB RB O
of IN IN O
general JJ JJ O
toxicity NN NN O
during IN IN O
the DT DT O
9 CD CD O
- : : O
week NN NN O
period NN NN O
. . . O

End NN NN O
- : : O
diastolic JJ JJ O
( ( ( O
ED NNP NNP O
) ) ) O
and CC CC O
end VB VB O
- : : O
systolic JJ JJ O
( ( ( O
ES NNP NNP O
) ) ) O
LV NNP NNP O
diameters NNS NNS O
/ NN NN O
BW NNP NNP O
significantly RB RB O
increased VBD VBD O
, , , O
whereas IN IN O
LV NNP NNP O
FS NNP NNP O
was VBD VBD O
decreased VBN VBN O
after IN IN O
9 CD CD O
weeks NNS NNS O
in IN IN O
the DT DT O
DOX NNP NNP B-CHEM
group NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

These DT DT O
parameters NNS NNS O
remained VBD VBD O
unchanged JJ JJ O
in IN IN O
controls NNS NNS O
. . . O

Histological NNP NNP O
evaluation NN NN O
of IN IN O
hearts NNS NNS O
from IN IN O
all DT DT O
rats NNS NNS O
given VBN VBN O
DOX NNP NNP B-CHEM
revealed VBD VBD O
significant JJ JJ O
slight JJ JJ O
degrees NNS NNS O
of IN IN O
perivascular NN NN O
and CC CC O
interstitial JJ JJ O
fibrosis NNS NNS O
. . . O

In IN IN O
7 CD CD O
of IN IN O
the DT DT O
18 CD CD O
rats NNS NNS O
, , , O
degeneration NN NN O
and CC CC O
myocyte NN NN O
vacuolisation NN NN O
were VBD VBD O
found VBN VBN O
. . . O

Only RB RB O
five CD CD O
of IN IN O
the DT DT O
controls NNS NNS O
exhibited VBN VBN O
evidence NN NN O
of IN IN O
very RB RB O
slight JJ JJ O
perivascular NN NN O
fibrosis NNS NNS O
. . . O

A DT DT O
significant JJ JJ O
rise NN NN O
in IN IN O
cTnT NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
DOX NNP NNP B-CHEM
rats NNS NNS O
after IN IN O
cumulative JJ JJ O
doses NNS NNS O
of IN IN O
7 CD CD O
. . . O
5 CD CD O
and CC CC O
12 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
in IN IN O
comparison NN NN O
with IN IN O
baseline NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

cTnT NN NN O
found VBD VBD O
in IN IN O
rats NNS NNS O
after IN IN O
12 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
were VBD VBD O
significantly RB RB O
greater JJR JJR O
than IN IN O
that DT DT O
found VBD VBD O
after IN IN O
7 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
DOX NNP NNP B-CHEM
. . . O

Maximal NNP NNP O
cTnI NN NN O
( ( ( O
pg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
and CC CC O
cTnT NN NN O
levels NNS NNS O
were VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
DOX NNP NNP B-CHEM
rats NNS NNS O
compared VBN VBN O
with IN IN O
controls NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
006 CD CD O
, , , O
0 CD CD O
. . . O
007 CD CD O
) ) ) O
. . . O

cTnI NN NN O
( ( ( O
ng NN NN O
/ NN NN O
ml NN NN O
) ) ) O
, , , O
CK NNP NNP O
- : : O
MB NNP NNP O
mass NN NN O
and CC CC O
CK NNP NNP O
remained VBD VBD O
unchanged JJ JJ O
in IN IN O
DOX NNP NNP B-CHEM
rats NNS NNS O
compared VBN VBN O
with IN IN O
controls NNS NNS O
. . . O

All DT DT O
markers NNS NNS O
remained VBD VBD O
stable JJ JJ O
in IN IN O
controls NNS NNS O
. . . O

Analysis NNP NNP O
of IN IN O
data NNS NNS O
revealed VBD VBD O
a DT DT O
significant JJ JJ O
correlation NN NN O
between IN IN O
maximal NN NN O
cTnT NN NN O
and CC CC O
ED NNP NNP O
and CC CC O
ES NNP NNP O
LV NNP NNP O
diameters NNS NNS O
/ NN NN O
BW NNP NNP O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
81 CD CD O
and CC CC O
0 CD CD O
. . . O
65 CD CD O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

A DT DT O
significant JJ JJ O
relationship NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
maximal NN NN O
cTnT NN NN O
and CC CC O
the DT DT O
extent NN NN O
of IN IN O
myocardial JJ JJ O
morphological JJ JJ O
changes NNS NNS O
, , , O
and CC CC O
between IN IN O
LV NNP NNP O
diameters NNS NNS O
/ NN NN O
BW NNP NNP O
and CC CC O
histological JJ JJ O
findings NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Among IN IN O
markers NNS NNS O
of IN IN O
ischemic JJ JJ O
injury NN NN O
after IN IN O
DOX NNP NNP B-CHEM
in IN IN O
rats NNS NNS O
, , , O
cTnT NN NN O
showed VBD VBD O
the DT DT O
greatest JJS JJS O
ability NN NN O
to TO TO O
detect VB VB O
myocardial NN NN O
damage NN NN O
assessed VBN VBN O
by IN IN O
echocardiographic JJ JJ O
detection NN NN O
and CC CC O
histological JJ JJ O
changes NNS NNS O
. . . O

Although IN IN O
there EX EX O
was VBD VBD O
a DT DT O
discrepancy NN NN O
between IN IN O
the DT DT O
amount NN NN O
of IN IN O
cTnI NN NN O
and CC CC O
cTnT NN NN O
after IN IN O
DOX NNP NNP B-CHEM
, , , O
probably RB RB O
due JJ JJ O
to TO TO O
heterogeneity NN NN O
in IN IN O
cross NN NN O
- - - O
reactivities NNS NNS O
of IN IN O
mAbs NN NN O
to TO TO O
various JJ JJ O
cTnI NN NN O
and CC CC O
cTnT NN NN O
forms NNS NNS O
, , , O
it PRP PRP O
is VBZ VBZ O
likely JJ JJ O
that IN IN O
cTnT NN NN O
in IN IN O
rats NNS NNS O
after IN IN O
DOX NNP NNP B-CHEM
indicates VBZ VBZ O
cell NN NN O
damage NN NN O
determined VBN VBN O
by IN IN O
the DT DT O
magnitude NN NN O
of IN IN O
injury NN NN O
induced VBD VBD O
and CC CC O
that IN IN O
cTnT NN NN O
should MD MD O
be VB VB O
a DT DT O
useful JJ JJ O
marker NN NN O
for IN IN O
the DT DT O
prediction NN NN O
of IN IN O
experimentally RB RB O
induced VBN VBN O
cardiotoxicity NN NN O
and CC CC O
possibly RB RB O
for IN IN O
cardioprotective JJ JJ O
experiments NNS NNS O
. . . O

Octreotide IN IN B-CHEM
- - - O
induced JJ JJ O
hypoxemia NN NN O
and CC CC O
pulmonary JJ JJ O
hypertension NN NN O
in IN IN O
premature JJ JJ O
neonates NNS NNS O
. . . O

The DT DT O
authors NNS NNS O
report VBP VBP O
2 CD CD O
cases NNS NNS O
of IN IN O
premature JJ JJ O
neonates NNS NNS O
who WP WP O
had VBD VBD O
enterocutaneous JJ JJ O
fistula NN NN O
complicating VBG VBG O
necrotizing VBG VBG O
enterocolitis NNS NNS O
. . . O

Pulmonary NNP NNP O
hypertension NN NN O
developed VBN VBN O
after IN IN O
administration NN NN O
of IN IN O
a DT DT O
somatostatin NN NN O
analogue NN NN O
, , , O
octreotide NN NN B-CHEM
, , , O
to TO TO O
enhance VB VB O
resolution NN NN O
of IN IN O
the DT DT O
fistula NN NN O
. . . O

The DT DT O
authors NNS NNS O
discuss VBP VBP O
the DT DT O
mechanism NN NN O
of IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
this DT DT O
complication NN NN O
and CC CC O
recommend VB VB O
caution NN NN O
of IN IN O
its PRP$ PRP$ O
use NN NN O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
premature NN NN O
neonates NNS NNS O
. . . O

The DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
in IN IN O
women NNS NNS O
prescribed VBN VBN O
cyproterone NN NN B-CHEM
acetate NN NN I-CHEM
in IN IN O
combination NN NN O
with IN IN O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
: : : O
a DT DT O
nested JJ JJ O
cohort NN NN O
analysis NN NN O
and CC CC O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Cyproterone NNP NNP B-CHEM
acetate NN NN I-CHEM
combined VBN VBN O
with IN IN O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
( ( ( O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
licensed VBN VBN O
in IN IN O
the DT DT O
UK NNP NNP O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
women NNS NNS O
with IN IN O
acne NN NN O
and CC CC O
hirsutism NN NN O
and CC CC O
is VBZ VBZ O
also RB RB O
a DT DT O
treatment NN NN O
option NN NN O
for IN IN O
polycystic JJ JJ O
ovary JJ JJ O
syndrome NN NN O
( ( ( O
PCOS NNP NNP O
) ) ) O
. . . O

Previous JJ JJ O
studies NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
( ( ( O
VTE NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
compared VBN VBN O
with IN IN O
conventional JJ JJ O
combined VBN VBN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
( ( ( O
COCs NNP NNP O
) ) ) O
. . . O

We PRP PRP O
believe VBP VBP O
the DT DT O
results NNS NNS O
of IN IN O
those DT DT O
studies NNS NNS O
may MD MD O
have VB VB O
been VBN VBN O
affected VBN VBN O
by IN IN O
residual JJ JJ O
confounding NN NN O
. . . O

METHODS NNP NNP O
: : : O
Using VBG VBG O
the DT DT O
General NNP NNP O
Practice NNP NNP O
Research NNP NNP O
Database NNP NNP O
we PRP PRP O
conducted VBD VBD O
a DT DT O
cohort NN NN O
analysis NN NN O
and CC CC O
case NN NN O
- - - O
control NN NN O
study NN NN O
nested VBD VBD O
within IN IN O
a DT DT O
population NN NN O
of IN IN O
women NNS NNS O
aged VBN VBN O
between IN IN O
15 CD CD O
and CC CC O
39 CD CD O
years NNS NNS O
with IN IN O
acne NN NN O
, , , O
hirsutism NN NN O
or CC CC O
PCOS NNP NNP O
to TO TO O
estimate VB VB O
the DT DT O
risk NN NN O
of IN IN O
VTE NNP NNP O
associated VBN VBN O
with IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
age NN NN O
- - - O
adjusted VBN VBN O
incidence NN NN O
rate NN NN O
ratio NN NN O
for IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
versus CC CC O
conventional JJ JJ O
COCs NNP NNP O
was VBD VBD O
2 CD CD O
. . . O
20 CD CD O
[ NN NN O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
( ( ( O
CI NNP NNP O
) ) ) O
1 CD CD O
. . . O
35 CD CD O
- : : O
3 CD CD O
. . . O
58 CD CD O
] NN NN O
. . . O

Using VBG VBG O
as IN IN O
the DT DT O
reference NN NN O
group NN NN O
women NNS NNS O
who WP WP O
were VBD VBD O
not RB RB O
using VBG VBG O
oral JJ JJ O
contraception NN NN O
, , , O
had VBD VBD O
no DT DT O
recent JJ JJ O
pregnancy NN NN O
or CC CC O
menopausal NN NN O
symptoms NNS NNS O
, , , O
the DT DT O
case NN NN O
- - - O
control NN NN O
analysis NN NN O
gave VBD VBD O
an DT DT O
adjusted JJ JJ O
odds NN NN O
ratio NN NN O
( ( ( O
OR CC CC O
( ( ( O
adj NN NN O
) ) ) O
) ) ) O
of IN IN O
7 CD CD O
. . . O
44 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
3 CD CD O
. . . O
67 CD CD O
- : : O
15 CD CD O
. . . O
08 CD CD O
) ) ) O
for IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
use NN NN O
compared VBN VBN O
with IN IN O
an DT DT O
OR CC CC O
( ( ( O
adj NN NN O
) ) ) O
of IN IN O
2 CD CD O
. . . O
58 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
60 CD CD O
- : : O
4 CD CD O
. . . O
18 CD CD O
) ) ) O
for IN IN O
use NN NN O
of IN IN O
conventional JJ JJ O
COCs NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
We PRP PRP O
have VBP VBP O
demonstrated VBN VBN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
VTE NNP NNP O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
in IN IN O
women NNS NNS O
with IN IN O
acne NN NN O
, , , O
hirsutism NN NN O
or CC CC O
PCOS NNP NNP O
although IN IN O
residual JJ JJ O
confounding NN NN O
by IN IN O
indication NN NN O
cannot NN NN O
be VB VB O
excluded VBN VBN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
treatment NN NN O
with IN IN O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
on IN IN O
gentamicin NN NN B-CHEM
nephrotoxicity NN NN O
in IN IN O
rats NNS NNS O
: : : O
a DT DT O
preliminary JJ JJ O
study NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
work NN NN O
we PRP PRP O
assessed VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
treatment NN NN O
of IN IN O
rats NNS NNS O
with IN IN O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
on IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
induced VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
( ( ( O
GM NNP NNP B-CHEM
) ) ) O
nephrotoxicity NN NN O
. . . O

Rats NNP NNP O
were VBD VBD O
treated VBN VBN O
with IN IN O
the DT DT O
vehicle NN NN O
( ( ( O
2 CD CD O
mL NN NN O
/ NN NN O
kg NN NN O
of IN IN O
distilled JJ JJ O
water NN NN O
and CC CC O
5 CD CD O
% NN NN O
w NN NN O
/ NN NN O
v NN NN O
cellulose NN NN O
, , , O
10 CD CD O
days NNS NNS O
) ) ) O
, , , O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
( ( ( O
2 CD CD O
mL NN NN O
/ NN NN O
kg NN NN O
of IN IN O
a DT DT O
10 CD CD O
% NN NN O
w NN NN O
/ NN NN O
v NN NN O
aqueous JJ JJ O
suspension NN NN O
of IN IN O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
powder NN NN O
, , , O
orally RB RB O
for IN IN O
10 CD CD O
days NNS NNS O
) ) ) O
, , , O
or CC CC O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
concomitantly RB RB O
with IN IN O
GM NNP NNP B-CHEM
( ( ( O
80mg CD CD O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
intramuscularly RB RB O
, , , O
during IN IN O
the DT DT O
last JJ JJ O
six CD CD O
days NNS NNS O
of IN IN O
the DT DT O
treatment NN NN O
period NN NN O
) ) ) O
. . . O

Nephrotoxicity NNP NNP O
was VBD VBD O
assessed VBN VBN O
by IN IN O
measuring VBG VBG O
the DT DT O
concentrations NNS NNS O
of IN IN O
creatinine NN NN B-CHEM
and CC CC O
urea NN NN B-CHEM
in IN IN O
the DT DT O
plasma NN NN O
and CC CC O
reduced VBD VBD O
glutathione NN NN B-CHEM
( ( ( O
GSH NNP NNP B-CHEM
) ) ) O
in IN IN O
the DT DT O
kidney NN NN O
cortex NN NN O
, , , O
and CC CC O
by IN IN O
light JJ JJ O
microscopic JJ JJ O
examination NN NN O
of IN IN O
kidney NN NN O
sections NNS NNS O
. . . O

The DT DT O
results NNS NNS O
indicated VBD VBD O
that IN IN O
concomitant NN NN O
treatment NN NN O
with IN IN O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
and CC CC O
GM NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
creatinine NN NN B-CHEM
and CC CC O
urea NN NN B-CHEM
by IN IN O
about IN IN O
183 CD CD O
and CC CC O
239 CD CD O
% NN NN O
, , , O
respectively RB RB O
( ( ( O
compared VBN VBN O
to TO TO O
432 CD CD O
and CC CC O
346 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
cellulose NN NN O
and CC CC O
GM NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
decreased VBD VBD O
that IN IN O
of IN IN O
cortical JJ JJ O
GSH NNP NNP B-CHEM
by IN IN O
21 CD CD O
% NN NN O
( ( ( O
compared VBN VBN O
to TO TO O
27 CD CD O
% NN NN O
in IN IN O
the DT DT O
cellulose NN NN O
plus CC CC O
GM NNP NNP B-CHEM
group NN NN O
) ) ) O
The DT DT O
GM NNP NNP B-CHEM
- - - O
induced JJ JJ O
proximal NN NN O
tubular NN NN O
necrosis NNS NNS O
appeared VBD VBD O
to TO TO O
be VB VB O
slightly RB RB O
less JJR JJR O
severe JJ JJ O
in IN IN O
rats NNS NNS O
given VBN VBN O
GM NNP NNP B-CHEM
together RB RB O
with IN IN O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
than IN IN O
in IN IN O
those DT DT O
given VBN VBN O
GM NNP NNP B-CHEM
and CC CC O
cellulose NN NN O
. . . O

It PRP PRP O
could MD MD O
be VB VB O
inferred VBN VBN O
that IN IN O
gum NN NN B-CHEM
Arabic NNP NNP I-CHEM
treatment NN NN O
has VBZ VBZ O
induced VBN VBN O
a DT DT O
modest JJ JJ O
amelioration NN NN O
of IN IN O
some DT DT O
of IN IN O
the DT DT O
histological JJ JJ O
and CC CC O
biochemical JJ JJ O
indices NNS NNS O
of IN IN O
GM NNP NNP B-CHEM
nephrotoxicity NN NN O
. . . O

Further RB RB O
work NN NN O
is VBZ VBZ O
warranted VBN VBN O
on IN IN O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
treatments NNS NNS O
on IN IN O
renal JJ JJ O
functional JJ JJ O
aspects NNS NNS O
in IN IN O
models NNS NNS O
of IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
and CC CC O
on IN IN O
the DT DT O
mechanism NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
involved VBN VBN O
. . . O

Increased NNP NNP O
frequency NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
with IN IN O
the DT DT O
combination NN NN O
of IN IN O
docetaxel NN NN B-CHEM
and CC CC O
thalidomide NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
metastatic JJ JJ O
androgen NN NN O
- - - O
independent JJ JJ O
prostate NN NN O
cancer NN NN O
. . . O

STUDY NNP NNP O
OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
frequency NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
( ( ( O
VTE NNP NNP O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
advanced JJ JJ O
androgen NN NN O
- - - O
independent JJ JJ O
prostate NN NN O
cancer NN NN O
who WP WP O
were VBD VBD O
treated VBN VBN O
with IN IN O
docetaxel NN NN B-CHEM
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
thalidomide NN NN B-CHEM
. . . O

DESIGN NNP NNP O
: : : O
Retrospective NNP NNP O
analysis NN NN O
of IN IN O
a DT DT O
randomized JJ JJ O
phase NN NN O
II NNP NNP O
trial NN NN O
. . . O

SETTING NNP NNP O
: : : O
National NNP NNP O
Institutes NNP NNP O
of IN IN O
Health NNP NNP O
clinical JJ JJ O
research NN NN O
center NN NN O
. . . O

PATIENTS NNS NNS O
: : : O
Seventy NNP NNP O
men NNS NNS O
, , , O
aged VBN VBN O
50 CD CD O
- : : O
80 CD CD O
years NNS NNS O
, , , O
with IN IN O
advanced JJ JJ O
androgen NN NN O
- - - O
independent JJ JJ O
prostate NN NN O
cancer NN NN O
. . . O

INTERVENTION NNP NNP O
: : : O
Each DT DT O
patient NN NN O
received VBD VBD O
either CC CC O
intravenous JJ JJ O
docetaxel NN NN B-CHEM
30 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
week NN NN O
for IN IN O
3 CD CD O
consecutive JJ JJ O
weeks NNS NNS O
, , , O
followed VBN VBN O
by IN IN O
1 CD CD O
week NN NN O
off IN IN O
, , , O
or CC CC O
the DT DT O
combination NN NN O
of IN IN O
continuous JJ JJ O
oral JJ JJ O
thalidomide NN NN B-CHEM
200 CD CD O
mg NN NN O
every DT DT O
evening NN NN O
plus CC CC O
the DT DT O
same JJ JJ O
docetaxel NN NN B-CHEM
regimen NNS NNS O
. . . O

This DT DT O
4 CD CD O
- : : O
week NN NN O
cycle NN NN O
was VBD VBD O
repeated VBN VBN O
until IN IN O
there EX EX O
was VBD VBD O
evidence NN NN O
of IN IN O
excessive JJ JJ O
toxicity NN NN O
or CC CC O
disease NN NN O
progression NN NN O
. . . O

MEASUREMENTS NNP NNP O
AND CC CC O
MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
None NN NN O
of IN IN O
23 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
docetaxel NN NN B-CHEM
alone RB RB O
developed VBN VBN O
VTE NNP NNP O
, , , O
whereas IN IN O
9 CD CD O
of IN IN O
47 CD CD O
patients NNS NNS O
( ( ( O
19 CD CD O
% NN NN O
) ) ) O
who WP WP O
received VBD VBD O
docetaxel NN NN B-CHEM
plus CC CC O
thalidomide NN NN B-CHEM
developed VBN VBN O
VTE NNP NNP O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
025 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
addition NN NN O
of IN IN O
thalidomide NN NN B-CHEM
to TO TO O
docetaxel VB VB B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
prostate JJ JJ O
cancer NN NN O
significantly RB RB O
increases VBZ VBZ O
the DT DT O
frequency NN NN O
of IN IN O
VTE NNP NNP O
. . . O

Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
potential JJ JJ O
complication NN NN O
when WRB WRB O
adding VBG VBG O
thalidomide IN IN B-CHEM
to TO TO O
chemotherapeutic JJ JJ O
regimens NNS NNS O
. . . O

Ticlopidine NNP NNP B-CHEM
- : : O
induced JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
2 CD CD O
cases NNS NNS O
of IN IN O
ticlopidine NN NN B-CHEM
- - - O
induced JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
, , , O
investigate VB VB O
its PRP$ PRP$ O
mechanism NN NN O
, , , O
and CC CC O
compare VB VB O
the DT DT O
observed VBD VBD O
main JJ JJ O
characteristics NNS NNS O
with IN IN O
those DT DT O
of IN IN O
the DT DT O
published VBN VBN O
cases NNS NNS O
. . . O

CASE NN NN O
SUMMARIES NNP NNP O
: : : O
Two CD CD O
patients NNS NNS O
developed VBN VBN O
prolonged JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
after IN IN O
receiving VBG VBG O
ticlopidine NN NN B-CHEM
following VBG VBG O
percutaneous JJ JJ O
coronary JJ JJ O
angioplasty NN NN O
, , , O
with IN IN O
complete JJ JJ O
remission NN NN O
during IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
. . . O

T NN NN O
- - - O
cell NN NN O
stimulation NN NN O
by IN IN O
therapeutic JJ JJ O
concentration NN NN O
of IN IN O
ticlopidine NN NN B-CHEM
was VBD VBD O
demonstrated VBN VBN O
in IN IN O
vitro NN NN O
in IN IN O
the DT DT O
patients NNS NNS O
, , , O
but CC CC O
not RB RB O
in IN IN O
healthy JJ JJ O
controls NNS NNS O
. . . O

DISCUSSION NNP NNP O
: : : O
Cholestatic JJ JJ O
hepatitis NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
of IN IN O
the DT DT O
antiplatelet NN NN O
agent NN NN O
ticlopidine NN NN B-CHEM
; : : O
several JJ JJ O
cases NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
but CC CC O
few JJ JJ O
in IN IN O
the DT DT O
English NNP NNP O
literature NN NN O
. . . O

Our PRP$ PRP$ O
patients NNS NNS O
developed VBN VBN O
jaundice NN NN O
following VBG VBG O
treatment NN NN O
with IN IN O
ticlopidine NN NN B-CHEM
and CC CC O
showed VBD VBD O
the DT DT O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
characteristics NNS NNS O
of IN IN O
cholestatic JJ JJ O
hepatitis NN NN O
, , , O
which WDT WDT O
resolved VBD VBD O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

Hepatitis NNP NNP O
may MD MD O
develop VB VB O
weeks NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
and CC CC O
may MD MD O
run VB VB O
a DT DT O
prolonged JJ JJ O
course NN NN O
, , , O
but CC CC O
complete JJ JJ O
remission NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
all DT DT O
reported VBD VBD O
cases NNS NNS O
. . . O

An DT DT O
objective NN NN O
causality NN NN O
assessment NN NN O
revealed VBD VBD O
that IN IN O
the DT DT O
adverse JJ JJ O
drug NN NN O
event NN NN O
was VBD VBD O
probably RB RB O
related VBN VBN O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
ticlopidine NN NN B-CHEM
. . . O

The DT DT O
mechanisms NNS NNS O
of IN IN O
this DT DT O
ticlopidine NN NN B-CHEM
- : : O
induced JJ JJ O
cholestasis NNS NNS O
are VBP VBP O
unclear JJ JJ O
. . . O

Immune NNP NNP O
mechanisms NNS NNS O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
drug NN NN O
' '' '' O
s VBZ VBZ O
hepatotoxicity NN NN O
, , , O
as IN IN O
suggested VBN VBN O
by IN IN O
the DT DT O
T NN NN O
- - - O
cell NN NN O
stimulation NN NN O
study NN NN O
reported VBD VBD O
here RB RB O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Cholestatic JJ JJ O
hepatitis NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
adverse JJ JJ O
effect NN NN O
of IN IN O
ticlopidine NN NN B-CHEM
that WDT WDT O
may MD MD O
be VB VB O
immune JJ JJ O
mediated JJ JJ O
. . . O

Patients NNS NNS O
receiving VBG VBG O
the DT DT O
drug NN NN O
should MD MD O
be VB VB O
monitored VBN VBN O
with IN IN O
liver NN NN O
function NN NN O
tests NNS NNS O
along IN IN O
with IN IN O
complete JJ JJ O
blood NN NN O
cell NN NN O
counts NNS NNS O
. . . O

This DT DT O
complication NN NN O
will MD MD O
be VB VB O
observed VBN VBN O
even RB RB O
less RBR RBR O
often RB RB O
in IN IN O
the DT DT O
future NN NN O
as IN IN O
ticlopidine NN NN B-CHEM
is VBZ VBZ O
being VBG VBG O
replaced VBN VBN O
by IN IN O
the DT DT O
newer JJR JJR O
antiplatelet NN NN O
agent NN NN O
clopidogrel NN NN B-CHEM
. . . O

Epithelial NNP NNP O
sodium NN NN B-CHEM
channel NN NN O
( ( ( O
ENaC NNP NNP O
) ) ) O
subunit NN NN O
mRNA NN NN O
and CC CC O
protein NN NN O
expression NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

In IN IN O
experimental JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
, , , O
urinary JJ JJ O
sodium NN NN B-CHEM
excretion NN NN O
is VBZ VBZ O
decreased VBN VBN O
during IN IN O
the DT DT O
early JJ JJ O
phase NN NN O
of IN IN O
the DT DT O
disease NN NN O
. . . O

The DT DT O
molecular JJ JJ O
mechanism NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
leading VBG VBG O
to TO TO O
salt NN NN O
retention NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
completely RB RB O
elucidated VBN VBN O
. . . O

The DT DT O
rate NN NN O
- - - O
limiting VBG VBG O
constituent NN NN O
of IN IN O
collecting VBG VBG O
duct NN NN O
sodium NN NN B-CHEM
transport NN NN O
is VBZ VBZ O
the DT DT O
epithelial NN NN O
sodium NN NN B-CHEM
channel NN NN O
( ( ( O
ENaC NNP NNP O
) ) ) O
. . . O

We PRP PRP O
examined VBD VBD O
the DT DT O
abundance NN NN O
of IN IN O
ENaC NNP NNP O
subunit NN NN O
mRNAs NN NN O
and CC CC O
proteins NNS NNS O
in IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

The DT DT O
time NN NN O
courses NNS NNS O
of IN IN O
urinary JJ JJ O
sodium NN NN B-CHEM
excretion NN NN O
, , , O
plasma NN NN O
aldosterone NN NN B-CHEM
concentration NN NN O
and CC CC O
proteinuria NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
treated VBN VBN O
with IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
either DT DT O
PAN NNP NNP B-CHEM
or CC CC O
vehicle NN NN O
. . . O

The DT DT O
relative JJ JJ O
amounts NNS NNS O
of IN IN O
alphaENaC NN NN O
, , , O
betaENaC NN NN O
and CC CC O
gammaENaC NN NN O
mRNAs NN NN O
were VBD VBD O
determined VBN VBN O
in IN IN O
kidneys NNS NNS O
from IN IN O
these DT DT O
rats NNS NNS O
by IN IN O
real JJ JJ O
- : : O
time NN NN O
quantitative JJ JJ O
TaqMan NNP NNP O
PCR NNP NNP O
, , , O
and CC CC O
the DT DT O
amounts NNS NNS O
of IN IN O
proteins NNS NNS O
by IN IN O
Western JJ JJ O
blot NN NN O
. . . O

The DT DT O
kinetics NNS NNS O
of IN IN O
urinary JJ JJ O
sodium NN NN B-CHEM
excretion NN NN O
and CC CC O
the DT DT O
appearance NN NN O
of IN IN O
proteinuria NN NN O
were VBD VBD O
comparable JJ JJ O
with IN IN O
those DT DT O
reported VBN VBN O
previously RB RB O
. . . O

Sodium NNP NNP B-CHEM
retention NN NN O
occurred VBD VBD O
on IN IN O
days NNS NNS O
2 CD CD O
, , , O
3 CD CD O
and CC CC O
6 CD CD O
after IN IN O
PAN NNP NNP B-CHEM
injection NN NN O
. . . O

A DT DT O
significant JJ JJ O
up RP RP O
- : : O
regulation NN NN O
of IN IN O
alphaENaC NN NN O
and CC CC O
betaENaC NN NN O
mRNA NN NN O
abundance NN NN O
on IN IN O
days NNS NNS O
1 CD CD O
and CC CC O
2 CD CD O
preceded VBN VBN O
sodium NN NN B-CHEM
retention NN NN O
on IN IN O
days NNS NNS O
2 CD CD O
and CC CC O
3 CD CD O
. . . O

Conversely RB RB O
, , , O
down RB RB O
- - - O
regulation NN NN O
of IN IN O
alphaENaC NN NN O
, , , O
betaENaC NN NN O
and CC CC O
gammaENaC NN NN O
mRNA NN NN O
expression NN NN O
on IN IN O
day NN NN O
3 CD CD O
occurred VBD VBD O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
high JJ JJ O
aldosterone NN NN B-CHEM
concentrations NNS NNS O
, , , O
and CC CC O
was VBD VBD O
followed VBN VBN O
by IN IN O
a DT DT O
return NN NN O
of IN IN O
sodium NN NN B-CHEM
excretion NN NN O
to TO TO O
control VB VB O
values NNS NNS O
. . . O

The DT DT O
amounts NNS NNS O
of IN IN O
alphaENaC NN NN O
, , , O
betaENaC NN NN O
and CC CC O
gammaENaC NN NN O
proteins NNS NNS O
were VBD VBD O
not RB RB O
increased VBN VBN O
during IN IN O
PAN NNP NNP B-CHEM
- : : O
induced JJ JJ O
sodium NN NN B-CHEM
retention NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
ENaC NNP NNP O
mRNA NN NN O
expression NN NN O
, , , O
especially RB RB O
alphaENaC NN NN O
, , , O
is VBZ VBZ O
increased VBN VBN O
in IN IN O
the DT DT O
very RB RB O
early JJ JJ O
phase NN NN O
of IN IN O
the DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
PAN NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
in IN IN O
rats NNS NNS O
, , , O
but CC CC O
appears VBZ VBZ O
to TO TO O
escape VB VB O
from IN IN O
the DT DT O
regulation NN NN O
by IN IN O
aldosterone NN NN B-CHEM
after IN IN O
day NN NN O
3 CD CD O
. . . O

Sub NNP NNP O
- : : O
chronic JJ JJ O
low JJ JJ O
dose NN NN O
gamma NN NN B-CHEM
- : : I-CHEM
vinyl NN NN I-CHEM
GABA NNP NNP I-CHEM
( ( ( O
vigabatrin NN NN B-CHEM
) ) ) O
inhibits NNS NNS O
cocaine JJ JJ B-CHEM
- : : O
induced JJ JJ O
increases NNS NNS O
in IN IN O
nucleus NN NN O
accumbens NNS NNS O
dopamine NN NN B-CHEM
. . . O

RATIONALE NNP NNP O
: : : O
gamma NN NN B-CHEM
- - - I-CHEM
Vinyl NNP NNP I-CHEM
GABA NNP NNP I-CHEM
( ( ( O
GVG NNP NNP B-CHEM
) ) ) O
irreversibly RB RB O
inhibits NNS NNS O
GABA NNP NNP B-CHEM
- : : O
transaminase NN NN O
. . . O

This DT DT O
non NN NN O
- : : O
receptor NN NN O
mediated JJ JJ O
inhibition NN NN O
requires VBZ VBZ O
de IN IN O
novo NN NN O
synthesis NN NN O
for IN IN O
restoration NN NN O
of IN IN O
functional JJ JJ O
GABA NNP NNP B-CHEM
catabolism NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
Given VBN VBN O
its PRP$ PRP$ O
preclinical JJ JJ O
success NN NN O
for IN IN O
treating VBG VBG O
substance NN NN O
abuse NN NN O
and CC CC O
the DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
visual JJ JJ O
field NN NN O
defects NNS NNS O
( ( ( O
VFD NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
cumulative JJ JJ O
lifetime NN NN O
exposure NN NN O
, , , O
we PRP PRP O
explored VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
sub NN NN O
- - - O
chronic JJ JJ O
low JJ JJ O
dose NN NN O
GVG NNP NNP B-CHEM
on IN IN O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
increases NNS NNS O
in IN IN O
nucleus NN NN O
accumbens NNS NNS O
( ( ( O
NAcc NNP NNP O
) ) ) O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
Using VBG VBG O
in IN IN O
vivo NN NN O
microdialysis NN NN O
, , , O
we PRP PRP O
compared VBD VBD O
acute JJ JJ O
exposure NN NN O
( ( ( O
450 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
to TO TO O
an DT DT O
identical JJ JJ O
sub NN NN O
- - - O
chronic JJ JJ O
exposure NN NN O
( ( ( O
150 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
for IN IN O
3 CD CD O
days NNS NNS O
) ) ) O
, , , O
followed VBN VBN O
by IN IN O
1 CD CD O
- : : O
or CC CC O
3 CD CD O
- : : O
day NN NN O
washout NN NN O
. . . O

Finally RB RB O
, , , O
we PRP PRP O
examined VBD VBD O
the DT DT O
low JJ JJ O
dose NN NN O
of IN IN O
150 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
) ) ) O
using VBG VBG O
a DT DT O
similar JJ JJ O
washout NN NN O
period NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Sub NNP NNP O
- - - O
chronic JJ JJ O
GVG NNP NNP B-CHEM
exposure NN NN O
inhibited VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
cocaine NN NN B-CHEM
for IN IN O
3 CD CD O
days NNS NNS O
, , , O
which WDT WDT O
exceeded VBD VBD O
in IN IN O
magnitude NN NN O
and CC CC O
duration NN NN O
the DT DT O
identical JJ JJ O
acute JJ JJ O
dose NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Sub NNP NNP O
- - - O
chronic JJ JJ O
low JJ JJ O
dose NN NN O
GVG NNP NNP B-CHEM
potentiates NNS NNS O
and CC CC O
extends VBZ VBZ O
the DT DT O
inhibition NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
increases NNS NNS O
in IN IN O
dopamine NN NN B-CHEM
, , , O
effectively RB RB O
reducing VBG VBG O
cumulative JJ JJ O
exposures NNS NNS O
and CC CC O
the DT DT O
risk NN NN O
for IN IN O
VFDS NNP NNP O
. . . O

MR NNP NNP O
imaging VBG VBG O
with IN IN O
quantitative JJ JJ O
diffusion NN NN O
mapping NN NN O
of IN IN O
tacrolimus NN NN B-CHEM
- - - O
induced JJ JJ O
neurotoxicity NN NN O
in IN IN O
organ NN NN O
transplant JJ JJ O
patients NNS NNS O
. . . O

Our PRP$ PRP$ O
objective NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
brain NN NN O
MR NNP NNP O
imaging VBG VBG O
findings NNS NNS O
and CC CC O
the DT DT O
utility NN NN O
of IN IN O
diffusion NN NN O
- - - O
weighted JJ JJ O
( ( ( O
DW NNP NNP O
) ) ) O
imaging VBG VBG O
in IN IN O
organ NN NN O
transplant JJ JJ O
patients NNS NNS O
who WP WP O
developed VBD VBD O
neurologic JJ JJ O
symptoms NNS NNS O
during IN IN O
tacrolimus NN NN B-CHEM
therapy NN NN O
. . . O

Brain NNP NNP O
MR NNP NNP O
studies NNS NNS O
, , , O
including VBG VBG O
DW NNP NNP O
imaging VBG VBG O
, , , O
were VBD VBD O
prospectively RB RB O
performed VBN VBN O
in IN IN O
14 CD CD O
organ NN NN O
transplant NN NN O
patients NNS NNS O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
who WP WP O
developed VBD VBD O
neurologic JJ JJ O
complications NNS NNS O
. . . O

In IN IN O
each DT DT O
patient NN NN O
who WP WP O
had VBD VBD O
abnormalities NNS NNS O
on IN IN O
the DT DT O
initial JJ JJ O
MR NNP NNP O
study NN NN O
, , , O
a DT DT O
follow VB VB O
- - - O
up RP RP O
MR NNP NNP O
study NN NN O
was VBD VBD O
performed VBN VBN O
1 CD CD O
month NN NN O
later RB RB O
. . . O

Apparent NNP NNP O
diffusion NN NN O
coefficient NN NN O
( ( ( O
ADC NNP NNP O
) ) ) O
values NNS NNS O
on IN IN O
the DT DT O
initial JJ JJ O
MR NNP NNP O
study NN NN O
were VBD VBD O
correlated VBN VBN O
with IN IN O
reversibility NN NN O
of IN IN O
the DT DT O
lesions NNS NNS O
. . . O

Of IN IN O
the DT DT O
14 CD CD O
patients NNS NNS O
, , , O
5 CD CD O
( ( ( O
35 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
white JJ JJ O
matter NN NN O
abnormalities NNS NNS O
, , , O
1 CD CD O
( ( ( O
7 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
putaminal JJ JJ O
hemorrhage NN NN O
, , , O
and CC CC O
8 CD CD O
( ( ( O
57 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
normal JJ JJ O
findings NNS NNS O
on IN IN O
initial JJ JJ O
MR NNP NNP O
images NNS NNS O
. . . O

Among IN IN O
the DT DT O
5 CD CD O
patients NNS NNS O
with IN IN O
white JJ JJ O
matter NN NN O
abnormalities NNS NNS O
, , , O
4 CD CD O
patients NNS NNS O
( ( ( O
80 CD CD O
. . . O
0 CD CD O
% NN NN O
) ) ) O
showed VBD VBD O
higher JJR JJR O
than IN IN O
normal JJ JJ O
ADC NNP NNP O
values NNS NNS O
on IN IN O
initial JJ JJ O
MR NNP NNP O
images NNS NNS O
, , , O
and CC CC O
all DT DT O
showed VBD VBD O
complete JJ JJ O
resolution NN NN O
on IN IN O
follow VB VB O
- - - O
up RP RP O
images NNS NNS O
. . . O

The DT DT O
remaining VBG VBG O
1 CD CD O
patient NN NN O
( ( ( O
20 CD CD O
. . . O
0 CD CD O
% NN NN O
) ) ) O
showed VBD VBD O
lower JJR JJR O
than IN IN O
normal JJ JJ O
ADC NNP NNP O
value NN NN O
and CC CC O
showed VBD VBD O
incomplete JJ JJ O
resolution NN NN O
with IN IN O
cortical JJ JJ O
laminar NN NN O
necrosis NN NN O
. . . O

Diffusion NNP NNP O
- - - O
weighted JJ JJ O
imaging VBG VBG O
may MD MD O
be VB VB O
useful JJ JJ O
in IN IN O
predicting VBG VBG O
the DT DT O
outcomes NNS NNS O
of IN IN O
the DT DT O
lesions NNS NNS O
of IN IN O
tacrolimus NN NN B-CHEM
- - - O
induced JJ JJ O
neurotoxicity NN NN O
. . . O

L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
transport NN NN O
in IN IN O
humans NNS NNS O
with IN IN O
cortisol NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
. . . O

A DT DT O
deficient NN NN O
L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
- - - O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
system NN NN O
is VBZ VBZ O
implicated VBN VBN O
in IN IN O
cortisol NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
. . . O

We PRP PRP O
investigate VBP VBP O
whether IN IN O
abnormalities NNS NNS O
in IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
uptake NN NN O
contribute NN NN O
to TO TO O
this DT DT O
deficiency NN NN O
. . . O

Eight CD CD O
healthy JJ JJ O
men NNS NNS O
were VBD VBD O
recruited VBN VBN O
. . . O

Hydrocortisone NNP NNP B-CHEM
acetate NN NN I-CHEM
( ( ( O
50 CD CD O
mg NN NN O
) ) ) O
was VBD VBD O
given VBN VBN O
orally RB RB O
every DT DT O
6 CD CD O
hours NNS NNS O
for IN IN O
24 CD CD O
hours NNS NNS O
after IN IN O
a DT DT O
5 CD CD O
- : : O
day NN NN O
fixed JJ JJ O
- : : O
salt NN NN O
diet NN NN O
( ( ( O
150 CD CD O
mmol NN NN O
/ NN NN O
d SYM SYM O
) ) ) O
. . . O

Crossover NNP NNP O
studies NNS NNS O
were VBD VBD O
performed VBN VBN O
2 CD CD O
weeks NNS NNS O
apart RB RB O
. . . O

Thirty NNP NNP O
milliliters NNS NNS O
of IN IN O
blood NN NN O
was VBD VBD O
obtained VBN VBN O
for IN IN O
isolation NN NN O
of IN IN O
peripheral JJ JJ O
blood NN NN O
mononuclear NN NN O
cells NNS NNS O
after IN IN O
each DT DT O
treatment NN NN O
period NN NN O
. . . O

L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
uptake NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
mononuclear NN NN O
cells NNS NNS O
incubated JJ JJ O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
( ( ( O
1 CD CD O
to TO TO O
300 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
, , , O
incorporating VBG VBG O
100 CD CD O
nmol NN NN O
/ NN NN O
L NNP NNP O
[ NN NN B-CHEM
3H CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
l NN NN I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
for IN IN O
a DT DT O
period NN NN O
of IN IN O
5 CD CD O
minutes NNS NNS O
at IN IN O
37 CD CD O
degrees NNS NNS O
C NNP NNP O
. . . O

Forearm NNP NNP O
[ NN NN B-CHEM
3H CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
L NNP NNP I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
extraction NN NN O
was VBD VBD O
calculated VBN VBN O
after IN IN O
infusion NN NN O
of IN IN O
[ NN NN B-CHEM
3H CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
L NNP NNP I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
into IN IN O
the DT DT O
brachial NN NN O
artery NN NN O
at IN IN O
a DT DT O
rate NN NN O
of IN IN O
100 CD CD O
nCi NN NN O
/ NN NN O
min NN NN O
for IN IN O
80 CD CD O
minutes NNS NNS O
. . . O

Deep JJ JJ O
forearm NN NN O
venous JJ JJ O
samples NNS NNS O
were VBD VBD O
collected VBN VBN O
for IN IN O
determination NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
extraction NN NN O
. . . O

Plasma NNP NNP O
cortisol NN NN B-CHEM
concentrations NNS NNS O
were VBD VBD O
significantly RB RB O
raised VBN VBN O
during IN IN O
the DT DT O
active JJ JJ O
phase NN NN O
( ( ( O
323 CD CD O
+ NN NN O
/ NN NN O
- : : O
43 CD CD O
to TO TO O
1082 CD CD O
+ NN NN O
/ NN NN O
- : : O
245 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Systolic NNP NNP O
blood NN NN O
pressure NN NN O
was VBD VBD O
elevated VBN VBN O
by IN IN O
an DT DT O
average NN NN O
of IN IN O
7 CD CD O
mm NN NN O
Hg NNP NNP O
. . . O

Neither DT DT O
L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
transport NN NN O
into IN IN O
mononuclear NN NN O
cells NNS NNS O
( ( ( O
placebo NN NN O
vs NNS NNS O
active JJ JJ O
, , , O
26 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
6 CD CD O
vs NNS NNS O
29 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
1 CD CD O
pmol NN NN O
/ NN NN O
10 CD CD O
000 CD CD O
cells NNS NNS O
per IN IN O
5 CD CD O
minutes NNS NNS O
, , , O
respectively RB RB O
, , , O
at IN IN O
an DT DT O
l NN NN B-CHEM
- - - I-CHEM
arginine JJ JJ I-CHEM
concentration NN NN O
of IN IN O
300 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
nor CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
extraction NN NN O
in IN IN O
the DT DT O
forearm NN NN O
( ( ( O
at IN IN O
80 CD CD O
minutes NNS NNS O
, , , O
placebo NN NN O
vs NNS NNS O
active JJ JJ O
, , , O
1 CD CD O
868 CD CD O
904 CD CD O
+ NN NN O
/ NN NN O
- : : O
434 CD CD O
962 CD CD O
vs NNS NNS O
2 CD CD O
013 CD CD O
910 CD CD O
+ NN NN O
/ NN NN O
- : : O
770 CD CD O
619 CD CD O
disintegrations NNS NNS O
per IN IN O
minute NN NN O
) ) ) O
was VBD VBD O
affected VBN VBN O
by IN IN O
cortisol NN NN B-CHEM
treatment NN NN O
; : : O
ie NN NN O
, , , O
that IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
uptake NN NN O
is VBZ VBZ O
not RB RB O
affected VBN VBN O
by IN IN O
short JJ JJ O
- - - O
term NN NN O
cortisol NN NN B-CHEM
treatment NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
cortisol NN NN B-CHEM
- : : O
induced JJ JJ O
increases NNS NNS O
in IN IN O
blood NN NN O
pressure NN NN O
are VBP VBP O
not RB RB O
associated VBN VBN O
with IN IN O
abnormalities NNS NNS O
in IN IN O
the DT DT O
l NN NN B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
transport NN NN O
system NN NN O
. . . O

Amount NNP NNP O
of IN IN O
bleeding VBG VBG O
and CC CC O
hematoma NN NN O
size NN NN O
in IN IN O
the DT DT O
collagenase NN NN O
- - - O
induced JJ JJ O
intracerebral JJ JJ O
hemorrhage NN NN O
rat NN NN O
model NN NN O
. . . O

The DT DT O
aggravated JJ JJ O
risk NN NN O
on IN IN O
intracerebral JJ JJ O
hemorrhage NN NN O
( ( ( O
ICH NNP NNP O
) ) ) O
with IN IN O
drugs NNS NNS O
used VBN VBN O
for IN IN O
stroke NN NN O
patients NNS NNS O
should MD MD O
be VB VB O
estimated VBN VBN O
carefully RB RB O
. . . O

We PRP PRP O
therefore RB RB O
established VBD VBD O
sensitive JJ JJ O
quantification NN NN O
methods NNS NNS O
and CC CC O
provided VBD VBD O
a DT DT O
rat NN NN O
ICH NNP NNP O
model NN NN O
for IN IN O
detection NN NN O
of IN IN O
ICH NNP NNP O
deterioration NN NN O
. . . O

In IN IN O
ICH NNP NNP O
intrastriatally RB RB O
induced VBN VBN O
by IN IN O
0 CD CD O
. . . O
014 CD CD O
- : : O
unit NN NN O
, , , O
0 CD CD O
. . . O
070 CD CD O
- : : O
unit NN NN O
, , , O
and CC CC O
0 CD CD O
. . . O
350 CD CD O
- : : O
unit NN NN O
collagenase NN NN O
, , , O
the DT DT O
amount NN NN O
of IN IN O
bleeding VBG VBG O
was VBD VBD O
measured VBN VBN O
using VBG VBG O
a DT DT O
hemoglobin NN NN O
assay NN NN O
developed VBN VBN O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
and CC CC O
was VBD VBD O
compared VBN VBN O
with IN IN O
the DT DT O
morphologically RB RB O
determined VBN VBN O
hematoma NN NN O
volume NN NN O
. . . O

The DT DT O
blood NN NN O
amounts NNS NNS O
and CC CC O
hematoma NN NN O
volumes NNS NNS O
were VBD VBD O
significantly RB RB O
correlated JJ JJ O
, , , O
and CC CC O
the DT DT O
hematoma NN NN O
induced VBN VBN O
by IN IN O
0 CD CD O
. . . O
014 CD CD O
- : : O
unit NN NN O
collagenase NN NN O
was VBD VBD O
adequate JJ JJ O
to TO TO O
detect VB VB O
ICH NNP NNP O
deterioration NN NN O
. . . O

In IN IN O
ICH NNP NNP O
induction NN NN O
using VBG VBG O
0 CD CD O
. . . O
014 CD CD O
- : : O
unit NN NN O
collagenase NN NN O
, , , O
heparin NN NN B-CHEM
enhanced VBD VBD O
the DT DT O
hematoma NN NN O
volume NN NN O
3 CD CD O
. . . O
4 CD CD O
- : : O
fold VB VB O
over IN IN O
that DT DT O
seen VBN VBN O
in IN IN O
control NN NN O
ICH NNP NNP O
animals NNS NNS O
and CC CC O
the DT DT O
bleeding VBG VBG O
7 CD CD O
. . . O
6 CD CD O
- : : O
fold NN NN O
. . . O

Data NNP NNP O
suggest VBP VBP O
that IN IN O
this DT DT O
sensitive JJ JJ O
hemoglobin NN NN O
assay NN NN O
is VBZ VBZ O
useful JJ JJ O
for IN IN O
ICH NNP NNP O
detection NN NN O
, , , O
and CC CC O
that IN IN O
a DT DT O
model NN NN O
with IN IN O
a DT DT O
small JJ JJ O
ICH NNP NNP O
induced VBD VBD O
with IN IN O
a DT DT O
low JJ JJ O
- - - O
dose NN NN O
collagenase NN NN O
should MD MD O
be VB VB O
used VBN VBN O
for IN IN O
evaluation NN NN O
of IN IN O
drugs NNS NNS O
that WDT WDT O
may MD MD O
affect VB VB O
ICH NNP NNP O
. . . O

Estradiol NNP NNP B-CHEM
reduces VBZ VBZ O
seizure NN NN O
- - - O
induced JJ JJ O
hippocampal NN NN O
injury NN NN O
in IN IN O
ovariectomized JJ JJ O
female NN NN O
but CC CC O
not RB RB O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

Estrogens NNP NNP O
protect VB VB O
ovariectomized JJ JJ O
rats NNS NNS O
from IN IN O
hippocampal JJ JJ O
injury NN NN O
induced VBN VBN O
by IN IN O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
( ( ( O
SE NNP NNP O
) ) ) O
. . . O

We PRP PRP O
compared VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
17beta CD CD B-CHEM
- : : I-CHEM
estradiol NN NN I-CHEM
in IN IN O
adult NN NN O
male JJ JJ O
and CC CC O
ovariectomized JJ JJ O
female JJ JJ O
rats NNS NNS O
subjected VBD VBD O
to TO TO O
lithium VB VB B-CHEM
- - - O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
SE NNP NNP O
. . . O

Rats NNP NNP O
received VBD VBD O
subcutaneous JJ JJ O
injections NNS NNS O
of IN IN O
17beta CD CD B-CHEM
- : : I-CHEM
estradiol NN NN I-CHEM
( ( ( O
2 CD CD O
microg NN NN O
/ NN NN O
rat NN NN O
) ) ) O
or CC CC O
oil NN NN O
once RB RB O
daily RB RB O
for IN IN O
four CD CD O
consecutive JJ JJ O
days NNS NNS O
. . . O

SE NNP NNP O
was VBD VBD O
induced VBN VBN O
20 CD CD O
h NN NN O
following VBG VBG O
the DT DT O
second JJ JJ O
injection NN NN O
and CC CC O
terminated VBD VBD O
3 CD CD O
h NN NN O
later RB RB O
. . . O

The DT DT O
extent NN NN O
of IN IN O
silver NN NN B-CHEM
- - - O
stained JJ JJ O
CA3 NNP NNP O
and CC CC O
CA1 NNP NNP O
hippocampal JJ JJ O
neurons NNS NNS O
was VBD VBD O
evaluated VBN VBN O
2 CD CD O
days NNS NNS O
after IN IN O
SE NNP NNP O
. . . O

17beta CD CD B-CHEM
- : : I-CHEM
Estradiol NNP NNP I-CHEM
did VBD VBD O
not RB RB O
alter VB VB O
the DT DT O
onset NN NN O
of IN IN O
first JJ JJ O
clonus NN NN O
in IN IN O
ovariectomized JJ JJ O
rats NNS NNS O
but CC CC O
accelerated VBD VBD O
it PRP PRP O
in IN IN O
males NNS NNS O
. . . O

17beta CD CD B-CHEM
- : : I-CHEM
Estradiol NNP NNP I-CHEM
reduced VBD VBD O
the DT DT O
argyrophilic JJ JJ O
neurons NNS NNS O
in IN IN O
the DT DT O
CA1 NNP NNP O
and CC CC O
CA3 NNP NNP O
- : : O
C NNP NNP O
sectors NNS NNS O
of IN IN O
ovariectomized JJ JJ O
rats NNS NNS O
. . . O

In IN IN O
males NNS NNS O
, , , O
estradiol NN NN B-CHEM
increased VBD VBD O
the DT DT O
total JJ JJ O
damage NN NN O
score NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
estradiol NN NN B-CHEM
on IN IN O
seizure NN NN O
threshold NN NN O
and CC CC O
damage NN NN O
may MD MD O
be VB VB O
altered VBN VBN O
by IN IN O
sex NN NN O
- - - O
related VBN VBN O
differences NNS NNS O
in IN IN O
the DT DT O
hormonal NN NN O
environment NN NN O
. . . O

Pseudoacromegaly NNP NNP O
induced VBN VBN O
by IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
minoxidil NN NN B-CHEM
. . . O

Acromegaly NNP NNP O
is VBZ VBZ O
an DT DT O
endocrine NN NN O
disorder NN NN O
caused VBN VBN O
by IN IN O
chronic JJ JJ O
excessive JJ JJ O
growth NN NN O
hormone NN NN O
secretion NN NN O
from IN IN O
the DT DT O
anterior NN NN O
pituitary JJ JJ O
gland NN NN O
. . . O

Significant JJ JJ O
disfiguring VBG VBG O
changes NNS NNS O
occur VBP VBP O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
bone NN NN O
, , , O
cartilage NN NN O
, , , O
and CC CC O
soft JJ JJ O
tissue NN NN O
hypertrophy NN NN O
, , , O
including VBG VBG O
the DT DT O
thickening NN NN O
of IN IN O
the DT DT O
skin NN NN O
, , , O
coarsening VBG VBG O
of IN IN O
facial JJ JJ O
features NNS NNS O
, , , O
and CC CC O
cutis NNS NNS O
verticis NN NN O
gyrata NN NN O
. . . O

Pseudoacromegaly NNP NNP O
, , , O
on IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
is VBZ VBZ O
the DT DT O
presence NN NN O
of IN IN O
similar JJ JJ O
acromegaloid NN NN O
features NNS NNS O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
elevated JJ JJ O
growth NN NN O
hormone NN NN O
or CC CC O
insulin NN NN O
- - - O
like IN IN O
growth NN NN O
factor NN NN O
levels NNS NNS O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
patient NN NN O
with IN IN O
pseudoacromegaly NN NN O
that WDT WDT O
resulted VBD VBD O
from IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
minoxidil NN NN B-CHEM
at IN IN O
an DT DT O
unusually RB RB O
high JJ JJ O
dose NN NN O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
case NN NN O
report NN NN O
of IN IN O
pseudoacromegaly NN NN O
as IN IN O
a DT DT O
side NN NN O
effect NN NN O
of IN IN O
minoxidil NN NN B-CHEM
use NN NN O
. . . O

Combined NNP NNP O
androgen NN NN O
blockade NN NN O
- : : O
induced JJ JJ O
anemia NN NN O
in IN IN O
prostate JJ JJ O
cancer NN NN O
patients NNS NNS O
without IN IN O
bone NN NN O
involvement NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
onset NN NN O
and CC CC O
extent NN NN O
of IN IN O
combined VBN VBN O
androgen NN NN O
blockade NN NN O
( ( ( O
CAB NNP NNP O
) ) ) O
- : : O
induced VBN VBN O
anemia NN NN O
in IN IN O
prostate JJ JJ O
cancer NN NN O
patients NNS NNS O
without IN IN O
bone NN NN O
involvement NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Forty CD CD O
- - - O
two CD CD O
patients NNS NNS O
with IN IN O
biopsy NN NN O
- - - O
proven VBN VBN O
prostatic JJ JJ O
adenocarcinoma NN NN O
[ NN NN O
26 CD CD O
with IN IN O
stage NN NN O
C NNP NNP O
( ( ( O
T3N0M0 NNP NNP O
) ) ) O
and CC CC O
16 CD CD O
with IN IN O
stage NN NN O
D1 NN NN O
( ( ( O
T3N1M0 NNP NNP O
) ) ) O
] NN NN O
were VBD VBD O
included VBN VBN O
in IN IN O
this DT DT O
study NN NN O
. . . O

All DT DT O
patients NNS NNS O
received VBD VBD O
CAB NNP NNP O
[ NN NN O
leuprolide NN NN B-CHEM
acetate NN NN I-CHEM
( ( ( O
LHRH NNP NNP B-CHEM
- - - I-CHEM
A DT DT I-CHEM
) ) ) O
3 CD CD O
. . . O
75 CD CD O
mg NN NN O
, , , O
intramuscularly RB RB O
, , , O
every DT DT O
28 CD CD O
days NNS NNS O
plus CC CC O
250 CD CD O
mg NN NN O
flutamide NN NN B-CHEM
, , , O
tid NN NN O
, , , O
per IN IN O
Os NNP NNP O
] NN NN O
and CC CC O
were VBD VBD O
evaluated VBN VBN O
for IN IN O
anemia NN NN O
by IN IN O
physical JJ JJ O
examination NN NN O
and CC CC O
laboratory NN NN O
tests NNS NNS O
at IN IN O
baseline NN NN O
and CC CC O
4 CD CD O
subsequent JJ JJ O
intervals NNS NNS O
( ( ( O
1 CD CD O
, , , O
2 CD CD O
, , , O
3 CD CD O
and CC CC O
6 CD CD O
months NNS NNS O
post JJ JJ O
- : : O
CAB NNP NNP O
) ) ) O
. . . O

Hb NNP NNP O
, , , O
PSA NNP NNP O
and CC CC O
Testosterone NNP NNP B-CHEM
measurements NNS NNS O
were VBD VBD O
recorded VBN VBN O
. . . O

Patients NNS NNS O
with IN IN O
stage NN NN O
D2 NN NN O
- : : O
3 CD CD O
disease NN NN O
, , , O
abnormal JJ JJ O
hemoglobin NN NN O
level NN NN O
or CC CC O
renal JJ JJ O
and CC CC O
liver NN NN O
function NN NN O
tests NNS NNS O
that WDT WDT O
were VBD VBD O
higher JJR JJR O
than IN IN O
the DT DT O
upper JJ JJ O
limits NNS NNS O
were VBD VBD O
excluded VBN VBN O
from IN IN O
the DT DT O
study NN NN O
. . . O

The DT DT O
duration NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
six CD CD O
months NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
mean NN NN O
hemoglobin NN NN O
( ( ( O
Hb NNP NNP O
) ) ) O
levels NNS NNS O
were VBD VBD O
significantly RB RB O
declined VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
from IN IN O
baseline NN NN O
of IN IN O
14 CD CD O
. . . O
2 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
to TO TO O
14 CD CD O
. . . O
0 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
, , , O
13 CD CD O
. . . O
5 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
, , , O
13 CD CD O
. . . O
2 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
and CC CC O
12 CD CD O
. . . O
7 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
at IN IN O
1 CD CD O
, , , O
2 CD CD O
, , , O
3 CD CD O
and CC CC O
6 CD CD O
months NNS NNS O
post JJ JJ O
- : : O
CAB NNP NNP O
, , , O
respectively RB RB O
. . . O

Severe NNP NNP O
and CC CC O
clinically RB RB O
evident JJ JJ O
anemia NN NN O
of IN IN O
Hb NNP NNP O
< NN NN O
11 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
with IN IN O
clinical JJ JJ O
symptoms NNS NNS O
was VBD VBD O
detected VBN VBN O
in IN IN O
6 CD CD O
patients NNS NNS O
( ( ( O
14 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

This DT DT O
CAB NNP NNP O
- : : O
induced JJ JJ O
anemia NN NN O
was VBD VBD O
normochromic JJ JJ O
and CC CC O
normocytic JJ JJ O
. . . O

At IN IN O
six CD CD O
months NNS NNS O
post JJ JJ O
- : : O
CAB NNP NNP O
, , , O
patients NNS NNS O
with IN IN O
severe JJ JJ O
anemia NN NN O
had VBD VBD O
a DT DT O
Hb NNP NNP O
mean VB VB O
value NN NN O
of IN IN O
10 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
( ( ( O
X NNP NNP O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
, , , O
whereas IN IN O
the DT DT O
other JJ JJ O
patients NNS NNS O
had VBD VBD O
mild JJ JJ O
anemia NN NN O
with IN IN O
Hb NNP NNP O
mean VB VB O
value NN NN O
of IN IN O
13 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
17 CD CD O
( ( ( O
X NNP NNP O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
. . . O

The DT DT O
development NN NN O
of IN IN O
severe JJ JJ O
anemia NN NN O
at IN IN O
6 CD CD O
months NNS NNS O
post JJ JJ O
- : : O
CAB NNP NNP O
was VBD VBD O
predictable JJ JJ O
by IN IN O
the DT DT O
reduction NN NN O
of IN IN O
Hb NNP NNP O
baseline NN NN O
value NN NN O
of IN IN O
more JJR JJR O
than IN IN O
2 CD CD O
. . . O
5 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
after IN IN O
3 CD CD O
months NNS NNS O
of IN IN O
CAB NNP NNP O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

The DT DT O
development NN NN O
of IN IN O
severe JJ JJ O
CAB NNP NNP O
- : : O
induced JJ JJ O
anemia NN NN O
in IN IN O
prostate JJ JJ O
cancer NN NN O
patients NNS NNS O
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
T NN NN O
baseline NN NN O
values NNS NNS O
( ( ( O
T NN NN O
< NN NN O
3 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
versus CC CC O
T NN NN O
> NN NN O
or CC CC O
= SYM SYM O
3 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
) ) ) O
, , , O
with IN IN O
age NN NN O
( ( ( O
< NN NN O
76 CD CD O
yrs NNS NNS O
versus CC CC O
> NN NN O
or CC CC O
= SYM SYM O
76 CD CD O
yrs NN NN O
) ) ) O
, , , O
and CC CC O
clinical JJ JJ O
stage NN NN O
( ( ( O
stage NN NN O
C NNP NNP O
versus CC CC O
stage NN NN O
D1 NN NN O
) ) ) O
. . . O

Severe NNP NNP O
and CC CC O
clinically RB RB O
evident JJ JJ O
anemia NN NN O
was VBD VBD O
easily RB RB O
corrected VBN VBN O
by IN IN O
subcutaneous JJ JJ O
injections NNS NNS O
( ( ( O
3 CD CD O
times NNS NNS O
/ NN NN O
week NN NN O
for IN IN O
1 CD CD O
month NN NN O
) ) ) O
of IN IN O
recombinant NN NN O
erythropoietin NN NN O
( ( ( O
rHuEPO NN NN O
- - - O
beta NN NN O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
rHuEPO NN NN O
- : : O
beta NN NN O
correctable JJ JJ O
CAB NNP NNP O
- : : O
induced JJ JJ O
anemia NN NN O
occurs VBZ VBZ O
in IN IN O
14 CD CD O
. . . O
3 CD CD O
% NN NN O
of IN IN O
prostate JJ JJ O
cancer NN NN O
patients NNS NNS O
after IN IN O
6 CD CD O
months NNS NNS O
of IN IN O
therapy NN NN O
. . . O

Delirium NNP NNP O
during IN IN O
clozapine NN NN B-CHEM
treatment NN NN O
: : : O
incidence NN NN O
and CC CC O
associated VBN VBN O
risk NN NN O
factors NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Incidence NNP NNP O
and CC CC O
risk NN NN O
factors NNS NNS O
for IN IN O
delirium NN NN O
during IN IN O
clozapine NN NN B-CHEM
treatment NN NN O
require VB VB O
further JJ JJ O
clarification NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
used VBD VBD O
computerized JJ JJ O
pharmacy NN NN O
records NNS NNS O
to TO TO O
identify VB VB O
all DT DT O
adult NN NN O
psychiatric JJ JJ O
inpatients NNS NNS O
treated VBN VBN O
with IN IN O
clozapine NN NN B-CHEM
( ( ( O
1995 CD CD O
- : : O
96 CD CD O
) ) ) O
, , , O
reviewed VBD VBD O
their PRP$ PRP$ O
medical JJ JJ O
records NNS NNS O
to TO TO O
score VB VB O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
delirium NN NN O
, , , O
and CC CC O
tested VBD VBD O
associations NNS NNS O
with IN IN O
potential JJ JJ O
risk NN NN O
factors NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Subjects NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
139 CD CD O
) ) ) O
were VBD VBD O
72 CD CD O
women NNS NNS O
and CC CC O
67 CD CD O
men NNS NNS O
, , , O
aged VBN VBN O
40 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
. . . O
1 CD CD O
years NNS NNS O
, , , O
hospitalized VBN VBN O
for IN IN O
24 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
23 CD CD O
. . . O
3 CD CD O
days NNS NNS O
, , , O
and CC CC O
given VBN VBN O
clozapine NN NN B-CHEM
, , , O
gradually RB RB O
increased VBN VBN O
to TO TO O
an DT DT O
average JJ JJ O
daily JJ JJ O
dose NN NN O
of IN IN O
282 CD CD O
+ NN NN O
/ NN NN O
- : : O
203 CD CD O
mg NN NN O
( ( ( O
3 CD CD O
. . . O
45 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
45 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
for IN IN O
18 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
. . . O
4 CD CD O
days NNS NNS O
. . . O

Delirium NNP NNP O
was VBD VBD O
diagnosed VBN VBN O
in IN IN O
14 CD CD O
( ( ( O
10 CD CD O
. . . O
1 CD CD O
% NN NN O
incidence NN NN O
, , , O
or CC CC O
1 CD CD O
. . . O
48 CD CD O
cases NNS NNS O
/ NN NN O
person NN NN O
- : : O
years NNS NNS O
of IN IN O
exposure NN NN O
) ) ) O
; : : O
71 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
cases NNS NNS O
were VBD VBD O
moderate JJ JJ O
or CC CC O
severe JJ JJ O
. . . O

Associated NNP NNP O
factors NNS NNS O
were VBD VBD O
co JJ JJ O
- : : O
treatment NN NN O
with IN IN O
other JJ JJ O
centrally RB RB O
antimuscarinic JJ JJ O
agents NNS NNS O
, , , O
poor JJ JJ O
clinical JJ JJ O
outcome NN NN O
, , , O
older JJR JJR O
age NN NN O
, , , O
and CC CC O
longer RBR RBR O
hospitalization NN NN O
( ( ( O
by IN IN O
17 CD CD O
. . . O
5 CD CD O
days NNS NNS O
, , , O
increasing VBG VBG O
cost NN NN O
) ) ) O
; : : O
sex NN NN O
, , , O
diagnosis NN NN O
or CC CC O
medical JJ JJ O
co NN NN O
- - - O
morbidity NN NN O
, , , O
and CC CC O
daily JJ JJ O
clozapine NN NN B-CHEM
dose NN NN O
, , , O
which WDT WDT O
fell VBD VBD O
with IN IN O
age NN NN O
, , , O
were VBD VBD O
unrelated JJ JJ O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Delirium NNP NNP O
was VBD VBD O
found VBN VBN O
in IN IN O
10 CD CD O
% NN NN O
of IN IN O
clozapine NN NN B-CHEM
- - - O
treated VBN VBN O
inpatients NNS NNS O
, , , O
particularly RB RB O
in IN IN O
older JJR JJR O
patients NNS NNS O
exposed VBD VBD O
to TO TO O
other JJ JJ O
central JJ JJ O
anticholinergics NNS NNS O
. . . O

Delirium NNP NNP O
was VBD VBD O
inconsistently RB RB O
recognized VBN VBN O
clinically RB RB O
in IN IN O
milder NN NN O
cases NNS NNS O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
increased VBN VBN O
length NN NN O
- - - O
of IN IN O
- - - O
stay NN NN O
and CC CC O
higher JJR JJR O
costs NNS NNS O
, , , O
and CC CC O
inferior JJ JJ O
clinical JJ JJ O
outcome NN NN O
. . . O

Neuroprotective NNP NNP O
action NN NN O
of IN IN O
MPEP NNP NNP B-CHEM
, , , O
a DT DT O
selective JJ JJ O
mGluR5 NN NN O
antagonist NN NN O
, , , O
in IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
dopaminergic JJ JJ O
neurotoxicity NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
a DT DT O
decrease NN NN O
in IN IN O
dopamine NN NN B-CHEM
outflow NN NN O
and CC CC O
inhibition NN NN O
of IN IN O
hyperthermia NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
examine VB VB O
the DT DT O
role NN NN O
of IN IN O
metabotropic NN NN O
glutamate NN NN B-CHEM
receptor NN NN O
5 CD CD O
( ( ( O
mGluR5 NN NN O
) ) ) O
in IN IN O
the DT DT O
toxic JJ JJ O
action NN NN O
of IN IN O
methamphetamine NN NN B-CHEM
on IN IN O
dopaminergic JJ JJ O
neurones NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Methamphetamine NNP NNP B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) ) ) O
, , , O
administered VBD VBD O
five CD CD O
times NNS NNS O
, , , O
reduced VBD VBD O
the DT DT O
levels NNS NNS O
of IN IN O
dopamine NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
in IN IN O
striatal JJ JJ O
tissue NN NN O
when WRB WRB O
measured VBN VBN O
72 CD CD O
h NN NN O
after IN IN O
the DT DT O
last JJ JJ O
injection NN NN O
. . . O

A DT DT O
selective JJ JJ O
antagonist NN NN O
of IN IN O
mGluR5 NN NN O
, , , O
2 CD CD B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
phenylethynyl NN NN I-CHEM
) ) ) I-CHEM
pyridine NN NN I-CHEM
( ( ( O
MPEP NNP NNP B-CHEM
; : : O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
, , , O
when WRB WRB O
administered VBN VBN O
five CD CD O
times NNS NNS O
immediately RB RB O
before IN IN O
each DT DT O
methamphetamine NN NN B-CHEM
injection NN NN O
reversed VBD VBD O
the DT DT O
above JJ JJ O
- - - O
mentioned VBN VBN O
methamphetamine NN NN B-CHEM
effects NNS NNS O
. . . O

A DT DT O
single JJ JJ O
MPEP NNP NNP B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
injection NN NN O
reduced VBD VBD O
the DT DT O
basal NN NN O
extracellular JJ JJ O
dopamine NN NN B-CHEM
level NN NN O
in IN IN O
the DT DT O
striatum NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
dopamine NN NN B-CHEM
release NN NN O
stimulated VBN VBN O
either CC CC O
by IN IN O
methamphetamine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) ) ) O
or CC CC O
by IN IN O
intrastriatally RB RB O
administered VBN VBN O
veratridine NN NN B-CHEM
( ( ( O
100 CD CD O
microM NN NN O
) ) ) O
. . . O

Moreover RB RB O
, , , O
it PRP PRP O
transiently RB RB O
diminished VBD VBD O
the DT DT O
methamphetamine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) ) ) O
- : : O
induced JJ JJ O
hyperthermia NN NN O
and CC CC O
reduced VBN VBN O
basal NN NN O
body NN NN O
temperature NN NN O
. . . O

MPEP NNP NNP B-CHEM
administered VBD VBD O
into IN IN O
the DT DT O
striatum NN NN O
at IN IN O
high JJ JJ O
concentrations NNS NNS O
( ( ( O
500 CD CD O
microM NN NN O
) ) ) O
increased VBN VBN O
extracellular NN NN O
dopamine NN NN B-CHEM
levels NNS NNS O
, , , O
while IN IN O
lower JJR JJR O
concentrations NNS NNS O
( ( ( O
50 CD CD O
- : : O
100 CD CD O
microM NN NN O
) ) ) O
were VBD VBD O
devoid NN NN O
of IN IN O
any DT DT O
effect NN NN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
study NN NN O
suggest VBP VBP O
that IN IN O
the DT DT O
blockade NN NN O
of IN IN O
mGluR5 NN NN O
by IN IN O
MPEP NNP NNP B-CHEM
may MD MD O
protect VB VB O
dopaminergic JJ JJ O
neurones NNS NNS O
against IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
toxicity NN NN O
. . . O

Neuroprotection NNP NNP O
rendered VBN VBN O
by IN IN O
MPEP NNP NNP B-CHEM
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
reduction NN NN O
of IN IN O
the DT DT O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
dopamine NN NN B-CHEM
efflux NN NN O
in IN IN O
the DT DT O
striatum NN NN O
due JJ JJ O
to TO TO O
the DT DT O
blockade NN NN O
of IN IN O
extrastriatal JJ JJ O
mGluR5 NN NN O
, , , O
and CC CC O
with IN IN O
a DT DT O
decrease NN NN O
in IN IN O
hyperthermia NN NN O
. . . O

Protective NNP NNP O
efficacy NN NN O
of IN IN O
neuroactive JJ JJ O
steroids NNS NNS B-CHEM
against IN IN O
cocaine NN NN B-CHEM
kindled JJ JJ O
- : : O
seizures NNS NNS O
in IN IN O
mice NN NN O
. . . O

Neuroactive NNP NNP O
steroids NNS NNS B-CHEM
demonstrate VBP VBP O
pharmacological JJ JJ O
actions NNS NNS O
that WDT WDT O
have VBP VBP O
relevance NN NN O
for IN IN O
a DT DT O
host NN NN O
of IN IN O
neurological JJ JJ O
and CC CC O
psychiatric JJ JJ O
disorders NNS NNS O
. . . O

They PRP PRP O
offer VBP VBP O
protection NN NN O
against IN IN O
seizures NNS NNS O
in IN IN O
a DT DT O
range NN NN O
of IN IN O
models NNS NNS O
and CC CC O
seem VBP VBP O
to TO TO O
inhibit VB VB O
certain JJ JJ O
stages NNS NNS O
of IN IN O
drug NN NN O
dependence NN NN O
in IN IN O
preclinical JJ JJ O
assessments NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
evaluate VB VB O
two CD CD O
endogenous JJ JJ O
and CC CC O
one CD CD O
synthetic JJ JJ O
neuroactive JJ JJ O
steroid NN NN B-CHEM
that IN IN O
positively RB RB O
modulate VBP VBP O
the DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
) ) ) O
receptor NN NN O
against IN IN O
the DT DT O
increase NN NN O
in IN IN O
sensitivity NN NN O
to TO TO O
the DT DT O
convulsant JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
engendered VBN VBN O
by IN IN O
repeated VBN VBN O
cocaine NN NN B-CHEM
administration NN NN O
( ( ( O
seizure NN NN O
kindling VBG VBG O
) ) ) O
. . . O

Allopregnanolone NNP NNP B-CHEM
( ( ( O
3alpha CD CD B-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- : : I-CHEM
5alpha CD CD I-CHEM
- : : I-CHEM
pregnan NN NN I-CHEM
- : : I-CHEM
20 CD CD I-CHEM
- : : I-CHEM
one CD CD I-CHEM
) ) ) O
, , , O
pregnanolone NN NN B-CHEM
( ( ( O
3alpha CD CD B-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- : : I-CHEM
5beta CD CD I-CHEM
- : : I-CHEM
pregnan NN NN I-CHEM
- : : I-CHEM
20 CD CD I-CHEM
- : : I-CHEM
one CD CD I-CHEM
) ) ) O
and CC CC O
ganaxolone NN NN B-CHEM
( ( ( O
a DT DT O
synthetic JJ JJ O
derivative NN NN O
of IN IN O
allopregnanolone NN NN B-CHEM
3alpha CD CD B-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- : : I-CHEM
3beta CD CD I-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
5alpha CD CD I-CHEM
- : : I-CHEM
pregnan NN NN I-CHEM
- : : I-CHEM
20 CD CD I-CHEM
- : : I-CHEM
one CD CD I-CHEM
) ) ) O
were VBD VBD O
tested VBN VBN O
for IN IN O
their PRP$ PRP$ O
ability NN NN O
to TO TO O
suppress VB VB O
the DT DT O
expression NN NN O
( ( ( O
anticonvulsant JJ JJ O
effect NN NN O
) ) ) O
and CC CC O
development NN NN O
( ( ( O
antiepileptogenic JJ JJ O
effect NN NN O
) ) ) O
of IN IN O
cocaine NN NN B-CHEM
- - - O
kindled JJ JJ O
seizures NNS NNS O
in IN IN O
male JJ JJ O
, , , O
Swiss NNP NNP O
- - - O
Webster NNP NNP O
mice NNS NNS O
. . . O

Kindled NNP NNP O
seizures NNS NNS O
were VBD VBD O
induced VBN VBN O
by IN IN O
daily JJ JJ O
administration NN NN O
of IN IN O
60 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
cocaine NN NN B-CHEM
for IN IN O
5 CD CD O
days NNS NNS O
. . . O

All DT DT O
of IN IN O
these DT DT O
positive JJ JJ O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
modulators NNS NNS O
suppressed VBD VBD O
the DT DT O
expression NN NN O
of IN IN O
kindled JJ JJ O
seizures NNS NNS O
, , , O
whereas IN IN O
only RB RB O
allopregnanolone NN NN B-CHEM
and CC CC O
ganaxolone NN NN B-CHEM
inhibited VBD VBD O
the DT DT O
development NN NN O
of IN IN O
kindling VBG VBG O
. . . O

Allopregnanolone NNP NNP B-CHEM
and CC CC O
pregnanolone NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
ganaxolone NN NN B-CHEM
, , , O
also RB RB O
reduced VBD VBD O
cumulative JJ JJ O
lethality NN NN O
associated VBN VBN O
with IN IN O
kindling VBG VBG O
. . . O

These DT DT O
findings NNS NNS O
demonstrate VBP VBP O
that IN IN O
some DT DT O
neuroactive JJ JJ O
steroids NNS NNS B-CHEM
attenuate VBP VBP O
convulsant NN NN O
and CC CC O
sensitizing VBG VBG O
properties NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
add VB VB O
to TO TO O
a DT DT O
growing VBG VBG O
literature NN NN O
on IN IN O
their PRP$ PRP$ O
potential JJ JJ O
use NN NN O
in IN IN O
the DT DT O
modulation NN NN O
of IN IN O
effects NNS NNS O
of IN IN O
drugs NNS NNS O
of IN IN O
abuse NN NN O
. . . O

Effect NN NN O
of IN IN O
humoral JJ JJ O
modulators NNS NNS O
of IN IN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
locomotor NN NN O
activity NN NN O
of IN IN O
mice NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
humoral JJ JJ O
modulators NNS NNS O
on IN IN O
the DT DT O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
locomotor NN NN O
activity NN NN O
of IN IN O
mice NNS NNS O
was VBD VBD O
studied VBN VBN O
. . . O

The DT DT O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
of IN IN O
morphine NN NN B-CHEM
- - - O
HC1 NNP NNP O
produced VBD VBD O
a DT DT O
marked JJ JJ O
increase NN NN O
in IN IN O
locomotor NN NN O
activity NN NN O
in IN IN O
mice NN NN O
. . . O

The DT DT O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
was VBD VBD O
potentiated VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
and CC CC O
attenuated VBN VBN O
by IN IN O
physostigmine NN NN B-CHEM
. . . O

In IN IN O
contrast NN NN O
, , , O
both DT DT O
methscopolamine NN NN B-CHEM
and CC CC O
neostigmine NN NN B-CHEM
, , , O
which WDT WDT O
do VBP VBP O
not RB RB O
penetrate VB VB O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
, , , O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
hyperactivity NN NN O
produced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
. . . O

Pretreatment NNP NNP O
of IN IN O
mice NNS NNS O
with IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
methyltyrosine NN NN I-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
one CD CD O
hour NN NN O
) ) ) O
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
tyrosine NN NN B-CHEM
hydroxylase NN NN O
, , , O
significantly RB RB O
decreased VBD VBD O
the DT DT O
activity NN NN O
- - - O
increasing VBG VBG O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
pretreatment NN NN O
with IN IN O
p NN NN B-CHEM
- - - I-CHEM
chlorophenylalamine NN NN I-CHEM
( ( ( O
3 CD CD O
X NNP NNP O
320 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
24 CD CD O
hr NN NN O
) ) ) O
, , , O
a DT DT O
serotonin NN NN B-CHEM
depletor NN NN O
, , , O
caused VBD VBD O
no DT DT O
significant JJ JJ O
change NN NN O
in IN IN O
the DT DT O
hyperactivity NN NN O
. . . O

The DT DT O
study NN NN O
suggests VBZ VBZ O
that IN IN O
the DT DT O
activity NN NN O
- - - O
increasing VBG VBG O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
are VBP VBP O
mediated VBN VBN O
by IN IN O
the DT DT O
release NN NN O
of IN IN O
catecholamines NNS NNS B-CHEM
from IN IN O
adrenergic JJ JJ O
neurons NNS NNS O
in IN IN O
the DT DT O
brain NN NN O
. . . O

And CC CC O
the DT DT O
results NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
the DT DT O
hypothesis NNS NNS O
that IN IN O
morphine NN NN B-CHEM
acts NNS NNS O
by IN IN O
retarding VBG VBG O
the DT DT O
release NN NN O
of IN IN O
acetylcholine NN NN B-CHEM
at IN IN O
some DT DT O
central JJ JJ O
cholinergic JJ JJ O
synapses NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
also RB RB O
suggested VBN VBN O
from IN IN O
collected VBN VBN O
evidence NN NN O
that IN IN O
the DT DT O
activity NN NN O
- - - O
increasing VBG VBG O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
in IN IN O
mice NNS NNS O
are VBP VBP O
mediated VBN VBN O
by IN IN O
mechanisms NNS NNS O
different JJ JJ O
from IN IN O
those DT DT O
which WDT WDT O
mediate VBP VBP O
the DT DT O
activity NN NN O
- - - O
increasing VBG VBG O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
uninephrectomy NN NN O
and CC CC O
high JJ JJ O
protein NN NN O
feeding NN NN O
on IN IN O
lithium NN NN B-CHEM
- : : O
induced JJ JJ O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
rats NNS NNS O
. . . O

Rats NNP NNP O
with IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
were VBD VBD O
subjected VBN VBN O
to TO TO O
high JJ JJ O
protein NN NN O
( ( ( O
HP NNP NNP O
) ) ) O
feeding NN NN O
, , , O
uninephrectomy NN NN O
( ( ( O
NX NNP NNP O
) ) ) O
or CC CC O
a DT DT O
combination NN NN O
of IN IN O
these DT DT O
, , , O
in IN IN O
an DT DT O
attempt NN NN O
to TO TO O
induce VB VB O
glomerular JJ JJ O
hyperfiltration NN NN O
and CC CC O
further JJ JJ O
progression NN NN O
of IN IN O
renal JJ JJ O
failure NN NN O
. . . O

Newborn NNP NNP O
female JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
fed VBN VBN O
a DT DT O
lithium NN NN B-CHEM
- - - O
containing VBG VBG O
diet NN NN O
( ( ( O
50 CD CD O
mmol NN NN O
/ NN NN O
kg NN NN O
) ) ) O
for IN IN O
8 CD CD O
weeks NNS NNS O
and CC CC O
then RB RB O
randomized JJ JJ O
to TO TO O
normal JJ JJ O
diet NN NN O
, , , O
HP NNP NNP O
diet NN NN O
( ( ( O
40 CD CD O
vs NNS NNS O
. . . O
19 CD CD O
% NN NN O
) ) ) O
, , , O
NX NNP NNP O
or CC CC O
HP NNP NNP O
+ NN NN O
NX NNP NNP O
for IN IN O
another DT DT O
8 CD CD O
weeks NNS NNS O
. . . O

Corresponding NNP NNP O
non NN NN O
- : : O
lithium NN NN B-CHEM
pretreated JJ JJ O
groups NNS NNS O
were VBD VBD O
generated VBN VBN O
. . . O

When WRB WRB O
comparing VBG VBG O
all DT DT O
lithium NN NN B-CHEM
treated VBN VBN O
versus CC CC O
non NN NN O
- - - O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
groups NNS NNS O
, , , O
lithium NN NN B-CHEM
caused VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
( ( ( O
GFR NNP NNP O
) ) ) O
without IN IN O
significant JJ JJ O
changes NNS NNS O
in IN IN O
effective JJ JJ O
renal NN NN O
plasma NN NN O
flow NN NN O
( ( ( O
as IN IN O
determined VBN VBN O
by IN IN O
a DT DT O
marker NN NN O
secreted VBD VBD O
into IN IN O
the DT DT O
proximal NN NN O
tubules NNS NNS O
) ) ) O
or CC CC O
lithium NN NN B-CHEM
clearance NN NN O
. . . O

Consequently RB RB O
, , , O
lithium NN NN B-CHEM
pretreatment NN NN O
caused VBD VBD O
a DT DT O
fall NN NN O
in IN IN O
filtration NN NN O
fraction NN NN O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
fractional JJ JJ O
Li NNP NNP B-CHEM
excretion NN NN O
. . . O

Lithium NNP NNP B-CHEM
also RB RB O
caused VBD VBD O
proteinuria NN NN O
and CC CC O
systolic JJ JJ O
hypertension NN NN O
in IN IN O
absence NN NN O
of IN IN O
glomerulosclerosis NN NN O
. . . O

HP NNP NNP O
failed VBD VBD O
to TO TO O
accentuante VB VB O
progression NN NN O
of IN IN O
renal JJ JJ O
failure NN NN O
and CC CC O
in IN IN O
fact NN NN O
tended VBD VBD O
to TO TO O
increase VB VB O
GFR NNP NNP O
and CC CC O
decrease VB VB O
plasma NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
in IN IN O
lithium NN NN B-CHEM
pretreated JJ JJ O
rats NNS NNS O
. . . O

NX NNP NNP O
caused VBD VBD O
an DT DT O
additive JJ JJ O
deterioration NN NN O
in IN IN O
GFR NNP NNP O
which WDT WDT O
, , , O
however RB RB O
, , , O
was VBD VBD O
ameliorated VBN VBN O
by IN IN O
HP NNP NNP O
. . . O

NX NNP NNP O
+ NN NN O
HP NNP NNP O
caused VBD VBD O
a DT DT O
further JJ JJ O
rise NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
in IN IN O
Li NNP NNP B-CHEM
- - - O
pretreated JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
Li NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
, , , O
even RB RB O
when WRB WRB O
the DT DT O
GFR NNP NNP O
is VBZ VBZ O
only RB RB O
modestly RB RB O
reduced VBN VBN O
, , , O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
proteinuria NNS NNS O
and CC CC O
arterial JJ JJ O
systolic JJ JJ O
hypertension NN NN O
. . . O

In IN IN O
this DT DT O
model NN NN O
of IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
the DT DT O
decline NN NN O
in IN IN O
GFR NNP NNP O
is VBZ VBZ O
not RB RB O
accompanied VBN VBN O
by IN IN O
a DT DT O
corresponding JJ JJ O
fall NN NN O
in IN IN O
effective JJ JJ O
renal NN NN O
plasma NN NN O
flow NN NN O
, , , O
which WDT WDT O
may MD MD O
be VB VB O
the DT DT O
functional JJ JJ O
expression NN NN O
of IN IN O
the DT DT O
formation NN NN O
of IN IN O
nonfiltrating VBG VBG O
atubular JJ JJ O
glomeruli NN NN O
. . . O

The DT DT O
fractional JJ JJ O
reabsorption NN NN O
of IN IN O
tubular JJ JJ O
fluid NN NN O
by IN IN O
the DT DT O
proximal NN NN O
tubules NNS NNS O
is VBZ VBZ O
reduced VBN VBN O
, , , O
leaving VBG VBG O
the DT DT O
distal NN NN O
delivery NN NN O
unchanged JJ JJ O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Treatment NN NN O
of IN IN O
Crohn NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
with IN IN O
fusidic JJ JJ B-CHEM
acid NN NN I-CHEM
: : : O
an DT DT O
antibiotic JJ JJ O
with IN IN O
immunosuppressive JJ JJ O
properties NNS NNS O
similar JJ JJ O
to TO TO O
cyclosporin NN NN B-CHEM
. . . O

Fusidic NNP NNP O
acid NN NN O
is VBZ VBZ O
an DT DT O
antibiotic JJ JJ O
with IN IN O
T NN NN O
- - - O
cell NN NN O
specific JJ JJ O
immunosuppressive JJ JJ O
effects NNS NNS O
similar JJ JJ O
to TO TO O
those DT DT O
of IN IN O
cyclosporin NN NN B-CHEM
. . . O

Because IN IN O
of IN IN O
the DT DT O
need NN NN O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
new JJ JJ O
treatments NNS NNS O
for IN IN O
Crohn NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
a DT DT O
pilot NN NN O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
estimate VB VB O
the DT DT O
pharmacodynamics NNS NNS O
and CC CC O
tolerability NN NN O
of IN IN O
fusidic JJ JJ B-CHEM
acid NN NN I-CHEM
treatment NN NN O
in IN IN O
chronic JJ JJ O
active JJ JJ O
, , , O
therapy NN NN O
- - - O
resistant JJ JJ O
patients NNS NNS O
. . . O

Eight CD CD O
Crohn NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patients NNS NNS O
were VBD VBD O
included VBN VBN O
. . . O

Fusidic NNP NNP B-CHEM
acid NN NN I-CHEM
was VBD VBD O
administered VBN VBN O
orally RB RB O
in IN IN O
a DT DT O
dose NN NN O
of IN IN O
500 CD CD O
mg NN NN O
t NN NN O
. . . O
d SYM SYM O
. . . O
s VBZ VBZ O
. . . O
and CC CC O
the DT DT O
treatment NN NN O
was VBD VBD O
planned VBN VBN O
to TO TO O
last VB VB O
8 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
disease NN NN O
activity NN NN O
was VBD VBD O
primarily RB RB O
measured VBN VBN O
by IN IN O
a DT DT O
modified VBN VBN O
individual JJ JJ O
grading VBG VBG O
score NN NN O
. . . O

Five CD CD O
of IN IN O
8 CD CD O
patients NNS NNS O
( ( ( O
63 CD CD O
% NN NN O
) ) ) O
improved VBN VBN O
during IN IN O
fusidic JJ JJ B-CHEM
acid NN NN I-CHEM
treatment NN NN O
: : : O
3 CD CD O
at IN IN O
two CD CD O
weeks NNS NNS O
and CC CC O
2 CD CD O
after IN IN O
four CD CD O
weeks NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
serious JJ JJ O
clinical JJ JJ O
side NN NN O
effects NNS NNS O
, , , O
but CC CC O
dose NN NN O
reduction NN NN O
was VBD VBD O
required VBN VBN O
in IN IN O
two CD CD O
patients NNS NNS O
because IN IN O
of IN IN O
nausea NN NN O
. . . O

Biochemically NNP NNP O
, , , O
an DT DT O
increase NN NN O
in IN IN O
alkaline NN NN O
phosphatases NNS NNS O
was VBD VBD O
noted VBN VBN O
in IN IN O
5 CD CD O
of IN IN O
8 CD CD O
cases NNS NNS O
( ( ( O
63 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
the DT DT O
greatest JJS JJS O
increases NNS NNS O
were VBD VBD O
seen VBN VBN O
in IN IN O
those DT DT O
who WP WP O
had VBD VBD O
elevated VBN VBN O
levels NNS NNS O
prior RB RB O
to TO TO O
treatment NN NN O
. . . O

All DT DT O
reversed VBN VBN O
to TO TO O
pre VB VB O
- - - O
treatment NN NN O
levels NNS NNS O
after IN IN O
cessation NN NN O
of IN IN O
treatment NN NN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
pilot NN NN O
study NN NN O
suggest VBP VBP O
that IN IN O
fusidic JJ JJ B-CHEM
acid NN NN I-CHEM
may MD MD O
be VB VB O
of IN IN O
benefit NN NN O
in IN IN O
selected VBN VBN O
chronic JJ JJ O
active JJ JJ O
Crohn NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patients NNS NNS O
in IN IN O
whom WP WP O
conventional JJ JJ O
treatment NN NN O
is VBZ VBZ O
ineffective JJ JJ O
. . . O

Because IN IN O
there EX EX O
seems VBZ VBZ O
to TO TO O
exist VB VB O
a DT DT O
scientific JJ JJ O
rationale NN NN O
for IN IN O
the DT DT O
use NN NN O
of IN IN O
fusidic JJ JJ B-CHEM
acid NN NN I-CHEM
at IN IN O
the DT DT O
cytokine NN NN O
level NN NN O
in IN IN O
inflammatory JJ JJ O
bowel NN NN O
disease NN NN O
, , , O
we PRP PRP O
suggest VBP VBP O
that IN IN O
the DT DT O
role NN NN O
of IN IN O
this DT DT O
treatment NN NN O
should MD MD O
be VB VB O
further RBR RBR O
investigated JJ JJ O
. . . O

Changes NNS NNS O
in IN IN O
depressive JJ JJ O
status NN NN O
associated VBN VBN O
with IN IN O
topical JJ JJ O
beta NN NN O
- - - O
blockers NNS NNS O
. . . O

Depression NNP NNP O
and CC CC O
sexual JJ JJ O
dysfunction NN NN O
have VBP VBP O
been VBN VBN O
related VBN VBN O
to TO TO O
side VB VB O
effects NNS NNS O
of IN IN O
topical JJ JJ O
beta NN NN O
- - - O
blockers NNS NNS O
. . . O

We PRP PRP O
performed VBD VBD O
a DT DT O
preliminary JJ JJ O
study NN NN O
in IN IN O
order NN NN O
to TO TO O
determine VB VB O
any DT DT O
difference NN NN O
between IN IN O
a DT DT O
non NN NN O
selective JJ JJ O
beta NN NN O
- : : O
blocker NN NN O
( ( ( O
timolol NN NN B-CHEM
) ) ) O
and CC CC O
a DT DT O
selective JJ JJ O
beta NN NN O
- : : O
blocker NN NN O
( ( ( O
betaxolol NN NN B-CHEM
) ) ) O
regarding VBG VBG O
CNS NNP NNP O
side NN NN O
effects NNS NNS O
. . . O

Eight CD CD O
glaucomatous JJ JJ O
patients NNS NNS O
chronically RB RB O
treated VBN VBN O
with IN IN O
timolol NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
% NN NN O
/ NN NN O
12h CD CD O
, , , O
suffering VBG VBG O
from IN IN O
depression NN NN O
diagnosed VBD VBD O
through IN IN O
DMS NNP NNP O
- - - O
III NNP NNP O
- : : O
R NNP NNP O
criteria NNS NNS O
, , , O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
study NN NN O
. . . O

During IN IN O
the DT DT O
six CD CD O
- - - O
month NN NN O
follow VB VB O
up RB RB O
, , , O
depression NN NN O
was VBD VBD O
quantified VBN VBN O
through IN IN O
the DT DT O
Beck NNP NNP O
and CC CC O
Zung NNP NNP O
- : : O
Conde NNP NNP O
scales NNS NNS O
every DT DT O
two CD CD O
months NNS NNS O
. . . O

In IN IN O
a DT DT O
double JJ JJ O
blind JJ JJ O
cross NN NN O
- - - O
over IN IN O
study NN NN O
with IN IN O
control NN NN O
group NN NN O
, , , O
the DT DT O
patients NNS NNS O
under IN IN O
timolol NN NN B-CHEM
treatment NN NN O
presented VBD VBD O
higher JJR JJR O
depression NN NN O
values NNS NNS O
measured VBN VBN O
through IN IN O
the DT DT O
Beck NNP NNP O
and CC CC O
the DT DT O
Zung NNP NNP O
- - - O
Conde NNP NNP O
scales NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
vs NNS NNS O
control NN NN O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
betaxolol NN NN B-CHEM
could MD MD O
be VB VB O
less JJR JJR O
of IN IN O
a DT DT O
depression NN NN O
- - - O
inducer NN NN O
than IN IN O
timolol NN NN B-CHEM
in IN IN O
predisposed VBN VBN O
patients NNS NNS O
. . . O

Protection NNP NNP O
against IN IN O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
neurotoxicity NN NN O
toward IN IN O
striatal JJ JJ O
dopamine NN NN B-CHEM
neurons NNS NNS O
in IN IN O
rodents NNS NNS O
by IN IN O
LY274614 NNP NNP B-CHEM
, , , O
an DT DT O
excitatory NN NN O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
antagonist NN NN O
. . . O

LY274614 NNP NNP B-CHEM
, , , O
3SR CD CD B-CHEM
, , , I-CHEM
4aRS CD CD I-CHEM
, , , I-CHEM
6SR CD CD I-CHEM
, , , I-CHEM
8aRS CD CD I-CHEM
- : : I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
phosphonomethyl NN NN I-CHEM
] NN NN I-CHEM
decahydr NN NN I-CHEM
oisoquinoline NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
carboxylic JJ JJ I-CHEM
acid NN NN I-CHEM
, , , O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
as IN IN O
a DT DT O
potent JJ JJ O
antagonist NN NN O
of IN IN O
the DT DT O
N NNP NNP B-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
subtype NN NN O
of IN IN O
glutamate NN NN B-CHEM
receptor NN NN O
. . . O

Here RB RB O
its PRP$ PRP$ O
ability NN NN O
to TO TO O
antagonize VB VB O
the DT DT O
prolonged JJ JJ O
depletion NN NN O
of IN IN O
dopamine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
by IN IN O
amphetamine NN NN B-CHEM
in IN IN O
iprindole NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
is VBZ VBZ O
reported VBN VBN O
. . . O

A DT DT O
single JJ JJ O
18 CD CD O
. . . O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
dose NN NN O
of IN IN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
amphetamine NN NN B-CHEM
hemisulfate NN NN O
, , , O
given VBN VBN O
to TO TO O
rats NNS NNS O
pretreated VBN VBN O
with IN IN O
iprindole NN NN B-CHEM
, , , O
resulted VBD VBD O
in IN IN O
persistent JJ JJ O
depletion NN NN O
of IN IN O
dopamine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
1 CD CD O
week NN NN O
later RB RB O
. . . O

This DT DT O
prolonged JJ JJ O
depletion NN NN O
of IN IN O
dopamine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
was VBD VBD O
antagonized VBN VBN O
by IN IN O
dizocilpine NN NN B-CHEM
( ( ( O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
, , , O
a DT DT O
non NN NN O
- - - O
competitive JJ JJ O
antagonist NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
) ) ) O
or CC CC O
by IN IN O
LY274614 NNP NNP B-CHEM
( ( ( O
a DT DT O
competitive JJ JJ O
antagonist NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
) ) ) O
. . . O

The DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
LY274614 NNP NNP B-CHEM
was VBD VBD O
dose JJ JJ O
- : : O
dependent JJ JJ O
, , , O
being VBG VBG O
maximum NN NN O
at IN IN O
10 CD CD O
- : : O
40 CD CD O
mgkg NN NN O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

A DT DT O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
of IN IN O
LY274614 NNP NNP B-CHEM
was VBD VBD O
effective JJ JJ O
in IN IN O
antagonizing VBG VBG O
the DT DT O
depletion NN NN O
of IN IN O
dopamine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
, , , O
when WRB WRB O
given VBN VBN O
as RB RB O
long RB RB O
as IN IN O
8 CD CD O
hr NN NN O
prior RB RB O
to TO TO O
amphetamine VB VB B-CHEM
but CC CC O
not RB RB O
when WRB WRB O
given VBN VBN O
24 CD CD O
hr NN NN O
prior RB RB O
to TO TO O
amphetamine VB VB B-CHEM
. . . O

Depletion NNP NNP O
of IN IN O
dopamine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
was VBD VBD O
also RB RB O
antagonized VBN VBN O
when WRB WRB O
LY274614 NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
after IN IN O
the DT DT O
injection NN NN O
of IN IN O
amphetamine NN NN B-CHEM
; : : O
LY274614 NNP NNP B-CHEM
protected VBD VBD O
when WRB WRB O
given VBN VBN O
up RP RP O
to TO TO O
4 CD CD O
hr NN NN O
after IN IN O
but CC CC O
not RB RB O
when WRB WRB O
given VBN VBN O
8 CD CD O
or CC CC O
24 CD CD O
hr NN NN O
after IN IN O
amphetamine NN NN B-CHEM
. . . O

The DT DT O
prolonged JJ JJ O
depletion NN NN O
of IN IN O
dopamine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
in IN IN O
mice NN NN O
, , , O
given VBN VBN O
multiple JJ JJ O
injections NNS NNS O
of IN IN O
methamphetamine NN NN B-CHEM
, , , O
was VBD VBD O
also RB RB O
antagonized VBN VBN O
dose NN NN O
- : : O
dependently RB RB O
and CC CC O
completely RB RB O
by IN IN O
LY274614 NNP NNP B-CHEM
. . . O

The DT DT O
data NNS NNS O
strengthen VBP VBP O
the DT DT O
evidence NN NN O
that IN IN O
the DT DT O
neurotoxic JJ JJ O
effect NN NN O
of IN IN O
amphetamine NN NN B-CHEM
and CC CC O
related VBN VBN O
compounds NNS NNS O
toward IN IN O
nigrostriatal JJ JJ O
dopamine NN NN B-CHEM
neurons NNS NNS O
involves NNS NNS O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
and CC CC O
that DT DT O
LY274614 NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
NMDA NNP NNP B-CHEM
receptor NN NN O
antagonist NN NN O
with IN IN O
long JJ JJ O
- - - O
lasting VBG VBG O
in IN IN O
vivo NN NN O
effects NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Ketoconazole NNP NNP B-CHEM
- : : O
induced JJ JJ O
neurologic JJ JJ O
sequelae NN NN O
. . . O

A DT DT O
77 CD CD O
- : : O
y NN NN O
- - - O
old JJ JJ O
patient NN NN O
developed VBN VBN O
weakness NN NN O
of IN IN O
extremities NNS NNS O
, , , O
legs NNS NNS O
paralysis NN NN O
, , , O
dysarthria NN NN O
and CC CC O
tremor NN NN O
1 CD CD O
h NN NN O
after IN IN O
ingestion NN NN O
of IN IN O
200 CD CD O
mg NN NN O
ketoconazole NN NN B-CHEM
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
in IN IN O
his PRP$ PRP$ O
life NN NN O
. . . O

All DT DT O
complaints NNS NNS O
faded VBD VBD O
away RB RB O
within IN IN O
24 CD CD O
h NN NN O
. . . O

Few JJ JJ O
days NNS NNS O
later RB RB O
, , , O
the DT DT O
patient NN NN O
used VBD VBD O
another DT DT O
200 CD CD O
mg NN NN O
ketoconazole NN NN B-CHEM
tablet NN NN O
, , , O
and CC CC O
within IN IN O
an DT DT O
hour NN NN O
experienced VBD VBD O
a DT DT O
similar JJ JJ O
clinical JJ JJ O
picture NN NN O
, , , O
which WDT WDT O
resolved VBD VBD O
again RB RB O
spontaneously RB RB O
within IN IN O
hours NNS NNS O
. . . O

Laboratory NNP NNP O
evaluations NNS NNS O
, , , O
including VBG VBG O
head NN NN O
CT NNP NNP O
scan VB VB O
, , , O
were VBD VBD O
normal JJ JJ O
. . . O

This DT DT O
case NN NN O
illustrates VBZ VBZ O
the DT DT O
need NN NN O
for IN IN O
close JJ JJ O
vigilance NN NN O
in IN IN O
adverse JJ JJ O
drug NN NN O
reactions NNS NNS O
, , , O
particularly RB RB O
in IN IN O
the DT DT O
elderly JJ JJ O
. . . O

Development NNP NNP O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
in IN IN O
parkinsonian JJ JJ O
monkeys NNS NNS O
may MD MD O
depend VB VB O
upon IN IN O
rate NN NN O
of IN IN O
symptom NN NN O
onset NN NN O
and CC CC O
/ NN NN O
or CC CC O
duration NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
( ( ( O
LIDs NNP NNP O
) ) ) O
present JJ JJ O
a DT DT O
major JJ JJ O
problem NN NN O
for IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
management NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
patients NNS NNS O
. . . O

Due JJ JJ O
to TO TO O
the DT DT O
interdependence NN NN O
of IN IN O
risk NN NN O
factors NNS NNS O
in IN IN O
clinical JJ JJ O
populations NNS NNS O
, , , O
it PRP PRP O
is VBZ VBZ O
difficult JJ JJ O
to TO TO O
independently RB RB O
examine VB VB O
factors NNS NNS O
that WDT WDT O
may MD MD O
influence VB VB O
the DT DT O
development NN NN O
of IN IN O
LIDs NNP NNP O
. . . O

Using VBG VBG O
macaque JJ JJ O
monkeys NNS NNS O
with IN IN O
different JJ JJ O
types NNS NNS O
of IN IN O
MPTP NNP NNP B-CHEM
- : : O
induced JJ JJ O
parkinsonism NN NN O
, , , O
the DT DT O
current JJ JJ O
study NN NN O
evaluated VBD VBD O
the DT DT O
degree NN NN O
to TO TO O
which WDT WDT O
rate NN NN O
of IN IN O
symptom NN NN O
progression NN NN O
, , , O
symptom NN NN O
severity NN NN O
, , , O
and CC CC O
response NN NN O
to TO TO O
and CC CC O
duration NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
LIDs NNP NNP O
. . . O

Monkeys NNP NNP O
with IN IN O
acute JJ JJ O
( ( ( O
short JJ JJ O
- - - O
term NN NN O
) ) ) O
MPTP NNP NNP B-CHEM
exposure NN NN O
, , , O
rapid JJ JJ O
symptom NN NN O
onset NN NN O
and CC CC O
short JJ JJ O
symptom NN NN O
duration NN NN O
prior RB RB O
to TO TO O
initiation NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
developed VBN VBN O
dyskinesia NN NN O
between IN IN O
11 CD CD O
and CC CC O
24 CD CD O
days NNS NNS O
of IN IN O
daily JJ JJ O
levodopa NN NN B-CHEM
administration NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
monkeys NNS NNS O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
MPTP NNP NNP B-CHEM
exposure NN NN O
, , , O
slow JJ JJ O
symptom NN NN O
progression NN NN O
and CC CC O
/ NN NN O
or CC CC O
long JJ JJ O
symptom NN NN O
duration NN NN O
prior RB RB O
to TO TO O
initiation NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
were VBD VBD O
more RBR RBR O
resistant JJ JJ O
to TO TO O
developing VBG VBG O
LIDs NNP NNP O
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
, , , O
dyskinesia NN NN O
developed VBN VBN O
no RB RB O
sooner JJR JJR O
than IN IN O
146 CD CD O
days NNS NNS O
of IN IN O
chronic JJ JJ O
levodopa NN NN B-CHEM
administration NN NN O
) ) ) O
. . . O

All DT DT O
animals NNS NNS O
were VBD VBD O
similarly RB RB O
symptomatic JJ JJ O
at IN IN O
the DT DT O
start NN NN O
of IN IN O
levodopa NN NN B-CHEM
treatment NN NN O
and CC CC O
had VBD VBD O
similar JJ JJ O
therapeutic JJ JJ O
responses NNS NNS O
to TO TO O
the DT DT O
drug NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
distinct JJ JJ O
differences NNS NNS O
in IN IN O
the DT DT O
propensity NN NN O
to TO TO O
develop VB VB O
LIDs NNP NNP O
in IN IN O
monkeys NNS NNS O
with IN IN O
different JJ JJ O
rates NNS NNS O
of IN IN O
symptom NN NN O
progression NN NN O
or CC CC O
symptom NN NN O
durations NNS NNS O
prior RB RB O
to TO TO O
levodopa VB VB B-CHEM
and CC CC O
demonstrate VB VB O
the DT DT O
value NN NN O
of IN IN O
these DT DT O
models NNS NNS O
for IN IN O
further JJ JJ O
studying VBG VBG O
the DT DT O
pathophysiology NN NN O
of IN IN O
LIDs NNP NNP O
. . . O

A DT DT O
diet NN NN O
promoting VBG VBG O
sugar NN NN O
dependency NN NN O
causes NNS NNS O
behavioral JJ JJ O
cross NN NN O
- - - O
sensitization NN NN O
to TO TO O
a DT DT O
low JJ JJ O
dose NN NN O
of IN IN O
amphetamine NN NN B-CHEM
. . . O

Previous JJ JJ O
research NN NN O
in IN IN O
this DT DT O
laboratory NN NN O
has VBZ VBZ O
shown VBN VBN O
that IN IN O
a DT DT O
diet NN NN O
of IN IN O
intermittent NN NN O
excessive JJ JJ O
sugar NN NN O
consumption NN NN O
produces VBZ VBZ O
a DT DT O
state NN NN O
with IN IN O
neurochemical JJ JJ O
and CC CC O
behavioral JJ JJ O
similarities NNS NNS O
to TO TO O
drug NN NN O
dependency NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
examined VBD VBD O
whether IN IN O
female JJ JJ O
rats NNS NNS O
on IN IN O
various JJ JJ O
regimens NNS NNS O
of IN IN O
sugar NN NN O
access NN NN O
would MD MD O
show VB VB O
behavioral JJ JJ O
cross NN NN O
- - - O
sensitization NN NN O
to TO TO O
a DT DT O
low JJ JJ O
dose NN NN O
of IN IN O
amphetamine NN NN B-CHEM
. . . O

After IN IN O
a DT DT O
30 CD CD O
- : : O
min NN NN O
baseline NN NN O
measure NN NN O
of IN IN O
locomotor NN NN O
activity NN NN O
( ( ( O
day NN NN O
0 CD CD O
) ) ) O
, , , O
animals NNS NNS O
were VBD VBD O
maintained VBN VBN O
on IN IN O
a DT DT O
cyclic JJ JJ O
diet NN NN O
of IN IN O
12 CD CD O
- : : O
h NN NN O
deprivation NN NN O
followed VBN VBN O
by IN IN O
12 CD CD O
- : : O
h NN NN O
access NN NN O
to TO TO O
10 CD CD O
% NN NN O
sucrose NN NN B-CHEM
solution NN NN O
and CC CC O
chow NN NN O
pellets NNS NNS O
( ( ( O
12 CD CD O
h NN NN O
access NN NN O
starting VBG VBG O
4 CD CD O
h NN NN O
after IN IN O
onset NN NN O
of IN IN O
the DT DT O
dark JJ JJ O
period NN NN O
) ) ) O
for IN IN O
21 CD CD O
days NNS NNS O
. . . O

Locomotor NNP NNP O
activity NN NN O
was VBD VBD O
measured VBN VBN O
again RB RB O
for IN IN O
30 CD CD O
min NN NN O
at IN IN O
the DT DT O
beginning NN NN O
of IN IN O
days NNS NNS O
1 CD CD O
and CC CC O
21 CD CD O
of IN IN O
sugar NN NN O
access NN NN O
. . . O

Beginning NNP NNP O
on IN IN O
day NN NN O
22 CD CD O
, , , O
all DT DT O
rats NNS NNS O
were VBD VBD O
maintained VBN VBN O
on IN IN O
ad NN NN O
libitum NN NN O
chow NN NN O
. . . O

Nine CD CD O
days NNS NNS O
later RB RB O
locomotor NN NN O
activity NN NN O
was VBD VBD O
measured VBN VBN O
in IN IN O
response NN NN O
to TO TO O
a DT DT O
single JJ JJ O
low JJ JJ O
dose NN NN O
of IN IN O
amphetamine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

The DT DT O
animals NNS NNS O
that WDT WDT O
had VBD VBD O
experienced VBN VBN O
cyclic JJ JJ O
sucrose NN NN B-CHEM
and CC CC O
chow NN NN O
were VBD VBD O
hyperactive JJ JJ O
in IN IN O
response NN NN O
to TO TO O
amphetamine VB VB B-CHEM
compared VBN VBN O
with IN IN O
four CD CD O
control NN NN O
groups NNS NNS O
( ( ( O
ad NN NN O
libitum NN NN O
10 CD CD O
% NN NN O
sucrose NN NN B-CHEM
and CC CC O
chow NN NN O
followed VBN VBN O
by IN IN O
amphetamine NN NN B-CHEM
injection NN NN O
, , , O
cyclic JJ JJ O
chow NN NN O
followed VBN VBN O
by IN IN O
amphetamine NN NN B-CHEM
injection NN NN O
, , , O
ad NN NN O
libitum NN NN O
chow NN NN O
with IN IN O
amphetamine NN NN B-CHEM
, , , O
or CC CC O
cyclic JJ JJ O
10 CD CD O
% NN NN O
sucrose NN NN B-CHEM
and CC CC O
chow NN NN O
with IN IN O
a DT DT O
saline NN NN O
injection NN NN O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
a DT DT O
diet NN NN O
comprised VBN VBN O
of IN IN O
alternating VBG VBG O
deprivation NN NN O
and CC CC O
access NN NN O
to TO TO O
a DT DT O
sugar NN NN O
solution NN NN O
and CC CC O
chow NN NN O
produces VBZ VBZ O
bingeing VBG VBG O
on IN IN O
sugar NN NN O
that WDT WDT O
leads VBZ VBZ O
to TO TO O
a DT DT O
long JJ JJ O
lasting JJ JJ O
state NN NN O
of IN IN O
increased VBN VBN O
sensitivity NN NN O
to TO TO O
amphetamine VB VB B-CHEM
, , , O
possibly RB RB O
due JJ JJ O
to TO TO O
a DT DT O
lasting JJ JJ O
alteration NN NN O
in IN IN O
the DT DT O
dopamine NN NN B-CHEM
system NN NN O
. . . O

Reversible NNP NNP O
dilated JJ JJ O
cardiomyopathy NN NN O
related VBN VBN O
to TO TO O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
therapy NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
dilated JJ JJ O
cardiomyopathy NN NN O
and CC CC O
clinical JJ JJ O
congestive JJ JJ O
heart NN NN O
failure NN NN O
after IN IN O
2 CD CD O
months NNS NNS O
of IN IN O
therapy NN NN O
with IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
( ( ( O
AmB NNP NNP B-CHEM
) ) ) O
for IN IN O
disseminated JJ JJ O
coccidioidomycosis NN NN O
. . . O

His PRP$ PRP$ O
echocardiographic JJ JJ O
abnormalities NNS NNS O
and CC CC O
heart NN NN O
failure NN NN O
resolved VBD VBD O
after IN IN O
posaconazole NN NN B-CHEM
was VBD VBD O
substituted VBN VBN O
for IN IN O
AmB NNP NNP B-CHEM
. . . O

It PRP PRP O
is VBZ VBZ O
important JJ JJ O
to TO TO O
recognize VB VB O
the DT DT O
rare JJ JJ O
and CC CC O
potentially RB RB O
reversible JJ JJ O
toxicity NN NN O
of IN IN O
AmB NNP NNP B-CHEM
. . . O

NO UH UH B-CHEM
- - - O
induced JJ JJ O
migraine NN NN O
attack NN NN O
: : : O
strong JJ JJ O
increase NN NN O
in IN IN O
plasma NN NN O
calcitonin NN NN B-CHEM
gene NN NN I-CHEM
- - - I-CHEM
related VBN VBN I-CHEM
peptide NN NN I-CHEM
( ( ( O
CGRP NNP NNP B-CHEM
) ) ) O
concentration NN NN O
and CC CC O
negative JJ JJ O
correlation NN NN O
with IN IN O
platelet NN NN O
serotonin NN NN B-CHEM
release NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
changes NNS NNS O
in IN IN O
the DT DT O
plasma NN NN O
calcitonin NN NN B-CHEM
gene NN NN I-CHEM
- - - I-CHEM
related VBN VBN I-CHEM
peptide NN NN I-CHEM
( ( ( O
CGRP NNP NNP B-CHEM
) ) ) O
concentration NN NN O
and CC CC O
platelet NN NN O
serotonin NN NN B-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytriptamine NN NN I-CHEM
, , , O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
) ) ) O
content NN NN O
during IN IN O
the DT DT O
immediate JJ JJ O
headache NN NN O
and CC CC O
the DT DT O
delayed JJ JJ O
genuine NN NN O
migraine NN NN O
attack NN NN O
provoked VBN VBN O
by IN IN O
nitroglycerin NN NN B-CHEM
. . . O

Fifteen NNP NNP O
female JJ JJ O
migraineurs NNS NNS O
( ( ( O
without IN IN O
aura NN NN O
) ) ) O
and CC CC O
eight CD CD O
controls NNS NNS O
participated VBN VBN O
in IN IN O
the DT DT O
study NN NN O
. . . O

Sublingual NNP NNP O
nitroglycerin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
. . . O

Blood NNP NNP O
was VBD VBD O
collected VBN VBN O
from IN IN O
the DT DT O
antecubital NN NN O
vein NN NN O
four CD CD O
times NNS NNS O
: : : O
60 CD CD O
min NN NN O
before IN IN O
and CC CC O
after IN IN O
the DT DT O
nitroglycerin NN NN B-CHEM
application NN NN O
, , , O
and CC CC O
60 CD CD O
and CC CC O
120 CD CD O
min NN NN O
after IN IN O
the DT DT O
beginning NN NN O
of IN IN O
the DT DT O
migraine NN NN O
attack NN NN O
( ( ( O
mean NN NN O
344 CD CD O
and CC CC O
404 CD CD O
min NN NN O
; : : O
12 CD CD O
subjects NNS NNS O
) ) ) O
. . . O

In IN IN O
those DT DT O
subjects NNS NNS O
who WP WP O
had VBD VBD O
no DT DT O
migraine NN NN O
attack NN NN O
( ( ( O
11 CD CD O
subjects NNS NNS O
) ) ) O
a DT DT O
similar JJ JJ O
time NN NN O
schedule NN NN O
was VBD VBD O
used VBN VBN O
. . . O

Plasma NNP NNP O
CGRP NNP NNP B-CHEM
concentration NN NN O
increased VBD VBD O
significantly RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
during IN IN O
the DT DT O
migraine NN NN O
attack NN NN O
and CC CC O
returned VBD VBD O
to TO TO O
baseline VB VB O
after IN IN O
the DT DT O
cessation NN NN O
of IN IN O
the DT DT O
migraine NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
both DT DT O
change NN NN O
and CC CC O
peak NN NN O
, , , O
showed VBD VBD O
significant JJ JJ O
positive JJ JJ O
correlations NNS NNS O
with IN IN O
migraine NN NN O
headache NN NN O
intensity NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

However RB RB O
, , , O
plasma NN NN O
CGRP NNP NNP B-CHEM
concentrations NNS NNS O
failed VBD VBD O
to TO TO O
change VB VB O
during IN IN O
immediate JJ JJ O
headache NN NN O
and CC CC O
in IN IN O
the DT DT O
subjects NNS NNS O
with IN IN O
no DT DT O
migraine NN NN O
attack NN NN O
. . . O

Basal NNP NNP O
CGRP NNP NNP B-CHEM
concentration NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
and CC CC O
platelet NN NN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
content NN NN O
tended VBD VBD O
to TO TO O
be VB VB O
lower JJR JJR O
in IN IN O
subjects NNS NNS O
who WP WP O
experienced VBD VBD O
a DT DT O
migraine NN NN O
attack NN NN O
. . . O

Platelet NNP NNP O
serotonin NN NN B-CHEM
content NN NN O
decreased VBD VBD O
significantly RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
after IN IN O
nitroglycerin NN NN B-CHEM
in IN IN O
subjects NNS NNS O
with IN IN O
no DT DT O
migraine NN NN O
attack NN NN O
but CC CC O
no DT DT O
consistent JJ JJ O
change NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
migraine NN NN O
attack NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
the DT DT O
fact NN NN O
that IN IN O
plasma NN NN O
CGRP NNP NNP B-CHEM
concentration NN NN O
correlates NNS NNS O
with IN IN O
the DT DT O
timing NN NN O
and CC CC O
severity NN NN O
of IN IN O
a DT DT O
migraine NN NN O
headache NN NN O
suggests VBZ VBZ O
a DT DT O
direct JJ JJ O
relationship NN NN O
between IN IN O
CGRP NNP NNP B-CHEM
and CC CC O
migraine NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
serotonin NN NN B-CHEM
release NN NN O
from IN IN O
platelets NNS NNS O
does VBZ VBZ O
not RB RB O
provoke VB VB O
migraine NN NN O
, , , O
it PRP PRP O
may MD MD O
even RB RB O
counteract VB VB O
the DT DT O
headache NN NN O
and CC CC O
the DT DT O
concomitant JJ JJ O
CGRP NNP NNP B-CHEM
release NN NN O
in IN IN O
this DT DT O
model NN NN O
. . . O

Hyperbaric NNP NNP O
oxygen NN NN B-CHEM
therapy NN NN O
for IN IN O
control NN NN O
of IN IN O
intractable JJ JJ O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
intractable JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
due JJ JJ O
to TO TO O
cyclophosphamide VB VB B-CHEM
therapy NN NN O
for IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
. . . O

Conservative JJ JJ O
treatment NN NN O
, , , O
including VBG VBG O
bladder NN NN O
irrigation NN NN O
with IN IN O
physiological JJ JJ O
saline NN NN O
and CC CC O
instillation NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
F2 NNP NNP I-CHEM
alpha NN NN I-CHEM
, , , O
failed VBD VBD O
to TO TO O
totally RB RB O
control VB VB O
hemorrhage NN NN O
. . . O

We PRP PRP O
then RB RB O
used VBD VBD O
hyperbaric JJ JJ O
oxygen NN NN B-CHEM
at IN IN O
an DT DT O
absolute JJ JJ O
pressure NN NN O
of IN IN O
2 CD CD O
atm NN NN O
, , , O
5 CD CD O
days NNS NNS O
a DT DT O
week NN NN O
for IN IN O
8 CD CD O
consecutive JJ JJ O
weeks NNS NNS O
. . . O

The DT DT O
bleeding NN NN O
ceased VBD VBD O
completely RB RB O
by IN IN O
the DT DT O
end NN NN O
of IN IN O
treatment NN NN O
and CC CC O
the DT DT O
patient NN NN O
remained VBD VBD O
free JJ JJ O
of IN IN O
hematuria NN NN O
thereafter NN NN O
. . . O

No DT DT O
side NN NN O
effect NN NN O
was VBD VBD O
noted VBN VBN O
during IN IN O
the DT DT O
course NN NN O
of IN IN O
therapy NN NN O
. . . O

In IN IN O
future JJ JJ O
, , , O
this DT DT O
form NN NN O
of IN IN O
therapy NN NN O
can MD MD O
offer VB VB O
a DT DT O
safe JJ JJ O
alternative NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

Acute JJ JJ O
psychosis NN NN O
due JJ JJ O
to TO TO O
treatment NN NN O
with IN IN O
phenytoin NN NN B-CHEM
in IN IN O
a DT DT O
nonepileptic JJ JJ O
patient NN NN O
. . . O

The DT DT O
development NN NN O
of IN IN O
psychosis NN NN O
related VBN VBN O
to TO TO O
antiepileptic JJ JJ O
drug NN NN O
treatment NN NN O
is VBZ VBZ O
usually RB RB O
attributed VBN VBN O
to TO TO O
the DT DT O
interaction NN NN O
between IN IN O
the DT DT O
epileptic JJ JJ O
brain NN NN O
substratum NN NN O
and CC CC O
the DT DT O
antiepileptic JJ JJ O
drugs NNS NNS O
. . . O

The DT DT O
case NN NN O
of IN IN O
a DT DT O
nonepileptic JJ JJ O
patient NN NN O
who WP WP O
developed VBD VBD O
psychosis NNS NNS O
following VBG VBG O
phenytoin NN NN B-CHEM
treatment NN NN O
for IN IN O
trigeminal JJ JJ O
neuralgia NN NN O
is VBZ VBZ O
described VBN VBN O
. . . O

This DT DT O
case NN NN O
suggests VBZ VBZ O
that IN IN O
the DT DT O
psychotic JJ JJ O
symptoms NNS NNS O
that WDT WDT O
occur VBP VBP O
following VBG VBG O
phenytoin NN NN B-CHEM
treatment NN NN O
in IN IN O
some DT DT O
epileptic JJ JJ O
patients NNS NNS O
may MD MD O
be VB VB O
the DT DT O
direct JJ JJ O
result NN NN O
of IN IN O
medication NN NN O
, , , O
unrelated JJ JJ O
to TO TO O
seizures NNS NNS O
. . . O

Risks NNS NNS O
of IN IN O
the DT DT O
consumption NN NN O
of IN IN O
beverages NNS NNS O
containing VBG VBG O
quinine NN NN B-CHEM
. . . O

Although IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
Food NNP NNP O
and CC CC O
Drug NN NN O
Administration NNP NNP O
banned VBD VBD O
its PRP$ PRP$ O
use NN NN O
for IN IN O
nocturnal NN NN O
leg NN NN O
cramps NNS NNS O
due JJ JJ O
to TO TO O
lack NN NN O
of IN IN O
safety NN NN O
and CC CC O
efficacy NN NN O
, , , O
quinine NN NN B-CHEM
is VBZ VBZ O
widely RB RB O
available JJ JJ O
in IN IN O
beverages NNS NNS O
including VBG VBG O
tonic NN NN O
water NN NN O
and CC CC O
bitter JJ JJ O
lemon NN NN O
. . . O

Numerous JJ JJ O
anecdotal JJ JJ O
reports NNS NNS O
suggest VBP VBP O
that IN IN O
products NNS NNS O
containing VBG VBG O
quinine NN NN B-CHEM
may MD MD O
produce VB VB O
neurological JJ JJ O
complications NNS NNS O
, , , O
including VBG VBG O
confusion NN NN O
, , , O
altered VBN VBN O
mental JJ JJ O
status NN NN O
, , , O
seizures NNS NNS O
, , , O
and CC CC O
coma NN NN O
, , , O
particularly RB RB O
in IN IN O
older JJR JJR O
women NNS NNS O
. . . O

Psychologists NNS NNS O
need VBP VBP O
to TO TO O
inquire NN NN O
about IN IN O
consumption NN NN O
of IN IN O
quinine NN NN B-CHEM
- - - O
containing VBG VBG O
beverages NNS NNS O
as IN IN O
part NN NN O
of IN IN O
an DT DT O
evaluation NN NN O
process NN NN O
. . . O

Transient NNP NNP O
platypnea NN NN O
- - - O
orthodeoxia NN NN O
- - - O
like IN IN O
syndrome NN NN O
induced VBN VBN O
by IN IN O
propafenone NN NN B-CHEM
overdose NN NN O
in IN IN O
a DT DT O
young JJ JJ O
woman NN NN O
with IN IN O
Ebstein NNP NNP O
' POS POS O
s VBZ VBZ O
anomaly NN NN O
. . . O

In IN IN O
this DT DT O
report NN NN O
we PRP PRP O
describe VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
37 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
white JJ JJ O
woman NN NN O
with IN IN O
Ebstein NNP NNP O
' POS POS O
s VBZ VBZ O
anomaly NN NN O
, , , O
who WP WP O
developed VBD VBD O
a DT DT O
rare JJ JJ O
syndrome NN NN O
called VBN VBN O
platypnea NN NN O
- - - O
orthodeoxia NN NN O
, , , O
characterized VBN VBN O
by IN IN O
massive JJ JJ O
right JJ JJ O
- - - O
to TO TO O
- - - O
left FW FW O
interatrial JJ JJ O
shunting VBG VBG O
with IN IN O
transient NN NN O
profound NN NN O
hypoxia NN NN O
and CC CC O
cyanosis NN NN O
. . . O

This DT DT O
shunt NN NN O
of IN IN O
blood NN NN O
via IN IN O
a DT DT O
patent NN NN O
foramen NN NN O
ovale NN NN O
occurred VBD VBD O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
a DT DT O
normal JJ JJ O
pulmonary JJ JJ O
artery NN NN O
pressure NN NN O
, , , O
and CC CC O
was VBD VBD O
probably RB RB O
precipitated VBN VBN O
by IN IN O
a DT DT O
propafenone NN NN B-CHEM
overdose NN NN O
. . . O

This DT DT O
drug NN NN O
caused VBD VBD O
biventricular JJ JJ O
dysfunction NN NN O
, , , O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
negative JJ JJ O
inotropic JJ JJ O
effect NN NN O
, , , O
and CC CC O
hypotension NN NN O
, , , O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
peripheral JJ JJ O
vasodilatory NN NN O
effect NN NN O
. . . O

These DT DT O
effects NNS NNS O
gave VBD VBD O
rise NN NN O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
right NN NN O
atrial JJ JJ O
pressure NN NN O
and CC CC O
a DT DT O
decrease NN NN O
in IN IN O
the DT DT O
left NN NN O
one CD CD O
with IN IN O
a DT DT O
consequent NN NN O
stretching VBG VBG O
of IN IN O
the DT DT O
foramen NNS NNS O
ovale NN NN O
and CC CC O
the DT DT O
creation NN NN O
of IN IN O
massive JJ JJ O
right JJ JJ O
- - - O
to TO TO O
- - - O
left FW FW O
shunting VBG VBG O
. . . O

In IN IN O
our PRP$ PRP$ O
case NN NN O
this DT DT O
interatrial JJ JJ O
shunt NN NN O
was VBD VBD O
very RB RB O
accurately RB RB O
detected VBD VBD O
at IN IN O
bubble JJ JJ O
contrast NN NN O
echocardiography NN NN O
. . . O

Noxious NNP NNP O
chemical NN NN O
stimulation NN NN O
of IN IN O
rat NN NN O
facial JJ JJ O
mucosa NN NN O
increases NNS NNS O
intracranial JJ JJ O
blood NN NN O
flow NN NN O
through IN IN O
a DT DT O
trigemino NN NN O
- - - O
parasympathetic JJ JJ O
reflex NN NN O
- - - O
- - - O
an DT DT O
experimental JJ JJ O
model NN NN O
for IN IN O
vascular NN NN O
dysfunctions NNS NNS O
in IN IN O
cluster NN NN O
headache NN NN O
. . . O

Cluster NNP NNP O
headache NN NN O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
typical JJ JJ O
autonomic JJ JJ O
dysfunctions NNS NNS O
including VBG VBG O
facial JJ JJ O
and CC CC O
intracranial JJ JJ O
vascular NN NN O
disturbances NNS NNS O
. . . O

Both DT DT O
the DT DT O
trigeminal NN NN O
and CC CC O
the DT DT O
cranial JJ JJ O
parasympathetic JJ JJ O
systems NNS NNS O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
mediating VBG VBG O
these DT DT O
dysfunctions NNS NNS O
. . . O

An DT DT O
experimental JJ JJ O
model NN NN O
was VBD VBD O
developed VBN VBN O
in IN IN O
the DT DT O
rat NN NN O
to TO TO O
measure VB VB O
changes NNS NNS O
in IN IN O
lacrimation NN NN O
and CC CC O
intracranial JJ JJ O
blood NN NN O
flow NN NN O
following VBG VBG O
noxious JJ JJ O
chemical NN NN O
stimulation NN NN O
of IN IN O
facial JJ JJ O
mucosa NN NN O
. . . O

Blood NNP NNP O
flow NN NN O
was VBD VBD O
monitored VBN VBN O
in IN IN O
arteries NNS NNS O
of IN IN O
the DT DT O
exposed VBN VBN O
cranial NN NN O
dura NN NN O
mater NN NN O
and CC CC O
the DT DT O
parietal NN NN O
cortex NN NN O
using VBG VBG O
laser NN NN O
Doppler NNP NNP O
flowmetry NN NN O
. . . O

Capsaicin NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
01 CD CD O
- : : O
1 CD CD O
mm NN NN O
) ) ) O
applied VBD VBD O
to TO TO O
oral JJ JJ O
or CC CC O
nasal NN NN O
mucosa NN NN O
induced JJ JJ O
increases NNS NNS O
in IN IN O
dural NN NN O
and CC CC O
cortical JJ JJ O
blood NN NN O
flow NN NN O
and CC CC O
provoked JJ JJ O
lacrimation NN NN O
. . . O

These DT DT O
responses NNS NNS O
were VBD VBD O
blocked VBN VBN O
by IN IN O
systemic JJ JJ O
pre NN NN O
- - - O
administration NN NN O
of IN IN O
hexamethonium NN NN B-CHEM
chloride NN NN I-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

The DT DT O
evoked JJ JJ O
increases NNS NNS O
in IN IN O
dural JJ JJ O
blood NN NN O
flow NN NN O
were VBD VBD O
also RB RB O
abolished VBN VBN O
by IN IN O
topical JJ JJ O
pre NN NN O
- - - O
administration NN NN O
of IN IN O
atropine NN NN B-CHEM
( ( ( O
1 CD CD O
mm NN NN O
) ) ) O
and CC CC O
[ NN NN O
Lys1 NNP NNP O
, , , O
Pro2 NNP NNP O
, , , O
5 CD CD O
, , , O
Arg3 NNP NNP O
, , , O
4 CD CD O
, , , O
Tyr6 NNP NNP O
] NN NN O
- : : O
VIP NNP NNP O
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mm NN NN O
) ) ) O
, , , O
a DT DT O
vasoactive JJ JJ O
intestinal JJ JJ O
polypeptide NN NN O
( ( ( O
VIP NNP NNP O
) ) ) O
antagonist NN NN O
, , , O
onto IN IN O
the DT DT O
exposed VBN VBN O
dura NN NN O
mater NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
noxious JJ JJ O
stimulation NN NN O
of IN IN O
facial JJ JJ O
mucosa NN NN O
increases NNS NNS O
intracranial JJ JJ O
blood NN NN O
flow NN NN O
and CC CC O
lacrimation NN NN O
via IN IN O
a DT DT O
trigemino NN NN O
- - - O
parasympathetic JJ JJ O
reflex NN NN O
. . . O

The DT DT O
blood NN NN O
flow NN NN O
responses NNS NNS O
seem VBP VBP O
to TO TO O
be VB VB O
mediated VBN VBN O
by IN IN O
the DT DT O
release NN NN O
of IN IN O
acetylcholine NN NN B-CHEM
and CC CC O
VIP NNP NNP O
within IN IN O
the DT DT O
meninges NNS NNS O
. . . O

Similar JJ JJ O
mechanisms NNS NNS O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
cluster NN NN O
headache NN NN O
. . . O

Organophosphate NNP NNP B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
and CC CC O
prevention NN NN O
of IN IN O
neuropathological JJ JJ O
damages NNS NNS O
. . . O

Such JJ JJ O
organophosphorus JJ JJ B-CHEM
( ( ( O
OP NNP NNP B-CHEM
) ) ) O
compounds NNS NNS O
as IN IN O
diisopropylfluorophosphate NN NN B-CHEM
( ( ( O
DFP NNP NNP B-CHEM
) ) ) O
, , , O
sarin NN NN B-CHEM
and CC CC O
soman NN NN B-CHEM
are VBP VBP O
potent JJ JJ O
inhibitors NNS NNS O
of IN IN O
acetylcholinesterases NNS NNS O
( ( ( O
AChEs NNP NNP O
) ) ) O
and CC CC O
butyrylcholinesterases NNS NNS O
( ( ( O
BChEs NNP NNP O
) ) ) O
. . . O

The DT DT O
acute JJ JJ O
toxicity NN NN O
of IN IN O
OPs NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
result NN NN O
of IN IN O
their PRP$ PRP$ O
irreversible JJ JJ O
binding JJ JJ O
with IN IN O
AChEs NNP NNP O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
, , , O
which WDT WDT O
elevates VBZ VBZ O
acetylcholine NN NN B-CHEM
( ( ( O
ACh NNP NNP B-CHEM
) ) ) O
levels NNS NNS O
. . . O

The DT DT O
protective JJ JJ O
action NN NN O
of IN IN O
subcutaneously RB RB O
( ( ( O
SC NNP NNP O
) ) ) O
administered VBD VBD O
antidotes NNS NNS O
or CC CC O
their PRP$ PRP$ O
combinations NNS NNS O
in IN IN O
DFP NNP NNP B-CHEM
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
) ) ) O
intoxication NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
9 CD CD O
- : : O
10 CD CD O
- : : O
weeks NNS NNS O
- : : O
old JJ JJ O
Han NNP NNP O
- : : O
Wistar NNP NNP O
male JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
rats NNS NNS O
received VBD VBD O
AChE NNP NNP O
reactivator NN NN O
pralidoxime NN NN B-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
chloride NN NN I-CHEM
( ( ( O
2PAM CD CD B-CHEM
) ) ) O
( ( ( O
30 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
) ) ) O
, , , O
anticonvulsant JJ JJ O
diazepam NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
) ) ) O
, , , O
A DT DT O
( ( ( O
1 CD CD O
) ) ) O
- : : O
adenosine NN NN B-CHEM
receptor NN NN O
agonist NN NN O
N NNP NNP B-CHEM
( ( ( I-CHEM
6 CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
cyclopentyl NN NN I-CHEM
adenosine NN NN I-CHEM
( ( ( O
CPA NNP NNP B-CHEM
) ) ) O
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
) ) ) O
, , , O
NMDA NNP NNP B-CHEM
- : : O
receptor NN NN O
antagonist NN NN O
dizocilpine NN NN B-CHEM
maleate NN NN I-CHEM
( ( ( O
+ NN NN O
- : : O
MK801 NNP NNP O
hydrogen NN NN O
maleate NN NN O
) ) ) O
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
) ) ) O
or CC CC O
their PRP$ PRP$ O
combinations NNS NNS O
with IN IN O
cholinolytic JJ JJ O
drug NN NN O
atropine NN NN B-CHEM
sulfate NN NN I-CHEM
( ( ( O
50 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
) ) ) O
immediately RB RB O
or CC CC O
30 CD CD O
min NN NN O
after IN IN O
the DT DT O
single JJ JJ O
SC NNP NNP O
injection NN NN O
of IN IN O
DFP NNP NNP B-CHEM
. . . O

The DT DT O
control NN NN O
rats NNS NNS O
received VBD VBD O
atropine JJ JJ B-CHEM
sulfate NN NN I-CHEM
, , , O
but CC CC O
also RB RB O
saline NN NN O
and CC CC O
olive JJ JJ O
oil NN NN O
instead RB RB O
of IN IN O
other JJ JJ O
antidotes NNS NNS O
and CC CC O
DFP NNP NNP B-CHEM
, , , O
respectively RB RB O
. . . O

All DT DT O
rats NNS NNS O
were VBD VBD O
terminated VBN VBN O
either CC CC O
24 CD CD O
h NN NN O
or CC CC O
3 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
DFP NNP NNP B-CHEM
injection NN NN O
. . . O

The DT DT O
rats NNS NNS O
treated VBN VBN O
with IN IN O
DFP NNP NNP B-CHEM
- : : O
atropine NN NN B-CHEM
showed VBD VBD O
severe JJ JJ O
typical JJ JJ O
OP NNP NNP B-CHEM
- : : O
induced JJ JJ O
toxicity NN NN O
signs NNS NNS O
. . . O

When WRB WRB O
CPA NNP NNP B-CHEM
, , , O
diazepam NN NN B-CHEM
or CC CC O
2PAM CD CD B-CHEM
was VBD VBD O
given VBN VBN O
immediately RB RB O
after IN IN O
DFP NNP NNP B-CHEM
- : : O
atropine NN NN B-CHEM
, , , O
these DT DT O
treatments NNS NNS O
prevented VBN VBN O
, , , O
delayed JJ JJ O
or CC CC O
shortened VBD VBD O
the DT DT O
occurrence NN NN O
of IN IN O
serious JJ JJ O
signs NNS NNS O
of IN IN O
poisoning NN NN O
. . . O

Atropine NNP NNP B-CHEM
- : : O
MK801 NNP NNP B-CHEM
did VBD VBD O
not RB RB O
offer VB VB O
any DT DT O
additional JJ JJ O
protection NN NN O
against IN IN O
DFP NNP NNP B-CHEM
toxicity NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
CPA NNP NNP B-CHEM
, , , O
diazepam NN NN B-CHEM
and CC CC O
2PAM CD CD B-CHEM
in IN IN O
combination NN NN O
with IN IN O
atropine NN NN B-CHEM
prevented VBD VBD O
the DT DT O
occurrence NN NN O
of IN IN O
serious JJ JJ O
signs NNS NNS O
of IN IN O
poisoning NN NN O
and CC CC O
thus RB RB O
reduced VBD VBD O
the DT DT O
toxicity NN NN O
of IN IN O
DFP NNP NNP B-CHEM
in IN IN O
rat NN NN O
. . . O

A DT DT O
pyridoxine NN NN B-CHEM
- - - O
dependent JJ JJ O
behavioral JJ JJ O
disorder NN NN O
unmasked JJ JJ O
by IN IN O
isoniazid NN NN B-CHEM
. . . O

A DT DT O
3 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
had VBD VBD O
behavioral JJ JJ O
deterioration NN NN O
, , , O
with IN IN O
hyperkinesis NN NN O
, , , O
irritability NN NN O
, , , O
and CC CC O
sleeping VBG VBG O
difficulties NNS NNS O
after IN IN O
the DT DT O
therapeutic JJ JJ O
administration NN NN O
of IN IN O
isoniazid NN NN B-CHEM
. . . O

The DT DT O
administration NN NN O
of IN IN O
pharmacologic JJ JJ O
doses NNS NNS O
of IN IN O
pyridoxine NN NN B-CHEM
hydrochloride NN NN I-CHEM
led VBN VBN O
to TO TO O
a DT DT O
disappearance NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

After IN IN O
discontinuing VBG VBG O
isoniazid NN NN B-CHEM
therapy NN NN O
a DT DT O
similar JJ JJ O
pattern NN NN O
of IN IN O
behavior NN NN O
was VBD VBD O
noted VBN VBN O
that WDT WDT O
was VBD VBD O
controlled VBN VBN O
by IN IN O
pyridoxine NN NN B-CHEM
. . . O

A DT DT O
placebo NN NN O
had VBD VBD O
no DT DT O
effect NN NN O
, , , O
but CC CC O
niacinamide RB RB B-CHEM
was VBD VBD O
as RB RB O
effective JJ JJ O
as IN IN O
pyridoxine NN NN B-CHEM
. . . O

Periodic NNP NNP O
withdrawal NN NN O
of IN IN O
pyridoxine NN NN B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
return NN NN O
of IN IN O
the DT DT O
hyperkinesis NN NN O
. . . O

The DT DT O
level NN NN O
of IN IN O
pyridoxal NN NN B-CHEM
in IN IN O
the DT DT O
blood NN NN O
was VBD VBD O
normal JJ JJ O
during IN IN O
the DT DT O
periods NNS NNS O
of IN IN O
relapse NN NN O
. . . O

Metabolic NNP NNP O
studies NNS NNS O
suggested VBD VBD O
a DT DT O
block NN NN O
in IN IN O
the DT DT O
kynurenine NN NN B-CHEM
pathway NN NN O
of IN IN O
tryptophan NN NN B-CHEM
metabolism NN NN O
. . . O

The DT DT O
patient NN NN O
has VBZ VBZ O
been VBN VBN O
followed VBN VBN O
for IN IN O
six CD CD O
years NNS NNS O
and CC CC O
has VBZ VBZ O
required VBN VBN O
pharmacologic JJ JJ O
doses NNS NNS O
of IN IN O
pyridoxine NN NN B-CHEM
to TO TO O
control VB VB O
her PRP$ PRP$ O
behavior NN NN O
. . . O

Recurrent NNP NNP O
excitation NN NN O
in IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
of IN IN O
a DT DT O
murine NN NN O
model NN NN O
of IN IN O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
. . . O

Similar JJ JJ O
to TO TO O
rats NNS NNS O
, , , O
systemic JJ JJ O
pilocarpine NN NN B-CHEM
injection NN NN O
causes NNS NNS O
status NN NN O
epilepticus NN NN O
( ( ( O
SE NNP NNP O
) ) ) O
and CC CC O
the DT DT O
eventual JJ JJ O
development NN NN O
of IN IN O
spontaneous JJ JJ O
seizures NNS NNS O
and CC CC O
mossy NN NN O
fiber NN NN O
sprouting VBG VBG O
in IN IN O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
and CC CC O
CD1 NNP NNP O
mice NN NN O
, , , O
but CC CC O
the DT DT O
physiological JJ JJ O
correlates NNS NNS O
of IN IN O
these DT DT O
events NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
identified VBN VBN O
in IN IN O
mice NNS NNS O
. . . O

Population NN NN O
responses NNS NNS O
in IN IN O
granule NN NN O
cells NNS NNS O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
were VBD VBD O
examined VBN VBN O
in IN IN O
transverse NN NN O
slices NNS NNS O
of IN IN O
the DT DT O
ventral NN NN O
hippocampus NN NN O
from IN IN O
pilocarpine NN NN B-CHEM
- - - O
treated VBN VBN O
and CC CC O
untreated JJ JJ O
mice NN NN O
. . . O

In IN IN O
Mg NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
- - - O
free JJ JJ O
bathing NN NN O
medium NN NN O
containing VBG VBG O
bicuculline NN NN B-CHEM
, , , O
conditions NNS NNS O
designed VBN VBN O
to TO TO O
increase VB VB O
excitability NN NN O
in IN IN O
the DT DT O
slices NNS NNS O
, , , O
electrical JJ JJ O
stimulation NN NN O
of IN IN O
the DT DT O
hilus NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
single JJ JJ O
population NN NN O
spike NN NN O
in IN IN O
granule NN NN O
cells NNS NNS O
from IN IN O
control NN NN O
mice NN NN O
and CC CC O
pilocarpine NN NN B-CHEM
- - - O
treated JJ JJ O
mice NN NN O
that WDT WDT O
did VBD VBD O
not RB RB O
experience VB VB O
SE NNP NNP O
. . . O

In IN IN O
SE NNP NNP O
survivors NNS NNS O
, , , O
similar JJ JJ O
stimulation NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
population NN NN O
spike NN NN O
followed VBN VBN O
, , , O
at IN IN O
a DT DT O
variable JJ JJ O
latency NN NN O
, , , O
by IN IN O
negative JJ JJ O
DC NNP NNP O
shifts NNS NNS O
and CC CC O
repetitive JJ JJ O
afterdischarges NNS NNS O
of IN IN O
3 CD CD O
- : : O
60 CD CD O
s VBZ VBZ O
duration NN NN O
, , , O
which WDT WDT O
were VBD VBD O
blocked VBN VBN O
by IN IN O
ionotropic JJ JJ O
glutamate NN NN B-CHEM
receptor NN NN O
antagonists NNS NNS O
. . . O

Focal NNP NNP O
glutamate NN NN B-CHEM
photostimulation NN NN O
of IN IN O
the DT DT O
granule NN NN O
cell NN NN O
layer NN NN O
at IN IN O
sites NNS NNS O
distant NN NN O
from IN IN O
the DT DT O
recording NN NN O
pipette NN NN O
resulted VBD VBD O
in IN IN O
population NN NN O
responses NNS NNS O
of IN IN O
1 CD CD O
- : : O
30 CD CD O
s VBZ VBZ O
duration NN NN O
in IN IN O
slices NNS NNS O
from IN IN O
SE NNP NNP O
survivors NNS NNS O
but CC CC O
not RB RB O
other JJ JJ O
groups NNS NNS O
. . . O

These DT DT O
data NNS NNS O
support VBP VBP O
the DT DT O
hypothesis NNS NNS O
that IN IN O
SE NNP NNP O
- : : O
induced JJ JJ O
mossy NN NN O
fiber NN NN O
sprouting VBG VBG O
and CC CC O
synaptic JJ JJ O
reorganization NN NN O
are VBP VBP O
relevant JJ JJ O
characteristics NNS NNS O
of IN IN O
seizure NN NN O
development NN NN O
in IN IN O
these DT DT O
murine NN NN O
strains NNS NNS O
, , , O
resembling VBG VBG O
rat NN NN O
models NNS NNS O
of IN IN O
human JJ JJ O
temporal NN NN O
lobe NN NN O
epilepsy NN NN O
. . . O

Urinary NNP NNP O
bladder NN NN O
cancer NN NN O
in IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
: : : O
risks NNS NNS O
and CC CC O
relation NN NN O
to TO TO O
cyclophosphamide VB VB B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
assess VB VB O
and CC CC O
characterise VB VB O
the DT DT O
risk NN NN O
of IN IN O
bladder NN NN O
cancer NN NN O
, , , O
and CC CC O
its PRP$ PRP$ O
relation NN NN O
to TO TO O
cyclophosphamide VB VB B-CHEM
, , , O
in IN IN O
patients NNS NNS O
with IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
the DT DT O
population NN NN O
based VBN VBN O
, , , O
nationwide JJ JJ O
Swedish JJ JJ O
Inpatient NNP NNP O
Register NNP NNP O
a DT DT O
cohort NN NN O
of IN IN O
1065 CD CD O
patients NNS NNS O
with IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
, , , O
1969 CD CD O
- : : O
95 CD CD O
, , , O
was VBD VBD O
identified VBN VBN O
. . . O

Through IN IN O
linkage NN NN O
with IN IN O
the DT DT O
Swedish JJ JJ O
Cancer NNP NNP O
Register NNP NNP O
, , , O
all DT DT O
subjects NNS NNS O
in IN IN O
this DT DT O
cohort NN NN O
diagnosed VBN VBN O
with IN IN O
bladder NN NN O
cancer NN NN O
were VBD VBD O
identified VBN VBN O
. . . O

Nested NNP NNP O
within IN IN O
the DT DT O
cohort NN NN O
, , , O
a DT DT O
matched JJ JJ O
case NN NN O
- - - O
control NN NN O
study NN NN O
was VBD VBD O
performed VBN VBN O
to TO TO O
estimate VB VB O
the DT DT O
association NN NN O
between IN IN O
cyclophosphamide NN NN B-CHEM
and CC CC O
bladder NN NN O
cancer NN NN O
using VBG VBG O
odds NNS NNS O
ratios NN NN O
( ( ( O
ORs NNP NNP O
) ) ) O
as IN IN O
relative JJ JJ O
risk NN NN O
. . . O

In IN IN O
the DT DT O
cohort NN NN O
the DT DT O
cumulative JJ JJ O
risk NN NN O
of IN IN O
bladder NN NN O
cancer NN NN O
after IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
, , , O
and CC CC O
the DT DT O
relative JJ JJ O
prevalence NN NN O
of IN IN O
a DT DT O
history NN NN O
of IN IN O
bladder NN NN O
cancer NN NN O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
diagnosis NN NN O
of IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
, , , O
were VBD VBD O
also RB RB O
estimated VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
median NN NN O
cumulative JJ JJ O
doses NNS NNS O
of IN IN O
cyclophosphamide NN NN B-CHEM
among IN IN O
cases NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
11 CD CD O
) ) ) O
and CC CC O
controls NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
25 CD CD O
) ) ) O
were VBD VBD O
113 CD CD O
g SYM SYM O
and CC CC O
25 CD CD O
g SYM SYM O
, , , O
respectively RB RB O
. . . O

The DT DT O
risk NN NN O
of IN IN O
bladder NN NN O
cancer NN NN O
doubled VBD VBD O
for IN IN O
every DT DT O
10 CD CD O
g SYM SYM O
increment NN NN O
in IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
OR CC CC O
= SYM SYM O
2 CD CD O
. . . O
0 CD CD O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
( ( ( O
CI NNP NNP O
) ) ) O
0 CD CD O
. . . O
8 CD CD O
to TO TO O
4 CD CD O
. . . O
9 CD CD O
) ) ) O
. . . O

Treatment NN NN O
duration NN NN O
longer RBR RBR O
than IN IN O
1 CD CD O
year NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
eightfold NN NN O
increased VBD VBD O
risk NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
7 CD CD O
. . . O
7 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
9 CD CD O
to TO TO O
69 CD CD O
) ) ) O
. . . O

The DT DT O
absolute JJ JJ O
risk NN NN O
for IN IN O
bladder NN NN O
cancer NN NN O
in IN IN O
the DT DT O
cohort NN NN O
reached VBD VBD O
10 CD CD O
% NN NN O
16 CD CD O
years NNS NNS O
after IN IN O
diagnosis NN NN O
of IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
, , , O
and CC CC O
a DT DT O
history NN NN O
of IN IN O
bladder NN NN O
cancer NN NN O
was VBD VBD O
( ( ( O
non NN NN O
- - - O
significantly RB RB O
) ) ) O
twice RB RB O
as RB RB O
common JJ JJ O
as IN IN O
expected VBN VBN O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
diagnosis NN NN O
of IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
results NNS NNS O
indicate VBP VBP O
a DT DT O
dose NN NN O
- - - O
response NN NN O
relationship NN NN O
between IN IN O
cyclophosphamide NN NN B-CHEM
and CC CC O
the DT DT O
risk NN NN O
of IN IN O
bladder NN NN O
cancer NN NN O
, , , O
high JJ JJ O
cumulative JJ JJ O
risks NNS NNS O
in IN IN O
the DT DT O
entire JJ JJ O
cohort NN NN O
, , , O
and CC CC O
also RB RB O
the DT DT O
possibility NN NN O
of IN IN O
risk NN NN O
factors NNS NNS O
operating VBG VBG O
even RB RB O
before IN IN O
Wegener NNP NNP O
' POS POS O
s VBZ VBZ O
granulomatosis NN NN O
. . . O

Differential NNP NNP O
modulation NN NN O
by IN IN O
estrogen NN NN B-CHEM
of IN IN O
alpha2 NN NN O
- - - O
adrenergic JJ JJ O
and CC CC O
I1 NNP NNP O
- : : O
imidazoline NN NN B-CHEM
receptor NN NN O
- : : O
mediated JJ JJ O
hypotension NN NN O
in IN IN O
female JJ JJ O
rats NNS NNS O
. . . O

We PRP PRP O
have VBP VBP O
recently RB RB O
shown VBN VBN O
that IN IN O
estrogen NN NN B-CHEM
negatively RB RB O
modulates VBZ VBZ O
the DT DT O
hypotensive JJ JJ O
effect NN NN O
of IN IN O
clonidine NN NN B-CHEM
( ( ( O
mixed JJ JJ O
alpha2 NN NN O
- - - O
/ NN NN O
I1 NNP NNP O
- - - O
receptor NN NN O
agonist NN NN O
) ) ) O
in IN IN O
female JJ JJ O
rats NNS NNS O
and CC CC O
implicates NNS NNS O
the DT DT O
cardiovascular JJ JJ O
autonomic JJ JJ O
control NN NN O
in IN IN O
this DT DT O
interaction NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
investigated VBD VBD O
whether IN IN O
this DT DT O
effect NN NN O
of IN IN O
estrogen NN NN B-CHEM
involves NNS NNS O
interaction NN NN O
with IN IN O
alpha2 NN NN O
- - - O
and CC CC O
/ NN NN O
or CC CC O
I1 NNP NNP O
- : : O
receptors NNS NNS O
. . . O

Changes NNS NNS O
evoked VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
intraperitoneal JJ JJ O
injection NN NN O
of IN IN O
rilmenidine NN NN B-CHEM
( ( ( O
600 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
alpha JJ JJ B-CHEM
- : : I-CHEM
methyldopa NN NN I-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
selective JJ JJ O
I1 NNP NNP O
- : : O
and CC CC O
alpha2 JJ JJ O
- - - O
receptor NN NN O
agonists NNS NNS O
, , , O
respectively RB RB O
, , , O
in IN IN O
blood NN NN O
pressure NN NN O
, , , O
hemodynamic JJ JJ O
variability NN NN O
, , , O
and CC CC O
locomotor NN NN O
activity NN NN O
were VBD VBD O
assessed VBN VBN O
in IN IN O
radiotelemetered VBN VBN O
sham NN NN O
- - - O
operated JJ JJ O
and CC CC O
ovariectomized JJ JJ O
( ( ( O
Ovx NNP NNP O
) ) ) O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
female JJ JJ O
rats NNS NNS O
with IN IN O
or CC CC O
without IN IN O
12 CD CD O
- : : O
wk NN NN O
estrogen NN NN B-CHEM
replacement NN NN O
. . . O

Three CD CD O
time NN NN O
domain NN NN O
indexes NNS NNS O
of IN IN O
hemodynamic JJ JJ O
variability NN NN O
were VBD VBD O
employed VBN VBN O
: : : O
the DT DT O
standard JJ JJ O
deviation NN NN O
of IN IN O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
as IN IN O
a DT DT O
measure NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
variability NN NN O
and CC CC O
the DT DT O
standard JJ JJ O
deviation NN NN O
of IN IN O
beat NN NN O
- - - O
to TO TO O
- - - O
beat NN NN O
intervals NNS NNS O
( ( ( O
SDRR NNP NNP O
) ) ) O
and CC CC O
the DT DT O
root NN NN O
mean NN NN O
square NN NN O
of IN IN O
successive JJ JJ O
differences NNS NNS O
in IN IN O
R NN NN O
- - - O
wave NN NN O
- - - O
to TO TO O
- - - O
R NN NN O
- - - O
wave NN NN O
intervals NNS NNS O
as IN IN O
measures NNS NNS O
of IN IN O
heart NN NN O
rate NN NN O
variability NN NN O
. . . O

In IN IN O
sham NN NN O
- - - O
operated JJ JJ O
rats NNS NNS O
, , , O
rilmenidine NN NN B-CHEM
or CC CC O
alpha NN NN B-CHEM
- - - I-CHEM
methyldopa NN NN I-CHEM
elicited VBD VBD O
similar JJ JJ O
hypotension NN NN O
that WDT WDT O
lasted VBD VBD O
at IN IN O
least JJS JJS O
5 CD CD O
h NN NN O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
reductions NNS NNS O
in IN IN O
standard JJ JJ O
deviation NN NN O
of IN IN O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
. . . O

SDRR NNP NNP O
was VBD VBD O
reduced VBN VBN O
only RB RB O
by IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
methyldopa NN NN I-CHEM
. . . O

Ovx NNP NNP O
significantly RB RB O
enhanced VBD VBD O
the DT DT O
hypotensive JJ JJ O
response NN NN O
to TO TO O
alpha VB VB B-CHEM
- : : I-CHEM
methyldopa NN NN I-CHEM
, , , O
in IN IN O
contrast NN NN O
to TO TO O
no DT DT O
effect NN NN O
on IN IN O
rilmenidine NN NN B-CHEM
hypotension NN NN O
. . . O

The DT DT O
enhanced JJ JJ O
alpha NN NN B-CHEM
- - - I-CHEM
methyldopa NN NN I-CHEM
hypotension NN NN O
in IN IN O
Ovx NNP NNP O
rats NNS NNS O
was VBD VBD O
paralleled VBN VBN O
with IN IN O
further JJ JJ O
reduction NN NN O
in IN IN O
SDRR NNP NNP O
and CC CC O
a DT DT O
reduced JJ JJ O
locomotor NN NN O
activity NN NN O
. . . O

Estrogen NNP NNP O
replacement NN NN O
( ( ( O
17beta CD CD B-CHEM
- : : I-CHEM
estradiol NN NN I-CHEM
subcutaneous JJ JJ O
pellet NN NN O
, , , O
14 CD CD O
. . . O
2 CD CD O
microg NN NN O
/ NN NN O
day NN NN O
, , , O
12 CD CD O
wk NN NN O
) ) ) O
of IN IN O
Ovx NNP NNP O
rats NNS NNS O
restored VBD VBD O
the DT DT O
hemodynamic JJ JJ O
and CC CC O
locomotor NN NN O
effects NNS NNS O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
methyldopa NN NN I-CHEM
to TO TO O
sham VB VB O
- - - O
operated JJ JJ O
levels NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
estrogen NN NN B-CHEM
downregulates NNS NNS O
alpha2 NN NN O
- : : O
but CC CC O
not RB RB O
I1 NNP NNP O
- : : O
receptor NN NN O
- - - O
mediated JJ JJ O
hypotension NN NN O
and CC CC O
highlight VBD VBD O
a DT DT O
role NN NN O
for IN IN O
the DT DT O
cardiac JJ JJ O
autonomic JJ JJ O
control NN NN O
in IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
methyldopa NN NN I-CHEM
- - - O
estrogen NN NN B-CHEM
interaction NN NN O
. . . O

Severe NNP NNP O
reversible JJ JJ O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
dysfunction NN NN O
due JJ JJ O
to TO TO O
accidental JJ JJ O
iatrogenic JJ JJ O
epinephrine NN NN B-CHEM
overdose NN NN O
. . . O

Catecholamine NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
due JJ JJ O
to TO TO O
chronic JJ JJ O
excess NN NN O
of IN IN O
endogenous JJ JJ O
catecholamines NNS NNS B-CHEM
has VBZ VBZ O
been VBN VBN O
recognized VBN VBN O
for IN IN O
decades NNS NNS O
as IN IN O
a DT DT O
clinical JJ JJ O
phenomenon NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
reports NNS NNS O
of IN IN O
myocardial NN NN O
dysfunction NN NN O
due JJ JJ O
to TO TO O
acute JJ JJ O
iatrogenic JJ JJ O
overdose NN NN O
are VBP VBP O
rare JJ JJ O
. . . O

A DT DT O
35 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
whose WP$ WP$ O
cervix NN NN O
uteri NN NN O
was VBD VBD O
inadvertently RB RB O
injected VBN VBN O
with IN IN O
8 CD CD O
mg NN NN O
of IN IN O
epinephrine NN NN B-CHEM
developed VBN VBN O
myocardial JJ JJ O
stunning NN NN O
that WDT WDT O
was VBD VBD O
characterized VBN VBN O
by IN IN O
severe JJ JJ O
hemodynamic JJ JJ O
compromise NN NN O
, , , O
profound NN NN O
, , , O
albeit IN IN O
transient NN NN O
, , , O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
dysfunction NN NN O
, , , O
and CC CC O
only RB RB O
modestly RB RB O
elevated VBD VBD O
biochemical JJ JJ O
markers NNS NNS O
of IN IN O
myocardial JJ JJ O
necrosis NN NN O
. . . O

Our PRP$ PRP$ O
case NN NN O
illustrates VBZ VBZ O
the DT DT O
serious JJ JJ O
consequences NNS NNS O
of IN IN O
medical JJ JJ O
errors NNS NNS O
that WDT WDT O
can MD MD O
be VB VB O
avoided VBN VBN O
through IN IN O
improved VBN VBN O
medication NN NN O
labeling VBG VBG O
and CC CC O
staff NN NN O
supervision NN NN O
. . . O

Cardioprotective NNP NNP O
effect NN NN O
of IN IN O
tincture NN NN B-CHEM
of IN IN I-CHEM
Crataegus NNP NNP I-CHEM
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

Tincture NNP NNP B-CHEM
of IN IN I-CHEM
Crataegus NNP NNP I-CHEM
( ( ( O
TCR NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
alcoholic JJ JJ B-CHEM
extract NN NN I-CHEM
of IN IN I-CHEM
the DT DT I-CHEM
berries NNS NNS I-CHEM
of IN IN I-CHEM
hawthorn NN NN I-CHEM
( ( ( O
Crataegus NNP NNP B-CHEM
oxycantha NN NN I-CHEM
) ) ) O
, , , O
is VBZ VBZ O
used VBN VBN O
in IN IN O
herbal JJ JJ O
and CC CC O
homeopathic JJ JJ O
medicine NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
done VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
TCR NNP NNP B-CHEM
on IN IN O
experimentally RB RB O
induced VBN VBN O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

Pretreatment NNP NNP O
of IN IN O
TCR NNP NNP B-CHEM
, , , O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mL NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
bodyweight NN NN O
per IN IN O
day NN NN O
, , , O
orally RB RB O
for IN IN O
30 CD CD O
days NNS NNS O
, , , O
prevented VBD VBD O
the DT DT O
increase NN NN O
in IN IN O
lipid NN NN O
peroxidation NN NN O
and CC CC O
activity NN NN O
of IN IN O
marker NN NN O
enzymes NNS NNS O
observed VBD VBD O
in IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
rats NNS NNS O
( ( ( O
85 CD CD O
mg NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
for IN IN O
2 CD CD O
days NNS NNS O
at IN IN O
an DT DT O
interval NN NN O
of IN IN O
24 CD CD O
h NN NN O
) ) ) O
. . . O

TCR NNP NNP B-CHEM
prevented VBD VBD O
the DT DT O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
decrease NN NN O
in IN IN O
antioxidant JJ JJ O
enzymes NNS NNS O
in IN IN O
the DT DT O
heart NN NN O
and CC CC O
increased VBD VBD O
the DT DT O
rate NN NN O
of IN IN O
ADP NNP NNP B-CHEM
- - - O
stimulated JJ JJ O
oxygen NN NN B-CHEM
uptake NN NN O
and CC CC O
respiratory JJ JJ O
coupling NN NN O
ratio NN NN O
. . . O

TCR NNP NNP B-CHEM
protected VBN VBN O
against IN IN O
pathological JJ JJ O
changes NNS NNS O
induced VBN VBN O
by IN IN O
isoproterenol NN NN B-CHEM
in IN IN O
rat NN NN O
heart NN NN O
. . . O

The DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
pretreatment NN NN O
with IN IN O
TCR NNP NNP B-CHEM
may MD MD O
be VB VB O
useful JJ JJ O
in IN IN O
preventing VBG VBG O
the DT DT O
damage NN NN O
induced VBN VBN O
by IN IN O
isoproterenol NN NN B-CHEM
in IN IN O
rat NN NN O
heart NN NN O
. . . O

Treatment NN NN O
of IN IN O
tinnitus NN NN O
by IN IN O
intratympanic JJ JJ O
instillation NN NN O
of IN IN O
lignocaine NN NN B-CHEM
( ( ( O
lidocaine NN NN B-CHEM
) ) ) O
2 CD CD O
per IN IN O
cent NN NN O
through IN IN O
ventilation NN NN O
tubes NNS NNS O
. . . O

Idiopathic NNP NNP O
subjective JJ JJ O
tinnitus NN NN O
( ( ( O
IST NNP NNP O
) ) ) O
is VBZ VBZ O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
obscure JJ JJ O
otological JJ JJ O
pathologies NNS NNS O
. . . O

This DT DT O
paper NN NN O
presents VBZ VBZ O
the DT DT O
results NNS NNS O
of IN IN O
treating VBG VBG O
IST NNP NNP O
by IN IN O
intratympanic JJ JJ O
instillation NN NN O
of IN IN O
lignocaine NN NN B-CHEM
( ( ( O
lidocaine NN NN B-CHEM
) ) ) O
2 CD CD O
per IN IN O
cent NN NN O
through IN IN O
a DT DT O
grommet NN NN O
, , , O
for IN IN O
five CD CD O
weekly JJ JJ O
courses NNS NNS O
. . . O

Fifty NNP NNP O
- : : O
two CD CD O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
intractable JJ JJ O
tinnitus NN NN O
entered VBD VBD O
this DT DT O
therapeutic JJ JJ O
trial NN NN O
, , , O
but CC CC O
only RB RB O
nine CD CD O
finished VBD VBD O
all DT DT O
five CD CD O
courses NNS NNS O
. . . O

In IN IN O
one CD CD O
patient NN NN O
, , , O
the DT DT O
tinnitus NN NN O
was VBD VBD O
almost RB RB O
completely RB RB O
abolished VBN VBN O
, , , O
but CC CC O
in IN IN O
all PDT PDT O
the DT DT O
nine CD CD O
patients NNS NNS O
the DT DT O
decompensated VBN VBN O
tinnitus NN NN O
changed VBN VBN O
to TO TO O
a DT DT O
compensated JJ JJ O
one CD CD O
. . . O

We PRP PRP O
suggest VBP VBP O
this DT DT O
mode NN NN O
of IN IN O
treatment NN NN O
for IN IN O
patients NNS NNS O
that WDT WDT O
were VBD VBD O
previously RB RB O
treated VBN VBN O
by IN IN O
drugs NNS NNS O
, , , O
acupuncture NN NN O
and CC CC O
biofeedback NN NN O
, , , O
with IN IN O
disappointing JJ JJ O
results NNS NNS O
. . . O

Patients NNS NNS O
should MD MD O
be VB VB O
warned VBN VBN O
about IN IN O
the DT DT O
side NN NN O
effects NNS NNS O
of IN IN O
vertigo NN NN O
and CC CC O
vomiting VBG VBG O
, , , O
which WDT WDT O
subsides NNS NNS O
gradually RB RB O
with IN IN O
every DT DT O
new JJ JJ O
instillation NN NN O
, , , O
and CC CC O
that IN IN O
the DT DT O
tinnitus NN NN O
may MD MD O
not RB RB O
disappear VB VB O
but CC CC O
will MD MD O
be VB VB O
alleviated VBN VBN O
, , , O
enabling VBG VBG O
them PRP PRP O
to TO TO O
cope VB VB O
more RBR RBR O
easily RB RB O
with IN IN O
the DT DT O
disease NN NN O
and CC CC O
lead VB VB O
a DT DT O
more RBR RBR O
normal JJ JJ O
life NN NN O
. . . O

The DT DT O
alpha3 NN NN O
and CC CC O
beta4 NN NN O
nicotinic JJ JJ O
acetylcholine NN NN B-CHEM
receptor NN NN O
subunits NNS NNS O
are VBP VBP O
necessary JJ JJ O
for IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
hypolocomotion NN NN O
in IN IN O
mice NN NN O
. . . O

Binding NNP NNP O
of IN IN O
nicotine NN NN B-CHEM
to TO TO O
nicotinic JJ JJ O
acetylcholine NN NN B-CHEM
receptors NNS NNS O
( ( ( O
nAChRs NN NN O
) ) ) O
elicits VBZ VBZ O
a DT DT O
series NN NN O
of IN IN O
dose NN NN O
- - - O
dependent JJ JJ O
behaviors NNS NNS O
that WDT WDT O
go VBP VBP O
from IN IN O
altered JJ JJ O
exploration NN NN O
, , , O
sedation NN NN O
, , , O
and CC CC O
tremors NNS NNS O
, , , O
to TO TO O
seizures NNS NNS O
and CC CC O
death NN NN O
. . . O

nAChRs NN NN O
are VBP VBP O
pentameric JJ JJ O
ion NN NN O
channels NNS NNS O
usually RB RB O
composed VBN VBN O
of IN IN O
alpha NN NN O
and CC CC O
beta NN NN O
subunits NNS NNS O
. . . O

A DT DT O
gene NN NN O
cluster NN NN O
comprises VBZ VBZ O
the DT DT O
alpha3 NN NN O
, , , O
alpha5 NN NN O
and CC CC O
beta4 NN NN O
subunits NNS NNS O
, , , O
which WDT WDT O
coassemble JJ JJ O
to TO TO O
form VB VB O
functional JJ JJ O
receptors NNS NNS O
. . . O

We PRP PRP O
examined VBD VBD O
the DT DT O
role NN NN O
of IN IN O
the DT DT O
beta4 NN NN O
subunits NNS NNS O
in IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
hypolocomotion NN NN O
in IN IN O
beta4 NN NN O
homozygous JJ JJ O
null NN NN O
( ( ( O
beta4 NN NN O
- - - O
/ NN NN O
- : : O
) ) ) O
and CC CC O
alpha3 NN NN O
heterozygous JJ JJ O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
. . . O

beta4 NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
were VBD VBD O
less RBR RBR O
sensitive JJ JJ O
to TO TO O
the DT DT O
effects NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
both DT DT O
at IN IN O
low JJ JJ O
doses NNS NNS O
, , , O
measured VBN VBN O
as IN IN O
decreased VBN VBN O
exploration NN NN O
in IN IN O
an DT DT O
open JJ JJ O
field NN NN O
, , , O
and CC CC O
at IN IN O
high JJ JJ O
doses NNS NNS O
, , , O
measured VBN VBN O
as IN IN O
sensitivity NN NN O
to TO TO O
nicotine VB VB B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
. . . O

Using VBG VBG O
in IN IN O
situ NN NN O
hybridization NN NN O
probes NNS NNS O
for IN IN O
the DT DT O
alpha3 NN NN O
and CC CC O
alpha5 NN NN O
subunits NNS NNS O
, , , O
we PRP PRP O
showed VBD VBD O
that IN IN O
alpha5 NN NN O
mRNA NN NN O
levels NNS NNS O
are VBP VBP O
unchanged JJ JJ O
, , , O
whereas IN IN O
alpha3 NN NN O
mRNA NN NN O
levels NNS NNS O
are VBP VBP O
selectively RB RB O
decreased VBN VBN O
in IN IN O
the DT DT O
mitral JJ JJ O
cell NN NN O
layer NN NN O
of IN IN O
the DT DT O
olfactory NN NN O
bulb NN NN O
, , , O
and CC CC O
the DT DT O
inferior JJ JJ O
and CC CC O
the DT DT O
superior JJ JJ O
colliculus NN NN O
of IN IN O
beta4 NN NN O
- - - O
/ NN NN O
- - - O
brains NNS NNS O
. . . O

alpha3 NN NN O
+ NN NN O
/ NN NN O
- : : O
mice NN NN O
were VBD VBD O
partially RB RB O
resistant JJ JJ O
to TO TO O
nicotine VB VB B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
when WRB WRB O
compared VBN VBN O
to TO TO O
wild JJ JJ O
- - - O
type NN NN O
littermates NNS NNS O
. . . O

mRNA NN NN O
levels NNS NNS O
for IN IN O
the DT DT O
alpha5 NN NN O
and CC CC O
the DT DT O
beta4 NN NN O
subunits NNS NNS O
were VBD VBD O
unchanged JJ JJ O
in IN IN O
alpha3 NN NN O
+ NN NN O
/ NN NN O
- : : O
brains NNS NNS O
. . . O

Together RB RB O
, , , O
these DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
beta4 NN NN O
and CC CC O
the DT DT O
alpha3 NN NN O
subunits NNS NNS O
are VBP VBP O
mediators NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
hypolocomotion NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
sevoflurane NN NN B-CHEM
on IN IN O
lidocaine NN NN B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
. . . O

The DT DT O
influence NN NN O
of IN IN O
sevoflurane NN NN B-CHEM
on IN IN O
lidocaine NN NN B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
was VBD VBD O
studied VBN VBN O
in IN IN O
cats NNS NNS O
. . . O

The DT DT O
convulsive JJ JJ O
threshold NN NN O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
was VBD VBD O
41 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
5 CD CD O
mg NN NN O
. . . O

l NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
with IN IN O
lidocaine NN NN B-CHEM
infusion NN NN O
( ( ( O
6 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
min NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
, , , O
increasing VBG VBG O
significantly RB RB O
to TO TO O
66 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
. . . O
9 CD CD O
mg NN NN O
. . . O

l NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
when WRB WRB O
the DT DT O
end NN NN O
- - - O
tidal JJ JJ O
concentration NN NN O
of IN IN O
sevoflurane NN NN B-CHEM
was VBD VBD O
0 CD CD O
. . . O
8 CD CD O
% NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
threshold NN NN O
( ( ( O
61 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
7 CD CD O
mg NN NN O
. . . O
l NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
during IN IN O
1 CD CD O
. . . O
6 CD CD O
% NN NN O
sevoflurane NN NN B-CHEM
was VBD VBD O
not RB RB O
significant JJ JJ O
from IN IN O
that DT DT O
during IN IN O
0 CD CD O
. . . O
8 CD CD O
% NN NN O
sevoflurane NN NN B-CHEM
, , , O
indicating VBG VBG O
a DT DT O
celling VBG VBG O
effect NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
the DT DT O
convulsive JJ JJ O
threshold NN NN O
between IN IN O
sevoflurane NN NN B-CHEM
and CC CC O
enflurane NN NN B-CHEM
. . . O

The DT DT O
rise NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
became VBD VBD O
less RBR RBR O
marked JJ JJ O
when WRB WRB O
higher JJR JJR O
concentrations NNS NNS O
of IN IN O
sevoflurane NN NN B-CHEM
or CC CC O
enflurane NN NN B-CHEM
were VBD VBD O
administered VBN VBN O
and CC CC O
the DT DT O
blood NN NN O
pressure NN NN O
at IN IN O
convulsions NNS NNS O
decreased VBN VBN O
significantly RB RB O
in IN IN O
1 CD CD O
. . . O
6 CD CD O
% NN NN O
sevoflurane NN NN B-CHEM
, , , O
and CC CC O
in IN IN O
0 CD CD O
. . . O
8 CD CD O
% NN NN O
and CC CC O
1 CD CD O
. . . O
6 CD CD O
% NN NN O
enflurane NN NN B-CHEM
. . . O

However RB RB O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
the DT DT O
lidocaine NN NN B-CHEM
concentrations NNS NNS O
measured VBN VBN O
when WRB WRB O
the DT DT O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
became VBD VBD O
70 CD CD O
mmHg NN NN O
. . . O

Apamin NNP NNP B-CHEM
, , , O
a DT DT O
selective JJ JJ O
blocker NN NN O
of IN IN O
calcium NN NN B-CHEM
- - - O
dependent JJ JJ O
potassium NN NN B-CHEM
channels NNS NNS O
, , , O
was VBD VBD O
administered VBN VBN O
intracerebroventricularly RB RB O
in IN IN O
rats NNS NNS O
anesthetized VBN VBN O
with IN IN O
0 CD CD O
. . . O
8 CD CD O
% NN NN O
sevoflurane NN NN B-CHEM
to TO TO O
investigate VB VB O
the DT DT O
mechanism NN NN O
of IN IN O
the DT DT O
anticonvulsive JJ JJ O
effects NNS NNS O
. . . O

Apamin NNP NNP B-CHEM
( ( ( O
10 CD CD O
ng NN NN O
) ) ) O
had VBD VBD O
a DT DT O
tendency NN NN O
to TO TO O
decrease VB VB O
the DT DT O
convulsive JJ JJ O
threshold NN NN O
( ( ( O
21 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
2 CD CD O
to TO TO O
19 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
. . . O
l NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
but CC CC O
this DT DT O
was VBD VBD O
not RB RB O
statistically RB RB O
significant JJ JJ O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
sevoflurane NN NN B-CHEM
reduces VBZ VBZ O
the DT DT O
convulsive JJ JJ O
effect NN NN O
of IN IN O
lidocaine NN NN B-CHEM
toxicity NN NN O
but CC CC O
carries VBZ VBZ O
some DT DT O
risk NN NN O
due JJ JJ O
to TO TO O
circulatory JJ JJ O
depression NN NN O
. . . O

Cardiac NNP NNP O
toxicity NN NN O
observed VBD VBD O
in IN IN O
association NN NN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
cyclophosphamide NN NN B-CHEM
- - - O
based JJ JJ O
chemotherapy NN NN O
for IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Cyclophosphamide NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
alkylating VBG VBG O
agent NN NN O
given VBN VBN O
frequently RB RB O
as IN IN O
a DT DT O
component NN NN O
of IN IN O
many JJ JJ O
conditioning NN NN O
regimens NNS NNS O
. . . O

In IN IN O
high JJ JJ O
doses NNS NNS O
, , , O
its PRP$ PRP$ O
nonhematological JJ JJ O
dose NN NN O
- - - O
limiting VBG VBG O
toxicity NN NN O
is VBZ VBZ O
cardiomyopathy JJ JJ O
. . . O

STUDY NNP NNP O
DESIGN NNP NNP O
: : : O
We PRP PRP O
combined VBD VBD O
paclitaxel NN NN B-CHEM
, , , O
melphalan NN NN B-CHEM
and CC CC O
high JJ JJ O
- - - O
dose NN NN O
cyclophosphamide NN NN B-CHEM
, , , O
thiotepa NN NN B-CHEM
, , , O
and CC CC O
carboplatin NN NN B-CHEM
in IN IN O
a DT DT O
triple JJ JJ O
sequential JJ JJ O
high JJ JJ O
- - - O
dose NN NN O
regimen NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
. . . O

Analysis NNP NNP O
was VBD VBD O
performed VBN VBN O
on IN IN O
61 CD CD O
women NNS NNS O
with IN IN O
chemotherapy NN NN O
- - - O
responsive JJ JJ O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
receiving VBG VBG O
96 CD CD O
- : : O
h NN NN O
infusional JJ JJ O
cyclophosphamide NN NN B-CHEM
as IN IN O
part NN NN O
of IN IN O
a DT DT O
triple JJ JJ O
sequential JJ JJ O
high JJ JJ O
- - - O
dose NN NN O
regimen NN NN O
to TO TO O
assess VB VB O
association NN NN O
between IN IN O
presence NN NN O
of IN IN O
peritransplant NN NN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
( ( ( O
CHF NNP NNP O
) ) ) O
and CC CC O
the DT DT O
following VBG VBG O
pretreatment NN NN O
characteristics NNS NNS O
: : : O
presence NN NN O
of IN IN O
electrocardiogram NN NN O
( ( ( O
EKG NNP NNP O
) ) ) O
abnormalities NNS NNS O
, , , O
age NN NN O
, , , O
hypertension NN NN O
, , , O
prior RB RB O
cardiac JJ JJ O
history NN NN O
, , , O
smoking NN NN O
, , , O
diabetes NN NN O
mellitus NN NN O
, , , O
prior JJ JJ O
use NN NN O
of IN IN O
anthracyclines NNS NNS B-CHEM
, , , O
and CC CC O
left VBD VBD O
- : : O
sided JJ JJ O
chest NN NN O
irradiation NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Six CD CD O
of IN IN O
61 CD CD O
women NNS NNS O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
clinically RB RB O
reversible JJ JJ O
grade NN NN O
3 CD CD O
CHF NNP NNP O
following VBG VBG O
infusional JJ JJ O
cyclophosphamide NN NN B-CHEM
with IN IN O
a DT DT O
median JJ JJ O
percent NN NN O
decline NN NN O
in IN IN O
ejection NN NN O
fraction NN NN O
of IN IN O
31 CD CD O
% NN NN O
. . . O

Incidence NNP NNP O
of IN IN O
transient NN NN O
cyclophosphamide NN NN B-CHEM
- - - O
related VBN VBN O
cardiac NN NN O
toxicity NN NN O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
is VBZ VBZ O
comparable JJ JJ O
to TO TO O
previous JJ JJ O
recorded JJ JJ O
literature NN NN O
. . . O

Older JJR JJR O
age NN NN O
was VBD VBD O
significantly RB RB O
correlated JJ JJ O
with IN IN O
the DT DT O
CHF NNP NNP O
development NN NN O
; : : O
with IN IN O
median JJ JJ O
ages NNS NNS O
for IN IN O
the DT DT O
entire JJ JJ O
group NN NN O
and CC CC O
for IN IN O
patients NNS NNS O
developing VBG VBG O
CHF NNP NNP O
of IN IN O
45 CD CD O
and CC CC O
59 CD CD O
, , , O
respectively RB RB O
. . . O

No DT DT O
association NN NN O
was VBD VBD O
found VBN VBN O
with IN IN O
other JJ JJ O
pretreatment JJ JJ O
characteristics NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
As IN IN O
a DT DT O
result NN NN O
of IN IN O
these DT DT O
findings NNS NNS O
, , , O
oncologists NNS NNS O
should MD MD O
carefully RB RB O
monitor VB VB O
fluid JJ JJ O
balance NN NN O
in IN IN O
older JJR JJR O
patients NNS NNS O
. . . O

Routine NNP NNP O
EKG NNP NNP O
monitoring VBG VBG O
during IN IN O
infusional JJ JJ O
cyclophosphamide NN NN B-CHEM
did VBD VBD O
not RB RB O
predict VB VB O
CHF NNP NNP O
development NN NN O
. . . O

Tremor NNP NNP O
side NN NN O
effects NNS NNS O
of IN IN O
salbutamol NN NN B-CHEM
, , , O
quantified VBN VBN O
by IN IN O
a DT DT O
laser NN NN O
pointer NN NN O
technique NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
study VB VB O
tremor NN NN O
side NN NN O
effects NNS NNS O
of IN IN O
salbutamol NN NN B-CHEM
an DT DT O
easily RB RB O
applicable JJ JJ O
, , , O
quick JJ JJ O
and CC CC O
low JJ JJ O
- - - O
priced JJ JJ O
method NN NN O
is VBZ VBZ O
needed VBN VBN O
. . . O

A DT DT O
new JJ JJ O
method NN NN O
using VBG VBG O
a DT DT O
commercially RB RB O
available JJ JJ O
, , , O
pen NN NN O
- - - O
shaped VBN VBN O
laser NN NN O
pointer NN NN O
was VBD VBD O
developed VBN VBN O
. . . O

Aim NNP NNP O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
sensitivity NN NN O
, , , O
reproducibility NN NN O
, , , O
reference NN NN O
values NNS NNS O
and CC CC O
the DT DT O
agreement NN NN O
with IN IN O
a DT DT O
questionnaire NN NN O
. . . O

METHODS NNP NNP O
: : : O
Tremor NNP NNP O
was VBD VBD O
measured VBN VBN O
using VBG VBG O
a DT DT O
laser NN NN O
pointer NN NN O
technique NN NN O
. . . O

To TO TO O
determine VB VB O
sensitivity NN NN O
we PRP PRP O
assessed VBD VBD O
tremor NN NN O
in IN IN O
44 CD CD O
patients NNS NNS O
with IN IN O
obstructive JJ JJ O
lung NN NN O
disease NN NN O
after IN IN O
administration NN NN O
of IN IN O
cumulative JJ JJ O
doses NNS NNS O
of IN IN O
salbutamol NN NN B-CHEM
. . . O

Subjects NNP NNP O
were VBD VBD O
asked VBN VBN O
to TO TO O
aim NN NN O
at IN IN O
the DT DT O
centre NN NN O
of IN IN O
a DT DT O
target NN NN O
, , , O
subdivided VBD VBD O
in IN IN O
concentric JJ JJ O
circles NNS NNS O
, , , O
from IN IN O
5 CD CD O
m NN NN O
distance NN NN O
. . . O

The DT DT O
circle NN NN O
in IN IN O
which WDT WDT O
the DT DT O
participant NN NN O
succeeded VBD VBD O
to TO TO O
aim VB VB O
was VBD VBD O
recorded VBN VBN O
in IN IN O
millimetres NNS NNS O
radius NN NN O
. . . O

In IN IN O
another DT DT O
series NN NN O
of IN IN O
measurements NNS NNS O
, , , O
reproducibility NN NN O
and CC CC O
reference NN NN O
values NNS NNS O
of IN IN O
the DT DT O
tremor NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
65 CD CD O
healthy JJ JJ O
subjects NNS NNS O
in IN IN O
three CD CD O
sessions NNS NNS O
, , , O
at IN IN O
9 CD CD O
a DT DT O
. . . O
m NN NN O
. . . O
, , , O
4 CD CD O
p NN NN O
. . . O
m NN NN O
. . . O
and CC CC O
9 CD CD O
a DT DT O
. . . O
m NN NN O
. . . O
, , , O
respectively RB RB O
, , , O
1 CD CD O
week NN NN O
later RB RB O
. . . O

Postural NNP NNP O
tremor NN NN O
was VBD VBD O
measured VBN VBN O
with IN IN O
the DT DT O
arm NN NN O
horizontally RB RB O
outstretched JJ JJ O
rest NN NN O
tremor NN NN O
with IN IN O
the DT DT O
arm NN NN O
supported VBN VBN O
by IN IN O
an DT DT O
armrest NN NN O
and CC CC O
finally RB RB O
tremor NN NN O
was VBD VBD O
measured VBN VBN O
after IN IN O
holding VBG VBG O
a DT DT O
2 CD CD O
- : : O
kg NN NN O
weight NN NN O
until IN IN O
exhaustion NN NN O
. . . O

Inter NNP NNP O
- : : O
observer NN NN O
variability NN NN O
was VBD VBD O
measured VBN VBN O
in IN IN O
a DT DT O
series NN NN O
of IN IN O
10 CD CD O
healthy JJ JJ O
subjects NNS NNS O
. . . O

Tremor NNP NNP O
was VBD VBD O
measured VBN VBN O
simultaneously RB RB O
by IN IN O
two CD CD O
independent JJ JJ O
observers NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Salbutamol NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
tremor NN NN O
severity NN NN O
in IN IN O
patients NNS NNS O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
way NN NN O
. . . O

Within IN IN O
healthy JJ JJ O
adults NNS NNS O
no DT DT O
age NN NN O
- - - O
dependency NN NN O
could MD MD O
be VB VB O
found VBN VBN O
( ( ( O
b SYM SYM O
= SYM SYM O
0 CD CD O
. . . O
262 CD CD O
mm NN NN O
/ NN NN O
year NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
72 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
agreement NN NN O
between IN IN O
the DT DT O
questionnaire NN NN O
and CC CC O
tremor NN NN O
severity NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
093 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
53 CD CD O
) ) ) O
. . . O

Postural NNP NNP O
tremor NN NN O
showed VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
between IN IN O
the DT DT O
first JJ JJ O
and CC CC O
third JJ JJ O
session NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
07 CD CD O
) ) ) O
. . . O

Support NN NN O
of IN IN O
the DT DT O
arm NN NN O
decreased VBD VBD O
tremor NN NN O
severity NN NN O
, , , O
exhaustion NN NN O
increased VBN VBN O
tremor NN NN O
severity NN NN O
significantly RB RB O
. . . O

A DT DT O
good JJ JJ O
agreement NN NN O
was VBD VBD O
found VBN VBN O
between IN IN O
two CD CD O
independent JJ JJ O
observers NNS NNS O
( ( ( O
interclass NN NN O
correlation NN NN O
coefficient NN NN O
0 CD CD O
. . . O
72 CD CD O
) ) ) O
. . . O

DISCUSSION NNP NNP O
: : : O
Quantifying VBG VBG O
tremor NN NN O
by IN IN O
using VBG VBG O
an DT DT O
inexpensive JJ JJ O
laser NN NN O
pointer NN NN O
is VBZ VBZ O
, , , O
with IN IN O
the DT DT O
exception NN NN O
of IN IN O
children NNS NNS O
( ( ( O
< NN NN O
12 CD CD O
years NNS NNS O
) ) ) O
a DT DT O
sensitive JJ JJ O
and CC CC O
reproducible JJ JJ O
method NN NN O
. . . O

Safety NNP NNP O
and CC CC O
adverse JJ JJ O
effects NNS NNS O
associated VBN VBN O
with IN IN O
raloxifene NN NN B-CHEM
: : : O
multiple JJ JJ O
outcomes NNS NNS O
of IN IN O
raloxifene NN NN B-CHEM
evaluation NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
examine VB VB O
the DT DT O
effect NN NN O
of IN IN O
raloxifene NN NN B-CHEM
on IN IN O
major JJ JJ O
adverse JJ JJ O
events NNS NNS O
that WDT WDT O
occur VBP VBP O
with IN IN O
postmenopausal NN NN O
estrogen NN NN B-CHEM
therapy NN NN O
or CC CC O
tamoxifen NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
Multiple NNP NNP O
Outcomes NNP NNP O
of IN IN O
Raloxifene NNP NNP B-CHEM
Evaluation NNP NNP O
, , , O
a DT DT O
multicenter NN NN O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
, , , O
enrolled VBD VBD O
7 CD CD O
, , , O
705 CD CD O
postmenopausal NN NN O
women NNS NNS O
with IN IN O
osteoporosis NN NN O
. . . O

Women NNP NNP O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
raloxifene NN NN B-CHEM
60 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
or CC CC O
120 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
or CC CC O
placebo NN NN O
. . . O

Outcomes NNP NNP O
included VBD VBD O
venous JJ JJ O
thromboembolism NN NN O
, , , O
cataracts NNS NNS O
, , , O
gallbladder NN NN O
disease NN NN O
, , , O
and CC CC O
endometrial JJ JJ O
hyperplasia NN NN O
or CC CC O
cancer NN NN O
. . . O

RESULTS NNS NNS O
: : : O
During IN IN O
a DT DT O
mean JJ JJ O
follow VB VB O
- - - O
up RP RP O
of IN IN O
3 CD CD O
. . . O
3 CD CD O
years NNS NNS O
, , , O
raloxifene NN NN B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
for IN IN O
venous JJ JJ O
thromboembolism NN NN O
( ( ( O
relative JJ JJ O
risk NN NN O
[ NN NN O
RR NNP NNP O
] NN NN O
2 CD CD O
. . . O
1 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
1 CD CD O
. . . O
2 CD CD O
- : : O
3 CD CD O
. . . O
8 CD CD O
) ) ) O
. . . O

The DT DT O
excess JJ JJ O
event NN NN O
rate NN NN O
was VBD VBD O
1 CD CD O
. . . O
8 CD CD O
per IN IN O
1 CD CD O
, , , O
000 CD CD O
woman NN NN O
- : : O
years NNS NNS O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
- : : O
0 CD CD O
. . . O
5 CD CD O
- : : O
4 CD CD O
. . . O
1 CD CD O
) ) ) O
, , , O
and CC CC O
the DT DT O
number NN NN O
needed VBN VBN O
to TO TO O
treat VB VB O
to TO TO O
cause VB VB O
1 CD CD O
event NN NN O
was VBD VBD O
170 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
100 CD CD O
- : : O
582 CD CD O
) ) ) O
over IN IN O
3 CD CD O
. . . O
3 CD CD O
years NNS NNS O
. . . O

Risk NN NN O
in IN IN O
the DT DT O
raloxifene NN NN B-CHEM
group NN NN O
was VBD VBD O
higher JJR JJR O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
for IN IN O
the DT DT O
first JJ JJ O
2 CD CD O
years NNS NNS O
, , , O
but CC CC O
decreased VBD VBD O
to TO TO O
about IN IN O
the DT DT O
same JJ JJ O
rate NN NN O
as IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
thereafter RB RB O
. . . O

Raloxifene NNP NNP B-CHEM
did VBD VBD O
not RB RB O
increase VB VB O
risk NN NN O
for IN IN O
cataracts NNS NNS O
( ( ( O
RR NNP NNP O
0 CD CD O
. . . O
9 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
8 CD CD O
- : : O
1 CD CD O
. . . O
1 CD CD O
) ) ) O
, , , O
gallbladder NN NN O
disease NN NN O
( ( ( O
RR NNP NNP O
1 CD CD O
. . . O
0 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
7 CD CD O
- : : O
1 CD CD O
. . . O
3 CD CD O
) ) ) O
, , , O
endometrial JJ JJ O
hyperplasia NN NN O
( ( ( O
RR NNP NNP O
1 CD CD O
. . . O
3 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
4 CD CD O
- : : O
5 CD CD O
. . . O
1 CD CD O
) ) ) O
, , , O
or CC CC O
endometrial JJ JJ O
cancer NN NN O
( ( ( O
RR NNP NNP O
0 CD CD O
. . . O
9 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
3 CD CD O
- : : O
2 CD CD O
. . . O
7 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Raloxifene NNP NNP B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
for IN IN O
venous JJ JJ O
thromboembolism NN NN O
, , , O
but CC CC O
there EX EX O
was VBD VBD O
no DT DT O
increased JJ JJ O
risk NN NN O
for IN IN O
cataracts NNS NNS O
, , , O
gallbladder NN NN O
disease NN NN O
, , , O
endometrial JJ JJ O
hyperplasia NN NN O
, , , O
or CC CC O
endometrial JJ JJ O
cancer NN NN O
. . . O

LEVEL NNP NNP O
OF IN IN O
EVIDENCE NN NN O
: : : O
I PRP PRP O

Optimization NNP NNP O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
. . . O

While IN IN O
there EX EX O
is VBZ VBZ O
no DT DT O
single JJ JJ O
correct JJ JJ O
starting NN NN O
dose NN NN O
for IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
, , , O
many JJ JJ O
individuals NNS NNS O
can MD MD O
be VB VB O
started VBN VBN O
on IN IN O
either CC CC O
the DT DT O
25 CD CD O
/ NN NN O
100 CD CD O
or CC CC O
controlled JJ JJ O
- : : O
release NN NN O
formula NN NN O
, , , O
following VBG VBG O
the DT DT O
general JJ JJ O
rule NN NN O
not RB RB O
to TO TO O
attempt VB VB O
to TO TO O
titrate VB VB O
carbidopa NN NN B-CHEM
- : : O
levodopa NN NN B-CHEM
to TO TO O
the DT DT O
point NN NN O
of IN IN O
" '' '' O
normality NN NN O
, , , O
" '' '' O
which WDT WDT O
can MD MD O
lead VB VB O
to TO TO O
toxicity NN NN O
. . . O

The DT DT O
physician NN NN O
should MD MD O
also RB RB O
determine VB VB O
the DT DT O
proper JJ JJ O
use NN NN O
of IN IN O
any DT DT O
adjunctive JJ JJ O
medications NNS NNS O
; : : O
such JJ JJ O
combined VBN VBN O
therapy NN NN O
has VBZ VBZ O
become VBN VBN O
the DT DT O
standard JJ JJ O
approach NN NN O
to TO TO O
treatment NN NN O
. . . O

Following VBG VBG O
the DT DT O
initial JJ JJ O
period NN NN O
of IN IN O
therapy NN NN O
, , , O
emerging VBG VBG O
difficulties NNS NNS O
require VBP VBP O
a DT DT O
reassessment NN NN O
of IN IN O
therapeutic JJ JJ O
approaches NNS NNS O
, , , O
such JJ JJ O
as IN IN O
dosage NN NN O
adjustment NN NN O
or CC CC O
introduction NN NN O
of IN IN O
a DT DT O
dopamine NN NN B-CHEM
agonist NN NN O
. . . O

Other JJ JJ O
possible JJ JJ O
adverse JJ JJ O
effects NNS NNS O
- - - O
- - - O
such JJ JJ O
as IN IN O
gastrointestinal JJ JJ O
disorders NNS NNS O
, , , O
orthostatic JJ JJ O
hypotension NN NN O
, , , O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
psychosis NN NN O
, , , O
sleep VB VB O
disturbances NNS NNS O
or CC CC O
parasomnias NNS NNS O
, , , O
or CC CC O
drug NN NN O
interactions NNS NNS O
- - - O
- - - O
also RB RB O
require VB VB O
carefully RB RB O
monitored VBN VBN O
individual JJ JJ O
treatment NN NN O
. . . O

Nonpharmacologic NNP NNP O
concerns NNS NNS O
can MD MD O
help VB VB O
the DT DT O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patient NN NN O
achieve NN NN O
and CC CC O
maintain VB VB O
optimal NN NN O
functioning NN NN O
, , , O
including VBG VBG O
daily JJ JJ O
exercise NN NN O
, , , O
physical JJ JJ O
therapy NN NN O
, , , O
and CC CC O
involvement NN NN O
with IN IN O
support NN NN O
groups NNS NNS O
. . . O

Long NNP NNP O
term NN NN O
audiological JJ JJ O
evaluation NN NN O
of IN IN O
beta NN NN O
- - - O
thalassemic JJ JJ O
patients NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
identify VB VB O
the DT DT O
incidence NN NN O
and CC CC O
to TO TO O
monitor VB VB O
the DT DT O
progression NN NN O
of IN IN O
hearing NN NN O
loss NN NN O
in IN IN O
children NNS NNS O
and CC CC O
young JJ JJ O
adults NNS NNS O
with IN IN O
beta NN NN O
- - - O
thalassemia NN NN O
major JJ JJ O
. . . O

METHODS NNP NNP O
: : : O
One CD CD O
hundred CD CD O
and CC CC O
four CD CD O
( ( ( O
104 CD CD O
) ) ) O
patients NNS NNS O
aged VBN VBN O
6 CD CD O
- : : O
35 CD CD O
years NNS NNS O
( ( ( O
mean NN NN O
17 CD CD O
, , , O
2 CD CD O
years NNS NNS O
) ) ) O
participated VBN VBN O
in IN IN O
the DT DT O
study NN NN O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
on IN IN O
a DT DT O
regular JJ JJ O
transfusion NN NN O
- - - O
chelation NN NN O
program NN NN O
maintaining VBG VBG O
a DT DT O
mean JJ JJ O
hemoglobin NN NN O
level NN NN O
of IN IN O
9 CD CD O
. . . O
5 CD CD O
gr NN NN O
/ NN NN O
dl NN NN O
. . . O

Subjects NNP NNP O
were VBD VBD O
receiving VBG VBG O
desferrioxamine NN NN B-CHEM
( ( ( O
DFO NNP NNP B-CHEM
) ) ) O
chelation NN NN O
treatment NN NN O
with IN IN O
a DT DT O
mean JJ JJ O
daily JJ JJ O
dose NN NN O
of IN IN O
50 CD CD O
- : : O
60 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
5 CD CD O
- : : O
6 CD CD O
days NNS NNS O
a DT DT O
week NN NN O
during IN IN O
the DT DT O
first JJ JJ O
six CD CD O
years NNS NNS O
of IN IN O
the DT DT O
study NN NN O
, , , O
which WDT WDT O
was VBD VBD O
then RB RB O
reduced VBN VBN O
to TO TO O
40 CD CD O
- : : O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
the DT DT O
following VBG VBG O
eight CD CD O
years NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
followed VBN VBN O
for IN IN O
8 CD CD O
- : : O
14 CD CD O
years NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Overall NNP NNP O
, , , O
21 CD CD O
out IN IN O
of IN IN O
104 CD CD O
patients NNS NNS O
( ( ( O
20 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
presented VBN VBN O
with IN IN O
high JJ JJ O
frequency NN NN O
sensorineural JJ JJ O
hearing NN NN O
loss NN NN O
( ( ( O
SNHL NNP NNP O
) ) ) O
, , , O
either CC CC O
unilateral JJ JJ O
or CC CC O
bilateral JJ JJ O
. . . O

No DT DT O
ototoxic NN NN O
factor NN NN O
, , , O
other JJ JJ O
than IN IN O
DFO NNP NNP B-CHEM
, , , O
was VBD VBD O
present JJ JJ O
in IN IN O
any DT DT O
of IN IN O
the DT DT O
patients NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
SNHL NNP NNP O
presented VBD VBD O
with IN IN O
relatively RB RB O
lower JJR JJR O
serum NN NN O
ferritin NN NN O
levels NNS NNS O
than IN IN O
those DT DT O
with IN IN O
normal JJ JJ O
hearing NN NN O
, , , O
however RB RB O
, , , O
no DT DT O
statistically RB RB O
significant JJ JJ O
difference NN NN O
was VBD VBD O
observed VBN VBN O
. . . O

Subjects NNP NNP O
with IN IN O
SNHL NNP NNP O
were VBD VBD O
submitted VBN VBN O
to TO TO O
DFO NNP NNP B-CHEM
reduction NN NN O
or CC CC O
temporary JJ JJ O
withdrawal NN NN O
. . . O

Following VBG VBG O
intervention NN NN O
, , , O
7 CD CD O
out IN IN O
of IN IN O
21 CD CD O
affected VBN VBN O
patients NNS NNS O
recovered VBN VBN O
, , , O
10 CD CD O
remained VBD VBD O
stable JJ JJ O
and CC CC O
4 CD CD O
demonstrated JJ JJ O
aggravation NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
findings NNS NNS O
are VBP VBP O
indicative JJ JJ O
of IN IN O
DFO NNP NNP B-CHEM
' POS POS O
s VBZ VBZ O
contributing VBG VBG O
role NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
hearing NN NN O
impairment NN NN O
. . . O

Regular JJ JJ O
audiologic JJ JJ O
evaluation NN NN O
is VBZ VBZ O
imperative JJ JJ O
in IN IN O
all DT DT O
thalassemic JJ JJ O
patients NNS NNS O
so IN IN O
that IN IN O
early JJ JJ O
changes NNS NNS O
may MD MD O
be VB VB O
recognized VBN VBN O
and CC CC O
treatment NN NN O
may MD MD O
be VB VB O
judiciously RB RB O
adjusted VBN VBN O
in IN IN O
order NN NN O
to TO TO O
prevent VB VB O
or CC CC O
reverse VB VB O
hearing VBG VBG O
impairment NN NN O
. . . O

Individual JJ JJ O
differences NNS NNS O
in IN IN O
renal JJ JJ O
ACE NNP NNP O
activity NN NN O
in IN IN O
healthy JJ JJ O
rats NNS NNS O
predict VBP VBP O
susceptibility NN NN O
to TO TO O
adriamycin VB VB B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
damage NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
In IN IN O
man NN NN O
, , , O
differences NNS NNS O
in IN IN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
( ( ( O
ACE NNP NNP O
) ) ) O
levels NNS NNS O
, , , O
related VBN VBN O
to TO TO O
ACE NNP NNP O
( ( ( O
I NN NN O
/ NN NN O
D NNP NNP O
) ) ) O
genotype NN NN O
, , , O
are VBP VBP O
associated VBN VBN O
with IN IN O
renal JJ JJ O
prognosis NN NN O
. . . O

This DT DT O
raises VBZ VBZ O
the DT DT O
hypothesis NNS NNS O
that IN IN O
individual JJ JJ O
differences NNS NNS O
in IN IN O
renal JJ JJ O
ACE NNP NNP O
activity NN NN O
are VBP VBP O
involved VBN VBN O
in IN IN O
renal JJ JJ O
susceptibility NN NN O
to TO TO O
inflicted JJ JJ O
damage NN NN O
. . . O

Therefore RB RB O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
predictive JJ JJ O
effect NN NN O
of IN IN O
renal JJ JJ O
ACE NNP NNP O
activity NN NN O
for IN IN O
the DT DT O
severity NN NN O
of IN IN O
renal JJ JJ O
damage NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
adriamycin NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Renal NNP NNP O
ACE NNP NNP O
activity NN NN O
( ( ( O
Hip NNP NNP B-CHEM
- : : I-CHEM
His PRP$ PRP$ I-CHEM
- - - I-CHEM
Leu NNP NNP I-CHEM
cleavage NN NN O
by IN IN O
cortical JJ JJ O
homogenates NNS NNS O
) ) ) O
was VBD VBD O
determined VBN VBN O
by IN IN O
renal JJ JJ O
biopsy NN NN O
in IN IN O
27 CD CD O
adult NN NN O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
. . . O

After IN IN O
1 CD CD O
week NN NN O
of IN IN O
recovery NN NN O
, , , O
proteinuria NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
adriamycin NN NN B-CHEM
[ NN NN O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
intravenously RB RB O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
n NN NN O
= SYM SYM O
18 CD CD O
; : : O
controls NNS NNS O
, , , O
saline NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
n NN NN O
= SYM SYM O
9 CD CD O
] NN NN O
. . . O

Proteinuria NNP NNP O
was VBD VBD O
measured VBN VBN O
every DT DT O
2 CD CD O
weeks NNS NNS O
. . . O

After IN IN O
12 CD CD O
weeks NNS NNS O
, , , O
rats NNS NNS O
were VBD VBD O
sacrificed VBN VBN O
and CC CC O
their PRP$ PRP$ O
kidneys NNS NNS O
harvested VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
As IN IN O
anticipated VBN VBN O
, , , O
adriamycin NN NN B-CHEM
elicited VBN VBN O
nephrotic JJ JJ O
range NN NN O
proteinuria NN NN O
, , , O
renal JJ JJ O
interstitial JJ JJ O
damage NN NN O
and CC CC O
mild JJ JJ O
focal JJ JJ O
glomerulosclerosis NN NN O
. . . O

Baseline NNP NNP O
renal JJ JJ O
ACE NNP NNP O
positively RB RB O
correlated VBD VBD O
with IN IN O
the DT DT O
relative JJ JJ O
rise NN NN O
in IN IN O
proteinuria NN NN O
after IN IN O
adriamycin NN NN B-CHEM
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
62 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
renal JJ JJ O
interstitial JJ JJ O
alpha NN NN O
- - - O
smooth JJ JJ O
muscle NN NN O
actin NN NN O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
49 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
interstitial JJ JJ O
macrophage NN NN O
influx NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
56 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
interstitial JJ JJ O
collagen NN NN O
III NNP NNP O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
53 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
glomerular NN NN O
alpha NN NN O
- : : O
smooth JJ JJ O
muscle NN NN O
actin NN NN O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
74 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
and CC CC O
glomerular JJ JJ O
desmin NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
48 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Baseline NNP NNP O
renal JJ JJ O
ACE NNP NNP O
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
focal JJ JJ O
glomerulosclerosis NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
22 CD CD O
, , , O
NS NNP NNP O
) ) ) O
. . . O

In IN IN O
controls NNS NNS O
, , , O
no DT DT O
predictive JJ JJ O
values NNS NNS O
for IN IN O
renal JJ JJ O
parameters NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

CONCLUSION NNP NNP O
: : : O
Individual NNP NNP O
differences NNS NNS O
in IN IN O
renal JJ JJ O
ACE NNP NNP O
activity NN NN O
predict NN NN O
the DT DT O
severity NN NN O
of IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
damage NN NN O
in IN IN O
this DT DT O
outbred JJ JJ O
rat NN NN O
strain NN NN O
. . . O

This DT DT O
supports VBZ VBZ O
the DT DT O
assumption NN NN O
that IN IN O
differences NNS NNS O
in IN IN O
renal JJ JJ O
ACE NNP NNP O
activity NN NN O
predispose NN NN O
to TO TO O
a DT DT O
less RBR RBR O
favourable JJ JJ O
course NN NN O
of IN IN O
renal JJ JJ O
damage NN NN O
. . . O

Recurrent NNP NNP O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
induced VBN VBN O
by IN IN O
azithromycin NN NN B-CHEM
. . . O

A DT DT O
14 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
is VBZ VBZ O
reported VBN VBN O
with IN IN O
recurrent NN NN O
, , , O
azithromycin NN NN B-CHEM
- - - O
induced JJ JJ O
, , , O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
. . . O

The DT DT O
second JJ JJ O
episode NN NN O
was VBD VBD O
more RBR RBR O
severe JJ JJ O
than IN IN O
the DT DT O
first JJ JJ O
; : : O
and CC CC O
although IN IN O
both DT DT O
were VBD VBD O
treated VBN VBN O
with IN IN O
intensive JJ JJ O
corticosteroid NN NN O
therapy NN NN O
, , , O
renal JJ JJ O
function NN NN O
remained VBD VBD O
impaired VBN VBN O
. . . O

Although IN IN O
most JJS JJS O
cases NNS NNS O
of IN IN O
antibiotic JJ JJ O
induced VBN VBN O
acute JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
are VBP VBP O
benign NN NN O
and CC CC O
self NN NN O
- - - O
limited JJ JJ O
, , , O
some DT DT O
patients NNS NNS O
are VBP VBP O
at IN IN O
risk NN NN O
for IN IN O
permanent JJ JJ O
renal JJ JJ O
injury NN NN O
. . . O

Spironolactone NNP NNP B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
insufficiency NN NN O
and CC CC O
hyperkalemia NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
heart NN NN O
failure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
A DT DT O
previous JJ JJ O
randomized JJ JJ O
controlled VBN VBN O
trial NN NN O
evaluating VBG VBG O
the DT DT O
use NN NN O
of IN IN O
spironolactone NN NN B-CHEM
in IN IN O
heart NN NN O
failure NN NN O
patients NNS NNS O
reported VBD VBD O
a DT DT O
low JJ JJ O
risk NN NN O
of IN IN O
hyperkalemia NN NN O
( ( ( O
2 CD CD O
% NN NN O
) ) ) O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
( ( ( O
0 CD CD O
% NN NN O
) ) ) O
. . . O

Because IN IN O
treatments NNS NNS O
for IN IN O
heart NN NN O
failure NN NN O
have VBP VBP O
changed VBN VBN O
since IN IN O
the DT DT O
benefits NNS NNS O
of IN IN O
spironolactone NN NN B-CHEM
were VBD VBD O
reported VBN VBN O
, , , O
the DT DT O
prevalence NN NN O
of IN IN O
these DT DT O
complications NNS NNS O
may MD MD O
differ VB VB O
in IN IN O
current JJ JJ O
clinical JJ JJ O
practice NN NN O
. . . O

We PRP PRP O
therefore RB RB O
sought VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
prevalence NN NN O
and CC CC O
clinical JJ JJ O
associations NNS NNS O
of IN IN O
hyperkalemia NN NN O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
in IN IN O
heart NN NN O
failure NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
spironolactone NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
performed VBD VBD O
a DT DT O
case NN NN O
control NN NN O
study NN NN O
of IN IN O
heart NN NN O
failure NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
spironolactone NN NN B-CHEM
in IN IN O
our PRP$ PRP$ O
clinical JJ JJ O
practice NN NN O
. . . O

Cases NNS NNS O
were VBD VBD O
patients NNS NNS O
who WP WP O
developed VBD VBD O
hyperkalemia NN NN O
( ( ( O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
> NN NN O
5 CD CD O
. . . O
0 CD CD O
mEq NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
or CC CC O
renal JJ JJ O
insufficiency NN NN O
( ( ( O
Cr NNP NNP B-CHEM
> NN NN O
or CC CC O
= SYM SYM O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
, , , O
and CC CC O
they PRP PRP O
were VBD VBD O
compared VBN VBN O
to TO TO O
2 CD CD O
randomly RB RB O
selected VBD VBD O
controls NNS NNS O
per IN IN O
case NN NN O
. . . O

Clinical NNP NNP O
characteristics NNS NNS O
, , , O
medications NNS NNS O
, , , O
and CC CC O
serum NN NN O
chemistries NNS NNS O
at IN IN O
baseline NN NN O
and CC CC O
follow VB VB O
- - - O
up RP RP O
time NN NN O
periods NNS NNS O
were VBD VBD O
compared VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Sixty NNP NNP O
- - - O
seven CD CD O
of IN IN O
926 CD CD O
patients NNS NNS O
( ( ( O
7 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
required VBN VBN O
discontinuation NN NN O
of IN IN O
spironolactone NN NN B-CHEM
due JJ JJ O
to TO TO O
hyperkalemia NN NN O
( ( ( O
n NN NN O
= SYM SYM O
33 CD CD O
) ) ) O
or CC CC O
renal JJ JJ O
failure NN NN O
( ( ( O
n NN NN O
= SYM SYM O
34 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
who WP WP O
developed VBD VBD O
hyperkalemia NN NN O
were VBD VBD O
older JJR JJR O
and CC CC O
more RBR RBR O
likely JJ JJ O
to TO TO O
have VB VB O
diabetes NNS NNS O
, , , O
had VBD VBD O
higher JJR JJR O
baseline NN NN O
serum NN NN O
potassium NN NN B-CHEM
levels NNS NNS O
and CC CC O
lower JJR JJR O
baseline NN NN O
potassium NN NN B-CHEM
supplement NN NN O
doses NNS NNS O
, , , O
and CC CC O
were VBD VBD O
more RBR RBR O
likely JJ JJ O
to TO TO O
be VB VB O
treated VBN VBN O
with IN IN O
beta NN NN O
- - - O
blockers NNS NNS O
than IN IN O
controls NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
134 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
who WP WP O
developed VBD VBD O
renal JJ JJ O
insufficiency NN NN O
had VBD VBD O
lower JJR JJR O
baseline NN NN O
body NN NN O
weight NN NN O
and CC CC O
higher JJR JJR O
baseline NN NN O
serum NN NN O
creatinine NN NN B-CHEM
, , , O
required VBN VBN O
higher JJR JJR O
doses NNS NNS O
of IN IN O
loop NN NN O
diuretics NNS NNS O
, , , O
and CC CC O
were VBD VBD O
more RBR RBR O
likely JJ JJ O
to TO TO O
be VB VB O
treated VBN VBN O
with IN IN O
thiazide NN NN B-CHEM
diuretics NNS NNS O
than IN IN O
controls NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Spironolactone NNP NNP B-CHEM
- - - O
induced JJ JJ O
hyperkalemia NN NN O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
are VBP VBP O
more RBR RBR O
common JJ JJ O
in IN IN O
our PRP$ PRP$ O
clinical JJ JJ O
experience NN NN O
than IN IN O
reported VBD VBD O
previously RB RB O
. . . O

This DT DT O
difference NN NN O
is VBZ VBZ O
explained VBN VBN O
by IN IN O
patient NN NN O
comorbidities NNS NNS O
and CC CC O
more RBR RBR O
frequent JJ JJ O
use NN NN O
of IN IN O
beta NN NN O
- - - O
blockers NNS NNS O
. . . O

Acute JJ JJ O
reserpine NN NN B-CHEM
and CC CC O
subchronic JJ JJ O
haloperidol NN NN B-CHEM
treatments NNS NNS O
change VBP VBP O
synaptosomal NN NN O
brain NN NN O
glutamate NN NN B-CHEM
uptake NN NN O
and CC CC O
elicit JJ JJ O
orofacial JJ JJ O
dyskinesia NN NN O
in IN IN O
rats NNS NNS O
. . . O

Reserpine NNP NNP B-CHEM
- : : O
and CC CC O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
orofacial JJ JJ O
dyskinesia NN NN O
are VBP VBP O
putative JJ JJ O
animal NN NN O
models NNS NNS O
of IN IN O
tardive JJ JJ O
dyskinesia NN NN O
( ( ( O
TD NNP NNP O
) ) ) O
whose WP$ WP$ O
pathophysiology NN NN O
has VBZ VBZ O
been VBN VBN O
related VBN VBN O
to TO TO O
free JJ JJ O
radical JJ JJ O
generation NN NN O
and CC CC O
oxidative JJ JJ O
stress NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
authors NNS NNS O
induced VBD VBD O
orofacial JJ JJ O
dyskinesia NN NN O
by IN IN O
acute JJ JJ O
reserpine NN NN B-CHEM
and CC CC O
subchronic JJ JJ O
haloperidol NN NN B-CHEM
administration NN NN O
to TO TO O
rats NNS NNS O
. . . O

Reserpine NNP NNP B-CHEM
injection NN NN O
( ( ( O
one CD CD O
dose NN NN O
of IN IN O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
every DT DT O
other JJ JJ O
day NN NN O
for IN IN O
3 CD CD O
days NNS NNS O
caused VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
vacuous JJ JJ O
chewing NN NN O
, , , O
tongue NN NN O
protrusion NN NN O
and CC CC O
duration NN NN O
of IN IN O
facial JJ JJ O
twitching NN NN O
, , , O
compared VBN VBN O
to TO TO O
the DT DT O
control NN NN O
. . . O

Haloperidol NNP NNP B-CHEM
administration NN NN O
( ( ( O
one CD CD O
dose NN NN O
of IN IN O
12 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
once RB RB O
a DT DT O
week NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
for IN IN O
4 CD CD O
weeks NNS NNS O
caused VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
vacuous JJ JJ O
chewing NN NN O
, , , O
tongue NN NN O
protrusion NN NN O
and CC CC O
duration NN NN O
of IN IN O
facial JJ JJ O
twitching VBG VBG O
observed VBN VBN O
in IN IN O
four CD CD O
weekly JJ JJ O
evaluations NNS NNS O
. . . O

After IN IN O
the DT DT O
treatments NNS NNS O
and CC CC O
behavioral JJ JJ O
observation NN NN O
, , , O
glutamate NN NN B-CHEM
uptake NN NN O
by IN IN O
segments NNS NNS O
of IN IN O
the DT DT O
brain NN NN O
was VBD VBD O
analyzed VBN VBN O
. . . O

A DT DT O
decreased VBN VBN O
glutamate NN NN B-CHEM
uptake NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
subcortical JJ JJ O
parts NNS NNS O
of IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
reserpine NN NN B-CHEM
and CC CC O
haloperidol NN NN B-CHEM
, , , O
compared VBN VBN O
to TO TO O
the DT DT O
control NN NN O
. . . O

Importantly NNP NNP O
, , , O
a DT DT O
decrease NN NN O
in IN IN O
glutamate NN NN B-CHEM
uptake NN NN O
correlates NNS NNS O
negatively RB RB O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
orofacial JJ JJ O
diskinesia NN NN O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
early JJ JJ O
changes NNS NNS O
in IN IN O
glutamate NN NN B-CHEM
transport NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
vacuous JJ JJ O
chewing VBG VBG O
movements NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Ceftriaxone NNP NNP B-CHEM
- - - O
associated VBN VBN O
biliary JJ JJ O
pseudolithiasis NNS NNS O
in IN IN O
paediatric JJ JJ O
surgical JJ JJ O
patients NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
well RB RB O
known VBN VBN O
that IN IN O
ceftriaxone NN NN B-CHEM
leads VBZ VBZ O
to TO TO O
pseudolithiasis NNS NNS O
in IN IN O
some DT DT O
patients NNS NNS O
. . . O

Clinical NNP NNP O
and CC CC O
experimental JJ JJ O
studies NNS NNS O
also RB RB O
suggest VBP VBP O
that IN IN O
situations NNS NNS O
causing VBG VBG O
gallbladder NN NN O
dysfunction NN NN O
, , , O
such JJ JJ O
as IN IN O
fasting NN NN O
, , , O
may MD MD O
have VB VB O
a DT DT O
role NN NN O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
pseudolithiasis NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
prospectively RB RB O
evaluated VBD VBD O
the DT DT O
incidence NN NN O
and CC CC O
clinical JJ JJ O
importance NN NN O
of IN IN O
pseudolithiasis NN NN O
in IN IN O
paediatric JJ JJ O
surgical JJ JJ O
patients NNS NNS O
receiving VBG VBG O
ceftriaxone NN NN B-CHEM
treatment NN NN O
, , , O
who WP WP O
often RB RB O
had VBD VBD O
to TO TO O
fast RB RB O
in IN IN O
the DT DT O
post NN NN O
- - - O
operative JJ JJ O
period NN NN O
. . . O

Fifty NNP NNP O
children NNS NNS O
who WP WP O
were VBD VBD O
given VBN VBN O
ceftriaxone NN NN B-CHEM
were VBD VBD O
evaluated VBN VBN O
by IN IN O
serial JJ JJ O
abdominal JJ JJ O
sonograms NNS NNS O
. . . O

Of IN IN O
those DT DT O
, , , O
13 CD CD O
( ( ( O
26 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
biliary JJ JJ O
pathology NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
or CC CC O
without IN IN O
pseudolithiasis NNS NNS O
revealed VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
with IN IN O
respect NN NN O
to TO TO O
age NN NN O
, , , O
sex NN NN O
, , , O
duration NN NN O
of IN IN O
the DT DT O
treatment NN NN O
and CC CC O
starvation NN NN O
variables NNS NNS O
. . . O

After IN IN O
cessation NN NN O
of IN IN O
the DT DT O
treatment NN NN O
, , , O
pseudolithiasis NN NN O
resolved VBD VBD O
spontaneously RB RB O
within IN IN O
a DT DT O
short JJ JJ O
period NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
pseudolithiasis NN NN O
is VBZ VBZ O
not RB RB O
affected VBN VBN O
by IN IN O
fasting VBG VBG O
. . . O

Coronary JJ JJ O
aneurysm NN NN O
after IN IN O
implantation NN NN O
of IN IN O
a DT DT O
paclitaxel NN NN B-CHEM
- - - O
eluting VBG VBG O
stent NN NN O
. . . O

Formation NNP NNP O
of IN IN O
coronary JJ JJ O
aneurysm NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
of IN IN O
stenting VBG VBG O
with IN IN O
bare JJ JJ O
metal NN NN O
stents NNS NNS O
, , , O
but CC CC O
based VBN VBN O
on IN IN O
experimental JJ JJ O
studies NNS NNS O
drug NN NN O
- : : O
eluting VBG VBG O
stents NNS NNS O
may MD MD O
induce VB VB O
toxic JJ JJ O
effects NNS NNS O
on IN IN O
the DT DT O
vessel NN NN O
wall NN NN O
with IN IN O
incomplete JJ JJ O
stent NN NN O
apposition NN NN O
, , , O
aneurysm NN NN O
formation NN NN O
and CC CC O
with IN IN O
the DT DT O
potential NN NN O
of IN IN O
stent NN NN O
thrombosis NN NN O
or CC CC O
vessel NN NN O
rupture NN NN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
43 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
developed VBD VBD O
a DT DT O
coronary JJ JJ O
aneurysm NN NN O
in IN IN O
the DT DT O
right NN NN O
coronary JJ JJ O
artery NN NN O
6 CD CD O
months NNS NNS O
after IN IN O
receiving VBG VBG O
a DT DT O
paclitaxel NN NN B-CHEM
- - - O
eluting VBG VBG O
stent NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
asymptomatic JJ JJ O
and CC CC O
the DT DT O
aneurysm NN NN O
was VBD VBD O
detected VBN VBN O
in IN IN O
a DT DT O
routine NN NN O
control NN NN O
. . . O

Angiography NNP NNP O
and CC CC O
intracoronary JJ JJ O
ultrasound NN NN O
demonstrated VBD VBD O
lack NN NN O
of IN IN O
contact NN NN O
between IN IN O
stent NN NN O
and CC CC O
vessel NN NN O
wall NN NN O
in IN IN O
a DT DT O
15 CD CD O
- : : O
mm NN NN O
long JJ JJ O
segment NN NN O
with IN IN O
maximal NN NN O
aneurysm NN NN O
diameter NN NN O
of IN IN O
6 CD CD O
. . . O
0 CD CD O
mm NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
successfully RB RB O
treated VBN VBN O
with IN IN O
a DT DT O
graft NN NN O
stent NN NN O
. . . O

Causes NNP NNP O
of IN IN O
acute JJ JJ O
thrombotic JJ JJ O
microangiopathy NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
kidney NN NN O
transplantation NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
Thrombotic NNP NNP O
microangiopathy NN NN O
is VBZ VBZ O
a DT DT O
well RB RB O
- - - O
known VBN VBN O
problem NN NN O
in IN IN O
patients NNS NNS O
following VBG VBG O
renal JJ JJ O
transplantation NN NN O
. . . O

In IN IN O
postrenal JJ JJ O
transplantation NN NN O
, , , O
thrombotic JJ JJ O
microangiopathy NN NN O
is VBZ VBZ O
often RB RB O
a DT DT O
reflection NN NN O
of IN IN O
hemolytic JJ JJ O
uremic JJ JJ O
syndrome NN NN O
. . . O

We PRP PRP O
aimed VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
causes NNS NNS O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
in IN IN O
a DT DT O
population NN NN O
of IN IN O
renal JJ JJ O
transplantation NN NN O
recipients NNS NNS O
and CC CC O
discuss VB VB O
the DT DT O
literature NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
We PRP PRP O
investigated VBD VBD O
the DT DT O
causes NNS NNS O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
during IN IN O
a DT DT O
1 CD CD O
- : : O
year NN NN O
period NN NN O
, , , O
from IN IN O
June NNP NNP O
2003 CD CD O
to TO TO O
June NNP NNP O
2004 CD CD O
, , , O
at IN IN O
the DT DT O
King NNP NNP O
Fahad NNP NNP O
National NNP NNP O
Guard NNP NNP O
Hospital NNP NNP O
in IN IN O
Riyadh NNP NNP O
, , , O
Saudi NNP NNP O
Arabia NNP NNP O
, , , O
by IN IN O
reviewing VBG VBG O
the DT DT O
slides NNS NNS O
of IN IN O
all DT DT O
transplant NN NN O
biopsies NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
25 CD CD O
) ) ) O
performed VBN VBN O
during IN IN O
this DT DT O
interval NN NN O
. . . O

Pre NNP NNP O
- : : O
and CC CC O
posttransplant JJ JJ O
crossmatching NN NN O
was VBD VBD O
done VBN VBN O
when WRB WRB O
possible JJ JJ O
. . . O

RESULTS NNS NNS O
: : : O
Five CD CD O
cases NNS NNS O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
were VBD VBD O
found VBN VBN O
. . . O

Three CD CD O
of IN IN O
these DT DT O
cases NNS NNS O
were VBD VBD O
from IN IN O
the DT DT O
25 CD CD O
transplantations NNS NNS O
performed VBN VBN O
at IN IN O
King NNP NNP O
Fahad NNP NNP O
National NNP NNP O
Guard NNP NNP O
Hospital NNP NNP O
, , , O
while IN IN O
the DT DT O
other JJ JJ O
2 CD CD O
transplantations NNS NNS O
had VBD VBD O
been VBN VBN O
performed VBN VBN O
abroad RB RB O
and CC CC O
were VBD VBD O
referred VBN VBN O
to TO TO O
us PRP PRP O
for IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

Three CD CD O
cases NNS NNS O
were VBD VBD O
related VBN VBN O
to TO TO O
cyclosporine NN NN B-CHEM
, , , O
and CC CC O
1 CD CD O
case NN NN O
was VBD VBD O
secondary JJ JJ O
to TO TO O
both DT DT O
cyclosporine NN NN B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
. . . O

The DT DT O
fifth JJ JJ O
case NN NN O
had VBD VBD O
features NNS NNS O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
related VBN VBN O
to TO TO O
an DT DT O
antiphospholipid JJ JJ O
syndrome NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
systemic JJ JJ O
lupus NN NN O
erythematosus NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
the DT DT O
literature NN NN O
, , , O
the DT DT O
most RBS RBS O
- - - O
frequent JJ JJ O
cause NN NN O
of IN IN O
hemolytic JJ JJ O
uremic JJ JJ O
syndrome NN NN O
in IN IN O
patients NNS NNS O
following VBG VBG O
renal JJ JJ O
transplantation NN NN O
is VBZ VBZ O
recurrence NN NN O
of IN IN O
the DT DT O
hemolytic JJ JJ O
uremic JJ JJ O
syndrome NN NN O
. . . O

Other JJ JJ O
causes NNS NNS O
include VBP VBP O
drug NN NN O
- - - O
related VBN VBN O
( ( ( O
cyclosporine NN NN B-CHEM
, , , O
tacrolimus NN NN B-CHEM
) ) ) O
toxicity NN NN O
, , , O
procoagulant JJ JJ O
status NN NN O
, , , O
and CC CC O
antibody NN NN O
- - - O
mediated JJ JJ O
rejection NN NN O
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
the DT DT O
most RBS RBS O
- - - O
frequent JJ JJ O
cause NN NN O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
was VBD VBD O
drug NN NN O
related VBN VBN O
, , , O
secondary JJ JJ O
mainly RB RB O
to TO TO O
cyclosporine VB VB B-CHEM
. . . O

In IN IN O
the DT DT O
current JJ JJ O
study NN NN O
, , , O
the DT DT O
frequency NN NN O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
was VBD VBD O
similar JJ JJ O
to TO TO O
the DT DT O
percentage NN NN O
reported VBD VBD O
in IN IN O
the DT DT O
literature NN NN O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
. . . O

Comparison NNP NNP O
of IN IN O
developmental NN NN O
toxicity NN NN O
of IN IN O
selective JJ JJ O
and CC CC O
non NN NN O
- - - O
selective JJ JJ O
cyclooxygenase NN NN O
- : : O
2 CD CD O
inhibitors NNS NNS O
in IN IN O
CRL NNP NNP O
: : : O
( ( ( O
WI NNP NNP O
) ) ) O
WUBR NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
- - - O
- - - O
DFU NNP NNP B-CHEM
and CC CC O
piroxicam NN NN B-CHEM
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Cyclooxygenase NN NN O
( ( ( O
COX NNP NNP O
) ) ) O
inhibitors NNS NNS O
are VBP VBP O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
often RB RB O
ingested JJ JJ O
drugs NNS NNS O
during IN IN O
pregnancy NN NN O
. . . O

Unlike IN IN O
general JJ JJ O
toxicity NN NN O
data NNS NNS O
, , , O
their PRP$ PRP$ O
prenatal NN NN O
toxic JJ JJ O
effects NNS NNS O
were VBD VBD O
not RB RB O
extensively RB RB O
studied VBD VBD O
before IN IN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
experiment NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
developmental JJ JJ O
toxicity NN NN O
of IN IN O
the DT DT O
non NN NN O
- - - O
selective JJ JJ O
( ( ( O
piroxicam NN NN B-CHEM
) ) ) O
and CC CC O
selective JJ JJ O
( ( ( O
DFU NNP NNP B-CHEM
; : : O
5 CD CD B-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
dimethyl NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
fluorophenyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylsulphonyl NN NN I-CHEM
) ) ) I-CHEM
phenyl NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
( ( ( I-CHEM
5H CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
furanon NN NN I-CHEM
) ) ) O
COX NNP NNP O
- : : O
2 CD CD O
inhibitors NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Drugs NNS NNS O
were VBD VBD O
separately RB RB O
, , , O
orally RB RB O
once RB RB O
daily RB RB O
dosed VBN VBN O
to TO TO O
pregnant JJ JJ O
rats NNS NNS O
from IN IN O
day NN NN O
8 CD CD O
to TO TO O
21 CD CD O
( ( ( O
GD1 NNP NNP O
= SYM SYM O
plug NN NN O
day NN NN O
) ) ) O
. . . O

Doses NNP NNP O
were VBD VBD O
set VBN VBN O
at IN IN O
0 CD CD O
. . . O
3 CD CD O
, , , O
3 CD CD O
. . . O
0 CD CD O
and CC CC O
30 CD CD O
. . . O
0mg CD CD O
/ NN NN O
kg NN NN O
for IN IN O
piroxicam NN NN B-CHEM
and CC CC O
0 CD CD O
. . . O
2 CD CD O
, , , O
2 CD CD O
. . . O
0 CD CD O
and CC CC O
20 CD CD O
. . . O
0mg CD CD O
/ NN NN O
kg NN NN O
for IN IN O
DFU NNP NNP B-CHEM
. . . O

Fetuses NNP NNP O
were VBD VBD O
delivered VBN VBN O
on IN IN O
GD NNP NNP O
21 CD CD O
and CC CC O
routinely RB RB O
examined VBD VBD O
. . . O

Comprehensive NNP NNP O
clinical JJ JJ O
and CC CC O
developmental JJ JJ O
measurements NNS NNS O
were VBD VBD O
done VBN VBN O
. . . O

The DT DT O
pooled JJ JJ O
statistical JJ JJ O
analysis NN NN O
for IN IN O
ventricular JJ JJ O
septal NN NN O
( ( ( O
VSD NNP NNP O
) ) ) O
and CC CC O
midline NN NN O
( ( ( O
MD NNP NNP O
) ) ) O
defects NNS NNS O
was VBD VBD O
performed VBN VBN O
for IN IN O
rat NN NN O
fetuses NNS NNS O
exposed VBN VBN O
to TO TO O
piroxicam NN NN B-CHEM
, , , O
selective JJ JJ O
and CC CC O
non NN NN O
- - - O
selective JJ JJ O
COX NNP NNP O
- : : O
2 CD CD O
inhibitor NN NN O
based VBN VBN O
on IN IN O
present JJ JJ O
and CC CC O
historic JJ JJ O
data NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Maternal NNP NNP O
toxicity NN NN O
, , , O
intrauterine NN NN O
growth NN NN O
retardation NN NN O
, , , O
and CC CC O
increase NN NN O
of IN IN O
external JJ JJ O
and CC CC O
skeletal JJ JJ O
variations NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
the DT DT O
highest JJS JJS O
dose NN NN O
of IN IN O
piroxicam NN NN B-CHEM
. . . O

Decrease NNP NNP O
of IN IN O
fetal JJ JJ O
length NN NN O
was VBD VBD O
the DT DT O
only JJ JJ O
signs NNS NNS O
of IN IN O
the DT DT O
DFU NNP NNP B-CHEM
developmental NN NN O
toxicity NN NN O
observed VBD VBD O
in IN IN O
pups NNS NNS O
exposed VBN VBN O
to TO TO O
the DT DT O
highest JJS JJS O
compound NN NN O
dose NN NN O
. . . O

Lack NNP NNP O
of IN IN O
teratogenicity NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
piroxicam NN NN B-CHEM
and CC CC O
DFU NNP NNP B-CHEM
- : : O
exposed VBN VBN O
groups NNS NNS O
. . . O

Prenatal NNP NNP O
exposure NN NN O
to TO TO O
non NN NN O
- - - O
selective JJ JJ O
COX NNP NNP O
inhibitors NNS NNS O
increases NNS NNS O
the DT DT O
risk NN NN O
of IN IN O
VSD NNP NNP O
and CC CC O
MD NNP NNP O
when WRB WRB O
compared VBN VBN O
to TO TO O
historic JJ JJ O
control NN NN O
but CC CC O
not RB RB O
with IN IN O
selective JJ JJ O
COX NNP NNP O
- : : O
2 CD CD O
inhibitors NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Both DT DT O
selective JJ JJ O
and CC CC O
non NN NN O
- - - O
selective JJ JJ O
COX NNP NNP O
- : : O
2 CD CD O
inhibitors NNS NNS O
were VBD VBD O
toxic JJ JJ O
for IN IN O
rats NNS NNS O
fetuses NNS NNS O
when WRB WRB O
administered VBN VBN O
in IN IN O
the DT DT O
highest JJS JJS O
dose NN NN O
. . . O

Unlike IN IN O
DFU NNP NNP B-CHEM
, , , O
piroxicam NN NN B-CHEM
was VBD VBD O
also RB RB O
highly RB RB O
toxic JJ JJ O
to TO TO O
the DT DT O
dams NNS NNS O
. . . O

Prenatal NNP NNP O
exposure NN NN O
to TO TO O
selective VB VB O
COX NNP NNP O
- : : O
2 CD CD O
inhibitors NNS NNS O
does VBZ VBZ O
not RB RB O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
ventricular NN NN O
septal NN NN O
and CC CC O
midline NN NN O
defects NNS NNS O
in IN IN O
rat NN NN O
when WRB WRB O
compared VBN VBN O
to TO TO O
non NN NN O
- - - O
selective JJ JJ O
drugs NNS NNS O
and CC CC O
historic JJ JJ O
control NN NN O
. . . O

Lone NNP NNP O
atrial JJ JJ O
fibrillation NN NN O
associated VBN VBN O
with IN IN O
creatine NN NN B-CHEM
monohydrate NN NN O
supplementation NN NN O
. . . O

Atrial NNP NNP O
fibrillation NN NN O
in IN IN O
young JJ JJ O
patients NNS NNS O
without IN IN O
structural JJ JJ O
heart NN NN O
disease NN NN O
is VBZ VBZ O
rare JJ JJ O
. . . O

Therefore RB RB O
, , , O
when WRB WRB O
the DT DT O
arrhythmia NN NN O
is VBZ VBZ O
present JJ JJ O
in IN IN O
this DT DT O
population NN NN O
, , , O
reversible JJ JJ O
causes NNS NNS O
must MD MD O
be VB VB O
identified VBN VBN O
and CC CC O
resolved VBN VBN O
. . . O

Thyroid NNP NNP O
disorders NNS NNS O
, , , O
illicit JJ JJ O
drug NN NN O
or CC CC O
stimulant JJ JJ O
use NN NN O
, , , O
and CC CC O
acute JJ JJ O
alcohol NN NN O
intoxication NN NN O
are VBP VBP O
among IN IN O
these DT DT O
causes NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
30 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Caucasian NNP NNP O
man NN NN O
who WP WP O
came VBD VBD O
to TO TO O
the DT DT O
emergency NN NN O
department NN NN O
in IN IN O
atrial JJ JJ O
fibrillation NN NN O
with IN IN O
rapid JJ JJ O
ventricular NN NN O
response NN NN O
. . . O

His PRP$ PRP$ O
medical JJ JJ O
history NN NN O
was VBD VBD O
unremarkable JJ JJ O
, , , O
except IN IN O
for IN IN O
minor JJ JJ O
fractures NNS NNS O
of IN IN O
the DT DT O
fingers NNS NNS O
and CC CC O
foot NN NN O
. . . O

Thyroid NNP NNP O
- : : O
stimulating VBG VBG O
hormone NN NN O
, , , O
magnesium NN NN B-CHEM
, , , O
and CC CC O
potassium NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
within IN IN O
normal JJ JJ O
limits NNS NNS O
, , , O
urine JJ JJ O
drug NN NN O
screen NN NN O
was VBD VBD O
negative JJ JJ O
, , , O
and CC CC O
alcohol NN NN B-CHEM
use NN NN O
was VBD VBD O
denied VBN VBN O
. . . O

However RB RB O
, , , O
when WRB WRB O
the DT DT O
patient NN NN O
was VBD VBD O
questioned VBN VBN O
about IN IN O
use NN NN O
of IN IN O
herbal JJ JJ O
products NNS NNS O
and CC CC O
supplements NNS NNS O
, , , O
the DT DT O
use NN NN O
of IN IN O
creatine NN NN B-CHEM
monohydrate NN NN O
was VBD VBD O
revealed VBN VBN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
, , , O
anticoagulated VBN VBN O
with IN IN O
unfractionated JJ JJ O
heparin NN NN B-CHEM
, , , O
and CC CC O
given VBN VBN O
intravenous JJ JJ O
diltiazem NN NN B-CHEM
for IN IN O
rate NN NN O
control NN NN O
and CC CC O
intravenous JJ JJ O
amiodarone NN NN B-CHEM
for IN IN O
rate NN NN O
and CC CC O
rhythm NN NN O
control NN NN O
. . . O

When WRB WRB O
discharged VBN VBN O
less JJR JJR O
than IN IN O
24 CD CD O
hours NNS NNS O
later RB RB O
, , , O
he PRP PRP O
was VBD VBD O
receiving VBG VBG O
metoprolol NN NN B-CHEM
and CC CC O
aspirin NN NN B-CHEM
, , , O
with IN IN O
follow VB VB O
- - - O
up RP RP O
plans NNS NNS O
for IN IN O
echocardiography NN NN O
and CC CC O
nuclear JJ JJ O
imaging VBG VBG O
to TO TO O
assess VB VB O
perfusion NN NN O
. . . O

Exogenous NNP NNP O
creatine NN NN B-CHEM
is VBZ VBZ O
used VBN VBN O
by IN IN O
athletes NNS NNS O
to TO TO O
theoretically RB RB O
improve VB VB O
exercise NN NN O
performance NN NN O
. . . O

Vegetarians NNP NNP O
may MD MD O
also RB RB O
take VB VB O
creatine NN NN B-CHEM
to TO TO O
replace VB VB O
what WP WP O
they PRP PRP O
are VBP VBP O
not RB RB O
consuming VBG VBG O
from IN IN O
meat NN NN O
, , , O
fish NN NN O
, , , O
and CC CC O
other JJ JJ O
animal NN NN O
products NNS NNS O
. . . O

Previous JJ JJ O
anecdotal JJ JJ O
reports NNS NNS O
have VBP VBP O
linked VBN VBN O
creatine NN NN B-CHEM
to TO TO O
the DT DT O
development NN NN O
of IN IN O
arrhythmia NN NN O
. . . O

Clinicians NNP NNP O
must MD MD O
be VB VB O
diligent JJ JJ O
when WRB WRB O
interviewing VBG VBG O
patients NNS NNS O
about IN IN O
their PRP$ PRP$ O
drug NN NN O
therapy NN NN O
histories NNS NNS O
and CC CC O
include VB VB O
questions NNS NNS O
about IN IN O
their PRP$ PRP$ O
use NN NN O
of IN IN O
herbal JJ JJ O
products NNS NNS O
and CC CC O
dietary JJ JJ O
supplements NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
important JJ JJ O
to TO TO O
report VB VB O
adverse JJ JJ O
effects NNS NNS O
associated VBN VBN O
with IN IN O
frequently RB RB O
consumed VBN VBN O
supplements NNS NNS O
and CC CC O
herbal JJ JJ O
products NNS NNS O
to TO TO O
the DT DT O
Food NNP NNP O
and CC CC O
Drug NN NN O
Administration NNP NNP O
and CC CC O
in IN IN O
the DT DT O
literature NN NN O
. . . O

Seizures NNP NNP O
induced VBN VBN O
by IN IN O
the DT DT O
cocaine NN NN B-CHEM
metabolite NN NN O
benzoylecgonine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
half NN NN O
- - - O
life NN NN O
( ( ( O
t1 NN NN O
/ NN NN O
2 CD CD O
) ) ) O
of IN IN O
cocaine NN NN B-CHEM
is VBZ VBZ O
relatively RB RB O
short JJ JJ O
, , , O
but CC CC O
some DT DT O
of IN IN O
the DT DT O
consequences NNS NNS O
of IN IN O
its PRP$ PRP$ O
use NN NN O
, , , O
such JJ JJ O
as IN IN O
seizures NNS NNS O
and CC CC O
strokes NNS NNS O
, , , O
can MD MD O
occur VB VB O
hours NNS NNS O
after IN IN O
exposure NN NN O
. . . O

This DT DT O
led VBD VBD O
us PRP PRP O
to TO TO O
hypothesize VB VB O
that IN IN O
a DT DT O
metabolite NN NN O
of IN IN O
cocaine NN NN B-CHEM
may MD MD O
be VB VB O
responsible JJ JJ O
for IN IN O
some DT DT O
of IN IN O
those DT DT O
delayed JJ JJ O
sequelae NN NN O
. . . O

We PRP PRP O
evaluated VBD VBD O
the DT DT O
potential NN NN O
of IN IN O
the DT DT O
major JJ JJ O
metabolite NN NN O
of IN IN O
cocaine NN NN B-CHEM
, , , O
benzoylecgonine NN NN B-CHEM
( ( ( O
BE VB VB B-CHEM
) ) ) O
, , , O
to TO TO O
cause VB VB O
seizures NNS NNS O
. . . O

Two CD CD O
separate JJ JJ O
equimolar NN NN O
doses NNS NNS O
( ( ( O
0 CD CD O
. . . O
2 CD CD O
and CC CC O
0 CD CD O
. . . O
4 CD CD O
mumol CD CD O
) ) ) O
of IN IN O
either DT DT O
cocaine NN NN B-CHEM
or CC CC O
BE VB VB B-CHEM
were VBD VBD O
injected VBN VBN O
ventricularly RB RB O
in IN IN O
unanesthetized JJ JJ O
juvenile NN NN O
rats NNS NNS O
. . . O

Treated NNP NNP O
rats NNS NNS O
were VBD VBD O
then RB RB O
evaluated VBN VBN O
for IN IN O
incidence NN NN O
, , , O
latency NN NN O
, , , O
and CC CC O
seizure NN NN O
pattern NN NN O
or CC CC O
for IN IN O
locomotor NN NN O
activity NN NN O
in IN IN O
animals NNS NNS O
without IN IN O
seizures NNS NNS O
. . . O

BE VB VB B-CHEM
- - - O
Induced NNP NNP O
seizures NNS NNS O
occurred VBD VBD O
more RBR RBR O
frequently RB RB O
and CC CC O
had VBD VBD O
significantly RB RB O
longer RB RB O
latencies NNS NNS O
than IN IN O
those DT DT O
induced VBN VBN O
by IN IN O
equimolar JJ JJ O
amounts NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
. . . O

Whereas IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
were VBD VBD O
best JJS JJS O
characterized VBN VBN O
as IN IN O
brief JJ JJ O
, , , O
generalized JJ JJ O
, , , O
and CC CC O
tonic NN NN O
and CC CC O
resulted VBD VBD O
in IN IN O
death NN NN O
, , , O
those DT DT O
induced VBN VBN O
by IN IN O
BE VB VB B-CHEM
were VBD VBD O
prolonged JJ JJ O
, , , O
often RB RB O
multiple JJ JJ O
and CC CC O
mixed JJ JJ O
in IN IN O
type NN NN O
, , , O
and CC CC O
rarely RB RB O
resulted VBD VBD O
in IN IN O
death NN NN O
. . . O

Electrical NNP NNP O
recordings NNS NNS O
from IN IN O
the DT DT O
hippocampus NN NN O
showed VBD VBD O
a DT DT O
rhythmic JJ JJ O
progression NN NN O
in IN IN O
EEG NNP NNP O
frequency NN NN O
and CC CC O
voltage NN NN O
with IN IN O
clinical JJ JJ O
seizure NN NN O
expression NN NN O
. . . O

BE VB VB B-CHEM
- - - O
Injected NNP NNP O
rats NNS NNS O
that WDT WDT O
did VBD VBD O
not RB RB O
have VB VB O
seizures NNS NNS O
had VBD VBD O
significantly RB RB O
more JJR JJR O
locomotor NN NN O
activity NN NN O
than IN IN O
cocaine NN NN B-CHEM
- - - O
injected JJ JJ O
animals NNS NNS O
without IN IN O
seizures NNS NNS O
. . . O

The DT DT O
finding VBG VBG O
that IN IN O
cocaine NN NN B-CHEM
- : : O
and CC CC O
BE VB VB B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
differ VBP VBP O
in IN IN O
several JJ JJ O
respects NNS NNS O
suggests VBZ VBZ O
more JJR JJR O
than IN IN O
one CD CD O
mechanism NN NN O
for IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
emphasizes VBZ VBZ O
the DT DT O
importance NN NN O
of IN IN O
a DT DT O
cocaine NN NN B-CHEM
metabolite NN NN O
, , , O
BE VB VB B-CHEM
. . . O

The DT DT O
selective JJ JJ O
5 CD CD O
- : : O
HT6 NNP NNP O
receptor NN NN O
antagonist NN NN O
Ro4368554 NNP NNP B-CHEM
restores NNS NNS O
memory NN NN O
performance NN NN O
in IN IN O
cholinergic JJ JJ O
and CC CC O
serotonergic JJ JJ O
models NNS NNS O
of IN IN O
memory NN NN O
deficiency NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Antagonists NNP NNP O
at IN IN O
serotonin NN NN B-CHEM
type NN NN O
6 CD CD O
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
( ( ( O
6 CD CD O
) ) ) O
) ) ) O
receptors NNS NNS O
show VBP VBP O
activity NN NN O
in IN IN O
models NNS NNS O
of IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
. . . O

Although IN IN O
the DT DT O
underlying VBG VBG O
mechanism NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
are VBP VBP O
not RB RB O
well RB RB O
understood VBN VBN O
, , , O
these DT DT O
effects NNS NNS O
may MD MD O
involve VB VB O
an DT DT O
increase NN NN O
in IN IN O
acetylcholine NN NN B-CHEM
( ( ( O
ACh NNP NNP B-CHEM
) ) ) O
levels NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
sought VBN VBN O
to TO TO O
characterize VB VB O
the DT DT O
cognitive JJ JJ O
- - - O
enhancing VBG VBG O
effects NNS NNS O
of IN IN O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
( ( ( O
6 CD CD O
) ) ) O
antagonist NN NN O
Ro4368554 NNP NNP B-CHEM
( ( ( O
3 CD CD B-CHEM
- : : I-CHEM
benzenesulfonyl NN NN I-CHEM
- : : I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
piperazin NN NN I-CHEM
- - - I-CHEM
1 CD CD I-CHEM
- - - I-CHEM
yl NN NN I-CHEM
) ) ) I-CHEM
1H CD CD I-CHEM
- : : I-CHEM
indole NN NN I-CHEM
) ) ) O
in IN IN O
a DT DT O
rat NN NN O
object VBP VBP O
recognition NN NN O
task NN NN O
employing VBG VBG O
a DT DT O
cholinergic JJ JJ O
( ( ( O
scopolamine NN NN B-CHEM
pretreatment NN NN O
) ) ) O
and CC CC O
a DT DT O
serotonergic JJ JJ O
- - - O
( ( ( O
tryptophan NN NN B-CHEM
( ( ( O
TRP NNP NNP B-CHEM
) ) ) O
depletion NN NN O
) ) ) O
deficient JJ JJ O
model NN NN O
, , , O
and CC CC O
compared VBD VBD O
its PRP$ PRP$ O
pattern NN NN O
of IN IN O
action NN NN O
with IN IN O
that DT DT O
of IN IN O
the DT DT O
acetylcholinesterase NN NN O
inhibitor NN NN O
metrifonate NN NN B-CHEM
. . . O

Initial JJ JJ O
testing NN NN O
in IN IN O
a DT DT O
time NN NN O
- - - O
dependent JJ JJ O
forgetting VBG VBG O
task NN NN O
employing VBG VBG O
a DT DT O
24 CD CD O
- : : O
h NN NN O
delay NN NN O
between IN IN O
training NN NN O
and CC CC O
testing NN NN O
showed VBD VBD O
that IN IN O
metrifonate NN NN B-CHEM
improved VBD VBD O
object VBP VBP O
recognition NN NN O
( ( ( O
at IN IN O
10 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
, , , O
whereas IN IN O
Ro4368554 NNP NNP B-CHEM
was VBD VBD O
inactive JJ JJ O
. . . O

Both DT DT O
, , , O
Ro4368554 NNP NNP B-CHEM
( ( ( O
3 CD CD O
and CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
intraperitoneally RB RB O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
) ) ) O
and CC CC O
metrifonate NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
respectively RB RB O
) ) ) O
reversed JJ JJ O
memory NN NN O
deficits NNS NNS O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
and CC CC O
TRP NNP NNP B-CHEM
depletion NN NN O
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
and CC CC O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
respectively RB RB O
) ) ) O
. . . O

In IN IN O
conclusion NN NN O
, , , O
although IN IN O
Ro4368554 NNP NNP B-CHEM
did VBD VBD O
not RB RB O
improve VB VB O
a DT DT O
time NN NN O
- - - O
related VBN VBN O
retention NN NN O
deficit NN NN O
, , , O
it PRP PRP O
reversed VBD VBD O
a DT DT O
cholinergic JJ JJ O
and CC CC O
a DT DT O
serotonergic JJ JJ O
memory NN NN O
deficit NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
both DT DT O
mechanisms NNS NNS O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
facilitation NN NN O
of IN IN O
object VBP VBP O
memory NN NN O
by IN IN O
Ro4368554 NNP NNP B-CHEM
and CC CC O
, , , O
possibly RB RB O
, , , O
other JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
( ( ( O
6 CD CD O
) ) ) O
receptor NN NN O
antagonists NNS NNS O
. . . O

Evaluation NNP NNP O
of IN IN O
the DT DT O
anticocaine NN NN O
monoclonal JJ JJ O
antibody NN NN O
GNC92H2 NNP NNP B-CHEM
as IN IN O
an DT DT O
immunotherapy NN NN O
for IN IN O
cocaine NN NN O
overdose NN NN O
. . . O

The DT DT O
illicit JJ JJ O
use NN NN O
of IN IN O
cocaine NN NN B-CHEM
continues VBZ VBZ O
in IN IN O
epidemic JJ JJ O
proportions NNS NNS O
and CC CC O
treatment NN NN O
for IN IN O
cocaine NN NN O
overdose NN NN O
remains VBZ VBZ O
elusive JJ JJ O
. . . O

Current JJ JJ O
protein NN NN O
- - - O
based JJ JJ O
technology NN NN O
offers VBZ VBZ O
a DT DT O
new JJ JJ O
therapeutic JJ JJ O
venue NN NN O
by IN IN O
which WDT WDT O
antibodies NNS NNS O
bind VBP VBP O
the DT DT O
drug NN NN O
in IN IN O
the DT DT O
blood NN NN O
stream NN NN O
, , , O
inactivating VBG VBG O
its PRP$ PRP$ O
toxic JJ JJ O
effects NNS NNS O
. . . O

The DT DT O
therapeutic JJ JJ O
potential NN NN O
of IN IN O
the DT DT O
anticocaine NN NN O
antibody NN NN O
GNC92H2 NNP NNP B-CHEM
was VBD VBD O
examined VBN VBN O
using VBG VBG O
a DT DT O
model NN NN O
of IN IN O
cocaine NN NN O
overdose NN NN O
. . . O

Swiss NNP NNP O
albino NN NN O
mice NN NN O
prepared VBN VBN O
with IN IN O
intrajugular JJ JJ O
catheters NNS NNS O
were VBD VBD O
tested VBN VBN O
in IN IN O
photocell NN NN O
cages NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
93 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
LD50 NNP NNP O
) ) ) O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
GNC92H2 NNP NNP B-CHEM
infusions NNS NNS O
ranging VBG VBG O
from IN IN O
30 CD CD O
to TO TO O
190 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

GNC92H2 NNP NNP B-CHEM
was VBD VBD O
delivered VBN VBN O
30 CD CD O
min NN NN O
before IN IN O
, , , O
concomitantly RB RB O
or CC CC O
3 CD CD O
min NN NN O
after IN IN O
cocaine NN NN B-CHEM
treatment NN NN O
. . . O

Significant JJ JJ O
blockade NN NN O
of IN IN O
cocaine NN NN B-CHEM
toxicity NN NN O
was VBD VBD O
observed VBN VBN O
with IN IN O
the DT DT O
higher JJR JJR O
dose NN NN O
of IN IN O
GNC92H2 NNP NNP B-CHEM
( ( ( O
190 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
where WRB WRB O
premorbid NN NN O
behaviors NNS NNS O
were VBD VBD O
reduced VBN VBN O
up IN IN O
to TO TO O
40 CD CD O
% NN NN O
, , , O
seizures NNS NNS O
up IN IN O
to TO TO O
77 CD CD O
% NN NN O
and CC CC O
death NN NN O
by IN IN O
72 CD CD O
% NN NN O
. . . O

Importantly NNP NNP O
, , , O
GNC92H2 NNP NNP B-CHEM
prevented VBD VBD O
death NN NN O
even RB RB O
post NN NN O
- - - O
cocaine NN NN B-CHEM
injection NN NN O
. . . O

The DT DT O
results NNS NNS O
support VBP VBP O
the DT DT O
important JJ JJ O
potential NN NN O
of IN IN O
GNC92H2 NNP NNP B-CHEM
as IN IN O
a DT DT O
therapeutic JJ JJ O
tool NN NN O
against IN IN O
cocaine NN NN O
overdose NN NN O
. . . O

Electrocardiographic NNP NNP O
evidence NN NN O
of IN IN O
myocardial JJ JJ O
injury NN NN O
in IN IN O
psychiatrically RB RB O
hospitalized JJ JJ O
cocaine NN NN B-CHEM
abusers NNS NNS O
. . . O

The DT DT O
electrocardiograms NNS NNS O
( ( ( O
ECG NNP NNP O
) ) ) O
of IN IN O
99 CD CD O
cocaine NN NN B-CHEM
- : : O
abusing VBG VBG O
patients NNS NNS O
were VBD VBD O
compared VBN VBN O
with IN IN O
the DT DT O
ECGs NNP NNP O
of IN IN O
50 CD CD O
schizophrenic JJ JJ O
controls NNS NNS O
. . . O

Eleven CD CD O
of IN IN O
the DT DT O
cocaine NN NN B-CHEM
abusers NNS NNS O
and CC CC O
none NN NN O
of IN IN O
the DT DT O
controls NNS NNS O
had VBD VBD O
ECG NNP NNP O
evidence NN NN O
of IN IN O
significant JJ JJ O
myocardial NN NN O
injury NN NN O
defined VBD VBD O
as IN IN O
myocardial NN NN O
infarction NN NN O
, , , O
ischemia NN NN O
, , , O
and CC CC O
bundle NN NN O
branch NN NN O
block NN NN O
. . . O

Behavioral NNP NNP O
effects NNS NNS O
of IN IN O
urotensin JJ JJ B-CHEM
- - - I-CHEM
II NNP NNP I-CHEM
centrally RB RB O
administered VBD VBD O
in IN IN O
mice NN NN O
. . . O

Urotensin NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
( ( ( O
U NNP NNP B-CHEM
- - - I-CHEM
II NNP NNP I-CHEM
) ) ) O
receptors NNS NNS O
are VBP VBP O
widely RB RB O
distributed VBN VBN O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Intracerebroventricular NNP NNP O
( ( ( O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
injection NN NN O
of IN IN O
U NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
causes NNS NNS O
hypertension NN NN O
and CC CC O
bradycardia NNS NNS O
and CC CC O
stimulates NNS NNS O
prolactin NN NN O
and CC CC O
thyrotropin NN NN O
secretion NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
behavioral JJ JJ O
effects NNS NNS O
of IN IN O
centrally RB RB O
administered VBN VBN O
U NNP NNP B-CHEM
- - - I-CHEM
II NN NN I-CHEM
have VBP VBP O
received VBN VBN O
little JJ JJ O
attention NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
tested VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
injections NNS NNS O
of IN IN O
U NNP NNP B-CHEM
- - - I-CHEM
II NNP NNP I-CHEM
on IN IN O
behavioral JJ JJ O
, , , O
metabolic JJ JJ O
, , , O
and CC CC O
endocrine NN NN O
responses NNS NNS O
in IN IN O
mice NN NN O
. . . O

Administration NNP NNP O
of IN IN O
graded JJ JJ O
doses NNS NNS O
of IN IN O
U NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
( ( ( O
1 CD CD O
- : : O
10 CD CD O
, , , O
000 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
) ) ) O
provoked JJ JJ O
: : : O
( ( ( O
1 CD CD O
) ) ) O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
head NN NN O
dips NNS NNS O
in IN IN O
the DT DT O
hole NN NN O
- - - O
board NN NN O
test NN NN O
; : : O
( ( ( O
2 CD CD O
) ) ) O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
entries NNS NNS O
in IN IN O
the DT DT O
white JJ JJ O
chamber NN NN O
in IN IN O
the DT DT O
black JJ JJ O
- - - O
and CC CC O
- - - O
white JJ JJ O
compartment NN NN O
test NN NN O
, , , O
and CC CC O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
entries NNS NNS O
in IN IN O
the DT DT O
central JJ JJ O
platform NN NN O
and CC CC O
open JJ JJ O
arms NNS NNS O
in IN IN O
the DT DT O
plus CC CC O
- - - O
maze NN NN O
test NN NN O
; : : O
and CC CC O
( ( ( O
3 CD CD O
) ) ) O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
duration NN NN O
of IN IN O
immobility NN NN O
in IN IN O
the DT DT O
forced JJ JJ O
- - - O
swimming NN NN O
test NN NN O
and CC CC O
tail NN NN O
suspension NN NN O
test NN NN O
. . . O

Intracerebroventricular NNP NNP O
injection NN NN O
of IN IN O
U NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
also RB RB O
caused VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
: : : O
food NN NN O
intake NN NN O
at IN IN O
doses NNS NNS O
of IN IN O
100 CD CD O
and CC CC O
1 CD CD O
, , , O
000 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
, , , O
water NN NN O
intake NN NN O
at IN IN O
doses NNS NNS O
of IN IN O
100 CD CD O
- : : O
10 CD CD O
, , , O
000 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
, , , O
and CC CC O
horizontal NN NN O
locomotion NN NN O
activity NN NN O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
10 CD CD O
, , , O
000 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
. . . O

Whatever WDT WDT O
was VBD VBD O
the DT DT O
dose NN NN O
, , , O
the DT DT O
central JJ JJ O
administration NN NN O
of IN IN O
U NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
body NN NN O
temperature NN NN O
, , , O
nociception NN NN O
, , , O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
penile NN NN O
erection NN NN O
and CC CC O
climbing VBG VBG O
behavior NN NN O
, , , O
and CC CC O
stress NN NN O
- - - O
induced JJ JJ O
plasma NN NN O
corticosterone NN NN B-CHEM
level NN NN O
. . . O

Taken VBN VBN O
together RB RB O
, , , O
the DT DT O
present JJ JJ O
study NN NN O
demonstrates VBZ VBZ O
that IN IN O
the DT DT O
central JJ JJ O
injection NN NN O
of IN IN O
U NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
at IN IN O
doses NNS NNS O
of IN IN O
1 CD CD O
- : : O
10 CD CD O
, , , O
000 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
induces NNS NNS O
anxiogenic JJ JJ O
- : : O
and CC CC O
depressant JJ JJ O
- - - O
like IN IN O
effects NNS NNS O
in IN IN O
mouse NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
U NNP NNP B-CHEM
- : : I-CHEM
II NNP NNP I-CHEM
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
some DT DT O
aspects NNS NNS O
of IN IN O
psychiatric JJ JJ O
disorders NNS NNS O
. . . O

Learning NNP NNP O
of IN IN O
rats NNS NNS O
under IN IN O
amnesia NN NN O
caused VBN VBN O
by IN IN O
pentobarbital NN NN B-CHEM
. . . O

Dissociated NNP NNP O
learning VBG VBG O
of IN IN O
rats NNS NNS O
in IN IN O
the DT DT O
normal JJ JJ O
state NN NN O
and CC CC O
the DT DT O
state NN NN O
of IN IN O
amnesia NN NN O
produced VBN VBN O
by IN IN O
pentobarbital NN NN B-CHEM
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
ip NNP NNP O
) ) ) O
was VBD VBD O
carried VBN VBN O
out IN IN O
. . . O

Rats NNP NNP O
were VBD VBD O
trained VBN VBN O
to TO TO O
approach VB VB O
a DT DT O
shelf NN NN O
where WRB WRB O
they PRP PRP O
received VBD VBD O
food NN NN O
reinforcement NN NN O
. . . O

In IN IN O
Group NNP NNP O
1 CD CD O
the DT DT O
rats NNS NNS O
were VBD VBD O
trained VBN VBN O
under IN IN O
the DT DT O
influence NN NN O
of IN IN O
pentobarbital NN NN B-CHEM
to TO TO O
run VB VB O
to TO TO O
the DT DT O
same JJ JJ O
shelf NN NN O
as IN IN O
in IN IN O
the DT DT O
normal JJ JJ O
state NN NN O
. . . O

In IN IN O
Group NNP NNP O
2 CD CD O
the DT DT O
rats NNS NNS O
were VBD VBD O
trained VBN VBN O
to TO TO O
approach NN NN O
different JJ JJ O
shelves NNS NNS O
in IN IN O
different JJ JJ O
drug NN NN O
states NNS NNS O
. . . O

It PRP PRP O
was VBD VBD O
shown VBN VBN O
that IN IN O
memory NN NN O
dissociation NN NN O
occurred VBD VBD O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Differences NNS NNS O
in IN IN O
the DT DT O
parameters NNS NNS O
of IN IN O
training NN NN O
under IN IN O
the DT DT O
influence NN NN O
of IN IN O
pentobarbital JJ JJ B-CHEM
between IN IN O
Groups NNS NNS O
1 CD CD O
and CC CC O
2 CD CD O
were VBD VBD O
revealed VBN VBN O
. . . O

These DT DT O
findings NNS NNS O
show VBP VBP O
that IN IN O
the DT DT O
brain NN NN O
- - - O
dissociated JJ JJ O
state NN NN O
induced VBN VBN O
by IN IN O
pentobarbital NN NN B-CHEM
is VBZ VBZ O
formed VBN VBN O
with IN IN O
the DT DT O
participation NN NN O
of IN IN O
the DT DT O
mechanisms NNS NNS O
of IN IN O
information NN NN O
perception NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
short JJ JJ O
- - - O
term NN NN O
raloxifene NN NN B-CHEM
therapy NN NN O
on IN IN O
fibrinolysis NN NN O
markers NNS NNS O
: : : O
TAFI NNP NNP O
, , , O
tPA NN NN O
, , , O
and CC CC O
PAI NNP NNP O
- : : O
1 CD CD O
. . . O

BACKGROUND NNP NNP O
: : : O
Markers NNP NNP O
of IN IN O
fibrinolysis NN NN O
, , , O
thrombin NN NN O
- - - O
activatable JJ JJ O
fibrinolysis NN NN O
inhibitor NN NN O
( ( ( O
TAFI NNP NNP O
) ) ) O
, , , O
tissue NN NN O
- - - O
type NN NN O
plasminogen NN NN O
activator NN NN O
( ( ( O
tPA NN NN O
) ) ) O
, , , O
and CC CC O
plasminogen NN NN O
activator NN NN O
inhibitor NN NN O
- : : O
1 CD CD O
( ( ( O
PAI NNP NNP O
- - - O
1 CD CD O
) ) ) O
levels NNS NNS O
were VBD VBD O
studied VBN VBN O
for IN IN O
the DT DT O
evaluation NN NN O
of IN IN O
short JJ JJ O
- - - O
term NN NN O
effects NNS NNS O
of IN IN O
raloxifene NN NN B-CHEM
administration NN NN O
in IN IN O
postmenopausal NN NN O
women NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Thirty NNP NNP O
- - - O
nine CD CD O
postmenopausal NN NN O
women NNS NNS O
with IN IN O
osteopenia NN NN O
or CC CC O
osteoporosis NN NN O
were VBD VBD O
included VBN VBN O
in IN IN O
this DT DT O
prospective JJ JJ O
, , , O
controlled VBN VBN O
clinical JJ JJ O
study NN NN O
. . . O

Twenty CD CD O
- - - O
five CD CD O
women NNS NNS O
were VBD VBD O
given VBN VBN O
raloxifene NN NN B-CHEM
hydrochloride NN NN I-CHEM
( ( ( O
60 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
plus CC CC O
calcium NN NN B-CHEM
( ( ( O
500 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
. . . O

Age NNP NNP O
- - - O
matched JJ JJ O
controls NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
14 CD CD O
) ) ) O
were VBD VBD O
given VBN VBN O
only RB RB O
calcium NN NN B-CHEM
. . . O

Plasma NNP NNP O
TAFI NNP NNP O
, , , O
tPA NN NN O
, , , O
and CC CC O
PAI NNP NNP O
- : : O
1 CD CD O
antigen NN NN O
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
at IN IN O
baseline NN NN O
and CC CC O
after IN IN O
3 CD CD O
months NNS NNS O
of IN IN O
treatment NN NN O
by IN IN O
commercially RB RB O
available JJ JJ O
ELISA NNP NNP O
kits NNS NNS O
. . . O

Variations NNP NNP O
of IN IN O
individuals NNS NNS O
were VBD VBD O
assessed VBN VBN O
by IN IN O
Wilcoxon NNP NNP O
' POS POS O
s VBZ VBZ O
test NN NN O
. . . O

Relationship NNP NNP O
between IN IN O
those DT DT O
markers NNS NNS O
and CC CC O
demographic JJ JJ O
characteristics NNS NNS O
were VBD VBD O
investigated VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Three CD CD O
months NNS NNS O
of IN IN O
raloxifene NN NN B-CHEM
treatment NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
plasma NN NN O
TAFI NNP NNP O
antigen NN NN O
concentrations NNS NNS O
( ( ( O
16 CD CD O
% NN NN O
change NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
and CC CC O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
tPA NN NN O
antigen NN NN O
concentrations NNS NNS O
( ( ( O
25 CD CD O
% NN NN O
change NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

A DT DT O
significant JJ JJ O
correlation NN NN O
was VBD VBD O
found VBN VBN O
between IN IN O
baseline NN NN O
TAFI NNP NNP O
antigen NN NN O
concentrations NNS NNS O
and CC CC O
the DT DT O
duration NN NN O
of IN IN O
amenorrhea NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
; : : O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
33 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
We PRP PRP O
suggest VBP VBP O
that IN IN O
the DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
due JJ JJ O
to TO TO O
raloxifene VB VB B-CHEM
treatment NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
increased VBN VBN O
tPA NN NN O
levels NNS NNS O
, , , O
but CC CC O
not RB RB O
TAFI NNP NNP O
levels NNS NNS O
. . . O

Valproate NNP NNP B-CHEM
- : : O
induced JJ JJ O
encephalopathy NN NN O
. . . O

Valproate NNP NNP B-CHEM
- : : O
induced JJ JJ O
encephalopathy NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
syndrome NN NN O
that WDT WDT O
may MD MD O
manifest VB VB O
in IN IN O
otherwise RB RB O
normal JJ JJ O
epileptic JJ JJ O
individuals NNS NNS O
. . . O

It PRP PRP O
may MD MD O
even RB RB O
present VB VB O
in IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
tolerated VBN VBN O
this DT DT O
medicine NN NN O
well RB RB O
in IN IN O
the DT DT O
past NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
usually RB RB O
but CC CC O
not RB RB O
necessarily RB RB O
associated VBN VBN O
with IN IN O
hyperammonemia NN NN O
. . . O

The DT DT O
EEG NNP NNP O
shows VBZ VBZ O
characteristic JJ JJ O
triphasic NN NN O
waves NNS NNS O
in IN IN O
most JJS JJS O
patients NNS NNS O
with IN IN O
this DT DT O
complication NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
valproate NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
is VBZ VBZ O
presented VBN VBN O
. . . O

The DT DT O
problems NNS NNS O
in IN IN O
diagnosing VBG VBG O
this DT DT O
condition NN NN O
are VBP VBP O
subsequently RB RB O
discussed VBN VBN O
. . . O

Recurrent NNP NNP O
dysphonia NN NN O
and CC CC O
acitretin NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
woman NN NN O
complaining VBG VBG O
of IN IN O
dysphonia NN NN O
while IN IN O
she PRP PRP O
was VBD VBD O
treated VBN VBN O
by IN IN O
acitretin NN NN B-CHEM
. . . O

Her PRP$ PRP$ O
symptoms NNS NNS O
totally RB RB O
regressed VBN VBN O
after IN IN O
drug NN NN O
withdrawal NN NN O
and CC CC O
reappeared VBD VBD O
when WRB WRB O
acitretin NN NN B-CHEM
was VBD VBD O
reintroduced VBN VBN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
case NN NN O
of IN IN O
acitretin NN NN B-CHEM
- - - O
induced JJ JJ O
dysphonia NN NN O
. . . O

This DT DT O
effect NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
pharmacological JJ JJ O
effect NN NN O
of IN IN O
this DT DT O
drug NN NN O
on IN IN O
mucous JJ JJ O
membranes NNS NNS O
. . . O

Nitro NNP NNP B-CHEM
- : : I-CHEM
L NNP NNP I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
methyl NN NN I-CHEM
ester NN NN I-CHEM
: : : O
a DT DT O
potential JJ JJ O
protector NN NN O
against IN IN O
gentamicin NN NN B-CHEM
ototoxicity NN NN O
. . . O

The DT DT O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO NNP NNP B-CHEM
) ) ) O
inhibitor NN NN O
nitro NN NN B-CHEM
- : : I-CHEM
L NNP NNP I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
methyl NN NN I-CHEM
ester NN NN I-CHEM
( ( ( O
L NNP NNP B-CHEM
- - - I-CHEM
NAME NNP NNP I-CHEM
) ) ) O
may MD MD O
act VB VB O
as IN IN O
an DT DT O
otoprotectant NN NN O
against IN IN O
high JJ JJ O
- - - O
frequency NN NN O
hearing NN NN O
loss NN NN O
caused VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
, , , O
but CC CC O
further JJ JJ O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
confirm VB VB O
this DT DT O
. . . O
Aminoglycoside NNP NNP B-CHEM
antibiotics NNS NNS O
are VBP VBP O
still RB RB O
widely RB RB O
used VBN VBN O
by IN IN O
virtue NN NN O
of IN IN O
their PRP$ PRP$ O
efficacy NN NN O
and CC CC O
low JJ JJ O
cost NN NN O
. . . O

Their PRP$ PRP$ O
ototoxicity NN NN O
is VBZ VBZ O
a DT DT O
serious JJ JJ O
health NN NN O
problem NN NN O
and CC CC O
, , , O
as IN IN O
their PRP$ PRP$ O
ototoxic JJ JJ O
mechanism NN NN O
involves VBZ VBZ O
the DT DT O
production NN NN O
of IN IN O
NO NN NN B-CHEM
, , , O
we PRP PRP O
need VBP VBP O
to TO TO O
assess VB VB O
the DT DT O
use NN NN O
of IN IN O
NO NN NN B-CHEM
inhibitors NNS NNS O
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
aminoglycoside NN NN B-CHEM
- - - O
induced JJ JJ O
sensorineural JJ JJ O
hearing NN NN O
loss NN NN O
. . . O

In IN IN O
this DT DT O
experimental JJ JJ O
study NN NN O
we PRP PRP O
used VBD VBD O
30 CD CD O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
, , , O
27 CD CD O
of IN IN O
which WDT WDT O
had VBD VBD O
gentamicin NN NN B-CHEM
instilled VBN VBN O
into IN IN O
the DT DT O
middle JJ JJ O
ear NN NN O
. . . O

The DT DT O
otoprotectant JJ JJ O
L NNP NNP B-CHEM
- : : I-CHEM
NAME NNP NNP I-CHEM
was VBD VBD O
administered VBN VBN O
topically RB RB O
to TO TO O
12 CD CD O
/ NN NN O
27 CD CD O
animals NNS NNS O
. . . O

Its PRP$ PRP$ O
effect NN NN O
was VBD VBD O
determined VBN VBN O
in IN IN O
terms NNS NNS O
of IN IN O
attenuation NN NN O
of IN IN O
hearing NN NN O
loss NN NN O
, , , O
measured VBN VBN O
by IN IN O
shifts NNS NNS O
in IN IN O
the DT DT O
auditory NN NN O
brainstem NN NN O
response NN NN O
threshold NN NN O
. . . O

L NNP NNP B-CHEM
- : : I-CHEM
NAME NNP NNP I-CHEM
reduced VBD VBD O
gentamicin NN NN B-CHEM
- : : O
induced JJ JJ O
hearing NN NN O
loss NN NN O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
frequency NN NN O
range NN NN O
, , , O
but CC CC O
gave VBD VBD O
no DT DT O
protection NN NN O
in IN IN O
the DT DT O
middle JJ JJ O
or CC CC O
low JJ JJ O
frequencies NNS NNS O
. . . O

Safety NNP NNP O
profile NN NN O
of IN IN O
a DT DT O
nicotine NN NN B-CHEM
lozenge NN NN O
compared VBN VBN O
with IN IN O
that DT DT O
of IN IN O
nicotine NN NN B-CHEM
gum NN NN O
in IN IN O
adult NN NN O
smokers NNS NNS O
with IN IN O
underlying VBG VBG O
medical JJ JJ O
conditions NNS NNS O
: : : O
a DT DT O
12 CD CD O
- : : O
week NN NN O
, , , O
randomized JJ JJ O
, , , O
open JJ JJ O
- - - O
label NN NN O
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Nicotine NNP NNP B-CHEM
polacrilex NN NN O
lozenges NNS NNS O
deliver RB RB O
25 CD CD O
% NN NN O
to TO TO O
27 CD CD O
% NN NN O
more JJR JJR O
nicotine NN NN B-CHEM
compared VBN VBN O
with IN IN O
equivalent JJ JJ O
doses NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
polacrilex NN NN O
gum NN NN O
. . . O

The DT DT O
increased VBN VBN O
nicotine NN NN B-CHEM
exposure NN NN O
from IN IN O
the DT DT O
lozenge NN NN O
has VBZ VBZ O
raised VBN VBN O
questions NNS NNS O
about IN IN O
the DT DT O
relative JJ JJ O
safety NN NN O
of IN IN O
the DT DT O
lozenge NN NN O
and CC CC O
gum NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
compare VB VB O
the DT DT O
safety NN NN O
profiles NNS NNS O
of IN IN O
the DT DT O
4 CD CD O
- : : O
mg NN NN O
nicotine NN NN B-CHEM
lozenge NN NN O
and CC CC O
4 CD CD O
- : : O
mg NN NN O
nicotine NN NN B-CHEM
gum NN NN O
in IN IN O
smokers NNS NNS O
with IN IN O
selected VBN VBN O
label NN NN O
- - - O
restricted JJ JJ O
diseases NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
was VBD VBD O
a DT DT O
multicenter NN NN O
, , , O
randomized JJ JJ O
, , , O
open JJ JJ O
- - - O
label NN NN O
study NN NN O
in IN IN O
adult NN NN O
smokers NNS NNS O
with IN IN O
heart NN NN O
disease NN NN O
, , , O
hypertension NN NN O
not RB RB O
controlled VBN VBN O
by IN IN O
medication NN NN O
, , , O
and CC CC O
/ NN NN O
or CC CC O
diabetes NN NN O
mellitus NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
in IN IN O
a DT DT O
1 CD CD O
: : : O
1 CD CD O
ratio NN NN O
to TO TO O
receive VB VB O
the DT DT O
4 CD CD O
- : : O
mg NN NN O
nicotine NN NN B-CHEM
lozenge NN NN O
or CC CC O
4 CD CD O
- : : O
mg NN NN O
nicotine NN NN B-CHEM
gum NN NN O
. . . O

Safety NNP NNP O
assessments NNS NNS O
were VBD VBD O
made VBN VBN O
at IN IN O
baseline NN NN O
and CC CC O
at IN IN O
2 CD CD O
, , , O
4 CD CD O
, , , O
6 CD CD O
, , , O
and CC CC O
12 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
product NN NN O
use NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Nine CD CD O
hundred CD CD O
one CD CD O
patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
treatment NN NN O
, , , O
447 CD CD O
who WP WP O
received VBD VBD O
the DT DT O
lozenge NN NN O
and CC CC O
454 CD CD O
who WP WP O
received VBD VBD O
the DT DT O
gum NN NN O
( ( ( O
safety NN NN O
population NN NN O
) ) ) O
. . . O

The DT DT O
majority NN NN O
were VBD VBD O
women NNS NNS O
( ( ( O
52 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
. . . O

Patients NNS NNS O
' POS POS O
mean VB VB O
age NN NN O
was VBD VBD O
53 CD CD O
. . . O
9 CD CD O
years NNS NNS O
, , , O
their PRP$ PRP$ O
mean NN NN O
weight NN NN O
was VBD VBD O
193 CD CD O
. . . O
9 CD CD O
pounds NNS NNS O
, , , O
and CC CC O
they PRP PRP O
smoked VBD VBD O
a DT DT O
mean NN NN O
of IN IN O
25 CD CD O
. . . O
2 CD CD O
cigarettes NNS NNS O
per IN IN O
day NN NN O
at IN IN O
baseline NN NN O
. . . O

Five CD CD O
hundred CD CD O
fifty NN NN O
- - - O
three CD CD O
patients NNS NNS O
, , , O
264 CD CD O
taking VBG VBG O
the DT DT O
lozenge NN NN O
and CC CC O
289 CD CD O
taking VBG VBG O
the DT DT O
gum NN NN O
, , , O
used VBD VBD O
the DT DT O
study NN NN O
product NN NN O
for IN IN O
> NN NN O
or CC CC O
= SYM SYM O
4 CD CD O
days NNS NNS O
per IN IN O
week NN NN O
during IN IN O
the DT DT O
first JJ JJ O
2 CD CD O
weeks NNS NNS O
( ( ( O
evaluable JJ JJ O
population NN NN O
) ) ) O
. . . O

The DT DT O
nicotine NN NN B-CHEM
lozenge NN NN O
and CC CC O
nicotine NN NN B-CHEM
gum NN NN O
were VBD VBD O
equally RB RB O
well RB RB O
tolerated VBD VBD O
, , , O
despite IN IN O
increased VBN VBN O
nicotine NN NN B-CHEM
exposure NN NN O
from IN IN O
the DT DT O
lozenge NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
in IN IN O
the DT DT O
2 CD CD O
groups NNS NNS O
was VBD VBD O
similar JJ JJ O
during IN IN O
the DT DT O
first JJ JJ O
2 CD CD O
weeks NNS NNS O
of IN IN O
product NN NN O
use NN NN O
( ( ( O
evaluation NN NN O
population NN NN O
: : : O
55 CD CD O
. . . O
3 CD CD O
% NN NN O
lozenge NN NN O
, , , O
54 CD CD O
. . . O
7 CD CD O
% NN NN O
gum NN NN O
) ) ) O
, , , O
as RB RB O
well RB RB O
as IN IN O
during IN IN O
the DT DT O
entire JJ JJ O
study NN NN O
( ( ( O
safety NN NN O
population NN NN O
: : : O
63 CD CD O
. . . O
8 CD CD O
% NN NN O
and CC CC O
58 CD CD O
. . . O
6 CD CD O
% NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

Stratification NNP NNP O
of IN IN O
patients NNS NNS O
by IN IN O
sex NN NN O
, , , O
age NN NN O
, , , O
extent NN NN O
of IN IN O
concurrent NN NN O
smoking NN NN O
, , , O
extent NN NN O
of IN IN O
product NN NN O
use NN NN O
, , , O
and CC CC O
severity NN NN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
revealed VBD VBD O
no DT DT O
clinically RB RB O
significant JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
lozenge NN NN O
and CC CC O
gum NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
nausea NN NN O
( ( ( O
17 CD CD O
. . . O
2 CD CD O
% NN NN O
and CC CC O
16 CD CD O
. . . O
1 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
- - - O
3 CD CD O
. . . O
7 CD CD O
to TO TO O
6 CD CD O
. . . O
0 CD CD O
) ) ) O
, , , O
hiccups NNS NNS O
( ( ( O
10 CD CD O
. . . O
7 CD CD O
% NN NN O
and CC CC O
6 CD CD O
. . . O
6 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
. . . O
5 CD CD O
to TO TO O
7 CD CD O
. . . O
8 CD CD O
) ) ) O
, , , O
and CC CC O
headache NN NN O
( ( ( O
8 CD CD O
. . . O
7 CD CD O
% NN NN O
and CC CC O
9 CD CD O
. . . O
9 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
Cl NNP NNP O
, , , O
- - - O
5 CD CD O
. . . O
0 CD CD O
to TO TO O
2 CD CD O
. . . O
6 CD CD O
) ) ) O
. . . O

Serious JJ JJ O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
reported VBN VBN O
in IN IN O
11 CD CD O
and CC CC O
13 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
respective JJ JJ O
groups NNS NNS O
. . . O

Fewer JJR JJR O
than IN IN O
6 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
either DT DT O
group NN NN O
were VBD VBD O
considered VBN VBN O
by IN IN O
the DT DT O
investigator NN NN O
to TO TO O
have VB VB O
a DT DT O
worsening VBG VBG O
of IN IN O
their PRP$ PRP$ O
overall JJ JJ O
disease NN NN O
condition NN NN O
during IN IN O
the DT DT O
study NN NN O
. . . O

The DT DT O
majority NN NN O
of IN IN O
patients NNS NNS O
( ( ( O
> NN NN O
60 CD CD O
% NN NN O
) ) ) O
experienced VBD VBD O
no DT DT O
change NN NN O
in IN IN O
their PRP$ PRP$ O
disease NN NN O
status NN NN O
from IN IN O
baseline NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
4 CD CD O
- : : O
mg NN NN O
nicotine NN NN B-CHEM
lozenge NN NN O
and CC CC O
4 CD CD O
- : : O
mg NN NN O
nicotine NN NN B-CHEM
gum NN NN O
had VBD VBD O
comparable JJ JJ O
safety NN NN O
profiles NNS NNS O
in IN IN O
these DT DT O
patients NNS NNS O
with IN IN O
label NN NN O
- - - O
restricted JJ JJ O
medical JJ JJ O
conditions NNS NNS O
. . . O

Pharmacological NNP NNP O
modulation NN NN O
of IN IN O
pain NN NN O
- - - O
related VBN VBN O
brain NN NN O
activity NN NN O
during IN IN O
normal JJ JJ O
and CC CC O
central JJ JJ O
sensitization NN NN O
states NNS NNS O
in IN IN O
humans NNS NNS O
. . . O

Abnormal NNP NNP O
processing NN NN O
of IN IN O
somatosensory NN NN O
inputs NNS NNS O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
central JJ JJ O
sensitization NN NN O
) ) ) O
is VBZ VBZ O
the DT DT O
mechanism NN NN O
accounting VBG VBG O
for IN IN O
the DT DT O
enhanced JJ JJ O
pain NN NN O
sensitivity NN NN O
in IN IN O
the DT DT O
skin NN NN O
surrounding VBG VBG O
tissue NN NN O
injury NN NN O
( ( ( O
secondary JJ JJ O
hyperalgesia NN NN O
) ) ) O
. . . O

Secondary JJ JJ O
hyperalgesia NN NN O
shares NNS NNS O
clinical JJ JJ O
characteristics NNS NNS O
with IN IN O
neurogenic JJ JJ O
hyperalgesia NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
neuropathic JJ JJ O
pain NN NN O
. . . O

Abnormal NNP NNP O
brain NN NN O
responses NNS NNS O
to TO TO O
somatosensory JJ JJ O
stimuli NN NN O
have VBP VBP O
been VBN VBN O
found VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
hyperalgesia NN NN O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
normal JJ JJ O
subjects NNS NNS O
during IN IN O
experimental JJ JJ O
central JJ JJ O
sensitization NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
gabapentin NN NN B-CHEM
, , , O
a DT DT O
drug NN NN O
effective JJ JJ O
in IN IN O
neuropathic JJ JJ O
pain NN NN O
patients NNS NNS O
, , , O
on IN IN O
brain NN NN O
processing NN NN O
of IN IN O
nociceptive JJ JJ O
information NN NN O
in IN IN O
normal JJ JJ O
and CC CC O
central JJ JJ O
sensitization NN NN O
states NNS NNS O
. . . O

Using VBG VBG O
functional JJ JJ O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
fMRI NN NN O
) ) ) O
in IN IN O
normal JJ JJ O
volunteers NNS NNS O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
gabapentin NN NN B-CHEM
- - - O
induced JJ JJ O
modulation NN NN O
of IN IN O
brain NN NN O
activity NN NN O
in IN IN O
response NN NN O
to TO TO O
nociceptive JJ JJ O
mechanical JJ JJ O
stimulation NN NN O
of IN IN O
normal JJ JJ O
skin NN NN O
and CC CC O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
secondary JJ JJ O
hyperalgesia NN NN O
. . . O

The DT DT O
dose NN NN O
of IN IN O
gabapentin NN NN B-CHEM
was VBD VBD O
1 CD CD O
, , , O
800 CD CD O
mg NN NN O
per IN IN O
os NN NN O
, , , O
in IN IN O
a DT DT O
single JJ JJ O
administration NN NN O
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
( ( ( O
i NNP NNP O
) ) ) O
gabapentin NN NN B-CHEM
reduced VBD VBD O
the DT DT O
activations NNS NNS O
in IN IN O
the DT DT O
bilateral NN NN O
operculoinsular NN NN O
cortex NN NN O
, , , O
independently RB RB O
of IN IN O
the DT DT O
presence NN NN O
of IN IN O
central JJ JJ O
sensitization NN NN O
; : : O
( ( ( O
ii NN NN O
) ) ) O
gabapentin NN NN B-CHEM
reduced VBD VBD O
the DT DT O
activation NN NN O
in IN IN O
the DT DT O
brainstem NN NN O
, , , O
only RB RB O
during IN IN O
central JJ JJ O
sensitization NN NN O
; : : O
( ( ( O
iii NN NN O
) ) ) O
gabapentin NN NN B-CHEM
suppressed VBN VBN O
stimulus JJ JJ O
- - - O
induced JJ JJ O
deactivations NNS NNS O
, , , O
only RB RB O
during IN IN O
central JJ JJ O
sensitization NN NN O
; : : O
this DT DT O
effect NN NN O
was VBD VBD O
more RBR RBR O
robust JJ JJ O
than IN IN O
the DT DT O
effect NN NN O
on IN IN O
brain NN NN O
activation NN NN O
. . . O

The DT DT O
observed VBN VBN O
drug NN NN O
- - - O
induced JJ JJ O
effects NNS NNS O
were VBD VBD O
not RB RB O
due JJ JJ O
to TO TO O
changes NNS NNS O
in IN IN O
the DT DT O
baseline NN NN O
fMRI NN NN O
signal NN NN O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
gabapentin NN NN B-CHEM
has VBZ VBZ O
a DT DT O
measurable JJ JJ O
antinociceptive JJ JJ O
effect NN NN O
and CC CC O
a DT DT O
stronger JJR JJR O
antihyperalgesic JJ JJ O
effect NN NN O
most RBS RBS O
evident JJ JJ O
in IN IN O
the DT DT O
brain NN NN O
areas NNS NNS O
undergoing VBG VBG O
deactivation NN NN O
, , , O
thus RB RB O
supporting VBG VBG O
the DT DT O
concept NN NN O
that DT DT O
gabapentin NN NN B-CHEM
is VBZ VBZ O
more RBR RBR O
effective JJ JJ O
in IN IN O
modulating VBG VBG O
nociceptive JJ JJ O
transmission NN NN O
when WRB WRB O
central JJ JJ O
sensitization NN NN O
is VBZ VBZ O
present JJ JJ O
. . . O

Investigation NNP NNP O
of IN IN O
mitochondrial JJ JJ O
involvement NN NN O
in IN IN O
the DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
epilepsy NN NN O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
. . . O

Mitochondrial NNP NNP O
abnormalities NNS NNS O
have VBP VBP O
been VBN VBN O
associated VBN VBN O
with IN IN O
several JJ JJ O
aspects NNS NNS O
of IN IN O
epileptogenesis NN NN O
, , , O
such JJ JJ O
as IN IN O
energy NN NN O
generation NN NN O
, , , O
control NN NN O
of IN IN O
cell NN NN O
death NN NN O
, , , O
neurotransmitter NN NN O
synthesis NN NN O
, , , O
and CC CC O
free JJ JJ O
radical JJ JJ O
( ( ( O
FR NNP NNP O
) ) ) O
production NN NN O
. . . O

Increased NNP NNP O
production NN NN O
of IN IN O
FRs NNP NNP O
may MD MD O
cause VB VB O
mtDNA NN NN O
damage NN NN O
leading VBG VBG O
to TO TO O
decreased VBD VBD O
activities NNS NNS O
of IN IN O
oxidative JJ JJ O
phosphorylation NN NN O
complexes NNS NNS O
containing VBG VBG O
mtDNA NN NN O
- - - O
encoded JJ JJ O
subunits NNS NNS O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
whether IN IN O
increased VBN VBN O
generation NN NN O
of IN IN O
FR NNP NNP O
during IN IN O
status NN NN O
epilepticus NN NN O
would MD MD O
be VB VB O
sufficient JJ JJ O
to TO TO O
provoke VB VB O
abnormalities NNS NNS O
in IN IN O
mtDNA NN NN O
and CC CC O
in IN IN O
the DT DT O
expression NN NN O
and CC CC O
activity NN NN O
of IN IN O
cytochrome JJ JJ O
c SYM SYM O
oxidase NN NN O
( ( ( O
CCO NNP NNP O
) ) ) O
, , , O
complex JJ JJ O
IV NNP NNP O
of IN IN O
the DT DT O
respiratory JJ JJ O
chain NN NN O
, , , O
in IN IN O
the DT DT O
chronic JJ JJ O
phase NN NN O
of IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
model NN NN O
of IN IN O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
. . . O

DNA NNP NNP O
analysis NN NN O
revealed VBD VBD O
low JJ JJ O
amounts NNS NNS O
of IN IN O
a DT DT O
4 CD CD O
. . . O
8 CD CD O
kb NN NN O
mtDNA NN NN O
deletion NN NN O
but CC CC O
with IN IN O
no DT DT O
differences NNS NNS O
in IN IN O
frequency NN NN O
or CC CC O
quantity NN NN O
in IN IN O
the DT DT O
control NN NN O
and CC CC O
experimental JJ JJ O
groups NNS NNS O
. . . O

We PRP PRP O
did VBD VBD O
not RB RB O
find VB VB O
abnormalities NNS NNS O
in IN IN O
the DT DT O
expression NN NN O
and CC CC O
distribution NN NN O
of IN IN O
an DT DT O
mtDNA NN NN O
- - - O
encoded JJ JJ O
subunit NN NN O
of IN IN O
CCO NNP NNP O
( ( ( O
CCO NNP NNP O
- : : O
I PRP PRP O
) ) ) O
or CC CC O
a DT DT O
relative JJ JJ O
decrease NN NN O
in IN IN O
CCO NNP NNP O
- : : O
I PRP PRP O
when WRB WRB O
compared VBN VBN O
with IN IN O
nuclear JJ JJ O
- - - O
encoded JJ JJ O
subunits NNS NNS O
( ( ( O
CCO NNP NNP O
- : : O
IV NNP NNP O
and CC CC O
SDH NNP NNP O
- : : O
fp NN NN O
) ) ) O
. . . O

No DT DT O
abnormality NN NN O
in IN IN O
CCO NNP NNP O
activity NN NN O
was VBD VBD O
observed VBN VBN O
through IN IN O
histochemistry NN NN O
. . . O

Although IN IN O
evidences NNS NNS O
of IN IN O
mitochondrial JJ JJ O
abnormalities NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
previously RB RB O
published VBN VBN O
studies NNS NNS O
, , , O
our PRP$ PRP$ O
results NNS NNS O
do VBP VBP O
not RB RB O
suggest VB VB O
that IN IN O
the DT DT O
FRs NNP NNP O
, , , O
generated VBD VBD O
during IN IN O
the DT DT O
acute JJ JJ O
phase NN NN O
, , , O
determined VBN VBN O
important JJ JJ O
abnormalities NNS NNS O
in IN IN O
mtDNA NN NN O
, , , O
in IN IN O
expression NN NN O
of IN IN O
CCO NNP NNP O
- : : O
I PRP PRP O
, , , O
and CC CC O
in IN IN O
CCO NNP NNP O
activity NN NN O
. . . O

Adverse NNP NNP O
effect NN NN O
of IN IN O
the DT DT O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
nitrendipine NN NN B-CHEM
on IN IN O
nephrosclerosis NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
renovascular JJ JJ O
hypertension NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
a DT DT O
6 CD CD O
- : : O
week NN NN O
treatment NN NN O
with IN IN O
the DT DT O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
nitrendipine NN NN B-CHEM
or CC CC O
the DT DT O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
enalapril NN NN B-CHEM
on IN IN O
blood NN NN O
pressure NN NN O
, , , O
albuminuria NN NN O
, , , O
renal JJ JJ O
hemodynamics NNS NNS O
, , , O
and CC CC O
morphology NN NN O
of IN IN O
the DT DT O
nonclipped JJ JJ O
kidney NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
rats NNS NNS O
with IN IN O
two CD CD O
- - - O
kidney NN NN O
, , , O
one CD CD O
clip NN NN O
renovascular NN NN O
hypertension NN NN O
. . . O

Six CD CD O
weeks NNS NNS O
after IN IN O
clipping VBG VBG O
of IN IN O
one CD CD O
renal JJ JJ O
artery NN NN O
, , , O
hypertensive JJ JJ O
rats NNS NNS O
( ( ( O
178 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
three CD CD O
groups NNS NNS O
: : : O
untreated JJ JJ O
hypertensive JJ JJ O
controls NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
, , , O
enalapril NN NN B-CHEM
- - - O
treated VBN VBN O
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
, , , O
or CC CC O
nitrendipine NN NN B-CHEM
- - - O
treated VBN VBN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
. . . O

Sham NNP NNP O
- - - O
operated JJ JJ O
rats NNS NNS O
served VBD VBD O
as IN IN O
normotensive JJ JJ O
controls NNS NNS O
( ( ( O
128 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
. . . O

After IN IN O
6 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
, , , O
renal JJ JJ O
hemodynamics NNS NNS O
( ( ( O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
and CC CC O
renal JJ JJ O
plasma NN NN O
flow NN NN O
) ) ) O
were VBD VBD O
measured VBN VBN O
in IN IN O
the DT DT O
anesthetized JJ JJ O
rats NNS NNS O
. . . O

Renal NNP NNP O
tissue NN NN O
was VBD VBD O
obtained VBN VBN O
for IN IN O
determination NN NN O
of IN IN O
glomerular NN NN O
size NN NN O
and CC CC O
sclerosis NN NN O
. . . O

Enalapril NNP NNP B-CHEM
but CC CC O
not RB RB O
nitrendipine NN NN B-CHEM
reduced VBN VBN O
blood NN NN O
pressure NN NN O
significantly RB RB O
. . . O

After IN IN O
6 CD CD O
weeks NNS NNS O
of IN IN O
therapy NN NN O
, , , O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
was VBD VBD O
not RB RB O
different JJ JJ O
among IN IN O
the DT DT O
studied JJ JJ O
groups NNS NNS O
. . . O

Renal NNP NNP O
plasma NN NN O
flow NN NN O
increased VBD VBD O
, , , O
but CC CC O
albumin NN NN O
excretion NN NN O
and CC CC O
glomerulosclerosis NN NN O
did VBD VBD O
not RB RB O
change VB VB O
after IN IN O
enalapril NN NN B-CHEM
treatment NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
in IN IN O
the DT DT O
nitrendipine NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
albuminuria NNS NNS O
increased VBN VBN O
from IN IN O
12 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
progressively RB RB O
to TO TO O
163 CD CD O
+ NN NN O
/ NN NN O
- : : O
55 CD CD O
compared VBN VBN O
with IN IN O
19 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
mg NN NN O
/ NN NN O
24 CD CD O
hr NN NN O
in IN IN O
the DT DT O
hypertensive JJ JJ O
controls NNS NNS O
. . . O

Furthermore RB RB O
, , , O
glomerulosclerosis NN NN O
index NN NN O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
the DT DT O
nitrendipine NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
hypertensive JJ JJ O
controls NNS NNS O
( ( ( O
0 CD CD O
. . . O
38 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
versus CC CC O
0 CD CD O
. . . O
13 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
04 CD CD O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
glomerular NN NN O
size NN NN O
was VBD VBD O
higher JJR JJR O
in IN IN O
the DT DT O
nitrendipine NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
( ( ( O
14 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
17 CD CD O
10 CD CD O
( ( ( O
- : : O
3 CD CD O
) ) ) O
mm2 NN NN O
) ) ) O
but CC CC O
lower JJR JJR O
in IN IN O
the DT DT O
enalapril NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
( ( ( O
11 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
15 CD CD O
10 CD CD O
( ( ( O
- : : O
3 CD CD O
) ) ) O
mm2 NN NN O
) ) ) O
compared VBN VBN O
with IN IN O
the DT DT O
hypertensive JJ JJ O
controls NNS NNS O
( ( ( O
12 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
17 CD CD O
10 CD CD O
( ( ( O
- : : O
3 CD CD O
) ) ) O
mm2 NN NN O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Ketoconazole NNP NNP B-CHEM
induced VBD VBD O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
without IN IN O
concomitant JJ JJ O
use NN NN O
of IN IN O
QT NNP NNP O
interval NN NN O
- : : O
prolonging VBG VBG O
drug NN NN O
. . . O

Ketoconazole NNP NNP B-CHEM
is VBZ VBZ O
not RB RB O
known VBN VBN O
to TO TO O
be VB VB O
proarrhythmic JJ JJ O
without IN IN O
concomitant JJ JJ O
use NN NN O
of IN IN O
QT NNP NNP O
interval NN NN O
- : : O
prolonging VBG VBG O
drugs NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
woman NN NN O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
who WP WP O
developed VBD VBD O
a DT DT O
markedly RB RB O
prolonged JJ JJ O
QT NNP NNP O
interval NN NN O
and CC CC O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
( ( ( O
TdP NNP NNP O
) ) ) O
after IN IN O
taking VBG VBG O
ketoconazole NN NN B-CHEM
for IN IN O
treatment NN NN O
of IN IN O
fungal JJ JJ O
infection NN NN O
. . . O

Her PRP$ PRP$ O
QT NNP NNP O
interval NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
upon IN IN O
withdrawal NN NN O
of IN IN O
ketoconazole NN NN B-CHEM
. . . O

Genetic JJ JJ O
study NN NN O
did VBD VBD O
not RB RB O
find VB VB O
any DT DT O
mutation NN NN O
in IN IN O
her PRP$ PRP$ O
genes NNS NNS O
that WDT WDT O
encode NN NN O
cardiac NN NN O
IKr NNP NNP O
channel NN NN O
proteins NNS NNS O
. . . O

We PRP PRP O
postulate VBP VBP O
that IN IN O
by IN IN O
virtue NN NN O
of IN IN O
its PRP$ PRP$ O
direct JJ JJ O
blocking JJ JJ O
action NN NN O
on IN IN O
IKr NNP NNP O
, , , O
ketoconazole NN NN B-CHEM
alone RB RB O
may MD MD O
prolong VB VB O
QT NNP NNP O
interval NN NN O
and CC CC O
induce VB VB O
TdP NNP NNP O
. . . O

This DT DT O
calls VBZ VBZ O
for IN IN O
attention NN NN O
when WRB WRB O
ketoconazole NN NN B-CHEM
is VBZ VBZ O
administered VBN VBN O
to TO TO O
patients NNS NNS O
with IN IN O
risk NN NN O
factors NNS NNS O
for IN IN O
acquired VBN VBN O
long JJ JJ O
QT NNP NNP O
syndrome NN NN O
. . . O

Cerebral NNP NNP O
vasculitis NNS NNS O
following VBG VBG O
oral JJ JJ O
methylphenidate NN NN B-CHEM
intake NN NN O
in IN IN O
an DT DT O
adult NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

Methylphenidate NNP NNP B-CHEM
is VBZ VBZ O
structurally RB RB O
and CC CC O
functionally RB RB O
similar JJ JJ O
to TO TO O
amphetamine VB VB B-CHEM
. . . O

Cerebral NNP NNP O
vasculitis NNS NNS O
associated VBN VBN O
with IN IN O
amphetamine NN NN O
abuse NN NN O
is VBZ VBZ O
well RB RB O
documented VBN VBN O
, , , O
and CC CC O
in IN IN O
rare JJ JJ O
cases NNS NNS O
ischaemic JJ JJ O
stroke NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
after IN IN O
methylphenidate NN NN B-CHEM
intake NN NN O
in IN IN O
children NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
63 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
who WP WP O
was VBD VBD O
treated VBN VBN O
with IN IN O
methylphenidate NN NN B-CHEM
due JJ JJ O
to TO TO O
hyperactivity NN NN O
and CC CC O
suffered VBD VBD O
from IN IN O
multiple JJ JJ O
ischaemic JJ JJ O
strokes NNS NNS O
. . . O

We PRP PRP O
consider VBP VBP O
drug NN NN O
- - - O
induced JJ JJ O
cerebral JJ JJ O
vasculitis NNS NNS O
as IN IN O
the DT DT O
most RBS RBS O
likely JJ JJ O
cause NN NN O
of IN IN O
recurrent JJ JJ O
ischaemic JJ JJ O
strokes NNS NNS O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
any DT DT O
pathological JJ JJ O
findings NNS NNS O
during IN IN O
the DT DT O
diagnostic JJ JJ O
work NN NN O
- - - O
up RP RP O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
methylphenidate NN NN B-CHEM
mediated JJ JJ O
vasculitis NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
neurological JJ JJ O
symptoms NNS NNS O
and CC CC O
a DT DT O
history NN NN O
of IN IN O
methylphenidate NN NN B-CHEM
therapy NN NN O
. . . O

This DT DT O
potential JJ JJ O
side NN NN O
- - - O
effect NN NN O
, , , O
though IN IN O
very RB RB O
rare JJ JJ O
, , , O
represents VBZ VBZ O
one CD CD O
more JJR JJR O
reason NN NN O
to TO TO O
be VB VB O
very RB RB O
restrictive JJ JJ O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
methylphenidate NN NN B-CHEM
. . . O

MDMA NNP NNP B-CHEM
polydrug NN NN O
users NNS NNS O
show VBP VBP O
process NN NN O
- - - O
specific JJ JJ O
central JJ JJ O
executive NN NN O
impairments NNS NNS O
coupled VBN VBN O
with IN IN O
impaired JJ JJ O
social JJ JJ O
and CC CC O
emotional JJ JJ O
judgement NN NN O
processes NNS NNS O
. . . O

In IN IN O
recent JJ JJ O
years NNS NNS O
working VBG VBG O
memory NN NN O
deficits NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
users NNS NNS O
of IN IN O
MDMA NNP NNP B-CHEM
( ( ( O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylenedioxymethamphetamine NN NN I-CHEM
, , , O
ecstasy JJ JJ B-CHEM
) ) ) O
. . . O

The DT DT O
current JJ JJ O
study NN NN O
aimed VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
impact NN NN O
of IN IN O
MDMA NNP NNP B-CHEM
use NN NN O
on IN IN O
three CD CD O
separate JJ JJ O
central JJ JJ O
executive NN NN O
processes NNS NNS O
( ( ( O
set VBN VBN O
shifting VBG VBG O
, , , O
inhibition NN NN O
and CC CC O
memory NN NN O
updating VBG VBG O
) ) ) O
and CC CC O
also RB RB O
on IN IN O
" '' '' O
prefrontal NN NN O
" '' '' O
mediated JJ JJ O
social JJ JJ O
and CC CC O
emotional JJ JJ O
judgement NN NN O
processes NNS NNS O
. . . O

Fifteen CD CD O
polydrug NN NN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
and CC CC O
15 CD CD O
polydrug NN NN O
non NN NN O
- : : O
ecstasy JJ JJ B-CHEM
user NN NN O
controls NNS NNS O
completed VBD VBD O
a DT DT O
general JJ JJ O
drug NN NN O
use NN NN O
questionnaire NN NN O
, , , O
the DT DT O
Brixton NNP NNP O
Spatial NNP NNP O
Anticipation NNP NNP O
task NN NN O
( ( ( O
set VBN VBN O
shifting VBG VBG O
) ) ) O
, , , O
Backward NNP NNP O
Digit NNP NNP O
Span NNP NNP O
procedure NN NN O
( ( ( O
memory NN NN O
updating VBG VBG O
) ) ) O
, , , O
Inhibition NNP NNP O
of IN IN O
Return NN NN O
( ( ( O
inhibition NN NN O
) ) ) O
, , , O
an DT DT O
emotional JJ JJ O
intelligence NN NN O
scale NN NN O
, , , O
the DT DT O
Tromso NNP NNP O
Social NNP NNP O
Intelligence NNP NNP O
Scale NNP NNP O
and CC CC O
the DT DT O
Dysexecutive NNP NNP O
Questionnaire NNP NNP O
( ( ( O
DEX NNP NNP O
) ) ) O
. . . O

Compared VBN VBN O
with IN IN O
MDMA NNP NNP B-CHEM
- - - O
free JJ JJ O
polydrug NN NN O
controls NNS NNS O
, , , O
MDMA NNP NNP B-CHEM
polydrug NN NN O
users NNS NNS O
showed VBD VBD O
impairments NNS NNS O
in IN IN O
set VBN VBN O
shifting VBG VBG O
and CC CC O
memory NN NN O
updating VBG VBG O
, , , O
and CC CC O
also RB RB O
in IN IN O
social JJ JJ O
and CC CC O
emotional JJ JJ O
judgement NN NN O
processes NNS NNS O
. . . O

The DT DT O
latter JJ JJ O
two CD CD O
deficits NNS NNS O
remained VBD VBD O
significant JJ JJ O
after IN IN O
controlling VBG VBG O
for IN IN O
other JJ JJ O
drug NN NN O
use NN NN O
. . . O

These DT DT O
data NNS NNS O
lend VBP VBP O
further JJ JJ O
support NN NN O
to TO TO O
the DT DT O
proposal NN NN O
that IN IN O
cognitive JJ JJ O
processes NNS NNS O
mediated VBN VBN O
by IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
may MD MD O
be VB VB O
impaired VBN VBN O
by IN IN O
recreational JJ JJ O
ecstasy JJ JJ B-CHEM
use NN NN O
. . . O

Phase NNP NNP O
II NNP NNP O
study NN NN O
of IN IN O
the DT DT O
amsacrine NN NN B-CHEM
analogue NN NN O
CI NNP NNP B-CHEM
- : : I-CHEM
921 CD CD I-CHEM
( ( ( O
NSC NNP NNP B-CHEM
343499 CD CD I-CHEM
) ) ) O
in IN IN O
non NN NN O
- - - O
small JJ JJ O
cell NN NN O
lung NN NN O
cancer NN NN O
. . . O

CI NNP NNP B-CHEM
- : : I-CHEM
921 CD CD I-CHEM
( ( ( O
NSC NNP NNP B-CHEM
343499 CD CD I-CHEM
; : : O
9 CD CD B-CHEM
- : : I-CHEM
[ NN NN I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
methoxy NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
( ( ( I-CHEM
methylsulphonyl NN NN I-CHEM
) ) ) I-CHEM
amino JJ JJ I-CHEM
] NN NN I-CHEM
phenyl NN NN I-CHEM
] NN NN I-CHEM
amino JJ JJ I-CHEM
] NN NN I-CHEM
- : : I-CHEM
N NNP NNP I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
dimethyl NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
acridinecarboxamide NN NN I-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
topoisomerase NN NN O
II NNP NNP O
poison NN NN O
with IN IN O
high JJ JJ O
experimental JJ JJ O
antitumour NN NN O
activity NN NN O
. . . O

It PRP PRP O
was VBD VBD O
administered VBN VBN O
by IN IN O
15 CD CD O
min NN NN O
infusion NN NN O
to TO TO O
16 CD CD O
evaluable JJ JJ O
patients NNS NNS O
with IN IN O
non NN NN O
- - - O
small JJ JJ O
cell NN NN O
lung NN NN O
cancer NN NN O
( ( ( O
NSCLC NNP NNP O
) ) ) O
( ( ( O
7 CD CD O
with IN IN O
no DT DT O
prior JJ JJ O
treatment NN NN O
, , , O
9 CD CD O
patients NNS NNS O
in IN IN O
relapse NN NN O
following VBG VBG O
surgery NN NN O
/ NN NN O
radiotherapy NN NN O
) ) ) O
at IN IN O
a DT DT O
dose NN NN O
( ( ( O
648 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
divided VBN VBN O
over IN IN O
3 CD CD O
days NNS NNS O
, , , O
repeated VBN VBN O
every DT DT O
3 CD CD O
weeks NNS NNS O
) ) ) O
determined VBN VBN O
by IN IN O
phase NN NN O
I PRP PRP O
trial NN NN O
. . . O

Patients NNS NNS O
had VBD VBD O
a DT DT O
median JJ JJ O
performance NN NN O
status NN NN O
of IN IN O
1 CD CD O
( ( ( O
WHO WP WP O
) ) ) O
, , , O
and CC CC O
median JJ JJ O
age NN NN O
of IN IN O
61 CD CD O
years NNS NNS O
. . . O

The DT DT O
histology NN NN O
comprised VBD VBD O
squamous JJ JJ O
carcinoma NN NN O
( ( ( O
11 CD CD O
) ) ) O
, , , O
adenocarcinoma NN NN O
( ( ( O
1 CD CD O
) ) ) O
, , , O
mixed JJ JJ O
histology NN NN O
( ( ( O
2 CD CD O
) ) ) O
, , , O
bronchio NN NN O
- - - O
alveolar JJ JJ O
carcinoma NN NN O
( ( ( O
1 CD CD O
) ) ) O
and CC CC O
large JJ JJ O
cell NN NN O
undifferentiated JJ JJ O
carcinoma NN NN O
( ( ( O
1 CD CD O
) ) ) O
. . . O

Neutropenia NNP NNP O
grade NN NN O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
3 CD CD O
was VBD VBD O
seen VBN VBN O
in IN IN O
15 CD CD O
patients NNS NNS O
, , , O
infections NNS NNS O
with IN IN O
recovery NN NN O
in IN IN O
3 CD CD O
, , , O
and CC CC O
grand JJ JJ O
mal NN NN O
seizures NNS NNS O
in IN IN O
1 CD CD O
patient NN NN O
. . . O

Grade NNP NNP O
less JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
2 CD CD O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
occurred VBN VBN O
in IN IN O
66 CD CD O
% NN NN O
courses NNS NNS O
and CC CC O
phlebitis NNS NNS O
in IN IN O
the DT DT O
infusion NN NN O
arm NN NN O
in IN IN O
37 CD CD O
% NN NN O
. . . O

1 CD CD O
patient NN NN O
with IN IN O
squamous JJ JJ O
cell NN NN O
carcinoma NN NN O
achieved VBD VBD O
a DT DT O
partial JJ JJ O
response NN NN O
lasting VBG VBG O
5 CD CD O
months NNS NNS O
. . . O

Further RB RB O
testing NN NN O
in IN IN O
this DT DT O
and CC CC O
other JJ JJ O
tumour NN NN O
types NNS NNS O
using VBG VBG O
multiple JJ JJ O
daily JJ JJ O
schedules NNS NNS O
is VBZ VBZ O
warranted VBN VBN O
. . . O

Pharmacokinetics NNP NNP O
of IN IN O
desipramine NN NN B-CHEM
HCl NNP NNP I-CHEM
when WRB WRB O
administered VBN VBN O
with IN IN O
cinacalcet NN NN B-CHEM
HCl NNP NNP I-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
In IN IN O
vitro NN NN O
work NN NN O
has VBZ VBZ O
demonstrated VBN VBN O
that IN IN O
cinacalcet NN NN B-CHEM
is VBZ VBZ O
a DT DT O
strong JJ JJ O
inhibitor NN NN O
of IN IN O
cytochrome NN NN O
P450 NNP NNP O
isoenzyme NN NN O
( ( ( O
CYP NNP NNP O
) ) ) O
2D6 CD CD O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
effect NN NN O
of IN IN O
cinacalcet NN NN B-CHEM
on IN IN O
CYP2D6 NNP NNP O
activity NN NN O
, , , O
using VBG VBG O
desipramine NN NN B-CHEM
as IN IN O
a DT DT O
probe NN NN O
substrate NN NN O
, , , O
in IN IN O
healthy JJ JJ O
subjects NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Seventeen NNP NNP O
subjects NNS NNS O
who WP WP O
were VBD VBD O
genotyped VBN VBN O
as IN IN O
CYP2D6 NNP NNP O
extensive JJ JJ O
metabolizers NNS NNS O
were VBD VBD O
enrolled VBN VBN O
in IN IN O
this DT DT O
randomized JJ JJ O
, , , O
open JJ JJ O
- - - O
label NN NN O
, , , O
crossover NN NN O
study NN NN O
to TO TO O
receive VB VB O
a DT DT O
single JJ JJ O
oral JJ JJ O
dose NN NN O
of IN IN O
desipramine NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
) ) ) O
on IN IN O
two CD CD O
separate JJ JJ O
occasions NNS NNS O
, , , O
once RB RB O
alone RB RB O
and CC CC O
once RB RB O
after IN IN O
multiple JJ JJ O
doses NNS NNS O
of IN IN O
cinacalcet NN NN B-CHEM
( ( ( O
90 CD CD O
mg NN NN O
for IN IN O
7 CD CD O
days NNS NNS O
) ) ) O
. . . O

Blood NNP NNP O
samples NNS NNS O
were VBD VBD O
obtained VBN VBN O
predose NN NN O
and CC CC O
up IN IN O
to TO TO O
72 CD CD O
h NN NN O
postdose NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Fourteen NNP NNP O
subjects NNS NNS O
completed VBD VBD O
both DT DT O
treatment NN NN O
arms NNS NNS O
. . . O

Relative NNP NNP O
to TO TO O
desipramine VB VB B-CHEM
alone RB RB O
, , , O
mean VB VB O
AUC NNP NNP O
and CC CC O
C NNP NNP O
( ( ( O
max NN NN O
) ) ) O
of IN IN O
desipramine NN NN B-CHEM
increased VBD VBD O
3 CD CD O
. . . O
6 CD CD O
- : : O
and CC CC O
1 CD CD O
. . . O
8 CD CD O
- : : O
fold VB VB O
when WRB WRB O
coadministered VBN VBN O
with IN IN O
cinacalcet NN NN B-CHEM
. . . O

The DT DT O
t NN NN O
( ( ( O
1 CD CD O
/ NN NN O
2 CD CD O
, , , O
z SYM SYM O
) ) ) O
of IN IN O
desipramine NN NN B-CHEM
was VBD VBD O
longer RBR RBR O
when WRB WRB O
desipramine NN NN B-CHEM
was VBD VBD O
coadministered VBN VBN O
with IN IN O
cinacalcet NN NN B-CHEM
( ( ( O
21 CD CD O
. . . O
0 CD CD O
versus CC CC O
43 CD CD O
. . . O
3 CD CD O
hs NN NN O
) ) ) O
. . . O

The DT DT O
t NN NN O
( ( ( O
max NN NN O
) ) ) O
was VBD VBD O
similar JJ JJ O
between IN IN O
the DT DT O
regimens NNS NNS O
. . . O

Fewer NNP NNP O
subjects NNS NNS O
reported VBD VBD O
adverse JJ JJ O
events NNS NNS O
following VBG VBG O
treatment NN NN O
with IN IN O
desipramine NN NN B-CHEM
alone RB RB O
than IN IN O
when WRB WRB O
receiving VBG VBG O
desipramine NN NN B-CHEM
with IN IN O
cinacalcet NN NN B-CHEM
( ( ( O
33 CD CD O
versus CC CC O
86 CD CD O
% NN NN O
) ) ) O
, , , O
the DT DT O
most RBS RBS O
frequent NN NN O
of IN IN O
which WDT WDT O
( ( ( O
nausea NN NN O
and CC CC O
headache NN NN O
) ) ) O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
for IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
either DT DT O
desipramine NN NN B-CHEM
or CC CC O
cinacalcet NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
study NN NN O
demonstrates VBZ VBZ O
that IN IN O
cinacalcet NN NN B-CHEM
is VBZ VBZ O
a DT DT O
strong JJ JJ O
inhibitor NN NN O
of IN IN O
CYP2D6 NNP NNP O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
during IN IN O
concomitant JJ JJ O
treatment NN NN O
with IN IN O
cinacalcet NN NN B-CHEM
, , , O
dose NN NN O
adjustment NN NN O
may MD MD O
be VB VB O
necessary JJ JJ O
for IN IN O
drugs NNS NNS O
that WDT WDT O
demonstrate VBP VBP O
a DT DT O
narrow JJ JJ O
therapeutic JJ JJ O
index NN NN O
and CC CC O
are VBP VBP O
metabolized VBN VBN O
by IN IN O
CYP2D6 NNP NNP O
. . . O

Case NN NN O
report NN NN O
: : : O
acute JJ JJ O
unintentional JJ JJ O
carbachol NN NN B-CHEM
intoxication NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Intoxications NNP NNP O
with IN IN O
carbachol NN NN B-CHEM
, , , O
a DT DT O
muscarinic JJ JJ O
cholinergic JJ JJ O
receptor NN NN O
agonist NN NN O
are VBP VBP O
rare JJ JJ O
. . . O

We PRP PRP O
report VBP VBP O
an DT DT O
interesting JJ JJ O
case NN NN O
investigating VBG VBG O
a DT DT O
( ( ( O
near IN IN O
) ) ) O
fatal JJ JJ O
poisoning NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
son NN NN O
of IN IN O
an DT DT O
84 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
discovered VBD VBD O
a DT DT O
newspaper NN NN O
report NN NN O
stating VBG VBG O
clinical JJ JJ O
success NN NN O
with IN IN O
plant NN NN O
extracts NNS NNS O
in IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

The DT DT O
mode NN NN O
of IN IN O
action NN NN O
was VBD VBD O
said VBN VBN O
to TO TO O
be VB VB O
comparable JJ JJ O
to TO TO O
that DT DT O
of IN IN O
the DT DT O
synthetic JJ JJ O
compound NN NN O
' '' '' O
carbamylcholin NN NN B-CHEM
' '' '' O
; : : O
that WDT WDT O
is VBZ VBZ O
, , , O
carbachol NN NN B-CHEM
. . . O

He PRP PRP O
bought VBD VBD O
25 CD CD O
g SYM SYM O
of IN IN O
carbachol NN NN B-CHEM
as IN IN O
pure JJ JJ O
substance NN NN O
in IN IN O
a DT DT O
pharmacy NN NN O
, , , O
and CC CC O
the DT DT O
father NN NN O
was VBD VBD O
administered VBN VBN O
400 CD CD O
to TO TO O
500 CD CD O
mg NN NN O
. . . O

Carbachol NNP NNP B-CHEM
concentrations NNS NNS O
in IN IN O
serum NN NN O
and CC CC O
urine NN NN O
on IN IN O
day NN NN O
1 CD CD O
and CC CC O
2 CD CD O
of IN IN O
hospital NN NN O
admission NN NN O
were VBD VBD O
analysed VBN VBN O
by IN IN O
HPLC NNP NNP O
- : : O
mass NN NN O
spectrometry NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Minutes NNP NNP O
after IN IN O
oral JJ JJ O
administration NN NN O
, , , O
the DT DT O
patient NN NN O
developed VBN VBN O
nausea NN NN O
, , , O
sweating VBG VBG O
and CC CC O
hypotension NN NN O
, , , O
and CC CC O
finally RB RB O
collapsed VBD VBD O
. . . O

Bradycardia NNP NNP O
, , , O
cholinergic JJ JJ O
symptoms NNS NNS O
and CC CC O
asystole NN NN O
occurred VBD VBD O
. . . O

Initial JJ JJ O
cardiopulmonary JJ JJ O
resuscitation NN NN O
and CC CC O
immediate JJ JJ O
treatment NN NN O
with IN IN O
adrenaline NN NN B-CHEM
( ( ( O
epinephrine NN NN B-CHEM
) ) ) O
, , , O
atropine NN NN B-CHEM
and CC CC O
furosemide NN NN B-CHEM
was VBD VBD O
successful JJ JJ O
. . . O

On IN IN O
hospital NN NN O
admission NN NN O
, , , O
blood NN NN O
pressure NN NN O
of IN IN O
the DT DT O
intubated JJ JJ O
, , , O
bradyarrhythmic JJ JJ O
patient NN NN O
was VBD VBD O
100 CD CD O
/ NN NN O
65 CD CD O
mmHg NN NN O
. . . O

Further RB RB O
signs NNS NNS O
were VBD VBD O
hyperhidrosis NN NN O
, , , O
hypersalivation NN NN O
, , , O
bronchorrhoea NN NN O
, , , O
and CC CC O
severe JJ JJ O
miosis NN NN O
; : : O
the DT DT O
electrocardiographic JJ JJ O
finding VBG VBG O
was VBD VBD O
atrio JJ JJ O
- : : O
ventricular NN NN O
dissociation NN NN O
. . . O

High NNP NNP O
doses NNS NNS O
of IN IN O
atropine NN NN B-CHEM
( ( ( O
up IN IN O
to TO TO O
50 CD CD O
mg NN NN O
per IN IN O
24 CD CD O
hours NNS NNS O
) ) ) O
, , , O
adrenaline NN NN B-CHEM
and CC CC O
dopamine NN NN B-CHEM
were VBD VBD O
necessary JJ JJ O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
extubated VBN VBN O
1 CD CD O
week NN NN O
later RB RB O
. . . O

However RB RB O
, , , O
increased VBD VBD O
dyspnoea NN NN O
and CC CC O
bronchospasm NN NN O
necessitated JJ JJ O
reintubation NN NN O
. . . O

Respiratory NNP NNP O
insufficiency NN NN O
was VBD VBD O
further RB RB O
worsened VBN VBN O
by IN IN O
Proteus NNP NNP O
mirabilis NNS NNS O
infection NN NN O
and CC CC O
severe JJ JJ O
bronchoconstriction NN NN O
. . . O

One CD CD O
week NN NN O
later RB RB O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
again RB RB O
extubated VBN VBN O
and CC CC O
3 CD CD O
days NNS NNS O
later RB RB O
was VBD VBD O
transferred VBN VBN O
to TO TO O
a DT DT O
peripheral JJ JJ O
ward NN NN O
. . . O

On IN IN O
the DT DT O
next JJ JJ O
day NN NN O
he PRP PRP O
died VBD VBD O
, , , O
probably RB RB O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
heart NN NN O
failure NN NN O
. . . O

Serum NNP NNP O
samples NNS NNS O
from IN IN O
the DT DT O
first JJ JJ O
and CC CC O
second JJ JJ O
days NNS NNS O
contained VBD VBD O
3 CD CD O
. . . O
6 CD CD O
and CC CC O
1 CD CD O
. . . O
9 CD CD O
mg NN NN O
/ NN NN O
l NN NN O
carbachol NN NN B-CHEM
, , , O
respectively RB RB O
. . . O

The DT DT O
corresponding JJ JJ O
urine NN NN O
concentrations NNS NNS O
amounted VBN VBN O
to TO TO O
374 CD CD O
and CC CC O
554 CD CD O
mg NN NN O
/ NN NN O
l NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
case NN NN O
started VBD VBD O
with IN IN O
a DT DT O
media NNS NNS O
report NN NN O
in IN IN O
a DT DT O
popular JJ JJ O
newspaper NN NN O
, , , O
initiated VBN VBN O
by IN IN O
published VBN VBN O
, , , O
peer NN NN O
- - - O
reviewed JJ JJ O
research NN NN O
on IN IN O
herbals NNS NNS O
, , , O
and CC CC O
involved VBD VBD O
human JJ JJ O
failure NN NN O
in IN IN O
a DT DT O
case NN NN O
history NN NN O
, , , O
medical JJ JJ O
examination NN NN O
and CC CC O
clinical JJ JJ O
treatment NN NN O
. . . O

For IN IN O
the DT DT O
first JJ JJ O
time NN NN O
, , , O
an DT DT O
analytical JJ JJ O
method NN NN O
for IN IN O
the DT DT O
determination NN NN O
of IN IN O
carbachol NN NN B-CHEM
in IN IN O
plasma NN NN O
and CC CC O
urine NN NN O
has VBZ VBZ O
been VBN VBN O
developed VBN VBN O
. . . O

The DT DT O
analysed JJ JJ O
carbachol NN NN B-CHEM
concentration NN NN O
exceeded VBD VBD O
the DT DT O
supposed JJ JJ O
serum NN NN O
level NN NN O
resulting VBG VBG O
from IN IN O
a DT DT O
therapeutic JJ JJ O
dose NN NN O
by IN IN O
a DT DT O
factor NN NN O
of IN IN O
130 CD CD O
to TO TO O
260 CD CD O
. . . O

Especially RB RB O
in IN IN O
old JJ JJ O
patients NNS NNS O
, , , O
intensivists NNS NNS O
should MD MD O
consider VB VB O
intoxications NNS NNS O
( ( ( O
with IN IN O
cholinergics NNS NNS O
) ) ) O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
acute JJ JJ O
cardiovascular JJ JJ O
failure NN NN O
. . . O

Pharmacological NNP NNP O
evidence NN NN O
for IN IN O
the DT DT O
potential NN NN O
of IN IN O
Daucus NNP NNP O
carota NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
cognitive JJ JJ O
dysfunctions NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
aimed VBN VBN O
at IN IN O
investigating VBG VBG O
the DT DT O
effects NNS NNS O
of IN IN O
Daucus NNP NNP O
carota NN NN O
seeds NNS NNS O
on IN IN O
cognitive JJ JJ O
functions NNS NNS O
, , , O
total JJ JJ O
serum NN NN O
cholesterol NN NN B-CHEM
levels NNS NNS O
and CC CC O
brain NN NN O
cholinesterase NN NN O
activity NN NN O
in IN IN O
mice NN NN O
. . . O

The DT DT O
ethanolic JJ JJ O
extract NN NN B-CHEM
of IN IN I-CHEM
Daucus NNP NNP I-CHEM
carota NN NN I-CHEM
seeds NNS NNS I-CHEM
( ( ( O
DCE NNP NNP B-CHEM
) ) ) O
was VBD VBD O
administered VBN VBN O
orally RB RB O
in IN IN O
three CD CD O
doses NNS NNS O
( ( ( O
100 CD CD O
, , , O
200 CD CD O
, , , O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
for IN IN O
seven CD CD O
successive JJ JJ O
days NNS NNS O
to TO TO O
different JJ JJ O
groups NNS NNS O
of IN IN O
young JJ JJ O
and CC CC O
aged JJ JJ O
mice NN NN O
. . . O

Elevated NNP NNP O
plus CC CC O
maze NN NN O
and CC CC O
passive JJ JJ O
avoidance NN NN O
apparatus NN NN O
served VBD VBD O
as IN IN O
the DT DT O
exteroceptive JJ JJ O
behavioral JJ JJ O
models NNS NNS O
for IN IN O
testing VBG VBG O
memory NN NN O
. . . O

Diazepam NNP NNP B-CHEM
- : : O
, , , O
scopolamine NN NN B-CHEM
- - - O
and CC CC O
ageing VBG VBG O
- : : O
induced JJ JJ O
amnesia NN NN O
served VBD VBD O
as IN IN O
the DT DT O
interoceptive JJ JJ O
behavioral JJ JJ O
models NNS NNS O
. . . O

DCE NNP NNP B-CHEM
( ( ( O
200 CD CD O
, , , O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
showed VBD VBD O
significant JJ JJ O
improvement NN NN O
in IN IN O
memory NN NN O
scores NNS NNS O
of IN IN O
young JJ JJ O
and CC CC O
aged JJ JJ O
mice NN NN O
. . . O

The DT DT O
extent NN NN O
of IN IN O
memory NN NN O
improvement NN NN O
evoked VBN VBN O
by IN IN O
DCE NNP NNP B-CHEM
was VBD VBD O
23 CD CD O
% NN NN O
at IN IN O
the DT DT O
dose NN NN O
of IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
and CC CC O
35 CD CD O
% NN NN O
at IN IN O
the DT DT O
dose NN NN O
of IN IN O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
in IN IN O
young JJ JJ O
mice NN NN O
using VBG VBG O
elevated JJ JJ O
plus CC CC O
maze NN NN O
. . . O

Similarly RB RB O
, , , O
significant JJ JJ O
improvements NNS NNS O
in IN IN O
memory NN NN O
scores NNS NNS O
were VBD VBD O
observed VBN VBN O
using VBG VBG O
passive JJ JJ O
avoidance NN NN O
apparatus NN NN O
and CC CC O
aged JJ JJ O
mice NN NN O
. . . O

Furthermore RB RB O
, , , O
DCE NNP NNP B-CHEM
reversed VBD VBD O
the DT DT O
amnesia NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
and CC CC O
diazepam NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

Daucus NNP NNP B-CHEM
carota NN NN I-CHEM
extract NN NN I-CHEM
( ( ( O
200 CD CD O
, , , O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
reduced VBN VBN O
significantly RB RB O
the DT DT O
brain NN NN O
acetylcholinesterase NN NN O
activity NN NN O
and CC CC O
cholesterol NN NN B-CHEM
levels NNS NNS O
in IN IN O
young JJ JJ O
and CC CC O
aged JJ JJ O
mice NN NN O
. . . O

The DT DT O
extent NN NN O
of IN IN O
inhibition NN NN O
of IN IN O
brain NN NN O
cholinesterase NN NN O
activity NN NN O
evoked VBN VBN O
by IN IN O
DCE NNP NNP B-CHEM
at IN IN O
the DT DT O
dose NN NN O
of IN IN O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
was VBD VBD O
22 CD CD O
% NN NN O
in IN IN O
young JJ JJ O
and CC CC O
19 CD CD O
% NN NN O
in IN IN O
aged JJ JJ O
mice NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
remarkable JJ JJ O
reduction NN NN O
in IN IN O
total JJ JJ O
cholesterol NN NN B-CHEM
level NN NN O
as RB RB O
well RB RB O
, , , O
to TO TO O
the DT DT O
extent NN NN O
of IN IN O
23 CD CD O
% NN NN O
in IN IN O
young JJ JJ O
and CC CC O
21 CD CD O
% NN NN O
in IN IN O
aged JJ JJ O
animals NNS NNS O
with IN IN O
this DT DT O
dose NN NN O
of IN IN O
DCE NNP NNP B-CHEM
. . . O

Therefore RB RB O
, , , O
DCE NNP NNP B-CHEM
may MD MD O
prove VB VB O
to TO TO O
be VB VB O
a DT DT O
useful JJ JJ O
remedy NN NN O
for IN IN O
the DT DT O
management NN NN O
of IN IN O
cognitive JJ JJ O
dysfunctions NNS NNS O
on IN IN O
account NN NN O
of IN IN O
its PRP$ PRP$ O
multifarious JJ JJ O
beneficial JJ JJ O
effects NNS NNS O
such JJ JJ O
as IN IN O
, , , O
memory NN NN O
improving VBG VBG O
property NN NN O
, , , O
cholesterol NN NN B-CHEM
lowering VBG VBG O
property NN NN O
and CC CC O
anticholinesterase NN NN O
activity NN NN O
. . . O

Valproic NNP NNP B-CHEM
acid NN NN I-CHEM
induced VBN VBN O
encephalopathy JJ JJ O
- - - O
- - - O
19 CD CD O
new JJ JJ O
cases NNS NNS O
in IN IN O
Germany NNP NNP O
from IN IN O
1994 CD CD O
to TO TO O
2003 CD CD O
- : : O
- : : O
a DT DT O
side NN NN O
effect NN NN O
associated VBN VBN O
to TO TO O
VPA NNP NNP B-CHEM
- : : O
therapy NN NN O
not RB RB O
only RB RB O
in IN IN O
young JJ JJ O
children NNS NNS O
. . . O

Valproic NNP NNP B-CHEM
acid NN NN I-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
broad JJ JJ O
- - - O
spectrum NN NN O
antiepileptic JJ JJ O
drug NN NN O
and CC CC O
is VBZ VBZ O
usually RB RB O
well RB RB O
- - - O
tolerated JJ JJ O
. . . O

Rare NNP NNP O
serious JJ JJ O
complications NNS NNS O
may MD MD O
occur VB VB O
in IN IN O
some DT DT O
patients NNS NNS O
, , , O
including VBG VBG O
haemorrhagic JJ JJ O
pancreatitis NNS NNS O
, , , O
bone NN NN O
marrow NN NN O
suppression NN NN O
, , , O
VPA NNP NNP B-CHEM
- : : O
induced JJ JJ O
hepatotoxicity NN NN O
and CC CC O
VPA NNP NNP B-CHEM
- : : O
induced JJ JJ O
encephalopathy NN NN O
. . . O

The DT DT O
typical JJ JJ O
signs NNS NNS O
of IN IN O
VPA NNP NNP B-CHEM
- : : O
induced JJ JJ O
encephalopathy NN NN O
are VBP VBP O
impaired VBN VBN O
consciousness NN NN O
, , , O
sometimes RB RB O
marked VBN VBN O
EEG NNP NNP O
background NN NN O
slowing VBG VBG O
, , , O
increased VBN VBN O
seizure NN NN O
frequency NN NN O
, , , O
with IN IN O
or CC CC O
without IN IN O
hyperammonemia NN NN O
. . . O

There EX EX O
is VBZ VBZ O
still RB RB O
no DT DT O
proof NN NN O
of IN IN O
causative JJ JJ O
effect NN NN O
of IN IN O
VPA NNP NNP B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
encephalopathy NN NN O
, , , O
but CC CC O
only RB RB O
of IN IN O
an DT DT O
association NN NN O
with IN IN O
an DT DT O
assumed JJ JJ O
causal NN NN O
relation NN NN O
. . . O

We PRP PRP O
report VBP VBP O
19 CD CD O
patients NNS NNS O
with IN IN O
VPA NNP NNP B-CHEM
- - - O
associated VBN VBN O
encephalopathy NN NN O
in IN IN O
Germany NNP NNP O
from IN IN O
the DT DT O
years NNS NNS O
1994 CD CD O
to TO TO O
2003 CD CD O
, , , O
none NN NN O
of IN IN O
whom WP WP O
had VBD VBD O
been VBN VBN O
published VBN VBN O
previously RB RB O
. . . O

Cerebral NNP NNP O
haemorrhage NN NN O
induced VBN VBN O
by IN IN O
warfarin NN NN B-CHEM
- : : O
the DT DT O
influence NN NN O
of IN IN O
drug NN NN O
- - - O
drug NN NN O
interactions NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
frequency NN NN O
, , , O
severity NN NN O
and CC CC O
preventability NN NN O
of IN IN O
warfarin NN NN B-CHEM
- - - O
induced JJ JJ O
cerebral NN NN O
haemorrhages NNS NNS O
due JJ JJ O
to TO TO O
warfarin NN NN B-CHEM
and CC CC O
warfarin NN NN B-CHEM
- - - O
drug NN NN O
interactions NNS NNS O
in IN IN O
patients NNS NNS O
living VBG VBG O
in IN IN O
the DT DT O
county NN NN O
of IN IN O
Osterg NNP NNP O
tland NN NN O
, , , O
Sweden NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
All DT DT O
patients NNS NNS O
with IN IN O
a DT DT O
diagnosed JJ JJ O
cerebral JJ JJ O
haemorrhage NN NN O
at IN IN O
three CD CD O
hospitals NNS NNS O
during IN IN O
the DT DT O
period NN NN O
2000 CD CD O
- : : O
2002 CD CD O
were VBD VBD O
identified VBN VBN O
. . . O

Medical JJ JJ O
records NNS NNS O
were VBD VBD O
studied VBN VBN O
retrospectively RB RB O
to TO TO O
evaluate VB VB O
whether IN IN O
warfarin NN NN B-CHEM
and CC CC O
warfarin NN NN B-CHEM
- - - O
drug NN NN O
interactions NNS NNS O
could MD MD O
have VB VB O
caused VBN VBN O
the DT DT O
cerebral JJ JJ O
haemorrhage NN NN O
. . . O

The DT DT O
proportion NN NN O
of IN IN O
possibly RB RB O
avoidable JJ JJ O
cases NNS NNS O
due JJ JJ O
to TO TO O
drug NN NN O
interactions NNS NNS O
was VBD VBD O
estimated VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Among IN IN O
593 CD CD O
patients NNS NNS O
with IN IN O
cerebral JJ JJ O
haemorrhage NN NN O
, , , O
59 CD CD O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
assessed VBN VBN O
as IN IN O
related VBN VBN O
to TO TO O
warfarin NN NN B-CHEM
treatment NN NN O
. . . O

This DT DT O
imply VBP VBP O
an DT DT O
incidence NN NN O
of IN IN O
1 CD CD O
. . . O
7 CD CD O
/ NN NN O
100 CD CD O
, , , O
000 CD CD O
treatment NN NN O
years NNS NNS O
. . . O

Of IN IN O
the DT DT O
59 CD CD O
cases NNS NNS O
, , , O
26 CD CD O
( ( ( O
44 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
a DT DT O
fatal JJ JJ O
outcome NN NN O
, , , O
compared VBN VBN O
to TO TO O
136 CD CD O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
among IN IN O
the DT DT O
non NN NN O
- - - O
warfarin NN NN B-CHEM
patients NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

A DT DT O
warfarin NN NN B-CHEM
- - - O
drug NN NN O
interaction NN NN O
could MD MD O
have VB VB O
contributed VBN VBN O
to TO TO O
the DT DT O
haemorrhage NN NN O
in IN IN O
24 CD CD O
( ( ( O
41 CD CD O
% NN NN O
) ) ) O
of IN IN O
the DT DT O
warfarin NN NN B-CHEM
patients NNS NNS O
and CC CC O
in IN IN O
7 CD CD O
of IN IN O
these DT DT O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
the DT DT O
bleeding NN NN O
complication NN NN O
was VBD VBD O
considered VBN VBN O
being VBG VBG O
possible JJ JJ O
to TO TO O
avoid VB VB O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Warfarin NNP NNP B-CHEM
- - - O
induced JJ JJ O
cerebral NN NN O
haemorrhages NNS NNS O
are VBP VBP O
a DT DT O
major JJ JJ O
clinical JJ JJ O
problem NN NN O
with IN IN O
a DT DT O
high JJ JJ O
fatality NN NN O
rate NN NN O
. . . O

Almost RB RB O
half NN NN O
of IN IN O
the DT DT O
cases NNS NNS O
was VBD VBD O
related VBN VBN O
to TO TO O
a DT DT O
warfarin NN NN B-CHEM
- - - O
drug NN NN O
interaction NN NN O
. . . O

A DT DT O
significant JJ JJ O
proportion NN NN O
of IN IN O
warfarin NN NN B-CHEM
- - - O
related VBN VBN O
cerebral JJ JJ O
haemorrhages NNS NNS O
might MD MD O
have VB VB O
been VBN VBN O
prevented VBN VBN O
if IN IN O
greater JJR JJR O
caution NN NN O
had VBD VBD O
been VBN VBN O
taken VBN VBN O
when WRB WRB O
prescribing VBG VBG O
drugs NNS NNS O
known VBN VBN O
to TO TO O
interact VB VB O
with IN IN O
warfarin NN NN B-CHEM
. . . O

Antipsychotic JJ JJ O
- - - O
like IN IN O
profile NN NN O
of IN IN O
thioperamide NN NN B-CHEM
, , , O
a DT DT O
selective JJ JJ O
H3 NNP NNP O
- : : O
receptor NN NN O
antagonist NN NN O
in IN IN O
mice NN NN O
. . . O

Experimental NNP NNP O
and CC CC O
clinical JJ JJ O
evidence NN NN O
points NNS NNS O
to TO TO O
a DT DT O
role NN NN O
of IN IN O
central JJ JJ O
histaminergic JJ JJ O
system NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
schizophrenia NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
study VB VB O
the DT DT O
effect NN NN O
of IN IN O
histamine NN NN B-CHEM
H NNP NNP O
( ( ( O
3 CD CD O
) ) ) O
- : : O
receptor NN NN O
ligands NNS NNS O
on IN IN O
neuroleptic JJ JJ O
- : : O
induced JJ JJ O
catalepsy NN NN O
, , , O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
climbing NN NN O
behavior NN NN O
and CC CC O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
activities NNS NNS O
in IN IN O
mice NN NN O
. . . O

Catalepsy NNP NNP O
was VBD VBD O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
, , , O
while IN IN O
apomorphine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
and CC CC O
amphetamine NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
were VBD VBD O
used VBN VBN O
for IN IN O
studying VBG VBG O
climbing VBG VBG O
behavior NN NN O
and CC CC O
locomotor NN NN O
activities NNS NNS O
, , , O
respectively RB RB O
. . . O

( ( ( B-CHEM
R NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
methylhistamine NN NN I-CHEM
( ( ( O
RAMH NNP NNP B-CHEM
) ) ) O
( ( ( O
5 CD CD O
microg NN NN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
and CC CC O
thioperamide NN NN B-CHEM
( ( ( O
THP NNP NNP B-CHEM
) ) ) O
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
per IN IN O
se FW FW O
did VBD VBD O
not RB RB O
cause VB VB O
catalepsy NN NN O
. . . O

Administration NNP NNP O
of IN IN O
THP NNP NNP B-CHEM
( ( ( O
3 CD CD O
. . . O
75 CD CD O
, , , O
7 CD CD O
. . . O
5 CD CD O
and CC CC O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
1 CD CD O
h NN NN O
prior RB RB O
to TO TO O
haloperidol VB VB B-CHEM
resulted VBD VBD O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
catalepsy NN NN O
times NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

However RB RB O
, , , O
pretreatment NN NN O
with IN IN O
RAMH NNP NNP B-CHEM
significantly RB RB O
reversed VBD VBD O
such JJ JJ O
an DT DT O
effect NN NN O
of IN IN O
THP NNP NNP B-CHEM
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

RAMH NNP NNP B-CHEM
per IN IN O
se FW FW O
showed VBD VBD O
significant JJ JJ O
reduction NN NN O
in IN IN O
locomotor NN NN O
time NN NN O
, , , O
distance NN NN O
traveled VBN VBN O
and CC CC O
average JJ JJ O
speed NN NN O
but CC CC O
THP NNP NNP B-CHEM
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
per IN IN O
se FW FW O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
these DT DT O
parameters NNS NNS O
. . . O

On IN IN O
amphetamine NN NN B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
, , , O
THP NNP NNP B-CHEM
( ( ( O
3 CD CD O
. . . O
75 CD CD O
and CC CC O
7 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
reduced VBN VBN O
locomotor NN NN O
time NN NN O
, , , O
distance NN NN O
traveled VBN VBN O
and CC CC O
average JJ JJ O
speed NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Pretreatment NNP NNP O
with IN IN O
RAMH NNP NNP B-CHEM
( ( ( O
5 CD CD O
microg NN NN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
could MD MD O
partially RB RB O
reverse VB VB O
such JJ JJ O
effects NNS NNS O
of IN IN O
THP NNP NNP B-CHEM
( ( ( O
3 CD CD O
. . . O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

Climbing NNP NNP O
behavior NN NN O
induced VBN VBN O
by IN IN O
apomorphine NN NN B-CHEM
was VBD VBD O
reduced VBN VBN O
in IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
THP NNP NNP B-CHEM
. . . O

Such JJ JJ O
an DT DT O
effect NN NN O
was VBD VBD O
, , , O
however RB RB O
, , , O
reversed VBD VBD O
in IN IN O
presence NN NN O
of IN IN O
RAMH NNP NNP B-CHEM
. . . O

THP NNP NNP B-CHEM
exhibited VBD VBD O
an DT DT O
antipsychotic JJ JJ O
- - - O
like IN IN O
profile NN NN O
by IN IN O
potentiating VBG VBG O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
, , , O
reducing VBG VBG O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
and CC CC O
reducing VBG VBG O
apomorphine JJ JJ B-CHEM
- - - O
induced JJ JJ O
climbing VBG VBG O
in IN IN O
mice NN NN O
. . . O

Such JJ JJ O
effects NNS NNS O
of IN IN O
THP NNP NNP B-CHEM
were VBD VBD O
reversed VBN VBN O
by IN IN O
RAMH NNP NNP B-CHEM
indicating VBG VBG O
the DT DT O
involvement NN NN O
of IN IN O
histamine NN NN B-CHEM
H NNP NNP O
( ( ( O
3 CD CD O
) ) ) O
- : : O
receptors NNS NNS O
. . . O

Findings NNS NNS O
suggest VBP VBP O
a DT DT O
potential JJ JJ O
for IN IN O
H NNP NNP O
( ( ( O
3 CD CD O
) ) ) O
- : : O
receptor NN NN O
antagonists NNS NNS O
in IN IN O
improving VBG VBG O
the DT DT O
refractory NN NN O
cases NNS NNS O
of IN IN O
schizophrenia NN NN O
. . . O

Cauda NNP NNP O
equina NN NN O
syndrome NN NN O
after IN IN O
epidural JJ JJ O
steroid NN NN B-CHEM
injection NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
Conventional NNP NNP O
treatment NN NN O
methods NNS NNS O
of IN IN O
lumbusacral JJ JJ O
radiculopathy NN NN O
are VBP VBP O
physical JJ JJ O
therapy NN NN O
, , , O
epidural JJ JJ O
steroid NN NN B-CHEM
injections NNS NNS O
, , , O
oral JJ JJ O
medications NNS NNS O
, , , O
and CC CC O
spinal JJ JJ O
manipulative JJ JJ O
therapy NN NN O
. . . O

Cauda NNP NNP O
equina NN NN O
syndrome NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
of IN IN O
epidural JJ JJ O
anesthesia NN NN O
. . . O

The DT DT O
following VBG VBG O
case NN NN O
is VBZ VBZ O
a DT DT O
report NN NN O
of IN IN O
cauda NN NN O
equina NN NN O
syndrome NN NN O
possibly RB RB O
caused VBN VBN O
by IN IN O
epidural JJ JJ O
injection NN NN O
of IN IN O
triamcinolone NN NN B-CHEM
and CC CC O
bupivacaine NN NN B-CHEM
. . . O

CLINICAL NNP NNP O
FEATURES NNP NNP O
: : : O
A DT DT O
50 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
low JJ JJ O
back RB RB O
and CC CC O
right JJ JJ O
leg NN NN O
pain NN NN O
was VBD VBD O
scheduled VBN VBN O
for IN IN O
epidural JJ JJ O
steroid NN NN B-CHEM
injection NN NN O
. . . O

INTERVENTION NNP NNP O
AND CC CC O
OUTCOME NNP NNP O
: : : O
An DT DT O
18 CD CD O
- : : O
gauge NN NN O
Touhy NNP NNP O
needle NN NN O
was VBD VBD O
inserted VBN VBN O
until IN IN O
loss NN NN O
of IN IN O
resistance NN NN O
occurred VBD VBD O
at IN IN O
the DT DT O
L4 NNP NNP O
- : : O
5 CD CD O
level NN NN O
. . . O

Spread NNP NNP O
of IN IN O
the DT DT O
contrast NN NN O
medium NN NN O
within IN IN O
the DT DT O
epidural JJ JJ O
space NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
radiographic JJ JJ O
imaging VBG VBG O
. . . O

After IN IN O
verifying VBG VBG O
the DT DT O
epidural JJ JJ O
space NN NN O
, , , O
bupivacaine NN NN B-CHEM
and CC CC O
triamcinolone NN NN B-CHEM
diacetate NN NN I-CHEM
were VBD VBD O
injected VBN VBN O
. . . O

After IN IN O
the DT DT O
injection NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
radicular NN NN O
symptoms NNS NNS O
. . . O

Three CD CD O
hours NNS NNS O
later RB RB O
, , , O
she PRP PRP O
complained VBD VBD O
of IN IN O
perineal NN NN O
numbness NNS NNS O
and CC CC O
lower JJR JJR O
extremity NN NN O
weakness NN NN O
. . . O

The DT DT O
neurologic JJ JJ O
evaluation NN NN O
revealed VBD VBD O
loss NN NN O
of IN IN O
sensation NN NN O
in IN IN O
the DT DT O
saddle NN NN O
area NN NN O
and CC CC O
medial JJ JJ O
aspect NN NN O
of IN IN O
her PRP$ PRP$ O
right JJ JJ O
leg NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
the DT DT O
perception NN NN O
of IN IN O
pinprick NN NN O
test NN NN O
. . . O

Deep JJ JJ O
- : : O
tendon NN NN O
reflexes NNS NNS O
were VBD VBD O
decreased VBN VBN O
especially RB RB O
in IN IN O
the DT DT O
right NN NN O
leg NN NN O
. . . O

She PRP PRP O
was VBD VBD O
unable JJ JJ O
to TO TO O
urinate VB VB O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
symptoms NNS NNS O
improved VBN VBN O
slightly RB RB O
over IN IN O
the DT DT O
next JJ JJ O
few JJ JJ O
hours NNS NNS O
. . . O

She PRP PRP O
had VBD VBD O
a DT DT O
gradual JJ JJ O
return NN NN O
of IN IN O
motor NN NN O
function NN NN O
and CC CC O
ability NN NN O
of IN IN O
feeling NN NN O
Foley NNP NNP O
catheter NN NN O
. . . O

All DT DT O
of IN IN O
the DT DT O
symptoms NNS NNS O
were VBD VBD O
completely RB RB O
resolved VBN VBN O
over IN IN O
the DT DT O
next JJ JJ O
8 CD CD O
hours NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Complications NNP NNP O
associated VBN VBN O
with IN IN O
epidural JJ JJ O
steroid NN NN B-CHEM
injections NNS NNS O
are VBP VBP O
rare JJ JJ O
. . . O

Clinical NNP NNP O
examination NN NN O
and CC CC O
continued VBD VBD O
vigilance NN NN O
for IN IN O
neurologic JJ JJ O
deterioration NN NN O
after IN IN O
epidural JJ JJ O
steroid NN NN B-CHEM
injections NNS NNS O
is VBZ VBZ O
important JJ JJ O
. . . O

High NNP NNP O
- - - O
dose NN NN O
testosterone NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
atherosclerosis NNS NNS O
in IN IN O
postmenopausal NN NN O
women NNS NNS O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
study VB VB O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
effects NNS NNS O
of IN IN O
androgen NN NN O
treatment NN NN O
on IN IN O
atherosclerosis NNS NNS O
in IN IN O
postmenopausal NN NN O
women NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
a DT DT O
population NN NN O
- - - O
based JJ JJ O
study NN NN O
in IN IN O
513 CD CD O
naturally RB RB O
postmenopausal NN NN O
women NNS NNS O
aged VBD VBD O
54 CD CD O
- : : O
67 CD CD O
years NNS NNS O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
association NN NN O
between IN IN O
self NN NN O
- - - O
reported VBN VBN O
intramuscularly RB RB O
administered VBN VBN O
high JJ JJ O
- - - O
dose NN NN O
estrogen NN NN B-CHEM
- : : O
testosterone NN NN B-CHEM
therapy NN NN O
( ( ( O
estradiol NN NN B-CHEM
- : : I-CHEM
and CC CC I-CHEM
testosterone CD CD I-CHEM
esters NNS NNS I-CHEM
) ) ) O
and CC CC O
aortic JJ JJ O
atherosclerosis NN NN O
. . . O

Aortic NNP NNP O
atherosclerosis NN NN O
was VBD VBD O
diagnosed VBN VBN O
by IN IN O
radiographic JJ JJ O
detection NN NN O
of IN IN O
calcified VBN VBN O
deposits NNS NNS O
in IN IN O
the DT DT O
abdominal JJ JJ O
aorta NN NN O
, , , O
which WDT WDT O
have VBP VBP O
been VBN VBN O
shown VBN VBN O
to TO TO O
reflect VB VB O
intima JJ JJ O
atherosclerosis NNS NNS O
. . . O

Hormone NNP NNP O
therapy NN NN O
users NNS NNS O
were VBD VBD O
compared VBN VBN O
with IN IN O
never RB RB O
users NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Intramuscular NNP NNP O
hormone NN NN O
therapy NN NN O
use NN NN O
for IN IN O
1 CD CD O
year NN NN O
or CC CC O
longer RB RB O
was VBD VBD O
reported VBN VBN O
by IN IN O
25 CD CD O
women NNS NNS O
. . . O

In IN IN O
almost RB RB O
half NN NN O
of IN IN O
these DT DT O
women NNS NNS O
severe JJ JJ O
atherosclerosis NN NN O
of IN IN O
the DT DT O
aorta NN NN O
was VBD VBD O
present JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
11 CD CD O
) ) ) O
, , , O
while IN IN O
in IN IN O
women NNS NNS O
without IN IN O
hormone NN NN O
use NN NN O
severe JJ JJ O
atherosclerosis NN NN O
of IN IN O
the DT DT O
aorta NN NN O
was VBD VBD O
present JJ JJ O
in IN IN O
less JJR JJR O
than IN IN O
20 CD CD O
% NN NN O
( ( ( O
OR CC CC O
3 CD CD O
. . . O
1 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
1 CD CD O
- : : O
8 CD CD O
. . . O
5 CD CD O
, , , O
adjusted VBN VBN O
for IN IN O
age NN NN O
, , , O
years NNS NNS O
since IN IN O
menopause NN NN O
, , , O
smoking NN NN O
, , , O
and CC CC O
body NN NN O
mass NN NN O
index NN NN O
) ) ) O
. . . O

The DT DT O
association NN NN O
remained VBD VBD O
after IN IN O
additional JJ JJ O
adjustment NN NN O
for IN IN O
diabetes NN NN O
, , , O
cholesterol NN NN B-CHEM
level NN NN O
, , , O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
, , , O
or CC CC O
alcohol NN NN B-CHEM
use NN NN O
. . . O

No DT DT O
association NN NN O
was VBD VBD O
found VBN VBN O
for IN IN O
hormone NN NN O
use NN NN O
less JJR JJR O
than IN IN O
1 CD CD O
year NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
high JJ JJ O
- - - O
dose NN NN O
testosterone NN NN B-CHEM
therapy NN NN O
may MD MD O
adversely RB RB O
affect VB VB O
atherosclerosis NNS NNS O
in IN IN O
postmenopausal NN NN O
women NNS NNS O
and CC CC O
indicate VB VB O
that IN IN O
androgen NN NN O
replacement NN NN O
in IN IN O
these DT DT O
women NNS NNS O
may MD MD O
not RB RB O
be VB VB O
harmless JJ JJ O
. . . O

Optimising NNP NNP O
stroke NN NN O
prevention NN NN O
in IN IN O
non NN NN O
- - - O
valvular NN NN O
atrial JJ JJ O
fibrillation NN NN O
. . . O

Atrial NNP NNP O
fibrillation NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
substantial JJ JJ O
morbidity NN NN O
and CC CC O
mortality NN NN O
. . . O

Pooled NNP NNP O
data NNS NNS O
from IN IN O
trials NNS NNS O
comparing VBG VBG O
antithrombotic JJ JJ O
treatment NN NN O
with IN IN O
placebo NN NN O
have VBP VBP O
shown VBN VBN O
that IN IN O
warfarin NN NN B-CHEM
reduces VBZ VBZ O
the DT DT O
risk NN NN O
of IN IN O
stroke NN NN O
by IN IN O
62 CD CD O
% NN NN O
, , , O
and CC CC O
that IN IN O
aspirin NN NN B-CHEM
alone RB RB O
reduces VBZ VBZ O
the DT DT O
risk NN NN O
by IN IN O
22 CD CD O
% NN NN O
. . . O

Overall RB RB O
, , , O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
, , , O
warfarin NN NN B-CHEM
is VBZ VBZ O
superior JJ JJ O
to TO TO O
aspirin VB VB B-CHEM
in IN IN O
preventing VBG VBG O
strokes NNS NNS O
, , , O
with IN IN O
a DT DT O
relative JJ JJ O
risk NN NN O
reduction NN NN O
of IN IN O
36 CD CD O
% NN NN O
. . . O

Ximelagatran NNP NNP B-CHEM
, , , O
an DT DT O
oral JJ JJ O
direct JJ JJ O
thrombin NN NN O
inhibitor NN NN O
, , , O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
as RB RB O
efficient JJ JJ O
as IN IN O
vitamin NN NN B-CHEM
K NNP NNP I-CHEM
antagonist NN NN O
drugs NNS NNS O
in IN IN O
the DT DT O
prevention NN NN O
of IN IN O
embolic JJ JJ O
events NNS NNS O
, , , O
but CC CC O
has VBZ VBZ O
been VBN VBN O
recently RB RB O
withdrawn VBN VBN O
because IN IN O
of IN IN O
abnormal JJ JJ O
liver NN NN O
function NN NN O
tests NNS NNS O
. . . O

The DT DT O
ACTIVE JJ JJ O
- - - O
W NNP NNP O
( ( ( O
Atrial NNP NNP O
Fibrillation NNP NNP O
Clopidogrel NNP NNP B-CHEM
Trial NN NN O
with IN IN O
Irbesartan NNP NNP B-CHEM
for IN IN O
Prevention NNP NNP O
of IN IN O
Vascular NNP NNP O
Events NNS NNS O
) ) ) O
study NN NN O
has VBZ VBZ O
demonstrated VBN VBN O
that IN IN O
warfarin NN NN B-CHEM
is VBZ VBZ O
superior JJ JJ O
to TO TO O
platelet VB VB O
therapy NN NN O
( ( ( O
clopidogrel NN NN B-CHEM
plus CC CC O
aspirin NN NN B-CHEM
) ) ) O
in IN IN O
the DT DT O
prevention NN NN O
af NN NN O
embolic JJ JJ O
events NNS NNS O
. . . O

Idraparinux NNP NNP B-CHEM
, , , O
a DT DT O
Factor NNP NNP O
Xa NNP NNP O
inhibitor NN NN O
, , , O
is VBZ VBZ O
being VBG VBG O
evaluated VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
atrial JJ JJ O
fibrillation NN NN O
. . . O

Angiotensin NNP NNP B-CHEM
- : : O
converting VBG VBG O
enzyme NN NN O
inhibitors NNS NNS O
and CC CC O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
- : : O
blocking VBG VBG O
drugs NNS NNS O
hold NN NN O
promise NN NN O
in IN IN O
atrial JJ JJ O
fibrillation NN NN O
through IN IN O
cardiac JJ JJ O
remodelling NN NN O
. . . O

Preliminary NNP NNP O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
statins NNS NNS B-CHEM
could MD MD O
interfere VB VB O
with IN IN O
the DT DT O
risk NN NN O
of IN IN O
recurrence NN NN O
after IN IN O
electrical JJ JJ O
cardioversion NN NN O
. . . O

Finally RB RB O
, , , O
percutaneous JJ JJ O
methods NNS NNS O
for IN IN O
the DT DT O
exclusion NN NN O
of IN IN O
left VBD VBD O
atrial JJ JJ O
appendage NN NN O
are VBP VBP O
under IN IN O
investigation NN NN O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
. . . O

Anti NNP NNP O
- : : O
oxidant JJ JJ O
effects NNS NNS O
of IN IN O
atorvastatin NN NN B-CHEM
in IN IN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

1 CD CD O
. . . O

Dexamethasone NNP NNP B-CHEM
( ( ( O
Dex NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypertension NN NN O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
endothelial JJ JJ O
dysfunction NN NN O
associated VBN VBN O
with IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO NNP NNP B-CHEM
) ) ) O
deficiency NN NN O
and CC CC O
increased VBN VBN O
superoxide NN NN B-CHEM
( ( ( O
O2 NNP NNP B-CHEM
- : : I-CHEM
) ) ) O
production NN NN O
. . . O

Atorvastatin NNP NNP B-CHEM
( ( ( O
Ato NNP NNP B-CHEM
) ) ) O
possesses NNS NNS O
pleiotropic JJ JJ O
properties NNS NNS O
that WDT WDT O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
to TO TO O
improve VB VB O
endothelial JJ JJ O
function NN NN O
through IN IN O
increased VBN VBN O
availability NN NN O
of IN IN O
NO NN NN B-CHEM
and CC CC O
reduced VBN VBN O
O2 NNP NNP B-CHEM
- : : I-CHEM
production NN NN O
in IN IN O
various JJ JJ O
forms NNS NNS O
of IN IN O
hypertension NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
whether IN IN O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
Ato NNP NNP B-CHEM
could MD MD O
prevent VB VB O
endothelial NN NN O
NO DT DT B-CHEM
synthase NN NN O
( ( ( O
eNOS NN NN O
) ) ) O
downregulation NN NN O
and CC CC O
the DT DT O
increase NN NN O
in IN IN O
O2 NNP NNP B-CHEM
- : : I-CHEM
in IN IN O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
( ( ( O
SD NNP NNP O
) ) ) O
rats NNS NNS O
, , , O
thereby RB RB O
reducing VBG VBG O
blood NN NN O
pressure NN NN O
. . . O

2 CD CD O
. . . O

Male NNP NNP O
SD NNP NNP O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
30 CD CD O
) ) ) O
were VBD VBD O
treated VBN VBN O
with IN IN O
Ato NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
in IN IN O
drinking NN NN O
water NN NN O
) ) ) O
or CC CC O
tap VB VB O
water NN NN O
for IN IN O
15 CD CD O
days NNS NNS O
. . . O

Dexamethasone NNP NNP B-CHEM
( ( ( O
10 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
or CC CC O
saline NN NN O
was VBD VBD O
started VBN VBN O
after IN IN O
4 CD CD O
days NNS NNS O
in IN IN O
Ato NNP NNP B-CHEM
- - - O
treated JJ JJ O
and CC CC O
non NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
and CC CC O
continued VBD VBD O
for IN IN O
11 CD CD O
- : : O
13 CD CD O
days NNS NNS O
. . . O

Systolic NNP NNP O
blood NN NN O
pressure NN NN O
( ( ( O
SBP NNP NNP O
) ) ) O
was VBD VBD O
measured VBN VBN O
on IN IN O
alternate JJ JJ O
days NNS NNS O
using VBG VBG O
the DT DT O
tail NN NN O
- - - O
cuff NN NN O
method NN NN O
. . . O

Endothelial NNP NNP O
function NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
acetylcholine NN NN B-CHEM
- - - O
induced JJ JJ O
vasorelaxation NN NN O
and CC CC O
phenylephrine NN NN B-CHEM
- - - O
induced JJ JJ O
vasoconstriction NN NN O
in IN IN O
aortic JJ JJ O
segments NNS NNS O
. . . O

Vascular NNP NNP O
eNOS NN NN O
mRNA NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
semi NN NN O
- - - O
quantitative JJ JJ O
reverse NN NN O
transcription NN NN O
- : : O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. . . O

3 CD CD O
. . . O

In IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
Dex NNP NNP B-CHEM
alone RB RB O
, , , O
SBP NNP NNP O
was VBD VBD O
increased VBN VBN O
from IN IN O
109 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
to TO TO O
133 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mmHg NN NN O
on IN IN O
Days NNS NNS O
4 CD CD O
and CC CC O
Day NNP NNP O
14 CD CD O
, , , O
respectively RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
Ato NNP NNP B-CHEM
+ NN NN O
Dex NNP NNP B-CHEM
group NN NN O
, , , O
SBP NNP NNP O
was VBD VBD O
increased VBN VBN O
from IN IN O
113 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
to TO TO O
119 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mmHg NN NN O
on IN IN O
Days NNS NNS O
4 CD CD O
to TO TO O
14 CD CD O
, , , O
respectively RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
but CC CC O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
SBP NNP NNP O
in IN IN O
the DT DT O
group NN NN O
treated VBN VBN O
with IN IN O
Dex NNP NNP B-CHEM
alone RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Endothelial NNP NNP O
- : : O
dependent JJ JJ O
relaxation NN NN O
and CC CC O
eNOS NN NN O
mRNA NN NN O
expression NN NN O
were VBD VBD O
greater JJR JJR O
in IN IN O
the DT DT O
Dex NNP NNP B-CHEM
+ NN NN O
Ato NNP NNP B-CHEM
group NN NN O
than IN IN O
in IN IN O
the DT DT O
Dex NNP NNP B-CHEM
only RB RB O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
and CC CC O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

Aortic NNP NNP O
superoxide NN NN B-CHEM
production NN NN O
was VBD VBD O
lower JJR JJR O
in IN IN O
the DT DT O
Dex NNP NNP B-CHEM
+ NN NN O
Ato NNP NNP B-CHEM
group NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
group NN NN O
treated VBN VBN O
with IN IN O
Dex NNP NNP B-CHEM
alone RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

4 CD CD O
. . . O

Treatment NN NN O
with IN IN O
Ato NNP NNP B-CHEM
improved VBD VBD O
endothelial JJ JJ O
function NN NN O
, , , O
reduced VBN VBN O
superoxide NN NN B-CHEM
production NN NN O
and CC CC O
reduced VBN VBN O
SBP NNP NNP O
in IN IN O
Dex NNP NNP B-CHEM
- - - O
treated JJ JJ O
SD NNP NNP O
rats NNS NNS O
. . . O

Severe NNP NNP O
citrate NN NN B-CHEM
toxicity NN NN O
complicating NN NN O
volunteer NN NN O
apheresis NN NN O
platelet NN NN O
donation NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
severe JJ JJ O
citrate NN NN B-CHEM
toxicity NN NN O
during IN IN O
volunteer NN NN O
donor NN NN O
apheresis NNS NNS O
platelet NN NN O
collection NN NN O
. . . O

The DT DT O
donor NN NN O
was VBD VBD O
a DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
, , , O
first JJ JJ O
- - - O
time NN NN O
apheresis NN NN O
platelet NN NN O
donor NN NN O
. . . O

Past NNP NNP O
medical JJ JJ O
history NN NN O
was VBD VBD O
remarkable JJ JJ O
for IN IN O
hypertension NN NN O
, , , O
hyperlipidemia NN NN O
, , , O
and CC CC O
depression NN NN O
. . . O

Reported NNP NNP O
medications NNS NNS O
included VBN VBN O
bumetanide NN NN B-CHEM
, , , O
pravastatin NN NN B-CHEM
, , , O
and CC CC O
paroxetine NN NN B-CHEM
. . . O

Thirty NNP NNP O
minutes NNS NNS O
from IN IN O
the DT DT O
start NN NN O
of IN IN O
the DT DT O
procedure NN NN O
, , , O
the DT DT O
donor NN NN O
noted VBD VBD O
tingling VBG VBG O
around IN IN O
the DT DT O
mouth NN NN O
, , , O
hands NNS NNS O
, , , O
and CC CC O
feet NNS NNS O
. . . O

She PRP PRP O
then RB RB O
very RB RB O
rapidly RB RB O
developed VBN VBN O
acute JJ JJ O
onset NN NN O
of IN IN O
severe JJ JJ O
facial NN NN O
and CC CC O
extremity NN NN O
tetany NN NN O
. . . O

Empirical NNP NNP O
treatment NN NN O
with IN IN O
intravenous JJ JJ O
calcium NN NN B-CHEM
gluconate NN NN I-CHEM
was VBD VBD O
initiated VBN VBN O
, , , O
and CC CC O
muscle NN NN O
contractions NNS NNS O
slowly RB RB O
subsided VBN VBN O
over IN IN O
approximately RB RB O
10 CD CD O
to TO TO O
15 CD CD O
minutes NNS NNS O
. . . O

The DT DT O
events NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
a DT DT O
severe JJ JJ O
reaction NN NN O
to TO TO O
calcium NN NN B-CHEM
chelation NN NN O
by IN IN O
sodium NN NN B-CHEM
citrate NN NN I-CHEM
anticoagulant NN NN O
resulting VBG VBG O
in IN IN O
symptomatic JJ JJ O
systemic JJ JJ O
hypocalcemia NN NN O
. . . O

Upon IN IN O
additional JJ JJ O
retrospective NN NN O
analysis NN NN O
, , , O
it PRP PRP O
was VBD VBD O
noted VBN VBN O
that IN IN O
bumetanide NN NN B-CHEM
is VBZ VBZ O
a DT DT O
loop NN NN B-CHEM
diuretic JJ JJ I-CHEM
that WDT WDT O
may MD MD O
cause VB VB O
significant JJ JJ O
hypocalcemia NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
careful JJ JJ O
screening NN NN O
for IN IN O
medications NNS NNS O
and CC CC O
underlying VBG VBG O
conditions NNS NNS O
predisposing VBG VBG O
to TO TO O
hypocalcemia NN NN O
is VBZ VBZ O
recommended VBN VBN O
to TO TO O
help VB VB O
prevent VB VB O
severe JJ JJ O
reactions NNS NNS O
due JJ JJ O
to TO TO O
citrate VB VB B-CHEM
toxicity NN NN O
. . . O

Laboratory NNP NNP O
measurement NN NN O
of IN IN O
pre NN NN O
- - - O
procedure NN NN O
serum NN NN O
calcium NN NN B-CHEM
levels NNS NNS O
in IN IN O
selected JJ JJ O
donors NNS NNS O
may MD MD O
identify VB VB O
cases NNS NNS O
requiring VBG VBG O
heightened JJ JJ O
vigilance NN NN O
. . . O

The DT DT O
case NN NN O
also RB RB O
illustrates VBZ VBZ O
the DT DT O
importance NN NN O
of IN IN O
maintaining VBG VBG O
preparedness NN NN O
for IN IN O
managing VBG VBG O
rare JJ JJ O
but CC CC O
serious JJ JJ O
reactions NNS NNS O
in IN IN O
volunteer NN NN O
apheresis NN NN O
blood NN NN O
donors NNS NNS O
. . . O

Sirolimus NNP NNP B-CHEM
- - - O
associated VBN VBN O
proteinuria NN NN O
and CC CC O
renal JJ JJ O
dysfunction NN NN O
. . . O

Sirolimus NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
novel NN NN O
immunosuppressant NN NN O
with IN IN O
potent NN NN O
antiproliferative JJ JJ O
actions NNS NNS O
through IN IN O
its PRP$ PRP$ O
ability NN NN O
to TO TO O
inhibit VB VB O
the DT DT O
raptor NN NN O
- - - O
containing VBG VBG O
mammalian JJ JJ O
target NN NN O
of IN IN O
rapamycin NN NN B-CHEM
protein NN NN O
kinase NN NN O
. . . O

Sirolimus NNP NNP B-CHEM
represents VBZ VBZ O
a DT DT O
major JJ JJ O
therapeutic JJ JJ O
advance NN NN O
in IN IN O
the DT DT O
prevention NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
allograft NN NN O
rejection NN NN O
and CC CC O
chronic JJ JJ O
allograft NN NN O
nephropathy NN NN O
. . . O

Its PRP$ PRP$ O
role NN NN O
in IN IN O
the DT DT O
therapy NN NN O
of IN IN O
glomerulonephritis NNS NNS O
, , , O
autoimmunity NN NN O
, , , O
cystic JJ JJ O
renal NN NN O
diseases NNS NNS O
and CC CC O
renal JJ JJ O
cancer NN NN O
is VBZ VBZ O
under IN IN O
investigation NN NN O
. . . O

Because IN IN O
sirolimus NN NN B-CHEM
does VBZ VBZ O
not RB RB O
share VB VB O
the DT DT O
vasomotor NN NN O
renal JJ JJ O
adverse JJ JJ O
effects NNS NNS O
exhibited VBN VBN O
by IN IN O
calcineurin NN NN O
inhibitors NNS NNS O
, , , O
it PRP PRP O
has VBZ VBZ O
been VBN VBN O
designated VBN VBN O
a DT DT O
' POS POS O
non NN NN O
- - - O
nephrotoxic JJ JJ O
drug NN NN O
' '' '' O
. . . O

However RB RB O
, , , O
clinical JJ JJ O
reports NNS NNS O
suggest VBP VBP O
that IN IN O
, , , O
under IN IN O
some DT DT O
circumstances NNS NNS O
, , , O
sirolimus NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
proteinuria NNS NNS O
and CC CC O
acute JJ JJ O
renal JJ JJ O
dysfunction NN NN O
. . . O

A DT DT O
common JJ JJ O
risk NN NN O
factor NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
presence NN NN O
of IN IN O
pre NN NN O
- - - O
existing VBG VBG O
chronic JJ JJ O
renal JJ JJ O
damage NN NN O
. . . O

The DT DT O
mechanisms NNS NNS O
of IN IN O
sirolimus NN NN B-CHEM
- - - O
associated VBN VBN O
proteinuria NNS NNS O
are VBP VBP O
multifactorial JJ JJ O
and CC CC O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
glomerular NN NN O
capillary JJ JJ O
pressure NN NN O
following VBG VBG O
calcineurin NN NN O
inhibitor NN NN O
withdrawal NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
also RB RB O
been VBN VBN O
suggested VBN VBN O
that IN IN O
sirolimus NN NN B-CHEM
directly RB RB O
causes NNS NNS O
increased VBN VBN O
glomerular NN NN O
permeability NN NN O
/ NN NN O
injury NN NN O
, , , O
but CC CC O
evidence NN NN O
for IN IN O
this DT DT O
mechanism NN NN O
is VBZ VBZ O
currently RB RB O
inconclusive JJ JJ O
. . . O

The DT DT O
acute JJ JJ O
renal JJ JJ O
dysfunction NN NN O
associated VBN VBN O
with IN IN O
sirolimus NN NN B-CHEM
( ( ( O
such JJ JJ O
as IN IN O
in IN IN O
delayed JJ JJ O
graft NN NN O
function NN NN O
) ) ) O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
suppression NN NN O
of IN IN O
compensatory JJ JJ O
renal JJ JJ O
cell NN NN O
proliferation NN NN O
and CC CC O
survival NN NN O
/ NN NN O
repair NN NN O
processes NNS NNS O
. . . O

Although IN IN O
these DT DT O
adverse JJ JJ O
effects NNS NNS O
occur VBP VBP O
in IN IN O
some DT DT O
patients NNS NNS O
, , , O
their PRP$ PRP$ O
occurrence NN NN O
could MD MD O
be VB VB O
minimised VBN VBN O
by IN IN O
knowledge NN NN O
of IN IN O
the DT DT O
molecular JJ JJ O
effects NNS NNS O
of IN IN O
sirolimus NN NN B-CHEM
on IN IN O
the DT DT O
kidney NN NN O
, , , O
the DT DT O
use NN NN O
of IN IN O
sirolimus NN NN B-CHEM
in IN IN O
appropriate JJ JJ O
patient NN NN O
populations NNS NNS O
, , , O
close NN NN O
monitoring NN NN O
of IN IN O
proteinuria NN NN O
and CC CC O
renal JJ JJ O
function NN NN O
, , , O
use NN NN O
of IN IN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
inhibitors NNS NNS O
or CC CC O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
blockers NNS NNS O
if IN IN O
proteinuria NN NN O
occurs VBZ VBZ O
and CC CC O
withdrawal NN NN O
if IN IN O
needed VBN VBN O
. . . O

Further RB RB O
long RB RB O
- - - O
term NN NN O
analysis NN NN O
of IN IN O
renal JJ JJ O
allograft NN NN O
studies NNS NNS O
using VBG VBG O
sirolimus NN NN B-CHEM
as IN IN O
de IN IN O
novo NN NN O
immunosuppression NN NN O
along IN IN O
with IN IN O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
studies NNS NNS O
will MD MD O
refine VB VB O
these DT DT O
issues NNS NNS O
in IN IN O
the DT DT O
future NN NN O
. . . O

Proteinuria NNP NNP O
after IN IN O
conversion NN NN O
to TO TO O
sirolimus VB VB B-CHEM
in IN IN O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
. . . O

Sirolimus NNP NNP B-CHEM
( ( ( O
SRL NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
new JJ JJ O
, , , O
potent JJ JJ O
immunosuppressive JJ JJ O
agent NN NN O
. . . O

More RBR RBR O
recently RB RB O
, , , O
proteinuria NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
as IN IN O
a DT DT O
consequence NN NN O
of IN IN O
sirolimus NN NN B-CHEM
therapy NN NN O
, , , O
although IN IN O
the DT DT O
mechanism NN NN O
has VBZ VBZ O
remained VBN VBN O
unclear JJ JJ O
. . . O

We PRP PRP O
retrospectively RB RB O
examined VBD VBD O
the DT DT O
records NNS NNS O
of IN IN O
25 CD CD O
renal JJ JJ O
transplant NN NN O
patients NNS NNS O
, , , O
who WP WP O
developed VBD VBD O
or CC CC O
displayed VBN VBN O
increased VBN VBN O
proteinuria NN NN O
after IN IN O
SRL NNP NNP B-CHEM
conversion NN NN O
. . . O

The DT DT O
patient NN NN O
cohort NN NN O
( ( ( O
14 CD CD O
men NNS NNS O
, , , O
11 CD CD O
women NNS NNS O
) ) ) O
was VBD VBD O
treated VBN VBN O
with IN IN O
SRL NNP NNP B-CHEM
as IN IN O
conversion NN NN O
therapy NN NN O
, , , O
due JJ JJ O
to TO TO O
chronic JJ JJ O
allograft NN NN O
nephropathy NN NN O
( ( ( O
CAN MD MD O
) ) ) O
( ( ( O
n NN NN O
= SYM SYM O
15 CD CD O
) ) ) O
neoplasia NN NN O
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
; : : O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
, , , O
Four CD CD O
skin NN NN O
cancers NNS NNS O
, , , O
One CD CD O
intestinal JJ JJ O
tumors NNS NNS O
, , , O
One CD CD O
renal JJ JJ O
cell NN NN O
carsinom NN NN O
) ) ) O
or CC CC O
BK NNP NNP O
virus NN NN O
nephropathy NN NN O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
. . . O

SRL NNP NNP B-CHEM
was VBD VBD O
started VBN VBN O
at IN IN O
a DT DT O
mean NN NN O
of IN IN O
78 CD CD O
+ NN NN O
/ NN NN O
- : : O
42 CD CD O
( ( ( O
15 CD CD O
to TO TO O
163 CD CD O
) ) ) O
months NNS NNS O
after IN IN O
transplantation NN NN O
. . . O

Mean VB VB O
follow VB VB O
- - - O
up RP RP O
on IN IN O
SRL NNP NNP B-CHEM
therapy NN NN O
was VBD VBD O
20 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
( ( ( O
6 CD CD O
to TO TO O
43 CD CD O
) ) ) O
months NNS NNS O
. . . O

Proteinuria NNP NNP O
increased VBD VBD O
from IN IN O
0 CD CD O
. . . O
445 CD CD O
( ( ( O
0 CD CD O
to TO TO O
1 CD CD O
. . . O
5 CD CD O
) ) ) O
g SYM SYM O
/ NN NN O
d SYM SYM O
before IN IN O
conversion NN NN O
to TO TO O
3 CD CD O
. . . O
2 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
( ( ( O
0 CD CD O
. . . O
2 CD CD O
to TO TO O
12 CD CD O
) ) ) O
after IN IN O
conversion NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Before IN IN O
conversion NN NN O
8 CD CD O
( ( ( O
32 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
had VBD VBD O
no DT DT O
proteinuria NN NN O
, , , O
whereas IN IN O
afterwards NNS NNS O
all DT DT O
patients NNS NNS O
had VBD VBD O
proteinuria NN NN O
. . . O

In IN IN O
28 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
proteinuria VBP VBP O
remained VBD VBD O
unchanged JJ JJ O
, , , O
whereas IN IN O
it PRP PRP O
increased VBD VBD O
in IN IN O
68 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

In IN IN O
40 CD CD O
% NN NN O
it PRP PRP O
increased VBN VBN O
by IN IN O
more JJR JJR O
than IN IN O
100 CD CD O
% NN NN O
. . . O

Twenty CD CD O
- - - O
eight CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
showed VBD VBD O
increased VBN VBN O
proteinuria NNS NNS O
to TO TO O
the DT DT O
nephrotic JJ JJ O
range NN NN O
. . . O

Biopsies NNP NNP O
performed VBD VBD O
in IN IN O
five CD CD O
patients NNS NNS O
revealed VBD VBD O
new JJ JJ O
pathological JJ JJ O
changes NNS NNS O
: : : O
One CD CD O
membranoproliferative JJ JJ O
glomerulopathy NN NN O
and CC CC O
interstitial JJ JJ O
nephritis NN NN O
. . . O

These DT DT O
patients NNS NNS O
showed VBD VBD O
persistently RB RB O
good JJ JJ O
graft NN NN O
function NN NN O
. . . O

Serum NNP NNP O
creatinine NN NN B-CHEM
values NNS NNS O
did VBD VBD O
not RB RB O
change VB VB O
significantly RB RB O
: : : O
1 CD CD O
. . . O
98 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
8 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
before IN IN O
SRL NNP NNP B-CHEM
therapy NN NN O
and CC CC O
2 CD CD O
. . . O
53 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
9 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
at IN IN O
last JJ JJ O
follow VB VB O
- - - O
up RP RP O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
14 CD CD O
) ) ) O
. . . O

Five CD CD O
grafts NNS NNS O
were VBD VBD O
lost VBN VBN O
and CC CC O
the DT DT O
patients NNS NNS O
returned VBD VBD O
to TO TO O
dialysis NN NN O
. . . O

Five CD CD O
patients NNS NNS O
displayed VBD VBD O
CAN MD MD O
and CC CC O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
. . . O

Mean VB VB O
urinary JJ JJ O
protein NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
returned VBD VBD O
to TO TO O
dialysis NN NN O
was VBD VBD O
1 CD CD O
. . . O
26 CD CD O
( ( ( O
0 CD CD O
. . . O
5 CD CD O
to TO TO O
3 CD CD O
. . . O
5 CD CD O
) ) ) O
g SYM SYM O
/ NN NN O
d SYM SYM O
before IN IN O
and CC CC O
4 CD CD O
. . . O
7 CD CD O
( ( ( O
3 CD CD O
to TO TO O
12 CD CD O
) ) ) O
g SYM SYM O
/ NN NN O
d SYM SYM O
after IN IN O
conversion NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
. . . O

Mean VB VB O
serum NN NN O
creatinine NN NN B-CHEM
level NN NN O
before IN IN O
conversion NN NN O
was VBD VBD O
2 CD CD O
. . . O
21 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
and CC CC O
thereafter RB RB O
, , , O
4 CD CD O
. . . O
93 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
. . . O

Heavy JJ JJ O
proteinuria NNS NNS O
was VBD VBD O
common JJ JJ O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
SRL NNP NNP B-CHEM
as IN IN O
rescue NN NN O
therapy NN NN O
for IN IN O
renal JJ JJ O
transplantation NN NN O
. . . O

Therefore RB RB O
, , , O
conversion NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
for IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
not RB RB O
developed VBN VBN O
advanced VBD VBD O
CAN MD MD O
and CC CC O
proteinuria VB VB O
. . . O

The DT DT O
possibility NN NN O
of IN IN O
de IN IN O
novo NN NN O
glomerular NN NN O
pathology NN NN O
under IN IN O
SRL NNP NNP B-CHEM
treatment NN NN O
requires VBZ VBZ O
further JJ JJ O
investigation NN NN O
by IN IN O
renal JJ JJ O
biopsy NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
ifosfamide NN NN B-CHEM
renal JJ JJ O
toxicity NN NN O
in IN IN O
children NNS NNS O
treated VBN VBN O
for IN IN O
malignant JJ JJ O
mesenchymal NN NN O
tumors NNS NNS O
: : : O
an DT DT O
International NNP NNP O
Society NNP NNP O
of IN IN O
Pediatric NNP NNP O
Oncology NNP NNP O
report NN NN O
. . . O

The DT DT O
renal JJ JJ O
function NN NN O
of IN IN O
74 CD CD O
children NNS NNS O
with IN IN O
malignant JJ JJ O
mesenchymal NN NN O
tumors NNS NNS O
in IN IN O
complete JJ JJ O
remission NN NN O
and CC CC O
who WP WP O
have VBP VBP O
received VBN VBN O
the DT DT O
same JJ JJ O
ifosfamide NN NN B-CHEM
chemotherapy NN NN O
protocol NN NN O
( ( ( O
International NNP NNP O
Society NNP NNP O
of IN IN O
Pediatric NNP NNP O
Oncology NNP NNP O
Malignant NNP NNP O
Mesenchymal NNP NNP O
Tumor NNP NNP O
Study NNP NNP O
84 CD CD O
[ NN NN O
SIOP NNP NNP O
MMT NNP NNP O
84 CD CD O
] NN NN O
) ) ) O
were VBD VBD O
studied VBN VBN O
1 CD CD O
year NN NN O
after IN IN O
the DT DT O
completion NN NN O
of IN IN O
treatment NN NN O
. . . O

Total NNP NNP O
cumulative JJ JJ O
doses NNS NNS O
were VBD VBD O
36 CD CD O
or CC CC O
60 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
( ( ( O
six CD CD O
or CC CC O
10 CD CD O
cycles NNS NNS O
of IN IN O
ifosfamide NN NN B-CHEM
, , , I-CHEM
vincristine NN NN I-CHEM
, , , I-CHEM
and CC CC I-CHEM
dactinomycin NN NN I-CHEM
[ NN NN O
IVA NNP NNP B-CHEM
] NN NN O
) ) ) O
. . . O

None NN NN O
of IN IN O
them PRP PRP O
had VBD VBD O
received VBN VBN O
cisplatin NN NN B-CHEM
chemotherapy NN NN O
. . . O

Ages NNS NNS O
ranged VBN VBN O
from IN IN O
4 CD CD O
months NNS NNS O
to TO TO O
17 CD CD O
years NNS NNS O
; : : O
58 CD CD O
patients NNS NNS O
were VBD VBD O
males NNS NNS O
and CC CC O
42 CD CD O
females NNS NNS O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
primary JJ JJ O
tumor NN NN O
site NN NN O
was VBD VBD O
the DT DT O
head NN NN O
and CC CC O
neck NN NN O
. . . O

Renal NNP NNP O
function NN NN O
was VBD VBD O
investigated VBN VBN O
by IN IN O
measuring VBG VBG O
plasma NN NN O
and CC CC O
urinary JJ JJ O
electrolytes NNS NNS O
, , , O
glucosuria NN NN O
, , , O
proteinuria NN NN O
, , , O
aminoaciduria NN NN O
, , , O
urinary JJ JJ O
pH NN NN O
, , , O
osmolarity NN NN O
, , , O
creatinine NN NN B-CHEM
clearance NN NN O
, , , O
phosphate NN NN B-CHEM
tubular JJ JJ O
reabsorption NN NN O
, , , O
beta NN NN O
2 CD CD O
microglobulinuria NN NN O
, , , O
and CC CC O
lysozymuria NN NN O
. . . O

Fifty NNP NNP O
- : : O
eight CD CD O
patients NNS NNS O
( ( ( O
78 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
normal JJ JJ O
renal NN NN O
tests NNS NNS O
, , , O
whereas IN IN O
16 CD CD O
patients NNS NNS O
( ( ( O
22 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
renal JJ JJ O
abnormalities NNS NNS O
. . . O

Two CD CD O
subsets NNS NNS O
of IN IN O
patients NNS NNS O
were VBD VBD O
identified VBN VBN O
from IN IN O
this DT DT O
latter JJ JJ O
group NN NN O
: : : O
the DT DT O
first JJ JJ O
included VBD VBD O
four CD CD O
patients NNS NNS O
( ( ( O
5 CD CD O
% NN NN O
of IN IN O
the DT DT O
total JJ JJ O
population NN NN O
) ) ) O
who WP WP O
developed VBD VBD O
major JJ JJ O
toxicity NN NN O
resulting VBG VBG O
in IN IN O
Fanconi NNP NNP O
' POS POS O
s VBZ VBZ O
syndrome NN NN O
( ( ( O
TDFS NNP NNP O
) ) ) O
; : : O
and CC CC O
the DT DT O
second JJ JJ O
group NN NN O
included VBD VBD O
five CD CD O
patients NNS NNS O
with IN IN O
elevated VBD VBD O
beta NN NN O
2 CD CD O
microglobulinuria NN NN O
and CC CC O
low JJ JJ O
phosphate NN NN B-CHEM
reabsorption NN NN O
. . . O

The DT DT O
remaining VBG VBG O
seven CD CD O
patients NNS NNS O
had VBD VBD O
isolated VBN VBN O
beta NN NN O
2 CD CD O
microglobulinuria NN NN O
. . . O

Severe NNP NNP O
toxicity NN NN O
was VBD VBD O
correlated VBN VBN O
with IN IN O
the DT DT O
higher JJR JJR O
cumulative JJ JJ O
dose NN NN O
of IN IN O
60 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
, , , O
a DT DT O
younger JJR JJR O
age NN NN O
( ( ( O
less JJR JJR O
than IN IN O
2 CD CD O
1 CD CD O
/ NN NN O
2 CD CD O
years NNS NNS O
old JJ JJ O
) ) ) O
, , , O
and CC CC O
a DT DT O
predominance NN NN O
of IN IN O
vesicoprostatic JJ JJ O
tumor NN NN O
involvement NN NN O
. . . O

This DT DT O
low JJ JJ O
percentage NN NN O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
of IN IN O
TDFS NNP NNP O
must MD MD O
be VB VB O
evaluated VBN VBN O
with IN IN O
respect NN NN O
to TO TO O
the DT DT O
efficacy NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
mesenchymal JJ JJ O
tumors NNS NNS O
in IN IN O
children NNS NNS O
. . . O

Progressive NNP NNP O
myopathy NN NN O
with IN IN O
up RB RB O
- : : O
regulation NN NN O
of IN IN O
MHC NNP NNP O
- : : O
I PRP PRP O
associated VBD VBD O
with IN IN O
statin NN NN B-CHEM
therapy NN NN O
. . . O

Statins NNP NNP B-CHEM
can MD MD O
cause VB VB O
a DT DT O
necrotizing VBG VBG O
myopathy NN NN O
and CC CC O
hyperCKaemia NN NN O
which WDT WDT O
is VBZ VBZ O
reversible JJ JJ O
on IN IN O
cessation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

What WP WP O
is VBZ VBZ O
less JJR JJR O
well RB RB O
known VBN VBN O
is VBZ VBZ O
a DT DT O
phenomenon NN NN O
whereby NN NN O
statins NNS NNS B-CHEM
may MD MD O
induce VB VB O
a DT DT O
myopathy NN NN O
, , , O
which WDT WDT O
persists VBZ VBZ O
or CC CC O
may MD MD O
progress NN NN O
after IN IN O
stopping VBG VBG O
the DT DT O
drug NN NN O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
muscle NN NN O
pathology NN NN O
in IN IN O
8 CD CD O
such JJ JJ O
cases NNS NNS O
. . . O

All DT DT O
had VBD VBD O
myofibre NN NN O
necrosis NNS NNS O
but CC CC O
only RB RB O
3 CD CD O
had VBD VBD O
an DT DT O
inflammatory JJ JJ O
infiltrate NN NN O
. . . O

In IN IN O
all DT DT O
cases NNS NNS O
there RB RB O
was VBD VBD O
diffuse NN NN O
or CC CC O
multifocal JJ JJ O
up RP RP O
- : : O
regulation NN NN O
of IN IN O
MHC NNP NNP O
- : : O
I PRP PRP O
expression NN NN O
even RB RB O
in IN IN O
non NN NN O
- - - O
necrotic JJ JJ O
fibres NNS NNS O
. . . O

Progressive NNP NNP O
improvement NN NN O
occurred VBD VBD O
in IN IN O
7 CD CD O
cases NNS NNS O
after IN IN O
commencement NN NN O
of IN IN O
prednisolone NN NN B-CHEM
and CC CC O
methotrexate NN NN B-CHEM
, , , O
and CC CC O
in IN IN O
one CD CD O
case NN NN O
spontaneously RB RB O
. . . O

These DT DT O
observations NNS NNS O
suggest VBP VBP O
that IN IN O
statins NNS NNS B-CHEM
may MD MD O
initiate VB VB O
an DT DT O
immune JJ JJ O
- - - O
mediated JJ JJ O
myopathy NN NN O
that WDT WDT O
persists NNS NNS O
after IN IN O
withdrawal NN NN O
of IN IN O
the DT DT O
drug NN NN O
and CC CC O
responds VBZ VBZ O
to TO TO O
immunosuppressive VB VB O
therapy NN NN O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
this DT DT O
myopathy NN NN O
is VBZ VBZ O
uncertain JJ JJ O
but CC CC O
may MD MD O
involve VB VB O
the DT DT O
induction NN NN O
by IN IN O
statins NNS NNS B-CHEM
of IN IN O
an DT DT O
endoplasmic JJ JJ O
reticulum NN NN O
stress NN NN O
response NN NN O
with IN IN O
associated VBN VBN O
up RP RP O
- : : O
regulation NN NN O
of IN IN O
MHC NNP NNP O
- : : O
I PRP PRP O
expression NN NN O
and CC CC O
antigen NN NN O
presentation NN NN O
by IN IN O
muscle NN NN O
fibres NNS NNS O
. . . O

Use NN NN O
of IN IN O
chromosome NN NN O
substitution NN NN O
strains NNS NNS O
to TO TO O
identify VB VB O
seizure JJ JJ O
susceptibility NN NN O
loci NN NN O
in IN IN O
mice NN NN O
. . . O

Seizure NNP NNP O
susceptibility NN NN O
varies NNS NNS O
among IN IN O
inbred JJ JJ O
mouse NN NN O
strains NNS NNS O
. . . O

Chromosome NNP NNP O
substitution NN NN O
strains NNS NNS O
( ( ( O
CSS NNP NNP O
) ) ) O
, , , O
in IN IN O
which WDT WDT O
a DT DT O
single JJ JJ O
chromosome NN NN O
from IN IN O
one CD CD O
inbred JJ JJ O
strain NN NN O
( ( ( O
donor NN NN O
) ) ) O
has VBZ VBZ O
been VBN VBN O
transferred VBN VBN O
onto IN IN O
a DT DT O
second JJ JJ O
strain NN NN O
( ( ( O
host NN NN O
) ) ) O
by IN IN O
repeated VBN VBN O
backcrossing VBG VBG O
, , , O
may MD MD O
be VB VB O
used VBN VBN O
to TO TO O
identify VB VB O
quantitative JJ JJ O
trait NN NN O
loci NN NN O
( ( ( O
QTLs NNP NNP O
) ) ) O
that DT DT O
contribute VBP VBP O
to TO TO O
seizure VB VB O
susceptibility NN NN O
. . . O

QTLs NNP NNP O
for IN IN O
susceptibility NN NN O
to TO TO O
pilocarpine VB VB B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
, , , O
a DT DT O
model NN NN O
of IN IN O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
, , , O
have VBP VBP O
not RB RB O
been VBN VBN O
reported VBN VBN O
, , , O
and CC CC O
CSS NNP NNP O
have VBP VBP O
not RB RB O
previously RB RB O
been VBN VBN O
used VBN VBN O
to TO TO O
localize VB VB O
seizure NN NN O
susceptibility NN NN O
genes NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
QTLs NNP NNP O
identified VBD VBD O
using VBG VBG O
a DT DT O
B6 NNP NNP O
( ( ( O
host NN NN O
) ) ) O
x SYM SYM O
A DT DT O
/ NN NN O
J NNP NNP O
( ( ( O
donor NN NN O
) ) ) O
CSS NNP NNP O
panel NN NN O
to TO TO O
localize NN NN O
genes NNS NNS O
involved VBN VBN O
in IN IN O
susceptibility NN NN O
to TO TO O
pilocarpine VB VB B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
. . . O

Three CD CD O
hundred CD CD O
fifty NN NN O
- : : O
five CD CD O
adult NN NN O
male JJ JJ O
CSS NNP NNP O
mice NN NN O
, , , O
58 CD CD O
B6 NNP NNP O
, , , O
and CC CC O
39 CD CD O
A DT DT O
/ NN NN O
J NNP NNP O
were VBD VBD O
tested VBN VBN O
for IN IN O
susceptibility NN NN O
to TO TO O
pilocarpine VB VB B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
. . . O

Highest NNP NNP O
stage NN NN O
reached VBD VBD O
and CC CC O
latency NN NN O
to TO TO O
each DT DT O
stage NN NN O
were VBD VBD O
recorded VBN VBN O
for IN IN O
all DT DT O
mice NN NN O
. . . O

B6 NNP NNP O
mice NNS NNS O
were VBD VBD O
resistant JJ JJ O
to TO TO O
seizures NNS NNS O
and CC CC O
slower JJR JJR O
to TO TO O
reach VB VB O
stages NNS NNS O
compared VBN VBN O
to TO TO O
A DT DT O
/ NN NN O
J NNP NNP O
mice NN NN O
. . . O

The DT DT O
CSS NNP NNP O
for IN IN O
Chromosomes NNP NNP O
10 CD CD O
and CC CC O
18 CD CD O
progressed VBN VBN O
to TO TO O
the DT DT O
most JJS JJS O
severe JJ JJ O
stages NNS NNS O
, , , O
diverging VBG VBG O
dramatically RB RB O
from IN IN O
the DT DT O
B6 NNP NNP O
phenotype NN NN O
. . . O

Latencies NNP NNP O
to TO TO O
stages NNS NNS O
were VBD VBD O
also RB RB O
significantly RB RB O
shorter VB VB O
for IN IN O
CSS10 NNP NNP O
and CC CC O
CSS18 NNP NNP O
mice NN NN O
. . . O

CSS NNP NNP O
mapping VBG VBG O
suggests VBZ VBZ O
seizure NN NN O
susceptibility NN NN O
loci NN NN O
on IN IN O
mouse NN NN O
Chromosomes NNP NNP O
10 CD CD O
and CC CC O
18 CD CD O
. . . O

This DT DT O
approach NN NN O
provides VBZ VBZ O
a DT DT O
framework NN NN O
for IN IN O
identifying VBG VBG O
potentially RB RB O
novel NN NN O
homologous JJ JJ O
candidate NN NN O
genes NNS NNS O
for IN IN O
human JJ JJ O
temporal NN NN O
lobe NN NN O
epilepsy NN NN O
. . . O

In IN IN O
vitro NN NN O
characterization NN NN O
of IN IN O
parasympathetic JJ JJ O
and CC CC O
sympathetic JJ JJ O
responses NNS NNS O
in IN IN O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
cystitis NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
. . . O

In IN IN O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
cystitis NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
, , , O
detrusor NN NN O
function NN NN O
is VBZ VBZ O
impaired VBN VBN O
and CC CC O
the DT DT O
expression NN NN O
and CC CC O
effects NNS NNS O
of IN IN O
muscarinic JJ JJ O
receptors NNS NNS O
altered VBN VBN O
. . . O

Whether IN IN O
or CC CC O
not RB RB O
the DT DT O
neuronal JJ JJ O
transmission NN NN O
may MD MD O
be VB VB O
affected VBN VBN O
by IN IN O
cystitis NNS NNS O
was VBD VBD O
presently RB RB O
investigated VBN VBN O
. . . O

Responses NNS NNS O
of IN IN O
urinary JJ JJ O
strip NN NN O
preparations NNS NNS O
from IN IN O
control NN NN O
and CC CC O
cyclophosphamide NN NN B-CHEM
- - - O
pretreated JJ JJ O
rats NNS NNS O
to TO TO O
electrical JJ JJ O
field NN NN O
stimulation NN NN O
and CC CC O
to TO TO O
agonists NNS NNS O
were VBD VBD O
assessed VBN VBN O
in IN IN O
the DT DT O
absence NN NN O
and CC CC O
presence NN NN O
of IN IN O
muscarinic JJ JJ O
, , , O
adrenergic JJ JJ O
and CC CC O
purinergic JJ JJ O
receptor NN NN O
antagonists NNS NNS O
. . . O

Generally RB RB O
, , , O
atropine NN NN B-CHEM
reduced VBN VBN O
contractions NNS NNS O
, , , O
but CC CC O
in IN IN O
contrast NN NN O
to TO TO O
controls NNS NNS O
, , , O
it PRP PRP O
also RB RB O
reduced VBD VBD O
responses NNS NNS O
to TO TO O
low JJ JJ O
electrical JJ JJ O
field NN NN O
stimulation NN NN O
intensity NN NN O
( ( ( O
1 CD CD O
- : : O
5 CD CD O
Hz NNP NNP O
) ) ) O
in IN IN O
inflamed VBN VBN O
preparations NNS NNS O
. . . O

In IN IN O
both DT DT O
types NNS NNS O
, , , O
purinoceptor NN NN O
desensitization NN NN O
with IN IN O
alpha NN NN B-CHEM
, , , I-CHEM
beta NN NN I-CHEM
- - - I-CHEM
methylene NN NN I-CHEM
adenosine NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
triphosphate NN NN I-CHEM
( ( ( O
alpha NN NN B-CHEM
, , , I-CHEM
beta NN NN I-CHEM
- - - I-CHEM
meATP NN NN I-CHEM
) ) ) O
caused VBD VBD O
further JJ JJ O
reductions NNS NNS O
at IN IN O
low JJ JJ O
frequencies NNS NNS O
( ( ( O
< NN NN O
10 CD CD O
Hz NNP NNP O
) ) ) O
. . . O

The DT DT O
muscarinic JJ JJ O
receptor NN NN O
antagonists NNS NNS O
atropine NN NN B-CHEM
, , , O
4 CD CD B-CHEM
- : : I-CHEM
diphenylacetoxy NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
methylpiperidine NN NN I-CHEM
( ( ( O
4 CD CD B-CHEM
- : : I-CHEM
DAMP NNP NNP I-CHEM
) ) ) O
( ( ( O
' POS POS O
M NNP NNP O
( ( ( O
1 CD CD O
) ) ) O
/ NN NN O
M NNP NNP O
( ( ( O
3 CD CD O
) ) ) O
/ NN NN O
M NNP NNP O
( ( ( O
5 CD CD O
) ) ) O
- : : O
selective JJ JJ O
' POS POS O
) ) ) O
, , , O
methoctramine NN NN B-CHEM
( ( ( O
' POS POS O
M NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
- : : O
selective JJ JJ O
' POS POS O
) ) ) O
and CC CC O
pirenzepine NN NN B-CHEM
( ( ( O
' POS POS O
M NNP NNP O
( ( ( O
1 CD CD O
) ) ) O
- : : O
selective JJ JJ O
' POS POS O
) ) ) O
antagonized VBD VBD O
the DT DT O
tonic JJ JJ O
component NN NN O
of IN IN O
the DT DT O
electrical JJ JJ O
field NN NN O
stimulation NN NN O
- - - O
evoked JJ JJ O
contractile NN NN O
response NN NN O
more RBR RBR O
potently RB RB O
than IN IN O
the DT DT O
phasic JJ JJ O
component NN NN O
. . . O

4 CD CD B-CHEM
- : : I-CHEM
DAMP NNP NNP I-CHEM
inhibited VBD VBD O
the DT DT O
tonic NN NN O
contractions NNS NNS O
in IN IN O
controls NNS NNS O
more RBR RBR O
potently RB RB O
than IN IN O
methoctramine NN NN B-CHEM
and CC CC O
pirenzepine NN NN B-CHEM
. . . O

In IN IN O
inflamed JJ JJ O
preparations NNS NNS O
, , , O
the DT DT O
muscarinic JJ JJ O
receptor NN NN O
antagonism NN NN O
on IN IN O
the DT DT O
phasic JJ JJ O
component NN NN O
of IN IN O
the DT DT O
electrical JJ JJ O
field NN NN O
stimulation NN NN O
- - - O
evoked JJ JJ O
contraction NN NN O
was VBD VBD O
decreased VBN VBN O
and CC CC O
the DT DT O
pirenzepine NN NN B-CHEM
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
DAMP NNP NNP I-CHEM
antagonism NN NN O
on IN IN O
the DT DT O
tonic NN NN O
component NN NN O
was VBD VBD O
much RB RB O
less RBR RBR O
efficient JJ JJ O
than IN IN O
in IN IN O
controls NNS NNS O
. . . O

In IN IN O
contrast NN NN O
to TO TO O
controls NNS NNS O
, , , O
methoctramine NN NN B-CHEM
increased VBN VBN O
- - - O
- - - O
instead RB RB O
of IN IN O
decreased VBD VBD O
- - - O
- : : O
the DT DT O
tonic NN NN O
responses NNS NNS O
at IN IN O
high JJ JJ O
frequencies NNS NNS O
. . . O

While IN IN O
contractions NNS NNS O
to TO TO O
carbachol NN NN B-CHEM
and CC CC O
ATP NNP NNP B-CHEM
were VBD VBD O
the DT DT O
same JJ JJ O
in IN IN O
inflamed VBN VBN O
and CC CC O
in IN IN O
control NN NN O
strips NNS NNS O
when WRB WRB O
related VBN VBN O
to TO TO O
a DT DT O
reference NN NN O
potassium NN NN B-CHEM
response NN NN O
, , , O
isoprenaline NN NN B-CHEM
- - - O
induced JJ JJ O
relaxations NNS NNS O
were VBD VBD O
smaller JJR JJR O
in IN IN O
inflamed JJ JJ O
strips NNS NNS O
. . . O

Thus RB RB O
, , , O
in IN IN O
cystitis NN NN O
substantial JJ JJ O
changes NNS NNS O
of IN IN O
the DT DT O
efferent NN NN O
functional JJ JJ O
responses NNS NNS O
occur VBP VBP O
. . . O

While IN IN O
postjunctional JJ JJ O
beta NN NN O
- - - O
adrenoceptor NN NN O
- - - O
mediated JJ JJ O
relaxations NNS NNS O
are VBP VBP O
reduced VBN VBN O
, , , O
effects NNS NNS O
by IN IN O
prejunctional JJ JJ O
inhibitory NN NN O
muscarinic JJ JJ O
receptors NNS NNS O
may MD MD O
be VB VB O
increased VBN VBN O
. . . O

Direct NNP NNP O
inhibition NN NN O
of IN IN O
cardiac JJ JJ O
hyperpolarization NN NN O
- - - O
activated JJ JJ O
cyclic JJ JJ B-CHEM
nucleotide NN NN I-CHEM
- - - O
gated JJ JJ O
pacemaker NN NN O
channels NNS NNS O
by IN IN O
clonidine NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Inhibition NNP NNP O
of IN IN O
cardiac JJ JJ O
sympathetic JJ JJ O
tone NN NN O
represents VBZ VBZ O
an DT DT O
important JJ JJ O
strategy NN NN O
for IN IN O
treatment NN NN O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
, , , O
including VBG VBG O
arrhythmia NN NN O
, , , O
coronary JJ JJ O
heart NN NN O
disease NN NN O
, , , O
and CC CC O
chronic JJ JJ O
heart NN NN O
failure NN NN O
. . . O

Activation NNP NNP O
of IN IN O
presynaptic JJ JJ O
alpha2 NN NN O
- - - O
adrenoceptors NNS NNS O
is VBZ VBZ O
the DT DT O
most RBS RBS O
widely RB RB O
accepted VBN VBN O
mechanism NN NN O
of IN IN O
action NN NN O
of IN IN O
the DT DT O
antisympathetic JJ JJ O
drug NN NN O
clonidine NN NN B-CHEM
; : : O
however RB RB O
, , , O
other JJ JJ O
target NN NN O
proteins NNS NNS O
have VBP VBP O
been VBN VBN O
postulated VBN VBN O
to TO TO O
contribute VB VB O
to TO TO O
the DT DT O
in IN IN O
vivo NN NN O
actions NNS NNS O
of IN IN O
clonidine NN NN B-CHEM
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
To TO TO O
test VB VB O
whether IN IN O
clonidine NN NN B-CHEM
elicits NNS NNS O
pharmacological JJ JJ O
effects NNS NNS O
independent JJ JJ O
of IN IN O
alpha2 NN NN O
- - - O
adrenoceptors NNS NNS O
, , , O
we PRP PRP O
have VBP VBP O
generated VBN VBN O
mice NN NN O
with IN IN O
a DT DT O
targeted JJ JJ O
deletion NN NN O
of IN IN O
all DT DT O
3 CD CD O
alpha2 NN NN O
- : : O
adrenoceptor NN NN O
subtypes NNS NNS O
( ( ( O
alpha2ABC NN NN O
- - - O
/ NN NN O
- - - O
) ) ) O
. . . O

Alpha2ABC NNP NNP O
- : : O
/ NN NN O
- : : O
mice NN NN O
were VBD VBD O
completely RB RB O
unresponsive JJ JJ O
to TO TO O
the DT DT O
analgesic NN NN O
and CC CC O
hypnotic JJ JJ O
effects NNS NNS O
of IN IN O
clonidine NN NN B-CHEM
; : : O
however RB RB O
, , , O
clonidine NN NN B-CHEM
significantly RB RB O
lowered VBD VBD O
heart NN NN O
rate NN NN O
in IN IN O
alpha2ABC NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
by IN IN O
up IN IN O
to TO TO O
150 CD CD O
bpm NN NN O
. . . O

Clonidine NNP NNP B-CHEM
- : : O
induced JJ JJ O
bradycardia NN NN O
in IN IN O
conscious JJ JJ O
alpha2ABC NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
was VBD VBD O
32 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
10 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
26 CD CD O
. . . O
6 CD CD O
% NN NN O
( ( ( O
100 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
of IN IN O
the DT DT O
effect NN NN O
in IN IN O
wild JJ JJ O
- - - O
type NN NN O
mice NN NN O
. . . O

A DT DT O
similar JJ JJ O
bradycardic JJ JJ O
effect NN NN O
of IN IN O
clonidine NN NN B-CHEM
was VBD VBD O
observed VBN VBN O
in IN IN O
isolated VBN VBN O
spontaneously RB RB O
beating NN NN O
right NN NN O
atria NN NN O
from IN IN O
alpha2ABC NN NN O
- : : O
knockout NN NN O
and CC CC O
wild JJ JJ O
- - - O
type NN NN O
mice NN NN O
. . . O

Clonidine NNP NNP B-CHEM
inhibited VBD VBD O
the DT DT O
native JJ JJ O
pacemaker NN NN O
current JJ JJ O
( ( ( O
I NN NN O
( ( ( O
f SYM SYM O
) ) ) O
) ) ) O
in IN IN O
isolated VBN VBN O
sinoatrial JJ JJ O
node NN NN O
pacemaker NN NN O
cells NNS NNS O
and CC CC O
the DT DT O
I PRP PRP O
( ( ( O
f SYM SYM O
) ) ) O
- : : O
generating VBG VBG O
hyperpolarization NN NN O
- - - O
activated JJ JJ O
cyclic JJ JJ B-CHEM
nucleotide NN NN I-CHEM
- - - O
gated JJ JJ O
( ( ( O
HCN NNP NNP O
) ) ) O
2 CD CD O
and CC CC O
HCN4 NNP NNP O
channels NNS NNS O
in IN IN O
transfected JJ JJ O
HEK293 NNP NNP O
cells NNS NNS O
. . . O

As IN IN O
a DT DT O
consequence NN NN O
of IN IN O
blocking VBG VBG O
I PRP PRP O
( ( ( O
f SYM SYM O
) ) ) O
, , , O
clonidine NN NN B-CHEM
reduced VBD VBD O
the DT DT O
slope NN NN O
of IN IN O
the DT DT O
diastolic JJ JJ O
depolarization NN NN O
and CC CC O
the DT DT O
frequency NN NN O
of IN IN O
pacemaker NN NN O
potentials NNS NNS O
in IN IN O
sinoatrial JJ JJ O
node NN NN O
cells NNS NNS O
from IN IN O
wild JJ JJ O
- - - O
type NN NN O
and CC CC O
alpha2ABC NN NN O
- - - O
knockout NN NN O
mice NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Direct NNP NNP O
inhibition NN NN O
of IN IN O
cardiac JJ JJ O
HCN NNP NNP O
pacemaker NN NN O
channels NNS NNS O
contributes VBZ VBZ O
to TO TO O
the DT DT O
bradycardic JJ JJ O
effects NNS NNS O
of IN IN O
clonidine NN NN B-CHEM
gene NN NN O
- - - O
targeted VBN VBN O
mice NN NN O
in IN IN O
vivo NN NN O
, , , O
and CC CC O
thus RB RB O
, , , O
clonidine NN NN B-CHEM
- - - O
like IN IN O
drugs NNS NNS O
represent VBP VBP O
novel NN NN O
structures NNS NNS O
for IN IN O
future JJ JJ O
HCN NNP NNP O
channel NN NN O
inhibitors NNS NNS O
. . . O

Granulomatous JJ JJ O
hepatitis NN NN O
due JJ JJ O
to TO TO O
combination NN NN B-CHEM
of IN IN I-CHEM
amoxicillin NN NN I-CHEM
and CC CC I-CHEM
clavulanic JJ JJ I-CHEM
acid NN NN I-CHEM
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
with IN IN O
amoxicillin NN NN B-CHEM
- - - I-CHEM
clavulanic JJ JJ I-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
hepatitis NN NN O
with IN IN O
histologic JJ JJ O
multiple JJ JJ O
granulomas NNS NNS O
. . . O

This DT DT O
type NN NN O
of IN IN O
lesion NN NN O
broadens NNS NNS O
the DT DT O
spectrum NN NN O
of IN IN O
liver NN NN O
injury NN NN O
due JJ JJ O
to TO TO O
this DT DT O
drug NN NN O
combination NN NN O
, , , O
mainly RB RB O
represented VBN VBN O
by IN IN O
a DT DT O
benign NN NN O
cholestatic JJ JJ O
syndrome NN NN O
. . . O

The DT DT O
association NN NN O
of IN IN O
granulomas NN NN O
and CC CC O
eosinophilia NN NN O
favor NN NN O
an DT DT O
immunoallergic JJ JJ O
mechanism NN NN O
. . . O

As IN IN O
penicillin NN NN B-CHEM
derivatives NNS NNS O
and CC CC O
amoxicillin NN NN B-CHEM
alone RB RB O
are VBP VBP O
known VBN VBN O
to TO TO O
induce VB VB O
such JJ JJ O
types NNS NNS O
of IN IN O
lesions NNS NNS O
, , , O
the DT DT O
amoxicillin NN NN B-CHEM
component NN NN O
, , , O
with IN IN O
or CC CC O
without IN IN O
a DT DT O
potentiating VBG VBG O
effect NN NN O
of IN IN O
clavulanic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
might MD MD O
have VB VB O
a DT DT O
major JJ JJ O
role NN NN O
. . . O

Dobutamine NNP NNP B-CHEM
stress NN NN O
echocardiography NN NN O
: : : O
a DT DT O
sensitive JJ JJ O
indicator NN NN O
of IN IN O
diminished JJ JJ O
myocardial NN NN O
function NN NN O
in IN IN O
asymptomatic JJ JJ O
doxorubicin NN NN B-CHEM
- - - O
treated VBN VBN O
long JJ JJ O
- - - O
term NN NN O
survivors NNS NNS O
of IN IN O
childhood NN NN O
cancer NN NN O
. . . O

Doxorubicin NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
anticancer NN NN O
chemotherapeutic JJ JJ O
agent NN NN O
known VBN VBN O
to TO TO O
cause VB VB O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
cardiomyopathy NN NN O
. . . O

To TO TO O
develop VB VB O
a DT DT O
more RBR RBR O
sensitive JJ JJ O
echocardiographic JJ JJ O
screening NN NN O
test NN NN O
for IN IN O
cardiac JJ JJ O
damage NN NN O
due JJ JJ O
to TO TO O
doxorubicin VB VB B-CHEM
, , , O
a DT DT O
cohort NN NN O
study NN NN O
was VBD VBD O
performed VBN VBN O
using VBG VBG O
dobutamine NN NN B-CHEM
infusion NN NN O
to TO TO O
differentiate VB VB O
asymptomatic JJ JJ O
long JJ JJ O
- - - O
term NN NN O
survivors NNS NNS O
of IN IN O
childhood NN NN O
cancer NN NN O
treated VBN VBN O
with IN IN O
doxorubicin NN NN B-CHEM
from IN IN O
healthy JJ JJ O
control NN NN O
subjects NNS NNS O
. . . O

Echocardiographic NNP NNP O
data NNS NNS O
from IN IN O
the DT DT O
experimental JJ JJ O
group NN NN O
of IN IN O
21 CD CD O
patients NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
16 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
years NNS NNS O
) ) ) O
treated VBN VBN O
from IN IN O
1 CD CD O
. . . O
6 CD CD O
to TO TO O
14 CD CD O
. . . O
3 CD CD O
years NNS NNS O
( ( ( O
median JJ JJ O
5 CD CD O
. . . O
3 CD CD O
) ) ) O
before IN IN O
this DT DT O
study NN NN O
with IN IN O
27 CD CD O
to TO TO O
532 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
mean NN NN O
196 CD CD O
) ) ) O
were VBD VBD O
compared VBN VBN O
with IN IN O
echocardiographic JJ JJ O
data NNS NNS O
from IN IN O
12 CD CD O
normal JJ JJ O
age NN NN O
- - - O
matched JJ JJ O
control NN NN O
subjects NNS NNS O
. . . O

Graded NNP NNP O
dobutamine NN NN B-CHEM
infusions NNS NNS O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
, , , O
2 CD CD O
. . . O
5 CD CD O
, , , O
5 CD CD O
and CC CC O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
per IN IN O
min NN NN O
were VBD VBD O
administered VBN VBN O
. . . O

Echocardiographic NNP NNP O
Doppler NNP NNP O
studies NNS NNS O
were VBD VBD O
performed VBN VBN O
before IN IN O
infusion NN NN O
and CC CC O
after IN IN O
15 CD CD O
min NN NN O
of IN IN O
infusion NN NN O
at IN IN O
each DT DT O
rate NN NN O
. . . O

Dobutamine NNP NNP B-CHEM
infusion NN NN O
at IN IN O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
per IN IN O
min NN NN O
was VBD VBD O
discontinued VBN VBN O
after IN IN O
six CD CD O
studies NNS NNS O
secondary JJ JJ O
to TO TO O
a DT DT O
50 CD CD O
% NN NN O
incidence NN NN O
rate NN NN O
of IN IN O
adverse JJ JJ O
symptoms NNS NNS O
. . . O

The DT DT O
most RBS RBS O
important JJ JJ O
findings NNS NNS O
were VBD VBD O
that IN IN O
compared VBN VBN O
with IN IN O
values NNS NNS O
in IN IN O
control NN NN O
subjects NNS NNS O
, , , O
end NN NN O
- : : O
systolic JJ JJ O
left VBD VBD O
ventricular JJ JJ O
posterior NN NN O
wall NN NN O
dimension NN NN O
and CC CC O
percent NN NN O
of IN IN O
left VBD VBD O
ventricular NN NN O
posterior NN NN O
wall NN NN O
thickening VBG VBG O
in IN IN O
doxorubicin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
were VBD VBD O
decreased VBN VBN O
at IN IN O
baseline NN NN O
study NN NN O
and CC CC O
these DT DT O
findings NNS NNS O
were VBD VBD O
more RBR RBR O
clearly RB RB O
delineated VBN VBN O
with IN IN O
dobutamine NN NN B-CHEM
stimulation NN NN O
. . . O

End NN NN O
- : : O
systolic JJ JJ O
left VBD VBD O
ventricular JJ JJ O
posterior NN NN O
wall NN NN O
dimension NN NN O
at IN IN O
baseline NN NN O
for IN IN O
the DT DT O
doxorubicin NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
was VBD VBD O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
9 CD CD O
mm NN NN O
versus CC CC O
13 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
5 CD CD O
mm NN NN O
for IN IN O
control NN NN O
subjects NNS NNS O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

End NN NN O
- : : O
systolic JJ JJ O
left VBD VBD O
ventricular JJ JJ O
posterior NN NN O
wall NN NN O
dimension NN NN O
at IN IN O
the DT DT O
5 CD CD O
- : : O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
per IN IN O
min NN NN O
dobutamine NN NN B-CHEM
infusion NN NN O
for IN IN O
the DT DT O
doxorubicin NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
was VBD VBD O
14 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
4 CD CD O
mm NN NN O
versus CC CC O
19 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
6 CD CD O
mm NN NN O
for IN IN O
control NN NN O
subjects NNS NNS O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Influence NNP NNP O
of IN IN O
smoking VBG VBG B-CHEM
on IN IN O
developing VBG VBG O
cochlea NN NN O
. . . O

Does VBZ VBZ O
smoking NN NN B-CHEM
during IN IN O
pregnancy NN NN O
affect VB VB O
the DT DT O
amplitudes NNS NNS O
of IN IN O
transient NN NN O
evoked VBD VBD O
otoacoustic JJ JJ O
emissions NNS NNS O
in IN IN O
newborns NNS NNS O
? . . O

OBJECTIVE NNP NNP O
: : : O
Maternal NNP NNP O
tobacco NN NN O
smoking NN NN B-CHEM
has VBZ VBZ O
negative JJ JJ O
effects NNS NNS O
on IN IN O
fetal JJ JJ O
growth NN NN O
. . . O

The DT DT O
influence NN NN O
of IN IN O
smoking NN NN B-CHEM
during IN IN O
pregnancy NN NN O
on IN IN O
the DT DT O
developing VBG VBG O
cochlea NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
estimated VBN VBN O
, , , O
although IN IN O
smoking NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
positively RB RB O
associated VBN VBN O
with IN IN O
hearing NN NN O
loss NN NN O
in IN IN O
adults NNS NNS O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
maternal JJ JJ O
smoking NN NN B-CHEM
on IN IN O
transient NN NN O
evoked JJ JJ O
otoacoustic JJ JJ O
emissions NNS NNS O
( ( ( O
TEOAEs NNP NNP O
) ) ) O
of IN IN O
healthy JJ JJ O
neonates NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
as IN IN O
part NN NN O
of IN IN O
neonatal JJ JJ O
screening NN NN O
for IN IN O
hearing NN NN O
impairment NN NN O
and CC CC O
involved VBD VBD O
both DT DT O
ears NNS NNS O
of IN IN O
200 CD CD O
newborns NNS NNS O
. . . O

Newborns NNP NNP O
whose WP$ WP$ O
mothers NNS NNS O
reported VBD VBD O
smoking VBG VBG B-CHEM
during IN IN O
pregnancy NN NN O
( ( ( O
n NN NN O
= SYM SYM O
200 CD CD O
ears NNS NNS O
) ) ) O
were VBD VBD O
compared VBN VBN O
to TO TO O
a DT DT O
control NN NN O
group NN NN O
of IN IN O
newborns NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
200 CD CD O
ears NNS NNS O
) ) ) O
, , , O
whose WP$ WP$ O
mothers NNS NNS O
were VBD VBD O
non NN NN O
- : : O
smokers NNS NNS O
. . . O

Exposure NNP NNP O
to TO TO O
tobacco NN NN O
was VBD VBD O
characterized VBN VBN O
as IN IN O
low JJ JJ O
( ( ( O
< NN NN O
5 CD CD O
cigarettes NNS NNS O
per IN IN O
day NN NN O
, , , O
n NN NN O
= SYM SYM O
88 CD CD O
ears NNS NNS O
) ) ) O
, , , O
moderate JJ JJ O
( ( ( O
5 CD CD O
< NN NN O
or CC CC O
= SYM SYM O
cigarettes NNS NNS O
per IN IN O
day NN NN O
< NN NN O
10 CD CD O
, , , O
n NN NN O
= SYM SYM O
76 CD CD O
) ) ) O
or CC CC O
high JJ JJ O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
10 CD CD O
cigarettes NNS NNS O
per IN IN O
day NN NN O
, , , O
n NN NN O
= SYM SYM O
36 CD CD O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
exposed VBN VBN O
neonates NNS NNS O
, , , O
TEOAEs NNP NNP O
mean VB VB O
response NN NN O
( ( ( O
across IN IN O
frequency NN NN O
) ) ) O
and CC CC O
mean VB VB O
amplitude NN NN O
at IN IN O
4000Hz CD CD O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
in IN IN O
non NN NN O
- - - O
exposed VBN VBN O
neonates NNS NNS O
. . . O

Comparisons NNP NNP O
between IN IN O
exposed VBN VBN O
newborns NNS NNS O
' POS POS O
subgroups NNS NNS O
revealed VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
. . . O

However RB RB O
, , , O
by IN IN O
comparing VBG VBG O
each DT DT O
subgroup NN NN O
to TO TO O
control VB VB O
group NN NN O
, , , O
we PRP PRP O
found VBD VBD O
statistically RB RB O
significant JJ JJ O
decreases NNS NNS O
of IN IN O
TEOAEs NNP NNP O
amplitudes NNS NNS O
at IN IN O
4000Hz CD CD O
for IN IN O
all DT DT O
three CD CD O
groups NNS NNS O
. . . O

Mean VB VB O
TEOAEs NNP NNP O
responses NNS NNS O
of IN IN O
highly RB RB O
exposed VBN VBN O
newborns NNS NNS O
were VBD VBD O
also RB RB O
significantly RB RB O
lower JJR JJR O
in IN IN O
comparison NN NN O
to TO TO O
our PRP$ PRP$ O
control NN NN O
group NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
utero NN NN O
, , , O
exposure NN NN O
to TO TO O
tobacco NN NN O
smoking NN NN B-CHEM
seems VBZ VBZ O
to TO TO O
have VB VB O
a DT DT O
small JJ JJ O
impact NN NN O
on IN IN O
outer JJ JJ O
hair NN NN O
cells NNS NNS O
. . . O

These DT DT O
effects NNS NNS O
seem VBP VBP O
to TO TO O
be VB VB O
equally RB RB O
true JJ JJ O
for IN IN O
all DT DT O
exposed VBN VBN O
newborns NNS NNS O
, , , O
regardless RB RB O
of IN IN O
the DT DT O
degree NN NN O
of IN IN O
exposure NN NN O
. . . O

Further RB RB O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
in IN IN O
order NN NN O
to TO TO O
establish VB VB O
a DT DT O
potential JJ JJ O
negative JJ JJ O
effect NN NN O
of IN IN O
maternal JJ JJ O
smoking NN NN B-CHEM
on IN IN O
the DT DT O
neonate NN NN O
' '' '' O
s VBZ VBZ O
hearing NN NN O
acuity NN NN O
. . . O

Simvastatin NNP NNP B-CHEM
- : : O
induced JJ JJ O
bilateral NN NN O
leg NN NN O
compartment NN NN O
syndrome NN NN O
and CC CC O
myonecrosis NN NN O
associated VBN VBN O
with IN IN O
hypothyroidism NN NN O
. . . O

A DT DT O
54 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
hypothyroid NN NN O
male JJ JJ O
taking VBG VBG O
thyroxine NN NN B-CHEM
and CC CC O
simvastatin NN NN B-CHEM
presented VBN VBN O
with IN IN O
bilateral JJ JJ O
leg NN NN O
compartment NN NN O
syndrome NN NN O
and CC CC O
myonecrosis NN NN O
. . . O

Urgent NNP NNP O
fasciotomies NNS NNS O
were VBD VBD O
performed VBN VBN O
and CC CC O
the DT DT O
patient NN NN O
made VBD VBD O
an DT DT O
uneventful JJ JJ O
recovery NN NN O
with IN IN O
the DT DT O
withdrawal NN NN O
of IN IN O
simvastatin NN NN B-CHEM
. . . O

It PRP PRP O
is VBZ VBZ O
likely JJ JJ O
that IN IN O
this DT DT O
complication NN NN O
will MD MD O
be VB VB O
seen VBN VBN O
more RBR RBR O
often RB RB O
with IN IN O
the DT DT O
increased VBN VBN O
worldwide NN NN O
use NN NN O
of IN IN O
this DT DT O
drug NN NN O
and CC CC O
its PRP$ PRP$ O
approval NN NN O
for IN IN O
all DT DT O
arteriopathic JJ JJ O
patients NNS NNS O
. . . O

Neuroinflammation NNP NNP O
and CC CC O
behavioral JJ JJ O
abnormalities NNS NNS O
after IN IN O
neonatal JJ JJ O
terbutaline NN NN B-CHEM
treatment NN NN O
in IN IN O
rats NNS NNS O
: : : O
implications NNS NNS O
for IN IN O
autism NN NN O
. . . O

Autism NNP NNP O
is VBZ VBZ O
a DT DT O
neurodevelopmental JJ JJ O
disorder NN NN O
presenting VBG VBG O
before IN IN O
3 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
with IN IN O
deficits NNS NNS O
in IN IN O
communication NN NN O
and CC CC O
social JJ JJ O
skills NNS NNS O
and CC CC O
repetitive JJ JJ O
behaviors NNS NNS O
. . . O

In IN IN O
addition NN NN O
to TO TO O
genetic JJ JJ O
influences NNS NNS O
, , , O
recent JJ JJ O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
prenatal JJ JJ O
drug NN NN O
or CC CC O
chemical NN NN O
exposures NNS NNS O
are VBP VBP O
risk NN NN O
factors NNS NNS O
for IN IN O
autism NN NN O
. . . O

Terbutaline NNP NNP B-CHEM
, , , O
a DT DT O
beta2 NN NN O
- - - O
adrenoceptor NN NN O
agonist NN NN O
used VBN VBN O
to TO TO O
arrest VB VB O
preterm NN NN O
labor NN NN O
, , , O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
increased VBN VBN O
concordance NN NN O
for IN IN O
autism NN NN O
in IN IN O
dizygotic JJ JJ O
twins NNS NNS O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
terbutaline NN NN B-CHEM
on IN IN O
microglial JJ JJ O
activation NN NN O
in IN IN O
different JJ JJ O
brain NN NN O
regions NNS NNS O
and CC CC O
behavioral JJ JJ O
outcomes NNS NNS O
in IN IN O
developing VBG VBG O
rats NNS NNS O
. . . O

Newborn NNP NNP O
rats NNS NNS O
were VBD VBD O
given VBN VBN O
terbutaline NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
daily JJ JJ O
on IN IN O
postnatal JJ JJ O
days NNS NNS O
( ( ( O
PN NNP NNP O
) ) ) O
2 CD CD O
to TO TO O
5 CD CD O
or CC CC O
PN NNP NNP O
11 CD CD O
to TO TO O
14 CD CD O
and CC CC O
examined VBD VBD O
24 CD CD O
h NN NN O
after IN IN O
the DT DT O
last JJ JJ O
dose NN NN O
and CC CC O
at IN IN O
PN NNP NNP O
30 CD CD O
. . . O

Immunohistochemical NNP NNP O
studies NNS NNS O
showed VBD VBD O
that DT DT O
administration NN NN O
of IN IN O
terbutaline NN NN B-CHEM
on IN IN O
PN NNP NNP O
2 CD CD O
to TO TO O
5 CD CD O
produced VBD VBD O
a DT DT O
robust JJ JJ O
increase NN NN O
in IN IN O
microglial NN NN O
activation NN NN O
on IN IN O
PN NNP NNP O
30 CD CD O
in IN IN O
the DT DT O
cerebral NN NN O
cortex NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
cerebellar NN NN O
and CC CC O
cerebrocortical JJ JJ O
white JJ JJ O
matter NN NN O
. . . O

None NN NN O
of IN IN O
these DT DT O
effects NNS NNS O
occurred VBD VBD O
in IN IN O
animals NNS NNS O
given VBN VBN O
terbutaline NN NN B-CHEM
on IN IN O
PN NNP NNP O
11 CD CD O
to TO TO O
14 CD CD O
. . . O

In IN IN O
behavioral JJ JJ O
tests NNS NNS O
, , , O
animals NNS NNS O
treated VBN VBN O
with IN IN O
terbutaline NN NN B-CHEM
on IN IN O
PN NNP NNP O
2 CD CD O
to TO TO O
5 CD CD O
showed VBD VBD O
consistent JJ JJ O
patterns NNS NNS O
of IN IN O
hyper NN NN O
- - - O
reactivity NN NN O
to TO TO O
novelty NN NN O
and CC CC O
aversive JJ JJ O
stimuli NN NN O
when WRB WRB O
assessed VBN VBN O
in IN IN O
a DT DT O
novel NN NN O
open JJ JJ O
field NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
the DT DT O
acoustic JJ JJ O
startle NN NN O
response NN NN O
test NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
beta2 NN NN O
- : : O
adrenoceptor NN NN O
overstimulation NN NN O
during IN IN O
an DT DT O
early JJ JJ O
critical JJ JJ O
period NN NN O
results NNS NNS O
in IN IN O
microglial JJ JJ O
activation NN NN O
associated VBN VBN O
with IN IN O
innate JJ JJ O
neuroinflammatory NN NN O
pathways NNS NNS O
and CC CC O
behavioral JJ JJ O
abnormalities NNS NNS O
, , , O
similar JJ JJ O
to TO TO O
those DT DT O
described VBN VBN O
in IN IN O
autism NN NN O
. . . O

This DT DT O
study NN NN O
provides VBZ VBZ O
a DT DT O
useful JJ JJ O
animal NN NN O
model NN NN O
for IN IN O
understanding NN NN O
the DT DT O
neuropathological JJ JJ O
processes NNS NNS O
underlying VBG VBG O
autism NN NN O
spectrum NN NN O
disorders NNS NNS O
. . . O

Upregulation NNP NNP O
of IN IN O
brain NN NN O
expression NN NN O
of IN IN O
P NN NN O
- - - O
glycoprotein NN NN O
in IN IN O
MRP2 NNP NNP O
- : : O
deficient JJ JJ O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
resembles NNS NNS O
seizure VBP VBP O
- - - O
induced JJ JJ O
up RB RB O
- - - O
regulation NN NN O
of IN IN O
this DT DT O
drug NN NN O
efflux NN NN O
transporter NN NN O
in IN IN O
normal JJ JJ O
rats NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
The DT DT O
multidrug NN NN O
resistance NN NN O
protein NN NN O
2 CD CD O
( ( ( O
MRP2 NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
drug NN NN O
efflux NN NN O
transporter NN NN O
that WDT WDT O
is VBZ VBZ O
expressed VBN VBN O
predominantly RB RB O
at IN IN O
the DT DT O
apical JJ JJ O
domain NN NN O
of IN IN O
hepatocytes NNS NNS O
but CC CC O
seems VBZ VBZ O
also RB RB O
to TO TO O
be VB VB O
expressed VBN VBN O
at IN IN O
the DT DT O
apical JJ JJ O
membrane NN NN O
of IN IN O
brain NN NN O
capillary JJ JJ O
endothelial NN NN O
cells NNS NNS O
that WDT WDT O
form NN NN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
( ( ( O
BBB NNP NNP O
) ) ) O
. . . O

MRP2 NNP NNP O
is VBZ VBZ O
absent JJ JJ O
in IN IN O
the DT DT O
transport NN NN O
- - - O
deficient NN NN O
( ( ( O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
) ) ) O
Wistar NNP NNP O
rat NN NN O
mutant NN NN O
, , , O
so IN IN O
that IN IN O
this DT DT O
rat NN NN O
strain NN NN O
was VBD VBD O
very RB RB O
helpful JJ JJ O
in IN IN O
defining VBG VBG O
substrates NNS NNS O
of IN IN O
MRP2 NNP NNP O
by IN IN O
comparing VBG VBG O
tissue NN NN O
concentrations NNS NNS O
or CC CC O
functional JJ JJ O
activities NNS NNS O
of IN IN O
compounds NNS NNS O
in IN IN O
MRP2 NNP NNP O
- : : O
deficient NN NN O
rats NNS NNS O
with IN IN O
those DT DT O
in IN IN O
transport NN NN O
- - - O
competent JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
. . . O

By IN IN O
using VBG VBG O
this DT DT O
strategy NN NN O
to TO TO O
study VB VB O
the DT DT O
involvement NN NN O
of IN IN O
MRP2 NNP NNP O
in IN IN O
brain NN NN O
access NN NN O
of IN IN O
antiepileptic JJ JJ O
drugs NNS NNS O
( ( ( O
AEDs NNP NNP O
) ) ) O
, , , O
we PRP PRP O
recently RB RB O
reported VBD VBD O
that DT DT O
phenytoin NN NN B-CHEM
is VBZ VBZ O
a DT DT O
substrate NN NN O
for IN IN O
MRP2 NNP NNP O
in IN IN O
the DT DT O
BBB NNP NNP O
. . . O

However RB RB O
, , , O
one CD CD O
drawback NN NN O
of IN IN O
such JJ JJ O
studies NNS NNS O
in IN IN O
genetically RB RB O
deficient JJ JJ O
rats NNS NNS O
is VBZ VBZ O
the DT DT O
fact NN NN O
that IN IN O
compensatory JJ JJ O
changes NNS NNS O
with IN IN O
upregulation NN NN O
of IN IN O
other JJ JJ O
transporters NNS NNS O
can MD MD O
occur VB VB O
. . . O

This DT DT O
prompted VBD VBD O
us PRP PRP O
to TO TO O
study VB VB O
the DT DT O
brain NN NN O
expression NN NN O
of IN IN O
P NN NN O
- - - O
glycoprotein NN NN O
( ( ( O
Pgp NNP NNP O
) ) ) O
, , , O
a DT DT O
major JJ JJ O
drug NN NN O
efflux NN NN O
transporter NN NN O
in IN IN O
many JJ JJ O
tissues NNS NNS O
, , , O
including VBG VBG O
the DT DT O
BBB NNP NNP O
, , , O
in IN IN O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
compared VBN VBN O
with IN IN O
nonmutant NN NN O
( ( ( O
wild JJ JJ O
- - - O
type NN NN O
) ) ) O
Wistar NNP NNP O
rats NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
expression NN NN O
of IN IN O
MRP2 NNP NNP O
and CC CC O
Pgp NNP NNP O
in IN IN O
brain NN NN O
and CC CC O
liver NN NN O
sections NNS NNS O
of IN IN O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
and CC CC O
normal JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
was VBD VBD O
determined VBN VBN O
with IN IN O
immunohistochemistry NN NN O
, , , O
by IN IN O
using VBG VBG O
a DT DT O
novel NN NN O
, , , O
highly RB RB O
selective JJ JJ O
monoclonal NN NN O
MRP2 NNP NNP O
antibody NN NN O
and CC CC O
the DT DT O
monoclonal JJ JJ O
Pgp NNP NNP O
antibody NN NN O
C219 NNP NNP O
, , , O
respectively RB RB O
. . . O

RESULTS NNS NNS O
: : : O
Immunofluorescence NNP NNP O
staining VBG VBG O
with IN IN O
the DT DT O
MRP2 NNP NNP O
antibody NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
label VB VB O
a DT DT O
high JJ JJ O
number NN NN O
of IN IN O
microvessels NNS NNS O
throughout IN IN O
the DT DT O
brain NN NN O
in IN IN O
normal JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
, , , O
whereas IN IN O
such JJ JJ O
labeling NN NN O
was VBD VBD O
absent JJ JJ O
in IN IN O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
. . . O

TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
exhibited VBD VBD O
a DT DT O
significant JJ JJ O
up RP RP O
- : : O
regulation NN NN O
of IN IN O
Pgp NNP NNP O
in IN IN O
brain NN NN O
capillary JJ JJ O
endothelial NN NN O
cells NNS NNS O
compared VBN VBN O
with IN IN O
wild JJ JJ O
- - - O
type NN NN O
controls NNS NNS O
. . . O

No DT DT O
such JJ JJ O
obvious JJ JJ O
upregulation NN NN O
of IN IN O
Pgp NNP NNP O
was VBD VBD O
observed VBN VBN O
in IN IN O
liver NN NN O
sections NNS NNS O
. . . O

A DT DT O
comparable JJ JJ O
overexpression NN NN O
of IN IN O
Pgp NNP NNP O
in IN IN O
the DT DT O
BBB NNP NNP O
was VBD VBD O
obtained VBN VBN O
after IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
wild JJ JJ O
- - - O
type NN NN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Experiments NNS NNS O
with IN IN O
systemic JJ JJ O
administration NN NN O
of IN IN O
the DT DT O
Pgp NNP NNP O
substrate NN NN O
phenobarbital NN NN B-CHEM
and CC CC O
the DT DT O
selective JJ JJ O
Pgp NNP NNP O
inhibitor NN NN O
tariquidar NN NN B-CHEM
in IN IN O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
substantiated VBN VBN O
that IN IN O
Pgp NNP NNP O
is VBZ VBZ O
functional JJ JJ O
and CC CC O
compensates NNS NNS O
for IN IN O
the DT DT O
lack NN NN O
of IN IN O
MRP2 NNP NNP O
in IN IN O
the DT DT O
BBB NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
data NNS NNS O
on IN IN O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
indicate VBP VBP O
that IN IN O
Pgp NNP NNP O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
compensation NN NN O
of IN IN O
MRP2 NNP NNP O
deficiency NN NN O
in IN IN O
the DT DT O
BBB NNP NNP O
. . . O

Because IN IN O
such JJ JJ O
a DT DT O
compensatory JJ JJ O
mechanism NN NN O
most RBS RBS O
likely JJ JJ O
occurs VBZ VBZ O
to TO TO O
reduce VB VB O
injury NN NN O
to TO TO O
the DT DT O
brain NN NN O
from IN IN O
cytotoxic JJ JJ O
compounds NNS NNS O
, , , O
the DT DT O
present JJ JJ O
data NNS NNS O
substantiate VBP VBP O
the DT DT O
concept NN NN O
that WDT WDT O
MRP2 NNP NNP O
performs VBZ VBZ O
a DT DT O
protective JJ JJ O
role NN NN O
in IN IN O
the DT DT O
BBB NNP NNP O
. . . O

Furthermore RB RB O
, , , O
our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
TR NNP NNP O
( ( ( O
- : : O
) ) ) O
rats NNS NNS O
are VBP VBP O
an DT DT O
interesting JJ JJ O
tool NN NN O
to TO TO O
study VB VB O
consequences NNS NNS O
of IN IN O
overexpression NN NN O
of IN IN O
Pgp NNP NNP O
in IN IN O
the DT DT O
BBB NNP NNP O
on IN IN O
access NN NN O
of IN IN O
drugs NNS NNS O
in IN IN O
the DT DT O
brain NN NN O
, , , O
without IN IN O
the DT DT O
need NN NN O
of IN IN O
inducing VBG VBG O
seizures NNS NNS O
or CC CC O
other JJ JJ O
Pgp NNP NNP O
- : : O
enhancing VBG VBG O
events NNS NNS O
for IN IN O
this DT DT O
purpose NN NN O
. . . O

Role NN NN O
of IN IN O
xanthine NN NN B-CHEM
oxidase NN NN O
in IN IN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
rats NNS NNS O
. . . O

1 CD CD O
. . . O

Glucocorticoid NNP NNP O
- : : O
induced JJ JJ O
hypertension NN NN O
( ( ( O
GC NNP NNP O
- - - O
HT NNP NNP O
) ) ) O
in IN IN O
the DT DT O
rat NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
- - - O
redox JJ JJ O
imbalance NN NN O
. . . O

2 CD CD O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
role NN NN O
of IN IN O
xanthine NN NN B-CHEM
oxidase NN NN O
( ( ( O
XO NNP NNP O
) ) ) O
, , , O
which WDT WDT O
is VBZ VBZ O
implicated VBN VBN O
in IN IN O
the DT DT O
production NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN O
species NNS NNS O
, , , O
in IN IN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
( ( ( O
dex NN NN B-CHEM
- - - O
HT NNP NNP O
) ) ) O
. . . O

3 CD CD O
. . . O

Thirty NNP NNP O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
divided VBN VBN O
randomly RB RB O
into IN IN O
four CD CD O
treatment NN NN O
groups NNS NNS O
: : : O
saline NN NN O
, , , O
dexamethasone NN NN B-CHEM
( ( ( O
dex NN NN B-CHEM
) ) ) O
, , , O
allopurinol JJ JJ B-CHEM
plus CC CC O
saline NN NN O
, , , O
and CC CC O
allopurinol NN NN B-CHEM
plus CC CC O
dex NN NN B-CHEM
. . . O

4 CD CD O
. . . O

Systolic NNP NNP O
blood NN NN O
pressures NNS NNS O
( ( ( O
SBP NNP NNP O
) ) ) O
and CC CC O
bodyweights NNS NNS O
were VBD VBD O
recorded VBN VBN O
each DT DT O
alternate JJ JJ O
day NN NN O
. . . O

Thymus NNP NNP O
weight NN NN O
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
marker NN NN O
of IN IN O
glucocorticoid NN NN O
activity NN NN O
, , , O
and CC CC O
serum NN NN O
urate JJ JJ B-CHEM
to TO TO O
assess VB VB O
XO NNP NNP O
inhibition NN NN O
. . . O

5 CD CD O
. . . O

Dex NNP NNP B-CHEM
increased VBD VBD O
SBP NNP NNP O
( ( ( O
110 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
- : : O
126 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
mmHg NN NN O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
decreased VBD VBD O
thymus NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
bodyweights NNS NNS O
( ( ( O
P NN NN O
" '' '' O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Allopurinol NNP NNP B-CHEM
decreased VBD VBD O
serum NN NN O
urate NN NN B-CHEM
from IN IN O
76 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
to TO TO O
30 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
in IN IN O
saline NN NN O
and CC CC O
from IN IN O
84 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
to TO TO O
28 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
in IN IN O
dex NN NN B-CHEM
- - - O
treated VBN VBN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
groups NNS NNS O
. . . O

6 CD CD O
. . . O

Allopurinol NNP NNP B-CHEM
did VBD VBD O
not RB RB O
prevent VB VB O
dex NN NN B-CHEM
- - - O
HT NNP NNP O
. . . O

This DT DT O
, , , O
together RB RB O
with IN IN O
our PRP$ PRP$ O
previous JJ JJ O
findings NNS NNS O
that WDT WDT O
allopurinol NN NN B-CHEM
failed VBD VBD O
to TO TO O
prevent VB VB O
adrenocorticotrophic JJ JJ O
hormone NN NN O
induced JJ JJ O
hypertension NN NN O
, , , O
suggests VBZ VBZ O
that IN IN O
XO NNP NNP O
activity NN NN O
is VBZ VBZ O
not RB RB O
a DT DT O
major JJ JJ O
determinant NN NN O
of IN IN O
GC NNP NNP O
- : : O
HT NNP NNP O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Side NNP NNP O
effects NNS NNS O
of IN IN O
postoperative JJ JJ O
administration NN NN O
of IN IN O
methylprednisolone NN NN B-CHEM
and CC CC O
gentamicin NN NN B-CHEM
into IN IN O
the DT DT O
posterior NN NN O
sub NN NN O
- : : O
Tenon NNP NNP O
' POS POS O
s VBZ VBZ O
space NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
assess VB VB O
the DT DT O
incidence NN NN O
of IN IN O
postoperative JJ JJ O
emetic JJ JJ O
side NN NN O
effects NNS NNS O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
methylprednisolone NN NN B-CHEM
and CC CC O
gentamicin NN NN B-CHEM
into IN IN O
the DT DT O
posterior NN NN O
sub NN NN O
- : : O
Tenon NNP NNP O
' POS POS O
s VBZ VBZ O
space NN NN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
routine JJ JJ O
cataract NN NN O
surgery NN NN O
. . . O

SETTING NNP NNP O
: : : O
St NNP NNP O
. . . O

Luke NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
, , , O
Gwardamangia NNP NNP O
, , , O
Malta NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
double JJ JJ O
- : : O
armed VBN VBN O
prospective JJ JJ O
study NN NN O
comprised VBD VBD O
40 CD CD O
patients NNS NNS O
who WP WP O
had VBD VBD O
uneventful JJ JJ O
sutureless JJ JJ O
phacoemulsification NN NN O
under IN IN O
sub NN NN O
- - - O
Tenon NNP NNP O
' POS POS O
s VBZ VBZ O
local JJ JJ O
infiltration NN NN O
of IN IN O
3 CD CD O
mL NN NN O
of IN IN O
plain JJ JJ O
lignocaine NN NN B-CHEM
. . . O

At IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
procedure NN NN O
, , , O
Group NNP NNP O
A DT DT O
( ( ( O
n NN NN O
= SYM SYM O
20 CD CD O
) ) ) O
had VBD VBD O
20 CD CD O
mg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
mL NN NN O
of IN IN O
methylprednisolone NN NN B-CHEM
and CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
mL NN NN O
of IN IN O
gentamicin NN NN B-CHEM
injected VBN VBN O
into IN IN O
the DT DT O
posterior NN NN O
sub NN NN O
- : : O
Tenon NNP NNP O
' POS POS O
s VBZ VBZ O
space NN NN O
and CC CC O
Group NNP NNP O
B NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
20 CD CD O
) ) ) O
had VBD VBD O
the DT DT O
same JJ JJ O
combination NN NN O
injected VBN VBN O
into IN IN O
the DT DT O
anterior NN NN O
sub NN NN O
- : : O
Tenon NNP NNP O
' POS POS O
s VBZ VBZ O
space NN NN O
. . . O

Postoperatively NNP NNP O
, , , O
all DT DT O
patients NNS NNS O
were VBD VBD O
assessed VBN VBN O
for IN IN O
symptoms NNS NNS O
of IN IN O
nausea NN NN O
, , , O
vomiting VBG VBG O
, , , O
and CC CC O
headache NN NN O
. . . O

A DT DT O
chi NN NN O
- - - O
square JJ JJ O
test NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
statistical JJ JJ O
significance NN NN O
of IN IN O
results NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Sixty CD CD O
percent NN NN O
in IN IN O
Group NNP NNP O
A DT DT O
developed JJ JJ O
postoperative JJ JJ O
emetic JJ JJ O
symptoms NNS NNS O
, , , O
headache NN NN O
, , , O
or CC CC O
both DT DT O
; : : O
1 CD CD O
patient NN NN O
in IN IN O
Group NNP NNP O
B NNP NNP O
developed VBD VBD O
symptoms NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
administration NN NN O
of IN IN O
methylprednisolone NN NN B-CHEM
and CC CC O
gentamicin NN NN B-CHEM
in IN IN O
the DT DT O
posterior NN NN O
sub NN NN O
- : : O
Tenon NNP NNP O
' POS POS O
s VBZ VBZ O
space NN NN O
was VBD VBD O
related VBN VBN O
to TO TO O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
including VBG VBG O
nausea NN NN O
, , , O
vomiting VBG VBG O
, , , O
and CC CC O
headache NN NN O
. . . O

All DT DT O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
self NN NN O
- - - O
limiting NN NN O
. . . O

Assessment NNP NNP O
of IN IN O
a DT DT O
new JJ JJ O
non NN NN O
- - - O
invasive JJ JJ O
index NN NN O
of IN IN O
cardiac JJ JJ O
performance NN NN O
for IN IN O
detection NN NN O
of IN IN O
dobutamine NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Electrocardiography NNP NNP O
has VBZ VBZ O
a DT DT O
very RB RB O
low JJ JJ O
sensitivity NN NN O
in IN IN O
detecting VBG VBG O
dobutamine NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
assess VB VB O
the DT DT O
added JJ JJ O
diagnostic JJ JJ O
value NN NN O
of IN IN O
a DT DT O
new JJ JJ O
cardiac NN NN O
performance NN NN O
index NN NN O
( ( ( O
dP NN NN O
/ NN NN O
dtejc NN NN O
) ) ) O
measurement NN NN O
, , , O
based VBN VBN O
on IN IN O
brachial JJ JJ O
artery NN NN O
flow NN NN O
changes NNS NNS O
, , , O
as IN IN O
compared VBN VBN O
to TO TO O
standard JJ JJ O
12 CD CD O
- : : O
lead NN NN O
ECG NNP NNP O
, , , O
for IN IN O
detecting VBG VBG O
dobutamine NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
, , , O
using VBG VBG O
Tc99m NNP NNP B-CHEM
- : : I-CHEM
Sestamibi NNP NNP I-CHEM
single JJ JJ O
- - - O
photon NN NN O
emission NN NN O
computed VBN VBN O
tomography NN NN O
as IN IN O
the DT DT O
gold NN NN O
standard NN NN O
of IN IN O
comparison NN NN O
to TO TO O
assess VB VB O
the DT DT O
presence NN NN O
or CC CC O
absence NN NN O
of IN IN O
ischemia NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
study NN NN O
group NN NN O
comprised VBD VBD O
40 CD CD O
patients NNS NNS O
undergoing VBG VBG O
Sestamibi NNP NNP B-CHEM
- - - O
SPECT NNP NNP O
/ NN NN O
dobutamine NN NN B-CHEM
stress NN NN O
test NN NN O
. . . O

Simultaneous NNP NNP O
measurements NNS NNS O
of IN IN O
ECG NNP NNP O
and CC CC O
brachial JJ JJ O
artery NN NN O
dP NN NN O
/ NN NN O
dtejc NN NN O
were VBD VBD O
performed VBN VBN O
at IN IN O
each DT DT O
dobutamine NN NN B-CHEM
level NN NN O
. . . O

In IN IN O
19 CD CD O
of IN IN O
the DT DT O
40 CD CD O
patients NNS NNS O
perfusion NN NN O
defects NNS NNS O
compatible JJ JJ O
with IN IN O
ischemia NN NN O
were VBD VBD O
detected VBN VBN O
on IN IN O
SPECT NNP NNP O
. . . O

The DT DT O
increase NN NN O
in IN IN O
dP NN NN O
/ NN NN O
dtejc NN NN O
during IN IN O
infusion NN NN O
of IN IN O
dobutamine NN NN B-CHEM
in IN IN O
this DT DT O
group NN NN O
was VBD VBD O
severely RB RB O
impaired VBN VBN O
as IN IN O
compared VBN VBN O
to TO TO O
the DT DT O
non NN NN O
- - - O
ischemic JJ JJ O
group NN NN O
. . . O

dP NN NN O
/ NN NN O
dtejc NN NN O
outcome NN NN O
was VBD VBD O
combined VBN VBN O
with IN IN O
the DT DT O
ECG NNP NNP O
results NNS NNS O
, , , O
giving VBG VBG O
an DT DT O
ECG NNP NNP O
- - - O
enhanced JJ JJ O
value NN NN O
, , , O
and CC CC O
compared VBD VBD O
to TO TO O
ECG NNP NNP O
alone RB RB O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
sensitivity NN NN O
improved VBN VBN O
dramatically RB RB O
from IN IN O
16 CD CD O
% NN NN O
to TO TO O
79 CD CD O
% NN NN O
, , , O
positive JJ JJ O
predictive JJ JJ O
value NN NN O
increased VBD VBD O
from IN IN O
60 CD CD O
% NN NN O
to TO TO O
68 CD CD O
% NN NN O
and CC CC O
negative JJ JJ O
predictive JJ JJ O
value NN NN O
from IN IN O
54 CD CD O
% NN NN O
to TO TO O
78 CD CD O
% NN NN O
, , , O
and CC CC O
specificity NN NN O
decreased VBD VBD O
from IN IN O
90 CD CD O
% NN NN O
to TO TO O
67 CD CD O
% NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
If IN IN O
ECG NNP NNP O
alone RB RB O
is VBZ VBZ O
used VBN VBN O
for IN IN O
specificity NN NN O
, , , O
the DT DT O
combination NN NN O
with IN IN O
dP NN NN O
/ NN NN O
dtejc NN NN O
improved VBN VBN O
the DT DT O
sensitivity NN NN O
of IN IN O
the DT DT O
test NN NN O
and CC CC O
could MD MD O
be VB VB O
a DT DT O
cost NN NN O
- - - O
savings NNS NNS O
alternative JJ JJ O
to TO TO O
cardiac VB VB O
imaging VBG VBG O
or CC CC O
perfusion NN NN O
studies NNS NNS O
to TO TO O
detect VB VB O
myocardial NN NN O
ischemia NN NN O
, , , O
especially RB RB O
in IN IN O
patients NNS NNS O
unable JJ JJ O
to TO TO O
exercise VB VB O
. . . O

Cocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
: : : O
clinical JJ JJ O
observations NNS NNS O
and CC CC O
pathogenetic JJ JJ O
considerations NNS NNS O
. . . O

Clinical NNP NNP O
and CC CC O
experimental JJ JJ O
data NNS NNS O
published VBN VBN O
to TO TO O
date NN NN O
suggest JJS JJS O
several JJ JJ O
possible JJ JJ O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
cocaine VBP VBP B-CHEM
may MD MD O
result VB VB O
in IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

In IN IN O
individuals NNS NNS O
with IN IN O
preexisting VBG VBG O
, , , O
high JJ JJ O
- - - O
grade NN NN O
coronary JJ JJ O
arterial NN NN O
narrowing NN NN O
, , , O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
may MD MD O
result VB VB O
from IN IN O
an DT DT O
increase NN NN O
in IN IN O
myocardial JJ JJ O
oxygen NN NN B-CHEM
demand NN NN O
associated VBN VBN O
with IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
rate NN NN O
- - - O
pressure NN NN O
product NN NN O
. . . O

In IN IN O
other JJ JJ O
individuals NNS NNS O
with IN IN O
no DT DT O
underlying VBG VBG O
atherosclerotic JJ JJ O
obstruction NN NN O
, , , O
coronary JJ JJ O
occlusion NN NN O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
spasm VB VB O
, , , O
thrombus NN NN O
, , , O
or CC CC O
both DT DT O
. . . O

With IN IN O
regard NN NN O
to TO TO O
spasm NN NN O
, , , O
the DT DT O
clinical JJ JJ O
findings NNS NNS O
are VBP VBP O
largely RB RB O
circumstantial JJ JJ O
, , , O
and CC CC O
the DT DT O
locus NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
vasoconstriction NN NN O
remains VBZ VBZ O
speculative JJ JJ O
. . . O

Although IN IN O
certain JJ JJ O
clinical JJ JJ O
and CC CC O
experimental JJ JJ O
findings NNS NNS O
support VBP VBP O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
spasm NN NN O
involves VBZ VBZ O
the DT DT O
epicardial JJ JJ O
, , , O
medium NN NN O
- - - O
size NN NN O
vessels NNS NNS O
, , , O
other JJ JJ O
data NNS NNS O
suggest VBP VBP O
intramural JJ JJ O
vasoconstriction NN NN O
. . . O

Diffuse NNP NNP O
intramural JJ JJ O
vasoconstriction NN NN O
is VBZ VBZ O
not RB RB O
consistent JJ JJ O
with IN IN O
reports NNS NNS O
of IN IN O
segmental NN NN O
, , , O
discrete JJ JJ O
infarction NN NN O
. . . O

Whereas IN IN O
certain JJ JJ O
in IN IN O
vivo NN NN O
data NNS NNS O
suggest VBP VBP O
that IN IN O
these DT DT O
effects NNS NNS O
are VBP VBP O
alpha JJ JJ O
- - - O
mediated JJ JJ O
, , , O
other JJ JJ O
in IN IN O
vitro NN NN O
data NNS NNS O
suggest VBP VBP O
the DT DT O
opposite JJ JJ O
. . . O

The DT DT O
finding NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
vasoconstriction NN NN O
in IN IN O
segments NNS NNS O
of IN IN O
( ( ( O
noninnervated VBN VBN O
) ) ) O
human JJ JJ O
umbilical JJ JJ O
artery NN NN O
suggests VBZ VBZ O
that IN IN O
the DT DT O
presence NN NN O
or CC CC O
absence NN NN O
of IN IN O
intact JJ JJ O
innervation NN NN O
is VBZ VBZ O
not RB RB O
sufficient JJ JJ O
to TO TO O
explain VB VB O
the DT DT O
discrepant NN NN O
data NNS NNS O
involving VBG VBG O
the DT DT O
possibility NN NN O
of IN IN O
alpha NN NN O
- - - O
mediated JJ JJ O
effects NNS NNS O
. . . O

Finally RB RB O
, , , O
the DT DT O
contribution NN NN O
of IN IN O
a DT DT O
primary JJ JJ O
, , , O
thrombotic JJ JJ O
effect NN NN O
of IN IN O
cocaine NN NN B-CHEM
has VBZ VBZ O
not RB RB O
been VBN VBN O
excluded VBN VBN O
. . . O

Proteomic NNP NNP O
analysis NN NN O
of IN IN O
striatal JJ JJ O
proteins NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
model NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
DOPA NNP NNP I-CHEM
- : : O
induced JJ JJ O
dyskinesia NN NN O
. . . O

L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
- : : O
induced JJ JJ O
dyskinesia NN NN O
( ( ( O
LID NNP NNP O
) ) ) O
is VBZ VBZ O
among IN IN O
the DT DT O
motor NN NN O
complications NNS NNS O
that WDT WDT O
arise VBP VBP O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
patients NNS NNS O
after IN IN O
a DT DT O
prolonged JJ JJ O
treatment NN NN O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
. . . O

To TO TO O
this DT DT O
day NN NN O
, , , O
transcriptome NN NN O
analysis NN NN O
has VBZ VBZ O
been VBN VBN O
performed VBN VBN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
LID NNP NNP O
[ NN NN O
Neurobiol NNP NNP O
. . . O
Dis NNP NNP O
. . . O
, , , O
17 CD CD O
( ( ( O
2004 CD CD O
) ) ) O
, , , O
219 CD CD O
] NN NN O
but CC CC O
information NN NN O
regarding VBG VBG O
the DT DT O
proteome NN NN O
is VBZ VBZ O
still RB RB O
lacking VBG VBG O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
changes NNS NNS O
occurring VBG VBG O
at IN IN O
the DT DT O
protein NN NN O
level NN NN O
in IN IN O
striatal JJ JJ O
samples NNS NNS O
obtained VBN VBN O
from IN IN O
the DT DT O
unilaterally RB RB O
6 CD CD B-CHEM
- : : I-CHEM
hydroxydopamine NN NN I-CHEM
- - - O
lesion NN NN O
rat NN NN O
model NN NN O
of IN IN O
PD NNP NNP O
treated VBN VBN O
with IN IN O
saline NN NN O
, , , O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
or CC CC O
bromocriptine NN NN B-CHEM
using VBG VBG O
two CD CD O
- - - O
dimensional JJ JJ O
difference NN NN O
gel NN NN O
electrophoresis NN NN O
and CC CC O
mass NN NN O
spectrometry NN NN O
( ( ( O
MS NNP NNP O
) ) ) O
. . . O

Rats NNP NNP O
treated VBN VBN O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
were VBD VBD O
allocated VBN VBN O
to TO TO O
two CD CD O
groups NNS NNS O
based VBN VBN O
on IN IN O
the DT DT O
presence NN NN O
or CC CC O
absence NN NN O
of IN IN O
LID NNP NNP O
. . . O

Among IN IN O
the DT DT O
2000 CD CD O
spots NNS NNS O
compared VBN VBN O
for IN IN O
statistical JJ JJ O
difference NN NN O
, , , O
67 CD CD O
spots NNS NNS O
were VBD VBD O
significantly RB RB O
changed VBN VBN O
in IN IN O
abundance NN NN O
and CC CC O
identified VBN VBN O
using VBG VBG O
matrix NN NN O
- - - O
assisted VBN VBN O
laser NN NN O
desorption NN NN O
/ NN NN O
ionization NN NN O
time NN NN O
- : : O
of IN IN O
- - - O
flight NN NN O
MS NNP NNP O
, , , O
atmospheric JJ JJ O
pressure NN NN O
matrix NN NN O
- - - O
assisted VBN VBN O
laser NN NN O
desorption NN NN O
/ NN NN O
ionization NN NN O
and CC CC O
HPLC NNP NNP O
coupled VBD VBD O
tandem JJ JJ O
MS NNP NNP O
( ( ( O
LC NNP NNP O
/ NN NN O
MS NNP NNP O
/ NN NN O
MS NNP NNP O
) ) ) O
. . . O

Out IN IN O
of IN IN O
these DT DT O
67 CD CD O
proteins NNS NNS O
, , , O
LID NNP NNP O
significantly RB RB O
changed VBD VBD O
the DT DT O
expression NN NN O
level NN NN O
of IN IN O
five CD CD O
proteins NNS NNS O
: : : O
alphabeta NN NN O
- - - O
crystalin NN NN O
, , , O
gamma NN NN O
- - - O
enolase NN NN O
, , , O
guanidoacetate NN NN O
methyltransferase NN NN O
, , , O
vinculin NN NN O
, , , O
and CC CC O
proteasome VB VB O
alpha NN NN O
- : : O
2 CD CD O
subunit NN NN O
. . . O

Complementary NNP NNP O
techniques NNS NNS O
such JJ JJ O
as IN IN O
western JJ JJ O
immunoblotting NN NN O
and CC CC O
immunohistochemistry NN NN O
were VBD VBD O
performed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
validity NN NN O
of IN IN O
the DT DT O
data NNS NNS O
obtained VBN VBN O
using VBG VBG O
the DT DT O
proteomic JJ JJ O
approach NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
this DT DT O
study NN NN O
provides VBZ VBZ O
new JJ JJ O
insights NNS NNS O
into IN IN O
the DT DT O
protein NN NN O
changes NNS NNS O
occurring VBG VBG O
in IN IN O
LID NNP NNP O
. . . O

Cardiac NNP NNP O
Angiography NNP NNP O
in IN IN O
Renally RB RB O
Impaired NNP NNP O
Patients NNS NNS O
( ( ( O
CARE NNP NNP O
) ) ) O
study NN NN O
: : : O
a DT DT O
randomized JJ JJ O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
of IN IN O
contrast NN NN O
- - - O
induced JJ JJ O
nephropathy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
kidney NN NN O
disease NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
No DT DT O
direct JJ JJ O
comparisons NNS NNS O
exist VBP VBP O
of IN IN O
the DT DT O
renal JJ JJ O
tolerability NN NN O
of IN IN O
the DT DT O
low JJ JJ O
- - - O
osmolality NN NN O
contrast NN NN B-CHEM
medium NN NN I-CHEM
iopamidol NN NN B-CHEM
with IN IN O
that DT DT O
of IN IN O
the DT DT O
iso NN NN O
- - - O
osmolality NN NN O
contrast NN NN B-CHEM
medium NN NN I-CHEM
iodixanol NN NN B-CHEM
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
The DT DT O
present JJ JJ O
study NN NN O
is VBZ VBZ O
a DT DT O
multicenter NN NN O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
comparison NN NN O
of IN IN O
iopamidol NN NN B-CHEM
and CC CC O
iodixanol NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
kidney NN NN O
disease NN NN O
( ( ( O
estimated VBN VBN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
, , , O
20 CD CD O
to TO TO O
59 CD CD O
mL NN NN O
/ NN NN O
min NN NN O
) ) ) O
who WP WP O
underwent VBD VBD O
cardiac JJ JJ O
angiography NN NN O
or CC CC O
percutaneous JJ JJ O
coronary JJ JJ O
interventions NNS NNS O
. . . O

Serum NNP NNP O
creatinine NN NN B-CHEM
( ( ( O
SCr NNP NNP O
) ) ) O
levels NNS NNS O
and CC CC O
estimated VBN VBN O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
were VBD VBD O
assessed VBN VBN O
at IN IN O
baseline NN NN O
and CC CC O
2 CD CD O
to TO TO O
5 CD CD O
days NNS NNS O
after IN IN O
receiving VBG VBG O
medications NNS NNS O
. . . O

The DT DT O
primary JJ JJ O
outcome NN NN O
was VBD VBD O
a DT DT O
postdose NN NN O
SCr NNP NNP O
increase NN NN O
> NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
44 CD CD O
. . . O
2 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
over IN IN O
baseline NN NN O
. . . O

Secondary JJ JJ O
outcomes NNS NNS O
were VBD VBD O
a DT DT O
postdose NN NN O
SCr NNP NNP O
increase NN NN O
> NN NN O
or CC CC O
= SYM SYM O
25 CD CD O
% NN NN O
, , , O
a DT DT O
postdose NN NN O
estimated VBN VBN O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
decrease NN NN O
of IN IN O
> NN NN O
or CC CC O
= SYM SYM O
25 CD CD O
% NN NN O
, , , O
and CC CC O
the DT DT O
mean JJ JJ O
peak NN NN O
change NN NN O
in IN IN O
SCr NNP NNP O
. . . O

In IN IN O
414 CD CD O
patients NNS NNS O
, , , O
contrast NN NN O
volume NN NN O
, , , O
presence NN NN O
of IN IN O
diabetes NN NN O
mellitus NN NN O
, , , O
use NN NN O
of IN IN O
N NNP NNP B-CHEM
- - - I-CHEM
acetylcysteine NN NN I-CHEM
, , , O
mean VB VB O
baseline NN NN O
SCr NNP NNP O
, , , O
and CC CC O
estimated VBD VBD O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
were VBD VBD O
comparable JJ JJ O
in IN IN O
the DT DT O
2 CD CD O
groups NNS NNS O
. . . O

SCr NNP NNP O
increases NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
occurred VBD VBD O
in IN IN O
4 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
9 CD CD O
of IN IN O
204 CD CD O
patients NNS NNS O
) ) ) O
after IN IN O
iopamidol NN NN B-CHEM
and CC CC O
6 CD CD O
. . . O
7 CD CD O
% NN NN O
( ( ( O
14 CD CD O
of IN IN O
210 CD CD O
patients NNS NNS O
) ) ) O
after IN IN O
iodixanol NN NN B-CHEM
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
39 CD CD O
) ) ) O
, , , O
whereas IN IN O
rates NNS NNS O
of IN IN O
SCr NNP NNP O
increases NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
25 CD CD O
% NN NN O
were VBD VBD O
9 CD CD O
. . . O
8 CD CD O
% NN NN O
and CC CC O
12 CD CD O
. . . O
4 CD CD O
% NN NN O
, , , O
respectively RB RB O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
44 CD CD O
) ) ) O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
diabetes NN NN O
, , , O
SCr NNP NNP O
increases NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
were VBD VBD O
5 CD CD O
. . . O
1 CD CD O
% NN NN O
( ( ( O
4 CD CD O
of IN IN O
78 CD CD O
patients NNS NNS O
) ) ) O
with IN IN O
iopamidol NN NN B-CHEM
and CC CC O
13 CD CD O
. . . O
0 CD CD O
% NN NN O
( ( ( O
12 CD CD O
of IN IN O
92 CD CD O
patients NNS NNS O
) ) ) O
with IN IN O
iodixanol NN NN B-CHEM
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
11 CD CD O
) ) ) O
, , , O
whereas IN IN O
SCr NNP NNP O
increases NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
25 CD CD O
% NN NN O
were VBD VBD O
10 CD CD O
. . . O
3 CD CD O
% NN NN O
and CC CC O
15 CD CD O
. . . O
2 CD CD O
% NN NN O
, , , O
respectively RB RB O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
37 CD CD O
) ) ) O
. . . O

Mean VB VB O
post NN NN O
- : : O
SCr NNP NNP O
increases NNS NNS O
were VBD VBD O
significantly RB RB O
less JJR JJR O
with IN IN O
iopamidol NN NN B-CHEM
( ( ( O
all DT DT O
patients NNS NNS O
: : : O
0 CD CD O
. . . O
07 CD CD O
versus CC CC O
0 CD CD O
. . . O
12 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
, , , O
6 CD CD O
. . . O
2 CD CD O
versus CC CC O
10 CD CD O
. . . O
6 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
03 CD CD O
; : : O
patients NNS NNS O
with IN IN O
diabetes NN NN O
: : : O
0 CD CD O
. . . O
07 CD CD O
versus CC CC O
0 CD CD O
. . . O
16 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
, , , O
6 CD CD O
. . . O
2 CD CD O
versus CC CC O
14 CD CD O
. . . O
1 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
rate NN NN O
of IN IN O
contrast NN NN O
- - - O
induced JJ JJ O
nephropathy NN NN O
, , , O
defined VBN VBN O
by IN IN O
multiple JJ JJ O
end NN NN O
points NNS NNS O
, , , O
is VBZ VBZ O
not RB RB O
statistically RB RB O
different JJ JJ O
after IN IN O
the DT DT O
intraarterial JJ JJ O
administration NN NN O
of IN IN O
iopamidol NN NN B-CHEM
or CC CC O
iodixanol NN NN B-CHEM
to TO TO O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
, , , O
with IN IN O
or CC CC O
without IN IN O
diabetes NNS NNS O
mellitus NN NN O
. . . O

Any DT DT O
true JJ JJ O
difference NN NN O
between IN IN O
the DT DT O
agents NNS NNS O
is VBZ VBZ O
small JJ JJ O
and CC CC O
not RB RB O
likely JJ JJ O
to TO TO O
be VB VB O
clinically RB RB O
significant JJ JJ O
. . . O

A DT DT O
novel NN NN O
compound NN NN O
, , , O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
, , , O
attenuates NNS NNS O
cognitive JJ JJ O
deficits NNS NNS O
and CC CC O
shows VBZ VBZ O
neuroprotective JJ JJ O
effects NNS NNS O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
dementia NN NN O
models NNS NNS O
. . . O

To TO TO O
develop VB VB O
a DT DT O
novel NN NN O
and CC CC O
effective JJ JJ O
drug NN NN O
that WDT WDT O
could MD MD O
enhance VB VB O
cognitive JJ JJ O
function NN NN O
and CC CC O
neuroprotection NN NN O
, , , O
we PRP PRP O
newly RB RB O
synthesized VBD VBD O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
by IN IN O
the DT DT O
esterification NN NN O
of IN IN O
maltol NN NN B-CHEM
and CC CC O
p NN NN B-CHEM
- - - I-CHEM
coumaric JJ JJ I-CHEM
acid NN NN I-CHEM
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
whether IN IN O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
could MD MD O
improve VB VB O
cognitive JJ JJ O
decline NN NN O
in IN IN O
scopolamine NN NN B-CHEM
- - - O
injected JJ JJ O
rats NNS NNS O
and CC CC O
in IN IN O
amyloid NN NN B-CHEM
beta NN NN I-CHEM
peptide NN NN I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
42 CD CD I-CHEM
) ) ) I-CHEM
- : : O
infused JJ JJ O
rats NNS NNS O
. . . O

Maltolyl NNP NNP B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
was VBD VBD O
found VBN VBN O
to TO TO O
attenuate VB VB O
cognitive JJ JJ O
deficits NNS NNS O
in IN IN O
both DT DT O
rat NN NN O
models NNS NNS O
using VBG VBG O
passive JJ JJ O
avoidance NN NN O
test NN NN O
and CC CC O
to TO TO O
reduce VB VB O
apoptotic JJ JJ O
cell NN NN O
death NN NN O
observed VBD VBD O
in IN IN O
the DT DT O
hippocampus NN NN O
of IN IN O
the DT DT O
amyloid NN NN B-CHEM
beta NN NN I-CHEM
peptide NN NN I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
42 CD CD I-CHEM
) ) ) I-CHEM
- : : O
infused JJ JJ O
rats NNS NNS O
. . . O

We PRP PRP O
also RB RB O
examined VBD VBD O
the DT DT O
neuroprotective JJ JJ O
effects NNS NNS O
of IN IN O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
in IN IN O
vitro NN NN O
using VBG VBG O
SH NNP NNP O
- : : O
SY5Y NNP NNP O
cells NNS NNS O
. . . O

Cells NNS NNS O
were VBD VBD O
pretreated VBN VBN O
with IN IN O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
, , , O
before IN IN O
exposed VBN VBN O
to TO TO O
amyloid VB VB B-CHEM
beta NN NN I-CHEM
peptide NN NN I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
42 CD CD I-CHEM
) ) ) I-CHEM
, , , O
glutamate NN NN B-CHEM
or CC CC O
H2O2 NNP NNP B-CHEM
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
significantly RB RB O
decreased VBD VBD O
apoptotic JJ JJ O
cell NN NN O
death NN NN O
and CC CC O
reduced VBD VBD O
reactive JJ JJ O
oxygen NN NN O
species NNS NNS O
, , , O
cytochrome JJ JJ O
c SYM SYM O
release NN NN O
, , , O
and CC CC O
caspase NN NN O
3 CD CD O
activation NN NN O
. . . O

Taking VBG VBG O
these DT DT O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
results NNS NNS O
together RB RB O
, , , O
our PRP$ PRP$ O
study NN NN O
suggests VBZ VBZ O
that IN IN O
maltolyl NN NN B-CHEM
p NN NN I-CHEM
- : : I-CHEM
coumarate NN NN I-CHEM
is VBZ VBZ O
a DT DT O
potentially RB RB O
effective JJ JJ O
candidate NN NN O
against IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
that WDT WDT O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
wide JJ JJ O
spread NN NN O
neuronal JJ JJ O
death NN NN O
and CC CC O
progressive JJ JJ O
decline NN NN O
of IN IN O
cognitive JJ JJ O
function NN NN O
. . . O

Attenuation NNP NNP O
of IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
nigrostriatal NN NN O
dopaminergic JJ JJ O
neurotoxicity NN NN O
in IN IN O
mice NN NN O
by IN IN O
lipopolysaccharide NN NN B-CHEM
pretreatment NN NN O
. . . O

Immunological NNP NNP O
activation NN NN O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
to TO TO O
play VB VB O
a DT DT O
role NN NN O
in IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
dopaminergic NN NN O
terminal NN NN O
damage NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
examined VBD VBD O
the DT DT O
roles NNS NNS O
of IN IN O
lipopolysaccharide NN NN B-CHEM
, , , O
a DT DT O
pro FW FW O
- - - O
inflammatory JJ JJ O
and CC CC O
inflammatory JJ JJ O
factor NN NN O
, , , O
treatment NN NN O
in IN IN O
modulating VBG VBG O
the DT DT O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
nigrostriatal NN NN O
dopamine NN NN B-CHEM
neurotoxicity NN NN O
. . . O

Lipopolysaccharide NNP NNP B-CHEM
pretreatment NN NN O
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
basal NN NN O
body NN NN O
temperature NN NN O
or CC CC O
methamphetamine NN NN B-CHEM
- - - O
elicited JJ JJ O
hyperthermia NN NN O
three CD CD O
days NNS NNS O
later RB RB O
. . . O

Such JJ JJ O
systemic JJ JJ O
lipopolysaccharide NN NN B-CHEM
treatment NN NN O
mitigated VBN VBN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
striatal NN NN O
dopamine NN NN B-CHEM
and CC CC O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydroxyphenylacetic JJ JJ I-CHEM
acid NN NN I-CHEM
depletions NNS NNS O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

As IN IN O
the DT DT O
most RBS RBS O
potent JJ JJ O
dose NN NN O
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
of IN IN O
lipopolysaccharide NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
two CD CD O
weeks NNS NNS O
, , , O
one CD CD O
day NN NN O
before IN IN O
or CC CC O
after IN IN O
the DT DT O
methamphetamine NN NN B-CHEM
dosing VBG VBG O
regimen NNS NNS O
, , , O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
striatal NN NN O
dopamine NN NN B-CHEM
and CC CC O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydroxyphenylacetic JJ JJ I-CHEM
acid NN NN I-CHEM
depletions NNS NNS O
remained VBD VBD O
unaltered JJ JJ O
. . . O

Moreover RB RB O
, , , O
systemic JJ JJ O
lipopolysaccharide NN NN B-CHEM
pretreatment NN NN O
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
attenuated VBD VBD O
local JJ JJ O
methamphetamine NN NN B-CHEM
infusion NN NN O
- : : O
produced VBN VBN O
dopamine NN NN B-CHEM
and CC CC O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydroxyphenylacetic JJ JJ I-CHEM
acid NN NN I-CHEM
depletions NNS NNS O
in IN IN O
the DT DT O
striatum NN NN O
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
lipopolysaccharide NN NN B-CHEM
is VBZ VBZ O
less RBR RBR O
likely JJ JJ O
due JJ JJ O
to TO TO O
interrupted VBN VBN O
peripheral JJ JJ O
distribution NN NN O
or CC CC O
metabolism NN NN O
of IN IN O
methamphetamine NN NN B-CHEM
. . . O

We PRP PRP O
concluded VBD VBD O
a DT DT O
critical JJ JJ O
time NN NN O
window NN NN O
for IN IN O
systemic JJ JJ O
lipopolysaccharide NN NN B-CHEM
pretreatment NN NN O
in IN IN O
exerting VBG VBG O
effective JJ JJ O
protection NN NN O
against IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
nigrostriatal NN NN O
dopamine NN NN B-CHEM
neurotoxicity NN NN O
. . . O

Acute JJ JJ O
myocarditis NNS NNS O
associated VBN VBN O
with IN IN O
clozapine NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
A DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
myocarditis NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
commencement NN NN O
of IN IN O
clozapine NN NN B-CHEM
is VBZ VBZ O
described VBN VBN O
, , , O
highlighting VBG VBG O
the DT DT O
onset NN NN O
, , , O
course NN NN O
and CC CC O
possible JJ JJ O
contributing VBG VBG O
factors NNS NNS O
. . . O

There EX EX O
is VBZ VBZ O
an DT DT O
urgent JJ JJ O
need VBP VBP O
to TO TO O
raise VB VB O
awareness NN NN O
about IN IN O
this DT DT O
potentially RB RB O
fatal JJ JJ O
complication NN NN O
of IN IN O
clozapine NN NN B-CHEM
use NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
20 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
with IN IN O
schizophrenia NN NN O
developed VBD VBD O
a DT DT O
sudden JJ JJ O
onset NN NN O
of IN IN O
myocarditis NN NN O
after IN IN O
commencement NN NN O
of IN IN O
clozapine NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
recovered VBD VBD O
with IN IN O
intensive JJ JJ O
medical JJ JJ O
support NN NN O
. . . O

The DT DT O
symptoms NNS NNS O
occurred VBD VBD O
around IN IN O
2 CD CD O
weeks NNS NNS O
after IN IN O
starting VBG VBG O
clozapine NN NN B-CHEM
in IN IN O
an DT DT O
inpatient NN NN O
setting VBG VBG O
. . . O

Possible JJ JJ O
contributing VBG VBG O
factors NNS NNS O
may MD MD O
have VB VB O
been VBN VBN O
concomitant JJ JJ O
antidepressant JJ JJ B-CHEM
use NN NN O
and CC CC O
unaccustomed VBD VBD O
physical JJ JJ O
activity NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Myocarditis NNP NNP O
is VBZ VBZ O
an DT DT O
increasingly RB RB O
recognized JJ JJ O
complication NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
clozapine NN NN B-CHEM
. . . O

It PRP PRP O
can MD MD O
be VB VB O
fatal JJ JJ O
if IN IN O
not RB RB O
recognized VBN VBN O
and CC CC O
treated VBN VBN O
early RB RB O
. . . O

Considering VBG VBG O
that IN IN O
clozapine NN NN B-CHEM
remains VBZ VBZ O
the DT DT O
gold NN NN O
standard JJ JJ O
in IN IN O
treatment NN NN O
of IN IN O
resistant JJ JJ O
psychosis NN NN O
, , , O
there EX EX O
is VBZ VBZ O
an DT DT O
urgent JJ JJ O
need VBP VBP O
to TO TO O
raise VB VB O
awareness NN NN O
among IN IN O
medical JJ JJ O
and CC CC O
paramedical JJ JJ O
staff NN NN O
involved VBN VBN O
in IN IN O
the DT DT O
care NN NN O
of IN IN O
these DT DT O
patients NNS NNS O
. . . O

There EX EX O
are VBP VBP O
also RB RB O
implications NNS NNS O
for IN IN O
recommendations NNS NNS O
and CC CC O
regulations NNS NNS O
regarding VBG VBG O
the DT DT O
use NN NN O
of IN IN O
clozapine NN NN B-CHEM
. . . O

Severe NNP NNP O
rhabdomyolysis NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
secondary JJ JJ O
to TO TO O
concomitant JJ JJ O
use NN NN O
of IN IN O
simvastatin NN NN B-CHEM
, , , O
amiodarone NN NN B-CHEM
, , , O
and CC CC O
atazanavir NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
severe JJ JJ O
interaction NN NN O
between IN IN O
simvastatin NN NN B-CHEM
, , , O
amiodarone NN NN B-CHEM
, , , O
and CC CC O
atazanavir NN NN B-CHEM
resulting VBG VBG O
in IN IN O
rhabdomyolysis NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
A DT DT O
72 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
white JJ JJ O
man NN NN O
with IN IN O
underlying VBG VBG O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
, , , O
atrial JJ JJ O
fibrillation NN NN O
, , , O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
and CC CC O
hyperlipidemia NN NN O
presented VBN VBN O
with IN IN O
generalized JJ JJ O
pain NN NN O
, , , O
fatigue NN NN O
, , , O
and CC CC O
dark JJ JJ O
orange NN NN O
urine NN NN O
for IN IN O
3 CD CD O
days NNS NNS O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
taking VBG VBG O
80 CD CD O
mg NN NN O
simvastatin NN NN B-CHEM
at IN IN O
bedtime NN NN O
( ( ( O
initiated VBN VBN O
27 CD CD O
days NNS NNS O
earlier RBR RBR O
) ) ) O
; : : O
amiodarone NN NN B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
400 CD CD O
mg NN NN O
daily NN NN O
for IN IN O
7 CD CD O
days NNS NNS O
, , , O
then RB RB O
200 CD CD O
mg NN NN O
daily JJ JJ O
( ( ( O
initiated VBN VBN O
19 CD CD O
days NNS NNS O
earlier RBR RBR O
) ) ) O
; : : O
and CC CC O
400 CD CD O
mg NN NN O
atazanavir NN NN B-CHEM
daily JJ JJ O
( ( ( O
initiated VBN VBN O
at IN IN O
least JJS JJS O
2 CD CD O
years NNS NNS O
previously RB RB O
) ) ) O
. . . O

Laboratory NNP NNP O
evaluation NN NN O
revealed VBD VBD O
66 CD CD O
, , , O
680 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
creatine NN NN B-CHEM
kinase NN NN O
, , , O
93 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
blood NN NN B-CHEM
urea JJ JJ I-CHEM
nitrogen NN NN I-CHEM
, , , O
4 CD CD O
. . . O
6 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
creatinine NN NN B-CHEM
, , , O
1579 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
aspartate NN NN B-CHEM
aminotransferase NN NN O
, , , O
and CC CC O
738 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
alanine NN NN B-CHEM
aminotransferase NN NN O
. . . O

Simvastatin NNP NNP B-CHEM
, , , O
amiodarone NN NN B-CHEM
, , , O
and CC CC O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
medications NNS NNS O
were VBD VBD O
all DT DT O
temporarily RB RB O
discontinued VBN VBN O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
given VBN VBN O
forced VBN VBN O
alkaline NN NN O
diuresis NN NN O
and CC CC O
started VBD VBD O
on IN IN O
dialysis NN NN O
. . . O

Nine CD CD O
days NNS NNS O
later RB RB O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
creatine NN NN B-CHEM
kinase NN NN O
had VBD VBD O
dropped VBN VBN O
to TO TO O
1695 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
and CC CC O
creatinine NN NN B-CHEM
was VBD VBD O
3 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
discharged VBN VBN O
and CC CC O
continued VBD VBD O
outpatient JJ JJ O
dialysis NN NN O
for IN IN O
1 CD CD O
month NN NN O
until IN IN O
his PRP$ PRP$ O
renal JJ JJ O
function NN NN O
recovered VBD VBD O
. . . O

DISCUSSION NNP NNP O
: : : O
The DT DT O
risk NN NN O
of IN IN O
rhabdomyolysis NN NN O
is VBZ VBZ O
increased VBN VBN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
concomitant JJ JJ O
drugs NNS NNS O
that WDT WDT O
inhibit NN NN O
simvastatin NN NN B-CHEM
metabolism NN NN O
. . . O

Simvastatin NNP NNP B-CHEM
is VBZ VBZ O
metabolized VBN VBN O
by IN IN O
CYP3A4 NNP NNP O
. . . O

Amiodarone NNP NNP B-CHEM
and CC CC O
atazanavir NN NN B-CHEM
are VBP VBP O
recognized VBN VBN O
CYP3A4 NNP NNP O
inhibitors NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Pharmacokinetic NNP NNP O
differences NNS NNS O
in IN IN O
statins NNS NNS B-CHEM
are VBP VBP O
an DT DT O
important JJ JJ O
consideration NN NN O
for IN IN O
assessing VBG VBG O
the DT DT O
risk NN NN O
of IN IN O
potential JJ JJ O
drug NN NN O
interactions NNS NNS O
. . . O

In IN IN O
patients NNS NNS O
requiring VBG VBG O
the DT DT O
concurrent JJ JJ O
use NN NN O
of IN IN O
statins NNS NNS B-CHEM
and CC CC O
CYP3A4 NNP NNP O
inhibitors NNS NNS O
, , , O
pravastatin NN NN B-CHEM
, , , O
fluvastatin NN NN B-CHEM
, , , O
and CC CC O
rosuvastatin NN NN B-CHEM
carry VB VB O
the DT DT O
lowest JJS JJS O
risk NN NN O
of IN IN O
drug NN NN O
interactions NNS NNS O
; : : O
atorvastatin NN NN B-CHEM
carries VBZ VBZ O
moderate JJ JJ O
risk NN NN O
, , , O
whereas IN IN O
simvastatin NN NN B-CHEM
and CC CC O
lovastatin NN NN B-CHEM
have VBP VBP O
the DT DT O
highest JJS JJS O
risk NN NN O
and CC CC O
should MD MD O
be VB VB O
avoided VBN VBN O
in IN IN O
patients NNS NNS O
taking VBG VBG O
concomitant NN NN O
CYP3A4 NNP NNP O
inhibitors NNS NNS O
. . . O

Interaction NNP NNP O
between IN IN O
warfarin NN NN B-CHEM
and CC CC O
levofloxacin NN NN B-CHEM
: : : O
case NN NN O
series NN NN O
. . . O

Warfarin NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
most RBS RBS O
widely RB RB O
used VBN VBN O
oral JJ JJ O
anticoagulant NN NN O
and CC CC O
is VBZ VBZ O
indicated VBN VBN O
for IN IN O
many JJ JJ O
clinical JJ JJ O
conditions NNS NNS O
. . . O

Levofloxacin NNP NNP B-CHEM
, , , O
a DT DT O
fluoroquinolone NN NN B-CHEM
, , , O
is VBZ VBZ O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
commonly RB RB O
prescribed VBN VBN O
antibiotics NNS NNS O
in IN IN O
clinical JJ JJ O
practice NN NN O
and CC CC O
is VBZ VBZ O
effective JJ JJ O
against IN IN O
Gram NNP NNP O
- : : O
positive JJ JJ O
, , , O
Gram NNP NNP O
- : : O
negative JJ JJ O
, , , O
and CC CC O
atypical JJ JJ O
bacteria NNS NNS O
. . . O

While IN IN O
small JJ JJ O
prospective JJ JJ O
studies NNS NNS O
have VBP VBP O
not RB RB O
revealed VBN VBN O
any DT DT O
significant JJ JJ O
drug NN NN O
- - - O
drug NN NN O
interaction NN NN O
between IN IN O
warfarin NN NN B-CHEM
and CC CC O
levofloxacin NN NN B-CHEM
, , , O
several JJ JJ O
case NN NN O
reports NNS NNS O
have VBP VBP O
indicated VBN VBN O
that IN IN O
levofloxacin NN NN B-CHEM
may MD MD O
significantly RB RB O
potentiate VB VB O
the DT DT O
anticoagulation NN NN O
effect NN NN O
of IN IN O
warfarin NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
3 CD CD O
cases NNS NNS O
of IN IN O
serious JJ JJ O
bleeding VBG VBG O
complications NNS NNS O
that WDT WDT O
appear VBP VBP O
to TO TO O
be VB VB O
the DT DT O
result NN NN O
of IN IN O
the DT DT O
interaction NN NN O
between IN IN O
warfarin NN NN B-CHEM
and CC CC O
levofloxacin NN NN B-CHEM
. . . O

Physicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
potential JJ JJ O
interaction NN NN O
and CC CC O
use VB VB O
caution NN NN O
when WRB WRB O
prescribing VBG VBG O
levofloxacin NN NN B-CHEM
to TO TO O
patients NNS NNS O
taking VBG VBG O
warfarin NN NN B-CHEM
. . . O

Mutations NNP NNP O
associated VBN VBN O
with IN IN O
lamivudine NN NN B-CHEM
- : : O
resistance NN NN O
in IN IN O
therapy NN NN O
- - - O
na NN NN B-CHEM
ve NN NN O
hepatitis NN NN O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
infected VBN VBN O
patients NNS NNS O
with IN IN O
and CC CC O
without IN IN O
HIV NNP NNP O
co NN NN O
- - - O
infection NN NN O
: : : O
implications NNS NNS O
for IN IN O
antiretroviral JJ JJ O
therapy NN NN O
in IN IN O
HBV NNP NNP O
and CC CC O
HIV NNP NNP O
co NN NN O
- - - O
infected JJ JJ O
South NNP NNP O
African NNP NNP O
patients NNS NNS O
. . . O

This DT DT O
was VBD VBD O
an DT DT O
exploratory JJ JJ O
study NN NN O
to TO TO O
investigate VB VB O
lamivudine NN NN B-CHEM
- : : O
resistant JJ JJ O
hepatitis NN NN O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
strains NNS NNS O
in IN IN O
selected VBN VBN O
lamivudine NN NN B-CHEM
- - - O
na NN NN B-CHEM
ve NN NN O
HBV NNP NNP O
carriers NNS NNS O
with IN IN O
and CC CC O
without IN IN O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
( ( ( O
HIV NNP NNP O
) ) ) O
co NN NN O
- - - O
infection NN NN O
in IN IN O
South NNP NNP O
African NNP NNP O
patients NNS NNS O
. . . O

Thirty NNP NNP O
- : : O
five CD CD O
lamivudine NN NN B-CHEM
- : : O
na NN NN B-CHEM
ve NN NN O
HBV NNP NNP O
infected VBD VBD O
patients NNS NNS O
with IN IN O
or CC CC O
without IN IN O
HIV NNP NNP O
co NN NN O
- - - O
infection NN NN O
were VBD VBD O
studied VBN VBN O
: : : O
15 CD CD O
chronic JJ JJ O
HBV NNP NNP O
mono NN NN O
- - - O
infected JJ JJ O
patients NNS NNS O
and CC CC O
20 CD CD O
HBV NNP NNP O
- : : O
HIV NNP NNP O
co NN NN O
- - - O
infected JJ JJ O
patients NNS NNS O
. . . O

The DT DT O
latter JJ JJ O
group NN NN O
was VBD VBD O
further JJ JJ O
sub NN NN O
- - - O
divided VBN VBN O
into IN IN O
13 CD CD O
occult NN NN O
HBV NNP NNP O
( ( ( O
HBsAg NNP NNP B-CHEM
- - - O
negative JJ JJ O
) ) ) O
and CC CC O
7 CD CD O
overt NN NN O
HBV NNP NNP O
( ( ( O
HBsAg NNP NNP B-CHEM
- - - O
positive JJ JJ O
) ) ) O
patients NNS NNS O
. . . O

HBsAg NNP NNP B-CHEM
, , , O
anti JJ JJ O
- : : O
HBs NNP NNP O
, , , O
anti JJ JJ O
- : : O
HBc NNP NNP O
, , , O
and CC CC O
anti JJ JJ O
- : : O
HIV NNP NNP O
1 CD CD O
/ NN NN O
2 CD CD O
were VBD VBD O
determined VBN VBN O
as IN IN O
part NN NN O
of IN IN O
routine JJ JJ O
diagnosis NN NN O
using VBG VBG O
Axsym NNP NNP O
assays NNS NNS O
( ( ( O
Abbott NNP NNP O
Laboratories NNP NNP O
, , , O
North NNP NNP O
Chicago NNP NNP O
, , , O
IL NNP NNP O
) ) ) O
. . . O

Serum NNP NNP O
samples NNS NNS O
were VBD VBD O
PCR NNP NNP O
amplified VBN VBN O
with IN IN O
HBV NNP NNP O
reverse NN NN O
transcriptase NN NN O
( ( ( O
RT NNP NNP O
) ) ) O
primers NNS NNS O
, , , O
followed VBN VBN O
by IN IN O
direct JJ JJ O
sequencing VBG VBG O
across IN IN O
the DT DT O
tyrosine NN NN B-CHEM
- - - O
methionine NN NN B-CHEM
- - - O
aspartate JJ JJ B-CHEM
- : : O
aspartate NN NN B-CHEM
( ( ( O
YMDD NNP NNP O
) ) ) O
motif NN NN O
of IN IN O
the DT DT O
major JJ JJ O
catalytic JJ JJ O
region NN NN O
in IN IN O
the DT DT O
C NNP NNP O
domain NN NN O
of IN IN O
the DT DT O
HBV NNP NNP O
RT NNP NNP O
enzyme NN NN O
. . . O

HBV NNP NNP O
viral JJ JJ O
load NN NN O
was VBD VBD O
performed VBN VBN O
with IN IN O
Amplicor NNP NNP O
HBV NNP NNP O
Monitor NNP NNP O
test NN NN O
v2 NN NN O
. . . O
0 CD CD O
( ( ( O
Roche NNP NNP O
Diagnostics NNP NNP O
, , , O
Penzberg NNP NNP O
, , , O
Germany NNP NNP O
) ) ) O
. . . O

HBV NNP NNP O
lamivudine NN NN B-CHEM
- : : O
resistant JJ JJ O
strains NNS NNS O
were VBD VBD O
detected VBN VBN O
in IN IN O
3 CD CD O
of IN IN O
15 CD CD O
mono NN NN O
- : : O
infected JJ JJ O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
patients NNS NNS O
and CC CC O
10 CD CD O
of IN IN O
20 CD CD O
HBV NNP NNP O
- : : O
HIV NNP NNP O
co NN NN O
- - - O
infected JJ JJ O
patients NNS NNS O
. . . O

To TO TO O
the DT DT O
best JJS JJS O
of IN IN O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
constitutes VBZ VBZ O
the DT DT O
first JJ JJ O
report NN NN O
of IN IN O
HBV NNP NNP O
lamivudine NN NN B-CHEM
- : : O
resistant JJ JJ O
strains NNS NNS O
in IN IN O
therapy NN NN O
- - - O
na NN NN B-CHEM
ve NN NN O
HBV NNP NNP O
- : : O
HIV NNP NNP O
co NN NN O
- - - O
infected JJ JJ O
patients NNS NNS O
. . . O

The DT DT O
HBV NNP NNP O
viral JJ JJ O
loads NNS NNS O
for IN IN O
mono NN NN O
- - - O
infected JJ JJ O
and CC CC O
co NN NN O
- - - O
infected JJ JJ O
patients NNS NNS O
ranged VBD VBD O
from IN IN O
3 CD CD O
. . . O
32 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
2 CD CD O
) ) ) O
to TO TO O
3 CD CD O
. . . O
82 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
7 CD CD O
) ) ) O
and CC CC O
< NN NN O
200 CD CD O
to TO TO O
4 CD CD O
. . . O
40 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
3 CD CD O
) ) ) O
copies NNS NNS O
/ NN NN O
ml NN NN O
, , , O
respectively RB RB O
. . . O

It PRP PRP O
remains VBZ VBZ O
to TO TO O
be VB VB O
seen VBN VBN O
whether IN IN O
such JJ JJ O
pre NN NN O
- - - O
existing VBG VBG O
antiviral JJ JJ O
mutations NNS NNS O
could MD MD O
result VB VB O
in IN IN O
widespread JJ JJ O
emergence NN NN O
of IN IN O
HBV NNP NNP O
resistant JJ JJ O
strains NNS NNS O
when WRB WRB O
lamivudine NN NN B-CHEM
- - - O
containing VBG VBG O
highly RB RB O
active JJ JJ O
antiretroviral NN NN O
( ( ( O
ARV NNP NNP O
) ) ) O
treatment NN NN O
( ( ( O
HAART NNP NNP O
) ) ) O
regimens NNS NNS O
become VBP VBP O
widely RB RB O
applied VBN VBN O
in IN IN O
South NNP NNP O
Africa NNP NNP O
, , , O
as IN IN O
this DT DT O
is VBZ VBZ O
likely JJ JJ O
to TO TO O
have VB VB O
potential JJ JJ O
implications NNS NNS O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
HBV NNP NNP O
- : : O
HIV NNP NNP O
co NN NN O
- - - O
infected JJ JJ O
patients NNS NNS O
. . . O

Rabbit NNP NNP O
syndrome NN NN O
, , , O
antidepressant JJ JJ B-CHEM
use NN NN O
, , , O
and CC CC O
cerebral JJ JJ O
perfusion NN NN O
SPECT NNP NNP O
scan JJ JJ O
findings NNS NNS O
. . . O

The DT DT O
rabbit NN NN O
syndrome NN NN O
is VBZ VBZ O
an DT DT O
extrapyramidal JJ JJ O
side NN NN O
effect NN NN O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
neuroleptic JJ JJ O
therapy NN NN O
. . . O

Its PRP$ PRP$ O
occurrence NN NN O
in IN IN O
a DT DT O
patient NN NN O
being VBG VBG O
treated VBN VBN O
with IN IN O
imipramine NN NN B-CHEM
is VBZ VBZ O
described VBN VBN O
, , , O
representing VBG VBG O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
this DT DT O
syndrome NN NN O
in IN IN O
conjunction NN NN O
with IN IN O
antidepressants NNS NNS B-CHEM
. . . O

Repeated NNP NNP O
cerebral JJ JJ O
perfusion NN NN O
SPECT NNP NNP O
scans NNS NNS O
revealed VBN VBN O
decreased VBD VBD O
basal NN NN O
ganglia NN NN O
perfusion NN NN O
while IN IN O
the DT DT O
movement NN NN O
disorder NN NN O
was VBD VBD O
present JJ JJ O
, , , O
and CC CC O
a DT DT O
return NN NN O
to TO TO O
normal JJ JJ O
perfusion NN NN O
when WRB WRB O
the DT DT O
rabbit NN NN O
syndrome NN NN O
resolved VBD VBD O
. . . O

Estrogen NNP NNP O
prevents NNS NNS O
cholesteryl NN NN B-CHEM
ester NN NN I-CHEM
accumulation NN NN O
in IN IN O
macrophages NNS NNS O
induced VBN VBN O
by IN IN O
the DT DT O
HIV NNP NNP O
protease NN NN O
inhibitor NN NN O
ritonavir NN NN B-CHEM
. . . O

Individuals NNS NNS O
with IN IN O
HIV NNP NNP O
can MD MD O
now RB RB O
live VB VB O
long JJ JJ O
lives NNS NNS O
with IN IN O
drug NN NN O
therapy NN NN O
that WDT WDT O
often RB RB O
includes VBZ VBZ O
protease NN NN O
inhibitors NNS NNS O
such JJ JJ O
as IN IN O
ritonavir NN NN B-CHEM
. . . O

Many JJ JJ O
patients NNS NNS O
, , , O
however RB RB O
, , , O
develop VBP VBP O
negative JJ JJ O
long JJ JJ O
- - - O
term NN NN O
side NN NN O
effects NNS NNS O
such JJ JJ O
as IN IN O
premature JJ JJ O
atherosclerosis NN NN O
. . . O

We PRP PRP O
have VBP VBP O
previously RB RB O
demonstrated VBN VBN O
that IN IN O
ritonavir NN NN B-CHEM
treatment NN NN O
increases NNS NNS O
atherosclerotic JJ JJ O
lesion NN NN O
formation NN NN O
in IN IN O
male JJ JJ O
mice NN NN O
to TO TO O
a DT DT O
greater JJR JJR O
extent NN NN O
than IN IN O
in IN IN O
female JJ JJ O
mice NN NN O
. . . O

Furthermore RB RB O
, , , O
peripheral JJ JJ O
blood NN NN O
monocytes NNS NNS O
isolated VBN VBN O
from IN IN O
ritonavir NN NN B-CHEM
- - - O
treated JJ JJ O
females NNS NNS O
had VBD VBD O
less JJR JJR O
cholesteryl NN NN B-CHEM
ester NN NN I-CHEM
accumulation NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
have VBP VBP O
investigated VBN VBN O
the DT DT O
molecular JJ JJ O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
female JJ JJ O
hormones NNS NNS O
influence NN NN O
cholesterol NN NN B-CHEM
metabolism NN NN O
in IN IN O
macrophages NNS NNS O
in IN IN O
response NN NN O
to TO TO O
the DT DT O
HIV NNP NNP O
protease NN NN O
inhibitor NN NN O
ritonavir NN NN B-CHEM
. . . O

We PRP PRP O
have VBP VBP O
utilized VBN VBN O
the DT DT O
human JJ JJ O
monocyte NN NN O
cell NN NN O
line NN NN O
, , , O
THP NNP NNP O
- : : O
1 CD CD O
as IN IN O
a DT DT O
model NN NN O
to TO TO O
address VB VB O
this DT DT O
question NN NN O
. . . O

Briefly NNP NNP O
, , , O
cells NNS NNS O
were VBD VBD O
differentiated VBN VBN O
for IN IN O
72 CD CD O
h NN NN O
with IN IN O
100 CD CD O
nM NN NN O
PMA NNP NNP O
to TO TO O
obtain VB VB O
a DT DT O
macrophage NN NN O
- - - O
like IN IN O
phenotype NN NN O
in IN IN O
the DT DT O
presence NN NN O
or CC CC O
absence NN NN O
of IN IN O
1 CD CD O
nM NN NN O
17beta CD CD B-CHEM
- : : I-CHEM
estradiol NN NN I-CHEM
( ( ( O
E2 NNP NNP B-CHEM
) ) ) O
, , , O
100 CD CD O
nM NN NN O
progesterone NN NN B-CHEM
or CC CC O
vehicle NN NN O
( ( ( O
0 CD CD O
. . . O
01 CD CD O
% NN NN O
ethanol NN NN B-CHEM
) ) ) O
. . . O

Cells NNS NNS O
were VBD VBD O
then RB RB O
treated VBN VBN O
with IN IN O
30 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
ritonavir NN NN B-CHEM
or CC CC O
vehicle NN NN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
aggregated VBN VBN O
LDL NNP NNP O
for IN IN O
24 CD CD O
h NN NN O
. . . O

Cell NNP NNP O
extracts NNS NNS O
were VBD VBD O
harvested VBN VBN O
, , , O
and CC CC O
lipid NN NN O
or CC CC O
total JJ JJ O
RNA NNP NNP O
was VBD VBD O
isolated VBN VBN O
. . . O

E2 NNP NNP B-CHEM
decreased VBD VBD O
the DT DT O
accumulation NN NN O
of IN IN O
cholesteryl NN NN B-CHEM
esters NNS NNS I-CHEM
in IN IN O
macrophages NNS NNS O
following VBG VBG O
ritonavir NN NN B-CHEM
treatment NN NN O
. . . O

Ritonavir NNP NNP B-CHEM
increased VBD VBD O
the DT DT O
expression NN NN O
of IN IN O
the DT DT O
scavenger NN NN O
receptor NN NN O
, , , O
CD36 NNP NNP O
mRNA NN NN O
, , , O
responsible JJ JJ O
for IN IN O
the DT DT O
uptake NN NN O
of IN IN O
LDL NNP NNP O
. . . O

Additionally RB RB O
, , , O
ritonavir NN NN B-CHEM
treatment NN NN O
selectively RB RB O
increased VBD VBD O
the DT DT O
relative JJ JJ O
levels NNS NNS O
of IN IN O
PPARgamma NNP NNP O
mRNA NN NN O
, , , O
a DT DT O
transcription NN NN O
factor NN NN O
responsible JJ JJ O
for IN IN O
the DT DT O
regulation NN NN O
of IN IN O
CD36 NNP NNP O
mRNA NN NN O
expression NN NN O
. . . O

Treatment NN NN O
with IN IN O
E2 NNP NNP B-CHEM
, , , O
however RB RB O
, , , O
failed VBD VBD O
to TO TO O
prevent VB VB O
these DT DT O
increases NNS NNS O
at IN IN O
the DT DT O
mRNA NN NN O
level NN NN O
. . . O

E2 NNP NNP B-CHEM
did VBD VBD O
, , , O
however RB RB O
, , , O
significantly RB RB O
suppress JJ JJ O
CD36 NNP NNP O
protein NN NN O
levels NNS NNS O
as IN IN O
measured VBN VBN O
by IN IN O
fluorescent NN NN O
immunocytochemistry NN NN O
. . . O

This DT DT O
data NNS NNS O
suggests VBZ VBZ O
that IN IN O
E2 NNP NNP B-CHEM
modifies VBZ VBZ O
the DT DT O
expression NN NN O
of IN IN O
CD36 NNP NNP O
at IN IN O
the DT DT O
level NN NN O
of IN IN O
protein NN NN O
expression NN NN O
in IN IN O
monocyte NN NN O
- - - O
derived VBN VBN O
macrophages NNS NNS O
resulting VBG VBG O
in IN IN O
reduced VBN VBN O
cholesteryl NN NN B-CHEM
ester NN NN I-CHEM
accumulation NN NN O
following VBG VBG O
ritonavir NN NN B-CHEM
treatment NN NN O
. . . O

Acute JJ JJ O
hepatitis NN NN O
attack NN NN O
after IN IN O
exposure NN NN O
to TO TO O
telithromycin NN NN B-CHEM
. . . O

INTRODUCTION NNP NNP O
: : : O
Antibiotic NNP NNP O
- - - O
associated JJ JJ O
hepatotoxicity NN NN O
is VBZ VBZ O
rare JJ JJ O
. . . O

With IN IN O
widespread JJ JJ O
use NN NN O
of IN IN O
antimicrobial JJ JJ O
agents NNS NNS O
, , , O
however RB RB O
, , , O
hepatic JJ JJ O
injury NN NN O
occurs VBZ VBZ O
frequently RB RB O
, , , O
and CC CC O
among IN IN O
adverse JJ JJ O
drug NN NN O
reactions NNS NNS O
, , , O
idiosyncratic JJ JJ O
reactions NNS NNS O
are VBP VBP O
the DT DT O
most RBS RBS O
serious JJ JJ O
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
25 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male JJ JJ O
patient NN NN O
, , , O
with IN IN O
a DT DT O
height NN NN O
of IN IN O
175 CD CD O
cm NN NN O
and CC CC O
weight NN NN O
of IN IN O
72 CD CD O
kg NN NN O
presented VBN VBN O
to TO TO O
Marmara NNP NNP O
University NNP NNP O
Hospital NNP NNP O
Emergency NNP NNP O
Department NNP NNP O
, , , O
Istanbul NNP NNP O
, , , O
Turkey NNP NNP O
, , , O
with IN IN O
5 CD CD O
days NNS NNS O
' POS POS O
history NN NN O
of IN IN O
jaundice NN NN O
, , , O
malaise NN NN O
, , , O
nausea NN NN O
, , , O
and CC CC O
vomiting VBG VBG O
. . . O

He PRP PRP O
had VBD VBD O
been VBN VBN O
prescribed VBN VBN O
telithromycin NN NN B-CHEM
400 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
PO NNP NNP O
to TO TO O
treat VB VB O
an DT DT O
upper JJ JJ O
respiratory JJ JJ O
tract NN NN O
infection NN NN O
7 CD CD O
days NNS NNS O
prior RB RB O
. . . O

Admission NNP NNP O
laboratory NN NN O
tests NNS NNS O
were VBD VBD O
as IN IN O
follows VBZ VBZ O
: : : O
alanine NN NN B-CHEM
aminotransferase NN NN O
, , , O
67 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
( ( ( O
reference NN NN O
range NN NN O
, , , O
10 CD CD O
- : : O
37 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
; : : O
aspartate NN NN B-CHEM
aminotransferase NN NN O
, , , O
98 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
( ( ( O
10 CD CD O
- : : O
40 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
; : : O
alkaline NN NN O
phosphatase NN NN O
, , , O
513 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
( ( ( O
0 CD CD O
- : : O
270 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
; : : O
gamma NN NN O
- : : O
glutamyltransferase NN NN O
, , , O
32 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
( ( ( O
7 CD CD O
- : : O
49 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
; : : O
amylase NN NN O
, , , O
46 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
( ( ( O
0 CD CD O
- : : O
220 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
; : : O
total JJ JJ O
bilirubin NN NN B-CHEM
, , , O
20 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
0 CD CD O
. . . O
2 CD CD O
- : : O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
; : : O
direct JJ JJ O
bilirubin NN NN B-CHEM
, , , O
14 CD CD O
. . . O
8 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
0 CD CD O
- : : O
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
; : : O
and CC CC O
albumin NN NN O
, , , O
4 CD CD O
. . . O
7 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
3 CD CD O
. . . O
5 CD CD O
- : : O
5 CD CD O
. . . O
4 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
. . . O

No DT DT O
toxin NN NN O
, , , O
alcohol NN NN B-CHEM
, , , O
or CC CC O
other JJ JJ O
drugs NNS NNS O
were VBD VBD O
reported VBN VBN O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
suffered VBN VBN O
a DT DT O
previous JJ JJ O
episode NN NN O
of IN IN O
" '' '' O
acute JJ JJ O
hepatitis NN NN O
of IN IN O
unknown JJ JJ O
origin NN NN O
, , , O
" '' '' O
that WDT WDT O
occurred VBD VBD O
after IN IN O
telithromycin NN NN B-CHEM
usage NN NN O
. . . O

Both DT DT O
incidents NNS NNS O
occurred VBD VBD O
within IN IN O
a DT DT O
year NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
Telithromycin NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
first JJ JJ O
of IN IN O
the DT DT O
ketolide NN NN O
antibacterials NNS NNS O
to TO TO O
receive VB VB O
US NNP NNP O
Food NNP NNP O
and CC CC O
Drug NN NN O
Administration NNP NNP O
approval NN NN O
for IN IN O
clinical JJ JJ O
use NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
infrequent NN NN O
and CC CC O
usually RB RB O
reversible JJ JJ O
severe JJ JJ O
hepatic JJ JJ O
dysfunction NN NN O
. . . O

Based VBN VBN O
on IN IN O
a DT DT O
score NN NN O
of IN IN O
8 CD CD O
on IN IN O
the DT DT O
Naranjo NNP NNP O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
probability NN NN O
scale NN NN O
, , , O
telithromycin NN NN B-CHEM
was VBD VBD O
the DT DT O
probable JJ JJ O
cause NN NN O
of IN IN O
acute JJ JJ O
hepatitis NN NN O
in IN IN O
this DT DT O
patient NN NN O
, , , O
and CC CC O
pathological JJ JJ O
findings NNS NNS O
suggested VBD VBD O
drug NN NN O
- : : O
induced JJ JJ O
toxic JJ JJ O
hepatitis NN NN O
. . . O

Recurrence NNP NNP O
of IN IN O
hepatitis NN NN O
attack NN NN O
might MD MD O
have VB VB O
been VBN VBN O
avoided VBN VBN O
if IN IN O
the DT DT O
initial JJ JJ O
incident NN NN O
had VBD VBD O
been VBN VBN O
communicated VBN VBN O
to TO TO O
the DT DT O
attending VBG VBG O
physician NN NN O
who WP WP O
prescribed VBD VBD O
telithromycin NN NN B-CHEM
the DT DT O
second JJ JJ O
time NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Here RB RB O
we PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
hepatitis NN NN O
probably RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
administration NN NN O
of IN IN O
telithromycin NN NN B-CHEM
. . . O

A DT DT O
study NN NN O
on IN IN O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
duration NN NN O
of IN IN O
subcutaneous JJ JJ O
heparin NN NN B-CHEM
injection NN NN O
on IN IN O
bruising VBG VBG O
and CC CC O
pain NN NN O
. . . O

AIM NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
to TO TO O
determine VB VB O
the DT DT O
effect NN NN O
of IN IN O
injection NN NN O
duration NN NN O
on IN IN O
bruising VBG VBG O
and CC CC O
pain NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
the DT DT O
subcutaneous JJ JJ O
injection NN NN O
of IN IN O
heparin NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Although IN IN O
different JJ JJ O
methods NNS NNS O
to TO TO O
prevent VB VB O
bruising JJ JJ O
and CC CC O
pain NN NN O
following VBG VBG O
the DT DT O
subcutaneous JJ JJ O
injection NN NN O
of IN IN O
heparin NN NN B-CHEM
have VBP VBP O
been VBN VBN O
widely RB RB O
studied VBN VBN O
and CC CC O
described VBN VBN O
, , , O
the DT DT O
effect NN NN O
of IN IN O
injection NN NN O
duration NN NN O
on IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
bruising VBG VBG O
and CC CC O
pain NN NN O
is VBZ VBZ O
little JJ JJ O
documented VBN VBN O
. . . O

DESIGN NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
as IN IN O
within IN IN O
- - - O
subject JJ JJ O
, , , O
quasi NN NN O
- - - O
experimental JJ JJ O
research NN NN O
. . . O

METHOD NNP NNP O
: : : O
The DT DT O
sample NN NN O
for IN IN O
the DT DT O
study NN NN O
consisted VBD VBD O
of IN IN O
50 CD CD O
patients NNS NNS O
to TO TO O
whom WP WP O
subcutaneous JJ JJ O
heparin NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
. . . O

Heparin NNP NNP B-CHEM
was VBD VBD O
injected VBN VBN O
over IN IN O
10 CD CD O
seconds NNS NNS O
on IN IN O
the DT DT O
right JJ JJ O
abdominal JJ JJ O
site NN NN O
and CC CC O
30 CD CD O
seconds NNS NNS O
on IN IN O
the DT DT O
left VBN VBN O
abdominal JJ JJ O
site NN NN O
. . . O

Injections NNP NNP O
areas NNS NNS O
were VBD VBD O
assessed VBN VBN O
for IN IN O
the DT DT O
presence NN NN O
of IN IN O
bruising VBG VBG O
at IN IN O
48 CD CD O
and CC CC O
72 CD CD O
hours NNS NNS O
after IN IN O
each DT DT O
injection NN NN O
. . . O

Dimensions NNP NNP O
of IN IN O
the DT DT O
bruising VBG VBG O
on IN IN O
the DT DT O
heparin NN NN B-CHEM
applied VBD VBD O
areas NNS NNS O
were VBD VBD O
measured VBN VBN O
using VBG VBG O
transparent NN NN O
millimetric JJ JJ O
measuring VBG VBG O
paper NN NN O
. . . O

The DT DT O
visual JJ JJ O
analog NN NN O
scale NN NN O
( ( ( O
VAS NNP NNP O
) ) ) O
was VBD VBD O
used VBN VBN O
to TO TO O
measure VB VB O
pain NN NN O
intensity NN NN O
and CC CC O
a DT DT O
stop NN NN O
- - - O
watch NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
time NN NN O
the DT DT O
pain NN NN O
period NN NN O
. . . O

Data NNP NNP O
were VBD VBD O
analysed VBN VBN O
using VBG VBG O
chi NN NN O
- - - O
square JJ JJ O
test NN NN O
, , , O
Mann NNP NNP O
- - - O
Whitney NNP NNP O
U NNP NNP O
, , , O
Wilcoxon NNP NNP O
signed VBD VBD O
ranks NNS NNS O
tests NNS NNS O
and CC CC O
correlation NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
percentage NN NN O
of IN IN O
bruising VBG VBG O
occurrence NN NN O
was VBD VBD O
64 CD CD O
% NN NN O
with IN IN O
the DT DT O
injection NN NN O
of IN IN O
10 CD CD O
seconds NNS NNS O
duration NN NN O
and CC CC O
42 CD CD O
% NN NN O
in IN IN O
the DT DT O
30 CD CD O
- : : O
second JJ JJ O
injection NN NN O
. . . O

It PRP PRP O
was VBD VBD O
determined VBN VBN O
that IN IN O
the DT DT O
size NN NN O
of IN IN O
the DT DT O
bruising NN NN O
was VBD VBD O
smaller JJR JJR O
in IN IN O
the DT DT O
30 CD CD O
- : : O
second JJ JJ O
injection NN NN O
. . . O

Pain NN NN O
intensity NN NN O
and CC CC O
pain NN NN O
period NN NN O
were VBD VBD O
statistically RB RB O
significantly RB RB O
lower JJR JJR O
for IN IN O
the DT DT O
30 CD CD O
- : : O
second JJ JJ O
injection NN NN O
than IN IN O
for IN IN O
the DT DT O
10 CD CD O
- : : O
second JJ JJ O
injection NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
It PRP PRP O
was VBD VBD O
determined VBN VBN O
that IN IN O
injection NN NN O
duration NN NN O
had VBD VBD O
an DT DT O
effect NN NN O
on IN IN O
bruising VBG VBG O
and CC CC O
pain NN NN O
following VBG VBG O
the DT DT O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
heparin NN NN B-CHEM
. . . O

This DT DT O
study NN NN O
should MD MD O
be VB VB O
repeated VBN VBN O
on IN IN O
a DT DT O
larger JJR JJR O
sample NN NN O
. . . O

RELEVANCE NNP NNP O
TO TO TO O
CLINICAL NNP NNP O
PRACTICE NNP NNP O
: : : O
When WRB WRB O
administering VBG VBG O
subcutaneous JJ JJ O
heparin NN NN B-CHEM
injections NNS NNS O
, , , O
it PRP PRP O
is VBZ VBZ O
important JJ JJ O
to TO TO O
extend VB VB O
the DT DT O
duration NN NN O
of IN IN O
the DT DT O
injection NN NN O
. . . O

Acute JJ JJ O
liver NN NN O
failure NN NN O
in IN IN O
two CD CD O
patients NNS NNS O
with IN IN O
regular JJ JJ O
alcohol NN NN B-CHEM
consumption NN NN O
ingesting VBG VBG O
paracetamol NN NN B-CHEM
at IN IN O
therapeutic JJ JJ O
dosage NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
possible JJ JJ O
role NN NN O
of IN IN O
alcohol NN NN B-CHEM
in IN IN O
the DT DT O
development NN NN O
of IN IN O
hepatotoxicity NN NN O
associated VBN VBN O
with IN IN O
therapeutic JJ JJ O
doses NNS NNS O
of IN IN O
paracetamol NN NN B-CHEM
( ( ( O
acetaminophen NN NN B-CHEM
) ) ) O
is VBZ VBZ O
currently RB RB O
debated VBN VBN O
. . . O

CASE NN NN O
REPORT NNP NNP O
: : : O
We PRP PRP O
describe VBP VBP O
2 CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
regular JJ JJ O
consumers NNS NNS O
of IN IN O
alcohol NN NN B-CHEM
and CC CC O
who WP WP O
developed JJ JJ O
liver NN NN O
failure NN NN O
within IN IN O
3 CD CD O
- : : O
5 CD CD O
days NNS NNS O
after IN IN O
hospitalization NN NN O
and CC CC O
stopping VBG VBG O
alcohol NN NN B-CHEM
consumption NN NN O
while IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
4 CD CD O
g SYM SYM O
paracetamol NN NN B-CHEM
/ NN NN O
day NN NN O
. . . O

A DT DT O
paracetamol JJ JJ B-CHEM
serum NN NN O
level NN NN O
obtained VBN VBN O
in IN IN O
one CD CD O
of IN IN O
these DT DT O
patients NNS NNS O
was VBD VBD O
not RB RB O
in IN IN O
the DT DT O
toxic JJ JJ O
range NN NN O
. . . O

Possible JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
hepatotoxicity NN NN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
therapeutic JJ JJ O
doses NNS NNS O
of IN IN O
paracetamol NN NN B-CHEM
are VBP VBP O
discussed VBN VBN O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
patients NNS NNS O
with IN IN O
risk NN NN O
factors NNS NNS O
, , , O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
regular JJ JJ O
consumption NN NN O
of IN IN O
alcohol NN NN B-CHEM
, , , O
liver NN NN O
failure NN NN O
is VBZ VBZ O
possible JJ JJ O
when WRB WRB O
therapeutic JJ JJ O
doses NNS NNS O
are VBP VBP O
ingested VBN VBN O
. . . O

We PRP PRP O
propose VBP VBP O
that IN IN O
the DT DT O
paracetamol NN NN B-CHEM
dose NN NN O
should MD MD O
not RB RB O
exceed VB VB O
2 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
in IN IN O
such JJ JJ O
patients NNS NNS O
and CC CC O
that IN IN O
their PRP$ PRP$ O
liver NN NN O
function NN NN O
should MD MD O
be VB VB O
monitored VBN VBN O
closely RB RB O
while IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
paracetamol NN NN B-CHEM
. . . O

Associations NNP NNP O
between IN IN O
use NN NN O
of IN IN O
benzodiazepines NNS NNS B-CHEM
or CC CC O
related VBN VBN O
drugs NNS NNS O
and CC CC O
health NN NN O
, , , O
physical JJ JJ O
abilities NNS NNS O
and CC CC O
cognitive JJ JJ O
function NN NN O
: : : O
a DT DT O
non NN NN O
- - - O
randomised JJ JJ O
clinical JJ JJ O
study NN NN O
in IN IN O
the DT DT O
elderly JJ JJ O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
associations NNS NNS O
between IN IN O
the DT DT O
use NN NN O
of IN IN O
benzodiazepines NNS NNS B-CHEM
or CC CC O
related VBN VBN O
drugs NNS NNS O
( ( ( O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
) ) ) O
and CC CC O
health NN NN O
, , , O
functional JJ JJ O
abilities NNS NNS O
and CC CC O
cognitive JJ JJ O
function NN NN O
in IN IN O
the DT DT O
elderly JJ JJ O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
non NN NN O
- - - O
randomised JJ JJ O
clinical JJ JJ O
study NN NN O
of IN IN O
patients NNS NNS O
aged VBN VBN O
> NN NN O
or CC CC O
= SYM SYM O
65 CD CD O
years NNS NNS O
admitted VBD VBD O
to TO TO O
acute JJ JJ O
hospital NN NN O
wards NNS NNS O
during IN IN O
1 CD CD O
month NN NN O
. . . O

164 CD CD O
patients NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
+ NN NN O
/ NN NN O
- : : O
standard JJ JJ O
deviation NN NN O
[ NN NN O
SD NNP NNP O
] NN NN O
81 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
8 CD CD O
years NNS NNS O
) ) ) O
were VBD VBD O
admitted VBN VBN O
. . . O

Of IN IN O
these DT DT O
, , , O
nearly RB RB O
half NN NN O
( ( ( O
n NN NN O
= SYM SYM O
78 CD CD O
) ) ) O
had VBD VBD O
used VBN VBN O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
before IN IN O
admission NN NN O
, , , O
and CC CC O
the DT DT O
remainder NN NN O
( ( ( O
n NN NN O
= SYM SYM O
86 CD CD O
) ) ) O
were VBD VBD O
non NN NN O
- : : O
users NNS NNS O
. . . O

Cognitive NNP NNP O
ability NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
the DT DT O
Mini NNP NNP O
- : : O
Mental NNP NNP O
State NNP NNP O
Examination NNP NNP O
( ( ( O
MMSE NNP NNP O
) ) ) O
. . . O

Patients NNS NNS O
scoring VBG VBG O
> NN NN O
or CC CC O
= SYM SYM O
20 CD CD O
MMSE NNP NNP O
sum NN NN O
points NNS NNS O
were VBD VBD O
interviewed VBN VBN O
( ( ( O
n NN NN O
= SYM SYM O
79 CD CD O
) ) ) O
and CC CC O
questioned VBN VBN O
regarding VBG VBG O
symptoms NNS NNS O
and CC CC O
functional JJ JJ O
abilities NNS NNS O
during IN IN O
the DT DT O
week NN NN O
prior RB RB O
to TO TO O
admission NN NN O
. . . O

Data NNP NNP O
on IN IN O
use NN NN O
of IN IN O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
before IN IN O
admission NN NN O
, , , O
current JJ JJ O
medications NNS NNS O
and CC CC O
discharge NN NN O
diagnoses NNS NNS O
were VBD VBD O
collected VBN VBN O
from IN IN O
medical JJ JJ O
records NNS NNS O
. . . O

Health NNP NNP O
, , , O
physical JJ JJ O
abilities NNS NNS O
and CC CC O
cognitive JJ JJ O
function NN NN O
were VBD VBD O
compared VBN VBN O
between IN IN O
BZD NNP NNP O
/ NN NN O
RD NNP NNP O
users NNS NNS O
and CC CC O
non NN NN O
- : : O
users NNS NNS O
, , , O
and CC CC O
adjustments NNS NNS O
were VBD VBD O
made VBN VBN O
for IN IN O
confounding VBG VBG O
variables NNS NNS O
. . . O

The DT DT O
residual JJ JJ O
serum NN NN O
concentrations NNS NNS O
of IN IN O
oxazepam NN NN B-CHEM
, , , O
temazepam NN NN B-CHEM
and CC CC O
zopiclone NN NN B-CHEM
were VBD VBD O
analysed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
mean NN NN O
+ NN NN O
/ NN NN O
- : : O
SD NNP NNP O
duration NN NN O
of IN IN O
BZD NNP NNP O
/ NN NN O
RD NNP NNP O
use NN NN O
was VBD VBD O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
years NNS NNS O
( ( ( O
range NN NN O
1 CD CD O
- : : O
31 CD CD O
) ) ) O
. . . O

Two CD CD O
or CC CC O
three CD CD O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
were VBD VBD O
concomitantly RB RB O
taken VBN VBN O
by IN IN O
26 CD CD O
% NN NN O
of IN IN O
users NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
20 CD CD O
) ) ) O
. . . O

Long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
was VBD VBD O
associated VBN VBN O
with IN IN O
female JJ JJ O
sex NN NN O
and CC CC O
use NN NN O
of IN IN O
a DT DT O
higher JJR JJR O
number NN NN O
of IN IN O
drugs NNS NNS O
with IN IN O
effects NNS NNS O
on IN IN O
the DT DT O
CNS NNP NNP O
, , , O
which WDT WDT O
tended VBD VBD O
to TO TO O
be VB VB O
related VBN VBN O
to TO TO O
diagnosed JJ JJ O
dementia NN NN O
. . . O

After IN IN O
adjustment NN NN O
for IN IN O
these DT DT O
variables NNS NNS O
as IN IN O
confounders NNS NNS O
, , , O
use NN NN O
of IN IN O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
cognitive JJ JJ O
function NN NN O
as IN IN O
measured VBN VBN O
by IN IN O
the DT DT O
MMSE NNP NNP O
. . . O

However RB RB O
, , , O
use NN NN O
of IN IN O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
was VBD VBD O
associated VBN VBN O
with IN IN O
dizziness NN NN O
, , , O
inability NN NN O
to TO TO O
sleep VB VB O
after IN IN O
awaking VBG VBG O
at IN IN O
night NN NN O
and CC CC O
tiredness NN NN O
in IN IN O
the DT DT O
mornings NNS NNS O
during IN IN O
the DT DT O
week NN NN O
prior RB RB O
to TO TO O
admission NN NN O
and CC CC O
with IN IN O
stronger NN NN O
depressive JJ JJ O
symptoms NNS NNS O
measured VBN VBN O
at IN IN O
the DT DT O
beginning NN NN O
of IN IN O
the DT DT O
hospital NN NN O
stay NN NN O
. . . O

Use NN NN O
of IN IN O
BZDs NNP NNP B-CHEM
/ NN NN O
RDs NNP NNP O
tended VBD VBD O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
a DT DT O
reduced JJ JJ O
ability NN NN O
to TO TO O
walk VB VB O
and CC CC O
shorter JJR JJR O
night NN NN O
- - - O
time NN NN O
sleep NN NN O
during IN IN O
the DT DT O
week NN NN O
prior RB RB O
to TO TO O
admission NN NN O
. . . O

A DT DT O
higher JJR JJR O
residual JJ JJ O
serum NN NN O
concentration NN NN O
of IN IN O
temazepam NN NN B-CHEM
correlated JJ JJ O
with IN IN O
a DT DT O
lower JJR JJR O
MMSE NNP NNP O
sum NN NN O
score NN NN O
after IN IN O
adjustment NN NN O
for IN IN O
confounding VBG VBG O
variables NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Long JJ JJ O
- - - O
term NN NN O
use NN NN O
and CC CC O
concomitant JJ JJ O
use NN NN O
of IN IN O
more JJR JJR O
than IN IN O
one CD CD O
BZD NNP NNP O
/ NN NN O
RD NNP NNP O
were VBD VBD O
common JJ JJ O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
hospitalised VBN VBN O
because IN IN O
of IN IN O
acute JJ JJ O
illnesses NNS NNS O
. . . O

Long JJ JJ O
- - - O
term NN NN O
use NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
daytime JJ JJ O
and CC CC O
night NN NN O
- - - O
time NN NN O
symptoms NNS NNS O
indicative JJ JJ O
of IN IN O
poorer NN NN O
health NN NN O
and CC CC O
potentially RB RB O
caused VBN VBN O
by IN IN O
the DT DT O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
these DT DT O
drugs NNS NNS O
. . . O

Acute JJ JJ O
vocal JJ JJ O
fold NN NN O
palsy NN NN O
after IN IN O
acute JJ JJ O
disulfiram NN NN B-CHEM
intoxication NN NN O
. . . O

Acute JJ JJ O
peripheral JJ JJ O
neuropathy NN NN O
caused VBN VBN O
by IN IN O
a DT DT O
disulfiram NN NN B-CHEM
overdose NN NN O
is VBZ VBZ O
very RB RB O
rare JJ JJ O
and CC CC O
there EX EX O
is VBZ VBZ O
no DT DT O
report NN NN O
of IN IN O
it PRP PRP O
leading VBG VBG O
to TO TO O
vocal JJ JJ O
fold NN NN O
palsy NN NN O
. . . O

A DT DT O
49 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
was VBD VBD O
transferred VBN VBN O
to TO TO O
our PRP$ PRP$ O
department NN NN O
because IN IN O
of IN IN O
quadriparesis NN NN O
, , , O
lancinating VBG VBG O
pain NN NN O
, , , O
sensory JJ JJ O
loss NN NN O
, , , O
and CC CC O
paresthesia NN NN O
of IN IN O
the DT DT O
distal JJ JJ O
limbs NNS NNS O
. . . O

One CD CD O
month NN NN O
previously RB RB O
, , , O
she PRP PRP O
had VBD VBD O
taken VBN VBN O
a DT DT O
single JJ JJ O
high JJ JJ O
dose NN NN O
of IN IN O
disulfiram NN NN B-CHEM
( ( ( O
130 CD CD O
tablets NNS NNS O
of IN IN O
ALCOHOL NNP NNP B-CHEM
STOP NNP NNP O
TAB NNP NNP O
, , , O
Shin NNP NNP O
- : : O
Poong NNP NNP O
Pharm NNP NNP O
. . . O
Co NNP NNP O
. . . O
, , , O
Ansan NNP NNP O
, , , O
Korea NNP NNP O
) ) ) O
in IN IN O
a DT DT O
suicide NN NN O
attempt NN NN O
. . . O

She PRP PRP O
was VBD VBD O
not RB RB O
an DT DT O
alcoholic JJ JJ O
. . . O

For IN IN O
the DT DT O
first JJ JJ O
few JJ JJ O
days NNS NNS O
after IN IN O
ingestion NN NN O
, , , O
she PRP PRP O
was VBD VBD O
in IN IN O
a DT DT O
confused JJ JJ O
state NN NN O
and CC CC O
had VBD VBD O
mild JJ JJ O
to TO TO O
moderate VB VB O
ataxia NN NN O
and CC CC O
giddiness NN NN O
. . . O

She PRP PRP O
noticed VBD VBD O
hoarseness NN NN O
and CC CC O
distally RB RB O
accentuated JJ JJ O
motor NN NN O
and CC CC O
sensory JJ JJ O
dysfunction NN NN O
after IN IN O
she PRP PRP O
had VBD VBD O
recovered VBN VBN O
from IN IN O
this DT DT O
state NN NN O
. . . O

A DT DT O
nerve NN NN O
conduction NN NN O
study NN NN O
was VBD VBD O
consistent JJ JJ O
with IN IN O
severe JJ JJ O
sensorimotor NN NN O
axonal JJ JJ O
polyneuropathy NN NN O
. . . O

Laryngeal NNP NNP O
electromyography NN NN O
( ( ( O
thyroarytenoid NN NN O
muscle NN NN O
) ) ) O
showed VBD VBD O
ample JJ JJ O
denervation NN NN O
potentials NNS NNS O
. . . O

Laryngoscopy NNP NNP O
revealed VBD VBD O
asymmetric JJ JJ O
vocal JJ JJ O
fold NN NN O
movements NNS NNS O
during IN IN O
phonation NN NN O
. . . O

Her PRP$ PRP$ O
vocal JJ JJ O
change NN NN O
and CC CC O
weakness NN NN O
began VBD VBD O
to TO TO O
improve VB VB O
spontaneously RB RB O
about IN IN O
3 CD CD O
weeks NNS NNS O
after IN IN O
transfer NN NN O
. . . O

This DT DT O
was VBD VBD O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
palsy NN NN O
of IN IN O
the DT DT O
recurrent JJ JJ O
laryngeal NN NN O
nerve NN NN O
and CC CC O
superimposed VBN VBN O
severe JJ JJ O
acute JJ JJ O
sensorimotor NN NN O
axonal JJ JJ O
polyneuropathy NN NN O
caused VBN VBN O
by IN IN O
high JJ JJ O
- - - O
dose NN NN O
disulfiram NN NN B-CHEM
intoxication NN NN O
. . . O

Encephalopathy NNP NNP O
induced VBN VBN O
by IN IN O
levetiracetam NN NN B-CHEM
added VBD VBD O
to TO TO O
valproate NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
We PRP PRP O
report VBP VBP O
on IN IN O
the DT DT O
manifestation NN NN O
of IN IN O
a DT DT O
levetiracetam NN NN B-CHEM
( ( ( O
LEV NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
encephalopathy NN NN O
. . . O

FINDINGS NNS NNS O
: : : O
A DT DT O
28 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
suffering VBG VBG O
from IN IN O
idiopathic JJ JJ O
epilepsy NN NN O
with IN IN O
generalized JJ JJ O
seizures NNS NNS O
was VBD VBD O
treated VBN VBN O
with IN IN O
LEV NNP NNP B-CHEM
( ( ( O
3000 CD CD O
mg NN NN O
) ) ) O
added VBD VBD O
to TO TO O
valproate NN NN B-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
( ( ( O
2000 CD CD O
mg NN NN O
) ) ) O
. . . O

Frequency NNP NNP O
of IN IN O
generalized JJ JJ O
tonic NN NN O
- - - O
clonic JJ JJ O
seizures NNS NNS O
increased VBN VBN O
from IN IN O
one CD CD O
per IN IN O
6 CD CD O
months NNS NNS O
to TO TO O
two CD CD O
per IN IN O
month NN NN O
. . . O

Neuropsychological NNP NNP O
testing NN NN O
showed VBD VBD O
impaired VBN VBN O
word NN NN O
fluency NN NN O
, , , O
psychomotor NN NN O
speed NN NN O
and CC CC O
working VBG VBG O
memory NN NN O
. . . O

The DT DT O
interictal JJ JJ O
electroencephalogram NN NN O
( ( ( O
EEG NNP NNP O
) ) ) O
showed VBD VBD O
a DT DT O
generalized JJ JJ O
slowing VBG VBG O
to TO TO O
5 CD CD O
per IN IN O
second NN NN O
theta NN NN O
rhythms NNS NNS O
with IN IN O
bilateral JJ JJ O
generalized JJ JJ O
high JJ JJ O
- - - O
amplitude NN NN O
discharges NNS NNS O
. . . O

OUTCOME NNP NNP O
: : : O
Following VBG VBG O
discontinuation NN NN O
of IN IN O
LEV NNP NNP B-CHEM
, , , O
EEG NNP NNP O
and CC CC O
neuropsychological JJ JJ O
findings NNS NNS O
improved VBN VBN O
and CC CC O
seizure JJ JJ O
frequency NN NN O
decreased VBD VBD O
. . . O

Norepinephrine NNP NNP B-CHEM
signaling VBG VBG O
through IN IN O
beta NN NN O
- - - O
adrenergic JJ JJ O
receptors NNS NNS O
is VBZ VBZ O
critical JJ JJ O
for IN IN O
expression NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
anxiety NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Cocaine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
widely RB RB O
abused VBN VBN O
psychostimulant NN NN O
that WDT WDT O
has VBZ VBZ O
both DT DT O
rewarding NN NN O
and CC CC O
aversive JJ JJ O
properties NNS NNS O
. . . O

While IN IN O
the DT DT O
mechanisms NNS NNS O
underlying VBG VBG O
cocaine NN NN B-CHEM
' '' '' O
s VBZ VBZ O
rewarding JJ JJ O
effects NNS NNS O
have VBP VBP O
been VBN VBN O
studied VBN VBN O
extensively RB RB O
, , , O
less JJR JJR O
attention NN NN O
has VBZ VBZ O
been VBN VBN O
paid VBN VBN O
to TO TO O
the DT DT O
unpleasant JJ JJ O
behavioral JJ JJ O
states NNS NNS O
induced VBN VBN O
by IN IN O
cocaine NN NN B-CHEM
, , , O
such JJ JJ O
as IN IN O
anxiety NN NN O
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
evaluated VBD VBD O
the DT DT O
performance NN NN O
of IN IN O
dopamine NN NN B-CHEM
beta NN NN O
- : : O
hydroxylase NN NN O
knockout NN NN O
( ( ( O
Dbh NNP NNP O
- - - O
/ NN NN O
- - - O
) ) ) O
mice NN NN O
, , , O
which WDT WDT O
lack NN NN O
norepinephrine NN NN B-CHEM
( ( ( O
NE NNP NNP B-CHEM
) ) ) O
, , , O
in IN IN O
the DT DT O
elevated JJ JJ O
plus CC CC O
maze NN NN O
( ( ( O
EPM NNP NNP O
) ) ) O
to TO TO O
examine VB VB O
the DT DT O
contribution NN NN O
of IN IN O
noradrenergic JJ JJ O
signaling VBG VBG O
to TO TO O
cocaine VB VB B-CHEM
- : : O
induced JJ JJ O
anxiety NN NN O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
found VBD VBD O
that IN IN O
cocaine NN NN B-CHEM
dose NN NN O
- : : O
dependently RB RB O
increased VBN VBN O
anxiety NN NN O
- - - O
like IN IN O
behavior NN NN O
in IN IN O
control NN NN O
( ( ( O
Dbh NNP NNP O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
, , , O
as IN IN O
measured VBN VBN O
by IN IN O
a DT DT O
decrease NN NN O
in IN IN O
open JJ JJ O
arm NN NN O
exploration NN NN O
. . . O

The DT DT O
Dbh NNP NNP O
- - - O
/ NN NN O
- - - O
mice NN NN O
had VBD VBD O
normal JJ JJ O
baseline NN NN O
performance NN NN O
in IN IN O
the DT DT O
EPM NNP NNP O
but CC CC O
were VBD VBD O
completely RB RB O
resistant JJ JJ O
to TO TO O
the DT DT O
anxiogenic JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
. . . O

Cocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
anxiety NN NN O
was VBD VBD O
also RB RB O
attenuated VBN VBN O
in IN IN O
Dbh NNP NNP O
+ NN NN O
/ NN NN O
- : : O
mice NN NN O
following VBG VBG O
administration NN NN O
of IN IN O
disulfiram NN NN B-CHEM
, , , O
a DT DT O
dopamine NN NN B-CHEM
beta NN NN O
- : : O
hydroxylase NN NN O
( ( ( O
DBH NNP NNP O
) ) ) O
inhibitor NN NN O
. . . O

In IN IN O
experiments NNS NNS O
using VBG VBG O
specific JJ JJ O
adrenergic JJ JJ O
antagonists NNS NNS O
, , , O
we PRP PRP O
found VBD VBD O
that IN IN O
pretreatment NN NN O
with IN IN O
the DT DT O
beta NN NN O
- - - O
adrenergic JJ JJ O
receptor NN NN O
antagonist NN NN O
propranolol NN NN B-CHEM
blocked VBN VBN O
cocaine JJ JJ B-CHEM
- - - O
induced JJ JJ O
anxiety NN NN O
- - - O
like IN IN O
behavior NN NN O
in IN IN O
Dbh NNP NNP O
+ NN NN O
/ NN NN O
- : : O
and CC CC O
wild JJ JJ O
- - - O
type NN NN O
C57BL6 NNP NNP O
/ NN NN O
J NNP NNP O
mice NN NN O
, , , O
while IN IN O
the DT DT O
alpha NN NN O
( ( ( O
1 CD CD O
) ) ) O
antagonist NN NN O
prazosin NN NN B-CHEM
and CC CC O
the DT DT O
alpha NN NN O
( ( ( O
2 CD CD O
) ) ) O
antagonist NN NN O
yohimbine NN NN B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
noradrenergic JJ JJ O
signaling VBG VBG O
via IN IN O
beta NN NN O
- - - O
adrenergic JJ JJ O
receptors NNS NNS O
is VBZ VBZ O
required VBN VBN O
for IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
anxiety NN NN O
in IN IN O
mice NN NN O
. . . O

Hypothalamic NNP NNP O
prolactin NN NN O
receptor NN NN O
messenger NN NN O
ribonucleic JJ JJ B-CHEM
acid NN NN I-CHEM
levels NNS NNS O
, , , O
prolactin NN NN O
signaling VBG VBG O
, , , O
and CC CC O
hyperprolactinemic JJ JJ O
inhibition NN NN O
of IN IN O
pulsatile NN NN O
luteinizing VBG VBG O
hormone NN NN O
secretion NN NN O
are VBP VBP O
dependent JJ JJ O
on IN IN O
estradiol NN NN B-CHEM
. . . O

Hyperprolactinemia NNP NNP O
can MD MD O
reduce VB VB O
fertility NN NN O
and CC CC O
libido NN NN O
. . . O

Although IN IN O
central JJ JJ O
prolactin NN NN O
actions NNS NNS O
are VBP VBP O
thought VBN VBN O
to TO TO O
contribute VB VB O
to TO TO O
this DT DT O
, , , O
the DT DT O
mechanisms NNS NNS O
are VBP VBP O
poorly RB RB O
understood VBN VBN O
. . . O

We PRP PRP O
first JJ JJ O
tested VBD VBD O
whether IN IN O
chronic JJ JJ O
hyperprolactinemia NN NN O
inhibited VBD VBD O
two CD CD O
neuroendocrine NN NN O
parameters NNS NNS O
necessary JJ JJ O
for IN IN O
female JJ JJ O
fertility NN NN O
: : : O
pulsatile NN NN O
LH NNP NNP O
secretion NN NN O
and CC CC O
the DT DT O
estrogen NN NN B-CHEM
- - - O
induced JJ JJ O
LH NNP NNP O
surge NN NN O
. . . O

Chronic NNP NNP O
hyperprolactinemia NN NN O
induced VBN VBN O
by IN IN O
the DT DT O
dopamine NN NN B-CHEM
antagonist NN NN O
sulpiride NN NN B-CHEM
caused VBD VBD O
a DT DT O
40 CD CD O
% NN NN O
reduction NN NN O
LH NNP NNP O
pulse NN NN O
frequency NN NN O
in IN IN O
ovariectomized JJ JJ O
rats NNS NNS O
, , , O
but CC CC O
only RB RB O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
chronic JJ JJ O
low JJ JJ O
levels NNS NNS O
of IN IN O
estradiol NN NN B-CHEM
. . . O

Sulpiride NNP NNP B-CHEM
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
magnitude NN NN O
of IN IN O
a DT DT O
steroid NN NN B-CHEM
- - - O
induced JJ JJ O
LH NNP NNP O
surge NN NN O
or CC CC O
the DT DT O
percentage NN NN O
of IN IN O
GnRH NNP NNP O
neurons NNS NNS O
activated VBN VBN O
during IN IN O
the DT DT O
surge NN NN O
. . . O

Estradiol NNP NNP B-CHEM
is VBZ VBZ O
known VBN VBN O
to TO TO O
influence VB VB O
expression NN NN O
of IN IN O
the DT DT O
long JJ JJ O
form NN NN O
of IN IN O
prolactin NN NN O
receptors NNS NNS O
( ( ( O
PRL NNP NNP O
- - - O
R NN NN O
) ) ) O
and CC CC O
components NNS NNS O
of IN IN O
prolactin NN NN O
' '' '' O
s VBZ VBZ O
signaling VBG VBG O
pathway NN NN O
. . . O

To TO TO O
test VB VB O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
estrogen NN NN B-CHEM
increases NNS NNS O
PRL NNP NNP O
- : : O
R NN NN O
expression NN NN O
and CC CC O
sensitivity NN NN O
to TO TO O
prolactin NN NN O
, , , O
we PRP PRP O
next JJ JJ O
demonstrated VBN VBN O
that IN IN O
estradiol NN NN B-CHEM
greatly RB RB O
augments NNS NNS O
prolactin NN NN O
- : : O
induced JJ JJ O
STAT5 NNP NNP O
activation NN NN O
. . . O

Lastly NNP NNP O
, , , O
we PRP PRP O
measured VBD VBD O
PRL NNP NNP O
- : : O
R NN NN O
and CC CC O
suppressor NN NN O
of IN IN O
cytokine NN NN O
signaling VBG VBG O
( ( ( O
SOCS NNP NNP O
- : : O
1 CD CD O
and CC CC O
- : : O
3 CD CD O
and CC CC O
CIS NNP NNP O
, , , O
which WDT WDT O
reflect VBP VBP O
the DT DT O
level NN NN O
of IN IN O
prolactin NN NN O
signaling VBG VBG O
) ) ) O
mRNAs NN NN O
in IN IN O
response NN NN O
to TO TO O
sulpiride VB VB B-CHEM
and CC CC O
estradiol VB VB B-CHEM
. . . O

Sulpiride NNP NNP B-CHEM
induced VBD VBD O
only RB RB O
SOCS NNP NNP O
- : : O
1 CD CD O
in IN IN O
the DT DT O
medial JJ JJ O
preoptic JJ JJ O
area NN NN O
, , , O
where WRB WRB O
GnRH NNP NNP O
neurons NNS NNS O
are VBP VBP O
regulated VBN VBN O
, , , O
but CC CC O
in IN IN O
the DT DT O
arcuate NN NN O
nucleus NN NN O
and CC CC O
choroid NN NN O
plexus NN NN O
, , , O
PRL NNP NNP O
- : : O
R NN NN O
, , , O
SOCS NNP NNP O
- : : O
3 CD CD O
, , , O
and CC CC O
CIS NNP NNP O
mRNA NN NN O
levels NNS NNS O
were VBD VBD O
also RB RB O
induced VBN VBN O
. . . O

Estradiol NNP NNP B-CHEM
enhanced VBD VBD O
these DT DT O
effects NNS NNS O
on IN IN O
SOCS NNP NNP O
- : : O
3 CD CD O
and CC CC O
CIS NNP NNP O
. . . O

Interestingly RB RB O
, , , O
estradiol NN NN B-CHEM
also RB RB O
induced VBD VBD O
PRL NNP NNP O
- : : O
R NN NN O
, , , O
SOCS NNP NNP O
- : : O
3 CD CD O
, , , O
and CC CC O
CIS NNP NNP O
mRNA NN NN O
levels NNS NNS O
independently RB RB O
. . . O

These DT DT O
data NNS NNS O
show VBP VBP O
that IN IN O
GnRH NNP NNP O
pulse NN NN O
frequency NN NN O
is VBZ VBZ O
inhibited VBN VBN O
by IN IN O
chronic JJ JJ O
hyperprolactinemia NN NN O
in IN IN O
a DT DT O
steroid NN NN B-CHEM
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

They PRP PRP O
also RB RB O
provide VBP VBP O
evidence NN NN O
for IN IN O
estradiol NN NN B-CHEM
- - - O
dependent JJ JJ O
and CC CC O
brain NN NN O
region NN NN O
- : : O
specific JJ JJ O
regulation NN NN O
of IN IN O
PRL NNP NNP O
- : : O
R NN NN O
expression NN NN O
and CC CC O
signaling VBG VBG O
responses NNS NNS O
by IN IN O
prolactin NN NN O
. . . O

Clonidine NNP NNP B-CHEM
for IN IN O
attention NN NN O
- - - O
deficit NN NN O
/ NN NN O
hyperactivity NN NN O
disorder NN NN O
: : : O
II NNP NNP O
. . . O

ECG NNP NNP O
changes NNS NNS O
and CC CC O
adverse JJ JJ O
events NNS NNS O
analysis NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
examine VB VB O
the DT DT O
safety NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
clonidine NN NN B-CHEM
used VBN VBN O
alone RB RB O
or CC CC O
with IN IN O
methylphenidate NN NN B-CHEM
in IN IN O
children NNS NNS O
with IN IN O
attention NN NN O
- - - O
deficit NN NN O
/ NN NN O
hyperactivity NN NN O
disorder NN NN O
( ( ( O
ADHD NNP NNP O
) ) ) O
. . . O

METHOD NNP NNP O
: : : O
In IN IN O
a DT DT O
16 CD CD O
- : : O
week NN NN O
multicenter NN NN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
, , , O
122 CD CD O
children NNS NNS O
with IN IN O
ADHD NNP NNP O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
clonidine VB VB B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
31 CD CD O
) ) ) O
, , , O
methylphenidate NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
29 CD CD O
) ) ) O
, , , O
clonidine NN NN B-CHEM
and CC CC O
methylphenidate NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
32 CD CD O
) ) ) O
, , , O
or CC CC O
placebo NN NN O
( ( ( O
n NN NN O
= SYM SYM O
30 CD CD O
) ) ) O
. . . O

Doses NNP NNP O
were VBD VBD O
flexibly RB RB O
titrated VBN VBN O
up RP RP O
to TO TO O
0 CD CD O
. . . O
6 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
clonidine NN NN B-CHEM
and CC CC O
60 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
methylphenidate NN NN B-CHEM
( ( ( O
both DT DT O
with IN IN O
divided VBN VBN O
dosing VBG VBG O
) ) ) O
. . . O

Groups NNS NNS O
were VBD VBD O
compared VBN VBN O
regarding VBG VBG O
adverse JJ JJ O
events NNS NNS O
and CC CC O
changes NNS NNS O
from IN IN O
baseline NN NN O
to TO TO O
week NN NN O
16 CD CD O
in IN IN O
electrocardiograms NNS NNS O
and CC CC O
vital JJ JJ O
signs NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
There EX EX O
were VBD VBD O
more JJR JJR O
incidents NNS NNS O
of IN IN O
bradycardia NN NN O
in IN IN O
subjects NNS NNS O
treated VBN VBN O
with IN IN O
clonidine NN NN B-CHEM
compared VBN VBN O
with IN IN O
those DT DT O
not RB RB O
treated VBN VBN O
with IN IN O
clonidine NN NN B-CHEM
( ( ( O
17 CD CD O
. . . O
5 CD CD O
% NN NN O
versus CC CC O
3 CD CD O
. . . O
4 CD CD O
% NN NN O
; : : O
p NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
, , , O
but CC CC O
no DT DT O
other JJ JJ O
significant JJ JJ O
group NN NN O
differences NNS NNS O
regarding VBG VBG O
electrocardiogram NN NN O
and CC CC O
other JJ JJ O
cardiovascular JJ JJ O
outcomes NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
suggestions NNS NNS O
of IN IN O
interactions NNS NNS O
between IN IN O
clonidine NN NN B-CHEM
and CC CC O
methylphenidate NN NN B-CHEM
regarding VBG VBG O
cardiovascular JJ JJ O
outcomes NNS NNS O
. . . O

Moderate NNP NNP O
or CC CC O
severe JJ JJ O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
more RBR RBR O
common JJ JJ O
in IN IN O
subjects NNS NNS O
on IN IN O
clonidine NN NN B-CHEM
( ( ( O
79 CD CD O
. . . O
4 CD CD O
% NN NN O
versus CC CC O
49 CD CD O
. . . O
2 CD CD O
% NN NN O
; : : O
p NN NN O
= SYM SYM O
. . . O
0006 CD CD O
) ) ) O
but CC CC O
not RB RB O
associated VBN VBN O
with IN IN O
higher JJR JJR O
rates NNS NNS O
of IN IN O
early JJ JJ O
study NN NN O
withdrawal NN NN O
. . . O

Drowsiness NNP NNP O
was VBD VBD O
common JJ JJ O
on IN IN O
clonidine NN NN B-CHEM
, , , O
but CC CC O
generally RB RB O
resolved VBN VBN O
by IN IN O
6 CD CD O
to TO TO O
8 CD CD O
weeks NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Clonidine NNP NNP B-CHEM
, , , O
used VBD VBD O
alone RB RB O
or CC CC O
with IN IN O
methylphenidate NN NN B-CHEM
, , , O
appears VBZ VBZ O
safe JJ JJ O
and CC CC O
well RB RB O
tolerated VBN VBN O
in IN IN O
childhood NN NN O
ADHD NNP NNP O
. . . O

Physicians NNP NNP O
prescribing VBG VBG O
clonidine NN NN B-CHEM
should MD MD O
monitor VB VB O
for IN IN O
bradycardia NN NN O
and CC CC O
advise VB VB O
patients NNS NNS O
about IN IN O
the DT DT O
high JJ JJ O
likelihood NN NN O
of IN IN O
initial JJ JJ O
drowsiness NN NN O
. . . O

Renal NNP NNP O
Fanconi NNP NNP O
syndrome NN NN O
and CC CC O
myopathy NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
: : : O
drug NN NN O
- - - O
related VBN VBN O
mitochondrial JJ JJ O
cytopathy NN NN O
? . . O

Advances NNP NNP O
in IN IN O
the DT DT O
field NN NN O
of IN IN O
transplantation NN NN O
provide VBP VBP O
a DT DT O
better JJR JJR O
quality NN NN O
of IN IN O
life NN NN O
and CC CC O
allow VB VB O
more RBR RBR O
favorable JJ JJ O
conditions NNS NNS O
for IN IN O
growth NN NN O
and CC CC O
development NN NN O
in IN IN O
children NNS NNS O
. . . O

However RB RB O
, , , O
combinations NNS NNS O
of IN IN O
different JJ JJ O
therapeutic JJ JJ O
regimens NNS NNS O
require VBP VBP O
consideration NN NN O
of IN IN O
potential JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
15 CD CD O
- : : O
yr NN NN O
- - - O
old JJ JJ O
girl NN NN O
who WP WP O
had VBD VBD O
orthotopic JJ JJ O
liver NN NN O
transplantation NN NN O
because IN IN O
of IN IN O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Tacrolimus NNP NNP B-CHEM
, , , O
MMF NNP NNP B-CHEM
, , , O
and CC CC O
steroids NNS NNS B-CHEM
were VBD VBD O
given VBN VBN O
as IN IN O
immunosuppressant NN NN O
. . . O

Lamivudine NNP NNP B-CHEM
was VBD VBD O
added VBN VBN O
because IN IN O
of IN IN O
de IN IN O
nova NN NN O
hepatitis NN NN O
B NNP NNP O
infection NN NN O
during IN IN O
her PRP$ PRP$ O
follow VB VB O
- - - O
up RP RP O
. . . O

Three CD CD O
yr NN NN O
after IN IN O
transplantation NN NN O
she PRP PRP O
developed VBD VBD O
renal JJ JJ O
Fanconi NNP NNP O
syndrome NN NN O
with IN IN O
severe JJ JJ O
metabolic JJ JJ O
acidosis NN NN O
, , , O
hypophosphatemia NN NN O
, , , O
glycosuria NN NN O
, , , O
and CC CC O
aminoaciduria NN NN O
. . . O

Although IN IN O
tacrolimus NN NN B-CHEM
was VBD VBD O
suspected VBN VBN O
to TO TO O
be VB VB O
the DT DT O
cause NN NN O
of IN IN O
late JJ JJ O
post NN NN O
- : : O
transplant NN NN O
renal JJ JJ O
acidosis NN NN O
and CC CC O
was VBD VBD O
replaced VBN VBN O
by IN IN O
sirolimus NN NN B-CHEM
, , , O
acidosis NN NN O
, , , O
and CC CC O
electrolyte NN NN O
imbalance NN NN O
got VBD VBD O
worse JJR JJR O
. . . O

Proximal NNP NNP O
muscle NN NN O
weakness NN NN O
has VBZ VBZ O
developed VBN VBN O
during IN IN O
her PRP$ PRP$ O
follow VB VB O
- - - O
up RP RP O
. . . O

Fanconi NNP NNP O
syndrome NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
myopathy NN NN O
, , , O
is VBZ VBZ O
well RB RB O
recognized VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
mitochondrial JJ JJ O
disorders NNS NNS O
and CC CC O
caused VBN VBN O
by IN IN O
depletion NN NN O
of IN IN O
mtDNA NN NN O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
our PRP$ PRP$ O
patient NN NN O
' POS POS O
s VBZ VBZ O
tubular NN NN O
dysfunction NN NN O
and CC CC O
myopathy NN NN O
may MD MD O
have VB VB O
resulted VBN VBN O
from IN IN O
mitochondrial JJ JJ O
dysfunction NN NN O
which WDT WDT O
is VBZ VBZ O
triggered VBN VBN O
by IN IN O
tacrolimus NN NN B-CHEM
and CC CC O
augmented VBN VBN O
by IN IN O
lamivudine NN NN B-CHEM
. . . O

Higher JJR JJR O
optical JJ JJ O
density NN NN O
of IN IN O
an DT DT O
antigen NN NN O
assay NN NN O
predicts NNS NNS O
thrombosis NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
correlate VB VB O
optical JJ JJ O
density NN NN O
and CC CC O
percent NN NN O
inhibition NN NN O
of IN IN O
a DT DT O
two CD CD O
- - - O
step NN NN O
heparin NN NN B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
( ( ( O
HIT NNP NNP O
) ) ) O
antigen NN NN O
assay NN NN O
with IN IN O
thrombosis NN NN O
; : : O
the DT DT O
assay NN NN O
utilizes JJ JJ O
reaction NN NN O
inhibition NN NN O
characteristics NNS NNS O
of IN IN O
a DT DT O
high JJ JJ O
heparin NN NN B-CHEM
concentration NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Patients NNS NNS O
with IN IN O
more JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
decrease NN NN O
in IN IN O
platelet NN NN O
count NN NN O
or CC CC O
thrombocytopenia NN NN O
( ( ( O
< NN NN O
150 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
L NNP NNP O
) ) ) O
after IN IN O
exposure NN NN O
to TO TO O
heparin NN NN B-CHEM
, , , O
who WP WP O
had VBD VBD O
a DT DT O
positive JJ JJ O
two CD CD O
- - - O
step NN NN O
antigen NN NN O
assay NN NN O
[ NN NN O
optical JJ JJ O
density NN NN O
( ( ( O
OD NNP NNP O
) ) ) O
> NN NN O
0 CD CD O
. . . O
4 CD CD O
and CC CC O
> NN NN O
50 CD CD O
inhibition NN NN O
with IN IN O
high JJ JJ O
concentration NN NN O
of IN IN O
heparin NN NN B-CHEM
] NN NN O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
study NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Forty NNP NNP O
of IN IN O
94 CD CD O
HIT NNP NNP O
patients NNS NNS O
had VBD VBD O
thrombosis NN NN O
at IN IN O
diagnosis NN NN O
; : : O
54 CD CD O
/ NN NN O
94 CD CD O
had VBD VBD O
isolated VBN VBN O
- : : O
HIT NNP NNP O
without IN IN O
thrombosis NNS NNS O
. . . O

Eight CD CD O
of IN IN O
the DT DT O
isolated JJ JJ O
- - - O
HIT NNP NNP O
patients NNS NNS O
developed VBD VBD O
thrombosis NN NN O
within IN IN O
the DT DT O
next JJ JJ O
30 CD CD O
d SYM SYM O
; : : O
thus RB RB O
, , , O
a DT DT O
total NN NN O
of IN IN O
48 CD CD O
patients NNS NNS O
had VBD VBD O
thrombosis NN NN O
at IN IN O
day NN NN O
30 CD CD O
. . . O

At IN IN O
diagnosis NN NN O
there EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
OD NNP NNP O
between IN IN O
HIT NNP NNP O
patients NNS NNS O
with IN IN O
thrombosis NN NN O
and CC CC O
those DT DT O
with IN IN O
isolated JJ JJ O
- - - O
HIT NNP NNP O
. . . O

However RB RB O
, , , O
OD NNP NNP O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
all DT DT O
patients NNS NNS O
with IN IN O
thrombosis NN NN O
( ( ( O
n NN NN O
= SYM SYM O
48 CD CD O
, , , O
1 CD CD O
. . . O
34 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
89 CD CD O
) ) ) O
, , , O
including VBG VBG O
isolated VBN VBN O
- : : O
HIT NNP NNP O
patients NNS NNS O
who WP WP O
later RB RB O
developed VBN VBN O
thrombosis NN NN O
within IN IN O
30 CD CD O
d SYM SYM O
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
, , , O
1 CD CD O
. . . O
84 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
64 CD CD O
) ) ) O
as IN IN O
compared VBN VBN O
to TO TO O
isolated JJ JJ O
- : : O
HIT NNP NNP O
patients NNS NNS O
who WP WP O
did VBD VBD O
not RB RB O
develop VB VB O
thrombosis NNS NNS O
( ( ( O
0 CD CD O
. . . O
96 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
75 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
011 CD CD O
and CC CC O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
008 CD CD O
) ) ) O
. . . O

The DT DT O
Receiver NNP NNP O
Operative NNP NNP O
Characteristic NNP NNP O
Curve NNP NNP O
showed VBD VBD O
that IN IN O
OD NNP NNP O
> NN NN O
1 CD CD O
. . . O
27 CD CD O
in IN IN O
the DT DT O
isolated JJ JJ O
- - - O
HIT NNP NNP O
group NN NN O
had VBD VBD O
a DT DT O
significantly RB RB O
higher JJR JJR O
chance NN NN O
of IN IN O
developing VBG VBG O
thrombosis NN NN O
by IN IN O
day NN NN O
30 CD CD O
. . . O

None NN NN O
of IN IN O
these DT DT O
groups NNS NNS O
showed VBD VBD O
significant JJ JJ O
difference NN NN O
in IN IN O
percent NN NN O
inhibition NN NN O
. . . O

Multivariate NNP NNP O
analysis NN NN O
showed VBD VBD O
a DT DT O
2 CD CD O
. . . O
8 CD CD O
- : : O
fold VB VB O
increased VBN VBN O
risk NN NN O
of IN IN O
thrombosis NN NN O
in IN IN O
females NNS NNS O
. . . O

Similarly RB RB O
, , , O
thrombotic JJ JJ O
risk NN NN O
increased VBN VBN O
with IN IN O
age NN NN O
and CC CC O
OD NNP NNP O
values NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Higher JJR JJR O
OD NNP NNP O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
significant JJ JJ O
risk NN NN O
of IN IN O
subsequent JJ JJ O
thrombosis NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
isolated VBN VBN O
- : : O
HIT NNP NNP O
; : : O
percent NN NN O
inhibition NN NN O
, , , O
however RB RB O
, , , O
was VBD VBD O
not RB RB O
predictive JJ JJ O
. . . O

Thalidomide NNP NNP B-CHEM
has VBZ VBZ O
limited VBN VBN O
single JJ JJ O
- - - O
agent NN NN O
activity NN NN O
in IN IN O
relapsed JJ JJ O
or CC CC O
refractory JJ JJ O
indolent NN NN O
non NN NN O
- : : O
Hodgkin NNP NNP O
lymphomas NNS NNS O
: : : O
a DT DT O
phase NN NN O
II NNP NNP O
trial NN NN O
of IN IN O
the DT DT O
Cancer NNP NNP O
and CC CC O
Leukemia NNP NNP O
Group NNP NNP O
B NNP NNP O
. . . O

Thalidomide NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
immunomodulatory JJ JJ O
agent NN NN O
with IN IN O
demonstrated VBN VBN O
activity NN NN O
in IN IN O
multiple JJ JJ O
myeloma NN NN O
, , , O
mantle JJ JJ O
cell NN NN O
lymphoma NN NN O
and CC CC O
lymphoplasmacytic JJ JJ O
lymphoma NN NN O
. . . O

Its PRP$ PRP$ O
activity NN NN O
is VBZ VBZ O
believed VBN VBN O
to TO TO O
be VB VB O
due JJ JJ O
modulation NN NN O
of IN IN O
the DT DT O
tumour NN NN O
milieu NN NN O
, , , O
including VBG VBG O
downregulation NN NN O
of IN IN O
angiogenesis NN NN O
and CC CC O
inflammatory JJ JJ O
cytokines NNS NNS O
. . . O

Between IN IN O
July NNP NNP O
2001 CD CD O
and CC CC O
April NNP NNP O
2004 CD CD O
, , , O
24 CD CD O
patients NNS NNS O
with IN IN O
relapsed JJ JJ O
/ NN NN O
refractory NN NN O
indolent NN NN O
lymphomas NNS NNS O
received VBD VBD O
thalidomide NN NN B-CHEM
200 CD CD O
mg NN NN O
daily JJ JJ O
with IN IN O
escalation NN NN O
by IN IN O
100 CD CD O
mg NN NN O
daily JJ JJ O
every DT DT O
1 CD CD O
- : : O
2 CD CD O
weeks NNS NNS O
as IN IN O
tolerated VBN VBN O
, , , O
up RB RB O
to TO TO O
a DT DT O
maximum NN NN O
of IN IN O
800 CD CD O
mg NN NN O
daily JJ JJ O
. . . O

Patients NNS NNS O
had VBD VBD O
received VBN VBN O
a DT DT O
median NN NN O
of IN IN O
2 CD CD O
( ( ( O
range NN NN O
, , , O
1 CD CD O
- : : O
4 CD CD O
) ) ) O
prior RB RB O
regimens VBZ VBZ O
. . . O

Of IN IN O
24 CD CD O
evaluable JJ JJ O
patients NNS NNS O
, , , O
two CD CD O
achieved VBD VBD O
a DT DT O
complete JJ JJ O
remission NN NN O
and CC CC O
one CD CD O
achieved VBD VBD O
a DT DT O
partial JJ JJ O
remission NN NN O
for IN IN O
an DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
of IN IN O
12 CD CD O
. . . O
5 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
: : : O
2 CD CD O
. . . O
6 CD CD O
- : : O
32 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
. . . O

Eleven CD CD O
patients NNS NNS O
progressed VBD VBD O
during IN IN O
therapy NN NN O
. . . O

Grade NNP NNP O
3 CD CD O
- : : O
4 CD CD O
adverse JJ JJ O
effects NNS NNS O
included VBD VBD O
myelosuppression NN NN O
, , , O
fatigue NN NN O
, , , O
somnolence NN NN O
/ NN NN O
depressed VBN VBN O
mood NN NN O
, , , O
neuropathy JJ JJ O
and CC CC O
dyspnea NN NN O
. . . O

Of IN IN O
concern NN NN O
was VBD VBD O
the DT DT O
occurrence NN NN O
of IN IN O
four CD CD O
thromboembolic JJ JJ O
events NNS NNS O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
failed VBD VBD O
to TO TO O
demonstrate VB VB O
an DT DT O
important JJ JJ O
response NN NN O
rate NN NN O
to TO TO O
single JJ JJ O
agent NN NN O
thalidomide NN NN B-CHEM
in IN IN O
indolent NN NN O
lymphomas NN NN O
and CC CC O
contrast NN NN O
with IN IN O
the DT DT O
higher JJR JJR O
activity NN NN O
level NN NN O
reported VBN VBN O
with IN IN O
the DT DT O
second JJ JJ O
generation NN NN O
immunomodulatory JJ JJ O
agent NN NN O
, , , O
lenalidomide NN NN B-CHEM
. . . O

Sex NN NN O
differences NNS NNS O
in IN IN O
NMDA NNP NNP B-CHEM
antagonist NN NN O
enhancement NN NN O
of IN IN O
morphine NN NN B-CHEM
antihyperalgesia NN NN O
in IN IN O
a DT DT O
capsaicin NN NN B-CHEM
model NN NN O
of IN IN O
persistent JJ JJ O
pain NN NN O
: : : O
comparisons NNS NNS O
to TO TO O
two CD CD O
models NNS NNS O
of IN IN O
acute JJ JJ O
pain NN NN O
. . . O

In IN IN O
acute JJ JJ O
pain NN NN O
models NNS NNS O
, , , O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
antagonists NNS NNS O
enhance NN NN O
the DT DT O
antinociceptive JJ JJ O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
to TO TO O
a DT DT O
greater JJR JJR O
extent NN NN O
in IN IN O
males NNS NNS O
than IN IN O
females NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
investigation NN NN O
was VBD VBD O
to TO TO O
extend VB VB O
these DT DT O
findings NNS NNS O
to TO TO O
a DT DT O
persistent JJ JJ O
pain NN NN O
model NN NN O
which WDT WDT O
could MD MD O
be VB VB O
distinguished VBN VBN O
from IN IN O
acute JJ JJ O
pain NN NN O
models NNS NNS O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
the DT DT O
nociceptive JJ JJ O
fibers NNS NNS O
activated VBD VBD O
, , , O
neurochemical JJ JJ O
substrates NNS NNS O
, , , O
and CC CC O
duration NN NN O
of IN IN O
the DT DT O
nociceptive JJ JJ O
stimulus NN NN O
. . . O

To TO TO O
this DT DT O
end NN NN O
, , , O
persistent JJ JJ O
hyperalgesia NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
administration NN NN O
of IN IN O
capsaicin NN NN B-CHEM
in IN IN O
the DT DT O
tail NN NN O
of IN IN O
gonadally RB RB O
intact JJ JJ O
F344 NNP NNP O
rats NNS NNS O
, , , O
following VBG VBG O
which WDT WDT O
the DT DT O
tail NN NN O
was VBD VBD O
immersed VBN VBN O
in IN IN O
a DT DT O
mildly RB RB O
noxious JJ JJ O
thermal NN NN O
stimulus NN NN O
, , , O
and CC CC O
tail NN NN O
- : : O
withdrawal NN NN O
latencies NNS NNS O
measured VBN VBN O
. . . O

For IN IN O
comparison NN NN O
, , , O
tests NNS NNS O
were VBD VBD O
conducted VBN VBN O
in IN IN O
two CD CD O
acute JJ JJ O
pain NN NN O
models NNS NNS O
, , , O
the DT DT O
hotplate NN NN O
and CC CC O
warm JJ JJ O
water NN NN O
tail NN NN O
- : : O
withdrawal NN NN O
procedures NNS NNS O
. . . O

In IN IN O
males NNS NNS O
, , , O
the DT DT O
non NN NN O
- - - O
competitive JJ JJ O
NMDA NNP NNP B-CHEM
antagonist NN NN O
dextromethorphan NN NN B-CHEM
enhanced VBD VBD O
the DT DT O
antihyperalgesic JJ JJ O
effect NN NN O
of IN IN O
low JJ JJ O
to TO TO O
moderate JJ JJ O
doses NNS NNS O
of IN IN O
morphine NN NN B-CHEM
in IN IN O
a DT DT O
dose NN NN O
- - - O
and CC CC O
time NN NN O
- : : O
dependent JJ JJ O
manner NN NN O
. . . O

Across IN IN O
the DT DT O
doses NNS NNS O
and CC CC O
pretreatment JJ JJ O
times NNS NNS O
examined VBD VBD O
, , , O
enhancement NN NN O
was VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
females NNS NNS O
. . . O

Enhancement NNP NNP O
of IN IN O
morphine NN NN B-CHEM
antinociception NN NN O
by IN IN O
dextromethorphan NN NN B-CHEM
was VBD VBD O
seen VBN VBN O
in IN IN O
both DT DT O
males NNS NNS O
and CC CC O
females NNS NNS O
in IN IN O
the DT DT O
acute JJ JJ O
pain NN NN O
models NNS NNS O
, , , O
with IN IN O
the DT DT O
magnitude NN NN O
of IN IN O
this DT DT O
effect NN NN O
being VBG VBG O
greater JJR JJR O
in IN IN O
males NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
demonstrate VBP VBP O
a DT DT O
sexually RB RB O
- - - O
dimorphic JJ JJ O
interaction NN NN O
between IN IN O
NMDA NNP NNP B-CHEM
antagonists NNS NNS O
and CC CC O
morphine NN NN B-CHEM
in IN IN O
a DT DT O
persistent JJ JJ O
pain NN NN O
model NN NN O
that WDT WDT O
can MD MD O
be VB VB O
distinguished VBN VBN O
from IN IN O
those DT DT O
observed VBN VBN O
in IN IN O
acute JJ JJ O
pain NN NN O
models NNS NNS O
. . . O

Development NNP NNP O
of IN IN O
proteinuria NNS NNS O
after IN IN O
switch NN NN O
to TO TO O
sirolimus NN NN B-CHEM
- - - O
based JJ JJ O
immunosuppression NN NN O
in IN IN O
long JJ JJ O
- - - O
term NN NN O
cardiac NN NN O
transplant NN NN O
patients NNS NNS O
. . . O

Calcineurin NNP NNP O
- : : O
inhibitor NN NN O
therapy NN NN O
can MD MD O
lead VB VB O
to TO TO O
renal JJ JJ O
dysfunction NN NN O
in IN IN O
heart NN NN O
transplantation NN NN O
patients NNS NNS O
. . . O

The DT DT O
novel NN NN O
immunosuppressive JJ JJ O
( ( ( O
IS VBZ VBZ O
) ) ) O
drug NN NN O
sirolmus NN NN B-CHEM
( ( ( O
Srl NNP NNP B-CHEM
) ) ) O
lacks VBZ VBZ O
nephrotoxic JJ JJ O
effects NNS NNS O
; : : O
however RB RB O
, , , O
proteinuria NN NN O
associated VBN VBN O
with IN IN O
Srl NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
following VBG VBG O
renal JJ JJ O
transplantation NN NN O
. . . O

In IN IN O
cardiac JJ JJ O
transplantation NN NN O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
proteinuria NN NN O
associated VBN VBN O
with IN IN O
Srl NNP NNP B-CHEM
is VBZ VBZ O
unknown JJ JJ O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
long JJ JJ O
- - - O
term NN NN O
cardiac NN NN O
transplant NN NN O
patients NNS NNS O
were VBD VBD O
switched VBN VBN O
from IN IN O
cyclosporine NN NN B-CHEM
to TO TO O
Srl NNP NNP B-CHEM
- - - O
based JJ JJ O
IS VBZ VBZ O
. . . O

Concomitant NNP NNP O
IS VBZ VBZ O
consisted VBN VBN O
of IN IN O
mycophenolate NN NN B-CHEM
mofetil NN NN I-CHEM
+ NN NN O
/ NN NN O
- : : O
steroids NNS NNS B-CHEM
. . . O

Proteinuria NNP NNP O
increased VBD VBD O
significantly RB RB O
from IN IN O
a DT DT O
median NN NN O
of IN IN O
0 CD CD O
. . . O
13 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
( ( ( O
range NN NN O
0 CD CD O
- : : O
5 CD CD O
. . . O
7 CD CD O
) ) ) O
preswitch NN NN O
to TO TO O
0 CD CD O
. . . O
23 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
( ( ( O
0 CD CD O
- : : O
9 CD CD O
. . . O
88 CD CD O
) ) ) O
at IN IN O
24 CD CD O
months NNS NNS O
postswitch NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0024 CD CD O
) ) ) O
. . . O

Before IN IN O
the DT DT O
switch NN NN O
, , , O
11 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
had VBD VBD O
high JJ JJ O
- - - O
grade NN NN O
proteinuria NN NN O
( ( ( O
> NN NN O
1 CD CD O
. . . O
0 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
) ) ) O
; : : O
this DT DT O
increased VBN VBN O
to TO TO O
22 CD CD O
. . . O
9 CD CD O
% NN NN O
postswitch NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
006 CD CD O
) ) ) O
. . . O

ACE NNP NNP B-CHEM
inhibitor NN NN I-CHEM
and CC CC O
angiotensin NN NN B-CHEM
- - - I-CHEM
releasing VBG VBG I-CHEM
blocker NN NN I-CHEM
( ( ( O
ARB NNP NNP B-CHEM
) ) ) O
therapy NN NN O
reduced VBD VBD O
proteinuria NN NN O
development NN NN O
. . . O

Patients NNS NNS O
without IN IN O
proteinuria NNS NNS O
had VBD VBD O
increased VBN VBN O
renal JJ JJ O
function NN NN O
( ( ( O
median NN NN O
42 CD CD O
. . . O
5 CD CD O
vs NNS NNS O
. . . O
64 CD CD O
. . . O
1 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
25 CD CD O
) ) ) O
, , , O
whereas IN IN O
patients NNS NNS O
who WP WP O
developed VBN VBN O
high JJ JJ O
- - - O
grade NN NN O
proteinuria NN NN O
showed VBD VBD O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
follow VB VB O
- - - O
up RP RP O
( ( ( O
median NN NN O
39 CD CD O
. . . O
6 CD CD O
vs NNS NNS O
. . . O
29 CD CD O
. . . O
2 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
125 CD CD O
) ) ) O
. . . O

Thus RB RB O
, , , O
proteinuria NNS NNS O
may MD MD O
develop VB VB O
in IN IN O
cardiac JJ JJ O
transplant NN NN O
patients NNS NNS O
after IN IN O
switch NN NN O
to TO TO O
Srl NNP NNP B-CHEM
, , , O
which WDT WDT O
may MD MD O
have VB VB O
an DT DT O
adverse JJ JJ O
effect NN NN O
on IN IN O
renal JJ JJ O
function NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

Srl NNP NNP B-CHEM
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
ACEi NNP NNP B-CHEM
/ NN NN O
ARB NNP NNP B-CHEM
therapy NN NN O
and CC CC O
patients NNS NNS O
monitored VBN VBN O
for IN IN O
proteinuria NN NN O
and CC CC O
increased VBN VBN O
renal JJ JJ O
dysfunction NN NN O
. . . O

Ginsenoside NNP NNP B-CHEM
Rg1 NNP NNP I-CHEM
restores NNS NNS O
the DT DT O
impairment NN NN O
of IN IN O
learning VBG VBG O
induced VBN VBN O
by IN IN O
chronic JJ JJ O
morphine NN NN B-CHEM
administration NN NN O
in IN IN O
rats NNS NNS O
. . . O

Rg1 NNP NNP B-CHEM
, , , O
as IN IN O
a DT DT O
ginsenoside NN NN B-CHEM
extracted VBN VBN O
from IN IN O
Panax NNP NNP O
ginseng NN NN O
, , , O
could MD MD O
ameliorate VB VB O
spatial JJ JJ O
learning NN NN O
impairment NN NN O
. . . O

Previous JJ JJ O
studies NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
that IN IN O
Rg1 NNP NNP B-CHEM
might MD MD O
be VB VB O
a DT DT O
useful JJ JJ O
agent NN NN O
for IN IN O
the DT DT O
prevention NN NN O
and CC CC O
treatment NN NN O
of IN IN O
the DT DT O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
effect NN NN O
of IN IN O
Rg1 NNP NNP B-CHEM
on IN IN O
learning VBG VBG O
impairment NN NN O
by IN IN O
chronic JJ JJ O
morphine NN NN B-CHEM
administration NN NN O
and CC CC O
the DT DT O
mechanism NN NN O
responsible JJ JJ O
for IN IN O
this DT DT O
effect NN NN O
. . . O

Male NNP NNP O
rats NNS NNS O
were VBD VBD O
subcutaneously RB RB O
injected VBN VBN O
with IN IN O
morphine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
twice RB RB O
a DT DT O
day NN NN O
at IN IN O
12 CD CD O
hour NN NN O
intervals NNS NNS O
for IN IN O
10 CD CD O
days NNS NNS O
, , , O
and CC CC O
Rg1 NNP NNP B-CHEM
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
intraperitoneally RB RB O
injected VBN VBN O
2 CD CD O
hours NNS NNS O
after IN IN O
the DT DT O
second JJ JJ O
injection NN NN O
of IN IN O
morphine NN NN B-CHEM
once RB RB O
a DT DT O
day NN NN O
for IN IN O
10 CD CD O
days NNS NNS O
. . . O

Spatial NNP NNP O
learning VBG VBG O
capacity NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
the DT DT O
Morris NNP NNP O
water NN NN O
maze NN NN O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
that IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
Morphine NNP NNP B-CHEM
/ NN NN O
Rg1 NNP NNP B-CHEM
decreased VBD VBD O
escape NN NN O
latency NN NN O
and CC CC O
increased VBD VBD O
the DT DT O
time NN NN O
spent VBD VBD O
in IN IN O
platform NN NN O
quadrant NN NN O
and CC CC O
entering VBG VBG O
frequency NN NN O
. . . O

By IN IN O
implantation NN NN O
of IN IN O
electrodes NNS NNS O
and CC CC O
electrophysiological JJ JJ O
recording NN NN O
in IN IN O
vivo NN NN O
, , , O
the DT DT O
results NNS NNS O
showed VBD VBD O
that IN IN O
Rg1 NNP NNP B-CHEM
restored VBD VBD O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
potentiation NN NN O
( ( ( O
LTP NNP NNP O
) ) ) O
impaired VBN VBN O
by IN IN O
morphine NN NN B-CHEM
in IN IN O
both DT DT O
freely RB RB O
moving VBG VBG O
and CC CC O
anaesthetised VBD VBD O
rats NNS NNS O
. . . O

The DT DT O
electrophysiological JJ JJ O
recording NN NN O
in IN IN O
vitro NN NN O
showed VBD VBD O
that IN IN O
Rg1 NNP NNP B-CHEM
restored VBD VBD O
the DT DT O
LTP NNP NNP O
in IN IN O
slices NNS NNS O
from IN IN O
the DT DT O
rats NNS NNS O
treated VBN VBN O
with IN IN O
morphine NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
changed VBN VBN O
LTP NNP NNP O
in IN IN O
the DT DT O
slices NNS NNS O
from IN IN O
normal JJ JJ O
saline NN NN O
- - - O
or CC CC O
morphine NN NN B-CHEM
/ NN NN O
Rg1 NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
; : : O
this DT DT O
restoration NN NN O
could MD MD O
be VB VB O
inhibited VBN VBN O
by IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptor NN NN O
antagonist NN NN O
MK801 NNP NNP B-CHEM
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
Rg1 NNP NNP B-CHEM
may MD MD O
significantly RB RB O
improve VB VB O
the DT DT O
spatial JJ JJ O
learning NN NN O
capacity NN NN O
impaired VBN VBN O
by IN IN O
chonic JJ JJ O
morphine NN NN B-CHEM
administration NN NN O
and CC CC O
restore VB VB O
the DT DT O
morphine NN NN B-CHEM
- - - O
inhibited JJ JJ O
LTP NNP NNP O
. . . O

This DT DT O
effect NN NN O
is VBZ VBZ O
NMDA NNP NNP B-CHEM
receptor NN NN O
dependent NN NN O
. . . O

Synthesis NNP NNP O
of IN IN O
N NNP NNP B-CHEM
- - - I-CHEM
pyrimidinyl NN NN I-CHEM
- - - I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
phenoxyacetamides NNS NNS I-CHEM
as IN IN O
adenosine NN NN B-CHEM
A2A NNP NNP O
receptor NN NN O
antagonists NNS NNS O
. . . O

A DT DT O
series NN NN O
of IN IN O
N NNP NNP B-CHEM
- - - I-CHEM
pyrimidinyl NN NN I-CHEM
- - - I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
phenoxyacetamide NN NN I-CHEM
adenosine NN NN B-CHEM
A DT DT O
( ( ( O
2A CD CD O
) ) ) O
antagonists NNS NNS O
is VBZ VBZ O
described VBN VBN O
. . . O

SAR NNP NNP O
studies NNS NNS O
led VBN VBN O
to TO TO O
compound NN NN O
14 CD CD O
with IN IN O
excellent JJ JJ O
potency NN NN O
( ( ( O
K NNP NNP O
( ( ( O
i NNP NNP O
) ) ) O
= SYM SYM O
0 CD CD O
. . . O
4 CD CD O
nM NN NN O
) ) ) O
, , , O
selectivity NN NN O
( ( ( O
A DT DT O
( ( ( O
1 CD CD O
) ) ) O
/ NN NN O
A DT DT O
( ( ( O
2A CD CD O
) ) ) O
> NN NN O
100 CD CD O
) ) ) O
, , , O
and CC CC O
efficacy NN NN O
( ( ( O
MED NNP NNP O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
in IN IN O
the DT DT O
rat NN NN O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
model NN NN O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Evidence NN NN O
for IN IN O
an DT DT O
involvement NN NN O
of IN IN O
D1 NN NN O
and CC CC O
D2 NN NN O
dopamine NN NN B-CHEM
receptors NNS NNS O
in IN IN O
mediating VBG VBG O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
in IN IN O
rats NNS NNS O
. . . O

Previous JJ JJ O
studies NNS NNS O
have VBP VBP O
suggested VBN VBN O
that IN IN O
repeated VBN VBN O
exposure NN NN O
of IN IN O
rats NNS NNS O
to TO TO O
the DT DT O
drug NN NN O
or CC CC O
to TO TO O
the DT DT O
experimental JJ JJ O
environment NN NN O
is VBZ VBZ O
necessary JJ JJ O
to TO TO O
observe VB VB O
nicotine NN NN B-CHEM
- : : O
induced JJ JJ O
locomotor NN NN O
stimulation NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
the DT DT O
role NN NN O
of IN IN O
habituation NN NN O
to TO TO O
the DT DT O
experimental JJ JJ O
environment NN NN O
on IN IN O
the DT DT O
stimulant JJ JJ O
effect NN NN O
of IN IN O
nicotine NN NN B-CHEM
in IN IN O
rats NNS NNS O
was VBD VBD O
examined VBN VBN O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
role NN NN O
of IN IN O
dopamine NN NN B-CHEM
receptors NNS NNS O
in IN IN O
mediating VBG VBG O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
stimulation NN NN O
was VBD VBD O
investigated VBN VBN O
by IN IN O
examining VBG VBG O
the DT DT O
effects NNS NNS O
of IN IN O
selective JJ JJ O
D1 NN NN O
and CC CC O
D2 NN NN O
dopamine NN NN B-CHEM
receptor NN NN O
antagonists NNS NNS O
on IN IN O
activity NN NN O
induced VBN VBN O
by IN IN O
nicotine NN NN B-CHEM
. . . O

Locomotor NNP NNP O
activity NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
tested VBN VBN O
in IN IN O
photocell NN NN O
cages NNS NNS O
. . . O

Nicotine NNP NNP B-CHEM
( ( ( O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
caused VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
locomotor NN NN O
activity NN NN O
in IN IN O
rats NNS NNS O
that WDT WDT O
were VBD VBD O
habituated VBN VBN O
to TO TO O
the DT DT O
test NN NN O
environment NN NN O
, , , O
but CC CC O
had VBD VBD O
only RB RB O
a DT DT O
weak JJ JJ O
and CC CC O
delayed VBN VBN O
stimulant JJ JJ O
action NN NN O
in IN IN O
rats NNS NNS O
that WDT WDT O
were VBD VBD O
unfamiliar JJ JJ O
with IN IN O
the DT DT O
test NN NN O
environment NN NN O
. . . O

The DT DT O
stimulant JJ JJ O
action NN NN O
of IN IN O
nicotine NN NN B-CHEM
was VBD VBD O
blocked VBN VBN O
by IN IN O
the DT DT O
central JJ JJ O
nicotinic JJ JJ O
antagonist NN NN O
mecamylamine NN NN B-CHEM
but CC CC O
not RB RB O
by IN IN O
the DT DT O
peripheral JJ JJ O
nicotinic JJ JJ O
blocker NN NN O
hexamethonium NN NN B-CHEM
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
response NN NN O
is VBZ VBZ O
probably RB RB O
mediated VBN VBN O
by IN IN O
central JJ JJ O
nicotinic JJ JJ O
receptors NNS NNS O
. . . O

Nicotine NNP NNP B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
was VBD VBD O
blocked VBN VBN O
by IN IN O
the DT DT O
selective JJ JJ O
D1 NNP NNP O
antagonist NN NN O
SCH NNP NNP B-CHEM
23390 CD CD I-CHEM
, , , O
the DT DT O
selective JJ JJ O
D2 NN NN O
antagonist NN NN O
raclopride NN NN B-CHEM
and CC CC O
the DT DT O
D1 NN NN O
/ NN NN O
D2 NN NN O
antagonist NN NN O
fluphenazine NN NN B-CHEM
. . . O

Pretreatment NNP NNP O
with IN IN O
the DT DT O
D2 NN NN O
agonist NN NN O
PHNO NNP NNP B-CHEM
enhanced VBD VBD O
nicotine NN NN B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
, , , O
whereas IN IN O
the DT DT O
D1 NNP NNP O
agonist NN NN O
SKF NNP NNP B-CHEM
38393 CD CD I-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
acute JJ JJ O
nicotine NN NN B-CHEM
injection NN NN O
induces NNS NNS O
a DT DT O
pronounced JJ JJ O
hyperactivity NN NN O
in IN IN O
rats NNS NNS O
habituated VBN VBN O
to TO TO O
the DT DT O
test NN NN O
environment NN NN O
. . . O

The DT DT O
effect NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
mediated VBN VBN O
by IN IN O
central JJ JJ O
nicotine NN NN B-CHEM
receptors NNS NNS O
, , , O
possibly RB RB O
located VBN VBN O
on IN IN O
dopaminergic JJ JJ O
neurons NNS NNS O
, , , O
and CC CC O
also RB RB O
requires VBZ VBZ O
the DT DT O
activation NN NN O
of IN IN O
both DT DT O
D1 NN NN O
and CC CC O
D2 NN NN O
dopamine NN NN B-CHEM
receptors NNS NNS O
. . . O

Central NNP NNP O
retinal JJ JJ O
vein NN NN O
occlusion NN NN O
associated VBN VBN O
with IN IN O
clomiphene NN NN B-CHEM
- - - O
induced JJ JJ O
ovulation NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
central JJ JJ O
retinal NN NN O
vein NN NN O
occlusion NN NN O
associated VBN VBN O
with IN IN O
clomiphene NN NN B-CHEM
citrate NN NN I-CHEM
( ( ( O
CC NNP NNP B-CHEM
) ) ) O
. . . O

DESIGN NNP NNP O
: : : O
Case NN NN O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
Ophthalmology NNP NNP O
clinic NN NN O
of IN IN O
an DT DT O
academic JJ JJ O
hospital NN NN O
. . . O

PATIENT NNP NNP O
( ( ( O
S NNP NNP O
) ) ) O
: : : O
A DT DT O
36 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
referred VBD VBD O
from IN IN O
the DT DT O
infertility NN NN O
clinic NN NN O
for IN IN O
blurred JJ JJ O
vision NN NN O
. . . O

INTERVENTION NNP NNP O
( ( ( O
S NNP NNP O
) ) ) O
: : : O
Ophthalmic NNP NNP O
examination NN NN O
after IN IN O
CC NNP NNP B-CHEM
therapy NN NN O
. . . O

MAIN NNP NNP O
OUTCOME NNP NNP O
MEASURE NNP NNP O
( ( ( O
S NNP NNP O
) ) ) O
: : : O
Central NNP NNP O
retinal NN NN O
vein NN NN O
occlusion NN NN O
after IN IN O
ovulation NN NN O
induction NN NN O
with IN IN O
CC NNP NNP B-CHEM
. . . O

RESULT NNP NNP O
( ( ( O
S NNP NNP O
) ) ) O
: : : O
A DT DT O
36 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Chinese JJ JJ O
woman NN NN O
developed VBN VBN O
central JJ JJ O
retinal JJ JJ O
vein NN NN O
occlusion NN NN O
after IN IN O
eight CD CD O
courses NNS NNS O
of IN IN O
CC NNP NNP B-CHEM
. . . O

A DT DT O
search NN NN O
of IN IN O
the DT DT O
literature NN NN O
on IN IN O
the DT DT O
thromboembolic JJ JJ O
complications NNS NNS O
of IN IN O
CC NNP NNP B-CHEM
does VBZ VBZ O
not RB RB O
include VB VB O
this DT DT O
severe JJ JJ O
ophthalmic JJ JJ O
complication NN NN O
, , , O
although IN IN O
mild JJ JJ O
visual JJ JJ O
disturbance NN NN O
after IN IN O
CC NNP NNP B-CHEM
intake NN NN O
is VBZ VBZ O
not RB RB O
uncommon JJ JJ O
. . . O

CONCLUSION NNP NNP O
( ( ( O
S NNP NNP O
) ) ) O
: : : O
This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
central JJ JJ O
retinal NN NN O
vein NN NN O
occlusion NN NN O
after IN IN O
treatment NN NN O
with IN IN O
CC NNP NNP B-CHEM
. . . O

Extra NNP NNP O
caution NN NN O
is VBZ VBZ O
warranted VBN VBN O
in IN IN O
treating VBG VBG O
infertility NN NN O
patients NNS NNS O
with IN IN O
CC NNP NNP B-CHEM
, , , O
and CC CC O
patients NNS NNS O
should MD MD O
be VB VB O
well RB RB O
informed VBN VBN O
of IN IN O
this DT DT O
side NN NN O
effect NN NN O
before IN IN O
commencement NN NN O
of IN IN O
therapy NN NN O
. . . O

Acute JJ JJ O
bronchodilating JJ JJ O
effects NNS NNS O
of IN IN O
ipratropium NN NN B-CHEM
bromide NN NN I-CHEM
and CC CC O
theophylline NN NN B-CHEM
in IN IN O
chronic JJ JJ O
obstructive JJ JJ O
pulmonary JJ JJ O
disease NN NN O
. . . O

The DT DT O
bronchodilator NN NN O
effects NNS NNS O
of IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
ipratropium NN NN B-CHEM
bromide NN NN I-CHEM
aerosol NN NN O
( ( ( O
36 CD CD O
micrograms NNS NNS O
) ) ) O
and CC CC O
short JJ JJ O
- - - O
acting VBG VBG O
theophylline NN NN B-CHEM
tablets NNS NNS O
( ( ( O
dose NN NN O
titrated VBN VBN O
to TO TO O
produce VB VB O
serum NN NN O
levels NNS NNS O
of IN IN O
10 CD CD O
- : : O
20 CD CD O
micrograms NNS NNS O
/ NN NN O
mL NN NN O
) ) ) O
were VBD VBD O
compared VBN VBN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled VBN VBN O
crossover NN NN O
study NN NN O
in IN IN O
21 CD CD O
patients NNS NNS O
with IN IN O
stable JJ JJ O
, , , O
chronic JJ JJ O
obstructive JJ JJ O
pulmonary JJ JJ O
disease NN NN O
. . . O

Mean VB VB O
peak NN NN O
forced VBD VBD O
expiratory NN NN O
volume NN NN O
in IN IN O
1 CD CD O
second JJ JJ O
( ( ( O
FEV1 NNP NNP O
) ) ) O
increases NNS NNS O
over IN IN O
baseline NN NN O
and CC CC O
the DT DT O
proportion NN NN O
of IN IN O
patients NNS NNS O
attaining VBG VBG O
at IN IN O
least JJS JJS O
a DT DT O
15 CD CD O
% NN NN O
increase NN NN O
in IN IN O
the DT DT O
FEV1 NNP NNP O
( ( ( O
responders NNS NNS O
) ) ) O
were VBD VBD O
31 CD CD O
% NN NN O
and CC CC O
90 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
for IN IN O
ipratropium NN NN B-CHEM
and CC CC O
17 CD CD O
% NN NN O
and CC CC O
50 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
for IN IN O
theophylline NN NN B-CHEM
. . . O

The DT DT O
average JJ JJ O
FEV1 NNP NNP O
increases NNS NNS O
during IN IN O
the DT DT O
6 CD CD O
- : : O
hour NN NN O
observation NN NN O
period NN NN O
were VBD VBD O
18 CD CD O
% NN NN O
for IN IN O
ipratropium NN NN B-CHEM
and CC CC O
8 CD CD O
% NN NN O
for IN IN O
theophylline NN NN B-CHEM
. . . O

The DT DT O
mean JJ JJ O
duration NN NN O
of IN IN O
action NN NN O
was VBD VBD O
3 CD CD O
. . . O
8 CD CD O
hours NNS NNS O
with IN IN O
ipratropium NN NN B-CHEM
and CC CC O
2 CD CD O
. . . O
4 CD CD O
hours NNS NNS O
with IN IN O
theophylline NN NN B-CHEM
. . . O

While IN IN O
side NN NN O
effects NNS NNS O
were VBD VBD O
rare JJ JJ O
, , , O
those DT DT O
experienced VBN VBN O
after IN IN O
theophylline NN NN B-CHEM
use NN NN O
did VBD VBD O
involve VB VB O
the DT DT O
cardiovascular JJ JJ O
and CC CC O
gastrointestinal JJ JJ O
systems NNS NNS O
. . . O

These DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
ipratropium NN NN B-CHEM
is VBZ VBZ O
a DT DT O
more RBR RBR O
potent JJ JJ O
bronchodilator NN NN O
than IN IN O
oral JJ JJ O
theophylline NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
airflow JJ JJ O
obstruction NN NN O
. . . O

Methamphetamine NNP NNP B-CHEM
- : : O
induced JJ JJ O
neurotoxicity NN NN O
and CC CC O
microglial JJ JJ O
activation NN NN O
are VBP VBP O
not RB RB O
mediated VBN VBN O
by IN IN O
fractalkine NN NN O
receptor NN NN O
signaling VBG VBG O
. . . O

Methamphetamine NNP NNP B-CHEM
( ( ( O
METH NNP NNP B-CHEM
) ) ) O
damages NNS NNS O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
nerve NN NN O
endings NNS NNS O
by IN IN O
a DT DT O
process NN NN O
that WDT WDT O
has VBZ VBZ O
been VBN VBN O
linked VBN VBN O
to TO TO O
microglial JJ JJ O
activation NN NN O
but CC CC O
the DT DT O
signaling VBG VBG O
pathways NNS NNS O
that WDT WDT O
mediate VBP VBP O
this DT DT O
response NN NN O
have VBP VBP O
not RB RB O
yet RB RB O
been VBN VBN O
delineated VBN VBN O
. . . O

Cardona NNP NNP O
et CC CC O
al NN NN O
. . . O

[ NN NN O
Nat NNP NNP O
. . . O
Neurosci NNP NNP O
. . . O
9 CD CD O
( ( ( O
2006 CD CD O
) ) ) O
, , , O
917 CD CD O
] NN NN O
recently RB RB O
identified VBD VBD O
the DT DT O
microglial JJ JJ O
- - - O
specific JJ JJ O
fractalkine NN NN O
receptor NN NN O
( ( ( O
CX3CR1 NNP NNP O
) ) ) O
as IN IN O
an DT DT O
important JJ JJ O
mediator NN NN O
of IN IN O
MPTP NNP NNP B-CHEM
- : : O
induced JJ JJ O
neurodegeneration NN NN O
of IN IN O
DA NNP NNP B-CHEM
neurons NNS NNS O
. . . O

Because IN IN O
the DT DT O
CNS NNP NNP O
damage NN NN O
caused VBN VBN O
by IN IN O
METH NNP NNP B-CHEM
and CC CC O
MPTP NNP NNP B-CHEM
is VBZ VBZ O
highly RB RB O
selective JJ JJ O
for IN IN O
the DT DT O
DA NNP NNP B-CHEM
neuronal JJ JJ O
system NN NN O
in IN IN O
mouse NN NN O
models NNS NNS O
of IN IN O
neurotoxicity NN NN O
, , , O
we PRP PRP O
hypothesized VBN VBN O
that IN IN O
the DT DT O
CX3CR1 NNP NNP O
plays VBZ VBZ O
a DT DT O
role NN NN O
in IN IN O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
neurotoxicity NN NN O
and CC CC O
microglial JJ JJ O
activation NN NN O
. . . O

Mice NNP NNP O
in IN IN O
which WDT WDT O
the DT DT O
CX3CR1 NNP NNP O
gene NN NN O
has VBZ VBZ O
been VBN VBN O
deleted VBN VBN O
and CC CC O
replaced VBN VBN O
with IN IN O
a DT DT O
cDNA NN NN O
encoding VBG VBG O
enhanced VBN VBN O
green JJ JJ O
fluorescent NN NN O
protein NN NN O
( ( ( O
eGFP NN NN O
) ) ) O
were VBD VBD O
treated VBN VBN O
with IN IN O
METH NNP NNP B-CHEM
and CC CC O
examined VBD VBD O
for IN IN O
striatal JJ JJ O
neurotoxicity NN NN O
. . . O

METH NNP NNP B-CHEM
depleted VBD VBD O
DA NNP NNP B-CHEM
, , , O
caused VBD VBD O
microglial JJ JJ O
activation NN NN O
, , , O
and CC CC O
increased JJ JJ O
body NN NN O
temperature NN NN O
in IN IN O
CX3CR1 NNP NNP O
knockout NN NN O
mice NN NN O
to TO TO O
the DT DT O
same JJ JJ O
extent NN NN O
and CC CC O
over IN IN O
the DT DT O
same JJ JJ O
time NN NN O
course NN NN O
seen VBN VBN O
in IN IN O
wild JJ JJ O
- - - O
type NN NN O
controls NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
METH NNP NNP B-CHEM
in IN IN O
CX3CR1 NNP NNP O
knockout NN NN O
mice NN NN O
were VBD VBD O
not RB RB O
gender NN NN O
- : : O
dependent JJ JJ O
and CC CC O
did VBD VBD O
not RB RB O
extend VB VB O
beyond IN IN O
the DT DT O
striatum NN NN O
. . . O

Striatal NNP NNP O
microglia NN NN O
expressing VBG VBG O
eGFP NN NN O
constitutively RB RB O
show VB VB O
morphological JJ JJ O
changes NNS NNS O
after IN IN O
METH NNP NNP B-CHEM
that WDT WDT O
are VBP VBP O
characteristic JJ JJ O
of IN IN O
activation NN NN O
. . . O

This DT DT O
response NN NN O
was VBD VBD O
restricted VBN VBN O
to TO TO O
the DT DT O
striatum NN NN O
and CC CC O
contrasted JJ JJ O
sharply NN NN O
with IN IN O
unresponsive JJ JJ O
eGFP NN NN O
- : : O
microglia NN NN O
in IN IN O
surrounding VBG VBG O
brain NN NN O
areas NNS NNS O
that WDT WDT O
are VBP VBP O
not RB RB O
damaged VBN VBN O
by IN IN O
METH NNP NNP B-CHEM
. . . O

We PRP PRP O
conclude VBP VBP O
from IN IN O
these DT DT O
studies NNS NNS O
that WDT WDT O
CX3CR1 NNP NNP O
signaling VBG VBG O
does VBZ VBZ O
not RB RB O
modulate VB VB O
METH NNP NNP B-CHEM
neurotoxicity NN NN O
or CC CC O
microglial JJ JJ O
activation NN NN O
. . . O

Furthermore RB RB O
, , , O
it PRP PRP O
appears VBZ VBZ O
that IN IN O
striatal JJ JJ O
- : : O
resident NN NN O
microglia NN NN O
respond NN NN O
to TO TO O
METH NNP NNP B-CHEM
with IN IN O
an DT DT O
activation NN NN O
cascade NN NN O
and CC CC O
then RB RB O
return VB VB O
to TO TO O
a DT DT O
surveying VBG VBG O
state NN NN O
without IN IN O
undergoing VBG VBG O
apoptosis NN NN O
or CC CC O
migration NN NN O
. . . O

Nicotine NNP NNP B-CHEM
- : : O
induced JJ JJ O
nystagmus NN NN O
correlates NNS NNS O
with IN IN O
midpontine NN NN O
activation NN NN O
. . . O

The DT DT O
pathomechanism NN NN O
of IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
nystagmus NN NN O
( ( ( O
NIN NNP NNP O
) ) ) O
is VBZ VBZ O
unknown JJ JJ O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
delineate VB VB O
brain NN NN O
structures NNS NNS O
that WDT WDT O
are VBP VBP O
involved VBN VBN O
in IN IN O
NIN NNP NNP O
generation NN NN O
. . . O

Eight CD CD O
healthy JJ JJ O
volunteers NNS NNS O
inhaled JJ JJ O
nicotine NN NN B-CHEM
in IN IN O
darkness NNS NNS O
during IN IN O
a DT DT O
functional JJ JJ O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
fMRI NN NN O
) ) ) O
experiment NN NN O
; : : O
eye NN NN O
movements NNS NNS O
were VBD VBD O
registered VBN VBN O
using VBG VBG O
video NN NN O
- - - O
oculography NN NN O
. . . O

NIN NNP NNP O
correlated VBD VBD O
with IN IN O
blood NN NN O
oxygen NN NN B-CHEM
level NN NN O
- : : O
dependent JJ JJ O
( ( ( O
BOLD NNP NNP O
) ) ) O
activity NN NN O
levels NNS NNS O
in IN IN O
a DT DT O
midpontine NN NN O
site NN NN O
in IN IN O
the DT DT O
posterior NN NN O
basis NN NN O
pontis NN NN O
. . . O

NIN NNP NNP O
- : : O
induced JJ JJ O
midpontine NN NN O
activation NN NN O
may MD MD O
correspond VB VB O
to TO TO O
activation NN NN O
of IN IN O
the DT DT O
dorsomedial JJ JJ O
pontine NN NN O
nuclei NN NN O
and CC CC O
the DT DT O
nucleus NN NN O
reticularis NN NN O
tegmenti JJ JJ O
pontis NN NN O
, , , O
structures NNS NNS O
known VBN VBN O
to TO TO O
participate VB VB O
in IN IN O
the DT DT O
generation NN NN O
of IN IN O
multidirectional JJ JJ O
saccades NNS NNS O
and CC CC O
smooth JJ JJ O
pursuit NN NN O
eye NN NN O
movements NNS NNS O
. . . O

Acute JJ JJ O
effects NNS NNS O
of IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
propylpentanoyl NN NN I-CHEM
) ) ) I-CHEM
urea NN NN I-CHEM
on IN IN O
hippocampal NN NN O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
neurotransmitters NNS NNS O
in IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizure NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
aimed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
anticonvulsant NN NN O
activity NN NN O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
effects NNS NNS O
on IN IN O
the DT DT O
level NN NN O
of IN IN O
hippocampal JJ JJ O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
neurotransmitters NNS NNS O
( ( ( O
glutamate NN NN B-CHEM
, , , O
aspartate NN NN B-CHEM
, , , O
glycine NN NN B-CHEM
and CC CC O
GABA NNP NNP B-CHEM
) ) ) O
of IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
propylpentanoyl NN NN I-CHEM
) ) ) I-CHEM
urea NN NN I-CHEM
( ( ( O
VPU NNP NNP B-CHEM
) ) ) O
in IN IN O
comparison NN NN O
to TO TO O
its PRP$ PRP$ O
parent NN NN O
compound NN NN O
, , , O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
. . . O

VPU NNP NNP B-CHEM
was VBD VBD O
more RBR RBR O
potent JJ JJ O
than IN IN O
VPA NNP NNP B-CHEM
, , , O
exhibiting VBG VBG O
the DT DT O
median NN NN O
effective JJ JJ O
dose NN NN O
( ( ( O
ED NNP NNP O
( ( ( O
50 CD CD O
) ) ) O
) ) ) O
of IN IN O
49 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
in IN IN O
protecting VBG VBG O
rats NNS NNS O
against IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizure NN NN O
whereas IN IN O
the DT DT O
corresponding JJ JJ O
value NN NN O
for IN IN O
VPA NNP NNP B-CHEM
was VBD VBD O
322 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

In IN IN O
vivo NN NN O
microdialysis NN NN O
demonstrated VBD VBD O
that IN IN O
an DT DT O
intraperitoneal JJ JJ O
administration NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
induced VBD VBD O
a DT DT O
pronounced JJ JJ O
increment NN NN O
of IN IN O
hippocampal JJ JJ O
glutamate NN NN B-CHEM
and CC CC O
aspartate NN NN B-CHEM
whereas IN IN O
no DT DT O
significant JJ JJ O
change NN NN O
was VBD VBD O
observed VBN VBN O
on IN IN O
the DT DT O
level NN NN O
of IN IN O
glycine NN NN B-CHEM
and CC CC O
GABA NNP NNP B-CHEM
. . . O

Pretreatment NNP NNP O
with IN IN O
either DT DT O
VPU NNP NNP B-CHEM
( ( ( O
50 CD CD O
and CC CC O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
VPA NNP NNP B-CHEM
( ( ( O
300 CD CD O
and CC CC O
600 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
completely RB RB O
abolished VBN VBN O
pilocarpine NN NN B-CHEM
- - - O
evoked JJ JJ O
increases NNS NNS O
in IN IN O
extracellular NN NN O
glutamate NN NN B-CHEM
and CC CC O
aspartate NN NN B-CHEM
. . . O

In IN IN O
addition NN NN O
, , , O
a DT DT O
statistically RB RB O
significant JJ JJ O
reduction NN NN O
was VBD VBD O
also RB RB O
observed VBN VBN O
on IN IN O
the DT DT O
level NN NN O
of IN IN O
GABA NNP NNP B-CHEM
and CC CC O
glycine NN NN B-CHEM
but CC CC O
less JJR JJR O
than IN IN O
a DT DT O
drastic JJ JJ O
reduction NN NN O
of IN IN O
glutamate NN NN B-CHEM
and CC CC O
aspartate NN NN B-CHEM
level NN NN O
. . . O

Based VBN VBN O
on IN IN O
the DT DT O
finding VBG VBG O
that IN IN O
VPU NNP NNP B-CHEM
and CC CC O
VPA NNP NNP B-CHEM
could MD MD O
protect VB VB O
the DT DT O
animals NNS NNS O
against IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizure NN NN O
it PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
reduction NN NN O
of IN IN O
inhibitory NN NN O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
neurotransmitters NNS NNS O
was VBD VBD O
comparatively RB RB O
minor JJ JJ O
and CC CC O
offset VBN VBN O
by IN IN O
a DT DT O
pronounced JJ JJ O
reduction NN NN O
of IN IN O
glutamate NN NN B-CHEM
and CC CC O
aspartate NN NN B-CHEM
. . . O

Therefore RB RB O
, , , O
like IN IN O
VPA NNP NNP B-CHEM
, , , O
the DT DT O
finding VBG VBG O
that IN IN O
VPU NNP NNP B-CHEM
could MD MD O
drastically RB RB O
reduce VB VB O
pilocarpine NN NN B-CHEM
- : : O
induced JJ JJ O
increases NNS NNS O
in IN IN O
glutamate NN NN B-CHEM
and CC CC O
aspartate NN NN B-CHEM
should MD MD O
account VB VB O
, , , O
at IN IN O
least JJS JJS O
partly RB RB O
, , , O
for IN IN O
its PRP$ PRP$ O
anticonvulsant NN NN O
activity NN NN O
observed VBD VBD O
in IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizure NN NN O
in IN IN O
experimental JJ JJ O
animals NNS NNS O
. . . O

Some DT DT O
other JJ JJ O
mechanism NN NN O
than IN IN O
those DT DT O
being VBG VBG O
reported VBN VBN O
herein NN NN O
should MD MD O
be VB VB O
further RBR RBR O
investigated JJ JJ O
. . . O

Protective JJ JJ O
effect NN NN O
of IN IN O
verapamil NN NN B-CHEM
on IN IN O
gastric JJ JJ O
hemorrhagic NN NN O
ulcers NNS NNS O
in IN IN O
severe JJ JJ O
atherosclerotic JJ JJ O
rats NNS NNS O
. . . O

Studies NNP NNP O
concerning VBG VBG O
with IN IN O
pathogenesis NNS NNS O
of IN IN O
gastric JJ JJ O
hemorrhage NN NN O
and CC CC O
mucosal NN NN O
ulceration NN NN O
produced VBN VBN O
in IN IN O
atherosclerotic JJ JJ O
rats NNS NNS O
are VBP VBP O
lacking VBG VBG O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
examine VB VB O
the DT DT O
role NN NN O
of IN IN O
gastric JJ JJ O
acid NN NN O
back RB RB O
- - - O
diffusion NN NN O
, , , O
mast NN NN O
cell NN NN O
histamine NN NN B-CHEM
release NN NN O
, , , O
lipid JJ JJ O
peroxide NN NN O
( ( ( O
LPO NNP NNP O
) ) ) O
generation NN NN O
and CC CC O
mucosal NN NN O
microvascular JJ JJ O
permeability NN NN O
in IN IN O
modulating VBG VBG O
gastric JJ JJ O
hemorrhage NN NN O
and CC CC O
ulcer NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
atherosclerosis NNS NNS O
induced VBN VBN O
by IN IN O
coadministration NN NN O
of IN IN O
vitamin NN NN B-CHEM
D2 NN NN I-CHEM
and CC CC O
cholesterol NN NN B-CHEM
. . . O

Additionally RB RB O
, , , O
the DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
verapamil NN NN B-CHEM
on IN IN O
this DT DT O
ulcer NN NN O
model NN NN O
was VBD VBD O
evaluated VBN VBN O
. . . O

Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
challenged VBN VBN O
intragastrically RB RB O
once RB RB O
daily JJ JJ O
for IN IN O
9 CD CD O
days NNS NNS O
with IN IN O
1 CD CD O
. . . O
0 CD CD O
ml NN NN O
/ NN NN O
kg NN NN O
of IN IN O
corn NN NN O
oil NN NN O
containing VBG VBG O
vitamin NN NN B-CHEM
D2 NN NN I-CHEM
and CC CC O
cholesterol NN NN B-CHEM
to TO TO O
induce VB VB O
atherosclerosis NNS NNS O
. . . O

Control NNP NNP O
rats NNS NNS O
received VBD VBD O
corn JJ JJ O
oil NN NN O
only RB RB O
. . . O

After IN IN O
gastric JJ JJ O
surgery NN NN O
, , , O
rat NN NN O
stomachs NN NN O
were VBD VBD O
irrigated VBN VBN O
for IN IN O
3 CD CD O
h NN NN O
with IN IN O
either DT DT O
simulated JJ JJ O
gastric JJ JJ O
juice NN NN O
or CC CC O
normal JJ JJ O
saline NN NN O
. . . O

Gastric NNP NNP O
acid NN NN O
back RB RB O
- - - O
diffusion NN NN O
, , , O
mucosal NN NN O
LPO NNP NNP O
generation NN NN O
, , , O
histamine NN NN B-CHEM
concentration NN NN O
, , , O
microvascular JJ JJ O
permeability NN NN O
, , , O
luminal JJ JJ B-CHEM
hemoglobin NN NN O
content NN NN O
and CC CC O
ulcer NN NN O
areas NNS NNS O
were VBD VBD O
determined VBN VBN O
. . . O

Elevated NNP NNP O
atherosclerotic JJ JJ O
parameters NNS NNS O
, , , O
such JJ JJ O
as IN IN O
serum NN NN O
calcium NN NN B-CHEM
, , , O
total JJ JJ O
cholesterol NN NN B-CHEM
and CC CC O
low JJ JJ O
- - - O
density NN NN O
lipoprotein NN NN O
concentration NN NN O
were VBD VBD O
obtained VBN VBN O
in IN IN O
atherosclerotic JJ JJ O
rats NNS NNS O
. . . O

Severe NNP NNP O
gastric JJ JJ O
ulcers NNS NNS O
accompanied VBD VBD O
with IN IN O
increased VBN VBN O
ulcerogenic JJ JJ O
factors NNS NNS O
, , , O
including VBG VBG O
gastric JJ JJ O
acid NN NN O
back RB RB O
- - - O
diffusion NN NN O
, , , O
histamine NN NN B-CHEM
release NN NN O
, , , O
LPO NNP NNP O
generation NN NN O
and CC CC O
luminal JJ JJ B-CHEM
hemoglobin NN NN O
content NN NN O
were VBD VBD O
also RB RB O
observed VBN VBN O
in IN IN O
these DT DT O
rats NNS NNS O
. . . O

Moreover RB RB O
, , , O
a DT DT O
positive JJ JJ O
correlation NN NN O
of IN IN O
histamine NN NN B-CHEM
to TO TO O
gastric VB VB O
hemorrhage NN NN O
and CC CC O
to TO TO O
ulcer NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
those DT DT O
atherosclerotic JJ JJ O
rats NNS NNS O
. . . O

This DT DT O
hemorrhagic JJ JJ O
ulcer NN NN O
and CC CC O
various JJ JJ O
ulcerogenic JJ JJ O
parameters NNS NNS O
were VBD VBD O
dose JJ JJ O
- : : O
dependently RB RB O
ameliorated VBN VBN O
by IN IN O
daily JJ JJ O
intragastric JJ JJ O
verapamil NN NN B-CHEM
. . . O

Atherosclerosis NNP NNP O
could MD MD O
produce VB VB O
gastric JJ JJ O
hemorrhagic JJ JJ O
ulcer NN NN O
via IN IN O
aggravation NN NN O
of IN IN O
gastric JJ JJ O
acid NN NN O
back RB RB O
- - - O
diffusion NN NN O
, , , O
LPO NNP NNP O
generation NN NN O
, , , O
histamine NN NN B-CHEM
release NN NN O
and CC CC O
microvascular JJ JJ O
permeability NN NN O
that WDT WDT O
could MD MD O
be VB VB O
ameliorated VBN VBN O
by IN IN O
verapamil NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

Lamivudine NNP NNP B-CHEM
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
reactivation NN NN O
in IN IN O
hepatitis NN NN B-CHEM
- - - I-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
( ( ( O
HBSAG NNP NNP B-CHEM
) ) ) O
seropositive JJ JJ O
cancer NN NN O
patients NNS NNS O
undergoing VBG VBG O
cytotoxic NN NN O
chemotherapy NN NN O
. . . O

Hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
is VBZ VBZ O
one CD CD O
of IN IN O
the DT DT O
major JJ JJ O
causes NNS NNS O
of IN IN O
chronic JJ JJ O
liver NN NN O
disease NN NN O
worldwide NN NN O
. . . O

Cancer NNP NNP O
patients NNS NNS O
who WP WP O
are VBP VBP O
chronic JJ JJ O
carriers NNS NNS O
of IN IN O
HBV NNP NNP O
have VBP VBP O
a DT DT O
higher JJR JJR O
hepatic JJ JJ O
complication NN NN O
rate NN NN O
while IN IN O
receiving VBG VBG O
cytotoxic NN NN O
chemotherapy NN NN O
( ( ( O
CT NNP NNP O
) ) ) O
and CC CC O
this DT DT O
has VBZ VBZ O
mainly RB RB O
been VBN VBN O
attributed VBN VBN O
to TO TO O
HBV NNP NNP O
reactivation NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
cancer NN NN O
patients NNS NNS O
who WP WP O
have VBP VBP O
solid JJ JJ O
and CC CC O
hematological JJ JJ O
malignancies NNS NNS O
with IN IN O
chronic JJ JJ O
HBV NNP NNP O
infection NN NN O
received VBD VBD O
the DT DT O
antiviral JJ JJ O
agent NN NN O
lamivudine NN NN B-CHEM
prior RB RB O
and CC CC O
during IN IN O
CT NNP NNP O
compared VBN VBN O
with IN IN O
historical JJ JJ O
control NN NN O
group NN NN O
who WP WP O
did VBD VBD O
not RB RB O
receive VB VB O
lamivudine NN NN B-CHEM
. . . O

The DT DT O
objectives NNS NNS O
were VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
efficacy NN NN O
of IN IN O
lamivudine NN NN B-CHEM
in IN IN O
reducing VBG VBG O
the DT DT O
incidence NN NN O
of IN IN O
HBV NNP NNP O
reactivation NN NN O
, , , O
and CC CC O
diminishing VBG VBG O
morbidity NN NN O
and CC CC O
mortality NN NN O
during IN IN O
CT NNP NNP O
. . . O

Two CD CD O
groups NNS NNS O
were VBD VBD O
compared VBN VBN O
in IN IN O
this DT DT O
study NN NN O
. . . O

The DT DT O
prophylactic JJ JJ O
lamivudin NN NN B-CHEM
group NN NN O
consisted VBN VBN O
of IN IN O
37 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
prophylactic JJ JJ O
lamivudine NN NN B-CHEM
treatment NN NN O
. . . O

The DT DT O
historical JJ JJ O
controls NNS NNS O
consisted VBN VBN O
of IN IN O
50 CD CD O
consecutive JJ JJ O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
CT NNP NNP O
without IN IN O
prophylactic JJ JJ O
lamivudine NN NN B-CHEM
. . . O

They PRP PRP O
were VBD VBD O
followed VBN VBN O
up RP RP O
during IN IN O
and CC CC O
for IN IN O
8 CD CD O
weeks NNS NNS O
after IN IN O
CT NNP NNP O
. . . O

The DT DT O
outcomes NNS NNS O
were VBD VBD O
compared VBN VBN O
for IN IN O
both DT DT O
groups NNS NNS O
. . . O

Of IN IN O
our PRP$ PRP$ O
control NN NN O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
50 CD CD O
) ) ) O
, , , O
21 CD CD O
patients NNS NNS O
( ( ( O
42 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
established VBN VBN O
hepatitis NN NN O
. . . O

Twelve CD CD O
( ( ( O
24 CD CD O
% NN NN O
) ) ) O
of IN IN O
them PRP PRP O
were VBD VBD O
evaluated VBN VBN O
as IN IN O
severe JJ JJ O
hepatitis NN NN O
. . . O

In IN IN O
the DT DT O
prophylactic JJ JJ O
lamivudine NN NN B-CHEM
group NN NN O
severe JJ JJ O
hepatitis NN NN O
were VBD VBD O
observed VBN VBN O
only RB RB O
in IN IN O
1 CD CD O
patient NN NN O
( ( ( O
2 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
of IN IN O
37 CD CD O
patients NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
006 CD CD O
) ) ) O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
mean NN NN O
ALT NNP NNP O
values NNS NNS O
revealed VBD VBD O
significantly RB RB O
higher JJR JJR O
mean NN NN O
alanine NN NN B-CHEM
aminotransferase NN NN O
( ( ( O
ALT NNP NNP O
) ) ) O
values NNS NNS O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
than IN IN O
the DT DT O
prophylactic JJ JJ O
lamivudine NN NN B-CHEM
group NN NN O
; : : O
154 CD CD O
: : : O
64 CD CD O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
32 CD CD O
) ) ) O
. . . O

Our PRP$ PRP$ O
study NN NN O
suggests VBZ VBZ O
that IN IN O
prophylactic JJ JJ O
lamivudine NN NN B-CHEM
significantly RB RB O
decreases VBZ VBZ O
the DT DT O
incidence NN NN O
of IN IN O
HBV NNP NNP O
reactivation NN NN O
and CC CC O
overall JJ JJ O
morbidity NN NN O
in IN IN O
cancer NN NN O
patients NNS NNS O
during IN IN O
and CC CC O
after IN IN O
immunosuppressive JJ JJ O
therapy NN NN O
. . . O

Further RB RB O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
most RBS RBS O
appropriate JJ JJ O
nucleoside NN NN B-CHEM
or CC CC O
nucleotide NN NN B-CHEM
analogue NN NN O
for IN IN O
antiviral JJ JJ O
prophylaxis NNS NNS O
during IN IN O
CT NNP NNP O
and CC CC O
the DT DT O
optimal NN NN O
duration NN NN O
of IN IN O
administration NN NN O
after IN IN O
completion NN NN O
of IN IN O
CT NNP NNP O
. . . O

Recovery NNP NNP O
of IN IN O
tacrolimus NN NN B-CHEM
- - - O
associated VBN VBN O
brachial JJ JJ O
neuritis NNS NNS O
after IN IN O
conversion NN NN O
to TO TO O
everolimus VB VB B-CHEM
in IN IN O
a DT DT O
pediatric JJ JJ O
renal NN NN O
transplant NN NN O
recipient JJ JJ O
- - - O
- - - O
case NN NN O
report NN NN O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

TAC NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
a DT DT O
potent JJ JJ O
immunosuppressive JJ JJ O
agent NN NN O
for IN IN O
solid JJ JJ O
organ NN NN O
transplantation NN NN O
in IN IN O
pediatrics NNS NNS O
. . . O

Neurotoxicity NNP NNP O
is VBZ VBZ O
a DT DT O
potentially RB RB O
serious JJ JJ O
toxic JJ JJ O
effect NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
encephalopathy NN NN O
, , , O
headaches NNS NNS O
, , , O
seizures NNS NNS O
, , , O
or CC CC O
neurological JJ JJ O
deficits NNS NNS O
. . . O

Here RB RB O
, , , O
we PRP PRP O
describe VBP VBP O
an DT DT O
eight CD CD O
- - - O
and CC CC O
- - - O
a DT DT O
- - - O
half NN NN O
- - - O
yr NN NN O
- - - O
old JJ JJ O
male JJ JJ O
renal JJ JJ O
transplant NN NN O
recipient NN NN O
with IN IN O
right NN NN O
BN NNP NNP O
. . . O

MRI NNP NNP O
demonstrated VBD VBD O
hyperintense NN NN O
T2 NNP NNP O
signals NNS NNS O
in IN IN O
the DT DT O
cervical JJ JJ O
cord NN NN O
and CC CC O
right NN NN O
brachial JJ JJ O
plexus NN NN O
roots NNS NNS O
indicative JJ JJ O
of IN IN O
both DT DT O
myelitis NNS NNS O
and CC CC O
right NN NN O
brachial JJ JJ O
plexitis NN NN O
. . . O

Symptoms NNP NNP O
persisted VBD VBD O
for IN IN O
three CD CD O
months NNS NNS O
despite IN IN O
TAC NNP NNP B-CHEM
dose NN NN O
reduction NN NN O
, , , O
administration NN NN O
of IN IN O
IVIG NNP NNP O
and CC CC O
four CD CD O
doses NNS NNS O
of IN IN O
methylprednisolone NN NN B-CHEM
pulse NN NN O
therapy NN NN O
. . . O

Improvement NNP NNP O
and CC CC O
eventually RB RB O
full JJ JJ O
recovery NN NN O
only RB RB O
occurred VBD VBD O
after IN IN O
TAC NNP NNP B-CHEM
was VBD VBD O
completely RB RB O
discontinued VBN VBN O
and CC CC O
successfully RB RB O
replaced VBN VBN O
by IN IN O
everolimus NN NN B-CHEM
. . . O

Omitting NNP NNP O
fentanyl NN NN B-CHEM
reduces VBZ VBZ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
, , , O
without IN IN O
increasing VBG VBG O
pain NN NN O
, , , O
after IN IN O
sevoflurane NN NN B-CHEM
for IN IN O
day NN NN O
surgery NN NN O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
OBJECTIVE NNP NNP O
: : : O
Despite IN IN O
advantages NNS NNS O
of IN IN O
induction NN NN O
and CC CC O
maintenance NN NN O
of IN IN O
anaesthesia NN NN O
with IN IN O
sevoflurane NN NN B-CHEM
, , , O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
occurs VBZ VBZ O
frequently RB RB O
. . . O

Fentanyl NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
commonly RB RB O
used VBN VBN O
supplement NN NN O
that WDT WDT O
may MD MD O
contribute VB VB O
to TO TO O
this DT DT O
, , , O
although IN IN O
it PRP PRP O
may MD MD O
also RB RB O
improve VB VB O
analgesia NN NN O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
double JJ JJ O
- : : O
blind JJ JJ O
study NN NN O
examined VBD VBD O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
and CC CC O
pain NN NN O
in IN IN O
the DT DT O
first JJ JJ O
24 CD CD O
h NN NN O
after IN IN O
sevoflurane NN NN B-CHEM
anaesthesia NN NN O
in IN IN O
216 CD CD O
adult NN NN O
day NN NN O
surgery NN NN O
patients NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
either CC CC O
receive VB VB O
or CC CC O
not RB RB O
receive VB VB O
1 CD CD O
1 CD CD O
fentanyl NN NN B-CHEM
, , , O
while IN IN O
a DT DT O
third JJ JJ O
group NN NN O
received VBD VBD O
dexamethasone NN NN B-CHEM
in IN IN O
addition NN NN O
to TO TO O
fentanyl NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
Omission NNP NNP O
of IN IN O
fentanyl NN NN B-CHEM
did VBD VBD O
not RB RB O
reduce VB VB O
the DT DT O
overall JJ JJ O
incidence NN NN O
of IN IN O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
, , , O
but CC CC O
did VBD VBD O
reduce VB VB O
the DT DT O
incidence NN NN O
of IN IN O
vomiting VBG VBG O
and CC CC O
/ NN NN O
or CC CC O
moderate NN NN O
to TO TO O
severe VB VB O
nausea NN NN O
prior RB RB O
to TO TO O
discharge VB VB O
from IN IN O
20 CD CD O
% NN NN O
and CC CC O
17 CD CD O
% NN NN O
with IN IN O
fentanyl NN NN B-CHEM
and CC CC O
fentanyl NN NN B-CHEM
- : : O
dexamethasone NN NN B-CHEM
, , , O
respectively RB RB O
, , , O
to TO TO O
5 CD CD O
% NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
013 CD CD O
) ) ) O
. . . O

Antiemetic NNP NNP O
requirements NNS NNS O
were VBD VBD O
reduced VBN VBN O
from IN IN O
24 CD CD O
% NN NN O
and CC CC O
31 CD CD O
% NN NN O
to TO TO O
7 CD CD O
% NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
0012 CD CD O
) ) ) O
. . . O

Dexamethasone NNP NNP B-CHEM
had VBD VBD O
no DT DT O
significant JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
incidence NN NN O
or CC CC O
severity NN NN O
of IN IN O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
. . . O

Combining VBG VBG O
the DT DT O
two CD CD O
fentanyl NN NN B-CHEM
groups NNS NNS O
revealed VBD VBD O
further JJ JJ O
significant JJ JJ O
benefits NNS NNS O
from IN IN O
the DT DT O
avoidance NN NN O
of IN IN O
opioids NNS NNS O
, , , O
reducing VBG VBG O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
and CC CC O
nausea NN NN O
prior RB RB O
to TO TO O
discharge VB VB O
from IN IN O
35 CD CD O
% NN NN O
and CC CC O
33 CD CD O
% NN NN O
to TO TO O
22 CD CD O
% NN NN O
and CC CC O
19 CD CD O
% NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
049 CD CD O
and CC CC O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
035 CD CD O
) ) ) O
, , , O
respectively RB RB O
, , , O
while IN IN O
nausea NN NN O
in IN IN O
the DT DT O
first JJ JJ O
24 CD CD O
h NN NN O
was VBD VBD O
decreased VBN VBN O
from IN IN O
42 CD CD O
% NN NN O
to TO TO O
27 CD CD O
% NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
034 CD CD O
) ) ) O
. . . O

Pain NN NN O
severity NN NN O
and CC CC O
analgesic JJ JJ O
requirements NNS NNS O
were VBD VBD O
unaffected JJ JJ O
by IN IN O
the DT DT O
omission NN NN O
of IN IN O
fentanyl NN NN B-CHEM
. . . O

Fentanyl NNP NNP B-CHEM
did VBD VBD O
reduce VB VB O
minor JJ JJ O
intraoperative JJ JJ O
movement NN NN O
but CC CC O
had VBD VBD O
no DT DT O
sevoflurane NN NN B-CHEM
- - - O
sparing VBG VBG O
effect NN NN O
and CC CC O
increased VBN VBN O
respiratory JJ JJ O
depression NN NN O
, , , O
hypotension NN NN O
and CC CC O
bradycardia NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
As IN IN O
fentanyl NN NN B-CHEM
exacerbated VBD VBD O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
without IN IN O
an DT DT O
improvement NN NN O
in IN IN O
postoperative JJ JJ O
pain NN NN O
and CC CC O
also RB RB O
had VBD VBD O
adverse JJ JJ O
cardiorespiratory NN NN O
effects NNS NNS O
, , , O
it PRP PRP O
appears VBZ VBZ O
to TO TO O
be VB VB O
an DT DT O
unnecessary JJ JJ O
and CC CC O
possibly RB RB O
detrimental JJ JJ O
supplement NN NN O
to TO TO O
sevoflurane VB VB B-CHEM
in IN IN O
day NN NN O
surgery NN NN O
. . . O

Valvular NNP NNP O
heart NN NN O
disease NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
treated VBN VBN O
with IN IN O
pergolide NN NN B-CHEM
. . . O

Course NN NN O
following VBG VBG O
treatment NN NN O
modifications NNS NNS O
. . . O

Valvular NNP NNP O
heart NN NN O
abnormalities NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
treated VBN VBN O
with IN IN O
pergolide NN NN B-CHEM
. . . O

However RB RB O
, , , O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
these DT DT O
abnormalities NNS NNS O
vary VBP VBP O
from IN IN O
study NN NN O
to TO TO O
study VB VB O
and CC CC O
their PRP$ PRP$ O
course NN NN O
after IN IN O
drug NN NN O
withdrawal NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
systematically RB RB O
assessed VBN VBN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
estimate VB VB O
the DT DT O
frequency NN NN O
and CC CC O
severity NN NN O
of IN IN O
valvular JJ JJ O
heart NN NN O
abnormality NN NN O
and CC CC O
its PRP$ PRP$ O
possible JJ JJ O
reversibility NN NN O
after IN IN O
drug NN NN O
withdrawal NN NN O
in IN IN O
a DT DT O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

METHODS NNP NNP O
: : : O
All DT DT O
PD NNP NNP O
patients NNS NNS O
in IN IN O
the DT DT O
Amiens NNP NNP O
area NN NN O
treated VBN VBN O
with IN IN O
pergolide NN NN B-CHEM
were VBD VBD O
invited VBN VBN O
to TO TO O
attend VB VB O
a DT DT O
cardiologic JJ JJ O
assessment NN NN O
including VBG VBG O
transthoracic NN NN O
echocardiography NN NN O
. . . O

Thirty NNP NNP O
PD NNP NNP O
patients NNS NNS O
participated VBD VBD O
in IN IN O
the DT DT O
study NN NN O
. . . O

A DT DT O
second JJ JJ O
echocardiography NN NN O
was VBD VBD O
performed VBN VBN O
( ( ( O
median NN NN O
interval NN NN O
: : : O
13 CD CD O
months NNS NNS O
) ) ) O
after IN IN O
pergolide NN NN B-CHEM
withdrawal NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
patients NNS NNS O
) ) ) O
. . . O

Controls NNP NNP O
were VBD VBD O
age NN NN O
- : : O
and CC CC O
sex NN NN O
- - - O
matched JJ JJ O
non NN NN O
- - - O
PD NNP NNP O
patients NNS NNS O
referred VBD VBD O
to TO TO O
the DT DT O
cardiology NN NN O
department NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Compared VBN VBN O
to TO TO O
controls NNS NNS O
, , , O
aortic JJ JJ O
regurgitation NN NN O
( ( ( O
OR CC CC O
: : : O
3 CD CD O
. . . O
1 CD CD O
; : : O
95 CD CD O
% NN NN O
IC NNP NNP O
: : : O
1 CD CD O
. . . O
1 CD CD O
- : : O
8 CD CD O
. . . O
8 CD CD O
) ) ) O
and CC CC O
mitral JJ JJ O
regurgitation NN NN O
( ( ( O
OR CC CC O
: : : O
10 CD CD O
. . . O
7 CD CD O
; : : O
95 CD CD O
% NN NN O
IC NNP NNP O
: : : O
2 CD CD O
. . . O
1 CD CD O
- : : O
53 CD CD O
) ) ) O
were VBD VBD O
more RBR RBR O
frequent JJ JJ O
in IN IN O
PD NNP NNP O
patients NNS NNS O
( ( ( O
tricuspid NN NN O
: : : O
NS NNP NNP O
) ) ) O
. . . O

The DT DT O
number NN NN O
of IN IN O
affected VBN VBN O
valves NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
) ) ) O
and CC CC O
the DT DT O
sum NN NN O
of IN IN O
regurgitation NN NN O
grades NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
09 CD CD O
) ) ) O
were VBD VBD O
higher JJR JJR O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
008 CD CD O
and CC CC O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
006 CD CD O
, , , O
respectively RB RB O
) ) ) O
in IN IN O
the DT DT O
pergolide NN NN B-CHEM
group NN NN O
. . . O

Severity NNP NNP O
of IN IN O
regurgitation NN NN O
was VBD VBD O
not RB RB O
correlated JJ JJ O
with IN IN O
pergolide NN NN B-CHEM
cumulative JJ JJ O
dose NN NN O
. . . O

A DT DT O
restrictive JJ JJ O
pattern NN NN O
of IN IN O
valvular JJ JJ O
regurgitation NN NN O
, , , O
suggestive NN NN O
of IN IN O
the DT DT O
role NN NN O
of IN IN O
pergolide NN NN B-CHEM
, , , O
was VBD VBD O
observed VBN VBN O
in IN IN O
12 CD CD O
/ NN NN O
30 CD CD O
( ( ( O
40 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
including VBG VBG O
two CD CD O
with IN IN O
heart NN NN O
failure NN NN O
. . . O

Pergolide NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
in IN IN O
10 CD CD O
patients NNS NNS O
with IN IN O
valvular JJ JJ O
heart NN NN O
disease NN NN O
, , , O
resulting VBG VBG O
in IN IN O
a DT DT O
lower JJR JJR O
regurgitation NN NN O
grade NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
at IN IN O
the DT DT O
second JJ JJ O
transthoracic NN NN O
echocardiography NN NN O
and CC CC O
the DT DT O
two CD CD O
patients NNS NNS O
with IN IN O
heart NN NN O
failure NN NN O
returned VBD VBD O
to TO TO O
nearly RB RB O
normal JJ JJ O
clinical JJ JJ O
examination NN NN O
. . . O

This DT DT O
study NN NN O
supports VBZ VBZ O
the DT DT O
high JJ JJ O
frequency NN NN O
of IN IN O
restrictive JJ JJ O
valve NN NN O
regurgitation NN NN O
in IN IN O
PD NNP NNP O
patients NNS NNS O
treated VBN VBN O
with IN IN O
pergolide NN NN B-CHEM
and CC CC O
reveals VBZ VBZ O
that IN IN O
a DT DT O
significant JJ JJ O
improvement NN NN O
is VBZ VBZ O
usual JJ JJ O
when WRB WRB O
the DT DT O
treatment NN NN O
is VBZ VBZ O
converted VBN VBN O
to TO TO O
non NN NN O
- - - O
ergot NN NN O
dopamine NN NN B-CHEM
agonists NNS NNS O
. . . O

Adriamycin NNP NNP B-CHEM
- : : O
induced JJ JJ O
autophagic JJ JJ O
cardiomyocyte NN NN O
death NN NN O
plays VBZ VBZ O
a DT DT O
pathogenic JJ JJ O
role NN NN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
heart NN NN O
failure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
mechanisms NNS NNS O
underlying VBG VBG O
heart NN NN O
failure NN NN O
induced VBN VBN O
by IN IN O
adriamycin NN NN B-CHEM
are VBP VBP O
very RB RB O
complicated VBN VBN O
and CC CC O
still RB RB O
unclear JJ JJ O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
whether IN IN O
autophagy NN NN O
was VBD VBD O
involved VBN VBN O
in IN IN O
the DT DT O
progression NN NN O
of IN IN O
heart NN NN O
failure NN NN O
induced VBN VBN O
by IN IN O
adriamycin NN NN B-CHEM
, , , O
so IN IN O
that IN IN O
we PRP PRP O
can MD MD O
develop VB VB O
a DT DT O
novel NN NN O
treatment NN NN O
strategy NN NN O
for IN IN O
heart NN NN O
failure NN NN O
. . . O

METHODS NNP NNP O
: : : O
3 CD CD B-CHEM
- : : I-CHEM
methyladenine NN NN I-CHEM
( ( ( O
3MA CD CD B-CHEM
) ) ) O
, , , O
a DT DT O
specific JJ JJ O
inhibitor NN NN O
on IN IN O
autophagy NN NN O
was VBD VBD O
used VBN VBN O
in IN IN O
a DT DT O
heart NN NN O
failure NN NN O
model NN NN O
of IN IN O
rats NNS NNS O
induced VBN VBN O
by IN IN O
adriamycin NN NN B-CHEM
. . . O

Neonatal NNP NNP O
cardiomyocytes NNS NNS O
were VBD VBD O
isolated VBN VBN O
from IN IN O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rat NN NN O
hearts NNS NNS O
and CC CC O
randomly RB RB O
divided VBN VBN O
into IN IN O
controls NNS NNS O
, , , O
an DT DT O
adriamycin NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
, , , O
and CC CC O
a DT DT O
3MA CD CD B-CHEM
plus CC CC O
adriamycin NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
. . . O

We PRP PRP O
then RB RB O
examined VBD VBD O
the DT DT O
morphology NN NN O
, , , O
expression NN NN O
of IN IN O
beclin NN NN O
1 CD CD O
gene NN NN O
, , , O
mitochondrial JJ JJ O
permeability NN NN O
transition NN NN O
( ( ( O
MPT NNP NNP O
) ) ) O
, , , O
and CC CC O
Na NNP NNP O
+ NN NN O
- : : O
K NNP NNP B-CHEM
+ NN NN O
ATPase NNP NNP O
activity NN NN O
in IN IN O
vivo NN NN O
. . . O

We PRP PRP O
also RB RB O
assessed VBD VBD O
cell NN NN O
viability NN NN O
, , , O
mitochondrial JJ JJ O
membrane NN NN O
potential JJ JJ O
changes NNS NNS O
and CC CC O
counted VBN VBN O
autophagic JJ JJ O
vacuoles NNS NNS O
in IN IN O
cultured JJ JJ O
cardiomyocytes NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
we PRP PRP O
analyzed VBD VBD O
the DT DT O
expression NN NN O
of IN IN O
autophagy NN NN O
associated VBN VBN O
gene NN NN O
, , , O
beclin NN NN O
1 CD CD O
using VBG VBG O
RT NNP NNP O
- : : O
PCR NNP NNP O
and CC CC O
Western JJ JJ O
blotting NN NN O
in IN IN O
an DT DT O
animal NN NN O
model NN NN O
. . . O

RESULTS NNS NNS O
: : : O
3MA CD CD B-CHEM
significantly RB RB O
improved VBN VBN O
cardiac JJ JJ O
function NN NN O
and CC CC O
reduced VBN VBN O
mitochondrial JJ JJ O
injury NN NN O
. . . O

Furthermore RB RB O
, , , O
adriamycin NN NN B-CHEM
induced VBD VBD O
the DT DT O
formation NN NN O
of IN IN O
autophagic JJ JJ O
vacuoles NNS NNS O
, , , O
and CC CC O
3MA CD CD B-CHEM
strongly RB RB O
downregulated VBD VBD O
the DT DT O
expression NN NN O
of IN IN O
beclin NN NN O
1 CD CD O
in IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
failing VBG VBG O
heart NN NN O
and CC CC O
inhibited VBD VBD O
the DT DT O
formation NN NN O
of IN IN O
autophagic JJ JJ O
vacuoles NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Autophagic NNP NNP O
cardiomyocyte NN NN O
death NN NN O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
heart NN NN O
failure NN NN O
in IN IN O
rats NNS NNS O
induced VBN VBN O
by IN IN O
adriamycin NN NN B-CHEM
. . . O

Mitochondrial NNP NNP O
injury NN NN O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
progression NN NN O
of IN IN O
heart NN NN O
failure NN NN O
caused VBN VBN O
by IN IN O
adriamycin NN NN B-CHEM
via IN IN O
the DT DT O
autophagy NN NN O
pathway NN NN O
. . . O

mToR NN NN O
inhibitors NNS NNS O
- : : O
induced VBN VBN O
proteinuria NN NN O
: : : O
mechanisms NNS NNS O
, , , O
significance NN NN O
, , , O
and CC CC O
management NN NN O
. . . O

Massive JJ JJ O
urinary JJ JJ O
protein NN NN O
excretion NN NN O
has VBZ VBZ O
been VBN VBN O
observed VBN VBN O
after IN IN O
conversion NN NN O
from IN IN O
calcineurin NN NN O
inhibitors NNS NNS O
to TO TO O
mammalian JJ JJ O
target NN NN O
of IN IN O
rapamycin NN NN B-CHEM
( ( ( O
mToR NN NN O
) ) ) O
inhibitors NNS NNS O
, , , O
especially RB RB O
sirolimus NN NN B-CHEM
, , , O
in IN IN O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
with IN IN O
chronic JJ JJ O
allograft NN NN O
nephropathy NN NN O
. . . O

Because IN IN O
proteinuria NN NN O
is VBZ VBZ O
a DT DT O
major JJ JJ O
predictive JJ JJ O
factor NN NN O
of IN IN O
poor JJ JJ O
transplantation NN NN O
outcome NN NN O
, , , O
many JJ JJ O
studies NNS NNS O
focused VBN VBN O
on IN IN O
this DT DT O
adverse JJ JJ O
event NN NN O
during IN IN O
the DT DT O
past JJ JJ O
years NNS NNS O
. . . O

Whether IN IN O
proteinuria NNS NNS O
was VBD VBD O
due JJ JJ O
to TO TO O
sirolimus VB VB B-CHEM
or CC CC O
only RB RB O
a DT DT O
consequence NN NN O
of IN IN O
calcineurin NN NN O
inhibitors NNS NNS O
withdrawal NN NN O
remained VBD VBD O
unsolved JJ JJ O
until IN IN O
high JJ JJ O
range NN NN O
proteinuria NN NN O
has VBZ VBZ O
been VBN VBN O
observed VBN VBN O
during IN IN O
sirolimus NN NN B-CHEM
therapy NN NN O
in IN IN O
islet NN NN O
transplantation NN NN O
and CC CC O
in IN IN O
patients NNS NNS O
who WP WP O
received VBD VBD O
sirolimus NN NN B-CHEM
de IN IN O
novo NN NN O
. . . O

Podocyte NNP NNP O
injury NN NN O
and CC CC O
focal JJ JJ O
segmental JJ JJ O
glomerulosclerosis NNS NNS O
have VBP VBP O
been VBN VBN O
related VBN VBN O
to TO TO O
mToR NN NN O
inhibition NN NN O
in IN IN O
some DT DT O
patients NNS NNS O
, , , O
but CC CC O
the DT DT O
pathways NNS NNS O
underlying VBG VBG O
these DT DT O
lesions NNS NNS O
remain VBP VBP O
hypothetic JJ JJ O
. . . O

We PRP PRP O
discuss VBP VBP O
herein NN NN O
the DT DT O
possible JJ JJ O
mechanisms NNS NNS O
and CC CC O
the DT DT O
significance NN NN O
of IN IN O
mToR NN NN O
blockade NN NN O
- : : O
induced JJ JJ O
proteinuria NN NN O
. . . O

Neuropsychiatric NNP NNP O
side NN NN O
effects NNS NNS O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
mefloquine NN NN B-CHEM
. . . O

This DT DT O
study NN NN O
describes VBZ VBZ O
neuropsychiatric JJ JJ O
side NN NN O
effects NNS NNS O
in IN IN O
patients NNS NNS O
after IN IN O
treatment NN NN O
with IN IN O
mefloquine NN NN B-CHEM
. . . O

Reactions NNP NNP O
consisted VBD VBD O
mainly RB RB O
of IN IN O
seizures NNS NNS O
, , , O
acute JJ JJ O
psychoses NNS NNS O
, , , O
anxiety NN NN O
neurosis NN NN O
, , , O
and CC CC O
major JJ JJ O
disturbances NNS NNS O
of IN IN O
sleep NN NN O
- - - O
wake NN NN O
rhythm NN NN O
. . . O

Side NNP NNP O
effects NNS NNS O
occurred VBD VBD O
after IN IN O
both DT DT O
therapeutic JJ JJ O
and CC CC O
prophylactic JJ JJ O
intake NN NN O
and CC CC O
were VBD VBD O
graded VBN VBN O
from IN IN O
moderate JJ JJ O
to TO TO O
severe JJ JJ O
. . . O

In IN IN O
a DT DT O
risk NN NN O
analysis NN NN O
of IN IN O
neuropsychiatric JJ JJ O
side NN NN O
effects NNS NNS O
in IN IN O
Germany NNP NNP O
, , , O
it PRP PRP O
is VBZ VBZ O
estimated VBN VBN O
that IN IN O
one CD CD O
of IN IN O
8 CD CD O
, , , O
000 CD CD O
mefloquine NN NN B-CHEM
users NNS NNS O
suffers NNS NNS O
from IN IN O
such JJ JJ O
reactions NNS NNS O
. . . O

The DT DT O
incidence NN NN O
calculation NN NN O
revealed VBD VBD O
that IN IN O
one CD CD O
of IN IN O
215 CD CD O
therapeutic JJ JJ O
users NNS NNS O
had VBD VBD O
reactions NNS NNS O
, , , O
compared VBN VBN O
with IN IN O
one CD CD O
of IN IN O
13 CD CD O
, , , O
000 CD CD O
in IN IN O
the DT DT O
prophylaxis NN NN O
group NN NN O
, , , O
making VBG VBG O
the DT DT O
risk NN NN O
of IN IN O
neuropsychiatric JJ JJ O
reactions NNS NNS O
after IN IN O
mefloquine NN NN B-CHEM
treatment NN NN O
60 CD CD O
times NNS NNS O
higher JJR JJR O
than IN IN O
after IN IN O
prophylaxis NNS NNS O
. . . O

Therefore RB RB O
, , , O
certain JJ JJ O
limitations NNS NNS O
for IN IN O
malaria NN NN O
prophylaxis NNS NNS O
and CC CC O
treatment NN NN O
with IN IN O
mefloquine NN NN B-CHEM
are VBP VBP O
recommended VBN VBN O
. . . O

Prenatal NNP NNP O
protein NN NN O
deprivation NN NN O
alters NNS NNS O
dopamine NN NN B-CHEM
- - - O
mediated JJ JJ O
behaviors NNS NNS O
and CC CC O
dopaminergic JJ JJ O
and CC CC O
glutamatergic JJ JJ O
receptor NN NN O
binding JJ JJ O
. . . O

Epidemiological NNP NNP O
evidence NN NN O
indicates VBZ VBZ O
that IN IN O
prenatal JJ JJ O
nutritional JJ JJ O
deprivation NN NN O
may MD MD O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
schizophrenia NN NN O
. . . O

The DT DT O
goal NN NN O
of IN IN O
these DT DT O
studies NNS NNS O
was VBD VBD O
to TO TO O
use VB VB O
an DT DT O
animal NN NN O
model NN NN O
to TO TO O
examine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
prenatal JJ JJ O
protein NN NN O
deprivation NN NN O
on IN IN O
behaviors NNS NNS O
and CC CC O
receptor NN NN O
binding JJ JJ O
with IN IN O
relevance NN NN O
to TO TO O
schizophrenia NN NN O
. . . O

We PRP PRP O
report VBP VBP O
that IN IN O
prenatally RB RB O
protein NN NN O
deprived VBN VBN O
( ( ( O
PD NNP NNP O
) ) ) O
female JJ JJ O
rats NNS NNS O
showed VBD VBD O
an DT DT O
increased VBN VBN O
stereotypic NN NN O
response NN NN O
to TO TO O
apomorphine NN NN B-CHEM
and CC CC O
an DT DT O
increased VBN VBN O
locomotor NN NN O
response NN NN O
to TO TO O
amphetamine VB VB B-CHEM
in IN IN O
adulthood NN NN O
. . . O

These DT DT O
differences NNS NNS O
were VBD VBD O
not RB RB O
observed VBN VBN O
during IN IN O
puberty NN NN O
. . . O

No DT DT O
changes NNS NNS O
in IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
or CC CC O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
- : : O
induced JJ JJ O
locomotion NN NN O
were VBD VBD O
seen VBN VBN O
following VBG VBG O
PD NNP NNP O
. . . O

In IN IN O
addition NN NN O
, , , O
PD NNP NNP O
female JJ JJ O
rats NNS NNS O
showed VBD VBD O
increased VBN VBN O
( ( ( O
3 CD CD O
) ) ) O
H NNP NNP B-CHEM
- - - O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
binding VBG VBG O
in IN IN O
the DT DT O
striatum NN NN O
and CC CC O
hippocampus NN NN O
, , , O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
cortex NN NN O
. . . O

PD NNP NNP O
female JJ JJ O
rats NNS NNS O
also RB RB O
showed VBN VBN O
increased VBN VBN O
( ( ( O
3 CD CD O
) ) ) O
H NNP NNP B-CHEM
- : : O
haloperidol NN NN B-CHEM
binding JJ JJ O
and CC CC O
decreased VBD VBD O
dopamine JJ JJ B-CHEM
transporter NN NN O
binding JJ JJ O
in IN IN O
striatum NN NN O
. . . O

No DT DT O
statistically RB RB O
significant JJ JJ O
changes NNS NNS O
in IN IN O
behavior NN NN O
or CC CC O
receptor NN NN O
binding JJ JJ O
were VBD VBD O
found VBN VBN O
in IN IN O
PD NNP NNP O
males NNS NNS O
with IN IN O
the DT DT O
exception NN NN O
of IN IN O
increased VBN VBN O
( ( ( O
3 CD CD O
) ) ) O
H NNP NNP B-CHEM
- - - O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
binding VBG VBG O
in IN IN O
cortex NN NN O
. . . O

This DT DT O
animal NN NN O
model NN NN O
may MD MD O
be VB VB O
useful JJ JJ O
to TO TO O
explore VB VB O
the DT DT O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
prenatal JJ JJ O
nutritional JJ JJ O
deficiency NN NN O
enhances NNS NNS O
risk NN NN O
for IN IN O
schizophrenia NN NN O
in IN IN O
humans NNS NNS O
and CC CC O
may MD MD O
also RB RB O
have VB VB O
implications NNS NNS O
for IN IN O
developmental NN NN O
processes NNS NNS O
leading VBG VBG O
to TO TO O
differential NN NN O
sensitivity NN NN O
to TO TO O
drugs NNS NNS O
of IN IN O
abuse NN NN O
. . . O

Adverse NNP NNP O
effects NNS NNS O
of IN IN O
topical JJ JJ O
papaverine NN NN B-CHEM
on IN IN O
auditory NN NN O
nerve NN NN O
function NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Papaverine NNP NNP B-CHEM
hydrochloride NN NN I-CHEM
is VBZ VBZ O
a DT DT O
direct JJ JJ O
- - - O
acting VBG VBG O
vasodilator NN NN O
used VBN VBN O
to TO TO O
manage VB VB O
vasospasm NN NN O
during IN IN O
various JJ JJ O
neurosurgical JJ JJ O
operations NNS NNS O
. . . O

Transient NNP NNP O
cranial NN NN O
nerve NN NN O
dysfunction NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
in IN IN O
a DT DT O
few JJ JJ O
cases NNS NNS O
with IN IN O
topical JJ JJ O
papaverine NN NN B-CHEM
. . . O

This DT DT O
study NN NN O
supports VBZ VBZ O
previous JJ JJ O
reports NNS NNS O
and CC CC O
provides VBZ VBZ O
neurophysiological JJ JJ O
evidence NN NN O
of IN IN O
an DT DT O
adverse JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
auditory NN NN O
nerve NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
conducted VBD VBD O
a DT DT O
retrospective NN NN O
review NN NN O
of IN IN O
70 CD CD O
consecutive JJ JJ O
microvascular NN NN O
decompression NN NN O
operations NNS NNS O
and CC CC O
studied VBD VBD O
those DT DT O
patients NNS NNS O
who WP WP O
received VBD VBD O
topical JJ JJ O
papaverine NN NN B-CHEM
for IN IN O
vasospasm NN NN O
. . . O

Topical NNP NNP O
papaverine NN NN B-CHEM
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
direct JJ JJ O
therapeutic JJ JJ O
action NN NN O
to TO TO O
manage VB VB O
vasospasm NN NN O
in IN IN O
a DT DT O
total NN NN O
of IN IN O
11 CD CD O
patients NNS NNS O
. . . O

The DT DT O
timing NN NN O
of IN IN O
papaverine NN NN B-CHEM
application NN NN O
and CC CC O
ongoing JJ JJ O
operative JJ JJ O
events NNS NNS O
was VBD VBD O
reviewed VBN VBN O
relative JJ JJ O
to TO TO O
changes NNS NNS O
in IN IN O
neurophysiological JJ JJ O
recordings NNS NNS O
. . . O

Brainstem NNP NNP O
auditory NN NN O
evoked VBD VBD O
potentials NNS NNS O
( ( ( O
BAEPs NNP NNP O
) ) ) O
were VBD VBD O
routinely RB RB O
used VBN VBN O
to TO TO O
monitor VB VB O
cochlear NN NN O
nerve NN NN O
function NN NN O
during IN IN O
these DT DT O
operations NNS NNS O
. . . O

FINDINGS NNS NNS O
: : : O
A DT DT O
temporal JJ JJ O
relationship NN NN O
was VBD VBD O
found VBN VBN O
between IN IN O
topical JJ JJ O
papaverine NN NN B-CHEM
and CC CC O
BAEP NNP NNP O
changes NNS NNS O
leading VBG VBG O
to TO TO O
complete VB VB O
waveform NN NN O
loss NN NN O
. . . O

The DT DT O
average JJ JJ O
temporal JJ JJ O
delay NN NN O
between IN IN O
papaverine NN NN B-CHEM
and CC CC O
the DT DT O
onset NN NN O
of IN IN O
an DT DT O
adverse JJ JJ O
BAEP NNP NNP O
change NN NN O
was VBD VBD O
5 CD CD O
min NN NN O
. . . O

In IN IN O
10 CD CD O
of IN IN O
11 CD CD O
patients NNS NNS O
, , , O
BAEP NNP NNP O
waves NNS NNS O
II NNP NNP O
/ NN NN O
III NNP NNP O
- - - O
V NNP NNP O
completely RB RB O
disappeared VBD VBD O
within IN IN O
2 CD CD O
to TO TO O
25 CD CD O
min NN NN O
after IN IN O
papaverine NN NN B-CHEM
. . . O

Eight CD CD O
of IN IN O
these DT DT O
10 CD CD O
patients NNS NNS O
had VBD VBD O
complete JJ JJ O
loss NN NN O
of IN IN O
BAEP NNP NNP O
waveforms NNS NNS O
within IN IN O
10 CD CD O
min NN NN O
. . . O

One CD CD O
patient NN NN O
showed VBD VBD O
no DT DT O
recovery NN NN O
of IN IN O
later RB RB O
waves NNS NNS O
and CC CC O
a DT DT O
delayed JJ JJ O
profound NN NN O
sensorineural JJ JJ O
hearing NN NN O
loss NN NN O
. . . O

The DT DT O
average JJ JJ O
recovery NN NN O
time NN NN O
of IN IN O
BAEP NNP NNP O
waveforms NNS NNS O
to TO TO O
pre VB VB O
- - - O
papaverine NN NN B-CHEM
baseline NN NN O
values NNS NNS O
was VBD VBD O
39 CD CD O
min NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Topical NNP NNP O
papaverine NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
vasospasm NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
the DT DT O
onset NN NN O
of IN IN O
a DT DT O
transient NN NN O
disturbance NN NN O
in IN IN O
neurophysiological JJ JJ O
function NN NN O
of IN IN O
the DT DT O
ascending VBG VBG O
auditory NN NN O
brainstem NN NN O
pathway NN NN O
. . . O

The DT DT O
complete JJ JJ O
disappearance NN NN O
of IN IN O
BAEP NNP NNP O
waveforms NNS NNS O
with IN IN O
a DT DT O
consistent JJ JJ O
temporal JJ JJ O
delay NN NN O
suggests VBZ VBZ O
a DT DT O
possible JJ JJ O
adverse JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
proximal NN NN O
eighth NN NN O
nerve NN NN O
. . . O

Recommendations NNP NNP O
to TO TO O
avoid VB VB O
potential JJ JJ O
cranial NN NN O
nerve NN NN O
deficits NNS NNS O
from IN IN O
papaverine NN NN B-CHEM
are VBP VBP O
provided VBN VBN O
. . . O

Simvastatin NNP NNP B-CHEM
- : : I-CHEM
ezetimibe NN NN I-CHEM
- : : O
induced JJ JJ O
hepatic JJ JJ O
failure NN NN O
necessitating VBG VBG O
liver NN NN O
transplantation NN NN O
. . . O

Abstract NNP NNP O
Serum NNP NNP O
aminotransferase NN NN O
elevations NNS NNS O
are VBP VBP O
a DT DT O
commonly RB RB O
known VBN VBN O
adverse JJ JJ O
effect NN NN O
of IN IN O
3 CD CD O
- : : O
hydroxy NN NN O
- : : O
3 CD CD O
- : : O
methylglutaryl NN NN O
coenzyme NN NN O
A DT DT O
reductase NN NN O
inhibitor NN NN O
( ( ( O
statin NN NN B-CHEM
) ) ) O
therapy NN NN O
. . . O

However RB RB O
, , , O
hepatotoxic JJ JJ O
events NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
widely RB RB O
published VBN VBN O
with IN IN O
ezetimibe NN NN B-CHEM
or CC CC O
the DT DT O
combination NN NN O
agent NN NN O
simvastatin NN NN B-CHEM
- : : I-CHEM
ezetimibe NN NN I-CHEM
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
70 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Hispanic NNP NNP O
woman NN NN O
who WP WP O
developed VBD VBD O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
necessitating VBG VBG O
liver NN NN O
transplantation NN NN O
10 CD CD O
weeks NNS NNS O
after IN IN O
conversion NN NN O
from IN IN O
simvastatin NN NN B-CHEM
40 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
to TO TO O
simvastatin NN NN B-CHEM
10 CD CD I-CHEM
mg NN NN I-CHEM
- : : I-CHEM
ezetimibe NN NN I-CHEM
40 CD CD I-CHEM
mg NN NN I-CHEM
/ NN NN O
day NN NN O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
lipid NN NN O
panel NN NN O
had VBD VBD O
been VBN VBN O
maintained VBN VBN O
with IN IN O
simvastatin NN NN B-CHEM
for IN IN O
18 CD CD O
months NNS NNS O
before IN IN O
the DT DT O
conversion NN NN O
without IN IN O
evidence NN NN O
of IN IN O
hepatotoxicity NN NN O
. . . O

A DT DT O
routine NN NN O
laboratory NN NN O
work NN NN O
- : : O
up RP RP O
10 CD CD O
weeks NNS NNS O
after IN IN O
conversion NN NN O
revealed VBD VBD O
elevated VBD VBD O
serum NN NN O
aminotransferase NN NN O
levels NNS NNS O
. . . O

Simvastatinezetimibe NNP NNP B-CHEM
and CC CC O
escitalopram NN NN B-CHEM
( ( ( O
which WDT WDT O
she PRP PRP O
was VBD VBD O
taking VBG VBG O
for IN IN O
depression NN NN O
) ) ) O
were VBD VBD O
discontinued VBN VBN O
, , , O
and CC CC O
other JJ JJ O
potential JJ JJ O
causes NNS NNS O
of IN IN O
hepatotoxicity NN NN O
were VBD VBD O
excluded VBN VBN O
. . . O

A DT DT O
repeat NN NN O
work NN NN O
- : : O
up RP RP O
revealed VBD VBD O
further JJ JJ O
elevations NNS NNS O
in IN IN O
aminotransferase NN NN O
levels NNS NNS O
, , , O
and CC CC O
liver NN NN O
biopsy NN NN O
revealed VBD VBD O
evidence NN NN O
of IN IN O
moderate JJ JJ O
- - - O
to TO TO O
- - - O
severe JJ JJ O
drug NN NN O
toxicity NN NN O
. . . O

She PRP PRP O
underwent JJ JJ O
liver NN NN O
transplantation NN NN O
with IN IN O
an DT DT O
uneventful JJ JJ O
postoperative JJ JJ O
course NN NN O
. . . O

Her PRP$ PRP$ O
aminotransferase NN NN O
levels NNS NNS O
returned VBD VBD O
to TO TO O
normal JJ JJ O
by IN IN O
postoperative JJ JJ O
day NN NN O
23 CD CD O
, , , O
and CC CC O
her PRP$ PRP$ O
2 CD CD O
- : : O
year NN NN O
follow VB VB O
- - - O
up RP RP O
showed VBD VBD O
no DT DT O
adverse JJ JJ O
events NNS NNS O
. . . O

Ezetimibe NNP NNP B-CHEM
undergoes NNS NNS O
extensive JJ JJ O
glucuronidation NN NN O
by IN IN O
uridine JJ JJ B-CHEM
diphosphate NN NN I-CHEM
glucoronosyltransferases NNS NNS O
( ( ( O
UGT NNP NNP O
) ) ) O
in IN IN O
the DT DT O
intestine NN NN O
and CC CC O
liver NN NN O
and CC CC O
may MD MD O
have VB VB O
inhibited VBN VBN O
the DT DT O
glucuronidation NN NN O
of IN IN O
simvastatin NN NN B-CHEM
hydroxy JJ JJ I-CHEM
acid NN NN I-CHEM
, , , O
resulting VBG VBG O
in IN IN O
increased VBN VBN O
simvastatin NN NN B-CHEM
exposure NN NN O
and CC CC O
subsequent JJ JJ O
hepatotoxicity NN NN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
case NN NN O
report NN NN O
of IN IN O
simvastatin NN NN B-CHEM
- - - I-CHEM
ezetimibe NN NN I-CHEM
- - - O
induced JJ JJ O
liver NN NN O
failure NN NN O
that WDT WDT O
resulted VBD VBD O
in IN IN O
liver NN NN O
transplantation NN NN O
. . . O

We PRP PRP O
postulate VBP VBP O
that IN IN O
the DT DT O
mechanism NN NN O
of IN IN O
the DT DT O
simvastatinezetimibe NN NN B-CHEM
- - - O
induced JJ JJ O
hepatotoxicity NN NN O
is VBZ VBZ O
the DT DT O
increased VBN VBN O
simvastatin NN NN B-CHEM
exposure NN NN O
by IN IN O
ezetimibe JJ JJ B-CHEM
inhibition NN NN O
of IN IN O
UGT NNP NNP O
enzymes NNS NNS O
. . . O

Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
potential JJ JJ O
hepatotoxicity NN NN O
with IN IN O
simvastatin NN NN B-CHEM
- - - I-CHEM
ezetimibe NN NN I-CHEM
especially RB RB O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
and CC CC O
should MD MD O
carefully RB RB O
monitor VB VB O
serum NN NN O
aminotransferase NN NN O
levels NNS NNS O
when WRB WRB O
starting VBG VBG O
therapy NN NN O
and CC CC O
titrating VBG VBG O
the DT DT O
dosage NN NN O
. . . O

Massive JJ JJ O
proteinuria NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
after IN IN O
oral JJ JJ O
bisphosphonate NN NN B-CHEM
( ( ( O
alendronate NN NN B-CHEM
) ) ) O
administration NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
focal JJ JJ O
segmental JJ JJ O
glomerulosclerosis NN NN O
. . . O

A DT DT O
61 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
Japanese JJ JJ O
man NN NN O
with IN IN O
nephrotic JJ JJ O
syndrome NN NN O
due JJ JJ O
to TO TO O
focal JJ JJ O
segmental JJ JJ O
glomerulosclerosis NN NN O
was VBD VBD O
initially RB RB O
responding VBG VBG O
well RB RB O
to TO TO O
steroid VB VB B-CHEM
therapy NN NN O
. . . O

The DT DT O
amount NN NN O
of IN IN O
daily JJ JJ O
urinary JJ JJ O
protein NN NN O
decreased VBD VBD O
from IN IN O
15 CD CD O
. . . O
6 CD CD O
to TO TO O
2 CD CD O
. . . O
8 CD CD O
g SYM SYM O
. . . O

Within IN IN O
14 CD CD O
days NNS NNS O
of IN IN O
the DT DT O
oral JJ JJ O
bisphosphonate NN NN B-CHEM
( ( ( O
alendronate NN NN B-CHEM
sodium NN NN I-CHEM
) ) ) O
administration NN NN O
, , , O
the DT DT O
amount NN NN O
of IN IN O
daily JJ JJ O
urinary JJ JJ O
protein NN NN O
increased VBD VBD O
rapidly RB RB O
up IN IN O
to TO TO O
12 CD CD O
. . . O
8 CD CD O
g SYM SYM O
with IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

After IN IN O
discontinuing VBG VBG O
the DT DT O
oral JJ JJ O
alendronate NN NN B-CHEM
, , , O
the DT DT O
patient NN NN O
underwent JJ JJ O
six CD CD O
cycles NNS NNS O
of IN IN O
hemodialysis NN NN O
and CC CC O
four CD CD O
cycles NNS NNS O
of IN IN O
LDL NNP NNP O
apheresis NN NN O
. . . O

Urinary NNP NNP O
volume NN NN O
and CC CC O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
recovered VBN VBN O
to TO TO O
the DT DT O
normal JJ JJ O
range NN NN O
, , , O
with IN IN O
urinary JJ JJ O
protein NN NN O
disappearing VBG VBG O
completely RB RB O
within IN IN O
40 CD CD O
days NNS NNS O
. . . O

This DT DT O
report NN NN O
demonstrates VBZ VBZ O
that IN IN O
not RB RB O
only RB RB O
intravenous JJ JJ O
, , , O
but CC CC O
also RB RB O
oral JJ JJ O
bisphosphonates NNS NNS B-CHEM
can MD MD O
aggravate VB VB O
proteinuria NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Serum NNP NNP O
- : : O
and CC CC O
glucocorticoid JJ JJ O
- - - O
inducible JJ JJ O
kinase NN NN O
1 CD CD O
in IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Doxorubicin NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
leads VBZ VBZ O
to TO TO O
epithelial NN NN O
sodium NN NN B-CHEM
channel NN NN O
( ( ( O
ENaC NNP NNP O
) ) ) O
- : : O
dependent NN NN O
volume NN NN O
retention NN NN O
and CC CC O
renal JJ JJ O
fibrosis NNS NNS O
. . . O

The DT DT O
aldosterone NN NN B-CHEM
- - - O
sensitive JJ JJ O
serum NN NN O
- : : O
and CC CC O
glucocorticoid JJ JJ O
- - - O
inducible JJ JJ O
kinase NN NN O
SGK1 NNP NNP O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
participate VB VB O
in IN IN O
the DT DT O
stimulation NN NN O
of IN IN O
ENaC NNP NNP O
and CC CC O
to TO TO O
mediate VB VB O
renal JJ JJ O
fibrosis NNS NNS O
following VBG VBG O
mineralocorticoid NN NN O
and CC CC O
salt NN NN O
excess NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
performed VBN VBN O
to TO TO O
elucidate VB VB O
the DT DT O
role NN NN O
of IN IN O
SGK1 NNP NNP O
in IN IN O
the DT DT O
volume NN NN O
retention NN NN O
and CC CC O
fibrosis NNS NNS O
during IN IN O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

To TO TO O
this DT DT O
end NN NN O
, , , O
doxorubicin NN NN B-CHEM
( ( ( O
15 CD CD O
mug NN NN O
/ NN NN O
g SYM SYM O
body NN NN O
wt NN NN O
) ) ) O
was VBD VBD O
injected VBN VBN O
intravenously RB RB O
into IN IN O
gene NN NN O
- - - O
targeted JJ JJ O
mice NN NN O
lacking VBG VBG O
SGK1 NNP NNP O
( ( ( O
sgk1 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
) ) ) O
and CC CC O
their PRP$ PRP$ O
wild JJ JJ O
- - - O
type NN NN O
littermates NNS NNS O
( ( ( O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
) ) ) O
. . . O

Doxorubicin NNP NNP B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
heavy JJ JJ O
proteinuria NN NN O
( ( ( O
> NN NN O
100 CD CD O
mg NN NN O
protein NN NN O
/ NN NN O
mg NN NN O
crea NN NN O
) ) ) O
in IN IN O
15 CD CD O
/ NN NN O
44 CD CD O
of IN IN O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
and CC CC O
15 CD CD O
/ NN NN O
44 CD CD O
of IN IN O
sgk1 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
leading VBG VBG O
to TO TO O
severe VB VB O
nephrotic JJ JJ O
syndrome NN NN O
with IN IN O
ascites NNS NNS O
, , , O
lipidemia NN NN O
, , , O
and CC CC O
hypoalbuminemia NN NN O
in IN IN O
both DT DT O
genotypes NNS NNS O
. . . O

Plasma NNP NNP O
aldosterone NN NN B-CHEM
levels NNS NNS O
increased VBN VBN O
in IN IN O
nephrotic JJ JJ O
mice NN NN O
of IN IN O
both DT DT O
genotypes NNS NNS O
and CC CC O
was VBD VBD O
followed VBN VBN O
by IN IN O
increased VBN VBN O
SGK1 NNP NNP O
protein NN NN O
expression NN NN O
in IN IN O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
mice NN NN O
. . . O

Urinary NNP NNP O
sodium NN NN B-CHEM
excretion NN NN O
reached VBD VBD O
signficantly RB RB O
lower JJR JJR O
values NNS NNS O
in IN IN O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
mice NN NN O
( ( ( O
15 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
mumol NN NN O
/ NN NN O
mg NN NN O
crea NN NN O
) ) ) O
than IN IN O
in IN IN O
sgk1 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
( ( ( O
35 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
mumol NN NN O
/ NN NN O
mg NN NN O
crea NN NN O
) ) ) O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
significantly RB RB O
higher JJR JJR O
body NN NN O
weight NN NN O
gain NN NN O
in IN IN O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
compared VBN VBN O
with IN IN O
sgk1 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
( ( ( O
+ NN NN O
6 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
vs NNS NNS O
. . . O
+ NN NN O
4 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
8 CD CD O
g SYM SYM O
) ) ) O
. . . O

During IN IN O
the DT DT O
course NN NN O
of IN IN O
nephrotic JJ JJ O
syndrome NN NN O
, , , O
serum NN NN O
urea NN NN B-CHEM
concentrations NNS NNS O
increased VBN VBN O
significantly RB RB O
faster RBR RBR O
in IN IN O
sgk1 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
than IN IN O
in IN IN O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
mice NN NN O
leading VBG VBG O
to TO TO O
uremia VB VB O
and CC CC O
a DT DT O
reduced JJ JJ O
median NN NN O
survival NN NN O
in IN IN O
sgk1 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
( ( ( O
29 CD CD O
vs NNS NNS O
. . . O
40 CD CD O
days NNS NNS O
in IN IN O
sgk1 NN NN O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
mice NN NN O
) ) ) O
. . . O

In IN IN O
conclusion NN NN O
, , , O
gene NN NN O
- - - O
targeted JJ JJ O
mice NN NN O
lacking VBG VBG O
SGK1 NNP NNP O
showed VBD VBD O
blunted VBN VBN O
volume NN NN O
retention NN NN O
, , , O
yet RB RB O
were VBD VBD O
not RB RB O
protected VBN VBN O
against IN IN O
renal JJ JJ O
fibrosis NNS NNS O
during IN IN O
experimental JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Severe NNP NNP O
thrombocytopenia NN NN O
and CC CC O
haemolytic JJ JJ O
anaemia NN NN O
associated VBN VBN O
with IN IN O
ciprofloxacin NN NN B-CHEM
: : : O
a DT DT O
case NN NN O
report NN NN O
with IN IN O
fatal JJ JJ O
outcome NN NN O
. . . O

Haematological NNP NNP O
adverse JJ JJ O
reactions NNS NNS O
associated VBN VBN O
with IN IN O
fatal JJ JJ O
outcome NN NN O
are VBP VBP O
rare JJ JJ O
during IN IN O
treatment NN NN O
with IN IN O
ciprofloxacin NN NN B-CHEM
. . . O

A DT DT O
30 CD CD O
- : : O
year NN NN O
old JJ JJ O
Caucasian NNP NNP O
man NN NN O
reported VBD VBD O
with IN IN O
abdominal JJ JJ O
pain NN NN O
and CC CC O
jaundice NN NN O
after IN IN O
3 CD CD O
- : : O
day NN NN O
administration NN NN O
of IN IN O
oral JJ JJ O
ciprofloxacin NN NN B-CHEM
for IN IN O
a DT DT O
suspect NN NN O
of IN IN O
urinary JJ JJ O
tract NN NN O
infection NN NN O
. . . O

Clinical NNP NNP O
evaluations NNS NNS O
suggested VBD VBD O
an DT DT O
initial JJ JJ O
diagnosis NN NN O
of IN IN O
severe JJ JJ O
thrombocytopenia NN NN O
and CC CC O
haemolysis NN NN O
. . . O

The DT DT O
patient NN NN O
progressively RB RB O
developed VBN VBN O
petechiae NN NN O
and CC CC O
purpura NN NN O
on IN IN O
thorax NN NN O
and CC CC O
lower JJR JJR O
limbs NNS NNS O
. . . O

Despite IN IN O
pharmacological JJ JJ O
and CC CC O
supportive JJ JJ O
interventions NNS NNS O
, , , O
laboratory NN NN O
parameters NNS NNS O
worsened VBD VBD O
and CC CC O
the DT DT O
patient NN NN O
died VBD VBD O
17 CD CD O
hours NNS NNS O
after IN IN O
admission NN NN O
. . . O

An DT DT O
accurate JJ JJ O
autopsy NN NN O
revealed VBD VBD O
most RBS RBS O
organs NNS NNS O
with IN IN O
diffuse NN NN O
petechial JJ JJ O
haemorrhages NNS NNS O
. . . O

No DT DT O
signs NNS NNS O
of IN IN O
bone NN NN O
marrow NN NN O
depression NN NN O
were VBD VBD O
found VBN VBN O
. . . O

No DT DT O
thrombi NN NN O
or CC CC O
signs NNS NNS O
of IN IN O
microangiopathies NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
arterial JJ JJ O
vessels NNS NNS O
. . . O

Blood NNP NNP O
and CC CC O
urine NN NN O
cultures NNS NNS O
did VBD VBD O
not RB RB O
show VB VB O
any DT DT O
bacterial JJ JJ O
growth NN NN O
. . . O

This DT DT O
case NN NN O
report NN NN O
shows NNS NNS O
that IN IN O
ciprofloxacin NN NN B-CHEM
may MD MD O
precipitate NN NN O
life NN NN O
- : : O
threatening VBG VBG O
thrombocytopenia NN NN O
and CC CC O
haemolytic JJ JJ O
anaemia NN NN O
, , , O
even RB RB O
in IN IN O
the DT DT O
early JJ JJ O
phases NNS NNS O
of IN IN O
treatment NN NN O
and CC CC O
without IN IN O
apparent JJ JJ O
previous JJ JJ O
exposures NNS NNS O
. . . O

Alpha NNP NNP B-CHEM
- : : I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
prevents NNS NNS O
mitochondrial JJ JJ O
damage NN NN O
and CC CC O
neurotoxicity NN NN O
in IN IN O
experimental JJ JJ O
chemotherapy NN NN O
neuropathy NN NN O
. . . O

The DT DT O
study NN NN O
investigates VBZ VBZ O
if IN IN O
alpha JJ JJ B-CHEM
- - - I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
is VBZ VBZ O
neuroprotective JJ JJ O
against IN IN O
chemotherapy NN NN O
induced JJ JJ O
neurotoxicity NN NN O
, , , O
if IN IN O
mitochondrial JJ JJ O
damage NN NN O
plays VBZ VBZ O
a DT DT O
critical JJ JJ O
role NN NN O
in IN IN O
toxic JJ JJ O
neurodegenerative JJ JJ O
cascade NN NN O
, , , O
and CC CC O
if IN IN O
neuroprotective JJ JJ O
effects NNS NNS O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
depend NN NN O
on IN IN O
mitochondria NN NN O
protection NN NN O
. . . O

We PRP PRP O
used VBD VBD O
an DT DT O
in IN IN O
vitro NN NN O
model NN NN O
of IN IN O
chemotherapy NN NN O
induced VBD VBD O
peripheral JJ JJ O
neuropathy NN NN O
that WDT WDT O
closely RB RB O
mimic JJ JJ O
the DT DT O
in IN IN O
vivo NN NN O
condition NN NN O
by IN IN O
exposing VBG VBG O
primary JJ JJ O
cultures NNS NNS O
of IN IN O
dorsal NN NN O
root NN NN O
ganglion NN NN O
( ( ( O
DRG NNP NNP O
) ) ) O
sensory JJ JJ O
neurons NNS NNS O
to TO TO O
paclitaxel VB VB B-CHEM
and CC CC O
cisplatin NN NN B-CHEM
, , , O
two CD CD O
widely RB RB O
used VBN VBN O
and CC CC O
highly RB RB O
effective JJ JJ O
chemotherapeutic JJ JJ O
drugs NNS NNS O
. . . O

This DT DT O
approach NN NN O
allowed VBD VBD O
investigating VBG VBG O
the DT DT O
efficacy NN NN O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
in IN IN O
preventing VBG VBG O
axonal JJ JJ O
damage NN NN O
and CC CC O
apoptosis NN NN O
and CC CC O
the DT DT O
function NN NN O
and CC CC O
ultrastructural JJ JJ O
morphology NN NN O
of IN IN O
mitochondria NN NN O
after IN IN O
exposure NN NN O
to TO TO O
toxic JJ JJ O
agents NNS NNS O
and CC CC O
alpha NN NN B-CHEM
- - - I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
. . . O

Our PRP$ PRP$ O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
both DT DT O
cisplatin NN NN B-CHEM
and CC CC O
paclitaxel NN NN B-CHEM
cause VB VB O
early JJ JJ O
mitochondrial JJ JJ O
impairment NN NN O
with IN IN O
loss NN NN O
of IN IN O
membrane NN NN O
potential JJ JJ O
and CC CC O
induction NN NN O
of IN IN O
autophagic JJ JJ O
vacuoles NNS NNS O
in IN IN O
neurons NNS NNS O
. . . O

Alpha NNP NNP B-CHEM
- : : I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
exerts NNS NNS O
neuroprotective JJ JJ O
effects NNS NNS O
against IN IN O
chemotherapy NN NN O
induced JJ JJ O
neurotoxicity NN NN O
in IN IN O
sensory JJ JJ O
neurons NNS NNS O
: : : O
it PRP PRP O
rescues VBZ VBZ O
the DT DT O
mitochondrial JJ JJ O
toxicity NN NN O
and CC CC O
induces VBZ VBZ O
the DT DT O
expression NN NN O
of IN IN O
frataxin NN NN O
, , , O
an DT DT O
essential JJ JJ O
mitochondrial NN NN O
protein NN NN O
with IN IN O
anti JJ JJ O
- : : O
oxidant NN NN O
and CC CC O
chaperone NN NN O
properties NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
mitochondrial JJ JJ O
toxicity NN NN O
is VBZ VBZ O
an DT DT O
early JJ JJ O
common JJ JJ O
event NN NN O
both DT DT O
in IN IN O
paclitaxel NN NN B-CHEM
and CC CC O
cisplatin NN NN B-CHEM
induced JJ JJ O
neurotoxicity NN NN O
. . . O

Alpha NNP NNP B-CHEM
- : : I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
protects NNS NNS O
sensory JJ JJ O
neurons NNS NNS O
through IN IN O
its PRP$ PRP$ O
anti JJ JJ O
- : : O
oxidant NN NN O
and CC CC O
mitochondrial JJ JJ O
regulatory JJ JJ O
functions NNS NNS O
, , , O
possibly RB RB O
inducing VBG VBG O
the DT DT O
expression NN NN O
of IN IN O
frataxin NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
alpha JJ JJ B-CHEM
- : : I-CHEM
lipoic JJ JJ I-CHEM
acid NN NN I-CHEM
might MD MD O
reduce VB VB O
the DT DT O
risk NN NN O
of IN IN O
developing VBG VBG O
peripheral JJ JJ O
nerve NN NN O
toxicity NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
chemotherapy NN NN O
and CC CC O
encourage VB VB O
further JJ JJ O
confirmatory NN NN O
clinical JJ JJ O
trials NNS NNS O
. . . O

Toxicity NNP NNP O
in IN IN O
rhesus NN NN O
monkeys NNS NNS O
following VBG VBG O
administration NN NN O
of IN IN O
the DT DT O
8 CD CD B-CHEM
- : : I-CHEM
aminoquinoline NN NN I-CHEM
8 CD CD B-CHEM
- : : I-CHEM
[ NN NN I-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
amino JJ JJ I-CHEM
- - - I-CHEM
l NN NN I-CHEM
- - - I-CHEM
methylbutyl NN NN I-CHEM
) ) ) I-CHEM
amino JJ JJ I-CHEM
] NN NN I-CHEM
- - - I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
l NN NN I-CHEM
- - - I-CHEM
hexyloxy NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
methoxy NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylquinoline NN NN I-CHEM
( ( ( O
WR242511 NNP NNP B-CHEM
) ) ) O
. . . O

INTRODUCTION NNP NNP O
: : : O
Many JJ JJ O
substances NNS NNS O
that WDT WDT O
form NN NN O
methemoglobin NN NN O
( ( ( O
MHb NNP NNP O
) ) ) O
effectively RB RB O
counter JJR JJR O
cyanide NN NN O
( ( ( O
CN NNP NNP O
) ) ) O
toxicity NN NN O
. . . O

Although IN IN O
MHb NNP NNP O
formers NNS NNS O
are VBP VBP O
generally RB RB O
applied VBN VBN O
as IN IN O
treatments NNS NNS O
for IN IN O
CN NNP NNP O
poisoning NN NN O
, , , O
it PRP PRP O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
that IN IN O
a DT DT O
stable JJ JJ O
, , , O
long JJ JJ O
- - - O
acting VBG VBG O
MHb NNP NNP O
former JJ JJ O
could MD MD O
serve VB VB O
as IN IN O
a DT DT O
CN NNP NNP O
pretreatment NN NN O
. . . O

Using VBG VBG O
this DT DT O
rationale NN NN O
, , , O
the DT DT O
8 CD CD B-CHEM
- : : I-CHEM
aminoquinoline NN NN I-CHEM
WR242511 NNP NNP B-CHEM
, , , O
a DT DT O
potent NN NN O
long JJ JJ O
- : : O
lasting JJ JJ O
MHb NNP NNP O
former JJ JJ O
in IN IN O
rodents NNS NNS O
and CC CC O
beagle NN NN O
dogs NNS NNS O
, , , O
was VBD VBD O
studied VBN VBN O
in IN IN O
the DT DT O
rhesus NN NN O
monkey NN NN O
for IN IN O
advanced VBN VBN O
development NN NN O
as IN IN O
a DT DT O
potential JJ JJ O
CN NNP NNP O
pretreatment NN NN O
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
this DT DT O
study NN NN O
, , , O
WR242511 NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
intravenously RB RB O
( ( ( O
IV NNP NNP O
) ) ) O
in IN IN O
2 CD CD O
female NN NN O
and CC CC O
4 CD CD O
male JJ JJ O
rhesus NN NN O
monkeys NNS NNS O
in IN IN O
doses NNS NNS O
of IN IN O
3 CD CD O
. . . O
5 CD CD O
and CC CC O
/ NN NN O
or CC CC O
7 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
a DT DT O
single JJ JJ O
male JJ JJ O
also RB RB O
received VBD VBD O
WR242511 NNP NNP B-CHEM
orally RB RB O
( ( ( O
PO NNP NNP O
) ) ) O
at IN IN O
7 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Health NNP NNP O
status NN NN O
and CC CC O
MHb NNP NNP O
levels NNS NNS O
were VBD VBD O
monitored VBN VBN O
following VBG VBG O
exposure NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
selected JJ JJ O
doses NNS NNS O
of IN IN O
WR242511 NNP NNP B-CHEM
, , , O
which WDT WDT O
produced VBD VBD O
significant JJ JJ O
methemoglobinemia NN NN O
in IN IN O
beagle NN NN O
dogs NNS NNS O
in IN IN O
earlier RBR RBR O
studies NNS NNS O
conducted VBN VBN O
elsewhere RB RB O
, , , O
produced VBN VBN O
very RB RB O
little JJ JJ O
MHb NNP NNP O
( ( ( O
mean VB VB O
< NN NN O
2 CD CD O
. . . O
0 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
rhesus NN NN O
monkey NN NN O
. . . O

Furthermore RB RB O
, , , O
transient NN NN O
hemoglobinuria NN NN O
was VBD VBD O
noted VBN VBN O
approximately RB RB O
60 CD CD O
minutes NNS NNS O
postinjection NN NN O
of IN IN O
WR242511 NNP NNP B-CHEM
( ( ( O
3 CD CD O
. . . O
5 CD CD O
or CC CC O
7 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
and CC CC O
2 CD CD O
lethalities NNS NNS O
occurred VBD VBD O
( ( ( O
one CD CD O
IV NNP NNP O
and CC CC O
one CD CD O
PO NNP NNP O
) ) ) O
following VBG VBG O
the DT DT O
7 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
. . . O

Myoglobinuria NNP NNP O
was VBD VBD O
also RB RB O
observed VBN VBN O
following VBG VBG O
the DT DT O
7 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
. . . O

Histopathology NNP NNP O
analyses NNS NNS O
in IN IN O
the DT DT O
2 CD CD O
animals NNS NNS O
that WDT WDT O
died VBD VBD O
revealed VBN VBN O
liver NN NN O
and CC CC O
kidney NN NN O
toxicity NN NN O
, , , O
with IN IN O
greater JJR JJR O
severity NN NN O
in IN IN O
the DT DT O
orally RB RB O
- - - O
treated JJ JJ O
animal NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
data NNS NNS O
demonstrate VBP VBP O
direct JJ JJ O
and CC CC O
/ NN NN O
or CC CC O
indirect JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
toxicity NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
WR242511 NNP NNP B-CHEM
should MD MD O
not RB RB O
be VB VB O
pursued VBN VBN O
as IN IN O
a DT DT O
pretreatment NN NN O
for IN IN O
CN NNP NNP O
poisoning NN NN O
unless IN IN O
the DT DT O
anti JJ JJ O
- : : O
CN NNP NNP O
characteristics NNS NNS O
of IN IN O
this DT DT O
compound NN NN O
can MD MD O
be VB VB O
successfully RB RB O
dissociated VBN VBN O
from IN IN O
those DT DT O
producing VBG VBG O
undesirable JJ JJ O
toxicity NN NN O
. . . O

Repetitive NNP NNP O
transcranial JJ JJ O
magnetic JJ JJ O
stimulation NN NN O
for IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

In IN IN O
a DT DT O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
single JJ JJ O
- - - O
blinded JJ JJ O
, , , O
crossover NN NN O
study NN NN O
, , , O
we PRP PRP O
assessed VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
" '' '' O
real JJ JJ O
" '' '' O
repetitive JJ JJ O
transcranial NN NN O
magnetic JJ JJ O
stimulation NN NN O
( ( ( O
rTMS NN NN O
) ) ) O
versus CC CC O
" '' '' O
sham NN NN O
" '' '' O
rTMS NN NN O
( ( ( O
placebo NN NN O
) ) ) O
on IN IN O
peak NN NN O
dose NN NN O
dyskinesias NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
. . . O

Ten CD CD O
patients NNS NNS O
with IN IN O
PD NNP NNP O
and CC CC O
prominent JJ JJ O
dyskinesias NNS NNS O
had VBD VBD O
rTMS NN NN O
( ( ( O
1 CD CD O
, , , O
800 CD CD O
pulses NNS NNS O
; : : O
1 CD CD O
Hz NNP NNP O
rate NN NN O
) ) ) O
delivered VBN VBN O
over IN IN O
the DT DT O
motor NN NN O
cortex NN NN O
for IN IN O
4 CD CD O
consecutive JJ JJ O
days NNS NNS O
twice RB RB O
, , , O
once RB RB O
real JJ JJ O
stimuli NN NN O
and CC CC O
once RB RB O
sham JJ JJ O
stimulation NN NN O
were VBD VBD O
used VBN VBN O
; : : O
evaluations NNS NNS O
were VBD VBD O
done VBN VBN O
at IN IN O
the DT DT O
baseline NN NN O
and CC CC O
1 CD CD O
day NN NN O
after IN IN O
the DT DT O
end NN NN O
of IN IN O
each DT DT O
of IN IN O
the DT DT O
treatment NN NN O
series NN NN O
. . . O

Direct NNP NNP O
comparison NN NN O
between IN IN O
sham NN NN O
and CC CC O
real JJ JJ O
rTMS NN NN O
effects NNS NNS O
showed VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
clinician NN NN O
- - - O
assessed JJ JJ O
dyskinesia NN NN O
severity NN NN O
. . . O

However RB RB O
, , , O
comparison NN NN O
with IN IN O
the DT DT O
baseline NN NN O
showed VBD VBD O
small JJ JJ O
but CC CC O
significant JJ JJ O
reduction NN NN O
in IN IN O
dyskinesia NN NN O
severity NN NN O
following VBG VBG O
real JJ JJ O
rTMS NN NN O
but CC CC O
not RB RB O
placebo NN NN O
. . . O

The DT DT O
major JJ JJ O
effect NN NN O
was VBD VBD O
on IN IN O
dystonia NN NN O
subscore NN NN O
. . . O

Similarly RB RB O
, , , O
in IN IN O
patient NN NN O
diaries NNS NNS O
, , , O
although IN IN O
both DT DT O
treatments NNS NNS O
caused VBN VBN O
reduction NN NN O
in IN IN O
subjective JJ JJ O
dyskinesia NN NN O
scores NNS NNS O
during IN IN O
the DT DT O
days NNS NNS O
of IN IN O
intervention NN NN O
, , , O
the DT DT O
effect NN NN O
was VBD VBD O
sustained VBN VBN O
for IN IN O
3 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
intervention NN NN O
for IN IN O
the DT DT O
real JJ JJ O
rTMS NN NN O
only RB RB O
. . . O

Following VBG VBG O
rTMS NN NN O
, , , O
no DT DT O
side NN NN O
effects NNS NNS O
and CC CC O
no DT DT O
adverse JJ JJ O
effects NNS NNS O
on IN IN O
motor NN NN O
function NN NN O
and CC CC O
PD NNP NNP O
symptoms NNS NNS O
were VBD VBD O
noted VBN VBN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
the DT DT O
existence NN NN O
of IN IN O
residual JJ JJ O
beneficial JJ JJ O
clinical JJ JJ O
aftereffects NNS NNS O
of IN IN O
consecutive JJ JJ O
daily JJ JJ O
applications NNS NNS O
of IN IN O
low JJ JJ O
- - - O
frequency NN NN O
rTMS NN NN O
on IN IN O
dyskinesias NN NN O
in IN IN O
PD NNP NNP O
. . . O

The DT DT O
effects NNS NNS O
may MD MD O
be VB VB O
further RB RB O
exploited VBN VBN O
for IN IN O
potential JJ JJ O
therapeutic JJ JJ O
uses NNS NNS O
. . . O

Intracavernous NNP NNP O
epinephrine NN NN B-CHEM
: : : O
a DT DT O
minimally RB RB O
invasive JJ JJ O
treatment NN NN O
for IN IN O
priapism NN NN O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
. . . O

Priapism NNP NNP O
is VBZ VBZ O
the DT DT O
prolonged JJ JJ O
erection NN NN O
of IN IN O
the DT DT O
penis NNS NNS O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
sexual JJ JJ O
arousal NN NN O
. . . O

A DT DT O
45 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
, , , O
an DT DT O
admitted JJ JJ O
frequent JJ JJ O
cocaine NN NN B-CHEM
user NN NN O
, , , O
presented VBN VBN O
to TO TO O
the DT DT O
Emergency NNP NNP O
Department NNP NNP O
( ( ( O
ED NNP NNP O
) ) ) O
on IN IN O
two CD CD O
separate JJ JJ O
occasions NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
priapism NN NN O
after IN IN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

The DT DT O
management NN NN O
options NNS NNS O
in IN IN O
the DT DT O
ED NNP NNP O
, , , O
as IN IN O
exemplified VBN VBN O
by IN IN O
four CD CD O
individual JJ JJ O
case NN NN O
reports NNS NNS O
, , , O
in IN IN O
particular JJ JJ O
the DT DT O
use NN NN O
of IN IN O
a DT DT O
minimally RB RB O
invasive JJ JJ O
method NN NN O
of IN IN O
intracorporal JJ JJ O
epinephrine NN NN B-CHEM
instillation NN NN O
, , , O
are VBP VBP O
discussed VBN VBN O
. . . O

Prophylactic NNP NNP O
use NN NN O
of IN IN O
lamivudine NN NN B-CHEM
with IN IN O
chronic JJ JJ O
immunosuppressive JJ JJ O
therapy NN NN O
for IN IN O
rheumatologic JJ JJ O
disorders NNS NNS O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
report VB VB O
our PRP$ PRP$ O
experience NN NN O
concerning VBG VBG O
the DT DT O
effectiveness NN NN O
of IN IN O
the DT DT O
prophylactic JJ JJ O
administration NN NN O
of IN IN O
lamivudine NN NN B-CHEM
in IN IN O
hepatitis NNP NNP B-CHEM
B NNP NNP I-CHEM
virus NN NN I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
( ( ( O
HBs NNP NNP B-CHEM
Ag NNP NNP I-CHEM
) ) ) O
positive JJ JJ O
patients NNS NNS O
with IN IN O
rheumatologic JJ JJ O
disease NN NN O
. . . O

From IN IN O
June NNP NNP O
2004 CD CD O
to TO TO O
October NNP NNP O
2006 CD CD O
, , , O
11 CD CD O
HBs NNP NNP B-CHEM
Ag NNP NNP I-CHEM
positive JJ JJ O
patients NNS NNS O
with IN IN O
rheumatologic JJ JJ O
diseases NNS NNS O
, , , O
who WP WP O
were VBD VBD O
on IN IN O
both DT DT O
immunosuppressive JJ JJ O
and CC CC O
prophylactic JJ JJ O
lamivudine NN NN B-CHEM
therapies NNS NNS O
, , , O
were VBD VBD O
retrospectively RB RB O
assessed VBN VBN O
. . . O

Liver NNP NNP O
function NN NN O
tests NNS NNS O
, , , O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
serologic JJ JJ O
markers NNS NNS O
, , , O
and CC CC O
HBV NNP NNP O
DNA NNP NNP O
levels NNS NNS O
of IN IN O
the DT DT O
patients NNS NNS O
during IN IN O
follow VB VB O
- - - O
up RP RP O
were VBD VBD O
obtained VBN VBN O
from IN IN O
hospital NN NN O
file NN NN O
records NNS NNS O
. . . O

Eleven CD CD O
patients NNS NNS O
( ( ( O
six CD CD O
male JJ JJ O
) ) ) O
with IN IN O
median JJ JJ O
age NN NN O
47 CD CD O
years NNS NNS O
( ( ( O
range NN NN O
27 CD CD O
- : : O
73 CD CD O
) ) ) O
, , , O
median JJ JJ O
disease NN NN O
duration NN NN O
50 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
9 CD CD O
- : : O
178 CD CD O
) ) ) O
and CC CC O
median JJ JJ O
follow VB VB O
- - - O
up RP RP O
period NN NN O
of IN IN O
patients NNS NNS O
13 CD CD O
. . . O
8 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
5 CD CD O
- : : O
27 CD CD O
) ) ) O
were VBD VBD O
enrolled VBN VBN O
in IN IN O
this DT DT O
study NN NN O
. . . O

Lamivudine NNP NNP B-CHEM
therapy NN NN O
was VBD VBD O
started VBN VBN O
3 CD CD O
- : : O
7 CD CD O
days NNS NNS O
prior RB RB O
to TO TO O
immunosuppressive VB VB O
therapy NN NN O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

Baseline NNP NNP O
, , , O
liver NN NN O
function NN NN O
tests NNS NNS O
were VBD VBD O
elevated VBN VBN O
in IN IN O
two CD CD O
patients NNS NNS O
( ( ( O
fourth JJ JJ O
patient NN NN O
: : : O
ALT NNP NNP O
: : : O
122 CD CD O
IU NNP NNP O
/ NN NN O
l NN NN O
, , , O
AST NNP NNP O
: : : O
111 CD CD O
IU NNP NNP O
/ NN NN O
l NN NN O
, , , O
tenth NN NN O
patient NN NN O
: : : O
ALT NNP NNP O
: : : O
294 CD CD O
IU NNP NNP O
/ NN NN O
l NN NN O
, , , O
AST NNP NNP O
: : : O
274 CD CD O
IU NNP NNP O
/ NN NN O
l NN NN O
, , , O
with IN IN O
minimal JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
liver NN NN O
biopsy NN NN O
in IN IN O
both DT DT O
) ) ) O
. . . O

Shortly RB RB O
after IN IN O
treatment NN NN O
their PRP$ PRP$ O
tests NNS NNS O
normalized JJ JJ O
and CC CC O
during IN IN O
follow VB VB O
- - - O
up RP RP O
period NN NN O
none NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
abnormal JJ JJ O
liver NN NN O
function NN NN O
tests NNS NNS O
. . . O

In IN IN O
four CD CD O
patients NNS NNS O
HBV NNP NNP O
DNA NNP NNP O
levels NNS NNS O
were VBD VBD O
higher JJR JJR O
than IN IN O
normal JJ JJ O
at IN IN O
baseline NN NN O
. . . O

Two CD CD O
of IN IN O
these DT DT O
normalized JJ JJ O
and CC CC O
the DT DT O
others NNS NNS O
increased VBD VBD O
later RB RB O
. . . O

In IN IN O
three CD CD O
additional JJ JJ O
patients NNS NNS O
, , , O
HBV NNP NNP O
DNA NNP NNP O
levels NNS NNS O
were VBD VBD O
increased VBN VBN O
during IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
significant JJ JJ O
clinical JJ JJ O
sings NNS NNS O
of IN IN O
HBV NNP NNP O
activation NN NN O
. . . O

Lamivudine NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
and CC CC O
was VBD VBD O
continued VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

Prophylactic NNP NNP O
administration NN NN O
of IN IN O
lamivudine NN NN B-CHEM
in IN IN O
patients NNS NNS O
who WP WP O
required VBD VBD O
immunosuppressive JJ JJ O
therapy NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
safe JJ JJ O
, , , O
well RB RB O
tolerated VBN VBN O
and CC CC O
effective JJ JJ O
in IN IN O
preventing VBG VBG O
HBV NNP NNP O
reactivation NN NN O
. . . O

Effect NN NN O
of IN IN O
green JJ JJ B-CHEM
tea NN NN I-CHEM
and CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
combination NN NN O
in IN IN O
isoproterenol NN NN B-CHEM
induced VBD VBD O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
aimed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
combined VBN VBN O
effects NNS NNS O
of IN IN O
green JJ JJ B-CHEM
tea NN NN I-CHEM
and CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
on IN IN O
heart NN NN O
weight NN NN O
, , , O
body NN NN O
weight NN NN O
, , , O
serum NN NN O
marker NN NN O
enzymes NNS NNS O
, , , O
lipid JJ JJ O
peroxidation NN NN O
, , , O
endogenous JJ JJ O
antioxidants NNS NNS O
and CC CC O
membrane NN NN O
bound VBN VBN O
ATPases NNP NNP O
in IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
ISO NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

Adult NNP NNP O
male JJ JJ O
albino NN NN O
rats NNS NNS O
, , , O
treated VBN VBN O
with IN IN O
ISO NNP NNP B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
for IN IN O
2 CD CD O
days NNS NNS O
at IN IN O
an DT DT O
interval NN NN O
of IN IN O
24 CD CD O
h NN NN O
caused VBD VBD O
a DT DT O
significant JJ JJ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
elevation NN NN O
of IN IN O
heart NN NN O
weight NN NN O
, , , O
serum NN NN O
marker NN NN O
enzymes NNS NNS O
, , , O
lipid JJ JJ O
peroxidation NN NN O
and CC CC O
Ca MD MD B-CHEM
+ NN NN O
2 CD CD O
ATPase NNP NNP O
level NN NN O
whereas IN IN O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
decrease VB VB O
in IN IN O
body NN NN O
weight NN NN O
, , , O
endogenous JJ JJ O
antioxidants NNS NNS O
, , , O
Na NNP NNP B-CHEM
+ NN NN O
/ NN NN O
K NNP NNP B-CHEM
+ NN NN O
ATPase NNP NNP O
and CC CC O
Mg NNP NNP B-CHEM
+ NN NN O
2 CD CD O
ATPase NNP NNP O
levels NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
green JJ JJ B-CHEM
tea NN NN I-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
and CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
together RB RB O
for IN IN O
30 CD CD O
consecutive JJ JJ O
days NNS NNS O
and CC CC O
challenged VBN VBN O
with IN IN O
ISO NNP NNP B-CHEM
on IN IN O
the DT DT O
day NN NN O
29th CD CD O
and CC CC O
30th CD CD O
, , , O
showed VBD VBD O
a DT DT O
significant JJ JJ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
decrease NN NN O
in IN IN O
heart NN NN O
weight NN NN O
, , , O
serum NN NN O
marker NN NN O
enzymes NNS NNS O
, , , O
lipid JJ JJ O
peroxidation NN NN O
, , , O
Ca NNP NNP B-CHEM
+ NN NN O
2 CD CD O
ATPase NNP NNP O
and CC CC O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
body NN NN O
weight NN NN O
, , , O
endogenous JJ JJ O
antioxidants NNS NNS O
, , , O
Na NNP NNP B-CHEM
+ NN NN O
/ NN NN O
K NNP NNP B-CHEM
+ NN NN O
ATPase NNP NNP O
and CC CC O
Mg NNP NNP B-CHEM
+ NN NN O
2 CD CD O
ATPase NNP NNP O
when WRB WRB O
compared VBN VBN O
with IN IN O
ISO NNP NNP B-CHEM
treated VBD VBD O
group NN NN O
and CC CC O
green JJ JJ B-CHEM
tea NN NN I-CHEM
or CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
alone RB RB O
treated VBD VBD O
groups NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
the DT DT O
synergistic JJ JJ O
protective JJ JJ O
effect NN NN O
of IN IN O
green JJ JJ B-CHEM
tea NN NN I-CHEM
and CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
during IN IN O
ISO NNP NNP B-CHEM
induced VBD VBD O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

Irreversible NNP NNP O
damage NN NN O
to TO TO O
the DT DT O
medullary JJ JJ O
interstitium NN NN O
in IN IN O
experimental JJ JJ O
analgesic NN NN O
nephropathy NN NN O
in IN IN O
F344 NNP NNP O
rats NNS NNS O
. . . O

Renal NNP NNP O
papillary JJ JJ O
necrosis NN NN O
( ( ( O
RPN NNP NNP O
) ) ) O
and CC CC O
a DT DT O
decreased JJ JJ O
urinary JJ JJ O
concentrating NN NN O
ability NN NN O
developed VBN VBN O
during IN IN O
continuous JJ JJ O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
aspirin NN NN B-CHEM
and CC CC O
paracetamol NN NN B-CHEM
in IN IN O
female JJ JJ O
Fischer NNP NNP O
344 CD CD O
rats NNS NNS O
. . . O

Renal NNP NNP O
structure NN NN O
and CC CC O
concentrating VBG VBG O
ability NN NN O
were VBD VBD O
examined VBN VBN O
after IN IN O
a DT DT O
recovery NN NN O
period NN NN O
of IN IN O
up IN IN O
to TO TO O
18 CD CD O
weeks NNS NNS O
, , , O
when WRB WRB O
no DT DT O
analgesics NNS NNS O
were VBD VBD O
given VBN VBN O
, , , O
to TO TO O
investigate VB VB O
whether IN IN O
the DT DT O
analgesic JJ JJ O
- - - O
induced JJ JJ O
changes NNS NNS O
were VBD VBD O
reversible JJ JJ O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
repair NN NN O
to TO TO O
the DT DT O
damaged JJ JJ O
medullary JJ JJ O
interstitial NN NN O
matrix NN NN O
, , , O
or CC CC O
proliferation NN NN O
of IN IN O
remaining VBG VBG O
undamaged JJ JJ O
type NN NN O
1 CD CD O
medullary JJ JJ O
interstitial NN NN O
cells NNS NNS O
after IN IN O
the DT DT O
recovery NN NN O
period NN NN O
following VBG VBG O
analgesic JJ JJ O
treatment NN NN O
. . . O

The DT DT O
recovery NN NN O
of IN IN O
urinary JJ JJ O
concentrating NN NN O
ability NN NN O
was VBD VBD O
related VBN VBN O
to TO TO O
the DT DT O
length NN NN O
of IN IN O
analgesic JJ JJ O
treatment NN NN O
and CC CC O
the DT DT O
extent NN NN O
of IN IN O
the DT DT O
resulting VBG VBG O
inner NN NN O
medullary JJ JJ O
structural JJ JJ O
damage NN NN O
. . . O

During IN IN O
the DT DT O
early JJ JJ O
stages NNS NNS O
of IN IN O
analgesic JJ JJ O
treatment NN NN O
, , , O
the DT DT O
changes NNS NNS O
in IN IN O
urinary JJ JJ O
concentrating NN NN O
ability NN NN O
were VBD VBD O
reversible JJ JJ O
, , , O
but CC CC O
after IN IN O
prolonged JJ JJ O
analgesic NN NN O
treatment NN NN O
, , , O
maximum NN NN O
urinary JJ JJ O
concentrating NN NN O
ability NN NN O
failed VBD VBD O
to TO TO O
recover VB VB O
. . . O

This DT DT O
study NN NN O
shows VBZ VBZ O
that IN IN O
prolonged JJ JJ O
analgesic JJ JJ O
treatment NN NN O
in IN IN O
Fischer NNP NNP O
344 CD CD O
rats NNS NNS O
causes NNS NNS O
progressive JJ JJ O
and CC CC O
irreversible JJ JJ O
damage NN NN O
to TO TO O
the DT DT O
interstitial NN NN O
matrix NN NN O
and CC CC O
type NN NN O
1 CD CD O
interstitial NN NN O
cells NNS NNS O
leading VBG VBG O
to TO TO O
RPN NNP NNP O
. . . O

The DT DT O
associated VBN VBN O
urinary JJ JJ O
concentrating NN NN O
defect NN NN O
is VBZ VBZ O
reversible JJ JJ O
only RB RB O
during IN IN O
the DT DT O
early JJ JJ O
stages NNS NNS O
of IN IN O
structural JJ JJ O
damage NN NN O
to TO TO O
the DT DT O
inner JJ JJ O
medulla NN NN O
. . . O

Testosterone NNP NNP B-CHEM
- - - O
dependent JJ JJ O
hypertension NN NN O
and CC CC O
upregulation NN NN O
of IN IN O
intrarenal JJ JJ O
angiotensinogen NN NN O
in IN IN O
Dahl NNP NNP O
salt NN NN B-CHEM
- - - O
sensitive JJ JJ O
rats NNS NNS O
. . . O

Blood NNP NNP O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
is VBZ VBZ O
more RBR RBR O
salt JJ JJ B-CHEM
sensitive NN NN O
in IN IN O
men NNS NNS O
than IN IN O
in IN IN O
premenopausal NN NN O
women NNS NNS O
. . . O

In IN IN O
Dahl NNP NNP O
salt NN NN B-CHEM
- - - O
sensitive JJ JJ O
rats NNS NNS O
( ( ( O
DS NNP NNP O
) ) ) O
, , , O
high JJ JJ O
- - - O
salt NN NN B-CHEM
( ( ( O
HS NNP NNP O
) ) ) O
diet NN NN O
increases NNS NNS O
BP NNP NNP O
more JJR JJR O
in IN IN O
males NNS NNS O
than IN IN O
females NNS NNS O
. . . O

In IN IN O
contrast NN NN O
to TO TO O
the DT DT O
systemic JJ JJ O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
suppressed VBN VBN O
in IN IN O
response NN NN O
to TO TO O
HS NNP NNP O
in IN IN O
male JJ JJ O
DS NNP NNP O
, , , O
intrarenal JJ JJ O
angiotensinogen NN NN O
expression NN NN O
is VBZ VBZ O
increased VBN VBN O
, , , O
and CC CC O
intrarenal JJ JJ O
levels NNS NNS O
of IN IN O
ANG NNP NNP O
II NNP NNP O
are VBP VBP O
not RB RB O
suppressed VBN VBN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
the DT DT O
hypothesis NNS NNS O
was VBD VBD O
tested VBN VBN O
that IN IN O
there EX EX O
is VBZ VBZ O
a DT DT O
sexual JJ JJ O
dimorphism NN NN O
in IN IN O
HS NNP NNP O
- : : O
induced JJ JJ O
upregulation NN NN O
of IN IN O
intrarenal JJ JJ O
angiotensinogen NN NN O
mediated VBN VBN O
by IN IN O
testosterone NN NN B-CHEM
that WDT WDT O
also RB RB O
causes VBZ VBZ O
increases NNS NNS O
in IN IN O
BP NNP NNP O
and CC CC O
renal JJ JJ O
injury NN NN O
. . . O

On IN IN O
a DT DT O
low JJ JJ O
- - - O
salt NN NN B-CHEM
( ( ( O
LS NNP NNP O
) ) ) O
diet NN NN O
, , , O
male JJ JJ O
DS NNP NNP O
had VBD VBD O
higher JJR JJR O
levels NNS NNS O
of IN IN O
intrarenal JJ JJ O
angiotensinogen NN NN O
mRNA NN NN O
than IN IN O
females NNS NNS O
. . . O

HS NNP NNP O
diet NN NN O
for IN IN O
4 CD CD O
wk NN NN O
increased VBD VBD O
renal JJ JJ O
cortical JJ JJ O
angiotensinogen NN NN O
mRNA NN NN O
and CC CC O
protein NN NN O
only RB RB O
in IN IN O
male JJ JJ O
DS NNP NNP O
, , , O
which WDT WDT O
was VBD VBD O
prevented VBN VBN O
by IN IN O
castration NN NN O
. . . O

Ovariectomy NNP NNP O
of IN IN O
female JJ JJ O
DS NNP NNP O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
intrarenal JJ JJ O
angiotensinogen NN NN O
expression NN NN O
on IN IN O
either DT DT O
diet NN NN O
. . . O

Radiotelemetric NNP NNP O
BP NNP NNP O
was VBD VBD O
similar JJ JJ O
between IN IN O
males NNS NNS O
and CC CC O
castrated VBD VBD O
rats NNS NNS O
on IN IN O
LS NNP NNP O
diet NN NN O
. . . O

HS NNP NNP O
diet NN NN O
for IN IN O
4 CD CD O
wk NN NN O
caused VBD VBD O
a DT DT O
progressive JJ JJ O
increase NN NN O
in IN IN O
BP NNP NNP O
, , , O
protein NN NN O
and CC CC O
albumin NN NN O
excretion NN NN O
, , , O
and CC CC O
glomerular JJ JJ O
sclerosis NN NN O
in IN IN O
male JJ JJ O
DS NNP NNP O
rats NNS NNS O
, , , O
which WDT WDT O
were VBD VBD O
attenuated VBN VBN O
by IN IN O
castration NN NN O
. . . O

Testosterone NNP NNP B-CHEM
replacement NN NN O
in IN IN O
castrated VBN VBN O
DS NNP NNP O
rats NNS NNS O
increased VBN VBN O
BP NNP NNP O
, , , O
renal JJ JJ O
injury NN NN O
, , , O
and CC CC O
upregulation NN NN O
of IN IN O
renal JJ JJ O
angiotensinogen NN NN O
associated VBN VBN O
with IN IN O
HS NNP NNP O
diet NN NN O
. . . O

Testosterone NNP NNP B-CHEM
contributes VBZ VBZ O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
hypertension NN NN O
and CC CC O
renal JJ JJ O
injury NN NN O
in IN IN O
male JJ JJ O
DS NNP NNP O
rats NNS NNS O
on IN IN O
HS NNP NNP O
diet JJ JJ O
possibly RB RB O
through IN IN O
upregulation NN NN O
of IN IN O
the DT DT O
intrarenal JJ JJ O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
. . . O

Explicit NNP NNP O
episodic JJ JJ O
memory NN NN O
for IN IN O
sensory JJ JJ O
- - - O
discriminative JJ JJ O
components NNS NNS O
of IN IN O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
pain NN NN O
: : : O
immediate JJ JJ O
and CC CC O
delayed VBD VBD O
ratings NNS NNS O
. . . O

Pain NN NN O
memory NN NN O
is VBZ VBZ O
thought VBN VBN O
to TO TO O
affect VB VB O
future JJ JJ O
pain NN NN O
sensitivity NN NN O
and CC CC O
thus RB RB O
contribute VB VB O
to TO TO O
clinical JJ JJ O
pain NN NN O
conditions NNS NNS O
. . . O

Systematic NNP NNP O
investigations NNS NNS O
of IN IN O
the DT DT O
human JJ JJ O
capacity NN NN O
to TO TO O
remember VB VB O
sensory JJ JJ O
features NNS NNS O
of IN IN O
experimental JJ JJ O
pain NN NN O
are VBP VBP O
sparse NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
address VB VB O
long JJ JJ O
- - - O
term NN NN O
pain NN NN O
memory NN NN O
, , , O
nine CD CD O
healthy JJ JJ O
male NN NN O
volunteers NNS NNS O
received VBD VBD O
intradermal JJ JJ O
injections NNS NNS O
of IN IN O
three CD CD O
doses NNS NNS O
of IN IN O
capsaicin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
05 CD CD O
, , , O
1 CD CD O
and CC CC O
20 CD CD O
microg NN NN O
, , , O
separated VBN VBN O
by IN IN O
15 CD CD O
min NN NN O
breaks NNS NNS O
) ) ) O
, , , O
each DT DT O
given VBN VBN O
three CD CD O
times NNS NNS O
in IN IN O
a DT DT O
balanced JJ JJ O
design NN NN O
across IN IN O
three CD CD O
sessions NNS NNS O
at IN IN O
one CD CD O
week NN NN O
intervals NNS NNS O
. . . O

Pain NN NN O
rating NN NN O
was VBD VBD O
performed VBN VBN O
using VBG VBG O
a DT DT O
computerized JJ JJ O
visual JJ JJ O
analogue NN NN O
scale NN NN O
( ( ( O
0 CD CD O
- : : O
100 CD CD O
) ) ) O
digitized JJ JJ O
at IN IN O
1 CD CD O
/ NN NN O
s VBZ VBZ O
, , , O
either CC CC O
immediately RB RB O
online NN NN O
or CC CC O
one CD CD O
hour NN NN O
or CC CC O
one CD CD O
day NN NN O
after IN IN O
injection NN NN O
. . . O

Subjects NNP NNP O
also RB RB O
recalled VBD VBD O
their PRP$ PRP$ O
pains NNS NNS O
one CD CD O
week NN NN O
later RB RB O
. . . O

Capsaicin NNP NNP B-CHEM
injection NN NN O
reliably RB RB O
induced VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
flare VBP VBP O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
without IN IN O
any DT DT O
difference NN NN O
within IN IN O
or CC CC O
across IN IN O
sessions NNS NNS O
. . . O

The DT DT O
strong JJ JJ O
burning NN NN O
pain NN NN O
decayed VBD VBD O
exponentially RB RB O
within IN IN O
a DT DT O
few JJ JJ O
minutes NNS NNS O
. . . O

Subjects NNP NNP O
were VBD VBD O
able JJ JJ O
to TO TO O
reliably RB RB O
discriminate JJ JJ O
pain NN NN O
magnitude NN NN O
and CC CC O
duration NN NN O
across IN IN O
capsaicin NN NN B-CHEM
doses NNS NNS O
( ( ( O
both DT DT O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
regardless RB RB O
of IN IN O
whether IN IN O
first JJ JJ O
- - - O
time NN NN O
ratings NNS NNS O
were VBD VBD O
requested VBN VBN O
immediately RB RB O
, , , O
after IN IN O
one CD CD O
hour NN NN O
or CC CC O
after IN IN O
one CD CD O
day NN NN O
. . . O

Pain NN NN O
recall NN NN O
after IN IN O
one CD CD O
week NN NN O
was VBD VBD O
similarly RB RB O
precise JJ JJ O
( ( ( O
magnitude NN NN O
: : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
, , , O
duration NN NN O
: : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Correlation NNP NNP O
with IN IN O
rating VBG VBG O
recall NN NN O
after IN IN O
one CD CD O
week NN NN O
was VBD VBD O
best JJS JJS O
when WRB WRB O
first JJ JJ O
- - - O
time NN NN O
ratings NNS NNS O
were VBD VBD O
requested VBN VBN O
as RB RB O
late RB RB O
as IN IN O
one CD CD O
day NN NN O
after IN IN O
injection NN NN O
( ( ( O
R NN NN O
( ( ( O
2 CD CD O
) ) ) O
= SYM SYM O
0 CD CD O
. . . O
79 CD CD O
) ) ) O
indicating VBG VBG O
that IN IN O
both DT DT O
rating VBG VBG O
retrievals NNS NNS O
utilized JJ JJ O
similar JJ JJ O
memory NN NN O
traces NNS NNS O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
a DT DT O
reliable JJ JJ O
memory NN NN O
for IN IN O
magnitude NN NN O
and CC CC O
duration NN NN O
of IN IN O
experimentally RB RB O
induced VBN VBN O
pain NN NN O
. . . O

The DT DT O
data NNS NNS O
further RB RB O
suggest VBP VBP O
that IN IN O
the DT DT O
consolidation NN NN O
of IN IN O
this DT DT O
memory NN NN O
is VBZ VBZ O
an DT DT O
important JJ JJ O
interim JJ JJ O
stage NN NN O
, , , O
and CC CC O
may MD MD O
take VB VB O
up IN IN O
to TO TO O
one CD CD O
day NN NN O
. . . O

Severe NNP NNP O
and CC CC O
long JJ JJ O
lasting JJ JJ O
cholestasis NN NN O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
co NN NN B-CHEM
- : : I-CHEM
trimoxazole NN NN I-CHEM
treatment NN NN O
for IN IN O
Pneumocystis NNP NNP O
pneumonia NN NN O
in IN IN O
HIV NNP NNP O
- - - O
infected JJ JJ O
patients NNS NNS O
- - - O
- - - O
a DT DT O
report NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

Pneumocystis NNP NNP O
pneumonia NN NN O
( ( ( O
PCP NNP NNP O
) ) ) O
, , , O
a DT DT O
common JJ JJ O
opportunistic JJ JJ O
infection NN NN O
in IN IN O
HIV NNP NNP O
- - - O
infected JJ JJ O
individuals NNS NNS O
, , , O
is VBZ VBZ O
generally RB RB O
treated VBN VBN O
with IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
co NN NN B-CHEM
- - - I-CHEM
trimoxazole NN NN I-CHEM
. . . O

However RB RB O
, , , O
treatment NN NN O
is VBZ VBZ O
often RB RB O
limited VBN VBN O
by IN IN O
adverse JJ JJ O
effects NNS NNS O
. . . O

Here RB RB O
, , , O
we PRP PRP O
report VBP VBP O
two CD CD O
cases NNS NNS O
of IN IN O
severely RB RB O
immunocompromised VBN VBN O
HIV NNP NNP O
- - - O
infected JJ JJ O
patients NNS NNS O
who WP WP O
developed VBD VBD O
severe JJ JJ O
intrahepatic JJ JJ O
cholestasis NN NN O
, , , O
and CC CC O
in IN IN O
one CD CD O
patient NN NN O
lesions NNS NNS O
mimicking VBG VBG O
liver NN NN O
abscess NN NN O
formation NN NN O
on IN IN O
radiologic JJ JJ O
exams NNS NNS O
, , , O
during IN IN O
co NN NN B-CHEM
- - - I-CHEM
trimoxazole NN NN I-CHEM
treatment NN NN O
for IN IN O
PCP NNP NNP O
. . . O

Whereas IN IN O
patient NN NN O
1 CD CD O
showed VBD VBD O
lesions NNS NNS O
of IN IN O
up IN IN O
to TO TO O
1 CD CD O
cm NN NN O
readily RB RB O
detectable JJ JJ O
on IN IN O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
under IN IN O
prolonged JJ JJ O
co NN NN B-CHEM
- - - I-CHEM
trimoxazole NN NN I-CHEM
treatment NN NN O
, , , O
therapy NN NN O
of IN IN O
patient NN NN O
2 CD CD O
was VBD VBD O
switched VBN VBN O
early RB RB O
. . . O

Bradykinin NNP NNP B-CHEM
receptors NNS NNS O
antagonists NNS NNS O
and CC CC O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
inhibitors NNS NNS O
in IN IN O
vincristine NN NN B-CHEM
and CC CC O
streptozotocin NN NN B-CHEM
induced VBN VBN O
hyperalgesia NN NN O
in IN IN O
chemotherapy NN NN O
and CC CC O
diabetic JJ JJ O
neuropathy NN NN O
rat NN NN O
model NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
The DT DT O
influence NN NN O
of IN IN O
an DT DT O
irreversible JJ JJ O
inhibitor NN NN O
of IN IN O
constitutive JJ JJ O
NO NNP NNP B-CHEM
synthase NN NN O
( ( ( O
L NNP NNP O
- : : O
NOArg NNP NNP O
; : : O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
, , , O
a DT DT O
relatively RB RB O
selective JJ JJ O
inhibitor NN NN O
of IN IN O
inducible JJ JJ O
NO NNP NNP B-CHEM
synthase NN NN O
( ( ( O
L NNP NNP O
- : : O
NIL NNP NNP O
; : : O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
and CC CC O
a DT DT O
relatively RB RB O
specific JJ JJ O
inhibitor NN NN O
of IN IN O
neuronal NN NN O
NO DT DT B-CHEM
synthase NN NN O
( ( ( O
7 CD CD O
- : : O
NI NNP NNP O
; : : O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
, , , O
on IN IN O
antihyperalgesic JJ JJ O
action NN NN O
of IN IN O
selective JJ JJ O
antagonists NNS NNS O
of IN IN O
B2 NNP NNP O
and CC CC O
B1 NNP NNP O
receptors NNS NNS O
: : : O
D NNP NNP O
- - - O
Arg NNP NNP O
- : : O
[ NN NN O
Hyp3 NNP NNP O
, , , O
Thi5 NNP NNP O
, , , O
D NNP NNP O
- : : O
Tic7 NNP NNP O
, , , O
Oic8 NNP NNP O
] NN NN O
bradykinin NN NN B-CHEM
( ( ( O
HOE NNP NNP B-CHEM
140 CD CD I-CHEM
; : : O
70 CD CD O
nmol NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
or CC CC O
des NNS NNS B-CHEM
Arg10 NNP NNP I-CHEM
HOE NNP NNP I-CHEM
140 CD CD I-CHEM
( ( ( O
70 CD CD O
nmol NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
respectively RB RB O
, , , O
in IN IN O
model NN NN O
of IN IN O
diabetic JJ JJ O
( ( ( O
streptozotocin NN NN O
- - - O
induced JJ JJ O
) ) ) O
and CC CC O
toxic JJ JJ O
( ( ( O
vincristine NN NN O
- - - O
induced JJ JJ O
) ) ) O
neuropathy NN NN O
was VBD VBD O
investigated VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
changes NNS NNS O
in IN IN O
pain NN NN O
thresholds NNS NNS O
were VBD VBD O
determined VBN VBN O
using VBG VBG O
mechanical JJ JJ O
stimuli NN NN O
- - - O
- - - O
the DT DT O
modification NN NN O
of IN IN O
the DT DT O
classic JJ JJ O
paw NN NN O
withdrawal NN NN O
test NN NN O
described VBN VBN O
by IN IN O
Randall NNP NNP O
- : : O
Selitto NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
paper NN NN O
confirm NN NN O
that DT DT O
inhibition NN NN O
of IN IN O
bradykinin NN NN B-CHEM
receptors NNS NNS O
and CC CC O
inducible JJ JJ O
NO NNP NNP B-CHEM
synthase NN NN O
but CC CC O
not RB RB O
neuronal JJ JJ O
NO NNP NNP B-CHEM
synthase NN NN O
activity NN NN O
reduces VBZ VBZ O
diabetic JJ JJ O
hyperalgesia NN NN O
. . . O

Pretreatment NNP NNP O
with IN IN O
L NNP NNP O
- : : O
NOArg NNP NNP O
and CC CC O
L NNP NNP O
- : : O
NIL NNP NNP O
but CC CC O
not RB RB O
7 CD CD O
- : : O
NI NNP NNP O
, , , O
significantly RB RB O
increases NNS NNS O
antihyperalgesic JJ JJ O
activity NN NN O
both DT DT O
HOE NNP NNP B-CHEM
140 CD CD I-CHEM
and CC CC O
des NNS NNS B-CHEM
Arg10 NNP NNP I-CHEM
HOE NNP NNP I-CHEM
140 CD CD I-CHEM
. . . O

It PRP PRP O
was VBD VBD O
also RB RB O
shown VBN VBN O
that IN IN O
both DT DT O
products NNS NNS O
of IN IN O
inducible JJ JJ O
NO DT DT B-CHEM
synthase NN NN O
and CC CC O
neuronal NN NN O
NO UH UH B-CHEM
synthase NN NN O
activation NN NN O
as RB RB O
well RB RB O
as IN IN O
bradykinin NN NN B-CHEM
are VBP VBP O
involved VBN VBN O
in IN IN O
hyperalgesia NN NN O
produced VBN VBN O
by IN IN O
vincristine NN NN B-CHEM
. . . O

Moreover RB RB O
, , , O
L NNP NNP O
- : : O
NOArg NNP NNP O
and CC CC O
7 CD CD O
- : : O
NI NNP NNP O
but CC CC O
not RB RB O
L NNP NNP O
- : : O
NIL NNP NNP O
intensify NN NN O
antihyperalgesic JJ JJ O
activity NN NN O
of IN IN O
HOE NNP NNP B-CHEM
140 CD CD I-CHEM
or CC CC O
des NNS NNS B-CHEM
- : : I-CHEM
Arg10HOE NNP NNP I-CHEM
140 CD CD I-CHEM
in IN IN O
toxic JJ JJ O
neuropathy NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Results NNS NNS O
of IN IN O
these DT DT O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
B1 NNP NNP O
and CC CC O
B2 NNP NNP O
receptors NNS NNS O
are VBP VBP O
engaged VBN VBN O
in IN IN O
transmission NN NN O
of IN IN O
nociceptive JJ JJ O
stimuli NN NN O
in IN IN O
both DT DT O
diabetic JJ JJ O
and CC CC O
toxic JJ JJ O
neuropathy NN NN O
. . . O

In IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
hyperalgesia NN NN O
, , , O
inducible JJ JJ O
NO DT DT B-CHEM
synthase NN NN O
participates VBZ VBZ O
in IN IN O
pronociceptive JJ JJ O
activity NN NN O
of IN IN O
bradykinin NN NN B-CHEM
, , , O
whereas IN IN O
in IN IN O
vincristine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperalgesia NN NN O
bradykinin NN NN B-CHEM
seemed VBD VBD O
to TO TO O
activate VB VB O
neuronal NN NN O
NO DT DT B-CHEM
synthase NN NN O
pathway NN NN O
. . . O

Therefore RB RB O
, , , O
concomitant JJ JJ O
administration NN NN O
of IN IN O
small JJ JJ O
doses NNS NNS O
of IN IN O
bradykinin NN NN B-CHEM
receptor NN NN O
antagonists NNS NNS O
and CC CC O
NO DT DT B-CHEM
synthase NN NN O
inhibitors NNS NNS O
can MD MD O
be VB VB O
effective JJ JJ O
in IN IN O
alleviation NN NN O
of IN IN O
neuropathic JJ JJ O
pain NN NN O
, , , O
even RB RB O
in IN IN O
hospital NN NN O
care NN NN O
. . . O

Confusion NNP NNP O
, , , O
a DT DT O
rather RB RB O
serious JJ JJ O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
with IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
: : : O
a DT DT O
review NN NN O
of IN IN O
the DT DT O
French JJ JJ O
Pharmacovigilance NNP NNP O
database NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Confusion NNP NNP O
is VBZ VBZ O
an DT DT O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
frequently RB RB O
observed VBD VBD O
with IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Some DT DT O
case NN NN O
reports NNS NNS O
are VBP VBP O
published VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
but CC CC O
no DT DT O
systematic JJ JJ O
study NN NN O
from IN IN O
a DT DT O
sample NN NN O
of IN IN O
patients NNS NNS O
has VBZ VBZ O
been VBN VBN O
published VBN VBN O
. . . O

We PRP PRP O
performed VBD VBD O
this DT DT O
study NN NN O
in IN IN O
order NN NN O
to TO TO O
describe VB VB O
the DT DT O
main JJ JJ O
characteristics NNS NNS O
of IN IN O
this DT DT O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
. . . O

METHODS NNP NNP O
: : : O
Using VBG VBG O
the DT DT O
French JJ JJ O
Pharmacovigilance NNP NNP O
database NN NN O
, , , O
we PRP PRP O
selected VBD VBD O
the DT DT O
cases NNS NNS O
of IN IN O
confusion NN NN O
reported VBD VBD O
since IN IN O
1985 CD CD O
with IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

RESULTS NNS NNS O
: : : O
272 CD CD O
cases NNS NNS O
of IN IN O
confusion NN NN O
were VBD VBD O
reported VBN VBN O
with IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
: : : O
153 CD CD O
women NNS NNS O
and CC CC O
119 CD CD O
men NNS NNS O
. . . O

Confusion NNP NNP O
mostly RB RB O
occurred VBD VBD O
during IN IN O
the DT DT O
two CD CD O
first JJ JJ O
weeks NNS NNS O
following VBG VBG O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
exposure NN NN O
( ( ( O
39 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
. . . O

It PRP PRP O
was VBD VBD O
" '' '' O
serious JJ JJ O
" '' '' O
for IN IN O
almost RB RB O
2 CD CD O
/ NN NN O
3 CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
( ( ( O
62 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
and CC CC O
its PRP$ PRP$ O
outcome NN NN O
favourable JJ JJ O
in IN IN O
most JJS JJS O
of IN IN O
the DT DT O
cases NNS NNS O
( ( ( O
82 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
this DT DT O
ADR NNP NNP O
was VBD VBD O
more RBR RBR O
frequent JJ JJ O
in IN IN O
patients NNS NNS O
aged VBN VBN O
between IN IN O
61 CD CD O
and CC CC O
80 CD CD O
years NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
work NN NN O
shows VBZ VBZ O
that DT DT O
confusion NN NN O
with IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
is VBZ VBZ O
a DT DT O
serious JJ JJ O
, , , O
rather RB RB O
frequent JJ JJ O
but CC CC O
reversible JJ JJ O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
. . . O

It PRP PRP O
occurs VBZ VBZ O
especially RB RB O
in IN IN O
older JJR JJR O
patients NNS NNS O
and CC CC O
during IN IN O
the DT DT O
first JJ JJ O
two CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

Reversible NNP NNP O
inferior JJ JJ O
colliculus NN NN O
lesion NN NN O
in IN IN O
metronidazole NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
: : : O
magnetic JJ JJ O
resonance NN NN O
findings NNS NNS O
on IN IN O
diffusion NN NN O
- : : O
weighted JJ JJ O
and CC CC O
fluid JJ JJ O
attenuated JJ JJ O
inversion NN NN O
recovery NN NN O
imaging VBG VBG O
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
is VBZ VBZ O
to TO TO O
present VB VB O
reversible JJ JJ O
inferior JJ JJ O
colliculus NN NN O
lesions NNS NNS O
in IN IN O
metronidazole NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
, , , O
to TO TO O
focus VB VB O
on IN IN O
the DT DT O
diffusion NN NN O
- - - O
weighted JJ JJ O
imaging VBG VBG O
( ( ( O
DWI NNP NNP O
) ) ) O
and CC CC O
fluid JJ JJ O
attenuated JJ JJ O
inversion NN NN O
recovery NN NN O
( ( ( O
FLAIR NNP NNP O
) ) ) O
imaging VBG VBG O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
From IN IN O
November NNP NNP O
2005 CD CD O
to TO TO O
September NNP NNP O
2007 CD CD O
, , , O
8 CD CD O
patients NNS NNS O
( ( ( O
5 CD CD O
men NNS NNS O
and CC CC O
3 CD CD O
women NNS NNS O
) ) ) O
were VBD VBD O
diagnosed VBN VBN O
as IN IN O
having VBG VBG O
metronidazole NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
( ( ( O
age NN NN O
range NN NN O
; : : O
43 CD CD O
- : : O
78 CD CD O
years NNS NNS O
) ) ) O
. . . O

They PRP PRP O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
metronidazole NN NN B-CHEM
( ( ( O
total JJ JJ O
dosage NN NN O
, , , O
45 CD CD O
- : : O
120 CD CD O
g SYM SYM O
; : : O
duration NN NN O
, , , O
30 CD CD O
days NNS NNS O
to TO TO O
2 CD CD O
months NNS NNS O
) ) ) O
to TO TO O
treat VB VB O
the DT DT O
infection NN NN O
in IN IN O
various JJ JJ O
organs NNS NNS O
. . . O

Initial JJ JJ O
brain NN NN O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
MRI NNP NNP O
) ) ) O
were VBD VBD O
obtained VBN VBN O
after IN IN O
the DT DT O
hospitalization NN NN O
, , , O
including VBG VBG O
DWI NNP NNP O
( ( ( O
8 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
apparent JJ JJ O
diffusion NN NN O
coefficient NN NN O
( ( ( O
ADC NNP NNP O
) ) ) O
map NN NN O
( ( ( O
4 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
FLAIR NNP NNP O
( ( ( O
7 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
and CC CC O
T2 NNP NNP O
- : : O
weighted JJ JJ O
image NN NN O
( ( ( O
8 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
. . . O

Follow VB VB O
- - - O
up RP RP O
MRIs NNP NNP O
were VBD VBD O
performed VBN VBN O
on IN IN O
5 CD CD O
patients NNS NNS O
from IN IN O
third JJ JJ O
to TO TO O
14th JJ JJ O
days NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
metronidazole NN NN B-CHEM
administration NN NN O
. . . O

Findings NNS NNS O
of IN IN O
initial JJ JJ O
and CC CC O
follow VB VB O
- - - O
up RP RP O
MRIs NNP NNP O
were VBD VBD O
retrospectively RB RB O
evaluated VBN VBN O
by IN IN O
2 CD CD O
neuroradiologists NNS NNS O
by IN IN O
consensus NN NN O
, , , O
to TO TO O
analyze VB VB O
the DT DT O
presence NN NN O
of IN IN O
abnormal JJ JJ O
signal NN NN O
intensities NNS NNS O
, , , O
their PRP$ PRP$ O
locations NNS NNS O
, , , O
and CC CC O
signal NN NN O
changes NNS NNS O
on IN IN O
follow VB VB O
- - - O
up RP RP O
images NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Initial JJ JJ O
MRIs NNP NNP O
showed VBD VBD O
abnormal JJ JJ O
high JJ JJ O
signal NN NN O
intensities NNS NNS O
on IN IN O
DWI NNP NNP O
and CC CC O
FLAIR NNP NNP O
( ( ( O
or CC CC O
T2 NNP NNP O
- : : O
weighted JJ JJ O
image NN NN O
) ) ) O
at IN IN O
the DT DT O
dentate NN NN O
nucleus NN NN O
( ( ( O
8 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
inferior JJ JJ O
colliculus NN NN O
( ( ( O
6 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
corpus NN NN O
callosum NN NN O
( ( ( O
2 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
pons NNS NNS O
( ( ( O
2 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
medulla NN NN O
( ( ( O
1 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
, , , O
and CC CC O
bilateral NN NN O
cerebral JJ JJ O
white JJ JJ O
matter NN NN O
( ( ( O
1 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
. . . O

High NNP NNP O
- - - O
signal NN NN O
intensity NN NN O
lesions NNS NNS O
on IN IN O
DWI NNP NNP O
tended VBD VBD O
to TO TO O
show VB VB O
low JJ JJ O
signal NN NN O
intensity NN NN O
on IN IN O
ADC NNP NNP O
map NN NN O
( ( ( O
3 CD CD O
/ NN NN O
4 CD CD O
) ) ) O
, , , O
but CC CC O
in IN IN O
one CD CD O
patient NN NN O
, , , O
high JJ JJ O
signal NN NN O
intensity NN NN O
was VBD VBD O
shown VBN VBN O
at IN IN O
bilateral JJ JJ O
dentate NN NN O
nuclei NN NN O
on IN IN O
not RB RB O
only RB RB O
DWI NNP NNP O
but CC CC O
also RB RB O
ADC NNP NNP O
map NN NN O
. . . O

All DT DT O
the DT DT O
lesions NNS NNS O
in IN IN O
dentate NN NN O
, , , O
inferior JJ JJ O
colliculus NN NN O
, , , O
pons NNS NNS O
, , , O
and CC CC O
medullas NNS NNS O
had VBD VBD O
been VBN VBN O
resolved VBN VBN O
completely RB RB O
on IN IN O
follow VB VB O
- - - O
up RP RP O
MRIs NNP NNP O
in IN IN O
5 CD CD O
patients NNS NNS O
, , , O
but CC CC O
in IN IN O
1 CD CD O
patient NN NN O
of IN IN O
them PRP PRP O
, , , O
corpus NN NN O
callosal NN NN O
lesion NN NN O
persisted VBD VBD O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Reversible NNP NNP O
inferior JJ JJ O
colliculus NN NN O
lesions NNS NNS O
could MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
the DT DT O
characteristic JJ JJ O
for IN IN O
metronidazole NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
, , , O
next JJ JJ O
to TO TO O
the DT DT O
dentate NN NN O
nucleus NN NN O
involvement NN NN O
. . . O

Clinically NNP NNP O
significant JJ JJ O
proteinuria NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
sirolimus NN NN B-CHEM
to TO TO O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Sirolimus NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
latest JJS JJS O
immunosuppressive JJ JJ O
agent NN NN O
used VBN VBN O
to TO TO O
prevent VB VB O
rejection NN NN O
, , , O
and CC CC O
may MD MD O
have VB VB O
less JJR JJR O
nephrotoxicity NN NN O
than IN IN O
calcineurin NN NN O
inhibitor NN NN O
( ( ( O
CNI NNP NNP O
) ) ) O
- - - O
based JJ JJ O
regimens NNS NNS O
. . . O

To TO TO O
date NN NN O
there EX EX O
has VBZ VBZ O
been VBN VBN O
little JJ JJ O
documentation NN NN O
of IN IN O
clinically RB RB O
significant JJ JJ O
proteinuria NN NN O
linked VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
sirolimus NN NN B-CHEM
. . . O

We PRP PRP O
have VBP VBP O
encountered VBN VBN O
several JJ JJ O
patients NNS NNS O
who WP WP O
developed VBD VBD O
substantial JJ JJ O
proteinuria NN NN O
associated VBN VBN O
with IN IN O
sirolimus NN NN B-CHEM
use NN NN O
. . . O

In IN IN O
each DT DT O
patient NN NN O
, , , O
the DT DT O
close JJ JJ O
temporal JJ JJ O
association NN NN O
between IN IN O
the DT DT O
commencement NN NN O
of IN IN O
sirolimus NN NN B-CHEM
therapy NN NN O
and CC CC O
proteinuria NN NN O
implicated VBN VBN O
sirolimus NN NN B-CHEM
as IN IN O
the DT DT O
most RBS RBS O
likely JJ JJ O
etiology NN NN O
of IN IN O
the DT DT O
proteinuria NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
analyzed VBD VBD O
the DT DT O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
information NN NN O
available JJ JJ O
for IN IN O
all DT DT O
119 CD CD O
patients NNS NNS O
transplanted VBD VBD O
at IN IN O
the DT DT O
Washington NNP NNP O
Hospital NNP NNP O
Center NNP NNP O
between IN IN O
1999 CD CD O
- : : O
2003 CD CD O
for IN IN O
whom WP WP O
sirolimus NN NN B-CHEM
was VBD VBD O
a DT DT O
component NN NN O
of IN IN O
their PRP$ PRP$ O
immunosuppressant JJ JJ O
regimen NNS NNS O
. . . O

In IN IN O
these DT DT O
patients NNS NNS O
, , , O
the DT DT O
magnitude NN NN O
of IN IN O
proteinuria NN NN O
was VBD VBD O
assessed VBN VBN O
on IN IN O
morning NN NN O
urine NN NN O
samples NNS NNS O
by IN IN O
turbidometric JJ JJ O
measurement NN NN O
or CC CC O
random JJ JJ O
urine NN NN O
protein NN NN O
: : : O
creatinine NN NN B-CHEM
ratios NN NN O
, , , O
an DT DT O
estimate NN NN O
of IN IN O
grams NNS NNS O
of IN IN O
proteinuria NN NN O
/ NN NN O
day NN NN O
. . . O

Laboratory NNP NNP O
results NNS NNS O
were VBD VBD O
compared VBN VBN O
between IN IN O
prior RB RB O
, , , O
during IN IN O
and CC CC O
following VBG VBG O
sirolimus NN NN B-CHEM
use NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Twenty CD CD O
- - - O
eight CD CD O
patients NNS NNS O
( ( ( O
24 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
increased VBN VBN O
proteinuria NNS NNS O
from IN IN O
baseline NN NN O
during IN IN O
their PRP$ PRP$ O
post NN NN O
- - - O
transplantation NN NN O
course NN NN O
. . . O

In IN IN O
21 CD CD O
patients NNS NNS O
an DT DT O
alternative JJ JJ O
cause NN NN O
of IN IN O
proteinuria NN NN O
was VBD VBD O
either CC CC O
obvious JJ JJ O
or CC CC O
insufficient JJ JJ O
data NNS NNS O
was VBD VBD O
available JJ JJ O
to TO TO O
be VB VB O
conclusive JJ JJ O
. . . O

In IN IN O
7 CD CD O
of IN IN O
the DT DT O
28 CD CD O
patients NNS NNS O
there RB RB O
was VBD VBD O
a DT DT O
striking JJ JJ O
temporal JJ JJ O
association NN NN O
between IN IN O
the DT DT O
initiation NN NN O
of IN IN O
sirolimus NN NN B-CHEM
and CC CC O
the DT DT O
development NN NN O
of IN IN O
nephrotic JJ JJ O
- - - O
range NN NN O
proteinuria NN NN O
. . . O

Proteinuria NNP NNP O
correlated JJ JJ O
most RBS RBS O
strongly RB RB O
with IN IN O
sirolimus NN NN B-CHEM
therapy NN NN O
when WRB WRB O
compared VBN VBN O
to TO TO O
other JJ JJ O
demographic JJ JJ O
and CC CC O
clinical JJ JJ O
variables NNS NNS O
. . . O

In IN IN O
most JJS JJS O
patients NNS NNS O
, , , O
discontinuation NN NN O
of IN IN O
sirolimus NN NN B-CHEM
resulted VBD VBD O
in IN IN O
a DT DT O
decrease NN NN O
, , , O
but CC CC O
not RB RB O
resolution NN NN O
, , , O
of IN IN O
proteinuria NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Sirolimus NNP NNP B-CHEM
induces NNS NNS O
or CC CC O
aggravates NNS NNS O
pre NN NN O
- : : O
existing VBG VBG O
proteinuria NN NN O
in IN IN O
an DT DT O
unpredictable JJ JJ O
subset NN NN O
of IN IN O
renal JJ JJ O
allograft NN NN O
recipients NNS NNS O
. . . O

Proteinuria NNP NNP O
may MD MD O
improve VB VB O
, , , O
but CC CC O
does VBZ VBZ O
not RB RB O
resolve VB VB O
, , , O
when WRB WRB O
sirolimus NN NN B-CHEM
is VBZ VBZ O
withdrawn VBN VBN O
. . . O

Components NNP NNP O
of IN IN O
lemon NN NN O
essential JJ JJ O
oil NN NN O
attenuate NN NN O
dementia NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
. . . O

The DT DT O
anti JJ JJ O
- : : O
dementia NN NN O
effects NNS NNS O
of IN IN O
s JJ JJ B-CHEM
- - - I-CHEM
limonene NN NN I-CHEM
and CC CC O
s VBZ VBZ B-CHEM
- - - I-CHEM
perillyl NN NN I-CHEM
alcohol NN NN I-CHEM
were VBD VBD O
observed VBN VBN O
using VBG VBG O
the DT DT O
passive JJ JJ O
avoidance NN NN O
test NN NN O
( ( ( O
PA NNP NNP O
) ) ) O
and CC CC O
the DT DT O
open JJ JJ O
field NN NN O
habituation NN NN O
test NN NN O
( ( ( O
OFH NNP NNP O
) ) ) O
. . . O

These DT DT O
lemon JJ JJ O
essential JJ JJ O
oils NNS NNS O
showed VBD VBD O
strong JJ JJ O
ability NN NN O
to TO TO O
improve VB VB O
memory NN NN O
impaired VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
; : : O
however RB RB O
, , , O
s VBZ VBZ B-CHEM
- - - I-CHEM
perillyl NN NN I-CHEM
alcohol NN NN I-CHEM
relieved VBD VBD O
the DT DT O
deficit NN NN O
of IN IN O
associative JJ JJ O
memory NN NN O
in IN IN O
PA NNP NNP O
only RB RB O
, , , O
and CC CC O
did VBD VBD O
not RB RB O
improve VB VB O
non NN NN O
- : : O
associative JJ JJ O
memory NN NN O
significantly RB RB O
in IN IN O
OFH NNP NNP O
. . . O

Analysis NNP NNP O
of IN IN O
neurotransmitter NN NN O
concentration NN NN O
in IN IN O
some DT DT O
brain NN NN O
regions NNS NNS O
on IN IN O
the DT DT O
test NN NN O
day NN NN O
showed VBD VBD O
that IN IN O
dopamine JJ JJ B-CHEM
concentration NN NN O
of IN IN O
the DT DT O
vehicle NN NN O
/ NN NN O
scopolamine NN NN B-CHEM
group NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
vehicle NN NN O
/ NN NN O
vehicle NN NN O
group NN NN O
, , , O
but CC CC O
this DT DT O
phenomenon NN NN O
was VBD VBD O
reversed VBN VBN O
when WRB WRB O
s VBZ VBZ B-CHEM
- - - I-CHEM
limonene NN NN I-CHEM
or CC CC O
s VBZ VBZ B-CHEM
- - - I-CHEM
perillyl NN NN I-CHEM
alcohol NN NN I-CHEM
were VBD VBD O
administered VBN VBN O
before IN IN O
the DT DT O
injection NN NN O
of IN IN O
scopolamine NN NN B-CHEM
. . . O

Simultaneously RB RB O
, , , O
we PRP PRP O
found VBD VBD O
that IN IN O
these DT DT O
two CD CD O
lemon JJ JJ O
essential JJ JJ O
oil NN NN O
components NNS NNS O
could MD MD O
inhibit VB VB O
acetylcholinesterase NN NN O
activity NN NN O
in IN IN O
vitro NN NN O
using VBG VBG O
the DT DT O
Ellman NNP NNP O
method NN NN O
. . . O

Attentional NNP NNP O
modulation NN NN O
of IN IN O
perceived VBN VBN O
pain NN NN O
intensity NN NN O
in IN IN O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
secondary JJ JJ O
hyperalgesia NN NN O
. . . O

Perceived NNP NNP O
pain NN NN O
intensity NN NN O
is VBZ VBZ O
modulated VBN VBN O
by IN IN O
attention NN NN O
. . . O

However RB RB O
, , , O
it PRP PRP O
is VBZ VBZ O
not RB RB O
known VBN VBN O
that IN IN O
how WRB WRB O
pain NN NN O
intensity NN NN O
ratings NNS NNS O
are VBP VBP O
affected VBN VBN O
by IN IN O
attention NN NN O
in IN IN O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
secondary JJ JJ O
hyperalgesia NN NN O
. . . O

Here RB RB O
we PRP PRP O
show VBP VBP O
that IN IN O
perceived VBD VBD O
pain NN NN O
intensity NN NN O
in IN IN O
secondary JJ JJ O
hyperalgesia NN NN O
is VBZ VBZ O
decreased VBN VBN O
when WRB WRB O
attention NN NN O
is VBZ VBZ O
distracted VBN VBN O
away RB RB O
from IN IN O
the DT DT O
painful JJ JJ O
pinprick NN NN O
stimulus NN NN O
with IN IN O
a DT DT O
visual JJ JJ O
task NN NN O
. . . O

Furthermore RB RB O
, , , O
it PRP PRP O
was VBD VBD O
found VBN VBN O
that IN IN O
the DT DT O
magnitude NN NN O
of IN IN O
attentional JJ JJ O
modulation NN NN O
in IN IN O
secondary JJ JJ O
hyperalgesia NN NN O
is VBZ VBZ O
very RB RB O
similar JJ JJ O
to TO TO O
that DT DT O
of IN IN O
capsaicin NN NN B-CHEM
- - - O
untreated JJ JJ O
, , , O
control NN NN O
condition NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
, , , O
showing VBG VBG O
no DT DT O
interaction NN NN O
between IN IN O
capsaicin NN NN B-CHEM
treatment NN NN O
and CC CC O
attentional JJ JJ O
modulation NN NN O
suggest VBP VBP O
that IN IN O
capsaicin NN NN B-CHEM
- : : O
induced JJ JJ O
secondary JJ JJ O
hyperalgesia NN NN O
and CC CC O
attention NN NN O
might MD MD O
affect VB VB O
mechanical JJ JJ O
pain NN NN O
through IN IN O
independent JJ JJ O
mechanisms NNS NNS O
. . . O

Cardioprotective NNP NNP O
effect NN NN O
of IN IN O
salvianolic JJ JJ B-CHEM
acid NN NN I-CHEM
A DT DT I-CHEM
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
cardioprotective JJ JJ O
potential NN NN O
of IN IN O
salvianolic JJ JJ B-CHEM
acid NN NN I-CHEM
A DT DT I-CHEM
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

Hemodynamic NNP NNP O
parameters NNS NNS O
and CC CC O
lead VB VB O
II NNP NNP O
electrocardiograph NN NN O
were VBD VBD O
monitored VBN VBN O
and CC CC O
recorded VBN VBN O
continuously RB RB O
. . . O

Cardiac NNP NNP O
marker NN NN O
enzymes NNS NNS O
and CC CC O
antioxidative JJ JJ O
parameters NNS NNS O
in IN IN O
serum NN NN O
and CC CC O
heart NN NN O
tissues NNS NNS O
were VBD VBD O
measured VBN VBN O
. . . O

Assay NNP NNP O
for IN IN O
mitochondrial JJ JJ O
respiratory NN NN O
function NN NN O
and CC CC O
histopathological JJ JJ O
examination NN NN O
of IN IN O
heart NN NN O
tissues NNS NNS O
were VBD VBD O
performed VBN VBN O
. . . O

Isoproterenol NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
showed VBD VBD O
significant JJ JJ O
increases NNS NNS O
in IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
lactate NN NN B-CHEM
dehydrogenase NN NN O
, , , O
aspartate NN NN B-CHEM
transaminase NN NN O
, , , O
creatine NN NN B-CHEM
kinase NN NN O
and CC CC O
malondialdehyde NN NN B-CHEM
and CC CC O
significant JJ JJ O
decreases NNS NNS O
in IN IN O
the DT DT O
activities NNS NNS O
of IN IN O
superoxide NN NN B-CHEM
dismutase NN NN O
, , , O
catalase NN NN O
and CC CC O
glutathione NN NN B-CHEM
peroxidase NN NN O
in IN IN O
serum NN NN O
and CC CC O
heart NN NN O
. . . O

These DT DT O
rats NNS NNS O
also RB RB O
showed VBD VBD O
declines NNS NNS O
in IN IN O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
pressure NN NN O
, , , O
maximum NN NN O
and CC CC O
minimum JJ JJ O
rate NN NN O
of IN IN O
developed VBN VBN O
left VBD VBD O
ventricular NN NN O
pressure NN NN O
, , , O
and CC CC O
elevation NN NN O
of IN IN O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
and CC CC O
ST NNP NNP O
- : : O
segment NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
mitochondrial JJ JJ O
respiratory JJ JJ O
dysfunction NN NN O
characterized VBN VBN O
by IN IN O
decreased VBN VBN O
respiratory NN NN O
control NN NN O
ratio NN NN O
and CC CC O
ADP NNP NNP B-CHEM
/ NN NN O
O NNP NNP O
was VBD VBD O
observed VBN VBN O
in IN IN O
isoproterenol NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
salvianolic JJ JJ B-CHEM
acid NN NN I-CHEM
A DT DT I-CHEM
for IN IN O
a DT DT O
period NN NN O
of IN IN O
8 CD CD O
days NNS NNS O
significantly RB RB O
attenuated VBN VBN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
dysfunction NN NN O
and CC CC O
myocardial NN NN O
injury NN NN O
and CC CC O
improved VBN VBN O
mitochondrial JJ JJ O
respiratory JJ JJ O
function NN NN O
. . . O

The DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
salvianolic JJ JJ B-CHEM
acid NN NN I-CHEM
A DT DT I-CHEM
against IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
damage NN NN O
was VBD VBD O
further RB RB O
confirmed VBN VBN O
by IN IN O
histopathological JJ JJ O
examination NN NN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
our PRP$ PRP$ O
study NN NN O
suggest VBP VBP O
that IN IN O
salvianolic JJ JJ B-CHEM
acid NN NN I-CHEM
A DT DT I-CHEM
possessing VBG VBG O
antioxidant NN NN O
activity NN NN O
has VBZ VBZ O
a DT DT O
significant JJ JJ O
protective JJ JJ O
effect NN NN O
against IN IN O
isoproterenol JJ JJ B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
glutamate NN NN B-CHEM
supplementation NN NN O
failed VBD VBD O
to TO TO O
protect VB VB O
against IN IN O
peripheral JJ JJ O
neurotoxicity NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
. . . O

Toxic NNP NNP O
peripheral JJ JJ O
neuropathy NN NN O
is VBZ VBZ O
still RB RB O
a DT DT O
significant JJ JJ O
limiting NN NN O
factor NN NN O
for IN IN O
chemotherapy NN NN O
with IN IN O
paclitaxel NN NN B-CHEM
( ( ( O
PAC NNP NNP B-CHEM
) ) ) O
, , , O
although IN IN O
glutamate NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
closely RB RB O
related VBN VBN O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
glutamine NN NN B-CHEM
were VBD VBD O
claimed VBN VBN O
to TO TO O
ameliorate VB VB O
PAC NNP NNP B-CHEM
neurotoxicity NN NN O
. . . O

This DT DT O
pilot NN NN O
trial NN NN O
aimed VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
role NN NN O
of IN IN O
glutamate NN NN B-CHEM
supplementation NN NN O
for IN IN O
preventing VBG VBG O
PAC NNP NNP B-CHEM
- : : O
induced JJ JJ O
peripheral NN NN O
neuropathy NN NN O
in IN IN O
a DT DT O
randomized JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled VBN VBN O
, , , O
double JJ JJ O
- - - O
blinded JJ JJ O
clinical JJ JJ O
and CC CC O
electro NN NN O
- - - O
diagnostic JJ JJ O
study NN NN O
. . . O

Forty CD CD O
- - - O
three CD CD O
ovarian JJ JJ O
cancer NN NN O
patients NNS NNS O
were VBD VBD O
available JJ JJ O
for IN IN O
analysis NN NN O
following VBG VBG O
six CD CD O
cycles NNS NNS O
of IN IN O
the DT DT O
same JJ JJ O
PAC NNP NNP B-CHEM
- : : O
containing VBG VBG O
regimen NNS NNS O
: : : O
23 CD CD O
had VBD VBD O
been VBN VBN O
supplemented VBN VBN O
by IN IN O
glutamate NN NN B-CHEM
all DT DT O
along IN IN O
the DT DT O
treatment NN NN O
period NN NN O
, , , O
at IN IN O
a DT DT O
daily JJ JJ O
dose NN NN O
of IN IN O
three CD CD O
times NNS NNS O
500 CD CD O
mg NN NN O
( ( ( O
group NN NN O
G NNP NNP O
) ) ) O
, , , O
and CC CC O
20 CD CD O
had VBD VBD O
received VBN VBN O
a DT DT O
placebo NN NN O
( ( ( O
group NN NN O
P NN NN O
) ) ) O
. . . O

Patients NNS NNS O
were VBD VBD O
evaluated VBN VBN O
by IN IN O
neurological JJ JJ O
examinations NNS NNS O
, , , O
questionnaires NNS NNS O
and CC CC O
sensory JJ JJ O
- - - O
motor NN NN O
nerve NN NN O
conduction NN NN O
studies NNS NNS O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
the DT DT O
frequency NN NN O
of IN IN O
signs NNS NNS O
or CC CC O
symptoms NNS NNS O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
although IN IN O
neurotoxicity NN NN O
symptoms NNS NNS O
presented VBN VBN O
mostly RB RB O
with IN IN O
lower JJR JJR O
scores NNS NNS O
of IN IN O
severity NN NN O
in IN IN O
group NN NN O
G NNP NNP O
. . . O

However RB RB O
, , , O
this DT DT O
difference NN NN O
reached VBD VBD O
statistical JJ JJ O
significance NN NN O
only RB RB O
with IN IN O
regard NN NN O
to TO TO O
reported VBD VBD O
pain NN NN O
sensation NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
011 CD CD O
) ) ) O
. . . O

Also RB RB O
the DT DT O
frequency NN NN O
of IN IN O
abnormal JJ JJ O
electro NN NN O
- : : O
diagnostic JJ JJ O
findings NNS NNS O
showed VBD VBD O
similarity NN NN O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
( ( ( O
G NNP NNP O
: : : O
7 CD CD O
/ NN NN O
23 CD CD O
= SYM SYM O
30 CD CD O
. . . O
4 CD CD O
% NN NN O
; : : O
P NN NN O
: : : O
6 CD CD O
/ NN NN O
20 CD CD O
= SYM SYM O
30 CD CD O
% NN NN O
) ) ) O
. . . O

This DT DT O
pilot NN NN O
study NN NN O
leads VBZ VBZ O
to TO TO O
the DT DT O
conclusion NN NN O
that IN IN O
glutamate NN NN B-CHEM
supplementation NN NN O
at IN IN O
the DT DT O
chosen NN NN O
regimen NN NN O
fails VBZ VBZ O
to TO TO O
protect VB VB O
against IN IN O
peripheral JJ JJ O
neurotoxicity NN NN O
of IN IN O
PAC NNP NNP B-CHEM
. . . O

Development NNP NNP O
of IN IN O
ocular NN NN O
myasthenia NN NN O
during IN IN O
pegylated VBN VBN B-CHEM
interferon NN NN I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
treatment NN NN O
for IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
. . . O

A DT DT O
63 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
experienced VBN VBN O
sudden JJ JJ O
diplopia NN NN O
after IN IN O
9 CD CD O
weeks NNS NNS O
of IN IN O
administration NN NN O
of IN IN O
pegylated VBN VBN B-CHEM
interferon NN NN I-CHEM
( ( ( I-CHEM
IFN NNP NNP I-CHEM
) ) ) I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
2b CD CD I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
for IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
( ( ( O
CHC NNP NNP O
) ) ) O
. . . O

Ophthalmologic NNP NNP O
examinations NNS NNS O
showed VBD VBD O
ptosis NNS NNS O
on IN IN O
the DT DT O
right JJ JJ O
upper JJ JJ O
lid JJ JJ O
and CC CC O
restricted JJ JJ O
right NN NN O
eye NN NN O
movement NN NN O
without IN IN O
any DT DT O
other JJ JJ O
neurological JJ JJ O
signs NNS NNS O
. . . O

A DT DT O
brain NN NN O
imaging VBG VBG O
study NN NN O
and CC CC O
repetitive JJ JJ O
nerve NN NN O
stimulation NN NN O
test NN NN O
indicated VBD VBD O
no DT DT O
abnormality NN NN O
. . . O

The DT DT O
acetylcholine NN NN B-CHEM
receptor NN NN O
antibody NN NN O
titer NN NN O
and CC CC O
response NN NN O
to TO TO O
acetylcholinesterase VB VB O
inhibitors NNS NNS O
were VBD VBD O
negative JJ JJ O
, , , O
and CC CC O
the DT DT O
results NNS NNS O
of IN IN O
thyroid NN NN O
function NN NN O
tests NNS NNS O
were VBD VBD O
normal JJ JJ O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
ophthalmological JJ JJ O
symptoms NNS NNS O
improved VBN VBN O
rapidly RB RB O
3 CD CD O
weeks NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
pegylated VBN VBN B-CHEM
IFN NNP NNP I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
2b CD CD I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
. . . O

The DT DT O
ocular NN NN O
myasthenia NN NN O
associated VBN VBN O
with IN IN O
combination NN NN O
therapy NN NN O
of IN IN O
pegylated VBN VBN B-CHEM
IFN NNP NNP I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
2b CD CD I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
for IN IN O
CHC NNP NNP O
is VBZ VBZ O
very RB RB O
rarely RB RB O
reported VBD VBD O
; : : O
therefore RB RB O
, , , O
we PRP PRP O
present JJ JJ O
this DT DT O
case NN NN O
with IN IN O
a DT DT O
review NN NN O
of IN IN O
the DT DT O
various JJ JJ O
eye NN NN O
complications NNS NNS O
of IN IN O
IFN NNP NNP B-CHEM
therapy NN NN O
. . . O

Learning NNP NNP O
and CC CC O
memory NN NN O
deficits NNS NNS O
in IN IN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
and CC CC O
their PRP$ PRP$ O
neural NN NN O
correlates NNS NNS O
during IN IN O
a DT DT O
face NN NN O
- - - O
learning VBG VBG O
task NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
consistently RB RB O
shown VBN VBN O
that IN IN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
display VBP VBP O
impairments NNS NNS O
in IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
performance NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
working VBG VBG O
memory NN NN O
processing NN NN O
in IN IN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
neural NN NN O
alterations NNS NNS O
in IN IN O
hippocampal NN NN O
and CC CC O
/ NN NN O
or CC CC O
cortical JJ JJ O
regions NNS NNS O
as IN IN O
measured VBN VBN O
by IN IN O
functional JJ JJ O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
fMRI NN NN O
) ) ) O
. . . O

Using VBG VBG O
functional JJ JJ O
imaging NN NN O
and CC CC O
a DT DT O
face NN NN O
- - - O
learning VBG VBG O
task NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
neural JJ JJ O
correlates NNS NNS O
of IN IN O
encoding VBG VBG O
and CC CC O
recalling VBG VBG O
face NN NN O
- - - O
name NN NN O
associations NNS NNS O
in IN IN O
20 CD CD O
recreational JJ JJ O
drug NN NN O
users NNS NNS O
whose WP$ WP$ O
predominant JJ JJ O
drug NN NN O
use NN NN O
was VBD VBD O
ecstasy JJ JJ B-CHEM
and CC CC O
20 CD CD O
controls NNS NNS O
. . . O

To TO TO O
address VB VB O
the DT DT O
potential JJ JJ O
confounding VBG VBG O
effects NNS NNS O
of IN IN O
the DT DT O
cannabis NN NN B-CHEM
use NN NN O
of IN IN O
the DT DT O
ecstasy NN NN B-CHEM
using VBG VBG O
group NN NN O
, , , O
a DT DT O
second JJ JJ O
analysis NN NN O
included VBD VBD O
14 CD CD O
previously RB RB O
tested VBD VBD O
cannabis NN NN B-CHEM
users NNS NNS O
( ( ( O
Nestor NNP NNP O
, , , O
L NNP NNP O
. . . O
, , , O
Roberts NNP NNP O
, , , O
G NNP NNP O
. . . O
, , , O
Garavan NNP NNP O
, , , O
H NNP NNP O
. . . O
, , , O
Hester NNP NNP O
, , , O
R NN NN O
. . . O
, , , O
2008 CD CD O
. . . O
Deficits NNP NNP O
in IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
: : : O
parahippocampal JJ JJ O
hyperactivity NN NN O
and CC CC O
frontocortical JJ JJ O
hypoactivity NN NN O
in IN IN O
cannabis NN NN B-CHEM
users NNS NNS O
. . . O
Neuroimage NNP NNP O
40 CD CD O
, , , O
1328 CD CD O
- : : O
1339 CD CD O
) ) ) O
. . . O

Ecstasy NNP NNP B-CHEM
users NNS NNS O
performed VBN VBN O
significantly RB RB O
worse JJR JJR O
in IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
and CC CC O
cannabis NN NN B-CHEM
users NNS NNS O
. . . O

A DT DT O
conjunction NN NN O
analysis NN NN O
of IN IN O
the DT DT O
encode NN NN O
and CC CC O
recall NN NN O
phases NNS NNS O
of IN IN O
the DT DT O
task NN NN O
revealed VBD VBD O
ecstasy JJ JJ B-CHEM
- - - O
specific JJ JJ O
hyperactivity NN NN O
in IN IN O
bilateral JJ JJ O
frontal NN NN O
regions NNS NNS O
, , , O
left VBD VBD O
temporal JJ JJ O
, , , O
right JJ JJ O
parietal NN NN O
, , , O
bilateral JJ JJ O
temporal NN NN O
, , , O
and CC CC O
bilateral JJ JJ O
occipital JJ JJ O
brain NN NN O
regions NNS NNS O
. . . O

Ecstasy NNP NNP B-CHEM
- : : O
specific JJ JJ O
hypoactivity NN NN O
was VBD VBD O
evident JJ JJ O
in IN IN O
the DT DT O
right NN NN O
dorsal NN NN O
anterior NN NN O
cingulated VBN VBN O
cortex NN NN O
( ( ( O
ACC NNP NNP O
) ) ) O
and CC CC O
left VBD VBD O
posterior NN NN O
cingulated VBD VBD O
cortex NN NN O
. . . O

In IN IN O
both DT DT O
ecstasy NN NN B-CHEM
and CC CC O
cannabis NN NN B-CHEM
groups NNS NNS O
brain NN NN O
activation NN NN O
was VBD VBD O
decreased VBN VBN O
in IN IN O
the DT DT O
right NN NN O
medial JJ JJ O
frontal JJ JJ O
gyrus NN NN O
, , , O
left VBD VBD O
parahippocampal NN NN O
gyrus NN NN O
, , , O
left VBD VBD O
dorsal NN NN O
cingulate NN NN O
gyrus NN NN O
, , , O
and CC CC O
left VBD VBD O
caudate NN NN O
. . . O

These DT DT O
results NNS NNS O
elucidated VBN VBN O
ecstasy JJ JJ B-CHEM
- - - O
related VBN VBN O
deficits NNS NNS O
, , , O
only RB RB O
some DT DT O
of IN IN O
which WDT WDT O
might MD MD O
be VB VB O
attributed VBN VBN O
to TO TO O
cannabis VB VB B-CHEM
use NN NN O
. . . O

These DT DT O
ecstasy JJ JJ B-CHEM
- - - O
specific JJ JJ O
effects NNS NNS O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
vulnerability NN NN O
of IN IN O
isocortical JJ JJ O
and CC CC O
allocortical JJ JJ O
regions NNS NNS O
to TO TO O
the DT DT O
neurotoxic JJ JJ O
effects NNS NNS O
of IN IN O
ecstasy NN NN B-CHEM
. . . O

Disulfiram NNP NNP B-CHEM
- - - O
like IN IN O
syndrome NN NN O
after IN IN O
hydrogen NN NN B-CHEM
cyanamide NN NN I-CHEM
professional JJ JJ O
skin NN NN O
exposure NN NN O
: : : O
two CD CD O
case NN NN O
reports NNS NNS O
in IN IN O
France NNP NNP O
. . . O

Hydrogen NNP NNP B-CHEM
cyanamide NN NN I-CHEM
is VBZ VBZ O
a DT DT O
plant NN NN O
growth NN NN O
regulator NN NN O
used VBN VBN O
in IN IN O
agriculture NN NN O
to TO TO O
induce VB VB O
bud NN NN O
break NN NN O
in IN IN O
fruit NN NN O
trees NNS NNS O
. . . O

Contact NN NN O
with IN IN O
the DT DT O
skin NN NN O
can MD MD O
result VB VB O
in IN IN O
percutaneous JJ JJ O
absorption NN NN O
of IN IN O
the DT DT O
substance NN NN O
that IN IN O
inhibits NNS NNS O
aldehyde NN NN B-CHEM
dehydrogenase NN NN O
and CC CC O
can MD MD O
induce VB VB O
acetaldehyde JJ JJ B-CHEM
syndrome NN NN O
in IN IN O
case NN NN O
of IN IN O
alcohol NN NN B-CHEM
use NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
report NN NN O
is VBZ VBZ O
to TO TO O
describe VB VB O
two CD CD O
cases NNS NNS O
of IN IN O
a DT DT O
disulfiram NN NN B-CHEM
- - - O
like IN IN O
syndrome NN NN O
following VBG VBG O
occupational JJ JJ O
exposure NN NN O
to TO TO O
hydrogen NN NN B-CHEM
cyanamide NN NN I-CHEM
. . . O

The DT DT O
first JJ JJ O
case NN NN O
involved VBD VBD O
a DT DT O
59 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
used VBD VBD O
Dormex NNP NNP B-CHEM
, , , O
which WDT WDT O
contains VBZ VBZ O
hydrogen NN NN B-CHEM
cyanamide NN NN I-CHEM
, , , O
without IN IN O
protection NN NN O
after IN IN O
consuming VBG VBG O
a DT DT O
large JJ JJ O
amount NN NN O
of IN IN O
alcohol NN NN B-CHEM
during IN IN O
a DT DT O
meal NN NN O
. . . O

In IN IN O
less JJR JJR O
than IN IN O
1 CD CD O
hour NN NN O
after IN IN O
the DT DT O
ingestion NN NN O
of IN IN O
alcohol NN NN B-CHEM
, , , O
he PRP PRP O
developed VBD VBD O
malaise NN NN O
with IN IN O
flushing NN NN O
of IN IN O
the DT DT O
face NN NN O
, , , O
tachycardia NN NN O
, , , O
and CC CC O
dyspnea NN NN O
. . . O

Manifestations NNP NNP O
regressed VBD VBD O
spontaneously RB RB O
under IN IN O
surveillance NN NN O
in IN IN O
the DT DT O
hospital NN NN O
. . . O

The DT DT O
second JJ JJ O
case NN NN O
occurred VBD VBD O
in IN IN O
a DT DT O
55 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
farmer NN NN O
following VBG VBG O
cutaneous JJ JJ O
contact NN NN O
with IN IN O
Dormex NNP NNP B-CHEM
. . . O

Five CD CD O
hours NNS NNS O
after IN IN O
exposure NN NN O
, , , O
he PRP PRP O
developed VBD VBD O
disulfiram NN NN B-CHEM
- - - O
like IN IN O
syndrome NN NN O
with IN IN O
flushing NN NN O
, , , O
tachycardia NN NN O
, , , O
and CC CC O
arterial JJ JJ O
hypotension NN NN O
after IN IN O
consuming VBG VBG O
three CD CD O
glasses NNS NNS O
of IN IN O
wine NN NN O
. . . O

The DT DT O
patient NN NN O
recovered VBD VBD O
spontaneously RB RB O
in IN IN O
3 CD CD O
hours NNS NNS O
under IN IN O
surveillance NN NN O
in IN IN O
the DT DT O
hospital NN NN O
. . . O

These DT DT O
cases NNS NNS O
confirm VBP VBP O
the DT DT O
necessity NN NN O
of IN IN O
avoiding VBG VBG O
alcohol NN NN B-CHEM
consumption NN NN O
as IN IN O
recommended VBN VBN O
in IN IN O
the DT DT O
instructions NNS NNS O
for IN IN O
use NN NN O
of IN IN O
Dormex NNP NNP B-CHEM
and CC CC O
of IN IN O
preventing VBG VBG O
cutaneous JJ JJ O
contact NN NN O
during IN IN O
use NN NN O
. . . O

Sulpiride NNP NNP B-CHEM
- : : O
induced JJ JJ O
tardive NN NN O
dystonia NN NN O
. . . O

Sulpiride NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
selective JJ JJ O
D2 NN NN O
- - - O
receptor NN NN O
antagonist NN NN O
with IN IN O
antipsychotic JJ JJ O
and CC CC O
antidepressant JJ JJ B-CHEM
properties NNS NNS O
. . . O

Although IN IN O
initially RB RB O
thought VBN VBN O
to TO TO O
be VB VB O
free JJ JJ O
of IN IN O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
, , , O
sulpiride NN NN B-CHEM
- - - O
induced JJ JJ O
tardive JJ JJ O
dyskinesia NN NN O
and CC CC O
parkinsonism NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
occasionally RB RB O
. . . O

We PRP PRP O
studied VBD VBD O
a DT DT O
37 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
developed VBD VBD O
persistent JJ JJ O
segmental NN NN O
dystonia NN NN O
within IN IN O
2 CD CD O
months NNS NNS O
after IN IN O
starting VBG VBG O
sulpiride NN NN B-CHEM
therapy NN NN O
. . . O

We PRP PRP O
could MD MD O
not RB RB O
find VB VB O
any DT DT O
previous JJ JJ O
reports NNS NNS O
of IN IN O
sulpiride NN NN B-CHEM
- - - O
induced JJ JJ O
tardive NN NN O
dystonia NN NN O
. . . O

Comparative NNP NNP O
cognitive JJ JJ O
and CC CC O
subjective JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
immediate JJ JJ O
- - - O
release NN NN O
oxycodone NN NN B-CHEM
in IN IN O
healthy JJ JJ O
middle NN NN O
- : : O
aged JJ JJ O
and CC CC O
older JJR JJR O
adults NNS NNS O
. . . O

This DT DT O
study NN NN O
measured VBD VBD O
the DT DT O
objective NN NN O
and CC CC O
subjective JJ JJ O
neurocognitive JJ JJ O
effects NNS NNS O
of IN IN O
a DT DT O
single JJ JJ O
10 CD CD O
- : : O
mg NN NN O
dose NN NN O
of IN IN O
immediate JJ JJ O
- - - O
release NN NN O
oxycodone NN NN B-CHEM
in IN IN O
healthy JJ JJ O
, , , O
older JJR JJR O
( ( ( O
> NN NN O
65 CD CD O
years NNS NNS O
) ) ) O
, , , O
and CC CC O
middle JJ JJ O
- : : O
aged JJ JJ O
( ( ( O
35 CD CD O
to TO TO O
55 CD CD O
years NNS NNS O
) ) ) O
adults NNS NNS O
who WP WP O
were VBD VBD O
not RB RB O
suffering VBG VBG O
from IN IN O
chronic JJ JJ O
or CC CC O
significant JJ JJ O
daily JJ JJ O
pain NN NN O
. . . O

Seventy NNP NNP O
- : : O
one CD CD O
participants NNS NNS O
completed VBD VBD O
2 CD CD O
separate JJ JJ O
study NN NN O
days NNS NNS O
and CC CC O
were VBD VBD O
blind JJ JJ O
to TO TO O
medication NN NN O
condition NN NN O
( ( ( O
placebo NN NN O
, , , O
10 CD CD O
- : : O
mg NN NN O
oxycodone NN NN B-CHEM
) ) ) O
. . . O

Plasma NNP NNP O
oxycodone NN NN B-CHEM
concentration NN NN O
peaked VBD VBD O
between IN IN O
60 CD CD O
and CC CC O
90 CD CD O
minutes NNS NNS O
postdose NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
and CC CC O
pupil NN NN O
size NN NN O
, , , O
an DT DT O
indication NN NN O
of IN IN O
physiological JJ JJ O
effects NNS NNS O
of IN IN O
the DT DT O
medication NN NN O
, , , O
peaked VBN VBN O
at IN IN O
approximately RB RB O
90 CD CD O
to TO TO O
120 CD CD O
minutes NNS NNS O
postdose NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
. . . O

Significant JJ JJ O
declines NNS NNS O
in IN IN O
simple JJ JJ O
and CC CC O
sustained JJ JJ O
attention NN NN O
, , , O
working VBG VBG O
memory NN NN O
, , , O
and CC CC O
verbal JJ JJ O
memory NN NN O
were VBD VBD O
observed VBN VBN O
at IN IN O
1 CD CD O
hour NN NN O
postdose NN NN O
compared VBN VBN O
to TO TO O
baseline NN NN O
for IN IN O
both DT DT O
age NN NN O
groups NNS NNS O
with IN IN O
a DT DT O
trend NN NN O
toward IN IN O
return NN NN O
to TO TO O
baseline VB VB O
by IN IN O
5 CD CD O
hours NNS NNS O
postdose NN NN O
. . . O

For IN IN O
almost RB RB O
all DT DT O
cognitive JJ JJ O
measures NNS NNS O
, , , O
there EX EX O
were VBD VBD O
no DT DT O
medication NN NN O
by IN IN O
age NN NN O
- - - O
interaction NN NN O
effects NNS NNS O
, , , O
which WDT WDT O
indicates VBZ VBZ O
that IN IN O
the DT DT O
2 CD CD O
age NN NN O
groups NNS NNS O
exhibited VBN VBN O
similar JJ JJ O
responses NNS NNS O
to TO TO O
the DT DT O
medication NN NN O
challenge NN NN O
. . . O

This DT DT O
study NN NN O
suggests VBZ VBZ O
that IN IN O
for IN IN O
healthy JJ JJ O
older JJR JJR O
adults NNS NNS O
who WP WP O
are VBP VBP O
not RB RB O
suffering VBG VBG O
from IN IN O
chronic JJ JJ O
pain NN NN O
, , , O
neurocognitive JJ JJ O
and CC CC O
pharmacodynamic JJ JJ O
changes NNS NNS O
in IN IN O
response NN NN O
to TO TO O
a DT DT O
10 CD CD O
- : : O
mg NN NN O
dose NN NN O
of IN IN O
immediate JJ JJ O
- - - O
release NN NN O
oxycodone NN NN B-CHEM
are VBP VBP O
similar JJ JJ O
to TO TO O
those DT DT O
observed VBD VBD O
for IN IN O
middle JJ JJ O
- - - O
aged JJ JJ O
adults NNS NNS O
. . . O

PERSPECTIVE NNP NNP O
: : : O
Study NNP NNP O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
metabolism NN NN O
, , , O
neurocognitive JJ JJ O
effects NNS NNS O
, , , O
and CC CC O
physical JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
oral JJ JJ O
oxycodone NN NN B-CHEM
are VBP VBP O
similar JJ JJ O
for IN IN O
healthy JJ JJ O
middle NN NN O
- : : O
aged JJ JJ O
and CC CC O
older JJR JJR O
adults NNS NNS O
. . . O

Therefore RB RB O
, , , O
clinicians NNS NNS O
should MD MD O
not RB RB O
avoid VB VB O
prescribing VBG VBG O
oral JJ JJ O
opioids NNS NNS O
to TO TO O
older JJR JJR O
adults NNS NNS O
based VBN VBN O
on IN IN O
the DT DT O
belief NN NN O
that IN IN O
older JJR JJR O
adults NNS NNS O
are VBP VBP O
at IN IN O
higher JJR JJR O
risk NN NN O
for IN IN O
side NN NN O
effects NNS NNS O
than IN IN O
younger JJR JJR O
adults NNS NNS O
. . . O

The DT DT O
glycine NN NN B-CHEM
transporter NN NN O
- : : O
1 CD CD O
inhibitor NN NN O
SSR103800 NNP NNP B-CHEM
displays NNS NNS O
a DT DT O
selective JJ JJ O
and CC CC O
specific JJ JJ O
antipsychotic JJ JJ O
- - - O
like IN IN O
profile NN NN O
in IN IN O
normal JJ JJ O
and CC CC O
transgenic JJ JJ O
mice NNS NNS O
. . . O

Schizophrenia NNP NNP O
has VBZ VBZ O
been VBN VBN O
initially RB RB O
associated VBN VBN O
with IN IN O
dysfunction NN NN O
in IN IN O
dopamine NN NN B-CHEM
neurotransmission NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
observation NN NN O
that IN IN O
antagonists NNS NNS O
of IN IN O
the DT DT O
glutamate NN NN B-CHEM
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptor NN NN O
produce NN NN O
schizophrenic JJ JJ O
- - - O
like IN IN O
symptoms NNS NNS O
in IN IN O
humans NNS NNS O
has VBZ VBZ O
led VBN VBN O
to TO TO O
the DT DT O
idea NN NN O
of IN IN O
a DT DT O
dysfunctioning NN NN O
of IN IN O
the DT DT O
glutamatergic JJ JJ O
system NN NN O
via IN IN O
its PRP$ PRP$ O
NMDA NNP NNP B-CHEM
receptor NN NN O
. . . O

As IN IN O
a DT DT O
result NN NN O
, , , O
there EX EX O
is VBZ VBZ O
a DT DT O
growing VBG VBG O
interest NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
pharmacological JJ JJ O
agents NNS NNS O
with IN IN O
potential JJ JJ O
antipsychotic JJ JJ O
properties NNS NNS O
that WDT WDT O
enhance NN NN O
the DT DT O
activity NN NN O
of IN IN O
the DT DT O
glutamatergic JJ JJ O
system NN NN O
via IN IN O
a DT DT O
modulation NN NN O
of IN IN O
the DT DT O
NMDA NNP NNP B-CHEM
receptor NN NN O
. . . O

Among IN IN O
them PRP PRP O
are VBP VBP O
glycine JJ JJ B-CHEM
transporter NN NN O
- : : O
1 CD CD O
( ( ( O
GlyT1 NNP NNP O
) ) ) O
inhibitors NNS NNS O
such JJ JJ O
as IN IN O
SSR103800 NNP NNP B-CHEM
, , , O
which WDT WDT O
indirectly RB RB O
enhance NN NN O
NMDA NNP NNP B-CHEM
receptor NN NN O
function NN NN O
by IN IN O
increasing VBG VBG O
the DT DT O
glycine NN NN B-CHEM
( ( ( O
a DT DT O
co NN NN O
- - - O
agonist NN NN O
for IN IN O
the DT DT O
NMDA NNP NNP B-CHEM
receptor NN NN O
) ) ) O
levels NNS NNS O
in IN IN O
the DT DT O
synapse NN NN O
. . . O

This DT DT O
study NN NN O
aimed VBN VBN O
at IN IN O
investigating VBG VBG O
the DT DT O
potential JJ JJ O
antipsychotic JJ JJ O
- - - O
like IN IN O
properties NNS NNS O
of IN IN O
SSR103800 NNP NNP B-CHEM
, , , O
with IN IN O
a DT DT O
particular JJ JJ O
focus NN NN O
on IN IN O
models NNS NNS O
of IN IN O
hyperactivity NN NN O
, , , O
involving VBG VBG O
either CC CC O
drug NN NN O
challenge NN NN O
( ( ( O
ie NN NN O
, , , O
amphetamine NN NN B-CHEM
and CC CC O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
) ) ) O
or CC CC O
transgenic JJ JJ O
mice NNS NNS O
( ( ( O
ie NN NN O
, , , O
NMDA NNP NNP B-CHEM
Nr1 NNP NNP O
( ( ( O
neo NN NN O
- - - O
/ NN NN O
- : : O
) ) ) O
and CC CC O
DAT NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
) ) ) O
. . . O

Results NNS NNS O
showed VBD VBD O
that IN IN O
SSR103800 NNP NNP B-CHEM
( ( ( O
10 CD CD O
- : : O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
blocked JJ JJ O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
the DT DT O
non NN NN O
- - - O
competitive JJ JJ O
NMDA NNP NNP B-CHEM
receptor NN NN O
antagonist NN NN O
, , , O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
and CC CC O
partially RB RB O
reversed VBD VBD O
spontaneous JJ JJ O
hyperactivity NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
Nr1 NNP NNP O
( ( ( O
neo NN NN O
- - - O
/ NN NN O
- - - O
) ) ) O
mice NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
SSR103800 NNP NNP B-CHEM
failed VBD VBD O
to TO TO O
affect VB VB O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
amphetamine NN NN B-CHEM
or CC CC O
naturally RB RB O
observed VBN VBN O
in IN IN O
dopamine NN NN B-CHEM
transporter NN NN O
( ( ( O
DAT NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
) ) ) O
knockout NN NN O
mice NN NN O
( ( ( O
10 CD CD O
- : : O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
. . . O

Importantly NNP NNP O
, , , O
both DT DT O
classical JJ JJ O
( ( ( O
haloperidol NN NN B-CHEM
) ) ) O
and CC CC O
atypical JJ JJ O
( ( ( O
olanzapine NN NN B-CHEM
, , , O
clozapine NN NN B-CHEM
and CC CC O
aripiprazole NN NN B-CHEM
) ) ) O
antipsychotics NNS NNS O
were VBD VBD O
effective JJ JJ O
in IN IN O
all PDT PDT O
these DT DT O
models NNS NNS O
of IN IN O
hyperactivity NN NN O
. . . O

However RB RB O
, , , O
unlike IN IN O
these DT DT O
latter JJ JJ O
, , , O
SSR103800 NNP NNP B-CHEM
did VBD VBD O
not RB RB O
produce VB VB O
catalepsy NN NN O
( ( ( O
retention NN NN O
on IN IN O
the DT DT O
bar NN NN O
test NN NN O
) ) ) O
up IN IN O
to TO TO O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O

Together RB RB O
these DT DT O
findings NNS NNS O
show VBP VBP O
that IN IN O
the DT DT O
GlyT1 NNP NNP O
inhibitor NN NN O
, , , O
SSR103800 NNP NNP B-CHEM
, , , O
produces VBZ VBZ O
antipsychotic JJ JJ O
- - - O
like IN IN O
effects NNS NNS O
, , , O
which WDT WDT O
differ VBP VBP O
from IN IN O
those DT DT O
observed VBN VBN O
with IN IN O
compounds NNS NNS O
primarily RB RB O
targeting VBG VBG O
the DT DT O
dopaminergic JJ JJ O
system NN NN O
, , , O
and CC CC O
has VBZ VBZ O
a DT DT O
reduced VBN VBN O
side NN NN O
- - - O
effect NN NN O
potential JJ JJ O
as IN IN O
compared VBN VBN O
with IN IN O
these DT DT O
latter JJ JJ O
drugs NNS NNS O
. . . O

Pyrrolidine NNP NNP B-CHEM
dithiocarbamate NN NN I-CHEM
protects VBZ VBZ O
the DT DT O
piriform NN NN O
cortex NN NN O
in IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
status NN NN O
epilepticus NN NN O
model NN NN O
. . . O

Pyrrolidine NNP NNP B-CHEM
dithiocarbamate NN NN I-CHEM
( ( ( O
PDTC NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
a DT DT O
dual JJ JJ O
mechanism NN NN O
of IN IN O
action NN NN O
as IN IN O
an DT DT O
antioxidant NN NN O
and CC CC O
an DT DT O
inhibitor NN NN O
of IN IN O
the DT DT O
transcription NN NN O
factor NN NN O
kappa NN NN O
- : : O
beta NN NN O
. . . O

Both DT DT O
, , , O
production NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
as RB RB O
well RB RB O
as IN IN O
activation NN NN O
of IN IN O
NF NNP NNP O
- - - O
kappaB NN NN O
have VBP VBP O
been VBN VBN O
implicated VBN VBN O
in IN IN O
severe JJ JJ O
neuronal NN NN O
damage NN NN O
in IN IN O
different JJ JJ O
sub NN NN O
- - - O
regions NNS NNS O
of IN IN O
the DT DT O
hippocampus NN NN O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
the DT DT O
surrounding VBG VBG O
cortices NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
PDTC NNP NNP B-CHEM
on IN IN O
status NN NN O
epilepticus NN NN O
- - - O
associated VBN VBN O
cell NN NN O
loss NN NN O
in IN IN O
the DT DT O
hippocampus NN NN O
and CC CC O
piriform NN NN O
cortex NN NN O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
the DT DT O
rat NN NN O
fractionated VBD VBD O
pilocarpine NN NN B-CHEM
model NN NN O
. . . O

Treatment NN NN O
with IN IN O
150 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
PDTC NNP NNP B-CHEM
before IN IN O
and CC CC O
following VBG VBG O
status NN NN O
epilepticus NN NN O
significantly RB RB O
increased VBD VBD O
the DT DT O
mortality NN NN O
rate NN NN O
to TO TO O
100 CD CD O
% NN NN O
. . . O

Administration NNP NNP O
of IN IN O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
PDTC NNP NNP B-CHEM
( ( ( O
low JJ JJ O
- - - O
dose NN NN O
) ) ) O
did VBD VBD O
not RB RB O
exert VB VB O
major JJ JJ O
effects NNS NNS O
on IN IN O
the DT DT O
development NN NN O
of IN IN O
a DT DT O
status NN NN O
epilepticus NN NN O
or CC CC O
the DT DT O
mortality NN NN O
rate NN NN O
. . . O

In IN IN O
vehicle NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
, , , O
status NN NN O
epilepticus NN NN O
caused VBD VBD O
pronounced VBN VBN O
neuronal NN NN O
damage NN NN O
in IN IN O
the DT DT O
piriform NN NN O
cortex NN NN O
comprising VBG VBG O
both DT DT O
pyramidal NN NN O
cells NNS NNS O
and CC CC O
interneurons NNS NNS O
. . . O

Low NNP NNP O
- - - O
dose NN NN O
PDTC NNP NNP B-CHEM
treatment NN NN O
almost RB RB O
completely RB RB O
protected VBN VBN O
from IN IN O
lesions NNS NNS O
in IN IN O
the DT DT O
piriform NN NN O
cortex NN NN O
. . . O

A DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
neuronal JJ JJ O
density NN NN O
of IN IN O
the DT DT O
hippocampal NN NN O
hilar NN NN O
formation NN NN O
was VBD VBD O
identified VBN VBN O
in IN IN O
vehicle NN NN O
- - - O
and CC CC O
PDTC NNP NNP B-CHEM
- : : O
treated VBN VBN O
rats NNS NNS O
following VBG VBG O
status NN NN O
epilepticus NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
the DT DT O
NF NNP NNP O
- - - O
kappaB NN NN O
inhibitor NN NN O
and CC CC O
antioxidant JJ JJ O
PDTC NNP NNP B-CHEM
protected VBD VBD O
the DT DT O
piriform NN NN O
cortex NN NN O
, , , O
whereas IN IN O
it PRP PRP O
did VBD VBD O
not RB RB O
affect VB VB O
hilar JJ JJ O
neuronal NN NN O
loss NN NN O
. . . O

These DT DT O
data NNS NNS O
might MD MD O
indicate VB VB O
that IN IN O
the DT DT O
generation NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
and CC CC O
activation NN NN O
of IN IN O
NF NNP NNP O
- : : O
kappaB NN NN O
plays VBZ VBZ O
a DT DT O
more RBR RBR O
central JJ JJ O
role NN NN O
in IN IN O
seizure NN NN O
- - - O
associated VBN VBN O
neuronal NN NN O
damage NN NN O
in IN IN O
the DT DT O
temporal NN NN O
cortex NN NN O
as IN IN O
compared VBN VBN O
to TO TO O
the DT DT O
hippocampal NN NN O
hilus NN NN O
. . . O

However RB RB O
, , , O
future JJ JJ O
investigations NNS NNS O
are VBP VBP O
necessary JJ JJ O
to TO TO O
exactly RB RB O
analyze VB VB O
the DT DT O
biochemical JJ JJ O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
PDTC NNP NNP B-CHEM
exerted VBD VBD O
its PRP$ PRP$ O
beneficial JJ JJ O
effects NNS NNS O
in IN IN O
the DT DT O
piriform NN NN O
cortex NN NN O
. . . O

Anaesthetists NNP NNP O
' POS POS O
nightmare NN NN O
: : : O
masseter NN NN O
spasm NN NN O
after IN IN O
induction NN NN O
in IN IN O
an DT DT O
undiagnosed JJ JJ O
case NN NN O
of IN IN O
myotonia NN NN O
congenita NN NN O
. . . O

We PRP PRP O
report VBP VBP O
an DT DT O
undiagnosed JJ JJ O
case NN NN O
of IN IN O
myotonia NN NN O
congenita NN NN O
in IN IN O
a DT DT O
24 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
previously RB RB O
healthy JJ JJ O
primigravida NN NN O
, , , O
who WP WP O
developed VBD VBD O
life NN NN O
threatening VBG VBG O
masseter NN NN O
spasm NN NN O
following VBG VBG O
a DT DT O
standard JJ JJ O
dose NN NN O
of IN IN O
intravenous JJ JJ O
suxamethonium NN NN B-CHEM
for IN IN O
induction NN NN O
of IN IN O
anaesthesia NN NN O
. . . O

Neither DT DT O
the DT DT O
patient NN NN O
nor CC CC O
the DT DT O
anaesthetist NN NN O
was VBD VBD O
aware JJ JJ O
of IN IN O
the DT DT O
diagnosis NN NN O
before IN IN O
this DT DT O
potentially RB RB O
lethal JJ JJ O
complication NN NN O
occurred VBD VBD O
. . . O

Twin NNP NNP O
preterm NN NN O
neonates NNS NNS O
with IN IN O
cardiac JJ JJ O
toxicity NN NN O
related VBN VBN O
to TO TO O
lopinavir NN NN B-CHEM
/ NN NN I-CHEM
ritonavir NN NN I-CHEM
therapy NN NN O
. . . O

We PRP PRP O
report VBP VBP O
twin JJ JJ O
neonates NNS NNS O
who WP WP O
were VBD VBD O
born VBN VBN O
prematurely RB RB O
at IN IN O
32 CD CD O
weeks NNS NNS O
of IN IN O
gestation NN NN O
to TO TO O
a DT DT O
mother NN NN O
with IN IN O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
infection NN NN O
. . . O

One CD CD O
of IN IN O
the DT DT O
twins NNS NNS O
developed VBN VBN O
complete JJ JJ O
heart NN NN O
block NN NN O
and CC CC O
dilated JJ JJ O
cardiomyopathy NN NN O
related VBN VBN O
to TO TO O
lopinavir NN NN B-CHEM
/ NN NN I-CHEM
ritonavir NN NN I-CHEM
therapy NN NN O
, , , O
a DT DT O
boosted JJ JJ O
protease NN NN O
- - - O
inhibitor NN NN O
agent NN NN O
, , , O
while IN IN O
the DT DT O
other JJ JJ O
twin NN NN O
developed VBN VBN O
mild JJ JJ O
bradycardia NNS NNS O
. . . O

We PRP PRP O
recommend VBP VBP O
caution NN NN O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
lopinavir NN NN B-CHEM
/ NN NN I-CHEM
ritonavir NN NN I-CHEM
in IN IN O
the DT DT O
immediate JJ JJ O
neonatal JJ JJ O
period NN NN O
. . . O

When WRB WRB O
drugs NNS NNS O
disappear VBP VBP O
from IN IN O
the DT DT O
patient NN NN O
: : : O
elimination NN NN O
of IN IN O
intravenous JJ JJ O
medication NN NN O
by IN IN O
hemodiafiltration NN NN O
. . . O

Twenty CD CD O
- - - O
three CD CD O
hours NNS NNS O
after IN IN O
heart NN NN O
transplantation NN NN O
, , , O
life NN NN O
- - - O
threatening VBG VBG O
acute JJ JJ O
right JJ JJ O
heart NN NN O
failure NN NN O
was VBD VBD O
diagnosed VBN VBN O
in IN IN O
a DT DT O
patient NN NN O
requiring VBG VBG O
continuous JJ JJ O
venovenous JJ JJ O
hemodiafiltration NN NN O
( ( ( O
CVVHDF NNP NNP O
) ) ) O
. . . O

Increasing NNP NNP O
doses NNS NNS O
of IN IN O
catecholamines NNS NNS B-CHEM
, , , O
sedatives NNS NNS O
, , , O
and CC CC O
muscle NN NN O
relaxants NNS NNS O
administered VBN VBN O
through IN IN O
a DT DT O
central JJ JJ O
venous JJ JJ O
catheter NN NN O
were VBD VBD O
ineffective JJ JJ O
. . . O

However RB RB O
, , , O
a DT DT O
bolus NN NN O
of IN IN O
epinephrine NN NN B-CHEM
injected VBN VBN O
through IN IN O
an DT DT O
alternative JJ JJ O
catheter NN NN O
provoked VBD VBD O
a DT DT O
hypertensive JJ JJ O
crisis NN NN O
. . . O

Thus RB RB O
, , , O
interference NN NN O
with IN IN O
the DT DT O
central JJ JJ O
venous JJ JJ O
infusion NN NN O
by IN IN O
the DT DT O
dialysis NN NN O
catheter NN NN O
was VBD VBD O
suspected VBN VBN O
. . . O

The DT DT O
catheters NNS NNS O
were VBD VBD O
changed VBN VBN O
, , , O
and CC CC O
hemodynamics NNS NNS O
stabilized JJ JJ O
at IN IN O
lower JJR JJR O
catecholamine NN NN B-CHEM
doses NNS NNS O
. . . O

When WRB WRB O
the DT DT O
effects NNS NNS O
of IN IN O
IV NNP NNP O
drugs NNS NNS O
are VBP VBP O
inadequate JJ JJ O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
CVVHDF NNP NNP O
, , , O
interference NN NN O
with IN IN O
adjacent JJ JJ O
catheters NNS NNS O
resulting VBG VBG O
in IN IN O
elimination NN NN O
of IN IN O
the DT DT O
drug NN NN O
by IN IN O
CVVHDF NNP NNP O
should MD MD O
be VB VB O
suspected VBN VBN O
. . . O

Less RBR RBR O
frequent JJ JJ O
lithium NN NN B-CHEM
administration NN NN O
and CC CC O
lower JJR JJR O
urine NN NN O
volume NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
determine VB VB O
whether IN IN O
patients NNS NNS O
maintained VBN VBN O
on IN IN O
a DT DT O
regimen NN NN O
of IN IN O
lithium NN NN B-CHEM
on IN IN O
a DT DT O
once RB RB O
- - - O
per IN IN O
- - - O
day NN NN O
schedule NN NN O
have VBP VBP O
lower JJR JJR O
urine NN NN O
volumes NNS NNS O
than IN IN O
do VBP VBP O
patients NNS NNS O
receiving VBG VBG O
multiple JJ JJ O
doses NNS NNS O
per IN IN O
day NN NN O
. . . O

METHOD NNP NNP O
: : : O
This DT DT O
was VBD VBD O
a DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
study NN NN O
of IN IN O
85 CD CD O
patients NNS NNS O
from IN IN O
a DT DT O
lithium NN NN B-CHEM
clinic NN NN O
who WP WP O
received VBD VBD O
different JJ JJ O
dose NN NN O
schedules NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
for IN IN O
measurement NN NN O
of IN IN O
lithium NN NN B-CHEM
level NN NN O
, , , O
creatinine JJ JJ B-CHEM
clearance NN NN O
, , , O
urine NN NN O
volume NN NN O
, , , O
and CC CC O
maximum NN NN O
osmolality NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Multiple NNP NNP O
daily JJ JJ O
doses NNS NNS O
of IN IN O
lithium NN NN B-CHEM
were VBD VBD O
associated VBN VBN O
with IN IN O
higher JJR JJR O
urine NN NN O
volumes NNS NNS O
. . . O

The DT DT O
dosing VBG VBG O
schedule NN NN O
, , , O
duration NN NN O
of IN IN O
lithium NN NN B-CHEM
treatment NN NN O
, , , O
and CC CC O
daily JJ JJ O
dose NN NN O
of IN IN O
lithium NN NN B-CHEM
did VBD VBD O
not RB RB O
affect VB VB O
maximum NN NN O
osmolality NN NN O
or CC CC O
creatinine NN NN B-CHEM
clearance NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Urine NNP NNP O
volume NN NN O
can MD MD O
be VB VB O
reduced VBN VBN O
by IN IN O
giving VBG VBG O
lithium NN NN B-CHEM
once RB RB O
daily JJ JJ O
and CC CC O
/ NN NN O
or CC CC O
by IN IN O
lowering VBG VBG O
the DT DT O
total JJ JJ O
daily JJ JJ O
dose NN NN O
. . . O

Lithium NNP NNP B-CHEM
- : : O
induced JJ JJ O
polyuria NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
related VBN VBN O
to TO TO O
extrarenal JJ JJ O
as RB RB O
well RB RB O
as IN IN O
to TO TO O
renal JJ JJ O
effects NNS NNS O
. . . O

Antibacterial NNP NNP O
medication NN NN O
use NN NN O
during IN IN O
pregnancy NN NN O
and CC CC O
risk NN NN O
of IN IN O
birth NN NN O
defects NNS NNS O
: : : O
National NNP NNP O
Birth NNP NNP O
Defects NNP NNP O
Prevention NNP NNP O
Study NNP NNP O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
estimate VB VB O
the DT DT O
association NN NN O
between IN IN O
antibacterial JJ JJ O
medications NNS NNS O
and CC CC O
selected VBN VBN O
birth NN NN O
defects NNS NNS O
. . . O

DESIGN NNP NNP O
, , , O
SETTING NNP NNP O
, , , O
AND CC CC O
PARTICIPANTS NNS NNS O
: : : O
Population NN NN O
- - - O
based JJ JJ O
, , , O
multisite NN NN O
, , , O
case NN NN O
- - - O
control NN NN O
study NN NN O
of IN IN O
women NNS NNS O
who WP WP O
had VBD VBD O
pregnancies NNS NNS O
affected VBN VBN O
by IN IN O
1 CD CD O
of IN IN O
more JJR JJR O
than IN IN O
30 CD CD O
eligible JJ JJ O
major JJ JJ O
birth NN NN O
defects NNS NNS O
identified VBN VBN O
via IN IN O
birth NN NN O
defect JJ JJ O
surveillance NN NN O
programs NNS NNS O
in IN IN O
10 CD CD O
states NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
13 CD CD O
155 CD CD O
) ) ) O
and CC CC O
control NN NN O
women NNS NNS O
randomly VBP VBP O
selected VBN VBN O
from IN IN O
the DT DT O
same JJ JJ O
geographical JJ JJ O
regions NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
4941 CD CD O
) ) ) O
. . . O

MAIN NNP NNP O
EXPOSURE NNP NNP O
: : : O
Reported NNP NNP O
maternal JJ JJ O
use NN NN O
of IN IN O
antibacterials NNS NNS O
( ( ( O
1 CD CD O
month NN NN O
before IN IN O
pregnancy NN NN O
through IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
first JJ JJ O
trimester NN NN O
) ) ) O
. . . O

MAIN NNP NNP O
OUTCOME NNP NNP O
MEASURE NNP NNP O
: : : O
Odds NNP NNP O
ratios NN NN O
( ( ( O
ORs NNP NNP O
) ) ) O
measuring VBG VBG O
the DT DT O
association NN NN O
between IN IN O
antibacterial JJ JJ O
use NN NN O
and CC CC O
selected VBD VBD O
birth NN NN O
defects NNS NNS O
adjusted VBN VBN O
for IN IN O
potential JJ JJ O
confounders NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
reported JJ JJ O
use NN NN O
of IN IN O
antibacterials NNS NNS O
increased VBN VBN O
during IN IN O
pregnancy NN NN O
, , , O
peaking VBG VBG O
during IN IN O
the DT DT O
third JJ JJ O
month NN NN O
. . . O

Sulfonamides NNP NNP B-CHEM
were VBD VBD O
associated VBN VBN O
with IN IN O
anencephaly NN NN O
( ( ( O
adjusted VBN VBN O
OR CC CC O
[ NN NN O
AOR NNP NNP O
] NN NN O
= SYM SYM O
3 CD CD O
. . . O
4 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
, , , O
1 CD CD O
. . . O
3 CD CD O
- : : O
8 CD CD O
. . . O
8 CD CD O
) ) ) O
, , , O
hypoplastic JJ JJ O
left JJ JJ O
heart NN NN O
syndrome NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
3 CD CD O
. . . O
2 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
3 CD CD O
- : : O
7 CD CD O
. . . O
6 CD CD O
) ) ) O
, , , O
coarctation NN NN O
of IN IN O
the DT DT O
aorta NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
2 CD CD O
. . . O
7 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
3 CD CD O
- : : O
5 CD CD O
. . . O
6 CD CD O
) ) ) O
, , , O
choanal JJ JJ O
atresia NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
8 CD CD O
. . . O
0 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
2 CD CD O
. . . O
7 CD CD O
- : : O
23 CD CD O
. . . O
5 CD CD O
) ) ) O
, , , O
transverse NN NN O
limb NN NN O
deficiency NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
2 CD CD O
. . . O
5 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
0 CD CD O
- : : O
5 CD CD O
. . . O
9 CD CD O
) ) ) O
, , , O
and CC CC O
diaphragmatic JJ JJ O
hernia NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
2 CD CD O
. . . O
4 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
1 CD CD O
- : : O
5 CD CD O
. . . O
4 CD CD O
) ) ) O
. . . O

Nitrofurantoins NNP NNP B-CHEM
were VBD VBD O
associated VBN VBN O
with IN IN O
anophthalmia NN NN O
or CC CC O
microphthalmos NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
3 CD CD O
. . . O
7 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
1 CD CD O
- : : O
12 CD CD O
. . . O
2 CD CD O
) ) ) O
, , , O
hypoplastic JJ JJ O
left JJ JJ O
heart NN NN O
syndrome NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
4 CD CD O
. . . O
2 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
9 CD CD O
- : : O
9 CD CD O
. . . O
1 CD CD O
) ) ) O
, , , O
atrial JJ JJ O
septal NN NN O
defects NNS NNS O
( ( ( O
AOR NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
9 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
1 CD CD O
- : : O
3 CD CD O
. . . O
4 CD CD O
) ) ) O
, , , O
and CC CC O
cleft VBD VBD O
lip NN NN O
with IN IN O
cleft NN NN O
palate NN NN O
( ( ( O
AOR NNP NNP O
= SYM SYM O
2 CD CD O
. . . O
1 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
2 CD CD O
- : : O
3 CD CD O
. . . O
9 CD CD O
) ) ) O
. . . O

Other JJ JJ O
antibacterial JJ JJ O
agents NNS NNS O
that WDT WDT O
showed VBD VBD O
associations NNS NNS O
included VBD VBD O
erythromycins NNS NNS B-CHEM
( ( ( O
2 CD CD O
defects NNS NNS O
) ) ) O
, , , O
penicillins NNS NNS B-CHEM
( ( ( O
1 CD CD O
defect NN NN O
) ) ) O
, , , O
cephalosporins NNS NNS B-CHEM
( ( ( O
1 CD CD O
defect NN NN O
) ) ) O
, , , O
and CC CC O
quinolones NNS NNS B-CHEM
( ( ( O
1 CD CD O
defect NN NN O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Reassuringly RB RB O
, , , O
penicillins NNS NNS B-CHEM
, , , O
erythromycins NNS NNS B-CHEM
, , , O
and CC CC O
cephalosporins NNS NNS B-CHEM
, , , O
although IN IN O
used VBN VBN O
commonly RB RB O
by IN IN O
pregnant JJ JJ O
women NNS NNS O
, , , O
were VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
many JJ JJ O
birth NN NN O
defects NNS NNS O
. . . O

Sulfonamides NNP NNP B-CHEM
and CC CC O
nitrofurantoins NNS NNS B-CHEM
were VBD VBD O
associated VBN VBN O
with IN IN O
several JJ JJ O
birth NN NN O
defects NNS NNS O
, , , O
indicating VBG VBG O
a DT DT O
need NN NN O
for IN IN O
additional JJ JJ O
scrutiny NN NN O
. . . O

Differential NNP NNP O
impact NN NN O
of IN IN O
immune JJ JJ O
escape NN NN O
mutations NNS NNS O
G145R NNP NNP O
and CC CC O
P120T NNP NNP O
on IN IN O
the DT DT O
replication NN NN O
of IN IN O
lamivudine NN NN B-CHEM
- - - O
resistant JJ JJ O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
virus NN NN I-CHEM
e SYM SYM I-CHEM
antigen NN NN I-CHEM
- : : O
positive JJ JJ O
and CC CC O
- - - O
negative JJ JJ O
strains NNS NNS O
. . . O

Immune NNP NNP O
escape NN NN O
variants NNS NNS O
of IN IN O
the DT DT O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
represent NN NN O
an DT DT O
emerging VBG VBG O
clinical JJ JJ O
challenge NN NN O
, , , O
because IN IN O
they PRP PRP O
can MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
vaccine NN NN O
escape NN NN O
, , , O
HBV NNP NNP O
reactivation NN NN O
, , , O
and CC CC O
failure NN NN O
of IN IN O
diagnostic JJ JJ O
tests NNS NNS O
. . . O

Recent JJ JJ O
data NNS NNS O
suggest VBP VBP O
a DT DT O
preferential JJ JJ O
selection NN NN O
of IN IN O
immune JJ JJ O
escape NN NN O
mutants NNS NNS O
in IN IN O
distinct JJ JJ O
peripheral JJ JJ O
blood NN NN O
leukocyte NN NN O
compartments NNS NNS O
of IN IN O
infected JJ JJ O
individuals NNS NNS O
. . . O

We PRP PRP O
therefore RB RB O
systematically RB RB O
analyzed VBD VBD O
the DT DT O
functional JJ JJ O
impact NN NN O
of IN IN O
the DT DT O
most RBS RBS O
prevalent JJ JJ O
immune JJ JJ O
escape NN NN O
variants NNS NNS O
, , , O
the DT DT O
sG145R NN NN O
and CC CC O
sP120T NN NN O
mutants NNS NNS O
, , , O
on IN IN O
the DT DT O
viral JJ JJ O
replication NN NN O
efficacy NN NN O
and CC CC O
antiviral JJ JJ O
drug NN NN O
susceptibility NN NN O
of IN IN O
common JJ JJ O
treatment NN NN O
- - - O
associated VBN VBN O
mutants NNS NNS O
with IN IN O
resistance NN NN O
to TO TO O
lamivudine VB VB B-CHEM
( ( ( O
LAM NNP NNP B-CHEM
) ) ) O
and CC CC O
/ NN NN O
or CC CC O
HBeAg NNP NNP B-CHEM
negativity NN NN O
. . . O

Replication NNP NNP O
- : : O
competent JJ JJ O
HBV NNP NNP O
strains NNS NNS O
with IN IN O
sG145R NN NN O
or CC CC O
sP120T NN NN O
and CC CC O
LAM NNP NNP B-CHEM
resistance NN NN O
( ( ( O
rtM204I NN NN O
or CC CC O
rtL180M NN NN O
/ NN NN O
rtM204V NN NN O
) ) ) O
were VBD VBD O
generated VBN VBN O
on IN IN O
an DT DT O
HBeAg NNP NNP B-CHEM
- - - O
positive JJ JJ O
and CC CC O
an DT DT O
HBeAg NNP NNP B-CHEM
- - - O
negative JJ JJ O
background NN NN O
with IN IN O
precore NN NN O
( ( ( O
PC NN NN O
) ) ) O
and CC CC O
basal NN NN O
core NN NN O
promoter NN NN O
( ( ( O
BCP NNP NNP O
) ) ) O
mutants NNS NNS O
. . . O

The DT DT O
sG145R NN NN O
mutation NN NN O
strongly RB RB O
reduced VBD VBD O
HBsAg NNP NNP B-CHEM
levels NNS NNS O
and CC CC O
was VBD VBD O
able JJ JJ O
to TO TO O
fully RB RB O
restore VB VB O
the DT DT O
impaired JJ JJ O
replication NN NN O
of IN IN O
LAM NNP NNP B-CHEM
- : : O
resistant JJ JJ O
HBV NNP NNP O
mutants NNS NNS O
to TO TO O
the DT DT O
levels NNS NNS O
of IN IN O
wild JJ JJ O
- - - O
type NN NN O
HBV NNP NNP O
, , , O
and CC CC O
PC NNP NNP O
or CC CC O
BCP NNP NNP O
mutations NNS NNS O
further RB RB O
enhanced VBD VBD O
viral JJ JJ O
replication NN NN O
. . . O

Although IN IN O
the DT DT O
sP120T NN NN O
substitution NN NN O
also RB RB O
impaired VBD VBD O
HBsAg NNP NNP B-CHEM
secretion NN NN O
, , , O
it PRP PRP O
did VBD VBD O
not RB RB O
enhance VB VB O
the DT DT O
replication NN NN O
of IN IN O
LAM NNP NNP B-CHEM
- : : O
resistant JJ JJ O
clones NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
concomitant JJ JJ O
occurrence NN NN O
of IN IN O
HBeAg NNP NNP B-CHEM
negativity NN NN O
( ( ( O
PC NN NN O
/ NN NN O
BCP NNP NNP O
) ) ) O
, , , O
sP120T NN NN O
, , , O
and CC CC O
LAM NNP NNP B-CHEM
resistance NN NN O
resulted VBD VBD O
in IN IN O
the DT DT O
restoration NN NN O
of IN IN O
replication NN NN O
to TO TO O
levels NNS NNS O
of IN IN O
wild JJ JJ O
- - - O
type NN NN O
HBV NNP NNP O
. . . O

In IN IN O
all DT DT O
clones NNS NNS O
with IN IN O
combined VBN VBN O
immune JJ JJ O
escape NN NN O
and CC CC O
LAM NNP NNP B-CHEM
resistance NN NN O
mutations NNS NNS O
, , , O
the DT DT O
nucleotide NN NN B-CHEM
analogues NNS NNS O
adefovir NN NN B-CHEM
and CC CC O
tenofovir NN NN B-CHEM
remained VBD VBD O
effective JJ JJ O
in IN IN O
suppressing VBG VBG O
viral JJ JJ O
replication NN NN O
in IN IN O
vitro NN NN O
. . . O

These DT DT O
findings NNS NNS O
reveal VBP VBP O
the DT DT O
differential JJ JJ O
impact NN NN O
of IN IN O
immune JJ JJ O
escape NN NN O
variants NNS NNS O
on IN IN O
the DT DT O
replication NN NN O
and CC CC O
drug NN NN O
susceptibility NN NN O
of IN IN O
complex JJ JJ O
HBV NNP NNP O
mutants NNS NNS O
, , , O
supporting VBG VBG O
the DT DT O
need NN NN O
of IN IN O
close JJ JJ O
surveillance NN NN O
and CC CC O
treatment NN NN O
adjustment NN NN O
in IN IN O
response NN NN O
to TO TO O
the DT DT O
selection NN NN O
of IN IN O
distinct JJ JJ O
mutational NN NN O
patterns NNS NNS O
. . . O

Hemolytic NNP NNP O
anemia NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
omeprazole NN NN B-CHEM
. . . O

Omeprazole NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
first JJ JJ O
drug NN NN O
designed VBN VBN O
to TO TO O
block VB VB O
the DT DT O
final JJ JJ O
step NN NN O
in IN IN O
the DT DT O
acid NN NN O
secretory NN NN O
process NN NN O
within IN IN O
the DT DT O
parietal JJ JJ O
cell NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
extremely RB RB O
effective JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
peptic JJ JJ O
ulcer NN NN O
disease NN NN O
, , , O
reflux NN NN O
esophagitis NN NN O
, , , O
and CC CC O
the DT DT O
Zollinger NNP NNP O
- : : O
Ellison NNP NNP O
syndrome NN NN O
. . . O

Although IN IN O
clinical JJ JJ O
experience NN NN O
with IN IN O
omeprazole NN NN B-CHEM
is VBZ VBZ O
still RB RB O
limited JJ JJ O
, , , O
many JJ JJ O
controlled VBN VBN O
studies NNS NNS O
have VBP VBP O
established VBN VBN O
the DT DT O
short JJ JJ O
- - - O
term NN NN O
safety NN NN O
of IN IN O
this DT DT O
drug NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
first JJ JJ O
case NN NN O
of IN IN O
a DT DT O
serious JJ JJ O
short JJ JJ O
- - - O
term NN NN O
adverse JJ JJ O
reaction NN NN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
omeprazole NN NN B-CHEM
: : : O
hemolytic JJ JJ O
anemia NN NN O
. . . O

The DT DT O
patient NN NN O
developed VBN VBN O
weakness NN NN O
, , , O
lethargy NN NN O
, , , O
and CC CC O
shortness NN NN O
of IN IN O
breath NN NN O
2 CD CD O
days NNS NNS O
after IN IN O
starting VBG VBG O
therapy NN NN O
with IN IN O
omeprazole NN NN B-CHEM
. . . O

Two CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
therapy NN NN O
, , , O
her PRP$ PRP$ O
hematocrit NN NN O
had VBD VBD O
decreased VBN VBN O
from IN IN O
44 CD CD O
. . . O
1 CD CD O
% NN NN O
to TO TO O
20 CD CD O
. . . O
4 CD CD O
% NN NN O
, , , O
and CC CC O
she PRP PRP O
had VBD VBD O
a DT DT O
positive JJ JJ O
direct JJ JJ O
Coombs NNP NNP O
antiglobulin NN NN O
test NN NN O
and CC CC O
an DT DT O
elevated VBD VBD O
indirect JJ JJ O
bilirubin NN NN B-CHEM
. . . O

After IN IN O
she PRP PRP O
discontinued VBD VBD O
the DT DT O
omeprazole NN NN B-CHEM
, , , O
her PRP$ PRP$ O
hemoglobin NN NN O
and CC CC O
hematocrit NN NN O
gradually RB RB O
returned VBD VBD O
to TO TO O
normal JJ JJ O
. . . O

The DT DT O
mechanism NN NN O
by IN IN O
which WDT WDT O
omeprazole NN NN B-CHEM
caused VBD VBD O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
hemolytic JJ JJ O
anemia NN NN O
is VBZ VBZ O
uncertain JJ JJ O
, , , O
but CC CC O
physicians NNS NNS O
should MD MD O
be VB VB O
alerted VBN VBN O
to TO TO O
this DT DT O
possible JJ JJ O
adverse JJ JJ O
effect NN NN O
. . . O

Phenylephrine NNP NNP B-CHEM
but CC CC O
not RB RB O
ephedrine VB VB B-CHEM
reduces NNS NNS O
frontal JJ JJ O
lobe NN NN O
oxygenation NN NN O
following VBG VBG O
anesthesia NN NN O
- - - O
induced JJ JJ O
hypotension NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Vasopressor NNP NNP O
agents NNS NNS O
are VBP VBP O
used VBN VBN O
to TO TO O
correct VB VB O
anesthesia NN NN O
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
the DT DT O
effect NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
and CC CC O
ephedrine NN NN B-CHEM
on IN IN O
frontal JJ JJ O
lobe NN NN O
oxygenation NN NN O
( ( ( O
S NNP NNP O
( ( ( O
c SYM SYM O
) ) ) O
O NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
) ) ) O
following VBG VBG O
anesthesia NN NN O
- - - O
induced JJ JJ O
hypotension NN NN O
. . . O

METHODS NNP NNP O
: : : O
Following VBG VBG O
induction NN NN O
of IN IN O
anesthesia NN NN O
by IN IN O
fentanyl NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
15 CD CD O
mg NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
and CC CC O
propofol NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
, , , O
13 CD CD O
patients NNS NNS O
received VBD VBD O
phenylephrine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
iv NN NN O
) ) ) O
and CC CC O
12 CD CD O
patients NNS NNS O
received VBD VBD O
ephedrine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
iv NN NN O
) ) ) O
to TO TO O
restore VB VB O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
. . . O

Heart NNP NNP O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
, , , O
MAP NNP NNP O
, , , O
stroke NN NN O
volume NN NN O
( ( ( O
SV NNP NNP O
) ) ) O
, , , O
cardiac JJ JJ O
output NN NN O
( ( ( O
CO NNP NNP O
) ) ) O
, , , O
and CC CC O
frontal JJ JJ O
lobe NN NN O
oxygenation NN NN O
( ( ( O
S NNP NNP O
( ( ( O
c SYM SYM O
) ) ) O
O NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
) ) ) O
were VBD VBD O
registered VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Induction NNP NNP O
of IN IN O
anesthesia NN NN O
was VBD VBD O
followed VBN VBN O
by IN IN O
a DT DT O
decrease NN NN O
in IN IN O
MAP NNP NNP O
, , , O
HR NNP NNP O
, , , O
SV NNP NNP O
, , , O
and CC CC O
CO NNP NNP O
concomitant NN NN O
with IN IN O
an DT DT O
elevation NN NN O
in IN IN O
S NNP NNP O
( ( ( O
c SYM SYM O
) ) ) O
O NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
. . . O

After IN IN O
administration NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
, , , O
MAP NNP NNP O
increased VBN VBN O
( ( ( O
51 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
to TO TO O
81 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
mmHg NN NN O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
; : : O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
. . . O

However RB RB O
, , , O
a DT DT O
14 CD CD O
% NN NN O
( ( ( O
from IN IN O
70 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
% NN NN O
to TO TO O
60 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
% NN NN O
) ) ) O
reduction NN NN O
in IN IN O
S NNP NNP O
( ( ( O
c SYM SYM O
) ) ) O
O NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
followed VBN VBN O
with IN IN O
no DT DT O
change NN NN O
in IN IN O
CO NNP NNP O
( ( ( O
3 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
1 CD CD O
to TO TO O
3 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
l NN NN O
min NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
. . . O

The DT DT O
administration NN NN O
of IN IN O
ephedrine NN NN B-CHEM
led VBN VBN O
to TO TO O
a DT DT O
similar JJ JJ O
increase NN NN O
in IN IN O
MAP NNP NNP O
( ( ( O
53 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
to TO TO O
79 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
mmHg NN NN O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
restored VBD VBD O
CO NNP NNP O
( ( ( O
3 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
2 CD CD O
to TO TO O
5 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
l NN NN O
min NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
, , , O
and CC CC O
preserved VBD VBD O
S NNP NNP O
( ( ( O
c SYM SYM O
) ) ) O
O NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
utilization NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
to TO TO O
correct VB VB O
hypotension NN NN O
induced VBN VBN O
by IN IN O
anesthesia NN NN O
has VBZ VBZ O
a DT DT O
negative JJ JJ O
impact NN NN O
on IN IN O
S NNP NNP O
( ( ( O
c SYM SYM O
) ) ) O
O NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
while IN IN O
ephedrine NN NN B-CHEM
maintains VBZ VBZ O
frontal JJ JJ O
lobe NN NN O
oxygenation NN NN O
potentially RB RB O
related VBN VBN O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
CO NNP NNP O
. . . O

Prolonged NNP NNP O
elevation NN NN O
of IN IN O
plasma NN NN O
argatroban NN NN B-CHEM
in IN IN O
a DT DT O
cardiac JJ JJ O
transplant NN NN O
patient NN NN O
with IN IN O
a DT DT O
suspected JJ JJ O
history NN NN O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
with IN IN O
thrombosis NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Direct NNP NNP O
thrombin NN NN O
inhibitors NNS NNS O
( ( ( O
DTIs NNP NNP O
) ) ) O
provide VB VB O
an DT DT O
alternative JJ JJ O
method NN NN O
of IN IN O
anticoagulation NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
( ( ( O
HIT NNP NNP O
) ) ) O
or CC CC O
HIT NNP NNP O
with IN IN O
thrombosis NN NN O
( ( ( O
HITT NNP NNP O
) ) ) O
undergoing VBG VBG O
cardiopulmonary JJ JJ O
bypass NN NN O
( ( ( O
CPB NNP NNP O
) ) ) O
. . . O

In IN IN O
the DT DT O
following VBG VBG O
report NN NN O
, , , O
a DT DT O
65 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
critically RB RB O
ill JJ JJ O
patient NN NN O
with IN IN O
a DT DT O
suspected JJ JJ O
history NN NN O
of IN IN O
HITT NNP NNP O
was VBD VBD O
administered VBN VBN O
argatroban IN IN B-CHEM
for IN IN O
anticoagulation NN NN O
on IN IN O
bypass NN NN O
during IN IN O
heart NN NN O
transplantation NN NN O
. . . O

The DT DT O
patient NN NN O
required VBD VBD O
massive JJ JJ O
transfusion NN NN O
support NN NN O
( ( ( O
55 CD CD O
units NNS NNS O
of IN IN O
red JJ JJ O
blood NN NN O
cells NNS NNS O
, , , O
42 CD CD O
units NNS NNS O
of IN IN O
fresh JJ JJ O
- - - O
frozen JJ JJ O
plasma NN NN O
, , , O
40 CD CD O
units NNS NNS O
of IN IN O
cryoprecipitate NN NN O
, , , O
40 CD CD O
units NNS NNS O
of IN IN O
platelets NNS NNS O
, , , O
and CC CC O
three CD CD O
doses NNS NNS O
of IN IN O
recombinant NN NN O
Factor NNP NNP O
VIIa NNP NNP O
) ) ) O
for IN IN O
severe JJ JJ O
intraoperative JJ JJ O
and CC CC O
postoperative JJ JJ O
bleeding NN NN O
. . . O

STUDY NNP NNP O
DESIGN NNP NNP O
AND CC CC O
METHODS NNP NNP O
: : : O
Plasma NNP NNP O
samples NNS NNS O
from IN IN O
before IN IN O
and CC CC O
after IN IN O
CPB NNP NNP O
were VBD VBD O
analyzed VBN VBN O
postoperatively RB RB O
for IN IN O
argatroban JJ JJ B-CHEM
concentration NN NN O
using VBG VBG O
a DT DT O
modified VBN VBN O
ecarin NN NN O
clotting VBG VBG O
time NN NN O
( ( ( O
ECT NNP NNP O
) ) ) O
assay NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Unexpectedly NNP NNP O
high JJ JJ O
concentrations NNS NNS O
of IN IN O
argatroban NN NN B-CHEM
were VBD VBD O
measured VBN VBN O
in IN IN O
these DT DT O
samples NNS NNS O
( ( ( O
range NN NN O
, , , O
0 CD CD O
- : : O
32 CD CD O
microg NN NN O
/ NN NN O
mL NN NN O
) ) ) O
, , , O
and CC CC O
a DT DT O
prolonged JJ JJ O
plasma NN NN O
argatroban NN NN B-CHEM
half NN NN O
life NN NN O
( ( ( O
t NN NN O
( ( ( O
1 CD CD O
/ NN NN O
2 CD CD O
) ) ) O
) ) ) O
of IN IN O
514 CD CD O
minutes NNS NNS O
was VBD VBD O
observed VBN VBN O
( ( ( O
published VBN VBN O
elimination NN NN O
t NN NN O
( ( ( O
1 CD CD O
/ NN NN O
2 CD CD O
) ) ) O
is VBZ VBZ O
39 CD CD O
- : : O
51 CD CD O
minutes NNS NNS O
[ NN NN O
< NN NN O
or CC CC O
= SYM SYM O
181 CD CD O
minutes NNS NNS O
with IN IN O
hepatic JJ JJ O
impairment NN NN O
] NN NN O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Correlation NNP NNP O
of IN IN O
plasma NN NN O
argatroban JJ JJ B-CHEM
concentration NN NN O
versus CC CC O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
coagulation NN NN O
variables NNS NNS O
and CC CC O
clinical JJ JJ O
course NN NN O
suggest VBP VBP O
that IN IN O
prolonged JJ JJ O
elevated VBD VBD O
levels NNS NNS O
of IN IN O
plasma NN NN O
argatroban NN NN B-CHEM
may MD MD O
have VB VB O
contributed VBN VBN O
to TO TO O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
extended VBN VBN O
coagulopathy NN NN O
. . . O

Because IN IN O
DTIs NNP NNP O
do VBP VBP O
not RB RB O
have VB VB O
reversal NN NN O
agents NNS NNS O
, , , O
surgical JJ JJ O
teams NNS NNS O
and CC CC O
transfusion NN NN O
services NNS NNS O
should MD MD O
remain VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
possibility NN NN O
of IN IN O
massive JJ JJ O
transfusion NN NN O
events NNS NNS O
during IN IN O
anticoagulation NN NN O
with IN IN O
these DT DT O
agents NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
report NN NN O
to TO TO O
measure VB VB O
plasma NN NN O
argatroban JJ JJ B-CHEM
concentration NN NN O
in IN IN O
the DT DT O
context NN NN O
of IN IN O
CPB NNP NNP O
and CC CC O
extended VBN VBN O
coagulopathy NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
the DT DT O
adjunctive JJ JJ O
bupropion NN NN B-CHEM
on IN IN O
male JJ JJ O
sexual JJ JJ O
dysfunction NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
selective JJ JJ B-CHEM
serotonin NN NN I-CHEM
reuptake NN NN I-CHEM
inhibitor NN NN I-CHEM
: : : O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
placebo NN NN O
- - - O
controlled JJ JJ O
and CC CC O
randomized JJ JJ O
study NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
adjunctive JJ JJ O
bupropion NN NN B-CHEM
sustained VBD VBD O
- : : O
release NN NN O
( ( ( O
SR NNP NNP O
) ) ) O
on IN IN O
male JJ JJ O
sexual JJ JJ O
dysfunction NN NN O
( ( ( O
SD NNP NNP O
) ) ) O
induced VBN VBN O
by IN IN O
a DT DT O
selective JJ JJ B-CHEM
serotonin NN NN I-CHEM
reuptake NN NN I-CHEM
inhibitor NN NN I-CHEM
( ( ( O
SSRI NNP NNP B-CHEM
) ) ) O
, , , O
as IN IN O
SD NNP NNP O
is VBZ VBZ O
a DT DT O
common JJ JJ O
side NN NN O
- - - O
effect NN NN O
of IN IN O
SSRIs NNP NNP B-CHEM
and CC CC O
the DT DT O
most RBS RBS O
effective JJ JJ O
treatments NNS NNS O
have VBP VBP O
yet RB RB O
to TO TO O
be VB VB O
determined VBN VBN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
The DT DT O
randomized JJ JJ O
sample NN NN O
consisted VBD VBD O
of IN IN O
234 CD CD O
euthymic JJ JJ O
men NNS NNS O
who WP WP O
were VBD VBD O
receiving VBG VBG O
some DT DT O
type NN NN O
of IN IN O
SSRI NNP NNP B-CHEM
. . . O

The DT DT O
men NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
bupropion NN NN B-CHEM
SR NNP NNP O
( ( ( O
150 CD CD O
mg NN NN O
twice RB RB O
daily RB RB O
, , , O
117 CD CD O
) ) ) O
or CC CC O
placebo NN NN O
( ( ( O
twice RB RB O
daily RB RB O
, , , O
117 CD CD O
) ) ) O
for IN IN O
12 CD CD O
weeks NNS NNS O
. . . O

Efficacy NNP NNP O
was VBD VBD O
evaluated VBN VBN O
using VBG VBG O
the DT DT O
Clinical NNP NNP O
Global NNP NNP O
Impression NNP NNP O
- : : O
Sexual NNP NNP O
Function NNP NNP O
( ( ( O
CGI NNP NNP O
- : : O
SF NNP NNP O
; : : O
the DT DT O
primary JJ JJ O
outcome NN NN O
measure NN NN O
) ) ) O
, , , O
the DT DT O
International NNP NNP O
Index NNP NNP O
of IN IN O
Erectile NNP NNP O
Function NNP NNP O
( ( ( O
IIEF NNP NNP O
) ) ) O
, , , O
Arizona NNP NNP O
Sexual NNP NNP O
Experience NNP NNP O
Scale NNP NNP O
( ( ( O
ASEX NNP NNP O
) ) ) O
, , , O
and CC CC O
Erectile NNP NNP O
Dysfunction NNP NNP O
Inventory NNP NNP O
of IN IN O
Treatment NN NN O
Satisfaction NNP NNP O
( ( ( O
EDITS NNP NNP O
) ) ) O
( ( ( O
secondary JJ JJ O
outcome NN NN O
measures NNS NNS O
) ) ) O
. . . O

Participants NNS NNS O
were VBD VBD O
followed VBN VBN O
biweekly IN IN O
during IN IN O
study NN NN O
period NN NN O
. . . O

RESULTS NNS NNS O
: : : O
After IN IN O
12 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
, , , O
the DT DT O
mean NN NN O
( ( ( O
sd NN NN O
) ) ) O
scores NNS NNS O
for IN IN O
CGI NNP NNP O
- - - O
SF NNP NNP O
were VBD VBD O
significantly RB RB O
lower JJR JJR O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
better JJR JJR O
, , , O
in IN IN O
patients NNS NNS O
on IN IN O
bupropion NN NN B-CHEM
SR NNP NNP O
, , , O
at IN IN O
2 CD CD O
. . . O
4 CD CD O
( ( ( O
1 CD CD O
. . . O
2 CD CD O
) ) ) O
, , , O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
, , , O
at IN IN O
3 CD CD O
. . . O
9 CD CD O
( ( ( O
1 CD CD O
. . . O
1 CD CD O
) ) ) O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Men NN NN O
who WP WP O
received VBD VBD O
bupropion NN NN B-CHEM
had VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
total JJ JJ O
IIEF NNP NNP O
score NN NN O
( ( ( O
54 CD CD O
. . . O
4 CD CD O
% NN NN O
vs NNS NNS O
1 CD CD O
. . . O
2 CD CD O
% NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
003 CD CD O
) ) ) O
, , , O
and CC CC O
in IN IN O
the DT DT O
five CD CD O
different JJ JJ O
domains NNS NNS O
of IN IN O
the DT DT O
IIEF NNP NNP O
. . . O

Total NNP NNP O
ASEX NNP NNP O
scores NNS NNS O
were VBD VBD O
significantly RB RB O
lower JJR JJR O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
better JJR JJR O
, , , O
among IN IN O
men NNS NNS O
who WP WP O
received VBD VBD O
bupropion NN NN B-CHEM
than IN IN O
placebo NN NN O
, , , O
at IN IN O
15 CD CD O
. . . O
5 CD CD O
( ( ( O
4 CD CD O
. . . O
3 CD CD O
) ) ) O
vs NN NN O
21 CD CD O
. . . O
5 CD CD O
( ( ( O
4 CD CD O
. . . O
7 CD CD O
) ) ) O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

The DT DT O
EDITS NNP NNP O
scores NNS NNS O
were VBD VBD O
67 CD CD O
. . . O
4 CD CD O
( ( ( O
10 CD CD O
. . . O
2 CD CD O
) ) ) O
for IN IN O
the DT DT O
bupropion NN NN B-CHEM
and CC CC O
36 CD CD O
. . . O
3 CD CD O
( ( ( O
11 CD CD O
. . . O
7 CD CD O
) ) ) O
for IN IN O
the DT DT O
placebo NN NN O
group NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

The DT DT O
ASEX NNP NNP O
score NN NN O
and CC CC O
CGI NNP NNP O
- : : O
SF NNP NNP O
score NN NN O
were VBD VBD O
correlated VBN VBN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
003 CD CD O
) ) ) O
. . . O

In IN IN O
linear JJ JJ O
regression NN NN O
analyses VBZ VBZ O
the DT DT O
CGI NNP NNP O
- - - O
SF NNP NNP O
score NN NN O
was VBD VBD O
not RB RB O
affected VBN VBN O
significantly RB RB O
by IN IN O
the DT DT O
duration NN NN O
of IN IN O
SD NNP NNP O
, , , O
type NN NN O
of IN IN O
SSRI NNP NNP B-CHEM
used VBD VBD O
and CC CC O
age NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Bupropion NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
treatment NN NN O
for IN IN O
male JJ JJ O
SD NNP NNP O
induced VBN VBN O
by IN IN O
SSRIs NNP NNP B-CHEM
. . . O

These DT DT O
results NNS NNS O
provide VBP VBP O
empirical JJ JJ O
support NN NN O
for IN IN O
conducting VBG VBG O
a DT DT O
further JJ JJ O
study NN NN O
of IN IN O
bupropion NN NN B-CHEM
. . . O

Prevention NNP NNP O
of IN IN O
seizures NNS NNS O
and CC CC O
reorganization NN NN O
of IN IN O
hippocampal JJ JJ O
functions NNS NNS O
by IN IN O
transplantation NN NN O
of IN IN O
bone NN NN O
marrow NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
acute JJ JJ O
phase NN NN O
of IN IN O
experimental JJ JJ O
epilepsy NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
therapeutic JJ JJ O
potential NN NN O
of IN IN O
bone NN NN O
marrow NN NN O
mononuclear NN NN O
cells NNS NNS O
( ( ( O
BMCs NNP NNP O
) ) ) O
in IN IN O
a DT DT O
model NN NN O
of IN IN O
epilepsy NN NN O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

BMCs NNP NNP O
obtained VBD VBD O
from IN IN O
green JJ JJ O
fluorescent NN NN O
protein NN NN O
( ( ( O
GFP NNP NNP O
) ) ) O
transgenic JJ JJ O
mice NN NN O
or CC CC O
rats NNS NNS O
were VBD VBD O
transplanted VBN VBN O
intravenously RB RB O
after IN IN O
induction NN NN O
of IN IN O
status NN NN O
epilepticus NN NN O
( ( ( O
SE NNP NNP O
) ) ) O
. . . O

Spontaneous NNP NNP O
recurrent JJ JJ O
seizures NNS NNS O
( ( ( O
SRS NNP NNP O
) ) ) O
were VBD VBD O
monitored VBN VBN O
using VBG VBG O
Racine NNP NNP O
' POS POS O
s VBZ VBZ O
seizure NN NN O
severity NN NN O
scale NN NN O
. . . O

All DT DT O
of IN IN O
the DT DT O
rats NNS NNS O
in IN IN O
the DT DT O
saline NN NN O
- - - O
treated VBN VBN O
epileptic JJ JJ O
control NN NN O
group NN NN O
developed VBN VBN O
SRS NNP NNP O
, , , O
whereas IN IN O
none NN NN O
of IN IN O
the DT DT O
BMC NNP NNP O
- - - O
treated JJ JJ O
epileptic JJ JJ O
animals NNS NNS O
had VBD VBD O
seizures NNS NNS O
in IN IN O
the DT DT O
short JJ JJ O
term NN NN O
( ( ( O
15 CD CD O
days NNS NNS O
after IN IN O
transplantation NN NN O
) ) ) O
, , , O
regardless RB RB O
of IN IN O
the DT DT O
BMC NNP NNP O
source NN NN O
. . . O

Over IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
chronic JJ JJ O
phase NN NN O
( ( ( O
120 CD CD O
days NNS NNS O
after IN IN O
transplantation NN NN O
) ) ) O
, , , O
only RB RB O
25 CD CD O
% NN NN O
of IN IN O
BMC NNP NNP O
- - - O
treated JJ JJ O
epileptic JJ JJ O
animals NNS NNS O
had VBD VBD O
seizures NNS NNS O
, , , O
but CC CC O
with IN IN O
a DT DT O
lower JJR JJR O
frequency NN NN O
and CC CC O
duration NN NN O
compared VBN VBN O
to TO TO O
the DT DT O
epileptic JJ JJ O
control NN NN O
group NN NN O
. . . O

The DT DT O
density NN NN O
of IN IN O
hippocampal JJ JJ O
neurons NNS NNS O
in IN IN O
the DT DT O
brains NNS NNS O
of IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
BMCs NNP NNP O
was VBD VBD O
markedly RB RB O
preserved VBN VBN O
. . . O

At IN IN O
hippocampal NN NN O
Schaeffer NNP NNP O
collateral NN NN O
- : : O
CA1 NNP NNP O
synapses NNS NNS O
, , , O
long JJ JJ O
- - - O
term NN NN O
potentiation NN NN O
was VBD VBD O
preserved VBN VBN O
in IN IN O
BMC NNP NNP O
- - - O
transplanted JJ JJ O
rats NNS NNS O
compared VBN VBN O
to TO TO O
epileptic JJ JJ O
controls NNS NNS O
. . . O

The DT DT O
donor NN NN O
- - - O
derived VBN VBN O
GFP NNP NNP O
( ( ( O
+ NN NN O
) ) ) O
cells NNS NNS O
were VBD VBD O
rarely RB RB O
found VBN VBN O
in IN IN O
the DT DT O
brains NNS NNS O
of IN IN O
transplanted JJ JJ O
epileptic JJ JJ O
rats NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
treatment NN NN O
with IN IN O
BMCs NNP NNP O
can MD MD O
prevent VB VB O
the DT DT O
development NN NN O
of IN IN O
chronic JJ JJ O
seizures NNS NNS O
, , , O
reduce VB VB O
neuronal JJ JJ O
loss NN NN O
, , , O
and CC CC O
influence NN NN O
the DT DT O
reorganization NN NN O
of IN IN O
the DT DT O
hippocampal NN NN O
neuronal NN NN O
network NN NN O
. . . O

Normalizing NNP NNP O
effects NNS NNS O
of IN IN O
modafinil NN NN B-CHEM
on IN IN O
sleep NN NN O
in IN IN O
chronic JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
effect NN NN O
of IN IN O
morning NN NN O
- - - O
dosed JJ JJ O
modafinil NN NN B-CHEM
on IN IN O
sleep NN NN O
and CC CC O
daytime JJ JJ O
sleepiness NNS NNS O
in IN IN O
chronic JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
Twenty NNP NNP O
cocaine NN NN B-CHEM
- : : O
dependent JJ JJ O
participants NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
receive VB VB O
modafinil NN NN B-CHEM
, , , O
400 CD CD O
mg NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
10 CD CD O
) ) ) O
, , , O
or CC CC O
placebo NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
10 CD CD O
) ) ) O
every DT DT O
morning NN NN O
at IN IN O
7 CD CD O
: : : O
30 CD CD O
a DT DT O
. . . O
m NN NN O
. . . O
for IN IN O
16 CD CD O
days NNS NNS O
in IN IN O
an DT DT O
inpatient NN NN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
randomized JJ JJ O
trial NN NN O
. . . O

Participants NNS NNS O
underwent JJ JJ O
polysomnographic JJ JJ O
sleep NN NN O
recordings NNS NNS O
on IN IN O
days NNS NNS O
1 CD CD O
to TO TO O
3 CD CD O
, , , O
7 CD CD O
to TO TO O
9 CD CD O
, , , O
and CC CC O
14 CD CD O
to TO TO O
16 CD CD O
( ( ( O
first JJ JJ O
, , , O
second JJ JJ O
, , , O
and CC CC O
third JJ JJ O
weeks NNS NNS O
of IN IN O
abstinence NN NN O
) ) ) O
. . . O

The DT DT O
Multiple NNP NNP O
Sleep NNP NNP O
Latency NNP NNP O
Test NNP NNP O
was VBD VBD O
performed VBN VBN O
at IN IN O
11 CD CD O
: : : O
30 CD CD O
a DT DT O
. . . O
m NN NN O
. . . O
, , , O
2 CD CD O
: : : O
00 CD CD O
p NN NN O
. . . O
m NN NN O
. . . O
, , , O
and CC CC O
4 CD CD O
: : : O
30 CD CD O
p NN NN O
. . . O
m NN NN O
. . . O
on IN IN O
days NNS NNS O
2 CD CD O
, , , O
8 CD CD O
, , , O
and CC CC O
15 CD CD O
. . . O

For IN IN O
comparison NN NN O
of IN IN O
sleep NN NN O
architecture NN NN O
variables NNS NNS O
, , , O
12 CD CD O
healthy JJ JJ O
comparison NN NN O
participants NNS NNS O
underwent VBD VBD O
a DT DT O
single JJ JJ O
night NN NN O
of IN IN O
experimental JJ JJ O
polysomnography NN NN O
that WDT WDT O
followed VBD VBD O
1 CD CD O
night NN NN O
of IN IN O
accommodation NN NN O
polysomnography NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Progressive NNP NNP O
abstinence NN NN O
from IN IN O
cocaine NN NN B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
worsening NN NN O
of IN IN O
all DT DT O
measured VBN VBN O
polysomnographic JJ JJ O
sleep NN NN O
outcomes NNS NNS O
. . . O

Compared VBN VBN O
with IN IN O
placebo NN NN O
, , , O
modafinil NN NN B-CHEM
decreased VBD VBD O
nighttime RB RB O
sleep NN NN O
latency NN NN O
and CC CC O
increased VBN VBN O
slow JJ JJ O
- - - O
wave NN NN O
sleep NN NN O
time NN NN O
in IN IN O
cocaine NN NN B-CHEM
- - - O
dependent JJ JJ O
participants NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
modafinil NN NN B-CHEM
interacted VBN VBN O
with IN IN O
the DT DT O
abstinence NN NN O
week NN NN O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
longer RBR RBR O
total JJ JJ O
sleep NN NN O
time NN NN O
and CC CC O
shorter JJR JJR O
REM NNP NNP O
sleep VB VB O
latency NN NN O
in IN IN O
the DT DT O
third JJ JJ O
week NN NN O
of IN IN O
abstinence NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
slow JJ JJ O
- - - O
wave NN NN O
sleep NN NN O
time NN NN O
, , , O
total JJ JJ O
sleep NN NN O
time NN NN O
, , , O
and CC CC O
sleep VB VB O
latency NN NN O
in IN IN O
cocaine NN NN B-CHEM
- - - O
dependent JJ JJ O
and CC CC O
healthy JJ JJ O
participants NNS NNS O
revealed VBD VBD O
a DT DT O
normalizing VBG VBG O
effect NN NN O
of IN IN O
modafinil NN NN B-CHEM
in IN IN O
cocaine NN NN B-CHEM
- - - O
dependent JJ JJ O
participants NNS NNS O
. . . O

Modafinil NNP NNP B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
increased VBN VBN O
daytime JJ JJ O
sleep NN NN O
latency NN NN O
, , , O
as IN IN O
measured VBN VBN O
by IN IN O
the DT DT O
Multiple NNP NNP O
Sleep NNP NNP O
Latency NNP NNP O
Test NNP NNP O
, , , O
and CC CC O
a DT DT O
nearly RB RB O
significant JJ JJ O
decrease NN NN O
in IN IN O
subjective JJ JJ O
daytime JJ JJ O
sleepiness NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Morning NNP NNP O
- - - O
dosed JJ JJ O
modafinil NN NN B-CHEM
promotes NNS NNS O
nocturnal JJ JJ O
sleep NN NN O
, , , O
normalizes NNS NNS O
sleep VBP VBP O
architecture NN NN O
, , , O
and CC CC O
decreases NNS NNS O
daytime JJ JJ O
sleepiness NNS NNS O
in IN IN O
abstinent NN NN O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

These DT DT O
effects NNS NNS O
may MD MD O
be VB VB O
relevant JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
cocaine NN NN B-CHEM
dependence NN NN O
. . . O

Safety NNP NNP O
of IN IN O
transesophageal NN NN O
echocardiography NN NN O
in IN IN O
adults NNS NNS O
: : : O
study NN NN O
in IN IN O
a DT DT O
multidisciplinary JJ JJ O
hospital NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
TEE NNP NNP O
is VBZ VBZ O
a DT DT O
semi NN NN O
- - - O
invasive JJ JJ O
tool NN NN O
broadly RB RB O
used VBN VBN O
and CC CC O
its PRP$ PRP$ O
utilization NN NN O
associated VBN VBN O
to TO TO O
sedatives NNS NNS O
drugs NNS NNS O
might MD MD O
to TO TO O
affect VB VB O
the DT DT O
procedure NN NN O
safety NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
to TO TO O
analyze VB VB O
aspects NNS NNS O
of IN IN O
TEE NNP NNP O
safety NN NN O
associated VBN VBN O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
Midazolan NNP NNP B-CHEM
( ( ( O
MZ NNP NNP B-CHEM
) ) ) O
and CC CC O
Flumazenil NNP NNP B-CHEM
( ( ( O
FL NNP NNP B-CHEM
) ) ) O
and CC CC O
the DT DT O
influence NN NN O
of IN IN O
the DT DT O
clinical JJ JJ O
variables NNS NNS O
on IN IN O
the DT DT O
event NN NN O
rate NN NN O
. . . O

METHOD NNP NNP O
: : : O
prospective JJ JJ O
study NN NN O
with IN IN O
137 CD CD O
patients NNS NNS O
that IN IN O
underwent JJ JJ O
TEE NNP NNP O
with IN IN O
MZ NNP NNP B-CHEM
associated VBN VBN O
to TO TO O
moderate JJ JJ O
sedation NN NN O
. . . O

We PRP PRP O
analyzed VBD VBD O
the DT DT O
following VBG VBG O
events NNS NNS O
: : : O
complications NNS NNS O
related VBN VBN O
with IN IN O
the DT DT O
topical JJ JJ O
anesthesia NN NN O
, , , O
with IN IN O
MZ NNP NNP B-CHEM
use NN NN O
and CC CC O
with IN IN O
the DT DT O
procedure NN NN O
. . . O

Uni NNP NNP O
- : : O
and CC CC O
multivariate JJ JJ O
analyses NNS NNS O
were VBD VBD O
used VBN VBN O
to TO TO O
test VB VB O
the DT DT O
influence NN NN O
of IN IN O
the DT DT O
clinical JJ JJ O
variables NNS NNS O
: : : O
age NN NN O
, , , O
sex NN NN O
, , , O
stroke NN NN O
, , , O
myocardiopathy NN NN O
( ( ( O
MP NNP NNP O
) ) ) O
, , , O
duration NN NN O
of IN IN O
the DT DT O
test NN NN O
, , , O
mitral JJ JJ O
regurgitation NN NN O
( ( ( O
MR NNP NNP O
) ) ) O
and CC CC O
the DT DT O
MZ NNP NNP B-CHEM
dose NN NN O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
patients NNS NNS O
( ( ( O
65 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
yrs NN NN O
; : : O
58 CD CD O
% NN NN O
males NNS NNS O
) ) ) O
finished VBD VBD O
the DT DT O
examination NN NN O
. . . O

The DT DT O
mean JJ JJ O
doses NNS NNS O
of IN IN O
MZ NNP NNP B-CHEM
and CC CC O
FL NNP NNP B-CHEM
were VBD VBD O
4 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
9 CD CD O
mg NN NN O
and CC CC O
0 CD CD O
. . . O
28 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
, , , O
respectively RB RB O
. . . O

The DT DT O
duration NN NN O
of IN IN O
the DT DT O
examination NN NN O
and CC CC O
the DT DT O
mean JJ JJ O
ejection NN NN O
fraction NN NN O
( ( ( O
EF NNP NNP O
) ) ) O
were VBD VBD O
16 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
1 CD CD O
minutes NNS NNS O
and CC CC O
60 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
% NN NN O
, , , O
respectively RB RB O
. . . O

Mild NNP NNP O
hypoxia NN NN O
( ( ( O
SO2 NNP NNP O
< NN NN O
90 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
event NN NN O
( ( ( O
11 CD CD O
patients NNS NNS O
) ) ) O
; : : O
3 CD CD O
patients NNS NNS O
( ( ( O
2 CD CD O
% NN NN O
) ) ) O
presented JJ JJ O
transient NN NN O
hypoxia NN NN O
due JJ JJ O
to TO TO O
upper JJ JJ O
airway NN NN O
obstruction NN NN O
by IN IN O
probe NN NN O
introduction NN NN O
and CC CC O
8 CD CD O
( ( ( O
5 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
due JJ JJ O
to TO TO O
hypoxia NN NN O
caused VBN VBN O
by IN IN O
MZ NNP NNP B-CHEM
use NN NN O
. . . O

Transient NNP NNP O
hypotension NN NN O
( ( ( O
SAP NNP NNP O
< NN NN O
90mmHg CD CD O
) ) ) O
occurred VBD VBD O
in IN IN O
1 CD CD O
patient NN NN O
( ( ( O
0 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
multivariate NN NN O
analysis NN NN O
showed VBD VBD O
that IN IN O
severe JJ JJ O
MR NNP NNP O
, , , O
MP NNP NNP O
( ( ( O
EF NNP NNP O
< NN NN O
45 CD CD O
% NN NN O
) ) ) O
and CC CC O
high JJ JJ O
doses NNS NNS O
of IN IN O
MZ NNP NNP B-CHEM
( ( ( O
> NN NN O
5mg CD CD O
) ) ) O
were VBD VBD O
associated VBN VBN O
with IN IN O
events NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

The DT DT O
EF NNP NNP O
was VBD VBD O
40 CD CD O
% NN NN O
, , , O
in IN IN O
the DT DT O
group NN NN O
with IN IN O
MP NNP NNP O
and CC CC O
44 CD CD O
% NN NN O
in IN IN O
the DT DT O
group NN NN O
with IN IN O
severe JJ JJ O
MR NNP NNP O
and CC CC O
it PRP PRP O
can MD MD O
be VB VB O
a DT DT O
factor NN NN O
associated VBN VBN O
with IN IN O
clinical JJ JJ O
events NNS NNS O
in IN IN O
the DT DT O
last JJ JJ O
group NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
TEE NNP NNP O
with IN IN O
sedation NN NN O
presents VBZ VBZ O
a DT DT O
low JJ JJ O
rate NN NN O
of IN IN O
events NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
severe JJ JJ O
events NNS NNS O
and CC CC O
there EX EX O
was VBD VBD O
no DT DT O
need NN NN O
to TO TO O
interrupt VB VB O
the DT DT O
examinations NNS NNS O
. . . O

Effect NN NN O
of IN IN O
direct JJ JJ O
intracoronary JJ JJ O
administration NN NN O
of IN IN O
methylergonovine NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
and CC CC O
without IN IN O
variant NN NN O
angina NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
intracoronary JJ JJ O
administration NN NN O
of IN IN O
methylergonovine NN NN B-CHEM
were VBD VBD O
studied VBN VBN O
in IN IN O
21 CD CD O
patients NNS NNS O
with IN IN O
variant NN NN O
angina NN NN O
and CC CC O
22 CD CD O
patients NNS NNS O
with IN IN O
atypical JJ JJ O
chest NN NN O
pain NN NN O
and CC CC O
in IN IN O
others NNS NNS O
without IN IN O
angina NN NN O
pectoris NN NN O
( ( ( O
control NN NN O
group NN NN O
) ) ) O
. . . O

Methylergonovine NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
continuously RB RB O
at IN IN O
a DT DT O
rate NN NN O
of IN IN O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
min NN NN O
up IN IN O
to TO TO O
50 CD CD O
micrograms NNS NNS O
. . . O

In IN IN O
all DT DT O
patients NNS NNS O
with IN IN O
variant NN NN O
angina NN NN O
, , , O
coronary JJ JJ O
spasm NN NN O
was VBD VBD O
provoked VBN VBN O
at IN IN O
a DT DT O
mean NN NN O
dose NN NN O
of IN IN O
28 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
micrograms NNS NNS O
( ( ( O
mean VB VB O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
. . . O

In IN IN O
the DT DT O
control NN NN O
group NN NN O
neither DT DT O
ischemic JJ JJ O
ST NNP NNP O
change NN NN O
nor CC CC O
localized JJ JJ O
spasm NN NN O
occurred VBD VBD O
. . . O

The DT DT O
basal NN NN O
tone NN NN O
of IN IN O
the DT DT O
right NN NN O
coronary JJ JJ O
artery NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
left NN NN O
coronary JJ JJ O
artery NN NN O
. . . O

The DT DT O
percentage NN NN O
of IN IN O
vasoconstriction NN NN O
of IN IN O
the DT DT O
right NN NN O
coronary JJ JJ O
artery NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
left NN NN O
coronary JJ JJ O
artery NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
spasm NN NN O
provocation NN NN O
tests NNS NNS O
, , , O
which WDT WDT O
use VBP VBP O
an DT DT O
intracoronary JJ JJ O
injection NN NN O
of IN IN O
a DT DT O
relatively RB RB O
low JJ JJ O
dose NN NN O
of IN IN O
methylergonovine NN NN B-CHEM
, , , O
have VBP VBP O
a DT DT O
high JJ JJ O
sensitivity NN NN O
in IN IN O
variant NN NN O
angina NN NN O
and CC CC O
the DT DT O
vasoreactivity NN NN O
of IN IN O
the DT DT O
right NN NN O
coronary JJ JJ O
artery NN NN O
may MD MD O
be VB VB O
greater JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
other JJ JJ O
coronary JJ JJ O
arteries NNS NNS O
. . . O

Oral NNP NNP O
manifestations NNS NNS O
of IN IN O
" '' '' O
meth NN NN O
mouth NN NN O
" '' '' O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

AIM NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
the DT DT O
documentation NN NN O
of IN IN O
this DT DT O
clinical JJ JJ O
case NN NN O
is VBZ VBZ O
to TO TO O
make VB VB O
clinicians NNS NNS O
aware JJ JJ O
of IN IN O
" '' '' O
meth NN NN O
mouth NN NN O
" '' '' O
and CC CC O
the DT DT O
medical JJ JJ O
risks NNS NNS O
associated VBN VBN O
with IN IN O
this DT DT O
serious JJ JJ O
condition NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Methamphetamine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
very RB RB O
addictive JJ JJ O
, , , O
powerful JJ JJ O
stimulant NN NN O
that IN IN O
increases NNS NNS O
wakefulness VBP VBP O
and CC CC O
physical JJ JJ O
activity NN NN O
and CC CC O
can MD MD O
produce VB VB O
other JJ JJ O
effects NNS NNS O
such JJ JJ O
as IN IN O
cardiac JJ JJ O
dysrhythmias NN NN O
, , , O
hypertension NN NN O
, , , O
hallucinations NNS NNS O
, , , O
and CC CC O
violent JJ JJ O
behavior NN NN O
. . . O

Dental NNP NNP O
patients NNS NNS O
abusing VBG VBG O
methamphetamine NN NN B-CHEM
can MD MD O
present VB VB O
with IN IN O
poor JJ JJ O
oral JJ JJ O
hygiene NN NN O
, , , O
xerostomia NN NN O
, , , O
rampant JJ JJ O
caries NNS NNS O
( ( ( O
" '' '' O
meth NN NN O
mouth NN NN O
" '' '' O
) ) ) O
, , , O
and CC CC O
excessive JJ JJ O
tooth NN NN O
wear NN NN O
. . . O

Oral NNP NNP O
rehabilitation NN NN O
of IN IN O
patients NNS NNS O
using VBG VBG O
methamphetamine NN NN B-CHEM
can MD MD O
be VB VB O
challenging VBG VBG O
. . . O

CASE NN NN O
DESCRIPTION NNP NNP O
: : : O
A DT DT O
30 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Caucasian NNP NNP O
woman NN NN O
presented VBN VBN O
with IN IN O
dental JJ JJ O
pain NN NN O
, , , O
bad JJ JJ O
breath NN NN O
, , , O
and CC CC O
self NN NN O
- - - O
reported VBN VBN O
poor JJ JJ O
esthetics NNS NNS O
. . . O

A DT DT O
comprehensive JJ JJ O
examination NN NN O
including VBG VBG O
her PRP$ PRP$ O
medical JJ JJ O
history NN NN O
, , , O
panoramic JJ JJ O
radiograph NN NN O
, , , O
and CC CC O
intraoral JJ JJ O
examination NN NN O
revealed VBD VBD O
19 CD CD O
carious JJ JJ O
lesions NNS NNS O
, , , O
which WDT WDT O
is VBZ VBZ O
not RB RB O
very RB RB O
common JJ JJ O
for IN IN O
a DT DT O
healthy JJ JJ O
adult NN NN O
. . . O

She PRP PRP O
reported VBD VBD O
her PRP$ PRP$ O
use NN NN O
of IN IN O
methamphetamine NN NN B-CHEM
for IN IN O
five CD CD O
years NNS NNS O
and CC CC O
had VBD VBD O
not RB RB O
experienced VBN VBN O
any DT DT O
major JJ JJ O
carious JJ JJ O
episodes NNS NNS O
before IN IN O
she PRP PRP O
started VBD VBD O
using VBG VBG O
the DT DT O
drug NN NN O
. . . O

SUMMARY NNP NNP O
: : : O
The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
medical JJ JJ O
and CC CC O
dental JJ JJ O
histories NNS NNS O
along IN IN O
with IN IN O
radiographic JJ JJ O
and CC CC O
clinical JJ JJ O
findings NNS NNS O
lead NN NN O
to TO TO O
a DT DT O
diagnosis NN NN O
of IN IN O
" '' '' O
meth NN NN O
mouth NN NN O
. . . O
" '' '' O
Although IN IN O
three CD CD O
different JJ JJ O
dental NN NN O
treatment NN NN O
modalities NNS NNS O
( ( ( O
either CC CC O
conventional JJ JJ O
or CC CC O
implant JJ JJ O
- - - O
supported VBN VBN O
) ) ) O
have VBP VBP O
been VBN VBN O
offered VBN VBN O
to TO TO O
the DT DT O
patient NN NN O
since IN IN O
August NNP NNP O
2007 CD CD O
, , , O
the DT DT O
patient NN NN O
has VBZ VBZ O
yet RB RB O
to TO TO O
initiate VB VB O
any DT DT O
treatment NN NN O
. . . O

CLINICAL NNP NNP O
SIGNIFICANCE NNP NNP O
: : : O
This DT DT O
clinical JJ JJ O
case NN NN O
showing VBG VBG O
oral JJ JJ O
manifestations NNS NNS O
of IN IN O
meth NN NN O
mouth NN NN O
was VBD VBD O
presented VBN VBN O
to TO TO O
help VB VB O
dental JJ JJ O
practitioners NNS NNS O
recognize VBP VBP O
and CC CC O
manage NN NN O
patients NNS NNS O
who WP WP O
may MD MD O
be VB VB O
abusing VBG VBG O
methamphetamines NNS NNS B-CHEM
. . . O

Dental NNP NNP O
practitioners NNS NNS O
also RB RB O
may MD MD O
be VB VB O
skeptical JJ JJ O
about IN IN O
the DT DT O
reliability NN NN O
of IN IN O
appointment NN NN O
keeping VBG VBG O
by IN IN O
these DT DT O
patients NNS NNS O
, , , O
as IN IN O
they PRP PRP O
frequently RB RB O
miss VBP VBP O
their PRP$ PRP$ O
appointments NNS NNS O
without IN IN O
reasonable JJ JJ O
justification NN NN O
. . . O

Antituberculosis NNP NNP B-CHEM
therapy NN NN O
- : : O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
failure NN NN O
: : : O
magnitude NN NN O
, , , O
profile NN NN O
, , , O
prognosis NN NN O
, , , O
and CC CC O
predictors NNS NNS O
of IN IN O
outcome NN NN O
. . . O

Antituberculosis NNP NNP B-CHEM
therapy NN NN O
( ( ( O
ATT NNP NNP O
) ) ) O
- : : O
associated VBN VBN O
acute JJ JJ O
liver NN NN O
failure NN NN O
( ( ( O
ATT NNP NNP O
- - - O
ALF NNP NNP O
) ) ) O
is VBZ VBZ O
the DT DT O
commonest JJS JJS O
drug NN NN O
- - - O
induced JJ JJ O
ALF NNP NNP O
in IN IN O
South NNP NNP O
Asia NNP NNP O
. . . O

Prospective NNP NNP O
studies NNS NNS O
on IN IN O
ATT NNP NNP O
- : : O
ALF NNP NNP O
are VBP VBP O
lacking VBG VBG O
. . . O

The DT DT O
current JJ JJ O
study NN NN O
prospectively RB RB O
evaluated VBD VBD O
the DT DT O
magnitude NN NN O
, , , O
clinical JJ JJ O
course NN NN O
, , , O
outcome NN NN O
, , , O
and CC CC O
prognostic JJ JJ O
factors NNS NNS O
in IN IN O
ATT NNP NNP O
- - - O
ALF NNP NNP O
. . . O

From IN IN O
January NNP NNP O
1986 CD CD O
to TO TO O
January NNP NNP O
2009 CD CD O
, , , O
1223 CD CD O
consecutive JJ JJ O
ALF NNP NNP O
patients NNS NNS O
were VBD VBD O
evaluated VBN VBN O
: : : O
ATT NNP NNP O
alone RB RB O
was VBD VBD O
the DT DT O
cause NN NN O
in IN IN O
70 CD CD O
( ( ( O
5 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
. . . O

Another DT DT O
15 CD CD O
( ( ( O
1 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
ATT NNP NNP O
and CC CC O
simultaneous JJ JJ O
hepatitis NN NN O
virus NN NN O
infection NN NN O
. . . O

In IN IN O
44 CD CD O
( ( ( O
62 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
, , , O
ATT NNP NNP O
was VBD VBD O
prescribed VBN VBN O
empirically RB RB O
without IN IN O
definitive JJ JJ O
evidence NN NN O
of IN IN O
tuberculosis NNS NNS O
. . . O

ATT NNP NNP O
- : : O
ALF NNP NNP O
patients NNS NNS O
were VBD VBD O
younger JJR JJR O
( ( ( O
32 CD CD O
. . . O
87 CD CD O
[ NN NN O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
. . . O
8 CD CD O
] NN NN O
years NNS NNS O
) ) ) O
, , , O
and CC CC O
49 CD CD O
( ( ( O
70 CD CD O
% NN NN O
) ) ) O
of IN IN O
them PRP PRP O
were VBD VBD O
women NNS NNS O
. . . O

Most JJS JJS O
had VBD VBD O
hyperacute JJ JJ O
presentation NN NN O
; : : O
the DT DT O
median NN NN O
icterus NN NN O
encephalopathy NN NN O
interval NN NN O
was VBD VBD O
4 CD CD O
. . . O
5 CD CD O
( ( ( O
0 CD CD O
- : : O
30 CD CD O
) ) ) O
days NNS NNS O
. . . O

The DT DT O
median JJ JJ O
duration NN NN O
of IN IN O
ATT NNP NNP O
before IN IN O
ALF NNP NNP O
was VBD VBD O
30 CD CD O
( ( ( O
7 CD CD O
- : : O
350 CD CD O
) ) ) O
days NNS NNS O
. . . O

At IN IN O
presentation NN NN O
, , , O
advanced VBD VBD O
encephalopathy JJ JJ O
and CC CC O
cerebral JJ JJ O
edema NN NN O
were VBD VBD O
present JJ JJ O
in IN IN O
51 CD CD O
( ( ( O
76 CD CD O
% NN NN O
) ) ) O
and CC CC O
29 CD CD O
( ( ( O
41 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
, , , O
respectively RB RB O
. . . O

Gastrointestinal NNP NNP O
bleed NN NN O
, , , O
seizures NNS NNS O
, , , O
infection NN NN O
, , , O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
were VBD VBD O
documented VBN VBN O
in IN IN O
seven CD CD O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
, , , O
five CD CD O
( ( ( O
7 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
26 CD CD O
( ( ( O
37 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
seven CD CD O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
, , , O
respectively RB RB O
. . . O

Compared VBN VBN O
with IN IN O
hepatitis NNP NNP O
E NNP NNP O
virus NN NN O
( ( ( O
HEV NNP NNP O
) ) ) O
and CC CC O
non NN NN O
- - - O
A DT DT O
non NN NN O
- - - O
E NNP NNP O
- : : O
induced JJ JJ O
ALF NNP NNP O
, , , O
ATT NNP NNP O
- : : O
ALF NNP NNP O
patients NNS NNS O
had VBD VBD O
nearly RB RB O
similar JJ JJ O
presentations NNS NNS O
except IN IN O
for IN IN O
older JJR JJR O
age NN NN O
and CC CC O
less JJR JJR O
elevation NN NN O
of IN IN O
liver NN NN O
enzymes NNS NNS O
. . . O

The DT DT O
mortality NN NN O
rate NN NN O
among IN IN O
patients NNS NNS O
with IN IN O
ATT NNP NNP O
- : : O
ALF NNP NNP O
was VBD VBD O
high JJ JJ O
( ( ( O
67 CD CD O
. . . O
1 CD CD O
% NN NN O
, , , O
n NN NN O
= SYM SYM O
47 CD CD O
) ) ) O
, , , O
and CC CC O
only RB RB O
23 CD CD O
( ( ( O
32 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
recovered VBN VBN O
with IN IN O
medical JJ JJ O
treatment NN NN O
. . . O

In IN IN O
multivariate NN NN O
analysis NN NN O
, , , O
three CD CD O
factors NNS NNS O
independently RB RB O
predicted VBN VBN O
mortality NN NN O
: : : O
serum NN NN O
bilirubin NN NN B-CHEM
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
10 CD CD O
. . . O
8 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
, , , O
prothrombin NN NN O
time NN NN O
( ( ( O
PT NNP NNP O
) ) ) O
prolongation NN NN O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
26 CD CD O
seconds NNS NNS O
) ) ) O
, , , O
and CC CC O
grade NN NN O
III NNP NNP O
/ NN NN O
IV NNP NNP O
encephalopathy NN NN O
at IN IN O
presentation NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
ATT NNP NNP O
- - - O
ALF NNP NNP O
constituted VBD VBD O
5 CD CD O
. . . O
7 CD CD O
% NN NN O
of IN IN O
ALF NNP NNP O
at IN IN O
our PRP$ PRP$ O
center NN NN O
and CC CC O
had VBD VBD O
a DT DT O
high JJ JJ O
mortality NN NN O
rate NN NN O
. . . O

Because IN IN O
the DT DT O
mortality NN NN O
rate NN NN O
is VBZ VBZ O
so RB RB O
high JJ JJ O
, , , O
determining VBG VBG O
which WDT WDT O
factors NNS NNS O
are VBP VBP O
predictors NNS NNS O
is VBZ VBZ O
less RBR RBR O
important JJ JJ O
. . . O

A DT DT O
high JJ JJ O
proportion NN NN O
of IN IN O
patients NNS NNS O
had VBD VBD O
consumed VBN VBN O
ATT NNP NNP O
empirically RB RB O
, , , O
which WDT WDT O
could MD MD O
have VB VB O
been VBN VBN O
prevented VBN VBN O
. . . O

Design NNP NNP O
and CC CC O
analysis NN NN O
of IN IN O
the DT DT O
HYPREN NNP NNP O
- : : O
trial NN NN O
: : : O
safety NN NN O
of IN IN O
enalapril NN NN B-CHEM
and CC CC O
prazosin NN NN B-CHEM
in IN IN O
the DT DT O
initial JJ JJ O
treatment NN NN O
phase NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
. . . O

Since IN IN O
the DT DT O
introduction NN NN O
of IN IN O
angiotensin NN NN B-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
( ( ( I-CHEM
ACE NNP NNP I-CHEM
) ) ) I-CHEM
inhibitors NNS NNS I-CHEM
into IN IN O
the DT DT O
adjunctive JJ JJ O
treatment NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
, , , O
cases NNS NNS O
of IN IN O
severe JJ JJ O
hypotension NN NN O
, , , O
especially RB RB O
on IN IN O
the DT DT O
first JJ JJ O
day NN NN O
of IN IN O
treatment NN NN O
, , , O
have VBP VBP O
occasionally RB RB O
been VBN VBN O
reported VBN VBN O
. . . O

To TO TO O
assess VB VB O
the DT DT O
safety NN NN O
of IN IN O
the DT DT O
ACE NNP NNP B-CHEM
inhibitor NN NN I-CHEM
enalapril NN NN B-CHEM
a DT DT O
multicenter NN NN O
, , , O
randomized JJ JJ O
, , , O
prazosin NN NN B-CHEM
- - - O
controlled JJ JJ O
trial NN NN O
was VBD VBD O
designed VBN VBN O
that IN IN O
compared VBD VBD O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
symptomatic JJ JJ O
hypotension NN NN O
on IN IN O
the DT DT O
first JJ JJ O
day NN NN O
of IN IN O
treatment NN NN O
. . . O

Trial NN NN O
medication NN NN O
was VBD VBD O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
enalapril NN NN B-CHEM
or CC CC O
0 CD CD O
. . . O
5 CD CD O
prazosin NN NN B-CHEM
. . . O

Subjects NNP NNP O
were VBD VBD O
1210 CD CD O
inpatients NNS NNS O
with IN IN O
New NNP NNP O
York NNP NNP O
Heart NNP NNP O
Association NNP NNP O
( ( ( O
NYHA NNP NNP O
) ) ) O
functional JJ JJ O
class NN NN O
II NNP NNP O
and CC CC O
III NNP NNP O
. . . O

Patients NNS NNS O
who WP WP O
received VBD VBD O
enalapril NN NN B-CHEM
experienced VBN VBN O
clinically RB RB O
and CC CC O
statistically RB RB O
significantly RB RB O
less RBR RBR O
symptomatic JJ JJ O
hypotension NN NN O
( ( ( O
5 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
than IN IN O
the DT DT O
patients NNS NNS O
who WP WP O
received VBD VBD O
prazosin NN NN B-CHEM
( ( ( O
12 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
. . . O

All DT DT O
patients NNS NNS O
recovered VBN VBN O
. . . O

It PRP PRP O
was VBD VBD O
concluded VBN VBN O
that IN IN O
treatment NN NN O
with IN IN O
enalapril NN NN B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
and CC CC O
it PRP PRP O
is VBZ VBZ O
, , , O
therefore RB RB O
, , , O
unreasonable JJ JJ O
to TO TO O
restrict VB VB O
the DT DT O
initiation NN NN O
of IN IN O
treatment NN NN O
with IN IN O
enalapril NN NN B-CHEM
to TO TO O
inpatients NNS NNS O
. . . O

Central NNP NNP O
nervous JJ JJ O
system NN NN O
complications NNS NNS O
during IN IN O
treatment NN NN O
of IN IN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
in IN IN O
a DT DT O
single JJ JJ O
pediatric JJ JJ O
institution NN NN O
. . . O

Central NNP NNP O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
complications NNS NNS O
during IN IN O
treatment NN NN O
of IN IN O
childhood NN NN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
( ( ( O
ALL NNP NNP O
) ) ) O
remain VB VB O
a DT DT O
challenging VBG VBG O
clinical JJ JJ O
problem NN NN O
. . . O

Outcome NNP NNP O
improvement NN NN O
with IN IN O
more RBR RBR O
intensive JJ JJ O
chemotherapy NN NN O
has VBZ VBZ O
significantly RB RB O
increased VBN VBN O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
. . . O

This DT DT O
study NN NN O
analyzed VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
neurological JJ JJ O
complications NNS NNS O
during IN IN O
ALL NNP NNP O
treatment NN NN O
in IN IN O
a DT DT O
single JJ JJ O
pediatric JJ JJ O
institution NN NN O
, , , O
focusing VBG VBG O
on IN IN O
clinical JJ JJ O
, , , O
radiological JJ JJ O
, , , O
and CC CC O
electrophysiological JJ JJ O
findings NNS NNS O
. . . O

Exclusion NNP NNP O
criteria NNS NNS O
included VBD VBD O
CNS NNP NNP O
leukemic JJ JJ O
infiltration NN NN O
at IN IN O
diagnosis NN NN O
, , , O
therapy NN NN O
- - - O
related VBN VBN O
peripheral JJ JJ O
neuropathy NN NN O
, , , O
late JJ JJ O
- - - O
onset NN NN O
encephalopathy NN NN O
, , , O
or CC CC O
long JJ JJ O
- - - O
term NN NN O
neurocognitive JJ JJ O
defects NNS NNS O
. . . O

During IN IN O
a DT DT O
9 CD CD O
- : : O
year NN NN O
period NN NN O
, , , O
we PRP PRP O
retrospectively RB RB O
collected VBD VBD O
27 CD CD O
neurological JJ JJ O
events NNS NNS O
( ( ( O
11 CD CD O
% NN NN O
) ) ) O
in IN IN O
as IN IN O
many JJ JJ O
patients NNS NNS O
, , , O
from IN IN O
253 CD CD O
children NNS NNS O
enrolled VBN VBN O
in IN IN O
the DT DT O
ALL NNP NNP O
front JJ JJ O
- - - O
line NN NN O
protocol NN NN O
. . . O

CNS NNP NNP O
complications NNS NNS O
included VBD VBD O
posterior NN NN O
reversible JJ JJ O
leukoencephalopathy NN NN O
syndrome NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
, , , O
stroke NN NN O
( ( ( O
n NN NN O
= SYM SYM O
5 CD CD O
) ) ) O
, , , O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
, , , O
high JJ JJ O
- - - O
dose NN NN O
methotrexate NN NN B-CHEM
toxicity NN NN O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
, , , O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
antidiuretic JJ JJ O
hormone NN NN O
secretion NN NN O
( ( ( O
n NN NN O
= SYM SYM O
1 CD CD O
) ) ) O
, , , O
and CC CC O
other JJ JJ O
unclassified JJ JJ O
events NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
. . . O

In IN IN O
conclusion NN NN O
, , , O
CNS NNP NNP O
complications NNS NNS O
are VBP VBP O
frequent JJ JJ O
events NNS NNS O
during IN IN O
ALL NNP NNP O
therapy NN NN O
, , , O
and CC CC O
require VB VB O
rapid JJ JJ O
detection NN NN O
and CC CC O
prompt VB VB O
treatment NN NN O
to TO TO O
limit VB VB O
permanent JJ JJ O
damage NN NN O
. . . O

Cocaine NNP NNP B-CHEM
causes NNS NNS O
memory NN NN O
and CC CC O
learning VBG VBG O
impairments NNS NNS O
in IN IN O
rats NNS NNS O
: : : O
involvement NN NN O
of IN IN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NNP NNP O
and CC CC O
oxidative JJ JJ O
stress NN NN O
, , , O
and CC CC O
prevention NN NN O
by IN IN O
topiramate NN NN B-CHEM
. . . O

Different JJ JJ O
mechanisms NNS NNS O
have VBP VBP O
been VBN VBN O
suggested VBN VBN O
for IN IN O
cocaine NN NN B-CHEM
toxicity NN NN O
including VBG VBG O
an DT DT O
increase NN NN O
in IN IN O
oxidative JJ JJ O
stress NN NN O
but CC CC O
the DT DT O
association NN NN O
between IN IN O
oxidative JJ JJ O
status NN NN O
in IN IN O
the DT DT O
brain NN NN O
and CC CC O
cocaine NN NN B-CHEM
induced JJ JJ O
- : : O
behaviour NN NN O
is VBZ VBZ O
poorly RB RB O
understood VBN VBN O
. . . O

Nuclear NNP NNP O
factor NN NN O
kappa NN NN O
B NNP NNP O
( ( ( O
NFkappaB NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
sensor NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
participates NNS NNS O
in IN IN O
memory NN NN O
formation NN NN O
that WDT WDT O
could MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
drug NN NN O
toxicity NN NN O
and CC CC O
addiction NN NN O
mechanisms NNS NNS O
. . . O

Therefore RB RB O
NFkappaB NNP NNP O
activity NN NN O
, , , O
oxidative JJ JJ O
stress NN NN O
, , , O
neuronal JJ JJ O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
( ( ( O
nNOS NN NN O
) ) ) O
activity NN NN O
, , , O
spatial JJ JJ O
learning NN NN O
and CC CC O
memory NN NN O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
effect NN NN O
of IN IN O
topiramate NN NN B-CHEM
, , , O
a DT DT O
previously RB RB O
proposed VBN VBN O
therapy NN NN O
for IN IN O
cocaine NN NN O
addiction NN NN O
, , , O
were VBD VBD O
evaluated VBN VBN O
in IN IN O
an DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
cocaine NN NN B-CHEM
administration NN NN O
in IN IN O
rats NNS NNS O
. . . O

NFkappaB NNP NNP O
activity NN NN O
was VBD VBD O
decreased VBN VBN O
in IN IN O
the DT DT O
frontal JJ JJ O
cortex NN NN O
of IN IN O
cocaine NN NN B-CHEM
treated VBN VBN O
rats NNS NNS O
, , , O
as RB RB O
well RB RB O
as IN IN O
GSH NNP NNP B-CHEM
concentration NN NN O
and CC CC O
glutathione NN NN B-CHEM
peroxidase NN NN O
activity NN NN O
in IN IN O
the DT DT O
hippocampus NN NN O
, , , O
whereas IN IN O
nNOS NN NN O
activity NN NN O
in IN IN O
the DT DT O
hippocampus NN NN O
was VBD VBD O
increased VBN VBN O
. . . O

Memory NN NN O
retrieval NN NN O
of IN IN O
experiences NNS NNS O
acquired VBN VBN O
prior RB RB O
to TO TO O
cocaine VB VB B-CHEM
administration NN NN O
was VBD VBD O
impaired VBN VBN O
and CC CC O
negatively RB RB O
correlated JJ JJ O
with IN IN O
NFkappaB NNP NNP O
activity NN NN O
in IN IN O
the DT DT O
frontal JJ JJ O
cortex NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
learning VBG VBG O
of IN IN O
new JJ JJ O
tasks NNS NNS O
was VBD VBD O
enhanced VBN VBN O
and CC CC O
correlated JJ JJ O
with IN IN O
the DT DT O
increase NN NN O
of IN IN O
nNOS NN NN O
activity NN NN O
and CC CC O
the DT DT O
decrease NN NN O
of IN IN O
glutathione NN NN B-CHEM
peroxidase NN NN O
. . . O

These DT DT O
results NNS NNS O
provide VBP VBP O
evidence NN NN O
for IN IN O
a DT DT O
possible JJ JJ O
mechanistic JJ JJ O
role NN NN O
of IN IN O
oxidative JJ JJ O
and CC CC O
nitrosative JJ JJ O
stress NN NN O
and CC CC O
NFkappaB NNP NNP O
in IN IN O
the DT DT O
alterations NNS NNS O
induced VBN VBN O
by IN IN O
cocaine NN NN B-CHEM
. . . O

Topiramate NNP NNP B-CHEM
prevented VBD VBD O
all PDT PDT O
the DT DT O
alterations NNS NNS O
observed VBD VBD O
, , , O
showing VBG VBG O
novel NN NN O
neuroprotective JJ JJ O
properties NNS NNS O
. . . O

Efficacy NNP NNP O
and CC CC O
safety NN NN O
of IN IN O
asenapine NN NN B-CHEM
in IN IN O
a DT DT O
placebo NN NN O
- - - O
and CC CC O
haloperidol NN NN B-CHEM
- - - O
controlled VBN VBN O
trial NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
exacerbation NN NN O
of IN IN O
schizophrenia NN NN O
. . . O

Asenapine NNP NNP B-CHEM
is VBZ VBZ O
approved VBN VBN O
by IN IN O
the DT DT O
Food NNP NNP O
and CC CC O
Drugs NNS NNS O
Administration NNP NNP O
in IN IN O
adults NNS NNS O
for IN IN O
acute JJ JJ O
treatment NN NN O
of IN IN O
schizophrenia NN NN O
or CC CC O
of IN IN O
manic JJ JJ O
or CC CC O
mixed JJ JJ O
episodes NNS NNS O
associated VBN VBN O
with IN IN O
bipolar NN NN O
I PRP PRP O
disorder VBP VBP O
with IN IN O
or CC CC O
without IN IN O
psychotic JJ JJ O
features NNS NNS O
. . . O

In IN IN O
a DT DT O
double JJ JJ O
- : : O
blind JJ JJ O
6 CD CD O
- : : O
week NN NN O
trial NN NN O
, , , O
458 CD CD O
patients NNS NNS O
with IN IN O
acute JJ JJ O
schizophrenia NN NN O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
fixed VB VB O
- - - O
dose NN NN O
treatment NN NN O
with IN IN O
asenapine NN NN B-CHEM
at IN IN O
5 CD CD O
mg NN NN O
twice RB RB O
daily JJ JJ O
( ( ( O
BID NNP NNP O
) ) ) O
, , , O
asenapine NN NN B-CHEM
at IN IN O
10 CD CD O
mg NN NN O
BID NNP NNP O
, , , O
placebo NN NN O
, , , O
or CC CC O
haloperidol NN NN B-CHEM
at IN IN O
4 CD CD O
mg NN NN O
BID NNP NNP O
( ( ( O
to TO TO O
verify VB VB O
assay NN NN O
sensitivity NN NN O
) ) ) O
. . . O

With IN IN O
last JJ JJ O
observations NNS NNS O
carried VBD VBD O
forward RB RB O
( ( ( O
LOCF NNP NNP O
) ) ) O
, , , O
mean VB VB O
Positive NNP NNP O
and CC CC O
Negative NNP NNP O
Syndrome NN NN O
Scale NNP NNP O
total JJ JJ O
score NN NN O
reductions NNS NNS O
from IN IN O
baseline NN NN O
to TO TO O
endpoint VB VB O
were VBD VBD O
significantly RB RB O
greater JJR JJR O
with IN IN O
asenapine NN NN B-CHEM
at IN IN O
5 CD CD O
mg NN NN O
BID NNP NNP O
( ( ( O
- : : O
16 CD CD O
. . . O
2 CD CD O
) ) ) O
and CC CC O
haloperidol NN NN B-CHEM
( ( ( O
- : : O
15 CD CD O
. . . O
4 CD CD O
) ) ) O
than IN IN O
placebo NN NN O
( ( ( O
- : : O
10 CD CD O
. . . O
7 CD CD O
; : : O
both DT DT O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
; : : O
using VBG VBG O
mixed JJ JJ O
model NN NN O
for IN IN O
repeated VBN VBN O
measures NNS NNS O
( ( ( O
MMRM NNP NNP O
) ) ) O
, , , O
changes NNS NNS O
at IN IN O
day NN NN O
42 CD CD O
were VBD VBD O
significantly RB RB O
greater JJR JJR O
with IN IN O
asenapine NN NN B-CHEM
at IN IN O
5 CD CD O
and CC CC O
10 CD CD O
mg NN NN O
BID NNP NNP O
( ( ( O
- : : O
21 CD CD O
. . . O
3 CD CD O
and CC CC O
- : : O
19 CD CD O
. . . O
4 CD CD O
, , , O
respectively RB RB O
) ) ) O
and CC CC O
haloperidol NN NN B-CHEM
( ( ( O
- : : O
20 CD CD O
. . . O
0 CD CD O
) ) ) O
than IN IN O
placebo NN NN O
( ( ( O
- : : O
14 CD CD O
. . . O
6 CD CD O
; : : O
all DT DT O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

On IN IN O
the DT DT O
Positive NNP NNP O
and CC CC O
Negative NNP NNP O
Syndrome NN NN O
Scale NNP NNP O
positive JJ JJ O
subscale NN NN O
, , , O
all DT DT O
treatments NNS NNS O
were VBD VBD O
superior JJ JJ O
to TO TO O
placebo NN NN O
with IN IN O
LOCF NNP NNP O
and CC CC O
MMRM NNP NNP O
; : : O
asenapine NN NN B-CHEM
at IN IN O
5 CD CD O
mg NN NN O
BID NNP NNP O
was VBD VBD O
superior JJ JJ O
to TO TO O
placebo NN NN O
on IN IN O
the DT DT O
negative JJ JJ O
subscale NN NN O
with IN IN O
MMRM NNP NNP O
and CC CC O
on IN IN O
the DT DT O
general JJ JJ O
psychopathology NN NN O
subscale NN NN O
with IN IN O
LOCF NNP NNP O
and CC CC O
MMRM NNP NNP O
. . . O

Treatment NN NN O
- - - O
related VBN VBN O
adverse JJ JJ O
events NNS NNS O
( ( ( O
AEs NNP NNP O
) ) ) O
occurred VBD VBD O
in IN IN O
44 CD CD O
% NN NN O
and CC CC O
52 CD CD O
% NN NN O
, , , O
57 CD CD O
% NN NN O
, , , O
and CC CC O
41 CD CD O
% NN NN O
of IN IN O
the DT DT O
asenapine NN NN B-CHEM
at IN IN O
5 CD CD O
and CC CC O
10 CD CD O
mg NN NN O
BID NNP NNP O
, , , O
haloperidol NN NN B-CHEM
, , , O
and CC CC O
placebo NN NN O
groups NNS NNS O
, , , O
respectively RB RB O
. . . O

Extrapyramidal NNP NNP O
symptoms NNS NNS O
reported VBD VBD O
as IN IN O
AEs NNP NNP O
occurred VBD VBD O
in IN IN O
15 CD CD O
% NN NN O
and CC CC O
18 CD CD O
% NN NN O
, , , O
34 CD CD O
% NN NN O
, , , O
and CC CC O
10 CD CD O
% NN NN O
of IN IN O
the DT DT O
asenapine NN NN B-CHEM
at IN IN O
5 CD CD O
and CC CC O
10 CD CD O
mg NN NN O
BID NNP NNP O
, , , O
haloperidol NN NN B-CHEM
, , , O
and CC CC O
placebo NN NN O
groups NNS NNS O
, , , O
respectively RB RB O
. . . O

Across IN IN O
all DT DT O
groups NNS NNS O
, , , O
no DT DT O
more JJR JJR O
than IN IN O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
had VBD VBD O
clinically RB RB O
significant JJ JJ O
weight NN NN O
change NN NN O
. . . O

Post NNP NNP O
hoc NN NN O
analyses NNS NNS O
indicated VBN VBN O
that IN IN O
efficacy NN NN O
was VBD VBD O
similar JJ JJ O
with IN IN O
asenapine NN NN B-CHEM
and CC CC O
haloperidol NN NN B-CHEM
; : : O
greater JJR JJR O
contrasts NNS NNS O
were VBD VBD O
seen VBN VBN O
in IN IN O
AEs NNP NNP O
, , , O
especially RB RB O
extrapyramidal JJ JJ O
symptoms NNS NNS O
. . . O

Salvage NNP NNP O
therapy NN NN O
with IN IN O
nelarabine NN NN B-CHEM
, , , O
etoposide NN NN B-CHEM
, , , O
and CC CC O
cyclophosphamide NN NN B-CHEM
in IN IN O
relapsed JJ JJ O
/ NN NN O
refractory NN NN O
paediatric JJ JJ O
T NN NN O
- - - O
cell NN NN O
lymphoblastic JJ JJ O
leukaemia NN NN O
and CC CC O
lymphoma NN NN O
. . . O

A DT DT O
combination NN NN O
of IN IN O
5 CD CD O
d SYM SYM O
of IN IN O
nelarabine NN NN B-CHEM
( ( ( O
AraG NNP NNP B-CHEM
) ) ) O
with IN IN O
5 CD CD O
d SYM SYM O
of IN IN O
etoposide NN NN B-CHEM
( ( ( O
VP NNP NNP B-CHEM
) ) ) O
and CC CC O
cyclophosphamide NN NN B-CHEM
( ( ( O
CPM NNP NNP B-CHEM
) ) ) O
and CC CC O
prophylactic JJ JJ O
intrathecal JJ JJ O
chemotherapy NN NN O
was VBD VBD O
used VBN VBN O
as IN IN O
salvage NN NN O
therapy NN NN O
in IN IN O
seven CD CD O
children NNS NNS O
with IN IN O
refractory NN NN O
or CC CC O
relapsed VBN VBN O
T NN NN O
- - - O
cell NN NN O
leukaemia NN NN O
or CC CC O
lymphoma NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
side NN NN O
effects NNS NNS O
attributable JJ JJ O
to TO TO O
the DT DT O
AraG NNP NNP B-CHEM
included VBD VBD O
Grade NNP NNP O
2 CD CD O
and CC CC O
3 CD CD O
sensory JJ JJ O
and CC CC O
motor NN NN O
neuropathy NN NN O
and CC CC O
musculoskeletal JJ JJ O
pain NN NN O
. . . O

Haematological NNP NNP O
toxicity NN NN O
was VBD VBD O
greater JJR JJR O
for IN IN O
the DT DT O
combination NN NN O
than IN IN O
AraG NNP NNP B-CHEM
alone RB RB O
, , , O
although IN IN O
median JJ JJ O
time NN NN O
to TO TO O
neutrophil VB VB O
and CC CC O
platelet VB VB O
recovery NN NN O
was VBD VBD O
consistent JJ JJ O
with IN IN O
other JJ JJ O
salvage NN NN O
therapies NNS NNS O
. . . O

All DT DT O
patients NNS NNS O
had VBD VBD O
some DT DT O
response NN NN O
to TO TO O
the DT DT O
combined VBN VBN O
therapy NN NN O
and CC CC O
five CD CD O
of IN IN O
the DT DT O
seven CD CD O
went VBD VBD O
into IN IN O
complete JJ JJ O
remission NN NN O
after IN IN O
one CD CD O
or CC CC O
two CD CD O
courses NNS NNS O
of IN IN O
AraG NNP NNP B-CHEM
/ NN NN O
VP NNP NNP B-CHEM
/ NN NN O
CPM NNP NNP B-CHEM
. . . O

Our PRP$ PRP$ O
experience NN NN O
supports VBZ VBZ O
the DT DT O
safety NN NN O
of IN IN O
giving VBG VBG O
AraG NNP NNP B-CHEM
as IN IN O
salvage NN NN O
therapy NN NN O
in IN IN O
synchrony NN NN O
with IN IN O
etoposide NN NN B-CHEM
and CC CC O
cyclophosphamide NN NN B-CHEM
, , , O
although IN IN O
neurological JJ JJ O
toxicity NN NN O
must MD MD O
be VB VB O
closely RB RB O
monitored VBN VBN O
. . . O

Effect NN NN O
of IN IN O
adriamycin NN NN B-CHEM
combined VBN VBN O
with IN IN O
whole JJ JJ O
body NN NN O
hyperthermia NN NN O
on IN IN O
tumor NN NN O
and CC CC O
normal JJ JJ O
tissues NNS NNS O
. . . O

Thermal NNP NNP O
enhancement NN NN O
of IN IN O
Adriamycin NNP NNP B-CHEM
- - - O
mediated JJ JJ O
antitumor NN NN O
activity NN NN O
and CC CC O
normal JJ JJ O
tissue NN NN O
toxicities NNS NNS O
by IN IN O
whole JJ JJ O
body NN NN O
hyperthermia NN NN O
were VBD VBD O
compared VBN VBN O
using VBG VBG O
a DT DT O
F344 NNP NNP O
rat NN NN O
model NN NN O
. . . O

Antitumor NNP NNP O
activity NN NN O
was VBD VBD O
studied VBN VBN O
using VBG VBG O
a DT DT O
tumor NN NN O
growth NN NN O
delay NN NN O
assay NN NN O
. . . O

Acute JJ JJ O
normal JJ JJ O
tissue NN NN O
toxicities NNS NNS O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
leukopenia NN NN O
and CC CC O
thrombocytopenia NN NN O
) ) ) O
and CC CC O
late JJ JJ O
normal JJ JJ O
tissue NN NN O
toxicities NNS NNS O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
myocardial NN NN O
and CC CC O
kidney NN NN O
injury NN NN O
) ) ) O
were VBD VBD O
evaluated VBN VBN O
by IN IN O
functional JJ JJ O
/ NN NN O
physiological JJ JJ O
assays NNS NNS O
and CC CC O
by IN IN O
morphological JJ JJ O
techniques NNS NNS O
. . . O

Whole JJ JJ O
body NN NN O
hyperthermia NN NN O
( ( ( O
120 CD CD O
min NN NN O
at IN IN O
41 CD CD O
. . . O
5 CD CD O
degrees NNS NNS O
C NNP NNP O
) ) ) O
enhanced VBD VBD O
both DT DT O
Adriamycin NNP NNP B-CHEM
- - - O
mediated JJ JJ O
antitumor NN NN O
activity NN NN O
and CC CC O
toxic JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

The DT DT O
thermal NN NN O
enhancement NN NN O
ratio NN NN O
calculated VBN VBN O
for IN IN O
antitumor NN NN O
activity NN NN O
was VBD VBD O
1 CD CD O
. . . O
6 CD CD O
. . . O

Thermal NNP NNP O
enhancement NN NN O
ratios NNS NNS O
estimated VBN VBN O
for IN IN O
" '' '' O
acute JJ JJ O
" '' '' O
hematological JJ JJ O
changes NNS NNS O
were VBD VBD O
1 CD CD O
. . . O
3 CD CD O
, , , O
whereas IN IN O
those DT DT O
estimated VBN VBN O
for IN IN O
" '' '' O
late JJ JJ O
" '' '' O
damage NN NN O
( ( ( O
based VBN VBN O
on IN IN O
morphological JJ JJ O
cardiac NN NN O
and CC CC O
renal JJ JJ O
lesions NNS NNS O
) ) ) O
varied VBN VBN O
between IN IN O
2 CD CD O
. . . O
4 CD CD O
and CC CC O
4 CD CD O
. . . O
3 CD CD O
. . . O

Thus RB RB O
, , , O
while IN IN O
whole JJ JJ O
body NN NN O
hyperthermia NN NN O
enhances NNS NNS O
Adriamycin NNP NNP B-CHEM
- : : O
mediated JJ JJ O
antitumor NN NN O
effect NN NN O
, , , O
normal JJ JJ O
tissue NN NN O
toxicity NN NN O
is VBZ VBZ O
also RB RB O
increased VBN VBN O
, , , O
and CC CC O
the DT DT O
potential JJ JJ O
therapeutic JJ JJ O
gain NN NN O
of IN IN O
the DT DT O
combined VBN VBN O
modality NN NN O
treatment NN NN O
is VBZ VBZ O
eroded VBN VBN O
. . . O

Permeability NNP NNP O
, , , O
ultrastructural JJ JJ O
changes NNS NNS O
, , , O
and CC CC O
distribution NN NN O
of IN IN O
novel NN NN O
proteins NNS NNS O
in IN IN O
the DT DT O
glomerular NN NN O
barrier NN NN O
in IN IN O
early JJ JJ O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
nephrosis NN NN O
. . . O

BACKGROUND NNP NNP O
/ NN NN O
AIMS NNP NNP O
: : : O
It PRP PRP O
is VBZ VBZ O
still RB RB O
unclear JJ JJ O
what WP WP O
happens VBZ VBZ O
in IN IN O
the DT DT O
glomerulus NN NN O
when WRB WRB O
proteinuria NN NN O
starts VBZ VBZ O
. . . O

Using VBG VBG O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
nephrosis NN NN O
( ( ( O
PAN NNP NNP O
) ) ) O
rats NNS NNS O
, , , O
we PRP PRP O
studied VBD VBD O
early JJ JJ O
ultrastructural JJ JJ O
and CC CC O
permeability NN NN O
changes NNS NNS O
in IN IN O
relation NN NN O
to TO TO O
the DT DT O
expression NN NN O
of IN IN O
the DT DT O
podocyte NN NN O
- - - O
associated VBN VBN O
molecules NNS NNS O
nephrin NN NN O
, , , O
a DT DT O
- - - O
actinin NN NN O
, , , O
dendrin NN NN O
, , , O
and CC CC O
plekhh2 NN NN O
, , , O
the DT DT O
last JJ JJ O
two CD CD O
of IN IN O
which WDT WDT O
were VBD VBD O
only RB RB O
recently RB RB O
discovered VBN VBN O
in IN IN O
podocytes NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Using VBG VBG O
immune JJ JJ O
stainings NNS NNS O
, , , O
semiquantitative JJ JJ O
measurement NN NN O
was VBD VBD O
performed VBN VBN O
under IN IN O
the DT DT O
electron NN NN O
microscope NN NN O
. . . O

Permeability NNP NNP O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
isolated VBN VBN O
kidney NN NN O
perfusion NN NN O
with IN IN O
tracers NNS NNS O
. . . O

Possible JJ JJ O
effects NNS NNS O
of IN IN O
ACE NNP NNP O
inhibition NN NN O
were VBD VBD O
tested VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
By IN IN O
day NN NN O
2 CD CD O
, , , O
some DT DT O
patchy NN NN O
foot NN NN O
process NN NN O
effacement NN NN O
, , , O
but CC CC O
no DT DT O
proteinuria NN NN O
, , , O
appeared VBD VBD O
. . . O

The DT DT O
amount NN NN O
of IN IN O
nephrin NN NN O
was VBD VBD O
reduced VBN VBN O
in IN IN O
both DT DT O
diseased VBN VBN O
and CC CC O
normal JJ JJ O
areas NNS NNS O
. . . O

The DT DT O
other JJ JJ O
proteins NNS NNS O
showed VBD VBD O
few JJ JJ O
changes NNS NNS O
, , , O
which WDT WDT O
were VBD VBD O
limited VBN VBN O
to TO TO O
diseased JJ JJ O
areas NNS NNS O
. . . O

By IN IN O
day NN NN O
4 CD CD O
, , , O
foot NN NN O
process NN NN O
effacement NN NN O
was VBD VBD O
complete JJ JJ O
and CC CC O
proteinuria NN NN O
appeared VBD VBD O
in IN IN O
parallel JJ JJ O
with IN IN O
signs NNS NNS O
of IN IN O
size NN NN O
barrier NN NN O
damage NN NN O
. . . O

Nephrin NNP NNP O
decreased VBD VBD O
further RB RB O
, , , O
while IN IN O
dendrin NN NN O
and CC CC O
plekhh2 NN NN O
also RB RB O
decreased VBD VBD O
but CC CC O
a DT DT O
- - - O
actinin NN NN O
remained VBD VBD O
unchanged JJ JJ O
. . . O

ACE NNP NNP O
inhibition NN NN O
had VBD VBD O
no DT DT O
significant JJ JJ O
protective JJ JJ O
effect NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
PAN NNP NNP O
glomeruli NN NN O
already RB RB O
showed VBD VBD O
significant JJ JJ O
pathology NN NN O
by IN IN O
day NN NN O
4 CD CD O
, , , O
despite IN IN O
relatively RB RB O
mild JJ JJ O
proteinuria NN NN O
. . . O

This DT DT O
was VBD VBD O
preceded VBN VBN O
by IN IN O
altered VBN VBN O
nephrin NN NN O
expression NN NN O
, , , O
supporting VBG VBG O
its PRP$ PRP$ O
pivotal JJ JJ O
role NN NN O
in IN IN O
podocyte NN NN O
morphology NN NN O
. . . O

The DT DT O
novel NN NN O
proteins NNS NNS O
dendrin NN NN O
and CC CC O
plekhh2 NN NN O
were VBD VBD O
both DT DT O
reduced VBN VBN O
, , , O
suggesting VBG VBG O
roles NNS NNS O
in IN IN O
PAN NNP NNP O
, , , O
whereas IN IN O
a DT DT O
- - - O
actinin NN NN O
was VBD VBD O
unchanged JJ JJ O
. . . O

A DT DT O
novel NN NN O
, , , O
multiple JJ JJ O
symptom NN NN O
model NN NN O
of IN IN O
obsessive JJ JJ O
- - - O
compulsive JJ JJ O
- - - O
like IN IN O
behaviors NNS NNS O
in IN IN O
animals NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Current JJ JJ O
animal NN NN O
models NNS NNS O
of IN IN O
obsessive JJ JJ O
- - - O
compulsive JJ JJ O
disorder NN NN O
( ( ( O
OCD NNP NNP O
) ) ) O
typically RB RB O
involve JJ JJ O
acute JJ JJ O
, , , O
drug NN NN O
- - - O
induced JJ JJ O
symptom NN NN O
provocation NN NN O
or CC CC O
a DT DT O
genetic JJ JJ O
association NN NN O
with IN IN O
stereotypies NNS NNS O
or CC CC O
anxiety NN NN O
. . . O

None NN NN O
of IN IN O
these DT DT O
current JJ JJ O
models NNS NNS O
demonstrate VBP VBP O
multiple JJ JJ O
OCD NNP NNP O
- - - O
like IN IN O
behaviors NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Neonatal NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
the DT DT O
tricyclic JJ JJ O
antidepressant NN NN B-CHEM
clomipramine NN NN B-CHEM
or CC CC O
vehicle NN NN O
between IN IN O
days NNS NNS O
9 CD CD O
and CC CC O
16 CD CD O
twice RB RB O
daily JJ JJ O
and CC CC O
behaviorally RB RB O
tested VBN VBN O
in IN IN O
adulthood NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Clomipramine NNP NNP B-CHEM
exposure NN NN O
in IN IN O
immature NN NN O
rats NNS NNS O
produced VBN VBN O
significant JJ JJ O
behavioral JJ JJ O
and CC CC O
biochemical JJ JJ O
changes NNS NNS O
that WDT WDT O
include VBP VBP O
enhanced JJ JJ O
anxiety NN NN O
( ( ( O
elevated VBD VBD O
plus CC CC O
maze NN NN O
and CC CC O
marble NN NN O
burying VBG VBG O
) ) ) O
, , , O
behavioral JJ JJ O
inflexibility NN NN O
( ( ( O
perseveration NN NN O
in IN IN O
the DT DT O
spontaneous JJ JJ O
alternation NN NN O
task NN NN O
and CC CC O
impaired VBN VBN O
reversal NN NN O
learning VBG VBG O
) ) ) O
, , , O
working VBG VBG O
memory NN NN O
impairment NN NN O
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
, , , O
win VB VB O
- - - O
shift NN NN O
paradigm NN NN O
) ) ) O
, , , O
hoarding VBG VBG O
, , , O
and CC CC O
corticostriatal JJ JJ O
dysfunction NN NN O
. . . O

Dopamine NNP NNP B-CHEM
D2 NN NN O
receptors NNS NNS O
were VBD VBD O
elevated VBN VBN O
in IN IN O
the DT DT O
striatum NN NN O
, , , O
whereas IN IN O
serotonin NN NN B-CHEM
2C CD CD O
, , , O
but CC CC O
not RB RB O
serotonin NN NN B-CHEM
1A CD CD O
, , , O
receptors NNS NNS O
were VBD VBD O
elevated VBN VBN O
in IN IN O
the DT DT O
orbital JJ JJ O
frontal NN NN O
cortex NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
demonstration NN NN O
of IN IN O
multiple JJ JJ O
symptoms NNS NNS O
consistent JJ JJ O
with IN IN O
an DT DT O
OCD NNP NNP O
- - - O
like IN IN O
profile NN NN O
in IN IN O
animals NNS NNS O
. . . O

Moreover RB RB O
, , , O
these DT DT O
behaviors NNS NNS O
are VBP VBP O
accompanied VBN VBN O
by IN IN O
biochemical JJ JJ O
changes NNS NNS O
in IN IN O
brain NN NN O
regions NNS NNS O
previously RB RB O
identified VBN VBN O
as IN IN O
relevant JJ JJ O
to TO TO O
OCD NNP NNP O
. . . O

This DT DT O
novel NN NN O
model NN NN O
of IN IN O
OCD NNP NNP O
demonstrates VBZ VBZ O
that IN IN O
drug NN NN O
exposure NN NN O
during IN IN O
a DT DT O
sensitive JJ JJ O
period NN NN O
can MD MD O
program NN NN O
disease NN NN O
- - - O
like IN IN O
systems NNS NNS O
permanently RB RB O
, , , O
which WDT WDT O
could MD MD O
have VB VB O
implications NNS NNS O
for IN IN O
current JJ JJ O
and CC CC O
future JJ JJ O
therapeutic JJ JJ O
strategies NNS NNS O
for IN IN O
this DT DT O
and CC CC O
other JJ JJ O
psychiatric JJ JJ O
disorders NNS NNS O
. . . O

Elevation NNP NNP O
of IN IN O
ADAM10 NNP NNP O
, , , O
ADAM17 NNP NNP O
, , , O
MMP NNP NNP O
- : : O
2 CD CD O
and CC CC O
MMP NNP NNP O
- : : O
9 CD CD O
expression NN NN O
with IN IN O
media NNS NNS O
degeneration NN NN O
features NNS NNS O
CaCl2 NNP NNP B-CHEM
- : : O
induced JJ JJ O
thoracic NN NN O
aortic JJ JJ O
aneurysm NN NN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
establish VB VB O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
thoracic NN NN O
aortic JJ JJ O
aneurysm NN NN O
( ( ( O
TAA NNP NNP O
) ) ) O
by IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
( ( ( O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
) ) ) O
- : : O
induced VBN VBN O
arterial JJ JJ O
injury NN NN O
and CC CC O
to TO TO O
explore VB VB O
the DT DT O
potential JJ JJ O
role NN NN O
of IN IN O
a DT DT O
disintegrin NN NN O
and CC CC O
metalloproteinase NN NN O
( ( ( O
ADAM NNP NNP O
) ) ) O
, , , O
matrix NN NN O
metalloproteinases NNS NNS O
( ( ( O
MMPs NNP NNP O
) ) ) O
and CC CC O
their PRP$ PRP$ O
endogenous JJ JJ O
inhibitors NNS NNS O
( ( ( O
TIMPs NNP NNP O
) ) ) O
in IN IN O
TAA NNP NNP O
formation NN NN O
. . . O

METHODS NNP NNP O
: : : O
Thoracic NNP NNP O
aorta NN NN O
of IN IN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
was VBD VBD O
exposed VBN VBN O
to TO TO O
0 CD CD O
. . . O
5M CD CD O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
or CC CC O
normal JJ JJ O
saline NN NN O
( ( ( O
NaCl NNP NNP B-CHEM
) ) ) O
. . . O

After IN IN O
12weeks CD CD O
, , , O
animals NNS NNS O
were VBD VBD O
euthanized VBN VBN O
, , , O
and CC CC O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
treated VBN VBN O
, , , O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
untreated JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
) ) ) O
and CC CC O
NaCl NNP NNP B-CHEM
- : : O
treated VBN VBN O
aortic JJ JJ O
segments NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
) ) ) O
were VBD VBD O
collected VBN VBN O
for IN IN O
histological JJ JJ O
and CC CC O
molecular JJ JJ O
assessments NNS NNS O
. . . O

MMP NNP NNP O
- : : O
TIMP NNP NNP O
and CC CC O
ADAM NNP NNP O
mRNAs NN NN O
were VBD VBD O
semi NN NN O
- : : O
quantitatively RB RB O
analyzed JJ JJ O
and CC CC O
protein NN NN O
expressions NNS NNS O
were VBD VBD O
determined VBN VBN O
by IN IN O
immunohistochemistry NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Despite IN IN O
similar JJ JJ O
external JJ JJ O
diameters NNS NNS O
among IN IN O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
treated VBN VBN O
, , , O
non NN NN O
- - - O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
treated VBN VBN O
and CC CC O
NaCl NNP NNP B-CHEM
- : : O
treated VBN VBN O
segments NNS NNS O
, , , O
aneurymal JJ JJ O
alteration NN NN O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
, , , O
50 CD CD O
% NN NN O
) ) ) O
, , , O
media NNS NNS O
degeneration NN NN O
with IN IN O
regional JJ JJ O
disruption NN NN O
, , , O
fragmentation NN NN O
of IN IN O
elastic JJ JJ O
fiber NN NN O
, , , O
and CC CC O
increased VBD VBD O
collagen NN NN O
deposition NN NN O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
, , , O
100 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
demonstrated VBN VBN O
in IN IN O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
treated VBN VBN O
segments NNS NNS O
. . . O

MMP NNP NNP O
- : : O
2 CD CD O
, , , O
MMP NNP NNP O
- : : O
9 CD CD O
, , , O
ADAM NNP NNP O
- : : O
10 CD CD O
and CC CC O
ADAM NNP NNP O
- : : O
17 CD CD O
mRNA NN NN O
levels NNS NNS O
were VBD VBD O
increased VBN VBN O
in IN IN O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
treated VBN VBN O
segments NNS NNS O
( ( ( O
all DT DT O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
with IN IN O
trends NNS NNS O
of IN IN O
elevation NN NN O
in IN IN O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
untreated JJ JJ O
segments NNS NNS O
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
NaCl NNP NNP B-CHEM
- - - O
treated JJ JJ O
segments NNS NNS O
. . . O

Immunohistochemistry NNP NNP O
displayed VBD VBD O
significantly RB RB O
increased VBN VBN O
expressions NNS NNS O
of IN IN O
MMP NNP NNP O
- : : O
2 CD CD O
, , , O
MMP NNP NNP O
- : : O
9 CD CD O
, , , O
ADAM NNP NNP O
- : : O
10 CD CD O
and CC CC O
ADAM NNP NNP O
- : : O
17 CD CD O
( ( ( O
all DT DT O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
in IN IN O
intima NN NN O
and CC CC O
media NNS NNS O
for IN IN O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
- : : O
treated VBN VBN O
segments NNS NNS O
. . . O

TIMP NNP NNP O
mRNA NN NN O
and CC CC O
tissue NN NN O
levels NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
obviously RB RB O
among IN IN O
the DT DT O
three CD CD O
aortic JJ JJ O
segments NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
study NN NN O
establishes VBZ VBZ O
a DT DT O
TAA NNP NNP O
model NN NN O
by IN IN O
periarterial JJ JJ O
CaCl NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
exposure NN NN O
in IN IN O
rats NNS NNS O
, , , O
and CC CC O
demonstrates VBZ VBZ O
a DT DT O
significant JJ JJ O
elevation NN NN O
of IN IN O
expression NN NN O
of IN IN O
MMP NNP NNP O
- : : O
2 CD CD O
, , , O
MMP NNP NNP O
- : : O
9 CD CD O
, , , O
ADAM10 NNP NNP O
and CC CC O
ADAM17 NNP NNP O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
vascular NN NN O
remodeling VBG VBG O
. . . O

Suxamethonium NNP NNP B-CHEM
induced VBD VBD O
prolonged JJ JJ O
apnea NN NN O
in IN IN O
a DT DT O
patient NN NN O
receiving VBG VBG O
electroconvulsive JJ JJ O
therapy NN NN O
. . . O

Suxamethonium NNP NNP B-CHEM
causes NNS NNS O
prolonged JJ JJ O
apnea NN NN O
in IN IN O
patients NNS NNS O
in IN IN O
whom WP WP O
pseudocholinesterase NN NN O
enzyme NN NN O
gets VBZ VBZ O
deactivated VBN VBN O
by IN IN O
organophosphorus NN NN B-CHEM
( ( ( I-CHEM
OP NNP NNP I-CHEM
) ) ) I-CHEM
poisons NNS NNS I-CHEM
. . . O

Here RB RB O
, , , O
we PRP PRP O
present JJ JJ O
a DT DT O
similar JJ JJ O
incident NN NN O
in IN IN O
a DT DT O
severely RB RB O
depressed VBN VBN O
patient NN NN O
who WP WP O
received VBD VBD O
electroconvulsive JJ JJ O
therapy NN NN O
( ( ( O
ECT NNP NNP O
) ) ) O
. . . O

Prolonged NNP NNP O
apnea NN NN O
in IN IN O
our PRP$ PRP$ O
case NN NN O
ensued VBD VBD O
because IN IN O
the DT DT O
information NN NN O
about IN IN O
suicidal NN NN O
attempt NN NN O
by IN IN O
OP NNP NNP B-CHEM
compound NN NN I-CHEM
was VBD VBD O
concealed VBN VBN O
from IN IN O
the DT DT O
treating NN NN O
team NN NN O
. . . O

Curcumin NNP NNP B-CHEM
ameliorates NNS NNS O
cognitive JJ JJ O
dysfunction NN NN O
and CC CC O
oxidative JJ JJ O
damage NN NN O
in IN IN O
phenobarbitone NN NN B-CHEM
and CC CC O
carbamazepine NN NN B-CHEM
administered VBD VBD O
rats NNS NNS O
. . . O

The DT DT O
antiepileptic JJ JJ O
drugs NNS NNS O
, , , O
phenobarbitone NN NN B-CHEM
and CC CC O
carbamazepine NN NN B-CHEM
are VBP VBP O
well RB RB O
known VBN VBN O
to TO TO O
cause VB VB O
cognitive JJ JJ O
impairment NN NN O
on IN IN O
chronic JJ JJ O
use NN NN O
. . . O

The DT DT O
increase NN NN O
in IN IN O
free JJ JJ O
radical JJ JJ O
generation NN NN O
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
as IN IN O
one CD CD O
of IN IN O
the DT DT O
important JJ JJ O
mechanisms NNS NNS O
of IN IN O
cognitive JJ JJ O
impairment NN NN O
by IN IN O
antiepileptic JJ JJ O
drugs NNS NNS O
. . . O

Curcumin NNP NNP B-CHEM
has VBZ VBZ O
shown VBN VBN O
antioxidant NN NN O
, , , O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
and CC CC O
neuro NN NN O
- - - O
protective JJ JJ O
properties NNS NNS O
. . . O

Therefore RB RB O
, , , O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
to TO TO O
investigate VB VB O
the DT DT O
effect NN NN O
of IN IN O
chronic JJ JJ O
curcumin NN NN B-CHEM
administration NN NN O
on IN IN O
phenobarbitone NN NN B-CHEM
- : : O
and CC CC O
carbamazepine JJ JJ B-CHEM
- - - O
induced JJ JJ O
cognitive JJ JJ O
impairment NN NN O
and CC CC O
oxidative JJ JJ O
stress NN NN O
in IN IN O
rats NNS NNS O
. . . O

Pharmacokinetic NNP NNP O
interactions NNS NNS O
of IN IN O
curcumin NN NN B-CHEM
with IN IN O
phenobarbitone NN NN B-CHEM
and CC CC O
carbamazepine NN NN B-CHEM
were VBD VBD O
also RB RB O
studied VBN VBN O
. . . O

Vehicle NNP NNP O
/ NN NN O
drugs NNS NNS O
were VBD VBD O
administered VBN VBN O
daily RB RB O
for IN IN O
21days CD CD O
to TO TO O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Passive NNP NNP O
avoidance NN NN O
paradigm NN NN O
and CC CC O
elevated VBD VBD O
plus CC CC O
maze JJ JJ O
test NN NN O
were VBD VBD O
used VBN VBN O
to TO TO O
assess VB VB O
cognitive JJ JJ O
function NN NN O
. . . O

At IN IN O
the DT DT O
end NN NN O
of IN IN O
study NN NN O
period NN NN O
, , , O
serum NN NN O
phenobarbitone NN NN B-CHEM
and CC CC O
carbamazepine NN NN B-CHEM
, , , O
whole JJ JJ O
brain NN NN O
malondialdehyde NN NN B-CHEM
and CC CC O
reduced VBN VBN O
glutathione NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
estimated VBN VBN O
. . . O

The DT DT O
administration NN NN O
of IN IN O
phenobarbitone NN NN B-CHEM
and CC CC O
carbamazepine NN NN B-CHEM
for IN IN O
21days CD CD O
caused VBD VBD O
a DT DT O
significant JJ JJ O
impairment NN NN O
of IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
as RB RB O
well RB RB O
as IN IN O
an DT DT O
increased VBN VBN O
oxidative JJ JJ O
stress NN NN O
. . . O

Concomitant NNP NNP O
curcumin NN NN B-CHEM
administration NN NN O
prevented VBD VBD O
the DT DT O
cognitive JJ JJ O
impairment NN NN O
and CC CC O
decreased VBD VBD O
the DT DT O
increased VBN VBN O
oxidative JJ JJ O
stress NN NN O
induced VBN VBN O
by IN IN O
these DT DT O
antiepileptic JJ JJ O
drugs NNS NNS O
. . . O

Curcumin NNP NNP B-CHEM
co NN NN O
- - - O
administration NN NN O
did VBD VBD O
not RB RB O
cause VB VB O
any DT DT O
significant JJ JJ O
alteration NN NN O
in IN IN O
the DT DT O
serum NN NN O
concentrations NNS NNS O
of IN IN O
both DT DT O
phenobarbitone NN NN B-CHEM
as RB RB O
well RB RB O
as IN IN O
carbamazepine NN NN B-CHEM
. . . O

These DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
curcumin NN NN B-CHEM
has VBZ VBZ O
beneficial JJ JJ O
effect NN NN O
in IN IN O
mitigating VBG VBG O
the DT DT O
deterioration NN NN O
of IN IN O
cognitive JJ JJ O
functions NNS NNS O
and CC CC O
oxidative JJ JJ O
damage NN NN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
phenobarbitone NN NN B-CHEM
and CC CC O
carbamazepine NN NN B-CHEM
without IN IN O
significantly RB RB O
altering VBG VBG O
their PRP$ PRP$ O
serum NN NN O
concentrations NNS NNS O
. . . O

The DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
curcumin NN NN B-CHEM
can MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
a DT DT O
potential JJ JJ O
safe JJ JJ O
and CC CC O
effective JJ JJ O
adjuvant NN NN O
to TO TO O
phenobarbitone VB VB B-CHEM
and CC CC O
carbamazepine VB VB B-CHEM
therapy NN NN O
in IN IN O
preventing VBG VBG O
cognitive JJ JJ O
impairment NN NN O
associated VBN VBN O
with IN IN O
these DT DT O
drugs NNS NNS O
. . . O

Can MD MD O
angiogenesis NNS NNS O
be VB VB O
a DT DT O
target NN NN O
of IN IN O
treatment NN NN O
for IN IN O
ribavirin NN NN B-CHEM
associated VBN VBN O
hemolytic JJ JJ O
anemia NN NN O
? . . O

BACKGROUND NNP NNP O
/ NN NN O
AIMS NNP NNP O
: : : O
Recently RB RB O
ribavirin NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
found VBN VBN O
to TO TO O
inhibit NN NN O
angiogenesis NNS NNS O
and CC CC O
a DT DT O
number NN NN O
of IN IN O
angiogenesis NN NN O
inhibitors NNS NNS O
such JJ JJ O
as IN IN O
sunitinib NN NN B-CHEM
and CC CC O
sorafenib NN NN B-CHEM
have VBP VBP O
been VBN VBN O
found VBN VBN O
to TO TO O
cause VB VB O
acute JJ JJ O
hemolysis NN NN O
. . . O

We PRP PRP O
aimed VBD VBD O
to TO TO O
investigate VB VB O
whether IN IN O
there EX EX O
is VBZ VBZ O
a DT DT O
relation NN NN O
between IN IN O
hemoglobin NN NN O
, , , O
haptoglobin NN NN O
and CC CC O
angiogenesis NNS NNS O
soluble JJ JJ O
markers NNS NNS O
which WDT WDT O
are VBP VBP O
modifiable JJ JJ O
and CC CC O
can MD MD O
help VB VB O
in IN IN O
developing VBG VBG O
strategies NNS NNS O
against IN IN O
anemia NN NN O
. . . O

METHODS NNP NNP O
: : : O
Fourteen CD CD O
patients NNS NNS O
chronically RB RB O
infected VBN VBN O
with IN IN O
hepatitis NNP NNP O
C NNP NNP O
virus NN NN O
were VBD VBD O
treated VBN VBN O
by IN IN O
pegylated JJ JJ B-CHEM
interferon NN NN I-CHEM
alpha NN NN I-CHEM
2a CD CD I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
. . . O

Serum NNP NNP O
hemoglobin NN NN O
, , , O
haptoglobin NN NN O
and CC CC O
angiogenesis NN NN O
markers NNS NNS O
of IN IN O
vascular JJ JJ O
endothelial JJ JJ O
growth NN NN O
factor NN NN O
and CC CC O
angiopoetin NN NN O
- - - O
2 CD CD O
were VBD VBD O
investigated VBN VBN O
before IN IN O
and CC CC O
after IN IN O
therapy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
observed VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
haptoglobin NN NN O
levels NNS NNS O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
treatment NN NN O
period NN NN O
. . . O

Hemoglobin NNP NNP O
levels NNS NNS O
also RB RB O
decreased VBN VBN O
but CC CC O
insignificantly RB RB O
by IN IN O
treatment NN NN O
. . . O

In IN IN O
contrast NN NN O
with IN IN O
the DT DT O
literature NN NN O
, , , O
serum NN NN O
levels NNS NNS O
of IN IN O
angiogenesis NN NN O
factors NNS NNS O
did VBD VBD O
not RB RB O
change VB VB O
significantly RB RB O
by IN IN O
pegylated JJ JJ B-CHEM
interferon NN NN I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
therapy NN NN O
. . . O

We PRP PRP O
found VBD VBD O
no DT DT O
correlation NN NN O
of IN IN O
angiogenesis NNS NNS O
soluble JJ JJ O
markers NNS NNS O
with IN IN O
either DT DT O
hemoglobin NN NN O
or CC CC O
haptoglobin NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
study NN NN O
in IN IN O
the DT DT O
literature NN NN O
investigating VBG VBG O
a DT DT O
link NN NN O
between IN IN O
angiogenesis NNS NNS O
soluble JJ JJ O
markers NNS NNS O
and CC CC O
ribavirin NN NN B-CHEM
induced VBN VBN O
anemia NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
hepatitis NNP NNP O
C NNP NNP O
and CC CC O
we PRP PRP O
could MD MD O
not RB RB O
find VB VB O
any DT DT O
relation NN NN O
. . . O

Future NNP NNP O
research NN NN O
with IN IN O
larger JJR JJR O
number NN NN O
of IN IN O
patients NNS NNS O
is VBZ VBZ O
needed VBN VBN O
to TO TO O
find VB VB O
out IN IN O
modifiable JJ JJ O
factors NNS NNS O
that WDT WDT O
will MD MD O
improve VB VB O
the DT DT O
safety NN NN O
of IN IN O
ribavirin NN NN B-CHEM
therapy NN NN O
. . . O

Reduction NNP NNP O
in IN IN O
injection NN NN O
pain NN NN O
using VBG VBG O
buffered JJ JJ O
lidocaine NN NN B-CHEM
as IN IN O
a DT DT O
local JJ JJ O
anesthetic JJ JJ O
before IN IN O
cardiac JJ JJ O
catheterization NN NN O
. . . O

Previous JJ JJ O
reports NNS NNS O
have VBP VBP O
suggested VBN VBN O
that IN IN O
pain NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
injection NN NN O
of IN IN O
lidocaine NN NN B-CHEM
is VBZ VBZ O
related VBN VBN O
to TO TO O
the DT DT O
acidic JJ JJ O
pH NN NN O
of IN IN O
the DT DT O
solution NN NN O
. . . O

To TO TO O
determine VB VB O
if IN IN O
the DT DT O
addition NN NN O
of IN IN O
a DT DT O
buffering VBG VBG O
solution NN NN O
to TO TO O
adjust VB VB O
the DT DT O
pH NN NN O
of IN IN O
lidocaine NN NN B-CHEM
into IN IN O
the DT DT O
physiologic JJ JJ O
range NN NN O
would MD MD O
reduce VB VB O
pain NN NN O
during IN IN O
injection NN NN O
, , , O
we PRP PRP O
performed VBD VBD O
a DT DT O
blinded JJ JJ O
randomized JJ JJ O
study NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
cardiac NN NN O
catheterization NN NN O
. . . O

Twenty NNP NNP O
patients NNS NNS O
were VBD VBD O
asked VBN VBN O
to TO TO O
quantify VB VB O
the DT DT O
severity NN NN O
of IN IN O
pain NN NN O
after IN IN O
receiving VBG VBG O
standard JJ JJ O
lidocaine NN NN B-CHEM
in IN IN O
one CD CD O
femoral JJ JJ O
area NN NN O
and CC CC O
buffered JJ JJ O
lidocaine NN NN B-CHEM
in IN IN O
the DT DT O
opposite JJ JJ O
femoral JJ JJ O
area NN NN O
. . . O

The DT DT O
mean NN NN O
pain NN NN O
score NN NN O
for IN IN O
buffered JJ JJ O
lidocaine NN NN B-CHEM
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
the DT DT O
mean NN NN O
score NN NN O
for IN IN O
standard JJ JJ O
lidocaine NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
9 CD CD O
vs NNS NNS O
. . . O
3 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
2 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
. . . O

The DT DT O
pH NN NN O
adjustment NN NN O
of IN IN O
standard JJ JJ O
lidocaine NN NN B-CHEM
can MD MD O
be VB VB O
accomplished VBN VBN O
easily RB RB O
in IN IN O
the DT DT O
catheterization NN NN O
laboratory NN NN O
before IN IN O
injection NN NN O
and CC CC O
results NNS NNS O
in IN IN O
a DT DT O
reduction NN NN O
of IN IN O
the DT DT O
pain NN NN O
occurring VBG VBG O
during IN IN O
the DT DT O
infiltration NN NN O
of IN IN O
tissues NNS NNS O
. . . O

Effect NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
glyceryl NN NN I-CHEM
- - - I-CHEM
phosphorylcholine NN NN I-CHEM
on IN IN O
amnesia NN NN O
caused VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
to TO TO O
test VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
glycerylphosphorylcholine NN NN I-CHEM
( ( ( O
L NNP NNP B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
GFC NNP NNP I-CHEM
) ) ) O
on IN IN O
memory NN NN O
impairment NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
in IN IN O
man NN NN O
. . . O

Thirty NNP NNP O
- : : O
two CD CD O
healthy JJ JJ O
young JJ JJ O
volunteers NNS NNS O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
four CD CD O
different JJ JJ O
groups NNS NNS O
. . . O

They PRP PRP O
were VBD VBD O
given VBN VBN O
a DT DT O
ten CD CD O
day NN NN O
pretreatment JJ JJ O
with IN IN O
either DT DT O
L NNP NNP B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
GFC NNP NNP I-CHEM
or CC CC O
placebo NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
and CC CC O
on IN IN O
the DT DT O
eleventh NN NN O
day NN NN O
either CC CC O
scopolamine NN NN B-CHEM
or CC CC O
placebo NN NN O
, , , O
i NNP NNP O
. . . O
m NN NN O
. . . O

Before IN IN O
and CC CC O
0 CD CD O
. . . O
5 CD CD O
, , , O
1 CD CD O
, , , O
2 CD CD O
, , , O
3 CD CD O
, , , O
and CC CC O
6 CD CD O
h NN NN O
after IN IN O
injection NN NN O
the DT DT O
subjects NNS NNS O
were VBD VBD O
given VBN VBN O
attention NN NN O
and CC CC O
mnemonic JJ JJ O
tests NNS NNS O
. . . O

The DT DT O
findings NNS NNS O
of IN IN O
this DT DT O
study NN NN O
indicate VBP VBP O
that IN IN O
the DT DT O
drug NN NN O
is VBZ VBZ O
able JJ JJ O
to TO TO O
antagonize VB VB O
impairment NN NN O
of IN IN O
attention NN NN O
and CC CC O
memory NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
. . . O

Safety NNP NNP O
of IN IN O
capecitabine NN NN B-CHEM
: : : O
a DT DT O
review NN NN O
. . . O

IMPORTANCE NNP NNP O
OF IN IN O
THE DT DT O
FIELD NNP NNP O
: : : O
Fluoropyrimidines NNP NNP B-CHEM
, , , O
in IN IN O
particular JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
, , , O
have VBP VBP O
been VBN VBN O
the DT DT O
mainstay NN NN O
of IN IN O
treatment NN NN O
for IN IN O
several JJ JJ O
solid JJ JJ O
tumors NNS NNS O
, , , O
including VBG VBG O
colorectal NN NN O
, , , O
breast NN NN O
and CC CC O
head NN NN O
and CC CC O
neck NN NN O
cancers NNS NNS O
, , , O
for IN IN O
> NN NN O
40 CD CD O
years NNS NNS O
. . . O

AREAS NNS NNS O
COVERED NNP NNP O
IN IN IN O
THIS DT DT O
REVIEW NNP NNP O
: : : O
This DT DT O
article NN NN O
reviews VBZ VBZ O
the DT DT O
pharmacology NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
capecitabine NN NN B-CHEM
with IN IN O
a DT DT O
special JJ JJ O
emphasis NN NN O
on IN IN O
its PRP$ PRP$ O
safety NN NN O
. . . O

WHAT WP WP O
THE DT DT O
READER NNP NNP O
WILL NNP NNP O
GAIN NNP NNP O
: : : O
The DT DT O
reader NN NN O
will MD MD O
gain VB VB O
better JJR JJR O
insight NN NN O
into IN IN O
the DT DT O
safety NN NN O
of IN IN O
capecitabine NN NN B-CHEM
in IN IN O
special JJ JJ O
populations NNS NNS O
such JJ JJ O
as IN IN O
patients NNS NNS O
with IN IN O
advanced JJ JJ O
age NN NN O
, , , O
renal NN NN O
and CC CC O
kidney NN NN O
disease NN NN O
. . . O

We PRP PRP O
also RB RB O
explore VBP VBP O
different JJ JJ O
dosing NN NN O
and CC CC O
schedules NNS NNS O
of IN IN O
capecitabine NN NN B-CHEM
administration NN NN O
. . . O

TAKE VB VB O
HOME NNP NNP O
MESSAGE NN NN O
: : : O
Capecitabine NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
oral JJ JJ O
prodrug NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
and CC CC O
was VBD VBD O
developed VBN VBN O
to TO TO O
fulfill VB VB O
the DT DT O
need NN NN O
for IN IN O
a DT DT O
more RBR RBR O
convenient JJ JJ O
therapy NN NN O
and CC CC O
provide VB VB O
an DT DT O
improved VBN VBN O
safety NN NN O
/ NN NN O
efficacy NN NN O
profile NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
shown VBN VBN O
promising JJ JJ O
results NNS NNS O
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
chemotherapeutic JJ JJ O
agents NNS NNS O
in IN IN O
colorectal NN NN O
, , , O
breast NN NN O
, , , O
pancreaticobiliary JJ JJ O
, , , O
gastric JJ JJ O
, , , O
renal JJ JJ O
cell NN NN O
and CC CC O
head NN NN O
and CC CC O
neck NN NN O
cancers NNS NNS O
. . . O

The DT DT O
most RBS RBS O
commonly RB RB O
reported VBD VBD O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
capecitabine NN NN B-CHEM
are VBP VBP O
diarrhea NN NN O
, , , O
nausea NN NN O
, , , O
vomiting VBG VBG O
, , , O
stomatitis NNS NNS O
and CC CC O
hand NN NN O
- - - O
foot NN NN O
syndrome NN NN O
. . . O

Capecitabine NNP NNP B-CHEM
has VBZ VBZ O
a DT DT O
well RB RB O
- - - O
established VBN VBN O
safety NN NN O
profile NN NN O
and CC CC O
can MD MD O
be VB VB O
given VBN VBN O
safely RB RB O
to TO TO O
patients NNS NNS O
with IN IN O
advanced JJ JJ O
age NN NN O
, , , O
hepatic JJ JJ O
and CC CC O
renal JJ JJ O
dysfunctions NNS NNS O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
: : : O
filling VBG VBG O
the DT DT O
bench NN NN O
- - - O
to TO TO O
- - - O
bedside NN NN O
gap NN NN O
. . . O

Levodopa NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
most RBS RBS O
effective JJ JJ O
drug NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
this DT DT O
dopamine NN NN B-CHEM
precursor NN NN O
is VBZ VBZ O
complicated VBN VBN O
by IN IN O
highly RB RB O
disabling VBG VBG O
fluctuations NNS NNS O
and CC CC O
dyskinesias NNS NNS O
. . . O

Although IN IN O
preclinical JJ JJ O
and CC CC O
clinical JJ JJ O
findings NNS NNS O
suggest VBP VBP O
pulsatile JJ JJ O
stimulation NN NN O
of IN IN O
striatal JJ JJ O
postsynaptic JJ JJ O
receptors NNS NNS O
as IN IN O
a DT DT O
key JJ JJ O
mechanism NN NN O
underlying VBG VBG O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NNS NNS O
, , , O
their PRP$ PRP$ O
pathogenesis NN NN O
is VBZ VBZ O
still RB RB O
unclear JJ JJ O
. . . O

In IN IN O
recent JJ JJ O
years NNS NNS O
, , , O
evidence NN NN O
from IN IN O
animal NN NN O
models NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
has VBZ VBZ O
provided VBN VBN O
important JJ JJ O
information NN NN O
to TO TO O
understand VB VB O
the DT DT O
effect NN NN O
of IN IN O
specific JJ JJ O
receptor NN NN O
and CC CC O
post NN NN O
- - - O
receptor NN NN O
molecular NN NN O
mechanisms NNS NNS O
underlying VBG VBG O
the DT DT O
development NN NN O
of IN IN O
dyskinetic JJ JJ O
movements NNS NNS O
. . . O

Recent JJ JJ O
preclinical JJ JJ O
and CC CC O
clinical JJ JJ O
data NNS NNS O
from IN IN O
promising JJ JJ O
lines NNS NNS O
of IN IN O
research NN NN O
focus NN NN O
on IN IN O
the DT DT O
differential JJ JJ O
role NN NN O
of IN IN O
presynaptic JJ JJ O
versus CC CC O
postsynaptic JJ JJ O
mechanisms NNS NNS O
, , , O
dopamine NN NN B-CHEM
receptor NN NN O
subtypes NNS NNS O
, , , O
ionotropic NN NN O
and CC CC O
metabotropic NN NN O
glutamate NN NN B-CHEM
receptors NNS NNS O
, , , O
and CC CC O
non NN NN O
- - - O
dopaminergic JJ JJ O
neurotransmitter NN NN O
systems NNS NNS O
in IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
. . . O

Effects NNP NNP O
of IN IN O
pallidal NN NN O
neurotensin NN NN B-CHEM
on IN IN O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
parkinsonian NN NN O
catalepsy NN NN O
: : : O
behavioral JJ JJ O
and CC CC O
electrophysiological JJ JJ O
studies NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
globus NN NN O
pallidus NN NN O
plays VBZ VBZ O
a DT DT O
critical JJ JJ O
role NN NN O
in IN IN O
movement NN NN O
regulation NN NN O
. . . O

Previous JJ JJ O
studies NNS NNS O
have VBP VBP O
indicated VBN VBN O
that IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
receives VBZ VBZ O
neurotensinergic JJ JJ O
innervation NN NN O
from IN IN O
the DT DT O
striatum NN NN O
, , , O
and CC CC O
systemic JJ JJ O
administration NN NN O
of IN IN O
a DT DT O
neurotensin NN NN B-CHEM
analog NN NN O
could MD MD O
produce VB VB O
antiparkinsonian JJ JJ O
effects NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
aimed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
pallidal NN NN O
neurotensin NN NN B-CHEM
on IN IN O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
parkinsonian NN NN O
symptoms NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Behavioral NNP NNP O
experiments NNS NNS O
and CC CC O
electrophysiological JJ JJ O
recordings NNS NNS O
were VBD VBD O
performed VBN VBN O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Bilateral NNP NNP O
infusions NNS NNS O
of IN IN O
neurotensin NN NN B-CHEM
into IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
reversed VBN VBN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
parkinsonian NN NN O
catalepsy NN NN O
in IN IN O
rats NNS NNS O
. . . O

Electrophysiological NNP NNP O
recordings NNS NNS O
showed VBD VBD O
that DT DT O
microinjection NN NN O
of IN IN O
neurotensin NN NN B-CHEM
induced JJ JJ O
excitation NN NN O
of IN IN O
pallidal NN NN O
neurons NNS NNS O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
systemic JJ JJ O
haloperidol NN NN B-CHEM
administration NN NN O
. . . O

The DT DT O
neurotensin NN NN B-CHEM
type NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
receptor NN NN I-CHEM
antagonist NN NN I-CHEM
SR48692 NNP NNP B-CHEM
blocked VBD VBD O
both DT DT O
the DT DT O
behavioral JJ JJ O
and CC CC O
the DT DT O
electrophysiological JJ JJ O
effects NNS NNS O
induced VBN VBN O
by IN IN O
neurotensin NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
Activation NNP NNP O
of IN IN O
pallidal NN NN O
neurotensin NN NN B-CHEM
receptors NNS NNS O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
neurotensin NN NN B-CHEM
- - - O
induced JJ JJ O
antiparkinsonian NN NN O
effects NNS NNS O
. . . O

Carmofur NNP NNP B-CHEM
- : : O
induced JJ JJ O
organic JJ JJ O
mental JJ JJ O
disorders NNS NNS O
. . . O

Organic NNP NNP O
mental JJ JJ O
disorder NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
a DT DT O
29 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
in IN IN O
the DT DT O
prognostic JJ JJ O
period NN NN O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
carmofur NN NN B-CHEM
- - - O
induced JJ JJ O
leukoencephalopathy NN NN O
. . . O

Symptoms NNP NNP O
such JJ JJ O
as IN IN O
euphoria NN NN O
, , , O
emotional JJ JJ O
lability NN NN O
and CC CC O
puerile NN NN O
attitude NN NN O
noted VBD VBD O
in IN IN O
the DT DT O
patient NN NN O
were VBD VBD O
diagnosed VBN VBN O
as IN IN O
organic JJ JJ O
personality NN NN O
syndrome NN NN O
according VBG VBG O
to TO TO O
the DT DT O
criteria NNS NNS O
defined VBN VBN O
in IN IN O
the DT DT O
DSM NNP NNP O
- - - O
III NNP NNP O
- - - O
R NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
referred VBN VBN O
to TO TO O
as IN IN O
a DT DT O
frontal JJ JJ O
lobe NN NN O
syndrome NN NN O
. . . O

Brain NNP NNP O
CT NNP NNP O
revealed VBD VBD O
a DT DT O
periventricular JJ JJ O
low JJ JJ O
density NN NN O
area NN NN O
in IN IN O
the DT DT O
frontal JJ JJ O
white JJ JJ O
matter NN NN O
and CC CC O
moderate JJ JJ O
dilatation NN NN O
of IN IN O
the DT DT O
lateral NN NN O
ventricles NNS NNS O
especially RB RB O
at IN IN O
the DT DT O
bilateral JJ JJ O
anterior NN NN O
horns NNS NNS O
. . . O

Consequently RB RB O
, , , O
carmofur NN NN B-CHEM
- - - O
induced JJ JJ O
leukoencephalopathy NN NN O
may MD MD O
uncommonly RB RB O
result VB VB O
in IN IN O
organic JJ JJ O
personality NN NN O
syndrome NN NN O
in IN IN O
the DT DT O
residual JJ JJ O
state NN NN O
. . . O

It PRP PRP O
may MD MD O
be VB VB O
attributed VBN VBN O
to TO TO O
the DT DT O
structural JJ JJ O
damage NN NN O
to TO TO O
the DT DT O
frontal JJ JJ O
lobe NN NN O
. . . O

Butyrylcholinesterase NNP NNP O
gene NN NN O
mutations NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
prolonged JJ JJ O
apnea NN NN O
after IN IN O
succinylcholine NN NN B-CHEM
for IN IN O
electroconvulsive JJ JJ O
therapy NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
patients NNS NNS O
undergoing VBG VBG O
electroconvulsive JJ JJ O
therapy NN NN O
( ( ( O
ECT NNP NNP O
) ) ) O
often RB RB O
receive VBP VBP O
succinylcholine NN NN B-CHEM
as IN IN O
part NN NN O
of IN IN O
the DT DT O
anesthetic JJ JJ O
procedure NN NN O
. . . O

The DT DT O
duration NN NN O
of IN IN O
action NN NN O
may MD MD O
be VB VB O
prolonged JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
genetic JJ JJ O
variants NNS NNS O
of IN IN O
the DT DT O
butyrylcholinesterase NN NN O
enzyme NN NN O
( ( ( O
BChE NNP NNP O
) ) ) O
, , , O
the DT DT O
most RBS RBS O
common JJ JJ O
being VBG VBG O
the DT DT O
K NNP NNP O
- : : O
and CC CC O
the DT DT O
A DT DT O
- - - O
variants NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
clinical JJ JJ O
significance NN NN O
of IN IN O
genetic JJ JJ O
variants NNS NNS O
in IN IN O
butyrylcholinesterase NN NN O
gene NN NN O
( ( ( O
BCHE NNP NNP O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
suspected JJ JJ O
prolonged JJ JJ O
duration NN NN O
of IN IN O
action NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
after IN IN O
ECT NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
a DT DT O
total NN NN O
of IN IN O
13 CD CD O
patients NNS NNS O
were VBD VBD O
referred VBN VBN O
to TO TO O
the DT DT O
Danish NNP NNP O
Cholinesterase NNP NNP O
Research NNP NNP O
Unit NNP NNP O
after IN IN O
ECT NNP NNP O
during IN IN O
38 CD CD O
months NNS NNS O
. . . O

We PRP PRP O
determined VBD VBD O
the DT DT O
BChE NNP NNP O
activity NN NN O
and CC CC O
the DT DT O
BCHE NNP NNP O
genotype NN NN O
using VBG VBG O
molecular JJ JJ O
genetic JJ JJ O
methods NNS NNS O
, , , O
the DT DT O
duration NN NN O
of IN IN O
apnea NN NN O
, , , O
time NN NN O
to TO TO O
sufficient VB VB O
spontaneous JJ JJ O
ventilation NN NN O
and CC CC O
whether IN IN O
neuromuscular JJ JJ O
monitoring NN NN O
was VBD VBD O
used VBN VBN O
. . . O

The DT DT O
duration NN NN O
of IN IN O
apnea NN NN O
was VBD VBD O
compared VBN VBN O
with IN IN O
published VBN VBN O
data NNS NNS O
on IN IN O
normal JJ JJ O
subjects NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
in IN IN O
11 CD CD O
patients NNS NNS O
, , , O
mutations NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
BCHE NNP NNP O
gene NN NN O
, , , O
the DT DT O
K NNP NNP O
- : : O
variant NN NN O
being VBG VBG O
the DT DT O
most RBS RBS O
frequent JJ JJ O
. . . O

The DT DT O
duration NN NN O
of IN IN O
apnea NN NN O
was VBD VBD O
5 CD CD O
- : : O
15 CD CD O
min NN NN O
compared VBN VBN O
with IN IN O
3 CD CD O
- : : O
5 CD CD O
. . . O
3 CD CD O
min NN NN O
from IN IN O
the DT DT O
literature NN NN O
. . . O

Severe NNP NNP O
distress NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
the DT DT O
recovery NN NN O
phase NN NN O
in IN IN O
two CD CD O
patients NNS NNS O
. . . O

Neuromuscular NNP NNP O
monitoring NN NN O
was VBD VBD O
used VBN VBN O
in IN IN O
two CD CD O
patients NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
eleven NN NN O
of IN IN O
13 CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
prolonged JJ JJ O
duration NN NN O
of IN IN O
action NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
had VBD VBD O
mutations NNS NNS O
in IN IN O
BCHE NNP NNP O
, , , O
indicating VBG VBG O
that IN IN O
this DT DT O
is VBZ VBZ O
the DT DT O
possible JJ JJ O
reason NN NN O
for IN IN O
a DT DT O
prolonged JJ JJ O
period NN NN O
of IN IN O
apnea NN NN O
. . . O

We PRP PRP O
recommend VBP VBP O
objective NN NN O
neuromuscular NN NN O
monitoring NN NN O
during IN IN O
the DT DT O
first JJ JJ O
ECT NNP NNP O
. . . O

Perhexiline NNP NNP B-CHEM
maleate NN NN I-CHEM
and CC CC O
peripheral JJ JJ O
neuropathy NN NN O
. . . O

Peripheral NNP NNP O
neuropathy NN NN O
has VBZ VBZ O
been VBN VBN O
noted VBN VBN O
as IN IN O
a DT DT O
complication NN NN O
of IN IN O
therapy NN NN O
with IN IN O
perhexiline NN NN B-CHEM
maleate NN NN I-CHEM
, , , O
a DT DT O
drug NN NN O
widely RB RB O
used VBN VBN O
in IN IN O
France NNP NNP O
( ( ( O
and CC CC O
in IN IN O
clinical JJ JJ O
trials NNS NNS O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
) ) ) O
for IN IN O
the DT DT O
prophylactic JJ JJ O
treatment NN NN O
of IN IN O
angina NN NN O
pectoris NN NN O
. . . O

In IN IN O
24 CD CD O
patients NNS NNS O
with IN IN O
this DT DT O
complication NN NN O
, , , O
the DT DT O
marked JJ JJ O
slowing NN NN O
of IN IN O
motor NN NN O
nerve NN NN O
conduction NN NN O
velocity NN NN O
and CC CC O
the DT DT O
electromyographic JJ JJ O
changes NNS NNS O
imply VBP VBP O
mainly RB RB O
a DT DT O
demyelinating VBG VBG O
disorder NN NN O
. . . O

Improvement NNP NNP O
was VBD VBD O
noted VBN VBN O
with IN IN O
cessation NN NN O
of IN IN O
therapy NN NN O
. . . O

In IN IN O
a DT DT O
few JJ JJ O
cases NNS NNS O
the DT DT O
presence NN NN O
of IN IN O
active JJ JJ O
denervation NN NN O
signified VBD VBD O
a DT DT O
poor JJ JJ O
prognosis NN NN O
, , , O
with IN IN O
only RB RB O
slight JJ JJ O
improvement NN NN O
. . . O

The DT DT O
underlying VBG VBG O
mechanism NN NN O
causing VBG VBG O
the DT DT O
neuropathy NN NN O
is VBZ VBZ O
not RB RB O
yet RB RB O
fully RB RB O
known VBN VBN O
, , , O
although IN IN O
some DT DT O
evidence NN NN O
indicates VBZ VBZ O
that IN IN O
it PRP PRP O
may MD MD O
be VB VB O
a DT DT O
lipid JJ JJ O
storage NN NN O
process NN NN O
. . . O

A DT DT O
phase NN NN O
I PRP PRP O
study NN NN O
of IN IN O
4 CD CD B-CHEM
' POS POS I-CHEM
- : : I-CHEM
0 CD CD I-CHEM
- : : I-CHEM
tetrahydropyranyladriamycin NN NN I-CHEM
. . . O

Clinical NNP NNP O
pharmacology NN NN O
and CC CC O
pharmacokinetics NNS NNS O
. . . O

A DT DT O
Phase NN NN O
I PRP PRP O
study VBP VBP O
of IN IN O
intravenous JJ JJ O
( ( ( O
IV NNP NNP O
) ) ) O
bolus NN NN O
4 CD CD B-CHEM
' POS POS I-CHEM
- : : I-CHEM
0 CD CD I-CHEM
- : : I-CHEM
tetrahydropyranyladriamycin NN NN I-CHEM
( ( ( O
Pirarubicin NNP NNP B-CHEM
) ) ) O
was VBD VBD O
done VBN VBN O
in IN IN O
55 CD CD O
patients NNS NNS O
in IN IN O
good JJ JJ O
performance NN NN O
status NN NN O
with IN IN O
refractory JJ JJ O
tumors NNS NNS O
. . . O

Twenty CD CD O
- - - O
six CD CD O
had VBD VBD O
minimal JJ JJ O
prior RB RB O
therapy NN NN O
( ( ( O
good JJ JJ O
risk NN NN O
) ) ) O
, , , O
23 CD CD O
had VBD VBD O
extensive JJ JJ O
prior RB RB O
therapy NN NN O
( ( ( O
poor JJ JJ O
risk NN NN O
) ) ) O
, , , O
and CC CC O
six CD CD O
had VBD VBD O
renal JJ JJ O
and CC CC O
/ NN NN O
or CC CC O
hepatic JJ JJ O
dysfunction NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
167 CD CD O
courses NNS NNS O
at IN IN O
doses NNS NNS O
of IN IN O
15 CD CD O
to TO TO O
70 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
were VBD VBD O
evaluable JJ JJ O
. . . O

Maximum NNP NNP O
tolerated VBD VBD O
dose NN NN O
in IN IN O
good JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
was VBD VBD O
70 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
and CC CC O
in IN IN O
poor JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
, , , O
60 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

The DT DT O
dose NN NN O
- - - O
limiting VBG VBG O
toxic JJ JJ O
effect NN NN O
was VBD VBD O
transient JJ JJ O
noncumulative JJ JJ O
granulocytopenia NN NN O
. . . O

Granulocyte NNP NNP O
nadir NN NN O
was VBD VBD O
on IN IN O
day NN NN O
14 CD CD O
( ( ( O
range NN NN O
, , , O
4 CD CD O
- : : O
22 CD CD O
) ) ) O
. . . O

Less RBR RBR O
frequent JJ JJ O
toxic JJ JJ O
effects NNS NNS O
included VBD VBD O
thrombocytopenia NN NN O
, , , O
anemia NN NN O
, , , O
nausea NN NN O
, , , O
mild JJ JJ O
alopecia NN NN O
, , , O
phlebitis NN NN O
, , , O
and CC CC O
mucositis NNS NNS O
. . . O

Myelosuppression NNP NNP O
was VBD VBD O
more JJR JJR O
in IN IN O
patients NNS NNS O
with IN IN O
hepatic JJ JJ O
dysfunction NN NN O
. . . O

Pharmacokinetic NNP NNP O
analyses NNS NNS O
in IN IN O
21 CD CD O
patients NNS NNS O
revealed VBD VBD O
Pirarubicin NNP NNP B-CHEM
plasma NN NN O
T NN NN O
1 CD CD O
/ NN NN O
2 CD CD O
alpha NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
85 CD CD O
minutes NNS NNS O
, , , O
T NN NN O
beta NN NN O
1 CD CD O
/ NN NN O
2 CD CD O
of IN IN O
25 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
5 CD CD O
minutes NNS NNS O
, , , O
and CC CC O
T NN NN O
1 CD CD O
/ NN NN O
2 CD CD O
gamma NN NN O
of IN IN O
23 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
. . . O
6 CD CD O
hours NNS NNS O
. . . O

The DT DT O
area NN NN O
under IN IN O
the DT DT O
curve NN NN O
was VBD VBD O
537 CD CD O
+ NN NN O
/ NN NN O
- : : O
149 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
x SYM SYM O
hours NNS NNS O
, , , O
volume NN NN O
of IN IN O
distribution NN NN O
( ( ( O
Vd NNP NNP O
) ) ) O
3504 CD CD O
+ NN NN O
/ NN NN O
- : : O
644 CD CD O
l NN NN O
/ NN NN O
m2 NN NN O
, , , O
and CC CC O
total JJ JJ O
clearance NN NN O
( ( ( O
ClT NNP NNP O
) ) ) O
was VBD VBD O
204 CD CD O
+ NN NN O
39 CD CD O
. . . O
3 CD CD O
l NN NN O
/ NN NN O
hour NN NN O
/ NN NN O
m2 NN NN O
. . . O

Adriamycinol NNP NNP B-CHEM
, , , O
doxorubicin NN NN B-CHEM
, , , O
adriamycinone NN NN B-CHEM
, , , O
and CC CC O
tetrahydropyranyladriamycinol NN NN B-CHEM
were VBD VBD O
the DT DT O
metabolites NNS NNS O
detected VBD VBD O
in IN IN O
plasma NN NN O
and CC CC O
the DT DT O
amount NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
was VBD VBD O
less RBR RBR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
10 CD CD O
% NN NN O
of IN IN O
the DT DT O
total JJ JJ O
metabolites NNS NNS O
. . . O

Urinary NNP NNP O
excretion NN NN O
of IN IN O
Pirarubicin NNP NNP B-CHEM
in IN IN O
the DT DT O
first JJ JJ O
24 CD CD O
hours NNS NNS O
was VBD VBD O
less JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
10 CD CD O
% NN NN O
. . . O

Activity NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
mesothelioma NN NN O
, , , O
leiomyosarcoma NN NN O
, , , O
and CC CC O
basal NN NN O
cell NN NN O
carcinoma NN NN O
. . . O

The DT DT O
recommended JJ JJ O
starting VBG VBG O
dose NN NN O
for IN IN O
Phase NN NN O
II NNP NNP O
trials NNS NNS O
is VBZ VBZ O
60 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
IV NNP NNP O
bolus NN NN O
every DT DT O
3 CD CD O
weeks NNS NNS O
. . . O

Ocular NNP NNP O
and CC CC O
auditory NN NN O
toxicity NN NN O
in IN IN O
hemodialyzed JJ JJ O
patients NNS NNS O
receiving VBG VBG O
desferrioxamine NN NN B-CHEM
. . . O

During IN IN O
an DT DT O
18 CD CD O
- : : O
month NN NN O
period NN NN O
of IN IN O
study NN NN O
41 CD CD O
hemodialyzed VBN VBN O
patients NNS NNS O
receiving VBG VBG O
desferrioxamine NN NN B-CHEM
( ( ( O
10 CD CD O
- : : O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BW NNP NNP O
/ NN NN O
3 CD CD O
times NNS NNS O
weekly JJ JJ O
) ) ) O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
were VBD VBD O
monitored VBN VBN O
for IN IN O
detection NN NN O
of IN IN O
audiovisual JJ JJ O
toxicity NN NN O
. . . O

6 CD CD O
patients NNS NNS O
presented VBN VBN O
clinical JJ JJ O
symptoms NNS NNS O
of IN IN O
visual JJ JJ O
or CC CC O
auditory JJ JJ O
toxicity NN NN O
. . . O

Moreover RB RB O
, , , O
detailed JJ JJ O
ophthalmologic JJ JJ O
and CC CC O
audiologic JJ JJ O
studies NNS NNS O
disclosed VBN VBN O
abnormalities NNS NNS O
in IN IN O
7 CD CD O
more JJR JJR O
asymptomatic JJ JJ O
patients NNS NNS O
. . . O

Visual NNP NNP O
toxicity NN NN O
was VBD VBD O
of IN IN O
retinal JJ JJ O
origin NN NN O
and CC CC O
was VBD VBD O
characterized VBN VBN O
by IN IN O
a DT DT O
tritan NN NN O
- - - O
type NN NN O
dyschromatopsy NN NN O
, , , O
sometimes RB RB O
associated VBN VBN O
with IN IN O
a DT DT O
loss NN NN O
of IN IN O
visual JJ JJ O
acuity NN NN O
and CC CC O
pigmentary JJ JJ O
retinal JJ JJ O
deposits NNS NNS O
. . . O

Auditory NNP NNP O
toxicity NN NN O
was VBD VBD O
characterized VBN VBN O
by IN IN O
a DT DT O
mid JJ JJ O
- - - O
to TO TO O
high JJ JJ O
- - - O
frequency NN NN O
neurosensorial JJ JJ O
hearing NN NN O
loss NN NN O
and CC CC O
the DT DT O
lesion NN NN O
was VBD VBD O
of IN IN O
the DT DT O
cochlear NN NN O
type NN NN O
. . . O

Desferrioxamine NNP NNP B-CHEM
withdrawal NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
complete JJ JJ O
recovery NN NN O
of IN IN O
visual JJ JJ O
function NN NN O
in IN IN O
1 CD CD O
patient NN NN O
and CC CC O
partial JJ JJ O
recovery NN NN O
in IN IN O
3 CD CD O
, , , O
and CC CC O
a DT DT O
complete JJ JJ O
reversal NN NN O
of IN IN O
hearing NN NN O
loss NN NN O
in IN IN O
3 CD CD O
patients NNS NNS O
and CC CC O
partial JJ JJ O
recovery NN NN O
in IN IN O
3 CD CD O
. . . O

This DT DT O
toxicity NN NN O
appeared VBD VBD O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
the DT DT O
higher JJR JJR O
doses NNS NNS O
of IN IN O
desferrioxamine NN NN B-CHEM
or CC CC O
coincided VBN VBN O
with IN IN O
the DT DT O
normalization NN NN O
of IN IN O
ferritin NN NN O
or CC CC O
aluminium NN NN B-CHEM
serum NN NN O
levels NNS NNS O
. . . O

The DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
audiovisual JJ JJ O
toxicity NN NN O
is VBZ VBZ O
not RB RB O
an DT DT O
infrequent JJ JJ O
complication NN NN O
in IN IN O
hemodialyzed JJ JJ O
patients NNS NNS O
receiving VBG VBG O
desferrioxamine NN NN B-CHEM
. . . O

Periodical NNP NNP O
audiovisual NN NN O
monitoring NN NN O
should MD MD O
be VB VB O
performed VBN VBN O
on IN IN O
hemodialyzed VBN VBN O
patients NNS NNS O
receiving VBG VBG O
the DT DT O
drug NN NN O
in IN IN O
order NN NN O
to TO TO O
detect VB VB O
adverse JJ JJ O
effects NNS NNS O
as RB RB O
early JJ JJ O
as IN IN O
possible JJ JJ O
. . . O

Serial NNP NNP O
epilepsy NN NN O
caused VBN VBN O
by IN IN O
levodopa NN NN B-CHEM
/ NN NN I-CHEM
carbidopa NN NN I-CHEM
administration NN NN O
in IN IN O
two CD CD O
patients NNS NNS O
on IN IN O
hemodialysis NN NN O
. . . O

Two CD CD O
patients NNS NNS O
with IN IN O
similar JJ JJ O
clinical JJ JJ O
features NNS NNS O
are VBP VBP O
presented VBN VBN O
: : : O
both DT DT O
patients NNS NNS O
had VBD VBD O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
on IN IN O
hemodialysis NN NN O
for IN IN O
many JJ JJ O
years NNS NNS O
but CC CC O
recently RB RB O
begun VBN VBN O
on IN IN O
a DT DT O
high JJ JJ O
- - - O
flux NN NN O
dialyzer NN NN O
; : : O
both DT DT O
had VBD VBD O
been VBN VBN O
receiving VBG VBG O
a DT DT O
carbidopa NN NN B-CHEM
/ NN NN I-CHEM
levodopa NN NN I-CHEM
preparation NN NN O
; : : O
and CC CC O
both DT DT O
had VBD VBD O
the DT DT O
onset NN NN O
of IN IN O
hallucinosis NN NN O
and CC CC O
recurrent JJ JJ O
seizures NNS NNS O
, , , O
which WDT WDT O
were VBD VBD O
refractory JJ JJ O
to TO TO O
anticonvulsants NNS NNS O
. . . O

The DT DT O
first JJ JJ O
patient NN NN O
died VBD VBD O
without IN IN O
a DT DT O
diagnosis NN NN O
; : : O
the DT DT O
second JJ JJ O
patient NN NN O
had VBD VBD O
a DT DT O
dramatic JJ JJ O
recovery NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
vitamin NN NN B-CHEM
B6 NNP NNP I-CHEM
. . . O

Neither DT DT O
patient NN NN O
was VBD VBD O
considered VBN VBN O
to TO TO O
have VB VB O
a DT DT O
renal JJ JJ O
state NN NN O
sufficiently RB RB O
severe JJ JJ O
enough RB RB O
to TO TO O
explain VB VB O
their PRP$ PRP$ O
presentation NN NN O
. . . O

Randomized NNP NNP O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
of IN IN O
mazindol NN NN B-CHEM
in IN IN O
Duchenne NNP NNP O
dystrophy NN NN O
. . . O

There EX EX O
is VBZ VBZ O
evidence NN NN O
that IN IN O
growth NN NN O
hormone NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
progression NN NN O
of IN IN O
weakness NN NN O
in IN IN O
Duchenne NNP NNP O
dystrophy NN NN O
. . . O

We PRP PRP O
conducted VBD VBD O
a DT DT O
12 CD CD O
- : : O
month NN NN O
controlled VBD VBD O
trial NN NN O
of IN IN O
mazindol NN NN B-CHEM
, , , O
a DT DT O
putative JJ JJ O
growth NN NN O
hormone NN NN O
secretion NN NN O
inhibitor NN NN O
, , , O
in IN IN O
83 CD CD O
boys NNS NNS O
with IN IN O
Duchenne NNP NNP O
dystrophy NN NN O
. . . O

Muscle NNP NNP O
strength NN NN O
, , , O
contractures NNS NNS O
, , , O
functional JJ JJ O
ability NN NN O
and CC CC O
pulmonary JJ JJ O
function NN NN O
were VBD VBD O
tested VBN VBN O
at IN IN O
baseline NN NN O
, , , O
and CC CC O
6 CD CD O
and CC CC O
12 CD CD O
months NNS NNS O
after IN IN O
treatment NN NN O
with IN IN O
mazindol NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
) ) ) O
or CC CC O
placebo NN NN O
. . . O

The DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
have VB VB O
a DT DT O
power NN NN O
of IN IN O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
90 CD CD O
to TO TO O
detect VB VB O
a DT DT O
slowing VBG VBG O
to TO TO O
25 CD CD O
% NN NN O
of IN IN O
the DT DT O
expected VBN VBN O
rate NN NN O
of IN IN O
progression NN NN O
of IN IN O
weakness NN NN O
at IN IN O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
. . . O

Mazindol NNP NNP B-CHEM
did VBD VBD O
not RB RB O
benefit VB VB O
strength NN NN O
at IN IN O
any DT DT O
point NN NN O
in IN IN O
the DT DT O
study NN NN O
. . . O

Side NNP NNP O
effects NNS NNS O
attributable JJ JJ O
to TO TO O
mazindol NN NN B-CHEM
included VBD VBD O
decreased VBN VBN O
appetite NN NN O
( ( ( O
36 CD CD O
% NN NN O
) ) ) O
, , , O
dry JJ JJ O
mouth NN NN O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
, , , O
behavioral JJ JJ O
change NN NN O
( ( ( O
22 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
gastrointestinal JJ JJ O
symptoms NNS NNS O
( ( ( O
18 CD CD O
% NN NN O
) ) ) O
; : : O
mazindol NN NN B-CHEM
dosage NN NN O
was VBD VBD O
reduced VBN VBN O
in IN IN O
43 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
mazindol NN NN B-CHEM
on IN IN O
GH NNP NNP O
secretion NN NN O
was VBD VBD O
estimated VBN VBN O
indirectly RB RB O
by IN IN O
comparing VBG VBG O
the DT DT O
postabsorptive JJ JJ O
IGF NNP NNP O
- : : O
I PRP PRP O
levels NNS NNS O
obtained VBN VBN O
following VBG VBG O
3 CD CD O
, , , O
6 CD CD O
, , , O
9 CD CD O
, , , O
and CC CC O
12 CD CD O
months NNS NNS O
in IN IN O
the DT DT O
mazindol NN NN B-CHEM
treated VBN VBN O
to TO TO O
those DT DT O
in IN IN O
the DT DT O
placebo NN NN O
groups NNS NNS O
. . . O

Although IN IN O
mazindol NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
gained VBN VBN O
less JJR JJR O
weight NN NN O
and CC CC O
height NN NN O
than IN IN O
placebo NN NN O
- - - O
treated VBN VBN O
patients NNS NNS O
, , , O
no DT DT O
significant JJ JJ O
effect NN NN O
on IN IN O
IGF NNP NNP O
- : : O
I PRP PRP O
levels NNS NNS O
was VBD VBD O
observed VBN VBN O
. . . O

Mazindol NNP NNP B-CHEM
doses NNS NNS O
not RB RB O
slow JJ JJ O
the DT DT O
progression NN NN O
of IN IN O
weakness NN NN O
in IN IN O
Duchenne NNP NNP O
dystrophy NN NN O
. . . O

Facilitation NNP NNP O
of IN IN O
memory NN NN O
retrieval NN NN O
by IN IN O
pre NN NN O
- - - O
test NN NN O
morphine NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
state NN NN O
dependency NN NN O
in IN IN O
the DT DT O
step NN NN O
- - - O
through IN IN O
type NN NN O
passive JJ JJ O
avoidance NN NN O
learning VBG VBG O
test NN NN O
in IN IN O
mice NN NN O
. . . O

Amnesia NNP NNP O
produced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
and CC CC O
cycloheximide NN NN B-CHEM
were VBD VBD O
reversed VBN VBN O
by IN IN O
morphine NN NN B-CHEM
given VBN VBN O
30 CD CD O
min NN NN O
before IN IN O
the DT DT O
test NN NN O
trial NN NN O
( ( ( O
pre NN NN O
- - - O
test NN NN O
) ) ) O
, , , O
and CC CC O
pre NN NN O
- - - O
test NN NN O
morphine NN NN B-CHEM
also RB RB O
facilitated VBD VBD O
the DT DT O
memory NN NN O
retrieval NN NN O
in IN IN O
the DT DT O
animals NNS NNS O
administered VBD VBD O
naloxone NN NN B-CHEM
during IN IN O
the DT DT O
training NN NN O
trial NN NN O
. . . O

Similarly RB RB O
, , , O
pre NN NN O
- - - O
test NN NN O
scopolamine NN NN B-CHEM
partially RB RB O
reversed VBD VBD O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
, , , O
but CC CC O
not RB RB O
significantly RB RB O
; : : O
and CC CC O
pre NN NN O
- - - O
test NN NN O
cycloheximide NN NN B-CHEM
failed VBD VBD O
to TO TO O
reverse VB VB O
the DT DT O
cycloheximide NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
facilitation NN NN O
of IN IN O
memory NN NN O
retrieval NN NN O
by IN IN O
pre NN NN O
- - - O
test NN NN O
morphine NN NN B-CHEM
might MD MD O
be VB VB O
the DT DT O
direct JJ JJ O
action NN NN O
of IN IN O
morphine NN NN B-CHEM
rather RB RB O
than IN IN O
a DT DT O
state NN NN O
dependent JJ JJ O
effect NN NN O
. . . O

Naloxone NNP NNP B-CHEM
reverses VBZ VBZ O
the DT DT O
antihypertensive JJ JJ O
effect NN NN O
of IN IN O
clonidine NN NN B-CHEM
. . . O

In IN IN O
unanesthetized JJ JJ O
, , , O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
the DT DT O
decrease NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
produced VBN VBN O
by IN IN O
intravenous JJ JJ O
clonidine NN NN B-CHEM
, , , O
5 CD CD O
to TO TO O
20 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
, , , O
was VBD VBD O
inhibited VBN VBN O
or CC CC O
reversed VBN VBN O
by IN IN O
nalozone NN NN B-CHEM
, , , O
0 CD CD O
. . . O
2 CD CD O
to TO TO O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

The DT DT O
hypotensive JJ JJ O
effect NN NN O
of IN IN O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
alpha NN NN B-CHEM
- : : I-CHEM
methyldopa NN NN I-CHEM
was VBD VBD O
also RB RB O
partially RB RB O
reversed VBN VBN O
by IN IN O
naloxone NN NN B-CHEM
. . . O

Naloxone NNP NNP B-CHEM
alone RB RB O
did VBD VBD O
not RB RB O
affect VB VB O
either CC CC O
blood NN NN O
pressure NN NN O
or CC CC O
heart NN NN O
rate NN NN O
. . . O

In IN IN O
brain NN NN O
membranes NNS NNS O
from IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
clonidine NN NN B-CHEM
, , , O
10 CD CD O
( ( ( O
- : : O
8 CD CD O
) ) ) O
to TO TO O
10 CD CD O
( ( ( O
- : : O
5 CD CD O
) ) ) O
M NNP NNP O
, , , O
did VBD VBD O
not RB RB O
influence VB VB O
stereoselective JJ JJ O
binding NN NN O
of IN IN O
[ NN NN B-CHEM
3H CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
naloxone NN NN I-CHEM
( ( ( O
8 CD CD O
nM NN NN O
) ) ) O
, , , O
and CC CC O
naloxone NN NN B-CHEM
, , , O
10 CD CD O
( ( ( O
- : : O
8 CD CD O
) ) ) O
to TO TO O
10 CD CD O
( ( ( O
- : : O
4 CD CD O
) ) ) O
M NNP NNP O
, , , O
did VBD VBD O
not RB RB O
influence VB VB O
clonidine NN NN B-CHEM
- : : O
suppressible JJ JJ O
binding NN NN O
of IN IN O
[ NN NN B-CHEM
3H CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
dihydroergocryptine NN NN I-CHEM
( ( ( O
1 CD CD O
nM NN NN O
) ) ) O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
in IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
the DT DT O
effects NNS NNS O
of IN IN O
central JJ JJ O
alpha NN NN O
- - - O
adrenoceptor NN NN O
stimulation NN NN O
involve JJ JJ O
activation NN NN O
of IN IN O
opiate JJ JJ O
receptors NNS NNS O
. . . O

As IN IN O
naloxone NN NN B-CHEM
and CC CC O
clonidine NN NN B-CHEM
do VBP VBP O
not RB RB O
appear VB VB O
to TO TO O
interact NN NN O
with IN IN O
the DT DT O
same JJ JJ O
receptor NN NN O
site NN NN O
, , , O
the DT DT O
observed VBD VBD O
functional JJ JJ O
antagonism NN NN O
suggests VBZ VBZ O
the DT DT O
release NN NN O
of IN IN O
an DT DT O
endogenous JJ JJ O
opiate NN NN O
by IN IN O
clonidine NN NN B-CHEM
or CC CC O
alpha NN NN B-CHEM
- - - I-CHEM
methyldopa NN NN I-CHEM
and CC CC O
the DT DT O
possible JJ JJ O
role NN NN O
of IN IN O
the DT DT O
opiate NN NN O
in IN IN O
the DT DT O
central JJ JJ O
control NN NN O
of IN IN O
sympathetic JJ JJ O
tone NN NN O
. . . O

Neurotoxicity NNP NNP O
of IN IN O
halogenated JJ JJ B-CHEM
hydroxyquinolines NNS NNS I-CHEM
: : : O
clinical JJ JJ O
analysis NN NN O
of IN IN O
cases NNS NNS O
reported VBD VBD O
outside IN IN O
Japan NNP NNP O
. . . O

An DT DT O
analysis NN NN O
is VBZ VBZ O
presented VBN VBN O
of IN IN O
220 CD CD O
cases NNS NNS O
of IN IN O
possible JJ JJ O
neurotoxic JJ JJ O
reactions NNS NNS O
to TO TO O
halogenated JJ JJ B-CHEM
hydroxyquinolines NNS NNS I-CHEM
reported VBD VBD O
from IN IN O
outside IN IN O
Japan NNP NNP O
. . . O

In IN IN O
80 CD CD O
cases NNS NNS O
insufficient JJ JJ O
information NN NN O
was VBD VBD O
available JJ JJ O
for IN IN O
adequate JJ JJ O
comment NN NN O
and CC CC O
in IN IN O
29 CD CD O
a DT DT O
relationship NN NN O
to TO TO O
the DT DT O
administration NN NN O
of IN IN O
clioquinol NN NN B-CHEM
could MD MD O
be VB VB O
excluded VBN VBN O
. . . O

Of IN IN O
the DT DT O
remainder NN NN O
, , , O
a DT DT O
relationship NN NN O
to TO TO O
clioquinol VB VB B-CHEM
was VBD VBD O
considered VBN VBN O
probable JJ JJ O
in IN IN O
42 CD CD O
and CC CC O
possible JJ JJ O
in IN IN O
69 CD CD O
cases NNS NNS O
. . . O

In IN IN O
six CD CD O
of IN IN O
the DT DT O
probable JJ JJ O
cases NNS NNS O
the DT DT O
neurological JJ JJ O
disturbance NN NN O
consisted VBD VBD O
of IN IN O
an DT DT O
acute JJ JJ O
reversible JJ JJ O
encephalopathy NN NN O
usually RB RB O
related VBN VBN O
to TO TO O
the DT DT O
ingestion NN NN O
of IN IN O
a DT DT O
high JJ JJ O
dose NN NN O
of IN IN O
clioquinol NN NN B-CHEM
over IN IN O
a DT DT O
short JJ JJ O
period NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
manifestation NN NN O
, , , O
observed VBD VBD O
in IN IN O
15 CD CD O
further JJ JJ O
cases NNS NNS O
, , , O
was VBD VBD O
isolated VBN VBN O
optic JJ JJ O
atrophy NN NN O
. . . O

This DT DT O
was VBD VBD O
most RBS RBS O
frequently RB RB O
found VBN VBN O
in IN IN O
children NNS NNS O
, , , O
many JJ JJ O
of IN IN O
whom WP WP O
had VBD VBD O
received VBN VBN O
clioquinol NN NN B-CHEM
as IN IN O
treatment NN NN O
for IN IN O
acrodermatitis NN NN O
enteropathica NN NN O
. . . O

In IN IN O
the DT DT O
remaining VBG VBG O
cases NNS NNS O
, , , O
a DT DT O
combination NN NN O
of IN IN O
myelopathy NN NN O
, , , O
visual JJ JJ O
disturbance NN NN O
, , , O
and CC CC O
peripheral JJ JJ O
neuropathy NN NN O
was VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
manifestation NN NN O
. . . O

Isolated NNP NNP O
myelopathy NN NN O
or CC CC O
peripheral JJ JJ O
neuropathy NN NN O
, , , O
or CC CC O
these DT DT O
manifestations NNS NNS O
occurring VBG VBG O
together RB RB O
, , , O
were VBD VBD O
infrequent NN NN O
. . . O

The DT DT O
onset NN NN O
of IN IN O
all DT DT O
manifestations NNS NNS O
( ( ( O
except IN IN O
toxic JJ JJ O
encephalopathy NN NN O
) ) ) O
was VBD VBD O
usually RB RB O
subacute JJ JJ O
, , , O
with IN IN O
subsequent JJ JJ O
partial JJ JJ O
recovery NN NN O
. . . O

Older JJR JJR O
subjects NNS NNS O
tended VBD VBD O
to TO TO O
display VB VB O
more JJR JJR O
side NN NN O
effects NNS NNS O
. . . O

The DT DT O
full JJ JJ O
syndrome NN NN O
of IN IN O
subacute NN NN O
myelo NN NN O
- : : O
optic JJ JJ O
neuropathy NN NN O
was VBD VBD O
more RBR RBR O
frequent JJ JJ O
in IN IN O
women NNS NNS O
, , , O
but CC CC O
they PRP PRP O
tended VBD VBD O
to TO TO O
have VB VB O
taken VBN VBN O
greater JJR JJR O
quantities NNS NNS O
of IN IN O
the DT DT O
drug NN NN O
. . . O

Prazosin NNP NNP B-CHEM
- : : O
induced JJ JJ O
stress NN NN O
incontinence NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
genuine JJ JJ O
stress NN NN O
incontinence NN NN O
due JJ JJ O
to TO TO O
prazosin NN NN B-CHEM
, , , O
a DT DT O
common JJ JJ O
antihypertensive JJ JJ O
drug NN NN O
, , , O
is VBZ VBZ O
presented VBN VBN O
. . . O

Prazosin NNP NNP B-CHEM
exerts VBZ VBZ O
its PRP$ PRP$ O
antihypertensive JJ JJ O
effects NNS NNS O
through IN IN O
vasodilatation NN NN O
caused VBN VBN O
by IN IN O
selective JJ JJ O
blockade NN NN O
of IN IN O
postsynaptic JJ JJ O
alpha NN NN O
- : : O
1 CD CD O
adrenergic JJ JJ O
receptors NNS NNS O
. . . O

As IN IN O
an DT DT O
alpha NN NN O
- - - O
blocker NN NN O
, , , O
it PRP PRP O
also RB RB O
exerts VBZ VBZ O
a DT DT O
significant JJ JJ O
relaxant JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
bladder NN NN O
neck NN NN O
and CC CC O
urethra NN NN O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
clinical JJ JJ O
course NN NN O
is VBZ VBZ O
described VBN VBN O
and CC CC O
correlated JJ JJ O
with IN IN O
initial JJ JJ O
urodynamic JJ JJ O
studies NNS NNS O
while IN IN O
on IN IN O
prazosin NN NN B-CHEM
and CC CC O
subsequent JJ JJ O
studies NNS NNS O
while IN IN O
taking VBG VBG O
verapamil NN NN B-CHEM
. . . O

Her PRP$ PRP$ O
incontinence NN NN O
resolved VBN VBN O
with IN IN O
the DT DT O
change NN NN O
of IN IN O
medication NN NN O
. . . O

The DT DT O
restoration NN NN O
of IN IN O
continence NN NN O
was VBD VBD O
accompanied VBN VBN O
by IN IN O
a DT DT O
substantial JJ JJ O
rise NN NN O
in IN IN O
maximum NN NN O
urethral JJ JJ O
pressure NN NN O
, , , O
maximum NN NN O
urethral JJ JJ O
closure NN NN O
pressure NN NN O
, , , O
and CC CC O
functional JJ JJ O
urethral JJ JJ O
length NN NN O
. . . O

Patients NNS NNS O
who WP WP O
present JJ JJ O
with IN IN O
stress NN NN O
incontinence NN NN O
while IN IN O
taking VBG VBG O
prazosin NN NN B-CHEM
should MD MD O
change VB VB O
their PRP$ PRP$ O
antihypertensive JJ JJ O
medication NN NN O
before IN IN O
considering VBG VBG O
surgery NN NN O
, , , O
because IN IN O
their PRP$ PRP$ O
incontinence NN NN O
may MD MD O
resolve VB VB O
spontaneously RB RB O
with IN IN O
a DT DT O
change NN NN O
in IN IN O
drug NN NN O
therapy NN NN O
. . . O

Myocardial NNP NNP O
infarction NN NN O
following VBG VBG O
sublingual JJ JJ O
administration NN NN O
of IN IN O
isosorbide NN NN B-CHEM
dinitrate NN NN I-CHEM
. . . O

A DT DT O
78 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
with IN IN O
healed JJ JJ O
septal JJ JJ O
necrosis NNS NNS O
suffered VBD VBD O
a DT DT O
recurrent NN NN O
myocardial NN NN O
infarction NN NN O
of IN IN O
the DT DT O
anterior NN NN O
wall NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
isosorbide NN NN B-CHEM
dinitrate NN NN I-CHEM
5 CD CD O
mg NN NN O
sublingually RB RB O
. . . O

After IN IN O
detailing VBG VBG O
the DT DT O
course NN NN O
of IN IN O
events NNS NNS O
, , , O
we PRP PRP O
discuss VBP VBP O
the DT DT O
role NN NN O
of IN IN O
paradoxical JJ JJ O
coronary JJ JJ O
spasm NN NN O
and CC CC O
hypotension NN NN O
- - - O
mediated JJ JJ O
myocardial NN NN O
ischemia NN NN O
occurring VBG VBG O
downstream JJ JJ O
to TO TO O
significant JJ JJ O
coronary JJ JJ O
arterial NN NN O
stenosis NN NN O
in IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
acute JJ JJ O
coronary JJ JJ O
insufficiency NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
respiratory JJ JJ O
effects NNS NNS O
of IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
infusions NNS NNS O
of IN IN O
morphine NN NN B-CHEM
and CC CC O
regional JJ JJ O
analgesia NN NN O
by IN IN O
extradural JJ JJ O
block NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
postoperative JJ JJ O
respiratory NN NN O
apnoea NN NN O
was VBD VBD O
compared VBN VBN O
between IN IN O
five CD CD O
patients NNS NNS O
receiving VBG VBG O
a DT DT O
continuous JJ JJ O
i NNP NNP O
. . . O
v NN NN O
. . . O
infusion NN NN O
of IN IN O
morphine NN NN B-CHEM
( ( ( O
mean NN NN O
73 CD CD O
. . . O
6 CD CD O
mg NN NN O
) ) ) O
and CC CC O
five CD CD O
patients NNS NNS O
receiving VBG VBG O
a DT DT O
continuous JJ JJ O
extradural JJ JJ O
infusion NN NN O
of IN IN O
0 CD CD O
. . . O
25 CD CD O
% NN NN O
bupivacaine NN NN B-CHEM
( ( ( O
mean NN NN O
192 CD CD O
mg NN NN O
) ) ) O
in IN IN O
the DT DT O
24 CD CD O
- : : O
h NN NN O
period NN NN O
following VBG VBG O
upper JJ JJ O
abdominal JJ JJ O
surgery NN NN O
. . . O

Monitoring NNP NNP O
consisted VBD VBD O
of IN IN O
airflow NN NN O
detection NN NN O
by IN IN O
a DT DT O
carbon NN NN B-CHEM
dioxide NN NN I-CHEM
analyser NN NN O
, , , O
chest NN NN O
wall NN NN O
movement NN NN O
detected VBN VBN O
by IN IN O
pneumatic JJ JJ O
capsules NNS NNS O
, , , O
and CC CC O
continuous JJ JJ O
electrocardiograph NN NN O
recorded VBN VBN O
with IN IN O
a DT DT O
Holter NNP NNP O
ambulatory NN NN O
monitor NN NN O
. . . O

Both DT DT O
obstructive JJ JJ O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
central JJ JJ O
apnoea NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
occurred VBD VBD O
more RBR RBR O
frequently RB RB O
in IN IN O
patients NNS NNS O
who WP WP O
had VBD VBD O
a DT DT O
morphine NN NN B-CHEM
infusion NN NN O
. . . O

There EX EX O
was VBD VBD O
also RB RB O
a DT DT O
higher JJR JJR O
incidence NN NN O
of IN IN O
tachyarrhythmias NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
ventricular JJ JJ O
ectopic NN NN O
beats NNS NNS O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
in IN IN O
the DT DT O
morphine NN NN B-CHEM
infusion NN NN O
group NN NN O
. . . O

Effects NNP NNP O
of IN IN O
aminophylline NN NN B-CHEM
on IN IN O
the DT DT O
threshold NN NN O
for IN IN O
initiating VBG VBG O
ventricular NN NN O
fibrillation NN NN O
during IN IN O
respiratory JJ JJ O
failure NN NN O
. . . O

Cardiac NNP NNP O
arrhythmias NNS NNS O
have VBP VBP O
frequently RB RB O
been VBN VBN O
reported VBN VBN O
in IN IN O
association NN NN O
with IN IN O
respiratory JJ JJ O
failure NN NN O
. . . O

The DT DT O
possible JJ JJ O
additive JJ JJ O
role NN NN O
of IN IN O
pharmacologic JJ JJ O
agents NNS NNS O
in IN IN O
precipitating VBG VBG O
cardiac JJ JJ O
disturbances NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
respiratory NN NN O
failure NN NN O
has VBZ VBZ O
only RB RB O
recently RB RB O
been VBN VBN O
emphasized VBN VBN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
aminophylline NN NN B-CHEM
on IN IN O
the DT DT O
ventricular NN NN O
fibrillation NN NN O
threshold NN NN O
during IN IN O
normal JJ JJ O
acid NN NN O
- - - O
base NN NN O
conditions NNS NNS O
and CC CC O
during IN IN O
respiratory JJ JJ O
failure NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
anesthetized JJ JJ O
open JJ JJ O
chest NN NN O
dogs NNS NNS O
. . . O

The DT DT O
ventricular NN NN O
fibrillation NN NN O
threshold NN NN O
was VBD VBD O
measured VBN VBN O
by IN IN O
passing VBG VBG O
a DT DT O
gated JJ JJ O
train NN NN O
of IN IN O
12 CD CD O
constant JJ JJ O
current JJ JJ O
pulses NNS NNS O
through IN IN O
the DT DT O
ventricular NN NN O
myocardium NN NN O
during IN IN O
the DT DT O
vulnerable JJ JJ O
period NN NN O
of IN IN O
the DT DT O
cardiac NN NN O
cycle NN NN O
. . . O

During IN IN O
the DT DT O
infusion NN NN O
of IN IN O
aminophylline NN NN B-CHEM
, , , O
the DT DT O
ventricular NN NN O
fibrillation NN NN O
threshold NN NN O
was VBD VBD O
reduced VBN VBN O
by IN IN O
30 CD CD O
to TO TO O
40 CD CD O
percent NN NN O
of IN IN O
the DT DT O
control NN NN O
when WRB WRB O
pH NN NN O
and CC CC O
partial JJ JJ O
pressures NNS NNS O
of IN IN O
oxygen NN NN B-CHEM
( ( ( O
PO2 NNP NNP B-CHEM
) ) ) O
and CC CC O
carbon NN NN B-CHEM
dioxide NN NN I-CHEM
( ( ( O
CO2 NNP NNP B-CHEM
) ) ) O
were VBD VBD O
kept VBN VBN O
within IN IN O
normal JJ JJ O
limits NNS NNS O
. . . O

When WRB WRB O
respiratory NN NN O
failure NN NN O
was VBD VBD O
produced VBN VBN O
by IN IN O
hypoventilation NN NN O
( ( ( O
pH NN NN O
7 CD CD O
. . . O
05 CD CD O
to TO TO O
7 CD CD O
. . . O
25 CD CD O
; : : O
PC02 NNP NNP O
70 CD CD O
to TO TO O
100 CD CD O
mm NN NN O
Hg NNP NNP O
: : : O
P02 NNP NNP O
20 CD CD O
to TO TO O
40 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
, , , O
infusion NN NN O
of IN IN O
aminophylline NN NN B-CHEM
resulted VBD VBD O
in IN IN O
an DT DT O
even RB RB O
greater JJR JJR O
decrease NN NN O
in IN IN O
ventricular NN NN O
fibrillation NN NN O
threshold NN NN O
to TO TO O
60 CD CD O
percent NN NN O
of IN IN O
the DT DT O
control NN NN O
level NN NN O
. . . O

These DT DT O
experiments NNS NNS O
suggest VBP VBP O
that IN IN O
although IN IN O
many JJ JJ O
factors NNS NNS O
may MD MD O
contribute VB VB O
to TO TO O
the DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
ventricular NN NN O
arrhythmias NNS NNS O
in IN IN O
respiratory JJ JJ O
failure NN NN O
, , , O
pharmacologic JJ JJ O
agents NNS NNS O
, , , O
particularly RB RB O
aminophylline JJ JJ B-CHEM
, , , O
may MD MD O
play VB VB O
a DT DT O
significant JJ JJ O
role NN NN O
. . . O

Pentoxifylline NNP NNP B-CHEM
( ( ( O
Trental NNP NNP B-CHEM
) ) ) O
does VBZ VBZ O
not RB RB O
inhibit VB VB O
dipyridamole NN NN B-CHEM
- : : O
induced JJ JJ O
coronary JJ JJ O
hyperemia NN NN O
: : : O
implications NNS NNS O
for IN IN O
dipyridamole NN NN B-CHEM
- - - O
thallium NN NN B-CHEM
- - - O
201 CD CD O
myocardial NN NN O
imaging VBG VBG O
. . . O

Dipyridamole NNP NNP B-CHEM
- : : O
thallium NN NN B-CHEM
- : : O
201 CD CD O
imaging VBG VBG O
is VBZ VBZ O
often RB RB O
performed VBN VBN O
in IN IN O
patients NNS NNS O
unable JJ JJ O
to TO TO O
exercise VB VB O
because IN IN O
of IN IN O
peripheral JJ JJ O
vascular NN NN O
disease NN NN O
. . . O

Many JJ JJ O
of IN IN O
these DT DT O
patients NNS NNS O
are VBP VBP O
taking VBG VBG O
pentoxifylline NN NN B-CHEM
( ( ( O
Trental NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
methylxanthine NN NN B-CHEM
derivative JJ JJ O
which WDT WDT O
may MD MD O
improve VB VB O
intermittent JJ JJ O
claudication NN NN O
. . . O

Whether IN IN O
pentoxifylline NN NN B-CHEM
inhibits NNS NNS O
dipyridamole JJ JJ B-CHEM
- : : O
induced JJ JJ O
coronary JJ JJ O
hyperemia NN NN O
like IN IN O
other JJ JJ O
methylxanthines NNS NNS B-CHEM
such JJ JJ O
as IN IN O
theophylline NN NN B-CHEM
and CC CC O
should MD MD O
be VB VB O
stopped VBN VBN O
prior RB RB O
to TO TO O
dipyridamole VB VB B-CHEM
- - - O
thallium NN NN B-CHEM
- - - O
201 CD CD O
imaging VBG VBG O
is VBZ VBZ O
unknown JJ JJ O
. . . O

Therefore RB RB O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
hyperemic JJ JJ O
response NN NN O
to TO TO O
dipyridamole NN NN B-CHEM
in IN IN O
seven CD CD O
open JJ JJ O
- - - O
chest NN NN O
anesthetized VBD VBD O
dogs NNS NNS O
after IN IN O
pretreatment NN NN O
with IN IN O
either DT DT O
pentoxifylline NN NN B-CHEM
( ( ( O
0 CD CD O
, , , O
7 CD CD O
. . . O
5 CD CD O
, , , O
or CC CC O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
or CC CC O
theophylline NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
. . . O

Baseline NNP NNP O
circumflex NN NN O
coronary JJ JJ O
blood NN NN O
flows NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
among IN IN O
treatment NN NN O
groups NNS NNS O
. . . O

Dipyridamole NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
coronary JJ JJ O
blood NN NN O
flow NN NN O
before IN IN O
and CC CC O
after IN IN O
7 CD CD O
. . . O
5 CD CD O
or CC CC O
15 CD CD O
mm NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
pentoxifylline NN NN B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

Neither DT DT O
dose NN NN O
of IN IN O
pentoxifylline NN NN B-CHEM
significantly RB RB O
decreased VBD VBD O
the DT DT O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
hyperemia NN NN O
, , , O
while IN IN O
peak NN NN O
coronary JJ JJ O
blood NN NN O
flow NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
after IN IN O
theophylline NN NN B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
pentoxyifylline NN NN B-CHEM
does VBZ VBZ O
not RB RB O
inhibit VB VB O
dipyridamole NN NN B-CHEM
- : : O
induced JJ JJ O
coronary JJ JJ O
hyperemia NN NN O
even RB RB O
at IN IN O
high JJ JJ O
doses NNS NNS O
. . . O

Cause NNP NNP O
of IN IN O
death NN NN O
among IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
: : : O
a DT DT O
rare JJ JJ O
mortality NN NN O
due JJ JJ O
to TO TO O
cerebral JJ JJ O
haemorrhage NN NN O
. . . O

Causes NNP NNP O
of IN IN O
death NN NN O
, , , O
with IN IN O
special JJ JJ O
reference NN NN O
to TO TO O
cerebral JJ JJ O
haemorrhage NN NN O
, , , O
among IN IN O
240 CD CD O
patients NNS NNS O
with IN IN O
pathologically RB RB O
verified JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
were VBD VBD O
investigated VBN VBN O
using VBG VBG O
the DT DT O
Annuals NNP NNP O
of IN IN O
the DT DT O
Pathological NNP NNP O
Autopsy NNP NNP O
Cases NNS NNS O
in IN IN O
Japan NNP NNP O
from IN IN O
1981 CD CD O
to TO TO O
1985 CD CD O
. . . O

The DT DT O
leading VBG VBG O
causes NNS NNS O
of IN IN O
death NN NN O
were VBD VBD O
pneumonia NN NN O
and CC CC O
bronchitis NN NN O
( ( ( O
44 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
malignant JJ JJ O
neoplasms NNS NNS O
( ( ( O
11 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
, , , O
heart NN NN O
diseases NNS NNS O
( ( ( O
4 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
cerebral JJ JJ O
infarction NN NN O
( ( ( O
3 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
and CC CC O
septicaemia NN NN O
( ( ( O
3 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

Cerebral NNP NNP O
haemorrhage NN NN O
was VBD VBD O
the DT DT O
11th CD CD O
most RBS RBS O
frequent JJ JJ O
cause NN NN O
of IN IN O
death NN NN O
, , , O
accounting VBG VBG O
for IN IN O
only RB RB O
0 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
deaths NNS NNS O
among IN IN O
the DT DT O
patients NNS NNS O
, , , O
whereas IN IN O
it PRP PRP O
was VBD VBD O
the DT DT O
5th CD CD O
most RBS RBS O
common JJ JJ O
cause NN NN O
of IN IN O
death NN NN O
among IN IN O
the DT DT O
Japanese JJ JJ O
general JJ JJ O
population NN NN O
in IN IN O
1985 CD CD O
. . . O

The DT DT O
low JJ JJ O
incidence NN NN O
of IN IN O
cerebral JJ JJ O
haemorrhage NN NN O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
death NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
may MD MD O
reflect VB VB O
the DT DT O
hypotensive JJ JJ O
effect NN NN O
of IN IN O
levodopa NN NN B-CHEM
and CC CC O
a DT DT O
hypotensive JJ JJ O
mechanism NN NN O
due JJ JJ O
to TO TO O
reduced VBN VBN O
noradrenaline NN NN B-CHEM
levels NNS NNS O
in IN IN O
the DT DT O
parkinsonian NN NN O
brain NN NN O
. . . O

Possible JJ JJ O
intramuscular JJ JJ O
midazolam NN NN B-CHEM
- - - O
associated VBN VBN O
cardiorespiratory NN NN O
arrest NN NN O
and CC CC O
death NN NN O
. . . O

Midazolam NNP NNP B-CHEM
hydrochloride NN NN I-CHEM
is VBZ VBZ O
commonly RB RB O
used VBN VBN O
for IN IN O
dental JJ JJ O
or CC CC O
endoscopic JJ JJ O
procedures NNS NNS O
. . . O

Although IN IN O
generally RB RB O
consisted VBN VBN O
safe JJ JJ O
when WRB WRB O
given VBN VBN O
intramuscularly RB RB O
, , , O
intravenous JJ JJ O
administration NN NN O
is VBZ VBZ O
known VBN VBN O
to TO TO O
cause VB VB O
respiratory NN NN O
and CC CC O
cardiovascular JJ JJ O
depression NN NN O
. . . O

This DT DT O
report NN NN O
describes VBZ VBZ O
the DT DT O
first JJ JJ O
published VBN VBN O
case NN NN O
of IN IN O
cardiorespiratory NN NN O
arrest NN NN O
and CC CC O
death NN NN O
associated VBN VBN O
with IN IN O
intramuscular JJ JJ O
administration NN NN O
of IN IN O
midazolam NN NN B-CHEM
. . . O

Information NNP NNP O
regarding VBG VBG O
midazolam NN NN B-CHEM
use NN NN O
is VBZ VBZ O
reviewed VBN VBN O
to TO TO O
provide VB VB O
recommendation NN NN O
for IN IN O
safe JJ JJ O
administration NN NN O
. . . O

Myasthenia NNP NNP O
gravis NN NN O
presenting VBG VBG O
as IN IN O
weakness NN NN O
after IN IN O
magnesium NN NN B-CHEM
administration NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
a DT DT O
patient NN NN O
with IN IN O
no DT DT O
prior JJ JJ O
history NN NN O
of IN IN O
neuromuscular JJ JJ O
disease NN NN O
who WP WP O
became VBD VBD O
virtually RB RB O
quadriplegic JJ JJ O
after IN IN O
parenteral JJ JJ O
magnesium NN NN B-CHEM
administration NN NN O
for IN IN O
preeclampsia NN NN O
. . . O

The DT DT O
serum NN NN O
magnesium NN NN B-CHEM
concentration NN NN O
was VBD VBD O
3 CD CD O
. . . O
0 CD CD O
mEq NN NN O
/ NN NN O
L NNP NNP O
, , , O
which WDT WDT O
is VBZ VBZ O
usually RB RB O
well RB RB O
tolerated VBN VBN O
. . . O

The DT DT O
magnesium NN NN B-CHEM
was VBD VBD O
stopped VBN VBN O
and CC CC O
she PRP PRP O
recovered VBD VBD O
over IN IN O
a DT DT O
few JJ JJ O
days NNS NNS O
. . . O

While IN IN O
she PRP PRP O
was VBD VBD O
weak JJ JJ O
, , , O
2 CD CD O
- : : O
Hz NNP NNP O
repetitive JJ JJ O
stimulation NN NN O
revealed VBD VBD O
a DT DT O
decrement NN NN O
without IN IN O
significant JJ JJ O
facilitation NN NN O
at IN IN O
rapid JJ JJ O
rates NNS NNS O
or CC CC O
after IN IN O
exercise NN NN O
, , , O
suggesting VBG VBG O
postsynaptic JJ JJ O
neuromuscular NN NN O
blockade NN NN O
. . . O

After IN IN O
her PRP$ PRP$ O
strength NN NN O
returned VBD VBD O
, , , O
repetitive JJ JJ O
stimulation NN NN O
was VBD VBD O
normal JJ JJ O
, , , O
but CC CC O
single JJ JJ O
fiber NN NN O
EMG NNP NNP O
revealed VBD VBD O
increased VBN VBN O
jitter NN NN O
and CC CC O
blocking VBG VBG O
. . . O

Her PRP$ PRP$ O
acetylcholine NN NN B-CHEM
receptor NN NN O
antibody NN NN O
level NN NN O
was VBD VBD O
markedly RB RB O
elevated VBD VBD O
. . . O

Although IN IN O
paralysis NN NN O
after IN IN O
magnesium NN NN B-CHEM
administration NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
known VBN VBN O
myasthenia NN NN O
gravis NN NN O
, , , O
it PRP PRP O
has VBZ VBZ O
not RB RB O
previously RB RB O
been VBN VBN O
reported VBN VBN O
to TO TO O
be VB VB O
the DT DT O
initial JJ JJ O
or CC CC O
only RB RB O
manifestation NN NN O
of IN IN O
the DT DT O
disease NN NN O
. . . O

Patients NNS NNS O
who WP WP O
are VBP VBP O
unusually RB RB O
sensitive JJ JJ O
to TO TO O
the DT DT O
neuromuscular JJ JJ O
effects NNS NNS O
of IN IN O
magnesium NN NN B-CHEM
should MD MD O
be VB VB O
suspected VBN VBN O
of IN IN O
having VBG VBG O
an DT DT O
underlying VBG VBG O
disorder NN NN O
of IN IN O
neuromuscular JJ JJ O
transmission NN NN O
. . . O

No DT DT O
enhancement NN NN O
by IN IN O
phenobarbital NN NN B-CHEM
of IN IN O
the DT DT O
hepatocarcinogenicity NN NN O
of IN IN O
a DT DT O
choline NN NN B-CHEM
- - - O
devoid JJ JJ O
diet NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

An DT DT O
experiment NN NN O
was VBD VBD O
performed VBN VBN O
to TO TO O
test VB VB O
whether IN IN O
inclusion NN NN O
of IN IN O
phenobarbital NN NN B-CHEM
in IN IN O
a DT DT O
choline NN NN B-CHEM
- - - O
devoid JJ JJ O
diet NN NN O
would MD MD O
increase VB VB O
the DT DT O
hepatocarcinogenicity NN NN O
of IN IN O
the DT DT O
diet NN NN O
. . . O

Groups NNS NNS O
of IN IN O
5 CD CD O
- : : O
week NN NN O
old JJ JJ O
male NN NN O
Fischer NNP NNP O
- : : O
344 CD CD O
rats NNS NNS O
were VBD VBD O
fed VBN VBN O
for IN IN O
7 CD CD O
- : : O
25 CD CD O
months NNS NNS O
semipurified JJ JJ O
choline NN NN B-CHEM
- - - O
devoid NN NN O
or CC CC O
choline NN NN B-CHEM
- - - O
supplemented JJ JJ O
diets NNS NNS O
, , , O
containing VBG VBG O
or CC CC O
not RB RB O
0 CD CD O
. . . O
06 CD CD O
% NN NN O
phenobarbital NN NN B-CHEM
. . . O

No DT DT O
hepatic JJ JJ O
preneoplastic JJ JJ O
nodules NNS NNS O
or CC CC O
hepatocellular NN NN O
carcinomas NN NN O
developed VBN VBN O
in IN IN O
rats NNS NNS O
fed VBN VBN O
the DT DT O
plain JJ JJ O
choline NN NN B-CHEM
- - - O
supplemented JJ JJ O
diet NN NN O
, , , O
while IN IN O
one CD CD O
preneoplastic JJ JJ O
nodule NN NN O
and CC CC O
one CD CD O
hepatocellular JJ JJ O
carcinoma NN NN O
developed VBN VBN O
in IN IN O
two CD CD O
rats NNS NNS O
fed VBD VBD O
the DT DT O
same JJ JJ O
diet NN NN O
containing VBG VBG O
phenobarbital NN NN B-CHEM
. . . O

The DT DT O
incidence NN NN O
of IN IN O
preneoplastic JJ JJ O
nodules NNS NNS O
and CC CC O
of IN IN O
hepatocellular NN NN O
carcinomas NN NN O
was VBD VBD O
10 CD CD O
% NN NN O
and CC CC O
37 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
in IN IN O
rats NNS NNS O
fed VBN VBN O
the DT DT O
plain JJ JJ O
choline NN NN B-CHEM
- - - O
devoid JJ JJ O
diet NN NN O
, , , O
and CC CC O
17 CD CD O
% NN NN O
and CC CC O
30 CD CD O
% NN NN O
, , , O
in IN IN O
rats NNS NNS O
fed VBN VBN O
the DT DT O
phenobarbital JJ JJ B-CHEM
- - - O
containing VBG VBG O
choline NN NN B-CHEM
- - - O
devoid JJ JJ O
diet NN NN O
. . . O

The DT DT O
results NNS NNS O
evinced VBD VBD O
no DT DT O
enhancement NN NN O
of IN IN O
the DT DT O
hepatocarcinogenicity NN NN O
of IN IN O
the DT DT O
choline NN NN B-CHEM
- - - O
devoid JJ JJ O
diet NN NN O
by IN IN O
phenobarbital NN NN B-CHEM
. . . O

Sporadic NNP NNP O
neoplastic JJ JJ O
lesions NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
organs NNS NNS O
other JJ JJ O
than IN IN O
the DT DT O
liver NN NN O
of IN IN O
some DT DT O
of IN IN O
the DT DT O
animals NNS NNS O
, , , O
irrespective JJ JJ O
of IN IN O
the DT DT O
diet NN NN O
fed VBN VBN O
. . . O

On IN IN O
two CD CD O
paradoxical JJ JJ O
side NN NN O
- - - O
effects NNS NNS O
of IN IN O
prednisolone NN NN B-CHEM
in IN IN O
rats NNS NNS O
, , , O
ribosomal NN NN O
RNA NNP NNP O
biosyntheses NNS NNS O
, , , O
and CC CC O
a DT DT O
mechanism NN NN O
of IN IN O
action NN NN O
. . . O

Liver NNP NNP O
enlargement NN NN O
and CC CC O
muscle NN NN O
wastage NN NN O
occurred VBD VBD O
in IN IN O
Wistar NNP NNP O
rats NNS NNS O
following VBG VBG O
the DT DT O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
prednisolone NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
liver NN NN O
both DT DT O
the DT DT O
content NN NN O
of IN IN O
RNA NNP NNP O
and CC CC O
the DT DT O
biosynthesis NN NN O
of IN IN O
ribosomal NN NN O
RNA NNP NNP O
increased VBD VBD O
while IN IN O
both DT DT O
the DT DT O
RNA NNP NNP O
content NN NN O
and CC CC O
ribosomal NN NN O
RNA NNP NNP O
biosynthesis NN NN O
were VBD VBD O
reduced VBN VBN O
in IN IN O
the DT DT O
gastrocnemius NN NN O
muscle NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
drug NN NN O
acted VBD VBD O
in IN IN O
a DT DT O
selective JJ JJ O
and CC CC O
tissue NN NN O
- - - O
specific JJ JJ O
manner NN NN O
to TO TO O
enhance VB VB O
ribosomal NN NN O
RNA NNP NNP O
synthesis NN NN O
in IN IN O
the DT DT O
liver NN NN O
and CC CC O
depress NNS NNS O
such JJ JJ O
synthesis NN NN O
in IN IN O
the DT DT O
muscle NN NN O
. . . O

This DT DT O
view NN NN O
supports VBZ VBZ O
the DT DT O
contention NN NN O
that IN IN O
the DT DT O
liver NN NN O
and CC CC O
muscle NN NN O
are VBP VBP O
independent JJ JJ O
sites NNS NNS O
of IN IN O
prednisolone NN NN B-CHEM
action NN NN O
. . . O

Differential NNP NNP O
effects NNS NNS O
of IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
hexachlorocyclohexane NN NN I-CHEM
( ( ( O
lindane NN NN B-CHEM
) ) ) O
on IN IN O
pharmacologically RB RB O
- : : O
induced JJ JJ O
seizures NNS NNS O
. . . O

Gamma NNP NNP B-CHEM
- : : I-CHEM
hexachlorocyclohexane NN NN I-CHEM
( ( ( O
gamma NN NN B-CHEM
- - - I-CHEM
HCH NNP NNP I-CHEM
) ) ) O
, , , O
the DT DT O
active JJ JJ O
ingredient NN NN O
of IN IN O
the DT DT O
insecticide NN NN O
lindane NN NN B-CHEM
, , , O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
decrease VB VB O
seizure NN NN O
threshold NN NN O
to TO TO O
pentylenetrazol NN NN O
( ( ( O
PTZ NNP NNP B-CHEM
) ) ) O
3 CD CD O
h NN NN O
after IN IN O
exposure NN NN O
to TO TO O
gamma VB VB B-CHEM
- : : I-CHEM
HCH NNP NNP I-CHEM
and CC CC O
conversely RB RB O
increase VB VB O
threshold NN NN O
to TO TO O
PTZ NNP NNP B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
24 CD CD O
h NN NN O
after IN IN O
exposure NN NN O
to TO TO O
gamma VB VB B-CHEM
- : : I-CHEM
HCH NNP NNP I-CHEM
( ( ( O
Vohland NNP NNP O
et CC CC O
al NN NN O
. . . O
1981 CD CD O
) ) ) O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
the DT DT O
severity NN NN O
of IN IN O
response NN NN O
to TO TO O
other JJ JJ O
seizure NN NN O
- - - O
inducing VBG VBG O
agents NNS NNS O
was VBD VBD O
tested VBN VBN O
in IN IN O
mice NN NN O
1 CD CD O
and CC CC O
24 CD CD O
h NN NN O
after IN IN O
intraperitoneal JJ JJ O
administration NN NN O
of IN IN O
80 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
gamma NN NN B-CHEM
- : : I-CHEM
HCH NNP NNP I-CHEM
. . . O

One CD CD O
hour NN NN O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
HCH NNP NNP I-CHEM
, , , O
the DT DT O
activity NN NN O
of IN IN O
seizure NN NN O
- - - O
inducing VBG VBG O
agents NNS NNS O
was VBD VBD O
increased VBN VBN O
, , , O
regardless RB RB O
of IN IN O
their PRP$ PRP$ O
mechanism NN NN O
, , , O
while IN IN O
24 CD CD O
h NN NN O
after IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
HCH NNP NNP I-CHEM
a DT DT O
differential JJ JJ O
response NN NN O
was VBD VBD O
observed VBN VBN O
. . . O

Seizure NNP NNP O
activity NN NN O
due JJ JJ O
to TO TO O
PTZ NNP NNP B-CHEM
and CC CC O
picrotoxin NN NN B-CHEM
( ( ( O
PTX NNP NNP B-CHEM
) ) ) O
was VBD VBD O
significantly RB RB O
decreased VBN VBN O
; : : O
however RB RB O
, , , O
seizure NN NN O
activity NN NN O
due JJ JJ O
to TO TO O
3 CD CD B-CHEM
- : : I-CHEM
mercaptopropionic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
MPA NNP NNP B-CHEM
) ) ) O
, , , O
bicuculline NN NN B-CHEM
( ( ( O
BCC NNP NNP B-CHEM
) ) ) O
, , , O
methyl NN NN B-CHEM
6 CD CD I-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
dimethoxy NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
ethyl NN NN I-CHEM
- - - I-CHEM
B NNP NNP I-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
- - - I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
carboxylate NN NN I-CHEM
( ( ( O
DMCM NNP NNP B-CHEM
) ) ) O
, , , O
or CC CC O
strychnine NN NN B-CHEM
( ( ( O
STR NNP NNP B-CHEM
) ) ) O
was VBD VBD O
not RB RB O
different JJ JJ O
from IN IN O
control NN NN O
. . . O

In IN IN O
vitro NN NN O
, , , O
gamma NN NN B-CHEM
- - - I-CHEM
HCH NNP NNP I-CHEM
, , , O
pentylenetetrazol NN NN B-CHEM
and CC CC O
picrotoxin NN NN B-CHEM
were VBD VBD O
shown VBN VBN O
to TO TO O
inhibit NN NN O
3H CD CD B-CHEM
- : : I-CHEM
TBOB NNP NNP I-CHEM
binding VBG VBG O
in IN IN O
mouse NN NN O
whole JJ JJ O
brain NN NN O
, , , O
with IN IN O
IC50 NNP NNP O
values NNS NNS O
of IN IN O
4 CD CD O
. . . O
6 CD CD O
, , , O
404 CD CD O
and CC CC O
9 CD CD O
. . . O
4 CD CD O
microM NN NN O
, , , O
respectively RB RB O
. . . O

MPA NNP NNP B-CHEM
, , , O
BCC NNP NNP B-CHEM
, , , O
DMCM NNP NNP B-CHEM
, , , O
and CC CC O
STR NNP NNP B-CHEM
showed VBD VBD O
no DT DT O
inhibition NN NN O
of IN IN O
3H CD CD B-CHEM
- : : I-CHEM
TBOB NNP NNP I-CHEM
( ( ( O
t NN NN B-CHEM
- - - I-CHEM
butyl NN NN I-CHEM
bicyclo NN NN I-CHEM
- : : I-CHEM
orthobenzoate NN NN I-CHEM
) ) ) O
binding JJ JJ O
at IN IN O
concentrations NNS NNS O
of IN IN O
100 CD CD O
micron NN NN O
. . . O

The DT DT O
pharmacological JJ JJ O
challenge NN NN O
data NNS NNS O
suggest VBP VBP O
that IN IN O
tolerance NN NN O
may MD MD O
occur VB VB O
to TO TO O
seizure VB VB O
activity NN NN O
induced VBN VBN O
by IN IN O
PTZ NNP NNP B-CHEM
and CC CC O
PTX NNP NNP B-CHEM
24 CD CD O
h NN NN O
after IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
HCH NNP NNP I-CHEM
, , , O
since IN IN O
the DT DT O
response NN NN O
to TO TO O
only RB RB O
these DT DT O
two CD CD O
seizure NN NN O
- : : O
inducing VBG VBG O
agents NNS NNS O
is VBZ VBZ O
decreased VBN VBN O
. . . O

The DT DT O
in IN IN O
vitro NN NN O
data NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
site NN NN O
responsible JJ JJ O
for IN IN O
the DT DT O
decrease NN NN O
in IN IN O
seizure NN NN O
activity NN NN O
24 CD CD O
h NN NN O
after IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
HCH NNP NNP I-CHEM
may MD MD O
be VB VB O
the DT DT O
GABA NNP NNP B-CHEM
- : : O
A DT DT O
receptor NN NN O
- - - O
linked VBN VBN O
chloride NN NN O
channel NN NN O
. . . O

Tolerance NNP NNP O
and CC CC O
antiviral JJ JJ O
effect NN NN O
of IN IN O
ribavirin NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
Argentine NNP NNP O
hemorrhagic JJ JJ O
fever NN NN O
. . . O

Tolerance NNP NNP O
and CC CC O
antiviral JJ JJ O
effect NN NN O
of IN IN O
ribavirin NN NN B-CHEM
was VBD VBD O
studied VBN VBN O
in IN IN O
6 CD CD O
patients NNS NNS O
with IN IN O
Argentine NNP NNP O
hemorrhagic JJ JJ O
fever NN NN O
( ( ( O
AHF NNP NNP O
) ) ) O
of IN IN O
more JJR JJR O
than IN IN O
8 CD CD O
days NNS NNS O
of IN IN O
evolution NN NN O
. . . O

Administration NNP NNP O
of IN IN O
ribavirin NN NN B-CHEM
resulted VBD VBD O
in IN IN O
a DT DT O
neutralization NN NN O
of IN IN O
viremia NN NN O
and CC CC O
a DT DT O
drop NN NN O
of IN IN O
endogenous JJ JJ O
interferon NN NN O
titers NNS NNS O
. . . O

The DT DT O
average JJ JJ O
time NN NN O
of IN IN O
death NN NN O
was VBD VBD O
delayed VBN VBN O
. . . O

A DT DT O
reversible JJ JJ O
anemia NN NN O
was VBD VBD O
the DT DT O
only RB RB O
adverse JJ JJ O
effect NN NN O
observed VBD VBD O
. . . O

From IN IN O
these DT DT O
results NNS NNS O
, , , O
we PRP PRP O
conclude VBP VBP O
that IN IN O
ribavirin NN NN B-CHEM
has VBZ VBZ O
an DT DT O
antiviral JJ JJ O
effect NN NN O
in IN IN O
advanced JJ JJ O
cases NNS NNS O
of IN IN O
AHF NNP NNP O
, , , O
and CC CC O
that DT DT O
anemia NN NN O
, , , O
the DT DT O
only JJ JJ O
secondary JJ JJ O
reaction NN NN O
observed VBD VBD O
, , , O
can MD MD O
be VB VB O
easily RB RB O
managed VBN VBN O
. . . O

The DT DT O
possible JJ JJ O
beneficial JJ JJ O
effect NN NN O
of IN IN O
ribavirin NN NN B-CHEM
during IN IN O
the DT DT O
initial JJ JJ O
days NNS NNS O
of IN IN O
AHF NNP NNP O
is VBZ VBZ O
discussed VBN VBN O
. . . O

Is VBZ VBZ O
the DT DT O
treatment NN NN O
of IN IN O
scabies NNS NNS O
hazardous JJ JJ O
? . . O

Treatment NN NN O
for IN IN O
scabies NNS NNS O
is VBZ VBZ O
usually RB RB O
initiated VBN VBN O
by IN IN O
general JJ JJ O
practitioners NNS NNS O
; : : O
most JJS JJS O
consider VB VB O
lindane NN NN B-CHEM
( ( ( O
gamma NN NN B-CHEM
benzene NN NN I-CHEM
hexachloride NN NN I-CHEM
) ) ) O
the DT DT O
treatment NN NN O
of IN IN O
choice NN NN O
. . . O

Lindane NNP NNP B-CHEM
is VBZ VBZ O
also RB RB O
widely RB RB O
used VBN VBN O
as IN IN O
an DT DT O
agricultural JJ JJ O
and CC CC O
industrial JJ JJ O
pesticide NN NN O
, , , O
and CC CC O
as IN IN O
a DT DT O
result NN NN O
the DT DT O
toxic JJ JJ O
profile NN NN O
of IN IN O
this DT DT O
insecticide NN NN O
is VBZ VBZ O
well RB RB O
understood VBN VBN O
. . . O

Evidence NN NN O
is VBZ VBZ O
accumulating VBG VBG O
that IN IN O
lindane NN NN B-CHEM
can MD MD O
be VB VB O
toxic JJ JJ O
to TO TO O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
and CC CC O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
aplastic JJ JJ O
anaemia NN NN O
. . . O

Preparations NNP NNP O
containing VBG VBG O
lindane NN NN B-CHEM
continue VB VB O
to TO TO O
be VB VB O
sold VBN VBN O
over IN IN O
the DT DT O
counter NN NN O
and CC CC O
may MD MD O
represent VB VB O
a DT DT O
hazard NN NN O
to TO TO O
poorly RB RB O
informed VBN VBN O
patients NNS NNS O
. . . O

This DT DT O
literature NN NN O
review NN NN O
suggests VBZ VBZ O
that IN IN O
general JJ JJ O
practitioners NNS NNS O
should MD MD O
prescribe VB VB O
scabicides NNS NNS O
with IN IN O
increased VBN VBN O
caution NN NN O
for IN IN O
certain JJ JJ O
at IN IN O
- - - O
risk NN NN O
groups NNS NNS O
, , , O
and CC CC O
give VB VB O
adequate JJ JJ O
warnings NNS NNS O
regarding VBG VBG O
potential JJ JJ O
toxicity NN NN O
. . . O

Mouse NNP NNP O
strain NN NN O
- : : O
dependent JJ JJ O
effect NN NN O
of IN IN O
amantadine NN NN B-CHEM
on IN IN O
motility NN NN O
and CC CC O
brain NN NN O
biogenic JJ JJ O
amines NNS NNS B-CHEM
. . . O

The DT DT O
effect NN NN O
of IN IN O
amantadine NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
injected JJ JJ O
i NNP NNP O
. . . O
p NN NN O
. . . O
in IN IN O
6 CD CD O
increments NNS NNS O
of IN IN O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
each DT DT O
over IN IN O
30 CD CD O
hr NN NN O
, , , O
on IN IN O
mouse NN NN O
motility NN NN O
and CC CC O
whole JJ JJ O
brain NN NN O
content NN NN O
of IN IN O
selected VBN VBN O
biogenic JJ JJ O
amines NNS NNS B-CHEM
and CC CC O
major JJ JJ O
metabolites NNS NNS O
was VBD VBD O
studied VBN VBN O
in IN IN O
4 CD CD O
strains NNS NNS O
of IN IN O
mice NNS NNS O
. . . O

These DT DT O
were VBD VBD O
the DT DT O
albino NN NN O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
ICR NNP NNP O
and CC CC O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
, , , O
the DT DT O
black JJ JJ O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
and CC CC O
the DT DT O
brown JJ JJ O
CDF NNP NNP O
- : : O
I PRP PRP O
mouse NN NN O
strains NNS NNS O
. . . O

Amantadine NNP NNP B-CHEM
treatment NN NN O
produced VBD VBD O
a DT DT O
biphasic JJ JJ O
effect NN NN O
on IN IN O
mouse NN NN O
motility NN NN O
. . . O

The DT DT O
initial JJ JJ O
dose NN NN O
of IN IN O
amantadine NN NN B-CHEM
depressed VBN VBN O
locomotor NN NN O
activity NN NN O
in IN IN O
all DT DT O
mouse NN NN O
strains NNS NNS O
studied VBN VBN O
with IN IN O
the DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mice NN NN O
being VBG VBG O
the DT DT O
most RBS RBS O
sensitive JJ JJ O
. . . O

Subsequent NNP NNP O
amantadine NN NN B-CHEM
treatments NNS NNS O
produced VBN VBN O
enhancement NN NN O
of IN IN O
motility NN NN O
from IN IN O
corresponding JJ JJ O
control NN NN O
in IN IN O
all DT DT O
mouse NN NN O
strains NNS NNS O
with IN IN O
the DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mice NN NN O
being VBG VBG O
the DT DT O
least JJS JJS O
sensitive JJ JJ O
. . . O

The DT DT O
locomotor NN NN O
activity NN NN O
was VBD VBD O
decreased VBN VBN O
from IN IN O
corresponding JJ JJ O
controls NNS NNS O
in IN IN O
all DT DT O
strains NNS NNS O
studied VBN VBN O
, , , O
except IN IN O
for IN IN O
the DT DT O
ICR NNP NNP O
mice NN NN O
, , , O
during IN IN O
an DT DT O
overnight JJ JJ O
drug NN NN O
- - - O
free JJ JJ O
period NN NN O
following VBG VBG O
the DT DT O
fourth JJ JJ O
amantadine NN NN B-CHEM
treatment NN NN O
. . . O

Readministration NNP NNP O
of IN IN O
amantadine NN NN B-CHEM
, , , O
after IN IN O
a DT DT O
drug NN NN O
- - - O
free JJ JJ O
overnight JJ JJ O
period NN NN O
, , , O
increased VBN VBN O
motility NN NN O
from IN IN O
respective JJ JJ O
saline NN NN O
control NN NN O
in IN IN O
all DT DT O
strains NNS NNS O
with IN IN O
exception NN NN O
of IN IN O
the DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mice NN NN O
where WRB WRB O
suppression NN NN O
of IN IN O
motility NN NN O
occurred VBD VBD O
. . . O

Treatment NN NN O
with IN IN O
amantadine NN NN B-CHEM
did VBD VBD O
not RB RB O
alter VB VB O
whole JJ JJ O
brain NN NN O
dopamine NN NN B-CHEM
levels NNS NNS O
but CC CC O
decreased VBD VBD O
the DT DT O
amounts NNS NNS O
of IN IN O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydroxyphenylacetic JJ JJ I-CHEM
acid NN NN I-CHEM
in IN IN O
the DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mice NN NN O
compared VBN VBN O
to TO TO O
saline NN NN O
control NN NN O
. . . O

Conversely RB RB O
, , , O
brain NN NN O
normetanephrine NN NN B-CHEM
concentration NN NN O
was VBD VBD O
increased VBN VBN O
from IN IN O
saline NN NN O
control NN NN O
by IN IN O
amantadine NN NN B-CHEM
in IN IN O
the DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mice NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
a DT DT O
strain NN NN O
- - - O
dependent JJ JJ O
effect NN NN O
of IN IN O
amantadine NN NN B-CHEM
on IN IN O
motility NN NN O
and CC CC O
indicate VBP VBP O
a DT DT O
differential JJ JJ O
response NN NN O
to TO TO O
the DT DT O
acute JJ JJ O
and CC CC O
multiple JJ JJ O
dose NN NN O
regimens NNS NNS O
used VBN VBN O
. . . O

The DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mouse NN NN O
was VBD VBD O
the DT DT O
most RBS RBS O
sensitive JJ JJ O
strain NN NN O
and CC CC O
could MD MD O
serve VB VB O
as IN IN O
the DT DT O
strain NN NN O
of IN IN O
choice NN NN O
for IN IN O
evaluating VBG VBG O
the DT DT O
side NN NN O
effects NNS NNS O
of IN IN O
amantadine NN NN B-CHEM
. . . O

The DT DT O
biochemical JJ JJ O
results NNS NNS O
of IN IN O
brain NN NN O
biogenic JJ JJ O
amines NNS NNS B-CHEM
of IN IN O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mouse NN NN O
strain NN NN O
suggest VBP VBP O
a DT DT O
probable JJ JJ O
decrease NN NN O
of IN IN O
catecholamine NN NN B-CHEM
turnover NN NN O
rate NN NN O
and CC CC O
/ NN NN O
or CC CC O
metabolism NN NN O
by IN IN O
monoamine NN NN O
oxidase NN NN O
and CC CC O
a DT DT O
resulting VBG VBG O
increase NN NN O
in IN IN O
O NNP NNP O
- : : O
methylation NN NN O
of IN IN O
norepinephrine NN NN B-CHEM
which WDT WDT O
may MD MD O
account VB VB O
for IN IN O
a DT DT O
behavioral JJ JJ O
depression NN NN O
caused VBN VBN O
by IN IN O
amantadine NN NN B-CHEM
in IN IN O
the DT DT O
BALB NNP NNP O
/ NN NN O
C NNP NNP O
mice NN NN O
. . . O

Chloroacetaldehyde NNP NNP B-CHEM
and CC CC O
its PRP$ PRP$ O
contribution NN NN O
to TO TO O
urotoxicity NN NN O
during IN IN O
treatment NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
or CC CC O
ifosfamide NN NN B-CHEM
. . . O

An DT DT O
experimental JJ JJ O
study NN NN O
/ NN NN O
short JJ JJ O
communication NN NN O
. . . O

Based VBN VBN O
on IN IN O
clinical JJ JJ O
data NNS NNS O
, , , O
indicating VBG VBG O
that IN IN O
chloroacetaldehyde NN NN B-CHEM
( ( ( O
CAA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
important JJ JJ O
metabolite NN NN O
of IN IN O
oxazaphosphorine NN NN O
cytostatics NNS NNS O
, , , O
an DT DT O
experimental JJ JJ O
study NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
in IN IN O
order NN NN O
to TO TO O
elucidate VB VB O
the DT DT O
role NN NN O
of IN IN O
CAA NNP NNP B-CHEM
in IN IN O
the DT DT O
development NN NN O
of IN IN O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

The DT DT O
data NNS NNS O
demonstrate VBP VBP O
that IN IN O
CAA NNP NNP B-CHEM
after IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
administration NN NN O
does VBZ VBZ O
not RB RB O
contribute VB VB O
to TO TO O
bladder VB VB O
damage NN NN O
. . . O

When WRB WRB O
instilled VBN VBN O
directly RB RB O
into IN IN O
the DT DT O
bladder NN NN O
, , , O
CAA NNP NNP B-CHEM
exerts NNS NNS O
urotoxic JJ JJ O
effects NNS NNS O
, , , O
it PRP PRP O
is VBZ VBZ O
, , , O
however RB RB O
, , , O
susceptible JJ JJ O
to TO TO O
detoxification NN NN O
with IN IN O
mesna NN NN B-CHEM
. . . O

Source NNP NNP O
of IN IN O
pain NN NN O
and CC CC O
primitive JJ JJ O
dysfunction NN NN O
in IN IN O
migraine NN NN O
: : : O
an DT DT O
identical JJ JJ O
site NN NN O
? . . O

Twenty NNP NNP O
common JJ JJ O
migraine NN NN O
patients NNS NNS O
received VBD VBD O
a DT DT O
one CD CD O
sided VBD VBD O
frontotemporal JJ JJ O
application NN NN O
of IN IN O
nitroglycerin NN NN B-CHEM
( ( ( O
10 CD CD O
patients NNS NNS O
) ) ) O
or CC CC O
placebo NN NN O
ointment NN NN O
( ( ( O
10 CD CD O
patients NNS NNS O
) ) ) O
in IN IN O
a DT DT O
double JJ JJ O
blind JJ JJ O
study NN NN O
. . . O

Early RB RB O
onset VBN VBN O
migraine JJ JJ O
attacks NNS NNS O
were VBD VBD O
induced VBN VBN O
by IN IN O
nitroglycerin NN NN B-CHEM
in IN IN O
seven CD CD O
out IN IN O
of IN IN O
10 CD CD O
patients NNS NNS O
versus CC CC O
no DT DT O
patient NN NN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

Subsequently RB RB O
20 CD CD O
migraine NN NN O
patients NNS NNS O
, , , O
who WP WP O
developed VBD VBD O
an DT DT O
early JJ JJ O
onset NN NN O
attack NN NN O
with IN IN O
frontotemporal JJ JJ O
nitroglycerin NN NN B-CHEM
, , , O
received VBD VBD O
the DT DT O
drug NN NN O
in IN IN O
a DT DT O
second JJ JJ O
induction NN NN O
test NN NN O
at IN IN O
other JJ JJ O
body NN NN O
areas NNS NNS O
. . . O

No DT DT O
early JJ JJ O
onset NN NN O
migraine NN NN O
was VBD VBD O
observed VBN VBN O
. . . O

Thus RB RB O
the DT DT O
migraine NN NN O
- - - O
inducing VBG VBG O
effect NN NN O
of IN IN O
nitroglycerin NN NN B-CHEM
seems VBZ VBZ O
to TO TO O
depend VB VB O
on IN IN O
direct JJ JJ O
stimulation NN NN O
of IN IN O
the DT DT O
habitual JJ JJ O
site NN NN O
of IN IN O
pain NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
the DT DT O
frontotemporal JJ JJ O
region NN NN O
is VBZ VBZ O
of IN IN O
crucial JJ JJ O
importance NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
a DT DT O
migraine NN NN O
crisis NN NN O
. . . O

This DT DT O
is VBZ VBZ O
not RB RB O
consistent JJ JJ O
with IN IN O
a DT DT O
CNS NNP NNP O
origin NN NN O
of IN IN O
migraine NN NN O
attack NN NN O
. . . O

Hypersensitivity NNP NNP O
to TO TO O
carbamazepine VB VB B-CHEM
presenting VBG VBG O
with IN IN O
a DT DT O
leukemoid NN NN O
reaction NN NN O
, , , O
eosinophilia NN NN O
, , , O
erythroderma NN NN O
, , , O
and CC CC O
renal JJ JJ O
failure NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
patient NN NN O
in IN IN O
whom WP WP O
hypersensitivity NN NN O
to TO TO O
carbamazepine VB VB B-CHEM
presented VBN VBN O
with IN IN O
generalized JJ JJ O
erythroderma NN NN O
, , , O
a DT DT O
severe JJ JJ O
leukemoid NN NN O
reaction NN NN O
, , , O
eosinophilia NN NN O
, , , O
hyponatremia NN NN O
, , , O
and CC CC O
renal JJ JJ O
failure NN NN O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
report NN NN O
of IN IN O
such JJ JJ O
an DT DT O
unusual JJ JJ O
reaction NN NN O
to TO TO O
carbamazepine VB VB B-CHEM
. . . O

Fluoxetine NNP NNP B-CHEM
- : : O
induced JJ JJ O
akathisia NN NN O
: : : O
clinical JJ JJ O
and CC CC O
theoretical JJ JJ O
implications NNS NNS O
. . . O

Five CD CD O
patients NNS NNS O
receiving VBG VBG O
fluoxetine NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
obsessive JJ JJ O
compulsive JJ JJ O
disorder NN NN O
or CC CC O
major JJ JJ O
depression NN NN O
developed VBN VBN O
akathisia NN NN O
. . . O

The DT DT O
typical JJ JJ O
fluoxetine NN NN B-CHEM
- - - O
induced JJ JJ O
symptoms NNS NNS O
of IN IN O
restlessness NN NN O
, , , O
constant JJ JJ O
pacing NN NN O
, , , O
purposeless JJ JJ O
movements NNS NNS O
of IN IN O
the DT DT O
feet NNS NNS O
and CC CC O
legs NNS NNS O
, , , O
and CC CC O
marked VBD VBD O
anxiety NN NN O
were VBD VBD O
indistinguishable JJ JJ O
from IN IN O
those DT DT O
of IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
akathisia NN NN O
. . . O

Three CD CD O
patients NNS NNS O
who WP WP O
had VBD VBD O
experienced VBN VBN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
akathisia NN NN O
in IN IN O
the DT DT O
past JJ JJ O
reported VBD VBD O
that IN IN O
the DT DT O
symptoms NNS NNS O
of IN IN O
fluoxetine NN NN B-CHEM
- - - O
induced JJ JJ O
akathisia NN NN O
were VBD VBD O
identical JJ JJ O
, , , O
although IN IN O
somewhat DT DT O
milder NN NN O
. . . O

Akathisia NNP NNP O
appeared VBD VBD O
to TO TO O
be VB VB O
a DT DT O
common JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
fluoxetine NN NN B-CHEM
and CC CC O
generally RB RB O
responded VBD VBD O
well RB RB O
to TO TO O
treatment NN NN O
with IN IN O
the DT DT O
beta NN NN O
- - - O
adrenergic JJ JJ O
antagonist NN NN O
propranolol NN NN B-CHEM
, , , O
dose NN NN O
reduction NN NN O
, , , O
or CC CC O
both DT DT O
. . . O

The DT DT O
authors NNS NNS O
suggest VBP VBP O
that IN IN O
fluoxetine JJ JJ B-CHEM
- : : O
induced JJ JJ O
akathisia NN NN O
may MD MD O
be VB VB O
caused VBN VBN O
by IN IN O
serotonergically RB RB O
mediated JJ JJ O
inhibition NN NN O
of IN IN O
dopaminergic JJ JJ O
neurotransmission NN NN O
and CC CC O
that IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
fluoxetine NN NN B-CHEM
- - - O
induced JJ JJ O
akathisia NN NN O
and CC CC O
tricyclic JJ JJ O
antidepressant NN NN B-CHEM
- - - O
induced JJ JJ O
" '' '' O
jitteriness NN NN O
" '' '' O
may MD MD O
be VB VB O
identical JJ JJ O
. . . O

Effect NN NN O
of IN IN O
converting VBG VBG O
enzyme NN NN O
inhibition NN NN O
on IN IN O
the DT DT O
course NN NN O
of IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
the DT DT O
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
( ( ( O
CEI NNP NNP O
) ) ) O
enalapril NN NN B-CHEM
was VBD VBD O
assessed VBN VBN O
in IN IN O
Munich NNP NNP O
- - - O
Wistar NNP NNP O
rats NNS NNS O
with IN IN O
established VBN VBN O
adriamycin NN NN B-CHEM
nephrosis NN NN O
. . . O

Rats NNP NNP O
were VBD VBD O
given VBN VBN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
adriamycin NN NN B-CHEM
and CC CC O
one CD CD O
month NN NN O
later RB RB O
divided VBD VBD O
into IN IN O
four CD CD O
groups NNS NNS O
matched VBD VBD O
for IN IN O
albuminuria NN NN O
, , , O
blood NN NN O
pressure NN NN O
, , , O
and CC CC O
plasma NN NN O
albumin NN NN O
concentration NN NN O
. . . O

Groups NNS NNS O
1 CD CD O
and CC CC O
3 CD CD O
remained VBD VBD O
untreated JJ JJ O
while IN IN O
groups NNS NNS O
2 CD CD O
and CC CC O
4 CD CD O
received VBD VBD O
enalapril NN NN B-CHEM
. . . O

Groups NNS NNS O
1 CD CD O
and CC CC O
2 CD CD O
underwent JJ JJ O
micropuncture NN NN O
studies NNS NNS O
after IN IN O
10 CD CD O
days NNS NNS O
. . . O

These DT DT O
short JJ JJ O
- - - O
term NN NN O
studies NNS NNS O
showed VBD VBD O
that IN IN O
enalapril NN NN B-CHEM
reduced VBD VBD O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
101 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
vs NNS NNS O
. . . O
124 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
group NN NN O
2 CD CD O
vs NNS NNS O
. . . O
1 CD CD O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
glomerular JJ JJ O
capillary JJ JJ O
pressure NN NN O
( ( ( O
54 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
vs NNS NNS O
. . . O
61 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
without IN IN O
reducing VBG VBG O
albuminuria NN NN O
( ( ( O
617 CD CD O
+ NN NN O
/ NN NN O
- : : O
50 CD CD O
vs NNS NNS O
. . . O
570 CD CD O
+ NN NN O
/ NN NN O
- : : O
47 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
or CC CC O
GFR NNP NNP O
( ( ( O
1 CD CD O
. . . O
03 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
04 CD CD O
vs NNS NNS O
. . . O
1 CD CD O
. . . O
04 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
11 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
) ) ) O
. . . O

Groups NNS NNS O
3 CD CD O
and CC CC O
4 CD CD O
were VBD VBD O
studied VBN VBN O
at IN IN O
four CD CD O
and CC CC O
at IN IN O
six CD CD O
months NNS NNS O
to TO TO O
assess VB VB O
the DT DT O
effect NN NN O
of IN IN O
enalapril NN NN B-CHEM
on IN IN O
progression NN NN O
of IN IN O
renal JJ JJ O
injury NN NN O
in IN IN O
adriamycin NN NN B-CHEM
nephrosis NN NN O
. . . O

Chronic NNP NNP O
enalapril NN NN B-CHEM
treatment NN NN O
reduced VBN VBN O
blood NN NN O
pressure NN NN O
without IN IN O
reducing VBG VBG O
albuminuria NN NN O
in IN IN O
group NN NN O
4 CD CD O
. . . O

Untreated NNP NNP O
group NN NN O
3 CD CD O
rats NNS NNS O
exhibited VBD VBD O
a DT DT O
progressive JJ JJ O
reduction NN NN O
in IN IN O
GFR NNP NNP O
( ( ( O
0 CD CD O
. . . O
35 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
08 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
at IN IN O
4 CD CD O
months NNS NNS O
, , , O
0 CD CD O
. . . O
27 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
07 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
at IN IN O
6 CD CD O
months NNS NNS O
) ) ) O
. . . O

Enalapril NNP NNP B-CHEM
treatment NN NN O
blunted VBD VBD O
but CC CC O
did VBD VBD O
not RB RB O
prevent VB VB O
reduction NN NN O
in IN IN O
GFR NNP NNP O
in IN IN O
group NN NN O
4 CD CD O
( ( ( O
0 CD CD O
. . . O
86 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
15 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
at IN IN O
4 CD CD O
months NNS NNS O
, , , O
0 CD CD O
. . . O
69 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
13 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
at IN IN O
6 CD CD O
months NNS NNS O
, , , O
both DT DT O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
vs NNS NNS O
. . . O
group NN NN O
3 CD CD O
) ) ) O
. . . O

Reduction NNP NNP O
in IN IN O
GFR NNP NNP O
was VBD VBD O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
glomerular NN NN O
sclerosis NN NN O
in IN IN O
both DT DT O
treated VBN VBN O
and CC CC O
untreated JJ JJ O
rats NNS NNS O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Clotiazepam NNP NNP B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
hepatitis NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
acute JJ JJ O
hepatitis NN NN O
with IN IN O
extensive JJ JJ O
hepatocellular NN NN O
necrosis NN NN O
, , , O
7 CD CD O
months NNS NNS O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
administration NN NN O
of IN IN O
clotiazepam NN NN B-CHEM
, , , O
a DT DT O
thienodiazepine NN NN B-CHEM
derivative JJ JJ O
. . . O

Clotiazepam NNP NNP B-CHEM
withdrawal NN NN O
was VBD VBD O
followed VBN VBN O
by IN IN O
prompt NN NN O
recovery NN NN O
. . . O

The DT DT O
administration NN NN O
of IN IN O
several JJ JJ O
benzodiazepines NNS NNS B-CHEM
, , , O
chemically RB RB O
related VBN VBN O
to TO TO O
clotiazepam NN NN B-CHEM
, , , O
did VBD VBD O
not RB RB O
interfere VB VB O
with IN IN O
recovery NN NN O
and CC CC O
did VBD VBD O
not RB RB O
induce VB VB O
any DT DT O
relapse NN NN O
of IN IN O
hepatitis NN NN O
. . . O

This DT DT O
observation NN NN O
shows VBZ VBZ O
that IN IN O
clotiazepam NN NN B-CHEM
can MD MD O
induce VB VB O
acute JJ JJ O
hepatitis NN NN O
and CC CC O
suggests VBZ VBZ O
that IN IN O
there EX EX O
is VBZ VBZ O
no DT DT O
cross NN NN O
hepatotoxicity NN NN O
between IN IN O
clotiazepam NN NN B-CHEM
and CC CC O
several JJ JJ O
benzodiazepines NNS NNS B-CHEM
. . . O

5 CD CD B-CHEM
- : : I-CHEM
azacytidine NN NN I-CHEM
potentiates NNS NNS O
initiation NN NN O
induced VBN VBN O
by IN IN O
carcinogens NNS NNS O
in IN IN O
rat NN NN O
liver NN NN O
. . . O

To TO TO O
test VB VB O
the DT DT O
validity NN NN O
of IN IN O
the DT DT O
hypothesis NNS NNS O
that DT DT O
hypomethylation NN NN O
of IN IN O
DNA NNP NNP O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
initiation NN NN O
of IN IN O
carcinogenic JJ JJ O
process NN NN O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
azacytidine NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
AzC NNP NNP I-CHEM
) ) ) O
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
DNA NNP NNP O
methylation NN NN O
, , , O
was VBD VBD O
given VBN VBN O
to TO TO O
rats NNS NNS O
during IN IN O
the DT DT O
phase NN NN O
of IN IN O
repair NN NN O
synthesis NN NN O
induced VBN VBN O
by IN IN O
the DT DT O
three CD CD O
carcinogens NNS NNS O
, , , O
benzo NN NN B-CHEM
[ NN NN I-CHEM
a DT DT I-CHEM
] NN NN I-CHEM
- - - I-CHEM
pyrene NN NN I-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
nitrosourea NN NN I-CHEM
( ( ( O
60 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
1 CD CD B-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
dimethylhydrazine NN NN I-CHEM
( ( ( O
1 CD CD B-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
DMH NNP NNP I-CHEM
) ) ) O
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

The DT DT O
initiated JJ JJ O
hepatocytes NNS NNS O
in IN IN O
the DT DT O
liver NN NN O
were VBD VBD O
assayed VBN VBN O
as IN IN O
the DT DT O
gamma NN NN O
- - - O
glutamyltransferase NN NN O
( ( ( O
gamma NN NN O
- - - O
GT NNP NNP O
) ) ) O
positive JJ JJ O
foci NN NN O
formed VBD VBD O
following VBG VBG O
a DT DT O
2 CD CD O
- : : O
week NN NN O
selection NN NN O
regimen NNS NNS O
consisting VBG VBG O
of IN IN O
dietary JJ JJ O
0 CD CD O
. . . O
02 CD CD O
% NN NN O
2 CD CD B-CHEM
- : : I-CHEM
acetylaminofluorene NN NN I-CHEM
coupled VBN VBN O
with IN IN O
a DT DT O
necrogenic JJ JJ O
dose NN NN O
of IN IN O
CCl4 NNP NNP B-CHEM
. . . O

The DT DT O
results NNS NNS O
obtained VBD VBD O
indicate VBP VBP O
that IN IN O
with IN IN O
all DT DT O
three CD CD O
carcinogens NNS NNS O
, , , O
administration NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
AzC NNP NNP I-CHEM
during IN IN O
repair NN NN O
synthesis NN NN O
increased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
initiated JJ JJ O
hepatocytes NNS NNS O
, , , O
for IN IN O
example NN NN O
10 CD CD O
- : : O
20 CD CD O
foci NN NN O
/ NN NN O
cm2 NN NN O
in IN IN O
5 CD CD B-CHEM
- : : I-CHEM
AzC NNP NNP I-CHEM
and CC CC O
carcinogen NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
compared VBN VBN O
with IN IN O
3 CD CD O
- : : O
5 CD CD O
foci NN NN O
/ NN NN O
cm2 NN NN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
carcinogen NN NN O
only RB RB O
. . . O

Administration NNP NNP O
of IN IN O
[ NN NN B-CHEM
3H CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
azadeoxycytidine NN NN I-CHEM
during IN IN O
the DT DT O
repair NN NN O
synthesis NN NN O
induced VBN VBN O
by IN IN O
1 CD CD B-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
DMH NNP NNP I-CHEM
further RBR RBR O
showed VBD VBD O
that DT DT O
0 CD CD O
. . . O
019 CD CD O
mol CD CD O
% NN NN O
of IN IN O
cytosine NN NN B-CHEM
residues NNS NNS O
in IN IN O
DNA NNP NNP O
were VBD VBD O
substituted VBN VBN O
by IN IN O
the DT DT O
analogue NN NN O
, , , O
indicating VBG VBG O
that DT DT O
incorporation NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
AzC NNP NNP I-CHEM
occurs VBZ VBZ O
during IN IN O
repair NN NN O
synthesis NN NN O
. . . O

In IN IN O
the DT DT O
absence NN NN O
of IN IN O
the DT DT O
carcinogen NN NN O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
AzC NNP NNP I-CHEM
given VBN VBN O
after IN IN O
a DT DT O
two CD CD O
thirds NNS NNS O
partial JJ JJ O
hepatectomy NN NN O
, , , O
when WRB WRB O
its PRP$ PRP$ O
incorporation NN NN O
should MD MD O
be VB VB O
maximum NN NN O
, , , O
failed VBD VBD O
to TO TO O
induce VB VB O
any DT DT O
gamma NN NN O
- - - O
GT NNP NNP O
positive JJ JJ O
foci NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
that DT DT O
hypomethylation NN NN O
of IN IN O
DNA NNP NNP O
per IN IN O
se FW FW O
may MD MD O
not RB RB O
be VB VB O
sufficient JJ JJ O
for IN IN O
initiation NN NN O
. . . O

Perhaps RB RB O
two CD CD O
events NNS NNS O
might MD MD O
be VB VB O
necessary JJ JJ O
for IN IN O
initiation NN NN O
, , , O
the DT DT O
first JJ JJ O
caused VBN VBN O
by IN IN O
the DT DT O
carcinogen NN NN O
and CC CC O
a DT DT O
second JJ JJ O
involving NN NN O
hypomethylation NN NN O
of IN IN O
DNA NNP NNP O
. . . O

Antihypertensive NNP NNP O
drugs NNS NNS O
and CC CC O
depression NN NN O
: : : O
a DT DT O
reappraisal NN NN O
. . . O

Eighty NNP NNP O
- - - O
nine CD CD O
new JJ JJ O
referral NN NN O
hypertensive NN NN O
out IN IN O
- - - O
patients NNS NNS O
and CC CC O
46 CD CD O
new JJ JJ O
referral NN NN O
non NN NN O
- : : O
hypertensive JJ JJ O
chronically RB RB O
physically RB RB O
ill JJ JJ O
out RP RP O
- - - O
patients NNS NNS O
completed VBD VBD O
a DT DT O
mood NN NN O
rating NN NN O
scale NN NN O
at IN IN O
regular JJ JJ O
intervals NNS NNS O
for IN IN O
one CD CD O
year NN NN O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
a DT DT O
high JJ JJ O
prevalence NN NN O
of IN IN O
depression NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
of IN IN O
patients NNS NNS O
, , , O
with IN IN O
no DT DT O
preponderance NN NN O
in IN IN O
the DT DT O
hypertensive JJ JJ O
group NN NN O
. . . O

Hypertensive NNP NNP O
patients NNS NNS O
with IN IN O
psychiatric JJ JJ O
histories NNS NNS O
had VBD VBD O
a DT DT O
higher JJR JJR O
prevalence NN NN O
of IN IN O
depression NN NN O
than IN IN O
the DT DT O
comparison NN NN O
patients NNS NNS O
. . . O

This DT DT O
was VBD VBD O
accounted VBN VBN O
for IN IN O
by IN IN O
a DT DT O
significant JJ JJ O
number NN NN O
of IN IN O
depressions NNS NNS O
occurring VBG VBG O
in IN IN O
methyl NN NN B-CHEM
dopa NN NN I-CHEM
treated VBN VBN O
patients NNS NNS O
with IN IN O
psychiatric JJ JJ O
histories NNS NNS O
. . . O

Chronic JJ JJ O
active JJ JJ O
hepatitis NN NN O
associated VBN VBN O
with IN IN O
diclofenac NN NN B-CHEM
sodium NN NN I-CHEM
therapy NN NN O
. . . O

Diclofenac NNP NNP B-CHEM
sodium NN NN I-CHEM
( ( ( O
Voltarol NNP NNP B-CHEM
, , , O
Geigy NNP NNP O
Pharmaceuticals NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
non NN NN O
- - - O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
derivative NN NN O
of IN IN O
phenylacetic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Although IN IN O
generally RB RB O
well RB RB O
- - - O
tolerated JJ JJ O
, , , O
asymptomatic JJ JJ O
abnormalities NNS NNS O
of IN IN O
liver NN NN O
function NN NN O
have VBP VBP O
been VBN VBN O
recorded VBN VBN O
and CC CC O
, , , O
less RBR RBR O
commonly RB RB O
, , , O
severe JJ JJ O
hepatitis NN NN O
induced VBN VBN O
by IN IN O
diclofenac NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
described VBD VBD O
developed VBN VBN O
chronic JJ JJ O
active JJ JJ O
hepatitis NN NN O
after IN IN O
six CD CD O
months NNS NNS O
therapy NN NN O
with IN IN O
diclofenac NN NN B-CHEM
sodium NN NN I-CHEM
which WDT WDT O
progressed VBD VBD O
despite IN IN O
the DT DT O
withdrawal NN NN O
of IN IN O
the DT DT O
drug NN NN O
, , , O
a DT DT O
finding VBG VBG O
not RB RB O
previously RB RB O
reported VBD VBD O
. . . O

Arterial NNP NNP O
hypertension NN NN O
as IN IN O
a DT DT O
complication NN NN O
of IN IN O
prolonged JJ JJ O
ketoconazole NN NN B-CHEM
treatment NN NN O
. . . O

Two CD CD O
of IN IN O
14 CD CD O
patients NNS NNS O
with IN IN O
Cushing NNP NNP O
' POS POS O
s VBZ VBZ O
syndrome NN NN O
treated VBN VBN O
on IN IN O
a DT DT O
long JJ JJ O
- - - O
term NN NN O
basis NN NN O
with IN IN O
ketoconazole NN NN B-CHEM
developed VBN VBN O
sustained JJ JJ O
hypertension NN NN O
. . . O

In IN IN O
both DT DT O
cases NNS NNS O
normal JJ JJ O
plasma NN NN O
and CC CC O
urinary JJ JJ O
free JJ JJ O
cortisol NN NN B-CHEM
levels NNS NNS O
had VBD VBD O
been VBN VBN O
achieved VBN VBN O
following VBG VBG O
ketoconazole NN NN B-CHEM
therapy NN NN O
, , , O
yet RB RB O
continuous JJ JJ O
blood NN NN O
pressure NN NN O
monitoring VBG VBG O
demonstrated VBN VBN O
hypertension NN NN O
31 CD CD O
( ( ( O
patient NN NN O
1 CD CD O
) ) ) O
and CC CC O
52 CD CD O
weeks NNS NNS O
( ( ( O
patient NN NN O
2 CD CD O
) ) ) O
after IN IN O
treatment NN NN O
. . . O

In IN IN O
patient NN NN O
1 CD CD O
, , , O
plasma NN NN O
levels NNS NNS O
of IN IN O
deoxycorticosterone NN NN B-CHEM
and CC CC O
11 CD CD B-CHEM
- : : I-CHEM
deoxycortisol NN NN I-CHEM
were VBD VBD O
elevated VBN VBN O
. . . O

In IN IN O
patient NN NN O
2 CD CD O
, , , O
in IN IN O
addition NN NN O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
both DT DT O
deoxycorticosterone NN NN B-CHEM
and CC CC O
11 CD CD B-CHEM
- : : I-CHEM
deoxycortisol NN NN I-CHEM
levels NNS NNS O
, , , O
plasma NN NN O
aldosterone NN NN B-CHEM
values NNS NNS O
were VBD VBD O
raised VBN VBN O
, , , O
with IN IN O
a DT DT O
concomitant JJ JJ O
suppression NN NN O
of IN IN O
renin NN NN O
levels NNS NNS O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
show VBP VBP O
that IN IN O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
ketoconazole NN NN B-CHEM
may MD MD O
induce VB VB O
enzyme NN NN O
blockade NN NN O
leading VBG VBG O
to TO TO O
mineralocorticoid VB VB O
- - - O
related VBN VBN O
hypertension NN NN O
. . . O

Effects NNP NNP O
of IN IN O
an DT DT O
inhibitor NN NN O
of IN IN O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
( ( ( O
Captopril NNP NNP B-CHEM
) ) ) O
on IN IN O
pulmonary JJ JJ O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
due JJ JJ O
to TO TO O
intravascular JJ JJ O
coagulation NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Induction NNP NNP O
of IN IN O
intravascular JJ JJ O
coagulation NN NN O
and CC CC O
inhibition NN NN O
of IN IN O
fibrinolysis NN NN O
by IN IN O
injection NN NN O
of IN IN O
thrombin NN NN O
and CC CC O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
AMCA NNP NNP B-CHEM
) ) ) O
in IN IN O
the DT DT O
rat NN NN O
gives VBZ VBZ O
rise NN NN O
to TO TO O
pulmonary JJ JJ O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
resembling VBG VBG O
that IN IN O
occurring VBG VBG O
after IN IN O
trauma NN NN O
or CC CC O
sepsis NN NN O
in IN IN O
man NN NN O
. . . O

Injection NNP NNP O
of IN IN O
Captopril NNP NNP B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
( ( ( O
ACE NNP NNP O
) ) ) O
, , , O
reduced VBD VBD O
both DT DT O
pulmonary JJ JJ O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
in IN IN O
this DT DT O
rat NN NN O
model NN NN O
. . . O

The DT DT O
lung NN NN O
weights NNS NNS O
were VBD VBD O
lower JJR JJR O
and CC CC O
PaO2 NNP NNP O
was VBD VBD O
improved VBN VBN O
in IN IN O
rats NNS NNS O
given VBN VBN O
this DT DT O
enzyme NN NN O
- : : O
blocking VBG VBG O
agent NN NN O
. . . O

The DT DT O
contents NNS NNS O
of IN IN O
albumin NN NN O
in IN IN O
the DT DT O
lungs NNS NNS O
were VBD VBD O
not RB RB O
changed VBN VBN O
, , , O
indicating VBG VBG O
that IN IN O
Captopril NNP NNP B-CHEM
did VBD VBD O
not RB RB O
influence VB VB O
the DT DT O
extravasation NN NN O
of IN IN O
protein NN NN O
. . . O

Renal NNP NNP O
damage NN NN O
as IN IN O
reflected VBN VBN O
by IN IN O
an DT DT O
increase NN NN O
in IN IN O
serum NN NN O
urea NN NN B-CHEM
and CC CC O
in IN IN O
kidney NN NN O
weight NN NN O
was VBD VBD O
prevented VBN VBN O
by IN IN O
Captopril NNP NNP B-CHEM
. . . O

The DT DT O
amount NN NN O
of IN IN O
fibrin NN NN O
in IN IN O
the DT DT O
kidneys NNS NNS O
was VBD VBD O
also RB RB O
considerably RB RB O
lower JJR JJR O
than IN IN O
in IN IN O
animals NNS NNS O
which WDT WDT O
received VBD VBD O
thrombin NN NN O
and CC CC O
AMCA NNP NNP B-CHEM
alone RB RB O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
Captopril NNP NNP B-CHEM
on IN IN O
the DT DT O
lungs NNS NNS O
may MD MD O
be VB VB O
attributable JJ JJ O
to TO TO O
a DT DT O
vasodilatory JJ JJ O
effect NN NN O
due JJ JJ O
to TO TO O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
circulating VBG VBG O
level NN NN O
of IN IN O
Angiotension NNP NNP B-CHEM
II NNP NNP I-CHEM
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
prostacyclin NN NN B-CHEM
( ( ( O
secondary JJ JJ O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
bradykinin NN NN B-CHEM
) ) ) O
. . . O

Captopril NNP NNP B-CHEM
may MD MD O
, , , O
by IN IN O
the DT DT O
same JJ JJ O
mechanism NN NN O
, , , O
reduce VB VB O
the DT DT O
increase NN NN O
in IN IN O
glomerular NN NN O
filtration NN NN O
that WDT WDT O
is VBZ VBZ O
known VBN VBN O
to TO TO O
occur VB VB O
after IN IN O
an DT DT O
injection NN NN O
of IN IN O
thrombin NN NN O
, , , O
thereby RB RB O
diminishing VBG VBG O
the DT DT O
aggregation NN NN O
of IN IN O
fibrin NN NN O
monomers NNS NNS O
in IN IN O
the DT DT O
glomeruli NN NN O
, , , O
with IN IN O
the DT DT O
result NN NN O
that IN IN O
less JJR JJR O
fibrin NN NN O
will MD MD O
be VB VB O
deposited VBN VBN O
and CC CC O
thus RB RB O
less JJR JJR O
kidney NN NN O
damage NN NN O
will MD MD O
be VB VB O
produced VBN VBN O
. . . O

Stroke NNP NNP O
associated VBN VBN O
with IN IN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
eight CD CD O
patients NNS NNS O
in IN IN O
whom WP WP O
cocaine NN NN B-CHEM
use NN NN O
was VBD VBD O
related VBN VBN O
to TO TO O
stroke NN NN O
and CC CC O
review NN NN O
39 CD CD O
cases NNS NNS O
from IN IN O
the DT DT O
literature NN NN O
. . . O

Among IN IN O
these DT DT O
47 CD CD O
patients NNS NNS O
the DT DT O
mean NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
age NN NN O
was VBD VBD O
32 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
. . . O
1 CD CD O
years NNS NNS O
; : : O
76 CD CD O
% NN NN O
( ( ( O
34 CD CD O
/ NN NN O
45 CD CD O
) ) ) O
were VBD VBD O
men NNS NNS O
. . . O

Stroke NNP NNP O
followed VBD VBD O
cocaine NN NN B-CHEM
use NN NN O
by IN IN O
inhalation NN NN O
, , , O
intranasal NN NN O
, , , O
intravenous JJ JJ O
, , , O
and CC CC O
intramuscular JJ JJ O
routes NNS NNS O
. . . O

Intracranial NNP NNP O
aneurysms NNS NNS O
or CC CC O
arteriovenous JJ JJ O
malformations NNS NNS O
were VBD VBD O
present JJ JJ O
in IN IN O
17 CD CD O
of IN IN O
32 CD CD O
patients NNS NNS O
studied VBN VBN O
angiographically RB RB O
or CC CC O
at IN IN O
autopsy NN NN O
; : : O
cerebral JJ JJ O
vasculitis NNS NNS O
was VBD VBD O
present JJ JJ O
in IN IN O
two CD CD O
patients NNS NNS O
. . . O

Cerebral NNP NNP O
infarction NN NN O
occurred VBD VBD O
in IN IN O
10 CD CD O
patients NNS NNS O
( ( ( O
22 CD CD O
% NN NN O
) ) ) O
, , , O
intracerebral JJ JJ O
hemorrhage NN NN O
in IN IN O
22 CD CD O
( ( ( O
49 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
subarachnoid VB VB O
hemorrhage NN NN O
in IN IN O
13 CD CD O
( ( ( O
29 CD CD O
% NN NN O
) ) ) O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
( ( ( O
1 CD CD O
) ) ) O
the DT DT O
apparent JJ JJ O
incidence NN NN O
of IN IN O
stroke NN NN O
related VBN VBN O
to TO TO O
cocaine VB VB B-CHEM
use NN NN O
is VBZ VBZ O
increasing VBG VBG O
; : : O
( ( ( O
2 CD CD O
) ) ) O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
stroke NN NN O
occurs VBZ VBZ O
primarily RB RB O
in IN IN O
young JJ JJ O
adults NNS NNS O
; : : O
( ( ( O
3 CD CD O
) ) ) O
stroke NN NN O
may MD MD O
follow VB VB O
any DT DT O
route NN NN O
of IN IN O
cocaine NN NN B-CHEM
administration NN NN O
; : : O
( ( ( O
4 CD CD O
) ) ) O
stroke NN NN O
after IN IN O
cocaine NN NN B-CHEM
use NN NN O
is VBZ VBZ O
frequently RB RB O
associated VBN VBN O
with IN IN O
intracranial JJ JJ O
aneurysms NNS NNS O
and CC CC O
arteriovenous JJ JJ O
malformations NNS NNS O
; : : O
and CC CC O
( ( ( O
5 CD CD O
) ) ) O
in IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
stroke NN NN O
, , , O
the DT DT O
frequency NN NN O
of IN IN O
intracranial JJ JJ O
hemorrhage NN NN O
exceeds VBZ VBZ O
that IN IN O
of IN IN O
cerebral JJ JJ O
infarction NN NN O
. . . O

A DT DT O
randomized JJ JJ O
comparison NN NN O
of IN IN O
labetalol NN NN B-CHEM
and CC CC O
nitroprusside IN IN B-CHEM
for IN IN O
induced JJ JJ O
hypotension NN NN O
. . . O

In IN IN O
a DT DT O
randomized JJ JJ O
study NN NN O
, , , O
labetalol NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
and CC CC O
nitroprusside NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
were VBD VBD O
compared VBN VBN O
in IN IN O
20 CD CD O
patients NNS NNS O
( ( ( O
10 CD CD O
in IN IN O
each DT DT O
group NN NN O
) ) ) O
scheduled VBN VBN O
for IN IN O
major JJ JJ O
orthopedic JJ JJ O
procedures NNS NNS O
. . . O

Each DT DT O
patient NN NN O
was VBD VBD O
subjected VBN VBN O
to TO TO O
an DT DT O
identical JJ JJ O
anesthetic JJ JJ O
protocol NN NN O
and CC CC O
similar JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
reductions NNS NNS O
in IN IN O
mean NN NN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
( ( ( O
50 CD CD O
to TO TO O
55 CD CD O
mmHg NN NN O
) ) ) O
. . . O

Nitroprusside NNP NNP O
infusion NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
significant JJ JJ O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
and CC CC O
cardiac JJ JJ O
output NN NN O
; : : O
rebound NN NN O
hypertension NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
three CD CD O
patients NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
nitroprusside NN NN B-CHEM
. . . O

Labetalol NNP NNP B-CHEM
administration NN NN O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
any DT DT O
of IN IN O
these DT DT O
findings NNS NNS O
. . . O

Arterial NNP NNP O
PO2 NNP NNP B-CHEM
decreased VBD VBD O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

It PRP PRP O
was VBD VBD O
concluded VBN VBN O
that IN IN O
labetalol NN NN B-CHEM
offers VBZ VBZ O
advantages NNS NNS O
over IN IN O
nitroprusside NN NN B-CHEM
. . . O

Sodium NNP NNP B-CHEM
status NN NN O
influences VBZ VBZ O
chronic JJ JJ O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
nephrotoxicity NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
nephrotoxic JJ JJ O
potential NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
intraperitoneally RB RB O
for IN IN O
3 CD CD O
weeks NNS NNS O
) ) ) O
has VBZ VBZ O
been VBN VBN O
investigated VBN VBN O
in IN IN O
salt NN NN O
- - - O
depleted VBN VBN O
, , , O
normal JJ JJ O
- - - O
salt NN NN O
, , , O
and CC CC O
salt NN NN O
- - - O
loaded JJ JJ O
rats NNS NNS O
. . . O

In IN IN O
salt NN NN O
- - - O
depleted JJ JJ O
rats NNS NNS O
, , , O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
decreased VBD VBD O
creatinine NN NN B-CHEM
clearance NN NN O
linearly RB RB O
with IN IN O
time NN NN O
, , , O
with IN IN O
an DT DT O
85 CD CD O
% NN NN O
reduction NN NN O
by IN IN O
week NN NN O
3 CD CD O
. . . O

In IN IN O
contrast NN NN O
, , , O
in IN IN O
normal JJ JJ O
- - - O
salt NN NN O
rats NNS NNS O
creatinine NN NN B-CHEM
clearance NN NN O
was VBD VBD O
decreased VBN VBN O
but CC CC O
to TO TO O
a DT DT O
lesser JJR JJR O
extent NN NN O
at IN IN O
week NN NN O
2 CD CD O
and CC CC O
3 CD CD O
, , , O
and CC CC O
in IN IN O
salt NN NN O
- - - O
loaded JJ JJ O
rats NNS NNS O
creatinine NN NN B-CHEM
clearance NN NN O
did VBD VBD O
not RB RB O
change VB VB O
for IN IN O
2 CD CD O
weeks NNS NNS O
and CC CC O
was VBD VBD O
decreased VBN VBN O
by IN IN O
43 CD CD O
% NN NN O
at IN IN O
week NN NN O
3 CD CD O
. . . O

All DT DT O
rats NNS NNS O
in IN IN O
the DT DT O
sodium NN NN B-CHEM
- - - O
depleted JJ JJ O
group NN NN O
had VBD VBD O
histopathological JJ JJ O
evidence NN NN O
of IN IN O
patchy NN NN O
tubular JJ JJ O
cytoplasmic JJ JJ O
degeneration NN NN O
in IN IN O
tubules NNS NNS O
that WDT WDT O
was VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
any DT DT O
normal JJ JJ O
- - - O
salt NN NN O
or CC CC O
salt NN NN O
- - - O
loaded JJ JJ O
rat NN NN O
. . . O

Concentrations NNP NNP O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
in IN IN O
plasma NN NN O
were VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
among IN IN O
the DT DT O
three CD CD O
groups NNS NNS O
at IN IN O
any DT DT O
time NN NN O
during IN IN O
the DT DT O
study NN NN O
. . . O

However RB RB O
, , , O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
3 CD CD O
weeks NNS NNS O
, , , O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
levels NNS NNS O
in IN IN O
the DT DT O
kidneys NNS NNS O
and CC CC O
liver NN NN O
were VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
salt NN NN O
- - - O
depleted VBN VBN O
and CC CC O
normal JJ JJ O
- - - O
salt NN NN O
rats NNS NNS O
than IN IN O
those DT DT O
in IN IN O
salt NN NN O
- - - O
loaded JJ JJ O
rats NNS NNS O
, , , O
with IN IN O
plasma NN NN O
/ NN NN O
kidney NN NN O
ratios NN NN O
of IN IN O
21 CD CD O
, , , O
14 CD CD O
, , , O
and CC CC O
8 CD CD O
in IN IN O
salt NN NN O
- - - O
depleted VBN VBN O
, , , O
normal JJ JJ O
- - - O
salt NN NN O
, , , O
and CC CC O
salt NN NN O
- - - O
loaded JJ JJ O
rats NNS NNS O
, , , O
respectively RB RB O
. . . O

In IN IN O
conclusion NN NN O
, , , O
reductions NNS NNS O
in IN IN O
creatinine NN NN B-CHEM
clearance NN NN O
and CC CC O
renal NN NN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
accumulation NN NN O
after IN IN O
chronic JJ JJ O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
administration NN NN O
were VBD VBD O
enhanced VBN VBN O
by IN IN O
salt NN NN O
depletion NN NN O
and CC CC O
attenuated VBN VBN O
by IN IN O
sodium NN NN B-CHEM
loading NN NN O
in IN IN O
rats NNS NNS O
. . . O

Flestolol NNP NNP B-CHEM
: : : O
an DT DT O
ultra JJ JJ O
- - - O
short JJ JJ O
- - - O
acting VBG VBG O
beta NN NN O
- - - O
adrenergic JJ JJ O
blocking VBG VBG O
agent NN NN O
. . . O

Flestolol NNP NNP B-CHEM
( ( ( O
ACC NNP NNP B-CHEM
- : : I-CHEM
9089 CD CD I-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
nonselective JJ JJ O
, , , O
competitive JJ JJ O
, , , O
ultra JJ JJ O
- - - O
short JJ JJ O
- - - O
acting VBG VBG O
beta NN NN O
- - - O
adrenergic JJ JJ O
blocking VBG VBG O
agent NN NN O
, , , O
without IN IN O
any DT DT O
intrinsic JJ JJ O
sympathomimetic JJ JJ O
activity NN NN O
. . . O

Flestolol NNP NNP B-CHEM
is VBZ VBZ O
metabolized VBN VBN O
by IN IN O
plasma NN NN O
esterases NNS NNS O
and CC CC O
has VBZ VBZ O
an DT DT O
elimination NN NN O
half NN NN O
- : : O
life NN NN O
of IN IN O
approximately RB RB O
6 CD CD O
. . . O
5 CD CD O
minutes NNS NNS O
. . . O

This DT DT O
agent NN NN O
was VBD VBD O
well RB RB O
tolerated VBN VBN O
in IN IN O
healthy JJ JJ O
volunteers NNS NNS O
at IN IN O
doses NNS NNS O
up IN IN O
to TO TO O
100 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
. . . O

In IN IN O
long JJ JJ O
- - - O
term NN NN O
infusion NN NN O
studies NNS NNS O
, , , O
flestolol NN NN B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
at IN IN O
the DT DT O
effective JJ JJ O
beta NN NN O
- - - O
blocking VBG VBG O
dose NN NN O
( ( ( O
5 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) ) ) O
for IN IN O
up IN IN O
to TO TO O
seven CD CD O
days NNS NNS O
. . . O

Flestolol NNP NNP B-CHEM
blood NN NN O
concentrations NNS NNS O
increased VBN VBN O
linearly RB RB O
with IN IN O
increasing VBG VBG O
dose NN NN O
and CC CC O
good JJ JJ O
correlation NN NN O
exists VBZ VBZ O
between IN IN O
blood NN NN O
concentrations NNS NNS O
of IN IN O
flestolol NN NN B-CHEM
and CC CC O
beta NN NN O
- - - O
adrenergic JJ JJ O
blockade NN NN O
. . . O

Flestolol NNP NNP B-CHEM
produced VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
attenuation NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
tachycardia NN NN O
. . . O

Electrophysiologic NNP NNP O
and CC CC O
hemodynamic JJ JJ O
effects NNS NNS O
of IN IN O
flestolol NN NN B-CHEM
are VBP VBP O
similar JJ JJ O
to TO TO O
those DT DT O
of IN IN O
other JJ JJ O
beta NN NN O
blockers NNS NNS O
. . . O

In IN IN O
contrast NN NN O
with IN IN O
other JJ JJ O
beta NN NN O
blockers NNS NNS O
, , , O
flestolol NN NN B-CHEM
- - - O
induced JJ JJ O
effects NNS NNS O
reverse NN NN O
rapidly RB RB O
( ( ( O
within IN IN O
30 CD CD O
minutes NNS NNS O
) ) ) O
following VBG VBG O
discontinuation NN NN O
because IN IN O
of IN IN O
its PRP$ PRP$ O
short JJ JJ O
half NN NN O
- - - O
life NN NN O
. . . O

Flestolol NNP NNP B-CHEM
effectively RB RB O
reduced VBD VBD O
heart NN NN O
rate NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
supraventricular NN NN O
tachyarrhythmia NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
unstable JJ JJ O
angina NN NN O
, , , O
flestolol NN NN B-CHEM
infusion NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
safe JJ JJ O
and CC CC O
effective JJ JJ O
in IN IN O
controlling VBG VBG O
chest NN NN O
pain NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
flestolol NN NN B-CHEM
is VBZ VBZ O
a DT DT O
potent NN NN O
, , , O
well RB RB O
- - - O
tolerated JJ JJ O
, , , O
ultra JJ JJ O
- - - O
short JJ JJ O
- - - O
acting VBG VBG O
beta NN NN O
- - - O
adrenergic JJ JJ O
blocking VBG VBG O
agent NN NN O
. . . O

Use NN NN O
of IN IN O
flestolol NN NN B-CHEM
in IN IN O
the DT DT O
critical JJ JJ O
care NN NN O
setting VBG VBG O
is VBZ VBZ O
currently RB RB O
undergoing VBG VBG O
investigation NN NN O
. . . O

Immunohistochemical NNP NNP O
, , , O
electron NN NN O
microscopic NN NN O
and CC CC O
morphometric JJ JJ O
studies NNS NNS O
of IN IN O
estrogen NN NN B-CHEM
- - - O
induced JJ JJ O
rat NN NN O
prolactinomas NNS NNS O
after IN IN O
bromocriptine NN NN B-CHEM
treatment NN NN O
. . . O

To TO TO O
clarify VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
bromocriptine NN NN B-CHEM
on IN IN O
prolactinoma NN NN O
cells NNS NNS O
in IN IN O
vivo NN NN O
, , , O
immunohistochemical JJ JJ O
, , , O
ultrastructural JJ JJ O
and CC CC O
morphometrical JJ JJ O
analyses NNS NNS O
were VBD VBD O
applied VBN VBN O
to TO TO O
estrogen NN NN B-CHEM
- - - O
induced JJ JJ O
rat NN NN O
prolactinoma NN NN O
cells NNS NNS O
1 CD CD O
h NN NN O
and CC CC O
6 CD CD O
h NN NN O
after IN IN O
injection NN NN O
of IN IN O
bromocriptine NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
of IN IN O
body NN NN O
weight NN NN O
) ) ) O
. . . O

One CD CD O
h NN NN O
after IN IN O
treatment NN NN O
, , , O
serum NN NN O
prolactin NN NN O
levels NNS NNS O
decreased VBD VBD O
markedly RB RB O
. . . O

Electron NNP NNP O
microscopy NN NN O
disclosed VBD VBD O
many JJ JJ O
secretory JJ JJ O
granules NNS NNS O
, , , O
slightly RB RB O
distorted JJ JJ O
rough JJ JJ O
endoplasmic JJ JJ O
reticulum NN NN O
, , , O
and CC CC O
partially RB RB O
dilated JJ JJ O
Golgi NNP NNP O
cisternae NN NN O
in IN IN O
the DT DT O
prolactinoma NN NN O
cells NNS NNS O
. . . O

Morphometric NNP NNP O
analysis NN NN O
revealed VBD VBD O
that IN IN O
the DT DT O
volume NN NN O
density NN NN O
of IN IN O
secretory NN NN O
granules NNS NNS O
increased VBN VBN O
, , , O
while IN IN O
the DT DT O
volume NN NN O
density NN NN O
of IN IN O
cytoplasmic JJ JJ O
microtubules NNS NNS O
decreased VBD VBD O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
lowered VBD VBD O
serum NN NN O
prolactin NN NN O
levels NNS NNS O
in IN IN O
the DT DT O
early JJ JJ O
phase NN NN O
of IN IN O
bromocriptine NN NN B-CHEM
treatment NN NN O
may MD MD O
result VB VB O
from IN IN O
an DT DT O
impaired JJ JJ O
secretion NN NN O
of IN IN O
prolactin NN NN O
due JJ JJ O
to TO TO O
decreasing VBG VBG O
numbers NNS NNS O
of IN IN O
cytoplasmic JJ JJ O
microtubules NNS NNS O
. . . O

At IN IN O
6 CD CD O
h NN NN O
after IN IN O
injection NN NN O
, , , O
serum NN NN O
prolactin NN NN O
levels NNS NNS O
were VBD VBD O
still RB RB O
considerably RB RB O
lower JJR JJR O
than IN IN O
in IN IN O
controls NNS NNS O
. . . O

The DT DT O
prolactinoma NN NN O
cells NNS NNS O
at IN IN O
this DT DT O
time NN NN O
were VBD VBD O
well RB RB O
granulated VBN VBN O
, , , O
with IN IN O
vesiculated JJ JJ O
rough JJ JJ O
endoplasmic JJ JJ O
reticulum NN NN O
and CC CC O
markedly RB RB O
dilated JJ JJ O
Golgi NNP NNP O
cisternae NN NN O
. . . O

Electron NNP NNP O
microscopical JJ JJ O
immunohistochemistry NN NN O
revealed VBD VBD O
positive JJ JJ O
reaction NN NN O
products NNS NNS O
noted VBD VBD O
on IN IN O
the DT DT O
secretory NN NN O
granules NNS NNS O
, , , O
Golgi NNP NNP O
cisternae NN NN O
, , , O
and CC CC O
endoplasmic JJ JJ O
reticulum NN NN O
of IN IN O
the DT DT O
untreated JJ JJ O
rat NN NN O
prolactinoma NN NN O
cells NNS NNS O
. . . O

However RB RB O
, , , O
only RB RB O
secretory JJ JJ O
granules NNS NNS O
showed VBD VBD O
the DT DT O
positive JJ JJ O
reaction NN NN O
products NNS NNS O
for IN IN O
prolactin NN NN O
6 CD CD O
h NN NN O
after IN IN O
bromocriptine NN NN B-CHEM
treatment NN NN O
of IN IN O
the DT DT O
adenoma NN NN O
cells NNS NNS O
. . . O

An DT DT O
increase NN NN O
in IN IN O
the DT DT O
volume NN NN O
density NN NN O
of IN IN O
secretory NN NN O
granules NNS NNS O
and CC CC O
a DT DT O
decrease NN NN O
in IN IN O
the DT DT O
volume NN NN O
densities NNS NNS O
of IN IN O
rough JJ JJ O
endoplasmic JJ JJ O
reticulum NN NN O
and CC CC O
microtubules NNS NNS O
was VBD VBD O
determined VBN VBN O
by IN IN O
morphometric JJ JJ O
analysis NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
bromocriptine NN NN B-CHEM
inhibits NNS NNS O
protein NN NN O
synthesis NN NN O
as RB RB O
well RB RB O
as IN IN O
bringing VBG VBG O
about IN IN O
a DT DT O
disturbance NN NN O
of IN IN O
the DT DT O
prolactin NN NN O
secretion NN NN O
. . . O

Sulfasalazine NNP NNP B-CHEM
- : : O
induced JJ JJ O
lupus NN NN O
erythematosus NN NN O
. . . O

Pneumonitis NNP NNP O
, , , O
bilateral JJ JJ O
pleural JJ JJ O
effusions NNS NNS O
, , , O
echocardiographic JJ JJ O
evidence NN NN O
of IN IN O
cardiac JJ JJ O
tamponade NN NN O
, , , O
and CC CC O
positive JJ JJ O
autoantibodies NNS NNS O
developed VBN VBN O
in IN IN O
a DT DT O
43 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
, , , O
who WP WP O
was VBD VBD O
receiving VBG VBG O
long JJ JJ O
- - - O
term NN NN O
sulfasalazine NN NN B-CHEM
therapy NN NN O
for IN IN O
chronic JJ JJ O
ulcerative JJ JJ O
colitis NNS NNS O
. . . O

After IN IN O
cessation NN NN O
of IN IN O
the DT DT O
sulfasalazine NN NN B-CHEM
and CC CC O
completion NN NN O
of IN IN O
a DT DT O
six CD CD O
- - - O
week NN NN O
course NN NN O
of IN IN O
corticosteroids NNS NNS O
, , , O
these DT DT O
problems NNS NNS O
resolved VBD VBD O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
four CD CD O
to TO TO O
six CD CD O
months NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
patient NN NN O
had VBD VBD O
sulfasalazine JJ JJ B-CHEM
- : : O
induced JJ JJ O
lupus NN NN O
, , , O
which WDT WDT O
manifested VBD VBD O
with IN IN O
serositis NNS NNS O
and CC CC O
pulmonary JJ JJ O
parenchymal NN NN O
involvement NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
joint JJ JJ O
symptoms NNS NNS O
. . . O

Physicians NNP NNP O
who WP WP O
use VBP VBP O
sulfasalazine NN NN B-CHEM
to TO TO O
treat VB VB O
patients NNS NNS O
with IN IN O
inflammatory JJ JJ O
bowel NN NN O
disease NN NN O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
signs NNS NNS O
of IN IN O
sulfasalazine NN NN B-CHEM
- - - O
induced JJ JJ O
lupus NN NN O
syndrome NN NN O
. . . O

Chronic JJ JJ O
carbamazepine JJ JJ B-CHEM
treatment NN NN O
in IN IN O
the DT DT O
rat NN NN O
: : : O
efficacy NN NN O
, , , O
toxicity NN NN O
, , , O
and CC CC O
effect NN NN O
on IN IN O
plasma NN NN O
and CC CC O
tissue NN NN O
folate JJ JJ B-CHEM
concentrations NNS NNS O
. . . O

Folate NNP NNP B-CHEM
depletion NN NN O
has VBZ VBZ O
often RB RB O
been VBN VBN O
a DT DT O
problem NN NN O
in IN IN O
chronic JJ JJ O
antiepileptic JJ JJ O
drug NN NN O
( ( ( O
AED NNP NNP O
) ) ) O
therapy NN NN O
. . . O

Carbamazepine NNP NNP B-CHEM
( ( ( O
CBZ NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
commonly RB RB O
used VBN VBN O
AED NNP NNP O
, , , O
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
in IN IN O
some DT DT O
clinical JJ JJ O
studies NNS NNS O
. . . O

A DT DT O
rat NN NN O
model NN NN O
was VBD VBD O
developed VBN VBN O
to TO TO O
examine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
chronic JJ JJ O
CBZ NNP NNP B-CHEM
treatment NN NN O
on IN IN O
folate NN NN B-CHEM
concentrations NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
. . . O

In IN IN O
the DT DT O
course NN NN O
of IN IN O
developing VBG VBG O
this DT DT O
model NN NN O
, , , O
a DT DT O
common JJ JJ O
vehicle NN NN O
, , , O
propylene NN NN B-CHEM
glycol NN NN I-CHEM
, , , O
by IN IN O
itself PRP PRP O
in IN IN O
high JJ JJ O
doses NNS NNS O
, , , O
was VBD VBD O
found VBN VBN O
to TO TO O
exhibit NN NN O
protective JJ JJ O
properties NNS NNS O
against IN IN O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
inhibited VBN VBN O
weight NN NN O
gain NN NN O
. . . O

Seizures NNP NNP O
induced VBN VBN O
by IN IN O
hexafluorodiethyl NN NN B-CHEM
ether NN NN I-CHEM
( ( ( O
HFDE NNP NNP B-CHEM
) ) ) O
were VBD VBD O
also RB RB O
found VBN VBN O
to TO TO O
be VB VB O
a DT DT O
more RBR RBR O
sensitive JJ JJ O
measure NN NN O
of IN IN O
protection NN NN O
by IN IN O
CBZ NNP NNP B-CHEM
than IN IN O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
maximal NN NN O
electroshock NN NN O
( ( ( O
MES NNP NNP O
) ) ) O
. . . O

Oral NNP NNP O
administration NN NN O
of IN IN O
CBZ NNP NNP B-CHEM
as IN IN O
an DT DT O
aqueous JJ JJ O
suspension NN NN O
every DT DT O
8 CD CD O
h NN NN O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
250 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
was VBD VBD O
continuously RB RB O
protective JJ JJ O
against IN IN O
HFDE NNP NNP B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
was VBD VBD O
minimally RB RB O
toxic JJ JJ O
as IN IN O
measured VBN VBN O
by IN IN O
weight NN NN O
gain NN NN O
over IN IN O
8 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

The DT DT O
CBZ NNP NNP B-CHEM
levels NNS NNS O
measured VBN VBN O
in IN IN O
plasma NN NN O
and CC CC O
brain NN NN O
of IN IN O
these DT DT O
animals NNS NNS O
, , , O
however RB RB O
, , , O
were VBD VBD O
below IN IN O
those DT DT O
normally RB RB O
considered VBN VBN O
protective JJ JJ O
. . . O

This DT DT O
treatment NN NN O
with IN IN O
CBZ NNP NNP B-CHEM
had VBD VBD O
no DT DT O
apparent JJ JJ O
adverse JJ JJ O
effect NN NN O
on IN IN O
folate JJ JJ B-CHEM
concentrations NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
, , , O
and CC CC O
, , , O
indeed RB RB O
, , , O
the DT DT O
folate JJ JJ B-CHEM
concentration NN NN O
increased VBD VBD O
in IN IN O
liver NN NN O
after IN IN O
6 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
and CC CC O
in IN IN O
plasma NN NN O
at IN IN O
8 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

Dipyridamole NNP NNP B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
. . . O

Angina NNP NNP O
and CC CC O
ischemic JJ JJ O
electrocardiographic JJ JJ O
changes NNS NNS O
occurred VBD VBD O
after IN IN O
administration NN NN O
of IN IN O
oral JJ JJ O
dipyridamole NN NN B-CHEM
in IN IN O
four CD CD O
patients NNS NNS O
awaiting VBG VBG O
urgent JJ JJ O
myocardial NN NN O
revascularization NN NN O
procedures NNS NNS O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
has VBZ VBZ O
not RB RB O
previously RB RB O
been VBN VBN O
reported VBN VBN O
as IN IN O
a DT DT O
side NN NN O
effect NN NN O
of IN IN O
preoperative JJ JJ O
dipyridamole NN NN B-CHEM
therapy NN NN O
, , , O
although IN IN O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
has VBZ VBZ O
been VBN VBN O
demonstrated VBN VBN O
to TO TO O
occur VB VB O
in IN IN O
animals NNS NNS O
and CC CC O
humans NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

Epicardial NNP NNP O
coronary JJ JJ O
collateral NN NN O
vessels NNS NNS O
were VBD VBD O
demonstrated VBN VBN O
in IN IN O
all DT DT O
four CD CD O
patients NNS NNS O
; : : O
a DT DT O
coronary JJ JJ O
" '' '' O
steal VB VB O
" '' '' O
phenomenon NN NN O
may MD MD O
be VB VB O
the DT DT O
mechanism NN NN O
of IN IN O
the DT DT O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
ischemia NN NN O
observed VBD VBD O
. . . O

Inhibition NNP NNP O
of IN IN O
sympathoadrenal JJ JJ O
activity NN NN O
by IN IN O
atrial JJ JJ O
natriuretic JJ JJ O
factor NN NN O
in IN IN O
dogs NNS NNS O
. . . O

In IN IN O
six CD CD O
conscious JJ JJ O
, , , O
trained VBN VBN O
dogs NNS NNS O
, , , O
maintained VBN VBN O
on IN IN O
a DT DT O
normal JJ JJ O
sodium NN NN B-CHEM
intake NN NN O
of IN IN O
2 CD CD O
to TO TO O
4 CD CD O
mEq NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, , , O
sympathetic JJ JJ O
activity NN NN O
was VBD VBD O
assessed VBN VBN O
as IN IN O
the DT DT O
release NN NN O
rate NN NN O
of IN IN O
norepinephrine NN NN B-CHEM
and CC CC O
epinephrine NN NN B-CHEM
during IN IN O
15 CD CD O
- : : O
minute NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
infusions NNS NNS O
of IN IN O
human JJ JJ O
alpha NN NN O
- : : O
atrial JJ JJ O
natriuretic JJ JJ O
factor NN NN O
. . . O

Mean VB VB O
arterial JJ JJ O
pressure NN NN O
( ( ( O
as IN IN O
a DT DT O
percentage NN NN O
of IN IN O
control NN NN O
+ NN NN O
/ NN NN O
- - - O
SEM NNP NNP O
) ) ) O
during IN IN O
randomized JJ JJ O
infusions NNS NNS O
of IN IN O
0 CD CD O
. . . O
03 CD CD O
, , , O
0 CD CD O
. . . O
1 CD CD O
, , , O
0 CD CD O
. . . O
3 CD CD O
, , , O
or CC CC O
1 CD CD O
. . . O
0 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
was VBD VBD O
99 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
, , , O
95 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
93 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
or CC CC O
79 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
% NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
respectively RB RB O
, , , O
but CC CC O
no DT DT O
tachycardia NN NN O
and CC CC O
no DT DT O
augmentation NN NN O
of IN IN O
the DT DT O
norepinephrine NN NN B-CHEM
release NN NN O
rate NN NN O
( ( ( O
up IN IN O
to TO TO O
0 CD CD O
. . . O
3 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) ) ) O
were VBD VBD O
observed VBN VBN O
, , , O
which WDT WDT O
is VBZ VBZ O
in IN IN O
contrast NN NN O
to TO TO O
comparable JJ JJ O
hypotension NN NN O
induced VBN VBN O
by IN IN O
hydralazine NN NN B-CHEM
or CC CC O
nitroglycerin NN NN B-CHEM
. . . O

The DT DT O
release NN NN O
rate NN NN O
of IN IN O
epinephrine NN NN B-CHEM
( ( ( O
control NN NN O
, , , O
6 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) ) ) O
declined VBD VBD O
immediately RB RB O
during IN IN O
infusions NNS NNS O
of IN IN O
atrial JJ JJ O
natriuretic JJ JJ O
factor NN NN O
to TO TO O
a DT DT O
minimum NN NN O
of IN IN O
49 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
% NN NN O
of IN IN O
control NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
during IN IN O
0 CD CD O
. . . O
1 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
and CC CC O
to TO TO O
63 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
% NN NN O
( ( ( O
0 CD CD O
. . . O
1 CD CD O
greater JJR JJR O
than IN IN O
p NN NN O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
or CC CC O
95 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
% NN NN O
( ( ( O
not RB RB O
significant JJ JJ O
) ) ) O
during IN IN O
0 CD CD O
. . . O
3 CD CD O
or CC CC O
1 CD CD O
. . . O
0 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
. . . O

Steady NNP NNP O
state NN NN O
arterial JJ JJ O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
atrial JJ JJ O
natriuretic JJ JJ O
factor NN NN O
were VBD VBD O
39 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
pg NN NN O
/ NN NN O
ml NN NN O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
during IN IN O
infusions NNS NNS O
of IN IN O
saline NN NN O
and CC CC O
284 CD CD O
+ NN NN O
/ NN NN O
- : : O
24 CD CD O
pg NN NN O
/ NN NN O
ml NN NN O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
and CC CC O
1520 CD CD O
+ NN NN O
/ NN NN O
- : : O
300 CD CD O
pg NN NN O
/ NN NN O
ml NN NN O
( ( ( O
n NN NN O
= SYM SYM O
9 CD CD O
) ) ) O
during IN IN O
0 CD CD O
. . . O
03 CD CD O
and CC CC O
0 CD CD O
. . . O
1 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
infusions NNS NNS O
of IN IN O
the DT DT O
factor NN NN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Inhibition NNP NNP O
of IN IN O
immunoreactive JJ JJ O
corticotropin NN NN O
- : : O
releasing VBG VBG O
factor NN NN O
secretion NN NN O
into IN IN O
the DT DT O
hypophysial JJ JJ O
- - - O
portal JJ JJ O
circulation NN NN O
by IN IN O
delayed JJ JJ O
glucocorticoid NN NN O
feedback NN NN O
. . . O

Nitroprusside NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
evokes NNS NNS O
ACTH NNP NNP O
secretion NN NN O
which WDT WDT O
is VBZ VBZ O
primarily RB RB O
mediated VBN VBN O
by IN IN O
enhanced JJ JJ O
secretion NN NN O
of IN IN O
immunoreactive JJ JJ O
corticotropin NN NN O
- : : O
releasing VBG VBG O
factor NN NN O
( ( ( O
irCRF NN NN O
) ) ) O
into IN IN O
the DT DT O
hypophysial JJ JJ O
- - - O
portal JJ JJ O
circulation NN NN O
. . . O

Portal NNP NNP O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
neither DT DT O
arginine NN NN B-CHEM
vasopressin NN NN I-CHEM
nor CC CC O
oxytocin NN NN B-CHEM
are VBP VBP O
significantly RB RB O
altered VBN VBN O
in IN IN O
this DT DT O
paradigm NN NN O
. . . O

Application NNP NNP O
of IN IN O
a DT DT O
delayed JJ JJ O
feedback NN NN O
signal NN NN O
, , , O
in IN IN O
the DT DT O
form NN NN O
of IN IN O
a DT DT O
2 CD CD O
- : : O
h NN NN O
systemic JJ JJ O
corticosterone NN NN B-CHEM
infusion NN NN O
in IN IN O
urethane NN NN B-CHEM
- - - O
anesthetized JJ JJ O
rats NNS NNS O
with IN IN O
pharmacological JJ JJ O
blockade NN NN O
of IN IN O
glucocorticoid NN NN O
synthesis NN NN O
, , , O
is VBZ VBZ O
without IN IN O
effect NN NN O
on IN IN O
the DT DT O
resting VBG VBG O
secretion NN NN O
of IN IN O
arginine NN NN B-CHEM
vasopressin NN NN I-CHEM
and CC CC O
oxytocin NN NN B-CHEM
at IN IN O
any DT DT O
corticosterone NN NN B-CHEM
feedback NN NN O
dose NN NN O
tested VBN VBN O
. . . O

Resting NNP NNP O
irCRF NN NN O
levels NNS NNS O
are VBP VBP O
suppressed VBN VBN O
only RB RB O
at IN IN O
the DT DT O
highest JJS JJS O
corticosterone NN NN B-CHEM
infusion NN NN O
rate NN NN O
, , , O
which WDT WDT O
resulted VBD VBD O
in IN IN O
systemic JJ JJ O
corticosterone NN NN B-CHEM
levels NNS NNS O
of IN IN O
40 CD CD O
micrograms NNS NNS O
/ NN NN O
dl NN NN O
. . . O

Suppression NNP NNP O
of IN IN O
irCRF NN NN O
secretion NN NN O
in IN IN O
response NN NN O
to TO TO O
nitroprusside VB VB B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
is VBZ VBZ O
observed VBN VBN O
and CC CC O
occurs VBZ VBZ O
at IN IN O
a DT DT O
plasma NN NN O
corticosterone NN NN B-CHEM
level NN NN O
between IN IN O
8 CD CD O
- : : O
12 CD CD O
micrograms NNS NNS O
/ NN NN O
dl NN NN O
. . . O

These DT DT O
studies NNS NNS O
provide VBP VBP O
further JJ JJ O
evidence NN NN O
for IN IN O
a DT DT O
strong JJ JJ O
central JJ JJ O
component NN NN O
of IN IN O
the DT DT O
delayed JJ JJ O
feedback NN NN O
process NN NN O
which WDT WDT O
is VBZ VBZ O
mediated VBN VBN O
by IN IN O
modulation NN NN O
of IN IN O
irCRF NN NN O
release NN NN O
. . . O

Noradrenergic NNP NNP O
involvement NN NN O
in IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
delta NN NN B-CHEM
9 CD CD I-CHEM
- : : I-CHEM
tetrahydrocannabinol NN NN I-CHEM
. . . O

In IN IN O
order NN NN O
to TO TO O
elucidate VB VB O
the DT DT O
role NN NN O
of IN IN O
the DT DT O
catecholaminergic JJ JJ O
system NN NN O
in IN IN O
the DT DT O
cataleptogenic JJ JJ O
effect NN NN O
of IN IN O
delta NN NN B-CHEM
9 CD CD I-CHEM
- : : I-CHEM
tetrahydrocannabinol NN NN I-CHEM
( ( ( O
THC NNP NNP B-CHEM
) ) ) O
, , , O
the DT DT O
effect NN NN O
of IN IN O
pretreatment NN NN O
with IN IN O
6 CD CD B-CHEM
- : : I-CHEM
hydroxydopamine NN NN I-CHEM
( ( ( O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
) ) ) O
or CC CC O
with IN IN O
desipramine NN NN B-CHEM
and CC CC O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
and CC CC O
lesions NNS NNS O
of IN IN O
the DT DT O
locus NN NN O
coeruleus NN NN O
were VBD VBD O
investigated VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
cataleptogenic JJ JJ O
effect NN NN O
of IN IN O
THC NNP NNP B-CHEM
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
and CC CC O
in IN IN O
rats NNS NNS O
with IN IN O
lesions NNS NNS O
of IN IN O
the DT DT O
locus NN NN O
coeruleus NN NN O
but CC CC O
not RB RB O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
desipramine NN NN B-CHEM
and CC CC O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
control NN NN O
rats NNS NNS O
. . . O

On IN IN O
the DT DT O
contrary NN NN O
, , , O
the DT DT O
cataleptogenic JJ JJ O
effect NN NN O
of IN IN O
haloperidol NN NN B-CHEM
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
desipramine NN NN B-CHEM
and CC CC O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
but CC CC O
not RB RB O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
or CC CC O
in IN IN O
rats NNS NNS O
with IN IN O
lesions NNS NNS O
of IN IN O
the DT DT O
locus NN NN O
coeruleus NN NN O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
noradrenergic JJ JJ O
neurons NNS NNS O
have VBP VBP O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
manifestation NN NN O
of IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
THC NNP NNP B-CHEM
, , , O
whereas IN IN O
dopaminergic JJ JJ O
neurons NNS NNS O
are VBP VBP O
important JJ JJ O
in IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
. . . O

Reversibility NNP NNP O
of IN IN O
captopril NN NN B-CHEM
- - - O
induced JJ JJ O
renal JJ JJ O
insufficiency NN NN O
after IN IN O
prolonged JJ JJ O
use NN NN O
in IN IN O
an DT DT O
unusual JJ JJ O
case NN NN O
of IN IN O
renovascular JJ JJ O
hypertension NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
severe JJ JJ O
hypertension NN NN O
with IN IN O
an DT DT O
occluded JJ JJ O
renal JJ JJ O
artery NN NN O
to TO TO O
a DT DT O
solitary JJ JJ O
kidney NN NN O
, , , O
who WP WP O
developed VBD VBD O
sudden JJ JJ O
deterioration NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
following VBG VBG O
treatment NN NN O
with IN IN O
captopril NN NN B-CHEM
. . . O

His PRP$ PRP$ O
renal JJ JJ O
function NN NN O
remained VBD VBD O
impaired VBN VBN O
but CC CC O
stable JJ JJ O
during IN IN O
2 CD CD O
years NNS NNS O
' POS POS O
treatment NN NN O
with IN IN O
captopril NN NN B-CHEM
but CC CC O
returned VBD VBD O
to TO TO O
pre VB VB O
- - - O
treatment NN NN O
levels NNS NNS O
soon RB RB O
after IN IN O
cessation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

This DT DT O
indicates VBZ VBZ O
reversibility NN NN O
in IN IN O
captopril NN NN B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
failure NN NN O
even RB RB O
after IN IN O
its PRP$ PRP$ O
prolonged JJ JJ O
use NN NN O
and CC CC O
suggests VBZ VBZ O
that IN IN O
no DT DT O
organic JJ JJ O
damage NN NN O
occurs VBZ VBZ O
to TO TO O
glomerular NN NN O
arterioles NNS NNS O
following VBG VBG O
chronic JJ JJ O
ACE NNP NNP O
inhibition NN NN O
. . . O

HMG NNP NNP O
CoA NNP NNP O
reductase NN NN O
inhibitors NNS NNS O
. . . O

Current NNP NNP O
clinical JJ JJ O
experience NN NN O
. . . O

Lovastatin NNP NNP B-CHEM
and CC CC O
simvastatin NN NN B-CHEM
are VBP VBP O
the DT DT O
2 CD CD O
best JJS JJS O
- : : O
known VBN VBN O
members NNS NNS O
of IN IN O
the DT DT O
class NN NN O
of IN IN O
hypolipidaemic JJ JJ O
agents NNS NNS O
known VBN VBN O
as IN IN O
HMG NNP NNP O
CoA NNP NNP O
reductase NN NN O
inhibitors NNS NNS O
. . . O

Clinical NNP NNP O
experience NN NN O
with IN IN O
lovastatin NN NN B-CHEM
includes VBZ VBZ O
over IN IN O
5000 CD CD O
patients NNS NNS O
, , , O
700 CD CD O
of IN IN O
whom WP WP O
have VBP VBP O
been VBN VBN O
treated VBN VBN O
for IN IN O
2 CD CD O
years NNS NNS O
or CC CC O
more JJR JJR O
, , , O
and CC CC O
experience NN NN O
with IN IN O
simvastatin NN NN B-CHEM
includes VBZ VBZ O
over IN IN O
3500 CD CD O
patients NNS NNS O
, , , O
of IN IN O
whom WP WP O
350 CD CD O
have VBP VBP O
been VBN VBN O
treated VBN VBN O
for IN IN O
18 CD CD O
months NNS NNS O
or CC CC O
more JJR JJR O
. . . O

Lovastatin NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
marketed VBN VBN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
for IN IN O
over IN IN O
6 CD CD O
months NNS NNS O
. . . O

Both DT DT O
agents NNS NNS O
show VBP VBP O
substantial JJ JJ O
clinical JJ JJ O
efficacy NN NN O
, , , O
with IN IN O
reductions NNS NNS O
in IN IN O
total JJ JJ O
cholesterol NN NN B-CHEM
of IN IN O
over IN IN O
30 CD CD O
% NN NN O
and CC CC O
in IN IN O
LDL NNP NNP O
- : : O
cholesterol NN NN B-CHEM
of IN IN O
40 CD CD O
% NN NN O
in IN IN O
clinical JJ JJ O
studies NNS NNS O
. . . O

Modest NNP NNP O
increases NNS NNS O
in IN IN O
HDL NNP NNP O
- : : O
cholesterol NN NN B-CHEM
levels NNS NNS O
of IN IN O
about IN IN O
10 CD CD O
% NN NN O
are VBP VBP O
also RB RB O
reported VBN VBN O
. . . O

Clinical NNP NNP O
tolerability NN NN O
of IN IN O
both DT DT O
agents NNS NNS O
has VBZ VBZ O
been VBN VBN O
good JJ JJ O
, , , O
with IN IN O
fewer JJR JJR O
than IN IN O
3 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
withdrawn VBP VBP O
from IN IN O
treatment NN NN O
because IN IN O
of IN IN O
clinical JJ JJ O
adverse NN NN O
experiences NNS NNS O
. . . O

Ophthalmological NNP NNP O
examinations NNS NNS O
in IN IN O
over IN IN O
1100 CD CD O
patients NNS NNS O
treated VBD VBD O
with IN IN O
one CD CD O
or CC CC O
the DT DT O
other JJ JJ O
agent NN NN O
have VBP VBP O
revealed VBN VBN O
no DT DT O
evidence NN NN O
of IN IN O
significant JJ JJ O
short JJ JJ O
term NN NN O
( ( ( O
up IN IN O
to TO TO O
2 CD CD O
years NNS NNS O
) ) ) O
cataractogenic JJ JJ O
potential JJ JJ O
. . . O

One CD CD O
to TO TO O
2 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
have VBP VBP O
elevations NNS NNS O
of IN IN O
serum NN NN O
transaminases NNS NNS O
to TO TO O
greater JJR JJR O
than IN IN O
3 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
limit NN NN O
of IN IN O
normal JJ JJ O
. . . O

These DT DT O
episodes NNS NNS O
are VBP VBP O
asymptomatic JJ JJ O
and CC CC O
reversible JJ JJ O
when WRB WRB O
therapy NN NN O
is VBZ VBZ O
discontinued VBN VBN O
. . . O

Minor NNP NNP O
elevations NNS NNS O
of IN IN O
creatine NN NN B-CHEM
kinase NN NN O
levels NNS NNS O
are VBP VBP O
reported VBN VBN O
in IN IN O
about IN IN O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Myopathy NNP NNP O
, , , O
associated VBN VBN O
in IN IN O
some DT DT O
cases NNS NNS O
with IN IN O
myoglobinuria NN NN O
, , , O
and CC CC O
in IN IN O
2 CD CD O
cases NNS NNS O
with IN IN O
transient JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
has VBZ VBZ O
been VBN VBN O
rarely RB RB O
reported VBN VBN O
with IN IN O
lovastatin NN NN B-CHEM
, , , O
especially RB RB O
in IN IN O
patients NNS NNS O
concomitantly RB RB O
treated VBN VBN O
with IN IN O
cyclosporin NN NN B-CHEM
, , , O
gemfibrozil NN NN B-CHEM
or CC CC O
niacin NN NN B-CHEM
. . . O

Lovastatin NNP NNP B-CHEM
and CC CC O
simvastatin NN NN B-CHEM
are VBP VBP O
both DT DT O
effective JJ JJ O
and CC CC O
well RB RB O
- - - O
tolerated JJ JJ O
agents NNS NNS O
for IN IN O
lowering VBG VBG O
elevated VBD VBD O
levels NNS NNS O
of IN IN O
serum NN NN O
cholesterol NN NN B-CHEM
. . . O

As IN IN O
wider JJR JJR O
use NN NN O
confirms VBZ VBZ O
their PRP$ PRP$ O
safety NN NN O
profile NN NN O
, , , O
they PRP PRP O
will MD MD O
gain VB VB O
increasing VBG VBG O
importance NN NN O
in IN IN O
the DT DT O
therapeutic JJ JJ O
approach NN NN O
to TO TO O
hypercholesterolaemia VB VB O
and CC CC O
its PRP$ PRP$ O
consequences NNS NNS O
. . . O

Hepatic NNP NNP O
reactions NNS NNS O
associated VBN VBN O
with IN IN O
ketoconazole NN NN B-CHEM
in IN IN O
the DT DT O
United NNP NNP O
Kingdom NNP NNP O
. . . O

Ketoconazole NNP NNP B-CHEM
was VBD VBD O
introduced VBN VBN O
in IN IN O
the DT DT O
United NNP NNP O
Kingdom NNP NNP O
in IN IN O
1981 CD CD O
. . . O

By IN IN O
November NNP NNP O
1984 CD CD O
the DT DT O
Committee NNP NNP O
on IN IN O
Safety NNP NNP O
of IN IN O
Medicines NNP NNP O
had VBD VBD O
received VBN VBN O
82 CD CD O
reports NNS NNS O
of IN IN O
possible JJ JJ O
hepatotoxicity NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
drug NN NN O
, , , O
including VBG VBG O
five CD CD O
deaths NNS NNS O
. . . O

An DT DT O
analysis NN NN O
of IN IN O
the DT DT O
75 CD CD O
cases NNS NNS O
that WDT WDT O
had VBD VBD O
been VBN VBN O
adequately RB RB O
followed VBN VBN O
up RP RP O
suggested VBD VBD O
that IN IN O
16 CD CD O
, , , O
including VBG VBG O
three CD CD O
deaths NNS NNS O
, , , O
were VBD VBD O
probably RB RB O
related VBN VBN O
to TO TO O
treatment NN NN O
with IN IN O
the DT DT O
drug NN NN O
. . . O

Of IN IN O
the DT DT O
remainder NN NN O
, , , O
48 CD CD O
were VBD VBD O
possibly RB RB O
related VBN VBN O
to TO TO O
treatment NN NN O
, , , O
five CD CD O
were VBD VBD O
unlikely JJ JJ O
to TO TO O
be VB VB O
so RB RB O
, , , O
and CC CC O
six CD CD O
were VBD VBD O
unclassifiable JJ JJ O
. . . O

The DT DT O
mean JJ JJ O
age NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
the DT DT O
16 CD CD O
probable JJ JJ O
cases NNS NNS O
was VBD VBD O
57 CD CD O
. . . O
9 CD CD O
, , , O
with IN IN O
hepatotoxicity NN NN O
being VBG VBG O
more JJR JJR O
common JJ JJ O
in IN IN O
women NNS NNS O
. . . O

The DT DT O
average JJ JJ O
duration NN NN O
of IN IN O
treatment NN NN O
before IN IN O
the DT DT O
onset NN NN O
of IN IN O
jaundice NN NN O
was VBD VBD O
61 CD CD O
days NNS NNS O
. . . O

None NN NN O
of IN IN O
these DT DT O
well RB RB O
validated VBN VBN O
cases NNS NNS O
occurred VBN VBN O
within IN IN O
the DT DT O
first JJ JJ O
10 CD CD O
days NNS NNS O
after IN IN O
treatment NN NN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
serum NN NN O
liver NN NN O
function NN NN O
tests NNS NNS O
suggested VBD VBD O
hepatocellular JJ JJ O
injury NN NN O
in IN IN O
10 CD CD O
( ( ( O
63 CD CD O
% NN NN O
) ) ) O
; : : O
the DT DT O
rest NN NN O
showed VBD VBD O
a DT DT O
mixed JJ JJ O
pattern NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
results NNS NNS O
of IN IN O
histological JJ JJ O
examination NN NN O
of IN IN O
the DT DT O
liver NN NN O
often RB RB O
showed VBD VBD O
evidence NN NN O
of IN IN O
cholestasis NNS NNS O
. . . O

The DT DT O
characteristics NNS NNS O
of IN IN O
the DT DT O
48 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
possible JJ JJ O
cases NNS NNS O
were VBD VBD O
similar JJ JJ O
. . . O

Allergic NNP NNP O
manifestations NNS NNS O
such JJ JJ O
as IN IN O
rash NN NN O
and CC CC O
eosinophilia NN NN O
were VBD VBD O
rare JJ JJ O
. . . O

Hepatitis NNP NNP O
was VBD VBD O
usually RB RB O
reversible JJ JJ O
when WRB WRB O
treatment NN NN O
was VBD VBD O
stopped VBN VBN O
, , , O
with IN IN O
the DT DT O
results NNS NNS O
of IN IN O
liver NN NN O
function NN NN O
tests NNS NNS O
returning VBG VBG O
to TO TO O
normal NN NN O
after IN IN O
an DT DT O
average NN NN O
of IN IN O
3 CD CD O
. . . O
1 CD CD O
months NNS NNS O
. . . O

In IN IN O
two CD CD O
of IN IN O
the DT DT O
three CD CD O
deaths NNS NNS O
probably RB RB O
associated VBN VBN O
with IN IN O
ketoconazole NN NN B-CHEM
treatment NN NN O
the DT DT O
drug NN NN O
had VBD VBD O
been VBN VBN O
continued VBN VBN O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
jaundice NN NN O
and CC CC O
other JJ JJ O
symptoms NNS NNS O
of IN IN O
hepatitis NN NN O
. . . O

Clinical NNP NNP O
and CC CC O
biochemical JJ JJ O
monitoring NN NN O
at IN IN O
regular JJ JJ O
intervals NNS NNS O
for IN IN O
evidence NN NN O
of IN IN O
hepatitis NN NN O
is VBZ VBZ O
advised VBN VBN O
during IN IN O
long JJ JJ O
term NN NN O
treatment NN NN O
with IN IN O
ketoconazole NN NN B-CHEM
to TO TO O
prevent VB VB O
possible JJ JJ O
serious JJ JJ O
hepatic JJ JJ O
injury NN NN O
. . . O

Glyburide NNP NNP B-CHEM
- : : O
induced JJ JJ O
hepatitis NN NN O
. . . O

Drug NN NN O
- : : O
induced JJ JJ O
hepatotoxicity NN NN O
, , , O
although IN IN O
common JJ JJ O
, , , O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
only RB RB O
infrequently RB RB O
with IN IN O
sulfonylureas NNS NNS B-CHEM
. . . O

For IN IN O
glyburide NN NN B-CHEM
, , , O
a DT DT O
second JJ JJ O
- - - O
generation NN NN O
sulfonylurea NN NN B-CHEM
, , , O
only RB RB O
two CD CD O
brief JJ JJ O
reports NNS NNS O
of IN IN O
hepatotoxicity NN NN O
exist NN NN O
. . . O

Two CD CD O
patients NNS NNS O
with IN IN O
type NN NN O
II NNP NNP O
diabetes NNS NNS O
mellitus NN NN O
developed VBN VBN O
an DT DT O
acute JJ JJ O
hepatitis NN NN O
- - - O
like IN IN O
syndrome NN NN O
soon RB RB O
after IN IN O
initiation NN NN O
of IN IN O
glyburide NN NN B-CHEM
therapy NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
serologic JJ JJ O
evidence NN NN O
of IN IN O
viral JJ JJ O
infection NN NN O
, , , O
and CC CC O
a DT DT O
liver NN NN O
biopsy NN NN O
sample NN NN O
showed VBD VBD O
a DT DT O
histologic JJ JJ O
pattern NN NN O
consistent JJ JJ O
with IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hepatitis NN NN O
. . . O

Both DT DT O
patients NNS NNS O
recovered VBD VBD O
quickly RB RB O
after IN IN O
stopping VBG VBG O
glyburide NN NN B-CHEM
therapy NN NN O
and CC CC O
have VBP VBP O
remained VBN VBN O
well RB RB O
for IN IN O
a DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
of IN IN O
1 CD CD O
year NN NN O
. . . O

Glyburide NNP NNP B-CHEM
can MD MD O
produce VB VB O
an DT DT O
acute JJ JJ O
hepatitis NN NN O
- - - O
like IN IN O
illness NN NN O
in IN IN O
some DT DT O
persons NNS NNS O
. . . O

Intracranial NNP NNP O
pressure NN NN O
increases NNS NNS O
during IN IN O
alfentanil NN NN B-CHEM
- - - O
induced JJ JJ O
rigidity NN NN O
. . . O

Intracranial NNP NNP O
pressure NN NN O
( ( ( O
ICP NNP NNP O
) ) ) O
was VBD VBD O
measured VBN VBN O
during IN IN O
alfentanil NN NN B-CHEM
- - - O
induced JJ JJ O
rigidity NN NN O
in IN IN O
rats NNS NNS O
. . . O

Ten CD CD O
rats NNS NNS O
had VBD VBD O
arterial JJ JJ O
, , , O
central JJ JJ O
venous JJ JJ O
( ( ( O
CVP NNP NNP O
) ) ) O
, , , O
and CC CC O
subdural JJ JJ O
cannulae NN NN O
inserted VBN VBN O
under IN IN O
halothane NN NN B-CHEM
anesthesia NN NN O
. . . O

The DT DT O
animals NNS NNS O
were VBD VBD O
mechanically RB RB O
ventilated VBN VBN O
to TO TO O
achieve VB VB O
normocarbia NN NN O
( ( ( O
PCO2 NNP NNP O
= SYM SYM O
42 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
mmHg NN NN O
, , , O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
. . . O

Following VBG VBG O
instrumentation NN NN O
, , , O
halothane NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
and CC CC O
alfentanil NN NN B-CHEM
( ( ( O
125 CD CD O
mu NN NN O
/ NN NN O
kg NN NN O
) ) ) O
administered VBD VBD O
iv NN NN O
during IN IN O
emergence NN NN O
from IN IN O
halothane NN NN B-CHEM
anesthesia NN NN O
. . . O

In IN IN O
the DT DT O
five CD CD O
rats NNS NNS O
that WDT WDT O
developed VBD VBD O
somatic JJ JJ O
rigidity NN NN O
, , , O
ICP NNP NNP O
and CC CC O
CVP NNP NNP O
increased VBD VBD O
significantly RB RB O
above IN IN O
baseline NN NN O
( ( ( O
delta NN NN O
ICP NNP NNP O
7 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
mmHg NN NN O
, , , O
delta NN NN O
CVP NNP NNP O
5 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
mmHg NN NN O
) ) ) O
. . . O

These DT DT O
variables NNS NNS O
returned VBD VBD O
to TO TO O
baseline VB VB O
when WRB WRB O
rigidity NN NN O
was VBD VBD O
abolished VBN VBN O
with IN IN O
metocurine NN NN B-CHEM
. . . O

In IN IN O
five CD CD O
rats NNS NNS O
that WDT WDT O
did VBD VBD O
not RB RB O
become VB VB O
rigid JJ JJ O
, , , O
ICP NNP NNP O
and CC CC O
CVP NNP NNP O
did VBD VBD O
not RB RB O
change VB VB O
following VBG VBG O
alfentanil NN NN B-CHEM
. . . O

These DT DT O
observations NNS NNS O
suggest VBP VBP O
that IN IN O
rigidity NN NN O
should MD MD O
be VB VB O
prevented VBN VBN O
when WRB WRB O
alfentanil NN NN B-CHEM
, , , O
and CC CC O
, , , O
presumably RB RB O
, , , O
other JJ JJ O
opiates NNS NNS O
, , , O
are VBP VBP O
used VBN VBN O
in IN IN O
the DT DT O
anesthetic JJ JJ O
management NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
ICP NNP NNP O
problems NNS NNS O
. . . O

Verapamil NNP NNP B-CHEM
withdrawal NN NN O
as IN IN O
a DT DT O
possible JJ JJ O
cause NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
in IN IN O
a DT DT O
hypertensive JJ JJ O
woman NN NN O
with IN IN O
a DT DT O
normal JJ JJ O
coronary JJ JJ O
angiogram NN NN O
. . . O

Verapamil NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
and CC CC O
relatively RB RB O
- : : O
safe JJ JJ O
antihypertensive JJ JJ O
drug NN NN O
. . . O

Serious JJ JJ O
adverse JJ JJ O
effects NNS NNS O
are VBP VBP O
uncommon JJ JJ O
and CC CC O
mainly RB RB O
have VB VB O
been VBN VBN O
related VBN VBN O
to TO TO O
the DT DT O
depression NN NN O
of IN IN O
cardiac JJ JJ O
contractility NN NN O
and CC CC O
conduction NN NN O
, , , O
especially RB RB O
when WRB WRB O
the DT DT O
drug NN NN O
is VBZ VBZ O
combined VBN VBN O
with IN IN O
beta NN NN O
- - - O
blocking VBG VBG O
agents NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
in IN IN O
which WDT WDT O
myocardial NN NN O
infarction NN NN O
coincided VBN VBN O
with IN IN O
the DT DT O
introduction NN NN O
of IN IN O
captopril NN NN B-CHEM
and CC CC O
the DT DT O
withdrawal NN NN O
of IN IN O
verapamil NN NN B-CHEM
in IN IN O
a DT DT O
previously RB RB O
asymptomatic JJ JJ O
woman NN NN O
with IN IN O
severe JJ JJ O
hypertension NN NN O
. . . O

Possible JJ JJ O
mechanisms NNS NNS O
that WDT WDT O
involve VBP VBP O
a DT DT O
verapamil NN NN B-CHEM
- - - O
related VBN VBN O
increase NN NN O
in IN IN O
platelet NN NN O
and CC CC O
/ NN NN O
or CC CC O
vascular NN NN O
alpha NN NN O
2 CD CD O
- : : O
adrenoreceptor NN NN O
affinity NN NN O
for IN IN O
catecholamines NNS NNS B-CHEM
are VBP VBP O
discussed VBN VBN O
. . . O

Haemolytic NNP NNP O
- : : O
uraemic JJ JJ O
syndrome NN NN O
after IN IN O
treatment NN NN O
with IN IN O
metronidazole NN NN B-CHEM
. . . O

This DT DT O
paper NN NN O
describes VBZ VBZ O
the DT DT O
clinical JJ JJ O
features NNS NNS O
of IN IN O
six CD CD O
children NNS NNS O
who WP WP O
developed VBD VBD O
the DT DT O
haemolytic JJ JJ O
- - - O
uraemic JJ JJ O
syndrome NN NN O
after IN IN O
treatment NN NN O
with IN IN O
metronidazole NN NN B-CHEM
. . . O

These DT DT O
children NNS NNS O
were VBD VBD O
older JJR JJR O
and CC CC O
were VBD VBD O
more RBR RBR O
likely JJ JJ O
to TO TO O
have VB VB O
undergone VBN VBN O
recent JJ JJ O
bowel NN NN O
surgery NN NN O
than IN IN O
are VBP VBP O
other JJ JJ O
children NNS NNS O
with IN IN O
this DT DT O
condition NN NN O
. . . O

While IN IN O
the DT DT O
involvement NN NN O
of IN IN O
metronidazole NN NN B-CHEM
in IN IN O
the DT DT O
aetiology NN NN O
of IN IN O
the DT DT O
haemolytic JJ JJ O
- - - O
uraemic JJ JJ O
syndrome NN NN O
is VBZ VBZ O
not RB RB O
established VBN VBN O
firmly RB RB O
, , , O
the DT DT O
action NN NN O
of IN IN O
this DT DT O
drug NN NN O
in IN IN O
sensitizing VBG VBG O
tissues NNS NNS O
to TO TO O
oxidation NN NN O
injury NN NN O
and CC CC O
the DT DT O
reported JJ JJ O
evidence NN NN O
of IN IN O
oxidation NN NN O
changes NNS NNS O
in IN IN O
the DT DT O
haemolytic JJ JJ O
- - - O
uraemic JJ JJ O
syndrome NN NN O
suggest VBP VBP O
a DT DT O
possible JJ JJ O
link NN NN O
between IN IN O
metronidazole NN NN B-CHEM
treatment NN NN O
and CC CC O
some DT DT O
cases NNS NNS O
of IN IN O
the DT DT O
haemolytic JJ JJ O
- - - O
uraemic JJ JJ O
syndrome NN NN O
. . . O

Adverse NNP NNP O
cardiac JJ JJ O
effects NNS NNS O
during IN IN O
induction NN NN O
chemotherapy NN NN O
treatment NN NN O
with IN IN O
cis NN NN B-CHEM
- - - I-CHEM
platin NN NN I-CHEM
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
. . . O

Survival NNP NNP O
for IN IN O
patients NNS NNS O
with IN IN O
advanced VBN VBN O
head NN NN O
and CC CC O
neck NN NN O
carcinoma NN NN O
and CC CC O
esophageal VB VB O
carcinoma NN NN O
is VBZ VBZ O
poor JJ JJ O
with IN IN O
radiotherapy NN NN O
and CC CC O
/ NN NN O
or CC CC O
surgery NN NN O
. . . O

Obviously RB RB O
, , , O
there EX EX O
is VBZ VBZ O
a DT DT O
need NN NN O
for IN IN O
effective JJ JJ O
chemotherapy NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
cis NN NN B-CHEM
- - - I-CHEM
platin NN NN I-CHEM
( ( ( O
80 CD CD O
- : : O
120 CD CD O
mg NN NN O
/ NN NN O
m2BSA NN NN O
) ) ) O
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
( ( ( O
1000 CD CD O
mg NN NN O
/ NN NN O
m2BSA NN NN O
daily JJ JJ O
as IN IN O
a DT DT O
continuous JJ JJ O
infusion NN NN O
during IN IN O
5 CD CD O
days NNS NNS O
) ) ) O
were VBD VBD O
given VBN VBN O
to TO TO O
76 CD CD O
patients NNS NNS O
before IN IN O
radiotherapy NN NN O
and CC CC O
surgery NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
clarify VB VB O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
adverse JJ JJ O
cardiac JJ JJ O
effects NNS NNS O
to TO TO O
this DT DT O
treatment NN NN O
. . . O

Before IN IN O
treatment NN NN O
all DT DT O
patients NNS NNS O
had VBD VBD O
a DT DT O
cardiac JJ JJ O
evaluation NN NN O
and CC CC O
during IN IN O
treatment NN NN O
serial JJ JJ O
ECG NNP NNP O
recordings NNS NNS O
were VBD VBD O
performed VBN VBN O
. . . O

In IN IN O
the DT DT O
pre NN NN O
- - - O
treatment NN NN O
evaluation NN NN O
, , , O
signs NNS NNS O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
were VBD VBD O
found VBN VBN O
in IN IN O
33 CD CD O
patients NNS NNS O
( ( ( O
43 CD CD O
% NN NN O
) ) ) O
. . . O

During IN IN O
treatment NN NN O
, , , O
adverse JJ JJ O
cardiac JJ JJ O
effects NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
14 CD CD O
patients NNS NNS O
( ( ( O
18 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
mean JJ JJ O
age NN NN O
of IN IN O
these DT DT O
patients NNS NNS O
was VBD VBD O
the DT DT O
same JJ JJ O
as IN IN O
for IN IN O
the DT DT O
entire JJ JJ O
group NN NN O
, , , O
64 CD CD O
years NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
cardiotoxicity NN NN O
was VBD VBD O
not RB RB O
higher JJR JJR O
in IN IN O
patients NNS NNS O
with IN IN O
signs NNS NNS O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
than IN IN O
in IN IN O
those DT DT O
without IN IN O
in IN IN O
the DT DT O
pre NN NN O
- - - O
treatment NN NN O
evaluation NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
signs NNS NNS O
of IN IN O
cardiotoxicity NN NN O
were VBD VBD O
chest NN NN O
pain NN NN O
, , , O
ST NNP NNP O
- : : O
T NN NN O
wave NN NN O
changes NNS NNS O
and CC CC O
atrial JJ JJ O
fibrillation NN NN O
. . . O

This DT DT O
was VBD VBD O
followed VBN VBN O
by IN IN O
ventricular JJ JJ O
fibrillation NN NN O
in IN IN O
one CD CD O
patient NN NN O
and CC CC O
sudden JJ JJ O
death NN NN O
in IN IN O
another DT DT O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
patients NNS NNS O
on IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
treatment NN NN O
should MD MD O
be VB VB O
under IN IN O
close JJ JJ O
supervision NN NN O
and CC CC O
that IN IN O
the DT DT O
treatment NN NN O
should MD MD O
be VB VB O
discontinued VBN VBN O
if IN IN O
chest NN NN O
pain NN NN O
or CC CC O
tachyarrhythmia NN NN O
is VBZ VBZ O
observed VBN VBN O
. . . O

Death NN NN O
from IN IN O
chemotherapy NN NN O
in IN IN O
gestational JJ JJ O
trophoblastic JJ JJ O
disease NN NN O
. . . O

Multiple NNP NNP O
cytotoxic JJ JJ O
drug NN NN O
administration NN NN O
is VBZ VBZ O
the DT DT O
generally RB RB O
accepted VBN VBN O
treatment NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
high JJ JJ O
- - - O
risk NN NN O
stage NN NN O
of IN IN O
choriocarcinoma NN NN O
. . . O

Based VBN VBN O
on IN IN O
this DT DT O
principle NN NN O
a DT DT O
27 CD CD O
- : : O
year NN NN O
old JJ JJ O
woman NN NN O
, , , O
classified VBN VBN O
as IN IN O
being VBG VBG O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
risk NN NN O
group NN NN O
( ( ( O
Goldstein NNP NNP O
and CC CC O
Berkowitz NNP NNP O
score NN NN O
: : : O
11 CD CD O
) ) ) O
, , , O
was VBD VBD O
treated VBN VBN O
with IN IN O
multiple JJ JJ O
cytotoxic JJ JJ O
drugs NNS NNS O
. . . O

The DT DT O
multiple JJ JJ O
drug NN NN O
schema NN NN O
consisted VBN VBN O
of IN IN O
: : : O
Etoposide NNP NNP B-CHEM
16 CD CD O
. . . O
213 CD CD O
, , , O
Methotrexate NNP NNP B-CHEM
, , , O
Cyclophosphamide NNP NNP B-CHEM
, , , O
Actomycin NNP NNP B-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
, , , O
and CC CC O
Cisplatin NNP NNP B-CHEM
. . . O

On IN IN O
the DT DT O
first JJ JJ O
day NN NN O
of IN IN O
the DT DT O
schedule NN NN O
, , , O
moderate JJ JJ O
high JJ JJ O
doses NNS NNS O
of IN IN O
Methotrexate NNP NNP B-CHEM
, , , O
Etoposide NNP NNP B-CHEM
and CC CC O
Cyclophosphamide NNP NNP B-CHEM
were VBD VBD O
administered VBN VBN O
. . . O

Within IN IN O
8 CD CD O
hours NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
therapy NN NN O
the DT DT O
patient NN NN O
died VBD VBD O
with IN IN O
a DT DT O
clinical JJ JJ O
picture NN NN O
resembling VBG VBG O
massive JJ JJ O
pulmonary JJ JJ O
obstruction NN NN O
due JJ JJ O
to TO TO O
choriocarcinomic JJ JJ O
tissue NN NN O
plugs NNS NNS O
, , , O
probably RB RB O
originating VBG VBG O
from IN IN O
the DT DT O
uterus NN NN O
. . . O

Formation NNP NNP O
of IN IN O
these DT DT O
plugs NNS NNS O
was VBD VBD O
probably RB RB O
due JJ JJ O
to TO TO O
extensive JJ JJ O
tumor NN NN O
necrosis NN NN O
at IN IN O
the DT DT O
level NN NN O
of IN IN O
the DT DT O
walls NNS NNS O
of IN IN O
the DT DT O
major JJ JJ O
uterine NN NN O
veins NNS NNS O
, , , O
which WDT WDT O
resulted VBD VBD O
in IN IN O
an DT DT O
open JJ JJ O
exchange NN NN O
of IN IN O
tumor NN NN O
plugs NNS NNS O
to TO TO O
the DT DT O
vascular NN NN O
spaces NNS NNS O
; : : O
decrease NN NN O
in IN IN O
tumor NN NN O
tissue NN NN O
coherence NN NN O
secondary JJ JJ O
to TO TO O
chemotherapy NN NN O
may MD MD O
have VB VB O
further RB RB O
contributed VBN VBN O
to TO TO O
the DT DT O
formation NN NN O
of IN IN O
tumor NN NN O
emboli NN NN O
. . . O

In IN IN O
view NN NN O
of IN IN O
the DT DT O
close JJ JJ O
time NN NN O
association NN NN O
between IN IN O
the DT DT O
start NN NN O
of IN IN O
chemotherapy NN NN O
and CC CC O
the DT DT O
acute JJ JJ O
onset NN NN O
of IN IN O
massive JJ JJ O
embolism NN NN O
other JJ JJ O
explanations NNS NNS O
, , , O
such JJ JJ O
as IN IN O
spontaneous JJ JJ O
necrosis NNS NNS O
, , , O
must MD MD O
be VB VB O
considered VBN VBN O
less RBR RBR O
likely JJ JJ O
. . . O

Patients NNS NNS O
with IN IN O
large JJ JJ O
pelvic NN NN O
tumor NN NN O
loads NNS NNS O
are VBP VBP O
, , , O
according VBG VBG O
to TO TO O
existing VBG VBG O
classifications NNS NNS O
, , , O
at IN IN O
high JJ JJ O
risk NN NN O
to TO TO O
die VB VB O
and CC CC O
to TO TO O
develop VB VB O
drug NN NN O
resistance NN NN O
. . . O

Notwithstanding IN IN O
these DT DT O
facts NNS NNS O
our PRP$ PRP$ O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
these DT DT O
patients NNS NNS O
might MD MD O
benefit VB VB O
from IN IN O
relatively RB RB O
mild JJ JJ O
initial JJ JJ O
treatment NN NN O
, , , O
especially RB RB O
true JJ JJ O
for IN IN O
patients NNS NNS O
not RB RB O
previously RB RB O
exposed VBN VBN O
to TO TO O
this DT DT O
drug NN NN O
. . . O

Close NNP NNP O
observation NN NN O
of IN IN O
the DT DT O
response NN NN O
status NN NN O
both DT DT O
clinically RB RB O
and CC CC O
with IN IN O
beta NN NN O
- - - O
hCG NN NN O
values NNS NNS O
may MD MD O
indicate VB VB O
whether IN IN O
and CC CC O
when WRB WRB O
more RBR RBR O
agressive JJ JJ O
combination NN NN O
chemotherapy NN NN O
should MD MD O
be VB VB O
started VBN VBN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Pulmonary NNP NNP O
shunt NN NN O
and CC CC O
cardiovascular JJ JJ O
responses NNS NNS O
to TO TO O
CPAP NNP NNP O
during IN IN O
nitroprusside IN IN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
continuous JJ JJ O
positive JJ JJ O
airway NN NN O
pressure NN NN O
( ( ( O
CPAP NNP NNP O
) ) ) O
on IN IN O
cardiovascular JJ JJ O
dynamics NNS NNS O
and CC CC O
pulmonary JJ JJ O
shunt NN NN O
( ( ( O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
) ) ) O
were VBD VBD O
investigated VBN VBN O
in IN IN O
12 CD CD O
dogs NNS NNS O
before IN IN O
and CC CC O
during IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
infusion NN NN O
that WDT WDT O
decreased VBD VBD O
mean VB VB O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
40 CD CD O
- : : O
50 CD CD O
per IN IN O
cent NN NN O
. . . O

Before IN IN O
nitroprusside NN NN B-CHEM
infusion NN NN O
, , , O
5 CD CD O
cm NN NN O
H2O NNP NNP B-CHEM
CPAP NNP NNP O
significantly RB RB O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
05 CD CD O
, , , O
decreased VBD VBD O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
significantly RB RB O
alter VB VB O
heart NN NN O
rate NN NN O
, , , O
cardiac JJ JJ O
output NN NN O
, , , O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
, , , O
or CC CC O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
. . . O

Ten CD CD O
cm NN NN O
H2O NNP NNP B-CHEM
CPAP NNP NNP O
before IN IN O
nitroprusside NN NN B-CHEM
infusion NN NN O
produced VBD VBD O
a DT DT O
further JJ JJ O
decrease NN NN O
in IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
significantly RB RB O
increased VBN VBN O
heart NN NN O
rate NN NN O
and CC CC O
decreased VBD VBD O
cardiac JJ JJ O
output NN NN O
and CC CC O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
. . . O

Nitroprusside NNP NNP B-CHEM
caused VBD VBD O
significant JJ JJ O
decreases NNS NNS O
in IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
and CC CC O
increases NNS NNS O
in IN IN O
heart NN NN O
rate NN NN O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
change VB VB O
cardiac JJ JJ O
output NN NN O
or CC CC O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
. . . O

Five CD CD O
cm NN NN O
H2O NNP NNP B-CHEM
CPAP NNP NNP O
during IN IN O
nitroprusside NN NN B-CHEM
did VBD VBD O
not RB RB O
further RB RB O
alter VB VB O
any DT DT O
of IN IN O
the DT DT O
above JJ JJ O
- - - O
mentioned VBN VBN O
variables NNS NNS O
. . . O

However RB RB O
, , , O
10 CD CD O
cm NN NN O
H2O NNP NNP B-CHEM
CPAP NNP NNP O
decreased VBD VBD O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
, , , O
cardiac JJ JJ O
output NN NN O
, , , O
and CC CC O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
nitroprusside JJ JJ B-CHEM
infusion NN NN O
rates NNS NNS O
that IN IN O
decrease NN NN O
mean NN NN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
by IN IN O
40 CD CD O
- : : O
50 CD CD O
per IN IN O
cent NN NN O
do VBP VBP O
not RB RB O
change VB VB O
cardiac JJ JJ O
output NN NN O
or CC CC O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
. . . O

During IN IN O
nitroprusside JJ JJ B-CHEM
infusion NN NN O
low JJ JJ O
levels NNS NNS O
of IN IN O
CPAP NNP NNP O
do VBP VBP O
not RB RB O
markedly RB RB O
alter VB VB O
cardiovascular JJ JJ O
dynamics NNS NNS O
, , , O
but CC CC O
high JJ JJ O
levels NNS NNS O
of IN IN O
CPAP NNP NNP O
( ( ( O
10 CD CD O
cm NN NN O
H2O NNP NNP B-CHEM
) ) ) O
, , , O
while IN IN O
decreasing VBG VBG O
QS NNP NNP O
/ NN NN O
QT NNP NNP O
, , , O
produce NN NN O
marked VBD VBD O
decreases NNS NNS O
in IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
cardiac JJ JJ O
output NN NN O
. . . O

Systolic NNP NNP O
pressure NN NN O
variation NN NN O
is VBZ VBZ O
greater JJR JJR O
during IN IN O
hemorrhage NN NN O
than IN IN O
during IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
in IN IN O
ventilated JJ JJ O
dogs NNS NNS O
. . . O

The DT DT O
systolic JJ JJ O
pressure NN NN O
variation NN NN O
( ( ( O
SPV NNP NNP O
) ) ) O
, , , O
which WDT WDT O
is VBZ VBZ O
the DT DT O
difference NN NN O
between IN IN O
the DT DT O
maximal NN NN O
and CC CC O
minimal JJ JJ O
values NNS NNS O
of IN IN O
the DT DT O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
SBP NNP NNP O
) ) ) O
after IN IN O
one CD CD O
positive JJ JJ O
- - - O
pressure NN NN O
breath NN NN O
, , , O
was VBD VBD O
studied VBN VBN O
in IN IN O
ventilated VBN VBN O
dogs NNS NNS O
subjected VBN VBN O
to TO TO O
hypotension NN NN O
. . . O

Mean VB VB O
arterial JJ JJ O
pressure NN NN O
was VBD VBD O
decreased VBN VBN O
to TO TO O
50 CD CD O
mm NN NN O
Hg NNP NNP O
for IN IN O
30 CD CD O
minutes NNS NNS O
either CC CC O
by IN IN O
hemorrhage NN NN O
( ( ( O
HEM NNP NNP O
, , , O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
or CC CC O
by IN IN O
continuous JJ JJ O
infusion NN NN O
of IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
( ( ( O
SNP NNP NNP B-CHEM
, , , O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
. . . O

During IN IN O
HEM NNP NNP O
- : : O
induced JJ JJ O
hypotension NN NN O
the DT DT O
cardiac NN NN O
output NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
and CC CC O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
higher JJR JJR O
compared VBN VBN O
with IN IN O
that DT DT O
in IN IN O
the DT DT O
SNP NNP NNP B-CHEM
group NN NN O
. . . O

The DT DT O
systemic JJ JJ O
, , , O
central JJ JJ O
venous JJ JJ O
, , , O
pulmonary JJ JJ O
capillary JJ JJ O
wedge NN NN O
pressures NNS NNS O
, , , O
and CC CC O
heart NN NN O
rates NNS NNS O
, , , O
were VBD VBD O
similar JJ JJ O
in IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

Analysis NNP NNP O
of IN IN O
the DT DT O
respiratory NN NN O
changes NNS NNS O
in IN IN O
the DT DT O
arterial JJ JJ O
pressure NN NN O
waveform NN NN O
enabled VBD VBD O
differentiation NN NN O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

The DT DT O
SPV NNP NNP O
during IN IN O
hypotension NN NN O
was VBD VBD O
15 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
7 CD CD O
mm NN NN O
Hg NNP NNP O
in IN IN O
the DT DT O
HEM NNP NNP O
group NN NN O
, , , O
compared VBN VBN O
with IN IN O
9 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
0 CD CD O
mm NN NN O
Hg NNP NNP O
in IN IN O
the DT DT O
SNP NNP NNP B-CHEM
group NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

The DT DT O
delta NN NN O
down RB RB O
, , , O
which WDT WDT O
is VBZ VBZ O
the DT DT O
measure NN NN O
of IN IN O
decrease NN NN O
of IN IN O
SBP NNP NNP O
after IN IN O
a DT DT O
mechanical JJ JJ O
breath NN NN O
, , , O
was VBD VBD O
20 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
4 CD CD O
and CC CC O
10 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
8 CD CD O
mm NN NN O
Hg NNP NNP O
in IN IN O
the DT DT O
HEM NNP NNP O
and CC CC O
SNP NNP NNP B-CHEM
groups NNS NNS O
, , , O
respectively RB RB O
, , , O
during IN IN O
hypotension NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
increases NNS NNS O
in IN IN O
the DT DT O
SPV NNP NNP O
and CC CC O
the DT DT O
delta NN NN O
down RB RB O
are VBP VBP O
characteristic JJ JJ O
of IN IN O
a DT DT O
hypotensive JJ JJ O
state NN NN O
due JJ JJ O
to TO TO O
a DT DT O
predominant NN NN O
decrease NN NN O
in IN IN O
preload NN NN O
. . . O

They PRP PRP O
are VBP VBP O
thus RB RB O
more RBR RBR O
important JJ JJ O
during IN IN O
absolute JJ JJ O
hypovolemia NN NN O
than IN IN O
during IN IN O
deliberate JJ JJ O
hypotension NN NN O
. . . O

Ventricular NNP NNP O
tachyarrhythmias NNS NNS O
during IN IN O
cesarean JJ JJ O
section NN NN O
after IN IN O
ritodrine NN NN B-CHEM
therapy NN NN O
: : : O
interaction NN NN O
with IN IN O
anesthetics NNS NNS O
. . . O

This DT DT O
case NN NN O
illustrates VBZ VBZ O
that IN IN O
patients NNS NNS O
receiving VBG VBG O
ritodrine NN NN B-CHEM
for IN IN O
preterm NN NN O
labor NN NN O
may MD MD O
risk VB VB O
interactions NNS NNS O
between IN IN O
the DT DT O
residual JJ JJ O
betamimetic JJ JJ O
effects NNS NNS O
of IN IN O
ritodrine NN NN B-CHEM
and CC CC O
the DT DT O
effects NNS NNS O
of IN IN O
anesthetics NNS NNS O
during IN IN O
cesarean JJ JJ O
section NN NN O
. . . O

Such JJ JJ O
interactions NNS NNS O
may MD MD O
result VB VB O
in IN IN O
serious JJ JJ O
cardiovascular JJ JJ O
complications NNS NNS O
even RB RB O
after IN IN O
cessation NN NN O
of IN IN O
an DT DT O
infusion NN NN O
of IN IN O
ritodrine NN NN B-CHEM
. . . O

Preoperative JJ JJ O
assessment NN NN O
should MD MD O
focus VB VB O
on IN IN O
cardiovascular JJ JJ O
status NN NN O
and CC CC O
serum NN NN O
potassium NN NN B-CHEM
level NN NN O
. . . O

Delaying NNP NNP O
induction NN NN O
of IN IN O
anesthesia NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
whenever WRB WRB O
possible JJ JJ O
. . . O

Careful NNP NNP O
fluid JJ JJ O
administration NN NN O
and CC CC O
cautious JJ JJ O
use NN NN O
of IN IN O
titrated JJ JJ O
doses NNS NNS O
of IN IN O
ephedrine NN NN B-CHEM
are VBP VBP O
advised VBN VBN O
. . . O

After IN IN O
delivery NN NN O
of IN IN O
the DT DT O
infant NN NN O
, , , O
there EX EX O
should MD MD O
be VB VB O
no DT DT O
contraindication NN NN O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
an DT DT O
alpha NN NN O
- - - O
adrenergic JJ JJ O
vasopressor NN NN O
such JJ JJ O
as IN IN O
phenylephrine NN NN B-CHEM
to TO TO O
treat VB VB O
hypotensive JJ JJ O
patients NNS NNS O
with IN IN O
tachycardia NN NN O
. . . O

Verapamil NNP NNP B-CHEM
- : : O
induced JJ JJ O
carbamazepine NN NN B-CHEM
neurotoxicity NN NN O
. . . O

A DT DT O
report NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

Two CD CD O
patients NNS NNS O
with IN IN O
signs NNS NNS O
of IN IN O
carbamazepine NN NN B-CHEM
neurotoxicity NN NN O
after IN IN O
combined JJ JJ O
treatment NN NN O
with IN IN O
verapamil NN NN B-CHEM
showed VBD VBD O
complete JJ JJ O
recovery NN NN O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
calcium NN NN B-CHEM
entry NN NN O
blocker NN NN O
. . . O

Use NN NN O
of IN IN O
verapamil NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
carbamazepine NN NN B-CHEM
should MD MD O
either CC CC O
be VB VB O
avoided VBN VBN O
or CC CC O
prescribed VBN VBN O
only RB RB O
with IN IN O
appropriate JJ JJ O
adjustment NN NN O
of IN IN O
the DT DT O
carbamazepine NN NN B-CHEM
dose NN NN O
( ( ( O
usually RB RB O
reduction NN NN O
of IN IN O
the DT DT O
carbamazepine NN NN B-CHEM
dose NN NN O
by IN IN O
one CD CD O
half NN NN O
) ) ) O
. . . O

Paracetamol NNP NNP B-CHEM
- - - O
associated VBN VBN O
coma NN NN O
, , , O
metabolic JJ JJ O
acidosis NN NN O
, , , O
renal JJ JJ O
and CC CC O
hepatic JJ JJ O
failure NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
metabolic JJ JJ O
acidosis NN NN O
, , , O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
and CC CC O
hepatic JJ JJ O
failure NN NN O
following VBG VBG O
paracetamol NN NN B-CHEM
ingestion NN NN O
is VBZ VBZ O
presented VBN VBN O
. . . O

The DT DT O
diagnostic JJ JJ O
difficulty NN NN O
at IN IN O
presentation NN NN O
is VBZ VBZ O
highlighted VBN VBN O
. . . O

Continuous NNP NNP O
arteriovenous JJ JJ O
haemofiltration NN NN O
proved VBD VBD O
a DT DT O
valuable JJ JJ O
means NNS NNS O
of IN IN O
maintaining VBG VBG O
fluid NN NN O
and CC CC O
electrolyte NN NN O
balance NN NN O
. . . O

The DT DT O
patient NN NN O
recovered VBD VBD O
. . . O

Sexual NNP NNP O
dysfunction NN NN O
among IN IN O
patients NNS NNS O
with IN IN O
arthritis NN NN O
. . . O

The DT DT O
relationship NN NN O
of IN IN O
arthritis NN NN O
and CC CC O
sexual JJ JJ O
dysfunction NN NN O
was VBD VBD O
investigated VBN VBN O
among IN IN O
169 CD CD O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
, , , O
osteoarthritis NNS NNS O
and CC CC O
spondyloarthropathy NN NN O
, , , O
130 CD CD O
of IN IN O
whom WP WP O
were VBD VBD O
pair JJ JJ O
- - - O
matched JJ JJ O
to TO TO O
controls NNS NNS O
. . . O

Assessments NNP NNP O
of IN IN O
marital JJ JJ O
happiness NN NN O
and CC CC O
depressed VBN VBN O
mood NN NN O
were VBD VBD O
also RB RB O
made VBN VBN O
using VBG VBG O
the DT DT O
CES NNP NNP O
- : : O
D NNP NNP O
and CC CC O
the DT DT O
Azrin NNP NNP O
Marital NNP NNP O
Happiness NNP NNP O
Scale NNP NNP O
( ( ( O
AMHS NNP NNP O
) ) ) O
. . . O

Sexual NNP NNP O
dysfunctions NNS NNS O
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
common JJ JJ O
among IN IN O
patients NNS NNS O
and CC CC O
controls NNS NNS O
, , , O
the DT DT O
majority NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
reporting VBG VBG O
one CD CD O
or CC CC O
more JJR JJR O
dysfunctions NNS NNS O
. . . O

Impotence NNP NNP O
was VBD VBD O
more RBR RBR O
common JJ JJ O
among IN IN O
male JJ JJ O
patients NNS NNS O
than IN IN O
controls NNS NNS O
and CC CC O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
co NN NN O
- - - O
morbidity NN NN O
and CC CC O
the DT DT O
taking VBG VBG O
of IN IN O
methotrexate NN NN B-CHEM
. . . O

Depressed NNP NNP O
mood NN NN O
was VBD VBD O
more RBR RBR O
common JJ JJ O
among IN IN O
patients NNS NNS O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
certain JJ JJ O
sexual JJ JJ O
difficulties NNS NNS O
, , , O
but CC CC O
not RB RB O
with IN IN O
impotence NN NN O
. . . O

Marital NNP NNP O
unhappiness NN NN O
, , , O
as IN IN O
indicated VBN VBN O
by IN IN O
AMHS NNP NNP O
scores NNS NNS O
, , , O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
arthritis NN NN O
but CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
sexual JJ JJ O
dysfunction NN NN O
, , , O
sexual JJ JJ O
dissatisfaction NN NN O
and CC CC O
being VBG VBG O
female JJ JJ O
. . . O

Does VBZ VBZ O
paracetamol NN NN B-CHEM
cause VB VB O
urothelial JJ JJ O
cancer NN NN O
or CC CC O
renal JJ JJ O
papillary JJ JJ O
necrosis NN NN O
? . . O

The DT DT O
risk NN NN O
of IN IN O
developing VBG VBG O
renal JJ JJ O
papillary JJ JJ O
necrosis NN NN O
or CC CC O
cancer NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
pelvis NN NN O
, , , O
ureter NN NN O
or CC CC O
bladder NN NN O
associated VBN VBN O
with IN IN O
consumption NN NN O
of IN IN O
either DT DT O
phenacetin NN NN B-CHEM
or CC CC O
paracetamol NN NN B-CHEM
was VBD VBD O
calculated VBN VBN O
from IN IN O
data NNS NNS O
acquired VBN VBN O
by IN IN O
questionnaire NN NN O
from IN IN O
381 CD CD O
cases NNS NNS O
and CC CC O
808 CD CD O
controls NNS NNS O
. . . O

The DT DT O
risk NN NN O
of IN IN O
renal NN NN O
papillary JJ JJ O
necrosis NN NN O
was VBD VBD O
increased VBN VBN O
nearly RB RB O
20 CD CD O
- : : O
fold NN NN O
by IN IN O
consumption NN NN O
of IN IN O
phenacetin NN NN B-CHEM
, , , O
which WDT WDT O
also RB RB O
increased VBN VBN O
the DT DT O
risk NN NN O
for IN IN O
cancer NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
pelvis NN NN O
and CC CC O
bladder NN NN O
but CC CC O
not RB RB O
for IN IN O
ureteric JJ JJ O
cancer NN NN O
. . . O

By IN IN O
contrast NN NN O
, , , O
we PRP PRP O
were VBD VBD O
unable JJ JJ O
to TO TO O
substantiate VB VB O
an DT DT O
increased JJ JJ O
risk NN NN O
from IN IN O
paracetamol NN NN B-CHEM
consumption NN NN O
for IN IN O
renal JJ JJ O
papillary JJ JJ O
necrosis NN NN O
or CC CC O
any DT DT O
of IN IN O
these DT DT O
cancers NNS NNS O
although IN IN O
there EX EX O
was VBD VBD O
a DT DT O
suggestion NN NN O
of IN IN O
an DT DT O
association NN NN O
with IN IN O
cancer NN NN O
of IN IN O
the DT DT O
ureter NN NN O
. . . O

Dapsone NNP NNP B-CHEM
- - - O
associated JJ JJ O
Heinz NNP NNP O
body NN NN O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
Cambodian JJ JJ O
woman NN NN O
with IN IN O
hemoglobin NN NN O
E NNP NNP O
trait NN NN O
. . . O

A DT DT O
Cambodian JJ JJ O
woman NN NN O
with IN IN O
hemoglobin NN NN O
E NNP NNP O
trait NN NN O
( ( ( O
AE NNP NNP O
) ) ) O
and CC CC O
leprosy JJ JJ O
developed VBD VBD O
a DT DT O
Heinz NNP NNP O
body NN NN O
hemolytic JJ JJ O
anemia NN NN O
while IN IN O
taking VBG VBG O
a DT DT O
dose NN NN O
of IN IN O
dapsone NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
not RB RB O
usually RB RB O
associated VBN VBN O
with IN IN O
clinical JJ JJ O
hemolysis NN NN O
. . . O

Her PRP$ PRP$ O
red JJ JJ O
blood NN NN O
cells NNS NNS O
( ( ( O
RBCs NNP NNP O
) ) ) O
had VBD VBD O
increased VBN VBN O
incubated JJ JJ O
Heinz NNP NNP O
body NN NN O
formation NN NN O
, , , O
decreased VBD VBD O
reduced VBN VBN O
glutathione NN NN B-CHEM
( ( ( O
GSH NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
decreased VBD VBD O
GSH NNP NNP B-CHEM
stability NN NN O
. . . O

The DT DT O
pentose NN NN B-CHEM
phosphate NN NN I-CHEM
shunt NN NN O
activity NN NN O
of IN IN O
the DT DT O
dapsone NN NN B-CHEM
- - - O
exposed VBN VBN O
AE NNP NNP O
RBCs NNP NNP O
was VBD VBD O
increased VBN VBN O
compared VBN VBN O
to TO TO O
normal JJ JJ O
RBCs NNP NNP O
. . . O

Although IN IN O
the DT DT O
AE NNP NNP O
RBCs NNP NNP O
from IN IN O
an DT DT O
individual JJ JJ O
not RB RB O
taking VBG VBG O
dapsone NN NN B-CHEM
had VBD VBD O
increased VBN VBN O
incubated JJ JJ O
Heinz NNP NNP O
body NN NN O
formation NN NN O
, , , O
the DT DT O
GSH NNP NNP B-CHEM
content NN NN O
and CC CC O
GSH NNP NNP B-CHEM
stability NN NN O
were VBD VBD O
normal JJ JJ O
. . . O

The DT DT O
pentose NN NN B-CHEM
phosphate NN NN I-CHEM
shunt NN NN O
activity NN NN O
of IN IN O
the DT DT O
non NN NN O
- - - O
dapsone NN NN B-CHEM
- - - O
exposed VBN VBN O
AE NNP NNP O
RBCs NNP NNP O
was VBD VBD O
decreased VBN VBN O
compared VBN VBN O
to TO TO O
normal JJ JJ O
RBCs NNP NNP O
. . . O

Thus RB RB O
, , , O
AE NNP NNP O
RBCs NNP NNP O
appear VB VB O
to TO TO O
have VB VB O
an DT DT O
increased VBN VBN O
sensitivity NN NN O
to TO TO O
oxidant VB VB O
stress NN NN O
both DT DT O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
, , , O
since IN IN O
dapsone NN NN B-CHEM
does VBZ VBZ O
not RB RB O
cause VB VB O
hemolytic JJ JJ O
anemia NN NN O
at IN IN O
this DT DT O
dose NN NN O
in IN IN O
hematologically RB RB O
normal JJ JJ O
individuals NNS NNS O
. . . O

Given VBN VBN O
the DT DT O
influx NN NN O
of IN IN O
Southeast NNP NNP O
Asians NNP NNP O
into IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
, , , O
oxidant JJ JJ O
medications NNS NNS O
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
caution NN NN O
, , , O
especially RB RB O
if IN IN O
an DT DT O
infection NN NN O
is VBZ VBZ O
present JJ JJ O
, , , O
in IN IN O
individuals NNS NNS O
of IN IN O
ethnic JJ JJ O
backgrounds NNS NNS O
that WDT WDT O
have VBP VBP O
an DT DT O
increased VBN VBN O
prevalence NN NN O
of IN IN O
hemoglobin NN NN O
E NNP NNP O
. . . O

Severe NNP NNP O
complications NNS NNS O
of IN IN O
antianginal JJ JJ O
drug NN NN O
therapy NN NN O
in IN IN O
a DT DT O
patient NN NN O
identified VBN VBN O
as IN IN O
a DT DT O
poor JJ JJ O
metabolizer NN NN O
of IN IN O
metoprolol NN NN B-CHEM
, , , O
propafenone NN NN B-CHEM
, , , O
diltiazem NN NN B-CHEM
, , , O
and CC CC O
sparteine NN NN B-CHEM
. . . O

A DT DT O
47 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
suffering VBG VBG O
from IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
CCU NNP NNP O
in IN IN O
shock NN NN O
with IN IN O
III NNP NNP O
. . . O

AV NNP NNP O
block NN NN O
, , , O
severe JJ JJ O
hypotension NN NN O
, , , O
and CC CC O
impairment NN NN O
of IN IN O
ventricular NN NN O
function NN NN O
. . . O

One CD CD O
week NN NN O
prior RB RB O
to TO TO O
admission NN NN O
a DT DT O
therapy NN NN O
with IN IN O
standard JJ JJ O
doses NNS NNS O
of IN IN O
metoprolol NN NN B-CHEM
( ( ( O
100 CD CD O
mg NN NN O
t NN NN O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O
and CC CC O
then RB RB O
100 CD CD O
mg NN NN O
b SYM SYM O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O
) ) ) O
had VBD VBD O
been VBN VBN O
initiated VBN VBN O
. . . O

Two CD CD O
days NNS NNS O
before IN IN O
admission NN NN O
diltiazem NN NN B-CHEM
( ( ( O
60 CD CD O
mg NN NN O
b SYM SYM O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O
) ) ) O
was VBD VBD O
prescribed VBN VBN O
in IN IN O
addition NN NN O
. . . O

Analyses NNP NNP O
of IN IN O
a DT DT O
blood NN NN O
sample NN NN O
revealed VBD VBD O
unusually RB RB O
high JJ JJ O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
metoprolol NN NN B-CHEM
( ( ( O
greater JJR JJR O
than IN IN O
3000 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
) ) ) O
and CC CC O
diltiazem NN NN B-CHEM
( ( ( O
526 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

The DT DT O
patient NN NN O
recovered VBD VBD O
within IN IN O
1 CD CD O
week NN NN O
following VBG VBG O
discontinuation NN NN O
of IN IN O
antianginal JJ JJ O
therapy NN NN O
. . . O

Three CD CD O
months NNS NNS O
later RB RB O
the DT DT O
patient NN NN O
was VBD VBD O
exposed VBN VBN O
to TO TO O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
metoprolol NN NN B-CHEM
, , , O
diltiazem NN NN B-CHEM
, , , O
propafenone NN NN B-CHEM
( ( ( O
since IN IN O
he PRP PRP O
had VBD VBD O
received VBN VBN O
this DT DT O
drug NN NN O
in IN IN O
the DT DT O
past JJ JJ O
) ) ) O
, , , O
and CC CC O
sparteine NN NN B-CHEM
( ( ( O
as IN IN O
a DT DT O
probe NN NN O
for IN IN O
the DT DT O
debrisoquine NN NN B-CHEM
/ NN NN O
sparteine NN NN B-CHEM
type NN NN O
polymorphism NN NN O
of IN IN O
oxidative JJ JJ O
drug NN NN O
metabolism NN NN O
) ) ) O
. . . O

It PRP PRP O
was VBD VBD O
found VBN VBN O
that IN IN O
he PRP PRP O
was VBD VBD O
a DT DT O
poor JJ JJ O
metabolizer NN NN O
of IN IN O
all DT DT O
four CD CD O
drugs NNS NNS O
, , , O
indicating VBG VBG O
that IN IN O
their PRP$ PRP$ O
metabolism NN NN O
is VBZ VBZ O
under IN IN O
the DT DT O
same JJ JJ O
genetic JJ JJ O
control NN NN O
. . . O

Therefore RB RB O
, , , O
patients NNS NNS O
belonging VBG VBG O
to TO TO O
the DT DT O
poor JJ JJ O
- - - O
metabolizer NN NN O
phenotype NN NN O
of IN IN O
sparteine NN NN B-CHEM
/ NN NN O
debrisoquine NN NN B-CHEM
polymorphism NN NN O
in IN IN O
drug NN NN O
metabolism NN NN O
, , , O
which WDT WDT O
constitutes VBZ VBZ O
6 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
the DT DT O
German JJ JJ O
population NN NN O
, , , O
may MD MD O
experience VB VB O
adverse JJ JJ O
drug NN NN O
reactions NNS NNS O
when WRB WRB O
treated VBN VBN O
with IN IN O
standard JJ JJ O
doses NNS NNS O
of IN IN O
one CD CD O
of IN IN O
these DT DT O
drugs NNS NNS O
alone RB RB O
. . . O

Moreover RB RB O
, , , O
the DT DT O
coadministration NN NN O
of IN IN O
these DT DT O
frequently RB RB O
used VBN VBN O
drugs NNS NNS O
is VBZ VBZ O
expected VBN VBN O
to TO TO O
be VB VB O
especially RB RB O
harmful JJ JJ O
in IN IN O
this DT DT O
subgroup NN NN O
of IN IN O
patients NNS NNS O
. . . O

Clinical NNP NNP O
experiences NNS NNS O
in IN IN O
an DT DT O
open JJ JJ O
and CC CC O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
sixty NN NN O
patients NNS NNS O
were VBD VBD O
trated VBN VBN O
with IN IN O
bromperidol NN NN B-CHEM
first RB RB O
in IN IN O
open JJ JJ O
conditions NNS NNS O
( ( ( O
20 CD CD O
patients NNS NNS O
) ) ) O
, , , O
then RB RB O
on IN IN O
a DT DT O
double JJ JJ O
blind JJ JJ O
basis NN NN O
( ( ( O
40 CD CD O
patients NNS NNS O
) ) ) O
with IN IN O
haloperidol NN NN B-CHEM
as IN IN O
the DT DT O
reference NN NN O
substance NN NN O
. . . O

The DT DT O
open JJ JJ O
study NN NN O
lasted VBD VBD O
for IN IN O
four CD CD O
weeks NNS NNS O
; : : O
the DT DT O
drug NN NN O
was VBD VBD O
administrated VBN VBN O
in IN IN O
the DT DT O
form NN NN O
of IN IN O
1 CD CD O
mg NN NN O
tablets NNS NNS O
. . . O

The DT DT O
daily JJ JJ O
dose NN NN O
( ( ( O
initial JJ JJ O
dose NN NN O
: : : O
1 CD CD O
mg NN NN O
; : : O
mean NN NN O
dose NN NN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
trial NN NN O
: : : O
4 CD CD O
. . . O
47 CD CD O
mg NN NN O
) ) ) O
was VBD VBD O
always RB RB O
administered VBN VBN O
in IN IN O
one CD CD O
single JJ JJ O
dose NN NN O
. . . O

Nineteen NNP NNP O
patients NNS NNS O
finished VBD VBD O
the DT DT O
trial NN NN O
, , , O
and CC CC O
in IN IN O
18 CD CD O
cases NNS NNS O
the DT DT O
therapeutic JJ JJ O
result NN NN O
was VBD VBD O
considered VBN VBN O
very RB RB O
good JJ JJ O
to TO TO O
good JJ JJ O
. . . O

These DT DT O
results NNS NNS O
were VBD VBD O
confirmed VBN VBN O
by IN IN O
statistical JJ JJ O
analysis NN NN O
. . . O

Nine CD CD O
patients NNS NNS O
exhibited VBN VBN O
mild NN NN O
to TO TO O
moderate VB VB O
extrapyramidal NN NN O
concomitant NN NN O
symptoms NNS NNS O
; : : O
no DT DT O
other JJ JJ O
side NN NN O
effects NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
detailed JJ JJ O
laboratory NN NN O
tests NNS NNS O
and CC CC O
evaluations NNS NNS O
of IN IN O
various JJ JJ O
quantitative JJ JJ O
and CC CC O
qualitative JJ JJ O
tolerability NN NN O
parameters NNS NNS O
were VBD VBD O
not RB RB O
indicative JJ JJ O
of IN IN O
toxic JJ JJ O
effects NNS NNS O
. . . O

In IN IN O
the DT DT O
double JJ JJ O
blind JJ JJ O
study NN NN O
with IN IN O
haloperidol NN NN B-CHEM
, , , O
both DT DT O
substances NNS NNS O
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
highly RB RB O
effective JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
psychotic JJ JJ O
syndromes NNS NNS O
belonging VBG VBG O
predominantly RB RB O
to TO TO O
the DT DT O
schizophrenia NN NN O
group NN NN O
. . . O

Certain JJ JJ O
clues NNS NNS O
, , , O
including VBG VBG O
the DT DT O
onset NN NN O
of IN IN O
action NN NN O
, , , O
seem VBP VBP O
to TO TO O
be VB VB O
indicative JJ JJ O
of IN IN O
the DT DT O
superiority NN NN O
of IN IN O
bromperidol NN NN B-CHEM
. . . O

No DT DT O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
with IN IN O
respect NN NN O
to TO TO O
side VB VB O
effects NNS NNS O
and CC CC O
general JJ JJ O
tolerability NN NN O
. . . O

Prolonged NNP NNP O
cholestasis NN NN O
after IN IN O
troleandomycin NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
hepatitis NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
in IN IN O
whom WP WP O
troleandomycin NN NN B-CHEM
- - - O
induced JJ JJ O
hepatitis NN NN O
was VBD VBD O
followed VBN VBN O
by IN IN O
prolonged JJ JJ O
anicteric JJ JJ O
cholestasis NN NN O
. . . O

Jaundice NNP NNP O
occurred VBD VBD O
after IN IN O
administration NN NN O
of IN IN O
troleandomycin NN NN B-CHEM
for IN IN O
7 CD CD O
days NNS NNS O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
hypereosinophilia NN NN O
. . . O

Jaundice NNP NNP O
disappeared VBD VBD O
within IN IN O
3 CD CD O
months NNS NNS O
but CC CC O
was VBD VBD O
followed VBN VBN O
by IN IN O
prolonged JJ JJ O
anicteric JJ JJ O
cholestasis NN NN O
marked VBN VBN O
by IN IN O
pruritus NN NN O
and CC CC O
high JJ JJ O
levels NNS NNS O
of IN IN O
alkaline NN NN O
phosphatase NN NN O
and CC CC O
gammaglutamyltransferase NN NN O
activities NNS NNS O
. . . O

Finally RB RB O
, , , O
pruritus NN NN O
disappeared VBD VBD O
within IN IN O
19 CD CD O
months NNS NNS O
, , , O
and CC CC O
liver NN NN O
tests NNS NNS O
returned VBD VBD O
to TO TO O
normal JJ JJ O
27 CD CD O
months NNS NNS O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
hepatitis NN NN O
. . . O

This DT DT O
observation NN NN O
demonstrates VBZ VBZ O
that IN IN O
prolonged JJ JJ O
cholestasis NNS NNS O
can MD MD O
follow VB VB O
troleandomycin JJ JJ B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
hepatitis NN NN O
. . . O

Serial NNP NNP O
studies NNS NNS O
of IN IN O
auditory NN NN O
neurotoxicity NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
deferoxamine NN NN B-CHEM
therapy NN NN O
. . . O

Visual NNP NNP O
and CC CC O
auditory NN NN O
neurotoxicity NN NN O
was VBD VBD O
previously RB RB O
documented VBN VBN O
in IN IN O
42 CD CD O
of IN IN O
89 CD CD O
patients NNS NNS O
with IN IN O
transfusion NN NN O
- - - O
dependent JJ JJ O
anemia NN NN O
who WP WP O
were VBD VBD O
receiving VBG VBG O
iron NN NN B-CHEM
chelation NN NN O
therapy NN NN O
with IN IN O
daily JJ JJ O
subcutaneous JJ JJ O
deferoxamine NN NN B-CHEM
. . . O

Twenty CD CD O
- - - O
two CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
affected JJ JJ O
group NN NN O
had VBD VBD O
abnormal JJ JJ O
audiograms NNS NNS O
with IN IN O
deficits NNS NNS O
mostly RB RB O
in IN IN O
the DT DT O
high JJ JJ O
frequency NN NN O
range NN NN O
of IN IN O
4 CD CD O
, , , O
000 CD CD O
to TO TO O
8 CD CD O
, , , O
000 CD CD O
Hz NNP NNP O
and CC CC O
in IN IN O
the DT DT O
hearing NN NN O
threshold NN NN O
levels NNS NNS O
of IN IN O
30 CD CD O
to TO TO O
100 CD CD O
decibels NNS NNS O
. . . O

When WRB WRB O
deferoxamine NN NN B-CHEM
therapy NN NN O
was VBD VBD O
discontinued VBN VBN O
and CC CC O
serial JJ JJ O
studies NNS NNS O
were VBD VBD O
performed VBN VBN O
, , , O
audiograms NNS NNS O
in IN IN O
seven CD CD O
cases NNS NNS O
reverted VBN VBN O
to TO TO O
normal JJ JJ O
or CC CC O
near IN IN O
normal JJ JJ O
within IN IN O
two CD CD O
to TO TO O
three CD CD O
weeks NNS NNS O
, , , O
and CC CC O
nine CD CD O
of IN IN O
13 CD CD O
patients NNS NNS O
with IN IN O
symptoms NNS NNS O
became VBD VBD O
asymptomatic JJ JJ O
. . . O

Audiograms NNP NNP O
from IN IN O
15 CD CD O
patients NNS NNS O
remained VBD VBD O
abnormal JJ JJ O
and CC CC O
four CD CD O
patients NNS NNS O
required VBN VBN O
hearing NN NN O
aids NNS NNS O
because IN IN O
of IN IN O
permanent JJ JJ O
disability NN NN O
. . . O

Since IN IN O
18 CD CD O
of IN IN O
the DT DT O
22 CD CD O
patients NNS NNS O
were VBD VBD O
initially RB RB O
receiving VBG VBG O
deferoxamine NN NN B-CHEM
doses NNS NNS O
in IN IN O
excess NN NN O
of IN IN O
the DT DT O
commonly RB RB O
recommended VBN VBN O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
dose NN NN O
, , , O
therapy NN NN O
was VBD VBD O
restarted VBN VBN O
with IN IN O
lower JJR JJR O
doses NNS NNS O
, , , O
usually RB RB O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
dose NN NN O
or CC CC O
less JJR JJR O
depending VBG VBG O
on IN IN O
the DT DT O
degree NN NN O
of IN IN O
auditory JJ JJ O
abnormality NN NN O
, , , O
and CC CC O
with IN IN O
the DT DT O
exception NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
no DT DT O
further JJ JJ O
toxicity NN NN O
was VBD VBD O
demonstrated VBN VBN O
. . . O

Auditory NNP NNP O
deterioration NN NN O
and CC CC O
improvement NN NN O
, , , O
demonstrated VBN VBN O
serially RB RB O
in IN IN O
individual JJ JJ O
patients NNS NNS O
receiving VBG VBG O
and CC CC O
not RB RB O
receiving VBG VBG O
deferoxamine NN NN B-CHEM
, , , O
respectively RB RB O
, , , O
provided VBD VBD O
convincing VBG VBG O
evidence NN NN O
for IN IN O
a DT DT O
cause NN NN O
- - - O
and CC CC O
- - - O
effect NN NN O
relation NN NN O
between IN IN O
deferoxamine NN NN B-CHEM
administration NN NN O
and CC CC O
ototoxicity NN NN O
. . . O

Based VBN VBN O
on IN IN O
these DT DT O
data NNS NNS O
, , , O
a DT DT O
plan NN NN O
of IN IN O
management NN NN O
was VBD VBD O
developed VBN VBN O
that WDT WDT O
allows VBZ VBZ O
effective JJ JJ O
yet RB RB O
safe JJ JJ O
administration NN NN O
of IN IN O
deferoxamine NN NN B-CHEM
. . . O

A DT DT O
dose NN NN O
of IN IN O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
is VBZ VBZ O
recommended VBN VBN O
in IN IN O
those DT DT O
without IN IN O
audiogram NN NN O
abnormalities NNS NNS O
. . . O

With IN IN O
mild JJ JJ O
toxicity NN NN O
, , , O
a DT DT O
reduction NN NN O
to TO TO O
30 CD CD O
or CC CC O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
dose NN NN O
should MD MD O
result VB VB O
in IN IN O
a DT DT O
reversal NN NN O
of IN IN O
the DT DT O
abnormal JJ JJ O
results NNS NNS O
to TO TO O
normal JJ JJ O
within IN IN O
four CD CD O
weeks NNS NNS O
. . . O

Moderate NNP NNP O
abnormalities NNS NNS O
require VBP VBP O
a DT DT O
reduction NN NN O
of IN IN O
deferoxamine NN NN B-CHEM
to TO TO O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
dose NN NN O
with IN IN O
careful JJ JJ O
monitoring NN NN O
. . . O

In IN IN O
those DT DT O
with IN IN O
symptoms NNS NNS O
of IN IN O
hearing NN NN O
loss NN NN O
, , , O
the DT DT O
drug NN NN O
should MD MD O
be VB VB O
stopped VBN VBN O
for IN IN O
four CD CD O
weeks NNS NNS O
, , , O
and CC CC O
when WRB WRB O
the DT DT O
audiogram NN NN O
is VBZ VBZ O
stable JJ JJ O
or CC CC O
improved VBN VBN O
, , , O
therapy NN NN O
should MD MD O
be VB VB O
restarted VBN VBN O
at IN IN O
10 CD CD O
to TO TO O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
dose NN NN O
. . . O

Serial NNP NNP O
audiograms NNS NNS O
should MD MD O
be VB VB O
performed VBN VBN O
every DT DT O
six CD CD O
months NNS NNS O
in IN IN O
those DT DT O
without IN IN O
problems NNS NNS O
and CC CC O
more RBR RBR O
frequently RB RB O
in IN IN O
young JJ JJ O
patients NNS NNS O
with IN IN O
normal JJ JJ O
serum NN NN O
ferritin NN NN O
values NNS NNS O
and CC CC O
in IN IN O
those DT DT O
with IN IN O
auditory JJ JJ O
dysfunction NN NN O
. . . O

Lidocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiac JJ JJ O
asystole NN NN O
. . . O

Intravenous NNP NNP O
administration NN NN O
of IN IN O
a DT DT O
single JJ JJ O
50 CD CD O
- : : O
mg NN NN O
bolus NN NN O
of IN IN O
lidocaine NN NN B-CHEM
in IN IN O
a DT DT O
67 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
resulted VBD VBD O
in IN IN O
profound NN NN O
depression NN NN O
of IN IN O
the DT DT O
activity NN NN O
of IN IN O
the DT DT O
sinoatrial JJ JJ O
and CC CC O
atrioventricular JJ JJ O
nodal NN NN O
pacemakers NNS NNS O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
no DT DT O
apparent NN NN O
associated VBN VBN O
conditions NNS NNS O
which WDT WDT O
might MD MD O
have VB VB O
predisposed VBN VBN O
him PRP PRP O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
bradyarrhythmias NN NN O
; : : O
and CC CC O
, , , O
thus RB RB O
, , , O
this DT DT O
probably RB RB O
represented VBD VBD O
a DT DT O
true JJ JJ O
idiosyncrasy NN NN O
to TO TO O
lidocaine VB VB B-CHEM
. . . O

Flurbiprofen NNP NNP B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
juvenile JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
. . . O

Thirty NNP NNP O
- : : O
four CD CD O
patients NNS NNS O
with IN IN O
juvenile NN NN O
rheumatoid NN NN O
arthritis NN NN O
, , , O
who WP WP O
were VBD VBD O
treated VBN VBN O
with IN IN O
flurbiprofen NN NN B-CHEM
at IN IN O
a DT DT O
maximum NN NN O
dose NN NN O
of IN IN O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, , , O
had VBD VBD O
statistically RB RB O
significant JJ JJ O
decreases NNS NNS O
from IN IN O
baseline NN NN O
in IN IN O
6 CD CD O
arthritis NN NN O
indices NNS NNS O
after IN IN O
12 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

Improvements NNP NNP O
were VBD VBD O
seen VBN VBN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
tender NN NN O
joints NNS NNS O
, , , O
the DT DT O
severity NN NN O
of IN IN O
swelling VBG VBG O
and CC CC O
tenderness NNS NNS O
, , , O
the DT DT O
time NN NN O
of IN IN O
walk NN NN O
50 CD CD O
feet NNS NNS O
, , , O
the DT DT O
duration NN NN O
of IN IN O
morning NN NN O
stiffness NN NN O
and CC CC O
the DT DT O
circumference NN NN O
of IN IN O
the DT DT O
left NN NN O
knee NN NN O
. . . O

The DT DT O
most RBS RBS O
frequently RB RB O
observed VBN VBN O
side NN NN O
effect NN NN O
was VBD VBD O
fecal JJ JJ O
occult NN NN O
blood NN NN O
( ( ( O
25 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
) ) ) O
; : : O
however RB RB O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
other JJ JJ O
evidence NN NN O
of IN IN O
gastrointestinal JJ JJ O
( ( ( O
GI NNP NNP O
) ) ) O
bleeding VBG VBG O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

One CD CD O
patient NN NN O
was VBD VBD O
prematurely RB RB O
discontinued VBN VBN O
from IN IN O
the DT DT O
study NN NN O
for IN IN O
severe JJ JJ O
headache NN NN O
and CC CC O
abdominal JJ JJ O
pain NN NN O
. . . O

Most JJS JJS O
side NN NN O
effects NNS NNS O
were VBD VBD O
mild JJ JJ O
and CC CC O
related VBN VBN O
to TO TO O
the DT DT O
GI NNP NNP O
tract NN NN O
. . . O

Hyperkalemia NNP NNP O
associated VBN VBN O
with IN IN O
sulindac NN NN B-CHEM
therapy NN NN O
. . . O

Hyperkalemia NNP NNP O
has VBZ VBZ O
recently RB RB O
been VBN VBN O
recognized VBN VBN O
as IN IN O
a DT DT O
complication NN NN O
of IN IN O
nonsteroidal NN NN O
antiinflammatory JJ JJ O
agents NNS NNS O
( ( ( O
NSAID NNP NNP O
) ) ) O
such JJ JJ O
as IN IN O
indomethacin NN NN B-CHEM
. . . O

Several JJ JJ O
recent JJ JJ O
studies NNS NNS O
have VBP VBP O
stressed VBN VBN O
the DT DT O
renal NN NN O
sparing JJ JJ O
features NNS NNS O
of IN IN O
sulindac NN NN B-CHEM
, , , O
owing VBG VBG O
to TO TO O
its PRP$ PRP$ O
lack NN NN O
of IN IN O
interference NN NN O
with IN IN O
renal JJ JJ O
prostacyclin NN NN B-CHEM
synthesis NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
4 CD CD O
patients NNS NNS O
in IN IN O
whom WP WP O
hyperkalemia NN NN O
ranging VBG VBG O
from IN IN O
6 CD CD O
. . . O
1 CD CD O
to TO TO O
6 CD CD O
. . . O
9 CD CD O
mEq NN NN O
/ NN NN O
l NN NN O
developed VBN VBN O
within IN IN O
3 CD CD O
to TO TO O
8 CD CD O
days NNS NNS O
of IN IN O
sulindac NN NN B-CHEM
administration NN NN O
. . . O

In IN IN O
all DT DT O
of IN IN O
them PRP PRP O
normal JJ JJ O
serum NN NN O
potassium NN NN B-CHEM
levels NNS NNS O
reached VBN VBN O
within IN IN O
2 CD CD O
to TO TO O
4 CD CD O
days NNS NNS O
of IN IN O
stopping VBG VBG O
sulindac NN NN B-CHEM
. . . O

As IN IN O
no DT DT O
other JJ JJ O
medications NNS NNS O
known VBN VBN O
to TO TO O
effect NN NN O
serum NN NN O
potassium NN NN B-CHEM
had VBD VBD O
been VBN VBN O
given VBN VBN O
concomitantly RB RB O
, , , O
this DT DT O
course NN NN O
of IN IN O
events NNS NNS O
is VBZ VBZ O
suggestive JJ JJ O
of IN IN O
a DT DT O
cause NN NN O
- - - O
and CC CC O
- - - O
effect NN NN O
relationship NN NN O
between IN IN O
sulindac NN NN B-CHEM
and CC CC O
hyperkalemia NN NN O
. . . O

These DT DT O
observations NNS NNS O
indicate VBP VBP O
that IN IN O
initial JJ JJ O
hopes NNS NNS O
that WDT WDT O
sulindac VBP VBP B-CHEM
may MD MD O
not RB RB O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
adverse JJ JJ O
renal JJ JJ O
effects NNS NNS O
of IN IN O
other JJ JJ O
NSAID NNP NNP O
are VBP VBP O
probably RB RB O
not RB RB O
justified JJ JJ O
. . . O

Drug NN NN O
- : : O
induced JJ JJ O
arterial JJ JJ O
spasm NN NN O
relieved VBN VBN O
by IN IN O
lidocaine NN NN B-CHEM
. . . O

Case NN NN O
report NN NN O
. . . O

Following VBG VBG O
major JJ JJ O
intracranial JJ JJ O
surgery NN NN O
in IN IN O
a DT DT O
35 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
, , , O
sodium NN NN B-CHEM
pentothal NN NN I-CHEM
was VBD VBD O
intravenously RB RB O
infused VBN VBN O
to TO TO O
minimize VB VB O
cerebral JJ JJ O
ischaemia NN NN O
. . . O

Intense NNP NNP O
vasospasm NN NN O
with IN IN O
threatened VBN VBN O
gangrene NN NN O
arose NN NN O
in IN IN O
the DT DT O
arm NN NN O
used VBN VBN O
for IN IN O
the DT DT O
infusion NN NN O
. . . O

Since IN IN O
the DT DT O
cranial JJ JJ O
condition NN NN O
precluded JJ JJ O
use NN NN O
of IN IN O
more JJR JJR O
usual JJ JJ O
methods NNS NNS O
, , , O
lidocaine NN NN B-CHEM
was VBD VBD O
given VBN VBN O
intra JJ JJ O
- - - O
arterially RB RB O
, , , O
with IN IN O
careful JJ JJ O
cardiovascular NN NN O
monitoring NN NN O
, , , O
to TO TO O
counteract VB VB O
the DT DT O
vasospasm NN NN O
. . . O

The DT DT O
treatment NN NN O
was VBD VBD O
rapidly RB RB O
successful JJ JJ O
. . . O

Regional NNP NNP O
localization NN NN O
of IN IN O
the DT DT O
antagonism NN NN O
of IN IN O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
by IN IN O
intracerebral JJ JJ O
calcitonin NN NN B-CHEM
injections NNS NNS O
. . . O

Calcitonin NNP NNP B-CHEM
receptors NNS NNS O
are VBP VBP O
found VBN VBN O
in IN IN O
the DT DT O
brain NN NN O
, , , O
and CC CC O
intracerebral JJ JJ O
infusions NNS NNS O
of IN IN O
calcitonin NN NN B-CHEM
can MD MD O
produce VB VB O
behavioral JJ JJ O
effects NNS NNS O
. . . O

Among IN IN O
these DT DT O
behavioral JJ JJ O
effects NNS NNS O
are VBP VBP O
decreases NNS NNS O
in IN IN O
food NN NN O
intake NN NN O
and CC CC O
decreases NNS NNS O
in IN IN O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
activity NN NN O
. . . O

In IN IN O
previous JJ JJ O
experiments NNS NNS O
we PRP PRP O
found VBD VBD O
that IN IN O
decreases NNS NNS O
in IN IN O
food NN NN O
intake NN NN O
were VBD VBD O
induced VBN VBN O
by IN IN O
local JJ JJ O
administration NN NN O
of IN IN O
calcitonin NN NN B-CHEM
into IN IN O
several JJ JJ O
hypothalamic JJ JJ O
sites NNS NNS O
and CC CC O
into IN IN O
the DT DT O
nucleus NN NN O
accumbens NNS NNS O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
experiment NN NN O
calcitonin NN NN B-CHEM
decreased VBD VBD O
locomotor NN NN O
activity NN NN O
when WRB WRB O
locally RB RB O
injected VBN VBN O
into IN IN O
the DT DT O
same JJ JJ O
sites NNS NNS O
where WRB WRB O
it PRP PRP O
decreases VBZ VBZ O
food NN NN O
intake NN NN O
. . . O

The DT DT O
areas NNS NNS O
where WRB WRB O
calcitonin NN NN B-CHEM
is VBZ VBZ O
most RBS RBS O
effective JJ JJ O
in IN IN O
decreasing VBG VBG O
locomotor NN NN O
activity NN NN O
are VBP VBP O
located VBN VBN O
in IN IN O
the DT DT O
hypothalamus NN NN O
and CC CC O
nucleus NN NN O
accumbens NNS NNS O
, , , O
suggesting VBG VBG O
that IN IN O
these DT DT O
areas NNS NNS O
are VBP VBP O
the DT DT O
major JJ JJ O
sites NNS NNS O
of IN IN O
action NN NN O
of IN IN O
calcitonin NN NN B-CHEM
in IN IN O
inhibiting VBG VBG O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
activity NN NN O
. . . O

The DT DT O
hematologic JJ JJ O
effects NNS NNS O
of IN IN O
cefonicid NN NN B-CHEM
and CC CC O
cefazedone NN NN B-CHEM
in IN IN O
the DT DT O
dog NN NN O
: : : O
a DT DT O
potential JJ JJ O
model NN NN O
of IN IN O
cephalosporin NN NN B-CHEM
hematotoxicity NN NN O
in IN IN O
man NN NN O
. . . O

Cephalosporin NNP NNP B-CHEM
antibiotics NNS NNS O
cause VBP VBP O
a DT DT O
variety NN NN O
of IN IN O
hematologic JJ JJ O
disturbances NNS NNS O
in IN IN O
man NN NN O
, , , O
the DT DT O
pathogeneses NNS NNS O
and CC CC O
hematopathology NN NN O
of IN IN O
which WDT WDT O
remain VBP VBP O
poorly RB RB O
characterized VBN VBN O
. . . O

There EX EX O
is VBZ VBZ O
a DT DT O
need NN NN O
for IN IN O
a DT DT O
well RB RB O
- - - O
defined VBN VBN O
animal NN NN O
model NN NN O
in IN IN O
which WDT WDT O
these DT DT O
blood NN NN O
dyscrasias NN NN O
can MD MD O
be VB VB O
studied VBN VBN O
. . . O

In IN IN O
four CD CD O
subacute JJ JJ O
toxicity NN NN O
studies NNS NNS O
, , , O
the DT DT O
intravenous JJ JJ O
administration NN NN O
of IN IN O
cefonicid NN NN B-CHEM
or CC CC O
cefazedone NN NN B-CHEM
to TO TO O
beagle NN NN O
dogs NNS NNS O
caused VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
incidence NN NN O
of IN IN O
anemia NN NN O
, , , O
neutropenia NN NN O
, , , O
and CC CC O
thrombocytopenia NN NN O
after IN IN O
1 CD CD O
- : : O
3 CD CD O
months NNS NNS O
of IN IN O
treatment NN NN O
. . . O

A DT DT O
nonregenerative JJ JJ O
anemia NN NN O
was VBD VBD O
the DT DT O
most RBS RBS O
compromising NN NN O
of IN IN O
the DT DT O
cytopenias NN NN O
and CC CC O
occurred VBD VBD O
in IN IN O
approximately RB RB O
50 CD CD O
% NN NN O
of IN IN O
dogs NNS NNS O
receiving VBG VBG O
400 CD CD O
- : : O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
cefonicid NN NN B-CHEM
or CC CC O
540 CD CD O
- : : O
840 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
cefazedone NN NN B-CHEM
. . . O

All DT DT O
three CD CD O
cytopenias NNS NNS O
were VBD VBD O
completely RB RB O
reversible JJ JJ O
following VBG VBG O
cessation NN NN O
of IN IN O
treatment NN NN O
; : : O
the DT DT O
time NN NN O
required VBN VBN O
for IN IN O
recovery NN NN O
of IN IN O
the DT DT O
erythron NN NN O
( ( ( O
approximately RB RB O
1 CD CD O
month NN NN O
) ) ) O
was VBD VBD O
considerably RB RB O
longer RB RB O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
granulocytes NNS NNS O
and CC CC O
platelets NNS NNS O
( ( ( O
hours NNS NNS O
to TO TO O
a DT DT O
few JJ JJ O
days NNS NNS O
) ) ) O
. . . O

Upon IN IN O
rechallenge NN NN O
with IN IN O
either DT DT O
cephalosporin NN NN B-CHEM
, , , O
the DT DT O
hematologic JJ JJ O
syndrome NN NN O
was VBD VBD O
reproduced VBN VBN O
in IN IN O
most JJS JJS O
dogs NNS NNS O
tested VBN VBN O
; : : O
cefonicid NN NN B-CHEM
( ( ( O
but CC CC O
not RB RB O
cefazedone NN NN B-CHEM
) ) ) O
- : : O
treated VBN VBN O
dogs NNS NNS O
showed VBD VBD O
a DT DT O
substantially RB RB O
reduced VBN VBN O
induction NN NN O
period NN NN O
( ( ( O
15 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
days NNS NNS O
) ) ) O
compared VBN VBN O
to TO TO O
that DT DT O
of IN IN O
the DT DT O
first JJ JJ O
exposure NN NN O
to TO TO O
the DT DT O
drug NN NN O
( ( ( O
61 CD CD O
+ NN NN O
/ NN NN O
- : : O
24 CD CD O
days NNS NNS O
) ) ) O
. . . O

This DT DT O
observation NN NN O
, , , O
along IN IN O
with IN IN O
the DT DT O
rapid JJ JJ O
rate NN NN O
of IN IN O
decline NN NN O
in IN IN O
red JJ JJ O
cell NN NN O
mass NN NN O
parameters NNS NNS O
of IN IN O
affected VBN VBN O
dogs NNS NNS O
, , , O
suggests VBZ VBZ O
that IN IN O
a DT DT O
hemolytic JJ JJ O
component NN NN O
complicated VBD VBD O
the DT DT O
red JJ JJ O
cell NN NN O
production NN NN O
problem NN NN O
and CC CC O
that IN IN O
multiple JJ JJ O
toxicologic JJ JJ O
mechanisms NNS NNS O
contributed VBD VBD O
to TO TO O
the DT DT O
cytopenia NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
administration NN NN O
of IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
cefonicid NN NN B-CHEM
or CC CC O
cefazedone NN NN B-CHEM
to TO TO O
dogs NNS NNS O
can MD MD O
induce VB VB O
hematotoxicity NN NN O
similar JJ JJ O
to TO TO O
the DT DT O
cephalosporin NN NN B-CHEM
- - - O
induced JJ JJ O
blood NN NN O
dyscrasias NN NN O
described VBD VBD O
in IN IN O
man NN NN O
and CC CC O
thus RB RB O
provides VBZ VBZ O
a DT DT O
useful JJ JJ O
model NN NN O
for IN IN O
studying VBG VBG O
the DT DT O
mechanisms NNS NNS O
of IN IN O
these DT DT O
disorders NNS NNS O
. . . O

Cerebral NNP NNP O
blood NN NN O
flow NN NN O
and CC CC O
metabolism NN NN O
during IN IN O
isoflurane NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
in IN IN O
patients NNS NNS O
subjected VBN VBN O
to TO TO O
surgery NN NN O
for IN IN O
cerebral JJ JJ O
aneurysms NNS NNS O
. . . O

Cerebral NNP NNP O
blood NN NN O
flow NN NN O
and CC CC O
cerebral JJ JJ O
metabolic JJ JJ O
rate NN NN O
for IN IN O
oxygen NN NN B-CHEM
were VBD VBD O
measured VBN VBN O
during IN IN O
isoflurane NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
in IN IN O
10 CD CD O
patients NNS NNS O
subjected VBD VBD O
to TO TO O
craniotomy NN NN O
for IN IN O
clipping VBG VBG O
of IN IN O
a DT DT O
cerebral JJ JJ O
aneurysm NN NN O
. . . O

Flow NNP NNP O
and CC CC O
metabolism NN NN O
were VBD VBD O
measured VBN VBN O
5 CD CD O
- : : O
13 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
subarachnoid NN NN O
haemorrhage NN NN O
by IN IN O
a DT DT O
modification NN NN O
of IN IN O
the DT DT O
classical JJ JJ O
Kety NNP NNP O
- : : O
Schmidt NNP NNP O
technique NN NN O
using VBG VBG O
xenon NN NN B-CHEM
- : : O
133 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
Anaesthesia NNP NNP O
was VBD VBD O
maintained VBN VBN O
with IN IN O
an DT DT O
inspired JJ JJ O
isoflurane NN NN B-CHEM
concentration NN NN O
of IN IN O
0 CD CD O
. . . O
75 CD CD O
% NN NN O
( ( ( O
plus CC CC O
67 CD CD O
% NN NN O
nitrous JJ JJ B-CHEM
oxide NN NN I-CHEM
in IN IN O
oxygen NN NN B-CHEM
) ) ) O
, , , O
during IN IN O
which WDT WDT O
CBF NNP NNP O
and CC CC O
CMRO2 NNP NNP O
were VBD VBD O
34 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
1 CD CD O
ml NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
min NN NN O
- : : O
1 CD CD O
and CC CC O
2 CD CD O
. . . O
32 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
16 CD CD O
ml NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
min NN NN O
- : : O
1 CD CD O
at IN IN O
PaCO2 NNP NNP O
4 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
kPa NN NN O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SEM NNP NNP O
) ) ) O
. . . O

Controlled NNP NNP O
hypotension NN NN O
to TO TO O
an DT DT O
average JJ JJ O
MAP NNP NNP O
of IN IN O
50 CD CD O
- : : O
55 CD CD O
mm NN NN O
Hg NNP NNP B-CHEM
was VBD VBD O
induced VBN VBN O
by IN IN O
increasing VBG VBG O
the DT DT O
dose NN NN O
of IN IN O
isoflurane NN NN B-CHEM
, , , O
and CC CC O
maintained VBD VBD O
at IN IN O
an DT DT O
inspired JJ JJ O
concentration NN NN O
of IN IN O
2 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
% NN NN O
. . . O

This DT DT O
resulted VBD VBD O
in IN IN O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
CMRO2 NNP NNP O
( ( ( O
to TO TO O
1 CD CD O
. . . O
73 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
16 CD CD O
ml NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
min NN NN O
- - - O
1 CD CD O
) ) ) O
, , , O
while IN IN O
CBF NNP NNP O
was VBD VBD O
unchanged JJ JJ O
. . . O

After IN IN O
the DT DT O
clipping NN NN O
of IN IN O
the DT DT O
aneurysm NN NN O
the DT DT O
isoflurane NN NN B-CHEM
concentration NN NN O
was VBD VBD O
reduced VBN VBN O
to TO TO O
0 CD CD O
. . . O
75 CD CD O
% NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
CBF NNP NNP O
, , , O
although IN IN O
CMRO2 NNP NNP O
was VBD VBD O
unchanged JJ JJ O
, , , O
compared VBN VBN O
with IN IN O
pre NN NN O
- - - O
hypotensive JJ JJ O
values NNS NNS O
. . . O

These DT DT O
changes NNS NNS O
might MD MD O
offer VB VB O
protection NN NN O
to TO TO O
brain NN NN O
tissue NN NN O
during IN IN O
periods NNS NNS O
of IN IN O
induced JJ JJ O
hypotension NN NN O
. . . O

Triazolam NNP NNP B-CHEM
- : : O
induced JJ JJ O
brief JJ JJ O
episodes NNS NNS O
of IN IN O
secondary JJ JJ O
mania NN NN O
in IN IN O
a DT DT O
depressed JJ JJ O
patient NN NN O
. . . O

Large JJ JJ O
doses NNS NNS O
of IN IN O
triazolam NN NN B-CHEM
repeatedly RB RB O
induced JJ JJ O
brief JJ JJ O
episodes NNS NNS O
of IN IN O
mania NN NN O
in IN IN O
a DT DT O
depressed VBN VBN O
elderly JJ JJ O
woman NN NN O
. . . O

Features NNP NNP O
of IN IN O
organic JJ JJ O
mental JJ JJ O
disorder NN NN O
( ( ( O
delirium NN NN O
) ) ) O
were VBD VBD O
not RB RB O
present JJ JJ O
. . . O

Manic NNP NNP O
excitement NN NN O
was VBD VBD O
coincident NN NN O
with IN IN O
the DT DT O
duration NN NN O
of IN IN O
action NN NN O
of IN IN O
triazolam NN NN B-CHEM
. . . O

The DT DT O
possible JJ JJ O
contribution NN NN O
of IN IN O
the DT DT O
triazolo NN NN B-CHEM
group NN NN O
to TO TO O
changes NNS NNS O
in IN IN O
affective JJ JJ O
status NN NN O
is VBZ VBZ O
discussed VBN VBN O
. . . O

The DT DT O
correlation NN NN O
between IN IN O
neurotoxic JJ JJ O
esterase NN NN O
inhibition NN NN O
and CC CC O
mipafox NN NN B-CHEM
- - - O
induced JJ JJ O
neuropathic JJ JJ O
damage NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
correlation NN NN O
between IN IN O
neuropathic JJ JJ O
damage NN NN O
and CC CC O
inhibition NN NN O
of IN IN O
neurotoxic JJ JJ O
esterase NN NN O
or CC CC O
neuropathy JJ JJ O
target NN NN O
enzyme NN NN O
( ( ( O
NTE NNP NNP O
) ) ) O
was VBD VBD O
examined VBN VBN O
in IN IN O
rats NNS NNS O
acutely RB RB O
exposed VBN VBN O
to TO TO O
Mipafox NNP NNP B-CHEM
( ( ( O
N NNP NNP B-CHEM
, , , I-CHEM
N NNP NNP I-CHEM
' POS POS I-CHEM
- : : I-CHEM
diisopropylphosphorodiamidofluoridate NN NN I-CHEM
) ) ) O
, , , O
a DT DT O
neurotoxic JJ JJ O
organophosphate NN NN B-CHEM
. . . O

Brain NNP NNP O
and CC CC O
spinal JJ JJ O
cord NN NN O
NTE NNP NNP O
activities NNS NNS O
were VBD VBD O
measured VBN VBN O
in IN IN O
Long NNP NNP O
- - - O
Evans NNP NNP O
male JJ JJ O
rats NNS NNS O
1 CD CD O
hr NN NN O
post NN NN O
- : : O
exposure NN NN O
to TO TO O
various JJ JJ O
dosages NNS NNS O
of IN IN O
Mipafox NNP NNP B-CHEM
( ( ( O
ip NNP NNP O
, , , O
1 CD CD O
- : : O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

These DT DT O
data NNS NNS O
were VBD VBD O
correlated VBN VBN O
with IN IN O
histologically RB RB O
scored VBN VBN O
cervical JJ JJ O
cord NN NN O
damage NN NN O
in IN IN O
a DT DT O
separate JJ JJ O
group NN NN O
of IN IN O
similarly RB RB O
dosed VBN VBN O
rats NNS NNS O
sampled VBN VBN O
14 CD CD O
- : : O
21 CD CD O
days NNS NNS O
post JJ JJ O
- : : O
exposure NN NN O
. . . O

Those DT DT O
dosages NNS NNS O
( ( ( O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
that WDT WDT O
inhibited JJ JJ O
mean NN NN O
NTE NNP NNP O
activity NN NN O
in IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
73 CD CD O
% NN NN O
and CC CC O
brain NN NN O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
67 CD CD O
% NN NN O
of IN IN O
control NN NN O
values NNS NNS O
produced VBN VBN O
severe JJ JJ O
( ( ( O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
3 CD CD O
) ) ) O
cervical JJ JJ O
cord NN NN O
pathology NN NN O
in IN IN O
85 CD CD O
% NN NN O
of IN IN O
the DT DT O
rats NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
dosages NNS NNS O
of IN IN O
Mipafox NNP NNP B-CHEM
( ( ( O
less RBR RBR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
which WDT WDT O
inhibited VBD VBD O
mean VB VB O
NTE NNP NNP O
activity NN NN O
in IN IN O
spinal JJ JJ O
cord NN NN O
less JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
61 CD CD O
% NN NN O
and CC CC O
brain NN NN O
less RBR RBR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
60 CD CD O
% NN NN O
produced VBD VBD O
this DT DT O
degree NN NN O
of IN IN O
cord NN NN O
damage NN NN O
in IN IN O
only RB RB O
9 CD CD O
% NN NN O
of IN IN O
the DT DT O
animals NNS NNS O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
a DT DT O
critical JJ JJ O
percentage NN NN O
of IN IN O
NTE NNP NNP O
inhibition NN NN O
in IN IN O
brain NN NN O
and CC CC O
spinal JJ JJ O
cord NN NN O
sampled VBD VBD O
shortly RB RB O
after IN IN O
Mipafox NNP NNP B-CHEM
exposure NN NN O
can MD MD O
predict VB VB O
neuropathic JJ JJ O
damage NN NN O
in IN IN O
rats NNS NNS O
several JJ JJ O
weeks NNS NNS O
later RB RB O
. . . O

Allergic NNP NNP O
reaction NN NN O
to TO TO O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
infusion NN NN O
. . . O

An DT DT O
allergic JJ JJ O
reaction NN NN O
consisting VBG VBG O
of IN IN O
angioneurotic JJ JJ O
edema NN NN O
secondary JJ JJ O
to TO TO O
continuous JJ JJ O
infusion NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
occurred VBD VBD O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
recurrent JJ JJ O
carcinoma NN NN O
of IN IN O
the DT DT O
oral JJ JJ O
cavity NN NN O
, , , O
cirrhosis NNS NNS O
, , , O
and CC CC O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
impaired VBN VBN O
renal JJ JJ O
function NN NN O
. . . O

This DT DT O
reaction NN NN O
occurred VBD VBD O
during IN IN O
the DT DT O
sixth JJ JJ O
and CC CC O
seventh JJ JJ O
courses NNS NNS O
of IN IN O
infusional JJ JJ O
chemotherapy NN NN O
. . . O

Oral NNP NNP O
diphenhydramine NN NN B-CHEM
and CC CC O
prednisone NN NN B-CHEM
were VBD VBD O
ineffective JJ JJ O
in IN IN O
preventing VBG VBG O
the DT DT O
recurrence NN NN O
of IN IN O
the DT DT O
allergic JJ JJ O
reaction NN NN O
. . . O

Discontinuance NNP NNP O
of IN IN O
effective JJ JJ O
chemotherapy NN NN O
in IN IN O
this DT DT O
patient NN NN O
during IN IN O
partial JJ JJ O
remission NN NN O
resulted VBD VBD O
in IN IN O
fatal JJ JJ O
disease NN NN O
progression NN NN O
. . . O

Myasthenia NNP NNP O
gravis NN NN O
caused VBN VBN O
by IN IN O
penicillamine NN NN B-CHEM
and CC CC O
chloroquine NN NN B-CHEM
therapy NN NN O
for IN IN O
rheumatoid NN NN O
arthritis NN NN O
. . . O

We PRP PRP O
have VBP VBP O
described VBN VBN O
a DT DT O
unique JJ JJ O
patient NN NN O
who WP WP O
had VBD VBD O
reversible JJ JJ O
and CC CC O
dose NN NN O
- - - O
related VBN VBN O
myasthenia NN NN O
gravis NN NN O
after IN IN O
penicillamine NN NN B-CHEM
and CC CC O
chloroquine NN NN B-CHEM
therapy NN NN O
for IN IN O
rheumatoid NN NN O
arthritis NN NN O
. . . O

Although IN IN O
acetylcholine NN NN B-CHEM
receptor NN NN O
antibodies NNS NNS O
were VBD VBD O
not RB RB O
detectable JJ JJ O
, , , O
the DT DT O
time NN NN O
course NN NN O
was VBD VBD O
consistent JJ JJ O
with IN IN O
an DT DT O
autoimmune JJ JJ O
process NN NN O
. . . O

On IN IN O
the DT DT O
mechanisms NNS NNS O
of IN IN O
the DT DT O
development NN NN O
of IN IN O
tolerance NN NN O
to TO TO O
the DT DT O
muscular JJ JJ O
rigidity NN NN O
produced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
development NN NN O
of IN IN O
tolerance NN NN O
to TO TO O
the DT DT O
muscular JJ JJ O
rigidity NN NN O
produced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
was VBD VBD O
studied VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

Saline NNP NNP O
- - - O
pretreated JJ JJ O
controls NNS NNS O
given VBN VBN O
a DT DT O
test NN NN O
dose NN NN O
of IN IN O
morphine NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
showed VBD VBD O
a DT DT O
pronounced JJ JJ O
rigidity NN NN O
recorded VBD VBD O
as IN IN O
tonic JJ JJ O
activity NN NN O
in IN IN O
the DT DT O
electromyogram NN NN O
. . . O

Rats NNP NNP O
treated VBN VBN O
for IN IN O
11 CD CD O
days NNS NNS O
with IN IN O
morphine NN NN B-CHEM
and CC CC O
withdrawn NN NN O
for IN IN O
36 CD CD O
- : : O
40 CD CD O
h NN NN O
showed VBD VBD O
differences NNS NNS O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
tolerance NN NN O
: : : O
about IN IN O
half NN NN O
of IN IN O
the DT DT O
animals NNS NNS O
showed VBD VBD O
a DT DT O
rigidity NN NN O
after IN IN O
the DT DT O
test NN NN O
dose NN NN O
of IN IN O
morphine NN NN B-CHEM
that WDT WDT O
was VBD VBD O
not RB RB O
significantly RB RB O
less JJR JJR O
than IN IN O
in IN IN O
the DT DT O
controls NNS NNS O
and CC CC O
were VBD VBD O
akinetic JJ JJ O
( ( ( O
A DT DT O
group NN NN O
) ) ) O
. . . O

The DT DT O
other JJ JJ O
rats NNS NNS O
showed VBD VBD O
a DT DT O
strong JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
rigidity NN NN O
and CC CC O
the DT DT O
occurrence NN NN O
of IN IN O
stereotyped JJ JJ O
( ( ( O
S NNP NNP O
) ) ) O
licking VBG VBG O
and CC CC O
/ NN NN O
or CC CC O
gnawing VBG VBG O
in IN IN O
presence NN NN O
of IN IN O
akinetic JJ JJ O
or CC CC O
hyperkinetic JJ JJ O
( ( ( O
K NNP NNP O
) ) ) O
behaviour NN NN O
( ( ( O
AS IN IN O
/ NN NN O
KS NNP NNP O
group NN NN O
) ) ) O
, , , O
suggesting VBG VBG O
signs NNS NNS O
of IN IN O
dopaminergic JJ JJ O
activation NN NN O
. . . O

The DT DT O
rigidity NN NN O
was VBD VBD O
considerably RB RB O
decreased VBN VBN O
in IN IN O
both DT DT O
groups NNS NNS O
after IN IN O
20 CD CD O
days NNS NNS O
' POS POS O
treatment NN NN O
. . . O

In IN IN O
a DT DT O
further JJ JJ O
series NN NN O
of IN IN O
experiments NNS NNS O
, , , O
haloperidol NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
was VBD VBD O
used VBN VBN O
in IN IN O
order NN NN O
to TO TO O
block VB VB O
the DT DT O
dopaminergic JJ JJ O
activation NN NN O
and CC CC O
to TO TO O
estimate VB VB O
the DT DT O
real JJ JJ O
degree NN NN O
of IN IN O
the DT DT O
tolerance NN NN O
to TO TO O
the DT DT O
rigidity NN NN O
without IN IN O
any DT DT O
dopaminergic JJ JJ O
interference NN NN O
. . . O

Haloperidol NNP NNP B-CHEM
enhanced VBD VBD O
the DT DT O
rigidity NN NN O
in IN IN O
the DT DT O
A DT DT O
group NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
level NN NN O
in IN IN O
the DT DT O
AS NNP NNP O
/ NN NN O
KS NNP NNP O
group NN NN O
remained VBD VBD O
considerably RB RB O
lower JJR JJR O
than IN IN O
in IN IN O
the DT DT O
A DT DT O
group NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
that DT DT O
rigidity NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
assumed VBN VBN O
to TO TO O
be VB VB O
due JJ JJ O
to TO TO O
an DT DT O
action NN NN O
of IN IN O
morphine NN NN B-CHEM
in IN IN O
the DT DT O
striatum NN NN O
, , , O
can MD MD O
be VB VB O
antagonized VBN VBN O
by IN IN O
another DT DT O
process NN NN O
leading VBG VBG O
to TO TO O
dopaminergic VB VB O
activation NN NN O
in IN IN O
the DT DT O
striatum NN NN O
. . . O

Nevertheless RB RB O
, , , O
there EX EX O
occurs VBZ VBZ O
some DT DT O
real JJ JJ O
tolerance NN NN O
to TO TO O
this DT DT O
effect NN NN O
. . . O

The DT DT O
rapid JJ JJ O
alternations NNS NNS O
of IN IN O
rigidity NN NN O
and CC CC O
the DT DT O
signs NNS NNS O
of IN IN O
dopaminergic JJ JJ O
activation NN NN O
observed VBD VBD O
in IN IN O
the DT DT O
animals NNS NNS O
of IN IN O
the DT DT O
AS NNP NNP O
/ NN NN O
KS NNP NNP O
group NN NN O
might MD MD O
be VB VB O
due JJ JJ O
to TO TO O
rapid JJ JJ O
shifts NNS NNS O
in IN IN O
the DT DT O
predominance NN NN O
of IN IN O
various JJ JJ O
DA NNP NNP O
- - - O
innervated JJ JJ O
structures NNS NNS O
. . . O

A DT DT O
case NN NN O
of IN IN O
massive JJ JJ O
rhabdomyolysis NNS NNS O
following VBG VBG O
molindone NN NN B-CHEM
administration NN NN O
. . . O

Rhabdomyolysis NNP NNP O
is VBZ VBZ O
a DT DT O
potentially RB RB O
lethal JJ JJ O
syndrome NN NN O
that IN IN O
psychiatric JJ JJ O
patients NNS NNS O
seem VBP VBP O
predisposed VBN VBN O
to TO TO O
develop VB VB O
. . . O

The DT DT O
clinical JJ JJ O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
, , , O
typical JJ JJ O
laboratory NN NN O
features NNS NNS O
, , , O
and CC CC O
complications NNS NNS O
of IN IN O
rhabdomyolysis NNS NNS O
are VBP VBP O
presented VBN VBN O
. . . O

The DT DT O
case NN NN O
of IN IN O
a DT DT O
schizophrenic JJ JJ O
patient NN NN O
is VBZ VBZ O
reported VBN VBN O
to TO TO O
illustrate VB VB O
massive JJ JJ O
rhabdomyolysis NNS NNS O
and CC CC O
subsequent JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
following VBG VBG O
molindone NN NN B-CHEM
administration NN NN O
. . . O

Physicians NNP NNP O
who WP WP O
prescribe VBP VBP O
molindone NN NN B-CHEM
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
reaction NN NN O
. . . O

Compression NNP NNP O
neuropathy NN NN O
of IN IN O
the DT DT O
radial JJ JJ O
nerve NN NN O
due JJ JJ O
to TO TO O
pentazocine VB VB B-CHEM
- : : O
induced JJ JJ O
fibrous JJ JJ O
myopathy NN NN O
. . . O

Fibrous NNP NNP O
myopathy NN NN O
is VBZ VBZ O
a DT DT O
common JJ JJ O
, , , O
well RB RB O
- - - O
known VBN VBN O
side NN NN O
effect NN NN O
of IN IN O
repeated VBN VBN O
pentazocine NN NN B-CHEM
injection NN NN O
. . . O

However RB RB O
, , , O
compression NN NN O
neuropathy JJ JJ O
due JJ JJ O
to TO TO O
fibrotic JJ JJ O
muscle NN NN O
affected VBN VBN O
by IN IN O
pentazocine NN NN B-CHEM
- - - O
induced JJ JJ O
myopathy NN NN O
has VBZ VBZ O
not RB RB O
previously RB RB O
been VBN VBN O
reported VBN VBN O
. . . O

In IN IN O
a DT DT O
37 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
documented VBN VBN O
pentazocine NN NN B-CHEM
- - - O
induced JJ JJ O
fibrous JJ JJ O
myopathy NN NN O
of IN IN O
triceps NNS NNS O
and CC CC O
deltoid NN NN O
muscles NNS NNS O
bilaterally RB RB O
and CC CC O
a DT DT O
three CD CD O
- - - O
week NN NN O
history NN NN O
of IN IN O
right JJ JJ O
wrist NN NN O
drop NN NN O
, , , O
electrodiagnostic JJ JJ O
examination NN NN O
showed VBD VBD O
a DT DT O
severe JJ JJ O
but CC CC O
partial JJ JJ O
lesion NN NN O
of IN IN O
the DT DT O
right NN NN O
radial NN NN O
nerve NN NN O
distal NN NN O
to TO TO O
the DT DT O
branches NNS NNS O
to TO TO O
the DT DT O
triceps NNS NNS O
, , , O
in IN IN O
addition NN NN O
to TO TO O
the DT DT O
fibrous JJ JJ O
myopathy NN NN O
. . . O

Surgery NNP NNP O
revealed VBD VBD O
the DT DT O
right JJ JJ O
radial NN NN O
nerve NN NN O
to TO TO O
be VB VB O
severely RB RB O
compressed VBN VBN O
by IN IN O
the DT DT O
densely RB RB O
fibrotic JJ JJ O
lateral NN NN O
head NN NN O
of IN IN O
the DT DT O
triceps NNS NNS O
. . . O

Decompression NNP NNP O
and CC CC O
neurolysis NN NN O
were VBD VBD O
performed VBN VBN O
with IN IN O
good JJ JJ O
subsequent JJ JJ O
recovery NN NN O
of IN IN O
function NN NN O
. . . O

Recurrent NNP NNP O
reversible JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
from IN IN O
amphotericin NN NN B-CHEM
. . . O

A DT DT O
patient NN NN O
with IN IN O
cryptogenic JJ JJ O
cirrhosis NNS NNS O
and CC CC O
disseminated VBD VBD O
sporotrichosis NN NN O
developed VBN VBN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
immediately RB RB O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
on IN IN O
four CD CD O
separate JJ JJ O
occasions NNS NNS O
. . . O

The DT DT O
abruptness NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
failure NN NN O
and CC CC O
its PRP$ PRP$ O
reversibility NN NN O
within IN IN O
days NNS NNS O
suggests VBZ VBZ O
that IN IN O
there EX EX O
was VBD VBD O
a DT DT O
functional JJ JJ O
component NN NN O
to TO TO O
the DT DT O
renal JJ JJ O
dysfunction NN NN O
. . . O

We PRP PRP O
propose VBP VBP O
that IN IN O
amphotericin NN NN B-CHEM
, , , O
in IN IN O
the DT DT O
setting NN NN O
of IN IN O
reduced VBN VBN O
effective JJ JJ O
arterial NN NN O
volume NN NN O
, , , O
may MD MD O
activate VB VB O
tubuloglomerular JJ JJ O
feedback NN NN O
, , , O
thereby RB RB O
contributing VBG VBG O
to TO TO O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Cerebral NNP NNP O
infarction NN NN O
with IN IN O
a DT DT O
single JJ JJ O
oral JJ JJ O
dose NN NN O
of IN IN O
phenylpropanolamine NN NN B-CHEM
. . . O

Phenylpropanolamine NNP NNP B-CHEM
( ( ( O
PPA NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
synthetic JJ JJ O
sympathomimetic JJ JJ O
that WDT WDT O
is VBZ VBZ O
structurally RB RB O
similar JJ JJ O
to TO TO O
amphetamine VB VB B-CHEM
, , , O
is VBZ VBZ O
available JJ JJ O
over IN IN O
the DT DT O
counter NN NN O
in IN IN O
anorectics NNS NNS O
, , , O
nasal NN NN O
congestants NNS NNS O
, , , O
and CC CC O
cold JJ JJ O
preparations NNS NNS O
. . . O

Its PRP$ PRP$ O
prolonged JJ JJ O
use NN NN O
or CC CC O
overuse NN NN O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
seizures NNS NNS O
, , , O
intracerebral JJ JJ O
hemorrhage NN NN O
, , , O
neuropsychiatric JJ JJ O
symptoms NNS NNS O
, , , O
and CC CC O
nonhemorrhagic JJ JJ O
cerebral JJ JJ O
infarction NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
young JJ JJ O
woman NN NN O
who WP WP O
suffered VBD VBD O
a DT DT O
cerebral JJ JJ O
infarction NN NN O
after IN IN O
taking VBG VBG O
a DT DT O
single JJ JJ O
oral JJ JJ O
dose NN NN O
of IN IN O
PPA NNP NNP B-CHEM
. . . O

Remission NNP NNP O
induction NN NN O
of IN IN O
meningeal NN NN O
leukemia NN NN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
intravenous JJ JJ O
methotrexate NN NN B-CHEM
. . . O

Twenty CD CD O
children NNS NNS O
with IN IN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
who WP WP O
developed VBD VBD O
meningeal JJ JJ O
disease NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
high JJ JJ O
- - - O
dose NN NN O
intravenous JJ JJ O
methotrexate NN NN B-CHEM
regimen NN NN O
that WDT WDT O
was VBD VBD O
designed VBN VBN O
to TO TO O
achieve VB VB O
and CC CC O
maintain VB VB O
CSF NNP NNP O
methotrexate JJ JJ B-CHEM
concentrations NNS NNS O
of IN IN O
10 CD CD O
( ( ( O
- : : O
5 CD CD O
) ) ) O
mol NN NN O
/ NN NN O
L NNP NNP O
without IN IN O
the DT DT O
need NN NN O
for IN IN O
concomitant JJ JJ O
intrathecal JJ JJ O
dosing NN NN O
. . . O

The DT DT O
methotrexate NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
as IN IN O
a DT DT O
loading NN NN O
dose NN NN O
of IN IN O
6 CD CD O
, , , O
000 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
for IN IN O
a DT DT O
period NN NN O
of IN IN O
one CD CD O
hour NN NN O
followed VBN VBN O
by IN IN O
an DT DT O
infusion NN NN O
of IN IN O
1 CD CD O
, , , O
200 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
h NN NN O
for IN IN O
23 CD CD O
hours NNS NNS O
. . . O

Leucovorin NNP NNP B-CHEM
rescue NN NN O
was VBD VBD O
initiated VBN VBN O
12 CD CD O
hours NNS NNS O
after IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
infusion NN NN O
with IN IN O
a DT DT O
loading VBG VBG O
dose NN NN O
of IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
followed VBN VBN O
by IN IN O
12 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
every DT DT O
three CD CD O
hours NNS NNS O
for IN IN O
six CD CD O
doses NNS NNS O
and CC CC O
then RB RB O
every DT DT O
six CD CD O
hours NNS NNS O
until IN IN O
the DT DT O
plasma NN NN O
methotrexate NN NN B-CHEM
level NN NN O
decreased VBD VBD O
to TO TO O
less JJR JJR O
than IN IN O
1 CD CD O
X NNP NNP O
10 CD CD O
( ( ( O
- : : O
7 CD CD O
) ) ) O
mol NN NN O
/ NN NN O
L NNP NNP O
. . . O

The DT DT O
mean NN NN O
steady JJ JJ O
- : : O
state NN NN O
plasma NN NN O
and CC CC O
CSF NNP NNP O
methotrexate NN NN B-CHEM
concentrations NNS NNS O
achieved VBN VBN O
were VBD VBD O
1 CD CD O
. . . O
1 CD CD O
X NNP NNP O
10 CD CD O
( ( ( O
- : : O
3 CD CD O
) ) ) O
mol NN NN O
/ NN NN O
L NNP NNP O
and CC CC O
3 CD CD O
. . . O
6 CD CD O
X NNP NNP O
10 CD CD O
( ( ( O
- : : O
5 CD CD O
) ) ) O
mol NN NN O
/ NN NN O
L NNP NNP O
, , , O
respectively RB RB O
. . . O

All DT DT O
20 CD CD O
patients NNS NNS O
responded VBD VBD O
to TO TO O
this DT DT O
regimen NN NN O
, , , O
16 CD CD O
/ NN NN O
20 CD CD O
( ( ( O
80 CD CD O
% NN NN O
) ) ) O
achieved VBD VBD O
a DT DT O
complete JJ JJ O
remission NN NN O
, , , O
and CC CC O
20 CD CD O
% NN NN O
obtained VBD VBD O
a DT DT O
partial JJ JJ O
remission NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
toxicities NNS NNS O
encountered VBN VBN O
were VBD VBD O
transient JJ JJ O
serum NN NN O
transaminase NN NN O
and CC CC O
bilirubin NN NN B-CHEM
elevations NNS NNS O
, , , O
neutropenia NN NN O
, , , O
and CC CC O
mucositis NNS NNS O
. . . O

One CD CD O
patient NN NN O
had VBD VBD O
focal JJ JJ O
seizures NNS NNS O
and CC CC O
transient NN NN O
hemiparesis NN NN O
but CC CC O
recovered VBD VBD O
completely RB RB O
. . . O

High NNP NNP O
- - - O
dose NN NN O
intravenous JJ JJ O
methotrexate NN NN B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
treatment NN NN O
for IN IN O
the DT DT O
induction NN NN O
of IN IN O
remission NN NN O
after IN IN O
meningeal NN NN O
relapse NN NN O
in IN IN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
. . . O

Interaction NNP NNP O
of IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
with IN IN O
antineoplastic JJ JJ O
agents NNS NNS O
. . . O

A DT DT O
synergistic JJ JJ O
effect NN NN O
of IN IN O
etoposide NN NN B-CHEM
and CC CC O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
was VBD VBD O
observed VBN VBN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
acute JJ JJ O
T NN NN O
- - - O
lymphocytic JJ JJ O
leukemia NN NN O
in IN IN O
relapse NN NN O
. . . O

The DT DT O
concomitant JJ JJ O
administration NN NN O
of IN IN O
etoposide NN NN B-CHEM
and CC CC O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
resulted VBD VBD O
in IN IN O
eradication NN NN O
of IN IN O
hitherto NN NN O
refractory NN NN O
leukemic JJ JJ O
infiltration NN NN O
of IN IN O
bone NN NN O
marrow NN NN O
. . . O

Severe JJ JJ O
side NN NN O
effects NNS NNS O
in IN IN O
terms NNS NNS O
of IN IN O
mental JJ JJ O
confusion NN NN O
and CC CC O
progressive JJ JJ O
hyperbilirubinemia NN NN O
, , , O
however RB RB O
, , , O
point NN NN O
to TO TO O
an DT DT O
enhancement NN NN O
not RB RB O
only RB RB O
of IN IN O
antineoplastic JJ JJ O
effects NNS NNS O
but CC CC O
also RB RB O
of IN IN O
toxicity NN NN O
in IN IN O
normal JJ JJ O
tissues NNS NNS O
. . . O

This DT DT O
report NN NN O
demonstrates VBZ VBZ O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
that IN IN O
the DT DT O
pharmacodynamic JJ JJ O
properties NNS NNS O
of IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
may MD MD O
not RB RB O
be VB VB O
confined VBN VBN O
strictly RB RB O
to TO TO O
suppression NN NN O
of IN IN O
normal JJ JJ O
T NN NN O
- - - O
cell NN NN O
functions NNS NNS O
. . . O

Incidence NNP NNP O
of IN IN O
neoplasms NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
exposed VBN VBN O
to TO TO O
different JJ JJ O
treatment NN NN O
regimens NNS NNS O
. . . O

Immunosuppressive JJ JJ O
drugs NNS NNS O
have VBP VBP O
been VBN VBN O
used VBN VBN O
during IN IN O
the DT DT O
last JJ JJ O
30 CD CD O
years NNS NNS O
in IN IN O
treatment NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
severe JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
. . . O

The DT DT O
drugs NNS NNS O
commonly RB RB O
used VBN VBN O
are VBP VBP O
cyclophosphamide JJ JJ B-CHEM
and CC CC O
chlorambucil NN NN B-CHEM
( ( ( O
alkylating VBG VBG B-CHEM
agents NNS NNS I-CHEM
) ) ) O
, , , O
azathioprine NN NN B-CHEM
( ( ( O
purine NN NN B-CHEM
analogue NN NN O
) ) ) O
, , , O
and CC CC O
methotrexate NN NN B-CHEM
( ( ( O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
analogue NN NN O
) ) ) O
. . . O

There EX EX O
is VBZ VBZ O
evidence NN NN O
that IN IN O
all DT DT O
four CD CD O
immunosuppressive JJ JJ O
drugs NNS NNS O
can MD MD O
reduce VB VB O
synovitis NNS NNS O
, , , O
but CC CC O
disease NN NN O
activity NN NN O
almost RB RB O
always RB RB O
recurs NNS NNS O
after IN IN O
therapy NN NN O
is VBZ VBZ O
stopped VBN VBN O
. . . O

Since IN IN O
adverse JJ JJ O
reactions NNS NNS O
are VBP VBP O
frequent JJ JJ O
, , , O
less JJR JJR O
than IN IN O
50 CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
are VBP VBP O
able JJ JJ O
to TO TO O
continue VB VB O
a DT DT O
particular JJ JJ O
drug NN NN O
for IN IN O
more JJR JJR O
than IN IN O
one CD CD O
year NN NN O
. . . O

Since IN IN O
it PRP PRP O
takes VBZ VBZ O
three CD CD O
to TO TO O
12 CD CD O
months NNS NNS O
to TO TO O
achieve VB VB O
maximal NN NN O
effects NNS NNS O
, , , O
those DT DT O
patients NNS NNS O
who WP WP O
are VBP VBP O
unable JJ JJ O
to TO TO O
continue VB VB O
the DT DT O
drug NN NN O
receive VBP VBP O
little JJ JJ O
benefit NN NN O
from IN IN O
it PRP PRP O
. . . O

Patients NNS NNS O
treated VBN VBN O
with IN IN O
alkylating VBG VBG B-CHEM
agents NNS NNS I-CHEM
have VBP VBP O
an DT DT O
increased VBN VBN O
risk NN NN O
of IN IN O
development NN NN O
of IN IN O
acute JJ JJ O
nonlymphocytic JJ JJ O
leukemia NN NN O
, , , O
and CC CC O
both DT DT O
alkylating VBG VBG B-CHEM
agents NNS NNS I-CHEM
and CC CC O
azathioprine NN NN B-CHEM
are VBP VBP O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
non NN NN O
- - - O
Hodgkin NNP NNP O
' POS POS O
s VBZ VBZ O
lymphoma NN NN O
. . . O

Cyclophosphamide NNP NNP B-CHEM
therapy NN NN O
increases NNS NNS O
the DT DT O
risk NN NN O
of IN IN O
carcinoma NN NN O
of IN IN O
the DT DT O
bladder NN NN O
. . . O

There EX EX O
have VBP VBP O
been VBN VBN O
several JJ JJ O
long JJ JJ O
- - - O
term NN NN O
studies NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
treated VBN VBN O
with IN IN O
azathioprine NN NN B-CHEM
and CC CC O
cyclophosphamide NN NN B-CHEM
and CC CC O
the DT DT O
incidence NN NN O
of IN IN O
most JJS JJS O
of IN IN O
the DT DT O
common JJ JJ O
cancers NNS NNS O
is VBZ VBZ O
not RB RB O
increased VBN VBN O
. . . O

Data NNP NNP O
on IN IN O
the DT DT O
possible JJ JJ O
increased JJ JJ O
risk NN NN O
of IN IN O
malignancy NN NN O
in IN IN O
rheumatoid NN NN O
arthritis NN NN O
are VBP VBP O
still RB RB O
being VBG VBG O
collected VBN VBN O
, , , O
and CC CC O
until IN IN O
further JJ JJ O
information NN NN O
is VBZ VBZ O
available JJ JJ O
, , , O
the DT DT O
use NN NN O
of IN IN O
immunosuppressive JJ JJ O
drugs NNS NNS O
, , , O
particularly RB RB O
alkylating VBG VBG B-CHEM
agents NNS NNS I-CHEM
, , , O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
rheumatoid NN NN O
arthritis NN NN O
should MD MD O
be VB VB O
reserved VBN VBN O
for IN IN O
patients NNS NNS O
with IN IN O
severe JJ JJ O
progressive JJ JJ O
disease NN NN O
or CC CC O
life NN NN O
- - - O
threatening VBG VBG O
complications NNS NNS O
. . . O

Warfarin NNP NNP B-CHEM
- : : O
induced JJ JJ O
iliopsoas NN NN O
hemorrhage NN NN O
with IN IN O
subsequent JJ JJ O
femoral JJ JJ O
nerve NN NN O
palsy NN NN O
. . . O

We PRP PRP O
present JJ JJ O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
28 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
on IN IN O
chronic JJ JJ O
warfarin NN NN B-CHEM
therapy NN NN O
who WP WP O
sustained VBD VBD O
a DT DT O
minor JJ JJ O
muscle NN NN O
tear NN NN O
and CC CC O
developed VBD VBD O
increasing VBG VBG O
pain NN NN O
and CC CC O
a DT DT O
flexure NN NN O
contracture NN NN O
of IN IN O
the DT DT O
right JJ JJ O
hip NN NN O
. . . O

Surgical NNP NNP O
exploration NN NN O
revealed VBD VBD O
an DT DT O
iliopsoas NN NN O
hematoma NN NN O
and CC CC O
femoral JJ JJ O
nerve NN NN O
entrapment NN NN O
, , , O
resulting VBG VBG O
in IN IN O
a DT DT O
femoral JJ JJ O
nerve NN NN O
palsy NN NN O
and CC CC O
partial JJ JJ O
loss NN NN O
of IN IN O
quadriceps NNS NNS O
functions NNS NNS O
. . . O

Anticoagulant NNP NNP O
- : : O
induced JJ JJ O
femoral NN NN O
nerve NN NN O
palsy NN NN O
represents VBZ VBZ O
the DT DT O
most RBS RBS O
common JJ JJ O
form NN NN O
of IN IN O
warfarin NN NN B-CHEM
- - - O
induced JJ JJ O
peripheral NN NN O
neuropathy NN NN O
; : : O
it PRP PRP O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
severe JJ JJ O
pain NN NN O
in IN IN O
the DT DT O
inguinal JJ JJ O
region NN NN O
, , , O
varying VBG VBG O
degrees NNS NNS O
of IN IN O
motor NN NN O
and CC CC O
sensory JJ JJ O
impairment NN NN O
, , , O
and CC CC O
flexure NN NN O
contracture NN NN O
of IN IN O
the DT DT O
involved VBN VBN O
extremity NN NN O
. . . O

Pneumonitis NNP NNP O
with IN IN O
pleural NN NN O
and CC CC O
pericardial JJ JJ O
effusion NN NN O
and CC CC O
neuropathy NN NN O
during IN IN O
amiodarone NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
patient NN NN O
with IN IN O
sinuatrial JJ JJ O
disease NN NN O
and CC CC O
implanted JJ JJ O
pacemaker NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
amiodarone NN NN B-CHEM
( ( ( O
maximum NN NN O
dose NN NN O
1000 CD CD O
mg NN NN O
, , , O
maintenance NN NN O
dose NN NN O
800 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
for IN IN O
10 CD CD O
months NNS NNS O
, , , O
for IN IN O
control NN NN O
of IN IN O
supraventricular JJ JJ O
tachyarrhythmias NNS NNS O
. . . O

He PRP PRP O
developed JJ JJ O
pneumonitis NNS NNS O
, , , O
pleural JJ JJ O
and CC CC O
pericardial JJ JJ O
effusions NNS NNS O
, , , O
and CC CC O
a DT DT O
predominantly RB RB O
proximal JJ JJ O
motor NN NN O
neuropathy NN NN O
. . . O

Immediate NNP NNP O
but CC CC O
gradual JJ JJ O
improvement NN NN O
followed VBD VBD O
withdrawal NN NN O
of IN IN O
amiodarone NN NN B-CHEM
and CC CC O
treatment NN NN O
with IN IN O
prednisolone NN NN B-CHEM
. . . O

Review NNP NNP O
of IN IN O
this DT DT O
and CC CC O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
indicates VBZ VBZ O
the DT DT O
need NN NN O
for IN IN O
early JJ JJ O
diagnosis NN NN O
of IN IN O
amiodarone NN NN B-CHEM
pneumonitis NN NN O
, , , O
immediate JJ JJ O
withdrawal NN NN O
of IN IN O
amiodarone NN NN B-CHEM
, , , O
and CC CC O
prompt VB VB O
but CC CC O
continued VBD VBD O
steroid JJ JJ B-CHEM
therapy NN NN O
to TO TO O
ensure VB VB O
full JJ JJ O
recovery NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
- - - O
induced JJ JJ O
sinoatrial NN NN O
block NN NN O
. . . O

We PRP PRP O
observed VBD VBD O
sinoatrial JJ JJ O
block NN NN O
due JJ JJ O
to TO TO O
chronic JJ JJ O
amiodarone NN NN B-CHEM
administration NN NN O
in IN IN O
a DT DT O
5 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
with IN IN O
primary JJ JJ O
cardiomyopathy NN NN O
, , , O
Wolff NNP NNP O
- - - O
Parkinson NNP NNP O
- : : O
White NNP NNP O
syndrome NN NN O
and CC CC O
supraventricular JJ JJ O
tachycardia NNS NNS O
. . . O

Reduction NNP NNP O
in IN IN O
the DT DT O
dosage NN NN O
of IN IN O
amiodarone NN NN B-CHEM
resulted VBD VBD O
in IN IN O
the DT DT O
disappearance NN NN O
of IN IN O
the DT DT O
sinoatrial JJ JJ O
block NN NN O
and CC CC O
the DT DT O
persistence NN NN O
of IN IN O
asymptomatic JJ JJ O
sinus NN NN O
bradycardia NN NN O
. . . O

Desipramine NNP NNP B-CHEM
- : : O
induced JJ JJ O
delirium NN NN O
at IN IN O
" '' '' O
subtherapeutic JJ JJ O
" '' '' O
concentrations NNS NNS O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

An DT DT O
elderly JJ JJ O
patient NN NN O
treated VBN VBN O
with IN IN O
low JJ JJ O
dose NN NN O
Desipramine NNP NNP B-CHEM
developed VBD VBD O
a DT DT O
delirium NN NN O
while IN IN O
her PRP$ PRP$ O
plasma NN NN O
level NN NN O
was VBD VBD O
in IN IN O
the DT DT O
" '' '' O
subtherapeutic JJ JJ O
" '' '' O
range NN NN O
. . . O

Delirium NNP NNP O
, , , O
which WDT WDT O
may MD MD O
be VB VB O
induced VBN VBN O
by IN IN O
tricyclic JJ JJ O
drug NN NN O
therapy NN NN O
in IN IN O
the DT DT O
elderly JJ JJ O
, , , O
can MD MD O
be VB VB O
caused VBN VBN O
by IN IN O
tricyclics NNS NNS O
with IN IN O
low JJ JJ O
anticholinergic JJ JJ O
potency NN NN O
. . . O

Therapeutic NNP NNP O
ranges NNS NNS O
for IN IN O
antidepressants NNS NNS B-CHEM
that WDT WDT O
have VBP VBP O
been VBN VBN O
derived VBN VBN O
from IN IN O
general JJ JJ O
adult NN NN O
population NN NN O
studies NNS NNS O
may MD MD O
not RB RB O
be VB VB O
appropriate JJ JJ O
for IN IN O
the DT DT O
elderly JJ JJ O
. . . O

Further NNP NNP O
studies NNS NNS O
of IN IN O
specifically RB RB O
elderly JJ JJ O
patients NNS NNS O
are VBP VBP O
now RB RB O
required VBN VBN O
to TO TO O
establish VB VB O
safer JJR JJR O
and CC CC O
more RBR RBR O
appropriate JJ JJ O
guidelines NNS NNS O
for IN IN O
drug NN NN O
therapy NN NN O
. . . O

Indomethacin NNP NNP B-CHEM
- : : O
induced JJ JJ O
renal NN NN O
insufficiency NN NN O
: : : O
recurrence NN NN O
on IN IN O
rechallenge NN NN O
. . . O

We PRP PRP O
have VBP VBP O
reported VBN VBN O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
oliguric JJ JJ O
renal NN NN O
failure NN NN O
with IN IN O
hyperkalemia NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
cirrhosis NNS NNS O
, , , O
ascites NNS NNS O
, , , O
and CC CC O
cor NN NN O
pulmonale NN NN O
after IN IN O
indomethacin NN NN B-CHEM
therapy NN NN O
. . . O

Prompt NNP NNP O
restoration NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
followed VBD VBD O
drug NN NN O
withdrawal NN NN O
, , , O
while IN IN O
re NN NN O
- : : O
exposure NN NN O
to TO TO O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
indomethacin NN NN B-CHEM
caused VBD VBD O
recurrence NN NN O
of IN IN O
acute JJ JJ O
reversible JJ JJ O
oliguria NN NN O
. . . O

Our PRP$ PRP$ O
case NN NN O
supports VBZ VBZ O
the DT DT O
hypothesis NNS NNS O
that IN IN O
endogenous JJ JJ O
renal JJ JJ O
prostaglandins NNS NNS B-CHEM
play VBP VBP O
a DT DT O
role NN NN O
in IN IN O
the DT DT O
maintenance NN NN O
of IN IN O
renal JJ JJ O
blood NN NN O
flow NN NN O
when WRB WRB O
circulating VBG VBG O
plasma NN NN O
volume NN NN O
is VBZ VBZ O
diminished VBN VBN O
. . . O

Since IN IN O
nonsteroidal NN NN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
agents NNS NNS O
interfere VBP VBP O
with IN IN O
this DT DT O
compensatory JJ JJ O
mechanism NN NN O
and CC CC O
may MD MD O
cause VB VB O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
they PRP PRP O
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
caution NN NN O
in IN IN O
such JJ JJ O
patients NNS NNS O
. . . O

Patterns NNS NNS O
of IN IN O
hepatic JJ JJ O
injury NN NN O
induced VBN VBN O
by IN IN O
methyldopa NN NN B-CHEM
. . . O

Twelve CD CD O
patients NNS NNS O
with IN IN O
liver NN NN O
disease NN NN O
related VBN VBN O
to TO TO O
methyldopa NN NN B-CHEM
were VBD VBD O
seen VBN VBN O
between IN IN O
1967 CD CD O
and CC CC O
1977 CD CD O
. . . O

Illness NNP NNP O
occurred VBD VBD O
within IN IN O
1 CD CD O
- : : O
- : : O
9 CD CD O
weeks NNS NNS O
of IN IN O
commencement NN NN O
of IN IN O
therapy NN NN O
in IN IN O
9 CD CD O
patients NNS NNS O
, , , O
the DT DT O
remaining VBG VBG O
3 CD CD O
patients NNS NNS O
having VBG VBG O
received VBN VBN O
the DT DT O
drug NN NN O
for IN IN O
13 CD CD O
months NNS NNS O
, , , O
15 CD CD O
months NNS NNS O
and CC CC O
7 CD CD O
years NNS NNS O
before IN IN O
experiencing VBG VBG O
symptoms NNS NNS O
. . . O

Jaundice NNP NNP O
with IN IN O
tender NN NN O
hepatomegaly NN NN O
, , , O
usually RB RB O
preceded VBN VBN O
by IN IN O
symptoms NNS NNS O
of IN IN O
malaise NN NN O
, , , O
anorexia NN NN O
, , , O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
, , , O
and CC CC O
associated VBN VBN O
with IN IN O
upper JJ JJ O
abdominal JJ JJ O
pain NN NN O
, , , O
was VBD VBD O
an DT DT O
invariable JJ JJ O
finding VBG VBG O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

Biochemical NNP NNP O
liver NN NN O
function NN NN O
tests NNS NNS O
indicated VBD VBD O
hepatocellular NN NN O
necrosis NN NN O
and CC CC O
correlated JJ JJ O
with IN IN O
histopathological JJ JJ O
evidence NN NN O
of IN IN O
hepatic JJ JJ O
injury NN NN O
, , , O
the DT DT O
spectrum NN NN O
of IN IN O
which WDT WDT O
ranged VBD VBD O
from IN IN O
fatty JJ JJ O
change NN NN O
and CC CC O
focal JJ JJ O
hepatocellular NN NN O
necrosis NN NN O
to TO TO O
massive JJ JJ O
hepatic JJ JJ O
necrosis NN NN O
. . . O

Most JJS JJS O
patients NNS NNS O
showed VBD VBD O
moderate JJ JJ O
to TO TO O
severe JJ JJ O
acute JJ JJ O
hepatitis NN NN O
or CC CC O
chronic JJ JJ O
active JJ JJ O
hepatitis NN NN O
with IN IN O
associated VBN VBN O
cholestasis NNS NNS O
. . . O

The DT DT O
drug NN NN O
was VBD VBD O
withdrawn VBN VBN O
on IN IN O
presentation NN NN O
to TO TO O
hospital NN NN O
in IN IN O
11 CD CD O
patients NNS NNS O
, , , O
with IN IN O
rapid JJ JJ O
clinical JJ JJ O
improvement NN NN O
in IN IN O
9 CD CD O
. . . O

One CD CD O
patient NN NN O
died VBD VBD O
, , , O
having VBG VBG O
presented VBN VBN O
in IN IN O
hepatic JJ JJ O
failure NN NN O
, , , O
and CC CC O
another DT DT O
, , , O
who WP WP O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
methyldopa NN NN B-CHEM
for IN IN O
7 CD CD O
years NNS NNS O
, , , O
showed VBD VBD O
slower JJR JJR O
clinical JJ JJ O
and CC CC O
biochemical JJ JJ O
resolution NN NN O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
several JJ JJ O
months NNS NNS O
. . . O

The DT DT O
remaining VBG VBG O
patient NN NN O
in IN IN O
the DT DT O
series NN NN O
developed VBN VBN O
fulminant JJ JJ O
hepatitis NN NN O
when WRB WRB O
the DT DT O
drug NN NN O
was VBD VBD O
accidentally RB RB O
recommenced VBN VBN O
1 CD CD O
year NN NN O
after IN IN O
a DT DT O
prior JJ JJ O
episode NN NN O
of IN IN O
methyldopa NN NN B-CHEM
- - - O
induced JJ JJ O
hepatitis NN NN O
. . . O

In IN IN O
this DT DT O
latter JJ JJ O
patient NN NN O
, , , O
and CC CC O
in IN IN O
2 CD CD O
others NNS NNS O
, , , O
the DT DT O
causal NN NN O
relationship NN NN O
between IN IN O
methyldopa NN NN B-CHEM
and CC CC O
hepatic JJ JJ O
dysfunction NN NN O
was VBD VBD O
proved VBN VBN O
with IN IN O
the DT DT O
recurrence NN NN O
of IN IN O
hepatitis NN NN O
within IN IN O
2 CD CD O
weeks NNS NNS O
of IN IN O
re NN NN O
- - - O
exposure NN NN O
to TO TO O
the DT DT O
drug NN NN O
. . . O

Suxamethonium NNP NNP B-CHEM
infusion NN NN O
rate NN NN O
and CC CC O
observed VBD VBD O
fasciculations NNS NNS O
. . . O

A DT DT O
dose NN NN O
- - - O
response NN NN O
study NN NN O
. . . O

Suxamethonium NNP NNP B-CHEM
chloride NN NN I-CHEM
( ( ( O
Sch NNP NNP B-CHEM
) ) ) O
was VBD VBD O
administered VBN VBN O
i NNP NNP O
. . . O
v NN NN O
. . . O
to TO TO O
36 CD CD O
adult NN NN O
males NNS NNS O
at IN IN O
six CD CD O
rates NNS NNS O
: : : O
0 CD CD O
. . . O
25 CD CD O
mg NN NN O
s VBZ VBZ O
- - - O
1 CD CD O
to TO TO O
20 CD CD O
mg NN NN O
s VBZ VBZ O
- - - O
1 CD CD O
. . . O

The DT DT O
infusion NN NN O
was VBD VBD O
discontinued VBN VBN O
either CC CC O
when WRB WRB O
there EX EX O
was VBD VBD O
no DT DT O
muscular JJ JJ O
response NN NN O
to TO TO O
tetanic JJ JJ O
stimulation NN NN O
of IN IN O
the DT DT O
ulnar NN NN O
nerve NN NN O
or CC CC O
when WRB WRB O
Sch NNP NNP B-CHEM
120 CD CD O
mg NN NN O
was VBD VBD O
exceeded VBN VBN O
. . . O

Six CD CD O
additional JJ JJ O
patients NNS NNS O
received VBD VBD O
a DT DT O
30 CD CD O
- : : O
mg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
bolus NN NN O
dose NN NN O
. . . O

Fasciculations NNP NNP O
in IN IN O
six CD CD O
areas NNS NNS O
of IN IN O
the DT DT O
body NN NN O
were VBD VBD O
scored VBN VBN O
from IN IN O
0 CD CD O
to TO TO O
3 CD CD O
and CC CC O
summated VBD VBD O
as IN IN O
a DT DT O
total JJ JJ O
fasciculation NN NN O
score NN NN O
. . . O

The DT DT O
times NNS NNS O
to TO TO O
first JJ JJ O
fasciculation NN NN O
, , , O
twitch VB VB O
suppression NN NN O
and CC CC O
tetanus JJ JJ O
suppression NN NN O
were VBD VBD O
inversely RB RB O
related VBN VBN O
to TO TO O
the DT DT O
infusion NN NN O
rates NNS NNS O
. . . O

Fasciculations NNP NNP O
in IN IN O
the DT DT O
six CD CD O
areas NNS NNS O
and CC CC O
the DT DT O
total JJ JJ O
fasciculation NN NN O
score NN NN O
were VBD VBD O
related VBN VBN O
directly RB RB O
to TO TO O
the DT DT O
rate NN NN O
of IN IN O
infusion NN NN O
. . . O

Total NNP NNP O
fasciculation NN NN O
scores NNS NNS O
in IN IN O
the DT DT O
30 CD CD O
- : : O
mg NN NN O
bolus NN NN O
group NN NN O
and CC CC O
the DT DT O
5 CD CD O
- : : O
mg NN NN O
s VBZ VBZ O
- : : O
1 CD CD O
and CC CC O
20 CD CD O
- : : O
mg NN NN O
s VBZ VBZ O
- - - O
1 CD CD O
infusion NN NN O
groups NNS NNS O
were VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
. . . O

Treatment NN NN O
of IN IN O
psoriasis NN NN O
with IN IN O
azathioprine NN NN B-CHEM
. . . O

Azathioprine NNP NNP B-CHEM
treatment NN NN O
benefited VBD VBD O
19 CD CD O
( ( ( O
66 CD CD O
% NN NN O
) ) ) O
out IN IN O
of IN IN O
29 CD CD O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
severe JJ JJ O
psoriasis NN NN O
. . . O

Haematological NNP NNP O
complications NNS NNS O
were VBD VBD O
not RB RB O
troublesome VBN VBN O
and CC CC O
results NNS NNS O
of IN IN O
biochemical JJ JJ O
liver NN NN O
function NN NN O
tests NNS NNS O
remained VBD VBD O
normal JJ JJ O
. . . O

Minimal NNP NNP O
cholestasis NN NN O
was VBD VBD O
seen VBN VBN O
in IN IN O
two CD CD O
cases NNS NNS O
and CC CC O
portal JJ JJ O
fibrosis NNS NNS O
of IN IN O
a DT DT O
reversible JJ JJ O
degree NN NN O
in IN IN O
eight CD CD O
. . . O

Liver NNP NNP O
biopsies NNS NNS O
should MD MD O
be VB VB O
undertaken VBN VBN O
at IN IN O
regular JJ JJ O
intervals NNS NNS O
if IN IN O
azathioprine NN NN B-CHEM
therapy NN NN O
is VBZ VBZ O
continued VBN VBN O
so IN IN O
that DT DT O
structural JJ JJ O
liver NN NN O
damage NN NN O
may MD MD O
be VB VB O
detected VBN VBN O
at IN IN O
an DT DT O
early JJ JJ O
and CC CC O
reversible JJ JJ O
stage NN NN O
. . . O

Angiosarcoma NNP NNP O
of IN IN O
the DT DT O
liver NN NN O
associated VBN VBN O
with IN IN O
diethylstilbestrol NN NN B-CHEM
. . . O

Angiosarcoma NNP NNP O
of IN IN O
the DT DT O
liver NN NN O
occurred VBD VBD O
in IN IN O
a DT DT O
76 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
for IN IN O
a DT DT O
well RB RB O
- - - O
differentiated JJ JJ O
adenocarcinoma NN NN O
of IN IN O
the DT DT O
liver NN NN O
with IN IN O
diethylstilbestrol NN NN B-CHEM
for IN IN O
13 CD CD O
years NNS NNS O
. . . O

Angiosarcoma NNP NNP O
was VBD VBD O
also RB RB O
present JJ JJ O
within IN IN O
pulmonary JJ JJ O
and CC CC O
renal JJ JJ O
arteries NNS NNS O
. . . O

The DT DT O
possibility NN NN O
that IN IN O
the DT DT O
intraarterial JJ JJ O
lesions NNS NNS O
might MD MD O
represent VB VB O
independent JJ JJ O
primary JJ JJ O
tumors NNS NNS O
is VBZ VBZ O
considered VBN VBN O
. . . O

Galanthamine NNP NNP B-CHEM
hydrobromide NN NN I-CHEM
, , , O
a DT DT O
longer RB RB O
acting VBG VBG O
anticholinesterase NN NN O
drug NN NN O
, , , O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
the DT DT O
central JJ JJ O
effects NNS NNS O
of IN IN O
scopolamine NN NN B-CHEM
( ( ( O
Hyoscine NNP NNP B-CHEM
) ) ) O
. . . O

Galanthamine NNP NNP B-CHEM
hydrobromide NN NN I-CHEM
, , , O
an DT DT O
anticholinesterase NN NN O
drug NN NN O
capable JJ JJ O
of IN IN O
penetrating VBG VBG O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
, , , O
was VBD VBD O
used VBN VBN O
in IN IN O
a DT DT O
patient NN NN O
demonstrating VBG VBG O
central JJ JJ O
effects NNS NNS O
of IN IN O
scopolamine NN NN B-CHEM
( ( ( O
hyoscine NN NN B-CHEM
) ) ) O
overdosage NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
longer RBR RBR O
acting VBG VBG O
than IN IN O
physostigmine NN NN B-CHEM
and CC CC O
is VBZ VBZ O
used VBN VBN O
in IN IN O
anaesthesia NN NN O
to TO TO O
reverse VB VB O
the DT DT O
non NN NN O
- - - O
depolarizing VBG VBG O
neuromuscular NN NN O
block NN NN O
. . . O

However RB RB O
, , , O
studies NNS NNS O
into IN IN O
the DT DT O
dose NN NN O
necessary JJ JJ O
to TO TO O
combating VBG VBG O
scopolamine NN NN B-CHEM
intoxication NN NN O
are VBP VBP O
indicated VBN VBN O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
subjective JJ JJ O
effects NNS NNS O
and CC CC O
plasma NN NN O
concentrations NNS NNS O
following VBG VBG O
oral JJ JJ O
and CC CC O
i NNP NNP O
. . . O
m NN NN O
. . . O
administration NN NN O
of IN IN O
flunitrazepam NN NN B-CHEM
in IN IN O
volunteers NNS NNS O
. . . O

Flunitrazepam NNP NNP B-CHEM
0 CD CD O
. . . O
5 CD CD O
, , , O
1 CD CD O
. . . O
0 CD CD O
or CC CC O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
was VBD VBD O
given VBN VBN O
by IN IN O
the DT DT O
oral JJ JJ O
or CC CC O
i NNP NNP O
. . . O
m NN NN O
. . . O
routes NNS NNS O
to TO TO O
groups NNS NNS O
of IN IN O
volunteers NNS NNS O
and CC CC O
its PRP$ PRP$ O
effects NNS NNS O
compared VBN VBN O
. . . O

Plasma NNP NNP O
concentrations NNS NNS O
of IN IN O
the DT DT O
drug NN NN O
were VBD VBD O
estimated VBN VBN O
by IN IN O
gas NN NN O
- - - O
liquid JJ JJ O
chromatography NN NN O
, , , O
in IN IN O
a DT DT O
smaller JJR JJR O
number NN NN O
of IN IN O
the DT DT O
subjects NNS NNS O
. . . O

The DT DT O
most RBS RBS O
striking JJ JJ O
effect NN NN O
was VBD VBD O
sedation NN NN O
which WDT WDT O
increased VBD VBD O
with IN IN O
the DT DT O
dose NN NN O
, , , O
2 CD CD O
mg NN NN O
producing VBG VBG O
deep JJ JJ O
sleep NN NN O
although IN IN O
the DT DT O
subjects NNS NNS O
could MD MD O
still RB RB O
be VB VB O
aroused VBN VBN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
i NNP NNP O
. . . O
m NN NN O
. . . O
administration NN NN O
were VBD VBD O
apparent JJ JJ O
earlier RBR RBR O
and CC CC O
sometimes RB RB O
lasted JJ JJ O
longer RBR RBR O
than IN IN O
those DT DT O
following VBG VBG O
oral JJ JJ O
administration NN NN O
. . . O

Dizziness NNP NNP O
was VBD VBD O
less RBR RBR O
marked JJ JJ O
than IN IN O
sedation NN NN O
, , , O
but CC CC O
increased VBN VBN O
with IN IN O
the DT DT O
dose NN NN O
. . . O

There EX EX O
was VBD VBD O
pain NN NN O
on IN IN O
i NNP NNP O
. . . O
m NN NN O
. . . O
injection NN NN O
of IN IN O
flunitrazepam NN NN B-CHEM
significantly RB RB O
more RBR RBR O
often RB RB O
than IN IN O
with IN IN O
isotonic JJ JJ O
saline NN NN O
. . . O

Plasma NNP NNP O
concentrations NNS NNS O
varied VBN VBN O
with IN IN O
dose NN NN O
and CC CC O
route NN NN O
and CC CC O
corresponded VBD VBD O
qualitatively RB RB O
with IN IN O
the DT DT O
subjective JJ JJ O
effects NNS NNS O
. . . O

The DT DT O
drug NN NN O
was VBD VBD O
still RB RB O
present JJ JJ O
in IN IN O
measurable JJ JJ O
quantities NNS NNS O
after IN IN O
24 CD CD O
h NN NN O
even RB RB O
with IN IN O
the DT DT O
smallest JJS JJS O
dose NN NN O
. . . O

Possible JJ JJ O
teratogenicity NN NN O
of IN IN O
sulphasalazine NN NN B-CHEM
. . . O

Three CD CD O
infants NNS NNS O
, , , O
born VBN VBN O
of IN IN O
two CD CD O
mothers NNS NNS O
with IN IN O
inflammatory JJ JJ O
bowel NN NN O
disease NN NN O
who WP WP O
received VBD VBD O
treatment NN NN O
with IN IN O
sulphasalazine NN NN B-CHEM
throughout IN IN O
pregnancy NN NN O
, , , O
were VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
major JJ JJ O
congenital NN NN O
anomalies NNS NNS O
. . . O

In IN IN O
the DT DT O
singleton NN NN O
pregnancy NN NN O
, , , O
the DT DT O
mother NN NN O
had VBD VBD O
ulcerative JJ JJ O
colitis NN NN O
, , , O
and CC CC O
the DT DT O
infant NN NN O
, , , O
a DT DT O
male JJ JJ O
, , , O
had VBD VBD O
coarctation NN NN O
of IN IN O
the DT DT O
aorta NN NN O
and CC CC O
a DT DT O
ventricular JJ JJ O
septal JJ JJ O
defect NN NN O
. . . O

In IN IN O
the DT DT O
twin NN NN O
pregnancy NN NN O
, , , O
the DT DT O
mother NN NN O
had VBD VBD O
Crohn NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

The DT DT O
first JJ JJ O
twin NN NN O
, , , O
a DT DT O
female JJ JJ O
, , , O
had VBD VBD O
a DT DT O
left VBN VBN O
Potter NNP NNP O
- : : O
type NN NN O
IIa NNP NNP O
polycystic JJ JJ O
kidney NN NN O
and CC CC O
a DT DT O
rudimentary JJ JJ O
left VBN VBN O
uterine NN NN O
cornu NN NN O
. . . O

The DT DT O
second JJ JJ O
twin NN NN O
, , , O
a DT DT O
male JJ JJ O
, , , O
had VBD VBD O
some DT DT O
features NNS NNS O
of IN IN O
Potter NNP NNP O
' POS POS O
s VBZ VBZ O
facies NNS NNS O
, , , O
hypoplastic JJ JJ O
lungs NNS NNS O
, , , O
absent JJ JJ O
kidneys NNS NNS O
and CC CC O
ureters NNS NNS O
, , , O
and CC CC O
talipes NNS NNS O
equinovarus NN NN O
. . . O

Despite IN IN O
reports NNS NNS O
to TO TO O
the DT DT O
contrary NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
sulphasalazine NN NN B-CHEM
may MD MD O
be VB VB O
teratogenic JJ JJ O
. . . O

Thrombotic NNP NNP O
microangiopathy NN NN O
and CC CC O
renal JJ JJ O
failure NN NN O
associated VBN VBN O
with IN IN O
antineoplastic JJ JJ O
chemotherapy NN NN O
. . . O

Five CD CD O
patients NNS NNS O
with IN IN O
carcinoma NN NN O
developed VBN VBN O
thrombotic JJ JJ O
microangiopathy NN NN O
( ( ( O
characterized VBN VBN O
by IN IN O
renal JJ JJ O
insufficiency NN NN O
, , , O
microangiopathic JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
, , , O
and CC CC O
usually RB RB O
thrombocytopenia NN NN O
) ) ) O
after IN IN O
treatment NN NN O
with IN IN O
cisplatin NN NN B-CHEM
, , , O
bleomycin NN NN B-CHEM
, , , O
and CC CC O
a DT DT O
vinca NN NN B-CHEM
alkaloid NN NN I-CHEM
. . . O

One CD CD O
patient NN NN O
had VBD VBD O
thrombotic JJ JJ O
thrombocytopenic NN NN O
purpura NN NN O
, , , O
three CD CD O
the DT DT O
hemolytic JJ JJ O
- - - O
uremic JJ JJ O
syndrome NN NN O
, , , O
and CC CC O
one CD CD O
an DT DT O
apparent JJ JJ O
forme NN NN O
fruste NN NN O
of IN IN O
one CD CD O
of IN IN O
these DT DT O
disorders NNS NNS O
. . . O

Histologic NNP NNP O
examination NN NN O
of IN IN O
the DT DT O
renal NN NN O
tissue NN NN O
showed VBD VBD O
evidence NN NN O
of IN IN O
intravascular JJ JJ O
coagulation NN NN O
, , , O
primarily RB RB O
affecting VBG VBG O
the DT DT O
small JJ JJ O
arteries NNS NNS O
, , , O
arterioles NNS NNS O
, , , O
and CC CC O
glomeruli NN NN O
. . . O

Because IN IN O
each DT DT O
patient NN NN O
was VBD VBD O
tumor NN NN O
- - - O
free JJ JJ O
or CC CC O
had VBD VBD O
only RB RB O
a DT DT O
small JJ JJ O
tumor NN NN O
at IN IN O
the DT DT O
onset NN NN O
of IN IN O
this DT DT O
syndrome NN NN O
, , , O
the DT DT O
thrombotic JJ JJ O
microangiopathy NN NN O
may MD MD O
have VB VB O
been VBN VBN O
induced VBN VBN O
by IN IN O
chemotherapy NN NN O
. . . O

Diagnosis NNP NNP O
of IN IN O
this DT DT O
potentially RB RB O
fatal JJ JJ O
complication NN NN O
may MD MD O
be VB VB O
delayed VBN VBN O
or CC CC O
missed VBN VBN O
if IN IN O
renal JJ JJ O
tissue NN NN O
or CC CC O
the DT DT O
peripheral JJ JJ O
blood NN NN O
smear NN NN O
is VBZ VBZ O
not RB RB O
examined VBN VBN O
, , , O
because IN IN O
renal JJ JJ O
failure NN NN O
may MD MD O
be VB VB O
ascribed VBN VBN O
to TO TO O
cisplatin VB VB B-CHEM
nephrotoxicity NN NN O
and CC CC O
the DT DT O
anemia NN NN O
and CC CC O
thrombocytopenia NN NN O
to TO TO O
drug NN NN O
- - - O
induced JJ JJ O
bone NN NN O
marrow NN NN O
suppression NN NN O
. . . O

International NNP NNP O
mexiletine NN NN B-CHEM
and CC CC O
placebo NN NN O
antiarrhythmic JJ JJ O
coronary JJ JJ O
trial NN NN O
: : : O
I PRP PRP O
. . . O

Report NNP NNP O
on IN IN O
arrhythmia NN NN O
and CC CC O
other JJ JJ O
findings NNS NNS O
. . . O

Impact NNP NNP O
Research NNP NNP O
Group NNP NNP O
. . . O

The DT DT O
antiarrhythmic JJ JJ O
effects NNS NNS O
of IN IN O
the DT DT O
sustained JJ JJ O
release NN NN O
form NN NN O
of IN IN O
mexiletine NN NN B-CHEM
( ( ( O
Mexitil NNP NNP B-CHEM
- - - I-CHEM
Perlongets NNP NNP I-CHEM
) ) ) O
were VBD VBD O
evaluated VBN VBN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
placebo NN NN O
trial NN NN O
in IN IN O
630 CD CD O
patients NNS NNS O
with IN IN O
recent JJ JJ O
documented VBN VBN O
myocardial NN NN O
infarction NN NN O
. . . O

The DT DT O
primary JJ JJ O
response NN NN O
variable JJ JJ O
was VBD VBD O
based VBN VBN O
on IN IN O
central JJ JJ O
reading NN NN O
of IN IN O
24 CD CD O
hour NN NN O
ambulatory NN NN O
electrocardiographic JJ JJ O
recordings NNS NNS O
and CC CC O
was VBD VBD O
defined VBN VBN O
as IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
30 CD CD O
or CC CC O
more JJR JJR O
single JJ JJ O
premature NN NN O
ventricular NN NN O
complexes NNS NNS O
in IN IN O
any DT DT O
two CD CD O
consecutive JJ JJ O
30 CD CD O
minute NN NN O
blocks NNS NNS O
or CC CC O
one CD CD O
or CC CC O
more JJR JJR O
runs VBZ VBZ O
of IN IN O
two CD CD O
or CC CC O
more JJR JJR O
premature NN NN O
ventricular NN NN O
complexes NNS NNS O
in IN IN O
the DT DT O
entire JJ JJ O
24 CD CD O
hour NN NN O
electrocardiographic JJ JJ O
recording NN NN O
. . . O

Large JJ JJ O
differences NNS NNS O
, , , O
regarded VBN VBN O
as IN IN O
statistically RB RB O
significant JJ JJ O
, , , O
between IN IN O
the DT DT O
mexiletine NN NN B-CHEM
and CC CC O
placebo NN NN O
groups NNS NNS O
were VBD VBD O
noted VBN VBN O
in IN IN O
that DT DT O
end NN NN O
point NN NN O
at IN IN O
months NNS NNS O
1 CD CD O
and CC CC O
4 CD CD O
, , , O
but CC CC O
only RB RB O
trends NNS NNS O
were VBD VBD O
observed VBN VBN O
at IN IN O
month NN NN O
12 CD CD O
. . . O

These DT DT O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
even RB RB O
though IN IN O
the DT DT O
serum NN NN O
mexiletine NN NN B-CHEM
levels NNS NNS O
obtained VBN VBN O
in IN IN O
this DT DT O
study NN NN O
were VBD VBD O
generally RB RB O
lower JJR JJR O
than IN IN O
those DT DT O
observed VBN VBN O
in IN IN O
studies NNS NNS O
that WDT WDT O
have VBP VBP O
used VBN VBN O
the DT DT O
regular JJ JJ O
form NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

There EX EX O
were VBD VBD O
more JJR JJR O
deaths NNS NNS O
in IN IN O
the DT DT O
mexiletine NN NN B-CHEM
group NN NN O
( ( ( O
7 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
( ( ( O
4 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
; : : O
the DT DT O
difference NN NN O
was VBD VBD O
not RB RB O
statistically RB RB O
significant JJ JJ O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
coronary JJ JJ O
events NNS NNS O
was VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Previously RB RB O
recognized VBN VBN O
side NN NN O
effects NNS NNS O
, , , O
particularly RB RB O
tremor NN NN O
and CC CC O
gastrointestinal JJ JJ O
problems NNS NNS O
, , , O
were VBD VBD O
more RBR RBR O
frequent JJ JJ O
in IN IN O
the DT DT O
mexiletine NN NN B-CHEM
group NN NN O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

Changes NNS NNS O
in IN IN O
heart NN NN O
size NN NN O
during IN IN O
long JJ JJ O
- - - O
term NN NN O
timolol NN NN B-CHEM
treatment NN NN O
after IN IN O
myocardial NN NN O
infarction NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
timolol NN NN B-CHEM
treatment NN NN O
on IN IN O
heart NN NN O
size NN NN O
after IN IN O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
evaluated VBN VBN O
by IN IN O
X NNP NNP O
- : : O
ray NNP NNP O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
including VBG VBG O
241 CD CD O
patients NNS NNS O
( ( ( O
placebo NN NN O
126 CD CD O
, , , O
timolol NN NN B-CHEM
115 CD CD O
) ) ) O
. . . O

The DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
was VBD VBD O
12 CD CD O
months NNS NNS O
. . . O

The DT DT O
timolol NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
showed VBD VBD O
a DT DT O
small JJ JJ O
but CC CC O
significant JJ JJ O
increase NN NN O
in IN IN O
heart NN NN O
size NN NN O
from IN IN O
baseline NN NN O
in IN IN O
contrast NN NN O
to TO TO O
a DT DT O
decrease NN NN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

These DT DT O
differences NNS NNS O
may MD MD O
be VB VB O
caused VBN VBN O
by IN IN O
timolol NN NN B-CHEM
- - - O
induced JJ JJ O
bradycardia NNS NNS O
and CC CC O
a DT DT O
compensatory NN NN O
increase NN NN O
in IN IN O
end NN NN O
- : : O
diastolic JJ JJ O
volume NN NN O
. . . O

The DT DT O
timolol NN NN B-CHEM
- - - O
related VBN VBN O
increase NN NN O
in IN IN O
heart NN NN O
size NN NN O
was VBD VBD O
observed VBN VBN O
only RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
normal JJ JJ O
and CC CC O
borderline NN NN O
heart NN NN O
size NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
cardiomegaly NN NN O
, , , O
the DT DT O
increase NN NN O
in IN IN O
heart NN NN O
size NN NN O
was VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

After IN IN O
re NN NN O
- - - O
infarction NN NN O
, , , O
heart NN NN O
size NN NN O
increased VBN VBN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
and CC CC O
remained VBD VBD O
unchanged JJ JJ O
in IN IN O
the DT DT O
timolol NN NN B-CHEM
group NN NN O
. . . O

Vitamin NNP NNP B-CHEM
D3 NNP NNP I-CHEM
toxicity NN NN O
in IN IN O
dairy NN NN O
cows NNS NNS O
. . . O

Large JJ JJ O
parenteral JJ JJ O
doses NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
( ( ( O
15 CD CD O
to TO TO O
17 CD CD O
. . . O
5 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
6 CD CD O
) ) ) O
IU NNP NNP O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
) ) ) O
were VBD VBD O
associated VBN VBN O
with IN IN O
prolonged JJ JJ O
hypercalcemia NN NN O
, , , O
hyperphosphatemia NN NN O
, , , O
and CC CC O
large JJ JJ O
increases NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
and CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
in IN IN O
the DT DT O
blood NN NN O
plasma NN NN O
of IN IN O
nonlactating VBG VBG O
nonpregnant NN NN O
and CC CC O
pregnant JJ JJ O
Jersey NNP NNP O
cows NNS NNS O
. . . O

Calcium NNP NNP B-CHEM
concentrations NNS NNS O
1 CD CD O
day NN NN O
postpartum NN NN O
were VBD VBD O
higher JJR JJR O
in IN IN O
cows NNS NNS O
treated VBN VBN O
with IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
about IN IN O
32 CD CD O
days NNS NNS O
prepartum NN NN O
( ( ( O
8 CD CD O
. . . O
8 CD CD O
mg NN NN O
/ NN NN O
100 CD CD O
ml NN NN O
) ) ) O
than IN IN O
in IN IN O
control NN NN O
cows NNS NNS O
( ( ( O
5 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
100 CD CD O
ml NN NN O
) ) ) O
. . . O

None NN NN O
of IN IN O
the DT DT O
cows NNS NNS O
treated VBN VBN O
with IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
showed VBD VBD O
signs NNS NNS O
of IN IN O
milk NN NN O
fever NN NN O
during IN IN O
the DT DT O
peripartal JJ JJ O
period NN NN O
; : : O
however RB RB O
, , , O
22 CD CD O
% NN NN O
of IN IN O
the DT DT O
control NN NN O
cows NNS NNS O
developed VBN VBN O
clinical JJ JJ O
signs NNS NNS O
of IN IN O
milk NN NN O
fever NN NN O
during IN IN O
this DT DT O
period NN NN O
. . . O

Signs NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
toxicity NN NN O
were VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
nonlactating VBG VBG O
nonpregnant NN NN O
cows NNS NNS O
; : : O
however RB RB O
, , , O
pregnant JJ JJ O
cows NNS NNS O
commonly RB RB O
developed VBN VBN O
severe JJ JJ O
signs NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
toxicity NN NN O
and CC CC O
10 CD CD O
of IN IN O
17 CD CD O
cows NNS NNS O
died VBD VBD O
. . . O

There EX EX O
was VBD VBD O
widespread JJ JJ O
metastatic JJ JJ O
calcification NN NN O
in IN IN O
the DT DT O
cows NNS NNS O
that WDT WDT O
died VBD VBD O
. . . O

Because IN IN O
of IN IN O
the DT DT O
extreme JJ JJ O
toxicity NN NN O
of IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
in IN IN O
pregnant JJ JJ O
Jersey NNP NNP O
cows NNS NNS O
and CC CC O
the DT DT O
low JJ JJ O
margin NN NN O
of IN IN O
safety NN NN O
between IN IN O
doses NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
that IN IN O
prevent VB VB O
milk NN NN O
fever NN NN O
and CC CC O
doses NNS NNS O
that WDT WDT O
induce NN NN O
milk NN NN O
fever NN NN O
, , , O
we PRP PRP O
concluded VBD VBD O
that IN IN O
vitamin NN NN B-CHEM
D3 NNP NNP I-CHEM
cannot NN NN O
be VB VB O
used VBN VBN O
practically RB RB O
to TO TO O
prevent VB VB O
milk NN NN O
fever NN NN O
when WRB WRB O
injected VBN VBN O
several JJ JJ O
weeks NNS NNS O
prepartum NN NN O
. . . O

Diseases NNP NNP O
of IN IN O
peripheral JJ JJ O
nerves NNS NNS O
as IN IN O
seen VBN VBN O
in IN IN O
the DT DT O
Nigerian NNP NNP O
African NNP NNP O
. . . O

The DT DT O
anatomical JJ JJ O
and CC CC O
aetiological JJ JJ O
diagnoses NNS NNS O
of IN IN O
peripheral JJ JJ O
nerve NN NN O
disease NN NN O
excluding VBG VBG O
its PRP$ PRP$ O
primary JJ JJ O
benign NN NN O
and CC CC O
malignant JJ JJ O
disorders NNS NNS O
, , , O
as IN IN O
seen VBN VBN O
in IN IN O
358 CD CD O
Nigerians NNP NNP O
are VBP VBP O
presented VBN VBN O
. . . O

There EX EX O
is VBZ VBZ O
a DT DT O
male JJ JJ O
preponderance NN NN O
and CC CC O
the DT DT O
peak NN NN O
incidence NN NN O
is VBZ VBZ O
in IN IN O
the DT DT O
fourth JJ JJ O
decade NN NN O
. . . O

Sensori NNP NNP O
- : : O
motor NN NN O
neuropathy NN NN O
was VBD VBD O
the DT DT O
commonest NN NN O
presentation NN NN O
( ( ( O
50 CD CD O
% NN NN O
) ) ) O
. . . O

Guillain NNP NNP O
- : : O
Barr NNP NNP O
syndrome NN NN O
was VBD VBD O
the DT DT O
commonest JJS JJS O
identifiable JJ JJ O
cause NN NN O
( ( ( O
15 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
, , , O
accounting VBG VBG O
for IN IN O
half NN NN O
of IN IN O
the DT DT O
cases NNS NNS O
with IN IN O
motor NN NN O
neuropathy NN NN O
. . . O

Peripheral NNP NNP O
neuropathy NN NN O
due JJ JJ O
to TO TO O
nutritional JJ JJ O
deficiency NN NN O
of IN IN O
thiamine NN NN B-CHEM
and CC CC O
riboflavin NN NN B-CHEM
was VBD VBD O
common JJ JJ O
( ( ( O
10 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
and CC CC O
presented VBN VBN O
mainly RB RB O
as IN IN O
sensory JJ JJ O
and CC CC O
sensori JJ JJ O
- - - O
motor NN NN O
neuropathy NN NN O
. . . O

Diabetes NNP NNP O
mellitus NN NN O
was VBD VBD O
the DT DT O
major JJ JJ O
cause NN NN O
of IN IN O
autonomic JJ JJ O
neuropathy NN NN O
. . . O

Isoniazid NNP NNP B-CHEM
was VBD VBD O
the DT DT O
most RBS RBS O
frequent JJ JJ O
agent NN NN O
in IN IN O
drug NN NN O
- - - O
induced JJ JJ O
neuropathy NN NN O
. . . O

Migraine NNP NNP O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
not RB RB O
an DT DT O
uncommon JJ JJ O
cause NN NN O
of IN IN O
cranial NN NN O
neuropathy NN NN O
although IN IN O
malignancies NNS NNS O
arising VBG VBG O
from IN IN O
the DT DT O
reticuloendothelial JJ JJ O
system NN NN O
or CC CC O
related VBN VBN O
structures NNS NNS O
of IN IN O
the DT DT O
head NN NN O
and CC CC O
neck NN NN O
were VBD VBD O
more RBR RBR O
frequent JJ JJ O
( ( ( O
26 CD CD O
% NN NN O
) ) ) O
. . . O

In IN IN O
26 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
all PDT PDT O
the DT DT O
cases NNS NNS O
, , , O
the DT DT O
aetiology NN NN O
of IN IN O
the DT DT O
neuropathy NN NN O
was VBD VBD O
undetermined JJ JJ O
. . . O

Heredofamilial NNP NNP O
and CC CC O
connective JJ JJ O
tissue NN NN O
disorders NNS NNS O
were VBD VBD O
rare JJ JJ O
. . . O

Some DT DT O
of IN IN O
the DT DT O
factors NNS NNS O
related VBN VBN O
to TO TO O
the DT DT O
clinical JJ JJ O
presentation NN NN O
and CC CC O
pathogenesis NNS NNS O
of IN IN O
the DT DT O
neuropathies NNS NNS O
are VBP VBP O
briefly RB RB O
discussed VBN VBN O
. . . O

Reduction NNP NNP O
in IN IN O
caffeine NN NN B-CHEM
toxicity NN NN O
by IN IN O
acetaminophen NN NN B-CHEM
. . . O

A DT DT O
patient NN NN O
who WP WP O
allegedly RB RB O
consumed VBD VBD O
100 CD CD O
tablets NNS NNS O
of IN IN O
an DT DT O
over IN IN O
- - - O
the DT DT O
- - - O
counter NN NN O
analgesic NN NN O
containing VBG VBG O
sodium NN NN B-CHEM
acetylsalicylate NN NN I-CHEM
, , , O
caffeine NN NN B-CHEM
, , , O
and CC CC O
acetaminophen VB VB B-CHEM
displayed VBD VBD O
no DT DT O
significant JJ JJ O
CNS NNP NNP O
stimulation NN NN O
despite IN IN O
the DT DT O
presence NN NN O
of IN IN O
175 CD CD O
micrograms NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
per IN IN O
mL NN NN O
of IN IN O
serum NN NN O
. . . O

Because IN IN O
salicylates NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
to TO TO O
augment VB VB O
the DT DT O
stimulatory JJ JJ O
effects NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
on IN IN O
the DT DT O
CNS NNP NNP O
, , , O
attention NN NN O
was VBD VBD O
focused VBN VBN O
on IN IN O
the DT DT O
possibility NN NN O
that IN IN O
the DT DT O
presence NN NN O
of IN IN O
acetaminophen NN NN B-CHEM
( ( ( O
52 CD CD O
micrograms NNS NNS O
/ NN NN O
mL NN NN O
) ) ) O
reduced VBD VBD O
the DT DT O
CNS NNP NNP O
toxicity NN NN O
of IN IN O
caffeine NN NN B-CHEM
. . . O

Studies NNS NNS O
in IN IN O
DBA NNP NNP O
/ NN NN O
2J CD CD O
mice NN NN O
showed VBD VBD O
that IN IN O
: : : O
1 CD CD O
) ) ) O
pretreatment NN NN O
with IN IN O
acetaminophen NN NN B-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
increased VBD VBD O
the DT DT O
interval NN NN O
between IN IN O
the DT DT O
administration NN NN O
of IN IN O
caffeine NN NN B-CHEM
( ( ( O
300 CD CD O
to TO TO O
450 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
IP NNP NNP O
) ) ) O
and CC CC O
the DT DT O
onset NN NN O
of IN IN O
fatal JJ JJ O
convulsions NNS NNS O
by IN IN O
a DT DT O
factor NN NN O
of IN IN O
about IN IN O
two CD CD O
; : : O
and CC CC O
2 CD CD O
) ) ) O
pretreatment NN NN O
with IN IN O
acetaminophen NN NN B-CHEM
( ( ( O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
reduced VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
audiogenic JJ JJ O
seizures NNS NNS O
produced VBN VBN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
caffeine NN NN B-CHEM
( ( ( O
12 CD CD O
. . . O
5 CD CD O
to TO TO O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
IP NNP NNP O
) ) ) O
. . . O

The DT DT O
frequency NN NN O
of IN IN O
sound NN NN O
- - - O
induced JJ JJ O
seizures NNS NNS O
after IN IN O
12 CD CD O
. . . O
5 CD CD O
or CC CC O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
caffeine NN NN B-CHEM
was VBD VBD O
reduced VBN VBN O
from IN IN O
50 CD CD O
to TO TO O
5 CD CD O
% NN NN O
by IN IN O
acetaminophen NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
absence NN NN O
of IN IN O
caffeine NN NN B-CHEM
, , , O
acetaminophen NN NN B-CHEM
( ( ( O
up IN IN O
to TO TO O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
did VBD VBD O
not RB RB O
modify VB VB O
the DT DT O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
maximal NN NN O
electroshock NN NN O
and CC CC O
did VBD VBD O
not RB RB O
alter VB VB O
the DT DT O
convulsant NN NN O
dose NN NN O
of IN IN O
pentylenetetrezol NN NN B-CHEM
in IN IN O
mice NN NN O
( ( ( O
tests NNS NNS O
performed VBN VBN O
by IN IN O
the DT DT O
Anticonvulsant NNP NNP O
Screening NNP NNP O
Project NNP NNP O
of IN IN O
NINCDS NNP NNP O
) ) ) O
. . . O

Acetaminophen NNP NNP B-CHEM
( ( ( O
up IN IN O
to TO TO O
150 CD CD O
micrograms NNS NNS O
/ NN NN O
mL NN NN O
) ) ) O
did VBD VBD O
not RB RB O
retard VB VB O
the DT DT O
incorporation NN NN O
of IN IN O
radioactive JJ JJ O
adenosine NN NN B-CHEM
into IN IN O
ATP NNP NNP B-CHEM
in IN IN O
slices NNS NNS O
of IN IN O
rat NN NN O
cerebral JJ JJ O
cortex NN NN O
. . . O

Thus RB RB O
the DT DT O
mechanism NN NN O
by IN IN O
which WDT WDT O
acetaminophen VBP VBP B-CHEM
antagonizes VBZ VBZ O
the DT DT O
actions NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
in IN IN O
the DT DT O
CNS NNP NNP O
remains VBZ VBZ O
unknown JJ JJ O
. . . O

A DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
of IN IN O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
dothiepin NN NN B-CHEM
hydrochloride NN NN I-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
major JJ JJ O
depressive JJ JJ O
disorder NN NN O
. . . O

In IN IN O
a DT DT O
6 CD CD O
- : : O
week NN NN O
double JJ JJ O
- : : O
blind JJ JJ O
parallel JJ JJ O
treatment NN NN O
study NN NN O
, , , O
dothiepin NN NN B-CHEM
and CC CC O
amitriptyline NN NN B-CHEM
were VBD VBD O
compared VBN VBN O
to TO TO O
placebo NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
33 CD CD O
depressed VBN VBN O
outpatients NNS NNS O
. . . O

Dothiepin NNP NNP B-CHEM
and CC CC O
amitriptyline NN NN B-CHEM
were VBD VBD O
equally RB RB O
effective JJ JJ O
in IN IN O
alleviating VBG VBG O
the DT DT O
symptoms NNS NNS O
of IN IN O
depressive JJ JJ O
illness NN NN O
, , , O
and CC CC O
both DT DT O
were VBD VBD O
significantly RB RB O
superior JJ JJ O
to TO TO O
placebo NN NN O
. . . O

The DT DT O
overall JJ JJ O
incidence NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
and CC CC O
the DT DT O
frequency NN NN O
and CC CC O
severity NN NN O
of IN IN O
blurred JJ JJ O
vision NN NN O
, , , O
dry JJ JJ O
mouth NN NN O
, , , O
and CC CC O
drowsiness NNS NNS O
were VBD VBD O
significantly RB RB O
less JJR JJR O
with IN IN O
dothiepin NN NN B-CHEM
than IN IN O
with IN IN O
amitriptyline NN NN B-CHEM
. . . O

Dothiepin NNP NNP B-CHEM
also RB RB O
produced VBD VBD O
fewer JJR JJR O
CNS NNP NNP O
and CC CC O
cardiovascular JJ JJ O
effects NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
clinically RB RB O
important JJ JJ O
changes NNS NNS O
in IN IN O
laboratory NN NN O
parameters NNS NNS O
. . . O

Dothiepin NNP NNP B-CHEM
thus RB RB O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
an DT DT O
effective JJ JJ O
antidepressant NN NN B-CHEM
drug NN NN O
associated VBN VBN O
with IN IN O
fewer JJR JJR O
side NN NN O
effects NNS NNS O
than IN IN O
amitriptyline NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
depressed VBN VBN O
outpatients NNS NNS O
. . . O

Behavioral NNP NNP O
effects NNS NNS O
of IN IN O
diazepam NN NN B-CHEM
and CC CC O
propranolol NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
panic NN NN O
disorder NN NN O
and CC CC O
agoraphobia NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
oral JJ JJ O
doses NNS NNS O
of IN IN O
diazepam NN NN B-CHEM
( ( ( O
single JJ JJ O
dose NN NN O
of IN IN O
10 CD CD O
mg NN NN O
and CC CC O
a DT DT O
median JJ JJ O
dose NN NN O
of IN IN O
30 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
2 CD CD O
weeks NNS NNS O
) ) ) O
and CC CC O
propranolol NN NN B-CHEM
( ( ( O
single JJ JJ O
dose NN NN O
of IN IN O
80 CD CD O
mg NN NN O
and CC CC O
a DT DT O
median JJ JJ O
dose NN NN O
of IN IN O
240 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
2 CD CD O
weeks NNS NNS O
) ) ) O
on IN IN O
psychological JJ JJ O
performance NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
panic NN NN O
disorders NNS NNS O
and CC CC O
agoraphobia NN NN O
were VBD VBD O
investigated VBN VBN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
randomized JJ JJ O
and CC CC O
crossover NN NN O
design NN NN O
. . . O

Both DT DT O
drugs NNS NNS O
impaired VBN VBN O
immediate JJ JJ O
free JJ JJ O
recall NN NN O
but CC CC O
the DT DT O
decrease NN NN O
was VBD VBD O
greater JJR JJR O
for IN IN O
diazepam NN NN B-CHEM
than IN IN O
propranolol NN NN B-CHEM
. . . O

Delayed NNP NNP O
free JJ JJ O
recall NN NN O
was VBD VBD O
also RB RB O
impaired VBN VBN O
but CC CC O
the DT DT O
two CD CD O
drugs NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
. . . O

Patients NNS NNS O
tapped VBD VBD O
faster RBR RBR O
after IN IN O
propranolol NN NN B-CHEM
than IN IN O
diazepam NN NN B-CHEM
and CC CC O
they PRP PRP O
were VBD VBD O
more RBR RBR O
sedated JJ JJ O
after IN IN O
diazepam NN NN B-CHEM
than IN IN O
propranolol NN NN B-CHEM
. . . O

After IN IN O
2 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
, , , O
patients NNS NNS O
tested VBN VBN O
5 CD CD O
- : : O
8 CD CD O
h NN NN O
after IN IN O
the DT DT O
last JJ JJ O
dose NN NN O
of IN IN O
medication NN NN O
did VBD VBD O
not RB RB O
show VB VB O
any DT DT O
decrement NN NN O
of IN IN O
performance NN NN O
. . . O

These DT DT O
results NNS NNS O
are VBP VBP O
similar JJ JJ O
to TO TO O
those DT DT O
previously RB RB O
found VBN VBN O
in IN IN O
healthy JJ JJ O
subjects NNS NNS O
. . . O

Accumulation NNP NNP O
of IN IN O
drugs NNS NNS O
was VBD VBD O
not RB RB O
reflected VBN VBN O
in IN IN O
prolonged JJ JJ O
behavioral JJ JJ O
impairment NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
glycopyrrolate NN NN B-CHEM
and CC CC O
atropine NN NN B-CHEM
in IN IN O
the DT DT O
prevention NN NN O
of IN IN O
bradycardia NNS NNS O
and CC CC O
arrhythmias NNS NNS O
following VBG VBG O
repeated VBN VBN O
doses NNS NNS O
of IN IN O
suxamethonium NN NN B-CHEM
in IN IN O
children NNS NNS O
. . . O

The DT DT O
effectiveness NN NN O
of IN IN O
administration NN NN O
of IN IN O
glycopyrrolate NN NN B-CHEM
5 CD CD O
and CC CC O
10 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
and CC CC O
atropine NN NN B-CHEM
10 CD CD O
and CC CC O
20 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
immediately RB RB O
before IN IN O
the DT DT O
induction NN NN O
of IN IN O
anaesthesia NN NN O
, , , O
to TO TO O
prevent VB VB O
arrhythmia NN NN O
and CC CC O
bradycardia NNS NNS O
following VBG VBG O
repeated VBN VBN O
doses NNS NNS O
of IN IN O
suxamethonium NN NN B-CHEM
in IN IN O
children NNS NNS O
, , , O
was VBD VBD O
studied VBN VBN O
. . . O

A DT DT O
control NN NN O
group NN NN O
was VBD VBD O
included VBN VBN O
for IN IN O
comparison NN NN O
with IN IN O
the DT DT O
lower JJR JJR O
dose NN NN O
range NN NN O
of IN IN O
glycopyrrolate NN NN B-CHEM
and CC CC O
atropine NN NN B-CHEM
. . . O

A DT DT O
frequency NN NN O
of IN IN O
bradycardia NN NN O
of IN IN O
50 CD CD O
% NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
, , , O
but CC CC O
this DT DT O
was VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
from IN IN O
the DT DT O
frequency NN NN O
with IN IN O
the DT DT O
active JJ JJ O
drugs NNS NNS O
. . . O

Bradycardia NNP NNP O
( ( ( O
defined VBN VBN O
as IN IN O
a DT DT O
decrease NN NN O
in IN IN O
heart NN NN O
rate NN NN O
to TO TO O
less JJR JJR O
than IN IN O
50 CD CD O
beat NN NN O
min NN NN O
- : : O
1 CD CD O
) ) ) O
was VBD VBD O
prevented VBN VBN O
when WRB WRB O
the DT DT O
larger JJR JJR O
dose NN NN O
of IN IN O
either DT DT O
active JJ JJ O
drug NN NN O
was VBD VBD O
used VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
recommended VBN VBN O
that IN IN O
either DT DT O
glycopyrrolate NN NN B-CHEM
10 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
or CC CC O
atropine NN NN B-CHEM
20 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
should MD MD O
immediately RB RB O
precede VB VB O
induction NN NN O
of IN IN O
anaesthesia NN NN O
, , , O
in IN IN O
children NNS NNS O
, , , O
if IN IN O
the DT DT O
repeated VBN VBN O
administration NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
is VBZ VBZ O
anticipated VBN VBN O
. . . O

Veno NNP NNP O
- : : O
occlusive JJ JJ O
liver NN NN O
disease NN NN O
after IN IN O
dacarbazine NN NN B-CHEM
therapy NN NN O
( ( ( O
DTIC NNP NNP B-CHEM
) ) ) O
for IN IN O
melanoma NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
veno NN NN O
- - - O
occlusive JJ JJ O
disease NN NN O
of IN IN O
the DT DT O
liver NN NN O
with IN IN O
fatal JJ JJ O
outcome NN NN O
after IN IN O
dacarbazine NN NN B-CHEM
( ( ( O
DTIC NNP NNP B-CHEM
) ) ) O
therapy NN NN O
for IN IN O
melanoma NN NN O
is VBZ VBZ O
reported VBN VBN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
fulminant JJ JJ O
clinical JJ JJ O
course NN NN O
from IN IN O
start NN NN O
of IN IN O
symptoms NNS NNS O
until IN IN O
death NN NN O
. . . O

At IN IN O
autopsy NN NN O
the DT DT O
liver NN NN O
was VBD VBD O
enlarged VBN VBN O
and CC CC O
firm NN NN O
with IN IN O
signs NNS NNS O
of IN IN O
venous JJ JJ O
congestion NN NN O
. . . O

Small JJ JJ O
- : : O
and CC CC O
medium NN NN O
- - - O
sized JJ JJ O
hepatic JJ JJ O
veins NNS NNS O
were VBD VBD O
blocked VBN VBN O
by IN IN O
thrombosis NN NN O
. . . O

Eosinophilic NNP NNP O
infiltrations NNS NNS O
were VBD VBD O
found VBN VBN O
around IN IN O
the DT DT O
vessels NNS NNS O
. . . O

Published VBN VBN O
cases NNS NNS O
from IN IN O
the DT DT O
literature NN NN O
are VBP VBP O
reviewed VBN VBN O
and CC CC O
pertinent JJ JJ O
features NNS NNS O
discussed VBN VBN O
. . . O

Maternal NNP NNP O
lithium NN NN B-CHEM
and CC CC O
neonatal JJ JJ O
Ebstein NNP NNP O
' POS POS O
s VBZ VBZ O
anomaly NN NN O
: : : O
evaluation NN NN O
with IN IN O
cross NN NN O
- - - O
sectional JJ JJ O
echocardiography NN NN O
. . . O

Cross NNP NNP O
- : : O
sectional JJ JJ O
echocardiography NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
two CD CD O
neonates NNS NNS O
whose WP$ WP$ O
mothers NNS NNS O
ingested JJ JJ O
lithium NN NN B-CHEM
during IN IN O
pregnancy NN NN O
. . . O

In IN IN O
one CD CD O
infant NN NN O
, , , O
Ebstein NNP NNP O
' POS POS O
s VBZ VBZ O
anomaly NN NN O
of IN IN O
the DT DT O
tricuspid JJ JJ O
valve NN NN O
was VBD VBD O
identified VBN VBN O
. . . O

In IN IN O
the DT DT O
other JJ JJ O
infant NN NN O
cross JJ JJ O
- : : O
sectional JJ JJ O
echocardiography NN NN O
provided VBN VBN O
reassurance NN NN O
that IN IN O
the DT DT O
infant NN NN O
did VBD VBD O
not RB RB O
have VB VB O
Ebstein NNP NNP O
' POS POS O
s VBZ VBZ O
anomaly NN NN O
. . . O

Cross NNP NNP O
- : : O
sectional NN NN O
echocardiographic JJ JJ O
screening NN NN O
of IN IN O
newborns NNS NNS O
exposed VBN VBN O
to TO TO O
lithium NN NN B-CHEM
during IN IN O
gestation NN NN O
can MD MD O
provide VB VB O
highly RB RB O
accurate JJ JJ O
, , , O
noninvasive JJ JJ O
assessment NN NN O
of IN IN O
the DT DT O
presence NN NN O
or CC CC O
absence NN NN O
of IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
malformations NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
training NN NN O
on IN IN O
the DT DT O
extent NN NN O
of IN IN O
experimental JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
aging VBG VBG O
rats NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
exercise NN NN O
on IN IN O
the DT DT O
severity NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
female JJ JJ O
albino NN NN O
rats NNS NNS O
of IN IN O
20 CD CD O
, , , O
40 CD CD O
, , , O
60 CD CD O
and CC CC O
80 CD CD O
weeks NNS NNS O
of IN IN O
age NN NN O
. . . O

The DT DT O
rats NNS NNS O
were VBD VBD O
trained VBN VBN O
to TO TO O
swim VBP VBP O
for IN IN O
a DT DT O
specific JJ JJ O
duration NN NN O
and CC CC O
for IN IN O
a DT DT O
particular JJ JJ O
period NN NN O
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
infarcts NNS NNS O
were VBD VBD O
confirmed VBN VBN O
by IN IN O
histological JJ JJ O
methods NNS NNS O
. . . O

Elevations NNP NNP O
in IN IN O
the DT DT O
serum NN NN O
GOT NNP NNP O
and CC CC O
GPT NNP NNP O
were VBD VBD O
maximum NN NN O
in IN IN O
the DT DT O
sedentary JJ JJ O
- - - O
isoproterenols NNS NNS B-CHEM
and CC CC O
minimum JJ JJ O
in IN IN O
the DT DT O
exercise NN NN O
- - - O
controls NNS NNS O
. . . O

These DT DT O
changes NNS NNS O
in IN IN O
the DT DT O
serum NN NN O
transaminases NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
corresponding JJ JJ O
depletions NNS NNS O
in IN IN O
the DT DT O
cardiac NN NN O
GOT NNP NNP O
and CC CC O
GPT NNP NNP O
. . . O

However RB RB O
, , , O
age NN NN O
was VBD VBD O
seen VBN VBN O
to TO TO O
interfere VB VB O
with IN IN O
the DT DT O
responses NNS NNS O
exhibited VBN VBN O
by IN IN O
the DT DT O
young JJ JJ O
and CC CC O
old JJ JJ O
rats NNS NNS O
. . . O

Studies NNP NNP O
dealing VBG VBG O
with IN IN O
myocardial NN NN O
infarction NN NN O
are VBP VBP O
more RBR RBR O
informative JJ JJ O
when WRB WRB O
dealt NN NN O
with IN IN O
age NN NN O
. . . O

Effect NN NN O
of IN IN O
polyethylene NN NN B-CHEM
glycol NN NN I-CHEM
400 CD CD I-CHEM
on IN IN O
adriamycin NN NN B-CHEM
toxicity NN NN O
in IN IN O
mice NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
a DT DT O
widely RB RB O
used VBN VBN O
organic JJ JJ O
solvent JJ JJ O
, , , O
polyethylene NN NN B-CHEM
glycol NN NN I-CHEM
400 CD CD I-CHEM
( ( ( O
PEG NNP NNP B-CHEM
400 CD CD I-CHEM
) ) ) O
, , , O
on IN IN O
the DT DT O
toxic JJ JJ O
action NN NN O
of IN IN O
an DT DT O
acute JJ JJ O
or CC CC O
chronic JJ JJ O
treatment NN NN O
with IN IN O
adriamycin NN NN B-CHEM
( ( ( O
ADR NNP NNP B-CHEM
) ) ) O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
mice NN NN O
. . . O

PEG NNP NNP B-CHEM
400 CD CD I-CHEM
impressively RB RB O
decreased VBD VBD O
both DT DT O
acute JJ JJ O
high JJ JJ O
- - - O
dose NN NN O
and CC CC O
chronic JJ JJ O
low JJ JJ O
- - - O
dose NN NN O
- - - O
ADR NNP NNP B-CHEM
- - - O
associated JJ JJ O
lethality NN NN O
. . . O

Light NNP NNP O
microscopic NN NN O
analysis NN NN O
showed VBD VBD O
a DT DT O
significant JJ JJ O
protection NN NN O
against IN IN O
ADR NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
morphological JJ JJ O
alterations NNS NNS O
. . . O

Such JJ JJ O
treatment NN NN O
did VBD VBD O
not RB RB O
diminish VB VB O
the DT DT O
ADR NNP NNP B-CHEM
antitumor NN NN O
activity NN NN O
in IN IN O
L1210 NNP NNP O
leukemia NN NN O
and CC CC O
in IN IN O
Ehrlich NNP NNP O
ascites VBZ VBZ O
tumor NN NN O
. . . O

Sublingual NNP NNP O
absorption NN NN O
of IN IN O
the DT DT O
quaternary JJ JJ B-CHEM
ammonium NN NN I-CHEM
antiarrhythmic JJ JJ O
agent NN NN O
, , , O
UM NNP NNP B-CHEM
- : : I-CHEM
272 CD CD I-CHEM
. . . O

UM NNP NNP B-CHEM
- : : I-CHEM
272 CD CD I-CHEM
( ( ( O
N NNP NNP B-CHEM
, , , I-CHEM
N NNP NNP I-CHEM
- - - I-CHEM
dimethylpropranolol NN NN I-CHEM
) ) ) O
, , , O
a DT DT O
quaternary JJ JJ O
antiarrhythmic JJ JJ O
agent NN NN O
, , , O
was VBD VBD O
administered VBN VBN O
sublingually RB RB O
to TO TO O
dogs NNS NNS O
with IN IN O
ouabain NN NN B-CHEM
- - - O
induced JJ JJ O
ventricular NN NN O
tachycardias NNS NNS O
. . . O

Both DT DT O
anti JJ JJ O
- : : O
arrhythmic JJ JJ O
efficacy NN NN O
and CC CC O
bioavailability NN NN O
were VBD VBD O
compared VBN VBN O
to TO TO O
oral JJ JJ O
drug NN NN O
. . . O

Sublingual NNP NNP O
UM NNP NNP B-CHEM
- : : I-CHEM
272 CD CD I-CHEM
converted VBN VBN O
ventricular NN NN O
tachycardia NNS NNS O
to TO TO O
sinus VB VB O
rhythm NN NN O
in IN IN O
all DT DT O
5 CD CD O
dogs NNS NNS O
. . . O

The DT DT O
area NN NN O
under IN IN O
the DT DT O
plasma NN NN O
concentration NN NN O
time NN NN O
curve NN NN O
at IN IN O
90 CD CD O
min NN NN O
was VBD VBD O
4 CD CD O
- : : O
12 CD CD O
times NNS NNS O
greater JJR JJR O
than IN IN O
for IN IN O
oral JJ JJ O
drug NN NN O
, , , O
suggesting VBG VBG O
the DT DT O
existence NN NN O
of IN IN O
an DT DT O
absorption NN NN O
- - - O
limiting NN NN O
process NN NN O
in IN IN O
the DT DT O
intestine NN NN O
, , , O
and CC CC O
providing VBG VBG O
an DT DT O
alternate JJ JJ O
form NN NN O
of IN IN O
administration NN NN O
for IN IN O
quaternary JJ JJ O
drugs NNS NNS O
. . . O

Early RB RB O
adjuvant JJ JJ O
adriamycin NN NN B-CHEM
in IN IN O
superficial JJ JJ O
bladder NN NN O
carcinoma NN NN O
. . . O

A DT DT O
multicenter NN NN O
study NN NN O
was VBD VBD O
performed VBN VBN O
in IN IN O
110 CD CD O
patients NNS NNS O
with IN IN O
superficial JJ JJ O
transitional JJ JJ O
cell NN NN O
carcinoma NN NN O
of IN IN O
the DT DT O
bladder NN NN O
. . . O

Adriamycin NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
50 CD CD O
ml NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
intravesically RB RB O
within IN IN O
24 CD CD O
h NN NN O
after IN IN O
transurethral JJ JJ O
resection NN NN O
of IN IN O
TA NNP NNP O
- : : O
T1 NNP NNP O
( ( ( O
O NNP NNP O
- - - O
A DT DT O
) ) ) O
bladder NN NN O
tumors NNS NNS O
. . . O

Instillation NNP NNP O
was VBD VBD O
repeated VBN VBN O
twice RB RB O
during IN IN O
the DT DT O
first JJ JJ O
week NN NN O
, , , O
then RB RB O
weekly JJ JJ O
during IN IN O
the DT DT O
first JJ JJ O
month NN NN O
and CC CC O
afterwards RB RB O
monthly JJ JJ O
for IN IN O
1 CD CD O
year NN NN O
. . . O

The DT DT O
tolerance NN NN O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
these DT DT O
110 CD CD O
patients NNS NNS O
, , , O
and CC CC O
29 CD CD O
patients NNS NNS O
presented VBN VBN O
with IN IN O
local JJ JJ O
side NN NN O
- - - O
effects NNS NNS O
. . . O

In IN IN O
24 CD CD O
of IN IN O
these DT DT O
patients NNS NNS O
chemical JJ JJ O
cystitis NNS NNS O
was VBD VBD O
severe JJ JJ O
enough RB RB O
for IN IN O
them PRP PRP O
to TO TO O
drop VB VB O
out IN IN O
of IN IN O
the DT DT O
study NN NN O
. . . O

No DT DT O
systemic JJ JJ O
side NN NN O
- - - O
effects NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

Recurrence NNP NNP O
was VBD VBD O
studied VBN VBN O
in IN IN O
82 CD CD O
evaluable JJ JJ O
patients NNS NNS O
after IN IN O
1 CD CD O
year NN NN O
of IN IN O
follow VB VB O
- - - O
up RP RP O
and CC CC O
in IN IN O
72 CD CD O
patients NNS NNS O
followed VBD VBD O
for IN IN O
2 CD CD O
- : : O
3 CD CD O
years NNS NNS O
( ( ( O
mean NN NN O
32 CD CD O
months NNS NNS O
) ) ) O
. . . O

Of IN IN O
the DT DT O
82 CD CD O
patients NNS NNS O
studied VBN VBN O
after IN IN O
1 CD CD O
year NN NN O
, , , O
23 CD CD O
had VBD VBD O
primary JJ JJ O
and CC CC O
59 CD CD O
recurrent NN NN O
disease NN NN O
. . . O

Of IN IN O
the DT DT O
82 CD CD O
evaluable JJ JJ O
patients NNS NNS O
, , , O
50 CD CD O
did VBD VBD O
not RB RB O
show VB VB O
any DT DT O
recurrence NN NN O
after IN IN O
1 CD CD O
year NN NN O
( ( ( O
61 CD CD O
% NN NN O
) ) ) O
, , , O
while IN IN O
32 CD CD O
presented VBN VBN O
with IN IN O
one CD CD O
or CC CC O
more JJR JJR O
recurrences NNS NNS O
( ( ( O
39 CD CD O
% NN NN O
) ) ) O
. . . O

Of IN IN O
these DT DT O
recurrences NNS NNS O
, , , O
27 CD CD O
were VBD VBD O
T1 NNP NNP O
tumors NNS NNS O
while IN IN O
five CD CD O
progressed VBD VBD O
to TO TO O
more JJR JJR O
highly RB RB O
invasive JJ JJ O
lesions NNS NNS O
. . . O

In IN IN O
patients NNS NNS O
that WDT WDT O
were VBD VBD O
free JJ JJ O
of IN IN O
recurrence NN NN O
during IN IN O
the DT DT O
first JJ JJ O
year NN NN O
, , , O
80 CD CD O
% NN NN O
remained VBD VBD O
tumor NN NN O
- - - O
free JJ JJ O
during IN IN O
the DT DT O
2 CD CD O
- : : O
to TO TO O
3 CD CD O
- : : O
year NN NN O
follow VB VB O
- - - O
up RP RP O
period NN NN O
. . . O

Of IN IN O
the DT DT O
patients NNS NNS O
developing VBG VBG O
one CD CD O
or CC CC O
more JJR JJR O
recurrences NNS NNS O
during IN IN O
the DT DT O
first JJ JJ O
year NN NN O
, , , O
only RB RB O
50 CD CD O
% NN NN O
presented VBN VBN O
with IN IN O
further JJ JJ O
recurrence NN NN O
once RB RB O
the DT DT O
instillations NNS NNS O
were VBD VBD O
stopped VBN VBN O
. . . O

The DT DT O
beneficial JJ JJ O
effect NN NN O
of IN IN O
Adriamycin NNP NNP B-CHEM
appears VBZ VBZ O
obvious JJ JJ O
and CC CC O
might MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
drug NN NN O
itself PRP PRP O
, , , O
the DT DT O
early JJ JJ O
and CC CC O
repeated VBN VBN O
instillations NNS NNS O
after IN IN O
TUR NNP NNP O
, , , O
or CC CC O
both DT DT O
. . . O

D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
- - - O
induced JJ JJ O
angiopathy NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
high JJ JJ O
dose NN NN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
treatment NN NN O
on IN IN O
aortic JJ JJ O
permeability NN NN O
to TO TO O
albumin VB VB O
and CC CC O
on IN IN O
the DT DT O
ultrastructure NN NN O
of IN IN O
the DT DT O
vessel NN NN O
. . . O

Male NNP NNP O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
( ( ( O
D NNP NNP B-CHEM
- - - I-CHEM
pen NN NN I-CHEM
) ) ) O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
for IN IN O
10 CD CD O
or CC CC O
42 CD CD O
days NNS NNS O
. . . O

Pair NNP NNP O
fed VBD VBD O
rats NNS NNS O
served VBN VBN O
as IN IN O
controls NNS NNS O
. . . O

Changes NNS NNS O
in IN IN O
aortic JJ JJ O
morphology NN NN O
were VBD VBD O
examined VBN VBN O
by IN IN O
light JJ JJ O
- - - O
and CC CC O
transmission NN NN O
- - - O
electron NN NN O
microscopy NN NN O
( ( ( O
TEM NNP NNP O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
endothelial JJ JJ O
permeability NN NN O
and CC CC O
the DT DT O
penetration NN NN O
through IN IN O
the DT DT O
aortic JJ JJ O
wall NN NN O
of IN IN O
albumin NN NN O
were VBD VBD O
studied VBN VBN O
10 CD CD O
minutes NNS NNS O
, , , O
24 CD CD O
and CC CC O
48 CD CD O
hours NNS NNS O
after IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
injection NN NN O
of IN IN O
human JJ JJ O
serum NN NN O
131I CD CD O
- : : O
albumin NN NN O
( ( ( O
131I CD CD O
- : : O
HSA NNP NNP O
) ) ) O
. . . O

TEM NNP NNP O
revealed VBD VBD O
extensive JJ JJ O
elastolysis NN NN O
in IN IN O
the DT DT O
arterial JJ JJ O
wall NN NN O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
pen NN NN I-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
, , , O
consistent JJ JJ O
with IN IN O
an DT DT O
inhibitory JJ JJ O
effect NN NN O
on IN IN O
crosslink NN NN O
formation NN NN O
. . . O

In IN IN O
experimental JJ JJ O
animals NNS NNS O
excess JJ JJ O
deposition NN NN O
of IN IN O
collagen NN NN O
and CC CC O
glycoaminoglycans NNS NNS O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
subendothelial NN NN O
and CC CC O
medial JJ JJ O
layer NN NN O
of IN IN O
the DT DT O
aortic JJ JJ O
wall NN NN O
, , , O
together RB RB O
with IN IN O
prominent JJ JJ O
basal NN NN O
membrane NN NN O
substance NN NN O
around IN IN O
aortic JJ JJ O
smooth NN NN O
muscle NN NN O
cells NNS NNS O
. . . O

The DT DT O
aorta NN NN O
/ NN NN O
serum NN NN O
- : : O
ratio NN NN O
and CC CC O
the DT DT O
radioactive JJ JJ O
build NN NN O
- - - O
up RP RP O
24 CD CD O
and CC CC O
48 CD CD O
hours NNS NNS O
after IN IN O
injection NN NN O
of IN IN O
131I CD CD O
- : : O
HSA NNP NNP O
was VBD VBD O
reduced VBN VBN O
in IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
pen NN NN I-CHEM
for IN IN O
42 CD CD O
days NNS NNS O
, , , O
indicating VBG VBG O
an DT DT O
impeded JJ JJ O
transmural JJ JJ O
transport NN NN O
of IN IN O
tracer NN NN O
which WDT WDT O
may MD MD O
be VB VB O
caused VBN VBN O
by IN IN O
a DT DT O
steric JJ JJ O
exclusion NN NN O
effect NN NN O
of IN IN O
abundant JJ JJ O
hyaluronate NN NN B-CHEM
. . . O

The DT DT O
endothelial JJ JJ O
ultrastructure NN NN O
was VBD VBD O
unaffected JJ JJ O
by IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
pen NN NN I-CHEM
, , , O
and CC CC O
no DT DT O
differences NNS NNS O
in IN IN O
aortic JJ JJ O
131I CD CD O
- : : O
HSA NNP NNP O
radioactivity NN NN O
or CC CC O
aorta NN NN O
/ NN NN O
serum NN NN O
- - - O
ratio NN NN O
were VBD VBD O
recorded VBN VBN O
between IN IN O
experimental JJ JJ O
and CC CC O
control NN NN O
groups NNS NNS O
10 CD CD O
minutes NNS NNS O
after IN IN O
tracer NN NN O
injection NN NN O
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
permeability NN NN O
of IN IN O
the DT DT O
endothelial JJ JJ O
barrier NN NN O
to TO TO O
albumin VB VB O
remained VBD VBD O
unaffected JJ JJ O
by IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
pen NN NN I-CHEM
treatment NN NN O
. . . O

These DT DT O
observations NNS NNS O
support VBP VBP O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
treatment NN NN O
with IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
pen NN NN I-CHEM
may MD MD O
induce VB VB O
a DT DT O
fibroproliferative JJ JJ O
response NN NN O
in IN IN O
rat NN NN O
aorta NN NN O
, , , O
possibly RB RB O
by IN IN O
an DT DT O
inhibitory JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
cross NN NN O
- - - O
linking NN NN O
of IN IN O
collagen NN NN O
and CC CC O
elastin NN NN O
. . . O

Effect NN NN O
of IN IN O
aspirin NN NN B-CHEM
on IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
[ NN NN I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
nitro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
furyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
thiazolyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
formamide NN NN I-CHEM
- - - O
induced JJ JJ O
epithelial NN NN O
proliferation NN NN O
in IN IN O
the DT DT O
urinary JJ JJ O
bladder NN NN O
and CC CC O
forestomach NN NN O
of IN IN O
the DT DT O
rat NN NN O
. . . O

The DT DT O
co NN NN O
- - - O
administration NN NN O
of IN IN O
aspirin NN NN B-CHEM
with IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
[ NN NN I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
nitro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
furyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
thiazolyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
formamide NN NN I-CHEM
( ( ( O
FANFT NNP NNP B-CHEM
) ) ) O
to TO TO O
rats NNS NNS O
resulted VBD VBD O
in IN IN O
a DT DT O
reduced JJ JJ O
incidence NN NN O
of IN IN O
FANFT NNP NNP B-CHEM
- : : O
induced JJ JJ O
bladder NN NN O
carcinomas NN NN O
but CC CC O
a DT DT O
concomitant JJ JJ O
induction NN NN O
of IN IN O
forestomach NN NN O
tumors NNS NNS O
. . . O

An DT DT O
autoradiographic JJ JJ O
study NN NN O
was VBD VBD O
performed VBN VBN O
on IN IN O
male JJ JJ O
F NN NN O
- - - O
344 CD CD O
rats NNS NNS O
fed VBN VBN O
diet JJ JJ O
containing VBG VBG O
FANFT NNP NNP B-CHEM
at IN IN O
a DT DT O
level NN NN O
of IN IN O
0 CD CD O
. . . O
2 CD CD O
% NN NN O
and CC CC O
/ NN NN O
or CC CC O
aspirin NN NN B-CHEM
at IN IN O
a DT DT O
level NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
effect NN NN O
of IN IN O
aspirin NN NN B-CHEM
on IN IN O
the DT DT O
increased VBN VBN O
cell NN NN O
proliferation NN NN O
induced VBN VBN O
by IN IN O
FANFT NNP NNP B-CHEM
in IN IN O
the DT DT O
forestomach NN NN O
and CC CC O
bladder NN NN O
. . . O

FANFT NNP NNP B-CHEM
- : : O
induced JJ JJ O
cell NN NN O
proliferation NN NN O
in IN IN O
the DT DT O
bladder NN NN O
was VBD VBD O
significantly RB RB O
suppressed VBN VBN O
by IN IN O
aspirin NN NN B-CHEM
co NN NN O
- : : O
administration NN NN O
after IN IN O
4 CD CD O
weeks NNS NNS O
but CC CC O
not RB RB O
after IN IN O
12 CD CD O
weeks NNS NNS O
. . . O

In IN IN O
the DT DT O
forestomach NN NN O
, , , O
and CC CC O
also RB RB O
in IN IN O
the DT DT O
liver NN NN O
, , , O
aspirin NN NN B-CHEM
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
FANFT NNP NNP B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
labeling VBG VBG O
index NN NN O
. . . O

The DT DT O
present JJ JJ O
results NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
the DT DT O
carcinogenicity NN NN O
experiment NN NN O
suggesting VBG VBG O
that IN IN O
different JJ JJ O
mechanisms NNS NNS O
are VBP VBP O
involved VBN VBN O
in IN IN O
FANFT NNP NNP B-CHEM
carcinogenesis NN NN O
in IN IN O
the DT DT O
bladder NN NN O
and CC CC O
forestomach NN NN O
, , , O
and CC CC O
that IN IN O
aspirin NN NN B-CHEM
' '' '' O
s VBZ VBZ O
effect NN NN O
on IN IN O
FANFT NNP NNP B-CHEM
in IN IN O
the DT DT O
forestomach NN NN O
is VBZ VBZ O
not RB RB O
due JJ JJ O
to TO TO O
an DT DT O
irritant JJ JJ O
effect NN NN O
associated VBN VBN O
with IN IN O
increased VBN VBN O
cell NN NN O
proliferation NN NN O
. . . O

Also RB RB O
, , , O
there EX EX O
appears VBZ VBZ O
to TO TO O
be VB VB O
an DT DT O
adaptation NN NN O
by IN IN O
the DT DT O
rats NNS NNS O
to TO TO O
the DT DT O
chronic JJ JJ O
ingestion NN NN O
of IN IN O
aspirin NN NN B-CHEM
. . . O

A DT DT O
case NN NN O
of IN IN O
tardive JJ JJ O
dyskinesia NN NN O
caused VBN VBN O
by IN IN O
metoclopramide NN NN B-CHEM
. . . O

Abnormal NNP NNP O
involuntary JJ JJ O
movements NNS NNS O
appeared VBD VBD O
in IN IN O
the DT DT O
mouth NN NN O
, , , O
tongue NN NN O
, , , O
neck NN NN O
and CC CC O
abdomen NN NN O
of IN IN O
a DT DT O
64 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male JJ JJ O
patient NN NN O
after IN IN O
he PRP PRP O
took VBD VBD O
metoclopramide NN NN B-CHEM
for IN IN O
gastrointestinal JJ JJ O
disorder NN NN O
in IN IN O
a DT DT O
regimen NN NN O
of IN IN O
30 CD CD O
mg NN NN O
per IN IN O
day NN NN O
for IN IN O
a DT DT O
total NN NN O
of IN IN O
about IN IN O
260 CD CD O
days NNS NNS O
. . . O

The DT DT O
symptoms NNS NNS O
exacerbated VBN VBN O
to TO TO O
a DT DT O
maximum NN NN O
in IN IN O
a DT DT O
month NN NN O
. . . O

When WRB WRB O
the DT DT O
metoclopramide NN NN B-CHEM
administration NN NN O
was VBD VBD O
discontinued VBN VBN O
, , , O
the DT DT O
abnormal JJ JJ O
movements NNS NNS O
gradually RB RB O
improved VBN VBN O
to TO TO O
a DT DT O
considerable JJ JJ O
extent NN NN O
. . . O

Attention NNP NNP O
to TO TO O
the DT DT O
possible JJ JJ O
induction NN NN O
of IN IN O
specific JJ JJ O
tardive JJ JJ O
dyskinesia NN NN O
is VBZ VBZ O
called VBN VBN O
for IN IN O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
this DT DT O
drug NN NN O
. . . O

Intra NNP NNP O
- : : O
arterial JJ JJ O
BCNU NNP NNP B-CHEM
chemotherapy NN NN O
for IN IN O
treatment NN NN O
of IN IN O
malignant JJ JJ O
gliomas NNS NNS O
of IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Because IN IN O
of IN IN O
the DT DT O
rapid JJ JJ O
systemic JJ JJ O
clearance NN NN O
of IN IN O
BCNU NNP NNP B-CHEM
( ( ( O
1 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
bis NN NN I-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
chloroethyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
nitrosourea NN NN I-CHEM
) ) ) O
, , , O
intra JJ JJ O
- - - O
arterial JJ JJ O
administration NN NN O
should MD MD O
provide VB VB O
a DT DT O
substantial JJ JJ O
advantage NN NN O
over IN IN O
intravenous JJ JJ O
administration NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
malignant JJ JJ O
gliomas NNS NNS O
. . . O

Thirty NNP NNP O
- : : O
six CD CD O
patients NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
BCNU NNP NNP B-CHEM
every DT DT O
6 CD CD O
to TO TO O
8 CD CD O
weeks NNS NNS O
, , , O
either CC CC O
by IN IN O
transfemoral JJ JJ O
catheterization NN NN O
of IN IN O
the DT DT O
internal JJ JJ O
carotid NN NN O
or CC CC O
vertebral JJ JJ O
artery NN NN O
or CC CC O
through IN IN O
a DT DT O
fully RB RB O
implantable JJ JJ O
intracarotid NN NN O
drug NN NN O
delivery NN NN O
system NN NN O
, , , O
beginning VBG VBG O
with IN IN O
a DT DT O
dose NN NN O
of IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
sq JJ JJ O
m NN NN O
body NN NN O
surface NN NN O
area NN NN O
. . . O

Twelve CD CD O
patients NNS NNS O
with IN IN O
Grade NNP NNP O
III NNP NNP O
or CC CC O
IV NNP NNP O
astrocytomas NNS NNS O
were VBD VBD O
treated VBN VBN O
after IN IN O
partial JJ JJ O
resection NN NN O
of IN IN O
the DT DT O
tumor NN NN O
without IN IN O
prior JJ JJ O
radiation NN NN O
therapy NN NN O
. . . O

After IN IN O
two CD CD O
to TO TO O
seven CD CD O
cycles NNS NNS O
of IN IN O
chemotherapy NN NN O
, , , O
nine CD CD O
patients NNS NNS O
showed VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
tumor NN NN O
size NN NN O
and CC CC O
surrounding VBG VBG O
edema NN NN O
on IN IN O
contrast NN NN O
- : : O
enhanced JJ JJ O
computerized JJ JJ O
tomography NN NN O
scans NNS NNS O
. . . O

In IN IN O
the DT DT O
nine CD CD O
responders NNS NNS O
, , , O
median JJ JJ O
duration NN NN O
of IN IN O
chemotherapy NN NN O
response NN NN O
from IN IN O
the DT DT O
time NN NN O
of IN IN O
operation NN NN O
was VBD VBD O
25 CD CD O
weeks NNS NNS O
( ( ( O
range NN NN O
12 CD CD O
to TO TO O
more JJR JJR O
than IN IN O
91 CD CD O
weeks NNS NNS O
) ) ) O
. . . O

The DT DT O
median JJ JJ O
duration NN NN O
of IN IN O
survival NN NN O
in IN IN O
the DT DT O
12 CD CD O
patients NNS NNS O
was VBD VBD O
54 CD CD O
weeks NNS NNS O
( ( ( O
range NN NN O
21 CD CD O
to TO TO O
more JJR JJR O
than IN IN O
156 CD CD O
weeks NNS NNS O
) ) ) O
, , , O
with IN IN O
an DT DT O
18 CD CD O
- : : O
month NN NN O
survival NN NN O
rate NN NN O
of IN IN O
42 CD CD O
% NN NN O
. . . O

Twenty CD CD O
- - - O
four CD CD O
patients NNS NNS O
with IN IN O
recurrent JJ JJ O
Grade NNP NNP O
I PRP PRP O
to TO TO O
IV NNP NNP O
astrocytomas NNS NNS O
, , , O
whose WP$ WP$ O
resection NN NN O
and CC CC O
irradiation NN NN O
therapy NN NN O
had VBD VBD O
failed VBN VBN O
, , , O
received VBD VBD O
two CD CD O
to TO TO O
eight CD CD O
courses NNS NNS O
of IN IN O
intra NN NN O
- - - O
arterial JJ JJ O
BCNU NNP NNP B-CHEM
therapy NN NN O
. . . O

Seventeen NNP NNP O
of IN IN O
these DT DT O
had VBD VBD O
a DT DT O
response NN NN O
or CC CC O
were VBD VBD O
stable JJ JJ O
for IN IN O
a DT DT O
median NN NN O
of IN IN O
20 CD CD O
weeks NNS NNS O
( ( ( O
range NN NN O
6 CD CD O
to TO TO O
more JJR JJR O
than IN IN O
66 CD CD O
weeks NNS NNS O
) ) ) O
. . . O

The DT DT O
catheterization NN NN O
procedure NN NN O
is VBZ VBZ O
safe JJ JJ O
, , , O
with IN IN O
no DT DT O
immediate JJ JJ O
complication NN NN O
in IN IN O
111 CD CD O
infusions NNS NNS O
of IN IN O
BCNU NNP NNP B-CHEM
. . . O

A DT DT O
delayed JJ JJ O
complication NN NN O
in IN IN O
nine CD CD O
patients NNS NNS O
has VBZ VBZ O
been VBN VBN O
unilateral JJ JJ O
loss NN NN O
of IN IN O
vision NN NN O
secondary JJ JJ O
to TO TO O
a DT DT O
retinal JJ JJ O
vasculitis NN NN O
. . . O

The DT DT O
frequency NN NN O
of IN IN O
visual JJ JJ O
loss NN NN O
decreased VBD VBD O
after IN IN O
the DT DT O
concentration NN NN O
of IN IN O
the DT DT O
ethanol NN NN B-CHEM
diluent NN NN O
was VBD VBD O
lowered VBN VBN O
. . . O

Provocation NNP NNP O
of IN IN O
postural JJ JJ O
hypotension NN NN O
by IN IN O
nitroglycerin NN NN B-CHEM
in IN IN O
diabetic JJ JJ O
autonomic JJ JJ O
neuropathy NN NN O
? . . O

The DT DT O
effect NN NN O
of IN IN O
nitroglycerin NN NN B-CHEM
on IN IN O
heart NN NN O
rate NN NN O
and CC CC O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
was VBD VBD O
compared VBN VBN O
in IN IN O
5 CD CD O
normal JJ JJ O
subjects NNS NNS O
, , , O
12 CD CD O
diabetic JJ JJ O
subjects NNS NNS O
without IN IN O
autonomic JJ JJ O
neuropathy NN NN O
, , , O
and CC CC O
5 CD CD O
diabetic JJ JJ O
subjects NNS NNS O
with IN IN O
autonomic JJ JJ O
neuropathy NN NN O
. . . O

The DT DT O
magnitude NN NN O
and CC CC O
time NN NN O
course NN NN O
of IN IN O
the DT DT O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
and CC CC O
the DT DT O
decrease NN NN O
in IN IN O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
after IN IN O
nitroglycerin NN NN B-CHEM
were VBD VBD O
similar JJ JJ O
in IN IN O
the DT DT O
normal JJ JJ O
and CC CC O
diabetic JJ JJ O
subjects NNS NNS O
without IN IN O
autonomic JJ JJ O
neuropathy NN NN O
, , , O
whereas IN IN O
a DT DT O
lesser JJR JJR O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
and CC CC O
a DT DT O
greater JJR JJR O
decrease NN NN O
in IN IN O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
occurred VBD VBD O
in IN IN O
the DT DT O
diabetic JJ JJ O
subjects NNS NNS O
with IN IN O
autonomic JJ JJ O
neuropathy NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
therefore RB RB O
suggested VBN VBN O
that IN IN O
caution NN NN O
should MD MD O
be VB VB O
exercised VBN VBN O
when WRB WRB O
prescribing VBG VBG O
vasodilator NN NN O
drugs NNS NNS O
in IN IN O
diabetic JJ JJ O
patients NNS NNS O
, , , O
particularly RB RB O
those DT DT O
with IN IN O
autonomic JJ JJ O
neuropathy NN NN O
. . . O

Blood NNP NNP O
pressure NN NN O
response NN NN O
to TO TO O
chronic JJ JJ O
low JJ JJ O
- - - O
dose NN NN O
intrarenal JJ JJ O
noradrenaline NN NN B-CHEM
infusion NN NN O
in IN IN O
conscious JJ JJ O
rats NNS NNS O
. . . O

Sodium NNP NNP B-CHEM
chloride NN NN I-CHEM
solution NN NN O
( ( ( O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
or CC CC O
noradrenaline NN NN B-CHEM
in IN IN O
doses NNS NNS O
of IN IN O
4 CD CD O
, , , O
12 CD CD O
and CC CC O
36 CD CD O
micrograms NNS NNS O
h NN NN O
- : : O
1 CD CD O
kg NN NN O
- : : O
1 CD CD O
was VBD VBD O
infused VBN VBN O
for IN IN O
five CD CD O
consecutive JJ JJ O
days NNS NNS O
, , , O
either CC CC O
intrarenally RB RB O
( ( ( O
by IN IN O
a DT DT O
new JJ JJ O
technique NN NN O
) ) ) O
or CC CC O
intravenously RB RB O
into IN IN O
rats NNS NNS O
with IN IN O
one CD CD O
kidney NN NN O
removed VBD VBD O
. . . O

Intrarenal NNP NNP O
infusion NN NN O
of IN IN O
noradrenaline NN NN B-CHEM
caused VBN VBN O
hypertension NN NN O
at IN IN O
doses NNS NNS O
which WDT WDT O
did VBD VBD O
not RB RB O
do VB VB O
so RB RB O
when WRB WRB O
infused JJ JJ O
intravenously RB RB O
. . . O

Intrarenal NNP NNP O
compared VBN VBN O
with IN IN O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
noradrenaline NN NN B-CHEM
caused VBD VBD O
higher JJR JJR O
plasma NN NN O
noradrenaline NN NN B-CHEM
concentrations NNS NNS O
and CC CC O
a DT DT O
shift NN NN O
of IN IN O
the DT DT O
plasma NN NN O
noradrenaline NN NN B-CHEM
concentration NN NN O
- : : O
blood NN NN O
pressure NN NN O
effect NN NN O
curve NN NN O
towards IN IN O
lower JJR JJR O
plasma NN NN O
noradrenaline NN NN B-CHEM
levels NNS NNS O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that DT DT O
hypertension NN NN O
after IN IN O
chronic JJ JJ O
intrarenal JJ JJ O
noradrenaline NN NN B-CHEM
infusion NN NN O
is VBZ VBZ O
produced VBN VBN O
by IN IN O
relatively RB RB O
higher JJR JJR O
levels NNS NNS O
of IN IN O
circulating VBG VBG O
noradrenaline NN NN B-CHEM
and CC CC O
by IN IN O
triggering VBG VBG O
of IN IN O
an DT DT O
additional JJ JJ O
intrarenal JJ JJ O
pressor NN NN O
mechanism NN NN O
. . . O

Characterization NNP NNP O
of IN IN O
estrogen NN NN B-CHEM
- - - O
induced JJ JJ O
adenohypophyseal NN NN O
tumors NNS NNS O
in IN IN O
the DT DT O
Fischer NNP NNP O
344 CD CD O
rat NN NN O
. . . O

Pituitary NNP NNP O
tumors NNS NNS O
were VBD VBD O
induced VBN VBN O
in IN IN O
F344 NNP NNP O
female JJ JJ O
rats NNS NNS O
by IN IN O
chronic JJ JJ O
treatment NN NN O
with IN IN O
diethylstilbestrol NN NN B-CHEM
( ( ( O
DES NNP NNP B-CHEM
, , , O
8 CD CD O
- : : O
10 CD CD O
mg NN NN O
) ) ) O
implanted JJ JJ O
subcutaneously RB RB O
in IN IN O
silastic JJ JJ O
capsules NNS NNS O
. . . O

Over IN IN O
a DT DT O
range NN NN O
of IN IN O
1 CD CD O
- : : O
150 CD CD O
days NNS NNS O
of IN IN O
DES NNP NNP B-CHEM
treatment NN NN O
, , , O
pairs NNS NNS O
of IN IN O
control NN NN O
and CC CC O
DES NNP NNP B-CHEM
- : : O
treated VBN VBN O
rats NNS NNS O
were VBD VBD O
sacrificed VBN VBN O
, , , O
and CC CC O
their PRP$ PRP$ O
pituitaries NNS NNS O
dissociated VBN VBN O
enzymatically RB RB O
into IN IN O
single JJ JJ O
- : : O
cell NN NN O
preparations NNS NNS O
. . . O

The DT DT O
cell NN NN O
populations NNS NNS O
were VBD VBD O
examined VBN VBN O
regarding VBG VBG O
total JJ JJ O
cell NN NN O
recovery NN NN O
correlated JJ JJ O
with IN IN O
gland NN NN O
weight NN NN O
, , , O
intracellular JJ JJ O
prolactin NN NN O
( ( ( O
PRL NNP NNP O
) ) ) O
content NN NN O
and CC CC O
subsequent JJ JJ O
release NN NN O
in IN IN O
primary JJ JJ O
culture NN NN O
, , , O
immunocytochemical JJ JJ O
PRL NNP NNP O
staining VBG VBG O
, , , O
density NN NN O
and CC CC O
/ NN NN O
or CC CC O
size NN NN O
alterations NNS NNS O
via IN IN O
separation NN NN O
on IN IN O
Ficoll NNP NNP O
- : : O
Hypaque NNP NNP O
and CC CC O
by IN IN O
unit NN NN O
gravity NN NN O
sedimentation NN NN O
, , , O
and CC CC O
cell NN NN O
cycle NN NN O
analysis NN NN O
, , , O
after IN IN O
acriflavine NN NN B-CHEM
DNA NNP NNP O
staining VBG VBG O
, , , O
by IN IN O
laser NN NN O
flow NN NN O
cytometry NN NN O
. . . O

Total NNP NNP O
cell NN NN O
yields NNS NNS O
from IN IN O
DES NNP NNP B-CHEM
- : : O
treated VBN VBN O
pituitaries NNS NNS O
increased VBN VBN O
from IN IN O
1 CD CD O
. . . O
3 CD CD O
times NNS NNS O
control NN NN O
yields NNS NNS O
at IN IN O
8 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
to TO TO O
58 CD CD O
. . . O
9 CD CD O
times NNS NNS O
control NN NN O
values NNS NNS O
by IN IN O
day NN NN O
150 CD CD O
. . . O

Intracellular NNP NNP O
PRL NNP NNP O
content NN NN O
ranged VBD VBD O
from IN IN O
1 CD CD O
. . . O
9 CD CD O
to TO TO O
9 CD CD O
. . . O
4 CD CD O
times NNS NNS O
control NN NN O
levels NNS NNS O
, , , O
and CC CC O
PRL NNP NNP O
release NN NN O
in IN IN O
vitro NN NN O
was VBD VBD O
significantly RB RB O
and CC CC O
consistently RB RB O
higher JJR JJR O
than IN IN O
controls NNS NNS O
, , , O
after IN IN O
at IN IN O
least JJS JJS O
8 CD CD O
days NNS NNS O
of IN IN O
DES NNP NNP B-CHEM
exposure NN NN O
. . . O

Beyond IN IN O
8 CD CD O
days NNS NNS O
of IN IN O
DES NNP NNP B-CHEM
exposure NN NN O
, , , O
the DT DT O
immunochemically RB RB O
PRL NNP NNP O
- : : O
positive JJ JJ O
proportion NN NN O
of IN IN O
cells NNS NNS O
increased VBN VBN O
to TO TO O
over IN IN O
50 CD CD O
% NN NN O
of IN IN O
the DT DT O
total JJ JJ O
population NN NN O
. . . O

Increased NNP NNP O
density NN NN O
and CC CC O
/ NN NN O
or CC CC O
size NN NN O
and CC CC O
PRL NNP NNP O
content NN NN O
were VBD VBD O
indicated VBN VBN O
for IN IN O
the DT DT O
majority NN NN O
of IN IN O
the DT DT O
PRL NNP NNP O
cell NN NN O
population NN NN O
in IN IN O
both DT DT O
types NNS NNS O
of IN IN O
separation NN NN O
protocols NNS NNS O
. . . O

All DT DT O
these DT DT O
effects NNS NNS O
of IN IN O
DES NNP NNP B-CHEM
were VBD VBD O
more RBR RBR O
pronounced JJ JJ O
among IN IN O
previously RB RB O
ovariectomized JJ JJ O
animals NNS NNS O
. . . O

The DT DT O
data NNS NNS O
extend VB VB O
the DT DT O
findings NNS NNS O
of IN IN O
other JJ JJ O
investigators NNS NNS O
, , , O
further RB RB O
establishing VBG VBG O
the DT DT O
DES NNP NNP B-CHEM
- - - O
induced JJ JJ O
tumor NN NN O
as IN IN O
a DT DT O
model NN NN O
for IN IN O
study NN NN O
of IN IN O
PRL NNP NNP O
cellular NN NN O
control NN NN O
mechanisms NNS NNS O
. . . O

Age NNP NNP O
and CC CC O
renal JJ JJ O
clearance NN NN O
of IN IN O
cimetidine NN NN B-CHEM
. . . O

In IN IN O
35 CD CD O
patients NNS NNS O
( ( ( O
ages NNS NNS O
20 CD CD O
to TO TO O
86 CD CD O
yr NN NN O
) ) ) O
receiving VBG VBG O
cimetidine NN NN B-CHEM
therapeutically RB RB O
two CD CD O
serum NN NN O
samples NNS NNS O
and CC CC O
all DT DT O
urine NN NN O
formed VBN VBN O
in IN IN O
the DT DT O
interim NN NN O
were VBD VBD O
collected VBN VBN O
for IN IN O
analysis NN NN O
of IN IN O
cimetidine NN NN B-CHEM
by IN IN O
high JJ JJ O
- - - O
pressure NN NN O
liquid NN NN O
chromatography NN NN O
and CC CC O
for IN IN O
creatinine NN NN B-CHEM
. . . O

Cimetidine NNP NNP B-CHEM
clearance NN NN O
decreased VBD VBD O
with IN IN O
age NN NN O
. . . O

The DT DT O
extrapolated VBN VBN O
6 CD CD O
- : : O
hr NN NN O
serum NN NN O
concentration NN NN O
of IN IN O
cimetidine NN NN B-CHEM
per IN IN O
unit NN NN O
dose NN NN O
, , , O
after IN IN O
intravenous JJ JJ O
cimetidine NN NN B-CHEM
, , , O
increased VBN VBN O
with IN IN O
age NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
. . . O

The DT DT O
ratio NN NN O
of IN IN O
cimetidine NN NN B-CHEM
clearance NN NN O
to TO TO O
creatinine VB VB B-CHEM
clearance NN NN O
( ( ( O
Rc NNP NNP O
) ) ) O
averaged VBD VBD O
4 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
0 CD CD O
, , , O
indicating VBG VBG O
net NN NN O
tubular NN NN O
secretion NN NN O
for IN IN O
cimetidine NN NN B-CHEM
. . . O

Rc NNP NNP O
seemed VBD VBD O
to TO TO O
be VB VB O
independent JJ JJ O
of IN IN O
age NN NN O
and CC CC O
decreased VBD VBD O
with IN IN O
increasing VBG VBG O
serum NN NN O
concentration NN NN O
of IN IN O
cimetidine NN NN B-CHEM
, , , O
suggesting VBG VBG O
that DT DT O
secretion NN NN O
of IN IN O
cimetidine NN NN B-CHEM
is VBZ VBZ O
a DT DT O
saturable JJ JJ O
process NN NN O
. . . O

There EX EX O
was VBD VBD O
only RB RB O
one CD CD O
case NN NN O
of IN IN O
dementia NN NN O
possibly RB RB O
due JJ JJ O
to TO TO O
cimetidine VB VB B-CHEM
( ( ( O
with IN IN O
a DT DT O
drug NN NN O
level NN NN O
of IN IN O
1 CD CD O
. . . O
9 CD CD O
microgram NN NN O
/ NN NN O
ml NN NN O
6 CD CD O
hr NN NN O
after IN IN O
a DT DT O
dose NN NN O
) ) ) O
in IN IN O
a DT DT O
group NN NN O
of IN IN O
13 CD CD O
patients NNS NNS O
without IN IN O
liver NN NN O
or CC CC O
kidney NN NN O
disease NN NN O
who WP WP O
had VBD VBD O
cimetidine NN NN B-CHEM
levels NNS NNS O
above IN IN O
1 CD CD O
. . . O
25 CD CD O
microgram NN NN O
/ NN NN O
ml NN NN O
. . . O

Thus RB RB O
, , , O
high JJ JJ O
cimetidine NN NN B-CHEM
levels NNS NNS O
alone RB RB O
do VBP VBP O
not RB RB O
always RB RB O
induce VB VB O
dementia NN NN O
. . . O

Further RB RB O
observations NNS NNS O
on IN IN O
the DT DT O
electrophysiologic JJ JJ O
effects NNS NNS O
of IN IN O
oral JJ JJ O
amiodarone NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
case NN NN O
is VBZ VBZ O
presented VBN VBN O
of IN IN O
a DT DT O
reversible JJ JJ O
intra NN NN O
- - - O
Hisian NNP NNP O
block NN NN O
occurring VBG VBG O
under IN IN O
amiodarone NN NN B-CHEM
treatment NN NN O
for IN IN O
atrial JJ JJ O
tachycardia NN NN O
in IN IN O
a DT DT O
patient NN NN O
without IN IN O
clear JJ JJ O
intraventricular JJ JJ O
conduction NN NN O
abnormalities NNS NNS O
. . . O

His PRP$ PRP$ O
bundle NN NN O
recordings NNS NNS O
showed VBD VBD O
an DT DT O
atrial JJ JJ O
tachycardia NN NN O
with IN IN O
intermittent JJ JJ O
exit NN NN O
block NN NN O
and CC CC O
greatly RB RB O
prolonged JJ JJ O
BH NNP NNP O
and CC CC O
HV NNP NNP O
intervals NNS NNS O
( ( ( O
40 CD CD O
and CC CC O
100 CD CD O
msec NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

Thirty NNP NNP O
days NNS NNS O
after IN IN O
amiodarone NN NN B-CHEM
discontinuation NN NN O
, , , O
His PRP$ PRP$ O
bundle NN NN O
electrograms NNS NNS O
showed VBD VBD O
atrial JJ JJ O
flutter NN NN O
without IN IN O
intra NN NN O
- - - O
Hisian NNP NNP O
or CC CC O
infra NN NN O
- - - O
Hisian NNP NNP O
delay NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
caution NN NN O
during IN IN O
long JJ JJ O
- - - O
term NN NN O
oral JJ JJ O
therapy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
or CC CC O
without IN IN O
clear JJ JJ O
intraventricular JJ JJ O
conduction NN NN O
defects NNS NNS O
. . . O

Development NNP NNP O
of IN IN O
clear JJ JJ O
cell NN NN O
adenocarcinoma NN NN O
in IN IN O
DES NNP NNP B-CHEM
- - - O
exposed VBN VBN O
offspring VBG VBG O
under IN IN O
observation NN NN O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
clear JJ JJ O
cell NN NN O
adenocarcinoma NN NN O
of IN IN O
the DT DT O
vagina NN NN O
detected VBD VBD O
at IN IN O
follow VB VB O
- - - O
up RP RP O
in IN IN O
young JJ JJ O
women NNS NNS O
exposed VBD VBD O
in IN IN O
utero NN NN O
to TO TO O
diethylstilbestrol NN NN B-CHEM
are VBP VBP O
reported VBN VBN O
. . . O

One CD CD O
patient NN NN O
, , , O
aged VBD VBD O
23 CD CD O
, , , O
had VBD VBD O
been VBN VBN O
followed VBN VBN O
for IN IN O
2 CD CD O
years NNS NNS O
before IN IN O
carcinoma NN NN O
was VBD VBD O
diagnosed VBN VBN O
; : : O
the DT DT O
second JJ JJ O
patient NN NN O
, , , O
aged VBD VBD O
22 CD CD O
, , , O
had VBD VBD O
been VBN VBN O
seen VBN VBN O
on IN IN O
a DT DT O
regular JJ JJ O
basis NN NN O
for IN IN O
5 CD CD O
years NNS NNS O
, , , O
8 CD CD O
months NNS NNS O
. . . O

In IN IN O
both DT DT O
instances NNS NNS O
, , , O
suspicion NN NN O
of IN IN O
the DT DT O
presence NN NN O
of IN IN O
carcinoma NN NN O
was VBD VBD O
aroused VBN VBN O
by IN IN O
the DT DT O
palpation NN NN O
of IN IN O
a DT DT O
small JJ JJ O
nodule NN NN O
in IN IN O
the DT DT O
vaginal JJ JJ O
fornix NN NN O
. . . O

Hysterosalpingography NNP NNP O
was VBD VBD O
performed VBN VBN O
on IN IN O
both DT DT O
patients NNS NNS O
and CC CC O
, , , O
in IN IN O
1 CD CD O
instance NN NN O
, , , O
an DT DT O
abnormal JJ JJ O
x NN NN O
- : : O
ray NNP NNP O
film NN NN O
was VBD VBD O
reflected VBN VBN O
by IN IN O
the DT DT O
gross JJ JJ O
appearance NN NN O
of IN IN O
the DT DT O
uterine JJ JJ O
cavity NN NN O
found VBD VBD O
in IN IN O
the DT DT O
surgical JJ JJ O
specimen NN NN O
. . . O

Neurologic NNP NNP O
effects NNS NNS O
of IN IN O
subarachnoid JJ JJ O
administration NN NN O
of IN IN O
2 CD CD B-CHEM
- : : I-CHEM
chloroprocaine NN NN I-CHEM
- : : I-CHEM
CE NNP NNP I-CHEM
, , , O
bupivacaine NN NN B-CHEM
, , , O
and CC CC O
low JJ JJ O
pH NN NN O
normal JJ JJ O
saline NN NN O
in IN IN O
dogs NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
neurologic JJ JJ O
consequences NNS NNS O
of IN IN O
deliberate JJ JJ O
subarachnoid NN NN O
injection NN NN O
of IN IN O
large JJ JJ O
volumes NNS NNS O
of IN IN O
2 CD CD B-CHEM
- : : I-CHEM
chloroprocaine NN NN I-CHEM
- : : I-CHEM
CE NNP NNP I-CHEM
in IN IN O
experimental JJ JJ O
animals NNS NNS O
. . . O

The DT DT O
possible JJ JJ O
role NN NN O
of IN IN O
low JJ JJ O
pH NN NN O
as RB RB O
well RB RB O
as IN IN O
total JJ JJ O
volume NN NN O
as IN IN O
potential JJ JJ O
factors NNS NNS O
in IN IN O
causing VBG VBG O
neurotoxicity NN NN O
was VBD VBD O
evaluated VBN VBN O
. . . O

The DT DT O
65 NN NN O
dogs NNS NNS O
in IN IN O
the DT DT O
study NN NN O
received VBD VBD O
injections NNS NNS O
in IN IN O
the DT DT O
subarachnoid NN NN O
space NN NN O
as IN IN O
follows VBZ VBZ O
: : : O
6 CD CD O
to TO TO O
8 CD CD O
ml NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
( ( ( O
N NNP NNP O
= SYM SYM O
15 CD CD O
) ) ) O
, , , O
2 CD CD B-CHEM
- : : I-CHEM
chloroprocaine NN NN I-CHEM
- : : I-CHEM
CE NNP NNP I-CHEM
( ( ( O
N NNP NNP O
= SYM SYM O
20 CD CD O
) ) ) O
, , , O
low JJ JJ O
pH NN NN O
normal JJ JJ O
saline NN NN O
( ( ( O
pH NN NN O
3 CD CD O
. . . O
0 CD CD O
) ) ) O
( ( ( O
N NNP NNP O
= SYM SYM O
20 CD CD O
) ) ) O
, , , O
or CC CC O
normal JJ JJ O
saline NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
10 CD CD O
) ) ) O
. . . O

Of IN IN O
the DT DT O
20 CD CD O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
subarachnoid JJ JJ O
injection NN NN O
of IN IN O
2 CD CD B-CHEM
- : : I-CHEM
chloroprocaine NN NN I-CHEM
- : : I-CHEM
CE NNP NNP I-CHEM
seven CD CD O
( ( ( O
35 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
hind NN NN O
- - - O
limb NN NN O
paralysis NN NN O
. . . O

None NN NN O
of IN IN O
the DT DT O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
bupivacaine NN NN B-CHEM
, , , O
normal JJ JJ O
saline NN NN O
, , , O
or CC CC O
normal JJ JJ O
saline NN NN O
titrated VBN VBN O
to TO TO O
a DT DT O
pH NN NN O
3 CD CD O
. . . O
0 CD CD O
developed VBN VBN O
hind NN NN O
- - - O
limb NN NN O
paralysis NN NN O
. . . O

Of IN IN O
the DT DT O
15 CD CD O
spinal JJ JJ O
cords NNS NNS O
of IN IN O
the DT DT O
animals NNS NNS O
that IN IN O
received VBD VBD O
2 CD CD B-CHEM
- : : I-CHEM
chloroprocaine NN NN I-CHEM
- : : I-CHEM
CE NNP NNP I-CHEM
, , , O
13 CD CD O
showed VBD VBD O
subpial JJ JJ O
necrosis NN NN O
; : : O
the DT DT O
nerve NN NN O
roots NNS NNS O
and CC CC O
subarachnoid VB VB O
vessels NNS NNS O
were VBD VBD O
normal JJ JJ O
. . . O

The DT DT O
spinal JJ JJ O
cords NNS NNS O
of IN IN O
the DT DT O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
bupivacaine NN NN B-CHEM
, , , O
low JJ JJ O
pH NN NN O
normal JJ JJ O
saline NN NN O
( ( ( O
pH NN NN O
3 CD CD O
. . . O
0 CD CD O
) ) ) O
, , , O
or CC CC O
normal JJ JJ O
saline NN NN O
did VBD VBD O
not RB RB O
show VB VB O
abnormal JJ JJ O
findings NNS NNS O
. . . O

Procainamide NNP NNP B-CHEM
- : : O
induced JJ JJ O
polymorphous JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

Seven CD CD O
cases NNS NNS O
of IN IN O
procainamide NN NN B-CHEM
- - - O
induced JJ JJ O
polymorphous JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
are VBP VBP O
presented VBN VBN O
. . . O

In IN IN O
four CD CD O
patients NNS NNS O
, , , O
polymorphous JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
appeared VBD VBD O
after IN IN O
intravenous JJ JJ O
administration NN NN O
of IN IN O
200 CD CD O
to TO TO O
400 CD CD O
mg NN NN O
of IN IN O
procainamide NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
sustained VBN VBN O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

In IN IN O
the DT DT O
remaining VBG VBG O
three CD CD O
patients NNS NNS O
, , , O
procainamide NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
orally RB RB O
for IN IN O
treatment NN NN O
of IN IN O
chronic JJ JJ O
premature NN NN O
ventricular NN NN O
contractions NNS NNS O
or CC CC O
atrial JJ JJ O
flutter NN NN O
. . . O

These DT DT O
patients NNS NNS O
had VBD VBD O
Q NNP NNP O
- : : O
T NN NN O
prolongation NN NN O
and CC CC O
recurrent JJ JJ O
syncope NN NN O
due JJ JJ O
to TO TO O
polymorphous JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

In IN IN O
four CD CD O
patients NNS NNS O
, , , O
the DT DT O
arrhythmia NN NN O
was VBD VBD O
rapidly RB RB O
diagnosed VBN VBN O
and CC CC O
treated VBN VBN O
with IN IN O
disappearance NN NN O
of IN IN O
further JJ JJ O
episodes NNS NNS O
of IN IN O
the DT DT O
arrhythmia NN NN O
. . . O

In IN IN O
two CD CD O
patients NNS NNS O
, , , O
the DT DT O
arrhythmia NN NN O
degenerated VBD VBD O
into IN IN O
irreversible JJ JJ O
ventricular NN NN O
fibrillation NN NN O
and CC CC O
both DT DT O
patients NNS NNS O
died VBD VBD O
. . . O

In IN IN O
the DT DT O
seventh NN NN O
patient NN NN O
, , , O
a DT DT O
permanent JJ JJ O
ventricular NN NN O
pacemaker NN NN O
was VBD VBD O
inserted VBN VBN O
and CC CC O
, , , O
despite IN IN O
continuation NN NN O
of IN IN O
procainamide NN NN B-CHEM
therapy NN NN O
, , , O
polymorphous JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
did VBD VBD O
not RB RB O
reoccur VB VB O
. . . O

These DT DT O
seven CD CD O
cases NNS NNS O
demonstrate VBP VBP O
that IN IN O
procainamide NN NN B-CHEM
can MD MD O
produce VB VB O
an DT DT O
acquired JJ JJ O
prolonged JJ JJ O
Q NNP NNP O
- : : O
T NN NN O
syndrome NN NN O
with IN IN O
polymorphous JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

Phenobarbitone NNP NNP B-CHEM
- - - O
induced JJ JJ O
enlargement NN NN O
of IN IN O
the DT DT O
liver NN NN O
in IN IN O
the DT DT O
rat NN NN O
: : : O
its PRP$ PRP$ O
relationship NN NN O
to TO TO O
carbon NN NN B-CHEM
tetrachloride IN IN I-CHEM
- - - O
induced JJ JJ O
cirrhosis NNS NNS O
. . . O

The DT DT O
yield NN NN O
of IN IN O
severe JJ JJ O
cirrhosis NNS NNS O
of IN IN O
the DT DT O
liver NN NN O
( ( ( O
defined VBN VBN O
as IN IN O
a DT DT O
shrunken NN NN O
finely RB RB O
nodular JJ JJ O
liver NN NN O
with IN IN O
micronodular JJ JJ O
histology NN NN O
, , , O
ascites NNS NNS O
greater JJR JJR O
than IN IN O
30 CD CD O
ml NN NN O
, , , O
plasma NN NN O
albumin RB RB O
less JJR JJR O
than IN IN O
2 CD CD O
. . . O
2 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
, , , O
splenomegaly NN NN O
2 CD CD O
- : : O
3 CD CD O
times NNS NNS O
normal JJ JJ O
, , , O
and CC CC O
testicular JJ JJ O
atrophy NN NN O
approximately RB RB O
half NN NN O
normal JJ JJ O
weight NN NN O
) ) ) O
after IN IN O
12 CD CD O
doses NNS NNS O
of IN IN O
carbon NN NN B-CHEM
tetrachloride NN NN I-CHEM
given VBN VBN O
intragastrically RB RB O
in IN IN O
the DT DT O
phenobarbitone NN NN B-CHEM
- - - O
primed JJ JJ O
rat NN NN O
was VBD VBD O
increased VBN VBN O
from IN IN O
25 CD CD O
% NN NN O
to TO TO O
56 CD CD O
% NN NN O
by IN IN O
giving VBG VBG O
the DT DT O
initial JJ JJ O
" '' '' O
calibrating VBG VBG O
" '' '' O
dose NN NN O
of IN IN O
carbon NN NN B-CHEM
tetrachloride NN NN I-CHEM
at IN IN O
the DT DT O
peak NN NN O
of IN IN O
the DT DT O
phenobarbitone NN NN B-CHEM
- - - O
induced JJ JJ O
enlargement NN NN O
of IN IN O
the DT DT O
liver NN NN O
. . . O

At IN IN O
this DT DT O
point NN NN O
it PRP PRP O
was VBD VBD O
assumed VBN VBN O
that IN IN O
the DT DT O
cytochrome NN NN O
P450 NNP NNP O
/ NN NN O
CCl4 NNP NNP B-CHEM
toxic JJ JJ O
state NN NN O
was VBD VBD O
both DT DT O
maximal NN NN O
and CC CC O
stable JJ JJ O
. . . O

The DT DT O
optimal NN NN O
rat NN NN O
size NN NN O
to TO TO O
begin VB VB O
phenobarbitone NN NN B-CHEM
was VBD VBD O
determined VBN VBN O
as IN IN O
100 CD CD O
g SYM SYM O
, , , O
and CC CC O
this DT DT O
size NN NN O
as IN IN O
a DT DT O
group NN NN O
had VBD VBD O
a DT DT O
mean NN NN O
maximum NN NN O
relative JJ JJ O
liver NN NN O
weight NN NN O
increase NN NN O
47 CD CD O
% NN NN O
greater JJR JJR O
than IN IN O
normal JJ JJ O
rats NNS NNS O
of IN IN O
the DT DT O
same JJ JJ O
body NN NN O
weight NN NN O
. . . O

The DT DT O
optimal NN NN O
time NN NN O
for IN IN O
the DT DT O
initial JJ JJ O
dose NN NN O
of IN IN O
carbon NN NN B-CHEM
tetrachloride NN NN I-CHEM
was VBD VBD O
after IN IN O
14 CD CD O
days NNS NNS O
on IN IN O
phenobarbitone NN NN B-CHEM
. . . O

Triamterene NNP NNP B-CHEM
nephrolithiasis NNS NNS O
complicating VBG VBG O
dyazide NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
triamterene NN NN B-CHEM
nephrolithiasis NN NN O
is VBZ VBZ O
reported VBN VBN O
in IN IN O
a DT DT O
man NN NN O
after IN IN O
4 CD CD O
years NNS NNS O
of IN IN O
hydrochlorothiazide NN NN B-CHEM
- - - I-CHEM
triamterene NN NN I-CHEM
therapy NN NN O
for IN IN O
hypertension NN NN O
. . . O

The DT DT O
stone NN NN O
passed VBD VBD O
spontaneously RB RB O
and CC CC O
was VBD VBD O
found VBN VBN O
to TO TO O
contain VB VB O
a DT DT O
triamterene NN NN B-CHEM
metabolite NN NN O
admixed NN NN O
with IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
salts NNS NNS I-CHEM
. . . O

Factors NNS NNS O
affecting VBG VBG O
triamterene NN NN B-CHEM
nephrolithiasis NNS NNS O
are VBP VBP O
discussed VBN VBN O
and CC CC O
2 CD CD O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
are VBP VBP O
reviewed VBN VBN O
. . . O

Busulfan NNP NNP B-CHEM
- : : O
induced JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

A DT DT O
case NN NN O
of IN IN O
a DT DT O
busulfan NN NN B-CHEM
- - - O
induced JJ JJ O
hemorrhage NN NN O
cystitis NN NN O
is VBZ VBZ O
reported VBN VBN O
. . . O

Spontaneous NNP NNP O
resolution NN NN O
occurred VBD VBD O
following VBG VBG O
cessation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

The DT DT O
similarity NN NN O
between IN IN O
the DT DT O
histologic JJ JJ O
appearances NNS NNS O
of IN IN O
busulfan NN NN B-CHEM
cystitis NNS NNS O
and CC CC O
both DT DT O
radiation NN NN O
and CC CC O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
cystitis NN NN O
is VBZ VBZ O
discussed VBN VBN O
and CC CC O
the DT DT O
world NN NN O
literature NN NN O
reviewed VBD VBD O
. . . O

In IN IN O
view NN NN O
of IN IN O
the DT DT O
known VBN VBN O
tendency NN NN O
of IN IN O
busulfan NN NN B-CHEM
to TO TO O
induce VB VB O
cellular JJ JJ O
atypia NN NN O
and CC CC O
carcinoma NN NN O
in IN IN O
other JJ JJ O
sites NNS NNS O
, , , O
periodic JJ JJ O
urinary JJ JJ O
cytology NN NN O
is VBZ VBZ O
suggested VBN VBN O
in IN IN O
patients NNS NNS O
on IN IN O
long JJ JJ O
- - - O
term NN NN O
therapy NN NN O
. . . O

Variant NNP NNP O
ventricular NN NN O
tachycardia NNS NNS O
in IN IN O
desipramine NN NN B-CHEM
toxicity NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
variant NN NN O
ventricular NN NN O
tachycardia NNS NNS O
induced VBN VBN O
by IN IN O
desipramine NN NN B-CHEM
toxicity NN NN O
. . . O

Unusual JJ JJ O
features NNS NNS O
of IN IN O
the DT DT O
arrhythmia NN NN O
are VBP VBP O
repetitive JJ JJ O
group NN NN O
beating NN NN O
, , , O
progressive JJ JJ O
shortening NN NN O
of IN IN O
the DT DT O
R NN NN O
- - - O
R NNP NNP O
interval NN NN O
, , , O
progressive JJ JJ O
widening NN NN O
of IN IN O
the DT DT O
QRS NNP NNP O
complex JJ JJ O
with IN IN O
eventual JJ JJ O
failure NN NN O
of IN IN O
intraventricular JJ JJ O
conduction NN NN O
, , , O
and CC CC O
changes NNS NNS O
in IN IN O
direction NN NN O
of IN IN O
the DT DT O
QRS NNP NNP O
axis NNS NNS O
. . . O

Recognition NNP NNP O
of IN IN O
variant NN NN O
ventricular NN NN O
tachycardia NN NN O
is VBZ VBZ O
important JJ JJ O
because IN IN O
therapy NN NN O
differs NNS NNS O
from IN IN O
that DT DT O
of IN IN O
classic JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

Rebound NNP NNP O
hypertensive JJ JJ O
after IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
prevented VBN VBN O
by IN IN O
saralasin NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
role NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
in IN IN O
the DT DT O
maintenance NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
during IN IN O
halothane NN NN B-CHEM
anesthesia NN NN O
and CC CC O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
( ( ( O
SNP NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypotension NN NN O
was VBD VBD O
evaluated VBN VBN O
. . . O

Control NNP NNP O
rats NNS NNS O
received VBD VBD O
halothane NN NN B-CHEM
anesthesia NN NN O
( ( ( O
1 CD CD O
MAC NNP NNP O
) ) ) O
for IN IN O
one CD CD O
hour NN NN O
, , , O
followed VBN VBN O
by IN IN O
SNP NNP NNP B-CHEM
infusion NN NN O
, , , O
40 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, , , O
for IN IN O
30 CD CD O
min NN NN O
, , , O
followed VBN VBN O
by IN IN O
a DT DT O
30 CD CD O
- : : O
min NN NN O
recovery NN NN O
period NN NN O
. . . O

A DT DT O
second JJ JJ O
group NN NN O
of IN IN O
rats NNS NNS O
was VBD VBD O
treated VBN VBN O
identically RB RB O
and CC CC O
, , , O
in IN IN O
addition NN NN O
, , , O
received VBD VBD O
an DT DT O
infusion NN NN O
of IN IN O
saralasin NN NN B-CHEM
( ( ( O
a DT DT O
competitive JJ JJ O
inhibitor NN NN O
of IN IN O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
) ) ) O
throughout IN IN O
the DT DT O
experimental JJ JJ O
period NN NN O
. . . O

In IN IN O
each DT DT O
group NN NN O
, , , O
SNP NNP NNP B-CHEM
infusion NN NN O
resulted VBD VBD O
in IN IN O
an DT DT O
initial JJ JJ O
decrease NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
from IN IN O
86 CD CD O
torr NN NN O
and CC CC O
83 CD CD O
torr NN NN O
, , , O
respectively RB RB O
, , , O
to TO TO O
48 CD CD O
torr NN NN O
. . . O

During IN IN O
the DT DT O
SNP NNP NNP B-CHEM
infusion NN NN O
the DT DT O
control NN NN O
animals NNS NNS O
demonstrated VBD VBD O
a DT DT O
progressive JJ JJ O
increase NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
to TO TO O
61 CD CD O
torr NN NN O
, , , O
whereas IN IN O
the DT DT O
saralasin NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
showed VBD VBD O
no DT DT O
change NN NN O
. . . O

Following VBG VBG O
discontinuation NN NN O
of IN IN O
SNP NNP NNP B-CHEM
, , , O
blood NN NN O
pressure NN NN O
in IN IN O
the DT DT O
control NN NN O
animals NNS NNS O
rebounded VBD VBD O
to TO TO O
94 CD CD O
torr NN NN O
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
78 CD CD O
torr NN NN O
in IN IN O
the DT DT O
saralasin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

This DT DT O
study NN NN O
indicates VBZ VBZ O
that IN IN O
with IN IN O
stable JJ JJ O
halothane NN NN B-CHEM
anesthesia NN NN O
, , , O
the DT DT O
partial JJ JJ O
recovery NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
during IN IN O
SNP NNP NNP B-CHEM
infusion NN NN O
and CC CC O
the DT DT O
post NN NN O
- - - O
SNP NNP NNP B-CHEM
rebound NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
can MD MD O
be VB VB O
completely RB RB O
blocked VBN VBN O
by IN IN O
saralasin NN NN B-CHEM
. . . O

This DT DT O
demonstrates VBZ VBZ O
the DT DT O
participation NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
in IN IN O
antagonizing VBG VBG O
the DT DT O
combined VBN VBN O
hypotensive JJ JJ O
effects NNS NNS O
of IN IN O
halothane NN NN B-CHEM
and CC CC O
SNP NNP NNP B-CHEM
. . . O

Clinical NNP NNP O
nephrotoxicity NN NN O
of IN IN O
tobramycin NN NN B-CHEM
and CC CC O
gentamicin NN NN B-CHEM
. . . O

A DT DT O
prospective JJ JJ O
study NN NN O
. . . O

Nearly RB RB O
3 CD CD O
. . . O
2 CD CD O
million CD CD O
people NNS NNS O
in IN IN O
this DT DT O
country NN NN O
receive VBP VBP O
aminoglycoside IN IN B-CHEM
antibiotics NNS NNS O
annually RB RB O
. . . O

Gentamicin NNP NNP B-CHEM
sulfate NN NN I-CHEM
and CC CC O
tobramycin NN NN B-CHEM
sulfate NN NN I-CHEM
continue VB VB O
to TO TO O
demonstrate VB VB O
ototoxicity NN NN O
and CC CC O
nephrotoxicity NN NN O
in IN IN O
both DT DT O
animal NN NN O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
62 CD CD O
patients NNS NNS O
with IN IN O
confirmed VBD VBD O
initial JJ JJ O
normal JJ JJ O
renal JJ JJ O
function NN NN O
and CC CC O
treated VBN VBN O
with IN IN O
2 CD CD O
to TO TO O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
of IN IN O
gentamicin NN NN B-CHEM
sulfate NN NN I-CHEM
or CC CC O
tobramycin NN NN B-CHEM
sulfate NN NN I-CHEM
for IN IN O
a DT DT O
minimum NN NN O
of IN IN O
seven CD CD O
days NNS NNS O
were VBD VBD O
followed VBN VBN O
up RP RP O
prospectively RB RB O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
aminoglycoside NN NN B-CHEM
- - - O
related VBN VBN O
renal JJ JJ O
failure NN NN O
, , , O
defined VBN VBN O
as IN IN O
at IN IN O
least JJS JJS O
a DT DT O
one CD CD O
- - - O
third JJ JJ O
reduction NN NN O
in IN IN O
renal JJ JJ O
function NN NN O
. . . O

In IN IN O
these DT DT O
62 CD CD O
patients NNS NNS O
, , , O
no DT DT O
other JJ JJ O
causes NNS NNS O
for IN IN O
renal JJ JJ O
failure NN NN O
could MD MD O
be VB VB O
identified VBN VBN O
. . . O

Five CD CD O
of IN IN O
33 CD CD O
( ( ( O
15 CD CD O
% NN NN O
) ) ) O
of IN IN O
the DT DT O
tobramycin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
and CC CC O
16 CD CD O
of IN IN O
29 CD CD O
( ( ( O
55 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
of IN IN O
the DT DT O
gentamicin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
had VBD VBD O
renal JJ JJ O
failure NN NN O
. . . O

Thus RB RB O
, , , O
gentamicin NN NN B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
renal JJ JJ O
failure NN NN O
more JJR JJR O
than IN IN O
three CD CD O
times NNS NNS O
as RB RB O
often RB RB O
as IN IN O
was VBD VBD O
tobramycin NN NN B-CHEM
. . . O

Metabolic NNP NNP O
involvement NN NN O
in IN IN O
adriamycin NN NN B-CHEM
cardiotoxicity NN NN O
. . . O

The DT DT O
cardiotoxic JJ JJ O
effects NNS NNS O
of IN IN O
adriamycin NN NN B-CHEM
were VBD VBD O
studied VBN VBN O
in IN IN O
mammalian NN NN O
myocardial NN NN O
cells NNS NNS O
in IN IN O
culture NN NN O
as IN IN O
a DT DT O
model NN NN O
system NN NN O
. . . O

Adriamycin NNP NNP B-CHEM
inhibited JJ JJ O
cell NN NN O
growth NN NN O
and CC CC O
the DT DT O
rhythmic JJ JJ O
contractions NNS NNS O
characteristic JJ JJ O
of IN IN O
myocardial NN NN O
cells NNS NNS O
in IN IN O
culture NN NN O
. . . O

A DT DT O
possible JJ JJ O
involvement NN NN O
of IN IN O
energy NN NN O
metabolism NN NN O
was VBD VBD O
suggested VBN VBN O
previously RB RB O
, , , O
and CC CC O
in IN IN O
this DT DT O
study NN NN O
the DT DT O
adenylate JJ JJ O
energy NN NN O
charge NN NN O
and CC CC O
phosphorylcreatine NN NN B-CHEM
mole NN NN O
fraction NN NN O
were VBD VBD O
determined VBN VBN O
in IN IN O
the DT DT O
adriamycin NN NN B-CHEM
- - - O
treated JJ JJ O
cells NNS NNS O
. . . O

The DT DT O
adenylate JJ JJ O
energy NN NN O
charge NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
significantly RB RB O
decreased VBN VBN O
, , , O
while IN IN O
the DT DT O
phophorylcreatine NN NN B-CHEM
mole NN NN O
fraction NN NN O
was VBD VBD O
unchanged JJ JJ O
. . . O

Such JJ JJ O
disparity NN NN O
suggests VBZ VBZ O
an DT DT O
inhibition NN NN O
of IN IN O
creatine NN NN B-CHEM
phosphokinase NN NN O
. . . O

The DT DT O
addition NN NN O
of IN IN O
1 CD CD O
mM NN NN O
adenosine NN NN B-CHEM
to TO TO O
the DT DT O
myocardial NN NN O
cell NN NN O
cultures NNS NNS O
markedly RB RB O
increases NNS NNS O
the DT DT O
ATP NNP NNP B-CHEM
concentration NN NN O
through IN IN O
a DT DT O
pathway NN NN O
reportedly RB RB O
leading VBG VBG O
to TO TO O
a DT DT O
compartmentalized JJ JJ O
ATP NNP NNP B-CHEM
pool NN NN O
. . . O

In IN IN O
the DT DT O
adriamycin NN NN B-CHEM
- - - O
treated VBN VBN O
cells NNS NNS O
, , , O
the DT DT O
addition NN NN O
of IN IN O
adenosine NN NN B-CHEM
increased VBD VBD O
the DT DT O
adenylate JJ JJ O
charge NN NN O
and CC CC O
, , , O
concomitant NN NN O
with IN IN O
this DT DT O
inrcease NN NN O
, , , O
the DT DT O
cells NNS NNS O
' POS POS O
functional JJ JJ O
integrity NN NN O
, , , O
in IN IN O
terms NNS NNS O
of IN IN O
percentage NN NN O
of IN IN O
beating NN NN O
cells NNS NNS O
and CC CC O
rate NN NN O
of IN IN O
contractions NNS NNS O
, , , O
was VBD VBD O
maintained VBN VBN O
. . . O

Age NNP NNP O
- : : O
dependent JJ JJ O
sensitivity NN NN O
of IN IN O
the DT DT O
rat NN NN O
to TO TO O
neurotoxic JJ JJ O
effects NNS NNS O
of IN IN O
streptomycin NN NN B-CHEM
. . . O

Streptomycin NNP NNP B-CHEM
sulfate NN NN O
( ( ( O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
was VBD VBD O
injected VBN VBN O
for IN IN O
various JJ JJ O
periods NNS NNS O
into IN IN O
preweanling VBG VBG O
rats NNS NNS O
and CC CC O
for IN IN O
3 CD CD O
weeks NNS NNS O
into IN IN O
weanling VBG VBG O
rats NNS NNS O
. . . O

Beginning NNP NNP O
at IN IN O
8 CD CD O
days NNS NNS O
of IN IN O
age NN NN O
, , , O
body NN NN O
movement NN NN O
and CC CC O
hearing NN NN O
were VBD VBD O
examined VBN VBN O
for IN IN O
6 CD CD O
and CC CC O
up IN IN O
to TO TO O
17 CD CD O
weeks NNS NNS O
, , , O
respectively RB RB O
. . . O

Abnormal NNP NNP O
movements NNS NNS O
and CC CC O
deafness NNS NNS O
occurred VBD VBD O
only RB RB O
in IN IN O
rats NNS NNS O
treated VBN VBN O
during IN IN O
the DT DT O
preweaning VBG VBG O
period NN NN O
; : : O
within IN IN O
this DT DT O
period NN NN O
the DT DT O
greatest JJS JJS O
sensitivities NNS NNS O
for IN IN O
these DT DT O
abnormalities NNS NNS O
occurred VBD VBD O
from IN IN O
2 CD CD O
to TO TO O
11 CD CD O
- : : O
17 CD CD O
and CC CC O
5 CD CD O
to TO TO O
11 CD CD O
days NNS NNS O
of IN IN O
age NN NN O
, , , O
respectively RB RB O
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
cochlea NN NN O
is VBZ VBZ O
more RBR RBR O
sensitive JJ JJ O
to TO TO O
streptomycin NN NN B-CHEM
than IN IN O
the DT DT O
site NN NN O
( ( ( O
vestibular NN NN O
or CC CC O
central JJ JJ O
) ) ) O
responsible JJ JJ O
for IN IN O
the DT DT O
dyskinesias NN NN O
. . . O

Late RB RB O
, , , O
late JJ JJ O
doxorubicin NN NN B-CHEM
cardiotoxicity NN NN O
. . . O

Cardiac NNP NNP O
toxicity NN NN O
is VBZ VBZ O
a DT DT O
major JJ JJ O
complication NN NN O
which WDT WDT O
limits VBZ VBZ O
the DT DT O
use NN NN O
of IN IN O
adriamycin NN NN B-CHEM
as IN IN O
a DT DT O
chemotherapeutic JJ JJ O
agent NN NN O
. . . O

Cardiomyopathy NNP NNP O
is VBZ VBZ O
frequent JJ JJ O
when WRB WRB O
the DT DT O
total NN NN O
dose NN NN O
exceeds NNS NNS O
600 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
and CC CC O
occurs VBZ VBZ O
within IN IN O
one CD CD O
to TO TO O
six CD CD O
months NNS NNS O
after IN IN O
cessation NN NN O
of IN IN O
therapy NN NN O
. . . O

A DT DT O
patient NN NN O
is VBZ VBZ O
reported VBN VBN O
who WP WP O
developed VBD VBD O
progressive JJ JJ O
cardiomyopathy NN NN O
two CD CD O
and CC CC O
one CD CD O
- - - O
half NN NN O
years NNS NNS O
after IN IN O
receiving VBG VBG O
580 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
which WDT WDT O
apparently RB RB O
represents VBZ VBZ O
late JJ JJ O
, , , O
late JJ JJ O
cardiotoxicity NN NN O
. . . O

Attenuation NNP NNP O
of IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
- - - O
insipidus NN NN O
- - - O
like IN IN O
syndrome NN NN O
by IN IN O
amiloride NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
amiloride NN NN B-CHEM
on IN IN O
lithium NN NN B-CHEM
- : : O
induced JJ JJ O
polydipsia NN NN O
and CC CC O
polyuria NN NN O
and CC CC O
on IN IN O
the DT DT O
lithium NN NN B-CHEM
concentration NN NN O
in IN IN O
the DT DT O
plasma NN NN O
, , , O
brain NN NN O
, , , O
kidney NN NN O
, , , O
thyroid NN NN O
and CC CC O
red JJ JJ O
blood NN NN O
cells NNS NNS O
was VBD VBD O
investigated VBN VBN O
in IN IN O
rats NNS NNS O
, , , O
chronically RB RB O
treated VBN VBN O
with IN IN O
LiCl NNP NNP B-CHEM
. . . O

Amiloride NNP NNP B-CHEM
reduced VBD VBD O
the DT DT O
drinking NN NN O
and CC CC O
urine JJ JJ O
volume NN NN O
of IN IN O
rats NNS NNS O
in IN IN O
an DT DT O
acute JJ JJ O
( ( ( O
6 CD CD O
or CC CC O
12 CD CD O
h NN NN O
) ) ) O
and CC CC O
a DT DT O
subacute NN NN O
( ( ( O
3 CD CD O
days NNS NNS O
) ) ) O
experiment NN NN O
. . . O

6 CD CD O
h NN NN O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
amiloride NN NN B-CHEM
, , , O
a DT DT O
reduction NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
lithium NN NN B-CHEM
content NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
medulla NN NN O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
other JJ JJ O
organs NNS NNS O
studied VBN VBN O
. . . O

At IN IN O
12 CD CD O
h NN NN O
, , , O
all PDT PDT O
the DT DT O
tissues NNS NNS O
showed VBD VBD O
a DT DT O
slight JJ JJ O
increase NN NN O
in IN IN O
lithium NN NN B-CHEM
levels NNS NNS O
. . . O

After IN IN O
3 CD CD O
days NNS NNS O
of IN IN O
combined VBN VBN O
treatment NN NN O
, , , O
a DT DT O
marked JJ JJ O
elevation NN NN O
in IN IN O
plasma NN NN O
and CC CC O
tissue NN NN O
lithium NN NN B-CHEM
levels NNS NNS O
accompanied VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
water NN NN O
intake NN NN O
. . . O

In IN IN O
all PDT PDT O
the DT DT O
experiments NNS NNS O
, , , O
the DT DT O
attenuation NN NN O
of IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
- - - O
insipidus NN NN O
- - - O
like IN IN O
syndrome NN NN O
by IN IN O
amiloride NN NN B-CHEM
was VBD VBD O
accompanied VBN VBN O
by IN IN O
a DT DT O
reduction NN NN O
of IN IN O
the DT DT O
ratio NN NN O
between IN IN O
the DT DT O
lithium NN NN B-CHEM
concentration NN NN O
in IN IN O
the DT DT O
renal JJ JJ O
medulla NN NN O
and CC CC O
its PRP$ PRP$ O
levels NNS NNS O
in IN IN O
the DT DT O
blood NN NN O
and CC CC O
an DT DT O
elevation NN NN O
in IN IN O
the DT DT O
plasma NN NN O
potassium NN NN B-CHEM
level NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
acute JJ JJ O
amiloride NN NN B-CHEM
administration NN NN O
to TO TO O
lithium VB VB B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
polydipsia NN NN O
and CC CC O
polyuria NN NN O
might MD MD O
relieve VB VB O
these DT DT O
patients NNS NNS O
but CC CC O
prolonged JJ JJ O
amiloride NN NN B-CHEM
supplementation NN NN O
would MD MD O
result VB VB O
in IN IN O
elevated VBD VBD O
lithium NN NN B-CHEM
levels NNS NNS O
and CC CC O
might MD MD O
be VB VB O
hazardous JJ JJ O
. . . O

Cardiovascular NNP NNP O
complications NNS NNS O
associated VBN VBN O
with IN IN O
terbutaline NN NN B-CHEM
treatment NN NN O
for IN IN O
preterm NN NN O
labor NN NN O
. . . O

Severe NNP NNP O
cardiovascular JJ JJ O
complications NNS NNS O
occurred VBD VBD O
in IN IN O
eight CD CD O
of IN IN O
160 CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
terbutaline NN NN B-CHEM
for IN IN O
preterm NN NN O
labor NN NN O
. . . O

Associated NNP NNP O
corticosteroid NN NN O
therapy NN NN O
and CC CC O
twin VB VB O
gestations NNS NNS O
appear VBP VBP O
to TO TO O
be VB VB O
predisposing VBG VBG O
factors NNS NNS O
. . . O

Potential JJ JJ O
mechanisms NNS NNS O
of IN IN O
the DT DT O
pathophysiology NN NN O
are VBP VBP O
briefly RB RB O
discussed VBN VBN O
. . . O

Toxic NNP NNP O
hepatitis NN NN O
induced VBN VBN O
by IN IN O
antithyroid NN NN O
drugs NNS NNS O
: : : O
four CD CD O
cases NNS NNS O
including VBG VBG O
one CD CD O
with IN IN O
cross NN NN O
- - - O
reactivity NN NN O
between IN IN O
carbimazole NN NN B-CHEM
and CC CC O
benzylthiouracil NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
conducted VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
occurrence NN NN O
of IN IN O
hepatic JJ JJ O
adverse NN NN O
effects NNS NNS O
encountered VBN VBN O
with IN IN O
antithyroid JJ JJ O
drugs NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Retrospective NNP NNP O
review NN NN O
of IN IN O
medical JJ JJ O
records NNS NNS O
of IN IN O
236 CD CD O
patients NNS NNS O
with IN IN O
hyperthyroidism NN NN O
admitted VBN VBN O
in IN IN O
our PRP$ PRP$ O
department NN NN O
( ( ( O
in IN IN O
- - - O
or CC CC O
out IN IN O
- - - O
patients NNS NNS O
) ) ) O
from IN IN O
1986 CD CD O
to TO TO O
1992 CD CD O
. . . O

RESULTS NNS NNS O
: : : O
Four CD CD O
patients NNS NNS O
( ( ( O
1 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
identified VBN VBN O
with IN IN O
toxic JJ JJ O
hepatitis NN NN O
which WDT WDT O
could MD MD O
reasonably RB RB O
be VB VB O
attributed VBN VBN O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
antithyroid NN NN O
agent NN NN O
. . . O

Two CD CD O
patients NNS NNS O
had VBD VBD O
a DT DT O
cholestatic JJ JJ O
hepatitis NN NN O
induced VBN VBN O
by IN IN O
carbimazole NN NN B-CHEM
( ( ( O
N NNP NNP B-CHEM
omercazole NN NN I-CHEM
) ) ) O
. . . O

Two CD CD O
others NNS NNS O
had VBD VBD O
a DT DT O
mixed JJ JJ O
( ( ( O
cholestatic JJ JJ O
and CC CC O
cytolytic JJ JJ O
) ) ) O
hepatitis NN NN O
following VBG VBG O
carbimazole NN NN B-CHEM
. . . O

One CD CD O
of IN IN O
the DT DT O
latter JJ JJ O
two CD CD O
patients NNS NNS O
further RB RB O
experienced VBD VBD O
a DT DT O
cytolytic JJ JJ O
hepatitis NN NN O
which WDT WDT O
appeared VBD VBD O
after IN IN O
Benzylthiouracil NNP NNP B-CHEM
( ( ( O
Basd NNP NNP B-CHEM
ne NN NN I-CHEM
) ) ) O
had VBD VBD O
replaced VBN VBN O
carbimazole NN NN B-CHEM
. . . O

Biological NNP NNP O
features NNS NNS O
of IN IN O
hepatitis NN NN O
disappeared VBD VBD O
in IN IN O
all DT DT O
cases NNS NNS O
after IN IN O
cessation NN NN O
of IN IN O
the DT DT O
incriminated JJ JJ O
drug NN NN O
, , , O
while IN IN O
biliary JJ JJ O
, , , O
viral JJ JJ O
and CC CC O
immunological JJ JJ O
searches NNS NNS O
were VBD VBD O
negative JJ JJ O
. . . O

Only RB RB O
2 CD CD O
patients NNS NNS O
of IN IN O
our PRP$ PRP$ O
retrospective NN NN O
study NN NN O
experienced VBD VBD O
a DT DT O
mild NN NN O
or CC CC O
severe JJ JJ O
neutropenia NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Toxic JJ JJ O
hepatitis NN NN O
is VBZ VBZ O
a DT DT O
potential JJ JJ O
adverse JJ JJ O
effect NN NN O
of IN IN O
antithyroid NN NN O
drugs NNS NNS O
which WDT WDT O
warrants NNS NNS O
, , , O
as IN IN O
for IN IN O
haematological JJ JJ O
disturbances NNS NNS O
, , , O
a DT DT O
pre NN NN O
- - - O
therapeutic JJ JJ O
determination NN NN O
and CC CC O
a DT DT O
careful JJ JJ O
follow VB VB O
- - - O
up RP RP O
of IN IN O
relevant JJ JJ O
biological JJ JJ O
markers NNS NNS O
. . . O

Moreover RB RB O
, , , O
hepatotoxicity NN NN O
may MD MD O
not RB RB O
be VB VB O
restricted VBN VBN O
to TO TO O
one CD CD O
class NN NN O
of IN IN O
antithyroid JJ JJ O
agents NNS NNS O
. . . O

Interactive JJ JJ O
effects NNS NNS O
of IN IN O
variations NNS NNS O
in IN IN O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
and CC CC O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
on IN IN O
rat NN NN O
atrial JJ JJ O
spontaneous JJ JJ O
frequency NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
varying VBG VBG O
the DT DT O
extracellular JJ JJ O
concentrations NNS NNS O
of IN IN O
Na NNP NNP B-CHEM
and CC CC O
Ca NNP NNP B-CHEM
( ( ( O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
and CC CC O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
) ) ) O
on IN IN O
both DT DT O
, , , O
the DT DT O
spontaneous JJ JJ O
beating NN NN O
and CC CC O
the DT DT O
negative JJ JJ O
chronotropic JJ JJ O
action NN NN O
of IN IN O
verapamil NN NN B-CHEM
, , , O
were VBD VBD O
studied VBN VBN O
in IN IN O
the DT DT O
isolated VBN VBN O
rat NN NN O
atria NNS NNS O
. . . O

Basal NNP NNP O
frequency NN NN O
( ( ( O
BF NNP NNP O
) ) ) O
evaluated VBN VBN O
by IN IN O
surface NN NN O
electrogram NN NN O
was VBD VBD O
223 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
. . . O
in IN IN O
control NN NN O
Krebs NNP NNP O
- : : O
Ringer NNP NNP O
containing VBG VBG O
137 CD CD O
mM NN NN O
Na NNP NNP B-CHEM
and CC CC O
1 CD CD O
. . . O
35 CD CD O
mM NN NN O
Ca NNP NNP B-CHEM
( ( ( O
N NNP NNP O
) ) ) O
. . . O

It PRP PRP O
decreased VBD VBD O
by IN IN O
16 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
% NN NN O
by IN IN O
lowering VBG VBG O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
to TO TO O
78 CD CD O
mM NN NN O
( ( ( O
LNa NNP NNP O
) ) ) O
, , , O
23 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
% NN NN O
by IN IN O
lowering VBG VBG O
simultaneously RB RB O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
to TO TO O
78 CD CD O
mM NN NN O
and CC CC O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
to TO TO O
0 CD CD O
. . . O
675 CD CD O
mM NN NN O
( ( ( O
LNa NNP NNP O
+ NN NN O
LCa NNP NNP O
) ) ) O
and CC CC O
31 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
% NN NN O
by IN IN O
lowering VBG VBG O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
to TO TO O
78 CD CD O
mM NN NN O
plus CC CC O
increasing VBG VBG O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
to TO TO O
3 CD CD O
. . . O
6 CD CD O
mM NN NN O
( ( ( O
LNa NNP NNP O
+ NN NN O
HCa NNP NNP O
) ) ) O
. . . O

At IN IN O
normal JJ JJ O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
, , , O
decrease NN NN O
( ( ( O
0 CD CD O
. . . O
675 CD CD O
mM NN NN O
) ) ) O
or CC CC O
increase NN NN O
( ( ( O
3 CD CD O
. . . O
6 CD CD O
mM NN NN O
) ) ) O
of IN IN O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
did VBD VBD O
not RB RB O
modify VB VB O
BF NNP NNP O
; : : O
a DT DT O
reduction NN NN O
of IN IN O
ten CD CD O
times NNS NNS O
( ( ( O
0 CD CD O
. . . O
135 CD CD O
mM NN NN O
of IN IN O
normal JJ JJ O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
was VBD VBD O
effective JJ JJ O
to TO TO O
reduce VB VB O
BF NNP NNP O
by IN IN O
40 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
% NN NN O
. . . O

All DT DT O
negative JJ JJ O
chronotropic NN NN O
effects NNS NNS O
were VBD VBD O
BF NNP NNP O
- : : O
dependent NN NN O
. . . O

Dose NNP NNP O
- : : O
dependent JJ JJ O
bradycardia NN NN O
induced VBN VBN O
by IN IN O
verapamil NN NN B-CHEM
was VBD VBD O
potentiated VBN VBN O
by IN IN O
LNa NNP NNP O
, , , O
LCa NNP NNP O
, , , O
and CC CC O
HCa NNP NNP O
. . . O

Independent NNP NNP O
but CC CC O
not RB RB O
additive JJ JJ O
effects NNS NNS O
of IN IN O
Na NNP NNP B-CHEM
and CC CC O
Ca NNP NNP B-CHEM
are VBP VBP O
shown VBN VBN O
by IN IN O
decreases NNS NNS O
in IN IN O
the DT DT O
values NNS NNS O
of IN IN O
[ NN NN O
verapamil NN NN B-CHEM
] NN NN O
o NN NN O
needed VBD VBD O
to TO TO O
reduce VB VB O
BF NNP NNP O
by IN IN O
30 CD CD O
% NN NN O
( ( ( O
IC30 NNP NNP O
) ) ) O
with IN IN O
the DT DT O
following VBG VBG O
order NN NN O
of IN IN O
inhibitory NN NN O
potency NN NN O
: : : O
LNa NNP NNP O
> NN NN O
LCa NNP NNP O
> NN NN O
HCa NNP NNP O
> NN NN O
N NNP NNP O
, , , O
resulting VBG VBG O
LNa NNP NNP O
+ NN NN O
HCa NNP NNP O
similar JJ JJ O
to TO TO O
LNa NNP NNP O
. . . O

The DT DT O
[ NN NN O
verapamil NN NN B-CHEM
] NN NN O
o NN NN O
that WDT WDT O
arrested VBD VBD O
atrial JJ JJ O
beating NN NN O
( ( ( O
AC NNP NNP O
) ) ) O
was VBD VBD O
also RB RB O
potentiated VBN VBN O
with IN IN O
the DT DT O
order NN NN O
LNa NNP NNP O
= SYM SYM O
LNa NNP NNP O
+ NN NN O
LCa NNP NNP O
= SYM SYM O
LNa NNP NNP O
+ NN NN O
HCa NNP NNP O
= SYM SYM O
LCa NNP NNP O
> NN NN O
HCa NNP NNP O
= SYM SYM O
N NNP NNP O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
rat NN NN O
atrial JJ JJ O
spontaneous JJ JJ O
beating NN NN O
is VBZ VBZ O
more RBR RBR O
dependent JJ JJ O
on IN IN O
[ NN NN O
Na NNP NNP B-CHEM
] NN NN O
o NN NN O
than IN IN O
on IN IN O
[ NN NN O
Ca NNP NNP B-CHEM
] NN NN O
o NN NN O
in IN IN O
a DT DT O
range NN NN O
of IN IN O
+ NN NN O
/ NN NN O
- : : O
50 CD CD O
% NN NN O
of IN IN O
their PRP$ PRP$ O
normal JJ JJ O
concentration NN NN O
. . . O

Also RB RB O
the DT DT O
enhancement NN NN O
of IN IN O
verapamil NN NN B-CHEM
effects NNS NNS O
on IN IN O
atrial JJ JJ O
beating NN NN O
was VBD VBD O
more RBR RBR O
pronounced JJ JJ O
at IN IN O
LNa NNP NNP O
than IN IN O
at IN IN O
LCa NNP NNP O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Pseudo NNP NNP O
- : : O
allergic JJ JJ O
reactions NNS NNS O
to TO TO O
corticosteroids NNS NNS B-CHEM
: : : O
diagnosis NN NN O
and CC CC O
alternatives NNS NNS O
. . . O

Two CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
parenteral JJ JJ O
paramethasone NN NN B-CHEM
( ( ( O
Triniol NNP NNP O
) ) ) O
and CC CC O
dexamethasone NN NN B-CHEM
( ( ( O
Sedionbel NNP NNP O
) ) ) O
are VBP VBP O
described VBN VBN O
. . . O

A DT DT O
few JJ JJ O
minutes NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
the DT DT O
drugs NNS NNS O
, , , O
they PRP PRP O
presented VBD VBD O
urticaria JJ JJ O
( ( ( O
patients NNS NNS O
1 CD CD O
and CC CC O
2 CD CD O
) ) ) O
and CC CC O
conjunctivitis NNS NNS O
( ( ( O
patient NN NN O
1 CD CD O
) ) ) O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
our PRP$ PRP$ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
' POS POS O
reactions NNS NNS O
, , , O
the DT DT O
immunological JJ JJ O
mechanisms NNS NNS O
involved VBN VBN O
and CC CC O
whether IN IN O
these DT DT O
patients NNS NNS O
would MD MD O
be VB VB O
able JJ JJ O
to TO TO O
tolerate VB VB O
any DT DT O
kind NN NN O
of IN IN O
corticoid NN NN O
. . . O

Clinical NNP NNP O
examinations NNS NNS O
and CC CC O
skin NN NN O
, , , O
oral JJ JJ O
and CC CC O
parenteral JJ JJ O
challenges NNS NNS O
with IN IN O
different JJ JJ O
corticosteroids NNS NNS B-CHEM
and CC CC O
ELISA NNP NNP O
tests NNS NNS O
were VBD VBD O
performed VBN VBN O
. . . O

In IN IN O
the DT DT O
two CD CD O
patients NNS NNS O
, , , O
skin NN NN O
and CC CC O
ELISA NNP NNP O
tests NNS NNS O
with IN IN O
paramethasone NN NN B-CHEM
were VBD VBD O
negative JJ JJ O
, , , O
as IN IN O
was VBD VBD O
the DT DT O
prick NN NN O
test NN NN O
with IN IN O
each DT DT O
of IN IN O
its PRP$ PRP$ O
excipients NNS NNS O
. . . O

A DT DT O
single JJ JJ O
- - - O
blind JJ JJ O
parenteral JJ JJ O
challenge NN NN O
with IN IN O
Triniol NNP NNP O
was VBD VBD O
positive JJ JJ O
in IN IN O
both DT DT O
patients NNS NNS O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
1 CD CD O
ml NN NN O
of IN IN O
the DT DT O
drug NN NN O
, , , O
and CC CC O
negative JJ JJ O
with IN IN O
its PRP$ PRP$ O
excipients NNS NNS O
. . . O

We PRP PRP O
also RB RB O
carried VBD VBD O
out IN IN O
oral JJ JJ O
and CC CC O
parenteral JJ JJ O
challenges NNS NNS O
with IN IN O
other JJ JJ O
corticosteroids NNS NNS B-CHEM
and CC CC O
found VBD VBD O
intolerance NN NN O
to TO TO O
some DT DT O
of IN IN O
them PRP PRP O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
paramethasone NN NN B-CHEM
caused VBD VBD O
pseudoallergic JJ JJ O
reactions NNS NNS O
in IN IN O
our PRP$ PRP$ O
patients NNS NNS O
. . . O

Corticosteroids NNP NNP O
different JJ JJ O
from IN IN O
paramethasone NN NN B-CHEM
also RB RB O
produced VBD VBD O
hypersensitivity NN NN O
reactions NNS NNS O
in IN IN O
these DT DT O
patients NNS NNS O
; : : O
however RB RB O
, , , O
a DT DT O
few JJ JJ O
of IN IN O
them PRP PRP O
were VBD VBD O
tolerated VBN VBN O
. . . O

The DT DT O
basic JJ JJ O
mechanisms NNS NNS O
of IN IN O
those DT DT O
reactions NNS NNS O
are VBP VBP O
not RB RB O
yet RB RB O
fully RB RB O
understood VBN VBN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
report NN NN O
of IN IN O
a DT DT O
pseudo NN NN O
- - - O
allergy NN NN O
caused VBN VBN O
by IN IN O
paramethasone NN NN B-CHEM
. . . O

Study NNP NNP O
of IN IN O
the DT DT O
role NN NN O
of IN IN O
vitamin NN NN B-CHEM
B12 NNP NNP I-CHEM
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
supplementation NN NN O
in IN IN O
preventing VBG VBG O
hematologic JJ JJ O
toxicity NN NN O
of IN IN O
zidovudine NN NN B-CHEM
. . . O

A DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
study NN NN O
was VBD VBD O
conducted VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
role NN NN O
of IN IN O
vitamin NN NN B-CHEM
B12 NNP NNP I-CHEM
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
supplementation NN NN O
in IN IN O
preventing VBG VBG O
zidovudine NN NN B-CHEM
( ( ( O
ZDV NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
bone NN NN O
marrow NN NN O
suppression NN NN O
. . . O

Seventy NNP NNP O
- - - O
five CD CD O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
( ( ( O
HIV NNP NNP O
) ) ) O
- : : O
infected JJ JJ O
patients NNS NNS O
with IN IN O
CD4 NNP NNP O
+ NN NN O
cell NN NN O
counts NNS NNS O
< NN NN O
500 CD CD O
/ NN NN O
mm3 NN NN O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
ZDV NNP NNP B-CHEM
( ( ( O
500 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
alone RB RB O
( ( ( O
group NN NN O
I PRP PRP O
, , , O
n NN NN O
= SYM SYM O
38 CD CD O
) ) ) O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
15 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
and CC CC O
intramascular JJ JJ O
vitamin NN NN B-CHEM
B12 NNP NNP I-CHEM
( ( ( O
1000 CD CD O
micrograms NNS NNS O
monthly RB RB O
) ) ) O
( ( ( O
group NN NN O
II NNP NNP O
, , , O
n NN NN O
= SYM SYM O
37 CD CD O
) ) ) O
. . . O

Finally RB RB O
, , , O
15 CD CD O
patients NNS NNS O
were VBD VBD O
excluded VBN VBN O
from IN IN O
the DT DT O
study NN NN O
( ( ( O
noncompliance NN NN O
14 CD CD O
, , , O
death NN NN O
1 CD CD O
) ) ) O
; : : O
thus RB RB O
, , , O
60 CD CD O
patients NNS NNS O
( ( ( O
31 CD CD O
in IN IN O
group NN NN O
I PRP PRP O
and CC CC O
29 CD CD O
in IN IN O
group NN NN O
II NNP NNP O
) ) ) O
were VBD VBD O
eligible JJ JJ O
for IN IN O
analysis NN NN O
. . . O

No DT DT O
significant JJ JJ O
differences NNS NNS O
between IN IN O
groups NNS NNS O
were VBD VBD O
found VBN VBN O
at IN IN O
enrollment NN NN O
. . . O

During IN IN O
the DT DT O
study NN NN O
, , , O
vitamin NN NN B-CHEM
B12 NNP NNP I-CHEM
and CC CC O
folate NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
group NN NN O
II NNP NNP O
patients NNS NNS O
; : : O
however RB RB O
, , , O
no DT DT O
differences NNS NNS O
in IN IN O
hemoglobin NN NN O
, , , O
hematocrit NN NN O
, , , O
mean VB VB O
corpuscular NN NN O
volume NN NN O
, , , O
and CC CC O
white JJ JJ O
- : : O
cell NN NN O
, , , O
neutrophil NN NN O
and CC CC O
platelet NN NN O
counts NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
groups NNS NNS O
at IN IN O
3 CD CD O
, , , O
6 CD CD O
, , , O
9 CD CD O
and CC CC O
12 CD CD O
months NNS NNS O
. . . O

Severe NNP NNP O
hematologic JJ JJ O
toxicity NN NN O
( ( ( O
neutrophil NN NN O
count NN NN O
< NN NN O
1000 CD CD O
/ NN NN O
mm3 NN NN O
and CC CC O
/ NN NN O
or CC CC O
hemoglobin NN NN O
< NN NN O
8 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
) ) ) O
occurred VBD VBD O
in IN IN O
4 CD CD O
patients NNS NNS O
assigned VBN VBN O
to TO TO O
group NN NN O
I PRP PRP O
and CC CC O
7 CD CD O
assigned VBN VBN O
to TO TO O
group NN NN O
II NNP NNP O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
correlation NN NN O
between IN IN O
vitamin NN NN B-CHEM
B12 NNP NNP I-CHEM
or CC CC O
folate NN NN B-CHEM
levels NNS NNS O
and CC CC O
development NN NN O
of IN IN O
myelosuppression NN NN O
. . . O

Vitamin NNP NNP B-CHEM
B12 NNP NNP I-CHEM
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
supplementation NN NN O
of IN IN O
ZDV NNP NNP B-CHEM
therapy NN NN O
does VBZ VBZ O
not RB RB O
seem VB VB O
useful JJ JJ O
in IN IN O
preventing VBG VBG O
or CC CC O
reducing VBG VBG O
ZDV NNP NNP B-CHEM
- : : O
induced JJ JJ O
myelotoxicity NN NN O
in IN IN O
the DT DT O
overall JJ JJ O
treated VBN VBN O
population NN NN O
, , , O
although IN IN O
a DT DT O
beneficial JJ JJ O
effect NN NN O
in IN IN O
certain JJ JJ O
subgroups NNS NNS O
of IN IN O
patients NNS NNS O
cannot NN NN O
be VB VB O
excluded VBN VBN O
. . . O

Safety NNP NNP O
and CC CC O
side NN NN O
- - - O
effects NNS NNS O
of IN IN O
alprazolam NN NN B-CHEM
. . . O

Controlled VBN VBN O
study NN NN O
in IN IN O
agoraphobia NN NN O
with IN IN O
panic NN NN O
disorder NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
widespread JJ JJ O
use NN NN O
of IN IN O
benzodiazepines NNS NNS B-CHEM
has VBZ VBZ O
led VBN VBN O
to TO TO O
increasing VBG VBG O
recognition NN NN O
of IN IN O
their PRP$ PRP$ O
unwanted JJ JJ O
effects NNS NNS O
. . . O

The DT DT O
efficacy NN NN O
of IN IN O
alprazolam NN NN B-CHEM
and CC CC O
placebo NN NN O
in IN IN O
panic NN NN O
disorder NN NN O
with IN IN O
agoraphobia NN NN O
, , , O
and CC CC O
the DT DT O
side NN NN O
- - - O
effect NN NN O
and CC CC O
adverse JJ JJ O
effect NN NN O
profiles NNS NNS O
of IN IN O
both DT DT O
drug NN NN O
groups NNS NNS O
were VBD VBD O
measured VBN VBN O
. . . O

METHOD NNP NNP O
: : : O
In IN IN O
London NNP NNP O
and CC CC O
Toronto NNP NNP O
154 CD CD O
patients NNS NNS O
who WP WP O
met VBD VBD O
DSM NNP NNP O
- : : O
III NNP NNP O
criteria NNS NNS O
for IN IN O
panic NN NN O
disorder NN NN O
with IN IN O
agoraphobia NN NN O
were VBD VBD O
randomised VBN VBN O
to TO TO O
alprazolam VB VB B-CHEM
or CC CC O
placebo NN NN O
. . . O

Subjects NNP NNP O
in IN IN O
each DT DT O
drug NN NN O
group NN NN O
also RB RB O
received VBD VBD O
either CC CC O
exposure NN NN O
or CC CC O
relaxation NN NN O
. . . O

Treatment NN NN O
was VBD VBD O
from IN IN O
weeks NNS NNS O
0 CD CD O
to TO TO O
8 CD CD O
and CC CC O
was VBD VBD O
then RB RB O
tapered VBN VBN O
from IN IN O
weeks NNS NNS O
8 CD CD O
to TO TO O
16 CD CD O
. . . O

RESULTS NNS NNS O
: : : O
Mean NNP NNP O
alprazolam NN NN B-CHEM
dose NN NN O
was VBD VBD O
5 CD CD O
mg NN NN O
daily JJ JJ O
. . . O

Compared VBN VBN O
with IN IN O
placebo NN NN O
subjects NNS NNS O
, , , O
alprazolam VBP VBP B-CHEM
patients NNS NNS O
developed VBN VBN O
more RBR RBR O
adverse JJ JJ O
reactions NNS NNS O
( ( ( O
21 CD CD O
% NN NN O
v NN NN O
. . . O
0 CD CD O
% NN NN O
) ) ) O
of IN IN O
depression NN NN O
, , , O
enuresis NN NN O
, , , O
disinhibition NN NN O
and CC CC O
aggression NN NN O
; : : O
and CC CC O
more JJR JJR O
side NN NN O
- - - O
effects NNS NNS O
, , , O
particularly RB RB O
sedation NN NN O
, , , O
irritability NN NN O
, , , O
impaired JJ JJ O
memory NN NN O
, , , O
weight NN NN O
loss NN NN O
and CC CC O
ataxia NN NN O
. . . O

Side NNP NNP O
- : : O
effects NNS NNS O
tended VBD VBD O
to TO TO O
diminish VB VB O
during IN IN O
treatment NN NN O
but CC CC O
remained VBD VBD O
significant JJ JJ O
at IN IN O
week NN NN O
8 CD CD O
. . . O

Despite IN IN O
this DT DT O
, , , O
the DT DT O
drop NN NN O
- - - O
out RP RP O
rate NN NN O
was VBD VBD O
low JJ JJ O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Alprazolam NNP NNP B-CHEM
caused VBD VBD O
side NN NN O
- : : O
effects NNS NNS O
and CC CC O
adverse JJ JJ O
effects NNS NNS O
during IN IN O
treatment NN NN O
but CC CC O
many JJ JJ O
patients NNS NNS O
were VBD VBD O
willing JJ JJ O
to TO TO O
accept VB VB O
these DT DT O
. . . O

Crescentic NNP NNP O
fibrillary JJ JJ O
glomerulonephritis NNS NNS O
associated VBN VBN O
with IN IN O
intermittent JJ JJ O
rifampin NN NN B-CHEM
therapy NN NN O
for IN IN O
pulmonary JJ JJ O
tuberculosis NNS NNS O
. . . O

This DT DT O
case NN NN O
study NN NN O
reveals VBZ VBZ O
an DT DT O
unusual JJ JJ O
finding NN NN O
of IN IN O
rapidly RB RB O
proliferative JJ JJ O
crescentic JJ JJ O
glomerulonephritis NN NN O
in IN IN O
a DT DT O
patient NN NN O
treated VBN VBN O
with IN IN O
rifampin NN NN B-CHEM
who WP WP O
had VBD VBD O
no DT DT O
other JJ JJ O
identifiable JJ JJ O
causes NNS NNS O
for IN IN O
developing VBG VBG O
this DT DT O
disease NN NN O
. . . O

This DT DT O
patient NN NN O
underwent NN NN O
a DT DT O
10 CD CD O
- : : O
month NN NN O
regimen NNS NNS O
of IN IN O
rifampin NN NN B-CHEM
and CC CC O
isoniazid NN NN B-CHEM
for IN IN O
pulmonary JJ JJ O
tuberculosis NN NN O
and CC CC O
was VBD VBD O
discovered VBN VBN O
to TO TO O
have VB VB O
developed VBN VBN O
signs NNS NNS O
of IN IN O
severe JJ JJ O
renal JJ JJ O
failure NN NN O
five CD CD O
weeks NNS NNS O
after IN IN O
completion NN NN O
of IN IN O
therapy NN NN O
. . . O

Renal NNP NNP O
biopsy NN NN O
revealed VBD VBD O
severe JJ JJ O
glomerulonephritis NNS NNS O
with IN IN O
crescents NNS NNS O
, , , O
electron NN NN O
dense NN NN O
fibrillar JJ JJ O
deposits NNS NNS O
and CC CC O
moderate JJ JJ O
lymphocytic JJ JJ O
interstitial JJ JJ O
infiltrate NN NN O
. . . O

Other JJ JJ O
possible JJ JJ O
causes NNS NNS O
of IN IN O
rapidly RB RB O
progressive JJ JJ O
glomerulonephritis NNS NNS O
were VBD VBD O
investigated VBN VBN O
and CC CC O
ruled VBN VBN O
out IN IN O
. . . O

This DT DT O
report NN NN O
documents NNS NNS O
the DT DT O
unusual JJ JJ O
occurrence NN NN O
of IN IN O
rapidly RB RB O
progressive JJ JJ O
glomerulonephritis NN NN O
with IN IN O
crescents NNS NNS O
and CC CC O
fibrillar JJ JJ O
glomerulonephritis NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
treated VBN VBN O
with IN IN O
rifampin NN NN B-CHEM
. . . O

Acute JJ JJ O
confusion NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
high JJ JJ O
- - - O
dose NN NN O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

A DT DT O
61 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
combination NN NN O
chemotherapy NN NN O
incorporating VBG VBG O
cisplatinum NN NN B-CHEM
, , , O
etoposide NN NN B-CHEM
, , , O
high JJ JJ O
- - - O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
2 CD CD O
, , , O
250 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
24 CD CD O
hours NNS NNS O
) ) ) O
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
for IN IN O
an DT DT O
inoperable JJ JJ O
gastric JJ JJ O
adenocarcinoma NN NN O
. . . O

He PRP PRP O
developed VBD VBD O
acute JJ JJ O
neurologic JJ JJ O
symptoms NNS NNS O
of IN IN O
mental JJ JJ O
confusion NN NN O
, , , O
disorientation NN NN O
and CC CC O
irritability NN NN O
, , , O
and CC CC O
then RB RB O
lapsed VBD VBD O
into IN IN O
a DT DT O
deep JJ JJ O
coma NN NN O
, , , O
lasting VBG VBG O
for IN IN O
approximately RB RB O
40 CD CD O
hours NNS NNS O
during IN IN O
the DT DT O
first JJ JJ O
dose NN NN O
( ( ( O
day NN NN O
2 CD CD O
) ) ) O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
infusion NN NN O
. . . O

This DT DT O
complication NN NN O
reappeared VBD VBD O
on IN IN O
day NN NN O
25 CD CD O
during IN IN O
the DT DT O
second JJ JJ O
dose NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
which WDT WDT O
were VBD VBD O
then RB RB O
the DT DT O
only JJ JJ O
drugs NNS NNS O
given VBN VBN O
. . . O

Because IN IN O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
was VBD VBD O
unlikely JJ JJ O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
this DT DT O
condition NN NN O
, , , O
neurotoxicity NN NN O
due JJ JJ O
to TO TO O
high JJ JJ O
- - - O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
was VBD VBD O
highly RB RB O
suspected VBN VBN O
. . . O

The DT DT O
pathogenesis NNS NNS O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
neurotoxicity NN NN O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
a DT DT O
Krebs NNP NNP O
cycle NN NN O
blockade NN NN O
by IN IN O
fluoroacetate NN NN B-CHEM
and CC CC O
fluorocitrate NN NN B-CHEM
, , , O
thiamine NN NN B-CHEM
deficiency NN NN O
, , , O
or CC CC O
dihydrouracil NN NN B-CHEM
dehydrogenase NN NN O
deficiency NN NN O
. . . O

High NNP NNP O
- : : O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
/ NN NN O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
infusion NN NN O
therapy NN NN O
has VBZ VBZ O
recently RB RB O
become VB VB O
a DT DT O
popular JJ JJ O
regimen NN NN O
for IN IN O
various JJ JJ O
cancers NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
necessary JJ JJ O
that IN IN O
both DT DT O
oncologists NNS NNS O
and CC CC O
neurologists NNS NNS O
be VB VB O
fully RB RB O
aware JJ JJ O
of IN IN O
this DT DT O
unusual JJ JJ O
complication NN NN O
. . . O

Effect NN NN O
of IN IN O
switching VBG VBG O
carbamazepine NN NN B-CHEM
to TO TO O
oxcarbazepine VB VB B-CHEM
on IN IN O
the DT DT O
plasma NN NN O
levels NNS NNS O
of IN IN O
neuroleptics NNS NNS O
. . . O

A DT DT O
case NN NN O
report NN NN O
. . . O

Carbamazepine NNP NNP B-CHEM
was VBD VBD O
switched VBN VBN O
to TO TO O
its PRP$ PRP$ O
10 CD CD O
- : : O
keto NN NN O
analogue NN NN O
oxcarbazepine NN NN B-CHEM
among IN IN O
six CD CD O
difficult JJ JJ O
- - - O
to TO TO O
- - - O
treat NN NN O
schizophrenic NN NN O
or CC CC O
organic JJ JJ O
psychotic JJ JJ O
patients NNS NNS O
using VBG VBG O
concomitantly RB RB O
haloperidol NN NN B-CHEM
, , , O
chlorpromazine NN NN B-CHEM
or CC CC O
clozapine NN NN B-CHEM
. . . O

This DT DT O
change NN NN O
resulted VBD VBD O
within IN IN O
2 CD CD O
- : : O
4 CD CD O
weeks NNS NNS O
in IN IN O
the DT DT O
50 CD CD O
- : : O
200 CD CD O
% NN NN O
increase NN NN O
in IN IN O
the DT DT O
plasma NN NN O
levels NNS NNS O
of IN IN O
these DT DT O
neuroleptics NNS NNS O
and CC CC O
the DT DT O
appearance NN NN O
of IN IN O
extrapyramidal NN NN O
symptoms NNS NNS O
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
showed VBD VBD O
any DT DT O
clinical JJ JJ O
deteriotation NN NN O
during IN IN O
the DT DT O
following VBG VBG O
3 CD CD O
- : : O
6 CD CD O
months NNS NNS O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
case NN NN O
report NN NN O
support NN NN O
the DT DT O
idea NN NN O
that IN IN O
in IN IN O
contrast NN NN O
with IN IN O
carbamazepine NN NN B-CHEM
oxcarbazepine NN NN B-CHEM
does VBZ VBZ O
not RB RB O
induce VB VB O
the DT DT O
hepatic JJ JJ O
microsomal NN NN O
enzyme NN NN O
systems NNS NNS O
regulating VBG VBG O
the DT DT O
inactivation NN NN O
of IN IN O
antipsychotic JJ JJ O
drugs NNS NNS O
. . . O

Time NNP NNP O
course NN NN O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
in IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
. . . O

Reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
have VBP VBP O
been VBN VBN O
implicated VBN VBN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
acute JJ JJ O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
nephropathy NN NN O
, , , O
with IN IN O
antioxidants NNS NNS O
significantly RB RB O
reducing VBG VBG O
the DT DT O
proteinuria NN NN O
. . . O

The DT DT O
temporal JJ JJ O
relationship NN NN O
between IN IN O
lipid JJ JJ O
peroxidation NN NN O
in IN IN O
the DT DT O
kidney NN NN O
and CC CC O
proteinuria NN NN O
was VBD VBD O
examined VBN VBN O
in IN IN O
this DT DT O
study NN NN O
. . . O

Rats NNP NNP O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
single JJ JJ O
IV NNP NNP O
injection NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
, , , O
( ( ( O
PAN NNP NNP B-CHEM
, , , O
7 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
24 CD CD O
hour NN NN O
urine JJ JJ O
samples NNS NNS O
were VBD VBD O
obtained VBN VBN O
prior RB RB O
to TO TO O
sacrifice VB VB O
on IN IN O
days NNS NNS O
3 CD CD O
, , , O
5 CD CD O
, , , O
7 CD CD O
, , , O
10 CD CD O
, , , O
17 CD CD O
, , , O
27 CD CD O
, , , O
41 CD CD O
( ( ( O
N NNP NNP O
= SYM SYM O
5 CD CD O
- : : O
10 CD CD O
per IN IN O
group NN NN O
) ) ) O
. . . O

The DT DT O
kidneys NNS NNS O
were VBD VBD O
removed VBN VBN O
, , , O
flushed JJ JJ O
with IN IN O
ice NN NN O
cold JJ JJ O
TRIS NNP NNP O
buffer NN NN O
. . . O

Kidney NNP NNP O
cortices NNS NNS O
from IN IN O
each DT DT O
animal NN NN O
were VBD VBD O
used VBN VBN O
to TO TO O
prepare VB VB O
homogenates NNS NNS O
. . . O

Tissue NNP NNP O
lipid JJ JJ O
peroxidation NN NN O
was VBD VBD O
measured VBN VBN O
in IN IN O
whole JJ JJ O
homogenates NNS NNS O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
lipid NN NN O
extracts NNS NNS O
from IN IN O
homogenates NNS NNS O
as IN IN O
thiobarbituric JJ JJ B-CHEM
acid NN NN I-CHEM
reactive JJ JJ O
substances NNS NNS O
. . . O

Proteinuria NNP NNP O
was VBD VBD O
evident JJ JJ O
at IN IN O
day NN NN O
5 CD CD O
, , , O
peaked VBD VBD O
at IN IN O
day NN NN O
7 CD CD O
and CC CC O
persisted VBD VBD O
to TO TO O
day NN NN O
27 CD CD O
. . . O

Lipid NNP NNP O
peroxidation NN NN O
in IN IN O
homogenates NNS NNS O
was VBD VBD O
maximal NN NN O
at IN IN O
day NN NN O
3 CD CD O
and CC CC O
declined VBD VBD O
rapidly RB RB O
to TO TO O
control VB VB O
levels NNS NNS O
by IN IN O
day NN NN O
17 CD CD O
. . . O

This DT DT O
study NN NN O
supports VBZ VBZ O
the DT DT O
role NN NN O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
in IN IN O
mediating VBG VBG O
the DT DT O
proteinuric JJ JJ O
injury NN NN O
in IN IN O
PAN NNP NNP B-CHEM
nephropathy NN NN O
. . . O

Composition NNP NNP O
of IN IN O
gall NN NN O
bladder NN NN O
stones NNS NNS O
associated VBN VBN O
with IN IN O
octreotide NN NN B-CHEM
: : : O
response NN NN O
to TO TO O
oral JJ JJ O
ursodeoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Octreotide NNP NNP B-CHEM
, , , O
an DT DT O
effective JJ JJ O
treatment NN NN O
for IN IN O
acromegaly NN NN O
, , , O
induces NNS NNS O
gall VBP VBP O
bladder NN NN O
stones NNS NNS O
in IN IN O
13 CD CD O
- : : O
60 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Because IN IN O
knowledge NN NN O
of IN IN O
stone NN NN O
composition NN NN O
is VBZ VBZ O
essential JJ JJ O
for IN IN O
studies NNS NNS O
of IN IN O
their PRP$ PRP$ O
pathogenesis NNS NNS O
, , , O
treatment NN NN O
, , , O
and CC CC O
prevention NN NN O
, , , O
this DT DT O
was VBD VBD O
investigated VBN VBN O
by IN IN O
direct JJ JJ O
and CC CC O
indirect JJ JJ O
methods NNS NNS O
in IN IN O
14 CD CD O
octreotide NN NN B-CHEM
treated VBN VBN O
acromegalic JJ JJ O
patients NNS NNS O
with IN IN O
gall NN NN O
stones NNS NNS O
. . . O

Chemical NNP NNP O
analysis NN NN O
of IN IN O
gall NN NN O
stones NNS NNS O
retrieved VBN VBN O
at IN IN O
cholecystectomy NN NN O
from IN IN O
two CD CD O
patients NNS NNS O
, , , O
showed VBD VBD O
that IN IN O
they PRP PRP O
contained VBD VBD O
71 CD CD O
% NN NN O
and CC CC O
87 CD CD O
% NN NN O
cholesterol NN NN B-CHEM
by IN IN O
weight NN NN O
. . . O

In IN IN O
the DT DT O
remaining VBG VBG O
12 CD CD O
patients NNS NNS O
, , , O
localised VBN VBN O
computed JJ JJ O
tomography NN NN O
of IN IN O
the DT DT O
gall NN NN O
bladder NN NN O
showed VBD VBD O
that IN IN O
eight CD CD O
had VBD VBD O
stones NNS NNS O
with IN IN O
maximum NN NN O
attenuation NN NN O
scores NNS NNS O
of IN IN O
< NN NN O
100 CD CD O
Hounsfield NNP NNP O
units NNS NNS O
( ( ( O
values NNS NNS O
of IN IN O
< NN NN O
100 CD CD O
HU NNP NNP O
predict VBP VBP O
cholesterol NN NN B-CHEM
rich JJ JJ O
, , , O
dissolvable JJ JJ O
stones NNS NNS O
) ) ) O
. . . O

Gall NNP NNP O
bladder NN NN O
bile NN NN O
was VBD VBD O
obtained VBN VBN O
by IN IN O
ultrasound NN NN O
guided VBN VBN O
, , , O
fine NN NN O
needle NN NN O
puncture NN NN O
from IN IN O
six CD CD O
patients NNS NNS O
. . . O

All DT DT O
six CD CD O
patients NNS NNS O
had VBD VBD O
supersaturated VBN VBN O
bile IN IN O
( ( ( O
mean VB VB O
( ( ( O
SEM NNP NNP O
) ) ) O
cholesterol NN NN B-CHEM
saturation NN NN O
index NN NN O
of IN IN O
1 CD CD O
. . . O
19 CD CD O
( ( ( O
0 CD CD O
. . . O
08 CD CD O
) ) ) O
( ( ( O
range NN NN O
1 CD CD O
. . . O
01 CD CD O
- : : O
1 CD CD O
. . . O
53 CD CD O
) ) ) O
) ) ) O
and CC CC O
all DT DT O
had VBD VBD O
abnormally RB RB O
rapid JJ JJ O
cholesterol NN NN B-CHEM
microcrystal JJ JJ O
nucleation NN NN O
times NNS NNS O
( ( ( O
< NN NN O
4 CD CD O
days NNS NNS O
( ( ( O
range NN NN O
1 CD CD O
- : : O
4 CD CD O
) ) ) O
) ) ) O
, , , O
whilst NN NN O
in IN IN O
four CD CD O
, , , O
the DT DT O
bile NN NN O
contained VBD VBD O
cholesterol NN NN B-CHEM
microcrystals NNS NNS O
immediately RB RB O
after IN IN O
sampling VBG VBG O
. . . O

Of IN IN O
the DT DT O
12 CD CD O
patients NNS NNS O
considered VBN VBN O
for IN IN O
oral JJ JJ O
ursodeoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
UDCA NNP NNP B-CHEM
) ) ) O
treatment NN NN O
, , , O
two CD CD O
had VBD VBD O
a DT DT O
blocked JJ JJ O
cystic JJ JJ O
duct NN NN O
and CC CC O
were VBD VBD O
not RB RB O
started VBN VBN O
on IN IN O
UDCA NNP NNP B-CHEM
while IN IN O
one CD CD O
was VBD VBD O
lost VBN VBN O
to TO TO O
follow VB VB O
up RP RP O
. . . O

After IN IN O
one CD CD O
year NN NN O
of IN IN O
treatment NN NN O
, , , O
five CD CD O
of IN IN O
the DT DT O
remaining VBG VBG O
nine CD CD O
patients NNS NNS O
showed VBD VBD O
either CC CC O
partial JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
3 CD CD O
) ) ) O
or CC CC O
complete JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
gall NN NN O
stone NN NN O
dissolution NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
their PRP$ PRP$ O
stones NNS NNS O
were VBD VBD O
cholesterol NN NN B-CHEM
rich JJ JJ O
. . . O

This DT DT O
corresponds NNS NNS O
, , , O
by IN IN O
actuarial JJ JJ O
( ( ( O
life NN NN O
table NN NN O
) ) ) O
analysis NN NN O
, , , O
to TO TO O
a DT DT O
combined JJ JJ O
gall NN NN O
stone NN NN O
dissolution NN NN O
rate NN NN O
of IN IN O
58 CD CD O
. . . O
3 CD CD O
( ( ( O
15 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
. . . O

In IN IN O
conclusion NN NN O
, , , O
octreotide NN NN B-CHEM
induced VBD VBD O
gall NN NN O
stones NNS NNS O
are VBP VBP O
generally RB RB O
small JJ JJ O
, , , O
multiple JJ JJ O
, , , O
and CC CC O
cholesterol NN NN B-CHEM
rich JJ JJ O
although IN IN O
, , , O
in IN IN O
common JJ JJ O
with IN IN O
spontaneous JJ JJ O
gall NN NN O
stone NN NN O
disease NN NN O
, , , O
at IN IN O
presentation NN NN O
some DT DT O
patients NNS NNS O
will MD MD O
have VB VB O
a DT DT O
blocked VBN VBN O
cystic JJ JJ O
duct NN NN O
and CC CC O
some DT DT O
gall NN NN O
stones NNS NNS O
containing VBG VBG O
calcium NN NN B-CHEM
. . . O

Erythema NNP NNP O
multiforme NN NN O
and CC CC O
hypersensitivity NN NN O
myocarditis NNS NNS O
caused VBN VBN O
by IN IN O
ampicillin NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
erythema NN NN O
multiforme NN NN O
and CC CC O
hypersensitivity NN NN O
myocarditis NNS NNS O
caused VBN VBN O
by IN IN O
ampicillin NN NN B-CHEM
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
13 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
ampicillin NN NN B-CHEM
and CC CC O
gentamicin NN NN B-CHEM
because IN IN O
of IN IN O
suspected VBD VBD O
septicemia NN NN O
. . . O

Medications NNP NNP O
were VBD VBD O
discontinued VBN VBN O
when WRB WRB O
erythema NN NN O
multiforme NN NN O
and CC CC O
congestive JJ JJ O
heart NN NN O
failure NN NN O
caused VBN VBN O
by IN IN O
myocarditis NNS NNS O
occurred VBD VBD O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
methylprednisolone NN NN B-CHEM
and CC CC O
gradually RB RB O
improved VBN VBN O
. . . O

Macrophage NNP NNP O
- - - O
migration NN NN O
inhibition NN NN O
( ( ( O
MIF NNP NNP O
) ) ) O
test NN NN O
with IN IN O
ampicillin NN NN B-CHEM
was VBD VBD O
positive JJ JJ O
. . . O

DISCUSSION NNP NNP O
: : : O
After IN IN O
most JJS JJS O
infections NNS NNS O
causing VBG VBG O
erythema NN NN O
multiforme NN NN O
and CC CC O
myocarditis NNS NNS O
were VBD VBD O
ruled VBN VBN O
out IN IN O
, , , O
a DT DT O
drug NN NN O
- - - O
induced JJ JJ O
allergic JJ JJ O
reaction NN NN O
was VBD VBD O
suspected VBN VBN O
. . . O

Positive JJ JJ O
MIF NNP NNP O
test NN NN O
for IN IN O
ampicillin NN NN B-CHEM
showed VBD VBD O
sensitization NN NN O
of IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
lymphocytes NNS NNS O
to TO TO O
ampicillin NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Hypersensitivity NNP NNP O
myocarditis NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
and CC CC O
dangerous JJ JJ O
manifestation NN NN O
of IN IN O
allergy NN NN O
to TO TO O
penicillins NNS NNS B-CHEM
. . . O

Clomipramine NNP NNP B-CHEM
- : : O
induced JJ JJ O
sleep NN NN O
disturbance NN NN O
does VBZ VBZ O
not RB RB O
impair VB VB O
its PRP$ PRP$ O
prolactin NN NN O
- - - O
releasing VBG VBG O
action NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
examine VB VB O
the DT DT O
role NN NN O
of IN IN O
sleep NN NN O
disturbance NN NN O
, , , O
induced VBN VBN O
by IN IN O
clomipramine NN NN B-CHEM
administration NN NN O
, , , O
on IN IN O
the DT DT O
secretory JJ JJ O
rate NN NN O
of IN IN O
prolactin NN NN O
( ( ( O
PRL NNP NNP O
) ) ) O
in IN IN O
addition NN NN O
to TO TO O
the DT DT O
direct JJ JJ O
drug NN NN O
effect NN NN O
. . . O

Two CD CD O
groups NNS NNS O
of IN IN O
supine NN NN O
subjects NNS NNS O
were VBD VBD O
studied VBN VBN O
under IN IN O
placebo NN NN O
- - - O
controlled JJ JJ O
conditions NNS NNS O
, , , O
one CD CD O
during IN IN O
the DT DT O
night NN NN O
, , , O
when WRB WRB O
sleeping VBG VBG O
( ( ( O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
and CC CC O
the DT DT O
other JJ JJ O
at IN IN O
daytime JJ JJ O
, , , O
when WRB WRB O
awake NN NN O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
. . . O

Each DT DT O
subject NN NN O
received VBD VBD O
a DT DT O
single JJ JJ O
50 CD CD O
mg NN NN O
dose NN NN O
of IN IN O
clomipramine NN NN B-CHEM
given VBN VBN O
orally RB RB O
2 CD CD O
hours NNS NNS O
before IN IN O
blood NN NN O
collection NN NN O
. . . O

Plasma NNP NNP O
PRL NNP NNP O
concentrations NNS NNS O
were VBD VBD O
analysed VBN VBN O
at IN IN O
10 CD CD O
min NN NN O
intervals NNS NNS O
and CC CC O
underlying VBG VBG O
secretory JJ JJ O
rates NNS NNS O
calculated VBN VBN O
by IN IN O
a DT DT O
deconvolution NN NN O
procedure NN NN O
. . . O

For IN IN O
both DT DT O
experiments NNS NNS O
the DT DT O
drug NN NN O
intake NN NN O
led VBN VBN O
to TO TO O
significant JJ JJ O
increases NNS NNS O
in IN IN O
PRL NNP NNP O
secretion NN NN O
, , , O
acting VBG VBG O
preferentially RB RB O
on IN IN O
tonic JJ JJ O
secretion NN NN O
as IN IN O
pulse NN NN O
amplitude NN NN O
and CC CC O
frequency NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
from IN IN O
corresponding JJ JJ O
control NN NN O
values NNS NNS O
. . . O

During IN IN O
the DT DT O
night NN NN O
clomipramine NN NN B-CHEM
ingestion NN NN O
altered VBD VBD O
the DT DT O
complete JJ JJ O
sleep NN NN O
architecture NN NN O
in IN IN O
that IN IN O
it PRP PRP O
suppressed VBD VBD O
REM NNP NNP O
sleep NN NN O
and CC CC O
the DT DT O
sleep NN NN O
cycles NNS NNS O
and CC CC O
induced VBN VBN O
increased VBN VBN O
wakefulness NN NN O
. . . O

As IN IN O
the DT DT O
relative JJ JJ O
increase NN NN O
in IN IN O
PRL NNP NNP O
secretion NN NN O
expressed VBD VBD O
as IN IN O
a DT DT O
percentage NN NN O
of IN IN O
the DT DT O
mean NN NN O
did VBD VBD O
not RB RB O
significantly RB RB O
differ VB VB O
between IN IN O
the DT DT O
night NN NN O
and CC CC O
day NN NN O
time NN NN O
studies NNS NNS O
( ( ( O
46 CD CD O
+ NN NN O
/ NN NN O
- : : O
19 CD CD O
% NN NN O
vs NNS NNS O
34 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
% NN NN O
) ) ) O
, , , O
it PRP PRP O
can MD MD O
be VB VB O
concluded VBN VBN O
that IN IN O
the DT DT O
observed VBN VBN O
sleep NN NN O
disturbance NN NN O
did VBD VBD O
not RB RB O
interfere VB VB O
with IN IN O
the DT DT O
drug NN NN O
action NN NN O
per IN IN O
se FW FW O
. . . O

The DT DT O
presence NN NN O
of IN IN O
REM NNP NNP O
sleep VB VB O
was VBD VBD O
shown VBN VBN O
not RB RB O
to TO TO O
be VB VB O
a DT DT O
determining VBG VBG O
factor NN NN O
either CC CC O
for IN IN O
secretory JJ JJ O
pulse NN NN O
amplitude NN NN O
and CC CC O
frequency NN NN O
, , , O
as IN IN O
, , , O
for IN IN O
both DT DT O
, , , O
mean VB VB O
nocturnal JJ JJ O
values NNS NNS O
were VBD VBD O
similar JJ JJ O
with IN IN O
and CC CC O
without IN IN O
prior RB RB O
clomipramine NN NN B-CHEM
ingestion NN NN O
. . . O

Survey NN NN O
of IN IN O
complications NNS NNS O
of IN IN O
indocyanine NN NN B-CHEM
green JJ JJ I-CHEM
angiography NN NN O
in IN IN O
Japan NNP NNP O
. . . O

PURPOSE NNP NNP O
: : : O
We PRP PRP O
evaluated VBD VBD O
the DT DT O
safety NN NN O
of IN IN O
indocyanine NN NN B-CHEM
green JJ JJ I-CHEM
for IN IN O
use NN NN O
in IN IN O
fundus NN NN O
angiography NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
sent VBD VBD O
a DT DT O
questionnaire NN NN O
concerning VBG VBG O
complications NNS NNS O
of IN IN O
indocyanine NN NN B-CHEM
green JJ JJ I-CHEM
to TO TO O
32 CD CD O
institutions NNS NNS O
in IN IN O
Japan NNP NNP O
, , , O
which WDT WDT O
were VBD VBD O
selected VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
the DT DT O
client NN NN O
list NN NN O
from IN IN O
the DT DT O
Topcon NNP NNP O
Company NNP NNP O
, , , O
which WDT WDT O
manufactures VBZ VBZ O
the DT DT O
indocyanine NN NN B-CHEM
green JJ JJ I-CHEM
fundus NN NN O
camera NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Ophthalmologists NNP NNP O
at IN IN O
15 CD CD O
institutions NNS NNS O
responded VBD VBD O
, , , O
reporting VBG VBG O
a DT DT O
total NN NN O
of IN IN O
3 CD CD O
, , , O
774 CD CD O
indocyanine NN NN B-CHEM
green JJ JJ I-CHEM
angiograms NNS NNS O
performed VBN VBN O
on IN IN O
2 CD CD O
, , , O
820 CD CD O
patients NNS NNS O
between IN IN O
June NNP NNP O
1984 CD CD O
and CC CC O
September NNP NNP O
1992 CD CD O
. . . O

Before IN IN O
angiography NN NN O
, , , O
intradermal NN NN O
or CC CC O
intravenous JJ JJ O
indocyanine NN NN B-CHEM
green JJ JJ I-CHEM
testing NN NN O
, , , O
or CC CC O
both DT DT O
was VBD VBD O
performed VBN VBN O
at IN IN O
13 CD CD O
of IN IN O
15 CD CD O
institutions NNS NNS O
. . . O

For IN IN O
three CD CD O
patients NNS NNS O
, , , O
the DT DT O
decision NN NN O
was VBD VBD O
made VBN VBN O
not RB RB O
to TO TO O
proceed VB VB O
with IN IN O
angiography NN NN O
after IN IN O
positive JJ JJ O
preangiographic JJ JJ O
testing NN NN O
. . . O

The DT DT O
dosage NN NN O
of IN IN O
indocyanine NN NN B-CHEM
green NN NN I-CHEM
used VBN VBN O
for IN IN O
angiography NN NN O
varied VBN VBN O
from IN IN O
25 CD CD O
to TO TO O
75 CD CD O
mg NN NN O
, , , O
depending VBG VBG O
upon IN IN O
the DT DT O
institution NN NN O
. . . O

There EX EX O
were VBD VBD O
13 CD CD O
cases NNS NNS O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
( ( ( O
0 CD CD O
. . . O
34 CD CD O
% NN NN O
) ) ) O
, , , O
ten CD CD O
of IN IN O
which WDT WDT O
were VBD VBD O
mild JJ JJ O
reactions NNS NNS O
such JJ JJ O
as IN IN O
nausea NN NN O
, , , O
exanthema NN NN O
, , , O
urtication NN NN O
, , , O
itchiness NN NN O
, , , O
and CC CC O
urgency NN NN O
to TO TO O
defecate VB VB O
, , , O
and CC CC O
did VBD VBD O
not RB RB O
require VB VB O
treatment NN NN O
. . . O

Also RB RB O
recorded VBD VBD O
were VBD VBD O
one CD CD O
case NN NN O
of IN IN O
pain NN NN O
of IN IN O
the DT DT O
vein NN NN O
, , , O
which WDT WDT O
required VBD VBD O
treatment NN NN O
, , , O
and CC CC O
two CD CD O
cases NNS NNS O
of IN IN O
hypotension NN NN O
. . . O

The DT DT O
two CD CD O
hypotensive JJ JJ O
patients NNS NNS O
required VBN VBN O
treatment NN NN O
for IN IN O
shock NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
A DT DT O
comparison NN NN O
of IN IN O
frequency NN NN O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
to TO TO O
indocyanine VB VB B-CHEM
green JJ JJ I-CHEM
with IN IN O
the DT DT O
previously RB RB O
reported VBD VBD O
frequency NN NN O
of IN IN O
such JJ JJ O
reactions NNS NNS O
to TO TO O
fluorescein VB VB B-CHEM
sodium NN NN I-CHEM
indicated VBD VBD O
that IN IN O
indocyanine NN NN B-CHEM
green NN NN I-CHEM
is VBZ VBZ O
a DT DT O
safe JJ JJ O
as IN IN O
fluorescein NN NN B-CHEM
for IN IN O
use NN NN O
in IN IN O
angiography NN NN O
. . . O

Angioedema NNP NNP O
following VBG VBG O
the DT DT O
intravenous JJ JJ O
administration NN NN O
of IN IN O
metoprolol NN NN B-CHEM
. . . O

A DT DT O
72 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
with IN IN O
" '' '' O
flash NN NN O
" '' '' O
pulmonary JJ JJ O
edema NN NN O
, , , O
preceded VBN VBN O
by IN IN O
chest NN NN O
pain NN NN O
, , , O
requiring VBG VBG O
intubation NN NN O
. . . O

Her PRP$ PRP$ O
medical JJ JJ O
history NN NN O
included VBD VBD O
coronary JJ JJ O
artery NN NN O
disease NN NN O
with IN IN O
previous JJ JJ O
myocardial NN NN O
infarctions NNS NNS O
, , , O
hypertension NN NN O
, , , O
and CC CC O
diabetes VBZ VBZ O
mellitus NN NN O
. . . O

A DT DT O
history NN NN O
of IN IN O
angioedema NN NN O
secondary JJ JJ O
to TO TO O
lisinopril NN NN B-CHEM
therapy NN NN O
was VBD VBD O
elicited VBN VBN O
. . . O

Current JJ JJ O
medications NNS NNS O
did VBD VBD O
not RB RB O
include VB VB O
angiotensin NN NN B-CHEM
- : : O
converting VBG VBG O
enzyme NN NN O
inhibitors NNS NNS O
or CC CC O
beta NN NN O
- - - O
blockers NNS NNS O
. . . O

She PRP PRP O
had VBD VBD O
no DT DT O
previous JJ JJ O
beta NN NN O
- - - O
blocking VBG VBG O
drug NN NN O
exposure NN NN O
. . . O

During IN IN O
the DT DT O
first JJ JJ O
day NN NN O
of IN IN O
hospitalization NN NN O
( ( ( O
while IN IN O
intubated JJ JJ O
) ) ) O
, , , O
intravenous JJ JJ O
metoprolol NN NN B-CHEM
was VBD VBD O
given VBN VBN O
, , , O
resulting VBG VBG O
in IN IN O
severe JJ JJ O
angioedema NN NN O
. . . O

The DT DT O
angioedema NN NN O
resolved VBD VBD O
after IN IN O
therapy NN NN O
with IN IN O
intravenous JJ JJ O
steroids NNS NNS B-CHEM
and CC CC O
diphenhydramine NN NN B-CHEM
hydrochloride NN NN O
. . . O

Effect NN NN O
of IN IN O
coniine NN NN B-CHEM
on IN IN O
the DT DT O
developing VBG VBG O
chick NN NN O
embryo NN NN O
. . . O

Coniine NNP NNP B-CHEM
, , , O
an DT DT O
alkaloid NN NN O
from IN IN O
Conium NNP NNP O
maculatum NN NN O
( ( ( O
poison NN NN O
hemlock NN NN O
) ) ) O
, , , O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
teratogenic JJ JJ O
in IN IN O
livestock NN NN O
. . . O

The DT DT O
major JJ JJ O
teratogenic JJ JJ O
outcome NN NN O
is VBZ VBZ O
arthrogryposis NN NN O
, , , O
presumably RB RB O
due JJ JJ O
to TO TO O
nicotinic JJ JJ O
receptor NN NN O
blockade NN NN O
. . . O

However RB RB O
, , , O
coniine NN NN B-CHEM
has VBZ VBZ O
failed VBN VBN O
to TO TO O
produce VB VB O
arthrogryposis NN NN O
in IN IN O
rats NNS NNS O
or CC CC O
mice NNS NNS O
and CC CC O
is VBZ VBZ O
only RB RB O
weakly RB RB O
teratogenic JJ JJ O
in IN IN O
rabbits NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
and CC CC O
compare VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
coniine NN NN B-CHEM
and CC CC O
nicotine NN NN B-CHEM
in IN IN O
the DT DT O
developing VBG VBG O
chick NN NN O
. . . O

Concentrations NNP NNP O
of IN IN O
coniine NN NN B-CHEM
and CC CC O
nicotine NN NN B-CHEM
sulfate NN NN O
were VBD VBD O
0 CD CD O
. . . O
015 CD CD O
% NN NN O
, , , O
0 CD CD O
. . . O
03 CD CD O
% NN NN O
, , , O
0 CD CD O
. . . O
075 CD CD O
% NN NN O
, , , O
0 CD CD O
. . . O
15 CD CD O
% NN NN O
, , , O
0 CD CD O
. . . O
75 CD CD O
% NN NN O
, , , O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
, , , O
3 CD CD O
% NN NN O
, , , O
and CC CC O
6 CD CD O
% NN NN O
and CC CC O
1 CD CD O
% NN NN O
, , , O
5 CD CD O
% NN NN O
, , , O
and CC CC O
10 CD CD O
% NN NN O
, , , O
respectively RB RB O
. . . O

Both DT DT O
compounds NNS NNS O
caused VBD VBD O
deformations NNS NNS O
and CC CC O
lethality NN NN O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

All DT DT O
concentrations NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
sulfate NN NN O
caused VBD VBD O
some DT DT O
lethality NN NN O
but CC CC O
a DT DT O
no DT DT O
effect NN NN O
level NN NN O
for IN IN O
coniine JJ JJ B-CHEM
lethality NN NN O
was VBD VBD O
0 CD CD O
. . . O
75 CD CD O
% NN NN O
. . . O

The DT DT O
deformations NNS NNS O
caused VBN VBN O
by IN IN O
both DT DT O
coniine NN NN B-CHEM
and CC CC O
nicotine NN NN B-CHEM
sulfate NN NN O
were VBD VBD O
excessive JJ JJ O
flexion NN NN O
or CC CC O
extension NN NN O
of IN IN O
one CD CD O
or CC CC O
more JJR JJR O
toes NNS NNS O
. . . O

No DT DT O
histopathological JJ JJ O
alterations NNS NNS O
or CC CC O
differences NNS NNS O
in IN IN O
bone NN NN O
formation NN NN O
were VBD VBD O
seen VBN VBN O
in IN IN O
the DT DT O
limbs NNS NNS O
or CC CC O
toes NNS NNS O
of IN IN O
any DT DT O
chicks NNS NNS O
from IN IN O
any DT DT O
group NN NN O
; : : O
however RB RB O
, , , O
extensive JJ JJ O
cranial JJ JJ O
hemorrhage NN NN O
occurred VBD VBD O
in IN IN O
all DT DT O
nicotine NN NN B-CHEM
sulfate NN NN O
- - - O
treated JJ JJ O
chicks NNS NNS O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
statistically RB RB O
significant JJ JJ O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
decrease NN NN O
in IN IN O
movement NN NN O
in IN IN O
coniine NN NN B-CHEM
and CC CC O
nicotine NN NN B-CHEM
sulfate NN NN O
treated VBN VBN O
chicks NNS NNS O
as IN IN O
determined VBN VBN O
by IN IN O
ultrasound NN NN O
. . . O

Control NNP NNP O
chicks NNS NNS O
were VBD VBD O
in IN IN O
motion NN NN O
an DT DT O
average NN NN O
of IN IN O
33 CD CD O
. . . O
67 CD CD O
% NN NN O
of IN IN O
the DT DT O
time NN NN O
, , , O
while IN IN O
coniine NN NN B-CHEM
- - - O
treated JJ JJ O
chicks NNS NNS O
were VBD VBD O
only RB RB O
moving VBG VBG O
8 CD CD O
. . . O
95 CD CD O
% NN NN O
of IN IN O
a DT DT O
5 CD CD O
- : : O
min NN NN O
interval NN NN O
, , , O
and CC CC O
no DT DT O
movement NN NN O
was VBD VBD O
observed VBN VBN O
for IN IN O
nicotine NN NN B-CHEM
sulfate NN NN O
treated VBN VBN O
chicks NNS NNS O
. . . O

In IN IN O
summary NN NN O
, , , O
the DT DT O
chick NN NN O
embryo NN NN O
provides VBZ VBZ O
a DT DT O
reliable JJ JJ O
and CC CC O
simple JJ JJ O
experimental JJ JJ O
animal NN NN O
model NN NN O
of IN IN O
coniine NN NN B-CHEM
- - - O
induced JJ JJ O
arthrogryposis NN NN O
. . . O

Data NNP NNP O
from IN IN O
this DT DT O
model NN NN O
support NN NN O
a DT DT O
mechanism NN NN O
involving VBG VBG O
nicotinic JJ JJ O
receptor NN NN O
blockade NN NN O
with IN IN O
subsequent NN NN O
decreased VBD VBD O
fetal JJ JJ O
movement NN NN O
. . . O

Immediate NNP NNP O
allergic JJ JJ O
reactions NNS NNS O
to TO TO O
amoxicillin NN NN B-CHEM
. . . O

A DT DT O
large JJ JJ O
group NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
suspected VBN VBN O
allergic JJ JJ O
reactions NNS NNS O
to TO TO O
beta NN NN B-CHEM
- - - I-CHEM
lactam NN NN I-CHEM
antibiotics NNS NNS O
was VBD VBD O
evaluated VBN VBN O
. . . O

A DT DT O
detailed JJ JJ O
clinical JJ JJ O
history NN NN O
, , , O
together RB RB O
with IN IN O
skin NN NN O
tests NNS NNS O
, , , O
RAST NNP NNP O
( ( ( O
radioallergosorbent NN NN O
test NN NN O
) ) ) O
, , , O
and CC CC O
controlled VBD VBD O
challenge NN NN O
tests NNS NNS O
, , , O
was VBD VBD O
used VBN VBN O
to TO TO O
establish VB VB O
whether IN IN O
patients NNS NNS O
allergic VBP VBP O
to TO TO O
beta NN NN B-CHEM
- - - I-CHEM
lactam NN NN I-CHEM
antibiotics NNS NNS O
had VBD VBD O
selective JJ JJ O
immediate JJ JJ O
allergic JJ JJ O
responses NNS NNS O
to TO TO O
amoxicillin NN NN B-CHEM
( ( ( O
AX NNP NNP B-CHEM
) ) ) O
or CC CC O
were VBD VBD O
cross JJ JJ O
- - - O
reacting VBG VBG O
with IN IN O
other JJ JJ O
penicillin NN NN B-CHEM
derivatives NNS NNS O
. . . O

Skin NNP NNP O
tests NNS NNS O
were VBD VBD O
performed VBN VBN O
with IN IN O
benzylpenicilloyl NN NN B-CHEM
- - - I-CHEM
poly NN NN I-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- : : I-CHEM
lysine NN NN I-CHEM
( ( ( O
BPO NNP NNP B-CHEM
- - - I-CHEM
PLL NNP NNP I-CHEM
) ) ) O
, , , O
benzylpenicilloate NN NN B-CHEM
, , , O
benzylpenicillin NN NN B-CHEM
( ( ( O
PG NNP NNP B-CHEM
) ) ) O
, , , O
ampicillin NN NN B-CHEM
( ( ( O
AMP NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
AX NNP NNP B-CHEM
. . . O

RAST NNP NNP O
for IN IN O
BPO NNP NNP B-CHEM
- : : I-CHEM
PLL NNP NNP I-CHEM
and CC CC O
AX NNP NNP B-CHEM
- : : O
PLL NNP NNP O
was VBD VBD O
done VBN VBN O
. . . O

When WRB WRB O
both DT DT O
skin NN NN O
test NN NN O
and CC CC O
RAST NNP NNP O
for IN IN O
BPO NNP NNP B-CHEM
were VBD VBD O
negative JJ JJ O
, , , O
single JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
challenge NN NN O
tests NNS NNS O
were VBD VBD O
done VBN VBN O
to TO TO O
ensure VB VB O
tolerance NN NN O
of IN IN O
PG NNP NNP B-CHEM
or CC CC O
sensitivity NN NN O
to TO TO O
AX NNP NNP B-CHEM
. . . O

A DT DT O
total NN NN O
of IN IN O
177 CD CD O
patients NNS NNS O
were VBD VBD O
diagnosed VBN VBN O
as IN IN O
allergic JJ JJ O
to TO TO O
beta VB VB B-CHEM
- : : I-CHEM
lactam NN NN I-CHEM
antibiotics NNS NNS O
. . . O

We PRP PRP O
selected VBD VBD O
the DT DT O
54 CD CD O
( ( ( O
30 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
cases NNS NNS O
of IN IN O
immediate JJ JJ O
AX NNP NNP B-CHEM
allergy NN NN O
with IN IN O
good JJ JJ O
tolerance NN NN O
of IN IN O
PG NNP NNP B-CHEM
. . . O

Anaphylaxis NNP NNP O
was VBD VBD O
seen VBN VBN O
in IN IN O
37 CD CD O
patients NNS NNS O
( ( ( O
69 CD CD O
% NN NN O
) ) ) O
, , , O
the DT DT O
other JJ JJ O
17 CD CD O
( ( ( O
31 CD CD O
% NN NN O
) ) ) O
having VBG VBG O
urticaria JJ JJ O
and CC CC O
/ NN NN O
or CC CC O
angioedema NN NN O
. . . O

All DT DT O
the DT DT O
patients NNS NNS O
were VBD VBD O
skin NN NN O
test NN NN O
negative JJ JJ O
to TO TO O
BPO NNP NNP B-CHEM
; : : O
49 CD CD O
of IN IN O
51 CD CD O
( ( ( O
96 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
also RB RB O
negative JJ JJ O
to TO TO O
MDM NNP NNP O
, , , O
and CC CC O
44 CD CD O
of IN IN O
46 CD CD O
( ( ( O
96 CD CD O
% NN NN O
) ) ) O
to TO TO O
PG NNP NNP B-CHEM
. . . O

Skin NNP NNP O
tests NNS NNS O
with IN IN O
AX NNP NNP B-CHEM
were VBD VBD O
positive JJ JJ O
in IN IN O
34 CD CD O
( ( ( O
63 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
. . . O

RAST NNP NNP O
was VBD VBD O
positive JJ JJ O
for IN IN O
AX NNP NNP B-CHEM
in IN IN O
22 CD CD O
patients NNS NNS O
( ( ( O
41 CD CD O
% NN NN O
) ) ) O
and CC CC O
to TO TO O
BPO NNP NNP B-CHEM
in IN IN O
just RB RB O
5 CD CD O
( ( ( O
9 CD CD O
% NN NN O
) ) ) O
. . . O

None NN NN O
of IN IN O
the DT DT O
sera NN NN O
with IN IN O
negative JJ JJ O
RAST NNP NNP O
for IN IN O
AX NNP NNP B-CHEM
were VBD VBD O
positive JJ JJ O
to TO TO O
BPO NNP NNP B-CHEM
. . . O

Challenge NNP NNP O
tests NNS NNS O
with IN IN O
AX NNP NNP B-CHEM
were VBD VBD O
performed VBN VBN O
in IN IN O
23 CD CD O
subjects NNS NNS O
( ( ( O
43 CD CD O
% NN NN O
) ) ) O
to TO TO O
establish VB VB O
the DT DT O
diagnosis NN NN O
of IN IN O
immediate JJ JJ O
allergic JJ JJ O
reaction NN NN O
to TO TO O
AX NNP NNP B-CHEM
, , , O
and CC CC O
in IN IN O
15 CD CD O
cases NNS NNS O
( ( ( O
28 CD CD O
% NN NN O
) ) ) O
both DT DT O
skin NN NN O
test NN NN O
and CC CC O
RAST NNP NNP O
for IN IN O
AX NNP NNP B-CHEM
were VBD VBD O
negative JJ JJ O
. . . O

PG NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
by IN IN O
all DT DT O
54 CD CD O
patients NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
the DT DT O
largest JJS JJS O
group NN NN O
of IN IN O
AX NNP NNP B-CHEM
- : : O
allergic JJ JJ O
patients NNS NNS O
who WP WP O
have VBP VBP O
tolerated VBN VBN O
PG NNP NNP B-CHEM
reported VBD VBD O
so RB RB O
far RB RB O
. . . O

Diagnosis NNP NNP O
of IN IN O
these DT DT O
patients NNS NNS O
can MD MD O
be VB VB O
achieved VBN VBN O
only RB RB O
if IN IN O
specific JJ JJ O
AX NNP NNP B-CHEM
- - - O
related VBN VBN O
reagents NNS NNS O
are VBP VBP O
employed VBN VBN O
. . . O

Further RB RB O
studies NNS NNS O
are VBP VBP O
necessary JJ JJ O
to TO TO O
determine VB VB O
the DT DT O
exact JJ JJ O
extent NN NN O
of IN IN O
this DT DT O
problem NN NN O
and CC CC O
to TO TO O
improve VB VB O
the DT DT O
efficacy NN NN O
of IN IN O
diagnostic JJ JJ O
methods NNS NNS O
. . . O

Reversal NNP NNP O
by IN IN O
phenylephrine NN NN B-CHEM
of IN IN O
the DT DT O
beneficial JJ JJ O
effects NNS NNS O
of IN IN O
intravenous JJ JJ O
nitroglycerin NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

Nitroglycerin NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
reduce VB VB O
ST NNP NNP O
- : : O
segment NN NN O
elevation NN NN O
during IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
, , , O
an DT DT O
effect NN NN O
potentiated JJ JJ O
in IN IN O
the DT DT O
dog NN NN O
by IN IN O
agents NNS NNS O
that WDT WDT O
reverse NN NN O
nitroglycerin NN NN B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

Our PRP$ PRP$ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
combined VBN VBN O
nitroglycerin NN NN B-CHEM
and CC CC O
phenylephrine NN NN B-CHEM
therapy NN NN O
. . . O

Ten CD CD O
patients NNS NNS O
with IN IN O
acute JJ JJ O
transmural JJ JJ O
myocardial NN NN O
infarctions NNS NNS O
received VBD VBD O
intravenous JJ JJ O
nitroglycerin NN NN B-CHEM
, , , O
sufficient JJ JJ O
to TO TO O
reduce VB VB O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
from IN IN O
107 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
to TO TO O
85 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
mm NN NN O
Hg NNP NNP O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
for IN IN O
60 CD CD O
minutes NNS NNS O
. . . O

Left NNP NNP O
ventricular NN NN O
filling VBG VBG O
pressure NN NN O
decreased VBD VBD O
from IN IN O
19 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
to TO TO O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mm NN NN O
Hg NNP NNP O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

SigmaST NNP NNP O
, , , O
the DT DT O
sum NN NN O
of IN IN O
ST NNP NNP O
- : : O
segment NN NN O
elevations NNS NNS O
in IN IN O
16 CD CD O
precordial JJ JJ O
leads VBZ VBZ O
, , , O
decreased VBN VBN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
with IN IN O
intravenous JJ JJ O
nitroglycerin NN NN B-CHEM
. . . O

Subsequent NNP NNP O
addition NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
infusion NN NN O
, , , O
sufficient JJ JJ O
to TO TO O
re VB VB O
- - - O
elevate JJ JJ O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
to TO TO O
106 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
mm NN NN O
Hg NNP NNP O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
for IN IN O
30 CD CD O
minutes NNS NNS O
, , , O
increased VBN VBN O
left VBD VBD O
ventricular NN NN O
filling VBG VBG O
pressure NN NN O
to TO TO O
17 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mm NN NN O
Hg NNP NNP O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
also RB RB O
significantly RB RB O
increased VBN VBN O
sigmaST NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that DT DT O
addition NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
to TO TO O
nitroglycerin NN NN B-CHEM
is VBZ VBZ O
not RB RB O
beneficial JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

Acetazolamide NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrolithiasis NN NN O
: : : O
implications NNS NNS O
for IN IN O
treatment NN NN O
of IN IN O
neuromuscular JJ JJ O
disorders NNS NNS O
. . . O

Carbonic NNP NNP O
anhydrase NN NN O
inhibitors NNS NNS O
can MD MD O
cause VB VB O
nephrolithiasis NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
20 CD CD O
patients NNS NNS O
receiving VBG VBG O
long JJ JJ O
- - - O
term NN NN O
carbonic JJ JJ O
anhydrase NN NN O
inhibitor NN NN O
treatment NN NN O
for IN IN O
periodic JJ JJ O
paralysis NN NN O
and CC CC O
myotonia NN NN O
. . . O

Three CD CD O
patients NNS NNS O
on IN IN O
acetazolamide NN NN B-CHEM
( ( ( O
15 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
renal JJ JJ O
calculi NN NN O
. . . O

Extracorporeal NNP NNP O
lithotripsy NN NN O
successfully RB RB O
removed VBD VBD O
a DT DT O
renal JJ JJ O
calculus NN NN O
in IN IN O
one CD CD O
patient NN NN O
and CC CC O
surgery NN NN O
removed VBD VBD O
a DT DT O
staghorn JJ JJ O
calculus NN NN O
in IN IN O
another DT DT O
, , , O
permitting VBG VBG O
continued VBD VBD O
treatment NN NN O
. . . O

Renal NNP NNP O
function NN NN O
remained VBD VBD O
normal JJ JJ O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

Nephrolithiasis NNP NNP O
is VBZ VBZ O
a DT DT O
complication NN NN O
of IN IN O
acetazolamide NN NN B-CHEM
but CC CC O
does VBZ VBZ O
not RB RB O
preclude VB VB O
its PRP$ PRP$ O
use NN NN O
. . . O

Effects NNP NNP O
of IN IN O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
on IN IN O
bupivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
toxicity NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
influence NN NN O
of IN IN O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
on IN IN O
bupivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
toxicity NN NN O
. . . O

For IN IN O
each DT DT O
of IN IN O
the DT DT O
three CD CD O
tested VBN VBN O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
( ( ( O
diltiazem NN NN B-CHEM
, , , O
verapamil NN NN B-CHEM
and CC CC O
bepridil NN NN B-CHEM
) ) ) O
6 CD CD O
groups NNS NNS O
of IN IN O
mice NNS NNS O
were VBD VBD O
treated VBN VBN O
by IN IN O
two CD CD O
different JJ JJ O
doses NNS NNS O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
2 CD CD O
and CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
or CC CC O
an DT DT O
equal JJ JJ O
volume NN NN O
of IN IN O
saline NN NN O
for IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
20 CD CD O
) ) ) O
; : : O
15 CD CD O
minutes NNS NNS O
later RB RB O
, , , O
all PDT PDT O
the DT DT O
animals NNS NNS O
were VBD VBD O
injected VBN VBN O
with IN IN O
a DT DT O
single JJ JJ O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
dose NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
. . . O

The DT DT O
convulsant NN NN O
activity NN NN O
, , , O
the DT DT O
time NN NN O
of IN IN O
latency NN NN O
to TO TO O
convulse VB VB O
and CC CC O
the DT DT O
mortality NN NN O
rate NN NN O
were VBD VBD O
assessed VBN VBN O
in IN IN O
each DT DT O
group NN NN O
. . . O

The DT DT O
local JJ JJ O
anesthetic JJ JJ O
- - - O
induced JJ JJ O
mortality NN NN O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
by IN IN O
the DT DT O
three CD CD O
different JJ JJ O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
. . . O

The DT DT O
convulsant NN NN O
activity NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
was VBD VBD O
not RB RB O
significantly RB RB O
modified VBN VBN O
but CC CC O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
decreased VBD VBD O
the DT DT O
time NN NN O
of IN IN O
latency NN NN O
to TO TO O
obtain VB VB O
bupivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
; : : O
this DT DT O
effect NN NN O
was VBD VBD O
less RBR RBR O
pronounced VBN VBN O
with IN IN O
bepridil NN NN B-CHEM
. . . O

Epidural NNP NNP O
blood NN NN O
flow NN NN O
during IN IN O
prostaglandin NN NN B-CHEM
E1 NNP NNP I-CHEM
or CC CC O
trimethaphan NN NN B-CHEM
induced VBN VBN O
hypotension NN NN O
. . . O

To TO TO O
evaluate VB VB O
the DT DT O
effect NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
E1 NNP NNP I-CHEM
( ( ( O
PGE1 NNP NNP B-CHEM
) ) ) O
or CC CC O
trimethaphan JJ JJ B-CHEM
( ( ( O
TMP NNP NNP B-CHEM
) ) ) O
induced JJ JJ O
hypotension NN NN O
on IN IN O
epidural JJ JJ O
blood NN NN O
flow NN NN O
( ( ( O
EBF NNP NNP O
) ) ) O
during IN IN O
spinal JJ JJ O
surgery NN NN O
, , , O
EBF NNP NNP O
was VBD VBD O
measured VBN VBN O
using VBG VBG O
the DT DT O
heat NN NN O
clearance NN NN O
method NN NN O
in IN IN O
30 CD CD O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
postero NN NN O
- : : O
lateral NN NN O
interbody NN NN O
fusion NN NN O
under IN IN O
isoflurane NN NN B-CHEM
anaesthesia NN NN O
. . . O

An DT DT O
initial JJ JJ O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
1 CD CD O
microgram NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
of IN IN O
PGE1 NNP NNP B-CHEM
( ( ( O
15 CD CD O
patients NNS NNS O
) ) ) O
, , , O
or CC CC O
10 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
of IN IN O
TMP NNP NNP B-CHEM
( ( ( O
15 CD CD O
patients NNS NNS O
) ) ) O
was VBD VBD O
administered VBN VBN O
intravenously RB RB O
after IN IN O
the DT DT O
dural NN NN O
opening NN NN O
and CC CC O
the DT DT O
dose NN NN O
was VBD VBD O
adjusted VBN VBN O
to TO TO O
maintain VB VB O
the DT DT O
mean NN NN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
at IN IN O
about IN IN O
60 CD CD O
mmHg NN NN O
. . . O

The DT DT O
hypotensive JJ JJ O
drug NN NN O
was VBD VBD O
discontinued VBN VBN O
at IN IN O
the DT DT O
completion NN NN O
of IN IN O
the DT DT O
operative JJ JJ O
procedure NN NN O
. . . O

After IN IN O
starting VBG VBG O
PGE1 NNP NNP B-CHEM
or CC CC O
TMP NNP NNP B-CHEM
, , , O
MAP NNP NNP O
and CC CC O
rate NN NN O
pressure NN NN O
product NN NN O
( ( ( O
RPP NNP NNP O
) ) ) O
decreased VBD VBD O
significantly RB RB O
compared VBN VBN O
with IN IN O
preinfusion NN NN O
values NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
and CC CC O
the DT DT O
degree NN NN O
of IN IN O
hypotension NN NN O
due JJ JJ O
to TO TO O
PGE1 NNP NNP B-CHEM
remained VBD VBD O
constant JJ JJ O
until IN IN O
60 CD CD O
min NN NN O
after IN IN O
its PRP$ PRP$ O
discontinuation NN NN O
. . . O

Heart NNP NNP O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
did VBD VBD O
not RB RB O
change VB VB O
in IN IN O
either DT DT O
group NN NN O
. . . O

EBFF NNP NNP O
did VBD VBD O
not RB RB O
change VB VB O
during IN IN O
PGE1 NNP NNP B-CHEM
infusion NN NN O
whereas IN IN O
in IN IN O
the DT DT O
TMP NNP NNP B-CHEM
group NN NN O
, , , O
EBF NNP NNP O
decreased VBD VBD O
significantly RB RB O
at IN IN O
30 CD CD O
and CC CC O
60 CD CD O
min NN NN O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
TMP NNP NNP B-CHEM
( ( ( O
preinfusion NN NN O
: : : O
45 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
. . . O
9 CD CD O
ml NN NN O
/ NN NN O
100g CD CD O
/ NN NN O
min NN NN O
. . . O
30 CD CD O
min NN NN O
: : : O
32 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
. . . O
9 CD CD O
ml NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
/ NN NN O
min NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O
60 CD CD O
min NN NN O
: : : O
30 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
. . . O
5 CD CD O
ml NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
/ NN NN O
min NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
PGE1 NNP NNP B-CHEM
may MD MD O
be VB VB O
preferable JJ JJ O
to TO TO O
TMP NNP NNP B-CHEM
for IN IN O
hypotensive JJ JJ O
anaesthesia NN NN O
in IN IN O
spinal JJ JJ O
surgery NN NN O
because IN IN O
TMP NNP NNP B-CHEM
decreased VBD VBD O
EBF NNP NNP O
. . . O

Dup NNP NNP B-CHEM
753 CD CD I-CHEM
prevents NNS NNS O
the DT DT O
development NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside IN IN I-CHEM
- - - O
induced JJ JJ O
nephrosis NN NN O
. . . O

The DT DT O
appearance NN NN O
of IN IN O
nephrotic JJ JJ O
syndromes NNS NNS O
such JJ JJ O
as IN IN O
proteinuria NN NN O
, , , O
hypoalbuminemia NN NN O
, , , O
hypercholesterolemia NN NN O
and CC CC O
increase NN NN O
in IN IN O
blood NN NN B-CHEM
nitrogen NN NN I-CHEM
urea NN NN I-CHEM
, , , O
induced VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
injection NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
was VBD VBD O
markedly RB RB O
inhibited VBN VBN O
by IN IN O
oral JJ JJ O
administration NN NN O
of IN IN O
Dup NNP NNP B-CHEM
753 CD CD I-CHEM
( ( ( O
losartan NN NN B-CHEM
) ) ) O
, , , O
a DT DT O
novel NN NN O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
antagonist NN NN O
, , , O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
1 CD CD O
or CC CC O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
a DT DT O
possible JJ JJ O
involvement NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside IN IN I-CHEM
- - - O
induced JJ JJ O
nephrosis NN NN O
. . . O

Neuroplasticity NNP NNP O
of IN IN O
the DT DT O
adult NN NN O
primate NN NN O
auditory NN NN O
cortex NN NN O
following VBG VBG O
cochlear NN NN O
hearing NN NN O
loss NN NN O
. . . O

Tonotopic NNP NNP O
organization NN NN O
is VBZ VBZ O
an DT DT O
essential JJ JJ O
feature NN NN O
of IN IN O
the DT DT O
primary JJ JJ O
auditory NN NN O
area NN NN O
( ( ( O
A1 NNP NNP O
) ) ) O
of IN IN O
primate NN NN O
cortex NN NN O
. . . O

In IN IN O
A1 NNP NNP O
of IN IN O
macaque NN NN O
monkeys NNS NNS O
, , , O
low JJ JJ O
frequencies NNS NNS O
are VBP VBP O
represented VBN VBN O
rostrolaterally RB RB O
and CC CC O
high JJ JJ O
frequencies NNS NNS O
are VBP VBP O
represented VBN VBN O
caudomedially RB RB O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
if IN IN O
changes NNS NNS O
occur VBP VBP O
in IN IN O
this DT DT O
tonotopic JJ JJ O
organization NN NN O
following VBG VBG O
cochlear NN NN O
hearing NN NN O
loss NN NN O
. . . O

Under IN IN O
anesthesia NN NN O
, , , O
the DT DT O
superior JJ JJ O
temporal NN NN O
gyrus NN NN O
of IN IN O
adult NN NN O
macaque NN NN O
monkeys NNS NNS O
was VBD VBD O
exposed VBN VBN O
, , , O
and CC CC O
the DT DT O
tonotopic JJ JJ O
organization NN NN O
of IN IN O
A1 NNP NNP O
was VBD VBD O
mapped VBN VBN O
using VBG VBG O
conventional JJ JJ O
microelectrode NN NN O
recording NN NN O
techniques NNS NNS O
. . . O

Following VBG VBG O
recovery NN NN O
, , , O
the DT DT O
monkeys NNS NNS O
were VBD VBD O
selectively RB RB O
deafened VBN VBN O
for IN IN O
high JJ JJ O
frequencies NNS NNS O
using VBG VBG O
kanamycin NN NN B-CHEM
and CC CC O
furosemide NN NN B-CHEM
. . . O

The DT DT O
actual JJ JJ O
frequencies NNS NNS O
deafened VBD VBD O
were VBD VBD O
determined VBN VBN O
by IN IN O
the DT DT O
loss NN NN O
of IN IN O
tone NN NN O
- - - O
burst NN NN O
elicited JJ JJ O
auditory NN NN O
brainstem NN NN O
responses NNS NNS O
. . . O

Three CD CD O
months NNS NNS O
after IN IN O
deafening VBG VBG O
, , , O
A1 NNP NNP O
was VBD VBD O
remapped VBN VBN O
. . . O

Postmortem NNP NNP O
cytoarchitectural JJ JJ O
features NNS NNS O
identifying VBG VBG O
A1 NNP NNP O
were VBD VBD O
correlated VBN VBN O
with IN IN O
the DT DT O
electrophysiologic JJ JJ O
data NNS NNS O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
deprived JJ JJ O
area NN NN O
of IN IN O
A1 NNP NNP O
undergoes NNS NNS O
extensive JJ JJ O
reorganization NN NN O
and CC CC O
becomes VBZ VBZ O
responsive JJ JJ O
to TO TO O
intact VB VB O
cochlear JJ JJ O
frequencies NNS NNS O
. . . O

The DT DT O
region NN NN O
of IN IN O
cortex NN NN O
that WDT WDT O
represents VBZ VBZ O
the DT DT O
low JJ JJ O
frequencies NNS NNS O
was VBD VBD O
not RB RB O
obviously RB RB O
affected VBN VBN O
by IN IN O
the DT DT O
cochlear NN NN O
hearing NN NN O
loss NN NN O
. . . O

Sodium NNP NNP B-CHEM
bicarbonate NN NN I-CHEM
alleviates NNS NNS O
penile VBP VBP O
pain NN NN O
induced VBN VBN O
by IN IN O
intracavernous JJ JJ O
injections NNS NNS O
for IN IN O
erectile NN NN O
dysfunction NN NN O
. . . O

In IN IN O
an DT DT O
attempt NN NN O
to TO TO O
determine VB VB O
whether IN IN O
penile JJ JJ O
pain NN NN O
associated VBN VBN O
with IN IN O
intracorporeal JJ JJ O
injections NNS NNS O
could MD MD O
be VB VB O
due JJ JJ O
to TO TO O
the DT DT O
acidity NN NN O
of IN IN O
the DT DT O
medication NN NN O
, , , O
we PRP PRP O
performed VBD VBD O
a DT DT O
randomized JJ JJ O
study NN NN O
comparing VBG VBG O
the DT DT O
incidence NN NN O
of IN IN O
penile NN NN O
pain NN NN O
following VBG VBG O
intracorporeal NN NN O
injections NNS NNS O
with IN IN O
or CC CC O
without IN IN O
the DT DT O
addition NN NN O
of IN IN O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
to TO TO O
the DT DT O
intracorporeal NN NN O
medications NNS NNS O
. . . O

A DT DT O
total NN NN O
of IN IN O
38 CD CD O
consecutive JJ JJ O
patients NNS NNS O
who WP WP O
presented VBD VBD O
to TO TO O
our PRP$ PRP$ O
clinic NN NN O
with IN IN O
impotence NN NN O
received VBD VBD O
0 CD CD O
. . . O
2 CD CD O
ml NN NN O
. . . O
of IN IN O
a DT DT O
combination NN NN O
of IN IN O
3 CD CD O
drugs NNS NNS O
: : : O
6 CD CD O
mg NN NN O
. . . O
papaverine NN NN B-CHEM
, , , O
100 CD CD O
micrograms NNS NNS O
. . . O
phentolamine NN NN B-CHEM
and CC CC O
10 CD CD O
micrograms NNS NNS O
. . . O
prostaglandin NN NN B-CHEM
E1 NNP NNP I-CHEM
with IN IN O
( ( ( O
pH NN NN O
7 CD CD O
. . . O
05 CD CD O
) ) ) O
or CC CC O
without IN IN O
( ( ( O
pH NN NN O
4 CD CD O
. . . O
17 CD CD O
) ) ) O
the DT DT O
addition NN NN O
of IN IN O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
( ( ( O
0 CD CD O
. . . O
03 CD CD O
mEq NN NN O
. . . O
) ) ) O
. . . O

Of IN IN O
the DT DT O
19 CD CD O
patients NNS NNS O
without IN IN O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
added VBD VBD O
to TO TO O
the DT DT O
medication NN NN O
11 CD CD O
( ( ( O
58 CD CD O
% NN NN O
) ) ) O
complained VBD VBD O
of IN IN O
penile NN NN O
pain NN NN O
due JJ JJ O
to TO TO O
the DT DT O
medication NN NN O
, , , O
while IN IN O
only RB RB O
1 CD CD O
of IN IN O
the DT DT O
19 CD CD O
men NNS NNS O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
who WP WP O
received VBD VBD O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
complained VBD VBD O
of IN IN O
penile NN NN O
pain NN NN O
. . . O

From IN IN O
these DT DT O
data NNS NNS O
we PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
penile NN NN O
pain NN NN O
following VBG VBG O
intracorporeal NN NN O
injections NNS NNS O
is VBZ VBZ O
most RBS RBS O
likely JJ JJ O
due JJ JJ O
to TO TO O
the DT DT O
acidity NN NN O
of IN IN O
the DT DT O
medication NN NN O
, , , O
which WDT WDT O
can MD MD O
be VB VB O
overcome VBN VBN O
by IN IN O
elevating VBG VBG O
the DT DT O
pH NN NN O
to TO TO O
a DT DT O
neutral JJ JJ O
level NN NN O
. . . O

The DT DT O
use NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
didanosine NN NN B-CHEM
( ( ( O
ddI NN NN B-CHEM
) ) ) O
in IN IN O
HIV NNP NNP O
antibody NN NN O
- - - O
positive JJ JJ O
individuals NNS NNS O
intolerant NN NN O
to TO TO O
zidovudine NN NN B-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O

One CD CD O
hundred CD CD O
and CC CC O
fifty NN NN O
- : : O
one CD CD O
patients NNS NNS O
intolerant NN NN O
to TO TO O
zidovudine NN NN B-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O
received VBD VBD O
didanosine NN NN B-CHEM
( ( ( O
ddI NN NN B-CHEM
) ) ) O
to TO TO O
a DT DT O
maximum NN NN O
dose NN NN O
of IN IN O
12 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
. . . O

Patient NNP NNP O
response NN NN O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
changes NNS NNS O
in IN IN O
CD4 NNP NNP O
+ NN NN O
lymphocyte NN NN O
subset NN NN O
count NN NN O
, , , O
HIV NNP NNP O
p24 NN NN O
antigen NN NN O
, , , O
weight NN NN O
, , , O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
. . . O

Seventy NNP NNP O
patients NNS NNS O
developed VBN VBN O
major JJ JJ O
opportunistic JJ JJ O
infections NNS NNS O
whilst VBP VBP O
on IN IN O
therapy NN NN O
; : : O
this DT DT O
was VBD VBD O
the DT DT O
first JJ JJ O
AIDS NNP NNP O
diagnosis NN NN O
in IN IN O
17 CD CD O
. . . O

Only RB RB O
minor JJ JJ O
changes NNS NNS O
in IN IN O
CD4 NNP NNP O
+ NN NN O
lymphocyte NN NN O
subset NN NN O
count NN NN O
were VBD VBD O
observed VBN VBN O
in IN IN O
AIDS NNP NNP O
patients NNS NNS O
, , , O
although IN IN O
a DT DT O
more RBR RBR O
significant JJ JJ O
rise NN NN O
occurred VBD VBD O
in IN IN O
those DT DT O
with IN IN O
earlier JJR JJR O
stages NNS NNS O
of IN IN O
disease NN NN O
. . . O

Of IN IN O
those DT DT O
positive JJ JJ O
for IN IN O
p24 NN NN O
antigen NN NN O
at IN IN O
the DT DT O
commencement NN NN O
of IN IN O
the DT DT O
study NN NN O
67 CD CD O
% NN NN O
showed VBD VBD O
a DT DT O
positive JJ JJ O
response NN NN O
, , , O
and CC CC O
this DT DT O
was VBD VBD O
most RBS RBS O
likely JJ JJ O
in IN IN O
those DT DT O
with IN IN O
CD4 NNP NNP O
+ NN NN O
lymphocyte NN NN O
subset NN NN O
counts NNS NNS O
above IN IN O
100 CD CD O
mm3 NN NN O
. . . O

A DT DT O
positive JJ JJ O
weight NN NN O
response NN NN O
was VBD VBD O
seen VBN VBN O
in IN IN O
16 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Most JJS JJS O
patients NNS NNS O
showed VBD VBD O
improvement NN NN O
in IN IN O
individual JJ JJ O
parameters NNS NNS O
and CC CC O
global JJ JJ O
score NN NN O
of IN IN O
quality NN NN O
of IN IN O
life NN NN O
. . . O

Adverse NNP NNP O
reactions NNS NNS O
possibly RB RB O
attributable JJ JJ O
to TO TO O
didanosine VB VB B-CHEM
were VBD VBD O
common JJ JJ O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
side NN NN O
- - - O
effect NN NN O
was VBD VBD O
diarrhoea NN NN O
, , , O
which WDT WDT O
resulted VBD VBD O
in IN IN O
cessation NN NN O
of IN IN O
therapy NN NN O
in IN IN O
19 CD CD O
individuals NNS NNS O
. . . O

Peripheral NNP NNP O
neuropathy NN NN O
occurred VBD VBD O
in IN IN O
12 CD CD O
patients NNS NNS O
and CC CC O
pancreatitis NNS NNS O
in IN IN O
six CD CD O
. . . O

Thirteen NNP NNP O
patients NNS NNS O
developed VBD VBD O
a DT DT O
raised JJ JJ O
serum NN NN O
amylase NN NN O
without IN IN O
abdominal JJ JJ O
pain NN NN O
. . . O

Seven CD CD O
patients NNS NNS O
developed VBN VBN O
glucose NN NN O
tolerance NN NN O
curves NNS NNS O
characteristic JJ JJ O
of IN IN O
diabetes NNS NNS O
but CC CC O
these DT DT O
were VBD VBD O
mild JJ JJ O
, , , O
did VBD VBD O
not RB RB O
require VB VB O
treatment NN NN O
and CC CC O
returned VBD VBD O
to TO TO O
normal JJ JJ O
on IN IN O
ceasing VBG VBG O
didanosine NN NN B-CHEM
. . . O

Immunohistochemical NNP NNP O
studies NNS NNS O
with IN IN O
antibodies NNS NNS O
to TO TO O
neurofilament NN NN O
proteins NNS NNS O
on IN IN O
axonal JJ JJ O
damage NN NN O
in IN IN O
experimental JJ JJ O
focal JJ JJ O
lesions NNS NNS O
in IN IN O
rat NN NN O
. . . O

Immunohistochemistry NNP NNP O
with IN IN O
monoclonal JJ JJ O
antibodies NNS NNS O
against IN IN O
neurofilament NN NN O
( ( ( O
NF NNP NNP O
) ) ) O
proteins NNS NNS O
of IN IN O
middle JJ JJ O
and CC CC O
high JJ JJ O
molecular JJ JJ O
weight NN NN O
class NN NN O
, , , O
NF NNP NNP O
- : : O
M NNP NNP O
and CC CC O
NF NNP NNP O
- : : O
H NNP NNP O
, , , O
was VBD VBD O
used VBN VBN O
to TO TO O
study VB VB O
axonal JJ JJ O
injury NN NN O
in IN IN O
the DT DT O
borderzone NN NN O
of IN IN O
focal JJ JJ O
lesions NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Focal NNP NNP O
injury NN NN O
in IN IN O
the DT DT O
cortex NN NN O
was VBD VBD O
produced VBN VBN O
by IN IN O
infusion NN NN O
of IN IN O
lactate NN NN B-CHEM
at IN IN O
acid NN NN O
pH NN NN O
or CC CC O
by IN IN O
stab NN NN O
caused VBN VBN O
by IN IN O
needle NN NN O
insertion NN NN O
. . . O

Infarcts NNP NNP O
in IN IN O
substantia NN NN O
nigra NN NN O
pars NNS NNS O
reticulata NN NN O
were VBD VBD O
evoked VBN VBN O
by IN IN O
prolonged JJ JJ O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
. . . O

Immunohistochemical NNP NNP O
staining VBG VBG O
for IN IN O
NFs NNP NNP O
showed VBD VBD O
characteristic JJ JJ O
terminal NN NN O
clubs NNS NNS O
of IN IN O
axons NNS NNS O
in IN IN O
the DT DT O
borderzone NN NN O
of IN IN O
lesions NNS NNS O
. . . O

Differences NNS NNS O
in IN IN O
the DT DT O
labelling VBG VBG O
pattern NN NN O
occurred VBD VBD O
with IN IN O
different JJ JJ O
antibodies NNS NNS O
which WDT WDT O
apparently RB RB O
depended VBN VBN O
on IN IN O
molecular JJ JJ O
weight NN NN O
class NN NN O
of IN IN O
NFs NNP NNP O
and CC CC O
phosphorylation NN NN O
state NN NN O
. . . O

These DT DT O
immunohistochemical JJ JJ O
changes NNS NNS O
of IN IN O
NFs NNP NNP O
can MD MD O
serve VB VB O
as IN IN O
a DT DT O
marker NN NN O
for IN IN O
axonal JJ JJ O
damage NN NN O
in IN IN O
various JJ JJ O
experimental JJ JJ O
traumatic JJ JJ O
or CC CC O
ischemic JJ JJ O
lesions NNS NNS O
. . . O

Pharmacokinetic NNP NNP O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
cimetidine NN NN B-CHEM
- - - O
associated VBN VBN O
mental JJ JJ O
confusion NN NN O
. . . O

15 CD CD O
cases NNS NNS O
of IN IN O
cimetidine NN NN B-CHEM
- - - O
associated VBN VBN O
mental JJ JJ O
confusion NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

In IN IN O
order NN NN O
that IN IN O
this DT DT O
syndrome NN NN O
might MD MD O
be VB VB O
investigated VBN VBN O
changes NNS NNS O
in IN IN O
mental JJ JJ O
status NN NN O
( ( ( O
M NNP NNP O
. . . O
S NNP NNP O
. . . O
) ) ) O
were VBD VBD O
correlated VBN VBN O
with IN IN O
serum NN NN O
concentrations NNS NNS O
and CC CC O
renal JJ JJ O
and CC CC O
hepatic JJ JJ O
function NN NN O
in IN IN O
36 CD CD O
patients NNS NNS O
, , , O
30 CD CD O
patients NNS NNS O
had VBD VBD O
no DT DT O
M NNP NNP O
. . . O
S NNP NNP O
. . . O
change NN NN O
on IN IN O
cimetidine NN NN B-CHEM
and CC CC O
6 CD CD O
had VBD VBD O
moderate JJ JJ O
to TO TO O
severe JJ JJ O
changes NNS NNS O
. . . O

These DT DT O
6 CD CD O
patients NNS NNS O
had VBD VBD O
both DT DT O
renal NN NN O
and CC CC O
liver NN NN O
dysfunction NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
as RB RB O
well RB RB O
as IN IN O
cimetidine NN NN B-CHEM
trough NN NN O
- : : O
concentrations NNS NNS O
of IN IN O
more JJR JJR O
than IN IN O
1 CD CD O
. . . O
25 CD CD O
microgram NN NN O
/ NN NN O
ml NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
severity NN NN O
of IN IN O
M NNP NNP O
. . . O
S NNP NNP O
. . . O
changes NNS NNS O
increased VBN VBN O
as IN IN O
trough JJ JJ O
- - - O
concentrations NNS NNS O
rose VBD VBD O
, , , O
5 CD CD O
patients NNS NNS O
had VBD VBD O
lumbar NN NN O
puncture NN NN O
. . . O

The DT DT O
cerebrospinal JJ JJ O
fluid NN NN O
: : : O
serum NN NN O
ratio NN NN O
of IN IN O
cimetidine NN NN B-CHEM
concentrations NNS NNS O
was VBD VBD O
0 CD CD O
. . . O
24 CD CD O
: : : O
1 CD CD O
and CC CC O
indicates VBZ VBZ O
that IN IN O
cimetidine NN NN B-CHEM
passes VBZ VBZ O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
; : : O
it PRP PRP O
also RB RB O
raises VBZ VBZ O
the DT DT O
possibility NN NN O
that DT DT O
M NNP NNP O
. . . O
S NNP NNP O
. . . O
changes NNS NNS O
are VBP VBP O
due JJ JJ O
to TO TO O
blockade VB VB O
of IN IN O
histamine NN NN B-CHEM
H2 NNP NNP O
- : : O
receptors NNS NNS O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Patients NNS NNS O
likely JJ JJ O
to TO TO O
have VB VB O
both DT DT O
raised VBN VBN O
trough IN IN O
- : : O
concentrations NNS NNS O
and CC CC O
mental JJ JJ O
confusion NN NN O
are VBP VBP O
those DT DT O
with IN IN O
both DT DT O
severe JJ JJ O
renal NN NN O
and CC CC O
hepatic JJ JJ O
dysfunction NN NN O
. . . O

They PRP PRP O
should MD MD O
be VB VB O
closely RB RB O
observed VBN VBN O
and CC CC O
should MD MD O
be VB VB O
given VBN VBN O
reduced JJ JJ O
doses NNS NNS O
of IN IN O
cimetidine NN NN B-CHEM
. . . O

Prospective JJ JJ O
study NN NN O
of IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
effects NNS NNS O
of IN IN O
somatostatin NN NN O
analog NN NN O
( ( ( O
octreotide NN NN B-CHEM
) ) ) O
on IN IN O
gallbladder NN NN O
function NN NN O
and CC CC O
gallstone NN NN O
formation NN NN O
in IN IN O
Chinese JJ JJ O
acromegalic JJ JJ O
patients NNS NNS O
. . . O

This DT DT O
article NN NN O
reports VBZ VBZ O
the DT DT O
changes NNS NNS O
in IN IN O
gallbladder NN NN O
function NN NN O
examined VBN VBN O
by IN IN O
ultrasonography NN NN O
in IN IN O
20 CD CD O
Chinese JJ JJ O
patients NNS NNS O
with IN IN O
active JJ JJ O
acromegaly NN NN O
treated VBN VBN O
with IN IN O
sc JJ JJ O
injection NN NN O
of IN IN O
the DT DT O
somatostatin NN NN O
analog NN NN O
octreotide NN NN B-CHEM
in IN IN O
dosages NNS NNS O
of IN IN O
300 CD CD O
- : : O
1500 CD CD O
micrograms NNS NNS O
/ NN NN O
day NN NN O
for IN IN O
a DT DT O
mean NN NN O
of IN IN O
24 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
. . . O
9 CD CD O
months NNS NNS O
. . . O

During IN IN O
treatment NN NN O
with IN IN O
octreotide NN NN B-CHEM
, , , O
17 CD CD O
patients NNS NNS O
developed VBN VBN O
sludge NN NN O
, , , O
10 CD CD O
had VBD VBD O
gallstones NNS NNS O
, , , O
and CC CC O
1 CD CD O
developed VBN VBN O
acute JJ JJ O
cholecystitis NNS NNS O
requiring VBG VBG O
surgery NN NN O
. . . O

In IN IN O
all DT DT O
of IN IN O
7 CD CD O
patients NNS NNS O
examined VBD VBD O
acutely RB RB O
, , , O
gallbladder NN NN O
contractility NN NN O
was VBD VBD O
inhibited VBN VBN O
after IN IN O
a DT DT O
single JJ JJ O
100 CD CD O
- : : O
micrograms NNS NNS O
injection NN NN O
. . . O

In IN IN O
8 CD CD O
patients NNS NNS O
followed VBD VBD O
for IN IN O
24 CD CD O
weeks NNS NNS O
, , , O
gallbladder NN NN O
contractility NN NN O
remained VBD VBD O
depressed VBN VBN O
throughout IN IN O
therapy NN NN O
. . . O

After IN IN O
withdrawal NN NN O
of IN IN O
octreotide NN NN B-CHEM
in IN IN O
10 CD CD O
patients NNS NNS O
without IN IN O
gallstones NNS NNS O
, , , O
8 CD CD O
patients NNS NNS O
assessed VBD VBD O
had VBD VBD O
return NN NN O
of IN IN O
normal JJ JJ O
gallbladder NN NN O
contractility NN NN O
within IN IN O
1 CD CD O
month NN NN O
. . . O

In IN IN O
8 CD CD O
of IN IN O
the DT DT O
remaining VBG VBG O
10 CD CD O
patients NNS NNS O
who WP WP O
developed VBD VBD O
gallstones NNS NNS O
during IN IN O
treatment NN NN O
, , , O
gallbladder NN NN O
contractility NN NN O
normalized JJ JJ O
in IN IN O
5 CD CD O
patients NNS NNS O
( ( ( O
3 CD CD O
of IN IN O
whom WP WP O
has VBZ VBZ O
disappearance NN NN O
of IN IN O
their PRP$ PRP$ O
stones NNS NNS O
within IN IN O
3 CD CD O
weeks NNS NNS O
) ) ) O
, , , O
and CC CC O
remained VBD VBD O
depressed VBN VBN O
in IN IN O
3 CD CD O
( ( ( O
2 CD CD O
of IN IN O
whom WP WP O
had VBD VBD O
stones NNS NNS O
present JJ JJ O
at IN IN O
6 CD CD O
months NNS NNS O
) ) ) O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
suppression NN NN O
of IN IN O
gallbladder NN NN O
contractility NN NN O
is VBZ VBZ O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
successive JJ JJ O
formation NN NN O
of IN IN O
bile NN NN O
sludge NN NN O
, , , O
gallstones NNS NNS O
, , , O
and CC CC O
cholecystitis NNS NNS O
during IN IN O
octreotide NN NN B-CHEM
therapy NN NN O
in IN IN O
Chinese JJ JJ O
acromegalic JJ JJ O
patients NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
therefore RB RB O
very RB RB O
important JJ JJ O
to TO TO O
follow VB VB O
the DT DT O
changes NNS NNS O
of IN IN O
gallbladder NN NN O
function NN NN O
during IN IN O
long JJ JJ O
- - - O
term NN NN O
octreotide NN NN B-CHEM
therapy NN NN O
of IN IN O
acromegalic JJ JJ O
patients NNS NNS O
. . . O

Increase VB VB O
of IN IN O
Parkinson NNP NNP O
disability NN NN O
after IN IN O
fluoxetine NN NN B-CHEM
medication NN NN O
. . . O

Depression NNP NNP O
is VBZ VBZ O
a DT DT O
major JJ JJ O
clinical JJ JJ O
feature NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
increased VBN VBN O
amount NN NN O
of IN IN O
motor NN NN O
disability NN NN O
in IN IN O
four CD CD O
patients NNS NNS O
with IN IN O
idiopathic JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
after IN IN O
exposure NN NN O
to TO TO O
the DT DT O
antidepressant NN NN B-CHEM
fluoxetine NN NN B-CHEM
. . . O

The DT DT O
possibility NN NN O
of IN IN O
a DT DT O
clinically RB RB O
relevant JJ JJ O
dopamine NN NN B-CHEM
- : : O
antagonistic JJ JJ O
capacity NN NN O
of IN IN O
fluoxetine NN NN B-CHEM
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patients NNS NNS O
must MD MD O
be VB VB O
considered VBN VBN O
. . . O

Sinus NNP NNP O
arrest NN NN O
associated VBN VBN O
with IN IN O
continuous JJ JJ O
- - - O
infusion NN NN O
cimetidine NN NN B-CHEM
. . . O

The DT DT O
administration NN NN O
of IN IN O
intermittent JJ JJ O
intravenous JJ JJ O
infusions NNS NNS O
of IN IN O
cimetidine NN NN B-CHEM
is VBZ VBZ O
infrequently RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
bradyarrhythmias NNS NNS O
. . . O

A DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
leukemia NN NN O
and CC CC O
no DT DT O
history NN NN O
of IN IN O
cardiac JJ JJ O
disease NN NN O
developed VBN VBN O
recurrent JJ JJ O
, , , O
brief JJ JJ O
episodes NNS NNS O
of IN IN O
apparent JJ JJ O
sinus NN NN O
arrest NN NN O
while IN IN O
receiving VBG VBG O
continuous JJ JJ O
- - - O
infusion NN NN O
cimetidine NN NN B-CHEM
50 CD CD O
mg NN NN O
/ NN NN O
hour NN NN O
. . . O

The DT DT O
arrhythmias NNS NNS O
were VBD VBD O
temporally RB RB O
related VBN VBN O
to TO TO O
cimetidine NN NN B-CHEM
administration NN NN O
, , , O
disappeared VBD VBD O
after IN IN O
dechallenge NN NN O
, , , O
and CC CC O
did VBD VBD O
not RB RB O
recur VB VB O
during IN IN O
ranitidine NN NN B-CHEM
treatment NN NN O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
sinus NN NN O
arrest NN NN O
associated VBN VBN O
with IN IN O
continuous JJ JJ O
- - - O
infusion NN NN O
cimetidine NN NN B-CHEM
. . . O

Phase NNP NNP O
II NNP NNP O
trial NN NN O
of IN IN O
vinorelbine NN NN B-CHEM
in IN IN O
metastatic JJ JJ O
squamous JJ JJ O
cell NN NN O
esophageal NN NN O
carcinoma NN NN O
. . . O

European JJ JJ O
Organization NNP NNP O
for IN IN O
Research NNP NNP O
and CC CC O
Treatment NN NN O
of IN IN O
Cancer NNP NNP O
Gastrointestinal NNP NNP O
Treat NNP NNP O
Cancer NNP NNP O
Cooperative NNP NNP O
Group NNP NNP O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
response NN NN O
rate NN NN O
and CC CC O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
vinorelbine NN NN B-CHEM
( ( ( O
VNB NNP NNP B-CHEM
) ) ) O
administered VBN VBN O
as IN IN O
a DT DT O
single JJ JJ O
agent NN NN O
in IN IN O
metastatic JJ JJ O
squamous JJ JJ O
cell NN NN O
esophageal NN NN O
carcinoma NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Forty CD CD O
- - - O
six CD CD O
eligible JJ JJ O
patients NNS NNS O
with IN IN O
measurable JJ JJ O
lesions NNS NNS O
were VBD VBD O
included VBN VBN O
and CC CC O
were VBD VBD O
stratified VBN VBN O
according VBG VBG O
to TO TO O
previous JJ JJ O
chemotherapy NN NN O
. . . O

Thirty NNP NNP O
patients NNS NNS O
without IN IN O
prior RB RB O
chemotherapy NN NN O
and CC CC O
16 CD CD O
pretreated VBN VBN O
with IN IN O
cisplatin NN NN B-CHEM
- - - O
based JJ JJ O
chemotherapy NN NN O
were VBD VBD O
assessable JJ JJ O
for IN IN O
toxicity NN NN O
and CC CC O
response NN NN O
. . . O

VNB NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
weekly RB RB O
as IN IN O
a DT DT O
25 CD CD O
- : : O
mg NN NN O
/ NN NN O
m2 NN NN O
short JJ JJ O
intravenous JJ JJ O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
infusion NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Six CD CD O
of IN IN O
30 CD CD O
patients NNS NNS O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
without IN IN O
prior RB RB O
chemotherapy NN NN O
achieved VBD VBD O
a DT DT O
partial JJ JJ O
response NN NN O
( ( ( O
PR NNP NNP O
) ) ) O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
, , , O
8 CD CD O
% NN NN O
to TO TO O
39 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
median JJ JJ O
duration NN NN O
of IN IN O
response NN NN O
was VBD VBD O
21 CD CD O
weeks NNS NNS O
( ( ( O
range NN NN O
, , , O
17 CD CD O
to TO TO O
28 CD CD O
) ) ) O
. . . O

One CD CD O
of IN IN O
16 CD CD O
patients NNS NNS O
( ( ( O
6 CD CD O
% NN NN O
) ) ) O
with IN IN O
prior RB RB O
chemotherapy NN NN O
had VBD VBD O
a DT DT O
complete JJ JJ O
response NN NN O
( ( ( O
CR NNP NNP O
) ) ) O
of IN IN O
31 CD CD O
weeks NNS NNS O
' POS POS O
duration NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
% NN NN O
to TO TO O
30 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
( ( ( O
World NNP NNP O
Health NNP NNP O
Organization NNP NNP O
[ NN NN O
WHO WP WP O
] NN NN O
criteria NNS NNS O
) ) ) O
was VBD VBD O
15 CD CD O
% NN NN O
( ( ( O
CR NNP NNP O
, , , O
2 CD CD O
% NN NN O
; : : O
PR NNP NNP O
13 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
6 CD CD O
% NN NN O
to TO TO O
29 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
median NN NN O
dose NN NN O
- : : O
intensity NN NN O
( ( ( O
DI NNP NNP O
) ) ) O
was VBD VBD O
20 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
wk NN NN O
. . . O

VNB NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
and CC CC O
zero CD CD O
instances NNS NNS O
of IN IN O
WHO WP WP O
grade NN NN O
4 CD CD O
nonhematologic JJ JJ O
toxicity NN NN O
occurred VBD VBD O
. . . O

At IN IN O
least JJS JJS O
one CD CD O
episode NN NN O
of IN IN O
grade NN NN O
3 CD CD O
or CC CC O
4 CD CD O
granulocytopenia NN NN O
was VBD VBD O
seen VBN VBN O
in IN IN O
59 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

A DT DT O
grade NN NN O
2 CD CD O
or CC CC O
3 CD CD O
infection NN NN O
occurred VBD VBD O
in IN IN O
16 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
but CC CC O
no DT DT O
toxic JJ JJ O
deaths NNS NNS O
occurred VBD VBD O
. . . O

Other JJ JJ O
side NN NN O
effects NNS NNS O
were VBD VBD O
rare JJ JJ O
, , , O
and CC CC O
peripheral JJ JJ O
neurotoxicity NN NN O
has VBZ VBZ O
been VBN VBN O
minor JJ JJ O
( ( ( O
26 CD CD O
% NN NN O
grade NN NN O
1 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
VNB NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
active JJ JJ O
agent NN NN O
in IN IN O
metastatic JJ JJ O
esophageal NN NN O
squamous JJ JJ O
cell NN NN O
carcinoma NN NN O
. . . O

Given VBN VBN O
its PRP$ PRP$ O
excellent JJ JJ O
tolerance NN NN O
profile NN NN O
and CC CC O
low JJ JJ O
toxicity NN NN O
, , , O
further JJ JJ O
evaluation NN NN O
of IN IN O
VNB NNP NNP B-CHEM
in IN IN O
combination NN NN O
therapy NN NN O
is VBZ VBZ O
warranted VBN VBN O
. . . O

Evaluation NNP NNP O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
of IN IN O
aponidine NN NN B-CHEM
hydrochloride NN NN I-CHEM
ophthalmic JJ JJ O
solution NN NN O
. . . O

We PRP PRP O
prospectively RB RB O
evaluated VBD VBD O
the DT DT O
adverse JJ JJ O
reactions NNS NNS O
of IN IN O
apraclonidine NN NN B-CHEM
in IN IN O
20 CD CD O
normal JJ JJ O
volunteers NNS NNS O
by IN IN O
instilling VBG VBG O
a DT DT O
single JJ JJ O
drop NN NN O
of IN IN O
1 CD CD O
% NN NN O
apraclonidine NN NN B-CHEM
in IN IN O
their PRP$ PRP$ O
right JJ JJ O
eyes NNS NNS O
. . . O

Examinations NNP NNP O
, , , O
including VBG VBG O
blood NN NN O
pressure NN NN O
, , , O
pulse NN NN O
rate NN NN O
, , , O
conjunctiva NN NN O
and CC CC O
cornea NN NN O
, , , O
intraocular JJ JJ O
pressure NN NN O
( ( ( O
IOP NNP NNP O
) ) ) O
, , , O
pupil NN NN O
diameter NN NN O
, , , O
basal NN NN O
tear VB VB O
secretion NN NN O
and CC CC O
margin NN NN O
reflex JJ JJ O
distance NN NN O
of IN IN O
both DT DT O
upper JJ JJ O
and CC CC O
lower JJR JJR O
eyelids NNS NNS O
, , , O
were VBD VBD O
performed VBN VBN O
prior RB RB O
to TO TO O
entry NN NN O
and CC CC O
at IN IN O
1 CD CD O
, , , O
3 CD CD O
, , , O
5 CD CD O
and CC CC O
7 CD CD O
hours NNS NNS O
after IN IN O
instillation NN NN O
. . . O

The DT DT O
ocular NN NN O
hypotensive JJ JJ O
effects NNS NNS O
were VBD VBD O
statistically RB RB O
significant JJ JJ O
for IN IN O
apraclonidine NN NN B-CHEM
- - - O
treated VBN VBN O
eyes NNS NNS O
throughout IN IN O
the DT DT O
study NN NN O
and CC CC O
also RB RB O
statistically RB RB O
significant JJ JJ O
for IN IN O
contralateral JJ JJ O
eyes NNS NNS O
from IN IN O
three CD CD O
hours NNS NNS O
after IN IN O
topical JJ JJ O
administration NN NN O
of IN IN O
1 CD CD O
% NN NN O
apraclonidine NN NN B-CHEM
. . . O

Decreases NNP NNP O
in IN IN O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
were VBD VBD O
statistically RB RB O
, , , O
but CC CC O
not RB RB O
clinically RB RB O
, , , O
significant JJ JJ O
. . . O

No DT DT O
significant JJ JJ O
changes NNS NNS O
in IN IN O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
, , , O
pulse NN NN O
rate NN NN O
and CC CC O
basal NN NN O
tear VB VB O
secretion NN NN O
were VBD VBD O
noted VBN VBN O
. . . O

Conjunctival NNP NNP O
blanching VBG VBG O
and CC CC O
mydriasis NNS NNS O
were VBD VBD O
commonly RB RB O
found VBN VBN O
. . . O

Upper NNP NNP O
lid JJ JJ O
retraction NN NN O
was VBD VBD O
frequently RB RB O
noted VBN VBN O
. . . O

While IN IN O
the DT DT O
elevations NNS NNS O
of IN IN O
the DT DT O
upper JJ JJ O
lid NN NN O
margin NN NN O
in IN IN O
most JJS JJS O
subjects NNS NNS O
were VBD VBD O
not RB RB O
more JJR JJR O
than IN IN O
2 CD CD O
mm NN NN O
and CC CC O
did VBD VBD O
not RB RB O
cause VB VB O
noticeable JJ JJ O
change NN NN O
in IN IN O
appearance NN NN O
, , , O
one CD CD O
subject JJ JJ O
suffered VBN VBN O
from IN IN O
mechanical JJ JJ O
entropion NN NN O
and CC CC O
marked VBD VBD O
corneal JJ JJ O
abrasion NN NN O
3 CD CD O
hours NNS NNS O
after IN IN O
instillation NN NN O
of IN IN O
the DT DT O
medication NN NN O
. . . O

This DT DT O
may MD MD O
well RB RB O
be VB VB O
a DT DT O
particularly RB RB O
notable JJ JJ O
finding VBG VBG O
in IN IN O
Asian JJ JJ O
people NNS NNS O
. . . O

Thiopentone NNP NNP B-CHEM
pretreatment NN NN O
for IN IN O
propofol NN NN B-CHEM
injection NN NN O
pain NN NN O
in IN IN O
ambulatory NN NN O
patients NNS NNS O
. . . O

This DT DT O
study NN NN O
investigated VBD VBD O
propofol NN NN B-CHEM
injection NN NN O
pain NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
ambulatory NN NN O
anaesthesia NN NN O
. . . O

In IN IN O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
, , , O
90 CD CD O
women NNS NNS O
were VBD VBD O
allocated VBN VBN O
to TO TO O
receive VB VB O
one CD CD O
of IN IN O
three CD CD O
treatments NNS NNS O
prior RB RB O
to TO TO O
induction NN NN O
of IN IN O
anaesthesia NN NN O
with IN IN O
propofol NN NN B-CHEM
. . . O

Patients NNS NNS O
in IN IN O
Group NNP NNP O
C NNP NNP O
received VBD VBD O
2 CD CD O
ml NN NN O
normal JJ JJ O
saline NN NN O
, , , O
Group NNP NNP O
L NNP NNP O
, , , O
2 CD CD O
ml NN NN O
, , , O
lidocaine NN NN B-CHEM
2 CD CD O
% NN NN O
( ( ( O
40 CD CD O
mg NN NN O
) ) ) O
and CC CC O
Group NNP NNP O
T NN NN O
, , , O
2 CD CD O
ml NN NN O
thiopentone NN NN B-CHEM
2 CD CD O
. . . O
5 CD CD O
% NN NN O
( ( ( O
50 CD CD O
mg NN NN O
) ) ) O
. . . O

Venous NNP NNP O
discomfort NN NN O
was VBD VBD O
assessed VBN VBN O
with IN IN O
a DT DT O
visual JJ JJ O
analogue NN NN O
scale NN NN O
( ( ( O
VAS NNP NNP O
) ) ) O
5 CD CD O
- : : O
15 CD CD O
sec NN NN O
after IN IN O
commencing VBG VBG O
propofol NN NN B-CHEM
administration NN NN O
using VBG VBG O
an DT DT O
infusion NN NN O
pump NN NN O
( ( ( O
rate NN NN O
1000 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
) ) ) O
. . . O

Loss NN NN O
of IN IN O
consciousness NN NN O
occurred VBD VBD O
in IN IN O
60 CD CD O
- : : O
90 CD CD O
sec NN NN O
. . . O

Visual NNP NNP O
analogue NN NN O
scores NNS NNS O
( ( ( O
mean VB VB O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
during IN IN O
induction NN NN O
were VBD VBD O
lower JJR JJR O
in IN IN O
Groups NNS NNS O
L NNP NNP O
( ( ( O
3 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
5 CD CD O
) ) ) O
and CC CC O
T NN NN O
( ( ( O
4 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
7 CD CD O
) ) ) O
than IN IN O
in IN IN O
Group NNP NNP O
C NNP NNP O
( ( ( O
5 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
3 CD CD O
) ) ) O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
0031 CD CD O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
venous JJ JJ O
discomfort NN NN O
was VBD VBD O
lower JJR JJR O
in IN IN O
Group NNP NNP O
L NNP NNP O
( ( ( O
76 CD CD O
. . . O
6 CD CD O
% NN NN O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
than IN IN O
in IN IN O
Group NNP NNP O
C NNP NNP O
( ( ( O
100 CD CD O
% NN NN O
) ) ) O
but CC CC O
not RB RB O
different JJ JJ O
from IN IN O
Group NNP NNP O
T NN NN O
( ( ( O
90 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
VAS NNP NNP O
scores NNS NNS O
for IN IN O
recall NN NN O
of IN IN O
pain NN NN O
in IN IN O
the DT DT O
recovery NN NN O
room NN NN O
were VBD VBD O
correlated VBN VBN O
with IN IN O
the DT DT O
VAS NNP NNP O
scores NNS NNS O
during IN IN O
induction NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
7045 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

Recovery NNP NNP O
room NN NN O
discharge NN NN O
times NNS NNS O
were VBD VBD O
similar JJ JJ O
: : : O
C NNP NNP O
( ( ( O
75 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
19 CD CD O
. . . O
4 CD CD O
min NN NN O
) ) ) O
; : : O
L NNP NNP O
73 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
21 CD CD O
. . . O
6 CD CD O
min NN NN O
) ) ) O
; : : O
T NN NN O
( ( ( O
77 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
18 CD CD O
. . . O
9 CD CD O
min NN NN O
) ) ) O
. . . O

Assessing VBG VBG O
their PRP$ PRP$ O
overall JJ JJ O
satisfaction NN NN O
, , , O
89 CD CD O
. . . O
7 CD CD O
% NN NN O
would MD MD O
choose VB VB O
propofol NN NN B-CHEM
anaesthesia NN NN O
again RB RB O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
lidocaine NN NN B-CHEM
reduces VBZ VBZ O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
propofol NN NN B-CHEM
injection NN NN O
pain NN NN O
in IN IN O
ambulatory NN NN O
patients NNS NNS O
whereas IN IN O
thiopentone NN NN B-CHEM
only RB RB O
reduces VBZ VBZ O
its PRP$ PRP$ O
severity NN NN O
. . . O

Persistent NNP NNP O
paralysis NN NN O
after IN IN O
prolonged JJ JJ O
use NN NN O
of IN IN O
atracurium NN NN B-CHEM
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
corticosteroids NNS NNS O
. . . O

Neuromuscular NNP NNP O
blocking VBG VBG O
agents NNS NNS O
( ( ( O
NMBAs NNP NNP O
) ) ) O
are VBP VBP O
often RB RB O
used VBN VBN O
for IN IN O
patients NNS NNS O
requiring VBG VBG O
prolonged JJ JJ O
mechanical JJ JJ O
ventilation NN NN O
. . . O

Reports NNS NNS O
of IN IN O
persistent JJ JJ O
paralysis NN NN O
after IN IN O
the DT DT O
discontinuance NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
have VBP VBP O
most RBS RBS O
often RB RB O
involved VBN VBN O
aminosteroid NN NN O
- - - O
based JJ JJ O
NMBAs NNP NNP O
such JJ JJ O
as IN IN O
vecuronium NN NN B-CHEM
bromide NN NN I-CHEM
, , , O
especially RB RB O
when WRB WRB O
used VBN VBN O
in IN IN O
conjunction NN NN O
with IN IN O
corticosteroids NNS NNS O
. . . O

Atracurium NNP NNP B-CHEM
besylate NN NN I-CHEM
, , , O
a DT DT O
short JJ JJ O
- - - O
acting VBG VBG O
benzylisoquinolinium NN NN B-CHEM
NMBA NNP NNP O
that WDT WDT O
is VBZ VBZ O
eliminated VBN VBN O
independently RB RB O
of IN IN O
renal JJ JJ O
or CC CC O
hepatic JJ JJ O
function NN NN O
, , , O
has VBZ VBZ O
also RB RB O
been VBN VBN O
associated VBN VBN O
with IN IN O
persistent JJ JJ O
paralysis NN NN O
, , , O
but CC CC O
only RB RB O
when WRB WRB O
used VBN VBN O
with IN IN O
corticosteroids NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
atracurium NN NN B-CHEM
- - - O
related VBN VBN O
paralysis NN NN O
persisting NN NN O
for IN IN O
approximately RB RB O
50 CD CD O
hours NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
who WP WP O
was VBD VBD O
not RB RB O
treated VBN VBN O
with IN IN O
corticosteroids NNS NNS O
. . . O

A DT DT O
phase NN NN O
I PRP PRP O
/ NN NN O
II NNP NNP O
study NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
plus CC CC O
cisplatin NN NN B-CHEM
as IN IN O
first JJ JJ O
- - - O
line NN NN O
therapy NN NN O
for IN IN O
head NN NN O
and CC CC O
neck NN NN O
cancers NNS NNS O
: : : O
preliminary JJ JJ O
results NNS NNS O
. . . O

Improved NNP NNP O
outcomes NNS NNS O
among IN IN O
patients NNS NNS O
with IN IN O
head NN NN O
and CC CC O
neck NN NN O
carcinomas NN NN O
require NN NN O
investigations NNS NNS O
of IN IN O
new JJ JJ O
drugs NNS NNS O
for IN IN O
induction NN NN O
therapy NN NN O
. . . O

Preliminary JJ JJ O
results NNS NNS O
of IN IN O
an DT DT O
Eastern NNP NNP O
Cooperative NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
study NN NN O
of IN IN O
single JJ JJ O
- - - O
agent NN NN O
paclitaxel NN NN B-CHEM
( ( ( O
Taxol NNP NNP B-CHEM
; : : O
Bristol NNP NNP O
- : : O
Myers NNP NNP O
Squibb NNP NNP O
Company NNP NNP O
, , , O
Princeton NNP NNP O
, , , O
NJ NNP NNP O
) ) ) O
reported VBD VBD O
a DT DT O
37 CD CD O
% NN NN O
response NN NN O
rate NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
head NN NN O
and CC CC O
neck NN NN O
cancer NN NN O
, , , O
and CC CC O
the DT DT O
paclitaxel NN NN B-CHEM
/ NN NN O
cisplatin NN NN B-CHEM
combination NN NN O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
successfully RB RB O
and CC CC O
has VBZ VBZ O
significantly RB RB O
improved VBN VBN O
median JJ JJ O
response NN NN O
duration NN NN O
in IN IN O
ovarian JJ JJ O
cancer NN NN O
patients NNS NNS O
. . . O

We PRP PRP O
initiated VBD VBD O
a DT DT O
phase NN NN O
I PRP PRP O
/ NN NN O
II NNP NNP O
trial NN NN O
to TO TO O
determine VB VB O
the DT DT O
response NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
escalating VBG VBG O
paclitaxel NN NN B-CHEM
doses NNS NNS O
combined VBN VBN O
with IN IN O
fixed JJ JJ O
- - - O
dose NN NN O
cisplatin NN NN B-CHEM
with IN IN O
granulocyte NN NN O
colony NN NN O
- : : O
stimulating VBG VBG O
factor NN NN O
support NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
untreated JJ JJ O
locally RB RB O
advanced VBD VBD O
inoperable JJ JJ O
head NN NN O
and CC CC O
neck NN NN O
carcinoma NN NN O
. . . O

To TO TO O
date NN NN O
, , , O
23 CD CD O
men NNS NNS O
with IN IN O
a DT DT O
median JJ JJ O
age NN NN O
of IN IN O
50 CD CD O
years NNS NNS O
and CC CC O
good JJ JJ O
performance NN NN O
status NN NN O
have VBP VBP O
entered VBN VBN O
the DT DT O
trial NN NN O
. . . O

Primary JJ JJ O
tumor NN NN O
sites NNS NNS O
were VBD VBD O
oropharynx NN NN O
, , , O
10 CD CD O
patients NNS NNS O
; : : O
hypopharynx NN NN O
, , , O
four CD CD O
; : : O
larynx NN NN O
, , , O
two CD CD O
; : : O
oral JJ JJ O
cavity NN NN O
, , , O
three CD CD O
; : : O
unknown JJ JJ O
primary JJ JJ O
, , , O
two CD CD O
; : : O
and CC CC O
nasal JJ JJ O
cavity NN NN O
and CC CC O
parotid NN NN O
gland NN NN O
, , , O
one CD CD O
each DT DT O
. . . O

Of IN IN O
20 CD CD O
patients NNS NNS O
evaluable JJ JJ O
for IN IN O
toxicity NN NN O
, , , O
four CD CD O
had VBD VBD O
stage NN NN O
III NNP NNP O
and CC CC O
16 CD CD O
had VBD VBD O
stage NN NN O
IV NNP NNP O
disease NN NN O
. . . O

Treatment NN NN O
, , , O
given VBN VBN O
every DT DT O
21 CD CD O
days NNS NNS O
for IN IN O
a DT DT O
maximum NN NN O
of IN IN O
three CD CD O
cycles NNS NNS O
, , , O
consisted VBN VBN O
of IN IN O
paclitaxel NN NN B-CHEM
by IN IN O
3 CD CD O
- : : O
hour NN NN O
infusion NN NN O
followed VBD VBD O
the DT DT O
next JJ JJ O
day NN NN O
by IN IN O
a DT DT O
fixed JJ JJ O
dose NN NN O
of IN IN O
cisplatin NN NN B-CHEM
( ( ( O
75 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
. . . O

The DT DT O
dose NN NN O
levels NNS NNS O
incorporate JJ JJ O
escalating VBG VBG O
paclitaxel NN NN B-CHEM
doses NNS NNS O
, , , O
and CC CC O
intrapatient NN NN O
escalations NNS NNS O
within IN IN O
a DT DT O
given JJ JJ O
dose NN NN O
level NN NN O
are VBP VBP O
permitted VBN VBN O
if IN IN O
toxicity NN NN O
permits VBZ VBZ O
. . . O

At IN IN O
the DT DT O
time NN NN O
of IN IN O
this DT DT O
writing VBG VBG O
, , , O
dose NN NN O
level NN NN O
4 CD CD O
( ( ( O
260 CD CD O
, , , O
270 CD CD O
, , , O
and CC CC O
280 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
is VBZ VBZ O
being VBG VBG O
evaluated VBN VBN O
; : : O
three CD CD O
patients NNS NNS O
from IN IN O
this DT DT O
level NN NN O
are VBP VBP O
evaluable JJ JJ O
. . . O

With IN IN O
paclitaxel NN NN B-CHEM
doses NNS NNS O
of IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
and CC CC O
higher JJR JJR O
, , , O
granulocyte NN NN O
colony NN NN O
- : : O
stimulating VBG VBG O
factor NN NN O
5 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
d SYM SYM O
is VBZ VBZ O
given VBN VBN O
( ( ( O
days NNS NNS O
4 CD CD O
through IN IN O
12 CD CD O
) ) ) O
. . . O

Of IN IN O
18 CD CD O
patients NNS NNS O
evaluable JJ JJ O
for IN IN O
response NN NN O
, , , O
seven CD CD O
( ( ( O
39 CD CD O
% NN NN O
) ) ) O
achieved VBD VBD O
a DT DT O
complete JJ JJ O
response NN NN O
and CC CC O
six CD CD O
( ( ( O
33 CD CD O
% NN NN O
) ) ) O
achieved VBD VBD O
a DT DT O
partial JJ JJ O
response NN NN O
. . . O

Three CD CD O
patients NNS NNS O
had VBD VBD O
no DT DT O
change NN NN O
and CC CC O
disease NN NN O
progressed VBD VBD O
in IN IN O
two CD CD O
. . . O

The DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
is VBZ VBZ O
72 CD CD O
% NN NN O
. . . O

Eleven CD CD O
responding VBG VBG O
patients NNS NNS O
had VBD VBD O
subsequent JJ JJ O
surgery NN NN O
/ NN NN O
radiotherapy NN NN O
or CC CC O
radical JJ JJ O
radiotherapy NN NN O
. . . O

Two CD CD O
pathologic JJ JJ O
complete JJ JJ O
responses NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
had VBD VBD O
achieved VBN VBN O
clinical JJ JJ O
complete JJ JJ O
responses NNS NNS O
. . . O

Alopecia NNP NNP O
, , , O
paresthesias NN NN O
, , , O
and CC CC O
arthralgias NN NN O
/ NN NN O
myalgias NN NN O
have VBP VBP O
occurred VBN VBN O
frequently RB RB O
, , , O
but CC CC O
with IN IN O
one CD CD O
exception NN NN O
( ( ( O
a DT DT O
grade NN NN O
3 CD CD O
myalgia NN NN O
) ) ) O
they PRP PRP O
have VBP VBP O
been VBN VBN O
grade NN NN O
1 CD CD O
or CC CC O
2 CD CD O
. . . O

No DT DT O
dose NN NN O
- - - O
limiting VBG VBG O
hematologic JJ JJ O
toxicity NN NN O
has VBZ VBZ O
been VBN VBN O
seen VBN VBN O
. . . O

Paclitaxel NNP NNP B-CHEM
/ NN NN O
cisplatin NN NN B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
first JJ JJ O
- - - O
line NN NN O
regimen NNS NNS O
for IN IN O
locoregionally RB RB O
advanced VBN VBN O
head NN NN O
and CC CC O
neck NN NN O
cancer NN NN O
and CC CC O
continued VBD VBD O
study NN NN O
is VBZ VBZ O
warranted VBN VBN O
. . . O

Results NNS NNS O
thus RB RB O
far RB RB O
suggest VB VB O
no DT DT O
dose NN NN O
- - - O
response NN NN O
effect NN NN O
for IN IN O
paclitaxel NN NN B-CHEM
doses NNS NNS O
above IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

Improvement NNP NNP O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesia NN NN O
by IN IN O
propranolol NN NN B-CHEM
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Seven CD CD O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
with IN IN O
severely RB RB O
disabling VBG VBG O
dyskinesia NN NN O
received VBD VBD O
low JJ JJ O
- - - O
dose NN NN O
propranolol NN NN B-CHEM
as IN IN O
an DT DT O
adjunct NN NN O
to TO TO O
the DT DT O
currently RB RB O
used VBN VBN O
medical JJ JJ O
treatment NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
40 CD CD O
% NN NN O
improvement NN NN O
in IN IN O
the DT DT O
dyskinesia NN NN O
score NN NN O
without IN IN O
increase NN NN O
of IN IN O
parkinsonian NN NN O
motor NN NN O
disability NN NN O
. . . O

Ballistic NNP NNP O
and CC CC O
choreic NN NN O
dyskinesia NN NN O
were VBD VBD O
markedly RB RB O
ameliorated VBN VBN O
, , , O
whereas IN IN O
dystonia NN NN O
was VBD VBD O
not RB RB O
. . . O

This DT DT O
study NN NN O
suggests VBZ VBZ O
that DT DT O
administration NN NN O
of IN IN O
low JJ JJ O
doses NNS NNS O
of IN IN O
beta NN NN O
- - - O
blockers NNS NNS O
may MD MD O
improve VB VB O
levodopa NN NN B-CHEM
- : : O
induced JJ JJ O
ballistic JJ JJ O
and CC CC O
choreic JJ JJ O
dyskinesia NN NN O
in IN IN O
PD NNP NNP O
. . . O

Habitual NNP NNP O
use NN NN O
of IN IN O
acetaminophen NN NN B-CHEM
as IN IN O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
: : : O
a DT DT O
comparison NN NN O
with IN IN O
phenacetin NN NN B-CHEM
. . . O

Six CD CD O
epidemiologic JJ JJ O
studies NNS NNS O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
and CC CC O
Europe NNP NNP O
indicate VBP VBP O
that IN IN O
habitual JJ JJ O
use NN NN O
of IN IN O
phenacetin NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
and CC CC O
end NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
( ( ( O
ESRD NNP NNP O
) ) ) O
, , , O
with IN IN O
a DT DT O
relative JJ JJ O
risk NN NN O
in IN IN O
the DT DT O
range NN NN O
of IN IN O
4 CD CD O
to TO TO O
19 CD CD O
. . . O

As IN IN O
a DT DT O
result NN NN O
of IN IN O
these DT DT O
and CC CC O
other JJ JJ O
studies NNS NNS O
, , , O
phenacetin NN NN B-CHEM
has VBZ VBZ O
now RB RB O
been VBN VBN O
withdrawn VBN VBN O
from IN IN O
the DT DT O
market NN NN O
in IN IN O
most JJS JJS O
countries NNS NNS O
. . . O

However RB RB O
, , , O
three CD CD O
case NN NN O
control NN NN O
studies NNS NNS O
, , , O
one CD CD O
each DT DT O
in IN IN O
North NNP NNP O
Carolina NNP NNP O
, , , O
northern JJ JJ O
Maryland NNP NNP O
, , , O
and CC CC O
West NNP NNP O
Berlin NNP NNP O
, , , O
Germany NNP NNP O
, , , O
showed VBD VBD O
that IN IN O
habitual JJ JJ O
use NN NN O
of IN IN O
acetaminophen NN NN B-CHEM
is VBZ VBZ O
also RB RB O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
and CC CC O
ESRD NNP NNP O
, , , O
with IN IN O
a DT DT O
relative JJ JJ O
risk NN NN O
in IN IN O
the DT DT O
range NN NN O
of IN IN O
2 CD CD O
to TO TO O
4 CD CD O
. . . O

These DT DT O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
both DT DT O
phenacetin NN NN B-CHEM
and CC CC O
acetaminophen NN NN B-CHEM
may MD MD O
contribute VB VB O
to TO TO O
the DT DT O
burden NN NN O
of IN IN O
ESRD NNP NNP O
, , , O
with IN IN O
the DT DT O
risk NN NN O
of IN IN O
the DT DT O
latter JJ JJ O
being VBG VBG O
somewhat RB RB O
less JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
former JJ JJ O
. . . O

This DT DT O
apparent JJ JJ O
difference NN NN O
in IN IN O
risk NN NN O
may MD MD O
not RB RB O
be VB VB O
due JJ JJ O
to TO TO O
differences NNS NNS O
in IN IN O
nephrotoxic JJ JJ O
potential NN NN O
of IN IN O
the DT DT O
drugs NNS NNS O
themselves PRP PRP O
. . . O

A DT DT O
lower JJR JJR O
relative JJ JJ O
risk NN NN O
would MD MD O
be VB VB O
expected VBN VBN O
for IN IN O
acetaminophen NN NN B-CHEM
if IN IN O
the DT DT O
risk NN NN O
of IN IN O
both DT DT O
drugs NNS NNS O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
analgesics NNS NNS O
was VBD VBD O
higher JJR JJR O
than IN IN O
the DT DT O
risk NN NN O
of IN IN O
either DT DT O
agent NN NN O
alone RB RB O
. . . O

Thus RB RB O
, , , O
acetaminophen NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
both DT DT O
as IN IN O
a DT DT O
single JJ JJ O
agent NN NN O
and CC CC O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
analgesics NNS NNS O
, , , O
whereas IN IN O
phenacetin NN NN B-CHEM
was VBD VBD O
available JJ JJ O
only RB RB O
in IN IN O
combinations NNS NNS O
. . . O

The DT DT O
possibility NN NN O
that IN IN O
habitual JJ JJ O
use NN NN O
of IN IN O
acetaminophen NN NN B-CHEM
alone RB RB O
increases VBZ VBZ O
the DT DT O
risk NN NN O
of IN IN O
ESRD NNP NNP O
has VBZ VBZ O
not RB RB O
been VBN VBN O
clearly RB RB O
demonstrated VBN VBN O
, , , O
but CC CC O
cannot NN NN O
be VB VB O
dismissed VBN VBN O
. . . O

Acetaminophen NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

Through IN IN O
30 CD CD O
years NNS NNS O
of IN IN O
widespread JJ JJ O
use NN NN O
, , , O
acetaminophen NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
a DT DT O
remarkably RB RB O
safe JJ JJ O
medication NN NN O
in IN IN O
therapeutic JJ JJ O
dosages NNS NNS O
. . . O

The DT DT O
potential JJ JJ O
for IN IN O
acetaminophen NN NN B-CHEM
to TO TO O
produce VB VB O
cardiovascular JJ JJ O
toxicities NNS NNS O
is VBZ VBZ O
very RB RB O
low JJ JJ O
. . . O

However RB RB O
, , , O
acetaminophen NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
demonstrated VBN VBN O
to TO TO O
produce VB VB O
symptoms NNS NNS O
of IN IN O
anaphylaxis NNS NNS O
, , , O
including VBG VBG O
hypotension NN NN O
, , , O
in IN IN O
sensitive JJ JJ O
individuals NNS NNS O
. . . O

This DT DT O
article NN NN O
describes VBZ VBZ O
two CD CD O
critically RB RB O
ill JJ JJ O
patients NNS NNS O
in IN IN O
whom WP WP O
transient NN NN O
episodes NNS NNS O
of IN IN O
hypotension NN NN O
reproducibly RB RB O
developed VBN VBN O
after IN IN O
administration NN NN O
of IN IN O
acetaminophen NN NN B-CHEM
. . . O

Other JJ JJ O
symptoms NNS NNS O
of IN IN O
allergic JJ JJ O
reactions NNS NNS O
were VBD VBD O
not RB RB O
clinically RB RB O
detectable JJ JJ O
. . . O

The DT DT O
hypotensive JJ JJ O
episodes NNS NNS O
were VBD VBD O
severe JJ JJ O
enough RB RB O
to TO TO O
require VB VB O
vasopressor NN NN O
administration NN NN O
. . . O

The DT DT O
reports NNS NNS O
illustrate VBP VBP O
the DT DT O
need NN NN O
for IN IN O
clinicians NNS NNS O
to TO TO O
consider VB VB O
acetaminophen NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
hypotension NN NN O
of IN IN O
unknown JJ JJ O
origin NN NN O
. . . O

Reduction NNP NNP O
of IN IN O
heparan NN NN B-CHEM
sulphate NN NN I-CHEM
- - - O
associated VBN VBN O
anionic JJ JJ O
sites NNS NNS O
in IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
of IN IN O
rats NNS NNS O
with IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

Heparan NNP NNP B-CHEM
sulphate NN NN I-CHEM
- - - O
associated VBN VBN O
anionic JJ JJ O
sites NNS NNS O
in IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
rats NNS NNS O
8 CD CD O
months NNS NNS O
after IN IN O
induction NN NN O
of IN IN O
diabetes NNS NNS O
by IN IN O
streptozotocin NN NN B-CHEM
and CC CC O
in IN IN O
age NN NN O
- - - O
adn NN NN O
sex NN NN O
- : : O
matched JJ JJ O
control NN NN O
rats NNS NNS O
, , , O
employing VBG VBG O
the DT DT O
cationic JJ JJ O
dye NN NN O
cuprolinic JJ JJ B-CHEM
blue JJ JJ I-CHEM
. . . O

Morphometric NNP NNP O
analysis NN NN O
at IN IN O
the DT DT O
ultrastructural JJ JJ O
level NN NN O
was VBD VBD O
performed VBN VBN O
using VBG VBG O
a DT DT O
computerized JJ JJ O
image NN NN O
processor NN NN O
. . . O

The DT DT O
heparan NN NN B-CHEM
sulphate JJ JJ I-CHEM
specificity NN NN O
of IN IN O
the DT DT O
cuprolinic JJ JJ B-CHEM
blue JJ JJ I-CHEM
staining VBG VBG O
was VBD VBD O
demonstrated VBN VBN O
by IN IN O
glycosaminoglycan JJ JJ B-CHEM
- - - O
degrading VBG VBG O
enzymes NNS NNS O
, , , O
showing VBG VBG O
that IN IN O
pretreatment NN NN O
of IN IN O
the DT DT O
sections NNS NNS O
with IN IN O
heparitinase NN NN O
abolished VBD VBD O
all DT DT O
staining VBG VBG O
, , , O
whereas IN IN O
chondroitinase NN NN O
ABC NNP NNP O
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

The DT DT O
majority NN NN O
of IN IN O
anionic JJ JJ O
sites NNS NNS O
( ( ( O
74 CD CD O
% NN NN O
in IN IN O
diabetic JJ JJ O
and CC CC O
81 CD CD O
% NN NN O
in IN IN O
control NN NN O
rats NNS NNS O
) ) ) O
were VBD VBD O
found VBN VBN O
within IN IN O
the DT DT O
lamina NN NN O
rara NN NN O
externa NN NN O
of IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
. . . O

A DT DT O
minority NN NN O
of IN IN O
anionic JJ JJ O
sites NNS NNS O
were VBD VBD O
scattered VBN VBN O
throughout IN IN O
the DT DT O
lamina NN NN O
densa NN NN O
and CC CC O
lamina NN NN O
rara NN NN O
interna NN NN O
, , , O
and CC CC O
were VBD VBD O
significantly RB RB O
smaller JJR JJR O
than IN IN O
those DT DT O
in IN IN O
the DT DT O
lamina NN NN O
rara NN NN O
externa NN NN O
of IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
and CC CC O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
for IN IN O
diabetic JJ JJ O
and CC CC O
control NN NN O
rats NNS NNS O
, , , O
respectively RB RB O
) ) ) O
. . . O

Diabetic NNP NNP O
rats NNS NNS O
progressively RB RB O
developed VBN VBN O
albuminuria NN NN O
reaching VBG VBG O
40 CD CD O
. . . O
3 CD CD O
( ( ( O
32 CD CD O
. . . O
2 CD CD O
- : : O
62 CD CD O
. . . O
0 CD CD O
) ) ) O
mg NN NN O
/ NN NN O
24 CD CD O
h NN NN O
after IN IN O
8 CD CD O
months NNS NNS O
in IN IN O
contrast NN NN O
to TO TO O
the DT DT O
control NN NN O
animals NNS NNS O
( ( ( O
0 CD CD O
. . . O
8 CD CD O
( ( ( O
0 CD CD O
. . . O
2 CD CD O
- : : O
0 CD CD O
. . . O
9 CD CD O
) ) ) O
mg NN NN O
/ NN NN O
24 CD CD O
h NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

At IN IN O
the DT DT O
same JJ JJ O
time NN NN O
, , , O
the DT DT O
number NN NN O
of IN IN O
heparan NN NN B-CHEM
sulphate NN NN I-CHEM
anionic JJ JJ O
sites NNS NNS O
and CC CC O
the DT DT O
total JJ JJ O
anionic JJ JJ O
site NN NN O
surface NN NN O
( ( ( O
number NN NN O
of IN IN O
anionic JJ JJ O
sites NNS NNS O
x SYM SYM O
mean VB VB O
anionic JJ JJ O
site NN NN O
surface NN NN O
) ) ) O
in IN IN O
the DT DT O
lamina NN NN O
rara NN NN O
externa NN NN O
of IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
was VBD VBD O
reduced VBN VBN O
by IN IN O
19 CD CD O
% NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
021 CD CD O
) ) ) O
and CC CC O
by IN IN O
26 CD CD O
% NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
, , , O
respectively RB RB O
. . . O

Number NNP NNP O
and CC CC O
total JJ JJ O
anionic JJ JJ O
site NN NN O
surface NN NN O
in IN IN O
the DT DT O
remaining VBG VBG O
part NN NN O
of IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
( ( ( O
lamina NN NN O
densa NN NN O
and CC CC O
lamina NN NN O
rara NN NN O
interna NN NN O
) ) ) O
were VBD VBD O
not RB RB O
significantly RB RB O
changed VBD VBD O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
in IN IN O
streptozotocin NN NN B-CHEM
- - - O
diabetic JJ JJ O
rats NNS NNS O
with IN IN O
an DT DT O
increased JJ JJ O
urinary JJ JJ O
albumin NN NN O
excretion NN NN O
, , , O
a DT DT O
reduced JJ JJ O
heparan NN NN B-CHEM
sulphate NN NN I-CHEM
charge NN NN O
barrier NN NN O
/ NN NN O
density NN NN O
is VBZ VBZ O
found VBN VBN O
at IN IN O
the DT DT O
lamina NN NN O
rara NN NN O
externa NN NN O
of IN IN O
the DT DT O
glomerular NN NN O
basement NN NN O
membrane NN NN O
. . . O

Mediation NNP NNP O
of IN IN O
enhanced JJ JJ O
reflex NN NN O
vagal JJ JJ O
bradycardia NN NN O
by IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
via IN IN O
central JJ JJ O
dopamine NN NN B-CHEM
formation NN NN O
in IN IN O
dogs NNS NNS O
. . . O

L NNP NNP B-CHEM
- : : I-CHEM
Dopa NNP NNP I-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
decreased VBD VBD O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
after IN IN O
extracerebral JJ JJ O
decarboxylase NN NN O
inhibition NN NN O
with IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
486 CD CD I-CHEM
( ( ( O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
in IN IN O
anesthetize NN NN O
MAO NNP NNP B-CHEM
- - - O
inhibited JJ JJ O
dogs NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
reflex JJ JJ O
bradycardia NNS NNS O
caused VBN VBN O
by IN IN O
injected JJ JJ O
norepinephrine NN NN B-CHEM
was VBD VBD O
significantly RB RB O
enhanced VBN VBN O
by IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
, , , O
DL NNP NNP B-CHEM
- : : I-CHEM
Threo NNP NNP I-CHEM
- - - I-CHEM
dihydroxyphenylserine NN NN I-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
blood NN NN O
pressure NN NN O
, , , O
heart NN NN O
rate NN NN O
or CC CC O
reflex NN NN O
responses NNS NNS O
to TO TO O
norepinephrine NN NN B-CHEM
. . . O

FLA NNP NNP B-CHEM
- : : I-CHEM
63 CD CD I-CHEM
, , , O
a DT DT O
dopamine NN NN B-CHEM
- - - O
beta NN NN O
- - - O
oxidase NN NN O
inhibitor NN NN O
, , , O
did VBD VBD O
not RB RB O
have VB VB O
any DT DT O
effect NN NN O
on IN IN O
the DT DT O
hypotension NN NN O
, , , O
bradycardia NN NN O
or CC CC O
reflex JJ JJ O
- : : O
enhancing VBG VBG O
effect NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
dopa NN NN I-CHEM
. . . O

Pimozide NNP NNP B-CHEM
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
actions NNS NNS O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
dopa NN NN I-CHEM
on IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
but CC CC O
completely RB RB O
blocked VBN VBN O
the DT DT O
enhancement NN NN O
of IN IN O
reflexes NNS NNS O
. . . O

Removal NNP NNP O
of IN IN O
the DT DT O
carotid NN NN O
sinuses NNS NNS O
caused VBD VBD O
an DT DT O
elevation NN NN O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
and CC CC O
abolished VBD VBD O
the DT DT O
negative JJ JJ O
chronotropic JJ JJ O
effect NN NN O
of IN IN O
norepinephrine NN NN B-CHEM
. . . O

However RB RB O
, , , O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
restored VBD VBD O
the DT DT O
bradycardia NN NN O
caused VBN VBN O
by IN IN O
norepinephrine NN NN B-CHEM
in IN IN O
addition NN NN O
to TO TO O
decreasing VBG VBG O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
. . . O

5 CD CD B-CHEM
- : : I-CHEM
HTP NNP NNP I-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
decreased VBD VBD O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
and CC CC O
decreased VBD VBD O
the DT DT O
reflex JJ JJ O
bradycardia NN NN O
to TO TO O
norepinephrine NN NN B-CHEM
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
enhances NNS NNS O
reflex JJ JJ O
bradycardia NN NN O
through IN IN O
central JJ JJ O
alpha NN NN O
- - - O
receptor NN NN O
stimulation NN NN O
. . . O

Furthermore RB RB O
, , , O
the DT DT O
effects NNS NNS O
are VBP VBP O
mediated VBN VBN O
through IN IN O
dopamine NN NN B-CHEM
rather RB RB O
than IN IN O
norepinephrine NN NN B-CHEM
and CC CC O
do VBP VBP O
not RB RB O
require VB VB O
the DT DT O
carotid NN NN O
sinus NN NN O
baroreceptors NNS NNS O
. . . O

Microangiopathic NNP NNP O
hemolytic JJ JJ O
anemia NN NN O
complicating VBG VBG O
FK506 NNP NNP B-CHEM
( ( ( O
tacrolimus NN NN B-CHEM
) ) ) O
therapy NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
3 CD CD O
episodes NNS NNS O
of IN IN O
microangiopathic JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
( ( ( O
MAHA NNP NNP O
) ) ) O
in IN IN O
2 CD CD O
solid JJ JJ O
organ NN NN O
recipients NNS NNS O
under IN IN O
FK506 NNP NNP B-CHEM
( ( ( O
tacrolimus NN NN B-CHEM
) ) ) O
therapy NN NN O
. . . O

In IN IN O
both DT DT O
cases NNS NNS O
, , , O
discontinuation NN NN O
of IN IN O
FK506 NNP NNP B-CHEM
and CC CC O
treatment NN NN O
with IN IN O
plasma NN NN O
exchange NN NN O
, , , O
fresh JJ JJ O
frozen VBN VBN O
plasma NN NN O
replacement NN NN O
, , , O
corticosteroids NNS NNS B-CHEM
, , , O
aspirin NN NN B-CHEM
, , , O
and CC CC O
dipyridamole NN NN B-CHEM
led VBN VBN O
to TO TO O
resolution NN NN O
of IN IN O
MAHA NNP NNP O
. . . O

In IN IN O
one CD CD O
patient NN NN O
, , , O
reintroduction NN NN O
of IN IN O
FK506 NNP NNP B-CHEM
led VBD VBD O
to TO TO O
rapid JJ JJ O
recurrence NN NN O
of IN IN O
MAHA NNP NNP O
. . . O

FK506 NNP NNP B-CHEM
- - - O
associated VBN VBN O
MAHA NNP NNP O
is VBZ VBZ O
probably RB RB O
rare JJ JJ O
but CC CC O
physicians NNS NNS O
must MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
severe JJ JJ O
complication NN NN O
. . . O

In IN IN O
our PRP$ PRP$ O
experience NN NN O
and CC CC O
according VBG VBG O
to TO TO O
the DT DT O
literature NN NN O
, , , O
FK506 NNP NNP B-CHEM
does VBZ VBZ O
not RB RB O
seem VB VB O
to TO TO O
cross VB VB O
- : : O
react NN NN O
with IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
( ( ( O
CyA NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
immuno NN NN O
- - - O
suppressive JJ JJ O
drug NN NN O
already RB RB O
known VBN VBN O
to TO TO O
induce VB VB O
MAHA NNP NNP O
. . . O

Effect NN NN O
of IN IN O
some DT DT O
anticancer NN NN O
drugs NNS NNS O
and CC CC O
combined VBD VBD O
chemotherapy NN NN O
on IN IN O
renal JJ JJ O
toxicity NN NN O
. . . O

The DT DT O
nephrotoxic JJ JJ O
action NN NN O
of IN IN O
anticancer NN NN O
drugs NNS NNS O
such JJ JJ O
as IN IN O
nitrogranulogen NN NN B-CHEM
( ( ( O
NG NNP NNP B-CHEM
) ) ) O
, , , O
methotrexate NN NN B-CHEM
( ( ( O
MTX NNP NNP B-CHEM
) ) ) O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
and CC CC O
cyclophosphamide NN NN B-CHEM
( ( ( O
CY NNP NNP B-CHEM
) ) ) O
administered VBD VBD O
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
[ NN NN O
MTX NNP NNP B-CHEM
+ NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
+ NN NN O
CY NNP NNP B-CHEM
( ( ( O
CMF NNP NNP O
) ) ) O
] NN NN O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
experiments NNS NNS O
on IN IN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

After IN IN O
drug NN NN O
administration NN NN O
, , , O
creatinine NN NN B-CHEM
concentrations NNS NNS O
in IN IN O
the DT DT O
plasma NN NN O
and CC CC O
in IN IN O
the DT DT O
urine NN NN O
of IN IN O
the DT DT O
rats NNS NNS O
were VBD VBD O
determined VBN VBN O
, , , O
as RB RB O
well RB RB O
as IN IN O
creatinine NN NN B-CHEM
clearance NN NN O
. . . O

Histopathologic NNP NNP O
evaluation NN NN O
of IN IN O
the DT DT O
kidneys NNS NNS O
was VBD VBD O
also RB RB O
performed VBN VBN O
. . . O

After IN IN O
MTX NNP NNP B-CHEM
administration NN NN O
a DT DT O
significant JJ JJ O
increase NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0228 CD CD O
) ) ) O
in IN IN O
the DT DT O
plasma NN NN O
creatinine NN NN B-CHEM
concentration NN NN O
and CC CC O
a DT DT O
significant JJ JJ O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
decrease NN NN O
in IN IN O
creatinine NN NN B-CHEM
clearance NN NN O
was VBD VBD O
noted VBN VBN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

After IN IN O
the DT DT O
administration NN NN O
of IN IN O
NG NNP NNP B-CHEM
, , , O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
and CC CC O
CY NNP NNP B-CHEM
neither DT DT O
a DT DT O
statistically RB RB O
significant JJ JJ O
increase NN NN O
in IN IN O
creatinine NN NN B-CHEM
concentration NN NN O
nor CC CC O
an DT DT O
increase NN NN O
in IN IN O
creatinine NN NN B-CHEM
clearance NN NN O
was VBD VBD O
observed VBN VBN O
compared VBN VBN O
to TO TO O
the DT DT O
group NN NN O
receiving VBG VBG O
no DT DT O
cytostatics NNS NNS O
. . . O

Following VBG VBG O
polytherapy NN NN O
according VBG VBG O
to TO TO O
the DT DT O
CMF NNP NNP O
regimen NN NN O
, , , O
a DT DT O
statistically RB RB O
significant JJ JJ O
decrease NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0343 CD CD O
) ) ) O
in IN IN O
creatinine NN NN B-CHEM
clearance NN NN O
was VBD VBD O
found VBN VBN O
, , , O
but CC CC O
creatinine JJ JJ B-CHEM
concentration NN NN O
did VBD VBD O
not RB RB O
increase VB VB O
significantly RB RB O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

CY NNP NNP B-CHEM
caused VBD VBD O
hemorrhagic JJ JJ O
cystitis NNS NNS O
in IN IN O
40 CD CD O
% NN NN O
of IN IN O
rats NNS NNS O
, , , O
but CC CC O
it PRP PRP O
did VBD VBD O
not RB RB O
cause VB VB O
this DT DT O
complication NN NN O
when WRB WRB O
combined VBN VBN O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
and CC CC O
MTX NNP NNP B-CHEM
. . . O

Histologic NNP NNP O
changes NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
rat NN NN O
kidneys NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
MTX NNP NNP B-CHEM
, , , O
CY NNP NNP B-CHEM
and CC CC O
NG NNP NNP B-CHEM
, , , O
while IN IN O
no DT DT O
such JJ JJ O
change NN NN O
was VBD VBD O
observed VBN VBN O
after IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
and CC CC O
joint JJ JJ O
administration NN NN O
of IN IN O
MTX NNP NNP B-CHEM
+ NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
+ NN NN O
CY NNP NNP B-CHEM
compared VBD VBD O
to TO TO O
controls NNS NNS O
. . . O

Our PRP$ PRP$ O
studies NNS NNS O
indicate VBP VBP O
that DT DT O
nephrotoxicity NN NN O
of IN IN O
MTX NNP NNP B-CHEM
+ NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
+ NN NN O
CY NNP NNP B-CHEM
administered VBD VBD O
jointly RB RB O
is VBZ VBZ O
lower JJR JJR O
than IN IN O
in IN IN O
monotherapy NN NN O
. . . O

The DT DT O
interpeduncular JJ JJ O
nucleus NN NN O
regulates NNS NNS O
nicotine NN NN B-CHEM
' '' '' O
s VBZ VBZ O
effects NNS NNS O
on IN IN O
free JJ JJ O
- : : O
field NN NN O
activity NN NN O
. . . O

Partial NNP NNP O
lesions NNS NNS O
were VBD VBD O
made VBN VBN O
with IN IN O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
the DT DT O
interpeduncular JJ JJ O
nucleus NN NN O
of IN IN O
the DT DT O
ventral JJ JJ O
midbrain NN NN O
of IN IN O
the DT DT O
rat NN NN O
. . . O

Compared VBN VBN O
with IN IN O
sham NN NN O
- - - O
operated JJ JJ O
controls NNS NNS O
, , , O
lesions NNS NNS O
significantly RB RB O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
25 CD CD O
) ) ) O
blunted VBD VBD O
the DT DT O
early JJ JJ O
( ( ( O
< NN NN O
60 CD CD O
min NN NN O
) ) ) O
free JJ JJ O
- - - O
field NN NN O
locomotor NN NN O
hypoactivity NN NN O
caused VBN VBN O
by IN IN O
nicotine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
i NNP NNP O
. . . O
m NN NN O
. . . O
) ) ) O
, , , O
enhanced VBD VBD O
the DT DT O
later JJ JJ O
( ( ( O
60 CD CD O
- : : O
120 CD CD O
min NN NN O
) ) ) O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
, , , O
and CC CC O
raised VBD VBD O
spontaneous JJ JJ O
nocturnal JJ JJ O
activity NN NN O
. . . O

Lesions NNP NNP O
reduced VBD VBD O
the DT DT O
extent NN NN O
of IN IN O
immunohistological JJ JJ O
staining VBG VBG O
for IN IN O
choline NN NN B-CHEM
acetyltransferase NN NN O
in IN IN O
the DT DT O
interpeduncular NN NN O
nucleus NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
025 CD CD O
) ) ) O
, , , O
but CC CC O
not RB RB O
for IN IN O
tyrosine NN NN B-CHEM
hydroxylase NN NN O
in IN IN O
the DT DT O
surrounding VBG VBG O
catecholaminergic JJ JJ O
A10 NNP NNP O
region NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
interpeduncular JJ JJ O
nucleus NN NN O
mediates NNS NNS O
nicotinic JJ JJ O
depression NN NN O
of IN IN O
locomotor NN NN O
activity NN NN O
and CC CC O
dampens NNS NNS O
nicotinic JJ JJ O
arousal NN NN O
mechanisms NNS NNS O
located VBN VBN O
elsewhere RB RB O
in IN IN O
the DT DT O
brain NN NN O
. . . O

Lithium NNP NNP B-CHEM
- - - O
associated VBN VBN O
cognitive JJ JJ O
and CC CC O
functional JJ JJ O
deficits NNS NNS O
reduced VBN VBN O
by IN IN O
a DT DT O
switch NN NN O
to TO TO O
divalproex NN NN B-CHEM
sodium NN NN I-CHEM
: : : O
a DT DT O
case NN NN O
series NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Lithium NNP NNP B-CHEM
remains VBZ VBZ O
a DT DT O
first JJ JJ O
- - - O
line NN NN O
treatment NN NN O
for IN IN O
the DT DT O
acute JJ JJ O
and CC CC O
maintenance NN NN O
treatment NN NN O
of IN IN O
bipolar JJ JJ O
disorder NN NN O
. . . O

Although IN IN O
much JJ JJ O
has VBZ VBZ O
been VBN VBN O
written VBN VBN O
about IN IN O
the DT DT O
management NN NN O
of IN IN O
the DT DT O
more RBR RBR O
common JJ JJ O
adverse NN NN O
effects NNS NNS O
of IN IN O
lithium NN NN B-CHEM
, , , O
such JJ JJ O
as IN IN O
polyuria NN NN O
and CC CC O
tremor NN NN O
, , , O
more RBR RBR O
subtle JJ JJ O
lithium NN NN B-CHEM
side NN NN O
effects NNS NNS O
such JJ JJ O
as IN IN O
cognitive JJ JJ O
deficits NNS NNS O
, , , O
loss NN NN O
of IN IN O
creativity NN NN O
, , , O
and CC CC O
functional JJ JJ O
impairments NNS NNS O
remain VBP VBP O
understudied JJ JJ O
. . . O

This DT DT O
report NN NN O
summarizes NNS NNS O
our PRP$ PRP$ O
experience NN NN O
in IN IN O
switching VBG VBG O
bipolar NN NN O
patients NNS NNS O
from IN IN O
lithium NN NN B-CHEM
to TO TO O
divalproex VB VB B-CHEM
sodium NN NN I-CHEM
to TO TO O
alleviate VB VB O
such JJ JJ O
cognitive JJ JJ O
and CC CC O
functional JJ JJ O
impairments NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
Open NNP NNP O
, , , O
case NN NN O
series NN NN O
design NN NN O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
report VBP VBP O
seven CD CD O
cases NNS NNS O
where WRB WRB O
substitution NN NN O
of IN IN O
lithium NN NN B-CHEM
, , , O
either CC CC O
fully RB RB O
or CC CC O
partially RB RB O
, , , O
with IN IN O
divalproex NN NN B-CHEM
sodium NN NN I-CHEM
was VBD VBD O
extremely RB RB O
helpful JJ JJ O
in IN IN O
reducing VBG VBG O
the DT DT O
cognitive JJ JJ O
, , , O
motivational JJ JJ O
, , , O
or CC CC O
creative JJ JJ O
deficits NNS NNS O
attributed VBD VBD O
to TO TO O
lithium NN NN B-CHEM
in IN IN O
our PRP$ PRP$ O
bipolar NN NN O
patients NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
this DT DT O
preliminary JJ JJ O
report NN NN O
, , , O
divalproex NN NN B-CHEM
sodium NN NN I-CHEM
was VBD VBD O
a DT DT O
superior JJ JJ O
alternative NN NN O
to TO TO O
lithium VB VB B-CHEM
in IN IN O
bipolar NN NN O
patients NNS NNS O
experiencing VBG VBG O
cognitive JJ JJ O
deficits NNS NNS O
, , , O
loss NN NN O
of IN IN O
creativity NN NN O
, , , O
and CC CC O
functional JJ JJ O
impairments NNS NNS O
. . . O

Effect NN NN O
of IN IN O
nifedipine NN NN B-CHEM
on IN IN O
renal JJ JJ O
function NN NN O
in IN IN O
liver NN NN O
transplant NN NN O
recipients NNS NNS O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
. . . O

The DT DT O
effect NN NN O
of IN IN O
nifedipine NN NN B-CHEM
on IN IN O
renal JJ JJ O
function NN NN O
in IN IN O
liver NN NN O
transplant NN NN O
recipients NNS NNS O
who WP WP O
were VBD VBD O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
was VBD VBD O
evaluated VBN VBN O
between IN IN O
January NNP NNP O
1992 CD CD O
and CC CC O
January NNP NNP O
1996 CD CD O
. . . O

Two CD CD O
groups NNS NNS O
of IN IN O
patients NNS NNS O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
were VBD VBD O
compared VBN VBN O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
1 CD CD O
year NN NN O
, , , O
one CD CD O
group NN NN O
comprising VBG VBG O
hypertensive JJ JJ O
patients NNS NNS O
who WP WP O
were VBD VBD O
receiving VBG VBG O
nifedipine NN NN B-CHEM
, , , O
and CC CC O
the DT DT O
other JJ JJ O
comprising VBG VBG O
nonhypertensive JJ JJ O
patients NNS NNS O
not RB RB O
receiving VBG VBG O
nifedipine NN NN B-CHEM
. . . O

The DT DT O
time NN NN O
from IN IN O
transplant NN NN O
to TO TO O
baseline VB VB O
was VBD VBD O
similar JJ JJ O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

Nifedipine NNP NNP B-CHEM
significantly RB RB O
improved VBD VBD O
kidney NN NN O
function NN NN O
as IN IN O
indicated VBN VBN O
by IN IN O
a DT DT O
significant JJ JJ O
lowering NN NN O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
at IN IN O
6 CD CD O
and CC CC O
12 CD CD O
months NNS NNS O
. . . O

The DT DT O
observed VBD VBD O
positive JJ JJ O
impact NN NN O
of IN IN O
nifedipine NN NN B-CHEM
on IN IN O
reducing VBG VBG O
the DT DT O
nephrotoxicity NN NN O
associated VBN VBN O
with IN IN O
tacrolimus NN NN B-CHEM
in IN IN O
liver NN NN O
transplant NN NN O
recipients NNS NNS O
should MD MD O
be VB VB O
an DT DT O
important JJ JJ O
factor NN NN O
in IN IN O
selecting VBG VBG O
an DT DT O
agent NN NN O
to TO TO O
treat VB VB O
hypertension NN NN O
in IN IN O
this DT DT O
population NN NN O
. . . O

Alpha NNP NNP O
and CC CC O
beta NN NN O
coma NN NN O
in IN IN O
drug NN NN O
intoxication NN NN O
uncomplicated VBN VBN O
by IN IN O
cerebral JJ JJ O
hypoxia NN NN O
. . . O

Four CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
rendered VBN VBN O
comatose NN NN O
or CC CC O
stuporous JJ JJ O
by IN IN O
drug NN NN O
intoxication NN NN O
, , , O
but CC CC O
who WP WP O
were VBD VBD O
not RB RB O
hypoxic JJ JJ O
, , , O
are VBP VBP O
described VBN VBN O
. . . O

Three CD CD O
patients NNS NNS O
received VBD VBD O
high JJ JJ O
doses NNS NNS O
of IN IN O
chlormethiazole NN NN B-CHEM
for IN IN O
alcohol NN NN B-CHEM
withdrawal NN NN O
symptoms NNS NNS O
, , , O
and CC CC O
one CD CD O
took VBD VBD O
a DT DT O
suicidal JJ JJ O
overdose NN NN O
of IN IN O
nitrazepam NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
with IN IN O
nitrazepam NN NN B-CHEM
overdose NN NN O
and CC CC O
two CD CD O
of IN IN O
those DT DT O
with IN IN O
chlormethiazole NN NN B-CHEM
intoxication NN NN O
conformed VBD VBD O
to TO TO O
the DT DT O
criteria NNS NNS O
of IN IN O
' POS POS O
alpha NN NN O
coma NN NN O
' '' '' O
, , , O
showing VBG VBG O
non NN NN O
- - - O
reactive JJ JJ O
generalized JJ JJ O
or CC CC O
frontally RB RB O
predominant JJ JJ O
alpha NN NN O
activity NN NN O
in IN IN O
the DT DT O
EEG NNP NNP O
. . . O

The DT DT O
fourth JJ JJ O
patient NN NN O
who WP WP O
was VBD VBD O
unconscious JJ JJ O
after IN IN O
chlormethiazole NN NN B-CHEM
administration NN NN O
exhibite NN NN O
generalized VBN VBN O
non NN NN O
- - - O
reactive JJ JJ O
activity NN NN O
in IN IN O
the DT DT O
slow JJ JJ O
beta NN NN O
range NN NN O
. . . O

All DT DT O
four CD CD O
recovered VBD VBD O
completely RB RB O
without IN IN O
neurological JJ JJ O
sequelae NN NN O
following VBG VBG O
the DT DT O
withdrawal NN NN O
of IN IN O
the DT DT O
offending VBG VBG O
agents NNS NNS O
. . . O

The DT DT O
similarities NNS NNS O
between IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
structural JJ JJ O
lesions NNS NNS O
and CC CC O
pharmacological JJ JJ O
depression NN NN O
of IN IN O
the DT DT O
brain NN NN O
stem NN NN O
reticular JJ JJ O
formation NN NN O
are VBP VBP O
discussed VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
in IN IN O
both DT DT O
situations NNS NNS O
disturbed VBN VBN O
reticulo NN NN O
- - - O
thalamic JJ JJ O
interactions NNS NNS O
are VBP VBP O
important JJ JJ O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
alpha NN NN O
coma NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
when WRB WRB O
this DT DT O
electroencephalographic JJ JJ O
and CC CC O
behavioural JJ JJ O
picture NN NN O
is VBZ VBZ O
seen VBN VBN O
in IN IN O
drug NN NN O
intoxication NN NN O
, , , O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
significant JJ JJ O
hypoxaemia NN NN O
, , , O
a DT DT O
favourable JJ JJ O
outcome NN NN O
may MD MD O
be VB VB O
anticipated VBN VBN O
. . . O

Magnetic NNP NNP O
resonance NN NN O
volumetry NN NN O
of IN IN O
the DT DT O
cerebellum NN NN O
in IN IN O
epileptic JJ JJ O
patients NNS NNS O
after IN IN O
phenytoin NN NN B-CHEM
overdosages NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
relationship NN NN O
between IN IN O
phenytoin NN NN B-CHEM
medication NN NN O
and CC CC O
cerebellar JJ JJ O
atrophy NN NN O
in IN IN O
patients NNS NNS O
who WP WP O
had VBD VBD O
experienced VBN VBN O
clinical JJ JJ O
intoxication NN NN O
. . . O

Five CD CD O
females NNS NNS O
and CC CC O
6 CD CD O
males NNS NNS O
, , , O
21 CD CD O
- : : O
59 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
, , , O
were VBD VBD O
examined VBN VBN O
with IN IN O
a DT DT O
1 CD CD O
. . . O
5 CD CD O
- : : O
T NN NN O
whole JJ JJ O
- : : O
body NN NN O
system NN NN O
using VBG VBG O
a DT DT O
circular JJ JJ O
polarized VBN VBN O
head NN NN O
coil NN NN O
. . . O

Conventional NNP NNP O
spin NN NN O
echo NN NN O
images NNS NNS O
were VBD VBD O
acquired VBN VBN O
in IN IN O
the DT DT O
sagittal NN NN O
and CC CC O
transverse NN NN O
orientation NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
we PRP PRP O
performed VBD VBD O
a DT DT O
high JJ JJ O
- - - O
resolution NN NN O
3D CD CD O
gradient NN NN O
echo NN NN O
, , , O
T1 NNP NNP O
- - - O
weighted JJ JJ O
sequences NNS NNS O
at IN IN O
a DT DT O
1 CD CD O
- : : O
mm NN NN O
slice NN NN O
thickness NN NN O
. . . O

The DT DT O
images NNS NNS O
were VBD VBD O
subsequently RB RB O
processed VBN VBN O
to TO TO O
obtain VB VB O
volumetric JJ JJ O
data NNS NNS O
for IN IN O
the DT DT O
cerebellum NN NN O
. . . O

Cerebellar NNP NNP O
volume NN NN O
for IN IN O
the DT DT O
patient NN NN O
group NN NN O
ranged VBN VBN O
between IN IN O
67 CD CD O
. . . O
66 CD CD O
and CC CC O
131 CD CD O
. . . O
08 CD CD O
ml NN NN O
( ( ( O
mean NN NN O
108 CD CD O
. . . O
9 CD CD O
ml NN NN O
) ) ) O
. . . O

In IN IN O
addition NN NN O
3D CD CD O
gradient NN NN O
echo NN NN O
data NNS NNS O
sets NNS NNS O
from IN IN O
10 CD CD O
healthy JJ JJ O
male NN NN O
and CC CC O
10 CD CD O
healthy JJ JJ O
female JJ JJ O
age NN NN O
- - - O
matched JJ JJ O
volunteers NNS NNS O
were VBD VBD O
used VBN VBN O
to TO TO O
compare VB VB O
cerebellar NN NN O
volumes NNS NNS O
. . . O

Using VBG VBG O
linear JJ JJ O
regression NN NN O
we PRP PRP O
found VBD VBD O
that IN IN O
no DT DT O
correlation NN NN O
exists VBZ VBZ O
between IN IN O
seizure NN NN O
duration NN NN O
, , , O
elevation NN NN O
of IN IN O
phenytoin NN NN B-CHEM
serum NN NN O
levels NNS NNS O
and CC CC O
cerebellar NN NN O
volume NN NN O
. . . O

However RB RB O
, , , O
multiple JJ JJ O
regression NN NN O
for IN IN O
the DT DT O
daily JJ JJ O
dosage NN NN O
, , , O
duration NN NN O
of IN IN O
phenytoin NN NN B-CHEM
treatment NN NN O
and CC CC O
cerebellar NN NN O
volume NN NN O
revealed VBD VBD O
a DT DT O
correlation NN NN O
of IN IN O
these DT DT O
parameters NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
phenytoin NN NN B-CHEM
overdosage NN NN O
does VBZ VBZ O
not RB RB O
necessarily RB RB O
result VB VB O
in IN IN O
cerebellar NN NN O
atrophy NN NN O
and CC CC O
it PRP PRP O
is VBZ VBZ O
unlikely JJ JJ O
that IN IN O
phenytoin NN NN B-CHEM
medication NN NN O
was VBD VBD O
the DT DT O
only JJ JJ O
cause NN NN O
of IN IN O
cerebellar JJ JJ O
atrophy NN NN O
in IN IN O
the DT DT O
remaining VBG VBG O
patients NNS NNS O
. . . O

Quantitative NNP NNP O
morphometric JJ JJ O
studies NNS NNS O
of IN IN O
the DT DT O
cerebellum NN NN O
provide VB VB O
valuable JJ JJ O
insights NNS NNS O
into IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
cerebellar JJ JJ O
disorders NNS NNS O
. . . O

Late JJ JJ O
recovery NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
in IN IN O
a DT DT O
woman NN NN O
with IN IN O
the DT DT O
hemolytic JJ JJ O
uremic JJ JJ O
syndrome NN NN O
. . . O

A DT DT O
case NN NN O
is VBZ VBZ O
reported VBN VBN O
of IN IN O
the DT DT O
hemolytic JJ JJ O
uremic JJ JJ O
syndrome NN NN O
( ( ( O
HUS NNP NNP O
) ) ) O
in IN IN O
a DT DT O
woman NN NN O
taking VBG VBG O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

She PRP PRP O
was VBD VBD O
treated VBN VBN O
with IN IN O
heparin NN NN B-CHEM
, , , O
dipyridamole NN NN B-CHEM
and CC CC O
hemodialysis NN NN O
; : : O
and CC CC O
after IN IN O
more JJR JJR O
than IN IN O
three CD CD O
months NNS NNS O
, , , O
her PRP$ PRP$ O
urinary JJ JJ O
output NN NN O
rose VBD VBD O
above IN IN O
500 CD CD O
ml NN NN O
; : : O
and CC CC O
six CD CD O
months NNS NNS O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
anuria NN NN O
, , , O
dialysis NN NN O
treatment NN NN O
was VBD VBD O
stopped VBN VBN O
. . . O

This DT DT O
case NN NN O
emphasizes VBZ VBZ O
the DT DT O
possibility NN NN O
that WDT WDT O
HUS NNP NNP O
in IN IN O
adults NNS NNS O
is VBZ VBZ O
not RB RB O
invariably RB RB O
irreversible JJ JJ O
and CC CC O
that IN IN O
, , , O
despite IN IN O
prolonged JJ JJ O
oliguria NN NN O
, , , O
recovery NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
can MD MD O
be VB VB O
obtained VBN VBN O
. . . O

Therefore RB RB O
, , , O
in IN IN O
adult NN NN O
patients NNS NNS O
affected VBN VBN O
by IN IN O
HUS NNP NNP O
, , , O
dialysis NN NN O
should MD MD O
not RB RB O
be VB VB O
discontinued VBN VBN O
prematurely RB RB O
; : : O
moreover RB RB O
, , , O
bilateral JJ JJ O
nephrectomy NN NN O
, , , O
for IN IN O
treatment NN NN O
of IN IN O
severe JJ JJ O
hypertension NN NN O
and CC CC O
microangiopathic JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
, , , O
should MD MD O
be VB VB O
performed VBN VBN O
with IN IN O
caution NN NN O
. . . O

Morphological NNP NNP O
features NNS NNS O
of IN IN O
encephalopathy NN NN O
after IN IN O
chronic JJ JJ O
administration NN NN O
of IN IN O
the DT DT O
antiepileptic JJ JJ O
drug NN NN O
valproate NN NN B-CHEM
to TO TO O
rats NNS NNS O
. . . O

A DT DT O
transmission NN NN O
electron NN NN O
microscopic JJ JJ O
study NN NN O
of IN IN O
capillaries NNS NNS O
in IN IN O
the DT DT O
cerebellar NN NN O
cortex NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
intragastric JJ JJ O
application NN NN O
of IN IN O
the DT DT O
antiepileptic JJ JJ O
drug NN NN O
sodium NN NN B-CHEM
valproate NN NN I-CHEM
( ( ( O
Vupral NNP NNP O
" '' '' O
Polfa NNP NNP O
" '' '' O
) ) ) O
at IN IN O
the DT DT O
effective JJ JJ O
dose NN NN O
of IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
b SYM SYM O
. . . O

w NN NN O
. . . O
once RB RB O
daily JJ JJ O
to TO TO O
rats NNS NNS O
for IN IN O
1 CD CD O
, , , O
3 CD CD O
, , , O
6 CD CD O
, , , O
9 CD CD O
and CC CC O
12 CD CD O
months NNS NNS O
revealed VBD VBD O
neurological JJ JJ O
disorders NNS NNS O
indicating VBG VBG O
cerebellum NN NN O
damage NN NN O
( ( ( O
" '' '' O
valproate NN NN B-CHEM
encephalopathy NN NN O
" '' '' O
) ) ) O
. . . O

The DT DT O
first JJ JJ O
ultrastructural JJ JJ O
changes NNS NNS O
in IN IN O
structural JJ JJ O
elements NNS NNS O
of IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
- - - O
barrier NN NN O
( ( ( O
BBB NNP NNP O
) ) ) O
in IN IN O
the DT DT O
cerebellar NN NN O
cortex NN NN O
were VBD VBD O
detectable JJ JJ O
after IN IN O
3 CD CD O
months NNS NNS O
of IN IN O
the DT DT O
experiment NN NN O
. . . O

They PRP PRP O
became VBD VBD O
more JJR JJR O
severe JJ JJ O
in IN IN O
the DT DT O
later JJ JJ O
months NNS NNS O
of IN IN O
the DT DT O
experiment NN NN O
, , , O
and CC CC O
were VBD VBD O
most RBS RBS O
severe JJ JJ O
after IN IN O
12 CD CD O
months NNS NNS O
, , , O
located VBN VBN O
mainly RB RB O
in IN IN O
the DT DT O
molecular JJ JJ O
layer NN NN O
of IN IN O
the DT DT O
cerebellar NN NN O
cortex NN NN O
. . . O

Lesions NNP NNP O
of IN IN O
the DT DT O
capillary JJ JJ O
included VBD VBD O
necrosis NN NN O
of IN IN O
endothelial JJ JJ O
cells NNS NNS O
. . . O

Organelles NNP NNP O
of IN IN O
these DT DT O
cells NNS NNS O
, , , O
in IN IN O
particular JJ JJ O
the DT DT O
mitochondria NN NN O
( ( ( O
increased VBN VBN O
number NN NN O
and CC CC O
size NN NN O
, , , O
distinct JJ JJ O
degeneration NN NN O
of IN IN O
their PRP$ PRP$ O
matrix NN NN O
and CC CC O
cristae NN NN O
) ) ) O
and CC CC O
Golgi NNP NNP O
apparatus NN NN O
were VBD VBD O
altered VBN VBN O
. . . O

Reduced NNP NNP O
size NN NN O
of IN IN O
capillary JJ JJ O
lumen NNS NNS O
and CC CC O
occlusion NN NN O
were VBD VBD O
caused VBN VBN O
by IN IN O
swollen NN NN O
endothelial NN NN O
cells NNS NNS O
which WDT WDT O
had VBD VBD O
luminal JJ JJ B-CHEM
protrusions NNS NNS O
and CC CC O
swollen NN NN O
microvilli NN NN O
. . . O

Pressure NN NN O
on IN IN O
the DT DT O
vessel NN NN O
wall NN NN O
was VBD VBD O
produced VBN VBN O
by IN IN O
enlarged JJ JJ O
perivascular NN NN O
astrocytic JJ JJ O
processes NNS NNS O
. . . O

Fragments NNP NNP O
of IN IN O
necrotic JJ JJ O
endothelial NN NN O
cells NNS NNS O
were VBD VBD O
in IN IN O
the DT DT O
vascular NN NN O
lumens NNS NNS O
and CC CC O
in IN IN O
these DT DT O
there EX EX O
was VBD VBD O
loosening VBG VBG O
and CC CC O
breaking VBG VBG O
of IN IN O
tight JJ JJ O
cellular NN NN O
junctions NNS NNS O
. . . O

Damage NNP NNP O
to TO TO O
the DT DT O
vascular NN NN O
basement NN NN O
lamina NN NN O
was VBD VBD O
also RB RB O
observed VBN VBN O
. . . O

Damage NNP NNP O
to TO TO O
the DT DT O
capillary NN NN O
was VBD VBD O
accompanied VBN VBN O
by IN IN O
marked JJ JJ O
damage NN NN O
to TO TO O
neuroglial JJ JJ O
cells NNS NNS O
, , , O
mainly RB RB O
to TO TO O
perivascular JJ JJ O
processes NNS NNS O
of IN IN O
astrocytes NNS NNS O
. . . O

The DT DT O
proliferation NN NN O
of IN IN O
astrocytes NNS NNS O
( ( ( O
Bergmann NNP NNP O
' POS POS O
s VBZ VBZ O
in IN IN O
particular JJ JJ O
) ) ) O
and CC CC O
occasionally RB RB O
of IN IN O
oligodendrocytes NNS NNS O
was VBD VBD O
found VBN VBN O
. . . O

Alterations NNP NNP O
in IN IN O
the DT DT O
structural JJ JJ O
elements NNS NNS O
of IN IN O
the DT DT O
BBB NNP NNP O
coexisted VBD VBD O
with IN IN O
marked JJ JJ O
lesions NNS NNS O
of IN IN O
neurons NNS NNS O
of IN IN O
the DT DT O
cerebellum NN NN O
( ( ( O
Purkinje NNP NNP O
cells NNS NNS O
are VBP VBP O
earliest JJS JJS O
) ) ) O
. . . O

In IN IN O
electron NN NN O
micrographs NNS NNS O
both DT DT O
luminal JJ JJ B-CHEM
and CC CC O
antiluminal JJ JJ O
sides NNS NNS O
of IN IN O
the DT DT O
BBB NNP NNP O
of IN IN O
the DT DT O
cerebellar NN NN O
cortex NN NN O
had VBD VBD O
similar JJ JJ O
lesions NNS NNS O
. . . O

The DT DT O
possible JJ JJ O
influence NN NN O
of IN IN O
the DT DT O
hepatic JJ JJ O
damage NN NN O
, , , O
mainly RB RB O
hyperammonemia NN NN O
, , , O
upon IN IN O
the DT DT O
development NN NN O
of IN IN O
valproate NN NN B-CHEM
encephalopathy NN NN O
is VBZ VBZ O
discussed VBN VBN O
. . . O

Fatal NNP NNP O
intracranial NN NN O
bleeding VBG VBG O
associated VBN VBN O
with IN IN O
prehospital JJ JJ O
use NN NN O
of IN IN O
epinephrine NN NN B-CHEM
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
paramedic JJ JJ O
misjudgment NN NN O
in IN IN O
the DT DT O
execution NN NN O
of IN IN O
a DT DT O
protocol NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
allergic JJ JJ O
reaction NN NN O
in IN IN O
a DT DT O
case NN NN O
of IN IN O
pulmonary JJ JJ O
edema NN NN O
with IN IN O
wheezing VBG VBG O
. . . O

The DT DT O
sudden JJ JJ O
onset NN NN O
of IN IN O
respiratory JJ JJ O
distress NN NN O
, , , O
rash NN NN O
, , , O
and CC CC O
a DT DT O
history NN NN O
of IN IN O
a DT DT O
new JJ JJ O
medicine NN NN O
led VBD VBD O
the DT DT O
two CD CD O
paramedics NNS NNS O
on IN IN O
the DT DT O
scene NN NN O
to TO TO O
administer VB VB O
subcutaneous JJ JJ O
epinephrine NN NN B-CHEM
. . . O

Subsequently RB RB O
, , , O
acute JJ JJ O
cardiac JJ JJ O
arrest NN NN O
and CC CC O
fatal JJ JJ O
subarachnoid NN NN O
hemorrhage NN NN O
occurred VBD VBD O
. . . O

Epinephrine NNP NNP B-CHEM
has VBZ VBZ O
a DT DT O
proven VBN VBN O
role NN NN O
in IN IN O
cardiac JJ JJ O
arrest NN NN O
in IN IN O
prehospital JJ JJ O
care NN NN O
; : : O
however RB RB O
, , , O
use NN NN O
by IN IN O
paramedics NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
suspected VBN VBN O
allergic JJ JJ O
reaction NN NN O
and CC CC O
severe JJ JJ O
hypertension NN NN O
should MD MD O
be VB VB O
viewed VBN VBN O
with IN IN O
caution NN NN O
. . . O

Role NN NN O
of IN IN O
activation NN NN O
of IN IN O
bradykinin NN NN B-CHEM
B2 NNP NNP O
receptors NNS NNS O
in IN IN O
disruption NN NN O
of IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
during IN IN O
acute JJ JJ O
hypertension NN NN O
. . . O

Cellular NNP NNP O
mechanisms NNS NNS O
which WDT WDT O
account NN NN O
for IN IN O
disruption NN NN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
during IN IN O
acute JJ JJ O
hypertension NN NN O
are VBP VBP O
not RB RB O
clear JJ JJ O
. . . O

The DT DT O
goal NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
role NN NN O
of IN IN O
synthesis NN NN O
/ NN NN O
release NN NN O
of IN IN O
bradykinin NN NN B-CHEM
to TO TO O
activate VB VB O
B2 NNP NNP O
receptors NNS NNS O
in IN IN O
disruption NN NN O
of IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
during IN IN O
acute JJ JJ O
hypertension NN NN O
. . . O

Permeability NNP NNP O
of IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
was VBD VBD O
quantitated VBN VBN O
by IN IN O
clearance NN NN O
of IN IN O
fluorescent NN NN O
- - - O
labeled JJ JJ O
dextran NN NN B-CHEM
before IN IN O
and CC CC O
during IN IN O
phenylephrine NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
hypertension NN NN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
vehicle NN NN O
and CC CC O
Hoe NNP NNP B-CHEM
- : : I-CHEM
140 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
microM NN NN O
) ) ) O
. . . O

Phenylephrine NNP NNP B-CHEM
infusion NN NN O
increased VBD VBD O
arterial JJ JJ O
pressure NN NN O
, , , O
arteriolar JJ JJ O
diameter NN NN O
and CC CC O
clearance NN NN O
of IN IN O
fluorescent NN NN O
dextran NN NN B-CHEM
by IN IN O
a DT DT O
similar JJ JJ O
magnitude NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that DT DT O
disruption NN NN O
of IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
during IN IN O
acute JJ JJ O
hypertension NN NN O
is VBZ VBZ O
not RB RB O
related VBN VBN O
to TO TO O
the DT DT O
synthesis NN NN O
/ NN NN O
release NN NN O
of IN IN O
bradykinin NN NN B-CHEM
to TO TO O
activate VB VB O
B2 NNP NNP O
receptors NNS NNS O
. . . O

Risk NN NN O
factors NNS NNS O
of IN IN O
sensorineural JJ JJ O
hearing NN NN O
loss NN NN O
in IN IN O
preterm NN NN O
infants NNS NNS O
. . . O

Among IN IN O
547 CD CD O
preterm JJ JJ O
infants NNS NNS O
of IN IN O
< NN NN O
or CC CC O
= SYM SYM O
34 CD CD O
weeks NNS NNS O
gestation NN NN O
born VBN VBN O
between IN IN O
1987 CD CD O
and CC CC O
1991 CD CD O
, , , O
8 CD CD O
children NNS NNS O
( ( ( O
1 CD CD O
. . . O
46 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
severe JJ JJ O
progressive JJ JJ O
and CC CC O
bilateral JJ JJ O
sensorineural JJ JJ O
hearing NN NN O
loss NN NN O
. . . O

Perinatal NNP NNP O
risk NN NN O
factors NNS NNS O
of IN IN O
infants NNS NNS O
with IN IN O
hearing NN NN O
loss NN NN O
were VBD VBD O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
two CD CD O
control NN NN O
groups NNS NNS O
matched VBD VBD O
for IN IN O
gestation NN NN O
and CC CC O
birth NN NN O
weight NN NN O
and CC CC O
for IN IN O
perinatal JJ JJ O
complications NNS NNS O
. . . O

Our PRP$ PRP$ O
observations NNS NNS O
demonstrated VBD VBD O
an DT DT O
association NN NN O
of IN IN O
hearing NN NN O
loss NN NN O
with IN IN O
a DT DT O
higher JJR JJR O
incidence NN NN O
of IN IN O
perinatal JJ JJ O
complications NNS NNS O
. . . O

Ototoxicity NNP NNP O
appeared VBD VBD O
closely RB RB O
related VBN VBN O
to TO TO O
a DT DT O
prolonged JJ JJ O
administration NN NN O
and CC CC O
higher JJR JJR O
total JJ JJ O
dose NN NN O
of IN IN O
ototoxic JJ JJ O
drugs NNS NNS O
, , , O
particularly RB RB O
aminoglycosides NNS NNS B-CHEM
and CC CC O
furosemide NN NN B-CHEM
. . . O

Finally RB RB O
, , , O
we PRP PRP O
strongly RB RB O
recommend VBP VBP O
to TO TO O
prospectively RB RB O
and CC CC O
regularly RB RB O
perform VB VB O
audiologic JJ JJ O
assessment NN NN O
in IN IN O
sick JJ JJ O
preterm NN NN O
children NNS NNS O
as IN IN O
hearing NN NN O
loss NN NN O
is VBZ VBZ O
of IN IN O
delayed JJ JJ O
onset NN NN O
and CC CC O
in IN IN O
most JJS JJS O
cases NNS NNS O
bilateral JJ JJ O
and CC CC O
severe JJ JJ O
. . . O

Seizure NNP NNP O
resulting VBG VBG O
from IN IN O
a DT DT O
venlafaxine NN NN B-CHEM
overdose NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
venlafaxine NN NN B-CHEM
overdose NN NN O
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
major JJ JJ O
depression NN NN O
took VBD VBD O
an DT DT O
overdose NN NN O
of IN IN O
venlafaxine NN NN B-CHEM
in IN IN O
an DT DT O
apparent JJ JJ O
suicide NN NN O
attempt NN NN O
. . . O

After IN IN O
the DT DT O
ingestion NN NN O
of IN IN O
26 CD CD O
venlafaxine NN NN B-CHEM
50 CD CD O
- : : O
mg NN NN O
tablets NNS NNS O
, , , O
the DT DT O
patient NN NN O
experienced VBD VBD O
a DT DT O
witnessed VBN VBN O
generalized JJ JJ O
seizure NN NN O
. . . O

She PRP PRP O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
medical JJ JJ O
intensive JJ JJ O
care NN NN O
unit NN NN O
, , , O
venlafaxine NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
, , , O
and CC CC O
no DT DT O
further JJ JJ O
sequelae NN NN O
were VBD VBD O
seen VBN VBN O
. . . O

DISCUSSION NNP NNP O
: : : O
To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
venlafaxine NN NN B-CHEM
overdose NN NN O
that WDT WDT O
resulted VBD VBD O
in IN IN O
a DT DT O
generalized JJ JJ O
seizure NN NN O
. . . O

Based VBN VBN O
on IN IN O
nonoverdose NN NN O
pharmacokinetics NNS NNS O
and CC CC O
pharmacodynamics NNS NNS O
of IN IN O
venlafaxine NN NN B-CHEM
and CC CC O
the DT DT O
potential JJ JJ O
risks NNS NNS O
of IN IN O
available JJ JJ O
interventions NNS NNS O
, , , O
no DT DT O
emergent NN NN O
therapy NN NN O
was VBD VBD O
instituted VBN VBN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
venlafaxine NN NN B-CHEM
overdose NN NN O
in IN IN O
our PRP$ PRP$ O
patient NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
single JJ JJ O
episode NN NN O
of IN IN O
generalized JJ JJ O
seizure NN NN O
but CC CC O
elicited VBD VBD O
no DT DT O
further RB RB O
sequelae NN NN O
. . . O

Combined NNP NNP O
effects NNS NNS O
of IN IN O
prolonged JJ JJ O
prostaglandin NN NN B-CHEM
E1 NNP NNP I-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
and CC CC O
haemodilution NN NN O
on IN IN O
human JJ JJ O
hepatic JJ JJ O
function NN NN O
. . . O

Combined NNP NNP O
effects NNS NNS O
of IN IN O
prolonged JJ JJ O
prostaglandin NN NN B-CHEM
E1 NNP NNP I-CHEM
( ( ( O
PGE1 NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypotension NN NN O
and CC CC O
haemodilution NN NN O
on IN IN O
hepatic JJ JJ O
function NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
30 CD CD O
patients NNS NNS O
undergoing VBG VBG O
hip NN NN O
surgery NN NN O
. . . O

The DT DT O
patients NNS NNS O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
one CD CD O
of IN IN O
three CD CD O
groups NNS NNS O
; : : O
those DT DT O
in IN IN O
group NN NN O
A DT DT O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
were VBD VBD O
subjected VBN VBN O
to TO TO O
controlled VBN VBN O
hypotension NN NN O
alone RB RB O
, , , O
those DT DT O
in IN IN O
group NN NN O
B NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
to TO TO O
haemodilution NN NN O
alone RB RB O
and CC CC O
those DT DT O
in IN IN O
group NN NN O
C NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
to TO TO O
both DT DT O
controlled JJ JJ O
hypotension NN NN O
and CC CC O
haemodilution NN NN O
. . . O

Haemodilution NNP NNP O
in IN IN O
groups NNS NNS O
B NNP NNP O
and CC CC O
C NNP NNP O
was VBD VBD O
produced VBN VBN O
by IN IN O
withdrawing VBG VBG O
approximately RB RB O
1000 CD CD O
mL NN NN O
of IN IN O
blood NN NN O
and CC CC O
replacing VBG VBG O
it PRP PRP O
with IN IN O
the DT DT O
same JJ JJ O
amount NN NN O
of IN IN O
dextran NN NN B-CHEM
solution NN NN O
, , , O
and CC CC O
final JJ JJ O
haematocrit NN NN O
values NNS NNS O
were VBD VBD O
21 CD CD O
or CC CC O
22 CD CD O
% NN NN O
. . . O

Controlled NNP NNP O
hypotension NN NN O
in IN IN O
groups NNS NNS O
A DT DT O
and CC CC O
C NNP NNP O
was VBD VBD O
induced VBN VBN O
with IN IN O
PGE1 NNP NNP B-CHEM
to TO TO O
maintain VB VB O
mean NN NN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
at IN IN O
55 CD CD O
mmHg NN NN O
for IN IN O
180 CD CD O
min NN NN O
. . . O

Measurements NNP NNP O
included VBD VBD O
arterial JJ JJ O
ketone NN NN O
body NN NN O
ratio NN NN O
( ( ( O
AKBR NNP NNP O
, , , O
aceto NN NN B-CHEM
- - - I-CHEM
acetate NN NN I-CHEM
/ NN NN O
3 CD CD B-CHEM
- : : I-CHEM
hydroxybutyrate NN NN I-CHEM
) ) ) O
and CC CC O
clinical JJ JJ O
hepatic JJ JJ O
function NN NN O
parameters NNS NNS O
. . . O

AKBR NNP NNP O
and CC CC O
biological JJ JJ O
hepatic JJ JJ O
function NN NN O
tests NNS NNS O
showed VBD VBD O
no DT DT O
change NN NN O
throughout IN IN O
the DT DT O
time NN NN O
course NN NN O
in IN IN O
groups NNS NNS O
A DT DT O
and CC CC O
B NNP NNP O
. . . O

In IN IN O
group NN NN O
C NNP NNP O
, , , O
AKBR NNP NNP O
showed VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
at IN IN O
120 CD CD O
min NN NN O
( ( ( O
- : : O
40 CD CD O
% NN NN O
) ) ) O
and CC CC O
at IN IN O
180 CD CD O
min NN NN O
( ( ( O
- : : O
49 CD CD O
% NN NN O
) ) ) O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
hypotension NN NN O
and CC CC O
at IN IN O
60 CD CD O
min NN NN O
( ( ( O
- : : O
32 CD CD O
% NN NN O
) ) ) O
after IN IN O
recovery NN NN O
of IN IN O
normotension NN NN O
, , , O
and CC CC O
SGOT NNP NNP O
, , , O
SGPT NNP NNP O
, , , O
LDH NNP NNP O
and CC CC O
total JJ JJ O
bilirubin NN NN B-CHEM
showed VBD VBD O
significant JJ JJ O
increases NNS NNS O
after IN IN O
operation NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
a DT DT O
prolonged JJ JJ O
combination NN NN O
of IN IN O
more JJR JJR O
than IN IN O
120 CD CD O
min NN NN O
of IN IN O
PGE1 NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
and CC CC O
moderate JJ JJ O
haemodilution NN NN O
would MD MD O
cause VB VB O
impairment NN NN O
of IN IN O
hepatic JJ JJ O
function NN NN O
. . . O

Cardiovascular NNP NNP O
alterations NNS NNS O
in IN IN O
rat NN NN O
fetuses NNS NNS O
exposed VBN VBN O
to TO TO O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
. . . O

Preclinical NNP NNP O
toxicologic JJ JJ O
investigation NN NN O
suggested VBD VBD O
that IN IN O
a DT DT O
new JJ JJ O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
, , , O
Ro NNP NNP B-CHEM
40 CD CD I-CHEM
- : : I-CHEM
5967 CD CD I-CHEM
, , , O
induced VBD VBD O
cardiovascular JJ JJ O
alterations NNS NNS O
in IN IN O
rat NN NN O
fetuses NNS NNS O
exposed VBN VBN O
to TO TO O
this DT DT O
agent NN NN O
during IN IN O
organogenesis NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
in IN IN O
general JJ JJ O
induce NN NN O
cardiovascular JJ JJ O
malformations NNS NNS O
indicating VBG VBG O
a DT DT O
pharmacologic JJ JJ O
class NN NN O
effect NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
three CD CD O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
of IN IN O
different JJ JJ O
structure NN NN O
, , , O
nifedipine NN NN B-CHEM
, , , O
diltiazem NN NN B-CHEM
, , , O
and CC CC O
verapamil NN NN B-CHEM
, , , O
along IN IN O
with IN IN O
the DT DT O
new JJ JJ O
agent NN NN O
. . . O

Pregnant NNP NNP O
rats NNS NNS O
were VBD VBD O
administered VBN VBN O
one CD CD O
of IN IN O
these DT DT O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
during IN IN O
the DT DT O
period NN NN O
of IN IN O
cardiac JJ JJ O
morphogenesis NN NN O
and CC CC O
the DT DT O
offspring VBG VBG O
examined VBN VBN O
on IN IN O
day NN NN O
20 CD CD O
of IN IN O
gestation NN NN O
for IN IN O
cardiovascular JJ JJ O
malformations NNS NNS O
. . . O

A DT DT O
low JJ JJ O
incidence NN NN O
of IN IN O
cardiovascular JJ JJ O
malformations NNS NNS O
was VBD VBD O
observed VBN VBN O
after IN IN O
exposure NN NN O
to TO TO O
each DT DT O
of IN IN O
the DT DT O
four CD CD O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
, , , O
but CC CC O
this DT DT O
incidence NN NN O
was VBD VBD O
statistically RB RB O
significant JJ JJ O
only RB RB O
for IN IN O
verapamil NN NN B-CHEM
and CC CC O
nifedipine NN NN B-CHEM
. . . O

All DT DT O
four CD CD O
agents NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
aortic JJ JJ O
arch NN NN O
branching VBG VBG O
variants NNS NNS O
, , , O
although IN IN O
significantly RB RB O
increased VBN VBN O
only RB RB O
for IN IN O
Ro NNP NNP B-CHEM
40 CD CD I-CHEM
- : : I-CHEM
5967 CD CD I-CHEM
and CC CC O
verapamil NN NN B-CHEM
. . . O

The DT DT O
site NN NN O
of IN IN O
common JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
sumatriptan NN NN B-CHEM
. . . O

Atypical NNP NNP O
sensations NNS NNS O
following VBG VBG O
the DT DT O
use NN NN O
of IN IN O
subcutaneous JJ JJ O
sumatriptan NN NN B-CHEM
are VBP VBP O
common JJ JJ O
, , , O
but CC CC O
of IN IN O
uncertain JJ JJ O
origin NN NN O
. . . O

They PRP PRP O
are VBP VBP O
almost RB RB O
always RB RB O
benign VB VB O
, , , O
but CC CC O
can MD MD O
be VB VB O
mistaken VBN VBN O
for IN IN O
a DT DT O
serious JJ JJ O
adverse JJ JJ O
event NN NN O
by IN IN O
the DT DT O
patient NN NN O
. . . O

Two CD CD O
patients NNS NNS O
are VBP VBP O
presented VBN VBN O
with IN IN O
tingling NN NN O
or CC CC O
burning NN NN O
sensations NNS NNS O
limited JJ JJ O
to TO TO O
areas NNS NNS O
of IN IN O
heat NN NN O
exposure NN NN O
or CC CC O
sunburn NN NN O
. . . O

In IN IN O
these DT DT O
individuals NNS NNS O
, , , O
side NN NN O
effects NNS NNS O
are VBP VBP O
most RBS RBS O
likely JJ JJ O
generated VBN VBN O
superficially RB RB O
in IN IN O
the DT DT O
skin NN NN O
. . . O

Macula NNP NNP O
toxicity NN NN O
after IN IN O
intravitreal NN NN O
amikacin NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Although IN IN O
intravitreal NN NN O
aminoglycosides NNS NNS B-CHEM
have VBP VBP O
substantially RB RB O
improved VBN VBN O
visual JJ JJ O
prognosis NN NN O
in IN IN O
endophthalmitis NN NN O
, , , O
macular NN NN O
infarction NN NN O
may MD MD O
impair VB VB O
full JJ JJ O
visual JJ JJ O
recovery NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
presumed JJ JJ O
amikacin NN NN B-CHEM
retinal JJ JJ O
toxicity NN NN O
following VBG VBG O
treatment NN NN O
with IN IN O
amikacin NN NN B-CHEM
and CC CC O
vancomycin NN NN B-CHEM
for IN IN O
alpha NN NN O
- - - O
haemolytic JJ JJ O
streptococcal JJ JJ O
endophthalmitis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Endophthalmitis NNP NNP O
resolved VBN VBN O
with IN IN O
improvement NN NN O
in IN IN O
visual JJ JJ O
acuity NN NN O
to TO TO O
6 CD CD O
/ NN NN O
24 CD CD O
at IN IN O
three CD CD O
months NNS NNS O
. . . O

Fundus NNP NNP O
fluorescein NN NN B-CHEM
angiography NN NN O
confirmed VBD VBD O
macular JJ JJ O
capillary JJ JJ O
closure NN NN O
and CC CC O
telangiectasis NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Currently RB RB O
accepted VBD VBD O
intravitreal NN NN O
antibiotic JJ JJ O
regimens NNS NNS O
may MD MD O
cause VB VB O
retinal JJ JJ O
toxicity NN NN O
and CC CC O
macular JJ JJ O
ischaemia NN NN O
. . . O

Treatment NN NN O
strategies NNS NNS O
aimed VBN VBN O
at IN IN O
avoiding VBG VBG O
retinal JJ JJ O
toxicity NN NN O
are VBP VBP O
discussed VBN VBN O
. . . O

The DT DT O
role NN NN O
of IN IN O
nicotine NN NN B-CHEM
in IN IN O
smoking NN NN O
- - - O
related VBN VBN O
cardiovascular JJ JJ O
disease NN NN O
. . . O

Nicotine NNP NNP B-CHEM
activates VBZ VBZ O
the DT DT O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
and CC CC O
in IN IN O
this DT DT O
way NN NN O
could MD MD O
contribute VB VB O
to TO TO O
cardiovascular JJ JJ O
disease NN NN O
. . . O

Animal NNP NNP O
studies NNS NNS O
and CC CC O
mechanistic JJ JJ O
studies NNS NNS O
indicate VBP VBP O
that IN IN O
nicotine NN NN B-CHEM
could MD MD O
play VB VB O
a DT DT O
role NN NN O
in IN IN O
accelerating VBG VBG O
atherosclerosis NN NN O
, , , O
but CC CC O
evidence NN NN O
among IN IN O
humans NNS NNS O
is VBZ VBZ O
too RB RB O
inadequate JJ JJ O
to TO TO O
be VB VB O
definitive JJ JJ O
about IN IN O
such JJ JJ O
an DT DT O
effect NN NN O
. . . O

Almost RB RB O
certainly RB RB O
, , , O
nicotine NN NN B-CHEM
via IN IN O
its PRP$ PRP$ O
hemodynamic JJ JJ O
effects NNS NNS O
contributes VBZ VBZ O
to TO TO O
acute JJ JJ O
cardiovascular JJ JJ O
events NNS NNS O
, , , O
although IN IN O
current JJ JJ O
evidence NN NN O
suggests VBZ VBZ O
that IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
are VBP VBP O
much RB RB O
less RBR RBR O
important JJ JJ O
than IN IN O
are VBP VBP O
the DT DT O
prothrombotic JJ JJ O
effects NNS NNS O
of IN IN O
cigarette NN NN O
smoking NN NN O
or CC CC O
the DT DT O
effects NNS NNS O
of IN IN O
carbon NN NN B-CHEM
monoxide NN NN I-CHEM
. . . O

Nicotine NNP NNP B-CHEM
does VBZ VBZ O
not RB RB O
appear VB VB O
to TO TO O
enhance NN NN O
thrombosis NN NN O
among IN IN O
humans NNS NNS O
. . . O

Clinical NNP NNP O
studies NNS NNS O
of IN IN O
pipe NN NN O
smokers NNS NNS O
and CC CC O
people NNS NNS O
using VBG VBG O
transdermal JJ JJ O
nicotine NN NN B-CHEM
support NN NN O
the DT DT O
idea NN NN O
that IN IN O
toxins NNS NNS O
other JJ JJ O
than IN IN O
nicotine NN NN B-CHEM
are VBP VBP O
the DT DT O
most RBS RBS O
important JJ JJ O
causes NNS NNS O
of IN IN O
acute JJ JJ O
cardiovascular JJ JJ O
events NNS NNS O
. . . O

Finally RB RB O
, , , O
the DT DT O
dose NN NN O
response NN NN O
for IN IN O
cardiovascular JJ JJ O
events NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
appears VBZ VBZ O
to TO TO O
be VB VB O
flat JJ JJ O
, , , O
suggesting VBG VBG O
that IN IN O
if IN IN O
nicotine NN NN B-CHEM
is VBZ VBZ O
involved VBN VBN O
, , , O
adverse JJ JJ O
effects NNS NNS O
might MD MD O
be VB VB O
seen VBN VBN O
with IN IN O
relatively RB RB O
low JJ JJ O
- - - O
level NN NN O
cigarette NN NN O
exposures NNS NNS O
. . . O

Iatrogenically RB RB O
induced VBN VBN O
intractable JJ JJ O
atrioventricular JJ JJ O
reentrant NN NN O
tachycardia NN NN O
after IN IN O
verapamil NN NN B-CHEM
and CC CC O
catheter NN NN O
ablation NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
Wolff NNP NNP O
- - - O
Parkinson NNP NNP O
- : : O
White NNP NNP O
syndrome NN NN O
and CC CC O
idiopathic JJ JJ O
dilated JJ JJ O
cardiomyopathy NN NN O
. . . O

In IN IN O
a DT DT O
patient NN NN O
with IN IN O
WPW NNP NNP O
syndrome NN NN O
and CC CC O
idiopathic JJ JJ O
dilated VBN VBN O
cardiomyopathy NN NN O
, , , O
intractable JJ JJ O
atrioventricular NN NN O
reentrant NN NN O
tachycardia NN NN O
( ( ( O
AVRT NNP NNP O
) ) ) O
was VBD VBD O
iatrogenically RB RB O
induced VBN VBN O
. . . O

QRS NNP NNP O
without IN IN O
preexcitation NN NN O
, , , O
caused VBN VBN O
by IN IN O
junctional JJ JJ O
escape NN NN O
beats NNS NNS O
after IN IN O
verapamil NN NN B-CHEM
or CC CC O
unidirectional JJ JJ O
antegrade NN NN O
block NN NN O
of IN IN O
accessory JJ JJ O
pathway NN NN O
after IN IN O
catheter NN NN O
ablation NN NN O
, , , O
established VBD VBD O
frequent JJ JJ O
AVRT NNP NNP O
attack NN NN O
. . . O

Epidemic NNP NNP O
of IN IN O
liver NN NN O
disease NN NN O
caused VBN VBN O
by IN IN O
hydrochlorofluorocarbons NNS NNS B-CHEM
used VBN VBN O
as IN IN O
ozone CD CD B-CHEM
- - - O
sparing VBG VBG O
substitutes NNS NNS O
of IN IN O
chlorofluorocarbons NNS NNS B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Hydrochlorofluorocarbons NNP NNP B-CHEM
( ( ( O
HCFCs NNP NNP B-CHEM
) ) ) O
are VBP VBP O
used VBN VBN O
increasingly RB RB O
in IN IN O
industry NN NN O
as IN IN O
substitutes NNS NNS O
for IN IN O
ozone NN NN B-CHEM
- - - O
depleting VBG VBG O
chlorofluorocarbons NNS NNS B-CHEM
( ( ( O
CFCs NNP NNP B-CHEM
) ) ) O
. . . O

Limited NNP NNP O
studies NNS NNS O
in IN IN O
animals NNS NNS O
indicate VBP VBP O
potential JJ JJ O
hepatotoxicity NN NN O
of IN IN O
some DT DT O
of IN IN O
these DT DT O
compounds NNS NNS O
. . . O

We PRP PRP O
investigated VBD VBD O
an DT DT O
epidemic JJ JJ O
of IN IN O
liver NN NN O
disease NN NN O
in IN IN O
nine CD CD O
industrial JJ JJ O
workers NNS NNS O
who WP WP O
had VBD VBD O
had VBN VBN O
repeated VBN VBN O
accidental JJ JJ O
exposure NN NN O
to TO TO O
a DT DT O
mixture NN NN O
of IN IN O
1 CD CD B-CHEM
, , , I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
dichloro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
trifluoroethane NN NN I-CHEM
( ( ( O
HCFC NNP NNP B-CHEM
123 CD CD I-CHEM
) ) ) O
and CC CC O
1 CD CD B-CHEM
- : : I-CHEM
chloro NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
tetrafluoroethane NN NN I-CHEM
( ( ( O
HCFC NNP NNP B-CHEM
124 CD CD I-CHEM
) ) ) O
. . . O

All DT DT O
nine CD CD O
exposed VBN VBN O
workers NNS NNS O
were VBD VBD O
affected VBN VBN O
to TO TO O
various JJ JJ O
degrees NNS NNS O
. . . O

Both DT DT O
compounds NNS NNS O
are VBP VBP O
metabolised VBN VBN O
in IN IN O
the DT DT O
same JJ JJ O
way NN NN O
as IN IN O
1 CD CD B-CHEM
- : : I-CHEM
bromo NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
chloro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
trifluoroethane NN NN I-CHEM
( ( ( O
halothane NN NN B-CHEM
) ) ) O
to TO TO O
form VB VB O
reactive JJ JJ O
trifluoroacetyl NN NN B-CHEM
halide NN NN O
intermediates NNS NNS O
, , , O
which WDT WDT O
have VBP VBP O
been VBN VBN O
implicated VBN VBN O
in IN IN O
the DT DT O
hepatotoxicity NN NN O
of IN IN O
halothane NN NN B-CHEM
. . . O

We PRP PRP O
aimed VBD VBD O
to TO TO O
test VB VB O
whether IN IN O
HCFCs NNP NNP B-CHEM
123 CD CD I-CHEM
and CC CC I-CHEM
124 NN NN I-CHEM
can MD MD O
result VB VB O
in IN IN O
serious JJ JJ O
liver NN NN O
disease NN NN O
. . . O

METHODS NNP NNP O
: : : O
For IN IN O
one CD CD O
severely RB RB O
affected VBN VBN O
worker NN NN O
liver NN NN O
biopsy NN NN O
and CC CC O
immunohistochemical JJ JJ O
stainings NNS NNS O
for IN IN O
the DT DT O
presence NN NN O
of IN IN O
trifluoroacetyl NN NN B-CHEM
protein NN NN O
adducts NNS NNS O
were VBD VBD O
done VBN VBN O
. . . O

The DT DT O
serum NN NN O
of IN IN O
six CD CD O
affected VBN VBN O
workers NNS NNS O
and CC CC O
five CD CD O
controls NNS NNS O
was VBD VBD O
tested VBN VBN O
for IN IN O
autoantibodies NNS NNS O
that WDT WDT O
react VBP VBP O
with IN IN O
human JJ JJ O
liver NN NN O
cytochrome NN NN O
- : : O
P450 NNP NNP O
2E1 CD CD O
( ( ( O
P450 NNP NNP O
2E1 CD CD O
) ) ) O
and CC CC O
P58 NNP NNP O
protein NN NN O
disulphide NN NN O
isomerase NN NN O
isoform NN NN O
( ( ( O
P58 NNP NNP O
) ) ) O
. . . O

FINDINGS NNS NNS O
: : : O
The DT DT O
liver NN NN O
biopsy NN NN O
sample NN NN O
showed VBD VBD O
hepatocellular NN NN O
necrosis NN NN O
which WDT WDT O
was VBD VBD O
prominent JJ JJ O
in IN IN O
perivenular NN NN O
zone NN NN O
three CD CD O
and CC CC O
extended VBN VBN O
focally RB RB O
from IN IN O
portal JJ JJ O
tracts NNS NNS O
to TO TO O
portal VB VB O
tracts NNS NNS O
and CC CC O
centrilobular JJ JJ O
areas NNS NNS O
( ( ( O
bridging VBG VBG O
necrosis NN NN O
) ) ) O
. . . O

Trifluoroacetyl NNP NNP B-CHEM
- - - O
adducted JJ JJ O
proteins NNS NNS O
were VBD VBD O
detected VBN VBN O
in IN IN O
surviving VBG VBG O
hepatocytes NNS NNS O
. . . O

Autoantibodies NNP NNP O
against IN IN O
P450 NNP NNP O
2E1 CD CD O
or CC CC O
P58 NNP NNP O
, , , O
previously RB RB O
associated VBN VBN O
with IN IN O
halothane JJ JJ O
hepatitis NN NN O
, , , O
were VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
serum NN NN O
of IN IN O
five CD CD O
affected VBN VBN O
workers NNS NNS O
. . . O

INTERPRETATION NN NN O
: : : O
Repeated NNP NNP O
exposure NN NN O
of IN IN O
human JJ JJ O
beings NNS NNS O
to TO TO O
HCFCs NNP NNP B-CHEM
123 CD CD I-CHEM
and CC CC I-CHEM
124 NN NN I-CHEM
can MD MD O
result VB VB O
in IN IN O
serious JJ JJ O
liver NN NN O
injury NN NN O
in IN IN O
a DT DT O
large JJ JJ O
proportion NN NN O
of IN IN O
the DT DT O
exposed VBN VBN O
population NN NN O
. . . O

Although IN IN O
the DT DT O
exact JJ JJ O
mechanism NN NN O
of IN IN O
hepatotoxicity NN NN O
of IN IN O
these DT DT O
agents NNS NNS O
is VBZ VBZ O
not RB RB O
known VBN VBN O
, , , O
the DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
trifluoroacetyl NN NN B-CHEM
- : : O
altered JJ JJ O
liver NN NN O
proteins NNS NNS O
are VBP VBP O
involved VBN VBN O
. . . O

In IN IN O
view NN NN O
of IN IN O
the DT DT O
potentially RB RB O
widespread JJ JJ O
use NN NN O
of IN IN O
these DT DT O
compounds NNS NNS O
, , , O
there EX EX O
is VBZ VBZ O
an DT DT O
urgent JJ JJ O
need VBP VBP O
to TO TO O
develop VB VB O
safer JJR JJR O
alternatives NNS NNS O
. . . O

Bile NNP NNP O
duct VB VB O
hamartoma NN NN O
occurring VBG VBG O
in IN IN O
association NN NN O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
danazol NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
bile NN NN O
duct NN NN O
hamartoma NN NN O
which WDT WDT O
developed VBD VBD O
in IN IN O
a DT DT O
patient NN NN O
who WP WP O
had VBD VBD O
been VBN VBN O
on IN IN O
long JJ JJ O
- - - O
term NN NN O
danazol NN NN B-CHEM
treatment NN NN O
. . . O

Such JJ JJ O
patients NNS NNS O
should MD MD O
be VB VB O
under IN IN O
close JJ JJ O
follow VB VB O
- - - O
up RP RP O
, , , O
preferably RB RB O
with IN IN O
periodic JJ JJ O
ultrasound JJ JJ O
examination NN NN O
of IN IN O
the DT DT O
liver NN NN O
. . . O

If IN IN O
the DT DT O
patient NN NN O
develops VBZ VBZ O
a DT DT O
liver NN NN O
mass NN NN O
, , , O
because IN IN O
of IN IN O
non NN NN O
- - - O
specific JJ JJ O
clinical JJ JJ O
features NNS NNS O
and CC CC O
imaging VBG VBG O
appearances NNS NNS O
, , , O
biopsy NN NN O
may MD MD O
be VB VB O
the DT DT O
only JJ JJ O
way NN NN O
to TO TO O
achieve VB VB O
a DT DT O
definitive JJ JJ O
diagnosis NN NN O
. . . O

Endocrine NNP NNP O
screening VBG VBG O
in IN IN O
1 CD CD O
, , , O
022 CD CD O
men NNS NNS O
with IN IN O
erectile NN NN O
dysfunction NN NN O
: : : O
clinical JJ JJ O
significance NN NN O
and CC CC O
cost NN NN O
- - - O
effective JJ JJ O
strategy NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
We PRP PRP O
reviewed VBD VBD O
the DT DT O
results NNS NNS O
of IN IN O
serum NN NN O
testosterone NN NN B-CHEM
and CC CC O
prolactin NN NN O
determination NN NN O
in IN IN O
1 CD CD O
, , , O
022 CD CD O
patients NNS NNS O
referred VBD VBD O
because IN IN O
of IN IN O
erectile NN NN O
dysfunction NN NN O
and CC CC O
compared VBD VBD O
the DT DT O
data NNS NNS O
with IN IN O
history NN NN O
, , , O
results NNS NNS O
of IN IN O
physical JJ JJ O
examination NN NN O
, , , O
other JJ JJ O
etiological JJ JJ O
investigations NNS NNS O
and CC CC O
effects NNS NNS O
of IN IN O
endocrine NN NN O
therapy NN NN O
to TO TO O
refine VB VB O
the DT DT O
rules NNS NNS O
of IN IN O
cost NN NN O
- - - O
effective JJ JJ O
endocrine NN NN O
screening VBG VBG O
and CC CC O
to TO TO O
pinpoint VB VB O
actual JJ JJ O
responsibility NN NN O
for IN IN O
hormonal NN NN O
abnormalities NNS NNS O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Testosterone NNP NNP B-CHEM
and CC CC O
prolactin NN NN O
were VBD VBD O
determined VBN VBN O
by IN IN O
radioimmunoassay NN NN O
. . . O

Every DT DT O
patient NN NN O
was VBD VBD O
screened VBN VBN O
for IN IN O
testosterone NN NN B-CHEM
and CC CC O
451 CD CD O
were VBD VBD O
screened VBN VBN O
for IN IN O
prolactin NN NN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
low JJ JJ O
sexual JJ JJ O
desire NN NN O
, , , O
gynecomastia NN NN O
or CC CC O
testosterone NN NN B-CHEM
less JJR JJR O
than IN IN O
4 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O

Determination NNP NNP O
was VBD VBD O
repeated VBN VBN O
in IN IN O
case NN NN O
of IN IN O
abnormal JJ JJ O
first JJ JJ O
results NNS NNS O
. . . O

Prolactin NNP NNP O
results NNS NNS O
were VBD VBD O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
a DT DT O
previous JJ JJ O
personal JJ JJ O
cohort NN NN O
of IN IN O
1 CD CD O
, , , O
340 CD CD O
patients NNS NNS O
with IN IN O
erectile NN NN O
dysfunction NN NN O
and CC CC O
systematic JJ JJ O
prolactin NN NN O
determination NN NN O
. . . O

Main NNP NNP O
clinical JJ JJ O
criteria NNS NNS O
tested VBN VBN O
regarding VBG VBG O
efficiency NN NN O
in IN IN O
hormone NN NN O
determination NN NN O
were VBD VBD O
low JJ JJ O
sexual JJ JJ O
desire NN NN O
, , , O
small JJ JJ O
testes NNS NNS O
and CC CC O
gynecomastia NN NN O
. . . O

Endocrine NNP NNP O
therapy NN NN O
consisted VBD VBD O
of IN IN O
testosterone NN NN B-CHEM
heptylate NN NN I-CHEM
or CC CC O
human JJ JJ O
chorionic NN NN O
gonadotropin NN NN O
for IN IN O
hypogonadism NN NN O
and CC CC O
bromocriptine NN NN B-CHEM
for IN IN O
hyperprolactinemia NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Testosterone NNP NNP B-CHEM
was VBD VBD O
less JJR JJR O
than IN IN O
3 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O
in IN IN O
107 CD CD O
patients NNS NNS O
but CC CC O
normal JJ JJ O
in IN IN O
40 CD CD O
% NN NN O
at IN IN O
repeat NN NN O
determination NN NN O
. . . O

The DT DT O
prevalence NN NN O
of IN IN O
repeatedly RB RB O
low JJ JJ O
testosterone NN NN B-CHEM
increased VBN VBN O
with IN IN O
age NN NN O
( ( ( O
4 CD CD O
% NN NN O
before IN IN O
age NN NN O
50 CD CD O
years NNS NNS O
and CC CC O
9 CD CD O
% NN NN O
50 CD CD O
years NNS NNS O
or CC CC O
older JJR JJR O
) ) ) O
. . . O

Two CD CD O
pituitary JJ JJ O
tumors NNS NNS O
were VBD VBD O
discovered VBN VBN O
after IN IN O
testosterone NN NN B-CHEM
determination NN NN O
. . . O

Most JJS JJS O
of IN IN O
the DT DT O
other JJ JJ O
low JJ JJ O
testosterone NN NN B-CHEM
levels NNS NNS O
seemed VBD VBD O
to TO TO O
result VB VB O
from IN IN O
nonorganic JJ JJ O
hypothalamic JJ JJ O
dysfunction NN NN O
because IN IN O
of IN IN O
normal JJ JJ O
serum NN NN O
luteinizing VBG VBG O
hormone NN NN O
and CC CC O
prolactin NN NN O
and CC CC O
to TO TO O
have VB VB O
only RB RB O
a DT DT O
small JJ JJ O
role NN NN O
in IN IN O
erectile NN NN O
dysfunction NN NN O
( ( ( O
definite NN NN O
improvement NN NN O
in IN IN O
only RB RB O
16 CD CD O
of IN IN O
44 CD CD O
[ NN NN O
36 CD CD O
% NN NN O
] NN NN O
after IN IN O
androgen NN NN O
therapy NN NN O
, , , O
normal JJ JJ O
morning NN NN O
or CC CC O
nocturnal JJ JJ O
erections NNS NNS O
in IN IN O
30 CD CD O
% NN NN O
and CC CC O
definite JJ JJ O
vasculogenic JJ JJ O
contributions NNS NNS O
in IN IN O
42 CD CD O
% NN NN O
) ) ) O
. . . O

Determining VBG VBG O
testosterone NN NN B-CHEM
only RB RB O
in IN IN O
cases NNS NNS O
of IN IN O
low JJ JJ O
sexual JJ JJ O
desire NN NN O
or CC CC O
abnormal JJ JJ O
physical JJ JJ O
examination NN NN O
would MD MD O
have VB VB O
missed VBN VBN O
40 CD CD O
% NN NN O
of IN IN O
the DT DT O
cases NNS NNS O
with IN IN O
low JJ JJ O
testosterone NN NN B-CHEM
, , , O
including VBG VBG O
37 CD CD O
% NN NN O
of IN IN O
those DT DT O
subsequently RB RB O
improved VBN VBN O
by IN IN O
androgen NN NN O
therapy NN NN O
. . . O

Prolactin NNP NNP O
exceeded VBD VBD O
20 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O
in IN IN O
5 CD CD O
men NNS NNS O
and CC CC O
was VBD VBD O
normal JJ JJ O
in IN IN O
2 CD CD O
at IN IN O
repeat NN NN O
determination NN NN O
. . . O

Only RB RB O
1 CD CD O
prolactinoma NN NN O
was VBD VBD O
discovered VBN VBN O
. . . O

These DT DT O
data NNS NNS O
are VBP VBP O
lower JJR JJR O
than IN IN O
those DT DT O
we PRP PRP O
found VBD VBD O
during IN IN O
the DT DT O
last JJ JJ O
2 CD CD O
decades NNS NNS O
( ( ( O
overall JJ JJ O
prolactin NN NN O
greater JJR JJR O
than IN IN O
20 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O
in IN IN O
1 CD CD O
. . . O
86 CD CD O
% NN NN O
of IN IN O
1 CD CD O
, , , O
821 CD CD O
patients NNS NNS O
, , , O
prolactinomas NNS NNS O
in IN IN O
7 CD CD O
, , , O
0 CD CD O
. . . O
38 CD CD O
% NN NN O
) ) ) O
. . . O

Bromocriptine NNP NNP B-CHEM
was VBD VBD O
definitely RB RB O
effective JJ JJ O
in IN IN O
cases NNS NNS O
with IN IN O
prolactin NN NN O
greater JJR JJR O
than IN IN O
35 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O

( ( ( O
8 CD CD O
of IN IN O
12 CD CD O
compared VBN VBN O
to TO TO O
only RB RB O
9 CD CD O
of IN IN O
22 CD CD O
cases NNS NNS O
with IN IN O
prolactin NN NN O
between IN IN O
20 CD CD O
and CC CC O
35 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O
) ) ) O
. . . O

Testosterone NNP NNP B-CHEM
was VBD VBD O
low JJ JJ O
in IN IN O
less JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
of IN IN O
cases NNS NNS O
with IN IN O
prolactin NN NN O
greater JJR JJR O
than IN IN O
35 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Low NNP NNP O
prevalences NNS NNS O
and CC CC O
effects NNS NNS O
of IN IN O
low JJ JJ O
testosterone NN NN B-CHEM
and CC CC O
high JJ JJ O
prolactin NN NN O
in IN IN O
erectile NN NN O
dysfunction NN NN O
cannot NN NN O
justify NN NN O
their PRP$ PRP$ O
routine JJ JJ O
determination NN NN O
. . . O

However RB RB O
, , , O
cost NN NN O
- - - O
effective JJ JJ O
screening NN NN O
strategies NNS NNS O
recommended VBD VBD O
so RB RB O
far RB RB O
missed VBD VBD O
40 CD CD O
to TO TO O
50 CD CD O
% NN NN O
of IN IN O
cases NNS NNS O
improved VBN VBN O
with IN IN O
endocrine NN NN O
therapy NN NN O
and CC CC O
the DT DT O
pituitary JJ JJ O
tumors NNS NNS O
. . . O

We PRP PRP O
now RB RB O
advocate VBP VBP O
that IN IN O
before IN IN O
age NN NN O
50 CD CD O
years NNS NNS O
testosterone NN NN B-CHEM
be VB VB O
determined VBN VBN O
only RB RB O
in IN IN O
cases NNS NNS O
of IN IN O
low JJ JJ O
sexual JJ JJ O
desire NN NN O
and CC CC O
abnormal JJ JJ O
physical JJ JJ O
examination NN NN O
but CC CC O
that IN IN O
it PRP PRP O
be VB VB O
measured VBN VBN O
in IN IN O
all DT DT O
men NNS NNS O
older JJR JJR O
than IN IN O
50 CD CD O
years NNS NNS O
. . . O

Prolactin NNP NNP O
should MD MD O
be VB VB O
determined VBN VBN O
only RB RB O
in IN IN O
cases NNS NNS O
of IN IN O
low JJ JJ O
sexual JJ JJ O
desire NN NN O
, , , O
gynecomastia NN NN O
and CC CC O
/ NN NN O
or CC CC O
testosterone NN NN B-CHEM
less JJR JJR O
than IN IN O
4 CD CD O
ng NN NN O
. . . O
/ NN NN O
ml NN NN O
. . . O

Extrapyramidal NNP NNP O
side NN NN O
effects NNS NNS O
with IN IN O
risperidone NN NN B-CHEM
and CC CC O
haloperidol NN NN B-CHEM
at IN IN O
comparable JJ JJ O
D2 NN NN O
receptor NN NN O
occupancy NN NN O
levels NNS NNS O
. . . O

Risperidone NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
antipsychotic JJ JJ O
drug NN NN O
with IN IN O
high JJ JJ O
affinity NN NN O
at IN IN O
dopamine NN NN B-CHEM
D2 NN NN O
and CC CC O
serotonin NN NN B-CHEM
5 CD CD I-CHEM
- : : I-CHEM
HT2 NNP NNP I-CHEM
receptors NNS NNS O
. . . O

Previous JJ JJ O
clinical JJ JJ O
studies NNS NNS O
have VBP VBP O
proposed VBN VBN O
that IN IN O
risperidone NN NN B-CHEM
' '' '' O
s VBZ VBZ O
pharmacologic JJ JJ O
profile NN NN O
may MD MD O
produce VB VB O
improved VBN VBN O
efficacy NN NN O
for IN IN O
negative JJ JJ O
psychotic JJ JJ O
symptoms NNS NNS O
and CC CC O
decreased VBD VBD O
propensity NN NN O
for IN IN O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
; : : O
features NNS NNS O
shared VBN VBN O
by IN IN O
so RB RB O
- : : O
called VBN VBN O
' POS POS O
atypical JJ JJ O
' POS POS O
neuroleptics NNS NNS O
. . . O

To TO TO O
determine VB VB O
if IN IN O
routine JJ JJ O
risperidone NN NN B-CHEM
treatment NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
a DT DT O
unique JJ JJ O
degree NN NN O
of IN IN O
D2 NN NN O
receptor NN NN O
occupancy NN NN O
and CC CC O
pattern NN NN O
of IN IN O
clinical JJ JJ O
effects NNS NNS O
, , , O
we PRP PRP O
used VBD VBD O
[ NN NN O
123I CD CD O
] NN NN O
IBZM NNP NNP O
SPECT NNP NNP O
to TO TO O
determine VB VB O
D2 NN NN O
occupancy NN NN O
in IN IN O
subjects NNS NNS O
treated VBN VBN O
with IN IN O
routine JJ JJ O
clinical JJ JJ O
doses NNS NNS O
of IN IN O
risperidone NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
) ) ) O
or CC CC O
haloperidol NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
. . . O

Both DT DT O
risperidone NN NN B-CHEM
and CC CC O
haloperidol NN NN B-CHEM
produced VBD VBD O
D2 NN NN O
occupancy NN NN O
levels NNS NNS O
between IN IN O
approximately RB RB O
60 CD CD O
and CC CC O
90 CD CD O
% NN NN O
at IN IN O
standard JJ JJ O
clinical JJ JJ O
doses NNS NNS O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
between IN IN O
occupancy NN NN O
levels NNS NNS O
obtained VBN VBN O
with IN IN O
haloperidol NN NN B-CHEM
or CC CC O
risperidone NN NN B-CHEM
. . . O

Drug NN NN O
- : : O
induced JJ JJ O
parkinsonism NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
subjects NNS NNS O
treated VBN VBN O
with IN IN O
risperidone NN NN B-CHEM
( ( ( O
42 CD CD O
% NN NN O
) ) ) O
and CC CC O
haloperidol NN NN B-CHEM
( ( ( O
29 CD CD O
% NN NN O
) ) ) O
and CC CC O
was VBD VBD O
observed VBN VBN O
at IN IN O
occupancy NN NN O
levels NNS NNS O
above IN IN O
60 CD CD O
% NN NN O
. . . O

Based VBN VBN O
on IN IN O
these DT DT O
observations NNS NNS O
, , , O
it PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
5 CD CD O
- : : O
HT2 NNP NNP O
blockade NN NN O
obtained VBN VBN O
with IN IN O
risperidone NN NN B-CHEM
at IN IN O
D2 NN NN O
occupancy NN NN O
rates NNS NNS O
of IN IN O
60 CD CD O
% NN NN O
and CC CC O
above IN IN O
does VBZ VBZ O
not RB RB O
appear VB VB O
to TO TO O
protect VB VB O
against IN IN O
the DT DT O
risk NN NN O
for IN IN O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
. . . O

Treatment NN NN O
of IN IN O
previously RB RB O
treated VBN VBN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
by IN IN O
mitoxantrone NN NN B-CHEM
and CC CC O
48 CD CD O
- : : O
hour NN NN O
continuous JJ JJ O
infusion NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
and CC CC O
leucovorin NN NN B-CHEM
( ( ( O
MFL NNP NNP B-CHEM
) ) ) O
: : : O
low JJ JJ O
palliative JJ JJ O
benefit NN NN O
and CC CC O
high JJ JJ O
treatment NN NN O
- - - O
related VBN VBN O
toxicity NN NN O
. . . O

For IN IN O
previously RB RB O
treated VBN VBN O
advanced VBN VBN O
breast NN NN O
cancer NN NN O
, , , O
there EX EX O
is VBZ VBZ O
no DT DT O
standard JJ JJ O
second JJ JJ O
- - - O
line NN NN O
therapy NN NN O
. . . O

Combination NNP NNP O
chemotherapy NN NN O
with IN IN O
mitoxantrone NN NN B-CHEM
, , , O
high JJ JJ O
- - - O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
and CC CC O
leucovorin NN NN B-CHEM
( ( ( O
MFL NNP NNP B-CHEM
regimen NN NN I-CHEM
) ) ) O
had VBD VBD O
been VBN VBN O
reported VBN VBN O
as IN IN O
an DT DT O
effective JJ JJ O
and CC CC O
well RB RB O
tolerated VBD VBD O
regimen NNS NNS O
. . . O

From IN IN O
October NNP NNP O
1993 CD CD O
to TO TO O
November NNP NNP O
1995 CD CD O
, , , O
we PRP PRP O
treated VBD VBD O
13 CD CD O
patients NNS NNS O
with IN IN O
previously RB RB O
chemotherapy NN NN O
- - - O
treated VBN VBN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
by IN IN O
mitoxantrone NN NN B-CHEM
, , , O
12 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
on IN IN O
day NN NN O
1 CD CD O
and CC CC O
continuous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
, , , O
3000 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
together RB RB O
with IN IN O
leucovorin NN NN B-CHEM
, , , O
300 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
for IN IN O
48 CD CD O
h NN NN O
from IN IN O
day NN NN O
1 CD CD O
to TO TO O
2 CD CD O
. . . O

Each DT DT O
course NN NN O
of IN IN O
chemotherapy NN NN O
was VBD VBD O
given VBN VBN O
every DT DT O
4 CD CD O
weeks NNS NNS O
. . . O

Most JJS JJS O
of IN IN O
these DT DT O
patients NNS NNS O
had VBD VBD O
more JJR JJR O
than IN IN O
two CD CD O
metastatic JJ JJ O
sites NNS NNS O
, , , O
with IN IN O
lung NN NN O
metastasis NN NN O
predominant NN NN O
. . . O

Seven CD CD O
patients NNS NNS O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
with IN IN O
anthracycline NN NN B-CHEM
. . . O

Seven CD CD O
patients NNS NNS O
had VBD VBD O
previously RB RB O
received VBN VBN O
radiotherapy NN NN O
and CC CC O
seven CD CD O
had VBD VBD O
received VBN VBN O
hormone NN NN O
therapy NN NN O
. . . O

Median JJ JJ O
number NN NN O
of IN IN O
courses NNS NNS O
of IN IN O
MFL NNP NNP B-CHEM
regimen NNS NNS I-CHEM
given VBN VBN O
was VBD VBD O
six CD CD O
and CC CC O
the DT DT O
median NN NN O
cumulative JJ JJ O
dose NN NN O
of IN IN O
mitoxantrone NN NN B-CHEM
was VBD VBD O
68 CD CD O
. . . O
35 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

One CD CD O
patient NN NN O
had VBD VBD O
complete JJ JJ O
response NN NN O
, , , O
seven CD CD O
had VBD VBD O
stable JJ JJ O
disease NN NN O
, , , O
none NN NN O
had VBD VBD O
partial JJ JJ O
response NN NN O
and CC CC O
five CD CD O
had VBD VBD O
progressive JJ JJ O
disease NN NN O
. . . O

The DT DT O
overall JJ JJ O
objective NN NN O
response NN NN O
rate NN NN O
was VBD VBD O
7 CD CD O
. . . O
6 CD CD O
% NN NN O
. . . O

The DT DT O
median JJ JJ O
follow VB VB O
- - - O
up RP RP O
period NN NN O
was VBD VBD O
14 CD CD O
months NNS NNS O
. . . O

Median NNP NNP O
survival NN NN O
was VBD VBD O
16 CD CD O
months NNS NNS O
. . . O

Median NNP NNP O
progression NN NN O
- - - O
free JJ JJ O
survival NN NN O
was VBD VBD O
5 CD CD O
months NNS NNS O
. . . O

A DT DT O
complete JJ JJ O
responder NN NN O
had VBD VBD O
relapse NN NN O
- - - O
free JJ JJ O
survival NN NN O
up IN IN O
to TO TO O
17 CD CD O
months NNS NNS O
. . . O

Major NNP NNP O
toxicities NNS NNS O
were VBD VBD O
cardiotoxicity NN NN O
and CC CC O
leukopenia NN NN O
. . . O

Eight CD CD O
patients NNS NNS O
were VBD VBD O
dead JJ JJ O
in IN IN O
the DT DT O
last JJ JJ O
follow VB VB O
- - - O
up RP RP O
; : : O
two CD CD O
of IN IN O
them PRP PRP O
died VBD VBD O
of IN IN O
treatment NN NN O
- - - O
related VBN VBN O
toxicity NN NN O
. . . O

The DT DT O
MFL NNP NNP B-CHEM
regimen NN NN I-CHEM
achieves NNS NNS O
little JJ JJ O
palliative JJ JJ O
benefit NN NN O
and CC CC O
induces NNS NNS O
severe JJ JJ O
toxicity NN NN O
at IN IN O
a DT DT O
fairly RB RB O
high JJ JJ O
rate NN NN O
. . . O

Administration NNP NNP O
of IN IN O
this DT DT O
regimen NN NN O
to TO TO O
breast NN NN O
cancer NN NN O
patients NNS NNS O
who WP WP O
have VBP VBP O
been VBN VBN O
treated VBN VBN O
by IN IN O
chemotherapy NN NN O
and CC CC O
those DT DT O
with IN IN O
impaired JJ JJ O
heart NN NN O
function NN NN O
requires VBZ VBZ O
careful JJ JJ O
attention NN NN O
. . . O

Ticlopidine NNP NNP B-CHEM
- : : O
induced JJ JJ O
aplastic JJ JJ O
anemia NN NN O
: : : O
report NN NN O
of IN IN O
three CD CD O
Chinese JJ JJ O
patients NNS NNS O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
three CD CD O
Chinese JJ JJ O
patients NNS NNS O
with IN IN O
ticlopidine NN NN B-CHEM
- - - O
induced JJ JJ O
aplastic JJ JJ O
anemia NN NN O
were VBD VBD O
reported VBN VBN O
and CC CC O
another DT DT O
13 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
English NNP NNP O
literature NN NN O
were VBD VBD O
reviewed VBN VBN O
. . . O

We PRP PRP O
attempted VBD VBD O
to TO TO O
find VB VB O
underlying VBG VBG O
similarities NNS NNS O
, , , O
evaluate VBP VBP O
the DT DT O
risk NN NN O
factors NNS NNS O
, , , O
and CC CC O
identify VB VB O
appropriate JJ JJ O
treatment NN NN O
for IN IN O
this DT DT O
complication NN NN O
. . . O

All DT DT O
but CC CC O
one CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
over IN IN O
60 CD CD O
years NNS NNS O
old JJ JJ O
, , , O
and CC CC O
the DT DT O
6 CD CD O
who WP WP O
died VBD VBD O
were VBD VBD O
all DT DT O
older JJR JJR O
than IN IN O
65 CD CD O
. . . O

Therefore RB RB O
, , , O
old JJ JJ O
age NN NN O
may MD MD O
be VB VB O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
developing VBG VBG O
this DT DT O
complication NN NN O
. . . O

Agranulocytosis NNP NNP O
occurred VBD VBD O
3 CD CD O
- : : O
20 CD CD O
weeks NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
ticlopidine NN NN B-CHEM
, , , O
so RB RB O
frequent JJ JJ O
examination NN NN O
of IN IN O
white JJ JJ O
cell NN NN O
count NN NN O
during IN IN O
treatment NN NN O
is VBZ VBZ O
recommended VBN VBN O
. . . O

There EX EX O
seemed VBD VBD O
to TO TO O
be VB VB O
no DT DT O
direct JJ JJ O
correlation NN NN O
between IN IN O
the DT DT O
dose NN NN O
or CC CC O
duration NN NN O
used VBN VBN O
and CC CC O
the DT DT O
severity NN NN O
of IN IN O
bone NN NN O
marrow NN NN O
suppression NN NN O
. . . O

Treatment NN NN O
for IN IN O
ticlopidine NN NN B-CHEM
- - - O
induced JJ JJ O
aplastic JJ JJ O
anemia NN NN O
with IN IN O
colony NN NN O
- - - O
stimulating VBG VBG O
factors NNS NNS O
seemed VBD VBD O
to TO TO O
have VB VB O
little JJ JJ O
effect NN NN O
. . . O

The DT DT O
fact NN NN O
that IN IN O
5 CD CD O
of IN IN O
the DT DT O
6 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
concurrent NN NN O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
died VBD VBD O
, , , O
should MD MD O
alert VB VB O
clinicians NNS NNS O
to TO TO O
be VB VB O
more RBR RBR O
cautious JJ JJ O
when WRB WRB O
using VBG VBG O
these DT DT O
two CD CD O
drugs NNS NNS O
simultaneously RB RB O
. . . O

Upregulation NNP NNP O
of IN IN O
the DT DT O
expression NN NN O
of IN IN O
vasopressin NN NN B-CHEM
gene NN NN O
in IN IN O
the DT DT O
paraventricular NN NN O
and CC CC O
supraoptic JJ JJ O
nuclei NN NN O
of IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
rat NN NN O
. . . O

The DT DT O
expression NN NN O
of IN IN O
arginine NN NN B-CHEM
vasopressin NN NN I-CHEM
( ( ( O
AVP NNP NNP B-CHEM
) ) ) O
gene NN NN O
in IN IN O
the DT DT O
paraventricular NN NN O
( ( ( O
PVN NNP NNP O
) ) ) O
and CC CC O
supraoptic JJ JJ O
nuclei NN NN O
( ( ( O
SON NNP NNP O
) ) ) O
was VBD VBD O
investigated VBN VBN O
in IN IN O
rats NNS NNS O
with IN IN O
lithium NN NN B-CHEM
( ( ( O
Li NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
polyuria NN NN O
, , , O
using VBG VBG O
in IN IN O
situ NN NN O
hybridization NN NN O
histochemistry NN NN O
and CC CC O
radioimmunoassay NN NN O
. . . O

The DT DT O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
consuming VBG VBG O
a DT DT O
diet NN NN O
that WDT WDT O
contained VBD VBD O
LiCl NNP NNP B-CHEM
( ( ( O
60 CD CD O
mmol NN NN O
/ NN NN O
kg NN NN O
) ) ) O
for IN IN O
4 CD CD O
weeks NNS NNS O
developed VBN VBN O
marked VBN VBN O
polyuria NN NN O
. . . O

The DT DT O
Li NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
produced VBD VBD O
a DT DT O
large JJ JJ O
volume NN NN O
of IN IN O
hypotonic JJ JJ O
urine NN NN O
with IN IN O
low JJ JJ O
ionic JJ JJ O
concentrations NNS NNS O
. . . O

Plasma NNP NNP O
sodium NN NN B-CHEM
concentrations NNS NNS O
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
slightly RB RB O
increased VBN VBN O
in IN IN O
the DT DT O
Li NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
compared VBN VBN O
with IN IN O
those DT DT O
in IN IN O
controls NNS NNS O
. . . O

Plasma NNP NNP O
concentration NN NN O
of IN IN O
AVP NNP NNP B-CHEM
and CC CC O
transcripts NNS NNS O
of IN IN O
AVP NNP NNP B-CHEM
gene NN NN O
in IN IN O
the DT DT O
PVN NNP NNP O
and CC CC O
SON NNP NNP O
were VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
the DT DT O
Li NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
compared VBN VBN O
with IN IN O
controls NNS NNS O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that DT DT O
dehydration NN NN O
and CC CC O
/ NN NN O
or CC CC O
the DT DT O
activation NN NN O
of IN IN O
visceral JJ JJ O
afferent NN NN O
inputs NNS NNS O
may MD MD O
contribute VB VB O
to TO TO O
the DT DT O
elevation NN NN O
of IN IN O
plasma NN NN O
AVP NNP NNP B-CHEM
and CC CC O
the DT DT O
upregulation NN NN O
of IN IN O
AVP NNP NNP B-CHEM
gene NN NN O
expression NN NN O
in IN IN O
the DT DT O
PVN NNP NNP O
and CC CC O
the DT DT O
SON NNP NNP O
of IN IN O
the DT DT O
Li NNP NNP B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
rat NN NN O
. . . O

Antinociceptive NNP NNP O
and CC CC O
antiamnesic JJ JJ O
properties NNS NNS O
of IN IN O
the DT DT O
presynaptic JJ JJ O
cholinergic NN NN O
amplifier NN NN O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
. . . O

The DT DT O
antinociceptive JJ JJ O
effect NN NN O
of IN IN O
3 CD CD B-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
tropyl NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
p NN NN I-CHEM
- - - I-CHEM
bromophenyl NN NN I-CHEM
) ) ) I-CHEM
propionate NN NN I-CHEM
[ NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
] NN NN O
( ( ( O
10 CD CD O
- : : O
40 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
; : : O
30 CD CD O
- : : O
60 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
p NN NN O
. . . O
o NN NN O
. . . O
; : : O
10 CD CD O
- : : O
30 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
; : : O
10 CD CD O
- : : O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
mouse NN NN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
was VBD VBD O
examined VBN VBN O
in IN IN O
mice NN NN O
, , , O
rats NNS NNS O
and CC CC O
guinea NN NN O
pigs NNS NNS O
by IN IN O
use NN NN O
of IN IN O
the DT DT O
hot JJ JJ O
- - - O
plate NN NN O
, , , O
abdominal JJ JJ O
- - - O
constriction NN NN O
, , , O
tail NN NN O
- : : O
flick NN NN O
and CC CC O
paw NN NN O
- - - O
pressure NN NN O
tests NNS NNS O
. . . O

( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
antinociception NN NN O
peaked VBD VBD O
15 CD CD O
min NN NN O
after IN IN O
injection NN NN O
and CC CC O
then RB RB O
slowly RB RB O
diminished VBN VBN O
. . . O

The DT DT O
antinociception NN NN O
produced VBN VBN O
by IN IN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
was VBD VBD O
prevented VBN VBN O
by IN IN O
the DT DT O
unselective JJ JJ O
muscarinic JJ JJ O
antagonist NN NN O
atropine NN NN B-CHEM
, , , O
the DT DT O
M1 NNP NNP O
- - - O
selective JJ JJ O
antagonists NNS NNS O
pirenzepine NN NN B-CHEM
and CC CC O
dicyclomine NN NN B-CHEM
and CC CC O
the DT DT O
acetylcholine NN NN B-CHEM
depletor NN NN O
hemicholinium NN NN B-CHEM
- : : I-CHEM
3 CD CD I-CHEM
, , , O
but CC CC O
not RB RB O
by IN IN O
the DT DT O
opioid NN NN O
antagonist NN NN O
naloxone NN NN B-CHEM
, , , O
the DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acidB NN NN I-CHEM
antagonist NN NN O
3 CD CD B-CHEM
- : : I-CHEM
aminopropyl NN NN I-CHEM
- - - I-CHEM
diethoxy NN NN I-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
phosphinic JJ JJ I-CHEM
acid NN NN I-CHEM
, , , O
the DT DT O
H3 NNP NNP O
agonist NN NN O
R NN NN B-CHEM
- : : I-CHEM
( ( ( I-CHEM
alpha NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
methylhistamine NN NN I-CHEM
, , , O
the DT DT O
D2 NN NN O
antagonist NN NN O
quinpirole NN NN B-CHEM
, , , O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine4 NN NN I-CHEM
antagonist NN NN O
2 CD CD B-CHEM
- : : I-CHEM
methoxy NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
amino JJ JJ I-CHEM
- - - I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
chlorobenzoic JJ JJ I-CHEM
acid NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
diethylamino NN NN I-CHEM
) ) ) I-CHEM
ethyl NN NN I-CHEM
ester NN NN I-CHEM
hydrochloride NN NN O
, , , O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamin1A NN NN I-CHEM
antagonist NN NN O
1 CD CD B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
methoxyphenyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
phthalimido NN NN I-CHEM
) ) ) I-CHEM
butyl NN NN I-CHEM
] NN NN I-CHEM
piperazine NN NN I-CHEM
hydrobromide NN NN O
and CC CC O
the DT DT O
polyamines NNS NNS O
depletor NN NN O
reserpine NN NN B-CHEM
. . . O

Based VBN VBN O
on IN IN O
these DT DT O
data NNS NNS O
, , , O
it PRP PRP O
can MD MD O
be VB VB O
postulated VBN VBN O
that IN IN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
exerted VBD VBD O
an DT DT O
antinociceptive JJ JJ O
effect NN NN O
mediated VBN VBN O
by IN IN O
a DT DT O
central JJ JJ O
potentiation NN NN O
of IN IN O
cholinergic JJ JJ O
transmission NN NN O
. . . O

( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
( ( ( O
10 CD CD O
- : : O
40 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
was VBD VBD O
able JJ JJ O
to TO TO O
prevent VB VB O
amnesia NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
and CC CC O
dicyclomine NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
in IN IN O
the DT DT O
mouse NN NN O
passive JJ JJ O
- : : O
avoidance NN NN O
test NN NN O
. . . O

Affinity NNP NNP O
profiles NNS NNS O
of IN IN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
for IN IN O
muscarinic JJ JJ O
receptor NN NN O
subtypes NNS NNS O
, , , O
determined VBN VBN O
by IN IN O
functional JJ JJ O
studies NNS NNS O
( ( ( O
rabbit NN NN O
vas NN NN O
deferens NNS NNS O
for IN IN O
M1 NNP NNP O
, , , O
guinea NN NN O
pig NN NN O
atrium NN NN O
for IN IN O
M2 NNP NNP O
, , , O
guinea NN NN O
pig NN NN O
ileum NN NN O
for IN IN O
M3 NNP NNP O
and CC CC O
immature NN NN O
guinea NN NN O
pig NN NN O
uterus NN NN O
for IN IN O
putative JJ JJ O
M4 NNP NNP O
) ) ) O
, , , O
have VBP VBP O
shown VBN VBN O
an DT DT O
M4 NNP NNP O
/ NN NN O
M1 NNP NNP O
selectivity NN NN O
ratio NN NN O
of IN IN O
10 CD CD O
. . . O
2 CD CD O
that WDT WDT O
might MD MD O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
antinociception NN NN O
and CC CC O
the DT DT O
anti JJ JJ O
- : : O
amnesic JJ JJ O
effect NN NN O
induced VBN VBN O
by IN IN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
through IN IN O
an DT DT O
increase NN NN O
in IN IN O
acetylcholine NN NN B-CHEM
extracellular NN NN O
levels NNS NNS O
. . . O

In IN IN O
the DT DT O
antinociceptive JJ JJ O
and CC CC O
antiamnesic JJ JJ O
dose NN NN O
range NN NN O
, , , O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
did VBD VBD O
not RB RB O
impair JJ JJ O
mouse NN NN O
performance NN NN O
evaluated VBN VBN O
by IN IN O
the DT DT O
rota NN NN O
- - - O
rod NN NN O
test NN NN O
and CC CC O
Animex NNP NNP O
apparatus NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
different JJ JJ O
anaesthetic JJ JJ O
agents NNS NNS O
in IN IN O
hearing NN NN O
loss NN NN O
following VBG VBG O
spinal JJ JJ O
anaesthesia NN NN O
. . . O

The DT DT O
cause NN NN O
of IN IN O
hearing NN NN O
loss NN NN O
after IN IN O
spinal JJ JJ O
anaesthesia NN NN O
is VBZ VBZ O
unknown JJ JJ O
. . . O

Up IN IN O
until IN IN O
now RB RB O
, , , O
the DT DT O
only RB RB O
factor NN NN O
studied VBN VBN O
has VBZ VBZ O
been VBN VBN O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
diameter NN NN O
of IN IN O
the DT DT O
spinal JJ JJ O
needle NN NN O
on IN IN O
post NN NN O
- : : O
operative JJ JJ O
sensorineural JJ JJ O
hearing NN NN O
loss NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
describe VB VB O
this DT DT O
hearing NN NN O
loss NN NN O
and CC CC O
to TO TO O
investigate VB VB O
other JJ JJ O
factors NNS NNS O
influencing VBG VBG O
the DT DT O
degree NN NN O
of IN IN O
hearing NN NN O
loss NN NN O
. . . O

Two CD CD O
groups NNS NNS O
of IN IN O
22 CD CD O
similar JJ JJ O
patients NNS NNS O
were VBD VBD O
studied VBN VBN O
: : : O
one CD CD O
group NN NN O
received VBD VBD O
6 CD CD O
mL NN NN O
prilocaine NN NN B-CHEM
2 CD CD O
% NN NN O
; : : O
and CC CC O
the DT DT O
other JJ JJ O
received VBD VBD O
3 CD CD O
mL NN NN O
bupivacaine NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
% NN NN O
. . . O

Patients NNS NNS O
given VBN VBN O
prilocaine NN NN B-CHEM
were VBD VBD O
more RBR RBR O
likely JJ JJ O
to TO TO O
develop VB VB O
hearing NN NN O
loss NN NN O
( ( ( O
10 CD CD O
out IN IN O
of IN IN O
22 CD CD O
) ) ) O
than IN IN O
those DT DT O
given VBN VBN O
bupivacaine NN NN B-CHEM
( ( ( O
4 CD CD O
out IN IN O
of IN IN O
22 CD CD O
) ) ) O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
average JJ JJ O
hearing NN NN O
loss NN NN O
for IN IN O
speech NN NN O
frequencies NNS NNS O
was VBD VBD O
about IN IN O
10 CD CD O
dB NN NN O
after IN IN O
prilocaine NN NN B-CHEM
and CC CC O
15 CD CD O
dB NN NN O
after IN IN O
bupivacaine NN NN B-CHEM
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
complained VBD VBD O
of IN IN O
subjective JJ JJ O
hearing NN NN O
loss NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
the DT DT O
patients NNS NNS O
was VBD VBD O
not RB RB O
possible JJ JJ O
. . . O

A DT DT O
transient NN NN O
neurological JJ JJ O
deficit NN NN O
following VBG VBG O
intrathecal JJ JJ O
injection NN NN O
of IN IN O
1 CD CD O
% NN NN O
hyperbaric JJ JJ O
bupivacaine NN NN B-CHEM
for IN IN O
unilateral JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
transient NN NN O
neurological JJ JJ O
deficit NN NN O
that WDT WDT O
occurred VBD VBD O
after IN IN O
unilateral JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
with IN IN O
8 CD CD O
mg NN NN O
of IN IN O
1 CD CD O
% NN NN O
hyperbaric JJ JJ O
bupivacaine NN NN B-CHEM
slowly RB RB O
injected VBN VBN O
through IN IN O
a DT DT O
25 CD CD O
- : : O
gauge NN NN O
pencil NN NN O
- : : O
point NN NN O
spinal JJ JJ O
needle NN NN O
. . . O

The DT DT O
surgery NN NN O
and CC CC O
anaesthesia NN NN O
were VBD VBD O
uneventful JJ JJ O
, , , O
but CC CC O
3 CD CD O
days NNS NNS O
after IN IN O
surgery NN NN O
, , , O
the DT DT O
patient NN NN O
reported VBD VBD O
an DT DT O
area NN NN O
of IN IN O
hypoaesthesia NN NN O
over IN IN O
L3 NNP NNP O
- : : O
L4 NNP NNP O
dermatomes NNS NNS O
of IN IN O
the DT DT O
leg NN NN O
which WDT WDT O
had VBD VBD O
been VBN VBN O
operated VBN VBN O
on IN IN O
( ( ( O
loss NN NN O
of IN IN O
pinprick NN NN O
sensation NN NN O
) ) ) O
without IN IN O
reduction NN NN O
in IN IN O
muscular JJ JJ O
strength NN NN O
. . . O

Sensation NNP NNP O
in IN IN O
this DT DT O
area NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
over IN IN O
the DT DT O
following VBG VBG O
2 CD CD O
weeks NNS NNS O
. . . O

Prospective NNP NNP O
multicentre NN NN O
studies NNS NNS O
with IN IN O
a DT DT O
large JJ JJ O
population NN NN O
and CC CC O
a DT DT O
long JJ JJ O
follow NN NN O
- - - O
up RP RP O
should MD MD O
be VB VB O
performed VBN VBN O
in IN IN O
order NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
incidence NN NN O
of IN IN O
this DT DT O
unusual JJ JJ O
side NN NN O
effect NN NN O
. . . O

However RB RB O
, , , O
we PRP PRP O
suggest VBP VBP O
that IN IN O
a DT DT O
low JJ JJ O
solution NN NN O
concentration NN NN O
should MD MD O
be VB VB O
preferred VBN VBN O
for IN IN O
unilateral JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
with IN IN O
a DT DT O
hyperbaric JJ JJ O
anaesthetic JJ JJ O
solution NN NN O
( ( ( O
if IN IN O
pencil NN NN O
- - - O
point NN NN O
needle NN NN O
and CC CC O
slow JJ JJ O
injection NN NN O
rate NN NN O
are VBP VBP O
employed VBN VBN O
) ) ) O
, , , O
in IN IN O
order NN NN O
to TO TO O
minimize VB VB O
the DT DT O
risk NN NN O
of IN IN O
a DT DT O
localized JJ JJ O
high JJ JJ O
peak NN NN O
anaesthetic JJ JJ O
concentration NN NN O
, , , O
which WDT WDT O
might MD MD O
lead VB VB O
to TO TO O
a DT DT O
transient NN NN O
neurological JJ JJ O
deficit NN NN O
. . . O

Transient NNP NNP O
neurologic JJ JJ O
symptoms NNS NNS O
after IN IN O
spinal JJ JJ O
anesthesia NN NN O
: : : O
a DT DT O
lower JJR JJR O
incidence NN NN O
with IN IN O
prilocaine NN NN B-CHEM
and CC CC O
bupivacaine NN NN B-CHEM
than IN IN O
with IN IN O
lidocaine NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Recent JJ JJ O
evidence NN NN O
suggests VBZ VBZ O
that IN IN O
transient JJ JJ O
neurologic JJ JJ O
symptoms NNS NNS O
( ( ( O
TNSs NNP NNP O
) ) ) O
frequently RB RB O
follow VB VB O
lidocaine NN NN B-CHEM
spinal JJ JJ O
anesthesia NN NN O
but CC CC O
are VBP VBP O
infrequent JJ JJ O
with IN IN O
bupivacaine NN NN B-CHEM
. . . O

However RB RB O
, , , O
identification NN NN O
of IN IN O
a DT DT O
short JJ JJ O
- - - O
acting VBG VBG O
local JJ JJ O
anesthetic JJ JJ O
to TO TO O
substitute VB VB O
for IN IN O
lidocaine NN NN B-CHEM
for IN IN O
brief JJ JJ O
surgical JJ JJ O
procedures NNS NNS O
remains VBZ VBZ O
an DT DT O
important JJ JJ O
goal NN NN O
. . . O

Prilocaine NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
amide NN NN O
local JJ JJ O
anesthetic JJ JJ O
with IN IN O
a DT DT O
duration NN NN O
of IN IN O
action NN NN O
similar JJ JJ O
to TO TO O
that DT DT O
of IN IN O
lidocaine NN NN B-CHEM
. . . O

Accordingly RB RB O
, , , O
the DT DT O
present JJ JJ O
, , , O
prospective JJ JJ O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
compares VBZ VBZ O
prilocaine NN NN B-CHEM
with IN IN O
lidocaine NN NN B-CHEM
and CC CC O
bupivacaine NN NN B-CHEM
with IN IN O
respect NN NN O
to TO TO O
duration NN NN O
of IN IN O
action NN NN O
and CC CC O
relative JJ JJ O
risk NN NN O
of IN IN O
TNSs NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Ninety NNP NNP O
patients NNS NNS O
classified VBN VBN O
as IN IN O
American JJ JJ O
Society NNP NNP O
of IN IN O
Anesthesiologists NNP NNP O
physical JJ JJ O
status NN NN O
I PRP PRP O
or CC CC O
II NNP NNP O
who WP WP O
were VBD VBD O
scheduled VBN VBN O
for IN IN O
short JJ JJ O
gynecologic JJ JJ O
procedures NNS NNS O
under IN IN O
spinal JJ JJ O
anesthesia NN NN O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
receive VB VB O
2 CD CD O
. . . O
5 CD CD O
ml NN NN O
2 CD CD O
% NN NN O
lidocaine NN NN B-CHEM
in IN IN O
7 CD CD O
. . . O
5 CD CD O
% NN NN O
glucose NN NN B-CHEM
, , , O
2 CD CD O
% NN NN O
prilocaine NN NN B-CHEM
in IN IN O
7 CD CD O
. . . O
5 CD CD O
% NN NN O
glucose NN NN B-CHEM
, , , O
or CC CC O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
bupivacaine NN NN B-CHEM
in IN IN O
7 CD CD O
. . . O
5 CD CD O
% NN NN O
glucose NN NN B-CHEM
. . . O

All DT DT O
solutions NNS NNS O
were VBD VBD O
provided VBN VBN O
in IN IN O
blinded JJ JJ O
vials NNS NNS O
by IN IN O
the DT DT O
hospital NN NN O
pharmacy NN NN O
. . . O

Details NNS NNS O
of IN IN O
spinal JJ JJ O
puncture NN NN O
, , , O
extension NN NN O
and CC CC O
regression NN NN O
of IN IN O
spinal JJ JJ O
block NN NN O
, , , O
and CC CC O
the DT DT O
times NNS NNS O
to TO TO O
reach VB VB O
discharge NN NN O
criteria NNS NNS O
were VBD VBD O
noted VBN VBN O
. . . O

In IN IN O
the DT DT O
evening NN NN O
of IN IN O
postoperative JJ JJ O
day NN NN O
1 CD CD O
, , , O
patients NNS NNS O
were VBD VBD O
evaluated VBN VBN O
for IN IN O
TNSs NNP NNP O
by IN IN O
a DT DT O
physician JJ JJ O
unaware NN NN O
of IN IN O
the DT DT O
drug NN NN O
administered VBN VBN O
and CC CC O
the DT DT O
details NNS NNS O
of IN IN O
the DT DT O
anesthetic JJ JJ O
procedure NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Nine CD CD O
of IN IN O
30 CD CD O
patients NNS NNS O
receiving VBG VBG O
lidocaine NN NN B-CHEM
experienced VBN VBN O
TNSs NNP NNP O
, , , O
1 CD CD O
of IN IN O
30 CD CD O
patients NNS NNS O
receiving VBG VBG O
prilocaine NN NN B-CHEM
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
had VBD VBD O
them PRP PRP O
, , , O
and CC CC O
none NN NN O
of IN IN O
30 CD CD O
patients NNS NNS O
receiving VBG VBG O
bupivacaine NN NN B-CHEM
had VBD VBD O
TNSs NNP NNP O
. . . O

Times NNP NNP O
to TO TO O
ambulate VB VB O
and CC CC O
to TO TO O
void NN NN O
were VBD VBD O
similar JJ JJ O
after IN IN O
lidocaine NN NN B-CHEM
and CC CC O
prilocaine NN NN B-CHEM
( ( ( O
150 CD CD O
vs NNS NNS O
. . . O
165 CD CD O
min NN NN O
and CC CC O
238 CD CD O
vs NNS NNS O
. . . O
253 CD CD O
min NN NN O
, , , O
respectively RB RB O
) ) ) O
but CC CC O
prolonged JJ JJ O
after IN IN O
bupivacaine NN NN B-CHEM
( ( ( O
200 CD CD O
and CC CC O
299 CD CD O
min NN NN O
, , , O
respectively RB RB O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Prilocaine NNP NNP B-CHEM
may MD MD O
be VB VB O
preferable JJ JJ O
to TO TO O
lidocaine VB VB B-CHEM
for IN IN O
short JJ JJ O
surgical JJ JJ O
procedures NNS NNS O
because IN IN O
it PRP PRP O
has VBZ VBZ O
a DT DT O
similar JJ JJ O
duration NN NN O
of IN IN O
action NN NN O
but CC CC O
a DT DT O
lower JJR JJR O
incidence NN NN O
of IN IN O
TNSs NNP NNP O
. . . O

Suxamethonium NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
arrest NN NN O
and CC CC O
death NN NN O
following VBG VBG O
5 CD CD O
days NNS NNS O
of IN IN O
immobilization NN NN O
. . . O

The DT DT O
present JJ JJ O
report NN NN O
describes VBZ VBZ O
a DT DT O
case NN NN O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
and CC CC O
subsequent JJ JJ O
death NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
hyperkalaemia NN NN O
following VBG VBG O
the DT DT O
use NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
in IN IN O
a DT DT O
23 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Malawian NNP NNP O
woman NN NN O
. . . O

Five CD CD O
days NNS NNS O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
the DT DT O
symptoms NNS NNS O
of IN IN O
meningitis NN NN O
, , , O
the DT DT O
patient NN NN O
aspirated VBD VBD O
stomach NN NN O
contents NNS NNS O
and CC CC O
needed VBD VBD O
endotracheal JJ JJ O
intubation NN NN O
. . . O

Forty CD CD O
seconds NNS NNS O
after IN IN O
injection NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
, , , O
bradycardia NNS NNS O
and CC CC O
cardiac JJ JJ O
arrest NN NN O
occurred VBD VBD O
. . . O

Attempts NNP NNP O
to TO TO O
resuscitate VB VB O
the DT DT O
patient NN NN O
were VBD VBD O
not RB RB O
successful JJ JJ O
. . . O

The DT DT O
serum NN NN O
level NN NN O
of IN IN O
potassium NN NN B-CHEM
was VBD VBD O
observed VBN VBN O
to TO TO O
be VB VB O
8 CD CD O
. . . O
4 CD CD O
mequiv NN NN O
L NNP NNP O
- : : O
1 CD CD O
. . . O

Apart RB RB O
from IN IN O
the DT DT O
reduction NN NN O
in IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
level NN NN O
of IN IN O
consciousness NN NN O
, , , O
there EX EX O
were VBD VBD O
no DT DT O
signs NNS NNS O
of IN IN O
motor NN NN O
neurone NN NN O
damage NN NN O
or CC CC O
of IN IN O
any DT DT O
of IN IN O
the DT DT O
other JJ JJ O
known VBN VBN O
predisposing VBG VBG O
conditions NNS NNS O
for IN IN O
hyperkalaemia NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
. . . O

It PRP PRP O
is VBZ VBZ O
postulated VBN VBN O
that IN IN O
her PRP$ PRP$ O
death NN NN O
was VBD VBD O
caused VBN VBN O
by IN IN O
hypersensitivity NN NN O
to TO TO O
suxamethonium NN NN B-CHEM
, , , O
associated VBN VBN O
with IN IN O
her PRP$ PRP$ O
5 CD CD O
- : : O
day NN NN O
immobilization NN NN O
. . . O

Acute JJ JJ O
hepatitis NN NN O
, , , O
autoimmune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
, , , O
and CC CC O
erythroblastocytopenia NN NN O
induced VBN VBN O
by IN IN O
ceftriaxone NN NN B-CHEM
. . . O

An DT DT O
80 CD CD O
- : : O
yr NN NN O
- - - O
old JJ JJ O
man NN NN O
developed VBN VBN O
acute JJ JJ O
hepatitis NN NN O
shortly RB RB O
after IN IN O
ingesting VBG VBG O
oral JJ JJ O
ceftriaxone NN NN B-CHEM
. . . O

Although IN IN O
the DT DT O
transaminases NNS NNS O
gradually RB RB O
returned VBD VBD O
to TO TO O
baseline VB VB O
after IN IN O
withholding VBG VBG O
the DT DT O
beta NN NN B-CHEM
lactam NN NN I-CHEM
antibiotic JJ JJ O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
gradual JJ JJ O
increase NN NN O
in IN IN O
serum NN NN O
bilirubin NN NN B-CHEM
and CC CC O
a DT DT O
decrease NN NN O
in IN IN O
hemoglobin NN NN O
concentration NN NN O
caused VBN VBN O
by IN IN O
an DT DT O
autoimmune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
and CC CC O
erythroblastocytopenia NN NN O
. . . O

These DT DT O
responded VBD VBD O
to TO TO O
systemic JJ JJ O
steroids NNS NNS B-CHEM
and CC CC O
immunoglobulins NNS NNS O
. . . O

Despite IN IN O
the DT DT O
widespread JJ JJ O
use NN NN O
of IN IN O
these DT DT O
agents NNS NNS O
this DT DT O
triad NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
has VBZ VBZ O
not RB RB O
previously RB RB O
been VBN VBN O
reported VBN VBN O
in IN IN O
connection NN NN O
with IN IN O
beta NN NN B-CHEM
lactam NN NN I-CHEM
antibiotics NNS NNS O
. . . O

Thyroxine NNP NNP B-CHEM
abuse NN NN O
: : : O
an DT DT O
unusual JJ JJ O
case NN NN O
of IN IN O
thyrotoxicosis NN NN O
in IN IN O
pregnancy NN NN O
. . . O

Eating NNP NNP O
disorders NNS NNS O
and CC CC O
the DT DT O
associated VBN VBN O
behavioural NN NN O
problems NNS NNS O
and CC CC O
drug NN NN O
abuse NN NN O
are VBP VBP O
uncommon JJ JJ O
in IN IN O
pregnancy NN NN O
. . . O

When WRB WRB O
they PRP PRP O
do VBP VBP O
occur VB VB O
they PRP PRP O
are VBP VBP O
often RB RB O
unrecognized JJ JJ O
because IN IN O
of IN IN O
denial NN NN O
but CC CC O
when WRB WRB O
significant JJ JJ O
may MD MD O
pose VB VB O
a DT DT O
risk NN NN O
to TO TO O
both DT DT O
the DT DT O
mother NN NN O
and CC CC O
her PRP$ PRP$ O
fetus NN NN O
. . . O

This DT DT O
case NN NN O
illustrates VBZ VBZ O
a DT DT O
number NN NN O
of IN IN O
problems NNS NNS O
that WDT WDT O
may MD MD O
be VB VB O
encountered VBN VBN O
in IN IN O
women NNS NNS O
with IN IN O
eating VBG VBG O
disorders NNS NNS O
in IN IN O
pregnancy NN NN O
, , , O
including VBG VBG O
prolonged JJ JJ O
and CC CC O
recurrent JJ JJ O
metabolic JJ JJ O
disturbances NNS NNS O
and CC CC O
diuretic JJ JJ O
abuse NN NN O
. . . O

In IN IN O
particular JJ JJ O
it PRP PRP O
illustrates VBZ VBZ O
the DT DT O
derangements NNS NNS O
of IN IN O
thyroid NN NN O
function NN NN O
seen VBN VBN O
in IN IN O
pregnant JJ JJ O
women NNS NNS O
with IN IN O
eating VBG VBG O
disorders NNS NNS O
and CC CC O
reminds VBZ VBZ O
us PRP PRP O
that IN IN O
when WRB WRB O
a DT DT O
cause NN NN O
for IN IN O
thyrotoxicosis NNS NNS O
remains VBZ VBZ O
obscure JJ JJ O
, , , O
thyroxine NN NN B-CHEM
abuse NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
and CC CC O
explored JJ JJ O
. . . O

Repeated NNP NNP O
trimipramine NN NN B-CHEM
induces NNS NNS O
dopamine VBP VBP B-CHEM
D2 NN NN O
/ NN NN O
D3 NNP NNP O
and CC CC O
alpha1 NN NN O
- - - O
adrenergic JJ JJ O
up RB RB O
- - - O
regulation NN NN O
. . . O

Trimipramine NNP NNP B-CHEM
( ( ( O
TRI NNP NNP B-CHEM
) ) ) O
, , , O
which WDT WDT O
shows VBZ VBZ O
a DT DT O
clinical JJ JJ O
antidepressant NN NN B-CHEM
activity NN NN O
, , , O
is VBZ VBZ O
chemically RB RB O
related VBN VBN O
to TO TO O
imipramine NN NN B-CHEM
but CC CC O
does VBZ VBZ O
not RB RB O
inhibit VB VB O
the DT DT O
reuptake NN NN O
of IN IN O
noradrenaline NN NN B-CHEM
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine NN NN I-CHEM
, , , O
nor CC CC O
does VBZ VBZ O
it PRP PRP O
induce VBP VBP O
beta NN NN O
- - - O
adrenergic JJ JJ O
down RB RB O
- - - O
regulation NN NN O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
its PRP$ PRP$ O
antidepressant JJ JJ B-CHEM
activity NN NN O
is VBZ VBZ O
still RB RB O
unknown JJ JJ O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
find VB VB O
out IN IN O
whether IN IN O
TRI NNP NNP B-CHEM
given VBN VBN O
repeatedly RB RB O
was VBD VBD O
able JJ JJ O
to TO TO O
induce VB VB O
adaptive JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
dopaminergic JJ JJ O
and CC CC O
alpha1 NN NN O
- - - O
adrenergic JJ JJ O
systems NNS NNS O
, , , O
demonstrated VBN VBN O
by IN IN O
us PRP PRP O
previously RB RB O
for IN IN O
various JJ JJ O
antidepressants NNS NNS B-CHEM
. . . O

TRI NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
to TO TO O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
and CC CC O
male JJ JJ O
Albino NNP NNP O
Swiss NNP NNP O
mice NN NN O
perorally RB RB O
twice RB RB O
daily JJ JJ O
for IN IN O
14 CD CD O
days NNS NNS O
. . . O

In IN IN O
the DT DT O
acute JJ JJ O
experiment NN NN O
TRI NNP NNP B-CHEM
( ( ( O
given VBN VBN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
does VBZ VBZ O
not RB RB O
antagonize VB VB O
the DT DT O
reserpine NN NN B-CHEM
hypothermia NN NN O
in IN IN O
mice NN NN O
and CC CC O
does VBZ VBZ O
not RB RB O
potentiate VB VB O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptophan NN NN I-CHEM
head NN NN O
twitches NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

TRI NNP NNP B-CHEM
given VBN VBN O
repeatedly RB RB O
to TO TO O
rats VB VB O
increases NNS NNS O
the DT DT O
locomotor NN NN O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
amphetamine NN NN I-CHEM
, , , O
quinpirole NN NN B-CHEM
and CC CC O
( ( ( O
+ NN NN O
) ) ) O
- : : O
7 CD CD O
- : : O
hydroxy NN NN O
- : : O
dipropyloaminotetralin NN NN O
( ( ( O
dopamine NN NN B-CHEM
D2 NN NN O
and CC CC O
D3 NNP NNP O
effects NNS NNS O
) ) ) O
. . . O

The DT DT O
stereotypies NNS NNS O
induced VBN VBN O
by IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
amphetamine NN NN I-CHEM
or CC CC O
apomorphine NN NN B-CHEM
are VBP VBP O
not RB RB O
potentiated VBN VBN O
by IN IN O
TRI NNP NNP B-CHEM
. . . O

It PRP PRP O
increases VBZ VBZ O
the DT DT O
behaviour NN NN O
stimulation NN NN O
evoked VBN VBN O
by IN IN O
phenylephrine NN NN B-CHEM
( ( ( O
given VBN VBN O
intraventricularly RB RB O
) ) ) O
in IN IN O
rats NNS NNS O
, , , O
evaluated VBN VBN O
in IN IN O
the DT DT O
open JJ JJ O
field NN NN O
test NN NN O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
aggressiveness NN NN O
evoked VBN VBN O
by IN IN O
clonidine NN NN B-CHEM
in IN IN O
mice NN NN O
, , , O
both DT DT O
these DT DT O
effects NNS NNS O
being VBG VBG O
mediated VBN VBN O
by IN IN O
an DT DT O
alpha1 NN NN O
- - - O
adrenergic JJ JJ O
receptor NN NN O
. . . O

It PRP PRP O
may MD MD O
be VB VB O
concluded VBN VBN O
that IN IN O
, , , O
like IN IN O
other JJ JJ O
tricyclic JJ JJ O
antidepressants NNS NNS B-CHEM
studied VBN VBN O
previously RB RB O
, , , O
TRI NNP NNP B-CHEM
given VBN VBN O
repeatedly RB RB O
increases NNS NNS O
the DT DT O
responsiveness NN NN O
of IN IN O
brain NN NN O
dopamine NN NN B-CHEM
D2 NN NN O
and CC CC O
D3 NNP NNP O
( ( ( O
locomotor NN NN O
activity NN NN O
but CC CC O
not RB RB O
stereotypy VB VB O
) ) ) O
as RB RB O
well RB RB O
as IN IN O
alpha1 NN NN O
- - - O
adrenergic JJ JJ O
receptors NNS NNS O
to TO TO O
their PRP$ PRP$ O
agonists NNS NNS O
. . . O

A DT DT O
question NN NN O
arises VBZ VBZ O
whether IN IN O
the DT DT O
reuptake NN NN O
inhibition NN NN O
is VBZ VBZ O
of IN IN O
any DT DT O
importance NN NN O
to TO TO O
the DT DT O
adaptive JJ JJ O
changes NNS NNS O
induced VBN VBN O
by IN IN O
repeated VBN VBN O
antidepressants NNS NNS B-CHEM
, , , O
suggested VBD VBD O
to TO TO O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
antidepressant NN NN B-CHEM
activity NN NN O
. . . O

Pethidine NNP NNP B-CHEM
- - - O
associated VBN VBN O
seizure NN NN O
in IN IN O
a DT DT O
healthy JJ JJ O
adolescent NN NN O
receiving VBG VBG O
pethidine NN NN B-CHEM
for IN IN O
postoperative JJ JJ O
pain NN NN O
control NN NN O
. . . O

A DT DT O
healthy JJ JJ O
17 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
received VBD VBD O
standard JJ JJ O
intermittent NN NN O
doses NNS NNS O
of IN IN O
pethidine NN NN B-CHEM
via IN IN O
a DT DT O
patient NN NN O
- - - O
controlled JJ JJ O
analgesia NN NN O
( ( ( O
PCA NNP NNP O
) ) ) O
pump NN NN O
for IN IN O
management NN NN O
of IN IN O
postoperative JJ JJ O
pain NN NN O
control NN NN O
. . . O

Twenty CD CD O
- - - O
three CD CD O
h NN NN O
postoperatively RB RB O
he PRP PRP O
developed VBD VBD O
a DT DT O
brief JJ JJ O
self NN NN O
- - - O
limited JJ JJ O
seizure NN NN O
. . . O

Both DT DT O
plasma NN NN O
pethidine NN NN B-CHEM
and CC CC O
norpethidine NN NN B-CHEM
were VBD VBD O
elevated VBN VBN O
in IN IN O
the DT DT O
range NN NN O
associated VBN VBN O
with IN IN O
clinical JJ JJ O
manifestations NNS NNS O
of IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
excitation NN NN O
. . . O

No DT DT O
other JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
CNS NNP NNP O
toxicity NN NN O
were VBD VBD O
identified VBN VBN O
. . . O

This DT DT O
method NN NN O
allowed VBD VBD O
frequent JJ JJ O
self NN NN O
- - - O
dosing NN NN O
of IN IN O
pethidine NN NN B-CHEM
at IN IN O
short JJ JJ O
time NN NN O
intervals NNS NNS O
and CC CC O
rapid JJ JJ O
accumulation NN NN O
of IN IN O
pethidine NN NN B-CHEM
and CC CC O
norpethidine NN NN B-CHEM
. . . O

The DT DT O
routine JJ JJ O
use NN NN O
of IN IN O
pethidine NN NN B-CHEM
via IN IN O
PCA NNP NNP O
even RB RB O
for IN IN O
a DT DT O
brief JJ JJ O
postoperative JJ JJ O
analgesia NN NN O
should MD MD O
be VB VB O
reconsidered VBN VBN O
. . . O

An DT DT O
unusual JJ JJ O
toxic JJ JJ O
reaction NN NN O
to TO TO O
axillary JJ JJ O
block NN NN O
by IN IN O
mepivacaine NN NN B-CHEM
with IN IN O
adrenaline NN NN B-CHEM
. . . O

An DT DT O
increase NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
, , , O
accompanied VBN VBN O
by IN IN O
atrial JJ JJ O
fibrillation NN NN O
, , , O
agitation NN NN O
, , , O
incomprehensible JJ JJ O
shouts NNS NNS O
and CC CC O
loss NN NN O
of IN IN O
consciousness NN NN O
, , , O
was VBD VBD O
observed VBN VBN O
in IN IN O
an DT DT O
elderly JJ JJ O
, , , O
ASA NNP NNP O
classification NN NN O
group NN NN O
II NNP NNP O
, , , O
cardiovascularly RB RB O
medicated VBN VBN O
male NN NN O
, , , O
12 CD CD O
min NN NN O
after IN IN O
performance NN NN O
of IN IN O
axillary JJ JJ O
block NN NN O
with IN IN O
mepivacaine NN NN B-CHEM
850 CD CD O
mg NN NN O
containing VBG VBG O
adrenaline NN NN B-CHEM
0 CD CD O
. . . O
225 CD CD O
mg NN NN O
, , , O
for IN IN O
correction NN NN O
of IN IN O
Dupuytren NNP NNP O
' POS POS O
s VBZ VBZ O
contracture NN NN O
. . . O

After IN IN O
intravenous JJ JJ O
administration NN NN O
of IN IN O
labetalol NN NN B-CHEM
, , , O
metoprolol NN NN B-CHEM
and CC CC O
midazolam NN NN B-CHEM
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
condition NN NN O
improved VBN VBN O
, , , O
and CC CC O
15 CD CD O
min NN NN O
later RB RB O
he PRP PRP O
woke VBD VBD O
up RB RB O
. . . O

The DT DT O
block NN NN O
was VBD VBD O
successful JJ JJ O
and CC CC O
surgery NN NN O
was VBD VBD O
conducted VBN VBN O
as IN IN O
scheduled VBN VBN O
despite IN IN O
persisting VBG VBG O
atrial JJ JJ O
fibrillation NN NN O
. . . O

Postoperatively NNP NNP O
, , , O
the DT DT O
patient NN NN O
refused VBD VBD O
DC NNP NNP O
cardioversion NN NN O
and CC CC O
was VBD VBD O
treated VBN VBN O
medically RB RB O
. . . O

Both DT DT O
the DT DT O
temporal JJ JJ O
relationship NN NN O
of IN IN O
events NNS NNS O
and CC CC O
the DT DT O
response NN NN O
to TO TO O
treatment NN NN O
suggest VBP VBP O
that IN IN O
a DT DT O
rapid JJ JJ O
systemic JJ JJ O
absorption NN NN O
of IN IN O
mepivacaine NN NN B-CHEM
with IN IN O
adrenaline NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
interaction NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
with IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
cardiovascular JJ JJ O
medications NNS NNS O
were VBD VBD O
responsible JJ JJ O
for IN IN O
the DT DT O
perioperative JJ JJ O
complications NNS NNS O
. . . O

Drug NN NN O
- - - O
associated VBN VBN O
acute JJ JJ O
- - - O
onset NN NN O
vanishing VBG VBG O
bile JJ JJ O
duct NN NN O
and CC CC O
Stevens NNP NNP O
- : : O
Johnson NNP NNP O
syndromes NNS NNS O
in IN IN O
a DT DT O
child NN NN O
. . . O

Acute JJ JJ O
vanishing VBG VBG O
bile NN NN O
duct NN NN O
syndrome NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
but CC CC O
established VBN VBN O
cause NN NN O
of IN IN O
progressive JJ JJ O
cholestasis NN NN O
in IN IN O
adults NNS NNS O
, , , O
is VBZ VBZ O
most RBS RBS O
often RB RB O
drug NN NN O
or CC CC O
toxin NN NN O
related VBN VBN O
, , , O
and CC CC O
is VBZ VBZ O
of IN IN O
unknown JJ JJ O
pathogenesis NNS NNS O
. . . O

It PRP PRP O
has VBZ VBZ O
not RB RB O
been VBN VBN O
reported VBN VBN O
previously RB RB O
in IN IN O
children NNS NNS O
. . . O

Stevens NNP NNP O
- : : O
Johnson NNP NNP O
syndrome NN NN O
is VBZ VBZ O
a DT DT O
well RB RB O
- - - O
recognized VBN VBN O
immune JJ JJ O
complex JJ JJ O
- - - O
mediated JJ JJ O
hypersensitivity NN NN O
reaction NN NN O
that IN IN O
affects NNS NNS O
all DT DT O
age NN NN O
groups NNS NNS O
, , , O
is VBZ VBZ O
drug NN NN O
or CC CC O
infection NN NN O
induced VBN VBN O
, , , O
and CC CC O
has VBZ VBZ O
classic JJ JJ O
systemic JJ JJ O
, , , O
mucosal NN NN O
, , , O
and CC CC O
dermatologic JJ JJ O
manifestations NNS NNS O
. . . O

A DT DT O
previously RB RB O
healthy JJ JJ O
child NN NN O
who WP WP O
developed VBD VBD O
acute JJ JJ O
, , , O
severe JJ JJ O
, , , O
rapidly RB RB O
progressive JJ JJ O
vanishing VBG VBG O
bile NN NN O
duct NN NN O
syndrome NN NN O
shortly RB RB O
after IN IN O
Stevens NNP NNP O
- : : O
Johnson NNP NNP O
syndrome NN NN O
is VBZ VBZ O
described VBN VBN O
; : : O
this DT DT O
was VBD VBD O
temporally RB RB O
associated VBN VBN O
with IN IN O
ibuprofen NN NN B-CHEM
use NN NN O
. . . O

Despite IN IN O
therapy NN NN O
with IN IN O
ursodeoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
prednisone NN NN B-CHEM
, , , O
and CC CC O
then RB RB O
tacrolimus NN NN B-CHEM
, , , O
her PRP$ PRP$ O
cholestatic JJ JJ O
disease NN NN O
was VBD VBD O
unrelenting VBG VBG O
, , , O
with IN IN O
cirrhosis NNS NNS O
shown VBN VBN O
by IN IN O
biopsy NN NN O
6 CD CD O
months NNS NNS O
after IN IN O
presentation NN NN O
. . . O

This DT DT O
case NN NN O
documents NNS NNS O
acute JJ JJ O
drug NN NN O
- - - O
related VBN VBN O
vanishing VBG VBG O
bile JJ JJ O
duct NN NN O
syndrome NN NN O
in IN IN O
the DT DT O
pediatric JJ JJ O
age NN NN O
group NN NN O
and CC CC O
suggests VBZ VBZ O
shared VBN VBN O
immune JJ JJ O
mechanisms NNS NNS O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
both DT DT O
Stevens NNP NNP O
- - - O
Johnson NNP NNP O
syndrome NN NN O
and CC CC O
vanishing VBG VBG O
bile JJ JJ O
duct NN NN O
syndrome NN NN O
. . . O

High NNP NNP O
incidence NN NN O
of IN IN O
primary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
associated VBN VBN O
with IN IN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
in IN IN O
Belgium NNP NNP O
. . . O

Primary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
, , , O
progressive JJ JJ O
and CC CC O
incurable JJ JJ O
disease NN NN O
, , , O
which WDT WDT O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
the DT DT O
intake NN NN O
of IN IN O
appetite NN NN B-CHEM
suppressant JJ JJ I-CHEM
drugs NNS NNS O
. . . O

The DT DT O
importance NN NN O
of IN IN O
this DT DT O
association NN NN O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
Belgium NNP NNP O
while IN IN O
this DT DT O
country NN NN O
still RB RB O
had VBD VBD O
no DT DT O
restriction NN NN O
on IN IN O
the DT DT O
prescription NN NN O
of IN IN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
. . . O

Thirty NNP NNP O
- : : O
five CD CD O
patients NNS NNS O
with IN IN O
primary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
and CC CC O
85 CD CD O
matched JJ JJ O
controls NNS NNS O
were VBD VBD O
recruited VBN VBN O
over IN IN O
32 CD CD O
months NNS NNS O
( ( ( O
1992 CD CD O
- : : O
1994 CD CD O
) ) ) O
in IN IN O
Belgium NNP NNP O
. . . O

Exposure NNP NNP O
to TO TO O
appetite VB VB B-CHEM
- - - I-CHEM
suppressants NNS NNS I-CHEM
was VBD VBD O
assessed VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
hospital NN NN O
records NNS NNS O
and CC CC O
standardized JJ JJ O
interview NN NN O
. . . O

Twenty CD CD O
- - - O
three CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
previously RB RB O
taken VBN VBN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
, , , O
mainly RB RB O
fenfluramines NNS NNS B-CHEM
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
only RB RB O
5 CD CD O
of IN IN O
the DT DT O
controls NNS NNS O
( ( ( O
66 CD CD O
versus CC CC O
6 CD CD O
% NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

Five CD CD O
patients NNS NNS O
died VBD VBD O
before IN IN O
the DT DT O
interview NN NN O
, , , O
all DT DT O
of IN IN O
them PRP PRP O
had VBD VBD O
taken VBN VBN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
. . . O

In IN IN O
8 CD CD O
patients NNS NNS O
the DT DT O
diagnosis NN NN O
of IN IN O
primary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
was VBD VBD O
uncertain JJ JJ O
, , , O
5 CD CD O
of IN IN O
them PRP PRP O
had VBD VBD O
taken VBN VBN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
. . . O

The DT DT O
patients NNS NNS O
who WP WP O
had VBD VBD O
been VBN VBN O
exposed VBN VBN O
to TO TO O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
tended VBD VBD O
to TO TO O
be VB VB O
on IN IN O
average JJ JJ O
more RBR RBR O
severely RB RB O
ill JJ JJ O
, , , O
and CC CC O
to TO TO O
have VB VB O
a DT DT O
shorter JJR JJR O
median JJ JJ O
delay NN NN O
between IN IN O
onset NN NN O
of IN IN O
symptoms NNS NNS O
and CC CC O
diagnosis NN NN O
. . . O

A DT DT O
policy NN NN O
of IN IN O
unrestricted JJ JJ O
prescription NN NN O
of IN IN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
may MD MD O
lead VB VB O
to TO TO O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
associated VBN VBN O
primary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
. . . O

Intake NNP NNP O
of IN IN O
appetite NN NN B-CHEM
suppressants NNS NNS I-CHEM
may MD MD O
accelerate VB VB O
the DT DT O
progression NN NN O
of IN IN O
the DT DT O
disease NN NN O
. . . O

Inappropriate NNP NNP O
use NN NN O
of IN IN O
carbamazepine NN NN B-CHEM
and CC CC O
vigabatrin NN NN B-CHEM
in IN IN O
typical JJ JJ O
absence NN NN O
seizures NNS NNS O
. . . O

Carbamazepine NNP NNP B-CHEM
and CC CC O
vigabatrin NN NN B-CHEM
are VBP VBP O
contraindicated VBN VBN O
in IN IN O
typical JJ JJ O
absence NN NN O
seizures NNS NNS O
. . . O

Of IN IN O
18 CD CD O
consecutive JJ JJ O
referrals NNS NNS O
of IN IN O
children NNS NNS O
with IN IN O
resistant JJ JJ O
typical JJ JJ O
absences NNS NNS O
only RB RB O
, , , O
eight CD CD O
were VBD VBD O
erroneously RB RB O
treated VBN VBN O
with IN IN O
carbamazepine NN NN B-CHEM
either CC CC O
as IN IN O
monotherapy NN NN O
or CC CC O
as IN IN O
an DT DT O
add NN NN O
- - - O
on IN IN O
. . . O

Vigabatrin NNP NNP B-CHEM
was VBD VBD O
also RB RB O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
two CD CD O
children NNS NNS O
. . . O

Frequency NNP NNP O
of IN IN O
absences NNS NNS O
increased VBN VBN O
in IN IN O
four CD CD O
children NNS NNS O
treated VBN VBN O
with IN IN O
carbamazepine NN NN B-CHEM
and CC CC O
two CD CD O
of IN IN O
these DT DT O
developed JJ JJ O
myoclonic JJ JJ O
jerks NNS NNS O
, , , O
which WDT WDT O
resolved VBD VBD O
on IN IN O
withdrawal NN NN O
of IN IN O
carbamazepine NN NN B-CHEM
. . . O

Absences NNP NNP O
were VBD VBD O
aggravated VBN VBN O
in IN IN O
both DT DT O
cases NNS NNS O
where WRB WRB O
vigabatrin NN NN B-CHEM
was VBD VBD O
added VBN VBN O
on IN IN O
to TO TO O
concurrent NN NN O
treatment NN NN O
. . . O

Optimal NNP NNP O
control NN NN O
of IN IN O
the DT DT O
absences NNS NNS O
was VBD VBD O
achieved VBN VBN O
with IN IN O
sodium NN NN B-CHEM
valproate NN NN I-CHEM
, , , O
lamotrigine NN NN B-CHEM
, , , O
or CC CC O
ethosuximide NN NN B-CHEM
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
. . . O

Choreoathetoid NNP NNP O
movements NNS NNS O
associated VBN VBN O
with IN IN O
rapid JJ JJ O
adjustment NN NN O
to TO TO O
methadone NN NN B-CHEM
. . . O

Choreatiform NNP NNP O
hyperkinesias NNS NNS O
are VBP VBP O
known VBN VBN O
to TO TO O
be VB VB O
occasional JJ JJ O
movement NN NN O
abnormalities NNS NNS O
during IN IN O
intoxications NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
but CC CC O
not RB RB O
opiates NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
a DT DT O
case NN NN O
report NN NN O
of IN IN O
euphoria NNS NNS O
and CC CC O
choreoathetoid NN NN O
movements NNS NNS O
both DT DT O
transiently RB RB O
induced VBN VBN O
by IN IN O
rapid JJ JJ O
adjustment NN NN O
to TO TO O
the DT DT O
selective JJ JJ O
mu NN NN O
- - - O
opioid NN NN O
receptor NN NN O
agonist NN NN O
methadone NN NN B-CHEM
in IN IN O
an DT DT O
inpatient NN NN O
previously RB RB O
abusing VBG VBG O
heroine NN NN B-CHEM
and CC CC O
cocaine NN NN B-CHEM
. . . O

In IN IN O
addition NN NN O
, , , O
minor JJ JJ O
EEG NNP NNP O
abnormalities NNS NNS O
occurred VBD VBD O
. . . O

Possible JJ JJ O
underlying VBG VBG O
neurobiological JJ JJ O
phenomena NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Adverse NNP NNP O
effects NNS NNS O
of IN IN O
the DT DT O
atypical JJ JJ O
antipsychotics NNS NNS O
. . . O

Collaborative NNP NNP O
Working NNP NNP O
Group NNP NNP O
on IN IN O
Clinical NNP NNP O
Trial NN NN O
Evaluations NNP NNP O
. . . O

Adverse NNP NNP O
effects NNS NNS O
of IN IN O
antipsychotics NNS NNS O
often RB RB O
lead VBP VBP O
to TO TO O
noncompliance NN NN O
. . . O

Thus RB RB O
, , , O
clinicians NNS NNS O
should MD MD O
address VB VB O
patients NNS NNS O
' POS POS O
concerns NNS NNS O
about IN IN O
adverse JJ JJ O
effects NNS NNS O
and CC CC O
attempt NN NN O
to TO TO O
choose VB VB O
medications NNS NNS O
that WDT WDT O
will MD MD O
improve VB VB O
their PRP$ PRP$ O
patients NNS NNS O
' POS POS O
quality NN NN O
of IN IN O
life NN NN O
as RB RB O
well RB RB O
as IN IN O
overall JJ JJ O
health NN NN O
. . . O

The DT DT O
side NN NN O
effect NN NN O
profiles NNS NNS O
of IN IN O
the DT DT O
atypical JJ JJ O
antipsychotics NNS NNS O
are VBP VBP O
more RBR RBR O
advantageous JJ JJ O
than IN IN O
those DT DT O
of IN IN O
the DT DT O
conventional JJ JJ O
neuroleptics NNS NNS O
. . . O

Conventional NNP NNP O
agents NNS NNS O
are VBP VBP O
associated VBN VBN O
with IN IN O
unwanted JJ JJ O
central JJ JJ O
nervous JJ JJ O
system NN NN O
effects NNS NNS O
, , , O
including VBG VBG O
extrapyramidal NN NN O
symptoms NNS NNS O
( ( ( O
EPS NNP NNP O
) ) ) O
, , , O
tardive JJ JJ O
dyskinesia NN NN O
, , , O
sedation NN NN O
, , , O
and CC CC O
possible JJ JJ O
impairment NN NN O
of IN IN O
some DT DT O
cognitive JJ JJ O
measures NNS NNS O
, , , O
as RB RB O
well RB RB O
as IN IN O
cardiac JJ JJ O
effects NNS NNS O
, , , O
orthostatic JJ JJ O
hypotension NN NN O
, , , O
hepatic JJ JJ O
changes NNS NNS O
, , , O
anticholinergic JJ JJ O
side NN NN O
effects NNS NNS O
, , , O
sexual JJ JJ O
dysfunction NN NN O
, , , O
and CC CC O
weight NN NN O
gain NN NN O
. . . O

The DT DT O
newer JJR JJR O
atypical JJ JJ O
agents NNS NNS O
have VBP VBP O
a DT DT O
lower JJR JJR O
risk NN NN O
of IN IN O
EPS NNP NNP O
, , , O
but CC CC O
are VBP VBP O
associated VBN VBN O
in IN IN O
varying VBG VBG O
degrees NNS NNS O
with IN IN O
sedation NN NN O
, , , O
cardiovascular JJ JJ O
effects NNS NNS O
, , , O
anticholinergic JJ JJ O
effects NNS NNS O
, , , O
weight NN NN O
gain NN NN O
, , , O
sexual JJ JJ O
dysfunction NN NN O
, , , O
hepatic JJ JJ O
effects NNS NNS O
, , , O
lowered VBD VBD O
seizure NN NN O
threshold NN NN O
( ( ( O
primarily RB RB O
clozapine NN NN B-CHEM
) ) ) O
, , , O
and CC CC O
agranulocytosis NN NN O
( ( ( O
clozapine NN NN B-CHEM
only RB RB O
) ) ) O
. . . O

Since IN IN O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
specific JJ JJ O
adverse JJ JJ O
effects NNS NNS O
differ VBP VBP O
among IN IN O
the DT DT O
various JJ JJ O
atypicals NNS NNS O
, , , O
the DT DT O
clinician NN NN O
should MD MD O
carefully RB RB O
consider VB VB O
which WDT WDT O
side NN NN O
effects NNS NNS O
are VBP VBP O
most RBS RBS O
likely JJ JJ O
to TO TO O
lead VB VB O
to TO TO O
the DT DT O
individual JJ JJ O
' POS POS O
s VBZ VBZ O
dissatisfaction NN NN O
and CC CC O
noncompliance NN NN O
before IN IN O
choosing VBG VBG O
an DT DT O
antipsychotic JJ JJ O
for IN IN O
a DT DT O
particular JJ JJ O
patient NN NN O
. . . O

A DT DT O
randomized JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled VBN VBN O
dose NN NN O
- - - O
comparison NN NN O
trial NN NN O
of IN IN O
haloperidol NN NN B-CHEM
for IN IN O
psychosis NN NN O
and CC CC O
disruptive JJ JJ O
behaviors NNS NNS O
in IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
goal NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
compare VB VB O
the DT DT O
efficacy NN NN O
and CC CC O
side NN NN O
effects NNS NNS O
of IN IN O
two CD CD O
doses NNS NNS O
of IN IN O
haloperidol NN NN B-CHEM
and CC CC O
placebo NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
psychosis NN NN O
and CC CC O
disruptive JJ JJ O
behaviors NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

METHOD NNP NNP O
: : : O
In IN IN O
a DT DT O
6 CD CD O
- : : O
week NN NN O
random JJ JJ O
- : : O
assignment NN NN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
( ( ( O
phase NN NN O
A DT DT O
) ) ) O
, , , O
haloperidol NN NN B-CHEM
, , , O
2 CD CD O
- : : O
3 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
( ( ( O
standard JJ JJ O
dose NN NN O
) ) ) O
, , , O
and CC CC O
haloperidol NN NN B-CHEM
, , , O
0 CD CD O
. . . O
50 CD CD O
- : : O
0 CD CD O
. . . O
75 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
( ( ( O
low JJ JJ O
dose NN NN O
) ) ) O
, , , O
were VBD VBD O
compared VBN VBN O
in IN IN O
71 CD CD O
outpatients NNS NNS O
with IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

For IN IN O
the DT DT O
subsequent JJ JJ O
6 CD CD O
- : : O
week NN NN O
double JJ JJ O
- : : O
blind JJ JJ O
crossover NN NN O
phase NN NN O
( ( ( O
phase NN NN O
B NNP NNP O
) ) ) O
, , , O
patients NNS NNS O
taking VBG VBG O
standard JJ JJ O
- - - O
or CC CC O
low JJ JJ O
- - - O
dose NN NN O
haloperidol NN NN B-CHEM
were VBD VBD O
switched VBN VBN O
to TO TO O
placebo NN NN O
, , , O
and CC CC O
patients NNS NNS O
taking VBG VBG O
placebo NN NN O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
standard JJ JJ O
- - - O
or CC CC O
low JJ JJ O
- - - O
dose NN NN O
haloperidol NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
For IN IN O
the DT DT O
60 CD CD O
patients NNS NNS O
who WP WP O
completed VBD VBD O
phase NN NN O
A DT DT O
, , , O
standard JJ JJ O
- - - O
dose NN NN O
haloperidol NN NN B-CHEM
was VBD VBD O
efficacious JJ JJ O
and CC CC O
superior JJ JJ O
to TO TO O
both DT DT O
low JJ JJ O
- - - O
dose NN NN O
haloperidol NN NN B-CHEM
and CC CC O
placebo NN NN O
for IN IN O
scores NNS NNS O
on IN IN O
the DT DT O
Brief NNP NNP O
Psychiatric NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
psychosis NN NN O
factor NN NN O
and CC CC O
on IN IN O
psychomotor NN NN O
agitation NN NN O
. . . O

Response NNP NNP O
rates NNS NNS O
according VBG VBG O
to TO TO O
three CD CD O
sets NNS NNS O
of IN IN O
criteria NNS NNS O
were VBD VBD O
greater JJR JJR O
with IN IN O
the DT DT O
standard JJ JJ O
dose NN NN O
( ( ( O
55 CD CD O
% NN NN O
- : : O
60 CD CD O
% NN NN O
) ) ) O
than IN IN O
the DT DT O
low JJ JJ O
dose NN NN O
( ( ( O
25 CD CD O
% NN NN O
- : : O
35 CD CD O
% NN NN O
) ) ) O
and CC CC O
placebo NN NN O
( ( ( O
25 CD CD O
% NN NN O
- : : O
30 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
advantage NN NN O
of IN IN O
standard JJ JJ O
dose NN NN O
over IN IN O
low JJ JJ O
dose NN NN O
was VBD VBD O
replicated VBN VBN O
in IN IN O
phase NN NN O
B NNP NNP O
. . . O

In IN IN O
phase NN NN O
A DT DT O
, , , O
extrapyramidal NN NN O
signs NNS NNS O
tended VBN VBN O
to TO TO O
be VB VB O
greater JJR JJR O
with IN IN O
the DT DT O
standard JJ JJ O
dose NN NN O
than IN IN O
in IN IN O
the DT DT O
other JJ JJ O
two CD CD O
conditions NNS NNS O
, , , O
primarily RB RB O
because IN IN O
of IN IN O
a DT DT O
subgroup NN NN O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
who WP WP O
developed VBD VBD O
moderate JJ JJ O
to TO TO O
severe JJ JJ O
signs NNS NNS O
. . . O

Low NNP NNP O
- - - O
dose NN NN O
haloperidol NN NN B-CHEM
did VBD VBD O
not RB RB O
differ VB VB O
from IN IN O
placebo NN NN O
on IN IN O
any DT DT O
measure NN NN O
of IN IN O
efficacy NN NN O
or CC CC O
side NN NN O
effects NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
results NNS NNS O
indicated VBD VBD O
a DT DT O
favorable JJ JJ O
therapeutic JJ JJ O
profile NN NN O
for IN IN O
haloperidol NN NN B-CHEM
in IN IN O
doses NNS NNS O
of IN IN O
2 CD CD O
- : : O
3 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
, , , O
although IN IN O
a DT DT O
subgroup NN NN O
developed VBN VBN O
moderate JJ JJ O
to TO TO O
severe JJ JJ O
extrapyramidal NN NN O
signs NNS NNS O
. . . O

A DT DT O
starting VBG VBG O
dose NN NN O
of IN IN O
1 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
with IN IN O
gradual JJ JJ O
, , , O
upward RB RB O
dose NN NN O
titration NN NN O
is VBZ VBZ O
recommended VBN VBN O
. . . O

The DT DT O
narrow JJ JJ O
therapeutic JJ JJ O
window NN NN O
observed VBD VBD O
with IN IN O
haloperidol NN NN B-CHEM
may MD MD O
also RB RB O
apply VB VB O
to TO TO O
other JJ JJ O
neuroleptics NNS NNS O
used VBN VBN O
in IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patients NNS NNS O
with IN IN O
psychosis NN NN O
and CC CC O
disruptive JJ JJ O
behaviors NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
acetylsalicylic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
dipyridamole NN NN B-CHEM
, , , O
and CC CC O
hydrocortisone NN NN B-CHEM
on IN IN O
epinephrine NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
injury NN NN O
in IN IN O
dogs NNS NNS O
. . . O

A DT DT O
reproducible JJ JJ O
model NN NN O
for IN IN O
producing VBG VBG O
diffuse NN NN O
myocardial NN NN O
injury NN NN O
( ( ( O
epinephrine NN NN B-CHEM
infusion NN NN O
) ) ) O
has VBZ VBZ O
been VBN VBN O
developed VBN VBN O
to TO TO O
study VB VB O
the DT DT O
cardioprotective JJ JJ O
effects NNS NNS O
of IN IN O
agents NNS NNS O
or CC CC O
maneuvers NNS NNS O
which WDT WDT O
might MD MD O
alter VB VB O
the DT DT O
evolution NN NN O
of IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

Infusions NNP NNP O
of IN IN O
epinephrine NN NN B-CHEM
( ( ( O
4 CD CD O
mug NN NN O
per IN IN O
kilogram NN NN O
per IN IN O
minute NN NN O
for IN IN O
6 CD CD O
hours NNS NNS O
) ) ) O
increased VBN VBN O
radiocalcium NN NN B-CHEM
uptakes NNS NNS O
into IN IN O
intact JJ JJ O
myocardium NN NN O
and CC CC O
each DT DT O
of IN IN O
its PRP$ PRP$ O
subcellular JJ JJ O
components NNS NNS O
with IN IN O
the DT DT O
mitochondrial JJ JJ O
fraction NN NN O
showing VBG VBG O
the DT DT O
most RBS RBS O
consistent JJ JJ O
changes NNS NNS O
when WRB WRB O
compared VBN VBN O
to TO TO O
saline VB VB O
- - - O
infused JJ JJ O
control NN NN O
animals NNS NNS O
( ( ( O
4 CD CD O
, , , O
957 CD CD O
vs NNS NNS O
. . . O
827 CD CD O
counts NNS NNS O
per IN IN O
minute NN NN O
per IN IN O
gram NN NN O
of IN IN O
dried JJ JJ O
tissue NN NN O
or CC CC O
fraction NN NN O
) ) ) O
. . . O

Myocardial NNP NNP O
concentrations NNS NNS O
of IN IN O
calcium NN NN B-CHEM
also RB RB O
increased VBD VBD O
significantly RB RB O
( ( ( O
12 CD CD O
. . . O
0 CD CD O
vs NNS NNS O
. . . O
5 CD CD O
. . . O
0 CD CD O
mg NN NN O
. . . O
per IN IN O
100 CD CD O
Gm NNP NNP O
. . . O
of IN IN O
fat JJ JJ O
- - - O
free JJ JJ O
dry JJ JJ O
weight NN NN O
) ) ) O
. . . O

Infusions NNP NNP O
of IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
sufficient JJ JJ O
to TO TO O
raise VB VB O
serum NN NN O
calcium NN NN B-CHEM
concentrations NNS NNS O
2 CD CD O
mEq NN NN O
. . . O
per IN IN O
liter NN NN O
failed VBD VBD O
to TO TO O
increase VB VB O
calcium NN NN B-CHEM
influx NN NN O
into IN IN O
the DT DT O
myocardial NN NN O
cell NN NN O
. . . O

Mitochondrial NNP NNP O
radiocalcium NN NN B-CHEM
uptakes NNS NNS O
were VBD VBD O
significantly RB RB O
decreased VBN VBN O
in IN IN O
animals NNS NNS O
pretreated VBN VBN O
with IN IN O
acetylsalicylic JJ JJ B-CHEM
acid NN NN I-CHEM
or CC CC O
dipyridamole NN NN B-CHEM
or CC CC O
when WRB WRB O
hydrocortisone NN NN B-CHEM
was VBD VBD O
added VBN VBN O
to TO TO O
the DT DT O
epinephrine NN NN B-CHEM
infusion NN NN O
( ( ( O
2 CD CD O
, , , O
682 CD CD O
, , , O
2 CD CD O
, , , O
803 CD CD O
, , , O
and CC CC O
3 CD CD O
, , , O
424 CD CD O
counts NNS NNS O
per IN IN O
minute NN NN O
per IN IN O
gram NN NN O
of IN IN O
dried JJ JJ O
fraction NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

Myocardial NNP NNP O
calcium NN NN B-CHEM
concentrations NNS NNS O
also RB RB O
were VBD VBD O
decreased VBN VBN O
( ( ( O
11 CD CD O
. . . O
2 CD CD O
, , , O
8 CD CD O
. . . O
3 CD CD O
, , , O
and CC CC O
8 CD CD O
. . . O
9 CD CD O
mg NN NN O
. . . O
per IN IN O
100 CD CD O
Gm NNP NNP O
. . . O
of IN IN O
fat JJ JJ O
- - - O
free JJ JJ O
dry JJ JJ O
weight NN NN O
, , , O
respectively RB RB O
) ) ) O
in IN IN O
the DT DT O
three CD CD O
treatment NN NN O
groups NNS NNS O
, , , O
being VBG VBG O
significantly RB RB O
decreased VBD VBD O
only RB RB O
in IN IN O
the DT DT O
last JJ JJ O
two CD CD O
. . . O

Evidence NN NN O
of IN IN O
microscopic NN NN O
damage NN NN O
was VBD VBD O
graded VBN VBN O
as IN IN O
less JJR JJR O
severe JJ JJ O
in IN IN O
the DT DT O
three CD CD O
treatment NN NN O
groups NNS NNS O
. . . O

Acetylsalicylic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
dipyridamole NN NN B-CHEM
, , , O
and CC CC O
hydrocortisone NN NN B-CHEM
all DT DT O
appear VBP VBP O
to TO TO O
have VB VB O
cardioprotective JJ JJ O
effects NNS NNS O
when WRB WRB O
tested VBN VBN O
in IN IN O
this DT DT O
model NN NN O
. . . O

Clinical NNP NNP O
and CC CC O
histopathologic JJ JJ O
examination NN NN O
of IN IN O
renal JJ JJ O
allografts NNS NNS O
treated VBN VBN O
with IN IN O
tacrolimus NN NN B-CHEM
( ( ( O
FK506 NNP NNP B-CHEM
) ) ) O
for IN IN O
at IN IN O
least JJS JJS O
one CD CD O
year NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
We PRP PRP O
clinically RB RB O
and CC CC O
pathologically RB RB O
analyzed JJ JJ O
renal JJ JJ O
allografts NNS NNS O
from IN IN O
1 CD CD O
9 CD CD O
renal JJ JJ O
transplant NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
tacrolimus NN NN B-CHEM
( ( ( O
FK506 NNP NNP B-CHEM
) ) ) O
for IN IN O
more JJR JJR O
than IN IN O
1 CD CD O
year NN NN O
. . . O

METHODS NNP NNP O
: : : O
Twenty CD CD O
- - - O
six CD CD O
renal JJ JJ O
allograft NN NN O
biopsy NN NN O
specimens NNS NNS O
from IN IN O
1 CD CD O
9 CD CD O
renal JJ JJ O
transplant NN NN O
patients NNS NNS O
who WP WP O
underwent JJ JJ O
transplantations NNS NNS O
between IN IN O
1991 CD CD O
and CC CC O
1993 CD CD O
were VBD VBD O
evaluated VBN VBN O
. . . O

Thirteen NNP NNP O
biopsies NNS NNS O
were VBD VBD O
performed VBN VBN O
from IN IN O
stable JJ JJ O
functioning VBG VBG O
renal JJ JJ O
allografts NNS NNS O
with IN IN O
informed JJ JJ O
consent NN NN O
( ( ( O
nonepisode NN NN O
biopsy NN NN O
) ) ) O
and CC CC O
the DT DT O
other JJ JJ O
13 CD CD O
were VBD VBD O
from IN IN O
dysfunctional JJ JJ O
renal NN NN O
allografts NNS NNS O
with IN IN O
a DT DT O
clinical JJ JJ O
indication NN NN O
for IN IN O
biopsy NN NN O
( ( ( O
episode NN NN O
biopsy NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
main JJ JJ O
pathologic JJ JJ O
diagnoses NNS NNS O
( ( ( O
some DT DT O
overlap VB VB O
) ) ) O
were VBD VBD O
acute JJ JJ O
rejection NN NN O
( ( ( O
AR NNP NNP O
; : : O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
, , , O
chronic JJ JJ O
rejection NN NN O
( ( ( O
CR NNP NNP O
; : : O
n NN NN O
= SYM SYM O
5 CD CD O
) ) ) O
, , , O
AR NNP NNP O
+ NN NN O
CR NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
, , , O
recurrent JJ JJ O
IgA NNP NNP O
nephropathy NN NN O
( ( ( O
n NN NN O
= SYM SYM O
5 CD CD O
) ) ) O
, , , O
normal JJ JJ O
findings NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
, , , O
minimal JJ JJ O
- - - O
type NN NN O
chronic JJ JJ O
FK506 NNP NNP B-CHEM
nephropathy JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
9 CD CD O
) ) ) O
, , , O
and CC CC O
mild JJ JJ O
- - - O
type NN NN O
FK506 NNP NNP B-CHEM
nephropathy NN NN O
( ( ( O
n NN NN O
= SYM SYM O
11 CD CD O
) ) ) O
. . . O

Of IN IN O
the DT DT O
nonepisode NN NN O
biopsies NNS NNS O
, , , O
7 CD CD O
and CC CC O
4 CD CD O
biopsies NNS NNS O
showed VBD VBD O
minimal JJ JJ O
- : : O
type NN NN O
and CC CC O
mild VB VB O
- : : O
type NN NN O
chronic JJ JJ O
FK506 NNP NNP B-CHEM
nephropathy NN NN O
, , , O
respectively RB RB O
. . . O

Chronic NNP NNP O
FK506 NNP NNP B-CHEM
nephropathy NN NN O
consisted VBD VBD O
of IN IN O
rough JJ JJ O
and CC CC O
foamy NN NN O
tubular JJ JJ O
vacuolization NN NN O
( ( ( O
5 CD CD O
biopsies NNS NNS O
) ) ) O
, , , O
arteriolopathy JJ JJ O
( ( ( O
angiodegeneration NN NN O
of IN IN O
the DT DT O
arteriolar JJ JJ O
wall NN NN O
; : : O
20 CD CD O
biopsies NNS NNS O
) ) ) O
, , , O
focal JJ JJ O
segmental NN NN O
glomerulosclerosis NN NN O
( ( ( O
4 CD CD O
biopsies NNS NNS O
) ) ) O
and CC CC O
the DT DT O
striped JJ JJ O
form NN NN O
of IN IN O
interstitial JJ JJ O
fibrosis NNS NNS O
( ( ( O
11 CD CD O
biopsies NNS NNS O
) ) ) O
. . . O

The DT DT O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
of IN IN O
patients NNS NNS O
in IN IN O
the DT DT O
mild JJ JJ O
- - - O
type NN NN O
chronic JJ JJ O
FK506 NNP NNP B-CHEM
nephropathy JJ JJ O
group NN NN O
, , , O
which WDT WDT O
included VBD VBD O
7 CD CD O
episode NN NN O
biopsies NNS NNS O
, , , O
were VBD VBD O
statistically RB RB O
higher JJR JJR O
than IN IN O
those DT DT O
in IN IN O
the DT DT O
minimum JJ JJ O
- - - O
type NN NN O
chronic JJ JJ O
FK506 NNP NNP B-CHEM
- : : O
nephropathy JJ JJ O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
study NN NN O
demonstrates VBZ VBZ O
that IN IN O
chronic JJ JJ O
FK506 NNP NNP B-CHEM
nephropathy JJ JJ O
consists VBZ VBZ O
primarily RB RB O
of IN IN O
arteriolopathy JJ JJ O
manifesting NN NN O
as IN IN O
insudative JJ JJ O
hyalinosis NN NN O
of IN IN O
the DT DT O
arteriolar JJ JJ O
wall NN NN O
, , , O
and CC CC O
suggests VBZ VBZ O
that IN IN O
mild JJ JJ O
- : : O
type NN NN O
chronic JJ JJ O
FK506 NNP NNP B-CHEM
nephropathy NN NN O
is VBZ VBZ O
a DT DT O
condition NN NN O
which WDT WDT O
may MD MD O
lead VB VB O
to TO TO O
deterioration NN NN O
of IN IN O
renal JJ JJ O
allograft NN NN O
function NN NN O
. . . O

Different JJ JJ O
lobular JJ JJ O
distributions NNS NNS O
of IN IN O
altered VBN VBN O
hepatocyte NN NN O
tight JJ JJ O
junctions NNS NNS O
in IN IN O
rat NN NN O
models NNS NNS O
of IN IN O
intrahepatic JJ JJ O
and CC CC O
extrahepatic JJ JJ O
cholestasis NN NN O
. . . O

Hepatocyte NNP NNP O
tight JJ JJ O
junctions NNS NNS O
( ( ( O
TJs NNP NNP O
) ) ) O
, , , O
the DT DT O
only RB RB O
intercellular JJ JJ O
barrier NN NN O
between IN IN O
the DT DT O
sinusoidal NN NN O
and CC CC O
the DT DT O
canalicular JJ JJ O
spaces NNS NNS O
, , , O
play VBP VBP O
a DT DT O
key JJ JJ O
role NN NN O
in IN IN O
bile NN NN O
formation NN NN O
. . . O

Although IN IN O
hepatocyte NN NN O
TJs NNP NNP O
are VBP VBP O
impaired VBN VBN O
in IN IN O
cholestasis NN NN O
, , , O
attempts NNS NNS O
to TO TO O
localize VB VB O
the DT DT O
precise JJ JJ O
site NN NN O
of IN IN O
hepatocyte NN NN O
TJ NNP NNP O
damage NN NN O
by IN IN O
freeze NN NN O
- : : O
fracture NN NN O
electron NN NN O
microscopy NN NN O
have VBP VBP O
produced VBN VBN O
limited JJ JJ O
information NN NN O
. . . O

Recently RB RB O
, , , O
several JJ JJ O
TJ NNP NNP O
- - - O
associated VBN VBN O
proteins NNS NNS O
like IN IN O
ZO NNP NNP O
- : : O
1 CD CD O
and CC CC O
7H6 CD CD O
have VBP VBP O
been VBN VBN O
identified VBN VBN O
and CC CC O
characterized VBN VBN O
. . . O

Immunolocalization NNP NNP O
of IN IN O
7H6 CD CD O
appears VBZ VBZ O
to TO TO O
closely RB RB O
correlate VB VB O
with IN IN O
paracellular JJ JJ O
permeability NN NN O
. . . O

We PRP PRP O
used VBD VBD O
rat NN NN O
models NNS NNS O
of IN IN O
intrahepatic JJ JJ O
cholestasis NN NN O
by IN IN O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
( ( ( O
EE NNP NNP B-CHEM
) ) ) O
treatment NN NN O
and CC CC O
extrahepatic JJ JJ O
cholestasis NN NN O
by IN IN O
bile NN NN O
duct NN NN O
ligation NN NN O
( ( ( O
BDL NNP NNP O
) ) ) O
to TO TO O
precisely RB RB O
determine VB VB O
the DT DT O
site NN NN O
of IN IN O
TJ NNP NNP O
damage NN NN O
. . . O

Alterations NNP NNP O
in IN IN O
hepatocyte NN NN O
TJs NNP NNP O
were VBD VBD O
assessed VBN VBN O
by IN IN O
double JJ JJ O
- : : O
immunolabeling VBG VBG O
for IN IN O
7H6 CD CD O
and CC CC O
ZO NNP NNP O
- : : O
1 CD CD O
using VBG VBG O
a DT DT O
confocal JJ JJ O
laser NN NN O
scanning VBG VBG O
microscope NN NN O
. . . O

In IN IN O
control NN NN O
rats NNS NNS O
, , , O
immunostaining VBG VBG O
for IN IN O
7H6 CD CD O
and CC CC O
ZO NNP NNP O
- : : O
1 CD CD O
colocalized VBN VBN O
to TO TO O
outline VB VB O
bile NN NN O
canaliculi NN NN O
in IN IN O
a DT DT O
continuous JJ JJ O
fashion NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
7H6 CD CD O
and CC CC O
ZO NNP NNP O
- : : O
1 CD CD O
immunostaining VBG VBG O
was VBD VBD O
more RBR RBR O
discontinuous JJ JJ O
, , , O
outlining VBG VBG O
the DT DT O
bile NN NN O
canaliculi NN NN O
after IN IN O
BDL NNP NNP O
. . . O

Immunostaining NNP NNP O
for IN IN O
7H6 CD CD O
, , , O
not RB RB O
ZO NNP NNP O
- : : O
1 CD CD O
, , , O
decreased VBD VBD O
and CC CC O
predominantly RB RB O
appeared VBN VBN O
as IN IN O
discrete JJ JJ O
signals NNS NNS O
in IN IN O
the DT DT O
submembranous JJ JJ O
cytoplasm NN NN O
of IN IN O
periportal JJ JJ O
hepatocytes NNS NNS O
after IN IN O
BDL NNP NNP O
. . . O

After IN IN O
EE NNP NNP B-CHEM
treatment NN NN O
, , , O
changes NNS NNS O
in IN IN O
immunostaining VBG VBG O
for IN IN O
7H6 CD CD O
and CC CC O
ZO NNP NNP O
- : : O
1 CD CD O
were VBD VBD O
similar JJ JJ O
to TO TO O
those DT DT O
seen VBN VBN O
in IN IN O
periportal JJ JJ O
hepatocytes NNS NNS O
after IN IN O
BDL NNP NNP O
, , , O
but CC CC O
distributed VBN VBN O
more RBR RBR O
diffusely RB RB O
throughout IN IN O
the DT DT O
lobule NN NN O
. . . O

This DT DT O
study NN NN O
is VBZ VBZ O
the DT DT O
first JJ JJ O
to TO TO O
demonstrate VB VB O
that DT DT O
impairment NN NN O
of IN IN O
hepatocyte NN NN O
TJs NNP NNP O
occurs VBZ VBZ O
heterogenously RB RB O
in IN IN O
the DT DT O
liver NN NN O
lobule NN NN O
after IN IN O
BDL NNP NNP O
and CC CC O
suggests VBZ VBZ O
that IN IN O
BDL NNP NNP O
and CC CC O
EE NNP NNP B-CHEM
treatments NNS NNS O
produce VBP VBP O
different JJ JJ O
lobular JJ JJ O
distributions NNS NNS O
of IN IN O
increased VBN VBN O
paracellular NN NN O
permeability NN NN O
. . . O

Memory NN NN O
facilitation NN NN O
and CC CC O
stimulation NN NN O
of IN IN O
endogenous JJ JJ O
nerve NN NN O
growth NN NN O
factor NN NN O
synthesis NN NN O
by IN IN O
the DT DT O
acetylcholine NN NN B-CHEM
releaser NN NN O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
( ( ( O
3alpha CD CD B-CHEM
- : : I-CHEM
tropyl NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
p NN NN I-CHEM
- - - I-CHEM
bromophenyl NN NN I-CHEM
) ) ) I-CHEM
propionate NN NN I-CHEM
) ) ) O
, , , O
the DT DT O
acetylcholine NN NN B-CHEM
releaser NN NN O
, , , O
on IN IN O
memory NN NN O
processes NNS NNS O
and CC CC O
nerve NN NN O
growth NN NN O
factor NN NN O
( ( ( O
NGF NNP NNP O
) ) ) O
synthesis NN NN O
were VBD VBD O
evaluated VBN VBN O
. . . O

In IN IN O
the DT DT O
mouse NN NN O
passive JJ JJ O
- : : O
avoidance NN NN O
test NN NN O
, , , O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
( ( ( O
10 CD CD O
- : : O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
administered VBD VBD O
20 CD CD O
min NN NN O
before IN IN O
the DT DT O
training NN NN O
session NN NN O
, , , O
prevented VBN VBN O
amnesia NN NN O
induced VBN VBN O
by IN IN O
both DT DT O
the DT DT O
non NN NN O
selective JJ JJ O
antimuscarinic JJ JJ O
drug NN NN O
scopolamine NN NN B-CHEM
and CC CC O
the DT DT O
M1 NNP NNP O
- - - O
selective JJ JJ O
antagonist NN NN O
S NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
- : : I-CHEM
) ) ) I-CHEM
- : : I-CHEM
ET NNP NNP I-CHEM
- : : I-CHEM
126 CD CD I-CHEM
. . . O

In IN IN O
the DT DT O
same JJ JJ O
experimental JJ JJ O
conditions NNS NNS O
, , , O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
( ( ( O
5 CD CD O
- : : O
20 CD CD O
microg NN NN O
per IN IN O
mouse NN NN O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
was VBD VBD O
also RB RB O
able JJ JJ O
to TO TO O
prevent VB VB O
antimuscarine NN NN O
- : : O
induced JJ JJ O
amnesia NN NN O
, , , O
demonstrating VBG VBG O
a DT DT O
central JJ JJ O
localization NN NN O
of IN IN O
the DT DT O
activity NN NN O
. . . O

At IN IN O
the DT DT O
highest JJS JJS O
effective JJ JJ O
doses NNS NNS O
, , , O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
did VBD VBD O
not RB RB O
produce VB VB O
any DT DT O
collateral NN NN O
symptoms NNS NNS O
as IN IN O
revealed VBN VBN O
by IN IN O
the DT DT O
Irwin NNP NNP O
test NN NN O
, , , O
and CC CC O
it PRP PRP O
did VBD VBD O
not RB RB O
modify VB VB O
spontaneous JJ JJ O
motility NN NN O
and CC CC O
inspection NN NN O
activity NN NN O
, , , O
as IN IN O
revealed VBN VBN O
by IN IN O
the DT DT O
hole NN NN O
- - - O
board NN NN O
test NN NN O
. . . O

PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
was VBD VBD O
also RB RB O
able JJ JJ O
to TO TO O
increase VB VB O
the DT DT O
amount NN NN O
of IN IN O
NGF NNP NNP O
secreted VBD VBD O
in IN IN O
vitro NN NN O
by IN IN O
astrocytes NNS NNS O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

The DT DT O
maximal NN NN O
NGF NNP NNP O
contents NNS NNS O
obtained VBN VBN O
by IN IN O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
were VBD VBD O
17 CD CD O
. . . O
6 CD CD O
- : : O
fold NN NN O
of IN IN O
the DT DT O
control NN NN O
value NN NN O
. . . O

During IN IN O
culture NN NN O
, , , O
no DT DT O
morphological JJ JJ O
changes NNS NNS O
were VBD VBD O
found VBN VBN O
at IN IN O
effective JJ JJ O
concentrations NNS NNS O
of IN IN O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
. . . O

The DT DT O
current JJ JJ O
work NN NN O
indicates VBZ VBZ O
the DT DT O
ability NN NN O
of IN IN O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
to TO TO O
induce VB VB O
beneficial JJ JJ O
effects NNS NNS O
on IN IN O
cognitive JJ JJ O
processes NNS NNS O
and CC CC O
stimulate JJ JJ O
activity NN NN O
of IN IN O
NGF NNP NNP O
synthesis NN NN O
in IN IN O
astroglial JJ JJ O
cells NNS NNS O
. . . O

Therefore RB RB O
, , , O
PG NNP NNP B-CHEM
- : : I-CHEM
9 CD CD I-CHEM
could MD MD O
represent VB VB O
a DT DT O
potential JJ JJ O
useful JJ JJ O
drug NN NN O
able JJ JJ O
to TO TO O
improve VB VB O
the DT DT O
function NN NN O
of IN IN O
impaired VBN VBN O
cognitive JJ JJ O
processes NNS NNS O
. . . O

Mechanisms NNP NNP O
of IN IN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

- : : O
Tacrolimus NNP NNP B-CHEM
( ( ( O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
powerful JJ JJ O
, , , O
widely RB RB O
used VBN VBN O
immunosuppressant NN NN O
. . . O

The DT DT O
clinical JJ JJ O
utility NN NN O
of IN IN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
is VBZ VBZ O
complicated VBN VBN O
by IN IN O
substantial JJ JJ O
hypertension NN NN O
and CC CC O
nephrotoxicity NN NN O
. . . O

To TO TO O
clarify VB VB O
the DT DT O
mechanisms NNS NNS O
of IN IN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
chronic JJ JJ O
effects NNS NNS O
of IN IN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
on IN IN O
the DT DT O
synthesis NN NN O
of IN IN O
endothelin NN NN O
- - - O
1 CD CD O
( ( ( O
ET NNP NNP O
- - - O
1 CD CD O
) ) ) O
, , , O
the DT DT O
expression NN NN O
of IN IN O
mRNA NN NN O
of IN IN O
ET NNP NNP O
- : : O
1 CD CD O
and CC CC O
endothelin NN NN O
- - - O
converting VBG VBG O
enzyme NN NN O
- : : O
1 CD CD O
( ( ( O
ECE NNP NNP O
- - - O
1 CD CD O
) ) ) O
, , , O
the DT DT O
endothelial JJ JJ O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
( ( ( O
eNOS NN NN O
) ) ) O
activity NN NN O
, , , O
and CC CC O
the DT DT O
expression NN NN O
of IN IN O
mRNA NN NN O
of IN IN O
eNOS NN NN O
and CC CC O
C NNP NNP O
- : : O
type NN NN O
natriuretic JJ JJ O
peptide NN NN O
( ( ( O
CNP NNP NNP O
) ) ) O
in IN IN O
rat NN NN O
blood NN NN O
vessels NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
specific JJ JJ O
endothelin NN NN O
type NN NN O
A DT DT O
receptor NN NN O
antagonist NN NN O
FR NNP NNP B-CHEM
139317 CD CD I-CHEM
on IN IN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
in IN IN O
rats NNS NNS O
was VBD VBD O
studied VBN VBN O
. . . O

FK NNP NNP B-CHEM
506 CD CD I-CHEM
, , , O
5 CD CD O
mg NN NN O
. . . O

kg NN NN O
- : : O
1 CD CD O
. . . O

d SYM SYM O
- : : O
1 CD CD O
given VBN VBN O
for IN IN O
4 CD CD O
weeks NNS NNS O
, , , O
elevated VBD VBD O
blood NN NN O
pressure NN NN O
from IN IN O
102 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
to TO TO O
152 CD CD O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
mm NN NN O
Hg NNP NNP O
and CC CC O
increased VBD VBD O
the DT DT O
synthesis NN NN O
of IN IN O
ET NNP NNP O
- : : O
1 CD CD O
and CC CC O
the DT DT O
levels NNS NNS O
of IN IN O
ET NNP NNP O
- : : O
1 CD CD O
mRNA NN NN O
in IN IN O
the DT DT O
mesenteric JJ JJ O
artery NN NN O
( ( ( O
240 CD CD O
% NN NN O
and CC CC O
230 CD CD O
% NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

Little JJ JJ O
change NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
expression NN NN O
of IN IN O
ECE NNP NNP O
- : : O
1 CD CD O
mRNA NN NN O
and CC CC O
CNP NNP NNP O
mRNA NN NN O
. . . O

FK NNP NNP B-CHEM
506 CD CD I-CHEM
decreased VBD VBD O
eNOS NN NN O
activity NN NN O
and CC CC O
the DT DT O
levels NNS NNS O
of IN IN O
eNOS NN NN O
mRNA NN NN O
in IN IN O
the DT DT O
aorta NN NN O
( ( ( O
48 CD CD O
% NN NN O
and CC CC O
55 CD CD O
% NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

The DT DT O
administration NN NN O
of IN IN O
FR NNP NNP B-CHEM
139317 CD CD I-CHEM
( ( ( O
10 CD CD O
mg NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
d SYM SYM O
- : : O
1 CD CD O
) ) ) O
prevented VBN VBN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
in IN IN O
rats NNS NNS O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
may MD MD O
increase VB VB O
blood NN NN O
pressure NN NN O
not RB RB O
only RB RB O
by IN IN O
increasing VBG VBG O
ET NNP NNP O
- : : O
1 CD CD O
production NN NN O
but CC CC O
also RB RB O
by IN IN O
decreasing VBG VBG O
NO DT DT B-CHEM
synthesis NN NN O
in IN IN O
the DT DT O
vasculature NN NN O
. . . O

22 CD CD B-CHEM
- : : I-CHEM
oxacalcitriol NN NN I-CHEM
suppresses NNS NNS O
secondary JJ JJ O
hyperparathyroidism NN NN O
without IN IN O
inducing VBG VBG O
low JJ JJ O
bone NN NN O
turnover NN NN O
in IN IN O
dogs NNS NNS O
with IN IN O
renal JJ JJ O
failure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Calcitriol NNP NNP B-CHEM
therapy NN NN O
suppresses NNS NNS O
serum NN NN O
levels NNS NNS O
of IN IN O
parathyroid NN NN O
hormone NN NN O
( ( ( O
PTH NNP NNP O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
renal JJ JJ O
failure NN NN O
but CC CC O
has VBZ VBZ O
several JJ JJ O
drawbacks NNS NNS O
, , , O
including VBG VBG O
hypercalcemia NN NN O
and CC CC O
/ NN NN O
or CC CC O
marked JJ JJ O
suppression NN NN O
of IN IN O
bone NN NN O
turnover NN NN O
, , , O
which WDT WDT O
may MD MD O
lead VB VB O
to TO TO O
adynamic JJ JJ O
bone NN NN O
disease NN NN O
. . . O

A DT DT O
new JJ JJ O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
analogue NN NN O
, , , O
22 CD CD B-CHEM
- : : I-CHEM
oxacalcitriol NN NN I-CHEM
( ( ( O
OCT NNP NNP B-CHEM
) ) ) O
, , , O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
have VB VB O
promising JJ JJ O
characteristics NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
OCT NNP NNP B-CHEM
on IN IN O
serum NN NN O
PTH NNP NNP O
levels NNS NNS O
and CC CC O
bone NN NN O
turnover NN NN O
in IN IN O
states NNS NNS O
of IN IN O
normal JJ JJ O
or CC CC O
impaired JJ JJ O
renal JJ JJ O
function NN NN O
. . . O

METHODS NNP NNP O
: : : O
Sixty NNP NNP O
dogs NNS NNS O
were VBD VBD O
either CC CC O
nephrectomized JJ JJ O
( ( ( O
Nx NNP NNP O
, , , O
N NNP NNP O
= SYM SYM O
38 CD CD O
) ) ) O
or CC CC O
sham NN NN O
- - - O
operated JJ JJ O
( ( ( O
Sham NNP NNP O
, , , O
N NNP NNP O
= SYM SYM O
22 CD CD O
) ) ) O
. . . O

The DT DT O
animals NNS NNS O
received VBD VBD O
supplemental JJ JJ O
phosphate NN NN B-CHEM
to TO TO O
enhance VB VB O
PTH NNP NNP O
secretion NN NN O
. . . O

Fourteen CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
phosphate NN NN B-CHEM
supplementation NN NN O
, , , O
half NN NN O
of IN IN O
the DT DT O
Nx NNP NNP O
and CC CC O
Sham NNP NNP O
dogs NNS NNS O
received VBD VBD O
doses NNS NNS O
of IN IN O
OCT NNP NNP B-CHEM
( ( ( O
three CD CD O
times NNS NNS O
per IN IN O
week NN NN O
) ) ) O
; : : O
the DT DT O
other JJ JJ O
half NN NN O
were VBD VBD O
given VBN VBN O
vehicle NN NN O
for IN IN O
60 CD CD O
weeks NNS NNS O
. . . O

Thereafter RB RB O
, , , O
the DT DT O
treatment NN NN O
modalities NNS NNS O
for IN IN O
a DT DT O
subset NN NN O
of IN IN O
animals NNS NNS O
were VBD VBD O
crossed VBN VBN O
over IN IN O
for IN IN O
an DT DT O
additional JJ JJ O
eight CD CD O
months NNS NNS O
. . . O

Biochemical NNP NNP O
and CC CC O
hormonal JJ JJ O
indices NNS NNS O
of IN IN O
calcium NN NN B-CHEM
and CC CC O
bone NN NN O
metabolism NN NN O
were VBD VBD O
measured VBN VBN O
throughout IN IN O
the DT DT O
study NN NN O
, , , O
and CC CC O
bone NN NN O
biopsies NNS NNS O
were VBD VBD O
done VBN VBN O
at IN IN O
baseline NN NN O
, , , O
60 CD CD O
weeks NNS NNS O
after IN IN O
OCT NNP NNP B-CHEM
or CC CC O
vehicle NN NN O
treatment NN NN O
, , , O
and CC CC O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
crossover NN NN O
period NN NN O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
Nx NNP NNP O
dogs NNS NNS O
, , , O
OCT NNP NNP B-CHEM
significantly RB RB O
decreased VBD VBD O
serum NN NN O
PTH NNP NNP O
levels NNS NNS O
soon RB RB O
after IN IN O
the DT DT O
induction NN NN O
of IN IN O
renal JJ JJ O
insufficiency NN NN O
. . . O

In IN IN O
long JJ JJ O
- - - O
standing NN NN O
secondary JJ JJ O
hyperparathyroidism NN NN O
, , , O
OCT NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
03 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
stabilized JJ JJ O
serum NN NN O
PTH NNP NNP O
levels NNS NNS O
during IN IN O
the DT DT O
first JJ JJ O
months NNS NNS O
. . . O

Serum NNP NNP O
PTH NNP NNP O
levels NNS NNS O
rose VBD VBD O
thereafter RB RB O
, , , O
but CC CC O
the DT DT O
rise NN NN O
was VBD VBD O
less RBR RBR O
pronounced JJ JJ O
compared VBN VBN O
with IN IN O
baseline NN NN O
than IN IN O
the DT DT O
rise NN NN O
seen VBN VBN O
in IN IN O
Nx NNP NNP O
control NN NN O
. . . O

These DT DT O
effects NNS NNS O
were VBD VBD O
accompanied VBN VBN O
by IN IN O
episodes NNS NNS O
of IN IN O
hypercalcemia NN NN O
and CC CC O
hyperphosphatemia NN NN O
. . . O

In IN IN O
animals NNS NNS O
with IN IN O
normal JJ JJ O
renal JJ JJ O
function NN NN O
, , , O
OCT NNP NNP B-CHEM
induced VBD VBD O
a DT DT O
transient NN NN O
decrease NN NN O
in IN IN O
serum NN NN O
PTH NNP NNP O
levels NNS NNS O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
1 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
, , , O
which WDT WDT O
was VBD VBD O
not RB RB O
sustained VBN VBN O
with IN IN O
lowering NN NN O
of IN IN O
the DT DT O
doses NNS NNS O
. . . O

In IN IN O
Nx NNP NNP O
dogs NNS NNS O
, , , O
OCT NNP NNP B-CHEM
reversed VBD VBD O
abnormal JJ JJ O
bone NN NN O
formation NN NN O
, , , O
such JJ JJ O
as IN IN O
woven NN NN O
osteoid NN NN O
and CC CC O
fibrosis NNS NNS O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
significantly RB RB O
alter VB VB O
the DT DT O
level NN NN O
of IN IN O
bone NN NN O
turnover NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
OCT NNP NNP B-CHEM
improved VBD VBD O
mineralization NN NN O
lag NN NN O
time NN NN O
, , , O
( ( ( O
that DT DT O
is VBZ VBZ O
, , , O
the DT DT O
rate NN NN O
at IN IN O
which WDT WDT O
osteoid NN NN O
mineralizes NNS NNS O
) ) ) O
in IN IN O
both DT DT O
Nx NNP NNP O
and CC CC O
Sham NNP NNP O
dogs NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
even RB RB O
though IN IN O
OCT NNP NNP B-CHEM
does VBZ VBZ O
not RB RB O
completely RB RB O
prevent VB VB O
the DT DT O
occurrence NN NN O
of IN IN O
hypercalcemia NN NN O
in IN IN O
experimental JJ JJ O
dogs NNS NNS O
with IN IN O
renal JJ JJ O
insufficiency NN NN O
, , , O
it PRP PRP O
may MD MD O
be VB VB O
of IN IN O
use NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
secondary JJ JJ O
hyperparathyroidism NN NN O
because IN IN O
it PRP PRP O
does VBZ VBZ O
not RB RB O
induce VB VB O
low JJ JJ O
bone NN NN O
turnover NN NN O
and CC CC O
, , , O
therefore RB RB O
, , , O
does VBZ VBZ O
not RB RB O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
adynamic JJ JJ O
bone NN NN O
disease NN NN O
. . . O

Hypotension NNP NNP O
, , , O
bradycardia NN NN O
, , , O
and CC CC O
asystole NN NN O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
intravenous JJ JJ O
methylprednisolone NN NN B-CHEM
in IN IN O
a DT DT O
monitored JJ JJ O
patient NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
hypotension NN NN O
, , , O
bradycardia NN NN O
, , , O
and CC CC O
asystole NN NN O
after IN IN O
intravenous JJ JJ O
administration NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
methylprednisolone NN NN B-CHEM
in IN IN O
a DT DT O
73 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
who WP WP O
underwent VBD VBD O
electrocardiographic JJ JJ O
( ( ( O
ECG NNP NNP O
) ) ) O
monitoring VBG VBG O
throughout IN IN O
the DT DT O
episode NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
history NN NN O
of IN IN O
ischemic JJ JJ O
cardiac NN NN O
disease NN NN O
9 CD CD O
years NNS NNS O
earlier RBR RBR O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
admitted VBN VBN O
with IN IN O
a DT DT O
pulmonary JJ JJ O
- - - O
renal JJ JJ O
syndrome NN NN O
with IN IN O
hemoptysis NN NN O
, , , O
rapidly RB RB O
progressive JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
and CC CC O
hypoxemia NN NN O
that WDT WDT O
required VBD VBD O
mechanical JJ JJ O
ventilation NN NN O
in IN IN O
the DT DT O
intensive JJ JJ O
care NN NN O
unit NN NN O
. . . O

After IN IN O
receiving VBG VBG O
advanced VBN VBN O
cardiopulmonary JJ JJ O
resuscitation NN NN O
, , , O
the DT DT O
patient NN NN O
recovered VBD VBD O
cardiac JJ JJ O
rhythm NN NN O
. . . O

The DT DT O
ECG NNP NNP O
showed VBD VBD O
a DT DT O
junctional JJ JJ O
rhythm NN NN O
without IN IN O
ventricular NN NN O
arrhythmia NN NN O
. . . O

This DT DT O
study NN NN O
reviews NN NN O
the DT DT O
current JJ JJ O
proposed VBN VBN O
mechanisms NNS NNS O
of IN IN O
sudden JJ JJ O
death NN NN O
after IN IN O
a DT DT O
high JJ JJ O
dose NN NN O
of IN IN O
intravenous JJ JJ O
methylprednisolone NN NN B-CHEM
( ( ( O
IVMP NNP NNP B-CHEM
) ) ) O
. . . O

These DT DT O
mechanisms NNS NNS O
are VBP VBP O
not RB RB O
well RB RB O
understood VBN VBN O
because IN IN O
, , , O
in IN IN O
most JJS JJS O
cases NNS NNS O
, , , O
the DT DT O
patients NNS NNS O
were VBD VBD O
not RB RB O
monitored VBN VBN O
at IN IN O
the DT DT O
moment NN NN O
of IN IN O
the DT DT O
event NN NN O
. . . O

Rapid NNP NNP O
infusion NN NN O
and CC CC O
underlying VBG VBG O
cardiac JJ JJ O
disease NN NN O
were VBD VBD O
important JJ JJ O
risk NN NN O
factors NNS NNS O
in IN IN O
the DT DT O
case NN NN O
reported VBD VBD O
here RB RB O
, , , O
and CC CC O
the DT DT O
authors NNS NNS O
discount NN NN O
ventricular NN NN O
arrhythmia NN NN O
as IN IN O
the DT DT O
main JJ JJ O
mechanism NN NN O
. . . O

Worsening NNP NNP O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NNS NNS O
by IN IN O
motor NN NN O
and CC CC O
mental JJ JJ O
tasks NNS NNS O
. . . O

Ten CD CD O
patients NNS NNS O
who WP WP O
had VBD VBD O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
with IN IN O
disabling VBG VBG O
dyskinesia NN NN O
were VBD VBD O
included VBN VBN O
in IN IN O
this DT DT O
study NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
role NN NN O
of IN IN O
mental JJ JJ O
( ( ( O
mental JJ JJ O
calculation NN NN O
) ) ) O
and CC CC O
motor NN NN O
( ( ( O
flexion NN NN O
/ NN NN O
extension NN NN O
of IN IN O
right NN NN O
fingers NNS NNS O
, , , O
flexion NN NN O
/ NN NN O
extension NN NN O
of IN IN O
left VBD VBD O
fingers NNS NNS O
, , , O
flexion NN NN O
/ NN NN O
extension NN NN O
of IN IN O
the DT DT O
neck NN NN O
, , , O
speaking VBG VBG O
aloud NN NN O
) ) ) O
tasks NNS NNS O
on IN IN O
the DT DT O
worsening NN NN O
of IN IN O
peak NN NN O
- - - O
dose VB VB O
dyskinesia NN NN O
following VBG VBG O
administration NN NN O
of IN IN O
an DT DT O
effective JJ JJ O
single NN NN O
dose NN NN O
of IN IN O
apomorphine NN NN B-CHEM
. . . O

Compared VBN VBN O
with IN IN O
the DT DT O
score NN NN O
at IN IN O
rest NN NN O
( ( ( O
1 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
) ) ) O
, , , O
a DT DT O
significant JJ JJ O
aggravation NN NN O
of IN IN O
the DT DT O
dyskinesia NN NN O
score NN NN O
was VBD VBD O
observed VBN VBN O
during IN IN O
speaking VBG VBG O
aloud NN NN O
( ( ( O
5 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
1 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
movements NNS NNS O
of IN IN O
right NN NN O
( ( ( O
4 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
left VBN VBN O
( ( ( O
3 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
8 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
fingers NNS NNS O
, , , O
movements NNS NNS O
of IN IN O
the DT DT O
neck NN NN O
( ( ( O
5 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
and CC CC O
mental JJ JJ O
calculation NN NN O
( ( ( O
3 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
activation NN NN O
tasks NNS NNS O
such JJ JJ O
as IN IN O
" '' '' O
speaking VBG VBG O
aloud NN NN O
" '' '' O
could MD MD O
be VB VB O
used VBN VBN O
for IN IN O
objective JJ JJ O
assessment NN NN O
of IN IN O
dyskinesia NN NN O
severity NN NN O
. . . O

Urine NNP NNP O
N NNP NNP O
- : : O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
D NNP NNP O
- - - O
glucosaminidase NN NN O
- - - O
- - - O
a DT DT O
marker NN NN O
of IN IN O
tubular NN NN O
damage NN NN O
? . . O

BACKGROUND NNP NNP O
: : : O
Although IN IN O
an DT DT O
indicator NN NN O
of IN IN O
renal NN NN O
tubular NN NN O
dysfunction NN NN O
, , , O
an DT DT O
increased JJ JJ O
urinary JJ JJ O
N NNP NNP O
- : : O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
D NNP NNP O
- : : O
glucosaminidase NN NN O
( ( ( O
NAG NNP NNP O
) ) ) O
activity NN NN O
might MD MD O
reflect VB VB O
increased VBN VBN O
lysosomal NN NN O
activity NN NN O
in IN IN O
renal NN NN O
tubular NN NN O
cells NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Puromycin NNP NNP B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
was VBD VBD O
administered VBN VBN O
to TO TO O
Sprague NNP NNP O
Dawley NNP NNP O
rats NNS NNS O
to TO TO O
induce VB VB O
proteinuria NN NN O
. . . O

Total NNP NNP O
protein NN NN O
, , , O
albumin NN NN O
, , , O
NAG NNP NNP O
activity NN NN O
and CC CC O
protein NN NN O
electrophoretic JJ JJ O
pattern NN NN O
were VBD VBD O
assessed VBN VBN O
in IN IN O
daily JJ JJ O
urine NN NN O
samples NNS NNS O
for IN IN O
33 CD CD O
days NNS NNS O
. . . O

The DT DT O
morphological JJ JJ O
appearance NN NN O
of IN IN O
the DT DT O
kidneys NNS NNS O
was VBD VBD O
examined VBN VBN O
on IN IN O
days NNS NNS O
three CD CD O
, , , O
four CD CD O
, , , O
six CD CD O
, , , O
eight CD CD O
and CC CC O
thirty CD CD O
three CD CD O
and CC CC O
the DT DT O
NAG NNP NNP O
isoenzyme NN NN O
patterns NNS NNS O
on IN IN O
days NNS NNS O
zero CD CD O
, , , O
four CD CD O
, , , O
eight CD CD O
and CC CC O
thirty CD CD O
three CD CD O
. . . O

RESULTS NNS NNS O
: : : O
Following VBG VBG O
intravenous JJ JJ O
PAN NNP NNP B-CHEM
urine NN NN O
volume NN NN O
and CC CC O
urine NN NN O
NAG NNP NNP O
activity NN NN O
increased VBD VBD O
significantly RB RB O
by IN IN O
day NN NN O
two CD CD O
, , , O
but CC CC O
returned VBD VBD O
to TO TO O
normal JJ JJ O
by IN IN O
day NN NN O
four CD CD O
. . . O

After IN IN O
day NN NN O
four CD CD O
all DT DT O
treated VBN VBN O
animals NNS NNS O
exhibited VBN VBN O
a DT DT O
marked VBN VBN O
rise NN NN O
in IN IN O
urine NN NN O
albumin NN NN O
, , , O
total JJ JJ O
protein NN NN O
excretion NN NN O
and CC CC O
NAG NNP NNP O
activity NN NN O
. . . O

Electrophoresis NNP NNP O
showed VBD VBD O
a DT DT O
generalised JJ JJ O
increase NN NN O
in IN IN O
middle NN NN O
and CC CC O
high JJ JJ O
molecular JJ JJ O
weight NN NN O
urine NN NN O
proteins NNS NNS O
from IN IN O
day NN NN O
four CD CD O
onwards NNS NNS O
. . . O

Protein NNP NNP O
droplets NNS NNS O
first JJ JJ O
appeared VBD VBD O
prominent NN NN O
in IN IN O
tubular NN NN O
cells NNS NNS O
on IN IN O
day NN NN O
four CD CD O
. . . O

Peak NNP NNP O
urine NN NN O
NAG NNP NNP O
activity NN NN O
and CC CC O
a DT DT O
change NN NN O
in IN IN O
NAG NNP NNP O
isoenzyme NN NN O
pattern NN NN O
coincided VBD VBD O
with IN IN O
both DT DT O
the DT DT O
peak NN NN O
proteinuria NN NN O
and CC CC O
the DT DT O
reduction NN NN O
in IN IN O
intracellular JJ JJ O
protein NN NN O
and CC CC O
NAG NNP NNP O
droplets NNS NNS O
( ( ( O
day NN NN O
six CD CD O
onwards NNS NNS O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
animal NN NN O
model NN NN O
demonstrates VBZ VBZ O
that IN IN O
an DT DT O
increase NN NN O
in IN IN O
lysosomal NN NN O
turnover NN NN O
and CC CC O
hence RB RB O
urine JJ JJ O
NAG NNP NNP O
activity NN NN O
, , , O
occurs VBZ VBZ O
when WRB WRB O
increased VBN VBN O
protein NN NN O
is VBZ VBZ O
presented VBN VBN O
to TO TO O
the DT DT O
tubular NN NN O
cells NNS NNS O
. . . O

Urine NNP NNP O
NAG NNP NNP O
activity NN NN O
is VBZ VBZ O
thus RB RB O
a DT DT O
measure NN NN O
of IN IN O
altered VBN VBN O
function NN NN O
in IN IN O
the DT DT O
renal JJ JJ O
tubules NNS NNS O
and CC CC O
not RB RB O
simply RB RB O
an DT DT O
indicator NN NN O
of IN IN O
damage NN NN O
. . . O

Cauda NNP NNP O
equina NN NN O
syndrome NN NN O
after IN IN O
spinal JJ JJ O
anaesthesia NN NN O
with IN IN O
hyperbaric JJ JJ O
5 CD CD O
% NN NN O
lignocaine NN NN B-CHEM
: : : O
a DT DT O
review NN NN O
of IN IN O
six CD CD O
cases NNS NNS O
of IN IN O
cauda NN NN O
equina NN NN O
syndrome NN NN O
reported VBD VBD O
to TO TO O
the DT DT O
Swedish NNP NNP O
Pharmaceutical NNP NNP O
Insurance NNP NNP O
1993 CD CD O
- : : O
1997 CD CD O
. . . O

Six CD CD O
cases NNS NNS O
of IN IN O
cauda NN NN O
equina NN NN O
syndrome NN NN O
with IN IN O
varying NN NN O
severity NN NN O
were VBD VBD O
reported VBN VBN O
to TO TO O
the DT DT O
Swedish NNP NNP O
Pharmaceutical NNP NNP O
Insurance NNP NNP O
during IN IN O
the DT DT O
period NN NN O
1993 CD CD O
- : : O
1997 CD CD O
. . . O

All DT DT O
were VBD VBD O
associated VBN VBN O
with IN IN O
spinal JJ JJ O
anaesthesia NN NN O
using VBG VBG O
hyperbaric JJ JJ O
5 CD CD O
% NN NN O
lignocaine NN NN B-CHEM
. . . O

Five CD CD O
cases NNS NNS O
had VBD VBD O
single JJ JJ O
- : : O
shot NN NN O
spinal JJ JJ O
anaesthesia NN NN O
and CC CC O
one CD CD O
had VBD VBD O
a DT DT O
repeat NN NN O
spinal JJ JJ O
anaesthetic JJ JJ O
due JJ JJ O
to TO TO O
inadequate JJ JJ O
block NN NN O
. . . O

The DT DT O
dose NN NN O
of IN IN O
hyperbaric JJ JJ O
5 CD CD O
% NN NN O
lignocaine NN NN B-CHEM
administered VBD VBD O
ranged VBN VBN O
from IN IN O
60 CD CD O
to TO TO O
120 CD CD O
mg NN NN O
. . . O

Three CD CD O
of IN IN O
the DT DT O
cases NNS NNS O
were VBD VBD O
most RBS RBS O
likely JJ JJ O
caused VBN VBN O
by IN IN O
direct JJ JJ O
neurotoxicity NN NN O
of IN IN O
hyperbaric JJ JJ O
5 CD CD O
% NN NN O
lignocaine NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
other JJ JJ O
3 CD CD O
cases NNS NNS O
, , , O
direct JJ JJ O
neurotoxicity NN NN O
was VBD VBD O
also RB RB O
probable JJ JJ O
, , , O
but CC CC O
unfortunately RB RB O
radiological JJ JJ O
investigations NNS NNS O
were VBD VBD O
not RB RB O
done VBN VBN O
to TO TO O
definitely RB RB O
exclude VB VB O
a DT DT O
compressive JJ JJ O
aetiology NN NN O
. . . O

All DT DT O
cases NNS NNS O
sustained VBD VBD O
permanent JJ JJ O
neurological JJ JJ O
deficits NNS NNS O
. . . O

We PRP PRP O
recommend VBP VBP O
that IN IN O
hyperbaric JJ JJ O
lignocaine NN NN B-CHEM
should MD MD O
be VB VB O
administered VBN VBN O
in IN IN O
concentrations NNS NNS O
not RB RB O
greater JJR JJR O
than IN IN O
2 CD CD O
% NN NN O
and CC CC O
at IN IN O
a DT DT O
total JJ JJ O
dose NN NN O
preferably RB RB O
not RB RB O
exceeding VBG VBG O
60 CD CD O
mg NN NN O
. . . O

Systemic NNP NNP O
toxicity NN NN O
following VBG VBG O
administration NN NN O
of IN IN O
sirolimus NN NN B-CHEM
( ( ( O
formerly RB RB O
rapamycin NN NN B-CHEM
) ) ) O
for IN IN O
psoriasis NN NN O
: : : O
association NN NN O
of IN IN O
capillary JJ JJ O
leak NN NN O
syndrome NN NN O
with IN IN O
apoptosis NN NN O
of IN IN O
lesional JJ JJ O
lymphocytes NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Sirolimus NNP NNP B-CHEM
( ( ( O
formerly RB RB O
rapamycin NN NN B-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
immunosuppressive JJ JJ O
agent NN NN O
that WDT WDT O
interferes NNS NNS O
with IN IN O
T NN NN O
- - - O
cell NN NN O
activation NN NN O
. . . O

After IN IN O
2 CD CD O
individuals NNS NNS O
with IN IN O
psoriasis NN NN O
developed VBD VBD O
a DT DT O
capillary JJ JJ O
leak NN NN O
syndrome NN NN O
following VBG VBG O
treatment NN NN O
with IN IN O
oral JJ JJ O
sirolimus NN NN B-CHEM
lesional JJ JJ O
skin NN NN O
cells NNS NNS O
and CC CC O
activated VBD VBD O
peripheral JJ JJ O
blood NN NN O
cells NNS NNS O
were VBD VBD O
analyzed VBN VBN O
for IN IN O
induction NN NN O
of IN IN O
apoptosis NN NN O
. . . O

OBSERVATIONS NNP NNP O
: : : O
A DT DT O
keratome NN NN O
skin NN NN O
specimen NNS NNS O
from IN IN O
1 CD CD O
patient NN NN O
with IN IN O
sirolimus NN NN B-CHEM
- - - O
induced JJ JJ O
capillary JJ JJ O
leak NN NN O
syndrome NN NN O
had VBD VBD O
a DT DT O
2 CD CD O
. . . O
3 CD CD O
- : : O
fold VB VB O
increase NN NN O
in IN IN O
percentage NN NN O
of IN IN O
apoptotic JJ JJ O
cells NNS NNS O
( ( ( O
to TO TO O
48 CD CD O
% NN NN O
) ) ) O
compared VBN VBN O
with IN IN O
an DT DT O
unaffected JJ JJ O
sirolimus NN NN B-CHEM
- - - O
treated JJ JJ O
patient NN NN O
with IN IN O
psoriasis NN NN O
( ( ( O
21 CD CD O
% NN NN O
) ) ) O
. . . O

Activated NNP NNP O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NNS NNS O
from IN IN O
patients NNS NNS O
with IN IN O
psoriasis NN NN O
tended VBD VBD O
to TO TO O
exhibit NN NN O
greater RBR RBR O
spontaneous JJ JJ O
or CC CC O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
apoptosis NN NN O
than IN IN O
did VBD VBD O
normal JJ JJ O
T NN NN O
cells NNS NNS O
, , , O
particularly RB RB O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
sirolimus NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Severe JJ JJ O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
sirolimus NN NN B-CHEM
include VBP VBP O
fever NN NN O
, , , O
anemia NN NN O
, , , O
and CC CC O
capillary JJ JJ O
leak NN NN O
syndrome NN NN O
. . . O

These DT DT O
symptoms NNS NNS O
may MD MD O
be VB VB O
the DT DT O
result NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
apoptosis NN NN O
of IN IN O
lesional JJ JJ O
leukocytes NNS NNS O
, , , O
especially RB RB O
activated VBN VBN O
T NN NN O
lymphocytes NNS NNS O
, , , O
and CC CC O
possibly RB RB O
release NN NN O
of IN IN O
inflammatory JJ JJ O
mediators NNS NNS O
. . . O

Because IN IN O
patients NNS NNS O
with IN IN O
severe JJ JJ O
psoriasis NNS NNS O
may MD MD O
develop VB VB O
capillary JJ JJ O
leak NN NN O
from IN IN O
various JJ JJ O
systemic JJ JJ O
therapies NNS NNS O
, , , O
clinical JJ JJ O
monitoring NN NN O
is VBZ VBZ O
advisable JJ JJ O
for IN IN O
patients NNS NNS O
with IN IN O
inflammatory JJ JJ O
diseases NNS NNS O
who WP WP O
are VBP VBP O
treated VBN VBN O
with IN IN O
immune JJ JJ O
modulators NNS NNS O
. . . O

Effect NN NN O
of IN IN O
lithium NN NN B-CHEM
maintenance NN NN O
therapy NN NN O
on IN IN O
thyroid NN NN O
and CC CC O
parathyroid NN NN O
function NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
assess VB VB O
changes NNS NNS O
induced VBN VBN O
by IN IN O
lithium NN NN B-CHEM
maintenance NN NN O
therapy NN NN O
on IN IN O
the DT DT O
incidence NN NN O
of IN IN O
thyroid NN NN O
, , , O
parathyroid NN NN O
and CC CC O
ion NN NN O
alterations NNS NNS O
. . . O

These DT DT O
were VBD VBD O
evaluated VBN VBN O
with IN IN O
respect NN NN O
to TO TO O
the DT DT O
duration NN NN O
of IN IN O
lithium NN NN B-CHEM
therapy NN NN O
, , , O
age NN NN O
, , , O
sex NN NN O
, , , O
and CC CC O
family NN NN O
history NN NN O
( ( ( O
whether IN IN O
or CC CC O
not RB RB O
the DT DT O
patient NN NN O
had VBD VBD O
a DT DT O
first JJ JJ O
- - - O
degree NN NN O
relative JJ JJ O
with IN IN O
thyroid NN NN O
disease NN NN O
) ) ) O
. . . O

DESIGN NNP NNP O
: : : O
Prospective JJ JJ O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
Affective NNP NNP O
Disorders NNP NNP O
Clinic NNP NNP O
at IN IN O
St NNP NNP O
. . . O

Mary NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
, , , O
Montreal NNP NNP O
. . . O

PATIENTS NNS NNS O
: : : O
One CD CD O
hundred CD CD O
and CC CC O
one CD CD O
patients NNS NNS O
( ( ( O
28 CD CD O
men NNS NNS O
and CC CC O
73 CD CD O
women NNS NNS O
) ) ) O
with IN IN O
bipolar JJ JJ O
disorder NN NN O
receiving VBG VBG O
lithium NN NN B-CHEM
maintenance NN NN O
therapy NN NN O
ranging VBG VBG O
from IN IN O
1 CD CD O
year NN NN O
' '' '' O
s VBZ VBZ O
to TO TO O
32 CD CD O
years NNS NNS O
' POS POS O
duration NN NN O
. . . O

The DT DT O
control NN NN O
group NN NN O
consisted VBD VBD O
of IN IN O
82 CD CD O
patients NNS NNS O
with IN IN O
no DT DT O
psychiatric JJ JJ O
or CC CC O
endocrinological JJ JJ O
diagnoses NNS NNS O
from IN IN O
the DT DT O
hospital NN NN O
' '' '' O
s VBZ VBZ O
out IN IN O
- - - O
patient NN NN O
clinics NNS NNS O
. . . O

OUTCOME NNP NNP O
MEASURES NNS NNS O
: : : O
Laboratory NNP NNP O
analyses NNS NNS O
of IN IN O
calcium NN NN B-CHEM
, , , O
magnesium NN NN B-CHEM
and CC CC O
thyroid NN NN O
- - - O
stimulating VBG VBG O
hormone NN NN O
levels NNS NNS O
performed VBN VBN O
before IN IN O
beginning VBG VBG O
lithium NN NN B-CHEM
therapy NN NN O
and CC CC O
at IN IN O
biannual JJ JJ O
follow VB VB O
- - - O
up RP RP O
. . . O

RESULTS NNS NNS O
: : : O
Hypothyroidism NNP NNP O
developed VBN VBN O
in IN IN O
40 CD CD O
patients NNS NNS O
, , , O
excluding VBG VBG O
8 CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
hypothyroid NN NN O
at IN IN O
baseline NN NN O
. . . O

All DT DT O
patients NNS NNS O
having VBG VBG O
first JJ JJ O
- - - O
degree NN NN O
relatives NNS NNS O
affected VBN VBN O
by IN IN O
thyroid JJ JJ O
illness NN NN O
had VBD VBD O
accelerated VBN VBN O
onset NN NN O
of IN IN O
hypothyroidism NN NN O
( ( ( O
3 CD CD O
. . . O
7 CD CD O
years NNS NNS O
after IN IN O
onset NN NN O
of IN IN O
lithium NN NN B-CHEM
therapy NN NN O
) ) ) O
compared VBN VBN O
with IN IN O
patients NNS NNS O
without IN IN O
a DT DT O
family NN NN O
history NN NN O
( ( ( O
8 CD CD O
. . . O
6 CD CD O
years NNS NNS O
after IN IN O
onset NN NN O
of IN IN O
lithium NN NN B-CHEM
therapy NN NN O
) ) ) O
. . . O

Women NNP NNP O
over IN IN O
60 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
were VBD VBD O
more RBR RBR O
often RB RB O
affected VBN VBN O
by IN IN O
hypothyroidism NN NN O
than IN IN O
women NNS NNS O
under IN IN O
60 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
( ( ( O
34 CD CD O
. . . O
6 CD CD O
% NN NN O
versus CC CC O
31 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
. . . O

Magnesium NNP NNP B-CHEM
levels NNS NNS O
in IN IN O
patients NNS NNS O
on IN IN O
lithium NN NN B-CHEM
treatment NN NN O
were VBD VBD O
unchanged JJ JJ O
from IN IN O
baseline NN NN O
levels NNS NNS O
. . . O

After IN IN O
lithium NN NN B-CHEM
treatment NN NN O
, , , O
calcium NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
higher JJR JJR O
than IN IN O
either DT DT O
baseline NN NN O
levels NNS NNS O
or CC CC O
control NN NN O
levels NNS NNS O
. . . O

Thus RB RB O
, , , O
lithium NN NN B-CHEM
treatment NN NN O
counteracted VBD VBD O
the DT DT O
decrease NN NN O
in IN IN O
plasma NN NN O
calcium NN NN B-CHEM
levels NNS NNS O
associated VBN VBN O
with IN IN O
aging VBG VBG O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Familial NNP NNP O
thyroid NN NN O
illness NN NN O
is VBZ VBZ O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
hypothyroidism NN NN O
and CC CC O
hypercalcemia NN NN O
during IN IN O
lithium NN NN B-CHEM
therapy NN NN O
. . . O

Severe NNP NNP O
immune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
associated VBN VBN O
with IN IN O
prophylactic JJ JJ O
use NN NN O
of IN IN O
cefotetan NN NN B-CHEM
in IN IN O
obstetric JJ JJ O
and CC CC O
gynecologic JJ JJ O
procedures NNS NNS O
. . . O

Second JJ JJ O
- : : O
and CC CC O
third JJ JJ O
- - - O
generation NN NN O
cephalosporins NNS NNS B-CHEM
, , , O
especially RB RB O
cefotetan NN NN B-CHEM
, , , O
are VBP VBP O
increasingly RB RB O
associated VBN VBN O
with IN IN O
severe JJ JJ O
, , , O
sometimes RB RB O
fatal JJ JJ O
immune NN NN O
hemolytic JJ JJ O
anemia NN NN O
. . . O

We PRP PRP O
noticed VBD VBD O
that IN IN O
10 CD CD O
of IN IN O
our PRP$ PRP$ O
35 CD CD O
cases NNS NNS O
of IN IN O
cefotetan NN NN B-CHEM
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemias NN NN O
were VBD VBD O
in IN IN O
patients NNS NNS O
who WP WP O
had VBD VBD O
received VBN VBN O
cefotetan NN NN B-CHEM
prophylactically RB RB O
for IN IN O
obstetric JJ JJ O
and CC CC O
gynecologic JJ JJ O
procedures NNS NNS O
. . . O

Eight CD CD O
of IN IN O
these DT DT O
cases NNS NNS O
of IN IN O
severe JJ JJ O
immune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
are VBP VBP O
described VBN VBN O
. . . O

Effects NNP NNP O
of IN IN O
nonsteroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
on IN IN O
hemostasis NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
aneurysmal NN NN O
subarachnoid NN NN O
hemorrhage NN NN O
. . . O

Platelet NNP NNP O
function NN NN O
is VBZ VBZ O
impaired VBN VBN O
by IN IN O
nonsteroidal NN NN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAIDs NNP NNP O
) ) ) O
with IN IN O
prominent NN NN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
properties NNS NNS O
. . . O

Their PRP$ PRP$ O
safety NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
intracranial JJ JJ O
surgery NN NN O
is VBZ VBZ O
under IN IN O
debate NN NN O
. . . O

Patients NNS NNS O
with IN IN O
aneurysmal NN NN O
subarachnoid NN NN O
hemorrhage NN NN O
( ( ( O
SAH NNP NNP O
) ) ) O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
ketoprofen NN NN B-CHEM
, , , O
100 CD CD O
mg NN NN O
, , , O
three CD CD O
times NNS NNS O
a DT DT O
day NN NN O
( ( ( O
ketoprofen NN NN B-CHEM
group NN NN O
, , , O
n NN NN O
= SYM SYM O
9 CD CD O
) ) ) O
or CC CC O
a DT DT O
weak JJ JJ O
NSAID NNP NNP O
, , , O
acetaminophen NN NN B-CHEM
, , , O
1 CD CD O
g SYM SYM O
, , , O
three CD CD O
times NNS NNS O
a DT DT O
day NN NN O
( ( ( O
acetaminophen NN NN B-CHEM
group NN NN O
, , , O
n NN NN O
= SYM SYM O
9 CD CD O
) ) ) O
starting VBG VBG O
immediately RB RB O
after IN IN O
the DT DT O
diagnosis NN NN O
of IN IN O
aneurysmal NN NN O
SAH NNP NNP O
. . . O

Treatment NN NN O
was VBD VBD O
continued VBN VBN O
for IN IN O
3 CD CD O
days NNS NNS O
postoperatively RB RB O
. . . O

Test NNP NNP O
blood NN NN O
samples NNS NNS O
were VBD VBD O
taken VBN VBN O
before IN IN O
treatment NN NN O
and CC CC O
surgery NN NN O
as RB RB O
well RB RB O
as IN IN O
on IN IN O
the DT DT O
first JJ JJ O
, , , O
third JJ JJ O
, , , O
and CC CC O
fifth JJ JJ O
postoperative JJ JJ O
mornings NNS NNS O
. . . O

Maximal NNP NNP O
platelet NN NN O
aggregation NN NN O
induced VBN VBN O
by IN IN O
6 CD CD O
microM NN NN O
of IN IN O
adenosine NN NN B-CHEM
diphosphate NN NN I-CHEM
decreased VBD VBD O
after IN IN O
administration NN NN O
of IN IN O
ketoprofen NN NN B-CHEM
. . . O

Aggregation NNP NNP O
was VBD VBD O
lower JJR JJR O
( ( ( O
P NN NN O
< NN NN O
. . . O
05 CD CD O
) ) ) O
in IN IN O
the DT DT O
ketoprofen NN NN B-CHEM
group NN NN O
than IN IN O
in IN IN O
the DT DT O
acetaminophen NN NN B-CHEM
group NN NN O
just RB RB O
before IN IN O
surgery NN NN O
and CC CC O
on IN IN O
the DT DT O
third JJ JJ O
postoperative JJ JJ O
day NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
maximal NN NN O
platelet NN NN O
aggregation NN NN O
increased VBN VBN O
in IN IN O
the DT DT O
acetaminophen NN NN B-CHEM
group NN NN O
on IN IN O
the DT DT O
third JJ JJ O
postoperative JJ JJ O
day NN NN O
as IN IN O
compared VBN VBN O
with IN IN O
the DT DT O
pretreatment NN NN O
platelet NN NN O
aggregation NN NN O
results NNS NNS O
( ( ( O
P NN NN O
< NN NN O
. . . O
05 CD CD O
) ) ) O
. . . O

One CD CD O
patient NN NN O
in IN IN O
the DT DT O
ketoprofen NN NN B-CHEM
group NN NN O
developed VBN VBN O
a DT DT O
postoperative JJ JJ O
intracranial JJ JJ O
hematoma NN NN O
. . . O

Coagulation NNP NNP O
( ( ( O
prothrombin NN NN O
time NN NN O
[ NN NN O
PT NNP NNP O
] NN NN O
, , , O
activated VBN VBN O
partial JJ JJ O
thromboplastin NN NN O
time NN NN O
[ NN NN O
APPT NNP NNP O
] NN NN O
, , , O
fibrinogen NN NN O
concentration NN NN O
, , , O
and CC CC O
antithrombin NN NN O
III NNP NNP O
[ NN NN O
AT IN IN O
III NNP NNP O
] NN NN O
) ) ) O
was VBD VBD O
comparable JJ JJ O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

Ketoprofen NNP NNP B-CHEM
but CC CC O
not RB RB O
acetaminophen VB VB B-CHEM
impaired JJ JJ O
platelet NN NN O
function NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
SAH NNP NNP O
. . . O

If IN IN O
ketoprofen NN NN B-CHEM
is VBZ VBZ O
used VBN VBN O
before IN IN O
surgery NN NN O
on IN IN O
cerebral JJ JJ O
artery NN NN O
aneurysms RB RB O
, , , O
it PRP PRP O
may MD MD O
pose VB VB O
an DT DT O
additional JJ JJ O
risk NN NN O
factor NN NN O
for IN IN O
hemorrhage NN NN O
. . . O

Nitric NNP NNP B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
expression NN NN O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
lead NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
. . . O

We PRP PRP O
recently RB RB O
showed VBD VBD O
elevated VBD VBD O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
( ( ( O
ROS NNP NNP O
) ) ) O
, , , O
reduced VBD VBD O
urinary JJ JJ O
excretion NN NN O
of IN IN O
NO DT DT B-CHEM
metabolites NNS NNS O
( ( ( O
NOx NNP NNP O
) ) ) O
, , , O
and CC CC O
increased VBD VBD O
NO DT DT B-CHEM
sequestration NN NN O
as IN IN O
nitrotyrosine NN NN B-CHEM
in IN IN O
various JJ JJ O
tissues NNS NNS O
in IN IN O
rats NNS NNS O
with IN IN O
lead NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
discern VB VB O
whether IN IN O
the DT DT O
reduction NN NN O
in IN IN O
urinary JJ JJ O
NOx NNP NNP O
in IN IN O
lead NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
is VBZ VBZ O
, , , O
in IN IN O
part NN NN O
, , , O
due JJ JJ O
to TO TO O
depressed VBN VBN O
NO DT DT B-CHEM
synthase NN NN O
( ( ( O
NOS NNP NNP O
) ) ) O
expression NN NN O
. . . O

Male NNP NNP O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
a DT DT O
lead NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
( ( ( O
given VBN VBN O
lead NN NN B-CHEM
acetate NN NN I-CHEM
, , , O
100 CD CD O
ppm NN NN O
, , , O
in IN IN O
drinking NN NN O
water NN NN O
and CC CC O
regular JJ JJ O
rat NN NN O
chow NN NN O
) ) ) O
, , , O
a DT DT O
group NN NN O
given VBN VBN O
lead NN NN B-CHEM
and CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
- : : O
fortified VBN VBN O
chow NN NN O
, , , O
or CC CC O
a DT DT O
normal JJ JJ O
control NN NN O
group NN NN O
given VBN VBN O
either CC CC O
regular JJ JJ O
food NN NN O
and CC CC O
water NN NN O
or CC CC O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
- : : O
fortified VBN VBN O
food NN NN O
for IN IN O
12 CD CD O
weeks NNS NNS O
. . . O

Tail NNP NNP O
blood NN NN O
pressure NN NN O
, , , O
urinary JJ JJ O
NOx NNP NNP O
excretion NN NN O
, , , O
plasma NN NN O
malondialdehyde NN NN B-CHEM
( ( ( O
MDA NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
endothelial JJ JJ O
and CC CC O
inducible JJ JJ O
NOS NNP NNP O
( ( ( O
eNOS NN NN O
and CC CC O
iNOS NN NN O
) ) ) O
isotypes NNS NNS O
in IN IN O
the DT DT O
aorta NN NN O
and CC CC O
kidney NN NN O
were VBD VBD O
measured VBN VBN O
. . . O

The DT DT O
lead NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
exhibited VBD VBD O
a DT DT O
rise NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
plasma NN NN O
MDA NNP NNP B-CHEM
concentration NN NN O
, , , O
a DT DT O
fall NN NN O
in IN IN O
urinary JJ JJ O
NOx NNP NNP O
excretion NN NN O
, , , O
and CC CC O
a DT DT O
paradoxical JJ JJ O
rise NN NN O
in IN IN O
vascular NN NN O
and CC CC O
renal JJ JJ O
tissue NN NN O
eNOS NN NN O
and CC CC O
iNOS NN NN O
expression NN NN O
. . . O

Vitamin NNP NNP B-CHEM
E NNP NNP I-CHEM
supplementation NN NN O
ameliorated JJ JJ O
hypertension NN NN O
, , , O
lowered VBD VBD O
plasma NN NN O
MDA NNP NNP B-CHEM
concentration NN NN O
, , , O
and CC CC O
raised VBD VBD O
urinary JJ JJ O
NOx NNP NNP O
excretion NN NN O
while IN IN O
significantly RB RB O
lowering VBG VBG O
vascular NN NN O
, , , O
but CC CC O
not RB RB O
renal JJ JJ O
, , , O
tissue NN NN O
eNOS NN NN O
and CC CC O
iNOS NN NN O
expression NN NN O
. . . O

Vitamin NNP NNP B-CHEM
E NNP NNP I-CHEM
supplementation NN NN O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
either DT DT O
blood NN NN O
pressure NN NN O
, , , O
plasma NN NN O
MDA NNP NNP B-CHEM
, , , O
or CC CC O
NOS NNP NNP O
expression NN NN O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

The DT DT O
study NN NN O
also RB RB O
revealed VBD VBD O
significant JJ JJ O
inhibition NN NN O
of IN IN O
NOS NNP NNP O
enzymatic JJ JJ O
activity NN NN O
by IN IN O
lead NN NN B-CHEM
in IN IN O
cell NN NN O
- - - O
free JJ JJ O
preparations NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
lead VB VB B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
this DT DT O
model NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
compensatory JJ JJ O
upregulation NN NN O
of IN IN O
renal JJ JJ O
and CC CC O
vascular JJ JJ O
eNOS NN NN O
and CC CC O
iNOS NN NN O
expression NN NN O
. . . O

This DT DT O
is VBZ VBZ O
, , , O
in IN IN O
part NN NN O
, , , O
due JJ JJ O
to TO TO O
ROS NNP NNP O
- : : O
mediated VBD VBD O
NO DT DT B-CHEM
inactivation NN NN O
, , , O
lead VB VB B-CHEM
- - - O
associated JJ JJ O
inhibition NN NN O
of IN IN O
NOS NNP NNP O
activity NN NN O
, , , O
and CC CC O
perhaps RB RB O
stimulatory JJ JJ O
actions NNS NNS O
of IN IN O
increased VBN VBN O
shear NN NN O
stress NN NN O
associated VBN VBN O
with IN IN O
hypertension NN NN O
. . . O

Glyceryl NNP NNP B-CHEM
trinitrate NN NN I-CHEM
induces NNS NNS O
attacks NNS NNS O
of IN IN O
migraine NN NN O
without IN IN O
aura NN NN O
in IN IN O
sufferers NNS NNS O
of IN IN O
migraine NN NN O
with IN IN O
aura NN NN O
. . . O

Migraine NNP NNP O
with IN IN O
aura NN NN O
and CC CC O
migraine NN NN O
without IN IN O
aura NN NN O
have VBP VBP O
the DT DT O
same JJ JJ O
pain NN NN O
phase NN NN O
, , , O
thus RB RB O
indicating VBG VBG O
that IN IN O
migraine NN NN O
with IN IN O
aura NN NN O
and CC CC O
migraine NN NN O
without IN IN O
aura NN NN O
share NN NN O
a DT DT O
common JJ JJ O
pathway NN NN O
of IN IN O
nociception NN NN O
. . . O

In IN IN O
recent JJ JJ O
years NNS NNS O
, , , O
increasing VBG VBG O
evidence NN NN O
has VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
messenger NN NN O
molecule NN NN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO DT DT B-CHEM
) ) ) O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
pain NN NN O
mechanisms NNS NNS O
of IN IN O
migraine NN NN O
without IN IN O
aura NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
clarify VB VB O
whether IN IN O
the DT DT O
same JJ JJ O
is VBZ VBZ O
true JJ JJ O
for IN IN O
migraine NN NN O
with IN IN O
aura NN NN O
, , , O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
we PRP PRP O
examined VBD VBD O
the DT DT O
headache NN NN O
response NN NN O
to TO TO O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
( ( ( O
GTN NNP NNP B-CHEM
) ) ) O
( ( ( O
0 CD CD O
. . . O
5 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
for IN IN O
20 CD CD O
min NN NN O
) ) ) O
in IN IN O
12 CD CD O
sufferers NNS NNS O
of IN IN O
migraine NN NN O
with IN IN O
aura NN NN O
. . . O

The DT DT O
specific JJ JJ O
aim NN NN O
was VBD VBD O
to TO TO O
elucidate VB VB O
whether IN IN O
an DT DT O
aura NN NN O
and CC CC O
/ NN NN O
or CC CC O
an DT DT O
attack NN NN O
of IN IN O
migraine NN NN O
without IN IN O
aura NN NN O
could MD MD O
be VB VB O
induced VBN VBN O
. . . O

Fourteen CD CD O
healthy JJ JJ O
subjects NNS NNS O
served VBD VBD O
as IN IN O
controls NNS NNS O
. . . O

Aura NNP NNP O
symptoms NNS NNS O
were VBD VBD O
not RB RB O
elicited VBN VBN O
in IN IN O
any DT DT O
subject NN NN O
. . . O

Headache NNP NNP O
was VBD VBD O
more JJR JJR O
severe JJ JJ O
in IN IN O
migraineurs NNS NNS O
than IN IN O
in IN IN O
the DT DT O
controls NNS NNS O
during IN IN O
and CC CC O
immediately RB RB O
after IN IN O
GTN NNP NNP B-CHEM
infusion NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
037 CD CD O
) ) ) O
as RB RB O
well RB RB O
as IN IN O
during IN IN O
the DT DT O
following VBG VBG O
11 CD CD O
h NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
008 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
controls NNS NNS O
, , , O
the DT DT O
GTN NNP NNP B-CHEM
- - - O
induced JJ JJ O
headache NN NN O
gradually RB RB O
disappeared VBD VBD O
, , , O
whereas IN IN O
in IN IN O
migraineurs NNS NNS O
peak NN NN O
headache NN NN O
intensity NN NN O
occurred VBD VBD O
at IN IN O
a DT DT O
mean JJ JJ O
time NN NN O
of IN IN O
240 CD CD O
min NN NN O
post NN NN O
- - - O
infusion NN NN O
. . . O

At IN IN O
this DT DT O
time NN NN O
the DT DT O
induced JJ JJ O
headache NN NN O
in IN IN O
6 CD CD O
of IN IN O
12 CD CD O
migraineurs NNS NNS O
fulfilled VBD VBD O
the DT DT O
diagnostic JJ JJ O
criteria NNS NNS O
for IN IN O
migraine NN NN O
without IN IN O
aura NN NN O
of IN IN O
the DT DT O
International NNP NNP O
Headache NNP NNP O
Society NNP NNP O
. . . O

The DT DT O
results NNS NNS O
therefore RB RB O
suggest VBP VBP O
that IN IN O
NO DT DT B-CHEM
is VBZ VBZ O
involved VBN VBN O
in IN IN O
the DT DT O
pain NN NN O
mechanisms NNS NNS O
of IN IN O
migraine NN NN O
with IN IN O
aura NN NN O
. . . O

Since IN IN O
cortical JJ JJ O
spreading VBG VBG O
depression NN NN O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
liberate VB VB O
NO NNP NNP B-CHEM
in IN IN O
animals NNS NNS O
, , , O
this DT DT O
finding VBG VBG O
may MD MD O
help VB VB O
our PRP$ PRP$ O
understanding NN NN O
of IN IN O
the DT DT O
coupling NN NN O
between IN IN O
cortical JJ JJ O
spreading VBG VBG O
depression NN NN O
and CC CC O
headache NN NN O
in IN IN O
migraine NN NN O
with IN IN O
aura NN NN O
. . . O

Rapid NNP NNP O
reversal NN NN O
of IN IN O
life NN NN O
- - - O
threatening VBG VBG O
diltiazem NN NN B-CHEM
- - - O
induced JJ JJ O
tetany NN NN O
with IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
tetany NN NN O
with IN IN O
sudden JJ JJ O
respiratory JJ JJ O
arrest NN NN O
after IN IN O
the DT DT O
infusion NN NN O
of IN IN O
intravenous JJ JJ O
diltiazem NN NN B-CHEM
. . . O

The DT DT O
administration NN NN O
of IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
rapidly RB RB O
resolved VBD VBD O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
tetany NN NN O
with IN IN O
prompt NN NN O
recovery NN NN O
of IN IN O
respiratory JJ JJ O
function NN NN O
, , , O
averting VBG VBG O
the DT DT O
need NN NN O
for IN IN O
more RBR RBR O
aggressive JJ JJ O
airway NN NN O
management NN NN O
and CC CC O
ventilatory JJ JJ O
support NN NN O
. . . O

The DT DT O
emergency NN NN O
physician NN NN O
should MD MD O
be VB VB O
aware JJ JJ O
that IN IN O
life NN NN O
- : : O
threatening VBG VBG O
tetany NN NN O
may MD MD O
accompany VB VB O
the DT DT O
administration NN NN O
of IN IN O
intravenous JJ JJ O
diltiazem NN NN B-CHEM
and CC CC O
that IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
may MD MD O
be VB VB O
a DT DT O
rapid JJ JJ O
and CC CC O
effective JJ JJ O
remedy NN NN O
. . . O

Predictors NNP NNP O
of IN IN O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
heart NN NN O
failure NN NN O
during IN IN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
therapy NN NN O
: : : O
results NNS NNS O
from IN IN O
the DT DT O
studies NNS NNS O
of IN IN O
left VBD VBD O
ventricular NN NN O
dysfunction NN NN O
( ( ( O
SOLVD NNP NNP O
) ) ) O

BACKGROUND NNP NNP O
: : : O
Although IN IN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
therapy NN NN O
reduces VBZ VBZ O
mortality NN NN O
rates NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
( ( ( O
CHF NNP NNP O
) ) ) O
, , , O
it PRP PRP O
may MD MD O
also RB RB O
cause VB VB O
decreased VBN VBN O
renal JJ JJ O
function NN NN O
. . . O

Little NNP NNP O
information NN NN O
is VBZ VBZ O
available JJ JJ O
to TO TO O
predict VB VB O
which WDT WDT O
patients NNS NNS O
are VBP VBP O
at IN IN O
highest JJS JJS O
risk NN NN O
for IN IN O
this DT DT O
complication NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
quantify VB VB O
specific JJ JJ O
clinical JJ JJ O
predictors NNS NNS O
of IN IN O
reduction NN NN O
in IN IN O
renal JJ JJ O
function NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
CHF NNP NNP O
who WP WP O
are VBP VBP O
prescribed VBN VBN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
therapy NN NN O
. . . O

METHOD NNP NNP O
: : : O
We PRP PRP O
analyzed VBD VBD O
data NNS NNS O
from IN IN O
the DT DT O
Studies NNS NNS O
of IN IN O
Left NNP NNP O
Ventricular NNP NNP O
Dysfunction NNP NNP O
( ( ( O
SOLVD NNP NNP O
) ) ) O
, , , O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
of IN IN O
enalapril NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
CHF NNP NNP O
. . . O

There EX EX O
were VBD VBD O
3379 CD CD O
patients NNS NNS O
randomly RB RB O
assigned VBN VBN O
to TO TO O
enalapril VB VB B-CHEM
with IN IN O
a DT DT O
median JJ JJ O
follow VB VB O
- - - O
up RP RP O
of IN IN O
974 CD CD O
days NNS NNS O
and CC CC O
3379 CD CD O
patients NNS NNS O
randomly RB RB O
assigned VBN VBN O
to TO TO O
placebo NN NN O
with IN IN O
a DT DT O
mean JJ JJ O
follow VB VB O
- - - O
up RP RP O
of IN IN O
967 CD CD O
days NNS NNS O
. . . O

Decreased NNP NNP O
renal JJ JJ O
function NN NN O
was VBD VBD O
defined VBN VBN O
as IN IN O
a DT DT O
rise NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
> NN NN O
/ NN NN O
= SYM SYM O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
44 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
from IN IN O
baseline NN NN O
. . . O

We PRP PRP O
used VBD VBD O
time NN NN O
- : : O
to TO TO O
- - - O
event NN NN O
analysis NN NN O
to TO TO O
identify VB VB O
potential JJ JJ O
predictors NNS NNS O
of IN IN O
decrease NN NN O
in IN IN O
renal JJ JJ O
function NN NN O
including VBG VBG O
age NN NN O
, , , O
baseline NN NN O
ejection NN NN O
fraction NN NN O
, , , O
baseline NN NN O
creatinine NN NN B-CHEM
, , , O
low JJ JJ O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
< NN NN O
100 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
, , , O
history NN NN O
of IN IN O
hypertension NN NN O
, , , O
diabetes NN NN O
, , , O
and CC CC O
use NN NN O
of IN IN O
antiplatelet NN NN O
, , , O
diuretic JJ JJ B-CHEM
, , , O
and CC CC O
beta NN NN O
- - - O
blocker NN NN O
therapy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Patients NNS NNS O
randomly RB RB O
assigned VBN VBN O
to TO TO O
enalapril VB VB B-CHEM
had VBD VBD O
a DT DT O
33 CD CD O
% NN NN O
greater JJR JJR O
likelihood NN NN O
of IN IN O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
than IN IN O
controls NNS NNS O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
003 CD CD O
) ) ) O
. . . O

By IN IN O
multivariate NN NN O
analysis NN NN O
, , , O
in IN IN O
both DT DT O
the DT DT O
placebo NN NN O
and CC CC O
enalapril NN NN B-CHEM
groups NNS NNS O
older JJR JJR O
age NN NN O
, , , O
diuretic JJ JJ B-CHEM
therapy NN NN O
, , , O
and CC CC O
diabetes NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
, , , O
whereas IN IN O
beta NN NN O
- - - O
blocker NN NN O
therapy NN NN O
and CC CC O
higher JJR JJR O
ejection NN NN O
fraction NN NN O
were VBD VBD O
renoprotective JJ JJ O
. . . O

Older JJR JJR O
age NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
greater JJR JJR O
risk NN NN O
of IN IN O
developing VBG VBG O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
, , , O
but CC CC O
significantly RB RB O
more RBR RBR O
so RB RB O
in IN IN O
the DT DT O
enalapril NN NN B-CHEM
group NN NN O
( ( ( O
enalapril NN NN B-CHEM
: : : O
risk NN NN O
ratio NN NN O
[ NN NN O
RR NNP NNP O
] NN NN O
1 CD CD O
. . . O
42 CD CD O
per IN IN O
10 CD CD O
years NNS NNS O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
1 CD CD O
. . . O
32 CD CD O
- : : O
1 CD CD O
. . . O
52 CD CD O
with IN IN O
enalapril NN NN B-CHEM
; : : O
placebo NN NN O
: : : O
RR NNP NNP O
1 CD CD O
. . . O
18 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
12 CD CD O
- : : O
1 CD CD O
. . . O
25 CD CD O
) ) ) O
. . . O

Diuretic NNP NNP B-CHEM
therapy NN NN O
was VBD VBD O
likewise RB RB O
associated VBN VBN O
with IN IN O
a DT DT O
greater JJR JJR O
risk NN NN O
of IN IN O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
in IN IN O
the DT DT O
enalapril NN NN B-CHEM
group NN NN O
( ( ( O
RR NNP NNP O
1 CD CD O
. . . O
89 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
70 CD CD O
- : : O
2 CD CD O
. . . O
08 CD CD O
) ) ) O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
( ( ( O
RR NNP NNP O
1 CD CD O
. . . O
35 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
09 CD CD O
- : : O
1 CD CD O
. . . O
66 CD CD O
) ) ) O
. . . O

Conversely RB RB O
, , , O
enalapril NN NN B-CHEM
had VBD VBD O
a DT DT O
relative JJ JJ O
renoprotective JJ JJ O
effect NN NN O
( ( ( O
RR NNP NNP O
1 CD CD O
. . . O
33 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
13 CD CD O
- : : O
1 CD CD O
. . . O
53 CD CD O
) ) ) O
compared VBN VBN O
with IN IN O
placebo NN NN O
( ( ( O
RR NNP NNP O
1 CD CD O
. . . O
96 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
57 CD CD O
- : : O
2 CD CD O
. . . O
44 CD CD O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
diabetes NN NN O
. . . O

A DT DT O
lower JJR JJR O
risk NN NN O
of IN IN O
renal JJ JJ O
impairment NN NN O
was VBD VBD O
seen VBN VBN O
in IN IN O
both DT DT O
groups NNS NNS O
with IN IN O
beta NN NN O
- - - O
blocker NN NN O
therapy NN NN O
( ( ( O
RR NNP NNP O
0 CD CD O
. . . O
70 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
57 CD CD O
- : : O
0 CD CD O
. . . O
85 CD CD O
) ) ) O
and CC CC O
higher JJR JJR O
baseline NN NN O
ejection NN NN O
fraction NN NN O
( ( ( O
RR NNP NNP O
0 CD CD O
. . . O
93 CD CD O
per IN IN O
5 CD CD O
% NN NN O
increment NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
91 CD CD O
- : : O
0 CD CD O
. . . O
96 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Enalapril NNP NNP B-CHEM
use NN NN O
caused VBD VBD O
a DT DT O
33 CD CD O
% NN NN O
increase NN NN O
in IN IN O
the DT DT O
risk NN NN O
of IN IN O
decreased VBD VBD O
renal JJ JJ O
function NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
CHF NNP NNP O
. . . O

Diuretic NNP NNP B-CHEM
use NN NN O
and CC CC O
advanced VBD VBD O
age NN NN O
increased VBD VBD O
this DT DT O
risk NN NN O
. . . O

Diabetes NNP NNP O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
renal JJ JJ O
impairment NN NN O
in IN IN O
all DT DT O
patients NNS NNS O
with IN IN O
CHF NNP NNP O
, , , O
but CC CC O
this DT DT O
risk NN NN O
was VBD VBD O
reduced VBN VBN O
in IN IN O
the DT DT O
enalapril NN NN B-CHEM
group NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

beta NN NN O
- : : O
Blocker NNP NNP O
therapy NN NN O
and CC CC O
higher JJR JJR O
ejection NN NN O
fraction NN NN O
were VBD VBD O
renoprotective JJ JJ O
in IN IN O
all DT DT O
patients NNS NNS O
regardless RB RB O
of IN IN O
therapy NN NN O
. . . O

Hypomania NNP NNP O
- - - O
like IN IN O
syndrome NN NN O
induced VBN VBN O
by IN IN O
olanzapine NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
female JJ JJ O
patient NN NN O
with IN IN O
a DT DT O
diagnosis NN NN O
of IN IN O
a DT DT O
not RB RB O
otherwise RB RB O
specified VBN VBN O
psychotic JJ JJ O
disorder NN NN O
( ( ( O
DSM NNP NNP O
- - - O
IV NNP NNP O
) ) ) O
who WP WP O
developed VBD VBD O
hypomania NN NN O
shortly RB RB O
after IN IN O
the DT DT O
introduction NN NN O
of IN IN O
olanzapine JJ JJ B-CHEM
treatment NN NN O
. . . O

Acetazolamide NNP NNP B-CHEM
- : : O
induced JJ JJ O
Gerstmann NNP NNP O
syndrome NN NN O
. . . O

Acute JJ JJ O
confusion NN NN O
induced VBN VBN O
by IN IN O
acetazolamide NN NN B-CHEM
is VBZ VBZ O
a DT DT O
well RB RB O
known VBN VBN O
adverse NN NN O
drug NN NN O
reaction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
renal JJ JJ O
impairment NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
acetazolamide NN NN B-CHEM
- - - O
induced JJ JJ O
Gerstmann NNP NNP O
syndrome NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
normal JJ JJ O
renal JJ JJ O
function NN NN O
, , , O
to TO TO O
highlight VB VB O
predisposing VBG VBG O
factors NNS NNS O
that WDT WDT O
are VBP VBP O
frequently RB RB O
overlooked VBN VBN O
. . . O

Vasopressin NNP NNP B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
milrinone NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
in IN IN O
severe JJ JJ O
heart NN NN O
failure NN NN O
. . . O

The DT DT O
use NN NN O
of IN IN O
phosphodiesterase NN NN O
inhibitors NNS NNS O
such JJ JJ O
as IN IN O
milrinone NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
severe JJ JJ O
heart NN NN O
failure NN NN O
is VBZ VBZ O
frequently RB RB O
restricted VBN VBN O
because IN IN O
they PRP PRP O
cause VBP VBP O
vasodilation NN NN O
and CC CC O
hypotension NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
decompensated JJ JJ O
heart NN NN O
failure NN NN O
with IN IN O
hypotension NN NN O
after IN IN O
treatment NN NN O
with IN IN O
milrinone NN NN B-CHEM
, , , O
low JJ JJ O
doses NNS NNS O
of IN IN O
vasopressin NN NN B-CHEM
restored VBD VBD O
blood NN NN O
pressure NN NN O
without IN IN O
inhibiting VBG VBG O
the DT DT O
inotropic JJ JJ O
effect NN NN O
of IN IN O
milrinone NN NN B-CHEM
. . . O

Treatment NN NN O
of IN IN O
tacrolimus NN NN B-CHEM
- - - O
related VBN VBN O
adverse JJ JJ O
effects NNS NNS O
by IN IN O
conversion NN NN O
to TO TO O
cyclosporine VB VB B-CHEM
in IN IN O
liver NN NN O
transplant NN NN O
recipients NNS NNS O
. . . O

When WRB WRB O
tacrolimus NN NN B-CHEM
side NN NN O
effects NNS NNS O
persist NN NN O
despite IN IN O
dose NN NN O
reduction NN NN O
, , , O
conversion NN NN O
to TO TO O
cyclosporine VB VB B-CHEM
- - - O
based JJ JJ O
immunosuppression NN NN O
( ( ( O
CyA NNP NNP O
) ) ) O
is VBZ VBZ O
necessary JJ JJ O
. . . O

We PRP PRP O
characterized VBD VBD O
tacrolimus NN NN B-CHEM
side NN NN O
effects NNS NNS O
that WDT WDT O
warranted VBD VBD O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
, , , O
and CC CC O
outcomes NNS NNS O
after IN IN O
conversion NN NN O
. . . O

Of IN IN O
388 CD CD O
liver NN NN O
recipients NNS NNS O
who WP WP O
received VBD VBD O
tacrolimus NN NN B-CHEM
as IN IN O
primary JJ JJ O
immunosuppression NN NN O
, , , O
70 CD CD O
required VBN VBN O
conversion NN NN O
to TO TO O
CyA NNP NNP O
. . . O

We PRP PRP O
recorded VBD VBD O
indication NN NN O
for IN IN O
conversion NN NN O
, , , O
whether IN IN O
conversion NN NN O
was VBD VBD O
early JJ JJ O
or CC CC O
late RB RB O
after IN IN O
transplantation NN NN O
, , , O
tacrolimus NN NN B-CHEM
dose NN NN O
and CC CC O
trough JJ JJ O
blood NN NN O
level NN NN O
at IN IN O
conversion NN NN O
, , , O
and CC CC O
incidence NN NN O
of IN IN O
rejection NN NN O
after IN IN O
conversion NN NN O
. . . O

Conversion NNP NNP O
was VBD VBD O
early JJ JJ O
in IN IN O
29 CD CD O
patients NNS NNS O
( ( ( O
41 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
and CC CC O
late JJ JJ O
in IN IN O
41 CD CD O
( ( ( O
58 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
. . . O

Indications NNP NNP O
for IN IN O
early JJ JJ O
conversion NN NN O
were VBD VBD O
neurotoxicity NN NN O
( ( ( O
20 CD CD O
) ) ) O
, , , O
( ( ( O
insulin NN NN O
- - - O
dependent JJ JJ O
) ) ) O
diabetes NNS NNS O
mellitus NN NN O
( ( ( O
IDDM NNP NNP O
) ) ) O
( ( ( O
5 CD CD O
) ) ) O
, , , O
nephrotoxicity NN NN O
( ( ( O
3 CD CD O
) ) ) O
, , , O
gastrointestinal JJ JJ O
( ( ( O
GI NNP NNP O
) ) ) O
toxicity NN NN O
( ( ( O
6 CD CD O
) ) ) O
, , , O
and CC CC O
cardiomyopathy NN NN O
( ( ( O
1 CD CD O
) ) ) O
, , , O
and CC CC O
for IN IN O
late JJ JJ O
conversion NN NN O
were VBD VBD O
neurotoxicity NN NN O
( ( ( O
15 CD CD O
) ) ) O
, , , O
IDDM NNP NNP O
( ( ( O
12 CD CD O
) ) ) O
, , , O
nephrotoxicity NN NN O
( ( ( O
3 CD CD O
) ) ) O
, , , O
GI NNP NNP O
toxicity NN NN O
( ( ( O
5 CD CD O
) ) ) O
, , , O
hepatotoxicity NN NN O
( ( ( O
6 CD CD O
) ) ) O
, , , O
post NN NN O
- - - O
transplant NN NN O
lmphoproliferate NN NN O
disease NN NN O
( ( ( O
PTLD NNP NNP O
) ) ) O
( ( ( O
2 CD CD O
) ) ) O
, , , O
cardiomyopathy NN NN O
( ( ( O
1 CD CD O
) ) ) O
, , , O
hemolytic JJ JJ O
anemia NN NN O
( ( ( O
1 CD CD O
) ) ) O
, , , O
and CC CC O
pruritus NN NN O
( ( ( O
1 CD CD O
) ) ) O
. . . O

All DT DT O
early JJ JJ O
- - - O
conversion NN NN O
patients NNS NNS O
showed VBD VBD O
improvement NN NN O
/ NN NN O
resolution NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

Among IN IN O
late JJ JJ O
- - - O
conversion NN NN O
patients NNS NNS O
, , , O
37 CD CD O
( ( ( O
90 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
improvement JJ JJ O
/ NN NN O
resolution NN NN O
; : : O
in IN IN O
4 CD CD O
( ( ( O
9 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
, , , O
adverse JJ JJ O
effects NNS NNS O
persisted VBD VBD O
. . . O

The DT DT O
overall JJ JJ O
rejection NN NN O
rate NN NN O
was VBD VBD O
30 CD CD O
% NN NN O
. . . O

Sixty NNP NNP O
- : : O
two CD CD O
patients NNS NNS O
( ( ( O
88 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
are VBP VBP O
alive JJ JJ O
with IN IN O
functioning VBG VBG O
grafts NNS NNS O
686 CD CD O
+ NN NN O
/ NN NN O
- : : O
362 CD CD O
days NNS NNS O
( ( ( O
range NN NN O
, , , O
154 CD CD O
- : : O
1433 CD CD O
days NNS NNS O
) ) ) O
after IN IN O
conversion NN NN O
. . . O

When WRB WRB O
tacrolimus NN NN B-CHEM
side NN NN O
effects NNS NNS O
are VBP VBP O
unresponsive JJ JJ O
to TO TO O
dose VB VB O
reduction NN NN O
, , , O
conversion NN NN O
to TO TO O
CyA NNP NNP O
can MD MD O
be VB VB O
accomplished VBN VBN O
safely RB RB O
, , , O
with IN IN O
no DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
rejection NN NN O
and CC CC O
excellent JJ JJ O
long JJ JJ O
- - - O
term NN NN O
outcome NN NN O
. . . O

Ocular NNP NNP O
manifestations NNS NNS O
of IN IN O
juvenile JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
. . . O

We PRP PRP O
followed VBD VBD O
210 CD CD O
cases NNS NNS O
of IN IN O
juvenile JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
closely RB RB O
for IN IN O
eleven CD CD O
years NNS NNS O
. . . O

Thirty NNP NNP O
- : : O
six CD CD O
of IN IN O
the DT DT O
210 CD CD O
patients NNS NNS O
( ( ( O
17 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
developed JJ JJ O
iridocyclitis NNS NNS O
. . . O

Iridocyclitis NNP NNP O
was VBD VBD O
seen VBN VBN O
most RBS RBS O
frequently RB RB O
in IN IN O
young JJ JJ O
female NN NN O
patients NNS NNS O
( ( ( O
0 CD CD O
to TO TO O
4 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
the DT DT O
monoarticular NN NN O
or CC CC O
pauciatricular JJ JJ O
form NN NN O
of IN IN O
the DT DT O
arthritis NN NN O
. . . O

However RB RB O
, , , O
30 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
developed VBD VBD O
uveitis RB RB O
after IN IN O
16 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
. . . O

Although IN IN O
61 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
had VBD VBD O
a DT DT O
noncontributory NN NN O
ocular JJ JJ O
history NN NN O
on IN IN O
entry NN NN O
, , , O
42 CD CD O
% NN NN O
had VBD VBD O
active JJ JJ O
uveitis NNS NNS O
on IN IN O
entry NN NN O
. . . O

Our PRP$ PRP$ O
approach NN NN O
was VBD VBD O
effective JJ JJ O
in IN IN O
detecting VBG VBG O
uveitis NNS NNS O
in IN IN O
new JJ JJ O
cases NNS NNS O
and CC CC O
exacerbations NNS NNS O
of IN IN O
uveitis NN NN O
in IN IN O
established VBN VBN O
cases NNS NNS O
. . . O

Forty CD CD O
- - - O
four CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
uveitis NNS NNS O
had VBD VBD O
one CD CD O
or CC CC O
more RBR RBR O
identifiable JJ JJ O
signs NNS NNS O
or CC CC O
symptoms NNS NNS O
, , , O
such JJ JJ O
as IN IN O
red JJ JJ O
eye NN NN O
, , , O
ocular JJ JJ O
pain NN NN O
, , , O
decreased VBD VBD O
visual JJ JJ O
acuity NN NN O
, , , O
or CC CC O
photophobia NN NN O
, , , O
in IN IN O
order NN NN O
of IN IN O
decreasing VBG VBG O
frequency NN NN O
. . . O

Even RB RB O
after IN IN O
early JJ JJ O
detection NN NN O
and CC CC O
prompt VB VB O
treatment NN NN O
, , , O
41 CD CD O
% NN NN O
of IN IN O
cases NNS NNS O
of IN IN O
uveitis NNS NNS O
did VBD VBD O
not RB RB O
respond VB VB O
to TO TO O
more JJR JJR O
than IN IN O
six CD CD O
months NNS NNS O
of IN IN O
intensive JJ JJ O
topical JJ JJ O
treatment NN NN O
with IN IN O
corticosteroids NNS NNS B-CHEM
and CC CC O
mydriatics NNS NNS O
. . . O

Despite IN IN O
this DT DT O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
dramatic JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
50 CD CD O
% NN NN O
incidence NN NN O
of IN IN O
blinding VBG VBG O
complications NNS NNS O
of IN IN O
uveitis NNS NNS O
cited VBD VBD O
in IN IN O
earlier RBR RBR O
studies NNS NNS O
. . . O

Cataract NNP NNP O
and CC CC O
band NN NN O
keratopathy NN NN O
occurred VBD VBD O
in IN IN O
only RB RB O
22 CD CD O
and CC CC O
13 CD CD O
% NN NN O
of IN IN O
our PRP$ PRP$ O
group NN NN O
, , , O
respectively RB RB O
. . . O

We PRP PRP O
used VBD VBD O
chloroquine NN NN B-CHEM
or CC CC O
hydroxychloroquine NN NN B-CHEM
in IN IN O
173 CD CD O
of IN IN O
210 CD CD O
cases NNS NNS O
and CC CC O
found VBD VBD O
only RB RB O
one CD CD O
case NN NN O
of IN IN O
chorioretinopathy JJ JJ O
attributable JJ JJ O
to TO TO O
these DT DT O
drugs NNS NNS O
. . . O

Systemically RB RB O
administered JJ JJ O
corticosteroids NNS NNS B-CHEM
were VBD VBD O
used VBN VBN O
in IN IN O
75 CD CD O
of IN IN O
210 CD CD O
cases NNS NNS O
; : : O
a DT DT O
significant JJ JJ O
number NN NN O
of IN IN O
posterior NN NN O
subcapsular NN NN O
cataracts NNS NNS O
was VBD VBD O
found VBN VBN O
. . . O

Typical JJ JJ O
keratoconjunctivitis NNS NNS O
sicca NN NN O
developed VBN VBN O
in IN IN O
three CD CD O
of IN IN O
the DT DT O
uveitis NN NN O
cases NNS NNS O
. . . O

This DT DT O
association NN NN O
with IN IN O
uveitis NNS NNS O
and CC CC O
JRA NNP NNP O
was VBD VBD O
not RB RB O
noted VBN VBN O
previously RB RB O
. . . O

Surgical NNP NNP O
treatment NN NN O
of IN IN O
cataracts NNS NNS O
, , , O
band NN NN O
keratopathy NN NN O
, , , O
and CC CC O
glaucoma NN NN O
achieved VBD VBD O
uniformly RB RB O
discouraging JJ JJ O
results NNS NNS O
. . . O

Cyclophosphamide NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NNS NNS O
in IN IN O
freely RB RB O
- : : O
moving VBG VBG O
conscious JJ JJ O
rats NNS NNS O
: : : O
behavioral JJ JJ O
approach NN NN O
to TO TO O
a DT DT O
new JJ JJ O
model NN NN O
of IN IN O
visceral JJ JJ O
pain NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
develop VB VB O
a DT DT O
model NN NN O
of IN IN O
visceral JJ JJ O
pain NN NN O
in IN IN O
rats NNS NNS O
using VBG VBG O
a DT DT O
behavioral JJ JJ O
approach NN NN O
. . . O

Cyclophosphamide NNP NNP B-CHEM
( ( ( O
CP NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
antitumoral JJ JJ O
agent NN NN O
known VBN VBN O
to TO TO O
produce VB VB O
toxic JJ JJ O
effects NNS NNS O
on IN IN O
the DT DT O
bladder NN NN O
wall NN NN O
through IN IN O
its PRP$ PRP$ O
main JJ JJ O
toxic JJ JJ O
metabolite NN NN O
acrolein NN NN B-CHEM
, , , O
was VBD VBD O
used VBN VBN O
to TO TO O
induce VB VB O
cystitis NNS NNS O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
CP NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
at IN IN O
doses NNS NNS O
of IN IN O
50 CD CD O
, , , O
100 CD CD O
and CC CC O
200 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

i NNP NNP O
. . . O
p NN NN O
. . . O
to TO TO O
male JJ JJ O
rats NNS NNS O
, , , O
and CC CC O
their PRP$ PRP$ O
behavior NN NN O
observed VBD VBD O
and CC CC O
scored VBD VBD O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
to TO TO O
4 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
on IN IN O
CP NNP NNP B-CHEM
- : : O
induced JJ JJ O
behavioral JJ JJ O
modifications NNS NNS O
were VBD VBD O
tested VBN VBN O
administered VBN VBN O
alone RB RB O
and CC CC O
after IN IN O
naloxone NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
90 CD CD O
minutes NNS NNS O
after IN IN O
CP NNP NNP B-CHEM
injection NN NN O
, , , O
that WDT WDT O
is VBZ VBZ O
, , , O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
administration NN NN O
of IN IN O
morphine NN NN B-CHEM
, , , O
the DT DT O
bladder NN NN O
was VBD VBD O
removed VBN VBN O
in IN IN O
some DT DT O
rats NNS NNS O
for IN IN O
histological JJ JJ O
examination NN NN O
. . . O

Finally RB RB O
, , , O
to TO TO O
show VB VB O
that IN IN O
the DT DT O
bladder NN NN O
is VBZ VBZ O
essential JJ JJ O
for IN IN O
the DT DT O
CP NNP NNP B-CHEM
- - - O
induced JJ JJ O
behavioral JJ JJ O
modifications NNS NNS O
, , , O
female JJ JJ O
rats NNS NNS O
also RB RB O
received VBD VBD O
CP NNP NNP B-CHEM
at IN IN O
doses NNS NNS O
of IN IN O
200 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

i NNP NNP O
. . . O
p NN NN O
. . . O
and CC CC O
of IN IN O
20 CD CD O
mg NN NN O
. . . O
by IN IN O
the DT DT O
intravesical JJ JJ O
route NN NN O
, , , O
and CC CC O
acrolein NN NN B-CHEM
at IN IN O
doses NNS NNS O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
. . . O
by IN IN O
the DT DT O
intravesical JJ JJ O
route NN NN O
and CC CC O
of IN IN O
5 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

i NNP NNP O
. . . O
v NN NN O
. . . O
RESULTS NNS NNS O
: : : O
CP NNP NNP B-CHEM
dose NN NN O
- : : O
relatedly RB RB O
induced VBD VBD O
marked VBN VBN O
behavioral JJ JJ O
modifications NNS NNS O
in IN IN O
male JJ JJ O
rats NNS NNS O
: : : O
breathing VBG VBG O
rate NN NN O
decrease NN NN O
, , , O
closing NN NN O
of IN IN O
the DT DT O
eyes NNS NNS O
and CC CC O
occurrence NN NN O
of IN IN O
specific JJ JJ O
postures NNS NNS O
. . . O

Morphine NNP NNP B-CHEM
dose NN NN O
- : : O
dependently RB RB O
reversed VBD VBD O
these DT DT O
behavioral JJ JJ O
disorders NNS NNS O
. . . O

A DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O
produced VBD VBD O
a DT DT O
reduction NN NN O
of IN IN O
almost RB RB O
50 CD CD O
% NN NN O
of IN IN O
the DT DT O
behavioral JJ JJ O
score NN NN O
induced VBN VBN O
by IN IN O
CP NNP NNP B-CHEM
200 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

This DT DT O
effect NN NN O
was VBD VBD O
completely RB RB O
prevented VBN VBN O
by IN IN O
pretreatment NN NN O
with IN IN O
naloxone NN NN B-CHEM
. . . O

At IN IN O
the DT DT O
time NN NN O
of IN IN O
administration NN NN O
of IN IN O
morphine NN NN B-CHEM
, , , O
histological JJ JJ O
modifications NNS NNS O
of IN IN O
the DT DT O
bladder NN NN O
wall NN NN O
, , , O
such JJ JJ O
as IN IN O
chorionic JJ JJ O
and CC CC O
muscle NN NN O
layer NN NN O
edema NN NN O
, , , O
were VBD VBD O
observed VBN VBN O
. . . O

In IN IN O
female JJ JJ O
rats NNS NNS O
, , , O
CP NNP NNP B-CHEM
200 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

i NNP NNP O
. . . O
p NN NN O
. . . O
produced VBD VBD O
the DT DT O
same JJ JJ O
marked VBD VBD O
behavioral JJ JJ O
modifications NNS NNS O
as IN IN O
those DT DT O
observed VBN VBN O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

Administered NNP NNP O
at IN IN O
the DT DT O
dose NN NN O
of IN IN O
20 CD CD O
mg NN NN O
. . . O
intravesically RB RB O
, , , O
CP NNP NNP B-CHEM
did VBD VBD O
not RB RB O
produce VB VB O
any DT DT O
behavioral JJ JJ O
effects NNS NNS O
, , , O
whereas IN IN O
acrolein NN NN B-CHEM
at IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
. . . O
intravesically RB RB O
induced VBN VBN O
behavioral JJ JJ O
modifications NNS NNS O
identical JJ JJ O
to TO TO O
those DT DT O
under IN IN O
CP NNP NNP B-CHEM
200 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
with IN IN O
the DT DT O
same JJ JJ O
maximal NN NN O
levels NNS NNS O
. . . O

Conversely RB RB O
, , , O
acrolein NN NN B-CHEM
5 CD CD O
mg NN NN O
. . . O
/ NN NN O
kg NN NN O
. . . O

i NNP NNP O
. . . O
v NN NN O
. . . O
did VBD VBD O
not RB RB O
produce VB VB O
any DT DT O
behavioral JJ JJ O
effects NNS NNS O
at IN IN O
all DT DT O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Overall RB RB O
, , , O
these DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
this DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
CP NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NNS NNS O
may MD MD O
be VB VB O
an DT DT O
interesting JJ JJ O
new JJ JJ O
behavioral JJ JJ O
model NN NN O
of IN IN O
inflammatory JJ JJ O
visceral JJ JJ O
pain NN NN O
, , , O
allowing VBG VBG O
a DT DT O
better JJR JJR O
understanding NN NN O
of IN IN O
these DT DT O
painful JJ JJ O
syndromes NNS NNS O
and CC CC O
thus RB RB O
a DT DT O
better JJR JJR O
therapeutic JJ JJ O
approach NN NN O
to TO TO O
them PRP PRP O
. . . O

Prednisolone NNP NNP B-CHEM
- - - O
induced JJ JJ O
muscle NN NN O
dysfunction NN NN O
is VBZ VBZ O
caused VBN VBN O
more JJR JJR O
by IN IN O
atrophy NN NN O
than IN IN O
by IN IN O
altered JJ JJ O
acetylcholine NN NN B-CHEM
receptor NN NN O
expression NN NN O
. . . O

Large JJ JJ O
doses NNS NNS O
of IN IN O
glucocorticoids NNS NNS O
can MD MD O
alter VB VB O
muscle NN NN O
physiology NN NN O
and CC CC O
susceptibility NN NN O
to TO TO O
neuromuscular JJ JJ O
blocking VBG VBG O
drugs NNS NNS O
by IN IN O
mechanisms NNS NNS O
not RB RB O
clearly RB RB O
understood VBN VBN O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
moderate JJ JJ O
and CC CC O
large JJ JJ O
doses NNS NNS O
of IN IN O
prednisolone NN NN B-CHEM
on IN IN O
muscle NN NN O
function NN NN O
and CC CC O
pharmacology NN NN O
, , , O
and CC CC O
their PRP$ PRP$ O
relationship NN NN O
to TO TO O
changes NNS NNS O
in IN IN O
muscle NN NN O
size NN NN O
and CC CC O
acetylcholine NN NN B-CHEM
receptor NN NN O
( ( ( O
AChR NNP NNP O
) ) ) O
expression NN NN O
. . . O

With IN IN O
institutional JJ JJ O
approval NN NN O
, , , O
35 CD CD O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
receive VB VB O
daily JJ JJ O
subcutaneous JJ JJ O
doses NNS NNS O
of IN IN O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
prednisolone NN NN B-CHEM
( ( ( O
P10 NNP NNP O
group NN NN O
) ) ) O
, , , O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
prednisolone NN NN B-CHEM
( ( ( O
P100 NNP NNP O
group NN NN O
) ) ) O
, , , O
or CC CC O
an DT DT O
equal JJ JJ O
volume NN NN O
of IN IN O
saline NN NN O
( ( ( O
S NNP NNP O
group NN NN O
) ) ) O
for IN IN O
7 CD CD O
days NNS NNS O
. . . O

A DT DT O
fourth JJ JJ O
group NN NN O
of IN IN O
rats NNS NNS O
was VBD VBD O
pair JJ JJ O
fed VBN VBN O
( ( ( O
food NN NN O
restricted VBD VBD O
) ) ) O
with IN IN O
the DT DT O
P100 NNP NNP O
rats NNS NNS O
for IN IN O
7 CD CD O
days NNS NNS O
( ( ( O
FR NNP NNP O
group NN NN O
) ) ) O
. . . O

On IN IN O
Day NNP NNP O
8 CD CD O
, , , O
the DT DT O
nerve NN NN O
- - - O
evoked JJ JJ O
peak NN NN O
twitch NN NN O
tensions NNS NNS O
, , , O
tetanic JJ JJ O
tensions NNS NNS O
, , , O
and CC CC O
fatigability NN NN O
, , , O
and CC CC O
the DT DT O
dose NN NN O
- - - O
response NN NN O
curves NNS NNS O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
in IN IN O
the DT DT O
tibialis NNS NNS O
cranialis JJ JJ O
muscle NN NN O
were VBD VBD O
measured VBN VBN O
in IN IN O
vivo NN NN O
and CC CC O
related VBN VBN O
to TO TO O
muscle NN NN O
mass NN NN O
or CC CC O
expression NN NN O
of IN IN O
AChRs NNP NNP O
. . . O

Rate NNP NNP O
of IN IN O
body NN NN O
weight NN NN O
gain NN NN O
was VBD VBD O
depressed VBN VBN O
in IN IN O
the DT DT O
P100 NNP NNP O
, , , O
FR NNP NNP O
, , , O
and CC CC O
P10 NNP NNP O
groups NNS NNS O
compared VBN VBN O
with IN IN O
the DT DT O
S NNP NNP O
group NN NN O
. . . O

Tibialis NNP NNP O
muscle NN NN O
mass NN NN O
was VBD VBD O
smaller JJR JJR O
in IN IN O
the DT DT O
P100 NNP NNP O
group NN NN O
than IN IN O
in IN IN O
the DT DT O
P10 NNP NNP O
or CC CC O
S NNP NNP O
groups NNS NNS O
. . . O

The DT DT O
evoked JJ JJ O
peak NN NN O
twitch NN NN O
and CC CC O
tetanic JJ JJ O
tensions NNS NNS O
were VBD VBD O
less JJR JJR O
in IN IN O
the DT DT O
P100 NNP NNP O
group NN NN O
than IN IN O
in IN IN O
the DT DT O
P10 NNP NNP O
or CC CC O
S NNP NNP O
groups NNS NNS O
, , , O
however RB RB O
, , , O
tension NN NN O
per IN IN O
milligram NN NN O
of IN IN O
muscle NN NN O
mass NN NN O
was VBD VBD O
greater JJR JJR O
in IN IN O
the DT DT O
P100 NNP NNP O
group NN NN O
than IN IN O
in IN IN O
the DT DT O
S NNP NNP O
group NN NN O
. . . O

The DT DT O
50 CD CD O
% NN NN O
effective JJ JJ O
dose NN NN O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
( ( ( O
microg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
the DT DT O
tibialis NN NN O
muscle NN NN O
was VBD VBD O
smaller JJR JJR O
in IN IN O
the DT DT O
P10 NNP NNP O
( ( ( O
33 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
4 CD CD O
) ) ) O
than IN IN O
in IN IN O
the DT DT O
S NNP NNP O
( ( ( O
61 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
0 CD CD O
) ) ) O
or CC CC O
the DT DT O
P100 NNP NNP O
( ( ( O
71 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
. . . O
6 CD CD O
) ) ) O
groups NNS NNS O
. . . O

AChR NNP NNP O
expression NN NN O
was VBD VBD O
less JJR JJR O
in IN IN O
the DT DT O
P10 NNP NNP O
group NN NN O
than IN IN O
in IN IN O
the DT DT O
S NNP NNP O
group NN NN O
. . . O

The DT DT O
evoked JJ JJ O
tensions NNS NNS O
correlated VBD VBD O
with IN IN O
muscle NN NN O
mass NN NN O
( ( ( O
r LS LS O
( ( ( O
2 CD CD O
) ) ) O
= SYM SYM O
0 CD CD O
. . . O
32 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
however RB RB O
, , , O
not RB RB O
with IN IN O
expression NN NN O
of IN IN O
AChR NNP NNP O
. . . O

The DT DT O
50 CD CD O
% NN NN O
effective JJ JJ O
dose NN NN O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
muscle NN NN O
mass NN NN O
or CC CC O
AChR NNP NNP O
expression NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
neuromuscular JJ JJ O
dysfunction NN NN O
after IN IN O
prednisolone NN NN B-CHEM
is VBZ VBZ O
dose JJ JJ O
- : : O
dependent NN NN O
, , , O
and CC CC O
derives VBZ VBZ O
primarily RB RB O
from IN IN O
muscle NN NN O
atrophy NN NN O
and CC CC O
derives VBZ VBZ O
less RBR RBR O
so RB RB O
from IN IN O
changes NNS NNS O
in IN IN O
AChR NNP NNP O
expression NN NN O
. . . O

IMPLICATIONS NNP NNP O
: : : O
The DT DT O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
chronic JJ JJ O
glucocorticoid NN NN O
therapy NN NN O
alters NNS NNS O
neuromuscular JJ JJ O
physiology NN NN O
and CC CC O
pharmacology NN NN O
are VBP VBP O
unclear JJ JJ O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
the DT DT O
observed VBN VBN O
effects NNS NNS O
are VBP VBP O
dose JJ JJ O
- - - O
dependent JJ JJ O
and CC CC O
derive JJ JJ O
primarily RB RB O
from IN IN O
muscle NN NN O
atrophy NN NN O
and CC CC O
derive VB VB O
less RBR RBR O
from IN IN O
changes NNS NNS O
in IN IN O
acetylcholine NN NN B-CHEM
receptor NN NN O
expression NN NN O
. . . O

Apomorphine NNP NNP B-CHEM
: : : O
an DT DT O
underutilized JJ JJ O
therapy NN NN O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Apomorphine NNP NNP B-CHEM
was VBD VBD O
the DT DT O
first JJ JJ O
dopaminergic JJ JJ O
drug NN NN O
ever RB RB O
used VBD VBD O
to TO TO O
treat VB VB O
symptoms NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

While IN IN O
powerful JJ JJ O
antiparkinsonian JJ JJ O
effects NNS NNS O
had VBD VBD O
been VBN VBN O
observed VBN VBN O
as RB RB O
early RB RB O
as IN IN O
1951 CD CD O
, , , O
the DT DT O
potential NN NN O
of IN IN O
treating VBG VBG O
fluctuating VBG VBG O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
by IN IN O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
apomorphine NN NN B-CHEM
has VBZ VBZ O
only RB RB O
recently RB RB O
become VB VB O
the DT DT O
subject NN NN O
of IN IN O
systematic JJ JJ O
study NN NN O
. . . O

A DT DT O
number NN NN O
of IN IN O
small JJ JJ O
scale NN NN O
clinical JJ JJ O
trials NNS NNS O
have VBP VBP O
unequivocally RB RB O
shown VBN VBN O
that IN IN O
intermittent JJ JJ O
subcutaneous JJ JJ O
apomorphine NN NN B-CHEM
injections NNS NNS O
produce VBP VBP O
antiparkinsonian JJ JJ O
benefit NN NN O
close RB RB O
if IN IN O
not RB RB O
identical JJ JJ O
to TO TO O
that DT DT O
seen VBN VBN O
with IN IN O
levodopa NN NN B-CHEM
and CC CC O
that IN IN O
apomorphine JJ JJ B-CHEM
rescue NN NN O
injections NNS NNS O
can MD MD O
reliably RB RB O
revert VB VB O
off RP RP O
- : : O
periods NNS NNS O
even RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
complex JJ JJ O
on IN IN O
- - - O
off RP RP O
motor NN NN O
swings NNS NNS O
. . . O

Continuous NNP NNP O
subcutaneous JJ JJ O
apomorphine NN NN B-CHEM
infusions NNS NNS O
can MD MD O
reduce VB VB O
daily JJ JJ O
off RP RP O
- - - O
time NN NN O
by IN IN O
more JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
in IN IN O
this DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
, , , O
which WDT WDT O
appears VBZ VBZ O
to TO TO O
be VB VB O
a DT DT O
stronger JJR JJR O
effect NN NN O
than IN IN O
that DT DT O
generally RB RB O
seen VBN VBN O
with IN IN O
add NN NN O
- - - O
on IN IN O
therapy NN NN O
with IN IN O
oral JJ JJ O
dopamine NN NN B-CHEM
agonists NNS NNS O
or CC CC O
COMT NNP NNP O
inhibitors NNS NNS O
. . . O

Extended NNP NNP O
follow VB VB O
- - - O
up RP RP O
studies NNS NNS O
of IN IN O
up IN IN O
to TO TO O
8 CD CD O
years NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
long JJ JJ O
- - - O
term NN NN O
persistence NN NN O
of IN IN O
apomorphine NN NN B-CHEM
efficacy NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
there EX EX O
is VBZ VBZ O
convincing VBG VBG O
clinical JJ JJ O
evidence NN NN O
that IN IN O
monotherapy NN NN O
with IN IN O
continuous JJ JJ O
subcutaneous JJ JJ O
apomorphine NN NN B-CHEM
infusions NNS NNS O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
marked JJ JJ O
reductions NNS NNS O
of IN IN O
preexisting VBG VBG O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
. . . O

The DT DT O
main JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
subcutaneous JJ JJ O
apomorphine NN NN B-CHEM
treatment NN NN O
are VBP VBP O
related VBN VBN O
to TO TO O
cutaneous JJ JJ O
tolerability NN NN O
problems NNS NNS O
, , , O
whereas IN IN O
sedation NN NN O
and CC CC O
psychiatric JJ JJ O
complications NNS NNS O
play VBP VBP O
a DT DT O
lesser JJR JJR O
role NN NN O
. . . O

Given VBN VBN O
the DT DT O
marked VBN VBN O
degree NN NN O
of IN IN O
efficacy NN NN O
of IN IN O
subcutaneous JJ JJ O
apomorphine NN NN B-CHEM
treatment NN NN O
in IN IN O
fluctuating VBG VBG O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
this DT DT O
approach NN NN O
seems VBZ VBZ O
to TO TO O
deserve VB VB O
more JJR JJR O
widespread JJ JJ O
clinical JJ JJ O
use NN NN O
. . . O

Probing NNP NNP O
peripheral NN NN O
and CC CC O
central JJ JJ O
cholinergic JJ JJ O
system NN NN O
responses NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
pharmacological JJ JJ O
response NN NN O
to TO TO O
drugs NNS NNS O
that WDT WDT O
act VBP VBP O
on IN IN O
the DT DT O
cholinergic JJ JJ O
system NN NN O
of IN IN O
the DT DT O
iris NN NN O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
to TO TO O
predict VB VB O
deficits NNS NNS O
in IN IN O
central JJ JJ O
cholinergic JJ JJ O
functioning VBG VBG O
due JJ JJ O
to TO TO O
diseases NNS NNS O
such JJ JJ O
as IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
yet RB RB O
correlations NNS NNS O
between IN IN O
central JJ JJ O
and CC CC O
peripheral JJ JJ O
responses NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
properly RB RB O
studied VBN VBN O
. . . O

This DT DT O
study NN NN O
assessed VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
normal JJ JJ O
aging NN NN O
on IN IN O
( ( ( O
1 CD CD O
) ) ) O
the DT DT O
tropicamide NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
pupil NN NN O
diameter NN NN O
, , , O
and CC CC O
( ( ( O
2 CD CD O
) ) ) O
the DT DT O
reversal NN NN O
of IN IN O
this DT DT O
effect NN NN O
with IN IN O
pilocarpine NN NN B-CHEM
. . . O

Scopolamine NNP NNP B-CHEM
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
positive JJ JJ O
control NN NN O
to TO TO O
detect VB VB O
age NN NN O
- : : O
dependent JJ JJ O
changes NNS NNS O
in IN IN O
central JJ JJ O
cholinergic JJ JJ O
functioning NN NN O
in IN IN O
the DT DT O
elderly JJ JJ O
. . . O

DESIGN NNP NNP O
: : : O
Randomized NNP NNP O
double JJ JJ O
- : : O
blind JJ JJ O
controlled JJ JJ O
trial NN NN O
. . . O

PARTICIPANTS NNS NNS O
: : : O
Ten CD CD O
healthy JJ JJ O
elderly JJ JJ O
( ( ( O
mean VB VB O
age NN NN O
70 CD CD O
) ) ) O
and CC CC O
9 CD CD O
young JJ JJ O
( ( ( O
mean VB VB O
age NN NN O
33 CD CD O
) ) ) O
volunteers NNS NNS O
. . . O

INTERVENTIONS NNP NNP O
: : : O
Pupil NNP NNP O
diameter NN NN O
was VBD VBD O
monitored VBN VBN O
using VBG VBG O
a DT DT O
computerized JJ JJ O
infrared JJ JJ O
pupillometer NN NN O
over IN IN O
4 CD CD O
hours NNS NNS O
. . . O

The DT DT O
study NN NN O
involved VBN VBN O
4 CD CD O
sessions NNS NNS O
. . . O

In IN IN O
1 CD CD O
session NN NN O
, , , O
tropicamide NN NN B-CHEM
( ( ( O
20 CD CD O
microL NN NN O
, , , O
0 CD CD O
. . . O
01 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
to TO TO O
one CD CD O
eye NN NN O
and CC CC O
placebo NN NN O
to TO TO O
the DT DT O
other JJ JJ O
. . . O

In IN IN O
another DT DT O
session NN NN O
, , , O
tropicamide NN NN B-CHEM
( ( ( O
20 CD CD O
microL NN NN O
, , , O
0 CD CD O
. . . O
01 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
to TO TO O
both DT DT O
eyes NNS NNS O
, , , O
followed VBD VBD O
23 CD CD O
minutes NNS NNS O
later RB RB O
by IN IN O
the DT DT O
application NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
( ( ( O
20 CD CD O
microL NN NN O
, , , O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
to TO TO O
one CD CD O
eye NN NN O
and CC CC O
placebo NN NN O
to TO TO O
the DT DT O
other JJ JJ O
. . . O

All DT DT O
eye NN NN O
drops NNS NNS O
were VBD VBD O
given VBN VBN O
in IN IN O
a DT DT O
randomized JJ JJ O
order NN NN O
. . . O

In IN IN O
2 CD CD O
separate JJ JJ O
sessions NNS NNS O
, , , O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
scopolamine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
, , , O
intravenously RB RB O
) ) ) O
or CC CC O
placebo NN NN O
was VBD VBD O
administered VBN VBN O
, , , O
and CC CC O
the DT DT O
effects NNS NNS O
on IN IN O
word NN NN O
recall NN NN O
were VBD VBD O
measured VBN VBN O
using VBG VBG O
the DT DT O
Buschke NNP NNP O
Selective NNP NNP O
Reminding NNP NNP O
Test NNP NNP O
over IN IN O
2 CD CD O
hours NNS NNS O
. . . O

OUTCOME NNP NNP O
MEASURES NNS NNS O
: : : O
Pupil NNP NNP O
size NN NN O
at IN IN O
time NN NN O
points NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
tropicamide NN NN B-CHEM
and CC CC O
pilocarpine NN NN B-CHEM
; : : O
scopolamine NN NN B-CHEM
- : : O
induced JJ JJ O
impairment NN NN O
in IN IN O
word NN NN O
recall NN NN O
. . . O

RESULTS NNS NNS O
: : : O
There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
between IN IN O
elderly JJ JJ O
and CC CC O
young JJ JJ O
volunteers NNS NNS O
in IN IN O
pupillary JJ JJ O
response NN NN O
to TO TO O
tropicamide VB VB B-CHEM
at IN IN O
any DT DT O
time NN NN O
point NN NN O
( ( ( O
p NN NN O
> NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
elderly JJ JJ O
group NN NN O
had VBD VBD O
a DT DT O
significantly RB RB O
greater JJR JJR O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
net NN NN O
decrease NN NN O
in IN IN O
pupil NN NN O
size NN NN O
85 CD CD O
, , , O
125 CD CD O
, , , O
165 CD CD O
and CC CC O
215 CD CD O
minutes NNS NNS O
after IN IN O
administration NN NN O
, , , O
compared VBN VBN O
with IN IN O
the DT DT O
young JJ JJ O
group NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Compared VBN VBN O
with IN IN O
the DT DT O
young JJ JJ O
group NN NN O
, , , O
the DT DT O
elderly JJ JJ O
group NN NN O
had VBD VBD O
greater JJR JJR O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
impairment NN NN O
in IN IN O
word NN NN O
recall NN NN O
60 CD CD O
, , , O
90 CD CD O
and CC CC O
120 CD CD O
minutes NNS NNS O
after IN IN O
administration NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
There EX EX O
is VBZ VBZ O
an DT DT O
age NN NN O
- - - O
related VBN VBN O
pupillary JJ JJ O
response NN NN O
to TO TO O
pilocarpine VB VB B-CHEM
that WDT WDT O
is VBZ VBZ O
not RB RB O
found VBN VBN O
with IN IN O
tropicamide NN NN B-CHEM
. . . O

Thus RB RB O
, , , O
pilocarpine NN NN B-CHEM
may MD MD O
be VB VB O
useful JJ JJ O
to TO TO O
assess VB VB O
variations NNS NNS O
in IN IN O
central JJ JJ O
cholinergic JJ JJ O
function NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
. . . O

Pain NN NN O
responses NNS NNS O
in IN IN O
methadone NN NN B-CHEM
- - - O
maintained JJ JJ O
opioid NN NN O
abusers NNS NNS O
. . . O

Providing NNP NNP O
pain NN NN O
management NN NN O
for IN IN O
known VBN VBN O
opioid NN NN O
abusers NNS NNS O
is VBZ VBZ O
a DT DT O
challenging VBG VBG O
clinical JJ JJ O
task NN NN O
, , , O
in IN IN O
part NN NN O
because IN IN O
little JJ JJ O
is VBZ VBZ O
known VBN VBN O
about IN IN O
their PRP$ PRP$ O
pain NN NN O
experience NN NN O
and CC CC O
analgesic NN NN O
requirements NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
describe VB VB O
pain NN NN O
tolerance NN NN O
and CC CC O
analgesic JJ JJ O
response NN NN O
in IN IN O
a DT DT O
sample NN NN O
of IN IN O
opioid JJ JJ O
addicts NNS NNS O
stabilized VBN VBN O
in IN IN O
methadone NN NN B-CHEM
- - - O
maintenance NN NN O
( ( ( O
MM NNP NNP O
) ) ) O
treatment NN NN O
( ( ( O
n NN NN O
= SYM SYM O
60 CD CD O
) ) ) O
in IN IN O
comparison NN NN O
to TO TO O
matched VBD VBD O
nondependent NN NN O
control NN NN O
subjects NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
60 CD CD O
) ) ) O
. . . O

By IN IN O
using VBG VBG O
a DT DT O
placebo NN NN O
- - - O
controlled VBN VBN O
, , , O
two CD CD O
- - - O
way NN NN O
factorial JJ JJ O
design NN NN O
, , , O
tolerance NN NN O
to TO TO O
cold VB VB O
- : : O
pressor NN NN O
( ( ( O
CP NNP NNP O
) ) ) O
pain NN NN O
was VBD VBD O
examined VBN VBN O
, , , O
both DT DT O
before IN IN O
and CC CC O
after IN IN O
oral JJ JJ O
administration NN NN O
of IN IN O
therapeutic JJ JJ O
doses NNS NNS O
of IN IN O
common JJ JJ O
opioid NN NN O
( ( ( O
hydromorphone NN NN B-CHEM
2 CD CD O
mg NN NN O
) ) ) O
and CC CC O
nonsteroidal JJ JJ O
anti NN NN O
- : : O
inflammatory JJ JJ O
( ( ( O
ketorolac NN NN B-CHEM
10 CD CD O
mg NN NN O
) ) ) O
analgesic JJ JJ O
agents NNS NNS O
. . . O

Results NNS NNS O
showed VBD VBD O
that IN IN O
MM NNP NNP O
individuals NNS NNS O
were VBD VBD O
significantly RB RB O
less JJR JJR O
tolerant NN NN O
of IN IN O
CP NNP NNP O
pain NN NN O
than IN IN O
control NN NN O
subjects NNS NNS O
, , , O
replicating VBG VBG O
previous JJ JJ O
work NN NN O
. . . O

Analgesic NNP NNP O
effects NNS NNS O
were VBD VBD O
significant JJ JJ O
neither DT DT O
for IN IN O
medication NN NN O
nor CC CC O
group NN NN O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
MM NNP NNP O
opioid NN NN O
abusers NNS NNS O
represent VBP VBP O
a DT DT O
pain NN NN O
- - - O
intolerant JJ JJ O
subset NN NN O
of IN IN O
clinical JJ JJ O
patients NNS NNS O
. . . O

Their PRP$ PRP$ O
complaints NNS NNS O
of IN IN O
pain NN NN O
should MD MD O
be VB VB O
evaluated VBN VBN O
seriously RB RB O
and CC CC O
managed VBD VBD O
aggressively RB RB O
. . . O

High NNP NNP O
- - - O
dose NN NN O
methylprednisolone NN NN B-CHEM
may MD MD O
do VB VB O
more JJR JJR O
harm NN NN O
for IN IN O
spinal JJ JJ O
cord NN NN O
injury NN NN O
. . . O

Because IN IN O
of IN IN O
the DT DT O
National NNP NNP O
Acute JJ JJ O
Spinal NNP NNP O
Cord NNP NNP O
Injury NNP NNP O
Studies NNPS NNPS O
( ( ( O
NASCIS NNP NNP O
) ) ) O
, , , O
high JJ JJ O
- - - O
dose NN NN O
methylprednisolone NN NN B-CHEM
became VBD VBD O
the DT DT O
standard JJ JJ O
of IN IN O
care NN NN O
for IN IN O
the DT DT O
acute JJ JJ O
spinal JJ JJ O
cord NN NN O
injury NN NN O
. . . O

In IN IN O
the DT DT O
NASCIS NNP NNP O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
mention NN NN O
regarding VBG VBG O
the DT DT O
possibility NN NN O
of IN IN O
acute JJ JJ O
corticosteroid NN NN B-CHEM
myopathy NN NN O
that IN IN O
high JJ JJ O
- - - O
dose NN NN O
methylprednisolone NN NN B-CHEM
may MD MD O
cause VB VB O
. . . O

The DT DT O
dosage NN NN O
of IN IN O
methylprednisolone NN NN B-CHEM
recommended VBN VBN O
by IN IN O
the DT DT O
NASCIS NNP NNP O
3 CD CD O
is VBZ VBZ O
the DT DT O
highest JJS JJS O
dose NN NN O
of IN IN O
steroids NNS NNS B-CHEM
ever RB RB O
being VBG VBG O
used VBN VBN O
during IN IN O
a DT DT O
2 CD CD O
- : : O
day NN NN O
period NN NN O
for IN IN O
any DT DT O
clinical JJ JJ O
condition NN NN O
. . . O

We PRP PRP O
hypothesize NN NN O
that IN IN O
it PRP PRP O
may MD MD O
cause VB VB O
some DT DT O
damage NN NN O
to TO TO O
the DT DT O
muscle NN NN O
of IN IN O
spinal JJ JJ O
cord NN NN O
injury NN NN O
patients NNS NNS O
. . . O

Further RB RB O
, , , O
steroid NN NN B-CHEM
myopathy JJ JJ O
recovers NNS NNS O
naturally RB RB O
and CC CC O
the DT DT O
neurological JJ JJ O
improvement NN NN O
shown VBN VBN O
in IN IN O
the DT DT O
NASCIS NNP NNP O
may MD MD O
be VB VB O
just RB RB O
a DT DT O
recording NN NN O
of IN IN O
this DT DT O
natural JJ JJ O
motor NN NN O
recovery NN NN O
from IN IN O
the DT DT O
steroid NN NN B-CHEM
myopathy NN NN O
, , , O
instead RB RB O
of IN IN O
any DT DT O
protection NN NN O
that IN IN O
methylprednisolone NN NN B-CHEM
offers VBZ VBZ O
to TO TO O
the DT DT O
spinal JJ JJ O
cord NN NN O
injury NN NN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
discussion NN NN O
considering VBG VBG O
the DT DT O
possibility NN NN O
that IN IN O
the DT DT O
methylprednisolone NN NN B-CHEM
recommended VBN VBN O
by IN IN O
NASCIS NNP NNP O
may MD MD O
cause VB VB O
acute JJ JJ O
corticosteroid NN NN B-CHEM
myopathy NN NN O
. . . O

Conversion NNP NNP O
to TO TO O
rapamycin VB VB B-CHEM
immunosuppression NN NN O
in IN IN O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
: : : O
report NN NN O
of IN IN O
an DT DT O
initial JJ JJ O
experience NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
evaluate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
RAPA NNP NNP B-CHEM
conversion NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
cyclosporine NN NN B-CHEM
( ( ( O
CsA NNP NNP B-CHEM
) ) ) O
or CC CC O
tacrolimus NN NN B-CHEM
( ( ( O
Tac NNP NNP B-CHEM
) ) ) O
toxicity NN NN O
. . . O

METHODS NNP NNP O
: : : O
Twenty NNP NNP O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
were VBD VBD O
switched VBN VBN O
to TO TO O
fixed VBN VBN O
dose NN NN O
rapamycin NN NN B-CHEM
( ( ( O
RAPA NNP NNP B-CHEM
) ) ) O
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
0 CD CD O
to TO TO O
204 CD CD O
months NNS NNS O
posttransplant JJ JJ O
. . . O

Drug NN NN O
monitoring NN NN O
was VBD VBD O
not RB RB O
initially RB RB O
used VBN VBN O
to TO TO O
adjust VB VB O
doses NNS NNS O
. . . O

The DT DT O
indications NNS NNS O
for IN IN O
switch NN NN O
were VBD VBD O
chronic JJ JJ O
CsA NNP NNP B-CHEM
or CC CC O
Tac NNP NNP B-CHEM
nephrotoxicity NN NN O
( ( ( O
12 CD CD O
) ) ) O
, , , O
acute JJ JJ O
CsA NNP NNP B-CHEM
or CC CC O
Tac NNP NNP B-CHEM
toxicity NN NN O
( ( ( O
3 CD CD O
) ) ) O
, , , O
severe JJ JJ O
facial JJ JJ O
dysmorphism NN NN O
( ( ( O
2 CD CD O
) ) ) O
, , , O
posttransplant JJ JJ O
lymphoproliferative JJ JJ O
disorder NN NN O
( ( ( O
PTLD NNP NNP O
) ) ) O
in IN IN O
remission NN NN O
( ( ( O
2 CD CD O
) ) ) O
, , , O
and CC CC O
hepatotoxicity NN NN O
in IN IN O
1 CD CD O
. . . O

Follow VB VB O
- - - O
up RP RP O
is VBZ VBZ O
7 CD CD O
to TO TO O
24 CD CD O
months NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
the DT DT O
12 CD CD O
patients NNS NNS O
switched VBD VBD O
because IN IN O
of IN IN O
chronic JJ JJ O
nephrotoxicity NN NN O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
[ NN NN O
233 CD CD O
+ NN NN O
/ NN NN O
- : : O
34 CD CD O
to TO TO O
210 CD CD O
+ NN NN O
/ NN NN O
- : : O
56 CD CD O
micromol NN NN O
/ NN NN O
liter NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
at IN IN O
6 CD CD O
months NNS NNS O
] NN NN O
. . . O

Facial NNP NNP O
dysmorphism NN NN O
improved VBN VBN O
in IN IN O
two CD CD O
patients NNS NNS O
. . . O

No DT DT O
relapse NN NN O
of IN IN O
PTLD NNP NNP O
was VBD VBD O
observed VBN VBN O
. . . O

Five CD CD O
patients NNS NNS O
developed VBN VBN O
pneumonia NN NN O
( ( ( O
two CD CD O
Pneumocystis NNP NNP O
carinii NN NN O
pneumonia NN NN O
, , , O
one CD CD O
infectious JJ JJ O
mononucleosis NN NN O
with IN IN O
polyclonal JJ JJ O
PTLD NNP NNP O
lung NN NN O
infiltrate NN NN O
) ) ) O
and CC CC O
two CD CD O
had VBD VBD O
bronchiolitis NNS NNS O
obliterans NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
deaths NNS NNS O
. . . O

RAPA NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
in IN IN O
four CD CD O
patients NNS NNS O
, , , O
because IN IN O
of IN IN O
pneumonia NN NN O
in IN IN O
two CD CD O
, , , O
PTLD NNP NNP O
in IN IN O
one CD CD O
, , , O
and CC CC O
oral JJ JJ O
aphtous JJ JJ O
ulcers NNS NNS O
in IN IN O
one CD CD O
. . . O

RAPA NNP NNP B-CHEM
levels NNS NNS O
were VBD VBD O
high JJ JJ O
( ( ( O
> NN NN O
15 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
) ) ) O
in IN IN O
7 CD CD O
of IN IN O
13 CD CD O
( ( ( O
54 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
RAPA NNP NNP B-CHEM
conversion NN NN O
provides VBZ VBZ O
adequate JJ JJ O
immunosuppression NN NN O
to TO TO O
enable VB VB O
CsA NNP NNP B-CHEM
withdrawal NN NN O
. . . O

However RB RB O
, , , O
when WRB WRB O
converting VBG VBG O
patients NNS NNS O
to TO TO O
RAPA NNP NNP B-CHEM
drug NN NN O
levels NNS NNS O
should MD MD O
be VB VB O
monitored VBN VBN O
to TO TO O
avoid VB VB O
over IN IN O
- - - O
immunosuppression NN NN O
and CC CC O
adequate JJ JJ O
antiviral NN NN O
and CC CC O
Pneumocystis NNP NNP O
carinii NN NN O
pneumonia NN NN O
prophylaxis NN NN O
should MD MD O
be VB VB O
given VBN VBN O
. . . O

Electro NNP NNP O
- : : O
oculography NN NN O
, , , O
electroretinography NN NN O
, , , O
visual JJ JJ O
evoked JJ JJ O
potentials NNS NNS O
, , , O
and CC CC O
multifocal JJ JJ O
electroretinography NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
vigabatrin NN NN B-CHEM
- - - O
attributed JJ JJ O
visual JJ JJ O
field NN NN O
constriction NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
Symptomatic NNP NNP O
visual NN NN O
field NN NN O
constriction NN NN O
thought VBD VBD O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
vigabatrin NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
. . . O

The DT DT O
current JJ JJ O
study NN NN O
investigated VBD VBD O
the DT DT O
visual JJ JJ O
fields NNS NNS O
and CC CC O
visual JJ JJ O
electrophysiology NN NN O
of IN IN O
eight CD CD O
patients NNS NNS O
with IN IN O
known VBN VBN O
vigabatrin NN NN B-CHEM
- - - O
attributed JJ JJ O
visual JJ JJ O
field NN NN O
loss NN NN O
, , , O
three CD CD O
of IN IN O
whom WP WP O
were VBD VBD O
reported VBN VBN O
previously RB RB O
. . . O

Six CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
no RB RB O
longer RB RB O
receiving VBG VBG O
vigabatrin NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
central JJ JJ O
and CC CC O
peripheral JJ JJ O
fields NNS NNS O
were VBD VBD O
examined VBN VBN O
with IN IN O
the DT DT O
Humphrey NNP NNP O
Visual NNP NNP O
Field NNP NNP O
Analyzer NNP NNP O
. . . O

Full NNP NNP O
visual JJ JJ O
electrophysiology NN NN O
, , , O
including VBG VBG O
flash JJ JJ O
electroretinography NN NN O
( ( ( O
ERG NNP NNP O
) ) ) O
, , , O
pattern NN NN O
electroretinography NN NN O
, , , O
multifocal JJ JJ O
ERG NNP NNP O
using VBG VBG O
the DT DT O
VERIS NNP NNP O
system NN NN O
, , , O
electro NN NN O
- - - O
oculography NN NN O
, , , O
and CC CC O
flash VBP VBP O
and CC CC O
pattern NN NN O
visual JJ JJ O
evoked JJ JJ O
potentials NNS NNS O
, , , O
was VBD VBD O
undertaken VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Seven CD CD O
patients NNS NNS O
showed VBD VBD O
marked VBN VBN O
visual JJ JJ O
field NN NN O
constriction NN NN O
with IN IN O
some DT DT O
sparing VBG VBG O
of IN IN O
the DT DT O
temporal JJ JJ O
visual JJ JJ O
field NN NN O
. . . O

The DT DT O
eighth NN NN O
exhibited VBD VBD O
concentric JJ JJ O
constriction NN NN O
. . . O

Most JJS JJS O
electrophysiological JJ JJ O
responses NNS NNS O
were VBD VBD O
usually RB RB O
just RB RB O
within IN IN O
normal JJ JJ O
limits NNS NNS O
; : : O
two CD CD O
patients NNS NNS O
had VBD VBD O
subnormal JJ JJ O
Arden NNP NNP O
electro NN NN O
- : : O
oculography NN NN O
indices NNS NNS O
; : : O
and CC CC O
one CD CD O
patient NN NN O
showed VBD VBD O
an DT DT O
abnormally RB RB O
delayed VBN VBN O
photopic NN NN O
b SYM SYM O
wave NN NN O
. . . O

However RB RB O
, , , O
five CD CD O
patients NNS NNS O
showed VBD VBD O
delayed VBN VBN O
30 CD CD O
- : : O
Hz NNP NNP O
flicker NN NN O
b SYM SYM O
waves NNS NNS O
, , , O
and CC CC O
seven CD CD O
patients NNS NNS O
showed VBD VBD O
delayed VBN VBN O
oscillatory JJ JJ O
potentials NNS NNS O
. . . O

Multifocal NNP NNP O
ERG NNP NNP O
showed VBD VBD O
abnormalities NNS NNS O
that WDT WDT O
sometimes RB RB O
correlated JJ JJ O
with IN IN O
the DT DT O
visual JJ JJ O
field NN NN O
appearance NN NN O
and CC CC O
confirmed VBD VBD O
that IN IN O
the DT DT O
deficit NN NN O
occurs VBZ VBZ O
at IN IN O
the DT DT O
retinal JJ JJ O
level NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Marked NNP NNP O
visual JJ JJ O
field NN NN O
constriction NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
vigabatrin NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
field NN NN O
defects NNS NNS O
and CC CC O
some DT DT O
electrophysiological JJ JJ O
abnormalities NNS NNS O
persist VBP VBP O
when WRB WRB O
vigabatrin NN NN B-CHEM
therapy NN NN O
is VBZ VBZ O
withdrawn VBN VBN O
. . . O

Myocardial NNP NNP O
ischemia NN NN O
due JJ JJ O
to TO TO O
coronary JJ JJ O
artery NN NN O
spasm NN NN O
during IN IN O
dobutamine NN NN B-CHEM
stress NN NN O
echocardiography NN NN O
. . . O

Dobutamine NNP NNP B-CHEM
stress NN NN O
echocardiography NN NN O
( ( ( O
DSE NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
useful JJ JJ O
and CC CC O
safe JJ JJ O
provocation NN NN O
test NN NN O
for IN IN O
myocardial NN NN O
ischemia NN NN O
. . . O

Until IN IN O
now RB RB O
, , , O
the DT DT O
test NN NN O
has VBZ VBZ O
been VBN VBN O
focused VBN VBN O
only RB RB O
on IN IN O
the DT DT O
organic JJ JJ O
lesion NN NN O
in IN IN O
the DT DT O
coronary JJ JJ O
artery NN NN O
, , , O
and CC CC O
positive JJ JJ O
DSE NNP NNP O
has VBZ VBZ O
indicated VBN VBN O
the DT DT O
presence NN NN O
of IN IN O
significant JJ JJ O
fixed VBN VBN O
coronary JJ JJ O
artery NN NN O
stenosis NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
is VBZ VBZ O
to TO TO O
examine VB VB O
whether IN IN O
myocardial JJ JJ O
ischemia NN NN O
due JJ JJ O
to TO TO O
coronary JJ JJ O
spasm NN NN O
is VBZ VBZ O
induced VBN VBN O
by IN IN O
dobutamine NN NN B-CHEM
. . . O

We PRP PRP O
performed VBD VBD O
DSE NNP NNP O
on IN IN O
51 CD CD O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
spastic JJ JJ O
angina NN NN O
but CC CC O
without IN IN O
significant JJ JJ O
fixed VBN VBN O
coronary JJ JJ O
artery NN NN O
stenosis NN NN O
. . . O

All DT DT O
patients NNS NNS O
had VBD VBD O
anginal JJ JJ O
attacks NNS NNS O
at IN IN O
rest NN NN O
with IN IN O
ST NNP NNP O
elevation NN NN O
on IN IN O
the DT DT O
electrocardiogram NN NN O
( ( ( O
variant NN NN O
angina NN NN O
) ) ) O
. . . O

Coronary JJ JJ O
spasm NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
intracoronary JJ JJ O
injection NN NN O
of IN IN O
acetylcholine NN NN B-CHEM
, , , O
and CC CC O
no DT DT O
fixed JJ JJ O
coronary JJ JJ O
artery NN NN O
stenosis NN NN O
was VBD VBD O
documented VBN VBN O
on IN IN O
angiograms NNS NNS O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

DSE NNP NNP O
was VBD VBD O
performed VBN VBN O
with IN IN O
intravenous JJ JJ O
dobutamine NN NN B-CHEM
infusion NN NN O
with IN IN O
an DT DT O
incremental JJ JJ O
doses NNS NNS O
of IN IN O
5 CD CD O
, , , O
10 CD CD O
, , , O
20 CD CD O
, , , O
30 CD CD O
, , , O
and CC CC O
40 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
every DT DT O
5 CD CD O
minutes NNS NNS O
. . . O

Of IN IN O
the DT DT O
51 CD CD O
patients NNS NNS O
, , , O
7 CD CD O
patients NNS NNS O
showed VBD VBD O
asynergy NN NN O
with IN IN O
ST NNP NNP O
elevation NN NN O
. . . O

All DT DT O
7 CD CD O
patients NNS NNS O
( ( ( O
13 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
chest NN NN O
pain NN NN O
during IN IN O
asynergy NN NN O
, , , O
and CC CC O
both DT DT O
chest NN NN O
pain NN NN O
and CC CC O
electrocardiographic JJ JJ O
changes NNS NNS O
were VBD VBD O
preceded VBN VBN O
by IN IN O
asynergy NN NN O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
dobutamine NN NN B-CHEM
can MD MD O
provoke VB VB O
coronary JJ JJ O
spasm NN NN O
in IN IN O
some DT DT O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
spastic JJ JJ O
angina NN NN O
. . . O

When WRB WRB O
DSE NNP NNP O
is VBZ VBZ O
performed VBN VBN O
to TO TO O
evaluate VB VB O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
not RB RB O
only RB RB O
fixed VBN VBN O
coronary JJ JJ O
stenosis NNS NNS O
, , , O
but CC CC O
also RB RB O
coronary JJ JJ O
spasm NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
a DT DT O
genesis NN NN O
of IN IN O
asynergy NN NN O
. . . O

Effect NN NN O
of IN IN O
intravenous JJ JJ O
metoprolol NN NN B-CHEM
or CC CC O
intravenous JJ JJ O
metoprolol NN NN B-CHEM
plus CC CC O
glucagon NN NN O
on IN IN O
dobutamine NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
. . . O

STUDY NNP NNP O
OBJECTIVE NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
effect NN NN O
of IN IN O
metoprolol NN NN B-CHEM
on IN IN O
dobutamine NN NN B-CHEM
stress NN NN O
testing NN NN O
with IN IN O
technetium NN NN B-CHEM
- - - I-CHEM
99m CD CD I-CHEM
sestamibi NN NN I-CHEM
single JJ JJ O
- : : O
photon NN NN O
emission NN NN O
computed VBN VBN O
tomography NN NN O
imaging VBG VBG O
and CC CC O
ST NNP NNP O
- : : O
segment NN NN O
monitoring NN NN O
, , , O
and CC CC O
to TO TO O
assess VB VB O
the DT DT O
impact NN NN O
of IN IN O
intravenous JJ JJ O
glucagon NN NN O
on IN IN O
metoprolol NN NN B-CHEM
' '' '' O
s VBZ VBZ O
effects NNS NNS O
. . . O

DESIGN NNP NNP O
: : : O
Randomized NNP NNP O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
. . . O

SETTING NNP NNP O
: : : O
Community NNP NNP O
hospital NN NN O
. . . O

PATIENTS NNS NNS O
: : : O
Twenty CD CD O
- - - O
two CD CD O
patients NNS NNS O
with IN IN O
known VBN VBN O
reversible JJ JJ O
perfusion NN NN O
defects NNS NNS O
. . . O

INTERVENTION NNP NNP O
: : : O
Patients NNS NNS O
underwent JJ JJ O
dobutamine NN NN B-CHEM
stress NN NN O
tests NNS NNS O
per IN IN O
standard JJ JJ O
protocol NN NN O
. . . O

Before IN IN O
dobutamine NN NN B-CHEM
was VBD VBD O
begun VBN VBN O
, , , O
no DT DT O
therapy NN NN O
was VBD VBD O
given VBN VBN O
during IN IN O
the DT DT O
first JJ JJ O
visit NN NN O
, , , O
and CC CC O
patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
on IN IN O
subsequent JJ JJ O
visits NNS NNS O
to TO TO O
receive VB VB O
metoprolol NN NN B-CHEM
or CC CC O
metoprolol NN NN B-CHEM
plus CC CC O
glucagon NN NN O
1 CD CD O
mg NN NN O
. . . O

Metoprolol NNP NNP B-CHEM
was VBD VBD O
dosed VBN VBN O
to TO TO O
achieve VB VB O
a DT DT O
resting VBG VBG O
predobutamine NN NN B-CHEM
heart NN NN O
rate NN NN O
below IN IN O
65 CD CD O
beats NNS NNS O
/ NN NN O
minute NN NN O
or CC CC O
a DT DT O
total JJ JJ O
intravenous JJ JJ O
dose NN NN O
of IN IN O
20 CD CD O
mg NN NN O
. . . O

MEASUREMENTS NNP NNP O
AND CC CC O
MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
Metoprolol NNP NNP B-CHEM
reduced VBD VBD O
maximum NN NN O
heart NN NN O
rate NN NN O
31 CD CD O
% NN NN O
, , , O
summed VBD VBD O
stress NN NN O
scores NNS NNS O
29 CD CD O
% NN NN O
, , , O
and CC CC O
summed VBD VBD O
difference NN NN O
scores NNS NNS O
43 CD CD O
% NN NN O
versus CC CC O
control NN NN O
. . . O

Metoprolol NNP NNP B-CHEM
plus CC CC O
glucagon NN NN O
also RB RB O
reduced VBD VBD O
the DT DT O
maximum NN NN O
heart NN NN O
rate NN NN O
29 CD CD O
% NN NN O
versus CC CC O
control NN NN O
. . . O

Summed NNP NNP O
stress NN NN O
and CC CC O
summed VBD VBD O
difference NN NN O
scores NNS NNS O
were VBD VBD O
not RB RB O
significantly RB RB O
reduced VBD VBD O
, , , O
although IN IN O
they PRP PRP O
were VBD VBD O
18 CD CD O
% NN NN O
and CC CC O
30 CD CD O
% NN NN O
lower JJR JJR O
, , , O
respectively RB RB O
, , , O
than IN IN O
control NN NN O
. . . O

No DT DT O
significant JJ JJ O
differences NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
any DT DT O
parameter NN NN O
between IN IN O
metoprolol NN NN B-CHEM
and CC CC O
metoprolol NN NN B-CHEM
- - - O
glucagon NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
During IN IN O
dobutamine NN NN B-CHEM
stress NN NN O
testing NN NN O
, , , O
metoprolol NN NN B-CHEM
attenuates NNS NNS O
or CC CC O
eliminates NNS NNS O
evidence NN NN O
of IN IN O
myocardial JJ JJ O
ischemia NN NN O
. . . O

Glucagon NNP NNP O
1 CD CD O
mg NN NN O
, , , O
although IN IN O
somewhat RB RB O
effective JJ JJ O
, , , O
does VBZ VBZ O
not RB RB O
correct VB VB O
this DT DT O
effect NN NN O
to TO TO O
the DT DT O
extent NN NN O
that IN IN O
it PRP PRP O
can MD MD O
be VB VB O
administered VBN VBN O
clinically RB RB O
. . . O

Evidence NN NN O
of IN IN O
functional JJ JJ O
somatotopy NN NN O
in IN IN O
GPi NNP NNP O
from IN IN O
results NNS NNS O
of IN IN O
pallidotomy NN NN O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
explore VB VB O
the DT DT O
functional JJ JJ O
anatomy NN NN O
of IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
internus NN NN O
( ( ( O
GPi NNP NNP O
) ) ) O
by IN IN O
studying VBG VBG O
the DT DT O
effects NNS NNS O
of IN IN O
unilateral JJ JJ O
pallidotomy NN NN O
on IN IN O
parkinsonian NN NN O
' '' '' O
off RP RP O
' POS POS O
signs NNS NNS O
and CC CC O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
( ( ( O
LID NNP NNP O
) ) ) O
. . . O

We PRP PRP O
found VBD VBD O
significant JJ JJ O
positive JJ JJ O
correlations NNS NNS O
between IN IN O
the DT DT O
preoperative JJ JJ O
levodopa NN NN B-CHEM
responsiveness NN NN O
of IN IN O
motor NN NN O
signs NNS NNS O
and CC CC O
the DT DT O
levodopa NN NN B-CHEM
responsiveness NN NN O
of IN IN O
scores NNS NNS O
in IN IN O
timed JJ JJ O
tests NNS NNS O
( ( ( O
Core NNP NNP O
Assessment NNP NNP O
Program NNP NNP O
for IN IN O
Intracerebral NNP NNP O
Transplantations NNP NNP O
) ) ) O
in IN IN O
the DT DT O
contralateral JJ JJ O
limbs NNS NNS O
and CC CC O
the DT DT O
improvement NN NN O
in IN IN O
these DT DT O
scores NNS NNS O
after IN IN O
surgery NN NN O
, , , O
whereas IN IN O
there EX EX O
was VBD VBD O
no DT DT O
correlation NN NN O
with IN IN O
the DT DT O
improvement NN NN O
in IN IN O
LID NNP NNP O
. . . O

We PRP PRP O
also RB RB O
found VBD VBD O
a DT DT O
highly RB RB O
significant JJ JJ O
correlation NN NN O
( ( ( O
P NN NN O
: : : O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
, , , O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
8 CD CD O
) ) ) O
between IN IN O
the DT DT O
volume NN NN O
of IN IN O
the DT DT O
ventral JJ JJ O
lesion NN NN O
in IN IN O
the DT DT O
GPi NNP NNP O
and CC CC O
the DT DT O
improvement NN NN O
in IN IN O
LID NNP NNP O
in IN IN O
the DT DT O
contralateral JJ JJ O
limbs NNS NNS O
, , , O
whereas IN IN O
there EX EX O
was VBD VBD O
no DT DT O
correlation NN NN O
between IN IN O
the DT DT O
ventral NN NN O
volume NN NN O
and CC CC O
the DT DT O
improvement NN NN O
in IN IN O
parkinsonian NN NN O
' '' '' O
off RP RP O
' POS POS O
signs NNS NNS O
. . . O

The DT DT O
volumes NNS NNS O
of IN IN O
the DT DT O
total JJ JJ O
lesion NN NN O
cylinder NN NN O
and CC CC O
the DT DT O
dorsal NN NN O
lesion NN NN O
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
the DT DT O
outcome NN NN O
of IN IN O
either DT DT O
dyskinesias NN NN O
or CC CC O
parkinsonian NN NN O
' '' '' O
off RP RP O
' POS POS O
signs NNS NNS O
. . . O

The DT DT O
differential JJ JJ O
predictive JJ JJ O
value NN NN O
of IN IN O
levodopa NN NN B-CHEM
responsiveness NN NN O
for IN IN O
the DT DT O
outcome NN NN O
of IN IN O
parkinsonian NN NN O
' '' '' O
off RP RP O
' POS POS O
signs NNS NNS O
and CC CC O
LID NNP NNP O
and CC CC O
the DT DT O
different JJ JJ O
correlations NNS NNS O
of IN IN O
ventral JJ JJ O
lesion NN NN O
volume NN NN O
with IN IN O
dyskinesias NN NN O
and CC CC O
parkinsonian NN NN O
' '' '' O
off RP RP O
' POS POS O
signs NNS NNS O
indicate VBP VBP O
that IN IN O
different JJ JJ O
anatomical JJ JJ O
or CC CC O
pathophysiological JJ JJ O
substrates NNS NNS O
may MD MD O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
generation NN NN O
of IN IN O
parkinsonian NN NN O
' '' '' O
off RP RP O
' POS POS O
signs NNS NNS O
and CC CC O
dyskinesias NNS NNS O
. . . O

Whereas NNP NNP O
cells NNS NNS O
in IN IN O
a DT DT O
wider JJR JJR O
area NN NN O
of IN IN O
the DT DT O
GPi NNP NNP O
may MD MD O
be VB VB O
implicated VBN VBN O
in IN IN O
parkinsonism NN NN O
, , , O
the DT DT O
ventral JJ JJ O
GPi NNP NNP O
seems VBZ VBZ O
to TO TO O
be VB VB O
crucial JJ JJ O
for IN IN O
the DT DT O
manifestation NN NN O
of IN IN O
LID NNP NNP O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
our PRP$ PRP$ O
observations NNS NNS O
are VBP VBP O
additional JJ JJ O
proof NN NN O
of IN IN O
the DT DT O
functional JJ JJ O
somatotopy NN NN O
of IN IN O
the DT DT O
systems NNS NNS O
within IN IN O
the DT DT O
GPi NNP NNP O
that WDT WDT O
mediate NN NN O
parkinsonism NN NN O
and CC CC O
dyskinesias NN NN O
, , , O
especially RB RB O
along IN IN O
the DT DT O
dorsoventral JJ JJ O
trajectory NN NN O
used VBN VBN O
in IN IN O
pallidotomy NN NN O
. . . O

The DT DT O
outcome NN NN O
of IN IN O
pallidotomy NN NN O
in IN IN O
which WDT WDT O
the DT DT O
lesion NN NN O
involves VBZ VBZ O
the DT DT O
ventral NN NN O
and CC CC O
dorsal NN NN O
GPi NNP NNP O
could MD MD O
be VB VB O
the DT DT O
net JJ JJ O
effect NN NN O
of IN IN O
alteration NN NN O
in IN IN O
the DT DT O
activity NN NN O
of IN IN O
pathways NNS NNS O
which WDT WDT O
mediate VBP VBP O
different JJ JJ O
symptoms NNS NNS O
, , , O
and CC CC O
hence RB RB O
could MD MD O
be VB VB O
variable JJ JJ O
. . . O

Screening NNP NNP O
for IN IN O
stimulant JJ JJ O
use NN NN O
in IN IN O
adult NN NN O
emergency NN NN O
department NN NN O
seizure NN NN O
patients NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
prevalence NN NN O
of IN IN O
positive JJ JJ O
plasma NN NN O
drug NN NN O
screening NN NN O
for IN IN O
cocaine NN NN B-CHEM
or CC CC O
amphetamine NN NN B-CHEM
in IN IN O
adult NN NN O
emergency NN NN O
department NN NN O
seizure NN NN O
patients NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
prospective JJ JJ O
study NN NN O
evaluated VBD VBD O
consecutive JJ JJ O
eligible JJ JJ O
seizure NN NN O
patients NNS NNS O
who WP WP O
had VBD VBD O
a DT DT O
plasma NN NN O
sample NN NN O
collected VBN VBN O
as IN IN O
part NN NN O
of IN IN O
their PRP$ PRP$ O
clinical JJ JJ O
evaluation NN NN O
. . . O

Plasma NNP NNP O
was VBD VBD O
tested VBN VBN O
for IN IN O
amphetamine NN NN B-CHEM
and CC CC O
the DT DT O
cocaine NN NN B-CHEM
metabolite NN NN O
benzoylecgonine NN NN B-CHEM
using VBG VBG O
enzyme NN NN O
- - - O
mediated JJ JJ O
immunoassay NN NN O
methodology NN NN O
. . . O

Plasma NNP NNP O
samples NNS NNS O
with IN IN O
benzoylecgonine NN NN B-CHEM
greater JJR JJR O
than IN IN O
150 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
or CC CC O
an DT DT O
amphetamine NN NN B-CHEM
greater JJR JJR O
than IN IN O
500 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
were VBD VBD O
defined VBN VBN O
as IN IN O
positive JJ JJ O
. . . O

Patient NNP NNP O
demographics NNS NNS O
, , , O
history NN NN O
of IN IN O
underlying VBG VBG O
drug NN NN O
or CC CC O
alcohol NN NN B-CHEM
- - - O
related VBN VBN O
seizure NN NN O
disorder NN NN O
, , , O
estimated VBN VBN O
time NN NN O
from IN IN O
seizure NN NN O
to TO TO O
sample NN NN O
collection NN NN O
, , , O
history NN NN O
or CC CC O
suspicion NN NN O
of IN IN O
cocaine NN NN O
or CC CC O
amphetamine NN NN O
abuse NN NN O
, , , O
results NNS NNS O
of IN IN O
clinical JJ JJ O
urine NN NN O
testing NN NN O
for IN IN O
drugs NNS NNS O
of IN IN O
abuse NN NN O
, , , O
and CC CC O
assay NN NN O
results NNS NNS O
were VBD VBD O
recorded VBN VBN O
without IN IN O
patient NN NN O
identifiers NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Fourteen CD CD O
of IN IN O
248 CD CD O
( ( ( O
5 CD CD O
. . . O
6 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
2 CD CD O
. . . O
7 CD CD O
% NN NN O
- : : O
8 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
plasma NN NN O
samples NNS NNS O
were VBD VBD O
positive JJ JJ O
by IN IN O
immunoassay NN NN O
testing NN NN O
for IN IN O
benzoylecgonine NN NN B-CHEM
and CC CC O
no DT DT O
samples NNS NNS O
( ( ( O
0 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
- : : O
1 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
positive JJ JJ O
for IN IN O
amphetamine NN NN B-CHEM
. . . O

Positive JJ JJ O
test NN NN O
results NNS NNS O
were VBD VBD O
more RBR RBR O
common JJ JJ O
in IN IN O
patient NN NN O
visits NNS NNS O
where WRB WRB O
there EX EX O
was VBD VBD O
a DT DT O
history NN NN O
or CC CC O
suspicion NN NN O
of IN IN O
cocaine NN NN O
or CC CC O
amphetamine NN NN O
abuse NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0005 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
During IN IN O
this DT DT O
study NN NN O
period NN NN O
, , , O
routine NN NN O
plasma NN NN O
screening NN NN O
for IN IN O
cocaine NN NN B-CHEM
and CC CC O
amphetamines NNS NNS B-CHEM
in IN IN O
adult NN NN O
seizure NN NN O
patients NNS NNS O
had VBD VBD O
a DT DT O
low JJ JJ O
yield NN NN O
. . . O

As IN IN O
a DT DT O
result NN NN O
, , , O
routine JJ JJ O
plasma NN NN O
screening NN NN O
would MD MD O
yield VB VB O
few JJ JJ O
cases NNS NNS O
of IN IN O
stimulant JJ JJ O
drug NN NN O
in IN IN O
which WDT WDT O
there EX EX O
was VBD VBD O
neither DT DT O
a DT DT O
history NN NN O
nor CC CC O
suspicion NN NN O
of IN IN O
drug NN NN O
abuse NN NN O
in IN IN O
this DT DT O
population NN NN O
. . . O

Contribution NNP NNP O
of IN IN O
sodium NN NN B-CHEM
valproate NN NN I-CHEM
to TO TO O
the DT DT O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
secretion NN NN O
of IN IN O
antidiuretic JJ JJ O
hormone NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
62 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
was VBD VBD O
administered VBN VBN O
sodium NN NN B-CHEM
valproate NN NN I-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
and CC CC O
who WP WP O
subsequently RB RB O
developed VBN VBN O
the DT DT O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
secretion NN NN O
of IN IN O
antidiuretic JJ JJ O
hormone NN NN O
( ( ( O
SIADH NNP NNP O
) ) ) O
. . . O

He PRP PRP O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
VPA NNP NNP B-CHEM
for IN IN O
treatment NN NN O
of IN IN O
idiopathic JJ JJ O
generalized JJ JJ O
tonic NN NN O
- - - O
clonic JJ JJ O
convulsions NNS NNS O
since IN IN O
he PRP PRP O
was VBD VBD O
56 CD CD O
years NNS NNS O
old JJ JJ O
. . . O

After IN IN O
substituting VBG VBG O
VPA NNP NNP B-CHEM
with IN IN O
zonisamide NN NN B-CHEM
, , , O
the DT DT O
serum NN NN O
sodium NN NN B-CHEM
level NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
. . . O

We PRP PRP O
consider VBP VBP O
this DT DT O
episode NN NN O
of IN IN O
SIADH NNP NNP O
to TO TO O
be VB VB O
the DT DT O
result NN NN O
of IN IN O
a DT DT O
combination NN NN O
of IN IN O
factors NNS NNS O
including VBG VBG O
a DT DT O
weakness NN NN O
of IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
and CC CC O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
administration NN NN O
of IN IN O
VPA NNP NNP B-CHEM
. . . O

Association NNP NNP O
of IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
production NN NN O
and CC CC O
apoptosis NN NN O
in IN IN O
a DT DT O
model NN NN O
of IN IN O
experimental JJ JJ O
nephropathy NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
In IN IN O
recent JJ JJ O
studies NNS NNS O
increased VBN VBN O
amounts NNS NNS O
of IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO DT DT B-CHEM
) ) ) O
and CC CC O
apoptosis NNS NNS O
have VBP VBP O
been VBN VBN O
implicated VBN VBN O
in IN IN O
various JJ JJ O
pathological JJ JJ O
conditions NNS NNS O
in IN IN O
the DT DT O
kidney NN NN O
. . . O

We PRP PRP O
have VBP VBP O
studied VBN VBN O
the DT DT O
role NN NN O
of IN IN O
NO NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
association NN NN O
with IN IN O
apoptosis NN NN O
in IN IN O
an DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
nephrotic JJ JJ O
syndrome NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
adriamycin NN NN B-CHEM
( ( ( O
ADR NNP NNP B-CHEM
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
alteration NN NN O
in IN IN O
the DT DT O
NO DT DT B-CHEM
pathway NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
measuring VBG VBG O
nitrite NN NN B-CHEM
levels NNS NNS O
in IN IN O
serum NN NN O
/ NN NN O
urine NN NN O
and CC CC O
by IN IN O
evaluating VBG VBG O
the DT DT O
changes NNS NNS O
in IN IN O
vascular NN NN O
reactivity NN NN O
of IN IN O
the DT DT O
isolated VBN VBN O
perfused VBN VBN O
rat NN NN O
kidney NN NN O
( ( ( O
IPRK NNP NNP O
) ) ) O
system NN NN O
. . . O

Rats NNP NNP O
were VBD VBD O
stratified VBN VBN O
into IN IN O
control NN NN O
groups NNS NNS O
and CC CC O
ADR NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
groups NNS NNS O
. . . O

These DT DT O
two CD CD O
groups NNS NNS O
were VBD VBD O
then RB RB O
divided VBN VBN O
into IN IN O
: : : O
group NN NN O
1 CD CD O
, , , O
animals NNS NNS O
receiving VBG VBG O
saline NN NN O
; : : O
and CC CC O
group NN NN O
2 CD CD O
, , , O
animals NNS NNS O
receiving VBG VBG O
aminoguanidine NN NN B-CHEM
( ( ( O
AG NNP NNP B-CHEM
) ) ) O
which WDT WDT O
is VBZ VBZ O
a DT DT O
specific JJ JJ O
inhibitor NN NN O
of IN IN O
inducible JJ JJ O
- - - O
NO DT DT B-CHEM
synthase NN NN O
. . . O

On IN IN O
day NN NN O
21 CD CD O
, , , O
rats NNS NNS O
were VBD VBD O
sacrificed VBN VBN O
after IN IN O
obtaining VBG VBG O
material NN NN O
for IN IN O
biochemical JJ JJ O
analysis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Histopathological NNP NNP O
examination NN NN O
of IN IN O
the DT DT O
kidneys NNS NNS O
of IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
ADR NNP NNP B-CHEM
revealed VBD VBD O
focal JJ JJ O
areas NNS NNS O
of IN IN O
mesangial NN NN O
proliferation NN NN O
and CC CC O
mild JJ JJ O
tubulointerstitial JJ JJ O
inflammation NN NN O
. . . O

They PRP PRP O
also RB RB O
had VBD VBD O
significantly RB RB O
higher JJR JJR O
levels NNS NNS O
of IN IN O
proteinuria NN NN O
compared VBN VBN O
with IN IN O
control NN NN O
and CC CC O
treatment NN NN O
groups NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Urine NNP NNP O
nitrite NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
the DT DT O
ADR NNP NNP B-CHEM
- : : O
nephropathy JJ JJ O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
IPRK NNP NNP O
phenylephrine NN NN B-CHEM
and CC CC O
acetylcholine NN NN B-CHEM
related VBN VBN O
responses NNS NNS O
were VBD VBD O
significantly RB RB O
impaired VBN VBN O
in IN IN O
the DT DT O
ADR NNP NNP B-CHEM
- : : O
nephropathy JJ JJ O
group NN NN O
. . . O

Apoptosis NNP NNP O
was VBD VBD O
not RB RB O
detected VBN VBN O
in IN IN O
controls NNS NNS O
. . . O

However RB RB O
, , , O
in IN IN O
the DT DT O
ADR NNP NNP B-CHEM
- : : O
nephropathy JJ JJ O
group NN NN O
, , , O
numerous JJ JJ O
apoptotic JJ JJ O
cells NNS NNS O
were VBD VBD O
identified VBN VBN O
in IN IN O
the DT DT O
tubulointerstitial JJ JJ O
areas NNS NNS O
. . . O

Double NNP NNP O
staining VBG VBG O
revealed VBN VBN O
numerous JJ JJ O
interstitial JJ JJ O
apoptotic JJ JJ O
cells NNS NNS O
to TO TO O
stain VB VB O
for IN IN O
ED1 NNP NNP O
, , , O
a DT DT O
marker NN NN O
for IN IN O
monocytes NNS NNS O
/ NN NN O
macrophages NNS NNS O
. . . O

Treatment NN NN O
with IN IN O
AG NNP NNP B-CHEM
prevented VBD VBD O
the DT DT O
impairment NN NN O
of IN IN O
renal JJ JJ O
vascular NN NN O
bed NN NN O
responses NNS NNS O
and CC CC O
reduced VBD VBD O
both DT DT O
urine NN NN O
nitrite NN NN B-CHEM
levels NNS NNS O
and CC CC O
apoptosis NNS NNS O
to TO TO O
control VB VB O
levels NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
We PRP PRP O
suggest VBP VBP O
that IN IN O
interactions NNS NNS O
between IN IN O
NO NN NN B-CHEM
and CC CC O
apoptosis NNS NNS O
are VBP VBP O
important JJ JJ O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
the DT DT O
ADR NNP NNP B-CHEM
- - - O
induced JJ JJ O
nephrosis NN NN O
. . . O

Dual NNP NNP O
effects NNS NNS O
of IN IN O
melatonin NN NN B-CHEM
on IN IN O
barbiturate NN NN B-CHEM
- : : O
induced JJ JJ O
narcosis NN NN O
in IN IN O
rats NNS NNS O
. . . O

Melatonin NNP NNP B-CHEM
affects VBZ VBZ O
the DT DT O
circadian NN NN O
sleep NN NN O
/ NN NN O
wake NN NN O
cycle NN NN O
, , , O
but CC CC O
it PRP PRP O
is VBZ VBZ O
not RB RB O
clear JJ JJ O
whether IN IN O
it PRP PRP O
may MD MD O
influence VB VB O
drug NN NN O
- : : O
induced JJ JJ O
narcosis NN NN O
. . . O

Sodium NNP NNP B-CHEM
thiopenthal NN NN I-CHEM
was VBD VBD O
administered VBN VBN O
intraperitoneally RB RB O
into IN IN O
male JJ JJ O
rats NNS NNS O
pre NN NN O
- : : O
treated VBN VBN O
with IN IN O
melatonin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
05 CD CD O
, , , O
0 CD CD O
. . . O
5 CD CD O
, , , O
5 CD CD O
and CC CC O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

Melatonin NNP NNP B-CHEM
pre NN NN O
- : : O
treatment NN NN O
affected VBN VBN O
in IN IN O
a DT DT O
dual JJ JJ O
manner NN NN O
barbiturate NN NN B-CHEM
narcosis NNS NNS O
, , , O
however RB RB O
, , , O
no DT DT O
dose NN NN O
- - - O
effect NN NN O
correlation NN NN O
was VBD VBD O
found VBN VBN O
. . . O

In IN IN O
particular JJ JJ O
, , , O
low JJ JJ O
doses NNS NNS O
reduced VBD VBD O
the DT DT O
latency NN NN O
to TO TO O
and CC CC O
prolonged VBD VBD O
the DT DT O
duration NN NN O
of IN IN O
barbiturate JJ JJ B-CHEM
narcosis NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
highest JJS JJS O
dose NN NN O
of IN IN O
melatonin NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
caused VBD VBD O
a DT DT O
paradoxical JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
latency NN NN O
and CC CC O
produced VBD VBD O
a DT DT O
sustained JJ JJ O
reduction NN NN O
of IN IN O
the DT DT O
duration NN NN O
of IN IN O
narcosis NN NN O
, , , O
and CC CC O
a DT DT O
reduction NN NN O
in IN IN O
mortality NN NN O
rate NN NN O
. . . O

Melatonin NNP NNP B-CHEM
0 CD CD O
. . . O
5 CD CD O
and CC CC O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
influenced VBN VBN O
the DT DT O
duration NN NN O
but CC CC O
not RB RB O
the DT DT O
latency NN NN O
of IN IN O
ketamine NN NN B-CHEM
- - - O
or CC CC O
diazepam NN NN B-CHEM
- - - O
induced JJ JJ O
narcosis NN NN O
. . . O

Thus RB RB O
, , , O
the DT DT O
dual JJ JJ O
action NN NN O
of IN IN O
melatonin NN NN B-CHEM
on IN IN O
pharmacological JJ JJ O
narcosis NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
specific JJ JJ O
for IN IN O
the DT DT O
barbiturate JJ JJ B-CHEM
mechanism NN NN O
of IN IN O
action NN NN O
. . . O

Reduced NNP NNP O
cardiotoxicity NN NN O
and CC CC O
preserved VBD VBD O
antitumor NN NN O
efficacy NN NN O
of IN IN O
liposome NN NN O
- - - O
encapsulated JJ JJ O
doxorubicin NN NN B-CHEM
and CC CC O
cyclophosphamide NN NN B-CHEM
compared VBN VBN O
with IN IN O
conventional JJ JJ O
doxorubicin NN NN B-CHEM
and CC CC O
cyclophosphamide NN NN B-CHEM
in IN IN O
a DT DT O
randomized JJ JJ O
, , , O
multicenter NN NN O
trial NN NN O
of IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
determine VB VB O
whether IN IN O
Myocet NNP NNP B-CHEM
( ( ( O
liposome JJ JJ O
- - - O
encapsulated JJ JJ O
doxorubicin NN NN B-CHEM
; : : O
The DT DT O
Liposome NNP NNP O
Company NNP NNP O
, , , O
Elan NNP NNP O
Corporation NNP NNP O
, , , O
Princeton NNP NNP O
, , , O
NJ NNP NNP O
) ) ) O
in IN IN O
combination NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
significantly RB RB O
reduces VBZ VBZ O
doxorubicin NN NN B-CHEM
cardiotoxicity NN NN O
while IN IN O
providing VBG VBG O
comparable JJ JJ O
antitumor NN NN O
efficacy NN NN O
in IN IN O
first JJ JJ O
- - - O
line NN NN O
treatment NN NN O
of IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
( ( ( O
MBC NNP NNP O
) ) ) O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Two CD CD O
hundred CD CD O
ninety CD CD O
- : : O
seven CD CD O
patients NNS NNS O
with IN IN O
MBC NNP NNP O
and CC CC O
no DT DT O
prior RB RB O
chemotherapy NN NN O
for IN IN O
metastatic JJ JJ O
disease NN NN O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
60 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
of IN IN O
Myocet NNP NNP B-CHEM
( ( ( O
M NNP NNP O
) ) ) O
or CC CC O
conventional JJ JJ O
doxorubicin NN NN B-CHEM
( ( ( O
A DT DT O
) ) ) O
, , , O
in IN IN O
combination NN NN O
with IN IN O
600 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
of IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
C NNP NNP O
) ) ) O
, , , O
every DT DT O
3 CD CD O
weeks NNS NNS O
until IN IN O
disease NN NN O
progression NN NN O
or CC CC O
unacceptable JJ JJ O
toxicity NN NN O
. . . O

Cardiotoxicity NNP NNP O
was VBD VBD O
defined VBN VBN O
by IN IN O
reductions NNS NNS O
in IN IN O
left VBD VBD O
- - - O
ventricular JJ JJ O
ejection NN NN O
fraction NN NN O
, , , O
assessed VBN VBN O
by IN IN O
serial NN NN O
multigated VBN VBN O
radionuclide NN NN O
angiography NN NN O
scans NNS NNS O
, , , O
or CC CC O
congestive JJ JJ O
heart NN NN O
failure NN NN O
( ( ( O
CHF NNP NNP O
) ) ) O
. . . O

Antitumor NNP NNP O
efficacy NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
objective NN NN O
tumor NN NN O
response NN NN O
rates NNS NNS O
( ( ( O
World NNP NNP O
Health NNP NNP O
Organization NNP NNP O
criteria NNS NNS O
) ) ) O
, , , O
time NN NN O
to TO TO O
progression NN NN O
, , , O
and CC CC O
survival NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Six CD CD O
percent NN NN O
of IN IN O
MC NNP NNP O
patients NNS NNS O
versus CC CC O
21 CD CD O
% NN NN O
( ( ( O
including VBG VBG O
five CD CD O
cases NNS NNS O
of IN IN O
CHF NNP NNP O
) ) ) O
of IN IN O
AC NNP NNP O
patients NNS NNS O
developed VBN VBN O
cardiotoxicity NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
0002 CD CD O
) ) ) O
. . . O

Median NNP NNP O
cumulative JJ JJ O
doxorubicin NN NN B-CHEM
dose NN NN O
at IN IN O
onset NN NN O
was VBD VBD O
more JJR JJR O
than IN IN O
2 CD CD O
, , , O
220 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
for IN IN O
MC NNP NNP O
versus CC CC O
480 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
for IN IN O
AC NNP NNP O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
0001 CD CD O
, , , O
hazard NN NN O
ratio NN NN O
, , , O
5 CD CD O
. . . O
04 CD CD O
) ) ) O
. . . O

MC NNP NNP O
patients NNS NNS O
also RB RB O
experienced VBN VBN O
less JJR JJR O
grade NN NN O
4 CD CD O
neutropenia NN NN O
. . . O

Antitumor NNP NNP O
efficacy NN NN O
of IN IN O
MC NNP NNP O
versus CC CC O
AC NNP NNP O
was VBD VBD O
comparable JJ JJ O
: : : O
objective JJ JJ O
response NN NN O
rates NNS NNS O
, , , O
43 CD CD O
% NN NN O
versus CC CC O
43 CD CD O
% NN NN O
; : : O
median JJ JJ O
time NN NN O
to TO TO O
progression NN NN O
, , , O
5 CD CD O
. . . O
1 CD CD O
% NN NN O
versus CC CC O
5 CD CD O
. . . O
5 CD CD O
months NNS NNS O
; : : O
median JJ JJ O
time NN NN O
to TO TO O
treatment NN NN O
failure NN NN O
, , , O
4 CD CD O
. . . O
6 CD CD O
versus CC CC O
4 CD CD O
. . . O
4 CD CD O
months NNS NNS O
; : : O
and CC CC O
median JJ JJ O
survival NN NN O
, , , O
19 CD CD O
versus CC CC O
16 CD CD O
months NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Myocet NNP NNP B-CHEM
improves VBZ VBZ O
the DT DT O
therapeutic JJ JJ O
index NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
by IN IN O
significantly RB RB O
reducing VBG VBG O
cardiotoxicity NN NN O
and CC CC O
grade NN NN O
4 CD CD O
neutropenia NN NN O
and CC CC O
provides VBZ VBZ O
comparable JJ JJ O
antitumor NN NN O
efficacy NN NN O
, , , O
when WRB WRB O
used VBN VBN O
in IN IN O
combination NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
as IN IN O
first JJ JJ O
- - - O
line NN NN O
therapy NN NN O
for IN IN O
MBC NNP NNP O
. . . O

The DT DT O
role NN NN O
of IN IN O
nitrergic JJ JJ O
system NN NN O
in IN IN O
lidocaine NN NN B-CHEM
- - - O
induced JJ JJ O
convulsion NN NN O
in IN IN O
the DT DT O
mouse NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
N NNP NNP B-CHEM
- - - I-CHEM
nitro NN NN I-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
ester NN NN I-CHEM
( ( ( O
L NNP NNP B-CHEM
- - - I-CHEM
NAME NN NN I-CHEM
) ) ) O
a DT DT O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO NNP NNP B-CHEM
) ) ) O
synthase NN NN O
inhibitor NN NN O
and CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
, , , O
a DT DT O
NO NNP NNP B-CHEM
precursor NN NN O
, , , O
were VBD VBD O
investigated VBN VBN O
on IN IN O
lidocaine NN NN B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
. . . O

In IN IN O
the DT DT O
first JJ JJ O
experiment NN NN O
, , , O
four CD CD O
groups NNS NNS O
of IN IN O
mice NNS NNS O
received VBD VBD O
physiological JJ JJ O
saline NN NN O
( ( ( O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
, , , O
L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
( ( ( O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
L NNP NNP B-CHEM
- : : I-CHEM
NAME NN NN I-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
and CC CC O
diazepam NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
respectively RB RB O
. . . O

Thirty NNP NNP O
minutes NNS NNS O
after IN IN O
these DT DT O
injections NNS NNS O
, , , O
all DT DT O
mice NN NN O
received VBD VBD O
lidocaine NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

In IN IN O
the DT DT O
second JJ JJ O
experiment NN NN O
, , , O
four CD CD O
groups NNS NNS O
of IN IN O
mice NNS NNS O
received VBD VBD O
similar JJ JJ O
treatment NN NN O
in IN IN O
the DT DT O
first JJ JJ O
experiment NN NN O
, , , O
and CC CC O
30 CD CD O
min NN NN O
after IN IN O
these DT DT O
injections NNS NNS O
, , , O
all DT DT O
mice NN NN O
received VBD VBD O
a DT DT O
higher JJR JJR O
dose NN NN O
of IN IN O
lidocaine NN NN B-CHEM
( ( ( O
80 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

L NNP NNP B-CHEM
- : : I-CHEM
NAME NN NN I-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
and CC CC O
diazepam NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
significantly RB RB O
decreased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
lidocaine NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
- : : O
induced JJ JJ O
convulsions NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
treatment NN NN O
increased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
lidocaine NN NN B-CHEM
( ( ( O
80 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
- : : O
induced JJ JJ O
convulsions NNS NNS O
significantly RB RB O
. . . O

These DT DT O
results NNS NNS O
may MD MD O
suggest VB VB O
that IN IN O
NO DT DT B-CHEM
is VBZ VBZ O
a DT DT O
proconvulsant NN NN O
mediator NN NN O
in IN IN O
lidocaine NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
. . . O

Erythropoietin NNP NNP O
restores VBZ VBZ O
the DT DT O
anemia NN NN O
- - - O
induced JJ JJ O
reduction NN NN O
in IN IN O
cyclophosphamide NN NN B-CHEM
cytotoxicity NN NN O
in IN IN O
rat NN NN O
tumors NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
examine VB VB O
the DT DT O
impact NN NN O
of IN IN O
anemia NN NN O
prevention NN NN O
by IN IN O
recombinant JJ JJ O
human JJ JJ O
erythropoietin NN NN O
( ( ( O
rHuEPO NN NN O
) ) ) O
treatment NN NN O
on IN IN O
the DT DT O
cytotoxicity NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
in IN IN O
solid JJ JJ O
experimental JJ JJ O
tumors NNS NNS O
. . . O

Anemia NNP NNP O
was VBD VBD O
induced VBN VBN O
using VBG VBG O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
carboplatin NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
resulting VBG VBG O
in IN IN O
a DT DT O
long JJ JJ O
- - - O
lasting JJ JJ O
reduction NN NN O
( ( ( O
30 CD CD O
% NN NN O
) ) ) O
of IN IN O
the DT DT O
hemoglobin NN NN O
concentration NN NN O
. . . O

In IN IN O
a DT DT O
second JJ JJ O
group NN NN O
, , , O
the DT DT O
development NN NN O
of IN IN O
anemia NN NN O
was VBD VBD O
prevented VBN VBN O
by IN IN O
rHuEPO NN NN O
( ( ( O
1000 CD CD O
IU NNP NNP O
/ NN NN O
kg NN NN O
) ) ) O
administered JJ JJ O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
three CD CD O
times NNS NNS O
/ NN NN O
week NN NN O
starting VBG VBG O
7 CD CD O
days NNS NNS O
before IN IN O
carboplatin NN NN B-CHEM
application NN NN O
. . . O

Four CD CD O
days NNS NNS O
after IN IN O
carboplatin NN NN B-CHEM
treatment NN NN O
, , , O
tumors NNS NNS O
( ( ( O
DS NNP NNP O
- : : O
sarcoma NN NN O
of IN IN O
the DT DT O
rat NN NN O
) ) ) O
were VBD VBD O
implanted VBN VBN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
onto IN IN O
the DT DT O
hind NN NN O
food NN NN O
dorsum NN NN O
. . . O

Neither DT DT O
carboplatin NN NN B-CHEM
nor CC CC O
rHuEPO NN NN O
treatment NN NN O
influenced VBN VBN O
tumor NN NN O
growth NN NN O
rate NN NN O
per IN IN O
se FW FW O
. . . O

When WRB WRB O
tumors NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
60 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
5 CD CD O
days NNS NNS O
after IN IN O
implantation NN NN O
, , , O
a DT DT O
growth NN NN O
delay NN NN O
with IN IN O
a DT DT O
subsequent JJ JJ O
regrowth NN NN O
of IN IN O
the DT DT O
tumors NNS NNS O
was VBD VBD O
observed VBN VBN O
. . . O

In IN IN O
the DT DT O
anemia NN NN O
group NN NN O
, , , O
the DT DT O
growth NN NN O
delay NN NN O
was VBD VBD O
significantly RB RB O
shorter JJR JJR O
compared VBN VBN O
with IN IN O
nonanemic JJ JJ O
controls NNS NNS O
( ( ( O
13 CD CD O
. . . O
3 CD CD O
days NNS NNS O
versus CC CC O
8 CD CD O
. . . O
6 CD CD O
days NNS NNS O
) ) ) O
. . . O

In IN IN O
the DT DT O
group NN NN O
where WRB WRB O
anemia NN NN O
was VBD VBD O
prevented VBN VBN O
by IN IN O
rHuEPO NN NN O
treatment NN NN O
, , , O
growth NN NN O
delay NN NN O
was VBD VBD O
comparable JJ JJ O
with IN IN O
that DT DT O
of IN IN O
nonanemic JJ JJ O
controls NNS NNS O
( ( ( O
13 CD CD O
. . . O
3 CD CD O
days NNS NNS O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
chemotherapy NN NN O
- : : O
induced JJ JJ O
anemia NN NN O
reduces VBZ VBZ O
cytotoxicity NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
in IN IN O
tumors NNS NNS O
, , , O
whereas IN IN O
correction NN NN O
of IN IN O
anemia NN NN O
by IN IN O
rHuEPO NN NN O
treatment NN NN O
( ( ( O
epoetin NN NN O
alpha NN NN O
) ) ) O
increases VBZ VBZ O
the DT DT O
sensitivity NN NN O
, , , O
probably RB RB O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
an DT DT O
improved VBN VBN O
oxygen NN NN B-CHEM
supply NN NN O
to TO TO O
tumor VB VB O
tissue NN NN O
. . . O

Fatal NNP NNP O
haemorrhagic JJ JJ O
myocarditis NNS NNS O
secondary JJ JJ O
to TO TO O
cyclophosphamide VB VB B-CHEM
therapy NN NN O
. . . O

Haemorrhagic NNP NNP O
myocarditis NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
but CC CC O
important JJ JJ O
complication NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
therapy NN NN O
. . . O

Echocardiographic NNP NNP O
identification NN NN O
of IN IN O
the DT DT O
disorder NN NN O
can MD MD O
be VB VB O
made VBN VBN O
. . . O

We PRP PRP O
believe VBP VBP O
that IN IN O
the DT DT O
ultrasound JJ JJ O
features NNS NNS O
of IN IN O
this DT DT O
disorder NN NN O
have VBP VBP O
not RB RB O
been VBN VBN O
previously RB RB O
reported VBN VBN O
. . . O

Effects NNP NNP O
of IN IN O
verapamil NN NN B-CHEM
on IN IN O
atrial JJ JJ O
fibrillation NN NN O
and CC CC O
its PRP$ PRP$ O
electrophysiological JJ JJ O
determinants NNS NNS O
in IN IN O
dogs NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Atrial NNP NNP O
tachycardia NNS NNS O
- : : O
induced VBN VBN O
remodeling VBG VBG O
promotes NNS NNS O
the DT DT O
occurrence NN NN O
and CC CC O
maintenance NN NN O
of IN IN O
atrial JJ JJ O
fibrillation NN NN O
( ( ( O
AF NNP NNP O
) ) ) O
and CC CC O
decreases NNS NNS O
L NNP NNP O
- : : O
type NN NN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
current JJ JJ O
. . . O

There EX EX O
is VBZ VBZ O
also RB RB O
a DT DT O
clinical JJ JJ O
suggestion NN NN O
that IN IN O
acute JJ JJ O
L NNP NNP O
- : : O
type NN NN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
) ) ) O
channel NN NN O
blockade NN NN O
can MD MD O
promote VB VB O
AF NNP NNP O
, , , O
consistent JJ JJ O
with IN IN O
an DT DT O
AF NNP NNP O
promoting VBG VBG O
effect NN NN O
of IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
channel NN NN O
inhibition NN NN O
. . . O

METHODS NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
potential JJ JJ O
mechanisms NNS NNS O
of IN IN O
AF NNP NNP O
promotion NN NN O
by IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
channel NN NN O
blockers NNS NNS O
, , , O
we PRP PRP O
administered VBD VBD O
verapamil NN NN B-CHEM
to TO TO O
morphine VB VB B-CHEM
- : : O
chloralose VB VB B-CHEM
anesthetized JJ JJ O
dogs NNS NNS O
. . . O

Diltiazem NNP NNP B-CHEM
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
comparison NN NN O
drug NN NN O
and CC CC O
autonomic JJ JJ O
blockade NN NN O
with IN IN O
atropine NN NN B-CHEM
and CC CC O
nadolol NN NN B-CHEM
was VBD VBD O
applied VBN VBN O
in IN IN O
some DT DT O
experiments NNS NNS O
. . . O

Epicardial NNP NNP O
mapping VBG VBG O
with IN IN O
240 CD CD O
epicardial JJ JJ O
electrodes NNS NNS O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
activation NN NN O
during IN IN O
AF NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
Verapamil NNP NNP B-CHEM
caused VBD VBD O
AF NNP NNP O
promotion NN NN O
in IN IN O
six CD CD O
dogs NNS NNS O
, , , O
increasing VBG VBG O
mean NN NN O
duration NN NN O
of IN IN O
AF NNP NNP O
induced VBN VBN O
by IN IN O
burst NN NN O
pacing NN NN O
, , , O
from IN IN O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
s VBZ VBZ O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
S NNP NNP O
. . . O
E NNP NNP O
. . . O
) ) ) O
to TO TO O
95 CD CD O
+ NN NN O
/ NN NN O
- : : O
39 CD CD O
s VBZ VBZ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
vs NNS NNS O
. . . O
control NN NN O
) ) ) O
at IN IN O
a DT DT O
loading NN NN O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
and CC CC O
228 CD CD O
+ NN NN O
/ NN NN O
- : : O
101 CD CD O
s VBZ VBZ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0005 CD CD O
vs NNS NNS O
. . . O
control NN NN O
) ) ) O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Underlying NNP NNP O
electrophysiological JJ JJ O
mechanisms NNS NNS O
were VBD VBD O
studied VBN VBN O
in IN IN O
detail NN NN O
in IN IN O
five CD CD O
additional JJ JJ O
dogs NNS NNS O
under IN IN O
control NN NN O
conditions NNS NNS O
and CC CC O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
the DT DT O
higher JJR JJR O
dose NN NN O
of IN IN O
verapamil NN NN B-CHEM
. . . O

In IN IN O
these DT DT O
experiments NNS NNS O
, , , O
verapamil NN NN B-CHEM
shortened VBD VBD O
mean VB VB O
effective JJ JJ O
refractory NN NN O
period NN NN O
( ( ( O
ERP NNP NNP O
) ) ) O
from IN IN O
122 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
to TO TO O
114 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
ms NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
at IN IN O
a DT DT O
cycle NN NN O
length NN NN O
of IN IN O
300 CD CD O
ms NN NN O
, , , O
decreased VBD VBD O
ERP NNP NNP O
heterogeneity NN NN O
( ( ( O
from IN IN O
15 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
to TO TO O
10 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
% NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
heterogeneously RB RB O
accelerated VBD VBD O
atrial JJ JJ O
conduction NN NN O
and CC CC O
decreased VBD VBD O
the DT DT O
cycle NN NN O
length NN NN O
of IN IN O
AF NNP NNP O
( ( ( O
94 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
to TO TO O
84 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
ms NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
. . . O

Diltiazem NNP NNP B-CHEM
did VBD VBD O
not RB RB O
affect VB VB O
ERP NNP NNP O
, , , O
AF NNP NNP O
cycle NN NN O
length NN NN O
or CC CC O
AF NNP NNP O
duration NN NN O
, , , O
but CC CC O
produced VBD VBD O
conduction NN NN O
acceleration NN NN O
similar JJ JJ O
to TO TO O
that DT DT O
caused VBN VBN O
by IN IN O
verapamil NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
5 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
presence NN NN O
of IN IN O
autonomic JJ JJ O
blockade NN NN O
, , , O
verapamil NN NN B-CHEM
failed VBD VBD O
to TO TO O
promote VB VB O
AF NNP NNP O
and CC CC O
increased VBN VBN O
, , , O
rather RB RB O
than IN IN O
decreasing VBG VBG O
, , , O
refractoriness NN NN O
. . . O

Neither DT DT O
verapamil NN NN B-CHEM
nor CC CC O
diltiazem NN NN B-CHEM
affected VBN VBN O
atrial JJ JJ O
conduction NN NN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
autonomic JJ JJ O
blockade NN NN O
. . . O

Epicardial NNP NNP O
mapping VBG VBG O
suggested VBN VBN O
that IN IN O
verapamil NN NN B-CHEM
promoted VBN VBN O
AF NNP NNP O
by IN IN O
increasing VBG VBG O
the DT DT O
number NN NN O
of IN IN O
simultaneous JJ JJ O
wavefronts NNS NNS O
reflected VBN VBN O
by IN IN O
separate JJ JJ O
zones NNS NNS O
of IN IN O
reactivation NN NN O
in IN IN O
each DT DT O
cycle NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Verapamil NNP NNP B-CHEM
promotes NNS NNS O
AF NNP NNP O
in IN IN O
normal JJ JJ O
dogs NNS NNS O
by IN IN O
promoting VBG VBG O
multiple JJ JJ O
circuit NN NN O
reentry NN NN O
, , , O
an DT DT O
effect NN NN O
dependent JJ JJ O
on IN IN O
intact JJ JJ O
autonomic JJ JJ O
tone NN NN O
and CC CC O
not RB RB O
shared VBN VBN O
by IN IN O
diltiazem NN NN B-CHEM
. . . O

Calcitonin NNP NNP O
gene NN NN O
- - - O
related VBN VBN O
peptide NN NN O
levels NNS NNS O
during IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
- - - O
induced JJ JJ O
headache NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
tension NN NN O
- : : O
type NN NN O
headache NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
that IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO NNP NNP B-CHEM
) ) ) O
induced VBN VBN O
headache NN NN O
in IN IN O
primary JJ JJ O
headaches NNS NNS O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
release NN NN O
of IN IN O
calcitonin NN NN O
gene NN NN O
- - - O
related VBN VBN O
peptide NN NN O
( ( ( O
CGRP NNP NNP O
) ) ) O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
we PRP PRP O
aimed VBD VBD O
to TO TO O
investigate VB VB O
plasma NN NN O
levels NNS NNS O
of IN IN O
CGRP NNP NNP O
during IN IN O
headache NN NN O
induced VBN VBN O
by IN IN O
the DT DT O
NO DT DT B-CHEM
donor NN NN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
( ( ( O
GTN NNP NNP B-CHEM
) ) ) O
in IN IN O
16 CD CD O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
tension NN NN O
- : : O
type NN NN O
headache NN NN O
and CC CC O
16 CD CD O
healthy JJ JJ O
controls NNS NNS O
. . . O

The DT DT O
subjects NNS NNS O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
receive VB VB O
0 CD CD O
. . . O
5 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
GTN NNP NNP B-CHEM
or CC CC O
placebo NN NN O
over IN IN O
20 CD CD O
min NN NN O
on IN IN O
two CD CD O
headache NN NN O
- - - O
free JJ JJ O
days NNS NNS O
. . . O

Blood NNP NNP O
samples NNS NNS O
were VBD VBD O
collected VBN VBN O
at IN IN O
baseline NN NN O
, , , O
10 CD CD O
, , , O
20 CD CD O
and CC CC O
60 CD CD O
min NN NN O
after IN IN O
start NN NN O
of IN IN O
infusion NN NN O
. . . O

Both DT DT O
patients NNS NNS O
and CC CC O
controls NNS NNS O
developed VBN VBN O
significantly RB RB O
stronger RBR RBR O
immediate JJ JJ O
headache NN NN O
on IN IN O
the DT DT O
GTN NNP NNP B-CHEM
day NN NN O
than IN IN O
on IN IN O
the DT DT O
placebo NN NN O
day NN NN O
and CC CC O
the DT DT O
headache NN NN O
was VBD VBD O
significantly RB RB O
more RBR RBR O
pronounced JJ JJ O
in IN IN O
patients NNS NNS O
than IN IN O
in IN IN O
controls NNS NNS O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
difference NN NN O
between IN IN O
the DT DT O
area NN NN O
under IN IN O
the DT DT O
CGRP NNP NNP O
curve NN NN O
( ( ( O
AUCCGRP NNP NNP O
) ) ) O
on IN IN O
GTN NNP NNP B-CHEM
vs NNS NNS O
. . . O
placebo NN NN O
day NN NN O
in IN IN O
either DT DT O
patients NNS NNS O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
65 CD CD O
) ) ) O
or CC CC O
controls NNS NNS O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
48 CD CD O
) ) ) O
. . . O

The DT DT O
AUCCGRP NNP NNP O
recorded VBD VBD O
on IN IN O
the DT DT O
GTN NNP NNP B-CHEM
day NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
between IN IN O
patients NNS NNS O
and CC CC O
controls NNS NNS O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
36 CD CD O
) ) ) O
. . . O

Both DT DT O
in IN IN O
patients NNS NNS O
and CC CC O
controls NNS NNS O
, , , O
CGRP NNP NNP O
levels NNS NNS O
changed VBN VBN O
significantly RB RB O
over IN IN O
time NN NN O
, , , O
on IN IN O
both DT DT O
the DT DT O
GTN NNP NNP B-CHEM
and CC CC O
placebo NN NN O
days NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
indicates VBZ VBZ O
that IN IN O
NO UH UH B-CHEM
- : : O
induced JJ JJ O
immediate JJ JJ O
headache NN NN O
is VBZ VBZ O
not RB RB O
associated VBN VBN O
with IN IN O
release NN NN O
of IN IN O
CGRP NNP NNP O
. . . O

Fluconazole NNP NNP B-CHEM
- : : O
induced JJ JJ O
torsade NN NN O
de IN IN O
pointes NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
present VB VB O
a DT DT O
case NN NN O
of IN IN O
fluconazole NN NN B-CHEM
- - - O
associated VBN VBN O
torsade NN NN O
de IN IN O
pointes NNS NNS O
( ( ( O
TDP NNP NNP O
) ) ) O
and CC CC O
discuss VB VB O
fluconazole NN NN B-CHEM
' '' '' O
s VBZ VBZ O
role NN NN O
in IN IN O
causing VBG VBG O
TDP NNP NNP O
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
68 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
white JJ JJ O
woman NN NN O
with IN IN O
Candida NNP NNP O
glabrata NNS NNS O
isolated VBN VBN O
from IN IN O
a DT DT O
presacral JJ JJ O
abscess NN NN O
developed VBN VBN O
TDP NNP NNP O
eight CD CD O
days NNS NNS O
after IN IN O
commencing VBG VBG O
oral JJ JJ O
fluconazole NN NN B-CHEM
The DT DT O
patient NN NN O
had VBD VBD O
no DT DT O
other JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
TDP NNP NNP O
, , , O
including VBG VBG O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
cardiomyopathy NN NN O
, , , O
congestive JJ JJ O
heart NN NN O
failure NN NN O
, , , O
and CC CC O
electrolyte NN NN O
abnormalities NNS NNS O
There EX EX O
was VBD VBD O
a DT DT O
temporal JJ JJ O
association NN NN O
between IN IN O
the DT DT O
initiation NN NN O
of IN IN O
fluconazole NN NN B-CHEM
and CC CC O
TDP NNP NNP O
. . . O

The DT DT O
TDP NNP NNP O
resolved VBD VBD O
when WRB WRB O
fluconazole NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
; : : O
however RB RB O
, , , O
the DT DT O
patient NN NN O
continued VBD VBD O
to TO TO O
have VB VB O
premature NN NN O
ventricular NN NN O
contractions NNS NNS O
and CC CC O
nonsustained VBD VBD O
ventricular JJ JJ O
tachycardia NNS NNS O
( ( ( O
NSVT NNP NNP O
) ) ) O
until IN IN O
six CD CD O
days NNS NNS O
after IN IN O
drug NN NN O
cessation NN NN O
DISCUSSION NNP NNP O
: : : O
Use NN NN O
of IN IN O
the DT DT O
Naranjo NNP NNP O
probability NN NN O
scale NN NN O
indicates VBZ VBZ O
a DT DT O
probable JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
use NN NN O
of IN IN O
fluconazole NN NN B-CHEM
and CC CC O
the DT DT O
development NN NN O
of IN IN O
TDP NNP NNP O
. . . O

The DT DT O
possible JJ JJ O
mechanism NN NN O
is VBZ VBZ O
depression NN NN O
of IN IN O
rapidly RB RB O
activating VBG VBG O
delayed VBN VBN O
rectifier JJR JJR O
potassium NN NN B-CHEM
currents NNS NNS O
. . . O

In IN IN O
our PRP$ PRP$ O
patient NN NN O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
other JJ JJ O
etiology NN NN O
identified VBN VBN O
that WDT WDT O
could MD MD O
explain VB VB O
QT NNP NNP O
prolongation NN NN O
or CC CC O
TDP NNP NNP O
The DT DT O
complete JJ JJ O
disappearance NN NN O
of IN IN O
NSVT NNP NNP O
and CC CC O
premature NN NN O
ventricular NN NN O
contractions NNS NNS O
followed VBN VBN O
by IN IN O
normalization NN NN O
of IN IN O
QT NNP NNP O
interval NN NN O
after IN IN O
the DT DT O
drug NN NN O
was VBD VBD O
stopped VBN VBN O
strongly RB RB O
suggests VBZ VBZ O
fluconazole NN NN B-CHEM
as IN IN O
the DT DT O
etiology NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
that DT DT O
fluconazole NN NN B-CHEM
, , , O
even RB RB O
at IN IN O
low JJ JJ O
doses NNS NNS O
, , , O
may MD MD O
cause VB VB O
prolongation NN NN O
of IN IN O
the DT DT O
QT NNP NNP O
interval NN NN O
, , , O
leading VBG VBG O
to TO TO O
TDP NNP NNP O
. . . O

Serial NNP NNP O
electrocardiographic JJ JJ O
monitoring VBG VBG O
may MD MD O
be VB VB O
considered VBN VBN O
when WRB WRB O
fluconazole NN NN B-CHEM
is VBZ VBZ O
administered VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
are VBP VBP O
at IN IN O
risk NN NN O
for IN IN O
ventricular NN NN O
arrhythmias NNS NNS O
. . . O

Cutaneous NNP NNP O
leucocytoclastic JJ JJ O
vasculitis NN NN O
associated VBN VBN O
with IN IN O
oxacillin NN NN B-CHEM
. . . O

A DT DT O
67 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
was VBD VBD O
treated VBN VBN O
with IN IN O
oxacillin NN NN B-CHEM
for IN IN O
one CD CD O
week NN NN O
because IN IN O
of IN IN O
Staphylococcus NNP NNP O
aureus NN NN O
bacteremia NN NN O
, , , O
developed VBN VBN O
renal JJ JJ O
failure NN NN O
and CC CC O
diffuse NN NN O
, , , O
symmetric JJ JJ O
, , , O
palpable JJ JJ O
purpuric JJ JJ O
lesions NNS NNS O
on IN IN O
his PRP$ PRP$ O
feet NNS NNS O
. . . O

Necrotic NNP NNP O
blisters NNS NNS O
were VBD VBD O
noted VBN VBN O
on IN IN O
his PRP$ PRP$ O
fingers NNS NNS O
. . . O

Skin NNP NNP O
biopsies NNS NNS O
showed VBD VBD O
findings NNS NNS O
diagnostic JJ JJ O
of IN IN O
leucocytoclastic JJ JJ O
vasculitis NN NN O
. . . O

Oxacillin NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
and CC CC O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
corticosteroids NNS NNS B-CHEM
. . . O

The DT DT O
rash NN NN O
disappeared VBD VBD O
after IN IN O
three CD CD O
weeks NNS NNS O
and CC CC O
renal JJ JJ O
function NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
. . . O

Leucocytoclastic NNP NNP O
vasculitis NN NN O
presents VBZ VBZ O
as IN IN O
palpable JJ JJ O
purpura NN NN O
of IN IN O
the DT DT O
lower JJR JJR O
extremities NNS NNS O
often RB RB O
accompanied VBN VBN O
by IN IN O
abdominal JJ JJ O
pain NN NN O
, , , O
arthralgia NN NN O
, , , O
and CC CC O
renal JJ JJ O
involvement NN NN O
. . . O

Etiologic NNP NNP O
factors NNS NNS O
or CC CC O
associated VBN VBN O
disorders NNS NNS O
include VBP VBP O
infections NNS NNS O
, , , O
medications NNS NNS O
, , , O
collagen NN NN O
vascular NN NN O
disease NN NN O
and CC CC O
neoplasia NN NN O
. . . O

However RB RB O
, , , O
in IN IN O
half NN NN O
of IN IN O
the DT DT O
cases NNS NNS O
no DT DT O
etiologic JJ JJ O
factor NN NN O
is VBZ VBZ O
identified VBN VBN O
. . . O

Usually RB RB O
it PRP PRP O
is VBZ VBZ O
a DT DT O
self NN NN O
- - - O
limited JJ JJ O
disorder NN NN O
, , , O
but CC CC O
corticosteroid NN NN B-CHEM
therapy NN NN O
may MD MD O
be VB VB O
needed VBN VBN O
in IN IN O
life NN NN O
- - - O
threatening VBG VBG O
cases NNS NNS O
since IN IN O
early JJ JJ O
treatment NN NN O
with IN IN O
corticosteroids NNS NNS B-CHEM
in IN IN O
severe JJ JJ O
cases NNS NNS O
can MD MD O
prevent VB VB O
complications NNS NNS O
. . . O

Oxacillin NNP NNP B-CHEM
should MD MD O
be VB VB O
included VBN VBN O
among IN IN O
the DT DT O
drugs NNS NNS O
that WDT WDT O
can MD MD O
cause VB VB O
leucocytoclastic JJ JJ O
vasculitis NN NN O
. . . O

The DT DT O
renal JJ JJ O
pathology NN NN O
in IN IN O
a DT DT O
case NN NN O
of IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NN NN O
insipidus NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
is VBZ VBZ O
reported VBN VBN O
. . . O

At IN IN O
necropsy NN NN O
microscopy NN NN O
shoed JJ JJ O
unique JJ JJ O
and CC CC O
extensive JJ JJ O
damage NN NN O
to TO TO O
cells NNS NNS O
lining VBG VBG O
the DT DT O
distal JJ JJ O
nephron NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
these DT DT O
changes NNS NNS O
represent VBP VBP O
a DT DT O
specific JJ JJ O
toxic JJ JJ O
effect NN NN O
of IN IN O
lithium NN NN B-CHEM
, , , O
reported VBD VBD O
here RB RB O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
in IN IN O
man NN NN O
. . . O

Cholestatic NNP NNP O
jaundice NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
metformin NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
cholestatic JJ JJ O
jaundice NN NN O
shortly RB RB O
after IN IN O
initiation NN NN O
of IN IN O
treatment NN NN O
with IN IN O
metformin NN NN B-CHEM
hydrochloride NN NN I-CHEM
. . . O

Ultrasound NNP NNP O
of IN IN O
the DT DT O
liver NN NN O
and CC CC O
abdominal JJ JJ O
CT NNP NNP O
were VBD VBD O
normal JJ JJ O
. . . O

An DT DT O
ERCP NNP NNP O
showed VBD VBD O
normal JJ JJ O
biliary JJ JJ O
anatomy NN NN O
. . . O

A DT DT O
percutaneous JJ JJ O
liver NN NN O
biopsy NN NN O
was VBD VBD O
obtained VBN VBN O
showing VBG VBG O
marked JJ JJ O
cholestasis NN NN O
, , , O
with IN IN O
portal JJ JJ O
edema NN NN O
, , , O
ductular JJ JJ O
proliferation NN NN O
, , , O
and CC CC O
acute JJ JJ O
inflammation NN NN O
. . . O

Metformin NNP NNP B-CHEM
hydrochloride NN NN I-CHEM
was VBD VBD O
discontinued VBN VBN O
, , , O
and CC CC O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
jaundice NN NN O
resolved VBN VBN O
slowly RB RB O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
several JJ JJ O
months NNS NNS O
. . . O

Given VBN VBN O
the DT DT O
onset NN NN O
of IN IN O
his PRP$ PRP$ O
jaundice NN NN O
2 CD CD O
wk NN NN O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
metformin NN NN B-CHEM
, , , O
we PRP PRP O
believe VBP VBP O
that IN IN O
this DT DT O
case NN NN O
represents VBZ VBZ O
an DT DT O
example NN NN O
of IN IN O
metformin NN NN B-CHEM
- - - O
associated VBN VBN O
hepatotoxicity NN NN O
, , , O
the DT DT O
first JJ JJ O
such JJ JJ O
case NN NN O
reported VBD VBD O
. . . O

Systemic NNP NNP O
toxicity NN NN O
and CC CC O
resuscitation NN NN O
in IN IN O
bupivacaine NN NN B-CHEM
- - - O
, , , O
levobupivacaine NN NN B-CHEM
- - - O
, , , O
or CC CC O
ropivacaine NN NN B-CHEM
- - - O
infused JJ JJ O
rats NNS NNS O
. . . O

We PRP PRP O
compared VBD VBD O
the DT DT O
systemic JJ JJ O
toxicity NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
, , , O
levobupivacaine NN NN B-CHEM
, , , O
and CC CC O
ropivacaine NN NN B-CHEM
in IN IN O
anesthetized JJ JJ O
rats NNS NNS O
. . . O

We PRP PRP O
also RB RB O
compared VBD VBD O
the DT DT O
ability NN NN O
to TO TO O
resuscitate VB VB O
rats NNS NNS O
after IN IN O
lethal JJ JJ O
doses NNS NNS O
of IN IN O
these DT DT O
local JJ JJ O
anesthetics NNS NNS O
. . . O

Bupivacaine NNP NNP B-CHEM
, , , O
levobupivacaine NN NN B-CHEM
, , , O
or CC CC O
ropivacaine NN NN B-CHEM
was VBD VBD O
infused VBN VBN O
at IN IN O
a DT DT O
rate NN NN O
of IN IN O
2 CD CD O
mg NN NN O
. . . O

kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O

min NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
while IN IN O
electrocardiogram NN NN O
, , , O
electroencephalogram NN NN O
, , , O
and CC CC O
arterial JJ JJ O
pressure NN NN O
were VBD VBD O
continuously RB RB O
monitored VBN VBN O
. . . O

When WRB WRB O
asystole NN NN O
was VBD VBD O
recorded VBN VBN O
, , , O
drug NN NN O
infusion NN NN O
was VBD VBD O
stopped VBN VBN O
and CC CC O
a DT DT O
resuscitation NN NN O
sequence NN NN O
was VBD VBD O
begun VBN VBN O
. . . O

Epinephrine NNP NNP B-CHEM
0 CD CD O
. . . O
01 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
was VBD VBD O
administered VBN VBN O
at IN IN O
1 CD CD O
- : : O
min NN NN O
intervals NNS NNS O
while IN IN O
external JJ JJ O
cardiac JJ JJ O
compressions NNS NNS O
were VBD VBD O
applied VBN VBN O
. . . O

Resuscitation NNP NNP O
was VBD VBD O
considered VBN VBN O
successful JJ JJ O
when WRB WRB O
a DT DT O
systolic JJ JJ O
arterial NN NN O
pressure NN NN O
> NN NN O
or CC CC O
= SYM SYM O
100 CD CD O
mm NN NN O
Hg NNP NNP O
was VBD VBD O
achieved VBN VBN O
within IN IN O
5 CD CD O
min NN NN O
. . . O

The DT DT O
cumulative JJ JJ O
doses NNS NNS O
of IN IN O
levobupivacaine NN NN B-CHEM
and CC CC O
ropivacaine NN NN B-CHEM
that WDT WDT O
produced VBD VBD O
seizures NNS NNS O
were VBD VBD O
similar JJ JJ O
and CC CC O
were VBD VBD O
larger JJR JJR O
than IN IN O
those DT DT O
of IN IN O
bupivacaine NN NN B-CHEM
. . . O

The DT DT O
cumulative JJ JJ O
doses NNS NNS O
of IN IN O
levobupivacaine NN NN B-CHEM
that WDT WDT O
produced VBD VBD O
dysrhythmias NNS NNS O
and CC CC O
asystole NN NN O
were VBD VBD O
smaller JJR JJR O
than IN IN O
the DT DT O
corresponding JJ JJ O
doses NNS NNS O
of IN IN O
ropivacaine NN NN B-CHEM
, , , O
but CC CC O
they PRP PRP O
were VBD VBD O
larger JJR JJR O
than IN IN O
those DT DT O
of IN IN O
bupivacaine NN NN B-CHEM
. . . O

The DT DT O
number NN NN O
of IN IN O
successful JJ JJ O
resuscitations NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
among IN IN O
groups NNS NNS O
. . . O

However RB RB O
, , , O
a DT DT O
smaller JJR JJR O
dose NN NN O
of IN IN O
epinephrine NN NN B-CHEM
was VBD VBD O
required VBN VBN O
in IN IN O
the DT DT O
Ropivacaine NNP NNP B-CHEM
group NN NN O
than IN IN O
in IN IN O
the DT DT O
other JJ JJ O
groups NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
systemic JJ JJ O
toxicity NN NN O
of IN IN O
levobupivacaine NN NN B-CHEM
is VBZ VBZ O
intermediate JJ JJ O
between IN IN O
that DT DT O
of IN IN O
ropivacaine NN NN B-CHEM
and CC CC O
bupivacaine NN NN B-CHEM
when WRB WRB O
administered VBN VBN O
at IN IN O
the DT DT O
same JJ JJ O
rate NN NN O
and CC CC O
that IN IN O
ropivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
arrest NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
more RBR RBR O
susceptible JJ JJ O
to TO TO O
treatment NN NN O
than IN IN O
that DT DT O
induced VBN VBN O
by IN IN O
bupivacaine NN NN B-CHEM
or CC CC O
levobupivacaine NN NN B-CHEM
. . . O

Amphotericin NNP NNP B-CHEM
B NNP NNP I-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
AIDS NNP NNP O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
multiple JJ JJ O
episodes NNS NNS O
of IN IN O
seizure NN NN O
activity NN NN O
in IN IN O
an DT DT O
AIDS NNP NNP O
patent NN NN O
following VBG VBG O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
infusion NN NN O
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
46 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
African NNP NNP O
- - - O
American JJ JJ O
man NN NN O
experienced VBN VBN O
recurrent JJ JJ O
grand JJ JJ O
mal NN NN O
seizures NNS NNS O
during IN IN O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
, , , O
then RB RB O
petit NN NN O
mal NN NN O
seizures NNS NNS O
as IN IN O
the DT DT O
infusion NN NN O
was VBD VBD O
stopped VBN VBN O
and CC CC O
the DT DT O
drug NN NN O
concentrations NNS NNS O
decreased VBN VBN O
with IN IN O
time NN NN O
. . . O

The DT DT O
patients NNS NNS O
concurrent NN NN O
medications NNS NNS O
included VBD VBD O
didanosine NN NN B-CHEM
, , , O
hydroxyzine NN NN B-CHEM
, , , O
promethazine NN NN B-CHEM
, , , O
hydrocortisone NN NN B-CHEM
, , , O
and CC CC O
prochlorperazine NN NN B-CHEM
. . . O

Despite IN IN O
administration NN NN O
of IN IN O
phenytoin NN NN B-CHEM
and CC CC O
lorazepam NN NN B-CHEM
, , , O
the DT DT O
seizures NNS NNS O
persisted VBD VBD O
and CC CC O
occurred VBD VBD O
only RB RB O
during IN IN O
amphotercin NN NN B-CHEM
B NNP NNP I-CHEM
administration NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
AIDS NNP NNP O
and CC CC O
cryptococcal JJ JJ O
meningitis NN NN O
, , , O
both DT DT O
of IN IN O
which WDT WDT O
the DT DT O
patient NN NN O
had VBD VBD O
, , , O
can MD MD O
potentially RB RB O
cause VB VB O
seizures NNS NNS O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
a DT DT O
history NN NN O
of IN IN O
alcohol NN NN O
abuse NN NN O
; : : O
alcohol NN NN B-CHEM
intake NN NN O
as RB RB O
well RB RB O
as IN IN O
withdrawal NN NN O
can MD MD O
also RB RB O
cause VB VB O
seizures NNS NNS O
. . . O

Didanosine NNP NNP B-CHEM
also RB RB O
has VBZ VBZ O
a DT DT O
potential JJ JJ O
for IN IN O
inducing VBG VBG O
seizures NNS NNS O
. . . O

However RB RB O
, , , O
these DT DT O
other JJ JJ O
potential JJ JJ O
causes NNS NNS O
of IN IN O
seizure NN NN O
were VBD VBD O
ruled VBN VBN O
out IN IN O
. . . O

The DT DT O
time NN NN O
course NN NN O
of IN IN O
events NNS NNS O
suggested VBD VBD O
that IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
was VBD VBD O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
seizures NNS NNS O
in IN IN O
this DT DT O
AIDS NNP NNP O
patient NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Amphotericin NNP NNP B-CHEM
B NNP NNP I-CHEM
seems VBZ VBZ O
to TO TO O
be VB VB O
the DT DT O
probable JJ JJ O
cause NN NN O
of IN IN O
the DT DT O
seizures NNS NNS O
. . . O

To TO TO O
date NN NN O
, , , O
only RB RB O
three CD CD O
cases NNS NNS O
of IN IN O
seizures NNS NNS O
associated VBN VBN O
with IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
, , , O
but CC CC O
healthcare NN NN O
providers NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
potential NN NN O
for IN IN O
this DT DT O
rare JJ JJ O
adverse JJ JJ O
effect NN NN O
. . . O

Sirolimus NNP NNP B-CHEM
and CC CC O
mycophenolate NN NN B-CHEM
mofetil NN NN I-CHEM
for IN IN O
calcineurin NN NN O
- - - O
free JJ JJ O
immunosuppression NN NN O
in IN IN O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
. . . O

Calcineurin NNP NNP O
inhibitors NNS NNS O
, , , O
such JJ JJ O
as IN IN O
cyclosporine NN NN B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
, , , O
have VBP VBP O
been VBN VBN O
available JJ JJ O
for IN IN O
almost RB RB O
20 CD CD O
years NNS NNS O
. . . O

Although IN IN O
these DT DT O
drugs NNS NNS O
are VBP VBP O
highly RB RB O
effective JJ JJ O
and CC CC O
represent VB VB O
the DT DT O
mainstay NN NN O
of IN IN O
transplant JJ JJ O
immunosuppression NN NN O
, , , O
they PRP PRP O
are VBP VBP O
associated VBN VBN O
with IN IN O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
nephrotoxicity NN NN O
. . . O

Acute JJ JJ O
nephrotoxicity NN NN O
, , , O
which WDT WDT O
occurs VBZ VBZ O
in IN IN O
the DT DT O
early JJ JJ O
period NN NN O
after IN IN O
transplantation NN NN O
, , , O
leads VBZ VBZ O
to TO TO O
a DT DT O
higher JJR JJR O
rate NN NN O
of IN IN O
dialysis NN NN O
, , , O
and CC CC O
chronic JJ JJ O
nephrotoxicity NN NN O
may MD MD O
eventually RB RB O
result VB VB O
in IN IN O
graft NN NN O
loss NN NN O
. . . O

Acute JJ JJ O
and CC CC O
chronic JJ JJ O
nephrotoxicity NN NN O
is VBZ VBZ O
becoming VBG VBG O
more RBR RBR O
common JJ JJ O
as IN IN O
the DT DT O
use NN NN O
of IN IN O
marginal JJ JJ O
kidneys NNS NNS O
for IN IN O
transplantation NN NN O
increases NNS NNS O
. . . O

Two CD CD O
recently RB RB O
available JJ JJ O
immunosuppressive JJ JJ O
agents NNS NNS O
, , , O
mycophenolate NN NN B-CHEM
mofetil NN NN I-CHEM
and CC CC O
sirolimus NN NN B-CHEM
( ( ( O
rapamycin NN NN B-CHEM
) ) ) O
, , , O
have VBP VBP O
no DT DT O
nephrotoxicity NN NN O
. . . O

The DT DT O
use NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
agents NNS NNS O
has VBZ VBZ O
led VBN VBN O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
new JJ JJ O
paradigms NN NN O
of IN IN O
immunosuppressive JJ JJ O
therapy NN NN O
. . . O

This DT DT O
paper NN NN O
reviews NN NN O
the DT DT O
results NNS NNS O
of IN IN O
clinical JJ JJ O
trials NNS NNS O
that WDT WDT O
have VBP VBP O
investigated VBN VBN O
these DT DT O
new JJ JJ O
approaches NNS NNS O
to TO TO O
immunosuppression NN NN O
in IN IN O
renal JJ JJ O
transplant NN NN O
recipients NNS NNS O
. . . O

Tolerability NNP NNP O
of IN IN O
nimesulide NN NN B-CHEM
and CC CC O
paracetamol NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
NSAID NNP NNP B-CHEM
- : : O
induced JJ JJ O
urticaria NN NN O
/ NN NN O
angioedema NN NN O
. . . O

Previous JJ JJ O
studies NNS NNS O
evaluated VBD VBD O
the DT DT O
tolerance NN NN O
of IN IN O
nimesulide NN NN B-CHEM
and CC CC O
paracetamol NN NN B-CHEM
in IN IN O
subjects NNS NNS O
with IN IN O
cutaneous JJ JJ O
, , , O
respiratory JJ JJ O
and CC CC O
anaphylactoid JJ JJ O
reactions NNS NNS O
induced VBN VBN O
by IN IN O
nonsteroidal NN NN B-CHEM
anti JJ JJ I-CHEM
- : : I-CHEM
inflammatory JJ JJ I-CHEM
drugs NNS NNS I-CHEM
( ( ( O
NSAIDs NNP NNP B-CHEM
) ) ) O
. . . O

In IN IN O
this DT DT O
study NN NN O
we PRP PRP O
investigated VBD VBD O
tolerability NN NN O
and CC CC O
reliability NN NN O
of IN IN O
nimesulide NN NN B-CHEM
and CC CC O
paracetamol NN NN B-CHEM
in IN IN O
a DT DT O
very RB RB O
large JJ JJ O
number NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
an DT DT O
exclusive JJ JJ O
well RB RB O
- - - O
documented VBN VBN O
history NN NN O
of IN IN O
NSAID NNP NNP B-CHEM
- : : O
induced JJ JJ O
urticaria NN NN O
/ NN NN O
angioedema NN NN O
. . . O

Furthermore RB RB O
, , , O
we PRP PRP O
evaluated VBD VBD O
whether IN IN O
some DT DT O
factors NNS NNS O
have VBP VBP O
the DT DT O
potential JJ JJ O
to TO TO O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
reaction NN NN O
to TO TO O
paracetamol VB VB B-CHEM
and CC CC O
nimesulide NN NN B-CHEM
. . . O

A DT DT O
single JJ JJ O
- - - O
placebo NN NN O
- - - O
controlled JJ JJ O
oral JJ JJ O
challenge NN NN O
procedure NN NN O
with IN IN O
nimesulide NN NN B-CHEM
or CC CC O
paracetamol NN NN B-CHEM
was VBD VBD O
applied VBN VBN O
to TO TO O
829 CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
NSAID NNP NNP B-CHEM
- : : O
induced JJ JJ O
urticaria NN NN O
/ NN NN O
angioedema NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
75 CD CD O
/ NN NN O
829 CD CD O
( ( ( O
9 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
experienced VBN VBN O
reactions NNS NNS O
to TO TO O
nimesulide VB VB B-CHEM
or CC CC O
paracetamol NN NN B-CHEM
. . . O

Of IN IN O
the DT DT O
715 CD CD O
patients NNS NNS O
tested VBN VBN O
with IN IN O
nimesulide NN NN B-CHEM
62 CD CD O
( ( ( O
8 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
showed VBD VBD O
a DT DT O
positive JJ JJ O
test NN NN O
, , , O
while IN IN O
of IN IN O
114 CD CD O
subjects NNS NNS O
submitted VBN VBN O
to TO TO O
the DT DT O
challenge NN NN O
with IN IN O
paracetamol NN NN B-CHEM
, , , O
13 CD CD O
( ( ( O
9 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
did VBD VBD O
not RB RB O
tolerate VB VB O
this DT DT O
drug NN NN O
. . . O

Furthermore RB RB O
, , , O
18 CD CD O
. . . O
28 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
chronic JJ JJ O
urticaria NNS NNS O
and CC CC O
11 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
subjects NNS NNS O
with IN IN O
an DT DT O
history NN NN O
of IN IN O
NSAID NNP NNP B-CHEM
- : : O
induced JJ JJ O
urticaria NN NN O
/ NN NN O
angioedema NN NN O
or CC CC O
angioedema NN NN O
alone RB RB O
( ( ( O
with IN IN O
or CC CC O
without IN IN O
chronic JJ JJ O
urticaria NNS NNS O
) ) ) O
resulted VBN VBN O
to TO TO O
be VB VB O
intolerant JJ JJ O
to TO TO O
alternative JJ JJ O
drugs NNS NNS O
. . . O

Taken VBN VBN O
together RB RB O
, , , O
our PRP$ PRP$ O
results NNS NNS O
confirm NN NN O
the DT DT O
good JJ JJ O
tolerability NN NN O
of IN IN O
nimesulide NN NN B-CHEM
and CC CC O
paracetamol NN NN B-CHEM
in IN IN O
patients NNS NNS O
who WP WP O
experienced VBD VBD O
urticaria JJ JJ O
/ NN NN O
angioedema NN NN O
caused VBN VBN O
by IN IN O
NSAIDs NNP NNP B-CHEM
. . . O

However RB RB O
, , , O
the DT DT O
risk NN NN O
of IN IN O
reaction NN NN O
to TO TO O
these DT DT O
alternative JJ JJ O
study NN NN O
drugs NNS NNS O
is VBZ VBZ O
statistically RB RB O
increased VBN VBN O
by IN IN O
a DT DT O
history NN NN O
of IN IN O
chronic JJ JJ O
urticaria NNS NNS O
and CC CC O
, , , O
above IN IN O
all DT DT O
, , , O
by IN IN O
a DT DT O
history NN NN O
of IN IN O
NSAID NNP NNP B-CHEM
- : : O
induced JJ JJ O
angioedema NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
aqueous JJ JJ O
and CC CC O
gellan NN NN O
ophthalmic JJ JJ O
timolol NN NN B-CHEM
with IN IN O
placebo NN NN O
on IN IN O
the DT DT O
24 CD CD O
- : : O
hour NN NN O
heart NN NN O
rate NN NN O
response NN NN O
in IN IN O
patients NNS NNS O
on IN IN O
treatment NN NN O
for IN IN O
glaucoma NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
Topical NNP NNP O
beta NN NN O
- : : O
blocker NN NN O
treatment NN NN O
is VBZ VBZ O
routine JJ JJ O
therapy NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
glaucoma NN NN O
. . . O

Therapy NNP NNP O
results NNS NNS O
in IN IN O
systemic JJ JJ O
absorption NN NN O
, , , O
however RB RB O
, , , O
the DT DT O
degree NN NN O
of IN IN O
reduction NN NN O
of IN IN O
resting VBG VBG O
and CC CC O
peak NN NN O
heart NN NN O
rate NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
quantified VBN VBN O
. . . O

DESIGN NNP NNP O
: : : O
This DT DT O
trial NN NN O
evaluated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
placebo NN NN O
, , , O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
aqueous JJ JJ O
timolol NN NN B-CHEM
( ( ( O
timolol NN NN B-CHEM
solution NN NN O
) ) ) O
and CC CC O
a DT DT O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
timolol NN NN B-CHEM
suspension NN NN O
that WDT WDT O
forms VBZ VBZ O
a DT DT O
gel NN NN O
on IN IN O
application NN NN O
to TO TO O
the DT DT O
conjunctiva NN NN O
( ( ( O
timolol NN NN B-CHEM
gellan NN NN O
) ) ) O
on IN IN O
the DT DT O
24 CD CD O
- : : O
hour NN NN O
heart NN NN O
rate NN NN O
in IN IN O
patients NNS NNS O
currently RB RB O
being VBG VBG O
treated VBN VBN O
for IN IN O
glaucoma NN NN O
to TO TO O
quantify VB VB O
the DT DT O
reduction NN NN O
in IN IN O
mean NN NN O
heart NN NN O
rate NN NN O
. . . O

METHODS NNP NNP O
: : : O
Forty CD CD O
- - - O
three CD CD O
Caucasian NNP NNP O
patients NNS NNS O
with IN IN O
primary JJ JJ O
open JJ JJ O
- : : O
angle NN NN O
glaucoma NN NN O
or CC CC O
ocular JJ JJ O
hypertension NN NN O
with IN IN O
a DT DT O
mean NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
age NN NN O
of IN IN O
63 CD CD O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
) ) ) O
years NNS NNS O
were VBD VBD O
randomized JJ JJ O
and CC CC O
crossed VBN VBN O
over IN IN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
masked JJ JJ O
manner NN NN O
to TO TO O
14 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
placebo NN NN O
( ( ( O
morning NN NN O
and CC CC O
evening NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
) ) ) O
, , , O
timolol NN NN B-CHEM
solution NN NN O
( ( ( O
morning NN NN O
and CC CC O
evening NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
) ) ) O
, , , O
or CC CC O
timolol NN NN B-CHEM
gellan NN NN O
( ( ( O
morning NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
with IN IN O
placebo NN NN O
in IN IN O
the DT DT O
evening NN NN O
) ) ) O
. . . O

On IN IN O
the DT DT O
13th CD CD O
day NN NN O
of IN IN O
each DT DT O
period NN NN O
, , , O
heart NN NN O
rate NN NN O
was VBD VBD O
recorded VBN VBN O
continuously RB RB O
during IN IN O
a DT DT O
typical JJ JJ O
, , , O
ambulant JJ JJ O
24 CD CD O
- : : O
hour NN NN O
period NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Both DT DT O
timolol NN NN B-CHEM
solution NN NN O
and CC CC O
timolol NN NN B-CHEM
gellan NN NN O
reduced VBD VBD O
the DT DT O
mean NN NN O
24 CD CD O
- : : O
hour NN NN O
heart NN NN O
rate NN NN O
compared VBN VBN O
with IN IN O
placebo NN NN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
. . . O
001 CD CD O
) ) ) O
, , , O
and CC CC O
this DT DT O
reduction NN NN O
was VBD VBD O
most JJS JJS O
pronounced VBN VBN O
during IN IN O
the DT DT O
daytime JJ JJ O
( ( ( O
- : : O
7 CD CD O
. . . O
5 CD CD O
% NN NN O
change NN NN O
in IN IN O
mean NN NN O
heart NN NN O
rate NN NN O
, , , O
- - - O
5 CD CD O
. . . O
7 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
) ) ) O
. . . O

Timolol NNP NNP B-CHEM
gellan NN NN O
showed VBD VBD O
a DT DT O
numerically RB RB O
but CC CC O
not RB RB O
significantly RB RB O
smaller JJR JJR O
reduction NN NN O
in IN IN O
24 CD CD O
- : : O
hour NN NN O
heart NN NN O
rate NN NN O
, , , O
compared VBN VBN O
with IN IN O
timolol NN NN B-CHEM
solution NN NN O
. . . O

During IN IN O
the DT DT O
night NN NN O
, , , O
the DT DT O
mean NN NN O
12 CD CD O
- : : O
hour NN NN O
heart NN NN O
rate NN NN O
on IN IN O
placebo NN NN O
and CC CC O
timolol NN NN B-CHEM
gellan NN NN O
were VBD VBD O
both DT DT O
significantly RB RB O
less JJR JJR O
than IN IN O
on IN IN O
timolol NN NN B-CHEM
solution NN NN O
; : : O
the DT DT O
difference NN NN O
between IN IN O
solution NN NN O
and CC CC O
gellan NN NN O
treatments NNS NNS O
was VBD VBD O
statistically RB RB O
significant JJ JJ O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Both DT DT O
timolol NN NN B-CHEM
solution NN NN O
and CC CC O
timolol NN NN B-CHEM
gellan NN NN O
decrease VB VB O
the DT DT O
mean NN NN O
24 CD CD O
- : : O
hour NN NN O
heart NN NN O
rate NN NN O
compared VBN VBN O
with IN IN O
placebo NN NN O
. . . O

This DT DT O
response NN NN O
was VBD VBD O
most JJS JJS O
pronounced VBN VBN O
during IN IN O
the DT DT O
active JJ JJ O
daytime JJ JJ O
period NN NN O
. . . O

These DT DT O
data NNS NNS O
quantify VBP VBP O
the DT DT O
modest JJS JJS O
bradycardia NN NN O
associated VBN VBN O
with IN IN O
ophthalmic JJ JJ O
beta NN NN O
- - - O
blocker NN NN O
therapy NN NN O
in IN IN O
a DT DT O
typical JJ JJ O
patient NN NN O
population NN NN O
on IN IN O
therapy NN NN O
for IN IN O
glaucoma NN NN O
. . . O

Although IN IN O
exercise NN NN O
performance NN NN O
was VBD VBD O
not RB RB O
assessed VBN VBN O
in IN IN O
this DT DT O
trial NN NN O
, , , O
reductions NNS NNS O
of IN IN O
this DT DT O
magnitude NN NN O
should MD MD O
not RB RB O
have VB VB O
substantial JJ JJ O
clinical JJ JJ O
consequences NNS NNS O
. . . O

Management NNP NNP O
strategies NNS NNS O
for IN IN O
ribavirin NN NN B-CHEM
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
hepatitis NNP NNP O
C NNP NNP O
: : : O
clinical JJ JJ O
and CC CC O
economic JJ JJ O
implications NNS NNS O
. . . O

OBJECTIVES NNP NNP O
: : : O
Recently RB RB O
published VBN VBN O
studies NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
increased VBN VBN O
efficacy NN NN O
and CC CC O
cost NN NN O
- - - O
effectiveness NN NN O
of IN IN O
combination NN NN O
therapy NN NN O
with IN IN O
interferon NN NN O
and CC CC O
alpha NN NN O
- - - O
2b CD CD O
/ NN NN O
ribavirin NN NN B-CHEM
compared VBN VBN O
with IN IN O
interferon NN NN B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
monotherapy NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
( ( ( O
CHC NNP NNP O
) ) ) O
. . . O

Combination NNP NNP O
therapy NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
a DT DT O
clinically RB RB O
important JJ JJ O
adverse JJ JJ O
effect NN NN O
: : : O
ribavirin NN NN B-CHEM
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
( ( ( O
RIHA NNP NNP O
) ) ) O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
direct JJ JJ O
health NN NN O
- - - O
care NN NN O
costs NNS NNS O
and CC CC O
management NN NN O
of IN IN O
RIHA NNP NNP O
during IN IN O
treatment NN NN O
of IN IN O
CHC NNP NNP O
in IN IN O
a DT DT O
clinical JJ JJ O
trial NN NN O
setting VBG VBG O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
systematic JJ JJ O
literature NN NN O
review NN NN O
was VBD VBD O
conducted VBN VBN O
to TO TO O
synthesize VB VB O
information NN NN O
on IN IN O
the DT DT O
incidence NN NN O
and CC CC O
management NN NN O
of IN IN O
RIHA NNP NNP O
. . . O

Decision NNP NNP O
- : : O
analytic JJ JJ O
techniques NNS NNS O
were VBD VBD O
used VBN VBN O
to TO TO O
estimate VB VB O
the DT DT O
cost NN NN O
of IN IN O
treating VBG VBG O
RIHA NNP NNP O
. . . O

Uncertainty NNP NNP O
was VBD VBD O
evaluated VBN VBN O
using VBG VBG O
sensitivity NN NN O
analyses NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
RIHA NNP NNP O
, , , O
defined VBN VBN O
as IN IN O
a DT DT O
reduction NN NN O
in IN IN O
hemoglobin NN NN O
to TO TO O
less JJR JJR O
than IN IN O
100 CD CD O
g SYM SYM O
/ NN NN O
L NNP NNP O
, , , O
occurs VBZ VBZ O
in IN IN O
approximately RB RB O
7 CD CD O
% NN NN O
to TO TO O
9 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
combination NN NN O
therapy NN NN O
. . . O

The DT DT O
standard NN NN O
of IN IN O
care NN NN O
for IN IN O
management NN NN O
of IN IN O
RIHA NNP NNP O
is VBZ VBZ O
reduction NN NN O
or CC CC O
discontinuation NN NN O
of IN IN O
the DT DT O
ribavirin NN NN B-CHEM
dosage NN NN O
. . . O

We PRP PRP O
estimated VBD VBD O
the DT DT O
direct JJ JJ O
cost NN NN O
of IN IN O
treating VBG VBG O
clinically RB RB O
significant JJ JJ O
RIHA NNP NNP O
to TO TO O
be VB VB O
170 CD CD O
per IN IN O
patient NN NN O
receiving VBG VBG O
combination NN NN O
therapy NN NN O
per IN IN O
48 CD CD O
- : : O
week NN NN O
treatment NN NN O
course NN NN O
( ( ( O
range NN NN O
68 CD CD O
- : : O
692 CD CD O
) ) ) O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
the DT DT O
one CD CD O
- - - O
way NN NN O
sensitivity NN NN O
analyses NNS NNS O
ranged VBN VBN O
from IN IN O
57 CD CD O
to TO TO O
317 CD CD O
. . . O

In IN IN O
comparison NN NN O
, , , O
the DT DT O
cost NN NN O
of IN IN O
48 CD CD O
weeks NNS NNS O
of IN IN O
combination NN NN O
therapy NN NN O
is VBZ VBZ O
16 CD CD O
, , , O
459 CD CD O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
direct JJ JJ O
cost NN NN O
of IN IN O
treating VBG VBG O
clinically RB RB O
significant JJ JJ O
RIHA NNP NNP O
is VBZ VBZ O
1 CD CD O
% NN NN O
( ( ( O
170 CD CD O
/ NN NN O
16 CD CD O
, , , O
459 CD CD O
) ) ) O
of IN IN O
drug NN NN O
treatment NN NN O
costs NNS NNS O
. . . O

Questions NNS NNS O
remain VBP VBP O
about IN IN O
the DT DT O
optimal NN NN O
dose NN NN O
of IN IN O
ribavirin NN NN B-CHEM
and CC CC O
the DT DT O
incidence NN NN O
of IN IN O
RIHA NNP NNP O
in IN IN O
a DT DT O
real JJ JJ O
- - - O
world NN NN O
population NN NN O
. . . O

Despite IN IN O
these DT DT O
uncertainties NNS NNS O
, , , O
this DT DT O
initial JJ JJ O
evaluation NN NN O
of IN IN O
the DT DT O
direct JJ JJ O
cost NN NN O
of IN IN O
treating VBG VBG O
RIHA NNP NNP O
provides VBZ VBZ O
an DT DT O
estimate NN NN O
of IN IN O
the DT DT O
cost NN NN O
and CC CC O
management NN NN O
implications NNS NNS O
of IN IN O
this DT DT O
clinically RB RB O
important JJ JJ O
adverse JJ JJ O
effect NN NN O
. . . O

Preliminary NNP NNP O
efficacy NN NN O
assessment NN NN O
of IN IN O
intrathecal JJ JJ O
injection NN NN O
of IN IN O
an DT DT O
American JJ JJ O
formulation NN NN O
of IN IN O
adenosine NN NN B-CHEM
in IN IN O
humans NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Preclinical NNP NNP O
studies NNS NNS O
of IN IN O
intrathecal JJ JJ O
adenosine NN NN B-CHEM
suggest VBP VBP O
it PRP PRP O
may MD MD O
be VB VB O
effective JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
pain NN NN O
in IN IN O
humans NNS NNS O
, , , O
and CC CC O
preliminary JJ JJ O
studies NNS NNS O
in IN IN O
volunteers NNS NNS O
and CC CC O
patients NNS NNS O
with IN IN O
a DT DT O
Swedish JJ JJ O
formulation NN NN O
of IN IN O
adenosine NN NN B-CHEM
suggests VBZ VBZ O
it PRP PRP O
may MD MD O
be VB VB O
effective JJ JJ O
in IN IN O
hypersensitivity NN NN O
states NNS NNS O
but CC CC O
not RB RB O
with IN IN O
acute JJ JJ O
noxious JJ JJ O
stimulation NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
screen NN NN O
for IN IN O
efficacy NN NN O
of IN IN O
a DT DT O
different JJ JJ O
formulation NN NN O
of IN IN O
adenosine NN NN B-CHEM
marketed VBN VBN O
in IN IN O
the DT DT O
US NNP NNP O
, , , O
using VBG VBG O
both DT DT O
acute JJ JJ O
noxious JJ JJ O
stimulation NN NN O
and CC CC O
capsaicin NN NN B-CHEM
- - - O
evoked JJ JJ O
mechanical JJ JJ O
hypersensitivity NN NN O
. . . O

METHODS NNP NNP O
: : : O
Following VBG VBG O
Food NNP NNP O
and CC CC O
Drug NN NN O
Administration NNP NNP O
and CC CC O
institutional JJ JJ O
review NN NN O
board NN NN O
approval NN NN O
and CC CC O
written VBN VBN O
informed JJ JJ O
consent NN NN O
, , , O
65 CD CD O
volunteers NNS NNS O
were VBD VBD O
studied VBN VBN O
in IN IN O
two CD CD O
trials NNS NNS O
: : : O
an DT DT O
open JJ JJ O
- - - O
label NN NN O
, , , O
dose NN NN O
- - - O
escalating VBG VBG O
trial NN NN O
with IN IN O
intrathecal JJ JJ O
adenosine NN NN B-CHEM
doses NNS NNS O
of IN IN O
0 CD CD O
. . . O
25 CD CD O
- : : O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
and CC CC O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
of IN IN O
adenosine NN NN B-CHEM
, , , O
2 CD CD O
mg NN NN O
. . . O

Cerebrospinal NNP NNP O
fluid NN NN O
was VBD VBD O
obtained VBN VBN O
for IN IN O
pharmacokinetic JJ JJ O
analysis NN NN O
, , , O
and CC CC O
pain NN NN O
ratings NNS NNS O
in IN IN O
response NN NN O
to TO TO O
acute JJ JJ O
heat NN NN O
stimuli NN NN O
and CC CC O
areas NNS NNS O
of IN IN O
mechanical JJ JJ O
hyperalgesia NN NN O
and CC CC O
allodynia NN NN O
after IN IN O
intradermal JJ JJ O
capsaicin NN NN B-CHEM
injection NN NN O
were VBD VBD O
determined VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Adenosine NNP NNP B-CHEM
produced VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
pain NN NN O
report NN NN O
to TO TO O
acute JJ JJ O
noxious JJ JJ O
thermal NN NN O
or CC CC O
chemical NN NN O
stimulation NN NN O
but CC CC O
reduced VBN VBN O
mechanical JJ JJ O
hyperalgesia NN NN O
and CC CC O
allodynia NN NN O
from IN IN O
intradermal JJ JJ O
capsaicin NN NN B-CHEM
injection NN NN O
for IN IN O
at IN IN O
least JJS JJS O
24 CD CD O
h NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
residence NN NN O
time NN NN O
of IN IN O
adenosine NN NN B-CHEM
in IN IN O
cerebrospinal JJ JJ O
fluid NN NN O
was VBD VBD O
short JJ JJ O
( ( ( O
< NN NN O
4 CD CD O
h NN NN O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
results NNS NNS O
show VBP VBP O
selective JJ JJ O
inhibition NN NN O
by IN IN O
intrathecal JJ JJ O
adenosine NN NN B-CHEM
of IN IN O
hypersensitivity NN NN O
, , , O
presumed VBD VBD O
to TO TO O
reflect VB VB O
central JJ JJ O
sensitization NN NN O
in IN IN O
humans NNS NNS O
after IN IN O
peripheral JJ JJ O
capsaicin NN NN B-CHEM
injection NN NN O
. . . O

The DT DT O
long JJ JJ O
- - - O
lasting JJ JJ O
effect NN NN O
is VBZ VBZ O
consistent JJ JJ O
with IN IN O
that DT DT O
observed VBD VBD O
in IN IN O
preliminary JJ JJ O
reports NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
neuropathic JJ JJ O
pain NN NN O
and CC CC O
is VBZ VBZ O
not RB RB O
due JJ JJ O
to TO TO O
prolonged JJ JJ O
residence NN NN O
of IN IN O
adenosine NN NN B-CHEM
in IN IN O
cerebrospinal JJ JJ O
fluid NN NN O
. . . O

Delayed JJ JJ O
- : : O
onset NN NN O
heparin NN NN B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Heparin NNP NNP B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
presents VBZ VBZ O
5 CD CD O
to TO TO O
12 CD CD O
days NNS NNS O
after IN IN O
heparin NN NN B-CHEM
exposure NN NN O
, , , O
with IN IN O
or CC CC O
without IN IN O
arterial JJ JJ O
or CC CC O
venous JJ JJ O
thromboemboli NN NN O
. . . O

Delayed NNP NNP O
recognition NN NN O
and CC CC O
treatment NN NN O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
contribute NN NN O
to TO TO O
poor JJ JJ O
patient NN NN O
outcomes NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
and CC CC O
increase VB VB O
awareness NN NN O
of IN IN O
a DT DT O
clinical JJ JJ O
scenario NN NN O
in IN IN O
which WDT WDT O
the DT DT O
onset NN NN O
or CC CC O
manifestations NNS NNS O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
are VBP VBP O
delayed VBN VBN O
. . . O

DESIGN NNP NNP O
: : : O
Retrospective NNP NNP O
case NN NN O
series NN NN O
. . . O

SETTING NNP NNP O
: : : O
Three CD CD O
large JJ JJ O
urban JJ JJ O
hospitals NNS NNS O
( ( ( O
with IN IN O
active JJ JJ O
cardiovascular JJ JJ O
surgery NN NN O
programs NNS NNS O
) ) ) O
. . . O

PATIENTS NNS NNS O
: : : O
14 CD CD O
patients NNS NNS O
seen VBN VBN O
over IN IN O
a DT DT O
3 CD CD O
- : : O
year NN NN O
period NN NN O
in IN IN O
whom WP WP O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
became VBD VBD O
apparent JJ JJ O
on IN IN O
delayed JJ JJ O
presentation NN NN O
with IN IN O
thromboembolic JJ JJ O
complications NNS NNS O
. . . O

MEASUREMENTS NNP NNP O
: : : O
Platelet NNP NNP O
counts NNS NNS O
, , , O
onset NN NN O
of IN IN O
objectively RB RB O
determined VBN VBN O
thromboembolism NN NN O
, , , O
results NNS NNS O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
platelet NN NN O
factor NN NN O
4 CD CD O
antibody NN NN O
tests NNS NNS O
, , , O
and CC CC O
outcomes NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Patients NNS NNS O
went VBD VBD O
home NN NN O
after IN IN O
hospitalizations NNS NNS O
that WDT WDT O
had VBD VBD O
included VBN VBN O
heparin NN NN B-CHEM
exposure NN NN O
- - - O
- - - O
in IN IN O
most JJS JJS O
cases NNS NNS O
, , , O
with IN IN O
no DT DT O
thrombocytopenia NN NN O
recognized JJ JJ O
- : : O
- - - O
only RB RB O
to TO TO O
return VB VB O
to TO TO O
the DT DT O
hospital NN NN O
( ( ( O
median NN NN O
, , , O
day NN NN O
14 CD CD O
) ) ) O
with IN IN O
thromboembolic JJ JJ O
complications NNS NNS O
. . . O

Thromboemboli NNP NNP O
were VBD VBD O
venous JJ JJ O
( ( ( O
12 CD CD O
patients NNS NNS O
, , , O
7 CD CD O
with IN IN O
pulmonary JJ JJ O
emboli NN NN O
) ) ) O
or CC CC O
arterial JJ JJ O
( ( ( O
4 CD CD O
patients NNS NNS O
) ) ) O
or CC CC O
both DT DT O
. . . O

Platelet NNP NNP O
counts NNS NNS O
were VBD VBD O
mildly RB RB O
decreased VBN VBN O
in IN IN O
all DT DT O
but CC CC O
2 CD CD O
patients NNS NNS O
on IN IN O
second JJ JJ O
presentation NN NN O
. . . O

On IN IN O
readmission NN NN O
, , , O
11 CD CD O
patients NNS NNS O
received VBD VBD O
therapeutic JJ JJ O
heparin NN NN B-CHEM
, , , O
which WDT WDT O
worsened VBD VBD O
the DT DT O
patients NNS NNS O
' POS POS O
clinical JJ JJ O
condition NN NN O
and CC CC O
, , , O
in IN IN O
all DT DT O
11 CD CD O
cases NNS NNS O
, , , O
decreased VBD VBD O
the DT DT O
platelet NN NN O
count NN NN O
( ( ( O
mean VB VB O
at IN IN O
readmission NN NN O
, , , O
143 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
cells NNS NNS O
/ NN NN O
L NNP NNP O
; : : O
mean VB VB O
nadir NN NN O
after IN IN O
heparin NN NN B-CHEM
re NN NN O
- : : O
exposure NN NN O
, , , O
39 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
cells NNS NNS O
/ NN NN O
L NNP NNP O
) ) ) O
. . . O

Results NNS NNS O
of IN IN O
serologic JJ JJ O
tests NNS NNS O
for IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
antibodies NNS NNS O
were VBD VBD O
positive JJ JJ O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

Subsequent NNP NNP O
treatments NNS NNS O
included VBD VBD O
alternative JJ JJ O
anticoagulants NNS NNS O
( ( ( O
11 CD CD O
patients NNS NNS O
) ) ) O
, , , O
thrombolytic JJ JJ O
drugs NNS NNS O
( ( ( O
3 CD CD O
patients NNS NNS O
) ) ) O
, , , O
inferior JJ JJ O
vena NN NN O
cava NN NN O
filters NNS NNS O
( ( ( O
3 CD CD O
patients NNS NNS O
) ) ) O
and CC CC O
, , , O
eventually RB RB O
, , , O
warfarin NN NN B-CHEM
( ( ( O
11 CD CD O
patients NNS NNS O
) ) ) O
. . . O

Three CD CD O
patients NNS NNS O
died VBD VBD O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Delayed JJ JJ O
- - - O
onset NN NN O
heparin NN NN B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
is VBZ VBZ O
increasingly RB RB O
being VBG VBG O
recognized VBN VBN O
. . . O

To TO TO O
avoid VB VB O
disastrous JJ JJ O
outcomes NNS NNS O
, , , O
physicians NNS NNS O
must MD MD O
consider VB VB O
heparin NN NN B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
whenever WRB WRB O
a DT DT O
recently RB RB O
hospitalized VBN VBN O
patient NN NN O
returns NNS NNS O
with IN IN O
thromboembolism NN NN O
; : : O
therapy NN NN O
with IN IN O
alternative JJ JJ O
anticoagulants NNS NNS O
, , , O
not RB RB O
heparin NN NN B-CHEM
, , , O
should MD MD O
be VB VB O
initiated VBN VBN O
. . . O

Treatment NN NN O
of IN IN O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
with IN IN O
a DT DT O
dopamine NN NN B-CHEM
agonist NN NN O
in IN IN O
children NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Risperidone NNP NNP B-CHEM
, , , O
a DT DT O
potent JJ JJ O
antagonist NN NN O
of IN IN O
both DT DT O
serotonergic JJ JJ O
( ( ( O
5HT2A CD CD O
) ) ) O
and CC CC O
dopaminergic JJ JJ O
D2 NN NN O
receptors NNS NNS O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
hyperprolactinemia NN NN O
in IN IN O
adults NNS NNS O
and CC CC O
children NNS NNS O
. . . O

Chronically RB RB O
elevated VBD VBD O
prolactin NN NN O
levels NNS NNS O
in IN IN O
children NNS NNS O
with IN IN O
prolactinomas NNS NNS O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
arrested VBN VBN O
growth NN NN O
and CC CC O
development NN NN O
resulting VBG VBG O
in IN IN O
either DT DT O
delayed JJ JJ O
puberty NN NN O
or CC CC O
short JJ JJ O
stature NN NN O
. . . O

These DT DT O
possibilities NNS NNS O
stress VBP VBP O
the DT DT O
importance NN NN O
of IN IN O
developing VBG VBG O
a DT DT O
safe JJ JJ O
and CC CC O
effective JJ JJ O
approach NN NN O
to TO TO O
drug NN NN O
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
in IN IN O
youth NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
successful JJ JJ O
treatment NN NN O
of IN IN O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
with IN IN O
cabergoline NN NN B-CHEM
in IN IN O
youth NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
undertook VBP VBP O
a DT DT O
retrospective NN NN O
case NN NN O
review NN NN O
of IN IN O
four CD CD O
children NNS NNS O
with IN IN O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
treated VBN VBN O
with IN IN O
cabergoline NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
Four CD CD O
males NNS NNS O
( ( ( O
age NN NN O
6 CD CD O
- : : O
11 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
Diagnostic NNP NNP O
and CC CC O
Statistical NNP NNP O
Manual NNP NNP O
of IN IN O
Mental NNP NNP O
Disorders NNP NNP O
( ( ( O
fourth JJ JJ O
edition NN NN O
) ) ) O
bipolar JJ JJ O
disorder NN NN O
or CC CC O
psychoses NNS NNS O
, , , O
with IN IN O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
elevations NNS NNS O
in IN IN O
serum NN NN O
prolactin NN NN O
levels NNS NNS O
( ( ( O
57 CD CD O
. . . O
5 CD CD O
- : : O
129 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
, , , O
normal JJ JJ O
5 CD CD O
- : : O
15 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
) ) ) O
, , , O
were VBD VBD O
treated VBN VBN O
with IN IN O
cabergoline NN NN B-CHEM
( ( ( O
mean NN NN O
dose NN NN O
2 CD CD O
. . . O
13 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
09 CD CD O
mg NN NN O
/ NN NN O
week NN NN O
) ) ) O
. . . O

When WRB WRB O
serum NN NN O
prolactin NN NN O
levels NNS NNS O
normalized JJ JJ O
in IN IN O
all DT DT O
four CD CD O
subjects NNS NNS O
( ( ( O
mean NN NN O
11 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
. . . O
9 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
) ) ) O
, , , O
the DT DT O
cabergoline NN NN B-CHEM
dose NN NN O
was VBD VBD O
reduced VBN VBN O
to TO TO O
1 CD CD O
mg NN NN O
/ NN NN O
week NN NN O
in IN IN O
three CD CD O
of IN IN O
four CD CD O
subjects NNS NNS O
. . . O

The DT DT O
mean JJ JJ O
duration NN NN O
of IN IN O
therapy NN NN O
with IN IN O
cabergoline NN NN B-CHEM
was VBD VBD O
523 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
129 CD CD O
. . . O
7 CD CD O
days NNS NNS O
, , , O
and CC CC O
the DT DT O
mean JJ JJ O
duration NN NN O
of IN IN O
therapy NN NN O
with IN IN O
risperidone NN NN B-CHEM
was VBD VBD O
788 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
162 CD CD O
. . . O
5 CD CD O
days NNS NNS O
. . . O

Cabergoline NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
without IN IN O
adverse JJ JJ O
effects NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Cabergoline NNP NNP B-CHEM
may MD MD O
be VB VB O
useful JJ JJ O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
in IN IN O
youth NN NN O
; : : O
however RB RB O
, , , O
further JJ JJ O
research NN NN O
is VBZ VBZ O
needed VBN VBN O
. . . O

Acute JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
after IN IN O
exposure NN NN O
to TO TO O
isoflurane NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
following VBG VBG O
exposure NN NN O
to TO TO O
the DT DT O
inhalational JJ JJ O
anesthetic JJ JJ O
isoflurane NN NN B-CHEM
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
70 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
healthy JJ JJ O
woman NN NN O
from IN IN O
Iraq NNP NNP O
developed VBD VBD O
acute JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
3 CD CD O
weeks NNS NNS O
following VBG VBG O
repair NN NN O
of IN IN O
the DT DT O
right NN NN O
rotator NN NN O
cuff NN NN O
under IN IN O
general JJ JJ O
anesthesia NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
for IN IN O
viral JJ JJ O
, , , O
autoimmune JJ JJ O
, , , O
or CC CC O
metabolic JJ JJ O
causes NNS NNS O
of IN IN O
hepatitis NN NN O
. . . O

No DT DT O
other JJ JJ O
medications NNS NNS O
were VBD VBD O
involved VBN VBN O
except IN IN O
for IN IN O
dipyrone NN NN B-CHEM
for IN IN O
analgesia NN NN O
. . . O

The DT DT O
alanine NN NN B-CHEM
aminotransferase NN NN O
was VBD VBD O
elevated VBN VBN O
to TO TO O
a DT DT O
peak NN NN O
concentration NN NN O
of IN IN O
1533 CD CD O
U NNP NNP O
/ NN NN O
L NNP NNP O
and CC CC O
the DT DT O
serum NN NN O
bilirubin NN NN B-CHEM
reached VBD VBD O
a DT DT O
peak NN NN O
of IN IN O
17 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
. . . O

There EX EX O
was VBD VBD O
slow JJ JJ O
improvement NN NN O
over IN IN O
4 CD CD O
months NNS NNS O
. . . O

Accidental NNP NNP O
reexposure NN NN O
by IN IN O
the DT DT O
patient NN NN O
to TO TO O
dipyrone NN NN B-CHEM
was VBD VBD O
uneventful JJ JJ O
. . . O

DISCUSSION NNP NNP O
: : : O
The DT DT O
clinical JJ JJ O
and CC CC O
histologic JJ JJ O
picture NN NN O
of IN IN O
this DT DT O
case NN NN O
resembles VBZ VBZ O
halothane JJ JJ O
hepatitis NN NN O
, , , O
which WDT WDT O
has VBZ VBZ O
a DT DT O
significant JJ JJ O
mortality NN NN O
rate NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Isoflurane NNP NNP B-CHEM
, , , O
a DT DT O
common JJ JJ O
anesthetic JJ JJ O
agent NN NN O
, , , O
can MD MD O
cause VB VB O
severe JJ JJ O
cholestatic JJ JJ O
hepatitis NN NN O
. . . O

Torsade NNP NNP O
de IN IN O
pointes NNS NNS O
induced VBN VBN O
by IN IN O
metoclopramide NN NN B-CHEM
in IN IN O
an DT DT O
elderly JJ JJ O
woman NN NN O
with IN IN O
preexisting VBG VBG O
complete JJ JJ O
left VBD VBD O
bundle NN NN O
branch NN NN O
block NN NN O
. . . O

There EX EX O
is VBZ VBZ O
a DT DT O
growing VBG VBG O
list NN NN O
of IN IN O
drugs NNS NNS O
implicated VBN VBN O
in IN IN O
acquired VBN VBN O
long JJ JJ O
QT NNP NNP O
syndrome NN NN O
and CC CC O
torsade VB VB O
de JJ JJ O
pointes NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
torsadogenic JJ JJ O
potential NN NN O
of IN IN O
metoclopramide NN NN B-CHEM
, , , O
a DT DT O
commonly RB RB O
used VBN VBN O
antiemetic JJ JJ O
and CC CC O
prokinetic JJ JJ O
drug NN NN O
, , , O
has VBZ VBZ O
not RB RB O
been VBN VBN O
reported VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
, , , O
despite IN IN O
its PRP$ PRP$ O
chemical NN NN O
similarity NN NN O
to TO TO O
procainamide VB VB B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
a DT DT O
92 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
preexisting VBG VBG O
complete JJ JJ O
left VBD VBD O
bundle NN NN O
branch NN NN O
block NN NN O
who WP WP O
developed VBD VBD O
torsade NN NN O
de IN IN O
pointes NNS NNS O
after IN IN O
intravenous JJ JJ O
and CC CC O
oral JJ JJ O
administration NN NN O
of IN IN O
metoclopramide NN NN B-CHEM
. . . O

This DT DT O
patient NN NN O
also RB RB O
developed VBD VBD O
torsade VB VB O
de IN IN O
pointes NNS NNS O
when WRB WRB O
cisapride NN NN B-CHEM
and CC CC O
erythromycin NN NN B-CHEM
were VBD VBD O
given VBN VBN O
simultaneously RB RB O
. . . O

These DT DT O
two CD CD O
episodes NNS NNS O
were VBD VBD O
suppressed VBN VBN O
successfully RB RB O
after IN IN O
discontinuing VBG VBG O
the DT DT O
offending JJ JJ O
drugs NNS NNS O
and CC CC O
administering VBG VBG O
class NN NN O
IB NNP NNP O
drugs NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
documentation NN NN O
that IN IN O
metoclopramide NN NN B-CHEM
provokes NNS NNS O
torsade FW FW O
de IN IN O
pointes NNS NNS O
clinically RB RB O
. . . O

Metoclopramide NNP NNP B-CHEM
should MD MD O
be VB VB O
used VBN VBN O
cautiously RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
risk NN NN O
of IN IN O
torsade NN NN O
de IN IN O
pointes NNS NNS O
. . . O

Dopamine NNP NNP B-CHEM
D2 NN NN O
receptor NN NN O
signaling VBG VBG O
controls NNS NNS O
neuronal JJ JJ O
cell NN NN O
death NN NN O
induced VBN VBN O
by IN IN O
muscarinic JJ JJ O
and CC CC O
glutamatergic JJ JJ O
drugs NNS NNS O
. . . O

Dopamine NNP NNP B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
, , , O
through IN IN O
D1 NN NN O
/ NN NN O
D2 NN NN O
receptor NN NN O
- : : O
mediated JJ JJ O
signaling VBG VBG O
, , , O
plays VBZ VBZ O
a DT DT O
major JJ JJ O
role NN NN O
in IN IN O
the DT DT O
control NN NN O
of IN IN O
epileptic JJ JJ O
seizures NNS NNS O
arising VBG VBG O
in IN IN O
the DT DT O
limbic NN NN O
system NN NN O
. . . O

Excitotoxicity NNP NNP O
leading VBG VBG O
to TO TO O
neuronal NN NN O
cell NN NN O
death NN NN O
in IN IN O
the DT DT O
affected JJ JJ O
areas NNS NNS O
is VBZ VBZ O
a DT DT O
major JJ JJ O
consequence NN NN O
of IN IN O
seizures NNS NNS O
at IN IN O
the DT DT O
cellular NN NN O
level NN NN O
. . . O

In IN IN O
this DT DT O
respect NN NN O
, , , O
little JJ JJ O
is VBZ VBZ O
known VBN VBN O
about IN IN O
the DT DT O
role NN NN O
of IN IN O
DA NNP NNP B-CHEM
receptors NNS NNS O
in IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
epilepsy NN NN O
- - - O
induced JJ JJ O
neuronal NN NN O
cell NN NN O
death NN NN O
. . . O

Here RB RB O
we PRP PRP O
analyze VBP VBP O
the DT DT O
occurrence NN NN O
of IN IN O
seizures NNS NNS O
and CC CC O
neurotoxicity NN NN O
in IN IN O
D2R NNP NNP O
- - - O
/ NN NN O
- - - O
mice NN NN O
treated VBN VBN O
with IN IN O
the DT DT O
cholinergic JJ JJ O
agonist NN NN O
pilocarpine NN NN B-CHEM
. . . O

We PRP PRP O
compared VBD VBD O
these DT DT O
results NNS NNS O
with IN IN O
those DT DT O
previously RB RB O
obtained VBN VBN O
with IN IN O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
KA NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
potent JJ JJ O
glutamate NN NN B-CHEM
agonist NN NN O
. . . O

Importantly NNP NNP O
, , , O
D2R NNP NNP O
- : : O
/ NN NN O
- : : O
mice NN NN O
develop NN NN O
seizures NNS NNS O
at IN IN O
doses NNS NNS O
of IN IN O
both DT DT O
drugs NNS NNS O
that WDT WDT O
are VBP VBP O
not RB RB O
epileptogenic JJ JJ O
for IN IN O
WT NNP NNP O
littermates NNS NNS O
and CC CC O
show VB VB O
greater JJR JJR O
neurotoxicity NN NN O
. . . O

However RB RB O
, , , O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
result NN NN O
in IN IN O
a DT DT O
more RBR RBR O
widespread JJ JJ O
neuronal JJ JJ O
death NN NN O
in IN IN O
both DT DT O
WT NNP NNP O
and CC CC O
D2R NNP NNP O
- : : O
/ NN NN O
- : : O
brains NNS NNS O
in IN IN O
comparison NN NN O
to TO TO O
KA NNP NNP B-CHEM
. . . O

Thus RB RB O
, , , O
the DT DT O
absence NN NN O
of IN IN O
D2R NNP NNP O
lowers NNS NNS O
the DT DT O
threshold NN NN O
for IN IN O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
both DT DT O
glutamate NN NN B-CHEM
and CC CC O
acetylcholine NN NN B-CHEM
. . . O

Moreover RB RB O
, , , O
the DT DT O
dopaminergic JJ JJ O
control NN NN O
of IN IN O
epilepsy NN NN O
- - - O
induced JJ JJ O
neurodegeneration NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
mediated VBN VBN O
by IN IN O
distinct JJ JJ O
interactions NNS NNS O
of IN IN O
D2R NNP NNP O
signaling VBG VBG O
with IN IN O
these DT DT O
two CD CD O
neurotransmitters NNS NNS O
. . . O

Steroid NNP NNP B-CHEM
structure NN NN O
and CC CC O
pharmacological JJ JJ O
properties NNS NNS O
determine VBP VBP O
the DT DT O
anti JJ JJ O
- : : O
amnesic JJ JJ O
effects NNS NNS O
of IN IN O
pregnenolone NN NN B-CHEM
sulphate NN NN I-CHEM
in IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
in IN IN O
rats NNS NNS O
. . . O

Pregnenolone NNP NNP B-CHEM
sulphate NN NN I-CHEM
( ( ( O
PREGS NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
generated VBN VBN O
interest NN NN O
as IN IN O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
potent JJ JJ O
memory NN NN O
- - - O
enhancing VBG VBG O
neurosteroids NNS NNS O
to TO TO O
be VB VB O
examined VBN VBN O
in IN IN O
rodent NN NN O
learning VBG VBG O
studies NNS NNS O
, , , O
with IN IN O
particular JJ JJ O
importance NN NN O
in IN IN O
the DT DT O
ageing NN NN O
process NN NN O
. . . O

The DT DT O
mechanism NN NN O
by IN IN O
which WDT WDT O
this DT DT O
endogenous JJ JJ O
steroid NN NN B-CHEM
enhances NNS NNS O
memory NN NN O
formation NN NN O
is VBZ VBZ O
hypothesized VBN VBN O
to TO TO O
involve VB VB O
actions NNS NNS O
on IN IN O
glutamatergic JJ JJ O
and CC CC O
GABAergic NNP NNP O
systems NNS NNS O
. . . O

This DT DT O
hypothesis NNS NNS O
stems VBP VBP O
from IN IN O
findings NNS NNS O
that IN IN O
PREGS NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
potent JJ JJ O
positive JJ JJ O
modulator NN NN O
of IN IN O
N NNP NNP B-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
d SYM SYM I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
receptors NNS NNS O
( ( ( O
NMDARs NNP NNP O
) ) ) O
and CC CC O
a DT DT O
negative JJ JJ O
modulator NN NN O
of IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
A DT DT O
) ) ) O
receptors NNS NNS O
( ( ( O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
Rs NNP NNP O
) ) ) O
. . . O

Moreover RB RB O
, , , O
PREGS NNP NNP B-CHEM
is VBZ VBZ O
able JJ JJ O
to TO TO O
reverse VB VB O
the DT DT O
amnesic JJ JJ O
- - - O
like IN IN O
effects NNS NNS O
of IN IN O
NMDAR NNP NNP O
and CC CC O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
R NN NN O
ligands NNS NNS O
. . . O

To TO TO O
investigate VB VB O
this DT DT O
hypothesis NN NN O
, , , O
the DT DT O
present JJ JJ O
study NN NN O
in IN IN O
rats NNS NNS O
examined VBD VBD O
the DT DT O
memory NN NN O
- - - O
altering VBG VBG O
abilities NNS NNS O
of IN IN O
structural JJ JJ O
analogs NNS NNS O
of IN IN O
PREGS NNP NNP B-CHEM
, , , O
which WDT WDT O
differ VBP VBP O
in IN IN O
their PRP$ PRP$ O
modulation NN NN O
of IN IN O
NMDAR NNP NNP O
and CC CC O
/ NN NN O
or CC CC O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
R NN NN O
function NN NN O
. . . O

The DT DT O
analogs NNS NNS O
tested VBN VBN O
were VBD VBD O
: : : O
11 CD CD B-CHEM
- : : I-CHEM
ketopregnenolone NN NN I-CHEM
sulphate NN NN I-CHEM
( ( ( O
an DT DT O
agent NN NN O
that WDT WDT O
is VBZ VBZ O
inactive JJ JJ O
at IN IN O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
Rs NNP NNP O
and CC CC O
NMDARs NNP NNP O
) ) ) O
, , , O
epipregnanolone NN NN B-CHEM
( ( ( I-CHEM
[ NN NN I-CHEM
3beta CD CD I-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- : : I-CHEM
5beta CD CD I-CHEM
- : : I-CHEM
pregnan NN NN I-CHEM
- : : I-CHEM
20 CD CD I-CHEM
- : : I-CHEM
one CD CD I-CHEM
] NN NN I-CHEM
sulphate NN NN I-CHEM
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
both DT DT O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
Rs NNP NNP O
and CC CC O
NMDARs NNP NNP O
) ) ) O
, , , O
and CC CC O
a DT DT O
newly RB RB O
synthesized VBN VBN O
( ( ( O
- : : O
) ) ) O
PREGS NNP NNP B-CHEM
enantiomer NN NN O
( ( ( O
which WDT WDT O
is VBZ VBZ O
identical JJ JJ O
to TO TO O
PREGS NNP NNP B-CHEM
in IN IN O
effects NNS NNS O
on IN IN O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
Rs NNP NNP O
and CC CC O
NMDARs NNP NNP O
) ) ) O
. . . O

The DT DT O
memory NN NN O
- - - O
enhancing VBG VBG O
effects NNS NNS O
of IN IN O
PREGS NNP NNP B-CHEM
and CC CC O
its PRP$ PRP$ O
analogs NNS NNS O
were VBD VBD O
tested VBN VBN O
in IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
using VBG VBG O
the DT DT O
model NN NN O
of IN IN O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
. . . O

Both DT DT O
PREGS NNP NNP B-CHEM
and CC CC O
its PRP$ PRP$ O
( ( ( O
- : : O
) ) ) O
enantiomer NN NN O
blocked VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
scopolamine NN NN B-CHEM
. . . O

The DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
, , , O
unlike IN IN O
PREGS NNP NNP B-CHEM
, , , O
11 CD CD B-CHEM
- : : I-CHEM
ketopregnenolone NN NN I-CHEM
sulphate NN NN I-CHEM
and CC CC O
epipregnanolone NN NN B-CHEM
sulphate NN NN I-CHEM
failed VBD VBD O
to TO TO O
block VB VB O
the DT DT O
effect NN NN O
of IN IN O
scopolamine NN NN B-CHEM
, , , O
suggesting VBG VBG O
that IN IN O
altering VBG VBG O
the DT DT O
modulation NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
diminishes NNS NNS O
the DT DT O
memory NN NN O
- - - O
enhancing VBG VBG O
effects NNS NNS O
of IN IN O
PREGS NNP NNP B-CHEM
. . . O

Moreover RB RB O
, , , O
enantioselectivity NN NN O
was VBD VBD O
demonstrated VBN VBN O
by IN IN O
the DT DT O
ability NN NN O
of IN IN O
natural JJ JJ O
PREGS NNP NNP B-CHEM
to TO TO O
be VB VB O
an DT DT O
order NN NN O
of IN IN O
magnitude NN NN O
more RBR RBR O
effective JJ JJ O
than IN IN O
its PRP$ PRP$ O
synthetic JJ JJ O
enantiomer NN NN O
in IN IN O
reversing VBG VBG O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
. . . O

These DT DT O
results NNS NNS O
identify VBP VBP O
a DT DT O
novel NN NN O
neuropharmacological JJ JJ O
site NN NN O
for IN IN O
the DT DT O
modulation NN NN O
of IN IN O
memory NN NN O
processes NNS NNS O
by IN IN O
neuroactive JJ JJ O
steroids NNS NNS B-CHEM
. . . O

Activation NNP NNP O
of IN IN O
poly NN NN B-CHEM
( ( ( I-CHEM
ADP NNP NNP I-CHEM
- - - I-CHEM
ribose NN NN I-CHEM
) ) ) I-CHEM
polymerase NN NN O
contributes VBZ VBZ O
to TO TO O
development NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
heart NN NN O
failure NN NN O
. . . O

Activation NNP NNP O
of IN IN O
the DT DT O
nuclear JJ JJ O
enzyme NN NN O
poly NN NN B-CHEM
( ( ( I-CHEM
ADP NNP NNP I-CHEM
- - - I-CHEM
ribose NN NN I-CHEM
) ) ) I-CHEM
polymerase NN NN O
( ( ( O
PARP NNP NNP O
) ) ) O
by IN IN O
oxidant JJ JJ O
- - - O
mediated JJ JJ O
DNA NNP NNP O
damage NN NN O
is VBZ VBZ O
an DT DT O
important JJ JJ O
pathway NN NN O
of IN IN O
cell NN NN O
dysfunction NN NN O
and CC CC O
tissue NN NN O
injury NN NN O
in IN IN O
conditions NNS NNS O
associated VBN VBN O
with IN IN O
oxidative JJ JJ O
stress NN NN O
. . . O

Increased NNP NNP O
oxidative JJ JJ O
stress NN NN O
is VBZ VBZ O
a DT DT O
major JJ JJ O
factor NN NN O
implicated VBN VBN O
in IN IN O
the DT DT O
cardiotoxicity NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
widely RB RB O
used VBN VBN O
antitumor NN NN O
anthracycline NN NN B-CHEM
antibiotic JJ JJ O
. . . O

Thus RB RB O
, , , O
we PRP PRP O
hypothesized VBN VBN O
that IN IN O
the DT DT O
activation NN NN O
of IN IN O
PARP NNP NNP O
may MD MD O
contribute VB VB O
to TO TO O
the DT DT O
DOX NNP NNP B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Using VBG VBG O
a DT DT O
dual JJ JJ O
approach NN NN O
of IN IN O
PARP NNP NNP O
- : : O
1 CD CD O
suppression NN NN O
, , , O
by IN IN O
genetic JJ JJ O
deletion NN NN O
or CC CC O
pharmacological JJ JJ O
inhibition NN NN O
with IN IN O
the DT DT O
phenanthridinone NN NN O
PARP NNP NNP O
inhibitor NN NN O
PJ34 NNP NNP B-CHEM
, , , O
we PRP PRP O
now RB RB O
demonstrate VBP VBP O
the DT DT O
role NN NN O
of IN IN O
PARP NNP NNP O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
cardiac JJ JJ O
dysfunction NN NN O
induced VBN VBN O
by IN IN O
DOX NNP NNP B-CHEM
. . . O

PARP NNP NNP O
- : : O
1 CD CD O
+ NN NN O
/ NN NN O
+ NN NN O
and CC CC O
PARP NNP NNP O
- : : O
1 CD CD O
- : : O
/ NN NN O
- : : O
mice NN NN O
received VBD VBD O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
DOX NNP NNP B-CHEM
( ( ( O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
) ) ) O
. . . O

Five CD CD O
days NNS NNS O
after IN IN O
DOX NNP NNP B-CHEM
administration NN NN O
, , , O
left VBD VBD O
ventricular NN NN O
performance NN NN O
was VBD VBD O
significantly RB RB O
depressed VBN VBN O
in IN IN O
PARP NNP NNP O
- : : O
1 CD CD O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
, , , O
but CC CC O
only RB RB O
to TO TO O
a DT DT O
smaller JJR JJR O
extent NN NN O
in IN IN O
PARP NNP NNP O
- : : O
1 CD CD O
- : : O
/ NN NN O
- - - O
ones NNS NNS O
. . . O

Similar JJ JJ O
experiments NNS NNS O
were VBD VBD O
conducted VBN VBN O
in IN IN O
BALB NNP NNP O
/ NN NN O
c SYM SYM O
mice NN NN O
treated VBN VBN O
with IN IN O
PJ34 NNP NNP B-CHEM
or CC CC O
vehicle NN NN O
. . . O

Treatment NN NN O
with IN IN O
a DT DT O
PJ34 NNP NNP B-CHEM
significantly RB RB O
improved VBD VBD O
cardiac JJ JJ O
dysfunction NN NN O
and CC CC O
increased VBD VBD O
the DT DT O
survival NN NN O
of IN IN O
the DT DT O
animals NNS NNS O
. . . O

In IN IN O
addition NN NN O
PJ34 NNP NNP B-CHEM
significantly RB RB O
reduced VBD VBD O
the DT DT O
DOX NNP NNP B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
serum NN NN O
lactate NN NN B-CHEM
dehydrogenase NN NN O
and CC CC O
creatine NN NN B-CHEM
kinase NN NN O
activities NNS NNS O
but CC CC O
not RB RB O
metalloproteinase VB VB O
activation NN NN O
in IN IN O
the DT DT O
heart NN NN O
. . . O

Thus RB RB O
, , , O
PARP NNP NNP O
activation NN NN O
contributes VBZ VBZ O
to TO TO O
the DT DT O
cardiotoxicity NN NN O
of IN IN O
DOX NNP NNP B-CHEM
. . . O

PARP NNP NNP O
inhibitors NNS NNS O
may MD MD O
exert VB VB O
protective JJ JJ O
effects NNS NNS O
against IN IN O
the DT DT O
development NN NN O
of IN IN O
severe JJ JJ O
cardiac NN NN O
complications NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
DOX NNP NNP B-CHEM
treatment NN NN O
. . . O

Spironolactone NNP NNP B-CHEM
: : : O
is VBZ VBZ O
it PRP PRP O
a DT DT O
novel NN NN O
drug NN NN O
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
- - - O
related VBN VBN O
hypokalemia NN NN O
in IN IN O
cancer NN NN O
patients NNS NNS O
? . . O

OBJECTIVE NNP NNP O
: : : O
Nephrotoxicity NNP NNP O
is VBZ VBZ O
the DT DT O
major JJ JJ O
adverse JJ JJ O
effect NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
( ( ( O
AmB NNP NNP B-CHEM
) ) ) O
, , , O
often RB RB O
limiting VBG VBG O
administration NN NN O
of IN IN O
full JJ JJ O
dosage NN NN O
. . . O

Selective NNP NNP O
distal NN NN O
tubular NN NN O
epithelial JJ JJ O
toxicity NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
profound JJ JJ O
potassium NN NN B-CHEM
wasting NN NN O
that WDT WDT O
is VBZ VBZ O
a DT DT O
major JJ JJ O
clinical JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
treatment NN NN O
with IN IN O
AmB NNP NNP B-CHEM
. . . O

Potassium NNP NNP B-CHEM
depletion NN NN O
also RB RB O
potentiates VBZ VBZ O
the DT DT O
tubular JJ JJ O
toxicity NN NN O
of IN IN O
AmB NNP NNP B-CHEM
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
ability NN NN O
of IN IN O
spironolactone NN NN B-CHEM
to TO TO O
reduce VB VB O
potassium NN NN B-CHEM
requirements NNS NNS O
and CC CC O
to TO TO O
prevent VB VB O
hypokalemia NN NN O
in IN IN O
neutropenic JJ JJ O
patients NNS NNS O
on IN IN O
AmB NNP NNP B-CHEM
treatment NN NN O
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
this DT DT O
study NN NN O
26 CD CD O
patients NNS NNS O
with IN IN O
various JJ JJ O
hematological JJ JJ O
disorders NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
intravenous JJ JJ O
AmB NNP NNP B-CHEM
alone RB RB O
or CC CC O
AmB NNP NNP B-CHEM
and CC CC O
oral JJ JJ O
spironolactone NN NN B-CHEM
100 CD CD O
mg NN NN O
twice RB RB O
daily RB RB O
when WRB WRB O
developing VBG VBG O
a DT DT O
proven NN NN O
or CC CC O
suspected JJ JJ O
fungal JJ JJ O
infection NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Patients NNS NNS O
receiving VBG VBG O
concomitant NN NN O
AmB NNP NNP B-CHEM
and CC CC O
spironolactone NN NN B-CHEM
had VBD VBD O
significantly RB RB O
higher JJR JJR O
plasma NN NN O
potassium NN NN B-CHEM
levels NNS NNS O
than IN IN O
those DT DT O
receiving VBG VBG O
AmB NNP NNP B-CHEM
alone RB RB O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
0027 CD CD O
) ) ) O
. . . O

Those DT DT O
patients NNS NNS O
receiving VBG VBG O
AmB NNP NNP B-CHEM
and CC CC O
spironolactone NN NN B-CHEM
required VBN VBN O
significantly RB RB O
less RBR RBR O
potassium JJ JJ B-CHEM
supplementation NN NN O
to TO TO O
maintain VB VB O
their PRP$ PRP$ O
plasma NN NN O
potassium NN NN B-CHEM
within IN IN O
the DT DT O
normal JJ JJ O
range NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
022 CD CD O
) ) ) O
. . . O

Moreover RB RB O
, , , O
urinary JJ JJ O
potassium NN NN B-CHEM
losses NNS NNS O
were VBD VBD O
significantly RB RB O
less JJR JJR O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
AmB NNP NNP B-CHEM
and CC CC O
spironolactone NN NN B-CHEM
than IN IN O
those DT DT O
receiving VBG VBG O
AmB NNP NNP B-CHEM
alone RB RB O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
040 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
study NN NN O
showed VBD VBD O
that IN IN O
spironolactone NN NN B-CHEM
can MD MD O
reduce VB VB O
potassium NN NN B-CHEM
requirements NNS NNS O
and CC CC O
prevent VB VB O
hypokalemia NN NN O
by IN IN O
reducing VBG VBG O
urinary JJ JJ O
potassium NN NN B-CHEM
loss NN NN O
in IN IN O
neutropenic JJ JJ O
patients NNS NNS O
on IN IN O
AmB NNP NNP B-CHEM
treatment NN NN O
. . . O

Erectile NNP NNP O
dysfunction NN NN O
occurs VBZ VBZ O
following VBG VBG O
substantia NN NN O
nigra NN NN O
lesions NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Erectile NNP NNP O
function NN NN O
was VBD VBD O
assessed VBN VBN O
6 CD CD O
weeks NNS NNS O
following VBG VBG O
uni NN NN O
- : : O
and CC CC O
bilateral JJ JJ O
injections NNS NNS O
of IN IN O
6 CD CD B-CHEM
- : : I-CHEM
hydroxydopamine NN NN I-CHEM
in IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
nucleus NN NN O
of IN IN O
the DT DT O
brain NN NN O
. . . O

Behavioral NNP NNP O
apomorphine NN NN B-CHEM
- : : O
induced JJ JJ O
penile NN NN O
erections NNS NNS O
were VBD VBD O
reduced VBN VBN O
( ( ( O
5 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
and CC CC O
increased VBN VBN O
( ( ( O
3 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
in IN IN O
uni NN NN O
- - - O
and CC CC O
bilateral NN NN O
lesioned VBD VBD O
animals NNS NNS O
. . . O

Intracavernous NNP NNP O
pressures NNS NNS O
, , , O
following VBG VBG O
electrical JJ JJ O
stimulation NN NN O
of IN IN O
the DT DT O
cavernous JJ JJ O
nerve NN NN O
, , , O
decreased VBD VBD O
in IN IN O
lesioned JJ JJ O
animals NNS NNS O
. . . O

Lesions NNP NNP O
of IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
were VBD VBD O
confirmed VBN VBN O
by IN IN O
histology NN NN O
. . . O

Concentration NNP NNP O
of IN IN O
dopamine NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
were VBD VBD O
decreased VBN VBN O
in IN IN O
the DT DT O
striatum NN NN O
of IN IN O
substantia NN NN O
nigra NN NN O
lesioned VBD VBD O
rats NNS NNS O
. . . O

Lesions NNP NNP O
of IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
are VBP VBP O
therefore RB RB O
associated VBN VBN O
with IN IN O
erectile JJ JJ O
dysfunction NN NN O
in IN IN O
rats NNS NNS O
and CC CC O
may MD MD O
serve VB VB O
as IN IN O
a DT DT O
model NN NN O
to TO TO O
study VB VB O
erectile NN NN O
dysfunction NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Nicotine NNP NNP B-CHEM
potentiation NN NN O
of IN IN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
in IN IN O
mice NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
effects NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
on IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
in IN IN O
mice NNS NNS O
have VBP VBP O
been VBN VBN O
investigated VBN VBN O
. . . O

Morphine NNP NNP B-CHEM
but CC CC O
not RB RB O
nicotine NN NN B-CHEM
induced VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
catalepsy NN NN O
. . . O

The DT DT O
response NN NN O
of IN IN O
morphine NN NN B-CHEM
was VBD VBD O
potentiated VBN VBN O
by IN IN O
nicotine NN NN B-CHEM
. . . O

Intraperitoneal NNP NNP O
administration NN NN O
of IN IN O
atropine NN NN B-CHEM
, , , O
naloxone NN NN B-CHEM
, , , O
mecamylamine NN NN B-CHEM
, , , O
and CC CC O
hexamethonium NN NN B-CHEM
to TO TO O
mice NNS NNS O
reduced VBN VBN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
combination NN NN O
of IN IN O
morphine NN NN B-CHEM
with IN IN O
nicotine NN NN B-CHEM
. . . O

Intracerebroventricular NNP NNP O
injection NN NN O
of IN IN O
atropine NN NN B-CHEM
, , , O
hexamethonium NN NN B-CHEM
, , , O
and CC CC O
naloxone NN NN B-CHEM
also RB RB O
decreased VBD VBD O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
plus CC CC O
nicotine NN NN B-CHEM
. . . O

Intraperitoneal NNP NNP O
administration NN NN O
of IN IN O
atropine NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
intraperitoneal VB VB O
or CC CC O
intracerebroventricular JJ JJ O
injection NN NN O
of IN IN O
hexamethonium NN NN B-CHEM
, , , O
decreased VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
morphine NN NN B-CHEM
. . . O

It PRP PRP O
was VBD VBD O
concluded VBN VBN O
that IN IN O
morphine NN NN B-CHEM
catalepsy NN NN O
can MD MD O
be VB VB O
elicited VBN VBN O
by IN IN O
opioid NN NN O
and CC CC O
cholinergic JJ JJ O
receptors NNS NNS O
, , , O
and CC CC O
the DT DT O
potentiation NN NN O
of IN IN O
morphine NN NN B-CHEM
induced VBN VBN O
by IN IN O
nicotine NN NN B-CHEM
may MD MD O
also RB RB O
be VB VB O
mediated VBN VBN O
through IN IN O
cholinergic JJ JJ O
receptor NN NN O
mechanisms NNS NNS O
. . . O

Force NNP NNP O
overflow NN NN O
and CC CC O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

We PRP PRP O
assessed VBD VBD O
force JJ JJ O
coordination NN NN O
of IN IN O
the DT DT O
hand NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
and CC CC O
its PRP$ PRP$ O
relationship NN NN O
to TO TO O
motor NN NN O
complications NNS NNS O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
, , , O
particularly RB RB O
to TO TO O
levodopa VB VB B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
( ( ( O
LID NNP NNP O
) ) ) O
. . . O

We PRP PRP O
studied VBD VBD O
two CD CD O
groups NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patients NNS NNS O
with IN IN O
( ( ( O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
+ NN NN O
LID NNP NNP O
, , , O
n NN NN O
= SYM SYM O
23 CD CD O
) ) ) O
and CC CC O
without IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
( ( ( O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
- - - O
LID NNP NNP O
, , , O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
, , , O
and CC CC O
age NN NN O
- - - O
matched JJ JJ O
healthy JJ JJ O
controls NNS NNS O
. . . O

The DT DT O
motor NN NN O
score NN NN O
of IN IN O
the DT DT O
Unified NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
, , , O
a DT DT O
dyskinesia NN NN O
score NN NN O
and CC CC O
force NN NN O
in IN IN O
a DT DT O
grip NN NN O
- - - O
lift VB VB O
paradigm NN NN O
were VBD VBD O
assessed VBN VBN O
ON IN IN O
and CC CC O
OFF NNP NNP O
levodopa NN NN B-CHEM
. . . O

A DT DT O
pathological JJ JJ O
increase NN NN O
of IN IN O
forces NNS NNS O
was VBD VBD O
seen VBN VBN O
in IN IN O
ON IN IN O
- - - O
state NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
+ NN NN O
LID NNP NNP O
only RB RB O
. . . O

In IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
+ NN NN O
LID NNP NNP O
, , , O
the DT DT O
force NN NN O
involved VBN VBN O
in IN IN O
pressing VBG VBG O
down RP RP O
the DT DT O
object NN NN O
before IN IN O
lifting VBG VBG O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
by IN IN O
levodopa NN NN B-CHEM
( ( ( O
by IN IN O
61 CD CD O
% NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

An DT DT O
overshooting NN NN O
of IN IN O
peak NN NN O
grip NN NN O
force NN NN O
by IN IN O
51 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
of IN IN O
static JJ JJ O
grip NN NN O
force NN NN O
by IN IN O
45 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
ON IN IN O
- - - O
compared VBN VBN O
with IN IN O
the DT DT O
OFF NNP NNP O
- - - O
drug NN NN O
condition NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
no DT DT O
excessive JJ JJ O
force NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
- - - O
LID NNP NNP O
. . . O

Peak NNP NNP O
grip NN NN O
force NN NN O
in IN IN O
ON IN IN O
- - - O
state NN NN O
was VBD VBD O
140 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
higher JJR JJR O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
+ NN NN O
LID NNP NNP O
than IN IN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
- - - O
LID NNP NNP O
, , , O
while IN IN O
static JJ JJ O
grip NN NN O
force NN NN O
was VBD VBD O
increased VBN VBN O
by IN IN O
138 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
between IN IN O
groups NNS NNS O
. . . O

Severity NNP NNP O
of IN IN O
peak NN NN O
- - - O
dose NN NN O
dyskinesias NN NN O
was VBD VBD O
strongly RB RB O
correlated JJ JJ O
with IN IN O
grip NN NN O
force NN NN O
in IN IN O
ON IN IN O
- - - O
state NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
79 CD CD O
with IN IN O
peak NN NN O
force NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

No DT DT O
correlation NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
forces NNS NNS O
and CC CC O
the DT DT O
motor NN NN O
score NN NN O
as RB RB O
well RB RB O
as IN IN O
with IN IN O
the DT DT O
daily JJ JJ O
dose NN NN O
of IN IN O
dopaminergic JJ JJ O
medication NN NN O
. . . O

Force NNP NNP O
excess NN NN O
was VBD VBD O
only RB RB O
observed VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
LID NNP NNP O
and CC CC O
motor NN NN O
fluctuations NNS NNS O
. . . O

A DT DT O
close JJ JJ O
relationship NN NN O
was VBD VBD O
seen VBN VBN O
between IN IN O
the DT DT O
overshooting NN NN O
of IN IN O
forces NNS NNS O
and CC CC O
dyskinesias NN NN O
in IN IN O
the DT DT O
ON IN IN O
- - - O
drug NN NN O
condition NN NN O
. . . O

We PRP PRP O
postulate VBP VBP O
that IN IN O
both DT DT O
LID NNP NNP O
and CC CC O
grip NN NN O
force NN NN O
excess NN NN O
share NN NN O
common JJ JJ O
pathophysiological JJ JJ O
mechanisms NNS NNS O
related VBN VBN O
to TO TO O
motor NN NN O
fluctuations NNS NNS O
. . . O

Behavioral NNP NNP O
effects NNS NNS O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
on IN IN O
reserpine NN NN B-CHEM
- : : O
treated JJ JJ O
mice NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
dizocilpine NN NN B-CHEM
( ( ( O
MK NNP NNP B-CHEM
- - - I-CHEM
801 CD CD I-CHEM
) ) ) O
, , , O
a DT DT O
noncompetitive JJ JJ O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptor NN NN O
antagonist NN NN O
, , , O
were VBD VBD O
studied VBN VBN O
on IN IN O
dopamine NN NN B-CHEM
- - - O
related VBN VBN O
behaviors NNS NNS O
induced VBN VBN O
by IN IN O
reserpine NN NN B-CHEM
treatments NNS NNS O
. . . O

This DT DT O
study NN NN O
focuses VBZ VBZ O
on IN IN O
behavioral JJ JJ O
syndromes NNS NNS O
that WDT WDT O
may MD MD O
used VBN VBN O
as IN IN O
models NNS NNS O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
or CC CC O
tardive JJ JJ O
dyskinesia NN NN O
, , , O
and CC CC O
its PRP$ PRP$ O
response NN NN O
after IN IN O
glutamatergic JJ JJ O
blockage NN NN O
. . . O

Reserpine NNP NNP B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
administered VBD VBD O
once RB RB O
every DT DT O
other JJ JJ O
day NN NN O
for IN IN O
4 CD CD O
days NNS NNS O
, , , O
produced VBD VBD O
increases NNS NNS O
in IN IN O
orofacial JJ JJ O
dyskinesia NN NN O
, , , O
tongue NN NN O
protrusion NN NN O
and CC CC O
vacuous JJ JJ O
chewing VBG VBG O
in IN IN O
mice NN NN O
, , , O
which WDT WDT O
are VBP VBP O
signs NNS NNS O
indicative JJ JJ O
of IN IN O
tardive JJ JJ O
dyskinesia NN NN O
. . . O

Reserpine NNP NNP B-CHEM
also RB RB O
produced VBD VBD O
tremor NN NN O
and CC CC O
catalepsy NN NN O
, , , O
which WDT WDT O
are VBP VBP O
signs NNS NNS O
suggestive JJ JJ O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
administered VBD VBD O
30 CD CD O
min NN NN O
before IN IN O
the DT DT O
observation NN NN O
test NN NN O
, , , O
prevented VBD VBD O
the DT DT O
vacuous JJ JJ O
chewing VBG VBG O
movements NNS NNS O
, , , O
tongue NN NN O
protrusions NNS NNS O
and CC CC O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
reserpine NN NN B-CHEM
. . . O

However RB RB O
, , , O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
injection NN NN O
produced VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
of IN IN O
tremor NN NN O
in IN IN O
reserpine NN NN B-CHEM
- - - O
treated JJ JJ O
mice NN NN O
. . . O

Reserpine NNP NNP B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
administered VBD VBD O
90 CD CD O
min NN NN O
before IN IN O
the DT DT O
test NN NN O
and CC CC O
followed VBN VBN O
by IN IN O
apomophine NN NN B-CHEM
injection NN NN O
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
5 CD CD O
min NN NN O
before IN IN O
the DT DT O
test NN NN O
, , , O
did VBD VBD O
not RB RB O
produce VB VB O
oral JJ JJ O
dyskinesia NN NN O
in IN IN O
mice NN NN O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
reserpine NN NN B-CHEM
induced VBN VBN O
increases NNS NNS O
in IN IN O
tremor NN NN O
and CC CC O
catalepsy NN NN O
compared VBN VBN O
to TO TO O
control VB VB O
mice NN NN O
. . . O

MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
administration NN NN O
attenuated VBD VBD O
the DT DT O
catalepsy NN NN O
and CC CC O
tremor NN NN O
induced VBN VBN O
by IN IN O
reserpine NN NN B-CHEM
. . . O

Pretreatment NNP NNP O
with IN IN O
reserpine NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
24 CD CD O
h NN NN O
before IN IN O
the DT DT O
observation NN NN O
test NN NN O
produced VBD VBD O
increases NNS NNS O
in IN IN O
vacuous JJ JJ O
chewing NN NN O
movements NNS NNS O
and CC CC O
tongue NN NN O
protrusion NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
increases NNS NNS O
in IN IN O
tremor NN NN O
and CC CC O
catalepsy NN NN O
, , , O
whereas IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
injection NN NN O
90 CD CD O
min NN NN O
before IN IN O
the DT DT O
test NN NN O
reversed VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
reserpine NN NN B-CHEM
. . . O

These DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
reserpine NN NN B-CHEM
produces VBZ VBZ O
different JJ JJ O
and CC CC O
abnormal JJ JJ O
movements NNS NNS O
, , , O
which WDT WDT O
are VBP VBP O
related VBN VBN O
to TO TO O
dose VB VB O
and CC CC O
schedule VB VB O
employed VBN VBN O
and CC CC O
can MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
parkinsonian JJ JJ O
- - - O
like IN IN O
and CC CC O
tardive JJ JJ O
dsykinesia NN NN O
signs NNS NNS O
. . . O

The DT DT O
glutamatergic JJ JJ O
blockage NN NN O
produced VBN VBN O
by IN IN O
NMDA NNP NNP B-CHEM
can MD MD O
restore VB VB O
these DT DT O
signs NNS NNS O
, , , O
such JJ JJ O
as IN IN O
vacuous JJ JJ O
chewing NN NN O
movements NNS NNS O
, , , O
tongue NN NN O
protrusions NNS NNS O
, , , O
catalepsy NN NN O
and CC CC O
tremor NN NN O
according VBG VBG O
to TO TO O
the DT DT O
employed JJ JJ O
model NN NN O
. . . O

Risperidone NNP NNP B-CHEM
- - - O
associated VBN VBN O
, , , O
benign NN NN O
transient NN NN O
visual JJ JJ O
disturbances NNS NNS O
in IN IN O
schizophrenic JJ JJ O
patients NNS NNS O
with IN IN O
a DT DT O
past JJ JJ O
history NN NN O
of IN IN O
LSD NNP NNP B-CHEM
abuse NN NN O
. . . O

Two CD CD O
schizophrenic JJ JJ O
patients NNS NNS O
, , , O
who WP WP O
had VBD VBD O
a DT DT O
prior JJ JJ O
history NN NN O
of IN IN O
LSD NNP NNP B-CHEM
abuse NN NN O
and CC CC O
who WP WP O
had VBD VBD O
previously RB RB O
developed VBN VBN O
EPS NNP NNP O
with IN IN O
classic JJ JJ O
antipsychotics NNS NNS O
, , , O
were VBD VBD O
successfully RB RB O
treated VBN VBN O
with IN IN O
risperidone NN NN B-CHEM
. . . O

They PRP PRP O
both DT DT O
reported VBD VBD O
short JJ JJ O
episodes NNS NNS O
of IN IN O
transient NN NN O
visual JJ JJ O
disturbances NNS NNS O
, , , O
which WDT WDT O
appeared VBD VBD O
immediately RB RB O
after IN IN O
starting VBG VBG O
treatment NN NN O
with IN IN O
risperidone NN NN B-CHEM
. . . O

This DT DT O
imagery NN NN O
resembled JJ JJ O
visual JJ JJ O
disturbances NNS NNS O
previously RB RB O
experienced VBN VBN O
as IN IN O
" '' '' O
flashbacks VBZ VBZ O
" '' '' O
related VBN VBN O
to TO TO O
prior RB RB O
LSD NNP NNP B-CHEM
consumption NN NN O
. . . O

Risperidone NNP NNP B-CHEM
administration NN NN O
was VBD VBD O
continued VBN VBN O
and CC CC O
the DT DT O
visual JJ JJ O
disturbances NNS NNS O
gradually RB RB O
wore VBD VBD O
off RP RP O
. . . O

During IN IN O
a DT DT O
six CD CD O
- - - O
month NN NN O
follow VB VB O
- - - O
up RP RP O
period NN NN O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
recurrence NN NN O
of IN IN O
visual JJ JJ O
disturbances NNS NNS O
. . . O

This DT DT O
phenomenon NN NN O
may MD MD O
be VB VB O
interpreted VBN VBN O
as IN IN O
a DT DT O
benign NN NN O
, , , O
short JJ JJ O
- - - O
term NN NN O
and CC CC O
self NN NN O
- - - O
limiting VBG VBG O
side NN NN O
effect NN NN O
which WDT WDT O
does VBZ VBZ O
not RB RB O
contraindicate VB VB O
the DT DT O
use NN NN O
of IN IN O
risperidone NN NN B-CHEM
or CC CC O
interfere RB RB O
with IN IN O
treatment NN NN O
. . . O

Conclusions NNP NNP O
based VBN VBN O
on IN IN O
two CD CD O
case NN NN O
reports NNS NNS O
should MD MD O
be VB VB O
taken VBN VBN O
with IN IN O
appropriate JJ JJ O
caution NN NN O
. . . O

Topiramate NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrolithiasis NN NN O
. . . O

Topiramate NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
recently RB RB O
developed VBN VBN O
antiepileptic JJ JJ O
medication NN NN O
that WDT WDT O
is VBZ VBZ O
becoming VBG VBG O
more RBR RBR O
widely RB RB O
prescribed VBN VBN O
because IN IN O
of IN IN O
its PRP$ PRP$ O
efficacy NN NN O
in IN IN O
treating VBG VBG O
refractory NN NN O
seizures NNS NNS O
. . . O

Urologists NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
that IN IN O
this DT DT O
medication NN NN O
can MD MD O
cause VB VB O
metabolic JJ JJ O
acidosis NN NN O
in IN IN O
patients NNS NNS O
secondary JJ JJ O
to TO TO O
inhibition NN NN O
of IN IN O
carbonic JJ JJ O
anhydrase NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
a DT DT O
distal JJ JJ O
tubular NN NN O
acidification NN NN O
defect NN NN O
may MD MD O
result VB VB O
, , , O
thus RB RB O
impairing VBG VBG O
the DT DT O
normal JJ JJ O
compensatory NN NN O
drop NN NN O
in IN IN O
urine NN NN O
pH NN NN O
. . . O

These DT DT O
factors NNS NNS O
can MD MD O
lead VB VB O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
calcium NN NN B-CHEM
phosphate NN NN I-CHEM
nephrolithiasis NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
first JJ JJ O
two CD CD O
cases NNS NNS O
of IN IN O
topiramate JJ JJ B-CHEM
- - - O
induced JJ JJ O
nephrolithiasis NN NN O
in IN IN O
the DT DT O
urologic JJ JJ O
literature NN NN O
. . . O

Ketamine NNP NNP B-CHEM
in IN IN O
war NN NN O
/ NN NN O
tropical JJ JJ O
surgery NN NN O
( ( ( O
a DT DT O
final JJ JJ O
tribute NN NN O
to TO TO O
the DT DT O
racemic JJ JJ O
mixture NN NN O
) ) ) O
. . . O

A DT DT O
technique NN NN O
of IN IN O
continuous JJ JJ O
intravenous JJ JJ O
anaesthesia NN NN O
with IN IN O
ketamine NN NN B-CHEM
was VBD VBD O
used VBN VBN O
successfully RB RB O
during IN IN O
the DT DT O
Somalia NNP NNP O
civil JJ JJ O
war NN NN O
in IN IN O
1994 CD CD O
and CC CC O
in IN IN O
north RB RB O
Uganda NNP NNP O
in IN IN O
1999 CD CD O
for IN IN O
64 CD CD O
operations NNS NNS O
in IN IN O
62 CD CD O
patients NNS NNS O
, , , O
aged VBN VBN O
from IN IN O
6 CD CD O
weeks NNS NNS O
to TO TO O
70 CD CD O
years NNS NNS O
, , , O
undergoing VBG VBG O
limb NN NN O
and CC CC O
abdominal JJ JJ O
surgery NN NN O
including VBG VBG O
caesarian JJ JJ O
sections NNS NNS O
and CC CC O
interventions NNS NNS O
in IN IN O
neonates NNS NNS O
. . . O

Operations NNP NNP O
lasting VBG VBG O
up RP RP O
to TO TO O
2h PRP PRP O
could MD MD O
be VB VB O
performed VBN VBN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
sophisticated JJ JJ O
equipment NN NN O
such JJ JJ O
as IN IN O
pulse NN NN O
oximeters NNS NNS O
or CC CC O
ventilators NNS NNS O
in IN IN O
patients NNS NNS O
on IN IN O
spontaneous JJ JJ O
ventilation NN NN O
breathing VBG VBG O
air NN NN O
/ NN NN O
oxygen NN NN B-CHEM
only RB RB O
. . . O

After IN IN O
premedication NN NN O
with IN IN O
diazepam NN NN B-CHEM
, , , O
glycopyrrolate NN NN B-CHEM
and CC CC O
local JJ JJ O
anaesthesia NN NN O
, , , O
and CC CC O
induction NN NN O
with IN IN O
standard JJ JJ O
doses NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
, , , O
a DT DT O
maintenance NN NN O
dose NN NN O
of IN IN O
10 CD CD O
- : : O
20 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
of IN IN O
ketamine NN NN B-CHEM
proved VBD VBD O
safe JJ JJ O
and CC CC O
effective JJ JJ O
. . . O

Emphasis NNP NNP O
was VBD VBD O
placed VBN VBN O
on IN IN O
bedside NN NN O
clinical JJ JJ O
monitoring NN NN O
, , , O
relying VBG VBG O
heavily RB RB O
on IN IN O
the DT DT O
heart NN NN O
rate NN NN O
. . . O

Diazepam NNP NNP B-CHEM
, , , O
unless IN IN O
contraindicated JJ JJ O
or CC CC O
risky JJ JJ O
, , , O
remains VBZ VBZ O
the DT DT O
only JJ JJ O
necessary JJ JJ O
complementary JJ JJ O
drug NN NN O
to TO TO O
ketamine VB VB B-CHEM
as IN IN O
it PRP PRP O
buffers VBZ VBZ O
its PRP$ PRP$ O
cardiovascular JJ JJ O
response NN NN O
and CC CC O
decreases VBZ VBZ O
the DT DT O
duration NN NN O
and CC CC O
intensity NN NN O
of IN IN O
operative JJ JJ O
and CC CC O
postoperative JJ JJ O
hallucinations NNS NNS O
. . . O

Local JJ JJ O
anaesthetic JJ JJ O
blocks NNS NNS O
were VBD VBD O
useful JJ JJ O
in IN IN O
decreasing VBG VBG O
the DT DT O
requirement NN NN O
for IN IN O
postoperative JJ JJ O
analgesia NN NN O
. . . O

An DT DT O
antisialogue NN NN O
was VBD VBD O
usually RB RB O
unnecessary JJ JJ O
in IN IN O
operations NNS NNS O
lasting VBG VBG O
up RP RP O
to TO TO O
2 CD CD O
h NN NN O
, , , O
glycopyrrolate NN NN B-CHEM
being VBG VBG O
the DT DT O
best JJS JJS O
choice NN NN O
for IN IN O
its PRP$ PRP$ O
lowest JJS JJS O
psychotropic NN NN O
and CC CC O
chronotropic JJ JJ O
effects NNS NNS O
, , , O
especially RB RB O
in IN IN O
a DT DT O
hot JJ JJ O
climate NN NN O
. . . O

Experience NN NN O
in IN IN O
war NN NN O
/ NN NN O
tropical JJ JJ O
settings NNS NNS O
suggests VBZ VBZ O
this DT DT O
technique NN NN O
could MD MD O
be VB VB O
useful JJ JJ O
in IN IN O
civilian JJ JJ O
contexts NNS NNS O
such JJ JJ O
as IN IN O
outdoor JJ JJ O
life NN NN O
- : : O
saving VBG VBG O
emergency NN NN O
surgery NN NN O
or CC CC O
in IN IN O
mass NN NN O
casualties NNS NNS O
where WRB WRB O
, , , O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
amputation NN NN O
and CC CC O
rapid JJ JJ O
extrication NN NN O
were VBD VBD O
required VBN VBN O
. . . O

Intravenous NNP NNP O
ribavirin NN NN B-CHEM
treatment NN NN O
for IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
in IN IN O
immunocompromised JJ JJ O
children NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Adenovirus NNP NNP O
is VBZ VBZ O
an DT DT O
important JJ JJ O
cause NN NN O
of IN IN O
morbidity NN NN O
and CC CC O
mortality NN NN O
in IN IN O
the DT DT O
immunocompromised JJ JJ O
host NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
in IN IN O
pediatrics NNS NNS O
is VBZ VBZ O
increasing VBG VBG O
in IN IN O
association NN NN O
with IN IN O
growing VBG VBG O
numbers NNS NNS O
of IN IN O
immunocompromised JJ JJ O
children NNS NNS O
, , , O
where WRB WRB O
case NN NN O
fatality NN NN O
rates NNS NNS O
as RB RB O
high JJ JJ O
as IN IN O
50 CD CD O
% NN NN O
to TO TO O
80 CD CD O
% NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

There EX EX O
are VBP VBP O
no DT DT O
approved VBD VBD O
antiviral JJ JJ O
agents NNS NNS O
with IN IN O
proven VBN VBN O
efficacy NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
, , , O
nor CC CC O
are VBP VBP O
there EX EX O
any DT DT O
prospective JJ JJ O
randomized JJ JJ O
, , , O
controlled VBN VBN O
trials NNS NNS O
of IN IN O
potentially RB RB O
useful JJ JJ O
anti NN NN O
- : : O
adenovirus NN NN O
therapies NNS NNS O
. . . O

Apparent NNP NNP O
clinical JJ JJ O
success NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
is VBZ VBZ O
limited VBN VBN O
to TO TO O
a DT DT O
few JJ JJ O
case NN NN O
reports NNS NNS O
and CC CC O
small JJ JJ O
series NN NN O
. . . O

Experience NN NN O
is VBZ VBZ O
greatest JJS JJS O
with IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
and CC CC O
cidofovir NN NN B-CHEM
. . . O

Ribavirin NNP NNP B-CHEM
, , , O
a DT DT O
guanosine NN NN B-CHEM
analogue NN NN O
, , , O
has VBZ VBZ O
broad JJ JJ O
antiviral JJ JJ O
activity NN NN O
against IN IN O
both DT DT O
RNA NNP NNP O
and CC CC O
DNA NNP NNP O
viruses NNS NNS O
, , , O
including VBG VBG O
documented VBN VBN O
activity NN NN O
against IN IN O
adenovirus NN NN O
in IN IN O
vitro NN NN O
. . . O

Ribavirin NNP NNP B-CHEM
is VBZ VBZ O
licensed VBN VBN O
in IN IN O
aerosol NN NN O
form NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
respiratory JJ JJ O
syncytial NN NN O
virus NN NN O
infection NN NN O
, , , O
and CC CC O
orally RB RB O
in IN IN O
combination NN NN O
with IN IN O
interferon NN NN O
to TO TO O
treat VB VB O
hepatitis NNP NNP O
C NNP NNP O
. . . O

Intravenous NNP NNP O
ribavirin NN NN B-CHEM
is VBZ VBZ O
the DT DT O
treatment NN NN O
of IN IN O
choice NN NN O
for IN IN O
infection NN NN O
with IN IN O
hemorrhagic JJ JJ O
fever NN NN O
viruses NNS NNS O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
effect NN NN O
of IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
is VBZ VBZ O
reversible JJ JJ O
mild JJ JJ O
anemia NN NN O
. . . O

The DT DT O
use NN NN O
of IN IN O
cidofovir NN NN B-CHEM
in IN IN O
severe JJ JJ O
adenovirus NN NN O
infection NN NN O
has VBZ VBZ O
been VBN VBN O
limited VBN VBN O
by IN IN O
adverse JJ JJ O
effects NNS NNS O
, , , O
the DT DT O
most RBS RBS O
significant JJ JJ O
of IN IN O
which WDT WDT O
is VBZ VBZ O
nephrotoxicity NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
We PRP PRP O
report VBP VBP O
our PRP$ PRP$ O
experience NN NN O
with IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
therapy NN NN O
for IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
in IN IN O
a DT DT O
series NN NN O
of IN IN O
immunocompromised JJ JJ O
children NNS NNS O
and CC CC O
review NN NN O
the DT DT O
literature NN NN O
. . . O

DESIGN NNP NNP O
/ NN NN O
METHODS NNP NNP O
: : : O
We PRP PRP O
retrospectively RB RB O
reviewed VBD VBD O
the DT DT O
medical JJ JJ O
records NNS NNS O
of IN IN O
5 CD CD O
children NNS NNS O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
for IN IN O
documented VBN VBN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
adenovirus JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
after IN IN O
cardiac JJ JJ O
and CC CC O
bone NN NN O
marrow NN NN O
transplants NNS NNS O
, , , O
respectively RB RB O
. . . O

The DT DT O
bone NN NN O
marrow NN NN O
transplant JJ JJ O
patient NN NN O
also RB RB O
received VBD VBD O
intravenous JJ JJ O
cidofovir NN NN B-CHEM
for IN IN O
progressive JJ JJ O
disseminated VBD VBD O
disease NN NN O
. . . O

An DT DT O
additional JJ JJ O
3 CD CD O
children NNS NNS O
developed VBN VBN O
adenovirus NN NN O
pneumonia NN NN O
; : : O
2 CD CD O
were VBD VBD O
neonates NNS NNS O
, , , O
1 CD CD O
of IN IN O
whom WP WP O
had VBD VBD O
partial JJ JJ O
DiGeorge NNP NNP O
syndrome NN NN O
. . . O

The DT DT O
remaining VBG VBG O
infant NN NN O
had VBD VBD O
recently RB RB O
undergone VBN VBN O
a DT DT O
cardiac JJ JJ O
transplant NN NN O
. . . O

Intravenous NNP NNP O
ribavirin NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
on IN IN O
a DT DT O
compassionate NN NN O
- - - O
use NN NN O
protocol NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Complete NNP NNP O
clinical JJ JJ O
recovery NN NN O
followed VBD VBD O
later RB RB O
by IN IN O
viral JJ JJ O
clearance NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
2 CD CD O
children NNS NNS O
: : : O
the DT DT O
cardiac JJ JJ O
transplant NN NN O
recipient NN NN O
with IN IN O
adenovirus NN NN O
hemorrhagic JJ JJ O
cystitis NN NN O
and CC CC O
the DT DT O
immunocompetent NN NN O
neonate NN NN O
with IN IN O
adenovirus NN NN O
pneumonia NN NN O
. . . O

The DT DT O
remaining VBG VBG O
3 CD CD O
children NNS NNS O
died VBD VBD O
of IN IN O
adenovirus NN NN O
disease NN NN O
. . . O

Intravenous NNP NNP O
ribavirin NN NN B-CHEM
therapy NN NN O
was VBD VBD O
well RB RB O
tolerated VBN VBN O
. . . O

Use NN NN O
of IN IN O
cidofovir NN NN B-CHEM
in IN IN O
1 CD CD O
child NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
progressive JJ JJ O
renal NN NN O
failure NN NN O
and CC CC O
neutropenia NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
Our PRP$ PRP$ O
series NN NN O
of IN IN O
patients NNS NNS O
is VBZ VBZ O
representative NN NN O
of IN IN O
the DT DT O
spectrum NN NN O
of IN IN O
immunocompromised JJ JJ O
children NNS NNS O
at IN IN O
greatest JJS JJS O
risk NN NN O
for IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
, , , O
namely RB RB O
solid JJ JJ O
- - - O
organ NN NN O
and CC CC O
bone NN NN O
marrow NN NN O
transplant NN NN O
recipients NNS NNS O
, , , O
neonates NNS NNS O
, , , O
and CC CC O
children NNS NNS O
with IN IN O
immunodeficiency NN NN O
. . . O

Although IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
was VBD VBD O
not RB RB O
effective JJ JJ O
for IN IN O
all DT DT O
children NNS NNS O
with IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
in IN IN O
this DT DT O
series NN NN O
or CC CC O
in IN IN O
the DT DT O
literature NN NN O
, , , O
therapy NN NN O
is VBZ VBZ O
unlikely JJ JJ O
to TO TO O
be VB VB O
of IN IN O
benefit NN NN O
if IN IN O
begun NN NN O
late JJ JJ O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
the DT DT O
infection NN NN O
. . . O

Early JJ JJ O
identification NN NN O
, , , O
eg NN NN O
by IN IN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
of IN IN O
those DT DT O
patients NNS NNS O
at IN IN O
risk NN NN O
of IN IN O
disseminated VBN VBN O
adenovirus NN NN O
disease NN NN O
may MD MD O
permit VB VB O
earlier RBR RBR O
antiviral JJ JJ O
treatment NN NN O
and CC CC O
better JJR JJR O
evaluation NN NN O
of IN IN O
therapeutic JJ JJ O
response NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Two CD CD O
of IN IN O
5 CD CD O
children NNS NNS O
with IN IN O
severe JJ JJ O
adenovirus NN NN O
disease NN NN O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
recovered VBD VBD O
. . . O

The DT DT O
availability NN NN O
of IN IN O
newer JJR JJR O
rapid JJ JJ O
diagnostic JJ JJ O
techniques NNS NNS O
, , , O
such JJ JJ O
as IN IN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
, , , O
may MD MD O
make VB VB O
earlier RBR RBR O
, , , O
more RBR RBR O
effective JJ JJ O
treatment NN NN O
of IN IN O
adenovirus JJ JJ O
infection NN NN O
possible JJ JJ O
. . . O

Given VBN VBN O
the DT DT O
seriousness NN NN O
and CC CC O
increasing VBG VBG O
prevalence NN NN O
of IN IN O
adenovirus NN NN O
disease NN NN O
in IN IN O
certain JJ JJ O
hosts NNS NNS O
, , , O
especially RB RB O
children NNS NNS O
, , , O
a DT DT O
large JJ JJ O
, , , O
multicenter RBR RBR O
clinical JJ JJ O
trial NN NN O
of IN IN O
potentially RB RB O
useful JJ JJ O
anti NN NN O
- : : O
adenoviral JJ JJ O
therapies NNS NNS O
, , , O
such JJ JJ O
as IN IN O
intravenous JJ JJ O
ribavirin NN NN B-CHEM
, , , O
is VBZ VBZ O
clearly RB RB O
required VBN VBN O
to TO TO O
demonstrate VB VB O
the DT DT O
most RBS RBS O
effective JJ JJ O
and CC CC O
least JJS JJS O
toxic JJ JJ O
therapy NN NN O
. . . O

Delayed NNP NNP O
asystolic JJ JJ O
cardiac NN NN O
arrest NN NN O
after IN IN O
diltiazem NN NN B-CHEM
overdose NN NN O
; : : O
resuscitation NN NN O
with IN IN O
high JJ JJ O
dose NN NN O
intravenous JJ JJ O
calcium NN NN B-CHEM
. . . O

A DT DT O
51 CD CD O
year NN NN O
old JJ JJ O
man NN NN O
took VBD VBD O
a DT DT O
mixed JJ JJ O
overdose NN NN O
including VBG VBG O
1 CD CD O
. . . O
8 CD CD O
- : : O
3 CD CD O
. . . O
6 CD CD O
g SYM SYM O
of IN IN O
diltiazem NN NN B-CHEM
, , , O
paracetamol NN NN B-CHEM
, , , O
aspirin NN NN B-CHEM
, , , O
isosorbide NN NN B-CHEM
nitrate NN NN B-CHEM
, , , O
and CC CC O
alcohol NN NN B-CHEM
. . . O

He PRP PRP O
initially RB RB O
presented VBN VBN O
to TO TO O
hospital NN NN O
after IN IN O
six CD CD O
hours NNS NNS O
with IN IN O
mild JJ JJ O
hypotension NN NN O
and CC CC O
was VBD VBD O
treated VBN VBN O
with IN IN O
activated VBN VBN O
charcoal NN NN O
and CC CC O
intravenous JJ JJ O
fluids NNS NNS O
. . . O

Eighteen NNP NNP O
hours NNS NNS O
after IN IN O
the DT DT O
overdose NN NN O
he PRP PRP O
had VBD VBD O
two CD CD O
generalised VBN VBN O
tonic JJ JJ O
- - - O
clonic JJ JJ O
seizures NNS NNS O
. . . O

The DT DT O
patient NN NN O
remained VBD VBD O
unresponsive JJ JJ O
with IN IN O
junctional JJ JJ O
bradycardia NN NN O
, , , O
unrecordable JJ JJ O
blood NN NN O
pressure NN NN O
, , , O
and CC CC O
then RB RB O
became VBD VBD O
asystolic JJ JJ O
. . . O

He PRP PRP O
was VBD VBD O
resuscitated VBN VBN O
with IN IN O
high JJ JJ O
dose NN NN O
( ( ( O
13 CD CD O
. . . O
5 CD CD O
g SYM SYM O
) ) ) O
intravenous JJ JJ O
calcium NN NN B-CHEM
and CC CC O
adrenaline NN NN B-CHEM
( ( ( O
epinephrine NN NN B-CHEM
) ) ) O
. . . O

He PRP PRP O
required VBD VBD O
inotropic JJ JJ O
support NN NN O
and CC CC O
temporary JJ JJ O
pacing NN NN O
over IN IN O
the DT DT O
next JJ JJ O
48 CD CD O
hours NNS NNS O
. . . O

This DT DT O
case NN NN O
suggests VBZ VBZ O
there EX EX O
is VBZ VBZ O
a DT DT O
role NN NN O
for IN IN O
aggressive JJ JJ O
high NN NN O
dose NN NN O
intravenous JJ JJ O
calcium NN NN B-CHEM
therapy NN NN O
in IN IN O
severe JJ JJ O
diltiazem NN NN B-CHEM
overdose NN NN O
, , , O
particularly RB RB O
with IN IN O
the DT DT O
onset NN NN O
of IN IN O
asystole NN NN O
. . . O

It PRP PRP O
should MD MD O
be VB VB O
considered VBN VBN O
early RB RB O
in IN IN O
cases NNS NNS O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
after IN IN O
diltiazem NN NN B-CHEM
overdose NN NN O
. . . O

The DT DT O
case NN NN O
also RB RB O
highlights VBZ VBZ O
the DT DT O
problems NNS NNS O
with IN IN O
delayed JJ JJ O
toxicity NN NN O
when WRB WRB O
whole JJ JJ O
bowel NN NN O
irrigation NN NN O
is VBZ VBZ O
not RB RB O
administered VBN VBN O
. . . O

Low NNP NNP B-CHEM
- - - I-CHEM
molecular JJ JJ I-CHEM
- - - I-CHEM
weight NN NN I-CHEM
heparin NN NN I-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
mechanical JJ JJ O
heart NN NN O
valves NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
interruption NN NN O
of IN IN O
oral JJ JJ O
anticoagulant NN NN O
( ( ( O
OAC NNP NNP O
) ) ) O
administration NN NN O
is VBZ VBZ O
sometimes RB RB O
indicated VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
mechanical JJ JJ O
heart NN NN O
valves NNS NNS O
, , , O
mainly RB RB O
before IN IN O
noncardiac NN NN O
surgery NN NN O
, , , O
non NN NN O
- - - O
surgical JJ JJ O
interventions NNS NNS O
, , , O
and CC CC O
pregnancy NN NN O
. . . O

Unfractionated NNP NNP B-CHEM
heparin NN NN I-CHEM
( ( ( O
UH NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
currently RB RB O
the DT DT O
substitute NN NN O
for IN IN O
selected VBN VBN O
patients NNS NNS O
. . . O

Low NNP NNP B-CHEM
- - - I-CHEM
molecular JJ JJ I-CHEM
- - - I-CHEM
weight NN NN I-CHEM
heparin NN NN I-CHEM
( ( ( O
LMWH NNP NNP B-CHEM
) ) ) O
offers VBZ VBZ O
theoretical JJ JJ O
advantages NNS NNS O
over IN IN O
UH NNP NNP B-CHEM
, , , O
but CC CC O
is VBZ VBZ O
not RB RB O
currently RB RB O
considered VBN VBN O
in IN IN O
clinical JJ JJ O
guidelines NNS NNS O
as IN IN O
an DT DT O
alternative NN NN O
to TO TO O
UH NNP NNP B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
prosthetic JJ JJ O
valves NNS NNS O
. . . O

HYPOTHESIS NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
review VB VB O
the DT DT O
data NNS NNS O
accumulated VBN VBN O
so RB RB O
far RB RB O
on IN IN O
the DT DT O
use NN NN O
of IN IN O
LMWH NNP NNP B-CHEM
in IN IN O
this DT DT O
patient NN NN O
population NN NN O
and CC CC O
to TO TO O
discuss VB VB O
its PRP$ PRP$ O
applicability NN NN O
in IN IN O
common JJ JJ O
practice NN NN O
. . . O

METHODS NNP NNP O
: : : O
For IN IN O
this DT DT O
paper NN NN O
, , , O
the DT DT O
current JJ JJ O
medical JJ JJ O
literature NN NN O
on IN IN O
LMWH NNP NNP B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
mechanical JJ JJ O
heart NN NN O
valves NNS NNS O
was VBD VBD O
extensively RB RB O
reviewed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
There EX EX O
were VBD VBD O
eight CD CD O
series NNS NNS O
and CC CC O
six CD CD O
case NN NN O
reports NNS NNS O
. . . O

None NN NN O
of IN IN O
the DT DT O
studies NNS NNS O
was VBD VBD O
randomized JJ JJ O
, , , O
and CC CC O
only RB RB O
one CD CD O
was VBD VBD O
prospective JJ JJ O
. . . O

Data NNP NNP O
to TO TO O
establish VB VB O
the DT DT O
thromboembolic JJ JJ O
risk NN NN O
were VBD VBD O
incomplete JJ JJ O
. . . O

After IN IN O
excluding VBG VBG O
case NN NN O
reports NNS NNS O
, , , O
the DT DT O
following VBG VBG O
groups NNS NNS O
were VBD VBD O
constructed VBN VBN O
: : : O
( ( ( O
a DT DT O
) ) ) O
short JJ JJ O
- - - O
term NN NN O
administration NN NN O
, , , O
after IN IN O
valve NN NN O
insertion NN NN O
( ( ( O
n NN NN O
= SYM SYM O
212 CD CD O
) ) ) O
; : : O
( ( ( O
b SYM SYM O
) ) ) O
short JJ JJ O
- - - O
term NN NN O
, , , O
perioperative JJ JJ O
( ( ( O
noncardiac NN NN O
) ) ) O
/ NN NN O
periprocedural NN NN O
( ( ( O
n NN NN O
= SYM SYM O
114 CD CD O
) ) ) O
; : : O
( ( ( O
c SYM SYM O
) ) ) O
long JJ JJ O
- - - O
term NN NN O
, , , O
due JJ JJ O
to TO TO O
intolerance VB VB O
to TO TO O
OAC NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
16 CD CD O
) ) ) O
; : : O
( ( ( O
d SYM SYM O
) ) ) O
long JJ JJ O
- - - O
term NN NN O
, , , O
in IN IN O
pregnancy NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
. . . O

The DT DT O
incidence NN NN O
rate NN NN O
of IN IN O
thromboembolism NN NN O
was VBD VBD O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
for IN IN O
all PDT PDT O
the DT DT O
studies NNS NNS O
and CC CC O
0 CD CD O
. . . O
5 CD CD O
, , , O
0 CD CD O
, , , O
20 CD CD O
, , , O
and CC CC O
0 CD CD O
% NN NN O
in IN IN O
groups NNS NNS O
a DT DT O
, , , O
b SYM SYM O
, , , O
c SYM SYM O
, , , O
and CC CC O
d SYM SYM O
, , , O
respectively RB RB O
; : : O
for IN IN O
hemorrhage NN NN O
, , , O
the DT DT O
overall JJ JJ O
rate NN NN O
was VBD VBD O
3 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
3 CD CD O
. . . O
8 CD CD O
, , , O
2 CD CD O
. . . O
6 CD CD O
, , , O
10 CD CD O
, , , O
and CC CC O
0 CD CD O
% NN NN O
for IN IN O
the DT DT O
respective JJ JJ O
groups NNS NNS O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
patients NNS NNS O
with IN IN O
mechanical JJ JJ O
heart NN NN O
valves NNS NNS O
, , , O
short JJ JJ O
- - - O
term NN NN O
LMWH NNP NNP B-CHEM
therapy NN NN O
compares NNS NNS O
favorably RB RB O
with IN IN O
UH NNP NNP B-CHEM
. . . O

Data NNP NNP O
on IN IN O
mid JJ JJ O
- : : O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
LMWH NNP NNP B-CHEM
administration NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
are VBP VBP O
sparse NN NN O
. . . O

Further RB RB O
randomized JJ JJ O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
confirm VB VB O
the DT DT O
safety NN NN O
and CC CC O
precise JJ JJ O
indications NNS NNS O
for IN IN O
the DT DT O
use NN NN O
of IN IN O
LMWH NNP NNP B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
mechanical JJ JJ O
heart NN NN O
valves NNS NNS O
. . . O

Cardiac NNP NNP O
arrest NN NN O
after IN IN O
intravenous JJ JJ O
metoclopramide NN NN B-CHEM
- - - O
a DT DT O
case NN NN O
of IN IN O
five CD CD O
repeated VBN VBN O
injections NNS NNS O
of IN IN O
metoclopramide NN NN B-CHEM
causing VBG VBG O
five CD CD O
episodes NNS NNS O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
patient NN NN O
where WRB WRB O
intravenous JJ JJ O
injection NN NN O
of IN IN O
metoclopramide NN NN B-CHEM
was VBD VBD O
immediately RB RB O
followed VBN VBN O
by IN IN O
asystole NN NN O
repeatedly RB RB O
. . . O

The DT DT O
patient NN NN O
received VBD VBD O
metoclopramide NN NN B-CHEM
10 CD CD O
mg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
five CD CD O
times NNS NNS O
during IN IN O
48 CD CD O
h NN NN O
. . . O

After IN IN O
interviewing VBG VBG O
the DT DT O
attending NN NN O
nurses NNS NNS O
and CC CC O
reviewing VBG VBG O
the DT DT O
written VBN VBN O
documentation NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
clear JJ JJ O
that IN IN O
every DT DT O
administration NN NN O
of IN IN O
metoclopramide NN NN B-CHEM
was VBD VBD O
immediately RB RB O
( ( ( O
within IN IN O
s VBZ VBZ O
) ) ) O
followed VBN VBN O
by IN IN O
asystole NN NN O
. . . O

The DT DT O
asystole NN NN O
lasted VBD VBD O
15 CD CD O
- : : O
30 CD CD O
s VBZ VBZ O
on IN IN O
four CD CD O
occasions NNS NNS O
, , , O
on IN IN O
one CD CD O
occasion NN NN O
it PRP PRP O
lasted VBD VBD O
2 CD CD O
min NN NN O
. . . O

The DT DT O
patient NN NN O
received VBD VBD O
atropine NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
- : : O
1 CD CD O
mg NN NN O
and CC CC O
chest NN NN O
compressions NNS NNS O
, , , O
before IN IN O
sinus NN NN O
rhythm NN NN O
again RB RB O
took VBD VBD O
over IN IN O
. . . O

We PRP PRP O
interpret VBP VBP O
this DT DT O
as IN IN O
episodes NNS NNS O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
caused VBN VBN O
by IN IN O
metoclopramide NN NN B-CHEM
. . . O

The DT DT O
rapid JJ JJ O
injection NN NN O
via IN IN O
the DT DT O
central JJ JJ O
venous JJ JJ O
route NN NN O
and CC CC O
the DT DT O
concomitant JJ JJ O
tapering NN NN O
of IN IN O
dopamine NN NN B-CHEM
infusion NN NN O
might MD MD O
have VB VB O
contributed VBN VBN O
in IN IN O
precipitating VBG VBG O
the DT DT O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
. . . O

Immunohistochemical JJ JJ O
study NN NN O
on IN IN O
inducible JJ JJ O
type NN NN O
of IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
iNOS NN NN O
) ) ) O
, , , O
basic JJ JJ O
fibroblast NN NN O
growth NN NN O
factor NN NN O
( ( ( O
bFGF NN NN O
) ) ) O
and CC CC O
tumor NN NN O
growth NN NN O
factor NN NN O
- : : O
beta1 NN NN O
( ( ( O
TGF NNP NNP O
- - - O
beta1 NN NN O
) ) ) O
in IN IN O
arteritis NN NN O
induced VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
fenoldopam NN NN B-CHEM
and CC CC O
theophylline NN NN B-CHEM
, , , O
vasodilators NNS NNS O
. . . O

Arteritis NNP NNP O
induced VBD VBD O
in IN IN O
rats NNS NNS O
by IN IN O
vasodilators NNS NNS O
, , , O
fenoldopam NN NN B-CHEM
and CC CC O
theophylline NN NN B-CHEM
, , , O
was VBD VBD O
examined VBN VBN O
immunohistochemically RB RB O
for IN IN O
expressions NNS NNS O
of IN IN O
inducible JJ JJ O
type NN NN O
of IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
( ( ( O
iNOS NN NN O
) ) ) O
, , , O
basic JJ JJ O
fibroblast NN NN O
growth NN NN O
factor NN NN O
( ( ( O
bFGF NN NN O
) ) ) O
and CC CC O
tumor NN NN O
growth NN NN O
factor NN NN O
- : : O
beta1 NN NN O
( ( ( O
TGF NNP NNP O
- - - O
beta1 NN NN O
) ) ) O
. . . O

Rats NNP NNP O
were VBD VBD O
administered VBN VBN O
fenoldopam NN NN B-CHEM
for IN IN O
24 CD CD O
hours NNS NNS O
by IN IN O
intravenous JJ JJ O
infusion NN NN O
with IN IN O
or CC CC O
without IN IN O
following VBG VBG O
repeated VBN VBN O
daily JJ JJ O
oral JJ JJ O
administrations NNS NNS O
of IN IN O
theophylline NN NN B-CHEM
. . . O

Irrespective NNP NNP O
of IN IN O
theophylline NN NN B-CHEM
administration NN NN O
, , , O
iNOS NN NN O
antigens NNS NNS O
were VBD VBD O
remarkably RB RB O
abundant JJ JJ O
in IN IN O
ED NNP NNP O
- : : O
1 CD CD O
- : : O
positive JJ JJ O
cells NNS NNS O
on IN IN O
day NN NN O
5 CD CD O
and CC CC O
8 CD CD O
post NN NN O
- : : O
fenoldopam NN NN B-CHEM
- : : O
infusion NN NN O
( ( ( O
DPI NNP NNP O
) ) ) O
; : : O
bFGF NN NN O
antigens NNS NNS O
were VBD VBD O
remarkably RB RB O
abundant JJ JJ O
in IN IN O
ED NNP NNP O
- : : O
1 CD CD O
- : : O
positive JJ JJ O
cells NNS NNS O
on IN IN O
1 CD CD O
and CC CC O
3 CD CD O
DPI NNP NNP O
; : : O
TGF NNP NNP O
- : : O
beta1 NN NN O
antigens NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
ED NNP NNP O
- : : O
1 CD CD O
- : : O
positive JJ JJ O
cells NNS NNS O
on IN IN O
and CC CC O
after IN IN O
5 CD CD O
DPI NNP NNP O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
peak NN NN O
expression NN NN O
of IN IN O
iNOS NN NN O
antigen NN NN O
was VBD VBD O
followed VBN VBN O
by IN IN O
that DT DT O
of IN IN O
bFGF NN NN O
antigen NN NN O
, , , O
and CC CC O
bFGF NN NN O
may MD MD O
have VB VB O
a DT DT O
suppressive JJ JJ O
effect NN NN O
on IN IN O
iNOS NN NN O
expression NN NN O
in IN IN O
these DT DT O
rat NN NN O
arteritis NNS NNS O
models NNS NNS O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
TGF NNP NNP O
- : : O
beta1 NN NN O
was VBD VBD O
not RB RB O
considered VBN VBN O
to TO TO O
have VB VB O
a DT DT O
suppressive JJ JJ O
effect NN NN O
on IN IN O
iNOS NN NN O
expression NN NN O
in IN IN O
these DT DT O
models NNS NNS O
. . . O

The DT DT O
striatum NN NN O
as IN IN O
a DT DT O
target NN NN O
for IN IN O
anti JJ JJ O
- : : O
rigor NN NN O
effects NNS NNS O
of IN IN O
an DT DT O
antagonist NN NN O
of IN IN O
mGluR1 NN NN O
, , , O
but CC CC O
not RB RB O
an DT DT O
agonist NN NN O
of IN IN O
group NN NN O
II NNP NNP O
metabotropic NN NN O
glutamate NN NN B-CHEM
receptors NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
find VB VB O
out IN IN O
whether IN IN O
the DT DT O
metabotropic NN NN O
receptor NN NN O
1 CD CD O
( ( ( O
mGluR1 NN NN O
) ) ) O
and CC CC O
group NN NN O
II NNP NNP O
mGluRs NN NN O
, , , O
localized JJ JJ O
in IN IN O
the DT DT O
striatum NN NN O
, , , O
are VBP VBP O
involved VBN VBN O
in IN IN O
antiparkinsonian JJ JJ O
- - - O
like IN IN O
effects NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Haloperidol NNP NNP B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
induced VBN VBN O
parkinsonian NN NN O
- - - O
like IN IN O
muscle NN NN O
rigidity NN NN O
, , , O
measured VBN VBN O
as IN IN O
an DT DT O
increased JJ JJ O
resistance NN NN O
of IN IN O
a DT DT O
rat NN NN O
' '' '' O
s VBZ VBZ O
hind NN NN O
foot NN NN O
to TO TO O
passive JJ JJ O
flexion NN NN O
and CC CC O
extension NN NN O
at IN IN O
the DT DT O
ankle NN NN O
joint NN NN O
. . . O

( ( ( B-CHEM
RS NNP NNP I-CHEM
) ) ) I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
aminoindan NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
dicarboxylic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
AIDA NNP NNP B-CHEM
; : : O
0 CD CD O
. . . O
5 CD CD O
- : : O
15 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
) ) ) O
, , , O
a DT DT O
potent JJ JJ O
and CC CC O
selective JJ JJ O
mGluR1 NN NN O
antagonist NN NN O
, , , O
or CC CC O
( ( ( B-CHEM
2R CD CD I-CHEM
, , , I-CHEM
4R CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
aminopyrrolidine NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dicarboxylate NN NN I-CHEM
( ( ( O
2R CD CD B-CHEM
, , , I-CHEM
4R CD CD I-CHEM
- : : I-CHEM
APDC NNP NNP I-CHEM
; : : O
7 CD CD O
. . . O
5 CD CD O
- : : O
15 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
) ) ) O
, , , O
a DT DT O
selective JJ JJ O
group NN NN O
II NNP NNP O
agonist NN NN O
, , , O
was VBD VBD O
injected VBN VBN O
bilaterally RB RB O
into IN IN O
the DT DT O
striatum NN NN O
of IN IN O
haloperidol NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

AIDA NNP NNP B-CHEM
in IN IN O
doses NNS NNS O
of IN IN O
7 CD CD O
. . . O
5 CD CD O
- : : O
15 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
diminished VBD VBD O
the DT DT O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
muscle NN NN O
rigidity NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
2R CD CD B-CHEM
, , , I-CHEM
4R CD CD I-CHEM
- : : I-CHEM
APDC NNP NNP I-CHEM
injections NNS NNS O
were VBD VBD O
ineffective JJ JJ O
. . . O

The DT DT O
present JJ JJ O
results NNS NNS O
may MD MD O
suggest VB VB O
that IN IN O
the DT DT O
blockade NN NN O
of IN IN O
striatal JJ JJ O
mGluR1 NN NN O
, , , O
but CC CC O
not RB RB O
the DT DT O
stimulation NN NN O
of IN IN O
group NN NN O
II NNP NNP O
mGluRs NN NN O
, , , O
may MD MD O
ameliorate VB VB O
parkinsonian JJ JJ O
muscle NN NN O
rigidity NN NN O
. . . O

A DT DT O
phase NN NN O
II NNP NNP O
study NN NN O
of IN IN O
thalidomide NN NN B-CHEM
in IN IN O
advanced JJ JJ O
metastatic JJ JJ O
renal JJ JJ O
cell NN NN O
carcinoma NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
toxicity NN NN O
and CC CC O
activity NN NN O
of IN IN O
thalidomide NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
metastatic JJ JJ O
renal NN NN O
cell NN NN O
cancer NN NN O
and CC CC O
to TO TO O
measure VB VB O
changes NNS NNS O
of IN IN O
one CD CD O
angiogenic JJ JJ O
factor NN NN O
, , , O
vascular JJ JJ O
endothelial JJ JJ O
growth NN NN O
factor NN NN O
( ( ( O
VEGF NNP NNP O
) ) ) O
165 CD CD O
, , , O
with IN IN O
therapy NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
29 CD CD O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
on IN IN O
a DT DT O
study NN NN O
of IN IN O
thalidomide NN NN B-CHEM
using VBG VBG O
an DT DT O
intra NN NN O
- - - O
patient NN NN O
dose NN NN O
escalation NN NN O
schedule NN NN O
. . . O

Patients NNS NNS O
began VBD VBD O
thalidomide NN NN B-CHEM
at IN IN O
400 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
and CC CC O
escalated VBN VBN O
as IN IN O
tolerated VBN VBN O
to TO TO O
1200 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
by IN IN O
day NN NN O
54 CD CD O
. . . O

Fifty NNP NNP O
- - - O
nine CD CD O
per IN IN O
cent NN NN O
of IN IN O
patients NNS NNS O
had VBD VBD O
had VBN VBN O
previous JJ JJ O
therapy NN NN O
with IN IN O
IL NNP NNP O
- : : O
2 CD CD O
and CC CC O
52 CD CD O
% NN NN O
were VBD VBD O
performance NN NN O
status NN NN O
2 CD CD O
or CC CC O
3 CD CD O
. . . O

Systemic NNP NNP O
plasma NN NN O
VEGF165 NNP NNP O
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
by IN IN O
dual JJ JJ O
monoclonal JJ JJ O
ELISA NNP NNP O
in IN IN O
8 CD CD O
patients NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
24 CD CD O
patients NNS NNS O
were VBD VBD O
evaluable JJ JJ O
for IN IN O
response NN NN O
with IN IN O
one CD CD O
partial JJ JJ O
response NN NN O
of IN IN O
11 CD CD O
months NNS NNS O
duration NN NN O
of IN IN O
a DT DT O
patient NN NN O
with IN IN O
hepatic JJ JJ O
and CC CC O
pulmonary JJ JJ O
metastases NNS NNS O
( ( ( O
4 CD CD O
% NN NN O
) ) ) O
, , , O
one CD CD O
minor JJ JJ O
response NN NN O
, , , O
and CC CC O
2 CD CD O
patients NNS NNS O
stable JJ JJ O
for IN IN O
over IN IN O
6 CD CD O
months NNS NNS O
. . . O

Somnolence NNP NNP O
and CC CC O
constipation NN NN O
were VBD VBD O
prominent JJ JJ O
toxicities NNS NNS O
and CC CC O
most JJS JJS O
patients NNS NNS O
could MD MD O
not RB RB O
tolerate VB VB O
the DT DT O
1200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
dose NN NN O
level NN NN O
. . . O

Systemic NNP NNP O
plasma NN NN O
VEGF165 NNP NNP O
levels NNS NNS O
did VBD VBD O
not RB RB O
change VB VB O
with IN IN O
therapy NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
These DT DT O
results NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
a DT DT O
low JJ JJ O
level NN NN O
of IN IN O
activity NN NN O
of IN IN O
thalidomide NN NN B-CHEM
in IN IN O
renal JJ JJ O
cell NN NN O
carcinoma NN NN O
. . . O

Administration NNP NNP O
of IN IN O
doses NNS NNS O
over IN IN O
800 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
was VBD VBD O
difficult JJ JJ O
to TO TO O
achieve VB VB O
in IN IN O
this DT DT O
patient NN NN O
population NN NN O
, , , O
however RB RB O
lower JJR JJR O
doses NNS NNS O
were VBD VBD O
practical JJ JJ O
. . . O

The DT DT O
dose NN NN O
- - - O
response NN NN O
relationship NN NN O
, , , O
if IN IN O
any DT DT O
, , , O
of IN IN O
thalidomide NN NN B-CHEM
for IN IN O
renal JJ JJ O
cell NN NN O
carcinoma NN NN O
is VBZ VBZ O
unclear JJ JJ O
. . . O

Can MD MD O
lidocaine NN NN B-CHEM
reduce VB VB O
succinylcholine NN NN B-CHEM
induced VBN VBN O
postoperative JJ JJ O
myalgia NN NN O
? . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
effect NN NN O
of IN IN O
lidocaine NN NN B-CHEM
pretreatment NN NN O
on IN IN O
reduction NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
- - - O
induced JJ JJ O
myalgia NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
general JJ JJ O
anesthesia NN NN O
for IN IN O
gynecological JJ JJ O
surgery NN NN O
. . . O

One CD CD O
hundred CD CD O
and CC CC O
thirty CD CD O
- : : O
five CD CD O
patients NNS NNS O
were VBD VBD O
assigned VBN VBN O
to TO TO O
one CD CD O
of IN IN O
three CD CD O
groups NNS NNS O
in IN IN O
a DT DT O
prospective JJ JJ O
, , , O
double JJ JJ O
blind JJ JJ O
, , , O
randomized JJ JJ O
manner NN NN O
. . . O

Group NNP NNP O
PS NNP NNP O
, , , O
the DT DT O
control NN NN O
group NN NN O
, , , O
received VBD VBD O
normal JJ JJ O
saline NN NN O
and CC CC O
succinylcholine NN NN B-CHEM
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
x SYM SYM O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
; : : O
Group NNP NNP O
LS NNP NNP O
, , , O
lidocaine NN NN B-CHEM
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
x SYM SYM O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
and CC CC O
succinylcholine NN NN B-CHEM
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
x SYM SYM O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
; : : O
Group NNP NNP O
PR NNP NNP O
, , , O
normal JJ JJ O
saline NN NN O
and CC CC O
rocuronium NN NN B-CHEM
0 CD CD O
. . . O
6 CD CD O
mg NN NN O
x SYM SYM O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O

Morphine NNP NNP B-CHEM
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
x SYM SYM O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
iv NN NN O
was VBD VBD O
given VBN VBN O
for IN IN O
premedication NN NN O
and CC CC O
all DT DT O
patients NNS NNS O
were VBD VBD O
monitored VBN VBN O
with IN IN O
a DT DT O
noninvasive JJ JJ O
blood NN NN O
pressure NN NN O
monitor NN NN O
, , , O
ECG NNP NNP O
and CC CC O
pulse NN NN O
oximetry NN NN O
. . . O

Anesthesia NNP NNP O
was VBD VBD O
induced VBN VBN O
with IN IN O
5 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
thiopental JJ JJ B-CHEM
iv NN NN O
. . . O
followed VBN VBN O
by IN IN O
succinylcholine NN NN B-CHEM
( ( ( O
Group NNP NNP O
PS NNP NNP O
, , , O
LS NNP NNP O
) ) ) O
or CC CC O
rocuronium NN NN B-CHEM
( ( ( O
Group NNP NNP O
PR NNP NNP O
) ) ) O
for IN IN O
tracheal NN NN O
intubation NN NN O
. . . O

Following VBG VBG O
administration NN NN O
of IN IN O
these DT DT O
agents NNS NNS O
, , , O
the DT DT O
presence NN NN O
, , , O
and CC CC O
degree NN NN O
of IN IN O
fasciculation NN NN O
were VBD VBD O
assessed VBN VBN O
visually RB RB O
on IN IN O
a DT DT O
four CD CD O
point NN NN O
scale NN NN O
by IN IN O
one CD CD O
investigator NN NN O
who WP WP O
was VBD VBD O
blinded JJ JJ O
to TO TO O
the DT DT O
drug NN NN O
administered VBN VBN O
. . . O

The DT DT O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
of IN IN O
each DT DT O
patient NN NN O
were VBD VBD O
monitored VBN VBN O
on IN IN O
nine CD CD O
occasions NNS NNS O
. . . O

Twenty CD CD O
- - - O
four CD CD O
hours NNS NNS O
later RB RB O
, , , O
any DT DT O
myalgia NN NN O
experienced VBN VBN O
was VBD VBD O
assessed VBN VBN O
according VBG VBG O
to TO TO O
a DT DT O
structured JJ JJ O
questionaire NN NN O
and CC CC O
graded VBN VBN O
by IN IN O
a DT DT O
four CD CD O
point NN NN O
scale NN NN O
by IN IN O
one CD CD O
investigator NN NN O
blinded VBD VBD O
to TO TO O
the DT DT O
intraoperative JJ JJ O
management NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
muscle NN NN O
fasciculation NN NN O
was VBD VBD O
not RB RB O
found VBN VBN O
in IN IN O
Group NNP NNP O
PR NNP NNP O
while IN IN O
the DT DT O
patients NNS NNS O
in IN IN O
Group NNP NNP O
LS NNP NNP O
had VBD VBD O
a DT DT O
lower JJR JJR O
incidence NN NN O
of IN IN O
muscle NN NN O
fasciculation NN NN O
than IN IN O
those DT DT O
in IN IN O
Group NNP NNP O
PS NNP NNP O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

At IN IN O
24 CD CD O
h NN NN O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
myalgia NN NN O
was VBD VBD O
higher JJR JJR O
in IN IN O
Group NNP NNP O
PS NNP NNP O
than IN IN O
in IN IN O
Group NNP NNP O
LS NNP NNP O
and CC CC O
PR NNP NNP O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

A DT DT O
correlation NN NN O
was VBD VBD O
not RB RB O
found VBN VBN O
between IN IN O
the DT DT O
incidence NN NN O
of IN IN O
myalgia NN NN O
and CC CC O
the DT DT O
occurrence NN NN O
of IN IN O
muscle NN NN O
fasciculation NN NN O
. . . O

The DT DT O
changes NNS NNS O
in IN IN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
were VBD VBD O
not RB RB O
significant JJ JJ O
among IN IN O
the DT DT O
three CD CD O
groups NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
where WRB WRB O
succinylcholine NN NN B-CHEM
is VBZ VBZ O
used VBN VBN O
, , , O
lidocaine NN NN B-CHEM
is VBZ VBZ O
proven VBN VBN O
to TO TO O
be VB VB O
the DT DT O
useful JJ JJ O
pretreatment NN NN O
agent NN NN O
for IN IN O
the DT DT O
reduction NN NN O
of IN IN O
postoperative JJ JJ O
myalgia NN NN O
. . . O

Reduced NNP NNP O
sodium NN NN B-CHEM
channel NN NN O
density NN NN O
, , , O
altered VBN VBN O
voltage NN NN O
dependence NN NN O
of IN IN O
inactivation NN NN O
, , , O
and CC CC O
increased VBD VBD O
susceptibility NN NN O
to TO TO O
seizures NNS NNS O
in IN IN O
mice NN NN O
lacking VBG VBG O
sodium NN NN B-CHEM
channel NN NN O
beta NN NN O
2 CD CD O
- : : O
subunits NNS NNS O
. . . O

Sodium NNP NNP B-CHEM
channel NN NN O
beta NN NN O
- : : O
subunits NNS NNS O
modulate VBP VBP O
channel NN NN O
gating VBG VBG O
, , , O
assembly RB RB O
, , , O
and CC CC O
cell NN NN O
surface NN NN O
expression NN NN O
in IN IN O
heterologous JJ JJ O
cell NN NN O
systems NNS NNS O
. . . O

We PRP PRP O
generated VBD VBD O
beta2 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
to TO TO O
investigate VB VB O
the DT DT O
role NN NN O
of IN IN O
beta2 NN NN O
in IN IN O
control NN NN O
of IN IN O
sodium NN NN B-CHEM
channel NN NN O
density NN NN O
, , , O
localization NN NN O
, , , O
and CC CC O
function NN NN O
in IN IN O
neurons NNS NNS O
in IN IN O
vivo NN NN O
. . . O

Measurements NNP NNP O
of IN IN O
[ NN NN O
( ( ( O
3 CD CD O
) ) ) O
H NNP NNP O
] NN NN O
saxitoxin NN NN B-CHEM
( ( ( O
STX NNP NNP B-CHEM
) ) ) O
binding VBG VBG O
showed VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
level NN NN O
of IN IN O
plasma JJ JJ O
membrane NN NN O
sodium NN NN B-CHEM
channels NNS NNS O
in IN IN O
beta2 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
neurons NNS NNS O
. . . O

The DT DT O
loss NN NN O
of IN IN O
beta2 NN NN O
resulted VBD VBD O
in IN IN O
negative JJ JJ O
shifts NNS NNS O
in IN IN O
the DT DT O
voltage NN NN O
dependence NN NN O
of IN IN O
inactivation NN NN O
as RB RB O
well RB RB O
as IN IN O
significant JJ JJ O
decreases NNS NNS O
in IN IN O
sodium NN NN B-CHEM
current JJ JJ O
density NN NN O
in IN IN O
acutely RB RB O
dissociated VBN VBN O
hippocampal JJ JJ O
neurons NNS NNS O
. . . O

The DT DT O
integral NN NN O
of IN IN O
the DT DT O
compound NN NN O
action NN NN O
potential JJ JJ O
in IN IN O
optic JJ JJ O
nerve NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
, , , O
and CC CC O
the DT DT O
threshold NN NN O
for IN IN O
action NN NN O
potential JJ JJ O
generation NN NN O
was VBD VBD O
increased VBN VBN O
, , , O
indicating VBG VBG O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
level NN NN O
of IN IN O
functional JJ JJ O
plasma NN NN O
membrane NN NN O
sodium NN NN B-CHEM
channels NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
conduction NN NN O
velocity NN NN O
, , , O
the DT DT O
number NN NN O
and CC CC O
size NN NN O
of IN IN O
axons NNS NNS O
in IN IN O
the DT DT O
optic JJ JJ O
nerve NN NN O
, , , O
and CC CC O
the DT DT O
specific JJ JJ O
localization NN NN O
of IN IN O
Na NNP NNP B-CHEM
( ( ( O
v NN NN O
) ) ) O
1 CD CD O
. . . O
6 CD CD O
channels NNS NNS O
in IN IN O
the DT DT O
nodes NNS NNS O
of IN IN O
Ranvier NNP NNP O
were VBD VBD O
unchanged JJ JJ O
. . . O

beta2 NN NN O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NNS NNS O
displayed VBN VBN O
increased VBN VBN O
susceptibility NN NN O
to TO TO O
seizures NNS NNS O
, , , O
as IN IN O
indicated VBN VBN O
by IN IN O
reduced VBN VBN O
latency NN NN O
and CC CC O
threshold NN NN O
for IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
, , , O
but CC CC O
seemed VBD VBD O
normal JJ JJ O
in IN IN O
other JJ JJ O
neurological JJ JJ O
tests NNS NNS O
. . . O

Our PRP$ PRP$ O
observations NNS NNS O
show VBP VBP O
that IN IN O
beta2 NN NN O
- : : O
subunits NNS NNS O
play VBP VBP O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
regulation NN NN O
of IN IN O
sodium NN NN B-CHEM
channel NN NN O
density NN NN O
and CC CC O
function NN NN O
in IN IN O
neurons NNS NNS O
in IN IN O
vivo NN NN O
and CC CC O
are VBP VBP O
required VBN VBN O
for IN IN O
normal JJ JJ O
action NN NN O
potential JJ JJ O
generation NN NN O
and CC CC O
control NN NN O
of IN IN O
excitability NN NN O
. . . O

Acute JJ JJ O
liver NN NN O
failure NN NN O
with IN IN O
concurrent NN NN O
bupropion NN NN B-CHEM
and CC CC O
carbimazole NN NN B-CHEM
therapy NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
fatal JJ JJ O
liver NN NN O
failure NN NN O
possibly RB RB O
associated VBN VBN O
with IN IN O
concurrent JJ JJ O
use NN NN O
of IN IN O
bupropion NN NN B-CHEM
and CC CC O
carbimazole NN NN B-CHEM
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
41 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Chinese JJ JJ O
man NN NN O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
hyperthyroidism NN NN O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
with IN IN O
carbimazole NN NN B-CHEM
and CC CC O
propranolol NN NN B-CHEM
for IN IN O
the DT DT O
past JJ JJ O
5 CD CD O
years NNS NNS O
. . . O

He PRP PRP O
received VBD VBD O
a DT DT O
10 CD CD O
- : : O
day NN NN O
course NN NN O
of IN IN O
bupropion NN NN B-CHEM
as IN IN O
an DT DT O
aid NN NN O
for IN IN O
smoking NN NN O
cessation NN NN O
10 CD CD O
weeks NNS NNS O
prior RB RB O
to TO TO O
presentation NN NN O
. . . O

He PRP PRP O
developed VBD VBD O
acute JJ JJ O
liver NN NN O
failure NN NN O
with IN IN O
rapid JJ JJ O
deterioration NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

Liver NNP NNP O
biopsy NN NN O
showed VBD VBD O
evidence NN NN O
of IN IN O
nonspecific JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
injury NN NN O
. . . O

His PRP$ PRP$ O
condition NN NN O
was VBD VBD O
further RBR RBR O
complicated VBN VBN O
by IN IN O
sepsis NN NN O
and CC CC O
coagulopathy NN NN O
. . . O

Death NN NN O
resulted VBD VBD O
19 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
onset NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

The DT DT O
likelihood NN NN O
that DT DT O
bupropion NN NN B-CHEM
induced JJ JJ O
hepatotoxicity NN NN O
in IN IN O
our PRP$ PRP$ O
patient NN NN O
was VBD VBD O
possible JJ JJ O
, , , O
based VBN VBN O
on IN IN O
the DT DT O
Naranjo NNP NNP O
probability NN NN O
scale NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
Although IN IN O
there EX EX O
is VBZ VBZ O
increasing VBG VBG O
evidence NN NN O
of IN IN O
hepatotoxicity NN NN O
induced VBN VBN O
by IN IN O
bupropion NN NN B-CHEM
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
case NN NN O
of IN IN O
fatality NN NN O
that WDT WDT O
could MD MD O
have VB VB O
resulted VBN VBN O
from IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
in IN IN O
a DT DT O
patient NN NN O
receiving VBG VBG O
bupropion NN NN B-CHEM
while IN IN O
on IN IN O
concomitant JJ JJ O
treatment NN NN O
with IN IN O
carbimazole NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
possibility NN NN O
of IN IN O
acute JJ JJ O
liver NN NN O
insult NN NN O
induced VBN VBN O
by IN IN O
bupropion NN NN B-CHEM
given VBN VBN O
concurrently RB RB O
with IN IN O
other JJ JJ O
hepatotoxic JJ JJ O
drugs NNS NNS O
. . . O

Pyeloureteral NNP NNP O
filling VBG VBG O
defects NNS NNS O
associated VBN VBN O
with IN IN O
systemic JJ JJ O
anticoagulation NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

The DT DT O
etiology NN NN O
of IN IN O
pyeloureteritis NN NN O
cystica NN NN O
has VBZ VBZ O
long RB RB O
been VBN VBN O
attributed VBN VBN O
to TO TO O
chronic JJ JJ O
infection NN NN O
and CC CC O
inflammation NN NN O
. . . O

A DT DT O
case NN NN O
is VBZ VBZ O
presented VBN VBN O
that WDT WDT O
is VBZ VBZ O
unique JJ JJ O
in IN IN O
that IN IN O
the DT DT O
acute JJ JJ O
onset NN NN O
and CC CC O
the DT DT O
rapid JJ JJ O
resolution NN NN O
of IN IN O
pyeloureteral JJ JJ O
filling NN NN O
defects NNS NNS O
in IN IN O
this DT DT O
patient NN NN O
were VBD VBD O
documented VBN VBN O
by IN IN O
radiography NN NN O
. . . O

There EX EX O
is VBZ VBZ O
no DT DT O
evidence NN NN O
of IN IN O
antecedent NN NN O
or CC CC O
concurrent NN NN O
infection NN NN O
in IN IN O
this DT DT O
patient NN NN O
. . . O

The DT DT O
disease NN NN O
occurred VBD VBD O
subsequent JJ JJ O
to TO TO O
the DT DT O
initiation NN NN O
of IN IN O
heparin NN NN B-CHEM
therapy NN NN O
for IN IN O
suspected VBN VBN O
pelvic JJ JJ O
thrombophlebitis NNS NNS O
and CC CC O
cleared VBD VBD O
rapidly RB RB O
subsequent JJ JJ O
to TO TO O
its PRP$ PRP$ O
discontinuation NN NN O
. . . O

The DT DT O
rate NN NN O
of IN IN O
resolution NN NN O
of IN IN O
the DT DT O
radiographic JJ JJ O
findings NNS NNS O
may MD MD O
be VB VB O
helpful JJ JJ O
in IN IN O
distinguishing VBG VBG O
between IN IN O
true JJ JJ O
pyeloureteritis NNS NNS O
cystica NN NN O
and CC CC O
submucosal NN NN O
hemorrhage NN NN O
. . . O

Nephrotoxic NNP NNP O
effects NNS NNS O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
undergoing VBG VBG O
angiography NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
use NN NN O
of IN IN O
iodinated JJ JJ O
contrast NN NN O
medium NN NN O
can MD MD O
result VB VB O
in IN IN O
nephropathy NN NN O
. . . O

Whether IN IN O
iso NN NN O
- - - O
osmolar JJ JJ O
contrast NN NN O
medium NN NN O
is VBZ VBZ O
less JJR JJR O
nephrotoxic JJ JJ O
than IN IN O
low JJ JJ O
- - - O
osmolar JJ JJ O
contrast NN NN O
medium NN NN O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
is VBZ VBZ O
uncertain JJ JJ O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
conducted VBD VBD O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
prospective JJ JJ O
, , , O
multicenter NN NN O
study NN NN O
comparing VBG VBG O
the DT DT O
nephrotoxic JJ JJ O
effects NNS NNS O
of IN IN O
an DT DT O
iso NN NN O
- - - O
osmolar JJ JJ O
, , , O
dimeric JJ JJ O
, , , O
nonionic JJ JJ O
contrast NN NN O
medium NN NN O
, , , O
iodixanol NN NN B-CHEM
, , , O
with IN IN O
those DT DT O
of IN IN O
a DT DT O
low JJ JJ O
- - - O
osmolar NN NN O
, , , O
nonionic JJ JJ O
, , , O
monomeric JJ JJ O
contrast NN NN O
medium NN NN O
, , , O
iohexol NN NN B-CHEM
. . . O

The DT DT O
study NN NN O
involved VBN VBN O
129 CD CD O
patients NNS NNS O
with IN IN O
diabetes NN NN O
with IN IN O
serum NN NN O
creatinine NN NN B-CHEM
concentrations NNS NNS O
of IN IN O
1 CD CD O
. . . O
5 CD CD O
to TO TO O
3 CD CD O
. . . O
5 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
who WP WP O
underwent VBD VBD O
coronary JJ JJ O
or CC CC O
aortofemoral JJ JJ O
angiography NN NN O
. . . O

The DT DT O
primary JJ JJ O
end NN NN O
point NN NN O
was VBD VBD O
the DT DT O
peak NN NN O
increase NN NN O
from IN IN O
base NN NN O
line NN NN O
in IN IN O
the DT DT O
creatinine NN NN B-CHEM
concentration NN NN O
during IN IN O
the DT DT O
three CD CD O
days NNS NNS O
after IN IN O
angiography NN NN O
. . . O

Other JJ JJ O
end NN NN O
points NNS NNS O
were VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
creatinine NN NN B-CHEM
concentration NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
or CC CC O
more JJR JJR O
, , , O
an DT DT O
increase NN NN O
of IN IN O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
or CC CC O
more JJR JJR O
, , , O
and CC CC O
a DT DT O
change NN NN O
in IN IN O
the DT DT O
creatinine NN NN B-CHEM
concentration NN NN O
from IN IN O
day NN NN O
0 CD CD O
to TO TO O
day NN NN O
7 CD CD O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
creatinine NN NN B-CHEM
concentration NN NN O
increased VBN VBN O
significantly RB RB O
less JJR JJR O
in IN IN O
patients NNS NNS O
who WP WP O
received VBD VBD O
iodixanol NN NN B-CHEM
. . . O

From IN IN O
day NN NN O
0 CD CD O
to TO TO O
day NN NN O
3 CD CD O
, , , O
the DT DT O
mean JJ JJ O
peak NN NN O
increase NN NN O
in IN IN O
creatinine NN NN B-CHEM
was VBD VBD O
0 CD CD O
. . . O
13 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
in IN IN O
the DT DT O
iodixanol NN NN B-CHEM
group NN NN O
and CC CC O
0 CD CD O
. . . O
55 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
in IN IN O
the DT DT O
iohexol NN NN B-CHEM
group NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
; : : O
the DT DT O
increase NN NN O
with IN IN O
iodixanol NN NN B-CHEM
minus CC CC O
the DT DT O
increase NN NN O
with IN IN O
iohexol NN NN B-CHEM
, , , O
- - - O
0 CD CD O
. . . O
42 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
[ NN NN O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
- - - O
0 CD CD O
. . . O
73 CD CD O
to TO TO O
- : : O
0 CD CD O
. . . O
22 CD CD O
] NN NN O
) ) ) O
. . . O

Two CD CD O
of IN IN O
the DT DT O
64 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
iodixanol NN NN B-CHEM
group NN NN O
( ( ( O
3 CD CD O
percent NN NN O
) ) ) O
had VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
creatinine NN NN B-CHEM
concentration NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
or CC CC O
more JJR JJR O
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
17 CD CD O
of IN IN O
the DT DT O
65 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
iohexol NN NN B-CHEM
group NN NN O
( ( ( O
26 CD CD O
percent NN NN O
) ) ) O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
002 CD CD O
; : : O
odds NNS NNS O
ratio NN NN O
for IN IN O
such JJ JJ O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
iodixanol NN NN B-CHEM
group NN NN O
, , , O
0 CD CD O
. . . O
09 CD CD O
[ NN NN O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
0 CD CD O
. . . O
02 CD CD O
to TO TO O
0 CD CD O
. . . O
41 CD CD O
] NN NN O
) ) ) O
. . . O

No DT DT O
patient NN NN O
receiving VBG VBG O
iodixanol NN NN B-CHEM
had VBD VBD O
an DT DT O
increase NN NN O
of IN IN O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
or CC CC O
more JJR JJR O
, , , O
but CC CC O
10 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
iohexol NN NN B-CHEM
group NN NN O
( ( ( O
15 CD CD O
percent NN NN O
) ) ) O
did VBD VBD O
. . . O

The DT DT O
mean NN NN O
change NN NN O
in IN IN O
the DT DT O
creatinine NN NN B-CHEM
concentration NN NN O
from IN IN O
day NN NN O
0 CD CD O
to TO TO O
day NN NN O
7 CD CD O
was VBD VBD O
0 CD CD O
. . . O
07 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
in IN IN O
the DT DT O
iodixanol NN NN B-CHEM
group NN NN O
and CC CC O
0 CD CD O
. . . O
24 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
in IN IN O
the DT DT O
iohexol NN NN B-CHEM
group NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
003 CD CD O
; : : O
value NN NN O
in IN IN O
the DT DT O
iodixanol NN NN B-CHEM
group NN NN O
minus CC CC O
the DT DT O
value NN NN O
in IN IN O
the DT DT O
iohexol NN NN B-CHEM
group NN NN O
, , , O
- - - O
0 CD CD O
. . . O
17 CD CD O
mg NN NN O
per IN IN O
deciliter NN NN O
[ NN NN O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
- - - O
0 CD CD O
. . . O
34 CD CD O
to TO TO O
- : : O
0 CD CD O
. . . O
07 CD CD O
] NN NN O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Nephropathy NNP NNP O
induced VBN VBN O
by IN IN O
contrast NN NN O
medium NN NN O
may MD MD O
be VB VB O
less RBR RBR O
likely JJ JJ O
to TO TO O
develop VB VB O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
when WRB WRB O
iodixanol NN NN B-CHEM
is VBZ VBZ O
used VBN VBN O
rather RB RB O
than IN IN O
a DT DT O
low JJ JJ O
- - - O
osmolar NN NN O
, , , O
nonionic JJ JJ O
contrast NN NN O
medium NN NN O
. . . O

Protective JJ JJ O
effect NN NN O
of IN IN O
edaravone NN NN B-CHEM
against IN IN O
streptomycin NN NN B-CHEM
- - - O
induced JJ JJ O
vestibulotoxicity NN NN O
in IN IN O
the DT DT O
guinea NN NN O
pig NN NN O
. . . O

This DT DT O
study NN NN O
investigated JJ JJ O
alleviation NN NN O
of IN IN O
streptomycin NN NN B-CHEM
- - - O
induced JJ JJ O
vestibulotoxicity NN NN O
by IN IN O
edaravone NN NN B-CHEM
in IN IN O
guinea NN NN O
pigs NNS NNS O
. . . O

Edaravone NNP NNP B-CHEM
, , , O
a DT DT O
free JJ JJ O
radical JJ JJ O
scavenger NN NN O
, , , O
has VBZ VBZ O
potent JJ JJ O
free JJ JJ O
radical JJ JJ O
quenching VBG VBG O
action NN NN O
and CC CC O
is VBZ VBZ O
used VBN VBN O
in IN IN O
clinical JJ JJ O
practice NN NN O
to TO TO O
treat VB VB O
cerebral JJ JJ O
infarction NN NN O
. . . O

Streptomycin NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
to TO TO O
the DT DT O
inner NN NN O
ear NN NN O
by IN IN O
osmotic JJ JJ O
pump NN NN O
for IN IN O
24 CD CD O
h NN NN O
, , , O
and CC CC O
edaravone NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
or CC CC O
saline NN NN O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
was VBD VBD O
intraperitoneally RB RB O
injected VBN VBN O
once RB RB O
a DT DT O
day NN NN O
for IN IN O
7 CD CD O
days NNS NNS O
. . . O

We PRP PRP O
observed VBD VBD O
horizontal NN NN O
vestibulo NN NN O
- : : O
ocular JJ JJ O
reflex NN NN O
as IN IN O
a DT DT O
marker NN NN O
of IN IN O
postoperative JJ JJ O
vestibular NN NN O
function NN NN O
. . . O

Animals NNS NNS O
injected VBN VBN O
with IN IN O
saline NN NN O
showed VBD VBD O
statistically RB RB O
smaller JJR JJR O
gains NNS NNS O
than IN IN O
those DT DT O
injected VBN VBN O
with IN IN O
edaravone NN NN B-CHEM
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
edaravone NN NN B-CHEM
suppresses NNS NNS O
streptomycin NN NN B-CHEM
- : : O
induced JJ JJ O
vestibulotoxicity NN NN O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
oromandibular NN NN O
dystonia NN NN O
in IN IN O
progressive JJ JJ O
supranuclear NN NN O
palsy NN NN O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesias NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
and CC CC O
multiple JJ JJ O
system NN NN O
atrophy NN NN O
. . . O

Cranial NNP NNP O
dystonias NNS NNS O
are VBP VBP O
rare JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
progressive JJ JJ O
supranuclear NN NN O
palsy NN NN O
( ( ( O
PSP NNP NNP O
) ) ) O
. . . O

In IN IN O
this DT DT O
report NN NN O
we PRP PRP O
describe VBP VBP O
an DT DT O
unusual JJ JJ O
case NN NN O
of IN IN O
reversible JJ JJ O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
Oromandibular NNP NNP O
dystonia NN NN O
( ( ( O
OMD NNP NNP O
) ) ) O
in IN IN O
a DT DT O
PSP NNP NNP O
patient NN NN O
to TO TO O
highlight VB VB O
the DT DT O
importance NN NN O
of IN IN O
recognizing VBG VBG O
this DT DT O
drug NN NN O
related VBN VBN O
complication NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
PSP NNP NNP O
, , , O
and CC CC O
discuss VB VB O
the DT DT O
possible JJ JJ O
underlying VBG VBG O
pathophysiology NN NN O
. . . O

Case NN NN O
report NN NN O
: : : O
Dexatrim NNP NNP B-CHEM
( ( ( O
Phenylpropanolamine NNP NNP B-CHEM
) ) ) O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
. . . O

Phenylpropanolamine NNP NNP B-CHEM
( ( ( O
PPA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
sympathetic JJ JJ O
amine NN NN B-CHEM
used VBN VBN O
in IN IN O
over IN IN O
- - - O
the DT DT O
- - - O
counter NN NN O
cold JJ JJ O
remedies NNS NNS O
and CC CC O
weight NN NN O
- - - O
control NN NN O
preparations NNS NNS O
worldwide NN NN O
. . . O

Its PRP$ PRP$ O
use NN NN O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
hypertensive JJ JJ O
episodes NNS NNS O
and CC CC O
hemorrhagic JJ JJ O
strokes NNS NNS O
in IN IN O
younger JJR JJR O
women NNS NNS O
. . . O

Several JJ JJ O
reports NNS NNS O
have VBP VBP O
linked VBN VBN O
the DT DT O
abuse NN NN O
of IN IN O
PPA NNP NNP B-CHEM
with IN IN O
myocardial JJ JJ O
injury NN NN O
, , , O
especially RB RB O
when WRB WRB O
overdose NN NN O
is VBZ VBZ O
involved VBN VBN O
. . . O

We PRP PRP O
report VBP VBP O
here RB RB O
the DT DT O
first JJ JJ O
case NN NN O
of IN IN O
Dexatrim NNP NNP B-CHEM
( ( ( O
PPA NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
myocardial NN NN O
injury NN NN O
in IN IN O
a DT DT O
young JJ JJ O
woman NN NN O
who WP WP O
was VBD VBD O
using VBG VBG O
it PRP PRP O
at IN IN O
recommended JJ JJ O
doses NNS NNS O
for IN IN O
weight NN NN O
control NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
we PRP PRP O
review VBP VBP O
the DT DT O
7 CD CD O
other JJ JJ O
cases NNS NNS O
of IN IN O
PPA NNP NNP B-CHEM
related VBD VBD O
myocardial JJ JJ O
injury NN NN O
that WDT WDT O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
so RB RB O
far RB RB O
. . . O

Physicians NNP NNP O
and CC CC O
patients NNS NNS O
should MD MD O
be VB VB O
alert VB VB O
to TO TO O
the DT DT O
potential JJ JJ O
cardiac NN NN O
risk NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
PPA NNP NNP B-CHEM
, , , O
even RB RB O
at IN IN O
doses NNS NNS O
generally RB RB O
considered VBN VBN O
to TO TO O
be VB VB O
safe JJ JJ O
. . . O

Differential NNP NNP O
diagnosis NN NN O
of IN IN O
high JJ JJ O
serum NN NN O
creatine NN NN B-CHEM
kinase NN NN O
levels NNS NNS O
in IN IN O
systemic JJ JJ O
lupus NN NN O
erythematosus NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
clinical JJ JJ O
and CC CC O
bioptic JJ JJ O
findings NNS NNS O
for IN IN O
a DT DT O
57 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
severe JJ JJ O
chloroquine NN NN B-CHEM
- - - O
induced JJ JJ O
myopathy NN NN O
. . . O

Since IN IN O
1989 CD CD O
, , , O
she PRP PRP O
had VBD VBD O
been VBN VBN O
suffering VBG VBG O
from IN IN O
systemic JJ JJ O
lupus NN NN O
erythematosus NN NN O
( ( ( O
SLE NNP NNP O
) ) ) O
with IN IN O
renal JJ JJ O
involvement NN NN O
and CC CC O
undergone JJ JJ O
periods NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
azathioprine NN NN B-CHEM
and CC CC O
cyclophosphamide NN NN B-CHEM
. . . O

Additional JJ JJ O
therapy NN NN O
with IN IN O
chloroquine NN NN B-CHEM
( ( ( O
CQ NNP NNP B-CHEM
) ) ) O
was VBD VBD O
started VBN VBN O
because IN IN O
of IN IN O
arthralgia NN NN O
. . . O

At IN IN O
the DT DT O
same JJ JJ O
time NN NN O
, , , O
slightly RB RB O
increased VBN VBN O
creatine NN NN B-CHEM
kinase NN NN O
( ( ( O
CK NNP NNP O
) ) ) O
levels NNS NNS O
were VBD VBD O
noted VBN VBN O
. . . O

Myositis NNP NNP O
was VBD VBD O
suspected VBN VBN O
, , , O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
steroids NNS NNS B-CHEM
. . . O

The DT DT O
CK NNP NNP O
increase NN NN O
persisted VBD VBD O
, , , O
however RB RB O
, , , O
and CC CC O
she PRP PRP O
developed VBD VBD O
progressive JJ JJ O
muscular JJ JJ O
weakness NN NN O
and CC CC O
muscular JJ JJ O
atrophy NN NN O
. . . O

Routine NNP NNP O
controls NNS NNS O
revealed VBD VBD O
markedly RB RB O
elevated VBD VBD O
CK NNP NNP O
levels NNS NNS O
of IN IN O
1 CD CD O
, , , O
700 CD CD O
U NNP NNP O
/ NN NN O
l NN NN O
. . . O

The DT DT O
neurological JJ JJ O
and CC CC O
electrophysiological JJ JJ O
findings NNS NNS O
were VBD VBD O
not RB RB O
typical JJ JJ O
of IN IN O
myositis NNS NNS O
. . . O

Thus RB RB O
, , , O
muscle NN NN O
biopsy NN NN O
of IN IN O
the DT DT O
deltoid NN NN O
muscle NN NN O
was VBD VBD O
performed VBN VBN O
in IN IN O
order NN NN O
to TO TO O
exclude VB VB O
polymyositis NN NN O
or CC CC O
toxic JJ JJ O
myopathy NN NN O
. . . O

As IN IN O
it PRP PRP O
revealed VBD VBD O
chloroquine JJ JJ B-CHEM
- : : O
induced JJ JJ O
myopathy NN NN O
, , , O
medication NN NN O
was VBD VBD O
stopped VBN VBN O
. . . O

Discriminating NNP NNP O
between IN IN O
primary JJ JJ O
SLE NNP NNP O
- : : O
induced JJ JJ O
affection NN NN O
of IN IN O
the DT DT O
musculoskeletal JJ JJ O
system NN NN O
and CC CC O
drug NN NN O
- - - O
induced JJ JJ O
side NN NN O
effects NNS NNS O
is VBZ VBZ O
important JJ JJ O
for IN IN O
appropriate JJ JJ O
treatment NN NN O
of IN IN O
SLE NNP NNP O
patients NNS NNS O
. . . O

Seizure NNP NNP O
associated VBN VBN O
with IN IN O
sleep NN NN O
deprivation NN NN O
and CC CC O
sustained VBD VBD O
- : : O
release NN NN O
bupropion NN NN B-CHEM
. . . O

This DT DT O
case NN NN O
report NN NN O
describes VBZ VBZ O
a DT DT O
generalized JJ JJ O
seizure NN NN O
associated VBN VBN O
with IN IN O
sustained JJ JJ O
- - - O
release NN NN O
bupropion NN NN B-CHEM
use NN NN O
and CC CC O
sleep VB VB O
deprivation NN NN O
. . . O

The DT DT O
subject NN NN O
, , , O
a DT DT O
31 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female JJ JJ O
smoker NN NN O
, , , O
was VBD VBD O
participating VBG VBG O
in IN IN O
a DT DT O
clinical JJ JJ O
trial NN NN O
evaluating VBG VBG O
an DT DT O
investigational JJ JJ O
medication NN NN O
for IN IN O
smoking NN NN O
cessation NN NN O
that WDT WDT O
used VBD VBD O
sustained JJ JJ O
- - - O
release NN NN O
bupropion NN NN B-CHEM
as IN IN O
an DT DT O
active JJ JJ O
control NN NN O
. . . O

After IN IN O
5 CD CD O
weeks NNS NNS O
of IN IN O
bupropion NN NN B-CHEM
use NN NN O
, , , O
the DT DT O
subject NN NN O
experienced VBD VBD O
a DT DT O
generalized JJ JJ O
tonic NN NN O
clonic JJ JJ O
seizure NN NN O
after IN IN O
staying VBG VBG O
up RP RP O
nearly RB RB O
all DT DT O
night NN NN O
packing VBG VBG O
and CC CC O
moving VBG VBG O
to TO TO O
a DT DT O
new JJ JJ O
residence NN NN O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
no DT DT O
other JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
seizures NNS NNS O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
sleep VBP VBP O
deprivation NN NN O
may MD MD O
add VB VB O
to TO TO O
the DT DT O
risk NN NN O
of IN IN O
bupropion NN NN B-CHEM
- - - O
associated VBN VBN O
seizures NNS NNS O
. . . O

Postoperative NNP NNP O
myalgia NN NN O
after IN IN O
succinylcholine NN NN B-CHEM
: : : O
no DT DT O
evidence NN NN O
for IN IN O
an DT DT O
inflammatory JJ JJ O
origin NN NN O
. . . O

A DT DT O
common JJ JJ O
side NN NN O
effect NN NN O
associated VBN VBN O
with IN IN O
succinylcholine NN NN B-CHEM
is VBZ VBZ O
postoperative JJ JJ O
myalgia NN NN O
. . . O

The DT DT O
pathogenesis NNS NNS O
of IN IN O
this DT DT O
myalgia NN NN O
is VBZ VBZ O
still RB RB O
unclear JJ JJ O
; : : O
inflammation NN NN O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
but CC CC O
without IN IN O
convincing VBG VBG O
evidence NN NN O
. . . O

We PRP PRP O
designed VBD VBD O
the DT DT O
present JJ JJ O
study NN NN O
to TO TO O
investigate VB VB O
whether IN IN O
an DT DT O
inflammatory JJ JJ O
reaction NN NN O
contributes VBZ VBZ O
to TO TO O
this DT DT O
myalgia NN NN O
. . . O

The DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
- - - O
associated VBN VBN O
myalgia NN NN O
was VBD VBD O
determined VBN VBN O
in IN IN O
64 CD CD O
patients NNS NNS O
pretreated VBN VBN O
with IN IN O
saline NN NN O
or CC CC O
dexamethasone NN NN B-CHEM
before IN IN O
succinylcholine NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
32 CD CD O
for IN IN O
each DT DT O
) ) ) O
. . . O

Incidence NNP NNP O
and CC CC O
severity NN NN O
of IN IN O
myalgia NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
: : : O
15 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
dexamethasone NN NN B-CHEM
group NN NN O
complained VBD VBD O
of IN IN O
myalgia NN NN O
compared VBN VBN O
with IN IN O
18 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
saline NN NN O
group NN NN O
, , , O
and CC CC O
severe JJ JJ O
myalgia NN NN O
was VBD VBD O
reported VBN VBN O
by IN IN O
five CD CD O
patients NNS NNS O
and CC CC O
three CD CD O
patients NNS NNS O
, , , O
respectively RB RB O
( ( ( O
not RB RB O
significant JJ JJ O
) ) ) O
. . . O

At IN IN O
48 CD CD O
h NN NN O
after IN IN O
surgery NN NN O
, , , O
12 CD CD O
patients NNS NNS O
in IN IN O
both DT DT O
groups NNS NNS O
still RB RB O
suffered VBN VBN O
from IN IN O
myalgia NN NN O
( ( ( O
not RB RB O
significant JJ JJ O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
interleukin NN NN O
- : : O
6 CD CD O
( ( ( O
IL NNP NNP O
- - - O
6 CD CD O
) ) ) O
as IN IN O
an DT DT O
early JJ JJ O
marker NN NN O
of IN IN O
inflammation NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
a DT DT O
subgroup NN NN O
of IN IN O
10 CD CD O
patients NNS NNS O
pretreated VBN VBN O
with IN IN O
saline NN NN O
. . . O

We PRP PRP O
found VBD VBD O
an DT DT O
increase NN NN O
of IN IN O
IL NNP NNP O
- : : O
6 CD CD O
for IN IN O
only RB RB O
three CD CD O
patients NNS NNS O
, , , O
but CC CC O
only RB RB O
one CD CD O
patient NN NN O
reported VBD VBD O
myalgia NN NN O
; : : O
no DT DT O
relationship NN NN O
between IN IN O
myalgia NN NN O
and CC CC O
the DT DT O
increase NN NN O
of IN IN O
IL NNP NNP O
- : : O
6 CD CD O
was VBD VBD O
found VBN VBN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
there EX EX O
is VBZ VBZ O
no DT DT O
evidence NN NN O
for IN IN O
an DT DT O
inflammatory JJ JJ O
origin NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
- - - O
associated VBN VBN O
myalgia NN NN O
. . . O

IMPLICATIONS NNP NNP O
: : : O
Administration NNP NNP O
of IN IN O
dexamethasone NN NN B-CHEM
before IN IN O
succinylcholine NN NN B-CHEM
was VBD VBD O
not RB RB O
effective JJ JJ O
in IN IN O
decreasing VBG VBG O
the DT DT O
incidence NN NN O
or CC CC O
the DT DT O
severity NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
- - - O
induced JJ JJ O
postoperative JJ JJ O
myalgia NN NN O
. . . O

Furthermore RB RB O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
relationship NN NN O
between IN IN O
postoperative JJ JJ O
myalgia NN NN O
and CC CC O
time NN NN O
course NN NN O
of IN IN O
interleukin NN NN O
- - - O
6 CD CD O
concentrations NNS NNS O
, , , O
a DT DT O
marker NN NN O
of IN IN O
inflammation NN NN O
. . . O

Pretreatment NNP NNP O
with IN IN O
dexamethasone NN NN B-CHEM
is VBZ VBZ O
not RB RB O
justified VBN VBN O
to TO TO O
prevent VB VB O
postoperative JJ JJ O
myalgia NN NN O
after IN IN O
succinylcholine NN NN B-CHEM
. . . O

Effect NN NN O
of IN IN O
lindane NN NN B-CHEM
on IN IN O
hepatic JJ JJ O
and CC CC O
brain NN NN O
cytochrome NN NN O
P450s NNP NNP O
and CC CC O
influence NN NN O
of IN IN O
P450 NNP NNP O
modulation NN NN O
in IN IN O
lindane NN NN B-CHEM
induced JJ JJ O
neurotoxicity NN NN O
. . . O

Oral NNP NNP O
administration NN NN O
of IN IN O
lindane NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
, , , O
5 CD CD O
, , , O
10 CD CD O
and CC CC O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
body NN NN O
weight NN NN O
) ) ) O
for IN IN O
5 CD CD O
days NNS NNS O
was VBD VBD O
found VBN VBN O
to TO TO O
produce VB VB O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
activity NN NN O
of IN IN O
P450 NNP NNP O
dependent JJ JJ O
7 CD CD O
- : : O
ethoxyresorufin NN NN O
- - - O
O NNP NNP O
- : : O
deethylase NN NN O
( ( ( O
EROD NNP NNP O
) ) ) O
, , , O
7 CD CD O
- : : O
pentoxyresorufin NN NN O
- - - O
O NNP NNP O
- : : O
dealkylase NN NN O
( ( ( O
PROD NNP NNP O
) ) ) O
and CC CC O
N NNP NNP B-CHEM
- : : I-CHEM
nitrosodimethylamine NN NN I-CHEM
demethylase NN NN O
( ( ( O
NDMA NNP NNP B-CHEM
- - - O
d SYM SYM O
) ) ) O
in IN IN O
rat NN NN O
brain NN NN O
and CC CC O
liver NN NN O
. . . O

A DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
hepatic JJ JJ O
and CC CC O
brain NN NN O
P450 NNP NNP O
monooxygenases NNS NNS O
was VBD VBD O
also RB RB O
observed VBN VBN O
when WRB WRB O
the DT DT O
duration NN NN O
of IN IN O
exposure NN NN O
of IN IN O
low JJ JJ O
dose NN NN O
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
of IN IN O
lindane NN NN B-CHEM
was VBD VBD O
increased VBN VBN O
from IN IN O
5 CD CD O
days NNS NNS O
to TO TO O
15 CD CD O
or CC CC O
21 CD CD O
days NNS NNS O
. . . O

As IN IN O
observed VBN VBN O
with IN IN O
different JJ JJ O
doses NNS NNS O
, , , O
the DT DT O
magnitude NN NN O
of IN IN O
induction NN NN O
in IN IN O
the DT DT O
activity NN NN O
of IN IN O
P450 NNP NNP O
monooxygenases NNS NNS O
was VBD VBD O
several JJ JJ O
fold VB VB O
higher JJR JJR O
in IN IN O
liver NN NN O
microsomes NNS NNS O
when WRB WRB O
compared VBN VBN O
with IN IN O
the DT DT O
brain NN NN O
. . . O

Western JJ JJ O
blotting NN NN O
studies NNS NNS O
have VBP VBP O
indicated VBN VBN O
that IN IN O
the DT DT O
increase NN NN O
in IN IN O
the DT DT O
P450 NNP NNP O
enzymes NNS NNS O
could MD MD O
be VB VB O
due JJ JJ O
to TO TO O
the DT DT O
increase NN NN O
in IN IN O
the DT DT O
expression NN NN O
of IN IN O
P450 NNP NNP O
1A1 CD CD O
/ NN NN O
1A2 CD CD O
, , , O
2B1 CD CD O
/ NN NN O
2B2 CD CD O
and CC CC O
2E1 CD CD O
isoenzymes NNS NNS O
. . . O

In IN IN O
vitro NN NN O
studies NNS NNS O
using VBG VBG O
organic JJ JJ O
inhibitors NNS NNS O
specific JJ JJ O
for IN IN O
individual JJ JJ O
P450 NNP NNP O
isoenzymes NNS NNS O
and CC CC O
antibody NN NN O
inhibition NN NN O
experiments NNS NNS O
have VBP VBP O
further RBR RBR O
demonstrated VBN VBN O
that IN IN O
the DT DT O
increase NN NN O
in IN IN O
the DT DT O
activity NN NN O
of IN IN O
PROD NNP NNP O
, , , O
EROD NNP NNP O
and CC CC O
NDMA NNP NNP B-CHEM
- : : O
d SYM SYM O
are VBP VBP O
due JJ JJ O
to TO TO O
the DT DT O
increase NN NN O
in IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
P450 NNP NNP O
2B1 CD CD O
/ NN NN O
2B2 CD CD O
, , , O
1A1 CD CD O
/ NN NN O
1A2 CD CD O
and CC CC O
2E1 CD CD O
isoenzymes NNS NNS O
, , , O
respectively RB RB O
. . . O

Induction NNP NNP O
studies NNS NNS O
have VBP VBP O
further RBR RBR O
shown VBN VBN O
that IN IN O
while IN IN O
pretreatment NN NN O
of IN IN O
3 CD CD B-CHEM
- : : I-CHEM
methylcholanthrene NN NN I-CHEM
( ( ( O
MC NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
inducer NN NN O
of IN IN O
P4501A1 NNP NNP O
/ NN NN O
1A2 CD CD O
, , , O
did VBD VBD O
not RB RB O
produce VB VB O
any DT DT O
significant JJ JJ O
effect NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
lindane NN NN B-CHEM
induced JJ JJ O
convulsions NNS NNS O
, , , O
pretreatment NN NN O
with IN IN O
phenobarbital NN NN B-CHEM
( ( ( O
PB NNP NNP O
) ) ) O
, , , O
an DT DT O
inducer NN NN O
of IN IN O
P450 NNP NNP O
2B1 CD CD O
/ NN NN O
2B2 CD CD O
or CC CC O
ethanol NN NN B-CHEM
, , , O
an DT DT O
inducer NN NN O
of IN IN O
P450 NNP NNP O
2E1 CD CD O
catalysed VBN VBN O
reactions NNS NNS O
, , , O
significantly RB RB O
increased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
lindane NN NN B-CHEM
induced JJ JJ O
convulsions NNS NNS O
. . . O

Similarly RB RB O
, , , O
when WRB WRB O
the DT DT O
P450 NNP NNP O
- - - O
mediated JJ JJ O
metabolism NN NN O
of IN IN O
lindane NN NN B-CHEM
was VBD VBD O
blocked VBN VBN O
by IN IN O
cobalt NN NN B-CHEM
chloride NN NN I-CHEM
incidence NN NN O
of IN IN O
convulsions NNS NNS O
was VBD VBD O
increased VBN VBN O
in IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
lindane NN NN B-CHEM
indicating VBG VBG O
that IN IN O
lindane NN NN B-CHEM
per IN IN O
se FW FW O
or CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
formed VBN VBN O
by IN IN O
PB NNP NNP O
or CC CC O
ethanol NN NN B-CHEM
inducible JJ JJ O
P450 NNP NNP O
isoenzymes NNS NNS O
are VBP VBP O
involved VBN VBN O
in IN IN O
its PRP$ PRP$ O
neurobehavioral JJ JJ O
toxicity NN NN O
. . . O

Absolute NNP NNP O
and CC CC O
attributable JJ JJ O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
in IN IN O
women NNS NNS O
on IN IN O
combined VBN VBN O
cyproterone NN NN B-CHEM
acetate NN NN I-CHEM
and CC CC O
ethinylestradiol NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
achieve VB VB O
absolute JJ JJ O
risk NN NN O
estimates NNS NNS O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
( ( ( O
VTE NNP NNP O
) ) ) O
among IN IN O
women NNS NNS O
on IN IN O
cyproterone NN NN B-CHEM
acetate NN NN I-CHEM
plus CC CC O
ethinylestradiol NN NN B-CHEM
( ( ( O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
among IN IN O
women NNS NNS O
on IN IN O
combined VBN VBN B-CHEM
oral JJ JJ I-CHEM
contraceptives NNS NNS I-CHEM
( ( ( O
COCs NNP NNP B-CHEM
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
From IN IN O
the DT DT O
Danish NNP NNP O
National NNP NNP O
Register NNP NNP O
of IN IN O
Patients NNS NNS O
( ( ( O
NRP NNP NNP O
) ) ) O
, , , O
1996 CD CD O
to TO TO O
1998 CD CD O
, , , O
the DT DT O
records NNS NNS O
of IN IN O
1 CD CD O
. . . O
1 CD CD O
million CD CD O
Danish JJ JJ O
women NNS NNS O
, , , O
ages NNS NNS O
15 CD CD O
to TO TO O
44 CD CD O
years NNS NNS O
, , , O
were VBD VBD O
searched VBN VBN O
for IN IN O
evidence NN NN O
of IN IN O
VTE NNP NNP O
. . . O

COC NNP NNP B-CHEM
use NN NN O
was VBD VBD O
ascertained VBN VBN O
through IN IN O
mailed JJ JJ O
questionnaires NNS NNS O
. . . O

Sales NNS NNS O
statistics NNS NNS O
of IN IN O
COCs NNP NNP B-CHEM
and CC CC O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
were VBD VBD O
provided VBN VBN O
through IN IN O
Danish JJ JJ O
Drug NN NN O
Statistics NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
During IN IN O
the DT DT O
time NN NN O
frame NN NN O
of IN IN O
the DT DT O
study NN NN O
, , , O
330 CD CD O
women NNS NNS O
were VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
had VBN VBN O
VTE NNP NNP O
while IN IN O
on IN IN O
COCs NNP NNP B-CHEM
. . . O

Of IN IN O
these DT DT O
women NNS NNS O
, , , O
67 CD CD O
were VBD VBD O
on IN IN O
levonorgestrel NN NN B-CHEM
- : : O
containing VBG VBG O
COCs NNP NNP B-CHEM
. . . O

Eleven NNP NNP O
were VBD VBD O
on IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
. . . O

The DT DT O
corresponding JJ JJ O
absolute JJ JJ O
risk NN NN O
of IN IN O
VTE NNP NNP O
was VBD VBD O
3 CD CD O
. . . O
4 CD CD O
( ( ( O
range NN NN O
, , , O
3 CD CD O
. . . O
1 CD CD O
- : : O
3 CD CD O
. . . O
8 CD CD O
) ) ) O
per IN IN O
10 CD CD O
000 CD CD O
women NNS NNS O
years NNS NNS O
among IN IN O
the DT DT O
women NNS NNS O
on IN IN O
COCs NNP NNP B-CHEM
, , , O
4 CD CD O
. . . O
2 CD CD O
( ( ( O
range NN NN O
, , , O
3 CD CD O
. . . O
2 CD CD O
- : : O
5 CD CD O
. . . O
2 CD CD O
) ) ) O
per IN IN O
10 CD CD O
000 CD CD O
women NNS NNS O
years NNS NNS O
among IN IN O
women NNS NNS O
on IN IN O
levonorgestrel NN NN B-CHEM
- : : O
containing VBG VBG O
COCs NNP NNP B-CHEM
, , , O
and CC CC O
3 CD CD O
. . . O
1 CD CD O
( ( ( O
range NN NN O
, , , O
1 CD CD O
. . . O
3 CD CD O
- : : O
4 CD CD O
. . . O
9 CD CD O
) ) ) O
per IN IN O
10 CD CD O
000 CD CD O
women NNS NNS O
years NNS NNS O
among IN IN O
the DT DT O
women NNS NNS O
on IN IN O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
the DT DT O
absolute JJ JJ O
risk NN NN O
of IN IN O
VTE NNP NNP O
among IN IN O
Danish JJ JJ O
women NNS NNS O
on IN IN O
COCs NNP NNP B-CHEM
is VBZ VBZ O
similar JJ JJ O
to TO TO O
that DT DT O
among IN IN O
women NNS NNS O
taking VBG VBG O
CPA NNP NNP B-CHEM
/ NN NN O
EE NNP NNP B-CHEM
. . . O

Comparison NNP NNP O
of IN IN O
developmental NN NN O
toxicology NN NN O
of IN IN O
aspirin NN NN B-CHEM
( ( ( O
acetylsalicylic JJ JJ B-CHEM
acid NN NN I-CHEM
) ) ) O
in IN IN O
rats NNS NNS O
using VBG VBG O
selected VBN VBN O
dosing VBG VBG O
paradigms NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Analysis NNP NNP O
of IN IN O
the DT DT O
literature NN NN O
for IN IN O
nonsteroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAIDs NNP NNP O
) ) ) O
suggests VBZ VBZ O
that IN IN O
a DT DT O
low JJ JJ O
incidence NN NN O
of IN IN O
developmental NN NN O
anomalies NNS NNS O
occurs VBZ VBZ O
in IN IN O
rats NNS NNS O
given VBN VBN O
NSAIDs NNP NNP O
on IN IN O
specific JJ JJ O
days NNS NNS O
during IN IN O
organogenesis NN NN O
. . . O

Aspirin NNP NNP B-CHEM
( ( ( O
acetylsalicylic JJ JJ B-CHEM
acid NN NN I-CHEM
[ NN NN O
ASA NNP NNP B-CHEM
] NN NN O
) ) ) O
, , , O
an DT DT O
irreversible JJ JJ O
cyclooxygenase NN NN O
1 CD CD O
and CC CC O
2 CD CD O
inhibitor NN NN O
, , , O
induces NNS NNS O
developmental NN NN O
anomalies NNS NNS O
when WRB WRB O
administered VBN VBN O
to TO TO O
Wistar NNP NNP O
rats NNS NNS O
on IN IN O
gestational JJ JJ O
day NN NN O
( ( ( O
GD NNP NNP O
) ) ) O
9 CD CD O
, , , O
10 CD CD O
, , , O
or CC CC O
11 CD CD O
( ( ( O
Kimmel NNP NNP O
CA NNP NNP O
, , , O
Wilson NNP NNP O
JG NNP NNP O
, , , O
Schumacher NNP NNP O
HJ NNP NNP O
. . . O
Teratology NNP NNP O
4 CD CD O
: : : O
15 CD CD O
- : : O
24 CD CD O
, , , O
1971 CD CD O
) ) ) O
. . . O

There EX EX O
are VBP VBP O
no DT DT O
published VBN VBN O
ASA NNP NNP B-CHEM
studies NNS NNS O
using VBG VBG O
the DT DT O
multiple JJ JJ O
dosing VBG VBG O
paradigm NN NN O
of IN IN O
GDs NNP NNP O
6 CD CD O
to TO TO O
17 CD CD O
. . . O

Objectives NNP NNP O
of IN IN O
the DT DT O
current JJ JJ O
study NN NN O
were VBD VBD O
to TO TO O
compare VB VB O
results NNS NNS O
between IN IN O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
( ( ( O
SD NNP NNP O
) ) ) O
and CC CC O
Wistar NNP NNP O
strains NNS NNS O
when WRB WRB O
ASA NNP NNP B-CHEM
is VBZ VBZ O
administered VBN VBN O
on IN IN O
GD NNP NNP O
9 CD CD O
, , , O
10 CD CD O
, , , O
or CC CC O
11 CD CD O
; : : O
to TO TO O
compare VB VB O
the DT DT O
malformation NN NN O
patterns NNS NNS O
following VBG VBG O
single NN NN O
and CC CC O
multiple JJ JJ O
dosings NNS NNS O
during IN IN O
organogenesis NN NN O
in IN IN O
SD NNP NNP O
rats NNS NNS O
; : : O
and CC CC O
to TO TO O
test VB VB O
the DT DT O
hypothesis NNS NNS O
that IN IN O
maternal JJ JJ O
gastrointestinal JJ JJ O
toxicity NN NN O
confounds VBZ VBZ O
the DT DT O
detection NN NN O
of IN IN O
low JJ JJ O
incidence NN NN O
malformations NNS NNS O
with IN IN O
ASA NNP NNP B-CHEM
when WRB WRB O
a DT DT O
multiple JJ JJ O
dosing VBG VBG O
paradigm NN NN O
is VBZ VBZ O
used VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
ASA NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
as IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
on IN IN O
GD NNP NNP O
9 CD CD O
( ( ( O
0 CD CD O
, , , O
250 CD CD O
, , , O
500 CD CD O
, , , O
or CC CC O
625 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
10 CD CD O
( ( ( O
0 CD CD O
, , , O
500 CD CD O
, , , O
625 CD CD O
, , , O
or CC CC O
750 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
or CC CC O
11 CD CD O
( ( ( O
0 CD CD O
, , , O
500 CD CD O
, , , O
750 CD CD O
, , , O
or CC CC O
1000 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
from IN IN O
GD NNP NNP O
6 CD CD O
to TO TO O
GD NNP NNP O
17 CD CD O
( ( ( O
0 CD CD O
, , , O
50 CD CD O
, , , O
125 CD CD O
, , , O
or CC CC O
250 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
a DT DT O
day NN NN O
) ) ) O
in IN IN O
the DT DT O
multiple JJ JJ O
dose NN NN O
study NN NN O
to TO TO O
SD NNP NNP O
rats NNS NNS O
. . . O

Animals NNS NNS O
were VBD VBD O
killed VBN VBN O
on IN IN O
GD NNP NNP O
21 CD CD O
, , , O
and CC CC O
fetuses NNS NNS O
were VBD VBD O
examined VBN VBN O
viscerally RB RB O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
literature NN NN O
evaluation NN NN O
suggested VBD VBD O
that IN IN O
NSAIDs NNP NNP O
induce NN NN O
ventricular JJ JJ O
septal NN NN O
defects NNS NNS O
( ( ( O
VSDs NNP NNP O
) ) ) O
and CC CC O
midline NN NN O
defects NNS NNS O
( ( ( O
MDs NNP NNP O
) ) ) O
in IN IN O
rats NNS NNS O
and CC CC O
diaphragmatic JJ JJ O
hernia NN NN O
( ( ( O
DH NNP NNP O
) ) ) O
, , , O
MDs NNP NNP O
, , , O
and CC CC O
VSDs NNP NNP O
in IN IN O
rabbits NNS NNS O
( ( ( O
Cook NNP NNP O
JC NNP NNP O
et CC CC O
al NN NN O
. . . O
, , , O
2003 CD CD O
) ) ) O
; : : O
hence RB RB O
, , , O
the DT DT O
present JJ JJ O
study NN NN O
focused VBN VBN O
on IN IN O
these DT DT O
malformations NNS NNS O
, , , O
even RB RB O
though IN IN O
ASA NNP NNP B-CHEM
induces NNS NNS O
several JJ JJ O
other JJ JJ O
low JJ JJ O
- - - O
incidence NN NN O
malformations NNS NNS O
. . . O

In IN IN O
single JJ JJ O
dose NN NN O
studies NNS NNS O
, , , O
DH NNP NNP O
, , , O
MD NNP NNP O
, , , O
and CC CC O
VSD NNP NNP O
were VBD VBD O
induced VBN VBN O
on IN IN O
GDs NNP NNP O
9 CD CD O
and CC CC O
10 CD CD O
. . . O

VSD NNP NNP O
also RB RB O
was VBD VBD O
noted VBN VBN O
following VBG VBG O
treatment NN NN O
on IN IN O
GD NNP NNP O
11 CD CD O
. . . O

In IN IN O
contrast NN NN O
, , , O
DH NNP NNP O
and CC CC O
MD NNP NNP O
were VBD VBD O
noted VBN VBN O
in IN IN O
the DT DT O
multiple JJ JJ O
dose NN NN O
study NN NN O
design NN NN O
only RB RB O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
, , , O
and CC CC O
VSD NNP NNP O
was VBD VBD O
noted VBN VBN O
across IN IN O
all DT DT O
dose NN NN O
groups NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
High NNP NNP O
concordance NN NN O
in IN IN O
major JJ JJ O
developmental NN NN O
anomalies NNS NNS O
between IN IN O
Wistar NNP NNP O
and CC CC O
SD NNP NNP O
rats NNS NNS O
were VBD VBD O
noted VBN VBN O
with IN IN O
the DT DT O
exception NN NN O
of IN IN O
VSD NNP NNP O
in IN IN O
the DT DT O
SD NNP NNP O
rats NNS NNS O
and CC CC O
hydrocephalus NN NN O
in IN IN O
the DT DT O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Variations NNP NNP O
and CC CC O
malformations NNS NNS O
were VBD VBD O
similar JJ JJ O
when WRB WRB O
ASA NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
as IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
or CC CC O
during IN IN O
the DT DT O
period NN NN O
of IN IN O
organogenesis NN NN O
( ( ( O
GDs NNP NNP O
6 CD CD O
to TO TO O
17 CD CD O
) ) ) O
. . . O

It PRP PRP O
was VBD VBD O
also RB RB O
evident JJ JJ O
that IN IN O
, , , O
by IN IN O
titrating VBG VBG O
the DT DT O
dose NN NN O
to TO TO O
achieve VB VB O
a DT DT O
maximum NN NN O
tolerated VBN VBN O
dose NN NN O
, , , O
malformations NNS NNS O
that WDT WDT O
normally RB RB O
occur VB VB O
at IN IN O
low JJ JJ O
incidence NN NN O
, , , O
as IN IN O
reported VBN VBN O
from IN IN O
previous JJ JJ O
single NN NN O
dose NN NN O
studies NNS NNS O
, , , O
could MD MD O
also RB RB O
be VB VB O
induced VBN VBN O
with IN IN O
ASA NNP NNP B-CHEM
given VBN VBN O
at IN IN O
multiple JJ JJ O
doses NNS NNS O
. . . O

Reversal NNP NNP O
of IN IN O
central JJ JJ O
benzodiazepine NN NN B-CHEM
effects NNS NNS O
by IN IN O
flumazenil NN NN B-CHEM
after IN IN O
intravenous JJ JJ O
conscious JJ JJ O
sedation NN NN O
with IN IN O
diazepam NN NN B-CHEM
and CC CC O
opioids NNS NNS O
: : : O
report NN NN O
of IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
multicenter NN NN O
study NN NN O
. . . O

The DT DT O
Flumazenil NNP NNP B-CHEM
in IN IN O
Intravenous NNP NNP O
Conscious NNP NNP O
Sedation NNP NNP O
with IN IN O
Diazepam NNP NNP B-CHEM
Multicenter NNP NNP O
Study NNP NNP O
Group NNP NNP O
II NNP NNP O
. . . O

The DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
a DT DT O
new JJ JJ O
benzodiazepine NN NN B-CHEM
antagonist NN NN O
, , , O
flumazenil NN NN B-CHEM
, , , O
were VBD VBD O
assessed VBN VBN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
multicenter NN NN O
study NN NN O
. . . O

Flumazenil NNP NNP B-CHEM
( ( ( O
mean VB VB O
dose NN NN O
, , , O
0 CD CD O
. . . O
76 CD CD O
mg NN NN O
) ) ) O
or CC CC O
placebo NN NN O
( ( ( O
mean NN NN O
dose NN NN O
, , , O
8 CD CD O
. . . O
9 CD CD O
ml NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
intravenously RB RB O
to TO TO O
130 CD CD O
and CC CC O
67 CD CD O
patients NNS NNS O
, , , O
respectively RB RB O
, , , O
who WP WP O
had VBD VBD O
been VBN VBN O
given VBN VBN O
diazepam NN NN B-CHEM
in IN IN O
conjunction NN NN O
with IN IN O
an DT DT O
opioid NN NN O
( ( ( O
fentanyl NN NN B-CHEM
, , , O
meperidine NN NN B-CHEM
, , , O
or CC CC O
morphine NN NN B-CHEM
) ) ) O
for IN IN O
the DT DT O
induction NN NN O
and CC CC O
maintenance NN NN O
of IN IN O
intravenous JJ JJ O
conscious JJ JJ O
sedation NN NN O
for IN IN O
diagnostic JJ JJ O
or CC CC O
therapeutic JJ JJ O
surgical JJ JJ O
procedures NNS NNS O
. . . O

The DT DT O
group NN NN O
assessable JJ JJ O
for IN IN O
efficacy NN NN O
comprised VBD VBD O
122 CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
flumazenil NN NN B-CHEM
and CC CC O
64 CD CD O
patients NNS NNS O
given VBN VBN O
placebo NN NN O
. . . O

After IN IN O
5 CD CD O
minutes NNS NNS O
, , , O
80 CD CD O
/ NN NN O
115 CD CD O
( ( ( O
70 CD CD O
% NN NN O
) ) ) O
flumazenil NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
, , , O
compared VBN VBN O
with IN IN O
21 CD CD O
/ NN NN O
63 CD CD O
( ( ( O
33 CD CD O
% NN NN O
) ) ) O
placebo NN NN O
- - - O
treated VBN VBN O
patients NNS NNS O
, , , O
were VBD VBD O
completely RB RB O
awake JJ JJ O
and CC CC O
alert VB VB O
, , , O
as IN IN O
indicated VBN VBN O
by IN IN O
a DT DT O
score NN NN O
of IN IN O
5 CD CD O
on IN IN O
the DT DT O
Observer NNP NNP O
' POS POS O
s VBZ VBZ O
Assessment NNP NNP O
of IN IN O
Alertness NNP NNP O
/ NN NN O
Sedation NNP NNP O
Scale NNP NNP O
. . . O

Ninety CD CD O
- - - O
five CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
each DT DT O
group NN NN O
who WP WP O
attained VBD VBD O
a DT DT O
score NN NN O
of IN IN O
5 CD CD O
at IN IN O
the DT DT O
5 CD CD O
- : : O
minute NN NN O
assessment NN NN O
showed VBD VBD O
no DT DT O
loss NN NN O
of IN IN O
alertness NN NN O
throughout IN IN O
the DT DT O
180 CD CD O
- : : O
minute NN NN O
assessment NN NN O
period NN NN O
. . . O

Flumazenil NNP NNP B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
also RB RB O
performed VBN VBN O
significantly RB RB O
better RBR RBR O
on IN IN O
the DT DT O
Finger NNP NNP O
- : : O
to TO TO O
- - - O
Nose NN NN O
Test NNP NNP O
and CC CC O
the DT DT O
recall NN NN O
of IN IN O
pictures NNS NNS O
shown VBN VBN O
at IN IN O
the DT DT O
5 CD CD O
- : : O
minute NN NN O
assessment NN NN O
. . . O

Flumazenil NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
, , , O
with IN IN O
no DT DT O
serious JJ JJ O
adverse JJ JJ O
effects NNS NNS O
reported VBD VBD O
. . . O

Thirty NNP NNP O
- : : O
nine CD CD O
( ( ( O
30 CD CD O
% NN NN O
) ) ) O
of IN IN O
flumazenil NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
, , , O
compared VBN VBN O
with IN IN O
17 CD CD O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
of IN IN O
placebo NN NN O
- - - O
treated VBN VBN O
patients NNS NNS O
had VBD VBD O
one CD CD O
or CC CC O
more JJR JJR O
drug NN NN O
- - - O
related VBN VBN O
adverse JJ JJ O
experiences NNS NNS O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
in IN IN O
the DT DT O
flumazenil NN NN B-CHEM
group NN NN O
and CC CC O
nausea NN NN O
and CC CC O
injection NN NN O
- - - O
site NN NN O
pain NN NN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

Flumazenil NNP NNP B-CHEM
was VBD VBD O
found VBN VBN O
to TO TO O
promptly RB RB O
reverse VB VB O
sedation NN NN O
induced VBN VBN O
by IN IN O
diazepam NN NN B-CHEM
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
opioids NNS NNS O
. . . O

Methylphenidate NNP NNP B-CHEM
- : : O
induced JJ JJ O
obsessive JJ JJ O
- - - O
compulsive JJ JJ O
symptoms NNS NNS O
in IN IN O
an DT DT O
elderly JJ JJ O
man NN NN O
. . . O

An DT DT O
82 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
treatment NN NN O
- - - O
resistant JJ JJ O
depression NN NN O
and CC CC O
early JJ JJ O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
was VBD VBD O
started VBN VBN O
on IN IN O
methylphenidate NN NN B-CHEM
. . . O

Significant JJ JJ O
obsessive JJ JJ O
- - - O
compulsive JJ JJ O
behavior NN NN O
ensued VBD VBD O
but CC CC O
diminished VBN VBN O
over IN IN O
several JJ JJ O
weeks NNS NNS O
when WRB WRB O
methylphenidate NN NN B-CHEM
was VBD VBD O
replaced VBN VBN O
by IN IN O
fluvoxamine NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
no DT DT O
prior RB RB O
psychiatric JJ JJ O
history NN NN O
, , , O
but CC CC O
he PRP PRP O
had VBD VBD O
a DT DT O
sister NN NN O
with IN IN O
obsessive JJ JJ O
- - - O
compulsive JJ JJ O
disorder NN NN O
. . . O

It PRP PRP O
appears VBZ VBZ O
that IN IN O
methylphenidate VBP VBP B-CHEM
precipitated VBN VBN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
pathological JJ JJ O
behavior NN NN O
. . . O

Ciprofloxacin NNP NNP B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
and CC CC O
autoimmune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
. . . O

Ciprofloxacin NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
several JJ JJ O
side NN NN O
effects NNS NNS O
including VBG VBG O
interstitial JJ JJ O
nephritis NNS NNS O
and CC CC O
hemolytic JJ JJ O
anemia NN NN O
. . . O

The DT DT O
combination NN NN O
of IN IN O
both DT DT O
side NN NN O
effects NNS NNS O
is VBZ VBZ O
extremely RB RB O
rare JJ JJ O
. . . O

In IN IN O
this DT DT O
report NN NN O
, , , O
we PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
ciprofloxacin NN NN B-CHEM
- - - O
induced JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
and CC CC O
autoimmune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
. . . O

Hemolytic NNP NNP O
anemia NN NN O
improved VBN VBN O
after IN IN O
stopping VBG VBG O
the DT DT O
drug NN NN O
and CC CC O
initiation NN NN O
of IN IN O
steroid NN NN B-CHEM
therapy NN NN O
. . . O

Unfortunately RB RB O
, , , O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
was VBD VBD O
irreversible JJ JJ O
and CC CC O
the DT DT O
patient NN NN O
developed VBN VBN O
end VB VB O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
. . . O

Potential NNP NNP O
deleterious JJ JJ O
effect NN NN O
of IN IN O
furosemide NN NN B-CHEM
in IN IN O
radiocontrast NN NN O
nephropathy NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
efficacy NN NN O
of IN IN O
furosemide NN NN B-CHEM
in IN IN O
addition NN NN O
to TO TO O
intravenous JJ JJ O
fluids NNS NNS O
in IN IN O
the DT DT O
prevention NN NN O
of IN IN O
radiocontrast NN NN O
nephropathy NN NN O
. . . O

18 CD CD O
patients NNS NNS O
, , , O
referred VBD VBD O
to TO TO O
a DT DT O
radiocontrast NN NN O
study NN NN O
, , , O
considered VBN VBN O
at IN IN O
risk NN NN O
because IN IN O
of IN IN O
preexisting VBG VBG O
renal JJ JJ O
insufficiency NN NN O
, , , O
were VBD VBD O
enrolled VBN VBN O
in IN IN O
a DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
controlled VBN VBN O
trial NN NN O
, , , O
performed VBN VBN O
at IN IN O
the DT DT O
secondary JJ JJ O
care NN NN O
center NN NN O
of IN IN O
a DT DT O
1 CD CD O
, , , O
100 CD CD O
- : : O
bed NN NN O
private JJ JJ O
university NN NN O
hospital NN NN O
. . . O

In IN IN O
addition NN NN O
to TO TO O
fluids NNS NNS O
, , , O
the DT DT O
treatment NN NN O
group NN NN O
received VBD VBD O
furosemide NN NN B-CHEM
( ( ( O
mean NN NN O
dose NN NN O
110 CD CD O
mg NN NN O
) ) ) O
intravenously RB RB O
30 CD CD O
min NN NN O
prior RB RB O
to TO TO O
the DT DT O
injection NN NN O
of IN IN O
contrast NN NN O
material NN NN O
. . . O

The DT DT O
control NN NN O
group NN NN O
received VBD VBD O
fluids NNS NNS O
( ( ( O
mean NN NN O
3 CD CD O
liters NNS NNS O
) ) ) O
. . . O

Radiological NNP NNP O
studies NNS NNS O
were VBD VBD O
mostly RB RB O
angiographies NNS NNS O
performed VBN VBN O
with IN IN O
both DT DT O
ionic JJ JJ O
and CC CC O
non NN NN O
- - - O
ionic JJ JJ O
contrast NN NN O
material NN NN O
, , , O
at IN IN O
an DT DT O
average JJ JJ O
dose NN NN O
of IN IN O
245 CD CD O
ml NN NN O
. . . O

Renal NNP NNP O
function NN NN O
significantly RB RB O
deteriorated VBD VBD O
in IN IN O
the DT DT O
group NN NN O
pretreated VBN VBN O
with IN IN O
furosemide NN NN B-CHEM
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
005 CD CD O
by IN IN O
ANOVA NNP NNP O
) ) ) O
, , , O
with IN IN O
a DT DT O
rise NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
from IN IN O
145 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
to TO TO O
182 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
mumol NN NN O
/ NN NN O
l NN NN O
at IN IN O
24 CD CD O
h NN NN O
, , , O
while IN IN O
no DT DT O
change NN NN O
occurred VBD VBD O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
from IN IN O
141 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
to TO TO O
142 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
mumol NN NN O
/ NN NN O
l NN NN O
) ) ) O
. . . O

Renal NNP NNP O
failure NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
weight NN NN O
loss NN NN O
in IN IN O
the DT DT O
furosemide NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
. . . O

Furosemide NNP NNP B-CHEM
may MD MD O
be VB VB O
deleterious JJ JJ O
in IN IN O
the DT DT O
prevention NN NN O
of IN IN O
radiocontrast NN NN O
nephropathy NN NN O
. . . O

Progestational NNP NNP O
agents NNS NNS O
and CC CC O
blood NN NN O
coagulation NN NN O
. . . O

VII NNP NNP O
. . . O

Thromboembolic NNP NNP O
and CC CC O
other JJ JJ O
complications NNS NNS O
of IN IN O
oral JJ JJ B-CHEM
contraceptive JJ JJ I-CHEM
therapy NN NN O
in IN IN O
relationship NN NN O
to TO TO O
pretreatment NN NN O
levels NNS NNS O
of IN IN O
blood NN NN O
coagulation NN NN O
factors NNS NNS O
: : : O
summary JJ JJ O
report NN NN O
of IN IN O
a DT DT O
ten CD CD O
- - - O
year NN NN O
study NN NN O
. . . O

During IN IN O
a DT DT O
ten CD CD O
- - - O
year NN NN O
period NN NN O
, , , O
348 CD CD O
women NNS NNS O
were VBD VBD O
studied VBN VBN O
for IN IN O
a DT DT O
total NN NN O
of IN IN O
5 CD CD O
, , , O
877 CD CD O
patient NN NN O
months NNS NNS O
in IN IN O
four CD CD O
separate JJ JJ O
studies NNS NNS O
relating VBG VBG O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
to TO TO O
changes NNS NNS O
in IN IN O
hematologic JJ JJ O
parameters NNS NNS O
. . . O

Significant JJ JJ O
increases NNS NNS O
in IN IN O
certain JJ JJ O
factors NNS NNS O
of IN IN O
the DT DT O
blood NN NN O
coagulation NN NN O
and CC CC O
fibrinolysin NN NN O
systems NNS NNS O
( ( ( O
factors NNS NNS O
I PRP PRP O
, , , O
II NNP NNP O
, , , O
VII NNP NNP O
, , , O
VIII NNP NNP O
, , , O
IX NNP NNP O
, , , O
and CC CC O
X NNP NNP O
and CC CC O
plasminogen NN NN O
) ) ) O
were VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
treated VBN VBN O
groups NNS NNS O
. . . O

Severe NNP NNP O
complications NNS NNS O
developed VBN VBN O
in IN IN O
four CD CD O
patients NNS NNS O
. . . O

All DT DT O
four CD CD O
had VBD VBD O
an DT DT O
abnormal JJ JJ O
blood NN NN O
coagulation NN NN O
profile NN NN O
, , , O
suggesting VBG VBG O
" '' '' O
hypercoagulability NN NN O
" '' '' O
before IN IN O
initiation NN NN O
of IN IN O
therapy NN NN O
. . . O

Some DT DT O
of IN IN O
these DT DT O
findings NNS NNS O
represented VBD VBD O
the DT DT O
most RBS RBS O
extreme NN NN O
abnormalities NNS NNS O
seen VBN VBN O
in IN IN O
the DT DT O
entire JJ JJ O
group NN NN O
of IN IN O
patients NNS NNS O
; : : O
some DT DT O
increased VBD VBD O
further JJ JJ O
during IN IN O
therapy NN NN O
. . . O

One CD CD O
of IN IN O
these DT DT O
patients NNS NNS O
developed VBD VBD O
a DT DT O
myocardial NN NN O
infarction NN NN O
before IN IN O
receiving VBG VBG O
any DT DT O
medication NN NN O
, , , O
shortly RB RB O
after IN IN O
the DT DT O
base NN NN O
- - - O
line NN NN O
values NNS NNS O
were VBD VBD O
obtained VBN VBN O
. . . O

One CD CD O
patient NN NN O
developed VBN VBN O
retinopathy JJ JJ O
19 CD CD O
months NNS NNS O
after IN IN O
she PRP PRP O
began VBD VBD O
therapy NN NN O
, , , O
and CC CC O
another DT DT O
developed JJ JJ O
thrombophlebitis NN NN O
after IN IN O
27 CD CD O
months NNS NNS O
of IN IN O
therapy NN NN O
. . . O

The DT DT O
fourth JJ JJ O
patient NN NN O
developed VBN VBN O
thrombophlebitis NNS NNS O
14 CD CD O
days NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
contraceptive JJ JJ O
therapy NN NN O
. . . O

All DT DT O
four CD CD O
patients NNS NNS O
were VBD VBD O
of IN IN O
the DT DT O
A DT DT O
or CC CC O
AB NNP NNP O
blood NN NN O
group NN NN O
. . . O

Previous JJ JJ O
studies NNS NNS O
suggested VBD VBD O
the DT DT O
possiblility NN NN O
of IN IN O
increased VBN VBN O
propensity NN NN O
for IN IN O
thromboembolic JJ JJ O
episodes NNS NNS O
in IN IN O
patients NNS NNS O
possessing VBG VBG O
the DT DT O
A DT DT O
antigen NN NN O
. . . O

It PRP PRP O
appears VBZ VBZ O
from IN IN O
these DT DT O
data NNS NNS O
that WDT WDT O
hematologic JJ JJ O
work NN NN O
- - - O
ups NNS NNS O
may MD MD O
be VB VB O
useful JJ JJ O
in IN IN O
women NNS NNS O
who WP WP O
are VBP VBP O
about IN IN O
to TO TO O
start VB VB O
long JJ JJ O
- - - O
term NN NN O
oral JJ JJ B-CHEM
contraceptive JJ JJ I-CHEM
therapy NN NN O
. . . O

Orthostatic NNP NNP O
hypotension NN NN O
occurs VBZ VBZ O
following VBG VBG O
alpha NN NN O
2 CD CD O
- : : O
adrenoceptor NN NN O
blockade NN NN O
in IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
- - - O
pretreated JJ JJ O
conscious JJ JJ O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

1 CD CD O
. . . O

Studies NNS NNS O
were VBD VBD O
performed VBN VBN O
to TO TO O
evaluate VB VB O
whether IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
treatment NN NN O
alters NNS NNS O
the DT DT O
alpha NN NN O
2 CD CD O
- : : O
adrenoceptor NN NN O
function NN NN O
for IN IN O
orthostatic JJ JJ O
control NN NN O
of IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
in IN IN O
conscious JJ JJ O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
( ( ( O
SHR NNP NNP O
) ) ) O
. . . O

2 CD CD O
. . . O

Conscious NNP NNP O
SHR NNP NNP O
( ( ( O
male JJ JJ O
300 CD CD O
- : : O
350 CD CD O
g SYM SYM O
) ) ) O
were VBD VBD O
subjected VBN VBN O
to TO TO O
90 CD CD O
degrees NNS NNS O
head NN NN O
- - - O
up RP RP O
tilts NNS NNS O
for IN IN O
60 CD CD O
s VBZ VBZ O
following VBG VBG O
acute JJ JJ O
administration NN NN O
of IN IN O
prazosin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
or CC CC O
rauwolscine NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
. . . O

Orthostatic NNP NNP O
hypotension NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
the DT DT O
average JJ JJ O
decrease NN NN O
( ( ( O
% NN NN O
) ) ) O
in IN IN O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
( ( ( O
MAP NNP NNP O
femoral JJ JJ O
) ) ) O
over IN IN O
the DT DT O
60 CD CD O
- : : O
s VBZ VBZ O
tilt NN NN O
period NN NN O
. . . O

The DT DT O
basal NN NN O
MAP NNP NNP O
of IN IN O
conscious JJ JJ O
SHR NNP NNP O
was VBD VBD O
reduced VBN VBN O
to TO TO O
a DT DT O
similar JJ JJ O
extent NN NN O
by IN IN O
prazosin NN NN B-CHEM
( ( ( O
- : : O
23 CD CD O
% NN NN O
( ( ( O
- : : O
) ) ) O
- : : O
26 CD CD O
% NN NN O
MAP NNP NNP O
) ) ) O
and CC CC O
rauwolscine NN NN B-CHEM
( ( ( O
- : : O
16 CD CD O
% NN NN O
( ( ( O
- : : O
) ) ) O
- : : O
33 CD CD O
% NN NN O
MAP NNP NNP O
) ) ) O
. . . O

However RB RB O
, , , O
the DT DT O
head NN NN O
- - - O
up RP RP O
tilt NN NN O
induced JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
in IN IN O
the DT DT O
SHR NNP NNP O
treated VBN VBN O
with IN IN O
prazosin NN NN B-CHEM
( ( ( O
- : : O
16 CD CD O
% NN NN O
MAP NNP NNP O
, , , O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
, , , O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
SHR NNP NNP O
treated VBN VBN O
with IN IN O
rauwolscine NN NN B-CHEM
( ( ( O
less JJR JJR O
than IN IN O
+ NN NN O
2 CD CD O
% NN NN O
MAP NNP NNP O
, , , O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
. . . O

3 CD CD O
. . . O

Conscious NNP NNP O
SHR NNP NNP O
were VBD VBD O
treated VBN VBN O
for IN IN O
4 CD CD O
days NNS NNS O
with IN IN O
prazosin NN NN B-CHEM
at IN IN O
2 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
day NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
p NN NN O
. . . O
for IN IN O
chronic JJ JJ O
alpha NN NN O
1 CD CD O
- : : O
adrenoceptor NN NN O
blockade NN NN O
. . . O

MAP NNP NNP O
in IN IN O
conscious JJ JJ O
SHR NNP NNP O
after IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
treatment NN NN O
was VBD VBD O
14 CD CD O
% NN NN O
lower JJR JJR O
than IN IN O
in IN IN O
the DT DT O
untreated JJ JJ O
SHR NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
. . . O

Head NNP NNP O
- : : O
up RP RP O
tilts NNS NNS O
in IN IN O
these DT DT O
rats NNS NNS O
did VBD VBD O
not RB RB O
produce VB VB O
orthostatic JJ JJ O
hypotension NN NN O
when WRB WRB O
performed VBN VBN O
either CC CC O
prior RB RB O
to TO TO O
or CC CC O
after IN IN O
acute JJ JJ O
dosing NN NN O
of IN IN O
prazosin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

Conversely RB RB O
, , , O
administration NN NN O
of IN IN O
rauwolscine NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
in IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
treated VBN VBN O
SHR NNP NNP O
decreased VBD VBD O
the DT DT O
basal NN NN O
MAP NNP NNP O
by IN IN O
12 CD CD O
- : : O
31 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
, , , O
and CC CC O
subsequent JJ JJ O
tilts NNS NNS O
induced VBD VBD O
further JJ JJ O
drops NNS NNS O
of IN IN O
MAP NNP NNP O
by IN IN O
19 CD CD O
- : : O
23 CD CD O
% NN NN O
in IN IN O
these DT DT O
rats NNS NNS O
. . . O

4 CD CD O
. . . O

The DT DT O
pressor NN NN O
responses NNS NNS O
and CC CC O
bradycardia NNS NNS O
to TO TO O
the DT DT O
alpha NN NN O
1 CD CD O
- : : O
agonist NN NN O
cirazoline NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
6 CD CD O
and CC CC O
2 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
, , , O
the DT DT O
alpha NN NN O
2 CD CD O
- : : O
agonist NN NN O
Abbott NNP NNP B-CHEM
- : : I-CHEM
53693 CD CD I-CHEM
( ( ( O
1 CD CD O
and CC CC O
3 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
, , , O
and CC CC O
noradrenaline NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
and CC CC O
1 CD CD O
. . . O
0 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
were VBD VBD O
determined VBN VBN O
in IN IN O
conscious JJ JJ O
SHR NNP NNP O
with IN IN O
and CC CC O
without IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
pretreatment NN NN O
. . . O

Both DT DT O
the DT DT O
pressor NN NN O
and CC CC O
bradycardia NN NN O
effects NNS NNS O
of IN IN O
cirazoline NN NN B-CHEM
were VBD VBD O
abolished VBN VBN O
in IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
treated VBN VBN O
SHR NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
as IN IN O
compared VBN VBN O
to TO TO O
the DT DT O
untreated JJ JJ O
SHR NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
the DT DT O
pressor NN NN O
effects NNS NNS O
of IN IN O
Abbott NNP NNP B-CHEM
- : : I-CHEM
53693 CD CD I-CHEM
were VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
of IN IN O
SHR NNP NNP O
, , , O
but CC CC O
the DT DT O
accompanying VBG VBG O
bradycardia NN NN O
was VBD VBD O
greater JJR JJR O
in IN IN O
SHR NNP NNP O
with IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
treatment NN NN O
than IN IN O
without IN IN O
such JJ JJ O
treatment NN NN O
. . . O

Furthermore RB RB O
, , , O
the DT DT O
bradycardia NN NN O
that WDT WDT O
accompanied VBD VBD O
the DT DT O
noradrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
pressor NN NN O
effect NN NN O
in IN IN O
SHR NNP NNP O
was VBD VBD O
similar JJ JJ O
with IN IN O
and CC CC O
without IN IN O
chronic JJ JJ O
prazosin NN NN B-CHEM
treatment NN NN O
despite IN IN O
a DT DT O
47 CD CD O
- : : O
71 CD CD O
% NN NN O
reduction NN NN O
of IN IN O
the DT DT O
pressor NN NN O
effect NN NN O
in IN IN O
chronic JJ JJ O
alpha NN NN O
1 CD CD O
- : : O
receptor NN NN O
blocked VBD VBD O
SHR NNP NNP O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
400 CD CD O
WORDS NNP NNP O
) ) ) O

Hemolytic NNP NNP O
- : : O
uremic JJ JJ O
syndrome NN NN O
associated VBN VBN O
with IN IN O
ingestion NN NN O
of IN IN O
quinine NN NN B-CHEM
. . . O

Hemolytic NNP NNP O
- : : O
uremic JJ JJ O
syndrome NN NN O
following VBG VBG O
quinine NN NN B-CHEM
ingestion NN NN O
is VBZ VBZ O
a DT DT O
newly RB RB O
described VBN VBN O
phenomenon NN NN O
, , , O
with IN IN O
just RB RB O
two CD CD O
previous JJ JJ O
descriptions NNS NNS O
of IN IN O
4 CD CD O
cases NNS NNS O
in IN IN O
the DT DT O
literature NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
5th CD CD O
case NN NN O
. . . O

The DT DT O
reaction NN NN O
may MD MD O
be VB VB O
mediated VBN VBN O
by IN IN O
the DT DT O
presence NN NN O
of IN IN O
antibodies NNS NNS O
reactive JJ JJ O
against IN IN O
platelets NNS NNS O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
quinine NN NN B-CHEM
. . . O

Treatment NN NN O
has VBZ VBZ O
included VBN VBN O
use NN NN O
of IN IN O
plasma NN NN O
exchange NN NN O
, , , O
prednisone NN NN B-CHEM
, , , O
aspirin NN NN B-CHEM
, , , O
and CC CC O
dipyridamole NN NN B-CHEM
. . . O

The DT DT O
patients NNS NNS O
have VBP VBP O
all DT DT O
regained VBN VBN O
some DT DT O
degree NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

However RB RB O
, , , O
it PRP PRP O
is VBZ VBZ O
unclear JJ JJ O
whether IN IN O
pharmacological JJ JJ O
treatment NN NN O
or CC CC O
spontaneous JJ JJ O
resolution NN NN O
is VBZ VBZ O
responsible JJ JJ O
for IN IN O
the DT DT O
improvement NN NN O
. . . O

Quinine NNP NNP B-CHEM
- - - O
associated VBN VBN O
hemolytic JJ JJ O
- - - O
uremic JJ JJ O
syndrome NN NN O
probably RB RB O
occurs VBZ VBZ O
more RBR RBR O
often RB RB O
than IN IN O
is VBZ VBZ O
recognized VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
important JJ JJ O
to TO TO O
recognize VB VB O
this DT DT O
reaction NN NN O
when WRB WRB O
it PRP PRP O
occurs VBZ VBZ O
and CC CC O
to TO TO O
avoid VB VB O
further JJ JJ O
quinine NN NN B-CHEM
exposure NN NN O
, , , O
since IN IN O
the DT DT O
reaction NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
recurrent JJ JJ O
. . . O

Amnestic NNP NNP O
syndrome NN NN O
associated VBN VBN O
with IN IN O
propranolol NN NN B-CHEM
toxicity NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

An DT DT O
elderly JJ JJ O
woman NN NN O
developed VBN VBN O
an DT DT O
Alzheimer NNP NNP O
- - - O
like IN IN O
subacute NN NN O
dementia NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
propranolol NN NN B-CHEM
toxicity NN NN O
. . . O

Analysis NNP NNP O
of IN IN O
the DT DT O
manifestations NNS NNS O
showed VBD VBD O
that IN IN O
severe JJ JJ O
impairment NN NN O
of IN IN O
memory NN NN O
accounted VBD VBD O
for IN IN O
virtually RB RB O
all DT DT O
of IN IN O
the DT DT O
abnormalities NNS NNS O
. . . O

There EX EX O
is VBZ VBZ O
evidence NN NN O
that IN IN O
cerebral JJ JJ O
reactions NNS NNS O
to TO TO O
drug NN NN O
toxicity NN NN O
can MD MD O
exhibit NN NN O
patterns NNS NNS O
that WDT WDT O
suggest VBP VBP O
highly RB RB O
selective JJ JJ O
involvement NN NN O
of IN IN O
functional JJ JJ O
subdivisions NNS NNS O
of IN IN O
the DT DT O
brain NN NN O
. . . O

Cefotetan NNP NNP B-CHEM
- : : O
induced JJ JJ O
immune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
. . . O

Immune NNP NNP O
hemolytic JJ JJ O
anemia NN NN O
due JJ JJ O
to TO TO O
a DT DT O
drug NN NN O
- - - O
adsorption NN NN O
mechanism NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
primarily RB RB O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
penicillins NNS NNS B-CHEM
and CC CC O
first JJ JJ O
- - - O
generation NN NN O
cephalosporins NNS NNS B-CHEM
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
anemia NN NN O
while IN IN O
receiving VBG VBG O
intravenous JJ JJ O
cefotetan NN NN B-CHEM
. . . O

Cefotetan NNP NNP B-CHEM
- : : O
dependent JJ JJ O
antibodies NNS NNS O
were VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
serum NN NN O
and CC CC O
in IN IN O
an DT DT O
eluate NN NN O
prepared VBN VBN O
from IN IN O
his PRP$ PRP$ O
red JJ JJ O
blood NN NN O
cells NNS NNS O
. . . O

The DT DT O
eluate NN NN O
also RB RB O
reacted VBD VBD O
weakly NN NN O
with IN IN O
red JJ JJ O
blood NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
cefotetan NN NN B-CHEM
, , , O
suggesting VBG VBG O
the DT DT O
concomitant JJ JJ O
formation NN NN O
of IN IN O
warm JJ JJ O
- - - O
reactive JJ JJ O
autoantibodies NNS NNS O
. . . O

These DT DT O
observations NNS NNS O
, , , O
in IN IN O
conjunction NN NN O
with IN IN O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
evidence NN NN O
of IN IN O
extravascular JJ JJ O
hemolysis NN NN O
, , , O
are VBP VBP O
consistent JJ JJ O
with IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
, , , O
possibly RB RB O
involving VBG VBG O
both DT DT O
drug NN NN O
- - - O
adsorption NN NN O
and CC CC O
autoantibody NN NN O
formation NN NN O
mechanisms NNS NNS O
. . . O

This DT DT O
case NN NN O
emphasizes VBZ VBZ O
the DT DT O
need NN NN O
for IN IN O
increased VBN VBN O
awareness NN NN O
of IN IN O
hemolytic JJ JJ O
reactions NNS NNS O
to TO TO O
all DT DT O
cephalosporins NNS NNS B-CHEM
. . . O

Use NN NN O
of IN IN O
dexamethasone NN NN B-CHEM
with IN IN O
mesna NN NN B-CHEM
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
- - - O
induced JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

AIM NNP NNP O
: : : O
Hemorrhagic NNP NNP O
cystitis NNS NNS O
( ( ( O
HC NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
limiting VBG VBG O
side NN NN O
- - - O
effect NN NN O
of IN IN O
chemotherapy NN NN O
with IN IN O
ifosfamide NN NN B-CHEM
( ( ( O
IFS NNP NNP B-CHEM
) ) ) O
. . . O

In IN IN O
the DT DT O
study NN NN O
presented VBN VBN O
here RB RB O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
use NN NN O
of IN IN O
dexamethasone NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
mesna NN NN B-CHEM
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
IFS NNP NNP B-CHEM
- : : O
induced JJ JJ O
HC NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
( ( ( O
150 CD CD O
- : : O
200 CD CD O
g SYM SYM O
; : : O
6 CD CD O
rats NNS NNS O
per IN IN O
group NN NN O
) ) ) O
were VBD VBD O
treated VBN VBN O
with IN IN O
saline NN NN O
or CC CC O
mesna NN NN B-CHEM
5 CD CD O
min NN NN O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
before IN IN O
and CC CC O
2 CD CD O
and CC CC O
6 CD CD O
h NN NN O
after IN IN O
( ( ( O
v NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
administration NN NN O
of IN IN O
IFS NNP NNP B-CHEM
. . . O

One CD CD O
, , , O
two CD CD O
or CC CC O
three CD CD O
doses NNS NNS O
of IN IN O
mesna NN NN B-CHEM
were VBD VBD O
replaced VBN VBN O
with IN IN O
dexamethasone NN NN B-CHEM
alone RB RB O
or CC CC O
with IN IN O
dexamethasone NN NN B-CHEM
plus CC CC O
mesna NN NN B-CHEM
. . . O

Cystitis NNP NNP O
was VBD VBD O
evaluated VBN VBN O
24 CD CD O
h NN NN O
after IN IN O
its PRP$ PRP$ O
induction NN NN O
by IN IN O
the DT DT O
changes NNS NNS O
in IN IN O
bladder NN NN O
wet JJ JJ O
weight NN NN O
and CC CC O
by IN IN O
macroscopic NN NN O
and CC CC O
microscopic NN NN O
analysis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
replacement NN NN O
of IN IN O
the DT DT O
last JJ JJ O
dose NN NN O
or CC CC O
the DT DT O
last JJ JJ O
two CD CD O
doses NNS NNS O
of IN IN O
mesna NN NN B-CHEM
with IN IN O
dexamethasone NN NN B-CHEM
reduced VBD VBD O
the DT DT O
increase NN NN O
in IN IN O
bladder NN NN O
wet JJ JJ O
weight NN NN O
induced VBN VBN O
by IN IN O
IFS NNP NNP B-CHEM
by IN IN O
84 CD CD O
. . . O
79 CD CD O
% NN NN O
and CC CC O
89 CD CD O
. . . O
13 CD CD O
% NN NN O
, , , O
respectively RB RB O
. . . O

In IN IN O
addition NN NN O
, , , O
it PRP PRP O
almost RB RB O
abolished VBD VBD O
the DT DT O
macroscopic NN NN O
and CC CC O
microscopic JJ JJ O
alterations NNS NNS O
induced VBN VBN O
by IN IN O
IFS NNP NNP B-CHEM
. . . O

Moreover RB RB O
, , , O
the DT DT O
addition NN NN O
of IN IN O
dexamethasone NN NN B-CHEM
to TO TO O
the DT DT O
last JJ JJ O
two CD CD O
doses NNS NNS O
of IN IN O
mesna NN NN B-CHEM
was VBD VBD O
more RBR RBR O
efficient JJ JJ O
than IN IN O
three CD CD O
doses NNS NNS O
of IN IN O
mesna NN NN B-CHEM
alone RB RB O
when WRB WRB O
evaluated VBN VBN O
microscopically RB RB O
. . . O

CONCLUSION NNP NNP O
: : : O
Dexamethasone NNP NNP B-CHEM
in IN IN O
combination NN NN O
with IN IN O
mesna NN NN B-CHEM
was VBD VBD O
efficient JJ JJ O
in IN IN O
blocking VBG VBG O
IFS NNP NNP B-CHEM
- : : O
induced JJ JJ O
HC NNP NNP O
. . . O

However RB RB O
, , , O
the DT DT O
replacement NN NN O
of IN IN O
last JJ JJ O
two CD CD O
doses NNS NNS O
of IN IN O
mesna NN NN B-CHEM
with IN IN O
saline NN NN O
or CC CC O
all DT DT O
of IN IN O
the DT DT O
mesna NN NN B-CHEM
doses NNS NNS O
with IN IN O
dexamethasone NN NN B-CHEM
did VBD VBD O
not RB RB O
prevent VB VB O
HC NNP NNP O
. . . O

All DT DT B-CHEM
- - - I-CHEM
trans NNS NNS I-CHEM
- : : I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
erythema NN NN O
nodosum NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
promyelocytic JJ JJ O
leukemia NN NN O
. . . O

Erythema NNP NNP O
nodosum NN NN O
associated VBN VBN O
with IN IN O
all DT DT B-CHEM
- - - I-CHEM
trans NNS NNS I-CHEM
- : : I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
ATRA NNP NNP B-CHEM
) ) ) O
for IN IN O
acute JJ JJ O
promyelocytic JJ JJ O
leukemia NN NN O
( ( ( O
APL NNP NNP O
) ) ) O
is VBZ VBZ O
very RB RB O
rare JJ JJ O
. . . O

We PRP PRP O
describe VBP VBP O
four CD CD O
patients NNS NNS O
with IN IN O
classic JJ JJ O
APL NNP NNP O
who WP WP O
developed VBD VBD O
erythema NN NN O
nodosum NN NN O
during IN IN O
ATRA NNP NNP B-CHEM
therapy NN NN O
. . . O

Fever NNP NNP O
and CC CC O
subsequent JJ JJ O
multiple JJ JJ O
painful JJ JJ O
erythematous JJ JJ O
nodules NNS NNS O
over IN IN O
extremities NNS NNS O
developed VBN VBN O
on IN IN O
D11 NNP NNP O
, , , O
D16 NNP NNP O
, , , O
D17 NNP NNP O
, , , O
and CC CC O
D19 NNP NNP O
, , , O
respectively RB RB O
, , , O
after IN IN O
ATRA NNP NNP B-CHEM
therapy NN NN O
. . . O

The DT DT O
skin NN NN O
biopsy NN NN O
taken VBN VBN O
from IN IN O
each DT DT O
patient NN NN O
was VBD VBD O
consistent JJ JJ O
with IN IN O
erythema NN NN O
nodosum NN NN O
. . . O

All DT DT O
patients NNS NNS O
received VBD VBD O
short JJ JJ O
course NN NN O
of IN IN O
steroids NNS NNS B-CHEM
. . . O

Fever NNP NNP O
subsided VBD VBD O
rapidly RB RB O
and CC CC O
the DT DT O
skin NN NN O
lesions NNS NNS O
regressed VBD VBD O
completely RB RB O
. . . O

All DT DT O
patients NNS NNS O
achieved VBN VBN O
complete JJ JJ O
remission NN NN O
without IN IN O
withdrawal NN NN O
of IN IN O
ATRA NNP NNP B-CHEM
. . . O

ATRA NNP NNP B-CHEM
seemed VBD VBD O
to TO TO O
be VB VB O
the DT DT O
most RBS RBS O
possible JJ JJ O
etiology NN NN O
of IN IN O
erythema NN NN O
nodosum NN NN O
in IN IN O
our PRP$ PRP$ O
patients NNS NNS O
. . . O

Short JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
steroid NN NN B-CHEM
is VBZ VBZ O
very RB RB O
effective JJ JJ O
in IN IN O
ATRA NNP NNP B-CHEM
- : : O
induced JJ JJ O
erythema NN NN O
nodosum NN NN O
. . . O

Effect NN NN O
of IN IN O
some DT DT O
convulsants NNS NNS O
on IN IN O
the DT DT O
protective JJ JJ O
activity NN NN O
of IN IN O
loreclezole NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
combinations NNS NNS O
with IN IN O
valproate NN NN B-CHEM
or CC CC O
clonazepam NN NN B-CHEM
in IN IN O
amygdala NN NN O
- - - O
kindled JJ JJ O
rats NNS NNS O
. . . O

Loreclezole NNP NNP B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
exerted VBD VBD O
a DT DT O
significant JJ JJ O
protective JJ JJ O
action NN NN O
in IN IN O
amygdala NN NN O
- - - O
kindled JJ JJ O
rats NNS NNS O
, , , O
reducing VBG VBG O
both DT DT O
seizure NN NN O
and CC CC O
afterdischarge NN NN O
durations NNS NNS O
. . . O

The DT DT O
combinations NNS NNS O
of IN IN O
loreclezole NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
with IN IN O
valproate NN NN B-CHEM
, , , O
clonazepam NN NN B-CHEM
, , , O
or CC CC O
carbamazepine NN NN B-CHEM
( ( ( O
applied VBN VBN O
at IN IN O
their PRP$ PRP$ O
subprotective JJ JJ O
doses NNS NNS O
) ) ) O
also RB RB O
exhibited VBN VBN O
antiseizure NN NN O
effect NN NN O
in IN IN O
this DT DT O
test NN NN O
. . . O

However RB RB O
, , , O
only RB RB O
two CD CD O
first JJ JJ O
combinations NNS NNS O
occurred VBD VBD O
to TO TO O
be VB VB O
of IN IN O
pharmacodynamic JJ JJ O
nature NN NN O
. . . O

Among IN IN O
several JJ JJ O
chemoconvulsants NNS NNS O
, , , O
bicuculline NN NN B-CHEM
, , , O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartic JJ JJ I-CHEM
acid NN NN I-CHEM
and CC CC O
BAY NNP NNP B-CHEM
k NN NN I-CHEM
- : : I-CHEM
8644 CD CD I-CHEM
( ( ( O
the DT DT O
opener NN NN O
of IN IN O
L NNP NNP O
- : : O
type NN NN O
calcium NN NN B-CHEM
channels NNS NNS O
) ) ) O
reversed VBD VBD O
the DT DT O
protective JJ JJ O
activity NN NN O
of IN IN O
loreclezole NN NN B-CHEM
alone RB RB O
and CC CC O
its PRP$ PRP$ O
combination NN NN O
with IN IN O
valproate NN NN B-CHEM
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
bicuculline NN NN B-CHEM
, , , O
aminophylline NN NN B-CHEM
and CC CC O
BAY NNP NNP B-CHEM
k NN NN I-CHEM
- : : I-CHEM
8644 CD CD I-CHEM
inhibited VBD VBD O
the DT DT O
anticonvulsive JJ JJ O
action NN NN O
of IN IN O
loreclezole NN NN B-CHEM
combined VBN VBN O
with IN IN O
clonazepam NN NN B-CHEM
. . . O

The DT DT O
results NNS NNS O
support VBP VBP O
the DT DT O
hypothesis NNS NNS O
that IN IN O
the DT DT O
protective JJ JJ O
activity NN NN O
of IN IN O
loreclezole NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
combinations NNS NNS O
with IN IN O
other JJ JJ O
antiepileptics NNS NNS O
may MD MD O
involve VB VB O
potentiation NN NN O
of IN IN O
GABAergic NNP NNP O
neurotransmission NN NN O
and CC CC O
blockade NN NN O
of IN IN O
L NNP NNP O
- : : O
type NN NN O
of IN IN O
calcium NN NN B-CHEM
channels NNS NNS O
. . . O

Mitochondrial NNP NNP O
DNA NNP NNP O
and CC CC O
its PRP$ PRP$ O
respiratory JJ JJ O
chain NN NN O
products NNS NNS O
are VBP VBP O
defective JJ JJ O
in IN IN O
doxorubicin NN NN B-CHEM
nephrosis NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Doxorubicin NNP NNP B-CHEM
induces NNS NNS O
a DT DT O
self NN NN O
- - - O
perpetuating VBG VBG O
nephropathy NN NN O
characterized VBN VBN O
by IN IN O
early JJ JJ O
glomerular NN NN O
and CC CC O
late JJ JJ O
- : : O
onset NN NN O
tubular NN NN O
lesions NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
potential JJ JJ O
role NN NN O
of IN IN O
mitochondrial JJ JJ O
injury NN NN O
in IN IN O
the DT DT O
onset NN NN O
of IN IN O
these DT DT O
lesions NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Rats NNP NNP O
were VBD VBD O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
doxorubicin NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
week NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
) ) ) O
for IN IN O
7 CD CD O
weeks NNS NNS O
and CC CC O
were VBD VBD O
sacrificed VBN VBN O
either CC CC O
1 CD CD O
week NN NN O
( ( ( O
' POS POS O
short JJ JJ O
- - - O
term NN NN O
' '' '' O
) ) ) O
or CC CC O
30 CD CD O
weeks NNS NNS O
( ( ( O
' POS POS O
long JJ JJ O
- - - O
term NN NN O
' '' '' O
) ) ) O
following VBG VBG O
the DT DT O
last JJ JJ O
dose NN NN O
. . . O

Additional JJ JJ O
rats NNS NNS O
received VBD VBD O
a DT DT O
single JJ JJ O
dose NN NN O
either CC CC O
6 CD CD O
days NNS NNS O
or CC CC O
2 CD CD O
h NN NN O
prior RB RB O
to TO TO O
euthanasia VB VB O
. . . O

All DT DT O
rats NNS NNS O
were VBD VBD O
killed VBN VBN O
at IN IN O
48 CD CD O
weeks NNS NNS O
of IN IN O
age NN NN O
. . . O

Glomerular NNP NNP O
and CC CC O
tubular JJ JJ O
injury NN NN O
was VBD VBD O
monitored VBN VBN O
and CC CC O
correlated JJ JJ O
to TO TO O
the DT DT O
activity NN NN O
or CC CC O
expression NN NN O
of IN IN O
respiratory JJ JJ O
chain NN NN O
components NNS NNS O
. . . O

Finally RB RB O
, , , O
we PRP PRP O
quantified VBD VBD O
both DT DT O
nuclear JJ JJ O
and CC CC O
mitochondrial JJ JJ O
DNA NNP NNP O
( ( ( O
mtDNA NN NN O
) ) ) O
as RB RB O
well RB RB O
as IN IN O
superoxide NN NN B-CHEM
production NN NN O
and CC CC O
the DT DT O
4834 CD CD O
base NN NN O
pair NN NN O
' '' '' O
common JJ JJ O
' POS POS O
mtDNA NN NN O
deletion NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
' POS POS O
long JJ JJ O
- - - O
term NN NN O
' '' '' O
group NN NN O
had VBD VBD O
significant JJ JJ O
glomerular NN NN O
and CC CC O
tubular JJ JJ O
lesions NNS NNS O
, , , O
depressed VBN VBN O
activities NNS NNS O
of IN IN O
mtDNA NN NN O
- - - O
encoded JJ JJ O
NADH NNP NNP O
dehydrogenase NN NN O
and CC CC O
cytochrome VB VB O
- : : O
c SYM SYM O
oxidase NN NN O
( ( ( O
COX NNP NNP O
) ) ) O
and CC CC O
increased VBN VBN O
citrate NN NN B-CHEM
synthase NN NN O
activity NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
expression NN NN O
of IN IN O
the DT DT O
mtDNA NN NN O
- - - O
encoded JJ JJ O
COX NNP NNP O
subunit NN NN O
I PRP PRP O
was VBD VBD O
reduced VBN VBN O
and CC CC O
mtDNA JJ JJ O
levels NNS NNS O
were VBD VBD O
decreased VBN VBN O
. . . O

In IN IN O
' POS POS O
short JJ JJ O
- - - O
term NN NN O
' '' '' O
rats NNS NNS O
, , , O
there EX EX O
were VBD VBD O
fewer JJR JJR O
tubular NN NN O
lesions NNS NNS O
, , , O
but CC CC O
similar JJ JJ O
numbers NNS NNS O
of IN IN O
glomerular NN NN O
lesions NNS NNS O
activity NN NN O
. . . O

Among IN IN O
all DT DT O
animals NNS NNS O
, , , O
glomerular NN NN O
and CC CC O
tubular JJ JJ O
injury NN NN O
were VBD VBD O
inversely RB RB O
correlated JJ JJ O
with IN IN O
mtDNA NN NN O
levels NNS NNS O
, , , O
mtDNA NN NN O
- - - O
encoded JJ JJ O
respiratory JJ JJ O
chain NN NN O
activities NNS NNS O
and CC CC O
with IN IN O
the DT DT O
expression NN NN O
of IN IN O
the DT DT O
mtDNA NN NN O
- - - O
encoded JJ JJ O
respiratory JJ JJ O
chain NN NN O
subunit NN NN O
COX NNP NNP O
- : : O
I PRP PRP O
. . . O

Injury NNP NNP O
was VBD VBD O
positively RB RB O
correlated JJ JJ O
with IN IN O
superoxide NN NN B-CHEM
production NN NN O
and CC CC O
the DT DT O
activities NNS NNS O
of IN IN O
nucleus NN NN O
- - - O
encoded JJ JJ O
mitochondrial NN NN O
or CC CC O
cytoplasmic JJ JJ O
enzymes NNS NNS O
. . . O

Kidneys NNP NNP O
from IN IN O
the DT DT O
' POS POS O
long JJ JJ O
- - - O
term NN NN O
' '' '' O
group NN NN O
showed VBD VBD O
more JJR JJR O
mtDNA NN NN O
deletions NNS NNS O
than IN IN O
in IN IN O
' POS POS O
short JJ JJ O
- - - O
term NN NN O
' '' '' O
animals NNS NNS O
and CC CC O
these DT DT O
were VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
the DT DT O
other JJ JJ O
groups NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
results NNS NNS O
suggest VBP VBP O
an DT DT O
important JJ JJ O
role NN NN O
for IN IN O
quantitative JJ JJ O
and CC CC O
qualitative JJ JJ O
mtDNA NN NN O
alterations NNS NNS O
through IN IN O
the DT DT O
reduction NN NN O
of IN IN O
mtDNA NN NN O
- - - O
encoded JJ JJ O
respiratory JJ JJ O
chain NN NN O
function NN NN O
and CC CC O
induction NN NN O
of IN IN O
superoxide NN NN B-CHEM
in IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
lesions NNS NNS O
. . . O

A DT DT O
randomized JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
crossover NN NN O
study NN NN O
of IN IN O
ephedrine NN NN B-CHEM
for IN IN O
SSRI NNP NNP O
- : : O
induced JJ JJ O
female JJ JJ O
sexual JJ JJ O
dysfunction NN NN O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
ephedrine NN NN B-CHEM
, , , O
an DT DT O
alpha NN NN O
- - - O
and CC CC O
beta NN NN O
- - - O
adrenergic JJ JJ O
agonist NN NN O
previously RB RB O
shown VBN VBN O
to TO TO O
enhance VB VB O
genital JJ JJ O
blood NN NN O
flow NN NN O
in IN IN O
women NNS NNS O
, , , O
has VBZ VBZ O
beneficial JJ JJ O
effects NNS NNS O
in IN IN O
reversing VBG VBG O
antidepressant NN NN O
- : : O
induced VBN VBN O
sexual JJ JJ O
dysfunction NN NN O
. . . O

Nineteen NNP NNP O
sexually RB RB O
dysfunctional JJ JJ O
women NNS NNS O
receiving VBG VBG O
either CC CC O
fluoxetine NN NN B-CHEM
, , , O
sertraline NN NN B-CHEM
, , , O
or CC CC O
paroxetine NN NN B-CHEM
participated VBN VBN O
in IN IN O
an DT DT O
eight CD CD O
- - - O
week NN NN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
cross JJ JJ O
- - - O
over IN IN O
study NN NN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
ephedrine NN NN B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
) ) ) O
on IN IN O
self NN NN O
- - - O
report NN NN O
measures NNS NNS O
of IN IN O
sexual JJ JJ O
desire NN NN O
, , , O
arousal NN NN O
, , , O
orgasm NN NN O
, , , O
and CC CC O
sexual JJ JJ O
satisfaction NN NN O
. . . O

Although IN IN O
there EX EX O
were VBD VBD O
significant JJ JJ O
improvements NNS NNS O
relative JJ JJ O
to TO TO O
baseline VB VB O
in IN IN O
sexual JJ JJ O
desire NN NN O
and CC CC O
orgasm NN NN O
intensity NN NN O
/ NN NN O
pleasure NN NN O
on IN IN O
50 CD CD O
mg NN NN O
ephedrine NN NN B-CHEM
1 CD CD O
- : : O
hr NN NN O
prior RB RB O
to TO TO O
sexual JJ JJ O
activity NN NN O
, , , O
significant JJ JJ O
improvements NNS NNS O
in IN IN O
these DT DT O
measures NNS NNS O
, , , O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
sexual JJ JJ O
arousal NN NN O
and CC CC O
orgasmic JJ JJ O
ability NN NN O
also RB RB O
were VBD VBD O
noted VBN VBN O
with IN IN O
placebo NN NN O
. . . O

These DT DT O
findings NNS NNS O
highlight VBD VBD O
the DT DT O
importance NN NN O
of IN IN O
conducting VBG VBG O
placebo NN NN O
- - - O
controlled JJ JJ O
trials NNS NNS O
for IN IN O
this DT DT O
condition NN NN O
. . . O

Does VBZ VBZ O
hormone NN NN O
therapy NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
have VBP VBP O
a DT DT O
detrimental JJ JJ O
effect NN NN O
on IN IN O
memory NN NN O
and CC CC O
cognition NN NN O
? . . O

A DT DT O
pilot NN NN O
study NN NN O
. . . O

This DT DT O
pilot NN NN O
study NN NN O
examines VBZ VBZ O
whether IN IN O
hormone NN NN O
therapy NN NN O
for IN IN O
breast NN NN O
cancer NN NN O
affects NNS NNS O
cognition NN NN O
. . . O

Patients NNS NNS O
participating VBG VBG O
in IN IN O
a DT DT O
randomised JJ JJ O
trial NN NN O
of IN IN O
anastrozole NN NN B-CHEM
, , , O
tamoxifen NN NN B-CHEM
alone RB RB O
or CC CC O
combined VBN VBN O
( ( ( O
ATAC NNP NNP O
) ) ) O
( ( ( O
n NN NN O
= SYM SYM O
94 CD CD O
) ) ) O
and CC CC O
a DT DT O
group NN NN O
of IN IN O
women NNS NNS O
without IN IN O
breast NN NN O
cancer NN NN O
( ( ( O
n NN NN O
= SYM SYM O
35 CD CD O
) ) ) O
completed VBD VBD O
a DT DT O
battery NN NN O
of IN IN O
neuropsychological JJ JJ O
measures NNS NNS O
. . . O

Compared VBN VBN O
with IN IN O
the DT DT O
control NN NN O
group NN NN O
, , , O
the DT DT O
patients NNS NNS O
were VBD VBD O
impaired VBN VBN O
on IN IN O
a DT DT O
processing NN NN O
speed NN NN O
task NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
032 CD CD O
) ) ) O
and CC CC O
on IN IN O
a DT DT O
measure NN NN O
of IN IN O
immediate JJ JJ O
verbal JJ JJ O
memory NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
026 CD CD O
) ) ) O
after IN IN O
controlling VBG VBG O
for IN IN O
the DT DT O
use NN NN O
of IN IN O
hormone NN NN O
replacement NN NN O
therapy NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Patient NNP NNP O
group NN NN O
performance NN NN O
was VBD VBD O
not RB RB O
significantly RB RB O
related VBN VBN O
to TO TO O
length NN NN O
of IN IN O
treatment NN NN O
or CC CC O
measures NNS NNS O
of IN IN O
psychological JJ JJ O
morbidity NN NN O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
specific JJ JJ O
impairments NNS NNS O
in IN IN O
processing NN NN O
speed NN NN O
and CC CC O
verbal JJ JJ O
memory NN NN O
in IN IN O
women NNS NNS O
receiving VBG VBG O
hormonal NN NN O
therapy NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
. . . O

Verbal NNP NNP O
memory NN NN O
may MD MD O
be VB VB O
especially RB RB O
sensitive JJ JJ O
to TO TO O
changes NNS NNS O
in IN IN O
oestrogen NN NN B-CHEM
levels NNS NNS O
, , , O
a DT DT O
finding VBG VBG O
commonly RB RB O
reported VBN VBN O
in IN IN O
studies NNS NNS O
of IN IN O
hormone NN NN O
replacement NN NN O
therapy NN NN O
in IN IN O
healthy JJ JJ O
women NNS NNS O
. . . O

In IN IN O
view NN NN O
of IN IN O
the DT DT O
increased JJ JJ O
use NN NN O
of IN IN O
hormone NN NN O
therapies NNS NNS O
in IN IN O
an DT DT O
adjuvant NN NN O
and CC CC O
preventative JJ JJ O
setting VBG VBG O
their PRP$ PRP$ O
impact NN NN O
on IN IN O
cognitive JJ JJ O
functioning NN NN O
should MD MD O
be VB VB O
investigated VBN VBN O
more RBR RBR O
thoroughly RB RB O
. . . O

Expression NNP NNP O
of IN IN O
p300 NN NN O
protects NNS NNS O
cardiac JJ JJ O
myocytes NNS NNS O
from IN IN O
apoptosis NN NN O
in IN IN O
vivo NN NN O
. . . O

Doxorubicin NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
anti JJ JJ O
- : : O
tumor NN NN O
agent NN NN O
that IN IN O
represses NNS NNS O
cardiac JJ JJ O
- : : O
specific JJ JJ O
gene NN NN O
expression NN NN O
and CC CC O
induces NNS NNS O
myocardial JJ JJ O
cell NN NN O
apoptosis NN NN O
. . . O

Doxorubicin NNP NNP B-CHEM
depletes VBZ VBZ O
cardiac JJ JJ O
p300 NN NN O
, , , O
a DT DT O
transcriptional JJ JJ O
coactivator NN NN O
that WDT WDT O
is VBZ VBZ O
required VBN VBN O
for IN IN O
the DT DT O
maintenance NN NN O
of IN IN O
the DT DT O
differentiated JJ JJ O
phenotype NN NN O
of IN IN O
cardiac JJ JJ O
myocytes NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
role NN NN O
of IN IN O
p300 NN NN O
in IN IN O
protection NN NN O
against IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
apoptosis NN NN O
is VBZ VBZ O
unknown JJ JJ O
. . . O

Transgenic NNP NNP O
mice NNS NNS O
overexpressing VBG VBG O
p300 NN NN O
in IN IN O
the DT DT O
heart NN NN O
and CC CC O
wild JJ JJ O
- - - O
type NN NN O
mice NN NN O
were VBD VBD O
subjected VBN VBN O
to TO TO O
doxorubicin NN NN B-CHEM
treatment NN NN O
. . . O

Compared VBN VBN O
with IN IN O
wild JJ JJ O
- - - O
type NN NN O
mice NN NN O
, , , O
transgenic JJ JJ O
mice NNS NNS O
exhibited VBD VBD O
higher JJR JJR O
survival NN NN O
rate NN NN O
as RB RB O
well RB RB O
as IN IN O
more JJR JJR O
preserved VBN VBN O
left VBD VBD O
ventricular NN NN O
function NN NN O
and CC CC O
cardiac JJ JJ O
expression NN NN O
of IN IN O
alpha NN NN O
- - - O
sarcomeric JJ JJ O
actin NN NN O
. . . O

Doxorubicin NNP NNP B-CHEM
induced VBD VBD O
myocardial NN NN O
cell NN NN O
apoptosis NN NN O
in IN IN O
wild JJ JJ O
- - - O
type NN NN O
mice NN NN O
but CC CC O
not RB RB O
in IN IN O
transgenic JJ JJ O
mice NNS NNS O
. . . O

Expression NNP NNP O
of IN IN O
p300 NN NN O
increased VBD VBD O
the DT DT O
cardiac JJ JJ O
level NN NN O
of IN IN O
bcl NN NN O
- - - O
2 CD CD O
and CC CC O
mdm NN NN O
- - - O
2 CD CD O
, , , O
but CC CC O
not RB RB O
that IN IN O
of IN IN O
p53 NN NN O
or CC CC O
other JJ JJ O
members NNS NNS O
of IN IN O
the DT DT O
bcl NN NN O
- - - O
2 CD CD O
family NN NN O
. . . O

These DT DT O
findings NNS NNS O
demonstrate VBP VBP O
that DT DT O
overexpression NN NN O
of IN IN O
p300 NN NN O
protects NNS NNS O
cardiac JJ JJ O
myocytes NNS NNS O
from IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
apoptosis NN NN O
and CC CC O
reduces VBZ VBZ O
the DT DT O
extent NN NN O
of IN IN O
acute JJ JJ O
heart NN NN O
failure NN NN O
in IN IN O
adult NN NN O
mice NN NN O
in IN IN O
vivo NN NN O
. . . O

Methimazole NNP NNP B-CHEM
- : : O
induced JJ JJ O
cholestatic JJ JJ O
jaundice NN NN O
. . . O

Methimazole NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
widely RB RB O
used VBN VBN O
and CC CC O
generally RB RB O
well RB RB O
- - - O
tolerated JJ JJ O
antithyroid NN NN O
agent NN NN O
. . . O

A DT DT O
43 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
had VBD VBD O
severe JJ JJ O
jaundice NN NN O
and CC CC O
itching VBG VBG O
1 CD CD O
month NN NN O
after IN IN O
receiving VBG VBG O
methimazole NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
tid NN NN O
) ) ) O
and CC CC O
propranolol NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
tid NN NN O
) ) ) O
for IN IN O
treatment NN NN O
of IN IN O
hyperthyroidism NN NN O
. . . O

The DT DT O
patient NN NN O
continued VBD VBD O
treatment NN NN O
for IN IN O
another DT DT O
4 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
appearance NN NN O
of IN IN O
jaundice NN NN O
until IN IN O
she PRP PRP O
finished VBD VBD O
both DT DT O
medications NNS NNS O
. . . O

When WRB WRB O
seen VBN VBN O
at IN IN O
the DT DT O
emergency NN NN O
department NN NN O
2 CD CD O
weeks NNS NNS O
later RB RB O
, , , O
she PRP PRP O
still RB RB O
had VBD VBD O
severe JJ JJ O
icterus NN NN O
, , , O
pruritus NN NN O
, , , O
and CC CC O
hyperbilirubinemia NN NN O
, , , O
formed VBD VBD O
mainly RB RB O
of IN IN O
the DT DT O
conjugated JJ JJ O
fraction NN NN O
. . . O

Methimazole NNP NNP B-CHEM
- : : O
induced JJ JJ O
cholestasis NN NN O
was VBD VBD O
diagnosed VBN VBN O
, , , O
and CC CC O
propranolol NN NN B-CHEM
therapy NN NN O
was VBD VBD O
resumed VBN VBN O
. . . O

Over IN IN O
the DT DT O
following VBG VBG O
9 CD CD O
days NNS NNS O
, , , O
the DT DT O
symptoms NNS NNS O
improved VBN VBN O
and CC CC O
plasma NN NN O
bilirubin NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
normal JJ JJ O
after IN IN O
12 CD CD O
weeks NNS NNS O
without IN IN O
methimazole NN NN B-CHEM
. . . O

In IN IN O
rare JJ JJ O
cases NNS NNS O
within IN IN O
the DT DT O
first JJ JJ O
few JJ JJ O
weeks NNS NNS O
of IN IN O
therapy NN NN O
, , , O
this DT DT O
drug NN NN O
can MD MD O
cause VB VB O
severe JJ JJ O
and CC CC O
reversible JJ JJ O
cholestatic JJ JJ O
jaundice NN NN O
. . . O

Physicians NNP NNP O
and CC CC O
patients NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
adverse JJ JJ O
effect NN NN O
so IN IN O
that IN IN O
, , , O
upon IN IN O
occurrence NN NN O
, , , O
they PRP PRP O
can MD MD O
discontinue VB VB O
methimazole NN NN B-CHEM
therapy NN NN O
and CC CC O
avoid VB VB O
unnecessary JJ JJ O
invasive JJ JJ O
procedures NNS NNS O
. . . O

Atrial NNP NNP O
fibrillation NN NN O
following VBG VBG O
chemotherapy NN NN O
for IN IN O
stage NN NN O
IIIE NNP NNP O
diffuse NN NN O
large JJ JJ O
B NNP NNP O
- - - O
cell NN NN O
gastric JJ JJ O
lymphoma NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
myotonic JJ JJ O
dystrophy NN NN O
( ( ( O
Steinert NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
) ) ) O
. . . O

The DT DT O
authors NNS NNS O
describe VBP VBP O
the DT DT O
unusual JJ JJ O
association NN NN O
between IN IN O
diffuse NN NN O
B NNP NNP O
- - - O
cell NN NN O
gastric JJ JJ O
lymphoma NN NN O
and CC CC O
myotonic JJ JJ O
dystrophy NN NN O
, , , O
the DT DT O
most RBS RBS O
common JJ JJ O
form NN NN O
of IN IN O
adult NN NN O
muscular NN NN O
dystrophy NN NN O
, , , O
and CC CC O
sudden JJ JJ O
atrial JJ JJ O
fibrillation NN NN O
following VBG VBG O
one CD CD O
cycle NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
- - - O
based JJ JJ O
chemotherapy NN NN O
in IN IN O
the DT DT O
same JJ JJ O
patient NN NN O
. . . O

Atrial NNP NNP O
fibrillation NN NN O
or CC CC O
other JJ JJ O
cardiac JJ JJ O
arrhythmias NNS NNS O
are VBP VBP O
unusual JJ JJ O
complications NNS NNS O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
chemotherapy NN NN O
. . . O

The DT DT O
cardiac JJ JJ O
toxicity NN NN O
intrinsically RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
aggressive JJ JJ O
chemotherapy NN NN O
employed VBD VBD O
could MD MD O
function NN NN O
as IN IN O
a DT DT O
triggering VBG VBG O
factor NN NN O
for IN IN O
the DT DT O
arrhythmia NN NN O
in IN IN O
the DT DT O
predisposed JJ JJ O
myocardium NN NN O
of IN IN O
this DT DT O
patient NN NN O
. . . O

Hypersensitivity NNP NNP O
immune JJ JJ O
reaction NN NN O
as IN IN O
a DT DT O
mechanism NN NN O
for IN IN O
dilevalol NN NN B-CHEM
- - - O
associated JJ JJ O
hepatitis NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
assess VB VB O
lymphocyte NN NN O
reactivity NN NN O
to TO TO O
dilevalol VB VB B-CHEM
and CC CC O
to TO TO O
serum NN NN O
containing VBG VBG O
putative JJ JJ O
ex NN NN O
vivo NN NN O
dilevalol NN NN B-CHEM
antigens NNS NNS O
or CC CC O
metabolites NNS NNS O
in IN IN O
a DT DT O
case NN NN O
of IN IN O
dilevalol NN NN B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
. . . O

PATIENT NNP NNP O
: : : O
A DT DT O
58 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
a DT DT O
clinical JJ JJ O
diagnosis NN NN O
of IN IN O
dilevalol NN NN B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
. . . O

METHODS NNP NNP O
: : : O
Peripheral NNP NNP O
blood NN NN O
mononuclear NN NN O
cells NNS NNS O
collected VBN VBN O
from IN IN O
the DT DT O
patient NN NN O
were VBD VBD O
cultured JJ JJ O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
a DT DT O
solution NN NN O
of IN IN O
dilevalol NN NN B-CHEM
and CC CC O
also RB RB O
with IN IN O
sera NN NN O
collected VBN VBN O
from IN IN O
a DT DT O
volunteer NN NN O
before IN IN O
and CC CC O
after IN IN O
dilevalol NN NN B-CHEM
intake NN NN O
. . . O

A DT DT O
similar JJ JJ O
protocol NN NN O
was VBD VBD O
performed VBN VBN O
with IN IN O
lymphocytes NNS NNS O
from IN IN O
a DT DT O
healthy JJ JJ O
subject NN NN O
. . . O

RESULTS NNS NNS O
: : : O
No DT DT O
lymphocyte NN NN O
proliferation NN NN O
was VBD VBD O
observed VBN VBN O
either CC CC O
in IN IN O
the DT DT O
patient NN NN O
or CC CC O
in IN IN O
the DT DT O
healthy JJ JJ O
volunteer NN NN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
dilevalol NN NN B-CHEM
solutions NNS NNS O
. . . O

A DT DT O
significant JJ JJ O
proliferative JJ JJ O
response NN NN O
to TO TO O
serum VB VB O
collected VBN VBN O
after IN IN O
dilevalol NN NN B-CHEM
intake NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
case NN NN O
of IN IN O
the DT DT O
patient NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
proliferative JJ JJ O
response NN NN O
to TO TO O
the DT DT O
serum NN NN O
collected VBN VBN O
before IN IN O
the DT DT O
drug NN NN O
intake NN NN O
. . . O

No DT DT O
reactivity NN NN O
was VBD VBD O
found VBN VBN O
when WRB WRB O
lymphocytes NNS NNS O
from IN IN O
the DT DT O
healthy JJ JJ O
subject NN NN O
were VBD VBD O
tested VBN VBN O
under IN IN O
similar JJ JJ O
conditions NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
methodology NN NN O
used VBN VBN O
allowed VBD VBD O
the DT DT O
detection NN NN O
of IN IN O
lymphocyte NN NN O
sensitization NN NN O
to TO TO O
sera NN NN O
containing VBG VBG O
ex FW FW O
vivo NN NN O
- - - O
prepared VBN VBN O
dilevalol NN NN B-CHEM
antigens NNS NNS O
, , , O
suggesting VBG VBG O
the DT DT O
involvement NN NN O
of IN IN O
an DT DT O
immunologic JJ JJ O
mechanism NN NN O
in IN IN O
dilevalol NN NN B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
. . . O

Increased NNP NNP O
expression NN NN O
and CC CC O
apical JJ JJ O
targeting NN NN O
of IN IN O
renal JJ JJ O
ENaC NNP NNP O
subunits NNS NNS O
in IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
in IN IN O
rats NNS NNS O
. . . O

Nephrotic NNP NNP O
syndrome NN NN O
is VBZ VBZ O
often RB RB O
accompanied VBN VBN O
by IN IN O
sodium NN NN B-CHEM
retention NN NN O
and CC CC O
generalized JJ JJ O
edema NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
molecular JJ JJ O
basis NN NN O
for IN IN O
the DT DT O
decreased VBN VBN O
renal JJ JJ O
sodium NN NN B-CHEM
excretion NN NN O
remains NNS NNS O
undefined JJ JJ O
. . . O

We PRP PRP O
hypothesized VBN VBN O
that IN IN O
epithelial NN NN O
Na NNP NNP B-CHEM
channel NN NN O
( ( ( O
ENaC NNP NNP O
) ) ) O
subunit NN NN O
dysregulation NN NN O
may MD MD O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
increased VBN VBN O
sodium NN NN B-CHEM
retention NN NN O
. . . O

An DT DT O
experimental JJ JJ O
group NN NN O
of IN IN O
rats NNS NNS O
was VBD VBD O
treated VBN VBN O
with IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
; : : O
180 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
iv NN NN O
) ) ) O
, , , O
whereas IN IN O
the DT DT O
control NN NN O
group NN NN O
received VBD VBD O
only RB RB O
vehicle NN NN O
. . . O

After IN IN O
7 CD CD O
days NNS NNS O
, , , O
PAN NNP NNP B-CHEM
treatment NN NN O
induced VBD VBD O
significant JJ JJ O
proteinuria NN NN O
, , , O
hypoalbuminemia NN NN O
, , , O
decreased VBD VBD O
urinary JJ JJ O
sodium NN NN B-CHEM
excretion NN NN O
, , , O
and CC CC O
extensive JJ JJ O
ascites NNS NNS O
. . . O

The DT DT O
protein NN NN O
abundance NN NN O
of IN IN O
alpha NN NN O
- - - O
ENaC NNP NNP O
and CC CC O
beta NN NN O
- - - O
ENaC NNP NNP O
was VBD VBD O
increased VBN VBN O
in IN IN O
the DT DT O
inner JJ JJ O
stripe NN NN O
of IN IN O
the DT DT O
outer JJ JJ O
medulla NN NN O
( ( ( O
ISOM NNP NNP O
) ) ) O
and CC CC O
in IN IN O
the DT DT O
inner JJ JJ O
medulla NN NN O
( ( ( O
IM NNP NNP O
) ) ) O
but CC CC O
was VBD VBD O
not RB RB O
altered VBN VBN O
in IN IN O
the DT DT O
cortex NN NN O
. . . O

gamma NN NN O
- : : O
ENaC NNP NNP O
abundance NN NN O
was VBD VBD O
increased VBN VBN O
in IN IN O
the DT DT O
cortex NN NN O
, , , O
ISOM NNP NNP O
, , , O
and CC CC O
IM NNP NNP O
. . . O

Immunoperoxidase NNP NNP O
brightfield NN NN O
- : : O
and CC CC O
laser JJR JJR O
- : : O
scanning VBG VBG O
confocal JJ JJ O
fluorescence NN NN O
microscopy NN NN O
demonstrated VBN VBN O
increased VBN VBN O
targeting NN NN O
of IN IN O
alpha NN NN O
- - - O
ENaC NNP NNP O
, , , O
beta NN NN O
- - - O
ENaC NNP NNP O
, , , O
and CC CC O
gamma NN NN O
- - - O
ENaC NNP NNP O
subunits NNS NNS O
to TO TO O
the DT DT O
apical JJ JJ O
plasma NN NN O
membrane NN NN O
in IN IN O
the DT DT O
distal NN NN O
convoluted VBD VBD O
tubule NN NN O
( ( ( O
DCT2 NNP NNP O
) ) ) O
, , , O
connecting VBG VBG O
tubule NN NN O
, , , O
and CC CC O
cortical JJ JJ O
and CC CC O
medullary JJ JJ O
collecting VBG VBG O
duct NN NN O
segments NNS NNS O
. . . O

Immunoelectron NNP NNP O
microscopy NN NN O
further RB RB O
revealed VBD VBD O
an DT DT O
increased JJ JJ O
labeling VBG VBG O
of IN IN O
alpha NN NN O
- - - O
ENaC NNP NNP O
in IN IN O
the DT DT O
apical JJ JJ O
plasma NN NN O
membrane NN NN O
of IN IN O
cortical JJ JJ O
collecting VBG VBG O
duct NN NN O
principal JJ JJ O
cells NNS NNS O
of IN IN O
PAN NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
, , , O
indicating VBG VBG O
enhanced VBN VBN O
apical JJ JJ O
targeting NN NN O
of IN IN O
alpha NN NN O
- - - O
ENaC NNP NNP O
subunits NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
protein NN NN O
abundances NNS NNS O
of IN IN O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
/ NN NN O
H NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
exchanger NN NN O
type NN NN O
3 CD CD O
( ( ( O
NHE3 NNP NNP O
) ) ) O
, , , O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
2Cl CD CD B-CHEM
( ( ( O
- : : O
) ) ) O
cotransporter NN NN O
( ( ( O
BSC NNP NNP O
- - - O
1 CD CD O
) ) ) O
, , , O
and CC CC O
thiazide NN NN B-CHEM
- - - O
sensitive JJ JJ O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
Cl NNP NNP B-CHEM
( ( ( O
- : : O
) ) ) O
cotransporter NN NN O
( ( ( O
TSC NNP NNP O
) ) ) O
were VBD VBD O
decreased VBN VBN O
. . . O

Moreover RB RB O
, , , O
the DT DT O
abundance NN NN O
of IN IN O
the DT DT O
alpha NN NN O
( ( ( O
1 CD CD O
) ) ) O
- : : O
subunit NN NN O
of IN IN O
the DT DT O
Na NNP NNP B-CHEM
- - - O
K NNP NNP B-CHEM
- : : O
ATPase NNP NNP O
was VBD VBD O
decreased VBN VBN O
in IN IN O
the DT DT O
cortex NN NN O
and CC CC O
ISOM NNP NNP O
, , , O
but CC CC O
it PRP PRP O
remained VBD VBD O
unchanged JJ JJ O
in IN IN O
the DT DT O
IM NNP NNP O
. . . O

In IN IN O
conclusion NN NN O
, , , O
the DT DT O
increased JJ JJ O
or CC CC O
sustained JJ JJ O
expression NN NN O
of IN IN O
ENaC NNP NNP O
subunits NNS NNS O
combined VBN VBN O
with IN IN O
increased VBN VBN O
apical JJ JJ O
targeting NN NN O
in IN IN O
the DT DT O
DCT2 NNP NNP O
, , , O
connecting VBG VBG O
tubule NN NN O
, , , O
and CC CC O
collecting VBG VBG O
duct NN NN O
are VBP VBP O
likely JJ JJ O
to TO TO O
play VB VB O
a DT DT O
role NN NN O
in IN IN O
the DT DT O
sodium NN NN B-CHEM
retention NN NN O
associated VBN VBN O
with IN IN O
PAN NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

The DT DT O
decreased VBN VBN O
abundance NN NN O
of IN IN O
NHE3 NNP NNP O
, , , O
BSC NNP NNP O
- : : O
1 CD CD O
, , , O
TSC NNP NNP O
, , , O
and CC CC O
Na NNP NNP B-CHEM
- : : O
K NNP NNP B-CHEM
- : : O
ATPase NNP NNP O
may MD MD O
play VB VB O
a DT DT O
compensatory JJ JJ O
role NN NN O
to TO TO O
promote VB VB O
sodium NN NN B-CHEM
excretion NN NN O
. . . O

Pallidal NNP NNP O
stimulation NN NN O
: : : O
an DT DT O
alternative JJ JJ O
to TO TO O
pallidotomy NN NN O
? . . O

A DT DT O
resurgence NN NN O
of IN IN O
interest NN NN O
in IN IN O
the DT DT O
surgical JJ JJ O
treatment NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
came VBD VBD O
with IN IN O
the DT DT O
rediscovery NN NN O
of IN IN O
posteroventral JJ JJ O
pallidotomy NN NN O
by IN IN O
Laitinen NNP NNP O
in IN IN O
1985 CD CD O
. . . O

Laitinen NNP NNP O
' POS POS O
s VBZ VBZ O
procedure NN NN O
improved VBN VBN O
most JJS JJS O
symptoms NNS NNS O
in IN IN O
drug NN NN O
- - - O
resistant JJ JJ O
PD NNP NNP O
, , , O
which WDT WDT O
engendered VBD VBD O
wide JJ JJ O
interest NN NN O
in IN IN O
the DT DT O
neurosurgical JJ JJ O
community NN NN O
. . . O

Another DT DT O
lesioning VBG VBG O
procedure NN NN O
, , , O
ventrolateral JJ JJ O
thalamotomy NN NN O
, , , O
has VBZ VBZ O
become VBN VBN O
a DT DT O
powerful JJ JJ O
alternative NN NN O
to TO TO O
stimulate VB VB O
the DT DT O
nucleus NN NN O
ventralis NNS NNS O
intermedius NN NN O
, , , O
producing VBG VBG O
high JJ JJ O
long JJ JJ O
- - - O
term NN NN O
success NN NN O
rates NNS NNS O
and CC CC O
low JJ JJ O
morbidity NN NN O
rates NNS NNS O
. . . O

Pallidal NNP NNP O
stimulation NN NN O
has VBZ VBZ O
not RB RB O
met VBN VBN O
with IN IN O
the DT DT O
same JJ JJ O
success NN NN O
. . . O

According VBG VBG O
to TO TO O
the DT DT O
literature NN NN O
pallidotomy NN NN O
improves VBZ VBZ O
the DT DT O
" '' '' O
on IN IN O
" '' '' O
symptoms NNS NNS O
of IN IN O
PD NNP NNP O
, , , O
such JJ JJ O
as IN IN O
dyskinesias NNS NNS O
, , , O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
" '' '' O
off IN IN O
" '' '' O
symptoms NNS NNS O
, , , O
such JJ JJ O
as IN IN O
rigidity NN NN O
, , , O
bradykinesia NN NN O
, , , O
and CC CC O
on IN IN O
- - - O
off RP RP O
fluctuations NNS NNS O
. . . O

Pallidal NNP NNP O
stimulation NN NN O
improves VBZ VBZ O
bradykinesia NN NN O
and CC CC O
rigidity NN NN O
to TO TO O
a DT DT O
minor JJ JJ O
extent NN NN O
; : : O
however RB RB O
, , , O
its PRP$ PRP$ O
strength NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
in IN IN O
improving VBG VBG O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
. . . O

Stimulation NNP NNP O
often RB RB O
produces VBZ VBZ O
an DT DT O
improvement NN NN O
in IN IN O
the DT DT O
hyper NN NN O
- - - O
or CC CC O
dyskinetic JJ JJ O
upper NN NN O
limbs NNS NNS O
, , , O
but CC CC O
increases VBZ VBZ O
the DT DT O
" '' '' O
freezing VBG VBG O
" '' '' O
phenomenon NN NN O
in IN IN O
the DT DT O
lower JJR JJR O
limbs NNS NNS O
at IN IN O
the DT DT O
same JJ JJ O
time NN NN O
. . . O

Considering VBG VBG O
the DT DT O
small JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
independence NN NN O
, , , O
the DT DT O
high JJ JJ O
costs NNS NNS O
of IN IN O
bilateral JJ JJ O
implants NNS NNS O
, , , O
and CC CC O
the DT DT O
difficulty NN NN O
most JJS JJS O
patients NNS NNS O
experience NN NN O
in IN IN O
handling VBG VBG O
the DT DT O
devices NNS NNS O
, , , O
the DT DT O
question NN NN O
arises VBZ VBZ O
as IN IN O
to TO TO O
whether IN IN O
bilateral JJ JJ O
pallidal NN NN O
stimulation NN NN O
is VBZ VBZ O
a DT DT O
real JJ JJ O
alternative NN NN O
to TO TO O
pallidotomy NN NN O
. . . O

Effects NNP NNP O
of IN IN O
the DT DT O
cyclooxygenase NN NN O
- - - O
2 CD CD O
specific JJ JJ O
inhibitor NN NN O
valdecoxib NN NN B-CHEM
versus CC CC O
nonsteroidal JJ JJ O
antiinflammatory NN NN O
agents NNS NNS O
and CC CC O
placebo NN NN O
on IN IN O
cardiovascular JJ JJ O
thrombotic JJ JJ O
events NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
arthritis NN NN O
. . . O

There EX EX O
have VBP VBP O
been VBN VBN O
concerns NNS NNS O
that IN IN O
the DT DT O
risk NN NN O
of IN IN O
cardiovascular JJ JJ O
thrombotic JJ JJ O
events NNS NNS O
may MD MD O
be VB VB O
higher JJR JJR O
with IN IN O
cyclooxygenase NN NN O
( ( ( O
COX NNP NNP O
) ) ) O
- : : O
2 CD CD O
- : : O
specific JJ JJ O
inhibitors NNS NNS O
than IN IN O
nonselective JJ JJ O
nonsteroidal NN NN O
antiinflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAIDs NNP NNP O
) ) ) O
. . . O

We PRP PRP O
evaluated VBD VBD O
cardiovascular JJ JJ O
event NN NN O
data NNS NNS O
for IN IN O
valdecoxib NN NN B-CHEM
, , , O
a DT DT O
new JJ JJ O
COX NNP NNP O
- : : O
2 CD CD O
- : : O
specific JJ JJ O
inhibitor NN NN O
in IN IN O
approximately RB RB O
8000 CD CD O
patients NNS NNS O
with IN IN O
osteoarthritis NNS NNS O
and CC CC O
rheumatoid VB VB O
arthritis NN NN O
treated VBN VBN O
with IN IN O
this DT DT O
agent NN NN O
in IN IN O
randomized JJ JJ O
clinical JJ JJ O
trials NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
cardiovascular JJ JJ O
thrombotic JJ JJ O
events NNS NNS O
( ( ( O
cardiac NN NN O
, , , O
cerebrovascular NN NN O
and CC CC O
peripheral JJ JJ O
vascular NN NN O
, , , O
or CC CC O
arterial JJ JJ O
thrombotic JJ JJ O
) ) ) O
was VBD VBD O
determined VBN VBN O
by IN IN O
analyzing VBG VBG O
pooled JJ JJ O
valdecoxib NN NN B-CHEM
( ( ( O
10 CD CD O
- : : O
80 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
, , , O
nonselective JJ JJ O
NSAID NNP NNP O
( ( ( O
diclofenac NN NN B-CHEM
75 CD CD O
mg NN NN O
bid NN NN O
, , , O
ibuprofen NN NN B-CHEM
800 CD CD O
mg NN NN O
tid NN NN O
, , , O
or CC CC O
naproxen NN NN B-CHEM
500 CD CD O
mg NN NN O
bid NN NN O
) ) ) O
and CC CC O
placebo NN NN O
data NNS NNS O
from IN IN O
10 CD CD O
randomized JJ JJ O
osteoarthritis NNS NNS O
and CC CC O
rheumatoid NN NN O
arthritis NN NN O
trials NNS NNS O
that WDT WDT O
were VBD VBD O
6 CD CD O
- : : O
52 CD CD O
weeks NNS NNS O
in IN IN O
duration NN NN O
. . . O

The DT DT O
incidence NN NN O
rates NNS NNS O
of IN IN O
events NNS NNS O
were VBD VBD O
determined VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
7934 CD CD O
) ) ) O
and CC CC O
in IN IN O
users NNS NNS O
of IN IN O
low JJ JJ O
- - - O
dose NN NN O
( ( ( O
< NN NN O
or CC CC O
= SYM SYM O
325 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
aspirin NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
1051 CD CD O
) ) ) O
and CC CC O
nonusers NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
6883 CD CD O
) ) ) O
. . . O

Crude NNP NNP O
and CC CC O
exposure NN NN O
- - - O
adjusted VBN VBN O
incidences NNS NNS O
of IN IN O
thrombotic JJ JJ O
events NNS NNS O
were VBD VBD O
similar JJ JJ O
for IN IN O
valdecoxib NN NN B-CHEM
, , , O
NSAIDs NNP NNP O
, , , O
and CC CC O
placebo NN NN O
. . . O

The DT DT O
risk NN NN O
of IN IN O
serious JJ JJ O
thrombotic JJ JJ O
events NNS NNS O
was VBD VBD O
also RB RB O
similar JJ JJ O
for IN IN O
each DT DT O
valdecoxib NN NN B-CHEM
dose NN NN O
. . . O

Thrombotic NNP NNP O
risk NN NN O
was VBD VBD O
consistently RB RB O
higher JJR JJR O
for IN IN O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
users NNS NNS O
than IN IN O
nonusers NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
( ( ( O
placebo NN NN O
, , , O
1 CD CD O
. . . O
4 CD CD O
% NN NN O
vs NNS NNS O
. . . O
0 CD CD O
% NN NN O
; : : O
valdecoxib NN NN B-CHEM
, , , O
1 CD CD O
. . . O
7 CD CD O
% NN NN O
vs NNS NNS O
. . . O
0 CD CD O
. . . O
2 CD CD O
% NN NN O
; : : O
NSAIDs NNP NNP O
, , , O
1 CD CD O
. . . O
9 CD CD O
% NN NN O
vs NNS NNS O
. . . O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
rates NNS NNS O
of IN IN O
events NNS NNS O
in IN IN O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
were VBD VBD O
similar JJ JJ O
for IN IN O
all DT DT O
3 CD CD O
treatment NN NN O
groups NNS NNS O
and CC CC O
across IN IN O
valdecoxib NN NN B-CHEM
doses NNS NNS O
. . . O

Short JJ JJ O
- : : O
and CC CC O
intermediate JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
therapeutic JJ JJ O
( ( ( O
10 CD CD O
or CC CC O
20 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
and CC CC O
supratherapeutic JJ JJ O
( ( ( O
40 CD CD O
or CC CC O
80 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
valdecoxib NN NN B-CHEM
doses NNS NNS O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
thrombotic JJ JJ O
events NNS NNS O
relative JJ JJ O
to TO TO O
nonselective JJ JJ O
NSAIDs NNP NNP O
or CC CC O
placebo NN NN O
in IN IN O
osteoarthritis NN NN O
and CC CC O
rheumatoid JJ JJ O
arthritis NN NN O
patients NNS NNS O
in IN IN O
controlled VBN VBN O
clinical JJ JJ O
trials NNS NNS O
. . . O

Hypersensitivity NNP NNP O
myocarditis NN NN O
complicating VBG VBG O
hypertrophic JJ JJ O
cardiomyopathy JJ JJ O
heart NN NN O
. . . O

The DT DT O
present JJ JJ O
report NN NN O
describes VBZ VBZ O
a DT DT O
case NN NN O
of IN IN O
eosinophilic JJ JJ O
myocarditis NNS NNS O
complicating VBG VBG O
hypertrophic JJ JJ O
cardiomyopathy NN NN O
. . . O

The DT DT O
47 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
female JJ JJ O
patient NN NN O
, , , O
known VBN VBN O
to TO TO O
have VB VB O
hypertrophic JJ JJ O
cardiomyopathy NN NN O
, , , O
was VBD VBD O
admitted VBN VBN O
with IN IN O
biventricular JJ JJ O
failure NN NN O
and CC CC O
managed VBD VBD O
aggressively RB RB O
with IN IN O
dobutamine NN NN B-CHEM
infusion NN NN O
and CC CC O
other JJ JJ O
drugs NNS NNS O
while IN IN O
being VBG VBG O
assessed VBN VBN O
for IN IN O
heart NN NN O
transplantation NN NN O
. . . O

On IN IN O
transthoracic NN NN O
echocardiogram NN NN O
, , , O
she PRP PRP O
had VBD VBD O
moderate JJ JJ O
left VBN VBN O
ventricular NN NN O
dysfunction NN NN O
with IN IN O
regional JJ JJ O
variability NN NN O
and CC CC O
moderate JJ JJ O
mitral JJ JJ O
regurgitation NN NN O
. . . O

The DT DT O
recipient NN NN O
' '' '' O
s VBZ VBZ O
heart NN NN O
showed VBN VBN O
the DT DT O
features NNS NNS O
of IN IN O
apical JJ JJ O
hypertrophic JJ JJ O
cardiomyopathy NN NN O
and CC CC O
myocarditis NN NN O
with IN IN O
abundant JJ JJ O
eosinophils NNS NNS O
. . . O

Myocarditis NNP NNP O
is VBZ VBZ O
rare JJ JJ O
and CC CC O
eosinophilic JJ JJ O
myocarditis NN NN O
is VBZ VBZ O
rarer NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
likely JJ JJ O
that IN IN O
the DT DT O
hypersensitivity NN NN O
( ( ( O
eosinophilic JJ JJ O
) ) ) O
myocarditis NN NN O
was VBD VBD O
related VBN VBN O
to TO TO O
dobutamine NN NN B-CHEM
infusion NN NN O
therapy NN NN O
. . . O

Eosinophilic NNP NNP O
myocarditis NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
with IN IN O
an DT DT O
incidence NN NN O
of IN IN O
2 CD CD O
. . . O
4 CD CD O
% NN NN O
to TO TO O
7 CD CD O
. . . O
2 CD CD O
% NN NN O
in IN IN O
explanted JJ JJ O
hearts NNS NNS O
and CC CC O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
multidrug NN NN O
therapy NN NN O
. . . O

Time NNP NNP O
trends NNS NNS O
in IN IN O
warfarin NN NN B-CHEM
- - - O
associated VBN VBN O
hemorrhage NN NN O
. . . O

The DT DT O
annual JJ JJ O
incidence NN NN O
of IN IN O
warfarin NN NN B-CHEM
- - - O
related VBN VBN O
bleeding VBG VBG O
at IN IN O
Brigham NNP NNP O
and CC CC O
Women NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
increased VBN VBN O
from IN IN O
0 CD CD O
. . . O
97 CD CD O
/ NN NN O
1 CD CD O
, , , O
000 CD CD O
patient NN NN O
admissions NNS NNS O
in IN IN O
the DT DT O
first JJ JJ O
time NN NN O
period NN NN O
( ( ( O
January NNP NNP O
1995 CD CD O
to TO TO O
October NNP NNP O
1998 CD CD O
) ) ) O
to TO TO O
1 CD CD O
. . . O
19 CD CD O
/ NN NN O
1 CD CD O
, , , O
000 CD CD O
patient NN NN O
admissions NNS NNS O
in IN IN O
the DT DT O
second JJ JJ O
time NN NN O
period NN NN O
( ( ( O
November NNP NNP O
1998 CD CD O
to TO TO O
August NNP NNP O
2002 CD CD O
) ) ) O
of IN IN O
this DT DT O
study NN NN O
. . . O

The DT DT O
proportion NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
major JJ JJ O
and CC CC O
intracranial JJ JJ O
bleeding VBG VBG O
increased VBN VBN O
from IN IN O
20 CD CD O
. . . O
2 CD CD O
% NN NN O
and CC CC O
1 CD CD O
. . . O
9 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
in IN IN O
the DT DT O
first JJ JJ O
time NN NN O
period NN NN O
, , , O
to TO TO O
33 CD CD O
. . . O
3 CD CD O
% NN NN O
and CC CC O
7 CD CD O
. . . O
8 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
in IN IN O
the DT DT O
second JJ JJ O
. . . O

Yohimbine NNP NNP B-CHEM
treatment NN NN O
of IN IN O
sexual JJ JJ O
side NN NN O
effects NNS NNS O
induced VBN VBN O
by IN IN O
serotonin NN NN B-CHEM
reuptake NN NN O
blockers NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Preclinical NNP NNP O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
yohimbine NN NN B-CHEM
facilitates NNS NNS O
sexual JJ JJ O
behavior NN NN O
and CC CC O
may MD MD O
be VB VB O
helpful JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
male JJ JJ O
impotence NN NN O
. . . O

A DT DT O
single JJ JJ O
case NN NN O
report NN NN O
suggests VBZ VBZ O
that IN IN O
yohimbine NN NN B-CHEM
may MD MD O
be VB VB O
used VBN VBN O
to TO TO O
treat VB VB O
the DT DT O
sexual JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
clomipramine NN NN B-CHEM
. . . O

This DT DT O
study NN NN O
evaluated VBD VBD O
yohimbine NN NN B-CHEM
as IN IN O
a DT DT O
treatment NN NN O
for IN IN O
the DT DT O
sexual JJ JJ O
side NN NN O
effects NNS NNS O
caused VBN VBN O
by IN IN O
serotonin NN NN B-CHEM
reuptake NN NN O
blockers NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
Six CD CD O
patients NNS NNS O
with IN IN O
either DT DT O
obsessive JJ JJ O
compulsive JJ JJ O
disorder NN NN O
, , , O
trichotillomania NN NN O
, , , O
anxiety NN NN O
, , , O
or CC CC O
affective JJ JJ O
disorders NNS NNS O
who WP WP O
suffered VBD VBD O
sexual JJ JJ O
side NN NN O
effects NNS NNS O
after IN IN O
treatment NN NN O
with IN IN O
serotonin NN NN B-CHEM
reuptake NN NN O
blockers NNS NNS O
were VBD VBD O
given VBN VBN O
yohimbine NN NN B-CHEM
on IN IN O
a DT DT O
p NN NN O
. . . O
r LS LS O
. . . O
n NN NN O
. . . O
basis NN NN O
in IN IN O
an DT DT O
open JJ JJ O
clinical JJ JJ O
trial NN NN O
. . . O

Various JJ JJ O
doses NNS NNS O
of IN IN O
yohimbine NN NN B-CHEM
were VBD VBD O
used VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
ideal JJ JJ O
dose NN NN O
for IN IN O
each DT DT O
patient NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Five CD CD O
of IN IN O
the DT DT O
six CD CD O
patients NNS NNS O
experienced VBD VBD O
improved VBN VBN O
sexual JJ JJ O
functioning NN NN O
after IN IN O
taking VBG VBG O
yohimbine NN NN B-CHEM
. . . O

One CD CD O
patient NN NN O
who WP WP O
failed VBD VBD O
to TO TO O
comply VB VB O
with IN IN O
yohimbine NN NN B-CHEM
treatment NN NN O
had VBD VBD O
no DT DT O
therapeutic JJ JJ O
effects NNS NNS O
. . . O

Side NNP NNP O
effects NNS NNS O
of IN IN O
yohimbine NN NN B-CHEM
included VBD VBD O
excessive JJ JJ O
sweating NN NN O
, , , O
increased VBN VBN O
anxiety NN NN O
, , , O
and CC CC O
a DT DT O
wound NN NN O
- - - O
up RP RP O
feeling NN NN O
in IN IN O
some DT DT O
patients NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
study NN NN O
indicate VBP VBP O
that IN IN O
yohimbine NN NN B-CHEM
may MD MD O
be VB VB O
an DT DT O
effective JJ JJ O
treatment NN NN O
for IN IN O
the DT DT O
sexual JJ JJ O
side NN NN O
effects NNS NNS O
caused VBN VBN O
by IN IN O
serotonin NN NN B-CHEM
reuptake NN NN O
blockers NNS NNS O
. . . O

Future NNP NNP O
controlled VBN VBN O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
further VB VB O
investigate VB VB O
the DT DT O
effectiveness NN NN O
and CC CC O
safety NN NN O
of IN IN O
yohimbine NN NN B-CHEM
for IN IN O
this DT DT O
indication NN NN O
. . . O

Hemorrhagic NNP NNP O
cystitis NNS NNS O
complicating VBG VBG O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. . . O

Hemorrhagic NNP NNP O
cystitis NN NN O
is VBZ VBZ O
a DT DT O
potentially RB RB O
serious JJ JJ O
complication NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
cyclophosphamide NN NN B-CHEM
therapy NN NN O
administered VBD VBD O
before IN IN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. . . O

As IN IN O
standard JJ JJ O
practice NN NN O
at IN IN O
our PRP$ PRP$ O
institution NN NN O
, , , O
patients NNS NNS O
who WP WP O
are VBP VBP O
scheduled VBN VBN O
to TO TO O
receive VB VB O
a DT DT O
bone NN NN O
marrow NN NN O
transplant NN NN O
are VBP VBP O
treated VBN VBN O
prophylactically RB RB O
with IN IN O
forced JJ JJ O
hydration NN NN O
and CC CC O
bladder NN NN O
irrigation NN NN O
. . . O

In IN IN O
an DT DT O
attempt NN NN O
to TO TO O
obviate VB VB O
the DT DT O
inconvenience NN NN O
of IN IN O
bladder NN NN O
irrigation NN NN O
, , , O
we PRP PRP O
conducted VBD VBD O
a DT DT O
feasibility NN NN O
trial NN NN O
of IN IN O
uroprophylaxis NNS NNS O
with IN IN O
mesna NN NN B-CHEM
, , , O
which WDT WDT O
neutralizes VBZ VBZ O
the DT DT O
hepatic JJ JJ O
metabolite NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
that IN IN O
causes NNS NNS O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

Of IN IN O
97 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
standard JJ JJ O
prophylaxis NN NN O
, , , O
4 CD CD O
had VBD VBD O
symptomatic JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
two CD CD O
of IN IN O
four CD CD O
consecutive JJ JJ O
patients NNS NNS O
who WP WP O
received VBD VBD O
mesna NN NN B-CHEM
uroprophylaxis NNS NNS O
before IN IN O
allogeneic NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
had VBD VBD O
severe JJ JJ O
hemorrhagic JJ JJ O
cystitis NN NN O
for IN IN O
at IN IN O
least JJS JJS O
2 CD CD O
weeks NNS NNS O
. . . O

Because IN IN O
of IN IN O
this DT DT O
suboptimal NN NN O
result NN NN O
, , , O
we PRP PRP O
resumed VBD VBD O
the DT DT O
use NN NN O
of IN IN O
bladder NN NN O
irrigation NN NN O
and CC CC O
forced VBD VBD O
hydration NN NN O
to TO TO O
minimize VB VB O
the DT DT O
risk NN NN O
of IN IN O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

Consensus NNP NNP O
statement NN NN O
concerning VBG VBG O
cardiotoxicity NN NN O
occurring VBG VBG O
during IN IN O
haematopoietic JJ JJ O
stem NN NN O
cell NN NN O
transplantation NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
autoimmune JJ JJ O
diseases NNS NNS O
, , , O
with IN IN O
special JJ JJ O
reference NN NN O
to TO TO O
systemic JJ JJ O
sclerosis NN NN O
and CC CC O
multiple JJ JJ O
sclerosis NN NN O
. . . O

Autologous NNP NNP O
haematopoietic JJ JJ O
stem NN NN O
cell NN NN O
transplantation NN NN O
is VBZ VBZ O
now RB RB O
a DT DT O
feasible JJ JJ O
and CC CC O
effective JJ JJ O
treatment NN NN O
for IN IN O
selected VBN VBN O
patients NNS NNS O
with IN IN O
severe JJ JJ O
autoimmune JJ JJ O
diseases NNS NNS O
. . . O

Worldwide NNP NNP O
, , , O
over IN IN O
650 CD CD O
patients NNS NNS O
have VBP VBP O
been VBN VBN O
transplanted VBN VBN O
in IN IN O
the DT DT O
context NN NN O
of IN IN O
phase NN NN O
I PRP PRP O
and CC CC O
II NNP NNP O
clinical JJ JJ O
trials NNS NNS O
. . . O

The DT DT O
results NNS NNS O
are VBP VBP O
encouraging VBG VBG O
enough JJ JJ O
to TO TO O
begin VB VB O
randomised VBN VBN O
phase NN NN O
III NNP NNP O
trials NNS NNS O
. . . O

However RB RB O
, , , O
as IN IN O
predicted VBN VBN O
, , , O
significant JJ JJ O
transplant NN NN O
- - - O
related VBN VBN O
morbidity NN NN O
and CC CC O
mortality NN NN O
have VBP VBP O
been VBN VBN O
observed VBN VBN O
. . . O

This DT DT O
is VBZ VBZ O
primarily RB RB O
due JJ JJ O
to TO TO O
complications NNS NNS O
related VBN VBN O
to TO TO O
either CC CC O
the DT DT O
stage NN NN O
of IN IN O
the DT DT O
disease NN NN O
at IN IN O
transplant NN NN O
or CC CC O
due JJ JJ O
to TO TO O
infections NNS NNS O
. . . O

The DT DT O
number NN NN O
of IN IN O
deaths NNS NNS O
related VBN VBN O
to TO TO O
cardiac JJ JJ O
toxicity NN NN O
is VBZ VBZ O
low JJ JJ O
. . . O

However RB RB O
, , , O
caution NN NN O
is VBZ VBZ O
required VBN VBN O
when WRB WRB O
cyclophosphamide NN NN B-CHEM
or CC CC O
anthracyclines NNS NNS B-CHEM
such JJ JJ O
as IN IN O
mitoxantrone NN NN B-CHEM
are VBP VBP O
used VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
possible JJ JJ O
underlying VBG VBG O
heart NN NN O
damage NN NN O
, , , O
for IN IN O
example NN NN O
, , , O
systemic JJ JJ O
sclerosis NN NN O
patients NNS NNS O
. . . O

In IN IN O
November NNP NNP O
2002 CD CD O
, , , O
a DT DT O
meeting NN NN O
was VBD VBD O
held VBN VBN O
in IN IN O
Florence NNP NNP O
, , , O
bringing VBG VBG O
together RB RB O
a DT DT O
number NN NN O
of IN IN O
experts NNS NNS O
in IN IN O
various JJ JJ O
fields NNS NNS O
, , , O
including VBG VBG O
rheumatology NN NN O
, , , O
cardiology NN NN O
, , , O
neurology NN NN O
, , , O
pharmacology NN NN O
and CC CC O
transplantation NN NN O
medicine NN NN O
. . . O

The DT DT O
object NN NN O
of IN IN O
the DT DT O
meeting NN NN O
was VBD VBD O
to TO TO O
analyse VB VB O
existing VBG VBG O
data NNS NNS O
, , , O
both DT DT O
published VBN VBN O
or CC CC O
available JJ JJ O
, , , O
in IN IN O
the DT DT O
European JJ JJ O
Group NNP NNP O
for IN IN O
Blood NNP NNP O
and CC CC O
Marrow NNP NNP O
Transplantation NNP NNP O
autoimmune NN NN O
disease NN NN O
database NN NN O
, , , O
and CC CC O
to TO TO O
propose VB VB O
a DT DT O
safe JJ JJ O
approach NN NN O
to TO TO O
such JJ JJ O
patients NNS NNS O
. . . O

A DT DT O
full JJ JJ O
cardiological JJ JJ O
assessment NN NN O
before IN IN O
and CC CC O
during IN IN O
the DT DT O
transplant NN NN O
emerged VBD VBD O
as IN IN O
the DT DT O
major JJ JJ O
recommendation NN NN O
. . . O

Does VBZ VBZ O
supplemental JJ JJ O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
increase NN NN O
cardiovascular NN NN O
disease NN NN O
risk NN NN O
in IN IN O
women NNS NNS O
with IN IN O
diabetes NN NN O
? . . O

BACKGROUND NNP NNP O
: : : O
Vitamin NNP NNP B-CHEM
C NNP NNP I-CHEM
acts NNS NNS O
as IN IN O
a DT DT O
potent JJ JJ O
antioxidant NN NN O
; : : O
however RB RB O
, , , O
it PRP PRP O
can MD MD O
also RB RB O
be VB VB O
a DT DT O
prooxidant NN NN O
and CC CC O
glycate NN NN O
protein NN NN O
under IN IN O
certain JJ JJ O
circumstances NNS NNS O
in IN IN O
vitro NN NN O
. . . O

These DT DT O
observations NNS NNS O
led VBD VBD O
us PRP PRP O
to TO TO O
hypothesize VB VB O
that IN IN O
a DT DT O
high JJ JJ O
intake NN NN O
of IN IN O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
in IN IN O
diabetic JJ JJ O
persons NNS NNS O
might MD MD O
promote VB VB O
atherosclerosis NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
objective NN NN O
was VBD VBD O
to TO TO O
examine VB VB O
the DT DT O
relation NN NN O
between IN IN O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
intake NN NN O
and CC CC O
mortality NN NN O
from IN IN O
cardiovascular JJ JJ O
disease NN NN O
. . . O

DESIGN NNP NNP O
: : : O
We PRP PRP O
studied VBD VBD O
the DT DT O
relation NN NN O
between IN IN O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
intake NN NN O
and CC CC O
mortality NN NN O
from IN IN O
total JJ JJ O
cardiovascular JJ JJ O
disease NN NN O
( ( ( O
n NN NN O
= SYM SYM O
281 CD CD O
) ) ) O
, , , O
coronary JJ JJ O
artery NN NN O
disease NN NN O
( ( ( O
n NN NN O
= SYM SYM O
175 CD CD O
) ) ) O
, , , O
and CC CC O
stroke NN NN O
( ( ( O
n NN NN O
= SYM SYM O
57 CD CD O
) ) ) O
in IN IN O
1923 CD CD O
postmenopausal NN NN O
women NNS NNS O
who WP WP O
reported VBD VBD O
being VBG VBG O
diabetic JJ JJ O
at IN IN O
baseline NN NN O
. . . O

Diet NNP NNP O
was VBD VBD O
assessed VBN VBN O
with IN IN O
a DT DT O
food NN NN O
- - - O
frequency NN NN O
questionnaire NN NN O
at IN IN O
baseline NN NN O
, , , O
and CC CC O
subjects NNS NNS O
initially RB RB O
free JJ JJ O
of IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
were VBD VBD O
prospectively RB RB O
followed VBN VBN O
for IN IN O
15 CD CD O
y NN NN O
. . . O

RESULTS NNS NNS O
: : : O
After IN IN O
adjustment NN NN O
for IN IN O
cardiovascular JJ JJ O
disease NN NN O
risk NN NN O
factors NNS NNS O
, , , O
type NN NN O
of IN IN O
diabetes NN NN O
medication NN NN O
used VBN VBN O
, , , O
duration NN NN O
of IN IN O
diabetes NN NN O
, , , O
and CC CC O
intakes NNS NNS O
of IN IN O
folate NN NN B-CHEM
, , , O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
, , , O
and CC CC O
beta NN NN B-CHEM
- - - I-CHEM
carotene NN NN I-CHEM
, , , O
the DT DT O
adjusted VBN VBN O
relative JJ JJ O
risks NNS NNS O
of IN IN O
total JJ JJ O
cardiovascular JJ JJ O
disease NN NN O
mortality NN NN O
were VBD VBD O
1 CD CD O
. . . O
0 CD CD O
, , , O
0 CD CD O
. . . O
97 CD CD O
, , , O
1 CD CD O
. . . O
11 CD CD O
, , , O
1 CD CD O
. . . O
47 CD CD O
, , , O
and CC CC O
1 CD CD O
. . . O
84 CD CD O
( ( ( O
P NN NN O
for IN IN O
trend NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
across IN IN O
quintiles NNS NNS O
of IN IN O
total JJ JJ O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
intake NN NN O
from IN IN O
food NN NN O
and CC CC O
supplements NNS NNS O
. . . O

Adjusted NNP NNP O
relative JJ JJ O
risks NNS NNS O
of IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
were VBD VBD O
1 CD CD O
. . . O
0 CD CD O
, , , O
0 CD CD O
. . . O
81 CD CD O
, , , O
0 CD CD O
. . . O
99 CD CD O
, , , O
1 CD CD O
. . . O
26 CD CD O
, , , O
and CC CC O
1 CD CD O
. . . O
91 CD CD O
( ( ( O
P NN NN O
for IN IN O
trend NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
and CC CC O
of IN IN O
stroke NN NN O
were VBD VBD O
1 CD CD O
. . . O
0 CD CD O
, , , O
0 CD CD O
. . . O
52 CD CD O
, , , O
1 CD CD O
. . . O
23 CD CD O
, , , O
2 CD CD O
. . . O
22 CD CD O
, , , O
and CC CC O
2 CD CD O
. . . O
57 CD CD O
( ( ( O
P NN NN O
for IN IN O
trend NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

When WRB WRB O
dietary JJ JJ O
and CC CC O
supplemental JJ JJ O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
were VBD VBD O
analyzed VBN VBN O
separately RB RB O
, , , O
only RB RB O
supplemental JJ JJ O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
showed VBD VBD O
a DT DT O
positive JJ JJ O
association NN NN O
with IN IN O
mortality NN NN O
endpoints NNS NNS O
. . . O

Vitamin NNP NNP B-CHEM
C NNP NNP I-CHEM
intake NN NN O
was VBD VBD O
unrelated JJ JJ O
to TO TO O
mortality NN NN O
from IN IN O
cardiovascular JJ JJ O
disease NN NN O
in IN IN O
the DT DT O
nondiabetic JJ JJ O
subjects NNS NNS O
at IN IN O
baseline NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
A DT DT O
high JJ JJ O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
intake NN NN O
from IN IN O
supplements NNS NNS O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
mortality NN NN O
in IN IN O
postmenopausal NN NN O
women NNS NNS O
with IN IN O
diabetes NN NN O
. . . O

Optical NNP NNP O
coherence NN NN O
tomography NN NN O
can MD MD O
measure VB VB O
axonal JJ JJ O
loss NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
ethambutol NN NN B-CHEM
- - - O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
map VB VB O
and CC CC O
identify VB VB O
the DT DT O
pattern NN NN O
, , , O
in IN IN O
vivo NN NN O
, , , O
of IN IN O
axonal JJ JJ O
degeneration NN NN O
in IN IN O
ethambutol NN NN B-CHEM
- - - O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
using VBG VBG O
optical JJ JJ O
coherence NN NN O
tomography NN NN O
( ( ( O
OCT NNP NNP O
) ) ) O
. . . O

Ethambutol NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
antimycobacterial JJ JJ O
agent NN NN O
often RB RB O
used VBD VBD O
to TO TO O
treat VB VB O
tuberculosis NNS NNS O
. . . O

A DT DT O
serious JJ JJ O
complication NN NN O
of IN IN O
ethambutol NN NN B-CHEM
is VBZ VBZ O
an DT DT O
optic JJ JJ O
neuropathy NN NN O
that IN IN O
impairs NNS NNS O
visual JJ JJ O
acuity NN NN O
, , , O
contrast NN NN O
sensitivity NN NN O
, , , O
and CC CC O
color NN NN O
vision NN NN O
. . . O

However RB RB O
, , , O
early JJ JJ O
on IN IN O
, , , O
when WRB WRB O
the DT DT O
toxic JJ JJ O
optic JJ JJ O
neuropathy NN NN O
is VBZ VBZ O
mild JJ JJ O
and CC CC O
partly RB RB O
reversible JJ JJ O
, , , O
the DT DT O
funduscopic NN NN O
findings NNS NNS O
are VBP VBP O
often RB RB O
subtle JJ JJ O
and CC CC O
easy JJ JJ O
to TO TO O
miss VB VB O
. . . O

METHODS NNP NNP O
: : : O
Three CD CD O
subjects NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
ethambutol NN NN B-CHEM
( ( ( O
EMB NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
of IN IN O
short JJ JJ O
- - - O
, , , O
intermediate JJ JJ O
- - - O
, , , O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
visual JJ JJ O
deficits NNS NNS O
were VBD VBD O
administered VBN VBN O
a DT DT O
full JJ JJ O
neuro NN NN O
- - - O
ophthalmologic JJ JJ O
examination NN NN O
including VBG VBG O
visual JJ JJ O
acuity NN NN O
, , , O
color NN NN O
vision NN NN O
, , , O
contrast NN NN O
sensitivity NN NN O
, , , O
and CC CC O
fundus NN NN O
examination NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
OCT NNP NNP O
( ( ( O
OCT NNP NNP O
3000 CD CD O
, , , O
Humphrey NNP NNP O
- : : O
Zeiss NNP NNP O
, , , O
Dublin NNP NNP O
, , , O
CA NNP NNP O
) ) ) O
was VBD VBD O
performed VBN VBN O
on IN IN O
both DT DT O
eyes NNS NNS O
of IN IN O
each DT DT O
subject NN NN O
using VBG VBG O
the DT DT O
retinal JJ JJ O
nerve NN NN O
fiber NN NN O
layer NN NN O
( ( ( O
RNFL NNP NNP O
) ) ) O
analysis NN NN O
protocol NN NN O
. . . O

OCT NNP NNP O
interpolates VBZ VBZ O
data NNS NNS O
from IN IN O
100 CD CD O
points NNS NNS O
around IN IN O
the DT DT O
optic JJ JJ O
nerve NN NN O
to TO TO O
effectively RB RB O
map VB VB O
out RP RP O
the DT DT O
RNFL NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
results NNS NNS O
were VBD VBD O
compared VBN VBN O
to TO TO O
the DT DT O
calculated JJ JJ O
average JJ JJ O
RNFL NNP NNP O
of IN IN O
normal JJ JJ O
eyes NNS NNS O
accumulated VBN VBN O
from IN IN O
four CD CD O
prior RB RB O
studies VBZ VBZ O
using VBG VBG O
OCT NNP NNP O
, , , O
n NN NN O
= SYM SYM O
661 CD CD O
. . . O

In IN IN O
all DT DT O
subjects NNS NNS O
with IN IN O
history NN NN O
of IN IN O
EMB NNP NNP B-CHEM
- : : O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
mean JJ JJ O
loss NN NN O
of IN IN O
72 CD CD O
% NN NN O
nerve NN NN O
fiber NN NN O
layer NN NN O
thickness NN NN O
in IN IN O
the DT DT O
temporal JJ JJ O
quadrant NN NN O
( ( ( O
patient NN NN O
A DT DT O
, , , O
with IN IN O
eventual JJ JJ O
recovery NN NN O
of IN IN O
visual JJ JJ O
acuity NN NN O
and CC CC O
fields NNS NNS O
, , , O
58 CD CD O
% NN NN O
loss NN NN O
; : : O
patient NN NN O
B NNP NNP O
, , , O
with IN IN O
intermediate JJ JJ O
visual JJ JJ O
deficits NNS NNS O
, , , O
68 CD CD O
% NN NN O
loss NN NN O
; : : O
patient NN NN O
C NNP NNP O
, , , O
with IN IN O
chronic JJ JJ O
visual JJ JJ O
deficits NNS NNS O
, , , O
90 CD CD O
% NN NN O
loss NN NN O
) ) ) O
, , , O
with IN IN O
an DT DT O
average JJ JJ O
mean NN NN O
optic JJ JJ O
nerve NN NN O
thickness NN NN O
of IN IN O
26 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
microm NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
combined JJ JJ O
mean NN NN O
loss NN NN O
of IN IN O
46 CD CD O
% NN NN O
of IN IN O
fibers NNS NNS O
from IN IN O
the DT DT O
superior NN NN O
, , , O
inferior JJ JJ O
, , , O
and CC CC O
nasal NN NN O
quadrants NNS NNS O
in IN IN O
the DT DT O
( ( ( O
six CD CD O
) ) ) O
eyes NNS NNS O
of IN IN O
all DT DT O
three CD CD O
subjects NNS NNS O
( ( ( O
mean VB VB O
average JJ JJ O
thickness NN NN O
of IN IN O
55 CD CD O
+ NN NN O
/ NN NN O
- : : O
29 CD CD O
microm NN NN O
) ) ) O
. . . O

In IN IN O
both DT DT O
sets NNS NNS O
( ( ( O
four CD CD O
) ) ) O
of IN IN O
eyes NNS NNS O
of IN IN O
the DT DT O
subjects NNS NNS O
with IN IN O
persistent JJ JJ O
visual JJ JJ O
deficits NNS NNS O
( ( ( O
patients NNS NNS O
B NNP NNP O
and CC CC O
C NNP NNP O
) ) ) O
, , , O
there EX EX O
was VBD VBD O
an DT DT O
average JJ JJ O
loss NN NN O
of IN IN O
79 CD CD O
% NN NN O
of IN IN O
nerve NN NN O
fiber NN NN O
thickness NN NN O
in IN IN O
the DT DT O
temporal JJ JJ O
quadrant NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
OCT NNP NNP O
results NNS NNS O
in IN IN O
these DT DT O
patients NNS NNS O
with IN IN O
EMB NNP NNP B-CHEM
- : : O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
show NN NN O
considerable JJ JJ O
loss NN NN O
especially RB RB O
of IN IN O
the DT DT O
temporal JJ JJ O
fibers NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
consistent JJ JJ O
with IN IN O
prior RB RB O
histopathological JJ JJ O
studies NNS NNS O
that WDT WDT O
show VBP VBP O
predominant JJ JJ O
loss NN NN O
of IN IN O
parvo NN NN O
- - - O
cellular JJ JJ O
axons NNS NNS O
( ( ( O
or CC CC O
small JJ JJ O
- - - O
caliber NN NN O
axons NNS NNS O
) ) ) O
within IN IN O
the DT DT O
papillo NN NN O
- - - O
macular JJ JJ O
bundle NN NN O
in IN IN O
toxic JJ JJ O
or CC CC O
hereditary JJ JJ O
optic JJ JJ O
neuropathies NNS NNS O
. . . O

OCT NNP NNP O
can MD MD O
be VB VB O
a DT DT O
valuable JJ JJ O
tool NN NN O
in IN IN O
the DT DT O
quantitative JJ JJ O
analysis NN NN O
of IN IN O
optic JJ JJ O
neuropathies NNS NNS O
. . . O

Additionally RB RB O
, , , O
in IN IN O
terms NNS NNS O
of IN IN O
management NN NN O
of IN IN O
EMB NNP NNP B-CHEM
- : : O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
important JJ JJ O
to TO TO O
properly RB RB O
manage VB VB O
ethambutol NN NN B-CHEM
dosing VBG VBG O
in IN IN O
patients NNS NNS O
with IN IN O
renal JJ JJ O
impairment NN NN O
and CC CC O
to TO TO O
achieve VB VB O
proper JJ JJ O
transition NN NN O
to TO TO O
a DT DT O
maintenance NN NN O
dose NN NN O
once RB RB O
an DT DT O
appropriate JJ JJ O
loading NN NN O
dose NN NN O
has VBZ VBZ O
been VBN VBN O
reached VBN VBN O
. . . O

Hypoxia NNP NNP O
in IN IN O
renal JJ JJ O
disease NN NN O
with IN IN O
proteinuria NN NN O
and CC CC O
/ NN NN O
or CC CC O
glomerular JJ JJ O
hypertension NN NN O
. . . O

Despite IN IN O
the DT DT O
increasing VBG VBG O
need VBP VBP O
to TO TO O
identify VB VB O
and CC CC O
quantify VB VB O
tissue NN NN O
oxygenation NN NN O
at IN IN O
the DT DT O
cellular NN NN O
level NN NN O
, , , O
relatively RB RB O
few JJ JJ O
methods NNS NNS O
have VBP VBP O
been VBN VBN O
available JJ JJ O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
developed VBD VBD O
a DT DT O
new JJ JJ O
hypoxia NN NN O
- - - O
responsive JJ JJ O
reporter NN NN O
vector NN NN O
using VBG VBG O
a DT DT O
hypoxia NN NN O
- - - O
responsive JJ JJ O
element NN NN O
of IN IN O
the DT DT O
5 CD CD O
' POS POS O
vascular NN NN O
endothelial JJ JJ O
growth NN NN O
factor NN NN O
untranslated JJ JJ O
region NN NN O
and CC CC O
generated VBD VBD O
a DT DT O
novel NN NN O
hypoxia NN NN O
- : : O
sensing VBG VBG O
transgenic JJ JJ O
rat NN NN O
. . . O

We PRP PRP O
then RB RB O
applied VBD VBD O
this DT DT O
animal NN NN O
model NN NN O
to TO TO O
the DT DT O
detection NN NN O
of IN IN O
tubulointerstitial JJ JJ O
hypoxia NN NN O
in IN IN O
the DT DT O
diseased JJ JJ O
kidney NN NN O
. . . O

With IN IN O
this DT DT O
model NN NN O
, , , O
we PRP PRP O
were VBD VBD O
able JJ JJ O
to TO TO O
identify VB VB O
diffuse NN NN O
cortical JJ JJ O
hypoxia NN NN O
in IN IN O
the DT DT O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
and CC CC O
focal JJ JJ O
and CC CC O
segmental JJ JJ O
hypoxia NN NN O
in IN IN O
the DT DT O
remnant NN NN O
kidney NN NN O
model NN NN O
. . . O

Expression NNP NNP O
of IN IN O
the DT DT O
hypoxia NN NN O
- - - O
responsive JJ JJ O
transgene NN NN O
increased VBN VBN O
throughout IN IN O
the DT DT O
observation NN NN O
period NN NN O
, , , O
reaching VBG VBG O
2 CD CD O
. . . O
2 CD CD O
- : : O
fold NN NN O
at IN IN O
2 CD CD O
weeks NNS NNS O
in IN IN O
the DT DT O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
model NN NN O
and CC CC O
2 CD CD O
. . . O
6 CD CD O
- : : O
fold NN NN O
at IN IN O
4 CD CD O
weeks NNS NNS O
in IN IN O
the DT DT O
remnant NN NN O
kidney NN NN O
model NN NN O
, , , O
whereas IN IN O
that DT DT O
of IN IN O
vascular NN NN O
endothelial JJ JJ O
growth NN NN O
factor NN NN O
showed VBD VBD O
a DT DT O
mild JJ JJ O
decrease NN NN O
, , , O
reflecting VBG VBG O
distinct JJ JJ O
behaviors NNS NNS O
of IN IN O
the DT DT O
two CD CD O
genes NNS NNS O
. . . O

The DT DT O
degree NN NN O
of IN IN O
hypoxia NN NN O
showed VBD VBD O
a DT DT O
positive JJ JJ O
correlation NN NN O
with IN IN O
microscopic NN NN O
tubulointerstitial JJ JJ O
injury NN NN O
in IN IN O
both DT DT O
models NNS NNS O
. . . O

Finally RB RB O
, , , O
we PRP PRP O
identified VBD VBD O
the DT DT O
localization NN NN O
of IN IN O
proliferating VBG VBG O
cell NN NN O
nuclear JJ JJ O
antigen NN NN O
- - - O
positive JJ JJ O
, , , O
ED NNP NNP O
- : : O
1 CD CD O
- : : O
positive JJ JJ O
, , , O
and CC CC O
terminal NN NN O
dUTP NN NN O
nick JJ JJ O
- - - O
end NN NN O
labeled VBD VBD O
- : : O
positive JJ JJ O
cells NNS NNS O
in IN IN O
the DT DT O
hypoxic NN NN O
cortical JJ JJ O
area NN NN O
in IN IN O
the DT DT O
remnant NN NN O
kidney NN NN O
model NN NN O
. . . O

We PRP PRP O
propose VBP VBP O
here RB RB O
a DT DT O
possible JJ JJ O
pathological JJ JJ O
tie NN NN O
between IN IN O
chronic JJ JJ O
tubulointerstitial JJ JJ O
hypoxia NN NN O
and CC CC O
progressive JJ JJ O
glomerular NN NN O
diseases NNS NNS O
. . . O

Adequate NNP NNP O
timing NN NN O
of IN IN O
ribavirin NN NN B-CHEM
reduction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
hemolysis NN NN O
during IN IN O
combination NN NN O
therapy NN NN O
of IN IN O
interferon NN NN B-CHEM
and CC CC O
ribavirin NN NN B-CHEM
for IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Hemolytic NNP NNP O
anemia NN NN O
is VBZ VBZ O
one CD CD O
of IN IN O
the DT DT O
major JJ JJ O
adverse JJ JJ O
events NNS NNS O
of IN IN O
the DT DT O
combination NN NN O
therapy NN NN O
of IN IN O
interferon NN NN B-CHEM
and CC CC O
ribavirin NN NN B-CHEM
. . . O

Because IN IN O
of IN IN O
ribavirin NN NN B-CHEM
- - - O
related VBN VBN O
hemolytic JJ JJ O
anemia NN NN O
, , , O
dose NN NN O
reduction NN NN O
is VBZ VBZ O
a DT DT O
common JJ JJ O
event NN NN O
in IN IN O
this DT DT O
therapy NN NN O
. . . O

In IN IN O
this DT DT O
clinical JJ JJ O
retrospective NN NN O
cohort NN NN O
study NN NN O
we PRP PRP O
have VBP VBP O
examined VBN VBN O
the DT DT O
suitable JJ JJ O
timing NN NN O
of IN IN O
ribavirin NN NN B-CHEM
reduction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
hemolysis NN NN O
during IN IN O
combination NN NN O
therapy NN NN O
. . . O

METHODS NNP NNP O
: : : O
Thirty NNP NNP O
- - - O
seven CD CD O
of IN IN O
160 CD CD O
patients NNS NNS O
who WP WP O
had VBD VBD O
HCV NNP NNP O
- : : O
genotype NN NN O
1b CD CD O
, , , O
had VBD VBD O
high JJ JJ O
virus NN NN O
load NN NN O
, , , O
and CC CC O
received VBD VBD O
24 CD CD O
- : : O
week NN NN O
combination NN NN O
therapy NN NN O
developed VBN VBN O
anemia NN NN O
with IN IN O
hemoglobin NN NN O
level NN NN O
< NN NN O
10 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
or CC CC O
anemia NN NN O
- - - O
related VBN VBN O
signs NNS NNS O
during IN IN O
therapy NN NN O
. . . O

After IN IN O
that DT DT O
, , , O
these DT DT O
37 CD CD O
patients NNS NNS O
were VBD VBD O
reduced VBN VBN O
one CD CD O
tablet NN NN O
of IN IN O
ribavirin NN NN B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
) ) ) O
per IN IN O
day NN NN O
. . . O

After IN IN O
reduction NN NN O
of IN IN O
ribavirin NN NN B-CHEM
, , , O
27 CD CD O
of IN IN O
37 CD CD O
patients NNS NNS O
could MD MD O
continue VB VB O
combination NN NN O
therapy NN NN O
for IN IN O
a DT DT O
total NN NN O
of IN IN O
24 CD CD O
weeks NNS NNS O
( ( ( O
group NN NN O
A DT DT O
) ) ) O
. . . O

However RB RB O
, , , O
10 CD CD O
of IN IN O
37 CD CD O
patients NNS NNS O
with IN IN O
reduction NN NN O
of IN IN O
ribavirin NN NN B-CHEM
could MD MD O
not RB RB O
continue VB VB O
combination NN NN O
therapy NN NN O
because IN IN O
their PRP$ PRP$ O
< NN NN O
8 CD CD O
. . . O
5 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
hemoglobin NN NN O
values NNS NNS O
decreased VBD VBD O
to TO TO O
or CC CC O
anemia NN NN O
- - - O
related VBN VBN O
severe JJ JJ O
side NN NN O
effects NNS NNS O
occurred VBD VBD O
( ( ( O
group NN NN O
B NNP NNP O
) ) ) O
. . . O

We PRP PRP O
assessed VBD VBD O
the DT DT O
final JJ JJ O
efficacy NN NN O
and CC CC O
safety NN NN O
after IN IN O
reduction NN NN O
of IN IN O
ribavirin NN NN B-CHEM
in IN IN O
groups NNS NNS O
A DT DT O
and CC CC O
B NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
sustained JJ JJ O
virological JJ JJ O
response NN NN O
( ( ( O
SVR NNP NNP O
) ) ) O
was VBD VBD O
29 CD CD O
. . . O
6 CD CD O
% NN NN O
( ( ( O
8 CD CD O
/ NN NN O
27 CD CD O
) ) ) O
in IN IN O
group NN NN O
A DT DT O
and CC CC O
10 CD CD O
% NN NN O
( ( ( O
1 CD CD O
/ NN NN O
10 CD CD O
) ) ) O
in IN IN O
group NN NN O
B NNP NNP O
, , , O
respectively RB RB O
. . . O

A DT DT O
34 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
12 CD CD O
/ NN NN O
27 CD CD O
) ) ) O
of IN IN O
SVR NNP NNP O
+ NN NN O
biological JJ JJ O
response NN NN O
in IN IN O
group NN NN O
A DT DT O
was VBD VBD O
higher JJR JJR O
than IN IN O
10 CD CD O
% NN NN O
( ( ( O
1 CD CD O
/ NN NN O
10 CD CD O
) ) ) O
in IN IN O
group NN NN O
B NNP NNP O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
051 CD CD O
) ) ) O
, , , O
with IN IN O
slight JJ JJ O
significance NN NN O
. . . O

With IN IN O
respect NN NN O
to TO TO O
hemoglobin NN NN O
level NN NN O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
ribavirin NN NN B-CHEM
reduction NN NN O
, , , O
a DT DT O
rate NN NN O
of IN IN O
continuation NN NN O
of IN IN O
therapy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
> NN NN O
or CC CC O
= SYM SYM O
10 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
hemoglobin NN NN O
was VBD VBD O
higher JJR JJR O
than IN IN O
that DT DT O
in IN IN O
patients NNS NNS O
with IN IN O
< NN NN O
10 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
036 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Reduction NNP NNP O
of IN IN O
ribavirin NN NN B-CHEM
at IN IN O
hemoglobin NN NN O
level NN NN O
> NN NN O
or CC CC O
= SYM SYM O
10 CD CD O
g SYM SYM O
/ NN NN O
dl NN NN O
is VBZ VBZ O
suitable JJ JJ O
in IN IN O
terms NNS NNS O
of IN IN O
efficacy NN NN O
and CC CC O
side NN NN O
effects NNS NNS O
. . . O

Aging NNP NNP O
process NN NN O
of IN IN O
epithelial NN NN O
cells NNS NNS O
of IN IN O
the DT DT O
rat NN NN O
prostate NN NN O
lateral NN NN O
lobe NN NN O
in IN IN O
experimental JJ JJ O
hyperprolactinemia NN NN O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
examine VB VB O
the DT DT O
influence NN NN O
of IN IN O
hyperprolactinemia NN NN O
, , , O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
( ( ( O
HAL NNP NNP B-CHEM
) ) ) O
on IN IN O
age NN NN O
related VBN VBN O
morphology NN NN O
and CC CC O
function NN NN O
changes NNS NNS O
of IN IN O
epithelial NN NN O
cells NNS NNS O
in IN IN O
rat NN NN O
prostate NN NN O
lateral NN NN O
lobe NN NN O
. . . O

The DT DT O
study NN NN O
was VBD VBD O
performed VBN VBN O
on IN IN O
sexually RB RB O
mature NN NN O
male JJ JJ O
rats NNS NNS O
. . . O

Serum NNP NNP O
concentrations NNS NNS O
of IN IN O
prolactin NN NN O
( ( ( O
PRL NNP NNP B-CHEM
) ) ) O
and CC CC O
testosterone NN NN B-CHEM
( ( ( O
T NN NN B-CHEM
) ) ) O
were VBD VBD O
measured VBN VBN O
. . . O

Tissue NNP NNP O
sections NNS NNS O
were VBD VBD O
evaluated VBN VBN O
with IN IN O
light JJ JJ O
and CC CC O
electron NN NN O
microscopy NN NN O
. . . O

Immunohistochemical NNP NNP O
reactions NNS NNS O
for IN IN O
Anti NNP NNP O
- : : O
Proliferating NNP NNP O
Cell NNP NNP O
Nuclear NNP NNP O
Antigen NNP NNP O
( ( ( O
PCNA NNP NNP O
) ) ) O
were VBD VBD O
performed VBN VBN O
. . . O

In IN IN O
rats NNS NNS O
of IN IN O
the DT DT O
experimental JJ JJ O
group NN NN O
, , , O
the DT DT O
mean JJ JJ O
concentration NN NN O
of IN IN O
: : : O
PRL NNP NNP B-CHEM
was VBD VBD O
more JJR JJR O
than IN IN O
twice RB RB O
higher JJR JJR O
, , , O
whereas IN IN O
T NN NN B-CHEM
concentration NN NN O
was VBD VBD O
almost RB RB O
twice RB RB O
lower JJR JJR O
than IN IN O
that DT DT O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

Light NNP NNP O
microscopy NN NN O
visualized VBD VBD O
the DT DT O
following VBG VBG O
: : : O
hypertrophy NN NN O
and CC CC O
epithelium NN NN O
hyperplasia NN NN O
of IN IN O
the DT DT O
glandular NN NN O
ducts NNS NNS O
, , , O
associated VBN VBN O
with IN IN O
increased VBN VBN O
PCNA NNP NNP O
expression NN NN O
. . . O

Electron NNP NNP O
microscopy NN NN O
revealed VBD VBD O
changes NNS NNS O
in IN IN O
columnar NN NN O
epithelial NN NN O
cells NNS NNS O
, , , O
concerning VBG VBG O
organelles NNS NNS O
, , , O
engaged VBN VBN O
in IN IN O
protein NN NN O
synthesis NN NN O
and CC CC O
secretion NN NN O
. . . O

Relation NNP NNP O
of IN IN O
perfusion NN NN O
defects NNS NNS O
observed VBD VBD O
with IN IN O
myocardial JJ JJ O
contrast NN NN O
echocardiography NN NN O
to TO TO O
the DT DT O
severity NN NN O
of IN IN O
coronary JJ JJ O
stenosis NN NN O
: : : O
correlation NN NN O
with IN IN O
thallium NN NN B-CHEM
- - - O
201 CD CD O
single JJ JJ O
- - - O
photon NN NN O
emission NN NN O
tomography NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
previously RB RB O
shown VBN VBN O
that IN IN O
myocardial JJ JJ O
contrast NN NN O
echocardiography NN NN O
is VBZ VBZ O
a DT DT O
valuable JJ JJ O
technique NN NN O
for IN IN O
delineating VBG VBG O
regions NNS NNS O
of IN IN O
myocardial JJ JJ O
underperfusion NN NN O
secondary JJ JJ O
to TO TO O
coronary JJ JJ O
occlusion NN NN O
and CC CC O
to TO TO O
critical JJ JJ O
coronary JJ JJ O
stenoses NNS NNS O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
hyperemic JJ JJ O
stimulation NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
myocardial JJ JJ O
contrast NN NN O
echocardiography NN NN O
performed VBN VBN O
with IN IN O
a DT DT O
stable JJ JJ O
solution NN NN O
of IN IN O
sonicated JJ JJ O
albumin NN NN O
could MD MD O
detect VB VB O
regions NNS NNS O
of IN IN O
myocardial JJ JJ O
underperfusion NN NN O
resulting VBG VBG O
from IN IN O
various JJ JJ O
degrees NNS NNS O
of IN IN O
coronary JJ JJ O
stenosis NN NN O
. . . O

The DT DT O
perfusion NN NN O
defect NN NN O
produced VBN VBN O
in IN IN O
16 CD CD O
open JJ JJ O
chest NN NN O
dogs NNS NNS O
was VBD VBD O
compared VBN VBN O
with IN IN O
the DT DT O
anatomic JJ JJ O
area NN NN O
at IN IN O
risk NN NN O
measured VBN VBN O
by IN IN O
the DT DT O
postmortem NN NN O
dual JJ JJ O
- - - O
perfusion NN NN O
technique NN NN O
and CC CC O
with IN IN O
thallium NN NN B-CHEM
- - - O
201 CD CD O
single JJ JJ O
- - - O
photon NN NN O
emission NN NN O
tomography NN NN O
( ( ( O
SPECT NNP NNP O
) ) ) O
. . . O

During IN IN O
a DT DT O
transient NN NN O
( ( ( O
20 CD CD O
- : : O
s VBZ VBZ O
) ) ) O
coronary JJ JJ O
occlusion NN NN O
, , , O
a DT DT O
perfusion NN NN O
defect NN NN O
was VBD VBD O
observed VBN VBN O
with IN IN O
contrast NN NN O
echocardiography NN NN O
in IN IN O
14 CD CD O
of IN IN O
the DT DT O
15 CD CD O
dogs NNS NNS O
in IN IN O
which WDT WDT O
the DT DT O
occlusion NN NN O
was VBD VBD O
produced VBN VBN O
. . . O

The DT DT O
perfusion NN NN O
defect NN NN O
correlated JJ JJ O
significantly RB RB O
with IN IN O
the DT DT O
anatomic JJ JJ O
area NN NN O
at IN IN O
risk NN NN O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
74 CD CD O
; : : O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

During IN IN O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
hyperemia NN NN O
, , , O
12 CD CD O
of IN IN O
the DT DT O
16 CD CD O
dogs NNS NNS O
with IN IN O
a DT DT O
partial JJ JJ O
coronary JJ JJ O
stenosis NNS NNS O
had VBD VBD O
a DT DT O
visible JJ JJ O
area NN NN O
of IN IN O
hypoperfusion NN NN O
by IN IN O
contrast NN NN O
echocardiography NN NN O
. . . O

The DT DT O
four CD CD O
dogs NNS NNS O
without IN IN O
a DT DT O
perfusion NN NN O
defect NN NN O
had VBD VBD O
a DT DT O
stenosis NN NN O
that WDT WDT O
resulted VBD VBD O
in IN IN O
a DT DT O
mild NN NN O
( ( ( O
0 CD CD O
% NN NN O
to TO TO O
50 CD CD O
% NN NN O
) ) ) O
reduction NN NN O
in IN IN O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
hyperemia NN NN O
. . . O

The DT DT O
size NN NN O
of IN IN O
the DT DT O
perfusion NN NN O
defect NN NN O
during IN IN O
stenosis NNS NNS O
correlated JJ JJ O
significantly RB RB O
with IN IN O
the DT DT O
anatomic JJ JJ O
area NN NN O
at IN IN O
risk NN NN O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
61 CD CD O
; : : O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

Thallium NNP NNP B-CHEM
- : : O
201 CD CD O
SPECT NNP NNP O
demonstrated VBD VBD O
a DT DT O
perfusion NN NN O
defect NN NN O
in IN IN O
all DT DT O
14 CD CD O
dogs NNS NNS O
analyzed VBD VBD O
during IN IN O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
hyperemia NN NN O
; : : O
the DT DT O
size NN NN O
of IN IN O
the DT DT O
perfusion NN NN O
defect NN NN O
correlated JJ JJ O
with IN IN O
the DT DT O
anatomic JJ JJ O
area NN NN O
at IN IN O
risk NN NN O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
58 CD CD O
; : : O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
and CC CC O
with IN IN O
the DT DT O
perfusion NN NN O
defect NN NN O
by IN IN O
contrast NN NN O
echocardiography NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
58 CD CD O
; : : O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
. . . O

Thus RB RB O
, , , O
myocardial JJ JJ O
contrast NN NN O
echocardiography NN NN O
can MD MD O
be VB VB O
used VBN VBN O
to TO TO O
visualize VB VB O
and CC CC O
quantitate VB VB O
the DT DT O
amount NN NN O
of IN IN O
jeopardized JJ JJ O
myocardium NN NN O
during IN IN O
moderate NN NN O
to TO TO O
severe JJ JJ O
degrees NNS NNS O
of IN IN O
coronary JJ JJ O
stenosis NN NN O
. . . O

The DT DT O
results NNS NNS O
obtained VBN VBN O
show NN NN O
a DT DT O
correlation NN NN O
with IN IN O
the DT DT O
anatomic JJ JJ O
area NN NN O
at IN IN O
risk NN NN O
similar JJ JJ O
to TO TO O
that DT DT O
obtained VBD VBD O
with IN IN O
thallium NN NN B-CHEM
- - - O
201 CD CD O
SPECT NNP NNP O
. . . O

The DT DT O
activation NN NN O
of IN IN O
spinal JJ JJ O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
receptors NNS NNS O
may MD MD O
contribute VB VB O
to TO TO O
degeneration NN NN O
of IN IN O
spinal JJ JJ O
motor NN NN O
neurons NNS NNS O
induced VBN VBN O
by IN IN O
neuraxial JJ JJ O
morphine NN NN B-CHEM
after IN IN O
a DT DT O
noninjurious JJ JJ O
interval NN NN O
of IN IN O
spinal JJ JJ O
cord NN NN O
ischemia NN NN O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
relationship NN NN O
between IN IN O
the DT DT O
degeneration NN NN O
of IN IN O
spinal JJ JJ O
motor NN NN O
neurons NNS NNS O
and CC CC O
activation NN NN O
of IN IN O
N NNP NNP B-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
d SYM SYM I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptors NNS NNS O
after IN IN O
neuraxial JJ JJ O
morphine NN NN B-CHEM
following VBG VBG O
a DT DT O
noninjurious JJ JJ O
interval NN NN O
of IN IN O
aortic JJ JJ O
occlusion NN NN O
in IN IN O
rats NNS NNS O
. . . O

Spinal NNP NNP O
cord NN NN O
ischemia NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
aortic JJ JJ O
occlusion NN NN O
for IN IN O
6 CD CD O
min NN NN O
with IN IN O
a DT DT O
balloon NN NN O
catheter NN NN O
. . . O

In IN IN O
a DT DT O
microdialysis NN NN O
study NN NN O
, , , O
10 CD CD O
muL NN NN O
of IN IN O
saline NN NN O
( ( ( O
group NN NN O
C NNP NNP O
; : : O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
or CC CC O
30 CD CD O
mug NN NN O
of IN IN O
morphine NN NN B-CHEM
( ( ( O
group NN NN O
M NNP NNP O
; : : O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
was VBD VBD O
injected VBN VBN O
intrathecally RB RB O
( ( ( O
IT PRP PRP O
) ) ) O
0 CD CD O
. . . O
5 CD CD O
h NN NN O
after IN IN O
reflow NN NN O
, , , O
and CC CC O
30 CD CD O
mug NN NN O
of IN IN O
morphine NN NN B-CHEM
( ( ( O
group NN NN O
SM NNP NNP O
; : : O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
or CC CC O
10 CD CD O
muL NN NN O
of IN IN O
saline NN NN O
( ( ( O
group NN NN O
SC NNP NNP O
; : : O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
was VBD VBD O
injected VBN VBN O
IT PRP PRP O
0 CD CD O
. . . O
5 CD CD O
h NN NN O
after IN IN O
sham NN NN O
operation NN NN O
. . . O

Microdialysis NNP NNP O
samples NNS NNS O
were VBD VBD O
collected VBN VBN O
preischemia NN NN O
, , , O
before IN IN O
IT PRP PRP O
injection NN NN O
, , , O
and CC CC O
at IN IN O
2 CD CD O
, , , O
4 CD CD O
, , , O
8 CD CD O
, , , O
24 CD CD O
, , , O
and CC CC O
48 CD CD O
h NN NN O
of IN IN O
reperfusion NN NN O
( ( ( O
after IN IN O
IT PRP PRP O
injection NN NN O
) ) ) O
. . . O

Second JJ JJ O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
IT PRP PRP O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
( ( ( O
30 CD CD O
mug NN NN O
) ) ) O
on IN IN O
the DT DT O
histopathologic JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
after IN IN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
spastic JJ JJ O
paraparesis NN NN O
. . . O

After IN IN O
IT PRP PRP O
morphine NN NN B-CHEM
, , , O
the DT DT O
cerebrospinal JJ JJ O
fluid NN NN O
( ( ( O
CSF NNP NNP O
) ) ) O
glutamate NN NN B-CHEM
concentration NN NN O
was VBD VBD O
increased VBN VBN O
in IN IN O
group NN NN O
M NNP NNP O
relative JJ JJ O
to TO TO O
both DT DT O
baseline NN NN O
and CC CC O
group NN NN O
C NNP NNP O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

This DT DT O
increase NN NN O
persisted VBD VBD O
for IN IN O
8 CD CD O
hrs NN NN O
. . . O

IT PRP PRP O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
significantly RB RB O
reduced VBD VBD O
the DT DT O
number NN NN O
of IN IN O
dark JJ JJ O
- - - O
stained JJ JJ O
alpha NN NN O
- : : O
motoneurons NNS NNS O
after IN IN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
spastic JJ JJ O
paraparesis NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
saline NN NN O
group NN NN O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
IT PRP PRP O
morphine NN NN B-CHEM
induces NNS NNS O
spastic JJ JJ O
paraparesis NN NN O
with IN IN O
a DT DT O
concomitant NN NN O
increase NN NN O
in IN IN O
CSF NNP NNP O
glutamate NN NN B-CHEM
, , , O
which WDT WDT O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
NMDA NNP NNP B-CHEM
receptor NN NN O
activation NN NN O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
opioids NNS NNS O
may MD MD O
be VB VB O
neurotoxic JJ JJ O
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
spinal JJ JJ O
cord NN NN O
ischemia NN NN O
via IN IN O
NMDA NNP NNP B-CHEM
receptor NN NN O
activation NN NN O
. . . O

Acute JJ JJ O
low JJ JJ O
back RB RB O
pain NN NN O
during IN IN O
intravenous JJ JJ O
administration NN NN O
of IN IN O
amiodarone NN NN B-CHEM
: : : O
a DT DT O
report NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

Amiodarone NNP NNP B-CHEM
represents VBZ VBZ O
an DT DT O
effective JJ JJ O
antiarrhythmic JJ JJ O
drug NN NN O
for IN IN O
cardioversion NN NN O
of IN IN O
recent JJ JJ O
- - - O
onset NN NN O
atrial JJ JJ O
fibrillation NN NN O
( ( ( O
AF NNP NNP O
) ) ) O
and CC CC O
maintenance NN NN O
of IN IN O
sinus NN NN O
rhythm NN NN O
. . . O

We PRP PRP O
briefly NN NN O
describe VB VB O
two CD CD O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
recent JJ JJ O
- - - O
onset NN NN O
atrial JJ JJ O
fibrillation NN NN O
, , , O
who WP WP O
experienced VBD VBD O
an DT DT O
acute JJ JJ O
devastating VBG VBG O
low JJ JJ O
back RB RB O
pain NN NN O
a DT DT O
few JJ JJ O
minutes NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
intravenous JJ JJ O
amiodarone NN NN B-CHEM
loading NN NN O
. . . O

Notably RB RB O
, , , O
this DT DT O
side NN NN O
effect NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
ever RB RB O
reported VBN VBN O
in IN IN O
the DT DT O
medical JJ JJ O
literature NN NN O
. . . O

Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
reaction NN NN O
since IN IN O
prompt JJ JJ O
termination NN NN O
of IN IN O
parenteral JJ JJ O
administration NN NN O
leads VBZ VBZ O
to TO TO O
complete VB VB O
resolution NN NN O
. . . O

Quantitative NNP NNP O
drug NN NN O
levels NNS NNS O
in IN IN O
stimulant NN NN O
psychosis NN NN O
: : : O
relationship NN NN O
to TO TO O
symptom VB VB O
severity NN NN O
, , , O
catecholamines NNS NNS B-CHEM
and CC CC O
hyperkinesia NN NN O
. . . O

To TO TO O
examine VB VB O
the DT DT O
relationship NN NN O
between IN IN O
quantitative JJ JJ O
stimulant NN NN O
drug NN NN O
levels NNS NNS O
, , , O
catecholamines NNS NNS B-CHEM
, , , O
and CC CC O
psychotic JJ JJ O
symptoms NNS NNS O
, , , O
nineteen NN NN O
patients NNS NNS O
in IN IN O
a DT DT O
psychiatric JJ JJ O
emergency NN NN O
service NN NN O
with IN IN O
a DT DT O
diagnosis NN NN O
of IN IN O
amphetamine NN NN B-CHEM
- - - O
or CC CC O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
psychosis NN NN O
were VBD VBD O
interviewed VBN VBN O
, , , O
and CC CC O
plasma NN NN O
and CC CC O
urine NN NN O
were VBD VBD O
collected VBN VBN O
for IN IN O
quantitative JJ JJ O
assays NNS NNS O
of IN IN O
stimulant JJ JJ O
drug NN NN O
and CC CC O
catecholamine NN NN B-CHEM
metabolite NN NN O
levels NNS NNS O
. . . O

Methamphetamine NNP NNP B-CHEM
or CC CC O
amphetamine NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
related VBN VBN O
to TO TO O
several JJ JJ O
psychopathology NN NN O
scores NNS NNS O
and CC CC O
the DT DT O
global JJ JJ O
hyperkinesia NN NN O
rating NN NN O
. . . O

HVA NNP NNP O
levels NNS NNS O
were VBD VBD O
related VBN VBN O
to TO TO O
global JJ JJ O
hyperkinesia NN NN O
but CC CC O
not RB RB O
to TO TO O
psychopathology NN NN O
ratings NNS NNS O
. . . O

Although IN IN O
many JJ JJ O
other JJ JJ O
factors NNS NNS O
such JJ JJ O
as IN IN O
sensitization NN NN O
may MD MD O
play VB VB O
a DT DT O
role NN NN O
, , , O
intensity NN NN O
of IN IN O
stimulant NN NN O
- - - O
induced JJ JJ O
psychotic JJ JJ O
symptoms NNS NNS O
and CC CC O
stereotypies NNS NNS O
appears VBZ VBZ O
to TO TO O
be VB VB O
at IN IN O
least JJS JJS O
in IN IN O
part NN NN O
dose NN NN O
- - - O
related VBN VBN O
. . . O

Pheochromocytoma NNP NNP O
unmasked JJ JJ O
by IN IN O
amisulpride NN NN B-CHEM
and CC CC O
tiapride NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
the DT DT O
unmasking VBG VBG O
of IN IN O
pheochromocytoma NN NN O
in IN IN O
a DT DT O
patient NN NN O
treated VBN VBN O
with IN IN O
amisulpride NN NN B-CHEM
and CC CC O
tiapride NN NN B-CHEM
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
42 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
white JJ JJ O
man NN NN O
developed VBN VBN O
acute JJ JJ O
hypertension NN NN O
with IN IN O
severe JJ JJ O
headache NN NN O
and CC CC O
vomiting VBG VBG O
2 CD CD O
hours NNS NNS O
after IN IN O
the DT DT O
first JJ JJ O
doses NNS NNS O
of IN IN O
amisulpride NN NN B-CHEM
100 CD CD O
mg NN NN O
and CC CC O
tiapride NN NN B-CHEM
100 CD CD O
mg NN NN O
. . . O

Both DT DT O
drugs NNS NNS O
were VBD VBD O
immediately RB RB O
discontinued VBN VBN O
, , , O
and CC CC O
the DT DT O
patient NN NN O
recovered VBD VBD O
after IN IN O
subsequent JJ JJ O
nicardipine NN NN B-CHEM
and CC CC O
verapamil NN NN B-CHEM
treatment NN NN O
. . . O

Abdominal NNP NNP O
ultrasound NN NN O
showed VBD VBD O
an DT DT O
adrenal JJ JJ O
mass NN NN O
, , , O
and CC CC O
postoperative JJ JJ O
histologic JJ JJ O
examination NN NN O
confirmed VBD VBD O
the DT DT O
diagnosis NN NN O
of IN IN O
pheochromocytoma NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
Drug NN NN O
- - - O
induced JJ JJ O
symptoms NNS NNS O
of IN IN O
pheochromocytoma NN NN O
are VBP VBP O
often RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
substituted VBN VBN O
benzamide IN IN B-CHEM
drugs NNS NNS O
, , , O
but CC CC O
the DT DT O
underlying VBG VBG O
mechanism NN NN O
is VBZ VBZ O
unknown JJ JJ O
. . . O

In IN IN O
our PRP$ PRP$ O
case NN NN O
, , , O
use NN NN O
of IN IN O
the DT DT O
Naranjo NNP NNP O
probability NN NN O
scale NN NN O
indicated VBD VBD O
a DT DT O
possible JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
hypertensive JJ JJ O
crisis NN NN O
and CC CC O
amisulpride NN NN B-CHEM
and CC CC O
tiapride NN NN B-CHEM
therapy NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
As IN IN O
of IN IN O
March NNP NNP O
24 CD CD O
, , , O
2005 CD CD O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
amisulpride NN NN B-CHEM
- - - O
and CC CC O
tiapride NN NN B-CHEM
- - - O
induced JJ JJ O
hypertensive JJ JJ O
crisis NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
pheochromocytoma NN NN O
. . . O

Physicians NNP NNP O
and CC CC O
other JJ JJ O
healthcare NN NN O
professionals NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
potential JJ JJ O
adverse JJ JJ O
effect NN NN O
of IN IN O
tiapride NN NN B-CHEM
and CC CC O
amisulpride NN NN B-CHEM
. . . O

Minor NNP NNP O
neurological JJ JJ O
dysfunction NN NN O
, , , O
cognitive JJ JJ O
development NN NN O
, , , O
and CC CC O
somatic JJ JJ O
development NN NN O
at IN IN O
the DT DT O
age NN NN O
of IN IN O
3 CD CD O
to TO TO O
7 CD CD O
years NNS NNS O
after IN IN O
dexamethasone NN NN B-CHEM
treatment NN NN O
in IN IN O
very RB RB O
- : : O
low JJ JJ O
birth NN NN O
- - - O
weight NN NN O
infants NNS NNS O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
minor JJ JJ O
neurological JJ JJ O
dysfunction NN NN O
, , , O
cognitive JJ JJ O
development NN NN O
, , , O
and CC CC O
somatic JJ JJ O
development NN NN O
after IN IN O
dexamethasone NN NN B-CHEM
therapy NN NN O
in IN IN O
very RB RB O
- - - O
low JJ JJ O
- - - O
birthweight NN NN O
infants NNS NNS O
. . . O

Thirty NNP NNP O
- - - O
three CD CD O
children NNS NNS O
after IN IN O
dexamethasone NN NN B-CHEM
treatment NN NN O
were VBD VBD O
matched VBN VBN O
to TO TO O
33 CD CD O
children NNS NNS O
without IN IN O
dexamethasone NN NN B-CHEM
treatment NN NN O
. . . O

Data NNP NNP O
were VBD VBD O
assessed VBN VBN O
at IN IN O
the DT DT O
age NN NN O
of IN IN O
3 CD CD O
- : : O
7 CD CD O
years NNS NNS O
. . . O

Dexamethasone NNP NNP B-CHEM
was VBD VBD O
started VBN VBN O
between IN IN O
the DT DT O
7th CD CD O
and CC CC O
the DT DT O
28th JJ JJ O
day NN NN O
of IN IN O
life NN NN O
over IN IN O
7 CD CD O
days NNS NNS O
with IN IN O
a DT DT O
total JJ JJ O
dose NN NN O
of IN IN O
2 CD CD O
. . . O
35 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
. . . O

Exclusion NNP NNP O
criteria NNS NNS O
were VBD VBD O
asphyxia NN NN O
, , , O
malformations NNS NNS O
, , , O
major JJ JJ O
surgical JJ JJ O
interventions NNS NNS O
, , , O
small JJ JJ O
for IN IN O
gestational JJ JJ O
age NN NN O
, , , O
intraventricular JJ JJ O
haemorrhage NN NN O
grades NNS NNS O
III NNP NNP O
and CC CC O
IV NNP NNP O
, , , O
periventricular JJ JJ O
leukomalacia NN NN O
, , , O
and CC CC O
severe JJ JJ O
psychomotor NN NN O
retardation NN NN O
. . . O

Each DT DT O
child NN NN O
was VBD VBD O
examined VBN VBN O
by IN IN O
a DT DT O
neuropediatrician NN NN O
for IN IN O
minor JJ JJ O
neurological JJ JJ O
dysfunctions NNS NNS O
and CC CC O
tested VBN VBN O
by IN IN O
a DT DT O
psychologist NN NN O
for IN IN O
cognitive JJ JJ O
development NN NN O
with IN IN O
a DT DT O
Kaufman NNP NNP O
Assessment NNP NNP O
Battery NNP NNP O
for IN IN O
Children NNP NNP O
and CC CC O
a DT DT O
Draw NNP NNP O
- - - O
a DT DT O
- - - O
Man NN NN O
Test NNP NNP O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
differences NNS NNS O
in IN IN O
demographic JJ JJ O
data NNS NNS O
, , , O
growth NN NN O
, , , O
and CC CC O
socio JJ JJ O
- - - O
economic JJ JJ O
status NN NN O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

Fine NNP NNP O
motor NN NN O
skills NNS NNS O
and CC CC O
gross JJ JJ O
motor NN NN O
function NN NN O
were VBD VBD O
significantly RB RB O
better JJR JJR O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
Draw NNP NNP O
- - - O
a DT DT O
- - - O
Man NN NN O
Test NNP NNP O
, , , O
the DT DT O
control NN NN O
group NN NN O
showed VBD VBD O
better JJR JJR O
results NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
differences NNS NNS O
in IN IN O
development NN NN O
of IN IN O
speech NN NN O
, , , O
social JJ JJ O
development NN NN O
, , , O
and CC CC O
the DT DT O
Kaufman NNP NNP O
Assessment NNP NNP O
Battery NNP NNP O
for IN IN O
Children NNP NNP O
. . . O

After IN IN O
dexamethasone NN NN B-CHEM
treatment NN NN O
, , , O
children NNS NNS O
showed VBD VBD O
a DT DT O
higher JJR JJR O
rate NN NN O
of IN IN O
minor JJ JJ O
neurological JJ JJ O
dysfunctions NNS NNS O
. . . O

Neurological NNP NNP O
development NN NN O
was VBD VBD O
affected VBN VBN O
even RB RB O
without IN IN O
neurological JJ JJ O
diagnosis NN NN O
. . . O

Further RB RB O
long RB RB O
- - - O
term NN NN O
follow VB VB O
- - - O
up RP RP O
studies NNS NNS O
will MD MD O
be VB VB O
necessary JJ JJ O
to TO TO O
fully RB RB O
evaluate VB VB O
the DT DT O
impact NN NN O
of IN IN O
dexamethasone NN NN B-CHEM
on IN IN O
neurological JJ JJ O
and CC CC O
cognitive JJ JJ O
development NN NN O
. . . O

Valproic NNP NNP B-CHEM
acid NN NN I-CHEM
I PRP PRP O
: : : O
time NN NN O
course NN NN O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
biomarkers NNS NNS O
, , , O
liver NN NN O
toxicity NN NN O
, , , O
and CC CC O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
metabolite NN NN O
levels NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

A DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
, , , O
which WDT WDT O
is VBZ VBZ O
a DT DT O
widely RB RB O
used VBN VBN O
antiepileptic JJ JJ O
drug NN NN O
, , , O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
oxidative JJ JJ O
stress NN NN O
in IN IN O
rats NNS NNS O
, , , O
as IN IN O
recently RB RB O
demonstrated VBN VBN O
by IN IN O
elevated JJ JJ O
levels NNS NNS O
of IN IN O
15 CD CD B-CHEM
- : : I-CHEM
F NN NN I-CHEM
( ( ( I-CHEM
2t CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
isoprostane NN NN I-CHEM
( ( ( O
15 CD CD B-CHEM
- : : I-CHEM
F NN NN I-CHEM
( ( ( I-CHEM
2t CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
IsoP NNP NNP I-CHEM
) ) ) O
. . . O

To TO TO O
determine VB VB O
whether IN IN O
there EX EX O
was VBD VBD O
a DT DT O
temporal JJ JJ O
relationship NN NN O
between IN IN O
VPA NNP NNP B-CHEM
- : : O
associated VBN VBN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
hepatotoxicity NN NN O
, , , O
adult NN NN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
ip NNP NNP O
with IN IN O
VPA NNP NNP B-CHEM
( ( ( O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
saline NN NN O
( ( ( O
vehicle NN NN O
) ) ) O
once RB RB O
daily JJ JJ O
for IN IN O
2 CD CD O
, , , O
4 CD CD O
, , , O
7 CD CD O
, , , O
10 CD CD O
, , , O
or CC CC O
14 CD CD O
days NNS NNS O
. . . O

Oxidative NNP NNP O
stress NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
determining VBG VBG O
plasma NN NN O
and CC CC O
liver NN NN O
levels NNS NNS O
of IN IN O
15 CD CD B-CHEM
- : : I-CHEM
F NN NN I-CHEM
( ( ( I-CHEM
2t CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
IsoP NNP NNP I-CHEM
, , , O
lipid JJ JJ B-CHEM
hydroperoxides NNS NNS I-CHEM
( ( ( O
LPO NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
thiobarbituric JJ JJ B-CHEM
acid NN NN I-CHEM
reactive JJ JJ I-CHEM
substances NNS NNS I-CHEM
( ( ( O
TBARs NNP NNP B-CHEM
) ) ) O
. . . O

Plasma NNP NNP O
and CC CC O
liver NN NN O
15 CD CD B-CHEM
- : : I-CHEM
F NN NN I-CHEM
( ( ( I-CHEM
2t CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
IsoP NNP NNP I-CHEM
were VBD VBD O
elevated VBN VBN O
and CC CC O
reached VBN VBN O
a DT DT O
plateau NN NN O
after IN IN O
day NN NN O
2 CD CD O
of IN IN O
VPA NNP NNP B-CHEM
treatment NN NN O
compared VBN VBN O
to TO TO O
control VB VB O
. . . O

Liver NNP NNP O
LPO NNP NNP B-CHEM
levels NNS NNS O
were VBD VBD O
not RB RB O
elevated VBD VBD O
until IN IN O
day NN NN O
7 CD CD O
of IN IN O
treatment NN NN O
( ( ( O
1 CD CD O
. . . O
8 CD CD O
- : : O
fold VB VB O
versus CC CC O
control NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Liver NNP NNP O
and CC CC O
plasma NN NN O
TBARs NNP NNP B-CHEM
were VBD VBD O
not RB RB O
increased VBN VBN O
until IN IN O
14 CD CD O
days NNS NNS O
( ( ( O
2 CD CD O
- : : O
fold JJ JJ O
vs NNS NNS O
. . . O
control NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Liver NNP NNP O
toxicity NN NN O
was VBD VBD O
evaluated VBN VBN O
based VBN VBN O
on IN IN O
serum NN NN O
levels NNS NNS O
of IN IN O
alpha NN NN O
- - - O
glutathione NN NN B-CHEM
S NNP NNP O
- : : O
transferase NN NN O
( ( ( O
alpha NN NN O
- - - O
GST NNP NNP O
) ) ) O
and CC CC O
by IN IN O
histology NN NN O
. . . O

Serum NNP NNP O
alpha NN NN O
- : : O
GST NNP NNP O
levels NNS NNS O
were VBD VBD O
significantly RB RB O
elevated VBN VBN O
by IN IN O
day NN NN O
4 CD CD O
, , , O
which WDT WDT O
corresponded VBD VBD O
to TO TO O
hepatotoxicity NN NN O
as IN IN O
shown VBN VBN O
by IN IN O
the DT DT O
increasing VBG VBG O
incidence NN NN O
of IN IN O
inflammation NN NN O
of IN IN O
the DT DT O
liver NN NN O
capsule NN NN O
, , , O
necrosis NN NN O
, , , O
and CC CC O
steatosis NN NN O
throughout IN IN O
the DT DT O
study NN NN O
. . . O

The DT DT O
liver NN NN O
levels NNS NNS O
of IN IN O
beta NN NN O
- - - O
oxidation NN NN O
metabolites NNS NNS O
of IN IN O
VPA NNP NNP B-CHEM
were VBD VBD O
decreased VBN VBN O
by IN IN O
day NN NN O
14 CD CD O
, , , O
while IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
4 CD CD B-CHEM
- : : I-CHEM
ene NN NN I-CHEM
- : : I-CHEM
VPA NNP NNP I-CHEM
and CC CC O
( ( ( O
E NNP NNP O
) ) ) O
- : : O
2 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
diene NN NN I-CHEM
- - - I-CHEM
VPA NNP NNP I-CHEM
were VBD VBD O
not RB RB O
elevated VBN VBN O
throughout IN IN O
the DT DT O
study NN NN O
. . . O

Overall RB RB O
, , , O
these DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
VPA NNP NNP B-CHEM
treatment NN NN O
results NNS NNS O
in IN IN O
oxidative JJ JJ O
stress NN NN O
, , , O
as IN IN O
measured VBN VBN O
by IN IN O
levels NNS NNS O
of IN IN O
15 CD CD B-CHEM
- : : I-CHEM
F NN NN I-CHEM
( ( ( I-CHEM
2t CD CD I-CHEM
) ) ) I-CHEM
- : : I-CHEM
IsoP NNP NNP I-CHEM
, , , O
which WDT WDT O
precedes VBZ VBZ O
the DT DT O
onset NN NN O
of IN IN O
necrosis NN NN O
, , , O
steatosis NN NN O
, , , O
and CC CC O
elevated VBD VBD O
levels NNS NNS O
of IN IN O
serum NN NN O
alpha NN NN O
- : : O
GST NNP NNP O
. . . O

Assessment NNP NNP O
of IN IN O
perinatal JJ JJ O
hepatitis NN NN O
B NNP NNP O
and CC CC O
rubella NN NN O
prevention NN NN O
in IN IN O
New NNP NNP O
Hampshire NNP NNP O
delivery NN NN O
hospitals NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
current JJ JJ O
performance NN NN O
on IN IN O
recommended JJ JJ O
perinatal JJ JJ O
hepatitis NN NN O
B NNP NNP O
and CC CC O
rubella NN NN O
prevention NN NN O
practices NNS NNS O
in IN IN O
New NNP NNP O
Hampshire NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Data NNP NNP O
were VBD VBD O
extracted VBN VBN O
from IN IN O
2021 CD CD O
paired VBD VBD O
mother NN NN O
- : : O
infant NN NN O
records NNS NNS O
for IN IN O
the DT DT O
year NN NN O
2000 CD CD O
birth NN NN O
cohort NN NN O
in IN IN O
New NNP NNP O
Hampshire NNP NNP O
' POS POS O
s VBZ VBZ O
25 CD CD O
delivery NN NN O
hospitals NNS NNS O
. . . O

Assessment NNP NNP O
was VBD VBD O
done VBN VBN O
on IN IN O
the DT DT O
following VBG VBG O
: : : O
prenatal JJ JJ O
screening NN NN O
for IN IN O
hepatitis NN NN O
B NNP NNP O
and CC CC O
rubella NN NN O
, , , O
administration NN NN O
of IN IN O
the DT DT O
hepatitis NN NN O
B NNP NNP O
vaccine NN NN O
birth NN NN O
dose NN NN O
to TO TO O
all DT DT O
infants NNS NNS O
, , , O
administration NN NN O
of IN IN O
hepatitis NN NN O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
to TO TO O
infants NNS NNS O
who WP WP O
were VBD VBD O
born VBN VBN O
to TO TO O
hepatitis VB VB B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
- : : O
positive JJ JJ O
mothers NNS NNS O
, , , O
rubella NN NN O
immunity NN NN O
, , , O
and CC CC O
administration NN NN O
of IN IN O
in IN IN O
- - - O
hospital NN NN O
postpartum NN NN O
rubella NN NN O
vaccine NN NN O
to TO TO O
rubella VB VB O
nonimmune NN NN O
women NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Prenatal NNP NNP O
screening VBG VBG O
rates NNS NNS O
for IN IN O
hepatitis NN NN O
B NNP NNP O
( ( ( O
98 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
and CC CC O
rubella NN NN O
( ( ( O
99 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
high JJ JJ O
. . . O

Hepatitis NNP NNP O
B NNP NNP O
vaccine NN NN O
birth NN NN O
dose NN NN O
was VBD VBD O
administered VBN VBN O
to TO TO O
76 CD CD O
. . . O
2 CD CD O
% NN NN O
of IN IN O
all DT DT O
infants NNS NNS O
. . . O

All DT DT O
infants NNS NNS O
who WP WP O
were VBD VBD O
born VBN VBN O
to TO TO O
hepatitis VB VB B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
- : : O
positive JJ JJ O
mothers NNS NNS O
also RB RB O
received VBD VBD O
hepatitis NN NN O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
. . . O

Multivariate NNP NNP O
logistic JJ JJ O
regression NN NN O
showed VBD VBD O
that IN IN O
the DT DT O
month NN NN O
of IN IN O
delivery NN NN O
and CC CC O
infant JJ JJ O
birth NN NN O
weight NN NN O
were VBD VBD O
independent JJ JJ O
predictors NNS NNS O
of IN IN O
hepatitis NN NN O
B NNP NNP O
vaccination NN NN O
. . . O

The DT DT O
proportion NN NN O
of IN IN O
infants NNS NNS O
who WP WP O
were VBD VBD O
vaccinated VBN VBN O
in IN IN O
January NNP NNP O
and CC CC O
February NNP NNP O
2000 CD CD O
( ( ( O
48 CD CD O
. . . O
5 CD CD O
% NN NN O
and CC CC O
67 CD CD O
. . . O
5 CD CD O
% NN NN O
, , , O
respectively RB RB O
) ) ) O
was VBD VBD O
less JJR JJR O
than IN IN O
any DT DT O
other JJ JJ O
months NNS NNS O
, , , O
whereas IN IN O
the DT DT O
proportion NN NN O
who WP WP O
were VBD VBD O
vaccinated VBN VBN O
in IN IN O
December NNP NNP O
2000 CD CD O
( ( ( O
88 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
the DT DT O
highest JJS JJS O
. . . O

Women NNP NNP O
who WP WP O
were VBD VBD O
born VBN VBN O
between IN IN O
1971 CD CD O
and CC CC O
1975 CD CD O
had VBD VBD O
the DT DT O
highest JJS JJS O
rate NN NN O
of IN IN O
rubella NN NN O
nonimmunity NN NN O
( ( ( O
9 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
. . . O

In IN IN O
- - - O
hospital NN NN O
postpartum NN NN O
rubella NN NN O
vaccine NN NN O
administration NN NN O
was VBD VBD O
documented VBN VBN O
for IN IN O
75 CD CD O
. . . O
6 CD CD O
% NN NN O
of IN IN O
nonimmune NN NN O
women NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
study NN NN O
documents NNS NNS O
good JJ JJ O
compliance NN NN O
in IN IN O
New NNP NNP O
Hampshire NNP NNP O
' POS POS O
s VBZ VBZ O
birthing VBG VBG O
hospitals NNS NNS O
with IN IN O
national JJ JJ O
guidelines NNS NNS O
for IN IN O
perinatal JJ JJ O
hepatitis NN NN O
B NNP NNP O
and CC CC O
rubella NN NN O
prevention NN NN O
and CC CC O
highlights NNS NNS O
potential JJ JJ O
areas NNS NNS O
for IN IN O
improvement NN NN O
. . . O

Succinylcholine NNP NNP B-CHEM
- : : O
induced JJ JJ O
masseter NN NN O
muscle NN NN O
rigidity NN NN O
during IN IN O
bronchoscopic NN NN O
removal NN NN O
of IN IN O
a DT DT O
tracheal NN NN O
foreign JJ JJ O
body NN NN O
. . . O

Masseter NNP NNP O
muscle NN NN O
rigidity NN NN O
during IN IN O
general JJ JJ O
anesthesia NN NN O
is VBZ VBZ O
considered VBN VBN O
an DT DT O
early JJ JJ O
warning NN NN O
sign NN NN O
of IN IN O
a DT DT O
possible JJ JJ O
episode NN NN O
of IN IN O
malignant JJ JJ O
hyperthermia NN NN O
. . . O

The DT DT O
decision NN NN O
whether IN IN O
to TO TO O
continue VB VB O
or CC CC O
discontinue VB VB O
the DT DT O
procedure NN NN O
depends VBZ VBZ O
on IN IN O
the DT DT O
urgency NN NN O
of IN IN O
the DT DT O
surgery NN NN O
and CC CC O
severity NN NN O
of IN IN O
masseter NN NN O
muscle NN NN O
rigidity NN NN O
. . . O

Here RB RB O
, , , O
we PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
severe JJ JJ O
masseter NN NN O
muscle NN NN O
rigidity NN NN O
( ( ( O
jaw NN NN O
of IN IN O
steel NN NN O
) ) ) O
after IN IN O
succinylcholine NN NN B-CHEM
( ( ( O
Sch NNP NNP B-CHEM
) ) ) O
administration NN NN O
during IN IN O
general JJ JJ O
anesthetic JJ JJ O
management NN NN O
for IN IN O
rigid NN NN O
bronchoscopic NN NN O
removal NN NN O
of IN IN O
a DT DT O
tracheal NN NN O
foreign JJ JJ O
body NN NN O
. . . O

Anesthesia NNP NNP O
was VBD VBD O
continued VBN VBN O
uneventfully RB RB O
with IN IN O
propofol NN NN B-CHEM
infusion NN NN O
while IN IN O
all DT DT O
facilities NNS NNS O
were VBD VBD O
available JJ JJ O
to TO TO O
detect VB VB O
and CC CC O
treat VB VB O
malignant JJ JJ O
hyperthermia NN NN O
. . . O

Dexrazoxane NNP NNP B-CHEM
protects VBZ VBZ O
against IN IN O
myelosuppression NN NN O
from IN IN O
the DT DT O
DNA NNP NNP O
cleavage NN NN O
- : : O
enhancing VBG VBG O
drugs NNS NNS O
etoposide NN NN B-CHEM
and CC CC O
daunorubicin NN NN B-CHEM
but CC CC O
not RB RB O
doxorubicin NN NN B-CHEM
. . . O

PURPOSE NNP NNP O
: : : O
The DT DT O
anthracyclines NNS NNS B-CHEM
daunorubicin NN NN B-CHEM
and CC CC O
doxorubicin NN NN B-CHEM
and CC CC O
the DT DT O
epipodophyllotoxin NN NN B-CHEM
etoposide NN NN B-CHEM
are VBP VBP O
potent JJ JJ O
DNA NNP NNP O
cleavage NN NN O
- : : O
enhancing VBG VBG O
drugs NNS NNS O
that WDT WDT O
are VBP VBP O
widely RB RB O
used VBN VBN O
in IN IN O
clinical JJ JJ O
oncology NN NN O
; : : O
however RB RB O
, , , O
myelosuppression NN NN O
and CC CC O
cardiac JJ JJ O
toxicity NN NN O
limit NN NN O
their PRP$ PRP$ O
use NN NN O
. . . O

Dexrazoxane NNP NNP B-CHEM
( ( ( O
ICRF NNP NNP B-CHEM
- - - I-CHEM
187 CD CD I-CHEM
) ) ) O
is VBZ VBZ O
recommended VBN VBN O
for IN IN O
protection NN NN O
against IN IN O
anthracycline NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

EXPERIMENTAL NNP NNP O
DESIGN NNP NNP O
: : : O
Because IN IN O
of IN IN O
their PRP$ PRP$ O
widespread JJ JJ O
use NN NN O
, , , O
the DT DT O
hematologic JJ JJ O
toxicity NN NN O
following VBG VBG O
coadministration NN NN O
of IN IN O
dexrazoxane NN NN B-CHEM
and CC CC O
these DT DT O
three CD CD O
structurally RB RB O
different JJ JJ O
DNA NNP NNP O
cleavage NN NN O
enhancers NNS NNS O
was VBD VBD O
investigated VBN VBN O
: : : O
Sensitivity NNP NNP O
of IN IN O
human JJ JJ O
and CC CC O
murine NN NN O
blood NN NN O
progenitor NN NN O
cells NNS NNS O
to TO TO O
etoposide VB VB B-CHEM
, , , O
daunorubicin NN NN B-CHEM
, , , O
and CC CC O
doxorubicin NN NN B-CHEM
+ NN NN O
/ NN NN O
- : : O
dexrazoxane NN NN B-CHEM
was VBD VBD O
determined VBN VBN O
in IN IN O
granulocyte NN NN O
- - - O
macrophage NN NN O
colony NN NN O
forming VBG VBG O
assays NNS NNS O
. . . O

Likewise NNP NNP O
, , , O
in IN IN O
vivo NN NN O
, , , O
B6D2F1 NNP NNP O
mice NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
etoposide NN NN B-CHEM
, , , O
daunorubicin NN NN B-CHEM
, , , O
and CC CC O
doxorubicin NN NN B-CHEM
, , , O
with IN IN O
or CC CC O
without IN IN O
dexrazoxane NN NN B-CHEM
over IN IN O
a DT DT O
wide JJ JJ O
range NN NN O
of IN IN O
doses NNS NNS O
: : : O
posttreatment NN NN O
, , , O
a DT DT O
full JJ JJ O
hematologic NN NN O
evaluation NN NN O
was VBD VBD O
done VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Nontoxic NNP NNP O
doses NNS NNS O
of IN IN O
dexrazoxane NN NN B-CHEM
reduced VBN VBN O
myelosuppression NN NN O
and CC CC O
weight NN NN O
loss NN NN O
from IN IN O
daunorubicin NN NN B-CHEM
and CC CC O
etoposide NN NN B-CHEM
in IN IN O
mice NN NN O
and CC CC O
antagonized VBD VBD O
their PRP$ PRP$ O
antiproliferative JJ JJ O
effects NNS NNS O
in IN IN O
the DT DT O
colony NN NN O
assay NN NN O
; : : O
however RB RB O
, , , O
dexrazoxane NN NN B-CHEM
neither DT DT O
reduced VBN VBN O
myelosuppression NN NN O
, , , O
weight NN NN O
loss NN NN O
, , , O
nor CC CC O
the DT DT O
in IN IN O
vitro NN NN O
cytotoxicity NN NN O
from IN IN O
doxorubicin NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
Although IN IN O
our PRP$ PRP$ O
findings NNS NNS O
support VBP VBP O
the DT DT O
observation NN NN O
that IN IN O
dexrazoxane NN NN B-CHEM
reduces VBZ VBZ O
neither DT DT O
hematologic JJ JJ O
activity NN NN O
nor CC CC O
antitumor NN NN O
activity NN NN O
from IN IN O
doxorubicin NN NN B-CHEM
clinically RB RB O
, , , O
the DT DT O
potent JJ JJ O
antagonism NN NN O
of IN IN O
daunorubicin NN NN B-CHEM
activity NN NN O
raises VBZ VBZ O
concern NN NN O
; : : O
a DT DT O
possible JJ JJ O
interference NN NN O
with IN IN O
anticancer NN NN O
efficacy NN NN O
certainly RB RB O
would MD MD O
call VB VB O
for IN IN O
renewed JJ JJ O
attention NN NN O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
also RB RB O
suggest VBP VBP O
that IN IN O
significant JJ JJ O
etoposide NN NN B-CHEM
dose NN NN O
escalation NN NN O
is VBZ VBZ O
perhaps RB RB O
possible JJ JJ O
by IN IN O
the DT DT O
use NN NN O
of IN IN O
dexrazoxane NN NN B-CHEM
. . . O

Clinical NNP NNP O
trials NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
brain NN NN O
metastases NNS NNS O
combining VBG VBG O
dexrazoxane NN NN B-CHEM
and CC CC O
high JJ JJ O
doses NNS NNS O
of IN IN O
etoposide NN NN B-CHEM
is VBZ VBZ O
ongoing JJ JJ O
with IN IN O
the DT DT O
aim NN NN O
of IN IN O
improving VBG VBG O
efficacy NN NN O
without IN IN O
aggravating VBG VBG O
hematologic JJ JJ O
toxicity NN NN O
. . . O

If IN IN O
successful JJ JJ O
, , , O
this DT DT O
represents VBZ VBZ O
an DT DT O
exciting JJ JJ O
mechanism NN NN O
for IN IN O
pharmacologic JJ JJ O
regulation NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
from IN IN O
cytotoxic JJ JJ O
chemotherapy NN NN O
. . . O

Assessment NNP NNP O
of IN IN O
the DT DT O
onset NN NN O
and CC CC O
persistence NN NN O
of IN IN O
amnesia NN NN O
during IN IN O
procedural JJ JJ O
sedation NN NN O
with IN IN O
propofol NN NN B-CHEM
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
assess VB VB O
patients NNS NNS O
' POS POS O
ability NN NN O
to TO TO O
repeat VB VB O
and CC CC O
recall VB VB O
words NNS NNS O
presented VBN VBN O
to TO TO O
them PRP PRP O
while IN IN O
undergoing VBG VBG O
procedural JJ JJ O
sedation NN NN O
with IN IN O
propofol NN NN B-CHEM
, , , O
and CC CC O
correlate JJ JJ O
their PRP$ PRP$ O
recall NN NN O
with IN IN O
their PRP$ PRP$ O
level NN NN O
of IN IN O
awareness NN NN O
as IN IN O
measured VBN VBN O
by IN IN O
bispectral NN NN O
index NN NN O
( ( ( O
BIS NNP NNP O
) ) ) O
monitoring VBG VBG O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
was VBD VBD O
a DT DT O
prospective JJ JJ O
, , , O
single JJ JJ O
- - - O
intervention NN NN O
study NN NN O
of IN IN O
consenting VBG VBG O
adult NN NN O
patients NNS NNS O
undergoing VBG VBG O
procedural JJ JJ O
sedation NN NN O
with IN IN O
propofol NN NN B-CHEM
between IN IN O
December NNP NNP O
28 CD CD O
, , , O
2002 CD CD O
, , , O
and CC CC O
October NNP NNP O
31 CD CD O
, , , O
2003 CD CD O
. . . O

BIS NNP NNP O
monitoring NN NN O
was VBD VBD O
initiated VBN VBN O
starting VBG VBG O
3 CD CD O
minutes NNS NNS O
before IN IN O
the DT DT O
procedure NN NN O
and CC CC O
continuing VBG VBG O
until IN IN O
the DT DT O
patient NN NN O
had VBD VBD O
regained VBN VBN O
baseline NN NN O
mental JJ JJ O
status NN NN O
. . . O

At IN IN O
1 CD CD O
- : : O
minute NN NN O
intervals NNS NNS O
during IN IN O
the DT DT O
procedural JJ JJ O
sedation NN NN O
, , , O
until IN IN O
the DT DT O
patient NN NN O
regained VBD VBD O
baseline NN NN O
mental JJ JJ O
status NN NN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
procedure NN NN O
, , , O
a DT DT O
word NN NN O
from IN IN O
a DT DT O
standardized JJ JJ O
list NN NN O
was VBD VBD O
read VBN VBN O
aloud RB RB O
, , , O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
asked VBN VBN O
to TO TO O
immediately RB RB O
repeat VB VB O
the DT DT O
word NN NN O
to TO TO O
the DT DT O
investigator NN NN O
. . . O

The DT DT O
BIS NNP NNP O
score NN NN O
at IN IN O
the DT DT O
time NN NN O
the DT DT O
word NN NN O
was VBD VBD O
read VBN VBN O
and CC CC O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
ability NN NN O
to TO TO O
repeat VB VB O
the DT DT O
word NN NN O
were VBD VBD O
recorded VBN VBN O
. . . O

After IN IN O
the DT DT O
procedure NN NN O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
asked VBN VBN O
to TO TO O
state VB VB O
all DT DT O
of IN IN O
the DT DT O
words NNS NNS O
from IN IN O
the DT DT O
list NN NN O
that IN IN O
he PRP PRP O
or CC CC O
she PRP PRP O
could MD MD O
recall VB VB O
, , , O
and CC CC O
to TO TO O
identify VB VB O
the DT DT O
last JJ JJ O
word NN NN O
recalled VBD VBD O
from IN IN O
prior RB RB O
to TO TO O
the DT DT O
start NN NN O
of IN IN O
the DT DT O
procedure NN NN O
and CC CC O
the DT DT O
first JJ JJ O
word NN NN O
recalled VBD VBD O
from IN IN O
after IN IN O
the DT DT O
procedure NN NN O
was VBD VBD O
completed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Seventy NNP NNP O
- - - O
five CD CD O
consenting VBG VBG O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
; : : O
one CD CD O
patient NN NN O
was VBD VBD O
excluded VBN VBN O
from IN IN O
data NNS NNS O
analysis NN NN O
for IN IN O
a DT DT O
protocol NN NN O
violation NN NN O
. . . O

No DT DT O
serious JJ JJ O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
noted VBN VBN O
during IN IN O
the DT DT O
procedural JJ JJ O
sedations NNS NNS O
. . . O

The DT DT O
mean NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
standard JJ JJ O
deviation NN NN O
) ) ) O
time NN NN O
of IN IN O
data NNS NNS O
collection NN NN O
was VBD VBD O
16 CD CD O
. . . O
4 CD CD O
minutes NNS NNS O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
. . . O
1 CD CD O
; : : O
range NN NN O
5 CD CD O
to TO TO O
34 CD CD O
minutes NNS NNS O
) ) ) O
. . . O

The DT DT O
mean NN NN O
initial JJ JJ O
( ( ( O
preprocedure NN NN O
) ) ) O
BIS NNP NNP O
score NN NN O
was VBD VBD O
97 CD CD O
. . . O
1 CD CD O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
3 CD CD O
; : : O
range NN NN O
92 CD CD O
to TO TO O
99 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
lowest JJS JJS O
BIS NNP NNP O
score NN NN O
occurring VBG VBG O
during IN IN O
these DT DT O
procedural JJ JJ O
sedations NNS NNS O
was VBD VBD O
66 CD CD O
. . . O
9 CD CD O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
. . . O
4 CD CD O
; : : O
range NN NN O
33 CD CD O
to TO TO O
91 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
lowest JJS JJS O
BIS NNP NNP O
score NN NN O
corresponding JJ JJ O
to TO TO O
the DT DT O
ability NN NN O
of IN IN O
the DT DT O
patient NN NN O
to TO TO O
immediately RB RB O
repeat VB VB O
words NNS NNS O
read VBN VBN O
from IN IN O
the DT DT O
list NN NN O
was VBD VBD O
77 CD CD O
. . . O
1 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
74 CD CD O
. . . O
3 CD CD O
to TO TO O
80 CD CD O
. . . O
0 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
highest JJS JJS O
BIS NNP NNP O
score NN NN O
corresponding JJ JJ O
to TO TO O
the DT DT O
inability NN NN O
to TO TO O
repeat NN NN O
words NNS NNS O
was VBD VBD O
81 CD CD O
. . . O
5 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
78 CD CD O
. . . O
1 CD CD O
to TO TO O
84 CD CD O
. . . O
8 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
BIS NNP NNP O
score NN NN O
corresponding JJ JJ O
to TO TO O
the DT DT O
last JJ JJ O
word NN NN O
recalled VBD VBD O
from IN IN O
prior RB RB O
to TO TO O
the DT DT O
initiation NN NN O
of IN IN O
the DT DT O
sedation NN NN O
was VBD VBD O
96 CD CD O
. . . O
7 CD CD O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
4 CD CD O
; : : O
range NN NN O
84 CD CD O
to TO TO O
98 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
BIS NNP NNP O
score NN NN O
corresponding JJ JJ O
to TO TO O
the DT DT O
first JJ JJ O
word NN NN O
recalled VBD VBD O
after IN IN O
the DT DT O
procedure NN NN O
was VBD VBD O
completed VBN VBN O
was VBD VBD O
91 CD CD O
. . . O
2 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
88 CD CD O
. . . O
1 CD CD O
to TO TO O
94 CD CD O
. . . O
3 CD CD O
) ) ) O
. . . O

All DT DT O
patients NNS NNS O
recalled VBN VBN O
at IN IN O
least JJS JJS O
one CD CD O
word NN NN O
that WDT WDT O
had VBD VBD O
been VBN VBN O
read VBN VBN O
to TO TO O
them PRP PRP O
during IN IN O
the DT DT O
protocol NN NN O
. . . O

The DT DT O
mean NN NN O
lowest JJS JJS O
BIS NNP NNP O
score NN NN O
for IN IN O
any DT DT O
recalled JJ JJ O
word NN NN O
was VBD VBD O
91 CD CD O
. . . O
5 CD CD O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
. . . O
1 CD CD O
; : : O
range NN NN O
79 CD CD O
to TO TO O
98 CD CD O
) ) ) O
, , , O
and CC CC O
no DT DT O
words NNS NNS O
were VBD VBD O
recalled VBN VBN O
when WRB WRB O
the DT DT O
corresponding JJ JJ O
BIS NNP NNP O
score NN NN O
was VBD VBD O
less JJR JJR O
than IN IN O
90 CD CD O
. . . O

CONCLUSIONS NNP NNP O
: : : O
There EX EX O
is VBZ VBZ O
a DT DT O
range NN NN O
of IN IN O
BIS NNP NNP O
scores NNS NNS O
during IN IN O
which WDT WDT O
sedated VBD VBD O
patients NNS NNS O
are VBP VBP O
able JJ JJ O
to TO TO O
repeat VB VB O
words NNS NNS O
read VBP VBP O
to TO TO O
them PRP PRP O
but CC CC O
are VBP VBP O
not RB RB O
able JJ JJ O
to TO TO O
subsequently RB RB O
recall VB VB O
these DT DT O
words NNS NNS O
. . . O

Furthermore RB RB O
, , , O
patients NNS NNS O
had VBD VBD O
no DT DT O
recall NN NN O
of IN IN O
words NNS NNS O
repeated VBN VBN O
prior RB RB O
to TO TO O
procedural JJ JJ O
sedation NN NN O
in IN IN O
BIS NNP NNP O
ranges NNS NNS O
associated VBN VBN O
with IN IN O
recall NN NN O
after IN IN O
procedural JJ JJ O
sedation NN NN O
, , , O
suggestive JJ JJ O
of IN IN O
retrograde NN NN O
amnesia NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
pulmonary JJ JJ O
toxicity NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
antiarrhythmic JJ JJ O
agent NN NN O
whose WP$ WP$ O
utility NN NN O
is VBZ VBZ O
limited VBN VBN O
by IN IN O
many JJ JJ O
side NN NN O
- - - O
effects NNS NNS O
, , , O
the DT DT O
most RBS RBS O
problematic JJ JJ O
being NN NN O
pneumonitis NNS NNS O
. . . O

The DT DT O
pulmonary JJ JJ O
toxicity NN NN O
of IN IN O
amiodarone NN NN B-CHEM
is VBZ VBZ O
thought VBN VBN O
to TO TO O
result VB VB O
from IN IN O
direct JJ JJ O
injury NN NN O
related VBD VBD O
to TO TO O
the DT DT O
intracellular JJ JJ O
accumulation NN NN O
of IN IN O
phospholipid NN NN O
and CC CC O
T NN NN O
cell NN NN O
- - - O
mediated JJ JJ O
hypersensitivity NN NN O
pneumonitis NN NN O
. . . O

The DT DT O
clinical JJ JJ O
and CC CC O
radiographic JJ JJ O
features NNS NNS O
of IN IN O
amiodarone NN NN B-CHEM
- - - O
induced JJ JJ O
pulmonary JJ JJ O
toxicity NN NN O
are VBP VBP O
characteristic JJ JJ O
but CC CC O
nonspecific JJ JJ O
. . . O

The DT DT O
diagnosis NN NN O
depends VBZ VBZ O
on IN IN O
exclusion NN NN O
of IN IN O
other JJ JJ O
entities NNS NNS O
, , , O
such JJ JJ O
as IN IN O
heart NN NN O
failure NN NN O
, , , O
infection NN NN O
, , , O
and CC CC O
malignancy NN NN O
. . . O

While IN IN O
withdrawal NN NN O
of IN IN O
amiodarone NN NN B-CHEM
leads VBZ VBZ O
to TO TO O
clinical JJ JJ O
improvement NN NN O
in IN IN O
majority NN NN O
of IN IN O
cases NNS NNS O
, , , O
this DT DT O
is VBZ VBZ O
not RB RB O
always RB RB O
possible JJ JJ O
or CC CC O
advisable JJ JJ O
. . . O

Dose NNP NNP O
reduction NN NN O
or CC CC O
concomitant NN NN O
steroid NN NN B-CHEM
therapy NN NN O
may MD MD O
have VB VB O
a DT DT O
role NN NN O
in IN IN O
selected VBN VBN O
patients NNS NNS O
. . . O

Two CD CD O
prodrugs NNS NNS O
of IN IN O
potent NN NN O
and CC CC O
selective JJ JJ O
GluR5 NNP NNP O
kainate NN NN B-CHEM
receptor NN NN O
antagonists NNS NNS O
actives NNS NNS O
in IN IN O
three CD CD O
animal NN NN O
models NNS NNS O
of IN IN O
pain NN NN O
. . . O

Amino JJ JJ O
acids NNS NNS O
5 CD CD O
and CC CC O
7 CD CD O
, , , O
two CD CD O
potent JJ JJ O
and CC CC O
selective JJ JJ O
competitive JJ JJ O
GluR5 NNP NNP O
KA NNP NNP B-CHEM
receptor NN NN O
antagonists NNS NNS O
, , , O
exhibited VBN VBN O
high JJ JJ O
GluR5 NNP NNP O
receptor NN NN O
affinity NN NN O
over IN IN O
other JJ JJ O
glutamate NN NN B-CHEM
receptors NNS NNS O
. . . O

Their PRP$ PRP$ O
ester NN NN O
prodrugs NNS NNS O
6 CD CD O
and CC CC O
8 CD CD O
were VBD VBD O
orally RB RB O
active JJ JJ O
in IN IN O
three CD CD O
models NNS NNS O
of IN IN O
pain NN NN O
: : : O
reversal NN NN O
of IN IN O
formalin NN NN B-CHEM
- - - O
induced JJ JJ O
paw NN NN O
licking VBG VBG O
, , , O
carrageenan NN NN B-CHEM
- - - O
induced JJ JJ O
thermal NN NN O
hyperalgesia NN NN O
, , , O
and CC CC O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
mechanical JJ JJ O
hyperalgesia NN NN O
. . . O

Possible JJ JJ O
azithromycin NN NN B-CHEM
- - - O
associated VBN VBN O
hiccups NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
persistent JJ JJ O
hiccups NNS NNS O
associated VBN VBN O
by IN IN O
azithromycin NN NN B-CHEM
therapy NN NN O
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
76 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
presented VBN VBN O
with IN IN O
persistent JJ JJ O
hiccups NNS NNS O
after IN IN O
beginning VBG VBG O
azithromycin NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
pharyngitis NNS NNS O
. . . O

Hiccups NNP NNP O
were VBD VBD O
persistent JJ JJ O
and CC CC O
exhausting VBG VBG O
. . . O

Discontinuation NNP NNP O
of IN IN O
azithromycin NN NN B-CHEM
and CC CC O
therapy NN NN O
with IN IN O
baclofen NN NN B-CHEM
finally RB RB O
resolved VBD VBD O
hiccups NNS NNS O
. . . O

No DT DT O
organic JJ JJ O
cause NN NN O
of IN IN O
hiccups NNS NNS O
was VBD VBD O
identified VBN VBN O
despite IN IN O
extensive JJ JJ O
investigation NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
Pharmacotherapeutic JJ JJ O
agents NNS NNS O
have VBP VBP O
been VBN VBN O
uncommonly RB RB O
associated VBN VBN O
with IN IN O
hiccups NNS NNS O
. . . O

Corticosteroids NNP NNP O
( ( ( O
dexamethasone NN NN B-CHEM
and CC CC O
methylprednisolone NN NN B-CHEM
) ) ) O
, , , O
benzodiazepines NNS NNS B-CHEM
( ( ( O
midazolam NN NN B-CHEM
) ) ) O
and CC CC O
general JJ JJ O
anaesthesia NN NN O
have VBP VBP O
been VBN VBN O
the DT DT O
specific JJ JJ O
agents NNS NNS O
mentioned VBD VBD O
most RBS RBS O
frequently RB RB O
in IN IN O
the DT DT O
literature NN NN O
as IN IN O
being VBG VBG O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
hiccups NNS NNS O
. . . O

Few JJ JJ O
cases NNS NNS O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hiccups NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
related VBN VBN O
to TO TO O
macrolide NN NN B-CHEM
antimicrobials NNS NNS O
. . . O

Using VBG VBG O
the DT DT O
Naranjo NNP NNP O
adverse JJ JJ O
effect NN NN O
reaction NN NN O
probability NN NN O
scale NN NN O
this DT DT O
event NN NN O
could MD MD O
be VB VB O
classified VBN VBN O
as IN IN O
possible JJ JJ O
( ( ( O
score NN NN O
5 CD CD O
points NNS NNS O
) ) ) O
, , , O
mostly RB RB O
because IN IN O
of IN IN O
the DT DT O
close JJ JJ O
temporal NN NN O
sequence NN NN O
, , , O
previous JJ JJ O
reports NNS NNS O
on IN IN O
this DT DT O
reaction NN NN O
with IN IN O
other JJ JJ O
macrolides NNS NNS B-CHEM
and CC CC O
the DT DT O
absence NN NN O
of IN IN O
any DT DT O
alternative JJ JJ O
explanation NN NN O
for IN IN O
hiccups NNS NNS O
. . . O

Our PRP$ PRP$ O
hypothesis NNS NNS O
is VBZ VBZ O
that IN IN O
a DT DT O
vagal JJ JJ O
mechanism NN NN O
mediated VBN VBN O
by IN IN O
azithromycin NN NN B-CHEM
could MD MD O
be VB VB O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
hiccups NNS NNS O
in IN IN O
our PRP$ PRP$ O
patient NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Diagnosis NNP NNP O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hiccups NNS NNS O
is VBZ VBZ O
difficult JJ JJ O
and CC CC O
often RB RB O
achieved VBN VBN O
only RB RB O
by IN IN O
a DT DT O
process NN NN O
of IN IN O
elimination NN NN O
. . . O

However RB RB O
, , , O
macrolide NN NN B-CHEM
antimicrobials NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
hiccups NNS NNS O
and CC CC O
vagal JJ JJ O
mechanism NN NN O
could MD MD O
explain VB VB O
the DT DT O
development NN NN O
of IN IN O
this DT DT O
side NN NN O
- - - O
effect NN NN O
. . . O

Calcium NNP NNP B-CHEM
carbonate NN NN I-CHEM
toxicity NN NN O
: : : O
the DT DT O
updated JJ JJ O
milk NN NN O
- - - O
alkali NN NN O
syndrome NN NN O
; : : O
report NN NN O
of IN IN O
3 CD CD O
cases NNS NNS O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
3 CD CD O
patients NNS NNS O
with IN IN O
calcium NN NN B-CHEM
carbonate NN NN I-CHEM
- : : O
induced JJ JJ O
hypercalcemia NN NN O
and CC CC O
gain VB VB O
insights NNS NNS O
into IN IN O
the DT DT O
cause NN NN O
and CC CC O
management NN NN O
of IN IN O
the DT DT O
milk NN NN O
- - - O
alkali NN NN O
syndrome NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
report VBP VBP O
the DT DT O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
data NNS NNS O
in IN IN O
3 CD CD O
patients NNS NNS O
who WP WP O
presented VBD VBD O
with IN IN O
severe JJ JJ O
hypercalcemia NN NN O
( ( ( O
corrected VBN VBN O
serum NN NN O
calcium NN NN B-CHEM
> NN NN O
or CC CC O
= SYM SYM O
14 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
and CC CC O
review NN NN O
the DT DT O
pertinent NN NN O
literature NN NN O
on IN IN O
milk NN NN O
- : : O
alkali NN NN O
syndrome NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
3 CD CD O
patients NNS NNS O
had VBD VBD O
acute JJ JJ O
renal JJ JJ O
insufficiency NN NN O
, , , O
relative JJ JJ O
metabolic JJ JJ O
alkalosis NN NN O
, , , O
and CC CC O
low JJ JJ O
parathyroid NN NN O
hormone NN NN O
( ( ( O
PTH NNP NNP O
) ) ) O
, , , O
PTH NNP NNP O
- - - O
related VBN VBN O
peptide NN NN O
, , , O
and CC CC O
1 CD CD B-CHEM
, , , I-CHEM
25 CD CD I-CHEM
- : : I-CHEM
dihydroxyvitamin NN NN I-CHEM
D NNP NNP I-CHEM
concentrations NNS NNS O
. . . O

No DT DT O
malignant JJ JJ O
lesion NN NN O
was VBD VBD O
found VBN VBN O
. . . O

Treatment NN NN O
included VBD VBD O
aggressive JJ JJ O
hydration NN NN O
and CC CC O
varied JJ JJ O
amounts NNS NNS O
of IN IN O
furosemide NN NN B-CHEM
. . . O

The DT DT O
2 CD CD O
patients NNS NNS O
with IN IN O
the DT DT O
higher JJR JJR O
serum NN NN O
calcium NN NN B-CHEM
concentrations NNS NNS O
received VBD VBD O
pamidronate JJ JJ B-CHEM
intravenously RB RB O
( ( ( O
60 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
, , , O
respectively RB RB O
) ) ) O
, , , O
which WDT WDT O
caused VBD VBD O
severe JJ JJ O
hypocalcemia NN NN O
. . . O

Of IN IN O
the DT DT O
3 CD CD O
patients NNS NNS O
, , , O
2 CD CD O
were VBD VBD O
ingesting VBG VBG O
acceptable JJ JJ O
doses NNS NNS O
of IN IN O
elemental JJ JJ O
calcium NN NN B-CHEM
( ( ( O
1 CD CD O
g SYM SYM O
and CC CC O
2 CD CD O
g SYM SYM O
daily JJ JJ O
, , , O
respectively RB RB O
) ) ) O
in IN IN O
the DT DT O
form NN NN O
of IN IN O
calcium NN NN B-CHEM
carbonate NN NN I-CHEM
. . . O

In IN IN O
addition NN NN O
to TO TO O
our PRP$ PRP$ O
highlighted JJ JJ O
cases NNS NNS O
, , , O
we PRP PRP O
review VBP VBP O
the DT DT O
history NN NN O
, , , O
classification NN NN O
, , , O
pathophysiologic JJ JJ O
features NNS NNS O
, , , O
and CC CC O
treatment NN NN O
of IN IN O
milk NN NN O
- - - O
alkali NN NN O
syndrome NN NN O
and CC CC O
summarize VB VB O
the DT DT O
cases NNS NNS O
reported VBD VBD O
from IN IN O
early JJ JJ O
1995 CD CD O
to TO TO O
November NNP NNP O
2003 CD CD O
. . . O

CONCLUSION NNP NNP O
: : : O
Milk NNP NNP O
- - - O
alkali NN NN O
syndrome NN NN O
may MD MD O
be VB VB O
a DT DT O
common JJ JJ O
cause NN NN O
of IN IN O
unexplained JJ JJ O
hypercalcemia NN NN O
and CC CC O
can MD MD O
be VB VB O
precipitated VBN VBN O
by IN IN O
small JJ JJ O
amounts NNS NNS O
of IN IN O
orally RB RB O
ingested VBN VBN O
calcium NN NN B-CHEM
carbonate NN NN I-CHEM
in IN IN O
susceptible JJ JJ O
persons NNS NNS O
. . . O

Treatment NN NN O
with IN IN O
hydration NN NN O
, , , O
furosemide NN NN B-CHEM
, , , O
and CC CC O
discontinuation NN NN O
of IN IN O
the DT DT O
calcium NN NN B-CHEM
and CC CC O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
source NN NN O
is VBZ VBZ O
adequate JJ JJ O
. . . O

Pamidronate NNP NNP B-CHEM
treatment NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
considerable JJ JJ O
risk NN NN O
for IN IN O
hypocalcemia NN NN O
, , , O
even RB RB O
in IN IN O
cases NNS NNS O
of IN IN O
initially RB RB O
severe JJ JJ O
hypercalcemia NN NN O
. . . O

Warfarin NNP NNP B-CHEM
- : : O
induced JJ JJ O
leukocytoclastic JJ JJ O
vasculitis NN NN O
. . . O

Skin NNP NNP O
reactions NNS NNS O
associated VBN VBN O
with IN IN O
oral JJ JJ O
coumarin NN NN B-CHEM
- - - O
derived VBN VBN O
anticoagulants NNS NNS O
are VBP VBP O
an DT DT O
uncommon JJ JJ O
occurrence NN NN O
. . . O

Leukocytoclastic NNP NNP O
vasculitis NN NN O
( ( ( O
LV NNP NNP O
) ) ) O
is VBZ VBZ O
primarily RB RB O
a DT DT O
cutaneous JJ JJ O
small JJ JJ O
vessel NN NN O
vasculitis NN NN O
, , , O
though IN IN O
systemic JJ JJ O
involvement NN NN O
may MD MD O
be VB VB O
encountered VBN VBN O
. . . O

We PRP PRP O
report VBP VBP O
4 CD CD O
patients NNS NNS O
with IN IN O
late JJ JJ O
- - - O
onset NN NN O
LV NNP NNP O
probably RB RB O
due JJ JJ O
to TO TO O
warfarin NN NN B-CHEM
. . . O

All DT DT O
4 CD CD O
patients NNS NNS O
presented VBN VBN O
with IN IN O
skin NN NN O
eruptions NNS NNS O
that WDT WDT O
developed VBD VBD O
after IN IN O
receiving VBG VBG O
warfarin NN NN B-CHEM
for IN IN O
several JJ JJ O
years NNS NNS O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
skin NN NN O
lesion NN NN O
biopsies NNS NNS O
were VBD VBD O
available JJ JJ O
in IN IN O
3 CD CD O
patients NNS NNS O
, , , O
confirming VBG VBG O
LV NNP NNP O
Cutaneous NNP NNP O
lesions NNS NNS O
resolved VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
after IN IN O
warfarin NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
. . . O

In IN IN O
2 CD CD O
of IN IN O
the DT DT O
4 CD CD O
patients NNS NNS O
, , , O
rechallenge NN NN O
with IN IN O
warfarin NN NN B-CHEM
led VBN VBN O
to TO TO O
recurrence NN NN O
of IN IN O
the DT DT O
lesions NNS NNS O
. . . O

LV NNP NNP O
may MD MD O
be VB VB O
a DT DT O
late JJ JJ O
- - - O
onset NN NN O
adverse NN NN O
reaction NN NN O
associated VBN VBN O
with IN IN O
warfarin NN NN B-CHEM
therapy NN NN O
. . . O

Cocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
brainstem NN NN O
seizures NNS NNS O
and CC CC O
behavior NN NN O
. . . O

A DT DT O
variety NN NN O
of IN IN O
abnormal JJ JJ O
sensory NN NN O
/ NN NN O
motor NN NN O
behaviors NNS NNS O
associated VBN VBN O
with IN IN O
electrical JJ JJ O
discharges NNS NNS O
recorded VBD VBD O
from IN IN O
the DT DT O
bilateral JJ JJ O
brainstem NN NN O
were VBD VBD O
induced VBN VBN O
in IN IN O
adult NN NN O
WKY NNP NNP O
rats NNS NNS O
by IN IN O
mechanical JJ JJ O
( ( ( O
electrode NN NN O
implants NNS NNS O
) ) ) O
and CC CC O
DC NNP NNP O
electrical JJ JJ O
current JJ JJ O
stimulations NNS NNS O
and CC CC O
by IN IN O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
administration NN NN O
of IN IN O
cocaine NN NN B-CHEM
. . . O

The DT DT O
electrode NN NN O
implant NN NN O
implicated VBN VBN O
one CD CD O
side NN NN O
or CC CC O
the DT DT O
other JJ JJ O
of IN IN O
the DT DT O
reticular JJ JJ O
system NN NN O
of IN IN O
the DT DT O
brainstem NN NN O
but CC CC O
subjects NNS NNS O
were VBD VBD O
not RB RB O
incapacitated VBN VBN O
by IN IN O
the DT DT O
stimulations NNS NNS O
. . . O

Cocaine NNP NNP B-CHEM
( ( ( O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
injected VBN VBN O
subcutaneously RB RB O
for IN IN O
an DT DT O
acute JJ JJ O
experiment NN NN O
and CC CC O
subsequent JJ JJ O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
doses NNS NNS O
twice RB RB O
daily JJ JJ O
for IN IN O
3 CD CD O
days NNS NNS O
in IN IN O
a DT DT O
chronic JJ JJ O
study NN NN O
. . . O

Cocaine NNP NNP B-CHEM
generated VBD VBD O
more RBR RBR O
abnormal JJ JJ O
behaviors NNS NNS O
in IN IN O
the DT DT O
brainstem NN NN O
perturbation NN NN O
group NN NN O
, , , O
especially RB RB O
the DT DT O
electrically RB RB O
perturbated VBN VBN O
subjects NNS NNS O
. . . O

The DT DT O
abnormal JJ JJ O
behaviors NNS NNS O
were VBD VBD O
yawning VBG VBG O
, , , O
retrocollis NNS NNS O
, , , O
hyperactivity NN NN O
, , , O
hypersensitivity NN NN O
, , , O
" '' '' O
beating VBG VBG O
drum NN NN O
" '' '' O
behavior NN NN O
, , , O
squealing VBG VBG O
, , , O
head NN NN O
bobbing NN NN O
, , , O
circling VBG VBG O
, , , O
sniffing VBG VBG O
, , , O
abnormal JJ JJ O
posturing NN NN O
, , , O
and CC CC O
facial JJ JJ O
twitching VBG VBG O
. . . O

Shifts NNP NNP O
in IN IN O
the DT DT O
power NN NN O
frequency NN NN O
spectra NN NN O
of IN IN O
the DT DT O
discharge NN NN O
patterns NNS NNS O
were VBD VBD O
noted VBN VBN O
between IN IN O
quiet JJ JJ O
and CC CC O
pacing VBG VBG O
behavioral JJ JJ O
states NNS NNS O
. . . O

Hypersensitivity NNP NNP O
to TO TO O
various JJ JJ O
auditory NN NN O
, , , O
tactile NN NN O
, , , O
and CC CC O
visual JJ JJ O
stimulation NN NN O
was VBD VBD O
present JJ JJ O
and CC CC O
shifts NNS NNS O
in IN IN O
the DT DT O
brainstem NN NN O
ambient NN NN O
power NN NN O
spectral JJ JJ O
frequency NN NN O
occurred VBD VBD O
in IN IN O
response NN NN O
to TO TO O
tactile NN NN O
stimulation NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
brainstem NN NN O
generates VBZ VBZ O
and CC CC O
propagates VBZ VBZ O
pathological JJ JJ O
discharges NNS NNS O
that WDT WDT O
can MD MD O
be VB VB O
elicited VBN VBN O
by IN IN O
mechanical JJ JJ O
and CC CC O
DC NNP NNP O
electrical JJ JJ O
perturbation NN NN O
. . . O

Cocaine NNP NNP B-CHEM
was VBD VBD O
found VBN VBN O
to TO TO O
activate VB VB O
the DT DT O
discharge NN NN O
system NN NN O
and CC CC O
thus RB RB O
induce VB VB O
abnormal JJ JJ O
behaviors NNS NNS O
that WDT WDT O
are VBP VBP O
generated VBN VBN O
at IN IN O
the DT DT O
discharge NN NN O
site NN NN O
and CC CC O
at IN IN O
distant JJ JJ O
sites NNS NNS O
to TO TO O
which WDT WDT O
the DT DT O
discharge NN NN O
propagates NNS NNS O
. . . O

Cognitive NNP NNP O
functions NNS NNS O
may MD MD O
also RB RB O
be VB VB O
involved VBN VBN O
since IN IN O
dopaminergic JJ JJ O
and CC CC O
serotonergic JJ JJ O
cellular NN NN O
elements NNS NNS O
at IN IN O
the DT DT O
brainstem NN NN O
level NN NN O
are VBP VBP O
also RB RB O
implicated VBN VBN O
. . . O

rTMS NN NN O
of IN IN O
supplementary JJ JJ O
motor NN NN O
area NN NN O
modulates NNS NNS O
therapy NN NN O
- : : O
induced VBN VBN O
dyskinesias NN NN O
in IN IN O
Parkinson NNP NNP O
disease NN NN O
. . . O

The DT DT O
neural NN NN O
mechanisms NNS NNS O
and CC CC O
circuitry NN NN O
involved VBN VBN O
in IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesia NN NN O
are VBP VBP O
unclear JJ JJ O
. . . O

Using VBG VBG O
repetitive JJ JJ O
transcranial NN NN O
magnetic JJ JJ O
stimulation NN NN O
( ( ( O
rTMS NN NN O
) ) ) O
over IN IN O
the DT DT O
supplementary JJ JJ O
motor NN NN O
area NN NN O
( ( ( O
SMA NNP NNP O
) ) ) O
in IN IN O
a DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
Parkinson NNP NNP O
disease NN NN O
, , , O
the DT DT O
authors NNS NNS O
investigated VBD VBD O
whether IN IN O
modulation NN NN O
of IN IN O
SMA NNP NNP O
excitability NN NN O
may MD MD O
result VB VB O
in IN IN O
a DT DT O
modification NN NN O
of IN IN O
a DT DT O
dyskinetic JJ JJ O
state NN NN O
induced VBN VBN O
by IN IN O
continuous JJ JJ O
apomorphine NN NN B-CHEM
infusion NN NN O
. . . O

rTMS NN NN O
at IN IN O
1 CD CD O
Hz NNP NNP O
was VBD VBD O
observed VBN VBN O
to TO TO O
markedly RB RB O
reduce VB VB O
drug NN NN O
- : : O
induced JJ JJ O
dyskinesias NN NN O
, , , O
whereas IN IN O
5 CD CD O
- : : O
Hz NNP NNP O
rTMS NN NN O
induced VBD VBD O
a DT DT O
slight JJ JJ O
but CC CC O
not RB RB O
significant JJ JJ O
increase NN NN O
. . . O

Intracavitary NNP NNP O
chemotherapy NN NN O
( ( ( O
paclitaxel NN NN B-CHEM
/ NN NN O
carboplatin NN NN B-CHEM
liquid JJ JJ O
crystalline NN NN O
cubic NN NN O
phases NNS NNS O
) ) ) O
for IN IN O
recurrent JJ JJ O
glioblastoma NN NN O
- - - O
- - - O
clinical JJ JJ O
observations NNS NNS O
. . . O

Human NNP NNP O
malignant NN NN O
brain NN NN O
tumors NNS NNS O
have VBP VBP O
a DT DT O
poor JJ JJ O
prognosis NN NN O
in IN IN O
spite NN NN O
of IN IN O
surgery NN NN O
and CC CC O
radiation NN NN O
therapy NN NN O
. . . O

Cubic NNP NNP O
phases NNS NNS O
consist NN NN O
of IN IN O
curved VBD VBD O
biocontinuous JJ JJ O
lipid JJ JJ O
bilayers NNS NNS O
, , , O
separating VBG VBG O
two CD CD O
congruent JJ JJ O
networks NNS NNS O
of IN IN O
water NN NN O
channels NNS NNS O
. . . O

Used VBN VBN O
as IN IN O
a DT DT O
host NN NN O
for IN IN O
cytotoxic JJ JJ O
drugs NNS NNS O
, , , O
the DT DT O
gel NN NN O
- - - O
like IN IN O
matrix NN NN O
can MD MD O
easily RB RB O
be VB VB O
applied VBN VBN O
to TO TO O
the DT DT O
walls NNS NNS O
of IN IN O
a DT DT O
surgical JJ JJ O
resection NN NN O
cavity NN NN O
. . . O

For IN IN O
human JJ JJ O
glioblastoma NN NN O
recurrences NNS NNS O
, , , O
the DT DT O
feasibility NN NN O
, , , O
safety NN NN O
, , , O
and CC CC O
short JJ JJ O
- - - O
term NN NN O
effects NNS NNS O
of IN IN O
a DT DT O
surgical JJ JJ O
intracavitary JJ JJ O
application NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
and CC CC O
carboplatin NN NN B-CHEM
encapsulated VBN VBN O
by IN IN O
liquid JJ JJ O
crystalline NN NN O
cubic NN NN O
phases NNS NNS O
are VBP VBP O
examined VBN VBN O
in IN IN O
a DT DT O
pilot NN NN O
study NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
12 CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
recurrence NN NN O
of IN IN O
a DT DT O
glioblastoma NN NN O
multiforme NN NN O
underwent NN NN O
re NN NN O
- - - O
resection NN NN O
and CC CC O
received VBD VBD O
an DT DT O
intracavitary JJ JJ O
application NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
and CC CC O
carboplatin NN NN B-CHEM
cubic NN NN O
phases NNS NNS O
in IN IN O
different JJ JJ O
dosages NNS NNS O
. . . O

Six CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
received VBD VBD O
more JJR JJR O
than IN IN O
15 CD CD O
mg NN NN O
paclitaxel NN NN B-CHEM
and CC CC O
suffered VBD VBD O
from IN IN O
moderate NN NN O
to TO TO O
severe JJ JJ O
brain NN NN O
edema NN NN O
, , , O
while IN IN O
the DT DT O
remaining VBG VBG O
patients NNS NNS O
received VBD VBD O
only RB RB O
a DT DT O
total NN NN O
of IN IN O
15 CD CD O
mg NN NN O
paclitaxel NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
latter JJ JJ O
group NN NN O
, , , O
brain NN NN O
edema NN NN O
was VBD VBD O
markedly RB RB O
reduced VBN VBN O
and CC CC O
dealt VBN VBN O
medically RB RB O
. . . O

Intracavitary NNP NNP O
chemotherapy NN NN O
in IN IN O
recurrent JJ JJ O
glioblastoma NN NN O
using VBG VBG O
cubic NN NN O
phases NNS NNS O
is VBZ VBZ O
feasible JJ JJ O
and CC CC O
safe JJ JJ O
, , , O
yet RB RB O
the DT DT O
clinical JJ JJ O
benefit NN NN O
remains VBZ VBZ O
to TO TO O
be VB VB O
examined VBN VBN O
in IN IN O
a DT DT O
clinical JJ JJ O
phase NN NN O
II NNP NNP O
study NN NN O
. . . O

Lamotrigine NNP NNP B-CHEM
associated VBN VBN O
with IN IN O
exacerbation NN NN O
or CC CC O
de IN IN O
novo NN NN O
myoclonus NN NN O
in IN IN O
idiopathic JJ JJ O
generalized JJ JJ O
epilepsies NNS NNS O
. . . O

Five CD CD O
patients NNS NNS O
with IN IN O
idiopathic JJ JJ O
generalized JJ JJ O
epilepsies NNS NNS O
( ( ( O
IGE NNP NNP O
) ) ) O
treated VBN VBN O
with IN IN O
lamotrigine NN NN B-CHEM
( ( ( O
LTG NNP NNP B-CHEM
) ) ) O
experienced VBN VBN O
exacerbation NN NN O
or CC CC O
de IN IN O
novo NN NN O
appearance NN NN O
of IN IN O
myoclonic JJ JJ O
jerks NNS NNS O
( ( ( O
MJ NNP NNP O
) ) ) O
. . . O

In IN IN O
three CD CD O
patients NNS NNS O
, , , O
LTG NNP NNP B-CHEM
exacerbated VBD VBD O
MJ NNP NNP O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
with IN IN O
early JJ JJ O
aggravation NN NN O
during IN IN O
titration NN NN O
. . . O

MJ NNP NNP O
disappeared VBD VBD O
when WRB WRB O
LTG NNP NNP B-CHEM
dose NN NN O
was VBD VBD O
decreased VBN VBN O
by IN IN O
25 CD CD O
to TO TO O
50 CD CD O
% NN NN O
. . . O

In IN IN O
two CD CD O
patients NNS NNS O
, , , O
LTG NNP NNP B-CHEM
exacerbated VBD VBD O
MJ NNP NNP O
in IN IN O
a DT DT O
delayed JJ JJ O
but CC CC O
more JJR JJR O
severe JJ JJ O
manner NN NN O
, , , O
with IN IN O
myoclonic JJ JJ O
status NN NN O
that IN IN O
only RB RB O
ceased VBN VBN O
after IN IN O
LTG NNP NNP B-CHEM
withdrawal NN NN O
. . . O

Absence NNP NNP O
of IN IN O
acute JJ JJ O
cerebral JJ JJ O
vasoconstriction NN NN O
after IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
subarachnoid NN NN O
hemorrhage NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Cocaine NNP NNP B-CHEM
use NN NN O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
neurovascular JJ JJ O
complications NNS NNS O
, , , O
including VBG VBG O
arterial JJ JJ O
vasoconstriction NN NN O
and CC CC O
vasculitis NNS NNS O
. . . O

However RB RB O
, , , O
there EX EX O
are VBP VBP O
few JJ JJ O
studies NNS NNS O
of IN IN O
angiographic JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
on IN IN O
human JJ JJ O
cerebral NN NN O
arteries NNS NNS O
. . . O

Information NNP NNP O
on IN IN O
these DT DT O
effects NNS NNS O
could MD MD O
be VB VB O
obtained VBN VBN O
from IN IN O
angiograms NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
subarachnoid NN NN O
hemorrhage NN NN O
( ( ( O
SAH NNP NNP O
) ) ) O
who WP WP O
underwent JJ JJ O
angiography NN NN O
shortly RB RB O
after IN IN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
screened VBD VBD O
patients NNS NNS O
with IN IN O
SAH NNP NNP O
retrospectively RB RB O
and CC CC O
identified VBD VBD O
those DT DT O
with IN IN O
positive JJ JJ O
urine NN NN O
toxicology NN NN O
for IN IN O
cocaine NN NN B-CHEM
or CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
. . . O

Quantitative NNP NNP O
arterial JJ JJ O
diameter NN NN O
measurements NNS NNS O
from IN IN O
angiograms NNS NNS O
of IN IN O
these DT DT O
patients NNS NNS O
were VBD VBD O
compared VBN VBN O
to TO TO O
measurements NNS NNS O
from IN IN O
control NN NN O
patients NNS NNS O
with IN IN O
SAH NNP NNP O
who WP WP O
were VBD VBD O
matched VBN VBN O
for IN IN O
factors NNS NNS O
known VBN VBN O
to TO TO O
influence VB VB O
arterial JJ JJ O
diameter NN NN O
. . . O

Qualitative NNP NNP O
comparisons NNS NNS O
of IN IN O
small JJ JJ O
artery NN NN O
changes NNS NNS O
also RB RB O
were VBD VBD O
made VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Thirteen NNP NNP O
patients NNS NNS O
with IN IN O
positive JJ JJ O
cocaine NN NN B-CHEM
toxicology NN NN O
were VBD VBD O
compared VBN VBN O
to TO TO O
26 CD CD O
controls NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
between IN IN O
groups NNS NNS O
in IN IN O
the DT DT O
mean NN NN O
diameters NNS NNS O
of IN IN O
the DT DT O
intradural JJ JJ O
internal JJ JJ O
carotid NN NN O
, , , O
sphenoidal NN NN O
segment NN NN O
of IN IN O
the DT DT O
middle JJ JJ O
cerebral NN NN O
, , , O
precommunicating VBG VBG O
segment NN NN O
of IN IN O
the DT DT O
anterior NN NN O
cerebral NN NN O
, , , O
or CC CC O
basilar NN NN O
arteries NNS NNS O
( ( ( O
p NN NN O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
for IN IN O
all DT DT O
comparisons NNS NNS O
, , , O
unpaired JJ JJ O
t NN NN O
- - - O
tests NNS NNS O
) ) ) O
. . . O

There EX EX O
also RB RB O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
between IN IN O
groups NNS NNS O
when WRB WRB O
expressing VBG VBG O
diameters NNS NNS O
as IN IN O
the DT DT O
sum NN NN O
of IN IN O
the DT DT O
precommunicating VBG VBG O
segment NN NN O
of IN IN O
the DT DT O
anterior NN NN O
cerebral NN NN O
+ NN NN O
sphenoidal JJ JJ O
segment NN NN O
of IN IN O
the DT DT O
middle JJ JJ O
cerebral JJ JJ O
+ NN NN O
supraclinoid JJ JJ O
internal JJ JJ O
carotid NN NN O
artery NN NN O
+ NN NN O
basilar JJ JJ O
artery NN NN O
divided VBN VBN O
by IN IN O
the DT DT O
diameter NN NN O
of IN IN O
the DT DT O
petrous JJ JJ O
internal JJ JJ O
carotid NN NN O
artery NN NN O
( ( ( O
p NN NN O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
, , , O
unpaired JJ JJ O
t NN NN O
- - - O
tests NNS NNS O
) ) ) O
. . . O

Qualitative NNP NNP O
assessments NNS NNS O
showed VBD VBD O
two CD CD O
arterial JJ JJ O
irregularities NNS NNS O
in IN IN O
the DT DT O
distal JJ JJ O
vasculature NN NN O
in IN IN O
each DT DT O
group NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
No DT DT O
quantitative JJ JJ O
evidence NN NN O
for IN IN O
narrowing VBG VBG O
of IN IN O
large JJ JJ O
cerebral NN NN O
arteries NNS NNS O
or CC CC O
qualitative JJ JJ O
angiographic JJ JJ O
evidence NN NN O
for IN IN O
distal JJ JJ O
narrowing NN NN O
or CC CC O
vasculitis NN NN O
could MD MD O
be VB VB O
found VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
angiography NN NN O
after IN IN O
aneurysmal NN NN O
SAH NNP NNP O
associated VBN VBN O
with IN IN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

Methamphetamine NNP NNP B-CHEM
causes NNS NNS O
alterations NNS NNS O
in IN IN O
the DT DT O
MAP NNP NNP O
kinase NN NN O
- - - O
related VBN VBN O
pathways NNS NNS O
in IN IN O
the DT DT O
brains NNS NNS O
of IN IN O
mice NNS NNS O
that WDT WDT O
display NN NN O
increased VBD VBD O
aggressiveness NNS NNS O
. . . O

Aggressive JJ JJ O
behaviors NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
suffer VBP VBP O
from IN IN O
some DT DT O
psychiatric JJ JJ O
disorders NNS NNS O
, , , O
and CC CC O
are VBP VBP O
common JJ JJ O
in IN IN O
methamphetamine NN NN B-CHEM
( ( ( O
METH NNP NNP B-CHEM
) ) ) O
abusers NNS NNS O
. . . O

Herein NNP NNP O
, , , O
we PRP PRP O
report VBP VBP O
that IN IN O
multiple JJ JJ O
( ( ( O
but CC CC O
not RB RB O
single JJ JJ O
) ) ) O
injections NNS NNS O
of IN IN O
METH NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
aggressiveness NNS NNS O
in IN IN O
male JJ JJ O
CD NN NN O
- - - O
1 CD CD O
mice NN NN O
. . . O

This DT DT O
increase NN NN O
in IN IN O
aggressiveness NN NN O
was VBD VBD O
not RB RB O
secondary JJ JJ O
to TO TO O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
. . . O

Analysis NNP NNP O
of IN IN O
protein NN NN O
expression NN NN O
using VBG VBG O
antibody NN NN O
microarrays NNS NNS O
and CC CC O
Western JJ JJ O
blotting VBG VBG O
revealed VBN VBN O
differential JJ JJ O
changes NNS NNS O
in IN IN O
MAP NNP NNP O
kinase NN NN O
- - - O
related VBN VBN O
pathways NNS NNS O
after IN IN O
multiple JJ JJ O
and CC CC O
single JJ JJ O
METH NNP NNP B-CHEM
injections NNS NNS O
. . . O

There EX EX O
were VBD VBD O
statistically RB RB O
significant JJ JJ O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
decreases NNS NNS O
in IN IN O
MEK1 NNP NNP O
, , , O
Erk2p NNP NNP O
, , , O
GSK3alpha NNP NNP O
, , , O
14 CD CD O
- : : O
3 CD CD O
- : : O
3e CD CD O
, , , O
and CC CC O
MEK7 NNP NNP O
in IN IN O
the DT DT O
striata NN NN O
of IN IN O
mice NN NN O
after IN IN O
multiple JJ JJ O
injections NNS NNS O
of IN IN O
METH NNP NNP B-CHEM
. . . O

MEK1 NNP NNP O
was VBD VBD O
significantly RB RB O
decreased VBD VBD O
also RB RB O
after IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
METH NNP NNP B-CHEM
, , , O
but CC CC O
to TO TO O
a DT DT O
much JJ JJ O
lesser JJR JJR O
degree NN NN O
than IN IN O
after IN IN O
multiple JJ JJ O
injections NNS NNS O
of IN IN O
METH NNP NNP B-CHEM
. . . O

In IN IN O
the DT DT O
frontal JJ JJ O
cortex NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
statistically RB RB O
significant JJ JJ O
decrease NN NN O
in IN IN O
GSK3alpha NNP NNP O
after IN IN O
multiple JJ JJ O
( ( ( O
but CC CC O
not RB RB O
single JJ JJ O
) ) ) O
injections NNS NNS O
of IN IN O
METH NNP NNP B-CHEM
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
alterations NNS NNS O
in IN IN O
MAP NNP NNP O
kinase NN NN O
- - - O
related VBN VBN O
pathways NNS NNS O
in IN IN O
the DT DT O
prefronto NN NN O
- - - O
striatal JJ JJ O
circuitries NNS NNS O
might MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
manifestation NN NN O
of IN IN O
aggressive JJ JJ O
behaviors NNS NNS O
in IN IN O
mice NN NN O
. . . O

Amisulpride NNP NNP B-CHEM
related VBN VBN O
tic JJ JJ O
- - - O
like IN IN O
symptoms NNS NNS O
in IN IN O
an DT DT O
adolescent NN NN O
schizophrenic JJ JJ O
. . . O

Tic NNP NNP O
disorders NNS NNS O
can MD MD O
be VB VB O
effectively RB RB O
treated VBN VBN O
by IN IN O
atypical JJ JJ O
antipsychotics NNS NNS O
such JJ JJ O
as IN IN O
risperidone NN NN B-CHEM
, , , O
olanzapine NN NN B-CHEM
and CC CC O
ziprasidone NN NN B-CHEM
. . . O

However RB RB O
, , , O
there EX EX O
are VBP VBP O
two CD CD O
case NN NN O
reports NNS NNS O
that IN IN O
show NN NN O
tic JJ JJ O
- - - O
like IN IN O
symptoms NNS NNS O
, , , O
including VBG VBG O
motor NN NN O
and CC CC O
phonic JJ JJ O
variants NNS NNS O
, , , O
occurring VBG VBG O
during IN IN O
treatment NN NN O
with IN IN O
quetiapine NN NN B-CHEM
or CC CC O
clozapine NN NN B-CHEM
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
15 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
schizophrenic NN NN O
who WP WP O
developed VBD VBD O
frequent JJ JJ O
involuntary JJ JJ O
eye NN NN O
- - - O
blinking JJ JJ O
movements NNS NNS O
after IN IN O
5 CD CD O
months NNS NNS O
of IN IN O
amisulpride NN NN B-CHEM
treatment NN NN O
( ( ( O
1000 CD CD O
mg NN NN O
per IN IN O
day NN NN O
) ) ) O
. . . O

The DT DT O
tic JJ JJ O
- - - O
like IN IN O
symptoms NNS NNS O
resolved VBD VBD O
completely RB RB O
after IN IN O
we PRP PRP O
reduced VBD VBD O
the DT DT O
dose NN NN O
of IN IN O
amisulpride NN NN B-CHEM
down IN IN O
to TO TO O
800 CD CD O
mg NN NN O
per IN IN O
day NN NN O
. . . O

However RB RB O
, , , O
her PRP$ PRP$ O
psychosis NN NN O
recurred VBD VBD O
after IN IN O
the DT DT O
dose NN NN O
reduction NN NN O
. . . O

We PRP PRP O
then RB RB O
placed VBD VBD O
her PRP PRP O
on IN IN O
an DT DT O
additional JJ JJ O
100 CD CD O
mg NN NN O
per IN IN O
day NN NN O
of IN IN O
quetiapine NN NN B-CHEM
. . . O

She PRP PRP O
has VBZ VBZ O
been VBN VBN O
in IN IN O
complete JJ JJ O
remission NN NN O
under IN IN O
the DT DT O
combined VBN VBN O
medications NNS NNS O
for IN IN O
more JJR JJR O
than IN IN O
one CD CD O
year NN NN O
and CC CC O
maintains VBZ VBZ O
a DT DT O
fair JJ JJ O
role NN NN O
function NN NN O
. . . O

No DT DT O
more RBR RBR O
tic JJ JJ O
- - - O
like IN IN O
symptoms NNS NNS O
or CC CC O
other JJ JJ O
side NN NN O
effects NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

Together RB RB O
with IN IN O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
, , , O
our PRP$ PRP$ O
patient NN NN O
suggests VBZ VBZ O
that IN IN O
tic JJ JJ O
- - - O
like IN IN O
symptoms NNS NNS O
might MD MD O
occur VB VB O
in IN IN O
certain JJ JJ O
vulnerable JJ JJ O
individuals NNS NNS O
during IN IN O
treatment NN NN O
with IN IN O
atypical JJ JJ O
antipsychotics NNS NNS O
such JJ JJ O
as IN IN O
quetiapine NN NN B-CHEM
, , , O
clozapine NN NN B-CHEM
, , , O
or CC CC O
amisulpride NN NN B-CHEM
. . . O

Chloroquine NNP NNP B-CHEM
related VBN VBN O
complete JJ JJ O
heart NN NN O
block NN NN O
with IN IN O
blindness NN NN O
: : : O
case NN NN O
report NN NN O
. . . O

A DT DT O
27 CD CD O
- : : O
year NN NN O
old JJ JJ O
African NNP NNP O
woman NN NN O
with IN IN O
history NN NN O
of IN IN O
regular JJ JJ O
chloroquine NN NN B-CHEM
ingestion NN NN O
presented VBN VBN O
with IN IN O
progressive JJ JJ O
deterioration NN NN O
of IN IN O
vision NN NN O
, , , O
easy JJ JJ O
fatiguability NN NN O
, , , O
dyspnoea NN NN O
, , , O
dizziness NN NN O
progressing VBG VBG O
to TO TO O
syncopal VB VB O
attacks NNS NNS O
. . . O

Ophthalmological NNP NNP O
assessment NN NN O
revealed JJ JJ O
features NNS NNS O
of IN IN O
chloroquine NN NN B-CHEM
retinopathy NN NN O
, , , O
cardiac JJ JJ O
assessment NN NN O
revealed JJ JJ O
features NNS NNS O
of IN IN O
heart NN NN O
failure NN NN O
and CC CC O
a DT DT O
complete JJ JJ O
heart NN NN O
block NN NN O
with IN IN O
right NN NN O
bundle NN NN O
branch NN NN O
block NN NN O
pattern NN NN O
. . . O

The DT DT O
heart NN NN O
block NN NN O
was VBD VBD O
treated VBN VBN O
by IN IN O
pacemaker NN NN O
insertion NN NN O
and CC CC O
the DT DT O
heart NN NN O
failure NN NN O
resolved VBD VBD O
spontaneously RB RB O
following VBG VBG O
chloroquine NN NN B-CHEM
discontinuation NN NN O
. . . O

She PRP PRP O
however RB RB O
remains VBZ VBZ O
blind JJ JJ O
. . . O

Effects NNP NNP O
of IN IN O
suprofen NN NN B-CHEM
on IN IN O
the DT DT O
isolated VBN VBN O
perfused VBN VBN O
rat NN NN O
kidney NN NN O
. . . O

Although IN IN O
suprofen NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
greater JJR JJR O
than IN IN O
100 CD CD O
subjects NNS NNS O
, , , O
the DT DT O
mechanism NN NN O
of IN IN O
damage NN NN O
remains NNS NNS O
unclear JJ JJ O
. . . O

The DT DT O
direct JJ JJ O
nephrotoxic JJ JJ O
effects NNS NNS O
of IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
15 CD CD O
mg NN NN O
of IN IN O
suprofen NN NN B-CHEM
were VBD VBD O
compared VBN VBN O
in IN IN O
the DT DT O
recirculating VBG VBG O
isolated VBN VBN O
rat NN NN O
kidney NN NN O
perfused VBN VBN O
with IN IN O
cell NN NN O
- - - O
free JJ JJ O
buffer NN NN O
with IN IN O
or CC CC O
without IN IN O
the DT DT O
addition NN NN O
of IN IN O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
of IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

There EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
in IN IN O
renal JJ JJ O
sodium NN NN B-CHEM
excretion NN NN O
, , , O
oxygen NN NN B-CHEM
consumption NN NN O
, , , O
or CC CC O
urinary JJ JJ O
flow NN NN O
rates NNS NNS O
in IN IN O
kidneys NNS NNS O
perfused VBN VBN O
with IN IN O
suprofen NN NN B-CHEM
compared VBN VBN O
with IN IN O
the DT DT O
drug NN NN O
- - - O
free JJ JJ O
control NN NN O
groups NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
a DT DT O
significant JJ JJ O
decline NN NN O
in IN IN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
was VBD VBD O
found VBN VBN O
after IN IN O
the DT DT O
introduction NN NN O
of IN IN O
suprofen NN NN B-CHEM
to TO TO O
the DT DT O
kidney NN NN O
perfused VBN VBN O
with IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
; : : O
no DT DT O
changes NNS NNS O
were VBD VBD O
found VBN VBN O
with IN IN O
suprofen NN NN B-CHEM
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

A DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
baseline NN NN O
excretion NN NN O
rate NN NN O
of IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
was VBD VBD O
found VBN VBN O
in IN IN O
rats NNS NNS O
given VBN VBN O
suprofen NN NN B-CHEM
, , , O
compared VBN VBN O
with IN IN O
drug NN NN O
- - - O
free JJ JJ O
controls NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
fractional JJ JJ O
excretion NN NN O
of IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
was VBD VBD O
unchanged JJ JJ O
between IN IN O
the DT DT O
groups NNS NNS O
over IN IN O
the DT DT O
experimental JJ JJ O
period NN NN O
. . . O

In IN IN O
summary JJ JJ O
, , , O
suprofen NN NN B-CHEM
causes NNS NNS O
acute JJ JJ O
declines NNS NNS O
in IN IN O
renal JJ JJ O
function NN NN O
, , , O
most RBS RBS O
likely JJ JJ O
by IN IN O
directly RB RB O
altering VBG VBG O
the DT DT O
intrarenal JJ JJ O
distribution NN NN O
of IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Microinjection NNP NNP O
of IN IN O
ritanserin NN NN B-CHEM
into IN IN O
the DT DT O
CA1 NNP NNP O
region NN NN O
of IN IN O
hippocampus NN NN O
improves VBZ VBZ O
scopolamine JJ JJ B-CHEM
- : : O
induced JJ JJ O
amnesia NN NN O
in IN IN O
adult NN NN O
male JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
ritanserin NN NN B-CHEM
( ( ( O
5 CD CD O
- : : O
HT2 NNP NNP O
antagonist NN NN O
) ) ) O
on IN IN O
scopolamine NN NN B-CHEM
( ( ( O
muscarinic JJ JJ O
cholinergic JJ JJ O
antagonist NN NN O
) ) ) O
- : : O
induced VBN VBN O
amnesia NN NN O
in IN IN O
Morris NNP NNP O
water NN NN O
maze NN NN O
( ( ( O
MWM NNP NNP O
) ) ) O
was VBD VBD O
investigated VBN VBN O
. . . O

Rats NNP NNP O
were VBD VBD O
divided VBN VBN O
into IN IN O
eight CD CD O
groups NNS NNS O
and CC CC O
bilaterally RB RB O
cannulated VBN VBN O
into IN IN O
CA1 NNP NNP O
region NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
. . . O

One CD CD O
week NN NN O
later RB RB O
, , , O
they PRP PRP O
received VBD VBD O
repeatedly JJ JJ O
vehicles NNS NNS O
( ( ( O
saline NN NN O
, , , O
DMSO NNP NNP B-CHEM
, , , O
saline NN NN O
+ NN NN O
DMSO NNP NNP B-CHEM
) ) ) O
, , , O
scopolamine NN NN B-CHEM
( ( ( O
2 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
saline NN NN O
/ NN NN O
side NN NN O
; : : O
30 CD CD O
min NN NN O
before IN IN O
training NN NN O
) ) ) O
, , , O
ritanserin NN NN B-CHEM
( ( ( O
2 CD CD O
, , , O
4 CD CD O
and CC CC O
8 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
DMSO NNP NNP B-CHEM
/ NN NN O
side NN NN O
; : : O
20 CD CD O
min NN NN O
before IN IN O
training NN NN O
) ) ) O
and CC CC O
scopolamine NN NN B-CHEM
( ( ( O
2 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
; : : O
30 CD CD O
min NN NN O
before IN IN O
ritanserin NN NN B-CHEM
injection NN NN O
) ) ) O
+ NN NN O
ritanserin NN NN B-CHEM
( ( ( O
4 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
DMSO NNP NNP B-CHEM
) ) ) O
through IN IN O
cannulae NN NN O
each DT DT O
day NN NN O
. . . O

Animals NNS NNS O
were VBD VBD O
tested VBN VBN O
for IN IN O
four CD CD O
consecutive JJ JJ O
days NNS NNS O
( ( ( O
4 CD CD O
trial NN NN O
/ NN NN O
day NN NN O
) ) ) O
in IN IN O
MWM NNP NNP O
during IN IN O
which WDT WDT O
the DT DT O
position NN NN O
of IN IN O
hidden VBN VBN O
platform NN NN O
was VBD VBD O
unchanged JJ JJ O
. . . O

In IN IN O
the DT DT O
fifth JJ JJ O
day NN NN O
, , , O
the DT DT O
platform NN NN O
was VBD VBD O
elevated VBN VBN O
above IN IN O
the DT DT O
water NN NN O
surface NN NN O
in IN IN O
another DT DT O
position NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
function NN NN O
of IN IN O
motor NN NN O
, , , O
motivational JJ JJ O
and CC CC O
visual JJ JJ O
systems NNS NNS O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
escape NN NN O
latencies NNS NNS O
and CC CC O
traveled VBN VBN O
distances NNS NNS O
to TO TO O
find VB VB O
platform NN NN O
in IN IN O
scopolamine NN NN B-CHEM
- - - O
treated VBN VBN O
group NN NN O
as IN IN O
compared VBN VBN O
to TO TO O
saline VB VB O
group NN NN O
. . . O

Ritanserin NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
( ( ( O
4 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
/ NN NN O
side NN NN O
) ) ) O
showed VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
mentioned VBN VBN O
parameters NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
DMSO NNP NNP B-CHEM
- - - O
treated JJ JJ O
group NN NN O
. . . O

However RB RB O
, , , O
scopolamine NN NN B-CHEM
and CC CC O
ritanserin NN NN B-CHEM
co NN NN O
- - - O
administration NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
escape NN NN O
latencies NNS NNS O
and CC CC O
traveled VBN VBN O
distances NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
show VBP VBP O
that DT DT O
microinjection NN NN O
of IN IN O
ritanserin NN NN B-CHEM
into IN IN O
the DT DT O
CA1 NNP NNP O
region NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
improves VBZ VBZ O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
. . . O

PTU NNP NNP B-CHEM
- - - O
associated JJ JJ O
vasculitis NNS NNS O
in IN IN O
a DT DT O
girl NN NN O
with IN IN O
Turner NNP NNP O
Syndrome NN NN O
and CC CC O
Graves NNP NNP O
' POS POS O
disease NN NN O
. . . O

Palpable NNP NNP O
purpura NN NN O
is VBZ VBZ O
a DT DT O
concerning VBG VBG O
clinical JJ JJ O
finding VBG VBG O
in IN IN O
pediatric JJ JJ O
patients NNS NNS O
and CC CC O
can MD MD O
have VB VB O
many JJ JJ O
causes NNS NNS O
, , , O
including VBG VBG O
infectious JJ JJ O
and CC CC O
autoimmune JJ JJ O
processes NNS NNS O
. . . O

A DT DT O
rare JJ JJ O
cause NN NN O
, , , O
drug NN NN O
- - - O
induced JJ JJ O
vasculitis NNS NNS O
, , , O
may MD MD O
result VB VB O
from IN IN O
the DT DT O
production NN NN O
of IN IN O
antineutrophil NN NN O
cytoplasmic JJ JJ O
antibodies NNS NNS O
( ( ( O
ANCAs NNP NNP O
) ) ) O
in IN IN O
response NN NN O
to TO TO O
a DT DT O
medication NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
girl NN NN O
with IN IN O
Turner NNP NNP O
syndrome NN NN O
and CC CC O
Graves NNP NNP O
' POS POS O
disease NN NN O
who WP WP O
presented VBD VBD O
with IN IN O
palpable JJ JJ O
purpuric JJ JJ O
lesions NNS NNS O
. . . O

The DT DT O
diagnosis NN NN O
of IN IN O
propylthiouracil NN NN B-CHEM
( ( ( O
PTU NNP NNP B-CHEM
) ) ) O
- : : O
associated VBN VBN O
vasculitis NN NN O
was VBD VBD O
made VBN VBN O
by IN IN O
observation NN NN O
of IN IN O
consistent JJ JJ O
clinical JJ JJ O
features NNS NNS O
, , , O
the DT DT O
detection NN NN O
of IN IN O
elevated VBD VBD O
ANA NNP NNP O
and CC CC O
ANCA NNP NNP O
in IN IN O
the DT DT O
blood NN NN O
, , , O
and CC CC O
the DT DT O
observed VBD VBD O
clinical JJ JJ O
resolution NN NN O
of IN IN O
symptoms NNS NNS O
following VBG VBG O
withdrawal NN NN O
of IN IN O
PTU NNP NNP B-CHEM
. . . O

Subsequent NNP NNP O
treatment NN NN O
of IN IN O
persistent JJ JJ O
hyperthyroidism NN NN O
with IN IN O
radioablation NN NN O
did VBD VBD O
not RB RB O
result VB VB O
in IN IN O
an DT DT O
exacerbation NN NN O
of IN IN O
the DT DT O
vasculitis NNS NNS O
, , , O
a DT DT O
complication NN NN O
described VBD VBD O
in IN IN O
prior RB RB O
case NN NN O
reports NNS NNS O
. . . O

Daidzein NNP NNP B-CHEM
activates NNS NNS O
choline NN NN B-CHEM
acetyltransferase NN NN O
from IN IN O
MC NNP NNP O
- : : O
IXC NNP NNP O
cells NNS NNS O
and CC CC O
improves NNS NNS O
drug NN NN O
- : : O
induced JJ JJ O
amnesia NN NN O
. . . O

The DT DT O
choline NN NN B-CHEM
acetyltransferase NN NN O
( ( ( O
ChAT NNP NNP O
) ) ) O
activator NN NN O
, , , O
which WDT WDT O
enhances VBZ VBZ O
cholinergic JJ JJ O
transmission NN NN O
via IN IN O
an DT DT O
augmentation NN NN O
of IN IN O
the DT DT O
enzymatic JJ JJ O
production NN NN O
of IN IN O
acetylcholine NN NN B-CHEM
( ( ( O
ACh NNP NNP B-CHEM
) ) ) O
, , , O
is VBZ VBZ O
an DT DT O
important JJ JJ O
factor NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
AD NNP NNP O
) ) ) O
. . . O

Methanolic NNP NNP O
extracts NNS NNS O
from IN IN O
Pueraria NNP NNP O
thunbergiana NN NN O
exhibited VBD VBD O
an DT DT O
activation NN NN O
effect NN NN O
( ( ( O
46 CD CD O
% NN NN O
) ) ) O
on IN IN O
ChAT NNP NNP O
in IN IN O
vitro NN NN O
. . . O

Via IN IN O
the DT DT O
sequential JJ JJ O
isolation NN NN O
of IN IN O
Pueraria NNP NNP O
thunbergiana NN NN O
, , , O
the DT DT O
active JJ JJ O
component NN NN O
was VBD VBD O
ultimately RB RB O
identified VBN VBN O
as IN IN O
daidzein NN NN B-CHEM
( ( ( O
4 CD CD B-CHEM
' POS POS I-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
dihydroxy NN NN I-CHEM
- : : I-CHEM
isoflavone NN NN I-CHEM
) ) ) O
. . . O

In IN IN O
order NN NN O
to TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
daidzein NN NN B-CHEM
from IN IN O
Pueraria NNP NNP O
thunbergiana NN NN O
on IN IN O
scopolamine NN NN B-CHEM
- : : O
induced JJ JJ O
impairments NNS NNS O
of IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
, , , O
we PRP PRP O
conducted VBD VBD O
a DT DT O
series NN NN O
of IN IN O
in IN IN O
vivo NN NN O
tests NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
daidzein NN NN B-CHEM
( ( ( O
4 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) ) ) O
to TO TO O
mice NNS NNS O
was VBD VBD O
shown VBN VBN O
significantly RB RB O
to TO TO O
reverse VB VB O
scopolamine NN NN B-CHEM
- : : O
induced JJ JJ O
amnesia NN NN O
, , , O
according VBG VBG O
to TO TO O
the DT DT O
results NNS NNS O
of IN IN O
a DT DT O
Y NNP NNP O
- - - O
maze NN NN O
test NN NN O
. . . O

Injections NNP NNP O
of IN IN O
scopolamine NN NN B-CHEM
into IN IN O
mice NNS NNS O
resulted VBD VBD O
in IN IN O
impaired JJ JJ O
performance NN NN O
on IN IN O
Y NNP NNP O
- : : O
maze NN NN O
tests NNS NNS O
( ( ( O
a DT DT O
37 CD CD O
% NN NN O
decreases NNS NNS O
in IN IN O
alternation NN NN O
behavior NN NN O
) ) ) O
. . . O

By IN IN O
way NN NN O
of IN IN O
contrast NN NN O
, , , O
mice NN NN O
treated VBN VBN O
with IN IN O
daidzein JJ JJ B-CHEM
prior RB RB O
to TO TO O
the DT DT O
scopolamine NN NN B-CHEM
injections NNS NNS O
were VBD VBD O
noticeably RB RB O
protected VBN VBN O
from IN IN O
this DT DT O
performance NN NN O
impairment NN NN O
( ( ( O
an DT DT O
approximately RB RB O
12 CD CD O
% NN NN O
- : : O
21 CD CD O
% NN NN O
decrease NN NN O
in IN IN O
alternation NN NN O
behavior NN NN O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
daidzein NN NN B-CHEM
might MD MD O
play VB VB O
a DT DT O
role NN NN O
in IN IN O
acetylcholine NN NN B-CHEM
biosynthesis NN NN O
as IN IN O
a DT DT O
ChAT NNP NNP O
activator NN NN O
, , , O
and CC CC O
that IN IN O
it PRP PRP O
also RB RB O
ameliorates VBZ VBZ O
scopolamine JJ JJ B-CHEM
- : : O
induced JJ JJ O
amnesia NN NN O
. . . O

Urinary NNP NNP O
symptoms NNS NNS O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
changes NNS NNS O
in IN IN O
Thai NNP NNP O
women NNS NNS O
with IN IN O
overactive JJ JJ O
bladder NN NN O
after IN IN O
tolterodine NN NN B-CHEM
treatment NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
study VB VB O
the DT DT O
urinary JJ JJ O
symptoms NNS NNS O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
changes NNS NNS O
in IN IN O
Thai NNP NNP O
women NNS NNS O
with IN IN O
overactive JJ JJ O
bladder NN NN O
( ( ( O
OAB NNP NNP O
) ) ) O
after IN IN O
tolterodine NN NN B-CHEM
treatment NN NN O
. . . O

MATERIAL NN NN O
AND CC CC O
METHOD NNP NNP O
: : : O
Thirty NNP NNP O
women NNS NNS O
( ( ( O
aged VBN VBN O
30 CD CD O
- : : O
77 CD CD O
years NNS NNS O
) ) ) O
diagnosed VBN VBN O
as IN IN O
having VBG VBG O
OAB NNP NNP O
at IN IN O
the DT DT O
Gynecology NNP NNP O
Clinic NNP NNP O
, , , O
King NNP NNP O
Chulalongkorn NNP NNP O
Memorial NNP NNP O
Hospital NNP NNP O
from IN IN O
January NNP NNP O
to TO TO O
April NNP NNP O
2004 CD CD O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
. . . O

Tolterodine NNP NNP B-CHEM
2 CD CD O
mg NN NN O
, , , O
twice RB RB O
daily JJ JJ O
was VBD VBD O
given VBN VBN O
. . . O

After IN IN O
8 CD CD O
weeks NNS NNS O
treatment NN NN O
, , , O
changes NNS NNS O
in IN IN O
micturition NN NN O
diary JJ JJ O
variables NNS NNS O
and CC CC O
tolerability NN NN O
were VBD VBD O
determined VBN VBN O
. . . O

Short NNP NNP O
form NN NN O
36 CD CD O
( ( ( O
SF36 NNP NNP O
) ) ) O
questionaires NNS NNS O
( ( ( O
Thai NNP NNP O
version NN NN O
) ) ) O
were VBD VBD O
given VBN VBN O
before IN IN O
and CC CC O
after IN IN O
8 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

RESULTS NNS NNS O
: : : O
At IN IN O
8 CD CD O
weeks NNS NNS O
, , , O
all DT DT O
micturition NN NN O
per IN IN O
day NN NN O
decreased VBD VBD O
from IN IN O
16 CD CD O
. . . O

7 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O

3 CD CD O
to TO TO O
6 CD CD O
. . . O

7 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
4 CD CD O
times NNS NNS O
per IN IN O
day NN NN O
. . . O

The DT DT O
number NN NN O
of IN IN O
nocturia NN NN O
episodes NNS NNS O
decreased VBN VBN O
from IN IN O
5 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
2 CD CD O
to TO TO O
1 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
times NNS NNS O
per IN IN O
night NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
side NN NN O
effect NN NN O
was VBD VBD O
dry JJ JJ O
month NN NN O
in IN IN O
5 CD CD O
cases NNS NNS O
( ( ( O
16 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
with IN IN O
2 CD CD O
cases NNS NNS O
reporting VBG VBG O
a DT DT O
moderate JJ JJ O
degree NN NN O
and CC CC O
1 CD CD O
case NN NN O
with IN IN O
severe JJ JJ O
degree NN NN O
. . . O

Only RB RB O
one CD CD O
case NN NN O
( ( ( O
3 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
withdrew VBD VBD O
from IN IN O
the DT DT O
present JJ JJ O
study NN NN O
due JJ JJ O
to TO TO O
a DT DT O
severe JJ JJ O
dry JJ JJ O
mouth NN NN O
. . . O

The DT DT O
SF NNP NNP O
- : : O
36 CD CD O
scores NNS NNS O
changed VBN VBN O
significantly RB RB O
in IN IN O
the DT DT O
domains NNS NNS O
of IN IN O
physical JJ JJ O
functioning NN NN O
, , , O
role NN NN O
function NN NN O
emotional JJ JJ O
, , , O
social JJ JJ O
function NN NN O
and CC CC O
mental JJ JJ O
heath NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Tolterodine NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
and CC CC O
its PRP$ PRP$ O
effects NNS NNS O
improved VBN VBN O
the DT DT O
quality NN NN O
of IN IN O
life NN NN O
in IN IN O
Thai NNP NNP O
women NNS NNS O
with IN IN O
OAB NNP NNP O
. . . O

Remifentanil NNP NNP B-CHEM
pretreatment NN NN O
reduces NNS NNS O
myoclonus NN NN O
after IN IN O
etomidate NN NN B-CHEM
. . . O

STUDY NNP NNP O
OBJECTIVE NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
compare VB VB O
the DT DT O
effect NN NN O
of IN IN O
pretreatment NN NN O
with IN IN O
remifentanil NN NN B-CHEM
1 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
and CC CC O
the DT DT O
effect NN NN O
of IN IN O
gender NN NN O
on IN IN O
the DT DT O
incidence NN NN O
of IN IN O
myoclonus NN NN O
after IN IN O
anesthesia NN NN O
induction NN NN O
with IN IN O
etomidate NN NN B-CHEM
. . . O

DESIGN NNP NNP O
: : : O
This DT DT O
was VBD VBD O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
The DT DT O
study NN NN O
was VBD VBD O
conducted VBN VBN O
at IN IN O
a DT DT O
university NN NN O
hospital NN NN O
. . . O

PATIENTS NNS NNS O
: : : O
Sixty NNP NNP O
patients NNS NNS O
were VBD VBD O
pretreated VBN VBN O
in IN IN O
a DT DT O
randomized JJ JJ O
double JJ JJ O
- - - O
blinded JJ JJ O
fashion NN NN O
with IN IN O
remifentanil NN NN B-CHEM
1 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
or CC CC O
placebo NN NN O
. . . O

Two CD CD O
minutes NNS NNS O
after IN IN O
remifentanil NN NN B-CHEM
or CC CC O
placebo NN NN O
injection NN NN O
, , , O
etomidate NN NN B-CHEM
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
was VBD VBD O
given VBN VBN O
. . . O

MEASUREMENTS NNP NNP O
: : : O
Myoclonus NNP NNP O
was VBD VBD O
recorded VBN VBN O
with IN IN O
a DT DT O
scale NN NN O
of IN IN O
0 CD CD O
to TO TO O
3 CD CD O
. . . O

The DT DT O
grade NN NN O
of IN IN O
sedation NN NN O
( ( ( O
none NN NN O
, , , O
mild NN NN O
, , , O
moderate NN NN O
, , , O
severe JJ JJ O
) ) ) O
, , , O
nausea NN NN O
, , , O
pruritus NN NN O
, , , O
and CC CC O
apnea NN NN O
were VBD VBD O
recorded VBN VBN O
after IN IN O
injection NN NN O
of IN IN O
both DT DT O
drugs NNS NNS O
. . . O

MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
The DT DT O
incidence NN NN O
of IN IN O
myoclonus NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
the DT DT O
remifentanil NN NN B-CHEM
group NN NN O
( ( ( O
6 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
( ( ( O
70 CD CD O
% NN NN O
) ) ) O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
experienced VBN VBN O
sedation NN NN O
, , , O
apnea NN NN O
, , , O
nausea NN NN O
, , , O
or CC CC O
pruritus NN NN O
after IN IN O
injection NN NN O
of IN IN O
both DT DT O
drugs NNS NNS O
. . . O

In IN IN O
the DT DT O
placebo NN NN O
group NN NN O
, , , O
male JJ JJ O
patients NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
significantly RB RB O
increased VBN VBN O
incidence NN NN O
of IN IN O
myoclonus NN NN O
after IN IN O
etomidate JJ JJ B-CHEM
administration NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Pretreatment NNP NNP O
with IN IN O
remifentanil NN NN B-CHEM
1 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
reduced VBD VBD O
myoclonus NN NN O
after IN IN O
etomidate JJ JJ B-CHEM
induction NN NN O
without IN IN O
side NN NN O
effects NNS NNS O
such JJ JJ O
as IN IN O
sedation NN NN O
, , , O
apnea NN NN O
, , , O
nausea NN NN O
, , , O
or CC CC O
pruritus NN NN O
. . . O

Men NN NN O
experience NN NN O
increased VBN VBN O
incidence NN NN O
of IN IN O
myoclonus NN NN O
than IN IN O
women NNS NNS O
after IN IN O
etomidate JJ JJ B-CHEM
administration NN NN O
. . . O

Memory NN NN O
function NN NN O
and CC CC O
serotonin NN NN B-CHEM
transporter NN NN O
promoter NN NN O
gene NN NN O
polymorphism NN NN O
in IN IN O
ecstasy NN NN B-CHEM
( ( ( O
MDMA NNP NNP B-CHEM
) ) ) O
users NNS NNS O
. . . O

Although IN IN O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylenedioxymethamphetamine NN NN I-CHEM
( ( ( O
MDMA NNP NNP B-CHEM
or CC CC O
ecstasy NN NN B-CHEM
) ) ) O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
damage VB VB O
brain NN NN O
serotonin NN NN B-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
) ) ) O
neurons NNS NNS O
in IN IN O
animals NNS NNS O
and CC CC O
possibly RB RB O
humans NNS NNS O
, , , O
little JJ JJ O
is VBZ VBZ O
known VBN VBN O
about IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
consequences NNS NNS O
of IN IN O
MDMA NNP NNP B-CHEM
- : : O
induced VBN VBN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
neurotoxic NN NN O
lesions NNS NNS O
on IN IN O
functions NNS NNS O
in IN IN O
which WDT WDT O
5 CD CD B-CHEM
- - - I-CHEM
HT NNP NNP I-CHEM
is VBZ VBZ O
involved VBN VBN O
, , , O
such JJ JJ O
as IN IN O
cognitive JJ JJ O
function NN NN O
. . . O

Because IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
transporters NNS NNS O
play VBP VBP O
a DT DT O
key JJ JJ O
element NN NN O
in IN IN O
the DT DT O
regulation NN NN O
of IN IN O
synaptic JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
transmission NN NN O
it PRP PRP O
may MD MD O
be VB VB O
important JJ JJ O
to TO TO O
control VB VB O
for IN IN O
the DT DT O
potential JJ JJ O
covariance NN NN O
effect NN NN O
of IN IN O
a DT DT O
polymorphism NN NN O
in IN IN O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
transporter NN NN O
promoter NN NN O
gene NN NN O
region NN NN O
( ( ( O
5 CD CD O
- : : O
HTTLPR NNP NNP O
) ) ) O
when WRB WRB O
studying VBG VBG O
the DT DT O
effects NNS NNS O
of IN IN O
MDMA NNP NNP B-CHEM
as RB RB O
well RB RB O
as IN IN O
cognitive JJ JJ O
functioning NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
moderate JJ JJ O
and CC CC O
heavy JJ JJ O
MDMA NNP NNP B-CHEM
use NN NN O
on IN IN O
cognitive JJ JJ O
function NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
abstention NN NN O
from IN IN O
MDMA NNP NNP B-CHEM
, , , O
in IN IN O
subjects NNS NNS O
genotyped VBN VBN O
for IN IN O
5 CD CD O
- : : O
HTTLPR NNP NNP O
. . . O

A DT DT O
second JJ JJ O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
these DT DT O
effects NNS NNS O
differ VBP VBP O
for IN IN O
females NNS NNS O
and CC CC O
males NNS NNS O
. . . O

Fifteen NNP NNP O
moderate JJ JJ O
MDMA NNP NNP B-CHEM
users NNS NNS O
( ( ( O
< NN NN O
55 CD CD O
lifetime NN NN O
tablets NNS NNS O
) ) ) O
, , , O
22 CD CD O
heavy JJ JJ O
MDMA NNP NNP B-CHEM
+ NN NN O
users NNS NNS O
( ( ( O
> NN NN O
55 CD CD O
lifetime NN NN O
tablets NNS NNS O
) ) ) O
, , , O
16 CD CD O
ex FW FW O
- : : O
MDMA NNP NNP B-CHEM
+ NN NN O
users NNS NNS O
( ( ( O
last JJ JJ O
tablet NN NN O
> NN NN O
1 CD CD O
year NN NN O
ago RB RB O
) ) ) O
and CC CC O
13 CD CD O
controls NNS NNS O
were VBD VBD O
compared VBN VBN O
on IN IN O
a DT DT O
battery NN NN O
of IN IN O
neuropsychological JJ JJ O
tests NNS NNS O
. . . O

DNA NNP NNP O
from IN IN O
peripheral NN NN O
nuclear NN NN O
blood NN NN O
cells NNS NNS O
was VBD VBD O
genotyped VBN VBN O
for IN IN O
5 CD CD O
- : : O
HTTLPR NNP NNP O
using VBG VBG O
standard JJ JJ O
polymerase NN NN O
chain NN NN O
reaction NN NN O
methods NNS NNS O
. . . O
A DT DT O
significant JJ JJ O
group NN NN O
effect NN NN O
was VBD VBD O
observed VBN VBN O
only RB RB O
on IN IN O
memory NN NN O
function NN NN O
tasks NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
04 CD CD O
) ) ) O
but CC CC O
not RB RB O
on IN IN O
reaction NN NN O
times NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
61 CD CD O
) ) ) O
or CC CC O
attention NN NN O
/ NN NN O
executive NN NN O
functioning VBG VBG O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
59 CD CD O
) ) ) O
. . . O

Heavy NNP NNP O
and CC CC O
ex FW FW O
- - - O
MDMA NNP NNP B-CHEM
+ NN NN O
users NNS NNS O
performed VBN VBN O
significantly RB RB O
poorer NN NN O
on IN IN O
memory NN NN O
tasks NNS NNS O
than IN IN O
controls NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
no DT DT O
evidence NN NN O
of IN IN O
memory NN NN O
impairment NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
moderate JJ JJ O
MDMA NNP NNP B-CHEM
users NNS NNS O
. . . O

No DT DT O
significant JJ JJ O
effect NN NN O
of IN IN O
5 CD CD O
- : : O
HTTLPR NNP NNP O
or CC CC O
gender NN NN O
was VBD VBD O
observed VBN VBN O
. . . O

While IN IN O
the DT DT O
use NN NN O
of IN IN O
MDMA NNP NNP B-CHEM
in IN IN O
quantities NNS NNS O
that WDT WDT O
may MD MD O
be VB VB O
considered VBN VBN O
" '' '' O
moderate JJ JJ O
" '' '' O
is VBZ VBZ O
not RB RB O
associated VBN VBN O
with IN IN O
impaired JJ JJ O
memory NN NN O
functioning VBG VBG O
, , , O
heavy JJ JJ O
use NN NN O
of IN IN O
MDMA NNP NNP B-CHEM
use NN NN O
may MD MD O
lead VB VB O
to TO TO O
long JJ JJ O
lasting JJ JJ O
memory NN NN O
impairments NNS NNS O
. . . O

No DT DT O
effect NN NN O
of IN IN O
5 CD CD O
- : : O
HTTLPR NNP NNP O
or CC CC O
gender NN NN O
on IN IN O
memory NN NN O
function NN NN O
or CC CC O
MDMA NNP NNP B-CHEM
use NN NN O
was VBD VBD O
observed VBN VBN O
. . . O

Role NN NN O
of IN IN O
mangiferin NN NN B-CHEM
on IN IN O
biochemical JJ JJ O
alterations NNS NNS O
and CC CC O
antioxidant JJ JJ O
status NN NN O
in IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
current JJ JJ O
study NN NN O
dealt NN NN O
with IN IN O
the DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
mangiferin NN NN B-CHEM
, , , O
a DT DT O
polyphenol NN NN B-CHEM
from IN IN O
Mangifera NNP NNP O
indica NN NN O
Linn NNP NNP O
. . . O

( ( ( O
Anacardiaceae NNP NNP O
) ) ) O
, , , O
on IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
ISPH NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
myocardial NN NN O
infarction NN NN O
( ( ( O
MI NNP NNP O
) ) ) O
in IN IN O
rats NNS NNS O
through IN IN O
its PRP$ PRP$ O
antioxidative JJ JJ O
mechanism NN NN O
. . . O

Subcutaneous NNP NNP O
injection NN NN O
of IN IN O
ISPH NNP NNP B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
in IN IN O
1 CD CD O
ml NN NN O
saline NN NN O
) ) ) O
to TO TO O
rats NNS NNS O
for IN IN O
2 CD CD O
consecutive JJ JJ O
days NNS NNS O
caused VBD VBD O
myocardial NN NN O
damage NN NN O
in IN IN O
rat NN NN O
heart NN NN O
, , , O
which WDT WDT O
was VBD VBD O
determined VBN VBN O
by IN IN O
the DT DT O
increased JJ JJ O
activity NN NN O
of IN IN O
serum NN NN O
lactate NN NN B-CHEM
dehydrogenase NN NN O
( ( ( O
LDH NNP NNP O
) ) ) O
and CC CC O
creatine NN NN B-CHEM
phosphokinase NN NN O
isoenzymes NNS NNS O
( ( ( O
CK NNP NNP O
- - - O
MB NNP NNP O
) ) ) O
, , , O
increased VBD VBD O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
level NN NN O
and CC CC O
reduced VBN VBN O
plasma NN NN O
iron NN NN B-CHEM
binding JJ JJ O
capacity NN NN O
. . . O

The DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
mangiferin NN NN B-CHEM
was VBD VBD O
analyzed VBN VBN O
by IN IN O
triphenyl NN NN B-CHEM
tetrazolium NN NN I-CHEM
chloride NN NN I-CHEM
( ( ( O
TTC NNP NNP B-CHEM
) ) ) O
test NN NN O
used VBN VBN O
for IN IN O
macroscopic JJ JJ O
enzyme NN NN O
mapping VBG VBG O
assay NN NN O
of IN IN O
the DT DT O
ischemic JJ JJ O
myocardium NN NN O
. . . O

The DT DT O
heart NN NN O
tissue NN NN O
antioxidant JJ JJ O
enzymes NNS NNS O
such JJ JJ O
as IN IN O
superoxide NN NN B-CHEM
dismutase NN NN O
, , , O
catalase NN NN O
, , , O
glutathione NN NN B-CHEM
peroxidase NN NN O
, , , O
glutathione NN NN B-CHEM
transferase NN NN O
and CC CC O
glutathione NN NN B-CHEM
reductase NN NN O
activities NNS NNS O
, , , O
non NN NN O
- - - O
enzymic JJ JJ O
antioxidants NNS NNS O
such JJ JJ O
as IN IN O
cerruloplasmin NN NN O
, , , O
Vitamin NNP NNP B-CHEM
C NNP NNP I-CHEM
, , , O
Vitamin NNP NNP B-CHEM
E NNP NNP I-CHEM
and CC CC O
glutathione NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
altered VBN VBN O
in IN IN O
MI NNP NNP O
rats NNS NNS O
. . . O

Upon IN IN O
pretreatment NN NN O
with IN IN O
mangiferin NN NN B-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
suspended VBN VBN O
in IN IN O
2 CD CD O
ml NN NN O
of IN IN O
dimethyl NN NN B-CHEM
sulphoxide NN NN I-CHEM
) ) ) O
given VBN VBN O
intraperitoneally RB RB O
for IN IN O
28 CD CD O
days NNS NNS O
to TO TO O
MI NNP NNP O
rats NNS NNS O
protected VBD VBD O
the DT DT O
above JJ JJ O
- - - O
mentioned VBN VBN O
parameters NNS NNS O
to TO TO O
fall VB VB O
from IN IN O
the DT DT O
normal JJ JJ O
levels NNS NNS O
. . . O

Activities NNS NNS O
of IN IN O
heart NN NN O
tissue NN NN O
enzymic JJ JJ O
antioxidants NNS NNS O
and CC CC O
serum NN NN O
non NN NN O
- : : O
enzymic JJ JJ O
antioxidants NNS NNS O
levels NNS NNS O
rose VBD VBD O
significantly RB RB O
upon IN IN O
mangiferin NN NN B-CHEM
administration NN NN O
as IN IN O
compared VBN VBN O
to TO TO O
ISPH NNP NNP B-CHEM
- : : O
induced JJ JJ O
MI NNP NNP O
rats NNS NNS O
. . . O

From IN IN O
the DT DT O
present JJ JJ O
study NN NN O
it PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
mangiferin NN NN B-CHEM
exerts VBZ VBZ O
a DT DT O
beneficial JJ JJ O
effect NN NN O
against IN IN O
ISPH NNP NNP B-CHEM
- : : O
induced JJ JJ O
MI NNP NNP O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
antioxidant JJ JJ O
potential NN NN O
, , , O
which WDT WDT O
regulated VBD VBD O
the DT DT O
tissues NNS NNS O
defense NN NN O
system NN NN O
against IN IN O
cardiac JJ JJ O
damage NN NN O
. . . O

Cardiovascular NNP NNP O
risk NN NN O
with IN IN O
cyclooxygenase NN NN B-CHEM
inhibitors NNS NNS I-CHEM
: : : O
general JJ JJ O
problem NN NN O
with IN IN O
substance NN NN O
specific JJ JJ O
differences NNS NNS O
? . . O

Randomised NNP NNP O
clinical JJ JJ O
trials NNS NNS O
and CC CC O
observational JJ JJ O
studies NNS NNS O
have VBP VBP O
shown VBN VBN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
, , , O
stroke NN NN O
, , , O
hypertension NN NN O
and CC CC O
heart NN NN O
failure NN NN O
during IN IN O
treatment NN NN O
with IN IN O
cyclooxygenase NN NN B-CHEM
inhibitors NNS NNS I-CHEM
. . . O

Adverse NNP NNP O
cardiovascular JJ JJ O
effects NNS NNS O
occurred VBD VBD O
mainly RB RB O
, , , O
but CC CC O
not RB RB O
exclusively RB RB O
, , , O
in IN IN O
patients NNS NNS O
with IN IN O
concomitant NN NN O
risk NN NN O
factors NNS NNS O
. . . O

Cyclooxygenase NNP NNP B-CHEM
inhibitors NNS NNS I-CHEM
cause VBP VBP O
complex JJ JJ O
changes NNS NNS O
in IN IN O
renal NN NN O
, , , O
vascular NN NN O
and CC CC O
cardiac JJ JJ O
prostanoid NN NN O
profiles NNS NNS O
thereby RB RB O
increasing VBG VBG O
vascular NN NN O
resistance NN NN O
and CC CC O
fluid JJ JJ O
retention NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
cardiovascular JJ JJ O
adverse JJ JJ O
events NNS NNS O
tends NNS NNS O
to TO TO O
increase VB VB O
with IN IN O
the DT DT O
daily JJ JJ O
dose NN NN O
and CC CC O
total JJ JJ O
exposure NN NN O
time NN NN O
. . . O

A DT DT O
comparison NN NN O
of IN IN O
individual JJ JJ O
selective JJ JJ O
and CC CC O
unselective JJ JJ O
cyclooxygenase NN NN B-CHEM
inhibitors NNS NNS I-CHEM
suggests VBZ VBZ O
substance NN NN O
- - - O
specific JJ JJ O
differences NNS NNS O
, , , O
which WDT WDT O
may MD MD O
depend VB VB O
on IN IN O
differences NNS NNS O
in IN IN O
pharmacokinetic JJ JJ O
parameters NNS NNS O
or CC CC O
inhibitory NN NN O
potency NN NN O
and CC CC O
may MD MD O
be VB VB O
contributed VBN VBN O
by IN IN O
prostaglandin NN NN B-CHEM
- - - O
independent JJ JJ O
effects NNS NNS O
. . . O

Diagnostic NNP NNP O
markers NNS NNS O
such JJ JJ O
as IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
terminal NN NN I-CHEM
pro FW FW I-CHEM
brain NN NN I-CHEM
natriuretic JJ JJ I-CHEM
peptide NN NN I-CHEM
( ( ( O
NT NNP NNP B-CHEM
- - - I-CHEM
proBNP NN NN I-CHEM
) ) ) O
or CC CC O
high JJ JJ O
- - - O
sensitive JJ JJ O
C NNP NNP O
- - - O
reactive JJ JJ O
protein NN NN O
might MD MD O
help VB VB O
in IN IN O
the DT DT O
early JJ JJ O
identification NN NN O
of IN IN O
patients NNS NNS O
at IN IN O
risk NN NN O
, , , O
thus RB RB O
avoiding VBG VBG O
the DT DT O
occurrence NN NN O
of IN IN O
serious JJ JJ O
cardiovascular JJ JJ O
toxicity NN NN O
. . . O

Pilocarpine NNP NNP B-CHEM
seizures NNS NNS O
cause VBP VBP O
age NN NN O
- - - O
dependent JJ JJ O
impairment NN NN O
in IN IN O
auditory NN NN O
location NN NN O
discrimination NN NN O
. . . O

Children NNS NNS O
who WP WP O
have VBP VBP O
status NN NN O
epilepticus NN NN O
have VBP VBP O
continuous JJ JJ O
or CC CC O
rapidly RB RB O
repeating VBG VBG O
seizures NNS NNS O
that WDT WDT O
may MD MD O
be VB VB O
life NN NN O
- : : O
threatening VBG VBG O
and CC CC O
may MD MD O
cause VB VB O
life NN NN O
- : : O
long JJ JJ O
changes NNS NNS O
in IN IN O
brain NN NN O
and CC CC O
behavior NN NN O
. . . O

The DT DT O
extent NN NN O
to TO TO O
which WDT WDT O
status NN NN O
epilepticus NN NN O
causes NNS NNS O
deficits NNS NNS O
in IN IN O
auditory NN NN O
discrimination NN NN O
is VBZ VBZ O
unknown JJ JJ O
. . . O

A DT DT O
naturalistic JJ JJ O
auditory NN NN O
location NN NN O
discrimination NN NN O
method NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
this DT DT O
question NN NN O
using VBG VBG O
an DT DT O
animal NN NN O
model NN NN O
of IN IN O
status NN NN O
epilepticus NN NN O
. . . O

Male NNP NNP O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
injected VBN VBN O
with IN IN O
saline NN NN O
on IN IN O
postnatal NN NN O
day NN NN O
( ( ( O
P NN NN O
) ) ) O
20 CD CD O
, , , O
or CC CC O
a DT DT O
convulsant NN NN O
dose NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
on IN IN O
P20 NNP NNP O
or CC CC O
P45 NNP NNP O
. . . O

Pilocarpine NNP NNP B-CHEM
on IN IN O
either DT DT O
day NN NN O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
; : : O
status NN NN O
epilepticus NN NN O
at IN IN O
P45 NNP NNP O
resulted VBD VBD O
in IN IN O
CA3 NNP NNP O
cell NN NN O
loss NN NN O
and CC CC O
spontaneous JJ JJ O
seizures NNS NNS O
, , , O
whereas IN IN O
P20 NNP NNP O
rats NNS NNS O
had VBD VBD O
no DT DT O
cell NN NN O
loss NN NN O
or CC CC O
spontaneous JJ JJ O
seizures NNS NNS O
. . . O

Mature NNP NNP O
rats NNS NNS O
were VBD VBD O
trained VBN VBN O
with IN IN O
sound NN NN O
- - - O
source NN NN O
location NN NN O
and CC CC O
sound NN NN O
- - - O
silence NN NN O
discriminations NNS NNS O
. . . O

Control NNP NNP O
( ( ( O
saline NN NN O
P20 NNP NNP O
) ) ) O
rats NNS NNS O
acquired VBD VBD O
both DT DT O
discriminations NNS NNS O
immediately RB RB O
. . . O

In IN IN O
status NN NN O
epilepticus NN NN O
( ( ( O
P20 NNP NNP O
) ) ) O
rats NNS NNS O
, , , O
acquisition NN NN O
of IN IN O
the DT DT O
sound NN NN O
- - - O
source NN NN O
location NN NN O
discrimination NN NN O
was VBD VBD O
moderately RB RB O
impaired VBN VBN O
. . . O

Status NNP NNP O
epilepticus NN NN O
( ( ( O
P45 NNP NNP O
) ) ) O
rats NNS NNS O
failed VBD VBD O
to TO TO O
acquire VB VB O
either CC CC O
sound NN NN O
- - - O
source NN NN O
location NN NN O
or CC CC O
sound NN NN O
- - - O
silence NN NN O
discriminations NNS NNS O
. . . O

Status NNP NNP O
epilepticus NN NN O
in IN IN O
rat NN NN O
causes NNS NNS O
an DT DT O
age NN NN O
- - - O
dependent JJ JJ O
, , , O
long JJ JJ O
- - - O
term NN NN O
impairment NN NN O
in IN IN O
auditory NN NN O
discrimination NN NN O
. . . O

This DT DT O
impairment JJ JJ O
may MD MD O
explain VB VB O
one CD CD O
cause NN NN O
of IN IN O
impaired VBN VBN O
auditory NN NN O
location NN NN O
discrimination NN NN O
in IN IN O
humans NNS NNS O
. . . O

Nerve NNP NNP O
growth NN NN O
factor NN NN O
and CC CC O
prostaglandins NNS NNS B-CHEM
in IN IN O
the DT DT O
urine NN NN O
of IN IN O
female JJ JJ O
patients NNS NNS O
with IN IN O
overactive JJ JJ O
bladder NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
NGF NNP NNP O
and CC CC O
PGs NNP NNP B-CHEM
in IN IN O
the DT DT O
bladder NN NN O
can MD MD O
be VB VB O
affected VBN VBN O
by IN IN O
pathological JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
bladder NN NN O
and CC CC O
these DT DT O
changes NNS NNS O
can MD MD O
be VB VB O
detected VBN VBN O
in IN IN O
urine NN NN O
. . . O

We PRP PRP O
investigated VBD VBD O
changes NNS NNS O
in IN IN O
urinary JJ JJ O
NGF NNP NNP O
and CC CC O
PGs NNP NNP B-CHEM
in IN IN O
women NNS NNS O
with IN IN O
OAB NNP NNP O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
The DT DT O
study NN NN O
groups NNS NNS O
included VBD VBD O
65 CD CD O
women NNS NNS O
with IN IN O
OAB NNP NNP O
and CC CC O
20 CD CD O
without IN IN O
bladder NN NN O
symptoms NNS NNS O
who WP WP O
served VBD VBD O
as IN IN O
controls NNS NNS O
. . . O

Evaluation NNP NNP O
included VBD VBD O
patient NN NN O
history NN NN O
, , , O
urinalysis NN NN O
, , , O
a DT DT O
voiding VBG VBG O
diary NN NN O
and CC CC O
urodynamic JJ JJ O
studies NNS NNS O
. . . O

Urine NNP NNP O
samples NNS NNS O
were VBD VBD O
collected VBN VBN O
. . . O

NGF NNP NNP O
, , , O
PGE2 NNP NNP B-CHEM
, , , O
PGF2alpha NNP NNP B-CHEM
and CC CC O
PGI2 NNP NNP B-CHEM
were VBD VBD O
measured VBN VBN O
using VBG VBG O
enzyme NN NN O
- - - O
linked JJ JJ O
immunosorbent NN NN O
assay NN NN O
and CC CC O
compared VBN VBN O
between IN IN O
the DT DT O
groups NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
correlations NNS NNS O
between IN IN O
urinary JJ JJ O
NGF NNP NNP O
and CC CC O
PG NNP NNP B-CHEM
, , , O
and CC CC O
urodynamic JJ JJ O
parameters NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
OAB NNP NNP O
were VBD VBD O
examined VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Urinary NNP NNP O
NGF NNP NNP O
, , , O
PGE2 NNP NNP B-CHEM
and CC CC O
PGF2alpha NNP NNP B-CHEM
were VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
OAB NNP NNP O
compared VBN VBN O
with IN IN O
controls NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

However RB RB O
, , , O
urinary JJ JJ O
PGI2 NNP NNP B-CHEM
was VBD VBD O
not RB RB O
different JJ JJ O
between IN IN O
controls NNS NNS O
and CC CC O
patients NNS NNS O
with IN IN O
OAB NNP NNP O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
OAB NNP NNP O
urinary JJ JJ O
PGE2 NNP NNP B-CHEM
positively RB RB O
correlated VBD VBD O
with IN IN O
volume NN NN O
at IN IN O
first JJ JJ O
desire NN NN O
to TO TO O
void NN NN O
and CC CC O
maximum NN NN O
cystometric JJ JJ O
capacity NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Urinary NNP NNP O
NGF NNP NNP O
, , , O
PGF2alpha NNP NNP B-CHEM
and CC CC O
PGI2 NNP NNP B-CHEM
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
urodynamic JJ JJ O
parameters NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
OAB NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
NGF NNP NNP O
and CC CC O
PGs NNP NNP B-CHEM
have VBP VBP O
important JJ JJ O
roles NNS NNS O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
OAB NNP NNP O
symptoms NNS NNS O
in IN IN O
female JJ JJ O
patients NNS NNS O
. . . O

Urinary NNP NNP O
levels NNS NNS O
of IN IN O
these DT DT O
factors NNS NNS O
may MD MD O
be VB VB O
used VBN VBN O
as IN IN O
markers NNS NNS O
to TO TO O
evaluate VB VB O
OAB NNP NNP O
symptoms NNS NNS O
. . . O

Definition NNP NNP O
and CC CC O
management NN NN O
of IN IN O
anemia NN NN O
in IN IN O
patients NNS NNS O
infected VBN VBN O
with IN IN O
hepatitis NNP NNP O
C NNP NNP O
virus NN NN O
. . . O

Chronic JJ JJ O
infection NN NN O
with IN IN O
hepatitis NNP NNP O
C NNP NNP O
virus NN NN O
( ( ( O
HCV NNP NNP O
) ) ) O
can MD MD O
progress VB VB O
to TO TO O
cirrhosis NNS NNS O
, , , O
hepatocellular NN NN O
carcinoma NN NN O
, , , O
and CC CC O
end VB VB O
- : : O
stage NN NN O
liver NN NN O
disease NN NN O
. . . O

The DT DT O
current JJ JJ O
best JJS JJS O
treatment NN NN O
for IN IN O
HCV NNP NNP O
infection NN NN O
is VBZ VBZ O
combination NN NN O
therapy NN NN O
with IN IN O
pegylated VBN VBN O
interferon NN NN B-CHEM
and CC CC O
ribavirin NN NN B-CHEM
. . . O

Although IN IN O
this DT DT O
regimen NN NN O
produces VBZ VBZ O
sustained VBN VBN O
virologic JJ JJ O
responses NNS NNS O
( ( ( O
SVRs NNP NNP O
) ) ) O
in IN IN O
approximately RB RB O
50 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
it PRP PRP O
can MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
a DT DT O
potentially RB RB O
dose JJ JJ O
- - - O
limiting VBG VBG O
hemolytic JJ JJ O
anemia NN NN O
. . . O

Hemoglobin NNP NNP O
concentrations NNS NNS O
decrease RB RB O
mainly RB RB O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
ribavirin NN NN B-CHEM
- - - O
induced JJ JJ O
hemolysis NN NN O
, , , O
and CC CC O
this DT DT O
anemia NN NN O
can MD MD O
be VB VB O
problematic JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
HCV NNP NNP O
infection NN NN O
, , , O
especially RB RB O
those DT DT O
who WP WP O
have VBP VBP O
comorbid NN NN O
renal NN NN O
or CC CC O
cardiovascular JJ JJ O
disorders NNS NNS O
. . . O

In IN IN O
general JJ JJ O
, , , O
anemia NN NN O
can MD MD O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
morbidity NN NN O
and CC CC O
mortality NN NN O
, , , O
and CC CC O
may MD MD O
have VB VB O
negative JJ JJ O
effects NNS NNS O
on IN IN O
cerebral JJ JJ O
function NN NN O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
. . . O

Although IN IN O
ribavirin NN NN B-CHEM
- - - O
associated VBN VBN O
anemia NN NN O
can MD MD O
be VB VB O
reversed VBN VBN O
by IN IN O
dose NN NN O
reduction NN NN O
or CC CC O
discontinuation NN NN O
, , , O
this DT DT O
approach NN NN O
compromises VBZ VBZ O
outcomes NNS NNS O
by IN IN O
significantly RB RB O
decreasing VBG VBG O
SVR NNP NNP O
rates NNS NNS O
. . . O

Recombinant NNP NNP O
human JJ JJ O
erythropoietin NN NN O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
to TO TO O
manage VB VB O
ribavirin NN NN B-CHEM
- - - O
associated VBN VBN O
anemia NN NN O
but CC CC O
has VBZ VBZ O
other JJ JJ O
potential JJ JJ O
disadvantages NNS NNS O
. . . O

Viramidine NNP NNP B-CHEM
, , , O
a DT DT O
liver NN NN O
- - - O
targeting VBG VBG O
prodrug NN NN O
of IN IN O
ribavirin NN NN B-CHEM
, , , O
has VBZ VBZ O
the DT DT O
potential JJ JJ O
to TO TO O
maintain VB VB O
the DT DT O
virologic JJ JJ O
efficacy NN NN O
of IN IN O
ribavirin NN NN B-CHEM
while IN IN O
decreasing VBG VBG O
the DT DT O
risk NN NN O
of IN IN O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
. . . O

Impact NNP NNP O
of IN IN O
alcohol NN NN B-CHEM
exposure NN NN O
after IN IN O
pregnancy NN NN O
recognition NN NN O
on IN IN O
ultrasonographic JJ JJ O
fetal JJ JJ O
growth NN NN O
measures NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
More JJR JJR O
than IN IN O
3 CD CD O
decades NNS NNS O
after IN IN O
Jones NNP NNP O
and CC CC O
Smith NNP NNP O
( ( ( O
1973 CD CD O
) ) ) O
reported VBD VBD O
on IN IN O
the DT DT O
devastation NN NN O
caused VBN VBN O
by IN IN O
alcohol NN NN B-CHEM
exposure NN NN O
on IN IN O
fetal JJ JJ O
development NN NN O
, , , O
the DT DT O
rates NNS NNS O
of IN IN O
heavy JJ JJ O
drinking NN NN O
during IN IN O
pregnancy NN NN O
remain VB VB O
relatively RB RB O
unchanged JJ JJ O
. . . O

Early JJ JJ O
identification NN NN O
of IN IN O
fetal JJ JJ O
alcohol NN NN B-CHEM
exposure NN NN O
and CC CC O
maternal JJ JJ O
abstinence NN NN O
led VBN VBN O
to TO TO O
better JJR JJR O
infant NN NN O
outcomes NNS NNS O
. . . O

This DT DT O
study NN NN O
examined VBD VBD O
the DT DT O
utility NN NN O
of IN IN O
biometry NN NN O
for IN IN O
detecting VBG VBG O
alcohol NN NN B-CHEM
- - - O
related JJ JJ O
fetal JJ JJ O
growth NN NN O
impairment NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
obtained VBD VBD O
fetal JJ JJ O
ultrasound JJ JJ O
measures NNS NNS O
from IN IN O
routine JJ JJ O
ultrasound NN NN O
examinations NNS NNS O
for IN IN O
167 CD CD O
pregnant JJ JJ O
hazardous JJ JJ O
drinkers NNS NNS O
who WP WP O
were VBD VBD O
enrolled VBN VBN O
in IN IN O
a DT DT O
brief JJ JJ O
alcohol NN NN B-CHEM
intervention NN NN O
study NN NN O
. . . O

The DT DT O
fetal JJ JJ O
measures NNS NNS O
for IN IN O
women NNS NNS O
who WP WP O
quit VBD VBD O
after IN IN O
learning VBG VBG O
of IN IN O
their PRP$ PRP$ O
pregnancies NNS NNS O
were VBD VBD O
compared VBN VBN O
with IN IN O
measures NNS NNS O
for IN IN O
women NNS NNS O
who WP WP O
continued VBD VBD O
some DT DT O
drinking VBG VBG O
throughout IN IN O
the DT DT O
course NN NN O
of IN IN O
their PRP$ PRP$ O
pregnancies NNS NNS O
. . . O

Because IN IN O
intensity NN NN O
of IN IN O
alcohol NN NN B-CHEM
consumption NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
poorer NN NN O
fetal JJ JJ O
outcomes NNS NNS O
, , , O
separate JJ JJ O
analyses NNS NNS O
were VBD VBD O
conducted VBN VBN O
for IN IN O
the DT DT O
heavy JJ JJ O
( ( ( O
average NN NN O
of IN IN O
> NN NN O
or CC CC O
= SYM SYM O
5 CD CD O
drinks NNS NNS O
per IN IN O
drinking NN NN O
day NN NN O
) ) ) O
alcohol NN NN B-CHEM
consumers NNS NNS O
. . . O

Fetal NNP NNP O
measures NNS NNS O
from IN IN O
the DT DT O
heavy JJ JJ O
- - - O
exposed JJ JJ O
fetuses NNS NNS O
were VBD VBD O
also RB RB O
compared VBN VBN O
with IN IN O
measures NNS NNS O
from IN IN O
a DT DT O
nondrinking VBG VBG O
group NN NN O
that WDT WDT O
was VBD VBD O
representative NN NN O
of IN IN O
normal JJ JJ O
, , , O
uncomplicated JJ JJ O
pregnancies NNS NNS O
from IN IN O
our PRP$ PRP$ O
clinics NNS NNS O
. . . O

Analyses NNP NNP O
of IN IN O
covariance NN NN O
were VBD VBD O
used VBN VBN O
to TO TO O
determine VB VB O
whether IN IN O
there EX EX O
were VBD VBD O
differences NNS NNS O
between IN IN O
groups NNS NNS O
after IN IN O
controlling VBG VBG O
for IN IN O
influences NNS NNS O
of IN IN O
gestational JJ JJ O
age NN NN O
and CC CC O
drug NN NN O
abuse NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Nearly RB RB O
half NN NN O
of IN IN O
the DT DT O
pregnant JJ JJ O
drinkers NNS NNS O
abstained VBD VBD O
after IN IN O
learning VBG VBG O
of IN IN O
their PRP$ PRP$ O
pregnancies NNS NNS O
. . . O

When WRB WRB O
women NNS NNS O
reportedly RB RB O
quit VBD VBD O
drinking VBG VBG O
early JJ JJ O
in IN IN O
their PRP$ PRP$ O
pregnancies NNS NNS O
, , , O
fetal JJ JJ O
growth NN NN O
measures NNS NNS O
were VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
from IN IN O
a DT DT O
non NN NN O
- - - O
alcohol NN NN B-CHEM
- - - O
exposed VBN VBN O
group NN NN O
, , , O
regardless RB RB O
of IN IN O
prior RB RB O
drinking NN NN O
patterns NNS NNS O
. . . O

Any DT DT O
alcohol NN NN B-CHEM
consumption NN NN O
postpregnancy NN NN O
recognition NN NN O
among IN IN O
the DT DT O
heavy JJ JJ O
drinkers NNS NNS O
resulted VBD VBD O
in IN IN O
reduced VBN VBN O
cerebellar NN NN O
growth NN NN O
as RB RB O
well RB RB O
as IN IN O
decreased VBN VBN O
cranial JJ JJ O
to TO TO O
body NN NN O
growth NN NN O
in IN IN O
comparison NN NN O
with IN IN O
women NNS NNS O
who WP WP O
either CC CC O
quit VBD VBD O
drinking VBG VBG O
or CC CC O
who WP WP O
were VBD VBD O
nondrinkers NNS NNS O
. . . O

Amphetamine NNP NNP B-CHEM
abuse NN NN O
was VBD VBD O
predictive JJ JJ O
of IN IN O
larger JJR JJR O
cranial NN NN O
to TO TO O
body NN NN O
growth NN NN O
ratios NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Alterations NNP NNP O
in IN IN O
fetal JJ JJ O
biometric JJ JJ O
measurements NNS NNS O
were VBD VBD O
observed VBN VBN O
among IN IN O
the DT DT O
heavy JJ JJ O
drinkers NNS NNS O
only RB RB O
when WRB WRB O
they PRP PRP O
continued VBD VBD O
drinking VBG VBG O
after IN IN O
becoming VBG VBG O
aware JJ JJ O
of IN IN O
their PRP$ PRP$ O
pregnancies NNS NNS O
. . . O

Although IN IN O
the DT DT O
reliance NN NN O
on IN IN O
self NN NN O
- - - O
reported VBN VBN O
drinking NN NN O
is VBZ VBZ O
a DT DT O
limitation NN NN O
in IN IN O
this DT DT O
study NN NN O
, , , O
these DT DT O
findings NNS NNS O
support VBP VBP O
the DT DT O
benefits NNS NNS O
of IN IN O
early JJ JJ O
abstinence NN NN O
and CC CC O
the DT DT O
potential JJ JJ O
for IN IN O
ultrasound NN NN O
examinations NNS NNS O
in IN IN O
the DT DT O
detection NN NN O
of IN IN O
fetal JJ JJ O
alcohol NN NN B-CHEM
effects NNS NNS O
. . . O

Ethambutol NNP NNP B-CHEM
- - - O
associated VBN VBN O
optic JJ JJ O
neuropathy NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Ethambutol NNP NNP B-CHEM
is VBZ VBZ O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
tuberculosis NNS NNS O
, , , O
which WDT WDT O
is VBZ VBZ O
still RB RB O
prevalent JJ JJ O
in IN IN O
Southeast NNP NNP O
Asia NNP NNP O
, , , O
and CC CC O
can MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
permanent JJ JJ O
visual JJ JJ O
loss NN NN O
. . . O

We PRP PRP O
report VBP VBP O
3 CD CD O
cases NNS NNS O
which WDT WDT O
presented VBN VBN O
with IN IN O
bitemporal JJ JJ O
hemianopia NN NN O
. . . O

CLINICAL NNP NNP O
PICTURE NNP NNP O
: : : O
Three CD CD O
patients NNS NNS O
with IN IN O
ethambutol NN NN B-CHEM
- - - O
associated VBN VBN O
toxic JJ JJ O
optic JJ JJ O
neuropathy NN NN O
are VBP VBP O
described VBN VBN O
. . . O

All DT DT O
3 CD CD O
patients NNS NNS O
had VBD VBD O
loss NN NN O
of IN IN O
central JJ JJ O
visual JJ JJ O
acuity NN NN O
, , , O
colour NN NN O
vision NN NN O
( ( ( O
Ishihara NNP NNP O
) ) ) O
and CC CC O
visual JJ JJ O
field NN NN O
. . . O

The DT DT O
visual JJ JJ O
field NN NN O
loss NN NN O
had VBD VBD O
a DT DT O
bitemporal JJ JJ O
flavour NN NN O
, , , O
suggesting VBG VBG O
involvement NN NN O
of IN IN O
the DT DT O
optic JJ JJ O
chiasm NN NN O
. . . O

TREATMENT NN NN O
: : : O
Despite IN IN O
stopping VBG VBG O
ethambutol NN NN B-CHEM
on IN IN O
diagnosis NN NN O
, , , O
visual JJ JJ O
function NN NN O
continued VBD VBD O
to TO TO O
deteriorate VB VB O
for IN IN O
a DT DT O
few JJ JJ O
months NNS NNS O
. . . O

Subsequent NNP NNP O
improvement NN NN O
was VBD VBD O
mild JJ JJ O
in IN IN O
2 CD CD O
cases NNS NNS O
. . . O

In IN IN O
the DT DT O
third JJ JJ O
case NN NN O
, , , O
visual JJ JJ O
acuity NN NN O
and CC CC O
colour NN NN O
vision NN NN O
normalised VBN VBN O
but CC CC O
the DT DT O
optic JJ JJ O
discs NN NN O
were VBD VBD O
pale JJ JJ O
. . . O

OUTCOME NNP NNP O
: : : O
All DT DT O
3 CD CD O
patients NNS NNS O
had VBD VBD O
some DT DT O
permanent JJ JJ O
loss NN NN O
of IN IN O
visual JJ JJ O
function NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Ethambutol NNP NNP B-CHEM
usage NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
permanent JJ JJ O
visual JJ JJ O
loss NN NN O
and CC CC O
should MD MD O
be VB VB O
avoided VBN VBN O
if IN IN O
possible JJ JJ O
or CC CC O
used VBN VBN O
with IN IN O
caution NN NN O
and CC CC O
proper JJ JJ O
ophthalmological JJ JJ O
follow VB VB O
- - - O
up RP RP O
. . . O

The DT DT O
author NN NN O
postulates NNS NNS O
that IN IN O
in IN IN O
cases NNS NNS O
of IN IN O
ethambutol NN NN B-CHEM
associated VBN VBN O
chiasmopathy JJ JJ O
, , , O
ethambutol NN NN B-CHEM
may MD MD O
initially RB RB O
affect VB VB O
the DT DT O
optic JJ JJ O
nerves NNS NNS O
and CC CC O
subsequently RB RB O
progress NN NN O
to TO TO O
involve VB VB O
the DT DT O
optic JJ JJ O
chiasm NN NN O
. . . O

Possible JJ JJ O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
related VBN VBN O
to TO TO O
concomitant JJ JJ O
treatment NN NN O
with IN IN O
paroxetine NN NN B-CHEM
and CC CC O
alprazolam NN NN B-CHEM
. . . O

A DT DT O
74 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
depressive JJ JJ O
symptoms NNS NNS O
was VBD VBD O
admitted VBN VBN O
to TO TO O
a DT DT O
psychiatric JJ JJ O
hospital NN NN O
due JJ JJ O
to TO TO O
insomnia NN NN O
, , , O
loss NN NN O
of IN IN O
appetite NN NN O
, , , O
exhaustion NN NN O
, , , O
and CC CC O
agitation NN NN O
. . . O

Medical NNP NNP O
treatment NN NN O
was VBD VBD O
initiated VBN VBN O
at IN IN O
a DT DT O
daily JJ JJ O
dose NN NN O
of IN IN O
20 CD CD O
mg NN NN O
paroxetine NN NN B-CHEM
and CC CC O
1 CD CD O
. . . O
2 CD CD O
mg NN NN O
alprazolam NN NN B-CHEM
. . . O

On IN IN O
the DT DT O
10th JJ JJ O
day NN NN O
of IN IN O
paroxetine NN NN B-CHEM
and CC CC O
alprazolam JJ JJ B-CHEM
treatment NN NN O
, , , O
the DT DT O
patient NN NN O
exhibited VBN VBN O
marked VBN VBN O
psychomotor NN NN O
retardation NN NN O
, , , O
disorientation NN NN O
, , , O
and CC CC O
severe JJ JJ O
muscle NN NN O
rigidity NN NN O
with IN IN O
tremors NNS NNS O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
a DT DT O
fever NN NN O
( ( ( O
38 CD CD O
. . . O
2 CD CD O
degrees NNS NNS O
C NNP NNP O
) ) ) O
, , , O
fluctuating VBG VBG O
blood NN NN O
pressure NN NN O
( ( ( O
between IN IN O
165 CD CD O
/ NN NN O
90 CD CD O
and CC CC O
130 CD CD O
/ NN NN O
70 CD CD O
mg NN NN O
mm NN NN O
Hg NNP NNP O
) ) ) O
, , , O
and CC CC O
severe JJ JJ O
extrapyramidal NN NN O
symptoms NNS NNS O
. . . O

Laboratory NNP NNP O
tests NNS NNS O
showed VBD VBD O
an DT DT O
elevation NN NN O
of IN IN O
creatine NN NN B-CHEM
phosphokinase NN NN O
( ( ( O
2218 CD CD O
IU NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
, , , O
aspartate NN NN B-CHEM
aminotransferase NN NN O
( ( ( O
134 CD CD O
IU NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
, , , O
alanine NN NN B-CHEM
aminotransferase NN NN O
( ( ( O
78 CD CD O
IU NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
, , , O
and CC CC O
BUN NNP NNP O
( ( ( O
27 CD CD O
. . . O
9 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
levels NNS NNS O
. . . O

The DT DT O
patient NN NN O
received VBD VBD O
bromocriptine NN NN B-CHEM
and CC CC O
diazepam NN NN B-CHEM
to TO TO O
treat VB VB O
his PRP$ PRP$ O
symptoms NNS NNS O
. . . O

7 CD CD O
days NNS NNS O
later RB RB O
, , , O
the DT DT O
fever NN NN O
disappeared VBD VBD O
and CC CC O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
serum NN NN O
CPK NNP NNP O
levels NNS NNS O
were VBD VBD O
normalized JJ JJ O
( ( ( O
175 CD CD O
IU NNP NNP O
/ NN NN O
L NNP NNP O
) ) ) O
. . . O

This DT DT O
patient NN NN O
presented VBN VBN O
with IN IN O
symptoms NNS NNS O
of IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
( ( ( O
NMS NNP NNP O
) ) ) O
, , , O
thus RB RB O
demonstrating VBG VBG O
that IN IN O
NMS NNP NNP O
- : : O
like IN IN O
symptoms NNS NNS O
can MD MD O
occur VB VB O
after IN IN O
combined VBN VBN O
paroxetine NN NN B-CHEM
and CC CC O
alprazolam JJ JJ B-CHEM
treatment NN NN O
. . . O

The DT DT O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
score NN NN O
obtained VBN VBN O
by IN IN O
the DT DT O
Naranjo NNP NNP O
algorithm NN NN O
was VBD VBD O
6 CD CD O
in IN IN O
our PRP$ PRP$ O
case NN NN O
, , , O
indicating VBG VBG O
a DT DT O
probable JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
NMS NNP NNP O
- - - O
like IN IN O
adverse JJ JJ O
symptoms NNS NNS O
and CC CC O
the DT DT O
combined JJ JJ O
treatment NN NN O
used VBN VBN O
in IN IN O
this DT DT O
case NN NN O
. . . O

The DT DT O
involvement NN NN O
of IN IN O
physiologic JJ JJ O
and CC CC O
environmental JJ JJ O
aspects NNS NNS O
specific JJ JJ O
to TO TO O
this DT DT O
patient NN NN O
was VBD VBD O
suspected VBN VBN O
. . . O

Several JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
NMS NNP NNP O
should MD MD O
be VB VB O
noted VBN VBN O
in IN IN O
elderly JJ JJ O
depressive JJ JJ O
patients NNS NNS O
whose WP$ WP$ O
symptoms NNS NNS O
often RB RB O
include VBP VBP O
dehydration NN NN O
, , , O
agitation NN NN O
, , , O
malnutrition NN NN O
, , , O
and CC CC O
exhaustion NN NN O
. . . O

Careful NNP NNP O
therapeutic JJ JJ O
intervention NN NN O
is VBZ VBZ O
necessary JJ JJ O
in IN IN O
cases NNS NNS O
involving VBG VBG O
elderly JJ JJ O
patients NNS NNS O
who WP WP O
suffer VBP VBP O
from IN IN O
depression NN NN O
. . . O

Down IN IN O
- - - O
regulation NN NN O
of IN IN O
norepinephrine NN NN B-CHEM
transporter NN NN O
function NN NN O
induced VBN VBN O
by IN IN O
chronic JJ JJ O
administration NN NN O
of IN IN O
desipramine NN NN B-CHEM
linking VBG VBG O
to TO TO O
the DT DT O
alteration NN NN O
of IN IN O
sensitivity NN NN O
of IN IN O
local JJ JJ O
- - - O
anesthetics NNS NNS O
- - - O
induced JJ JJ O
convulsions NNS NNS O
and CC CC O
the DT DT O
counteraction NN NN O
by IN IN O
co NN NN O
- - - O
administration NN NN O
with IN IN O
local JJ JJ O
anesthetics NNS NNS O
. . . O

Alterations NNP NNP O
of IN IN O
norepinephrine NN NN B-CHEM
transporter NN NN O
( ( ( O
NET NNP NNP O
) ) ) O
function NN NN O
by IN IN O
chronic JJ JJ O
inhibition NN NN O
of IN IN O
NET NNP NNP O
in IN IN O
relation NN NN O
to TO TO O
sensitization NN NN O
to TO TO O
seizures NNS NNS O
induce NN NN O
by IN IN O
cocaine NN NN B-CHEM
and CC CC O
local JJ JJ O
anesthetics NNS NNS O
were VBD VBD O
studied VBN VBN O
in IN IN O
mice NN NN O
. . . O

Daily NNP NNP O
administration NN NN O
of IN IN O
desipramine NN NN B-CHEM
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
the DT DT O
NET NNP NNP O
, , , O
for IN IN O
5 CD CD O
days NNS NNS O
decreased VBD VBD O
[ NN NN O
( ( ( O
3 CD CD O
) ) ) O
H NNP NNP O
] NN NN O
norepinephrine NN NN B-CHEM
uptake NN NN O
in IN IN O
the DT DT O
P2 NNP NNP O
fractions NNS NNS O
of IN IN O
hippocampus NN NN O
but CC CC O
not RB RB O
cortex VB VB O
, , , O
striatum NN NN O
or CC CC O
amygdalae NN NN O
. . . O

Co NNP NNP O
- : : O
administration NN NN O
of IN IN O
lidocaine NN NN B-CHEM
, , , O
bupivacaine NN NN B-CHEM
or CC CC O
tricaine NN NN B-CHEM
with IN IN O
desipramine NN NN B-CHEM
reversed VBD VBD O
this DT DT O
effect NN NN O
. . . O

Daily NNP NNP O
treatment NN NN O
of IN IN O
cocaine NN NN B-CHEM
increased VBN VBN O
[ NN NN O
( ( ( O
3 CD CD O
) ) ) O
H NNP NNP O
] NN NN O
norepinephrine NN NN B-CHEM
uptake NN NN O
into IN IN O
the DT DT O
hippocampus NN NN O
. . . O

Daily NNP NNP O
administration NN NN O
of IN IN O
desipramine NN NN B-CHEM
increased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
appearance NN NN O
of IN IN O
lidocaine NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
and CC CC O
decreased VBD VBD O
that IN IN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
. . . O

Co NNP NNP O
- : : O
administration NN NN O
of IN IN O
lidocaine NN NN B-CHEM
with IN IN O
desipramine NN NN B-CHEM
reversed VBD VBD O
the DT DT O
changes NNS NNS O
of IN IN O
convulsive JJ JJ O
activity NN NN O
of IN IN O
lidocaine NN NN B-CHEM
and CC CC O
cocaine NN NN B-CHEM
induced VBN VBN O
by IN IN O
repeated VBN VBN O
administration NN NN O
of IN IN O
desipramine NN NN B-CHEM
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
down RB RB O
- : : O
regulation NN NN O
of IN IN O
hippocampal JJ JJ O
NET NNP NNP O
induced VBN VBN O
by IN IN O
chronic JJ JJ O
administration NN NN O
of IN IN O
desipramine NN NN B-CHEM
may MD MD O
be VB VB O
relevant JJ JJ O
to TO TO O
desipramine VB VB B-CHEM
- : : O
induced JJ JJ O
sensitization NN NN O
of IN IN O
lidocaine NN NN B-CHEM
convulsions NNS NNS O
. . . O

Inhibition NNP NNP O
of IN IN O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
channels NNS NNS O
by IN IN O
local JJ JJ O
anesthetics NNS NNS O
may MD MD O
regulate VB VB O
desipramine NN NN B-CHEM
- : : O
induced VBN VBN O
down RB RB O
- - - O
regulation NN NN O
of IN IN O
NET NNP NNP O
function NN NN O
. . . O

Repeated NNP NNP O
administration NN NN O
of IN IN O
cocaine NN NN B-CHEM
induces NNS NNS O
up RP RP O
- : : O
regulation NN NN O
of IN IN O
hippocampal JJ JJ O
NET NNP NNP O
function NN NN O
. . . O

Desipramine NNP NNP B-CHEM
- : : O
induced JJ JJ O
sensitization NN NN O
of IN IN O
lidocaine NN NN B-CHEM
seizures NNS NNS O
may MD MD O
have VB VB O
a DT DT O
mechanism NN NN O
distinct JJ JJ O
from IN IN O
kindling VBG VBG O
resulting VBG VBG O
from IN IN O
repeated VBN VBN O
administration NN NN O
of IN IN O
cocaine NN NN B-CHEM
. . . O

Atorvastatin NNP NNP B-CHEM
prevented VBD VBD O
and CC CC O
reversed VBN VBN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

To TO TO O
assess VB VB O
the DT DT O
antioxidant JJ JJ O
effects NNS NNS O
of IN IN O
atorvastatin NN NN B-CHEM
( ( ( O
atorva NN NN B-CHEM
) ) ) O
on IN IN O
dexamethasone NN NN B-CHEM
( ( ( O
dex NN NN B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypertension NN NN O
, , , O
60 CD CD O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
atorva NN NN B-CHEM
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
or CC CC O
tap VB VB O
water NN NN O
for IN IN O
15 CD CD O
days NNS NNS O
. . . O

Dex NNP NNP B-CHEM
increased VBD VBD O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
SBP NNP NNP O
) ) ) O
from IN IN O
109 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
8 CD CD O
to TO TO O
135 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
mmHg NN NN O
and CC CC O
plasma NN NN O
superoxide NN NN B-CHEM
( ( ( O
5711 CD CD O
+ NN NN O
/ NN NN O
- : : O
284 CD CD O
. . . O
9 CD CD O
saline NN NN O
, , , O
7931 CD CD O
+ NN NN O
/ NN NN O
- : : O
392 CD CD O
. . . O
8 CD CD O
U NNP NNP O
/ NN NN O
ml NN NN O
dex NN NN B-CHEM
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

In IN IN O
this DT DT O
prevention NN NN O
study NN NN O
, , , O
SBP NNP NNP O
in IN IN O
the DT DT O
atorva NN NN B-CHEM
+ NN NN O
dex NN NN B-CHEM
group NN NN O
was VBD VBD O
increased VBN VBN O
from IN IN O
115 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
4 CD CD O
to TO TO O
124 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
5 CD CD O
mmHg NN NN O
, , , O
but CC CC O
this DT DT O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
in IN IN O
the DT DT O
dex NN NN B-CHEM
- - - O
only RB RB O
group NN NN O
( ( ( O
P NN NN O
' '' '' O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Atorva NNP NNP B-CHEM
reversed VBD VBD O
dex NN NN B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
( ( ( O
129 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
mmHg NN NN O
, , , O
vs NNS NNS O
. . . O
135 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
mmHg NN NN O
P NN NN O
' '' '' O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
decreased VBD VBD O
plasma NN NN O
superoxide NN NN B-CHEM
( ( ( O
7931 CD CD O
+ NN NN O
/ NN NN O
- : : O
392 CD CD O
. . . O
8 CD CD O
dex NN NN B-CHEM
, , , O
1187 CD CD O
+ NN NN O
/ NN NN O
- : : O
441 CD CD O
. . . O
2 CD CD O
atorva NN NN B-CHEM
+ NN NN O
dex NN NN B-CHEM
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

Plasma NNP NNP O
nitrate NN NN B-CHEM
/ NN NN O
nitrite NN NN B-CHEM
( ( ( O
NOx NNP NNP O
) ) ) O
was VBD VBD O
decreased VBN VBN O
in IN IN O
dex NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
compared VBN VBN O
to TO TO O
saline VB VB O
- - - O
treated JJ JJ O
rats NNS NNS O
( ( ( O
11 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
08 CD CD O
microm NN NN O
, , , O
15 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
17 CD CD O
microm NN NN O
, , , O
respectively RB RB O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Atorva NNP NNP B-CHEM
affected VBD VBD O
neither DT DT O
plasma JJ JJ O
NOx NNP NNP O
nor CC CC O
thymus NN NN O
weight NN NN O
. . . O

Thus RB RB O
, , , O
atorvastatin NN NN B-CHEM
prevented VBN VBN O
and CC CC O
reversed VBN VBN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Peripheral NNP NNP O
neuropathy NN NN O
caused VBN VBN O
by IN IN O
high JJ JJ O
- - - O
dose NN NN O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
treatment NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
acute JJ JJ O
myeloid NN NN O
leukemia NN NN O
. . . O

The DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
toxicity NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
is VBZ VBZ O
well RB RB O
recognized VBN VBN O
, , , O
but CC CC O
the DT DT O
toxicity NN NN O
of IN IN O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
in IN IN O
the DT DT O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
has VBZ VBZ O
been VBN VBN O
infrequently RB RB O
reported VBN VBN O
. . . O

A DT DT O
49 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
Japanese JJ JJ O
man NN NN O
was VBD VBD O
diagnosed VBN VBN O
with IN IN O
acute JJ JJ O
myeloid NN NN O
leukemia NN NN O
. . . O

After IN IN O
he PRP PRP O
achieved VBD VBD O
complete JJ JJ O
remission NN NN O
, , , O
he PRP PRP O
received VBD VBD O
high JJ JJ O
- - - O
dose NN NN O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
treatment NN NN O
( ( ( O
2 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
twice RB RB O
a DT DT O
day NN NN O
for IN IN O
5 CD CD O
days NNS NNS O
; : : O
total JJ JJ O
, , , O
20 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
) ) ) O
as IN IN O
consolidation NN NN O
therapy NN NN O
. . . O

The DT DT O
first JJ JJ O
course NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
resulted VBD VBD O
in IN IN O
no DT DT O
unusual JJ JJ O
symptoms NNS NNS O
, , , O
but CC CC O
on IN IN O
day NN NN O
21 CD CD O
of IN IN O
the DT DT O
second JJ JJ O
course NN NN O
of IN IN O
treatment NN NN O
, , , O
the DT DT O
patient NN NN O
complained VBD VBD O
of IN IN O
numbness NN NN O
in IN IN O
his PRP$ PRP$ O
right JJ JJ O
foot NN NN O
. . . O

Electromyogram NNP NNP O
and CC CC O
nerve NN NN O
- - - O
conduction NN NN O
studies NNS NNS O
showed VBD VBD O
peripheral JJ JJ O
neuropathy NN NN O
in IN IN O
both DT DT O
peroneal NN NN O
nerves NNS NNS O
. . . O

This DT DT O
neuropathy NN NN O
was VBD VBD O
gradually RB RB O
resolving VBG VBG O
; : : O
however RB RB O
, , , O
after IN IN O
the DT DT O
patient NN NN O
received VBD VBD O
allogeneic NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
, , , O
the DT DT O
symptoms NNS NNS O
worsened VBD VBD O
, , , O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
graft NN NN O
- - - O
versus CC CC O
- - - O
host NN NN O
disease NN NN O
, , , O
and CC CC O
the DT DT O
symptoms NNS NNS O
subsequently RB RB O
responded VBN VBN O
to TO TO O
methylprednisolone NN NN B-CHEM
. . . O

Although IN IN O
the DT DT O
mechanisms NNS NNS O
of IN IN O
peripheral JJ JJ O
neuropathy NN NN O
are VBP VBP O
still RB RB O
unclear JJ JJ O
, , , O
high JJ JJ O
- - - O
dose NN NN O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
is VBZ VBZ O
a DT DT O
therapy NN NN O
that WDT WDT O
is VBZ VBZ O
potentially RB RB O
toxic JJ JJ O
to TO TO O
the DT DT O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
, , , O
and CC CC O
auto NN NN O
/ NN NN O
alloimmunity NN NN O
may MD MD O
play VB VB O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
these DT DT O
mechanisms NNS NNS O
. . . O

Effect NN NN O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
tocopherol NN NN I-CHEM
and CC CC O
deferoxamine NN NN B-CHEM
on IN IN O
methamphetamine NN NN B-CHEM
- : : O
induced JJ JJ O
neurotoxicity NN NN O
. . . O

Methamphetamine NNP NNP B-CHEM
( ( ( O
MA NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
dopaminergic JJ JJ O
neurotoxicity NN NN O
is VBZ VBZ O
believed VBN VBN O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
increased JJ JJ O
formation NN NN O
of IN IN O
free JJ JJ O
radicals NNS NNS O
. . . O

This DT DT O
study NN NN O
examined VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
tocopherol NN NN I-CHEM
( ( ( O
alpha NN NN B-CHEM
- - - I-CHEM
TC NNP NNP I-CHEM
) ) ) O
, , , O
a DT DT O
scavenger NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
, , , O
and CC CC O
deferoxamine NN NN B-CHEM
( ( ( O
DFO NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
iron NN NN B-CHEM
chelator NN NN O
, , , O
on IN IN O
the DT DT O
MA NNP NNP B-CHEM
- - - O
induced JJ JJ O
neurotoxicity NN NN O
. . . O

Male NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
MA NNP NNP B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
every DT DT O
2 CD CD O
h NN NN O
for IN IN O
four CD CD O
injections NNS NNS O
) ) ) O
. . . O

The DT DT O
rat NN NN O
received VBD VBD O
either CC CC O
alpha JJ JJ B-CHEM
- : : I-CHEM
TC NNP NNP I-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
intraperitoneally RB RB O
for IN IN O
3 CD CD O
days NNS NNS O
and CC CC O
30 CD CD O
min NN NN O
prior RB RB O
to TO TO O
MA NNP NNP B-CHEM
administration NN NN O
or CC CC O
DFO NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
subcutaneously RB RB O
30 CD CD O
min NN NN O
before IN IN O
MA NNP NNP B-CHEM
administration NN NN O
. . . O

The DT DT O
concentrations NNS NNS O
of IN IN O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
, , , O
serotonin NN NN B-CHEM
and CC CC O
their PRP$ PRP$ O
metabolites NNS NNS O
decreased VBD VBD O
significantly RB RB O
after IN IN O
MA NNP NNP B-CHEM
administration NN NN O
, , , O
which WDT WDT O
was VBD VBD O
inhibited VBN VBN O
by IN IN O
the DT DT O
alpha NN NN B-CHEM
- - - I-CHEM
TC NNP NNP I-CHEM
and CC CC O
DFO NNP NNP B-CHEM
pretreatment NN NN O
. . . O

alpha NN NN B-CHEM
- : : I-CHEM
TC NNP NNP I-CHEM
and CC CC O
DFO NNP NNP B-CHEM
attenuated VBD VBD O
the DT DT O
MA NNP NNP B-CHEM
- - - O
induced JJ JJ O
hyperthermia NN NN O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
alterations NNS NNS O
in IN IN O
the DT DT O
locomotor NN NN O
activity NN NN O
. . . O

The DT DT O
level NN NN O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
was VBD VBD O
higher JJR JJR O
and CC CC O
the DT DT O
reduced JJ JJ O
glutathione NN NN B-CHEM
concentration NN NN O
was VBD VBD O
lower JJR JJR O
in IN IN O
the DT DT O
MA NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
. . . O

These DT DT O
changes NNS NNS O
were VBD VBD O
significantly RB RB O
attenuated VBN VBN O
by IN IN O
alpha NN NN B-CHEM
- : : I-CHEM
TC NNP NNP I-CHEM
and CC CC O
DFO NNP NNP B-CHEM
. . . O

This DT DT O
suggests VBZ VBZ O
that IN IN O
alpha NN NN B-CHEM
- : : I-CHEM
TC NNP NNP I-CHEM
and CC CC O
DFO NNP NNP B-CHEM
ameliorate VBP VBP O
the DT DT O
MA NNP NNP B-CHEM
- - - O
induced JJ JJ O
neuronal NN NN O
damage NN NN O
by IN IN O
decreasing VBG VBG O
the DT DT O
level NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
. . . O

Blockade NNP NNP O
of IN IN O
both DT DT O
D NNP NNP O
- : : O
1 CD CD O
and CC CC O
D NNP NNP O
- : : O
2 CD CD O
dopamine NN NN B-CHEM
receptors NNS NNS O
may MD MD O
induce VB VB O
catalepsy NN NN O
in IN IN O
mice NN NN O
. . . O

1 CD CD O
. . . O

The DT DT O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
dopamine NN NN B-CHEM
antagonists NNS NNS O
has VBZ VBZ O
been VBN VBN O
tested VBN VBN O
and CC CC O
the DT DT O
possible JJ JJ O
dopamine NN NN B-CHEM
subtypes NNS NNS O
involved VBN VBN O
in IN IN O
catalepsy NN NN O
was VBD VBD O
determined VBN VBN O
. . . O

2 CD CD O
. . . O

Dopamine NNP NNP B-CHEM
antagonist NN NN O
fluphenazine NN NN B-CHEM
, , , O
D NNP NNP O
- : : O
1 CD CD O
antagonist NN NN O
SCH NNP NNP B-CHEM
23390 CD CD I-CHEM
or CC CC O
D NNP NNP O
- : : O
2 CD CD O
antagonist NN NN O
sulpiride NN NN B-CHEM
induced JJ JJ O
catalepsy NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
fluphenazine NN NN B-CHEM
and CC CC O
sulpiride NN NN B-CHEM
was VBD VBD O
dose JJ JJ O
- - - O
dependent NN NN O
. . . O

Combination NNP NNP O
of IN IN O
SCH NNP NNP B-CHEM
23390 CD CD I-CHEM
with IN IN O
sulpiride NN NN B-CHEM
did VBD VBD O
not RB RB O
induce VB VB O
catalepsy NN NN O
potentiation NN NN O
. . . O

3 CD CD O
. . . O

D NNP NNP O
- : : O
1 CD CD O
agonist NN NN O
SKF NNP NNP B-CHEM
38393 CD CD I-CHEM
or CC CC O
D NNP NNP O
- : : O
2 CD CD O
agonist NN NN O
quinpirole NN NN B-CHEM
decreased VBD VBD O
the DT DT O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
fluphenazine NN NN B-CHEM
, , , O
SCH NNP NNP B-CHEM
23390 CD CD I-CHEM
or CC CC O
sulpiride NN NN B-CHEM
. . . O

4 CD CD O
. . . O

Combination NNP NNP O
of IN IN O
SKF NNP NNP B-CHEM
38393 CD CD I-CHEM
with IN IN O
quinpirole NN NN B-CHEM
did VBD VBD O
not RB RB O
cause VB VB O
potentiated JJ JJ O
inhibitory NN NN O
effect NN NN O
on IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
dopamine NN NN B-CHEM
antagonists NNS NNS O
. . . O

5 CD CD O
. . . O

The DT DT O
data NNS NNS O
may MD MD O
indicate VB VB O
that IN IN O
although IN IN O
D NNP NNP O
- : : O
2 CD CD O
receptor NN NN O
blockade NN NN O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
catalepsy NN NN O
, , , O
the DT DT O
D NNP NNP O
- : : O
1 CD CD O
receptor NN NN O
may MD MD O
plan VB VB O
a DT DT O
role NN NN O
. . . O

Sustained NNP NNP O
clinical JJ JJ O
improvement NN NN O
of IN IN O
a DT DT O
patient NN NN O
with IN IN O
decompensated JJ JJ O
hepatitis NN NN O
B NNP NNP O
virus NN NN O
- - - O
related JJ JJ O
cirrhosis NNS NNS O
after IN IN O
treatment NN NN O
with IN IN O
lamivudine NN NN B-CHEM
monotherapy NN NN O
. . . O

Hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
infection NN NN O
, , , O
which WDT WDT O
causes VBZ VBZ O
liver NN NN O
cirrhosis NNS NNS O
and CC CC O
hepatocellular NN NN O
carcinoma NN NN O
, , , O
remains VBZ VBZ O
a DT DT O
major JJ JJ O
health NN NN O
problem NN NN O
in IN IN O
Asian JJ JJ O
countries NNS NNS O
. . . O

Recent JJ JJ O
development NN NN O
of IN IN O
vaccine NN NN O
for IN IN O
prevention NN NN O
is VBZ VBZ O
reported VBN VBN O
to TO TO O
be VB VB O
successful JJ JJ O
in IN IN O
reducing VBG VBG O
the DT DT O
size NN NN O
of IN IN O
chronically RB RB O
infected VBN VBN O
carriers NNS NNS O
, , , O
although IN IN O
the DT DT O
standard JJ JJ O
medical JJ JJ O
therapies NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
established VBN VBN O
up RP RP O
to TO TO O
now RB RB O
. . . O

In IN IN O
this DT DT O
report NN NN O
, , , O
we PRP PRP O
encountered VBD VBD O
a DT DT O
patient NN NN O
with IN IN O
decompensated VBN VBN O
HBV NNP NNP O
- - - O
related JJ JJ O
cirrhosis NNS NNS O
who WP WP O
exhibited VBD VBD O
the DT DT O
dramatic JJ JJ O
improvements NNS NNS O
after IN IN O
antiviral JJ JJ O
therapy NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
a DT DT O
50 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
. . . O

Previous JJ JJ O
conventional JJ JJ O
medical JJ JJ O
treatments NNS NNS O
were VBD VBD O
not RB RB O
effective JJ JJ O
for IN IN O
this DT DT O
patient NN NN O
, , , O
thus RB RB O
this DT DT O
patient NN NN O
had VBD VBD O
been VBN VBN O
referred VBN VBN O
to TO TO O
our PRP$ PRP$ O
hospital NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
administration NN NN O
of IN IN O
lamivudine NN NN B-CHEM
, , , O
a DT DT O
reverse NN NN O
transcriptase NN NN O
inhibitor NN NN O
, , , O
for IN IN O
23 CD CD O
months NNS NNS O
dramatically RB RB O
improved VBN VBN O
her PRP$ PRP$ O
liver NN NN O
severity NN NN O
. . . O

During IN IN O
this DT DT O
period NN NN O
, , , O
no DT DT O
drug NN NN O
resistant JJ JJ O
mutant NN NN O
HBV NNP NNP O
emerged VBD VBD O
, , , O
and CC CC O
the DT DT O
serum NN NN O
HBV NNP NNP O
- : : O
DNA NNP NNP O
level NN NN O
was VBD VBD O
continuously RB RB O
suppressed VBN VBN O
. . . O

These DT DT O
virological JJ JJ O
responses NNS NNS O
were VBD VBD O
also RB RB O
maintained VBN VBN O
even RB RB O
after IN IN O
the DT DT O
antiviral NN NN O
therapy NN NN O
was VBD VBD O
discontinued VBN VBN O
. . . O

Moreover RB RB O
, , , O
both DT DT O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
and CC CC I-CHEM
e SYM SYM I-CHEM
antigen NN NN I-CHEM
were VBD VBD O
observed VBN VBN O
to TO TO O
have VB VB O
disappeared VBN VBN O
in IN IN O
this DT DT O
patient NN NN O
. . . O

The DT DT O
administration NN NN O
of IN IN O
lamivudine NN NN B-CHEM
to TO TO O
patients NNS NNS O
with IN IN O
HBV NNP NNP O
- - - O
related JJ JJ O
cirrhosis NNS NNS O
, , , O
like IN IN O
our PRP$ PRP$ O
present JJ JJ O
case NN NN O
, , , O
should MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
an DT DT O
initial JJ JJ O
medical JJ JJ O
therapeutic JJ JJ O
option NN NN O
, , , O
especially RB RB O
in IN IN O
countries NNS NNS O
where WRB WRB O
liver NN NN O
transplantation NN NN O
is VBZ VBZ O
not RB RB O
reliably RB RB O
available JJ JJ O
. . . O

Antiarrhythmic NNP NNP O
effects NNS NNS O
of IN IN O
optical JJ JJ O
isomers NNS NNS O
of IN IN O
cibenzoline NN NN B-CHEM
on IN IN O
canine NN NN O
ventricular NN NN O
arrhythmias NNS NNS O
. . . O

Antiarrhythmic NNP NNP O
effects NNS NNS O
of IN IN O
( ( ( O
+ NN NN O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
and CC CC O
( ( ( O
- : : O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
were VBD VBD O
examined VBN VBN O
using VBG VBG O
two CD CD O
canine NN NN O
ventricular NN NN O
arrhythmia NN NN O
models NNS NNS O
. . . O

Digitalis NNP NNP B-CHEM
arrhythmia NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
suppressed VBN VBN O
by IN IN O
Na NNP NNP B-CHEM
channel NN NN O
blockers NNS NNS O
, , , O
was VBD VBD O
induced VBN VBN O
by IN IN O
intermittent JJ JJ O
intravenous JJ JJ O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
injection NN NN O
of IN IN O
ouabain NN NN B-CHEM
in IN IN O
pentobarbital JJ JJ B-CHEM
- - - O
anesthetized JJ JJ O
dogs NNS NNS O
. . . O

Adrenaline NNP NNP O
arrhythmia NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
suppressed VBN VBN O
by IN IN O
Ca MD MD B-CHEM
channel NN NN O
blockers NNS NNS O
, , , O
was VBD VBD O
induced VBN VBN O
by IN IN O
adrenaline NN NN B-CHEM
infusion NN NN O
in IN IN O
halothane NN NN B-CHEM
- - - O
anesthetized JJ JJ O
dogs NNS NNS O
. . . O

Ten CD CD O
and CC CC O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
( ( ( O
+ NN NN O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
suppressed VBD VBD O
digitalis NNS NNS B-CHEM
- : : O
and CC CC O
adrenaline JJ JJ B-CHEM
- - - O
induced JJ JJ O
arrhythmias NNS NNS O
, , , O
respectively RB RB O
. . . O

The DT DT O
minimum JJ JJ O
effective JJ JJ O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
( ( ( O
+ NN NN O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
for IN IN O
digitalis NNS NNS B-CHEM
- : : O
and CC CC O
adrenaline JJ JJ B-CHEM
- - - O
induced JJ JJ O
arrhythmias NNS NNS O
were VBD VBD O
1 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
4 CD CD O
and CC CC O
2 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
micrograms NNS NNS O
/ NN NN O
ml NN NN O
, , , O
respectively RB RB O
( ( ( O
mean VB VB O
+ NN NN O
/ NN NN O
- : : O
SD NNP NNP O
, , , O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
. . . O

A DT DT O
lower JJR JJR O
dose NN NN O
of IN IN O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
of IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
suppressed VBD VBD O
the DT DT O
digitalis NNS NNS B-CHEM
- - - O
induced JJ JJ O
arrhythmia NN NN O
, , , O
whereas IN IN O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
was VBD VBD O
needed VBN VBN O
to TO TO O
suppress VB VB O
adrenaline NN NN B-CHEM
- : : O
induced JJ JJ O
arrhythmias NNS NNS O
. . . O

The DT DT O
minimum JJ JJ O
effective JJ JJ O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
for IN IN O
digitalis NNS NNS B-CHEM
- : : O
and CC CC O
adrenaline JJ JJ B-CHEM
- - - O
induced JJ JJ O
arrhythmia NN NN O
were VBD VBD O
0 CD CD O
. . . O
06 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
04 CD CD O
and CC CC O
0 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
micrograms NNS NNS O
/ NN NN O
ml NN NN O
, , , O
respectively RB RB O
( ( ( O
mean VB VB O
+ NN NN O
/ NN NN O
- : : O
SD NNP NNP O
, , , O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
. . . O

The DT DT O
stronger JJR JJR O
antiarrhythmic JJ JJ O
effect NN NN O
of IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
cibenzoline NN NN B-CHEM
indicates VBZ VBZ O
that IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
isomer NN NN O
may MD MD O
have VB VB O
an DT DT O
effect NN NN O
nearly RB RB O
5 CD CD O
- : : O
20 CD CD O
times NNS NNS O
stronger JJR JJR O
in IN IN O
suppressing VBG VBG O
Na NNP NNP B-CHEM
channels NNS NNS O
, , , O
but CC CC O
effects NNS NNS O
of IN IN O
both DT DT O
drugs NNS NNS O
on IN IN O
Ca NNP NNP B-CHEM
channels NNS NNS O
may MD MD O
be VB VB O
almost RB RB O
equipotent NN NN O
. . . O

Passage NNP NNP O
of IN IN O
mannitol NN NN B-CHEM
into IN IN O
the DT DT O
brain NN NN O
around IN IN O
gliomas NN NN O
: : : O
a DT DT O
potential JJ JJ O
cause NN NN O
of IN IN O
rebound NN NN O
phenomenon NN NN O
. . . O

A DT DT O
study NN NN O
on IN IN O
21 CD CD O
patients NNS NNS O
. . . O

AIM NNP NNP O
: : : O
Widespread NNP NNP O
use NN NN O
of IN IN O
mannitol NN NN B-CHEM
to TO TO O
reduce VB VB O
brain NN NN O
edema NN NN O
and CC CC O
lower JJR JJR O
elevated VBD VBD O
ICP NNP NNP O
in IN IN O
brain NN NN O
tumor NN NN O
patients NNS NNS O
continues VBZ VBZ O
to TO TO O
be VB VB O
afflicted VBN VBN O
by IN IN O
the DT DT O
so RB RB O
- - - O
called VBN VBN O
rebound NN NN O
phenomenon NN NN O
. . . O

Leakage NNP NNP O
of IN IN O
mannitol NN NN B-CHEM
into IN IN O
the DT DT O
brain NN NN O
parenchyma NN NN O
through IN IN O
an DT DT O
altered VBN VBN O
BBB NNP NNP O
and CC CC O
secondary JJ JJ O
reversal NN NN O
of IN IN O
osmotic JJ JJ O
gradient NN NN O
is VBZ VBZ O
considered VBN VBN O
the DT DT O
major JJ JJ O
cause NN NN O
of IN IN O
rebound NN NN O
. . . O

This DT DT O
has VBZ VBZ O
only RB RB O
been VBN VBN O
demonstrated VBN VBN O
experimentally RB RB O
in IN IN O
animals NNS NNS O
. . . O

As IN IN O
a DT DT O
contribution NN NN O
to TO TO O
this DT DT O
issue NN NN O
we PRP PRP O
decided VBD VBD O
to TO TO O
research VB VB O
the DT DT O
possible JJ JJ O
passage NN NN O
of IN IN O
mannitol NN NN B-CHEM
into IN IN O
the DT DT O
brain NN NN O
after IN IN O
administration NN NN O
to TO TO O
21 CD CD O
brain NN NN O
tumor NN NN O
patients NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Mannitol NNP NNP B-CHEM
( ( ( O
18 CD CD O
% NN NN O
solution NN NN O
; : : O
1 CD CD O
g SYM SYM O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
as IN IN O
a DT DT O
bolus NN NN O
to TO TO O
patients NNS NNS O
( ( ( O
ten CD CD O
had VBD VBD O
malignant JJ JJ O
glioma NN NN O
, , , O
seven CD CD O
brain NN NN O
metastases NNS NNS O
and CC CC O
four CD CD O
meningioma NN NN O
) ) ) O
about IN IN O
30 CD CD O
minutes NNS NNS O
before IN IN O
craniotomy NN NN O
. . . O

During IN IN O
resection NN NN O
, , , O
a DT DT O
sample NN NN O
of IN IN O
the DT DT O
surrounding VBG VBG O
edematous JJ JJ O
white JJ JJ O
matter NN NN O
was VBD VBD O
taken VBN VBN O
at IN IN O
the DT DT O
same JJ JJ O
time NN NN O
as IN IN O
a DT DT O
10 CD CD O
ml NN NN O
venous JJ JJ O
blood NN NN O
sample NN NN O
. . . O

Mannitol NNP NNP B-CHEM
concentrations NNS NNS O
were VBD VBD O
measured VBN VBN O
in IN IN O
plasma NN NN O
and CC CC O
white JJ JJ O
matter NN NN O
by IN IN O
a DT DT O
modified VBN VBN O
version NN NN O
of IN IN O
the DT DT O
enzyme NN NN O
assay NN NN O
of IN IN O
Blonquist NNP NNP O
et CC CC O
al NN NN O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
most JJS JJS O
glioma NN NN O
patients NNS NNS O
, , , O
mannitol NN NN B-CHEM
concentrations NNS NNS O
in IN IN O
white JJ JJ O
matter NN NN O
were VBD VBD O
2 CD CD O
to TO TO O
6 CD CD O
times NNS NNS O
higher JJR JJR O
than IN IN O
in IN IN O
plasma NN NN O
( ( ( O
mean NN NN O
3 CD CD O
. . . O
5 CD CD O
times NNS NNS O
) ) ) O
. . . O

In IN IN O
meningioma NN NN O
and CC CC O
metastases NNS NNS O
patients NNS NNS O
plasma VBP VBP O
concentrations NNS NNS O
of IN IN O
mannitol NN NN B-CHEM
were VBD VBD O
higher JJR JJR O
than IN IN O
white JJ JJ O
matter NN NN O
concentrations NNS NNS O
except IN IN O
in IN IN O
three CD CD O
cases NNS NNS O
with IN IN O
infiltration NN NN O
by IN IN O
neoplastic JJ JJ O
cells NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
results NNS NNS O
of IN IN O
our PRP$ PRP$ O
study NN NN O
show NN NN O
that IN IN O
even RB RB O
after IN IN O
a DT DT O
single JJ JJ O
bolus NN NN O
, , , O
mannitol NN NN B-CHEM
may MD MD O
leak VB VB O
through IN IN O
the DT DT O
altered VBN VBN O
BBB NNP NNP O
near IN IN O
gliomas NNS NNS O
, , , O
reversing VBG VBG O
the DT DT O
initial JJ JJ O
plasma NN NN O
- - - O
to TO TO O
- - - O
blood NN NN O
osmotic JJ JJ O
gradient NN NN O
, , , O
aggravating VBG VBG O
peritumoral JJ JJ O
edema NN NN O
and CC CC O
promoting VBG VBG O
rebound NN NN O
of IN IN O
ICP NNP NNP O
. . . O

Placebo NNP NNP O
- - - O
level NN NN O
incidence NN NN O
of IN IN O
extrapyramidal NN NN O
symptoms NNS NNS O
( ( ( O
EPS NNP NNP O
) ) ) O
with IN IN O
quetiapine NN NN B-CHEM
in IN IN O
controlled VBN VBN O
studies NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
bipolar NN NN O
mania NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
extrapyramidal NN NN O
symptoms NNS NNS O
( ( ( O
EPS NNP NNP O
) ) ) O
, , , O
including VBG VBG O
akathisia NN NN O
, , , O
with IN IN O
quetiapine NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
bipolar NN NN O
mania NN NN O
. . . O

METHODS NNP NNP O
: : : O
Data NNP NNP O
were VBD VBD O
analyzed VBN VBN O
from IN IN O
four CD CD O
similarly RB RB O
designed VBN VBN O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
3 CD CD O
- : : O
to TO TO O
12 CD CD O
- : : O
week NN NN O
studies NNS NNS O
. . . O

Two CD CD O
studies NNS NNS O
evaluated VBD VBD O
quetiapine NN NN B-CHEM
monotherapy NN NN O
( ( ( O
up IN IN O
to TO TO O
800 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
( ( ( O
n NN NN O
= SYM SYM O
209 CD CD O
) ) ) O
versus CC CC O
placebo NN NN O
( ( ( O
n NN NN O
= SYM SYM O
198 CD CD O
) ) ) O
, , , O
with IN IN O
lithium NN NN B-CHEM
or CC CC O
haloperidol NN NN B-CHEM
monotherapy NN NN O
as IN IN O
respective JJ JJ O
active JJ JJ O
controls NNS NNS O
. . . O

Two CD CD O
studies NNS NNS O
evaluated VBD VBD O
quetiapine NN NN B-CHEM
( ( ( O
up IN IN O
to TO TO O
800 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
in IN IN O
combination NN NN O
with IN IN O
a DT DT O
mood NN NN O
stabilizer NN NN O
( ( ( O
lithium NN NN B-CHEM
or CC CC O
divalproex NN NN B-CHEM
, , , O
QTP NNP NNP B-CHEM
+ NN NN O
Li NNP NNP B-CHEM
/ NN NN O
DVP NNP NNP B-CHEM
) ) ) O
( ( ( O
n NN NN O
= SYM SYM O
196 CD CD O
) ) ) O
compared VBN VBN O
to TO TO O
placebo NN NN O
and CC CC O
mood NN NN O
stabilizer NN NN O
( ( ( O
PBO NNP NNP O
+ NN NN O
Li NNP NNP B-CHEM
/ NN NN O
DVP NNP NNP B-CHEM
) ) ) O
( ( ( O
n NN NN O
= SYM SYM O
203 CD CD O
) ) ) O
. . . O

Extrapyramidal NNP NNP O
symptoms NNS NNS O
were VBD VBD O
evaluated VBN VBN O
using VBG VBG O
the DT DT O
Simpson NNP NNP O
- : : O
Angus NNP NNP O
Scale NNP NNP O
( ( ( O
SAS NNP NNP O
) ) ) O
, , , O
the DT DT O
Barnes NNP NNP O
Akathisia NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
( ( ( O
BARS NNP NNP O
) ) ) O
, , , O
adverse JJ JJ O
event NN NN O
reports NNS NNS O
and CC CC O
anticholinergic JJ JJ O
drug NN NN O
usage NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
incidence NN NN O
of IN IN O
EPS NNP NNP O
- - - O
related JJ JJ O
adverse JJ JJ O
events NNS NNS O
, , , O
including VBG VBG O
akathisia NN NN O
, , , O
was VBD VBD O
no DT DT O
different JJ JJ O
with IN IN O
quetiapine NN NN B-CHEM
monotherapy NN NN O
( ( ( O
12 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
than IN IN O
with IN IN O
placebo NN NN O
( ( ( O
13 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
. . . O

Similarly RB RB O
, , , O
EPS NNP NNP O
- - - O
related JJ JJ O
adverse JJ JJ O
events NNS NNS O
with IN IN O
QTP NNP NNP B-CHEM
+ NN NN O
Li NNP NNP B-CHEM
/ NN NN O
DVP NNP NNP B-CHEM
( ( ( O
21 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
no DT DT O
different JJ JJ O
than IN IN O
with IN IN O
PBO NNP NNP O
+ NN NN O
Li NNP NNP B-CHEM
/ NN NN O
DVP NNP NNP B-CHEM
( ( ( O
19 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
. . . O

Adverse NNP NNP O
events NNS NNS O
related VBN VBN O
to TO TO O
EPS NNP NNP O
occurred VBD VBD O
in IN IN O
59 CD CD O
. . . O
6 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
haloperidol NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
99 CD CD O
) ) ) O
monotherapy NN NN O
, , , O
whereas IN IN O
26 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
lithium NN NN B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
98 CD CD O
) ) ) O
monotherapy NN NN O
experienced VBD VBD O
adverse JJ JJ O
events NNS NNS O
related VBN VBN O
to TO TO O
EPS NNP NNP O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
akathisia NN NN O
was VBD VBD O
low JJ JJ O
and CC CC O
similar JJ JJ O
with IN IN O
quetiapine NN NN B-CHEM
monotherapy NN NN O
( ( ( O
3 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
and CC CC O
placebo NN NN O
( ( ( O
6 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
with IN IN O
QTP NNP NNP B-CHEM
+ NN NN O
Li NNP NNP B-CHEM
/ NN NN O
DVP NNP NNP B-CHEM
( ( ( O
3 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
and CC CC O
PBO NNP NNP O
+ NN NN O
Li NNP NNP B-CHEM
/ NN NN O
DVP NNP NNP B-CHEM
( ( ( O
4 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
. . . O

Lithium NNP NNP B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
significantly RB RB O
higher JJR JJR O
incidence NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
of IN IN O
tremor NN NN O
( ( ( O
18 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
than IN IN O
quetiapine NN NN B-CHEM
( ( ( O
5 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
; : : O
cerebellar NN NN O
tremor NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
a DT DT O
known VBN VBN O
adverse JJ JJ O
effect NN NN O
of IN IN O
lithium NN NN B-CHEM
, , , O
may MD MD O
have VB VB O
contributed VBN VBN O
to TO TO O
the DT DT O
elevated JJ JJ O
rate NN NN O
of IN IN O
tremor NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
lithium NN NN B-CHEM
therapy NN NN O
. . . O

Haloperidol NNP NNP B-CHEM
induced VBD VBD O
a DT DT O
significantly RB RB O
higher JJR JJR O
incidence NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
of IN IN O
akathisia NN NN O
( ( ( O
33 CD CD O
. . . O
3 CD CD O
% NN NN O
versus CC CC O
5 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
, , , O
tremor NN NN O
( ( ( O
30 CD CD O
. . . O
3 CD CD O
% NN NN O
versus CC CC O
7 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
extrapyramidal NN NN O
syndrome NN NN O
( ( ( O
35 CD CD O
. . . O
4 CD CD O
% NN NN O
versus CC CC O
5 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
than IN IN O
quetiapine NN NN B-CHEM
. . . O

No DT DT O
significant JJ JJ O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
quetiapine NN NN B-CHEM
and CC CC O
placebo NN NN O
on IN IN O
SAS NNP NNP O
and CC CC O
BARS NNP NNP O
scores NNS NNS O
. . . O

Anticholinergic NNP NNP O
use NN NN O
was VBD VBD O
low JJ JJ O
and CC CC O
similar JJ JJ O
with IN IN O
quetiapine NN NN B-CHEM
or CC CC O
placebo NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
bipolar NN NN O
mania NN NN O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
EPS NNP NNP O
, , , O
including VBG VBG O
akathisia NN NN O
, , , O
with IN IN O
quetiapine NN NN B-CHEM
therapy NN NN O
is VBZ VBZ O
similar JJ JJ O
to TO TO O
that DT DT O
with IN IN O
placebo NN NN O
. . . O

Is VBZ VBZ O
phenytoin NN NN B-CHEM
administration NN NN O
safe JJ JJ O
in IN IN O
a DT DT O
hypothermic JJ JJ O
child NN NN O
? . . O

A DT DT O
male JJ JJ O
neonate NN NN O
with IN IN O
a DT DT O
Chiari NNP NNP O
malformation NN NN O
and CC CC O
a DT DT O
leaking VBG VBG O
myelomeningocoele NN NN O
underwent JJ JJ O
ventriculoperitoneal NN NN O
shunt NN NN O
insertion NN NN O
followed VBN VBN O
by IN IN O
repair NN NN O
of IN IN O
myelomeningocoele NN NN O
. . . O

During IN IN O
anaesthesia NN NN O
and CC CC O
surgery NN NN O
, , , O
he PRP PRP O
inadvertently RB RB O
became VBD VBD O
moderately RB RB O
hypothermic JJ JJ O
. . . O

Intravenous NNP NNP O
phenytoin NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
during IN IN O
the DT DT O
later JJ JJ O
part NN NN O
of IN IN O
the DT DT O
surgery NN NN O
for IN IN O
seizure NN NN O
prophylaxis NN NN O
. . . O

Following VBG VBG O
phenytoin NN NN B-CHEM
administration NN NN O
, , , O
the DT DT O
patient NN NN O
developed VBN VBN O
acute JJ JJ O
severe JJ JJ O
bradycardia NNS NNS O
, , , O
refractory NN NN O
to TO TO O
atropine VB VB B-CHEM
and CC CC O
adrenaline VB VB B-CHEM
. . . O

The DT DT O
cardiac JJ JJ O
depressant NN NN O
actions NNS NNS O
of IN IN O
phenytoin NN NN B-CHEM
and CC CC O
hypothermia NN NN O
can MD MD O
be VB VB O
additive JJ JJ O
. . . O

Administration NNP NNP O
of IN IN O
phenytoin NN NN B-CHEM
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
hypothermia NN NN O
may MD MD O
lead VB VB O
to TO TO O
an DT DT O
adverse JJ JJ O
cardiac JJ JJ O
event NN NN O
in IN IN O
children NNS NNS O
. . . O

As IN IN O
phenytoin NN NN B-CHEM
is VBZ VBZ O
a DT DT O
commonly RB RB O
used VBN VBN O
drug NN NN O
, , , O
clinicians NNS NNS O
need VBP VBP O
to TO TO O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
interaction NN NN O
. . . O

Valproate NNP NNP B-CHEM
- : : O
induced JJ JJ O
chorea NN NN O
and CC CC O
encephalopathy NN NN O
in IN IN O
atypical JJ JJ O
nonketotic JJ JJ O
hyperglycinemia NN NN O
. . . O

Nonketotic NNP NNP O
hyperglycinemia NN NN O
is VBZ VBZ O
a DT DT O
disorder NN NN O
of IN IN O
amino JJ JJ O
acid NN NN O
metabolism NN NN O
in IN IN O
which WDT WDT O
a DT DT O
defect NN NN O
in IN IN O
the DT DT O
glycine NN NN B-CHEM
cleavage NN NN O
system NN NN O
leads VBZ VBZ O
to TO TO O
an DT DT O
accumulation NN NN O
of IN IN O
glycine NN NN B-CHEM
in IN IN O
the DT DT O
brain NN NN O
and CC CC O
other JJ JJ O
body NN NN O
compartments NNS NNS O
. . . O

In IN IN O
the DT DT O
classical JJ JJ O
form NN NN O
it PRP PRP O
presents VBZ VBZ O
as IN IN O
neonatal JJ JJ O
apnea NN NN O
, , , O
intractable JJ JJ O
seizures NNS NNS O
, , , O
and CC CC O
hypotonia NN NN O
, , , O
followed VBN VBN O
by IN IN O
significant JJ JJ O
psychomotor NN NN O
retardation NN NN O
. . . O

An DT DT O
important JJ JJ O
subset NN NN O
of IN IN O
children NNS NNS O
with IN IN O
nonketotic JJ JJ O
hyperglycinemia NN NN O
are VBP VBP O
atypical JJ JJ O
variants NNS NNS O
who WP WP O
present JJ JJ O
in IN IN O
a DT DT O
heterogeneous JJ JJ O
manner NN NN O
. . . O

This DT DT O
report NN NN O
describes VBZ VBZ O
a DT DT O
patient NN NN O
with IN IN O
mild JJ JJ O
language NN NN O
delay NN NN O
and CC CC O
mental JJ JJ O
retardation NN NN O
, , , O
who WP WP O
was VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
nonketotic JJ JJ O
hyperglycinemia NN NN O
following VBG VBG O
her PRP$ PRP$ O
presentation NN NN O
with IN IN O
acute JJ JJ O
encephalopathy NN NN O
and CC CC O
chorea NN NN O
shortly RB RB O
after IN IN O
initiation NN NN O
of IN IN O
valproate NN NN B-CHEM
therapy NN NN O
. . . O

Delayed NNP NNP O
institution NN NN O
of IN IN O
hypertension NN NN O
during IN IN O
focal JJ JJ O
cerebral NN NN O
ischemia NN NN O
: : : O
effect NN NN O
on IN IN O
brain NN NN O
edema NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
induced JJ JJ O
hypertension NN NN O
instituted VBD VBD O
after IN IN O
a DT DT O
2 CD CD O
- : : O
h NN NN O
delay NN NN O
following VBG VBG O
middle JJ JJ O
cerebral JJ JJ O
artery NN NN O
occlusion NN NN O
( ( ( O
MCAO NNP NNP O
) ) ) O
on IN IN O
brain NN NN O
edema NN NN O
formation NN NN O
and CC CC O
histochemical JJ JJ O
injury NN NN O
was VBD VBD O
studied VBN VBN O
. . . O

Under IN IN O
isoflurane JJ JJ B-CHEM
anesthesia NN NN O
, , , O
the DT DT O
MCA NNP NNP O
of IN IN O
14 CD CD O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
was VBD VBD O
occluded VBN VBN O
. . . O

In IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
, , , O
the DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
was VBD VBD O
not RB RB O
manipulated VBN VBN O
. . . O

In IN IN O
the DT DT O
hypertensive JJ JJ O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
, , , O
the DT DT O
MAP NNP NNP O
was VBD VBD O
elevated VBN VBN O
by IN IN O
25 CD CD O
- : : O
30 CD CD O
mm NN NN O
Hg NNP NNP O
beginning VBG VBG O
2 CD CD O
h NN NN O
after IN IN O
MCAO NNP NNP O
. . . O

Four CD CD O
hours NNS NNS O
after IN IN O
MCAO NNP NNP O
, , , O
the DT DT O
rats NNS NNS O
were VBD VBD O
killed VBN VBN O
and CC CC O
the DT DT O
brains NNS NNS O
harvested VBN VBN O
. . . O

The DT DT O
brains NNS NNS O
were VBD VBD O
sectioned VBN VBN O
along IN IN O
coronal JJ JJ O
planes NNS NNS O
spanning VBG VBG O
the DT DT O
distribution NN NN O
of IN IN O
ischemia NN NN O
produced VBN VBN O
by IN IN O
MCAO NNP NNP O
. . . O

Specific JJ JJ O
gravity NN NN O
( ( ( O
SG NNP NNP O
) ) ) O
was VBD VBD O
determined VBN VBN O
in IN IN O
the DT DT O
subcortex NN NN O
and CC CC O
in IN IN O
two CD CD O
sites NNS NNS O
in IN IN O
the DT DT O
cortex NN NN O
( ( ( O
core NN NN O
and CC CC O
periphery NN NN O
of IN IN O
the DT DT O
ischemic JJ JJ O
territory NN NN O
) ) ) O
. . . O

The DT DT O
extent NN NN O
of IN IN O
neuronal JJ JJ O
injury NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
2 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
triphenyltetrazolium NN NN I-CHEM
staining VBG VBG O
. . . O

In IN IN O
the DT DT O
ischemic JJ JJ O
core NN NN O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
difference NN NN O
in IN IN O
SG NNP NNP O
in IN IN O
the DT DT O
subcortex NN NN O
and CC CC O
cortex NN NN O
in IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

In IN IN O
the DT DT O
periphery NN NN O
of IN IN O
the DT DT O
ischemic JJ JJ O
territory NN NN O
, , , O
SG NNP NNP O
in IN IN O
the DT DT O
cortex NN NN O
was VBD VBD O
greater JJR JJR O
( ( ( O
less RBR RBR O
edema NN NN O
accumulation NN NN O
) ) ) O
in IN IN O
the DT DT O
hypertensive JJ JJ O
group NN NN O
( ( ( O
1 CD CD O
. . . O
041 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
001 CD CD O
vs NNS NNS O
1 CD CD O
. . . O
039 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
001 CD CD O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
area NN NN O
of IN IN O
histochemical JJ JJ O
injury NN NN O
( ( ( O
as IN IN O
a DT DT O
percent NN NN O
of IN IN O
the DT DT O
cross NN NN O
- - - O
sectional JJ JJ O
area NN NN O
of IN IN O
the DT DT O
hemisphere NN NN O
) ) ) O
was VBD VBD O
less JJR JJR O
in IN IN O
the DT DT O
hypertensive JJ JJ O
group NN NN O
( ( ( O
33 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
% NN NN O
vs NNS NNS O
21 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
% NN NN O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
phenylephrine NN NN B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
instituted VBD VBD O
2 CD CD O
h NN NN O
after IN IN O
MCAO NNP NNP O
does VBZ VBZ O
not RB RB O
aggravate VB VB O
edema NN NN O
in IN IN O
the DT DT O
ischemic JJ JJ O
core NN NN O
, , , O
that IN IN O
it PRP PRP O
improves VBZ VBZ O
edema NN NN O
in IN IN O
the DT DT O
periphery NN NN O
of IN IN O
the DT DT O
ischemic JJ JJ O
territory NN NN O
, , , O
and CC CC O
that IN IN O
it PRP PRP O
reduces VBZ VBZ O
the DT DT O
area NN NN O
of IN IN O
histochemical JJ JJ O
neuronal NN NN O
dysfunction NN NN O
. . . O

Behavioral NNP NNP O
effects NNS NNS O
of IN IN O
pubertal JJ JJ O
anabolic JJ JJ O
androgenic JJ JJ O
steroid JJ JJ B-CHEM
exposure NN NN O
in IN IN O
male JJ JJ O
rats NNS NNS O
with IN IN O
low JJ JJ O
serotonin NN NN B-CHEM
. . . O

The DT DT O
goal NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
interactive JJ JJ O
effects NNS NNS O
of IN IN O
chronic JJ JJ O
anabolic JJ JJ O
androgenic JJ JJ O
steroid NN NN B-CHEM
( ( ( O
AAS NNP NNP O
) ) ) O
exposure NN NN O
and CC CC O
brain NN NN O
serotonin NN NN B-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine NN NN I-CHEM
, , , O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
) ) ) O
depletion NN NN O
on IN IN O
behavior NN NN O
of IN IN O
pubertal JJ JJ O
male NN NN O
rats NNS NNS O
. . . O

Serotonin NNP NNP B-CHEM
was VBD VBD O
depleted VBN VBN O
beginning VBG VBG O
on IN IN O
postnatal NN NN O
day NN NN O
26 CD CD O
with IN IN O
parachlorophenylalanine NN NN B-CHEM
( ( ( O
PCPA NNP NNP B-CHEM
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
every DT DT O
other JJ JJ O
day NN NN O
) ) ) O
; : : O
controls NNS NNS O
received VBD VBD O
saline NN NN O
. . . O

At IN IN O
puberty NN NN O
( ( ( O
P40 NNP NNP O
) ) ) O
, , , O
half PDT PDT O
the DT DT O
PCPA NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
and CC CC O
half PDT PDT O
the DT DT O
saline NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
began VBD VBD O
treatment NN NN O
with IN IN O
testosterone NN NN B-CHEM
( ( ( O
T NN NN B-CHEM
, , , O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
5 CD CD O
days NNS NNS O
/ NN NN O
week NN NN O
) ) ) O
. . . O

Behavioral NNP NNP O
measures NNS NNS O
included VBN VBN O
locomotion NN NN O
, , , O
irritability NN NN O
, , , O
copulation NN NN O
, , , O
partner NN NN O
preference NN NN O
, , , O
and CC CC O
aggression NN NN O
. . . O

Animals NNS NNS O
were VBD VBD O
tested VBN VBN O
for IN IN O
aggression NN NN O
in IN IN O
their PRP$ PRP$ O
home NN NN O
cage NN NN O
, , , O
both DT DT O
with IN IN O
and CC CC O
without IN IN O
physical JJ JJ O
provocation NN NN O
( ( ( O
mild JJ JJ O
tail NN NN O
pinch NN NN O
) ) ) O
. . . O

Brain NNP NNP O
levels NNS NNS O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
and CC CC O
its PRP$ PRP$ O
metabolite NN NN O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
hydroxyindoleacetic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HIAA NNP NNP I-CHEM
) ) ) O
, , , O
were VBD VBD O
determined VBN VBN O
using VBG VBG O
HPLC NNP NNP O
. . . O

PCPA NNP NNP B-CHEM
significantly RB RB O
and CC CC O
substantially RB RB O
depleted VBN VBN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
HIAA NNP NNP I-CHEM
in IN IN O
all DT DT O
brain NN NN O
regions NNS NNS O
examined VBD VBD O
. . . O

Chronic NNP NNP O
T NN NN B-CHEM
treatment NN NN O
significantly RB RB O
decreased VBD VBD O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
HIAA NNP NNP I-CHEM
in IN IN O
certain JJ JJ O
brain NN NN O
areas NNS NNS O
, , , O
but CC CC O
to TO TO O
a DT DT O
much JJ JJ O
lesser JJR JJR O
extent NN NN O
than IN IN O
PCPA NNP NNP B-CHEM
. . . O

Chronic JJ JJ O
exposure NN NN O
to TO TO O
PCPA NNP NNP B-CHEM
alone RB RB O
significantly RB RB O
decreased VBN VBN O
locomotor NN NN O
activity NN NN O
and CC CC O
increased VBN VBN O
irritability NN NN O
but CC CC O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
sexual JJ JJ O
behavior NN NN O
, , , O
partner NN NN O
preference NN NN O
, , , O
or CC CC O
aggression NN NN O
. . . O

T NN NN B-CHEM
alone RB RB O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
locomotion NN NN O
, , , O
irritability NN NN O
, , , O
or CC CC O
sexual JJ JJ O
behavior NN NN O
but CC CC O
increased VBN VBN O
partner NN NN O
preference NN NN O
and CC CC O
aggression NN NN O
. . . O

The DT DT O
most RBS RBS O
striking JJ JJ O
effect NN NN O
of IN IN O
combining VBG VBG O
T NN NN B-CHEM
+ NN NN O
PCPA NNP NNP B-CHEM
was VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
attack NN NN O
frequency NN NN O
as RB RB O
well RB RB O
as IN IN O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
latency NN NN O
to TO TO O
attack VB VB O
, , , O
particularly RB RB O
following VBG VBG O
physical JJ JJ O
provocation NN NN O
. . . O

Based VBN VBN O
on IN IN O
these DT DT O
data NNS NNS O
, , , O
it PRP PRP O
can MD MD O
be VB VB O
speculated VBN VBN O
that IN IN O
pubertal JJ JJ O
AAS NNP NNP O
users NNS NNS O
with IN IN O
low JJ JJ O
central JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
may MD MD O
be VB VB O
especially RB RB O
prone NN NN O
to TO TO O
exhibit VB VB O
aggressive JJ JJ O
behavior NN NN O
. . . O

Effects NNP NNP O
of IN IN O
UMB24 NNP NNP B-CHEM
and CC CC O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
SM NNP NNP B-CHEM
21 CD CD I-CHEM
, , , O
putative JJ JJ O
sigma2 NN NN O
- - - O
preferring VBG VBG O
antagonists NNS NNS O
, , , O
on IN IN O
behavioral JJ JJ O
toxic JJ JJ O
and CC CC O
stimulant JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
in IN IN O
mice NN NN O
. . . O

Earlier RBR RBR O
studies NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
that DT DT O
antagonism NN NN O
of IN IN O
sigma1 NN NN O
receptors NNS NNS O
attenuates NNS NNS O
the DT DT O
convulsive JJ JJ O
, , , O
lethal NN NN O
, , , O
locomotor NN NN O
stimulatory NN NN O
and CC CC O
rewarding VBG VBG O
actions NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
in IN IN O
mice NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
contribution NN NN O
of IN IN O
sigma2 NN NN O
receptors NNS NNS O
is VBZ VBZ O
unclear JJ JJ O
because IN IN O
experimental JJ JJ O
tools NNS NNS O
to TO TO O
selectively RB RB O
target VB VB O
this DT DT O
subtype NN NN O
are VBP VBP O
unavailable JJ JJ O
. . . O

To TO TO O
begin VB VB O
addressing VBG VBG O
this DT DT O
need NN NN O
, , , O
we PRP PRP O
characterized VBD VBD O
UMB24 NNP NNP B-CHEM
( ( ( O
1 CD CD B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
phenethyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
pyridyl NN NN I-CHEM
) ) ) I-CHEM
- - - I-CHEM
piperazine NN NN I-CHEM
) ) ) O
and CC CC O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
SM NNP NNP B-CHEM
21 CD CD I-CHEM
( ( ( O
3alpha CD CD B-CHEM
- : : I-CHEM
tropanyl NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
chorophenoxy NN NN I-CHEM
) ) ) I-CHEM
butyrate NN NN I-CHEM
) ) ) O
in IN IN O
receptor NN NN O
binding JJ JJ O
and CC CC O
behavioral JJ JJ O
studies NNS NNS O
. . . O

Receptor NNP NNP O
binding JJ JJ O
studies NNS NNS O
confirmed VBD VBD O
that IN IN O
UMB24 NNP NNP B-CHEM
and CC CC O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
SM NNP NNP B-CHEM
21 CD CD I-CHEM
display NN NN O
preferential JJ JJ O
affinity NN NN O
for IN IN O
sigma2 NN NN O
over IN IN O
sigma1 NN NN O
receptors NNS NNS O
. . . O

In IN IN O
behavioral JJ JJ O
studies NNS NNS O
, , , O
pretreatment NN NN O
of IN IN O
Swiss NNP NNP O
Webster NNP NNP O
mice NNS NNS O
with IN IN O
UMB24 NNP NNP B-CHEM
or CC CC O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
SM NNP NNP B-CHEM
21 CD CD I-CHEM
significantly RB RB O
attenuated VBN VBN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
and CC CC O
locomotor NN NN O
activity NN NN O
, , , O
but CC CC O
not RB RB O
lethality NN NN O
. . . O

When WRB WRB O
administered VBD VBD O
alone RB RB O
, , , O
( ( ( O
+ NN NN O
/ NN NN O
- : : O
) ) ) O
- : : O
SM NNP NNP B-CHEM
21 CD CD I-CHEM
produced VBN VBN O
no DT DT O
significant JJ JJ O
effects NNS NNS O
compared VBN VBN O
to TO TO O
control VB VB O
injections NNS NNS O
of IN IN O
saline NN NN O
, , , O
but CC CC O
UMB24 NNP NNP B-CHEM
had VBD VBD O
locomotor NN NN O
depressant NN NN O
actions NNS NNS O
. . . O

Together RB RB O
, , , O
the DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
sigma2 NN NN O
receptor NN NN O
antagonists NNS NNS O
have VBP VBP O
the DT DT O
potential JJ JJ O
to TO TO O
attenuate VB VB O
some DT DT O
of IN IN O
the DT DT O
behavioral JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
, , , O
and CC CC O
further JJ JJ O
development NN NN O
of IN IN O
more RBR RBR O
selective JJ JJ O
, , , O
high JJ JJ O
affinity NN NN O
ligands NNS NNS O
are VBP VBP O
warranted VBN VBN O
. . . O

Cardiac NNP NNP O
arrest NN NN O
in IN IN O
a DT DT O
child NN NN O
with IN IN O
cerebral JJ JJ O
palsy NN NN O
undergoing VBG VBG O
sevoflurane NN NN B-CHEM
induction NN NN O
of IN IN O
anesthesia NN NN O
after IN IN O
preoperative JJ JJ O
clonidine NN NN B-CHEM
. . . O

Clonidine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
frequently RB RB O
administered VBN VBN O
alpha2 NN NN O
- - - O
adrenergic JJ JJ O
agonist NN NN O
which WDT WDT O
can MD MD O
decrease VB VB O
heart NN NN O
rate NN NN O
and CC CC O
blood NN NN O
pressure NN NN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
5 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
child NN NN O
with IN IN O
cerebral JJ JJ O
palsy NN NN O
and CC CC O
seizure NN NN O
disorder NN NN O
, , , O
receiving VBG VBG O
clonidine NN NN B-CHEM
for IN IN O
restlessness NN NN O
, , , O
who WP WP O
presented VBD VBD O
for IN IN O
placement NN NN O
of IN IN O
a DT DT O
baclofen NN NN B-CHEM
pump NN NN O
. . . O

Without IN IN O
the DT DT O
knowledge NN NN O
of IN IN O
the DT DT O
medical JJ JJ O
personnel NNS NNS O
, , , O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
mother NN NN O
administered VBN VBN O
three CD CD O
doses NNS NNS O
of IN IN O
clonidine NN NN B-CHEM
during IN IN O
the DT DT O
evening NN NN O
before IN IN O
and CC CC O
morning NN NN O
of IN IN O
surgery NN NN O
to TO TO O
reduce VB VB O
anxiety NN NN O
. . . O

During IN IN O
induction NN NN O
of IN IN O
anesthesia NN NN O
, , , O
the DT DT O
patient NN NN O
developed VBN VBN O
bradycardia NNS NNS O
and CC CC O
hypotension NN NN O
requiring VBG VBG O
cardiac JJ JJ O
resuscitation NN NN O
. . . O

There EX EX O
are VBP VBP O
no DT DT O
previous JJ JJ O
reports NNS NNS O
of IN IN O
clonidine NN NN B-CHEM
- - - O
associated VBN VBN O
cardiac JJ JJ O
arrest NN NN O
in IN IN O
a DT DT O
child NN NN O
undergoing VBG VBG O
induction NN NN O
of IN IN O
anesthesia NN NN O
. . . O

Angiotensin NNP NNP O
- : : O
converting VBG VBG O
enzyme NN NN O
( ( ( O
ACE NNP NNP O
) ) ) O
inhibitor NN NN O
- - - O
associated VBN VBN O
angioedema NN NN O
of IN IN O
the DT DT O
stomach NN NN O
and CC CC O
small JJ JJ O
intestine NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

This DT DT O
is VBZ VBZ O
a DT DT O
case NN NN O
report NN NN O
on IN IN O
a DT DT O
45 CD CD O
- : : O
year NN NN O
old JJ JJ O
African NNP NNP O
- - - O
American JJ JJ O
female NN NN O
with IN IN O
newly RB RB O
diagnosed VBN VBN O
hypertension NN NN O
, , , O
who WP WP O
was VBD VBD O
started VBN VBN O
on IN IN O
a DT DT O
combination NN NN O
pill NN NN O
of IN IN O
amlodipine NN NN B-CHEM
/ NN NN O
benazapril NN NN B-CHEM
10 CD CD O
/ NN NN O
5 CD CD O
mg NN NN O
. . . O

The DT DT O
very RB RB O
next JJ JJ O
day NN NN O
, , , O
she PRP PRP O
presented VBD VBD O
at IN IN O
the DT DT O
emergency NN NN O
room NN NN O
( ( ( O
ER NNP NNP O
) ) ) O
with IN IN O
abdominal JJ JJ O
pain NN NN O
, , , O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
. . . O

Physical JJ JJ O
exam NN NN O
, , , O
complete JJ JJ O
metabolic JJ JJ O
panel NN NN O
, , , O
and CC CC O
hemogram NN NN O
were VBD VBD O
in IN IN O
the DT DT O
normal JJ JJ O
range NN NN O
. . . O

She PRP PRP O
was VBD VBD O
discharged VBN VBN O
from IN IN O
the DT DT O
ER NNP NNP O
after IN IN O
a DT DT O
few JJ JJ O
hours NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
fluid JJ JJ O
and CC CC O
analgesics NNS NNS O
. . . O

However RB RB O
, , , O
she PRP PRP O
returned VBD VBD O
to TO TO O
the DT DT O
ER NNP NNP O
the DT DT O
next JJ JJ O
day NN NN O
with IN IN O
the DT DT O
same JJ JJ O
complaints NNS NNS O
. . . O

This DT DT O
time NN NN O
the DT DT O
physical JJ JJ O
exam NN NN O
was VBD VBD O
significant JJ JJ O
for IN IN O
a DT DT O
distended JJ JJ O
abdomen NN NN O
with IN IN O
dullness NN NN O
to TO TO O
percussion NN NN O
. . . O

CT NNP NNP O
scan VB VB O
of IN IN O
the DT DT O
abdomen NN NN O
revealed VBD VBD O
markedly RB RB O
thickened VBN VBN O
antrum NN NN O
of IN IN O
the DT DT O
stomach NN NN O
, , , O
duodenum NN NN O
and CC CC O
jejunum NN NN O
, , , O
along IN IN O
with IN IN O
fluid JJ JJ O
in IN IN O
the DT DT O
abdominal NN NN O
and CC CC O
pelvic JJ JJ O
cavity NN NN O
. . . O

Angiotensin NNP NNP O
- : : O
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
( ( ( O
ACEI NNP NNP O
) ) ) O
- : : O
induced JJ JJ O
angioedema NN NN O
was VBD VBD O
suspected VBN VBN O
, , , O
and CC CC O
anti JJ JJ O
- : : O
hypertensive JJ JJ O
medications NNS NNS O
were VBD VBD O
discontinued VBN VBN O
. . . O

Her PRP$ PRP$ O
symptoms NNS NNS O
improved VBN VBN O
within IN IN O
the DT DT O
next JJ JJ O
24 CD CD O
hours NNS NNS O
, , , O
and CC CC O
repeat NN NN O
CT NNP NNP O
after IN IN O
72 CD CD O
hours NNS NNS O
revealed VBD VBD O
marked VBN VBN O
improvement NN NN O
in IN IN O
stomach NN NN O
and CC CC O
small JJ JJ O
bowel NN NN O
thickening VBG VBG O
and CC CC O
resolution NN NN O
of IN IN O
ascites NNS NNS O
. . . O

The DT DT O
recognition NN NN O
of IN IN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
( ( ( O
ACE NNP NNP O
) ) ) O
and CC CC O
angiotensin NN NN B-CHEM
receptor NN NN O
blocker NN NN O
( ( ( O
ARB NNP NNP O
) ) ) O
intestinal JJ JJ O
angioedema NN NN O
constitutes VBZ VBZ O
a DT DT O
challenge NN NN O
to TO TO O
primary JJ JJ O
care NN NN O
physicians NNS NNS O
, , , O
internists NNS NNS O
, , , O
emergency NN NN O
room NN NN O
personal JJ JJ O
and CC CC O
surgeons NNS NNS O
. . . O

Carbamazepine NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
dysfunction NN NN O
. . . O

Characterization NNP NNP O
of IN IN O
two CD CD O
distinct JJ JJ O
clinical JJ JJ O
syndromes NNS NNS O
. . . O

A DT DT O
patient NN NN O
with IN IN O
sinus NN NN O
bradycardia NNS NNS O
and CC CC O
atrioventricular JJ JJ O
block NN NN O
, , , O
induced VBN VBN O
by IN IN O
carbamazepine NN NN B-CHEM
, , , O
prompted VBD VBD O
an DT DT O
extensive JJ JJ O
literature NN NN O
review NN NN O
of IN IN O
all DT DT O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
. . . O

From IN IN O
the DT DT O
analysis NN NN O
of IN IN O
these DT DT O
cases NNS NNS O
, , , O
two CD CD O
distinct JJ JJ O
forms NNS NNS O
of IN IN O
carbamazepine NN NN B-CHEM
- - - O
associated VBN VBN O
cardiac JJ JJ O
dysfunction NN NN O
emerged VBD VBD O
. . . O

One CD CD O
patient NN NN O
group NN NN O
developed VBN VBN O
sinus JJ JJ O
tachycardias NNS NNS O
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
a DT DT O
massive JJ JJ O
carbamazepine NN NN B-CHEM
overdose NN NN O
. . . O

The DT DT O
second JJ JJ O
group NN NN O
consisted VBD VBD O
almost RB RB O
exclusively RB RB O
of IN IN O
elderly JJ JJ O
women NNS NNS O
who WP WP O
developed VBD VBD O
potentially RB RB O
life NN NN O
- : : O
threatening VBG VBG O
bradyarrhythmias NN NN O
or CC CC O
atrioventricular JJ JJ O
conduction NN NN O
delay NN NN O
, , , O
associated VBN VBN O
with IN IN O
either DT DT O
therapeutic JJ JJ O
or CC CC O
modestly RB RB O
elevated VBD VBD O
carbamazepine JJ JJ B-CHEM
serum NN NN O
levels NNS NNS O
. . . O

Because IN IN O
carbamazepine NN NN B-CHEM
is VBZ VBZ O
widely RB RB O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
many JJ JJ O
neurologic JJ JJ O
and CC CC O
psychiatric JJ JJ O
conditions NNS NNS O
, , , O
the DT DT O
recognition NN NN O
of IN IN O
the DT DT O
latter NN NN O
syndrome NN NN O
has VBZ VBZ O
important JJ JJ O
implications NNS NNS O
for IN IN O
the DT DT O
use NN NN O
of IN IN O
this DT DT O
drug NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
. . . O

Detection NNP NNP O
of IN IN O
abnormal JJ JJ O
cardiac NN NN O
adrenergic JJ JJ O
neuron NN NN O
activity NN NN O
in IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
with IN IN O
iodine NN NN B-CHEM
- - - I-CHEM
125 CD CD I-CHEM
- - - I-CHEM
metaiodobenzylguanidine NN NN I-CHEM
. . . O

Radiolabeled NNP NNP B-CHEM
metaiodobenzylguanidine NN NN I-CHEM
( ( ( O
MIBG NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
analog NN NN O
of IN IN O
norepinephrine NN NN B-CHEM
( ( ( O
NE NNP NNP B-CHEM
) ) ) O
, , , O
serves VBZ VBZ O
as IN IN O
an DT DT O
index NN NN O
of IN IN O
adrenergic JJ JJ O
neuron NN NN O
integrity NN NN O
and CC CC O
function NN NN O
. . . O

Using VBG VBG O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
, , , O
we PRP PRP O
tested VBD VBD O
the DT DT O
hypothesis NNS NNS O
that IN IN O
abnormal JJ JJ O
cardiac NN NN O
adrenergic JJ JJ O
neuron NN NN O
activity NN NN O
may MD MD O
appear VB VB O
and CC CC O
be VB VB O
exacerbated VBN VBN O
dose VB VB O
- - - O
dependently RB RB O
in IN IN O
adriamycin NN NN B-CHEM
cardiomyopathy NN NN O
. . . O

The DT DT O
degree NN NN O
of IN IN O
vacuolar JJ JJ O
degeneration NN NN O
of IN IN O
myocardial NN NN O
cells NNS NNS O
was VBD VBD O
analyzed VBN VBN O
in IN IN O
relation NN NN O
to TO TO O
the DT DT O
duration NN NN O
of IN IN O
adriamycin NN NN B-CHEM
treatment NN NN O
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
once RB RB O
a DT DT O
week NN NN O
) ) ) O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
abnormalities NNS NNS O
or CC CC O
only RB RB O
isolated VBN VBN O
degeneration NN NN O
in IN IN O
the DT DT O
1 CD CD O
- : : O
or CC CC O
2 CD CD O
- : : O
wk NN NN O
treatment NN NN O
groups NNS NNS O
, , , O
isolated VBN VBN O
or CC CC O
scattered VBN VBN O
degeneration NN NN O
in IN IN O
half NN NN O
of IN IN O
the DT DT O
3 CD CD O
- : : O
wk NN NN O
group NN NN O
, , , O
frequent NN NN O
scattered VBN VBN O
degeneration NN NN O
in IN IN O
the DT DT O
4 CD CD O
- : : O
wk NN NN O
group NN NN O
, , , O
scattered VBN VBN O
or CC CC O
focal JJ JJ O
degeneration NN NN O
in IN IN O
the DT DT O
5 CD CD O
- : : O
wk NN NN O
group NN NN O
, , , O
and CC CC O
extensive JJ JJ O
degeneration NN NN O
in IN IN O
the DT DT O
8 CD CD O
- : : O
wk NN NN O
group NN NN O
. . . O

Myocardial NNP NNP O
accumulation NN NN O
of IN IN O
[ NN NN O
125I CD CD O
] NN NN O
MIBG NNP NNP B-CHEM
4 CD CD O
hr NN NN O
after IN IN O
intravenous JJ JJ O
injection NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
between IN IN O
the DT DT O
controls NNS NNS O
and CC CC O
the DT DT O
groups NNS NNS O
treated VBN VBN O
3 CD CD O
wk NN NN O
or CC CC O
less JJR JJR O
. . . O

However RB RB O
, , , O
the DT DT O
4 CD CD O
- : : O
wk NN NN O
group NN NN O
had VBD VBD O
a DT DT O
slightly RB RB O
lower JJR JJR O
accumulation NN NN O
in IN IN O
the DT DT O
right NN NN O
ventricular NN NN O
wall NN NN O
( ( ( O
82 CD CD O
% NN NN O
of IN IN O
the DT DT O
control NN NN O
) ) ) O
and CC CC O
significantly RB RB O
lower JJR JJR O
accumulation NN NN O
in IN IN O
the DT DT O
left NN NN O
ventricular NN NN O
wall NN NN O
( ( ( O
about IN IN O
66 CD CD O
% NN NN O
of IN IN O
the DT DT O
control NN NN O
: : : O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
5 CD CD O
- : : O
wk NN NN O
group NN NN O
, , , O
MIBG NNP NNP B-CHEM
accumulation NN NN O
in IN IN O
the DT DT O
right NN NN O
and CC CC O
left VBD VBD O
ventricular JJ JJ O
wall NN NN O
was VBD VBD O
35 CD CD O
% NN NN O
and CC CC O
27 CD CD O
% NN NN O
of IN IN O
that DT DT O
in IN IN O
controls NNS NNS O
, , , O
respectively RB RB O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
8 CD CD O
- : : O
wk NN NN O
group NN NN O
, , , O
MIBG NNP NNP B-CHEM
accumulation NN NN O
in IN IN O
the DT DT O
right NN NN O
and CC CC O
left VBD VBD O
ventricular JJ JJ O
wall NN NN O
was VBD VBD O
18 CD CD O
% NN NN O
and CC CC O
14 CD CD O
% NN NN O
of IN IN O
that DT DT O
in IN IN O
controls NNS NNS O
, , , O
respectively RB RB O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Thus RB RB O
, , , O
MIBG NNP NNP B-CHEM
accumulation NN NN O
in IN IN O
the DT DT O
myocardium NN NN O
decreased VBD VBD O
in IN IN O
an DT DT O
adriamycin NN NN B-CHEM
dose NN NN O
- : : O
dependent JJ JJ O
manner NN NN O
. . . O

The DT DT O
appearance NN NN O
of IN IN O
impaired JJ JJ O
cardiac JJ JJ O
adrenergic JJ JJ O
neuron NN NN O
activity NN NN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
slight JJ JJ O
myocardial NN NN O
impairment NN NN O
( ( ( O
scattered VBN VBN O
or CC CC O
focal JJ JJ O
vacuolar NN NN O
degeneration NN NN O
) ) ) O
indicates VBZ VBZ O
that IN IN O
MIBG NNP NNP B-CHEM
scintigraphy NN NN O
may MD MD O
be VB VB O
a DT DT O
useful JJ JJ O
method NN NN O
for IN IN O
detection NN NN O
of IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
. . . O

Syncope NNP NNP O
and CC CC O
QT NNP NNP O
prolongation NN NN O
among IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
methadone NN NN B-CHEM
for IN IN O
heroin NN NN B-CHEM
dependence NN NN O
in IN IN O
the DT DT O
city NN NN O
of IN IN O
Copenhagen NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Methadone NNP NNP B-CHEM
is VBZ VBZ O
prescribed VBN VBN O
to TO TO O
heroin VB VB B-CHEM
addicts NNS NNS O
to TO TO O
decrease VB VB O
illicit JJ JJ O
opioid NN NN O
use NN NN O
. . . O

Prolongation NNP NNP O
of IN IN O
the DT DT O
QT NNP NNP O
interval NN NN O
in IN IN O
the DT DT O
ECG NNP NNP O
of IN IN O
patients NNS NNS O
with IN IN O
torsade NN NN O
de IN IN O
pointes NNS NNS O
( ( ( O
TdP NNP NNP O
) ) ) O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
in IN IN O
methadone NN NN B-CHEM
users NNS NNS O
. . . O

As IN IN O
heroin NN NN B-CHEM
addicts NNS NNS O
sometimes RB RB O
faint VBP VBP O
while IN IN O
using VBG VBG O
illicit JJ JJ O
drugs NNS NNS O
, , , O
doctors NNS NNS O
might MD MD O
attribute VB VB O
too RB RB O
many JJ JJ O
episodes NNS NNS O
of IN IN O
syncope NN NN O
to TO TO O
illicit JJ JJ O
drug NN NN O
use NN NN O
and CC CC O
thereby RB RB O
underestimate VB VB O
the DT DT O
incidence NN NN O
of IN IN O
TdP NNP NNP O
in IN IN O
this DT DT O
special JJ JJ O
population NN NN O
, , , O
and CC CC O
the DT DT O
high JJ JJ O
mortality NN NN O
in IN IN O
this DT DT O
population NN NN O
may MD MD O
, , , O
in IN IN O
part NN NN O
, , , O
be VB VB O
caused VBN VBN O
by IN IN O
the DT DT O
proarrhythmic JJ JJ O
effect NN NN O
of IN IN O
methadone NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
this DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
study NN NN O
interview NN NN O
, , , O
ECGs NNP NNP O
and CC CC O
blood NN NN O
samples NNS NNS O
were VBD VBD O
collected VBN VBN O
in IN IN O
a DT DT O
population NN NN O
of IN IN O
adult NN NN O
heroin NN NN B-CHEM
addicts NNS NNS O
treated VBN VBN O
with IN IN O
methadone NN NN B-CHEM
or CC CC O
buprenorphine NN NN B-CHEM
on IN IN O
a DT DT O
daily JJ JJ O
basis NN NN O
. . . O

Of IN IN O
the DT DT O
patients NNS NNS O
at IN IN O
the DT DT O
Drug NN NN O
Addiction NNP NNP O
Service NNP NNP O
in IN IN O
the DT DT O
municipal NN NN O
of IN IN O
Copenhagen NNP NNP O
, , , O
450 CD CD O
( ( ( O
approximately RB RB O
52 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
included VBN VBN O
. . . O

The DT DT O
QT NNP NNP O
interval NN NN O
was VBD VBD O
estimated VBN VBN O
from IN IN O
12 CD CD O
lead NN NN O
ECGs NNP NNP O
. . . O

All DT DT O
participants NNS NNS O
were VBD VBD O
interviewed VBN VBN O
about IN IN O
any DT DT O
experience NN NN O
of IN IN O
syncope NN NN O
. . . O

The DT DT O
association NN NN O
between IN IN O
opioid NN NN O
dose NN NN O
and CC CC O
QT NNP NNP O
, , , O
and CC CC O
methadone NN NN B-CHEM
dose NN NN O
and CC CC O
reporting VBG VBG O
of IN IN O
syncope NN NN O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
multivariate NN NN O
linear NN NN O
regression NN NN O
and CC CC O
logistic JJ JJ O
regression NN NN O
, , , O
respectively RB RB O
. . . O

RESULTS NNS NNS O
: : : O
Methadone NNP NNP B-CHEM
dose NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
longer RBR RBR O
QT NNP NNP O
interval NN NN O
of IN IN O
0 CD CD O
. . . O
140 CD CD O
ms NN NN O
/ NN NN O
mg NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

No DT DT O
association NN NN O
between IN IN O
buprenorphine NN NN B-CHEM
and CC CC O
QTc NNP NNP O
was VBD VBD O
found VBN VBN O
. . . O

Among IN IN O
the DT DT O
subjects NNS NNS O
treated VBN VBN O
with IN IN O
methadone NN NN B-CHEM
, , , O
28 CD CD O
% NN NN O
men NNS NNS O
and CC CC O
32 CD CD O
% NN NN O
women NNS NNS O
had VBD VBD O
prolonged JJ JJ O
QTc NNP NNP O
interval NN NN O
. . . O

None NN NN O
of IN IN O
the DT DT O
subjects NNS NNS O
treated VBN VBN O
with IN IN O
buprenorphine NN NN B-CHEM
had VBD VBD O
QTc NNP NNP O
interval NN NN O
> NN NN O
0 CD CD O
. . . O
440 CD CD O
s VBZ VBZ O
( ( ( O
( ( ( O
1 CD CD O
/ NN NN O
2 CD CD O
) ) ) O
) ) ) O
. . . O

A DT DT O
50 CD CD O
mg NN NN O
higher JJR JJR O
methadone NN NN B-CHEM
dose NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
1 CD CD O
. . . O
2 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
1 CD CD O
to TO TO O
1 CD CD O
. . . O
4 CD CD O
) ) ) O
times NNS NNS O
higher JJR JJR O
odds NNS NNS O
for IN IN O
syncope NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Methadone NNP NNP B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
QT NNP NNP O
prolongation NN NN O
and CC CC O
higher JJR JJR O
reporting VBG VBG O
of IN IN O
syncope NN NN O
in IN IN O
a DT DT O
population NN NN O
of IN IN O
heroin NN NN B-CHEM
addicts NNS NNS O
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
induced VBN VBN O
by IN IN O
ziprasidone NN NN B-CHEM
on IN IN O
the DT DT O
second JJ JJ O
day NN NN O
of IN IN O
treatment NN NN O
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
( ( ( O
NMS NNP NNP O
) ) ) O
is VBZ VBZ O
the DT DT O
rarest NN NN O
and CC CC O
most RBS RBS O
serious JJ JJ O
of IN IN O
the DT DT O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
movement NN NN O
disorders NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
( ( ( O
NMS NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
ziprasidone NN NN B-CHEM
. . . O

Although IN IN O
conventional JJ JJ O
neuroleptics NNS NNS O
are VBP VBP O
more RBR RBR O
frequently RB RB O
associated VBN VBN O
with IN IN O
NMS NNP NNP O
, , , O
atypical JJ JJ O
antipsychotic JJ JJ O
drugs NNS NNS O
like IN IN O
ziprasidone NN NN B-CHEM
may MD MD O
also RB RB O
be VB VB O
a DT DT O
cause NN NN O
. . . O

The DT DT O
patient NN NN O
is VBZ VBZ O
a DT DT O
24 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
schizophrenia NN NN O
who WP WP O
developed VBD VBD O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
of IN IN O
NMS NNP NNP O
after IN IN O
2 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
an DT DT O
80 CD CD O
- : : O
mg NN NN O
/ NN NN O
day NN NN O
dose NN NN O
of IN IN O
orally RB RB O
administrated VBN VBN O
ziprasidone NN NN B-CHEM
. . . O

This DT DT O
case NN NN O
is VBZ VBZ O
the DT DT O
earliest JJS JJS O
( ( ( O
second JJ JJ O
day NN NN O
of IN IN O
treatment NN NN O
) ) ) O
NMS NNP NNP O
due JJ JJ O
to TO TO O
ziprasidone NN NN B-CHEM
reported VBD VBD O
in IN IN O
the DT DT O
literature NN NN O
. . . O

Peripheral NNP NNP O
iron NN NN B-CHEM
dextran NN NN I-CHEM
induced JJ JJ O
degeneration NN NN O
of IN IN O
dopaminergic JJ JJ O
neurons NNS NNS O
in IN IN O
rat NN NN O
substantia NN NN O
nigra NN NN O
. . . O

Iron NNP NNP B-CHEM
accumulation NN NN O
is VBZ VBZ O
considered VBN VBN O
to TO TO O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

To TO TO O
demonstrate VB VB O
the DT DT O
relationship NN NN O
between IN IN O
peripheral JJ JJ O
iron NN NN B-CHEM
overload NN NN O
and CC CC O
dopaminergic JJ JJ O
neuron NN NN O
loss NN NN O
in IN IN O
rat NN NN O
substantia NN NN O
nigra NN NN O
( ( ( O
SN NNP NNP O
) ) ) O
, , , O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
we PRP PRP O
used VBD VBD O
fast RB RB O
cyclic JJ JJ O
voltammetry NN NN O
, , , O
tyrosine NN NN B-CHEM
hydroxylase NN NN O
( ( ( O
TH NNP NNP O
) ) ) O
immunohistochemistry NN NN O
, , , O
Perls NNP NNP O
' POS POS O
iron NN NN B-CHEM
staining VBG VBG O
, , , O
and CC CC O
high JJ JJ O
performance NN NN O
liquid JJ JJ O
chromatography NN NN O
- - - O
electrochemical JJ JJ O
detection NN NN O
to TO TO O
study VB VB O
the DT DT O
degeneration NN NN O
of IN IN O
dopaminergic JJ JJ O
neurons NNS NNS O
and CC CC O
increased VBN VBN O
iron NN NN B-CHEM
content NN NN O
in IN IN O
the DT DT O
SN NNP NNP O
of IN IN O
iron NN NN B-CHEM
dextran NN NN I-CHEM
overloaded JJ JJ O
animals NNS NNS O
. . . O

The DT DT O
findings NNS NNS O
showed VBD VBD O
that IN IN O
peripheral JJ JJ O
iron NN NN B-CHEM
dextran NN NN I-CHEM
overload NN NN O
increased VBD VBD O
the DT DT O
iron NN NN B-CHEM
staining VBG VBG O
positive JJ JJ O
cells NNS NNS O
and CC CC O
reduced VBD VBD O
the DT DT O
number NN NN O
of IN IN O
TH NNP NNP O
- - - O
immunoreactive JJ JJ O
neurons NNS NNS O
in IN IN O
the DT DT O
SN NNP NNP O
. . . O

As IN IN O
a DT DT O
result NN NN O
, , , O
dopamine NN NN B-CHEM
release NN NN O
and CC CC O
content NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
its PRP$ PRP$ O
metabolites NNS NNS O
contents NNS NNS O
were VBD VBD O
decreased VBN VBN O
in IN IN O
caudate NN NN O
putamen NNS NNS O
. . . O

Even RB RB O
more RBR RBR O
dramatic JJ JJ O
changes NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
chronic JJ JJ O
overload NN NN O
group NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
peripheral JJ JJ O
iron NN NN B-CHEM
dextran NN NN I-CHEM
can MD MD O
increase VB VB O
the DT DT O
iron NN NN B-CHEM
level NN NN O
in IN IN O
the DT DT O
SN NNP NNP O
, , , O
where WRB WRB O
excessive JJ JJ O
iron NN NN B-CHEM
causes VBZ VBZ O
the DT DT O
degeneration NN NN O
of IN IN O
dopaminergic JJ JJ O
neurons NNS NNS O
. . . O

The DT DT O
chronic JJ JJ O
iron NN NN B-CHEM
overload NN NN O
may MD MD O
be VB VB O
more RBR RBR O
destructive JJ JJ O
to TO TO O
dopaminergic JJ JJ O
neurons NNS NNS O
than IN IN O
the DT DT O
acute JJ JJ O
iron NN NN B-CHEM
overload NN NN O
. . . O

Attenuated NNP NNP O
disruption NN NN O
of IN IN O
prepulse NN NN O
inhibition NN NN O
by IN IN O
dopaminergic JJ JJ O
stimulation NN NN O
after IN IN O
maternal JJ JJ O
deprivation NN NN O
and CC CC O
adolescent NN NN O
corticosterone NN NN B-CHEM
treatment NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
development NN NN O
of IN IN O
schizophrenia NN NN O
may MD MD O
include VB VB O
an DT DT O
early JJ JJ O
neurodevelopmental NN NN O
stress NN NN O
component NN NN O
which WDT WDT O
increases VBZ VBZ O
vulnerability NN NN O
to TO TO O
later RB RB O
stressful JJ JJ O
life NN NN O
events NNS NNS O
, , , O
in IN IN O
combination NN NN O
leading VBG VBG O
to TO TO O
overt VB VB O
disease NN NN O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
an DT DT O
early JJ JJ O
stress NN NN O
, , , O
in IN IN O
the DT DT O
form NN NN O
of IN IN O
maternal JJ JJ O
deprivation NN NN O
, , , O
combined VBN VBN O
with IN IN O
a DT DT O
later RB RB O
stress NN NN O
, , , O
simulated VBN VBN O
by IN IN O
chronic JJ JJ O
periadolescent NN NN O
corticosterone NN NN B-CHEM
treatment NN NN O
, , , O
on IN IN O
behaviour NN NN O
in IN IN O
rats NNS NNS O
. . . O

Acute JJ JJ O
treatment NN NN O
with IN IN O
apomorphine NN NN B-CHEM
caused VBD VBD O
disruption NN NN O
of IN IN O
prepulse NN NN O
inhibition NN NN O
( ( ( O
PPI NNP NNP O
) ) ) O
in IN IN O
controls NNS NNS O
and CC CC O
in IN IN O
rats NNS NNS O
that WDT WDT O
had VBD VBD O
undergone VBN VBN O
either CC CC O
maternal JJ JJ O
deprivation NN NN O
or CC CC O
corticosterone NN NN B-CHEM
treatment NN NN O
, , , O
but CC CC O
was VBD VBD O
surprisingly RB RB O
absent JJ JJ O
in IN IN O
rats NNS NNS O
that WDT WDT O
had VBD VBD O
undergone VBN VBN O
the DT DT O
combined VBN VBN O
early JJ JJ O
and CC CC O
late JJ JJ O
stress NN NN O
. . . O

Amphetamine NNP NNP B-CHEM
treatment NN NN O
significantly RB RB O
disrupted VBD VBD O
PPI NNP NNP O
in IN IN O
both DT DT O
non NN NN O
- - - O
deprived JJ JJ O
groups NNS NNS O
, , , O
but CC CC O
was VBD VBD O
absent JJ JJ O
in IN IN O
both DT DT O
maternally RB RB O
deprived VBN VBN O
groups NNS NNS O
. . . O

The DT DT O
serotonin NN NN B-CHEM
- - - O
1A CD CD O
receptor NN NN O
agonist NN NN O
, , , O
8 CD CD B-CHEM
- - - I-CHEM
OH UH UH I-CHEM
- - - I-CHEM
DPAT NNP NNP I-CHEM
, , , O
induced VBD VBD O
a DT DT O
significant JJ JJ O
disruption NN NN O
of IN IN O
PPI NNP NNP O
in IN IN O
all DT DT O
groups NNS NNS O
. . . O

Amphetamine NNP NNP B-CHEM
- : : O
induced JJ JJ O
locomotor NN NN O
hyperactivity NN NN O
was VBD VBD O
similar JJ JJ O
in IN IN O
all DT DT O
groups NNS NNS O
. . . O

These DT DT O
results NNS NNS O
show VBP VBP O
an DT DT O
inhibitory JJ JJ O
interaction NN NN O
of IN IN O
early JJ JJ O
stress NN NN O
, , , O
caused VBN VBN O
by IN IN O
maternal JJ JJ O
deprivation NN NN O
, , , O
combined VBN VBN O
with IN IN O
' POS POS O
adolescent NN NN O
' '' '' O
stress NN NN O
, , , O
simulated VBN VBN O
by IN IN O
corticosterone NN NN B-CHEM
treatment NN NN O
, , , O
on IN IN O
dopaminergic JJ JJ O
regulation NN NN O
of IN IN O
PPI NNP NNP O
. . . O

The DT DT O
altered VBN VBN O
effects NNS NNS O
of IN IN O
apomorphine NN NN B-CHEM
and CC CC O
amphetamine NN NN B-CHEM
could MD MD O
indicate VB VB O
differential NN NN O
changes NNS NNS O
in IN IN O
dopamine NN NN B-CHEM
receptor NN NN O
signalling VBG VBG O
leading VBG VBG O
to TO TO O
functional JJ JJ O
desensitisation NN NN O
, , , O
or CC CC O
altered JJ JJ O
modulation NN NN O
of IN IN O
sensory JJ JJ O
gating VBG VBG O
in IN IN O
the DT DT O
nucleus NN NN O
accumbens NNS NNS O
by IN IN O
limbic NN NN O
structures NNS NNS O
such JJ JJ O
as IN IN O
the DT DT O
hippocampus NN NN O
. . . O

An DT DT O
extremely RB RB O
rare JJ JJ O
case NN NN O
of IN IN O
delusional JJ JJ O
parasitosis NN NN O
in IN IN O
a DT DT O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
patient NN NN O
during IN IN O
pegylated VBN VBN B-CHEM
interferon NN NN I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
2b CD CD I-CHEM
and CC CC O
ribavirin NN NN B-CHEM
treatment NN NN O
. . . O

During IN IN O
treatment NN NN O
of IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
patients NNS NNS O
with IN IN O
interferon NN NN O
and CC CC O
ribavirin NN NN B-CHEM
, , , O
a DT DT O
lot NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
are VBP VBP O
described VBN VBN O
. . . O

Twenty CD CD O
- - - O
three CD CD O
percent NN NN O
to TO TO O
44 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
develop VBP VBP O
depression NN NN O
. . . O

A DT DT O
minority NN NN O
of IN IN O
patients NNS NNS O
evolve VB VB O
to TO TO O
psychosis NNS NNS O
. . . O

To TO TO O
the DT DT O
best JJS JJS O
of IN IN O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
no DT DT O
cases NNS NNS O
of IN IN O
psychogenic JJ JJ O
parasitosis NNS NNS O
occurring VBG VBG O
during IN IN O
interferon NN NN O
therapy NN NN O
have VBP VBP O
been VBN VBN O
described VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
49 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
developed VBD VBD O
a DT DT O
delusional JJ JJ O
parasitosis NN NN O
during IN IN O
treatment NN NN O
with IN IN O
pegylated VBN VBN B-CHEM
interferon NN NN I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
2b CD CD I-CHEM
weekly JJ JJ O
and CC CC O
ribavirin NN NN B-CHEM
. . . O

She PRP PRP O
complained VBD VBD O
of IN IN O
seeing VBG VBG O
parasites NNS NNS O
and CC CC O
the DT DT O
larvae NN NN O
of IN IN O
fleas NNS NNS O
in IN IN O
her PRP$ PRP$ O
stools NNS NNS O
. . . O

This DT DT O
could MD MD O
not RB RB O
be VB VB O
confirmed VBN VBN O
by IN IN O
any DT DT O
technical JJ JJ O
examination NN NN O
. . . O

All DT DT O
the DT DT O
complaints NNS NNS O
disappeared VBD VBD O
after IN IN O
stopping VBG VBG O
pegylated VBN VBN B-CHEM
interferon NN NN I-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
2b CD CD I-CHEM
and CC CC O
reappeared VBD VBD O
after IN IN O
restarting VBG VBG O
it PRP PRP O
. . . O

She PRP PRP O
had VBD VBD O
a DT DT O
complete JJ JJ O
sustained VBN VBN O
viral JJ JJ O
response NN NN O
. . . O

Hepatonecrosis NNP NNP O
and CC CC O
cholangitis NNS NNS O
related VBN VBN O
to TO TO O
long JJ JJ O
- - - O
term NN NN O
phenobarbital NN NN B-CHEM
therapy NN NN O
: : : O
an DT DT O
autopsy NN NN O
report NN NN O
of IN IN O
two CD CD O
patients NNS NNS O
. . . O

Phenobarbital NNP NNP B-CHEM
( ( ( O
PB NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
a DT DT O
reputation NN NN O
for IN IN O
safety NN NN O
, , , O
and CC CC O
it PRP PRP O
is VBZ VBZ O
commonly RB RB O
believed VBN VBN O
that IN IN O
PB NNP NNP B-CHEM
- : : O
related VBN VBN O
increases NNS NNS O
in IN IN O
serum NN NN O
aminotransferase NN NN O
levels NNS NNS O
do VBP VBP O
not RB RB O
indicate VB VB O
or CC CC O
predict VBP VBP O
the DT DT O
development NN NN O
of IN IN O
significant JJ JJ O
chronic JJ JJ O
liver NN NN O
disease NN NN O
. . . O

Here RB RB O
we PRP PRP O
report VBP VBP O
of IN IN O
two CD CD O
adult NN NN O
patients NNS NNS O
with IN IN O
a DT DT O
long JJ JJ O
history NN NN O
of IN IN O
epilepsy NN NN O
treated VBN VBN O
with IN IN O
PB NNP NNP B-CHEM
who WP WP O
died VBD VBD O
suddenly RB RB O
: : : O
one CD CD O
as IN IN O
consequence NN NN O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
, , , O
the DT DT O
other JJ JJ O
of IN IN O
acute JJ JJ O
bronchopneumonia NN NN O
. . . O

At IN IN O
autopsy NN NN O
, , , O
analysis NN NN O
of IN IN O
liver NN NN O
parenchyma NN NN O
revealed VBD VBD O
rich JJ JJ O
portal JJ JJ O
inflammatory NN NN O
infiltrate NN NN O
, , , O
which WDT WDT O
consisted VBD VBD O
of IN IN O
mixed JJ JJ O
eosinophil NN NN O
and CC CC O
monocyte NN NN O
cells NNS NNS O
, , , O
associated VBN VBN O
with IN IN O
several JJ JJ O
foci NN NN O
of IN IN O
necrosis NN NN O
surrounded VBN VBN O
by IN IN O
a DT DT O
hard JJ JJ O
ring NN NN O
of IN IN O
non NN NN O
- - - O
specific JJ JJ O
granulomatous JJ JJ O
tissue NN NN O
. . . O

Inflammatory NNP NNP O
reactions NNS NNS O
of IN IN O
internal JJ JJ O
and CC CC O
external JJ JJ O
hepatic JJ JJ O
biliary JJ JJ O
ducts NNS NNS O
were VBD VBD O
also RB RB O
seen VBN VBN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
illustrate VBP VBP O
that IN IN O
PB NNP NNP B-CHEM
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
liver NN NN O
damage NN NN O
, , , O
which WDT WDT O
may MD MD O
lead VB VB O
to TO TO O
more RBR RBR O
serious JJ JJ O
and CC CC O
deleterious JJ JJ O
consequences NNS NNS O
. . . O

For IN IN O
this DT DT O
reason NN NN O
, , , O
each DT DT O
clinician NN NN O
should MD MD O
recognize VB VB O
this DT DT O
entity NN NN O
in IN IN O
the DT DT O
differential JJ JJ O
diagnosis NN NN O
of IN IN O
PB NNP NNP B-CHEM
- - - O
related VBN VBN O
asymptomatic JJ JJ O
chronic JJ JJ O
hepatic JJ JJ O
enzyme NN NN O
dysfunction NN NN O
. . . O

Delayed NNP NNP O
leukoencephalopathy JJ JJ O
with IN IN O
stroke NN NN O
- - - O
like IN IN O
presentation NN NN O
in IN IN O
chemotherapy NN NN O
recipients NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
A DT DT O
transient NN NN O
leukoencephalopathy NN NN O
mimicking VBG VBG O
cerebrovascular NN NN O
accident NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
as IN IN O
a DT DT O
complication NN NN O
of IN IN O
chemotherapy NN NN O
, , , O
most RBS RBS O
commonly RB RB O
in IN IN O
recipients NNS NNS O
of IN IN O
intrathecal JJ JJ O
methotrexate NN NN B-CHEM
for IN IN O
childhood NN NN O
leukaemia NN NN O
. . . O

Recently RB RB O
published VBN VBN O
neuroimaging VBG VBG O
data NNS NNS O
suggest VBP VBP O
a DT DT O
common JJ JJ O
pathophysiology NN NN O
associated VBN VBN O
with IN IN O
a DT DT O
variety NN NN O
of IN IN O
chemotherapy NN NN O
agents NNS NNS O
and CC CC O
modes NNS NNS O
of IN IN O
administration NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
reviewed VBD VBD O
the DT DT O
medical JJ JJ O
literature NN NN O
for IN IN O
single JJ JJ O
reports NNS NNS O
and CC CC O
case NN NN O
series NN NN O
of IN IN O
patients NNS NNS O
presenting VBG VBG O
with IN IN O
stroke NN NN O
- - - O
like IN IN O
episodes NNS NNS O
while IN IN O
receiving VBG VBG O
systemic JJ JJ O
or CC CC O
intrathecal JJ JJ O
chemotherapy NN NN O
. . . O

We PRP PRP O
only RB RB O
included VBD VBD O
studies NNS NNS O
providing VBG VBG O
detailed JJ JJ O
neuroimaging NN NN O
data NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
cerebrovascular JJ JJ O
accidents NNS NNS O
were VBD VBD O
excluded VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
identified VBD VBD O
27 CD CD O
reports NNS NNS O
of IN IN O
toxic JJ JJ O
leukoencephalopathy JJ JJ O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
methotrexate NN NN B-CHEM
( ( ( O
intrathecal JJ JJ O
, , , O
systemic JJ JJ O
) ) ) O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
and CC CC O
its PRP$ PRP$ O
derivative JJ JJ O
carmofur NN NN B-CHEM
, , , O
and CC CC O
capecitabine NN NN B-CHEM
. . . O

Diffusion NNP NNP O
weighted VBD VBD O
imaging VBG VBG O
( ( ( O
DWI NNP NNP O
) ) ) O
of IN IN O
all DT DT O
patients NNS NNS O
revealed VBD VBD O
well RB RB O
demarcated VBN VBN O
hyperintense NN NN O
lesions NNS NNS O
within IN IN O
the DT DT O
subcortical JJ JJ O
white JJ JJ O
matter NN NN O
of IN IN O
the DT DT O
cerebral JJ JJ O
hemispheres NNS NNS O
and CC CC O
the DT DT O
corpus NN NN O
callosum NN NN O
, , , O
corresponding JJ JJ O
to TO TO O
areas NNS NNS O
of IN IN O
decreased VBD VBD O
proton NN NN O
diffusion NN NN O
on IN IN O
apparent JJ JJ O
diffusion NN NN O
coefficient NN NN O
( ( ( O
ADC NNP NNP O
) ) ) O
maps NNS NNS O
( ( ( O
available JJ JJ O
in IN IN O
21 CD CD O
/ NN NN O
27 CD CD O
patients NNS NNS O
) ) ) O
. . . O

Lesions NNP NNP O
exceeded VBD VBD O
the DT DT O
confines NNS NNS O
of IN IN O
adjacent JJ JJ O
vascular NN NN O
territories NNS NNS O
. . . O

Complete JJ JJ O
resolution NN NN O
of IN IN O
symptoms NNS NNS O
within IN IN O
1 CD CD O
- : : O
4 CD CD O
days NNS NNS O
was VBD VBD O
accompanied VBN VBN O
by IN IN O
normalisation NN NN O
of IN IN O
ADC NNP NNP O
abnormalities NNS NNS O
. . . O

However RB RB O
, , , O
fluid JJ JJ O
attenuated JJ JJ O
inversion NN NN O
recovery NN NN O
( ( ( O
FLAIR NNP NNP O
) ) ) O
sequences NNS NNS O
frequently RB RB O
revealed VBN VBN O
persistent JJ JJ O
white JJ JJ O
matter NN NN O
abnormalities NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Several JJ JJ O
pathophysiological JJ JJ O
models NNS NNS O
of IN IN O
delayed VBD VBD O
leukoencephalopathy NN NN O
after IN IN O
exposure NN NN O
to TO TO O
intrathecal JJ JJ O
or CC CC O
systemic JJ JJ O
chemotherapy NN NN O
have VBP VBP O
been VBN VBN O
proposed VBN VBN O
. . . O

DWI NNP NNP O
findings NNS NNS O
in IN IN O
this DT DT O
cohort NN NN O
are VBP VBP O
indicative JJ JJ O
of IN IN O
cytotoxic NN NN O
oedema NN NN O
within IN IN O
cerebral JJ JJ O
white JJ JJ O
matter NN NN O
and CC CC O
lend VB VB O
support NN NN O
to TO TO O
an DT DT O
at IN IN O
least JJS JJS O
partially RB RB O
reversible JJ JJ O
metabolic JJ JJ O
derangement NN NN O
as IN IN O
the DT DT O
basis NN NN O
for IN IN O
this DT DT O
syndrome NN NN O
. . . O

Prenatal NNP NNP O
exposure NN NN O
to TO TO O
fluoxetine VB VB B-CHEM
induces NNS NNS O
fetal JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

RATIONALE NNP NNP O
: : : O
Fluoxetine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitor NN NN O
antidepressant NN NN O
widely RB RB O
used VBN VBN O
by IN IN O
pregnant JJ JJ O
women NNS NNS O
. . . O

Epidemiological NNP NNP O
data NNS NNS O
suggest VBP VBP O
that IN IN O
fluoxetine JJ JJ B-CHEM
exposure NN NN O
prenatally RB RB O
increases VBZ VBZ O
the DT DT O
prevalence NN NN O
of IN IN O
persistent JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
syndrome NN NN O
of IN IN O
the DT DT O
newborn NN NN O
. . . O

The DT DT O
mechanism NN NN O
responsible JJ JJ O
for IN IN O
this DT DT O
effect NN NN O
is VBZ VBZ O
unclear JJ JJ O
and CC CC O
paradoxical JJ JJ O
, , , O
considering VBG VBG O
the DT DT O
current JJ JJ O
evidence NN NN O
of IN IN O
a DT DT O
pulmonary JJ JJ O
hypertension NN NN O
protective JJ JJ O
fluoxetine NN NN B-CHEM
effect NN NN O
in IN IN O
adult NN NN O
rodents NNS NNS O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
fluoxetine NN NN B-CHEM
effect NN NN O
on IN IN O
fetal JJ JJ O
rat NN NN O
pulmonary JJ JJ O
vascular NN NN O
smooth JJ JJ O
muscle NN NN O
mechanical JJ JJ O
properties NNS NNS O
and CC CC O
cell NN NN O
proliferation NN NN O
rate NN NN O
. . . O

METHODS NNP NNP O
: : : O
Pregnant NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
fluoxetine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
from IN IN O
Day NNP NNP O
11 CD CD O
through IN IN O
Day NNP NNP O
21 CD CD O
of IN IN O
gestation NN NN O
. . . O

MEASUREMENTS NNP NNP O
AND CC CC O
MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
Fetuses NNP NNP O
were VBD VBD O
delivered VBN VBN O
by IN IN O
cesarean JJ JJ O
section NN NN O
. . . O

As IN IN O
compared VBN VBN O
with IN IN O
controls NNS NNS O
, , , O
fluoxetine JJ JJ B-CHEM
exposure NN NN O
resulted VBD VBD O
in IN IN O
fetal JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
as IN IN O
evidenced VBN VBN O
by IN IN O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
weight NN NN O
ratio NN NN O
of IN IN O
the DT DT O
right NN NN O
ventricle NN NN O
to TO TO O
the DT DT O
left NN NN O
ventricle NN NN O
plus CC CC O
septum NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
and CC CC O
by IN IN O
an DT DT O
increase NN NN O
in IN IN O
pulmonary JJ JJ O
arterial NN NN O
medial NN NN O
thickness NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Postnatal NNP NNP O
mortality NN NN O
was VBD VBD O
increased VBN VBN O
among IN IN O
experimental JJ JJ O
animals NNS NNS O
, , , O
and CC CC O
arterial JJ JJ O
oxygen NN NN B-CHEM
saturation NN NN O
was VBD VBD O
96 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
% NN NN O
in IN IN O
1 CD CD O
- : : O
day NN NN O
- : : O
old JJ JJ O
control NN NN O
animals NNS NNS O
and CC CC O
significantly RB RB O
lower JJR JJR O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
in IN IN O
fluoxetine NN NN B-CHEM
- - - O
exposed VBN VBN O
pups NNS NNS O
( ( ( O
79 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
% NN NN O
) ) ) O
. . . O

In IN IN O
vitro NN NN O
, , , O
fluoxetine NN NN B-CHEM
induced VBN VBN O
pulmonary JJ JJ O
arterial JJ JJ O
muscle NN NN O
contraction NN NN O
in IN IN O
fetal JJ JJ O
, , , O
but CC CC O
not RB RB O
adult VB VB O
, , , O
animals NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
and CC CC O
reduced VBN VBN O
serotonin NN NN B-CHEM
- - - O
induced JJ JJ O
contraction NN NN O
at IN IN O
both DT DT O
ages NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

After IN IN O
in IN IN O
utero JJ JJ O
exposure NN NN O
to TO TO O
a DT DT O
low JJ JJ O
fluoxetine NN NN B-CHEM
concentration NN NN O
the DT DT O
pulmonary JJ JJ O
arterial NN NN O
smooth JJ JJ O
muscle NN NN O
cell NN NN O
proliferation NN NN O
rate NN NN O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
fetal JJ JJ O
, , , O
but CC CC O
not RB RB O
adult NN NN O
, , , O
cells NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
contrast NN NN O
to TO TO O
the DT DT O
adult NN NN O
, , , O
fluoxetine JJ JJ B-CHEM
exposure NN NN O
in IN IN O
utero NN NN O
induces NNS NNS O
pulmonary JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
fetal JJ JJ O
rat NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
a DT DT O
developmentally RB RB O
regulated VBN VBN O
increase NN NN O
in IN IN O
pulmonary JJ JJ O
vascular NN NN O
smooth JJ JJ O
muscle NN NN O
proliferation NN NN O
. . . O

Disulfiram NNP NNP B-CHEM
- : : O
induced JJ JJ O
transient NN NN O
optic JJ JJ O
and CC CC O
peripheral JJ JJ O
neuropathy NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

AIM NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
optic JJ JJ O
and CC CC O
peripheral JJ JJ O
neuropathy NN NN O
after IN IN O
chronic JJ JJ O
use NN NN O
of IN IN O
disulfiram NN NN B-CHEM
for IN IN O
alcohol NN NN O
dependence NN NN O
management NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
A DT DT O
case NN NN O
report NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
57 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
presented VBN VBN O
with IN IN O
gradual JJ JJ O
loss NN NN O
of IN IN O
vision NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
with IN IN O
intermittent JJ JJ O
headaches NNS NNS O
for IN IN O
2 CD CD O
months NNS NNS O
. . . O

He PRP PRP O
also RB RB O
complained VBD VBD O
of IN IN O
paraesthesia NN NN O
with IN IN O
numbness NN NN O
in IN IN O
both DT DT O
feet NNS NNS O
. . . O

His PRP$ PRP$ O
vision NN NN O
was VBD VBD O
6 CD CD O
/ NN NN O
15 CD CD O
and CC CC O
2 CD CD O
/ NN NN O
60 CD CD O
in IN IN O
the DT DT O
right NN NN O
and CC CC O
left VBD VBD O
eyes NNS NNS O
, , , O
respectively RB RB O
. . . O

Fundoscopy NNP NNP O
revealed VBD VBD O
bilaterally RB RB O
swollen VBN VBN O
optic JJ JJ O
nerve NN NN O
heads NNS NNS O
. . . O

Visual NNP NNP O
field NN NN O
testing NN NN O
confirmed VBD VBD O
bilateral JJ JJ O
central JJ JJ O
- - - O
caecal JJ JJ O
scotomata NN NN O
. . . O

He PRP PRP O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
disulfiram NN NN B-CHEM
for IN IN O
alcohol NN NN O
dependence NN NN O
for IN IN O
the DT DT O
preceding VBG VBG O
3 CD CD O
years NNS NNS O
. . . O

Disulfiram NNP NNP B-CHEM
discontinuation NN NN O
lead NN NN O
to TO TO O
an DT DT O
immediate JJ JJ O
symptomatic JJ JJ O
improvement NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Physicians NNP NNP O
initiating VBG VBG O
long JJ JJ O
- - - O
term NN NN O
disulfiram NN NN B-CHEM
therapy NN NN O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
these DT DT O
adverse JJ JJ O
effects NNS NNS O
. . . O

They PRP PRP O
should MD MD O
recommend VB VB O
annual JJ JJ O
ophthalmic JJ JJ O
reviews NNS NNS O
with IN IN O
visual JJ JJ O
field NN NN O
testing NN NN O
. . . O

Patients NNS NNS O
should MD MD O
be VB VB O
reassured VBN VBN O
with IN IN O
respect NN NN O
to TO TO O
the DT DT O
reversibility NN NN O
of IN IN O
these DT DT O
adverse JJ JJ O
effects NNS NNS O
. . . O

Intraocular NNP NNP O
pressure NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
uveitis NNS NNS O
treated VBN VBN O
with IN IN O
fluocinolone NN NN B-CHEM
acetonide NN NN I-CHEM
implants NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
the DT DT O
incidence NN NN O
and CC CC O
management NN NN O
of IN IN O
elevated VBD VBD O
intraocular JJ JJ O
pressure NN NN O
( ( ( O
IOP NNP NNP O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
uveitis NNS NNS O
treated VBN VBN O
with IN IN O
the DT DT O
fluocinolone NN NN B-CHEM
acetonide NN NN I-CHEM
( ( ( O
FA NNP NNP B-CHEM
) ) ) O
intravitreal NN NN O
implant NN NN O
. . . O

DESIGN NNP NNP O
: : : O
Pooled NNP NNP O
data NNS NNS O
from IN IN O
3 CD CD O
multicenter NN NN O
, , , O
double JJ JJ O
- - - O
masked JJ JJ O
, , , O
randomized JJ JJ O
, , , O
controlled VBN VBN O
, , , O
phase NN NN O
2b CD CD O
/ NN NN O
3 CD CD O
clinical JJ JJ O
trials NNS NNS O
evaluating VBG VBG O
the DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
the DT DT O
0 CD CD O
. . . O
59 CD CD O
- : : O
mg NN NN O
or CC CC O
2 CD CD O
. . . O
1 CD CD O
- : : O
mg NN NN O
FA NNP NNP B-CHEM
intravitreal NN NN O
implant NN NN O
or CC CC O
standard JJ JJ O
therapy NN NN O
were VBD VBD O
analyzed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
During IN IN O
the DT DT O
3 CD CD O
- : : O
year NN NN O
follow VB VB O
- - - O
up RP RP O
, , , O
71 CD CD O
. . . O
0 CD CD O
% NN NN O
of IN IN O
implanted JJ JJ O
eyes NNS NNS O
had VBD VBD O
an DT DT O
IOP NNP NNP O
increase NN NN O
of IN IN O
10 CD CD O
mm NN NN O
Hg NNP NNP O
or CC CC O
more JJR JJR O
than IN IN O
baseline NN NN O
and CC CC O
55 CD CD O
. . . O
1 CD CD O
% NN NN O
, , , O
24 CD CD O
. . . O
7 CD CD O
% NN NN O
, , , O
and CC CC O
6 CD CD O
. . . O
2 CD CD O
% NN NN O
of IN IN O
eyes NNS NNS O
reached VBD VBD O
an DT DT O
IOP NNP NNP O
of IN IN O
30 CD CD O
mm NN NN O
Hg NNP NNP O
or CC CC O
more JJR JJR O
, , , O
40 CD CD O
mm NN NN O
Hg NNP NNP O
or CC CC O
more JJR JJR O
, , , O
and CC CC O
50 CD CD O
mm NN NN O
Hg NNP NNP O
or CC CC O
more JJR JJR O
, , , O
respectively RB RB O
. . . O

Topical NNP NNP O
IOP NNP NNP O
- : : O
lowering VBG VBG O
medication NN NN O
was VBD VBD O
administered VBN VBN O
in IN IN O
74 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
implanted JJ JJ O
eyes NNS NNS O
, , , O
and CC CC O
IOP NNP NNP O
- : : O
lowering VBG VBG O
surgeries NNS NNS O
, , , O
most JJS JJS O
of IN IN O
which WDT WDT O
were VBD VBD O
trabeculectomies NNS NNS O
( ( ( O
76 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
, , , O
were VBD VBD O
performed VBN VBN O
on IN IN O
36 CD CD O
. . . O
6 CD CD O
% NN NN O
of IN IN O
implanted JJ JJ O
eyes NNS NNS O
. . . O

Intraocular NNP NNP O
pressure NN NN O
- : : O
lowering VBG VBG O
surgeries NNS NNS O
were VBD VBD O
considered VBN VBN O
a DT DT O
success NN NN O
( ( ( O
postoperative JJ JJ O
IOP NNP NNP O
of IN IN O
6 CD CD O
- : : O
21 CD CD O
mm NN NN O
Hg NNP NNP O
with IN IN O
or CC CC O
without IN IN O
additional JJ JJ O
IOP NNP NNP O
- : : O
lowering VBG VBG O
medication NN NN O
) ) ) O
in IN IN O
85 CD CD O
. . . O
1 CD CD O
% NN NN O
of IN IN O
eyes NNS NNS O
at IN IN O
1 CD CD O
year NN NN O
. . . O

The DT DT O
rate NN NN O
of IN IN O
hypotony NN NN O
( ( ( O
IOP NNP NNP O
< NN NN O
/ NN NN O
= SYM SYM O
5 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
following VBG VBG O
IOP NNP NNP O
- : : O
lowering VBG VBG O
surgery NN NN O
( ( ( O
42 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
not RB RB O
different JJ JJ O
from IN IN O
that DT DT O
of IN IN O
implanted JJ JJ O
eyes NNS NNS O
not RB RB O
subjected VBN VBN O
to TO TO O
surgery NN NN O
( ( ( O
35 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
09 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Elevated NNP NNP O
IOP NNP NNP O
is VBZ VBZ O
a DT DT O
significant JJ JJ O
complication NN NN O
with IN IN O
the DT DT O
FA NNP NNP O
intravitreal NN NN O
implant NN NN O
but CC CC O
may MD MD O
be VB VB O
controlled VBN VBN O
with IN IN O
medication NN NN O
and CC CC O
surgery NN NN O
. . . O

Myocardial NNP NNP O
Fas NNP NNP O
ligand NN NN O
expression NN NN O
increases NNS NNS O
susceptibility NN NN O
to TO TO O
AZT NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Dilated NNP NNP O
cardiomyopathy NN NN O
( ( ( O
DCM NNP NNP O
) ) ) O
and CC CC O
myocarditis NNS NNS O
occur VBP VBP O
in IN IN O
many JJ JJ O
HIV NNP NNP O
- - - O
infected JJ JJ O
individuals NNS NNS O
, , , O
resulting VBG VBG O
in IN IN O
symptomatic JJ JJ O
heart NN NN O
failure NN NN O
in IN IN O
up IN IN O
to TO TO O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Highly RB RB O
active JJ JJ O
antiretroviral NN NN O
therapy NN NN O
( ( ( O
HAART NNP NNP O
) ) ) O
has VBZ VBZ O
significantly RB RB O
reduced VBN VBN O
morbidity NN NN O
and CC CC O
mortality NN NN O
of IN IN O
acquired JJ JJ O
immunodeficiency NN NN O
syndrome NN NN O
( ( ( O
AIDS NNP NNP O
) ) ) O
, , , O
but CC CC O
has VBZ VBZ O
resulted VBN VBN O
in IN IN O
an DT DT O
increase NN NN O
in IN IN O
cardiac NN NN O
and CC CC O
skeletal JJ JJ O
myopathies NNS NNS O
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
In IN IN O
order NN NN O
to TO TO O
investigate VB VB O
whether IN IN O
the DT DT O
HAART NNP NNP O
component NN NN O
zidovudine NN NN B-CHEM
( ( ( O
3 CD CD B-CHEM
' POS POS I-CHEM
- : : I-CHEM
azido NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
' POS POS I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
deoxythymidine NN NN I-CHEM
; : : O
AZT NNP NNP B-CHEM
) ) ) O
triggers NNS NNS O
the DT DT O
Fas NNP NNP O
- - - O
dependent JJ JJ O
cell NN NN O
- - - O
death NN NN O
pathway NN NN O
and CC CC O
cause VB VB O
cytoskeletal JJ JJ O
disruption NN NN O
in IN IN O
a DT DT O
murine NN NN O
model NN NN O
of IN IN O
DCM NNP NNP O
, , , O
8 CD CD O
- - - O
week NN NN O
- - - O
old JJ JJ O
transgenic NN NN O
( ( ( O
expressing VBG VBG O
Fas NNP NNP O
ligand NN NN O
in IN IN O
the DT DT O
myocardium NN NN O
: : : O
FasL NNP NNP O
Tg NNP NNP O
) ) ) O
and CC CC O
non NN NN O
- - - O
transgenic JJ JJ O
( ( ( O
NTg NNP NNP O
) ) ) O
mice NN NN O
received VBD VBD O
water NN NN O
ad NN NN O
libitum NN NN O
containing VBG VBG O
different JJ JJ O
concentrations NNS NNS O
of IN IN O
AZT NNP NNP B-CHEM
( ( ( O
0 CD CD O
, , , O
0 CD CD O
. . . O
07 CD CD O
, , , O
0 CD CD O
. . . O
2 CD CD O
, , , O
and CC CC O
0 CD CD O
. . . O
7 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

After IN IN O
6 CD CD O
weeks NNS NNS O
, , , O
cardiac NN NN O
function NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
echocardiography NN NN O
and CC CC O
morphology NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
histopathologic JJ JJ O
and CC CC O
immunohistochemical JJ JJ O
methods NNS NNS O
. . . O

NTg NNP NNP O
and CC CC O
untreated JJ JJ O
FasL NNP NNP O
Tg NNP NNP O
mice NN NN O
showed VBD VBD O
little JJ JJ O
or CC CC O
no DT DT O
change NN NN O
in IN IN O
cardiac JJ JJ O
structure NN NN O
or CC CC O
function NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
AZT NNP NNP B-CHEM
- - - O
treated JJ JJ O
FasL NNP NNP O
Tg NNP NNP O
mice NN NN O
developed VBN VBN O
cardiac JJ JJ O
dilation NN NN O
and CC CC O
depressed JJ JJ O
cardiac JJ JJ O
function NN NN O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
, , , O
with IN IN O
concomitant NN NN O
inflammatory JJ JJ O
infiltration NN NN O
of IN IN O
both DT DT O
ventricles NNS NNS O
. . . O

These DT DT O
changes NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
sarcolemmal NN NN O
expression NN NN O
of IN IN O
Fas NNP NNP O
and CC CC O
FasL NNP NNP O
, , , O
as RB RB O
well RB RB O
as IN IN O
increased VBN VBN O
activation NN NN O
of IN IN O
caspase NN NN O
3 CD CD O
, , , O
translocation NN NN O
of IN IN O
calpain NN NN O
1 CD CD O
to TO TO O
the DT DT O
sarcolemma NN NN O
and CC CC O
sarcomere NN NN O
, , , O
and CC CC O
increased JJ JJ O
numbers NNS NNS O
of IN IN O
cells NNS NNS O
undergoing VBG VBG O
apoptosis NN NN O
. . . O

These DT DT O
were VBD VBD O
associated VBN VBN O
with IN IN O
changes NNS NNS O
in IN IN O
dystrophin NN NN O
and CC CC O
cardiac NN NN O
troponin NN NN O
I PRP PRP O
localization NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
loss NN NN O
of IN IN O
sarcolemmal NN NN O
integrity NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
expression NN NN O
of IN IN O
Fas NNP NNP O
ligand NN NN O
in IN IN O
the DT DT O
myocardium NN NN O
, , , O
as IN IN O
identified VBN VBN O
in IN IN O
HIV NNP NNP O
- - - O
positive JJ JJ O
patients NNS NNS O
, , , O
might MD MD O
increase VB VB O
the DT DT O
susceptibility NN NN O
to TO TO O
HAART NNP NNP O
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
due JJ JJ O
to TO TO O
activation NN NN O
of IN IN O
apoptotic JJ JJ O
pathways NNS NNS O
, , , O
resulting VBG VBG O
in IN IN O
cardiac JJ JJ O
dilation NN NN O
and CC CC O
dysfunction NN NN O
. . . O

Gastrointestinal NNP NNP O
tolerability NN NN O
of IN IN O
etoricoxib NN NN B-CHEM
in IN IN O
rheumatoid NN NN O
arthritis NN NN O
patients NNS NNS O
: : : O
results NNS NNS O
of IN IN O
the DT DT O
etoricoxib NN NN B-CHEM
vs NNS NNS O
diclofenac NN NN B-CHEM
sodium NN NN I-CHEM
gastrointestinal JJ JJ O
tolerability NN NN O
and CC CC O
effectiveness NN NN O
trial NN NN O
( ( ( O
EDGE NNP NNP O
- - - O
II NNP NNP O
) ) ) O
. . . O

OBJECTIVE NNP NNP O
: : : O
A DT DT O
randomised JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
to TO TO O
compare VB VB O
the DT DT O
gastrointestinal NN NN O
( ( ( O
GI NNP NNP O
) ) ) O
tolerability NN NN O
, , , O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
etoricoxib NN NN B-CHEM
and CC CC O
diclofenac NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
( ( ( O
RA NNP NNP O
) ) ) O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
A DT DT O
total NN NN O
of IN IN O
4086 CD CD O
patients NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
60 CD CD O
. . . O
8 CD CD O
years NNS NNS O
) ) ) O
diagnosed VBN VBN O
with IN IN O
RA NNP NNP O
were VBD VBD O
enrolled VBN VBN O
and CC CC O
received VBN VBN O
etoricoxib NN NN B-CHEM
90 CD CD O
mg NN NN O
daily JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
2032 CD CD O
) ) ) O
or CC CC O
diclofenac NN NN B-CHEM
75 CD CD O
mg NN NN O
twice RB RB O
daily JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
2054 CD CD O
) ) ) O
. . . O

Use NN NN O
of IN IN O
gastroprotective JJ JJ O
agents NNS NNS O
and CC CC O
low JJ JJ O
- - - O
dose NN NN O
aspirin NN NN B-CHEM
was VBD VBD O
allowed VBN VBN O
. . . O

The DT DT O
prespecified JJ JJ O
primary JJ JJ O
end NN NN O
point NN NN O
consisted VBD VBD O
of IN IN O
the DT DT O
cumulative JJ JJ O
rate NN NN O
of IN IN O
patient NN NN O
discontinuations NNS NNS O
due JJ JJ O
to TO TO O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
GI NNP NNP O
adverse NN NN O
experiences NNS NNS O
( ( ( O
AEs NNP NNP O
) ) ) O
. . . O

General NNP NNP O
safety NN NN O
was VBD VBD O
also RB RB O
assessed VBN VBN O
, , , O
including VBG VBG O
adjudicated VBN VBN O
thrombotic JJ JJ O
cardiovascular JJ JJ O
event NN NN O
data NNS NNS O
. . . O

Efficacy NNP NNP O
was VBD VBD O
evaluated VBN VBN O
using VBG VBG O
the DT DT O
Patient NNP NNP O
Global NNP NNP O
Assessment NNP NNP O
of IN IN O
Disease NNP NNP O
Status NNP NNP O
( ( ( O
PGADS NNP NNP O
; : : O
0 CD CD O
- : : O
4 CD CD O
point NN NN O
scale NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Mean NNP NNP O
( ( ( O
SD NNP NNP O
; : : O
maximum NN NN O
) ) ) O
duration NN NN O
of IN IN O
treatment NN NN O
was VBD VBD O
19 CD CD O
. . . O
3 CD CD O
( ( ( O
10 CD CD O
. . . O
3 CD CD O
; : : O
32 CD CD O
. . . O
9 CD CD O
) ) ) O
and CC CC O
19 CD CD O
. . . O
1 CD CD O
( ( ( O
10 CD CD O
. . . O
4 CD CD O
; : : O
33 CD CD O
. . . O
1 CD CD O
) ) ) O
months NNS NNS O
in IN IN O
the DT DT O
etoricoxib NN NN B-CHEM
and CC CC O
diclofenac NN NN B-CHEM
groups NNS NNS O
, , , O
respectively RB RB O
. . . O

The DT DT O
cumulative JJ JJ O
discontinuation NN NN O
rate NN NN O
due JJ JJ O
to TO TO O
GI NNP NNP O
AEs NNP NNP O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
with IN IN O
etoricoxib NN NN B-CHEM
than IN IN O
diclofenac NN NN B-CHEM
( ( ( O
5 CD CD O
. . . O
2 CD CD O
vs NNS NNS O
8 CD CD O
. . . O
5 CD CD O
events NNS NNS O
per IN IN O
100 CD CD O
patient NN NN O
- : : O
years NNS NNS O
, , , O
respectively RB RB O
; : : O
hazard NN NN O
ratio NN NN O
0 CD CD O
. . . O
62 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
47 CD CD O
, , , O
0 CD CD O
. . . O
81 CD CD O
; : : O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
) ) ) O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
discontinuations NNS NNS O
for IN IN O
hypertension NN NN O
- - - O
related VBN VBN O
and CC CC O
oedema NN NN O
- - - O
related VBN VBN O
AEs NNP NNP O
were VBD VBD O
significantly RB RB O
higher JJR JJR O
with IN IN O
etoricoxib NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
% NN NN O
and CC CC O
1 CD CD O
. . . O
1 CD CD O
% NN NN O
respectively RB RB O
) ) ) O
compared VBN VBN O
with IN IN O
diclofenac NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
and CC CC O
0 CD CD O
. . . O
4 CD CD O
% NN NN O
respectively RB RB O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
for IN IN O
hypertension NN NN O
and CC CC O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
for IN IN O
oedema NN NN O
) ) ) O
. . . O

Etoricoxib NNP NNP B-CHEM
and CC CC O
diclofenac NN NN B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
similar JJ JJ O
efficacy NN NN O
( ( ( O
PGADS NNP NNP O
mean VB VB O
changes NNS NNS O
from IN IN O
baseline NN NN O
- - - O
0 CD CD O
. . . O
62 CD CD O
vs NNS NNS O
- : : O
0 CD CD O
. . . O
58 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Etoricoxib NNP NNP B-CHEM
90 CD CD O
mg NN NN O
demonstrated VBD VBD O
a DT DT O
significantly RB RB O
lower JJR JJR O
risk NN NN O
for IN IN O
discontinuing VBG VBG O
treatment NN NN O
due JJ JJ O
to TO TO O
GI NNP NNP O
AEs NNP NNP O
compared VBD VBD O
with IN IN O
diclofenac NN NN B-CHEM
150 CD CD O
mg NN NN O
. . . O

Discontinuations NNP NNP O
from IN IN O
renovascular NN NN O
AEs NNP NNP O
, , , O
although IN IN O
less JJR JJR O
common JJ JJ O
than IN IN O
discontinuations NNS NNS O
from IN IN O
GI NNP NNP O
AEs NNP NNP O
, , , O
were VBD VBD O
significantly RB RB O
higher JJR JJR O
with IN IN O
etoricoxib NN NN B-CHEM
. . . O

Anxiogenic NNP NNP O
potential JJ JJ O
of IN IN O
ciprofloxacin NN NN B-CHEM
and CC CC O
norfloxacin NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

INTRODUCTION NNP NNP O
: : : O
The DT DT O
possible JJ JJ O
anxiogenic JJ JJ O
effects NNS NNS O
of IN IN O
fluoroquinolones NNS NNS B-CHEM
, , , O
namely RB RB O
ciprofloxacin NN NN B-CHEM
and CC CC O
norfloxacin NN NN B-CHEM
, , , O
were VBD VBD O
investigated VBN VBN O
in IN IN O
adult NN NN O
Charles NNP NNP O
Foster NNP NNP O
albino NN NN O
rats NNS NNS O
of IN IN O
either DT DT O
sex NN NN O
, , , O
weighing VBG VBG O
150 CD CD O
- : : O
200 CD CD O
g SYM SYM O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
drugs NNS NNS O
were VBD VBD O
given VBN VBN O
orally RB RB O
, , , O
in IN IN O
doses NNS NNS O
of IN IN O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
five CD CD O
consecutive JJ JJ O
days NNS NNS O
and CC CC O
the DT DT O
experiments NNS NNS O
were VBD VBD O
performed VBN VBN O
on IN IN O
the DT DT O
fifth JJ JJ O
day NN NN O
. . . O

The DT DT O
tests NNS NNS O
included VBD VBD O
open JJ JJ O
- - - O
field NN NN O
exploratory NN NN O
behaviour NN NN O
, , , O
elevated VBD VBD O
plus CC CC O
maze NN NN O
and CC CC O
elevated VBD VBD O
zero CD CD O
maze NN NN O
, , , O
social JJ JJ O
interaction NN NN O
and CC CC O
novelty NN NN O
- - - O
suppressed JJ JJ O
feeding NN NN O
latency NN NN O
behaviour NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
ciprofloxacin NN NN B-CHEM
- : : O
and CC CC O
norfloxacin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
showed VBD VBD O
anxious JJ JJ O
behaviour NN NN O
in IN IN O
comparison NN NN O
to TO TO O
control VB VB O
rats NNS NNS O
in IN IN O
all PDT PDT O
the DT DT O
parameters NNS NNS O
studied VBN VBN O
. . . O

However RB RB O
, , , O
ciprofloxacin NN NN B-CHEM
- - - O
and CC CC O
norfloxacin NN NN B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
from IN IN O
each DT DT O
other JJ JJ O
in IN IN O
various JJ JJ O
behavioural NN NN O
parameters NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
present JJ JJ O
experimental JJ JJ O
findings NNS NNS O
substantiate VBP VBP O
the DT DT O
clinically RB RB O
observed VBN VBN O
anxiogenic JJ JJ O
potential JJ JJ O
of IN IN O
ciprofloxacin NN NN B-CHEM
and CC CC O
norfloxacin NN NN B-CHEM
. . . O

Reduction NNP NNP O
of IN IN O
pain NN NN O
during IN IN O
induction NN NN O
with IN IN O
target NN NN O
- - - O
controlled JJ JJ O
propofol NN NN B-CHEM
and CC CC O
remifentanil NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Pain NN NN O
on IN IN O
injection NN NN O
of IN IN O
propofol NN NN B-CHEM
is VBZ VBZ O
unpleasant JJ JJ O
. . . O

We PRP PRP O
hypothesized VBN VBN O
that IN IN O
propofol NN NN B-CHEM
infusion NN NN O
pain NN NN O
might MD MD O
be VB VB O
prevented VBN VBN O
by IN IN O
infusing VBG VBG O
remifentanil NN NN B-CHEM
before IN IN O
starting VBG VBG O
the DT DT O
propofol NN NN B-CHEM
infusion NN NN O
in IN IN O
a DT DT O
clinical JJ JJ O
setting NN NN O
where WRB WRB O
target NN NN O
- - - O
controlled JJ JJ O
infusions NNS NNS O
( ( ( O
TCI NNP NNP O
) ) ) O
of IN IN O
both DT DT O
drugs NNS NNS O
were VBD VBD O
used VBN VBN O
. . . O

A DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
was VBD VBD O
performed VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
effect NN NN O
- - - O
site NN NN O
concentration NN NN O
( ( ( O
Ce NNP NNP O
) ) ) O
of IN IN O
remifentanil NN NN B-CHEM
to TO TO O
prevent VB VB O
the DT DT O
pain NN NN O
without IN IN O
producing VBG VBG O
complications NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
total NN NN O
of IN IN O
128 CD CD O
patients NNS NNS O
undergoing VBG VBG O
general JJ JJ O
surgery NN NN O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
to TO TO O
receive VB VB O
normal JJ JJ O
saline NN NN O
( ( ( O
control NN NN O
) ) ) O
or CC CC O
remifentanil NN NN B-CHEM
to TO TO O
a DT DT O
target NN NN O
Ce NNP NNP O
of IN IN O
2 CD CD O
ng NN NN O
ml NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
( ( ( O
R2 NNP NNP O
) ) ) O
, , , O
4 CD CD O
ng NN NN O
ml NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
( ( ( O
R4 NNP NNP O
) ) ) O
, , , O
or CC CC O
6 CD CD O
ng NN NN O
ml NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
( ( ( O
R6 NNP NNP O
) ) ) O
administered VBD VBD O
via IN IN O
TCI NNP NNP O
. . . O

After IN IN O
the DT DT O
target NN NN O
Ce NNP NNP O
was VBD VBD O
achieved VBN VBN O
, , , O
the DT DT O
infusion NN NN O
of IN IN O
propofol NN NN B-CHEM
was VBD VBD O
started VBN VBN O
. . . O

Remifentanil NNP NNP B-CHEM
- - - O
related VBN VBN O
complications NNS NNS O
were VBD VBD O
assessed VBN VBN O
during IN IN O
the DT DT O
remifentanil NN NN B-CHEM
infusion NN NN O
, , , O
and CC CC O
pain NN NN O
caused VBN VBN O
by IN IN O
propofol NN NN B-CHEM
was VBD VBD O
evaluated VBN VBN O
using VBG VBG O
a DT DT O
four CD CD O
- - - O
point NN NN O
scale NN NN O
during IN IN O
the DT DT O
propofol NN NN B-CHEM
infusion NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
incidence NN NN O
of IN IN O
pain NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
Groups NNS NNS O
R4 NNP NNP O
and CC CC O
R6 NNP NNP O
than IN IN O
in IN IN O
the DT DT O
control NN NN O
and CC CC O
R2 NNP NNP O
groups NNS NNS O
( ( ( O
12 CD CD O
/ NN NN O
32 CD CD O
and CC CC O
6 CD CD O
/ NN NN O
31 CD CD O
vs NNS NNS O
26 CD CD O
/ NN NN O
31 CD CD O
and CC CC O
25 CD CD O
/ NN NN O
32 CD CD O
, , , O
respectively RB RB O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Pain NN NN O
was VBD VBD O
less RBR RBR O
severe JJ JJ O
in IN IN O
Groups NNS NNS O
R4 NNP NNP O
and CC CC O
R6 NNP NNP O
than IN IN O
in IN IN O
the DT DT O
control NN NN O
and CC CC O
R2 NNP NNP O
groups NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

However RB RB O
, , , O
both DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
pain NN NN O
were VBD VBD O
not RB RB O
different JJ JJ O
between IN IN O
Groups NNS NNS O
R4 NNP NNP O
and CC CC O
R6 NNP NNP O
. . . O

No DT DT O
significant JJ JJ O
complications NNS NNS O
were VBD VBD O
observed VBN VBN O
during IN IN O
the DT DT O
study NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
During IN IN O
induction NN NN O
of IN IN O
anaesthesia NN NN O
with IN IN O
TCI NNP NNP O
of IN IN O
propofol NN NN B-CHEM
and CC CC O
remifentanil NN NN B-CHEM
, , , O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
propofol NN NN B-CHEM
infusion NN NN O
pain NN NN O
was VBD VBD O
achieved VBN VBN O
without IN IN O
significant JJ JJ O
complications NNS NNS O
by IN IN O
prior JJ JJ O
administration NN NN O
of IN IN O
remifentanil NN NN B-CHEM
at IN IN O
a DT DT O
target NN NN O
Ce NNP NNP O
of IN IN O
4 CD CD O
ng NN NN O
ml NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O

Dexmedetomidine NNP NNP B-CHEM
and CC CC O
cardiac NN NN O
protection NN NN O
for IN IN O
non NN NN O
- - - O
cardiac NN NN O
surgery NN NN O
: : : O
a DT DT O
meta NN NN O
- - - O
analysis NN NN O
of IN IN O
randomised VBD VBD O
controlled VBN VBN O
trials NNS NNS O
. . . O

We PRP PRP O
conducted VBD VBD O
a DT DT O
systematic JJ JJ O
review NN NN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
dexmedetomidine NN NN B-CHEM
on IN IN O
cardiac JJ JJ O
outcomes NNS NNS O
following VBG VBG O
non NN NN O
- - - O
cardiac JJ JJ O
surgery NN NN O
. . . O

We PRP PRP O
included VBD VBD O
prospective JJ JJ O
, , , O
randomised VBN VBN O
peri NN NN O
- - - O
operative JJ JJ O
studies NNS NNS O
of IN IN O
dexmedetomidine NN NN B-CHEM
that WDT WDT O
reported VBD VBD O
mortality NN NN O
, , , O
cardiac JJ JJ O
morbidity NN NN O
or CC CC O
adverse JJ JJ O
drug NN NN O
events NNS NNS O
. . . O

A DT DT O
PubMed NNP NNP O
Central NNP NNP O
and CC CC O
EMBASE NNP NNP O
search NN NN O
was VBD VBD O
conducted VBN VBN O
up IN IN O
to TO TO O
July NNP NNP O
2007 CD CD O
. . . O

The DT DT O
reference NN NN O
lists NNS NNS O
of IN IN O
identified VBN VBN O
papers NNS NNS O
were VBD VBD O
examined VBN VBN O
for IN IN O
further JJ JJ O
trials NNS NNS O
. . . O

Of IN IN O
425 CD CD O
studies NNS NNS O
identified VBN VBN O
, , , O
20 CD CD O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
meta NN NN O
- - - O
analysis NN NN O
( ( ( O
840 CD CD O
patients NNS NNS O
) ) ) O
. . . O

Dexmedetomidine NNP NNP B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
trend NN NN O
towards IN IN O
improved VBN VBN O
cardiac NN NN O
outcomes NNS NNS O
; : : O
all DT DT O
- - - O
cause NN NN O
mortality NN NN O
( ( ( O
OR CC CC O
0 CD CD O
. . . O
27 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
01 CD CD O
- : : O
7 CD CD O
. . . O
13 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
44 CD CD O
) ) ) O
, , , O
non NN NN O
- - - O
fatal JJ JJ O
myocardial NN NN O
infarction NN NN O
( ( ( O
OR CC CC O
0 CD CD O
. . . O
26 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
04 CD CD O
- : : O
1 CD CD O
. . . O
60 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
14 CD CD O
) ) ) O
, , , O
and CC CC O
myocardial NN NN O
ischaemia NN NN O
( ( ( O
OR CC CC O
0 CD CD O
. . . O
65 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
26 CD CD O
- : : O
1 CD CD O
. . . O
63 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
36 CD CD O
) ) ) O
. . . O

Peri NNP NNP O
- : : O
operative JJ JJ O
hypotension NN NN O
( ( ( O
26 CD CD O
% NN NN O
, , , O
OR CC CC O
3 CD CD O
. . . O
80 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
91 CD CD O
- : : O
7 CD CD O
. . . O
54 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
and CC CC O
bradycardia NNS NNS O
( ( ( O
17 CD CD O
% NN NN O
, , , O
OR CC CC O
5 CD CD O
. . . O
45 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
2 CD CD O
. . . O
98 CD CD O
- : : O
9 CD CD O
. . . O
95 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
00001 CD CD O
) ) ) O
were VBD VBD O
significantly RB RB O
increased VBN VBN O
. . . O

An DT DT O
anticholinergic NN NN O
did VBD VBD O
not RB RB O
reduce VB VB O
the DT DT O
incidence NN NN O
of IN IN O
bradycardia NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
43 CD CD O
) ) ) O
. . . O

A DT DT O
randomised JJ JJ O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
of IN IN O
dexmedetomidine NN NN B-CHEM
is VBZ VBZ O
warranted VBN VBN O
. . . O

Myocardial NNP NNP O
infarction NN NN O
in IN IN O
pregnancy NN NN O
associated VBN VBN O
with IN IN O
clomiphene NN NN B-CHEM
citrate NN NN I-CHEM
for IN IN O
ovulation NN NN O
induction NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Clomiphene NNP NNP B-CHEM
citrate NN NN I-CHEM
( ( ( O
CC NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
commonly RB RB O
prescribed VBN VBN O
for IN IN O
ovulation NN NN O
induction NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
considered VBN VBN O
safe JJ JJ O
, , , O
with IN IN O
minimal JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

Thromboembolism NNP NNP O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
but CC CC O
life NN NN O
- - - O
threatening VBG VBG O
complication NN NN O
that WDT WDT O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
after IN IN O
ovulation NN NN O
induction NN NN O
with IN IN O
CC NNP NNP B-CHEM
. . . O

Spontaneous NNP NNP O
coronary JJ JJ O
thrombosis NN NN O
or CC CC O
thromboembolism NN NN O
with IN IN O
subsequent JJ JJ O
clot NN NN O
lysis NN NN O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
as IN IN O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
common JJ JJ O
causes NNS NNS O
of IN IN O
myocardial NN NN O
infarction NN NN O
( ( ( O
MI NNP NNP O
) ) ) O
during IN IN O
pregnancy NN NN O
, , , O
with IN IN O
a DT DT O
subsequently RB RB O
normal JJ JJ O
coronary JJ JJ O
angiogram NN NN O
. . . O

CASE NN NN O
: : : O
A DT DT O
33 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
a DT DT O
5 CD CD O
- : : O
week NN NN O
gestation NN NN O
had VBD VBD O
recently RB RB O
received VBN VBN O
CC NNP NNP B-CHEM
for IN IN O
ovulation NN NN O
induction NN NN O
and CC CC O
presented VBN VBN O
with IN IN O
chest NN NN O
pain NN NN O
. . . O

An DT DT O
electrocardiogram NN NN O
showed VBD VBD O
a DT DT O
lateral NN NN O
and CC CC O
anterior NN NN O
wall NN NN O
myocardial NN NN O
infarction NN NN O
. . . O

Cardiac NNP NNP O
enzymes NNS NNS O
showed VBD VBD O
a DT DT O
peak NN NN O
rise NN NN O
in IN IN O
troponin NN NN O
I PRP PRP O
to TO TO O
9 CD CD O
. . . O
10 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
. . . O

An DT DT O
initial JJ JJ O
exercise NN NN O
stress NN NN O
test NN NN O
was VBD VBD O
normal JJ JJ O
. . . O

At IN IN O
the DT DT O
time NN NN O
of IN IN O
admission NN NN O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
at IN IN O
high JJ JJ O
risk NN NN O
of IN IN O
radiation NN NN O
injury NN NN O
to TO TO O
the DT DT O
fetus NN NN O
, , , O
so RB RB O
a DT DT O
coronary JJ JJ O
angiogram NN NN O
was VBD VBD O
postponed VBN VBN O
until IN IN O
the DT DT O
second JJ JJ O
trimester NN NN O
. . . O

It PRP PRP O
showed VBD VBD O
normal JJ JJ O
coronary JJ JJ O
vessels NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
appears VBZ VBZ O
to TO TO O
be VB VB O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
documenting VBG VBG O
a DT DT O
possible JJ JJ O
association NN NN O
between IN IN O
CC NNP NNP B-CHEM
and CC CC O
myocardial NN NN O
infarction NN NN O
. . . O

Thrombosis NNP NNP O
might MD MD O
be VB VB O
a DT DT O
rare JJ JJ O
but CC CC O
hazardous JJ JJ O
complication NN NN O
of IN IN O
CC NNP NNP B-CHEM
. . . O

Given VBN VBN O
this DT DT O
life NN NN O
- : : O
threatening VBG VBG O
complication NN NN O
, , , O
appropriate JJ JJ O
prophylactic JJ JJ O
measures NNS NNS O
should MD MD O
be VB VB O
used VBN VBN O
in IN IN O
high JJ JJ O
- - - O
risk NN NN O
woman NN NN O
undergoing VBG VBG O
ovarian JJ JJ O
stimulation NN NN O
. . . O

Reverse NNP NNP O
or CC CC O
inverted VBN VBN O
left VBN VBN O
ventricular NN NN O
apical JJ JJ O
ballooning NN NN O
syndrome NN NN O
( ( ( O
reverse NN NN O
Takotsubo NNP NNP O
cardiomyopathy NN NN O
) ) ) O
in IN IN O
a DT DT O
young JJ JJ O
woman NN NN O
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
amphetamine NN NN B-CHEM
use NN NN O
. . . O

Transient NNP NNP O
left VBD VBD O
ventricular NN NN O
apical JJ JJ O
ballooning VBG VBG O
syndrome NN NN O
was VBD VBD O
first RB RB O
described VBN VBN O
in IN IN O
Japan NNP NNP O
as IN IN O
" '' '' O
Takotsubo NNP NNP O
cardiomyopathy NN NN O
. . . O
" '' '' O
This DT DT O
syndrome NN NN O
has VBZ VBZ O
been VBN VBN O
identified VBN VBN O
in IN IN O
many JJ JJ O
other JJ JJ O
countries NNS NNS O
. . . O

Many JJ JJ O
variations NNS NNS O
of IN IN O
this DT DT O
syndrome NN NN O
have VBP VBP O
been VBN VBN O
recently RB RB O
described VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

One CD CD O
of IN IN O
the DT DT O
rarest NN NN O
is VBZ VBZ O
the DT DT O
reverse NN NN O
type NN NN O
of IN IN O
this DT DT O
syndrome NN NN O
, , , O
with IN IN O
hyperdynamic JJ JJ O
apex NN NN O
and CC CC O
complete JJ JJ O
akinesia NN NN O
of IN IN O
the DT DT O
base NN NN O
( ( ( O
as IN IN O
opposed VBN VBN O
to TO TO O
the DT DT O
classic JJ JJ O
apical JJ JJ O
ballooning NN NN O
) ) ) O
. . . O

In IN IN O
this DT DT O
article NN NN O
, , , O
we PRP PRP O
report VBP VBP O
an DT DT O
interesting JJ JJ O
case NN NN O
of IN IN O
a DT DT O
young JJ JJ O
woman NN NN O
who WP WP O
presented VBN VBN O
with IN IN O
this DT DT O
rare JJ JJ O
type NN NN O
of IN IN O
reverse NN NN O
apical JJ JJ O
ballooning NN NN O
syndrome NN NN O
occurring VBG VBG O
after IN IN O
amphetamine NN NN B-CHEM
use NN NN O
. . . O

This DT DT O
report NN NN O
is VBZ VBZ O
followed VBN VBN O
by IN IN O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

Results NNS NNS O
of IN IN O
a DT DT O
comparative JJ JJ O
, , , O
phase NN NN O
III NNP NNP O
, , , O
12 CD CD O
- : : O
week NN NN O
, , , O
multicenter NN NN O
, , , O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
assessment NN NN O
of IN IN O
the DT DT O
efficacy NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
a DT DT O
fixed JJ JJ O
- - - O
dose JJ JJ O
combination NN NN O
of IN IN O
telmisartan NN NN B-CHEM
and CC CC O
amlodipine NN NN B-CHEM
versus CC CC O
amlodipine NN NN B-CHEM
monotherapy NN NN O
in IN IN O
Indian JJ JJ O
adults NNS NNS O
with IN IN O
stage NN NN O
II NNP NNP O
hypertension NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
efficacy NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
a DT DT O
new JJ JJ O
fixed JJ JJ O
- - - O
dose NN NN O
combination NN NN O
( ( ( O
FDC NNP NNP O
) ) ) O
of IN IN O
telmisartan NN NN B-CHEM
40 CD CD O
mg NN NN O
+ NN NN O
amlodipine NN NN B-CHEM
5 CD CD O
mg NN NN O
( ( ( O
T NN NN O
+ NN NN O
A DT DT O
) ) ) O
compared VBN VBN O
with IN IN O
amlodipine NN NN B-CHEM
5 CD CD O
- : : O
mg NN NN O
monotherapy NN NN O
( ( ( O
A DT DT O
) ) ) O
in IN IN O
adult NN NN O
Indian JJ JJ O
patients NNS NNS O
with IN IN O
stage NN NN O
II NNP NNP O
hypertension NN NN O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
comparative JJ JJ O
, , , O
Phase NNP NNP O
III NNP NNP O
, , , O
12 CD CD O
- : : O
week NN NN O
, , , O
multicenter NN NN O
, , , O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
Indian JJ JJ O
patients NNS NNS O
aged VBD VBD O
18 CD CD O
to TO TO O
65 CD CD O
years NNS NNS O
with IN IN O
established VBN VBN O
stage NN NN O
II NNP NNP O
hypertension NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
oral JJ JJ O
FDC NNP NNP O
of IN IN O
T NN NN O
+ NN NN O
A DT DT O
or CC CC O
A DT DT O
QD NNP NNP O
before IN IN O
breakfast NN NN O
for IN IN O
12 CD CD O
weeks NNS NNS O
; : : O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
and CC CC O
heart NN NN O
rate NN NN O
were VBD VBD O
measured VBN VBN O
in IN IN O
the DT DT O
sitting VBG VBG O
position NN NN O
. . . O

Primary JJ JJ O
efficacy NN NN O
end NN NN O
points NNS NNS O
were VBD VBD O
reduction NN NN O
in IN IN O
clinical JJ JJ O
systolic JJ JJ O
BP NNP NNP O
( ( ( O
SBP NNP NNP O
) ) ) O
/ NN NN O
diastolic JJ JJ O
BP NNP NNP O
( ( ( O
DBP NNP NNP O
) ) ) O
from IN IN O
baseline NN NN O
to TO TO O
study VB VB O
end NN NN O
and CC CC O
number NN NN O
of IN IN O
responders NNS NNS O
( ( ( O
ie NN NN O
, , , O
patients NNS NNS O
who WP WP O
achieved VBD VBD O
target NN NN O
SBP NNP NNP O
/ NN NN O
DBP NNP NNP O
< NN NN O
130 CD CD O
/ NN NN O
< NN NN O
80 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
at IN IN O
end NN NN O
of IN IN O
study NN NN O
. . . O

Tolerability NNP NNP O
was VBD VBD O
assessed VBN VBN O
by IN IN O
treatment NN NN O
- - - O
emergent JJ JJ O
adverse JJ JJ O
events NNS NNS O
, , , O
identified VBN VBN O
using VBG VBG O
physical JJ JJ O
examination NN NN O
, , , O
laboratory NN NN O
analysis NN NN O
, , , O
and CC CC O
electrocardiography NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
210 CD CD O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
in IN IN O
the DT DT O
study NN NN O
; : : O
203 CD CD O
patients NNS NNS O
( ( ( O
143 CD CD O
men NNS NNS O
, , , O
60 CD CD O
women NNS NNS O
) ) ) O
completed VBD VBD O
the DT DT O
study NN NN O
while IN IN O
7 CD CD O
were VBD VBD O
lost VBN VBN O
to TO TO O
follow VB VB O
- - - O
up RP RP O
( ( ( O
4 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
T NN NN O
+ NN NN O
A DT DT O
group NN NN O
and CC CC O
3 CD CD O
in IN IN O
the DT DT O
A DT DT O
group NN NN O
) ) ) O
and CC CC O
considered VBN VBN O
with IN IN O
- - - O
drawn NN NN O
. . . O

At IN IN O
study NN NN O
end NN NN O
, , , O
statistically RB RB O
significant JJ JJ O
percentage NN NN O
reductions NNS NNS O
from IN IN O
baseline NN NN O
within IN IN O
groups NNS NNS O
and CC CC O
between IN IN O
groups NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
SBP NNP NNP O
( ( ( O
T NN NN O
+ NN NN O
A DT DT O
[ NN NN O
- - - O
27 CD CD O
. . . O
4 CD CD O
% NN NN O
] NN NN O
; : : O
A DT DT O
[ NN NN O
- - - O
16 CD CD O
. . . O
6 CD CD O
% NN NN O
] NN NN O
) ) ) O
and CC CC O
DBP NNP NNP O
( ( ( O
T NN NN O
+ NN NN O
A DT DT O
[ NN NN O
- - - O
20 CD CD O
. . . O
1 CD CD O
% NN NN O
] NN NN O
; : : O
A DT DT O
[ NN NN O
- - - O
13 CD CD O
. . . O
3 CD CD O
% NN NN O
] NN NN O
) ) ) O
( ( ( O
all DT DT O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Response NNP NNP O
rates NNS NNS O
were VBD VBD O
87 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
89 CD CD O
/ NN NN O
102 CD CD O
) ) ) O
in IN IN O
the DT DT O
T NN NN O
+ NN NN O
A DT DT O
group NN NN O
and CC CC O
69 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
70 CD CD O
/ NN NN O
101 CD CD O
) ) ) O
in IN IN O
the DT DT O
A DT DT O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
prevalences NNS NNS O
of IN IN O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
between IN IN O
the DT DT O
2 CD CD O
treatment NN NN O
groups NNS NNS O
( ( ( O
T NN NN O
+ NN NN O
A DT DT O
, , , O
16 CD CD O
. . . O
0 CD CD O
% NN NN O
[ NN NN O
17 CD CD O
/ NN NN O
106 CD CD O
] NN NN O
; : : O
A DT DT O
, , , O
15 CD CD O
. . . O
4 CD CD O
% NN NN O
[ NN NN O
16 CD CD O
/ NN NN O
104 CD CD O
] NN NN O
) ) ) O
. . . O

Peripheral NNP NNP O
edema NN NN O
was VBD VBD O
reported VBN VBN O
in IN IN O
8 CD CD O
. . . O
5 CD CD O
% NN NN O
patients NNS NNS O
( ( ( O
9 CD CD O
/ NN NN O
106 CD CD O
) ) ) O
in IN IN O
the DT DT O
T NN NN O
+ NN NN O
A DT DT O
group NN NN O
compared VBN VBN O
with IN IN O
13 CD CD O
. . . O
5 CD CD O
% NN NN O
( ( ( O
14 CD CD O
/ NN NN O
104 CD CD O
) ) ) O
in IN IN O
the DT DT O
A DT DT O
group NN NN O
, , , O
and CC CC O
cough NN NN O
was VBD VBD O
reported VBN VBN O
in IN IN O
3 CD CD O
. . . O
8 CD CD O
% NN NN O
patients NNS NNS O
( ( ( O
4 CD CD O
/ NN NN O
106 CD CD O
) ) ) O
in IN IN O
the DT DT O
T NN NN O
+ NN NN O
A DT DT O
group NN NN O
and CC CC O
1 CD CD O
. . . O
0 CD CD O
% NN NN O
( ( ( O
1 CD CD O
/ NN NN O
104 CD CD O
) ) ) O
patients NNS NNS O
in IN IN O
the DT DT O
A DT DT O
group NN NN O
; : : O
these DT DT O
differences NNS NNS O
did VBD VBD O
not RB RB O
reach VB VB O
statistical JJ JJ O
significance NN NN O
. . . O

The DT DT O
incidences NNS NNS O
of IN IN O
headache NN NN O
, , , O
dizziness NN NN O
, , , O
and CC CC O
diarrhea NN NN O
were VBD VBD O
similar JJ JJ O
between IN IN O
the DT DT O
2 CD CD O
groups NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Among IN IN O
these DT DT O
Indian JJ JJ O
patients NNS NNS O
with IN IN O
stage NN NN O
II NNP NNP O
hypertension NN NN O
, , , O
the DT DT O
FDC NNP NNP O
of IN IN O
T NN NN O
+ NN NN O
A DT DT O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
significantly RB RB O
more RBR RBR O
effective JJ JJ O
, , , O
with IN IN O
regard NN NN O
to TO TO O
BP NNP NNP O
reductions NNS NNS O
, , , O
than IN IN O
A DT DT O
, , , O
and CC CC O
both DT DT O
treatments NNS NNS O
were VBD VBD O
well RB RB O
tolerated VBN VBN O
. . . O

Increased NNP NNP O
mental JJ JJ O
slowing VBG VBG O
associated VBN VBN O
with IN IN O
the DT DT O
APOE NNP NNP O
epsilon4 NN NN O
allele NN NN O
after IN IN O
trihexyphenidyl NN NN B-CHEM
oral JJ JJ O
anticholinergic JJ JJ O
challenge NN NN O
in IN IN O
healthy JJ JJ O
elderly JJ JJ O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
objectives NNS NNS O
of IN IN O
this DT DT O
study NN NN O
were VBD VBD O
to TO TO O
examine VB VB O
the DT DT O
relationship NN NN O
between IN IN O
APOE NNP NNP O
epsilon4 NN NN O
and CC CC O
subjective JJ JJ O
effects NNS NNS O
of IN IN O
trihexyphenidyl NN NN B-CHEM
on IN IN O
measures NNS NNS O
reflecting VBG VBG O
sedation NN NN O
and CC CC O
confusion NN NN O
and CC CC O
to TO TO O
investigate VB VB O
the DT DT O
relationship NN NN O
between IN IN O
trihexyphenidyl NN NN B-CHEM
- - - O
induced JJ JJ O
subjective JJ JJ O
effects NNS NNS O
and CC CC O
objective JJ JJ O
memory NN NN O
performance NN NN O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
study NN NN O
comprised VBD VBD O
24 CD CD O
cognitively RB RB O
intact JJ JJ O
, , , O
health NN NN O
elderly JJ JJ O
adults NNS NNS O
( ( ( O
12 CD CD O
APOE NNP NNP O
epsilon4 NN NN O
carriers NNS NNS O
) ) ) O
at IN IN O
an DT DT O
outpatient NN NN O
geriatric JJ JJ O
psychiatry NN NN O
research NN NN O
clinic NN NN O
. . . O

This DT DT O
was VBD VBD O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled VBN VBN O
, , , O
three CD CD O
- - - O
way NN NN O
, , , O
crossover NN NN O
experimental JJ JJ O
design NN NN O
. . . O

All DT DT O
participants NNS NNS O
received VBD VBD O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
or CC CC O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
trihexyphenidyl NN NN B-CHEM
or CC CC O
placebo NN NN O
administered VBN VBN O
in IN IN O
counterbalanced VBN VBN O
sequences NNS NNS O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
three CD CD O
consecutive JJ JJ O
weeks NNS NNS O
. . . O

Bond NNP NNP O
and CC CC O
Lader NNP NNP O
' POS POS O
s VBZ VBZ O
visual JJ JJ O
analog NN NN O
scales NNS NNS O
and CC CC O
alternate JJ JJ O
versions NNS NNS O
of IN IN O
the DT DT O
Buschke NNP NNP O
Selective NNP NNP O
Reminding NNP NNP O
Test NNP NNP O
were VBD VBD O
administered VBN VBN O
in IN IN O
a DT DT O
repeated VBN VBN O
measures NNS NNS O
design NN NN O
at IN IN O
baseline NN NN O
, , , O
1 CD CD O
, , , O
2 CD CD O
. . . O
5 CD CD O
, , , O
and CC CC O
5 CD CD O
hours NNS NNS O
postdrug NN NN O
administration NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
2 CD CD O
. . . O
0 CD CD O
- : : O
mg NN NN O
oral JJ JJ O
dose NN NN O
of IN IN O
trihexyphenidyl NN NN B-CHEM
resulted VBD VBD O
in IN IN O
increased VBN VBN O
subjective JJ JJ O
ratings NNS NNS O
of IN IN O
mental JJ JJ O
slowness NN NN O
in IN IN O
carriers NNS NNS O
of IN IN O
the DT DT O
APOE NNP NNP O
epsilon4 NN NN O
allele NN NN O
only RB RB O
. . . O

Drug NN NN O
effects NNS NNS O
as IN IN O
determined VBN VBN O
by IN IN O
difference NN NN O
scores NNS NNS O
between IN IN O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
trihexyphenidyl NN NN B-CHEM
and CC CC O
placebo NN NN O
on IN IN O
ratings NNS NNS O
of IN IN O
mental JJ JJ O
slowness NN NN O
significantly RB RB O
correlated JJ JJ O
with IN IN O
total JJ JJ O
and CC CC O
delayed VBD VBD O
recall VB VB O
on IN IN O
the DT DT O
Buschke NNP NNP O
Selective NNP NNP O
Reminding NNP NNP O
Test NNP NNP O
in IN IN O
carriers NNS NNS O
of IN IN O
the DT DT O
APOE NNP NNP O
epsilon4 NN NN O
allele NN NN O
only RB RB O
. . . O

However RB RB O
, , , O
no DT DT O
significant JJ JJ O
effects NNS NNS O
were VBD VBD O
found VBN VBN O
with IN IN O
other JJ JJ O
visual JJ JJ O
analog NN NN O
scales NNS NNS O
reflecting VBG VBG O
subjective JJ JJ O
sedation NN NN O
and CC CC O
clear JJ JJ O
- - - O
headedness NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
epsilon4 NN NN O
allele NN NN O
in IN IN O
healthy JJ JJ O
elderly RB RB O
was VBD VBD O
associated VBN VBN O
with IN IN O
increased VBN VBN O
subjective JJ JJ O
mental JJ JJ O
slowing NN NN O
after IN IN O
trihexyphenidyl NN NN B-CHEM
anticholinergic JJ JJ O
challenge NN NN O
. . . O

An DT DT O
evaluation NN NN O
of IN IN O
amikacin NN NN B-CHEM
nephrotoxicity NN NN O
in IN IN O
the DT DT O
hematology NN NN O
/ NN NN O
oncology NN NN O
population NN NN O
. . . O

Amikacin NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
aminoglycoside NN NN B-CHEM
commonly RB RB O
used VBD VBD O
to TO TO O
provide VB VB O
empirical JJ JJ O
double JJ JJ O
gram NN NN O
- - - O
negative JJ JJ O
treatment NN NN O
for IN IN O
febrile NN NN O
neutropenia NN NN O
and CC CC O
other JJ JJ O
suspected JJ JJ O
infections NNS NNS O
. . . O

Strategies NNS NNS O
of IN IN O
extended VBN VBN O
- - - O
interval NN NN O
and CC CC O
conventional JJ JJ O
dosing NN NN O
have VBP VBP O
been VBN VBN O
utilized JJ JJ O
extensively RB RB O
in IN IN O
the DT DT O
general JJ JJ O
medical JJ JJ O
population NN NN O
; : : O
however RB RB O
, , , O
data NNS NNS O
are VBP VBP O
lacking VBG VBG O
to TO TO O
support VB VB O
a DT DT O
dosing VBG VBG O
strategy NN NN O
in IN IN O
the DT DT O
hematology NN NN O
/ NN NN O
oncology NN NN O
population NN NN O
. . . O

To TO TO O
evaluate VB VB O
amikacin NN NN B-CHEM
- - - O
associated VBN VBN O
nephrotoxicity NN NN O
in IN IN O
an DT DT O
adult NN NN O
hematology NN NN O
/ NN NN O
oncology NN NN O
population NN NN O
, , , O
a DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
open JJ JJ O
- - - O
label NN NN O
trial NN NN O
was VBD VBD O
conducted VBN VBN O
at IN IN O
a DT DT O
university NN NN O
- - - O
affiliated JJ JJ O
medical JJ JJ O
center NN NN O
. . . O

Forty CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
diagnosis NN NN O
consistent JJ JJ O
with IN IN O
a DT DT O
hematologic JJ JJ O
/ NN NN O
oncologic JJ JJ O
disorder NN NN O
that WDT WDT O
required VBD VBD O
treatment NN NN O
with IN IN O
an DT DT O
aminoglycoside NN NN B-CHEM
were VBD VBD O
randomized VBN VBN O
to TO TO O
either CC CC O
conventional JJ JJ O
or CC CC O
extended VBN VBN O
- : : O
interval NN NN O
amikacin NN NN B-CHEM
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
nephrotoxicity NN NN O
by IN IN O
means NNS NNS O
of IN IN O
an DT DT O
increase NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
and CC CC O
evaluation NN NN O
of IN IN O
efficacy NN NN O
via IN IN O
amikacin NN NN B-CHEM
serum NN NN O
concentrations NNS NNS O
with IN IN O
respective JJ JJ O
pathogens NNS NNS O
were VBD VBD O
assessed VBN VBN O
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
nephrotoxicity NN NN O
was VBD VBD O
similar JJ JJ O
between IN IN O
the DT DT O
conventional JJ JJ O
and CC CC O
extended VBN VBN O
- : : O
interval NN NN O
groups NNS NNS O
, , , O
at IN IN O
10 CD CD O
% NN NN O
and CC CC O
5 CD CD O
% NN NN O
, , , O
respectively RB RB O
( ( ( O
P NN NN O
= SYM SYM O
1 CD CD O
. . . O
00 CD CD O
) ) ) O
. . . O

Six CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
conventional JJ JJ O
group NN NN O
had VBD VBD O
a DT DT O
positive JJ JJ O
culture NN NN O
, , , O
compared VBN VBN O
with IN IN O
none NN NN O
in IN IN O
the DT DT O
extended JJ JJ O
- - - O
interval NN NN O
group NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
nephrotoxicity NN NN O
was VBD VBD O
similar JJ JJ O
between IN IN O
the DT DT O
two CD CD O
dosing VBG VBG O
regimens NNS NNS O
, , , O
but CC CC O
the DT DT O
distribution NN NN O
of IN IN O
risk NN NN O
factors NNS NNS O
was VBD VBD O
variable JJ JJ O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

Efficacy NNP NNP O
could MD MD O
not RB RB O
be VB VB O
assessed VBN VBN O
. . . O

High NNP NNP O
dose NN NN O
dexmedetomidine NN NN B-CHEM
as IN IN O
the DT DT O
sole JJ JJ O
sedative NN NN O
for IN IN O
pediatric JJ JJ O
MRI NNP NNP O
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
large JJ JJ O
- - - O
scale NN NN O
retrospective NN NN O
review NN NN O
evaluates VBZ VBZ O
the DT DT O
sedation NN NN O
profile NN NN O
of IN IN O
dexmedetomidine NN NN B-CHEM
. . . O

AIM NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
hemodynamic JJ JJ O
responses NNS NNS O
, , , O
efficacy NN NN O
and CC CC O
adverse JJ JJ O
events NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
high JJ JJ O
dose NN NN O
dexmedetomidine NN NN B-CHEM
as IN IN O
the DT DT O
sole JJ JJ O
sedative NN NN O
for IN IN O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
MRI NNP NNP O
) ) ) O
studies NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Dexmedetomidine NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
at IN IN O
our PRP$ PRP$ O
institution NN NN O
since IN IN O
2005 CD CD O
to TO TO O
provide VB VB O
sedation NN NN O
for IN IN O
pediatric JJ JJ O
radiological JJ JJ O
imaging VBG VBG O
studies NNS NNS O
. . . O

Over IN IN O
time NN NN O
, , , O
an DT DT O
effective JJ JJ O
protocol NN NN O
utilizing VBG VBG O
high JJ JJ O
dose NN NN O
dexmedetomidine NN NN B-CHEM
as IN IN O
the DT DT O
sole JJ JJ O
sedative JJ JJ O
agent NN NN O
has VBZ VBZ O
evolved VBN VBN O
. . . O

METHODS NNP NNP O
/ NN NN O
MATERIALS NNS NNS O
: : : O
As IN IN O
part NN NN O
of IN IN O
the DT DT O
ongoing JJ JJ O
Quality NNP NNP O
Assurance NNP NNP O
process NN NN O
, , , O
data NNS NNS O
on IN IN O
all DT DT O
sedations NNS NNS O
are VBP VBP O
reviewed VBN VBN O
monthly JJ JJ O
and CC CC O
protocols NNS NNS O
modified VBN VBN O
as IN IN O
needed VBN VBN O
. . . O

Data NNP NNP O
were VBD VBD O
analyzed VBN VBN O
from IN IN O
all DT DT O
747 CD CD O
consecutive JJ JJ O
patients NNS NNS O
who WP WP O
received VBD VBD O
dexmedetomidine NN NN B-CHEM
for IN IN O
MRI NNP NNP O
sedation NN NN O
from IN IN O
April NNP NNP O
2005 CD CD O
to TO TO O
April NNP NNP O
2007 CD CD O
. . . O

RESULTS NNS NNS O
: : : O
Since IN IN O
2005 CD CD O
, , , O
the DT DT O
10 CD CD O
- : : O
min NN NN O
loading VBG VBG O
dose NN NN O
of IN IN O
our PRP$ PRP$ O
dexmedetomidine NN NN B-CHEM
protocol NN NN O
increased VBN VBN O
from IN IN O
2 CD CD O
to TO TO O
3 CD CD O
microg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
and CC CC O
the DT DT O
infusion NN NN O
rate NN NN O
increased VBN VBN O
from IN IN O
1 CD CD O
to TO TO O
1 CD CD O
. . . O
5 CD CD O
to TO TO O
2 CD CD O
microg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
h NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O

The DT DT O
current JJ JJ O
sedation NN NN O
protocol NN NN O
progressively RB RB O
increased VBD VBD O
the DT DT O
rate NN NN O
of IN IN O
successful JJ JJ O
sedation NN NN O
( ( ( O
able JJ JJ O
to TO TO O
complete VB VB O
the DT DT O
imaging VBG VBG O
study NN NN O
) ) ) O
when WRB WRB O
using VBG VBG O
dexmedetomidine NN NN B-CHEM
alone RB RB O
from IN IN O
91 CD CD O
. . . O
8 CD CD O
% NN NN O
to TO TO O
97 CD CD O
. . . O
6 CD CD O
% NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
009 CD CD O
) ) ) O
, , , O
reducing VBG VBG O
the DT DT O
requirement NN NN O
for IN IN O
adjuvant JJ JJ O
pentobarbital NN NN B-CHEM
in IN IN O
the DT DT O
event NN NN O
of IN IN O
sedation NN NN O
failure NN NN O
with IN IN O
dexmedetomidine NN NN B-CHEM
alone RB RB O
and CC CC O
decreased VBD VBD O
the DT DT O
mean JJ JJ O
recovery NN NN O
time NN NN O
by IN IN O
10 CD CD O
min NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Although IN IN O
dexmedetomidine NN NN B-CHEM
sedation NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
16 CD CD O
% NN NN O
incidence NN NN O
of IN IN O
bradycardia NN NN O
, , , O
all DT DT O
concomitant JJ JJ O
mean NN NN O
arterial JJ JJ O
blood NN NN O
pressures NNS NNS O
were VBD VBD O
within IN IN O
20 CD CD O
% NN NN O
of IN IN O
age NN NN O
- - - O
adjusted VBN VBN O
normal JJ JJ O
range NN NN O
and CC CC O
oxygen NN NN B-CHEM
saturations NNS NNS O
were VBD VBD O
95 CD CD O
% NN NN O
or CC CC O
higher JJR JJR O
. . . O

CONCLUSION NNP NNP O
: : : O
Dexmedetomidine NNP NNP B-CHEM
in IN IN O
high JJ JJ O
doses NNS NNS O
provides VBZ VBZ O
adequate JJ JJ O
sedation NN NN O
for IN IN O
pediatric JJ JJ O
MRI NNP NNP O
studies NNS NNS O
. . . O

While IN IN O
use NN NN O
of IN IN O
high JJ JJ O
dose NN NN O
dexmedetomidine NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
decreases NNS NNS O
in IN IN O
heart NN NN O
rate NN NN O
and CC CC O
blood NN NN O
pressure NN NN O
outside IN IN O
the DT DT O
established VBN VBN O
' POS POS O
awake NN NN O
' '' '' O
norms NNS NNS O
, , , O
this DT DT O
deviation NN NN O
is VBZ VBZ O
generally RB RB O
within IN IN O
20 CD CD O
% NN NN O
of IN IN O
norms NNS NNS O
, , , O
and CC CC O
is VBZ VBZ O
not RB RB O
associated VBN VBN O
with IN IN O
adverse JJ JJ O
sequelae NN NN O
. . . O

Dexmedetomidine NNP NNP B-CHEM
is VBZ VBZ O
useful JJ JJ O
as IN IN O
the DT DT O
sole JJ JJ O
sedative NN NN O
for IN IN O
pediatric JJ JJ O
MRI NNP NNP O
. . . O

Hepatotoxicity NNP NNP O
associated VBN VBN O
with IN IN O
sulfasalazine NN NN B-CHEM
in IN IN O
inflammatory JJ JJ O
arthritis NN NN O
: : : O
A DT DT O
case NN NN O
series NN NN O
from IN IN O
a DT DT O
local JJ JJ O
surveillance NN NN O
of IN IN O
serious JJ JJ O
adverse JJ JJ O
events NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Spontaneous NNP NNP O
reporting VBG VBG O
systems NNS NNS O
for IN IN O
adverse JJ JJ O
drug NN NN O
reactions NNS NNS O
( ( ( O
ADRs NNP NNP O
) ) ) O
are VBP VBP O
handicapped VBN VBN O
by IN IN O
under IN IN O
- : : O
reporting NN NN O
and CC CC O
limited JJ JJ O
detail NN NN O
on IN IN O
individual JJ JJ O
cases NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
an DT DT O
investigation NN NN O
from IN IN O
a DT DT O
local JJ JJ O
surveillance NN NN O
for IN IN O
serious JJ JJ O
adverse JJ JJ O
drug NN NN O
reactions NNS NNS O
associated VBN VBN O
with IN IN O
disease NN NN O
modifying VBG VBG O
anti JJ JJ O
- : : O
rheumatic JJ JJ O
drugs NNS NNS O
that WDT WDT O
was VBD VBD O
triggered VBN VBN O
by IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
liver NN NN O
failure NN NN O
in IN IN O
two CD CD O
of IN IN O
our PRP$ PRP$ O
patients NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Serious JJ JJ O
ADR NNP NNP O
reports NNS NNS O
have VBP VBP O
been VBN VBN O
solicited VBN VBN O
from IN IN O
local JJ JJ O
clinicians NNS NNS O
by IN IN O
regular JJ JJ O
postcards NNS NNS O
over IN IN O
the DT DT O
past JJ JJ O
seven CD CD O
years NNS NNS O
. . . O

Patients NNS NNS O
' POS POS O
, , , O
who WP WP O
had VBD VBD O
hepatotoxicity NN NN O
on IN IN O
sulfasalazine NN NN B-CHEM
and CC CC O
met VBD VBD O
a DT DT O
definition NN NN O
of IN IN O
a DT DT O
serious JJ JJ O
ADR NNP NNP O
, , , O
were VBD VBD O
identified VBN VBN O
. . . O

Two CD CD O
clinicians NNS NNS O
reviewed VBN VBN O
structured VBN VBN O
case NN NN O
reports NNS NNS O
and CC CC O
assessed VBN VBN O
causality NN NN O
by IN IN O
consensus NN NN O
and CC CC O
by IN IN O
using VBG VBG O
a DT DT O
causality NN NN O
assessment NN NN O
instrument NN NN O
. . . O

The DT DT O
likely JJ JJ O
frequency NN NN O
of IN IN O
hepatotoxicity NN NN O
with IN IN O
sulfasalazine NN NN B-CHEM
was VBD VBD O
estimated VBN VBN O
by IN IN O
making VBG VBG O
a DT DT O
series NN NN O
of IN IN O
conservative JJ JJ O
assumptions NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Ten CD CD O
cases NNS NNS O
were VBD VBD O
identified VBN VBN O
: : : O
eight CD CD O
occurred VBD VBD O
during IN IN O
surveillance NN NN O
. . . O

Eight CD CD O
patients NNS NNS O
were VBD VBD O
hospitalised VBN VBN O
, , , O
two CD CD O
in IN IN O
hepatic JJ JJ O
failure NN NN O
- : : O
one CD CD O
died VBD VBD O
after IN IN O
a DT DT O
liver NN NN O
transplant NN NN O
. . . O

All DT DT O
but CC CC O
one CD CD O
event NN NN O
occurred VBD VBD O
within IN IN O
6 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

Seven CD CD O
patients NNS NNS O
had VBD VBD O
a DT DT O
skin NN NN O
rash NN NN O
, , , O
three CD CD O
eosinophilia NNS NNS O
and CC CC O
one CD CD O
interstitial JJ JJ O
nephritis NN NN O
. . . O

Five CD CD O
patients NNS NNS O
were VBD VBD O
of IN IN O
Black NNP NNP O
British NNP NNP O
of IN IN O
African NNP NNP O
or CC CC O
Caribbean NNP NNP O
descent NN NN O
. . . O

Liver NNP NNP O
enzymes NNS NNS O
showed VBD VBD O
a DT DT O
hepatocellular NN NN O
pattern NN NN O
in IN IN O
four CD CD O
cases NNS NNS O
and CC CC O
a DT DT O
mixed JJ JJ O
pattern NN NN O
in IN IN O
six CD CD O
. . . O

Drug NN NN O
- - - O
related VBN VBN O
hepatotoxicity NN NN O
was VBD VBD O
judged VBN VBN O
probable JJ JJ O
or CC CC O
highly RB RB O
probable JJ JJ O
in IN IN O
8 CD CD O
patients NNS NNS O
. . . O

The DT DT O
likely JJ JJ O
frequency NN NN O
of IN IN O
serious JJ JJ O
hepatotoxicity NN NN O
with IN IN O
sulfasalazine NN NN B-CHEM
was VBD VBD O
estimated VBN VBN O
at IN IN O
0 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
treated VBN VBN O
patients NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Serious JJ JJ O
hepatotoxicity NN NN O
associated VBN VBN O
with IN IN O
sulfasalazine NN NN B-CHEM
appears VBZ VBZ O
to TO TO O
be VB VB O
under IN IN O
- - - O
appreciated VBN VBN O
and CC CC O
intensive JJ JJ O
monitoring NN NN O
and CC CC O
vigilance NN NN O
in IN IN O
the DT DT O
first JJ JJ O
6 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
is VBZ VBZ O
especially RB RB O
important JJ JJ O
. . . O

Complete JJ JJ O
atrioventricular NN NN O
block NN NN O
secondary JJ JJ O
to TO TO O
lithium NN NN B-CHEM
therapy NN NN O
. . . O

Sinus NNP NNP O
node NN NN O
dysfunction NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
most RBS RBS O
frequently RB RB O
among IN IN O
the DT DT O
adverse JJ JJ O
cardiovascular JJ JJ O
effects NNS NNS O
of IN IN O
lithium NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
present JJ JJ O
case NN NN O
, , , O
complete JJ JJ O
atrioventricular NN NN O
( ( ( O
AV NNP NNP O
) ) ) O
block NN NN O
with IN IN O
syncopal JJ JJ O
attacks NNS NNS O
developed VBN VBN O
secondary JJ JJ O
to TO TO O
lithium NN NN B-CHEM
therapy NN NN O
, , , O
necessitating VBG VBG O
permanent JJ JJ O
pacemaker NN NN O
implantation NN NN O
. . . O

Serum NNP NNP O
lithium NN NN B-CHEM
levels NNS NNS O
remained VBD VBD O
under IN IN O
or CC CC O
within IN IN O
the DT DT O
therapeutic JJ JJ O
range NN NN O
during IN IN O
the DT DT O
syncopal JJ JJ O
attacks NNS NNS O
. . . O

Lithium NNP NNP B-CHEM
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
extreme JJ JJ O
caution NN NN O
, , , O
especially RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
mild JJ JJ O
disturbance NN NN O
of IN IN O
AV NNP NNP O
conduction NN NN O
. . . O

Exaggerated NNP NNP O
expression NN NN O
of IN IN O
inflammatory JJ JJ O
mediators NNS NNS O
in IN IN O
vasoactive JJ JJ O
intestinal JJ JJ O
polypeptide NN NN O
knockout NN NN O
( ( ( O
VIP NNP NNP O
- - - O
/ NN NN O
- - - O
) ) ) O
mice NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CYP NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cystitis NN NN O
. . . O

Vasoactive NNP NNP O
intestinal JJ JJ O
polypeptide NN NN O
( ( ( O
VIP NNP NNP O
) ) ) O
is VBZ VBZ O
an DT DT O
immunomodulatory NN NN O
neuropeptide NN NN O
distributed VBN VBN O
in IN IN O
micturition NN NN O
pathways NNS NNS O
. . . O

VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
exhibit NN NN O
altered VBN VBN O
bladder NN NN O
function NN NN O
and CC CC O
neurochemical JJ JJ O
properties NNS NNS O
in IN IN O
micturition NN NN O
pathways NNS NNS O
after IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CYP NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cystitis NN NN O
. . . O

Given VBN VBN O
VIP NNP NNP O
' POS POS O
s VBZ VBZ O
role NN NN O
as IN IN O
an DT DT O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
mediator NN NN O
, , , O
we PRP PRP O
hypothesized VBN VBN O
that IN IN O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
would MD MD O
exhibit VB VB O
enhanced VBN VBN O
inflammatory NN NN O
mediator NN NN O
expression NN NN O
after IN IN O
cystitis NNS NNS O
. . . O

A DT DT O
mouse NN NN O
inflammatory JJ JJ O
cytokine NN NN O
and CC CC O
receptor NN NN O
RT2 NNP NNP O
profiler NN NN O
array NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
determine VB VB O
regulated VBN VBN O
transcripts NNS NNS O
in IN IN O
the DT DT O
urinary JJ JJ O
bladder NN NN O
of IN IN O
wild JJ JJ O
type NN NN O
( ( ( O
WT NNP NNP O
) ) ) O
and CC CC O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
with IN IN O
or CC CC O
without IN IN O
CYP NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NN NN O
( ( ( O
150 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
i NNP NNP O
. . . O
p NN NN O
. . . O
; : : O
48 CD CD O
h NN NN O
) ) ) O
. . . O

Four CD CD O
binary JJ JJ O
comparisons NNS NNS O
were VBD VBD O
made VBN VBN O
: : : O
WT NNP NNP O
control NN NN O
versus CC CC O
CYP NNP NNP B-CHEM
treatment NN NN O
( ( ( O
48 CD CD O
h NN NN O
) ) ) O
, , , O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
control NN NN O
versus CC CC O
CYP NNP NNP B-CHEM
treatment NN NN O
( ( ( O
48 CD CD O
h NN NN O
) ) ) O
, , , O
WT NNP NNP O
control NN NN O
versus CC CC O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
control NN NN O
, , , O
and CC CC O
WT NNP NNP O
with IN IN O
CYP NNP NNP B-CHEM
treatment NN NN O
( ( ( O
48 CD CD O
h NN NN O
) ) ) O
versus CC CC O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
with IN IN O
CYP NNP NNP B-CHEM
treatment NN NN O
( ( ( O
48 CD CD O
h NN NN O
) ) ) O
. . . O

The DT DT O
genes NNS NNS O
presented VBN VBN O
represent NN NN O
( ( ( O
1 CD CD O
) ) ) O
greater JJR JJR O
than IN IN O
1 CD CD O
. . . O
5 CD CD O
- : : O
fold JJ JJ O
change NN NN O
in IN IN O
either DT DT O
direction NN NN O
and CC CC O
( ( ( O
2 CD CD O
) ) ) O
the DT DT O
p NN NN O
value NN NN O
is VBZ VBZ O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
for IN IN O
the DT DT O
comparison NN NN O
being VBG VBG O
made VBN VBN O
. . . O

Several JJ JJ O
regulated JJ JJ O
genes NNS NNS O
were VBD VBD O
validated VBN VBN O
using VBG VBG O
enzyme NN NN O
- - - O
linked VBN VBN O
immunoassays NNS NNS O
including VBG VBG O
IL NNP NNP O
- : : O
1beta CD CD O
and CC CC O
CXCL1 NNP NNP O
. . . O

CYP NNP NNP B-CHEM
treatment NN NN O
significantly RB RB O
( ( ( O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
increased VBN VBN O
expression NN NN O
of IN IN O
CXCL1 NNP NNP O
and CC CC O
IL NNP NNP O
- : : O
1beta CD CD O
in IN IN O
the DT DT O
urinary JJ JJ O
bladder NN NN O
of IN IN O
WT NNP NNP O
and CC CC O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
, , , O
but CC CC O
expression NN NN O
in IN IN O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
with IN IN O
CYP NNP NNP B-CHEM
treatment NN NN O
was VBD VBD O
significantly RB RB O
( ( ( O
p NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
greater JJR JJR O
( ( ( O
4 CD CD O
. . . O
2 CD CD O
- : : O
to TO TO O
13 CD CD O
- : : O
fold VB VB O
increase NN NN O
) ) ) O
than IN IN O
that DT DT O
observed VBD VBD O
in IN IN O
WT NNP NNP O
urinary JJ JJ O
bladder NN NN O
( ( ( O
3 CD CD O
. . . O
6 CD CD O
- : : O
to TO TO O
5 CD CD O
- : : O
fold VB VB O
increase NN NN O
) ) ) O
. . . O

The DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
in IN IN O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
with IN IN O
bladder NN NN O
inflammation NN NN O
, , , O
inflammatory JJ JJ O
mediators NNS NNS O
are VBP VBP O
increased VBN VBN O
above IN IN O
that DT DT O
observed VBD VBD O
in IN IN O
WT NNP NNP O
with IN IN O
CYP NNP NNP B-CHEM
. . . O

This DT DT O
shift NN NN O
in IN IN O
balance NN NN O
may MD MD O
contribute VB VB O
to TO TO O
increased VBN VBN O
bladder NN NN O
dysfunction NN NN O
in IN IN O
VIP NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
with IN IN O
bladder NN NN O
inflammation NN NN O
and CC CC O
altered VBN VBN O
neurochemical JJ JJ O
expression NN NN O
in IN IN O
micturition NN NN O
pathways NNS NNS O
. . . O

Debrisoquine NNP NNP B-CHEM
phenotype NN NN O
and CC CC O
the DT DT O
pharmacokinetics NNS NNS O
and CC CC O
beta NN NN O
- - - O
2 CD CD O
receptor NN NN O
pharmacodynamics NNS NNS O
of IN IN O
metoprolol NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
enantiomers NNS NNS O
. . . O

The DT DT O
metabolism NN NN O
of IN IN O
the DT DT O
cardioselective JJ JJ O
beta NN NN O
- - - O
blocker NN NN O
metoprolol NN NN B-CHEM
is VBZ VBZ O
under IN IN O
genetic JJ JJ O
control NN NN O
of IN IN O
the DT DT O
debrisoquine NN NN B-CHEM
/ NN NN O
sparteine NN NN B-CHEM
type NN NN O
. . . O

The DT DT O
two CD CD O
metabolic JJ JJ O
phenotypes NNS NNS O
, , , O
extensive JJ JJ O
( ( ( O
EM NNP NNP O
) ) ) O
and CC CC O
poor JJ JJ O
metabolizers NNS NNS O
( ( ( O
PM NNP NNP O
) ) ) O
, , , O
show NN NN O
different JJ JJ O
stereoselective JJ JJ O
metabolism NN NN O
, , , O
resulting VBG VBG O
in IN IN O
apparently RB RB O
higher JJR JJR O
beta NN NN O
- : : O
1 CD CD O
adrenoceptor NN NN O
antagonistic JJ JJ O
potency NN NN O
of IN IN O
racemic JJ JJ O
metoprolol NN NN B-CHEM
in IN IN O
EMs NNP NNP O
. . . O

We PRP PRP O
investigated VBD VBD O
if IN IN O
the DT DT O
latter NN NN O
also RB RB O
applies VBZ VBZ O
to TO TO O
the DT DT O
beta NN NN O
- - - O
2 CD CD O
adrenoceptor NN NN O
antagonism NN NN O
by IN IN O
metoprolol NN NN B-CHEM
. . . O

The DT DT O
drug NN NN O
effect NN NN O
studied VBN VBN O
was VBD VBD O
the DT DT O
antagonism NN NN O
by IN IN O
metoprolol NN NN B-CHEM
of IN IN O
terbutaline NN NN B-CHEM
- - - O
induced JJ JJ O
hypokalemia NN NN O
. . . O

By IN IN O
using VBG VBG O
pharmacokinetic JJ JJ O
pharmacodynamic JJ JJ O
modeling NN NN O
the DT DT O
pharmacodynamics NNS NNS O
of IN IN O
racemic JJ JJ O
metoprolol NN NN B-CHEM
and CC CC O
the DT DT O
active JJ JJ O
S NNP NNP O
- : : O
isomer NN NN O
, , , O
were VBD VBD O
quantitated VBN VBN O
in IN IN O
EMs NNP NNP O
and CC CC O
PMs NNP NNP O
in IN IN O
terms NNS NNS O
of IN IN O
IC50 NNP NNP O
values NNS NNS O
, , , O
representing VBG VBG O
metoprolol NN NN B-CHEM
plasma NN NN O
concentrations NNS NNS O
resulting VBG VBG O
in IN IN O
half NN NN O
- - - O
maximum NN NN O
receptor NN NN O
occupancy NN NN O
. . . O

Six CD CD O
EMs NNP NNP O
received VBD VBD O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
of IN IN O
terbutaline NN NN B-CHEM
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
on IN IN O
two CD CD O
different JJ JJ O
occasions NNS NNS O
: : : O
1 CD CD O
) ) ) O
1 CD CD O
hr NN NN O
after IN IN O
administration NN NN O
of IN IN O
a DT DT O
placebo NN NN O
and CC CC O
2 CD CD O
) ) ) O
1 CD CD O
hr NN NN O
after IN IN O
150 CD CD O
mg NN NN O
of IN IN O
metoprolol NN NN B-CHEM
p NN NN O
. . . O
o NN NN O
. . . O

Five CD CD O
PMs NNP NNP O
were VBD VBD O
studied VBN VBN O
according VBG VBG O
to TO TO O
the DT DT O
same JJ JJ O
protocol NN NN O
, , , O
except IN IN O
for IN IN O
a DT DT O
higher JJR JJR O
terbutaline NN NN B-CHEM
dose NN NN O
( ( ( O
0 CD CD O
. . . O
75 CD CD O
mg NN NN O
) ) ) O
on IN IN O
day NN NN O
2 CD CD O
. . . O

Blood NNP NNP O
samples NNS NNS O
for IN IN O
the DT DT O
analysis NN NN O
of IN IN O
plasma NN NN O
potassium NN NN B-CHEM
, , , O
terbutaline NN NN B-CHEM
, , , O
metoprolol NN NN B-CHEM
( ( ( O
racemic JJ JJ O
, , , O
R NN NN O
- - - O
and CC CC O
S NNP NNP O
- - - O
isomer NN NN O
) ) ) O
, , , O
and CC CC O
alpha NN NN B-CHEM
- - - I-CHEM
hydroxymetoprolol NN NN I-CHEM
concentrations NNS NNS O
were VBD VBD O
taken VBN VBN O
at IN IN O
regular JJ JJ O
time NN NN O
intervals NNS NNS O
, , , O
during IN IN O
8 CD CD O
hr NN NN O
after IN IN O
metoprolol NN NN B-CHEM
. . . O

In IN IN O
PMs NNP NNP O
, , , O
metoprolol NN NN B-CHEM
increased VBD VBD O
the DT DT O
terbutaline NN NN B-CHEM
area NN NN O
under IN IN O
the DT DT O
plasma NN NN O
concentration NN NN O
vs NNS NNS O
. . . O
time NN NN O
curve NN NN O
( ( ( O
+ NN NN O
67 CD CD O
% NN NN O
) ) ) O
. . . O

Higher JJR JJR O
metoprolol NN NN B-CHEM
/ NN NN O
alpha NN NN B-CHEM
- : : I-CHEM
hydroxymetoprolol NN NN I-CHEM
ratios NNS NNS O
in IN IN O
PMs NNP NNP O
were VBD VBD O
predictive JJ JJ O
for IN IN O
higher JJR JJR O
R NN NN O
- - - O
/ NN NN O
S NNP NNP O
- - - O
isomer NN NN O
ratios NN NN O
of IN IN O
unchanged JJ JJ O
drug NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
difference NN NN O
in IN IN O
metoprolol NN NN B-CHEM
potency NN NN O
with IN IN O
higher JJR JJR O
racemic JJ JJ O
metoprolol NN NN B-CHEM
IC50 NNP NNP O
values NNS NNS O
in IN IN O
PMs NNP NNP O
( ( ( O
72 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
ng NN NN O
. . . O
ml NN NN O
- : : O
1 CD CD O
) ) ) O
than IN IN O
EMs NNP NNP O
( ( ( O
42 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
ng NN NN O
. . . O
ml NN NN O
- : : O
1 CD CD O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
001 CD CD O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

The DT DT O
hemodynamics NNS NNS O
of IN IN O
oxytocin NN NN B-CHEM
and CC CC O
other JJ JJ O
vasoactive JJ JJ O
agents NNS NNS O
during IN IN O
neuraxial JJ JJ O
anesthesia NN NN O
for IN IN O
cesarean NN NN O
delivery NN NN O
: : : O
findings NNS NNS O
in IN IN O
six CD CD O
cases NNS NNS O
. . . O

Oxytocin NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
commonly RB RB O
used VBN VBN O
uterotonic JJ JJ O
that WDT WDT O
can MD MD O
cause VB VB O
significant JJ JJ O
and CC CC O
even RB RB O
fatal JJ JJ O
hypotension NN NN O
, , , O
particularly RB RB O
when WRB WRB O
given VBN VBN O
as IN IN O
a DT DT O
bolus NN NN O
. . . O

The DT DT O
resulting VBG VBG O
hypotension NN NN O
can MD MD O
be VB VB O
produced VBN VBN O
by IN IN O
a DT DT O
decrease NN NN O
in IN IN O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
or CC CC O
cardiac JJ JJ O
output NN NN O
through IN IN O
a DT DT O
decrease NN NN O
in IN IN O
venous JJ JJ O
return NN NN O
. . . O

Parturients NNP NNP O
with IN IN O
normal JJ JJ O
volume NN NN O
status NN NN O
, , , O
heart NN NN O
valves NNS NNS O
and CC CC O
pulmonary JJ JJ O
vasculature NN NN O
most RBS RBS O
often RB RB O
respond NN NN O
to TO TO O
this DT DT O
hypotension NN NN O
with IN IN O
a DT DT O
compensatory NN NN O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
and CC CC O
stroke NN NN O
volume NN NN O
. . . O

Oxytocin NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
at IN IN O
cesarean NN NN O
delivery NN NN O
may MD MD O
be VB VB O
incorrectly RB RB O
attributed VBN VBN O
to TO TO O
blood NN NN O
loss NN NN O
. . . O

Pulse NNP NNP O
power NN NN O
analysis NN NN O
( ( ( O
also RB RB O
called VBN VBN O
" '' '' O
pulse NN NN O
contour NN NN O
analysis NN NN O
" '' '' O
) ) ) O
of IN IN O
an DT DT O
arterial JJ JJ O
pressure NN NN O
wave NN NN O
form NN NN O
allows VBZ VBZ O
continuous JJ JJ O
evaluation NN NN O
of IN IN O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
and CC CC O
cardiac JJ JJ O
output NN NN O
in IN IN O
real JJ JJ O
time NN NN O
, , , O
thereby RB RB O
elucidating VBG VBG O
the DT DT O
causative JJ JJ O
factors NNS NNS O
behind IN IN O
changes NNS NNS O
in IN IN O
blood NN NN O
pressure NN NN O
. . . O

Pulse NNP NNP O
power NN NN O
analysis NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
six CD CD O
cases NNS NNS O
of IN IN O
cesarean JJ JJ O
delivery NN NN O
performed VBN VBN O
under IN IN O
neuraxial JJ JJ O
anesthesia NN NN O
. . . O

Hypotension NNP NNP O
in IN IN O
response NN NN O
to TO TO O
oxytocin NN NN B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
decrease NN NN O
in IN IN O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
and CC CC O
a DT DT O
compensatory NN NN O
increase NN NN O
in IN IN O
stroke NN NN O
volume NN NN O
, , , O
heart NN NN O
rate NN NN O
and CC CC O
cardiac JJ JJ O
output NN NN O
. . . O

Pulse NNP NNP O
power NN NN O
analysis NN NN O
may MD MD O
be VB VB O
helpful JJ JJ O
in IN IN O
determining VBG VBG O
the DT DT O
etiology NN NN O
of IN IN O
and CC CC O
treating VBG VBG O
hypotension NN NN O
during IN IN O
cesarean NN NN O
delivery NN NN O
under IN IN O
neuraxial JJ JJ O
anesthesia NN NN O
. . . O

Protective NNP NNP O
effects NNS NNS O
of IN IN O
antithrombin NN NN O
on IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
nephrosis NN NN O
in IN IN O
rats NNS NNS O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
antithrombin NN NN O
, , , O
a DT DT O
plasma NN NN O
inhibitor NN NN O
of IN IN O
coagulation NN NN O
factors NNS NNS O
, , , O
in IN IN O
rats NNS NNS O
with IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
nephrosis NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
an DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
human JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Antithrombin NNP NNP O
( ( ( O
50 CD CD O
or CC CC O
500 CD CD O
IU NNP NNP O
/ NN NN O
kg NN NN O
/ NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
was VBD VBD O
administered VBN VBN O
to TO TO O
rats NNS NNS O
once RB RB O
a DT DT O
day NN NN O
for IN IN O
10 CD CD O
days NNS NNS O
immediately RB RB O
after IN IN O
the DT DT O
injection NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
. . . O

Treatment NN NN O
with IN IN O
antithrombin NN NN O
attenuated VBD VBD O
the DT DT O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
hematological JJ JJ O
abnormalities NNS NNS O
. . . O

Puromycin NNP NNP B-CHEM
aminonucleoside IN IN I-CHEM
- - - O
induced JJ JJ O
renal NN NN O
dysfunction NN NN O
and CC CC O
hyperlipidemia NN NN O
were VBD VBD O
also RB RB O
suppressed VBN VBN O
. . . O

Histopathological NNP NNP O
examination NN NN O
revealed VBD VBD O
severe JJ JJ O
renal JJ JJ O
damage NN NN O
such JJ JJ O
as IN IN O
proteinaceous JJ JJ O
casts NNS NNS O
in IN IN O
tubuli NN NN O
and CC CC O
tubular JJ JJ O
expansion NN NN O
in IN IN O
the DT DT O
kidney NN NN O
of IN IN O
control NN NN O
rats NNS NNS O
, , , O
while IN IN O
an DT DT O
improvement NN NN O
of IN IN O
the DT DT O
damage NN NN O
was VBD VBD O
seen VBN VBN O
in IN IN O
antithrombin NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
antithrombin NN NN O
treatment NN NN O
markedly RB RB O
suppressed VBD VBD O
puromycin NN NN B-CHEM
aminonucleoside IN IN I-CHEM
- - - O
induced JJ JJ O
apoptosis NN NN O
of IN IN O
renal JJ JJ O
tubular NN NN O
epithelial NN NN O
cells NNS NNS O
. . . O

Furthermore RB RB O
, , , O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
- : : O
induced JJ JJ O
increases NNS NNS O
in IN IN O
renal NN NN O
cytokine NN NN O
content NN NN O
were VBD VBD O
also RB RB O
decreased VBN VBN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
thrombin NN NN O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside IN IN I-CHEM
- - - O
induced JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Treatment NN NN O
with IN IN O
antithrombin NN NN O
may MD MD O
be VB VB O
clinically RB RB O
effective JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Heparin NNP NNP B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Unfractionated NNP NNP B-CHEM
heparin NN NN I-CHEM
sodium NN NN I-CHEM
( ( ( O
UFH NNP NNP B-CHEM
) ) ) O
or CC CC O
low JJ JJ B-CHEM
- - - I-CHEM
molecular JJ JJ I-CHEM
weight NN NN I-CHEM
heparin NN NN I-CHEM
( ( ( O
LMWH NNP NNP O
) ) ) O
is VBZ VBZ O
used VBN VBN O
in IN IN O
anticoagulant JJ JJ O
protocols NNS NNS O
at IN IN O
several JJ JJ O
institutions NNS NNS O
to TO TO O
prevent VB VB O
thrombosis NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
. . . O

Heparin NNP NNP B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
( ( ( O
HIT NNP NNP O
) ) ) O
is VBZ VBZ O
an DT DT O
adverse JJ JJ O
immune JJ JJ O
- - - O
mediated JJ JJ O
reaction NN NN O
to TO TO O
heparin NN NN B-CHEM
, , , O
resulting VBG VBG O
in IN IN O
platelet NN NN O
count NN NN O
decreases NNS NNS O
of IN IN O
more JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
. . . O

The DT DT O
frequencies NNS NNS O
of IN IN O
HIT NNP NNP O
after IN IN O
liver NN NN O
transplantation NN NN O
and CC CC O
platelet NN NN O
factor NN NN O
4 CD CD O
/ NN NN O
heparin NN NN B-CHEM
- - - O
reactive JJ JJ O
antibody NN NN O
( ( ( O
HIT NNP NNP O
antibody NN NN O
) ) ) O
positivity NN NN O
in IN IN O
liver NN NN O
transplantation NN NN O
patients NNS NNS O
, , , O
however RB RB O
, , , O
are VBP VBP O
unknown JJ JJ O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
The DT DT O
32 CD CD O
men NNS NNS O
and CC CC O
20 CD CD O
women NNS NNS O
underwent VBD VBD O
living VBG VBG O
donor JJ JJ O
liver NN NN O
transplantation NN NN O
. . . O

We PRP PRP O
started VBD VBD O
LMWH NNP NNP O
( ( ( O
25 CD CD O
IU NNP NNP O
/ NN NN O
kg NN NN O
/ NN NN O
h NN NN O
) ) ) O
on IN IN O
postoperative JJ JJ O
day NN NN O
( ( ( O
POD NNP NNP O
) ) ) O
1 CD CD O
, , , O
switching VBG VBG O
to TO TO O
UFH NNP NNP B-CHEM
( ( ( O
5000 CD CD O
U NNP NNP O
/ NN NN O
d SYM SYM O
) ) ) O
on IN IN O
POD NNP NNP O
2 CD CD O
or CC CC O
3 CD CD O
. . . O

The DT DT O
dose NN NN O
of IN IN O
UFH NNP NNP B-CHEM
was VBD VBD O
changed VBN VBN O
according VBG VBG O
to TO TO O
the DT DT O
activated JJ JJ O
clotting VBG VBG O
time NN NN O
level NN NN O
. . . O

HIT NNP NNP O
antibody NN NN O
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
the DT DT O
day NN NN O
before IN IN O
surgery NN NN O
and CC CC O
on IN IN O
POD NNP NNP O
7 CD CD O
and CC CC O
14 CD CD O
. . . O

Platelet NNP NNP O
count NN NN O
was VBD VBD O
measured VBN VBN O
daily RB RB O
for IN IN O
3 CD CD O
weeks NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
average JJ JJ O
platelet NN NN O
counts NNS NNS O
preoperatively RB RB O
, , , O
and CC CC O
on IN IN O
POD NNP NNP O
7 CD CD O
, , , O
14 CD CD O
, , , O
and CC CC O
21 CD CD O
were VBD VBD O
65 CD CD O
, , , O
88 CD CD O
, , , O
149 CD CD O
, , , O
and CC CC O
169 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
L NNP NNP O
, , , O
respectively RB RB O
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
hepatic JJ JJ O
artery NN NN O
thrombosis NN NN O
on IN IN O
POD NNP NNP O
11 CD CD O
and CC CC O
19 CD CD O
, , , O
respectively RB RB O
, , , O
although IN IN O
they PRP PRP O
were VBD VBD O
HIT NNP NNP O
antibody NN NN O
- : : O
negative JJ JJ O
and CC CC O
their PRP$ PRP$ O
platelet NN NN O
counts NNS NNS O
were VBD VBD O
stable JJ JJ O
. . . O

In IN IN O
2 CD CD O
other JJ JJ O
patients NNS NNS O
, , , O
the DT DT O
platelet NN NN O
count NN NN O
decreased VBD VBD O
suddenly RB RB O
from IN IN O
107 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
L NNP NNP O
on IN IN O
POD NNP NNP O
4 CD CD O
to TO TO O
65 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
L NNP NNP O
on IN IN O
POD NNP NNP O
6 CD CD O
and CC CC O
from IN IN O
76 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
L NNP NNP O
on IN IN O
POD NNP NNP O
7 CD CD O
to TO TO O
33 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
L NNP NNP O
on IN IN O
POD NNP NNP O
9 CD CD O
, , , O
respectively RB RB O
. . . O

The DT DT O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
platelet NN NN O
aggregation NN NN O
test NN NN O
was VBD VBD O
negative JJ JJ O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

The DT DT O
percentage NN NN O
of IN IN O
HIT NNP NNP O
antibody NN NN O
- - - O
positive JJ JJ O
patients NNS NNS O
was VBD VBD O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
preoperatively RB RB O
, , , O
5 CD CD O
. . . O
6 CD CD O
% NN NN O
on IN IN O
POD NNP NNP O
7 CD CD O
, , , O
and CC CC O
5 CD CD O
. . . O
6 CD CD O
% NN NN O
on IN IN O
POD NNP NNP O
14 CD CD O
. . . O

None NN NN O
of IN IN O
the DT DT O
subjects NNS NNS O
/ NN NN O
patients NNS NNS O
developed VBN VBN O
UFH NNP NNP B-CHEM
- - - O
related VBN VBN O
HIT NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
our PRP$ PRP$ O
series NN NN O
, , , O
the DT DT O
occurrence NN NN O
of IN IN O
HIT NNP NNP O
after IN IN O
liver NN NN O
transplantation NN NN O
was VBD VBD O
uncommon JJ JJ O
. . . O

Doxorubicin NNP NNP B-CHEM
cardiomyopathy JJ JJ O
- - - O
induced JJ JJ O
inflammation NN NN O
and CC CC O
apoptosis NNS NNS O
are VBP VBP O
attenuated VBN VBN O
by IN IN O
gene NN NN O
deletion NN NN O
of IN IN O
the DT DT O
kinin NN NN O
B1 NNP NNP O
receptor NN NN O
. . . O

Clinical NNP NNP O
use NN NN O
of IN IN O
the DT DT O
anthracycline NN NN B-CHEM
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
limited VBN VBN O
by IN IN O
its PRP$ PRP$ O
cardiotoxic JJ JJ O
effects NNS NNS O
, , , O
which WDT WDT O
are VBP VBP O
attributed VBN VBN O
to TO TO O
the DT DT O
induction NN NN O
of IN IN O
apoptosis NN NN O
. . . O

To TO TO O
elucidate VB VB O
the DT DT O
possible JJ JJ O
role NN NN O
of IN IN O
the DT DT O
kinin NN NN O
B1 NNP NNP O
receptor NN NN O
( ( ( O
B1R NNP NNP O
) ) ) O
during IN IN O
the DT DT O
development NN NN O
of IN IN O
DOX NNP NNP B-CHEM
cardiomyopathy NN NN O
, , , O
we PRP PRP O
studied VBD VBD O
B1R NNP NNP O
knockout NN NN O
mice NN NN O
( ( ( O
B1R NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
) ) ) O
by IN IN O
investigating VBG VBG O
cardiac JJ JJ O
inflammation NN NN O
and CC CC O
apoptosis NN NN O
after IN IN O
induction NN NN O
of IN IN O
DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
. . . O

DOX NNP NNP B-CHEM
control NN NN O
mice NN NN O
showed VBD VBD O
cardiac JJ JJ O
dysfunction NN NN O
measured VBN VBN O
by IN IN O
pressure NN NN O
- - - O
volume NN NN O
loops NNS NNS O
in IN IN O
vivo NN NN O
. . . O

This DT DT O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
reduced JJ JJ O
activation NN NN O
state NN NN O
of IN IN O
AKT NNP NNP O
, , , O
as RB RB O
well RB RB O
as IN IN O
an DT DT O
increased VBN VBN O
bax NN NN O
/ NN NN O
bcl2 NN NN O
ratio NN NN O
in IN IN O
Western JJ JJ O
blots NNS NNS O
, , , O
indicating VBG VBG O
cardiac JJ JJ O
apoptosis NN NN O
. . . O

Furthermore RB RB O
, , , O
mRNA NN NN O
levels NNS NNS O
of IN IN O
the DT DT O
proinflammatory NN NN O
cytokine NN NN O
interleukin NN NN O
6 CD CD O
were VBD VBD O
increased VBN VBN O
in IN IN O
the DT DT O
cardiac NN NN O
tissue NN NN O
. . . O

In IN IN O
DOX NNP NNP B-CHEM
B1R NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
, , , O
cardiac JJ JJ O
dysfunction NN NN O
was VBD VBD O
improved VBN VBN O
compared VBN VBN O
to TO TO O
DOX NNP NNP B-CHEM
control NN NN O
mice NN NN O
, , , O
which WDT WDT O
was VBD VBD O
associated VBN VBN O
with IN IN O
normalization NN NN O
of IN IN O
the DT DT O
bax NN NN O
/ NN NN O
bcl NN NN O
- : : O
2 CD CD O
ratio NN NN O
and CC CC O
interleukin NN NN O
6 CD CD O
, , , O
as RB RB O
well RB RB O
as IN IN O
AKT NNP NNP O
activation NN NN O
state NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
B1R NNP NNP O
is VBZ VBZ O
detrimental JJ JJ O
in IN IN O
DOX NNP NNP B-CHEM
cardiomyopathy NN NN O
in IN IN O
that IN IN O
it PRP PRP O
mediates VBZ VBZ O
the DT DT O
inflammatory JJ JJ O
response NN NN O
and CC CC O
apoptosis NN NN O
. . . O

These DT DT O
insights NNS NNS O
might MD MD O
have VB VB O
useful JJ JJ O
implications NNS NNS O
for IN IN O
future JJ JJ O
studies NNS NNS O
utilizing VBG VBG O
B1R NNP NNP O
antagonists NNS NNS O
for IN IN O
treatment NN NN O
of IN IN O
human JJ JJ O
DOX NNP NNP B-CHEM
cardiomyopathy NN NN O
. . . O

Detailed NNP NNP O
spectral JJ JJ O
profile NN NN O
analysis NN NN O
of IN IN O
penicillin NN NN B-CHEM
- - - O
induced JJ JJ O
epileptiform NN NN O
activity NN NN O
in IN IN O
anesthetized JJ JJ O
rats NNS NNS O
. . . O

Penicillin NNP NNP B-CHEM
model NN NN O
is VBZ VBZ O
a DT DT O
widely RB RB O
used VBN VBN O
experimental JJ JJ O
model NN NN O
for IN IN O
epilepsy NN NN O
research NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
we PRP PRP O
aimed VBD VBD O
to TO TO O
portray VB VB O
a DT DT O
detailed VBN VBN O
spectral JJ JJ O
analysis NN NN O
of IN IN O
penicillin NN NN B-CHEM
- - - O
induced JJ JJ O
epileptiform NN NN O
activity NN NN O
in IN IN O
comparison NN NN O
with IN IN O
basal NN NN O
brain NN NN O
activity NN NN O
in IN IN O
anesthetized JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
anesthetized VBN VBN O
with IN IN O
i NNP NNP O
. . . O
p NN NN O
. . . O
urethane NN NN B-CHEM
and CC CC O
connected VBN VBN O
to TO TO O
an DT DT O
electrocorticogram NN NN O
setup NN NN O
. . . O

After IN IN O
a DT DT O
short JJ JJ O
period NN NN O
of IN IN O
basal NN NN O
activity NN NN O
recording NN NN O
, , , O
epileptic JJ JJ O
focus NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
injecting VBG VBG O
400IU CD CD O
/ NN NN O
2 CD CD O
microl NN NN O
penicillin NN NN B-CHEM
- : : I-CHEM
G NNP NNP I-CHEM
potassium NN NN I-CHEM
into IN IN O
the DT DT O
left NN NN O
lateral NN NN O
ventricle NN NN O
while IN IN O
the DT DT O
cortical JJ JJ O
activity NN NN O
was VBD VBD O
continuously RB RB O
recorded VBN VBN O
. . . O

Basal NNP NNP O
activity NN NN O
, , , O
latent NN NN O
period NN NN O
and CC CC O
the DT DT O
penicillin NN NN B-CHEM
- - - O
induced JJ JJ O
epileptiform NN NN O
activity NN NN O
periods NNS NNS O
were VBD VBD O
then RB RB O
analyzed VBN VBN O
using VBG VBG O
both DT DT O
conventional JJ JJ O
methods NNS NNS O
and CC CC O
spectral JJ JJ O
analysis NN NN O
. . . O

Spectral NNP NNP O
analyses NNS NNS O
were VBD VBD O
conducted VBN VBN O
by IN IN O
dividing VBG VBG O
the DT DT O
whole JJ JJ O
spectrum NN NN O
into IN IN O
different JJ JJ O
frequency NN NN O
bands NNS NNS O
including VBG VBG O
delta NN NN O
, , , O
theta NN NN O
( ( ( O
slow JJ JJ O
and CC CC O
fast RB RB O
) ) ) O
, , , O
alpha JJ JJ O
- - - O
sigma NN NN O
, , , O
beta NN NN O
( ( ( O
1 CD CD O
and CC CC O
2 CD CD O
) ) ) O
and CC CC O
gamma NN NN O
( ( ( O
1 CD CD O
and CC CC O
2 CD CD O
) ) ) O
bands NNS NNS O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
show VBP VBP O
that IN IN O
the DT DT O
most RBS RBS O
affected VBN VBN O
frequency NN NN O
bands NNS NNS O
were VBD VBD O
delta NN NN O
, , , O
theta NN NN O
, , , O
beta NN NN O
- : : O
2 CD CD O
and CC CC O
gamma NN NN O
- - - O
2 CD CD O
bands NNS NNS O
during IN IN O
the DT DT O
epileptiform NN NN O
activity NN NN O
and CC CC O
there EX EX O
were VBD VBD O
marked VBN VBN O
differences NNS NNS O
in IN IN O
terms NNS NNS O
of IN IN O
spectral JJ JJ O
densities NNS NNS O
between IN IN O
three CD CD O
investigated VBN VBN O
episodes NNS NNS O
( ( ( O
basal NN NN O
activity NN NN O
, , , O
latent NN NN O
period NN NN O
and CC CC O
epileptiform NN NN O
activity NN NN O
) ) ) O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
may MD MD O
help VB VB O
to TO TO O
analyze VB VB O
novel NN NN O
data NNS NNS O
obtained VBN VBN O
using VBG VBG O
similar JJ JJ O
experimental JJ JJ O
models NNS NNS O
and CC CC O
the DT DT O
simple JJ JJ O
analysis NN NN O
method NN NN O
described VBD VBD O
here RB RB O
can MD MD O
be VB VB O
used VBN VBN O
in IN IN O
similar JJ JJ O
studies NNS NNS O
to TO TO O
investigate VB VB O
the DT DT O
basic JJ JJ O
neuronal JJ JJ O
mechanism NN NN O
of IN IN O
this DT DT O
or CC CC O
other JJ JJ O
types NNS NNS O
of IN IN O
experimental JJ JJ O
epilepsies NNS NNS O
. . . O

High NNP NNP O
fat JJ JJ B-CHEM
diet NN NN O
- - - O
fed VBN VBN O
obese NN NN O
rats NNS NNS O
are VBP VBP O
highly RB RB O
sensitive JJ JJ O
to TO TO O
doxorubicin VB VB B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Often RB RB O
, , , O
chemotherapy NN NN O
by IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
Adriamycin NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
limited VBN VBN O
due JJ JJ O
to TO TO O
life NN NN O
threatening VBG VBG O
cardiotoxicity NN NN O
in IN IN O
patients NNS NNS O
during IN IN O
and CC CC O
posttherapy NN NN O
. . . O

Recently RB RB O
, , , O
we PRP PRP O
have VBP VBP O
shown VBN VBN O
that IN IN O
moderate JJ JJ O
diet NN NN O
restriction NN NN O
remarkably RB RB O
protects VBZ VBZ O
against IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

This DT DT O
cardioprotection NN NN O
is VBZ VBZ O
accompanied VBN VBN O
by IN IN O
decreased JJ JJ O
cardiac JJ JJ O
oxidative JJ JJ O
stress NN NN O
and CC CC O
triglycerides NNS NNS B-CHEM
and CC CC O
increased VBN VBN O
cardiac NN NN O
fatty JJ JJ O
- : : O
acid NN NN O
oxidation NN NN O
, , , O
ATP NNP NNP B-CHEM
synthesis NN NN O
, , , O
and CC CC O
upregulated JJ JJ O
JAK NNP NNP O
/ NN NN O
STAT3 NNP NNP O
pathway NN NN O
. . . O

In IN IN O
the DT DT O
current JJ JJ O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
whether IN IN O
a DT DT O
physiological JJ JJ O
intervention NN NN O
by IN IN O
feeding VBG VBG O
40 CD CD O
% NN NN O
high JJ JJ O
fat JJ JJ B-CHEM
diet NN NN O
( ( ( O
HFD NNP NNP O
) ) ) O
, , , O
which WDT WDT O
induces VBZ VBZ O
obesity NN NN O
in IN IN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
( ( ( O
250 CD CD O
- : : O
275 CD CD O
g SYM SYM O
) ) ) O
, , , O
sensitizes NNS NNS O
to TO TO O
doxorubicin VB VB B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

A DT DT O
LD NNP NNP O
( ( ( O
10 CD CD O
) ) ) O
dose NN NN O
( ( ( O
8 CD CD O
mg NN NN O
doxorubicin NN NN B-CHEM
/ NN NN O
kg NN NN O
, , , O
ip NNP NNP O
) ) ) O
administered VBN VBN O
on IN IN O
day NN NN O
43 CD CD O
of IN IN O
the DT DT O
HFD NNP NNP O
feeding NN NN O
regimen NNS NNS O
led VBN VBN O
to TO TO O
higher JJR JJR O
cardiotoxicity NN NN O
, , , O
cardiac JJ JJ O
dysfunction NN NN O
, , , O
lipid JJ JJ O
peroxidation NN NN O
, , , O
and CC CC O
80 CD CD O
% NN NN O
mortality NN NN O
in IN IN O
the DT DT O
obese NN NN O
( ( ( O
OB NNP NNP O
) ) ) O
rats NNS NNS O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
any DT DT O
significant JJ JJ O
renal NN NN O
or CC CC O
hepatic JJ JJ O
toxicity NN NN O
. . . O

Doxorubicin NNP NNP B-CHEM
toxicokinetics NNS NNS O
studies NNS NNS O
revealed VBD VBD O
no DT DT O
change NN NN O
in IN IN O
accumulation NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
and CC CC O
doxorubicinol NN NN B-CHEM
( ( ( O
toxic JJ JJ O
metabolite NN NN O
) ) ) O
in IN IN O
the DT DT O
normal JJ JJ O
diet NN NN O
- - - O
fed VBN VBN O
( ( ( O
ND NNP NNP O
) ) ) O
and CC CC O
OB NNP NNP O
hearts NNS NNS O
. . . O

Mechanistic NNP NNP O
studies NNS NNS O
revealed VBD VBD O
that IN IN O
OB NNP NNP O
rats NNS NNS O
are VBP VBP O
sensitized VBN VBN O
due JJ JJ O
to TO TO O
: : : O
( ( ( O
1 CD CD O
) ) ) O
higher JJR JJR O
oxyradical JJ JJ O
stress NN NN O
leading VBG VBG O
to TO TO O
upregulation NN NN O
of IN IN O
uncoupling VBG VBG O
proteins NNS NNS O
2 CD CD O
and CC CC O
3 CD CD O
, , , O
( ( ( O
2 CD CD O
) ) ) O
downregulation NN NN O
of IN IN O
cardiac JJ JJ O
peroxisome NN NN O
proliferators NNS NNS O
activated VBN VBN O
receptor NN NN O
- - - O
alpha NN NN O
, , , O
( ( ( O
3 CD CD O
) ) ) O
decreased VBD VBD O
plasma NN NN O
adiponectin NN NN O
levels NNS NNS O
, , , O
( ( ( O
4 CD CD O
) ) ) O
decreased VBD VBD O
cardiac JJ JJ O
fatty NN NN O
- - - O
acid NN NN O
oxidation NN NN O
( ( ( O
666 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
. . . O
0 CD CD O
nmol NN NN O
/ NN NN O
min NN NN O
/ NN NN O
g SYM SYM O
heart NN NN O
in IN IN O
ND NNP NNP O
versus CC CC O
400 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
. . . O
8 CD CD O
nmol NN NN O
/ NN NN O
min NN NN O
/ NN NN O
g SYM SYM O
heart NN NN O
in IN IN O
OB NNP NNP O
) ) ) O
, , , O
( ( ( O
5 CD CD O
) ) ) O
decreased VBD VBD O
mitochondrial JJ JJ O
AMP NNP NNP B-CHEM
- : : O
alpha2 NN NN O
protein NN NN O
kinase NN NN O
, , , O
and CC CC O
( ( ( O
6 CD CD O
) ) ) O
86 CD CD O
% NN NN O
drop NN NN O
in IN IN O
cardiac JJ JJ O
ATP NNP NNP B-CHEM
levels NNS NNS O
accompanied VBN VBN O
by IN IN O
decreased VBN VBN O
ATP NNP NNP B-CHEM
/ NN NN O
ADP NNP NNP B-CHEM
ratio NN NN O
after IN IN O
doxorubicin NN NN B-CHEM
administration NN NN O
. . . O

Decreased NNP NNP O
cardiac JJ JJ O
erythropoietin NN NN O
and CC CC O
increased VBN VBN O
SOCS3 NNP NNP O
further RBR RBR O
downregulated VBD VBD O
the DT DT O
cardioprotective JJ JJ O
JAK NNP NNP O
/ NN NN O
STAT3 NNP NNP O
pathway NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
HFD NNP NNP O
- : : O
induced VBN VBN O
obese NN NN O
rats NNS NNS O
are VBP VBP O
highly RB RB O
sensitized VBN VBN O
to TO TO O
doxorubicin VB VB B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
by IN IN O
substantially RB RB O
downregulating VBG VBG O
cardiac JJ JJ O
mitochondrial NN NN O
ATP NNP NNP B-CHEM
generation NN NN O
, , , O
increasing VBG VBG O
oxidative JJ JJ O
stress NN NN O
and CC CC O
downregulating VBG VBG O
the DT DT O
JAK NNP NNP O
/ NN NN O
STAT3 NNP NNP O
pathway NN NN O
. . . O

Isoproterenol NNP NNP B-CHEM
induces NNS NNS O
primary JJ JJ O
loss NN NN O
of IN IN O
dystrophin NN NN O
in IN IN O
rat NN NN O
hearts NNS NNS O
: : : O
correlation NN NN O
with IN IN O
myocardial JJ JJ O
injury NN NN O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
damage NN NN O
is VBZ VBZ O
unknown JJ JJ O
, , , O
but CC CC O
a DT DT O
mismatch NN NN O
of IN IN O
oxygen NN NN B-CHEM
supply NN NN O
vs NNS NNS O
. . . O
demand NN NN O
following NN NN O
coronary JJ JJ O
hypotension NN NN O
and CC CC O
myocardial JJ JJ O
hyperactivity NN NN O
is VBZ VBZ O
the DT DT O
best JJS JJS O
explanation NN NN O
for IN IN O
the DT DT O
complex JJ JJ O
morphological JJ JJ O
alterations NNS NNS O
observed VBD VBD O
. . . O

Severe NNP NNP O
alterations NNS NNS O
in IN IN O
the DT DT O
structural JJ JJ O
integrity NN NN O
of IN IN O
the DT DT O
sarcolemma NN NN O
of IN IN O
cardiomyocytes NNS NNS O
have VBP VBP O
been VBN VBN O
demonstrated VBN VBN O
to TO TO O
be VB VB O
caused VBN VBN O
by IN IN O
isoproterenol NN NN B-CHEM
. . . O

Taking VBG VBG O
into IN IN O
account NN NN O
that IN IN O
the DT DT O
sarcolemmal NN NN O
integrity NN NN O
is VBZ VBZ O
stabilized VBN VBN O
by IN IN O
the DT DT O
dystrophin NN NN O
- - - O
glycoprotein NN NN O
complex JJ JJ O
( ( ( O
DGC NNP NNP O
) ) ) O
that IN IN O
connects NNS NNS O
actin NN NN O
and CC CC O
laminin NN NN O
in IN IN O
contractile NN NN O
machinery NN NN O
and CC CC O
extracellular NN NN O
matrix NN NN O
and CC CC O
by IN IN O
integrins NNS NNS O
, , , O
this DT DT O
study NN NN O
tests VBZ VBZ O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
isoproterenol NN NN B-CHEM
affects VBZ VBZ O
sarcolemmal JJ JJ O
stability NN NN O
through IN IN O
changes NNS NNS O
in IN IN O
the DT DT O
DGC NNP NNP O
and CC CC O
integrins NNS NNS O
. . . O

We PRP PRP O
found VBD VBD O
different JJ JJ O
sensitivity NN NN O
of IN IN O
the DT DT O
DGC NNP NNP O
and CC CC O
integrin NN NN O
to TO TO O
isoproterenol VB VB B-CHEM
subcutaneous JJ JJ O
administration NN NN O
. . . O

Immunofluorescent NNP NNP O
staining VBG VBG O
revealed VBN VBN O
that IN IN O
dystrophin NN NN O
is VBZ VBZ O
the DT DT O
most RBS RBS O
sensitive JJ JJ O
among IN IN O
the DT DT O
structures NNS NNS O
connecting VBG VBG O
the DT DT O
actin NN NN O
in IN IN O
the DT DT O
cardiomyocyte NN NN O
cytoskeleton NN NN O
and CC CC O
the DT DT O
extracellular NN NN O
matrix NN NN O
. . . O

The DT DT O
sarcomeric JJ JJ O
actin NN NN O
dissolution NN NN O
occurred VBD VBD O
after IN IN O
the DT DT O
reduction NN NN O
or CC CC O
loss NN NN O
of IN IN O
dystrophin NN NN O
. . . O

Subsequently RB RB O
, , , O
after IN IN O
lysis NN NN O
of IN IN O
myofilaments NNS NNS O
, , , O
gamma NN NN O
- - - O
sarcoglycan NN NN O
, , , O
beta NN NN O
- - - O
dystroglycan NN NN O
, , , O
beta1 NN NN O
- - - O
integrin NN NN O
, , , O
and CC CC O
laminin NN NN O
alpha NN NN O
- : : O
2 CD CD O
expressions NNS NNS O
were VBD VBD O
reduced VBN VBN O
followed VBN VBN O
by IN IN O
their PRP$ PRP$ O
breakdown NN NN O
, , , O
as IN IN O
epiphenomena NN NN O
of IN IN O
the DT DT O
myocytolytic JJ JJ O
process NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
administration NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
to TO TO O
rats VB VB O
results NNS NNS O
in IN IN O
primary JJ JJ O
loss NN NN O
of IN IN O
dystrophin NN NN O
, , , O
the DT DT O
most RBS RBS O
sensitive JJ JJ O
among IN IN O
the DT DT O
structural JJ JJ O
proteins NNS NNS O
that WDT WDT O
form NN NN O
the DT DT O
DGC NNP NNP O
that IN IN O
connects VBZ VBZ O
the DT DT O
extracellular NN NN O
matrix NN NN O
and CC CC O
the DT DT O
cytoskeleton NN NN O
in IN IN O
cardiomyocyte NN NN O
. . . O

These DT DT O
changes NNS NNS O
, , , O
related VBN VBN O
to TO TO O
ischaemic JJ JJ O
injury NN NN O
, , , O
explain VB VB O
the DT DT O
severe JJ JJ O
alterations NNS NNS O
in IN IN O
the DT DT O
structural JJ JJ O
integrity NN NN O
of IN IN O
the DT DT O
sarcolemma NN NN O
of IN IN O
cardiomyocytes NNS NNS O
and CC CC O
hence RB RB O
severe JJ JJ O
and CC CC O
irreversible JJ JJ O
injury NN NN O
induced VBN VBN O
by IN IN O
isoproterenol NN NN B-CHEM
. . . O

Etiologic NNP NNP O
factors NNS NNS O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
liver NN NN O
tumors NNS NNS O
associated VBN VBN O
with IN IN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

Within IN IN O
the DT DT O
last JJ JJ O
several JJ JJ O
years NNS NNS O
, , , O
previously RB RB O
rare JJ JJ O
liver NN NN O
tumors NNS NNS O
have VBP VBP O
been VBN VBN O
seen VBN VBN O
in IN IN O
young JJ JJ O
women NNS NNS O
using VBG VBG O
oral JJ JJ B-CHEM
contraceptive JJ JJ I-CHEM
steroids NNS NNS B-CHEM
. . . O

The DT DT O
Registry NNP NNP O
for IN IN O
Liver NNP NNP O
Tumors NNP NNP O
Associated NNP NNP O
with IN IN O
Oral NNP NNP B-CHEM
Contraceptives NNP NNP I-CHEM
at IN IN O
the DT DT O
University NNP NNP O
of IN IN O
California NNP NNP O
, , , O
Irvine NNP NNP O
, , , O
has VBZ VBZ O
clearly RB RB O
identified VBN VBN O
27 CD CD O
cases NNS NNS O
. . . O

The DT DT O
recent JJ JJ O
literature NN NN O
contains VBZ VBZ O
44 CD CD O
case NN NN O
reports NNS NNS O
. . . O

Common NNP NNP O
to TO TO O
these DT DT O
71 CD CD O
cases NNS NNS O
has VBZ VBZ O
been VBN VBN O
a DT DT O
histopathologic JJ JJ O
diagnosis NN NN O
of IN IN O
focal JJ JJ O
nodular NN NN O
hyperplasia NN NN O
, , , O
adenoma NN NN O
, , , O
hamartoma NN NN O
, , , O
and CC CC O
hepatoma NN NN O
. . . O

Significant JJ JJ O
statistical JJ JJ O
etiologic NN NN O
factors NNS NNS O
include VBP VBP O
prolonged JJ JJ O
uninterrupted JJ JJ O
usage NN NN O
of IN IN O
oral JJ JJ B-CHEM
contraceptive JJ JJ I-CHEM
steroids NNS NNS B-CHEM
. . . O

Eight CD CD O
deaths NNS NNS O
and CC CC O
liver NN NN O
rupture NN NN O
in IN IN O
18 CD CD O
patients NNS NNS O
attest VBP VBP O
to TO TO O
the DT DT O
seriousness NN NN O
of IN IN O
this DT DT O
new JJ JJ O
potentially RB RB O
lethal JJ JJ O
adverse JJ JJ O
phenomenon NN NN O
. . . O

Ifosfamide NNP NNP B-CHEM
continuous JJ JJ O
infusion NN NN O
without IN IN O
mesna NN NN B-CHEM
. . . O

A DT DT O
phase NN NN O
I PRP PRP O
trial NN NN O
of IN IN O
a DT DT O
14 CD CD O
- : : O
day NN NN O
cycle NN NN O
. . . O

Twenty NNP NNP O
patients NNS NNS O
received VBD VBD O
27 CD CD O
courses NNS NNS O
of IN IN O
ifosfamide RB RB B-CHEM
administered VBN VBN O
as IN IN O
a DT DT O
24 CD CD O
- : : O
hour NN NN O
continuous JJ JJ O
infusion NN NN O
for IN IN O
14 CD CD O
days NNS NNS O
without IN IN O
Mesna NNP NNP B-CHEM
. . . O

The DT DT O
goal NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
deliver VB VB O
a DT DT O
dose NN NN O
rate NN NN O
and CC CC O
total JJ JJ O
cumulative JJ JJ O
dose NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
that WDT WDT O
would MD MD O
be VB VB O
comparable JJ JJ O
to TO TO O
standard JJ JJ O
bolus NN NN O
or CC CC O
short JJ JJ O
- - - O
term NN NN O
infusions NNS NNS O
administered VBN VBN O
with IN IN O
Mesna NNP NNP B-CHEM
. . . O

Dose NNP NNP O
escalations NNS NNS O
proceeded VBD VBD O
from IN IN O
200 CD CD O
to TO TO O
300 CD CD O
, , , O
400 CD CD O
, , , O
450 CD CD O
, , , O
500 CD CD O
, , , O
and CC CC O
550 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
. . . O

Four CD CD O
patients NNS NNS O
developed VBN VBN O
transient NN NN O
microscopic NN NN O
hematuria NN NN O
at IN IN O
400 CD CD O
, , , O
450 CD CD O
, , , O
and CC CC O
500 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
instances NNS NNS O
of IN IN O
macroscopic JJ JJ O
hematuria NN NN O
. . . O

At IN IN O
550 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
, , , O
three CD CD O
patients NNS NNS O
experienced VBN VBN O
nonurologic JJ JJ O
toxicity NN NN O
; : : O
confusion NN NN O
( ( ( O
1 CD CD O
) ) ) O
, , , O
nausea NN NN O
( ( ( O
1 CD CD O
) ) ) O
, , , O
and CC CC O
Grade NNP NNP O
2 CD CD O
leukopenia NN NN O
( ( ( O
1 CD CD O
) ) ) O
. . . O

The DT DT O
recommended JJ JJ O
dose NN NN O
of IN IN O
500 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
delivers VBZ VBZ O
a DT DT O
total JJ JJ O
dose NN NN O
of IN IN O
7 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
per IN IN O
cycle NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
comparable JJ JJ O
to TO TO O
that DT DT O
delivered VBD VBD O
in IN IN O
clinical JJ JJ O
practice NN NN O
for IN IN O
bolus NN NN O
or CC CC O
short JJ JJ O
- - - O
term NN NN O
infusion NN NN O
. . . O

Because IN IN O
few JJ JJ O
patients NNS NNS O
received VBD VBD O
multiple JJ JJ O
courses NNS NNS O
over IN IN O
time NN NN O
, , , O
the DT DT O
cumulative JJ JJ O
effects NNS NNS O
are VBP VBP O
indeterminate JJ JJ O
in IN IN O
the DT DT O
present JJ JJ O
trial NN NN O
. . . O

The DT DT O
frequency NN NN O
and CC CC O
predictability NN NN O
of IN IN O
hematuria NN NN O
are VBP VBP O
not RB RB O
precise JJ JJ O
, , , O
and CC CC O
at IN IN O
least JJS JJS O
daily JJ JJ O
monitoring NN NN O
by IN IN O
urine JJ JJ O
Hematest NNP NNP O
is VBZ VBZ O
essential JJ JJ O
, , , O
adding VBG VBG O
Mesna NNP NNP B-CHEM
to TO TO O
the DT DT O
infusate NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
persistent JJ JJ O
hematuria NN NN O
. . . O

The DT DT O
protracted JJ JJ O
infusion NN NN O
schedule NN NN O
for IN IN O
ifosfamide NN NN B-CHEM
permits NNS NNS O
convenient JJ JJ O
outpatient JJ JJ O
administration NN NN O
without IN IN O
Mesna NNP NNP B-CHEM
and CC CC O
reduces VBZ VBZ O
the DT DT O
drug NN NN O
cost NN NN O
of IN IN O
clinical JJ JJ O
usage NN NN O
of IN IN O
this DT DT O
agent NN NN O
by IN IN O
up IN IN O
to TO TO O
890 CD CD O
per IN IN O
cycle NN NN O
. . . O

Clinical NNP NNP O
activity NN NN O
was VBD VBD O
demonstrated VBN VBN O
in IN IN O
a DT DT O
single JJ JJ O
patient NN NN O
, , , O
but CC CC O
a DT DT O
comparative JJ JJ O
trial NN NN O
of IN IN O
standard JJ JJ O
bolus NN NN O
schedules NNS NNS O
with IN IN O
the DT DT O
protracted JJ JJ O
infusion NN NN O
schedule NN NN O
will MD MD O
be VB VB O
necessary JJ JJ O
to TO TO O
determine VB VB O
if IN IN O
the DT DT O
clinical JJ JJ O
effectiveness NN NN O
of IN IN O
the DT DT O
drug NN NN O
is VBZ VBZ O
maintained VBN VBN O
. . . O

A DT DT O
case NN NN O
of IN IN O
ventricular NN NN O
tachycardia NNS NNS O
related VBN VBN O
to TO TO O
caffeine NN NN B-CHEM
pretreatment NN NN O
. . . O

Suboptimal NNP NNP O
seizure NN NN O
duration NN NN O
is VBZ VBZ O
commonly RB RB O
encountered VBN VBN O
in IN IN O
electroconvulsive JJ JJ O
therapy NN NN O
practice NN NN O
, , , O
especially RB RB O
in IN IN O
older JJR JJR O
patients NNS NNS O
with IN IN O
higher JJR JJR O
seizure NN NN O
thresholds NNS NNS O
. . . O

Intravenous NNP NNP O
caffeine NN NN B-CHEM
is VBZ VBZ O
commonly RB RB O
used VBN VBN O
to TO TO O
improve VB VB O
seizure NN NN O
duration NN NN O
and CC CC O
quality NN NN O
in IN IN O
such JJ JJ O
patients NNS NNS O
and CC CC O
is VBZ VBZ O
generally RB RB O
well RB RB O
tolerated VBN VBN O
aside RB RB O
from IN IN O
occasional JJ JJ O
reports NNS NNS O
of IN IN O
relatively RB RB O
benign NN NN O
ventricular NN NN O
ectopy NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
patient NN NN O
with IN IN O
no DT DT O
previous JJ JJ O
history NN NN O
of IN IN O
cardiac JJ JJ O
disease NN NN O
or CC CC O
arrhythmia NN NN O
who WP WP O
developed VBD VBD O
sustained JJ JJ O
bigeminy NN NN O
and CC CC O
2 CD CD O
brief JJ JJ O
runs VBZ VBZ O
of IN IN O
ventricular JJ JJ O
tachycardia NNS NNS O
after IN IN O
caffeine NN NN B-CHEM
administration NN NN O
. . . O

Although IN IN O
intravenous JJ JJ O
caffeine NN NN B-CHEM
is VBZ VBZ O
generally RB RB O
well RB RB O
tolerated VBD VBD O
, , , O
the DT DT O
clinician NN NN O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
potential JJ JJ O
for IN IN O
unpredictable JJ JJ O
and CC CC O
serious JJ JJ O
ventricular JJ JJ O
arrhythmias NNS NNS O
. . . O

Fatal NNP NNP O
haemopericardium NN NN O
and CC CC O
gastrointestinal JJ JJ O
haemorrhage NN NN O
due JJ JJ O
to TO TO O
possible JJ JJ O
interaction NN NN O
of IN IN O
cranberry NN NN O
juice NN NN O
with IN IN O
warfarin NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
fatal JJ JJ O
internal JJ JJ O
haemorrhage NN NN O
in IN IN O
an DT DT O
elderly JJ JJ O
man NN NN O
who WP WP O
consumed VBD VBD O
only RB RB O
cranberry VB VB O
juice NN NN O
for IN IN O
two CD CD O
weeks NNS NNS O
while IN IN O
maintaining VBG VBG O
his PRP$ PRP$ O
usual JJ JJ O
dosage NN NN O
of IN IN O
warfarin NN NN B-CHEM
. . . O

We PRP PRP O
propose VBP VBP O
that IN IN O
naturally RB RB O
occurring VBG VBG O
compounds NNS NNS O
such JJ JJ O
as IN IN O
flavonoids NNS NNS B-CHEM
, , , O
which WDT WDT O
are VBP VBP O
present JJ JJ O
in IN IN O
fruit NN NN O
juices NNS NNS O
, , , O
may MD MD O
increase VB VB O
the DT DT O
potency NN NN O
of IN IN O
warfarin NN NN B-CHEM
by IN IN O
competing VBG VBG O
for IN IN O
the DT DT O
enzymes NNS NNS O
that WDT WDT O
normally RB RB O
inactivate JJ JJ O
warfarin NN NN B-CHEM
. . . O

While IN IN O
traditionally RB RB O
regarded VBN VBN O
as IN IN O
foodstuffs NNS NNS O
, , , O
consumption NN NN O
of IN IN O
fruit NN NN O
juices NNS NNS O
should MD MD O
be VB VB O
considered VBN VBN O
when WRB WRB O
patients NNS NNS O
develop VBP VBP O
adverse NN NN O
drug NN NN O
reactions NNS NNS O
. . . O

Effect NN NN O
of IN IN O
increasing VBG VBG O
intraperitoneal NN NN O
infusion NN NN O
rates NNS NNS O
on IN IN O
bupropion NN NN B-CHEM
hydrochloride NN NN I-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
mice NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
It PRP PRP O
is VBZ VBZ O
not RB RB O
known VBN VBN O
if IN IN O
there EX EX O
is VBZ VBZ O
a DT DT O
relationship NN NN O
between IN IN O
input NN NN O
rate NN NN O
and CC CC O
incidence NN NN O
of IN IN O
bupropion NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
important JJ JJ O
, , , O
since IN IN O
different JJ JJ O
controlled JJ JJ O
release NN NN O
formulations NNS NNS O
of IN IN O
bupropion NN NN B-CHEM
release NN NN O
the DT DT O
active JJ JJ O
drug NN NN O
at IN IN O
different JJ JJ O
rates NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
investigated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
varying VBG VBG O
the DT DT O
intraperitoneal JJ JJ O
infusion NN NN O
rates NNS NNS O
of IN IN O
bupropion NN NN B-CHEM
HCl NNP NNP I-CHEM
120 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
a DT DT O
known VBN VBN O
convulsive NN NN O
dose NN NN O
50 CD CD O
( ( ( O
CD50 NNP NNP O
) ) ) O
, , , O
on IN IN O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
bupropion NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
in IN IN O
the DT DT O
Swiss NNP NNP O
albino NN NN O
mice NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
69 CD CD O
mice NN NN O
, , , O
approximately RB RB O
7 CD CD O
weeks NNS NNS O
of IN IN O
age NN NN O
, , , O
and CC CC O
weighing VBG VBG O
21 CD CD O
. . . O
0 CD CD O
to TO TO O
29 CD CD O
. . . O
1 CD CD O
g SYM SYM O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
bupropion NN NN B-CHEM
HCl NNP NNP I-CHEM
120 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
treatment NN NN O
by IN IN O
intraperitoneal NN NN O
( ( ( O
IP NNP NNP O
) ) ) O
administration NN NN O
in IN IN O
7 CD CD O
groups NNS NNS O
( ( ( O
9 CD CD O
to TO TO O
10 CD CD O
animals NNS NNS O
per IN IN O
group NN NN O
) ) ) O
. . . O

Bupropion NNP NNP B-CHEM
HCl NNP NNP I-CHEM
was VBD VBD O
infused VBN VBN O
through IN IN O
a DT DT O
surgically RB RB O
implanted VBN VBN O
IP NNP NNP O
dosing VBG VBG O
catheter NN NN O
with IN IN O
infusions NNS NNS O
in IN IN O
each DT DT O
group NN NN O
of IN IN O
0 CD CD O
min NN NN O
, , , O
15 CD CD O
min NN NN O
, , , O
30 CD CD O
min NN NN O
, , , O
60 CD CD O
min NN NN O
, , , O
90 CD CD O
min NN NN O
, , , O
120 CD CD O
min NN NN O
, , , O
and CC CC O
240 CD CD O
min NN NN O
. . . O

The DT DT O
number NN NN O
, , , O
time NN NN O
of IN IN O
onset NN NN O
, , , O
duration NN NN O
and CC CC O
the DT DT O
intensity NN NN O
of IN IN O
the DT DT O
convulsions NNS NNS O
or CC CC O
absence NN NN O
of IN IN O
convulsions NNS NNS O
were VBD VBD O
recorded VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
results NNS NNS O
showed VBD VBD O
that IN IN O
IP NNP NNP O
administration NN NN O
of IN IN O
bupropion NN NN B-CHEM
HCl NNP NNP I-CHEM
120 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
by IN IN O
bolus JJ JJ O
injection NN NN O
induced VBN VBN O
convulsions NNS NNS O
in IN IN O
6 CD CD O
out IN IN O
of IN IN O
10 CD CD O
mice NN NN O
( ( ( O
60 CD CD O
% NN NN O
of IN IN O
convulsing VBG VBG O
mice NN NN O
) ) ) O
in IN IN O
group NN NN O
1 CD CD O
. . . O

Logistic NNP NNP O
regression NN NN O
analysis NN NN O
revealed VBD VBD O
that IN IN O
infusion NN NN O
time NN NN O
was VBD VBD O
significant JJ JJ O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0004 CD CD O
; : : O
odds NN NN O
ratio NN NN O
= SYM SYM O
0 CD CD O
. . . O
974 CD CD O
) ) ) O
and CC CC O
increasing VBG VBG O
the DT DT O
IP NNP NNP O
infusion NN NN O
time NN NN O
of IN IN O
bupropion NN NN B-CHEM
HCl NNP NNP I-CHEM
120 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
91 CD CD O
% NN NN O
reduced VBN VBN O
odds NNS NNS O
of IN IN O
convulsions NNS NNS O
at IN IN O
infusion NN NN O
times NNS NNS O
of IN IN O
15 CD CD O
to TO TO O
90 CD CD O
min NN NN O
compared VBN VBN O
to TO TO O
bolus JJ JJ O
injection NN NN O
. . . O

Further RB RB O
increase NN NN O
in IN IN O
infusion NN NN O
time NN NN O
resulted VBD VBD O
in IN IN O
further JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
odds NNS NNS O
of IN IN O
convulsions NNS NNS O
to TO TO O
99 CD CD O
. . . O
8 CD CD O
% NN NN O
reduction NN NN O
at IN IN O
240 CD CD O
min NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
conclusion NN NN O
, , , O
the DT DT O
demonstration NN NN O
of IN IN O
an DT DT O
inverse JJ JJ O
relationship NN NN O
between IN IN O
infusion NN NN O
time NN NN O
of IN IN O
a DT DT O
fixed JJ JJ O
and CC CC O
convulsive JJ JJ O
dose NN NN O
of IN IN O
bupropion NN NN B-CHEM
and CC CC O
the DT DT O
risk NN NN O
of IN IN O
convulsions NNS NNS O
in IN IN O
a DT DT O
prospective JJ JJ O
study NN NN O
is VBZ VBZ O
novel NN NN O
. . . O

Graft NNP NNP O
- : : O
versus CC CC O
- : : O
host NN NN O
disease NN NN O
prophylaxis NN NN O
with IN IN O
everolimus NN NN B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
sinusoidal JJ JJ O
obstruction NN NN O
syndrome NN NN O
and CC CC O
microangiopathy NN NN O
: : : O
results NNS NNS O
of IN IN O
the DT DT O
EVTAC NNP NNP O
trial NN NN O
. . . O

A DT DT O
calcineurin NN NN O
inhibitor NN NN O
combined VBN VBN O
with IN IN O
methotrexate NN NN B-CHEM
is VBZ VBZ O
the DT DT O
standard JJ JJ O
prophylaxis NN NN O
for IN IN O
graft NN NN O
- - - O
versus CC CC O
- - - O
host NN NN O
disease NN NN O
( ( ( O
GVHD NNP NNP O
) ) ) O
after IN IN O
allogeneic NN NN O
hematopoietic JJ JJ O
stem NN NN O
cell NN NN O
transplantation NN NN O
( ( ( O
HSCT NNP NNP O
) ) ) O
. . . O

Everolimus NNP NNP B-CHEM
, , , O
a DT DT O
derivative JJ JJ O
of IN IN O
sirolimus NN NN B-CHEM
, , , O
seems VBZ VBZ O
to TO TO O
mediate VB VB O
antileukemia NN NN O
effects NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
a DT DT O
combination NN NN O
of IN IN O
everolimus NN NN B-CHEM
and CC CC O
tacrolimus NN NN B-CHEM
in IN IN O
24 CD CD O
patients NNS NNS O
( ( ( O
median JJ JJ O
age NN NN O
, , , O
62 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
either DT DT O
myelodysplastic JJ JJ O
syndrome NN NN O
( ( ( O
MDS NNP NNP O
; : : O
n NN NN O
= SYM SYM O
17 CD CD O
) ) ) O
or CC CC O
acute JJ JJ O
myeloid NN NN O
leukemia NN NN O
( ( ( O
AML NNP NNP O
; : : O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
undergoing VBG VBG O
intensive JJ JJ O
conditioning NN NN O
followed VBN VBN O
by IN IN O
HSCT NNP NNP O
from IN IN O
related VBN VBN O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
or CC CC O
unrelated JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
20 CD CD O
) ) ) O
donors NNS NNS O
. . . O

All DT DT O
patients NNS NNS O
engrafted VBN VBN O
, , , O
and CC CC O
only RB RB O
1 CD CD O
patient NN NN O
experienced VBD VBD O
grade NN NN O
IV NNP NNP O
mucositis NN NN O
. . . O

Nine CD CD O
patients NNS NNS O
( ( ( O
37 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
acute JJ JJ O
grade NN NN O
II NNP NNP O
- : : O
IV NNP NNP O
GVHD NNP NNP O
, , , O
and CC CC O
11 CD CD O
of IN IN O
17 CD CD O
evaluable JJ JJ O
patients NNS NNS O
( ( ( O
64 CD CD O
% NN NN O
) ) ) O
developed JJ JJ O
chronic JJ JJ O
extensive JJ JJ O
GVHD NNP NNP O
. . . O

Transplantation NNP NNP O
- - - O
associated VBN VBN O
microangiopathy NN NN O
( ( ( O
TMA NNP NNP O
) ) ) O
occurred VBD VBD O
in IN IN O
7 CD CD O
patients NNS NNS O
( ( ( O
29 CD CD O
% NN NN O
) ) ) O
, , , O
with IN IN O
2 CD CD O
cases NNS NNS O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

The DT DT O
study NN NN O
was VBD VBD O
terminated VBN VBN O
prematurely RB RB O
because IN IN O
an DT DT O
additional JJ JJ O
6 CD CD O
patients NNS NNS O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
sinusoidal JJ JJ O
obstruction NN NN O
syndrome NN NN O
( ( ( O
SOS NNP NNP O
) ) ) O
, , , O
which WDT WDT O
was VBD VBD O
fatal JJ JJ O
in IN IN O
2 CD CD O
cases NNS NNS O
. . . O

With IN IN O
a DT DT O
median JJ JJ O
follow VB VB O
- - - O
up RP RP O
of IN IN O
26 CD CD O
months NNS NNS O
, , , O
the DT DT O
2 CD CD O
- : : O
year NN NN O
overall JJ JJ O
survival NN NN O
rate NN NN O
was VBD VBD O
47 CD CD O
% NN NN O
. . . O

Although IN IN O
this DT DT O
new JJ JJ O
combination NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
effective JJ JJ O
as IN IN O
a DT DT O
prophylactic JJ JJ O
regimen NN NN O
for IN IN O
acute JJ JJ O
GVHD NNP NNP O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
TMA NNP NNP O
and CC CC O
SOS NNP NNP O
is VBZ VBZ O
considerably RB RB O
higher JJR JJR O
than IN IN O
seen VBN VBN O
with IN IN O
other JJ JJ O
regimens NNS NNS O
. . . O

Longitudinal NNP NNP O
assessment NN NN O
of IN IN O
air NN NN O
conduction NN NN O
audiograms NNS NNS O
in IN IN O
a DT DT O
phase NN NN O
III NNP NNP O
clinical JJ JJ O
trial NN NN O
of IN IN O
difluoromethylornithine NN NN B-CHEM
and CC CC O
sulindac NN NN B-CHEM
for IN IN O
prevention NN NN O
of IN IN O
sporadic JJ JJ O
colorectal JJ JJ O
adenomas NNS NNS O
. . . O

A DT DT O
phase NN NN O
III NNP NNP O
clinical JJ JJ O
trial NN NN O
assessed VBD VBD O
the DT DT O
recurrence NN NN O
of IN IN O
adenomatous JJ JJ O
polyps NN NN O
after IN IN O
treatment NN NN O
for IN IN O
36 CD CD O
months NNS NNS O
with IN IN O
difluoromethylornithine NN NN B-CHEM
( ( ( O
DFMO NNP NNP B-CHEM
) ) ) O
plus CC CC O
sulindac NN NN B-CHEM
or CC CC O
matched VBD VBD O
placebos NN NN O
. . . O

Temporary NNP NNP O
hearing NN NN O
loss NN NN O
is VBZ VBZ O
a DT DT O
known VBN VBN O
toxicity NN NN O
of IN IN O
treatment NN NN O
with IN IN O
DFMO NNP NNP B-CHEM
, , , O
thus RB RB O
a DT DT O
comprehensive JJ JJ O
approach NN NN O
was VBD VBD O
developed VBN VBN O
to TO TO O
analyze VB VB O
serial JJ JJ O
air NN NN O
conduction NN NN O
audiograms NNS NNS O
. . . O

The DT DT O
generalized JJ JJ O
estimating VBG VBG O
equation NN NN O
method NN NN O
estimated VBD VBD O
the DT DT O
mean JJ JJ O
difference NN NN O
between IN IN O
treatment NN NN O
arms NNS NNS O
with IN IN O
regard NN NN O
to TO TO O
change VB VB O
in IN IN O
air NN NN O
conduction NN NN O
pure JJ JJ O
tone NN NN O
thresholds NNS NNS O
while IN IN O
accounting VBG VBG O
for IN IN O
within IN IN O
- - - O
subject JJ JJ O
correlation NN NN O
due JJ JJ O
to TO TO O
repeated VBN VBN O
measurements NNS NNS O
at IN IN O
frequencies NNS NNS O
. . . O

Based VBN VBN O
on IN IN O
290 CD CD O
subjects NNS NNS O
, , , O
there EX EX O
was VBD VBD O
an DT DT O
average JJ JJ O
difference NN NN O
of IN IN O
0 CD CD O
. . . O
50 CD CD O
dB NN NN O
between IN IN O
subjects NNS NNS O
treated VBN VBN O
with IN IN O
DFMO NNP NNP B-CHEM
plus CC CC O
sulindac NN NN B-CHEM
compared VBN VBN O
with IN IN O
those DT DT O
treated VBN VBN O
with IN IN O
placebo NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
- - - O
0 CD CD O
. . . O
64 CD CD O
to TO TO O
1 CD CD O
. . . O
63 CD CD O
dB NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
39 CD CD O
) ) ) O
, , , O
adjusted VBN VBN O
for IN IN O
baseline NN NN O
values NNS NNS O
, , , O
age NN NN O
, , , O
and CC CC O
frequencies NNS NNS O
. . . O

In IN IN O
the DT DT O
normal JJ JJ O
speech NN NN O
range NN NN O
of IN IN O
500 CD CD O
to TO TO O
3 CD CD O
, , , O
000 CD CD O
Hz NNP NNP O
, , , O
an DT DT O
estimated JJ JJ O
difference NN NN O
of IN IN O
0 CD CD O
. . . O
99 CD CD O
dB NN NN O
( ( ( O
- : : O
0 CD CD O
. . . O
17 CD CD O
to TO TO O
2 CD CD O
. . . O
14 CD CD O
dB NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
09 CD CD O
) ) ) O
was VBD VBD O
detected VBN VBN O
. . . O

Dose NNP NNP O
intensity NN NN O
did VBD VBD O
not RB RB O
add VB VB O
information NN NN O
to TO TO O
models NNS NNS O
. . . O

There EX EX O
were VBD VBD O
14 CD CD O
of IN IN O
151 CD CD O
( ( ( O
9 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
DFMO NNP NNP B-CHEM
plus CC CC O
sulindac NN NN B-CHEM
group NN NN O
and CC CC O
4 CD CD O
of IN IN O
139 CD CD O
( ( ( O
2 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
who WP WP O
experienced VBD VBD O
at IN IN O
least JJS JJS O
15 CD CD O
dB NN NN O
hearing NN NN O
reduction NN NN O
from IN IN O
baseline NN NN O
in IN IN O
2 CD CD O
or CC CC O
more RBR RBR O
consecutive JJ JJ O
frequencies NNS NNS O
across IN IN O
the DT DT O
entire JJ JJ O
range NN NN O
tested VBN VBN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

Follow VB VB O
- - - O
up RP RP O
air NN NN O
conduction NN NN O
done VBN VBN O
at IN IN O
least JJS JJS O
6 CD CD O
months NNS NNS O
after IN IN O
end NN NN O
of IN IN O
treatment NN NN O
showed VBD VBD O
an DT DT O
adjusted JJ JJ O
mean NN NN O
difference NN NN O
in IN IN O
hearing NN NN O
thresholds NNS NNS O
of IN IN O
1 CD CD O
. . . O
08 CD CD O
dB NN NN O
( ( ( O
- : : O
0 CD CD O
. . . O
81 CD CD O
to TO TO O
2 CD CD O
. . . O
96 CD CD O
dB NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
26 CD CD O
) ) ) O
between IN IN O
treatment NN NN O
arms NNS NNS O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
the DT DT O
proportion NN NN O
of IN IN O
subjects NNS NNS O
in IN IN O
the DT DT O
DFMO NNP NNP B-CHEM
plus CC CC O
sulindac NN NN B-CHEM
group NN NN O
who WP WP O
experienced VBD VBD O
clinically RB RB O
significant JJ JJ O
hearing NN NN O
loss NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

The DT DT O
estimated VBN VBN O
attributable JJ JJ O
risk NN NN O
of IN IN O
ototoxicity NN NN O
from IN IN O
exposure NN NN O
to TO TO O
the DT DT O
drug NN NN O
is VBZ VBZ O
8 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
- - - O
2 CD CD O
. . . O
0 CD CD O
% NN NN O
to TO TO O
18 CD CD O
. . . O
8 CD CD O
% NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
12 CD CD O
) ) ) O
. . . O

There EX EX O
is VBZ VBZ O
a DT DT O
< NN NN O
2 CD CD O
dB NN NN O
difference NN NN O
in IN IN O
mean NN NN O
threshold NN NN O
for IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
DFMO NNP NNP B-CHEM
plus CC CC O
sulindac NN NN B-CHEM
compared VBN VBN O
with IN IN O
those DT DT O
treated VBN VBN O
with IN IN O
placebo NN NN O
. . . O

Proteinase NNP NNP O
3 CD CD O
- : : O
antineutrophil NN NN O
cytoplasmic JJ JJ O
antibody NN NN O
- : : O
( ( ( O
PR3 NNP NNP O
- - - O
ANCA NNP NNP O
) ) ) O
positive JJ JJ O
necrotizing VBG VBG O
glomerulonephritis NN NN O
after IN IN O
restarting VBG VBG O
sulphasalazine NN NN B-CHEM
treatment NN NN O
. . . O

A DT DT O
59 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
ulcerative JJ JJ O
colitis NN NN O
developed VBN VBN O
red JJ JJ O
eyes NNS NNS O
, , , O
pleural JJ JJ O
effusion NN NN O
, , , O
eosinophilia NN NN O
and CC CC O
urinary JJ JJ O
abnormalities NNS NNS O
after IN IN O
restarting VBG VBG O
of IN IN O
sulphasalazine NN NN B-CHEM
treatment NN NN O
. . . O

Light NNP NNP O
microscopy NN NN O
of IN IN O
a DT DT O
kidney NN NN O
biopsy NN NN O
revealed VBD VBD O
segmental JJ JJ O
necrotizing VBG VBG O
glomerulonephritis NN NN O
without IN IN O
deposition NN NN O
of IN IN O
immunoglobulin NN NN O
or CC CC O
complement NN NN O
. . . O

Proteinase NNP NNP O
3 CD CD O
- : : O
antineutrophil NN NN O
cytoplasmic JJ JJ O
antibody NN NN O
( ( ( O
PR3 NNP NNP O
- - - O
ANCA NNP NNP O
) ) ) O
titer NN NN O
was VBD VBD O
elevated VBN VBN O
at IN IN O
183 CD CD O
ELISA NNP NNP O
units NNS NNS O
( ( ( O
EU NNP NNP O
) ) ) O
in IN IN O
sera NN NN O
( ( ( O
normal JJ JJ O
range NN NN O
less JJR JJR O
than IN IN O
10 CD CD O
EU NNP NNP O
) ) ) O
, , , O
myeloperoxidase NN NN O
- - - O
ANCA NNP NNP O
was VBD VBD O
negative JJ JJ O
. . . O

PR3 NNP NNP O
- : : O
ANCA NNP NNP O
titer NN NN O
was VBD VBD O
250 CD CD O
and CC CC O
1 CD CD O
, , , O
070 CD CD O
EU NNP NNP O
in IN IN O
pleural JJ JJ O
effusions NNS NNS O
on IN IN O
right NN NN O
and CC CC O
left VBD VBD O
side NN NN O
, , , O
respectively RB RB O
. . . O

Although IN IN O
cessation NN NN O
of IN IN O
sulphasalazine NN NN B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
improvements NNS NNS O
in IN IN O
fever NN NN O
, , , O
red JJ JJ O
eyes NNS NNS O
, , , O
chest NN NN O
pain NN NN O
, , , O
titer NN NN O
of IN IN O
C NNP NNP O
- - - O
reactive JJ JJ O
protein NN NN O
and CC CC O
volume NN NN O
of IN IN O
the DT DT O
pleural JJ JJ O
effusions NNS NNS O
, , , O
we PRP PRP O
initiated VBD VBD O
steroid NN NN B-CHEM
therapy NN NN O
, , , O
because IN IN O
PR3 NNP NNP O
- : : O
ANCA NNP NNP O
titer NN NN O
rose VBD VBD O
to TO TO O
320 CD CD O
EU NNP NNP O
, , , O
eosinophil NN NN O
count NN NN O
increased VBN VBN O
to TO TO O
1 CD CD O
, , , O
100 CD CD O
cells NNS NNS O
/ NN NN O
microl NN NN O
, , , O
and CC CC O
the DT DT O
pleural JJ JJ O
effusion NN NN O
remained VBD VBD O
. . . O

One CD CD O
month NN NN O
after IN IN O
steroid NN NN B-CHEM
therapy NN NN O
, , , O
the DT DT O
pleural JJ JJ O
effusion NN NN O
disappeared VBD VBD O
, , , O
and CC CC O
PR3 NNP NNP O
- : : O
ANCA NNP NNP O
titer NN NN O
normalized JJ JJ O
3 CD CD O
months NNS NNS O
later RB RB O
. . . O

This DT DT O
case NN NN O
suggests VBZ VBZ O
that IN IN O
sulphasalazine NN NN B-CHEM
can MD MD O
induce VB VB O
PR3 NNP NNP O
- : : O
ANCA NNP NNP O
- : : O
positive JJ JJ O
necrotizing VBG VBG O
glomerulonephritis NNS NNS O
. . . O

Comparison NNP NNP O
of IN IN O
unilateral JJ JJ O
pallidotomy NN NN O
and CC CC O
subthalamotomy NN NN O
findings NNS NNS O
in IN IN O
advanced JJ JJ O
idiopathic JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

A DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
pilot NN NN O
study NN NN O
to TO TO O
compare VB VB O
the DT DT O
results NNS NNS O
of IN IN O
stereotactic JJ JJ O
unilateral JJ JJ O
pallidotomy NN NN O
and CC CC O
subthalamotomy NN NN O
in IN IN O
advanced VBN VBN O
idiopathic JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
refractory NN NN O
to TO TO O
medical JJ JJ O
treatment NN NN O
was VBD VBD O
designed VBN VBN O
. . . O

Ten CD CD O
consecutive JJ JJ O
patients NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
, , , O
58 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
8 CD CD O
years NNS NNS O
; : : O
7 CD CD O
men NNS NNS O
, , , O
3 CD CD O
women NNS NNS O
) ) ) O
with IN IN O
similar JJ JJ O
characteristics NNS NNS O
at IN IN O
the DT DT O
duration NN NN O
of IN IN O
disease NN NN O
( ( ( O
mean VB VB O
disease NN NN O
time NN NN O
, , , O
8 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
5 CD CD O
years NNS NNS O
) ) ) O
, , , O
disabling VBG VBG O
motor NN NN O
fluctuations NNS NNS O
( ( ( O
Hoehn NNP NNP O
_ NN NN O
Yahr NNP NNP O
stage NN NN O
3 CD CD O
- : : O
5 CD CD O
in IN IN O
off IN IN O
- - - O
drug NN NN O
phases NNS NNS O
) ) ) O
and CC CC O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
were VBD VBD O
selected VBN VBN O
. . . O

All DT DT O
patients NNS NNS O
had VBD VBD O
bilateral JJ JJ O
symptoms NNS NNS O
and CC CC O
their PRP$ PRP$ O
levodopa NN NN B-CHEM
equivalent NN NN O
dosing VBG VBG O
were VBD VBD O
analysed VBN VBN O
. . . O

Six CD CD O
patients NNS NNS O
were VBD VBD O
operated VBN VBN O
on IN IN O
in IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
interna NN NN O
( ( ( O
GPi NNP NNP O
) ) ) O
and CC CC O
four CD CD O
in IN IN O
the DT DT O
subthalamic JJ JJ O
nucleus NN NN O
( ( ( O
STN NNP NNP O
) ) ) O
. . . O

Clinical NNP NNP O
evaluation NN NN O
included VBD VBD O
the DT DT O
use NN NN O
of IN IN O
the DT DT O
Unified NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
( ( ( O
UPDRS NNP NNP O
) ) ) O
, , , O
Hoehn NNP NNP O
_ NN NN O
Yahr NNP NNP O
score NN NN O
and CC CC O
Schwab NNP NNP O
England NNP NNP O
activities NNS NNS O
of IN IN O
daily JJ JJ O
living NN NN O
( ( ( O
ADL NNP NNP O
) ) ) O
score NN NN O
in IN IN O
' POS POS O
on IN IN O
' POS POS O
- : : O
and CC CC O
' POS POS O
off IN IN O
' POS POS O
- : : O
drug NN NN O
conditions NNS NNS O
before IN IN O
surgery NN NN O
and CC CC O
6 CD CD O
months NNS NNS O
after IN IN O
surgery NN NN O
. . . O

There EX EX O
was VBD VBD O
statistically RB RB O
significant JJ JJ O
improvement NN NN O
in IN IN O
all DT DT O
contralateral JJ JJ O
major JJ JJ O
parkinsonian NN NN O
motor NN NN O
signs NNS NNS O
in IN IN O
all DT DT O
patients NNS NNS O
followed VBN VBN O
for IN IN O
6 CD CD O
months NNS NNS O
. . . O

Levodopa NNP NNP B-CHEM
equivalent NN NN O
daily JJ JJ O
intake NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
in IN IN O
the DT DT O
STN NNP NNP O
group NN NN O
. . . O

Changes NNS NNS O
in IN IN O
UPDRS NNP NNP O
, , , O
Hoehn NNP NNP O
_ NN NN O
Yahr NNP NNP O
and CC CC O
Schwab NNP NNP O
England NNP NNP O
ADL NNP NNP O
scores NNS NNS O
were VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Cognitive NNP NNP O
functions NNS NNS O
were VBD VBD O
unchanged JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Complications NNP NNP O
were VBD VBD O
observed VBN VBN O
in IN IN O
two CD CD O
patients NNS NNS O
: : : O
one CD CD O
had VBD VBD O
a DT DT O
left VBN VBN O
homonymous JJ JJ O
hemianopsia NN NN O
after IN IN O
pallidotomy NN NN O
and CC CC O
another DT DT O
one CD CD O
developed VBN VBN O
left VBD VBD O
hemiballistic JJ JJ O
movements NNS NNS O
3 CD CD O
days NNS NNS O
after IN IN O
subthalamotomy NN NN O
which WDT WDT O
partly RB RB O
improved VBN VBN O
within IN IN O
1 CD CD O
month NN NN O
with IN IN O
Valproate NNP NNP B-CHEM
1000 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
. . . O

The DT DT O
findings NNS NNS O
of IN IN O
this DT DT O
study NN NN O
suggest VBP VBP O
that IN IN O
lesions NNS NNS O
of IN IN O
the DT DT O
unilateral JJ JJ O
STN NNP NNP O
and CC CC O
GPi NNP NNP O
are VBP VBP O
equally RB RB O
effective JJ JJ O
treatment NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
PD NNP NNP O
refractory NN NN O
to TO TO O
medical JJ JJ O
treatment NN NN O
. . . O

DSMM NNP NNP O
XI NNP NNP O
study NN NN O
: : : O
dose NN NN O
definition NN NN O
for IN IN O
intravenous JJ JJ O
cyclophosphamide NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
bortezomib NN NN B-CHEM
/ NN NN O
dexamethasone NN NN B-CHEM
for IN IN O
remission NN NN O
induction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
newly RB RB O
diagnosed VBN VBN O
myeloma NN NN O
. . . O

A DT DT O
clinical JJ JJ O
trial NN NN O
was VBD VBD O
initiated VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
recommended JJ JJ O
dose NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
bortezomib NN NN B-CHEM
and CC CC O
dexamethasone NN NN B-CHEM
as IN IN O
induction NN NN O
treatment NN NN O
before IN IN O
stem NN NN O
cell NN NN O
transplantation NN NN O
for IN IN O
younger JJR JJR O
patients NNS NNS O
with IN IN O
newly RB RB O
diagnosed VBN VBN O
multiple JJ JJ O
myeloma NN NN O
( ( ( O
MM NNP NNP O
) ) ) O
. . . O

Thirty NNP NNP O
patients NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
three CD CD O
21 CD CD O
- : : O
day NN NN O
cycles NNS NNS O
of IN IN O
bortezomib NN NN B-CHEM
1 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
on IN IN O
days NNS NNS O
1 CD CD O
, , , O
4 CD CD O
, , , O
8 CD CD O
, , , O
and CC CC O
11 CD CD O
plus CC CC O
dexamethasone NN NN B-CHEM
40 CD CD O
mg NN NN O
on IN IN O
the DT DT O
day NN NN O
of IN IN O
bortezomib NN NN B-CHEM
injection NN NN O
and CC CC O
the DT DT O
day NN NN O
after IN IN O
plus CC CC O
cyclophosphamide NN NN B-CHEM
at IN IN O
900 CD CD O
, , , O
1 CD CD O
, , , O
200 CD CD O
, , , O
or CC CC O
1 CD CD O
, , , O
500 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
on IN IN O
day NN NN O
1 CD CD O
. . . O

The DT DT O
maximum NN NN O
tolerated VBD VBD O
dose NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
was VBD VBD O
defined VBN VBN O
as IN IN O
900 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
. . . O

At IN IN O
this DT DT O
dose NN NN O
level NN NN O
, , , O
92 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
achieved VBN VBN O
at IN IN O
least JJS JJS O
a DT DT O
partial JJ JJ O
response NN NN O
. . . O

The DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
[ NN NN O
complete JJ JJ O
response NN NN O
( ( ( O
CR NNP NNP O
) ) ) O
plus CC CC O
partial JJ JJ O
response NN NN O
( ( ( O
PR NNP NNP O
) ) ) O
] NN NN O
across IN IN O
all DT DT O
dose NN NN O
levels NNS NNS O
was VBD VBD O
77 CD CD O
% NN NN O
, , , O
with IN IN O
a DT DT O
10 CD CD O
% NN NN O
CR NNP NNP O
rate NN NN O
. . . O

No DT DT O
patient NN NN O
experienced VBD VBD O
progressive JJ JJ O
disease NN NN O
. . . O

The DT DT O
most RBS RBS O
frequent JJ JJ O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
hematological JJ JJ O
and CC CC O
gastrointestinal JJ JJ O
toxicities NNS NNS O
as RB RB O
well RB RB O
as IN IN O
neuropathy NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
bortezomib NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
at IN IN O
900 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
and CC CC O
dexamethasone NN NN B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
induction NN NN O
treatment NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
newly RB RB O
diagnosed VBN VBN O
MM NNP NNP O
that IN IN O
warrants NNS NNS O
further JJ JJ O
investigation NN NN O
. . . O

Naloxone NNP NNP B-CHEM
reversal NN NN O
of IN IN O
hypotension NN NN O
due JJ JJ O
to TO TO O
captopril VB VB B-CHEM
overdose NN NN O
. . . O

The DT DT O
hemodynamic JJ JJ O
effects NNS NNS O
of IN IN O
captopril NN NN B-CHEM
and CC CC O
other JJ JJ O
angiotensin NN NN B-CHEM
- - - I-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
inhibitors NNS NNS I-CHEM
may MD MD O
be VB VB O
mediated VBN VBN O
by IN IN O
the DT DT O
endogenous JJ JJ O
opioid NN NN O
system NN NN O
. . . O

The DT DT O
opioid NN NN O
antagonist NN NN O
naloxone NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
block VB VB O
or CC CC O
reverse VB VB O
the DT DT O
hypotensive JJ JJ O
actions NNS NNS O
of IN IN O
captopril NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
an DT DT O
intentional JJ JJ O
captopril NN NN B-CHEM
overdose NN NN O
, , , O
manifested VBN VBN O
by IN IN O
marked JJ JJ O
hypotension NN NN O
, , , O
that WDT WDT O
resolved VBD VBD O
promptly RB RB O
with IN IN O
the DT DT O
administration NN NN O
of IN IN O
naloxone NN NN B-CHEM
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
captopril NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
treated VBN VBN O
with IN IN O
naloxone NN NN B-CHEM
. . . O

Our PRP$ PRP$ O
experience NN NN O
demonstrates VBZ VBZ O
a DT DT O
possible JJ JJ O
role NN NN O
of IN IN O
naloxone NN NN B-CHEM
in IN IN O
the DT DT O
reversal NN NN O
of IN IN O
hypotension NN NN O
resulting VBG VBG O
from IN IN O
captopril NN NN B-CHEM
. . . O

Identification NNP NNP O
of IN IN O
a DT DT O
simple JJ JJ O
and CC CC O
sensitive JJ JJ O
microplate NN NN O
method NN NN O
for IN IN O
the DT DT O
detection NN NN O
of IN IN O
oversulfated JJ JJ O
chondroitin NN NN B-CHEM
sulfate NN NN I-CHEM
in IN IN O
heparin NN NN B-CHEM
products NNS NNS O
. . . O

Heparin NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
commonly RB RB O
implemented VBN VBN O
anticoagulant NN NN O
used VBN VBN O
to TO TO O
treat VB VB O
critically RB RB O
ill JJ JJ O
patients NNS NNS O
. . . O

Recently RB RB O
, , , O
a DT DT O
number NN NN O
of IN IN O
commercial JJ JJ O
lots NNS NNS O
of IN IN O
heparin NN NN B-CHEM
products NNS NNS O
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
contaminated VBN VBN O
with IN IN O
an DT DT O
oversulfated JJ JJ O
chondroitin NN NN B-CHEM
sulfate NN NN I-CHEM
( ( ( O
OSCS NNP NNP O
) ) ) O
derivative JJ JJ O
that WDT WDT O
could MD MD O
elicit VB VB O
a DT DT O
hypotensive JJ JJ O
response NN NN O
in IN IN O
pigs NNS NNS O
following VBG VBG O
a DT DT O
single JJ JJ O
high JJ JJ O
- - - O
dose NN NN O
infusion NN NN O
. . . O

Using VBG VBG O
both DT DT O
contaminated JJ JJ O
heparin NN NN B-CHEM
products NNS NNS O
and CC CC O
the DT DT O
synthetically RB RB O
produced VBN VBN O
derivative JJ JJ O
, , , O
we PRP PRP O
showed VBD VBD O
that IN IN O
the DT DT O
OSCS NNP NNP O
produces VBZ VBZ O
dose FW FW O
- - - O
dependent JJ JJ O
hypotension NN NN O
in IN IN O
pigs NNS NNS O
. . . O

The DT DT O
no DT DT O
observed VBD VBD O
effect NN NN O
level NN NN O
( ( ( O
NOEL NNP NNP O
) ) ) O
for IN IN O
this DT DT O
contaminant JJ JJ O
appears VBZ VBZ O
to TO TO O
be VB VB O
approximately RB RB O
1mg CD CD O
/ NN NN O
kg NN NN O
, , , O
corresponding JJ JJ O
to TO TO O
a DT DT O
contamination NN NN O
level NN NN O
of IN IN O
approximately RB RB O
3 CD CD O
% NN NN O
. . . O

We PRP PRP O
also RB RB O
demonstrated VBD VBD O
that IN IN O
OSCS NNP NNP O
can MD MD O
be VB VB O
identified VBN VBN O
in IN IN O
heparin NN NN B-CHEM
products NNS NNS O
using VBG VBG O
a DT DT O
simple JJ JJ O
, , , O
inexpensive JJ JJ O
, , , O
commercially RB RB O
available JJ JJ O
heparin NN NN B-CHEM
enzyme NN NN O
immunoassay NN NN O
( ( ( O
EIA NNP NNP O
) ) ) O
kit NN NN O
that WDT WDT O
has VBZ VBZ O
a DT DT O
limit NN NN O
of IN IN O
detection NN NN O
of IN IN O
approximately RB RB O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
, , , O
well RB RB O
below IN IN O
the DT DT O
NOEL NNP NNP O
. . . O

This DT DT O
kit NN NN O
may MD MD O
provide VB VB O
a DT DT O
useful JJ JJ O
method NN NN O
to TO TO O
test VB VB O
heparin NN NN B-CHEM
products NNS NNS O
for IN IN O
contamination NN NN O
with IN IN O
oversulfated JJ JJ O
GAG NNP NNP O
derivatives NNS NNS O
. . . O

5 CD CD B-CHEM
flourouracil NN NN I-CHEM
- : : O
induced JJ JJ O
apical JJ JJ O
ballooning NN NN O
syndrome NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

The DT DT O
apical JJ JJ O
ballooning NN NN O
syndrome NN NN O
( ( ( O
ABS NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
recently RB RB O
described VBN VBN O
stress NN NN O
- - - O
mediated JJ JJ O
acute JJ JJ O
cardiac JJ JJ O
syndrome NN NN O
characterized VBN VBN O
by IN IN O
transient NN NN O
wall NN NN O
- - - O
motion NN NN O
abnormalities NNS NNS O
involving VBG VBG O
the DT DT O
apex NN NN O
and CC CC O
midventricle NN NN O
with IN IN O
hyperkinesis NN NN O
of IN IN O
the DT DT O
basal NN NN O
left VBD VBD O
ventricular NN NN O
( ( ( O
LV NNP NNP O
) ) ) O
segments NNS NNS O
without IN IN O
obstructive JJ JJ O
epicardial NN NN O
coronary JJ JJ O
disease NN NN O
. . . O

Cardiotoxicity NNP NNP O
is VBZ VBZ O
not RB RB O
an DT DT O
uncommon JJ JJ O
adverse JJ JJ O
effect NN NN O
of IN IN O
chemotherapeutic JJ JJ O
agents NNS NNS O
. . . O

However RB RB O
, , , O
there EX EX O
are VBP VBP O
no DT DT O
reports NNS NNS O
of IN IN O
ABS NNP NNP O
secondary JJ JJ O
to TO TO O
chemotherapeutic JJ JJ O
agents NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
woman NN NN O
who WP WP O
developed VBD VBD O
the DT DT O
syndrome NN NN O
after IN IN O
chemotherapy NN NN O
for IN IN O
metastatic JJ JJ O
cancer NN NN O
. . . O

A DT DT O
79 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
presented VBN VBN O
with IN IN O
typical JJ JJ O
ischemic JJ JJ O
chest NN NN O
pain NN NN O
, , , O
elevated VBD VBD O
cardiac JJ JJ O
enzymes NNS NNS O
with IN IN O
significant JJ JJ O
ST NNP NNP O
- : : O
segment NN NN O
abnormalities NNS NNS O
on IN IN O
her PRP$ PRP$ O
electrocardiogram NN NN O
. . . O

She PRP PRP O
underwent JJ JJ O
recent JJ JJ O
chemotherapy NN NN O
with IN IN O
fluorouracil NN NN B-CHEM
for IN IN O
metastatic JJ JJ O
colorectal NN NN O
cancer NN NN O
. . . O

Echocardiography NNP NNP O
revealed VBD VBD O
a DT DT O
wall NN NN O
- - - O
motion NN NN O
abnormality NN NN O
involving VBG VBG O
the DT DT O
apical JJ JJ O
and CC CC O
periapical JJ JJ O
segments NNS NNS O
which WDT WDT O
appeared VBD VBD O
akinetic JJ JJ O
. . . O

Coronary JJ JJ O
angiography NN NN O
revealed VBD VBD O
no DT DT O
obstructive JJ JJ O
coronary JJ JJ O
lesions NNS NNS O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
stabilized VBN VBN O
with IN IN O
medical JJ JJ O
therapy NN NN O
. . . O

Four CD CD O
weeks NNS NNS O
later RB RB O
she PRP PRP O
remained VBD VBD O
completely RB RB O
asymptomatic JJ JJ O
. . . O

Echocardiogram NNP NNP O
revealed VBD VBD O
a DT DT O
normal JJ JJ O
ejection NN NN O
fraction NN NN O
and CC CC O
a DT DT O
resolution NN NN O
of IN IN O
the DT DT O
apical JJ JJ O
akinesis NN NN O
. . . O

Pathogenetic NNP NNP O
mechanisms NNS NNS O
of IN IN O
cardiac JJ JJ O
complications NNS NNS O
in IN IN O
cancer NN NN O
patients NNS NNS O
undergoing VBG VBG O
chemotherapy NN NN O
include VBP VBP O
coronary JJ JJ O
vasospasm NN NN O
, , , O
endothelial JJ JJ O
damage NN NN O
and CC CC O
consequent NN NN O
thrombus NN NN O
formation NN NN O
. . . O

In IN IN O
our PRP$ PRP$ O
patient NN NN O
, , , O
both DT DT O
supraphysiologic JJ JJ O
levels NNS NNS O
of IN IN O
plasma NN NN O
catecholamines NNS NNS B-CHEM
and CC CC O
stress NN NN O
related VBN VBN O
neuropeptides NNS NNS O
caused VBN VBN O
by IN IN O
cancer NN NN O
diagnosis NN NN O
as RB RB O
well RB RB O
as IN IN O
chemotherapy NN NN O
may MD MD O
have VB VB O
contributed VBN VBN O
the DT DT O
development NN NN O
of IN IN O
ABS NNP NNP O
. . . O

Rapid NNP NNP O
reversal NN NN O
of IN IN O
anticoagulation NN NN O
reduces VBZ VBZ O
hemorrhage NN NN O
volume NN NN O
in IN IN O
a DT DT O
mouse NN NN O
model NN NN O
of IN IN O
warfarin NN NN B-CHEM
- - - O
associated VBN VBN O
intracerebral JJ JJ O
hemorrhage NN NN O
. . . O

Warfarin NNP NNP B-CHEM
- - - O
associated VBN VBN O
intracerebral JJ JJ O
hemorrhage NN NN O
( ( ( O
W NNP NNP O
- - - O
ICH NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
severe JJ JJ O
type NN NN O
of IN IN O
stroke NN NN O
. . . O

There EX EX O
is VBZ VBZ O
no DT DT O
consensus NN NN O
on IN IN O
the DT DT O
optimal NN NN O
treatment NN NN O
for IN IN O
W NNP NNP O
- : : O
ICH NNP NNP O
. . . O

Using VBG VBG O
a DT DT O
mouse NN NN O
model NN NN O
, , , O
we PRP PRP O
tested VBD VBD O
whether IN IN O
the DT DT O
rapid JJ JJ O
reversal NN NN O
of IN IN O
anticoagulation NN NN O
using VBG VBG O
human JJ JJ O
prothrombin NN NN B-CHEM
complex JJ JJ I-CHEM
concentrate NN NN I-CHEM
( ( ( O
PCC NNP NNP B-CHEM
) ) ) O
can MD MD O
reduce VB VB O
hemorrhagic JJ JJ O
blood NN NN O
volume NN NN O
. . . O

Male NNP NNP O
CD NNP NNP O
- : : O
1 CD CD O
mice NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
warfarin NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
over IN IN O
24 CD CD O
h NN NN O
) ) ) O
, , , O
resulting VBG VBG O
in IN IN O
a DT DT O
mean NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- - - O
s VBZ VBZ O
. . . O
d SYM SYM O
. . . O
) ) ) O
International NNP NNP O
Normalized NNP NNP O
Ratio NN NN O
of IN IN O
3 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
. . . O

First LS LS O
, , , O
we PRP PRP O
showed VBD VBD O
that IN IN O
an DT DT O
intravenous JJ JJ O
administration NN NN O
of IN IN O
human JJ JJ O
PCC NNP NNP B-CHEM
rapidly RB RB O
reversed VBD VBD O
anticoagulation NN NN O
in IN IN O
mice NN NN O
. . . O

Second JJ JJ O
, , , O
a DT DT O
stereotactic JJ JJ O
injection NN NN O
of IN IN O
collagenase NN NN O
was VBD VBD O
administered VBN VBN O
to TO TO O
induce VB VB O
hemorrhage NN NN O
in IN IN O
the DT DT O
right NN NN O
striatum NN NN O
. . . O

Forty CD CD O
- - - O
five CD CD O
minutes NNS NNS O
later RB RB O
, , , O
the DT DT O
animals NNS NNS O
were VBD VBD O
randomly RB RB O
treated VBN VBN O
with IN IN O
PCC NNP NNP B-CHEM
( ( ( O
100 CD CD O
U NNP NNP O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
saline NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
per IN IN O
group NN NN O
) ) ) O
. . . O

Twenty CD CD O
- - - O
four CD CD O
hours NNS NNS O
after IN IN O
hemorrhage NN NN O
induction NN NN O
, , , O
hemorrhagic JJ JJ O
blood NN NN O
volume NN NN O
was VBD VBD O
quantified VBN VBN O
using VBG VBG O
a DT DT O
photometric JJ JJ O
hemoglobin NN NN O
assay NN NN O
. . . O

The DT DT O
mean NN NN O
hemorrhagic JJ JJ O
blood NN NN O
volume NN NN O
was VBD VBD O
reduced VBN VBN O
in IN IN O
PCC NNP NNP B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
( ( ( O
6 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
1 CD CD O
microL NN NN O
) ) ) O
compared VBN VBN O
with IN IN O
saline NN NN O
controls NNS NNS O
( ( ( O
15 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
. . . O
2 CD CD O
microL NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
015 CD CD O
) ) ) O
. . . O

In IN IN O
the DT DT O
saline NN NN O
group NN NN O
, , , O
45 CD CD O
% NN NN O
of IN IN O
the DT DT O
mice NN NN O
developed VBN VBN O
large JJ JJ O
hematomas NN NN O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
> NN NN O
15 CD CD O
microL NN NN O
) ) ) O
. . . O

In IN IN O
contrast NN NN O
, , , O
such JJ JJ O
extensive JJ JJ O
lesions NNS NNS O
were VBD VBD O
never RB RB O
found VBN VBN O
in IN IN O
the DT DT O
PCC NNP NNP B-CHEM
group NN NN O
. . . O

We PRP PRP O
provide VBP VBP O
experimental JJ JJ O
data NNS NNS O
suggesting VBG VBG O
PCC NNP NNP B-CHEM
to TO TO O
be VB VB O
an DT DT O
effective JJ JJ O
acute JJ JJ O
treatment NN NN O
for IN IN O
W NNP NNP O
- : : O
ICH NNP NNP O
in IN IN O
terms NNS NNS O
of IN IN O
reducing VBG VBG O
hemorrhagic JJ JJ O
blood NN NN O
volume NN NN O
. . . O

Future NNP NNP O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
therapeutic JJ JJ O
potential JJ JJ O
emerging VBG VBG O
from IN IN O
our PRP$ PRP$ O
finding VBG VBG O
for IN IN O
human JJ JJ O
W NNP NNP O
- : : O
ICH NNP NNP O
. . . O

Long NNP NNP O
term NN NN O
hormone NN NN O
therapy NN NN O
for IN IN O
perimenopausal NN NN O
and CC CC O
postmenopausal NN NN O
women NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Hormone NNP NNP O
therapy NN NN O
( ( ( O
HT NNP NNP O
) ) ) O
is VBZ VBZ O
widely RB RB O
used VBN VBN O
for IN IN O
controlling VBG VBG O
menopausal NN NN O
symptoms NNS NNS O
and CC CC O
has VBZ VBZ O
also RB RB O
been VBN VBN O
used VBN VBN O
for IN IN O
the DT DT O
management NN NN O
and CC CC O
prevention NN NN O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
, , , O
osteoporosis NN NN O
and CC CC O
dementia NN NN O
in IN IN O
older JJR JJR O
women NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
an DT DT O
updated JJ JJ O
version NN NN O
of IN IN O
the DT DT O
original JJ JJ O
Cochrane NNP NNP O
review NN NN O
first RB RB O
published VBN VBN O
in IN IN O
2005 CD CD O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
assess VB VB O
the DT DT O
effect NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
HT NNP NNP O
on IN IN O
mortality NN NN O
, , , O
cardiovascular JJ JJ O
outcomes NNS NNS O
, , , O
cancer NN NN O
, , , O
gallbladder NN NN O
disease NN NN O
, , , O
cognition NN NN O
, , , O
fractures NNS NNS O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
. . . O

SEARCH NNP NNP O
STRATEGY NNP NNP O
: : : O
We PRP PRP O
searched VBD VBD O
the DT DT O
following VBG VBG O
databases NNS NNS O
to TO TO O
November NNP NNP O
2007 CD CD O
: : : O
Trials NNP NNP O
Register NNP NNP O
of IN IN O
the DT DT O
Cochrane NNP NNP O
Menstrual NNP NNP O
Disorders NNP NNP O
and CC CC O
Subfertility NNP NNP O
Group NNP NNP O
, , , O
Cochrane NNP NNP O
Central NNP NNP O
Register NNP NNP O
of IN IN O
Controlled NNP NNP O
Trials NNP NNP O
, , , O
MEDLINE NNP NNP O
, , , O
EMBASE NNP NNP O
, , , O
Biological NNP NNP O
Abstracts NNP NNP O
. . . O

Also RB RB O
relevant JJ JJ O
non NN NN O
- - - O
indexed JJ JJ O
journals NNS NNS O
and CC CC O
conference NN NN O
abstracts NNS NNS O
. . . O

SELECTION NN NN O
CRITERIA NNP NNP O
: : : O
Randomised NNP NNP O
double JJ JJ O
- : : O
blind JJ JJ O
trials NNS NNS O
of IN IN O
HT NNP NNP O
versus CC CC O
placebo NN NN O
, , , O
taken VBN VBN O
for IN IN O
at IN IN O
least JJS JJS O
one CD CD O
year NN NN O
by IN IN O
perimenopausal NN NN O
or CC CC O
postmenopausal NN NN O
women NNS NNS O
. . . O

HT NNP NNP O
included VBD VBD O
oestrogens NNS NNS B-CHEM
, , , O
with IN IN O
or CC CC O
without IN IN O
progestogens NNS NNS B-CHEM
, , , O
via IN IN O
oral NN NN O
, , , O
transdermal NN NN O
, , , O
subcutaneous JJ JJ O
or CC CC O
transnasal NN NN O
routes NNS NNS O
. . . O

DATA NNP NNP O
COLLECTION NNP NNP O
AND CC CC O
ANALYSIS NNP NNP O
: : : O
Two CD CD O
authors NNS NNS O
independently RB RB O
assessed VBN VBN O
trial NN NN O
quality NN NN O
and CC CC O
extracted VBD VBD O
data NNS NNS O
. . . O

MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
Nineteen NNP NNP O
trials NNS NNS O
involving VBG VBG O
41 CD CD O
, , , O
904 CD CD O
women NNS NNS O
were VBD VBD O
included VBN VBN O
. . . O

In IN IN O
relatively RB RB O
healthy JJ JJ O
women NNS NNS O
, , , O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
significantly RB RB O
increased VBD VBD O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thrombo NN NN O
- - - O
embolism NN NN O
or CC CC O
coronary JJ JJ O
event NN NN O
( ( ( O
after IN IN O
one CD CD O
year NN NN O
' '' '' O
s VBZ VBZ O
use NN NN O
) ) ) O
, , , O
stroke NN NN O
( ( ( O
after IN IN O
three CD CD O
years NNS NNS O
) ) ) O
, , , O
breast NN NN O
cancer NN NN O
and CC CC O
gallbladder NN NN O
disease NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
oestrogen NN NN B-CHEM
- : : O
only RB RB O
HT NNP NNP O
significantly RB RB O
increased VBD VBD O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thrombo NN NN O
- - - O
embolism NN NN O
, , , O
stroke NN NN O
and CC CC O
gallbladder NN NN O
disease NN NN O
( ( ( O
after IN IN O
one CD CD O
to TO TO O
two CD CD O
years NNS NNS O
, , , O
three CD CD O
years NNS NNS O
and CC CC O
seven CD CD O
years NNS NNS O
' POS POS O
use NN NN O
respectively RB RB O
) ) ) O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
significantly RB RB O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
. . . O

The DT DT O
only RB RB O
statistically RB RB O
significant JJ JJ O
benefits NNS NNS O
of IN IN O
HT NNP NNP O
were VBD VBD O
a DT DT O
decreased VBN VBN O
incidence NN NN O
of IN IN O
fractures NNS NNS O
and CC CC O
( ( ( O
for IN IN O
combined VBN VBN O
HT NNP NNP O
) ) ) O
colon NN NN O
cancer NN NN O
, , , O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
. . . O

Among IN IN O
women NNS NNS O
aged VBN VBN O
over IN IN O
65 CD CD O
who WP WP O
were VBD VBD O
relatively RB RB O
healthy JJ JJ O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
generally RB RB O
fit VB VB O
, , , O
without IN IN O
overt NN NN O
disease NN NN O
) ) ) O
and CC CC O
taking VBG VBG O
continuous JJ JJ O
combined VBN VBN O
HT NNP NNP O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
statistically RB RB O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
dementia NN NN O
. . . O

Among IN IN O
women NNS NNS O
with IN IN O
cardiovascular JJ JJ O
disease NN NN O
, , , O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
significantly RB RB O
increased VBD VBD O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thrombo NN NN O
- - - O
embolism NN NN O
. . . O
One CD CD O
trial NN NN O
analysed VBN VBN O
subgroups NNS NNS O
of IN IN O
2839 CD CD O
relatively RB RB O
healthy JJ JJ O
50 CD CD O
to TO TO O
59 CD CD O
year NN NN O
old JJ JJ O
women NNS NNS O
taking VBG VBG O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
and CC CC O
1637 CD CD O
taking VBG VBG O
oestrogen NN NN B-CHEM
- - - O
only RB RB O
HT NNP NNP O
, , , O
versus CC CC O
similar JJ JJ O
- - - O
sized JJ JJ O
placebo NN NN O
groups NNS NNS O
. . . O

The DT DT O
only RB RB O
significantly RB RB O
increased VBN VBN O
risk NN NN O
reported VBD VBD O
was VBD VBD O
for IN IN O
venous JJ JJ O
thrombo NN NN O
- : : O
embolism NN NN O
in IN IN O
women NNS NNS O
taking VBG VBG O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
: : : O
their PRP$ PRP$ O
absolute JJ JJ O
risk NN NN O
remained VBD VBD O
low JJ JJ O
, , , O
at IN IN O
less JJR JJR O
than IN IN O
1 CD CD O
/ NN NN O
500 CD CD O
. . . O

However RB RB O
, , , O
this DT DT O
study NN NN O
was VBD VBD O
not RB RB O
powered VBN VBN O
to TO TO O
detect VB VB O
differences NNS NNS O
between IN IN O
groups NNS NNS O
of IN IN O
younger JJR JJR O
women NNS NNS O
. . . O

AUTHORS NNP NNP O
' POS POS O
CONCLUSIONS NNP NNP O
: : : O
HT NNP NNP O
is VBZ VBZ O
not RB RB O
indicated VBN VBN O
for IN IN O
the DT DT O
routine JJ JJ O
management NN NN O
of IN IN O
chronic JJ JJ O
disease NN NN O
. . . O

We PRP PRP O
need VBP VBP O
more JJR JJR O
evidence NN NN O
on IN IN O
the DT DT O
safety NN NN O
of IN IN O
HT NNP NNP O
for IN IN O
menopausal NN NN O
symptom NN NN O
control NN NN O
, , , O
though IN IN O
short JJ JJ O
- - - O
term NN NN O
use NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
relatively RB RB O
safe JJ JJ O
for IN IN O
healthy JJ JJ O
younger NN NN O
women NNS NNS O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
AIDS NNP NNP O
on IN IN O
tenofovir NN NN B-CHEM
while IN IN O
receiving VBG VBG O
prolonged JJ JJ O
vancomycin NN NN B-CHEM
course NN NN O
for IN IN O
osteomyelitis NN NN O
. . . O

Renal NNP NNP O
failure NN NN O
developed VBN VBN O
after IN IN O
a DT DT O
prolonged JJ JJ O
course NN NN O
of IN IN O
vancomycin NN NN B-CHEM
therapy NN NN O
in IN IN O
2 CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
receiving VBG VBG O
tenofovir NN NN B-CHEM
disoproxil NN NN I-CHEM
fumarate NN NN I-CHEM
as IN IN O
part NN NN O
of IN IN O
an DT DT O
antiretroviral JJ JJ O
regimen NN NN O
. . . O

Tenofovir NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
Fanconi NNP NNP O
syndrome NN NN O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
because IN IN O
of IN IN O
its PRP$ PRP$ O
effects NNS NNS O
on IN IN O
the DT DT O
proximal NN NN O
renal JJ JJ O
tubule NN NN O
. . . O

Vancomycin NNP NNP B-CHEM
nephrotoxicity NN NN O
is VBZ VBZ O
infrequent NN NN O
but CC CC O
may MD MD O
result VB VB O
from IN IN O
coadministration NN NN O
with IN IN O
a DT DT O
nephrotoxic JJ JJ O
agent NN NN O
. . . O

Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
that IN IN O
tenofovir NN NN B-CHEM
may MD MD O
raise VB VB O
the DT DT O
risk NN NN O
of IN IN O
renal JJ JJ O
failure NN NN O
during IN IN O
prolonged JJ JJ O
administration NN NN O
of IN IN O
vancomycin NN NN B-CHEM
. . . O

Recurrent NNP NNP O
dysosmia NN NN O
induced VBN VBN O
by IN IN O
pyrazinamide NN NN B-CHEM
. . . O

Pyrazinamide NNP NNP B-CHEM
can MD MD O
have VB VB O
adverse JJ JJ O
effects NNS NNS O
such JJ JJ O
as IN IN O
hepatic JJ JJ O
toxicity NN NN O
, , , O
hyperuricemia NN NN O
or CC CC O
digestive JJ JJ O
disorders NNS NNS O
. . . O

In IN IN O
rare JJ JJ O
cases NNS NNS O
, , , O
alterations NNS NNS O
in IN IN O
taste NN NN O
and CC CC O
smell NN NN O
function NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
for IN IN O
pyrazinamide NN NN B-CHEM
when WRB WRB O
combined VBN VBN O
with IN IN O
other JJ JJ O
drugs NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
reversible JJ JJ O
olfactory NN NN O
disorder NN NN O
related VBN VBN O
to TO TO O
pyrazinamide VB VB B-CHEM
in IN IN O
a DT DT O
woman NN NN O
, , , O
with IN IN O
a DT DT O
positive JJ JJ O
rechallenge NN NN O
. . . O

The DT DT O
patient NN NN O
presented VBD VBD O
every DT DT O
day NN NN O
a DT DT O
sensation NN NN O
of IN IN O
smelling VBG VBG O
something NN NN O
burning NN NN O
15 CD CD O
min NN NN O
after IN IN O
drug NN NN O
intake NN NN O
. . . O

Dysosmia NNP NNP O
disappeared VBD VBD O
completely RB RB O
after IN IN O
pyrazinamide NN NN B-CHEM
withdrawal NN NN O
and CC CC O
recurred VBD VBD O
after IN IN O
its PRP$ PRP$ O
rechallenge NN NN O
. . . O

The DT DT O
case NN NN O
was VBD VBD O
reported VBN VBN O
to TO TO O
the DT DT O
Tunisian NNP NNP O
Centre NNP NNP O
of IN IN O
Pharmacovigilance NNP NNP O
. . . O

Mice NNP NNP O
lacking VBG VBG O
mPGES NN NN O
- : : O
1 CD CD O
are VBP VBP O
resistant JJ JJ O
to TO TO O
lithium VB VB B-CHEM
- - - O
induced JJ JJ O
polyuria NN NN O
. . . O

Cyclooxygenase NNP NNP O
- : : O
2 CD CD O
activity NN NN O
is VBZ VBZ O
required VBN VBN O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
polyuria NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
involvement NN NN O
of IN IN O
a DT DT O
specific JJ JJ O
, , , O
terminal NN NN O
prostaglandin NN NN B-CHEM
( ( ( O
PG NNP NNP B-CHEM
) ) ) O
isomerase NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
evaluated VBN VBN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
assess VB VB O
lithium NN NN B-CHEM
- : : O
induced JJ JJ O
polyuria NN NN O
in IN IN O
mice NN NN O
deficient NN NN O
in IN IN O
microsomal NN NN O
prostaglandin NN NN B-CHEM
E NNP NNP I-CHEM
synthase NN NN O
- : : O
1 CD CD O
( ( ( O
mPGES NN NN O
- - - O
1 CD CD O
) ) ) O
. . . O

A DT DT O
2 CD CD O
- : : O
wk NN NN O
administration NN NN O
of IN IN O
LiCl NNP NNP B-CHEM
( ( ( O
4 CD CD O
mmol NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
day NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
ip NNP NNP O
) ) ) O
in IN IN O
mPGES NN NN O
- - - O
1 CD CD O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
led VBN VBN O
to TO TO O
a DT DT O
marked VBD VBD O
polyuria NN NN O
with IN IN O
hyposmotic JJ JJ O
urine NN NN O
. . . O

This DT DT O
was VBD VBD O
associated VBN VBN O
with IN IN O
elevated VBD VBD O
renal JJ JJ O
mPGES NN NN O
- : : O
1 CD CD O
protein NN NN O
expression NN NN O
and CC CC O
increased VBN VBN O
urine NN NN O
PGE NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
excretion NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
mPGES NN NN O
- - - O
1 CD CD O
- - - O
/ NN NN O
- - - O
mice NN NN O
were VBD VBD O
largely RB RB O
resistant JJ JJ O
to TO TO O
lithium VB VB B-CHEM
- - - O
induced JJ JJ O
polyuria NN NN O
and CC CC O
a DT DT O
urine NN NN O
concentrating VBG VBG O
defect NN NN O
, , , O
accompanied VBN VBN O
by IN IN O
nearly RB RB O
complete JJ JJ O
blockade NN NN O
of IN IN O
high JJ JJ O
urine NN NN O
PGE NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
and CC CC O
cAMP NN NN O
output NN NN O
. . . O

Immunoblotting NNP NNP O
, , , O
immunohistochemistry NN NN O
, , , O
and CC CC O
quantitative JJ JJ O
( ( ( O
q NN NN O
) ) ) O
RT NNP NNP O
- : : O
PCR NNP NNP O
consistently RB RB O
detected VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
aquaporin NN NN O
- - - O
2 CD CD O
( ( ( O
AQP2 NNP NNP O
) ) ) O
protein NN NN O
expression NN NN O
in IN IN O
both DT DT O
the DT DT O
renal NN NN O
cortex NN NN O
and CC CC O
medulla NN NN O
of IN IN O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
. . . O

This DT DT O
decrease NN NN O
was VBD VBD O
significantly RB RB O
attenuated VBN VBN O
in IN IN O
the DT DT O
- - - O
/ NN NN O
- - - O
mice NN NN O
. . . O

qRT NN NN O
- : : O
PCR NNP NNP O
detected VBD VBD O
similar JJ JJ O
patterns NNS NNS O
of IN IN O
changes NNS NNS O
in IN IN O
AQP2 NNP NNP O
mRNA NN NN O
in IN IN O
the DT DT O
medulla NN NN O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
cortex NN NN O
. . . O

Similarly RB RB O
, , , O
the DT DT O
total JJ JJ O
protein NN NN O
abundance NN NN O
of IN IN O
the DT DT O
Na NNP NNP B-CHEM
- - - O
K NNP NNP B-CHEM
- : : O
2Cl CD CD B-CHEM
cotransporter NN NN O
( ( ( O
NKCC2 NNP NNP O
) ) ) O
in IN IN O
the DT DT O
medulla NN NN O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
cortex NN NN O
of IN IN O
the DT DT O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
by IN IN O
lithium NN NN B-CHEM
treatment NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
dowregulation NN NN O
of IN IN O
renal JJ JJ O
medullary JJ JJ O
NKCC2 NNP NNP O
expression NN NN O
was VBD VBD O
significantly RB RB O
attenuated VBN VBN O
in IN IN O
the DT DT O
- - - O
/ NN NN O
- - - O
mice NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
mPGES NN NN O
- : : O
1 CD CD O
- : : O
derived VBD VBD O
PGE NNP NNP B-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
) ) ) I-CHEM
mediates VBZ VBZ O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
polyuria NN NN O
likely JJ JJ O
via IN IN O
inhibition NN NN O
of IN IN O
AQP2 NNP NNP O
and CC CC O
NKCC2 NNP NNP O
expression NN NN O
. . . O

Preservation NNP NNP O
of IN IN O
renal JJ JJ O
blood NN NN O
flow NN NN O
during IN IN O
hypotension NN NN O
induced VBN VBN O
with IN IN O
fenoldopam NN NN B-CHEM
in IN IN O
dogs NNS NNS O
. . . O

The DT DT O
introduction NN NN O
of IN IN O
drugs NNS NNS O
that WDT WDT O
could MD MD O
induce VB VB O
hypotension NN NN O
with IN IN O
different JJ JJ O
pharmacological JJ JJ O
actions NNS NNS O
would MD MD O
be VB VB O
advantageous JJ JJ O
because IN IN O
side NN NN O
effects NNS NNS O
unique JJ JJ O
to TO TO O
a DT DT O
specific JJ JJ O
drug NN NN O
could MD MD O
be VB VB O
minimized VBN VBN O
by IN IN O
selecting VBG VBG O
appropriate JJ JJ O
therapy NN NN O
. . . O

Specific JJ JJ O
dopamine NN NN B-CHEM
- : : O
1 CD CD O
, , , O
( ( ( O
DA1 NNP NNP B-CHEM
) ) ) O
and CC CC O
dopamine NN NN B-CHEM
- : : O
2 CD CD O
( ( ( O
DA2 NNP NNP B-CHEM
) ) ) O
receptor NN NN O
agonists NNS NNS O
are VBP VBP O
now RB RB O
under IN IN O
clinical JJ JJ O
investigation NN NN O
. . . O

Fenoldopam NNP NNP B-CHEM
mesylate NN NN I-CHEM
is VBZ VBZ O
a DT DT O
specific JJ JJ O
DA1 NNP NNP O
receptor NN NN O
agonist NN NN O
that IN IN O
lowers NNS NNS O
blood NN NN O
pressure NN NN O
by IN IN O
vasodilatation NN NN O
. . . O

The DT DT O
hypothesis NNS NNS O
that IN IN O
fenoldopam NN NN B-CHEM
could MD MD O
be VB VB O
used VBN VBN O
to TO TO O
induce VB VB O
hypotension NN NN O
and CC CC O
preserve VB VB O
blood NN NN O
flow NN NN O
to TO TO O
the DT DT O
kidney NN NN O
was VBD VBD O
tested VBN VBN O
. . . O

Systemic NNP NNP O
aortic JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
renal JJ JJ O
blood NN NN O
flow NN NN O
were VBD VBD O
measured VBN VBN O
continuously RB RB O
with IN IN O
a DT DT O
carotid NN NN O
arterial NN NN O
catheter NN NN O
and CC CC O
an DT DT O
electromagnetic JJ JJ O
flow NN NN O
probe NN NN O
respectively RB RB O
, , , O
in IN IN O
order NN NN O
to TO TO O
compare VB VB O
the DT DT O
cardiovascular JJ JJ O
and CC CC O
renal JJ JJ O
vascular JJ JJ O
effects NNS NNS O
of IN IN O
fenoldopam NN NN B-CHEM
and CC CC O
sodium NN NN B-CHEM
nitroprusside NN NN B-CHEM
in IN IN O
ten CD CD O
dogs NNS NNS O
under IN IN O
halothane NN NN B-CHEM
general JJ JJ O
anaesthesia NN NN O
. . . O

Mean VB VB O
arterial JJ JJ O
pressure NN NN O
was VBD VBD O
decreased VBN VBN O
30 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
per IN IN O
cent NN NN O
from IN IN O
control NN NN O
with IN IN O
infusion NN NN O
of IN IN O
fenoldopam NN NN B-CHEM
( ( ( O
3 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
0 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
) ) ) O
and CC CC O
34 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
per IN IN O
cent NN NN O
with IN IN O
infusion NN NN O
of IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN B-CHEM
( ( ( O
5 CD CD O
. . . O
9 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
) ) ) O
( ( ( O
NS NNP NNP O
) ) ) O
. . . O

Renal NNP NNP O
blood NN NN O
flow NN NN O
( ( ( O
RBF NNP NNP O
) ) ) O
increased VBN VBN O
during IN IN O
fenoldopam NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
per IN IN O
cent NN NN O
and CC CC O
decreased VBD VBD O
21 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
per IN IN O
cent NN NN O
during IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Sodium NNP NNP O
nitroprusside NN NN B-CHEM
is VBZ VBZ O
a DT DT O
non NN NN O
- - - O
selective JJ JJ O
arteriolar NN NN O
and CC CC O
venous JJ JJ O
vasodilator NN NN O
that WDT WDT O
can MD MD O
produce VB VB O
redistribution NN NN O
of IN IN O
blood NN NN O
flow NN NN O
away RB RB O
from IN IN O
the DT DT O
kidney NN NN O
during IN IN O
induced JJ JJ O
hypotension NN NN O
. . . O

Fenoldopam NNP NNP O
is VBZ VBZ O
a DT DT O
selective JJ JJ O
dopamine NN NN B-CHEM
- : : O
1 CD CD O
( ( ( O
DA1 NNP NNP O
) ) ) O
receptor NN NN O
agonist NN NN O
that WDT WDT O
causes VBZ VBZ O
vasodilatation NN NN O
to TO TO O
the DT DT O
kidney NN NN O
and CC CC O
other JJ JJ O
organs NNS NNS O
with IN IN O
DA1 NNP NNP O
receptors NNS NNS O
and CC CC O
preserves VBZ VBZ O
blood NN NN O
flow NN NN O
to TO TO O
the DT DT O
kidney NN NN O
during IN IN O
induced JJ JJ O
hypotension NN NN O
. . . O

Seizures NNP NNP O
associated VBN VBN O
with IN IN O
levofloxacin NN NN B-CHEM
: : : O
case NN NN O
presentation NN NN O
and CC CC O
literature NN NN O
review NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
who WP WP O
developed JJ JJ O
seizures NNS NNS O
shortly RB RB O
after IN IN O
initiating VBG VBG O
treatment NN NN O
with IN IN O
levofloxacin NN NN B-CHEM
and CC CC O
to TO TO O
discuss VB VB O
the DT DT O
potential JJ JJ O
drug NN NN O
- - - O
drug NN NN O
interactions NNS NNS O
related VBN VBN O
to TO TO O
the DT DT O
inhibition NN NN O
of IN IN O
cytochrome NN NN O
P450 NNP NNP O
( ( ( O
CYP NNP NNP O
) ) ) O
1A2 CD CD O
in IN IN O
this DT DT O
case NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
in IN IN O
other JJ JJ O
cases NNS NNS O
, , , O
of IN IN O
levofloxacin NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Several JJ JJ O
biomedical JJ JJ O
databases NNS NNS O
were VBD VBD O
searched VBN VBN O
including VBG VBG O
MEDLINE NNP NNP O
, , , O
Cochrane NNP NNP O
and CC CC O
Ovid NNP NNP O
. . . O

The DT DT O
main JJ JJ O
search NN NN O
terms NNS NNS O
utilized JJ JJ O
were VBD VBD O
case NN NN O
report NN NN O
and CC CC O
levofloxacin NN NN B-CHEM
. . . O

The DT DT O
search NN NN O
was VBD VBD O
limited JJ JJ O
to TO TO O
studies NNS NNS O
published VBN VBN O
in IN IN O
English NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
Six CD CD O
cases NNS NNS O
of IN IN O
levofloxacin NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

Drug NN NN O
- : : O
drug NN NN O
interactions NNS NNS O
related VBN VBN O
to TO TO O
the DT DT O
inhibition NN NN O
of IN IN O
CYP1A2 NNP NNP O
by IN IN O
levofloxacin NN NN B-CHEM
are VBP VBP O
likely JJ JJ O
involved VBN VBN O
in IN IN O
the DT DT O
clinical JJ JJ O
outcome NN NN O
of IN IN O
these DT DT O
cases NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Clinicians NNP NNP O
are VBP VBP O
exhorted VBN VBN O
to TO TO O
pay VB VB O
close VB VB O
attention NN NN O
when WRB WRB O
initiating VBG VBG O
levofloxacin NN NN B-CHEM
therapy NN NN O
in IN IN O
patients NNS NNS O
taking VBG VBG O
medications NNS NNS O
with IN IN O
epileptogenic JJ JJ O
properties NNS NNS O
that WDT WDT O
are VBP VBP O
CYP1A2 NNP NNP O
substrates NNS NNS O
. . . O

Dextran NNP NNP B-CHEM
- : : O
etodolac NN NN B-CHEM
conjugates NNS NNS O
: : : O
synthesis NN NN O
, , , O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
evaluation NN NN O
. . . O

Etodolac NNP NNP B-CHEM
( ( ( O
E NNP NNP B-CHEM
) ) ) O
, , , O
is VBZ VBZ O
a DT DT O
non NN NN O
- - - O
narcotic JJ JJ O
analgesic NN NN O
and CC CC O
antiinflammatory JJ JJ O
drug NN NN O
. . . O

A DT DT O
biodegradable JJ JJ O
polymer NN NN O
dextran NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
utilized JJ JJ O
as IN IN O
a DT DT O
carrier NN NN O
for IN IN O
synthesis NN NN O
of IN IN O
etodolac NN NN B-CHEM
- - - O
dextran NN NN B-CHEM
conjugates NNS NNS O
( ( ( O
ED NNP NNP O
) ) ) O
to TO TO O
improve VB VB O
its PRP$ PRP$ O
aqueous JJ JJ O
solubility NN NN O
and CC CC O
reduce VB VB O
gastrointestinal JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

An DT DT O
activated JJ JJ O
moiety NN NN O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
N NNP NNP B-CHEM
- : : I-CHEM
acylimidazole NN NN I-CHEM
derivative NN NN O
of IN IN O
etodolac NN NN B-CHEM
( ( ( O
EAI NNP NNP B-CHEM
) ) ) O
, , , O
was VBD VBD O
condensed VBN VBN O
with IN IN O
the DT DT O
polysaccharide NN NN O
polymer NN NN O
dextran NN NN B-CHEM
of IN IN O
different JJ JJ O
molecular JJ JJ O
weights NNS NNS O
( ( ( O
40000 CD CD O
, , , O
60000 CD CD O
, , , O
110000 CD CD O
and CC CC O
200000 CD CD O
) ) ) O
. . . O

IR NNP NNP O
spectral JJ JJ O
data NNS NNS O
confirmed VBD VBD O
formation NN NN O
of IN IN O
ester NN NN O
bonding VBG VBG O
in IN IN O
the DT DT O
conjugates NNS NNS O
. . . O

Etodolac NNP NNP B-CHEM
contents NNS NNS O
were VBD VBD O
evaluated VBN VBN O
by IN IN O
UV NNP NNP O
- : : O
spectrophotometric JJ JJ O
analysis NN NN O
. . . O

The DT DT O
molecular JJ JJ O
weights NNS NNS O
were VBD VBD O
determined VBN VBN O
by IN IN O
measuring VBG VBG O
viscosity NN NN O
using VBG VBG O
the DT DT O
Mark NNP NNP O
- : : O
Howink NNP NNP O
- : : O
Sakurada NNP NNP O
equation NN NN O
. . . O

In IN IN O
vitro NN NN O
hydrolysis NNS NNS O
of IN IN O
ED NNP NNP O
was VBD VBD O
done VBN VBN O
in IN IN O
aqueous JJ JJ O
buffers NNS NNS O
( ( ( O
pH NN NN O
1 CD CD O
. . . O
2 CD CD O
, , , O
7 CD CD O
. . . O
4 CD CD O
, , , O
9 CD CD O
) ) ) O
and CC CC O
in IN IN O
80 CD CD O
% NN NN O
( ( ( O
v NN NN O
/ NN NN O
v NN NN O
) ) ) O
human JJ JJ O
plasma NN NN O
( ( ( O
pH NN NN O
7 CD CD O
. . . O
4 CD CD O
) ) ) O
. . . O

At IN IN O
pH NN NN O
9 CD CD O
, , , O
a DT DT O
higher JJR JJR O
rate NN NN O
of IN IN O
etodolac NN NN B-CHEM
release NN NN O
from IN IN O
ED NNP NNP O
was VBD VBD O
observed VBN VBN O
as IN IN O
compared VBN VBN O
to TO TO O
aqueous JJ JJ O
buffer NN NN O
of IN IN O
pH NN NN O
7 CD CD O
. . . O
4 CD CD O
and CC CC O
80 CD CD O
% NN NN O
human JJ JJ O
plasma NN NN O
( ( ( O
pH NN NN O
7 CD CD O
. . . O
4 CD CD O
) ) ) O
, , , O
following VBG VBG O
first JJ JJ O
- - - O
order NN NN O
kinetics NNS NNS O
. . . O

In IN IN O
vivo NN NN O
investigations NNS NNS O
were VBD VBD O
performed VBN VBN O
in IN IN O
animals NNS NNS O
. . . O

Acute JJ JJ O
analgesic JJ JJ O
and CC CC O
antiinflammatory JJ JJ O
activities NNS NNS O
were VBD VBD O
ascertained VBN VBN O
using VBG VBG O
acetic JJ JJ B-CHEM
acid NN NN I-CHEM
induced VBD VBD O
writhing VBG VBG O
model NN NN O
( ( ( O
mice NN NN O
) ) ) O
and CC CC O
carrageenan NN NN B-CHEM
- - - O
induced JJ JJ O
rat NN NN O
paw NN NN O
edema NN NN O
model NN NN O
, , , O
respectively RB RB O
. . . O

In IN IN O
comparison NN NN O
to TO TO O
control VB VB O
, , , O
E NNP NNP B-CHEM
and CC CC O
ED1 NNP NNP O
- : : O
ED4 NNP NNP O
showed VBD VBD O
highly RB RB O
significant JJ JJ O
analgesic NN NN O
and CC CC O
antiinflammatory JJ JJ O
activities NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Biological NNP NNP O
evaluation NN NN O
suggested VBD VBD O
that IN IN O
conjugates NNS NNS O
( ( ( O
ED1 NNP NNP O
- - - O
ED4 NNP NNP O
) ) ) O
retained VBD VBD O
comparable JJ JJ O
analgesic NN NN O
and CC CC O
antiinflammatory JJ JJ O
activities NNS NNS O
with IN IN O
remarkably RB RB O
reduced VBN VBN O
ulcerogenicity NN NN O
as IN IN O
compared VBN VBN O
to TO TO O
their PRP$ PRP$ O
parent NN NN O
drug NN NN O
- - - O
- - - O
etodolac NN NN B-CHEM
. . . O

The DT DT O
antiarrhythmic JJ JJ O
effect NN NN O
and CC CC O
possible JJ JJ O
ionic JJ JJ O
mechanisms NNS NNS O
of IN IN O
pilocarpine NN NN B-CHEM
on IN IN O
animal NN NN O
models NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
pilocarpine NN NN B-CHEM
and CC CC O
explore VB VB O
the DT DT O
underlying VBG VBG O
ionic JJ JJ O
mechanism NN NN O
, , , O
using VBG VBG O
both DT DT O
aconitine NN NN B-CHEM
- - - O
induced JJ JJ O
rat NN NN O
and CC CC O
ouabain VB VB B-CHEM
- : : O
induced JJ JJ O
guinea NN NN O
pig NN NN O
arrhythmia NN NN O
models NNS NNS O
. . . O

Confocal NNP NNP O
microscopy NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
measure VB VB O
intracellular JJ JJ O
free JJ JJ O
- - - O
calcium NN NN B-CHEM
concentrations NNS NNS O
( ( ( O
[ NN NN O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
] NN NN O
( ( ( O
i NNP NNP O
) ) ) O
) ) ) O
in IN IN O
isolated VBN VBN O
myocytes NNS NNS O
. . . O

The DT DT O
current JJ JJ O
data NNS NNS O
showed VBD VBD O
that IN IN O
pilocarpine NN NN B-CHEM
significantly RB RB O
delayed VBD VBD O
onset NN NN O
of IN IN O
arrhythmias NNS NNS O
, , , O
decreased VBD VBD O
the DT DT O
time NN NN O
course NN NN O
of IN IN O
ventricular NN NN O
tachycardia NNS NNS O
and CC CC O
fibrillation NN NN O
, , , O
reduced VBN VBN O
arrhythmia NN NN O
score NN NN O
, , , O
and CC CC O
increased VBD VBD O
the DT DT O
survival NN NN O
time NN NN O
of IN IN O
arrhythmic JJ JJ O
rats NNS NNS O
and CC CC O
guinea NN NN O
pigs NNS NNS O
. . . O

[ NN NN O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
] NN NN O
( ( ( O
i NNP NNP O
) ) ) O
overload NN NN O
induced VBN VBN O
by IN IN O
aconitine NN NN B-CHEM
or CC CC O
ouabain NN NN B-CHEM
was VBD VBD O
reduced VBN VBN O
in IN IN O
isolated VBN VBN O
myocytes NNS NNS O
pretreated VBN VBN O
with IN IN O
pilocarpine NN NN B-CHEM
. . . O

Moreover RB RB O
, , , O
M NNP NNP O
( ( ( O
3 CD CD O
) ) ) O
- : : O
muscarinic JJ JJ O
acetylcholine NN NN B-CHEM
receptor NN NN O
( ( ( O
mAChR NN NN O
) ) ) O
antagonist NN NN O
4 CD CD B-CHEM
- : : I-CHEM
DAMP NNP NNP I-CHEM
( ( ( O
4 CD CD B-CHEM
- : : I-CHEM
diphenylacetoxy NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- - - I-CHEM
methylpiperidine NN NN I-CHEM
- - - I-CHEM
methiodide NN NN I-CHEM
) ) ) O
partially RB RB O
abolished VBD VBD O
the DT DT O
beneficial JJ JJ O
effects NNS NNS O
of IN IN O
pilocarpine NN NN B-CHEM
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
pilocarpine NN NN B-CHEM
produced VBD VBD O
antiarrhythmic JJ JJ O
actions NNS NNS O
on IN IN O
arrhythmic JJ JJ O
rat NN NN O
and CC CC O
guinea NN NN O
pig NN NN O
models NNS NNS O
induced VBN VBN O
by IN IN O
aconitine NN NN B-CHEM
or CC CC O
ouabain NN NN B-CHEM
via IN IN O
stimulating VBG VBG O
the DT DT O
cardiac JJ JJ O
M NNP NNP O
( ( ( O
3 CD CD O
) ) ) O
- : : O
mAChR NN NN O
. . . O

The DT DT O
mechanism NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
improvement NN NN O
of IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
handling VBG VBG O
. . . O

Effect NN NN O
of IN IN O
Hibiscus NNP NNP B-CHEM
rosa NN NN I-CHEM
sinensis NN NN I-CHEM
on IN IN O
reserpine NN NN B-CHEM
- : : O
induced JJ JJ O
neurobehavioral NN NN O
and CC CC O
biochemical JJ JJ O
alterations NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Effect NN NN O
of IN IN O
methanolic JJ JJ O
extract NN NN O
of IN IN O
Hibiscus NNP NNP B-CHEM
rosa NN NN I-CHEM
sinensis NN NN I-CHEM
( ( ( O
100 CD CD O
- : : O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
studied VBN VBN O
on IN IN O
reserpine NN NN B-CHEM
- : : O
induced JJ JJ O
orofacial JJ JJ O
dyskinesia NN NN O
and CC CC O
neurochemical JJ JJ O
alterations NNS NNS O
. . . O

The DT DT O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
intraperitoneal NN NN O
reserpine NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
ip NNP NNP O
) ) ) O
for IN IN O
3 CD CD O
days NNS NNS O
every DT DT O
other JJ JJ O
day NN NN O
. . . O

On IN IN O
day NN NN O
5 CD CD O
, , , O
vacuous JJ JJ O
chewing VBG VBG O
movements NNS NNS O
and CC CC O
tongue NN NN O
protrusions NNS NNS O
were VBD VBD O
counted VBN VBN O
for IN IN O
5 CD CD O
min NN NN O
. . . O

Reserpine NNP NNP B-CHEM
treated VBD VBD O
rats NNS NNS O
significantly RB RB O
developed VBN VBN O
vacuous JJ JJ O
chewing JJ JJ O
movements NNS NNS O
and CC CC O
tongue NN NN O
protrusions NNS NNS O
however RB RB O
, , , O
coadministration NN NN O
of IN IN O
Hibiscus NNP NNP B-CHEM
rosa NN NN I-CHEM
sinensis NNS NNS I-CHEM
roots NNS NNS O
extract NN NN O
( ( ( O
100 CD CD O
, , , O
200 CD CD O
and CC CC O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
per IN IN O
orally RB RB O
) ) ) O
attenuated VBD VBD O
the DT DT O
effects NNS NNS O
. . . O

Biochemical NNP NNP O
analysis NN NN O
of IN IN O
brain NN NN O
revealed VBD VBD O
that IN IN O
the DT DT O
reserpine NN NN B-CHEM
treatment NN NN O
significantly RB RB O
increased VBD VBD O
lipid JJ JJ O
peroxidation NN NN O
and CC CC O
decreased VBD VBD O
levels NNS NNS O
of IN IN O
superoxide NN NN B-CHEM
dismutase NN NN O
( ( ( O
SOD NNP NNP O
) ) ) O
, , , O
catalase NN NN O
( ( ( O
CAT NNP NNP O
) ) ) O
and CC CC O
glutathione NN NN B-CHEM
reductase NN NN O
( ( ( O
GSH NNP NNP O
) ) ) O
, , , O
an DT DT O
index NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
process NN NN O
. . . O

Coadministration NNP NNP O
of IN IN O
extract NN NN O
significantly RB RB O
reduced VBD VBD O
the DT DT O
lipid JJ JJ O
peroxidation NN NN O
and CC CC O
reversed VBD VBD O
the DT DT O
decrease NN NN O
in IN IN O
brain NN NN O
SOD NNP NNP O
, , , O
CAT NNP NNP O
and CC CC O
GSH NNP NNP O
levels NNS NNS O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
suggested VBD VBD O
that IN IN O
Hibiscus NNP NNP B-CHEM
rosa NN NN I-CHEM
sinensis NNS NNS I-CHEM
had VBD VBD O
a DT DT O
protective JJ JJ O
role NN NN O
against IN IN O
reserpine NN NN B-CHEM
- - - O
induced JJ JJ O
orofacial JJ JJ O
dyskinesia NN NN O
and CC CC O
oxidative JJ JJ O
stress NN NN O
. . . O

Dynamic NNP NNP O
response NN NN O
of IN IN O
blood NN NN O
vessel NN NN O
in IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
we PRP PRP O
postulated VBD VBD O
that IN IN O
during IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
induced VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
the DT DT O
transient NN NN O
or CC CC O
dynamic JJ JJ O
response NN NN O
of IN IN O
blood NN NN O
vessels NNS NNS O
could MD MD O
be VB VB O
affected VBN VBN O
, , , O
and CC CC O
that IN IN O
antioxidants NNS NNS O
can MD MD O
prevent VB VB O
the DT DT O
changes NNS NNS O
in IN IN O
dynamic JJ JJ O
responses NNS NNS O
of IN IN O
blood NN NN O
vessels NNS NNS O
. . . O

The DT DT O
new JJ JJ O
approach NN NN O
to TO TO O
ex VB VB O
vivo NN NN O
blood NN NN O
vessel NN NN O
experiments NNS NNS O
in IN IN O
which WDT WDT O
not RB RB O
only RB RB O
the DT DT O
end NN NN O
points NNS NNS O
of IN IN O
vessels NNS NNS O
response NN NN O
within IN IN O
the DT DT O
time NN NN O
interval NN NN O
is VBZ VBZ O
considered VBN VBN O
, , , O
but CC CC O
also RB RB O
dynamics NNS NNS O
of IN IN O
this DT DT O
response NN NN O
, , , O
was VBD VBD O
used VBN VBN O
in IN IN O
this DT DT O
paper NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
confirm VBP VBP O
the DT DT O
alteration NN NN O
in IN IN O
dynamic JJ JJ O
response NN NN O
of IN IN O
blood NN NN O
vessels NNS NNS O
during IN IN O
the DT DT O
change NN NN O
of IN IN O
pressure NN NN O
in IN IN O
gentamicin NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

The DT DT O
beneficial JJ JJ O
effects NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
administration NN NN O
to TO TO O
gentamicin VB VB B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
are VBP VBP O
also RB RB O
confirmed VBN VBN O
through IN IN O
: : : O
lower JJR JJR O
level NN NN O
of IN IN O
blood NN NN O
urea NN NN B-CHEM
and CC CC O
creatinine NN NN B-CHEM
and CC CC O
higher JJR JJR O
level NN NN O
of IN IN O
potassium NN NN B-CHEM
. . . O

The DT DT O
pressure NN NN O
dynamic JJ JJ O
responses NNS NNS O
of IN IN O
isolated VBN VBN O
blood NN NN O
vessels NNS NNS O
show VBP VBP O
a DT DT O
faster RBR RBR O
pressure NN NN O
change NN NN O
in IN IN O
gentamicin NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
( ( ( O
8 CD CD O
. . . O
07 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
7 CD CD O
s VBZ VBZ O
vs NNS NNS O
. . . O
5 CD CD O
. . . O
64 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
18 CD CD O
s VBZ VBZ O
) ) ) O
. . . O

Vitamin NNP NNP B-CHEM
C NNP NNP I-CHEM
administration NN NN O
induced VBD VBD O
slowdown NN NN O
of IN IN O
pressure NN NN O
change NN NN O
back RB RB O
to TO TO O
the DT DT O
control NN NN O
values NNS NNS O
. . . O

The DT DT O
pressure NN NN O
dynamic JJ JJ O
properties NNS NNS O
, , , O
quantitatively RB RB O
defined VBN VBN O
by IN IN O
comparative JJ JJ O
pressure NN NN O
dynamic JJ JJ O
and CC CC O
total JJ JJ O
pressure NN NN O
dynamic JJ JJ O
, , , O
confirm NN NN O
the DT DT O
alteration NN NN O
in IN IN O
dynamic JJ JJ O
response NN NN O
of IN IN O
blood NN NN O
vessels NNS NNS O
during IN IN O
the DT DT O
change NN NN O
of IN IN O
pressure NN NN O
in IN IN O
gentamicin NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
and CC CC O
beneficial JJ JJ O
effects NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
C NNP NNP I-CHEM
administration NN NN O
. . . O

Reversible NNP NNP O
myocardial NN NN O
hypertrophy NN NN O
induced VBN VBN O
by IN IN O
tacrolimus NN NN B-CHEM
in IN IN O
a DT DT O
pediatric JJ JJ O
heart NN NN O
transplant NN NN O
recipient JJ JJ O
: : : O
case NN NN O
report NN NN O
. . . O

Tacrolimus NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
potent JJ JJ O
immunosuppressant NN NN O
that WDT WDT O
is VBZ VBZ O
frequently RB RB O
used VBN VBN O
in IN IN O
organ NN NN O
transplantation NN NN O
. . . O

However RB RB O
, , , O
adverse JJ JJ O
effects NNS NNS O
include VBP VBP O
cardiac JJ JJ O
toxicity NN NN O
. . . O

Herein NNP NNP O
we PRP PRP O
describe VBP VBP O
transient JJ JJ O
myocardial NN NN O
hypertrophy NN NN O
induced VBN VBN O
by IN IN O
tacrolimus NN NN B-CHEM
after IN IN O
heart NN NN O
transplantation NN NN O
. . . O

The DT DT O
hypertrophy NN NN O
caused VBD VBD O
no DT DT O
clinical JJ JJ O
symptoms NNS NNS O
but CC CC O
was VBD VBD O
noted VBN VBN O
because IN IN O
of IN IN O
elevation NN NN O
of IN IN O
plasma NN NN O
brain NN NN O
natriuretic JJ JJ O
peptide NN NN O
concentration NN NN O
and CC CC O
confirmed VBD VBD O
at IN IN O
echocardiography NN NN O
. . . O

Initially RB RB O
, , , O
allograft NN NN O
rejection NN NN O
was VBD VBD O
feared VBN VBN O
; : : O
however RB RB O
, , , O
myocardial NN NN O
biopsy NN NN O
samples NNS NNS O
revealed VBD VBD O
only RB RB O
interstitial JJ JJ O
edema NN NN O
and CC CC O
mild JJ JJ O
myocardial NN NN O
hypertrophy NN NN O
; : : O
neither DT DT O
cellular JJ JJ O
nor CC CC O
humoral JJ JJ O
rejection NN NN O
was VBD VBD O
detected VBN VBN O
. . . O

The DT DT O
blood NN NN O
tacrolimus NN NN B-CHEM
concentration NN NN O
was VBD VBD O
higher JJR JJR O
than IN IN O
usual JJ JJ O
at IN IN O
that DT DT O
time NN NN O
; : : O
thus RB RB O
, , , O
tacrolimus NN NN B-CHEM
dosage NN NN O
was VBD VBD O
reduced VBN VBN O
. . . O

Myocardial NNP NNP O
hypertrophy NN NN O
completely RB RB O
resolved VBN VBN O
upon IN IN O
reducing VBG VBG O
the DT DT O
target NN NN O
concentration NN NN O
of IN IN O
tacrolimus NN NN B-CHEM
and CC CC O
did VBD VBD O
not RB RB O
recur VB VB O
, , , O
as IN IN O
confirmed VBN VBN O
at IN IN O
echocardiography NN NN O
and CC CC O
myocardial NN NN O
biopsy NN NN O
. . . O

Thus RB RB O
, , , O
we PRP PRP O
conclude VBP VBP O
that IN IN O
tacrolimus NN NN B-CHEM
induces NNS NNS O
reversible JJ JJ O
myocardial NN NN O
hypertrophy NN NN O
. . . O

In IN IN O
patients NNS NNS O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
therapy NN NN O
, , , O
blood NN NN O
concentration NN NN O
should MD MD O
be VB VB O
carefully RB RB O
controlled VBN VBN O
and CC CC O
extreme JJ JJ O
attention NN NN O
paid VBN VBN O
to TO TO O
cardiac VB VB O
involvement NN NN O
. . . O

Nimodipine NNP NNP B-CHEM
prevents NNS NNS O
memory NN NN O
impairment NN NN O
caused VBN VBN O
by IN IN O
nitroglycerin NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
in IN IN O
adult NN NN O
mice NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Hypotension NNP NNP O
and CC CC O
a DT DT O
resultant JJ JJ O
decrease NN NN O
in IN IN O
cerebral JJ JJ O
blood NN NN O
flow NN NN O
have VBP VBP O
been VBN VBN O
implicated VBN VBN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
cognitive JJ JJ O
dysfunction NN NN O
. . . O

We PRP PRP O
tested VBD VBD O
the DT DT O
hypothesis NNS NNS O
that IN IN O
nimodipine NN NN B-CHEM
( ( ( O
NIMO NNP NNP B-CHEM
) ) ) O
administered VBN VBN O
at IN IN O
the DT DT O
onset NN NN O
of IN IN O
nitroglycerin NN NN B-CHEM
( ( ( O
NTG NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypotension NN NN O
would MD MD O
preserve VB VB O
long JJ JJ O
- - - O
term NN NN O
associative JJ JJ O
memory NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
passive JJ JJ O
avoidance NN NN O
( ( ( O
PA NNP NNP O
) ) ) O
paradigm NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
assess VB VB O
memory NN NN O
retention NN NN O
. . . O

For IN IN O
PA NNP NNP O
training NN NN O
, , , O
latencies NNS NNS O
( ( ( O
seconds NNS NNS O
) ) ) O
were VBD VBD O
recorded VBN VBN O
for IN IN O
entry NN NN O
from IN IN O
a DT DT O
suspended JJ JJ O
platform NN NN O
into IN IN O
a DT DT O
Plexiglas NNP NNP O
tube NN NN O
where WRB WRB O
a DT DT O
shock NN NN O
was VBD VBD O
automatically RB RB O
delivered VBN VBN O
. . . O

Latencies NNP NNP O
were VBD VBD O
recorded VBN VBN O
48 CD CD O
h NN NN O
later RB RB O
for IN IN O
a DT DT O
testing NN NN O
trial NN NN O
. . . O

Ninety CD CD O
- - - O
six CD CD O
Swiss NNP NNP O
- : : O
Webster NNP NNP O
mice NNS NNS O
( ( ( O
30 CD CD O
- : : O
35 CD CD O
g SYM SYM O
, , , O
6 CD CD O
- : : O
8 CD CD O
wk NN NN O
) ) ) O
, , , O
were VBD VBD O
randomized VBN VBN O
into IN IN O
6 CD CD O
groups NNS NNS O
1 CD CD O
) ) ) O
saline NN NN O
( ( ( O
control NN NN O
) ) ) O
, , , O
2 CD CD O
) ) ) O
NTG NNP NNP B-CHEM
immediately RB RB O
after IN IN O
learning VBG VBG O
, , , O
3 CD CD O
) ) ) O
NTG NNP NNP B-CHEM
3 CD CD O
h NN NN O
after IN IN O
learning VBG VBG O
, , , O
4 CD CD O
) ) ) O
NTG NNP NNP B-CHEM
and CC CC O
NIMO NNP NNP B-CHEM
, , , O
5 CD CD O
) ) ) O
vehicle NN NN O
, , , O
and CC CC O
6 CD CD O
) ) ) O
NIMO NNP NNP B-CHEM
alone RB RB O
. . . O

The DT DT O
extent NN NN O
of IN IN O
hypotension NN NN O
and CC CC O
changes NNS NNS O
in IN IN O
brain NN NN O
tissue NN NN O
oxygenation NN NN O
( ( ( O
PbtO NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
) ) ) O
and CC CC O
in IN IN O
cerebral JJ JJ O
blood NN NN O
flow NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
a DT DT O
separate JJ JJ O
group NN NN O
of IN IN O
animals NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
groups NNS NNS O
exhibited VBD VBD O
similar JJ JJ O
training NN NN O
latencies NNS NNS O
( ( ( O
17 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
6 CD CD O
s VBZ VBZ O
) ) ) O
. . . O

Mice NNP NNP O
subjected VBD VBD O
to TO TO O
hypotensive VB VB O
episodes NNS NNS O
showed VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
latency NN NN O
time NN NN O
( ( ( O
178 CD CD O
+ NN NN O
/ NN NN O
- : : O
156 CD CD O
s VBZ VBZ O
) ) ) O
compared VBN VBN O
with IN IN O
those DT DT O
injected VBN VBN O
with IN IN O
saline NN NN O
, , , O
NTG NNP NNP B-CHEM
+ NN NN O
NIMO NNP NNP B-CHEM
, , , O
or CC CC O
delayed VBD VBD O
NTG NNP NNP B-CHEM
( ( ( O
580 CD CD O
+ NN NN O
/ NN NN O
- : : O
81 CD CD O
s VBZ VBZ O
, , , O
557 CD CD O
+ NN NN O
/ NN NN O
- : : O
67 CD CD O
s VBZ VBZ O
, , , O
and CC CC O
493 CD CD O
+ NN NN O
/ NN NN O
- : : O
146 CD CD O
s VBZ VBZ O
, , , O
respectively RB RB O
) ) ) O
. . . O

A DT DT O
Kruskal NNP NNP O
- : : O
Wallis NNP NNP O
1 CD CD O
- : : O
way NN NN O
analysis NN NN O
of IN IN O
variance NN NN O
indicated VBD VBD O
a DT DT O
significant JJ JJ O
difference NN NN O
among IN IN O
the DT DT O
4 CD CD O
treatment NN NN O
groups NNS NNS O
( ( ( O
H NNP NNP O
= SYM SYM O
15 CD CD O
. . . O
34 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

In IN IN O
a DT DT O
separate JJ JJ O
group NN NN O
of IN IN O
mice NN NN O
not RB RB O
subjected VBD VBD O
to TO TO O
behavioral JJ JJ O
studies NNS NNS O
, , , O
the DT DT O
same JJ JJ O
dose NN NN O
of IN IN O
NTG NNP NNP B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
3 CD CD O
) ) ) O
and CC CC O
NTG NNP NNP B-CHEM
+ NN NN O
NIMO NNP NNP B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
3 CD CD O
) ) ) O
caused VBD VBD O
mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
to TO TO O
decrease VB VB O
from IN IN O
85 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
8 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
to TO TO O
31 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
8 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
and CC CC O
from IN IN O
86 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
7 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
to TO TO O
32 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
, , , O
respectively RB RB O
. . . O

Mean NNP NNP O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
in IN IN O
mice NN NN O
treated VBN VBN O
with IN IN O
NIMO NNP NNP B-CHEM
alone RB RB O
decreased VBD VBD O
from IN IN O
88 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
8 CD CD O
mm NN NN O
Hg NNP NNP O
to TO TO O
80 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
9 CD CD O
mm NN NN O
Hg NNP NNP O
. . . O

The DT DT O
intergroup NN NN O
difference NN NN O
was VBD VBD O
statistically RB RB O
significant JJ JJ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

PbtO NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
decreased VBD VBD O
from IN IN O
51 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
5 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
to TO TO O
33 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
2 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
in IN IN O
the DT DT O
NTG NNP NNP B-CHEM
group NN NN O
and CC CC O
from IN IN O
38 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
1 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
to TO TO O
25 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
0 CD CD O
mm NN NN O
Hg NNP NNP O
sem NN NN O
in IN IN O
the DT DT O
NTG NNP NNP B-CHEM
+ NN NN O
NIMO NNP NNP B-CHEM
groups NNS NNS O
, , , O
respectively RB RB O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
among IN IN O
groups NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
a DT DT O
PA NNP NNP O
retention NN NN O
paradigm NN NN O
, , , O
the DT DT O
injection NN NN O
of IN IN O
NTG NNP NNP B-CHEM
immediately RB RB O
after IN IN O
learning VBG VBG O
produced VBD VBD O
a DT DT O
significant JJ JJ O
impairment NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
associative JJ JJ O
memory NN NN O
in IN IN O
mice NN NN O
, , , O
whereas IN IN O
delayed VBN VBN O
induced JJ JJ O
hypotension NN NN O
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

NIMO NNP NNP B-CHEM
attenuated VBD VBD O
the DT DT O
disruption NN NN O
in IN IN O
consolidation NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
memory NN NN O
caused VBN VBN O
by IN IN O
NTG NNP NNP B-CHEM
but CC CC O
did VBD VBD O
not RB RB O
improve VB VB O
latency NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
hypotension NN NN O
. . . O

The DT DT O
observed VBD VBD O
effect NN NN O
of IN IN O
NIMO NNP NNP B-CHEM
may MD MD O
have VB VB O
been VBN VBN O
attributable JJ JJ O
to TO TO O
the DT DT O
preservation NN NN O
of IN IN O
calcium NN NN B-CHEM
homeostasis NN NN O
during IN IN O
hypotension NN NN O
, , , O
because IN IN O
there EX EX O
were VBD VBD O
no DT DT O
differences NNS NNS O
in IN IN O
the DT DT O
PbtO NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
indices NNS NNS O
among IN IN O
groups NNS NNS O
. . . O

Metabotropic NNP NNP O
glutamate NN NN B-CHEM
7 CD CD O
receptor NN NN O
subtype NN NN O
modulates NNS NNS O
motor NN NN O
symptoms NNS NNS O
in IN IN O
rodent NN NN O
models NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Metabotropic NNP NNP O
glutamate NN NN B-CHEM
( ( ( O
mGlu NN NN O
) ) ) O
receptors NNS NNS O
modulate VBP VBP O
synaptic JJ JJ O
transmission NN NN O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
and CC CC O
represent VB VB O
promising VBG VBG O
therapeutic JJ JJ O
targets NNS NNS O
for IN IN O
symptomatic JJ JJ O
treatment NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
. . . O

Among IN IN O
the DT DT O
eight CD CD O
mGlu NN NN O
receptor NN NN O
subtypes NNS NNS O
, , , O
mGlu7 NN NN O
receptor NN NN O
is VBZ VBZ O
prominently RB RB O
expressed VBN VBN O
in IN IN O
the DT DT O
basal NN NN O
ganglia NN NN O
, , , O
but CC CC O
its PRP$ PRP$ O
role NN NN O
in IN IN O
restoring VBG VBG O
motor NN NN O
function NN NN O
in IN IN O
animal NN NN O
models NNS NNS O
of IN IN O
PD NNP NNP O
is VBZ VBZ O
not RB RB O
known VBN VBN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
N NNP NNP B-CHEM
, , , I-CHEM
N NNP NNP I-CHEM
' POS POS I-CHEM
- : : I-CHEM
dibenzhydrylethane NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
diamine NN NN I-CHEM
dihydrochloride NN NN I-CHEM
( ( ( O
AMN082 NNP NNP B-CHEM
) ) ) O
, , , O
the DT DT O
first JJ JJ O
selective JJ JJ O
allosteric JJ JJ O
activator NN NN O
of IN IN O
mGlu7 NN NN O
receptors NNS NNS O
, , , O
were VBD VBD O
thus RB RB O
tested VBN VBN O
in IN IN O
different JJ JJ O
rodent NN NN O
models NNS NNS O
of IN IN O
PD NNP NNP O
. . . O

Here RB RB O
, , , O
we PRP PRP O
show VBP VBP O
that IN IN O
oral JJ JJ O
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
intrastriatal JJ JJ O
administration NN NN O
( ( ( O
0 CD CD O
. . . O
1 CD CD O
and CC CC O
0 CD CD O
. . . O
5 CD CD O
nmol CD CD O
) ) ) O
of IN IN O
AMN082 NNP NNP B-CHEM
reverses NNS NNS O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
in IN IN O
rats NNS NNS O
. . . O

AMN082 NNP NNP B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
and CC CC O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
reduces VBZ VBZ O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
rotations NNS NNS O
in IN IN O
unilateral JJ JJ O
6 CD CD B-CHEM
- : : I-CHEM
hydroxydopamine NN NN I-CHEM
( ( ( O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
) ) ) O
- : : O
lesioned VBD VBD O
rats NNS NNS O
. . . O

In IN IN O
a DT DT O
more RBR RBR O
complex JJ JJ O
task NN NN O
commonly RB RB O
used VBD VBD O
to TO TO O
evaluate VB VB O
major JJ JJ O
akinetic JJ JJ O
symptoms NNS NNS O
of IN IN O
PD NNP NNP O
patients NNS NNS O
, , , O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
AMN082 NNP NNP B-CHEM
reverses VBZ VBZ O
the DT DT O
increased VBN VBN O
reaction NN NN O
time NN NN O
to TO TO O
respond VB VB O
to TO TO O
a DT DT O
cue NN NN O
of IN IN O
bilateral NN NN O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
- : : O
lesioned JJ JJ O
rats NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
AMN082 NNP NNP B-CHEM
reduces VBZ VBZ O
the DT DT O
duration NN NN O
of IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
in IN IN O
a DT DT O
mGlu7 NN NN O
receptor NN NN O
- : : O
dependent JJ JJ O
manner NN NN O
in IN IN O
wild JJ JJ O
- - - O
type NN NN O
but CC CC O
not RB RB O
mGlu7 VB VB O
receptor NN NN O
knockout NN NN O
mice NN NN O
. . . O

Higher JJR JJR O
doses NNS NNS O
of IN IN O
AMN082 NNP NNP B-CHEM
( ( ( O
10 CD CD O
and CC CC O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
have VBP VBP O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
same JJ JJ O
models NNS NNS O
of IN IN O
PD NNP NNP O
. . . O

Overall NNP NNP O
these DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
mGlu7 NN NN O
receptor NN NN O
activation NN NN O
can MD MD O
reverse VB VB O
motor NN NN O
dysfunction NN NN O
associated VBN VBN O
with IN IN O
reduced VBN VBN O
dopamine NN NN B-CHEM
activity NN NN O
. . . O

Selective NNP NNP O
ligands NNS NNS O
of IN IN O
mGlu7 NN NN O
receptor NN NN O
subtypes NNS NNS O
may MD MD O
thus RB RB O
be VB VB O
considered VBN VBN O
as IN IN O
promising JJ JJ O
compounds NNS NNS O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
antiparkinsonian JJ JJ O
therapeutic JJ JJ O
strategies NNS NNS O
. . . O

Sorafenib NNP NNP B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
due JJ JJ O
to TO TO O
coronary JJ JJ O
artery NN NN O
spasm NN NN O
. . . O

A DT DT O
65 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
advanced VBD VBD O
renal JJ JJ O
cell NN NN O
carcinoma NN NN O
was VBD VBD O
admitted VBN VBN O
due JJ JJ O
to TO TO O
continuing VBG VBG O
chest NN NN O
pain NN NN O
at IN IN O
rest NN NN O
. . . O

Two CD CD O
weeks NNS NNS O
before IN IN O
his PRP$ PRP$ O
admission NN NN O
, , , O
sorafenib NN NN B-CHEM
had VBD VBD O
been VBN VBN O
started VBN VBN O
. . . O

He PRP PRP O
was VBD VBD O
diagnosed VBN VBN O
with IN IN O
non NN NN O
- - - O
ST NNP NNP O
- - - O
elevation NN NN O
myocardial NN NN O
infarction NN NN O
by IN IN O
laboratory NN NN O
data NNS NNS O
and CC CC O
electrocardiogram NN NN O
. . . O

Enhanced NNP NNP O
heart NN NN O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
also RB RB O
showed VBD VBD O
subendocardial JJ JJ O
infarction NN NN O
. . . O

However RB RB O
, , , O
there EX EX O
was VBD VBD O
no DT DT O
stenosis NN NN O
in IN IN O
coronary JJ JJ O
arteries NNS NNS O
on IN IN O
angiography NN NN O
. . . O

Coronary JJ JJ O
artery NN NN O
spasm NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
a DT DT O
provocative JJ JJ O
test NN NN O
. . . O

Cessation NNP NNP O
of IN IN O
sorafenib NN NN B-CHEM
and CC CC O
administration NN NN O
of IN IN O
Ca MD MD B-CHEM
- - - O
channel NN NN O
blocker NN NN O
and CC CC O
nitrates NNS NNS B-CHEM
ameliorated VBD VBD O
his PRP$ PRP$ O
symptoms NNS NNS O
, , , O
but CC CC O
relapse NN NN O
occurred VBD VBD O
after IN IN O
resumption NN NN O
of IN IN O
sorafenib NN NN B-CHEM
. . . O

Addition NN NN O
of IN IN O
oral JJ JJ O
nicorandil NN NN B-CHEM
reduced VBD VBD O
his PRP$ PRP$ O
symptoms NNS NNS O
and CC CC O
maintained VBN VBN O
stable JJ JJ O
angina NN NN O
status NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
first JJ JJ O
case NN NN O
of IN IN O
sorafenib NN NN B-CHEM
- - - O
induced JJ JJ O
coronary JJ JJ O
artery NN NN O
spasm NN NN O
. . . O

Sorafenib NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
multikinase NN NN O
inhibitor NN NN O
that WDT WDT O
targets NNS NNS O
signaling VBG VBG O
pathways NNS NNS O
necessary JJ JJ O
for IN IN O
cellular NN NN O
proliferation NN NN O
and CC CC O
survival NN NN O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
the DT DT O
Rho NNP NNP O
/ NN NN O
ROCK NNP NNP O
pathway NN NN O
has VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
coronary JJ JJ O
artery NN NN O
spasm NN NN O
. . . O

Our PRP$ PRP$ O
report NN NN O
may MD MD O
show VB VB O
an DT DT O
adverse JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
Rho NNP NNP O
/ NN NN O
ROCK NNP NNP O
pathway NN NN O
by IN IN O
sorafenib NN NN B-CHEM
use NN NN O
. . . O

A DT DT O
novel NN NN O
animal NN NN O
model NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
ability NN NN O
of IN IN O
a DT DT O
drug NN NN O
delivery NN NN O
system NN NN O
to TO TO O
promote VB VB O
the DT DT O
passage NN NN O
through IN IN O
the DT DT O
BBB NNP NNP O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
investigation NN NN O
was VBD VBD O
to TO TO O
explore VB VB O
the DT DT O
potentiality NN NN O
of IN IN O
a DT DT O
novel NN NN O
animal NN NN O
model NN NN O
to TO TO O
be VB VB O
used VBN VBN O
for IN IN O
the DT DT O
in IN IN O
vivo NN NN O
evaluation NN NN O
of IN IN O
the DT DT O
ability NN NN O
of IN IN O
a DT DT O
drug NN NN O
delivery NN NN O
system NN NN O
to TO TO O
promote VB VB O
the DT DT O
passage NN NN O
through IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
( ( ( O
BBB NNP NNP O
) ) ) O
and CC CC O
/ NN NN O
or CC CC O
to TO TO O
improve VB VB O
the DT DT O
brain NN NN O
localization NN NN O
of IN IN O
a DT DT O
bioactive JJ JJ O
compound NN NN O
. . . O

A DT DT O
Tween NNP NNP O
80 CD CD O
- : : O
coated JJ JJ O
poly NN NN B-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- : : I-CHEM
lactid JJ JJ I-CHEM
acid NN NN I-CHEM
nanoparticles NNS NNS O
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
model NN NN O
of IN IN O
colloidal JJ JJ O
drug NN NN O
delivery NN NN O
system NN NN O
, , , O
able JJ JJ O
to TO TO O
trespass VB VB O
the DT DT O
BBB NNP NNP O
. . . O

Tacrine NNP NNP B-CHEM
, , , O
administered VBN VBN O
in IN IN O
LiCl NNP NNP B-CHEM
pre NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
, , , O
induces NNS NNS O
electrocorticographic JJ JJ O
seizures NNS NNS O
and CC CC O
delayed VBD VBD O
hippocampal JJ JJ O
damage NN NN O
. . . O

The DT DT O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
tacrine NN NN B-CHEM
- - - O
loaded VBN VBN O
poly NN NN B-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- : : I-CHEM
lactid JJ JJ I-CHEM
acid NN NN I-CHEM
nanoparticles NNS NNS O
( ( ( O
5mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
a DT DT O
saline JJ JJ O
solution NN NN O
of IN IN O
tacrine NN NN B-CHEM
( ( ( O
5mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
an DT DT O
empty JJ JJ O
colloidal NN NN O
nanoparticle NN NN O
suspension NN NN O
were VBD VBD O
compared VBN VBN O
following VBG VBG O
i NNP NNP O
. . . O
p NN NN O
. . . O
administration NN NN O
in IN IN O
LiCl NNP NNP B-CHEM
- - - O
pre NN NN O
- - - O
treated VBN VBN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

All DT DT O
the DT DT O
animals NNS NNS O
treated VBN VBN O
with IN IN O
tacrine NN NN B-CHEM
- - - O
loaded JJ JJ O
nanoparticles NNS NNS O
showed VBD VBD O
an DT DT O
earlier JJR JJR O
outcome NN NN O
of IN IN O
CNS NNP NNP O
adverse JJ JJ O
symptoms NNS NNS O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
epileptic JJ JJ O
onset NN NN O
, , , O
with IN IN O
respect NN NN O
to TO TO O
those DT DT O
animals NNS NNS O
treated VBN VBN O
with IN IN O
the DT DT O
free JJ JJ O
compound NN NN O
( ( ( O
10 CD CD O
min NN NN O
vs NNS NNS O
. . . O
22 CD CD O
min NN NN O
respectively RB RB O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
tacrine NN NN B-CHEM
- - - O
loaded JJ JJ O
nanoparticles NNS NNS O
administration NN NN O
induced VBD VBD O
damage NN NN O
of IN IN O
neuronal NN NN O
cells NNS NNS O
in IN IN O
CA1 NNP NNP O
field NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
in IN IN O
all DT DT O
treated JJ JJ O
animals NNS NNS O
, , , O
while IN IN O
the DT DT O
saline NN NN O
solution NN NN O
of IN IN O
tacrine NN NN B-CHEM
only RB RB O
in IN IN O
60 CD CD O
% NN NN O
of IN IN O
animals NNS NNS O
. . . O

Empty JJ JJ O
nanoparticles NNS NNS O
provided VBD VBD O
similar JJ JJ O
results NNS NNS O
to TO TO O
control VB VB O
( ( ( O
saline NN NN O
- - - O
treated VBN VBN O
) ) ) O
group NN NN O
of IN IN O
animals NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
the DT DT O
evaluation NN NN O
of IN IN O
time NN NN O
- - - O
to TO TO O
- - - O
onset NN NN O
of IN IN O
symptoms NNS NNS O
and CC CC O
the DT DT O
severity NN NN O
of IN IN O
neurodegenerative JJ JJ O
processes NNS NNS O
induced VBN VBN O
by IN IN O
the DT DT O
tacrine NN NN B-CHEM
- - - O
lithium NN NN B-CHEM
model NN NN O
of IN IN O
epilepsy NN NN O
in IN IN O
the DT DT O
rat NN NN O
, , , O
could MD MD O
be VB VB O
used VBN VBN O
to TO TO O
evaluate VB VB O
preliminarily RB RB O
the DT DT O
capability NN NN O
of IN IN O
a DT DT O
drug NN NN O
delivery NN NN O
system NN NN O
to TO TO O
trespass VB VB O
( ( ( O
or CC CC O
not RB RB O
) ) ) O
the DT DT O
BBB NNP NNP O
in IN IN O
vivo NN NN O
. . . O

High NNP NNP O
- - - O
dose NN NN O
tranexamic JJ JJ B-CHEM
Acid NNP NNP I-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
nonischemic JJ JJ O
clinical JJ JJ O
seizures NNS NNS O
in IN IN O
cardiac JJ JJ O
surgical JJ JJ O
patients NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
In IN IN O
2 CD CD O
separate JJ JJ O
centers NNS NNS O
, , , O
we PRP PRP O
observed VBD VBD O
a DT DT O
notable JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
postoperative JJ JJ O
convulsive JJ JJ O
seizures NNS NNS O
from IN IN O
1 CD CD O
. . . O
3 CD CD O
% NN NN O
to TO TO O
3 CD CD O
. . . O
8 CD CD O
% NN NN O
in IN IN O
patients NNS NNS O
having VBG VBG O
undergone JJ JJ O
major JJ JJ O
cardiac JJ JJ O
surgical JJ JJ O
procedures NNS NNS O
. . . O

These DT DT O
events NNS NNS O
were VBD VBD O
temporally RB RB O
coincident NN NN O
with IN IN O
the DT DT O
initial JJ JJ O
use NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
TXA NNP NNP B-CHEM
) ) ) O
therapy NN NN O
after IN IN O
withdrawal NN NN O
of IN IN O
aprotinin NN NN O
from IN IN O
general JJ JJ O
clinical JJ JJ O
usage NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
review NN NN O
was VBD VBD O
to TO TO O
perform VB VB O
a DT DT O
retrospective NN NN O
analysis NN NN O
to TO TO O
examine VB VB O
whether IN IN O
there EX EX O
was VBD VBD O
a DT DT O
relation NN NN O
between IN IN O
TXA NNP NNP B-CHEM
usage NN NN O
and CC CC O
seizures NNS NNS O
after IN IN O
cardiac JJ JJ O
surgery NN NN O
. . . O

METHODS NNP NNP O
: : : O
An DT DT O
in IN IN O
- - - O
depth NN NN O
chart NN NN O
review NN NN O
was VBD VBD O
undertaken VBN VBN O
in IN IN O
all DT DT O
24 CD CD O
patients NNS NNS O
who WP WP O
developed VBD VBD O
perioperative JJ JJ O
seizures NNS NNS O
. . . O

Electroencephalographic NNP NNP O
activity NN NN O
was VBD VBD O
recorded VBN VBN O
in IN IN O
11 CD CD O
of IN IN O
these DT DT O
patients NNS NNS O
, , , O
and CC CC O
all DT DT O
patients NNS NNS O
had VBD VBD O
a DT DT O
formal JJ JJ O
neurological JJ JJ O
evaluation NN NN O
and CC CC O
brain NN NN O
imaging VBG VBG O
studies NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Twenty CD CD O
- : : O
one CD CD O
of IN IN O
the DT DT O
24 CD CD O
patients NNS NNS O
did VBD VBD O
not RB RB O
have VB VB O
evidence NN NN O
of IN IN O
new JJ JJ O
cerebral JJ JJ O
ischemic JJ JJ O
injury NN NN O
, , , O
but CC CC O
seizures NNS NNS O
were VBD VBD O
likely JJ JJ O
due JJ JJ O
to TO TO O
ischemic JJ JJ O
brain NN NN O
injury NN NN O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

All DT DT O
patients NNS NNS O
with IN IN O
seizures NNS NNS O
did VBD VBD O
not RB RB O
have VB VB O
permanent JJ JJ O
neurological JJ JJ O
abnormalities NNS NNS O
. . . O

All DT DT O
24 CD CD O
patients NNS NNS O
with IN IN O
seizures NNS NNS O
received VBN VBN O
high JJ JJ O
doses NNS NNS O
of IN IN O
TXA NNP NNP B-CHEM
intraoperatively RB RB O
ranging VBG VBG O
from IN IN O
61 CD CD O
to TO TO O
259 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
had VBD VBD O
a DT DT O
mean JJ JJ O
age NN NN O
of IN IN O
69 CD CD O
. . . O
9 CD CD O
years NNS NNS O
, , , O
and CC CC O
21 CD CD O
of IN IN O
24 CD CD O
had VBD VBD O
undergone JJ JJ O
open JJ JJ O
chamber NN NN O
rather RB RB O
than IN IN O
coronary JJ JJ O
bypass NN NN O
procedures NNS NNS O
. . . O

All DT DT O
but CC CC O
one CD CD O
patient NN NN O
were VBD VBD O
managed VBN VBN O
using VBG VBG O
cardiopulmonary JJ JJ O
bypass NN NN O
. . . O

No DT DT O
evidence NN NN O
of IN IN O
brain NN NN O
ischemic JJ JJ O
, , , O
metabolic JJ JJ O
, , , O
or CC CC O
hyperthermia NN NN O
- - - O
induced JJ JJ O
causes NNS NNS O
for IN IN O
their PRP$ PRP$ O
seizures NNS NNS O
was VBD VBD O
apparent JJ JJ O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
use NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
TXA NNP NNP B-CHEM
in IN IN O
older JJR JJR O
patients NNS NNS O
in IN IN O
conjunction NN NN O
with IN IN O
cardiopulmonary JJ JJ O
bypass NN NN O
and CC CC O
open JJ JJ O
- - - O
chamber NN NN O
cardiac NN NN O
surgery NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
clinical JJ JJ O
seizures NNS NNS O
in IN IN O
susceptible JJ JJ O
patients NNS NNS O
. . . O

Electrocardiographic NNP NNP O
changes NNS NNS O
and CC CC O
cardiac NN NN O
arrhythmias NNS NNS O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
psychotropic JJ JJ O
drugs NNS NNS O
. . . O

Eight CD CD O
patients NNS NNS O
had VBD VBD O
cardiac JJ JJ O
manifestations NNS NNS O
that WDT WDT O
were VBD VBD O
life NN NN O
- : : O
threatening VBG VBG O
in IN IN O
five CD CD O
while IN IN O
taking VBG VBG O
psychotropic JJ JJ O
drugs NNS NNS O
, , , O
either CC CC O
phenothiazines NNS NNS B-CHEM
or CC CC O
tricyclic JJ JJ O
antidepressants NNS NNS O
. . . O

Although IN IN O
most JJS JJS O
patients NNS NNS O
were VBD VBD O
receiving VBG VBG O
several JJ JJ O
drugs NNS NNS O
, , , O
Mellaril NNP NNP B-CHEM
( ( ( O
thioridazine NN NN B-CHEM
) ) ) O
appeared VBD VBD O
to TO TO O
be VB VB O
responsible JJ JJ O
for IN IN O
five CD CD O
cases NNS NNS O
of IN IN O
ventricular JJ JJ O
tachycardia NNS NNS O
, , , O
one CD CD O
of IN IN O
which WDT WDT O
was VBD VBD O
fatal JJ JJ O
in IN IN O
a DT DT O
35 CD CD O
year NN NN O
old JJ JJ O
woman NN NN O
. . . O

Supraventricular NNP NNP O
tachycardia NNS NNS O
developed VBN VBN O
in IN IN O
one CD CD O
patient NN NN O
receiving VBG VBG O
Thorazine NNP NNP B-CHEM
( ( ( O
chlorpromazine NN NN B-CHEM
) ) ) O
. . . O

Aventyl NNP NNP B-CHEM
( ( ( O
nortriptyline NN NN B-CHEM
) ) ) O
and CC CC O
Elavil NNP NNP B-CHEM
( ( ( O
amitriptyline NN NN B-CHEM
) ) ) O
each DT DT O
produced VBN VBN O
left VBD VBD O
bundle NN NN O
branch NN NN O
block NN NN O
in IN IN O
a DT DT O
73 CD CD O
year NN NN O
old JJ JJ O
woman NN NN O
. . . O

Electrocardiographic NNP NNP O
T NN NN O
and CC CC O
U NNP NNP O
wave NN NN O
abnormalities NNS NNS O
were VBD VBD O
present JJ JJ O
in IN IN O
most JJS JJS O
patients NNS NNS O
. . . O

The DT DT O
ventricular NN NN O
arrhythmias NNS NNS O
responded VBD VBD O
to TO TO O
intravenous JJ JJ O
administration NN NN O
of IN IN O
lidocaine NN NN B-CHEM
and CC CC O
to TO TO O
direct VB VB O
current JJ JJ O
electric JJ JJ O
shock NN NN O
; : : O
ventricular NN NN O
pacing NN NN O
was VBD VBD O
required VBN VBN O
in IN IN O
some DT DT O
instances NNS NNS O
and CC CC O
intravenous JJ JJ O
administration NN NN O
of IN IN O
propranolol NN NN B-CHEM
combined VBN VBN O
with IN IN O
ventricular JJ JJ O
pacing NN NN O
in IN IN O
one CD CD O
. . . O

The DT DT O
tachyarrhythmias NN NN O
generally RB RB O
subsided VBD VBD O
within IN IN O
48 CD CD O
hours NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
the DT DT O
drugs NNS NNS O
was VBD VBD O
stopped VBN VBN O
. . . O

Five CD CD O
of IN IN O
the DT DT O
eight CD CD O
patients NNS NNS O
were VBD VBD O
50 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
or CC CC O
younger JJR JJR O
; : : O
only RB RB O
one CD CD O
clearly RB RB O
had VBD VBD O
antecedent JJ JJ O
heart NN NN O
disease NN NN O
. . . O

Major NNP NNP O
cardiac JJ JJ O
arrhythmias NNS NNS O
are VBP VBP O
a DT DT O
potential JJ JJ O
hazard NN NN O
in IN IN O
patients NNS NNS O
without IN IN O
heart NN NN O
disease NN NN O
who WP WP O
are VBP VBP O
receiving VBG VBG O
customary JJ JJ O
therapeutic JJ JJ O
doses NNS NNS O
of IN IN O
psychotropic JJ JJ O
drugs NNS NNS O
. . . O

A DT DT O
prospective JJ JJ O
clinical JJ JJ O
trial NN NN O
is VBZ VBZ O
suggested VBN VBN O
to TO TO O
quantify VB VB O
the DT DT O
risk NN NN O
of IN IN O
cardiac JJ JJ O
complications NNS NNS O
to TO TO O
patients NNS NNS O
receiving VBG VBG O
phenothiazines NNS NNS B-CHEM
or CC CC O
tricyclic JJ JJ O
antidepressant NN NN O
drugs NNS NNS O
. . . O

Sensitivity NNP NNP O
of IN IN O
erythroid NN NN O
progenitor NN NN O
colonies NNS NNS O
to TO TO O
erythropoietin VB VB O
in IN IN O
azidothymidine NN NN B-CHEM
treated VBN VBN O
immunodeficient JJ JJ O
mice NN NN O
. . . O

The DT DT O
anaemia NN NN O
induced VBN VBN O
by IN IN O
3 CD CD B-CHEM
' POS POS I-CHEM
- : : I-CHEM
azido NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
' POS POS I-CHEM
dideoxythymidine NN NN I-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
poorly RB RB O
understood VBN VBN O
. . . O

We PRP PRP O
have VBP VBP O
used VBN VBN O
a DT DT O
murine NN NN O
model NN NN O
of IN IN O
AIDS NNP NNP O
, , , O
infection NN NN O
of IN IN O
female JJ JJ O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
mice NN NN O
with IN IN O
LP NNP NNP O
- : : O
BM5 NNP NNP O
murine NN NN O
leukaemia NN NN O
( ( ( O
MuLV NNP NNP O
) ) ) O
virus NN NN O
, , , O
to TO TO O
determine VB VB O
if IN IN O
AZT NNP NNP B-CHEM
- : : O
induced JJ JJ O
anaemia NN NN O
is VBZ VBZ O
due JJ JJ O
, , , O
in IN IN O
part NN NN O
, , , O
to TO TO O
decreased VBD VBD O
responsiveness NNS NNS O
of IN IN O
erythropoietic JJ JJ O
precursors NNS NNS O
( ( ( O
BFU NNP NNP O
- : : O
e SYM SYM O
) ) ) O
to TO TO O
erythropoietin NN NN O
( ( ( O
EPO NNP NNP O
) ) ) O
. . . O

Mice NNP NNP O
in IN IN O
the DT DT O
early JJ JJ O
stage NN NN O
of IN IN O
LP NNP NNP O
- : : O
BM5 NNP NNP O
MuLV NNP NNP O
disease NN NN O
were VBD VBD O
given VBN VBN O
AZT NNP NNP B-CHEM
in IN IN O
their PRP$ PRP$ O
drinking NN NN O
water NN NN O
at IN IN O
1 CD CD O
. . . O
0 CD CD O
and CC CC O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
. . . O

AZT NNP NNP B-CHEM
produced VBD VBD O
anaemia NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
, , , O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
fashion NN NN O
. . . O

Despite IN IN O
the DT DT O
anaemia NN NN O
, , , O
the DT DT O
number NN NN O
of IN IN O
splenic JJ JJ O
and CC CC O
bone NN NN O
marrow NN NN O
BFU NNP NNP O
- : : O
e SYM SYM O
in IN IN O
AZT NNP NNP B-CHEM
treated VBD VBD O
mice NNS NNS O
increased VBN VBN O
up IN IN O
to TO TO O
five CD CD O
- - - O
fold NN NN O
over IN IN O
levels NNS NNS O
observed VBD VBD O
in IN IN O
infected VBN VBN O
untreated JJ JJ O
animals NNS NNS O
after IN IN O
15 CD CD O
d SYM SYM O
of IN IN O
treatment NN NN O
. . . O

Colony NNP NNP O
formation NN NN O
by IN IN O
splenic JJ JJ O
and CC CC O
bone NN NN O
marrow NN NN O
BFUe NNP NNP O
was VBD VBD O
stimulated VBN VBN O
at IN IN O
lower JJR JJR O
concentrations NNS NNS O
of IN IN O
EPO NNP NNP O
in IN IN O
mice NN NN O
receiving VBG VBG O
AZT NNP NNP B-CHEM
for IN IN O
15 CD CD O
d SYM SYM O
than IN IN O
for IN IN O
infected JJ JJ O
, , , O
untreated JJ JJ O
mice NN NN O
. . . O

By IN IN O
day NN NN O
30 CD CD O
, , , O
sensitivity NN NN O
of IN IN O
both DT DT O
splenic JJ JJ O
and CC CC O
bone NN NN O
marrow NN NN O
BFU NNP NNP O
- : : O
e SYM SYM O
of IN IN O
treated VBN VBN O
animals NNS NNS O
returned VBD VBD O
to TO TO O
that DT DT O
observed VBD VBD O
from IN IN O
cells NNS NNS O
of IN IN O
infected JJ JJ O
untreated JJ JJ O
animals NNS NNS O
. . . O

The DT DT O
mean NN NN O
plasma NN NN O
levels NNS NNS O
of IN IN O
EPO NNP NNP O
observed VBD VBD O
in IN IN O
AZT NNP NNP B-CHEM
treated VBD VBD O
mice NN NN O
were VBD VBD O
appropriate JJ JJ O
for IN IN O
the DT DT O
degree NN NN O
of IN IN O
anaemia NN NN O
observed VBD VBD O
when WRB WRB O
compared VBN VBN O
with IN IN O
phenylhydrazine NN NN B-CHEM
( ( ( O
PHZ NNP NNP B-CHEM
) ) ) O
treated VBN VBN O
mice NN NN O
. . . O

The DT DT O
numbers NNS NNS O
of IN IN O
BFU NNP NNP O
- : : O
e SYM SYM O
and CC CC O
the DT DT O
percentage NN NN O
of IN IN O
bone NN NN O
marrow NN NN O
erythroblasts NNS NNS O
observed VBD VBD O
were VBD VBD O
comparable JJ JJ O
in IN IN O
AZT NNP NNP B-CHEM
and CC CC O
PHZ NNP NNP B-CHEM
treated VBD VBD O
mice NN NN O
with IN IN O
similar JJ JJ O
degrees NNS NNS O
of IN IN O
anaemia NN NN O
. . . O

However RB RB O
, , , O
reticulocytosis NN NN O
was VBD VBD O
inappropriate JJ JJ O
for IN IN O
the DT DT O
degree NN NN O
of IN IN O
anaemia NN NN O
observed VBD VBD O
in IN IN O
AZT NNP NNP B-CHEM
treated VBD VBD O
infected JJ JJ O
mice NN NN O
. . . O

AZT NNP NNP B-CHEM
- : : O
induced JJ JJ O
peripheral NN NN O
anaemia NN NN O
in IN IN O
the DT DT O
face NN NN O
of IN IN O
increased VBN VBN O
numbers NNS NNS O
of IN IN O
BFU NNP NNP O
- : : O
e SYM SYM O
and CC CC O
increased VBN VBN O
levels NNS NNS O
of IN IN O
plasma NN NN O
EPO NNP NNP O
suggest VBP VBP O
a DT DT O
lesion NN NN O
in IN IN O
terminal NN NN O
differentiation NN NN O
. . . O

Sedation NNP NNP O
depth NN NN O
during IN IN O
spinal JJ JJ O
anesthesia NN NN O
and CC CC O
the DT DT O
development NN NN O
of IN IN O
postoperative JJ JJ O
delirium NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
undergoing VBG VBG O
hip NN NN O
fracture NN NN O
repair NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
determine VB VB O
whether IN IN O
limiting VBG VBG O
intraoperative JJ JJ O
sedation NN NN O
depth NN NN O
during IN IN O
spinal JJ JJ O
anesthesia NN NN O
for IN IN O
hip NN NN O
fracture NN NN O
repair NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
can MD MD O
decrease VB VB O
the DT DT O
prevalence NN NN O
of IN IN O
postoperative JJ JJ O
delirium NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
We PRP PRP O
performed VBD VBD O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
randomized JJ JJ O
controlled VBN VBN O
trial NN NN O
at IN IN O
an DT DT O
academic JJ JJ O
medical JJ JJ O
center NN NN O
of IN IN O
elderly JJ JJ O
patients NNS NNS O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
65 CD CD O
years NNS NNS O
) ) ) O
without IN IN O
preoperative JJ JJ O
delirium NN NN O
or CC CC O
severe JJ JJ O
dementia NN NN O
who WP WP O
underwent JJ JJ O
hip NN NN O
fracture NN NN O
repair NN NN O
under IN IN O
spinal JJ JJ O
anesthesia NN NN O
with IN IN O
propofol NN NN B-CHEM
sedation NN NN O
. . . O

Sedation NNP NNP O
depth NN NN O
was VBD VBD O
titrated VBN VBN O
using VBG VBG O
processed JJ JJ O
electroencephalography NN NN O
with IN IN O
the DT DT O
bispectral NN NN O
index NN NN O
( ( ( O
BIS NNP NNP O
) ) ) O
, , , O
and CC CC O
patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
deep JJ JJ O
( ( ( O
BIS NNP NNP O
, , , O
approximately RB RB O
50 CD CD O
) ) ) O
or CC CC O
light JJ JJ O
( ( ( O
BIS NNP NNP O
, , , O
> NN NN O
or CC CC O
= SYM SYM O
80 CD CD O
) ) ) O
sedation NN NN O
. . . O

Postoperative NNP NNP O
delirium NN NN O
was VBD VBD O
assessed VBN VBN O
as IN IN O
defined VBN VBN O
by IN IN O
Diagnostic NNP NNP O
and CC CC O
Statistical NNP NNP O
Manual NNP NNP O
of IN IN O
Mental NNP NNP O
Disorders NNP NNP O
( ( ( O
Third NNP NNP O
Edition NNP NNP O
Revised NNP NNP O
) ) ) O
criteria NNS NNS O
using VBG VBG O
the DT DT O
Confusion NNP NNP O
Assessment NNP NNP O
Method NNP NNP O
beginning VBG VBG O
at IN IN O
any DT DT O
time NN NN O
from IN IN O
the DT DT O
second JJ JJ O
day NN NN O
after IN IN O
surgery NN NN O
. . . O

RESULTS NNS NNS O
: : : O
From IN IN O
April NNP NNP O
2 CD CD O
, , , O
2005 CD CD O
, , , O
through IN IN O
October NNP NNP O
30 CD CD O
, , , O
2008 CD CD O
, , , O
a DT DT O
total NN NN O
of IN IN O
114 CD CD O
patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
. . . O

The DT DT O
prevalence NN NN O
of IN IN O
postoperative JJ JJ O
delirium NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
the DT DT O
light JJ JJ O
sedation NN NN O
group NN NN O
( ( ( O
11 CD CD O
/ NN NN O
57 CD CD O
[ NN NN O
19 CD CD O
% NN NN O
] NN NN O
vs NNS NNS O
23 CD CD O
/ NN NN O
57 CD CD O
[ NN NN O
40 CD CD O
% NN NN O
] NN NN O
in IN IN O
the DT DT O
deep JJ JJ O
sedation NN NN O
group NN NN O
; : : O
P NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
, , , O
indicating VBG VBG O
that IN IN O
1 CD CD O
incident NN NN O
of IN IN O
delirium NN NN O
will MD MD O
be VB VB O
prevented VBN VBN O
for IN IN O
every DT DT O
4 CD CD O
. . . O
7 CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
light JJ JJ O
sedation NN NN O
. . . O

The DT DT O
mean NN NN O
+ NN NN O
/ NN NN O
- : : O
SD NNP NNP O
number NN NN O
of IN IN O
days NNS NNS O
of IN IN O
delirium NN NN O
during IN IN O
hospitalization NN NN O
was VBD VBD O
lower JJR JJR O
in IN IN O
the DT DT O
light JJ JJ O
sedation NN NN O
group NN NN O
than IN IN O
in IN IN O
the DT DT O
deep JJ JJ O
sedation NN NN O
group NN NN O
( ( ( O
0 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
5 CD CD O
days NNS NNS O
vs NNS NNS O
1 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
0 CD CD O
days NNS NNS O
; : : O
P NN NN O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
use NN NN O
of IN IN O
light JJ JJ O
propofol NN NN B-CHEM
sedation NN NN O
decreased VBD VBD O
the DT DT O
prevalence NN NN O
of IN IN O
postoperative JJ JJ O
delirium NN NN O
by IN IN O
50 CD CD O
% NN NN O
compared VBN VBN O
with IN IN O
deep JJ JJ O
sedation NN NN O
. . . O

Limiting NNP NNP O
depth NN NN O
of IN IN O
sedation NN NN O
during IN IN O
spinal JJ JJ O
anesthesia NN NN O
is VBZ VBZ O
a DT DT O
simple JJ JJ O
, , , O
safe JJ JJ O
, , , O
and CC CC O
cost NN NN O
- - - O
effective JJ JJ O
intervention NN NN O
for IN IN O
preventing VBG VBG O
postoperative JJ JJ O
delirium NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
that WDT WDT O
could MD MD O
be VB VB O
widely RB RB O
and CC CC O
readily RB RB O
adopted VBN VBN O
. . . O

The DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
Nrf2 NNP NNP O
in IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
Diabetic NNP NNP O
nephropathy NN NN O
is VBZ VBZ O
one CD CD O
of IN IN O
the DT DT O
major JJ JJ O
causes NNS NNS O
of IN IN O
renal JJ JJ O
failure NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
accompanied VBN VBN O
by IN IN O
the DT DT O
production NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
( ( ( O
ROS NNP NNP O
) ) ) O
. . . O

Nrf2 NNP NNP O
is VBZ VBZ O
the DT DT O
primary JJ JJ O
transcription NN NN O
factor NN NN O
that IN IN O
controls NNS NNS O
the DT DT O
antioxidant JJ JJ O
response NN NN O
essential JJ JJ O
for IN IN O
maintaining VBG VBG O
cellular NN NN O
redox NN NN O
homeostasis NN NN O
. . . O

Here RB RB O
, , , O
we PRP PRP O
report VBP VBP O
our PRP$ PRP$ O
findings NNS NNS O
demonstrating VBG VBG O
a DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
Nrf2 NNP NNP O
against IN IN O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

RESEARCH NNP NNP O
DESIGN NNP NNP O
AND CC CC O
METHODS NNP NNP O
: : : O
We PRP PRP O
explore VBP VBP O
the DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
Nrf2 NNP NNP O
against IN IN O
diabetic JJ JJ O
nephropathy NN NN O
using VBG VBG O
human JJ JJ O
kidney NN NN O
biopsy NN NN O
tissues NNS NNS O
from IN IN O
diabetic JJ JJ O
nephropathy NN NN O
patients NNS NNS O
, , , O
a DT DT O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
model NN NN O
in IN IN O
Nrf2 NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
, , , O
and CC CC O
cultured JJ JJ O
human JJ JJ O
mesangial NN NN O
cells NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
glomeruli NN NN O
of IN IN O
human JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
patients NNS NNS O
were VBD VBD O
under IN IN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
had VBD VBD O
elevated VBN VBN O
Nrf2 NNP NNP O
levels NNS NNS O
. . . O

In IN IN O
the DT DT O
animal NN NN O
study NN NN O
, , , O
Nrf2 NNP NNP O
was VBD VBD O
demonstrated VBN VBN O
to TO TO O
be VB VB O
crucial JJ JJ O
in IN IN O
ameliorating VBG VBG O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
damage NN NN O
. . . O

This DT DT O
is VBZ VBZ O
evident JJ JJ O
by IN IN O
Nrf2 NNP NNP O
( ( ( O
- : : O
/ NN NN O
- : : O
) ) ) O
mice NN NN O
having VBG VBG O
higher JJR JJR O
ROS NNP NNP O
production NN NN O
and CC CC O
suffering VBG VBG O
from IN IN O
greater JJR JJR O
oxidative JJ JJ O
DNA NNP NNP O
damage NN NN O
and CC CC O
renal JJ JJ O
injury NN NN O
compared VBN VBN O
with IN IN O
Nrf2 NNP NNP O
( ( ( O
+ NN NN O
/ NN NN O
+ NN NN O
) ) ) O
mice NN NN O
. . . O

Mechanistic NNP NNP O
studies NNS NNS O
in IN IN O
both DT DT O
in IN IN O
vivo NN NN O
and CC CC O
in IN IN O
vitro NN NN O
systems NNS NNS O
showed VBD VBD O
that IN IN O
the DT DT O
Nrf2 NNP NNP O
- - - O
mediated JJ JJ O
protection NN NN O
against IN IN O
diabetic JJ JJ O
nephropathy NN NN O
is VBZ VBZ O
, , , O
at IN IN O
least JJS JJS O
, , , O
partially RB RB O
through IN IN O
inhibition NN NN O
of IN IN O
transforming VBG VBG O
growth NN NN O
factor NN NN O
- : : O
beta1 NN NN O
( ( ( O
TGF NNP NNP O
- - - O
beta1 NN NN O
) ) ) O
and CC CC O
reduction NN NN O
of IN IN O
extracellular NN NN O
matrix NN NN O
production NN NN O
. . . O

In IN IN O
human JJ JJ O
renal NN NN O
mesangial NN NN O
cells NNS NNS O
, , , O
high JJ JJ O
glucose NN NN B-CHEM
induced VBN VBN O
ROS NNP NNP O
production NN NN O
and CC CC O
activated JJ JJ O
expression NN NN O
of IN IN O
Nrf2 NNP NNP O
and CC CC O
its PRP$ PRP$ O
downstream JJ JJ O
genes NNS NNS O
. . . O

Furthermore RB RB O
, , , O
activation NN NN O
or CC CC O
overexpression NN NN O
of IN IN O
Nrf2 NNP NNP O
inhibited VBD VBD O
the DT DT O
promoter NN NN O
activity NN NN O
of IN IN O
TGF NNP NNP O
- : : O
beta1 NN NN O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
, , , O
whereas IN IN O
knockdown NN NN O
of IN IN O
Nrf2 NNP NNP O
by IN IN O
siRNA NN NN O
enhanced JJ JJ O
TGF NNP NNP O
- : : O
beta1 NN NN O
transcription NN NN O
and CC CC O
fibronectin NN NN O
production NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
work NN NN O
clearly RB RB O
indicates VBZ VBZ O
a DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
Nrf2 NNP NNP O
in IN IN O
diabetic JJ JJ O
nephropathy NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
dietary JJ JJ O
or CC CC O
therapeutic JJ JJ O
activation NN NN O
of IN IN O
Nrf2 NNP NNP O
could MD MD O
be VB VB O
used VBN VBN O
as IN IN O
a DT DT O
strategy NN NN O
to TO TO O
prevent VB VB O
or CC CC O
slow VB VB O
down RP RP O
the DT DT O
progression NN NN O
of IN IN O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

Metformin NNP NNP B-CHEM
prevents NNS NNS O
experimental JJ JJ O
gentamicin NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
by IN IN O
a DT DT O
mitochondria NN NN O
- - - O
dependent JJ JJ O
pathway NN NN O
. . . O

The DT DT O
antidiabetic JJ JJ O
drug NN NN O
metformin NN NN B-CHEM
can MD MD O
diminish VB VB O
apoptosis NNS NNS O
induced VBN VBN O
by IN IN O
oxidative JJ JJ O
stress NN NN O
in IN IN O
endothelial JJ JJ O
cells NNS NNS O
and CC CC O
prevent VB VB O
vascular JJ JJ O
dysfunction NN NN O
even RB RB O
in IN IN O
nondiabetic JJ JJ O
patients NNS NNS O
. . . O

Here RB RB O
we PRP PRP O
tested VBD VBD O
whether IN IN O
it PRP PRP O
has VBZ VBZ O
a DT DT O
beneficial JJ JJ O
effect NN NN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
gentamicin NN NN B-CHEM
toxicity NN NN O
. . . O

Mitochondrial NNP NNP O
analysis NN NN O
, , , O
respiration NN NN O
intensity NN NN O
, , , O
levels NNS NNS O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
, , , O
permeability NN NN O
transition NN NN O
, , , O
and CC CC O
cytochrome JJ JJ O
c SYM SYM O
release NN NN O
were VBD VBD O
assessed VBN VBN O
3 CD CD O
and CC CC O
6 CD CD O
days NNS NNS O
after IN IN O
gentamicin NN NN B-CHEM
administration NN NN O
. . . O

Metformin NNP NNP B-CHEM
treatment NN NN O
fully RB RB O
blocked VBN VBN O
gentamicin NN NN B-CHEM
- - - O
mediated JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

This DT DT O
was VBD VBD O
accompanied VBN VBN O
by IN IN O
a DT DT O
lower JJR JJR O
activity NN NN O
of IN IN O
N NNP NNP O
- - - O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
D NNP NNP O
- : : O
glucosaminidase NN NN O
, , , O
together RB RB O
with IN IN O
a DT DT O
decrease NN NN O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
and CC CC O
increase NN NN O
of IN IN O
antioxidant NN NN O
systems NNS NNS O
. . . O

Metformin NNP NNP B-CHEM
also RB RB O
protected VBD VBD O
the DT DT O
kidney NN NN O
from IN IN O
histological JJ JJ O
damage NN NN O
6 CD CD O
days NNS NNS O
after IN IN O
gentamicin NN NN B-CHEM
administration NN NN O
. . . O

These DT DT O
in IN IN O
vivo NN NN O
markers NNS NNS O
of IN IN O
kidney NN NN O
dysfunction NN NN O
and CC CC O
their PRP$ PRP$ O
correction NN NN O
by IN IN O
metformin NN NN B-CHEM
were VBD VBD O
complemented VBN VBN O
by IN IN O
in IN IN O
vitro NN NN O
studies NNS NNS O
of IN IN O
mitochondrial JJ JJ O
function NN NN O
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
gentamicin NN NN B-CHEM
treatment NN NN O
depleted VBN VBN O
respiratory JJ JJ O
components NNS NNS O
( ( ( O
cytochrome JJ JJ O
c SYM SYM O
, , , O
NADH NNP NNP O
) ) ) O
, , , O
probably RB RB O
due JJ JJ O
to TO TO O
the DT DT O
opening NN NN O
of IN IN O
mitochondrial JJ JJ O
transition NN NN O
pores NNS NNS O
. . . O

These DT DT O
injuries NNS NNS O
, , , O
partly RB RB O
mediated VBN VBN O
by IN IN O
a DT DT O
rise NN NN O
in IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
from IN IN O
the DT DT O
electron NN NN O
transfer NN NN O
chain NN NN O
, , , O
were VBD VBD O
significantly RB RB O
decreased VBN VBN O
by IN IN O
metformin NN NN B-CHEM
. . . O

Thus RB RB O
, , , O
our PRP$ PRP$ O
study NN NN O
suggests VBZ VBZ O
that IN IN O
pleiotropic JJ JJ O
effects NNS NNS O
of IN IN O
metformin NN NN B-CHEM
can MD MD O
lessen VB VB O
gentamicin NN NN B-CHEM
nephrotoxicity NN NN O
and CC CC O
improve VB VB O
mitochondrial JJ JJ O
homeostasis NN NN O
. . . O

Risk NN NN O
of IN IN O
nephropathy NN NN O
after IN IN O
consumption NN NN O
of IN IN O
nonionic JJ JJ O
contrast NN NN B-CHEM
media NNS NNS I-CHEM
by IN IN O
children NNS NNS O
undergoing VBG VBG O
cardiac NN NN O
angiography NN NN O
: : : O
a DT DT O
prospective JJ JJ O
study NN NN O
. . . O

Despite IN IN O
increasing VBG VBG O
reports NNS NNS O
on IN IN O
nonionic JJ JJ O
contrast NN NN B-CHEM
media NNS NNS I-CHEM
- : : O
induced VBN VBN O
nephropathy NN NN O
( ( ( O
CIN NNP NNP O
) ) ) O
in IN IN O
hospitalized JJ JJ O
adult NN NN O
patients NNS NNS O
during IN IN O
cardiac JJ JJ O
procedures NNS NNS O
, , , O
the DT DT O
studies NNS NNS O
in IN IN O
pediatrics NNS NNS O
are VBP VBP O
limited JJ JJ O
, , , O
with IN IN O
even RB RB O
less JJR JJR O
focus NN NN O
on IN IN O
possible JJ JJ O
predisposing NN NN O
factors NNS NNS O
and CC CC O
preventive JJ JJ O
measures NNS NNS O
for IN IN O
patients NNS NNS O
undergoing VBG VBG O
cardiac NN NN O
angiography NN NN O
. . . O

This DT DT O
prospective JJ JJ O
study NN NN O
determined VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
CIN NNP NNP O
for IN IN O
two CD CD O
nonionic JJ JJ O
contrast NN NN B-CHEM
media NNS NNS I-CHEM
( ( ( O
CM NNP NNP B-CHEM
) ) ) O
, , , O
iopromide NN NN B-CHEM
and CC CC O
iohexol NN NN B-CHEM
, , , O
among IN IN O
80 CD CD O
patients NNS NNS O
younger JJR JJR O
than IN IN O
18 CD CD O
years NNS NNS O
and CC CC O
compared VBN VBN O
the DT DT O
rates NNS NNS O
for IN IN O
this DT DT O
complication NN NN O
in IN IN O
relation NN NN O
to TO TO O
the DT DT O
type NN NN O
and CC CC O
dosage NN NN O
of IN IN O
CM NNP NNP B-CHEM
and CC CC O
the DT DT O
presence NN NN O
of IN IN O
cyanosis NN NN O
. . . O

The DT DT O
80 CD CD O
patients NNS NNS O
in IN IN O
the DT DT O
study NN NN O
consecutively RB RB O
received VBD VBD O
either CC CC O
iopromide IN IN B-CHEM
( ( ( O
group NN NN O
A DT DT O
, , , O
n NN NN O
= SYM SYM O
40 CD CD O
) ) ) O
or CC CC O
iohexol NN NN B-CHEM
( ( ( O
group NN NN O
B NNP NNP O
, , , O
n NN NN O
= SYM SYM O
40 CD CD O
) ) ) O
. . . O

Serum NNP NNP O
sodium NN NN B-CHEM
( ( ( O
Na NNP NNP B-CHEM
) ) ) O
, , , O
potassium NN NN B-CHEM
( ( ( O
K NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
creatinine NN NN B-CHEM
( ( ( O
Cr NNP NNP B-CHEM
) ) ) O
were VBD VBD O
measured VBN VBN O
24 CD CD O
h NN NN O
before RB RB O
angiography NN NN O
as IN IN O
baseline NN NN O
values NNS NNS O
, , , O
then RB RB O
measured VBN VBN O
again RB RB O
at IN IN O
12 CD CD O
- : : O
, , , O
24 CD CD O
- : : O
, , , O
and CC CC O
48 CD CD O
- : : O
h NN NN O
intervals NNS NNS O
after IN IN O
CM NNP NNP B-CHEM
use NN NN O
. . . O

Urine NNP NNP O
samples NNS NNS O
for IN IN O
Na NNP NNP B-CHEM
and CC CC O
Cr NNP NNP B-CHEM
also RB RB O
were VBD VBD O
checked VBN VBN O
at IN IN O
the DT DT O
same JJ JJ O
intervals NNS NNS O
. . . O

Risk NN NN O
of IN IN O
renal JJ JJ O
failure NN NN O
, , , O
Injury NNP NNP O
to TO TO O
the DT DT O
kidney NN NN O
, , , O
Failure NN NN O
of IN IN O
kidney NN NN O
function NN NN O
, , , O
Loss NN NN O
of IN IN O
kidney NN NN O
function NN NN O
, , , O
and CC CC O
End NN NN O
- : : O
stage NN NN O
renal NN NN O
damage NN NN O
( ( ( O
RIFLE NNP NNP O
criteria NNS NNS O
) ) ) O
were VBD VBD O
used VBN VBN O
to TO TO O
define VB VB O
CIN NNP NNP O
and CC CC O
its PRP$ PRP$ O
incidence NN NN O
in IN IN O
the DT DT O
study NN NN O
population NN NN O
. . . O

Accordingly RB RB O
, , , O
among IN IN O
the DT DT O
15 CD CD O
CIN NNP NNP O
patients NNS NNS O
( ( ( O
18 CD CD O
. . . O
75 CD CD O
% NN NN O
) ) ) O
, , , O
7 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
in IN IN O
group NN NN O
A DT DT O
had VBD VBD O
increased VBN VBN O
risk NN NN O
and CC CC O
3 CD CD O
. . . O
75 CD CD O
% NN NN O
had VBD VBD O
renal JJ JJ O
injury NN NN O
, , , O
whereas IN IN O
5 CD CD O
% NN NN O
of IN IN O
group NN NN O
B NNP NNP O
had VBD VBD O
increased VBN VBN O
risk NN NN O
and CC CC O
2 CD CD O
. . . O
5 CD CD O
% NN NN O
had VBD VBD O
renal JJ JJ O
injury NN NN O
. . . O

Whereas IN IN O
33 CD CD O
. . . O
3 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
CIN NNP NNP O
were VBD VBD O
among IN IN O
those DT DT O
who WP WP O
received VBD VBD O
the DT DT O
proper JJ JJ O
dosage NN NN O
of IN IN O
CM NNP NNP B-CHEM
, , , O
the DT DT O
percentage NN NN O
increased VBD VBD O
to TO TO O
66 CD CD O
. . . O
6 CD CD O
% NN NN O
among IN IN O
those DT DT O
who WP WP O
received VBD VBD O
larger JJR JJR O
doses NNS NNS O
, , , O
with IN IN O
a DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
CIN NNP NNP O
related VBD VBD O
to TO TO O
the DT DT O
different JJ JJ O
dosages NNS NNS O
of IN IN O
CM NNP NNP B-CHEM
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
014 CD CD O
) ) ) O
. . . O

Among IN IN O
the DT DT O
15 CD CD O
patients NNS NNS O
with IN IN O
CIN NNP NNP O
, , , O
6 CD CD O
had VBD VBD O
cyanotic JJ JJ O
congenital JJ JJ O
heart NN NN O
diseases NNS NNS O
, , , O
but CC CC O
the DT DT O
incidence NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
from IN IN O
that DT DT O
for IN IN O
the DT DT O
noncyanotic JJ JJ O
patients NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
243 CD CD O
) ) ) O
. . . O

Although IN IN O
clinically RB RB O
silent JJ JJ O
, , , O
CIN NNP NNP O
is VBZ VBZ O
not RB RB O
rare JJ JJ O
in IN IN O
pediatrics NNS NNS O
. . . O

The DT DT O
incidence NN NN O
depends VBZ VBZ O
on IN IN O
dosage NN NN O
but CC CC O
not RB RB O
on IN IN O
the DT DT O
type NN NN O
of IN IN O
consumed VBN VBN O
nonionic JJ JJ O
CM NNP NNP B-CHEM
, , , O
nor CC CC O
on IN IN O
the DT DT O
presence NN NN O
of IN IN O
cyanosis NN NN O
, , , O
and CC CC O
although IN IN O
CIN NNP NNP O
usually RB RB O
is VBZ VBZ O
reversible JJ JJ O
, , , O
more JJR JJR O
concern NN NN O
is VBZ VBZ O
needed VBN VBN O
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
such JJ JJ O
a DT DT O
complication NN NN O
in IN IN O
children NNS NNS O
. . . O

Renal NNP NNP O
function NN NN O
and CC CC O
hemodynamics NNS NNS O
during IN IN O
prolonged JJ JJ O
isoflurane NN NN B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
in IN IN O
humans NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
isoflurane NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
on IN IN O
glomerular NN NN O
function NN NN O
and CC CC O
renal JJ JJ O
blood NN NN O
flow NN NN O
was VBD VBD O
investigated VBN VBN O
in IN IN O
20 CD CD O
human JJ JJ O
subjects NNS NNS O
. . . O

Glomerular NNP NNP O
filtration NN NN O
rate NN NN O
( ( ( O
GFR NNP NNP O
) ) ) O
and CC CC O
effective JJ JJ O
renal JJ JJ O
plasma NN NN O
flow NN NN O
( ( ( O
ERPF NNP NNP O
) ) ) O
were VBD VBD O
measured VBN VBN O
by IN IN O
inulin NN NN O
and CC CC O
para NN NN B-CHEM
- : : I-CHEM
aminohippurate NN NN I-CHEM
( ( ( O
PAH NNP NNP B-CHEM
) ) ) O
clearance NN NN O
, , , O
respectively RB RB O
. . . O

Anesthesia NNP NNP O
was VBD VBD O
maintained VBN VBN O
with IN IN O
fentanyl NN NN B-CHEM
, , , O
nitrous JJ JJ B-CHEM
oxide NN NN I-CHEM
, , , O
oxygen NN NN B-CHEM
, , , O
and CC CC O
isoflurane NN NN B-CHEM
. . . O

Hypotension NNP NNP O
was VBD VBD O
induced VBN VBN O
for IN IN O
236 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
. . . O
1 CD CD O
min NN NN O
by IN IN O
increasing VBG VBG O
the DT DT O
isoflurane NN NN B-CHEM
inspired JJ JJ O
concentration NN NN O
to TO TO O
maintain VB VB O
a DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
of IN IN O
59 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
4 CD CD O
mmHg NN NN O
. . . O

GFR NNP NNP O
and CC CC O
ERPF NNP NNP O
decreased VBD VBD O
with IN IN O
the DT DT O
induction NN NN O
of IN IN O
anesthesia NN NN O
but CC CC O
not RB RB O
significantly RB RB O
more JJR JJR O
during IN IN O
hypotension NN NN O
. . . O

Postoperatively NNP NNP O
, , , O
ERPF NNP NNP O
returned VBD VBD O
to TO TO O
preoperative JJ JJ O
values NNS NNS O
, , , O
whereas IN IN O
GFR NNP NNP O
was VBD VBD O
higher JJR JJR O
than IN IN O
preoperative JJ JJ O
values NNS NNS O
. . . O

Renal NNP NNP O
vascular NN NN O
resistance NN NN O
increased VBN VBN O
during IN IN O
anesthesia NN NN O
but CC CC O
decreased VBD VBD O
when WRB WRB O
hypotension NN NN O
was VBD VBD O
induced VBN VBN O
, , , O
allowing VBG VBG O
the DT DT O
maintenance NN NN O
of IN IN O
renal JJ JJ O
blood NN NN O
flow NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
renal JJ JJ O
compensatory NN NN O
mechanisms NNS NNS O
are VBP VBP O
preserved VBN VBN O
during IN IN O
isoflurane NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
and CC CC O
that IN IN O
renal JJ JJ O
function NN NN O
and CC CC O
hemodynamics NNS NNS O
quickly RB RB O
return VBP VBP O
to TO TO O
normal JJ JJ O
when WRB WRB O
normotension NN NN O
is VBZ VBZ O
resumed VBN VBN O
. . . O

Brainstem NNP NNP O
dysgenesis NN NN O
in IN IN O
an DT DT O
infant NN NN O
prenatally RB RB O
exposed VBN VBN O
to TO TO O
cocaine NN NN B-CHEM
. . . O

Many JJ JJ O
authors NNS NNS O
described VBD VBD O
the DT DT O
effects NNS NNS O
on IN IN O
the DT DT O
fetus NN NN O
of IN IN O
maternal JJ JJ O
cocaine NN NN O
abuse NN NN O
during IN IN O
pregnancy NN NN O
. . . O

Vasoconstriction NNP NNP O
appears VBZ VBZ O
to TO TO O
be VB VB O
the DT DT O
common JJ JJ O
mechanism NN NN O
of IN IN O
action NN NN O
leading VBG VBG O
to TO TO O
a DT DT O
wide JJ JJ O
range NN NN O
of IN IN O
fetal JJ JJ O
anomalies NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
an DT DT O
infant NN NN O
with IN IN O
multiple JJ JJ O
cranial JJ JJ O
- - - O
nerve NN NN O
involvement NN NN O
attributable JJ JJ O
to TO TO O
brainstem NN NN O
dysgenesis NN NN O
, , , O
born VBN VBN O
to TO TO O
a DT DT O
cocaine NN NN O
- - - O
addicted JJ JJ O
mother NN NN O
. . . O

A DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
evaluation NN NN O
of IN IN O
the DT DT O
effect NN NN O
of IN IN O
risperidone NN NN B-CHEM
and CC CC O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
on IN IN O
bone NN NN O
mineral JJ JJ O
density NN NN O
in IN IN O
boys NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
effect NN NN O
of IN IN O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
on IN IN O
trabecular NN NN O
bone NN NN O
mineral JJ JJ O
density NN NN O
( ( ( O
BMD NNP NNP O
) ) ) O
in IN IN O
children NNS NNS O
and CC CC O
adolescents NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
Medically NNP NNP O
healthy JJ JJ O
7 CD CD O
- : : O
to TO TO O
17 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
males NNS NNS O
chronically RB RB O
treated VBN VBN O
, , , O
in IN IN O
a DT DT O
naturalistic JJ JJ O
setting NN NN O
, , , O
with IN IN O
risperidone NN NN B-CHEM
were VBD VBD O
recruited VBN VBN O
for IN IN O
this DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
study NN NN O
through IN IN O
child NN NN O
psychiatry NN NN O
outpatient NN NN O
clinics NNS NNS O
between IN IN O
November NNP NNP O
2005 CD CD O
and CC CC O
June NNP NNP O
2007 CD CD O
. . . O

Anthropometric NNP NNP O
measurements NNS NNS O
and CC CC O
laboratory NN NN O
testing NN NN O
were VBD VBD O
conducted VBN VBN O
. . . O

The DT DT O
clinical JJ JJ O
diagnoses NNS NNS O
were VBD VBD O
based VBN VBN O
on IN IN O
chart NN NN O
review NN NN O
, , , O
and CC CC O
developmental NN NN O
and CC CC O
treatment NN NN O
history NN NN O
was VBD VBD O
obtained VBN VBN O
from IN IN O
the DT DT O
medical JJ JJ O
record NN NN O
. . . O

Volumetric NNP NNP O
BMD NNP NNP O
of IN IN O
the DT DT O
ultradistal JJ JJ O
radius NN NN O
was VBD VBD O
measured VBN VBN O
using VBG VBG O
peripheral JJ JJ O
quantitative JJ JJ O
computed JJ JJ O
tomography NN NN O
, , , O
and CC CC O
areal NN NN O
BMD NNP NNP O
of IN IN O
the DT DT O
lumbar NN NN O
spine NN NN O
was VBD VBD O
estimated VBN VBN O
using VBG VBG O
dual JJ JJ O
- - - O
energy NN NN O
x SYM SYM O
- : : O
ray NNP NNP O
absorptiometry NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Hyperprolactinemia NNP NNP O
was VBD VBD O
present JJ JJ O
in IN IN O
49 CD CD O
% NN NN O
of IN IN O
83 CD CD O
boys NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
41 CD CD O
) ) ) O
treated VBN VBN O
with IN IN O
risperidone NN NN B-CHEM
for IN IN O
a DT DT O
mean NN NN O
of IN IN O
2 CD CD O
. . . O
9 CD CD O
years NNS NNS O
. . . O

Serum NNP NNP O
testosterone NN NN B-CHEM
concentration NN NN O
increased VBN VBN O
with IN IN O
pubertal JJ JJ O
status NN NN O
but CC CC O
was VBD VBD O
not RB RB O
affected VBN VBN O
by IN IN O
hyperprolactinemia NN NN O
. . . O

As IN IN O
expected VBN VBN O
, , , O
bone NN NN O
mineral NN NN O
content NN NN O
and CC CC O
BMD NNP NNP O
increased VBD VBD O
with IN IN O
sexual JJ JJ O
maturity NN NN O
. . . O

After IN IN O
adjusting VBG VBG O
for IN IN O
the DT DT O
stage NN NN O
of IN IN O
sexual JJ JJ O
development NN NN O
and CC CC O
height NN NN O
and CC CC O
BMI NNP NNP O
z SYM SYM O
scores NNS NNS O
, , , O
serum NN NN O
prolactin NN NN O
was VBD VBD O
negatively RB RB O
associated VBN VBN O
with IN IN O
trabecular JJ JJ O
volumetric JJ JJ O
BMD NNP NNP O
at IN IN O
the DT DT O
ultradistal JJ JJ O
radius NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
03 CD CD O
) ) ) O
. . . O

Controlling NNP NNP O
for IN IN O
relevant JJ JJ O
covariates NNS NNS O
, , , O
we PRP PRP O
also RB RB O
found VBD VBD O
treatment NN NN O
with IN IN O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
( ( ( O
SSRIs NNP NNP O
) ) ) O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
lower JJR JJR O
trabecular NN NN O
BMD NNP NNP O
at IN IN O
the DT DT O
radius NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
03 CD CD O
) ) ) O
and CC CC O
BMD NNP NNP O
z SYM SYM O
score NN NN O
at IN IN O
the DT DT O
lumbar NN NN O
spine NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
05 CD CD O
) ) ) O
. . . O

These DT DT O
findings NNS NNS O
became VBD VBD O
more RBR RBR O
marked JJ JJ O
when WRB WRB O
the DT DT O
analysis NN NN O
was VBD VBD O
restricted VBN VBN O
to TO TO O
non NN NN O
- - - O
Hispanic JJ JJ O
white JJ JJ O
patients NNS NNS O
. . . O

Of IN IN O
13 CD CD O
documented VBN VBN O
fractures NNS NNS O
, , , O
3 CD CD O
occurred VBD VBD O
after IN IN O
risperidone NN NN B-CHEM
and CC CC O
SSRIs NNP NNP O
were VBD VBD O
started VBN VBN O
, , , O
and CC CC O
none NN NN O
occurred VBD VBD O
in IN IN O
patients NNS NNS O
with IN IN O
hyperprolactinemia NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
study NN NN O
to TO TO O
link VB VB O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
and CC CC O
SSRI NNP NNP O
treatment NN NN O
to TO TO O
lower JJR JJR O
BMD NNP NNP O
in IN IN O
children NNS NNS O
and CC CC O
adolescents NNS NNS O
. . . O

Future NNP NNP O
research NN NN O
should MD MD O
evaluate VB VB O
the DT DT O
longitudinal JJ JJ O
course NN NN O
of IN IN O
this DT DT O
adverse JJ JJ O
event NN NN O
to TO TO O
determine VB VB O
its PRP$ PRP$ O
temporal JJ JJ O
stability NN NN O
and CC CC O
whether IN IN O
a DT DT O
higher JJR JJR O
fracture NN NN O
rate NN NN O
ensues NNS NNS O
. . . O

Fear NN NN O
- - - O
potentiated JJ JJ O
startle NN NN O
, , , O
but CC CC O
not RB RB O
light JJ JJ O
- - - O
enhanced JJ JJ O
startle NN NN O
, , , O
is VBZ VBZ O
enhanced VBN VBN O
by IN IN O
anxiogenic JJ JJ O
drugs NNS NNS O
. . . O

RATIONALE NNP NNP O
AND CC CC O
OBJECTIVES NNP NNP O
: : : O
The DT DT O
light JJ JJ O
- - - O
enhanced JJ JJ O
startle NN NN O
paradigm NN NN O
( ( ( O
LES NNP NNP O
) ) ) O
is VBZ VBZ O
suggested VBN VBN O
to TO TO O
model NN NN O
anxiety NN NN O
, , , O
because IN IN O
of IN IN O
the DT DT O
non NN NN O
- - - O
specific JJ JJ O
cue NN NN O
and CC CC O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
effect NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
fear NN NN O
- - - O
potentiated JJ JJ O
startle NN NN O
( ( ( O
FPS NNP NNP O
) ) ) O
is VBZ VBZ O
suggested VBN VBN O
to TO TO O
model VB VB O
conditioned VBN VBN O
fear NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
pharmacological JJ JJ O
profiles NNS NNS O
of IN IN O
these DT DT O
two CD CD O
paradigms NNS NNS O
are VBP VBP O
very RB RB O
similar JJ JJ O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
putative JJ JJ O
anxiogenic JJ JJ O
drugs NNS NNS O
on IN IN O
LES NNP NNP O
and CC CC O
FPS NNP NNP O
and CC CC O
aimed VBN VBN O
at IN IN O
determining VBG VBG O
the DT DT O
sensitivity NN NN O
of IN IN O
LES NNP NNP O
for IN IN O
anxiogenic JJ JJ O
drugs NNS NNS O
and CC CC O
to TO TO O
potentially RB RB O
showing VBG VBG O
a DT DT O
pharmacological JJ JJ O
differentiation NN NN O
between IN IN O
these DT DT O
two CD CD O
paradigms NN NN O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
received VBD VBD O
each DT DT O
dose NN NN O
of IN IN O
the DT DT O
alpha NN NN O
( ( ( O
2 CD CD O
) ) ) O
- : : O
adrenoceptor NN NN O
antagonist NN NN O
yohimbine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
25 CD CD O
- : : O
1 CD CD O
. . . O
0mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
( ( ( O
2C CD CD O
) ) ) O
receptor NN NN O
agonist NN NN O
m NN NN B-CHEM
- : : I-CHEM
chlorophenylpiperazine NN NN I-CHEM
( ( ( O
mCPP NN NN B-CHEM
, , , O
0 CD CD O
. . . O
5 CD CD O
- : : O
2 CD CD O
. . . O
0mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
the DT DT O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
inverse NN NN O
receptor NN NN O
agonist NN NN O
pentylenetetrazole NN NN B-CHEM
( ( ( O
PTZ NNP NNP B-CHEM
, , , O
3 CD CD O
- : : O
30mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
were VBD VBD O
subsequently RB RB O
tested VBN VBN O
in IN IN O
either DT DT O
LES NNP NNP O
or CC CC O
FPS NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
None NN NN O
of IN IN O
the DT DT O
drugs NNS NNS O
enhanced VBN VBN O
LES NNP NNP O
, , , O
whereas IN IN O
mCPP NN NN B-CHEM
increased VBD VBD O
percentage NN NN O
FPS NNP NNP O
and CC CC O
yohimbine NN NN B-CHEM
increased VBD VBD O
absolute JJ JJ O
FPS NNP NNP O
values NNS NNS O
. . . O

Furthermore RB RB O
, , , O
yohimbine NN NN B-CHEM
increased VBN VBN O
baseline NN NN O
startle NN NN O
amplitude NN NN O
in IN IN O
the DT DT O
LES NNP NNP O
, , , O
while IN IN O
mCPP NN NN B-CHEM
suppressed VBD VBD O
baseline NN NN O
startle NN NN O
in IN IN O
both DT DT O
the DT DT O
LES NNP NNP O
and CC CC O
FPS NNP NNP O
and CC CC O
PTZ NNP NNP B-CHEM
suppressed VBD VBD O
baseline NN NN O
startle NN NN O
in IN IN O
the DT DT O
FPS NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
contrast NN NN O
to TO TO O
findings NNS NNS O
in IN IN O
the DT DT O
FPS NNP NNP O
paradigm NN NN O
, , , O
none NN NN O
of IN IN O
the DT DT O
drugs NNS NNS O
were VBD VBD O
able JJ JJ O
to TO TO O
exacerbate VB VB O
the DT DT O
LES NNP NNP O
response NN NN O
. . . O

Thus RB RB O
, , , O
a DT DT O
clear JJ JJ O
pharmacological JJ JJ O
differentiation NN NN O
was VBD VBD O
found VBN VBN O
between IN IN O
LES NNP NNP O
and CC CC O
FPS NNP NNP O
. . . O

Rosaceiform NNP NNP O
dermatitis NNS NNS O
associated VBN VBN O
with IN IN O
topical JJ JJ O
tacrolimus NN NN B-CHEM
treatment NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
herein NN NN O
3 CD CD O
patients NNS NNS O
who WP WP O
developed VBD VBD O
rosacea NN NN O
- - - O
like IN IN O
dermatitis NN NN O
eruptions NNS NNS O
while IN IN O
using VBG VBG O
0 CD CD O
. . . O
03 CD CD O
% NN NN O
or CC CC O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
tacrolimus NN NN B-CHEM
ointment NN NN O
for IN IN O
facial JJ JJ O
dermatitis NN NN O
. . . O

Skin NNP NNP O
biopsy NN NN O
specimens NNS NNS O
showed VBD VBD O
telangiectasia NN NN O
and CC CC O
noncaseating VBG VBG O
epithelioid JJ JJ O
granulomatous JJ JJ O
tissue NN NN O
formation NN NN O
in IN IN O
the DT DT O
papillary JJ JJ O
to TO TO O
mid JJ JJ O
dermis NN NN O
. . . O

Continuous NNP NNP O
topical JJ JJ O
use NN NN O
of IN IN O
immunomodulators NNS NNS O
such JJ JJ O
as IN IN O
tacrolimus NN NN B-CHEM
or CC CC O
pimecrolimus NN NN B-CHEM
should MD MD O
be VB VB O
regarded VBN VBN O
as IN IN O
a DT DT O
potential JJ JJ O
cause NN NN O
of IN IN O
rosaceiform NN NN O
dermatitis NNS NNS O
, , , O
although IN IN O
many JJ JJ O
cases NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
reported VBN VBN O
. . . O

Coenzyme NNP NNP B-CHEM
Q10 NNP NNP I-CHEM
treatment NN NN O
ameliorates NNS NNS O
acute JJ JJ O
cisplatin NN NN B-CHEM
nephrotoxicity NN NN O
in IN IN O
mice NN NN O
. . . O

The DT DT O
nephroprotective JJ JJ O
effect NN NN O
of IN IN O
coenzyme NN NN B-CHEM
Q10 NNP NNP I-CHEM
was VBD VBD O
investigated VBN VBN O
in IN IN O
mice NN NN O
with IN IN O
acute JJ JJ O
renal JJ JJ O
injury NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
i NNP NNP O
. . . O
p NN NN O
. . . O
injection NN NN O
of IN IN O
cisplatin NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

Coenzyme NNP NNP B-CHEM
Q10 NNP NNP I-CHEM
treatment NN NN O
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
was VBD VBD O
applied VBN VBN O
for IN IN O
6 CD CD O
consecutive JJ JJ O
days NNS NNS O
, , , O
starting VBG VBG O
1 CD CD O
day NN NN O
before IN IN O
cisplatin NN NN B-CHEM
administration NN NN O
. . . O

Coenzyme NNP NNP B-CHEM
Q10 NNP NNP I-CHEM
significantly RB RB O
reduced VBD VBD O
blood NN NN B-CHEM
urea JJ JJ I-CHEM
nitrogen NN NN I-CHEM
and CC CC O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
which WDT WDT O
were VBD VBD O
increased VBN VBN O
by IN IN O
cisplatin NN NN B-CHEM
. . . O

Coenzyme NNP NNP B-CHEM
Q10 NNP NNP I-CHEM
significantly RB RB O
compensated VBD VBD O
deficits NNS NNS O
in IN IN O
the DT DT O
antioxidant NN NN O
defense NN NN O
mechanisms NNS NNS O
( ( ( O
reduced VBN VBN B-CHEM
glutathione NN NN I-CHEM
level NN NN O
and CC CC O
superoxide JJ JJ B-CHEM
dismutase NN NN O
activity NN NN O
) ) ) O
, , , O
suppressed VBD VBD O
lipid JJ JJ O
peroxidation NN NN O
, , , O
decreased VBD VBD O
the DT DT O
elevations NNS NNS O
of IN IN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- : : O
alpha NN NN O
, , , O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
and CC CC O
platinum NN NN B-CHEM
ion NN NN O
concentration NN NN O
, , , O
and CC CC O
attenuated VBD VBD O
the DT DT O
reductions NNS NNS O
of IN IN O
selenium NN NN B-CHEM
and CC CC O
zinc NN NN B-CHEM
ions NNS NNS O
in IN IN O
renal JJ JJ O
tissue NN NN O
resulted VBD VBD O
from IN IN O
cisplatin NN NN B-CHEM
administration NN NN O
. . . O

Also RB RB O
, , , O
histopathological JJ JJ O
renal NN NN O
tissue NN NN O
damage NN NN O
mediated VBN VBN O
by IN IN O
cisplatin NN NN B-CHEM
was VBD VBD O
ameliorated VBN VBN O
by IN IN O
coenzyme NN NN B-CHEM
Q10 NNP NNP I-CHEM
treatment NN NN O
. . . O

Immunohistochemical NNP NNP O
analysis NN NN O
revealed VBD VBD O
that IN IN O
coenzyme NN NN B-CHEM
Q10 NNP NNP I-CHEM
significantly RB RB O
decreased VBD VBD O
the DT DT O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
overexpression NN NN O
of IN IN O
inducible JJ JJ O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
, , , O
nuclear JJ JJ O
factor NN NN O
- : : O
kappaB NN NN O
, , , O
caspase NN NN O
- : : O
3 CD CD O
and CC CC O
p53 NN NN O
in IN IN O
renal JJ JJ O
tissue NN NN O
. . . O

It PRP PRP O
was VBD VBD O
concluded VBN VBN O
that IN IN O
coenzyme NN NN B-CHEM
Q10 NNP NNP I-CHEM
represents VBZ VBZ O
a DT DT O
potential JJ JJ O
therapeutic JJ JJ O
option NN NN O
to TO TO O
protect VB VB O
against IN IN O
acute JJ JJ O
cisplatin NN NN B-CHEM
nephrotoxicity NN NN O
commonly RB RB O
encountered VBD VBD O
in IN IN O
clinical JJ JJ O
practice NN NN O
. . . O

Reversible NNP NNP O
cholestasis NN NN O
with IN IN O
bile NN NN O
duct NN NN O
injury NN NN O
following VBG VBG O
azathioprine NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
case NN NN O
report NN NN O
. . . O

A DT DT O
67 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
, , , O
with IN IN O
primary JJ JJ O
polymyositis NNS NNS O
and CC CC O
without IN IN O
previous JJ JJ O
evidence NN NN O
of IN IN O
liver NN NN O
disease NN NN O
, , , O
developed VBN VBN O
clinical JJ JJ O
and CC CC O
biochemical JJ JJ O
features NNS NNS O
of IN IN O
severe JJ JJ O
cholestasis NN NN O
3 CD CD O
months NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
azathioprine NN NN B-CHEM
therapy NN NN O
. . . O

Liver NNP NNP O
biopsy NN NN O
showed VBD VBD O
cholestasis NNS NNS O
with IN IN O
both DT DT O
cytological JJ JJ O
and CC CC O
architectural JJ JJ O
alterations NNS NNS O
of IN IN O
interlobular JJ JJ O
bile NN NN O
ducts NNS NNS O
. . . O

Azathioprine NNP NNP B-CHEM
withdrawal NN NN O
resulted VBD VBD O
after IN IN O
7 CD CD O
weeks NNS NNS O
in IN IN O
the DT DT O
resolution NN NN O
of IN IN O
clinical JJ JJ O
and CC CC O
biochemical JJ JJ O
abnormalities NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
believed VBN VBN O
that IN IN O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
reversible JJ JJ O
azathioprine NN NN B-CHEM
- - - O
induced JJ JJ O
cholestasis NN NN O
associated VBN VBN O
with IN IN O
histological JJ JJ O
evidence NN NN O
of IN IN O
bile JJ JJ O
duct NN NN O
injury NN NN O
. . . O

Dopamine NNP NNP B-CHEM
is VBZ VBZ O
not RB RB O
essential JJ JJ O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
neurotoxicity NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
widely RB RB O
believed VBN VBN O
that IN IN O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
mediates NNS NNS O
methamphetamine NN NN B-CHEM
( ( ( O
METH NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
toxicity NN NN O
to TO TO O
brain VB VB O
dopaminergic JJ JJ O
neurons NNS NNS O
, , , O
because IN IN O
drugs NNS NNS O
that WDT WDT O
interfere NN NN O
with IN IN O
DA NNP NNP B-CHEM
neurotransmission NN NN O
decrease NN NN O
toxicity NN NN O
, , , O
whereas IN IN O
drugs NNS NNS O
that WDT WDT O
increase NN NN O
DA NNP NNP B-CHEM
neurotransmission NN NN O
enhance NN NN O
toxicity NN NN O
. . . O

However RB RB O
, , , O
temperature NN NN O
effects NNS NNS O
of IN IN O
drugs NNS NNS O
that WDT WDT O
have VBP VBP O
been VBN VBN O
used VBN VBN O
to TO TO O
manipulate VB VB O
brain NN NN O
DA NNP NNP B-CHEM
neurotransmission NN NN O
confound NN NN O
interpretation NN NN O
of IN IN O
the DT DT O
data NNS NNS O
. . . O

Here RB RB O
we PRP PRP O
show VBP VBP O
that IN IN O
the DT DT O
recently RB RB O
reported VBN VBN O
ability NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
dihydroxyphenylalanine NN NN I-CHEM
to TO TO O
reverse VB VB O
the DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
para NN NN I-CHEM
- - - I-CHEM
tyrosine NN NN I-CHEM
on IN IN O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
DA NNP NNP B-CHEM
neurotoxicity NN NN O
is VBZ VBZ O
also RB RB O
confounded VBN VBN O
by IN IN O
drug NN NN O
effects NNS NNS O
on IN IN O
body NN NN O
temperature NN NN O
. . . O

Further RB RB O
, , , O
we PRP PRP O
show VBP VBP O
that IN IN O
mice NNS NNS O
genetically RB RB O
engineered VBN VBN O
to TO TO O
be VB VB O
deficient NN NN O
in IN IN O
brain NN NN O
DA NNP NNP B-CHEM
develop FW FW O
METH NNP NNP B-CHEM
neurotoxicity NN NN O
, , , O
as RB RB O
long RB RB O
as IN IN O
the DT DT O
thermic JJ JJ O
effects NNS NNS O
of IN IN O
METH NNP NNP B-CHEM
are VBP VBP O
preserved VBN VBN O
. . . O

In IN IN O
addition NN NN O
, , , O
we PRP PRP O
demonstrate VBP VBP O
that IN IN O
mice NNS NNS O
genetically RB RB O
engineered VBN VBN O
to TO TO O
have VB VB O
unilateral JJ JJ O
brain NN NN O
DA NNP NNP B-CHEM
deficits NNS NNS O
develop VB VB O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
dopaminergic JJ JJ O
deficits NNS NNS O
that WDT WDT O
are VBP VBP O
of IN IN O
comparable JJ JJ O
magnitude NN NN O
on IN IN O
both DT DT O
sides NNS NNS O
of IN IN O
the DT DT O
brain NN NN O
. . . O

Taken VBN VBN O
together RB RB O
, , , O
these DT DT O
findings NNS NNS O
demonstrate VBP VBP O
that IN IN O
DA NNP NNP B-CHEM
is VBZ VBZ O
not RB RB O
essential JJ JJ O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
dopaminergic JJ JJ O
neurotoxicity NN NN O
and CC CC O
suggest VB VB O
that IN IN O
mechanisms NNS NNS O
independent NN NN O
of IN IN O
DA NNP NNP B-CHEM
warrant NN NN O
more JJR JJR O
intense JJ JJ O
investigation NN NN O
. . . O

Swallowing VBG VBG O
- - - O
induced JJ JJ O
atrial NN NN O
tachyarrhythmia NN NN O
triggered VBN VBN O
by IN IN O
salbutamol NN NN B-CHEM
: : : O
case NN NN O
report NN NN O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

CASE NN NN O
: : : O
A DT DT O
49 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
experienced VBN VBN O
chest NN NN O
discomfort NN NN O
while IN IN O
swallowing VBG VBG O
. . . O

On IN IN O
electrocardiogram NN NN O
, , , O
episodes NNS NNS O
of IN IN O
atrial JJ JJ O
tachyarrhythmia NN NN O
were VBD VBD O
recorded VBN VBN O
immediately RB RB O
after IN IN O
swallowing VBG VBG O
; : : O
24 CD CD O
- : : O
hour NN NN O
Holter NNP NNP O
monitoring VBG VBG O
recorded VBN VBN O
several JJ JJ O
events NNS NNS O
. . . O

The DT DT O
arrhythmia NN NN O
resolved VBD VBD O
after IN IN O
therapy NN NN O
with IN IN O
atenolol NN NN B-CHEM
, , , O
but CC CC O
recurred VBD VBD O
a DT DT O
year NN NN O
later RB RB O
. . . O

The DT DT O
patient NN NN O
noticed VBD VBD O
that IN IN O
before IN IN O
these DT DT O
episodes NNS NNS O
he PRP PRP O
had VBD VBD O
been VBN VBN O
using VBG VBG O
an DT DT O
inhalator NN NN O
of IN IN O
salbutamol NN NN B-CHEM
. . . O

After IN IN O
stopping VBG VBG O
the DT DT O
beta NN NN O
- - - O
agonist NN NN O
, , , O
and CC CC O
after IN IN O
a DT DT O
week NN NN O
with IN IN O
the DT DT O
atenolol NN NN B-CHEM
, , , O
the DT DT O
arrhythmia NN NN O
disappeared VBD VBD O
. . . O

DISCUSSION NNP NNP O
: : : O
Swallowing VBG VBG O
- - - O
induced JJ JJ O
atrial NN NN O
tachyarrhythmia NN NN O
( ( ( O
SIAT NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
phenomenon NN NN O
. . . O

Fewer JJR JJR O
than IN IN O
50 CD CD O
cases NNS NNS O
of IN IN O
SIAT NNP NNP O
have VBP VBP O
been VBN VBN O
described VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

This DT DT O
article NN NN O
summarizes NNS NNS O
all PDT PDT O
the DT DT O
cases NNS NNS O
published VBN VBN O
, , , O
creating VBG VBG O
a DT DT O
comprehensive JJ JJ O
review NN NN O
of IN IN O
the DT DT O
current JJ JJ O
knowledge NN NN O
and CC CC O
approach NN NN O
to TO TO O
SIAT NNP NNP O
. . . O

It PRP PRP O
discusses NNS NNS O
demographics NNS NNS O
, , , O
clinical JJ JJ O
characteristics NNS NNS O
and CC CC O
types NNS NNS O
of IN IN O
arrhythmia NN NN O
, , , O
postulated JJ JJ O
mechanisms NNS NNS O
of IN IN O
SIAT NNP NNP O
, , , O
and CC CC O
different JJ JJ O
treatment NN NN O
possibilities NNS NNS O
such JJ JJ O
as IN IN O
medications NNS NNS O
, , , O
surgery NN NN O
, , , O
and CC CC O
radiofrequency NN NN O
catheter NN NN O
ablation NN NN O
( ( ( O
RFCA NNP NNP O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Salbutamol NNP NNP B-CHEM
is VBZ VBZ O
presented VBN VBN O
here RB RB O
as IN IN O
a DT DT O
possible JJ JJ O
trigger NN NN O
for IN IN O
SIAT NNP NNP O
. . . O

Although IN IN O
it PRP PRP O
is VBZ VBZ O
difficult JJ JJ O
to TO TO O
define VB VB O
causality NN NN O
in IN IN O
a DT DT O
case NN NN O
report NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
logical JJ JJ O
to TO TO O
think VB VB O
that IN IN O
a DT DT O
beta NN NN O
- - - O
agonist NN NN O
like IN IN O
salbutamol NN NN B-CHEM
( ( ( O
known VBN VBN O
to TO TO O
induce VB VB O
tachycardia NNS NNS O
) ) ) O
may MD MD O
be VB VB O
the DT DT O
trigger NN NN O
of IN IN O
adrenergic JJ JJ O
reflexes NNS NNS O
originating VBG VBG O
in IN IN O
the DT DT O
esophagus NN NN O
while IN IN O
swallowing VBG VBG O
and CC CC O
that IN IN O
a DT DT O
beta NN NN O
- - - O
blocker NN NN O
such JJ JJ O
as IN IN O
atenolol NN NN B-CHEM
( ( ( O
that IN IN O
blocks NNS NNS O
the DT DT O
adrenergic JJ JJ O
activity NN NN O
) ) ) O
may MD MD O
relieve VB VB O
it PRP PRP O
. . . O

The DT DT O
ability NN NN O
of IN IN O
insulin NN NN O
treatment NN NN O
to TO TO O
reverse VB VB O
or CC CC O
prevent VB VB O
the DT DT O
changes NNS NNS O
in IN IN O
urinary JJ JJ O
bladder NN NN O
function NN NN O
caused VBN VBN O
by IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NN NN O
mellitus NN NN O
. . . O

1 CD CD O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
insulin NN NN O
treatment NN NN O
on IN IN O
in IN IN O
vivo NN NN O
and CC CC O
in IN IN O
vitro NN NN O
urinary JJ JJ O
bladder NN NN O
function NN NN O
in IN IN O
streptozotocin NN NN B-CHEM
- - - O
diabetic JJ JJ O
rats NNS NNS O
were VBD VBD O
investigated VBN VBN O
. . . O

2 CD CD O
. . . O

Diabetes NNP NNP O
of IN IN O
2 CD CD O
months NNS NNS O
duration NN NN O
resulted VBD VBD O
in IN IN O
decreases NNS NNS O
in IN IN O
body NN NN O
weight NN NN O
and CC CC O
increases NNS NNS O
in IN IN O
fluid JJ JJ O
consumption NN NN O
, , , O
urine NN NN O
volume NN NN O
, , , O
frequency NN NN O
of IN IN O
micturition NN NN O
, , , O
and CC CC O
average JJ JJ O
volume NN NN O
per IN IN O
micturition NN NN O
; : : O
effects NNS NNS O
which WDT WDT O
were VBD VBD O
prevented VBN VBN O
by IN IN O
insulin NN NN O
treatment NN NN O
. . . O

3 CD CD O
. . . O

Insulin NNP NNP O
treatment NN NN O
also RB RB O
prevented VBD VBD O
the DT DT O
increases NNS NNS O
in IN IN O
contractile NN NN O
responses NNS NNS O
of IN IN O
bladder NN NN O
body NN NN O
strips NNS NNS O
from IN IN O
diabetic JJ JJ O
rats NNS NNS O
to TO TO O
nerve VB VB O
stimulation NN NN O
, , , O
ATP NNP NNP B-CHEM
, , , O
and CC CC O
bethanechol NN NN B-CHEM
. . . O

4 CD CD O
. . . O

Diabetes NNP NNP O
of IN IN O
4 CD CD O
months NNS NNS O
duration NN NN O
also RB RB O
resulted VBD VBD O
in IN IN O
decreases NNS NNS O
in IN IN O
body NN NN O
weight NN NN O
, , , O
and CC CC O
increases NNS NNS O
in IN IN O
fluid JJ JJ O
consumption NN NN O
, , , O
urine NN NN O
volume NN NN O
, , , O
frequency NN NN O
of IN IN O
micturition NN NN O
, , , O
and CC CC O
average JJ JJ O
volume NN NN O
per IN IN O
micturition NN NN O
, , , O
effects NNS NNS O
which WDT WDT O
were VBD VBD O
reversed VBN VBN O
by IN IN O
insulin NN NN O
treatment NN NN O
for IN IN O
the DT DT O
final JJ JJ O
2 CD CD O
months NNS NNS O
of IN IN O
the DT DT O
study NN NN O
. . . O

5 CD CD O
. . . O

Insulin NNP NNP O
treatment NN NN O
reversed VBD VBD O
the DT DT O
increases NNS NNS O
in IN IN O
contractile NN NN O
responses NNS NNS O
of IN IN O
bladder NN NN O
body NN NN O
strips NNS NNS O
from IN IN O
diabetic JJ JJ O
rats NNS NNS O
to TO TO O
nerve VB VB O
stimulation NN NN O
, , , O
ATP NNP NNP B-CHEM
, , , O
and CC CC O
bethanechol NN NN B-CHEM
. . . O

6 CD CD O
. . . O

The DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
on IN IN O
urinary JJ JJ O
bladder NN NN O
function NN NN O
are VBP VBP O
both DT DT O
prevented VBN VBN O
and CC CC O
reversed VBN VBN O
by IN IN O
insulin NN NN O
treatment NN NN O
. . . O

Glutamatergic NNP NNP O
neurotransmission NN NN O
mediated VBN VBN O
by IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
in IN IN O
the DT DT O
inferior JJ JJ O
colliculus NN NN O
can MD MD O
modulate VB VB O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
. . . O

The DT DT O
inferior JJ JJ O
colliculus NN NN O
( ( ( O
IC NNP NNP O
) ) ) O
is VBZ VBZ O
primarily RB RB O
involved VBN VBN O
in IN IN O
the DT DT O
processing NN NN O
of IN IN O
auditory JJ JJ O
information NN NN O
, , , O
but CC CC O
it PRP PRP O
is VBZ VBZ O
distinguished VBN VBN O
from IN IN O
other JJ JJ O
auditory NN NN O
nuclei NN NN O
in IN IN O
the DT DT O
brainstem NN NN O
by IN IN O
its PRP$ PRP$ O
connections NNS NNS O
with IN IN O
structures NNS NNS O
of IN IN O
the DT DT O
motor NN NN O
system NN NN O
. . . O

Functional NNP NNP O
evidence NN NN O
relating VBG VBG O
the DT DT O
IC NNP NNP O
to TO TO O
motor NN NN O
behavior NN NN O
derives VBZ VBZ O
from IN IN O
experiments NNS NNS O
showing VBG VBG O
that DT DT O
activation NN NN O
of IN IN O
the DT DT O
IC NNP NNP O
by IN IN O
electrical JJ JJ O
stimulation NN NN O
or CC CC O
excitatory NN NN O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
microinjection NN NN O
causes NNS NNS O
freezing NN NN O
, , , O
escape NN NN O
- - - O
like IN IN O
behavior NN NN O
, , , O
and CC CC O
immobility NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
nature NN NN O
of IN IN O
this DT DT O
immobility NN NN O
is VBZ VBZ O
still RB RB O
unclear JJ JJ O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
examined VBD VBD O
the DT DT O
influence NN NN O
of IN IN O
excitatory JJ JJ O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
mediated JJ JJ O
mechanisms NNS NNS O
in IN IN O
the DT DT O
IC NNP NNP O
on IN IN O
the DT DT O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
the DT DT O
dopamine NN NN B-CHEM
receptor NN NN O
blocker NN NN O
haloperidol NN NN B-CHEM
administered VBN VBN O
systemically RB RB O
( ( ( O
1 CD CD O
or CC CC O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
rats NNS NNS O
. . . O

Haloperidol NNP NNP B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
was VBD VBD O
challenged VBN VBN O
with IN IN O
prior RB RB O
intracollicular JJ JJ O
microinjections NNS NNS O
of IN IN O
glutamate NN NN B-CHEM
NMDA NNP NNP B-CHEM
receptor NN NN O
antagonists NNS NNS O
, , , O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
( ( ( O
15 CD CD O
or CC CC O
30 CD CD O
mmol NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
) ) ) O
and CC CC O
AP7 NNP NNP B-CHEM
( ( ( O
10 CD CD O
or CC CC O
20 CD CD O
nmol NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
) ) ) O
, , , O
or CC CC O
of IN IN O
the DT DT O
NMDA NNP NNP B-CHEM
receptor NN NN O
agonist NN NN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
d SYM SYM I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
, , , O
20 CD CD O
or CC CC O
30 CD CD O
nmol NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
) ) ) O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
that IN IN O
intracollicular JJ JJ O
microinjection NN NN O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
and CC CC O
AP7 NNP NNP B-CHEM
previous JJ JJ O
to TO TO O
systemic JJ JJ O
injections NNS NNS O
of IN IN O
haloperidol NN NN B-CHEM
significantly RB RB O
attenuated VBD VBD O
the DT DT O
catalepsy NN NN O
, , , O
as IN IN O
indicated VBN VBN O
by IN IN O
a DT DT O
reduced JJ JJ O
latency NN NN O
to TO TO O
step VB VB O
down RB RB O
from IN IN O
a DT DT O
horizontal NN NN O
bar NN NN O
. . . O

Accordingly RB RB O
, , , O
intracollicular JJ JJ O
microinjection NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
increased VBD VBD O
the DT DT O
latency NN NN O
to TO TO O
step VB VB O
down RP RP O
the DT DT O
bar NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
glutamate NN NN B-CHEM
- - - O
mediated JJ JJ O
mechanisms NNS NNS O
in IN IN O
the DT DT O
neural NN NN O
circuits NNS NNS O
at IN IN O
the DT DT O
IC NNP NNP O
level NN NN O
influence NN NN O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
and CC CC O
participate VB VB O
in IN IN O
the DT DT O
regulation NN NN O
of IN IN O
motor NN NN O
activity NN NN O
. . . O

Severe NNP NNP O
congestive JJ JJ O
heart NN NN O
failure NN NN O
patient NN NN O
on IN IN O
amiodarone NN NN B-CHEM
presenting VBG VBG O
with IN IN O
myxedemic JJ JJ O
coma NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

This DT DT O
is VBZ VBZ O
a DT DT O
case NN NN O
report NN NN O
of IN IN O
myxedema NN NN O
coma NN NN O
secondary JJ JJ O
to TO TO O
amiodarone VB VB B-CHEM
- - - O
induced JJ JJ O
hypothyroidism NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
severe JJ JJ O
congestive JJ JJ O
heart NN NN O
failure NN NN O
( ( ( O
CHF NNP NNP O
) ) ) O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
and CC CC O
after IN IN O
reviewing VBG VBG O
the DT DT O
literature NN NN O
there EX EX O
is VBZ VBZ O
one CD CD O
case NN NN O
report NN NN O
of IN IN O
myxedema NN NN O
coma NN NN O
during IN IN O
long JJ JJ O
term NN NN O
amiodarone NN NN B-CHEM
therapy NN NN O
. . . O

Myxedema NNP NNP O
coma NN NN O
is VBZ VBZ O
a DT DT O
life NN NN O
threatening VBG VBG O
condition NN NN O
that IN IN O
carries VBZ VBZ O
a DT DT O
mortality NN NN O
reaching VBG VBG O
as RB RB O
high JJ JJ O
as IN IN O
20 CD CD O
% NN NN O
with IN IN O
treatment NN NN O
. . . O

The DT DT O
condition NN NN O
is VBZ VBZ O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
thyroxine NN NN B-CHEM
( ( ( O
T4 NNP NNP B-CHEM
) ) ) O
or CC CC O
intravenous JJ JJ O
tri NN NN B-CHEM
- - - I-CHEM
iodo NN NN I-CHEM
- - - I-CHEM
thyronine NN NN I-CHEM
( ( ( O
T3 NNP NNP B-CHEM
) ) ) O
. . . O

Patients NNS NNS O
with IN IN O
CHF NNP NNP O
on IN IN O
amiodarone NN NN B-CHEM
may MD MD O
suffer VB VB O
serious JJ JJ O
morbidity NN NN O
and CC CC O
mortality NN NN O
from IN IN O
hypothyroidism NN NN O
, , , O
and CC CC O
thus RB RB O
may MD MD O
deserve VB VB O
closer JJR JJR O
follow VB VB O
up RP RP O
for IN IN O
thyroid NN NN O
stimulating VBG VBG O
hormone NN NN O
( ( ( O
TSH NNP NNP O
) ) ) O
levels NNS NNS O
. . . O

This DT DT O
case NN NN O
report NN NN O
carries VBZ VBZ O
an DT DT O
important JJ JJ O
clinical JJ JJ O
application NN NN O
given VBN VBN O
the DT DT O
frequent JJ JJ O
usage NN NN O
of IN IN O
amiodarone NN NN B-CHEM
among IN IN O
CHF NNP NNP O
patients NNS NNS O
. . . O

The DT DT O
myriad JJ JJ O
clinical JJ JJ O
presentation NN NN O
of IN IN O
myxedema NN NN O
coma NN NN O
and CC CC O
its PRP$ PRP$ O
serious JJ JJ O
morbidity NN NN O
and CC CC O
mortality NN NN O
stresses VBZ VBZ O
the DT DT O
need NN NN O
to TO TO O
suspect VB VB O
this DT DT O
clinical JJ JJ O
syndrome NN NN O
among IN IN O
CHF NNP NNP O
patients NNS NNS O
presenting VBG VBG O
with IN IN O
hypotension NN NN O
, , , O
weakness NN NN O
or CC CC O
other JJ JJ O
unexplained JJ JJ O
symptoms NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
active JJ JJ O
constituents NNS NNS O
of IN IN O
Crocus NNP NNP O
sativus NN NN O
L NNP NNP O
. . . O
, , , O
crocin NN NN B-CHEM
on IN IN O
streptozocin NN NN B-CHEM
- : : O
induced JJ JJ O
model NN NN O
of IN IN O
sporadic JJ JJ O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
involvement NN NN O
of IN IN O
water NN NN O
- - - O
soluble JJ JJ O
carotenoids NNS NNS B-CHEM
, , , O
crocins NNS NNS B-CHEM
, , , O
as IN IN O
the DT DT O
main JJ JJ O
and CC CC O
active JJ JJ O
components NNS NNS O
of IN IN O
Crocus NNP NNP O
sativus NN NN O
L NNP NNP O
. . . O
extract NN NN O
in IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
processes NNS NNS O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
effect NN NN O
of IN IN O
crocins NNS NNS B-CHEM
on IN IN O
sporadic JJ JJ O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
induced VBN VBN O
by IN IN O
intracerebroventricular JJ JJ O
( ( ( O
icv NN NN O
) ) ) O
streptozocin NN NN B-CHEM
( ( ( O
STZ NNP NNP B-CHEM
) ) ) O
in IN IN O
male JJ JJ O
rats NNS NNS O
was VBD VBD O
investigated VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
adult NN NN O
Wistar NNP NNP O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
90 CD CD O
and CC CC O
260 CD CD O
- : : O
290 CD CD O
g SYM SYM O
) ) ) O
were VBD VBD O
divided VBN VBN O
into IN IN O
1 CD CD O
, , , O
control NN NN O
; : : O
2 CD CD O
and CC CC O
3 CD CD O
, , , O
crocins NNS NNS B-CHEM
( ( ( O
15 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
; : : O
4 CD CD O
, , , O
STZ NNP NNP B-CHEM
; : : O
5 CD CD O
and CC CC O
6 CD CD O
, , , O
STZ NNP NNP B-CHEM
+ NN NN O
crocins NNS NNS B-CHEM
( ( ( O
15 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
groups NNS NNS O
. . . O

In IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
groups NNS NNS O
, , , O
rats NNS NNS O
were VBD VBD O
injected VBN VBN O
with IN IN O
STZ NNP NNP B-CHEM
- : : O
icv NN NN O
bilaterally RB RB O
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
first JJ JJ O
day NN NN O
and CC CC O
3 CD CD O
days NNS NNS O
later RB RB O
, , , O
a DT DT O
similar JJ JJ O
STZ NNP NNP B-CHEM
- : : O
icv NN NN O
application NN NN O
was VBD VBD O
repeated VBN VBN O
. . . O

In IN IN O
STZ NNP NNP B-CHEM
+ NN NN O
crocin JJ JJ B-CHEM
animal NN NN O
groups NNS NNS O
, , , O
crocin NN NN B-CHEM
was VBD VBD O
applied VBN VBN O
in IN IN O
doses NNS NNS O
of IN IN O
15 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
one CD CD O
day NN NN O
pre NN NN O
- : : O
surgery NN NN O
and CC CC O
continued VBD VBD O
for IN IN O
three CD CD O
weeks NNS NNS O
. . . O

Prescription NNP NNP O
of IN IN O
crocin NN NN B-CHEM
in IN IN O
each DT DT O
dose NN NN O
was VBD VBD O
repeated VBN VBN O
once RB RB O
for IN IN O
two CD CD O
days NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
learning VBG VBG O
and CC CC O
memory NN NN O
performance NN NN O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
passive JJ JJ O
avoidance NN NN O
paradigm NN NN O
, , , O
and CC CC O
for IN IN O
spatial JJ JJ O
cognition NN NN O
evaluation NN NN O
, , , O
Y NNP NNP O
- : : O
maze NN NN O
task NN NN O
was VBD VBD O
used VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
It PRP PRP O
was VBD VBD O
found VBN VBN O
out IN IN O
that IN IN O
crocin NN NN B-CHEM
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
- : : O
treated VBN VBN O
STZ NNP NNP B-CHEM
- - - O
injected JJ JJ O
rats NNS NNS O
show VBP VBP O
higher JJR JJR O
correct JJ JJ O
choices NNS NNS O
and CC CC O
lower JJR JJR O
errors NNS NNS O
in IN IN O
Y NNP NNP O
- : : O
maze NN NN O
than IN IN O
vehicle NN NN O
- - - O
treated VBN VBN O
STZ NNP NNP B-CHEM
- - - O
injected JJ JJ O
rats NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
crocin NN NN B-CHEM
in IN IN O
the DT DT O
mentioned VBN VBN O
dose NN NN O
could MD MD O
significantly RB RB O
attenuated VBD VBD O
learning VBG VBG O
and CC CC O
memory NN NN O
impairment NN NN O
in IN IN O
treated VBN VBN O
STZ NNP NNP B-CHEM
- - - O
injected JJ JJ O
group NN NN O
in IN IN O
passive JJ JJ O
avoidance NN NN O
test NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Therefore RB RB O
, , , O
these DT DT O
results NNS NNS O
demonstrate VBP VBP O
the DT DT O
effectiveness NN NN O
of IN IN O
crocin NN NN B-CHEM
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
antagonizing VBG VBG O
the DT DT O
cognitive JJ JJ O
deficits NNS NNS O
caused VBN VBN O
by IN IN O
STZ NNP NNP B-CHEM
- : : O
icv NN NN O
in IN IN O
rats NNS NNS O
and CC CC O
its PRP$ PRP$ O
potential JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
neurodegenerative JJ JJ O
diseases NNS NNS O
such JJ JJ O
as IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Serotonin NNP NNP B-CHEM
6 CD CD O
receptor NN NN O
gene NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
psychosis NN NN O
in IN IN O
a DT DT O
Japanese JJ JJ O
population NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Altered NNP NNP O
serotonergic JJ JJ O
neural NN NN O
transmission NN NN O
is VBZ VBZ O
hypothesized VBN VBN O
to TO TO O
be VB VB O
a DT DT O
susceptibility NN NN O
factor NN NN O
for IN IN O
psychotic JJ JJ O
disorders NNS NNS O
such JJ JJ O
as IN IN O
schizophrenia NN NN O
. . . O

The DT DT O
serotonin NN NN B-CHEM
6 CD CD O
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HT6 NNP NNP I-CHEM
) ) ) O
receptor NN NN O
is VBZ VBZ O
therapeutically RB RB O
targeted VBN VBN O
by IN IN O
several JJ JJ O
second JJ JJ O
generation NN NN O
antipsychotics NNS NNS O
, , , O
such JJ JJ O
as IN IN O
clozapine NN NN B-CHEM
and CC CC O
olanzapine NN NN B-CHEM
, , , O
and CC CC O
d SYM SYM B-CHEM
- : : I-CHEM
amphetamine NN NN I-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
in IN IN O
rats NNS NNS O
is VBZ VBZ O
corrected VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
a DT DT O
selective JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT6 NNP NNP I-CHEM
receptor NN NN O
antagonist NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
disrupted JJ JJ O
prepulse NN NN O
inhibition NN NN O
induced VBN VBN O
by IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
amphetamine NN NN I-CHEM
or CC CC O
phencyclidine NN NN B-CHEM
was VBD VBD O
restored VBN VBN O
by IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HT6 NNP NNP I-CHEM
receptor NN NN O
antagonist NN NN O
in IN IN O
an DT DT O
animal NN NN O
study NN NN O
using VBG VBG O
rats NNS NNS O
. . . O

These DT DT O
animal NN NN O
models NNS NNS O
were VBD VBD O
considered VBN VBN O
to TO TO O
reflect VB VB O
the DT DT O
positive JJ JJ O
symptoms NNS NNS O
of IN IN O
schizophrenia NN NN O
, , , O
and CC CC O
the DT DT O
above JJ JJ O
evidence NN NN O
suggests VBZ VBZ O
that IN IN O
altered VBN VBN O
5 CD CD B-CHEM
- : : I-CHEM
HT6 NNP NNP I-CHEM
receptors NNS NNS O
are VBP VBP O
involved VBN VBN O
in IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
psychotic JJ JJ O
disorders NNS NNS O
. . . O

The DT DT O
symptoms NNS NNS O
of IN IN O
methamphetamine NN NN B-CHEM
( ( ( O
METH NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
psychosis NNS NNS O
are VBP VBP O
similar JJ JJ O
to TO TO O
those DT DT O
of IN IN O
paranoid NN NN O
type NN NN O
schizophrenia NN NN O
. . . O

Therefore RB RB O
, , , O
we PRP PRP O
conducted VBD VBD O
an DT DT O
analysis NN NN O
of IN IN O
the DT DT O
association NN NN O
of IN IN O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT6 NNP NNP I-CHEM
gene NN NN O
( ( ( O
HTR6 NNP NNP O
) ) ) O
with IN IN O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
psychosis NN NN O
. . . O

METHOD NNP NNP O
: : : O
Using VBG VBG O
five CD CD O
tagging VBG VBG O
SNPs NNP NNP O
( ( ( O
rs6693503 NN NN O
, , , O
rs1805054 NN NN O
, , , O
rs4912138 NN NN O
, , , O
rs3790757 NN NN O
and CC CC O
rs9659997 NN NN O
) ) ) O
, , , O
we PRP PRP O
conducted VBD VBD O
a DT DT O
genetic JJ JJ O
association NN NN O
analysis NN NN O
of IN IN O
case NN NN O
- - - O
control NN NN O
samples NNS NNS O
( ( ( O
197 CD CD O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
psychosis NN NN O
patients NNS NNS O
and CC CC O
337 CD CD O
controls NNS NNS O
) ) ) O
in IN IN O
the DT DT O
Japanese JJ JJ O
population NN NN O
. . . O

The DT DT O
age NN NN O
and CC CC O
sex NN NN O
of IN IN O
the DT DT O
control NN NN O
subjects NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
from IN IN O
those DT DT O
of IN IN O
the DT DT O
methamphetamine NN NN B-CHEM
dependence NN NN O
patients NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
rs6693503 NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
psychosis NN NN O
patients NNS NNS O
in IN IN O
the DT DT O
allele NN NN O
/ NN NN O
genotype NN NN O
- - - O
wise JJ JJ O
analysis NN NN O
. . . O

Moreover RB RB O
, , , O
this DT DT O
association NN NN O
remained VBD VBD O
significant JJ JJ O
after IN IN O
Bonferroni NNP NNP O
correction NN NN O
. . . O

In IN IN O
the DT DT O
haplotype NN NN O
- - - O
wise JJ JJ O
analysis NN NN O
, , , O
we PRP PRP O
detected VBD VBD O
an DT DT O
association NN NN O
between IN IN O
two CD CD O
markers NNS NNS O
( ( ( O
rs6693503 NN NN O
and CC CC O
rs1805054 NN NN O
) ) ) O
and CC CC O
three CD CD O
markers NNS NNS O
( ( ( O
rs6693503 NN NN O
, , , O
rs1805054 NN NN O
and CC CC O
rs4912138 NN NN O
) ) ) O
in IN IN O
HTR6 NNP NNP O
and CC CC O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
psychosis NN NN O
patients NNS NNS O
, , , O
respectively RB RB O
. . . O

CONCLUSION NNP NNP O
: : : O
HTR6 NNP NNP O
may MD MD O
play VB VB O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
METH NNP NNP B-CHEM
- : : O
induced JJ JJ O
psychosis NN NN O
in IN IN O
the DT DT O
Japanese JJ JJ O
population NN NN O
. . . O

Neural NNP NNP O
correlates NNS NNS O
of IN IN O
S NNP NNP B-CHEM
- - - I-CHEM
ketamine NN NN I-CHEM
induced VBD VBD O
psychosis NNS NNS O
during IN IN O
overt NN NN O
continuous JJ JJ O
verbal NN NN O
fluency NN NN O
. . . O

The DT DT O
glutamatergic NN NN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptor NN NN O
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
in IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
schizophrenia NN NN O
. . . O

Administered NNP NNP O
to TO TO O
healthy JJ JJ O
volunteers NNS NNS O
, , , O
a DT DT O
subanesthetic JJ JJ O
dose NN NN O
of IN IN O
the DT DT O
non NN NN O
- - - O
competitive JJ JJ O
NMDA NNP NNP B-CHEM
receptor NN NN O
antagonist NN NN O
ketamine NN NN B-CHEM
leads VBZ VBZ O
to TO TO O
psychopathological JJ JJ O
symptoms NNS NNS O
similar JJ JJ O
to TO TO O
those DT DT O
observed VBD VBD O
in IN IN O
schizophrenia NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
schizophrenia NN NN O
, , , O
ketamine NN NN B-CHEM
exacerbates VBZ VBZ O
the DT DT O
core NN NN O
symptoms NNS NNS O
of IN IN O
illness NN NN O
, , , O
supporting VBG VBG O
the DT DT O
hypothesis NNS NNS O
of IN IN O
a DT DT O
glutamatergic JJ JJ O
dysfunction NN NN O
. . . O

In IN IN O
a DT DT O
counterbalanced NN NN O
, , , O
placebo NN NN O
- - - O
controlled VBN VBN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
design NN NN O
, , , O
healthy JJ JJ O
subjects NNS NNS O
were VBD VBD O
administered VBN VBN O
a DT DT O
continuous JJ JJ O
subanesthetic JJ JJ O
S NNP NNP B-CHEM
- - - I-CHEM
ketamine NN NN I-CHEM
infusion NN NN O
while IN IN O
differences NNS NNS O
in IN IN O
BOLD NNP NNP O
responses NNS NNS O
measured VBN VBN O
with IN IN O
fMRI NN NN O
were VBD VBD O
detected VBN VBN O
. . . O

During IN IN O
the DT DT O
scanning VBG VBG O
period NN NN O
, , , O
subjects NNS NNS O
performed VBN VBN O
continuous JJ JJ O
overt NN NN O
verbal JJ JJ O
fluency NN NN O
tasks NNS NNS O
( ( ( O
phonological JJ JJ O
, , , O
lexical JJ JJ O
and CC CC O
semantic JJ JJ O
) ) ) O
. . . O

Ketamine NNP NNP B-CHEM
- : : O
induced JJ JJ O
psychopathological JJ JJ O
symptoms NNS NNS O
were VBD VBD O
assessed VBN VBN O
with IN IN O
the DT DT O
Positive JJ JJ O
and CC CC O
Negative NNP NNP O
Syndrome NN NN O
Scale NNP NNP O
( ( ( O
PANSS NNP NNP O
) ) ) O
. . . O

Ketamine NNP NNP B-CHEM
elicited VBD VBD O
psychosis NN NN O
like IN IN O
psychopathology NN NN O
. . . O

Post NNP NNP O
- : : O
hoc NN NN O
t NN NN O
- - - O
tests NNS NNS O
revealed VBD VBD O
significant JJ JJ O
differences NNS NNS O
between IN IN O
placebo NN NN O
and CC CC O
ketamine NN NN B-CHEM
for IN IN O
the DT DT O
amounts NNS NNS O
of IN IN O
words NNS NNS O
generated VBN VBN O
during IN IN O
lexical JJ JJ O
and CC CC O
semantic JJ JJ O
verbal NN NN O
fluency NN NN O
, , , O
while IN IN O
the DT DT O
phonological JJ JJ O
domain NN NN O
remained VBD VBD O
unaffected JJ JJ O
. . . O

Ketamine NNP NNP B-CHEM
led VBD VBD O
to TO TO O
enhanced VB VB O
cortical JJ JJ O
activations NNS NNS O
in IN IN O
supramarginal JJ JJ O
and CC CC O
frontal JJ JJ O
brain NN NN O
regions NNS NNS O
for IN IN O
phonological JJ JJ O
and CC CC O
lexical JJ JJ O
verbal NN NN O
fluency NN NN O
, , , O
but CC CC O
not RB RB O
for IN IN O
semantic JJ JJ O
verbal NN NN O
fluency NN NN O
. . . O

Ketamine NNP NNP B-CHEM
induces NNS NNS O
activation NN NN O
changes NNS NNS O
in IN IN O
healthy JJ JJ O
subjects NNS NNS O
similar JJ JJ O
to TO TO O
those DT DT O
observed VBD VBD O
in IN IN O
patients NNS NNS O
with IN IN O
schizophrenia NN NN O
, , , O
particularly RB RB O
in IN IN O
frontal JJ JJ O
and CC CC O
temporal JJ JJ O
brain NN NN O
regions NNS NNS O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
provide VBP VBP O
further JJ JJ O
support NN NN O
for IN IN O
the DT DT O
hypothesis NNS NNS O
of IN IN O
an DT DT O
NMDA NNP NNP B-CHEM
receptor NN NN O
dysfunction NN NN O
in IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
schizophrenia NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
prognosis NN NN O
for IN IN O
transplant NN NN O
- - - O
free JJ JJ O
survivors NNS NNS O
of IN IN O
paracetamol NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
failure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
prognosis NN NN O
for IN IN O
transplant NN NN O
- - - O
free JJ JJ O
survivors NNS NNS O
of IN IN O
paracetamol NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
failure NN NN O
remains NNS NNS O
unknown JJ JJ O
. . . O

AIM NNP NNP O
: : : O
To TO TO O
examine VB VB O
whether IN IN O
paracetamol NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
failure NN NN O
increases NNS NNS O
long JJ JJ O
- - - O
term NN NN O
mortality NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
followed VBD VBD O
up RP RP O
all DT DT O
transplant JJ JJ O
- - - O
free JJ JJ O
survivors NNS NNS O
of IN IN O
paracetamol NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
injury NN NN O
, , , O
hospitalized VBN VBN O
in IN IN O
a DT DT O
Danish NNP NNP O
national JJ JJ O
referral NN NN O
centre NN NN O
during IN IN O
1984 CD CD O
- : : O
2004 CD CD O
. . . O

We PRP PRP O
compared VBD VBD O
age NN NN O
- - - O
specific JJ JJ O
mortality NN NN O
rates NNS NNS O
from IN IN O
1 CD CD O
year NN NN O
post NN NN O
- : : O
discharge NN NN O
through IN IN O
2008 CD CD O
between IN IN O
those DT DT O
in IN IN O
whom WP WP O
the DT DT O
liver NN NN O
injury NN NN O
led VBN VBN O
to TO TO O
an DT DT O
acute JJ JJ O
liver NN NN O
failure NN NN O
and CC CC O
those DT DT O
in IN IN O
whom WP WP O
it PRP PRP O
did VBD VBD O
not RB RB O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
included VBD VBD O
641 CD CD O
patients NNS NNS O
. . . O

On IN IN O
average JJ JJ O
, , , O
age NN NN O
- - - O
specific JJ JJ O
mortality NN NN O
rates NNS NNS O
were VBD VBD O
slightly RB RB O
higher JJR JJR O
for IN IN O
the DT DT O
101 CD CD O
patients NNS NNS O
whose WP$ WP$ O
paracetamol NN NN B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
had VBD VBD O
caused VBN VBN O
an DT DT O
acute JJ JJ O
liver NN NN O
failure NN NN O
( ( ( O
adjusted VBN VBN O
mortality NN NN O
rate NN NN O
ratio NN NN O
= SYM SYM O
1 CD CD O
. . . O
70 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
02 CD CD O
- : : O
2 CD CD O
. . . O
85 CD CD O
) ) ) O
, , , O
but CC CC O
the DT DT O
association NN NN O
was VBD VBD O
age NN NN O
- : : O
dependent NN NN O
, , , O
and CC CC O
no DT DT O
survivors NNS NNS O
of IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
died VBD VBD O
of IN IN O
liver NN NN O
disease NN NN O
, , , O
whereas IN IN O
suicides NNS NNS O
were VBD VBD O
frequent JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

These DT DT O
observations NNS NNS O
speak VBP VBP O
against IN IN O
long JJ JJ O
- - - O
term NN NN O
effects NNS NNS O
of IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
. . . O

More RBR RBR O
likely JJ JJ O
, , , O
the DT DT O
elevated JJ JJ O
mortality NN NN O
rate NN NN O
ratio NN NN O
resulted VBD VBD O
from IN IN O
incomplete JJ JJ O
adjustment NN NN O
for IN IN O
the DT DT O
greater JJR JJR O
prevalence NN NN O
of IN IN O
substance NN NN O
abuse NN NN O
among IN IN O
survivors NNS NNS O
of IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Paracetamol NNP NNP B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
failure NN NN O
did VBD VBD O
not RB RB O
affect VB VB O
long JJ JJ O
- - - O
term NN NN O
mortality NN NN O
. . . O

Clinical NNP NNP O
follow VB VB O
- - - O
up RP RP O
may MD MD O
be VB VB O
justified VBN VBN O
by IN IN O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
liver NN NN O
failure NN NN O
, , , O
but CC CC O
not RB RB O
by IN IN O
the DT DT O
liver NN NN O
failure NN NN O
itself PRP PRP O
. . . O

In IN IN O
vivo NN NN O
characterization NN NN O
of IN IN O
a DT DT O
dual JJ JJ O
adenosine NN NN B-CHEM
A2A NNP NNP I-CHEM
/ NN NN I-CHEM
A1 NNP NNP I-CHEM
receptor NN NN I-CHEM
antagonist NN NN I-CHEM
in IN IN O
animal NN NN O
models NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

The DT DT O
in IN IN O
vivo NN NN O
characterization NN NN O
of IN IN O
a DT DT O
dual JJ JJ O
adenosine NN NN B-CHEM
A DT DT I-CHEM
( ( ( I-CHEM
2A CD CD I-CHEM
) ) ) I-CHEM
/ NN NN I-CHEM
A DT DT I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
) ) ) I-CHEM
receptor NN NN I-CHEM
antagonist NN NN I-CHEM
in IN IN O
several JJ JJ O
animal NN NN O
models NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
is VBZ VBZ O
described VBN VBN O
. . . O

Discovery NNP NNP O
and CC CC O
scale NN NN O
- - - O
up RP RP O
syntheses NNS NNS O
of IN IN O
compound NN NN O
1 CD CD O
are VBP VBP O
described VBN VBN O
in IN IN O
detail NN NN O
, , , O
highlighting VBG VBG O
optimization NN NN O
steps NNS NNS O
that WDT WDT O
increased VBD VBD O
the DT DT O
overall JJ JJ O
yield NN NN O
of IN IN O
1 CD CD O
from IN IN O
10 CD CD O
. . . O
0 CD CD O
% NN NN O
to TO TO O
30 CD CD O
. . . O
5 CD CD O
% NN NN O
. . . O

Compound NNP NNP O
1 CD CD O
is VBZ VBZ O
a DT DT O
potent NN NN O
A DT DT O
( ( ( O
2A CD CD O
) ) ) O
/ NN NN O
A DT DT O
( ( ( O
1 CD CD O
) ) ) O
receptor NN NN O
antagonist NN NN O
in IN IN O
vitro NN NN O
( ( ( O
A DT DT O
( ( ( O
2A CD CD O
) ) ) O
K NNP NNP O
( ( ( O
i NNP NNP O
) ) ) O
= SYM SYM O
4 CD CD O
. . . O
1 CD CD O
nM NN NN O
; : : O
A DT DT O
( ( ( O
1 CD CD O
) ) ) O
K NNP NNP O
( ( ( O
i NNP NNP O
) ) ) O
= SYM SYM O
17 CD CD O
. . . O
0 CD CD O
nM NN NN O
) ) ) O
that WDT WDT O
has VBZ VBZ O
excellent JJ JJ O
activity NN NN O
, , , O
after IN IN O
oral JJ JJ O
administration NN NN O
, , , O
across IN IN O
a DT DT O
number NN NN O
of IN IN O
animal NN NN O
models NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
including VBG VBG O
mouse NN NN O
and CC CC O
rat NN NN O
models NNS NNS O
of IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
, , , O
mouse NN NN O
model NN NN O
of IN IN O
reserpine NN NN B-CHEM
- - - O
induced JJ JJ O
akinesia NN NN O
, , , O
rat NN NN O
6 CD CD B-CHEM
- : : I-CHEM
hydroxydopamine NN NN I-CHEM
( ( ( O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
) ) ) O
lesion NN NN O
model NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
rotation NN NN O
, , , O
and CC CC O
MPTP NNP NNP B-CHEM
- : : O
treated VBN VBN O
non NN NN O
- : : O
human JJ JJ O
primate NN NN O
model NN NN O
. . . O

Effects NNP NNP O
of IN IN O
the DT DT O
hippocampal NN NN O
deep JJ JJ O
brain NN NN O
stimulation NN NN O
on IN IN O
cortical JJ JJ O
epileptic JJ JJ O
discharges NNS NNS O
in IN IN O
penicillin NN NN B-CHEM
- - - O
induced JJ JJ O
epilepsy NN NN O
model NN NN O
in IN IN O
rats NNS NNS O
. . . O

AIM NNP NNP O
: : : O
Experimental NNP NNP O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
have VBP VBP O
revealed VBN VBN O
that IN IN O
hippocampal JJ JJ O
DBS NNP NNP O
can MD MD O
control VB VB O
epileptic JJ JJ O
activity NN NN O
, , , O
but CC CC O
the DT DT O
mechanism NN NN O
of IN IN O
action NN NN O
is VBZ VBZ O
obscure JJ JJ O
and CC CC O
optimal JJ JJ O
stimulation NN NN O
parameters NNS NNS O
are VBP VBP O
not RB RB O
clearly RB RB O
defined VBN VBN O
. . . O

The DT DT O
aim NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
high JJ JJ O
frequency NN NN O
hippocampal JJ JJ O
stimulation NN NN O
on IN IN O
cortical JJ JJ O
epileptic JJ JJ O
activity NN NN O
in IN IN O
penicillin NN NN B-CHEM
- - - O
induced JJ JJ O
epilepsy NN NN O
model NN NN O
. . . O

MATERIAL NN NN O
AND CC CC O
METHODS NNP NNP O
: : : O
Twenty CD CD O
- - - O
five CD CD O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
implanted VBN VBN O
DBS NNP NNP O
electrodes NNS NNS O
. . . O

In IN IN O
group NN NN O
- - - O
1 CD CD O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
hippocampal NN NN O
DBS NNP NNP O
was VBD VBD O
off IN IN O
and CC CC O
in IN IN O
the DT DT O
group NN NN O
- : : O
2 CD CD O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
hippocampal NN NN O
DBS NNP NNP O
was VBD VBD O
on IN IN O
( ( ( O
185 CD CD O
Hz NNP NNP O
, , , O
0 CD CD O
. . . O
5V CD CD O
, , , O
1V CD CD O
, , , O
2V CD CD O
, , , O
and CC CC O
5V CD CD O
for IN IN O
60 CD CD O
sec NN NN O
) ) ) O
following VBG VBG O
penicillin NN NN B-CHEM
G NNP NNP I-CHEM
injection NN NN O
intracortically RB RB O
. . . O

In IN IN O
the DT DT O
control NN NN O
group NN NN O
hippocampal NN NN O
DBS NNP NNP O
was VBD VBD O
on IN IN O
following VBG VBG O
8 CD CD O
l NN NN O
saline NN NN O
injection NN NN O
intracortically RB RB O
. . . O

EEG NNP NNP O
recordings NNS NNS O
were VBD VBD O
obtained VBN VBN O
before IN IN O
and CC CC O
15 CD CD O
minutes NNS NNS O
following VBG VBG O
penicillin NN NN B-CHEM
- - - I-CHEM
G NNP NNP I-CHEM
injection NN NN O
, , , O
and CC CC O
at IN IN O
10th CD CD O
minutes NNS NNS O
following VBG VBG O
each DT DT O
stimulus NN NN O
for IN IN O
analysis NN NN O
in IN IN O
terms NNS NNS O
of IN IN O
frequency NN NN O
, , , O
amplitude NN NN O
, , , O
and CC CC O
power NN NN O
spectrum NN NN O
. . . O

RESULTS NNS NNS O
: : : O
High NNP NNP O
frequency NN NN O
hippocampal NN NN O
DBS NNP NNP O
suppressed VBD VBD O
the DT DT O
acute JJ JJ O
penicillin NN NN B-CHEM
- - - O
induced JJ JJ O
cortical JJ JJ O
epileptic JJ JJ O
activity NN NN O
independent JJ JJ O
from IN IN O
stimulus NN NN O
intensity NN NN O
. . . O

In IN IN O
the DT DT O
control NN NN O
group NN NN O
, , , O
hippocampal NN NN O
stimulation NN NN O
alone RB RB O
lead NN NN O
only RB RB O
to TO TO O
diffuse VB VB O
slowing VBG VBG O
of IN IN O
cerebral JJ JJ O
bioelectrical JJ JJ O
activity NN NN O
at IN IN O
5V CD CD O
stimulation NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
revealed VBD VBD O
that IN IN O
continuous JJ JJ O
high JJ JJ O
frequency NN NN O
stimulation NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
suppressed VBD VBD O
acute JJ JJ O
cortical JJ JJ O
epileptic JJ JJ O
activity NN NN O
effectively RB RB O
without IN IN O
causing VBG VBG O
secondary JJ JJ O
epileptic JJ JJ O
discharges NNS NNS O
. . . O

These DT DT O
results NNS NNS O
are VBP VBP O
important JJ JJ O
in IN IN O
terms NNS NNS O
of IN IN O
defining VBG VBG O
the DT DT O
optimal NN NN O
parameters NNS NNS O
of IN IN O
hippocampal JJ JJ O
DBS NNP NNP O
in IN IN O
patients NNS NNS O
with IN IN O
epilepsy NN NN O
. . . O

CCNU NNP NNP B-CHEM
( ( ( O
lomustine NN NN B-CHEM
) ) ) O
toxicity NN NN O
in IN IN O
dogs NNS NNS O
: : : O
a DT DT O
retrospective NN NN O
study NN NN O
( ( ( O
2002 CD CD O
- : : O
07 CD CD O
) ) ) O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
the DT DT O
incidence NN NN O
of IN IN O
haematological JJ JJ O
, , , O
renal JJ JJ O
, , , O
hepatic JJ JJ O
and CC CC O
gastrointestinal JJ JJ O
toxicities NNS NNS O
in IN IN O
tumour NN NN O
- - - O
bearing NN NN O
dogs NNS NNS O
receiving VBG VBG O
1 CD CD B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
chloroethyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
cyclohexyl NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
nitrosourea NN NN I-CHEM
( ( ( O
CCNU NNP NNP B-CHEM
) ) ) O
. . . O

DESIGN NNP NNP O
: : : O
The DT DT O
medical JJ JJ O
records NNS NNS O
of IN IN O
206 CD CD O
dogs NNS NNS O
that WDT WDT O
were VBD VBD O
treated VBN VBN O
with IN IN O
CCNU NNP NNP B-CHEM
at IN IN O
the DT DT O
Melbourne NNP NNP O
Veterinary NNP NNP O
Specialist NNP NNP O
Centre NNP NNP O
between IN IN O
February NNP NNP O
2002 CD CD O
and CC CC O
December NNP NNP O
2007 CD CD O
were VBD VBD O
retrospectively RB RB O
evaluated VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
the DT DT O
206 CD CD O
dogs NNS NNS O
treated VBN VBN O
with IN IN O
CCNU NNP NNP B-CHEM
, , , O
185 CD CD O
met VBD VBD O
the DT DT O
inclusion NN NN O
criteria NNS NNS O
for IN IN O
at IN IN O
least JJS JJS O
one CD CD O
class NN NN O
of IN IN O
toxicity NN NN O
. . . O

CCNU NNP NNP B-CHEM
was VBD VBD O
used VBN VBN O
most JJS JJS O
commonly RB RB O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
lymphoma NN NN O
, , , O
mast NN NN O
cell NN NN O
tumour NN NN O
, , , O
brain NN NN O
tumour NN NN O
, , , O
histiocytic JJ JJ O
tumours NNS NNS O
and CC CC O
epitheliotropic JJ JJ O
lymphoma NN NN O
. . . O

Throughout IN IN O
treatment NN NN O
, , , O
56 CD CD O
. . . O
9 CD CD O
% NN NN O
of IN IN O
dogs NNS NNS O
experienced VBN VBN O
neutropenia NN NN O
, , , O
34 CD CD O
. . . O
2 CD CD O
% NN NN O
experienced VBN VBN O
anaemia NN NN O
and CC CC O
14 CD CD O
. . . O
2 CD CD O
% NN NN O
experienced VBN VBN O
thrombocytopenia NN NN O
. . . O

Gastrointestinal NNP NNP O
toxicosis NN NN O
was VBD VBD O
detected VBN VBN O
in IN IN O
37 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
dogs NNS NNS O
, , , O
the DT DT O
most RBS RBS O
common JJ JJ O
sign NN NN O
of IN IN O
which WDT WDT O
was VBD VBD O
vomiting VBG VBG O
( ( ( O
24 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

Potential NNP NNP O
renal JJ JJ O
toxicity NN NN O
and CC CC O
elevated VBD VBD O
alanine NN NN B-CHEM
transaminase NN NN O
( ( ( O
ALT NNP NNP O
) ) ) O
concentration NN NN O
were VBD VBD O
reported VBN VBN O
in IN IN O
12 CD CD O
. . . O
2 CD CD O
% NN NN O
and CC CC O
48 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
dogs NNS NNS O
, , , O
respectively RB RB O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
hepatic JJ JJ O
failure NN NN O
was VBD VBD O
1 CD CD O
. . . O
2 CD CD O
% NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
CCNU NNP NNP B-CHEM
- - - O
associated VBN VBN O
toxicity NN NN O
in IN IN O
dogs NNS NNS O
is VBZ VBZ O
common JJ JJ O
, , , O
but CC CC O
is VBZ VBZ O
usually RB RB O
not RB RB O
life NN NN O
threatening VBG VBG O
. . . O

Central NNP NNP O
vein NN NN O
thrombosis NNS NNS O
and CC CC O
topical JJ JJ O
dipivalyl NN NN B-CHEM
epinephrine NN NN I-CHEM
. . . O

A DT DT O
report NN NN O
is VBZ VBZ O
given VBN VBN O
on IN IN O
an DT DT O
83 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
who WP WP O
acquired VBD VBD O
central JJ JJ O
vein NN NN O
thrombosis NN NN O
in IN IN O
her PRP$ PRP$ O
seeing VBG VBG O
eye NN NN O
one CD CD O
day NN NN O
after IN IN O
having VBG VBG O
started VBN VBN O
topical JJ JJ O
medication NN NN O
with IN IN O
dipivalyl NN NN B-CHEM
epinephrine NN NN I-CHEM
for IN IN O
advanced JJ JJ O
glaucoma NN NN O
discovered VBD VBD O
in IN IN O
the DT DT O
other JJ JJ O
eye NN NN O
. . . O

From IN IN O
present JJ JJ O
knowledge NN NN O
about IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
adrenergic JJ JJ O
eye NN NN O
drops NNS NNS O
on IN IN O
ocular NN NN O
blood NN NN O
circulation NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
difficult JJ JJ O
to TO TO O
suggest VB VB O
an DT DT O
association NN NN O
between IN IN O
the DT DT O
two CD CD O
events NNS NNS O
, , , O
which WDT WDT O
may MD MD O
be VB VB O
coincidental JJ JJ O
only RB RB O
. . . O

Benzylacyclouridine NNP NNP B-CHEM
reverses NNS NNS O
azidothymidine NN NN B-CHEM
- : : O
induced JJ JJ O
marrow NN NN O
suppression NN NN O
without IN IN O
impairment NN NN O
of IN IN O
anti JJ JJ O
- : : O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
activity NN NN O
. . . O

Increased NNP NNP O
extracellular JJ JJ O
concentrations NNS NNS O
of IN IN O
uridine NN NN B-CHEM
( ( ( O
Urd NNP NNP B-CHEM
) ) ) O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
to TO TO O
reduce VB VB O
, , , O
in IN IN O
vitro NN NN O
, , , O
azidothymidine NN NN B-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
inhibition NN NN O
of IN IN O
human JJ JJ O
granulocyte NN NN O
- : : O
macrophage NN NN O
progenitor NN NN O
cells NNS NNS O
without IN IN O
impairment NN NN O
of IN IN O
its PRP$ PRP$ O
antihuman JJ JJ O
immunodeficiency NN NN O
virus NN NN O
( ( ( O
HIV NNP NNP O
) ) ) O
activity NN NN O
. . . O

Because IN IN O
of IN IN O
the DT DT O
clinical JJ JJ O
toxicities NNS NNS O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
Urd NNP NNP B-CHEM
administration NN NN O
, , , O
the DT DT O
ability NN NN O
of IN IN O
benzylacyclouridine NN NN B-CHEM
( ( ( O
BAU NNP NNP B-CHEM
) ) ) O
to TO TO O
effect NN NN O
, , , O
in IN IN O
vivo NN NN O
, , , O
AZT NNP NNP B-CHEM
- : : O
induced JJ JJ O
anemia NN NN O
and CC CC O
leukopenia NN NN O
was VBD VBD O
assessed VBN VBN O
. . . O

This DT DT O
agent NN NN O
inhibits NNS NNS O
Urd NNP NNP B-CHEM
catabolism NN NN O
and CC CC O
, , , O
in IN IN O
vivo NN NN O
, , , O
increases NNS NNS O
the DT DT O
plasma NN NN O
concentration NN NN O
of IN IN O
Urd NNP NNP B-CHEM
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
, , , O
without IN IN O
Urd NNP NNP B-CHEM
- : : O
related VBN VBN O
toxicity NN NN O
. . . O

In IN IN O
mice NNS NNS O
rendered JJ JJ O
anemic JJ JJ O
and CC CC O
leukopenic JJ JJ O
by IN IN O
the DT DT O
administration NN NN O
of IN IN O
AZT NNP NNP B-CHEM
for IN IN O
28 CD CD O
days NNS NNS O
in IN IN O
drinking NN NN O
water NN NN O
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
mL NN NN O
) ) ) O
, , , O
the DT DT O
continued JJ JJ O
administration NN NN O
of IN IN O
AZT NNP NNP B-CHEM
plus CC CC O
daily JJ JJ O
BAU NNP NNP B-CHEM
( ( ( O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
orally RB RB O
) ) ) O
partially RB RB O
reversed VBN VBN O
AZT NNP NNP B-CHEM
- : : O
induced JJ JJ O
anemia NN NN O
and CC CC O
leukopenia NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
05 CD CD O
) ) ) O
, , , O
increased VBD VBD O
peripheral JJ JJ O
reticulocytes NNS NNS O
( ( ( O
to TO TO O
4 CD CD O
. . . O
9 CD CD O
% NN NN O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
01 CD CD O
) ) ) O
, , , O
increased VBN VBN O
cellularity NN NN O
in IN IN O
the DT DT O
marrow NN NN O
, , , O
and CC CC O
improved VBD VBD O
megaloblastosis NNS NNS O
. . . O

When WRB WRB O
coadministered VBN VBN O
with IN IN O
AZT NNP NNP B-CHEM
from IN IN O
the DT DT O
onset NN NN O
of IN IN O
drug NN NN O
administration NN NN O
, , , O
BAU NNP NNP B-CHEM
reduced VBD VBD O
AZT NNP NNP B-CHEM
- : : O
induced JJ JJ O
marrow NN NN O
toxicity NN NN O
. . . O

In IN IN O
vitro NN NN O
, , , O
at IN IN O
a DT DT O
concentration NN NN O
of IN IN O
100 CD CD O
mumol NN NN O
/ NN NN O
L NNP NNP O
, , , O
BAU NNP NNP B-CHEM
possesses VBZ VBZ O
minimal JJ JJ O
anti NN NN O
- : : O
HIV NNP NNP O
activity NN NN O
and CC CC O
has VBZ VBZ O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
ability NN NN O
of IN IN O
AZT NNP NNP B-CHEM
to TO TO O
reverse VB VB O
the DT DT O
HIV NNP NNP O
- - - O
induced JJ JJ O
cytopathic JJ JJ O
effect NN NN O
in IN IN O
MT4 NNP NNP O
cells NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
and CC CC O
biochemical JJ JJ O
implications NNS NNS O
of IN IN O
these DT DT O
findings NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Lethal NNP NNP O
anuria NNS NNS O
complicating VBG VBG O
high JJ JJ O
dose NN NN O
ifosfamide NN NN B-CHEM
chemotherapy NN NN O
in IN IN O
a DT DT O
breast NN NN O
cancer NN NN O
patient NN NN O
with IN IN O
an DT DT O
impaired JJ JJ O
renal JJ JJ O
function NN NN O
. . . O

A DT DT O
sixty NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
advanced VBN VBN O
breast NN NN O
cancer NN NN O
, , , O
previously RB RB O
treated VBN VBN O
with IN IN O
cisplatin NN NN B-CHEM
, , , O
developed VBN VBN O
an DT DT O
irreversible JJ JJ O
lethal NN NN O
renal JJ JJ O
failure NN NN O
with IN IN O
anuria NN NN O
, , , O
the DT DT O
day NN NN O
after IN IN O
5 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
bolus NN NN O
ifosfamide NN NN B-CHEM
. . . O

Postrenal NNP NNP O
failure NN NN O
was VBD VBD O
excluded VBN VBN O
by IN IN O
echography NN NN O
. . . O

A DT DT O
prerenal JJ JJ O
component NN NN O
could MD MD O
have VB VB O
contributed VBN VBN O
to TO TO O
renal JJ JJ O
failure NN NN O
because IN IN O
of IN IN O
a DT DT O
transient NN NN O
hypotension NN NN O
, , , O
due JJ JJ O
to TO TO O
an DT DT O
increasing JJ JJ O
ascitis NN NN O
, , , O
occurring VBG VBG O
just RB RB O
before IN IN O
anuria NN NN O
. . . O

However RB RB O
, , , O
correction NN NN O
of IN IN O
the DT DT O
hemodynamic JJ JJ O
parameters NNS NNS O
did VBD VBD O
not RB RB O
improve VB VB O
renal JJ JJ O
function NN NN O
. . . O

Ifosfamide NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
known VBN VBN O
nephrotoxic NN NN O
drug NN NN O
with IN IN O
demonstrated VBN VBN O
tubulopathies NNS NNS O
. . . O

We PRP PRP O
strongly RB RB O
suspect VBP VBP O
that IN IN O
this DT DT O
lethal JJ JJ O
anuria NN NN O
was VBD VBD O
mainly RB RB O
due JJ JJ O
to TO TO O
ifosfamide VB VB B-CHEM
, , , O
occurring VBG VBG O
in IN IN O
a DT DT O
patient NN NN O
having VBG VBG O
received VBN VBN O
previous JJ JJ O
cisplatin NN NN B-CHEM
chemotherapy NN NN O
and CC CC O
with IN IN O
poor JJ JJ O
kidney NN NN O
perfusion NN NN O
due JJ JJ O
to TO TO O
transient JJ JJ O
hypotension NN NN O
. . . O

We PRP PRP O
recommend VBP VBP O
careful JJ JJ O
use NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
in IN IN O
patients NNS NNS O
pretreated VBN VBN O
with IN IN O
nephrotoxic JJ JJ O
chemotherapy NN NN O
and CC CC O
inadequate JJ JJ O
renal JJ JJ O
perfusion NN NN O
. . . O

Nociceptive NNP NNP O
effects NNS NNS O
induced VBN VBN O
by IN IN O
intrathecal JJ JJ O
administration NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
D2 NN NN I-CHEM
, , , I-CHEM
E2 NNP NNP I-CHEM
, , , I-CHEM
or CC CC I-CHEM
F2 NNP NNP I-CHEM
alpha NN NN I-CHEM
to TO TO O
conscious JJ JJ O
mice NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
intrathecal JJ JJ O
administration NN NN O
of IN IN O
prostaglandins NNS NNS B-CHEM
on IN IN O
pain NN NN O
responses NNS NNS O
in IN IN O
conscious JJ JJ O
mice NN NN O
were VBD VBD O
evaluated VBN VBN O
by IN IN O
using VBG VBG O
hot JJ JJ O
plate NN NN O
and CC CC O
acetic JJ JJ B-CHEM
acid NN NN I-CHEM
writhing VBG VBG O
tests NNS NNS O
. . . O

Prostaglandin NNP NNP B-CHEM
D2 NN NN I-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
- : : O
3 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
) ) ) O
had VBD VBD O
a DT DT O
hyperalgesic JJ JJ O
action NN NN O
on IN IN O
the DT DT O
response NN NN O
to TO TO O
a DT DT O
hot JJ JJ O
plate NN NN O
during IN IN O
a DT DT O
3 CD CD O
- : : O
60 CD CD O
min NN NN O
period NN NN O
after IN IN O
injection NN NN O
. . . O

Prostaglandin NNP NNP B-CHEM
E2 NNP NNP I-CHEM
showed VBD VBD O
a DT DT O
hyperalgesic JJ JJ O
effect NN NN O
at IN IN O
doses NNS NNS O
of IN IN O
1 CD CD O
pg NN NN B-CHEM
to TO TO O
10 CD CD O
ng NN NN O
/ NN NN O
mouse NN NN O
, , , O
but CC CC O
the DT DT O
effect NN NN O
lasted VBD VBD O
shorter JJR JJR O
( ( ( O
3 CD CD O
- : : O
30 CD CD O
min NN NN O
) ) ) O
than IN IN O
that DT DT O
of IN IN O
prostaglandin NN NN B-CHEM
D2 NN NN I-CHEM
. . . O

Similar JJ JJ O
results NNS NNS O
were VBD VBD O
obtained VBN VBN O
by IN IN O
acetic JJ JJ B-CHEM
acid NN NN I-CHEM
writhing VBG VBG O
tests NNS NNS O
. . . O

The DT DT O
hyperalgesic JJ JJ O
effect NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
D2 NN NN I-CHEM
was VBD VBD O
blocked VBN VBN O
by IN IN O
simultaneous JJ JJ O
injection NN NN O
of IN IN O
a DT DT O
substance NN NN O
P NN NN O
antagonist NN NN O
( ( ( O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
100 CD CD O
ng NN NN O
) ) ) O
but CC CC O
not RB RB O
by IN IN O
AH6809 NNP NNP B-CHEM
, , , O
a DT DT O
prostanoid NN NN O
EP1 NNP NNP O
- : : O
receptor NN NN O
antagonist NN NN O
. . . O

Conversely RB RB O
, , , O
prostaglandin NN NN B-CHEM
E2 NNP NNP I-CHEM
- : : O
induced JJ JJ O
hyperalgesia NN NN O
was VBD VBD O
blocked VBN VBN O
by IN IN O
AH6809 NNP NNP B-CHEM
( ( ( O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
500 CD CD O
ng NN NN O
) ) ) O
but CC CC O
not RB RB O
by IN IN O
the DT DT O
substance NN NN O
P NN NN O
antagonist NN NN O
. . . O

Prostaglandin NNP NNP B-CHEM
F2 NNP NNP I-CHEM
alpha NN NN I-CHEM
had VBD VBD O
little JJ JJ O
effect NN NN O
on IN IN O
pain NN NN O
responses NNS NNS O
. . . O

These DT DT O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
both DT DT O
prostaglandin NN NN B-CHEM
D2 NN NN I-CHEM
and CC CC O
prostaglandin NN NN B-CHEM
E2 NNP NNP I-CHEM
exert NN NN O
hyperalgesia NN NN O
in IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
, , , O
but CC CC O
in IN IN O
different JJ JJ O
ways NNS NNS O
. . . O

D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
localized JJ JJ O
scleroderma NN NN O
. . . O

Localized NNP NNP O
scleroderma NN NN O
has VBZ VBZ O
no DT DT O
recognized VBN VBN O
internal JJ JJ O
organ NN NN O
involvement NN NN O
but CC CC O
may MD MD O
be VB VB O
disfiguring VBG VBG O
and CC CC O
disabling VBG VBG O
when WRB WRB O
the DT DT O
cutaneous JJ JJ O
lesions NNS NNS O
are VBP VBP O
extensive JJ JJ O
or CC CC O
affect JJ JJ O
children NNS NNS O
. . . O

There EX EX O
is VBZ VBZ O
no DT DT O
accepted VBN VBN O
or CC CC O
proven VBN VBN O
treatment NN NN O
for IN IN O
localized JJ JJ O
scleroderma NN NN O
. . . O

Case NN NN O
reports NNS NNS O
of IN IN O
11 CD CD O
patients NNS NNS O
with IN IN O
severe JJ JJ O
, , , O
extensive JJ JJ O
localized JJ JJ O
scleroderma NN NN O
who WP WP O
were VBD VBD O
treated VBN VBN O
with IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
are VBP VBP O
summarized VBN VBN O
in IN IN O
this DT DT O
article NN NN O
. . . O

This DT DT O
drug NN NN O
was VBD VBD O
judged VBN VBN O
to TO TO O
have VB VB O
a DT DT O
favorable JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
disease NN NN O
course NN NN O
in IN IN O
7 CD CD O
( ( ( O
64 CD CD O
% NN NN O
) ) ) O
of IN IN O
11 CD CD O
patients NNS NNS O
. . . O

Improvement NNP NNP O
began VBD VBD O
within IN IN O
3 CD CD O
to TO TO O
6 CD CD O
months NNS NNS O
and CC CC O
consisted VBN VBN O
of IN IN O
cessation NN NN O
of IN IN O
active JJ JJ O
cutaneous JJ JJ O
lesions NNS NNS O
in IN IN O
all DT DT O
7 CD CD O
patients NNS NNS O
, , , O
skin NN NN O
softening VBG VBG O
in IN IN O
5 CD CD O
, , , O
and CC CC O
more RBR RBR O
normal JJ JJ O
growth NN NN O
of IN IN O
the DT DT O
affected VBN VBN O
limb NN NN O
in IN IN O
2 CD CD O
of IN IN O
3 CD CD O
children NNS NNS O
. . . O

Joint NNP NNP O
stiffness NN NN O
and CC CC O
contractures NNS NNS O
also RB RB O
improved VBN VBN O
. . . O

The DT DT O
dose NN NN O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
associated VBN VBN O
with IN IN O
a DT DT O
favorable JJ JJ O
response NN NN O
was VBD VBD O
as RB RB O
low JJ JJ O
as IN IN O
2 CD CD O
to TO TO O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
given VBN VBN O
over IN IN O
a DT DT O
period NN NN O
ranging VBG VBG O
from IN IN O
15 CD CD O
to TO TO O
53 CD CD O
months NNS NNS O
. . . O

D NNP NNP B-CHEM
- : : I-CHEM
Penicillamine NNP NNP I-CHEM
caused VBD VBD O
nephrotic JJ JJ O
syndrome NN NN O
in IN IN O
1 CD CD O
patient NN NN O
and CC CC O
milder NN NN O
reversible JJ JJ O
proteinuria NN NN O
in IN IN O
3 CD CD O
other JJ JJ O
patients NNS NNS O
; : : O
none NN NN O
developed VBN VBN O
renal JJ JJ O
insufficiency NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
may MD MD O
be VB VB O
effective JJ JJ O
in IN IN O
severe JJ JJ O
cases NNS NNS O
of IN IN O
localized JJ JJ O
scleroderma NN NN O
. . . O

Cerebral NNP NNP O
sinus NN NN O
thrombosis NNS NNS O
as IN IN O
a DT DT O
potential JJ JJ O
hazard NN NN O
of IN IN O
antifibrinolytic JJ JJ O
treatment NN NN O
in IN IN O
menorrhagia NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
42 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
developed VBD VBD O
superior JJ JJ O
sagittal NN NN O
and CC CC O
left VBD VBD O
transverse NN NN O
sinus NN NN O
thrombosis NN NN O
associated VBN VBN O
with IN IN O
prolonged JJ JJ O
epsilon NN NN B-CHEM
- - - I-CHEM
aminocaproic JJ JJ I-CHEM
acid NN NN I-CHEM
therapy NN NN O
for IN IN O
menorrhagia NN NN O
. . . O

This DT DT O
antifibrinolytic JJ JJ O
agent NN NN O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
in IN IN O
women NNS NNS O
with IN IN O
menorrhagia NN NN O
to TO TO O
promote VB VB O
clotting VBG VBG O
and CC CC O
reduce VB VB O
blood NN NN O
loss NN NN O
. . . O

Although IN IN O
increased VBN VBN O
risk NN NN O
of IN IN O
thromboembolic JJ JJ O
disease NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
during IN IN O
treatment NN NN O
with IN IN O
epsilon NN NN B-CHEM
- - - I-CHEM
aminocaproic JJ JJ I-CHEM
acid NN NN I-CHEM
, , , O
cerebral JJ JJ O
sinus NN NN O
thrombosis NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
previously RB RB O
described VBN VBN O
. . . O

Careful NNP NNP O
use NN NN O
of IN IN O
epsilon NN NN B-CHEM
- - - I-CHEM
aminocaproic JJ JJ I-CHEM
acid NN NN I-CHEM
therapy NN NN O
is VBZ VBZ O
recommended VBN VBN O
. . . O

Seizure NNP NNP O
activity NN NN O
with IN IN O
imipenem NN NN B-CHEM
therapy NN NN O
: : : O
incidence NN NN O
and CC CC O
risk NN NN O
factors NNS NNS O
. . . O

Two CD CD O
elderly JJ JJ O
patients NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
either DT DT O
cerebral JJ JJ O
vascular NN NN O
accident NN NN O
( ( ( O
CVA NNP NNP O
) ) ) O
or CC CC O
head NN NN O
trauma NN NN O
and CC CC O
no DT DT O
evidence NN NN O
of IN IN O
renal JJ JJ O
disease NN NN O
developed VBN VBN O
seizures NNS NNS O
while IN IN O
receiving VBG VBG O
maximum NN NN O
doses NNS NNS O
of IN IN O
imipenem NN NN B-CHEM
/ NN NN I-CHEM
cilastatin NN NN I-CHEM
. . . O

Neither DT DT O
patient NN NN O
had VBD VBD O
reported VBN VBN O
previous JJ JJ O
seizures NNS NNS O
or CC CC O
seizure NN NN O
- - - O
like IN IN O
activity NN NN O
nor CC CC O
was VBD VBD O
receiving VBG VBG O
anticonvulsant JJ JJ O
agents NNS NNS O
. . . O

All DT DT O
seizures NNS NNS O
were VBD VBD O
controlled VBN VBN O
with IN IN O
therapeutic JJ JJ O
doses NNS NNS O
of IN IN O
phenytoin NN NN B-CHEM
. . . O

Both DT DT O
patients NNS NNS O
had VBD VBD O
received VBN VBN O
maximum NN NN O
doses NNS NNS O
of IN IN O
other JJ JJ O
beta NN NN B-CHEM
- - - I-CHEM
lactam NN NN I-CHEM
antibiotics NNS NNS O
without IN IN O
evidence NN NN O
of IN IN O
seizure NN NN O
activity NN NN O
. . . O

Midline NNP NNP O
B3 NNP NNP O
serotonin NN NN B-CHEM
nerves NNS NNS O
in IN IN O
rat NN NN O
medulla NN NN O
are VBP VBP O
involved VBN VBN O
in IN IN O
hypotensive JJ JJ O
effect NN NN O
of IN IN O
methyldopa NN NN B-CHEM
. . . O

Previous JJ JJ O
experiments NNS NNS O
in IN IN O
this DT DT O
laboratory NN NN O
have VBP VBP O
shown VBN VBN O
that DT DT O
microinjection NN NN O
of IN IN O
methyldopa NN NN B-CHEM
onto IN IN O
the DT DT O
ventrolateral JJ JJ O
cells NNS NNS O
of IN IN O
the DT DT O
B3 NNP NNP O
serotonin NN NN B-CHEM
neurons NNS NNS O
in IN IN O
the DT DT O
medulla NN NN O
elicits VBZ VBZ O
a DT DT O
hypotensive JJ JJ O
response NN NN O
mediated VBN VBN O
by IN IN O
a DT DT O
projection NN NN O
descending VBG VBG O
into IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
. . . O

The DT DT O
present JJ JJ O
experiments NNS NNS O
were VBD VBD O
designed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
role NN NN O
of IN IN O
the DT DT O
midline NN NN O
cells NNS NNS O
of IN IN O
the DT DT O
B3 NNP NNP O
serotonin NN NN B-CHEM
neurons NNS NNS O
in IN IN O
the DT DT O
medulla NN NN O
, , , O
coinciding VBG VBG O
with IN IN O
the DT DT O
raphe NN NN O
magnus NN NN O
. . . O

In IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
, , , O
stroke NN NN O
- - - O
prone NN NN O
rats NNS NNS O
, , , O
microinjection NN NN O
of IN IN O
methyldopa NN NN B-CHEM
into IN IN O
the DT DT O
area NN NN O
of IN IN O
the DT DT O
midline NN NN O
B3 NNP NNP O
serotonin NN NN B-CHEM
cell NN NN O
group NN NN O
in IN IN O
the DT DT O
ventral NN NN O
medulla NN NN O
caused VBD VBD O
a DT DT O
potent JJ JJ O
hypotension NN NN O
of IN IN O
30 CD CD O
- : : O
40 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
which WDT WDT O
was VBD VBD O
maximal NN NN O
2 CD CD O
- : : O
3 CD CD O
h NN NN O
after IN IN O
administration NN NN O
and CC CC O
was VBD VBD O
abolished VBN VBN O
by IN IN O
the DT DT O
serotonin NN NN B-CHEM
neurotoxin NN NN O
5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
dihydroxytryptamine NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
DHT NNP NNP I-CHEM
) ) ) O
injected VBN VBN O
intracerebroventricularly RB RB O
. . . O

However RB RB O
, , , O
intraspinal JJ JJ O
injection NN NN O
of IN IN O
5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
DHT NNP NNP I-CHEM
to TO TO O
produce VB VB O
a DT DT O
more RBR RBR O
selective JJ JJ O
lesion NN NN O
of IN IN O
only RB RB O
descending VBG VBG O
serotonin NN NN B-CHEM
projections NNS NNS O
in IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
did VBD VBD O
not RB RB O
affect VB VB O
this DT DT O
hypotension NN NN O
. . . O

Further RB RB O
, , , O
5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
DHT NNP NNP I-CHEM
lesion NN NN O
of IN IN O
serotonin NN NN B-CHEM
nerves NNS NNS O
travelling VBG VBG O
in IN IN O
the DT DT O
median NN NN O
forebrain NN NN O
bundle NN NN O
, , , O
one CD CD O
of IN IN O
the DT DT O
main JJ JJ O
ascending VBG VBG O
pathways NNS NNS O
from IN IN O
the DT DT O
B3 NNP NNP O
serotonin NN NN B-CHEM
cells NNS NNS O
, , , O
did VBD VBD O
not RB RB O
affect VB VB O
the DT DT O
fall NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
associated VBN VBN O
with IN IN O
a DT DT O
midline NN NN O
B3 NNP NNP O
serotonin NN NN B-CHEM
methyldopa NN NN B-CHEM
injection NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
therefore RB RB O
that IN IN O
, , , O
unlike IN IN O
the DT DT O
ventrolateral JJ JJ O
B3 NNP NNP O
cells NNS NNS O
which WDT WDT O
mediate VBP VBP O
a DT DT O
methyldopa NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
via IN IN O
descending VBG VBG O
projections NNS NNS O
, , , O
the DT DT O
midline NN NN O
serotonin NN NN B-CHEM
B3 NNP NNP O
cells NNS NNS O
in IN IN O
the DT DT O
medulla NN NN O
contribute NN NN O
to TO TO O
the DT DT O
hypotensive JJ JJ O
action NN NN O
of IN IN O
methyldopa NN NN B-CHEM
, , , O
either CC CC O
by IN IN O
way NN NN O
of IN IN O
an DT DT O
ascending VBG VBG O
projection NN NN O
which WDT WDT O
does VBZ VBZ O
not RB RB O
pass VB VB O
through IN IN O
the DT DT O
median JJ JJ O
forebrain NN NN O
bundle NN NN O
, , , O
or CC CC O
through IN IN O
a DT DT O
projection NN NN O
restricted VBN VBN O
to TO TO O
the DT DT O
caudal NN NN O
brainstem NN NN O
. . . O

Antiarrhythmic NNP NNP O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
cibenzoline NN NN B-CHEM
on IN IN O
canine NN NN O
ventricular NN NN O
arrhythmias NNS NNS O
. . . O

Using VBG VBG O
two CD CD O
- : : O
stage NN NN O
coronary JJ JJ O
ligation NN NN O
- - - O
, , , O
digitalis NNS NNS B-CHEM
- : : O
, , , O
and CC CC O
adrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
canine NN NN O
ventricular NN NN O
arrhythmias NNS NNS O
, , , O
antiarrhythmic JJ JJ O
effects NNS NNS O
of IN IN O
cibenzoline NN NN B-CHEM
were VBD VBD O
examined VBN VBN O
and CC CC O
the DT DT O
minimum JJ JJ O
effective JJ JJ O
plasma NN NN O
concentration NN NN O
for IN IN O
each DT DT O
arrhythmia NN NN O
model NN NN O
was VBD VBD O
determined VBN VBN O
. . . O

Cibenzoline NNP NNP B-CHEM
suppressed VBD VBD O
all PDT PDT O
the DT DT O
arrhythmias NN NN O
, , , O
and CC CC O
the DT DT O
minimum JJ JJ O
effective JJ JJ O
plasma NN NN O
concentrations NNS NNS O
for IN IN O
arrhythmias NNS NNS O
induced VBN VBN O
by IN IN O
24 CD CD O
- : : O
h NN NN O
coronary JJ JJ O
ligation NN NN O
, , , O
48 CD CD O
- : : O
h NN NN O
coronary JJ JJ O
ligation NN NN O
, , , O
digitalis NNS NNS B-CHEM
, , , O
and CC CC O
adrenaline NN NN B-CHEM
were VBD VBD O
1 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
( ( ( O
by IN IN O
8 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
, , , O
1 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
( ( ( O
by IN IN O
8 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
, , , O
0 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
( ( ( O
by IN IN O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
, , , O
and CC CC O
3 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
( ( ( O
by IN IN O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
micrograms VBZ VBZ O
/ NN NN O
ml NN NN O
, , , O
respectively RB RB O
( ( ( O
mean VB VB O
+ NN NN O
/ NN NN O
- : : O
SDM NNP NNP O
, , , O
n NN NN O
= SYM SYM O
6 CD CD O
- : : O
7 CD CD O
) ) ) O
. . . O

The DT DT O
concentration NN NN O
for IN IN O
adrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
arrhythmia NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
those DT DT O
for IN IN O
the DT DT O
other JJ JJ O
types NNS NNS O
of IN IN O
arrhythmias NNS NNS O
. . . O

This DT DT O
pharmacological JJ JJ O
profile NN NN O
is VBZ VBZ O
similar JJ JJ O
to TO TO O
those DT DT O
of IN IN O
mexiletine NN NN B-CHEM
and CC CC O
tocainide NN NN B-CHEM
, , , O
and CC CC O
all DT DT O
three CD CD O
drugs NNS NNS O
have VBP VBP O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
stimulant JJ JJ O
action NN NN O
. . . O

Because IN IN O
cibenzoline NN NN B-CHEM
had VBD VBD O
only RB RB O
weak JJ JJ O
hypotensive JJ JJ O
and CC CC O
sinus JJ JJ O
node NN NN O
depressive JJ JJ O
effects NNS NNS O
and CC CC O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
orally RB RB O
active JJ JJ O
when WRB WRB O
given VBN VBN O
to TO TO O
coronary JJ JJ O
ligation NN NN O
arrhythmia NN NN O
dogs NNS NNS O
, , , O
its PRP$ PRP$ O
clinical JJ JJ O
usefulness NN NN O
is VBZ VBZ O
expected VBN VBN O
. . . O

Continuous NNP NNP O
ambulatory NN NN O
ECG NNP NNP O
monitoring VBG VBG O
during IN IN O
fluorouracil NN NN B-CHEM
therapy NN NN O
: : : O
a DT DT O
prospective JJ JJ O
study NN NN O
. . . O

Although IN IN O
there EX EX O
have VBP VBP O
been VBN VBN O
anecdotal JJ JJ O
reports NNS NNS O
of IN IN O
cardiac JJ JJ O
toxicity NN NN O
associated VBN VBN O
with IN IN O
fluorouracil NN NN B-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
therapy NN NN O
, , , O
this DT DT O
phenomenon NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
studied VBN VBN O
in IN IN O
a DT DT O
systematic JJ JJ O
fashion NN NN O
. . . O

We PRP PRP O
prospectively RB RB O
performed VBD VBD O
continuous JJ JJ O
ambulatory NN NN O
ECG NNP NNP O
monitoring VBG VBG O
on IN IN O
25 CD CD O
patients NNS NNS O
undergoing VBG VBG O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
for IN IN O
treatment NN NN O
of IN IN O
solid JJ JJ O
tumors NNS NNS O
in IN IN O
order NN NN O
to TO TO O
assess VB VB O
the DT DT O
incidence NN NN O
of IN IN O
ischemic JJ JJ O
ST NNP NNP O
changes NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
monitored VBN VBN O
for IN IN O
23 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
hours NNS NNS O
before IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
, , , O
and CC CC O
98 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
hours NNS NNS O
during IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
. . . O

Anginal NNP NNP O
episodes NNS NNS O
were VBD VBD O
rare JJ JJ O
: : : O
only RB RB O
one CD CD O
patient NN NN O
had VBD VBD O
angina NN NN O
( ( ( O
during IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
) ) ) O
. . . O

However RB RB O
, , , O
asymptomatic JJ JJ O
ST NNP NNP O
changes NNS NNS O
( ( ( O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
1 CD CD O
mm NN NN O
ST NNP NNP O
deviation NN NN O
) ) ) O
were VBD VBD O
common JJ JJ O
: : : O
six CD CD O
of IN IN O
25 CD CD O
patients NNS NNS O
( ( ( O
24 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
ST NNP NNP O
changes NNS NNS O
before IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
v NN NN O
17 CD CD O
( ( ( O
68 CD CD O
% NN NN O
) ) ) O
during IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
002 CD CD O
) ) ) O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
ischemic JJ JJ O
episodes NNS NNS O
per IN IN O
patient NN NN O
per IN IN O
hour NN NN O
was VBD VBD O
0 CD CD O
. . . O
05 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
02 CD CD O
prior RB RB O
to TO TO O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
v NN NN O
0 CD CD O
. . . O
13 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
03 CD CD O
during IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
001 CD CD O
) ) ) O
; : : O
the DT DT O
duration NN NN O
of IN IN O
ECG NNP NNP O
changes NNS NNS O
was VBD VBD O
0 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
minutes NNS NNS O
per IN IN O
patient NN NN O
per IN IN O
hour NN NN O
before IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
v NN NN O
1 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
minutes NNS NNS O
per IN IN O
patient NN NN O
per IN IN O
hour NN NN O
during IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
01 CD CD O
) ) ) O
. . . O

ECG NNP NNP O
changes NNS NNS O
were VBD VBD O
more RBR RBR O
common JJ JJ O
among IN IN O
patients NNS NNS O
with IN IN O
known VBN VBN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

There EX EX O
were VBD VBD O
two CD CD O
cases NNS NNS O
of IN IN O
sudden JJ JJ O
death NN NN O
, , , O
both DT DT O
of IN IN O
which WDT WDT O
occurred VBD VBD O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
chemotherapy NN NN O
course NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
infusion NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
silent NN NN O
ST NNP NNP O
segment NN NN O
deviation NN NN O
suggestive JJ JJ O
of IN IN O
ischemia NN NN O
, , , O
particularly RB RB O
among IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

The DT DT O
mechanism NN NN O
and CC CC O
clinical JJ JJ O
significance NN NN O
of IN IN O
these DT DT O
ECG NNP NNP O
changes NNS NNS O
remain VBP VBP O
to TO TO O
be VB VB O
determined VBN VBN O
. . . O

Nature NNP NNP O
, , , O
time NN NN O
course NN NN O
and CC CC O
dose NN NN O
dependence NN NN O
of IN IN O
zidovudine NN NN B-CHEM
- - - O
related VBN VBN O
side NN NN O
effects NNS NNS O
: : : O
results NNS NNS O
from IN IN O
the DT DT O
Multicenter NNP NNP O
Canadian NNP NNP O
Azidothymidine NNP NNP B-CHEM
Trial NN NN O
. . . O

To TO TO O
characterize VB VB O
the DT DT O
nature NN NN O
, , , O
time NN NN O
course NN NN O
and CC CC O
dose VB VB O
dependency NN NN O
of IN IN O
zidovudine NN NN B-CHEM
- - - O
related VBN VBN O
side NN NN O
effects NNS NNS O
, , , O
we PRP PRP O
undertook VBP VBP O
a DT DT O
multicenter NN NN O
, , , O
prospective JJ JJ O
, , , O
dose VB VB O
- - - O
range NN NN O
finding VBG VBG O
study NN NN O
. . . O

Our PRP$ PRP$ O
study NN NN O
group NN NN O
consisted VBN VBN O
of IN IN O
74 CD CD O
HIV NNP NNP O
- : : O
positive JJ JJ O
homosexual JJ JJ O
men NNS NNS O
belonging VBG VBG O
to TO TO O
groups NNS NNS O
II NNP NNP O
B NNP NNP O
, , , O
III NNP NNP O
and CC CC O
IV NNP NNP O
C2 NNP NNP O
from IN IN O
the DT DT O
Centers NNPS NNPS O
for IN IN O
Disease NNP NNP O
Control NNP NNP O
( ( ( O
CDC NNP NNP O
) ) ) O
classification NN NN O
of IN IN O
HIV NNP NNP O
disease NN NN O
. . . O

Following VBG VBG O
a DT DT O
3 CD CD O
- : : O
week NN NN O
observation NN NN O
period NN NN O
, , , O
volunteers NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
zidovudine NN NN B-CHEM
600 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
18 CD CD O
weeks NNS NNS O
, , , O
900 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
9 CD CD O
weeks NNS NNS O
and CC CC O
1200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
9 CD CD O
weeks NNS NNS O
, , , O
followed VBN VBN O
by IN IN O
a DT DT O
washout NN NN O
period NN NN O
of IN IN O
6 CD CD O
weeks NNS NNS O
after IN IN O
which WDT WDT O
they PRP PRP O
were VBD VBD O
re NN NN O
- - - O
started VBN VBN O
on IN IN O
1200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
or CC CC O
the DT DT O
highest JJS JJS O
tolerated VBN VBN O
dose NN NN O
at IN IN O
8 CD CD O
- : : O
hourly JJ JJ O
intervals NNS NNS O
. . . O

Subjects NNP NNP O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
4 CD CD O
- : : O
hourly JJ JJ O
or CC CC O
8 CD CD O
- : : O
hourly JJ JJ O
regimens NNS NNS O
within IN IN O
CDC NNP NNP O
groups NNS NNS O
while IN IN O
taking VBG VBG O
600 CD CD O
and CC CC O
1200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
. . . O

Clinical NNP NNP O
and CC CC O
laboratory NN NN O
evaluations NNS NNS O
were VBD VBD O
performed VBN VBN O
at IN IN O
3 CD CD O
- - - O
week NN NN O
intervals NNS NNS O
. . . O

Symptomatic NNP NNP O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
present JJ JJ O
in IN IN O
96 CD CD O
% NN NN O
of IN IN O
subjects NNS NNS O
, , , O
most RBS RBS O
commonly RB RB O
nausea NN NN O
( ( ( O
64 CD CD O
% NN NN O
) ) ) O
, , , O
fatigue NN NN O
( ( ( O
55 CD CD O
% NN NN O
) ) ) O
and CC CC O
headache NN NN O
( ( ( O
49 CD CD O
% NN NN O
) ) ) O
. . . O

These DT DT O
were VBD VBD O
generally RB RB O
self NN NN O
- - - O
limited JJ JJ O
, , , O
reappearing VBG VBG O
briefly NN NN O
at IN IN O
each DT DT O
dose NN NN O
increment NN NN O
. . . O

A DT DT O
decrease NN NN O
in IN IN O
hemoglobin NN NN O
occurred VBD VBD O
shortly RB RB O
after IN IN O
initiation NN NN O
of IN IN O
therapy NN NN O
. . . O

This DT DT O
was VBD VBD O
not RB RB O
dose VB VB O
dependent JJ JJ O
and CC CC O
reversed VBD VBD O
rapidly RB RB O
upon IN IN O
discontinuation NN NN O
of IN IN O
treatment NN NN O
. . . O

A DT DT O
red JJ JJ O
blood NN NN O
cell NN NN O
count NN NN O
decrease NN NN O
, , , O
a DT DT O
mean JJ JJ O
cell NN NN O
volume NN NN O
increase NN NN O
and CC CC O
a DT DT O
granulocyte NN NN O
count NN NN O
decrease NN NN O
developed VBN VBN O
early RB RB O
in IN IN O
a DT DT O
dose NN NN O
- - - O
independent JJ JJ O
fashion NN NN O
, , , O
reverting VBG VBG O
at IN IN O
least JJS JJS O
partially RB RB O
during IN IN O
the DT DT O
washout NN NN O
phase NN NN O
. . . O

The DT DT O
decrease NN NN O
in IN IN O
reticulocyte NN NN O
count NN NN O
was VBD VBD O
dose NN NN O
related VBN VBN O
between IN IN O
600 CD CD O
and CC CC O
900 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
with IN IN O
no DT DT O
further JJ JJ O
change NN NN O
when WRB WRB O
the DT DT O
dose NN NN O
was VBD VBD O
escalated VBN VBN O
to TO TO O
1200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
. . . O

Bone NNP NNP O
marrow NN NN O
changes NNS NNS O
occurred VBD VBD O
rapidly RB RB O
as IN IN O
demonstrated VBN VBN O
by IN IN O
megaloblastosis NN NN O
in IN IN O
95 CD CD O
% NN NN O
of IN IN O
65 CD CD O
specimens NNS NNS O
at IN IN O
week NN NN O
18 CD CD O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

National NNP NNP O
project NN NN O
on IN IN O
the DT DT O
prevention NN NN O
of IN IN O
mother NN NN O
- - - O
to TO TO O
- - - O
infant NN NN O
infection NN NN O
by IN IN O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
in IN IN O
Japan NNP NNP O
. . . O

In IN IN O
Japan NNP NNP O
, , , O
a DT DT O
nationwide JJ JJ O
prevention NN NN O
program NN NN O
against IN IN O
mother NN NN O
- - - O
to TO TO O
- - - O
infant NN NN O
infection NN NN O
by IN IN O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
started VBD VBD O
in IN IN O
1985 CD CD O
. . . O

This DT DT O
program NN NN O
consists VBZ VBZ O
of IN IN O
double JJ JJ O
screenings NNS NNS O
of IN IN O
pregnant JJ JJ O
women NNS NNS O
and CC CC O
prophylactic JJ JJ O
treatment NN NN O
to TO TO O
the DT DT O
infants NNS NNS O
born VBN VBN O
to TO TO O
both DT DT O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
( ( ( O
HBsAg NNP NNP B-CHEM
) ) ) O
and CC CC O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
e SYM SYM I-CHEM
antigen NN NN I-CHEM
( ( ( O
HBeAg NNP NNP B-CHEM
) ) ) O
positive JJ JJ O
mothers NNS NNS O
. . . O

These DT DT O
infants NNS NNS O
are VBP VBP O
treated VBN VBN O
with IN IN O
two CD CD O
injections NNS NNS O
of IN IN O
hepatitis NN NN O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
( ( ( O
HBIG NNP NNP O
) ) ) O
and CC CC O
at IN IN O
least JJS JJS O
three CD CD O
injections NNS NNS O
of IN IN O
plasma NN NN O
derived VBN VBN O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
vaccine NN NN I-CHEM
. . . O

We PRP PRP O
sent VBD VBD O
questionnaires NNS NNS O
about IN IN O
the DT DT O
numbers NNS NNS O
of IN IN O
each DT DT O
procedure NN NN O
or CC CC O
examination NN NN O
during IN IN O
nine CD CD O
months NNS NNS O
of IN IN O
investigation NN NN O
period NN NN O
to TO TO O
each DT DT O
local JJ JJ O
government NN NN O
in IN IN O
1986 CD CD O
and CC CC O
1987 CD CD O
. . . O

93 CD CD O
. . . O
4 CD CD O
% NN NN O
pregnant JJ JJ O
women NNS NNS O
had VBD VBD O
the DT DT O
chance NN NN O
to TO TO O
be VB VB O
examined VBN VBN O
for IN IN O
HBsAg NNP NNP B-CHEM
, , , O
and CC CC O
the DT DT O
positive JJ JJ O
rate NN NN O
was VBD VBD O
1 CD CD O
. . . O
4 CD CD O
to TO TO O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
. . . O

The DT DT O
HBeAg NNP NNP B-CHEM
positive JJ JJ O
rate NN NN O
in IN IN O
HBsAg NNP NNP B-CHEM
positive JJ JJ O
was VBD VBD O
23 CD CD O
to TO TO O
26 CD CD O
% NN NN O
. . . O

The DT DT O
HBsAg NNP NNP B-CHEM
positive JJ JJ O
rate NN NN O
in IN IN O
neonates NNS NNS O
and CC CC O
in IN IN O
infants NNS NNS O
before IN IN O
two CD CD O
months NNS NNS O
were VBD VBD O
3 CD CD O
% NN NN O
and CC CC O
2 CD CD O
% NN NN O
respectively RB RB O
. . . O

Some DT DT O
problems NNS NNS O
may MD MD O
arise VB VB O
, , , O
because IN IN O
27 CD CD O
to TO TO O
30 CD CD O
% NN NN O
of IN IN O
infants NNS NNS O
need VBP VBP O
the DT DT O
fourth JJ JJ O
vaccination NN NN O
in IN IN O
some DT DT O
restricted JJ JJ O
areas NNS NNS O
. . . O

Involvement NNP NNP O
of IN IN O
the DT DT O
mu NN NN O
- - - O
opiate JJ JJ O
receptor NN NN O
in IN IN O
peripheral JJ JJ O
analgesia NN NN O
. . . O

The DT DT O
intradermal JJ JJ O
injection NN NN O
of IN IN O
mu NN NN O
( ( ( O
morphine NN NN B-CHEM
, , , O
Tyr NNP NNP B-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- - - I-CHEM
Ala FW FW I-CHEM
- - - I-CHEM
Gly NNP NNP I-CHEM
- - - I-CHEM
NMe NNP NNP I-CHEM
- - - I-CHEM
Phe NNP NNP I-CHEM
- - - I-CHEM
Gly NNP NNP I-CHEM
- : : I-CHEM
ol NN NN I-CHEM
and CC CC O
morphiceptin NN NN B-CHEM
) ) ) O
, , , O
kappa NN NN O
( ( ( O
trans NNS NNS B-CHEM
- : : I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dichloro NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
pyrrolidinyl NN NN I-CHEM
) ) ) I-CHEM
cyclohexyl NN NN I-CHEM
] NN NN I-CHEM
benzeneactemide NN NN I-CHEM
) ) ) O
and CC CC O
delta NN NN O
( ( ( O
[ NN NN B-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
Pen2 NNP NNP I-CHEM
. . . I-CHEM
5 CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
enkephalin NN NN I-CHEM
and CC CC O
[ NN NN B-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
Ser2 NNP NNP I-CHEM
] NN NN I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
Leu NNP NNP I-CHEM
] NN NN I-CHEM
enkephalin NN NN I-CHEM
- - - I-CHEM
Thr NNP NNP I-CHEM
) ) ) O
selective JJ JJ O
opioid NN NN O
- - - O
agonists NNS NNS O
, , , O
by IN IN O
themselves PRP PRP O
, , , O
did VBD VBD O
not RB RB O
significantly RB RB O
affect VB VB O
the DT DT O
mechanical JJ JJ O
nociceptive JJ JJ O
threshold NN NN O
in IN IN O
the DT DT O
hindpaw NN NN O
of IN IN O
the DT DT O
rat NN NN O
. . . O

Intradermal NNP NNP O
injection NN NN O
of IN IN O
mu NN NN O
, , , O
but CC CC O
not RB RB O
delta VB VB O
or CC CC O
kappa NN NN O
opioid NN NN O
- : : O
agonists NNS NNS O
, , , O
however RB RB O
, , , O
produced VBD VBD O
dose NN NN O
- : : O
dependent JJ JJ O
inhibition NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
E2 NNP NNP I-CHEM
- : : O
induced JJ JJ O
hyperalgesia NN NN O
. . . O

The DT DT O
analgesic JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
mu NN NN O
- - - O
agonist NN NN O
morphine NN NN B-CHEM
was VBD VBD O
dose JJ JJ O
- : : O
dependently RB RB O
antagonized VBN VBN O
by IN IN O
naloxone NN NN B-CHEM
and CC CC O
prevented VBN VBN O
by IN IN O
co NN NN O
- - - O
injection NN NN O
of IN IN O
pertussis NN NN O
toxin NN NN O
. . . O

Morphine NNP NNP B-CHEM
did VBD VBD O
not RB RB O
, , , O
however RB RB O
, , , O
alter NN NN O
the DT DT O
hyperalgesia NN NN O
induced VBN VBN O
by IN IN O
8 CD CD B-CHEM
- : : I-CHEM
bromo NN NN I-CHEM
cyclic JJ JJ I-CHEM
adenosine NN NN I-CHEM
monophosphate NN NN I-CHEM
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
analgesic JJ JJ O
action NN NN O
of IN IN O
opioids NNS NNS O
on IN IN O
the DT DT O
peripheral JJ JJ O
terminals NNS NNS O
of IN IN O
primary JJ JJ O
afferents NNS NNS O
is VBZ VBZ O
via IN IN O
a DT DT O
binding JJ JJ O
site NN NN O
with IN IN O
characteristics NNS NNS O
of IN IN O
the DT DT O
mu NN NN O
- - - O
opioid NN NN O
receptor NN NN O
and CC CC O
that IN IN O
this DT DT O
action NN NN O
is VBZ VBZ O
mediated VBN VBN O
by IN IN O
inhibition NN NN O
of IN IN O
the DT DT O
cyclic JJ JJ B-CHEM
adenosine NN NN I-CHEM
monophosphate NN NN I-CHEM
second JJ JJ O
messenger NN NN O
system NN NN O
. . . O

Involvement NNP NNP O
of IN IN O
locus NN NN O
coeruleus NN NN O
and CC CC O
noradrenergic JJ JJ O
neurotransmission NN NN O
in IN IN O
fentanyl NN NN B-CHEM
- - - O
induced JJ JJ O
muscular NN NN O
rigidity NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Whereas IN IN O
muscular JJ JJ O
rigidity NN NN O
is VBZ VBZ O
a DT DT O
well RB RB O
- - - O
known VBN VBN O
side NN NN O
effect NN NN O
that WDT WDT O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
fentanyl NN NN B-CHEM
anesthesia NN NN O
, , , O
a DT DT O
paucity NN NN O
of IN IN O
information NN NN O
exists VBZ VBZ O
with IN IN O
regard NN NN O
to TO TO O
its PRP$ PRP$ O
underlying VBG VBG O
mechanism NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
. . . O

We PRP PRP O
investigated VBD VBD O
in IN IN O
this DT DT O
study NN NN O
the DT DT O
possible JJ JJ O
engagement NN NN O
of IN IN O
locus JJ JJ O
coeruleus NN NN O
of IN IN O
the DT DT O
pons NNS NNS O
in IN IN O
this DT DT O
phenomenon NN NN O
, , , O
using VBG VBG O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
anesthetized VBN VBN O
with IN IN O
ketamine NN NN B-CHEM
. . . O

Under IN IN O
proper JJ JJ O
control NN NN O
of IN IN O
respiration NN NN O
, , , O
body NN NN O
temperature NN NN O
and CC CC O
end NN NN O
- : : O
tidal NN NN O
CO2 NNP NNP B-CHEM
, , , O
intravenous JJ JJ O
administration NN NN O
of IN IN O
fentanyl NN NN B-CHEM
( ( ( O
50 CD CD O
or CC CC O
100 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
consistently RB RB O
promoted VBN VBN O
an DT DT O
increase NN NN O
in IN IN O
electromyographic JJ JJ O
activity NN NN O
recorded VBD VBD O
from IN IN O
the DT DT O
gastrocnemius NN NN O
and CC CC O
abdominal JJ JJ O
rectus NN NN O
muscles NNS NNS O
. . . O

Such JJ JJ O
an DT DT O
induced JJ JJ O
muscular NN NN O
rigidity NN NN O
by IN IN O
the DT DT O
narcotic JJ JJ O
agent NN NN O
was VBD VBD O
significantly RB RB O
antagonized VBN VBN O
or CC CC O
even RB RB O
reduced VBN VBN O
by IN IN O
prior RB RB O
electrolytic JJ JJ O
lesions NNS NNS O
of IN IN O
the DT DT O
locus NN NN O
coeruleus NN NN O
or CC CC O
pretreatment NN NN O
with IN IN O
the DT DT O
alpha NN NN O
- - - O
adrenoceptor NN NN O
blocker NN NN O
, , , O
prazosin NN NN B-CHEM
. . . O

Microinjection NNP NNP O
of IN IN O
fentanyl NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
micrograms NNS NNS O
/ NN NN O
50 CD CD O
nl NN NN O
) ) ) O
directly RB RB O
into IN IN O
this DT DT O
pontine NN NN O
nucleus NN NN O
, , , O
on IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
elicited JJ JJ O
discernible JJ JJ O
electromyographic JJ JJ O
excitation NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
speculated VBN VBN O
that IN IN O
the DT DT O
induction NN NN O
of IN IN O
muscular JJ JJ O
rigidity NN NN O
by IN IN O
fentanyl NN NN B-CHEM
may MD MD O
involve VB VB O
the DT DT O
coerulospinal JJ JJ O
noradrenergic JJ JJ O
fibers NNS NNS O
to TO TO O
the DT DT O
spinal JJ JJ O
motoneurons NNS NNS O
. . . O

Dexmedetomidine NNP NNP B-CHEM
, , , O
acting VBG VBG O
through IN IN O
central JJ JJ O
alpha NN NN O
- : : O
2 CD CD O
adrenoceptors NNS NNS O
, , , O
prevents NNS NNS O
opiate JJ JJ O
- : : O
induced JJ JJ O
muscle NN NN O
rigidity NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

The DT DT O
highly RB RB O
- - - O
selective JJ JJ O
alpha NN NN O
- : : O
2 CD CD O
adrenergic JJ JJ O
agonist NN NN O
dexmedetomidine NN NN B-CHEM
( ( ( O
D NNP NNP B-CHEM
- - - I-CHEM
MED NNP NNP I-CHEM
) ) ) O
is VBZ VBZ O
capable JJ JJ O
of IN IN O
inducing VBG VBG O
muscle NN NN O
flaccidity NN NN O
and CC CC O
anesthesia NN NN O
in IN IN O
rats NNS NNS O
and CC CC O
dogs NNS NNS O
. . . O

Intense NNP NNP O
generalized JJ JJ O
muscle NN NN O
rigidity NN NN O
is VBZ VBZ O
an DT DT O
undesirable JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
potent JJ JJ O
opiate NN NN O
agonists NNS NNS O
. . . O

Although IN IN O
the DT DT O
neurochemistry NN NN O
of IN IN O
opiate JJ JJ O
- - - O
induced JJ JJ O
rigidity NN NN O
has VBZ VBZ O
yet RB RB O
to TO TO O
be VB VB O
fully RB RB O
elucidated VBN VBN O
, , , O
recent JJ JJ O
work NN NN O
suggests VBZ VBZ O
a DT DT O
role NN NN O
for IN IN O
a DT DT O
central JJ JJ O
adrenergic JJ JJ O
mechanism NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
authors NNS NNS O
determined VBD VBD O
if IN IN O
treatment NN NN O
with IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
prevents NNS NNS O
the DT DT O
muscle NN NN O
rigidity NN NN O
caused VBN VBN O
by IN IN O
high JJ JJ O
- - - O
dose NN NN O
alfentanil NN NN B-CHEM
anesthesia NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Animals NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
42 CD CD O
) ) ) O
were VBD VBD O
treated VBN VBN O
intraperitoneally RB RB O
with IN IN O
one CD CD O
of IN IN O
the DT DT O
following VBG VBG O
six CD CD O
regimens NNS NNS O
: : : O
1 CD CD O
) ) ) O
L NNP NNP O
- : : O
MED NNP NNP O
( ( ( O
the DT DT O
inactive JJ JJ O
L NNP NNP O
- : : O
isomer NN NN O
of IN IN O
medetomidine NN NN B-CHEM
) ) ) O
, , , O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
; : : O
2 CD CD O
) ) ) O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
, , , O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
; : : O
3 CD CD O
) ) ) O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
, , , O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
; : : O
4 CD CD O
) ) ) O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
[ NN NN O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
] NN NN O
and CC CC O
the DT DT O
central JJ JJ O
- - - O
acting VBG VBG O
alpha NN NN O
- : : O
2 CD CD O
antagonist NN NN O
, , , O
idazoxan NN NN B-CHEM
[ NN NN O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
] NN NN O
; : : O
5 CD CD O
) ) ) O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
[ NN NN O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
] NN NN O
and CC CC O
the DT DT O
peripheral JJ JJ O
- - - O
acting VBG VBG O
alpha NN NN O
- : : O
2 CD CD O
antagonist NN NN O
DG NNP NNP B-CHEM
- : : I-CHEM
5128 CD CD I-CHEM
[ NN NN O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
] NN NN O
, , , O
or CC CC O
; : : O
6 CD CD O
) ) ) O
saline NN NN O
. . . O

Baseline NNP NNP O
electromyographic JJ JJ O
activity NN NN O
was VBD VBD O
recorded VBN VBN O
from IN IN O
the DT DT O
gastrocnemius NN NN O
muscle NN NN O
before IN IN O
and CC CC O
after IN IN O
drug NN NN O
treatment NN NN O
. . . O

Each DT DT O
rat NN NN O
was VBD VBD O
then RB RB O
injected VBN VBN O
with IN IN O
alfentanil NN NN B-CHEM
( ( ( O
ALF NNP NNP B-CHEM
, , , O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) ) ) O
. . . O

ALF NNP NNP B-CHEM
injection NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
marked JJ JJ O
increase NN NN O
in IN IN O
hindlimb NN NN O
EMG NNP NNP O
activity NN NN O
in IN IN O
the DT DT O
L NNP NNP O
- : : O
MED NNP NNP O
treatment NN NN O
group NN NN O
which WDT WDT O
was VBD VBD O
indistinguishable JJ JJ O
from IN IN O
that DT DT O
seen VBN VBN O
in IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
saline NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
prevented VBN VBN O
alfentanil NN NN B-CHEM
- - - O
induced JJ JJ O
muscle NN NN O
rigidity NN NN O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
fashion NN NN O
. . . O

The DT DT O
small JJ JJ O
EMG NNP NNP O
values NNS NNS O
obtained VBN VBN O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
group NN NN O
were VBD VBD O
comparable JJ JJ O
with IN IN O
those DT DT O
recorded VBN VBN O
in IN IN O
earlier JJR JJR O
studies NNS NNS O
from IN IN O
control NN NN O
animals NNS NNS O
not RB RB O
given VBN VBN O
any DT DT O
opiate NN NN O
. . . O

The DT DT O
high JJ JJ O
- - - O
dose NN NN O
D NNP NNP B-CHEM
- : : I-CHEM
MED NNP NNP I-CHEM
animals NNS NNS O
were VBD VBD O
flaccid NN NN O
, , , O
akinetic JJ JJ O
, , , O
and CC CC O
lacked VBD VBD O
a DT DT O
startle JJ JJ O
response NN NN O
during IN IN O
the DT DT O
entire JJ JJ O
experimental JJ JJ O
period NN NN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Some DT DT O
central JJ JJ O
effects NNS NNS O
of IN IN O
repeated VBN VBN O
treatment NN NN O
with IN IN O
fluvoxamine NN NN B-CHEM
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
repeated VBN VBN O
treatment NN NN O
with IN IN O
fluvoxamine NN NN B-CHEM
, , , O
a DT DT O
selective JJ JJ O
serotonin NN NN B-CHEM
uptake NN NN O
inhibitor NN NN O
, , , O
on IN IN O
behavioral JJ JJ O
effects NNS NNS O
of IN IN O
dopaminomimetics NNS NNS O
and CC CC O
methoxamine NN NN B-CHEM
and CC CC O
on IN IN O
the DT DT O
animal NN NN O
behavior NN NN O
in IN IN O
the DT DT O
" '' '' O
behavioral JJ JJ O
despair NN NN O
" '' '' O
test NN NN O
. . . O

A DT DT O
repeated VBN VBN O
treatment NN NN O
with IN IN O
fluvoxamine NN NN B-CHEM
( ( ( O
twice RB RB O
daily RB RB O
for IN IN O
14 CD CD O
days NNS NNS O
) ) ) O
potentiated VBN VBN O
in IN IN O
mice NN NN O
and CC CC O
in IN IN O
rats NNS NNS O
( ( ( O
weaker NN NN O
) ) ) O
the DT DT O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
. . . O

The DT DT O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
nomifensine NN NN B-CHEM
in IN IN O
mice NNS NNS O
remained VBD VBD O
unaffected JJ JJ O
by IN IN O
fluvoxamine NN NN B-CHEM
. . . O

The DT DT O
stimulation NN NN O
of IN IN O
locomotor NN NN O
activity NN NN O
by IN IN O
intracerebroventricularly RB RB O
administered JJ JJ O
methoxamine NN NN B-CHEM
was VBD VBD O
not RB RB O
affected VBN VBN O
by IN IN O
repeated VBN VBN O
treatment NN NN O
with IN IN O
fluvoxamine NN NN B-CHEM
. . . O

Given VBN VBN O
three CD CD O
times NNS NNS O
fluvoxamine NN NN B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
immobilization NN NN O
time NN NN O
in IN IN O
the DT DT O
" '' '' O
behavioral JJ JJ O
despair NN NN O
" '' '' O
test NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
fluvoxamine NN NN B-CHEM
given VBN VBN O
repeatedly JJ JJ O
acts NNS NNS O
differently RB RB O
than IN IN O
citalopram NN NN B-CHEM
, , , O
another DT DT O
selective JJ JJ O
serotonin NN NN B-CHEM
uptake NN NN O
inhibitor NN NN O
, , , O
and CC CC O
differs NNS NNS O
also RB RB O
from IN IN O
other JJ JJ O
antidepressant JJ JJ O
drugs NNS NNS O
. . . O

Protective JJ JJ O
effect NN NN O
of IN IN O
a DT DT O
specific JJ JJ O
platelet NN NN O
- - - O
activating VBG VBG O
factor NN NN O
antagonist NN NN O
, , , O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
, , , O
on IN IN O
bupivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
cardiovascular JJ JJ O
impairments NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
the DT DT O
local JJ JJ O
anaesthetic JJ JJ O
bupivacaine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
or CC CC O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
to TO TO O
rats NNS NNS O
elicited VBD VBD O
a DT DT O
marked JJ JJ O
decrease NN NN O
of IN IN O
mean NN NN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
MBP NNP NNP O
) ) ) O
and CC CC O
heart NN NN O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
leading VBG VBG O
to TO TO O
death NN NN O
( ( ( O
in IN IN O
67 CD CD O
% NN NN O
or CC CC O
90 CD CD O
% NN NN O
of IN IN O
animals NNS NNS O
respectively RB RB O
) ) ) O
. . . O

Intravenous NNP NNP O
injection NN NN O
of IN IN O
the DT DT O
specific JJ JJ O
platelet NN NN O
- - - O
activating VBG VBG O
factor NN NN O
( ( ( O
PAF NNP NNP O
) ) ) O
antagonist NN NN O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
30 CD CD O
min NN NN O
before IN IN O
bupivacaine NN NN B-CHEM
administration NN NN O
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
suppressed VBD VBD O
both DT DT O
the DT DT O
decrease NN NN O
of IN IN O
MBP NNP NNP O
and CC CC O
HR NNP NNP O
. . . O

In IN IN O
contrast NN NN O
, , , O
doses NNS NNS O
of IN IN O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
given VBN VBN O
30 CD CD O
min NN NN O
before IN IN O
or CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
administered VBN VBN O
5 CD CD O
min NN NN O
before IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
injection NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
were VBD VBD O
ineffective JJ JJ O
. . . O

When WRB WRB O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
was VBD VBD O
injected VBN VBN O
immediately RB RB O
after IN IN O
bupivacaine NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
a DT DT O
partial JJ JJ O
reversion NN NN O
of IN IN O
the DT DT O
decrease NN NN O
of IN IN O
MBP NNP NNP O
and CC CC O
HR NNP NNP O
was VBD VBD O
observed VBN VBN O
, , , O
whereas IN IN O
the DT DT O
dose NN NN O
of IN IN O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
was VBD VBD O
ineffective JJ JJ O
. . . O

A DT DT O
partial JJ JJ O
recovery NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
ECG NNP NNP O
alterations NNS NNS O
was VBD VBD O
observed VBN VBN O
after IN IN O
pretreatment NN NN O
of IN IN O
the DT DT O
rats NNS NNS O
with IN IN O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
. . . O

Since IN IN O
the DT DT O
administration NN NN O
of IN IN O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
, , , O
at IN IN O
all DT DT O
doses NNS NNS O
studied VBN VBN O
, , , O
did VBD VBD O
not RB RB O
alter VB VB O
MBP NNP NNP O
and CC CC O
HR NNP NNP O
at IN IN O
the DT DT O
doses NNS NNS O
used VBN VBN O
, , , O
the DT DT O
bulk NN NN O
of IN IN O
these DT DT O
results NNS NNS O
clearly RB RB O
demonstrate VBP VBP O
a DT DT O
protective JJ JJ O
action NN NN O
of IN IN O
BN NNP NNP B-CHEM
52021 CD CD I-CHEM
, , , O
a DT DT O
specific JJ JJ O
antagonist NN NN O
of IN IN O
PAF NNP NNP O
, , , O
against IN IN O
bupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiovascular JJ JJ O
toxicity NN NN O
. . . O

Thus RB RB O
, , , O
consistent JJ JJ O
with IN IN O
its PRP$ PRP$ O
direct JJ JJ O
effect NN NN O
on IN IN O
heart NN NN O
, , , O
PAF NNP NNP O
appears VBZ VBZ O
to TO TO O
be VB VB O
implicated VBN VBN O
in IN IN O
bupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiovascular JJ JJ O
alterations NNS NNS O
. . . O

The DT DT O
epidemiology NN NN O
of IN IN O
the DT DT O
acute JJ JJ O
flank NN NN O
pain NN NN O
syndrome NN NN O
from IN IN O
suprofen NN NN B-CHEM
. . . O

Suprofen NNP NNP B-CHEM
, , , O
a DT DT O
new JJ JJ O
nonsteroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drug NN NN O
, , , O
was VBD VBD O
marketed VBN VBN O
in IN IN O
early JJ JJ O
1986 CD CD O
as IN IN O
an DT DT O
analgesic JJ JJ O
agent NN NN O
. . . O

Until IN IN O
physicians NNS NNS O
began VBD VBD O
reporting VBG VBG O
an DT DT O
unusual JJ JJ O
acute JJ JJ O
flank NN NN O
pain NN NN O
syndrome NN NN O
to TO TO O
the DT DT O
spontaneous JJ JJ O
reporting NN NN O
system NN NN O
, , , O
700 CD CD O
, , , O
000 CD CD O
persons NNS NNS O
used VBN VBN O
the DT DT O
drug NN NN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
. . . O

Through IN IN O
August NNP NNP O
1986 CD CD O
, , , O
a DT DT O
total NN NN O
of IN IN O
163 CD CD O
cases NNS NNS O
of IN IN O
this DT DT O
syndrome NN NN O
were VBD VBD O
reported VBN VBN O
. . . O

To TO TO O
elucidate VB VB O
the DT DT O
epidemiology NN NN O
of IN IN O
the DT DT O
syndrome NN NN O
, , , O
a DT DT O
case NN NN O
- - - O
control NN NN O
study NN NN O
was VBD VBD O
performed VBN VBN O
, , , O
comparing VBG VBG O
62 CD CD O
of IN IN O
the DT DT O
case NN NN O
patients NNS NNS O
who WP WP O
had VBD VBD O
been VBN VBN O
reported VBN VBN O
to TO TO O
the DT DT O
spontaneous JJ JJ O
reporting NN NN O
system NN NN O
to TO TO O
185 CD CD O
suprofen NN NN B-CHEM
- : : O
exposed VBN VBN O
control NN NN O
subjects NNS NNS O
who WP WP O
did VBD VBD O
not RB RB O
have VB VB O
the DT DT O
syndrome NN NN O
. . . O

Case NN NN O
patients NNS NNS O
were VBD VBD O
more RBR RBR O
likely JJ JJ O
to TO TO O
be VB VB O
men NNS NNS O
( ( ( O
odds NNS NNS O
ratio NN NN O
, , , O
3 CD CD O
. . . O
8 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
2 CD CD O
- : : O
12 CD CD O
. . . O
1 CD CD O
) ) ) O
, , , O
suffer VB VB O
from IN IN O
hay NN NN O
fever NN NN O
and CC CC O
asthma NN NN O
( ( ( O
odds NNS NNS O
ratio NN NN O
, , , O
3 CD CD O
. . . O
4 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
0 CD CD O
- : : O
11 CD CD O
. . . O
9 CD CD O
) ) ) O
; : : O
to TO TO O
participate VB VB O
in IN IN O
regular JJ JJ O
exercise NN NN O
( ( ( O
odds NNS NNS O
ratio NN NN O
, , , O
5 CD CD O
. . . O
9 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
1 CD CD O
- : : O
30 CD CD O
. . . O
7 CD CD O
) ) ) O
, , , O
especially RB RB O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
Nautilus NNP NNP O
equipment NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
; : : O
and CC CC O
to TO TO O
use VB VB O
alcohol NN NN B-CHEM
( ( ( O
odds NNS NNS O
ratio NN NN O
, , , O
4 CD CD O
. . . O
4 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
1 CD CD O
- : : O
17 CD CD O
. . . O
5 CD CD O
) ) ) O
. . . O

Possible JJ JJ O
risk NN NN O
factors NNS NNS O
included VBD VBD O
young JJ JJ O
age NN NN O
, , , O
concurrent JJ JJ O
use NN NN O
of IN IN O
other JJ JJ O
analgesic JJ JJ O
agents NNS NNS O
( ( ( O
especially RB RB O
ibuprofen NN NN B-CHEM
) ) ) O
, , , O
preexisting VBG VBG O
renal JJ JJ O
disease NN NN O
, , , O
a DT DT O
history NN NN O
of IN IN O
kidney NN NN O
stones NNS NNS O
, , , O
a DT DT O
history NN NN O
of IN IN O
gout NN NN O
, , , O
a DT DT O
recent JJ JJ O
increase NN NN O
in IN IN O
activity NN NN O
, , , O
a DT DT O
recent JJ JJ O
increase NN NN O
in IN IN O
sun NN NN O
exposure NN NN O
, , , O
and CC CC O
residence NN NN O
in IN IN O
the DT DT O
Sunbelt NNP NNP O
. . . O

These DT DT O
were VBD VBD O
findings NNS NNS O
that WDT WDT O
were VBD VBD O
suggestive JJ JJ O
but CC CC O
did VBD VBD O
not RB RB O
reach VB VB O
conventional JJ JJ O
statistical JJ JJ O
significance NN NN O
. . . O

These DT DT O
findings NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
the DT DT O
postulated JJ JJ O
mechanism NN NN O
for IN IN O
this DT DT O
unusual JJ JJ O
syndrome NN NN O
: : : O
acute JJ JJ O
diffuse NN NN O
crystallization NN NN O
of IN IN O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
renal JJ JJ O
tubules NNS NNS O
. . . O

Phlorizin NNP NNP B-CHEM
- : : O
induced JJ JJ O
glycosuria NN NN O
does VBZ VBZ O
not RB RB O
prevent VB VB O
gentamicin NN NN B-CHEM
nephrotoxicity NN NN O
in IN IN O
rats NNS NNS O
. . . O

Because IN IN O
rats NNS NNS O
with IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetes NNS NNS O
mellitus NN NN O
( ( ( O
DM NNP NNP O
) ) ) O
have VBP VBP O
a DT DT O
high JJ JJ O
solute NN NN O
diuresis NN NN O
( ( ( O
glycosuria NN NN O
of IN IN O
10 CD CD O
to TO TO O
12 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
) ) ) O
, , , O
we PRP PRP O
have VBP VBP O
suggested VBN VBN O
that IN IN O
this DT DT O
may MD MD O
in IN IN O
part VB VB O
be VB VB O
responsible JJ JJ O
for IN IN O
their PRP$ PRP$ O
resistance NN NN O
to TO TO O
gentamicin VB VB B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
ARF NNP NNP O
) ) ) O
. . . O

The DT DT O
protection NN NN O
from IN IN O
gentamicin NN NN B-CHEM
nephrotoxicity NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
non NN NN O
- - - O
diabetic JJ JJ O
rats NNS NNS O
with IN IN O
chronic JJ JJ O
solute JJ JJ O
diuresis NN NN O
induced VBN VBN O
by IN IN O
blockage NN NN O
of IN IN O
tubular NN NN O
glucose NN NN B-CHEM
reabsorption NN NN O
with IN IN O
phlorizin NN NN B-CHEM
( ( ( O
P NN NN B-CHEM
) ) ) O
. . . O

DM NNP NNP O
rats NNS NNS O
with IN IN O
mild JJ JJ O
glycosuria NN NN O
( ( ( O
similar JJ JJ O
in IN IN O
degree NN NN O
to TO TO O
that DT DT O
of IN IN O
the DT DT O
P NN NN B-CHEM
treated VBN VBN O
animals NNS NNS O
) ) ) O
were VBD VBD O
also RB RB O
studied VBN VBN O
. . . O

Unanesthetized NNP NNP O
adult NN NN O
female NN NN O
, , , O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
divided VBN VBN O
in IN IN O
four CD CD O
groups NNS NNS O
and CC CC O
studied VBN VBN O
for IN IN O
15 CD CD O
days NNS NNS O
. . . O

Group NNP NNP O
1 CD CD O
( ( ( O
P NN NN B-CHEM
alone RB RB O
) ) ) O
received VBD VBD O
P NN NN B-CHEM
, , , O
360 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
, , , O
for IN IN O
15 CD CD O
days NNS NNS O
; : : O
Group NNP NNP O
II NNP NNP O
( ( ( O
P NN NN B-CHEM
+ NN NN O
gentamicin NN NN B-CHEM
) ) ) O
; : : O
Group NNP NNP O
III NNP NNP O
( ( ( O
gentamicin NN NN B-CHEM
alone RB RB O
) ) ) O
and CC CC O
Group NNP NNP O
IV NNP NNP O
( ( ( O
mild JJ JJ O
DM NNP NNP O
+ NN NN O
gentamicin NN NN B-CHEM
) ) ) O
. . . O

Nephrotoxic NNP NNP O
doses NNS NNS O
( ( ( O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
/ NN NN O
day NN NN O
) ) ) O
of IN IN O
gentamicin NN NN B-CHEM
were VBD VBD O
injected VBN VBN O
during IN IN O
the DT DT O
last JJ JJ O
nine CD CD O
days NNS NNS O
of IN IN O
study NN NN O
to TO TO O
the DT DT O
animals NNS NNS O
of IN IN O
groups NNS NNS O
II NNP NNP O
to TO TO O
IV NNP NNP O
. . . O

In IN IN O
Group NNP NNP O
I PRP PRP O
, , , O
P NN NN B-CHEM
induced VBD VBD O
a DT DT O
moderate JJ JJ O
and CC CC O
stable JJ JJ O
glycosuria NN NN O
( ( ( O
3 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
, , , O
SE NNP NNP O
) ) ) O
, , , O
and CC CC O
no DT DT O
functional JJ JJ O
or CC CC O
morphologic JJ JJ O
evidence NN NN O
of IN IN O
renal JJ JJ O
dysfunction NN NN O
( ( ( O
baseline NN NN O
CCr NNP NNP O
2 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
, , , O
undetectable JJ JJ O
lysozymuria NN NN O
) ) ) O
or CC CC O
damage NN NN O
( ( ( O
tubular NN NN O
necrosis NN NN O
score NN NN O
[ NN NN O
maximum NN NN O
4 CD CD O
] NN NN O
, , , O
zero CD CD O
) ) ) O
. . . O

In IN IN O
Group NNP NNP O
II NNP NNP O
, , , O
P NN NN B-CHEM
did VBD VBD O
not RB RB O
prevent VB VB O
gentamicin NN NN B-CHEM
- : : O
ARF NNP NNP O
( ( ( O
maximal NN NN O
decrease NN NN O
in IN IN O
CCr NNP NNP O
at IN IN O
day NN NN O
9 CD CD O
. . . O
89 CD CD O
% NN NN O
, , , O
P NN NN B-CHEM
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
; : : O
peak NN NN O
lysozymuria NN NN O
, , , O
1863 CD CD O
+ NN NN O
/ NN NN O
- : : O
321 CD CD O
micrograms NNS NNS O
/ NN NN O
day NN NN O
; : : O
and CC CC O
tubular JJ JJ O
necrosis NN NN O
score NN NN O
, , , O
3 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
) ) ) O
. . . O

These DT DT O
values NNS NNS O
were VBD VBD O
not RB RB O
different JJ JJ O
from IN IN O
those DT DT O
of IN IN O
Group NNP NNP O
III NNP NNP O
: : : O
maximal NN NN O
decrease NN NN O
in IN IN O
CCr NNP NNP O
73 CD CD O
% NN NN O
( ( ( O
P NN NN B-CHEM
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
; : : O
lysozymuria NN NN O
, , , O
2147 CD CD O
+ NN NN O
/ NN NN O
- : : O
701 CD CD O
micrograms NNS NNS O
/ NN NN O
day NN NN O
; : : O
tubular JJ JJ O
necrosis NN NN O
score NN NN O
, , , O
3 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Catalepsy NNP NNP O
induced VBN VBN O
by IN IN O
combinations NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
and CC CC O
morphine NN NN B-CHEM
: : : O
potentiation NN NN O
, , , O
antagonism NN NN O
, , , O
tolerance NN NN O
and CC CC O
cross JJ JJ O
- - - O
tolerance NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Previous JJ JJ O
studies NNS NNS O
demonstrated VBD VBD O
that IN IN O
both DT DT O
ketamine NN NN B-CHEM
and CC CC O
morphine NN NN B-CHEM
induced VBD VBD O
analgesia NN NN O
and CC CC O
catalepsy NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Pre NNP NNP O
- : : O
treatment NN NN O
with IN IN O
ketamine NN NN B-CHEM
produced VBN VBN O
cross JJ JJ O
- - - O
tolerance NN NN O
to TO TO O
morphine VB VB B-CHEM
, , , O
whereas IN IN O
pretreatment NN NN O
with IN IN O
morphine NN NN B-CHEM
did VBD VBD O
not RB RB O
induce VB VB O
cross JJ JJ O
- - - O
tolerance NN NN O
to TO TO O
ketamine VB VB B-CHEM
but CC CC O
rather RB RB O
augmented VBD VBD O
the DT DT O
cataleptic JJ JJ O
response NN NN O
; : : O
this DT DT O
augmentation NN NN O
was VBD VBD O
attributed VBN VBN O
to TO TO O
residual JJ JJ O
morphine NN NN B-CHEM
in IN IN O
the DT DT O
brain NN NN O
. . . O

The DT DT O
present JJ JJ O
studies NNS NNS O
explored VBD VBD O
the DT DT O
duration NN NN O
of IN IN O
the DT DT O
loss NN NN O
of IN IN O
righting VBG VBG O
reflex NN NN O
induced VBN VBN O
by IN IN O
sub NN NN O
- - - O
effective JJ JJ O
doses NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
and CC CC O
morphine NN NN B-CHEM
, , , O
administered VBD VBD O
simultaneously RB RB O
. . . O

There EX EX O
was VBD VBD O
mutual JJ JJ O
potentiation NN NN O
between IN IN O
sub NN NN O
- - - O
effective JJ JJ O
doses NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
and CC CC O
morphine NN NN B-CHEM
, , , O
but CC CC O
sub NN NN O
- - - O
effective JJ JJ O
doses NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
partly RB RB O
antagonized VBN VBN O
fully RB RB O
- : : O
effective JJ JJ O
doses NNS NNS O
of IN IN O
morphine NN NN B-CHEM
. . . O

Latency NNP NNP O
to TO TO O
the DT DT O
loss NN NN O
of IN IN O
righting VBG VBG O
reflex NN NN O
, , , O
rigidity NN NN O
and CC CC O
behavior NN NN O
on IN IN O
recovery NN NN O
, , , O
reflected VBD VBD O
the DT DT O
relative JJ JJ O
predominance NN NN O
of IN IN O
ketamine NN NN B-CHEM
or CC CC O
morphine NN NN B-CHEM
in IN IN O
each DT DT O
combination NN NN O
. . . O

Naloxone NNP NNP B-CHEM
inhibited VBD VBD O
the DT DT O
induced JJ JJ O
cataleptic JJ JJ O
effects NNS NNS O
. . . O

The DT DT O
degree NN NN O
and CC CC O
time NN NN O
course NN NN O
of IN IN O
development NN NN O
of IN IN O
tolerance NN NN O
to TO TO O
daily JJ JJ O
administration NN NN O
of IN IN O
sub NN NN O
- - - O
effective JJ JJ O
dose NN NN O
combinations NNS NNS O
of IN IN O
ketamine NN NN B-CHEM
and CC CC O
morphine NN NN B-CHEM
were VBD VBD O
similar JJ JJ O
. . . O

Rats NNP NNP O
, , , O
tolerant NN NN O
to TO TO O
ketamine VB VB B-CHEM
- : : O
dominant JJ JJ O
combinations NNS NNS O
, , , O
were VBD VBD O
cross JJ JJ O
- - - O
tolerant NN NN O
to TO TO O
both DT DT O
drugs NNS NNS O
, , , O
while IN IN O
those DT DT O
tolerant NN NN O
to TO TO O
morphine VB VB B-CHEM
- : : O
dominant JJ JJ O
combinations NNS NNS O
were VBD VBD O
cross JJ JJ O
- - - O
tolerant NN NN O
to TO TO O
morphine VB VB B-CHEM
but CC CC O
showed VBD VBD O
either CC CC O
no DT DT O
cross JJ JJ O
- - - O
tolerance NN NN O
or CC CC O
an DT DT O
augmented JJ JJ O
response NN NN O
to TO TO O
ketamine NN NN B-CHEM
. . . O

While IN IN O
the DT DT O
mutual JJ JJ O
potentiation NN NN O
, , , O
antagonism NN NN O
and CC CC O
tolerance NN NN O
suggest VBP VBP O
common JJ JJ O
mechanisms NNS NNS O
for IN IN O
the DT DT O
induced JJ JJ O
catalepsy NN NN O
, , , O
differences NNS NNS O
in IN IN O
latency NN NN O
, , , O
rigidity NN NN O
and CC CC O
behavior NN NN O
, , , O
asymmetry NN NN O
of IN IN O
cross NN NN O
- - - O
tolerance NN NN O
and CC CC O
a DT DT O
widely RB RB O
- - - O
different JJ JJ O
ID50 NNP NNP O
for IN IN O
naloxone NN NN B-CHEM
would MD MD O
argue VB VB O
against IN IN O
an DT DT O
action NN NN O
at IN IN O
a DT DT O
single JJ JJ O
opioid NN NN O
site NN NN O
. . . O

Hydrocortisone NNP NNP B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
humans NNS NNS O
: : : O
pressor NN NN O
responsiveness NN NN O
and CC CC O
sympathetic JJ JJ O
function NN NN O
. . . O

Oral NNP NNP O
hydrocortisone NN NN B-CHEM
increases NNS NNS O
blood NN NN O
pressure NN NN O
and CC CC O
enhances NNS NNS O
pressor NN NN O
responsiveness NN NN O
in IN IN O
normal JJ JJ O
human JJ JJ O
subjects NNS NNS O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
1 CD CD O
week NN NN O
of IN IN O
oral JJ JJ O
hydrocortisone NN NN B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
on IN IN O
blood NN NN O
pressure NN NN O
, , , O
cardiac JJ JJ O
output NN NN O
, , , O
total JJ JJ O
peripheral JJ JJ O
resistance NN NN O
, , , O
forearm NN NN O
vascular NN NN O
resistance NN NN O
, , , O
and CC CC O
norepinephrine NN NN B-CHEM
spillover NN NN O
to TO TO O
plasma VB VB O
in IN IN O
eight CD CD O
healthy JJ JJ O
male NN NN O
volunteers NNS NNS O
. . . O

Although IN IN O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
remained VBD VBD O
unchanged JJ JJ O
, , , O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
increased VBD VBD O
from IN IN O
119 CD CD O
to TO TO O
135 CD CD O
mm NN NN O
Hg NNP NNP O
( ( ( O
SED NNP NNP O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
4 CD CD O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
cardiac NN NN O
output NN NN O
( ( ( O
5 CD CD O
. . . O
85 CD CD O
- : : O
7 CD CD O
. . . O
73 CD CD O
l NN NN O
/ NN NN O
min NN NN O
, , , O
SED NNP NNP O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
46 CD CD O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Total NNP NNP O
peripheral JJ JJ O
vascular NN NN O
resistance NN NN O
fell VBD VBD O
from IN IN O
15 CD CD O
. . . O
1 CD CD O
to TO TO O
12 CD CD O
. . . O
2 CD CD O
mm NN NN O
Hg NNP NNP O
/ NN NN O
l NN NN O
/ NN NN O
min NN NN O
( ( ( O
SED NNP NNP O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
03 CD CD O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Resting NNP NNP O
forearm NN NN O
vascular NN NN O
resistance NN NN O
remained VBD VBD O
unchanged JJ JJ O
, , , O
but CC CC O
the DT DT O
reflex JJ JJ O
response NN NN O
to TO TO O
the DT DT O
cold JJ JJ O
pressor NN NN O
test NN NN O
was VBD VBD O
accentuated VBN VBN O
, , , O
the DT DT O
rise NN NN O
in IN IN O
resistance NN NN O
increasing VBG VBG O
from IN IN O
10 CD CD O
. . . O
5 CD CD O
mm NN NN O
Hg NNP NNP O
/ NN NN O
ml NN NN O
/ NN NN O
100 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
( ( ( O
R NN NN O
units NNS NNS O
) ) ) O
before IN IN O
treatment NN NN O
to TO TO O
32 CD CD O
. . . O
6 CD CD O
R NNP NNP O
units NNS NNS O
after IN IN O
treatment NN NN O
( ( ( O
SED NNP NNP O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
4 CD CD O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
025 CD CD O
) ) ) O
. . . O

The DT DT O
rise NN NN O
in IN IN O
forearm NN NN O
vascular NN NN O
resistance NN NN O
accompanying VBG VBG O
intra JJ JJ O
- - - O
arterial JJ JJ O
norepinephrine NN NN B-CHEM
( ( ( O
25 CD CD O
, , , O
50 CD CD O
, , , O
and CC CC O
100 CD CD O
ng NN NN O
/ NN NN O
min NN NN O
) ) ) O
was VBD VBD O
also RB RB O
significantly RB RB O
greater JJR JJR O
after IN IN O
hydrocortisone NN NN B-CHEM
, , , O
increasing VBG VBG O
from IN IN O
an DT DT O
average NN NN O
of IN IN O
14 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
4 CD CD O
R NNP NNP O
units NNS NNS O
before IN IN O
treatment NN NN O
to TO TO O
35 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
5 CD CD O
R NNP NNP O
units NNS NNS O
after IN IN O
hydrocortisone NN NN B-CHEM
( ( ( O
SED NNP NNP O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
0 CD CD O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

A DT DT O
shift NN NN O
to TO TO O
the DT DT O
left NN NN O
in IN IN O
the DT DT O
dose NN NN O
- - - O
response NN NN O
relation NN NN O
and CC CC O
fall NN NN O
in IN IN O
threshold NN NN O
suggested VBD VBD O
increased VBN VBN O
sensitivity NN NN O
to TO TO O
norepinephrine VB VB B-CHEM
after IN IN O
treatment NN NN O
. . . O

Measurement NNP NNP O
of IN IN O
resting VBG VBG O
norepinephrine NN NN B-CHEM
spillover NN NN O
rate NN NN O
to TO TO O
plasma VB VB O
and CC CC O
norepinephrine NN NN B-CHEM
uptake NN NN O
indicated VBD VBD O
that IN IN O
overall JJ JJ O
resting NN NN O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
activity NN NN O
was VBD VBD O
not RB RB O
increased VBN VBN O
. . . O

The DT DT O
rise NN NN O
in IN IN O
resting VBG VBG O
blood NN NN O
pressure NN NN O
with IN IN O
hydrocortisone NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
cardiac NN NN O
output NN NN O
( ( ( O
presumably RB RB O
due JJ JJ O
to TO TO O
increased VBN VBN O
blood NN NN O
volume NN NN O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Neuromuscular NNP NNP O
blockade NN NN O
with IN IN O
magnesium NN NN B-CHEM
sulfate NN NN I-CHEM
and CC CC O
nifedipine NN NN B-CHEM
. . . O

A DT DT O
patient NN NN O
who WP WP O
received VBD VBD O
tocolysis NNS NNS O
with IN IN O
nifedipine NN NN B-CHEM
developed VBN VBN O
neuromuscular JJ JJ O
blockade NN NN O
after IN IN O
500 CD CD O
mg NN NN O
of IN IN O
magnesium NN NN B-CHEM
sulfate NN NN I-CHEM
was VBD VBD O
administered VBN VBN O
. . . O

This DT DT O
reaction NN NN O
demonstrates VBZ VBZ O
that IN IN O
nifedipine NN NN B-CHEM
can MD MD O
seriously RB RB O
potentiate VB VB O
the DT DT O
toxicity NN NN O
of IN IN O
magnesium NN NN B-CHEM
. . . O

Caution NNP NNP O
should MD MD O
be VB VB O
exercised VBN VBN O
when WRB WRB O
these DT DT O
two CD CD O
tocolytics NNS NNS O
are VBP VBP O
combined VBN VBN O
. . . O

Chronic JJ JJ O
carbamazepine NN NN B-CHEM
inhibits VBZ VBZ O
the DT DT O
development NN NN O
of IN IN O
local JJ JJ O
anesthetic JJ JJ O
seizures NNS NNS O
kindled VBN VBN O
by IN IN O
cocaine NN NN B-CHEM
and CC CC O
lidocaine NN NN B-CHEM
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
carbamazepine NN NN B-CHEM
( ( ( O
CBZ NNP NNP B-CHEM
) ) ) O
treatment NN NN O
on IN IN O
local JJ JJ O
anesthetic JJ JJ O
- - - O
kindled JJ JJ O
seizures NNS NNS O
and CC CC O
lethality NN NN O
were VBD VBD O
evaluated VBN VBN O
in IN IN O
different JJ JJ O
stages NNS NNS O
of IN IN O
the DT DT O
kindling NN NN O
process NN NN O
and CC CC O
under IN IN O
different JJ JJ O
methods NNS NNS O
of IN IN O
CBZ NNP NNP B-CHEM
administration NN NN O
. . . O

Chronic NNP NNP O
oral JJ JJ O
CBZ NNP NNP B-CHEM
inhibited VBD VBD O
the DT DT O
development NN NN O
of IN IN O
both DT DT O
lidocaine NN NN B-CHEM
- - - O
and CC CC O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
, , , O
but CC CC O
had VBD VBD O
little JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
fully RB RB O
developed VBN VBN O
local JJ JJ O
anesthetic JJ JJ O
seizures NNS NNS O
. . . O

Chronic JJ JJ O
CBZ NNP NNP B-CHEM
also RB RB O
decreased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
seizure NN NN O
- - - O
related VBN VBN O
mortality NN NN O
in IN IN O
the DT DT O
cocaine NN NN B-CHEM
- - - O
injected JJ JJ O
rats NNS NNS O
. . . O

Acute JJ JJ O
CBZ NNP NNP B-CHEM
over IN IN O
a DT DT O
range NN NN O
of IN IN O
doses NNS NNS O
( ( ( O
15 CD CD O
- : : O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
completed VBN VBN O
lidocaine NN NN B-CHEM
- - - O
kindled JJ JJ O
or CC CC O
acute JJ JJ O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

Repeated NNP NNP O
i NNP NNP O
. . . O
p NN NN O
. . . O
injection NN NN O
of IN IN O
CBZ NNP NNP B-CHEM
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
also RB RB O
was VBD VBD O
without IN IN O
effect NN NN O
on IN IN O
the DT DT O
development NN NN O
of IN IN O
lidocaine NN NN B-CHEM
- - - O
or CC CC O
cocaine NN NN B-CHEM
- - - O
kindled JJ JJ O
seizures NNS NNS O
. . . O

The DT DT O
differential JJ JJ O
effects NNS NNS O
of IN IN O
CBZ NNP NNP B-CHEM
depending VBG VBG O
upon IN IN O
stage NN NN O
of IN IN O
seizure NN NN O
development NN NN O
suggest VBP VBP O
that IN IN O
distinct JJ JJ O
mechanisms NNS NNS O
underlie VBP VBP O
the DT DT O
development NN NN O
versus CC CC O
maintenance NN NN O
of IN IN O
local JJ JJ O
anesthetic JJ JJ O
- - - O
kindled JJ JJ O
seizures NNS NNS O
. . . O

The DT DT O
effectiveness NN NN O
of IN IN O
chronic JJ JJ O
but CC CC O
not RB RB O
repeated VBN VBN O
, , , O
intermittent JJ JJ O
injections NNS NNS O
of IN IN O
CBZ NNP NNP B-CHEM
suggests VBZ VBZ O
that IN IN O
different JJ JJ O
biochemical JJ JJ O
consequences NNS NNS O
result NN NN O
from IN IN O
the DT DT O
different JJ JJ O
treatment NN NN O
regimens NNS NNS O
. . . O

The DT DT O
possible JJ JJ O
utility NN NN O
of IN IN O
chronic JJ JJ O
CBZ NNP NNP B-CHEM
in IN IN O
preventing VBG VBG O
the DT DT O
development NN NN O
of IN IN O
toxic JJ JJ O
side NN NN O
effects NNS NNS O
in IN IN O
human JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
is VBZ VBZ O
suggested VBN VBN O
by IN IN O
these DT DT O
data NNS NNS O
, , , O
but CC CC O
remains VBZ VBZ O
to TO TO O
be VB VB O
directly RB RB O
evaluated VBN VBN O
. . . O

Magnetic NNP NNP O
resonance NN NN O
imaging VBG VBG O
of IN IN O
cerebral JJ JJ O
venous JJ JJ O
thrombosis NNS NNS O
secondary JJ JJ O
to TO TO O
" '' '' O
low JJ JJ O
- - - O
dose NN NN O
" '' '' O
birth NN NN O
control NN NN O
pills NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
and CC CC O
radiographic JJ JJ O
features NNS NNS O
of IN IN O
cerebral JJ JJ O
deep JJ JJ O
venous JJ JJ O
thrombosis NNS NNS O
in IN IN O
a DT DT O
21 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
white JJ JJ O
woman NN NN O
are VBP VBP O
presented VBN VBN O
. . . O

This DT DT O
nulliparous JJ JJ O
patient NN NN O
presented VBN VBN O
with IN IN O
relatively RB RB O
mild JJ JJ O
clinical JJ JJ O
symptoms NNS NNS O
and CC CC O
progressing VBG VBG O
mental JJ JJ O
status NN NN O
changes NNS NNS O
. . . O

The DT DT O
only RB RB O
known VBN VBN O
risk NN NN O
factor NN NN O
was VBD VBD O
" '' '' O
low JJ JJ O
- - - O
dose NN NN O
" '' '' O
oral JJ JJ B-CHEM
contraceptive JJ JJ I-CHEM
pills NNS NNS O
. . . O

The DT DT O
magnetic JJ JJ O
resonance NN NN O
image NN NN O
( ( ( O
MRI NNP NNP O
) ) ) O
showed VBD VBD O
increased VBN VBN O
signal NN NN O
intensity NN NN O
from IN IN O
the DT DT O
internal JJ JJ O
cerebral NN NN O
veins NNS NNS O
, , , O
vein NN NN O
of IN IN O
Galen NNP NNP O
, , , O
and CC CC O
straight JJ JJ O
sinus NN NN O
. . . O

The DT DT O
diagnosis NN NN O
was VBD VBD O
confirmed VBN VBN O
by IN IN O
arterial JJ JJ O
angiography NN NN O
. . . O

Beta NNP NNP O
- : : O
2 CD CD O
- : : O
adrenoceptor NN NN O
- - - O
mediated JJ JJ O
hypokalemia NN NN O
and CC CC O
its PRP$ PRP$ O
abolishment NN NN O
by IN IN O
oxprenolol NN NN B-CHEM
. . . O

The DT DT O
time NN NN O
course NN NN O
and CC CC O
concentration NN NN O
- - - O
effect NN NN O
relationship NN NN O
of IN IN O
terbutaline NN NN B-CHEM
- - - O
induced JJ JJ O
hypokalemia NN NN O
was VBD VBD O
studied VBN VBN O
, , , O
using VBG VBG O
computer NN NN O
- - - O
aided VBN VBN O
pharmacokinetic JJ JJ O
- - - O
dynamic JJ JJ O
modeling NN NN O
. . . O

Subsequently NNP NNP O
we PRP PRP O
investigated VBD VBD O
the DT DT O
efficacy NN NN O
of IN IN O
oxprenolol NN NN B-CHEM
in IN IN O
antagonizing VBG VBG O
such JJ JJ O
hypokalemia NN NN O
, , , O
together RB RB O
with IN IN O
the DT DT O
pharmacokinetic JJ JJ O
interaction NN NN O
between IN IN O
both DT DT O
drugs NNS NNS O
. . . O

Six CD CD O
healthy JJ JJ O
subjects NNS NNS O
were VBD VBD O
given VBN VBN O
a DT DT O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
subcutaneous JJ JJ O
dose NN NN O
of IN IN O
terbutaline NN NN B-CHEM
on IN IN O
two CD CD O
occasions NNS NNS O
: : : O
1 CD CD O
hour NN NN O
after IN IN O
oral JJ JJ O
administration NN NN O
of IN IN O
a DT DT O
placebo NN NN O
and CC CC O
1 CD CD O
hour NN NN O
after IN IN O
80 CD CD O
mg NN NN O
oxprenolol NN NN B-CHEM
orally RB RB O
. . . O

In IN IN O
the DT DT O
7 CD CD O
- : : O
hour NN NN O
period NN NN O
after IN IN O
terbutaline NN NN B-CHEM
administration NN NN O
, , , O
plasma NN NN O
samples NNS NNS O
were VBD VBD O
taken VBN VBN O
for IN IN O
determination NN NN O
of IN IN O
plasma NN NN O
potassium NN NN B-CHEM
levels NNS NNS O
and CC CC O
drug NN NN O
concentrations NNS NNS O
. . . O

The DT DT O
sigmoid NN NN O
Emax NNP NNP O
model NN NN O
offered VBD VBD O
a DT DT O
good JJ JJ O
description NN NN O
of IN IN O
the DT DT O
relation NN NN O
between IN IN O
terbutaline NN NN B-CHEM
concentrations NNS NNS O
and CC CC O
potassium NN NN B-CHEM
effects NNS NNS O
. . . O

Oxprenolol NNP NNP B-CHEM
caused VBD VBD O
decreases NNS NNS O
of IN IN O
65 CD CD O
% NN NN O
and CC CC O
56 CD CD O
% NN NN O
of IN IN O
terbutaline NN NN B-CHEM
volume NN NN O
of IN IN O
distribution NN NN O
and CC CC O
clearance NN NN O
, , , O
respectively RB RB O
, , , O
and CC CC O
an DT DT O
increase NN NN O
of IN IN O
130 CD CD O
% NN NN O
of IN IN O
its PRP$ PRP$ O
AUC NNP NNP O
. . . O

In IN IN O
spite NN NN O
of IN IN O
higher JJR JJR O
terbutaline NN NN B-CHEM
concentrations NNS NNS O
after IN IN O
oxprenolol NN NN B-CHEM
pretreatment NN NN O
, , , O
the DT DT O
hypokalemia NN NN O
was VBD VBD O
almost RB RB O
completely RB RB O
antagonized VBN VBN O
by IN IN O
the DT DT O
beta NN NN O
2 CD CD O
- : : O
blocking VBG VBG O
action NN NN O
. . . O

A DT DT O
dystonia NN NN O
- - - O
like IN IN O
syndrome NN NN O
after IN IN O
neuropeptide NN NN O
( ( ( O
MSH NNP NNP B-CHEM
/ NN NN O
ACTH NNP NNP B-CHEM
) ) ) O
stimulation NN NN O
of IN IN O
the DT DT O
rat NN NN O
locus NN NN O
ceruleus NN NN O
. . . O

The DT DT O
movement NN NN O
disorder NN NN O
investigated VBN VBN O
in IN IN O
these DT DT O
studies NNS NNS O
has VBZ VBZ O
some DT DT O
features NNS NNS O
in IN IN O
common JJ JJ O
with IN IN O
human JJ JJ O
idiopathic NN NN O
dystonia NN NN O
, , , O
and CC CC O
information NN NN O
obtained VBN VBN O
in IN IN O
these DT DT O
studies NNS NNS O
may MD MD O
be VB VB O
of IN IN O
potential JJ JJ O
clinical JJ JJ O
benefit NN NN O
. . . O

The DT DT O
present JJ JJ O
experimental JJ JJ O
results NNS NNS O
indicated VBD VBD O
that IN IN O
peptidergic JJ JJ O
stimulation NN NN O
of IN IN O
the DT DT O
LC NNP NNP O
resulted VBD VBD O
in IN IN O
a DT DT O
NE NNP NNP O
- - - O
mediated JJ JJ O
inhibition NN NN O
of IN IN O
cerebellar NN NN O
Purkinje NNP NNP O
cells NNS NNS O
located VBN VBN O
at IN IN O
terminals NNS NNS O
of IN IN O
the DT DT O
ceruleo NN NN O
- - - O
cerebellar JJ JJ O
pathway NN NN O
. . . O

However RB RB O
, , , O
it PRP PRP O
is VBZ VBZ O
not RB RB O
certain JJ JJ O
as IN IN O
to TO TO O
the DT DT O
following VBG VBG O
: : : O
( ( ( O
a DT DT O
) ) ) O
what WP WP O
receptors NNS NNS O
were VBD VBD O
stimulated VBN VBN O
by IN IN O
the DT DT O
ACTH NNP NNP B-CHEM
N NNP NNP O
- : : O
terminal NN NN O
fragments NNS NNS O
at IN IN O
the DT DT O
LC NNP NNP O
that WDT WDT O
resulted VBD VBD O
in IN IN O
this DT DT O
disorder NN NN O
; : : O
( ( ( O
b SYM SYM O
) ) ) O
whether IN IN O
NE NNP NNP O
, , , O
released VBD VBD O
onto IN IN O
Purkinje NNP NNP O
cell NN NN O
synapses NNS NNS O
located VBN VBN O
at IN IN O
terminals NNS NNS O
of IN IN O
the DT DT O
ceruleo NN NN O
- - - O
cerebellar JJ JJ O
pathway NN NN O
, , , O
did VBD VBD O
indeed RB RB O
cause VB VB O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
depression NN NN O
at IN IN O
Purkinje NNP NNP O
cell NN NN O
synapses NNS NNS O
( ( ( O
previously RB RB O
described VBN VBN O
by IN IN O
others NNS NNS O
) ) ) O
that WDT WDT O
resulted VBD VBD O
in IN IN O
the DT DT O
long JJ JJ O
duration NN NN O
of IN IN O
the DT DT O
movement NN NN O
disorder NN NN O
; : : O
( ( ( O
c SYM SYM O
) ) ) O
whether IN IN O
the DT DT O
inhibition NN NN O
of IN IN O
inhibitory NN NN O
Purkinje NNP NNP O
cells NNS NNS O
resulted VBD VBD O
in IN IN O
disinhibition NN NN O
or CC CC O
increased VBN VBN O
excitability NN NN O
of IN IN O
the DT DT O
unilateral JJ JJ O
cerebellar NN NN O
fastigial NN NN O
or CC CC O
interpositus NN NN O
nuclei NN NN O
, , , O
the DT DT O
output NN NN O
targets NNS NNS O
of IN IN O
the DT DT O
Purkinje NNP NNP O
cell NN NN O
axons NNS NNS O
, , , O
that WDT WDT O
may MD MD O
have VB VB O
been VBN VBN O
an DT DT O
important JJ JJ O
contributing VBG VBG O
factor NN NN O
to TO TO O
this DT DT O
disorder NN NN O
. . . O

These DT DT O
questions NNS NNS O
are VBP VBP O
currently RB RB O
being VBG VBG O
investigated VBN VBN O
. . . O

Enhanced NNP NNP O
stimulus NN NN O
- : : O
induced JJ JJ O
neurotransmitter NN NN O
overflow NN NN O
in IN IN O
epinephrine NN NN B-CHEM
- - - O
induced JJ JJ O
hypertensive JJ JJ O
rats NNS NNS O
is VBZ VBZ O
not RB RB O
mediated VBN VBN O
by IN IN O
prejunctional JJ JJ O
beta NN NN O
- - - O
adrenoceptor NN NN O
activation NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
examines VBZ VBZ O
the DT DT O
effect NN NN O
of IN IN O
6 CD CD O
- : : O
day NN NN O
epinephrine NN NN B-CHEM
treatment NN NN O
( ( ( O
100 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
per IN IN O
h NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
on IN IN O
stimulus NN NN O
- : : O
induced JJ JJ O
( ( ( O
1 CD CD O
Hz NNP NNP O
) ) ) O
endogenous JJ JJ O
neurotransmitter NN NN O
overflow NN NN O
from IN IN O
the DT DT O
isolated VBN VBN O
perfused JJ JJ O
kidney NN NN O
of IN IN O
vehicle NN NN O
- - - O
and CC CC O
epinephrine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Renal NNP NNP O
catecholamine NN NN B-CHEM
stores NNS NNS O
and CC CC O
stimulus NN NN O
- - - O
induced JJ JJ O
overflow NN NN O
in IN IN O
the DT DT O
vehicle NN NN O
- - - O
treated JJ JJ O
group NN NN O
consisted VBD VBD O
of IN IN O
norepinephrine NN NN B-CHEM
only RB RB O
. . . O

However RB RB O
, , , O
epinephrine NN NN B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
the DT DT O
incorporation NN NN O
of IN IN O
epinephrine NN NN B-CHEM
into IN IN O
renal JJ JJ O
catecholamine NN NN B-CHEM
stores NNS NNS O
such JJ JJ O
that IN IN O
approximately RB RB O
40 CD CD O
% NN NN O
of IN IN O
the DT DT O
catecholamine NN NN B-CHEM
present NN NN O
was VBD VBD O
epinephrine NN NN B-CHEM
while IN IN O
the DT DT O
norepinephrine NN NN B-CHEM
content NN NN O
was VBD VBD O
reduced VBN VBN O
by IN IN O
a DT DT O
similar JJ JJ O
degree NN NN O
. . . O

Total NNP NNP O
tissue NN NN O
catecholamine NN NN B-CHEM
content NN NN O
of IN IN O
the DT DT O
kidney NN NN O
on IN IN O
a DT DT O
molar NN NN O
basis NN NN O
was VBD VBD O
unchanged JJ JJ O
. . . O

Stimulus NNP NNP O
- : : O
induced JJ JJ O
fractional JJ JJ O
overflow NN NN O
of IN IN O
neurotransmitter NN NN O
from IN IN O
the DT DT O
epinephrine NN NN B-CHEM
- - - O
treated JJ JJ O
kidneys NNS NNS O
was VBD VBD O
approximately RB RB O
twice RB RB O
normal JJ JJ O
and CC CC O
consisted JJ JJ O
of IN IN O
both DT DT O
norepinephrine NN NN B-CHEM
and CC CC O
epinephrine NN NN B-CHEM
in IN IN O
proportions NNS NNS O
similar JJ JJ O
to TO TO O
those DT DT O
found VBN VBN O
in IN IN O
the DT DT O
kidney NN NN O
. . . O

This DT DT O
difference NN NN O
in IN IN O
fractional JJ JJ O
overflow NN NN O
between IN IN O
groups NNS NNS O
was VBD VBD O
not RB RB O
affected VBN VBN O
by IN IN O
neuronal NN NN O
and CC CC O
extraneuronal JJ JJ O
uptake JJ JJ O
blockade NN NN O
. . . O

Propranolol NNP NNP B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
stimulus NN NN O
- : : O
induced JJ JJ O
overflow NN NN O
in IN IN O
either DT DT O
group NN NN O
. . . O

Phentolamine NNP NNP B-CHEM
increased VBN VBN O
stimulus NN NN O
- - - O
induced JJ JJ O
overflow NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
although IN IN O
the DT DT O
increment NN NN O
in IN IN O
overflow NN NN O
was VBD VBD O
greater JJR JJR O
in IN IN O
the DT DT O
epinephrine NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
chronic JJ JJ O
epinephrine NN NN B-CHEM
treatment NN NN O
results NNS NNS O
in IN IN O
enhanced JJ JJ O
fractional NN NN O
neurotransmitter NN NN O
overflow NN NN O
. . . O

However RB RB O
, , , O
neither DT DT O
alterations NNS NNS O
in IN IN O
prejunctional JJ JJ O
beta NN NN O
- - - O
adrenoceptor NN NN O
influences NNS NNS O
nor CC CC O
alterations NNS NNS O
in IN IN O
neuronal NN NN O
and CC CC O
extraneuronal JJ JJ O
uptake NN NN O
mechanisms NNS NNS O
appear VBP VBP O
to TO TO O
be VB VB O
responsible JJ JJ O
for IN IN O
this DT DT O
alteration NN NN O
. . . O

Furthermore RB RB O
, , , O
data NNS NNS O
obtained VBN VBN O
with IN IN O
phentolamine NN NN B-CHEM
alone RB RB O
do VBP VBP O
not RB RB O
suggest VB VB O
alpha NN NN O
- - - O
adrenoceptor NN NN O
desensitization NN NN O
as IN IN O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
enhanced JJ JJ O
neurotransmitter NN NN O
overflow NN NN O
after IN IN O
epinephrine NN NN B-CHEM
treatment NN NN O
. . . O

GABA NNP NNP B-CHEM
involvement NN NN O
in IN IN O
naloxone NN NN B-CHEM
induced JJ JJ O
reversal NN NN O
of IN IN O
respiratory JJ JJ O
paralysis NNS NNS O
produced VBN VBN O
by IN IN O
thiopental NN NN B-CHEM
. . . O

No DT DT O
agent NN NN O
is VBZ VBZ O
yet RB RB O
available JJ JJ O
to TO TO O
reverse VB VB O
respiratory JJ JJ O
paralysis NN NN O
produced VBN VBN O
by IN IN O
CNS NNP NNP O
depressants NNS NNS O
, , , O
such JJ JJ O
as IN IN O
general JJ JJ O
anesthetics NNS NNS O
. . . O

In IN IN O
this DT DT O
study NN NN O
naloxone NN NN B-CHEM
reversed VBD VBD O
respiratory JJ JJ O
paralysis NN NN O
induced VBN VBN O
by IN IN O
thiopental NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
v NN NN O
. . . O
thiopental NN NN B-CHEM
produced VBD VBD O
anesthesia NN NN O
without IN IN O
altering VBG VBG O
respiratory NN NN O
rate NN NN O
, , , O
increased VBN VBN O
GABA NNP NNP B-CHEM
, , , O
decreased VBD VBD O
glutamate NN NN B-CHEM
, , , O
and CC CC O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
aspartate NN NN B-CHEM
or CC CC O
glycine NN NN B-CHEM
levels NNS NNS O
compared VBN VBN O
to TO TO O
controls NNS NNS O
in IN IN O
rat NN NN O
cortex NN NN O
and CC CC O
brain NN NN O
stem NN NN O
. . . O

Pretreatment NNP NNP O
of IN IN O
rats NNS NNS O
with IN IN O
thiosemicarbazide NN NN B-CHEM
for IN IN O
30 CD CD O
minutes NNS NNS O
abolished VBD VBD O
the DT DT O
anesthetic JJ JJ O
action NN NN O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
respiratory NN NN O
depressant JJ JJ O
action NN NN O
of IN IN O
thiopental NN NN B-CHEM
. . . O

50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
v NN NN O
. . . O
thiopental NN NN B-CHEM
produced VBD VBD O
respiratory JJ JJ O
arrest NN NN O
with IN IN O
further JJ JJ O
increase NN NN O
in IN IN O
GABA NNP NNP B-CHEM
and CC CC O
decrease NN NN O
in IN IN O
glutamate NN NN B-CHEM
again RB RB O
in IN IN O
cortex NN NN O
and CC CC O
brain NN NN O
stem NN NN O
without IN IN O
affecting VBG VBG O
any DT DT O
of IN IN O
the DT DT O
amino JJ JJ B-CHEM
acids NNS NNS I-CHEM
studied VBN VBN O
in IN IN O
four CD CD O
regions NNS NNS O
of IN IN O
rat NN NN O
brain NN NN O
. . . O

Naloxone NNP NNP B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
reversed VBD VBD O
respiratory JJ JJ O
paralysis NN NN O
, , , O
glutamate NN NN B-CHEM
and CC CC O
GABA NNP NNP B-CHEM
levels NNS NNS O
to TO TO O
control VB VB O
values NNS NNS O
in IN IN O
brain NN NN O
stem NN NN O
and CC CC O
cortex NN NN O
with IN IN O
no DT DT O
changes NNS NNS O
in IN IN O
caudate NN NN O
or CC CC O
cerebellum NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
naloxone NN NN B-CHEM
reverses NNS NNS O
respiratory JJ JJ O
paralysis NN NN O
produced VBN VBN O
by IN IN O
thiopental NN NN B-CHEM
and CC CC O
involves VBZ VBZ O
GABA NNP NNP B-CHEM
in IN IN O
its PRP$ PRP$ O
action NN NN O
. . . O

Diazepam NNP NNP B-CHEM
facilitates NNS NNS O
reflex JJ JJ O
bradycardia NN NN O
in IN IN O
conscious JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
diazepam NN NN B-CHEM
on IN IN O
cardiovascular JJ JJ O
function NN NN O
were VBD VBD O
assessed VBN VBN O
in IN IN O
conscious JJ JJ O
rats NNS NNS O
. . . O

Intravenous NNP NNP O
administration NN NN O
of IN IN O
diazepam NN NN B-CHEM
( ( ( O
1 CD CD O
- : : O
30 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
) ) ) O
produced VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
decrease NN NN O
in IN IN O
both DT DT O
the DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
and CC CC O
the DT DT O
heart NN NN O
rate NN NN O
. . . O

Also RB RB O
, , , O
reflex JJ JJ O
bradycardia NN NN O
was VBD VBD O
produced VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
adrenaline NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
25 CD CD O
- : : O
2 CD CD O
. . . O
5 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
) ) ) O
. . . O

Intravenous NNP NNP O
pretreatment NN NN O
of IN IN O
the DT DT O
rats NNS NNS O
with IN IN O
diazepam NN NN B-CHEM
, , , O
although IN IN O
causing VBG VBG O
no DT DT O
change NN NN O
in IN IN O
the DT DT O
adrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
pressor NN NN O
effect NN NN O
, , , O
did VBD VBD O
enhance NN NN O
the DT DT O
adrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
reflex NN NN O
bradycardia NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
diazepam NN NN B-CHEM
enhancement NN NN O
of IN IN O
adrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
reflex NN NN O
bradycardia NN NN O
was VBD VBD O
antagonized VBN VBN O
by IN IN O
pretreatment NN NN O
of IN IN O
rats NNS NNS O
with IN IN O
an DT DT O
intravenous JJ JJ O
dose NN NN O
of IN IN O
picrotoxin NN NN B-CHEM
( ( ( O
an DT DT O
agent NN NN O
blocks NNS NNS O
chloride NN NN B-CHEM
channels NNS NNS O
by IN IN O
binding VBG VBG O
to TO TO O
sites NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
benzodiazepine NN NN B-CHEM
- - - O
GABA NNP NNP B-CHEM
- - - O
chloride NN NN B-CHEM
channel NN NN O
macromolecular NN NN O
complex JJ JJ O
) ) ) O
. . . O

The DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
diazepam NN NN B-CHEM
acts NNS NNS O
through IN IN O
the DT DT O
benzodiazepine NN NN B-CHEM
- - - O
GABA NNP NNP B-CHEM
- - - O
chloride NN NN B-CHEM
channel NN NN O
macromolecular NN NN O
complex JJ JJ O
within IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
to TO TO O
facilitate VB VB O
reflex JJ JJ O
bradycardia NNS NNS O
mediated VBN VBN O
through IN IN O
baroreceptor NN NN O
reflexes NNS NNS O
in IN IN O
response NN NN O
to TO TO O
an DT DT O
acute JJ JJ O
increase NN NN O
in IN IN O
arterial JJ JJ O
pressure NN NN O
. . . O

Initial JJ JJ O
potassium NN NN B-CHEM
loss NN NN O
and CC CC O
hypokalaemia NN NN O
during IN IN O
chlorthalidone NN NN B-CHEM
administration NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
essential JJ JJ O
hypertension NN NN O
: : : O
the DT DT O
influence NN NN O
of IN IN O
dietary JJ JJ O
sodium NN NN B-CHEM
restriction NN NN O
. . . O

To TO TO O
investigate VB VB O
the DT DT O
initial JJ JJ O
potassium NN NN B-CHEM
loss NN NN O
and CC CC O
development NN NN O
of IN IN O
hypokalaemia NN NN O
during IN IN O
the DT DT O
administration NN NN O
of IN IN O
an DT DT O
oral JJ JJ O
diuretic JJ JJ O
, , , O
metabolic JJ JJ O
balance NN NN O
studies NNS NNS O
were VBD VBD O
performed VBN VBN O
in IN IN O
ten CD CD O
patients NNS NNS O
with IN IN O
essential JJ JJ O
hypertension NN NN O
who WP WP O
had VBD VBD O
shown VBN VBN O
hypokalaemia NN NN O
under IN IN O
prior RB RB O
oral JJ JJ O
diuretic JJ JJ O
treatment NN NN O
. . . O

Chlorthalidone NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
was VBD VBD O
given VBN VBN O
for IN IN O
14 CD CD O
days NNS NNS O
. . . O

Six CD CD O
patients NNS NNS O
received VBD VBD O
a DT DT O
normal JJ JJ O
- - - O
sodium NN NN B-CHEM
diet NN NN O
and CC CC O
four CD CD O
a DT DT O
low JJ JJ O
- - - O
sodium NN NN B-CHEM
( ( ( O
17 CD CD O
mmol NN NN O
/ NN NN O
day NN NN O
) ) ) O
diet NN NN O
. . . O

All DT DT O
patients NNS NNS O
had VBD VBD O
a DT DT O
normal JJ JJ O
initial JJ JJ O
total JJ JJ O
body NN NN O
potassium NN NN B-CHEM
( ( ( O
40K CD CD O
) ) ) O
. . . O

The DT DT O
electrolyte NN NN O
balances NNS NNS O
, , , O
weight NN NN O
, , , O
bromide NN NN O
space NN NN O
, , , O
plasma NN NN O
renin NN NN O
activity NN NN O
, , , O
and CC CC O
aldosterone NN NN B-CHEM
secretion NN NN O
rate NN NN O
were VBD VBD O
measured VBN VBN O
. . . O

In IN IN O
both DT DT O
groups NNS NNS O
a DT DT O
potassium NN NN B-CHEM
deficit NN NN O
developed VBN VBN O
, , , O
with IN IN O
proportionally RB RB O
larger JJR JJR O
losses NNS NNS O
from IN IN O
the DT DT O
extracellular NN NN O
than IN IN O
from IN IN O
the DT DT O
intracellular JJ JJ O
compartment NN NN O
. . . O

In IN IN O
the DT DT O
normal JJ JJ O
- - - O
sodium NN NN B-CHEM
group NN NN O
the DT DT O
highest JJS JJS O
mean NN NN O
potassium NN NN B-CHEM
deficit NN NN O
was VBD VBD O
176 CD CD O
mmol NN NN O
on IN IN O
day NN NN O
9 CD CD O
, , , O
after IN IN O
which WDT WDT O
some DT DT O
potassium NN NN B-CHEM
was VBD VBD O
regained VBN VBN O
; : : O
in IN IN O
the DT DT O
low JJ JJ O
- - - O
sodium NN NN B-CHEM
group NN NN O
the DT DT O
highest JJS JJS O
deficit NN NN O
was VBD VBD O
276 CD CD O
mmol NN NN O
on IN IN O
day NN NN O
13 CD CD O
. . . O

The DT DT O
normal JJ JJ O
- - - O
sodium NN NN B-CHEM
group NN NN O
showed VBD VBD O
an DT DT O
immediate JJ JJ O
but CC CC O
temporary JJ JJ O
rise NN NN O
of IN IN O
the DT DT O
renin NN NN O
and CC CC O
aldosterone NN NN B-CHEM
levels NNS NNS O
; : : O
in IN IN O
the DT DT O
low JJ JJ O
- - - O
sodium NN NN B-CHEM
group NN NN O
renin NN NN O
and CC CC O
aldosterone NN NN B-CHEM
increased VBD VBD O
more JJR JJR O
slowly RB RB O
but CC CC O
remained VBD VBD O
elevated JJ JJ O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
dietary JJ JJ O
sodium NN NN B-CHEM
restriction NN NN O
increases NNS NNS O
diuretic JJ JJ O
- : : O
induced JJ JJ O
potassium NN NN B-CHEM
loss NN NN O
, , , O
presumably RB RB O
by IN IN O
an DT DT O
increased JJ JJ O
activity NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
- - - O
aldosterone NN NN B-CHEM
system NN NN O
, , , O
while IN IN O
sodium NN NN B-CHEM
delivery NN NN O
to TO TO O
the DT DT O
distal JJ JJ O
renal NN NN O
tubules NNS NNS O
remains VBZ VBZ O
sufficiently RB RB O
high JJ JJ O
to TO TO O
allow VB VB O
increased VBN VBN O
potassium NN NN B-CHEM
secretion NN NN O
. . . O

Reversal NNP NNP O
of IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
catalepsy NN NN O
by IN IN O
novel NN NN O
aryl NN NN B-CHEM
- : : I-CHEM
piperazine NN NN I-CHEM
anxiolytic JJ JJ O
drugs NNS NNS O
. . . O

The DT DT O
novel NN NN O
anxiolytic JJ JJ O
drug NN NN O
, , , O
buspirone NN NN B-CHEM
, , , O
reverses NNS NNS O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
. . . O

A DT DT O
series NN NN O
of IN IN O
aryl NN NN B-CHEM
- - - I-CHEM
piperazine NN NN I-CHEM
analogues NNS NNS O
of IN IN O
buspirone NN NN B-CHEM
and CC CC O
other JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptaminergic JJ JJ I-CHEM
agonists NNS NNS I-CHEM
were VBD VBD O
tested VBN VBN O
for IN IN O
their PRP$ PRP$ O
ability NN NN O
to TO TO O
reverse VB VB O
haloperidol NN NN B-CHEM
induced VBN VBN O
catalepsy NN NN O
. . . O

Those DT DT O
drugs NNS NNS O
with IN IN O
strong JJ JJ O
affinity NN NN O
for IN IN O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine1a NN NN I-CHEM
receptors NNS NNS O
were VBD VBD O
able JJ JJ O
to TO TO O
reverse VB VB O
catalepsy NN NN O
. . . O

Drugs NNS NNS O
with IN IN O
affinity NN NN O
for IN IN O
other JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
receptors NNS NNS O
or CC CC O
weak JJ JJ O
affinity NN NN O
were VBD VBD O
ineffective JJ JJ O
. . . O

However RB RB O
, , , O
inhibition NN NN O
of IN IN O
postsynaptic JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
receptors NNS NNS O
neither DT DT O
inhibited JJ JJ O
nor CC CC O
potentiated JJ JJ O
reversal NN NN O
of IN IN O
catalepsy NN NN O
and CC CC O
leaves VBZ VBZ O
open JJ JJ O
the DT DT O
question NN NN O
as IN IN O
to TO TO O
the DT DT O
site NN NN O
or CC CC O
mechanism NN NN O
for IN IN O
this DT DT O
effect NN NN O
. . . O

Glycopyrronium NNP NNP B-CHEM
requirements NNS NNS O
for IN IN O
antagonism NN NN O
of IN IN O
the DT DT O
muscarinic JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
edrophonium NN NN B-CHEM
. . . O

We PRP PRP O
have VBP VBP O
compared VBN VBN O
, , , O
in IN IN O
60 CD CD O
adult NN NN O
patients NNS NNS O
, , , O
the DT DT O
cardiovascular JJ JJ O
effects NNS NNS O
of IN IN O
glycopyrronium NN NN B-CHEM
5 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
and CC CC O
10 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
given VBN VBN O
either CC CC O
simultaneously RB RB O
or CC CC O
1 CD CD O
min NN NN O
before IN IN O
edrophonium NN NN B-CHEM
1 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
. . . O

Significant JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
four CD CD O
groups NNS NNS O
were VBD VBD O
detected VBN VBN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Both DT DT O
groups NNS NNS O
receiving VBG VBG O
10 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
showed VBD VBD O
increases NNS NNS O
in IN IN O
heart NN NN O
rate NN NN O
of IN IN O
up IN IN O
to TO TO O
30 CD CD O
beat NN NN O
min NN NN O
- : : O
1 CD CD O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
limits NNS NNS O
28 CD CD O
- : : O
32 CD CD O
beat NN NN O
min NN NN O
- : : O
1 CD CD O
) ) ) O
. . . O

Use NN NN O
of IN IN O
glycopyrronium NN NN B-CHEM
5 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
provided VBN VBN O
greater NN NN O
cardiovascular JJ JJ O
stability NN NN O
and CC CC O
, , , O
given VBN VBN O
1 CD CD O
min NN NN O
before IN IN O
the DT DT O
edrophonium NN NN B-CHEM
, , , O
was VBD VBD O
sufficient JJ JJ O
to TO TO O
minimize VB VB O
early JJ JJ O
, , , O
edrophonium NN NN B-CHEM
- - - O
induced JJ JJ O
bradycardias NN NN O
. . . O

This DT DT O
low JJ JJ O
dose NN NN O
of IN IN O
glycopyrronium NN NN B-CHEM
provided VBN VBN O
good JJ JJ O
control NN NN O
of IN IN O
oropharyngeal JJ JJ O
secretions NNS NNS O
. . . O

Selective NNP NNP O
injection NN NN O
of IN IN O
iopentol NN NN B-CHEM
, , , O
iohexol NN NN B-CHEM
and CC CC O
metrizoate NN NN B-CHEM
into IN IN O
the DT DT O
left NN NN O
coronary JJ JJ O
artery NN NN O
of IN IN O
the DT DT O
dog NN NN O
. . . O

Induction NNP NNP O
of IN IN O
ventricular NN NN O
fibrillation NN NN O
and CC CC O
decrease NN NN O
of IN IN O
aortic JJ JJ O
pressure NN NN O
. . . O

In IN IN O
twenty CD CD O
beagle NN NN O
dogs NNS NNS O
selective JJ JJ O
injections NNS NNS O
were VBD VBD O
made VBN VBN O
into IN IN O
the DT DT O
left NN NN O
coronary JJ JJ O
artery NN NN O
with IN IN O
iopentol NN NN B-CHEM
, , , O
iohexol NN NN B-CHEM
and CC CC O
metrizoate NN NN B-CHEM
in IN IN O
doses NNS NNS O
of IN IN O
4 CD CD O
ml NN NN O
, , , O
8 CD CD O
ml NN NN O
and CC CC O
16 CD CD O
ml NN NN O
. . . O

Thirty NNP NNP O
- : : O
six CD CD O
iopentol NN NN B-CHEM
injections NNS NNS O
, , , O
35 CD CD O
iohexol NN NN B-CHEM
injections NNS NNS O
and CC CC O
37 CD CD O
metrizoate JJ JJ B-CHEM
injections NNS NNS O
were VBD VBD O
made VBN VBN O
. . . O

Frequencies NNP NNP O
of IN IN O
ventricular JJ JJ O
fibrillation NN NN O
were VBD VBD O
significantly RB RB O
lower JJR JJR O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
after IN IN O
iopentol NN NN B-CHEM
( ( ( O
0 CD CD O
% NN NN O
) ) ) O
and CC CC O
iohexol NN NN B-CHEM
( ( ( O
3 CD CD O
% NN NN O
) ) ) O
than IN IN O
after IN IN O
metrizoate NN NN B-CHEM
( ( ( O
22 CD CD O
% NN NN O
) ) ) O
. . . O

Iopentol NNP NNP B-CHEM
and CC CC O
iohexol NN NN B-CHEM
also RB RB O
produced VBD VBD O
significantly RB RB O
less JJR JJR O
decrease NN NN O
in IN IN O
aortic JJ JJ O
blood NN NN O
pressure NN NN O
than IN IN O
metrizoate NN NN B-CHEM
at IN IN O
the DT DT O
different JJ JJ O
doses NNS NNS O
. . . O

Thyroid NNP NNP O
function NN NN O
and CC CC O
urine JJ JJ O
- : : O
concentrating VBG VBG O
ability NN NN O
during IN IN O
lithium NN NN B-CHEM
treatment NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
that IN IN O
adenylate JJ JJ O
cyclase NN NN O
inhibition NN NN O
may MD MD O
be VB VB O
important JJ JJ O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
both DT DT O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
and CC CC O
hypothyroidism NN NN O
during IN IN O
lithium NN NN B-CHEM
treatment NN NN O
. . . O

We PRP PRP O
measured VBD VBD O
serum NN NN O
thyroxine NN NN B-CHEM
and CC CC O
urine JJ JJ O
- : : O
concentrating VBG VBG O
ability NN NN O
( ( ( O
Umax NNP NNP O
) ) ) O
in IN IN O
response NN NN O
to TO TO O
desmopressin NN NN O
( ( ( O
DDAVP NNP NNP O
) ) ) O
in IN IN O
85 CD CD O
patients NNS NNS O
receiving VBG VBG O
lithium NN NN B-CHEM
. . . O

Hypothyroidism NNP NNP O
developed VBD VBD O
in IN IN O
eight CD CD O
patients NNS NNS O
while IN IN O
they PRP PRP O
were VBD VBD O
taking VBG VBG O
lithium NN NN B-CHEM
. . . O

Impaired NNP NNP O
Umax NNP NNP O
was VBD VBD O
found VBN VBN O
in IN IN O
both DT DT O
euthyroid NN NN O
and CC CC O
hypothyroid NN NN O
patients NNS NNS O
while IN IN O
some DT DT O
hypothyroid NN NN O
patients NNS NNS O
concentrated VBD VBD O
their PRP$ PRP$ O
urine NN NN O
well RB RB O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
the DT DT O
dominant JJ JJ O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
lithium NN NN B-CHEM
exerts NNS NNS O
these DT DT O
two CD CD O
effects NNS NNS O
are VBP VBP O
different JJ JJ O
. . . O

Remodelling NNP NNP O
of IN IN O
nerve NN NN O
structure NN NN O
in IN IN O
experimental JJ JJ O
isoniazid NN NN B-CHEM
neuropathy NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

The DT DT O
neuropathy NN NN O
caused VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
isoniazid NN NN B-CHEM
in IN IN O
rats NNS NNS O
was VBD VBD O
studied VBN VBN O
with IN IN O
a DT DT O
computer NN NN O
- - - O
assisted VBN VBN O
morphometric JJ JJ O
method NN NN O
. . . O

Scatter NNP NNP O
diagrams NNS NNS O
of IN IN O
the DT DT O
g SYM SYM O
ratio NN NN O
( ( ( O
quotient NN NN O
fibre NN NN O
diameter NN NN O
/ NN NN O
axon NN NN O
diameter NN NN O
) ) ) O
define NN NN O
regenerating VBG VBG O
fibres NNS NNS O
as IN IN O
a DT DT O
distinct JJ JJ O
population NN NN O
, , , O
distinguishable JJ JJ O
from IN IN O
the DT DT O
surviving VBG VBG O
fibres NNS NNS O
by IN IN O
reduced JJ JJ O
sheath NN NN O
thickness NN NN O
and CC CC O
reduced VBN VBN O
axon NN NN O
calibre NN NN O
. . . O

There EX EX O
was VBD VBD O
also RB RB O
evidence NN NN O
of IN IN O
a DT DT O
subtle JJ JJ O
direct JJ JJ O
toxic JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
entire JJ JJ O
fibre NN NN O
population NN NN O
, , , O
causing VBG VBG O
axon NN NN O
shrinkage NN NN O
masked VBN VBN O
by IN IN O
readjustment NN NN O
of IN IN O
the DT DT O
myelin NN NN O
sheath NN NN O
. . . O

Multicenter NNP NNP O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
multiple JJ JJ O
- - - O
dose NN NN O
, , , O
parallel JJ JJ O
- - - O
groups NNS NNS O
efficacy NN NN O
and CC CC O
safety NN NN O
trial NN NN O
of IN IN O
azelastine NN NN B-CHEM
, , , O
chlorpheniramine NN NN B-CHEM
, , , O
and CC CC O
placebo NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
spring NN NN O
allergic JJ JJ O
rhinitis NN NN O
. . . O

Azelastine NNP NNP B-CHEM
, , , O
a DT DT O
novel NN NN O
antiallergic JJ JJ O
medication NN NN O
, , , O
was VBD VBD O
compared VBN VBN O
with IN IN O
chlorpheniramine NN NN B-CHEM
maleate NN NN I-CHEM
and CC CC O
placebo NN NN O
for IN IN O
efficacy NN NN O
and CC CC O
safety NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
spring NN NN O
allergic JJ JJ O
rhinitis NN NN O
in IN IN O
a DT DT O
multicenter NN NN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
multiple JJ JJ O
- - - O
dose NN NN O
, , , O
parallel JJ JJ O
- - - O
groups NNS NNS O
study NN NN O
. . . O

One CD CD O
hundred CD CD O
fifty NN NN O
- : : O
five CD CD O
subjects NNS NNS O
participated VBN VBN O
. . . O

Subjects NNP NNP O
ranged VBD VBD O
in IN IN O
age NN NN O
from IN IN O
18 CD CD O
to TO TO O
60 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
and CC CC O
had VBD VBD O
at IN IN O
least JJS JJS O
a DT DT O
2 CD CD O
- : : O
year NN NN O
history NN NN O
of IN IN O
spring NN NN O
allergic JJ JJ O
rhinitis NN NN O
, , , O
confirmed VBN VBN O
by IN IN O
positive JJ JJ O
skin NN NN O
test NN NN O
to TO TO O
spring NN NN O
aeroallergens NNS NNS O
. . . O

Medications NNP NNP O
were VBD VBD O
given VBN VBN O
four CD CD O
times NNS NNS O
daily JJ JJ O
; : : O
the DT DT O
azelastine NN NN B-CHEM
groups NNS NNS O
received VBD VBD O
0 CD CD O
. . . O
5 CD CD O
, , , O
1 CD CD O
. . . O
0 CD CD O
, , , O
or CC CC O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
in IN IN O
the DT DT O
morning NN NN O
and CC CC O
evening NN NN O
with IN IN O
placebo NN NN O
in IN IN O
the DT DT O
early JJ JJ O
and CC CC O
late JJ JJ O
afternoon NN NN O
; : : O
the DT DT O
chlorpheniramine NN NN B-CHEM
group NN NN O
received VBD VBD O
4 CD CD O
. . . O
0 CD CD O
mg CD CD O
four CD CD O
times NNS NNS O
daily RB RB O
. . . O

Daily NNP NNP O
subject JJ JJ O
symptom NN NN O
cards NNS NNS O
were VBD VBD O
completed VBN VBN O
during IN IN O
a DT DT O
screening VBG VBG O
period NN NN O
to TO TO O
assess VB VB O
pretreatment NN NN O
symptoms NNS NNS O
and CC CC O
during IN IN O
a DT DT O
4 CD CD O
- : : O
week NN NN O
treatment NN NN O
period NN NN O
while IN IN O
subjects NNS NNS O
received VBD VBD O
study NN NN O
medications NNS NNS O
. . . O

Individual NNP NNP O
symptoms NNS NNS O
, , , O
total JJ JJ O
symptoms NNS NNS O
, , , O
and CC CC O
major JJ JJ O
symptoms NNS NNS O
were VBD VBD O
compared VBN VBN O
to TO TO O
determine VB VB O
efficacy NN NN O
of IN IN O
medication NN NN O
. . . O

Elicited NNP NNP O
, , , O
volunteered VBD VBD O
, , , O
and CC CC O
observed VBD VBD O
adverse JJ JJ O
experiences NNS NNS O
were VBD VBD O
recorded VBN VBN O
for IN IN O
each DT DT O
subject NN NN O
and CC CC O
compared VBN VBN O
among IN IN O
groups NNS NNS O
. . . O

Vital NNP NNP O
signs NNS NNS O
, , , O
body NN NN O
weights NNS NNS O
, , , O
serum NN NN O
chemistry NN NN O
values NNS NNS O
, , , O
complete JJ JJ O
blood NN NN O
cell NN NN O
counts NNS NNS O
, , , O
urine NN NN O
studies NNS NNS O
, , , O
and CC CC O
electrocardiograms NNS NNS O
were VBD VBD O
obtained VBN VBN O
for IN IN O
each DT DT O
subject NN NN O
and CC CC O
compared VBN VBN O
among IN IN O
groups NNS NNS O
. . . O

Symptoms NNP NNP O
relief NN NN O
in IN IN O
the DT DT O
group NN NN O
receiving VBG VBG O
the DT DT O
highest JJS JJS O
concentration NN NN O
of IN IN O
azelastine NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
twice RB RB O
daily JJ JJ O
) ) ) O
was VBD VBD O
statistically RB RB O
greater JJR JJR O
than IN IN O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
during IN IN O
all DT DT O
weeks NNS NNS O
of IN IN O
the DT DT O
study NN NN O
. . . O

Lower JJR JJR O
doses NNS NNS O
of IN IN O
azelastine NN NN B-CHEM
were VBD VBD O
statistically RB RB O
more RBR RBR O
effective JJ JJ O
than IN IN O
placebo NN NN O
only RB RB O
during IN IN O
portions NNS NNS O
of IN IN O
the DT DT O
first JJ JJ O
3 CD CD O
weeks NNS NNS O
of IN IN O
the DT DT O
study NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
although IN IN O
the DT DT O
chlorpheniramine NN NN B-CHEM
group NN NN O
did VBD VBD O
have VB VB O
fewer JJR JJR O
symptoms NNS NNS O
than IN IN O
the DT DT O
placebo NN NN O
group NN NN O
during IN IN O
the DT DT O
study NN NN O
, , , O
the DT DT O
difference NN NN O
never RB RB O
reached VBD VBD O
statistical JJ JJ O
significance NN NN O
during IN IN O
any DT DT O
week NN NN O
of IN IN O
the DT DT O
study NN NN O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
serious JJ JJ O
side NN NN O
effects NNS NNS O
in IN IN O
any DT DT O
of IN IN O
the DT DT O
treatment NN NN O
groups NNS NNS O
. . . O

Drowsiness NNP NNP O
and CC CC O
altered VBN VBN O
taste NN NN O
perception NN NN O
were VBD VBD O
increased VBN VBN O
significantly RB RB O
over IN IN O
placebo NN NN O
only RB RB O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
azelastine NN NN B-CHEM
group NN NN O
. . . O

Azelastine NNP NNP B-CHEM
appears VBZ VBZ O
to TO TO O
be VB VB O
a DT DT O
safe JJ JJ O
, , , O
efficacious JJ JJ O
medication NN NN O
for IN IN O
seasonal JJ JJ O
allergic JJ JJ O
rhinitis NN NN O
. . . O

Toxicity NNP NNP O
due JJ JJ O
to TO TO O
remission NN NN O
inducing VBG VBG O
drugs NNS NNS O
in IN IN O
rheumatoid NN NN O
arthritis NN NN O
. . . O

Association NNP NNP O
with IN IN O
HLA NNP NNP O
- : : O
B35 NNP NNP O
and CC CC O
Cw4 NNP NNP O
antigens NNS NNS O
. . . O

Twenty CD CD O
- - - O
five CD CD O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
( ( ( O
RA NNP NNP O
) ) ) O
who WP WP O
developed VBD VBD O
toxicity NN NN O
while IN IN O
taking VBG VBG O
remission NN NN O
inducing VBG VBG O
drugs NNS NNS O
and CC CC O
30 CD CD O
without IN IN O
toxicity NN NN O
were VBD VBD O
studied VBN VBN O
for IN IN O
possible JJ JJ O
associations NNS NNS O
with IN IN O
class NN NN O
I PRP PRP O
and CC CC O
II NNP NNP O
HLA NNP NNP O
antigens NNS NNS O
. . . O

A DT DT O
strong JJ JJ O
association NN NN O
has VBZ VBZ O
been VBN VBN O
found VBN VBN O
between IN IN O
nephritis NNS NNS O
and CC CC O
dermatitis NNS NNS O
due JJ JJ O
to TO TO O
Tiopronin NNP NNP B-CHEM
( ( ( O
a DT DT O
D NNP NNP B-CHEM
- : : I-CHEM
Penicillamine NNP NNP I-CHEM
like IN IN O
compound NN NN O
) ) ) O
and CC CC O
class NN NN O
I PRP PRP O
antigens VBP VBP O
B35 NNP NNP O
- : : O
Cw4 NNP NNP O
, , , O
and CC CC O
between IN IN O
dermatitis NNS NNS O
due JJ JJ O
to TO TO O
gold VB VB B-CHEM
thiosulphate NN NN B-CHEM
and CC CC O
B35 NNP NNP O
. . . O

Compared VBN VBN O
to TO TO O
healthy JJ JJ O
controls NNS NNS O
a DT DT O
lower JJR JJR O
DR5 NNP NNP O
frequency NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
RA NNP NNP O
except IN IN O
for IN IN O
the DT DT O
Tiopronin NNP NNP B-CHEM
related VBN VBN O
nephritis NN NN O
group NN NN O
. . . O

Transient NNP NNP O
contralateral JJ JJ O
rotation NN NN O
following VBG VBG O
unilateral JJ JJ O
substantia NN NN O
nigra NN NN O
lesion NN NN O
reflects VBZ VBZ O
susceptibility NN NN O
of IN IN O
the DT DT O
nigrostriatal JJ JJ O
system NN NN O
to TO TO O
exhaustion NN NN O
by IN IN O
amphetamine NN NN B-CHEM
. . . O

Following VBG VBG O
unilateral JJ JJ O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
induced VBD VBD O
SN NNP NNP O
lesion NN NN O
, , , O
a DT DT O
transient JJ JJ O
period NN NN O
of IN IN O
contralateral JJ JJ O
rotation NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
precede VB VB O
the DT DT O
predominant NN NN O
ipsilateral JJ JJ O
circling NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
clarify VB VB O
the DT DT O
nature NN NN O
of IN IN O
this DT DT O
initial JJ JJ O
contralateral NN NN O
rotation NN NN O
we PRP PRP O
examined VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
duration NN NN O
of IN IN O
recovery NN NN O
period NN NN O
after IN IN O
the DT DT O
lesion NN NN O
, , , O
on IN IN O
amphetamine NN NN B-CHEM
- : : O
induced JJ JJ O
rotational NN NN O
behavior NN NN O
. . . O

Three CD CD O
days NNS NNS O
post JJ JJ O
lesion NN NN O
, , , O
most RBS RBS O
rats NNS NNS O
circled VBD VBD O
predominantly RB RB O
contralaterally RB RB O
to TO TO O
the DT DT O
lesion NN NN O
. . . O

Such JJ JJ O
contralateral JJ JJ O
rotation NN NN O
may MD MD O
result VB VB O
from IN IN O
either DT DT O
degeneration NN NN O
- - - O
induced JJ JJ O
breakdown NN NN O
of IN IN O
the DT DT O
DA NNP NNP O
pool NN NN O
, , , O
or CC CC O
lesion NN NN O
- - - O
induced JJ JJ O
increase NN NN O
of IN IN O
DA NNP NNP O
turnover NN NN O
in IN IN O
the DT DT O
spared JJ JJ O
neurons NNS NNS O
. . . O

A DT DT O
substantial JJ JJ O
degree NN NN O
of IN IN O
contralateral JJ JJ O
preference NN NN O
was VBD VBD O
still RB RB O
evident JJ JJ O
when WRB WRB O
amphetamine NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
24 CD CD O
days NNS NNS O
after IN IN O
lesioning VBG VBG O
, , , O
indicating VBG VBG O
involvement NN NN O
of IN IN O
spared VBN VBN O
cells NNS NNS O
in IN IN O
the DT DT O
contralateral JJ JJ O
rotation NN NN O
. . . O

However RB RB O
, , , O
regardless RB RB O
of IN IN O
the DT DT O
duration NN NN O
of IN IN O
recovery NN NN O
( ( ( O
and CC CC O
irrespective JJ JJ O
of IN IN O
either DT DT O
lesion NN NN O
volume NN NN O
, , , O
amphetamine NN NN B-CHEM
dose NN NN O
, , , O
or CC CC O
post NN NN O
- - - O
lesion NN NN O
motor NN NN O
exercise NN NN O
) ) ) O
, , , O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
rotation NN NN O
tended VBD VBD O
to TO TO O
become VB VB O
gradually RB RB O
more JJR JJR O
ipsilateral JJ JJ O
as IN IN O
the DT DT O
observation NN NN O
session NN NN O
progressed VBN VBN O
, , , O
and CC CC O
all DT DT O
rats NNS NNS O
circled VBD VBD O
ipsilaterally RB RB O
to TO TO O
the DT DT O
lesion NN NN O
in IN IN O
response NN NN O
to TO TO O
further VB VB O
amphetamine NN NN B-CHEM
injections NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
amphetamine NN NN B-CHEM
has VBZ VBZ O
an DT DT O
irreversible JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
post NN NN O
- - - O
lesion NN NN O
DA NNP NNP O
pool NN NN O
contributing VBG VBG O
to TO TO O
contralateral JJ JJ O
rotation NN NN O
. . . O

Mitomycin NNP NNP B-CHEM
C NNP NNP I-CHEM
associated VBN VBN O
hemolytic JJ JJ O
uremic JJ JJ O
syndrome NN NN O
. . . O

Mitomycin NNP NNP B-CHEM
C NNP NNP I-CHEM
associated VBN VBN O
Hemolytic NNP NNP O
Uremic NNP NNP O
Syndrome NN NN O
( ( ( O
HUS NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
potentially RB RB O
fatal JJ JJ O
but CC CC O
uncommon JJ JJ O
condition NN NN O
that WDT WDT O
is VBZ VBZ O
not RB RB O
yet RB RB O
widely RB RB O
recognised VBN VBN O
. . . O

It PRP PRP O
consists VBZ VBZ O
of IN IN O
microangiopathic JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
, , , O
thrombocytopenia NN NN O
and CC CC O
progressive JJ JJ O
renal NN NN O
failure NN NN O
associated VBN VBN O
with IN IN O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
treatment NN NN O
and CC CC O
affects VBZ VBZ O
about IN IN O
10 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
this DT DT O
agent NN NN O
. . . O

The DT DT O
renal JJ JJ O
failure NN NN O
usually RB RB O
develops VBZ VBZ O
about IN IN O
8 CD CD O
- : : O
10 CD CD O
mth NN NN O
after IN IN O
start NN NN O
of IN IN O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
treatment NN NN O
and CC CC O
the DT DT O
mortality NN NN O
is VBZ VBZ O
approximately RB RB O
60 CD CD O
% NN NN O
from IN IN O
renal JJ JJ O
failure NN NN O
or CC CC O
pulmonary JJ JJ O
edema NN NN O
. . . O

Renal NNP NNP O
lesions NNS NNS O
are VBP VBP O
similar JJ JJ O
to TO TO O
those DT DT O
seen VBN VBN O
in IN IN O
idiopathic JJ JJ O
HUS NNP NNP O
and CC CC O
include VB VB O
arteriolar NN NN O
fibrin NN NN O
thrombi NN NN O
, , , O
expanded VBN VBN O
subendothelial JJ JJ O
zones NNS NNS O
in IN IN O
glomerular NN NN O
capillary JJ JJ O
walls NNS NNS O
, , , O
ischemic JJ JJ O
wrinkling NN NN O
of IN IN O
glomerular NN NN O
basement NN NN O
membranes NNS NNS O
and CC CC O
mesangiolysis NNS NNS O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
action NN NN O
is VBZ VBZ O
postulated VBN VBN O
as IN IN O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
- - - O
induced JJ JJ O
endothelial NN NN O
cell NN NN O
damage NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
the DT DT O
clinical JJ JJ O
course NN NN O
and CC CC O
pathological JJ JJ O
findings NNS NNS O
in IN IN O
a DT DT O
65 CD CD O
yr NN NN O
- : : O
old JJ JJ O
man NN NN O
with IN IN O
gastric JJ JJ O
adenocarcinoma NN NN O
who WP WP O
developed VBD VBD O
renal JJ JJ O
failure NN NN O
and CC CC O
thrombocytopenia NN NN O
while IN IN O
on IN IN O
treatment NN NN O
with IN IN O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
and CC CC O
died VBD VBD O
in IN IN O
pulmonary JJ JJ O
edema NN NN O
. . . O

Ketanserin NNP NNP B-CHEM
pretreatment NN NN O
reverses NNS NNS O
alfentanil NN NN B-CHEM
- : : O
induced JJ JJ O
muscle NN NN O
rigidity NN NN O
. . . O

Systemic NNP NNP O
pretreatment NN NN O
with IN IN O
ketanserin NN NN B-CHEM
, , , O
a DT DT O
relatively RB RB O
specific JJ JJ O
type NN NN O
- : : O
2 CD CD O
serotonin NN NN B-CHEM
receptor NN NN O
antagonist NN NN O
, , , O
significantly RB RB O
attenuated VBD VBD O
the DT DT O
muscle NN NN O
rigidity NN NN O
produced VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
the DT DT O
potent JJ JJ O
short JJ JJ O
- - - O
acting VBG VBG O
opiate JJ JJ O
agonist NN NN O
alfentanil NN NN B-CHEM
. . . O

Following VBG VBG O
placement NN NN O
of IN IN O
subcutaneous JJ JJ O
electrodes NNS NNS O
in IN IN O
each DT DT O
animal NN NN O
' '' '' O
s VBZ VBZ O
left VBN VBN O
gastrocnemius NN NN O
muscle NN NN O
, , , O
rigidity NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
analyzing VBG VBG O
root NN NN O
- - - O
mean VB VB O
- - - O
square VB VB O
electromyographic JJ JJ O
activity NN NN O
. . . O

Intraperitoneal NNP NNP O
ketanserin NN NN B-CHEM
administration NN NN O
at IN IN O
doses NNS NNS O
of IN IN O
0 CD CD O
. . . O
63 CD CD O
and CC CC O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
prevented VBD VBD O
the DT DT O
alfentanil NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
electromyographic JJ JJ O
activity NN NN O
compared VBN VBN O
with IN IN O
animals NNS NNS O
pretreated VBN VBN O
with IN IN O
saline NN NN O
. . . O

Chlordiazepoxide NNP NNP B-CHEM
at IN IN O
doses NNS NNS O
up IN IN O
to TO TO O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
failed VBD VBD O
to TO TO O
significantly RB RB O
influence VB VB O
the DT DT O
rigidity NN NN O
produced VBN VBN O
by IN IN O
alfentanil NN NN B-CHEM
. . . O

Despite IN IN O
the DT DT O
absence NN NN O
of IN IN O
rigidity NN NN O
, , , O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
ketanserin NN NN B-CHEM
( ( ( O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
31 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
followed VBN VBN O
by IN IN O
alfentanil NN NN B-CHEM
were VBD VBD O
motionless NNS NNS O
, , , O
flaccid NN NN O
, , , O
and CC CC O
less RBR RBR O
responsive JJ JJ O
to TO TO O
external JJ JJ O
stimuli NN NN O
than IN IN O
were VBD VBD O
animals NNS NNS O
receiving VBG VBG O
alfentanil NN NN B-CHEM
alone RB RB O
. . . O

Rats NNP NNP O
that WDT WDT O
received VBD VBD O
ketanserin NN NN B-CHEM
and CC CC O
alfentanil NN NN B-CHEM
exhibited VBN VBN O
less JJR JJR O
rearing VBG VBG O
and CC CC O
exploratory JJ JJ O
behavior NN NN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
60 CD CD O
- : : O
min NN NN O
recording NN NN O
period NN NN O
than IN IN O
did VBD VBD O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
ketanserin NN NN B-CHEM
alone RB RB O
. . . O

These DT DT O
results NNS NNS O
, , , O
in IN IN O
combination NN NN O
with IN IN O
previous JJ JJ O
work NN NN O
, , , O
suggest VBP VBP O
that IN IN O
muscle NN NN O
rigidity NN NN O
, , , O
a DT DT O
clinically RB RB O
relevant JJ JJ O
side NN NN O
- - - O
effect NN NN O
of IN IN O
parenteral JJ JJ O
narcotic JJ JJ O
administration NN NN O
, , , O
may MD MD O
be VB VB O
partly RB RB O
mediated VBN VBN O
via IN IN O
serotonergic JJ JJ O
pathways NNS NNS O
. . . O

Pretreatment NNP NNP O
with IN IN O
type NN NN O
- - - O
2 CD CD O
serotonin NN NN B-CHEM
antagonists NNS NNS O
may MD MD O
be VB VB O
clinically RB RB O
useful JJ JJ O
in IN IN O
attenuating VBG VBG O
opiate JJ JJ O
- - - O
induced JJ JJ O
rigidity NN NN O
, , , O
although IN IN O
further JJ JJ O
studies NNS NNS O
will MD MD O
be VB VB O
necessary JJ JJ O
to TO TO O
assess VB VB O
the DT DT O
interaction NN NN O
of IN IN O
possibly RB RB O
enhanced VBN VBN O
CNS NNP NNP O
, , , O
cardiovascular JJ JJ O
, , , O
and CC CC O
respiratory JJ JJ O
depression NN NN O
. . . O

Antagonism NNP NNP O
of IN IN O
diazepam NN NN B-CHEM
- - - O
induced JJ JJ O
sedative JJ JJ O
effects NNS NNS O
by IN IN O
Ro15 NNP NNP B-CHEM
- : : I-CHEM
1788 CD CD I-CHEM
in IN IN O
patients NNS NNS O
after IN IN O
surgery NN NN O
under IN IN O
lumbar NN NN O
epidural JJ JJ O
block NN NN O
. . . O

A DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
placebo NN NN O
- - - O
controlled JJ JJ O
investigation NN NN O
of IN IN O
efficacy NN NN O
and CC CC O
safety NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
efficacy NN NN O
of IN IN O
Ro15 NNP NNP B-CHEM
- : : I-CHEM
1788 CD CD I-CHEM
and CC CC O
a DT DT O
placebo NN NN O
in IN IN O
reversing VBG VBG O
diazepam NN NN B-CHEM
- - - O
induced JJ JJ O
effects NNS NNS O
after IN IN O
surgery NN NN O
under IN IN O
epidural JJ JJ O
block NN NN O
, , , O
and CC CC O
to TO TO O
evaluate VB VB O
the DT DT O
local JJ JJ O
tolerance NN NN O
and CC CC O
general JJ JJ O
safety NN NN O
of IN IN O
Ro15 NNP NNP B-CHEM
- : : I-CHEM
1788 CD CD I-CHEM
. . . O

Fifty NNP NNP O
- : : O
seven CD CD O
patients NNS NNS O
were VBD VBD O
sedated VBN VBN O
with IN IN O
diazepam NN NN B-CHEM
for IN IN O
surgery NN NN O
under IN IN O
epidural JJ JJ O
anaesthesia NN NN O
. . . O

Antagonism NNP NNP O
of IN IN O
diazepam NN NN B-CHEM
- - - O
induced JJ JJ O
effects NNS NNS O
by IN IN O
Ro15 NNP NNP B-CHEM
- : : I-CHEM
1788 CD CD I-CHEM
was VBD VBD O
investigated VBN VBN O
postoperatively RB RB O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
subjective JJ JJ O
assessment NN NN O
of IN IN O
mood NN NN O
rating NN NN O
, , , O
an DT DT O
objective NN NN O
test NN NN O
of IN IN O
performance NN NN O
, , , O
a DT DT O
test NN NN O
for IN IN O
amnesia NN NN O
, , , O
and CC CC O
vital JJ JJ O
signs NNS NNS O
were VBD VBD O
recorded VBN VBN O
for IN IN O
up IN IN O
to TO TO O
300 CD CD O
min NN NN O
after IN IN O
administration NN NN O
of IN IN O
the DT DT O
trial NN NN O
drug NN NN O
. . . O

No DT DT O
significant JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
were VBD VBD O
observed VBN VBN O
for IN IN O
mood NN NN O
rating NN NN O
, , , O
amnesia NN NN O
, , , O
or CC CC O
vital JJ JJ O
signs NNS NNS O
. . . O

The DT DT O
Ro15 NNP NNP B-CHEM
- : : I-CHEM
1788 CD CD I-CHEM
group NN NN O
showed VBD VBD O
a DT DT O
significant JJ JJ O
improvement NN NN O
in IN IN O
the DT DT O
performance NN NN O
test NN NN O
up IN IN O
to TO TO O
120 CD CD O
min NN NN O
after IN IN O
administration NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
reaction NN NN O
at IN IN O
the DT DT O
injection NN NN O
site NN NN O
. . . O

Chorea NNP NNP O
associated VBN VBN O
with IN IN O
oral JJ JJ B-CHEM
contraception NN NN I-CHEM
. . . O

Three CD CD O
patients NNS NNS O
developed VBN VBN O
chorea NN NN O
while IN IN O
receiving VBG VBG O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

Two CD CD O
were VBD VBD O
young JJ JJ O
patients NNS NNS O
whose WP$ WP$ O
chorea NN NN O
developed VBN VBN O
long RB RB O
after IN IN O
treatment NN NN O
had VBD VBD O
been VBN VBN O
started VBN VBN O
and CC CC O
disappeared VBD VBD O
soon RB RB O
after IN IN O
it PRP PRP O
had VBD VBD O
been VBN VBN O
discontinued VBN VBN O
. . . O

The DT DT O
third JJ JJ O
patient NN NN O
had VBD VBD O
acute JJ JJ O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
chorea NN NN O
after IN IN O
prolonged JJ JJ O
oral JJ JJ B-CHEM
contraception NN NN I-CHEM
. . . O

Prolonged NNP NNP O
administration NN NN O
of IN IN O
female JJ JJ O
sex NN NN O
hormones NNS NNS O
is VBZ VBZ O
a DT DT O
possible JJ JJ O
cause NN NN O
of IN IN O
chorea NN NN O
in IN IN O
women NNS NNS O
who WP WP O
have VBP VBP O
not RB RB O
previously RB RB O
had VBD VBD O
chorea NN NN O
or CC CC O
rheumatic JJ JJ O
fever NN NN O
. . . O

Co NNP NNP O
- : : O
carcinogenic JJ JJ O
effect NN NN O
of IN IN O
retinyl NN NN B-CHEM
acetate NN NN I-CHEM
on IN IN O
forestomach NN NN O
carcinogenesis NN NN O
of IN IN O
male JJ JJ O
F344 NNP NNP O
rats NNS NNS O
induced VBN VBN O
with IN IN O
butylated JJ JJ B-CHEM
hydroxyanisole NN NN I-CHEM
. . . O

The DT DT O
potential JJ JJ O
modifying VBG VBG O
effect NN NN O
of IN IN O
retinyl NN NN B-CHEM
acetate NN NN I-CHEM
( ( ( O
RA NNP NNP B-CHEM
) ) ) O
on IN IN O
butylated VBN VBN B-CHEM
hydroxyanisole NN NN I-CHEM
( ( ( O
BHA NNP NNP B-CHEM
) ) ) O
- : : O
induced VBN VBN O
rat NN NN O
forestomach NN NN O
tumorigenesis NN NN O
was VBD VBD O
examined VBN VBN O
. . . O

Male NNP NNP O
F344 NNP NNP O
rats NNS NNS O
, , , O
5 CD CD O
weeks NNS NNS O
of IN IN O
age NN NN O
, , , O
were VBD VBD O
maintained VBN VBN O
on IN IN O
diet NN NN O
containing VBG VBG O
1 CD CD O
% NN NN O
or CC CC O
2 CD CD O
% NN NN O
BHA NNP NNP B-CHEM
by IN IN O
weight NN NN O
and CC CC O
simultaneously RB RB O
on IN IN O
drinking VBG VBG O
water NN NN O
supplemented VBD VBD O
with IN IN O
RA NNP NNP B-CHEM
at IN IN O
various JJ JJ O
concentrations NNS NNS O
( ( ( O
w NN NN O
/ NN NN O
v NN NN O
) ) ) O
for IN IN O
52 CD CD O
weeks NNS NNS O
. . . O

In IN IN O
groups NNS NNS O
given VBN VBN O
2 CD CD O
% NN NN O
BHA NNP NNP B-CHEM
, , , O
although IN IN O
marked VBN VBN O
hyperplastic JJ JJ O
changes NNS NNS O
of IN IN O
the DT DT O
forestomach NN NN O
epithelium NN NN O
were VBD VBD O
observed VBN VBN O
in IN IN O
all DT DT O
animals NNS NNS O
, , , O
co NN NN O
- - - O
administration NN NN O
of IN IN O
0 CD CD O
. . . O
25 CD CD O
% NN NN O
RA NNP NNP B-CHEM
significantly RB RB O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
increased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
forestomach NN NN O
tumors NNS NNS O
( ( ( O
squamous JJ JJ O
cell NN NN O
papilloma NN NN O
and CC CC O
carcinoma NN NN O
) ) ) O
to TO TO O
60 CD CD O
% NN NN O
( ( ( O
9 CD CD O
/ NN NN O
15 CD CD O
, , , O
2 CD CD O
rats NNS NNS O
with IN IN O
carcinoma NN NN O
) ) ) O
from IN IN O
15 CD CD O
% NN NN O
( ( ( O
3 CD CD O
/ NN NN O
20 CD CD O
, , , O
one CD CD O
rat NN NN O
with IN IN O
carcinoma NN NN O
) ) ) O
in IN IN O
the DT DT O
group NN NN O
given VBN VBN O
RA NNP NNP B-CHEM
- - - O
free JJ JJ O
water NN NN O
. . . O

In IN IN O
rats NNS NNS O
given VBN VBN O
1 CD CD O
% NN NN O
BHA NNP NNP B-CHEM
, , , O
RA NNP NNP B-CHEM
co NN NN O
- : : O
administered JJ JJ O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
05 CD CD O
, , , O
0 CD CD O
. . . O
1 CD CD O
, , , O
0 CD CD O
. . . O
2 CD CD O
or CC CC O
0 CD CD O
. . . O
25 CD CD O
% NN NN O
showed VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
enhancing VBG VBG O
effect NN NN O
on IN IN O
the DT DT O
development NN NN O
of IN IN O
the DT DT O
BHA NNP NNP B-CHEM
- - - O
induced JJ JJ O
epithelial NN NN O
hyperplasia NN NN O
. . . O

Tumors NNP NNP O
, , , O
all DT DT O
papillomas NN NN O
, , , O
were VBD VBD O
induced VBN VBN O
in IN IN O
3 CD CD O
rats NNS NNS O
( ( ( O
17 CD CD O
% NN NN O
) ) ) O
with IN IN O
0 CD CD O
. . . O
25 CD CD O
% NN NN O
RA NNP NNP B-CHEM
and CC CC O
in IN IN O
one CD CD O
rat NN NN O
( ( ( O
10 CD CD O
% NN NN O
) ) ) O
with IN IN O
0 CD CD O
. . . O
05 CD CD O
% NN NN O
RA NNP NNP B-CHEM
co NN NN O
- - - O
administration NN NN O
. . . O

RA NNP NNP B-CHEM
alone RB RB O
did VBD VBD O
not RB RB O
induce VB VB O
hyperplastic JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
forestomach NN NN O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
RA NNP NNP B-CHEM
acted VBD VBD O
as IN IN O
a DT DT O
co NN NN O
- - - O
carcinogen NN NN O
in IN IN O
the DT DT O
BHA NNP NNP B-CHEM
forestomach NN NN O
carcinogenesis NN NN O
of IN IN O
the DT DT O
rat NN NN O
. . . O

A DT DT O
prospective JJ JJ O
study NN NN O
on IN IN O
the DT DT O
dose NN NN O
dependency NN NN O
of IN IN O
cardiotoxicity NN NN O
induced VBN VBN O
by IN IN O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
. . . O

Since IN IN O
1975 CD CD O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
( ( ( O
MMC NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
to TO TO O
be VB VB O
cardiotoxic JJ JJ O
, , , O
especially RB RB O
when WRB WRB O
combined VBN VBN O
with IN IN O
or CC CC O
given VBN VBN O
following VBG VBG O
doxorubicin NN NN B-CHEM
. . . O

Data NNP NNP O
on IN IN O
dose NN NN O
dependency NN NN O
or CC CC O
incidence NN NN O
concerning VBG VBG O
this DT DT O
side NN NN O
effect NN NN O
were VBD VBD O
not RB RB O
known VBN VBN O
. . . O

We PRP PRP O
have VBP VBP O
initiated VBN VBN O
a DT DT O
prospective JJ JJ O
study NN NN O
to TO TO O
obtain VB VB O
some DT DT O
more JJR JJR O
data NNS NNS O
on IN IN O
these DT DT O
subjects NNS NNS O
. . . O

Forty CD CD O
- - - O
four CD CD O
MMC NNP NNP B-CHEM
- : : O
treated VBN VBN O
patients NNS NNS O
were VBD VBD O
studied VBN VBN O
, , , O
37 CD CD O
of IN IN O
them PRP PRP O
could MD MD O
be VB VB O
evaluated VBN VBN O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
studied VBN VBN O
by IN IN O
repeated VBN VBN O
physical JJ JJ O
examinations NNS NNS O
, , , O
chest NN NN O
X NNP NNP O
- : : O
rays NNS NNS O
, , , O
electro NN NN O
- - - O
and CC CC O
echocardiography NN NN O
and CC CC O
radionuclide NN NN O
left VBD VBD O
ventricular JJ JJ O
ejection NN NN O
fraction NN NN O
( ( ( O
EF NNP NNP O
) ) ) O
determinations NNS NNS O
. . . O

The DT DT O
results NNS NNS O
were VBD VBD O
evaluated VBN VBN O
per IN IN O
cumulative JJ JJ O
dose NN NN O
level NN NN O
. . . O

One CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
developed VBN VBN O
cardiac JJ JJ O
failure NN NN O
after IN IN O
30 CD CD O
mg NN NN O
m NN NN O
- : : O
2 CD CD O
MMC NNP NNP B-CHEM
and CC CC O
only RB RB O
150 CD CD O
mg NN NN O
m NN NN O
- : : O
2 CD CD O
doxorubicin NN NN B-CHEM
. . . O

The DT DT O
cardiac JJ JJ O
failure NN NN O
was VBD VBD O
predicted VBN VBN O
by IN IN O
a DT DT O
drop NN NN O
in IN IN O
EF NNP NNP O
determined VBD VBD O
during IN IN O
a DT DT O
cold JJ JJ O
pressor NN NN O
test NN NN O
. . . O

None NN NN O
of IN IN O
the DT DT O
other JJ JJ O
patients NNS NNS O
developed VBD VBD O
clinical JJ JJ O
cardiotoxicity NN NN O
, , , O
nor CC CC O
did VBD VBD O
the DT DT O
studied VBN VBN O
parameters NNS NNS O
change NN NN O
. . . O

The DT DT O
literature NN NN O
on IN IN O
this DT DT O
subject NN NN O
was VBD VBD O
also RB RB O
reviewed VBN VBN O
. . . O

Based VBN VBN O
on IN IN O
the DT DT O
combined VBN VBN O
data NNS NNS O
from IN IN O
the DT DT O
present JJ JJ O
study NN NN O
and CC CC O
the DT DT O
literature NN NN O
, , , O
we PRP PRP O
suggest VBP VBP O
that IN IN O
MMC NNP NNP B-CHEM
- : : O
related VBN VBN O
cardiotoxicity NN NN O
is VBZ VBZ O
dose JJ JJ O
dependent JJ JJ O
, , , O
occurring VBG VBG O
at IN IN O
cumulative JJ JJ O
dose NN NN O
levels NNS NNS O
of IN IN O
30 CD CD O
mg NN NN O
m NN NN O
- : : O
2 CD CD O
or CC CC O
more JJR JJR O
, , , O
mainly RB RB O
in IN IN O
patients NNS NNS O
also RB RB O
( ( ( O
previously RB RB O
or CC CC O
simultaneously RB RB O
) ) ) O
treated VBN VBN O
with IN IN O
doxorubicin NN NN B-CHEM
. . . O

The DT DT O
incidence NN NN O
is VBZ VBZ O
likely JJ JJ O
to TO TO O
be VB VB O
less JJR JJR O
than IN IN O
10 CD CD O
% NN NN O
even RB RB O
for IN IN O
this DT DT O
risk NN NN O
group NN NN O
. . . O

Reversible NNP NNP O
cerebral JJ JJ O
lesions NNS NNS O
associated VBN VBN O
with IN IN O
tiazofurin NN NN B-CHEM
usage NN NN O
: : : O
MR NNP NNP O
demonstration NN NN O
. . . O

Tiazofurin NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
experimental JJ JJ O
chemotherapeutic JJ JJ O
agent NN NN O
currently RB RB O
undergoing VBG VBG O
clinical JJ JJ O
evaluation NN NN O
. . . O

We PRP PRP O
report VBP VBP O
our PRP$ PRP$ O
results NNS NNS O
with IN IN O
magnetic JJ JJ O
resonance NN NN O
( ( ( O
MR NNP NNP O
) ) ) O
in IN IN O
demonstrating VBG VBG O
reversible JJ JJ O
cerebral NN NN O
abnormalities NNS NNS O
concurrent NN NN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
this DT DT O
drug NN NN O
. . . O

The DT DT O
abnormalities NNS NNS O
on IN IN O
MR NNP NNP O
were VBD VBD O
correlated VBN VBN O
with IN IN O
findings NNS NNS O
on IN IN O
CT NNP NNP O
as RB RB O
well RB RB O
as IN IN O
with IN IN O
cerebral JJ JJ O
angiography NN NN O
. . . O

The DT DT O
utility NN NN O
of IN IN O
MR NNP NNP O
in IN IN O
the DT DT O
evaluation NN NN O
of IN IN O
patients NNS NNS O
receiving VBG VBG O
this DT DT O
new JJ JJ O
agent NN NN O
is VBZ VBZ O
illustrated VBN VBN O
. . . O

Receptor NNP NNP O
mechanisms NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
hyperactivity NN NN O
in IN IN O
chronic JJ JJ O
nicotine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Rats NNP NNP O
were VBD VBD O
pretreated VBN VBN O
with IN IN O
saline NN NN O
or CC CC O
nicotine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
) ) ) O
by IN IN O
subcutaneously RB RB O
implanting VBG VBG O
each DT DT O
animal NN NN O
with IN IN O
an DT DT O
Alzet NNP NNP O
osmotic JJ JJ O
mini NN NN O
- - - O
pump NN NN O
which WDT WDT O
continuously RB RB O
released VBD VBD O
saline NN NN O
or CC CC O
nicotine NN NN B-CHEM
for IN IN O
1 CD CD O
, , , O
5 CD CD O
and CC CC O
14 CD CD O
days NNS NNS O
. . . O

At IN IN O
the DT DT O
end NN NN O
of IN IN O
each DT DT O
pretreatment NN NN O
period NN NN O
, , , O
animals NNS NNS O
were VBD VBD O
used VBN VBN O
for IN IN O
( ( ( O
i NNP NNP O
) ) ) O
determining VBG VBG O
their PRP$ PRP$ O
locomotor NN NN O
response NN NN O
to TO TO O
acutely RB RB O
injected VBN VBN O
nicotine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
and CC CC O
( ( ( O
ii NN NN O
) ) ) O
measuring VBG VBG O
the DT DT O
density NN NN O
of IN IN O
L NNP NNP O
- : : O
[ NN NN O
3H CD CD O
] NN NN O
nicotine NN NN B-CHEM
and CC CC O
[ NN NN O
3H CD CD O
] NN NN O
spiperone NN NN B-CHEM
binding JJ JJ O
sites NNS NNS O
in IN IN O
the DT DT O
striatum NN NN O
. . . O

We PRP PRP O
observed VBD VBD O
no DT DT O
changes NNS NNS O
in IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
response NN NN O
, , , O
striatal JJ JJ O
L NNP NNP O
- : : O
[ NN NN O
3H CD CD O
] NN NN O
nicotine NN NN B-CHEM
and CC CC O
[ NN NN O
3H CD CD O
] NN NN O
spiperone NN NN B-CHEM
binding JJ JJ O
in IN IN O
the DT DT O
animals NNS NNS O
pretreated VBN VBN O
with IN IN O
nicotine NN NN B-CHEM
for IN IN O
1 CD CD O
day NN NN O
. . . O

In IN IN O
rats NNS NNS O
which WDT WDT O
were VBD VBD O
pretreated VBN VBN O
with IN IN O
nicotine NN NN B-CHEM
for IN IN O
5 CD CD O
days NNS NNS O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
nicotine NN NN B-CHEM
- - - O
stimulated VBN VBN O
locomotor NN NN O
response NN NN O
which WDT WDT O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
L NNP NNP O
- : : O
[ NN NN O
3H CD CD O
] NN NN O
nicotine NN NN B-CHEM
binding JJ JJ O
sites NNS NNS O
and CC CC O
also RB RB O
with IN IN O
an DT DT O
elevated JJ JJ O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
level NN NN O
in IN IN O
the DT DT O
striatum NN NN O
. . . O

The DT DT O
number NN NN O
of IN IN O
striatal JJ JJ O
[ NN NN O
3H CD CD O
] NN NN O
spiperone NN NN B-CHEM
binding JJ JJ O
sites NNS NNS O
was VBD VBD O
not RB RB O
affected VBN VBN O
. . . O

In IN IN O
animals NNS NNS O
pretreated VBN VBN O
with IN IN O
nicotine NN NN B-CHEM
for IN IN O
14 CD CD O
days NNS NNS O
, , , O
the DT DT O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
response NN NN O
remained VBD VBD O
to TO TO O
be VB VB O
potentiated VBN VBN O
. . . O

However RB RB O
, , , O
this DT DT O
response NN NN O
was VBD VBD O
correlated VBN VBN O
with IN IN O
an DT DT O
elevated JJ JJ O
number NN NN O
of IN IN O
striatal JJ JJ O
[ NN NN O
3H CD CD O
] NN NN O
spiperone NN NN B-CHEM
binding JJ JJ O
sites NNS NNS O
, , , O
whereas IN IN O
the DT DT O
number NN NN O
of IN IN O
striatal JJ JJ O
L NNP NNP O
- : : O
[ NN NN O
3H CD CD O
] NN NN O
nicotine NN NN B-CHEM
binding JJ JJ O
sites NNS NNS O
and CC CC O
the DT DT O
striatal JJ JJ O
DA NNP NNP B-CHEM
level NN NN O
were VBD VBD O
normal JJ JJ O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
chronic JJ JJ O
nicotine NN NN B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
develop VBP VBP O
locomotor NN NN O
hyperactivity NN NN O
in IN IN O
response NN NN O
to TO TO O
nicotine NN NN B-CHEM
initially RB RB O
due JJ JJ O
to TO TO O
increases NNS NNS O
of IN IN O
both DT DT O
the DT DT O
density NN NN O
of IN IN O
nicotinic JJ JJ O
receptors NNS NNS O
and CC CC O
DA NNP NNP B-CHEM
concentration NN NN O
, , , O
followed VBN VBN O
by IN IN O
inducing VBG VBG O
DA NNP NNP B-CHEM
receptor NN NN O
supersensitivity NN NN O
in IN IN O
the DT DT O
striatum NN NN O
. . . O

Amelioration NNP NNP O
of IN IN O
bendrofluazide NN NN B-CHEM
- - - O
induced JJ JJ O
hypokalemia NN NN O
by IN IN O
timolol NN NN B-CHEM
. . . O

The DT DT O
beta NN NN O
adrenergic JJ JJ O
blocking VBG VBG O
drug NN NN O
, , , O
timolol NN NN B-CHEM
, , , O
tended VBD VBD O
to TO TO O
correct VB VB O
the DT DT O
hypokalemia NN NN O
of IN IN O
short JJ JJ O
- - - O
term NN NN O
bendrofluazide NN NN B-CHEM
treatment NN NN O
in IN IN O
6 CD CD O
healthy JJ JJ O
male NN NN O
subjects NNS NNS O
and CC CC O
although IN IN O
the DT DT O
effect NN NN O
was VBD VBD O
small JJ JJ O
it PRP PRP O
was VBD VBD O
significant JJ JJ O
. . . O

Timolol NNP NNP B-CHEM
also RB RB O
reduced VBD VBD O
the DT DT O
rise NN NN O
in IN IN O
plasma NN NN O
aldosterone NN NN B-CHEM
and CC CC O
urine JJ JJ O
potassium NN NN B-CHEM
excretion NN NN O
following VBG VBG O
bendrofluazide NN NN B-CHEM
and CC CC O
increased VBD VBD O
the DT DT O
urine JJ JJ O
sodium NN NN B-CHEM
/ NN NN O
potassium NN NN B-CHEM
ratio NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
a DT DT O
shift NN NN O
of IN IN O
potassium NN NN B-CHEM
from IN IN O
the DT DT O
intracellular NN NN O
to TO TO O
the DT DT O
extracellular NN NN O
space NN NN O
. . . O

St NNP NNP O
. . . O

Anthony NNP NNP O
' POS POS O
s VBZ VBZ O
fire NN NN O
, , , O
then RB RB O
and CC CC O
now RB RB O
: : : O
a DT DT O
case NN NN O
report NN NN O
and CC CC O
historical JJ JJ O
review NN NN O
. . . O

A DT DT O
rare JJ JJ O
case NN NN O
of IN IN O
morbid NN NN O
vasospasm NN NN O
, , , O
together RB RB O
with IN IN O
striking JJ JJ O
angiographic JJ JJ O
findings NNS NNS O
, , , O
is VBZ VBZ O
described VBN VBN O
secondary JJ JJ O
to TO TO O
the DT DT O
ingestion NN NN O
of IN IN O
methysergide NN NN B-CHEM
by IN IN O
a DT DT O
48 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
. . . O

A DT DT O
brief JJ JJ O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
on IN IN O
similar JJ JJ O
cases NNS NNS O
is VBZ VBZ O
presented VBN VBN O
. . . O

A DT DT O
discussion NN NN O
of IN IN O
the DT DT O
history NN NN O
of IN IN O
ergot NN NN B-CHEM
includes VBZ VBZ O
its PRP$ PRP$ O
original JJ JJ O
discovery NN NN O
, , , O
the DT DT O
epidemics NNS NNS O
of IN IN O
gangrene NN NN O
that IN IN O
it PRP PRP O
has VBZ VBZ O
caused VBN VBN O
through IN IN O
the DT DT O
ages NNS NNS O
and CC CC O
its PRP$ PRP$ O
past JJ JJ O
and CC CC O
present JJ JJ O
role NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
migraine NN NN O
headache NN NN O
. . . O

Despite IN IN O
the DT DT O
advent NN NN O
of IN IN O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
and CC CC O
beta NN NN O
- - - O
adrenergic JJ JJ O
antagonists NNS NNS O
, , , O
ergot NN NN B-CHEM
preparations NNS NNS O
continue VBP VBP O
to TO TO O
play VB VB O
a DT DT O
major JJ JJ O
role NN NN O
in IN IN O
migraine NN NN O
therapy NN NN O
, , , O
so IN IN O
that IN IN O
the DT DT O
danger NN NN O
of IN IN O
St NNP NNP O
. . . O

Anthony NNP NNP O
' POS POS O
s VBZ VBZ O
fire NN NN O
persists NNS NNS O
. . . O

Cardiac NNP NNP O
transplantation NN NN O
: : : O
improved VBN VBN O
quality NN NN O
of IN IN O
survival NN NN O
with IN IN O
a DT DT O
modified VBN VBN O
immunosuppressive JJ JJ O
protocol NN NN O
. . . O

The DT DT O
effects NNS NNS O
on IN IN O
renal JJ JJ O
function NN NN O
on IN IN O
two CD CD O
different JJ JJ O
immunosuppressive JJ JJ O
protocols NNS NNS O
were VBD VBD O
evaluated VBN VBN O
retrospectively RB RB O
in IN IN O
two CD CD O
subsequent JJ JJ O
groups NNS NNS O
of IN IN O
heart NN NN O
transplant NN NN O
recipients NNS NNS O
. . . O

In IN IN O
group NN NN O
I PRP PRP O
, , , O
cyclosporine NN NN B-CHEM
was VBD VBD O
given VBN VBN O
before IN IN O
the DT DT O
procedure NN NN O
at IN IN O
a DT DT O
loading NN NN O
dose NN NN O
of IN IN O
17 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
and CC CC O
then RB RB O
continued VBD VBD O
after IN IN O
the DT DT O
procedure NN NN O
to TO TO O
keep VB VB O
a DT DT O
whole JJ JJ O
blood NN NN O
level NN NN O
about IN IN O
1000 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
. . . O

In IN IN O
group NN NN O
II NNP NNP O
, , , O
cyclosporine NN NN B-CHEM
was VBD VBD O
started VBD VBD O
only RB RB O
after IN IN O
the DT DT O
procedure NN NN O
at IN IN O
a DT DT O
lower JJR JJR O
dosage NN NN O
and CC CC O
was VBD VBD O
complemented VBN VBN O
by IN IN O
azathioprine NN NN B-CHEM
, , , O
which WDT WDT O
was VBD VBD O
used VBN VBN O
for IN IN O
the DT DT O
first JJ JJ O
postoperative JJ JJ O
week NN NN O
. . . O

Group NNP NNP O
II NNP NNP O
showed VBD VBD O
a DT DT O
better RBR RBR O
perioperative JJ JJ O
renal NN NN O
function NN NN O
as IN IN O
determined VBN VBN O
by IN IN O
serum NN NN O
blood NN NN O
urea JJ JJ B-CHEM
nitrogen NN NN I-CHEM
and CC CC O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
. . . O

Group NNP NNP O
II NNP NNP O
also RB RB O
showed VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
of IN IN O
chronic JJ JJ O
nephrotoxicity NN NN O
secondary JJ JJ O
to TO TO O
long JJ JJ O
- - - O
term NN NN O
therapy NN NN O
with IN IN O
cyclosporine NN NN B-CHEM
. . . O

Despite IN IN O
this DT DT O
improvement NN NN O
in IN IN O
late JJ JJ O
renal NN NN O
function NN NN O
, , , O
group NN NN O
II NNP NNP O
still RB RB O
shows VBZ VBZ O
a DT DT O
slow JJ JJ O
rise NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
. . . O

We PRP PRP O
think VBP VBP O
that IN IN O
even RB RB O
these DT DT O
lower JJR JJR O
dosages NNS NNS O
of IN IN O
cyclosporine NN NN B-CHEM
can MD MD O
cause VB VB O
chronic JJ JJ O
nephrotoxicity NN NN O
and CC CC O
that IN IN O
further JJ JJ O
modification NN NN O
of IN IN O
the DT DT O
immunosuppressive JJ JJ O
regimen NN NN O
is VBZ VBZ O
required VBN VBN O
to TO TO O
completely RB RB O
abolish VB VB O
this DT DT O
toxic JJ JJ O
side NN NN O
effect NN NN O
. . . O

Ethopropazine NNP NNP B-CHEM
and CC CC O
benztropine NN NN B-CHEM
in IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
parkinsonism NN NN O
. . . O

In IN IN O
a DT DT O
12 CD CD O
- : : O
week NN NN O
controlled VBD VBD O
study NN NN O
ethopropazine NN NN B-CHEM
was VBD VBD O
compared VBN VBN O
to TO TO O
benztropine VB VB B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
parkinsonism NN NN O
induced VBN VBN O
by IN IN O
fluphenazine NN NN B-CHEM
enanthate NN NN I-CHEM
in IN IN O
60 CD CD O
schizophrenic JJ JJ O
outpatients NNS NNS O
. . . O

Ethopropazine NNP NNP B-CHEM
and CC CC O
benztropine NN NN B-CHEM
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
equally RB RB O
effective JJ JJ O
in IN IN O
controlling VBG VBG O
parkinsonian NN NN O
symptoms NNS NNS O
and CC CC O
were VBD VBD O
as RB RB O
efficacious JJ JJ O
as IN IN O
procyclidine NN NN B-CHEM
, , , O
their PRP$ PRP$ O
previous JJ JJ O
antiparkinsonian JJ JJ O
drug NN NN O
. . . O

However RB RB O
, , , O
benztropine NN NN B-CHEM
treated VBN VBN O
patients NNS NNS O
had VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
tardive JJ JJ O
dyskinesia NN NN O
compared VBN VBN O
to TO TO O
their PRP$ PRP$ O
condition NN NN O
during IN IN O
procyclindine NN NN B-CHEM
treatment NN NN O
, , , O
and CC CC O
significantly RB RB O
more JJR JJR O
anxiety NN NN O
and CC CC O
depression NN NN O
than IN IN O
ethopropazine NN NN B-CHEM
treated VBN VBN O
patients NNS NNS O
. . . O

This DT DT O
suggests VBZ VBZ O
that IN IN O
benztropine NN NN B-CHEM
is VBZ VBZ O
not RB RB O
the DT DT O
anticholinergic JJ JJ O
drug NN NN O
of IN IN O
choice NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
parkinsonian NN NN O
symptoms NNS NNS O
, , , O
because IN IN O
of IN IN O
its PRP$ PRP$ O
more JJR JJR O
toxic JJ JJ O
central JJ JJ O
and CC CC O
peripheral JJ JJ O
atropinic JJ JJ O
effect NN NN O
. . . O

Quinidine NNP NNP B-CHEM
phenylethylbarbiturate NN NN I-CHEM
- : : O
induced JJ JJ O
fulminant JJ JJ O
hepatitis NN NN O
in IN IN O
a DT DT O
pregnant JJ JJ O
woman NN NN O
. . . O

A DT DT O
case NN NN O
report NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
19 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Laotian NNP NNP O
patient NN NN O
affected VBN VBN O
by IN IN O
fulminant JJ JJ O
hepatitis NN NN O
during IN IN O
the DT DT O
third JJ JJ O
trimester NN NN O
of IN IN O
her PRP$ PRP$ O
pregnancy NN NN O
after IN IN O
a DT DT O
1 CD CD O
- : : O
month NN NN O
administration NN NN O
of IN IN O
quinidine NN NN B-CHEM
phenylethylbarbiturate NN NN I-CHEM
. . . O

After IN IN O
delivery NN NN O
, , , O
the DT DT O
patient NN NN O
underwent NN NN O
orthotopic JJ JJ O
liver NN NN O
transplantation NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
in IN IN O
good JJ JJ O
condition NN NN O
16 CD CD O
months NNS NNS O
after IN IN O
liver NN NN O
transplantation NN NN O
. . . O

Quinidine NNP NNP B-CHEM
itself PRP PRP O
or CC CC O
phenylethylbarbiturate NN NN B-CHEM
may MD MD O
be VB VB O
responsible JJ JJ O
for IN IN O
fulminant JJ JJ O
hepatitis NN NN O
in IN IN O
this DT DT O
patient NN NN O
. . . O

Mechanisms NNP NNP O
of IN IN O
myocardial NN NN O
ischemia NN NN O
induced VBN VBN O
by IN IN O
epinephrine NN NN B-CHEM
: : : O
comparison NN NN O
with IN IN O
exercise NN NN O
- - - O
induced JJ JJ O
ischemia NN NN O
. . . O

The DT DT O
role NN NN O
of IN IN O
epinephrine NN NN B-CHEM
in IN IN O
eliciting VBG VBG O
myocardial NN NN O
ischemia NN NN O
was VBD VBD O
examined VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

Objective NNP NNP O
signs NNS NNS O
of IN IN O
ischemia NN NN O
and CC CC O
factors NNS NNS O
increasing VBG VBG O
myocardial NN NN O
oxygen NN NN B-CHEM
consumption NN NN O
were VBD VBD O
compared VBN VBN O
during IN IN O
epinephrine NN NN B-CHEM
infusion NN NN O
and CC CC O
supine NN NN O
bicycle NN NN O
exercise NN NN O
. . . O

Both DT DT O
epinephrine NN NN B-CHEM
and CC CC O
exercise NN NN O
produced VBD VBD O
myocardial JJ JJ O
ischemia NN NN O
as IN IN O
evidenced VBN VBN O
by IN IN O
ST NNP NNP O
segment NN NN O
depression NN NN O
and CC CC O
angina NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
mechanisms NNS NNS O
of IN IN O
myocardial NN NN O
ischemia NN NN O
induced VBN VBN O
by IN IN O
epinephrine NN NN B-CHEM
were VBD VBD O
significantly RB RB O
different JJ JJ O
from IN IN O
those DT DT O
of IN IN O
exercise NN NN O
. . . O

Exercise NNP NNP O
- : : O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
was VBD VBD O
marked VBN VBN O
predominantly RB RB O
by IN IN O
increased JJ JJ O
heart NN NN O
rate NN NN O
and CC CC O
rate NN NN O
- : : O
pressure NN NN O
product NN NN O
with IN IN O
a DT DT O
minor JJ JJ O
contribution NN NN O
of IN IN O
end NN NN O
- : : O
diastolic JJ JJ O
volume NN NN O
, , , O
while IN IN O
epinephrine NN NN B-CHEM
- - - O
induced JJ JJ O
ischemia NN NN O
was VBD VBD O
characterized VBN VBN O
by IN IN O
a DT DT O
marked JJ JJ O
increase NN NN O
in IN IN O
contractility NN NN O
and CC CC O
a DT DT O
less RBR RBR O
pronounced JJ JJ O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
and CC CC O
rate NN NN O
- : : O
pressure NN NN O
product NN NN O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
ischemia NN NN O
produced VBN VBN O
by IN IN O
epinephrine NN NN B-CHEM
, , , O
as IN IN O
may MD MD O
occur VB VB O
during IN IN O
states NNS NNS O
of IN IN O
emotional JJ JJ O
distress NN NN O
, , , O
has VBZ VBZ O
a DT DT O
mechanism NN NN O
distinct JJ JJ O
from IN IN O
that DT DT O
due JJ JJ O
to TO TO O
physical JJ JJ O
exertion NN NN O
. . . O

Recent JJ JJ O
preclinical JJ JJ O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
with IN IN O
the DT DT O
thymidylate NN NN O
synthase NN NN O
inhibitor NN NN O
N10 NNP NNP B-CHEM
- : : I-CHEM
propargyl NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
, , , I-CHEM
8 CD CD I-CHEM
- : : I-CHEM
dideazafolic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
) ) ) O
. . . O

CB NNP NNP B-CHEM
3717 CD CD I-CHEM
, , , O
N10 NNP NNP B-CHEM
- : : I-CHEM
propargyl NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
, , , I-CHEM
8 CD CD I-CHEM
- : : I-CHEM
dideazafolic JJ JJ I-CHEM
acid NN NN I-CHEM
, , , O
is VBZ VBZ O
a DT DT O
tight JJ JJ O
- - - O
binding JJ JJ O
inhibitor NN NN O
of IN IN O
thymidylate NN NN O
synthase NN NN O
( ( ( O
TS NNP NNP O
) ) ) O
whose WP$ WP$ O
cytotoxicity NN NN O
is VBZ VBZ O
mediated VBN VBN O
solely RB RB O
through IN IN O
the DT DT O
inhibition NN NN O
of IN IN O
this DT DT O
enzyme NN NN O
. . . O

Recent JJ JJ O
preclinical JJ JJ O
studies NNS NNS O
have VBP VBP O
focused VBN VBN O
on IN IN O
the DT DT O
intracellular JJ JJ O
formation NN NN O
of IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
polyglutamates NNS NNS O
. . . O

Following VBG VBG O
a DT DT O
12 CD CD O
- : : O
hour NN NN O
exposure NN NN O
of IN IN O
L1210 NNP NNP O
cells NNS NNS O
to TO TO O
50 CD CD O
microM NN NN O
[ NN NN O
3H CD CD O
] NN NN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
, , , O
30 CD CD O
% NN NN O
of IN IN O
the DT DT O
extractable JJ JJ O
radioactivity NN NN O
could MD MD O
be VB VB O
accounted VBN VBN O
for IN IN O
as IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
tetra NN NN O
- : : O
and CC CC O
pentaglutamate NN NN O
, , , O
as IN IN O
determined VBN VBN O
by IN IN O
high JJ JJ O
- - - O
pressure NN NN O
liquid NN NN O
chromatography NN NN O
( ( ( O
HPLC NNP NNP O
) ) ) O
analyses NNS NNS O
. . . O

As IN IN O
inhibitors NNS NNS O
of IN IN O
isolated VBN VBN O
L1210 NNP NNP O
TS NNP NNP O
, , , O
CB NNP NNP O
3717 CD CD O
di NN NN O
- : : O
, , , O
tri NN NN O
- - - O
, , , O
tetra NN NN O
- - - O
and CC CC O
pentaglutamate NN NN O
are VBP VBP O
26 CD CD O
- : : O
, , , O
87 CD CD O
- : : O
, , , O
119 CD CD O
- : : O
and CC CC O
114 CD CD O
- : : O
fold VB VB O
more RBR RBR O
potent JJ JJ O
than IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
, , , O
respectively RB RB O
, , , O
and CC CC O
their PRP$ PRP$ O
formation NN NN O
may MD MD O
, , , O
therefore RB RB O
, , , O
be VB VB O
an DT DT O
important JJ JJ O
determinant NN NN O
of IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
cytotoxicity NN NN O
. . . O

In IN IN O
early JJ JJ O
clinical JJ JJ O
studies NNS NNS O
with IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
, , , O
activity NN NN O
has VBZ VBZ O
been VBN VBN O
seen VBN VBN O
in IN IN O
breast NN NN O
cancer NN NN O
, , , O
ovarian JJ JJ O
cancer NN NN O
, , , O
hepatoma NN NN O
, , , O
and CC CC O
mesothelioma NN NN O
. . . O

Toxicities NNP NNP O
included VBD VBD O
hepatotoxicity NN NN O
, , , O
malaise NN NN O
, , , O
and CC CC O
dose VB VB O
- : : O
limiting VBG VBG O
nephrotoxicity NN NN O
. . . O

This DT DT O
latter JJ JJ O
effect NN NN O
is VBZ VBZ O
thought VBN VBN O
to TO TO O
be VB VB O
due JJ JJ O
to TO TO O
drug NN NN O
precipitation NN NN O
within IN IN O
the DT DT O
renal JJ JJ O
tubule NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
the DT DT O
poor JJ JJ O
solubility NN NN O
of IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
under IN IN O
acidic JJ JJ O
conditions NNS NNS O
. . . O

In IN IN O
an DT DT O
attempt NN NN O
to TO TO O
overcome VB VB O
this DT DT O
problem NN NN O
, , , O
a DT DT O
clinical JJ JJ O
trial NN NN O
of IN IN O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
administered VBN VBN O
with IN IN O
alkaline NN NN O
diuresis NN NN O
is VBZ VBZ O
under IN IN O
way NN NN O
. . . O

Preliminary JJ JJ O
results NNS NNS O
at IN IN O
400 CD CD O
and CC CC O
500 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
suggest VBP VBP O
that IN IN O
a DT DT O
reduction NN NN O
in IN IN O
nephrotoxicity NN NN O
may MD MD O
have VB VB O
been VBN VBN O
achieved VBN VBN O
with IN IN O
only RB RB O
1 CD CD O
instance NN NN O
of IN IN O
renal JJ JJ O
toxicity NN NN O
in IN IN O
10 CD CD O
patients NNS NNS O
. . . O

Hepatotoxicity NNP NNP O
and CC CC O
malaise NN NN O
are VBP VBP O
again RB RB O
the DT DT O
most RBS RBS O
frequent JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

Evidence NN NN O
of IN IN O
antitumor NN NN O
activity NN NN O
has VBZ VBZ O
been VBN VBN O
seen VBN VBN O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

Pharmacokinetic NNP NNP O
investigations NNS NNS O
have VBP VBP O
shown VBN VBN O
that IN IN O
alkaline NN NN O
diuresis NN NN O
does VBZ VBZ O
not RB RB O
alter VB VB O
CB NNP NNP B-CHEM
3717 CD CD I-CHEM
plasma NN NN O
levels NNS NNS O
or CC CC O
urinary JJ JJ O
excretion NN NN O
and CC CC O
that DT DT O
satisfactory JJ JJ O
urinary JJ JJ O
alkalinization NN NN O
can MD MD O
be VB VB O
readily RB RB O
achieved VBN VBN O
. . . O

Type NNP NNP O
B NNP NNP O
hepatitis NN NN O
after IN IN O
needle NN NN O
- - - O
stick NN NN O
exposure NN NN O
: : : O
prevention NN NN O
with IN IN O
hepatitis NN NN O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
. . . O

Final NNP NNP O
report NN NN O
of IN IN O
the DT DT O
Veterans NNP NNP O
Administration NNP NNP O
Cooperative NNP NNP O
Study NNP NNP O
. . . O

Hepatitis NNP NNP O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
( ( ( O
HBIG NNP NNP O
) ) ) O
and CC CC O
immune JJ JJ O
serum NN NN O
globulin NN NN O
( ( ( O
ISG NNP NNP O
) ) ) O
were VBD VBD O
examined VBN VBN O
in IN IN O
a DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
to TO TO O
assess VB VB O
their PRP$ PRP$ O
relative JJ JJ O
efficacies NNS NNS O
in IN IN O
preventing VBG VBG O
type NN NN O
B NNP NNP O
hepatitis NN NN O
after IN IN O
needle NN NN O
- - - O
stick JJ JJ O
exposure NN NN O
to TO TO O
hepatitis VB VB B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
( ( ( O
HBsAG NNP NNP B-CHEM
) ) ) O
- : : O
positive JJ JJ O
donors NNS NNS O
. . . O

Clinical NNP NNP O
hepatitis NN NN O
developed VBN VBN O
in IN IN O
1 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
HBIG NNP NNP O
and CC CC O
in IN IN O
5 CD CD O
. . . O
9 CD CD O
% NN NN O
of IN IN O
ISG NNP NNP O
recipients NNS NNS O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
016 CD CD O
) ) ) O
, , , O
and CC CC O
seroconversion NN NN O
( ( ( O
anti JJ JJ O
- - - O
HBs NNP NNP O
) ) ) O
occurred VBD VBD O
in IN IN O
5 CD CD O
. . . O
6 CD CD O
% NN NN O
and CC CC O
20 CD CD O
. . . O
7 CD CD O
% NN NN O
of IN IN O
them PRP PRP O
respectively RB RB O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Mild NNP NNP O
and CC CC O
transient NN NN O
side NN NN O
- : : O
effects NNS NNS O
were VBD VBD O
noted VBN VBN O
in IN IN O
3 CD CD O
. . . O
0 CD CD O
% NN NN O
of IN IN O
ISG NNP NNP O
and CC CC O
in IN IN O
3 CD CD O
. . . O
2 CD CD O
% NN NN O
of IN IN O
HBIG NNP NNP O
recipients NNS NNS O
. . . O

Available NNP NNP O
donor NN NN O
sera NN NN O
were VBD VBD O
examined VBN VBN O
for IN IN O
DNA NNP NNP O
polymerase NN NN O
( ( ( O
DNAP NNP NNP O
) ) ) O
and CC CC O
e SYM SYM O
antigen NN NN O
and CC CC O
antibody NN NN O
( ( ( O
HBeAg NNP NNP B-CHEM
; : : O
anti JJ JJ O
- : : O
HBE NNP NNP O
) ) ) O
. . . O

Both DT DT O
DNAP NNP NNP O
and CC CC O
HBeAg NNP NNP B-CHEM
showed VBD VBD O
a DT DT O
highly RB RB O
statistically RB RB O
significant JJ JJ O
correlation NN NN O
with IN IN O
the DT DT O
infectivity NN NN O
of IN IN O
HBsAg NNP NNP B-CHEM
- - - O
positive JJ JJ O
donors NNS NNS O
. . . O

Hepatitis NNP NNP O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
remained VBD VBD O
significantly RB RB O
superior JJ JJ O
to TO TO O
ISG NNP NNP O
in IN IN O
preventing VBG VBG O
type NN NN O
B NNP NNP O
hepatitis NN NN O
even RB RB O
when WRB WRB O
the DT DT O
analysis NN NN O
was VBD VBD O
confined VBN VBN O
to TO TO O
these DT DT O
two CD CD O
high JJ JJ O
- - - O
risk NN NN O
subgroups NNS NNS O
. . . O

The DT DT O
efficacy NN NN O
of IN IN O
ISG NNP NNP O
in IN IN O
preventing VBG VBG O
type NN NN O
B NNP NNP O
hepatitis NN NN O
cannot NN NN O
be VB VB O
ascertained VBN VBN O
because IN IN O
a DT DT O
true JJ JJ O
placebo NN NN O
group NN NN O
was VBD VBD O
not RB RB O
included VBN VBN O
. . . O

Production NN NN O
of IN IN O
autochthonous JJ JJ O
prostate NN NN O
cancer NN NN O
in IN IN O
Lobund NNP NNP O
- - - O
Wistar NNP NNP O
rats NNS NNS O
by IN IN O
treatments NNS NNS O
with IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
nitroso NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
methylurea NN NN I-CHEM
and CC CC O
testosterone NN NN B-CHEM
. . . O

More JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
of IN IN O
Lobund NNP NNP O
- : : O
Wistar NNP NNP O
( ( ( O
L NNP NNP O
- - - O
W NNP NNP O
) ) ) O
strain NN NN O
rats NNS NNS O
developed VBN VBN O
large JJ JJ O
, , , O
palpable JJ JJ O
prostate NN NN O
adenocarcinomas NN NN O
( ( ( O
PAs NNP NNP O
) ) ) O
following VBG VBG O
treatments NNS NNS O
with IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
nitroso NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
methylurea NN NN I-CHEM
( ( ( O
CAS NNP NNP O
: : : O
684 CD CD O
- : : O
93 CD CD O
- : : O
5 CD CD O
) ) ) O
and CC CC O
testosterone NN NN B-CHEM
propionate NN NN I-CHEM
[ NN NN O
( ( ( O
TP NNP NNP B-CHEM
) ) ) O
CAS NNP NNP O
: : : O
57 CD CD O
- : : O
85 CD CD O
- : : O
2 CD CD O
] NN NN O
, , , O
and CC CC O
most JJS JJS O
of IN IN O
the DT DT O
tumor NN NN O
- - - O
bearing NN NN O
rats NNS NNS O
manifested JJ JJ O
metastatic JJ JJ O
lesions NNS NNS O
. . . O

The DT DT O
incubation NN NN O
periods NNS NNS O
averaged VBD VBD O
10 CD CD O
. . . O
6 CD CD O
months NNS NNS O
. . . O

Within IN IN O
the DT DT O
same JJ JJ O
timeframe NN NN O
, , , O
no DT DT O
L NNP NNP O
- : : O
W NNP NNP O
rat NN NN O
developed VBD VBD O
a DT DT O
similar JJ JJ O
palpable NN NN O
PA NNP NNP O
when WRB WRB O
treated VBN VBN O
only RB RB O
with IN IN O
TP NNP NNP B-CHEM
. . . O

In IN IN O
L NNP NNP O
- : : O
W NNP NNP O
rats NNS NNS O
, , , O
TP NNP NNP B-CHEM
acted VBD VBD O
as IN IN O
a DT DT O
tumor NN NN O
enhancement NN NN O
agent NN NN O
, , , O
with IN IN O
primary JJ JJ O
emphasis NN NN O
on IN IN O
the DT DT O
development NN NN O
of IN IN O
prostate JJ JJ O
cancer NN NN O
. . . O

Relative NNP NNP O
efficacy NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
netilmicin NN NN B-CHEM
and CC CC O
tobramycin NN NN B-CHEM
in IN IN O
oncology NN NN O
patients NNS NNS O
. . . O

We PRP PRP O
prospectively RB RB O
compared VBD VBD O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
netilmicin NN NN B-CHEM
sulfate NN NN I-CHEM
or CC CC O
tobramycin NN NN B-CHEM
sulfate NN NN I-CHEM
in IN IN O
conjunction NN NN O
with IN IN O
piperacillin NN NN B-CHEM
sodium NN NN I-CHEM
in IN IN O
118 CD CD O
immunocompromised JJ JJ O
patients NNS NNS O
with IN IN O
presumed VBN VBN O
severe JJ JJ O
infections NNS NNS O
. . . O

The DT DT O
two CD CD O
treatment NN NN O
regimens NNS NNS O
were VBD VBD O
equally RB RB O
efficacious JJ JJ O
. . . O

Nephrotoxicity NNP NNP O
occurred VBD VBD O
in IN IN O
a DT DT O
similar JJ JJ O
proportion NN NN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
netilmicin NN NN B-CHEM
and CC CC O
tobramycin NN NN B-CHEM
( ( ( O
17 CD CD O
% NN NN O
vs NNS NNS O
11 CD CD O
% NN NN O
) ) ) O
. . . O

Ototoxicity NNP NNP O
occurred VBD VBD O
in IN IN O
four CD CD O
( ( ( O
9 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
of IN IN O
42 CD CD O
netilmicin NN NN B-CHEM
and CC CC O
piperacillin NN NN B-CHEM
and CC CC O
in IN IN O
12 CD CD O
( ( ( O
22 CD CD O
% NN NN O
) ) ) O
of IN IN O
54 CD CD O
tobramycin NN NN B-CHEM
and CC CC O
piperacillin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
. . . O

Of IN IN O
those DT DT O
evaluated VBN VBN O
with IN IN O
posttherapy NN NN O
audiograms NNS NNS O
, , , O
three CD CD O
of IN IN O
four CD CD O
netilmicin NN NN B-CHEM
and CC CC O
piperacillin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
had VBD VBD O
auditory NN NN O
thresholds NNS NNS O
return VBP VBP O
to TO TO O
baseline VB VB O
compared VBN VBN O
with IN IN O
one CD CD O
of IN IN O
nine CD CD O
tobramycin NN NN B-CHEM
and CC CC O
piperacillin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
. . . O

The DT DT O
number NN NN O
of IN IN O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
15 CD CD O
- : : O
dB NN NN O
increases NNS NNS O
in IN IN O
auditory NN NN O
threshold NN NN O
as IN IN O
a DT DT O
proportion NN NN O
of IN IN O
total JJ JJ O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
15 CD CD O
- : : O
dB NN NN O
changes NNS NNS O
( ( ( O
increases NNS NNS O
and CC CC O
decreases NNS NNS O
) ) ) O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
netilmicin NN NN B-CHEM
and CC CC O
piperacillin NN NN B-CHEM
- - - O
vs NNS NNS O
tobramycin NN NN B-CHEM
and CC CC O
piperacillin NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
( ( ( O
18 CD CD O
of IN IN O
78 CD CD O
vs NNS NNS O
67 CD CD O
of IN IN O
115 CD CD O
) ) ) O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
aminoglycoside NN NN B-CHEM
- - - O
associated VBN VBN O
ototoxicity NN NN O
was VBD VBD O
less RBR RBR O
severe JJ JJ O
and CC CC O
more RBR RBR O
often RB RB O
reversible JJ JJ O
with IN IN O
netilmicin NN NN B-CHEM
than IN IN O
with IN IN O
tobramycin NN NN B-CHEM
. . . O

Urinary NNP NNP O
enzymes NNS NNS O
and CC CC O
protein NN NN O
patterns NNS NNS O
as IN IN O
indicators NNS NNS O
of IN IN O
injury NN NN O
to TO TO O
different JJ JJ O
regions NNS NNS O
of IN IN O
the DT DT O
kidney NN NN O
. . . O

Acute JJ JJ O
experimental JJ JJ O
models NNS NNS O
of IN IN O
renal JJ JJ O
damage NN NN O
to TO TO O
the DT DT O
proximal NN NN O
tubular NN NN O
, , , O
glomerular NN NN O
, , , O
and CC CC O
papillary JJ JJ O
regions NNS NNS O
of IN IN O
the DT DT O
rat NN NN O
were VBD VBD O
produced VBN VBN O
by IN IN O
administration NN NN O
of IN IN O
hexachloro NN NN B-CHEM
- - - I-CHEM
1 CD CD I-CHEM
: : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
butadiene NN NN I-CHEM
( ( ( O
HCBD NNP NNP B-CHEM
) ) ) O
, , , O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
2 CD CD B-CHEM
- : : I-CHEM
bromoethylamine NN NN I-CHEM
( ( ( O
BEA NNP NNP B-CHEM
) ) ) O
, , , O
respectively RB RB O
. . . O

Several JJ JJ O
routine JJ JJ O
indicators NNS NNS O
of IN IN O
nephrotoxicity NN NN O
, , , O
the DT DT O
enzymes NNS NNS O
alkaline NN NN O
phosphatase NN NN O
and CC CC O
N NNP NNP O
- : : O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
glucosaminidase NN NN O
, , , O
and CC CC O
the DT DT O
molecular JJ JJ O
weight NN NN O
of IN IN O
protein NN NN O
excretion NN NN O
were VBD VBD O
determined VBN VBN O
on IN IN O
urine JJ JJ O
samples NNS NNS O
. . . O

Tubular NNP NNP O
damage NN NN O
produced VBN VBN O
by IN IN O
HCBD NNP NNP B-CHEM
or CC CC O
BEA NNP NNP B-CHEM
was VBD VBD O
discriminated JJ JJ O
both DT DT O
quantitatively RB RB O
and CC CC O
qualitatively RB RB O
from IN IN O
glomerular NN NN O
damage NN NN O
produced VBN VBN O
by IN IN O
PAN NNP NNP B-CHEM
. . . O

The DT DT O
latter NN NN O
was VBD VBD O
characterized VBN VBN O
by IN IN O
a DT DT O
pronounced JJ JJ O
increase NN NN O
in IN IN O
protein NN NN O
excretion NN NN O
, , , O
especially RB RB O
proteins NNS NNS O
with IN IN O
molecular JJ JJ O
weight NN NN O
greater JJR JJR O
than IN IN O
40 CD CD O
, , , O
000 CD CD O
Da NNP NNP O
. . . O

In IN IN O
contrast NN NN O
, , , O
protein NN NN O
excretion NN NN O
in IN IN O
tubular NN NN O
damage NN NN O
was VBD VBD O
raised VBN VBN O
only RB RB O
slightly RB RB O
and CC CC O
characterized VBN VBN O
by IN IN O
excretion NN NN O
of IN IN O
proteins NNS NNS O
of IN IN O
a DT DT O
wide JJ JJ O
range NN NN O
of IN IN O
molecular JJ JJ O
weights NNS NNS O
. . . O

Proximal NNP NNP O
tubular NN NN O
damage NN NN O
caused VBN VBN O
by IN IN O
HCBD NNP NNP B-CHEM
and CC CC O
papillary JJ JJ O
damage NN NN O
caused VBN VBN O
by IN IN O
BEA NNP NNP B-CHEM
were VBD VBD O
distinguished VBN VBN O
both DT DT O
by IN IN O
conventional JJ JJ O
urinalysis NN NN O
( ( ( O
volume NN NN O
and CC CC O
specific JJ JJ O
gravity NN NN O
) ) ) O
and CC CC O
by IN IN O
measurement NN NN O
of IN IN O
the DT DT O
two CD CD O
urinary JJ JJ O
enzymes NNS NNS O
. . . O

Alkaline NNP NNP O
phosphatase NN NN O
and CC CC O
glucose NN NN B-CHEM
were VBD VBD O
markedly RB RB O
and CC CC O
transiently RB RB O
elevated VBD VBD O
in IN IN O
proximal NN NN O
tubular NN NN O
damage NN NN O
and CC CC O
N NNP NNP O
- : : O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
glucosaminidase NN NN O
showed VBD VBD O
a DT DT O
sustained JJ JJ O
elevation NN NN O
in IN IN O
papillary JJ JJ O
damage NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
both DT DT O
selective JJ JJ O
urinary JJ JJ O
enzymes NNS NNS O
and CC CC O
the DT DT O
molecular JJ JJ O
weight NN NN O
pattern NN NN O
of IN IN O
urinary JJ JJ O
proteins NNS NNS O
can MD MD O
be VB VB O
used VBN VBN O
to TO TO O
provide VB VB O
diagnostic JJ JJ O
information NN NN O
about IN IN O
the DT DT O
possible JJ JJ O
site NN NN O
of IN IN O
renal JJ JJ O
damage NN NN O
. . . O

A DT DT O
catch NN NN O
in IN IN O
the DT DT O
Reye NNP NNP O
. . . O

Twenty CD CD O
- - - O
six CD CD O
cases NNS NNS O
of IN IN O
Reye NNP NNP O
syndrome NN NN O
from IN IN O
The DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
, , , O
Camperdown NNP NNP O
, , , O
Australia NNP NNP O
, , , O
occurring VBG VBG O
between IN IN O
1973 CD CD O
and CC CC O
1982 CD CD O
were VBD VBD O
reviewed VBN VBN O
. . . O

Of IN IN O
these DT DT O
, , , O
20 CD CD O
cases NNS NNS O
met VBD VBD O
the DT DT O
US NNP NNP O
Public NNP NNP O
Health NNP NNP O
Service NNP NNP O
Centers NNPS NNPS O
for IN IN O
Disease NNP NNP O
Control NNP NNP O
criteria NNS NNS O
for IN IN O
the DT DT O
diagnosis NN NN O
of IN IN O
Reye NNP NNP O
syndrome NN NN O
. . . O

Aspirin NNP NNP B-CHEM
or CC CC O
salicylate JJ JJ B-CHEM
ingestion NN NN O
had VBD VBD O
occurred VBN VBN O
in IN IN O
only RB RB O
one CD CD O
of IN IN O
the DT DT O
20 CD CD O
cases NNS NNS O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
paracetamol NN NN B-CHEM
( ( ( O
acetaminophen NN NN B-CHEM
) ) ) O
had VBD VBD O
been VBN VBN O
administered VBN VBN O
in IN IN O
only RB RB O
six CD CD O
of IN IN O
the DT DT O
cases NNS NNS O
( ( ( O
30 CD CD O
% NN NN O
) ) ) O
. . . O

Pathologic NNP NNP O
confirmation NN NN O
of IN IN O
the DT DT O
diagnosis NN NN O
of IN IN O
Reye NNP NNP O
syndrome NN NN O
was VBD VBD O
accomplished VBN VBN O
in IN IN O
90 CD CD O
% NN NN O
of IN IN O
the DT DT O
cases NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
Reye NNP NNP O
syndrome NN NN O
in IN IN O
New NNP NNP O
South NNP NNP O
Wales NNP NNP O
, , , O
Australia NNP NNP O
, , , O
is VBZ VBZ O
estimated VBN VBN O
from IN IN O
this DT DT O
study NN NN O
to TO TO O
be VB VB O
approximately RB RB O
nine CD CD O
cases NNS NNS O
per IN IN O
1 CD CD O
million CD CD O
children NNS NNS O
compared VBN VBN O
with IN IN O
recent JJ JJ O
US NNP NNP O
data NNS NNS O
of IN IN O
ten CD CD O
to TO TO O
20 CD CD O
cases NNS NNS O
per IN IN O
1 CD CD O
million CD CD O
children NNS NNS O
and CC CC O
three CD CD O
to TO TO O
seven CD CD O
cases NNS NNS O
per IN IN O
1 CD CD O
million CD CD O
children NNS NNS O
in IN IN O
Great NNP NNP O
Britain NNP NNP O
. . . O

The DT DT O
mortality NN NN O
for IN IN O
these DT DT O
Reye NNP NNP O
syndrome NN NN O
cases NNS NNS O
in IN IN O
Australia NNP NNP O
was VBD VBD O
45 CD CD O
% NN NN O
as IN IN O
compared VBN VBN O
with IN IN O
a DT DT O
32 CD CD O
% NN NN O
case NN NN O
- : : O
fatality NN NN O
rate NN NN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
. . . O

In IN IN O
Australia NNP NNP O
, , , O
the DT DT O
pediatric JJ JJ O
usage NN NN O
of IN IN O
aspirin NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
extremely RB RB O
low JJ JJ O
for IN IN O
the DT DT O
past JJ JJ O
25 CD CD O
years NNS NNS O
( ( ( O
less JJR JJR O
than IN IN O
1 CD CD O
% NN NN O
of IN IN O
total JJ JJ O
dosage NN NN O
units NNS NNS O
sold VBD VBD O
) ) ) O
, , , O
with IN IN O
paracetamol NN NN B-CHEM
( ( ( O
acetaminophen NN NN B-CHEM
) ) ) O
dominating VBG VBG O
the DT DT O
pediatric JJ JJ O
analgesic NN NN O
and CC CC O
antipyretic JJ JJ O
market NN NN O
. . . O

Reye NNP NNP O
syndrome NN NN O
may MD MD O
be VB VB O
disappearing VBG VBG O
from IN IN O
Australia NNP NNP O
despite IN IN O
a DT DT O
total JJ JJ O
lack NN NN O
of IN IN O
association NN NN O
with IN IN O
salicylates NNS NNS B-CHEM
or CC CC O
aspirin NN NN B-CHEM
ingestion NN NN O
, , , O
since IN IN O
there EX EX O
were VBD VBD O
no DT DT O
cases NNS NNS O
found VBD VBD O
at IN IN O
The DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
in IN IN O
1983 CD CD O
, , , O
1984 CD CD O
, , , O
or CC CC O
1985 CD CD O
. . . O

Postpartum NNP NNP O
psychosis NN NN O
induced VBN VBN O
by IN IN O
bromocriptine NN NN B-CHEM
. . . O

Two CD CD O
multigravida NN NN O
patients NNS NNS O
with IN IN O
no DT DT O
prior RB RB O
psychiatric JJ JJ O
history NN NN O
were VBD VBD O
seen VBN VBN O
with IN IN O
postpartum NN NN O
psychosis NN NN O
, , , O
having VBG VBG O
received VBN VBN O
bromocriptine NN NN B-CHEM
for IN IN O
inhibition NN NN O
of IN IN O
lactation NN NN O
. . . O

Bromocriptine NNP NNP B-CHEM
given VBN VBN O
in IN IN O
high JJ JJ O
doses NNS NNS O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
psychosis NNS NNS O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
the DT DT O
drug NN NN O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

These DT DT O
cases NNS NNS O
demonstrate VBP VBP O
that IN IN O
bromocriptine NN NN B-CHEM
may MD MD O
cause VB VB O
psychosis NNS NNS O
even RB RB O
when WRB WRB O
given VBN VBN O
in IN IN O
low JJ JJ O
doses NNS NNS O
. . . O

Hyperglycemic NNP NNP O
acidotic JJ JJ O
coma NN NN O
and CC CC O
death NN NN O
in IN IN O
Kearns NNP NNP O
- : : O
Sayre NNP NNP O
syndrome NN NN O
. . . O

This DT DT O
paper NN NN O
presents VBZ VBZ O
the DT DT O
clinical JJ JJ O
and CC CC O
metabolic JJ JJ O
findings NNS NNS O
in IN IN O
two CD CD O
young JJ JJ O
boys NNS NNS O
with IN IN O
long JJ JJ O
- - - O
standing NN NN O
Kearns NNP NNP O
- : : O
Sayre NNP NNP O
syndrome NN NN O
. . . O

Following VBG VBG O
short JJ JJ O
exposure NN NN O
to TO TO O
oral JJ JJ O
prednisone NN NN B-CHEM
, , , O
both DT DT O
boys NNS NNS O
developed VBN VBN O
lethargy NN NN O
, , , O
increasing VBG VBG O
somnolence NN NN O
, , , O
polydipsia NN NN O
, , , O
polyphagia NN NN O
, , , O
and CC CC O
polyuria NN NN O
. . . O

Both DT DT O
presented VBN VBN O
in IN IN O
the DT DT O
emergency NN NN O
room NN NN O
with IN IN O
profound JJ JJ O
coma NN NN O
, , , O
hypotension NN NN O
, , , O
severe JJ JJ O
hyperglycemia NN NN O
, , , O
and CC CC O
acidosis NN NN O
. . . O

Nonketotic NNP NNP O
lactic JJ JJ O
acidosis NN NN O
was VBD VBD O
present JJ JJ O
in IN IN O
one CD CD O
and CC CC O
ketosis NN NN O
without IN IN O
a DT DT O
known VBN VBN O
serum NN NN O
lactate NN NN B-CHEM
level NN NN O
was VBD VBD O
present JJ JJ O
in IN IN O
the DT DT O
other JJ JJ O
. . . O

Respiratory NNP NNP O
failure NN NN O
rapidly RB RB O
ensued VBD VBD O
and CC CC O
both DT DT O
patients NNS NNS O
expired VBN VBN O
in IN IN O
spite NN NN O
of IN IN O
efforts NNS NNS O
at IN IN O
resuscitation NN NN O
. . . O

We PRP PRP O
believe VBP VBP O
these DT DT O
two CD CD O
cases NNS NNS O
represent VBP VBP O
a DT DT O
newly RB RB O
described VBN VBN O
and CC CC O
catastrophic JJ JJ O
metabolic JJ JJ O
- - - O
endocrine NN NN O
failure NN NN O
in IN IN O
the DT DT O
Kearns NNP NNP O
- : : O
Sayre NNP NNP O
syndrome NN NN O
. . . O

Experimental NNP NNP O
cyclosporine NN NN B-CHEM
nephrotoxicity NN NN O
: : : O
risk NN NN O
of IN IN O
concomitant NN NN O
chemotherapy NN NN O
. . . O

The DT DT O
role NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
( ( ( O
CSA NNP NNP B-CHEM
) ) ) O
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
various JJ JJ O
chemotherapeutics NNS NNS O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
renal JJ JJ O
toxicity NN NN O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
CSA NNP NNP B-CHEM
for IN IN O
4 CD CD O
weeks NNS NNS O
caused VBD VBD O
renal JJ JJ O
functional JJ JJ O
and CC CC O
structural JJ JJ O
changes NNS NNS O
similar JJ JJ O
to TO TO O
those DT DT O
reported VBN VBN O
in IN IN O
man NN NN O
. . . O

The DT DT O
combined VBN VBN O
administration NN NN O
of IN IN O
CSA NNP NNP B-CHEM
and CC CC O
various JJ JJ O
chemotherapeutic JJ JJ O
drugs NNS NNS O
with IN IN O
a DT DT O
nephrotoxic JJ JJ O
potential JJ JJ O
, , , O
such JJ JJ O
as IN IN O
gentamicin NN NN B-CHEM
( ( ( O
at IN IN O
therapeutic JJ JJ O
doses NNS NNS O
) ) ) O
, , , O
amphothericin NN NN B-CHEM
B NNP NNP I-CHEM
and CC CC O
ketoconazole NN NN B-CHEM
, , , O
which WDT WDT O
are VBP VBP O
frequently RB RB O
used VBN VBN O
in IN IN O
immunosuppressed VBN VBN O
patients NNS NNS O
, , , O
did VBD VBD O
not RB RB O
aggravate VB VB O
the DT DT O
CSA NNP NNP B-CHEM
induced VBD VBD O
toxicity NN NN O
in IN IN O
the DT DT O
rat NN NN O
model NN NN O
. . . O

Gentamicin NNP NNP B-CHEM
at IN IN O
toxic JJ JJ O
doses NNS NNS O
, , , O
however RB RB O
, , , O
increased VBD VBD O
CSA NNP NNP B-CHEM
nephrotoxicity NN NN O
. . . O

Thus RB RB O
, , , O
the DT DT O
nephrotoxicity NN NN O
induced VBN VBN O
by IN IN O
CSA NNP NNP B-CHEM
has VBZ VBZ O
a DT DT O
different JJ JJ O
pathogenetic JJ JJ O
mechanism NN NN O
. . . O

Diuretics NNP NNP O
, , , O
potassium NN NN B-CHEM
and CC CC O
arrhythmias NNS NNS O
in IN IN O
hypertensive JJ JJ O
coronary JJ JJ O
disease NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
that IN IN O
modest JJS JJS O
changes NNS NNS O
in IN IN O
plasma NN NN O
potassium NN NN B-CHEM
can MD MD O
alter VB VB O
the DT DT O
tendency NN NN O
towards IN IN O
cardiac JJ JJ O
arrhythmias NNS NNS O
. . . O

If IN IN O
this DT DT O
were VBD VBD O
so RB RB O
, , , O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
might MD MD O
be VB VB O
especially RB RB O
susceptible JJ JJ O
. . . O

Thus RB RB O
, , , O
myocardial JJ JJ O
electrical JJ JJ O
excitability NN NN O
was VBD VBD O
measured VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
mild JJ JJ O
essential JJ JJ O
hypertension NN NN O
and CC CC O
known VBN VBN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
after IN IN O
8 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
a DT DT O
potassium NN NN B-CHEM
- - - O
conserving VBG VBG O
diuretic JJ JJ O
( ( ( O
amiloride NN NN B-CHEM
) ) ) O
and CC CC O
a DT DT O
similar JJ JJ O
period NN NN O
on IN IN O
a DT DT O
potassium NN NN B-CHEM
- - - O
losing VBG VBG O
diuretic JJ JJ O
( ( ( O
chlorthalidone NN NN B-CHEM
) ) ) O
in IN IN O
a DT DT O
randomised JJ JJ O
study NN NN O
. . . O

Plasma NNP NNP O
potassium NN NN B-CHEM
concentrations NNS NNS O
were VBD VBD O
on IN IN O
average JJ JJ O
1 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
lower JJR JJR O
during IN IN O
the DT DT O
chlorthalidone NN NN B-CHEM
phase NN NN O
compared VBN VBN O
to TO TO O
amiloride VB VB B-CHEM
therapy NN NN O
. . . O

Blood NNP NNP O
pressure NN NN O
and CC CC O
volume NN NN O
states NNS NNS O
as IN IN O
assessed VBN VBN O
by IN IN O
bodyweight NN NN O
, , , O
plasma NN NN O
renin NN NN O
and CC CC O
noradrenaline NN NN B-CHEM
( ( ( O
norepinephrine NN NN B-CHEM
) ) ) O
concentrations NNS NNS O
were VBD VBD O
similar JJ JJ O
on IN IN O
the DT DT O
2 CD CD O
regimens NNS NNS O
. . . O

Compared VBN VBN O
to TO TO O
amiloride VB VB B-CHEM
treatment NN NN O
, , , O
the DT DT O
chlorthalidone NN NN B-CHEM
phase NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
frequency NN NN O
of IN IN O
ventricular NN NN O
ectopic NN NN O
beats NNS NNS O
( ( ( O
24 CD CD O
- : : O
hour NN NN O
Holter NNP NNP O
monitoring VBG VBG O
) ) ) O
and CC CC O
a DT DT O
higher JJR JJR O
Lown NNP NNP O
grading VBG VBG O
, , , O
increased VBN VBN O
upslope NN NN O
and CC CC O
duration NN NN O
of IN IN O
the DT DT O
monophasic JJ JJ O
action NN NN O
potential JJ JJ O
, , , O
prolonged JJ JJ O
ventricular NN NN O
effective JJ JJ O
refractory NN NN O
period NN NN O
, , , O
and CC CC O
increased VBD VBD O
electrical JJ JJ O
instability NN NN O
during IN IN O
programmed VBN VBN O
ventricular NN NN O
stimulation NN NN O
. . . O

The DT DT O
above JJ JJ O
results NNS NNS O
indicate VBP VBP O
that IN IN O
because IN IN O
potassium NN NN B-CHEM
- - - O
losing VBG VBG O
diuretic JJ JJ O
therapy NN NN O
can MD MD O
increase VB VB O
myocardial JJ JJ O
electrical JJ JJ O
excitability NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
ischaemic JJ JJ O
heart NN NN O
disease NN NN O
, , , O
even RB RB O
minor JJ JJ O
falls VBZ VBZ O
in IN IN O
plasma NN NN O
potassium NN NN B-CHEM
concentrations NNS NNS O
are VBP VBP O
probably RB RB O
best JJS JJS O
avoided VBN VBN O
in IN IN O
such JJ JJ O
patients NNS NNS O
. . . O

Transketolase NNP NNP O
abnormality NN NN O
in IN IN O
tolazamide NN NN B-CHEM
- - - O
induced JJ JJ O
Wernicke NNP NNP O
' POS POS O
s VBZ VBZ O
encephalopathy NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
a DT DT O
thiamine NN NN B-CHEM
- - - O
dependent JJ JJ O
enzyme NN NN O
, , , O
transketolase NN NN O
, , , O
from IN IN O
fibroblasts NNS NNS O
of IN IN O
a DT DT O
diabetic JJ JJ O
patient NN NN O
who WP WP O
developed VBD VBD O
Wernicke NNP NNP O
' POS POS O
s VBZ VBZ O
encephalopathy NN NN O
when WRB WRB O
treated VBN VBN O
with IN IN O
tolazamide NN NN B-CHEM
, , , O
in IN IN O
order NN NN O
to TO TO O
delineate VB VB O
if IN IN O
this DT DT O
patient NN NN O
also RB RB O
had VBD VBD O
transketolase NN NN O
abnormality NN NN O
[ NN NN O
high JJ JJ O
Km NN NN O
for IN IN O
thiamine NN NN B-CHEM
pyrophosphate NN NN I-CHEM
( ( ( O
TPP NNP NNP B-CHEM
) ) ) O
] NN NN O
, , , O
as IN IN O
previously RB RB O
reported VBD VBD O
in IN IN O
postalcoholic JJ JJ O
Wernicke NNP NNP O
- - - O
Korsakoff NNP NNP O
syndrome NN NN O
. . . O

In IN IN O
addition NN NN O
to TO TO O
this DT DT O
patient NN NN O
, , , O
we PRP PRP O
also RB RB O
studied VBD VBD O
this DT DT O
enzyme NN NN O
from IN IN O
three CD CD O
diabetic JJ JJ O
kindreds NNS NNS O
without IN IN O
any DT DT O
history NN NN O
of IN IN O
Wernicke NNP NNP O
' POS POS O
s VBZ VBZ O
encephalopathy NN NN O
and CC CC O
from IN IN O
four CD CD O
normal JJ JJ O
controls NNS NNS O
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
the DT DT O
above JJ JJ O
- - - O
mentioned JJ JJ O
patient NN NN O
and CC CC O
one CD CD O
of IN IN O
the DT DT O
diabetic JJ JJ O
kindreds NNS NNS O
with IN IN O
no DT DT O
history NN NN O
of IN IN O
Wernicke NNP NNP O
' POS POS O
s VBZ VBZ O
encephalopathy NN NN O
had VBD VBD O
abnormal JJ JJ O
transketolase NN NN O
as IN IN O
determined VBN VBN O
by IN IN O
its PRP$ PRP$ O
Km NN NN O
for IN IN O
TPP NNP NNP B-CHEM
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
a DT DT O
similarity NN NN O
between IN IN O
postalcoholic JJ JJ O
Wernicke NNP NNP O
- - - O
Korsakoff NNP NNP O
syndrome NN NN O
and CC CC O
the DT DT O
patient NN NN O
with IN IN O
tolazamide NN NN B-CHEM
- - - O
induced JJ JJ O
Wernicke NNP NNP O
' POS POS O
s VBZ VBZ O
encephalopathy NN NN O
from IN IN O
the DT DT O
standpoint NN NN O
of IN IN O
transketolase NN NN O
abnormality NN NN O
. . . O

Bradycardia NNP NNP O
due JJ JJ O
to TO TO O
trihexyphenidyl VB VB B-CHEM
hydrochloride NN NN I-CHEM
. . . O

A DT DT O
chronic JJ JJ O
schizophrenic JJ JJ O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
an DT DT O
anticholinergic JJ JJ O
drug NN NN O
, , , O
trihexyphenidyl NN NN B-CHEM
hydrochloride NN NN I-CHEM
. . . O

The DT DT O
patient NN NN O
developed VBN VBN O
, , , O
paradoxically RB RB O
, , , O
sinus JJ JJ O
bradycardia NNS NNS O
. . . O

The DT DT O
reaction NN NN O
was VBD VBD O
specific JJ JJ O
to TO TO O
trihexyphenidyl VB VB B-CHEM
and CC CC O
not RB RB O
to TO TO O
other JJ JJ O
anticholinergic JJ JJ O
drugs NNS NNS O
. . . O

This DT DT O
antidyskinetic JJ JJ O
drug NN NN O
is VBZ VBZ O
widely RB RB O
used VBN VBN O
in IN IN O
clinical JJ JJ O
psychiatric JJ JJ O
practice NN NN O
and CC CC O
physicians NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
side NN NN O
effect NN NN O
. . . O

Post NNP NNP O
- : : O
operative JJ JJ O
rigidity NN NN O
after IN IN O
fentanyl NN NN B-CHEM
administration NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
thoraco NN NN O
- - - O
abdominal JJ JJ O
rigidity NN NN O
leading VBG VBG O
to TO TO O
respiratory VB VB O
failure NN NN O
is VBZ VBZ O
described VBN VBN O
in IN IN O
the DT DT O
post NN NN O
- - - O
operative JJ JJ O
period NN NN O
in IN IN O
an DT DT O
elderly JJ JJ O
patient NN NN O
who WP WP O
received VBD VBD O
a DT DT O
moderate JJ JJ O
dose NN NN O
of IN IN O
fentanyl NN NN B-CHEM
. . . O

This DT DT O
was VBD VBD O
successfully RB RB O
reversed VBN VBN O
by IN IN O
naloxone NN NN B-CHEM
. . . O

The DT DT O
mechanisms NNS NNS O
possibly RB RB O
implicated VBN VBN O
in IN IN O
this DT DT O
accident NN NN O
are VBP VBP O
discussed VBN VBN O
. . . O

Anti NNP NNP O
- : : O
carcinogenic JJ JJ O
action NN NN O
of IN IN O
phenobarbital NN NN B-CHEM
given VBN VBN O
simultaneously RB RB O
with IN IN O
diethylnitrosamine NN NN B-CHEM
in IN IN O
the DT DT O
rat NN NN O
. . . O

The DT DT O
present JJ JJ O
work NN NN O
has VBZ VBZ O
been VBN VBN O
planned VBN VBN O
in IN IN O
order NN NN O
to TO TO O
elucidate VB VB O
the DT DT O
effect NN NN O
of IN IN O
phenobarbital JJ JJ B-CHEM
( ( ( O
PB NNP NNP B-CHEM
: : : O
15 CD CD O
mg NN NN O
per IN IN O
rat NN NN O
of IN IN O
ingested JJ JJ O
dose NN NN O
) ) ) O
on IN IN O
carcinogenesis NN NN O
when WRB WRB O
it PRP PRP O
is VBZ VBZ O
administered VBN VBN O
simultaneously RB RB O
with IN IN O
diethylnitrosamine NN NN B-CHEM
( ( ( O
DEN NNP NNP B-CHEM
: : : O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
. . . O

Wistar NNP NNP O
rats NNS NNS O
( ( ( O
180 CD CD O
g SYM SYM O
) ) ) O
were VBD VBD O
treated VBN VBN O
by IN IN O
DEN NNP NNP B-CHEM
alone RB RB O
or CC CC O
by IN IN O
DEN NNP NNP B-CHEM
+ NN NN O
PB NNP NNP B-CHEM
during IN IN O
2 CD CD O
, , , O
4 CD CD O
and CC CC O
6 CD CD O
weeks NNS NNS O
according VBG VBG O
to TO TO O
our PRP$ PRP$ O
schedule NN NN O
for IN IN O
hepatocarcinogenesis NN NN O
. . . O

After IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
treatment NN NN O
, , , O
the DT DT O
number NN NN O
and CC CC O
the DT DT O
size NN NN O
of IN IN O
induced VBN VBN O
PAS NNP NNP O
positive JJ JJ O
preneoplastic JJ JJ O
foci NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
when WRB WRB O
PB NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
simultaneously RB RB O
with IN IN O
DEN NNP NNP B-CHEM
for IN IN O
4 CD CD O
and CC CC O
6 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
mitotic JJ JJ O
inhibition NN NN O
and CC CC O
the DT DT O
production NN NN O
of IN IN O
micronuclei NN NN O
normally RB RB O
observed VBD VBD O
after IN IN O
partial JJ JJ O
hepatectomy NN NN O
in IN IN O
DEN NNP NNP B-CHEM
treated VBD VBD O
rats NNS NNS O
were VBD VBD O
also RB RB O
significantly RB RB O
decreased VBN VBN O
in IN IN O
DEN NNP NNP B-CHEM
+ NN NN O
PB NNP NNP B-CHEM
treated VBD VBD O
rats NNS NNS O
. . . O

When WRB WRB O
the DT DT O
treatment NN NN O
last JJ JJ O
only RB RB O
2 CD CD O
weeks NNS NNS O
, , , O
the DT DT O
presence NN NN O
of IN IN O
PB NNP NNP B-CHEM
did VBD VBD O
not RB RB O
change VB VB O
significantly RB RB O
the DT DT O
last JJ JJ O
parameters NNS NNS O
. . . O

In IN IN O
DEN NNP NNP B-CHEM
+ NN NN O
PB NNP NNP B-CHEM
treated VBD VBD O
rats NNS NNS O
, , , O
the DT DT O
survival NN NN O
was VBD VBD O
prolonged JJ JJ O
and CC CC O
the DT DT O
tumor NN NN O
incidence NN NN O
decreased VBD VBD O
as IN IN O
compared VBN VBN O
with IN IN O
the DT DT O
results NNS NNS O
obtained VBN VBN O
by IN IN O
DEN NNP NNP B-CHEM
alone RB RB O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
PB NNP NNP B-CHEM
, , , O
which WDT WDT O
promotes VBZ VBZ O
carcinogenesis NN NN O
when WRB WRB O
administered VBN VBN O
after IN IN O
the DT DT O
DEN NNP NNP B-CHEM
treatment NN NN O
, , , O
reduces VBZ VBZ O
the DT DT O
carcinogen NN NN O
effect NN NN O
when WRB WRB O
given VBN VBN O
simultaneously RB RB O
with IN IN O
DEN NNP NNP B-CHEM
. . . O

This DT DT O
' POS POS O
anti JJ JJ O
- : : O
carcinogen NN NN O
' '' '' O
effect NN NN O
acts NNS NNS O
on IN IN O
the DT DT O
initiation NN NN O
as RB RB O
well RB RB O
as IN IN O
on IN IN O
the DT DT O
promotion NN NN O
of IN IN O
the DT DT O
precancerous JJ JJ O
lesions NNS NNS O
. . . O

Biochemical NNP NNP O
investigations NNS NNS O
are VBP VBP O
in IN IN O
progress NN NN O
to TO TO O
obtain VB VB O
more JJR JJR O
information NN NN O
about IN IN O
this DT DT O
' POS POS O
paradoxical JJ JJ O
' POS POS O
PB NNP NNP B-CHEM
effect NN NN O
. . . O

Bilateral NNP NNP O
optic JJ JJ O
neuropathy NN NN O
due JJ JJ O
to TO TO O
combined VBN VBN O
ethambutol NN NN B-CHEM
and CC CC O
isoniazid NN NN B-CHEM
treatment NN NN O
. . . O

The DT DT O
case NN NN O
of IN IN O
a DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
who WP WP O
underwent VBD VBD O
an DT DT O
unsuccessful JJ JJ O
cadaver NN NN O
kidney NN NN O
transplantation NN NN O
and CC CC O
was VBD VBD O
treated VBN VBN O
with IN IN O
ethambutol NN NN B-CHEM
and CC CC O
isoniazid NN NN B-CHEM
is VBZ VBZ O
reported VBN VBN O
. . . O

A DT DT O
bilateral JJ JJ O
retrobulbar NN NN O
neuropathy NN NN O
with IN IN O
an DT DT O
unusual JJ JJ O
central JJ JJ O
bitemporal JJ JJ O
hemianopic NN NN O
scotoma NN NN O
was VBD VBD O
found VBN VBN O
. . . O

Ethambutol NNP NNP B-CHEM
was VBD VBD O
stopped VBN VBN O
and CC CC O
only RB RB O
small JJ JJ O
improvement NN NN O
of IN IN O
the DT DT O
visual JJ JJ O
acuity NN NN O
followed VBD VBD O
. . . O

Isoniazid NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
later RB RB O
, , , O
followed VBN VBN O
by IN IN O
a DT DT O
dramatic JJ JJ O
improvement NN NN O
in IN IN O
the DT DT O
visual JJ JJ O
acuity NN NN O
. . . O

The DT DT O
hazards NNS NNS O
of IN IN O
optic JJ JJ O
nerve NN NN O
toxicity NN NN O
due JJ JJ O
to TO TO O
ethambutol NN NN B-CHEM
are VBP VBP O
known VBN VBN O
. . . O

We PRP PRP O
emphasize VBP VBP O
the DT DT O
potential JJ JJ O
danger NN NN O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
ethambutol NN NN B-CHEM
and CC CC O
isoniazid NN NN B-CHEM
. . . O

A DT DT O
prospective JJ JJ O
study NN NN O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
associated VBN VBN O
with IN IN O
vancomycin NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
prospective JJ JJ O
evaluation NN NN O
of IN IN O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
vancomycin NN NN B-CHEM
was VBD VBD O
conducted VBN VBN O
in IN IN O
54 CD CD O
consecutive JJ JJ O
patients NNS NNS O
over IN IN O
a DT DT O
16 CD CD O
- : : O
month NN NN O
period NN NN O
. . . O

Vancomycin NNP NNP B-CHEM
was VBD VBD O
curative JJ JJ O
in IN IN O
95 CD CD O
% NN NN O
of IN IN O
43 CD CD O
patients NNS NNS O
with IN IN O
proven VBN VBN O
infection NN NN O
. . . O

Drugs NNS NNS O
were VBD VBD O
ceased VBN VBN O
in IN IN O
six CD CD O
patients NNS NNS O
because IN IN O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
; : : O
in IN IN O
three CD CD O
of IN IN O
these DT DT O
vancomycin NN NN B-CHEM
was VBD VBD O
considered VBN VBN O
the DT DT O
likely JJ JJ O
cause NN NN O
. . . O

Reactions NNP NNP O
included VBD VBD O
thrombophlebitis NN NN O
( ( ( O
20 CD CD O
of IN IN O
54 CD CD O
patients NNS NNS O
) ) ) O
, , , O
rash NN NN O
( ( ( O
4 CD CD O
of IN IN O
54 CD CD O
) ) ) O
, , , O
nephrotoxicity NN NN O
( ( ( O
4 CD CD O
of IN IN O
50 CD CD O
) ) ) O
, , , O
proteinuria NN NN O
( ( ( O
1 CD CD O
of IN IN O
50 CD CD O
) ) ) O
and CC CC O
ototoxicity NN NN O
( ( ( O
1 CD CD O
of IN IN O
11 CD CD O
patients NNS NNS O
tested VBN VBN O
by IN IN O
audiometry NN NN O
) ) ) O
. . . O

Thrombophlebitis NNP NNP O
occurred VBD VBD O
only RB RB O
with IN IN O
infusion NN NN O
through IN IN O
peripheral JJ JJ O
cannulae NN NN O
; : : O
nephrotoxicity NN NN O
and CC CC O
ototoxicity NN NN O
were VBD VBD O
confined VBN VBN O
to TO TO O
patients NNS NNS O
receiving VBG VBG O
an DT DT O
aminoglycoside NN NN B-CHEM
plus CC CC O
vancomycin NN NN B-CHEM
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
vancomycin NN NN B-CHEM
, , , O
administered VBD VBD O
appropriately RB RB O
, , , O
constitutes VBZ VBZ O
safe JJ JJ O
, , , O
effective JJ JJ O
therapy NN NN O
for IN IN O
infections NNS NNS O
caused VBN VBN O
by IN IN O
susceptible JJ JJ O
bacteria NN NN O
. . . O

Factors NNS NNS O
associated VBN VBN O
with IN IN O
nephrotoxicity NN NN O
and CC CC O
clinical JJ JJ O
outcome NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
amikacin NN NN B-CHEM
. . . O

Data NNP NNP O
from IN IN O
60 CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
amikacin NN NN B-CHEM
were VBD VBD O
analyzed VBN VBN O
for IN IN O
factors NNS NNS O
associated VBN VBN O
with IN IN O
nephrotoxicity NN NN O
. . . O

In IN IN O
42 CD CD O
of IN IN O
these DT DT O
patients NNS NNS O
, , , O
data NNS NNS O
were VBD VBD O
examined VBN VBN O
for IN IN O
factors NNS NNS O
associated VBN VBN O
with IN IN O
clinical JJ JJ O
outcome NN NN O
. . . O

Variables NNP NNP O
evaluated VBD VBD O
included VBN VBN O
patient NN NN O
weight NN NN O
, , , O
age NN NN O
, , , O
sex NN NN O
, , , O
serum NN NN O
creatinine NN NN B-CHEM
level NN NN O
, , , O
creatinine JJ JJ B-CHEM
clearance NN NN O
, , , O
duration NN NN O
of IN IN O
therapy NN NN O
, , , O
total JJ JJ O
dose NN NN O
, , , O
mean VB VB O
daily JJ JJ O
dose NN NN O
, , , O
organism NN NN O
minimum JJ JJ O
inhibitory NN NN O
concentration NN NN O
( ( ( O
MIC NNP NNP O
) ) ) O
, , , O
mean VB VB O
peak NN NN O
levels NNS NNS O
, , , O
mean VB VB O
trough IN IN O
levels NNS NNS O
, , , O
mean NN NN O
area NN NN O
under IN IN O
the DT DT O
serum NN NN O
concentration NN NN O
- : : O
time NN NN O
curve NN NN O
( ( ( O
AUC NNP NNP O
) ) ) O
, , , O
total JJ JJ O
AUC NNP NNP O
, , , O
mean VB VB O
AUC NNP NNP O
greater JJR JJR O
than IN IN O
MIC NNP NNP O
, , , O
total JJ JJ O
AUC NNP NNP O
greater JJR JJR O
than IN IN O
MIC NNP NNP O
, , , O
mean VB VB O
Schumacher NNP NNP O
' POS POS O
s VBZ VBZ O
intensity NN NN O
factor NN NN O
( ( ( O
IF IN IN O
) ) ) O
, , , O
total JJ JJ O
IF IN IN O
, , , O
In IN IN O
( ( ( O
mean VB VB O
maximum NN NN O
concentration NN NN O
[ NN NN O
Cmax NNP NNP O
] NN NN O
/ NN NN O
MIC NNP NNP O
) ) ) O
. . . O

Model NNP NNP O
- : : O
dependent JJ JJ O
pharmacokinetic JJ JJ O
parameters NNS NNS O
were VBD VBD O
calculated VBN VBN O
by IN IN O
computer NN NN O
based VBN VBN O
on IN IN O
a DT DT O
one CD CD O
- - - O
compartment NN NN O
model NN NN O
. . . O

When WRB WRB O
the DT DT O
parameters NNS NNS O
were VBD VBD O
examined VBN VBN O
individually RB RB O
, , , O
duration NN NN O
of IN IN O
therapy NN NN O
and CC CC O
total JJ JJ O
AUC NNP NNP O
correlated VBD VBD O
significantly RB RB O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
05 CD CD O
) ) ) O
with IN IN O
nephrotoxicity NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
a DT DT O
stepwise NN NN O
discriminant NN NN O
function NN NN O
analysis NN NN O
identified VBN VBN O
only RB RB O
duration NN NN O
of IN IN O
therapy NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
001 CD CD O
) ) ) O
as IN IN O
an DT DT O
important JJ JJ O
factor NN NN O
. . . O

Based VBN VBN O
on IN IN O
this DT DT O
model NN NN O
and CC CC O
on IN IN O
Bayes NNP NNP O
' POS POS O
theorem NN NN O
, , , O
the DT DT O
predictive JJ JJ O
accuracy NN NN O
of IN IN O
identifying VBG VBG O
" '' '' O
nephrotoxic JJ JJ O
" '' '' O
patients NNS NNS O
increased VBN VBN O
from IN IN O
0 CD CD O
. . . O
17 CD CD O
to TO TO O
0 CD CD O
. . . O
39 CD CD O
. . . O

When WRB WRB O
examined VBD VBD O
individually RB RB O
, , , O
mean VB VB O
IF IN IN O
, , , O
MIC NNP NNP O
, , , O
total JJ JJ O
dose NN NN O
, , , O
mean VB VB O
daily JJ JJ O
dose NN NN O
, , , O
and CC CC O
ln NN NN O
( ( ( O
mean VB VB O
Cmax NNP NNP O
/ NN NN O
MIC NNP NNP O
) ) ) O
correlated JJ JJ O
significantly RB RB O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
. . . O
05 CD CD O
) ) ) O
with IN IN O
cure NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
a DT DT O
simultaneous JJ JJ O
multivariable JJ JJ O
analysis NN NN O
identified VBN VBN O
IF IN IN O
, , , O
MIC NNP NNP O
, , , O
and CC CC O
total JJ JJ O
dose NN NN O
according VBG VBG O
to TO TO O
one CD CD O
model NN NN O
and CC CC O
ln NN NN O
( ( ( O
mean VB VB O
Cmax NNP NNP O
/ NN NN O
MIC NNP NNP O
) ) ) O
according VBG VBG O
to TO TO O
a DT DT O
second JJ JJ O
statistical JJ JJ O
model NN NN O
of IN IN O
parameters NNS NNS O
selected VBN VBN O
to TO TO O
have VB VB O
the DT DT O
greatest JJS JJS O
prospective JJ JJ O
value NN NN O
. . . O

Based VBN VBN O
on IN IN O
Bayes NNP NNP O
' POS POS O
theorem NN NN O
and CC CC O
the DT DT O
first JJ JJ O
model NN NN O
, , , O
the DT DT O
predictive JJ JJ O
accuracy NN NN O
of IN IN O
identifying VBG VBG O
patients NNS NNS O
not RB RB O
cured VBN VBN O
increased VBN VBN O
from IN IN O
0 CD CD O
. . . O
19 CD CD O
to TO TO O
0 CD CD O
. . . O
83 CD CD O
. . . O

For IN IN O
the DT DT O
second JJ JJ O
model NN NN O
, , , O
the DT DT O
predictive JJ JJ O
accuracy NN NN O
increased VBN VBN O
from IN IN O
0 CD CD O
. . . O
19 CD CD O
to TO TO O
0 CD CD O
. . . O
50 CD CD O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Cardiac NNP NNP O
toxicity NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
. . . O

Report NNP NNP O
of IN IN O
a DT DT O
case NN NN O
of IN IN O
spontaneous JJ JJ O
angina NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
with IN IN O
colon NN NN O
carcinoma NN NN O
and CC CC O
liver NN NN O
metastasis NN NN O
who WP WP O
presented VBD VBD O
chest NN NN O
pain NN NN O
after IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
administration NN NN O
. . . O

Clinical NNP NNP O
electrocardiographic JJ JJ O
evolution NN NN O
was VBD VBD O
similar JJ JJ O
to TO TO O
that DT DT O
observed VBD VBD O
in IN IN O
Prinzmetal NNP NNP O
' POS POS O
s VBZ VBZ O
angina NN NN O
, , , O
and CC CC O
chest NN NN O
pain NN NN O
promptly RB RB O
resolved VBN VBN O
with IN IN O
nifedipine NN NN B-CHEM
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
coronary JJ JJ O
spasm NN NN O
may MD MD O
be VB VB O
the DT DT O
cause NN NN O
of IN IN O
cardiotoxicity NN NN O
due JJ JJ O
to TO TO O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
, , , O
and CC CC O
that IN IN O
calcium NN NN B-CHEM
antagonists NNS NNS O
may MD MD O
probably RB RB O
be VB VB O
used VBN VBN O
in IN IN O
the DT DT O
prevention NN NN O
or CC CC O
treatment NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
cardiotoxicity NN NN O
. . . O

Dose NNP NNP O
- - - O
related VBN VBN O
beneficial NN NN O
and CC CC O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
dietary JJ JJ O
corticosterone NN NN B-CHEM
on IN IN O
organophosphorus JJ JJ B-CHEM
- : : O
induced VBN VBN O
delayed JJ JJ O
neuropathy JJ JJ O
in IN IN O
chickens NNS NNS O
. . . O

Tri NNP NNP B-CHEM
- : : I-CHEM
ortho NN NN I-CHEM
- : : I-CHEM
tolyl NN NN I-CHEM
phosphate NN NN I-CHEM
( ( ( O
TOTP NNP NNP B-CHEM
) ) ) O
, , , O
360 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
po NN NN O
, , , O
and CC CC O
0 CD CD B-CHEM
, , , I-CHEM
0 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
diisopropyl NN NN I-CHEM
phosphorofluoridate NN NN I-CHEM
( ( ( O
DFP NNP NNP B-CHEM
) ) ) O
, , , O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
, , , O
were VBD VBD O
administered VBN VBN O
to TO TO O
adult VB VB O
White NNP NNP O
Leghorn NNP NNP O
chickens NNS NNS O
24 CD CD O
hr NN NN O
after IN IN O
they PRP PRP O
were VBD VBD O
placed VBN VBN O
on IN IN O
diets NNS NNS O
containing VBG VBG O
0 CD CD O
to TO TO O
300 CD CD O
ppm NN NN O
corticosterone NN NN B-CHEM
. . . O

Supplemented NNP NNP O
diets NNS NNS O
were VBD VBD O
continued VBN VBN O
until IN IN O
clinical JJ JJ O
signs NNS NNS O
and CC CC O
lesions NNS NNS O
of IN IN O
delayed JJ JJ O
neuropathy NN NN O
appeared VBD VBD O
. . . O

Although IN IN O
low JJ JJ O
concentrations NNS NNS O
( ( ( O
less RBR RBR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
50 CD CD O
ppm NN NN O
) ) ) O
of IN IN O
corticosterone NN NN B-CHEM
had VBD VBD O
beneficial JJ JJ O
effects NNS NNS O
on IN IN O
TOTP NNP NNP B-CHEM
- : : O
induced JJ JJ O
neuropathy NN NN O
, , , O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
200 CD CD O
ppm NN NN O
exacerbated VBD VBD O
clinical JJ JJ O
signs NNS NNS O
in IN IN O
chickens NNS NNS O
given VBN VBN O
either CC CC O
TOTP NNP NNP B-CHEM
or CC CC O
DFP NNP NNP B-CHEM
. . . O

Neurotoxic NNP NNP O
esterase NN NN O
activities NNS NNS O
24 CD CD O
hr NN NN O
after IN IN O
TOTP NNP NNP B-CHEM
or CC CC O
DFP NNP NNP B-CHEM
were VBD VBD O
less JJR JJR O
than IN IN O
20 CD CD O
% NN NN O
of IN IN O
values NNS NNS O
measured VBN VBN O
in IN IN O
chickens NNS NNS O
not RB RB O
given VBN VBN O
organophosphorous JJ JJ B-CHEM
compounds NNS NNS O
. . . O

Chickens NNP NNP O
given VBN VBN O
200 CD CD O
ppm NN NN O
corticosterone NN NN B-CHEM
without IN IN O
TOTP NNP NNP B-CHEM
or CC CC O
DFP NNP NNP B-CHEM
had VBD VBD O
significantly RB RB O
elevated VBN VBN O
activity NN NN O
of IN IN O
plasma NN NN O
cholinesterase NN NN O
and CC CC O
significantly RB RB O
inhibited JJ JJ O
activity NN NN O
of IN IN O
liver NN NN O
carboxylesterase NN NN O
. . . O

Degenerating VBG VBG O
myelinated JJ JJ O
fibers NNS NNS O
were VBD VBD O
also RB RB O
evident JJ JJ O
in IN IN O
distal JJ JJ O
levels NNS NNS O
of IN IN O
the DT DT O
peripheral JJ JJ O
nerves NNS NNS O
of IN IN O
chickens NNS NNS O
given VBN VBN O
TOTP NNP NNP B-CHEM
or CC CC O
DFP NNP NNP B-CHEM
. . . O

Hepatotoxicity NNP NNP O
of IN IN O
amiodarone NN NN B-CHEM
. . . O

Amiodarone NNP NNP B-CHEM
has VBZ VBZ O
proved VBN VBN O
very RB RB O
effective JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
otherwise RB RB O
resistant JJ JJ O
cardiac JJ JJ O
tachyarrhythmias NN NN O
. . . O

The DT DT O
use NN NN O
of IN IN O
amiodarone NN NN B-CHEM
has VBZ VBZ O
, , , O
however RB RB O
, , , O
been VBN VBN O
limited JJ JJ O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
serious JJ JJ O
side NN NN O
- - - O
effects NNS NNS O
. . . O

A DT DT O
patient NN NN O
with IN IN O
cholestatic JJ JJ O
hepatitis NN NN O
due JJ JJ O
to TO TO O
amiodarone DT DT B-CHEM
treatment NN NN O
is VBZ VBZ O
presented VBN VBN O
below IN IN O
and CC CC O
a DT DT O
review NN NN O
of IN IN O
the DT DT O
hepatotoxicity NN NN O
of IN IN O
amiodarone NN NN B-CHEM
is VBZ VBZ O
given VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
solid JJ JJ O
evidence NN NN O
exists NNS NNS O
of IN IN O
hepatic JJ JJ O
injury NN NN O
due JJ JJ O
to TO TO O
amiodarone DT DT B-CHEM
treatment NN NN O
, , , O
including VBG VBG O
steatosis NN NN O
, , , O
alterations NNS NNS O
resembling VBG VBG O
alcoholic JJ JJ O
hepatitis NN NN O
, , , O
cholestatic JJ JJ O
hepatitis NN NN O
and CC CC O
micronodular JJ JJ O
cirrhosis NNS NNS O
of IN IN O
the DT DT O
liver NN NN O
. . . O

Patients NNS NNS O
receiving VBG VBG O
amiodarone NN NN B-CHEM
should MD MD O
be VB VB O
regularly RB RB O
screened VBN VBN O
with IN IN O
respect NN NN O
to TO TO O
hepatic JJ JJ O
enzyme NN NN O
levels NNS NNS O
. . . O

Therapy NNP NNP O
should MD MD O
be VB VB O
discontinued VBN VBN O
on IN IN O
the DT DT O
suspicion NN NN O
of IN IN O
cholestatic JJ JJ O
injury NN NN O
or CC CC O
hepatomegaly NN NN O
. . . O

Promotional NNP NNP O
effects NNS NNS O
of IN IN O
testosterone NN NN B-CHEM
and CC CC O
dietary JJ JJ O
fat JJ JJ O
on IN IN O
prostate NN NN O
carcinogenesis NN NN O
in IN IN O
genetically RB RB O
susceptible JJ JJ O
rats NNS NNS O
. . . O

Germfree NNP NNP O
( ( ( O
GF NNP NNP O
) ) ) O
Lobund NNP NNP O
strain NN NN O
Wistar NNP NNP O
( ( ( O
LW NNP NNP O
) ) ) O
rats NNS NNS O
, , , O
fed VBN VBN O
vegetable JJ JJ O
diet NN NN O
L NNP NNP O
- : : O
485 CD CD O
, , , O
have VBP VBP O
developed VBN VBN O
prostate JJ JJ O
adenocarcinomas NNS NNS O
spontaneously RB RB O
( ( ( O
10 CD CD O
% NN NN O
incidence NN NN O
) ) ) O
at IN IN O
average JJ JJ O
age NN NN O
34 CD CD O
months NNS NNS O
. . . O

Conventional NNP NNP O
LW NNP NNP O
rats NNS NNS O
, , , O
implanted VBN VBN O
with IN IN O
testosterone NN NN B-CHEM
at IN IN O
age NN NN O
4 CD CD O
months NNS NNS O
, , , O
developed VBD VBD O
a DT DT O
higher JJR JJR O
incidence NN NN O
of IN IN O
prostate JJ JJ O
cancer NN NN O
after IN IN O
an DT DT O
average JJ JJ O
interval NN NN O
of IN IN O
14 CD CD O
months NNS NNS O
: : : O
24 CD CD O
% NN NN O
had VBD VBD O
developed VBN VBN O
gross JJ JJ O
tumors NNS NNS O
, , , O
and CC CC O
40 CD CD O
% NN NN O
when WRB WRB O
it PRP PRP O
included VBD VBD O
microscopic JJ JJ O
tumors NNS NNS O
. . . O

Preliminary JJ JJ O
results NNS NNS O
indicate VBP VBP O
that IN IN O
testosterone NN NN B-CHEM
- - - O
treated VBN VBN O
LW NNP NNP O
rats NNS NNS O
that WDT WDT O
were VBD VBD O
fed VBN VBN O
the DT DT O
same JJ JJ O
diet NN NN O
, , , O
which WDT WDT O
was VBD VBD O
supplemented VBN VBN O
with IN IN O
corn NN NN O
oil NN NN O
up IN IN O
to TO TO O
20 CD CD O
% NN NN O
fat JJ JJ O
, , , O
developed VBN VBN O
prostate JJ JJ O
cancer NN NN O
after IN IN O
intervals NNS NNS O
of IN IN O
6 CD CD O
- : : O
12 CD CD O
months NNS NNS O
. . . O

Aged NNP NNP O
GF NNP NNP O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
( ( ( O
SD NNP NNP O
) ) ) O
rats NNS NNS O
have VBP VBP O
not RB RB O
developed VBN VBN O
prostate JJ JJ O
cancer NN NN O
spontaneously RB RB O
. . . O

Conventional NNP NNP O
SD NNP NNP O
rats NNS NNS O
fed VBN VBN O
diet JJ JJ O
L NNP NNP O
- : : O
485 CD CD O
and CC CC O
treated VBN VBN O
with IN IN O
testosterone NN NN B-CHEM
developed VBN VBN O
only RB RB O
prostatitis NNS NNS O
. . . O

Experimental NNP NNP O
designs NNS NNS O
should MD MD O
consider VB VB O
genetic JJ JJ O
susceptibility NN NN O
as IN IN O
a DT DT O
basic JJ JJ O
prerequisite NN NN O
for IN IN O
studies NNS NNS O
on IN IN O
experimental JJ JJ O
prostate NN NN O
cancer NN NN O
. . . O

Time NNP NNP O
course NN NN O
alterations NNS NNS O
of IN IN O
QTC NNP NNP O
interval NN NN O
due JJ JJ O
to TO TO O
hypaque JJ JJ B-CHEM
76 CD CD I-CHEM
. . . O

Sequential NNP NNP O
measurement NN NN O
of IN IN O
QT NNP NNP O
interval NN NN O
during IN IN O
left VBD VBD O
ventricular NN NN O
angiography NN NN O
was VBD VBD O
made VBN VBN O
30 CD CD O
seconds NNS NNS O
and CC CC O
one CD CD O
, , , O
three CD CD O
, , , O
five CD CD O
and CC CC O
ten CD CD O
minutes NNS NNS O
after IN IN O
injection NN NN O
of IN IN O
hypaque NN NN B-CHEM
76 CD CD I-CHEM
. . . O

The DT DT O
subjects NNS NNS O
were VBD VBD O
ten CD CD O
patients NNS NNS O
found VBD VBD O
to TO TO O
have VB VB O
normal JJ JJ O
left VBN VBN O
ventricles NNS NNS O
and CC CC O
coronary JJ JJ O
arteries NNS NNS O
. . . O

Significant JJ JJ O
QTC NNP NNP O
prolongation NN NN O
occurred VBD VBD O
in IN IN O
30 CD CD O
seconds NNS NNS O
to TO TO O
one CD CD O
minute NN NN O
in IN IN O
association NN NN O
with IN IN O
marked JJ JJ O
hypotension NN NN O
and CC CC O
elevation NN NN O
of IN IN O
cardiac JJ JJ O
output NN NN O
. . . O

Rat NNP NNP O
extraocular JJ JJ O
muscle NN NN O
regeneration NN NN O
. . . O

Repair NNP NNP O
of IN IN O
local JJ JJ O
anesthetic JJ JJ O
- - - O
induced JJ JJ O
damage NN NN O
. . . O

Local JJ JJ O
anesthetics NNS NNS O
that WDT WDT O
are VBP VBP O
commonly RB RB O
used VBN VBN O
in IN IN O
ophthalmic JJ JJ O
surgery NN NN O
( ( ( O
0 CD CD O
. . . O
75 CD CD O
% NN NN O
bupivacaine NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
2 CD CD O
. . . O
0 CD CD O
% NN NN O
mepivacaine NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
and CC CC O
2 CD CD O
. . . O
0 CD CD O
% NN NN O
lidocaine NN NN B-CHEM
hydrochloride NN NN I-CHEM
plus CC CC O
1 CD CD O
: : : O
100 CD CD O
, , , O
000 CD CD O
epinephrine NN NN B-CHEM
) ) ) O
were VBD VBD O
injected VBN VBN O
into IN IN O
the DT DT O
retrobulbar NN NN O
area NN NN O
of IN IN O
rat NN NN O
eyes NNS NNS O
. . . O

Controls NNP NNP O
were VBD VBD O
injected VBN VBN O
with IN IN O
physiological JJ JJ O
saline NN NN O
. . . O

All DT DT O
three CD CD O
anesthetics NNS NNS O
produced VBN VBN O
massive JJ JJ O
degeneration NN NN O
of IN IN O
the DT DT O
extraocular JJ JJ O
muscles NNS NNS O
. . . O

Muscle NNP NNP O
degeneration NN NN O
is VBZ VBZ O
followed VBN VBN O
by IN IN O
regeneration NN NN O
of IN IN O
the DT DT O
damaged JJ JJ O
muscle NN NN O
fibers NNS NNS O
. . . O

In IN IN O
addition NN NN O
to TO TO O
muscle NN NN O
damage NN NN O
, , , O
severe JJ JJ O
damage NN NN O
was VBD VBD O
also RB RB O
seen VBN VBN O
in IN IN O
harderian NN NN O
glands NNS NNS O
, , , O
especially RB RB O
after IN IN O
exposure NN NN O
to TO TO O
mepivacaine VB VB B-CHEM
and CC CC O
lidocaine VB VB B-CHEM
plus CC CC O
epinephrine VB VB B-CHEM
. . . O

With IN IN O
these DT DT O
findings NNS NNS O
in IN IN O
rats NNS NNS O
, , , O
it PRP PRP O
is VBZ VBZ O
hypothesized VBN VBN O
that IN IN O
the DT DT O
temporary JJ JJ O
diplopia NN NN O
sometimes RB RB O
seen VBN VBN O
in IN IN O
patients NNS NNS O
after IN IN O
ophthalmic JJ JJ O
surgery NN NN O
might MD MD O
be VB VB O
due JJ JJ O
to TO TO O
anesthetic JJ JJ O
- - - O
induced JJ JJ O
damage NN NN O
to TO TO O
the DT DT O
extraocular JJ JJ O
muscles NNS NNS O
. . . O

Gentamicin NNP NNP B-CHEM
nephropathy NN NN O
in IN IN O
a DT DT O
neonate NN NN O
. . . O

The DT DT O
clinical JJ JJ O
and CC CC O
autopsy NN NN O
findings NNS NNS O
in IN IN O
a DT DT O
premature NN NN O
baby NN NN O
who WP WP O
died VBD VBD O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
after IN IN O
therapy NN NN O
with IN IN O
gentamicin NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
and CC CC O
penicillin NN NN B-CHEM
are VBP VBP O
presented VBN VBN O
. . . O

The DT DT O
serum NN NN O
gentamicin NN NN B-CHEM
concentration NN NN O
had VBD VBD O
reached VBN VBN O
toxic JJ JJ O
levels NNS NNS O
when WRB WRB O
anuria NN NN O
developed VBN VBN O
. . . O

Numerous JJ JJ O
periodic JJ JJ B-CHEM
acid NN NN I-CHEM
Schiff NNP NNP O
( ( ( O
PAS NNP NNP O
) ) ) O
positive JJ JJ O
, , , O
diastase NN NN O
resistant JJ JJ O
cytoplasmic JJ JJ O
inclusion NN NN O
bodies NNS NNS O
which WDT WDT O
appeared VBD VBD O
as IN IN O
myelin NN NN O
figures NNS NNS O
in IN IN O
cytosegresomes NNS NNS O
under IN IN O
the DT DT O
electron NN NN O
microscope NN NN O
were VBD VBD O
identified VBN VBN O
in IN IN O
the DT DT O
proximal NN NN O
convoluted JJ JJ O
tubules NNS NNS O
. . . O

The DT DT O
pathological JJ JJ O
changes NNS NNS O
induced VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
in IN IN O
the DT DT O
human JJ JJ O
neonatal NN NN O
kidneys NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
previously RB RB O
reported VBN VBN O
. . . O

Induction NNP NNP O
by IN IN O
paracetamol NN NN B-CHEM
of IN IN O
bladder NN NN O
and CC CC O
liver NN NN O
tumours NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Effects NNP NNP O
on IN IN O
hepatocyte NN NN O
fine NN NN O
structure NN NN O
. . . O

Groups NNS NNS O
of IN IN O
male JJ JJ O
and CC CC O
female JJ JJ O
inbred JJ JJ O
Leeds NNP NNP O
strain VB VB O
rats NNS NNS O
were VBD VBD O
fed VBN VBN O
diets NNS NNS O
containing VBG VBG O
either CC CC O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
or CC CC O
1 CD CD O
. . . O
0 CD CD O
% NN NN O
paracetamol NN NN B-CHEM
by IN IN O
weight NN NN O
for IN IN O
up IN IN O
to TO TO O
18 CD CD O
months NNS NNS O
. . . O

At IN IN O
the DT DT O
1 CD CD O
. . . O
0 CD CD O
% NN NN O
dosage NN NN O
level NN NN O
, , , O
20 CD CD O
% NN NN O
of IN IN O
rats NNS NNS O
of IN IN O
both DT DT O
sexes NNS NNS O
developed VBN VBN O
neoplastic JJ JJ O
nodules NNS NNS O
of IN IN O
the DT DT O
liver NN NN O
, , , O
a DT DT O
statistically RB RB O
significant JJ JJ O
incidence NN NN O
. . . O

These DT DT O
rats NNS NNS O
also RB RB O
showed VBD VBD O
gross JJ JJ O
enlargement NN NN O
of IN IN O
their PRP$ PRP$ O
livers NNS NNS O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
foci NN NN O
of IN IN O
cellular JJ JJ O
alteration NN NN O
, , , O
the DT DT O
latter JJ JJ O
also RB RB O
being VBG VBG O
observed VBN VBN O
in IN IN O
the DT DT O
low JJ JJ O
dosage NN NN O
male JJ JJ O
rats NNS NNS O
. . . O

Papillomas NNP NNP O
of IN IN O
the DT DT O
transitional JJ JJ O
epithelium NN NN O
of IN IN O
the DT DT O
bladder NN NN O
developed VBN VBN O
in IN IN O
all DT DT O
paracetamol NN NN B-CHEM
- - - O
treated VBN VBN O
groups NNS NNS O
, , , O
and CC CC O
three CD CD O
rats NNS NNS O
bore RB RB O
bladder NN NN O
carcinomas NN NN O
. . . O

However RB RB O
, , , O
significant JJ JJ O
yields NNS NNS O
of IN IN O
bladder NN NN O
tumours NNS NNS O
were VBD VBD O
only RB RB O
obtained VBN VBN O
from IN IN O
low JJ JJ O
dosage NN NN O
females NNS NNS O
and CC CC O
high JJ JJ O
dosage NN NN O
males NNS NNS O
. . . O

Additionally RB RB O
, , , O
20 CD CD O
to TO TO O
25 CD CD O
% NN NN O
of IN IN O
paracetamol NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
developed VBN VBN O
hyperplasia NN NN O
of IN IN O
the DT DT O
bladder NN NN O
epithelium NN NN O
, , , O
which WDT WDT O
was VBD VBD O
not RB RB O
coincident NN NN O
with IN IN O
the DT DT O
presence NN NN O
of IN IN O
bladder NN NN O
calculi NN NN O
. . . O

A DT DT O
low JJ JJ O
yield NN NN O
of IN IN O
tumours NNS NNS O
at IN IN O
various JJ JJ O
other JJ JJ O
sites NNS NNS O
also RB RB O
arose VBD VBD O
following VBG VBG O
paracetamol NN NN B-CHEM
feeding NN NN O
. . . O

An DT DT O
electron NN NN O
microscope NN NN O
study NN NN O
of IN IN O
the DT DT O
livers NNS NNS O
of IN IN O
paracetamol NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
revealed VBD VBD O
ultrastructural JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
hepatocytes NNS NNS O
that IN IN O
resemble JJ JJ O
those DT DT O
that WDT WDT O
result NN NN O
from IN IN O
exposure NN NN O
to TO TO O
a DT DT O
variety NN NN O
of IN IN O
known VBN VBN O
hepatocarcinogens NNS NNS O
. . . O

Transient NNP NNP O
hemiparesis NN NN O
: : : O
a DT DT O
rare JJ JJ O
manifestation NN NN O
of IN IN O
diphenylhydantoin NN NN B-CHEM
toxicity NN NN O
. . . O

Report NNP NNP O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

Among IN IN O
the DT DT O
common JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
diphenylhydantoin NN NN B-CHEM
( ( ( O
DPH NNP NNP B-CHEM
) ) ) O
overdose NN NN O
, , , O
the DT DT O
most RBS RBS O
frequently RB RB O
encountered VBN VBN O
neurological JJ JJ O
signs NNS NNS O
are VBP VBP O
those DT DT O
of IN IN O
cerebellar JJ JJ O
dysfunction NN NN O
. . . O

Very RB RB O
rarely RB RB O
, , , O
the DT DT O
toxic JJ JJ O
neurological JJ JJ O
manifestations NNS NNS O
of IN IN O
this DT DT O
drug NN NN O
are VBP VBP O
of IN IN O
cerebral JJ JJ O
origin NN NN O
. . . O

Two CD CD O
patients NNS NNS O
are VBP VBP O
presented VBN VBN O
who WP WP O
suffered VBD VBD O
progressive JJ JJ O
hemiparesis NN NN O
due JJ JJ O
to TO TO O
DPH NNP NNP B-CHEM
overdose NN NN O
. . . O

Both DT DT O
had VBD VBD O
brain NN NN O
surgery NN NN O
before IN IN O
DPH NNP NNP B-CHEM
treatment NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
assumed VBN VBN O
that IN IN O
patients NNS NNS O
with IN IN O
some DT DT O
cerebral JJ JJ O
damage NN NN O
are VBP VBP O
liable JJ JJ O
to TO TO O
manifest VB VB O
DPH NNP NNP B-CHEM
toxicity NN NN O
as IN IN O
focal JJ JJ O
neurological JJ JJ O
signs NNS NNS O
. . . O

Tiapride NNP NNP B-CHEM
in IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
involuntary JJ JJ O
movements NNS NNS O
. . . O

Tiapride NNP NNP B-CHEM
, , , O
a DT DT O
substituted JJ JJ O
benzamide NN NN B-CHEM
derivative NN NN O
closely RB RB O
related VBD VBD O
to TO TO O
metoclopramide NN NN B-CHEM
, , , O
reduced VBN VBN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
peak NN NN O
dose NN NN O
involuntary JJ JJ O
movements NNS NNS O
in IN IN O
16 CD CD O
patients NNS NNS O
with IN IN O
idiopathic JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

However RB RB O
, , , O
an DT DT O
unacceptable JJ JJ O
increase NN NN O
in IN IN O
disability NN NN O
from IN IN O
Parkinsonism NNP NNP O
with IN IN O
aggravation NN NN O
of IN IN O
end NN NN O
- - - O
of IN IN O
- - - O
dose NN NN O
akinesia NN NN O
led VBN VBN O
to TO TO O
its PRP$ PRP$ O
cessation NN NN O
in IN IN O
14 CD CD O
patients NNS NNS O
. . . O

Tiapride NNP NNP B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
levodopa NN NN B-CHEM
- : : O
induced VBN VBN O
early JJ JJ O
morning NN NN O
of IN IN O
" '' '' O
off IN IN O
- - - O
period NN NN O
" '' '' O
segmental NN NN O
dystonia NN NN O
. . . O

These DT DT O
results NNS NNS O
fail VBP VBP O
to TO TO O
support VB VB O
the DT DT O
notion NN NN O
that IN IN O
levodopa NN NN B-CHEM
- : : O
induced JJ JJ O
dyskinesias NNS NNS O
are VBP VBP O
caused VBN VBN O
by IN IN O
overstimulation NN NN O
of IN IN O
a DT DT O
separate JJ JJ O
group NN NN O
of IN IN O
dopamine NN NN B-CHEM
receptors NNS NNS O
. . . O

Quinidine NNP NNP B-CHEM
hepatitis NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
administration NN NN O
of IN IN O
quinidine NN NN B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
persistent JJ JJ O
elevation NN NN O
of IN IN O
serum NN NN O
concentrations NNS NNS O
of IN IN O
SGOT NNP NNP O
, , , O
lactic JJ JJ B-CHEM
acid NN NN I-CHEM
dehydrogenase NN NN O
, , , O
and CC CC O
alkaline NN NN O
phosphatase NN NN O
. . . O

Liver NNP NNP O
biopsy NN NN O
showed VBD VBD O
active JJ JJ O
hepatitis NN NN O
. . . O

Discontinuance NNP NNP O
of IN IN O
quinidine NN NN B-CHEM
therapy NN NN O
led VBN VBN O
to TO TO O
normalization NN NN O
of IN IN O
liver NN NN O
function NN NN O
tests NNS NNS O
. . . O

A DT DT O
challenge NN NN O
dose NN NN O
of IN IN O
quinidine NN NN B-CHEM
caused VBD VBD O
clinical JJ JJ O
symptoms NNS NNS O
and CC CC O
abrupt JJ JJ O
elevation NN NN O
of IN IN O
SGOT NNP NNP O
, , , O
alkaline NN NN O
phosphatase NN NN O
, , , O
and CC CC O
lactic JJ JJ B-CHEM
acid NN NN I-CHEM
dehydrogenase NN NN O
values NNS NNS O
. . . O

We PRP PRP O
concluded VBD VBD O
that IN IN O
this DT DT O
patient NN NN O
had VBD VBD O
quinidine JJ JJ B-CHEM
hepatotoxicity NN NN O
and CC CC O
believe VBP VBP O
that IN IN O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
case NN NN O
reported VBD VBD O
with IN IN O
liver NN NN O
biopsy NN NN O
documentation NN NN O
. . . O

This DT DT O
report NN NN O
also RB RB O
suggests VBZ VBZ O
that IN IN O
, , , O
even RB RB O
after IN IN O
long JJ JJ O
- - - O
term NN NN O
administration NN NN O
, , , O
the DT DT O
hepatic JJ JJ O
toxicity NN NN O
is VBZ VBZ O
reversible JJ JJ O
. . . O

Arterial NNP NNP O
thromboembolism NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
systemic JJ JJ O
heparin NN NN B-CHEM
therapy NN NN O
: : : O
a DT DT O
complication NN NN O
associated VBN VBN O
with IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
. . . O

Arterial NNP NNP O
thromboembolism NN NN O
is VBZ VBZ O
a DT DT O
recognized JJ JJ O
complication NN NN O
of IN IN O
systemic JJ JJ O
heparin NN NN B-CHEM
therapy NN NN O
. . . O

Characteristic NNP NNP O
of IN IN O
the DT DT O
entity NN NN O
is VBZ VBZ O
arterial JJ JJ O
occlusion NN NN O
by IN IN O
platelet NN NN O
- - - O
fibrin NN NN O
thrombi NN NN O
with IN IN O
distal JJ JJ O
ischemia NN NN O
occurring VBG VBG O
four CD CD O
to TO TO O
twenty CD CD O
days NNS NNS O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
heparin NN NN B-CHEM
therapy NN NN O
, , , O
preceded VBN VBN O
by IN IN O
profound NN NN O
thrombocytopenia NN NN O
with IN IN O
platelet NN NN O
counts NNS NNS O
in IN IN O
the DT DT O
range NN NN O
of IN IN O
30 CD CD O
, , , O
000 CD CD O
to TO TO O
40 CD CD O
, , , O
000 CD CD O
per IN IN O
cubic NN NN O
millimeter NN NN O
. . . O

The DT DT O
clinically RB RB O
apparent JJ JJ O
occlusion NN NN O
may MD MD O
be VB VB O
preceded VBN VBN O
by IN IN O
gastrointestinal NN NN O
and CC CC O
musculoskeletal JJ JJ O
symptoms NNS NNS O
that WDT WDT O
appear VBP VBP O
to TO TO O
be VB VB O
ischemic JJ JJ O
in IN IN O
origin NN NN O
, , , O
and CC CC O
might MD MD O
serve VB VB O
to TO TO O
warn VB VB O
the DT DT O
clinician NN NN O
of IN IN O
these DT DT O
complications NNS NNS O
. . . O

Previous JJ JJ O
reports NNS NNS O
of IN IN O
these DT DT O
phenomena NN NN O
as RB RB O
well RB RB O
as IN IN O
recent JJ JJ O
studies NNS NNS O
of IN IN O
the DT DT O
effect NN NN O
of IN IN O
heparin NN NN B-CHEM
are VBP VBP O
reviewed VBN VBN O
. . . O

The DT DT O
common JJ JJ O
factor NN NN O
relating VBG VBG O
thromboembolism NN NN O
and CC CC O
thrombocytopenia NN NN O
is VBZ VBZ O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
platelet NN NN O
aggregation NN NN O
. . . O

Appropriate JJ JJ O
treatment NN NN O
consists NNS NNS O
of IN IN O
discontinuation NN NN O
of IN IN O
heparin NN NN B-CHEM
, , , O
and CC CC O
anticoagulation NN NN O
with IN IN O
sodium NN NN B-CHEM
warfarin NN NN I-CHEM
if IN IN O
necessary JJ JJ O
. . . O

Vascular NNP NNP O
procedures NNS NNS O
are VBP VBP O
performed VBN VBN O
as IN IN O
indicated VBN VBN O
. . . O

Pharmacology NNP NNP O
of IN IN O
GYKI NNP NNP B-CHEM
- : : I-CHEM
41 CD CD I-CHEM
099 CD CD I-CHEM
( ( ( O
chlorpropanol NN NN B-CHEM
, , , O
Tobanum NNP NNP B-CHEM
) ) ) O
a DT DT O
new JJ JJ O
potent NN NN O
beta NN NN O
- : : O
adrenergic JJ JJ O
antagonist NN NN O
. . . O

The DT DT O
compound NN NN O
GYKI NNP NNP B-CHEM
- : : I-CHEM
41 CD CD I-CHEM
099 CD CD I-CHEM
, , , O
as IN IN O
a DT DT O
beta NN NN O
- - - O
adrenergic JJ JJ O
antagonist NN NN O
, , , O
is VBZ VBZ O
3 CD CD O
- : : O
8 CD CD O
times NNS NNS O
more RBR RBR O
potent JJ JJ O
than IN IN O
propranolol NN NN B-CHEM
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
. . . O

Its PRP$ PRP$ O
antiarrhythmic JJ JJ O
effectiveness NN NN O
surpasses NNS NNS O
that IN IN O
of IN IN O
propranolol NN NN B-CHEM
and CC CC O
pindolol NN NN B-CHEM
inhibiting VBG VBG O
the DT DT O
ouabain NN NN B-CHEM
arrhythmia NN NN O
in IN IN O
dogs NNS NNS O
and CC CC O
cats NNS NNS O
. . . O

GYKI NNP NNP B-CHEM
- : : I-CHEM
41 CD CD I-CHEM
900 CD CD I-CHEM
has VBZ VBZ O
a DT DT O
negligible JJ JJ O
cardiodepressant NN NN O
activity NN NN O
; : : O
it PRP PRP O
is VBZ VBZ O
not RB RB O
cardioselective JJ JJ O
. . . O

The DT DT O
compound NN NN O
shows VBZ VBZ O
a DT DT O
rapid JJ JJ O
and CC CC O
long JJ JJ O
lasting JJ JJ O
effect NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
prolonged JJ JJ O
elimination NN NN O
of IN IN O
the DT DT O
radioactivity NN NN O
after IN IN O
the DT DT O
injection NN NN O
of IN IN O
14C CD CD B-CHEM
- : : I-CHEM
41 CD CD I-CHEM
099 CD CD I-CHEM
to TO TO O
rats NNS NNS O
and CC CC O
dogs NNS NNS O
. . . O

The DT DT O
half JJ JJ O
life NN NN O
of IN IN O
the DT DT O
unlabeled JJ JJ O
substance NN NN O
in IN IN O
humans NNS NNS O
was VBD VBD O
more JJR JJR O
than IN IN O
10 CD CD O
hours NNS NNS O
. . . O

Adverse NNP NNP O
reactions NNS NNS O
to TO TO O
bendrofluazide VB VB B-CHEM
and CC CC O
propranolol NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
mild JJ JJ O
hypertension NN NN O
. . . O

Report NNP NNP O
of IN IN O
Medical NNP NNP O
Research NNP NNP O
Council NNP NNP O
Working NNP NNP O
Party NNP NNP O
on IN IN O
Mild NNP NNP O
to TO TO O
Moderate NNP NNP O
Hypertension NNP NNP O
. . . O

Participants NNS NNS O
in IN IN O
the DT DT O
Medical NNP NNP O
Research NNP NNP O
Council NNP NNP O
treatment NN NN O
trial NN NN O
for IN IN O
mild JJ JJ O
hypertension NN NN O
are VBP VBP O
randomly RB RB O
allocated VBN VBN O
to TO TO O
one CD CD O
of IN IN O
four CD CD O
treatment NN NN O
groups NNS NNS O
: : : O
bendrofluazide NN NN B-CHEM
, , , O
propranolol NN NN B-CHEM
, , , O
or CC CC O
a DT DT O
placebo NN NN O
for IN IN O
either DT DT O
of IN IN O
these DT DT O
drugs NNS NNS O
. . . O

The DT DT O
trial NN NN O
is VBZ VBZ O
single JJ JJ O
- - - O
blind JJ JJ O
. . . O

23 CD CD O
582 CD CD O
patient NN NN O
- : : O
years NNS NNS O
of IN IN O
observation NN NN O
have VBP VBP O
been VBN VBN O
completed VBN VBN O
so RB RB O
far RB RB O
, , , O
10 CD CD O
684 CD CD O
on IN IN O
active JJ JJ O
drugs NNS NNS O
and CC CC O
12 CD CD O
898 CD CD O
on IN IN O
placebos NN NN O
. . . O

The DT DT O
results NNS NNS O
show VBP VBP O
an DT DT O
association NN NN O
between IN IN O
bendrofluazide NN NN B-CHEM
treatment NN NN O
and CC CC O
impotence NN NN O
, , , O
and CC CC O
impotence NN NN O
also RB RB O
occurred VBD VBD O
more RBR RBR O
frequently RB RB O
in IN IN O
patients NNS NNS O
taking VBG VBG O
propranolol NN NN B-CHEM
than IN IN O
in IN IN O
those DT DT O
taking VBG VBG O
placebos NN NN O
. . . O

Other JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
significantly RB RB O
linked VBN VBN O
with IN IN O
active JJ JJ O
drugs NNS NNS O
include VBP VBP O
impaired VBN VBN O
glucose NN NN O
tolerance NN NN O
in IN IN O
men NNS NNS O
and CC CC O
women NNS NNS O
and CC CC O
gout NN NN O
in IN IN O
men NNS NNS O
, , , O
associated VBN VBN O
with IN IN O
bendrofluazide NN NN B-CHEM
treatment NN NN O
, , , O
and CC CC O
Raynaud NNP NNP O
' POS POS O
s VBZ VBZ O
phenomenon NN NN O
and CC CC O
dyspnoea NN NN O
in IN IN O
men NNS NNS O
and CC CC O
women NNS NNS O
taking VBG VBG O
propranolol NN NN B-CHEM
. . . O

No DT DT O
corneal NN NN O
disease NN NN O
is VBZ VBZ O
known VBN VBN O
to TO TO O
have VB VB O
occurred VBN VBN O
in IN IN O
the DT DT O
propranolol NN NN B-CHEM
group NN NN O
. . . O

Mean VB VB O
serum NN NN O
potassium NN NN B-CHEM
level NN NN O
fell VBD VBD O
, , , O
and CC CC O
urea NN NN B-CHEM
and CC CC O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
levels NNS NNS O
rose VBD VBD O
, , , O
in IN IN O
men NNS NNS O
and CC CC O
women NNS NNS O
taking VBG VBG O
bendrofluazide NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
propranolol NN NN B-CHEM
group NN NN O
, , , O
serum NN NN O
potassium NN NN B-CHEM
and CC CC O
uric JJ JJ B-CHEM
acid NN NN I-CHEM
levels NNS NNS O
rose VBD VBD O
in IN IN O
both DT DT O
sexes NNS NNS O
, , , O
but CC CC O
the DT DT O
urea NN NN B-CHEM
level NN NN O
rose VBD VBD O
significantly RB RB O
in IN IN O
women NNS NNS O
only RB RB O
. . . O

Serotonergic NNP NNP O
drugs NNS NNS O
, , , O
benzodiazepines NNS NNS B-CHEM
and CC CC O
baclofen NN NN B-CHEM
block NN NN O
muscimol NN NN B-CHEM
- : : O
induced JJ JJ O
myoclonic JJ JJ O
jerks NNS NNS O
in IN IN O
a DT DT O
strain NN NN O
of IN IN O
mice NNS NNS O
. . . O

In IN IN O
male JJ JJ O
Swiss NNP NNP O
mice NN NN O
, , , O
muscimol NN NN B-CHEM
produced VBN VBN O
myoclonic JJ JJ O
jerks NNS NNS O
. . . O

A DT DT O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
dose NN NN O
induced VBD VBD O
this DT DT O
response NN NN O
in IN IN O
all DT DT O
of IN IN O
the DT DT O
mice NN NN O
tested VBD VBD O
and CC CC O
the DT DT O
peak NN NN O
response NN NN O
of IN IN O
73 CD CD O
jerks NNS NNS O
per IN IN O
min NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
27 CD CD O
and CC CC O
45 CD CD O
min NN NN O
. . . O

Increasing NNP NNP O
the DT DT O
brain NN NN O
serotonin NN NN B-CHEM
levels NNS NNS O
by IN IN O
the DT DT O
administration NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptophan NN NN I-CHEM
( ( ( O
80 CD CD O
- : : O
160 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
combination NN NN O
with IN IN O
a DT DT O
peripheral JJ JJ O
decarboxylase NN NN O
inhibitor NN NN O
resulted VBD VBD O
in IN IN O
an DT DT O
inhibition NN NN O
of IN IN O
the DT DT O
muscimol NN NN B-CHEM
effect NN NN O
. . . O

However RB RB O
, , , O
in IN IN O
a DT DT O
similar JJ JJ O
experiment NN NN O
l NN NN B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
( ( ( O
80 CD CD O
- : : O
160 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
without IN IN O
effect NN NN O
. . . O

In IN IN O
doses NNS NNS O
of IN IN O
3 CD CD O
- : : O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
the DT DT O
serotonin NN NN B-CHEM
receptor NN NN O
agonist NN NN O
MK NNP NNP B-CHEM
- : : I-CHEM
212 CD CD I-CHEM
caused VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
blockade NN NN O
of IN IN O
the DT DT O
response NN NN O
of IN IN O
muscimol NN NN B-CHEM
. . . O

Of IN IN O
the DT DT O
benzodiazepines NNS NNS B-CHEM
, , , O
clonazepam NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
- : : O
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
several JJ JJ O
fold VB VB O
more RBR RBR O
potent JJ JJ O
than IN IN O
diazepam NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
3 CD CD O
- : : O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
blocking VBG VBG O
the DT DT O
myoclonic JJ JJ O
jerks NNS NNS O
. . . O

While IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
baclofen NN NN B-CHEM
( ( ( O
1 CD CD O
- : : O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
proved VBD VBD O
to TO TO O
be VB VB O
an DT DT O
effective JJ JJ O
antagonist NN NN O
of IN IN O
muscimol NN NN B-CHEM
, , , O
its PRP$ PRP$ O
( ( ( O
+ NN NN O
) ) ) O
- : : O
isomer NN NN O
( ( ( O
5 CD CD O
- : : O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
lacked VBD VBD O
this DT DT O
property NN NN O
. . . O

Considering VBG VBG O
the DT DT O
fact NN NN O
that IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HTP NNP NNP I-CHEM
and CC CC O
the DT DT O
benzodiazepines NNS NNS B-CHEM
have VBP VBP O
been VBN VBN O
found VBN VBN O
to TO TO O
be VB VB O
beneficial JJ JJ O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
clinical JJ JJ O
myoclonus NN NN O
, , , O
the DT DT O
muscimol NN NN B-CHEM
- - - O
induced JJ JJ O
myoclonus NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
a DT DT O
satisfactory JJ JJ O
animal NN NN O
model NN NN O
that WDT WDT O
may MD MD O
prove VB VB O
useful JJ JJ O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
new JJ JJ O
drug NN NN O
treatments NNS NNS O
for IN IN O
this DT DT O
condition NN NN O
. . . O

Our PRP$ PRP$ O
present JJ JJ O
study NN NN O
indicated VBD VBD O
the DT DT O
possible JJ JJ O
value NN NN O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
212 CD CD I-CHEM
and CC CC O
( ( ( O
- : : O
) ) ) O
- : : O
baclofen NN NN B-CHEM
in IN IN O
the DT DT O
management NN NN O
of IN IN O
clinical JJ JJ O
myoclonus NN NN O
. . . O

Adverse NNP NNP O
interaction NN NN O
between IN IN O
beta NN NN B-CHEM
- - - I-CHEM
adrenergic JJ JJ I-CHEM
blocking VBG VBG I-CHEM
drugs NNS NNS I-CHEM
and CC CC O
verapamil NN NN B-CHEM
- - - O
- - - O
report NN NN O
of IN IN O
three CD CD O
cases NNS NNS O
. . . O

Three CD CD O
patients NNS NNS O
with IN IN O
ischaemic JJ JJ O
heart NN NN O
disease NN NN O
developed VBN VBN O
profound JJ JJ O
cardiac JJ JJ O
failure NN NN O
, , , O
hypotension NN NN O
and CC CC O
bradycardia NN NN O
during IN IN O
combined VBN VBN O
therapy NN NN O
with IN IN O
verapamil NN NN B-CHEM
and CC CC O
beta NN NN B-CHEM
- - - I-CHEM
adrenergic JJ JJ I-CHEM
blocking VBG VBG I-CHEM
drugs NNS NNS I-CHEM
. . . O

This DT DT O
clinical JJ JJ O
picture NN NN O
resolved VBD VBD O
completely RB RB O
with IN IN O
cessation NN NN O
of IN IN O
the DT DT O
combined VBN VBN O
therapy NN NN O
. . . O

Baseline NNP NNP O
left VBD VBD O
ventricular NN NN O
function NN NN O
, , , O
assessed VBN VBN O
by IN IN O
cardiac JJ JJ O
catheterisation NN NN O
or CC CC O
nuclear JJ JJ O
angiography NN NN O
, , , O
was VBD VBD O
normal JJ JJ O
in IN IN O
two CD CD O
patients NNS NNS O
and CC CC O
only RB RB O
mildly RB RB O
reduced VBN VBN O
in IN IN O
the DT DT O
other JJ JJ O
. . . O

Simultaneously NNP NNP O
administration NN NN O
of IN IN O
beta NN NN B-CHEM
- - - I-CHEM
adrenergic JJ JJ I-CHEM
blocking VBG VBG I-CHEM
drugs NNS NNS I-CHEM
and CC CC O
verapamil NN NN B-CHEM
may MD MD O
result VB VB O
in IN IN O
profound JJ JJ O
adverse JJ JJ O
interactions NNS NNS O
and CC CC O
should MD MD O
only RB RB O
be VB VB O
administered VBN VBN O
with IN IN O
great JJ JJ O
caution NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
effectiveness NN NN O
of IN IN O
ranitidine NN NN B-CHEM
and CC CC O
cimetidine NN NN B-CHEM
in IN IN O
inhibiting VBG VBG O
acid NN NN O
secretion NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
gastric JJ JJ O
hypersecretory NN NN O
states NNS NNS O
. . . O

The DT DT O
H2 NNP NNP O
- - - O
histamine NN NN B-CHEM
receptor NN NN O
antagonists NNS NNS O
ranitidine VBP VBP B-CHEM
and CC CC O
cimetidine NN NN B-CHEM
were VBD VBD O
compared VBN VBN O
for IN IN O
their PRP$ PRP$ O
abilities NNS NNS O
to TO TO O
control VB VB O
gastric JJ JJ O
acid NN NN O
hypersecretion NN NN O
on IN IN O
a DT DT O
short JJ JJ O
- - - O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
basis NN NN O
in IN IN O
22 CD CD O
patients NNS NNS O
with IN IN O
gastric JJ JJ O
acid NN NN O
hypersecretory NN NN O
states NNS NNS O
. . . O

Nineteen NNP NNP O
patients NNS NNS O
had VBD VBD O
Zollinger NNP NNP O
- : : O
Ellison NNP NNP O
syndrome NN NN O
, , , O
one CD CD O
patient NN NN O
had VBD VBD O
systemic JJ JJ O
mastocytosis NN NN O
, , , O
and CC CC O
two CD CD O
patients NNS NNS O
had VBD VBD O
idiopathic JJ JJ O
hypersecretion NN NN O
. . . O

The DT DT O
rates NNS NNS O
of IN IN O
onset NN NN O
of IN IN O
the DT DT O
action NN NN O
of IN IN O
cimetidine NN NN B-CHEM
and CC CC O
ranitidine NN NN B-CHEM
were VBD VBD O
the DT DT O
same JJ JJ O
. . . O

The DT DT O
actions NNS NNS O
of IN IN O
both DT DT O
drugs NNS NNS O
were VBD VBD O
increased VBN VBN O
by IN IN O
anticholinergic JJ JJ O
agents NNS NNS O
, , , O
and CC CC O
there EX EX O
was VBD VBD O
a DT DT O
close JJ JJ O
correlation NN NN O
between IN IN O
the DT DT O
daily JJ JJ O
maintenance NN NN O
dose NN NN O
of IN IN O
each DT DT O
drug NN NN O
needed VBN VBN O
to TO TO O
control VB VB O
acid NN NN O
secretion NN NN O
. . . O

However RB RB O
, , , O
ranitidine NN NN B-CHEM
was VBD VBD O
threefold VBN VBN O
more RBR RBR O
potent JJ JJ O
than IN IN O
cimetidine NN NN B-CHEM
both DT DT O
in IN IN O
acute JJ JJ O
inhibition NN NN O
studies NNS NNS O
and CC CC O
in IN IN O
the DT DT O
median NN NN O
maintenance NN NN O
dose NN NN O
needed VBN VBN O
( ( ( O
1 CD CD O
. . . O
2 CD CD O
g SYM SYM O
per IN IN O
day NN NN O
for IN IN O
ranitidine NN NN B-CHEM
and CC CC O
3 CD CD O
. . . O
6 CD CD O
g SYM SYM O
per IN IN O
day NN NN O
for IN IN O
cimetidine NN NN B-CHEM
) ) ) O
. . . O

Sixty CD CD O
percent NN NN O
of IN IN O
the DT DT O
males NNS NNS O
developed VBN VBN O
breast NN NN O
changes NNS NNS O
or CC CC O
impotence NN NN O
while IN IN O
taking VBG VBG O
cimetidine NN NN B-CHEM
and CC CC O
in IN IN O
all DT DT O
cases NNS NNS O
these DT DT O
changes NNS NNS O
disappeared VBD VBD O
when WRB WRB O
cimetidine NN NN B-CHEM
was VBD VBD O
replaced VBN VBN O
by IN IN O
ranitidine NN NN B-CHEM
. . . O

Treatment NN NN O
with IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
cimetidine NN NN B-CHEM
( ( ( O
one CD CD O
to TO TO O
60 CD CD O
months NNS NNS O
; : : O
median NN NN O
, , , O
11 CD CD O
months NNS NNS O
) ) ) O
or CC CC O
ranitidine NN NN B-CHEM
( ( ( O
two CD CD O
to TO TO O
31 CD CD O
months NNS NNS O
; : : O
median NN NN O
, , , O
14 CD CD O
months NNS NNS O
) ) ) O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
hepatic JJ JJ O
or CC CC O
hematologic JJ JJ O
toxicity NN NN O
or CC CC O
alterations NNS NNS O
of IN IN O
serum NN NN O
gastrin NN NN O
concentrations NNS NNS O
, , , O
but CC CC O
ranitidine NN NN B-CHEM
therapy NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
significantly RB RB O
lower JJR JJR O
serum NN NN O
creatinine NN NN B-CHEM
level NN NN O
than IN IN O
seen VBN VBN O
with IN IN O
cimetidine NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
results NNS NNS O
show VBP VBP O
that IN IN O
both DT DT O
drugs NNS NNS O
can MD MD O
adequately RB RB O
inhibit VB VB O
acid NN NN O
secretion NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
gastric JJ JJ O
hypersecretory NN NN O
states NNS NNS O
. . . O

Both DT DT O
are VBP VBP O
safe JJ JJ O
at IN IN O
high JJ JJ O
doses NNS NNS O
, , , O
but CC CC O
ranitidine NN NN B-CHEM
is VBZ VBZ O
threefold VBN VBN O
more RBR RBR O
potent JJ JJ O
and CC CC O
does VBZ VBZ O
not RB RB O
cause VB VB O
the DT DT O
antiandrogen NN NN O
side NN NN O
effects NNS NNS O
frequently RB RB O
seen VBN VBN O
with IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
cimetidine NN NN B-CHEM
. . . O

Epileptogenic JJ JJ O
properties NNS NNS O
of IN IN O
enflurane NN NN B-CHEM
and CC CC O
their PRP$ PRP$ O
clinical JJ JJ O
interpretation NN NN O
. . . O

Three CD CD O
cases NNS NNS O
of IN IN O
EEG NNP NNP O
changes NNS NNS O
induced VBN VBN O
by IN IN O
single JJ JJ O
exposure NN NN O
to TO TO O
enflurane VB VB B-CHEM
anesthesia NN NN O
are VBP VBP O
reported VBN VBN O
. . . O

In IN IN O
one CD CD O
patient NN NN O
, , , O
enflurane NN NN B-CHEM
administered VBD VBD O
during IN IN O
a DT DT O
donor NN NN O
nephrectomy NN NN O
resulted VBD VBD O
in IN IN O
unexpected JJ JJ O
partial JJ JJ O
motor NN NN O
seizures NNS NNS O
. . . O

Until IN IN O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
seizures NNS NNS O
was VBD VBD O
correctly RB RB O
identified VBN VBN O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
inappropriately RB RB O
treated VBN VBN O
with IN IN O
anticonvulsants NNS NNS O
. . . O

Two CD CD O
other JJ JJ O
patients NNS NNS O
suffered VBD VBD O
from IN IN O
partial JJ JJ O
, , , O
complex JJ JJ O
and CC CC O
generalized JJ JJ O
seizures NNS NNS O
uncontrolled JJ JJ O
by IN IN O
medication NN NN O
. . . O

Epileptic NNP NNP O
foci NN NN O
delineated VBD VBD O
and CC CC O
activated VBN VBN O
by IN IN O
enflurane NN NN B-CHEM
were VBD VBD O
surgically RB RB O
ablated VBN VBN O
and CC CC O
the DT DT O
patients NNS NNS O
are VBP VBP O
now RB RB O
seizure JJ JJ O
- - - O
free JJ JJ O
. . . O

Previous JJ JJ O
exposures NNS NNS O
to TO TO O
enflurane NN NN B-CHEM
have VBP VBP O
to TO TO O
be VB VB O
disclosed VBN VBN O
to TO TO O
avoid VB VB O
mistakes NNS NNS O
in IN IN O
clinical JJ JJ O
interpretation NN NN O
of IN IN O
the DT DT O
EEG NNP NNP O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
enflurane NN NN B-CHEM
may MD MD O
prove VB VB O
to TO TO O
be VB VB O
a DT DT O
safe JJ JJ O
fast RB RB O
acting VBG VBG O
activator NN NN O
of IN IN O
epileptic JJ JJ O
foci NN NN O
during IN IN O
corticography NN NN O
or CC CC O
depth NN NN O
electrode NN NN O
intraoperative JJ JJ O
recordings NNS NNS O
. . . O

Development NNP NNP O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
hypertrophy NN NN O
. . . O

The DT DT O
development NN NN O
of IN IN O
cardiac JJ JJ O
hypertrophy NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
adult NN NN O
female JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
following VBG VBG O
daily JJ JJ O
subcutaneous JJ JJ O
injections NNS NNS O
of IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
ISO NNP NNP B-CHEM
) ) ) O
( ( ( O
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) ) ) O
. . . O

A DT DT O
time NN NN O
course NN NN O
was VBD VBD O
established VBN VBN O
for IN IN O
the DT DT O
change NN NN O
in IN IN O
tissue NN NN O
mass NN NN O
, , , O
RNA NNP NNP O
and CC CC O
DNA NNP NNP O
content NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
hydroxyproline NN NN B-CHEM
content NN NN O
. . . O

Heart NNP NNP O
weight NN NN O
increased VBD VBD O
44 CD CD O
% NN NN O
after IN IN O
8 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
a DT DT O
half JJ JJ O
time NN NN O
of IN IN O
3 CD CD O
. . . O
4 CD CD O
days NNS NNS O
. . . O

Ventricular NNP NNP O
RNA NNP NNP O
content NN NN O
was VBD VBD O
elevated VBD VBD O
26 CD CD O
% NN NN O
after IN IN O
24 CD CD O
h NN NN O
of IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
and CC CC O
reached VBD VBD O
a DT DT O
maximal NN NN O
level NN NN O
following VBG VBG O
8 CD CD O
days NNS NNS O
of IN IN O
therapy NN NN O
. . . O

The DT DT O
half JJ JJ O
time NN NN O
for IN IN O
RNA NNP NNP O
accumulation NN NN O
was VBD VBD O
2 CD CD O
. . . O
0 CD CD O
days NNS NNS O
. . . O

The DT DT O
total JJ JJ O
content NN NN O
of IN IN O
hydroxyproline NN NN B-CHEM
remained VBD VBD O
stable JJ JJ O
during IN IN O
the DT DT O
first JJ JJ O
2 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
but CC CC O
increased VBD VBD O
46 CD CD O
% NN NN O
after IN IN O
4 CD CD O
days NNS NNS O
of IN IN O
therapy NN NN O
. . . O

Ventricular NNP NNP O
DNA NNP NNP O
content NN NN O
was VBD VBD O
unchanged JJ JJ O
during IN IN O
the DT DT O
early JJ JJ O
stage NN NN O
( ( ( O
1 CD CD O
- : : O
4 CD CD O
days NNS NNS O
) ) ) O
of IN IN O
hypertrophic JJ JJ O
growth NN NN O
but CC CC O
increased VBN VBN O
to TO TO O
a DT DT O
new JJ JJ O
steady JJ JJ O
- - - O
state NN NN O
level NN NN O
19 CD CD O
% NN NN O
above IN IN O
the DT DT O
controls NNS NNS O
after IN IN O
8 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
. . . O

Intraventricular NNP NNP O
pressures NNS NNS O
and CC CC O
coronary JJ JJ O
flow NN NN O
measures NNS NNS O
were VBD VBD O
similar JJ JJ O
for IN IN O
control NN NN O
and CC CC O
experimental JJ JJ O
animals NNS NNS O
following VBG VBG O
4 CD CD O
days NNS NNS O
of IN IN O
developed VBN VBN O
hypertrophy NN NN O
. . . O

However RB RB O
, , , O
dP NN NN O
/ NN NN O
dt NN NN O
in IN IN O
the DT DT O
ISO NNP NNP B-CHEM
- - - O
treated JJ JJ O
hearts NNS NNS O
was VBD VBD O
slightly RB RB O
but CC CC O
significantly RB RB O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
elevated VBD VBD O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
adaptive JJ JJ O
response NN NN O
to TO TO O
ISO NNP NNP B-CHEM
shows VBZ VBZ O
an DT DT O
early JJ JJ O
hypertrophic JJ JJ O
phase NN NN O
( ( ( O
1 CD CD O
- : : O
4 CD CD O
days NNS NNS O
) ) ) O
characterized VBN VBN O
by IN IN O
a DT DT O
substantial JJ JJ O
increase NN NN O
in IN IN O
RNA NNP NNP O
content NN NN O
and CC CC O
cardiac JJ JJ O
mass NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
changes NNS NNS O
in IN IN O
DNA NNP NNP O
. . . O

However RB RB O
, , , O
prolonged JJ JJ O
stimulation NN NN O
( ( ( O
8 CD CD O
- : : O
12 CD CD O
days NNS NNS O
) ) ) O
appears VBZ VBZ O
to TO TO O
represent VB VB O
a DT DT O
complex JJ JJ O
integration NN NN O
of IN IN O
both DT DT O
cellular NN NN O
hypertrophy NN NN O
and CC CC O
hyperplasia NN NN O
within IN IN O
the DT DT O
heart NN NN O
. . . O

Multiple JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
penicillamine NN NN B-CHEM
therapy NN NN O
in IN IN O
one CD CD O
patient NN NN O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
. . . O

Skin NNP NNP O
rashes NNS NNS O
, , , O
proteinuria NN NN O
, , , O
systemic JJ JJ O
lupus NN NN O
erythematosus NN NN O
, , , O
polymyositis NNS NNS O
and CC CC O
myasthenia NN NN O
gravis NN NN O
have VBP VBP O
all DT DT O
been VBN VBN O
recorded VBN VBN O
as IN IN O
complications NNS NNS O
of IN IN O
penicillamine NN NN B-CHEM
therapy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
. . . O

A DT DT O
patient NN NN O
who WP WP O
had VBD VBD O
developed VBN VBN O
all DT DT O
5 CD CD O
is VBZ VBZ O
now RB RB O
described VBN VBN O
. . . O

The DT DT O
skin NN NN O
lesion NN NN O
resembled JJ JJ O
elastosis NN NN O
perforans NNS NNS O
serpiginosa NN NN O
, , , O
which WDT WDT O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
as IN IN O
a DT DT O
rare JJ JJ O
side NN NN O
effect NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
but CC CC O
not RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
treated VBN VBN O
with IN IN O
penicillamine NN NN B-CHEM
. . . O

Obsolete NNP NNP O
but CC CC O
dangerous JJ JJ O
antacid NN NN O
preparations NNS NNS O
. . . O

One CD CD O
case NN NN O
of IN IN O
acute JJ JJ O
hypercalcaemia NN NN O
and CC CC O
two CD CD O
of IN IN O
recurrent JJ JJ O
nephrolithiasis NNS NNS O
are VBP VBP O
reported VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
had VBD VBD O
regularly RB RB O
consumed VBN VBN O
large JJ JJ O
amounts NNS NNS O
of IN IN O
calcium NN NN B-CHEM
carbon NN NN I-CHEM
- : : I-CHEM
ate NN NN I-CHEM
- : : O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
powders NNS NNS O
for IN IN O
more JJR JJR O
than IN IN O
20 CD CD O
years NNS NNS O
. . . O

The DT DT O
powders NNS NNS O
had VBD VBD O
been VBN VBN O
obtained VBN VBN O
from IN IN O
pharmacists NNS NNS O
unknown JJ JJ O
to TO TO O
the DT DT O
patients NNS NNS O
' POS POS O
medical JJ JJ O
practitioners NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
these DT DT O
preparations NNS NNS O
were VBD VBD O
responsible JJ JJ O
for IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
problems NNS NNS O
, , , O
and CC CC O
that IN IN O
such JJ JJ O
powders NNS NNS O
should MD MD O
no RB RB O
longer RB RB O
be VB VB O
freely RB RB O
obtainable JJ JJ O
. . . O

Doxorubicin NNP NNP B-CHEM
cardiomyopathy NN NN O
in IN IN O
children NNS NNS O
with IN IN O
left VBD VBD O
- - - O
sided JJ JJ O
Wilms NNP NNP O
tumor NN NN O
. . . O

Two CD CD O
children NNS NNS O
with IN IN O
Wilms NNP NNP O
tumor NN NN O
of IN IN O
the DT DT O
left NN NN O
kidney NN NN O
experienced VBN VBN O
severe JJ JJ O
anthracycline NN NN B-CHEM
cardiomyopathy NN NN O
after IN IN O
irradiation NN NN O
to TO TO O
the DT DT O
tumor NN NN O
bed NN NN O
and CC CC O
conventional JJ JJ O
dosage NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
. . . O

The DT DT O
cardiomyopathy NN NN O
is VBZ VBZ O
attributed VBN VBN O
1 CD CD O
) ) ) O
to TO TO O
the DT DT O
fact NN NN O
that IN IN O
radiation NN NN O
fields NNS NNS O
for IN IN O
left VBD VBD O
Wilms NNP NNP O
tumor NN NN O
include VBP VBP O
the DT DT O
lower JJR JJR O
portion NN NN O
of IN IN O
the DT DT O
heart NN NN O
and CC CC O
2 CD CD O
) ) ) O
to TO TO O
the DT DT O
interaction NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
and CC CC O
irradiation NN NN O
on IN IN O
cardiac JJ JJ O
muscle NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
recommended VBN VBN O
that IN IN O
doxorubicin NN NN B-CHEM
dosage NN NN O
be VB VB O
sharply RB RB O
restricted VBN VBN O
in IN IN O
children NNS NNS O
with IN IN O
Wilms NNP NNP O
tumor NN NN O
of IN IN O
the DT DT O
left VBN VBN O
kidney NN NN O
who WP WP O
receive VBP VBP O
postoperative JJ JJ O
irradiation NN NN O
. . . O

Effects NNP NNP O
of IN IN O
calcitonin NN NN O
on IN IN O
rat NN NN O
extrapyramidal JJ JJ O
motor NN NN O
system NN NN O
: : : O
behavioral JJ JJ O
and CC CC O
biochemical JJ JJ O
data NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
c SYM SYM O
. . . O
injection NN NN O
of IN IN O
human JJ JJ O
and CC CC O
salmon JJ JJ O
calcitonin NN NN O
on IN IN O
biochemical JJ JJ O
and CC CC O
behavioral JJ JJ O
parameters NNS NNS O
related VBN VBN O
to TO TO O
the DT DT O
extrapyramidal NN NN O
motor NN NN O
system NN NN O
, , , O
were VBD VBD O
investigated VBN VBN O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

Calcitonin NNP NNP O
injection NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
potentiation NN NN O
of IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
and CC CC O
a DT DT O
partial JJ JJ O
prevention NN NN O
of IN IN O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
. . . O

Moreover RB RB O
calcitonin NN NN O
induced VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
nigral JJ JJ O
GAD NNP NNP O
activity NN NN O
but CC CC O
no DT DT O
change NN NN O
in IN IN O
striatal JJ JJ O
DA NNP NNP B-CHEM
and CC CC O
DOPAC NNP NNP B-CHEM
concentration NN NN O
or CC CC O
GAD NNP NNP O
activity NN NN O
. . . O

The DT DT O
results NNS NNS O
are VBP VBP O
discussed VBN VBN O
in IN IN O
view NN NN O
of IN IN O
a DT DT O
primary JJ JJ O
action NN NN O
of IN IN O
calcitonin NN NN O
on IN IN O
the DT DT O
striatonigral JJ JJ O
GABAergic NNP NNP O
pathway NN NN O
mediating VBG VBG O
the DT DT O
DA NNP NNP B-CHEM
- - - O
related VBN VBN O
behavioral JJ JJ O
messages NNS NNS O
of IN IN O
striatal JJ JJ O
origin NN NN O
. . . O

Naloxazone NNP NNP B-CHEM
pretreatment NN NN O
modifies NNS NNS O
cardiorespiratory NN NN O
, , , O
temperature NN NN O
, , , O
and CC CC O
behavioral JJ JJ O
effects NNS NNS O
of IN IN O
morphine NN NN B-CHEM
. . . O

Behavioral NNP NNP O
and CC CC O
cardiorespiratory NN NN O
responses NNS NNS O
to TO TO O
a DT DT O
lethal JJ JJ O
dose NN NN O
of IN IN O
morphine NN NN B-CHEM
were VBD VBD O
evaluated VBN VBN O
in IN IN O
rats NNS NNS O
pretreated VBN VBN O
with IN IN O
saline NN NN O
or CC CC O
naloxazone NN NN B-CHEM
, , , O
an DT DT O
antagonist NN NN O
of IN IN O
high JJ JJ O
- - - O
affinity NN NN O
mu NN NN O
1 CD CD O
opioid NN NN O
receptors NNS NNS O
. . . O

Pretreatment NNP NNP O
with IN IN O
naloxazone NN NN B-CHEM
significantly RB RB O
blocked VBD VBD O
morphine JJ JJ B-CHEM
analgesia NN NN O
, , , O
catalepsy NN NN O
and CC CC O
hypothermia NN NN O
at IN IN O
a DT DT O
dose NN NN O
which WDT WDT O
completely RB RB O
eliminated VBN VBN O
high JJ JJ O
- - - O
affinity NN NN O
binding JJ JJ O
in IN IN O
brain NN NN O
membranes NNS NNS O
. . . O

Moreover RB RB O
, , , O
naloxazone NN NN B-CHEM
significantly RB RB O
attenuated VBD VBD O
the DT DT O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
and CC CC O
respiratory JJ JJ O
depression NN NN O
, , , O
whereas IN IN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
bradycardia NN NN O
was VBD VBD O
less RBR RBR O
affected JJ JJ O
. . . O

Results NNS NNS O
indicate VBP VBP O
that IN IN O
subpopulations NNS NNS O
of IN IN O
mu NN NN O
receptors NNS NNS O
may MD MD O
mediate VB VB O
selective JJ JJ O
behavioral NN NN O
and CC CC O
cardiorespiratory NN NN O
responses NNS NNS O
to TO TO O
morphine VB VB B-CHEM
. . . O

Modification NNP NNP O
of IN IN O
drug NN NN O
action NN NN O
by IN IN O
hyperammonemia NN NN O
. . . O

Pretreatment NNP NNP O
with IN IN O
ammonium NN NN B-CHEM
acetate NN NN I-CHEM
( ( ( O
NH4Ac NNP NNP B-CHEM
) ) ) O
( ( ( O
6 CD CD O
mmol NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
approximately RB RB O
doubled VBD VBD O
the DT DT O
time NN NN O
morphine NN NN B-CHEM
- : : O
treated VBN VBN O
mice NN NN O
remained VBD VBD O
on IN IN O
a DT DT O
hot JJ JJ O
surface NN NN O
and CC CC O
similarly RB RB O
increased VBN VBN O
muscular JJ JJ O
incoordination NN NN O
by IN IN O
diazepam NN NN B-CHEM
, , , O
but CC CC O
NH4Ac NNP NNP B-CHEM
treatment NN NN O
alone RB RB O
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

Thus RB RB O
, , , O
hyperammonemia NN NN O
is VBZ VBZ O
capable JJ JJ O
of IN IN O
altering VBG VBG O
drug NN NN O
action NN NN O
and CC CC O
must MD MD O
be VB VB O
considered VBN VBN O
along IN IN O
with IN IN O
impaired JJ JJ O
drug NN NN O
metabolism NN NN O
in IN IN O
enhanced JJ JJ O
drug NN NN O
responses NNS NNS O
associated VBN VBN O
with IN IN O
liver NN NN O
disease NN NN O
. . . O

Experiments NNS NNS O
in IN IN O
vitro NN NN O
showed VBD VBD O
that IN IN O
acetylcholine NN NN B-CHEM
- : : O
induced JJ JJ O
catecholamine NN NN B-CHEM
release NN NN O
from IN IN O
bovine JJ JJ O
adrenal NN NN O
medulla NN NN O
is VBZ VBZ O
depressed VBN VBN O
as RB RB O
much JJ JJ O
as IN IN O
50 CD CD O
% NN NN O
by IN IN O
0 CD CD O
. . . O
3 CD CD O
mM NN NN O
NH4Ac NNP NNP B-CHEM
and CC CC O
KCl NNP NNP B-CHEM
- : : O
induced JJ JJ O
contractions NNS NNS O
of IN IN O
guinea NN NN O
- - - O
pig NN NN O
ileum NN NN O
were VBD VBD O
inhibited VBN VBN O
20 CD CD O
% NN NN O
by IN IN O
5 CD CD O
mM NN NN O
NH4Ac NNP NNP B-CHEM
. . . O

Addition NN NN O
of IN IN O
excess JJ JJ O
calcium NN NN B-CHEM
reversed VBD VBD O
the DT DT O
depression NN NN O
in IN IN O
both DT DT O
tissues NNS NNS O
, , , O
but CC CC O
calcium NN NN B-CHEM
- - - O
independent JJ JJ O
catecholamine NN NN B-CHEM
release NN NN O
by IN IN O
acetaldehyde NN NN B-CHEM
was VBD VBD O
not RB RB O
blocked VBN VBN O
by IN IN O
NH4Ac NNP NNP B-CHEM
. . . O

These DT DT O
results NNS NNS O
suggested VBD VBD O
that IN IN O
ammonia NN NN B-CHEM
blocks NNS NNS O
calcium NN NN B-CHEM
channels NNS NNS O
. . . O

Parallels NNP NNP O
in IN IN O
the DT DT O
actions NNS NNS O
of IN IN O
NH4Ac NNP NNP B-CHEM
and CC CC O
the DT DT O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
verapamil NN NN B-CHEM
support NN NN O
this DT DT O
concept NN NN O
. . . O

Both DT DT O
verapamil NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
and CC CC O
NH4Ac NNP NNP B-CHEM
pretreatment NN NN O
enhanced VBD VBD O
morphine NN NN B-CHEM
analgesia NN NN O
- : : O
and CC CC O
diazepam NN NN B-CHEM
- - - O
induced JJ JJ O
muscular NN NN O
incoordination NN NN O
and CC CC O
antagonized JJ JJ O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
motor NN NN O
activity NN NN O
, , , O
and CC CC O
neither DT DT O
verapamil NN NN B-CHEM
nor CC CC O
NH4Ac NNP NNP B-CHEM
affected VBD VBD O
the DT DT O
convulsant JJ JJ O
action NN NN O
of IN IN O
metrazol NN NN B-CHEM
. . . O

The DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
hyperammonemia NN NN O
exerts VBZ VBZ O
a DT DT O
calcium NN NN B-CHEM
channel NN NN O
blocking VBG VBG O
action NN NN O
which WDT WDT O
enhances VBZ VBZ O
the DT DT O
effects NNS NNS O
of IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
depressants NNS NNS O
and CC CC O
certain JJ JJ O
opioid NN NN O
analgesics NNS NNS O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesia NN NN O
and CC CC O
thalamotomy NN NN O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesia NN NN O
of IN IN O
the DT DT O
limbs NNS NNS O
in IN IN O
thirteen NN NN O
cases NNS NNS O
of IN IN O
Parkinsonism NNP NNP O
, , , O
which WDT WDT O
was VBD VBD O
choreic NN NN O
, , , O
ballistic JJ JJ O
or CC CC O
dystonic JJ JJ O
in IN IN O
type NN NN O
, , , O
was VBD VBD O
alleviated VBN VBN O
almost RB RB O
completely RB RB O
by IN IN O
stereotaxic JJ JJ O
surgery NN NN O
using VBG VBG O
a DT DT O
microelectrode NN NN O
technique NN NN O
for IN IN O
the DT DT O
ventralis NNS NNS O
oralis JJ JJ O
anterior NN NN O
and CC CC O
posterior NN NN O
nuclei NN NN O
of IN IN O
the DT DT O
thalamus NN NN O
, , , O
but CC CC O
much RB RB O
less JJR JJR O
by IN IN O
the DT DT O
ventralis NNS NNS O
intermedius NN NN O
nucleus NN NN O
. . . O

Control NNP NNP O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
by IN IN O
thalamic JJ JJ O
lesions NNS NNS O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
routine JJ JJ O
treatment NN NN O
of IN IN O
Parkinsonism NNP NNP O
is VBZ VBZ O
discussed VBN VBN O
. . . O

Treatment NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
- - - O
induced JJ JJ O
urothelial JJ JJ O
toxicity NN NN O
by IN IN O
oral JJ JJ O
administration NN NN O
of IN IN O
sodium NN NN B-CHEM
2 CD CD I-CHEM
- : : I-CHEM
mercaptoethane NN NN I-CHEM
sulphonate NN NN I-CHEM
( ( ( O
MESNA NNP NNP B-CHEM
) ) ) O
to TO TO O
patients NNS NNS O
with IN IN O
inoperable JJ JJ O
lung NN NN O
cancer NN NN O
. . . O

The DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
oral JJ JJ O
administration NN NN O
of IN IN O
the DT DT O
thiol NN NN B-CHEM
compound NN NN O
sodium NN NN B-CHEM
2 CD CD I-CHEM
- : : I-CHEM
mercaptoethane NN NN I-CHEM
sulphonate NN NN I-CHEM
( ( ( O
MESNA NNP NNP B-CHEM
) ) ) O
against IN IN O
urothelial JJ JJ O
toxicity NN NN O
induced VBN VBN O
by IN IN O
ifosfamide NN NN B-CHEM
( ( ( O
IF IN IN B-CHEM
) ) ) O
was VBD VBD O
tested VBN VBN O
in IN IN O
a DT DT O
group NN NN O
of IN IN O
45 CD CD O
patients NNS NNS O
with IN IN O
inoperable JJ JJ O
lung NN NN O
cancer NN NN O
under IN IN O
treatment NN NN O
with IN IN O
IF IN IN B-CHEM
( ( ( O
2250 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
on IN IN O
days NNS NNS O
2 CD CD O
- : : O
5 CD CD O
) ) ) O
as IN IN O
part NN NN O
of IN IN O
a DT DT O
polychemotherapy NN NN O
regimen NNS NNS O
repeated VBN VBN O
in IN IN O
a DT DT O
4 CD CD O
- : : O
week NN NN O
cycle NN NN O
. . . O

MESNA NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
orally RB RB O
on IN IN O
the DT DT O
days NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
IF IN IN B-CHEM
in IN IN O
3 CD CD O
doses NNS NNS O
of IN IN O
840 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
each DT DT O
administered JJ JJ O
at IN IN O
0 CD CD O
hr NN NN O
( ( ( O
= SYM SYM O
injection NN NN O
of IN IN O
IF IN IN B-CHEM
) ) ) O
, , , O
4 CD CD O
hr NN NN O
and CC CC O
8 CD CD O
hr NN NN O
p NN NN O
. . . O
i NNP NNP O
. . . O

Out IN IN O
of IN IN O
a DT DT O
total NN NN O
of IN IN O
88 CD CD O
courses NNS NNS O
of IN IN O
this DT DT O
treatment NN NN O
we PRP PRP O
observed VBD VBD O
10 CD CD O
episodes NNS NNS O
of IN IN O
asymptomatic JJ JJ O
microscopic NN NN O
haematuria NN NN O
and CC CC O
no DT DT O
episodes NNS NNS O
of IN IN O
gross JJ JJ O
haematuria NN NN O
. . . O

In IN IN O
this DT DT O
group NN NN O
of IN IN O
45 CD CD O
patients NNS NNS O
under IN IN O
protection NN NN O
with IN IN O
MESNA NNP NNP B-CHEM
there EX EX O
were VBD VBD O
5 CD CD O
complete JJ JJ O
remissions NNS NNS O
and CC CC O
9 CD CD O
partial JJ JJ O
remissions NNS NNS O
( ( ( O
total JJ JJ O
31 CD CD O
% NN NN O
) ) ) O
. . . O

A DT DT O
further JJ JJ O
group NN NN O
of IN IN O
25 CD CD O
patients NNS NNS O
under IN IN O
polychemotherapy NN NN O
with IN IN O
IF IN IN B-CHEM
were VBD VBD O
treated VBN VBN O
by IN IN O
conventional JJ JJ O
prophylactic JJ JJ O
measures NNS NNS O
( ( ( O
raised VBN VBN O
fluid JJ JJ O
intake NN NN O
and CC CC O
forced VBD VBD O
diuresis NN NN O
) ) ) O
. . . O

In IN IN O
this DT DT O
group NN NN O
there EX EX O
were VBD VBD O
1 CD CD O
complete JJ JJ O
and CC CC O
5 CD CD O
partial JJ JJ O
remissions NNS NNS O
( ( ( O
total JJ JJ O
24 CD CD O
% NN NN O
) ) ) O
, , , O
but CC CC O
nearly RB RB O
all DT DT O
patients NNS NNS O
developed VBN VBN O
either CC CC O
gross JJ JJ O
haematuria NN NN O
and CC CC O
/ NN NN O
or CC CC O
symptoms NNS NNS O
of IN IN O
bladder NN NN O
irritation NN NN O
( ( ( O
cystitis NN NN O
and CC CC O
pollakisuria NN NN O
) ) ) O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
appreciable JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
MESNA NNP NNP B-CHEM
series NN NN O
and CC CC O
the DT DT O
conventional JJ JJ O
prophylaxis NN NN O
series NN NN O
with IN IN O
respect NN NN O
to TO TO O
either CC CC O
haematological JJ JJ O
or CC CC O
systemic JJ JJ O
toxicity NN NN O
of IN IN O
the DT DT O
cytostatic JJ JJ O
treatment NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
support VBP VBP O
the DT DT O
view NN NN O
that IN IN O
MESNA NNP NNP B-CHEM
, , , O
given VBN VBN O
orally RB RB O
in IN IN O
conjunction NN NN O
with IN IN O
combined VBN VBN O
cytostatic JJ JJ O
regimens NNS NNS O
which WDT WDT O
include VBP VBP O
IF IN IN B-CHEM
, , , O
simplifies VBZ VBZ O
the DT DT O
treatment NN NN O
and CC CC O
provides VBZ VBZ O
optimum JJ JJ O
protection NN NN O
for IN IN O
the DT DT O
urinary JJ JJ O
epithelium NN NN O
. . . O

Protection NNP NNP O
with IN IN O
oral JJ JJ O
MESNA NNP NNP B-CHEM
is VBZ VBZ O
particularly RB RB O
suitable JJ JJ O
for IN IN O
outpatients NNS NNS O
. . . O

Myoclonic NNP NNP O
, , , O
atonic JJ JJ O
, , , O
and CC CC O
absence NN NN O
seizures NNS NNS O
following VBG VBG O
institution NN NN O
of IN IN O
carbamazepine NN NN B-CHEM
therapy NN NN O
in IN IN O
children NNS NNS O
. . . O

Five CD CD O
children NNS NNS O
, , , O
aged VBD VBD O
3 CD CD O
to TO TO O
11 CD CD O
years NNS NNS O
, , , O
treated VBN VBN O
with IN IN O
carbamazepine NN NN B-CHEM
for IN IN O
epilepsy NN NN O
, , , O
had VBD VBD O
an DT DT O
acute JJ JJ O
aberrant JJ JJ O
reaction NN NN O
characterized VBN VBN O
by IN IN O
the DT DT O
onset NN NN O
of IN IN O
myoclonic JJ JJ O
, , , O
atypical JJ JJ O
absence NN NN O
and CC CC O
/ NN NN O
or CC CC O
atonic JJ JJ O
( ( ( O
minor JJ JJ O
motor NN NN O
) ) ) O
seizures NNS NNS O
within IN IN O
a DT DT O
few JJ JJ O
days NNS NNS O
. . . O

When WRB WRB O
the DT DT O
carbamazepine NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
, , , O
two CD CD O
of IN IN O
the DT DT O
children NNS NNS O
returned VBD VBD O
to TO TO O
their PRP$ PRP$ O
former JJ JJ O
state NN NN O
very RB RB O
quickly RB RB O
, , , O
two CD CD O
had VBD VBD O
the DT DT O
minor JJ JJ O
motor NN NN O
seizures NNS NNS O
resolve NN NN O
in IN IN O
3 CD CD O
and CC CC O
6 CD CD O
months NNS NNS O
, , , O
and CC CC O
one CD CD O
had VBD VBD O
the DT DT O
seizures NNS NNS O
persist NN NN O
. . . O

The DT DT O
child NN NN O
in IN IN O
whom WP WP O
the DT DT O
seizures NNS NNS O
persisted VBD VBD O
was VBD VBD O
later RB RB O
found VBN VBN O
to TO TO O
have VB VB O
ceroid NN NN O
lipofuscinosis NN NN O
. . . O

The DT DT O
other JJ JJ O
children NNS NNS O
are VBP VBP O
doing VBG VBG O
well RB RB O
on IN IN O
other JJ JJ O
anticonvulsants NNS NNS O
. . . O

Effect NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
synthetase NN NN O
inhibitors NNS NNS O
on IN IN O
experimentally RB RB O
induced VBN VBN O
convulsions NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

To TO TO O
investigate VB VB O
the DT DT O
relationship NN NN O
of IN IN O
prostaglandins NNS NNS B-CHEM
( ( ( O
PGs NNP NNP B-CHEM
) ) ) O
to TO TO O
seizure VB VB O
induction NN NN O
, , , O
the DT DT O
effects NNS NNS O
of IN IN O
six CD CD O
PG NNP NNP O
synthetase NN NN O
inhibitors NNS NNS O
on IN IN O
convulsions NNS NNS O
induced VBN VBN O
by IN IN O
flurothyl NN NN B-CHEM
, , , O
picrotoxin NN NN B-CHEM
, , , O
pentetrazol NN NN B-CHEM
( ( ( O
PTZ NNP NNP B-CHEM
) ) ) O
, , , O
electroshock NN NN O
or CC CC O
bicuculline NN NN B-CHEM
were VBD VBD O
evaluated VBN VBN O
. . . O

Ibuprofen NNP NNP B-CHEM
, , , O
sulindac NN NN B-CHEM
, , , O
mefenamic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
and CC CC O
low JJ JJ O
dose NN NN O
meclofenamic JJ JJ B-CHEM
acid NN NN I-CHEM
increased VBD VBD O
the DT DT O
latency NN NN O
- - - O
to TO TO O
- - - O
onset NN NN O
in IN IN O
the DT DT O
flurothyl NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
PTZ NNP NNP B-CHEM
models NNS NNS O
; : : O
the DT DT O
electroshock NN NN O
, , , O
picrotoxin NN NN B-CHEM
and CC CC O
bicuculline NN NN B-CHEM
models NNS NNS O
were VBD VBD O
not RB RB O
significantly RB RB O
affected VBN VBN O
by IN IN O
any DT DT O
of IN IN O
the DT DT O
pretreatment NN NN O
agents NNS NNS O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
PGs NNP NNP B-CHEM
are VBP VBP O
involved VBN VBN O
in IN IN O
the DT DT O
mechanism NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
underlying VBG VBG O
fluorthyl NN NN B-CHEM
- : : O
and CC CC O
PTZ NNP NNP B-CHEM
- : : O
induced JJ JJ O
convulsions NNS NNS O
, , , O
but CC CC O
not RB RB O
picrotoxin VB VB B-CHEM
- - - O
, , , O
electroshock NN NN O
- - - O
, , , O
or CC CC O
bicuculline NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
. . . O

Acute JJ JJ O
changes NNS NNS O
of IN IN O
blood NN NN O
ammonia NN NN B-CHEM
may MD MD O
predict VB VB O
short JJ JJ O
- - - O
term NN NN O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Valproic NNP NNP B-CHEM
acid NN NN I-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
was VBD VBD O
given VBN VBN O
to TO TO O
24 CD CD O
epileptic JJ JJ O
patients NNS NNS O
who WP WP O
were VBD VBD O
already RB RB O
being VBG VBG O
treated VBN VBN O
with IN IN O
other JJ JJ O
antiepileptic JJ JJ O
drugs NNS NNS O
. . . O

A DT DT O
standardized JJ JJ O
loading NN NN O
dose NN NN O
of IN IN O
VPA NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
, , , O
and CC CC O
venous JJ JJ O
blood NN NN O
was VBD VBD O
sampled VBN VBN O
at IN IN O
0 CD CD O
, , , O
1 CD CD O
, , , O
2 CD CD O
, , , O
3 CD CD O
, , , O
and CC CC O
4 CD CD O
hours NNS NNS O
. . . O

Ammonia NNP NNP B-CHEM
( ( ( O
NH3 NNP NNP B-CHEM
) ) ) O
was VBD VBD O
higher JJR JJR O
in IN IN O
patients NNS NNS O
who WP WP O
, , , O
during IN IN O
continuous JJ JJ O
therapy NN NN O
, , , O
complained VBD VBD O
of IN IN O
drowsiness NN NN O
( ( ( O
7 CD CD O
patients NNS NNS O
) ) ) O
than IN IN O
in IN IN O
those DT DT O
who WP WP O
were VBD VBD O
symptom JJ JJ O
- - - O
free JJ JJ O
( ( ( O
17 CD CD O
patients NNS NNS O
) ) ) O
, , , O
although IN IN O
VPA NNP NNP B-CHEM
plasma NN NN O
levels NNS NNS O
were VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

By IN IN O
measuring VBG VBG O
VPA NNP NNP B-CHEM
- : : O
induced JJ JJ O
changes NNS NNS O
of IN IN O
blood NN NN O
NH3 NNP NNP B-CHEM
content NN NN O
, , , O
it PRP PRP O
may MD MD O
be VB VB O
possible JJ JJ O
to TO TO O
identify VB VB O
patients NNS NNS O
at IN IN O
higher JJR JJR O
risk NN NN O
of IN IN O
obtundation NN NN O
when WRB WRB O
VPA NNP NNP B-CHEM
is VBZ VBZ O
given VBN VBN O
chronically RB RB O
. . . O

Effect NN NN O
of IN IN O
captopril NN NN B-CHEM
on IN IN O
pre NN NN O
- : : O
existing VBG VBG O
and CC CC O
aminonucleoside IN IN B-CHEM
- : : O
induced VBN VBN O
proteinuria NN NN O
in IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

Proteinuria NNP NNP O
is VBZ VBZ O
a DT DT O
side NN NN O
effect NN NN O
of IN IN O
captopril NN NN B-CHEM
treatment NN NN O
in IN IN O
hypertensive JJ JJ O
patients NNS NNS O
. . . O

The DT DT O
possibility NN NN O
of IN IN O
reproducing VBG VBG O
the DT DT O
same JJ JJ O
renal JJ JJ O
abnormality NN NN O
with IN IN O
captopril NN NN B-CHEM
was VBD VBD O
examined VBN VBN O
in IN IN O
SHR NNP NNP O
. . . O

Oral NNP NNP O
administration NN NN O
of IN IN O
captopril NN NN B-CHEM
at IN IN O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
14 CD CD O
days NNS NNS O
failed VBD VBD O
to TO TO O
aggravate VB VB O
proteinuria NN NN O
pre NN NN O
- : : O
existing VBG VBG O
in IN IN O
SHR NNP NNP O
. . . O

Also RB RB O
, , , O
captopril NN NN B-CHEM
treatment NN NN O
failed VBD VBD O
to TO TO O
potentiate VB VB O
or CC CC O
facilitate VB VB O
development NN NN O
of IN IN O
massive JJ JJ O
proteinuria NN NN O
invoked VBN VBN O
by IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
in IN IN O
SHR NNP NNP O
. . . O

Captopril NNP NNP B-CHEM
had VBD VBD O
little JJ JJ O
or CC CC O
no DT DT O
demonstrable JJ JJ O
effects NNS NNS O
on IN IN O
serum NN NN O
electrolyte NN NN O
concentrations NNS NNS O
, , , O
excretion NN NN O
of IN IN O
urine NN NN O
, , , O
sodium NN NN B-CHEM
and CC CC O
potassium NN NN B-CHEM
, , , O
endogenous JJ JJ O
creatinine NN NN B-CHEM
clearance NN NN O
, , , O
body NN NN O
weight NN NN O
, , , O
and CC CC O
food NN NN O
and CC CC O
water NN NN O
consumption NN NN O
. . . O

However RB RB O
, , , O
ketone NN NN B-CHEM
bodies NNS NNS O
were VBD VBD O
consistently RB RB O
present JJ JJ O
in IN IN O
urine NN NN O
and CC CC O
several JJ JJ O
lethalities NNS NNS O
occurred VBD VBD O
during IN IN O
multiple JJ JJ O
dosing NN NN O
of IN IN O
captopril NN NN B-CHEM
in IN IN O
SHR NNP NNP O
. . . O

Complete JJ JJ O
heart NN NN O
block NN NN O
following VBG VBG O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
trazodone NN NN B-CHEM
. . . O

Forty CD CD O
minutes NNS NNS O
after IN IN O
receiving VBG VBG O
a DT DT O
single JJ JJ O
starting VBG VBG O
dose NN NN O
of IN IN O
trazodone NN NN B-CHEM
, , , O
a DT DT O
patient NN NN O
developed VBN VBN O
complete JJ JJ O
heart NN NN O
block NN NN O
. . . O

The DT DT O
case NN NN O
illustrates VBZ VBZ O
that IN IN O
, , , O
despite IN IN O
the DT DT O
results NNS NNS O
of IN IN O
earlier RBR RBR O
studies NNS NNS O
, , , O
trazodone NN NN B-CHEM
' '' '' O
s VBZ VBZ O
effect NN NN O
on IN IN O
cardiac JJ JJ O
conduction NN NN O
may MD MD O
be VB VB O
severe JJ JJ O
in IN IN O
individuals NNS NNS O
at IN IN O
risk NN NN O
for IN IN O
conduction NN NN O
delay NN NN O
. . . O

Phenobarbital NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesia NN NN O
in IN IN O
a DT DT O
neurologically RB RB O
- - - O
impaired JJ JJ O
child NN NN O
. . . O

A DT DT O
2 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
child NN NN O
with IN IN O
known VBN VBN O
neurologic JJ JJ O
impairment NN NN O
developed VBD VBD O
a DT DT O
dyskinesia NN NN O
soon RB RB O
after IN IN O
starting VBG VBG O
phenobarbital NN NN B-CHEM
therapy NN NN O
for IN IN O
seizures NNS NNS O
. . . O

Known VBN VBN O
causes NNS NNS O
of IN IN O
movement NN NN O
disorders NNS NNS O
were VBD VBD O
eliminated VBN VBN O
after IN IN O
evaluation NN NN O
. . . O

On IN IN O
repeat NN NN O
challenge NN NN O
with IN IN O
phenobarbital NN NN B-CHEM
, , , O
the DT DT O
dyskinesia NN NN O
recurred VBD VBD O
. . . O

Phenobarbital NNP NNP B-CHEM
should MD MD O
be VB VB O
added VBN VBN O
to TO TO O
the DT DT O
list NN NN O
of IN IN O
anticonvulsant JJ JJ O
drugs NNS NNS O
that WDT WDT O
can MD MD O
cause VB VB O
movement NN NN O
disorders NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
amine NN NN B-CHEM
pretreatment NN NN O
on IN IN O
ketamine NN NN B-CHEM
catatonia NN NN O
in IN IN O
pinealectomized JJ JJ O
or CC CC O
hypophysectomized JJ JJ O
animals NNS NNS O
. . . O

The DT DT O
present JJ JJ O
studies NNS NNS O
were VBD VBD O
designed VBN VBN O
to TO TO O
clarify VB VB O
the DT DT O
role NN NN O
of IN IN O
catecholamines NNS NNS B-CHEM
and CC CC O
pineal NN NN O
idolamines NNS NNS O
on IN IN O
ketamine NN NN B-CHEM
- : : O
induced VBN VBN O
catatonia NN NN O
in IN IN O
the DT DT O
intact JJ JJ O
, , , O
pinealectomized JJ JJ O
or CC CC O
hypophysectomized VBN VBN O
chick NN NN O
and CC CC O
rat NN NN O
. . . O

In IN IN O
the DT DT O
pinealectomized JJ JJ O
chick NN NN O
, , , O
pretreatment NN NN O
with IN IN O
dopamine NN NN B-CHEM
increased VBD VBD O
the DT DT O
duration NN NN O
of IN IN O
catatonia NN NN O
( ( ( O
DOC NNP NNP O
) ) ) O
after IN IN O
ketamine NN NN B-CHEM
, , , O
but CC CC O
pretreatment NN NN O
with IN IN O
norepinephrine NN NN B-CHEM
did VBD VBD O
not RB RB O
. . . O

The DT DT O
pineal NN NN O
indolamines NNS NNS O
exhibited VBN VBN O
mixed JJ JJ O
actions NNS NNS O
. . . O

Serotonin NNP NNP B-CHEM
and CC CC O
N NNP NNP B-CHEM
- : : I-CHEM
acetyl NN NN I-CHEM
serotonin NN NN I-CHEM
which WDT WDT O
augmented VBD VBD O
ketamine NN NN B-CHEM
DOC NNP NNP O
, , , O
did VBD VBD O
not RB RB O
do VB VB O
so RB RB O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
the DT DT O
pineal NN NN O
gland NN NN O
, , , O
whereas IN IN O
melatonin NN NN B-CHEM
potentiated VBD VBD O
the DT DT O
ketamine NN NN B-CHEM
DOC NNP NNP O
in IN IN O
both DT DT O
the DT DT O
intact JJ JJ O
and CC CC O
pinealectomized JJ JJ O
chick NN NN O
. . . O

Ketamine NNP NNP B-CHEM
was VBD VBD O
more RBR RBR O
potent JJ JJ O
in IN IN O
the DT DT O
hypophysectomized JJ JJ O
chick NN NN O
and CC CC O
the DT DT O
circadian NN NN O
rhythm NN NN O
noted VBD VBD O
in IN IN O
the DT DT O
intact JJ JJ O
chick NN NN O
was VBD VBD O
absent JJ JJ O
; : : O
furthermore RB RB O
, , , O
melatonin NN NN B-CHEM
did VBD VBD O
not RB RB O
augment VB VB O
the DT DT O
ketamine NN NN B-CHEM
DOC NNP NNP O
whereas IN IN O
dopamine NN NN B-CHEM
continued VBD VBD O
to TO TO O
do VB VB O
so RB RB O
. . . O

This DT DT O
study NN NN O
did VBD VBD O
not RB RB O
demonstrate VB VB O
a DT DT O
species NNS NNS O
difference NN NN O
regarding VBG VBG O
the DT DT O
role NN NN O
of IN IN O
the DT DT O
amines NNS NNS B-CHEM
on IN IN O
the DT DT O
pineal NN NN O
in IN IN O
spite NN NN O
of IN IN O
the DT DT O
immature NN NN O
blood NN NN O
- : : O
brain NN NN O
barrier NN NN O
in IN IN O
the DT DT O
young JJ JJ O
chick NN NN O
and CC CC O
the DT DT O
intact JJ JJ O
barrier NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
these DT DT O
data NNS NNS O
indicate VBP VBP O
a DT DT O
direct JJ JJ O
role NN NN O
of IN IN O
the DT DT O
pituitary JJ JJ O
in IN IN O
the DT DT O
augmentation NN NN O
of IN IN O
ketamine NN NN B-CHEM
DOC NNP NNP O
induced VBN VBN O
by IN IN O
melatonin NN NN B-CHEM
. . . O

Furthermore RB RB O
, , , O
dopamine NN NN B-CHEM
appeared VBD VBD O
to TO TO O
act VB VB O
on IN IN O
systems NNS NNS O
more RBR RBR O
closely RB RB O
involved VBN VBN O
with IN IN O
the DT DT O
induction NN NN O
of IN IN O
ketamine NN NN B-CHEM
catatonia NN NN O
rather RB RB O
than IN IN O
directly RB RB O
on IN IN O
the DT DT O
pituitary JJ JJ O
. . . O

Heparin NNP NNP B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
, , , O
thrombosis NN NN O
, , , O
and CC CC O
hemorrhage NN NN O
. . . O

Sixty NNP NNP O
- : : O
two CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
are VBP VBP O
reported VBN VBN O
. . . O

Clinical NNP NNP O
manifestations NNS NNS O
of IN IN O
this DT DT O
disorder NN NN O
include VBP VBP O
hemorrhage NN NN O
or CC CC O
, , , O
more RBR RBR O
frequently RB RB O
, , , O
thromboembolic JJ JJ O
events NNS NNS O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
heparin NN NN B-CHEM
. . . O

Laboratory NNP NNP O
testing NN NN O
has VBZ VBZ O
revealed VBN VBN O
a DT DT O
falling VBG VBG O
platelet NN NN O
count NN NN O
, , , O
increased VBN VBN O
resistance NN NN O
to TO TO O
heparin NN NN B-CHEM
, , , O
and CC CC O
aggregation NN NN O
of IN IN O
platelets NNS NNS O
by IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
plasma NN NN O
when WRB WRB O
heparin NN NN B-CHEM
is VBZ VBZ O
added VBN VBN O
. . . O

Immunologic NNP NNP O
testing NN NN O
has VBZ VBZ O
demonstrated VBN VBN O
the DT DT O
presence NN NN O
of IN IN O
a DT DT O
heparin NN NN B-CHEM
- - - O
dependent JJ JJ O
platelet NN NN O
membrane NN NN O
antibody NN NN O
. . . O

The DT DT O
20 CD CD O
deaths NNS NNS O
, , , O
52 CD CD O
hemorrhagic JJ JJ O
and CC CC O
thromboembolic JJ JJ O
complications NNS NNS O
, , , O
and CC CC O
21 CD CD O
surgical JJ JJ O
procedures NNS NNS O
to TO TO O
manage VB VB O
the DT DT O
complications NNS NNS O
confirm VBP VBP O
the DT DT O
seriousness NN NN O
of IN IN O
the DT DT O
disorder NN NN O
. . . O

Specific JJ JJ O
risk NN NN O
factors NNS NNS O
have VBP VBP O
not RB RB O
been VBN VBN O
identified VBN VBN O
; : : O
therefore RB RB O
, , , O
all DT DT O
patients NNS NNS O
receiving VBG VBG O
heparin NN NN B-CHEM
should MD MD O
be VB VB O
monitored VBN VBN O
. . . O

If IN IN O
the DT DT O
platelet NN NN O
count NN NN O
falls VBZ VBZ O
to TO TO O
less JJR JJR O
than IN IN O
100 CD CD O
, , , O
000 CD CD O
/ NN NN O
mm3 NN NN O
, , , O
while IN IN O
the DT DT O
patient NN NN O
is VBZ VBZ O
receiving VBG VBG O
heparin NN NN B-CHEM
, , , O
platelet NN NN O
aggregation NN NN O
testing NN NN O
, , , O
using VBG VBG O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
plasma NN NN O
, , , O
is VBZ VBZ O
indicated VBN VBN O
. . . O

Management NNP NNP O
consists NNS NNS O
of IN IN O
cessation NN NN O
of IN IN O
heparin NN NN B-CHEM
, , , O
platelet NN NN O
anti NN NN O
- : : O
aggregating VBG VBG O
agents NNS NNS O
, , , O
and CC CC O
alternate JJ JJ O
forms NNS NNS O
of IN IN O
anticoagulation NN NN O
when WRB WRB O
indicated VBN VBN O
. . . O

Ventricular NNP NNP O
fibrillation NN NN O
from IN IN O
diatrizoate NN NN B-CHEM
with IN IN O
and CC CC O
without IN IN O
chelating VBG VBG O
agents NNS NNS O
. . . O

The DT DT O
toxicity NN NN O
of IN IN O
Renografin NNP NNP B-CHEM
76 CD CD I-CHEM
% NN NN I-CHEM
was VBD VBD O
compared VBN VBN O
with IN IN O
that DT DT O
of IN IN O
Hypaque NNP NNP B-CHEM
76 CD CD I-CHEM
% NN NN I-CHEM
by IN IN O
selective JJ JJ O
injection NN NN O
of IN IN O
each DT DT O
into IN IN O
the DT DT O
right NN NN O
coronary JJ JJ O
artery NN NN O
of IN IN O
dogs NNS NNS O
. . . O

Renografin NNP NNP B-CHEM
contains VBZ VBZ O
the DT DT O
chelating VBG VBG O
agents NNS NNS O
sodium NN NN B-CHEM
citrate NN NN I-CHEM
and CC CC O
disodium NN NN B-CHEM
edetate NN NN I-CHEM
, , , O
while IN IN O
Hypaque NNP NNP B-CHEM
contains VBZ VBZ O
calcium NN NN B-CHEM
disodium NN NN I-CHEM
edetate NN NN I-CHEM
and CC CC O
no DT DT O
sodium NN NN B-CHEM
citrate NN NN I-CHEM
. . . O

Ventricular NNP NNP O
fibrillation NN NN O
occurred VBD VBD O
significantly RB RB O
more RBR RBR O
often RB RB O
with IN IN O
Renografin NNP NNP B-CHEM
, , , O
suggesting VBG VBG O
that IN IN O
chelating VBG VBG O
agents NNS NNS O
contribute VBP VBP O
to TO TO O
toxicity NN NN O
in IN IN O
coronary JJ JJ O
angiography NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
efficacy NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
amiodarone NN NN B-CHEM
therapy NN NN O
for IN IN O
ventricular NN NN O
tachycardia NNS NNS O
or CC CC O
ventricular NN NN O
fibrillation NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
to TO TO O
154 CD CD O
patients NNS NNS O
who WP WP O
had VBD VBD O
sustained VBN VBN O
, , , O
symptomatic JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
( ( ( O
VT NNP NNP O
) ) ) O
( ( ( O
n NN NN O
= SYM SYM O
118 CD CD O
) ) ) O
or CC CC O
a DT DT O
cardiac JJ JJ O
arrest NN NN O
( ( ( O
n NN NN O
= SYM SYM O
36 CD CD O
) ) ) O
and CC CC O
who WP WP O
were VBD VBD O
refractory JJ JJ O
to TO TO O
conventional JJ JJ O
antiarrhythmic JJ JJ O
drugs NNS NNS O
. . . O

The DT DT O
loading NN NN O
dose NN NN O
was VBD VBD O
800 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
6 CD CD O
weeks NNS NNS O
and CC CC O
the DT DT O
maintenance NN NN O
dose NN NN O
was VBD VBD O
600 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
. . . O

Sixty NNP NNP O
- - - O
nine CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
continued VBD VBD O
treatment NN NN O
with IN IN O
amiodarone NN NN B-CHEM
and CC CC O
had VBD VBD O
no DT DT O
recurrence NN NN O
of IN IN O
symptomatic JJ JJ O
VT NNP NNP O
or CC CC O
ventricular NN NN O
fibrillation NN NN O
( ( ( O
VF NNP NNP O
) ) ) O
over IN IN O
a DT DT O
follow VB VB O
- - - O
up RP RP O
of IN IN O
6 CD CD O
to TO TO O
52 CD CD O
months NNS NNS O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- : : O
standard JJ JJ O
deviation NN NN O
14 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
2 CD CD O
) ) ) O
. . . O

Six CD CD O
percent NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
a DT DT O
nonfatal JJ JJ O
recurrence NN NN O
of IN IN O
VT NNP NNP O
and CC CC O
were VBD VBD O
successfully RB RB O
managed VBN VBN O
by IN IN O
continuing VBG VBG O
amiodarone NN NN B-CHEM
at IN IN O
a DT DT O
higher JJR JJR O
dose NN NN O
or CC CC O
by IN IN O
the DT DT O
addition NN NN O
of IN IN O
a DT DT O
conventional JJ JJ O
antiarrhythmic JJ JJ O
drug NN NN O
. . . O

One CD CD O
or CC CC O
more JJR JJR O
adverse JJ JJ O
drug NN NN O
reactions NNS NNS O
occurred VBD VBD O
in IN IN O
51 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Adverse NNP NNP O
effects NNS NNS O
forced VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
dose NN NN O
of IN IN O
amiodarone NN NN B-CHEM
in IN IN O
41 CD CD O
% NN NN O
and CC CC O
discontinuation NN NN O
of IN IN O
amiodarone NN NN B-CHEM
in IN IN O
10 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
symptomatic JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
were VBD VBD O
tremor NN NN O
or CC CC O
ataxia NN NN O
( ( ( O
35 CD CD O
% NN NN O
) ) ) O
, , , O
nausea NN NN O
and CC CC O
anorexia NN NN O
( ( ( O
8 CD CD O
% NN NN O
) ) ) O
, , , O
visual JJ JJ O
halos NN NN O
or CC CC O
blurring VBG VBG O
( ( ( O
6 CD CD O
% NN NN O
) ) ) O
, , , O
thyroid NN NN O
function NN NN O
abnormalities NNS NNS O
( ( ( O
6 CD CD O
% NN NN O
) ) ) O
and CC CC O
pulmonary JJ JJ O
interstitial JJ JJ O
infiltrates NNS NNS O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
. . . O

Although IN IN O
large JJ JJ O
- - - O
dose NN NN O
amiodarone NN NN B-CHEM
is VBZ VBZ O
highly RB RB O
effective JJ JJ O
in IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
of IN IN O
VT NNP NNP O
or CC CC O
VF NNP NNP O
refractory NN NN O
to TO TO O
conventional JJ JJ O
antiarrhythmic JJ JJ O
drugs NNS NNS O
, , , O
it PRP PRP O
causes VBZ VBZ O
significant JJ JJ O
toxicity NN NN O
in IN IN O
approximately RB RB O
50 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

However RB RB O
, , , O
when WRB WRB O
the DT DT O
dose NN NN O
is VBZ VBZ O
adjusted VBN VBN O
based VBN VBN O
on IN IN O
clinical JJ JJ O
response NN NN O
or CC CC O
the DT DT O
development NN NN O
of IN IN O
adverse JJ JJ O
effects NNS NNS O
, , , O
75 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
VT NNP NNP O
or CC CC O
VF NNP NNP O
can MD MD O
be VB VB O
successfully RB RB O
managed VBN VBN O
with IN IN O
amiodarone NN NN B-CHEM
. . . O

Why WRB WRB O
may MD MD O
epsilon VB VB B-CHEM
- - - I-CHEM
aminocaproic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
EACA NNP NNP B-CHEM
) ) ) O
induce NN NN O
myopathy NN NN O
in IN IN O
man NN NN O
? . . O

Report NNP NNP O
of IN IN O
a DT DT O
case NN NN O
and CC CC O
literature NN NN O
review NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
necrotizing VBG VBG O
myopathy JJ JJ O
due JJ JJ O
to TO TO O
a DT DT O
short JJ JJ O
epsilon NN NN B-CHEM
- - - I-CHEM
aminocaproic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
EACA NNP NNP B-CHEM
) ) ) O
treatment NN NN O
in IN IN O
a DT DT O
72 CD CD O
year NN NN O
- : : O
old JJ JJ O
patient NN NN O
with IN IN O
subarachnoid NN NN O
haemorrhage NN NN O
( ( ( O
SAH NNP NNP O
) ) ) O
is VBZ VBZ O
described VBN VBN O
. . . O

Pathogenetic NNP NNP O
hypotheses NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Cerebral NNP NNP O
hemorrhage NN NN O
associated VBN VBN O
with IN IN O
phenylpropanolamine NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
caffeine NN NN B-CHEM
. . . O

Phenylpropanolamine NNP NNP B-CHEM
( ( ( O
PPA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
drug NN NN O
that WDT WDT O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
serious JJ JJ O
side NN NN O
effects NNS NNS O
including VBG VBG O
stroke NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
often RB RB O
combined VBN VBN O
with IN IN O
caffeine NN NN B-CHEM
in IN IN O
diet NN NN O
preparations NNS NNS O
and CC CC O
" '' '' O
look VB VB O
- - - O
alike IN IN O
" '' '' O
pills NNS NNS O
. . . O

In IN IN O
order NN NN O
to TO TO O
determine VB VB O
if IN IN O
PPA NNP NNP B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
can MD MD O
lead VB VB O
to TO TO O
stroke NN NN O
in IN IN O
normotensive JJ JJ O
and CC CC O
/ NN NN O
or CC CC O
hypertensive JJ JJ O
rats NNS NNS O
, , , O
we PRP PRP O
administered VBD VBD O
the DT DT O
combination NN NN O
in IN IN O
six CD CD O
times NNS NNS O
the DT DT O
allowed VBN VBN O
human JJ JJ O
dose NN NN O
calculated VBN VBN O
on IN IN O
a DT DT O
per IN IN O
weight NN NN O
basis NN NN O
for IN IN O
the DT DT O
rats NNS NNS O
two CD CD O
times NNS NNS O
per IN IN O
day NN NN O
for IN IN O
five CD CD O
days NNS NNS O
. . . O

Subarachnoid NNP NNP O
and CC CC O
cerebral JJ JJ O
hemorrhage NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
18 CD CD O
% NN NN O
of IN IN O
the DT DT O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

A DT DT O
single JJ JJ O
PPA NNP NNP B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
administration NN NN O
( ( ( O
same JJ JJ O
dose NN NN O
) ) ) O
lead NN NN O
to TO TO O
acute JJ JJ O
hypertension NN NN O
in IN IN O
both DT DT O
the DT DT O
normotensive JJ JJ O
and CC CC O
hypertensive JJ JJ O
animals NNS NNS O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
PPA NNP NNP B-CHEM
/ NN NN O
caffeine NN NN B-CHEM
can MD MD O
lead VB VB O
to TO TO O
cerebral JJ JJ O
hemorrhage NN NN O
in IN IN O
previously RB RB O
hypertensive JJ JJ O
animals NNS NNS O
when WRB WRB O
administered VBN VBN O
in IN IN O
greater JJR JJR O
than IN IN O
the DT DT O
allowed JJ JJ O
dosage NN NN O
. . . O

An DT DT O
acute JJ JJ O
elevation NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
may MD MD O
be VB VB O
a DT DT O
contributing VBG VBG O
factor NN NN O
. . . O

Renal NNP NNP O
papillary JJ JJ O
necrosis NN NN O
due JJ JJ O
to TO TO O
naproxen NN NN B-CHEM
. . . O

A DT DT O
31 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
, , , O
who WP WP O
had VBD VBD O
previously RB RB O
been VBN VBN O
treated VBN VBN O
with IN IN O
sulindac NN NN B-CHEM
, , , O
fenoprofen NN NN B-CHEM
calcium NN NN I-CHEM
, , , O
high JJ JJ O
dose NN NN O
salicylates NNS NNS B-CHEM
and CC CC O
gold NN NN B-CHEM
salts NNS NNS O
, , , O
developed VBN VBN O
renal JJ JJ O
papillary JJ JJ O
necrosis NN NN O
( ( ( O
RPN NNP NNP O
) ) ) O
4 CD CD O
months NNS NNS O
after IN IN O
institution NN NN O
of IN IN O
naproxen NN NN B-CHEM
therapy NN NN O
. . . O

No DT DT O
other JJ JJ O
factor NN NN O
predisposing VBG VBG O
to TO TO O
RPN NNP NNP O
could MD MD O
be VB VB O
discovered VBN VBN O
. . . O

Sulindac NNP NNP B-CHEM
was VBD VBD O
substituted VBN VBN O
for IN IN O
naproxen NN NN B-CHEM
and CC CC O
no DT DT O
further JJ JJ O
adverse JJ JJ O
renal JJ JJ O
effects NNS NNS O
occurred VBD VBD O
over IN IN O
the DT DT O
next JJ JJ O
12 CD CD O
months NNS NNS O
. . . O

We PRP PRP O
review VBP VBP O
previous JJ JJ O
reports NNS NNS O
linking VBG VBG O
RPN NNP NNP O
to TO TO O
antiinflammatory JJ JJ O
drug NN NN O
use NN NN O
and CC CC O
discuss VB VB O
possible JJ JJ O
advantages NNS NNS O
of IN IN O
sulindac NN NN B-CHEM
in IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
experienced VBN VBN O
renal JJ JJ O
toxicity NN NN O
from IN IN O
other JJ JJ O
antiinflammatory JJ JJ O
agents NNS NNS O
. . . O

Nephrotoxic NNP NNP O
effects NNS NNS O
of IN IN O
aminoglycoside NN NN B-CHEM
treatment NN NN O
on IN IN O
renal JJ JJ O
protein NN NN O
reabsorption NN NN O
and CC CC O
accumulation NN NN O
. . . O

To TO TO O
quantify VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
gentamicin NN NN B-CHEM
, , , O
kanamycin NN NN B-CHEM
and CC CC O
netilmicin NN NN B-CHEM
on IN IN O
renal JJ JJ O
protein NN NN O
reabsorption NN NN O
and CC CC O
accumulation NN NN O
, , , O
these DT DT O
drugs NNS NNS O
were VBD VBD O
administered VBN VBN O
to TO TO O
rats NNS NNS O
intraperitoneally RB RB O
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
for IN IN O
7 CD CD O
, , , O
14 CD CD O
or CC CC O
21 CD CD O
days NNS NNS O
. . . O

Scanning NNP NNP O
electron NN NN O
microscopy NN NN O
of IN IN O
the DT DT O
glomerular NN NN O
endothelia NN NN O
, , , O
urinary JJ JJ O
measurements NNS NNS O
of IN IN O
sodium NN NN B-CHEM
, , , O
potassium NN NN B-CHEM
, , , O
endogenous JJ JJ O
lysozyme NN NN O
, , , O
N NNP NNP O
- : : O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
D NNP NNP O
- : : O
glucosaminidase NN NN O
( ( ( O
NAG NNP NNP O
) ) ) O
as RB RB O
well RB RB O
as IN IN O
clearance NN NN O
and CC CC O
accumulation NN NN O
experiments NNS NNS O
after IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
administration NN NN O
of IN IN O
egg NN NN O
- - - O
white JJ JJ O
lysozyme NN NN O
and CC CC O
measurements NNS NNS O
of IN IN O
inulin NN NN O
clearance NN NN O
( ( ( O
GFR NNP NNP O
) ) ) O
were VBD VBD O
done VBN VBN O
in IN IN O
each DT DT O
treatment NN NN O
group NN NN O
. . . O

Gentamicin NNP NNP B-CHEM
administration NN NN O
decreased VBD VBD O
diameter NN NN O
, , , O
density NN NN O
and CC CC O
shape NN NN O
of IN IN O
endothelial JJ JJ O
fenestrae NN NN O
. . . O

Kanamycin NNP NNP B-CHEM
and CC CC O
netilmicin NN NN B-CHEM
appeared VBD VBD O
to TO TO O
have VB VB O
no DT DT O
effect NN NN O
at IN IN O
the DT DT O
dose NN NN O
used VBN VBN O
. . . O

All DT DT O
three CD CD O
aminoglycosides NNS NNS B-CHEM
decreased VBD VBD O
GFR NNP NNP O
and CC CC O
increased VBN VBN O
urinary JJ JJ O
excretion NN NN O
of IN IN O
sodium NN NN B-CHEM
and CC CC O
potassium NN NN B-CHEM
. . . O

While IN IN O
gentamicin NN NN B-CHEM
and CC CC O
kanamycin NN NN B-CHEM
decreased VBD VBD O
the DT DT O
percentage NN NN O
reabsorption NN NN O
and CC CC O
accumulation NN NN O
of IN IN O
lysozyme NN NN O
after IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
administration NN NN O
of IN IN O
egg NN NN O
- - - O
white JJ JJ O
lysozyme NN NN O
netilmicin NN NN B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

Daily NNP NNP O
excretion NN NN O
of IN IN O
total JJ JJ O
protein NN NN O
, , , O
endogenous JJ JJ O
lysozyme NN NN O
and CC CC O
NAG NNP NNP O
increased VBD VBD O
only RB RB O
after IN IN O
treatment NN NN O
with IN IN O
kanamycin NN NN B-CHEM
and CC CC O
gentamicin NN NN B-CHEM
. . . O

Thus RB RB O
, , , O
aminoglycosides NNS NNS B-CHEM
may MD MD O
act VB VB O
as IN IN O
nephrotoxicants NNS NNS O
at IN IN O
glomerular NN NN O
and CC CC O
/ NN NN O
or CC CC O
tubular JJ JJ O
level NN NN O
inducing VBG VBG O
impairment NN NN O
of IN IN O
renal JJ JJ O
reabsorption NN NN O
and CC CC O
accumulation NN NN O
of IN IN O
proteins NNS NNS O
. . . O

Induction NNP NNP O
of IN IN O
the DT DT O
obstructive JJ JJ O
sleep NN NN O
apnea NN NN O
syndrome NN NN O
in IN IN O
a DT DT O
woman NN NN O
by IN IN O
exogenous JJ JJ O
androgen NN NN B-CHEM
administration NN NN O
. . . O

We PRP PRP O
documented VBD VBD O
airway NN NN O
occlusion NN NN O
during IN IN O
sleep NN NN O
and CC CC O
an DT DT O
abnormally RB RB O
high JJ JJ O
supraglottic JJ JJ O
resistance NN NN O
while IN IN O
awake NN NN O
in IN IN O
a DT DT O
54 CD CD O
- : : O
yr NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
had VBD VBD O
developed VBN VBN O
physical JJ JJ O
changes NNS NNS O
and CC CC O
the DT DT O
syndrome NN NN O
of IN IN O
obstructive JJ JJ O
sleep NN NN O
apnea NN NN O
while IN IN O
being VBG VBG O
administered VBN VBN O
exogenous JJ JJ O
androgens NNS NNS B-CHEM
. . . O

When WRB WRB O
the DT DT O
androgens NNS NNS B-CHEM
were VBD VBD O
withdrawn VBN VBN O
, , , O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
physical JJ JJ O
changes NNS NNS O
, , , O
symptoms NNS NNS O
, , , O
sleep VB VB O
study NN NN O
, , , O
and CC CC O
supraglottic JJ JJ O
resistance NN NN O
all DT DT O
returned VBD VBD O
to TO TO O
normal JJ JJ O
. . . O

A DT DT O
rechallenge NN NN O
with IN IN O
androgen NN NN B-CHEM
produced VBD VBD O
symptoms NNS NNS O
of IN IN O
obstructive JJ JJ O
sleep NN NN O
apnea NN NN O
that WDT WDT O
abated VBD VBD O
upon IN IN O
withdrawal NN NN O
of IN IN O
the DT DT O
hormone NN NN O
. . . O

Previous JJ JJ O
reports NNS NNS O
have VBP VBP O
favored VBN VBN O
a DT DT O
role NN NN O
of IN IN O
androgens NNS NNS B-CHEM
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
sleep NN NN O
apnea NN NN O
. . . O

Our PRP$ PRP$ O
report NN NN O
provides VBZ VBZ O
direct JJ JJ O
evidence NN NN O
for IN IN O
this DT DT O
role NN NN O
. . . O

Structural NNP NNP O
and CC CC O
functional JJ JJ O
measurements NNS NNS O
indicate VBP VBP O
that IN IN O
androgens NNS NNS B-CHEM
exert VB VB O
a DT DT O
permissive JJ JJ O
or CC CC O
necessary JJ JJ O
action NN NN O
on IN IN O
the DT DT O
structural JJ JJ O
configuration NN NN O
of IN IN O
the DT DT O
oropharynx NN NN O
that WDT WDT O
predisposes VBZ VBZ O
to TO TO O
obstruction NN NN O
during IN IN O
sleep NN NN O
. . . O

Development NNP NNP O
of IN IN O
the DT DT O
obstructive JJ JJ O
sleep NN NN O
apnea NN NN O
syndrome NN NN O
must MD MD O
be VB VB O
considered VBN VBN O
a DT DT O
possible JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
androgen NN NN B-CHEM
therapy NN NN O
. . . O

Cardiotoxic NNP NNP O
and CC CC O
possible JJ JJ O
leukemogenic JJ JJ O
effects NNS NNS O
of IN IN O
adriamycin NN NN B-CHEM
in IN IN O
nonhuman NN NN O
primates NNS NNS O
. . . O

10 CD CD O
monkeys NNS NNS O
( ( ( O
macaques NNS NNS O
) ) ) O
received VBN VBN O
adriamycin NN NN B-CHEM
by IN IN O
monthly JJ JJ O
intravenous JJ JJ O
injections NNS NNS O
at IN IN O
12 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

8 CD CD O
of IN IN O
the DT DT O
10 CD CD O
monkeys NNS NNS O
developed VBN VBN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
at IN IN O
an DT DT O
average JJ JJ O
cumulative JJ JJ O
adriamycin NN NN B-CHEM
dose NN NN O
( ( ( O
310 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
well RB RB O
below IN IN O
that DT DT O
considered VBD VBD O
the DT DT O
safe JJ JJ O
upper JJ JJ O
limit NN NN O
( ( ( O
550 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
in IN IN O
man NN NN O
. . . O

Histologically NNP NNP O
, , , O
the DT DT O
myocardial NN NN O
lesions NNS NNS O
resembled VBD VBD O
those DT DT O
found VBN VBN O
in IN IN O
human JJ JJ O
anthracycline NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
. . . O

1 CD CD O
of IN IN O
the DT DT O
10 CD CD O
monkeys NNS NNS O
developed VBN VBN O
acute JJ JJ O
myeloblastic JJ JJ O
leukemia NN NN O
after IN IN O
receiving VBG VBG O
324 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
of IN IN O
adriamycin NN NN B-CHEM
; : : O
the DT DT O
10th JJ JJ O
monkey NN NN O
is VBZ VBZ O
alive JJ JJ O
and CC CC O
well RB RB O
26 CD CD O
months NNS NNS O
after IN IN O
the DT DT O
last JJ JJ O
dose NN NN O
of IN IN O
drug NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
adriamycin NN NN B-CHEM
is VBZ VBZ O
a DT DT O
more RBR RBR O
potent JJ JJ O
cardiotoxin NN NN O
in IN IN O
monkeys NNS NNS O
than IN IN O
in IN IN O
man NN NN O
, , , O
and CC CC O
that IN IN O
leukemia NN NN O
may MD MD O
be VB VB O
a DT DT O
consequence NN NN O
of IN IN O
prolonged JJ JJ O
treatment NN NN O
with IN IN O
this DT DT O
drug NN NN O
. . . O

Tricuspid NNP NNP O
valve NN NN O
regurgitation NN NN O
and CC CC O
lithium NN NN B-CHEM
carbonate NN NN I-CHEM
toxicity NN NN O
in IN IN O
a DT DT O
newborn JJ JJ O
infant NN NN O
. . . O

A DT DT O
newborn JJ JJ O
with IN IN O
massive JJ JJ O
tricuspid JJ JJ O
regurgitation NN NN O
, , , O
atrial JJ JJ O
flutter NN NN O
, , , O
congestive JJ JJ O
heart NN NN O
failure NN NN O
, , , O
and CC CC O
a DT DT O
high JJ JJ O
serum NN NN O
lithium NN NN B-CHEM
level NN NN O
is VBZ VBZ O
described VBN VBN O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
patient NN NN O
to TO TO O
initially RB RB O
manifest VB VB O
tricuspid JJ JJ O
regurgitation NN NN O
and CC CC O
atrial JJ JJ O
flutter NN NN O
, , , O
and CC CC O
the DT DT O
11th CD CD O
described VBD VBD O
patient NN NN O
with IN IN O
cardiac JJ JJ O
disease NN NN O
among IN IN O
infants NNS NNS O
exposed VBN VBN O
to TO TO O
lithium VB VB B-CHEM
compounds NNS NNS O
in IN IN O
the DT DT O
first JJ JJ O
trimester NN NN O
of IN IN O
pregnancy NN NN O
. . . O

Sixty CD CD O
- - - O
three CD CD O
percent NN NN O
of IN IN O
these DT DT O
infants NNS NNS O
had VBD VBD O
tricuspid JJ JJ O
valve NN NN O
involvement NN NN O
. . . O

Lithium NNP NNP B-CHEM
carbonate NN NN I-CHEM
may MD MD O
be VB VB O
a DT DT O
factor NN NN O
in IN IN O
the DT DT O
increasing VBG VBG O
incidence NN NN O
of IN IN O
congenital JJ JJ O
heart NN NN O
disease NN NN O
when WRB WRB O
taken VBN VBN O
during IN IN O
early JJ JJ O
pregnancy NN NN O
. . . O

It PRP PRP O
also RB RB O
causes VBZ VBZ O
neurologic JJ JJ O
depression NN NN O
, , , O
cyanosis NN NN O
, , , O
and CC CC O
cardiac JJ JJ O
arrhythmia NN NN O
when WRB WRB O
consumed VBN VBN O
prior RB RB O
to TO TO O
delivery NN NN O
. . . O

Effects NNP NNP O
of IN IN O
the DT DT O
novel NN NN O
compound NN NN O
aniracetam NN NN B-CHEM
( ( ( O
Ro NNP NNP B-CHEM
13 CD CD I-CHEM
- : : I-CHEM
5057 CD CD I-CHEM
) ) ) O
upon IN IN O
impaired VBD VBD O
learning VBG VBG O
and CC CC O
memory NN NN O
in IN IN O
rodents NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
aniracetam NN NN B-CHEM
( ( ( O
Ro NNP NNP B-CHEM
13 CD CD I-CHEM
- : : I-CHEM
5057 CD CD I-CHEM
, , , O
1 CD CD B-CHEM
- : : I-CHEM
anisoyl NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
pyrrolidinone NN NN I-CHEM
) ) ) O
was VBD VBD O
studied VBN VBN O
on IN IN O
various JJ JJ O
forms NNS NNS O
of IN IN O
experimentally RB RB O
impaired VBN VBN O
cognitive JJ JJ O
functions NNS NNS O
( ( ( O
learning VBG VBG O
and CC CC O
memory NN NN O
) ) ) O
in IN IN O
rodents NNS NNS O
and CC CC O
produced VBD VBD O
the DT DT O
following VBG VBG O
effects NNS NNS O
: : : O
( ( ( O
1 CD CD O
) ) ) O
almost RB RB O
complete JJ JJ O
prevention NN NN O
of IN IN O
the DT DT O
incapacity NN NN O
to TO TO O
learn VB VB O
a DT DT O
discrete JJ JJ O
escape NN NN O
response NN NN O
in IN IN O
rats NNS NNS O
exposed VBN VBN O
to TO TO O
sublethal VB VB O
hypercapnia NN NN O
immediately RB RB O
before IN IN O
the DT DT O
acquisition NN NN O
session NN NN O
; : : O
( ( ( O
2 CD CD O
) ) ) O
partial JJ JJ O
( ( ( O
rats NNS NNS O
) ) ) O
or CC CC O
complete JJ JJ O
( ( ( O
mice NN NN O
) ) ) O
prevention NN NN O
of IN IN O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
short JJ JJ O
- - - O
term NN NN O
amnesia NN NN O
for IN IN O
a DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
; : : O
( ( ( O
3 CD CD O
) ) ) O
complete JJ JJ O
protection NN NN O
against IN IN O
amnesia NN NN O
for IN IN O
a DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
in IN IN O
rats NNS NNS O
submitted VBN VBN O
to TO TO O
electroconvulsive JJ JJ O
shock NN NN O
immediately RB RB O
after IN IN O
avoidance NN NN O
acquisition NN NN O
; : : O
( ( ( O
4 CD CD O
) ) ) O
prevention NN NN O
of IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
retention NN NN O
- : : O
or CC CC O
retrieval NN NN O
- - - O
deficit NN NN O
for IN IN O
a DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
induced VBN VBN O
in IN IN O
rats NNS NNS O
and CC CC O
mice NNS NNS O
by IN IN O
chloramphenicol NN NN B-CHEM
or CC CC O
cycloheximide NN NN B-CHEM
administered VBD VBD O
immediately RB RB O
after IN IN O
acquisition NN NN O
; : : O
( ( ( O
5 CD CD O
) ) ) O
reversal NN NN O
, , , O
when WRB WRB O
administered VBN VBN O
as RB RB O
late RB RB O
as IN IN O
1 CD CD O
h NN NN O
before IN IN O
the DT DT O
retention NN NN O
test NN NN O
, , , O
of IN IN O
the DT DT O
deficit NN NN O
in IN IN O
retention NN NN O
or CC CC O
retrieval NN NN O
of IN IN O
a DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
induced VBN VBN O
by IN IN O
cycloheximide NN NN B-CHEM
injected JJ JJ O
2 CD CD O
days NNS NNS O
previously RB RB O
; : : O
( ( ( O
6 CD CD O
) ) ) O
prevention NN NN O
of IN IN O
the DT DT O
deficit NN NN O
in IN IN O
the DT DT O
retrieval NN NN O
of IN IN O
an DT DT O
active JJ JJ O
avoidance NN NN O
task NN NN O
induced VBN VBN O
in IN IN O
mice NNS NNS O
by IN IN O
subconvulsant JJ JJ O
electroshock NN NN O
or CC CC O
hypercapnia NN NN O
applied VBN VBN O
immediately RB RB O
before IN IN O
retrieval NN NN O
testing NN NN O
( ( ( O
24 CD CD O
h NN NN O
after IN IN O
acquisition NN NN O
) ) ) O
. . . O

These DT DT O
improvements NNS NNS O
or CC CC O
normalizations NNS NNS O
of IN IN O
impaired JJ JJ O
cognitive JJ JJ O
functions NNS NNS O
were VBD VBD O
seen VBN VBN O
at IN IN O
oral JJ JJ O
aniracetam NN NN B-CHEM
doses NNS NNS O
of IN IN O
10 CD CD O
- : : O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Generally RB RB O
, , , O
the DT DT O
dose NN NN O
- - - O
response NN NN O
curves NNS NNS O
were VBD VBD O
bell NN NN O
- - - O
shaped VBN VBN O
. . . O

The DT DT O
mechanisms NNS NNS O
underlying VBG VBG O
the DT DT O
activity NN NN O
of IN IN O
aniracetam NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
' POS POS O
therapeutic JJ JJ O
window NN NN O
' '' '' O
are VBP VBP O
unknown JJ JJ O
. . . O

Piracetam NNP NNP B-CHEM
, , , O
another DT DT O
pyrrolidinone NN NN B-CHEM
derivative NN NN O
was VBD VBD O
used VBN VBN O
for IN IN O
comparison NN NN O
. . . O

It PRP PRP O
was VBD VBD O
active JJ JJ O
only RB RB O
in IN IN O
six CD CD O
of IN IN O
nine CD CD O
tests NNS NNS O
and CC CC O
had VBD VBD O
about IN IN O
one CD CD O
- : : O
tenth NN NN O
the DT DT O
potency NN NN O
of IN IN O
aniracetam NN NN B-CHEM
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
aniracetam NN NN B-CHEM
improves VBZ VBZ O
cognitive JJ JJ O
functions NNS NNS O
which WDT WDT O
are VBP VBP O
impaired VBN VBN O
by IN IN O
different JJ JJ O
procedure NN NN O
and CC CC O
in IN IN O
different JJ JJ O
phases NNS NNS O
of IN IN O
the DT DT O
learning VBG VBG O
and CC CC O
memory NN NN O
process NN NN O
. . . O

Effect NN NN O
of IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
on IN IN O
gross JJ JJ O
behavioural NN NN O
changes NNS NNS O
produced VBN VBN O
by IN IN O
carbachol NN NN B-CHEM
and CC CC O
eserine NN NN B-CHEM
in IN IN O
cats NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
injected VBN VBN O
into IN IN O
the DT DT O
cerebral JJ JJ O
ventricles NNS NNS O
of IN IN O
group NN NN O
- - - O
housed VBN VBN O
unanaesthetized JJ JJ O
cats NNS NNS O
upon IN IN O
vocalization NN NN O
( ( ( O
rage NN NN O
, , , O
hissing VBG VBG O
and CC CC O
snarling VBG VBG O
) ) ) O
, , , O
fighting VBG VBG O
( ( ( O
attack NN NN O
with IN IN O
paws NNS NNS O
and CC CC O
claws NNS NNS O
, , , O
defense NN NN O
with IN IN O
paws NNS NNS O
and CC CC O
claws NNS NNS O
and CC CC O
biting VBG VBG O
) ) ) O
, , , O
mydriasis NN NN O
, , , O
tremor NN NN O
and CC CC O
clonic JJ JJ O
- - - O
tonic JJ JJ O
convulsions NNS NNS O
produced VBN VBN O
by IN IN O
carbachol NN NN B-CHEM
and CC CC O
eserine NN NN B-CHEM
injected VBD VBD O
similarly RB RB O
was VBD VBD O
investigated VBN VBN O
. . . O

Calcium NNP NNP B-CHEM
chloride NN NN I-CHEM
depressed VBN VBN O
or CC CC O
almost RB RB O
completely RB RB O
abolished VBD VBD O
the DT DT O
vocalization NN NN O
and CC CC O
fighting VBG VBG O
due JJ JJ O
to TO TO O
carbachol VB VB B-CHEM
and CC CC O
eserine VB VB B-CHEM
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
mydriasis NN NN O
, , , O
tremor NN NN O
and CC CC O
clonic JJ JJ O
- - - O
tonic JJ JJ O
convulsions NNS NNS O
evoked VBN VBN O
by IN IN O
carbachol NN NN B-CHEM
and CC CC O
eserine NN NN B-CHEM
were VBD VBD O
not RB RB O
significantly RB RB O
changed VBN VBN O
by IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
. . . O

It PRP PRP O
is VBZ VBZ O
apparent JJ JJ O
that IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
can MD MD O
" '' '' O
dissociate VB VB O
" '' '' O
vocalization NN NN O
and CC CC O
fighting VBG VBG O
from IN IN O
autonomic JJ JJ O
and CC CC O
motor NN NN O
phenomena NN NN O
such JJ JJ O
as IN IN O
mydriasis NN NN O
, , , O
tremor NN NN O
and CC CC O
clonic JJ JJ O
- - - O
tonic JJ JJ O
convulsions NNS NNS O
caused VBN VBN O
by IN IN O
carbachol NN NN B-CHEM
and CC CC O
eserine NN NN B-CHEM
. . . O

Calcium NNP NNP B-CHEM
chloride NN NN I-CHEM
inhibited VBD VBD O
the DT DT O
vocalization NN NN O
and CC CC O
fighting VBG VBG O
produced VBN VBN O
by IN IN O
carbachol NN NN B-CHEM
and CC CC O
eserine NN NN B-CHEM
most RBS RBS O
probably RB RB O
by IN IN O
a DT DT O
nonspecific JJ JJ O
stabilizing VBG VBG O
action NN NN O
on IN IN O
central JJ JJ O
muscarinic JJ JJ O
cholinoceptive JJ JJ O
sites NNS NNS O
. . . O

These DT DT O
results NNS NNS O
further JJ JJ O
support NN NN O
the DT DT O
view NN NN O
that IN IN O
calcium NN NN B-CHEM
ions NNS NNS O
in IN IN O
excess NN NN O
have VBP VBP O
an DT DT O
atropine NN NN B-CHEM
- - - O
like IN IN O
action NN NN O
also RB RB O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Thiazide NNP NNP B-CHEM
diuretics NNS NNS O
, , , O
hypokalemia NN NN O
and CC CC O
cardiac JJ JJ O
arrhythmias NNS NNS O
. . . O

Thiazide NNP NNP B-CHEM
diuretics NNS NNS O
are VBP VBP O
widely RB RB O
accepted VBN VBN O
as IN IN O
the DT DT O
cornerstone NN NN O
of IN IN O
antihypertensive JJ JJ O
treatment NN NN O
programs NNS NNS O
. . . O

Hypokalemia NNP NNP O
is VBZ VBZ O
a DT DT O
commonly RB RB O
encountered VBN VBN O
metabolic JJ JJ O
consequence NN NN O
of IN IN O
chronic JJ JJ O
thiazide NN NN B-CHEM
therapy NN NN O
. . . O

We PRP PRP O
treated VBD VBD O
38 CD CD O
patients NNS NNS O
( ( ( O
22 CD CD O
low JJ JJ O
renin NN NN O
, , , O
16 CD CD O
normal JJ JJ O
renin NN NN O
) ) ) O
with IN IN O
moderate JJ JJ O
diastolic JJ JJ O
hypertension NN NN O
with IN IN O
hydrochlorothiazide NN NN B-CHEM
( ( ( O
HCTC NNP NNP B-CHEM
) ) ) O
administered VBN VBN O
on IN IN O
a DT DT O
twice RB RB O
daily JJ JJ O
schedule NN NN O
. . . O

Initial JJ JJ O
dose NN NN O
was VBD VBD O
50 CD CD O
mg NN NN O
and CC CC O
the DT DT O
dose NN NN O
was VBD VBD O
increased VBN VBN O
at IN IN O
monthly JJ JJ O
intervals NNS NNS O
to TO TO O
100 CD CD O
mg NN NN O
, , , O
150 CD CD O
mg NN NN O
and CC CC O
200 CD CD O
mg NN NN O
daily NN NN O
until IN IN O
blood NN NN O
pressure NN NN O
normalized VBD VBD O
. . . O

The DT DT O
serum NN NN O
K NNP NNP B-CHEM
during IN IN O
the DT DT O
control NN NN O
period NN NN O
was VBD VBD O
4 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
mEq NN NN O
/ NN NN O
l NN NN O
an DT DT O
on IN IN O
50 CD CD O
, , , O
100 CD CD O
, , , O
150 CD CD O
and CC CC O
200 CD CD O
mg NN NN O
HCTZ NNP NNP B-CHEM
daily JJ JJ O
3 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
, , , O
3 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
, , , O
2 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
, , , O
and CC CC O
2 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
mEq NN NN O
/ NN NN O
l NN NN O
, , , O
respectively RB RB O
. . . O

Corresponding NNP NNP O
figures NNS NNS O
for IN IN O
whole JJ JJ O
body NN NN O
K NNP NNP B-CHEM
were VBD VBD O
4107 CD CD O
+ NN NN O
/ NN NN O
- : : O
208 CD CD O
, , , O
3722 CD CD O
+ NN NN O
/ NN NN O
- : : O
319 CD CD O
, , , O
3628 CD CD O
+ NN NN O
/ NN NN O
- : : O
257 CD CD O
, , , O
3551 CD CD O
+ NN NN O
/ NN NN O
- : : O
336 CD CD O
, , , O
and CC CC O
3269 CD CD O
+ NN NN O
/ NN NN O
- : : O
380 CD CD O
mEq NN NN O
, , , O
respectively RB RB O
. . . O

In IN IN O
13 CD CD O
patients NNS NNS O
we PRP PRP O
observed VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
HCTZ NNP NNP B-CHEM
therapy NN NN O
( ( ( O
100 CD CD O
mg NN NN O
daily JJ JJ O
) ) ) O
on IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
PVC NNP NNP O
' POS POS O
s VBZ VBZ O
during IN IN O
rest NN NN O
as RB RB O
well RB RB O
as IN IN O
during IN IN O
static JJ JJ O
and CC CC O
dynamic JJ JJ O
exercise NN NN O
. . . O

During IN IN O
rest NN NN O
we PRP PRP O
observed VBD VBD O
0 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
08 CD CD O
PVC NNP NNP O
beats NNS NNS O
/ NN NN O
min NN NN O
+ NN NN O
/ NN NN O
- : : O
SEM NNP NNP O
and CC CC O
during IN IN O
static JJ JJ O
and CC CC O
dynamic JJ JJ O
exercise NN NN O
0 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
06 CD CD O
and CC CC O
0 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
15 CD CD O
, , , O
respectively RB RB O
. . . O

Corresponding NNP NNP O
figures NNS NNS O
during IN IN O
HCTZ NNP NNP B-CHEM
therapy NN NN O
100 CD CD O
mg NN NN O
daily NN NN O
were VBD VBD O
1 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
, , , O
3 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
and CC CC O
5 CD CD O
. . . O
7 CD CD O
4 CD CD O
/ NN NN O
- : : O
0 CD CD O
. . . O
8 CD CD O
, , , O
respectively RB RB O
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
PVC NNP NNP O
' POS POS O
s VBZ VBZ O
correlated JJ JJ O
significantly RB RB O
with IN IN O
the DT DT O
fall NN NN O
in IN IN O
serum NN NN O
K NNP NNP B-CHEM
+ NN NN O
observed VBD VBD O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
72 CD CD O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
. . . O

In IN IN O
conclusion NN NN O
we PRP PRP O
found VBD VBD O
that IN IN O
thiazide NN NN B-CHEM
diuretics NNS NNS O
cause VBP VBP O
hypokalemia NN NN O
and CC CC O
depletion NN NN O
of IN IN O
body NN NN O
potassium NN NN B-CHEM
. . . O

The DT DT O
more RBR RBR O
profound JJ JJ O
hypokalemia NN NN O
, , , O
the DT DT O
greater JJR JJR O
the DT DT O
propensity NN NN O
for IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
PVC NNP NNP O
' POS POS O
s VBZ VBZ O
. . . O

Circulating NNP NNP O
lysosomal NN NN O
enzymes NNS NNS O
and CC CC O
acute JJ JJ O
hepatic JJ JJ O
necrosis NN NN O
. . . O

The DT DT O
activities NNS NNS O
of IN IN O
the DT DT O
lysosomal NN NN O
enzymes NNS NNS O
acid NN NN O
and CC CC O
neutral JJ JJ O
protease NN NN O
, , , O
N NNP NNP O
- : : O
acetylglucosaminidase NN NN O
, , , O
and CC CC O
acid NN NN O
phosphatase NN NN O
were VBD VBD O
measured VBN VBN O
in IN IN O
the DT DT O
serum NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
fulminant NN NN O
hepatic JJ JJ O
failure NN NN O
. . . O

Acid NNP NNP O
protease NN NN O
( ( ( O
cathepsin NN NN O
D NNP NNP O
) ) ) O
activity NN NN O
was VBD VBD O
increased VBN VBN O
about IN IN O
tenfold NN NN O
in IN IN O
patients NNS NNS O
who WP WP O
died VBD VBD O
and CC CC O
nearly RB RB O
fourfold VBN VBN O
in IN IN O
those DT DT O
who WP WP O
survived VBD VBD O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
after IN IN O
paracetamol NN NN B-CHEM
overdose NN NN O
, , , O
whereas IN IN O
activities NNS NNS O
were VBD VBD O
increased VBN VBN O
equally RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
fulminant NN NN O
hepatic JJ JJ O
failure NN NN O
due JJ JJ O
to TO TO O
viral JJ JJ O
hepatitis NN NN O
whether IN IN O
or CC CC O
not RB RB O
they PRP PRP O
survived VBD VBD O
. . . O

A DT DT O
correlation NN NN O
was VBD VBD O
found VBN VBN O
between IN IN O
serum JJ JJ O
acid NN NN O
protease NN NN O
activity NN NN O
and CC CC O
prothrombin NN NN O
time NN NN O
, , , O
and CC CC O
the DT DT O
increase NN NN O
in IN IN O
cathepsin NN NN O
D NNP NNP O
activity NN NN O
was VBD VBD O
sustained VBN VBN O
over IN IN O
several JJ JJ O
days NNS NNS O
compared VBN VBN O
with IN IN O
aspartate NN NN B-CHEM
aminotransferase NN NN O
, , , O
which WDT WDT O
showed VBD VBD O
a DT DT O
sharp JJ JJ O
early JJ JJ O
peak NN NN O
and CC CC O
then RB RB O
a DT DT O
fall NN NN O
. . . O

Circulating NNP NNP O
lysosomal NN NN O
proteases NNS NNS O
can MD MD O
damage VB VB O
other JJ JJ O
organs NNS NNS O
, , , O
and CC CC O
measurement NN NN O
of IN IN O
their PRP$ PRP$ O
activity NN NN O
may MD MD O
therefore RB RB O
be VB VB O
of IN IN O
added JJ JJ O
value NN NN O
in IN IN O
assessing VBG VBG O
prognosis NN NN O
in IN IN O
this DT DT O
condition NN NN O
. . . O

Hepatic NNP NNP O
veno NN NN O
- - - O
occlusive JJ JJ O
disease NN NN O
caused VBN VBN O
by IN IN O
6 CD CD B-CHEM
- : : I-CHEM
thioguanine NN NN I-CHEM
. . . O

Clinically NNP NNP O
reversible JJ JJ O
veno NN NN O
- - - O
occlusive JJ JJ O
disease NN NN O
of IN IN O
the DT DT O
liver NN NN O
developed VBN VBN O
in IN IN O
a DT DT O
23 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
acute JJ JJ O
lymphocytic JJ JJ O
leukemia NN NN O
after IN IN O
10 CD CD O
months NNS NNS O
of IN IN O
maintenance NN NN O
therapy NN NN O
with IN IN O
6 CD CD B-CHEM
- : : I-CHEM
thioguanine NN NN I-CHEM
. . . O

Serial NNP NNP O
liver NN NN O
biopsies NNS NNS O
showed VBD VBD O
the DT DT O
development NN NN O
and CC CC O
resolution NN NN O
of IN IN O
intense JJ JJ O
sinusoidal NN NN O
engorgement NN NN O
. . . O

Although IN IN O
this DT DT O
disease NN NN O
was VBD VBD O
clinically RB RB O
reversible JJ JJ O
, , , O
some DT DT O
subintimal JJ JJ O
fibrosis NNS NNS O
about IN IN O
the DT DT O
terminal NN NN O
hepatic JJ JJ O
veins NNS NNS O
persisted VBD VBD O
. . . O

This DT DT O
case NN NN O
presented VBD VBD O
a DT DT O
unique JJ JJ O
opportunity NN NN O
to TO TO O
observe VB VB O
the DT DT O
histologic JJ JJ O
features NNS NNS O
of IN IN O
clinically RB RB O
reversible JJ JJ O
hepatic JJ JJ O
veno NN NN O
- - - O
occlusive JJ JJ O
disease NN NN O
over IN IN O
time NN NN O
, , , O
and CC CC O
may MD MD O
be VB VB O
the DT DT O
first JJ JJ O
case NN NN O
of IN IN O
veno NN NN O
- - - O
occlusive JJ JJ O
related VBN VBN O
solely RB RB O
to TO TO O
6 CD CD B-CHEM
- : : I-CHEM
thioguanine NN NN I-CHEM
. . . O

Chlorpropamide NNP NNP B-CHEM
- : : O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
. . . O

A DT DT O
65 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
adult NN NN O
- - - O
onset NN NN O
diabetes NN NN O
treated VBN VBN O
with IN IN O
chlorpropamide NN NN B-CHEM
( ( ( O
Diabenese NNP NNP B-CHEM
) ) ) O
had VBD VBD O
a DT DT O
toxic JJ JJ O
optic JJ JJ O
neuropathy NN NN O
that WDT WDT O
resolved VBD VBD O
with IN IN O
discontinuation NN NN O
of IN IN O
chlorpropamide NN NN B-CHEM
therapy NN NN O
. . . O

Visual NNP NNP O
loss NN NN O
occurs VBZ VBZ O
in IN IN O
diabetics NNS NNS O
for IN IN O
a DT DT O
variety NN NN O
of IN IN O
reasons NNS NNS O
, , , O
and CC CC O
accurate JJ JJ O
diagnosis NN NN O
is VBZ VBZ O
necessary JJ JJ O
to TO TO O
institute VB VB O
appropriate JJ JJ O
therapy NN NN O
. . . O

The DT DT O
possibility NN NN O
of IN IN O
a DT DT O
drug NN NN O
- - - O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
the DT DT O
differential JJ JJ O
diagnosis NN NN O
of IN IN O
visual JJ JJ O
loss NN NN O
in IN IN O
diabetics NNS NNS O
. . . O

Plasma NNP NNP O
and CC CC O
urinary JJ JJ O
lipids NNS NNS O
and CC CC O
lipoproteins NNS NNS O
during IN IN O
the DT DT O
development NN NN O
of IN IN O
nephrotic JJ JJ O
syndrome NN NN O
induced VBD VBD O
in IN IN O
the DT DT O
rat NN NN O
by IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
. . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
ascertain VB VB O
whether IN IN O
the DT DT O
alterations NNS NNS O
of IN IN O
plasma NN NN O
lipoproteins NNS NNS O
found VBD VBD O
in IN IN O
nephrotic JJ JJ O
syndrome NN NN O
induced VBN VBN O
by IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
were VBD VBD O
due JJ JJ O
to TO TO O
nephrotic JJ JJ O
syndrome NN NN O
per IN IN O
se FW FW O
, , , O
or CC CC O
, , , O
at IN IN O
least JJS JJS O
in IN IN O
part NN NN O
, , , O
to TO TO O
the DT DT O
aminonucleoside NN NN B-CHEM
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
changes NNS NNS O
in IN IN O
plasma NN NN O
and CC CC O
urinary JJ JJ O
lipoproteins NNS NNS O
during IN IN O
the DT DT O
administration NN NN O
of IN IN O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
7 CD CD O
days NNS NNS O
) ) ) O
and CC CC O
the DT DT O
subsequent JJ JJ O
development NN NN O
of IN IN O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Since IN IN O
massive JJ JJ O
albuminuria NNS NNS O
occurred VBD VBD O
after IN IN O
6 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
, , , O
the DT DT O
time NN NN O
- - - O
course NN NN O
study NN NN O
was VBD VBD O
divided VBN VBN O
into IN IN O
two CD CD O
stages NNS NNS O
: : : O
pre NN NN O
- - - O
nephrotic JJ JJ O
stage NN NN O
( ( ( O
day NN NN O
1 CD CD O
- : : O
5 CD CD O
) ) ) O
and CC CC O
nephrotic JJ JJ O
stage NN NN O
( ( ( O
day NN NN O
6 CD CD O
- : : O
11 CD CD O
) ) ) O
. . . O

In IN IN O
pre NN NN O
- - - O
nephrotic JJ JJ O
stage NN NN O
the DT DT O
plasma NN NN O
level NN NN O
of IN IN O
fatty JJ JJ B-CHEM
acids NNS NNS I-CHEM
, , , O
triacylglycerol NN NN B-CHEM
and CC CC O
VLDL NNP NNP O
decreased VBD VBD O
while IN IN O
that DT DT O
of IN IN O
phospholipid NN NN O
, , , O
cholesteryl NN NN B-CHEM
esters NNS NNS I-CHEM
and CC CC O
HDL NNP NNP O
remained VBD VBD O
constant JJ JJ O
. . . O

Plasma NNP NNP O
apolipoprotein NN NN O
A DT DT O
- - - O
I PRP PRP O
tended VBD VBD O
to TO TO O
increase VB VB O
( ( ( O
40 CD CD O
% NN NN O
increase NN NN O
at IN IN O
day NN NN O
5 CD CD O
) ) ) O
. . . O

At IN IN O
the DT DT O
beginning NN NN O
of IN IN O
nephrotic JJ JJ O
stage NN NN O
( ( ( O
day NN NN O
6 CD CD O
) ) ) O
the DT DT O
concentration NN NN O
of IN IN O
plasma NN NN O
albumin NN NN O
dropped VBD VBD O
to TO TO O
a DT DT O
very RB RB O
low JJ JJ O
level NN NN O
, , , O
while IN IN O
that DT DT O
of IN IN O
apolipoprotein NN NN O
A DT DT O
- - - O
I PRP PRP O
increased VBD VBD O
abruptly RB RB O
( ( ( O
4 CD CD O
- : : O
fold VB VB O
increase NN NN O
) ) ) O
and CC CC O
continued VBD VBD O
to TO TO O
rise VB VB O
, , , O
although IN IN O
less JJR JJR O
steeply NN NN O
, , , O
in IN IN O
the DT DT O
following VBG VBG O
days NNS NNS O
. . . O

The DT DT O
plasma NN NN O
concentration NN NN O
of IN IN O
HDL NNP NNP O
followed VBD VBD O
the DT DT O
same JJ JJ O
pattern NN NN O
. . . O

Plasma NNP NNP O
VLDL NNP NNP O
and CC CC O
LDL NNP NNP O
increased VBD VBD O
at IN IN O
a DT DT O
later JJ JJ O
stage NN NN O
( ( ( O
day NN NN O
9 CD CD O
) ) ) O
. . . O

Plasma NNP NNP O
apolipoprotein NN NN O
A DT DT O
- - - O
I PRP PRP O
was VBD VBD O
found VBN VBN O
not RB RB O
only RB RB O
in IN IN O
HDL NNP NNP O
( ( ( O
1 CD CD O
. . . O
063 CD CD O
- : : O
1 CD CD O
. . . O
210 CD CD O
g SYM SYM O
/ NN NN O
ml NN NN O
) ) ) O
but CC CC O
also RB RB O
in IN IN O
the DT DT O
LDL NNP NNP O
density NN NN O
class NN NN O
( ( ( O
1 CD CD O
. . . O
025 CD CD O
- : : O
1 CD CD O
. . . O
050 CD CD O
g SYM SYM O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

In IN IN O
the DT DT O
pre NN NN O
- - - O
nephrotic JJ JJ O
stage NN NN O
lipoproteinuria NN NN O
was VBD VBD O
negligible JJ JJ O
, , , O
while IN IN O
in IN IN O
the DT DT O
early JJ JJ O
nephrotic JJ JJ O
stage NN NN O
the DT DT O
urinary JJ JJ O
loss NN NN O
of IN IN O
plasma NN NN O
lipoproteins NNS NNS O
consisted VBD VBD O
mainly RB RB O
of IN IN O
HDL NNP NNP O
. . . O

These DT DT O
observations NNS NNS O
indicate VBP VBP O
that IN IN O
puromycin NN NN B-CHEM
aminonucleoside IN IN I-CHEM
alters NNS NNS O
plasma VBP VBP O
lipoproteins NNS NNS O
by IN IN O
lowering VBG VBG O
VLDL NNP NNP O
and CC CC O
increasing VBG VBG O
HDL NNP NNP O
. . . O

It PRP PRP O
is VBZ VBZ O
likely JJ JJ O
that IN IN O
the DT DT O
early JJ JJ O
and CC CC O
striking JJ JJ O
increase NN NN O
of IN IN O
plasma NN NN O
HDL NNP NNP O
found VBD VBD O
in IN IN O
nephrotic JJ JJ O
rats NNS NNS O
is VBZ VBZ O
related VBN VBN O
to TO TO O
a DT DT O
direct JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
drug NN NN O
on IN IN O
HDL NNP NNP O
metabolism NN NN O
. . . O

Fatal NNP NNP O
aplastic JJ JJ O
anemia NN NN O
following VBG VBG O
topical JJ JJ O
administration NN NN O
of IN IN O
ophthalmic JJ JJ O
chloramphenicol NN NN B-CHEM
. . . O

A DT DT O
73 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
died VBD VBD O
of IN IN O
aplastic JJ JJ O
anemia NN NN O
less JJR JJR O
than IN IN O
two CD CD O
months NNS NNS O
after IN IN O
undergoing VBG VBG O
cataract NN NN O
extraction NN NN O
and CC CC O
beginning VBG VBG O
topical JJ JJ O
therapy NN NN O
with IN IN O
chloramphenicol NN NN B-CHEM
. . . O

The DT DT O
first JJ JJ O
signs NNS NNS O
of IN IN O
pancytopenia NN NN O
began VBD VBD O
within IN IN O
one CD CD O
month NN NN O
of IN IN O
the DT DT O
surgery NN NN O
. . . O

The DT DT O
pattern NN NN O
of IN IN O
the DT DT O
aplastic JJ JJ O
anemia NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
idiosyncratic JJ JJ O
response NN NN O
to TO TO O
chloramphenicol NN NN B-CHEM
. . . O

This DT DT O
was VBD VBD O
the DT DT O
second JJ JJ O
report NN NN O
of IN IN O
fatal JJ JJ O
aplastic JJ JJ O
anemia NN NN O
after IN IN O
topical JJ JJ O
treatment NN NN O
with IN IN O
chloramphenicol NN NN B-CHEM
for IN IN O
ocular JJ JJ O
conditions NNS NNS O
, , , O
although IN IN O
two CD CD O
cases NNS NNS O
of IN IN O
reversible JJ JJ O
bone NN NN O
marrow NN NN O
hypoplasia NN NN O
have VBP VBP O
also RB RB O
been VBN VBN O
reported VBN VBN O
. . . O

Any DT DT O
other JJ JJ O
suspected JJ JJ O
cases NNS NNS O
of IN IN O
ocular JJ JJ O
toxicity NN NN O
associated VBN VBN O
with IN IN O
topically RB RB O
applied VBN VBN O
chloramphenicol NN NN B-CHEM
should MD MD O
be VB VB O
reported VBN VBN O
to TO TO O
the DT DT O
National NNP NNP O
Registry NNP NNP O
of IN IN O
Drug NN NN O
- - - O
Induced NNP NNP O
Ocular NNP NNP O
Side NNP NNP O
Effects NNPS NNPS O
, , , O
Oregon NNP NNP O
Health NNP NNP O
Sciences NNP NNP O
University NNP NNP O
, , , O
Portland NNP NNP O
, , , O
OR CC CC O
97201 CD CD O
. . . O

Midazolam NNP NNP B-CHEM
compared VBN VBN O
with IN IN O
thiopentone NN NN B-CHEM
as IN IN O
an DT DT O
induction NN NN O
agent NN NN O
. . . O

In IN IN O
patients NNS NNS O
premedicated VBN VBN O
with IN IN O
scopolamine NN NN B-CHEM
+ NN NN O
morphine NN NN B-CHEM
( ( ( O
+ NN NN O
5 CD CD O
mg NN NN O
nitrazepam NN NN B-CHEM
the DT DT O
evening NN NN O
before IN IN O
surgery NN NN O
) ) ) O
, , , O
the DT DT O
sleep NN NN O
- - - O
inducing VBG VBG O
effect NN NN O
of IN IN O
midazolam NN NN B-CHEM
0 CD CD O
. . . O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
was VBD VBD O
clearly RB RB O
slower JJR JJR O
in IN IN O
onset NN NN O
than IN IN O
that DT DT O
of IN IN O
thiopentone NN NN B-CHEM
4 CD CD O
. . . O
67 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
Somewhat NNP NNP O
fewer JJR JJR O
cardiovascular NN NN O
and CC CC O
local JJ JJ O
sequelae NN NN O
were VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
midazolam NN NN B-CHEM
group NN NN O
, , , O
but CC CC O
, , , O
although IN IN O
apnoea NN NN O
occurred VBD VBD O
less RBR RBR O
often RB RB O
in IN IN O
the DT DT O
midazolam NN NN B-CHEM
group NN NN O
it PRP PRP O
lasted VBD VBD O
longer RBR RBR O
. . . O

On IN IN O
the DT DT O
whole JJ JJ O
, , , O
the DT DT O
differences NNS NNS O
between IN IN O
midazolam NN NN B-CHEM
and CC CC O
thiopentone NN NN B-CHEM
had VBD VBD O
no DT DT O
apparent JJ JJ O
clinical JJ JJ O
consequences NNS NNS O
. . . O

Midazolam NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
new JJ JJ O
alternative JJ JJ O
agent NN NN O
for IN IN O
induction NN NN O
in IN IN O
combination NN NN O
anaesthesia NN NN O
. . . O

Extrapyramidal NNP NNP O
side NN NN O
effects NNS NNS O
and CC CC O
oral JJ JJ O
haloperidol NN NN B-CHEM
: : : O
an DT DT O
analysis NN NN O
of IN IN O
explanatory JJ JJ O
patient NN NN O
and CC CC O
treatment NN NN O
characteristics NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
( ( ( O
EPS NNP NNP O
) ) ) O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
98 CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
haloperidol NN NN B-CHEM
. . . O

The DT DT O
incidence NN NN O
of IN IN O
parkinsonism NN NN O
was VBD VBD O
higher JJR JJR O
at IN IN O
higher JJR JJR O
doses NNS NNS O
of IN IN O
haloperidol NN NN B-CHEM
and CC CC O
in IN IN O
younger JJR JJR O
patients NNS NNS O
. . . O

Prophylactic NNP NNP O
antiparkinsonian NN NN O
medication NN NN O
was VBD VBD O
effective JJ JJ O
in IN IN O
younger JJR JJR O
but CC CC O
not RB RB O
in IN IN O
older JJR JJR O
patients NNS NNS O
. . . O

However RB RB O
, , , O
these DT DT O
medications NNS NNS O
were VBD VBD O
more RBR RBR O
effective JJ JJ O
in IN IN O
both DT DT O
young JJ JJ O
and CC CC O
old JJ JJ O
patients NNS NNS O
when WRB WRB O
given VBN VBN O
after IN IN O
parkinsonism NN NN O
developed VBN VBN O
. . . O

Akathisia NNP NNP O
was VBD VBD O
controlled VBN VBN O
by IN IN O
the DT DT O
benzodiazepine NN NN B-CHEM
lorazepam NN NN B-CHEM
in IN IN O
14 CD CD O
out IN IN O
of IN IN O
16 CD CD O
patients NNS NNS O
, , , O
while IN IN O
prophylactic JJ JJ O
antiparkinsonians NNS NNS O
were VBD VBD O
ineffective JJ JJ O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
points NNS NNS O
to TO TO O
patient VB VB O
characteristics NNS NNS O
that WDT WDT O
may MD MD O
be VB VB O
of IN IN O
significance NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
EPS NNP NNP O
due JJ JJ O
to TO TO O
haloperidol NN NN B-CHEM
. . . O

Deaths NNP NNP O
from IN IN O
local JJ JJ O
anesthetic JJ JJ O
- - - O
induced JJ JJ O
convulsions NNS NNS O
in IN IN O
mice NN NN O
. . . O

Median NNP NNP O
convulsant NN NN O
( ( ( O
CD50 NNP NNP O
) ) ) O
and CC CC O
median JJ JJ O
lethal NN NN O
( ( ( O
LD50 NNP NNP O
) ) ) O
doses NNS NNS O
of IN IN O
three CD CD O
representative JJ JJ O
local JJ JJ O
anesthetics NNS NNS O
were VBD VBD O
determined VBN VBN O
in IN IN O
adult NN NN O
mice NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
threat NN NN O
to TO TO O
life NN NN O
of IN IN O
local JJ JJ O
anesthetic JJ JJ O
- - - O
induced JJ JJ O
convulsions NNS NNS O
. . . O

The DT DT O
CD50 NNP NNP O
and CC CC O
LD50 NNP NNP O
, , , O
respectively RB RB O
, , , O
were VBD VBD O
57 CD CD O
. . . O
7 CD CD O
and CC CC O
58 CD CD O
. . . O
7 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
bupivacaine NN NN B-CHEM
, , , O
111 CD CD O
. . . O
0 CD CD O
and CC CC O
133 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
lidocaine NN NN B-CHEM
, , , O
and CC CC O
243 CD CD O
. . . O
4 CD CD O
and CC CC O
266 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
chloroprocaine NN NN B-CHEM
. . . O

When WRB WRB O
given VBN VBN O
intraperitoneally RB RB O
, , , O
bupivacaine NN NN B-CHEM
thus RB RB O
was VBD VBD O
only RB RB O
about IN IN O
twice RB RB O
as RB RB O
toxic JJ JJ O
as IN IN O
lidocaine NN NN B-CHEM
and CC CC O
four CD CD O
times NNS NNS O
as RB RB O
toxic JJ JJ O
as IN IN O
chloroprocaine NN NN B-CHEM
. . . O

Convulsions NNP NNP O
always RB RB O
preceded JJ JJ O
death NN NN O
, , , O
except IN IN O
after IN IN O
precipitous JJ JJ O
cardiopulmonary JJ JJ O
arrest NN NN O
from IN IN O
extreme JJ JJ O
doses NNS NNS O
. . . O

A DT DT O
CD50 NNP NNP O
dose NN NN O
of IN IN O
local JJ JJ O
anesthetic JJ JJ O
( ( ( O
causing VBG VBG O
convulsions NNS NNS O
in IN IN O
50 CD CD O
% NN NN O
of IN IN O
mice NN NN O
) ) ) O
was VBD VBD O
fatal JJ JJ O
in IN IN O
90 CD CD O
% NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
, , , O
in IN IN O
57 CD CD O
% NN NN O
of IN IN O
the DT DT O
chloroprocaine NN NN B-CHEM
group NN NN O
, , , O
and CC CC O
in IN IN O
6 CD CD O
% NN NN O
of IN IN O
the DT DT O
lidocaine NN NN B-CHEM
group NN NN O
. . . O

The DT DT O
narrow JJ JJ O
gap NN NN O
between IN IN O
convulsant NN NN O
and CC CC O
lethal JJ JJ O
doses NNS NNS O
of IN IN O
local JJ JJ O
anesthetics NNS NNS O
indicates VBZ VBZ O
that IN IN O
untreated JJ JJ O
convulsions NNS NNS O
present JJ JJ O
much RB RB O
more JJR JJR O
of IN IN O
a DT DT O
threat NN NN O
to TO TO O
life NN NN O
than IN IN O
heretofore NN NN O
appreciated VBD VBD O
. . . O

REM NNP NNP O
sleep VB VB O
deprivation NN NN O
changes NNS NNS O
behavioral JJ JJ O
response NN NN O
to TO TO O
catecholaminergic JJ JJ O
and CC CC O
serotonergic JJ JJ O
receptor NN NN O
activation NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
REM NNP NNP O
sleep NN NN O
deprivation NN NN O
( ( ( O
REMD NNP NNP O
) ) ) O
on IN IN O
apomorphine NN NN B-CHEM
- : : O
induced JJ JJ O
aggressiveness NN NN O
and CC CC O
quipazine NN NN B-CHEM
- - - O
induced JJ JJ O
head NN NN O
twitches NNS NNS O
in IN IN O
rats NNS NNS O
were VBD VBD O
determined VBN VBN O
. . . O

Forty CD CD O
- : : O
eight CD CD O
hr NN NN O
of IN IN O
REMD NNP NNP O
increased VBD VBD O
apomorphine NN NN B-CHEM
- : : O
induced JJ JJ O
aggressiveness NN NN O
, , , O
and CC CC O
reduced VBD VBD O
( ( ( O
immediately RB RB O
after IN IN O
completing VBG VBG O
of IN IN O
REMD NNP NNP O
) ) ) O
or CC CC O
increased VBN VBN O
( ( ( O
96 CD CD O
hr NN NN O
after IN IN O
completing VBG VBG O
of IN IN O
REMD NNP NNP O
) ) ) O
quipazine NN NN B-CHEM
- - - O
induced JJ JJ O
head NN NN O
twitches NNS NNS O
. . . O

Results NNS NNS O
are VBP VBP O
discussed VBN VBN O
in IN IN O
terms NNS NNS O
of IN IN O
similarity NN NN O
to TO TO O
pharmacological JJ JJ O
effects NNS NNS O
of IN IN O
other JJ JJ O
antidepressive JJ JJ O
treatments NNS NNS O
. . . O

Fatal NNP NNP O
aplastic JJ JJ O
anemia NN NN O
due JJ JJ O
to TO TO O
indomethacin VB VB B-CHEM
- - - O
- - - O
lymphocyte NN NN O
transformation NN NN O
tests NNS NNS O
in IN IN O
vitro NN NN O
. . . O

Although IN IN O
indomethacin NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
as IN IN O
a DT DT O
possible JJ JJ O
cause NN NN O
of IN IN O
aplastic JJ JJ O
anemia NN NN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
a DT DT O
few JJ JJ O
clinical JJ JJ O
observations NNS NNS O
, , , O
its PRP$ PRP$ O
role NN NN O
has VBZ VBZ O
not RB RB O
been VBN VBN O
definitely RB RB O
established VBN VBN O
. . . O

A DT DT O
case NN NN O
of IN IN O
fatal JJ JJ O
aplastic JJ JJ O
anemia NN NN O
is VBZ VBZ O
described VBN VBN O
in IN IN O
which WDT WDT O
no DT DT O
drugs NNS NNS O
other JJ JJ O
than IN IN O
allopurinol NN NN B-CHEM
and CC CC O
indomethacin NN NN B-CHEM
were VBD VBD O
given VBN VBN O
. . . O

Indomethacin NNP NNP B-CHEM
was VBD VBD O
first RB RB O
given VBN VBN O
four CD CD O
weeks NNS NNS O
prior RB RB O
to TO TO O
the DT DT O
onset NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

A DT DT O
positive JJ JJ O
lymphocyte NN NN O
transformation NN NN O
test NN NN O
with IN IN O
indomethacin NN NN B-CHEM
in IN IN O
vitro NN NN O
further RB RB O
substantiates VBZ VBZ O
the DT DT O
potential JJ JJ O
role NN NN O
of IN IN O
this DT DT O
drug NN NN O
in IN IN O
causing VBG VBG O
aplastic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
susceptible JJ JJ O
patient NN NN O
. . . O

Fortunately RB RB O
, , , O
this DT DT O
seems VBZ VBZ O
to TO TO O
be VB VB O
a DT DT O
very RB RB O
rare JJ JJ O
complication NN NN O
. . . O

Dose NNP NNP O
- : : O
effect NN NN O
and CC CC O
structure NN NN O
- - - O
function NN NN O
relationships NNS NNS O
in IN IN O
doxorubicin NN NN B-CHEM
cardiomyopathy NN NN O
. . . O

The DT DT O
cardiomyopathy NN NN O
( ( ( O
CM NNP NNP O
) ) ) O
produced VBN VBN O
by IN IN O
the DT DT O
anticancer NN NN O
drug NN NN O
doxorubicin NN NN B-CHEM
( ( ( O
DXR NNP NNP B-CHEM
) ) ) O
( ( ( O
Adriamycin NNP NNP B-CHEM
) ) ) O
provides VBZ VBZ O
a DT DT O
unique JJ JJ O
opportunity NN NN O
to TO TO O
analyze VB VB O
dose NN NN O
- : : O
effect NN NN O
and CC CC O
structure NN NN O
- - - O
function NN NN O
relationships NNS NNS O
during IN IN O
development NN NN O
of IN IN O
myocardial NN NN O
disease NN NN O
. . . O

We PRP PRP O
measured VBD VBD O
the DT DT O
degree NN NN O
of IN IN O
morphologic JJ JJ O
damage NN NN O
by IN IN O
ultrastructural JJ JJ O
examination NN NN O
of IN IN O
endomyocardial JJ JJ O
biopsy NN NN O
and CC CC O
the DT DT O
degree NN NN O
of IN IN O
performance NN NN O
abnormally RB RB O
by IN IN O
right JJ JJ O
heart NN NN O
catheterization NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
DXR NNP NNP B-CHEM
. . . O

Morphologic NNP NNP O
damage NN NN O
was VBD VBD O
variable JJ JJ O
but CC CC O
was VBD VBD O
proportional JJ JJ O
to TO TO O
the DT DT O
total JJ JJ O
cumulative JJ JJ O
DXR NNP NNP B-CHEM
dose NN NN O
between IN IN O
100 CD CD O
and CC CC O
600 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

Performance NNP NNP O
abnormalities NNS NNS O
correlated VBD VBD O
weakly RB RB O
with IN IN O
dose NN NN O
, , , O
exhibited VBD VBD O
a DT DT O
curvilinear JJ JJ O
relationship NN NN O
, , , O
and CC CC O
had VBD VBD O
a DT DT O
" '' '' O
threshold NN NN O
" '' '' O
for IN IN O
expression NN NN O
. . . O

Catheterization NNP NNP O
abnormalities NNS NNS O
correlated JJ JJ O
well RB RB O
with IN IN O
morphologic JJ JJ O
damage NN NN O
( ( ( O
r NN NN O
= SYM SYM O
0 CD CD O
. . . O
57 CD CD O
to TO TO O
0 CD CD O
. . . O
78 CD CD O
) ) ) O
in IN IN O
a DT DT O
subgroup NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
whom WP WP O
exercise NN NN O
hemodynamics NNS NNS O
were VBD VBD O
measured VBN VBN O
, , , O
and CC CC O
this DT DT O
relationship NN NN O
also RB RB O
exhibited VBD VBD O
a DT DT O
curvilinear NN NN O
, , , O
threshold NN NN O
configuration NN NN O
. . . O

In IN IN O
DXR NNP NNP B-CHEM
- : : O
CM NNP NNP O
myocardial NN NN O
damage NN NN O
is VBZ VBZ O
proportional JJ JJ O
to TO TO O
the DT DT O
degree NN NN O
of IN IN O
cytotoxic JJ JJ O
insult NN NN O
( ( ( O
DXR NNP NNP B-CHEM
dose NN NN O
) ) ) O
while IN IN O
myocardial NN NN O
function NN NN O
is VBZ VBZ O
preserved VBN VBN O
until IN IN O
a DT DT O
critical JJ JJ O
dose NN NN O
or CC CC O
degree NN NN O
of IN IN O
damage NN NN O
is VBZ VBZ O
reached VBN VBN O
, , , O
after IN IN O
which WDT WDT O
myocardial JJ JJ O
performance NN NN O
deteriorates NNS NNS O
rapidly RB RB O
. . . O

Massive JJ JJ O
cerebral JJ JJ O
edema NN NN O
associated VBN VBN O
with IN IN O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
in IN IN O
acetaminophen NN NN B-CHEM
overdose NN NN O
: : : O
possible JJ JJ O
role NN NN O
of IN IN O
cranial JJ JJ O
decompression NN NN O
. . . O

Cerebral NNP NNP O
edema NN NN O
may MD MD O
complicate VB VB O
the DT DT O
course NN NN O
of IN IN O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
. . . O

Response NNP NNP O
to TO TO O
conventional JJ JJ O
therapy NN NN O
has VBZ VBZ O
been VBN VBN O
disappointing VBG VBG O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
patient NN NN O
with IN IN O
fatal JJ JJ O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
fulminant NN NN O
hepatic JJ JJ O
failure NN NN O
, , , O
with IN IN O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
of IN IN O
cerebral JJ JJ O
edema NN NN O
, , , O
unresponsive JJ JJ O
to TO TO O
conventional JJ JJ O
medical JJ JJ O
therapy NN NN O
. . . O

Cranial NNP NNP O
decompression NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
. . . O

A DT DT O
justification NN NN O
of IN IN O
the DT DT O
need NN NN O
for IN IN O
further JJ JJ O
evaluation NN NN O
of IN IN O
cranial JJ JJ O
decompression NN NN O
in IN IN O
such JJ JJ O
patients NNS NNS O
is VBZ VBZ O
presented VBN VBN O
. . . O

Subjective NNP NNP O
assessment NN NN O
of IN IN O
sexual JJ JJ O
dysfunction NN NN O
of IN IN O
patients NNS NNS O
on IN IN O
long JJ JJ O
- - - O
term NN NN O
administration NN NN O
of IN IN O
digoxin NN NN B-CHEM
. . . O

Various JJ JJ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
male JJ JJ O
patients NNS NNS O
who WP WP O
have VBP VBP O
received VBN VBN O
digoxin NN NN B-CHEM
on IN IN O
a DT DT O
longterm NN NN O
basis NN NN O
have VBP VBP O
increased VBN VBN O
levels NNS NNS O
of IN IN O
serum NN NN O
estrogen NN NN B-CHEM
and CC CC O
decreased VBD VBD O
levels NNS NNS O
of IN IN O
plasma NN NN O
testosterone NN NN B-CHEM
and CC CC O
luteinizing VBG VBG O
hormone NN NN O
( ( ( O
LH NNP NNP O
) ) ) O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
links NNS NNS O
between IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
administration NN NN O
of IN IN O
digoxin NN NN B-CHEM
therapy NN NN O
and CC CC O
sexual JJ JJ O
behavior NN NN O
, , , O
and CC CC O
the DT DT O
effect NN NN O
of IN IN O
digoxin NN NN B-CHEM
on IN IN O
plasma NN NN O
levels NNS NNS O
of IN IN O
estradiol NN NN B-CHEM
, , , O
testosterone NN NN B-CHEM
, , , O
and CC CC O
LH NNP NNP O
. . . O

The DT DT O
patients NNS NNS O
of IN IN O
the DT DT O
study NN NN O
and CC CC O
control NN NN O
group NN NN O
( ( ( O
without IN IN O
digoxin NN NN B-CHEM
) ) ) O
were VBD VBD O
of IN IN O
similar JJ JJ O
cardiac NN NN O
functional JJ JJ O
capacity NN NN O
and CC CC O
age NN NN O
( ( ( O
25 CD CD O
- : : O
40 CD CD O
years NNS NNS O
) ) ) O
and CC CC O
were VBD VBD O
randomly RB RB O
selected VBN VBN O
from IN IN O
the DT DT O
rheumatic JJ JJ O
heart NN NN O
disease NN NN O
patients NNS NNS O
. . . O

A DT DT O
subjective JJ JJ O
assessment NN NN O
of IN IN O
sexual JJ JJ O
behavior NN NN O
in IN IN O
the DT DT O
study NN NN O
and CC CC O
control NN NN O
groups NNS NNS O
was VBD VBD O
carried VBN VBN O
out IN IN O
, , , O
using VBG VBG O
parameters NNS NNS O
such JJ JJ O
as IN IN O
sexual JJ JJ O
desire NN NN O
, , , O
sexual JJ JJ O
excitement NN NN O
, , , O
and CC CC O
frequency NN NN O
of IN IN O
sexual JJ JJ O
relations NNS NNS O
. . . O

Personal NNP NNP O
interviews NNS NNS O
and CC CC O
a DT DT O
questionnaire NN NN O
were VBD VBD O
also RB RB O
used VBN VBN O
for IN IN O
the DT DT O
evaluation NN NN O
of IN IN O
sexual JJ JJ O
behavior NN NN O
. . . O

The DT DT O
findings NNS NNS O
support VBP VBP O
the DT DT O
reports NNS NNS O
concerning VBG VBG O
digoxin NN NN B-CHEM
effect NN NN O
on IN IN O
plasma NN NN O
estradiol NN NN B-CHEM
, , , O
testosterone NN NN B-CHEM
, , , O
and CC CC O
LH NNP NNP O
. . . O

The DT DT O
differences NNS NNS O
in IN IN O
the DT DT O
means NNS NNS O
were VBD VBD O
significant JJ JJ O
. . . O

Tests NNP NNP O
used VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
changes NNS NNS O
in IN IN O
sexual JJ JJ O
behavior NN NN O
showed VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
sexual JJ JJ O
desire NN NN O
, , , O
sexual JJ JJ O
excitement NN NN O
phase NN NN O
( ( ( O
erection NN NN O
) ) ) O
, , , O
and CC CC O
frequency NN NN O
of IN IN O
sexual JJ JJ O
relations NNS NNS O
in IN IN O
the DT DT O
study NN NN O
group NN NN O
. . . O

Endometrial NNP NNP O
carcinoma NN NN O
after IN IN O
Hodgkin NNP NNP O
disease NN NN O
in IN IN O
childhood NN NN O
. . . O

A DT DT O
34 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
developed VBN VBN O
metastic JJ JJ O
endometrial JJ JJ O
carcinoma NN NN O
after IN IN O
Hodgkin NNP NNP O
disease NN NN O
in IN IN O
childhood NN NN O
. . . O

She PRP PRP O
had VBD VBD O
ovarian JJ JJ O
failure NN NN O
after IN IN O
abdominal JJ JJ O
irradiation NN NN O
and CC CC O
chemotherapy NN NN O
for IN IN O
Hodgkin NNP NNP O
disease NN NN O
, , , O
and CC CC O
received VBD VBD O
exogenous JJ JJ O
estrogens NNS NNS B-CHEM
, , , O
a DT DT O
treatment NN NN O
implicated VBN VBN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
endometrial JJ JJ O
cancer NN NN O
in IN IN O
menopausal NN NN O
women NNS NNS O
. . . O

Young JJ JJ O
women NNS NNS O
on IN IN O
replacement NN NN O
estrogens NNS NNS B-CHEM
for IN IN O
ovarian JJ JJ O
failure NN NN O
after IN IN O
cancer NN NN O
therapy NN NN O
may MD MD O
also RB RB O
have VB VB O
increased VBN VBN O
risk NN NN O
of IN IN O
endometrial JJ JJ O
carcinoma NN NN O
and CC CC O
should MD MD O
be VB VB O
examined VBN VBN O
periodically RB RB O
. . . O

Long JJ JJ O
- - - O
term NN NN O
lithium NN NN B-CHEM
treatment NN NN O
and CC CC O
the DT DT O
kidney NN NN O
. . . O

Interim NNP NNP O
report NN NN O
on IN IN O
fifty NN NN O
patients NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
a DT DT O
report NN NN O
on IN IN O
the DT DT O
first JJ JJ O
part NN NN O
of IN IN O
our PRP$ PRP$ O
study NN NN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
lithium NN NN B-CHEM
treatment NN NN O
on IN IN O
the DT DT O
kidney NN NN O
. . . O

Creatinine NNP NNP B-CHEM
clearance NN NN O
, , , O
maximum NN NN O
urinary JJ JJ O
osmolality NN NN O
and CC CC O
24 CD CD O
hour NN NN O
urine NN NN O
volume NN NN O
have VBP VBP O
been VBN VBN O
tested VBN VBN O
in IN IN O
50 CD CD O
affectively RB RB O
ill JJ JJ O
patients NNS NNS O
who WP WP O
have VBP VBP O
been VBN VBN O
on IN IN O
long JJ JJ O
- - - O
term NN NN O
lithium NN NN B-CHEM
for IN IN O
more JJR JJR O
than IN IN O
one CD CD O
year NN NN O
. . . O

These DT DT O
findings NNS NNS O
have VBP VBP O
been VBN VBN O
compared VBN VBN O
with IN IN O
norms NNS NNS O
and CC CC O
with IN IN O
values NNS NNS O
of IN IN O
the DT DT O
same JJ JJ O
tests NNS NNS O
from IN IN O
screening VBG VBG O
prior RB RB O
to TO TO O
lithium NN NN B-CHEM
, , , O
available JJ JJ O
for IN IN O
most JJS JJS O
of IN IN O
our PRP$ PRP$ O
patients NNS NNS O
. . . O

No DT DT O
evidence NN NN O
was VBD VBD O
found VBN VBN O
for IN IN O
any DT DT O
reduction NN NN O
of IN IN O
glomerular NN NN O
filtration NN NN O
during IN IN O
lithium NN NN B-CHEM
treatment NN NN O
. . . O

Low NNP NNP O
clearance NN NN O
values NNS NNS O
found VBD VBD O
in IN IN O
several JJ JJ O
patients NNS NNS O
could MD MD O
be VB VB O
accounted VBN VBN O
for IN IN O
by IN IN O
their PRP$ PRP$ O
age NN NN O
and CC CC O
their PRP$ PRP$ O
pre NN NN O
- - - O
lithium NN NN B-CHEM
values NNS NNS O
. . . O

Urinary NNP NNP O
concentration NN NN O
defect NN NN O
appeared VBD VBD O
frequent JJ JJ O
but CC CC O
the DT DT O
extent NN NN O
of IN IN O
the DT DT O
impairment NN NN O
is VBZ VBZ O
difficult JJ JJ O
to TO TO O
assess VB VB O
because IN IN O
of IN IN O
the DT DT O
uncertainty NN NN O
about IN IN O
the DT DT O
norms NNS NNS O
applicable JJ JJ O
to TO TO O
this DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
. . . O

The DT DT O
concentration NN NN O
defect NN NN O
appeared VBD VBD O
reversible JJ JJ O
, , , O
at IN IN O
least JJS JJS O
in IN IN O
part NN NN O
. . . O

Polyuria NNP NNP O
above IN IN O
3 CD CD O
litres NNS NNS O
/ NN NN O
24 CD CD O
hours NNS NNS O
was VBD VBD O
found VBN VBN O
in IN IN O
10 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

An DT DT O
attempt NN NN O
is VBZ VBZ O
made VBN VBN O
to TO TO O
draw VB VB O
practical JJ JJ O
conclusions NNS NNS O
from IN IN O
the DT DT O
preliminary JJ JJ O
findings NNS NNS O
. . . O

Nephrotoxicity NNP NNP O
of IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
and CC CC O
FK506 NNP NNP B-CHEM
: : : O
inhibition NN NN O
of IN IN O
calcineurin NN NN O
phosphatase NN NN O
. . . O

Cyclosporin NNP NNP B-CHEM
A DT DT I-CHEM
( ( ( O
CsA NNP NNP B-CHEM
; : : O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
Fujimycine NNP NNP B-CHEM
( ( ( O
FK506 NNP NNP B-CHEM
; : : O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
but CC CC O
not RB RB O
the DT DT O
related VBN VBN O
macrolide NN NN B-CHEM
immunosuppressant JJ JJ O
rapamycin NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
caused VBD VBD O
a DT DT O
reduction NN NN O
of IN IN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
, , , O
degenerative JJ JJ O
changes NNS NNS O
of IN IN O
proximal NN NN O
tubular NN NN O
epithelium NN NN O
, , , O
and CC CC O
hypertrophy NN NN O
of IN IN O
the DT DT O
juxtaglomerular NN NN O
apparatus NN NN O
in IN IN O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
when WRB WRB O
given VBN VBN O
for IN IN O
10 CD CD O
days NNS NNS O
. . . O

The DT DT O
molecular JJ JJ O
mechanisms NNS NNS O
of IN IN O
CsA NNP NNP B-CHEM
and CC CC O
FK506 NNP NNP B-CHEM
toxicity NN NN O
were VBD VBD O
investigated VBN VBN O
. . . O

Cyclophilin NNP NNP O
A DT DT O
and CC CC O
FK506 NNP NNP B-CHEM
- : : O
binding JJ JJ O
protein NN NN O
, , , O
the DT DT O
main JJ JJ O
intracytoplasmic JJ JJ O
receptors NNS NNS O
for IN IN O
CsA NNP NNP B-CHEM
and CC CC O
FK506 NNP NNP B-CHEM
, , , O
respectively RB RB O
, , , O
were VBD VBD O
each DT DT O
detected VBN VBN O
in IN IN O
renal JJ JJ O
tissue NN NN O
extract NN NN O
. . . O

In IN IN O
the DT DT O
kidney NN NN O
, , , O
high JJ JJ O
levels NNS NNS O
of IN IN O
immunoreactive JJ JJ O
and CC CC O
enzymatically RB RB O
active JJ JJ O
calcineurin NN NN O
were VBD VBD O
found VBN VBN O
which WDT WDT O
were VBD VBD O
inhibited VBN VBN O
by IN IN O
the DT DT O
immunosuppressants NNS NNS O
CsA NNP NNP B-CHEM
and CC CC O
FK506 NNP NNP B-CHEM
, , , O
but CC CC O
not RB RB O
by IN IN O
rapamycin NN NN B-CHEM
. . . O

Finally RB RB O
, , , O
specific JJ JJ O
immunophilin NN NN O
- - - O
drug NN NN O
- - - O
calcineurin NN NN O
complexes NNS NNS O
formed VBN VBN O
only RB RB O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
CsA NNP NNP B-CHEM
and CC CC O
FK506 NNP NNP B-CHEM
, , , O
but CC CC O
not RB RB O
rapamycin VB VB B-CHEM
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
nephrotoxic JJ JJ O
effects NNS NNS O
of IN IN O
CsA NNP NNP B-CHEM
and CC CC O
FK506 NNP NNP B-CHEM
is VBZ VBZ O
likely JJ JJ O
mediated VBN VBN O
through IN IN O
binding JJ JJ O
to TO TO O
renal JJ JJ O
immunophilin NN NN O
and CC CC O
inhibiting VBG VBG O
calcineurin NN NN O
phosphatase NN NN O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
high JJ JJ O
dose NN NN O
carboplatin NN NN B-CHEM
chemotherapy NN NN O
. . . O

Carboplatin NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
cause VB VB O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
when WRB WRB O
administered VBN VBN O
in IN IN O
high JJ JJ O
doses NNS NNS O
to TO TO O
adult VB VB O
patients NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
4 CD CD O
1 CD CD O
/ NN NN O
2 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
who WP WP O
was VBD VBD O
treated VBN VBN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
carboplatin NN NN B-CHEM
for IN IN O
metastatic JJ JJ O
parameningeal NN NN O
embryonal JJ JJ O
rhabdomyosarcoma NN NN O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
developed VBN VBN O
followed VBN VBN O
by IN IN O
a DT DT O
slow JJ JJ O
partial JJ JJ O
recovery NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

Possible JJ JJ O
contributing JJ JJ O
factors NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Clinical NNP NNP O
evaluation NN NN O
on IN IN O
combined VBN VBN O
administration NN NN O
of IN IN O
oral JJ JJ O
prostacyclin NN NN B-CHEM
analogue NN NN O
beraprost NN NN B-CHEM
and CC CC O
phosphodiesterase NN NN O
inhibitor NN NN O
cilostazol NN NN B-CHEM
. . . O

Among IN IN O
various JJ JJ O
oral JJ JJ O
antiplatelets NNS NNS O
, , , O
a DT DT O
combination NN NN O
of IN IN O
a DT DT O
novel NN NN O
prostacyclin NN NN B-CHEM
analogue NN NN O
beraprost NN NN B-CHEM
( ( ( O
BPT NNP NNP B-CHEM
) ) ) O
and CC CC O
a DT DT O
potent JJ JJ O
phosphodiesterase NN NN O
inhibitor NN NN O
cilostazol NN NN B-CHEM
( ( ( O
CLZ NNP NNP B-CHEM
) ) ) O
may MD MD O
result VB VB O
in IN IN O
untoward JJ JJ O
clinical JJ JJ O
effects NNS NNS O
due JJ JJ O
to TO TO O
possible JJ JJ O
synergistic JJ JJ O
elevation NN NN O
of IN IN O
intracellular JJ JJ O
cAMP NN NN B-CHEM
( ( ( O
cyclic JJ JJ B-CHEM
adenosine NN NN I-CHEM
3 CD CD I-CHEM
' POS POS I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
monophosphate NN NN I-CHEM
) ) ) O
. . . O

Thereby NNP NNP O
, , , O
a DT DT O
clinical JJ JJ O
study NN NN O
of IN IN O
the DT DT O
combined VBN VBN O
administration NN NN O
of IN IN O
the DT DT O
two CD CD O
agents NNS NNS O
was VBD VBD O
attempted VBN VBN O
. . . O

Twelve NNP NNP O
healthy JJ JJ O
volunteers NNS NNS O
were VBD VBD O
assigned VBN VBN O
to TO TO O
take VB VB O
BPT NNP NNP B-CHEM
/ NN NN O
CLZ NNP NNP B-CHEM
in IN IN O
the DT DT O
following VBG VBG O
schedule NN NN O
; : : O
BPT NNP NNP B-CHEM
: : : O
40 CD CD O
micrograms NNS NNS O
at IN IN O
day NN NN O
1 CD CD O
and CC CC O
120 CD CD O
micrograms NNS NNS O
t NN NN O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O
from IN IN O
day NN NN O
7 CD CD O
to TO TO O
14 CD CD O
, , , O
CLZ NNP NNP B-CHEM
: : : O
200 CD CD O
mg NN NN O
t NN NN O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O
from IN IN O
day NN NN O
3 CD CD O
to TO TO O
14 CD CD O
. . . O

At IN IN O
various JJ JJ O
time NN NN O
intervals NNS NNS O
, , , O
physical JJ JJ O
examination NN NN O
and CC CC O
blood NN NN O
collection NN NN O
for IN IN O
ex NN NN O
vivo NN NN O
platelet NN NN O
aggregation NN NN O
and CC CC O
determination NN NN O
of IN IN O
intraplatelet NN NN O
cAMP NN NN B-CHEM
were VBD VBD O
performed VBN VBN O
. . . O

Throughout IN IN O
the DT DT O
observation NN NN O
period NN NN O
, , , O
no DT DT O
significant JJ JJ O
alteration NN NN O
in IN IN O
vital JJ JJ O
signs NNS NNS O
was VBD VBD O
observed VBN VBN O
. . . O

Seven CD CD O
out IN IN O
of IN IN O
12 CD CD O
subjects NNS NNS O
experienced VBN VBN O
headache NN NN O
of IN IN O
a DT DT O
short JJ JJ O
duration NN NN O
accompanying VBG VBG O
facial JJ JJ O
flush NN NN O
in IN IN O
one CD CD O
and CC CC O
nausea NN NN O
in IN IN O
one CD CD O
, , , O
especially RB RB O
after IN IN O
ingestion NN NN O
of IN IN O
CLZ NNP NNP B-CHEM
. . . O

All DT DT O
of IN IN O
these DT DT O
symptoms NNS NNS O
, , , O
probably RB RB O
caused VBN VBN O
by IN IN O
the DT DT O
vasodilating VBG VBG O
effect NN NN O
of IN IN O
the DT DT O
two CD CD O
agents NNS NNS O
, , , O
were VBD VBD O
of IN IN O
mild NN NN O
degree NN NN O
and CC CC O
no DT DT O
special JJ JJ O
treatment NN NN O
was VBD VBD O
required VBN VBN O
. . . O

Intraplatelet NNP NNP O
cAMP NN NN B-CHEM
content NN NN O
was VBD VBD O
gradually RB RB O
but CC CC O
significantly RB RB O
increased VBN VBN O
to TO TO O
9 CD CD O
. . . O
84 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
59 CD CD O
pmol NN NN O
per IN IN O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
platelets NNS NNS O
at IN IN O
day NN NN O
14 CD CD O
in IN IN O
comparison NN NN O
with IN IN O
the DT DT O
initial JJ JJ O
value NN NN O
( ( ( O
6 CD CD O
. . . O
87 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
25 CD CD O
pmol NN NN O
) ) ) O
. . . O

The DT DT O
platelet NN NN O
aggregability NN NN O
was VBD VBD O
significantly RB RB O
suppressed VBN VBN O
at IN IN O
various JJ JJ O
time NN NN O
intervals NNS NNS O
but CC CC O
no DT DT O
additive JJ JJ O
or CC CC O
synergistic JJ JJ O
inhibitory NN NN O
effect NN NN O
by IN IN O
the DT DT O
combined JJ JJ O
administration NN NN O
was VBD VBD O
noted VBN VBN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
the DT DT O
combined JJ JJ O
administration NN NN O
of IN IN O
BPT NNP NNP B-CHEM
/ NN NN O
CLZ NNP NNP B-CHEM
is VBZ VBZ O
safe JJ JJ O
at IN IN O
doses NNS NNS O
used VBN VBN O
in IN IN O
the DT DT O
study NN NN O
, , , O
though IN IN O
the DT DT O
beneficial JJ JJ O
clinical JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
combined VBN VBN O
administration NN NN O
has VBZ VBZ O
yet RB RB O
to TO TO O
be VB VB O
elucidated VBN VBN O
. . . O

Pravastatin NNP NNP B-CHEM
- - - O
associated VBN VBN O
myopathy NN NN O
. . . O

Report NNP NNP O
of IN IN O
a DT DT O
case NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
inflammatory JJ JJ O
myopathy NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
pravastatin NN NN B-CHEM
, , , O
a DT DT O
new JJ JJ O
hydrophilic JJ JJ O
3 CD CD O
- : : O
hydroxy NN NN O
- : : O
3 CD CD O
methylglutaril NN NN O
coenzyme NN NN O
A DT DT O
reductase NN NN O
inhibitor NN NN O
, , , O
is VBZ VBZ O
reported VBN VBN O
. . . O

The DT DT O
patient NN NN O
, , , O
a DT DT O
69 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
was VBD VBD O
affected VBN VBN O
by IN IN O
non NN NN O
- - - O
insulin NN NN O
- - - O
dependent JJ JJ O
diabetes NNS NNS O
mellitus NN NN O
and CC CC O
hypertension NN NN O
. . . O

He PRP PRP O
assumed VBD VBD O
pravastatin NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
because IN IN O
of IN IN O
hypercholesterolemia NN NN O
. . . O

He PRP PRP O
was VBD VBD O
admitted VBN VBN O
with IN IN O
acute JJ JJ O
myopathy NN NN O
of IN IN O
the DT DT O
lower JJR JJR O
limbs NNS NNS O
which WDT WDT O
resolved VBD VBD O
in IN IN O
a DT DT O
few JJ JJ O
days NNS NNS O
after IN IN O
pravastatin NN NN B-CHEM
discontinuation NN NN O
. . . O

A DT DT O
previously RB RB O
unknown JJ JJ O
hypothyroidism NN NN O
, , , O
probably RB RB O
due JJ JJ O
to TO TO O
chronic JJ JJ O
autoimmune JJ JJ O
thyroiditis NN NN O
, , , O
was VBD VBD O
evidenced VBN VBN O
. . . O

Muscle NNP NNP O
biopsy NN NN O
( ( ( O
left VBN VBN O
gastrocnemius NN NN O
) ) ) O
revealed VBD VBD O
a DT DT O
perimysial JJ JJ O
and CC CC O
endomysial JJ JJ O
inflammatory JJ JJ O
infiltrate NN NN O
with IN IN O
a DT DT O
prevalence NN NN O
of IN IN O
CD4 NNP NNP O
+ NN NN O
lymphocytes NNS NNS O
. . . O

While IN IN O
lovastatin NN NN B-CHEM
and CC CC O
simvastatin NN NN B-CHEM
have VBP VBP O
been VBN VBN O
associated VBN VBN O
with IN IN O
toxic JJ JJ O
myopathy NN NN O
, , , O
pravastatin NN NN B-CHEM
- - - O
associated VBN VBN O
myopathy NN NN O
could MD MD O
represent VB VB O
a DT DT O
distinct JJ JJ O
, , , O
inflammatory JJ JJ O
entity NN NN O
. . . O

Reversal NNP NNP O
of IN IN O
ammonia NN NN B-CHEM
coma NN NN O
in IN IN O
rats NNS NNS O
by IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
: : : O
a DT DT O
peripheral JJ JJ O
effect NN NN O
. . . O

Ammonia NNP NNP B-CHEM
coma NN NN O
was VBD VBD O
produced VBN VBN O
in IN IN O
rats NNS NNS O
within IN IN O
10 CD CD O
to TO TO O
15 CD CD O
minutes NNS NNS O
of IN IN O
an DT DT O
intraperitonealinjection NN NN O
of IN IN O
1 CD CD O
. . . O
7 CD CD O
mmol NN NN O
NH4CL NNP NNP B-CHEM
. . . O

This DT DT O
coma NN NN O
was VBD VBD O
prevented VBN VBN O
with IN IN O
1 CD CD O
. . . O
68 CD CD O
mmol NN NN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
given VBN VBN O
by IN IN O
gastric JJ JJ O
intubation NN NN O
15 CD CD O
minutes NNS NNS O
before IN IN O
the DT DT O
ammonium NN NN B-CHEM
salt NN NN I-CHEM
injection NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
was VBD VBD O
correlated VBN VBN O
with IN IN O
a DT DT O
decrease NN NN O
in IN IN O
blood NN NN O
and CC CC O
brain NN NN O
ammonia NN NN B-CHEM
, , , O
an DT DT O
increase NN NN O
in IN IN O
brain NN NN O
dopamine NN NN B-CHEM
, , , O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
renal JJ JJ O
excretion NN NN O
of IN IN O
ammonia NN NN B-CHEM
and CC CC O
urea NN NN B-CHEM
. . . O

Intraventricular NNP NNP O
infusion NN NN O
of IN IN O
dopamine NN NN B-CHEM
sufficient JJ JJ O
to TO TO O
raise VB VB O
the DT DT O
brain NN NN O
dopamine NN NN B-CHEM
to TO TO O
the DT DT O
same JJ JJ O
extent NN NN O
did VBD VBD O
not RB RB O
prevent VB VB O
the DT DT O
ammonia NN NN B-CHEM
coma NN NN O
nor CC CC O
affect VB VB O
the DT DT O
blood NN NN O
and CC CC O
brain NN NN O
ammonia NN NN B-CHEM
concentrations NNS NNS O
. . . O

Bilateral NNP NNP O
nephrectomy NN NN O
eliminated VBD VBD O
the DT DT O
beneficial JJ JJ O
effect NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
dopa NN NN I-CHEM
on IN IN O
blood NN NN O
and CC CC O
brain NN NN O
ammonia NN NN B-CHEM
and CC CC O
the DT DT O
ammonia NN NN B-CHEM
coma NN NN O
was VBD VBD O
not RB RB O
prevented VBN VBN O
. . . O

Thus RB RB O
, , , O
the DT DT O
reduction NN NN O
in IN IN O
blood NN NN O
and CC CC O
brain NN NN O
ammonia NN NN B-CHEM
and CC CC O
the DT DT O
prevention NN NN O
of IN IN O
ammonia NN NN B-CHEM
coma NN NN O
after IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
, , , O
can MD MD O
be VB VB O
accounted VBN VBN O
for IN IN O
by IN IN O
the DT DT O
peripheral JJ JJ O
effect NN NN O
of IN IN O
dopamine NN NN B-CHEM
on IN IN O
renal JJ JJ O
function NN NN O
rather RB RB O
than IN IN O
its PRP$ PRP$ O
central JJ JJ O
action NN NN O
. . . O

These DT DT O
results NNS NNS O
provide VBP VBP O
a DT DT O
reasonable JJ JJ O
explanation NN NN O
for IN IN O
the DT DT O
beneficial JJ JJ O
effects NNS NNS O
observed VBD VBD O
in IN IN O
some DT DT O
encephalopathic JJ JJ O
patients NNS NNS O
receiving VBG VBG O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
. . . O

Etoposide NNP NNP B-CHEM
- - - O
related VBN VBN O
myocardial NN NN O
infarction NN NN O
. . . O

The DT DT O
occurrence NN NN O
of IN IN O
a DT DT O
myocardial NN NN O
infarction NN NN O
is VBZ VBZ O
reported VBN VBN O
after IN IN O
chemotherapy NN NN O
containing VBG VBG O
etoposide NN NN B-CHEM
, , , O
in IN IN O
a DT DT O
man NN NN O
with IN IN O
no DT DT O
risk NN NN O
factors NNS NNS O
for IN IN O
coronary JJ JJ O
heart NN NN O
disease NN NN O
. . . O

Possible JJ JJ O
causal NN NN O
mechanisms NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Halogenated NNP NNP O
anesthetics NNS NNS O
form VBP VBP O
liver NN NN O
adducts NNS NNS O
and CC CC O
antigens NNS NNS O
that IN IN O
cross JJ JJ O
- : : O
react NN NN O
with IN IN O
halothane NN NN B-CHEM
- - - O
induced JJ JJ O
antibodies NNS NNS O
. . . O

Two CD CD O
halogenated VBN VBN O
anesthetics NNS NNS O
, , , O
enflurane NN NN B-CHEM
and CC CC O
isoflurane NN NN B-CHEM
, , , O
have VBP VBP O
been VBN VBN O
associated VBN VBN O
with IN IN O
an DT DT O
allergic JJ JJ O
- - - O
type NN NN O
hepatic JJ JJ O
injury NN NN O
both DT DT O
alone RB RB O
and CC CC O
following VBG VBG O
previous JJ JJ O
exposure NN NN O
to TO TO O
halothane NN NN B-CHEM
. . . O

Halothane NNP NNP B-CHEM
hepatitis NN NN O
appears VBZ VBZ O
to TO TO O
involve VB VB O
an DT DT O
aberrant NN NN O
immune JJ JJ O
response NN NN O
. . . O

An DT DT O
antibody NN NN O
response NN NN O
to TO TO O
a DT DT O
protein NN NN O
- - - O
bound VBN VBN O
biotransformation NN NN O
product NN NN O
( ( ( O
trifluoroacetyl NN NN B-CHEM
adduct NN NN O
) ) ) O
has VBZ VBZ O
been VBN VBN O
detected VBN VBN O
on IN IN O
halothane JJ JJ B-CHEM
hepatitis NN NN O
patients NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
performed VBN VBN O
to TO TO O
determine VB VB O
cross NN NN O
- - - O
reactivity NN NN O
between IN IN O
enflurane NN NN B-CHEM
and CC CC O
isoflurane NN NN B-CHEM
with IN IN O
the DT DT O
hypersensitivity NN NN O
induced VBN VBN O
by IN IN O
halothane NN NN B-CHEM
. . . O

The DT DT O
subcellular NN NN O
and CC CC O
lobular JJ JJ O
production NN NN O
of IN IN O
hepatic JJ JJ O
neoantigens NNS NNS O
recognized VBN VBN O
by IN IN O
halothane NN NN B-CHEM
- - - O
induced JJ JJ O
antibodies NNS NNS O
following VBG VBG O
enflurane NN NN B-CHEM
and CC CC O
isoflurane NN NN B-CHEM
, , , O
and CC CC O
the DT DT O
biochemical JJ JJ O
nature NN NN O
of IN IN O
these DT DT O
neoantigens NNS NNS O
was VBD VBD O
investigated VBN VBN O
in IN IN O
two CD CD O
animal NN NN O
models NNS NNS O
. . . O

Enflurane NNP NNP B-CHEM
administration NN NN O
resulted VBD VBD O
in IN IN O
neoantigens NNS NNS O
detected VBD VBD O
in IN IN O
both DT DT O
the DT DT O
microsomal NN NN O
and CC CC O
cytosolic JJ JJ O
fraction NN NN O
of IN IN O
liver NN NN O
homogenates NNS NNS O
and CC CC O
in IN IN O
the DT DT O
centrilobular JJ JJ O
region NN NN O
of IN IN O
the DT DT O
liver NN NN O
. . . O

In IN IN O
the DT DT O
same JJ JJ O
liver NN NN O
, , , O
biochemical JJ JJ O
analysis NN NN O
detected VBD VBD O
fluorinated JJ JJ O
liver NN NN O
adducts NNS NNS O
that WDT WDT O
were VBD VBD O
up IN IN O
to TO TO O
20 CD CD O
- : : O
fold VB VB O
greater JJR JJR O
in IN IN O
guinea NN NN O
pigs NNS NNS O
than IN IN O
in IN IN O
rats NNS NNS O
. . . O

This DT DT O
supports VBZ VBZ O
and CC CC O
extends VBZ VBZ O
previous JJ JJ O
evidence NN NN O
for IN IN O
a DT DT O
mechanism NN NN O
by IN IN O
which WDT WDT O
enflurane VBP VBP B-CHEM
and CC CC O
/ NN NN O
or CC CC O
isoflurane NN NN B-CHEM
could MD MD O
produce VB VB O
a DT DT O
hypersensitivity NN NN O
condition NN NN O
similar JJ JJ O
to TO TO O
that DT DT O
of IN IN O
halothane JJ JJ B-CHEM
hepatitis NN NN O
either CC CC O
alone RB RB O
or CC CC O
subsequent JJ JJ O
to TO TO O
halothane VB VB B-CHEM
administration NN NN O
. . . O

The DT DT O
guinea NN NN O
pig NN NN O
would MD MD O
appear VB VB O
to TO TO O
be VB VB O
a DT DT O
useful JJ JJ O
model NN NN O
for IN IN O
further JJ JJ O
investigations NNS NNS O
of IN IN O
the DT DT O
immunological JJ JJ O
response NN NN O
to TO TO O
these DT DT O
antigens NNS NNS O
. . . O

Cholinergic NNP NNP O
toxicity NN NN O
resulting VBG VBG O
from IN IN O
ocular JJ JJ O
instillation NN NN O
of IN IN O
echothiophate NN NN B-CHEM
iodide NN NN I-CHEM
eye NN NN O
drops NNS NNS O
. . . O

A DT DT O
patient NN NN O
developed VBD VBD O
a DT DT O
severe JJ JJ O
cholinergic JJ JJ O
syndrome NN NN O
from IN IN O
the DT DT O
use NN NN O
of IN IN O
echothiophate NN NN B-CHEM
iodide NN NN I-CHEM
ophthalmic JJ JJ O
drops NNS NNS O
, , , O
presented VBN VBN O
with IN IN O
profound JJ JJ O
muscle NN NN O
weakness NN NN O
and CC CC O
was VBD VBD O
initially RB RB O
given VBN VBN O
the DT DT O
diagnosis NN NN O
of IN IN O
myasthenia NN NN O
gravis NN NN O
. . . O

Red NNP NNP O
blood NN NN O
cell NN NN O
and CC CC O
serum NN NN O
cholinesterase NN NN O
levels NNS NNS O
were VBD VBD O
severely RB RB O
depressed VBN VBN O
and CC CC O
symptoms NNS NNS O
resolved VBD VBD O
spontaneously RB RB O
following VBG VBG O
discontinuation NN NN O
of IN IN O
the DT DT O
eye NN NN O
drops NNS NNS O
. . . O

Seizure NNP NNP O
after IN IN O
flumazenil NN NN B-CHEM
administration NN NN O
in IN IN O
a DT DT O
pediatric JJ JJ O
patient NN NN O
. . . O

Flumazenil NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
benzodiazepine NN NN B-CHEM
receptor NN NN O
antagonist NN NN O
used VBN VBN O
to TO TO O
reverse VB VB O
sedation NN NN O
and CC CC O
respiratory JJ JJ O
depression NN NN O
induced VBN VBN O
by IN IN O
benzodiazepines NNS NNS B-CHEM
. . . O

Seizures NNP NNP O
and CC CC O
cardiac JJ JJ O
arrhythmias NNS NNS O
have VBP VBP O
complicated VBN VBN O
its PRP$ PRP$ O
use NN NN O
in IN IN O
adult NN NN O
patients NNS NNS O
. . . O

Overdose NNP NNP O
patients NNS NNS O
who WP WP O
have VBP VBP O
coingested VBN VBN O
tricyclic JJ JJ O
antidepressants NNS NNS O
have VBP VBP O
a DT DT O
higher JJR JJR O
risk NN NN O
of IN IN O
these DT DT O
complications NNS NNS O
. . . O

Little NNP NNP O
information NN NN O
exists VBZ VBZ O
concerning VBG VBG O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
flumazenil NN NN B-CHEM
in IN IN O
children NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
occurrence NN NN O
of IN IN O
a DT DT O
generalized JJ JJ O
tonic NN NN O
- - - O
clonic JJ JJ O
seizure NN NN O
in IN IN O
a DT DT O
pediatric JJ JJ O
patient NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
flumazenil NN NN B-CHEM
. . . O

Phase NN NN O
I PRP PRP O
trial NN NN O
of IN IN O
13 CD CD B-CHEM
- : : I-CHEM
cis NN NN I-CHEM
- : : I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
in IN IN O
children NNS NNS O
with IN IN O
neuroblastoma NN NN O
following VBG VBG O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
Treatment NN NN O
of IN IN O
neuroblastoma NN NN O
cell NN NN O
lines NNS NNS O
with IN IN O
13 CD CD B-CHEM
- : : I-CHEM
cis NN NN I-CHEM
- : : I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
cis NN NN B-CHEM
- - - I-CHEM
RA NNP NNP I-CHEM
) ) ) O
can MD MD O
cause VB VB O
sustained JJ JJ O
inhibition NN NN O
of IN IN O
proliferation NN NN O
. . . O

Since IN IN O
cis NN NN B-CHEM
- : : I-CHEM
RA NNP NNP I-CHEM
has VBZ VBZ O
demonstrated VBN VBN O
clinical JJ JJ O
responses NNS NNS O
in IN IN O
neuroblastoma NN NN O
patients NNS NNS O
, , , O
it PRP PRP O
may MD MD O
be VB VB O
effective JJ JJ O
in IN IN O
preventing VBG VBG O
relapse NN NN O
after IN IN O
cytotoxic NN NN O
therapy NN NN O
. . . O

This DT DT O
phase NN NN O
I PRP PRP O
trial NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
maximal NN NN O
- - - O
tolerated JJ JJ O
dosage NN NN O
( ( ( O
MTD NNP NNP O
) ) ) O
, , , O
toxicities NNS NNS O
, , , O
and CC CC O
pharmacokinetics NNS NNS O
of IN IN O
cis NN NN B-CHEM
- - - I-CHEM
RA NNP NNP I-CHEM
administered VBD VBD O
on IN IN O
an DT DT O
intermittent NN NN O
schedule NN NN O
in IN IN O
children NNS NNS O
with IN IN O
neuroblastoma NN NN O
following VBG VBG O
bone NN NN O
marrow NN NN O
transplantation NN NN O
( ( ( O
BMT NNP NNP O
) ) ) O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Fifty CD CD O
- : : O
one CD CD O
assessable JJ JJ O
patients NNS NNS O
, , , O
2 CD CD O
to TO TO O
12 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
, , , O
were VBD VBD O
treated VBN VBN O
with IN IN O
oral JJ JJ O
cis NN NN B-CHEM
- - - I-CHEM
RA NNP NNP I-CHEM
administered VBD VBD O
in IN IN O
two CD CD O
equally RB RB O
divided VBD VBD O
doses NNS NNS O
daily RB RB O
for IN IN O
2 CD CD O
weeks NNS NNS O
, , , O
followed VBN VBN O
by IN IN O
a DT DT O
2 CD CD O
- : : O
week NN NN O
rest NN NN O
period NN NN O
, , , O
for IN IN O
up IN IN O
to TO TO O
12 CD CD O
courses NNS NNS O
. . . O

The DT DT O
dose NN NN O
was VBD VBD O
escalated VBN VBN O
from IN IN O
100 CD CD O
to TO TO O
200 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
until IN IN O
dose NN NN O
- - - O
limiting VBG VBG O
toxicity NN NN O
( ( ( O
DLT NNP NNP O
) ) ) O
was VBD VBD O
observed VBN VBN O
. . . O

A DT DT O
single JJ JJ O
intrapatient NN NN O
dose NN NN O
escalation NN NN O
was VBD VBD O
permitted VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
MTD NNP NNP O
of IN IN O
cis NN NN B-CHEM
- - - I-CHEM
RA NNP NNP I-CHEM
was VBD VBD O
160 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
. . . O

Dose NNP NNP O
- : : O
limiting VBG VBG O
toxicities NNS NNS O
in IN IN O
six CD CD O
of IN IN O
nine CD CD O
patients NNS NNS O
at IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
included VBN VBN O
hypercalcemia NN NN O
( ( ( O
n NN NN O
= SYM SYM O
3 CD CD O
) ) ) O
, , , O
rash NN NN O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
, , , O
and CC CC O
anemia NN NN O
/ NN NN O
thrombocytopenia NN NN O
/ NN NN O
emesis NN NN O
/ NN NN O
rash NN NN O
( ( ( O
n NN NN O
= SYM SYM O
1 CD CD O
) ) ) O
. . . O

All DT DT O
toxicities NNS NNS O
resolved VBN VBN O
after IN IN O
cis NN NN B-CHEM
- : : I-CHEM
RA NNP NNP I-CHEM
was VBD VBD O
discontinued VBN VBN O
. . . O

Three CD CD O
complete JJ JJ O
responses NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
marrow NN NN O
metastases NNS NNS O
. . . O

Serum NNP NNP O
levels NNS NNS O
of IN IN O
7 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
0 CD CD O
mumol NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
peak NN NN O
) ) ) O
and CC CC O
4 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
8 CD CD O
mumol NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
trough NN NN O
) ) ) O
at IN IN O
the DT DT O
MTD NNP NNP O
were VBD VBD O
maintained VBN VBN O
during IN IN O
14 CD CD O
days NNS NNS O
of IN IN O
therapy NN NN O
. . . O

The DT DT O
DLT NNP NNP O
correlated JJ JJ O
with IN IN O
serum NN NN O
levels NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
10 CD CD O
mumol NN NN O
/ NN NN O
L NNP NNP O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
MTD NNP NNP O
of IN IN O
cis NN NN B-CHEM
- - - I-CHEM
RA NNP NNP I-CHEM
given VBN VBN O
on IN IN O
this DT DT O
intermittent NN NN O
schedule NN NN O
was VBD VBD O
160 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
. . . O

Serum NNP NNP O
levels NNS NNS O
known VBN VBN O
to TO TO O
be VB VB O
effective JJ JJ O
against IN IN O
neuroblastoma NN NN O
in IN IN O
vitro NN NN O
were VBD VBD O
achieved VBN VBN O
at IN IN O
this DT DT O
dose NN NN O
. . . O

The DT DT O
DLT NNP NNP O
included VBD VBD O
hypercalcemia NN NN O
, , , O
and CC CC O
may MD MD O
be VB VB O
predicted VBN VBN O
by IN IN O
serum NN NN O
cis NN NN B-CHEM
- : : I-CHEM
RA NNP NNP I-CHEM
levels NNS NNS O
. . . O

Monitoring NNP NNP O
of IN IN O
serum NN NN O
calcium NN NN B-CHEM
and CC CC O
cis NN NN B-CHEM
- - - I-CHEM
RA NNP NNP I-CHEM
levels NNS NNS O
is VBZ VBZ O
indicated VBN VBN O
in IN IN O
future JJ JJ O
trials NNS NNS O
. . . O

Time NNP NNP O
dependence NN NN O
of IN IN O
plasma NN NN O
malondialdehyde NN NN B-CHEM
, , , O
oxypurines NNS NNS B-CHEM
, , , O
and CC CC O
nucleosides NNS NNS B-CHEM
during IN IN O
incomplete JJ JJ O
cerebral JJ JJ O
ischemia NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Incomplete NNP NNP O
cerebral JJ JJ O
ischemia NN NN O
( ( ( O
30 CD CD O
min NN NN O
) ) ) O
was VBD VBD O
induced VBN VBN O
in IN IN O
the DT DT O
rat NN NN O
by IN IN O
bilaterally RB RB O
clamping VBG VBG O
the DT DT O
common JJ JJ O
carotid NN NN O
arteries NNS NNS O
. . . O

Peripheral NNP NNP O
venous JJ JJ O
blood NN NN O
samples NNS NNS O
were VBD VBD O
withdrawn VBN VBN O
from IN IN O
the DT DT O
femoral NN NN O
vein NN NN O
four CD CD O
times NNS NNS O
( ( ( O
once RB RB O
every DT DT O
5 CD CD O
min NN NN O
) ) ) O
before IN IN O
ischemia NN NN O
( ( ( O
0 CD CD O
time NN NN O
) ) ) O
and CC CC O
5 CD CD O
, , , O
15 CD CD O
, , , O
and CC CC O
30 CD CD O
min NN NN O
after IN IN O
ischemia NN NN O
. . . O

Plasma NNP NNP O
extracts NNS NNS O
were VBD VBD O
analyzed VBN VBN O
by IN IN O
a DT DT O
highly RB RB O
sensitive JJ JJ O
high JJ JJ O
- - - O
performance NN NN O
liquid NN NN O
chromatographic JJ JJ O
method NN NN O
for IN IN O
the DT DT O
direct JJ JJ O
determination NN NN O
of IN IN O
malondialdehyde NN NN B-CHEM
, , , O
oxypurines NNS NNS B-CHEM
, , , O
and CC CC O
nucleosides NNS NNS B-CHEM
. . . O

During IN IN O
ischemia NN NN O
, , , O
a DT DT O
time NN NN O
- - - O
dependent JJ JJ O
increase NN NN O
of IN IN O
plasma NN NN O
oxypurines NNS NNS B-CHEM
and CC CC O
nucleosides NNS NNS B-CHEM
was VBD VBD O
observed VBN VBN O
. . . O

Plasma NNP NNP O
malondialdehyde NN NN B-CHEM
, , , O
which WDT WDT O
was VBD VBD O
present JJ JJ O
in IN IN O
minimal JJ JJ O
amount NN NN O
at IN IN O
zero CD CD O
time NN NN O
( ( ( O
0 CD CD O
. . . O
058 CD CD O
mumol NN NN O
/ NN NN O
liter NN NN O
plasma NN NN O
; : : O
SD NNP NNP O
0 CD CD O
. . . O
015 CD CD O
) ) ) O
, , , O
increased VBN VBN O
after IN IN O
5 CD CD O
min NN NN O
of IN IN O
ischemia NN NN O
, , , O
resulting VBG VBG O
in IN IN O
a DT DT O
fivefold JJ JJ O
increase NN NN O
after IN IN O
30 CD CD O
min NN NN O
of IN IN O
carotid NN NN O
occlusion NN NN O
( ( ( O
0 CD CD O
. . . O
298 CD CD O
mumol NN NN O
/ NN NN O
liter NN NN O
plasma NN NN O
; : : O
SD NNP NNP O
0 CD CD O
. . . O
078 CD CD O
) ) ) O
. . . O

Increased NNP NNP O
plasma NN NN O
malondialdehyde NN NN B-CHEM
was VBD VBD O
also RB RB O
recorded VBN VBN O
in IN IN O
two CD CD O
other JJ JJ O
groups NNS NNS O
of IN IN O
animals NNS NNS O
subjected VBN VBN O
to TO TO O
the DT DT O
same JJ JJ O
experimental JJ JJ O
model NN NN O
, , , O
one CD CD O
receiving VBG VBG O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
b SYM SYM O
. . . O
w NN NN O
. . . O
of IN IN O
the DT DT O
cyclooxygenase NN NN O
inhibitor NN NN O
acetylsalicylate JJ JJ B-CHEM
intravenously RB RB O
immediately RB RB O
before IN IN O
ischemia NN NN O
, , , O
the DT DT O
other JJ JJ O
receiving VBG VBG O
650 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
b SYM SYM O
. . . O
w NN NN O
. . . O
of IN IN O
the DT DT O
hypotensive JJ JJ O
drug NN NN O
nitroprusside NN NN B-CHEM
at IN IN O
a DT DT O
flow NN NN O
rate NN NN O
of IN IN O
103 CD CD O
microliters NNS NNS O
/ NN NN O
min NN NN O
intravenously RB RB O
during IN IN O
ischemia NN NN O
, , , O
although IN IN O
in IN IN O
this DT DT O
latter JJ JJ O
group NN NN O
malondialdehyde NN NN B-CHEM
was VBD VBD O
significantly RB RB O
higher JJR JJR O
. . . O

The DT DT O
present JJ JJ O
data NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
determination NN NN O
of IN IN O
malondialdehyde NN NN B-CHEM
, , , O
oxypurines NNS NNS B-CHEM
, , , O
and CC CC O
nucleosides NNS NNS B-CHEM
in IN IN O
peripheral JJ JJ O
blood NN NN O
, , , O
may MD MD O
be VB VB O
used VBN VBN O
to TO TO O
monitor VB VB O
the DT DT O
metabolic JJ JJ O
alterations NNS NNS O
of IN IN O
tissues NNS NNS O
occurring VBG VBG O
during IN IN O
ischemic JJ JJ O
phenomena NN NN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Acute JJ JJ O
renal JJ JJ O
toxicity NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
adriamycin NN NN B-CHEM
) ) ) O
- : : O
loaded VBN VBN O
cyanoacrylate NN NN B-CHEM
nanoparticles NNS NNS O
. . . O

Acute JJ JJ O
doxorubicin NN NN B-CHEM
- - - O
loaded VBN VBN O
nanoparticle NN NN O
( ( ( O
DXNP NNP NNP O
) ) ) O
renal JJ JJ O
toxicity NN NN O
was VBD VBD O
explored JJ JJ O
in IN IN O
both DT DT O
normal JJ JJ O
rats NNS NNS O
and CC CC O
rats NNS NNS O
with IN IN O
experimental JJ JJ O
glomerulonephritis NNS NNS O
. . . O

In IN IN O
normal JJ JJ O
rats NNS NNS O
, , , O
2 CD CD O
/ NN NN O
6 CD CD O
rats NNS NNS O
given VBN VBN O
free JJ JJ O
doxorubicin NN NN B-CHEM
( ( ( O
DX NNP NNP B-CHEM
) ) ) O
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
died VBD VBD O
within IN IN O
one CD CD O
week NN NN O
, , , O
whereas IN IN O
all DT DT O
control NN NN O
animals NNS NNS O
and CC CC O
all DT DT O
rats NNS NNS O
having VBG VBG O
received VBN VBN O
free JJ JJ O
NP NNP NNP O
or CC CC O
DXNP NNP NNP O
survived VBD VBD O
. . . O

A DT DT O
3 CD CD O
times NNS NNS O
higher JJR JJR O
proteinuria NN NN O
appeared VBD VBD O
in IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
DXNP NNP NNP O
than IN IN O
in IN IN O
those DT DT O
treated VBN VBN O
with IN IN O
DX NNP NNP B-CHEM
. . . O

Free NNP NNP O
NP NNP NNP O
did VBD VBD O
not RB RB O
provoke VB VB O
any DT DT O
proteinuria NN NN O
. . . O

Two CD CD O
hr NN NN O
post NN NN O
- : : O
injection NN NN O
, , , O
DXNP NNP NNP O
was VBD VBD O
2 CD CD O
. . . O
7 CD CD O
times NNS NNS O
more JJR JJR O
concentrated VBN VBN O
in IN IN O
kidneys NNS NNS O
than IN IN O
free JJ JJ O
DX NNP NNP B-CHEM
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
025 CD CD O
) ) ) O
. . . O

In IN IN O
rats NNS NNS O
with IN IN O
immune JJ JJ O
experimental JJ JJ O
glomerulonephritis NNS NNS O
, , , O
5 CD CD O
/ NN NN O
6 CD CD O
rats NNS NNS O
given VBN VBN O
DX NNP NNP B-CHEM
died VBD VBD O
within IN IN O
7 CD CD O
days NNS NNS O
, , , O
in IN IN O
contrast NN NN O
to TO TO O
animals NNS NNS O
treated VBN VBN O
by IN IN O
DXNP NNP NNP O
, , , O
NP NNP NNP O
, , , O
or CC CC O
untreated VBD VBD O
, , , O
which WDT WDT O
all DT DT O
survived VBD VBD O
. . . O

Proteinuria NNP NNP O
appeared VBD VBD O
in IN IN O
all DT DT O
series NN NN O
, , , O
but CC CC O
was VBD VBD O
2 CD CD O
- : : O
5 CD CD O
times NNS NNS O
more JJR JJR O
intense JJ JJ O
( ( ( O
p NN NN O
> NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
prolonged JJ JJ O
after IN IN O
doxorubicin NN NN B-CHEM
treatment NN NN O
( ( ( O
400 CD CD O
- : : O
700 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
, , , O
without IN IN O
significant JJ JJ O
difference NN NN O
between IN IN O
DXNP NNP NNP O
and CC CC O
DX NNP NNP B-CHEM
. . . O

Rats NNP NNP O
treated VBN VBN O
by IN IN O
unloaded JJ JJ O
NP NNP NNP O
behaved VBD VBD O
as IN IN O
controls NNS NNS O
. . . O

These DT DT O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
, , , O
in IN IN O
these DT DT O
experimental JJ JJ O
conditions NNS NNS O
, , , O
DXNP NNP NNP O
killed VBD VBD O
less JJR JJR O
animals NNS NNS O
than IN IN O
free JJ JJ O
DX NNP NNP B-CHEM
, , , O
despite IN IN O
of IN IN O
an DT DT O
enhanced JJ JJ O
renal JJ JJ O
toxicity NN NN O
of IN IN O
the DT DT O
former JJ JJ O
. . . O

Both DT DT O
effects NNS NNS O
( ( ( O
better JJR JJR O
survival NN NN O
and CC CC O
nephrosis NN NN O
) ) ) O
are VBP VBP O
most RBS RBS O
probably RB RB O
related VBN VBN O
to TO TO O
an DT DT O
enhanced JJ JJ O
capture NN NN O
of IN IN O
DXNP NNP NNP O
by IN IN O
cells NNS NNS O
of IN IN O
the DT DT O
mononuclear NN NN O
phagocyte NN NN O
system NN NN O
, , , O
including VBG VBG O
mesangial JJ JJ O
cells NNS NNS O
. . . O

Prostaglandin NNP NNP B-CHEM
E2 NNP NNP I-CHEM
- : : O
induced JJ JJ O
bladder NN NN O
hyperactivity NN NN O
in IN IN O
normal JJ JJ O
, , , O
conscious JJ JJ O
rats NNS NNS O
: : : O
involvement NN NN O
of IN IN O
tachykinins NNS NNS B-CHEM
? . . O

In IN IN O
normal JJ JJ O
conscious JJ JJ O
rats NNS NNS O
investigated VBN VBN O
by IN IN O
continuous JJ JJ O
cystometry NN NN O
, , , O
intravesically RB RB O
instilled JJ JJ O
prostaglandin NN NN B-CHEM
( ( ( I-CHEM
PG NNP NNP I-CHEM
) ) ) I-CHEM
E2 NNP NNP I-CHEM
facilitated VBD VBD O
micturition NN NN O
and CC CC O
increased VBN VBN O
basal NN NN O
intravesical JJ JJ O
pressure NN NN O
. . . O

The DT DT O
effect NN NN O
was VBD VBD O
attenuated VBN VBN O
by IN IN O
both DT DT O
the DT DT O
NK1 NNP NNP O
receptor NN NN O
selective JJ JJ O
antagonist NN NN O
RP NNP NNP B-CHEM
67 CD CD I-CHEM
, , , I-CHEM
580 CD CD I-CHEM
and CC CC O
the DT DT O
NK2 NNP NNP O
receptor NN NN O
selective JJ JJ O
antagonist NN NN O
SR NNP NNP B-CHEM
48 CD CD I-CHEM
, , , I-CHEM
968 CD CD I-CHEM
, , , O
given VBN VBN O
intra NN NN O
- : : O
arterially RB RB O
, , , O
suggesting VBG VBG O
that IN IN O
it PRP PRP O
was VBD VBD O
mediated VBN VBN O
by IN IN O
stimulation NN NN O
of IN IN O
both DT DT O
NK1 NNP NNP O
and CC CC O
NK2 NNP NNP O
receptors NNS NNS O
. . . O

Intra NNP NNP O
- : : O
arterially RB RB O
given VBN VBN O
PGE2 NNP NNP B-CHEM
produced VBD VBD O
a DT DT O
distinct JJ JJ O
increase NN NN O
in IN IN O
bladder NN NN O
pressure NN NN O
before IN IN O
initiating VBG VBG O
a DT DT O
micturition NN NN O
reflex NN NN O
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
PG NNP NNP B-CHEM
had VBD VBD O
a DT DT O
direct JJ JJ O
contractant JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
detrusor NN NN O
smooth JJ JJ O
muscle NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
intra NN NN O
- - - O
arterial JJ JJ O
PGE2 NNP NNP B-CHEM
could MD MD O
not RB RB O
be VB VB O
blocked VBN VBN O
by IN IN O
intra NN NN O
- : : O
arterial JJ JJ O
RP NNP NNP B-CHEM
67 CD CD I-CHEM
, , , I-CHEM
580 CD CD I-CHEM
or CC CC O
SR NNP NNP B-CHEM
48 CD CD I-CHEM
, , , I-CHEM
968 CD CD I-CHEM
, , , O
which WDT WDT O
opens VBZ VBZ O
the DT DT O
possibility NN NN O
that IN IN O
the DT DT O
micturition NN NN O
reflex NN NN O
elicited VBN VBN O
by IN IN O
intra NN NN O
- : : O
arterial JJ JJ O
PGE2 NNP NNP B-CHEM
was VBD VBD O
mediated VBN VBN O
by IN IN O
pathways NNS NNS O
other JJ JJ O
than IN IN O
the DT DT O
reflex NN NN O
initiated VBD VBD O
when WRB WRB O
the DT DT O
PG NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
intravesically RB RB O
. . . O

The DT DT O
present JJ JJ O
results NNS NNS O
thus RB RB O
suggest VBP VBP O
that IN IN O
intra JJ JJ O
- : : O
arterial JJ JJ O
PGE2 NNP NNP B-CHEM
, , , O
given VBN VBN O
near IN IN O
the DT DT O
bladder NN NN O
, , , O
may MD MD O
initiate VB VB O
micturition NN NN O
in IN IN O
the DT DT O
normal JJ JJ O
rat NN NN O
chiefly NN NN O
by IN IN O
directly RB RB O
contracting VBG VBG O
the DT DT O
smooth JJ JJ O
muscle NN NN O
of IN IN O
the DT DT O
detrusor NN NN O
. . . O

However RB RB O
, , , O
when WRB WRB O
given VBN VBN O
intravesically RB RB O
, , , O
PGE2 NNP NNP B-CHEM
may MD MD O
stimulate VB VB O
micturition NN NN O
by IN IN O
releasing VBG VBG O
tachykinins NNS NNS B-CHEM
from IN IN O
nerves NNS NNS O
in IN IN O
and CC CC O
/ NN NN O
or CC CC O
immediately RB RB O
below IN IN O
the DT DT O
urothelium NN NN O
. . . O

These DT DT O
tachykinins NNS NNS B-CHEM
, , , O
in IN IN O
turn NN NN O
, , , O
initiate VB VB O
a DT DT O
micturition NN NN O
reflex NN NN O
by IN IN O
stimulating VBG VBG O
NK1 NNP NNP O
and CC CC O
NK2 NNP NNP O
receptors NNS NNS O
. . . O

Prostanoids NNP NNP B-CHEM
may MD MD O
, , , O
via IN IN O
release NN NN O
of IN IN O
tachykinins NNS NNS B-CHEM
, , , O
contribute NN NN O
to TO TO O
both DT DT O
urge NN NN O
and CC CC O
bladder NN NN O
hyperactivity NN NN O
seen VBN VBN O
in IN IN O
inflammatory JJ JJ O
conditions NNS NNS O
of IN IN O
the DT DT O
lower JJR JJR O
urinary JJ JJ O
tract NN NN O
. . . O

Refractory NNP NNP O
cardiogenic JJ JJ O
shock NN NN O
and CC CC O
complete JJ JJ O
heart NN NN O
block NN NN O
after IN IN O
verapamil NN NN B-CHEM
SR NNP NNP O
and CC CC O
metoprolol NN NN B-CHEM
treatment NN NN O
. . . O

A DT DT O
case NN NN O
report NN NN O
. . . O

A DT DT O
seventy NN NN O
- - - O
eight CD CD O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
presented VBN VBN O
with IN IN O
complete JJ JJ O
heart NN NN O
block NN NN O
and CC CC O
refractory NN NN O
hypotension NN NN O
two CD CD O
days NNS NNS O
after IN IN O
a DT DT O
therapeutic JJ JJ O
dose NN NN O
of IN IN O
sustained JJ JJ O
- - - O
release NN NN O
verapamil NN NN B-CHEM
with IN IN O
concomitant JJ JJ O
use NN NN O
of IN IN O
metoprolol NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
continued VBD VBD O
to TO TO O
remain VB VB O
hypotensive JJ JJ O
with IN IN O
complete JJ JJ O
heart NN NN O
block NN NN O
, , , O
even RB RB O
with IN IN O
multiple JJ JJ O
uses NNS NNS O
of IN IN O
intravenous JJ JJ O
atropine NN NN B-CHEM
as RB RB O
well RB RB O
as IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
pressor NN NN O
agents NNS NNS O
such JJ JJ O
as IN IN O
dopamine NN NN B-CHEM
and CC CC O
dobutamine NN NN B-CHEM
. . . O

However RB RB O
, , , O
shortly RB RB O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
intravenous JJ JJ O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
, , , O
the DT DT O
refractory NN NN O
hypotension NN NN O
and CC CC O
complete JJ JJ O
heart NN NN O
block NN NN O
resolved VBD VBD O
. . . O

Protective JJ JJ O
effect NN NN O
of IN IN O
misoprostol NN NN B-CHEM
on IN IN O
indomethacin NN NN B-CHEM
induced VBN VBN O
renal JJ JJ O
dysfunction NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
possible JJ JJ O
protective JJ JJ O
effects NNS NNS O
of IN IN O
misoprostol NN NN B-CHEM
on IN IN O
renal JJ JJ O
function NN NN O
in IN IN O
hospitalized JJ JJ O
elderly JJ JJ O
patients NNS NNS O
treated VBN VBN O
with IN IN O
indomethacin NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
Forty CD CD O
- - - O
five CD CD O
hospitalized JJ JJ O
elderly JJ JJ O
patients NNS NNS O
( ( ( O
> NN NN O
65 CD CD O
years NNS NNS O
old JJ JJ O
) ) ) O
who WP WP O
required VBD VBD O
therapy NN NN O
with IN IN O
nonsteroidal NN NN O
antiinflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAID NNP NNP O
) ) ) O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
indomethacin NN NN B-CHEM
, , , O
150 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
( ( ( O
Group NNP NNP O
A DT DT O
) ) ) O
, , , O
or CC CC O
indomethacin NN NN B-CHEM
150 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
plus CC CC O
misoprostol NN NN B-CHEM
at IN IN O
0 CD CD O
. . . O
6 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
( ( ( O
Group NNP NNP O
B NNP NNP O
) ) ) O
. . . O

Laboratory NNP NNP O
variables NNS NNS O
of IN IN O
renal JJ JJ O
function NN NN O
[ NN NN O
serum NN NN O
creatinine NN NN B-CHEM
, , , O
blood NN NN B-CHEM
urea JJ JJ I-CHEM
nitrogen NN NN I-CHEM
( ( ( O
BUN NNP NNP B-CHEM
) ) ) O
and CC CC O
electrolytes NNS NNS O
] NN NN O
were VBD VBD O
evaluated VBN VBN O
before IN IN O
initiation NN NN O
of IN IN O
therapy NN NN O
and CC CC O
every DT DT O
2 CD CD O
days NNS NNS O
, , , O
until IN IN O
termination NN NN O
of IN IN O
the DT DT O
study NN NN O
( ( ( O
a DT DT O
period NN NN O
of IN IN O
at IN IN O
least JJS JJS O
6 CD CD O
days NNS NNS O
) ) ) O
. . . O

Response NNP NNP O
to TO TO O
treatment NN NN O
was VBD VBD O
estimated VBN VBN O
by IN IN O
the DT DT O
visual JJ JJ O
analog NN NN O
scale NN NN O
for IN IN O
severity NN NN O
of IN IN O
pain NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Forty CD CD O
- - - O
two CD CD O
patients NNS NNS O
completed VBD VBD O
the DT DT O
study NN NN O
, , , O
22 CD CD O
in IN IN O
Group NNP NNP O
A DT DT O
and CC CC O
20 CD CD O
in IN IN O
Group NNP NNP O
B NNP NNP O
. . . O

BUN NNP NNP B-CHEM
and CC CC O
creatinine NN NN B-CHEM
increased VBN VBN O
by IN IN O
> NN NN O
50 CD CD O
% NN NN O
of IN IN O
baseline NN NN O
levels NNS NNS O
in IN IN O
54 CD CD O
and CC CC O
45 CD CD O
% NN NN O
of IN IN O
Group NNP NNP O
A DT DT O
patients NNS NNS O
, , , O
respectively RB RB O
, , , O
compared VBN VBN O
to TO TO O
only RB RB O
20 CD CD O
and CC CC O
10 CD CD O
% NN NN O
of IN IN O
Group NNP NNP O
B NNP NNP O
patients NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Potassium NNP NNP B-CHEM
( ( ( O
K NNP NNP B-CHEM
) ) ) O
increment NN NN O
of IN IN O
0 CD CD O
. . . O
6 CD CD O
mEq NN NN O
/ NN NN O
l NN NN O
or CC CC O
more JJR JJR O
was VBD VBD O
observed VBN VBN O
in IN IN O
50 CD CD O
% NN NN O
of IN IN O
Group NNP NNP O
A DT DT O
, , , O
but CC CC O
in IN IN O
only RB RB O
15 CD CD O
% NN NN O
of IN IN O
Group NNP NNP O
B NNP NNP O
patients NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
increments NNS NNS O
in IN IN O
BUN NNP NNP B-CHEM
, , , O
creatinine NN NN B-CHEM
, , , O
and CC CC O
K NNP NNP B-CHEM
were VBD VBD O
reduced VBN VBN O
by IN IN O
63 CD CD O
, , , O
80 CD CD O
, , , O
and CC CC O
42 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
in IN IN O
Group NNP NNP O
B NNP NNP O
patients NNS NNS O
compared VBN VBN O
to TO TO O
Group NNP NNP O
A DT DT O
. . . O
Response NNP NNP O
to TO TO O
treatment NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
between IN IN O
the DT DT O
2 CD CD O
groups NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Hospitalized NNP NNP O
elderly JJ JJ O
patients NNS NNS O
are VBP VBP O
at IN IN O
risk NN NN O
for IN IN O
developing VBG VBG O
indomethacin NN NN B-CHEM
related VBN VBN O
renal JJ JJ O
dysfunction NN NN O
. . . O

Addition NN NN O
of IN IN O
misoprostol NN NN B-CHEM
can MD MD O
minimize VB VB O
this DT DT O
renal JJ JJ O
impairment NN NN O
without IN IN O
affecting VBG VBG O
pain NN NN O
control NN NN O
. . . O

Cognitive NNP NNP O
deterioration NN NN O
from IN IN O
long JJ JJ O
- - - O
term NN NN O
abuse NN NN O
of IN IN O
dextromethorphan NN NN B-CHEM
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

Dextromethorphan NNP NNP B-CHEM
( ( ( O
DM NNP NNP B-CHEM
) ) ) O
, , , O
the DT DT O
dextrorotatory JJ JJ O
isomer NN NN O
of IN IN O
3 CD CD B-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
methylmorphinan NN NN I-CHEM
, , , O
is VBZ VBZ O
the DT DT O
main JJ JJ O
ingredient NN NN O
in IN IN O
a DT DT O
number NN NN O
of IN IN O
widely RB RB O
available JJ JJ O
, , , O
over IN IN O
- - - O
the DT DT O
- - - O
counter NN NN O
antitussives NNS NNS O
. . . O

Initial JJ JJ O
studies NNS NNS O
( ( ( O
Bornstein NNP NNP O
1968 CD CD O
) ) ) O
showed VBD VBD O
that IN IN O
it PRP PRP O
possessed VBD VBD O
no DT DT O
respiratory NN NN O
suppressant JJ JJ O
effects NNS NNS O
and CC CC O
no DT DT O
addiction NN NN O
liability NN NN O
. . . O

Subsequently RB RB O
, , , O
however RB RB O
, , , O
several JJ JJ O
articles NNS NNS O
reporting VBG VBG O
abuse NN NN O
of IN IN O
this DT DT O
drug NN NN O
have VBP VBP O
appeared VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

The DT DT O
drug NN NN O
is VBZ VBZ O
known VBN VBN O
to TO TO O
cause VB VB O
a DT DT O
variety NN NN O
of IN IN O
acute JJ JJ O
toxic JJ JJ O
effects NNS NNS O
, , , O
ranging VBG VBG O
from IN IN O
nausea NN NN O
, , , O
restlessness NN NN O
, , , O
insomnia NN NN O
, , , O
ataxia NN NN O
, , , O
slurred VBD VBD O
speech NN NN O
and CC CC O
nystagmus NN NN O
to TO TO O
mood NN NN O
changes NNS NNS O
, , , O
perceptual JJ JJ O
alterations NNS NNS O
, , , O
inattention NN NN O
, , , O
disorientation NN NN O
and CC CC O
aggressive JJ JJ O
behavior NN NN O
( ( ( O
Rammer NNP NNP O
et CC CC O
al NN NN O
1988 CD CD O
; : : O
Katona NNP NNP O
and CC CC O
Watson NNP NNP O
1986 CD CD O
; : : O
Isbell NNP NNP O
and CC CC O
Fraser NNP NNP O
1953 CD CD O
; : : O
Devlin NNP NNP O
et CC CC O
al NN NN O
1985 CD CD O
; : : O
McCarthy NNP NNP O
1971 CD CD O
; : : O
Dodds NNP NNP O
and CC CC O
Revai NNP NNP O
1967 CD CD O
; : : O
Degkwitz NNP NNP O
1964 CD CD O
; : : O
Hildebrand NNP NNP O
et CC CC O
al NN NN O
1989 CD CD O
) ) ) O
. . . O

There EX EX O
have VBP VBP O
also RB RB O
been VBN VBN O
two CD CD O
reported VBN VBN O
fatalities NNS NNS O
from IN IN O
DM NNP NNP B-CHEM
overdoses NNS NNS O
( ( ( O
Fleming NNP NNP O
1986 CD CD O
) ) ) O
. . . O

However RB RB O
, , , O
there EX EX O
are VBP VBP O
no DT DT O
reports NNS NNS O
describing VBG VBG O
the DT DT O
effects NNS NNS O
of IN IN O
chronic JJ JJ O
abuse NN NN O
. . . O

This DT DT O
report NN NN O
describes VBZ VBZ O
a DT DT O
case NN NN O
of IN IN O
cognitive JJ JJ O
deterioration NN NN O
resulting VBG VBG O
from IN IN O
prolonged JJ JJ O
use NN NN O
of IN IN O
DM NNP NNP B-CHEM
. . . O

Effects NNP NNP O
of IN IN O
ouabain NN NN B-CHEM
on IN IN O
myocardial JJ JJ O
oxygen NN NN B-CHEM
supply NN NN O
and CC CC O
demand NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

A DT DT O
hemodynamic JJ JJ O
, , , O
volumetric JJ JJ O
, , , O
and CC CC O
metabolic JJ JJ O
study NN NN O
in IN IN O
patients NNS NNS O
without IN IN O
heart NN NN O
failure NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
digitalis NNS NNS B-CHEM
glycosides NNS NNS I-CHEM
on IN IN O
myocardial JJ JJ O
oxygen NN NN B-CHEM
supply NN NN O
and CC CC O
demand NN NN O
are VBP VBP O
of IN IN O
particular JJ JJ O
interest NN NN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
obstructive JJ JJ O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
but CC CC O
have VBP VBP O
not RB RB O
been VBN VBN O
measured VBN VBN O
previously RB RB O
in IN IN O
man NN NN O
. . . O

We PRP PRP O
assessed VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
ouabain NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
015 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) ) ) O
on IN IN O
hemodynamic JJ JJ O
, , , O
volumetric JJ JJ O
, , , O
and CC CC O
metabolic JJ JJ O
parameters NNS NNS O
in IN IN O
11 CD CD O
patients NNS NNS O
with IN IN O
severe JJ JJ O
chronic JJ JJ O
coronary JJ JJ O
artery NN NN O
disease NN NN O
without IN IN O
clinical JJ JJ O
congestive JJ JJ O
heart NN NN O
failure NN NN O
. . . O

Because IN IN O
the DT DT O
protocol NN NN O
was VBD VBD O
long JJ JJ O
and CC CC O
involved VBN VBN O
interventions NNS NNS O
which WDT WDT O
might MD MD O
affect VB VB O
the DT DT O
determinations NNS NNS O
, , , O
we PRP PRP O
also RB RB O
studied VBD VBD O
in IN IN O
nine CD CD O
patients NNS NNS O
using VBG VBG O
an DT DT O
identical JJ JJ O
protocol NN NN O
except IN IN O
that DT DT O
ouabain NN NN B-CHEM
administration NN NN O
was VBD VBD O
omitted VBN VBN O
. . . O

Left NNP NNP O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
and CC CC O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
volume NN NN O
fell VBD VBD O
in IN IN O
each DT DT O
patient NN NN O
given VBN VBN O
ouabain NN NN B-CHEM
, , , O
even RB RB O
though IN IN O
they PRP PRP O
were VBD VBD O
initially RB RB O
elevated VBN VBN O
in IN IN O
only RB RB O
two CD CD O
patients NNS NNS O
. . . O

Left NNP NNP O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
fell VBD VBD O
from IN IN O
11 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
4 CD CD O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
to TO TO O
5 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
mm NN NN O
Hg NNP NNP O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
volume NN NN O
fell VBD VBD O
from IN IN O
100 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
to TO TO O
82 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
ml NN NN O
/ NN NN O
m2 NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
1 CD CD O
h NN NN O
after IN IN O
ouabain NN NN B-CHEM
infusion NN NN O
was VBD VBD O
completed VBN VBN O
. . . O

The DT DT O
maximum NN NN O
velocity NN NN O
of IN IN O
contractile NN NN O
element NN NN O
shortening VBG VBG O
increased VBN VBN O
from IN IN O
1 CD CD O
. . . O
68 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
11 CD CD O
ml NN NN O
/ NN NN O
s VBZ VBZ O
to TO TO O
2 CD CD O
. . . O
18 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
21 CD CD O
muscle NN NN O
- : : O
lengths NNS NNS O
/ NN NN O
s VBZ VBZ O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
is VBZ VBZ O
consistent JJ JJ O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
contractility NN NN O
. . . O

No DT DT O
significant JJ JJ O
change NN NN O
in IN IN O
these DT DT O
parameters NNS NNS O
occurred VBD VBD O
in IN IN O
the DT DT O
control NN NN O
patients NNS NNS O
. . . O

No DT DT O
significant JJ JJ O
change NN NN O
in IN IN O
myocardial JJ JJ O
oxygen NN NN B-CHEM
consumption NN NN O
occurred VBD VBD O
after IN IN O
ouabain JJ JJ B-CHEM
administration NN NN O
but CC CC O
this DT DT O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
a DT DT O
greater JJR JJR O
decrease NN NN O
in IN IN O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
in IN IN O
the DT DT O
ouabain NN NN B-CHEM
patients NNS NNS O
than IN IN O
in IN IN O
the DT DT O
control NN NN O
patients NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
coronary JJ JJ O
artery NN NN O
disease NN NN O
who WP WP O
are VBP VBP O
not RB RB O
in IN IN O
clinical JJ JJ O
congestive JJ JJ O
heart NN NN O
failure NN NN O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
volume NN NN O
falls VBZ VBZ O
after IN IN O
ouabain JJ JJ B-CHEM
administration NN NN O
even RB RB O
when WRB WRB O
it PRP PRP O
is VBZ VBZ O
initially RB RB O
normal JJ JJ O
. . . O

Though IN IN O
this DT DT O
fall NN NN O
would MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
a DT DT O
decrease NN NN O
in IN IN O
wall NN NN O
tension NN NN O
, , , O
and CC CC O
, , , O
therefore RB RB O
, , , O
of IN IN O
myocardial JJ JJ O
oxygen NN NN B-CHEM
consumption NN NN O
, , , O
it PRP PRP O
may MD MD O
not RB RB O
be VB VB O
of IN IN O
sufficient JJ JJ O
magnitude NN NN O
to TO TO O
prevent VB VB O
a DT DT O
net JJ JJ O
increase NN NN O
in IN IN O
myocardial NN NN O
oxygen NN NN B-CHEM
consumption NN NN O
. . . O

Nevertheless RB RB O
, , , O
compensatory JJ JJ O
mechanisms NNS NNS O
prevent VB VB O
a DT DT O
deterioration NN NN O
of IN IN O
resting VBG VBG O
myocardial NN NN O
metabolism NN NN O
. . . O

Dexamethasone NNP NNP B-CHEM
- - - O
induced JJ JJ O
ocular NN NN O
hypertension NN NN O
in IN IN O
perfusion NN NN O
- - - O
cultured JJ JJ O
human JJ JJ O
eyes NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
Glucocorticoid NNP NNP O
administration NN NN O
can MD MD O
lead VB VB O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
ocular JJ JJ O
hypertension NN NN O
and CC CC O
corticosteroid VB VB O
glaucoma NN NN O
in IN IN O
a DT DT O
subset NN NN O
of IN IN O
the DT DT O
population NN NN O
through IN IN O
a DT DT O
decrease NN NN O
in IN IN O
the DT DT O
aqueous JJ JJ O
humor NN NN O
outflow NN NN O
facility NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
glucocorticoid JJ JJ O
treatment NN NN O
can MD MD O
directly RB RB O
affect VB VB O
the DT DT O
outflow JJ JJ O
facility NN NN O
of IN IN O
isolated VBN VBN O
, , , O
perfusion NN NN O
- - - O
cultured JJ JJ O
human JJ JJ O
eyes NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
anterior JJ JJ O
segments NNS NNS O
of IN IN O
human JJ JJ O
donor NN NN O
eyes NNS NNS O
from IN IN O
regional JJ JJ O
eye NN NN O
banks NNS NNS O
were VBD VBD O
placed VBN VBN O
in IN IN O
a DT DT O
constant JJ JJ O
flow NN NN O
, , , O
variable JJ JJ O
pressure NN NN O
perfusion NN NN O
culture NN NN O
system NN NN O
. . . O

Paired NNP NNP O
eyes NNS NNS O
were VBD VBD O
perfused VBN VBN O
in IN IN O
serum NN NN O
- - - O
free JJ JJ O
media NNS NNS O
with IN IN O
or CC CC O
without IN IN O
10 CD CD O
( ( ( O
- : : O
7 CD CD O
) ) ) O
M NNP NNP O
dexamethasone NN NN B-CHEM
for IN IN O
12 CD CD O
days NNS NNS O
. . . O

Intraocular NNP NNP O
pressure NN NN O
was VBD VBD O
monitored VBN VBN O
daily RB RB O
. . . O

After IN IN O
incubation NN NN O
, , , O
the DT DT O
eyes NNS NNS O
were VBD VBD O
morphologically RB RB O
characterized VBN VBN O
by IN IN O
light JJ JJ O
microscopy NN NN O
, , , O
transmission NN NN O
and CC CC O
scanning VBG VBG O
electron NN NN O
microscopy NN NN O
, , , O
and CC CC O
scanning VBG VBG O
laser JJR JJR O
confocal JJ JJ O
microscopy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
intraocular NN NN O
pressure NN NN O
developed VBN VBN O
in IN IN O
13 CD CD O
of IN IN O
the DT DT O
44 CD CD O
pairs NNS NNS O
of IN IN O
eyes NNS NNS O
perfused VBN VBN O
with IN IN O
dexamethasone NN NN B-CHEM
with IN IN O
an DT DT O
average JJ JJ O
pressure NN NN O
rise NN NN O
of IN IN O
17 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
8 CD CD O
mm NN NN O
Hg NNP NNP O
after IN IN O
12 CD CD O
days NNS NNS O
of IN IN O
dexamethasone NN NN B-CHEM
exposure NN NN O
. . . O

The DT DT O
contralateral NN NN O
control NN NN O
eyes NNS NNS O
, , , O
which WDT WDT O
did VBD VBD O
not RB RB O
receive VB VB O
dexamethasone NN NN B-CHEM
, , , O
maintained VBD VBD O
a DT DT O
stable JJ JJ O
intraocular NN NN O
pressure NN NN O
during IN IN O
the DT DT O
same JJ JJ O
period NN NN O
. . . O

The DT DT O
outflow JJ JJ O
pathway NN NN O
of IN IN O
the DT DT O
untreated JJ JJ O
eyes NNS NNS O
appeared VBD VBD O
morphologically RB RB O
normal JJ JJ O
. . . O

In IN IN O
contrast NN NN O
, , , O
the DT DT O
dexamethasone NN NN B-CHEM
- - - O
treated VBN VBN O
hypertensive JJ JJ O
eyes NNS NNS O
had VBD VBD O
thickened VBN VBN O
trabecular NN NN O
beams NNS NNS O
, , , O
decreased VBD VBD O
intertrabecular JJ JJ O
spaces NNS NNS O
, , , O
thickened VBN VBN O
juxtacanalicular JJ JJ O
tissue NN NN O
, , , O
activated VBN VBN O
trabecular NN NN O
meshwork NN NN O
cells NNS NNS O
, , , O
and CC CC O
increased VBD VBD O
amounts NNS NNS O
of IN IN O
amorphogranular JJ JJ O
extracellular NN NN O
material NN NN O
, , , O
especially RB RB O
in IN IN O
the DT DT O
juxtacanalicular NN NN O
tissue NN NN O
and CC CC O
beneath IN IN O
the DT DT O
endothelial JJ JJ O
lining NN NN O
of IN IN O
the DT DT O
canal NN NN O
of IN IN O
Schlemm NNP NNP O
. . . O

The DT DT O
dexamethasone NN NN B-CHEM
- - - O
treated VBN VBN O
nonresponder NN NN O
eyes NNS NNS O
appeared VBD VBD O
to TO TO O
be VB VB O
morphologically RB RB O
similar JJ JJ O
to TO TO O
the DT DT O
untreated JJ JJ O
eyes NNS NNS O
, , , O
although IN IN O
several JJ JJ O
subtle JJ JJ O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
morphologic JJ JJ O
changes NNS NNS O
were VBD VBD O
evident JJ JJ O
. . . O

CONCLUSION NNP NNP O
: : : O
Dexamethasone NNP NNP B-CHEM
treatment NN NN O
of IN IN O
isolated VBN VBN O
, , , O
perfusion NN NN O
- - - O
cultured JJ JJ O
human JJ JJ O
eyes NNS NNS O
led VBD VBD O
to TO TO O
the DT DT O
generation NN NN O
of IN IN O
ocular JJ JJ O
hypertension NN NN O
in IN IN O
approximately RB RB O
30 CD CD O
% NN NN O
of IN IN O
the DT DT O
dexamethasone NN NN B-CHEM
- - - O
treated JJ JJ O
eyes NNS NNS O
. . . O

Steroid NNP NNP B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
morphologic JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
trabecular NN NN O
meshwork NN NN O
similar JJ JJ O
to TO TO O
those DT DT O
reported VBN VBN O
for IN IN O
corticosteroid NN NN O
glaucoma NN NN O
and CC CC O
open JJ JJ O
angle NN NN O
glaucoma NN NN O
. . . O

This DT DT O
system NN NN O
may MD MD O
provide VB VB O
an DT DT O
acute JJ JJ O
model NN NN O
in IN IN O
which WDT WDT O
to TO TO O
study VB VB O
the DT DT O
pathogenic JJ JJ O
mechanisms NNS NNS O
involved VBN VBN O
in IN IN O
steroid NN NN O
glaucoma NN NN O
and CC CC O
primary JJ JJ O
open JJ JJ O
angle NN NN O
glaucoma NN NN O
. . . O

Auditory NNP NNP O
disturbance NN NN O
associated VBN VBN O
with IN IN O
interscalene NN NN O
brachial JJ JJ O
plexus NN NN O
block NN NN O
. . . O

We PRP PRP O
performed VBD VBD O
an DT DT O
audiometric JJ JJ O
study NN NN O
in IN IN O
20 CD CD O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
surgery NN NN O
of IN IN O
the DT DT O
shoulder NN NN O
region NN NN O
under IN IN O
an DT DT O
interscalene NN NN O
brachial JJ JJ O
plexus NN NN O
block NN NN O
( ( ( O
IBPB NNP NNP O
) ) ) O
. . . O

Bupivacaine NNP NNP B-CHEM
0 CD CD O
. . . O
75 CD CD O
% NN NN O
with IN IN O
adrenaline NN NN B-CHEM
was VBD VBD O
given VBN VBN O
followed VBN VBN O
by IN IN O
a DT DT O
24 CD CD O
- : : O
hr NN NN O
continuous JJ JJ O
infusion NN NN O
of IN IN O
0 CD CD O
. . . O
25 CD CD O
% NN NN O
bupivacaine NN NN B-CHEM
. . . O

Three CD CD O
audiometric JJ JJ O
threshold NN NN O
measurements NNS NNS O
( ( ( O
0 CD CD O
. . . O
25 CD CD O
- : : O
18 CD CD O
kHz NN NN O
) ) ) O
were VBD VBD O
made VBN VBN O
: : : O
the DT DT O
first JJ JJ O
before IN IN O
IBPB NNP NNP O
, , , O
the DT DT O
second JJ JJ O
2 CD CD O
- : : O
6 CD CD O
h NN NN O
after IN IN O
surgery NN NN O
and CC CC O
the DT DT O
third JJ JJ O
on IN IN O
the DT DT O
first JJ JJ O
day NN NN O
after IN IN O
operation NN NN O
. . . O

In IN IN O
four CD CD O
patients NNS NNS O
hearing VBG VBG O
impairment NN NN O
on IN IN O
the DT DT O
side NN NN O
of IN IN O
the DT DT O
block NN NN O
was VBD VBD O
demonstrated VBN VBN O
after IN IN O
operation NN NN O
, , , O
in IN IN O
three CD CD O
measurements NNS NNS O
on IN IN O
the DT DT O
day NN NN O
of IN IN O
surgery NN NN O
and CC CC O
in IN IN O
one CD CD O
on IN IN O
the DT DT O
following VBG VBG O
day NN NN O
. . . O

The DT DT O
frequencies NNS NNS O
at IN IN O
which WDT WDT O
the DT DT O
impairment NN NN O
occurred VBD VBD O
varied VBN VBN O
between IN IN O
patients NNS NNS O
; : : O
in IN IN O
one CD CD O
only RB RB O
low JJ JJ O
frequencies NNS NNS O
( ( ( O
0 CD CD O
. . . O
25 CD CD O
- : : O
0 CD CD O
. . . O
5 CD CD O
kHz NN NN O
) ) ) O
were VBD VBD O
involved VBN VBN O
. . . O

The DT DT O
maximum NN NN O
change NN NN O
in IN IN O
threshold NN NN O
was VBD VBD O
35 CD CD O
dB NN NN O
at IN IN O
6 CD CD O
kHz NN NN O
measured VBN VBN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
continuous JJ JJ O
infusion NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
. . . O

This DT DT O
patient NN NN O
had VBD VBD O
hearing VBG VBG O
threshold NN NN O
changes NNS NNS O
( ( ( O
15 CD CD O
- : : O
20 CD CD O
dB NN NN O
) ) ) O
at IN IN O
6 CD CD O
- : : O
10 CD CD O
kHz NN NN O
on IN IN O
the DT DT O
opposite JJ JJ O
side NN NN O
also RB RB O
. . . O

IBPB NNP NNP O
may MD MD O
cause VB VB O
transient NN NN O
auditory NN NN O
dysfunction NN NN O
in IN IN O
the DT DT O
ipsilateral JJ JJ O
ear NN NN O
, , , O
possibly RB RB O
via IN IN O
an DT DT O
effect NN NN O
on IN IN O
sympathetic JJ JJ O
innervation NN NN O
. . . O

The DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
combination NN NN O
N NNP NNP B-CHEM
- : : I-CHEM
butyl NN NN I-CHEM
- : : I-CHEM
deoxynojirimycin NN NN I-CHEM
( ( ( O
SC NNP NNP B-CHEM
- - - I-CHEM
48334 CD CD I-CHEM
) ) ) O
and CC CC O
zidovudine NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
HIV NNP NNP O
- : : O
1 CD CD O
infection NN NN O
and CC CC O
200 CD CD O
- : : O
500 CD CD O
CD4 NNP NNP O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
. . . O

We PRP PRP O
conducted VBD VBD O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
randomized JJ JJ O
phase NN NN O
II NNP NNP O
study NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
safety NN NN O
and CC CC O
activity NN NN O
of IN IN O
combination NN NN O
therapy NN NN O
with IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
butyl NN NN I-CHEM
- : : I-CHEM
deoxynojirimycin NN NN I-CHEM
( ( ( O
SC NNP NNP B-CHEM
- - - I-CHEM
48334 CD CD I-CHEM
) ) ) O
( ( ( O
an DT DT O
alpha NN NN O
- - - O
glucosidase NN NN O
I PRP PRP O
inhibitor VBP VBP O
) ) ) O
and CC CC O
zidovudine NN NN B-CHEM
versus CC CC O
zidovudine NN NN B-CHEM
alone RB RB O
. . . O

Patients NNS NNS O
with IN IN O
200 CD CD O
to TO TO O
500 CD CD O
CD4 NNP NNP O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
who WP WP O
tolerated VBD VBD O
< NN NN O
or CC CC O
= SYM SYM O
12 CD CD O
weeks NNS NNS O
of IN IN O
prior RB RB O
zidovudine NN NN B-CHEM
therapy NN NN O
received VBD VBD O
SC NNP NNP B-CHEM
- : : I-CHEM
48334 CD CD I-CHEM
( ( ( O
1000 CD CD O
mg NN NN O
every DT DT O
8 CD CD O
h NN NN O
) ) ) O
and CC CC O
zidovudine NN NN B-CHEM
( ( ( O
100 CD CD O
mg NN NN O
every DT DT O
8 CD CD O
h NN NN O
) ) ) O
or CC CC O
zidovudine NN NN B-CHEM
and CC CC O
placebo NN NN O
. . . O

Sixty NNP NNP O
patients NNS NNS O
received VBD VBD O
combination NN NN O
therapy NN NN O
and CC CC O
58 CD CD O
, , , O
zidovudine NN NN B-CHEM
and CC CC O
placebo NN NN O
. . . O

Twenty CD CD O
- - - O
three CD CD O
patients NNS NNS O
( ( ( O
38 CD CD O
% NN NN O
) ) ) O
and CC CC O
15 CD CD O
( ( ( O
26 CD CD O
% NN NN O
) ) ) O
, , , O
in IN IN O
the DT DT O
combination NN NN O
and CC CC O
zidovudine NN NN B-CHEM
groups NNS NNS O
, , , O
respectively RB RB O
, , , O
discontinued VBD VBD O
therapy NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
15 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
SC NNP NNP B-CHEM
- : : I-CHEM
48334 CD CD I-CHEM
steady JJ JJ O
- : : O
state NN NN O
trough NN NN O
level NN NN O
( ( ( O
4 CD CD O
. . . O
04 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
99 CD CD O
micrograms NNS NNS O
/ NN NN O
ml NN NN O
) ) ) O
was VBD VBD O
below IN IN O
the DT DT O
in IN IN O
vitro NN NN O
inhibitory NN NN O
concentration NN NN O
for IN IN O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
( ( ( O
HIV NNP NNP O
) ) ) O
. . . O

The DT DT O
mean NN NN O
increase NN NN O
in IN IN O
CD4 NNP NNP O
cells NNS NNS O
at IN IN O
week NN NN O
4 CD CD O
was VBD VBD O
73 CD CD O
. . . O
8 CD CD O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
and CC CC O
52 CD CD O
. . . O
4 CD CD O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
for IN IN O
the DT DT O
combination NN NN O
and CC CC O
zidovudine NN NN B-CHEM
groups NNS NNS O
, , , O
respectively RB RB O
( ( ( O
p NN NN O
> NN NN O
0 CD CD O
. . . O
36 CD CD O
) ) ) O
. . . O

For IN IN O
patients NNS NNS O
with IN IN O
prior RB RB O
zidovudine NN NN B-CHEM
therapy NN NN O
, , , O
the DT DT O
mean NN NN O
change NN NN O
in IN IN O
CD4 NNP NNP O
cells NNS NNS O
in IN IN O
the DT DT O
combination NN NN O
and CC CC O
zidovudine NN NN B-CHEM
groups NNS NNS O
was VBD VBD O
63 CD CD O
. . . O
7 CD CD O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
and CC CC O
4 CD CD O
. . . O
9 CD CD O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
at IN IN O
week NN NN O
8 CD CD O
and CC CC O
6 CD CD O
. . . O
8 CD CD O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
and CC CC O
- - - O
45 CD CD O
. . . O
1 CD CD O
cells NNS NNS O
/ NN NN O
mm3 NN NN O
at IN IN O
week NN NN O
16 CD CD O
, , , O
respectively RB RB O
. . . O

The DT DT O
number NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
suppression NN NN O
of IN IN O
HIV NNP NNP O
p24 NN NN O
antigenemia NN NN O
in IN IN O
the DT DT O
combination NN NN O
and CC CC O
zidovudine NN NN B-CHEM
groups NNS NNS O
was VBD VBD O
six CD CD O
( ( ( O
40 CD CD O
% NN NN O
) ) ) O
and CC CC O
two CD CD O
( ( ( O
11 CD CD O
% NN NN O
) ) ) O
at IN IN O
week NN NN O
4 CD CD O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
10 CD CD O
) ) ) O
and CC CC O
five CD CD O
( ( ( O
45 CD CD O
% NN NN O
) ) ) O
and CC CC O
two CD CD O
( ( ( O
14 CD CD O
% NN NN O
) ) ) O
at IN IN O
week NN NN O
24 CD CD O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
08 CD CD O
) ) ) O
, , , O
respectively RB RB O
. . . O

Diarrhea NNP NNP O
, , , O
flatulence NN NN O
, , , O
abdominal JJ JJ O
pain NN NN O
, , , O
and CC CC O
weight NN NN O
loss NN NN O
were VBD VBD O
common JJ JJ O
for IN IN O
combination NN NN O
recipients NNS NNS O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Prolonged NNP NNP O
paralysis NN NN O
due JJ JJ O
to TO TO O
nondepolarizing VBG VBG B-CHEM
neuromuscular NN NN I-CHEM
blocking VBG VBG I-CHEM
agents NNS NNS I-CHEM
and CC CC O
corticosteroids NNS NNS B-CHEM
. . . O

The DT DT O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
nondepolarizing VBG VBG B-CHEM
neuromuscular NN NN I-CHEM
blocking VBG VBG I-CHEM
agents NNS NNS I-CHEM
( ( ( O
ND NNP NNP B-CHEM
- - - I-CHEM
NMBA NNP NNP I-CHEM
) ) ) O
has VBZ VBZ O
recently RB RB O
been VBN VBN O
implicated VBN VBN O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
prolonged JJ JJ O
muscle NN NN O
weakness NN NN O
, , , O
although IN IN O
the DT DT O
site NN NN O
of IN IN O
the DT DT O
lesion NN NN O
and CC CC O
the DT DT O
predisposing VBG VBG O
factors NNS NNS O
have VBP VBP O
been VBN VBN O
unclear JJ JJ O
. . . O

We PRP PRP O
report VBP VBP O
3 CD CD O
patients NNS NNS O
( ( ( O
age NN NN O
37 CD CD O
- : : O
52 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
acute JJ JJ O
respiratory JJ JJ O
insufficiency NN NN O
who WP WP O
developed VBD VBD O
prolonged JJ JJ O
weakness NN NN O
following VBG VBG O
the DT DT O
discontinuation NN NN O
of IN IN O
ND NNP NNP B-CHEM
- - - I-CHEM
NMBAs NNP NNP I-CHEM
. . . O

Two CD CD O
patients NNS NNS O
also RB RB O
received VBD VBD O
intravenous JJ JJ O
corticosteroids NNS NNS B-CHEM
. . . O

Renal NNP NNP O
function NN NN O
was VBD VBD O
normal JJ JJ O
but CC CC O
hepatic JJ JJ O
function NN NN O
was VBD VBD O
impaired VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
, , , O
and CC CC O
all DT DT O
had VBD VBD O
acidosis NN NN O
. . . O

Electrophysiologic NNP NNP O
studies NNS NNS O
revealed VBD VBD O
low JJ JJ O
amplitude NN NN O
compound NN NN O
motor NN NN O
action NN NN O
potentials NNS NNS O
, , , O
normal JJ JJ O
sensory NN NN O
studies NNS NNS O
, , , O
and CC CC O
fibrillations NNS NNS O
. . . O

Repetitive NNP NNP O
stimulation NN NN O
at IN IN O
2 CD CD O
Hz NNP NNP O
showed VBD VBD O
a DT DT O
decremental JJ JJ O
response NN NN O
in IN IN O
2 CD CD O
patients NNS NNS O
. . . O

The DT DT O
serum NN NN O
vecuronium NN NN B-CHEM
level NN NN O
measured VBN VBN O
in IN IN O
1 CD CD O
patient NN NN O
14 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
drug NN NN O
had VBD VBD O
been VBN VBN O
discontinued VBN VBN O
was VBD VBD O
172 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
. . . O

A DT DT O
muscle NN NN O
biopsy NN NN O
in IN IN O
this DT DT O
patient NN NN O
showed VBD VBD O
loss NN NN O
of IN IN O
thick JJ JJ O
, , , O
myosin NN NN O
filaments NNS NNS O
. . . O

The DT DT O
weakness NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
is VBZ VBZ O
due JJ JJ O
to TO TO O
pathology NN NN O
at IN IN O
both DT DT O
the DT DT O
neuromuscular JJ JJ O
junction NN NN O
( ( ( O
most JJS JJS O
likely JJ JJ O
due JJ JJ O
to TO TO O
ND NNP NNP B-CHEM
- - - I-CHEM
NMBA NNP NNP I-CHEM
) ) ) O
and CC CC O
muscle NN NN O
( ( ( O
most JJS JJS O
likely JJ JJ O
due JJ JJ O
to TO TO O
corticosteroids NNS NNS B-CHEM
) ) ) O
. . . O

Hepatic NNP NNP O
dysfunction NN NN O
and CC CC O
acidosis NNS NNS O
are VBP VBP O
contributing VBG VBG O
risk NN NN O
factors NNS NNS O
. . . O

Failure NN NN O
of IN IN O
ancrod NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
arterial JJ JJ O
thrombosis NN NN O
. . . O

The DT DT O
morbidity NN NN O
and CC CC O
mortality NN NN O
associated VBN VBN O
with IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombosis NNS NNS O
remain VBP VBP O
high JJ JJ O
despite IN IN O
numerous JJ JJ O
empirical JJ JJ O
therapies NNS NNS O
. . . O

Ancrod NNP NNP O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
successfully RB RB O
for IN IN O
prophylaxis NN NN O
against IN IN O
development NN NN O
of IN IN O
thrombosis NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
heparin NN NN B-CHEM
induced JJ JJ O
platelet NN NN O
aggregation NN NN O
who WP WP O
require VBP VBP O
brief JJ JJ O
reexposure NN NN O
to TO TO O
heparin NN NN B-CHEM
, , , O
but CC CC O
its PRP$ PRP$ O
success NN NN O
in IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
developed VBN VBN O
the DT DT O
thrombosis NNS NNS O
syndrome NN NN O
is VBZ VBZ O
not RB RB O
well RB RB O
defined VBN VBN O
. . . O

The DT DT O
authors NNS NNS O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
failure NN NN O
of IN IN O
ancrod NN NN O
treatment NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombosis NN NN O
. . . O

Water NNP NNP O
intoxication NN NN O
associated VBN VBN O
with IN IN O
oxytocin NN NN B-CHEM
administration NN NN O
during IN IN O
saline NN NN O
- - - O
induced JJ JJ O
abortion NN NN O
. . . O

Four CD CD O
cases NNS NNS O
of IN IN O
water NN NN O
intoxication NN NN O
in IN IN O
connection NN NN O
with IN IN O
oxytocin NN NN B-CHEM
administration NN NN O
during IN IN O
saline NN NN O
- - - O
induced JJ JJ O
abortions NNS NNS O
are VBP VBP O
described VBN VBN O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
water NN NN O
intoxication NN NN O
is VBZ VBZ O
discussed VBN VBN O
in IN IN O
regard NN NN O
to TO TO O
these DT DT O
cases NNS NNS O
. . . O

Oxytocin NNP NNP B-CHEM
administration NN NN O
during IN IN O
midtrimester NN NN O
- : : O
induced JJ JJ O
abortions NNS NNS O
is VBZ VBZ O
advocated VBN VBN O
only RB RB O
if IN IN O
it PRP PRP O
can MD MD O
be VB VB O
carried VBN VBN O
out IN IN O
under IN IN O
careful JJ JJ O
observations NNS NNS O
of IN IN O
an DT DT O
alert NN NN O
nursing VBG VBG O
staff NN NN O
, , , O
aware JJ JJ O
of IN IN O
the DT DT O
symptoms NNS NNS O
of IN IN O
water NN NN O
intoxication NN NN O
and CC CC O
instructed VBN VBN O
to TO TO O
watch VB VB O
the DT DT O
diuresis NN NN O
and CC CC O
report NN NN O
such JJ JJ O
early JJ JJ O
signs NNS NNS O
of IN IN O
the DT DT O
syndrome NN NN O
as IN IN O
asthenia NN NN O
, , , O
muscular JJ JJ O
irritability NN NN O
, , , O
or CC CC O
headaches NNS NNS O
. . . O

The DT DT O
oxytocin NN NN B-CHEM
should MD MD O
be VB VB O
given VBN VBN O
only RB RB O
in IN IN O
Ringers NNP NNP O
lactate NN NN B-CHEM
or CC CC O
, , , O
alternately RB RB O
, , , O
in IN IN O
Ringers NNP NNP O
lactate NN NN B-CHEM
and CC CC O
a DT DT O
5 CD CD O
per IN IN O
cent NN NN O
dextrose NN NN B-CHEM
and CC CC O
water NN NN O
solutions NNS NNS O
. . . O

The DT DT O
urinary JJ JJ O
output NN NN O
should MD MD O
be VB VB O
monitored VBN VBN O
and CC CC O
the DT DT O
oxytocin NN NN B-CHEM
administration NN NN O
discontinued VBD VBD O
and CC CC O
the DT DT O
serum NN NN O
electrolytes NNS NNS O
checked VBN VBN O
if IN IN O
the DT DT O
urinary JJ JJ O
output NN NN O
decreases NNS NNS O
. . . O

The DT DT O
oxytocin NN NN B-CHEM
should MD MD O
not RB RB O
be VB VB O
administered VBN VBN O
in IN IN O
excess NN NN O
of IN IN O
36 CD CD O
hours NNS NNS O
. . . O

If IN IN O
the DT DT O
patient NN NN O
has VBZ VBZ O
not RB RB O
aborted VBN VBN O
by IN IN O
then RB RB O
the DT DT O
oxytocin NN NN B-CHEM
should MD MD O
be VB VB O
discontinued VBN VBN O
for IN IN O
10 CD CD O
to TO TO O
12 CD CD O
hours NNS NNS O
in IN IN O
order NN NN O
to TO TO O
perform VB VB O
electrolyte NN NN O
determinations NNS NNS O
and CC CC O
correct VB VB O
any DT DT O
electrolyte NN NN O
imbalance NN NN O
. . . O

Light NNP NNP O
chain NN NN O
proteinuria NN NN O
and CC CC O
cellular NN NN O
mediated JJ JJ O
immunity NN NN O
in IN IN O
rifampin NN NN B-CHEM
treated VBN VBN O
patients NNS NNS O
with IN IN O
tuberculosis NN NN O
. . . O

Light NNP NNP O
chain NN NN O
proteinuria NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
9 CD CD O
of IN IN O
17 CD CD O
tuberculosis NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
rifampin NN NN B-CHEM
. . . O

Concomitant NNP NNP O
assay NN NN O
of IN IN O
cellular NN NN O
mediated JJ JJ O
immunity NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
using VBG VBG O
skin NN NN O
test NN NN O
antigen NN NN O
and CC CC O
a DT DT O
lymphokine NN NN O
in IN IN O
vitro NN NN O
test NN NN O
provided VBN VBN O
results NNS NNS O
that WDT WDT O
were VBD VBD O
different JJ JJ O
. . . O

Response NNP NNP O
to TO TO O
Varidase NNP NNP O
skin NN NN O
test NN NN O
antigen NN NN O
was VBD VBD O
negative JJ JJ O
for IN IN O
all DT DT O
eight CD CD O
tuberculosis NN NN O
patients NNS NNS O
tested VBN VBN O
, , , O
but CC CC O
there EX EX O
occurred VBD VBD O
a DT DT O
hyper NN NN O
- - - O
responsiveness NN NN O
of IN IN O
the DT DT O
lymphocytes NNS NNS O
of IN IN O
these DT DT O
eight CD CD O
patients NNS NNS O
to TO TO O
phytomitogen NN NN O
( ( ( O
PHA NNP NNP O
- - - O
P NN NN O
) ) ) O
. . . O
as RB RB O
well RB RB O
as IN IN O
of IN IN O
those DT DT O
of IN IN O
seven CD CD O
other JJ JJ O
tuberculous JJ JJ O
patients NNS NNS O
. . . O

This DT DT O
last JJ JJ O
finding NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
time NN NN O
of IN IN O
testing NN NN O
and CC CC O
/ NN NN O
or CC CC O
endogenous JJ JJ O
serum NN NN O
binding JJ JJ O
of IN IN O
rifampin NN NN B-CHEM
which WDT WDT O
could MD MD O
have VB VB O
inhibited VBN VBN O
mitogen NN NN O
activity NN NN O
for IN IN O
the DT DT O
lymphocyte NN NN O
. . . O

KF17837 NNP NNP B-CHEM
: : : O
a DT DT O
novel NN NN O
selective JJ JJ O
adenosine NN NN B-CHEM
A2A NNP NNP O
receptor NN NN O
antagonist NN NN O
with IN IN O
anticataleptic JJ JJ O
activity NN NN O
. . . O

KF17837 NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
novel NN NN O
selective JJ JJ O
adenosine NN NN B-CHEM
A2A NNP NNP O
receptor NN NN O
antagonist NN NN O
. . . O

Oral NNP NNP O
administration NN NN O
of IN IN O
KF17837 NNP NNP B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
, , , O
10 CD CD O
. . . O
0 CD CD O
and CC CC O
30 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
significantly RB RB O
ameliorated VBD VBD O
the DT DT O
cataleptic JJ JJ O
responses NNS NNS O
induced VBN VBN O
by IN IN O
intracerebroventricular JJ JJ O
administration NN NN O
of IN IN O
an DT DT O
adenosine NN NN B-CHEM
A2A NNP NNP O
receptor NN NN O
agonist NN NN O
, , , O
CGS NNP NNP B-CHEM
21680 CD CD I-CHEM
( ( ( O
10 CD CD O
micrograms NNS NNS O
) ) ) O
, , , O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

KF17837 NNP NNP B-CHEM
also RB RB O
reduced VBD VBD O
the DT DT O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
and CC CC O
by IN IN O
reserpine NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

These DT DT O
anticataleptic JJ JJ O
effects NNS NNS O
were VBD VBD O
exhibited VBN VBN O
dose NN NN O
dependently RB RB O
at IN IN O
doses NNS NNS O
from IN IN O
0 CD CD O
. . . O
625 CD CD O
and CC CC O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
respectively RB RB O
. . . O

Moreover RB RB O
, , , O
KF17837 NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
625 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
potentiated VBD VBD O
the DT DT O
anticataleptic JJ JJ O
effects NNS NNS O
of IN IN O
a DT DT O
subthreshold JJ JJ O
dose NN NN O
of IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydroxyphenylalanine NN NN I-CHEM
( ( ( O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
; : : O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
plus CC CC O
benserazide NN NN B-CHEM
( ( ( O
6 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggested VBD VBD O
that IN IN O
KF17837 NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
centrally RB RB O
active JJ JJ O
adenosine NN NN B-CHEM
A2A NNP NNP O
receptor NN NN O
antagonist NN NN O
and CC CC O
that IN IN O
the DT DT O
dopaminergic JJ JJ O
function NN NN O
of IN IN O
the DT DT O
nigrostriatal JJ JJ O
pathway NN NN O
is VBZ VBZ O
potentiated VBN VBN O
by IN IN O
adenosine NN NN B-CHEM
A2A NNP NNP O
receptor NN NN O
antagonists NNS NNS O
. . . O

Furthermore RB RB O
, , , O
KF17837 NNP NNP B-CHEM
may MD MD O
be VB VB O
a DT DT O
useful JJ JJ O
drug NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
parkinsonism NN NN O
. . . O

Effect NN NN O
of IN IN O
nondopaminergic JJ JJ O
drugs NNS NNS O
on IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
in IN IN O
MPTP NNP NNP B-CHEM
- - - O
treated JJ JJ O
monkeys NNS NNS O
. . . O

A DT DT O
group NN NN O
of IN IN O
four CD CD O
monkeys NNS NNS O
was VBD VBD O
rendered VBN VBN O
parkinsonian JJ JJ O
with IN IN O
the DT DT O
toxin NN NN O
MPTP NNP NNP B-CHEM
. . . O

They PRP PRP O
were VBD VBD O
then RB RB O
treated VBN VBN O
chronically RB RB O
with IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
DOPA NNP NNP I-CHEM
/ NN NN I-CHEM
benserazide NN NN I-CHEM
50 CD CD O
/ NN NN O
12 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
given VBN VBN O
orally RB RB O
daily JJ JJ O
for IN IN O
2 CD CD O
months NNS NNS O
. . . O

This DT DT O
dose NN NN O
produced VBD VBD O
a DT DT O
striking JJ JJ O
antiparkinsonian JJ JJ O
effect NN NN O
, , , O
but CC CC O
all DT DT O
animals NNS NNS O
manifested JJ JJ O
dyskinesia NN NN O
. . . O

A DT DT O
series NN NN O
of IN IN O
agents NNS NNS O
acting VBG VBG O
primarily RB RB O
on IN IN O
neurotransmitters NNS NNS O
other JJ JJ O
than IN IN O
dopamine NN NN B-CHEM
were VBD VBD O
then RB RB O
tested VBN VBN O
in IN IN O
combination NN NN O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
to TO TO O
see VB VB O
if IN IN O
the DT DT O
dyskinetic JJ JJ O
movements NNS NNS O
would MD MD O
be VB VB O
modified VBN VBN O
. . . O

Several JJ JJ O
drugs NNS NNS O
, , , O
including VBG VBG O
clonidine NN NN B-CHEM
, , , O
physostigmine NN NN B-CHEM
, , , O
methysergide NN NN B-CHEM
, , , O
5 CD CD B-CHEM
- : : I-CHEM
MDOT NNP NNP I-CHEM
, , , O
propranolol NN NN B-CHEM
, , , O
and CC CC O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
, , , O
markedly RB RB O
reduced VBD VBD O
the DT DT O
dyskinetic JJ JJ O
movements NNS NNS O
but CC CC O
at IN IN O
the DT DT O
cost NN NN O
of IN IN O
a DT DT O
return NN NN O
of IN IN O
parkinsonian JJ JJ O
symptomatology NN NN O
. . . O

However RB RB O
, , , O
yohimbine NN NN B-CHEM
and CC CC O
meperidine NN NN B-CHEM
reduced VBN VBN O
predominantly RB RB O
the DT DT O
dyskinetic JJ JJ O
movements NNS NNS O
. . . O

Baclofen NNP NNP B-CHEM
was VBD VBD O
also RB RB O
useful JJ JJ O
in IN IN O
one CD CD O
monkey NN NN O
against IN IN O
a DT DT O
more RBR RBR O
dystonic JJ JJ O
form NN NN O
of IN IN O
dyskinesia NN NN O
. . . O

Atropine NNP NNP B-CHEM
converted VBD VBD O
the DT DT O
dystonic JJ JJ O
movements NNS NNS O
into IN IN O
chorea NN NN O
. . . O

Hallucinations NNP NNP O
and CC CC O
ifosfamide NN NN B-CHEM
- - - O
induced JJ JJ O
neurotoxicity NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Hallucinations NNP NNP O
as IN IN O
a DT DT O
symptom NN NN O
of IN IN O
central JJ JJ O
neurotoxicity NN NN O
are VBP VBP O
a DT DT O
known VBN VBN O
but CC CC O
poorly RB RB O
described VBD VBD O
side NN NN O
effect NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
. . . O

Most JJS JJS O
cases NNS NNS O
of IN IN O
ifosfamide JJ JJ B-CHEM
- - - O
induced JJ JJ O
hallucinations NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
with IN IN O
other JJ JJ O
mental JJ JJ O
status NN NN O
changes NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
authors NNS NNS O
interviewed VBD VBD O
six CD CD O
persons NNS NNS O
with IN IN O
ifosfamide NN NN B-CHEM
- - - O
induced JJ JJ O
hallucinations NNS NNS O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
a DT DT O
clear JJ JJ O
sensorium NN NN O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
receiving VBG VBG O
high JJ JJ O
- - - O
dose NN NN O
ifosfamide NN NN B-CHEM
as IN IN O
part NN NN O
of IN IN O
their PRP$ PRP$ O
bone NN NN O
marrow NN NN O
transplant JJ JJ O
procedure NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Hallucinations NNP NNP O
occurred VBD VBD O
only RB RB O
when WRB WRB O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
eyes NNS NNS O
were VBD VBD O
closed VBN VBN O
and CC CC O
, , , O
in IN IN O
all DT DT O
but CC CC O
one CD CD O
case NN NN O
, , , O
were VBD VBD O
reported VBN VBN O
as IN IN O
disturbing JJ JJ O
or CC CC O
frightening VBG VBG O
. . . O

Underreporting NNP NNP O
of IN IN O
these DT DT O
hallucinations NNS NNS O
by IN IN O
patients NNS NNS O
is VBZ VBZ O
likely JJ JJ O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Hallucinations NNP NNP O
may MD MD O
be VB VB O
the DT DT O
sole JJ JJ O
or CC CC O
first JJ JJ O
manifestation NN NN O
of IN IN O
neurotoxicity NN NN O
. . . O

The DT DT O
incidence NN NN O
may MD MD O
be VB VB O
dose JJ JJ O
and CC CC O
infusion NN NN O
- - - O
time NN NN O
related VBN VBN O
. . . O

The DT DT O
clinician NN NN O
should MD MD O
be VB VB O
alerted VBN VBN O
for IN IN O
possible JJ JJ O
ifosfamide NN NN B-CHEM
- - - O
induced JJ JJ O
hallucinations NNS NNS O
, , , O
which WDT WDT O
may MD MD O
occur VB VB O
without IN IN O
other JJ JJ O
signs NNS NNS O
of IN IN O
neurotoxicity NN NN O
. . . O

" '' '' O
Eyes NNS NNS O
- - - O
closed JJ JJ O
" '' '' O
hallucinatory JJ JJ O
experiences NNS NNS O
appear VBP VBP O
to TO TO O
be VB VB O
an DT DT O
unusual JJ JJ O
feature NN NN O
of IN IN O
this DT DT O
presentation NN NN O
. . . O

Patients NNS NNS O
anxious JJ JJ O
about IN IN O
this DT DT O
experience NN NN O
respond NN NN O
well RB RB O
to TO TO O
support VB VB O
and CC CC O
education NN NN O
about IN IN O
this DT DT O
occurrence NN NN O
. . . O

Optimal NNP NNP O
pharmacologic JJ JJ O
management NN NN O
of IN IN O
disturbed VBN VBN O
patients NNS NNS O
is VBZ VBZ O
unclear JJ JJ O
. . . O

If IN IN O
agitation NN NN O
becomes VBZ VBZ O
marked VBN VBN O
, , , O
high JJ JJ O
- - - O
potency NN NN O
neuroleptics NNS NNS O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
haloperidol NN NN B-CHEM
) ) ) O
may MD MD O
be VB VB O
effective JJ JJ O
. . . O

Photodistributed NNP NNP O
nifedipine NN NN B-CHEM
- : : O
induced JJ JJ O
facial JJ JJ O
telangiectasia NN NN O
. . . O

Five CD CD O
months NNS NNS O
after IN IN O
starting VBG VBG O
nifedipine NN NN B-CHEM
( ( ( O
Adalat NNP NNP B-CHEM
) ) ) O
, , , O
two CD CD O
patients NNS NNS O
developed VBN VBN O
photodistributed VBN VBN O
facial JJ JJ O
telangiectasia NN NN O
, , , O
which WDT WDT O
became VBD VBD O
more RBR RBR O
noticeable JJ JJ O
with IN IN O
time NN NN O
. . . O

Neither DT DT O
patient NN NN O
complained VBD VBD O
of IN IN O
photosensitivity NN NN O
or CC CC O
flushing VBG VBG O
. . . O

Both DT DT O
patients NNS NNS O
reported VBD VBD O
a DT DT O
significant JJ JJ O
cosmetic JJ JJ O
improvement NN NN O
after IN IN O
discontinuing VBG VBG O
the DT DT O
drug NN NN O
. . . O

One CD CD O
commenced VBD VBD O
the DT DT O
closely RB RB O
related VBN VBN O
drug NN NN O
amlodipine NN NN B-CHEM
3 CD CD O
years NNS NNS O
later RB RB O
, , , O
with IN IN O
recurrence NN NN O
of IN IN O
telangiectasia NN NN O
. . . O

The DT DT O
photodistribution NN NN O
of IN IN O
the DT DT O
telangiectasia NN NN O
suggests VBZ VBZ O
a DT DT O
significant JJ JJ O
drug NN NN O
/ NN NN O
light JJ JJ O
interaction NN NN O
. . . O

Penicillamine NNP NNP B-CHEM
- : : O
induced JJ JJ O
rapidly RB RB O
progressive JJ JJ O
glomerulonephritis NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
. . . O

A DT DT O
67 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
presented VBD VBD O
rapidly RB RB O
progressive JJ JJ O
glomerulonephritis NN NN O
( ( ( O
RPGN NNP NNP O
) ) ) O
after IN IN O
5 CD CD O
months NNS NNS O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
( ( ( O
250 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
treatment NN NN O
. . . O

Light NNP NNP O
microscopy NN NN O
study NN NN O
showed VBD VBD O
severe JJ JJ O
glomerulonephritis NNS NNS O
with IN IN O
crescent NN NN O
formation NN NN O
in IN IN O
60 CD CD O
% NN NN O
of IN IN O
the DT DT O
glomeruli NN NN O
and CC CC O
infiltration NN NN O
of IN IN O
inflammatory JJ JJ O
cells NNS NNS O
in IN IN O
the DT DT O
wall NN NN O
of IN IN O
an DT DT O
arteriole NN NN O
. . . O

Immunofluorescence NNP NNP O
revealed VBD VBD O
scanty NN NN O
granular NN NN O
IgG NNP NNP O
, , , O
IgA NNP NNP O
and CC CC O
C3 NNP NNP O
deposits NNS NNS O
along IN IN O
the DT DT O
capillary JJ JJ O
walls NNS NNS O
and CC CC O
mesangium NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
steroid NN NN B-CHEM
pulse NN NN O
, , , O
plasmapheresis NN NN O
, , , O
cyclophosphamide NN NN B-CHEM
and CC CC O
antiplatelet NN NN B-CHEM
agents NNS NNS I-CHEM
. . . O

A DT DT O
complete JJ JJ O
recovery NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
was VBD VBD O
achieved VBN VBN O
in IN IN O
a DT DT O
few JJ JJ O
weeks NNS NNS O
. . . O

This DT DT O
new JJ JJ O
case NN NN O
of IN IN O
RPGN NNP NNP O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
treatment NN NN O
emphasizes VBZ VBZ O
the DT DT O
need NN NN O
for IN IN O
frequent JJ JJ O
monitoring NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
and CC CC O
evaluation NN NN O
of IN IN O
urinary JJ JJ O
sediment NN NN O
and CC CC O
proteinuria NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

The DT DT O
prompt NN NN O
discontinuation NN NN O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
and CC CC O
vigorous JJ JJ O
treatment NN NN O
measures NNS NNS O
could MD MD O
allow VB VB O
for IN IN O
a DT DT O
good JJ JJ O
prognosis NN NN O
as IN IN O
in IN IN O
this DT DT O
case NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
polymyositis NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
primary JJ JJ O
biliary JJ JJ O
cirrhosis NNS NNS O
treated VBN VBN O
with IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
. . . O

Although IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
for IN IN O
many JJ JJ O
rheumatologic JJ JJ O
diseases NNS NNS O
, , , O
toxicity NN NN O
limits NNS NNS O
its PRP$ PRP$ O
usefulness JJ JJ O
in IN IN O
many JJ JJ O
patients NNS NNS O
. . . O

Polymyositis NNP NNP O
/ NN NN O
dermatomyositis NNS NNS O
can MD MD O
develop VB VB O
as IN IN O
one CD CD O
of IN IN O
the DT DT O
autoimmune JJ JJ O
complications NNS NNS O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
treatment NN NN O
, , , O
but CC CC O
its PRP$ PRP$ O
exact JJ JJ O
pathogenesis NNS NNS O
remains VBZ VBZ O
unclear JJ JJ O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
patient NN NN O
with IN IN O
primary JJ JJ O
biliary JJ JJ O
cirrhosis NNS NNS O
, , , O
who WP WP O
developed VBD VBD O
polymyositis NNS NNS O
while IN IN O
receiving VBG VBG O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
therapy NN NN O
. . . O

We PRP PRP O
described VBD VBD O
the DT DT O
special JJ JJ O
clinical JJ JJ O
course NN NN O
of IN IN O
the DT DT O
patient NN NN O
. . . O

Patients NNS NNS O
receiving VBG VBG O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
therapy NN NN O
should MD MD O
be VB VB O
followed VBN VBN O
carefully RB RB O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
autoimmune JJ JJ O
complications NNS NNS O
like IN IN O
polymyositis NN NN O
/ NN NN O
dermatomyositis NN NN O
. . . O

Hyperalgesia NNP NNP O
and CC CC O
myoclonus NN NN O
in IN IN O
terminal JJ JJ O
cancer NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
continuous JJ JJ O
intravenous JJ JJ O
morphine NN NN B-CHEM
. . . O

Eight CD CD O
cancer NN NN O
patients NNS NNS O
in IN IN O
the DT DT O
terminal NN NN O
stages NNS NNS O
of IN IN O
the DT DT O
disease NN NN O
treated VBN VBN O
with IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
intravenous JJ JJ O
morphine NN NN B-CHEM
developed VBN VBN O
hyperalgesia NN NN O
. . . O

All DT DT O
cases NNS NNS O
were VBD VBD O
retrospectively RB RB O
sampled VBN VBN O
from IN IN O
three CD CD O
different JJ JJ O
hospitals NNS NNS O
in IN IN O
Copenhagen NNP NNP O
. . . O

Five CD CD O
patients NNS NNS O
developed VBN VBN O
universal JJ JJ O
hyperalgesia NN NN O
and CC CC O
hyperesthesia NN NN O
which WDT WDT O
in IN IN O
2 CD CD O
cases NNS NNS O
were VBD VBD O
accompanied VBN VBN O
by IN IN O
myoclonus NN NN O
. . . O

In IN IN O
3 CD CD O
patients NNS NNS O
a DT DT O
pre NN NN O
- - - O
existing VBG VBG O
neuralgia NN NN O
increased VBD VBD O
to TO TO O
excruciating VBG VBG O
intensity NN NN O
and CC CC O
in IN IN O
2 CD CD O
of IN IN O
these DT DT O
cases NNS NNS O
myoclonus VBP VBP O
occurred JJ JJ O
simultaneously RB RB O
. . . O

Although IN IN O
only RB RB O
few JJ JJ O
clinical JJ JJ O
descriptions NNS NNS O
of IN IN O
the DT DT O
relationship NN NN O
between IN IN O
hyperalgesia NN NN O
/ NN NN O
myoclonus NN NN O
and CC CC O
high JJ JJ O
doses NNS NNS O
of IN IN O
morphine NN NN B-CHEM
are VBP VBP O
available JJ JJ O
, , , O
experimental JJ JJ O
support NN NN O
from IN IN O
animal NN NN O
studies NNS NNS O
indicates NNS NNS O
that IN IN O
morphine NN NN B-CHEM
, , , O
or CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
, , , O
plays VBZ VBZ O
a DT DT O
causative JJ JJ O
role NN NN O
for IN IN O
the DT DT O
observed VBN VBN O
behavioural NN NN O
syndrome NN NN O
. . . O

The DT DT O
possible JJ JJ O
mechanisms NNS NNS O
are VBP VBP O
discussed VBN VBN O
and CC CC O
treatment NN NN O
proposals NNS NNS O
given VBN VBN O
suggesting VBG VBG O
the DT DT O
use NN NN O
of IN IN O
more RBR RBR O
efficacious JJ JJ O
opioids NNS NNS O
with IN IN O
less JJR JJR O
excitatory JJ JJ O
potency NN NN O
in IN IN O
these DT DT O
situations NNS NNS O
. . . O

Liposomal NNP NNP O
daunorubicin NN NN B-CHEM
in IN IN O
advanced VBN VBN O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
: : : O
a DT DT O
phase NN NN O
II NNP NNP O
study NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
non NN NN O
- - - O
randomized JJ JJ O
Phase NNP NNP O
II NNP NNP O
clinical JJ JJ O
trial NN NN O
to TO TO O
assess VB VB O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
liposomal NN NN O
daunorubicin NN NN B-CHEM
( ( ( O
DaunoXome NNP NNP O
) ) ) O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
AIDS NNP NNP O
related VBD VBD O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
. . . O

Eleven CD CD O
homosexual JJ JJ O
men NNS NNS O
with IN IN O
advanced JJ JJ O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
were VBD VBD O
entered VBN VBN O
in IN IN O
the DT DT O
trial NN NN O
. . . O

Changes NNS NNS O
in IN IN O
size NN NN O
, , , O
colour NN NN O
and CC CC O
associated VBN VBN O
oedema NN NN O
of IN IN O
selected VBN VBN O
' POS POS O
target NN NN O
' '' '' O
lesions NNS NNS O
were VBD VBD O
measured VBN VBN O
. . . O

Clinical NNP NNP O
, , , O
biochemical JJ JJ O
and CC CC O
haematological JJ JJ O
toxicities NNS NNS O
were VBD VBD O
assessed VBN VBN O
. . . O

Ten CD CD O
subjects NNS NNS O
were VBD VBD O
evaluated VBN VBN O
. . . O

A DT DT O
partial JJ JJ O
response NN NN O
was VBD VBD O
achieved VBN VBN O
in IN IN O
four CD CD O
, , , O
of IN IN O
whom WP WP O
two CD CD O
subsequently RB RB O
relapsed VBD VBD O
. . . O

Stabilization NNP NNP O
of IN IN O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
occurred VBN VBN O
in IN IN O
the DT DT O
remaining VBG VBG O
six CD CD O
, , , O
maintained VBD VBD O
until IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
trial NN NN O
period NN NN O
in IN IN O
four CD CD O
. . . O

The DT DT O
drug NN NN O
was VBD VBD O
generally RB RB O
well RB RB O
tolerated VBD VBD O
, , , O
with IN IN O
few JJ JJ O
mild JJ JJ O
symptoms NNS NNS O
of IN IN O
toxicity NN NN O
. . . O

The DT DT O
main JJ JJ O
problem NN NN O
encountered VBD VBD O
was VBD VBD O
haematological JJ JJ O
toxicity NN NN O
, , , O
with IN IN O
three CD CD O
subjects NNS NNS O
experiencing VBG VBG O
severe JJ JJ O
neutropenia NN NN O
( ( ( O
neutrophil NN NN O
count NN NN O
< NN NN O
0 CD CD O
. . . O
5 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
9 CD CD O
) ) ) O
/ NN NN O
l NN NN O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
cardiotoxicity NN NN O
. . . O

In IN IN O
this DT DT O
small JJ JJ O
patient NN NN O
sample NN NN O
, , , O
liposomal JJ JJ O
daunorubicin NN NN B-CHEM
was VBD VBD O
an DT DT O
effective JJ JJ O
and CC CC O
well RB RB O
tolerated VBN VBN O
agent NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Kaposi NNP NNP O
' POS POS O
s VBZ VBZ O
sarcoma NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
effects NNS NNS O
of IN IN O
vincristine NN NN B-CHEM
on IN IN O
the DT DT O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Forty CD CD O
patients NNS NNS O
with IN IN O
Non NNP NNP O
- : : O
Hodgkin NNP NNP O
' POS POS O
s VBZ VBZ O
Lymphoma NNP NNP O
treated VBN VBN O
with IN IN O
vincristine NN NN B-CHEM
between IN IN O
1984 CD CD O
and CC CC O
1990 CD CD O
( ( ( O
cumulative JJ JJ O
dose NN NN O
12 CD CD O
mg NN NN O
in IN IN O
18 CD CD O
- : : O
24 CD CD O
weeks NNS NNS O
) ) ) O
were VBD VBD O
investigated VBN VBN O
in IN IN O
order NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
long JJ JJ O
term NN NN O
effects NNS NNS O
of IN IN O
vincristine NN NN B-CHEM
on IN IN O
the DT DT O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

The DT DT O
patients NNS NNS O
were VBD VBD O
interviewed VBN VBN O
with IN IN O
emphasis NN NN O
on IN IN O
neuropathic JJ JJ O
symptoms NNS NNS O
. . . O

Physical JJ JJ O
and CC CC O
quantitative JJ JJ O
sensory JJ JJ O
examination NN NN O
with IN IN O
determination NN NN O
of IN IN O
vibratory NN NN O
perception NN NN O
and CC CC O
thermal JJ JJ O
discrimination NN NN O
thresholds NNS NNS O
were VBD VBD O
performed VBN VBN O
, , , O
four CD CD O
to TO TO O
77 CD CD O
months NNS NNS O
( ( ( O
median NN NN O
34 CD CD O
months NNS NNS O
) ) ) O
after IN IN O
vincristine NN NN B-CHEM
treatment NN NN O
. . . O

Twenty CD CD O
- - - O
seven CD CD O
patients NNS NNS O
reported VBD VBD O
neuropathic JJ JJ O
symptoms NNS NNS O
. . . O

In IN IN O
13 CD CD O
of IN IN O
these DT DT O
27 CD CD O
patients NNS NNS O
symptoms NNS NNS O
were VBD VBD O
still RB RB O
present JJ JJ O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
examination NN NN O
. . . O

In IN IN O
these DT DT O
patients NNS NNS O
sensory VBP VBP O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
predominated VBN VBN O
. . . O

In IN IN O
the DT DT O
other JJ JJ O
14 CD CD O
patients NNS NNS O
symptoms NNS NNS O
had VBD VBD O
been VBN VBN O
present JJ JJ O
in IN IN O
the DT DT O
past NN NN O
. . . O

Symptoms NNP NNP O
persisted VBD VBD O
maximally RB RB O
40 CD CD O
months NNS NNS O
since IN IN O
cessation NN NN O
of IN IN O
therapy NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
age NN NN O
difference NN NN O
between IN IN O
patients NNS NNS O
with IN IN O
and CC CC O
without IN IN O
complaints NNS NNS O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
examination NN NN O
. . . O

Normal JJ JJ O
reflexes NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
two CD CD O
third JJ JJ O
of IN IN O
patients NNS NNS O
. . . O

Neuropathic NNP NNP O
complaints NNS NNS O
were VBD VBD O
not RB RB O
very RB RB O
troublesome VB VB O
on IN IN O
the DT DT O
long JJ JJ O
term NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
with IN IN O
the DT DT O
above JJ JJ O
mentioned VBN VBN O
vincristine NN NN B-CHEM
dose NN NN O
schedule NN NN O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
of IN IN O
vincristine NN NN B-CHEM
neuropathy NN NN O
are VBP VBP O
reversible JJ JJ O
for IN IN O
a DT DT O
great JJ JJ O
deal NN NN O
and CC CC O
prognosis NN NN O
is VBZ VBZ O
fairly RB RB O
good JJ JJ O
. . . O

Hepatic NNP NNP O
adenomas NN NN O
and CC CC O
focal JJ JJ O
nodular JJ JJ O
hyperplasia NN NN O
of IN IN O
the DT DT O
liver NN NN O
in IN IN O
young JJ JJ O
women NNS NNS O
on IN IN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
: : : O
case NN NN O
reports NNS NNS O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
hepatic JJ JJ O
adenoma NN NN O
and CC CC O
one CD CD O
of IN IN O
focal JJ JJ O
nodular NN NN O
hyperplasia NN NN O
presumably RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
, , , O
are VBP VBP O
reported VBN VBN O
. . . O

Special JJ JJ O
reference NN NN O
is VBZ VBZ O
made VBN VBN O
to TO TO O
their PRP$ PRP$ O
clinical JJ JJ O
presentation NN NN O
, , , O
which WDT WDT O
may MD MD O
be VB VB O
totally RB RB O
asymptomatic JJ JJ O
. . . O

Liver NNP NNP O
- - - O
function NN NN O
tests NNS NNS O
are VBP VBP O
of IN IN O
little JJ JJ O
diagnostic JJ JJ O
value NN NN O
, , , O
but CC CC O
valuable JJ JJ O
information NN NN O
may MD MD O
be VB VB O
obtained VBN VBN O
from IN IN O
both DT DT O
liver NN NN O
scanning VBG VBG O
and CC CC O
hepatic JJ JJ O
angiography NN NN O
. . . O

Histologic NNP NNP O
differences NNS NNS O
and CC CC O
clinical JJ JJ O
similarities NNS NNS O
between IN IN O
hepatic JJ JJ O
adenoma NN NN O
and CC CC O
focal JJ JJ O
nodular JJ JJ O
hyperplasia NN NN O
of IN IN O
the DT DT O
liver NN NN O
are VBP VBP O
discussed VBN VBN O
. . . O

Loss NN NN O
of IN IN O
glutamate NN NN B-CHEM
decarboxylase NN NN O
mRNA NN NN O
- : : O
containing VBG VBG O
neurons NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
dentate NN NN O
gyrus NN NN O
following VBG VBG O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

In IN IN O
situ NN NN O
hybridization NN NN O
methods NNS NNS O
were VBD VBD O
used VBN VBN O
to TO TO O
determine VB VB O
if IN IN O
glutamic JJ JJ B-CHEM
acid NN NN I-CHEM
decarboxylase NN NN O
( ( ( O
GAD NNP NNP O
) ) ) O
mRNA NN NN O
- - - O
containing VBG VBG O
neurons NNS NNS O
within IN IN O
the DT DT O
hilus NN NN O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
are VBP VBP O
vulnerable JJ JJ O
to TO TO O
seizure VB VB O
- - - O
induced JJ JJ O
damage NN NN O
in IN IN O
a DT DT O
model NN NN O
of IN IN O
chronic JJ JJ O
seizures NNS NNS O
. . . O

Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
injected VBN VBN O
intraperitoneally RB RB O
with IN IN O
pilocarpine NN NN B-CHEM
, , , O
and CC CC O
the DT DT O
hippocampal JJ JJ O
formation NN NN O
was VBD VBD O
studied VBN VBN O
histologically RB RB O
at IN IN O
1 CD CD O
, , , O
2 CD CD O
, , , O
4 CD CD O
, , , O
and CC CC O
8 CD CD O
week NN NN O
intervals NNS NNS O
after IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

In IN IN O
situ NN NN O
hybridization NN NN O
histochemistry NN NN O
, , , O
using VBG VBG O
a DT DT O
digoxigenin NN NN B-CHEM
- - - O
labeled JJ JJ O
GAD NNP NNP O
cRNA NN NN O
probe NN NN O
, , , O
demonstrated VBD VBD O
a DT DT O
substantial JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
GAD NNP NNP O
mRNA NN NN O
- : : O
containing VBG VBG O
neurons NNS NNS O
in IN IN O
the DT DT O
hilus NN NN O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
in IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
at IN IN O
all DT DT O
time NN NN O
intervals NNS NNS O
. . . O

Additional JJ JJ O
neuronanatomical JJ JJ O
studies NNS NNS O
, , , O
including VBG VBG O
cresyl NN NN B-CHEM
violet NN NN I-CHEM
staining VBG VBG O
, , , O
neuronal JJ JJ O
degeneration NN NN O
methods NNS NNS O
, , , O
and CC CC O
histochemical JJ JJ O
localization NN NN O
of IN IN O
glial JJ JJ O
fibrillary JJ JJ O
acidic JJ JJ O
protein NN NN O
, , , O
suggested VBD VBD O
that IN IN O
the DT DT O
decrease NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
GAD NNP NNP O
mRNA NN NN O
- : : O
containing VBG VBG O
neurons NNS NNS O
was VBD VBD O
related VBN VBN O
to TO TO O
neuronal JJ JJ O
loss NN NN O
rather RB RB O
than IN IN O
to TO TO O
a DT DT O
decrease NN NN O
in IN IN O
GAD NNP NNP O
mRNA NN NN O
levels NNS NNS O
. . . O

The DT DT O
loss NN NN O
of IN IN O
GAD NNP NNP O
mRNA NN NN O
- : : O
containing VBG VBG O
neurons NNS NNS O
in IN IN O
the DT DT O
hilus NN NN O
contrasted VBN VBN O
with IN IN O
the DT DT O
relative JJ JJ O
preservation NN NN O
of IN IN O
labeled VBN VBN O
putative JJ JJ O
basket NN NN O
cells NNS NNS O
along IN IN O
the DT DT O
inner JJ JJ O
margin NN NN O
of IN IN O
the DT DT O
granule NN NN O
cell NN NN O
layer NN NN O
. . . O

Quantitative NNP NNP O
analyses NNS NNS O
of IN IN O
labeled VBN VBN O
neurons NNS NNS O
in IN IN O
three CD CD O
regions NNS NNS O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
in IN IN O
the DT DT O
1 CD CD O
and CC CC O
2 CD CD O
week NN NN O
groups NNS NNS O
showed VBD VBD O
statistically RB RB O
significant JJ JJ O
decreases NNS NNS O
in IN IN O
the DT DT O
mean JJ JJ O
number NN NN O
of IN IN O
GAD NNP NNP O
mRNA NN NN O
- : : O
containing VBG VBG O
neurons NNS NNS O
in IN IN O
the DT DT O
hilus NN NN O
of IN IN O
both DT DT O
groups NNS NNS O
of IN IN O
experimental JJ JJ O
animals NNS NNS O
. . . O

No DT DT O
significant JJ JJ O
differences NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
molecular JJ JJ O
layer NN NN O
or CC CC O
the DT DT O
granule NN NN O
cell NN NN O
layer NN NN O
, , , O
which WDT WDT O
included VBD VBD O
labeled VBN VBN O
neurons NNS NNS O
along IN IN O
the DT DT O
lower JJR JJR O
margin NN NN O
of IN IN O
the DT DT O
granule NN NN O
cell NN NN O
layer NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
, , , O
in IN IN O
this DT DT O
model NN NN O
, , , O
a DT DT O
subpopulation NN NN O
of IN IN O
GAD NNP NNP O
mRNA NN NN O
- : : O
containing VBG VBG O
neurons NNS NNS O
within IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
is VBZ VBZ O
selectively RB RB O
vulnerable JJ JJ O
to TO TO O
seizure VB VB O
- - - O
induced JJ JJ O
damage NN NN O
. . . O

Such JJ JJ O
differential JJ JJ O
vulnerability NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
another DT DT O
indication NN NN O
of IN IN O
the DT DT O
heterogeneity NN NN O
of IN IN O
GABA NNP NNP B-CHEM
neurons NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
deliberate JJ JJ O
hypotension NN NN O
induced VBN VBN O
by IN IN O
labetalol NN NN B-CHEM
with IN IN O
isoflurane NN NN B-CHEM
on IN IN O
neuropsychological JJ JJ O
function NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
deliberate JJ JJ O
hypotension NN NN O
on IN IN O
brain NN NN O
function NN NN O
measured VBN VBN O
by IN IN O
neuropsychological JJ JJ O
tests NNS NNS O
was VBD VBD O
studied VBN VBN O
in IN IN O
41 CD CD O
adult NN NN O
patients NNS NNS O
. . . O

Twenty CD CD O
- - - O
four CD CD O
patients NNS NNS O
were VBD VBD O
anaesthetized VBN VBN O
for IN IN O
middle JJ JJ O
- - - O
ear NN NN O
surgery NN NN O
with IN IN O
deliberate JJ JJ O
hypotension NN NN O
induced VBN VBN O
by IN IN O
labetalol NN NN B-CHEM
with IN IN O
isoflurane NN NN B-CHEM
( ( ( O
hypotensive JJ JJ O
group NN NN O
) ) ) O
. . . O

Seventeen NNP NNP O
patients NNS NNS O
without IN IN O
hypotension NN NN O
served VBD VBD O
as IN IN O
a DT DT O
control NN NN O
group NN NN O
. . . O

The DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
was VBD VBD O
77 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mmHg NN NN O
( ( ( O
10 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
kPa NN NN O
) ) ) O
before IN IN O
hypotension NN NN O
and CC CC O
50 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
mmHg NN NN O
( ( ( O
6 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
0 CD CD O
kPa NN NN O
) ) ) O
during IN IN O
hypotension NN NN O
in IN IN O
the DT DT O
hypotensive JJ JJ O
group NN NN O
, , , O
and CC CC O
86 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mmHg NN NN O
( ( ( O
11 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
kPa NN NN O
) ) ) O
during IN IN O
anaesthesia NN NN O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

The DT DT O
following VBG VBG O
psychological JJ JJ O
tests NNS NNS O
were VBD VBD O
performed VBN VBN O
: : : O
four CD CD O
subtests NNS NNS O
of IN IN O
the DT DT O
Wechsler NNP NNP O
Adult NNP NNP O
Intelligence NNP NNP O
Scale NNP NNP O
( ( ( O
similarities NNS NNS O
, , , O
digit NN NN O
span NN NN O
, , , O
vocabulary JJ JJ O
and CC CC O
digit JJ JJ O
symbol NN NN O
) ) ) O
, , , O
Trail NNP NNP O
- : : O
Making VBG VBG O
tests NNS NNS O
A DT DT O
and CC CC O
B NNP NNP O
, , , O
Zung NNP NNP O
tests NNS NNS O
( ( ( O
self NN NN O
- - - O
rating NN NN O
anxiety NN NN O
scale NN NN O
and CC CC O
self NN NN O
- - - O
rating NN NN O
depression NN NN O
scale NN NN O
) ) ) O
and CC CC O
two CD CD O
- : : O
part NN NN O
memory NN NN O
test NN NN O
battery NN NN O
with IN IN O
immediate JJ JJ O
and CC CC O
delayed VBD VBD O
recall NN NN O
. . . O

The DT DT O
tests NNS NNS O
were VBD VBD O
performed VBN VBN O
preoperatively RB RB O
and CC CC O
2 CD CD O
days NNS NNS O
postoperatively RB RB O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
groups NNS NNS O
in IN IN O
any DT DT O
of IN IN O
the DT DT O
tests NNS NNS O
in IN IN O
the DT DT O
changes NNS NNS O
from IN IN O
preoperative JJ JJ O
value NN NN O
to TO TO O
postoperative JJ JJ O
value NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that DT DT O
hypotension NN NN O
induced VBN VBN O
by IN IN O
labetalol NN NN B-CHEM
with IN IN O
isoflurane NN NN B-CHEM
has VBZ VBZ O
no DT DT O
significant JJ JJ O
harmful JJ JJ O
effects NNS NNS O
on IN IN O
mental JJ JJ O
functions NNS NNS O
compared VBN VBN O
to TO TO O
normotensive JJ JJ O
anaesthesia NN NN O
. . . O

Apparent NNP NNP O
cure NN NN O
of IN IN O
rheumatoid JJ JJ O
arthritis NN NN O
by IN IN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
the DT DT O
induction NN NN O
of IN IN O
sustained VBN VBN O
remissions NNS NNS O
and CC CC O
possible JJ JJ O
cure NN NN O
of IN IN O
severe JJ JJ O
erosive JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
( ( ( O
RA NNP NNP O
) ) ) O
by IN IN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
( ( ( O
BMT NNP NNP O
) ) ) O
in IN IN O
2 CD CD O
patients NNS NNS O
. . . O

BMT NNP NNP O
was VBD VBD O
used VBN VBN O
to TO TO O
treat VB VB O
severe JJ JJ O
aplastic JJ JJ O
anemia NN NN O
which WDT WDT O
was VBD VBD O
caused VBN VBN O
by IN IN O
gold NN NN B-CHEM
in IN IN O
one CD CD O
case NN NN O
and CC CC O
D NNP NNP B-CHEM
- : : I-CHEM
penicillamine NN NN I-CHEM
in IN IN O
the DT DT O
other JJ JJ O
. . . O

In IN IN O
the DT DT O
8 CD CD O
and CC CC O
6 CD CD O
years NNS NNS O
since IN IN O
the DT DT O
transplants NNS NNS O
( ( ( O
representing VBG VBG O
8 CD CD O
and CC CC O
4 CD CD O
years NNS NNS O
since IN IN O
cessation NN NN O
of IN IN O
all DT DT O
immunosuppressive JJ JJ O
therapy NN NN O
, , , O
respectively RB RB O
) ) ) O
, , , O
the DT DT O
RA NNP NNP O
in IN IN O
each DT DT O
case NN NN O
has VBZ VBZ O
been VBN VBN O
completely RB RB O
quiescent JJ JJ O
. . . O

Although IN IN O
short JJ JJ O
term NN NN O
remission NN NN O
of IN IN O
severe JJ JJ O
RA NNP NNP O
following VBG VBG O
BMT NNP NNP O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
, , , O
these DT DT O
are VBP VBP O
the DT DT O
first JJ JJ O
cases NNS NNS O
for IN IN O
which WDT WDT O
prolonged JJ JJ O
followup NN NN O
has VBZ VBZ O
been VBN VBN O
available JJ JJ O
. . . O

This DT DT O
experience NN NN O
raises VBZ VBZ O
the DT DT O
question NN NN O
of IN IN O
the DT DT O
role NN NN O
of IN IN O
BMT NNP NNP O
itself PRP PRP O
as IN IN O
a DT DT O
therapeutic JJ JJ O
option NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
uncontrolled JJ JJ O
destructive JJ JJ O
synovitis NN NN O
. . . O

Seizures NNP NNP O
induced VBN VBN O
by IN IN O
combined VBN VBN O
levomepromazine NN NN B-CHEM
- - - O
fluvoxamine NN NN B-CHEM
treatment NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
combined VBN VBN O
levomepromazine NN NN B-CHEM
- - - O
fluvoxamine NN NN B-CHEM
treatment NN NN O
- : : O
induced JJ JJ O
seizures NNS NNS O
. . . O

It PRP PRP O
seems VBZ VBZ O
that IN IN O
combined JJ JJ O
treatment NN NN O
of IN IN O
fluvoxamine NN NN B-CHEM
with IN IN O
phenothiazines NNS NNS B-CHEM
may MD MD O
possess VB VB O
proconvulsive JJ JJ O
activity NN NN O
. . . O

Case NN NN O
report NN NN O
: : : O
pentamidine NN NN B-CHEM
and CC CC O
polymorphic JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
revisited VBN VBN O
. . . O

Pentamidine NNP NNP B-CHEM
isethionate NN NN I-CHEM
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
ventricular NN NN O
tachyarrhythmias NNS NNS O
, , , O
including VBG VBG O
torsade NN NN O
de IN IN O
pointes NNS NNS O
. . . O

This DT DT O
article NN NN O
reports VBZ VBZ O
two CD CD O
cases NNS NNS O
of IN IN O
this DT DT O
complication NN NN O
and CC CC O
reviews NNS NNS O
all DT DT O
reported VBD VBD O
cases NNS NNS O
to TO TO O
date NN NN O
. . . O

Pentamidine NNP NNP B-CHEM
- : : O
induced JJ JJ O
torsade NN NN O
de IN IN O
pointes NNS NNS O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
serum VB VB O
magnesium NN NN B-CHEM
levels NNS NNS O
and CC CC O
hypomagnesemia NN NN O
may MD MD O
synergistically RB RB O
induce VB VB O
torsade NN NN O
. . . O

Torsade NNP NNP O
de IN IN O
pointes NNS NNS O
occurred VBD VBD O
after IN IN O
an DT DT O
average NN NN O
of IN IN O
10 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
pentamidine NN NN B-CHEM
. . . O

In IN IN O
these DT DT O
patients NNS NNS O
, , , O
no DT DT O
other JJ JJ O
acute JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
pentamidine NN NN B-CHEM
were VBD VBD O
observed VBN VBN O
. . . O

Torsade NNP NNP O
de IN IN O
pointes NNS NNS O
can MD MD O
be VB VB O
treated VBN VBN O
when WRB WRB O
recognized VBN VBN O
early RB RB O
, , , O
possibly RB RB O
without IN IN O
discontinuation NN NN O
of IN IN O
pentamidine NN NN B-CHEM
. . . O

When WRB WRB O
QTc NNP NNP O
interval NN NN O
prolongation NN NN O
is VBZ VBZ O
observed VBN VBN O
, , , O
early JJ JJ O
magnesium NN NN B-CHEM
supplementation NN NN O
is VBZ VBZ O
advocated VBN VBN O
. . . O

Efficacy NNP NNP O
and CC CC O
tolerability NN NN O
of IN IN O
lovastatin NN NN B-CHEM
in IN IN O
3390 CD CD O
women NNS NNS O
with IN IN O
moderate JJ JJ O
hypercholesterolemia NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
lovastatin NN NN B-CHEM
in IN IN O
women NNS NNS O
with IN IN O
moderate JJ JJ O
hypercholesterolemia NN NN O
. . . O

DESIGN NNP NNP O
: : : O
The DT DT O
Expanded NNP NNP O
Clinical NNP NNP O
Evaluation NNP NNP O
of IN IN O
Lovastatin NNP NNP B-CHEM
( ( ( O
EXCEL NNP NNP O
) ) ) O
Study NNP NNP O
, , , O
a DT DT O
multicenter NN NN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
diet JJ JJ O
- - - O
and CC CC O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
, , , O
in IN IN O
which WDT WDT O
participants NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
receive VB VB O
placebo NN NN O
or CC CC O
lovastatin NN NN B-CHEM
at IN IN O
doses NNS NNS O
of IN IN O
20 CD CD O
or CC CC O
40 CD CD O
mg NN NN O
once RB RB O
daily JJ JJ O
, , , O
or CC CC O
20 CD CD O
or CC CC O
40 CD CD O
mg NN NN O
twice RB RB O
daily JJ JJ O
for IN IN O
48 CD CD O
weeks NNS NNS O
. . . O

SETTING NNP NNP O
: : : O
Ambulatory NNP NNP O
patients NNS NNS O
recruited VBN VBN O
by IN IN O
362 CD CD O
participating VBG VBG O
centers NNS NNS O
throughout IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
. . . O

PATIENTS NNS NNS O
: : : O
Women NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
3390 CD CD O
) ) ) O
from IN IN O
the DT DT O
total JJ JJ O
cohort NN NN O
of IN IN O
8245 CD CD O
volunteers NNS NNS O
. . . O

MEASUREMENTS NNP NNP O
: : : O
Plasma NNP NNP O
total JJ JJ O
, , , O
low JJ JJ O
- - - O
density NN NN O
lipoprotein NN NN O
( ( ( O
LDL NNP NNP O
) ) ) O
, , , O
and CC CC O
high JJ JJ O
- - - O
density NN NN O
lipoprotein NN NN O
( ( ( O
HDL NNP NNP O
) ) ) O
cholesterol NN NN B-CHEM
, , , O
and CC CC O
triglycerides NNS NNS B-CHEM
; : : O
and CC CC O
laboratory NN NN O
and CC CC O
clinical JJ JJ O
evidence NN NN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
monitored VBN VBN O
periodically RB RB O
throughout IN IN O
the DT DT O
study NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Among IN IN O
women NNS NNS O
, , , O
lovastatin NN NN B-CHEM
( ( ( O
20 CD CD O
to TO TO O
80 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
) ) ) O
produced VBD VBD O
sustained VBN VBN O
( ( ( O
12 CD CD O
- : : O
to TO TO O
48 CD CD O
- - - O
week NN NN O
) ) ) O
, , , O
dose NN NN O
- - - O
related VBN VBN O
changes NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
: : : O
decreases NNS NNS O
in IN IN O
LDL NNP NNP O
cholesterol NN NN B-CHEM
( ( ( O
24 CD CD O
% NN NN O
to TO TO O
40 CD CD O
% NN NN O
) ) ) O
and CC CC O
triglycerides NNS NNS B-CHEM
( ( ( O
9 CD CD O
% NN NN O
to TO TO O
18 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
increases NNS NNS O
in IN IN O
HDL NNP NNP O
cholesterol NN NN B-CHEM
( ( ( O
6 CD CD O
. . . O
7 CD CD O
% NN NN O
to TO TO O
8 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
. . . O

Depending VBG VBG O
on IN IN O
the DT DT O
dose NN NN O
, , , O
from IN IN O
82 CD CD O
% NN NN O
to TO TO O
95 CD CD O
% NN NN O
of IN IN O
lovastatin NN NN B-CHEM
- - - O
treated VBN VBN O
women NNS NNS O
achieved VBD VBD O
the DT DT O
National NNP NNP O
Cholesterol NNP NNP B-CHEM
Education NNP NNP O
Program NNP NNP O
goal NN NN O
of IN IN O
LDL NNP NNP O
cholesterol NN NN B-CHEM
levels NNS NNS O
less JJR JJR O
than IN IN O
4 CD CD O
. . . O
14 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
160 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
, , , O
and CC CC O
40 CD CD O
% NN NN O
to TO TO O
87 CD CD O
% NN NN O
achieved VBD VBD O
the DT DT O
goal NN NN O
of IN IN O
3 CD CD O
. . . O
36 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
130 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
. . . O

Successive NNP NNP O
transaminase NN NN O
elevations NNS NNS O
greater JJR JJR O
than IN IN O
three CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
limit NN NN O
of IN IN O
normal JJ JJ O
occurred VBD VBD O
in IN IN O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
of IN IN O
women NNS NNS O
and CC CC O
were VBD VBD O
dose JJ JJ O
dependent JJ JJ O
above IN IN O
the DT DT O
20 CD CD O
- : : O
mg NN NN O
dose NN NN O
. . . O

Myopathy NNP NNP O
, , , O
defined VBN VBN O
as IN IN O
muscle NN NN O
symptoms NNS NNS O
with IN IN O
creatine NN NN B-CHEM
kinase NN NN O
elevations NNS NNS O
greater JJR JJR O
than IN IN O
10 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
limit NN NN O
of IN IN O
normal JJ JJ O
, , , O
was VBD VBD O
rare JJ JJ O
and CC CC O
associated VBN VBN O
with IN IN O
the DT DT O
highest JJS JJS O
recommended VBN VBN O
daily JJ JJ O
dose NN NN O
of IN IN O
lovastatin NN NN B-CHEM
( ( ( O
80 CD CD O
mg NN NN O
) ) ) O
. . . O

Estrogen NNP NNP O
- : : O
replacement NN NN O
therapy NN NN O
appeared VBD VBD O
to TO TO O
have VB VB O
no DT DT O
effect NN NN O
on IN IN O
either CC CC O
the DT DT O
efficacy NN NN O
or CC CC O
safety NN NN O
profile NN NN O
of IN IN O
lovastatin NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
Lovastatin NNP NNP B-CHEM
is VBZ VBZ O
highly RB RB O
effective JJ JJ O
and CC CC O
generally RB RB O
well RB RB O
tolerated VBN VBN O
as IN IN O
therapy NN NN O
for IN IN O
primary JJ JJ O
hypercholesterolemia NN NN O
in IN IN O
women NNS NNS O
. . . O

Tetany NNP NNP O
and CC CC O
rhabdomyolysis NN NN O
due JJ JJ O
to TO TO O
surreptitious JJ JJ O
furosemide NN NN B-CHEM
- - - O
- - - O
importance NN NN O
of IN IN O
magnesium NN NN B-CHEM
supplementation NN NN O
. . . O

Diuretics NNP NNP O
may MD MD O
induce VB VB O
hypokalemia NN NN O
, , , O
hypocalcemia NN NN O
and CC CC O
hypomagnesemia NN NN O
. . . O

While IN IN O
severe JJ JJ O
hypokalemia NN NN O
may MD MD O
cause VB VB O
muscle NN NN O
weakness NN NN O
, , , O
severe JJ JJ O
hypomagnesemia NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
muscle NN NN O
spasms NNS NNS O
and CC CC O
tetany NN NN O
which WDT WDT O
cannot NN NN O
be VB VB O
corrected VBN VBN O
by IN IN O
potassium NN NN B-CHEM
and CC CC O
calcium NN NN B-CHEM
supplementation NN NN O
alone RB RB O
( ( ( O
1 CD CD O
, , , O
2 CD CD O
) ) ) O
. . . O

Surreptitious NNP NNP O
diuretic JJ JJ O
ingestion NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
, , , O
mainly RB RB O
in IN IN O
women NNS NNS O
who WP WP O
are VBP VBP O
concerned VBN VBN O
that IN IN O
they PRP PRP O
are VBP VBP O
obese JJ JJ O
or CC CC O
edematous JJ JJ O
. . . O

Symptomatic NNP NNP O
hypokalemia NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
in IN IN O
such JJ JJ O
patients NNS NNS O
( ( ( O
3 CD CD O
- : : O
7 CD CD O
) ) ) O
and CC CC O
in IN IN O
one CD CD O
case NN NN O
hypocalcemia NN NN O
was VBD VBD O
observed VBN VBN O
( ( ( O
8 CD CD O
) ) ) O
, , , O
but CC CC O
the DT DT O
effects NNS NNS O
of IN IN O
magnesium NN NN B-CHEM
depletion NN NN O
were VBD VBD O
not RB RB O
noted VBN VBN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

Ciprofloxacin NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrotoxicity NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
cancer NN NN O
. . . O

Nephrotoxicity NNP NNP O
associated VBN VBN O
with IN IN O
ciprofloxacin NN NN B-CHEM
is VBZ VBZ O
uncommon JJ JJ O
. . . O

Five CD CD O
patients NNS NNS O
with IN IN O
cancer NN NN O
who WP WP O
developed VBD VBD O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
that WDT WDT O
followed VBD VBD O
treatment NN NN O
with IN IN O
ciprofloxacin NN NN B-CHEM
are VBP VBP O
described VBN VBN O
and CC CC O
an DT DT O
additional JJ JJ O
15 CD CD O
cases NNS NNS O
reported VBD VBD O
in IN IN O
the DT DT O
literature NN NN O
are VBP VBP O
reviewed VBN VBN O
. . . O

Other JJ JJ O
than IN IN O
elevation NN NN O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
, , , O
characteristic JJ JJ O
clinical JJ JJ O
manifestations NNS NNS O
and CC CC O
abnormal JJ JJ O
laboratory NN NN O
findings NNS NNS O
are VBP VBP O
not RB RB O
frequently RB RB O
present JJ JJ O
. . . O

Allergic NNP NNP O
interstitial JJ JJ O
nephritis NN NN O
is VBZ VBZ O
believed VBN VBN O
to TO TO O
be VB VB O
the DT DT O
underlying VBG VBG O
pathological JJ JJ O
- - - O
process NN NN O
. . . O

Definitive NNP NNP O
diagnosis NN NN O
requires VBZ VBZ O
performance NN NN O
of IN IN O
renal NN NN O
biopsy NN NN O
, , , O
although IN IN O
this DT DT O
is VBZ VBZ O
not RB RB O
always RB RB O
feasible JJ JJ O
. . . O

An DT DT O
improvement NN NN O
in IN IN O
renal JJ JJ O
function NN NN O
that WDT WDT O
followed VBD VBD O
the DT DT O
discontinuation NN NN O
of IN IN O
the DT DT O
offending VBG VBG O
antibiotic JJ JJ O
supports VBZ VBZ O
the DT DT O
presumptive JJ JJ O
diagnosis NN NN O
of IN IN O
ciprofloxacin NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Venous NNP NNP O
complications NNS NNS O
of IN IN O
midazolam NN NN B-CHEM
versus CC CC O
diazepam NN NN B-CHEM
. . . O

Although IN IN O
some DT DT O
studies NNS NNS O
have VBP VBP O
suggested VBN VBN O
fewer RBR RBR O
venous JJ JJ O
complications NNS NNS O
are VBP VBP O
associated VBN VBN O
with IN IN O
midazolam NN NN B-CHEM
than IN IN O
with IN IN O
diazepam NN NN B-CHEM
for IN IN O
endoscopic NN NN O
procedures NNS NNS O
, , , O
this DT DT O
variable JJ JJ O
has VBZ VBZ O
not RB RB O
been VBN VBN O
well RB RB O
documented VBN VBN O
. . . O

We PRP PRP O
prospectively RB RB O
evaluated VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
venous JJ JJ O
complications NNS NNS O
after IN IN O
intravenous JJ JJ O
injection NN NN O
of IN IN O
diazepam NN NN B-CHEM
or CC CC O
midazolam NN NN B-CHEM
in IN IN O
122 CD CD O
consecutive JJ JJ O
patients NNS NNS O
undergoing VBG VBG O
colonoscopy NN NN O
and CC CC O
esophagogastroduodenoscopy NN NN O
. . . O

Overall RB RB O
, , , O
venous JJ JJ O
complications NNS NNS O
were VBD VBD O
more RBR RBR O
frequent JJ JJ O
with IN IN O
diazepam NN NN B-CHEM
( ( ( O
22 CD CD O
of IN IN O
62 CD CD O
patients NNS NNS O
) ) ) O
than IN IN O
with IN IN O
midazolam NN NN B-CHEM
( ( ( O
4 CD CD O
of IN IN O
60 CD CD O
patients NNS NNS O
) ) ) O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

A DT DT O
palpable JJ JJ O
venous JJ JJ O
cord NN NN O
was VBD VBD O
present JJ JJ O
in IN IN O
23 CD CD O
% NN NN O
( ( ( O
14 CD CD O
of IN IN O
62 CD CD O
) ) ) O
of IN IN O
patients NNS NNS O
in IN IN O
the DT DT O
diazepam NN NN B-CHEM
group NN NN O
, , , O
compared VBN VBN O
with IN IN O
2 CD CD O
% NN NN O
( ( ( O
1 CD CD O
of IN IN O
60 CD CD O
patients NNS NNS O
) ) ) O
in IN IN O
the DT DT O
midazolam NN NN B-CHEM
group NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

Pain NN NN O
at IN IN O
the DT DT O
injection NN NN O
site NN NN O
occurred VBD VBD O
in IN IN O
35 CD CD O
% NN NN O
( ( ( O
22 CD CD O
of IN IN O
62 CD CD O
) ) ) O
of IN IN O
patients NNS NNS O
in IN IN O
the DT DT O
diazepam NN NN B-CHEM
group NN NN O
compared VBN VBN O
with IN IN O
7 CD CD O
% NN NN O
( ( ( O
4 CD CD O
of IN IN O
60 CD CD O
patients NNS NNS O
) ) ) O
in IN IN O
the DT DT O
midazolam NN NN B-CHEM
group NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Swelling NNP NNP O
and CC CC O
warmth NN NN O
at IN IN O
the DT DT O
injection NN NN O
site NN NN O
were VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

Smoking NNP NNP O
, , , O
nonsteroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drug NN NN O
use NN NN O
, , , O
intravenous JJ JJ O
catheter NN NN O
site NN NN O
, , , O
dwell NN NN O
time NN NN O
of IN IN O
the DT DT O
needle NN NN O
, , , O
alcohol NN NN B-CHEM
use NN NN O
, , , O
and CC CC O
pain NN NN O
during IN IN O
the DT DT O
injection NN NN O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
incidence NN NN O
of IN IN O
venous JJ JJ O
complications NNS NNS O
. . . O

Clarithromycin NNP NNP B-CHEM
- - - O
associated VBN VBN O
visual JJ JJ O
hallucinations NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
on IN IN O
continuous JJ JJ O
ambulatory NN NN O
peritoneal NN NN O
dialysis NN NN O
. . . O

Visual NNP NNP O
hallucinations NNS NNS O
are VBP VBP O
a DT DT O
rare JJ JJ O
event NN NN O
in IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
and CC CC O
not RB RB O
related VBN VBN O
to TO TO O
uremia JJ JJ O
per IN IN O
se FW FW O
. . . O

Unreported NNP NNP O
in IN IN O
the DT DT O
literature NN NN O
is VBZ VBZ O
visual JJ JJ O
hallucinations NNS NNS O
occurring VBG VBG O
in IN IN O
association NN NN O
with IN IN O
the DT DT O
new JJ JJ O
macrolide NN NN B-CHEM
antibiotic JJ JJ O
, , , O
clarithromycin NN NN B-CHEM
. . . O

We PRP PRP O
describe VBP VBP O
such JJ JJ O
a DT DT O
case NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
end NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
( ( ( O
ESRD NNP NNP O
) ) ) O
maintained VBN VBN O
on IN IN O
continuous JJ JJ O
ambulatory NN NN O
peritoneal NN NN O
dialysis NN NN O
( ( ( O
CAPD NNP NNP O
) ) ) O
. . . O

The DT DT O
combination NN NN O
of IN IN O
a DT DT O
relatively RB RB O
high JJ JJ O
dose NN NN O
of IN IN O
clarithromycin NN NN B-CHEM
in IN IN O
face NN NN O
of IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
a DT DT O
functionally RB RB O
anephric JJ JJ O
patient NN NN O
, , , O
with IN IN O
underlying VBG VBG O
aluminum NN NN B-CHEM
intoxication NN NN O
, , , O
may MD MD O
have VB VB O
facilitated VBN VBN O
the DT DT O
appearance NN NN O
of IN IN O
this DT DT O
neurotoxic JJ JJ O
side NN NN O
effect NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
important JJ JJ O
to TO TO O
understand VB VB O
the DT DT O
pharmacokinetics NNS NNS O
of IN IN O
medications NNS NNS O
in IN IN O
face NN NN O
of IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
the DT DT O
possibility NN NN O
of IN IN O
drug NN NN O
interactions NNS NNS O
, , , O
and CC CC O
how WRB WRB O
these DT DT O
factors NNS NNS O
should MD MD O
help VB VB O
guide VB VB O
medication NN NN O
therapy NN NN O
in IN IN O
the DT DT O
ESRD NNP NNP O
patient NN NN O
. . . O

Changes NNS NNS O
in IN IN O
peroxisomes NNS NNS O
in IN IN O
preneoplastic JJ JJ O
liver NN NN O
and CC CC O
hepatoma NN NN O
of IN IN O
mice NN NN O
induced VBN VBN O
by IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
benzene NN NN I-CHEM
hexachloride NN NN I-CHEM
. . . O

Peroxisomes NNP NNP O
in IN IN O
hepatomas NN NN O
and CC CC O
hyperplastic JJ JJ O
preneoplastic JJ JJ O
liver NN NN O
lesions NNS NNS O
induced VBN VBN O
in IN IN O
mice NNS NNS O
by IN IN O
500 CD CD O
ppm NN NN O
alpha NN NN B-CHEM
- : : I-CHEM
benzene NN NN I-CHEM
hexachloride NN NN I-CHEM
were VBD VBD O
examined VBN VBN O
histochemically RB RB O
and CC CC O
electron NN NN O
microscopically RB RB O
. . . O

Although IN IN O
most JJS JJS O
of IN IN O
the DT DT O
hepatomas NN NN O
were VBD VBD O
well RB RB O
- - - O
differentiated JJ JJ O
tumors NNS NNS O
and CC CC O
contained VBD VBD O
a DT DT O
considerable JJ JJ O
number NN NN O
of IN IN O
peroxisomes NNS NNS O
, , , O
the DT DT O
tumor NN NN O
cells NNS NNS O
did VBD VBD O
not RB RB O
respond VB VB O
to TO TO O
ethyl VB VB B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
p NN NN I-CHEM
- - - I-CHEM
chlorophenoxyisobutyrate NN NN I-CHEM
with IN IN O
proliferation NN NN O
of IN IN O
peroxisomes NNS NNS O
. . . O

At IN IN O
the DT DT O
16th JJ JJ O
week NN NN O
of IN IN O
carcinogen NN NN O
feeding NN NN O
, , , O
hyperplastic JJ JJ O
nodules NNS NNS O
appeared VBD VBD O
and CC CC O
advanced VBD VBD O
to TO TO O
further VB VB O
stages NNS NNS O
. . . O

A DT DT O
majority NN NN O
of IN IN O
the DT DT O
nodules NNS NNS O
showed VBD VBD O
a DT DT O
considerable JJ JJ O
number NN NN O
of IN IN O
peroxisomes NNS NNS O
and CC CC O
the DT DT O
inductive JJ JJ O
proliferation NN NN O
of IN IN O
peroxisomes NNS NNS O
. . . O

Within IN IN O
the DT DT O
nodules NNS NNS O
, , , O
foci NN NN O
of IN IN O
proliferation NN NN O
of IN IN O
the DT DT O
cells NNS NNS O
that WDT WDT O
showed VBD VBD O
no DT DT O
inducibility NN NN O
of IN IN O
proliferation NN NN O
of IN IN O
peroxisomes NNS NNS O
appeared VBD VBD O
. . . O

These DT DT O
cells NNS NNS O
proliferated VBD VBD O
further JJ JJ O
, , , O
replacing VBG VBG O
the DT DT O
most JJS JJS O
part NN NN O
of IN IN O
the DT DT O
nodules NNS NNS O
, , , O
and CC CC O
with IN IN O
this DT DT O
process NN NN O
hepatomas NN NN O
appeared VBD VBD O
to TO TO O
have VB VB O
been VBN VBN O
formed VBN VBN O
. . . O

No DT DT O
abnormal JJ JJ O
matrical JJ JJ O
inclusions NNS NNS O
of IN IN O
peroxisomes NNS NNS O
were VBD VBD O
formed VBN VBN O
in IN IN O
the DT DT O
cells NNS NNS O
of IN IN O
hyperplastic JJ JJ O
nodules NNS NNS O
by IN IN O
ethyl NN NN B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
p NN NN I-CHEM
- - - I-CHEM
chlorophenoxyisobutyrate NN NN I-CHEM
unlike IN IN O
in IN IN O
the DT DT O
case NN NN O
of IN IN O
rats NNS NNS O
. . . O

Contribution NNP NNP O
of IN IN O
the DT DT O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
to TO TO O
salt VB VB O
- : : O
sensitivity NN NN O
in IN IN O
lifetime NN NN O
captopril NN NN B-CHEM
- - - O
treated VBN VBN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
test VB VB O
the DT DT O
hypothesis NNS NNS O
that IN IN O
, , , O
in IN IN O
lifetime NN NN O
captopril NN NN B-CHEM
- - - O
treated VBN VBN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
( ( ( O
SHR NNP NNP O
) ) ) O
, , , O
the DT DT O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
contributes VBZ VBZ O
importantly RB RB O
to TO TO O
the DT DT O
hypertensive JJ JJ O
effect NN NN O
of IN IN O
dietary JJ JJ B-CHEM
sodium NN NN I-CHEM
chloride NN NN I-CHEM
supplementation NN NN O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
SHR NNP NNP O
( ( ( O
aged VBD VBD O
6 CD CD O
weeks NNS NNS O
) ) ) O
that WDT WDT O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
from IN IN O
conception NN NN O
onward RB RB O
with IN IN O
either DT DT O
captopril NN NN B-CHEM
or CC CC O
vehicle NN NN O
remained VBD VBD O
on IN IN O
a DT DT O
basal NN NN O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
diet NN NN O
or CC CC O
were VBD VBD O
fed VBN VBN O
a DT DT O
high JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
diet NN NN O
. . . O

After IN IN O
2 CD CD O
weeks NNS NNS O
, , , O
the DT DT O
rats NNS NNS O
were VBD VBD O
subjected VBN VBN O
to TO TO O
ganglionic JJ JJ O
blockade NN NN O
and CC CC O
2 CD CD O
days NNS NNS O
later RB RB O
, , , O
an DT DT O
infusion NN NN O
of IN IN O
clonidine NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
Lifetime NNP NNP O
captopril NN NN B-CHEM
treatment NN NN O
significantly RB RB O
lowered VBD VBD O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Intravenous NNP NNP O
infusion NN NN O
of IN IN O
the DT DT O
ganglionic JJ JJ O
blocker NN NN O
hexamethonium NN NN B-CHEM
resulted VBD VBD O
in IN IN O
a DT DT O
rapid JJ JJ O
decline NN NN O
in IN IN O
MAP NNP NNP O
that WDT WDT O
eliminated VBD VBD O
the DT DT O
dietary JJ JJ B-CHEM
sodium NN NN I-CHEM
chloride NN NN I-CHEM
- : : O
induced JJ JJ O
increase NN NN O
in IN IN O
MAP NNP NNP O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Infusion NNP NNP O
of IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
alpha2 NN NN B-CHEM
- : : I-CHEM
adrenergic JJ JJ I-CHEM
receptor NN NN I-CHEM
agonist NN NN I-CHEM
clonidine NN NN B-CHEM
also RB RB O
resulted VBD VBD O
in IN IN O
a DT DT O
greater JJR JJR O
reduction NN NN O
in IN IN O
MAP NNP NNP O
in IN IN O
both DT DT O
groups NNS NNS O
of IN IN O
SHR NNP NNP O
that WDT WDT O
were VBD VBD O
fed VBN VBN O
the DT DT O
high JJ JJ O
( ( ( O
compared VBN VBN O
with IN IN O
the DT DT O
basal NN NN O
) ) ) O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
diet NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
both DT DT O
lifetime NN NN O
captopril NN NN B-CHEM
- : : O
treated VBN VBN O
and CC CC O
control NN NN O
SHR NNP NNP O
, , , O
the DT DT O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
contributes VBZ VBZ O
to TO TO O
the DT DT O
pressor NN NN O
effects NNS NNS O
of IN IN O
a DT DT O
high JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
diet NN NN O
. . . O

Angioedema NNP NNP O
associated VBN VBN O
with IN IN O
droperidol NN NN B-CHEM
administration NN NN O
. . . O

Angioedema NNP NNP O
, , , O
also RB RB O
known VBN VBN O
as IN IN O
angioneurotic JJ JJ O
edema NN NN O
or CC CC O
Quincke NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
is VBZ VBZ O
a DT DT O
well RB RB O
- - - O
demarcated JJ JJ O
, , , O
localized JJ JJ O
edema NN NN O
involving VBG VBG O
the DT DT O
subcutaneous JJ JJ O
tissues NNS NNS O
that WDT WDT O
may MD MD O
cause VB VB O
upper JJ JJ O
- - - O
airway NN NN O
obstruction NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
previously RB RB O
healthy JJ JJ O
19 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
no DT DT O
known VBN VBN O
drug NN NN O
allergies NNS NNS O
in IN IN O
whom WP WP O
angioedema NN NN O
with IN IN O
significant JJ JJ O
tongue NN NN O
swelling VBG VBG O
and CC CC O
protrusion NN NN O
developed VBN VBN O
within IN IN O
10 CD CD O
minutes NNS NNS O
of IN IN O
the DT DT O
administration NN NN O
of IN IN O
a DT DT O
single JJ JJ O
IV NNP NNP O
dose NN NN O
of IN IN O
droperidol NN NN B-CHEM
. . . O

Late NNP NNP O
cardiotoxicity NN NN O
after IN IN O
treatment NN NN O
for IN IN O
a DT DT O
malignant JJ JJ O
bone NN NN O
tumor NN NN O
. . . O

Cardiac NNP NNP O
function NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
long JJ JJ O
- - - O
term NN NN O
survivors NNS NNS O
of IN IN O
malignant JJ JJ O
bone NN NN O
tumors NNS NNS O
who WP WP O
were VBD VBD O
treated VBN VBN O
according VBG VBG O
to TO TO O
Rosen NNP NNP B-CHEM
' POS POS I-CHEM
s VBZ VBZ I-CHEM
T5 NNP NNP I-CHEM
or CC CC I-CHEM
T10 NNP NNP I-CHEM
protocol NN NN I-CHEM
, , , O
both DT DT O
including VBG VBG O
doxorubicin NN NN B-CHEM
. . . O

Thirty NNP NNP O
- : : O
one CD CD O
patients NNS NNS O
, , , O
age NN NN O
10 CD CD O
- : : O
45 CD CD O
years NNS NNS O
( ( ( O
median JJ JJ O
age NN NN O
17 CD CD O
. . . O
8 CD CD O
years NNS NNS O
) ) ) O
were VBD VBD O
evaluated VBN VBN O
2 CD CD O
. . . O
3 CD CD O
- : : O
14 CD CD O
. . . O
1 CD CD O
years NNS NNS O
( ( ( O
median JJ JJ O
8 CD CD O
. . . O
9 CD CD O
years NNS NNS O
) ) ) O
following VBG VBG O
completion NN NN O
of IN IN O
treatment NN NN O
. . . O

Cumulative NNP NNP O
doses NNS NNS O
of IN IN O
doxorubicin NN NN B-CHEM
were VBD VBD O
225 CD CD O
- : : O
550 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
( ( ( O
median NN NN O
dose NN NN O
360 CD CD O
) ) ) O
. . . O

The DT DT O
evaluation NN NN O
consisted VBD VBD O
of IN IN O
a DT DT O
history NN NN O
, , , O
physical JJ JJ O
examination NN NN O
, , , O
electrocardiogram NN NN O
( ( ( O
ECG NNP NNP O
) ) ) O
, , , O
signal NN NN O
averaged VBD VBD O
ECG NNP NNP O
, , , O
24 CD CD O
- : : O
hour NN NN O
ambulatory JJ JJ O
ECG NNP NNP O
, , , O
echocardiography NN NN O
and CC CC O
radionuclide NN NN O
angiography NN NN O
. . . O

Eighteen NNP NNP O
of IN IN O
31 CD CD O
( ( ( O
58 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
showed VBD VBD O
cardiac JJ JJ O
toxicity NN NN O
, , , O
defined VBN VBN O
as IN IN O
having VBG VBG O
one CD CD O
or CC CC O
more JJR JJR O
of IN IN O
the DT DT O
following VBG VBG O
abnormalities NNS NNS O
: : : O
late JJ JJ O
potentials NNS NNS O
, , , O
complex JJ JJ O
ventricular NN NN O
arrhythmias NNS NNS O
, , , O
left VBD VBD O
ventricular JJ JJ O
dilation NN NN O
, , , O
decreased VBD VBD O
shortening VBG VBG O
fraction NN NN O
, , , O
or CC CC O
decreased VBD VBD O
ejection NN NN O
fraction NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
cardiac JJ JJ O
abnormalities NNS NNS O
increased VBN VBN O
with IN IN O
length NN NN O
of IN IN O
follow VB VB O
- - - O
up RP RP O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
. . . O
05 CD CD O
) ) ) O
. . . O

No DT DT O
correlation NN NN O
could MD MD O
be VB VB O
demonstrated VBN VBN O
between IN IN O
cumulative JJ JJ O
dose NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
and CC CC O
cardiac JJ JJ O
status NN NN O
, , , O
except IN IN O
for IN IN O
heart NN NN O
rate NN NN O
variability NN NN O
. . . O

When WRB WRB O
adjusted VBN VBN O
to TO TO O
body NN NN O
surface NN NN O
area NN NN O
, , , O
the DT DT O
left NN NN O
ventricular NN NN O
posterior NN NN O
wall NN NN O
thickness NN NN O
( ( ( O
LVPW NNP NNP O
index NN NN O
) ) ) O
was VBD VBD O
decreased VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
is VBZ VBZ O
high JJ JJ O
and CC CC O
increases NNS NNS O
with IN IN O
follow VB VB O
- - - O
up RP RP O
, , , O
irrespective JJ JJ O
of IN IN O
cumulative JJ JJ O
dose NN NN O
. . . O

Life NNP NNP O
- : : O
long JJ JJ O
cardiac NN NN O
follow VB VB O
- - - O
up RP RP O
in IN IN O
these DT DT O
patients NNS NNS O
is VBZ VBZ O
warranted VBN VBN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
our PRP$ PRP$ O
study NN NN O
suggest NN NN O
that IN IN O
heart NN NN O
rate NN NN O
variability NN NN O
and CC CC O
LVPW NNP NNP O
index NN NN O
could MD MD O
be VB VB O
sensitive JJ JJ O
indicators NNS NNS O
for IN IN O
cardiotoxicity NN NN O
. . . O

Acute JJ JJ O
blood NN NN O
pressure NN NN O
elevations NNS NNS O
with IN IN O
caffeine NN NN B-CHEM
in IN IN O
men NNS NNS O
with IN IN O
borderline NN NN O
systemic JJ JJ O
hypertension NN NN O
. . . O

Whether IN IN O
the DT DT O
vasoconstrictive JJ JJ O
actions NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
are VBP VBP O
enhanced VBN VBN O
in IN IN O
hypertensive JJ JJ O
persons NNS NNS O
has VBZ VBZ O
not RB RB O
been VBN VBN O
demonstrated VBN VBN O
. . . O

Thus RB RB O
, , , O
caffeine NN NN B-CHEM
( ( ( O
3 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
versus CC CC O
placebo NN NN O
was VBD VBD O
tested VBN VBN O
in IN IN O
48 CD CD O
healthy JJ JJ O
men NNS NNS O
( ( ( O
aged VBN VBN O
20 CD CD O
to TO TO O
35 CD CD O
years NNS NNS O
) ) ) O
selected VBN VBN O
after IN IN O
screening VBG VBG O
on IN IN O
2 CD CD O
separate JJ JJ O
occasions NNS NNS O
. . . O

Borderline NNP NNP O
hypertensive JJ JJ O
men NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
24 CD CD O
) ) ) O
were VBD VBD O
selected VBN VBN O
with IN IN O
screening VBG VBG O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
of IN IN O
140 CD CD O
to TO TO O
160 CD CD O
mm NN NN O
Hg NNP NNP O
and CC CC O
/ NN NN O
or CC CC O
diastolic JJ JJ O
BP NNP NNP O
90 CD CD O
to TO TO O
99 CD CD O
mm NN NN O
Hg NNP NNP O
. . . O

Low NNP NNP O
- - - O
risk NN NN O
controls NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
24 CD CD O
) ) ) O
reported VBD VBD O
no DT DT O
parental JJ JJ O
history NN NN O
of IN IN O
hypertension NN NN O
and CC CC O
had VBD VBD O
screening VBG VBG O
BP NNP NNP O
< NN NN O
130 CD CD O
/ NN NN O
85 CD CD O
mm NN NN O
Hg NNP NNP O
. . . O

Participants NNS NNS O
were VBD VBD O
then RB RB O
tested VBN VBN O
on IN IN O
2 CD CD O
occasions NNS NNS O
after IN IN O
12 CD CD O
- : : O
hour NN NN O
abstinence NN NN O
from IN IN O
caffeine NN NN B-CHEM
in IN IN O
each DT DT O
of IN IN O
2 CD CD O
protocols NNS NNS O
; : : O
this DT DT O
required VBD VBD O
a DT DT O
total NN NN O
of IN IN O
4 CD CD O
laboratory NN NN O
visits NNS NNS O
. . . O

Caffeine NNP NNP B-CHEM
- : : O
induced JJ JJ O
changes NNS NNS O
in IN IN O
diastolic JJ JJ O
BP NNP NNP O
were VBD VBD O
2 CD CD O
to TO TO O
3 CD CD O
times NNS NNS O
larger JJR JJR O
in IN IN O
borderline NN NN O
subjects NNS NNS O
than IN IN O
in IN IN O
controls NNS NNS O
( ( ( O
+ NN NN O
8 CD CD O
. . . O
4 CD CD O
vs NNS NNS O
+ NN NN O
3 CD CD O
. . . O
8 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
, , , O
and CC CC O
were VBD VBD O
attributable JJ JJ O
to TO TO O
larger JJR JJR O
changes NNS NNS O
in IN IN O
impedance NN NN O
- - - O
derived JJ JJ O
measures NNS NNS O
of IN IN O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
( ( ( O
+ NN NN O
135 CD CD O
vs NNS NNS O
+ NN NN O
45 CD CD O
dynes NNS NNS O
. . . O
s VBZ VBZ O
. . . O
cm NN NN O
- : : O
5 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
004 CD CD O
) ) ) O
. . . O

These DT DT O
findings NNS NNS O
were VBD VBD O
consistent JJ JJ O
and CC CC O
reached VBN VBN O
significance NN NN O
in IN IN O
both DT DT O
protocols NNS NNS O
. . . O

The DT DT O
percentage NN NN O
of IN IN O
borderline NN NN O
subjects NNS NNS O
in IN IN O
whom WP WP O
diastolic JJ JJ O
BP NNP NNP O
changes NNS NNS O
exceeded VBD VBD O
the DT DT O
median NN NN O
control NN NN O
response NN NN O
was VBD VBD O
96 CD CD O
% NN NN O
. . . O

Consequently RB RB O
, , , O
whereas IN IN O
all DT DT O
participants NNS NNS O
exhibited VBN VBN O
normotensive JJ JJ O
levels NNS NNS O
during IN IN O
the DT DT O
resting VBG VBG O
predrug NN NN O
baseline NN NN O
, , , O
33 CD CD O
% NN NN O
of IN IN O
borderline NN NN O
subjects NNS NNS O
achieved VBN VBN O
hypertensive JJ JJ O
BP NNP NNP O
levels NNS NNS O
after IN IN O
caffeine NN NN B-CHEM
ingestion NN NN O
. . . O

Thus RB RB O
, , , O
in IN IN O
borderline NN NN O
hypertensive JJ JJ O
men NNS NNS O
, , , O
exaggerated JJ JJ O
responses NNS NNS O
to TO TO O
caffeine NN NN B-CHEM
were VBD VBD O
: : : O
selective JJ JJ O
for IN IN O
diastolic JJ JJ O
BP NNP NNP O
, , , O
consistent JJ JJ O
with IN IN O
greater JJR JJR O
vasoconstriction NN NN O
, , , O
replicated VBN VBN O
in IN IN O
2 CD CD O
protocols NNS NNS O
, , , O
and CC CC O
representative NN NN O
of IN IN O
nearly RB RB O
all DT DT O
borderline NN NN O
hypertensives NNS NNS O
. . . O

We PRP PRP O
suspect VBP VBP O
that IN IN O
the DT DT O
potential JJ JJ O
for IN IN O
caffeine NN NN B-CHEM
to TO TO O
stabilize VB VB O
high JJ JJ O
resistance NN NN O
states NNS NNS O
in IN IN O
susceptible JJ JJ O
persons NNS NNS O
suggests VBZ VBZ O
that IN IN O
its PRP$ PRP$ O
use NN NN O
may MD MD O
facilitate VB VB O
their PRP$ PRP$ O
disease NN NN O
progression NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
hinder NN NN O
accurate JJ JJ O
diagnosis NN NN O
and CC CC O
treatment NN NN O
. . . O

Absence NNP NNP O
of IN IN O
effect NN NN O
of IN IN O
sertraline NN NN B-CHEM
on IN IN O
time NN NN O
- - - O
based JJ JJ O
sensitization NN NN O
of IN IN O
cognitive JJ JJ O
impairment NN NN O
with IN IN O
haloperidol NN NN B-CHEM
. . . O

This DT DT O
double JJ JJ O
- : : O
blind JJ JJ O
, , , O
randomized JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
study NN NN O
evaluated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
haloperidol NN NN B-CHEM
alone RB RB O
and CC CC O
haloperidol NN NN B-CHEM
plus CC CC O
sertraline NN NN B-CHEM
on IN IN O
cognitive JJ JJ O
and CC CC O
psychomotor NN NN O
function NN NN O
in IN IN O
24 CD CD O
healthy JJ JJ O
male NN NN O
subjects NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
All DT DT O
subjects NNS NNS O
received VBD VBD O
placebo NN NN O
on IN IN O
Day NNP NNP O
1 CD CD O
and CC CC O
haloperidol NN NN B-CHEM
2 CD CD O
mg NN NN O
on IN IN O
Days NNS NNS O
2 CD CD O
and CC CC O
25 CD CD O
. . . O

From IN IN O
Days NNS NNS O
9 CD CD O
to TO TO O
25 CD CD O
, , , O
subjects NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
either CC CC O
sertraline NN NN B-CHEM
( ( ( O
12 CD CD O
subjects NNS NNS O
) ) ) O
or CC CC O
placebo NN NN O
( ( ( O
12 CD CD O
subjects NNS NNS O
) ) ) O
; : : O
the DT DT O
sertraline NN NN B-CHEM
dose NN NN O
was VBD VBD O
titrated VBN VBN O
from IN IN O
50 CD CD O
to TO TO O
200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
from IN IN O
Days NNS NNS O
9 CD CD O
to TO TO O
16 CD CD O
, , , O
and CC CC O
remained VBD VBD O
at IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
the DT DT O
final JJ JJ O
10 CD CD O
days NNS NNS O
of IN IN O
the DT DT O
drug NN NN O
administration NN NN O
period NN NN O
. . . O

Cognitive NNP NNP O
function NN NN O
testing NN NN O
was VBD VBD O
performed VBN VBN O
before IN IN O
dosing NN NN O
and CC CC O
over IN IN O
a DT DT O
24 CD CD O
- : : O
hour NN NN O
period NN NN O
after IN IN O
dosing VBG VBG O
on IN IN O
Days NNS NNS O
1 CD CD O
, , , O
2 CD CD O
, , , O
and CC CC O
25 CD CD O
. . . O

RESULTS NNS NNS O
: : : O
Impairment NNP NNP O
of IN IN O
cognitive JJ JJ O
function NN NN O
was VBD VBD O
observed VBN VBN O
6 CD CD O
to TO TO O
8 CD CD O
hours NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
haloperidol NN NN B-CHEM
on IN IN O
Day NNP NNP O
2 CD CD O
but CC CC O
was VBD VBD O
not RB RB O
evident JJ JJ O
23 CD CD O
hours NNS NNS O
after IN IN O
dosing VBG VBG O
. . . O

When WRB WRB O
single JJ JJ O
- - - O
dose NN NN O
haloperidol NN NN B-CHEM
was VBD VBD O
given VBN VBN O
again RB RB O
25 CD CD O
days NNS NNS O
later RB RB O
, , , O
greater JJR JJR O
impairment NN NN O
with IN IN O
earlier RBR RBR O
onset NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
several JJ JJ O
tests NNS NNS O
in IN IN O
both DT DT O
treatment NN NN O
groups NNS NNS O
, , , O
suggesting VBG VBG O
enhancement NN NN O
of IN IN O
this DT DT O
effect NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
indication NN NN O
that IN IN O
sertraline NN NN B-CHEM
exacerbated VBD VBD O
the DT DT O
impairment NN NN O
produced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
since IN IN O
an DT DT O
equivalent JJ JJ O
effect NN NN O
also RB RB O
occurred VBD VBD O
in IN IN O
the DT DT O
placebo NN NN O
group NN NN O
. . . O

Three CD CD O
subjects NNS NNS O
( ( ( O
2 CD CD O
on IN IN O
sertraline NN NN B-CHEM
and CC CC O
1 CD CD O
on IN IN O
placebo NN NN O
) ) ) O
withdrew VBD VBD O
from IN IN O
the DT DT O
study NN NN O
because IN IN O
of IN IN O
side NN NN O
effects NNS NNS O
. . . O

Ten CD CD O
subjects NNS NNS O
in IN IN O
each DT DT O
group NN NN O
reported VBD VBD O
side NN NN O
effects NNS NNS O
related VBN VBN O
to TO TO O
treatment NN NN O
. . . O

The DT DT O
side NN NN O
effect NN NN O
profiles NNS NNS O
of IN IN O
sertraline NN NN B-CHEM
and CC CC O
of IN IN O
placebo NN NN O
were VBD VBD O
similar JJ JJ O
. . . O

CONCLUSION NNP NNP O
: : : O
Haloperidol NNP NNP B-CHEM
produced VBD VBD O
a DT DT O
clear JJ JJ O
profile NN NN O
of IN IN O
cognitive JJ JJ O
impairment NN NN O
that WDT WDT O
was VBD VBD O
not RB RB O
worsened VBN VBN O
by IN IN O
concomitant JJ JJ O
sertraline NN NN B-CHEM
administration NN NN O
. . . O

Coexistence NNP NNP O
of IN IN O
cerebral JJ JJ O
venous JJ JJ O
sinus NN NN O
and CC CC O
internal JJ JJ O
carotid NN NN O
artery NN NN O
thrombosis NN NN O
associated VBN VBN O
with IN IN O
exogenous JJ JJ O
sex NN NN O
hormones NNS NNS O
. . . O

A DT DT O
case NN NN O
report NN NN O
. . . O

A DT DT O
forty NN NN O
- - - O
six CD CD O
year NN NN O
- - - O
old JJ JJ O
premenopausal NN NN O
woman NN NN O
developed VBN VBN O
headache NN NN O
, , , O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
, , , O
left VBD VBD O
hemiparesis NN NN O
and CC CC O
seizure VB VB O
two CD CD O
days NNS NNS O
after IN IN O
parenteral JJ JJ O
use NN NN O
of IN IN O
progesterone NN NN B-CHEM
and CC CC O
estradiol NN NN B-CHEM
. . . O

Diabetes NNP NNP O
mellitus NN NN O
( ( ( O
DM NNP NNP O
) ) ) O
was VBD VBD O
found VBN VBN O
during IN IN O
admission NN NN O
. . . O

Computed NNP NNP O
tomography NN NN O
showed VBD VBD O
a DT DT O
hemorrhagic JJ JJ O
infarct NN NN O
in IN IN O
the DT DT O
right JJ JJ O
frontal NN NN O
lobe NN NN O
and CC CC O
increased VBN VBN O
density NN NN O
in IN IN O
the DT DT O
superior JJ JJ O
sagittal NN NN O
sinus NN NN O
( ( ( O
SSS NNP NNP O
) ) ) O
. . . O

Left NNP NNP O
carotid NN NN O
angiography NN NN O
found VBD VBD O
occlusion NN NN O
of IN IN O
the DT DT O
left VBN VBN O
internal JJ JJ O
carotid NN NN O
artery NN NN O
( ( ( O
ICA NNP NNP O
) ) ) O
. . . O

Right RB RB O
carotid NN NN O
angiograms NNS NNS O
failed VBD VBD O
to TO TO O
show VB VB O
the DT DT O
SSS NNP NNP O
and CC CC O
inferior JJ JJ O
sagittal JJ JJ O
sinus NN NN O
, , , O
suggestive JJ JJ O
of IN IN O
venous JJ JJ O
sinus NN NN O
thrombosis NN NN O
. . . O

Coexistence NNP NNP O
of IN IN O
the DT DT O
cerebral JJ JJ O
artery NN NN O
and CC CC O
the DT DT O
venous JJ JJ O
sinus NN NN O
occlusion NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
infrequently RB RB O
. . . O

In IN IN O
this DT DT O
case NN NN O
, , , O
the DT DT O
authors NNS NNS O
postulate VBP VBP O
that IN IN O
the DT DT O
use NN NN O
of IN IN O
estradiol NN NN B-CHEM
and CC CC O
progesterone NN NN B-CHEM
and CC CC O
the DT DT O
underlying VBG VBG O
DM NNP NNP O
increased VBD VBD O
vascular JJ JJ O
thrombogenicity NN NN O
, , , O
which WDT WDT O
provided VBD VBD O
a DT DT O
common JJ JJ O
denominator NN NN O
for IN IN O
thrombosis NN NN O
of IN IN O
both DT DT O
the DT DT O
ICA NNP NNP O
and CC CC O
the DT DT O
venous JJ JJ O
sinus NN NN O
. . . O

Chemotherapy NNP NNP O
of IN IN O
advanced VBD VBD O
inoperable JJ JJ O
non NN NN O
- - - O
small JJ JJ O
cell NN NN O
lung NN NN O
cancer NN NN O
with IN IN O
paclitaxel NN NN B-CHEM
: : : O
a DT DT O
phase NN NN O
II NNP NNP O
trial NN NN O
. . . O

Paclitaxel NNP NNP B-CHEM
( ( ( O
Taxol NNP NNP B-CHEM
; : : O
Bristol NNP NNP O
- : : O
Myers NNP NNP O
Squibb NNP NNP O
Company NNP NNP O
, , , O
Princeton NNP NNP O
, , , O
NJ NNP NNP O
) ) ) O
has VBZ VBZ O
demonstrated VBN VBN O
significant JJ JJ O
antineoplastic JJ JJ O
activity NN NN O
against IN IN O
different JJ JJ O
tumor NN NN O
types NNS NNS O
, , , O
notably RB RB O
ovarian JJ JJ O
and CC CC O
breast JJ JJ O
carcinoma NN NN O
. . . O

Two CD CD O
phase NN NN O
II NNP NNP O
trials NNS NNS O
of IN IN O
24 CD CD O
- : : O
hour NN NN O
paclitaxel NN NN B-CHEM
infusions NNS NNS O
in IN IN O
chemotherapy NN NN O
- - - O
naive JJ JJ O
patients NNS NNS O
with IN IN O
stage NN NN O
IIIB NNP NNP O
or CC CC O
IV NNP NNP O
non NN NN O
- : : O
small JJ JJ O
cell NN NN O
lung NN NN O
cancer NN NN O
( ( ( O
NSCLC NNP NNP O
) ) ) O
reported VBD VBD O
response NN NN O
rates NNS NNS O
of IN IN O
21 CD CD O
% NN NN O
and CC CC O
24 CD CD O
% NN NN O
. . . O

Leukopenia NNP NNP O
was VBD VBD O
dose NN NN O
limiting VBG VBG O
: : : O
as RB RB O
many JJ JJ O
as IN IN O
62 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
experienced VBN VBN O
grade NN NN O
4 CD CD O
leukopenia NN NN O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
efficacy NN NN O
and CC CC O
toxicity NN NN O
of IN IN O
a DT DT O
3 CD CD O
- : : O
hour NN NN O
paclitaxel NN NN B-CHEM
infusion NN NN O
in IN IN O
a DT DT O
phase NN NN O
II NNP NNP O
trial NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
inoperable JJ JJ O
stage NN NN O
IIIB NNP NNP O
or CC CC O
IV NNP NNP O
NSCLC NNP NNP O
. . . O

The DT DT O
58 CD CD O
patients NNS NNS O
treated VBN VBN O
( ( ( O
41 CD CD O
men NNS NNS O
and CC CC O
17 CD CD O
women NNS NNS O
) ) ) O
had VBD VBD O
a DT DT O
median JJ JJ O
age NN NN O
of IN IN O
59 CD CD O
years NNS NNS O
( ( ( O
age NN NN O
range NN NN O
, , , O
25 CD CD O
to TO TO O
75 CD CD O
) ) ) O
and CC CC O
a DT DT O
performance NN NN O
status NN NN O
of IN IN O
0 CD CD O
through IN IN O
2 CD CD O
. . . O

Most JJS JJS O
patients NNS NNS O
( ( ( O
72 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
stage NN NN O
IV NNP NNP O
NSCLC NNP NNP O
. . . O

Paclitaxel NNP NNP B-CHEM
225 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
was VBD VBD O
infused VBN VBN O
over IN IN O
3 CD CD O
hours NNS NNS O
every DT DT O
3 CD CD O
weeks NNS NNS O
with IN IN O
standard JJ JJ O
prophylactic JJ JJ O
premedication NN NN O
. . . O

Of IN IN O
50 CD CD O
patients NNS NNS O
evaluable JJ JJ O
for IN IN O
response NN NN O
, , , O
12 CD CD O
( ( ( O
24 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
partial JJ JJ O
remission NN NN O
, , , O
26 CD CD O
( ( ( O
52 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
no DT DT O
change NN NN O
, , , O
and CC CC O
12 CD CD O
had VBD VBD O
disease NN NN O
progression NN NN O
( ( ( O
24 CD CD O
% NN NN O
) ) ) O
. . . O

Hematologic NNP NNP O
toxicities NNS NNS O
were VBD VBD O
mild JJ JJ O
: : : O
only RB RB O
one CD CD O
patient NN NN O
( ( ( O
2 CD CD O
% NN NN O
) ) ) O
developed JJ JJ O
grade NN NN O
3 CD CD O
or CC CC O
4 CD CD O
neutropenia NN NN O
, , , O
while IN IN O
29 CD CD O
% NN NN O
had VBD VBD O
grade NN NN O
1 CD CD O
or CC CC O
2 CD CD O
. . . O

Grade NNP NNP O
1 CD CD O
or CC CC O
2 CD CD O
polyneuropathy NN NN O
affected VBD VBD O
56 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
while IN IN O
only RB RB O
one CD CD O
( ( ( O
2 CD CD O
% NN NN O
) ) ) O
experienced VBN VBN O
severe JJ JJ O
polyneuropathy NN NN O
. . . O

Similarly RB RB O
, , , O
grade NN NN O
1 CD CD O
or CC CC O
2 CD CD O
myalgia NN NN O
/ NN NN O
arthralgia NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
63 CD CD O
. . . O
2 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
but CC CC O
only RB RB O
14 CD CD O
. . . O
3 CD CD O
% NN NN O
experienced VBN VBN O
grade NN NN O
3 CD CD O
or CC CC O
4 CD CD O
. . . O

Nausea NNP NNP O
and CC CC O
vomiting VBG VBG O
were VBD VBD O
infrequent JJ JJ O
, , , O
with IN IN O
14 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
experiencing VBG VBG O
grade NN NN O
1 CD CD O
or CC CC O
2 CD CD O
and CC CC O
only RB RB O
2 CD CD O
% NN NN O
experiencing VBG VBG O
grade NN NN O
3 CD CD O
or CC CC O
4 CD CD O
. . . O

Paclitaxel NNP NNP B-CHEM
is VBZ VBZ O
thus RB RB O
an DT DT O
active JJ JJ O
single JJ JJ O
agent NN NN O
in IN IN O
this DT DT O
patient NN NN O
population NN NN O
, , , O
with IN IN O
a DT DT O
3 CD CD O
- : : O
hour NN NN O
infusion NN NN O
proving VBG VBG O
comparably RB RB O
effective JJ JJ O
to TO TO O
a DT DT O
24 CD CD O
- : : O
hour NN NN O
infusion NN NN O
and CC CC O
superior NN NN O
in IN IN O
terms NNS NNS O
of IN IN O
the DT DT O
incidence NN NN O
of IN IN O
hematologic JJ JJ O
and CC CC O
nonhematologic JJ JJ O
toxicity NN NN O
. . . O

Further RB RB O
phase NN NN O
II NNP NNP O
studies NNS NNS O
with IN IN O
paclitaxel NN NN B-CHEM
combined VBD VBD O
with IN IN O
other JJ JJ O
drugs NNS NNS O
active JJ JJ O
against IN IN O
NSCLC NNP NNP O
are VBP VBP O
indicated VBN VBN O
, , , O
and CC CC O
phase NN NN O
III NNP NNP O
studies NNS NNS O
comparing VBG VBG O
paclitaxel NN NN B-CHEM
with IN IN O
standard JJ JJ O
chemotherapy NN NN O
remain NN NN O
to TO TO O
be VB VB O
completed VBN VBN O
. . . O

Paclitaxel NNP NNP B-CHEM
combined VBD VBD O
with IN IN O
carboplatin NN NN B-CHEM
in IN IN O
the DT DT O
first JJ JJ O
- - - O
line NN NN O
treatment NN NN O
of IN IN O
advanced JJ JJ O
ovarian JJ JJ O
cancer NN NN O
. . . O

In IN IN O
a DT DT O
phase NN NN O
I PRP PRP O
study VBP VBP O
to TO TO O
determine VB VB O
the DT DT O
maximum NN NN O
tolerated VBD VBD O
dose NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
( ( ( O
Taxol NNP NNP B-CHEM
; : : O
Bristol NNP NNP O
- : : O
Myers NNP NNP O
Squibb NNP NNP O
Company NNP NNP O
, , , O
Princeton NNP NNP O
, , , O
NJ NNP NNP O
) ) ) O
given VBN VBN O
as IN IN O
a DT DT O
3 CD CD O
- : : O
hour NN NN O
infusion NN NN O
in IN IN O
combination NN NN O
with IN IN O
carboplatin NN NN B-CHEM
administered JJ JJ O
every DT DT O
21 CD CD O
days NNS NNS O
to TO TO O
women NNS NNS O
with IN IN O
advanced JJ JJ O
ovarian JJ JJ O
cancer NN NN O
, , , O
paclitaxel NN NN B-CHEM
doses NNS NNS O
were VBD VBD O
escalated VBN VBN O
as IN IN O
follows VBZ VBZ O
: : : O
level NN NN O
1 CD CD O
, , , O
135 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
; : : O
level NN NN O
2 CD CD O
, , , O
160 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
; : : O
level NN NN O
3 CD CD O
, , , O
185 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
; : : O
and CC CC O
level NN NN O
4 CD CD O
, , , O
210 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

The DT DT O
fixed JJ JJ O
dose NN NN O
of IN IN O
carboplatin NN NN B-CHEM
at IN IN O
levels NNS NNS O
1 CD CD O
through IN IN O
4 CD CD O
was VBD VBD O
given VBN VBN O
to TO TO O
achieve VB VB O
an DT DT O
area NN NN O
under IN IN O
the DT DT O
concentration NN NN O
- - - O
time NN NN O
curve NN NN O
( ( ( O
AUC NNP NNP O
) ) ) O
of IN IN O
5 CD CD O
using VBG VBG O
the DT DT O
Calvert NNP NNP O
formula NN NN O
. . . O

In IN IN O
levels NNS NNS O
5 CD CD O
and CC CC O
6 CD CD O
the DT DT O
carboplatin NN NN B-CHEM
dose NN NN O
was VBD VBD O
targeted VBN VBN O
at IN IN O
AUCs NNP NNP O
of IN IN O
6 CD CD O
and CC CC O
7 CD CD O
. . . O
5 CD CD O
, , , O
respectively RB RB O
, , , O
combined VBN VBN O
with IN IN O
a DT DT O
fixed JJ JJ O
paclitaxel NN NN B-CHEM
dose NN NN O
of IN IN O
185 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

To TO TO O
date NN NN O
, , , O
30 CD CD O
previously RB RB O
untreated VBD VBD O
patients NNS NNS O
, , , O
all DT DT O
with IN IN O
a DT DT O
good JJ JJ O
performance NN NN O
status NN NN O
( ( ( O
Eastern NNP NNP O
Cooperative NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
0 CD CD O
to TO TO O
2 CD CD O
) ) ) O
have VBP VBP O
been VBN VBN O
entered VBN VBN O
into IN IN O
this DT DT O
ongoing JJ JJ O
study NN NN O
. . . O

The DT DT O
dose NN NN O
- - - O
limiting VBG VBG O
toxicity NN NN O
of IN IN O
the DT DT O
combination NN NN O
was VBD VBD O
myelosuppression NN NN O
( ( ( O
leukopenia NN NN O
, , , O
granulocytopenia NN NN O
, , , O
and CC CC O
thrombocytopenia NN NN O
) ) ) O
. . . O

Neurotoxicity NNP NNP O
was VBD VBD O
largely RB RB O
moderate JJ JJ O
. . . O

So RB RB O
far RB RB O
, , , O
14 CD CD O
patients NNS NNS O
are VBP VBP O
evaluable JJ JJ O
for IN IN O
response NN NN O
; : : O
of IN IN O
these DT DT O
, , , O
eight CD CD O
( ( ( O
57 CD CD O
% NN NN O
) ) ) O
showed VBD VBD O
objective NN NN O
( ( ( O
complete JJ JJ O
or CC CC O
partial JJ JJ O
) ) ) O
response NN NN O
and CC CC O
disease NN NN O
stabilized JJ JJ O
in IN IN O
six CD CD O
patients NNS NNS O
. . . O

No DT DT O
patient NN NN O
had VBD VBD O
disease NN NN O
progression NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
combination NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
185 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
administered VBN VBN O
as IN IN O
a DT DT O
3 CD CD O
- : : O
hour NN NN O
infusion NN NN O
followed VBD VBD O
immediately RB RB O
by IN IN O
a DT DT O
1 CD CD O
- : : O
hour NN NN O
infusion NN NN O
of IN IN O
carboplatin NN NN B-CHEM
at IN IN O
an DT DT O
AUC NNP NNP O
of IN IN O
6 CD CD O
can MD MD O
be VB VB O
administered VBN VBN O
safely RB RB O
in IN IN O
a DT DT O
21 CD CD O
- : : O
day NN NN O
schedule NN NN O
in IN IN O
the DT DT O
outpatient NN NN O
setting VBG VBG O
. . . O

The DT DT O
recommended JJ JJ O
dose NN NN O
for IN IN O
phase NN NN O
III NNP NNP O
studies NNS NNS O
is VBZ VBZ O
paclitaxel NN NN B-CHEM
185 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
and CC CC O
carboplatin NN NN B-CHEM
AUC NNP NNP O
6 CD CD O
. . . O

Effects NNP NNP O
of IN IN O
acute JJ JJ O
steroid NN NN B-CHEM
administration NN NN O
on IN IN O
ventilatory NN NN O
and CC CC O
peripheral JJ JJ O
muscles NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

Occasional NNP NNP O
case NN NN O
reports NNS NNS O
have VBP VBP O
shown VBN VBN O
that IN IN O
acute JJ JJ O
myopathy JJ JJ O
may MD MD O
occur VB VB O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
massive JJ JJ O
doses NNS NNS O
of IN IN O
corticosteroids NNS NNS B-CHEM
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
this DT DT O
myopathy NN NN O
is VBZ VBZ O
poorly RB RB O
understood VBN VBN O
. . . O

Therefore RB RB O
, , , O
60 CD CD O
male JJ JJ O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
receive VB VB O
daily JJ JJ O
injection NN NN O
of IN IN O
saline NN NN O
( ( ( O
C NNP NNP O
) ) ) O
, , , O
methylprednisolone NN NN B-CHEM
( ( ( O
M NNP NNP B-CHEM
) ) ) O
, , , O
or CC CC O
triamcinolone NN NN B-CHEM
( ( ( O
T NN NN B-CHEM
) ) ) O
80 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
d SYM SYM O
for IN IN O
5 CD CD O
d SYM SYM O
. . . O

Nutritional NNP NNP O
intake NN NN O
, , , O
measured VBN VBN O
daily RB RB O
in IN IN O
15 CD CD O
animals NNS NNS O
, , , O
showed VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
of IN IN O
food NN NN O
intake NN NN O
in IN IN O
the DT DT O
steroid NN NN B-CHEM
- - - O
treated VBN VBN O
groups NNS NNS O
( ( ( O
- : : O
50 CD CD O
and CC CC O
- : : O
79 CD CD O
% NN NN O
in IN IN O
M NNP NNP B-CHEM
and CC CC O
T NN NN B-CHEM
, , , O
respectively RB RB O
) ) ) O
. . . O

This DT DT O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
similar JJ JJ O
loss NN NN O
in IN IN O
body NN NN O
weight NN NN O
. . . O

In IN IN O
the DT DT O
45 CD CD O
remaining VBG VBG O
animals NNS NNS O
, , , O
diaphragm NN NN O
contractility NN NN O
and CC CC O
histopathologic JJ JJ O
features NNS NNS O
of IN IN O
several JJ JJ O
muscles NNS NNS O
were VBD VBD O
studied VBN VBN O
. . . O

Weights NNP NNP O
of IN IN O
respiratory NN NN O
and CC CC O
peripheral JJ JJ O
muscles NNS NNS O
were VBD VBD O
similarly RB RB O
decreased VBN VBN O
after IN IN O
steroid NN NN B-CHEM
treatment NN NN O
. . . O

Maximal NNP NNP O
twitches NNS NNS O
of IN IN O
the DT DT O
diaphragm NN NN O
were VBD VBD O
lower JJR JJR O
in IN IN O
the DT DT O
C NNP NNP O
group NN NN O
( ( ( O
653 CD CD O
+ NN NN O
/ NN NN O
- : : O
174 CD CD O
g SYM SYM O
/ NN NN O
cm NN NN O
( ( ( O
2 CD CD O
) ) ) O
) ) ) O
than IN IN O
in IN IN O
the DT DT O
M NNP NNP B-CHEM
group NN NN O
( ( ( O
837 CD CD O
+ NN NN O
/ NN NN O
- : : O
171 CD CD O
g SYM SYM O
/ NN NN O
cm NN NN O
( ( ( O
2 CD CD O
) ) ) O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
the DT DT O
T NN NN B-CHEM
group NN NN O
( ( ( O
765 CD CD O
+ NN NN O
/ NN NN O
- : : O
145 CD CD O
g SYM SYM O
/ NN NN O
cm NN NN O
( ( ( O
2 CD CD O
) ) ) O
, , , O
NS NNP NNP O
) ) ) O
. . . O

Half NNP NNP O
- - - O
relaxation NN NN O
time NN NN O
was VBD VBD O
prolonged JJ JJ O
in IN IN O
both DT DT O
steroid NN NN B-CHEM
groups NNS NNS O
, , , O
and CC CC O
time NN NN O
to TO TO O
peak VB VB O
tension NN NN O
was VBD VBD O
longer RBR RBR O
with IN IN O
M NNP NNP B-CHEM
, , , O
whereas IN IN O
tetanic JJ JJ O
tensions NNS NNS O
were VBD VBD O
similar JJ JJ O
. . . O

Steroid NNP NNP B-CHEM
treatment NN NN O
also RB RB O
induced VBD VBD O
a DT DT O
leftward NN NN O
shift NN NN O
of IN IN O
the DT DT O
force NN NN O
- - - O
frequency NN NN O
curve NN NN O
at IN IN O
25 CD CD O
and CC CC O
50 CD CD O
Hz NNP NNP O
when WRB WRB O
compared VBN VBN O
with IN IN O
saline NN NN O
treatment NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

ATPase NNP NNP O
staining VBG VBG O
of IN IN O
the DT DT O
diaphragm NN NN O
, , , O
scalenus JJ JJ O
medius NN NN O
, , , O
and CC CC O
gastrocnemius NN NN O
showed VBD VBD O
type NN NN O
IIb NNP NNP O
fiber NN NN O
atrophy NN NN O
in IN IN O
the DT DT O
steroid NN NN B-CHEM
groups NNS NNS O
and CC CC O
also RB RB O
diaphragmatic JJ JJ O
type NN NN O
IIa NNP NNP O
atrophy NN NN O
with IN IN O
T NN NN B-CHEM
, , , O
whereas IN IN O
histologic JJ JJ O
examinations NNS NNS O
revealed VBD VBD O
a DT DT O
normal JJ JJ O
muscular NN NN O
pattern NN NN O
with IN IN O
absence NN NN O
of IN IN O
necrosis NN NN O
. . . O

Finally RB RB O
, , , O
a DT DT O
pair NN NN O
- - - O
fed VBN VBN O
( ( ( O
PF NNP NNP O
) ) ) O
study NN NN O
, , , O
performed VBN VBN O
in IN IN O
18 CD CD O
rats NNS NNS O
( ( ( O
C NNP NNP O
, , , O
T NN NN B-CHEM
, , , O
and CC CC O
PF NNP NNP O
) ) ) O
, , , O
showed VBD VBD O
that IN IN O
muscle NN NN O
atrophy NN NN O
was VBD VBD O
considerably RB RB O
less JJR JJR O
pronounced VBN VBN O
in IN IN O
PF NNP NNP O
animals NNS NNS O
than IN IN O
in IN IN O
T NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
( ( ( O
1 CD CD O
) ) ) O
short JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
massive JJ JJ O
doses NNS NNS O
of IN IN O
steroids NNS NNS B-CHEM
induced VBN VBN O
severe JJ JJ O
respiratory NN NN O
and CC CC O
limb NN NN O
muscle NN NN O
wasting NN NN O
; : : O
( ( ( O
2 CD CD O
) ) ) O
both DT DT O
types NNS NNS O
of IN IN O
steroids NNS NNS B-CHEM
induced VBN VBN O
predominantly RB RB O
type NN NN O
IIb NNP NNP O
atrophy NN NN O
, , , O
resulting VBG VBG O
in IN IN O
the DT DT O
expected VBN VBN O
alterations NNS NNS O
in IN IN O
diaphragm NN NN O
contractile NN NN O
properties NNS NNS O
; : : O
( ( ( O
3 CD CD O
) ) ) O
neither DT DT O
steroid NN NN B-CHEM
caused VBD VBD O
muscle NN NN O
necrosis NN NN O
; : : O
( ( ( O
4 CD CD O
) ) ) O
type NN NN O
IIb NNP NNP O
atrophy NN NN O
was VBD VBD O
not RB RB O
caused VBN VBN O
by IN IN O
acute JJ JJ O
nutritional JJ JJ O
deprivation NN NN O
alone RB RB O
. . . O

Continuous NNP NNP O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
mesna NN NN B-CHEM
to TO TO O
prevent VB VB O
ifosfamide NN NN B-CHEM
- : : O
induced JJ JJ O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

Hemorrhagic NNP NNP O
cystitis NN NN O
is VBZ VBZ O
a DT DT O
major JJ JJ O
potential JJ JJ O
toxicity NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
that WDT WDT O
can MD MD O
be VB VB O
prevented VBN VBN O
by IN IN O
administering VBG VBG O
mesna NN NN B-CHEM
along IN IN O
with IN IN O
the DT DT O
cytotoxic JJ JJ O
agent NN NN O
. . . O

Mesna NNP NNP B-CHEM
is VBZ VBZ O
generally RB RB O
administered VBN VBN O
by IN IN O
the DT DT O
intravenous JJ JJ O
route NN NN O
, , , O
although IN IN O
experience NN NN O
with IN IN O
oral JJ JJ O
delivery NN NN O
of IN IN O
the DT DT O
drug NN NN O
has VBZ VBZ O
increased VBN VBN O
. . . O

The DT DT O
continuous JJ JJ O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
mesna NN NN B-CHEM
has VBZ VBZ O
the DT DT O
advantage NN NN O
of IN IN O
not RB RB O
requiring VBG VBG O
intravenous JJ JJ O
access NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
subcutaneous JJ JJ O
delivery NN NN O
of IN IN O
the DT DT O
neutralizing VBG VBG O
agent NN NN O
will MD MD O
not RB RB O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
risk NN NN O
of IN IN O
inadequate JJ JJ O
urinary JJ JJ O
mesna NN NN B-CHEM
concentrations NNS NNS O
, , , O
such JJ JJ O
as IN IN O
in IN IN O
a DT DT O
patient NN NN O
taking VBG VBG O
oral JJ JJ O
mesna NN NN B-CHEM
who WP WP O
experiences VBZ VBZ O
severe JJ JJ O
ifosfamide NN NN B-CHEM
- - - O
induced JJ JJ O
emesis NN NN O
and CC CC O
is VBZ VBZ O
unable JJ JJ O
to TO TO O
absorb VB VB O
the DT DT O
drug NN NN O
. . . O

Limited NNP NNP O
clinical JJ JJ O
experience NN NN O
with IN IN O
continuous JJ JJ O
subcutaneous JJ JJ O
mesna NN NN B-CHEM
administration NN NN O
suggests VBZ VBZ O
it PRP PRP O
is VBZ VBZ O
a DT DT O
safe JJ JJ O
, , , O
practical JJ JJ O
, , , O
and CC CC O
economic JJ JJ O
method NN NN O
of IN IN O
drug NN NN O
delivery NN NN O
that WDT WDT O
permits VBZ VBZ O
ifosfamide IN IN B-CHEM
to TO TO O
be VB VB O
administered VBN VBN O
successfully RB RB O
in IN IN O
the DT DT O
outpatient NN NN O
setting VBG VBG O
. . . O

Leg NN NN O
and CC CC O
back RB RB O
pain NN NN O
after IN IN O
spinal JJ JJ O
anaesthesia NN NN O
involving VBG VBG O
hyperbaric JJ JJ O
5 CD CD O
% NN NN O
lignocaine NN NN B-CHEM
. . . O

Fifty NNP NNP O
- : : O
four CD CD O
patients NNS NNS O
, , , O
aged VBN VBN O
27 CD CD O
- : : O
90 CD CD O
years NNS NNS O
, , , O
who WP WP O
were VBD VBD O
given VBN VBN O
lignocaine NN NN B-CHEM
5 CD CD O
% NN NN O
in IN IN O
6 CD CD O
. . . O
8 CD CD O
% NN NN O
glucose NN NN B-CHEM
solution NN NN O
for IN IN O
spinal JJ JJ O
anaesthesia NN NN O
were VBD VBD O
studied VBN VBN O
. . . O

Thirteen NNP NNP O
of IN IN O
these DT DT O
patients NNS NNS O
experienced VBN VBN O
pain NN NN O
in IN IN O
the DT DT O
legs NNS NNS O
and CC CC O
/ NN NN O
or CC CC O
back RB RB O
after IN IN O
recovery NN NN O
from IN IN O
anaesthesia NN NN O
. . . O

The DT DT O
patients NNS NNS O
affected VBN VBN O
were VBD VBD O
younger JJR JJR O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
the DT DT O
site NN NN O
of IN IN O
the DT DT O
dural JJ JJ O
puncture NN NN O
was VBD VBD O
higher JJR JJR O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
than IN IN O
those DT DT O
individuals NNS NNS O
without IN IN O
pain NN NN O
. . . O

Five CD CD O
of IN IN O
the DT DT O
13 CD CD O
patients NNS NNS O
( ( ( O
38 CD CD O
% NN NN O
) ) ) O
with IN IN O
pain NN NN O
and CC CC O
seven CD CD O
of IN IN O
the DT DT O
41 CD CD O
patients NNS NNS O
( ( ( O
17 CD CD O
% NN NN O
) ) ) O
without IN IN O
pain NN NN O
admitted VBN VBN O
to TO TO O
a DT DT O
high JJ JJ O
alcohol NN NN B-CHEM
intake NN NN O
, , , O
which WDT WDT O
might MD MD O
be VB VB O
a DT DT O
contributing VBG VBG O
factor NN NN O
. . . O

Leg NN NN O
and CC CC O
/ NN NN O
or CC CC O
back RB RB O
pain NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
the DT DT O
intrathecal JJ JJ O
use NN NN O
of IN IN O
hyperbaric JJ JJ O
5 CD CD O
% NN NN O
lignocaine NN NN B-CHEM
. . . O

The DT DT O
use NN NN O
of IN IN O
serum NN NN O
cholinesterase NN NN O
in IN IN O
succinylcholine NN NN B-CHEM
apnoea NN NN O
. . . O

Fifteen CD CD O
patients NNS NNS O
demonstrating VBG VBG O
unexpected JJ JJ O
prolonged JJ JJ O
apnoea NN NN O
lasting VBG VBG O
several JJ JJ O
hours NNS NNS O
after IN IN O
succinylcholine NN NN B-CHEM
have VBP VBP O
been VBN VBN O
treated VBN VBN O
by IN IN O
a DT DT O
new JJ JJ O
preparation NN NN O
of IN IN O
human JJ JJ O
serum NN NN O
cholinesterase NN NN O
. . . O

Adequate NNP NNP O
spontaneous JJ JJ O
respiration NN NN O
was VBD VBD O
re NN NN O
- - - O
established VBN VBN O
in IN IN O
an DT DT O
average JJ JJ O
period NN NN O
of IN IN O
ten CD CD O
minutes NNS NNS O
after IN IN O
the DT DT O
injection NN NN O
. . . O

In IN IN O
12 CD CD O
patients NNS NNS O
biochemical JJ JJ O
genetic JJ JJ O
examinations NNS NNS O
confirmed VBD VBD O
the DT DT O
presence NN NN O
of IN IN O
an DT DT O
atypical JJ JJ O
serum NN NN O
cholinesterase NN NN O
. . . O

In IN IN O
three CD CD O
patients NNS NNS O
none NN NN O
of IN IN O
the DT DT O
usual JJ JJ O
variants NNS NNS O
were VBD VBD O
found VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
therefore RB RB O
supposed VBN VBN O
that IN IN O
other JJ JJ O
unknown JJ JJ O
variants NNS NNS O
of IN IN O
serum NN NN O
cholinesterase NN NN O
exist VB VB O
which WDT WDT O
cannot NN NN O
hydrolyze NN NN O
succinylcholine NN NN B-CHEM
. . . O

The DT DT O
use NN NN O
of IN IN O
serum NN NN O
cholinesterase NN NN O
in IN IN O
succinylcholine NN NN B-CHEM
apnoea NN NN O
provided VBN VBN O
considerable JJ JJ O
relief NN NN O
to TO TO O
both DT DT O
patient NN NN O
and CC CC O
anaesthetist NN NN O
. . . O

Increased NNP NNP O
sulfation NN NN O
and CC CC O
decreased VBD VBD O
7alpha CD CD O
- : : O
hydroxylation NN NN O
of IN IN O
deoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
- : : O
induced JJ JJ O
cholestasis NN NN O
in IN IN O
rats NNS NNS O
. . . O

Deoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
conjugation NN NN O
, , , O
transport NN NN O
capacity NN NN O
, , , O
and CC CC O
metabolism NN NN O
were VBD VBD O
compared VBN VBN O
in IN IN O
control NN NN O
and CC CC O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Control NNP NNP O
rats NNS NNS O
were VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
a DT DT O
lower JJR JJR O
capacity NN NN O
to TO TO O
transport VB VB O
deoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
than IN IN O
taurodeoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
and CC CC O
both DT DT O
were VBD VBD O
decreased VBN VBN O
by IN IN O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
treatment NN NN O
. . . O

During IN IN O
[ NN NN O
24 CD CD O
- : : O
14C CD CD O
] NN NN O
sodium NN NN B-CHEM
deoxycholate NN NN I-CHEM
infusion NN NN O
, , , O
[ NN NN O
14C CD CD O
] NN NN O
biliary JJ JJ O
bile JJ JJ B-CHEM
acid NN NN I-CHEM
secretion NN NN O
increased VBN VBN O
, , , O
but CC CC O
bile JJ JJ O
flow NN NN O
did VBD VBD O
not RB RB O
change VB VB O
significantly RB RB O
in IN IN O
either DT DT O
control NN NN O
or CC CC O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Ethinyl NNP NNP B-CHEM
estradiol NN NN I-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
excreted VBD VBD O
significantly RB RB O
less JJR JJR O
14C CD CD O
as IN IN O
taurocholic JJ JJ B-CHEM
acid NN NN I-CHEM
than IN IN O
did VBD VBD O
control NN NN O
animals NNS NNS O
, , , O
consistent JJ JJ O
with IN IN O
an DT DT O
impairment NN NN O
of IN IN O
7alpha CD CD O
- : : O
hydroxylation NN NN O
of IN IN O
taurodeoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Ethinyl NNP NNP B-CHEM
estradiol NN NN I-CHEM
treatment NN NN O
did VBD VBD O
not RB RB O
impair JJ JJ O
conjugation NN NN O
of IN IN O
deoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
but CC CC O
did VBD VBD O
result NN NN O
in IN IN O
an DT DT O
increase NN NN O
in IN IN O
sulfation NN NN O
of IN IN O
taurodeoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
from IN IN O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
in IN IN O
controls NNS NNS O
to TO TO O
nearly RB RB O
4 CD CD O
. . . O
0 CD CD O
% NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
the DT DT O
hypothesis NNS NNS O
that IN IN O
the DT DT O
rat NN NN O
has VBZ VBZ O
a DT DT O
poorer NN NN O
tolerance NN NN O
for IN IN O
deoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
than IN IN O
do VBP VBP O
certain JJ JJ O
other JJ JJ O
species NNS NNS O
. . . O

Furthermore RB RB O
, , , O
the DT DT O
rat NN NN O
converts NNS NNS O
deoxycholic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
a DT DT O
poor JJ JJ O
choleretic JJ JJ O
, , , O
to TO TO O
taurocholic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
a DT DT O
good JJ JJ O
choleretic JJ JJ O
. . . O

When WRB WRB O
this DT DT O
conversion NN NN O
is VBZ VBZ O
impaired VBN VBN O
with IN IN O
ethinyl NN NN B-CHEM
estradiol NN NN I-CHEM
treatment NN NN O
, , , O
sulfation NN NN O
may MD MD O
be VB VB O
an DT DT O
important JJ JJ O
alternate JJ JJ O
pathway NN NN O
for IN IN O
excretion NN NN O
of IN IN O
this DT DT O
potentially RB RB O
harmful JJ JJ O
bile JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Influence NNP NNP O
of IN IN O
diet NN NN O
free JJ JJ O
of IN IN O
NAD NNP NNP B-CHEM
- - - O
precursors NNS NNS O
on IN IN O
acetaminophen NN NN B-CHEM
hepatotoxicity NN NN O
in IN IN O
mice NN NN O
. . . O

Recently RB RB O
, , , O
we PRP PRP O
demonstrated VBD VBD O
the DT DT O
hepatoprotective JJ JJ O
effects NNS NNS O
of IN IN O
nicotinic JJ JJ B-CHEM
acid NN NN I-CHEM
amide NN NN I-CHEM
, , , O
a DT DT O
selective JJ JJ O
inhibitor NN NN O
of IN IN O
poly NN NN B-CHEM
( ( ( I-CHEM
ADP NNP NNP I-CHEM
- - - I-CHEM
ribose NN NN I-CHEM
) ) ) I-CHEM
polymerase NN NN O
( ( ( O
PARP NNP NNP O
; : : O
EC NNP NNP O
2 CD CD O
. . . O
4 CD CD O
. . . O
2 CD CD O
. . . O
30 CD CD O
) ) ) O
on IN IN O
mice NN NN O
suffering VBG VBG O
from IN IN O
acetaminophen NN NN B-CHEM
( ( ( O
AAP NNP NNP B-CHEM
) ) ) O
- : : O
hepatitis NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
the DT DT O
AAP NNP NNP B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
involves VBZ VBZ O
a DT DT O
step NN NN O
which WDT WDT O
depends VBZ VBZ O
on IN IN O
adenoribosylation NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
investigates VBZ VBZ O
the DT DT O
effects NNS NNS O
of IN IN O
a DT DT O
diet NN NN O
free JJ JJ O
of IN IN O
precursors NNS NNS O
of IN IN O
NAD NNP NNP B-CHEM
, , , O
the DT DT O
substrate NN NN O
on IN IN O
which WDT WDT O
PARP NNP NNP O
acts NNS NNS O
, , , O
in IN IN O
female JJ JJ O
NMRI NNP NNP O
mice NN NN O
with IN IN O
AAP NNP NNP B-CHEM
hepatitis NN NN O
and CC CC O
evaluates VBZ VBZ O
the DT DT O
influence NN NN O
of IN IN O
simultaneous JJ JJ O
ethanol NN NN B-CHEM
consumption NN NN O
in IN IN O
these DT DT O
animals NNS NNS O
. . . O

Liver NNP NNP O
injuries NNS NNS O
were VBD VBD O
quantified VBN VBN O
as IN IN O
serum JJ JJ O
activities NNS NNS O
of IN IN O
glutamate NN NN B-CHEM
- - - O
oxaloacetate JJ JJ B-CHEM
transaminase NN NN O
( ( ( O
GOT NNP NNP O
) ) ) O
and CC CC O
glutamate NN NN B-CHEM
- - - O
pyruvate NN NN B-CHEM
transaminase NN NN O
( ( ( O
GPT NNP NNP O
) ) ) O
. . . O

While IN IN O
AAP NNP NNP B-CHEM
caused VBD VBD O
a DT DT O
117 CD CD O
- : : O
fold JJ JJ O
elevation NN NN O
of IN IN O
serum NN NN O
transaminase NN NN O
activities NNS NNS O
in IN IN O
mice NN NN O
kept VBD VBD O
on IN IN O
a DT DT O
standard JJ JJ O
laboratory NN NN O
diet NN NN O
, , , O
which WDT WDT O
was VBD VBD O
significantly RB RB O
exacerbated VBN VBN O
by IN IN O
ethanol NN NN B-CHEM
and CC CC O
inhibited VBN VBN O
by IN IN O
nicotinic JJ JJ B-CHEM
acid NN NN I-CHEM
amide NN NN I-CHEM
( ( ( O
NAA NNP NNP B-CHEM
) ) ) O
, , , O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
noted VBN VBN O
in IN IN O
animals NNS NNS O
fed VBD VBD O
a DT DT O
diet NN NN O
free JJ JJ O
of IN IN O
precursors NNS NNS O
of IN IN O
NAD NNP NNP B-CHEM
. . . O

In IN IN O
these DT DT O
animals NNS NNS O
, , , O
only RB RB O
minor JJ JJ O
increases NNS NNS O
of IN IN O
serum NN NN O
transaminase NN NN O
activities NNS NNS O
were VBD VBD O
measured VBN VBN O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
AAP NNP NNP B-CHEM
, , , O
and CC CC O
unlike IN IN O
the DT DT O
exacerbation NN NN O
caused VBN VBN O
by IN IN O
ethanol NN NN B-CHEM
in IN IN O
mice NN NN O
on IN IN O
a DT DT O
standard JJ JJ O
diet NN NN O
, , , O
the DT DT O
liver NN NN O
damage NN NN O
was VBD VBD O
inhibited VBN VBN O
by IN IN O
50 CD CD O
% NN NN O
by IN IN O
ethanol NN NN B-CHEM
. . . O

A DT DT O
further JJ JJ O
64 CD CD O
% NN NN O
reduction NN NN O
of IN IN O
hepatitis NN NN O
was VBD VBD O
observed VBN VBN O
, , , O
when WRB WRB O
NAA NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
to TO TO O
ethanol VB VB B-CHEM
/ NN NN O
AAP NNP NNP B-CHEM
- - - O
mice NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
provide VBP VBP O
evidence NN NN O
that IN IN O
the DT DT O
AAP NNP NNP B-CHEM
- - - O
induced JJ JJ O
hepatitis NN NN O
and CC CC O
its PRP$ PRP$ O
exacerbation NN NN O
by IN IN O
ethanol NN NN B-CHEM
can MD MD O
either CC CC O
be VB VB O
reduced VBN VBN O
by IN IN O
end NN NN O
- : : O
product NN NN O
inhibition NN NN O
of IN IN O
PARP NNP NNP O
by IN IN O
NAA NNP NNP B-CHEM
or CC CC O
by IN IN O
dietary JJ JJ O
depletion NN NN O
of IN IN O
the DT DT O
enzyme NN NN O
' '' '' O
s VBZ VBZ O
substrate NN NN O
NAD NNP NNP B-CHEM
. . . O

We PRP PRP O
see VBP VBP O
the DT DT O
main JJ JJ O
application NN NN O
of IN IN O
NAA NNP NNP B-CHEM
as IN IN O
for IN IN O
the DT DT O
combinational JJ JJ O
use NN NN O
in IN IN O
pharmaceutical JJ JJ O
preparations NNS NNS O
of IN IN O
acetaminophen NN NN B-CHEM
in IN IN O
order NN NN O
to TO TO O
avoid VB VB O
hepatic JJ JJ O
damage NN NN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
this DT DT O
widely RB RB O
used VBN VBN O
analgesic NN NN O
. . . O

Nightmares NNP NNP O
and CC CC O
hallucinations NNS NNS O
after IN IN O
long JJ JJ O
- - - O
term NN NN O
intake NN NN O
of IN IN O
tramadol NN NN B-CHEM
combined VBN VBN O
with IN IN O
antidepressants NNS NNS O
. . . O

Tramadol NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
weak JJ JJ O
opioid NN NN O
with IN IN O
effects NNS NNS O
on IN IN O
adrenergic JJ JJ O
and CC CC O
serotonergic JJ JJ O
neurotransmission NN NN O
that WDT WDT O
is VBZ VBZ O
used VBN VBN O
to TO TO O
treat VB VB O
cancer NN NN O
pain NN NN O
and CC CC O
chronic JJ JJ O
non NN NN O
malignant NN NN O
pain NN NN O
. . . O

This DT DT O
drug NN NN O
was VBD VBD O
initiated VBN VBN O
in IN IN O
association NN NN O
with IN IN O
paroxetine NN NN B-CHEM
and CC CC O
dosulepine NN NN B-CHEM
hydrochloride NN NN I-CHEM
in IN IN O
a DT DT O
tetraparetic JJ JJ O
patient NN NN O
with IN IN O
chronic JJ JJ O
pain NN NN O
. . . O

Fifty NNP NNP O
- : : O
six CD CD O
days NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
the DT DT O
treatment NN NN O
the DT DT O
patient NN NN O
presented VBN VBN O
hallucinations NNS NNS O
that WDT WDT O
only RB RB O
stopped VBD VBD O
after IN IN O
the DT DT O
withdrawal NN NN O
of IN IN O
psycho NN NN O
- - - O
active JJ JJ O
drugs NNS NNS O
and CC CC O
tramadol NN NN B-CHEM
. . . O

The DT DT O
case NN NN O
report NN NN O
questions NNS NNS O
the DT DT O
long JJ JJ O
term NN NN O
use NN NN O
of IN IN O
pain NN NN O
killers NNS NNS O
combined VBN VBN O
with IN IN O
psycho JJ JJ O
- - - O
active JJ JJ O
drugs NNS NNS O
in IN IN O
chronic JJ JJ O
non NN NN O
malignant NN NN O
pain NN NN O
, , , O
especially RB RB O
if IN IN O
pain NN NN O
is VBZ VBZ O
under IN IN O
control NN NN O
. . . O

Effect NN NN O
of IN IN O
calcium NN NN B-CHEM
chloride NN NN I-CHEM
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
therapy NN NN O
on IN IN O
desipramine NN NN B-CHEM
toxicity NN NN O
in IN IN O
rats NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Hypotension NNP NNP O
is VBZ VBZ O
a DT DT O
major JJ JJ O
contributor NN NN O
to TO TO O
mortality NN NN O
in IN IN O
tricyclic JJ JJ O
antidepressant NN NN O
overdose NN NN O
. . . O

Recent JJ JJ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
tricyclic JJ JJ O
antidepressants NNS NNS O
inhibit NN NN O
calcium NN NN B-CHEM
influx NN NN O
in IN IN O
some DT DT O
tissues NNS NNS O
. . . O

This DT DT O
study NN NN O
addressed VBD VBD O
the DT DT O
potential JJ JJ O
role NN NN O
of IN IN O
calcium NN NN B-CHEM
channel NN NN O
blockade NN NN O
in IN IN O
tricyclic JJ JJ O
antidepressant NN NN O
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

METHODS NNP NNP O
: : : O
Two CD CD O
interventions NNS NNS O
were VBD VBD O
studied VBN VBN O
that WDT WDT O
have VBP VBP O
been VBN VBN O
shown VBN VBN O
previously RB RB O
to TO TO O
improve VB VB O
blood NN NN O
pressure NN NN O
with IN IN O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
overdose NN NN O
. . . O

CaCl2 NNP NNP B-CHEM
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
. . . O

Anesthetized NNP NNP O
rats NNS NNS O
received VBD VBD O
the DT DT O
tricyclic JJ JJ O
antidepressant NN NN O
desipramine NN NN B-CHEM
IP NNP NNP O
to TO TO O
produce VB VB O
hypotension NN NN O
, , , O
QRS NNP NNP O
prolongation NN NN O
, , , O
and CC CC O
bradycardia NN NN O
. . . O

Fifteen NNP NNP O
min NN NN O
later RB RB O
, , , O
animals NNS NNS O
received VBD VBD O
CaCl2 NNP NNP B-CHEM
, , , O
NaHCO3 NNP NNP B-CHEM
, , , O
or CC CC O
saline NN NN O
. . . O

In IN IN O
a DT DT O
second JJ JJ O
experiment NN NN O
, , , O
rats NNS NNS O
received VBD VBD O
tricyclic JJ JJ O
antidepressant NN NN O
desipramine NN NN B-CHEM
IP NNP NNP O
followed VBD VBD O
in IN IN O
15 CD CD O
min NN NN O
by IN IN O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
or CC CC O
saline NN NN O
. . . O

RESULTS NNS NNS O
: : : O
NaHCO3 NNP NNP B-CHEM
briefly NN NN O
( ( ( O
5 CD CD O
min NN NN O
) ) ) O
reversed JJ JJ O
hypotension NN NN O
and CC CC O
QRS NNP NNP O
prolongation NN NN O
. . . O

CaCl2 NNP NNP B-CHEM
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
failed VBD VBD O
to TO TO O
improve VB VB O
blood NN NN O
pressure NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
ventricular NN NN O
arrhythmias NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
004 CD CD O
) ) ) O
and CC CC O
seizures NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
in IN IN O
the DT DT O
CaCl2 NNP NNP B-CHEM
group NN NN O
was VBD VBD O
higher JJR JJR O
than IN IN O
the DT DT O
other JJ JJ O
groups NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
administration NN NN O
of IN IN O
CaCl2 NNP NNP B-CHEM
or CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
did VBD VBD O
not RB RB O
reverse VB VB O
tricyclic JJ JJ O
antidepressant NN NN O
- : : O
induced JJ JJ O
hypotension NN NN O
in IN IN O
rats NNS NNS O
. . . O

CaCl2 NNP NNP B-CHEM
therapy NN NN O
may MD MD O
possibly RB RB O
worsen VB VB O
both DT DT O
cardiovascular NN NN O
and CC CC O
central JJ JJ O
nervous JJ JJ O
system NN NN O
toxicity NN NN O
. . . O

These DT DT O
findings NNS NNS O
do VBP VBP O
not RB RB O
support VB VB O
a DT DT O
role NN NN O
for IN IN O
calcium NN NN B-CHEM
channel NN NN O
inhibition NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
tricyclic JJ JJ O
antidepressant NN NN O
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

Valsartan NNP NNP B-CHEM
, , , O
a DT DT O
new JJ JJ O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
antagonist NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
essential JJ JJ O
hypertension NN NN O
: : : O
a DT DT O
comparative JJ JJ O
study NN NN O
of IN IN O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
against IN IN O
amlodipine NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
compare VB VB O
the DT DT O
antihypertensive JJ JJ O
efficacy NN NN O
of IN IN O
a DT DT O
new JJ JJ O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
antagonist NN NN O
, , , O
valsartan NN NN B-CHEM
, , , O
with IN IN O
a DT DT O
reference NN NN O
therapy NN NN O
, , , O
amlodipine NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
One CD CD O
hundred CD CD O
sixty NN NN O
- : : O
eight CD CD O
adult NN NN O
outpatients NNS NNS O
with IN IN O
mild JJ JJ O
to TO TO O
moderate JJ JJ O
hypertension NN NN O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
in IN IN O
double JJ JJ O
- - - O
blind JJ JJ O
fashion NN NN O
and CC CC O
equal JJ JJ O
number NN NN O
to TO TO O
receive VB VB O
80 CD CD O
mg NN NN O
valsartan NN NN B-CHEM
or CC CC O
5 CD CD O
mg NN NN O
amlodipine NN NN B-CHEM
for IN IN O
12 CD CD O
weeks NNS NNS O
. . . O

After IN IN O
8 CD CD O
weeks NNS NNS O
of IN IN O
therapy NN NN O
, , , O
in IN IN O
patients NNS NNS O
whose WP$ WP$ O
blood NN NN O
pressure NN NN O
remained VBD VBD O
uncontrolled JJ JJ O
, , , O
5 CD CD O
mg NN NN O
amlodipine NN NN B-CHEM
was VBD VBD O
added VBN VBN O
to TO TO O
the DT DT O
initial JJ JJ O
therapy NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
assessed VBN VBN O
at IN IN O
4 CD CD O
, , , O
8 CD CD O
, , , O
and CC CC O
12 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
primary JJ JJ O
efficacy NN NN O
variable JJ JJ O
was VBD VBD O
change NN NN O
from IN IN O
baseline NN NN O
in IN IN O
mean NN NN O
sitting VBG VBG O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
at IN IN O
8 CD CD O
weeks NNS NNS O
. . . O

Secondary JJ JJ O
variables NNS NNS O
included VBD VBD O
change NN NN O
in IN IN O
sitting VBG VBG O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
responder NN NN O
rates NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Both DT DT O
valsartan NN NN B-CHEM
and CC CC O
amlodipine NN NN B-CHEM
were VBD VBD O
effective JJ JJ O
at IN IN O
lowering VBG VBG O
blood NN NN O
pressure NN NN O
at IN IN O
4 CD CD O
, , , O
8 CD CD O
, , , O
and CC CC O
12 CD CD O
weeks NNS NNS O
. . . O

Similar JJ JJ O
decreases NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
both DT DT O
groups NNS NNS O
, , , O
with IN IN O
no DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
groups NNS NNS O
for IN IN O
any DT DT O
variable JJ JJ O
analyzed JJ JJ O
. . . O

For IN IN O
the DT DT O
primary JJ JJ O
variable JJ JJ O
the DT DT O
difference NN NN O
was VBD VBD O
0 CD CD O
. . . O
5 CD CD O
mm NN NN O
Hg NNP NNP O
in IN IN O
favor NN NN O
of IN IN O
valsartan NN NN B-CHEM
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
68 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
- - - O
2 CD CD O
. . . O
7 CD CD O
to TO TO O
1 CD CD O
. . . O
7 CD CD O
) ) ) O
. . . O

Responder NNP NNP O
rates NNS NNS O
at IN IN O
8 CD CD O
weeks NNS NNS O
were VBD VBD O
66 CD CD O
. . . O
7 CD CD O
% NN NN O
for IN IN O
valsartan NN NN B-CHEM
and CC CC O
60 CD CD O
. . . O
2 CD CD O
% NN NN O
for IN IN O
amlodipine NN NN B-CHEM
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
39 CD CD O
) ) ) O
. . . O

Both DT DT O
treatments NNS NNS O
were VBD VBD O
well RB RB O
tolerated VBN VBN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
drug NN NN O
- - - O
related VBN VBN O
dependent JJ JJ O
edema NN NN O
was VBD VBD O
somewhat RB RB O
higher JJR JJR O
in IN IN O
the DT DT O
amlodipine NN NN B-CHEM
group NN NN O
, , , O
particularly RB RB O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
10 CD CD O
mg NN NN O
per IN IN O
day NN NN O
( ( ( O
2 CD CD O
. . . O
4 CD CD O
% NN NN O
for IN IN O
80 CD CD O
mg NN NN O
valsartan NN NN B-CHEM
; : : O
3 CD CD O
. . . O
6 CD CD O
% NN NN O
for IN IN O
5 CD CD O
mg NN NN O
amlodipine NN NN B-CHEM
; : : O
0 CD CD O
% NN NN O
for IN IN O
valsartan NN NN B-CHEM
plus CC CC O
5 CD CD O
mg NN NN O
amlodipine NN NN B-CHEM
; : : O
14 CD CD O
. . . O
3 CD CD O
% NN NN O
for IN IN O
10 CD CD O
mg NN NN O
amlodipine NN NN B-CHEM
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
data NNS NNS O
show VBP VBP O
that IN IN O
valsartan NN NN B-CHEM
is VBZ VBZ O
at IN IN O
least JJS JJS O
as RB RB O
effective JJ JJ O
as IN IN O
amlodipine NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
mild JJ JJ O
to TO TO O
moderate JJ JJ O
hypertension NN NN O
. . . O

The DT DT O
results NNS NNS O
also RB RB O
show VBP VBP O
valsartan NN NN B-CHEM
to TO TO O
be VB VB O
well RB RB O
tolerated VBN VBN O
and CC CC O
suggest VBP VBP O
that IN IN O
it PRP PRP O
is VBZ VBZ O
not RB RB O
associated VBN VBN O
with IN IN O
side NN NN O
effects NNS NNS O
characteristic JJ JJ O
of IN IN O
this DT DT O
comparator NN NN O
class NN NN O
, , , O
dihydropyridine NN NN B-CHEM
calcium NN NN B-CHEM
antagonists NNS NNS O
. . . O

A DT DT O
measure NN NN O
of IN IN O
pupillary JJ JJ O
oscillation NN NN O
as IN IN O
a DT DT O
marker NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
paranoia NN NN O
. . . O

Cocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
paranoia NN NN O
( ( ( O
CIP NNP NNP O
) ) ) O
remains VBZ VBZ O
an DT DT O
important JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
model NN NN O
of IN IN O
idiopathic JJ JJ O
paranoia NN NN O
for IN IN O
which WDT WDT O
no DT DT O
psychophysiologic JJ JJ O
marker NN NN O
has VBZ VBZ O
yet RB RB O
emerged VBN VBN O
. . . O

Measures NNS NNS O
of IN IN O
pupillary JJ JJ O
oscillation NN NN O
were VBD VBD O
able JJ JJ O
to TO TO O
significantly RB RB O
distinguish VB VB O
a DT DT O
group NN NN O
of IN IN O
abstinent NN NN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
abusers NNS NNS O
endorsing VBG VBG O
past JJ JJ O
CIP NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
32 CD CD O
) ) ) O
from IN IN O
another DT DT O
group NN NN O
of IN IN O
crack NN NN B-CHEM
addicts NNS NNS O
who WP WP O
denied VBD VBD O
past JJ JJ O
CIP NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
29 CD CD O
) ) ) O
. . . O

Serotonin NNP NNP O
syndrome NN NN O
from IN IN O
venlafaxine NN NN B-CHEM
- - - O
tranylcypromine NN NN B-CHEM
interaction NN NN O
. . . O

Excessive NNP NNP O
stimulation NN NN O
of IN IN O
serotonin NN NN B-CHEM
5HT1A CD CD O
receptors NNS NNS O
causes VBZ VBZ O
a DT DT O
syndrome NN NN O
of IN IN O
serotonin NN NN B-CHEM
excess NN NN O
that WDT WDT O
consists VBZ VBZ O
of IN IN O
shivering VBG VBG O
, , , O
muscle NN NN O
rigidity NN NN O
, , , O
salivation NN NN O
, , , O
confusion NN NN O
, , , O
agitation NN NN O
and CC CC O
hyperthermia NN NN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
cause NN NN O
of IN IN O
this DT DT O
syndrome NN NN O
is VBZ VBZ O
an DT DT O
interaction NN NN O
between IN IN O
a DT DT O
monoamine NN NN O
oxidase NN NN O
inhibitor NN NN O
( ( ( O
MAOI NNP NNP O
) ) ) O
and CC CC O
a DT DT O
specific JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitor NN NN O
. . . O

Venlafaxine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
new JJ JJ O
antidepressant NN NN O
agent NN NN O
that WDT WDT O
inhibits VBZ VBZ O
the DT DT O
reuptake NN NN O
of IN IN O
serotonin NN NN B-CHEM
and CC CC O
norepinephrine NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
venlafaxine NN NN B-CHEM
- - - O
MAOI NNP NNP O
interaction NN NN O
that WDT WDT O
resulted VBD VBD O
in IN IN O
the DT DT O
serotonin NN NN O
syndrome NN NN O
in IN IN O
a DT DT O
23 CD CD O
- : : O
y NN NN O
- - - O
old JJ JJ O
male NN NN O
who WP WP O
was VBD VBD O
taking VBG VBG O
tranylcypromine NN NN B-CHEM
for IN IN O
depression NN NN O
. . . O

He PRP PRP O
had VBD VBD O
been VBN VBN O
well RB RB O
until IN IN O
the DT DT O
morning NN NN O
of IN IN O
presentation NN NN O
when WRB WRB O
he PRP PRP O
took VBD VBD O
1 CD CD O
/ NN NN O
2 CD CD O
tab NN NN O
of IN IN O
venlafaxine NN NN B-CHEM
. . . O

Within IN IN O
2 CD CD O
h NN NN O
he PRP PRP O
became VBD VBD O
confused VBN VBN O
with IN IN O
jerking VBG VBG O
movements NNS NNS O
of IN IN O
his PRP$ PRP$ O
extremities NNS NNS O
, , , O
tremors NNS NNS O
and CC CC O
rigidity NN NN O
. . . O

He PRP PRP O
was VBD VBD O
brought VBN VBN O
directly RB RB O
to TO TO O
a DT DT O
hospital NN NN O
where WRB WRB O
he PRP PRP O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
agitated VBN VBN O
and CC CC O
confused VBN VBN O
with IN IN O
shivering NN NN O
, , , O
myoclonic JJ JJ O
jerks NNS NNS O
, , , O
rigidity NN NN O
, , , O
salivation NN NN O
and CC CC O
diaphoresis NN NN O
. . . O

His PRP$ PRP$ O
pupils NNS NNS O
were VBD VBD O
7 CD CD O
mm NN NN O
and CC CC O
sluggishly RB RB O
reactive JJ JJ O
to TO TO O
light JJ JJ O
. . . O

Vital NNP NNP O
signs NNS NNS O
were VBD VBD O
: : : O
blood NN NN O
pressure NN NN O
120 CD CD O
/ NN NN O
67 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
heart NN NN O
rate NN NN O
127 CD CD O
/ NN NN O
min NN NN O
, , , O
respiratory NN NN O
rate NN NN O
28 CD CD O
/ NN NN O
min NN NN O
, , , O
and CC CC O
temperature NN NN O
97 CD CD O
F NN NN O
. . . O

After IN IN O
180 CD CD O
mg NN NN O
of IN IN O
diazepam NN NN B-CHEM
i NNP NNP O
. . . O
v NN NN O
. . . O
he PRP PRP O
remained VBD VBD O
tremulous JJ JJ O
with IN IN O
muscle NN NN O
rigidity NN NN O
and CC CC O
clenched JJ JJ O
jaws NNS NNS O
. . . O

He PRP PRP O
was VBD VBD O
intubated VBN VBN O
for IN IN O
airway NN NN O
protection NN NN O
and CC CC O
because IN IN O
of IN IN O
hypoventilation NN NN O
, , , O
and CC CC O
was VBD VBD O
paralyzed VBN VBN O
to TO TO O
control VB VB O
muscle NN NN O
rigidity NN NN O
. . . O

His PRP$ PRP$ O
subsequent JJ JJ O
course NN NN O
was VBD VBD O
remarkable JJ JJ O
for IN IN O
non NN NN O
- - - O
immune NN NN O
thrombocytopenia NN NN O
which WDT WDT O
resolved VBD VBD O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
maximal NN NN O
temperature NN NN O
was VBD VBD O
101 CD CD O
. . . O
2 CD CD O
F NN NN O
and CC CC O
his PRP$ PRP$ O
CPK NNP NNP O
remained VBD VBD O
< NN NN O
500 CD CD O
units NNS NNS O
/ NN NN O
L NNP NNP O
with IN IN O
no DT DT O
other JJ JJ O
evidence NN NN O
of IN IN O
rhabdomyolysis NN NN O
. . . O

His PRP$ PRP$ O
mental JJ JJ O
status NN NN O
normalized JJ JJ O
and CC CC O
he PRP PRP O
was VBD VBD O
transferred VBN VBN O
to TO TO O
a DT DT O
psychiatry NN NN O
ward NN NN O
. . . O

This DT DT O
patient NN NN O
survived VBD VBD O
without IN IN O
sequelae NN NN O
due JJ JJ O
to TO TO O
the DT DT O
aggressive JJ JJ O
sedation NN NN O
and CC CC O
neuromuscular JJ JJ O
paralysis NN NN O
. . . O

Cyclophosphamide NNP NNP B-CHEM
associated VBN VBN O
bladder NN NN O
cancer NN NN O
- - - O
- - - O
a DT DT O
highly RB RB O
aggressive JJ JJ O
disease NN NN O
: : : O
analysis NN NN O
of IN IN O
12 CD CD O
cases NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
We PRP PRP O
gained VBD VBD O
knowledge NN NN O
of IN IN O
the DT DT O
etiology NN NN O
, , , O
treatment NN NN O
and CC CC O
prevention NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
associated VBN VBN O
urothelial JJ JJ O
cancer NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
The DT DT O
medical JJ JJ O
records NNS NNS O
of IN IN O
6 CD CD O
men NNS NNS O
and CC CC O
6 CD CD O
women NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
55 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
cyclophosphamide NN NN B-CHEM
associated VBN VBN O
bladder NN NN O
cancer NN NN O
were VBD VBD O
reviewed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
tumors NNS NNS O
were VBD VBD O
grade NN NN O
3 CD CD O
or CC CC O
4 CD CD O
transitional JJ JJ O
cell NN NN O
carcinoma NN NN O
. . . O

Of IN IN O
the DT DT O
5 CD CD O
patients NNS NNS O
initially RB RB O
treated VBN VBN O
with IN IN O
endoscopic JJ JJ O
resection NN NN O
alone RB RB O
only RB RB O
1 CD CD O
is VBZ VBZ O
alive JJ JJ O
without IN IN O
disease NN NN O
. . . O

Of IN IN O
the DT DT O
6 CD CD O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
early JJ JJ O
cystectomy NN NN O
4 CD CD O
were VBD VBD O
alive JJ JJ O
at IN IN O
24 CD CD O
to TO TO O
111 CD CD O
months NNS NNS O
. . . O

The DT DT O
remaining VBG VBG O
patient NN NN O
with IN IN O
extensive JJ JJ O
cancer NN NN O
underwent JJ JJ O
partial JJ JJ O
cystectomy NN NN O
for IN IN O
palliation NN NN O
and CC CC O
died VBD VBD O
3 CD CD O
months NNS NNS O
later RB RB O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Cyclophosphamide NNP NNP B-CHEM
associated VBN VBN O
bladder NN NN O
tumor NN NN O
is VBZ VBZ O
an DT DT O
aggressive JJ JJ O
disease NN NN O
. . . O

However RB RB O
, , , O
long JJ JJ O
- - - O
term NN NN O
survival NN NN O
is VBZ VBZ O
possible JJ JJ O
when WRB WRB O
radical JJ JJ O
cystectomy NN NN O
is VBZ VBZ O
performed VBN VBN O
for IN IN O
bladder NN NN O
tumors NNS NNS O
with IN IN O
any DT DT O
sign NN NN O
of IN IN O
invasion NN NN O
and CC CC O
for IN IN O
recurrent JJ JJ O
high JJ JJ O
grade NN NN O
disease NN NN O
, , , O
even RB RB O
when WRB WRB O
noninvasive JJ JJ O
. . . O

A DT DT O
phase NN NN O
I PRP PRP O
clinical JJ JJ O
study NN NN O
of IN IN O
the DT DT O
antipurine NN NN B-CHEM
antifolate NN NN O
lometrexol NN NN B-CHEM
( ( ( O
DDATHF NNP NNP B-CHEM
) ) ) O
given VBN VBN O
with IN IN O
oral JJ JJ O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Lometrexol NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
antifolate NN NN O
which WDT WDT O
inhibits VBZ VBZ O
glycinamide NN NN B-CHEM
ribonucleotide NN NN I-CHEM
formyltransferase NN NN O
( ( ( O
GARFT NNP NNP O
) ) ) O
, , , O
an DT DT O
enzyme NN NN O
essential JJ JJ O
for IN IN O
de IN IN O
novo NN NN O
purine NN NN B-CHEM
synthesis NN NN O
. . . O

Extensive NNP NNP O
experimental JJ JJ O
and CC CC O
limited JJ JJ O
clinical JJ JJ O
data NNS NNS O
have VBP VBP O
shown VBN VBN O
that IN IN O
lometrexol NN NN B-CHEM
has VBZ VBZ O
activity NN NN O
against IN IN O
tumours NNS NNS O
which WDT WDT O
are VBP VBP O
refractory JJ JJ O
to TO TO O
other JJ JJ O
drugs NNS NNS O
, , , O
notably RB RB O
methotrexate JJ JJ B-CHEM
. . . O

However RB RB O
, , , O
the DT DT O
initial JJ JJ O
clinical JJ JJ O
development NN NN O
of IN IN O
lometrexol NN NN B-CHEM
was VBD VBD O
curtailed VBN VBN O
because IN IN O
of IN IN O
severe JJ JJ O
and CC CC O
cumulative JJ JJ O
antiproliferative JJ JJ O
toxicities NNS NNS O
. . . O

Preclinical NNP NNP O
murine NN NN O
studies NNS NNS O
demonstrated VBN VBN O
that IN IN O
the DT DT O
toxicity NN NN O
of IN IN O
lometrexol NN NN B-CHEM
can MD MD O
be VB VB O
prevented VBN VBN O
by IN IN O
low JJ JJ O
dose NN NN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
administration NN NN O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
for IN IN O
7 CD CD O
days NNS NNS O
prior RB RB O
to TO TO O
and CC CC O
7 CD CD O
days NNS NNS O
following VBG VBG O
a DT DT O
single JJ JJ O
bolus NN NN O
dose NN NN O
. . . O

This DT DT O
observation NN NN O
prompted VBD VBD O
a DT DT O
Phase NN NN O
I PRP PRP O
clinical JJ JJ O
study NN NN O
of IN IN O
lometrexol NN NN B-CHEM
given VBN VBN O
with IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
supplementation NN NN O
which WDT WDT O
has VBZ VBZ O
confirmed VBN VBN O
that IN IN O
the DT DT O
toxicity NN NN O
of IN IN O
lometrexol NN NN B-CHEM
can MD MD O
be VB VB O
markedly RB RB O
reduced VBN VBN O
by IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
supplementation NN NN O
. . . O

Thrombocytopenia NNP NNP O
and CC CC O
mucositis NNS NNS O
were VBD VBD O
the DT DT O
major JJ JJ O
toxicities NNS NNS O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
clear JJ JJ O
relationship NN NN O
between IN IN O
clinical JJ JJ O
toxicity NN NN O
and CC CC O
the DT DT O
extent NN NN O
of IN IN O
plasma NN NN O
folate NN NN B-CHEM
elevation NN NN O
. . . O

Associated NNP NNP O
studies NNS NNS O
demonstrated VBN VBN O
that IN IN O
lometrexol NN NN B-CHEM
plasma NN NN O
pharmacokinetics NNS NNS O
were VBD VBD O
not RB RB O
altered VBN VBN O
by IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
administration NN NN O
indicating VBG VBG O
that DT DT O
supplementation NN NN O
is VBZ VBZ O
unlikely JJ JJ O
to TO TO O
reduce VB VB O
toxicity NN NN O
by IN IN O
enhancing VBG VBG O
lometrexol NN NN B-CHEM
plasma NN NN O
clearance NN NN O
. . . O

The DT DT O
work NN NN O
described VBD VBD O
in IN IN O
this DT DT O
report NN NN O
has VBZ VBZ O
identified VBN VBN O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
a DT DT O
clinically RB RB O
acceptable JJ JJ O
schedule NN NN O
for IN IN O
the DT DT O
administration NN NN O
of IN IN O
a DT DT O
GARFT NNP NNP O
inhibitor NN NN O
. . . O

This DT DT O
information NN NN O
will MD MD O
facilitate VB VB O
the DT DT O
future JJ JJ O
evaluation NN NN O
of IN IN O
this DT DT O
class NN NN O
of IN IN O
compounds NNS NNS O
in IN IN O
cancer NN NN O
therapy NN NN O
. . . O

Fatal NNP NNP O
excited VBD VBD O
delirium NN NN O
following VBG VBG O
cocaine NN NN B-CHEM
use NN NN O
: : : O
epidemiologic JJ JJ O
findings NNS NNS O
provide VBP VBP O
new JJ JJ O
evidence NN NN O
for IN IN O
mechanisms NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
toxicity NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
an DT DT O
outbreak NN NN O
of IN IN O
deaths NNS NNS O
from IN IN O
cocaine NN NN B-CHEM
- - - O
induced VBN VBN O
excited VBN VBN O
delirium NN NN O
( ( ( O
EDDs NNP NNP O
) ) ) O
in IN IN O
Dade NNP NNP O
County NNP NNP O
, , , O
Florida NNP NNP O
between IN IN O
1979 CD CD O
and CC CC O
1990 CD CD O
. . . O

From IN IN O
a DT DT O
registry NN NN O
of IN IN O
all DT DT O
cocaine NN NN B-CHEM
- - - O
related VBN VBN O
deaths NNS NNS O
in IN IN O
Dade NNP NNP O
County NNP NNP O
, , , O
Florida NNP NNP O
, , , O
from IN IN O
1969 CD CD O
- : : O
1990 CD CD O
, , , O
58 CD CD O
EDDs NNP NNP O
were VBD VBD O
compared VBN VBN O
with IN IN O
125 CD CD O
victims NNS NNS O
of IN IN O
accidental NN NN O
cocaine NN NN B-CHEM
overdose NN NN O
without IN IN O
excited VBN VBN O
delirium NN NN O
. . . O

Compared VBN VBN O
with IN IN O
controls NNS NNS O
, , , O
EDDs NNP NNP O
were VBD VBD O
more RBR RBR O
frequently RB RB O
black JJ JJ O
, , , O
male JJ JJ O
, , , O
and CC CC O
younger JJR JJR O
. . . O

They PRP PRP O
were VBD VBD O
less RBR RBR O
likely JJ JJ O
to TO TO O
have VB VB O
a DT DT O
low JJ JJ O
body NN NN O
mass NN NN O
index NN NN O
, , , O
and CC CC O
more RBR RBR O
likely JJ JJ O
to TO TO O
have VB VB O
died VBN VBN O
in IN IN O
police NN NN O
custody NN NN O
, , , O
to TO TO O
have VB VB O
received VBN VBN O
medical JJ JJ O
treatment NN NN O
immediately RB RB O
before IN IN O
death NN NN O
, , , O
to TO TO O
have VB VB O
survived VBN VBN O
for IN IN O
a DT DT O
longer JJR JJR O
period NN NN O
, , , O
to TO TO O
have VB VB O
developed VBN VBN O
hyperthermia NN NN O
, , , O
and CC CC O
to TO TO O
have VB VB O
died VBN VBN O
in IN IN O
summer NN NN O
months NNS NNS O
. . . O

EDDs NNP NNP O
had VBD VBD O
concentrations NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
benzoylecgonine NN NN B-CHEM
in IN IN O
autopsy NN NN O
blood NN NN O
that WDT WDT O
were VBD VBD O
similar JJ JJ O
to TO TO O
those DT DT O
for IN IN O
controls NNS NNS O
. . . O

The DT DT O
epidemiologic JJ JJ O
findings NNS NNS O
are VBP VBP O
most RBS RBS O
consistent JJ JJ O
with IN IN O
the DT DT O
hypothesis NNS NNS O
that IN IN O
chronic JJ JJ O
cocaine NN NN B-CHEM
use NN NN O
disrupts NNS NNS O
dopaminergic JJ JJ O
function NN NN O
and CC CC O
, , , O
when WRB WRB O
coupled VBN VBN O
with IN IN O
recent JJ JJ O
cocaine NN NN B-CHEM
use NN NN O
, , , O
may MD MD O
precipitate VB VB O
agitation NN NN O
, , , O
delirium NN NN O
, , , O
aberrant JJ JJ O
thermoregulation NN NN O
, , , O
rhabdomyolysis NN NN O
, , , O
and CC CC O
sudden JJ JJ O
death NN NN O
. . . O

Pemoline NNP NNP B-CHEM
induced VBD VBD O
acute JJ JJ O
choreoathetosis NN NN O
: : : O
case NN NN O
report NN NN O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Pemoline NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
oxazolidine NN NN B-CHEM
derivative JJ JJ O
that WDT WDT O
is VBZ VBZ O
structurally RB RB O
different JJ JJ O
from IN IN O
amphetamines NNS NNS B-CHEM
and CC CC O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
attention NN NN O
deficit JJ JJ O
disorder NN NN O
. . . O

Pemoline NNP NNP B-CHEM
has VBZ VBZ O
not RB RB O
been VBN VBN O
commonly RB RB O
associated VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
acute JJ JJ O
movement NN NN O
disorders NNS NNS O
. . . O

The DT DT O
following VBG VBG O
case NN NN O
describes VBZ VBZ O
two CD CD O
children NNS NNS O
acutely RB RB O
poisoned VBN VBN O
with IN IN O
pemoline NN NN B-CHEM
who WP WP O
experienced VBD VBD O
profound JJ JJ O
choreoathetosis NN NN O
. . . O

CASE NN NN O
REPORT NNP NNP O
: : : O
Two CD CD O
, , , O
3 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
, , , O
identical JJ JJ O
twin JJ JJ O
siblings NNS NNS O
presented VBN VBN O
to TO TO O
the DT DT O
emergency NN NN O
department NN NN O
after IN IN O
found VBD VBD O
playing VBG VBG O
with IN IN O
a DT DT O
an DT DT O
empty JJ JJ O
bottle NN NN O
of IN IN O
pemoline NN NN B-CHEM
originally RB RB O
containing VBG VBG O
59 CD CD O
tablets NNS NNS O
. . . O

The DT DT O
children NNS NNS O
had VBD VBD O
a DT DT O
medical JJ JJ O
history NN NN O
significant JJ JJ O
for IN IN O
attention NN NN O
deficit JJ JJ O
disorder NN NN O
previously RB RB O
treated VBN VBN O
with IN IN O
methylphenidate JJ JJ B-CHEM
without IN IN O
success NN NN O
. . . O

This DT DT O
was VBD VBD O
their PRP$ PRP$ O
first JJ JJ O
day NN NN O
of IN IN O
pemoline NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
choreoathetoid NN NN O
movements NNS NNS O
began VBD VBD O
45 CD CD O
min NN NN O
to TO TO O
1 CD CD O
h NN NN O
after IN IN O
ingestion NN NN O
. . . O

The DT DT O
children NNS NNS O
gave VBD VBD O
no DT DT O
history NN NN O
of IN IN O
prior JJ JJ O
movement NN NN O
disorders NNS NNS O
and CC CC O
there EX EX O
was VBD VBD O
no DT DT O
family NN NN O
history NN NN O
of IN IN O
movement NN NN O
disorders NNS NNS O
. . . O

The DT DT O
children NNS NNS O
received VBD VBD O
gastrointestinal JJ JJ O
decontamination NN NN O
and CC CC O
high JJ JJ O
doses NNS NNS O
of IN IN O
intravenous JJ JJ O
benzodiazepines NNS NNS B-CHEM
in IN IN O
an DT DT O
attempt NN NN O
to TO TO O
control VB VB O
the DT DT O
choreoathetoid NN NN O
movements NNS NNS O
. . . O

Despite IN IN O
treatment NN NN O
, , , O
the DT DT O
children NNS NNS O
continued VBD VBD O
to TO TO O
have VB VB O
choreoathetosis NNS NNS O
for IN IN O
approximately RB RB O
24 CD CD O
hours NNS NNS O
. . . O

Forty CD CD O
- : : O
eight CD CD O
hours NNS NNS O
after IN IN O
admission NN NN O
, , , O
the DT DT O
children NNS NNS O
appeared VBD VBD O
to TO TO O
be VB VB O
at IN IN O
their PRP$ PRP$ O
baseline NN NN O
and CC CC O
were VBD VBD O
discharged JJ JJ O
home NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Pemoline NNP NNP B-CHEM
associated VBN VBN O
movement NN NN O
disorder NN NN O
has VBZ VBZ O
been VBN VBN O
rarely RB RB O
reported VBN VBN O
in IN IN O
the DT DT O
acute JJ JJ O
toxicology NN NN O
literature NN NN O
. . . O

The DT DT O
possibility NN NN O
of IN IN O
choreoathetoid NN NN O
movements NNS NNS O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
patients NNS NNS O
presenting VBG VBG O
after IN IN O
pemoline NN NN B-CHEM
overdose NN NN O
. . . O

Effect NN NN O
of IN IN O
myopic JJ JJ O
excimer NN NN O
laser NN NN O
photorefractive JJ JJ O
keratectomy NN NN O
on IN IN O
the DT DT O
electrophysiologic JJ JJ O
function NN NN O
of IN IN O
the DT DT O
retina NN NN O
and CC CC O
optic JJ JJ O
nerve NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
assess VB VB O
by IN IN O
electrophysiologic JJ JJ O
testing NN NN O
the DT DT O
effect NN NN O
of IN IN O
photorefractive JJ JJ O
keratectomy NN NN O
( ( ( O
PRK NNP NNP O
) ) ) O
on IN IN O
the DT DT O
retina NN NN O
and CC CC O
optic JJ JJ O
nerve NN NN O
. . . O

SETTING NNP NNP O
: : : O
Eye NNP NNP O
Clinic NNP NNP O
, , , O
S NNP NNP O
. . . O

Salvatore NNP NNP O
Hospital NNP NNP O
, , , O
L NNP NNP O
' POS POS O
Aquila NNP NNP O
University NNP NNP O
, , , O
Italy NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Standard NNP NNP O
pattern NN NN O
electroretinograms NNS NNS O
( ( ( O
P NN NN O
- - - O
ERGs NNP NNP O
) ) ) O
and CC CC O
standard JJ JJ O
pattern NN NN O
visual NN NN O
evoked JJ JJ O
potentials NNS NNS O
( ( ( O
P NN NN O
- - - O
VEPs NNP NNP O
) ) ) O
were VBD VBD O
done VBN VBN O
in IN IN O
25 CD CD O
eyes NNS NNS O
of IN IN O
25 CD CD O
patients NNS NNS O
who WP WP O
had VBD VBD O
myopic JJ JJ O
PRK NNP NNP O
for IN IN O
an DT DT O
attempted JJ JJ O
correction NN NN O
between IN IN O
5 CD CD O
. . . O
00 CD CD O
and CC CC O
15 CD CD O
. . . O
00 CD CD O
diopters NNS NNS O
( ( ( O
D NNP NNP O
) ) ) O
( ( ( O
mean NN NN O
8 CD CD O
. . . O
00 CD CD O
D NNP NNP O
) ) ) O
. . . O

Testing NNP NNP O
was VBD VBD O
done VBN VBN O
preoperatively RB RB O
and CC CC O
3 CD CD O
, , , O
6 CD CD O
, , , O
12 CD CD O
, , , O
and CC CC O
18 CD CD O
months NNS NNS O
postoperatively RB RB O
. . . O

The DT DT O
contralateral JJ JJ O
eyes NNS NNS O
served VBD VBD O
as IN IN O
controls NNS NNS O
. . . O

During IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
, , , O
3 CD CD O
patients NNS NNS O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
developed VBN VBN O
steroid NN NN B-CHEM
- - - O
induced VBN VBN O
elevated VBD VBD O
intraocular JJ JJ O
pressure NN NN O
( ( ( O
IOP NNP NNP O
) ) ) O
that IN IN O
resolved VBD VBD O
after IN IN O
corticosteroid NN NN B-CHEM
therapy NN NN O
was VBD VBD O
discontinued VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
No DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
were VBD VBD O
seen VBN VBN O
between IN IN O
treated VBN VBN O
and CC CC O
control NN NN O
eyes NNS NNS O
nor CC CC O
between IN IN O
treated VBN VBN O
eyes NNS NNS O
preoperatively RB RB O
and CC CC O
postoperatively RB RB O
. . . O

CONCLUSION NNP NNP O
: : : O
Myopic NNP NNP O
excimer NN NN O
laser NN NN O
PRK NNP NNP O
did VBD VBD O
not RB RB O
seem VB VB O
to TO TO O
affect VB VB O
the DT DT O
posterior NN NN O
segment NN NN O
. . . O

The DT DT O
transient NN NN O
steroid NN NN B-CHEM
- : : O
induced JJ JJ O
IOP NNP NNP O
rise NN NN O
did VBD VBD O
not RB RB O
seem VB VB O
to TO TO O
cause VB VB O
functional JJ JJ O
impairment NN NN O
. . . O

Neutrophil NNP NNP O
superoxide NN NN B-CHEM
and CC CC O
hydrogen NN NN B-CHEM
peroxide NN NN I-CHEM
production NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
. . . O

Defects NNP NNP O
in IN IN O
superoxide NN NN B-CHEM
and CC CC O
hydrogen NN NN B-CHEM
peroxide NN NN I-CHEM
production NN NN O
may MD MD O
be VB VB O
implicated VBN VBN O
in IN IN O
the DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
bacterial JJ JJ O
infections NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
( ( ( O
ALF NNP NNP O
) ) ) O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
oxygen NN NN B-CHEM
radical JJ JJ O
production NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
ALF NNP NNP O
due JJ JJ O
to TO TO O
paracetamol NN NN B-CHEM
overdose NN NN O
was VBD VBD O
compared VBN VBN O
with IN IN O
that DT DT O
of IN IN O
healthy JJ JJ O
volunteers NNS NNS O
. . . O

Neutrophils NNP NNP O
from IN IN O
14 CD CD O
ALF NNP NNP O
patients NNS NNS O
were VBD VBD O
stimulated VBN VBN O
via IN IN O
the DT DT O
complement NN NN O
receptors NNS NNS O
using VBG VBG O
zymosan NN NN O
opsonized JJ JJ O
with IN IN O
ALF NNP NNP O
or CC CC O
control NN NN O
serum NN NN O
. . . O

Superoxide NNP NNP B-CHEM
and CC CC O
hydrogen NN NN B-CHEM
peroxide NN NN I-CHEM
production NN NN O
by IN IN O
ALF NNP NNP O
neutrophils NNS NNS O
stimulated VBN VBN O
with IN IN O
zymosan NN NN O
opsonized JJ JJ O
with IN IN O
ALF NNP NNP O
serum NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
compared VBN VBN O
with IN IN O
the DT DT O
control NN NN O
subjects NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

This DT DT O
defect NN NN O
persisted JJ JJ O
when WRB WRB O
zymosan NN NN O
opsonized VBN VBN O
by IN IN O
control NN NN O
serum NN NN O
was VBD VBD O
used VBN VBN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Superoxide NNP NNP B-CHEM
and CC CC O
hydrogen NN NN B-CHEM
peroxide NN NN I-CHEM
production NN NN O
in IN IN O
neutrophils NNS NNS O
stimulated VBN VBN O
with IN IN O
formyl NN NN B-CHEM
- - - I-CHEM
methionyl NN NN I-CHEM
- - - I-CHEM
leucyl NN NN I-CHEM
- - - I-CHEM
phenylalanine NN NN I-CHEM
( ( ( O
fMLP NN NN B-CHEM
) ) ) O
from IN IN O
a DT DT O
further JJ JJ O
18 CD CD O
ALF NNP NNP O
patients NNS NNS O
was VBD VBD O
unaffected JJ JJ O
compared VBN VBN O
with IN IN O
control NN NN O
neutrophils NNS NNS O
. . . O

Serum NNP NNP O
C3 NNP NNP O
complement NN NN O
levels NNS NNS O
were VBD VBD O
significantly RB RB O
reduced VBN VBN O
in IN IN O
ALF NNP NNP O
patients NNS NNS O
compared VBN VBN O
with IN IN O
control NN NN O
subjects NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0005 CD CD O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
demonstrate VBP VBP O
a DT DT O
neutrophil NN NN O
defect NN NN O
in IN IN O
ALF NNP NNP O
due JJ JJ O
to TO TO O
paracetamol NN NN B-CHEM
overdose NN NN O
, , , O
that WDT WDT O
is VBZ VBZ O
complement JJ JJ O
dependent JJ JJ O
but CC CC O
independent JJ JJ O
of IN IN O
serum NN NN O
complement NN NN O
, , , O
possibly RB RB O
connected VBN VBN O
to TO TO O
the DT DT O
complement NN NN O
receptor NN NN O
. . . O

Cholesteryl NNP NNP B-CHEM
hemisuccinate NN NN I-CHEM
treatment NN NN O
protects NNS NNS O
rodents NNS NNS O
from IN IN O
the DT DT O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
acetaminophen NN NN B-CHEM
, , , O
adriamycin NN NN B-CHEM
, , , O
carbon NN NN B-CHEM
tetrachloride NN NN I-CHEM
, , , O
chloroform NN NN B-CHEM
and CC CC O
galactosamine NN NN B-CHEM
. . . O

In IN IN O
addition NN NN O
to TO TO O
its PRP$ PRP$ O
use NN NN O
as IN IN O
a DT DT O
stabilizer NN NN O
/ NN NN O
rigidifier NN NN O
of IN IN O
membranes NNS NNS O
, , , O
cholesteryl NN NN B-CHEM
hemisuccinate NN NN I-CHEM
, , , O
tris NN NN B-CHEM
salt NN NN I-CHEM
( ( ( O
CS NNP NNP B-CHEM
) ) ) O
administration NN NN O
has VBZ VBZ O
also RB RB O
been VBN VBN O
shown VBN VBN O
to TO TO O
protect VB VB O
rats NNS NNS O
from IN IN O
the DT DT O
hepatotoxic JJ JJ O
effects NNS NNS O
of IN IN O
carbon NN NN B-CHEM
tetrachloride NN NN I-CHEM
( ( ( O
CCl4 NNP NNP B-CHEM
) ) ) O
. . . O

To TO TO O
further VB VB O
our PRP$ PRP$ O
understanding NN NN O
of IN IN O
the DT DT O
mechanism NN NN O
of IN IN O
CS NNP NNP B-CHEM
cytoprotection NN NN O
, , , O
we PRP PRP O
examined VBD VBD O
in IN IN O
rats NNS NNS O
and CC CC O
mice NNS NNS O
the DT DT O
protective JJ JJ O
abilities NNS NNS O
of IN IN O
CS NNP NNP B-CHEM
and CC CC O
the DT DT O
non NN NN O
- - - O
hydrolyzable JJ JJ O
ether NN NN O
form NN NN O
of IN IN O
CS NNP NNP B-CHEM
, , , O
gamma NN NN B-CHEM
- - - I-CHEM
cholesteryloxybutyric JJ JJ I-CHEM
acid NN NN I-CHEM
, , , O
tris NN NN B-CHEM
salt NN NN I-CHEM
( ( ( O
CSE NNP NNP B-CHEM
) ) ) O
against IN IN O
acetaminophen NN NN B-CHEM
- - - O
, , , O
adriamycin NN NN B-CHEM
- - - O
, , , O
carbon NN NN B-CHEM
tetrachloride NN NN I-CHEM
- : : O
, , , O
chloroform NN NN B-CHEM
- - - O
and CC CC O
galactosamine NN NN B-CHEM
- - - O
induced JJ JJ O
toxicity NN NN O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
these DT DT O
studies NNS NNS O
demonstrated VBN VBN O
that IN IN O
CS NNP NNP B-CHEM
- : : O
mediated JJ JJ O
protection NN NN O
is VBZ VBZ O
not RB RB O
selective JJ JJ O
for IN IN O
a DT DT O
particular JJ JJ O
species NNS NNS O
, , , O
organ NN NN O
system NN NN O
or CC CC O
toxic JJ JJ O
chemical NN NN O
. . . O

A DT DT O
24 CD CD O
- : : O
h NN NN O
pretreatment NN NN O
of IN IN O
both DT DT O
rats NNS NNS O
and CC CC O
mice NNS NNS O
with IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
CS NNP NNP B-CHEM
( ( ( O
100mg CD CD O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
resulted VBD VBD O
in IN IN O
significant JJ JJ O
protection NN NN O
against IN IN O
the DT DT O
hepatotoxic JJ JJ O
effects NNS NNS O
of IN IN O
CCl4 NNP NNP B-CHEM
, , , O
CHCl3 NNP NNP B-CHEM
, , , O
acetaminophen NN NN B-CHEM
and CC CC O
galactosamine NN NN B-CHEM
and CC CC O
against IN IN O
the DT DT O
lethal NN NN O
( ( ( O
and CC CC O
presumably RB RB O
cardiotoxic JJ JJ O
) ) ) O
effect NN NN O
of IN IN O
adriamycin NN NN B-CHEM
administration NN NN O
. . . O

Maximal NNP NNP O
CS NNP NNP B-CHEM
- : : O
mediated JJ JJ O
protection NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
experimental JJ JJ O
animals NNS NNS O
pretreated VBD VBD O
24 CD CD O
h NN NN O
prior RB RB O
to TO TO O
the DT DT O
toxic JJ JJ O
insult NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
CS NNP NNP B-CHEM
intervenes NNS NNS O
in IN IN O
a DT DT O
critical JJ JJ O
cellular JJ JJ O
event NN NN O
that WDT WDT O
is VBZ VBZ O
an DT DT O
important JJ JJ O
common JJ JJ O
pathway NN NN O
to TO TO O
toxic VB VB O
cell NN NN O
death NN NN O
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
CS NNP NNP B-CHEM
protection NN NN O
does VBZ VBZ O
not RB RB O
appear VB VB O
to TO TO O
be VB VB O
dependent JJ JJ O
on IN IN O
the DT DT O
inhibition NN NN O
of IN IN O
chemical NN NN O
bioactivation NN NN O
to TO TO O
a DT DT O
toxic JJ JJ O
reactive JJ JJ O
intermediate JJ JJ O
( ( ( O
in IN IN O
light NN NN O
of IN IN O
the DT DT O
protection NN NN O
observed VBD VBD O
against IN IN O
galactosamine NN NN B-CHEM
hepatotoxicity NN NN O
) ) ) O
. . . O

However RB RB O
, , , O
based VBN VBN O
on IN IN O
the DT DT O
data NNS NNS O
presented VBN VBN O
, , , O
we PRP PRP O
can MD MD O
not RB RB O
exclude VB VB O
the DT DT O
possibility NN NN O
that IN IN O
CS NNP NNP B-CHEM
administration NN NN O
inhibits NNS NNS O
chemical JJ JJ O
bioactivation NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
do VBP VBP O
suggest VB VB O
that IN IN O
CS NNP NNP B-CHEM
- : : O
mediated JJ JJ O
protection NN NN O
is VBZ VBZ O
dependent JJ JJ O
on IN IN O
the DT DT O
action NN NN O
of IN IN O
the DT DT O
intact JJ JJ O
anionic JJ JJ O
CS NNP NNP B-CHEM
molecule NN NN O
( ( ( O
non NN NN O
- - - O
hydrolyzable JJ JJ O
CSE NNP NNP B-CHEM
was VBD VBD O
as RB RB O
protective JJ JJ O
as IN IN O
CS NNP NNP B-CHEM
) ) ) O
, , , O
whose WP$ WP$ O
mechanism NN NN O
has VBZ VBZ O
yet RB RB O
to TO TO O
be VB VB O
defined VBN VBN O
. . . O

A DT DT O
murine NN NN O
model NN NN O
of IN IN O
adenomyosis NN NN O
: : : O
the DT DT O
effects NNS NNS O
of IN IN O
hyperprolactinemia NN NN O
induced VBN VBN O
by IN IN O
fluoxetine NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
a DT DT O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitor NN NN O
, , , O
on IN IN O
adenomyosis NN NN O
induction NN NN O
in IN IN O
Wistar NNP NNP O
albino NN NN O
rats NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
whether IN IN O
fluoxetine NN NN B-CHEM
given VBN VBN O
to TO TO O
castrated JJ JJ O
and CC CC O
noncastrated JJ JJ O
rats NNS NNS O
caused VBD VBD O
hyperprolactinemia NN NN O
and CC CC O
its PRP$ PRP$ O
effects NNS NNS O
with IN IN O
respect NN NN O
to TO TO O
adenomyosis NNS NNS O
. . . O

DESIGN NNP NNP O
: : : O
Fluoxetine NNP NNP B-CHEM
, , , O
a DT DT O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitor NN NN O
, , , O
was VBD VBD O
given VBN VBN O
to TO TO O
Wistar NNP NNP O
Albino NNP NNP O
rats NNS NNS O
for IN IN O
98 CD CD O
days NNS NNS O
to TO TO O
produce VB VB O
hyperprolactinemia NN NN O
. . . O

The DT DT O
drug NN NN O
was VBD VBD O
given VBN VBN O
to TO TO O
two CD CD O
groups NNS NNS O
consisting VBG VBG O
of IN IN O
castrated VBN VBN O
and CC CC O
noncastrated JJ JJ O
rats NNS NNS O
and CC CC O
compared VBN VBN O
to TO TO O
two CD CD O
groups NNS NNS O
of IN IN O
castrated JJ JJ O
and CC CC O
noncastrated JJ JJ O
controls NNS NNS O
. . . O

Prolactin NNP NNP O
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
and CC CC O
the DT DT O
uteri NN NN O
of IN IN O
the DT DT O
rats NNS NNS O
were VBD VBD O
removed VBN VBN O
for IN IN O
histopathological JJ JJ O
analysis NN NN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
98 CD CD O
days NNS NNS O
. . . O

SETTING NNP NNP O
: : : O
Marmara NNP NNP O
University NNP NNP O
School NNP NNP O
of IN IN O
Medicine NNP NNP O
, , , O
Department NNP NNP O
of IN IN O
Histology NNP NNP O
and CC CC O
Embryology NNP NNP O
, , , O
Zeynep NNP NNP O
Kamil NNP NNP O
Women NNP NNP O
and CC CC O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Hospital NNP NNP O
. . . O

MAIN NNP NNP O
OUTCOME NNP NNP O
MEASURES NNS NNS O
: : : O
Serum NNP NNP O
prolactin NN NN O
levels NNS NNS O
, , , O
uterine JJ JJ O
histopathology NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
prolactin NN NN O
levels NNS NNS O
of IN IN O
castrated JJ JJ O
and CC CC O
noncastrated JJ JJ O
groups NNS NNS O
treated VBN VBN O
with IN IN O
fluoxetine NN NN B-CHEM
were VBD VBD O
statistically RB RB O
significantly RB RB O
higher JJR JJR O
when WRB WRB O
compared VBN VBN O
to TO TO O
their PRP$ PRP$ O
respective JJ JJ O
control NN NN O
groups NNS NNS O
. . . O

Histological NNP NNP O
studies NNS NNS O
revealed VBD VBD O
11 CD CD O
cases NNS NNS O
of IN IN O
adenomyosis NNS NNS O
, , , O
all DT DT O
within IN IN O
the DT DT O
noncastrated JJ JJ O
group NN NN O
receiving VBG VBG O
fluoxetine NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
It PRP PRP O
was VBD VBD O
suggested VBN VBN O
that IN IN O
high JJ JJ O
serum NN NN O
prolactin NN NN O
levels NNS NNS O
cause VBP VBP O
degeneration NN NN O
of IN IN O
myometrial JJ JJ O
cells NNS NNS O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
ovarian JJ JJ O
steroids NNS NNS B-CHEM
that WDT WDT O
results NNS NNS O
in IN IN O
a DT DT O
myometrial JJ JJ O
invasion NN NN O
by IN IN O
endometrial JJ JJ O
stroma NN NN O
. . . O

This DT DT O
invasion NN NN O
eventually RB RB O
progresses VBZ VBZ O
to TO TO O
adenomyosis NNS NNS O
. . . O

Postinfarction NNP NNP O
ventricular JJ JJ O
septal NN NN O
defect NN NN O
associated VBN VBN O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
steroid NN NN B-CHEM
therapy NN NN O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
postinfarction NN NN O
ventricular JJ JJ O
septal JJ JJ O
rupture NN NN O
in IN IN O
patients NNS NNS O
on IN IN O
long JJ JJ O
- - - O
term NN NN O
steroid NN NN B-CHEM
therapy NN NN O
are VBP VBP O
presented VBN VBN O
and CC CC O
the DT DT O
favourable JJ JJ O
outcome NN NN O
in IN IN O
both DT DT O
cases NNS NNS O
described VBD VBD O
. . . O

A DT DT O
possible JJ JJ O
association NN NN O
between IN IN O
steroid NN NN B-CHEM
therapy NN NN O
and CC CC O
subsequent JJ JJ O
postinfarction NN NN O
septal JJ JJ O
rupture NN NN O
is VBZ VBZ O
discussed VBN VBN O
. . . O

Neuroactive NNP NNP O
steroids NNS NNS B-CHEM
protect NN NN O
against IN IN O
pilocarpine NN NN B-CHEM
- : : O
and CC CC O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
limbic NN NN O
seizures NNS NNS O
and CC CC O
status NN NN O
epilepticus NN NN O
in IN IN O
mice NN NN O
. . . O

Several JJ JJ O
structurally RB RB O
related VBN VBN O
metabolites NNS NNS O
of IN IN O
progesterone NN NN B-CHEM
( ( ( O
3 CD CD B-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
pregnane NN NN I-CHEM
- : : I-CHEM
20 CD CD I-CHEM
- : : I-CHEM
ones NNS NNS I-CHEM
) ) ) O
and CC CC O
deoxycorticosterone NN NN B-CHEM
( ( ( O
3 CD CD B-CHEM
alpha NN NN I-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
pregnane NN NN I-CHEM
- : : I-CHEM
21 CD CD I-CHEM
- : : I-CHEM
diol NN NN I-CHEM
- : : I-CHEM
20 CD CD I-CHEM
- : : I-CHEM
ones NNS NNS I-CHEM
) ) ) O
and CC CC O
their PRP$ PRP$ O
3 CD CD O
beta NN NN O
- : : O
epimers NNS NNS O
were VBD VBD O
evaluated VBN VBN O
for IN IN O
protective JJ JJ O
activity NN NN O
against IN IN O
pilocarpine NN NN B-CHEM
- - - O
, , , O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
- : : O
and CC CC O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
mice NN NN O
. . . O

Steroids NNP NNP B-CHEM
with IN IN O
the DT DT O
3 CD CD O
- : : O
hydroxy NN NN O
group NN NN O
in IN IN O
the DT DT O
alpha NN NN O
- - - O
position NN NN O
and CC CC O
5 CD CD O
- : : O
H NNP NNP O
in IN IN O
the DT DT O
alpha NN NN O
- - - O
or CC CC O
beta NN NN O
- - - O
configurations NNS NNS O
were VBD VBD O
highly RB RB O
effective JJ JJ O
in IN IN O
protecting VBG VBG O
against IN IN O
pilocarpine NN NN B-CHEM
( ( ( O
416 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
- : : O
induced JJ JJ O
limbic NN NN O
motor NN NN O
seizures NNS NNS O
and CC CC O
status NN NN O
epilepticus NN NN O
( ( ( O
ED50 NNP NNP O
values NNS NNS O
, , , O
7 CD CD O
. . . O
0 CD CD O
- : : O
18 CD CD O
. . . O
7 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

The DT DT O
corresponding JJ JJ O
epimers NNS NNS O
with IN IN O
the DT DT O
3 CD CD O
- : : O
hydroxy NN NN O
group NN NN O
in IN IN O
the DT DT O
beta NN NN O
- - - O
position NN NN O
were VBD VBD O
also RB RB O
effective JJ JJ O
but CC CC O
less RBR RBR O
potent JJ JJ O
( ( ( O
ED50 NNP NNP O
values NNS NNS O
, , , O
33 CD CD O
. . . O
8 CD CD O
- : : O
63 CD CD O
. . . O
5 CD CD O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

Although IN IN O
the DT DT O
neuroactive JJ JJ O
steroids NNS NNS B-CHEM
were VBD VBD O
considerably RB RB O
less RBR RBR O
potent JJ JJ O
than IN IN O
the DT DT O
benzodiazepine NN NN B-CHEM
clonazepam NN NN B-CHEM
in IN IN O
protecting VBG VBG O
against IN IN O
pilocarpine NN NN B-CHEM
seizures NNS NNS O
, , , O
steroids NNS NNS B-CHEM
with IN IN O
the DT DT O
5 CD CD O
alpha NN NN O
, , , O
3 CD CD O
alpha NN NN O
- : : O
configuration NN NN O
had VBD VBD O
comparable JJ JJ O
or CC CC O
higher JJR JJR O
protective JJ JJ O
index NN NN O
values NNS NNS O
( ( ( O
TD50 NNP NNP O
for IN IN O
motor NN NN O
impairment NN NN O
divided VBN VBN O
by IN IN O
ED50 NNP NNP O
for IN IN O
seizure NN NN O
protection NN NN O
) ) ) O
than IN IN O
clonazepam NN NN B-CHEM
, , , O
indicating VBG VBG O
that IN IN O
some DT DT O
neuroactive JJ JJ O
steroids NNS NNS B-CHEM
may MD MD O
have VB VB O
lower JJR JJR O
relative JJ JJ O
toxicity NN NN O
. . . O

Steroids NNP NNP B-CHEM
with IN IN O
the DT DT O
5 CD CD O
alpha NN NN O
, , , O
3 CD CD O
alpha NN NN O
- : : O
or CC CC O
5 CD CD O
beta NN NN O
, , , O
3 CD CD O
alpha NN NN O
- : : O
configurations NNS NNS O
also RB RB O
produced VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
delay NN NN O
in IN IN O
the DT DT O
onset NN NN O
of IN IN O
limbic NN NN O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
32 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
completely RB RB O
protect VB VB O
against IN IN O
the DT DT O
seizures NNS NNS O
. . . O

However RB RB O
, , , O
when WRB WRB O
a DT DT O
second JJ JJ O
dose NN NN O
of IN IN O
the DT DT O
steroid NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
1 CD CD O
hr NN NN O
after IN IN O
the DT DT O
first JJ JJ O
dose NN NN O
, , , O
complete JJ JJ O
protection NN NN O
from IN IN O
the DT DT O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
limbic NN NN O
seizures NNS NNS O
and CC CC O
status NN NN O
epilepticus NN NN O
was VBD VBD O
obtained VBN VBN O
. . . O

The DT DT O
steroids NNS NNS B-CHEM
also RB RB O
caused VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
delay NN NN O
in IN IN O
NMDA NNP NNP B-CHEM
( ( ( O
257 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
- : : O
induced JJ JJ O
lethality NN NN O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
completely RB RB O
protect VB VB O
against IN IN O
NMDA NNP NNP B-CHEM
seizures NNS NNS O
or CC CC O
lethality NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
neuroactive JJ JJ O
steroids NNS NNS B-CHEM
are VBP VBP O
highly RB RB O
effective JJ JJ O
in IN IN O
protecting VBG VBG O
against IN IN O
pilocarpine NN NN B-CHEM
- : : O
and CC CC O
kainic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
status NN NN O
epilepticus NN NN O
in IN IN O
mice NN NN O
, , , O
and CC CC O
may MD MD O
be VB VB O
of IN IN O
utility NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
some DT DT O
forms NNS NNS O
of IN IN O
status NN NN O
epilepticus NN NN O
in IN IN O
humans NNS NNS O
. . . O

Hepatic NNP NNP O
and CC CC O
extrahepatic JJ JJ O
angiotensinogen NN NN O
gene NN NN O
expression NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
acute JJ JJ O
nephrotic JJ JJ O
syndrome NN NN O
. . . O

Plasma NNP NNP O
concentration NN NN O
and CC CC O
urine JJ JJ O
excretion NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
proteins NNS NNS O
are VBP VBP O
altered VBN VBN O
in IN IN O
rats NNS NNS O
with IN IN O
nephrotic JJ JJ O
syndrome NN NN O
( ( ( O
NS NNP NNP O
) ) ) O
. . . O

In IN IN O
this DT DT O
work NN NN O
the DT DT O
messenger NN NN O
ribonucleic JJ JJ O
acid NN NN O
( ( ( O
mRNA NN NN O
) ) ) O
levels NNS NNS O
of IN IN O
angiotensinogen NN NN O
( ( ( O
Ao NNP NNP O
) ) ) O
were VBD VBD O
analyzed VBN VBN O
with IN IN O
the DT DT O
slot NN NN O
- - - O
blot NN NN O
hybridization NN NN O
technique NN NN O
in IN IN O
liver NN NN O
and CC CC O
other JJ JJ O
extrahepatic JJ JJ O
tissues NNS NNS O
: : : O
kidney NN NN O
, , , O
heart NN NN O
, , , O
brain NN NN O
, , , O
and CC CC O
adrenal JJ JJ O
gland NN NN O
from IN IN O
control NN NN O
, , , O
nephrotic JJ JJ O
, , , O
and CC CC O
pair NN NN O
- - - O
fed VBN VBN O
( ( ( O
PF NNP NNP O
) ) ) O
rats NNS NNS O
. . . O

NS NNP NNP O
was VBD VBD O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
puromycin NN NN B-CHEM
amino JJ JJ I-CHEM
- : : I-CHEM
nucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
. . . O

Although IN IN O
a DT DT O
great JJ JJ O
urinary JJ JJ O
excretion NN NN O
and CC CC O
half NN NN O
- - - O
normal JJ JJ O
plasma NN NN O
levels NNS NNS O
of IN IN O
Ao NNP NNP O
were VBD VBD O
observed VBN VBN O
on IN IN O
day NN NN O
6 CD CD O
after IN IN O
PAN NNP NNP B-CHEM
injection NN NN O
, , , O
when WRB WRB O
NS NNP NNP O
was VBD VBD O
clearly RB RB O
established VBN VBN O
, , , O
hepatic JJ JJ O
Ao NNP NNP O
mRNA NN NN O
levels NNS NNS O
did VBD VBD O
not RB RB O
change VB VB O
. . . O

Furthermore RB RB O
, , , O
the DT DT O
Ao NNP NNP O
mRNA NN NN O
levels NNS NNS O
did VBD VBD O
not RB RB O
change VB VB O
in IN IN O
any DT DT O
of IN IN O
the DT DT O
extrahepatic JJ JJ O
tissues NNS NNS O
studied VBN VBN O
on IN IN O
day NN NN O
6 CD CD O
, , , O
nor CC CC O
did VBD VBD O
its PRP$ PRP$ O
hepatic JJ JJ O
levels NNS NNS O
at IN IN O
days NNS NNS O
1 CD CD O
, , , O
3 CD CD O
, , , O
5 CD CD O
, , , O
or CC CC O
7 CD CD O
after IN IN O
PAN NNP NNP B-CHEM
injection NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
hepatic JJ JJ O
and CC CC O
extrahepatic JJ JJ O
Ao NNP NNP O
mRNA NN NN O
levels NNS NNS O
are VBP VBP O
unaltered JJ JJ O
during IN IN O
the DT DT O
development NN NN O
of IN IN O
the DT DT O
acute JJ JJ O
NS NNP NNP O
induced VBN VBN O
by IN IN O
PAN NNP NNP B-CHEM
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
with IN IN O
risperidone NN NN B-CHEM
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
is VBZ VBZ O
thought VBN VBN O
to TO TO O
be VB VB O
a DT DT O
result NN NN O
of IN IN O
dopamine NN NN B-CHEM
D2 NN NN O
receptor NN NN O
blockade NN NN O
in IN IN O
the DT DT O
striatum NN NN O
of IN IN O
the DT DT O
basal NN NN O
ganglia NN NN O
. . . O

Risperidone NNP NNP B-CHEM
, , , O
a DT DT O
benzisoxazole NN NN B-CHEM
derivative JJ JJ O
antipsychotic JJ JJ O
, , , O
has VBZ VBZ O
high JJ JJ O
serotonin NN NN B-CHEM
5 CD CD O
- : : O
HT2 NNP NNP O
receptor NN NN O
blockade NN NN O
and CC CC O
dose VB VB O
- - - O
related VBN VBN O
D2 NN NN O
receptor NN NN O
blockade NN NN O
. . . O

The DT DT O
high JJ JJ O
ratio NN NN O
is VBZ VBZ O
believed VBN VBN O
to TO TO O
impart VB VB O
the DT DT O
low JJ JJ O
frequency NN NN O
of IN IN O
extrapyramidal NN NN O
symptoms NNS NNS O
with IN IN O
risperidone NN NN B-CHEM
at IN IN O
low JJ JJ O
dosages NNS NNS O
. . . O

With IN IN O
this DT DT O
low JJ JJ O
frequency NN NN O
of IN IN O
extrapyramidal NN NN O
symptoms NNS NNS O
, , , O
it PRP PRP O
was VBD VBD O
thought VBN VBN O
the DT DT O
frequency NN NN O
of IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
might MD MD O
also RB RB O
be VB VB O
lowered VBN VBN O
. . . O

A DT DT O
73 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
developed VBN VBN O
neuroleptic JJ JJ O
malignant JJ JJ O
syndrome NN NN O
after IN IN O
monotherapy NN NN O
with IN IN O
risperidone NN NN B-CHEM
. . . O

The DT DT O
syndrome NN NN O
reversed VBD VBD O
after IN IN O
discontinuing VBG VBG O
risperidone NN NN B-CHEM
and CC CC O
starting VBG VBG O
treatment NN NN O
with IN IN O
dantrolene NN NN B-CHEM
and CC CC O
bromocriptine NN NN B-CHEM
. . . O

It PRP PRP O
appears VBZ VBZ O
that IN IN O
the DT DT O
protection NN NN O
from IN IN O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
observed VBD VBD O
with IN IN O
risperidone NN NN B-CHEM
does VBZ VBZ O
not RB RB O
ensure VB VB O
protection NN NN O
from IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
. . . O

The DT DT O
attenuating VBG VBG O
effect NN NN O
of IN IN O
carteolol NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
a DT DT O
beta NN NN O
- - - O
adrenoceptor NN NN O
antagonist NN NN O
, , , O
on IN IN O
neuroleptic JJ JJ O
- : : O
induced JJ JJ O
catalepsy NN NN O
in IN IN O
rats NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
known VBN VBN O
that IN IN O
beta NN NN O
- : : O
adrenoceptor NN NN O
antagonists NNS NNS O
are VBP VBP O
effective JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
akathisia NN NN O
, , , O
one CD CD O
of IN IN O
the DT DT O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
that WDT WDT O
occur VBP VBP O
during IN IN O
neuroleptic JJ JJ O
treatment NN NN O
. . . O

Neuroleptic NNP NNP O
- : : O
induced JJ JJ O
catalepsy NN NN O
, , , O
a DT DT O
model NN NN O
of IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
, , , O
was VBD VBD O
considered VBN VBN O
suitable JJ JJ O
as IN IN O
a DT DT O
model NN NN O
for IN IN O
predicting VBG VBG O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
akathisia NN NN O
in IN IN O
humans NNS NNS O
, , , O
although IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
catalepsy NN NN O
was VBD VBD O
not RB RB O
considered VBN VBN O
a DT DT O
specific JJ JJ O
test NN NN O
for IN IN O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
akathisia NN NN O
. . . O

Therefore RB RB O
, , , O
the DT DT O
effects NNS NNS O
of IN IN O
carteolol NN NN B-CHEM
, , , O
a DT DT O
beta NN NN O
- - - O
adrenoceptor NN NN O
antagonist NN NN O
, , , O
on IN IN O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
in IN IN O
rats NNS NNS O
were VBD VBD O
behaviorally RB RB O
studied VBN VBN O
and CC CC O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
propranolol NN NN B-CHEM
and CC CC O
biperiden NN NN B-CHEM
, , , O
a DT DT O
muscarinic JJ JJ O
receptor NN NN O
antagonist NN NN O
. . . O

Carteolol NNP NNP B-CHEM
, , , O
as RB RB O
well RB RB O
as IN IN O
propranolol NN NN B-CHEM
and CC CC O
biperiden NN NN B-CHEM
, , , O
inhibited VBD VBD O
the DT DT O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
. . . O

The DT DT O
inhibitory JJ JJ O
effect NN NN O
of IN IN O
carteolol NN NN B-CHEM
was VBD VBD O
almost RB RB O
comparable JJ JJ O
to TO TO O
that DT DT O
of IN IN O
propranolol NN NN B-CHEM
, , , O
but CC CC O
was VBD VBD O
weaker JJR JJR O
than IN IN O
that DT DT O
of IN IN O
biperiden NN NN B-CHEM
. . . O

Carteolol NNP NNP B-CHEM
did VBD VBD O
not RB RB O
evoke VB VB O
postsynaptic JJ JJ O
dopamine NN NN B-CHEM
receptor NN NN O
- : : O
stimulating VBG VBG O
behavioral JJ JJ O
signs NNS NNS O
such JJ JJ O
as IN IN O
stereotypy NN NN O
and CC CC O
hyperlocomotion NN NN O
in IN IN O
rats NNS NNS O
. . . O

Carteolol NNP NNP B-CHEM
did VBD VBD O
not RB RB O
antagonize VB VB O
the DT DT O
inhibitory NN NN O
effects NNS NNS O
of IN IN O
haloperidol NN NN B-CHEM
on IN IN O
apomorphine NN NN B-CHEM
- : : O
induced JJ JJ O
stereotypy NN NN O
and CC CC O
locomotor NN NN O
activity NN NN O
in IN IN O
rats NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
carteolol NN NN B-CHEM
did VBD VBD O
not RB RB O
evoke NN NN O
5 CD CD O
- : : O
HT1A NNP NNP O
receptor NN NN O
- : : O
stimulating VBG VBG O
behavioral JJ JJ O
signs NNS NNS O
such JJ JJ O
as IN IN O
flat JJ JJ O
body NN NN O
posture NN NN O
and CC CC O
forepaw NN NN O
treading NN NN O
and CC CC O
did VBD VBD O
not RB RB O
inhibit NN NN O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptophan NN NN I-CHEM
- : : O
induced JJ JJ O
head NN NN O
twitch NN NN O
in IN IN O
rats NNS NNS O
. . . O

Finally RB RB O
, , , O
carteolol NN NN B-CHEM
did VBD VBD O
not RB RB O
inhibit VB VB O
physostigmine NN NN B-CHEM
- : : O
induced JJ JJ O
lethality NN NN O
in IN IN O
rats NNS NNS O
. . . O

These DT DT O
results NNS NNS O
strongly RB RB O
suggest VBP VBP O
that IN IN O
carteolol NN NN B-CHEM
improves VBZ VBZ O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
via IN IN O
its PRP$ PRP$ O
beta NN NN O
- - - O
adrenoceptor NN NN O
antagonistic JJ JJ O
activity NN NN O
and CC CC O
is VBZ VBZ O
expected VBN VBN O
to TO TO O
be VB VB O
effective JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
akathisia NN NN O
without IN IN O
attenuating VBG VBG O
neuroleptic JJ JJ O
- - - O
induced JJ JJ O
antipsychotic JJ JJ O
effects NNS NNS O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
postsynaptic JJ JJ O
dopamine NN NN B-CHEM
receptor NN NN O
antagonistic JJ JJ O
activity NN NN O
. . . O

Granulosa NNP NNP O
cell NN NN O
tumor NN NN O
of IN IN O
the DT DT O
ovary JJ JJ O
associated VBN VBN O
with IN IN O
antecedent NN NN O
tamoxifen NN NN B-CHEM
use NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Increased NNP NNP O
attention NN NN O
has VBZ VBZ O
been VBN VBN O
focused VBN VBN O
recently RB RB O
on IN IN O
the DT DT O
estrogenic JJ JJ O
effects NNS NNS O
of IN IN O
tamoxifen NN NN B-CHEM
. . . O

Review NNP NNP O
of IN IN O
the DT DT O
literature NN NN O
reveals VBZ VBZ O
an DT DT O
association NN NN O
between IN IN O
tamoxifen NN NN B-CHEM
use NN NN O
and CC CC O
gynecologic JJ JJ O
tumors NNS NNS O
. . . O

CASE NN NN O
: : : O
A DT DT O
52 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
postmenopausal NN NN O
woman NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
tamoxifen NN NN B-CHEM
for IN IN O
stage NN NN O
II NNP NNP O
estrogen NN NN B-CHEM
receptor NN NN O
- : : O
positive JJ JJ O
breast NN NN O
carcinoma NN NN O
. . . O

Her PRP$ PRP$ O
aspartate NN NN B-CHEM
transaminase NN NN O
and CC CC O
alanine NN NN B-CHEM
transaminase NN NN O
levels NNS NNS O
increase VBP VBP O
markedly RB RB O
after IN IN O
6 CD CD O
months NNS NNS O
of IN IN O
tamoxifen NN NN B-CHEM
use NN NN O
. . . O

After IN IN O
an DT DT O
additional JJ JJ O
17 CD CD O
months NNS NNS O
of IN IN O
elevated VBD VBD O
serum NN NN O
transaminases NNS NNS O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
a DT DT O
stage NN NN O
Ic NNP NNP O
granulosa NN NN O
cell NN NN O
tumor NN NN O
of IN IN O
the DT DT O
ovary JJ JJ O
. . . O

CONCLUSION NNP NNP O
: : : O
Patients NNS NNS O
with IN IN O
tamoxifen NN NN B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
dysfunction NN NN O
may MD MD O
be VB VB O
at IN IN O
increased VBN VBN O
risk NN NN O
for IN IN O
granulosa NN NN O
cell NN NN O
tumors NNS NNS O
because IN IN O
of IN IN O
alterations NNS NNS O
in IN IN O
tamoxifen NN NN B-CHEM
metabolism NN NN O
. . . O

Lifetime NNP NNP O
treatment NN NN O
of IN IN O
mice NNS NNS O
with IN IN O
azidothymidine NN NN B-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O
produces VBZ VBZ O
myelodysplasia NN NN O
. . . O

AZT NNP NNP B-CHEM
has VBZ VBZ O
induced VBN VBN O
a DT DT O
macrocytic JJ JJ O
anemia NN NN O
in IN IN O
AIDS NNP NNP O
patients NNS NNS O
on IN IN O
long JJ JJ O
term NN NN O
AZT NNP NNP B-CHEM
therapy NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
generally RB RB O
assumed VBN VBN O
that IN IN O
DNA NNP NNP O
elongation NN NN O
is VBZ VBZ O
stopped VBN VBN O
by IN IN O
the DT DT O
insertion NN NN O
of IN IN O
AZT NNP NNP B-CHEM
into IN IN O
the DT DT O
chain NN NN O
in IN IN O
place NN NN O
of IN IN O
thymidine NN NN B-CHEM
thus RB RB O
preventing VBG VBG O
the DT DT O
phosphate NN NN B-CHEM
hydroxyl NN NN O
linkages NNS NNS O
and CC CC O
therefore RB RB O
suppresses VBZ VBZ O
hemopoietic JJ JJ O
progenitor NN NN O
cell NN NN O
proliferation NN NN O
in IN IN O
an DT DT O
early JJ JJ O
stage NN NN O
of IN IN O
differentiation NN NN O
. . . O

CBA NNP NNP O
/ NN NN O
Ca NNP NNP O
male JJ JJ O
mice NN NN O
started VBD VBD O
on IN IN O
AZT NNP NNP B-CHEM
0 CD CD O
. . . O
75 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
H2O NNP NNP O
at IN IN O
84 CD CD O
days NNS NNS O
of IN IN O
age NN NN O
and CC CC O
kept VBD VBD O
on IN IN O
it PRP PRP O
for IN IN O
687 CD CD O
days NNS NNS O
when WRB WRB O
dosage NN NN O
reduced VBD VBD O
to TO TO O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
H2O NNP NNP O
for IN IN O
a DT DT O
group NN NN O
, , , O
another DT DT O
group NN NN O
removed VBD VBD O
from IN IN O
AZT NNP NNP B-CHEM
to TO TO O
see VB VB O
recovery NN NN O
, , , O
and CC CC O
third JJ JJ O
group NN NN O
remained VBD VBD O
on IN IN O
0 CD CD O
. . . O
75 CD CD O
mg NN NN O
. . . O

At IN IN O
687 CD CD O
days NNS NNS O
mice NN NN O
that WDT WDT O
had VBD VBD O
been VBN VBN O
on IN IN O
0 CD CD O
. . . O
75 CD CD O
mg NN NN O
had VBD VBD O
average JJ JJ O
platelet NN NN O
counts NNS NNS O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
6 CD CD O
) ) ) O
. . . O

Histological NNP NNP O
examination NN NN O
on IN IN O
9 CD CD O
of IN IN O
10 CD CD O
mice NN NN O
with IN IN O
such JJ JJ O
thrombocytopenia NN NN O
showed VBD VBD O
changes NNS NNS O
compatible JJ JJ O
with IN IN O
myelodysplastic JJ JJ O
syndrome NN NN O
( ( ( O
MDS NNP NNP O
) ) ) O
. . . O

A DT DT O
variety NN NN O
of IN IN O
histological JJ JJ O
patterns NNS NNS O
was VBD VBD O
observed VBN VBN O
. . . O

There EX EX O
were VBD VBD O
two CD CD O
cases NNS NNS O
of IN IN O
hypocellular JJ JJ O
myelodysplasia NN NN O
, , , O
two CD CD O
cases NNS NNS O
of IN IN O
hypersegmented JJ JJ O
myelodysplastic JJ JJ O
granulocytosis NN NN O
, , , O
two CD CD O
cases NNS NNS O
of IN IN O
hypercellular JJ JJ O
marrow NN NN O
with IN IN O
abnormal JJ JJ O
megakaryocytes NNS NNS O
with IN IN O
bizarre JJ JJ O
nuclei NN NN O
, , , O
one CD CD O
case NN NN O
of IN IN O
megakaryocytic JJ JJ O
myelosis NN NN O
associated VBN VBN O
with IN IN O
a DT DT O
hyperplastic JJ JJ O
marrow NN NN O
, , , O
dysmyelopoiesis NN NN O
and CC CC O
a DT DT O
hypocellular JJ JJ O
marrow NN NN O
and CC CC O
two CD CD O
cases NNS NNS O
of IN IN O
myelodysplasia NN NN O
with IN IN O
dyserythropoiesis NN NN O
, , , O
hemosiderosis NN NN O
and CC CC O
a DT DT O
hypocellular JJ JJ O
marrow NN NN O
. . . O

Above IN IN O
mentioned VBN VBN O
AZT NNP NNP B-CHEM
incorporation NN NN O
may MD MD O
have VB VB O
induced VBN VBN O
an DT DT O
ineffective JJ JJ O
hemopoiesis NN NN O
in IN IN O
the DT DT O
primitive JJ JJ O
hemopoietic JJ JJ O
progenitor NN NN O
cells NNS NNS O
, , , O
which WDT WDT O
is VBZ VBZ O
known VBN VBN O
to TO TO O
be VB VB O
seen VBN VBN O
commonly RB RB O
in IN IN O
the DT DT O
myelodysplastic JJ JJ O
syndrome NN NN O
. . . O

Biphasic NNP NNP O
response NN NN O
of IN IN O
the DT DT O
SA NNP NNP O
node NN NN O
of IN IN O
the DT DT O
dog NN NN O
heart NN NN O
in IN IN O
vivo NN NN O
to TO TO O
selective JJ JJ O
administration NN NN O
of IN IN O
ketamine NN NN B-CHEM
. . . O

Effect NN NN O
of IN IN O
ketamine NN NN B-CHEM
on IN IN O
the DT DT O
SA NNP NNP O
node NN NN O
of IN IN O
the DT DT O
dog NN NN O
heart NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
vivo NN NN O
using VBG VBG O
a DT DT O
selective JJ JJ O
perfusion NN NN O
technique NN NN O
of IN IN O
the DT DT O
SA NNP NNP O
node NN NN O
artery NN NN O
. . . O

Injections NNP NNP O
of IN IN O
ketamine NN NN B-CHEM
in IN IN O
doses NNS NNS O
from IN IN O
100 CD CD O
microgram NN NN O
to TO TO O
3 CD CD O
mg NN NN O
into IN IN O
the DT DT O
artery NN NN O
produced VBD VBD O
a DT DT O
depression NN NN O
of IN IN O
the DT DT O
SA NNP NNP O
nodal NN NN O
activity NN NN O
by IN IN O
a DT DT O
direct JJ JJ O
action NN NN O
. . . O

This DT DT O
depression NN NN O
was VBD VBD O
followed VBN VBN O
by IN IN O
the DT DT O
sudden JJ JJ O
appearance NN NN O
of IN IN O
a DT DT O
stimulatory NN NN O
phase NN NN O
. . . O

Bilateral NNP NNP O
vagotomy NN NN O
and CC CC O
sympathectomy NN NN O
or CC CC O
prior RB RB O
administration NN NN O
of IN IN O
a DT DT O
ganglion NN NN O
blocker NN NN O
failed VBD VBD O
to TO TO O
inhibit VB VB O
the DT DT O
occurrence NN NN O
of IN IN O
the DT DT O
ketamine NN NN B-CHEM
- - - O
induced JJ JJ O
tachycardia NN NN O
, , , O
while IN IN O
it PRP PRP O
was VBD VBD O
completely RB RB O
abolished VBN VBN O
in IN IN O
the DT DT O
reserpinized JJ JJ O
dogs NNS NNS O
or CC CC O
by IN IN O
a DT DT O
prior JJ JJ O
injection NN NN O
of IN IN O
a DT DT O
beta NN NN O
- - - O
blocking VBG VBG O
agent NN NN O
into IN IN O
the DT DT O
SA NNP NNP O
node NN NN O
artery NN NN O
. . . O

This DT DT O
may MD MD O
indicate VB VB O
that IN IN O
an DT DT O
activation NN NN O
of IN IN O
the DT DT O
peripheral JJ JJ O
adrenergic JJ JJ O
mechanism NN NN O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
induction NN NN O
of IN IN O
the DT DT O
excitatory JJ JJ O
effect NN NN O
of IN IN O
ketamine NN NN B-CHEM
injected VBN VBN O
in IN IN O
the DT DT O
SA NNP NNP O
node NN NN O
artery NN NN O
. . . O

Over IN IN O
expression NN NN O
of IN IN O
vascular NN NN O
endothelial JJ JJ O
growth NN NN O
factor NN NN O
and CC CC O
its PRP$ PRP$ O
receptor NN NN O
during IN IN O
the DT DT O
development NN NN O
of IN IN O
estrogen NN NN B-CHEM
- - - O
induced JJ JJ O
rat NN NN O
pituitary JJ JJ O
tumors NNS NNS O
may MD MD O
mediate VB VB O
estrogen NN NN B-CHEM
- - - O
initiated JJ JJ O
tumor NN NN O
angiogenesis NN NN O
. . . O

Estrogens NNP NNP B-CHEM
, , , O
which WDT WDT O
have VBP VBP O
been VBN VBN O
associated VBN VBN O
with IN IN O
several JJ JJ O
types NNS NNS O
of IN IN O
human JJ JJ O
and CC CC O
animal NN NN O
cancers NNS NNS O
, , , O
can MD MD O
induce VB VB O
tumor NN NN O
angiogenesis NN NN O
in IN IN O
the DT DT O
pituitary NN NN O
of IN IN O
Fischer NNP NNP O
344 CD CD O
rats NNS NNS O
. . . O

The DT DT O
mechanistic JJ JJ O
details NNS NNS O
of IN IN O
tumor NN NN O
angiogenesis NN NN O
induction NN NN O
, , , O
during IN IN O
estrogen NN NN B-CHEM
carcinogenesis NNS NNS O
, , , O
are VBP VBP O
still RB RB O
unknown JJ JJ O
. . . O

To TO TO O
elucidate VB VB O
the DT DT O
role NN NN O
of IN IN O
estrogen NN NN B-CHEM
in IN IN O
the DT DT O
regulation NN NN O
of IN IN O
tumor NN NN O
angiogenesis NN NN O
in IN IN O
the DT DT O
pituitary NN NN O
of IN IN O
female JJ JJ O
rats NNS NNS O
, , , O
the DT DT O
density NN NN O
of IN IN O
blood NN NN O
vessels NNS NNS O
was VBD VBD O
analysed VBN VBN O
using VBG VBG O
factor NN NN O
VIII NNP NNP O
related VBD VBD O
antigen NN NN O
( ( ( O
FVIIIRAg NNP NNP O
) ) ) O
immunohistochemistry NN NN O
and CC CC O
the DT DT O
expression NN NN O
of IN IN O
vascular NN NN O
endothelial JJ JJ O
growth NN NN O
factor NN NN O
/ NN NN O
vascular NN NN O
permeability NN NN O
factor NN NN O
( ( ( O
VEGF NNP NNP O
/ NN NN O
VPF NNP NNP O
) ) ) O
was VBD VBD O
examined VBN VBN O
by IN IN O
Western JJ JJ O
blot NN NN O
and CC CC O
immunohistochemical JJ JJ O
analysis NN NN O
. . . O

The DT DT O
expression NN NN O
of IN IN O
VEGF NNP NNP O
receptor NN NN O
( ( ( O
VEGFR NNP NNP O
- - - O
2 CD CD O
/ NN NN O
Flk NNP NNP O
- - - O
1 CD CD O
/ NN NN O
KDR NNP NNP O
) ) ) O
was VBD VBD O
also RB RB O
examined VBN VBN O
by IN IN O
immunohistochemistry NN NN O
. . . O

The DT DT O
results NNS NNS O
demonstrated VBN VBN O
that IN IN O
17beta CD CD B-CHEM
- : : I-CHEM
estradiol NN NN I-CHEM
( ( ( O
E2 NNP NNP B-CHEM
) ) ) O
induces NNS NNS O
neovascularization NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
growth NN NN O
and CC CC O
enlargement NN NN O
of IN IN O
blood NN NN O
vessels NNS NNS O
after IN IN O
7 CD CD O
days NNS NNS O
of IN IN O
exposure NN NN O
. . . O

The DT DT O
high JJ JJ O
tumor NN NN O
angiogenic JJ JJ O
potential NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
elevated JJ JJ O
VEGF NNP NNP O
/ NN NN O
VPF NNP NNP O
protein NN NN O
expression NN NN O
in IN IN O
the DT DT O
E2 NNP NNP B-CHEM
exposed VBD VBD O
pituitary JJ JJ O
of IN IN O
ovariectomized JJ JJ O
( ( ( O
OVEX NNP NNP O
) ) ) O
rats NNS NNS O
. . . O

VEGF NNP NNP O
/ NN NN O
VPF NNP NNP O
and CC CC O
FVIIIRAg NNP NNP O
immunohistochemistry NN NN O
and CC CC O
endothelial JJ JJ O
specific JJ JJ O
lectin NN NN O
( ( ( O
UEA1 NNP NNP O
) ) ) O
binding JJ JJ O
studies NNS NNS O
, , , O
indicate VBP VBP O
that IN IN O
the DT DT O
elevation NN NN O
of IN IN O
VEGF NNP NNP O
protein NN NN O
expression NN NN O
initially RB RB O
occurred VBD VBD O
in IN IN O
both DT DT O
blood NN NN O
vessels NNS NNS O
and CC CC O
non NN NN O
- - - O
endothelial JJ JJ O
cells NNS NNS O
. . . O

After IN IN O
15 CD CD O
days NNS NNS O
of IN IN O
E2 NNP NNP B-CHEM
exposure NN NN O
, , , O
VEGF NNP NNP O
/ NN NN O
VPF NNP NNP O
protein NN NN O
expression NN NN O
, , , O
in IN IN O
the DT DT O
non NN NN O
- - - O
endothelial JJ JJ O
cell NN NN O
population NN NN O
, , , O
sharply RB RB O
declined VBN VBN O
and CC CC O
was VBD VBD O
restricted VBN VBN O
to TO TO O
the DT DT O
blood NN NN O
vessels NNS NNS O
. . . O

The DT DT O
function NN NN O
of IN IN O
non NN NN O
- - - O
endothelial JJ JJ O
- - - O
derived VBN VBN O
VEGF NNP NNP O
is VBZ VBZ O
not RB RB O
clear JJ JJ O
. . . O

Furthermore RB RB O
, , , O
immunohistochemical JJ JJ O
studies NNS NNS O
demonstrated VBD VBD O
that IN IN O
VEGFR NNP NNP O
- : : O
2 CD CD O
( ( ( O
flk NN NN O
- - - O
1 CD CD O
/ NN NN O
KDR NNP NNP O
) ) ) O
, , , O
expression NN NN O
was VBD VBD O
elevated VBN VBN O
significantly RB RB O
in IN IN O
the DT DT O
endothelial JJ JJ O
cells NNS NNS O
of IN IN O
microblood NN NN O
vessels NNS NNS O
after IN IN O
7 CD CD O
days NNS NNS O
of IN IN O
E2 NNP NNP B-CHEM
exposure NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
over IN IN O
expression NN NN O
of IN IN O
VEGF NNP NNP O
and CC CC O
its PRP$ PRP$ O
receptor NN NN O
( ( ( O
VEGFR NNP NNP O
- - - O
2 CD CD O
) ) ) O
may MD MD O
play VB VB O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
initial JJ JJ O
step NN NN O
of IN IN O
the DT DT O
regulation NN NN O
of IN IN O
estrogen NN NN B-CHEM
induced VBN VBN O
tumor NN NN O
angiogenesis NN NN O
in IN IN O
the DT DT O
rat NN NN O
pituitary JJ JJ O
. . . O

Persistent NNP NNP O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
following VBG VBG O
lithium NN NN B-CHEM
therapy NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
severe JJ JJ O
hypernatraemic JJ JJ O
dehydration NN NN O
following VBG VBG O
a DT DT O
head NN NN O
injury NN NN O
. . . O

Ten CD CD O
years NNS NNS O
previously RB RB O
he PRP PRP O
had VBD VBD O
been VBN VBN O
diagnosed VBN VBN O
to TO TO O
have VB VB O
lithium NN NN B-CHEM
- : : O
induced JJ JJ O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
, , , O
and CC CC O
lithium NN NN B-CHEM
therapy NN NN O
had VBD VBD O
been VBN VBN O
discontinued VBN VBN O
. . . O

He PRP PRP O
remained VBD VBD O
thirsty JJ JJ O
and CC CC O
polyuric JJ JJ O
despite IN IN O
cessation NN NN O
of IN IN O
lithium NN NN B-CHEM
and CC CC O
investigations NNS NNS O
on IN IN O
admission NN NN O
showed VBD VBD O
him PRP PRP O
to TO TO O
have VB VB O
normal JJ JJ O
osmoregulated VBN VBN O
thirst NN NN O
and CC CC O
vasopressin NN NN B-CHEM
secretion NN NN O
, , , O
with IN IN O
clear JJ JJ O
evidence NN NN O
of IN IN O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
. . . O

Lithium NNP NNP B-CHEM
induced VBD VBD O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
is VBZ VBZ O
considered VBN VBN O
to TO TO O
be VB VB O
reversible JJ JJ O
on IN IN O
cessation NN NN O
of IN IN O
therapy NN NN O
but CC CC O
polyuria NN NN O
persisted VBD VBD O
in IN IN O
this DT DT O
patient NN NN O
for IN IN O
ten CD CD O
years NNS NNS O
after IN IN O
lithium NN NN B-CHEM
was VBD VBD O
stopped VBN VBN O
. . . O

We PRP PRP O
discuss VBP VBP O
the DT DT O
possible JJ JJ O
renal JJ JJ O
mechanisms NNS NNS O
and CC CC O
the DT DT O
implications NNS NNS O
for IN IN O
management NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
. . . O

Effects NNP NNP O
of IN IN O
NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
on IN IN O
cholinesterase NN NN O
and CC CC O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
on IN IN O
cholinesterase NN NN O
, , , O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
and CC CC O
spontaneous JJ JJ O
movement NN NN O
were VBD VBD O
examined VBN VBN O
and CC CC O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
the DT DT O
well RB RB O
- - - O
known VBN VBN O
cholinesterase NN NN O
inhibitors NNS NNS O
tacrine NN NN B-CHEM
and CC CC O
E NNP NNP B-CHEM
- : : I-CHEM
2020 CD CD I-CHEM
. . . O

NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
, , , O
tacrine NN NN B-CHEM
and CC CC O
E NNP NNP B-CHEM
- : : I-CHEM
2020 CD CD I-CHEM
all DT DT O
strongly RB RB O
inhibited VBN VBN O
acetylcholinesterase NN NN O
( ( ( O
AChE NNP NNP O
) ) ) O
in IN IN O
human JJ JJ O
red JJ JJ O
blood NN NN O
cells NNS NNS O
( ( ( O
IC50s NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
0 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
- : : O
6 CD CD O
) ) ) O
, , , O
2 CD CD O
. . . O
9 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
- : : O
7 CD CD O
) ) ) O
and CC CC O
3 CD CD O
. . . O
7 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
- : : O
8 CD CD O
) ) ) O
M NNP NNP O
, , , O
respectively RB RB O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
and CC CC O
tacrine NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
E NNP NNP B-CHEM
- : : I-CHEM
2020 CD CD I-CHEM
, , , O
strongly RB RB O
inhibited VBN VBN O
butyrylcholinestrase NN NN O
( ( ( O
BuChE NNP NNP O
) ) ) O
in IN IN O
human JJ JJ O
serum NN NN O
. . . O

All DT DT O
three CD CD O
drugs NNS NNS O
produced VBN VBN O
mixed JJ JJ O
inhibition NN NN O
of IN IN O
AChE NNP NNP O
activity NN NN O
. . . O

Moreover RB RB O
, , , O
the DT DT O
inhibitory JJ JJ O
effect NN NN O
of IN IN O
NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
on IN IN O
AChE NNP NNP O
was VBD VBD O
reversible JJ JJ O
. . . O

All DT DT O
compounds NNS NNS O
at IN IN O
0 CD CD O
. . . O
1 CD CD O
- : : O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
significantly RB RB O
improved VBN VBN O
the DT DT O
amnesia NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
in IN IN O
rats NNS NNS O
performing VBG VBG O
a DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
. . . O

The DT DT O
three CD CD O
compounds NNS NNS O
at IN IN O
1 CD CD O
and CC CC O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
did VBD VBD O
not RB RB O
significantly RB RB O
decrease VB VB O
spontaneous JJ JJ O
movement NN NN O
by IN IN O
rats NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
at IN IN O
a DT DT O
low JJ JJ O
dose NN NN O
( ( ( O
0 CD CD O
. . . O
1 CD CD O
- : : O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. . . O
o NN NN O
. . . O
) ) ) O
improves VBZ VBZ O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
but CC CC O
does VBZ VBZ O
not RB RB O
affect VB VB O
spontaneous JJ JJ O
movement NN NN O
. . . O

The DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
NIK NNP NNP B-CHEM
- : : I-CHEM
247 CD CD I-CHEM
may MD MD O
be VB VB O
a DT DT O
useful JJ JJ O
drug NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Potential NNP NNP O
therapeutic JJ JJ O
use NN NN O
of IN IN O
the DT DT O
selective JJ JJ O
dopamine NN NN B-CHEM
D1 NNP NNP O
receptor NN NN O
agonist NN NN O
, , , O
A DT DT B-CHEM
- - - I-CHEM
86929 CD CD I-CHEM
: : : O
an DT DT O
acute JJ JJ O
study NN NN O
in IN IN O
parkinsonian NN NN O
levodopa NN NN B-CHEM
- : : O
primed JJ JJ O
monkeys NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
utility NN NN O
of IN IN O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
D1 NNP NNP O
receptor NN NN O
agonists NNS NNS O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
is VBZ VBZ O
still RB RB O
unclear JJ JJ O
. . . O

The DT DT O
therapeutic JJ JJ O
use NN NN O
of IN IN O
selective JJ JJ O
DA NNP NNP B-CHEM
D1 NNP NNP O
receptor NN NN O
agonists NNS NNS O
such JJ JJ O
as IN IN O
SKF NNP NNP B-CHEM
- : : I-CHEM
82958 CD CD I-CHEM
( ( ( O
6 CD CD B-CHEM
- : : I-CHEM
chloro NN NN I-CHEM
- : : I-CHEM
7 CD CD I-CHEM
, , , I-CHEM
8 CD CD I-CHEM
- : : I-CHEM
dihydroxy NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
allyl NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
phenyl NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
tetrahydro NN NN I-CHEM
- : : I-CHEM
1H CD CD I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
benzaze NN NN I-CHEM
pine NN NN I-CHEM
hydrobromide NN NN I-CHEM
) ) ) O
and CC CC O
A DT DT B-CHEM
- : : I-CHEM
77636 CD CD I-CHEM
( ( ( O
[ NN NN B-CHEM
1R CD CD I-CHEM
, , , I-CHEM
3S CD CD I-CHEM
] NN NN I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
1 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
admantyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
aminomethyl NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydro NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
, , , I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
dihydroxy NN NN I-CHEM
- : : I-CHEM
1H CD CD I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
benzo NN NN I-CHEM
pyran NN NN I-CHEM
hydrochloride NN NN I-CHEM
) ) ) O
seems VBZ VBZ O
limited JJ JJ O
because IN IN O
of IN IN O
their PRP$ PRP$ O
duration NN NN O
of IN IN O
action NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
too RB RB O
short JJ JJ O
for IN IN O
SKF NNP NNP B-CHEM
- : : I-CHEM
82958 CD CD I-CHEM
( ( ( O
< NN NN O
1 CD CD O
hr NN NN O
) ) ) O
and CC CC O
too RB RB O
long RB RB O
for IN IN O
A DT DT B-CHEM
- - - I-CHEM
77636 CD CD I-CHEM
( ( ( O
> NN NN O
20 CD CD O
hr NN NN O
, , , O
leading VBG VBG O
to TO TO O
behavioral JJ JJ O
tolerance NN NN O
) ) ) O
. . . O

We PRP PRP O
therefore RB RB O
conducted VBD VBD O
the DT DT O
present JJ JJ O
acute JJ JJ O
dose NN NN O
- - - O
response NN NN O
study NN NN O
in IN IN O
four CD CD O
1 CD CD B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
phenyl NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
tetrahydropyridine NN NN I-CHEM
( ( ( O
MPTP NNP NNP B-CHEM
) ) ) O
- : : O
exposed VBN VBN O
cynomolgus JJ JJ O
monkeys NNS NNS O
primed VBN VBN O
to TO TO O
exhibit NN NN O
levodopa NN NN B-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
locomotor NN NN O
and CC CC O
dyskinetic JJ JJ O
effects NNS NNS O
on IN IN O
challenge NN NN O
with IN IN O
four CD CD O
doses NNS NNS O
( ( ( O
from IN IN O
0 CD CD O
. . . O
03 CD CD O
to TO TO O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
of IN IN O
A DT DT B-CHEM
- - - I-CHEM
86929 CD CD I-CHEM
( ( ( O
[ NN NN B-CHEM
- - - I-CHEM
] NN NN I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
5aR CD CD I-CHEM
, , , I-CHEM
11bS CD CD I-CHEM
] NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
, , , I-CHEM
5a CD CD I-CHEM
, , , I-CHEM
6 CD CD I-CHEM
, , , I-CHEM
7 CD CD I-CHEM
, , , I-CHEM
11b CD CD I-CHEM
- : : I-CHEM
hexahydro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
propyl NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
thia NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
+ NN NN I-CHEM
+ NN NN I-CHEM
+ NN NN I-CHEM
azacyclopent JJ JJ I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
ena NN NN I-CHEM
[ NN NN I-CHEM
c SYM SYM I-CHEM
] NN NN I-CHEM
phenathrene NN NN I-CHEM
- : : I-CHEM
9 CD CD I-CHEM
- : : I-CHEM
10 CD CD I-CHEM
- : : I-CHEM
diol NN NN I-CHEM
) ) ) O
, , , O
a DT DT O
selective JJ JJ O
and CC CC O
full JJ JJ O
DA NNP NNP B-CHEM
D1 NN NN O
- - - O
like IN IN O
receptor NN NN O
agonist NN NN O
with IN IN O
an DT DT O
intermediate JJ JJ O
duration NN NN O
of IN IN O
action NN NN O
. . . O

Levodopa NNP NNP B-CHEM
and CC CC O
the DT DT O
DA NNP NNP B-CHEM
D2 NN NN O
- - - O
like IN IN O
receptor NN NN O
agonist NN NN O
, , , O
LY NNP NNP B-CHEM
- : : I-CHEM
171555 CD CD I-CHEM
( ( ( O
[ NN NN B-CHEM
4aR CD CD I-CHEM
- : : I-CHEM
trans NNS NNS I-CHEM
] NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
, , , I-CHEM
4a CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
, , , I-CHEM
6 CD CD I-CHEM
, , , I-CHEM
7 CD CD I-CHEM
, , , I-CHEM
8 CD CD I-CHEM
, , , I-CHEM
8a CD CD I-CHEM
, , , I-CHEM
9 CD CD I-CHEM
- : : I-CHEM
o NN NN I-CHEM
- : : I-CHEM
dihydro NN NN I-CHEM
- : : I-CHEM
5n CD CD I-CHEM
- : : I-CHEM
propyl NN NN I-CHEM
- : : I-CHEM
2H CD CD I-CHEM
- : : I-CHEM
pyrazo NN NN I-CHEM
lo NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
quinoline NN NN I-CHEM
hydrochloride NN NN I-CHEM
) ) ) O
were VBD VBD O
also RB RB O
used VBN VBN O
for IN IN O
comparison NN NN O
. . . O

Acute JJ JJ O
administration NN NN O
of IN IN O
A DT DT B-CHEM
- - - I-CHEM
86929 CD CD I-CHEM
was VBD VBD O
as IN IN O
efficacious JJ JJ O
in IN IN O
alleviating VBG VBG O
MPTP NNP NNP B-CHEM
- : : O
induced JJ JJ O
parkinsonism NN NN O
as IN IN O
levodopa NN NN B-CHEM
and CC CC O
LY NNP NNP B-CHEM
- : : I-CHEM
171555 CD CD I-CHEM
, , , O
but CC CC O
was VBD VBD O
less RBR RBR O
likely JJ JJ O
to TO TO O
reproduce VB VB O
the DT DT O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
in IN IN O
these DT DT O
animals NNS NNS O
than IN IN O
with IN IN O
either DT DT O
LY NNP NNP B-CHEM
- : : I-CHEM
171555 CD CD I-CHEM
or CC CC O
subsequent JJ JJ O
challenge NN NN O
of IN IN O
levodopa NN NN B-CHEM
. . . O

Selective NNP NNP O
stimulation NN NN O
of IN IN O
the DT DT O
DA NNP NNP B-CHEM
D1 NNP NNP O
receptor NN NN O
may MD MD O
provide VB VB O
better JJR JJR O
integration NN NN O
of IN IN O
neural NN NN O
inputs NNS NNS O
transmitted VBN VBN O
to TO TO O
the DT DT O
internal JJ JJ O
segment NN NN O
of IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
( ( ( O
referred VBN VBN O
to TO TO O
as IN IN O
the DT DT O
basal NN NN O
ganglia NN NN O
output NN NN O
) ) ) O
compared VBN VBN O
with IN IN O
levodopa NN NN B-CHEM
and CC CC O
selective JJ JJ O
DA NNP NNP B-CHEM
D2 NN NN O
receptor NN NN O
agonist NN NN O
. . . O

Potent NNP NNP O
DA NNP NNP B-CHEM
D1 NNP NNP O
receptor NN NN O
agents NNS NNS O
with IN IN O
an DT DT O
intermediate JJ JJ O
duration NN NN O
of IN IN O
efficacy NN NN O
such JJ JJ O
as IN IN O
A DT DT B-CHEM
- - - I-CHEM
86929 CD CD I-CHEM
( ( ( O
approximately RB RB O
4 CD CD O
hr NN NN O
at IN IN O
higher JJR JJR O
doses NNS NNS O
tested VBN VBN O
) ) ) O
are VBP VBP O
potential JJ JJ O
therapeutic JJ JJ O
tools NNS NNS O
in IN IN O
PD NNP NNP O
and CC CC O
merit NN NN O
further JJ JJ O
attention NN NN O
. . . O

Neuropeptide NNP NNP O
- - - O
Y NNP NNP O
immunoreactivity NN NN O
in IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
model NN NN O
of IN IN O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
. . . O

Neuropeptide NNP NNP O
- : : O
Y NNP NNP O
( ( ( O
NPY NNP NNP O
) ) ) O
is VBZ VBZ O
expressed VBN VBN O
by IN IN O
granule NN NN O
cells NNS NNS O
and CC CC O
mossy JJ JJ O
fibres NNS NNS O
of IN IN O
the DT DT O
hippocampal NN NN O
dentate NN NN O
gyrus NN NN O
during IN IN O
experimental JJ JJ O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
( ( ( O
TLE NNP NNP O
) ) ) O
. . . O

This DT DT O
expression NN NN O
may MD MD O
represent VB VB O
an DT DT O
endogenous JJ JJ O
damping VBG VBG O
mechanism NN NN O
since IN IN O
NPY NNP NNP O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
block VB VB O
seizure NN NN O
- - - O
like IN IN O
events NNS NNS O
following VBG VBG O
high JJ JJ O
- - - O
frequency NN NN O
stimulation NN NN O
in IN IN O
hippocampal JJ JJ O
slices NNS NNS O
. . . O

The DT DT O
pilocarpine NN NN B-CHEM
( ( ( O
PILO NNP NNP B-CHEM
) ) ) O
model NN NN O
of IN IN O
epilepsy NN NN O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
an DT DT O
acute JJ JJ O
period NN NN O
of IN IN O
status NN NN O
epilepticus NN NN O
followed VBN VBN O
by IN IN O
spontaneous JJ JJ O
recurrent JJ JJ O
seizures NNS NNS O
and CC CC O
related VBN VBN O
brain NN NN O
damage NN NN O
. . . O

We PRP PRP O
report VBP VBP O
peroxidase NN NN O
- - - O
antiperoxidase NN NN O
immunostaining VBG VBG O
for IN IN O
NPY NNP NNP O
in IN IN O
several JJ JJ O
brain NN NN O
regions NNS NNS O
in IN IN O
this DT DT O
model NN NN O
. . . O

PILO NNP NNP B-CHEM
- - - O
injected JJ JJ O
animals NNS NNS O
exhibited VBN VBN O
NPY NNP NNP O
immunoreactivity NN NN O
in IN IN O
the DT DT O
region NN NN O
of IN IN O
the DT DT O
mossy NN NN O
fibre NN NN O
terminals NNS NNS O
, , , O
in IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
inner JJ JJ O
molecular JJ JJ O
layer NN NN O
and CC CC O
, , , O
in IN IN O
a DT DT O
few JJ JJ O
cases NNS NNS O
, , , O
within IN IN O
presumed VBN VBN O
granule NN NN O
cells NNS NNS O
. . . O

NPY NNP NNP O
immunoreactivity NN NN O
was VBD VBD O
also RB RB O
dramatically RB RB O
changed VBN VBN O
in IN IN O
the DT DT O
entorhinal JJ JJ O
cortex NN NN O
, , , O
amygdala NN NN O
and CC CC O
sensorimotor NN NN O
areas NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
PILO NNP NNP B-CHEM
injected JJ JJ O
animals NNS NNS O
exhibited VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
NPY NNP NNP O
- - - O
immunoreactive JJ JJ O
interneurons NNS NNS O
compared VBN VBN O
with IN IN O
controls NNS NNS O
. . . O

The DT DT O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
changes NNS NNS O
in IN IN O
NPY NNP NNP O
expression NN NN O
, , , O
including VBG VBG O
expression NN NN O
in IN IN O
the DT DT O
granule NN NN O
cells NNS NNS O
and CC CC O
mossy JJ JJ O
fibres NNS NNS O
and CC CC O
the DT DT O
loss NN NN O
of IN IN O
vulnerable JJ JJ O
NPY NNP NNP O
neurons NNS NNS O
, , , O
are VBP VBP O
present JJ JJ O
in IN IN O
the DT DT O
PILO NNP NNP B-CHEM
model NN NN O
of IN IN O
TLE NNP NNP O
. . . O

However RB RB O
, , , O
the DT DT O
significance NN NN O
of IN IN O
this DT DT O
changed JJ JJ O
synthesis NN NN O
of IN IN O
NPY NNP NNP O
remains VBZ VBZ O
to TO TO O
be VB VB O
determined VBN VBN O
. . . O

Posteroventral NNP NNP O
medial JJ JJ O
pallidotomy NN NN O
in IN IN O
advanced JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Posteroventral NNP NNP O
medial NN NN O
pallidotomy NN NN O
sometimes RB RB O
produces VBZ VBZ O
striking JJ JJ O
improvement NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
but CC CC O
the DT DT O
studies NNS NNS O
to TO TO O
date NN NN O
have VBP VBP O
involved VBN VBN O
small JJ JJ O
numbers NNS NNS O
of IN IN O
patients NNS NNS O
and CC CC O
short JJ JJ O
- - - O
term NN NN O
follow VB VB O
- - - O
up RP RP O
. . . O

METHODS NNP NNP O
: : : O
Forty CD CD O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
underwent JJ JJ O
serial NN NN O
, , , O
detailed JJ JJ O
assessments NNS NNS O
both DT DT O
after IN IN O
drug NN NN O
withdrawal NN NN O
( ( ( O
" '' '' O
off IN IN O
" '' '' O
period NN NN O
) ) ) O
and CC CC O
while IN IN O
taking VBG VBG O
their PRP$ PRP$ O
optimal NN NN O
medical JJ JJ O
regimens NNS NNS O
( ( ( O
" '' '' O
on IN IN O
" '' '' O
period NN NN O
) ) ) O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
examined VBN VBN O
preoperatively RB RB O
and CC CC O
39 CD CD O
were VBD VBD O
examined VBN VBN O
at IN IN O
six CD CD O
months NNS NNS O
; : : O
27 CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
also RB RB O
examined VBN VBN O
at IN IN O
one CD CD O
year NN NN O
, , , O
and CC CC O
11 CD CD O
at IN IN O
two CD CD O
years NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
percent NN NN O
improvements NNS NNS O
at IN IN O
six CD CD O
months NNS NNS O
were VBD VBD O
as IN IN O
follows VBZ VBZ O
: : : O
off RP RP O
- - - O
period NN NN O
score NN NN O
for IN IN O
overall JJ JJ O
motor NN NN O
function NN NN O
, , , O
28 CD CD O
percent NN NN O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
19 CD CD O
to TO TO O
38 CD CD O
percent NN NN O
) ) ) O
, , , O
with IN IN O
most JJS JJS O
of IN IN O
the DT DT O
improvement NN NN O
in IN IN O
the DT DT O
contralateral JJ JJ O
limbs NNS NNS O
; : : O
off RP RP O
- : : O
period NN NN O
score NN NN O
for IN IN O
activities NNS NNS O
of IN IN O
daily JJ JJ O
living NN NN O
, , , O
29 CD CD O
percent NN NN O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
19 CD CD O
to TO TO O
39 CD CD O
percent NN NN O
) ) ) O
; : : O
on IN IN O
- - - O
period NN NN O
score NN NN O
for IN IN O
contralateral JJ JJ O
dyskinesias NN NN O
, , , O
82 CD CD O
percent NN NN O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
72 CD CD O
to TO TO O
91 CD CD O
percent NN NN O
) ) ) O
; : : O
and CC CC O
on IN IN O
- : : O
period NN NN O
score NN NN O
for IN IN O
ipsilateral JJ JJ O
dyskinesias NN NN O
, , , O
44 CD CD O
percent NN NN O
( ( ( O
95 CD CD O
percent NN NN O
confidence NN NN O
interval NN NN O
, , , O
29 CD CD O
to TO TO O
59 CD CD O
percent NN NN O
) ) ) O
. . . O

The DT DT O
improvements NNS NNS O
in IN IN O
dyskinesias NN NN O
and CC CC O
the DT DT O
total JJ JJ O
scores NNS NNS O
for IN IN O
off IN IN O
- - - O
period NN NN O
parkinsonism NN NN O
, , , O
contralateral JJ JJ O
bradykinesia NN NN O
, , , O
and CC CC O
rigidity NN NN O
were VBD VBD O
sustained VBN VBN O
in IN IN O
the DT DT O
11 CD CD O
patients NNS NNS O
examined VBD VBD O
at IN IN O
two CD CD O
years NNS NNS O
. . . O

The DT DT O
improvement NN NN O
in IN IN O
ipsilateral JJ JJ O
dyskinesias NNS NNS O
was VBD VBD O
lost VBN VBN O
after IN IN O
one CD CD O
year NN NN O
, , , O
and CC CC O
the DT DT O
improvements NNS NNS O
in IN IN O
postural JJ JJ O
stability NN NN O
and CC CC O
gait NN NN O
lasted VBD VBD O
only RB RB O
three CD CD O
to TO TO O
six CD CD O
months NNS NNS O
. . . O

Approximately RB RB O
half PDT PDT O
the DT DT O
patients NNS NNS O
who WP WP O
had VBD VBD O
been VBN VBN O
dependent JJ JJ O
on IN IN O
assistance NN NN O
in IN IN O
activities NNS NNS O
of IN IN O
daily JJ JJ O
living NN NN O
in IN IN O
the DT DT O
off JJ JJ O
period NN NN O
before IN IN O
surgery NN NN O
became VBD VBD O
independent JJ JJ O
after IN IN O
surgery NN NN O
. . . O

The DT DT O
complications NNS NNS O
of IN IN O
surgery NN NN O
were VBD VBD O
generally RB RB O
well RB RB O
tolerated VBD VBD O
, , , O
and CC CC O
there EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
medication NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
late JJ JJ O
- : : O
stage NN NN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
pallidotomy NN NN O
significantly RB RB O
reduces VBZ VBZ O
levodopa JJ JJ B-CHEM
- : : O
induced JJ JJ O
dyskinesias NNS NNS O
and CC CC O
off RP RP O
- : : O
period NN NN O
disability NN NN O
. . . O

Much JJ JJ O
of IN IN O
the DT DT O
benefit NN NN O
is VBZ VBZ O
sustained VBN VBN O
at IN IN O
two CD CD O
years NNS NNS O
, , , O
although IN IN O
some DT DT O
improvements NNS NNS O
, , , O
such JJ JJ O
as IN IN O
those DT DT O
on IN IN O
the DT DT O
ipsilateral JJ JJ O
side NN NN O
and CC CC O
in IN IN O
axial JJ JJ O
symptoms NNS NNS O
, , , O
wane NN NN O
within IN IN O
the DT DT O
first JJ JJ O
year NN NN O
. . . O

The DT DT O
on IN IN O
- - - O
period NN NN O
symptoms NNS NNS O
that WDT WDT O
are VBP VBP O
resistant JJ JJ O
to TO TO O
dopaminergic JJ JJ O
therapy NN NN O
do VBP VBP O
not RB RB O
respond VB VB O
to TO TO O
pallidotomy NN NN O
. . . O

Clarithromycin NNP NNP B-CHEM
- : : O
induced JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

Clarithromycin NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
relatively RB RB O
new JJ JJ O
macrolide NN NN B-CHEM
antibiotic JJ JJ O
that IN IN O
offers VBZ VBZ O
twice RB RB O
- : : O
daily JJ JJ O
dosing NN NN O
. . . O

It PRP PRP O
differs NNS NNS O
from IN IN O
erythromycin NN NN B-CHEM
only RB RB O
in IN IN O
the DT DT O
methylation NN NN O
of IN IN O
the DT DT O
hydroxyl NN NN O
group NN NN O
at IN IN O
position NN NN O
6 CD CD O
. . . O

Although IN IN O
the DT DT O
side NN NN O
- - - O
effect NN NN O
profile NN NN O
of IN IN O
erythromycin NN NN B-CHEM
is VBZ VBZ O
established VBN VBN O
, , , O
including VBG VBG O
gastroenteritis NN NN O
and CC CC O
interactions NNS NNS O
with IN IN O
other JJ JJ O
drugs NNS NNS O
subject JJ JJ O
to TO TO O
hepatic JJ JJ O
mixed JJ JJ O
- - - O
function NN NN O
oxidase NN NN O
metabolism NN NN O
, , , O
experience NN NN O
with IN IN O
the DT DT O
newer JJR JJR O
macrolides NNS NNS B-CHEM
is VBZ VBZ O
still RB RB O
being VBG VBG O
recorded VBN VBN O
. . . O

Cardiotoxicity NNP NNP O
has VBZ VBZ O
been VBN VBN O
demonstrated VBN VBN O
after IN IN O
both DT DT O
intravenous JJ JJ O
and CC CC O
oral JJ JJ O
administration NN NN O
of IN IN O
erythromycin NN NN B-CHEM
but CC CC O
has VBZ VBZ O
never RB RB O
been VBN VBN O
reported VBN VBN O
with IN IN O
the DT DT O
newer JJR JJR O
macrolides NNS NNS B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
ventricular NN NN O
dysrhythmias NNS NNS O
that WDT WDT O
occurred VBD VBD O
after IN IN O
six CD CD O
therapeutic JJ JJ O
doses NNS NNS O
of IN IN O
clarithromycin NN NN B-CHEM
. . . O

The DT DT O
dysrhythmias NN NN O
resolved VBD VBD O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

Effect NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
on IN IN O
the DT DT O
sphincter NN NN O
of IN IN O
Oddi NNP NNP O
spasm NN NN O
evoked VBN VBN O
by IN IN O
prostigmine NN NN B-CHEM
- - - O
morphine NN NN B-CHEM
administration NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
In IN IN O
this DT DT O
study NN NN O
the DT DT O
effect NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
on IN IN O
the DT DT O
prostigmine NN NN B-CHEM
- - - O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
sphincter NN NN O
of IN IN O
Oddi NNP NNP O
spasm NN NN O
was VBD VBD O
evaluated VBN VBN O
in IN IN O
nine CD CD O
female JJ JJ O
patients NNS NNS O
with IN IN O
sphincter NN NN O
of IN IN O
Oddi NNP NNP O
dyskinesia NN NN O
. . . O

METHOD NNP NNP O
: : : O
Sphincter NNP NNP O
of IN IN O
Oddi NNP NNP O
spasm NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
prostigmine NN NN B-CHEM
- - - O
morphine NN NN B-CHEM
administration NN NN O
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
prostigmine NN NN B-CHEM
intramuscularly RB RB O
and CC CC O
10 CD CD O
mg NN NN O
morphine NN NN B-CHEM
subcutaneously RB RB O
) ) ) O
and CC CC O
visualized VBN VBN O
by IN IN O
quantitative JJ JJ O
hepatobiliary JJ JJ O
scintigraphy NN NN O
. . . O

The DT DT O
entire JJ JJ O
procedure NN NN O
was VBD VBD O
repeated VBN VBN O
during IN IN O
glyceryl NN NN B-CHEM
trinitrate JJ JJ I-CHEM
infusion NN NN O
( ( ( O
Nitrolingual NNP NNP B-CHEM
1 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
for IN IN O
120 CD CD O
min NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Prostigmine NNP NNP B-CHEM
- - - O
morphine NN NN B-CHEM
provocation NN NN O
caused VBD VBD O
significant JJ JJ O
increases NNS NNS O
in IN IN O
the DT DT O
time NN NN O
to TO TO O
peak VB VB O
activity NN NN O
( ( ( O
Tmax NNP NNP O
) ) ) O
over IN IN O
the DT DT O
hepatic JJ JJ O
hilum NN NN O
( ( ( O
HH NNP NNP O
: : : O
34 CD CD O
. . . O
33 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
05 CD CD O
vs NNS NNS O
. . . O
22 CD CD O
. . . O
77 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
26 CD CD O
) ) ) O
and CC CC O
the DT DT O
common JJ JJ O
bile NN NN O
duct NN NN O
( ( ( O
CBD NNP NNP O
: : : O
60 CD CD O
. . . O
44 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
99 CD CD O
vs NNS NNS O
. . . O
40 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
88 CD CD O
) ) ) O
and CC CC O
in IN IN O
the DT DT O
half NN NN O
- - - O
time NN NN O
of IN IN O
excretion NN NN O
( ( ( O
T1 NNP NNP O
/ NN NN O
2 CD CD O
) ) ) O
over IN IN O
the DT DT O
liver NN NN O
parenchyma NN NN O
( ( ( O
LP NNP NNP O
: : : O
120 CD CD O
. . . O
04 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
. . . O
01 CD CD O
vs NNS NNS O
. . . O
27 CD CD O
. . . O
37 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
19 CD CD O
) ) ) O
, , , O
HH NNP NNP O
( ( ( O
117 CD CD O
. . . O
61 CD CD O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
. . . O
71 CD CD O
vs NNS NNS O
. . . O
31 CD CD O
. . . O
85 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
99 CD CD O
) ) ) O
and CC CC O
CBD NNP NNP O
( ( ( O
158 CD CD O
. . . O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
. . . O
18 CD CD O
vs NNS NNS O
. . . O
40 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
24 CD CD O
) ) ) O
, , , O
indicating VBG VBG O
a DT DT O
complete JJ JJ O
spasm NN NN O
at IN IN O
the DT DT O
level NN NN O
of IN IN O
the DT DT O
sphincter NN NN O
of IN IN O
Oddi NNP NNP O
. . . O

Glyceryl NNP NNP B-CHEM
trinitrate NN NN I-CHEM
infusion NN NN O
completely RB RB O
normalized VBD VBD O
the DT DT O
prostigmine NN NN B-CHEM
- - - O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
alterations NNS NNS O
in IN IN O
these DT DT O
quantitative JJ JJ O
parameters NNS NNS O
( ( ( O
TmaX NNP NNP O
over IN IN O
the DT DT O
LP NNP NNP O
: : : O
11 CD CD O
. . . O
33 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
13 CD CD O
; : : O
over IN IN O
the DT DT O
HH NNP NNP O
: : : O
18 CD CD O
. . . O
88 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
48 CD CD O
; : : O
and CC CC O
over IN IN O
the DT DT O
CBD NNP NNP O
: : : O
36 CD CD O
. . . O
22 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
92 CD CD O
; : : O
and CC CC O
T1 NNP NNP O
/ NN NN O
2 CD CD O
over IN IN O
the DT DT O
LP NNP NNP O
: : : O
28 CD CD O
. . . O
21 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
83 CD CD O
; : : O
over IN IN O
the DT DT O
HH NNP NNP O
: : : O
33 CD CD O
. . . O
42 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
10 CD CD O
; : : O
and CC CC O
over IN IN O
the DT DT O
CBD NNP NNP O
: : : O
41 CD CD O
. . . O
66 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
33 CD CD O
) ) ) O
, , , O
suggesting VBG VBG O
an DT DT O
effective JJ JJ O
sphincter NN NN O
- : : O
relaxing VBG VBG O
effect NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
These DT DT O
results NNS NNS O
provide VBP VBP O
the DT DT O
first JJ JJ O
evidence NN NN O
of IN IN O
the DT DT O
effectiveness NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
on IN IN O
the DT DT O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
sphincter NN NN O
of IN IN O
Oddi NNP NNP O
spasm NN NN O
in IN IN O
humans NNS NNS O
. . . O

Since IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
is VBZ VBZ O
able JJ JJ O
to TO TO O
overcome VB VB O
even RB RB O
the DT DT O
drastic JJ JJ O
effect NN NN O
of IN IN O
morphine NN NN B-CHEM
, , , O
it PRP PRP O
might MD MD O
be VB VB O
of IN IN O
relevance NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
sphincter NN NN O
of IN IN O
Oddi NNP NNP O
dyskinesia NN NN O
. . . O

Immunopathology NNP NNP O
of IN IN O
penicillamine NN NN B-CHEM
- - - O
induced JJ JJ O
glomerular NN NN O
disease NN NN O
. . . O

Four CD CD O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
developed VBN VBN O
heavy JJ JJ O
proteinuria NN NN O
after IN IN O
five CD CD O
to TO TO O
12 CD CD O
months NNS NNS O
of IN IN O
treatment NN NN O
with IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
penicillamine NN NN I-CHEM
. . . O

Light NNP NNP O
microscopy NN NN O
of IN IN O
renal JJ JJ O
biopsy NN NN O
samples NNS NNS O
showed VBD VBD O
minimal JJ JJ O
glomerular NN NN O
capillary JJ JJ O
wall NN NN O
thickening VBG VBG O
and CC CC O
mesangial NN NN O
matrix NN NN O
increase NN NN O
, , , O
or CC CC O
no DT DT O
departure NN NN O
from IN IN O
normal JJ JJ O
. . . O

Electron NNP NNP O
microscopy NN NN O
, , , O
however RB RB O
, , , O
revealed VBD VBD O
subepithelial JJ JJ O
electron NN NN O
- - - O
dense JJ JJ O
deposits NNS NNS O
, , , O
fusion NN NN O
of IN IN O
epithelial NN NN O
cell NN NN O
foot NN NN O
processes NNS NNS O
, , , O
and CC CC O
evidence NN NN O
of IN IN O
mesangial JJ JJ O
cell NN NN O
hyperactivity NN NN O
. . . O

Immunofluorescence NNP NNP O
microscopy NN NN O
demonstrated VBD VBD O
granular JJ JJ O
capillary JJ JJ O
wall NN NN O
deposits NNS NNS O
of IN IN O
IgG NNP NNP O
and CC CC O
C3 NNP NNP O
. . . O

The DT DT O
findings NNS NNS O
were VBD VBD O
similar JJ JJ O
to TO TO O
those DT DT O
in IN IN O
early JJ JJ O
membranous JJ JJ O
glomerulonephritis NNS NNS O
, , , O
differences NNS NNS O
being VBG VBG O
observed VBN VBN O
however RB RB O
in IN IN O
the DT DT O
results NNS NNS O
of IN IN O
staining VBG VBG O
for IN IN O
the DT DT O
early JJ JJ O
- - - O
acting VBG VBG O
complement NN NN O
components NNS NNS O
C1q NNP NNP O
and CC CC O
C4 NNP NNP O
. . . O

It PRP PRP O
is VBZ VBZ O
tentatively RB RB O
concluded VBN VBN O
that IN IN O
complement NN NN O
was VBD VBD O
activated VBN VBN O
by IN IN O
the DT DT O
classical JJ JJ O
pathway NN NN O
. . . O

Experimental NNP NNP O
cranial JJ JJ O
pain NN NN O
elicited VBN VBN O
by IN IN O
capsaicin NN NN B-CHEM
: : : O
a DT DT O
PET NNP NNP O
study NN NN O
. . . O

Using VBG VBG O
a DT DT O
positron NN NN O
emission NN NN O
tomography NN NN O
( ( ( O
PET NNP NNP O
) ) ) O
study NN NN O
it PRP PRP O
was VBD VBD O
shown VBN VBN O
recently RB RB O
that IN IN O
in IN IN O
migraine NN NN O
without IN IN O
aura NN NN O
certain JJ JJ O
areas NNS NNS O
in IN IN O
the DT DT O
brain NN NN O
stem NN NN O
were VBD VBD O
activated VBN VBN O
during IN IN O
the DT DT O
headache NN NN O
state NN NN O
, , , O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
headache NN NN O
free JJ JJ O
interval NN NN O
. . . O

It PRP PRP O
was VBD VBD O
suggested VBN VBN O
that IN IN O
this DT DT O
brain NN NN O
stem NN NN O
activation NN NN O
is VBZ VBZ O
inherent JJ JJ O
to TO TO O
the DT DT O
migraine NN NN O
attack NN NN O
itself PRP PRP O
and CC CC O
represents VBZ VBZ O
the DT DT O
so RB RB O
called VBN VBN O
' POS POS O
migraine NN NN O
generator NN NN O
' '' '' O
. . . O

To TO TO O
test VB VB O
this DT DT O
hypothesis NN NN O
we PRP PRP O
performed VBD VBD O
an DT DT O
experimental JJ JJ O
pain NN NN O
study NN NN O
in IN IN O
seven CD CD O
healthy JJ JJ O
volunteers NNS NNS O
, , , O
using VBG VBG O
the DT DT O
same JJ JJ O
positioning NN NN O
in IN IN O
the DT DT O
PET NNP NNP O
scanner NN NN O
as IN IN O
in IN IN O
the DT DT O
migraine NN NN O
patients NNS NNS O
. . . O

A DT DT O
small JJ JJ O
amount NN NN O
of IN IN O
capsaicin NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
subcutaneously RB RB O
in IN IN O
the DT DT O
right NN NN O
forehead NN NN O
to TO TO O
evoke VB VB O
a DT DT O
burning NN NN O
painful JJ JJ O
sensation NN NN O
in IN IN O
the DT DT O
first JJ JJ O
division NN NN O
of IN IN O
the DT DT O
trigeminal JJ JJ O
nerve NN NN O
. . . O

Increases NNP NNP O
of IN IN O
regional JJ JJ O
cerebral JJ JJ O
blood NN NN O
flow NN NN O
( ( ( O
rCBF NN NN O
) ) ) O
were VBD VBD O
found VBN VBN O
bilaterally RB RB O
in IN IN O
the DT DT O
insula NN NN O
, , , O
in IN IN O
the DT DT O
anterior NN NN O
cingulate NN NN O
cortex NN NN O
, , , O
the DT DT O
cavernous JJ JJ O
sinus NN NN O
and CC CC O
the DT DT O
cerebellum NN NN O
. . . O

Using VBG VBG O
the DT DT O
same JJ JJ O
stereotactic JJ JJ O
space NN NN O
limits NNS NNS O
as IN IN O
in IN IN O
the DT DT O
above JJ JJ O
mentioned VBN VBN O
migraine NN NN O
study NN NN O
no DT DT O
brain NN NN O
stem NN NN O
activation NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
acute JJ JJ O
pain NN NN O
state NN NN O
compared VBN VBN O
to TO TO O
the DT DT O
pain NN NN O
free JJ JJ O
state NN NN O
. . . O

The DT DT O
increase NN NN O
of IN IN O
activation NN NN O
in IN IN O
the DT DT O
region NN NN O
of IN IN O
the DT DT O
cavernous JJ JJ O
sinus NN NN O
however RB RB O
, , , O
suggests VBZ VBZ O
that IN IN O
this DT DT O
structure NN NN O
is VBZ VBZ O
more RBR RBR O
likely JJ JJ O
to TO TO O
be VB VB O
involved VBN VBN O
in IN IN O
trigeminal JJ JJ O
transmitted JJ JJ O
pain NN NN O
as IN IN O
such JJ JJ O
, , , O
rather RB RB O
than IN IN O
in IN IN O
a DT DT O
specific JJ JJ O
type NN NN O
of IN IN O
headache NN NN O
as IN IN O
was VBD VBD O
suggested VBN VBN O
for IN IN O
cluster NN NN O
headache NN NN O
. . . O

Value NNP NNP O
of IN IN O
methylprednisolone NN NN B-CHEM
in IN IN O
prevention NN NN O
of IN IN O
the DT DT O
arthralgia NN NN O
- - - O
myalgia NN NN O
syndrome NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
total JJ JJ O
dose NN NN O
infusion NN NN O
of IN IN O
iron NN NN B-CHEM
dextran NN NN I-CHEM
: : : O
a DT DT O
double JJ JJ O
blind JJ JJ O
randomized JJ JJ O
trial NN NN O
. . . O

The DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
total JJ JJ O
dose NN NN O
infusion NN NN O
( ( ( O
TDI NNP NNP O
) ) ) O
of IN IN O
iron NN NN B-CHEM
dextran NN NN I-CHEM
has VBZ VBZ O
been VBN VBN O
well RB RB O
documented VBN VBN O
. . . O

In IN IN O
40 CD CD O
% NN NN O
of IN IN O
treated VBN VBN O
patients NNS NNS O
, , , O
an DT DT O
arthralgia NN NN O
- - - O
myalgia NN NN O
syndrome NN NN O
develops NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
prospective JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
whether IN IN O
intravenous JJ JJ O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
administration NN NN O
of IN IN O
methylprednisolone NN NN B-CHEM
( ( ( O
MP NNP NNP B-CHEM
) ) ) O
prevents NNS NNS O
this DT DT O
complication NN NN O
. . . O

Sixty NNP NNP O
- - - O
five CD CD O
patients NNS NNS O
, , , O
34 CD CD O
women NNS NNS O
and CC CC O
31 CD CD O
men NNS NNS O
, , , O
ages NNS NNS O
36 CD CD O
to TO TO O
80 CD CD O
years NNS NNS O
, , , O
received VBD VBD O
either CC CC O
normal JJ JJ O
saline NN NN O
before IN IN O
and CC CC O
after IN IN O
TDI NNP NNP O
( ( ( O
group NN NN O
1 CD CD O
) ) ) O
, , , O
125 CD CD O
mg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
MP NNP NNP B-CHEM
before IN IN O
and CC CC O
saline NN NN O
after IN IN O
TDI NNP NNP O
( ( ( O
group NN NN O
2 CD CD O
) ) ) O
, , , O
or CC CC O
125 CD CD O
mg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
MP NNP NNP B-CHEM
before IN IN O
and CC CC O
after IN IN O
TDI NNP NNP O
( ( ( O
group NN NN O
3 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
were VBD VBD O
observed VBN VBN O
for IN IN O
72 CD CD O
hours NNS NNS O
and CC CC O
reactions NNS NNS O
were VBD VBD O
recorded VBN VBN O
and CC CC O
graded VBN VBN O
according VBG VBG O
to TO TO O
severity NN NN O
. . . O

Fifty NNP NNP O
- : : O
eight CD CD O
percent NN NN O
of IN IN O
group NN NN O
1 CD CD O
patients NNS NNS O
, , , O
33 CD CD O
% NN NN O
of IN IN O
group NN NN O
2 CD CD O
, , , O
and CC CC O
26 CD CD O
% NN NN O
of IN IN O
group NN NN O
3 CD CD O
had VBD VBD O
reactions NNS NNS O
to TO TO O
TDI NNP NNP O
. . . O

The DT DT O
severity NN NN O
of IN IN O
reactions NNS NNS O
( ( ( O
minimal NN NN O
, , , O
mild NN NN O
, , , O
and CC CC O
moderate JJ JJ O
, , , O
respectively RB RB O
) ) ) O
was VBD VBD O
as IN IN O
follows VBZ VBZ O
: : : O
group NN NN O
1 CD CD O
- : : O
- : : O
6 CD CD O
, , , O
6 CD CD O
, , , O
and CC CC O
2 CD CD O
; : : O
group NN NN O
2 CD CD O
- : : O
- : : O
1 CD CD O
, , , O
5 CD CD O
, , , O
and CC CC O
0 CD CD O
; : : O
group NN NN O
3 CD CD O
- : : O
- : : O
5 CD CD O
, , , O
1 CD CD O
, , , O
and CC CC O
0 CD CD O
. . . O

Data NNP NNP O
were VBD VBD O
analyzed VBN VBN O
by IN IN O
the DT DT O
two CD CD O
- - - O
sided JJ JJ O
Fisher NNP NNP O
' POS POS O
s VBZ VBZ O
exact JJ JJ O
test NN NN O
using VBG VBG O
95 CD CD O
% NN NN O
confidence NN NN O
intervals NNS NNS O
with IN IN O
the DT DT O
approximation NN NN O
of IN IN O
Woolf NNP NNP O
. . . O

These DT DT O
data NNS NNS O
demonstrate VBP VBP O
that DT DT O
administration NN NN O
of IN IN O
MP NNP NNP B-CHEM
before IN IN O
and CC CC O
after IN IN O
TDI NNP NNP O
reduces VBZ VBZ O
the DT DT O
frequency NN NN O
and CC CC O
severity NN NN O
of IN IN O
the DT DT O
arthralgia NN NN O
- - - O
myalgia NN NN O
syndrome NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
125 CD CD O
mg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
MP NNP NNP B-CHEM
should MD MD O
be VB VB O
given VBN VBN O
routinely RB RB O
before RB RB O
and CC CC O
after IN IN O
TDI NNP NNP O
of IN IN O
iron NN NN B-CHEM
dextran NN NN I-CHEM
. . . O

Prolongation NNP NNP O
of IN IN O
the DT DT O
QT NNP NNP O
interval NN NN O
related VBN VBN O
to TO TO O
cisapride VB VB B-CHEM
- - - O
diltiazem NN NN B-CHEM
interaction NN NN O
. . . O

Cisapride NNP NNP B-CHEM
, , , O
a DT DT O
cytochrome NN NN O
P450 NNP NNP O
3A4 CD CD O
( ( ( O
CYP3A4 NNP NNP O
) ) ) O
substrate NN NN O
, , , O
is VBZ VBZ O
widely RB RB O
prescribed VBN VBN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
gastrointestinal JJ JJ O
motility NN NN O
disorders NNS NNS O
. . . O

Prolongation NNP NNP O
of IN IN O
QT NNP NNP O
interval NN NN O
, , , O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
, , , O
and CC CC O
sudden JJ JJ O
cardiac JJ JJ O
death NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
after IN IN O
concomitant JJ JJ O
administration NN NN O
with IN IN O
erythromycin NN NN B-CHEM
or CC CC O
azole NN NN B-CHEM
antifungal JJ JJ O
agents NNS NNS O
, , , O
but CC CC O
not RB RB O
with IN IN O
other JJ JJ O
CYP3A4 NNP NNP O
inhibitors NNS NNS O
. . . O

A DT DT O
possible JJ JJ O
drug NN NN O
interaction NN NN O
occurred VBD VBD O
in IN IN O
a DT DT O
45 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
was VBD VBD O
taking VBG VBG O
cisapride NN NN B-CHEM
for IN IN O
gastroesophageal NN NN O
reflux NN NN O
disorder NN NN O
and CC CC O
diltiazem NN NN B-CHEM
, , , O
an DT DT O
agent NN NN O
that WDT WDT O
has VBZ VBZ O
inhibitory JJ JJ O
effect NN NN O
on IN IN O
CYP3A4 NNP NNP O
, , , O
for IN IN O
hypertension NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
in IN IN O
near IN IN O
syncope NN NN O
and CC CC O
had VBD VBD O
QT NNP NNP O
- : : O
interval NN NN O
prolongation NN NN O
. . . O

After IN IN O
discontinuing VBG VBG O
cisapride NN NN B-CHEM
, , , O
the DT DT O
QT NNP NNP O
interval NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
and CC CC O
symptoms NNS NNS O
did VBD VBD O
not RB RB O
recur VB VB O
. . . O

We PRP PRP O
suggest VBP VBP O
that DT DT O
caution NN NN O
be VB VB O
taken VBN VBN O
when WRB WRB O
cisapride NN NN B-CHEM
is VBZ VBZ O
prescribed VBN VBN O
with IN IN O
any DT DT O
potent JJ JJ O
inhibitor NN NN O
of IN IN O
CYP3A4 NNP NNP O
, , , O
including VBG VBG O
diltiazem NN NN B-CHEM
. . . O

Cortical NNP NNP O
motor NN NN O
overactivation NN NN O
in IN IN O
parkinsonian NN NN O
patients NNS NNS O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
- : : O
induced JJ JJ O
peak NN NN O
- : : O
dose VB VB O
dyskinesia NN NN O
. . . O

We PRP PRP O
have VBP VBP O
studied VBN VBN O
the DT DT O
regional JJ JJ O
cerebral JJ JJ O
blood NN NN O
flow NN NN O
( ( ( O
rCBF NN NN O
) ) ) O
changes NNS NNS O
induced VBN VBN O
by IN IN O
the DT DT O
execution NN NN O
of IN IN O
a DT DT O
finger NN NN O
- - - O
to TO TO O
- - - O
thumb JJ JJ O
opposition NN NN O
motor NN NN O
task NN NN O
in IN IN O
the DT DT O
supplementary JJ JJ O
and CC CC O
primary JJ JJ O
motor NN NN O
cortex NN NN O
of IN IN O
two CD CD O
groups NNS NNS O
of IN IN O
parkinsonian NN NN O
patients NNS NNS O
on IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
medication NN NN O
, , , O
the DT DT O
first JJ JJ O
one CD CD O
without IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
induced VBD VBD O
dyskinesia NN NN O
( ( ( O
n NN NN O
= SYM SYM O
23 CD CD O
) ) ) O
and CC CC O
the DT DT O
other JJ JJ O
with IN IN O
moderate JJ JJ O
peak NN NN O
- : : O
dose NN NN O
dyskinesia NN NN O
( ( ( O
n NN NN O
= SYM SYM O
15 CD CD O
) ) ) O
, , , O
and CC CC O
of IN IN O
a DT DT O
group NN NN O
of IN IN O
14 CD CD O
normal JJ JJ O
subjects NNS NNS O
. . . O

Single NNP NNP O
photon NN NN O
emission NN NN O
tomography NN NN O
with IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
133Xe CD CD O
was VBD VBD O
used VBN VBN O
to TO TO O
measure VB VB O
the DT DT O
rCBF NN NN O
changes NNS NNS O
. . . O

The DT DT O
dyskinetic JJ JJ O
parkinsonian NN NN O
patients NNS NNS O
exhibited VBD VBD O
a DT DT O
pattern NN NN O
of IN IN O
response NN NN O
which WDT WDT O
was VBD VBD O
markedly RB RB O
different JJ JJ O
from IN IN O
those DT DT O
of IN IN O
the DT DT O
normal JJ JJ O
subjects NNS NNS O
and CC CC O
non NN NN O
- - - O
dyskinetic JJ JJ O
parkinsonian NN NN O
patients NNS NNS O
, , , O
with IN IN O
a DT DT O
significant JJ JJ O
overactivation NN NN O
in IN IN O
the DT DT O
supplementary JJ JJ O
motor NN NN O
area NN NN O
and CC CC O
the DT DT O
ipsi NN NN O
- - - O
and CC CC O
contralateral JJ JJ O
primary JJ JJ O
motor NN NN O
areas NNS NNS O
. . . O

These DT DT O
results NNS NNS O
are VBP VBP O
compatible JJ JJ O
with IN IN O
the DT DT O
hypothesis NNS NNS O
that IN IN O
an DT DT O
hyperkinetic JJ JJ O
abnormal NN NN O
involuntary JJ JJ O
movement NN NN O
, , , O
like IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
- : : O
induced JJ JJ O
peak NN NN O
dose NN NN O
dyskinesia NN NN O
, , , O
is VBZ VBZ O
due JJ JJ O
to TO TO O
a DT DT O
disinhibition NN NN O
of IN IN O
the DT DT O
primary JJ JJ O
and CC CC O
associated VBN VBN O
motor NN NN O
cortex NN NN O
secondary JJ JJ O
to TO TO O
an DT DT O
excessive JJ JJ O
outflow NN NN O
of IN IN O
the DT DT O
pallidothalamocortical JJ JJ O
motor NN NN O
loop NN NN O
. . . O

Open NNP NNP O
- : : O
label NN NN O
assessment NN NN O
of IN IN O
levofloxacin NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
acute JJ JJ O
bacterial JJ JJ O
sinusitis NN NN O
in IN IN O
adults NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
levofloxacin NN NN B-CHEM
( ( ( O
500 CD CD O
mg NN NN O
orally RB RB O
once RB RB O
daily JJ JJ O
for IN IN O
10 CD CD O
to TO TO O
14 CD CD O
days NNS NNS O
) ) ) O
in IN IN O
treating VBG VBG O
adult NN NN O
outpatients NNS NNS O
with IN IN O
acute JJ JJ O
bacterial JJ JJ O
sinusitis NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
A DT DT O
total NN NN O
of IN IN O
329 CD CD O
patients NNS NNS O
enrolled VBD VBD O
in IN IN O
the DT DT O
study NN NN O
at IN IN O
24 CD CD O
centers NNS NNS O
. . . O

All DT DT O
patients NNS NNS O
had VBD VBD O
a DT DT O
pre NN NN O
- - - O
therapy NN NN O
Gram NNP NNP O
' POS POS O
s VBZ VBZ O
stain VB VB O
and CC CC O
culture NN NN O
of IN IN O
sinus NN NN O
exudate NN NN O
obtained VBN VBN O
by IN IN O
antral JJ JJ O
puncture NN NN O
or CC CC O
nasal NN NN O
endoscopy NN NN O
. . . O

Clinical NNP NNP O
response NN NN O
was VBD VBD O
assessed VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
and CC CC O
sinus JJ JJ O
radiograph NN NN O
or CC CC O
computed JJ JJ O
tomography NN NN O
results NNS NNS O
. . . O

Microbiologic NNP NNP O
cure NN NN O
rates NNS NNS O
were VBD VBD O
determined VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
presumed VBN VBN O
plus CC CC O
documented VBN VBN O
eradication NN NN O
of IN IN O
the DT DT O
pre NN NN O
- - - O
therapy NN NN O
pathogen NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
most RBS RBS O
common JJ JJ O
pathogens NNS NNS O
were VBD VBD O
Haemophilus NNP NNP O
influenzae NN NN O
, , , O
Streptococcus NNP NNP O
pneumoniae NN NN O
, , , O
Staphylococcus NNP NNP O
aureus NN NN O
, , , O
and CC CC O
Moraxella NNP NNP O
catarrhalis NNS NNS O
. . . O

Of IN IN O
300 CD CD O
clinically RB RB O
evaluable JJ JJ O
patients NNS NNS O
, , , O
175 CD CD O
( ( ( O
58 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
cured VBN VBN O
and CC CC O
90 CD CD O
( ( ( O
30 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
improved VBN VBN O
at IN IN O
the DT DT O
post NN NN O
- - - O
therapy NN NN O
evaluation NN NN O
, , , O
resulting VBG VBG O
in IN IN O
a DT DT O
clinical JJ JJ O
success NN NN O
rate NN NN O
of IN IN O
88 CD CD O
% NN NN O
. . . O

Thirty NNP NNP O
- : : O
five CD CD O
patients NNS NNS O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
clinically RB RB O
failed VBD VBD O
treatment NN NN O
. . . O

The DT DT O
microbiologic JJ JJ O
eradication NN NN O
rate NN NN O
( ( ( O
presumed VBN VBN O
plus CC CC O
documented VBN VBN O
) ) ) O
among IN IN O
138 CD CD O
microbiologically RB RB O
evaluable JJ JJ O
patients NNS NNS O
was VBD VBD O
92 CD CD O
% NN NN O
. . . O

Microbiologic NNP NNP O
eradication NN NN O
rates NNS NNS O
( ( ( O
presumed VBN VBN O
plus CC CC O
documented VBN VBN O
) ) ) O
of IN IN O
the DT DT O
most RBS RBS O
common JJ JJ O
pathogens NNS NNS O
ranged VBN VBN O
from IN IN O
93 CD CD O
% NN NN O
( ( ( O
M NNP NNP O
. . . O
catarrhalis NNS NNS O
) ) ) O
to TO TO O
100 CD CD O
% NN NN O
( ( ( O
S NNP NNP O
. . . O
pneumoniae NN NN O
) ) ) O
at IN IN O
the DT DT O
post NN NN O
- - - O
therapy NN NN O
visit NN NN O
. . . O

All DT DT O
but CC CC O
one CD CD O
of IN IN O
the DT DT O
265 CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
cured VBN VBN O
or CC CC O
improved VBN VBN O
at IN IN O
post NN NN O
- - - O
therapy NN NN O
returned VBD VBD O
for IN IN O
a DT DT O
long JJ JJ O
- - - O
term NN NN O
follow VB VB O
- - - O
up RP RP O
visit NN NN O
; : : O
243 CD CD O
( ( ( O
92 CD CD O
% NN NN O
) ) ) O
remained VBD VBD O
well RB RB O
4 CD CD O
to TO TO O
6 CD CD O
weeks NNS NNS O
after IN IN O
therapy NN NN O
; : : O
and CC CC O
21 CD CD O
( ( ( O
8 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
a DT DT O
relapse NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

Adverse NNP NNP O
events NNS NNS O
considered VBN VBN O
to TO TO O
be VB VB O
related VBN VBN O
to TO TO O
levofloxacin NN NN B-CHEM
administration NN NN O
were VBD VBD O
reported VBN VBN O
by IN IN O
29 CD CD O
patients NNS NNS O
( ( ( O
9 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
drug NN NN O
- - - O
related VBN VBN O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
diarrhea NN NN O
, , , O
flatulence NN NN O
, , , O
and CC CC O
nausea NN NN O
; : : O
most JJS JJS O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
mild JJ JJ O
to TO TO O
moderate VB VB O
in IN IN O
severity NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
study NN NN O
indicate VBP VBP O
that IN IN O
levofloxacin NN NN B-CHEM
500 CD CD O
mg NN NN O
once RB RB O
daily RB RB O
is VBZ VBZ O
an DT DT O
effective JJ JJ O
and CC CC O
safe JJ JJ O
treatment NN NN O
for IN IN O
acute JJ JJ O
bacterial JJ JJ O
sinusitis NN NN O
. . . O

Iatrogenic JJ JJ O
risks NNS NNS O
of IN IN O
endometrial JJ JJ O
carcinoma NN NN O
after IN IN O
treatment NN NN O
for IN IN O
breast NN NN O
cancer NN NN O
in IN IN O
a DT DT O
large JJ JJ O
French JJ JJ O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

F NN NN O
d SYM SYM O
ration NN NN O
Nationale NNP NNP O
des NNS NNS O
Centres NNP NNP O
de IN IN O
Lutte NNP NNP O
Contre NNP NNP O
le VBD VBD O
Cancer NNP NNP O
( ( ( O
FNCLCC NNP NNP O
) ) ) O
. . . O

Since IN IN O
tamoxifen NN NN B-CHEM
is VBZ VBZ O
widely RB RB O
used VBN VBN O
in IN IN O
breast NN NN O
cancer NN NN O
treatment NN NN O
and CC CC O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
, , , O
its PRP$ PRP$ O
endometrial JJ JJ O
iatrogenic JJ JJ O
effects NNS NNS O
must MD MD O
be VB VB O
carefully RB RB O
examined VBN VBN O
. . . O

We PRP PRP O
have VBP VBP O
investigated VBN VBN O
the DT DT O
association NN NN O
between IN IN O
endometrial JJ JJ O
cancer NN NN O
and CC CC O
tamoxifen NN NN B-CHEM
use NN NN O
or CC CC O
other JJ JJ O
treatments NNS NNS O
in IN IN O
women NNS NNS O
treated VBN VBN O
for IN IN O
breast NN NN O
cancer NN NN O
in IN IN O
a DT DT O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

Cases NNS NNS O
of IN IN O
endometrial JJ JJ O
cancer NN NN O
diagnosed VBD VBD O
after IN IN O
breast NN NN O
cancer NN NN O
( ( ( O
n NN NN O
= SYM SYM O
135 CD CD O
) ) ) O
and CC CC O
467 CD CD O
controls NNS NNS O
matched VBN VBN O
for IN IN O
age NN NN O
, , , O
year NN NN O
of IN IN O
diagnosis NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
and CC CC O
hospital NN NN O
and CC CC O
survival NN NN O
time NN NN O
with IN IN O
an DT DT O
intact JJ JJ O
uterus JJ JJ O
were VBD VBD O
included VBN VBN O
. . . O

Women NNP NNP O
who WP WP O
had VBD VBD O
received VBN VBN O
tamoxifen NN NN B-CHEM
were VBD VBD O
significantly RB RB O
more RBR RBR O
likely JJ JJ O
to TO TO O
have VB VB O
endometrial JJ JJ O
cancer NN NN O
diagnosed VBN VBN O
than IN IN O
those DT DT O
who WP WP O
had VBD VBD O
not RB RB O
( ( ( O
crude NN NN O
relative JJ JJ O
risk NN NN O
= SYM SYM O
4 CD CD O
. . . O
9 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

Univariate NNP NNP O
and CC CC O
adjusted VBN VBN O
analyses NNS NNS O
showed VBN VBN O
that IN IN O
the DT DT O
risk NN NN O
increased VBN VBN O
with IN IN O
the DT DT O
length NN NN O
of IN IN O
treatment NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
or CC CC O
the DT DT O
cumulative JJ JJ O
dose NN NN O
of IN IN O
tamoxifen NN NN B-CHEM
received VBD VBD O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
, , , O
irrespective JJ JJ O
of IN IN O
the DT DT O
daily JJ JJ O
dose NN NN O
. . . O

Women NNP NNP O
who WP WP O
had VBD VBD O
undergone JJ JJ O
pelvic NN NN O
radiotherapy NN NN O
also RB RB O
had VBD VBD O
a DT DT O
higher JJR JJR O
risk NN NN O
( ( ( O
crude NN NN O
relative JJ JJ O
risk NN NN O
= SYM SYM O
7 CD CD O
. . . O
8 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

After IN IN O
adjusting VBG VBG O
for IN IN O
confounding VBG VBG O
factors NNS NNS O
, , , O
the DT DT O
risk NN NN O
was VBD VBD O
higher JJR JJR O
for IN IN O
tamoxifen NN NN B-CHEM
users NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0012 CD CD O
) ) ) O
, , , O
treatment NN NN O
for IN IN O
more JJR JJR O
than IN IN O
3 CD CD O
years NNS NNS O
( ( ( O
all DT DT O
p NN NN O
< NN NN O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
and CC CC O
pelvic JJ JJ O
radiotherapy NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
012 CD CD O
) ) ) O
. . . O

Women NNP NNP O
who WP WP O
had VBD VBD O
endometrial JJ JJ O
cancer NN NN O
and CC CC O
had VBD VBD O
received VBN VBN O
tamoxifen NN NN B-CHEM
had VBD VBD O
more RBR RBR O
advanced JJ JJ O
disease NN NN O
and CC CC O
poorer NN NN O
prognosis NN NN O
than IN IN O
those DT DT O
with IN IN O
endometrial JJ JJ O
cancer NN NN O
who WP WP O
had VBD VBD O
not RB RB O
received VBN VBN O
this DT DT O
treatment NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
a DT DT O
causal NN NN O
role NN NN O
of IN IN O
tamoxifen NN NN B-CHEM
in IN IN O
endometrial JJ JJ O
cancer NN NN O
, , , O
particularly RB RB O
when WRB WRB O
used VBN VBN O
as IN IN O
currently RB RB O
proposed VBN VBN O
for IN IN O
breast NN NN O
cancer NN NN O
prevention NN NN O
. . . O

Pelvic NNP NNP O
radiotherapy NN NN O
may MD MD O
be VB VB O
an DT DT O
additional JJ JJ O
iatrogenic JJ JJ O
factor NN NN O
for IN IN O
women NNS NNS O
with IN IN O
breast NN NN O
cancer NN NN O
. . . O

Endometrial NNP NNP O
cancers NNS NNS O
diagnosed VBD VBD O
in IN IN O
women NNS NNS O
treated VBN VBN O
with IN IN O
tamoxifen NN NN B-CHEM
have VBP VBP O
poorer NN NN O
prognosis NN NN O
. . . O

Women NNP NNP O
who WP WP O
receive VBP VBP O
tamoxifen NN NN B-CHEM
for IN IN O
breast NN NN O
cancer NN NN O
should MD MD O
be VB VB O
offered VBN VBN O
gynaecological JJ JJ O
surveillance NN NN O
during IN IN O
and CC CC O
after IN IN O
treatment NN NN O
. . . O

A DT DT O
long JJ JJ O
- - - O
term NN NN O
evaluation NN NN O
of IN IN O
the DT DT O
risk NN NN O
- - - O
benefit NN NN O
ratio NN NN O
of IN IN O
tamoxifen NN NN B-CHEM
as IN IN O
a DT DT O
preventive JJ JJ O
treatment NN NN O
for IN IN O
breast NN NN O
cancer NN NN O
is VBZ VBZ O
clearly RB RB O
warranted VBN VBN O
. . . O

Contribution NNP NNP O
of IN IN O
the DT DT O
glycine NN NN B-CHEM
site NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
in IN IN O
rostral NN NN O
and CC CC O
intermediate JJ JJ O
- - - O
caudal NN NN O
parts NNS NNS O
of IN IN O
the DT DT O
striatum NN NN O
to TO TO O
the DT DT O
regulation NN NN O
of IN IN O
muscle NN NN O
tone NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
contribution NN NN O
of IN IN O
the DT DT O
glycine NN NN B-CHEM
site NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
in IN IN O
the DT DT O
striatum NN NN O
to TO TO O
the DT DT O
regulation NN NN O
of IN IN O
muscle NN NN O
tone NN NN O
. . . O

Muscle NNP NNP O
tone NN NN O
was VBD VBD O
examined VBN VBN O
using VBG VBG O
a DT DT O
combined JJ JJ O
mechanoand NN NN O
electromyographic JJ JJ O
method NN NN O
, , , O
which WDT WDT O
measured VBD VBD O
simultaneously RB RB O
the DT DT O
muscle NN NN O
resistance NN NN O
( ( ( O
MMG NNP NNP O
) ) ) O
of IN IN O
the DT DT O
rat NN NN O
' '' '' O
s VBZ VBZ O
hind NN NN O
foot NN NN O
to TO TO O
passive JJ JJ O
extension NN NN O
and CC CC O
flexion NN NN O
in IN IN O
the DT DT O
ankle NN NN O
joint NN NN O
and CC CC O
the DT DT O
electromyographic JJ JJ O
activity NN NN O
( ( ( O
EMG NNP NNP O
) ) ) O
of IN IN O
the DT DT O
antagonistic JJ JJ O
muscles NNS NNS O
of IN IN O
that DT DT O
joint NN NN O
: : : O
gastrocnemius NN NN O
and CC CC O
tibialis NNS NNS O
anterior RB RB O
. . . O

Muscle NNP NNP O
rigidity NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
dichlorokynurenic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
DCKA NNP NNP I-CHEM
) ) ) O
, , , O
a DT DT O
selective JJ JJ O
glycine NN NN B-CHEM
site NN NN O
antagonist NN NN O
, , , O
injected VBN VBN O
in IN IN O
doses NNS NNS O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
and CC CC O
4 CD CD O
. . . O
5 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
bilaterally RB RB O
, , , O
into IN IN O
the DT DT O
rostral JJ JJ O
region NN NN O
of IN IN O
the DT DT O
striatum NN NN O
, , , O
decreased VBD VBD O
both DT DT O
the DT DT O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
muscle NN NN O
rigidity NN NN O
( ( ( O
MMG NNP NNP O
) ) ) O
and CC CC O
the DT DT O
enhanced JJ JJ O
electromyographic JJ JJ O
activity NN NN O
( ( ( O
EMG NNP NNP O
) ) ) O
. . . O

5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
DCKA NNP NNP I-CHEM
injected VBN VBN O
bilaterally RB RB O
in IN IN O
a DT DT O
dose NN NN O
of IN IN O
4 CD CD O
. . . O
5 CD CD O
microg NN NN O
/ NN NN O
0 CD CD O
. . . O
5 CD CD O
microl NN NN O
into IN IN O
the DT DT O
intermediate JJ JJ O
- - - O
caudal JJ JJ O
region NN NN O
of IN IN O
the DT DT O
striatum NN NN O
of IN IN O
rats NNS NNS O
not RB RB O
pretreated VBN VBN O
with IN IN O
haloperidol NN NN B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
muscle NN NN O
tone NN NN O
. . . O

The DT DT O
present NN NN O
results NNS NNS O
suggest VBP VBP O
that IN IN O
blockade NN NN O
of IN IN O
the DT DT O
glycine NN NN B-CHEM
site NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
in IN IN O
the DT DT O
rostral JJ JJ O
part NN NN O
of IN IN O
the DT DT O
striatum NN NN O
may MD MD O
be VB VB O
mainly RB RB O
responsible JJ JJ O
for IN IN O
the DT DT O
antiparkinsonian JJ JJ O
action NN NN O
of IN IN O
this DT DT O
drug NN NN O
. . . O

Carboplatin NNP NNP B-CHEM
toxic JJ JJ O
effects NNS NNS O
on IN IN O
the DT DT O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
of IN IN O
the DT DT O
rat NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
most RBS RBS O
striking JJ JJ O
of IN IN O
carboplatin NN NN B-CHEM
' '' '' O
s VBZ VBZ O
advantages NNS NNS O
( ( ( O
CBDCA NNP NNP B-CHEM
) ) ) O
over IN IN O
cisplatin NN NN B-CHEM
( ( ( O
CDDP NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
its PRP$ PRP$ O
markedly RB RB O
reduced VBN VBN O
rate NN NN O
of IN IN O
neurotoxic JJ JJ O
effects NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
use NN NN O
of IN IN O
CBDCA NNP NNP B-CHEM
higher JJR JJR O
- : : O
intensity NN NN O
schedules NNS NNS O
and CC CC O
the DT DT O
association NN NN O
with IN IN O
other JJ JJ O
neurotoxic JJ JJ O
drugs NNS NNS O
in IN IN O
polychemotherapy NN NN O
may MD MD O
cause VB VB O
some DT DT O
concern NN NN O
about IN IN O
its PRP$ PRP$ O
safety NN NN O
with IN IN O
respect NN NN O
to TO TO O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
damage NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Two CD CD O
different JJ JJ O
schedules NNS NNS O
of IN IN O
CBDCA NNP NNP B-CHEM
administration NN NN O
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
and CC CC O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
twice RB RB O
a DT DT O
week NN NN O
for IN IN O
nine CD CD O
times NNS NNS O
) ) ) O
were VBD VBD O
evaluated VBN VBN O
in IN IN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Neurotoxicity NNP NNP O
was VBD VBD O
assessed VBN VBN O
for IN IN O
behavioral JJ JJ O
( ( ( O
tail NN NN O
- : : O
flick NN NN O
test NN NN O
) ) ) O
, , , O
neurophysiological JJ JJ O
( ( ( O
nerve NN NN O
conduction NN NN O
velocity NN NN O
in IN IN O
the DT DT O
tail NN NN O
nerve NN NN O
) ) ) O
, , , O
morphological JJ JJ O
, , , O
morphometrical JJ JJ O
and CC CC O
analytical JJ JJ O
effects NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
CBDCA NNP NNP B-CHEM
administration NN NN O
induced VBD VBD O
dose NN NN O
- : : O
dependent JJ JJ O
peripheral JJ JJ O
neurotoxicity NN NN O
. . . O

Pain NN NN O
perception NN NN O
and CC CC O
nerve NN NN O
conduction NN NN O
velocity NN NN O
in IN IN O
the DT DT O
tail NN NN O
were VBD VBD O
significantly RB RB O
impaired VBN VBN O
, , , O
particularly RB RB O
after IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
treatment NN NN O
. . . O

The DT DT O
dorsal NN NN O
root NN NN O
ganglia NN NN O
sensory JJ JJ O
neurons NNS NNS O
and CC CC O
, , , O
to TO TO O
a DT DT O
lesser NN NN O
extent NN NN O
, , , O
satellite NN NN O
cells NNS NNS O
showed VBD VBD O
the DT DT O
same JJ JJ O
changes NNS NNS O
as IN IN O
those DT DT O
induced VBN VBN O
by IN IN O
CDDP NNP NNP B-CHEM
, , , O
mainly RB RB O
affecting VBG VBG O
the DT DT O
nucleus NN NN O
and CC CC O
nucleolus NN NN O
of IN IN O
ganglionic JJ JJ O
sensory JJ JJ O
neurons NNS NNS O
. . . O

Moreover RB RB O
, , , O
significant JJ JJ O
amounts NNS NNS O
of IN IN O
platinum NN NN B-CHEM
were VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
dorsal NN NN O
root NN NN O
ganglia NN NN O
and CC CC O
kidney NN NN O
after IN IN O
CBDCA NNP NNP B-CHEM
treatment NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
CBDCA NNP NNP B-CHEM
is VBZ VBZ O
neurotoxic JJ JJ O
in IN IN O
our PRP$ PRP$ O
model NN NN O
, , , O
and CC CC O
the DT DT O
type NN NN O
of IN IN O
pathological JJ JJ O
changes NNS NNS O
it PRP PRP O
induces NNS NNS O
are VBP VBP O
so RB RB O
closely RB RB O
similar JJ JJ O
to TO TO O
those DT DT O
caused VBN VBN O
by IN IN O
CDDP NNP NNP B-CHEM
that IN IN O
it PRP PRP O
is VBZ VBZ O
probable JJ JJ O
that DT DT O
neurotoxicity NN NN O
is VBZ VBZ O
induced VBN VBN O
in IN IN O
the DT DT O
two CD CD O
drugs NNS NNS O
by IN IN O
the DT DT O
same JJ JJ O
mechanism NN NN O
. . . O

This DT DT O
model NN NN O
can MD MD O
be VB VB O
used VBN VBN O
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
drugs NNS NNS O
to TO TO O
explore VB VB O
the DT DT O
effect NN NN O
of IN IN O
CBDCA NNP NNP B-CHEM
on IN IN O
the DT DT O
peripheral JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Effects NNP NNP O
of IN IN O
cisapride NN NN B-CHEM
on IN IN O
symptoms NNS NNS O
and CC CC O
postcibal NN NN O
small JJ JJ O
- : : O
bowel NN NN O
motor NN NN O
function NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
irritable JJ JJ O
bowel NN NN O
syndrome NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Irritable NNP NNP O
bowel NN NN O
syndrome NN NN O
is VBZ VBZ O
a DT DT O
common JJ JJ O
cause NN NN O
of IN IN O
abdominal JJ JJ O
pain NN NN O
and CC CC O
discomfort NN NN O
and CC CC O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
disordered JJ JJ O
gastrointestinal JJ JJ O
motility NN NN O
. . . O

Our PRP$ PRP$ O
aim NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
a DT DT O
prokinetic JJ JJ O
agent NN NN O
, , , O
cisapride NN NN B-CHEM
, , , O
on IN IN O
postprandial JJ JJ O
jejunal NN NN O
motility NN NN O
and CC CC O
symptoms NNS NNS O
in IN IN O
the DT DT O
irritable JJ JJ O
bowel NN NN O
syndrome NN NN O
( ( ( O
IBS NNP NNP O
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
Thirty NNP NNP O
- - - O
eight CD CD O
patients NNS NNS O
with IN IN O
IBS NNP NNP O
( ( ( O
constipation NN NN O
- - - O
predominant NN NN O
, , , O
n NN NN O
= SYM SYM O
17 CD CD O
; : : O
diarrhoea NN NN O
- : : O
predominant NN NN O
, , , O
n NN NN O
= SYM SYM O
21 CD CD O
) ) ) O
underwent NN NN O
24 CD CD O
- : : O
h NN NN O
ambulatory NN NN O
jejunal JJ JJ O
manometry NN NN O
before IN IN O
and CC CC O
after IN IN O
12 CD CD O
week NN NN O
' '' '' O
s VBZ VBZ O
treatment NN NN O
[ NN NN O
cisapride NN NN B-CHEM
, , , O
5 CD CD O
mg NN NN O
three CD CD O
times NNS NNS O
daily JJ JJ O
( ( ( O
n NN NN O
= SYM SYM O
19 CD CD O
) ) ) O
or CC CC O
placebo NN NN O
( ( ( O
n NN NN O
= SYM SYM O
19 CD CD O
) ) ) O
] NN NN O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
diarrhoea NN NN O
- - - O
predominant NN NN O
patients NNS NNS O
significant JJ JJ O
differences NNS NNS O
in IN IN O
contraction NN NN O
characteristics NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
the DT DT O
cisapride NN NN B-CHEM
and CC CC O
placebo NN NN O
groups NNS NNS O
. . . O

In IN IN O
cisapride NN NN B-CHEM
- - - O
treated VBN VBN O
diarrhoea NN NN O
- - - O
predominant NN NN O
patients NNS NNS O
the DT DT O
mean NN NN O
contraction NN NN O
amplitude NN NN O
was VBD VBD O
higher JJR JJR O
( ( ( O
29 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
2 CD CD O
versus CC CC O
24 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
6 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
cisapride NN NN B-CHEM
versus CC CC O
placebo NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
; : : O
pretreatment NN NN O
, , , O
25 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
0 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
, , , O
the DT DT O
mean JJ JJ O
contraction NN NN O
duration NN NN O
longer RBR RBR O
( ( ( O
3 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
versus CC CC O
3 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
sec NN NN O
, , , O
cisapride NN NN B-CHEM
versus CC CC O
placebo NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
; : : O
pretreatment NN NN O
, , , O
3 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
sec NN NN O
) ) ) O
, , , O
and CC CC O
the DT DT O
mean JJ JJ O
contraction NN NN O
frequency NN NN O
lower JJR JJR O
( ( ( O
2 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
versus CC CC O
2 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
4 CD CD O
cont NN NN O
. . . O
/ NN NN O
min NN NN O
, , , O
cisapride NN NN B-CHEM
versus CC CC O
placebo NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
; : : O
pretreatment NN NN O
, , , O
2 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
1 CD CD O
cont NN NN O
. . . O
/ NN NN O
min NN NN O
] NN NN O
than IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
placebo NN NN O
. . . O

No DT DT O
significant JJ JJ O
differences NNS NNS O
in IN IN O
jejunal JJ JJ O
motility NN NN O
were VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
constipation NN NN O
- - - O
predominant NN NN O
IBS NNP NNP O
group NN NN O
. . . O

Symptoms NNP NNP O
were VBD VBD O
assessed VBN VBN O
by IN IN O
using VBG VBG O
a DT DT O
visual JJ JJ O
analogue NN NN O
scale NN NN O
before IN IN O
and CC CC O
after IN IN O
treatment NN NN O
. . . O

Symptom NNP NNP O
scores NNS NNS O
relating VBG VBG O
to TO TO O
the DT DT O
severity NN NN O
of IN IN O
constipation NN NN O
were VBD VBD O
lower JJR JJR O
in IN IN O
cisapride NN NN B-CHEM
- - - O
treated VBN VBN O
constipation NN NN O
- - - O
predominant NN NN O
IBS NNP NNP O
patients NNS NNS O
[ NN NN O
score NN NN O
, , , O
54 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
versus CC CC O
67 CD CD O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
mm NN NN O
, , , O
cisapride NN NN B-CHEM
versus CC CC O
placebo NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
; : : O
pretreatment NN NN O
, , , O
62 CD CD O
+ NN NN O
/ NN NN O
- : : O
19 CD CD O
mm NN NN O
] NN NN O
. . . O

Diarrhoea NNP NNP O
- : : O
predominant NN NN O
IBS NNP NNP O
patients NNS NNS O
had VBD VBD O
a DT DT O
higher JJR JJR O
pain NN NN O
score NN NN O
after IN IN O
cisapride NN NN B-CHEM
therapy NN NN O
[ NN NN O
score NN NN O
, , , O
55 CD CD O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
versus CC CC O
34 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
mm NN NN O
, , , O
cisapride NN NN B-CHEM
versus CC CC O
placebo NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
; : : O
pretreatment NN NN O
, , , O
67 CD CD O
+ NN NN O
/ NN NN O
- : : O
19 CD CD O
mm NN NN O
] NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Cisapride NNP NNP B-CHEM
affects NNS NNS O
jejunal JJ JJ O
contraction NN NN O
characteristics NNS NNS O
and CC CC O
some DT DT O
symptoms NNS NNS O
in IN IN O
IBS NNP NNP O
. . . O

Prevention NNP NNP O
of IN IN O
breast NN NN O
cancer NN NN O
with IN IN O
tamoxifen NN NN B-CHEM
: : : O
preliminary JJ JJ O
findings NNS NNS O
from IN IN O
the DT DT O
Italian JJ JJ O
randomised VBN VBN O
trial NN NN O
among IN IN O
hysterectomised JJ JJ O
women NNS NNS O
. . . O

Italian JJ JJ O
Tamoxifen NNP NNP B-CHEM
Prevention NNP NNP O
Study NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Tamoxifen NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
candidate NN NN O
chemopreventive JJ JJ O
agent NN NN O
in IN IN O
breast NN NN O
cancer NN NN O
, , , O
although IN IN O
the DT DT O
drug NN NN O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
endometrial JJ JJ O
cancer NN NN O
. . . O

Therefore RB RB O
we PRP PRP O
did VBD VBD O
a DT DT O
trial NN NN O
in IN IN O
hysterectomised VBN VBN O
women NNS NNS O
of IN IN O
tamoxifen NN NN B-CHEM
as IN IN O
a DT DT O
chemopreventive JJ JJ O
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
October NNP NNP O
, , , O
1992 CD CD O
, , , O
we PRP PRP O
started VBD VBD O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
randomised VBN VBN O
trial NN NN O
of IN IN O
tamoxifen NN NN B-CHEM
in IN IN O
women NNS NNS O
( ( ( O
mainly RB RB O
in IN IN O
Italy NNP NNP O
) ) ) O
who WP WP O
did VBD VBD O
not RB RB O
have VB VB O
breast NN NN O
cancer NN NN O
and CC CC O
who WP WP O
had VBD VBD O
had VBD VBD O
a DT DT O
hysterectomy NN NN O
. . . O

Women NNP NNP O
were VBD VBD O
randomised VBN VBN O
to TO TO O
receive VB VB O
tamoxifen NN NN B-CHEM
20 CD CD O
mg NN NN O
per IN IN O
day NN NN O
or CC CC O
placebo NN NN O
, , , O
both DT DT O
orally RB RB O
for IN IN O
5 CD CD O
years NNS NNS O
. . . O

The DT DT O
original JJ JJ O
plan NN NN O
was VBD VBD O
to TO TO O
follow VB VB O
the DT DT O
intervention NN NN O
phase NN NN O
by IN IN O
5 CD CD O
years NNS NNS O
' POS POS O
follow VB VB O
- - - O
up RP RP O
. . . O

In IN IN O
June NNP NNP O
, , , O
1997 CD CD O
, , , O
the DT DT O
trialists NNS NNS O
and CC CC O
the DT DT O
data NNS NNS O
- : : O
monitoring VBG VBG O
committee NN NN O
decided VBD VBD O
to TO TO O
end VB VB O
recruitment NN NN O
primarily RB RB O
because IN IN O
of IN IN O
the DT DT O
number NN NN O
of IN IN O
women NNS NNS O
dropping VBG VBG O
out IN IN O
of IN IN O
the DT DT O
study NN NN O
. . . O

Recruitment NNP NNP O
ended VBD VBD O
on IN IN O
July NNP NNP O
11 CD CD O
, , , O
1997 CD CD O
, , , O
and CC CC O
the DT DT O
study NN NN O
will MD MD O
continue VB VB O
as IN IN O
planned VBN VBN O
. . . O

The DT DT O
primary JJ JJ O
endpoints NNS NNS O
are VBP VBP O
the DT DT O
occurrence NN NN O
of IN IN O
and CC CC O
deaths NNS NNS O
from IN IN O
breast NN NN O
cancer NN NN O
. . . O

This DT DT O
preliminary JJ JJ O
interim NN NN O
analysis NN NN O
is VBZ VBZ O
based VBN VBN O
on IN IN O
intention NN NN O
- : : O
to TO TO O
- - - O
treat NN NN O
. . . O

FINDINGS NNS NNS O
: : : O
5408 CD CD O
women NNS NNS O
were VBD VBD O
randomised VBN VBN O
; : : O
participating VBG VBG O
women NNS NNS O
have VBP VBP O
a DT DT O
median NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
46 CD CD O
months NNS NNS O
for IN IN O
major JJ JJ O
endpoints NNS NNS O
. . . O

41 CD CD O
cases NNS NNS O
of IN IN O
breast JJ JJ O
cancer NN NN O
occurred VBD VBD O
so RB RB O
far RB RB O
; : : O
there EX EX O
have VBP VBP O
been VBN VBN O
no DT DT O
deaths NNS NNS O
from IN IN O
breast NN NN O
cancer NN NN O
. . . O

There EX EX O
is VBZ VBZ O
no DT DT O
difference NN NN O
in IN IN O
breast NN NN O
- - - O
cancer NN NN O
frequency NN NN O
between IN IN O
the DT DT O
placebo NN NN O
( ( ( O
22 CD CD O
cases NNS NNS O
) ) ) O
and CC CC O
tamoxifen NN NN B-CHEM
( ( ( O
19 CD CD O
) ) ) O
arms NNS NNS O
. . . O

There EX EX O
is VBZ VBZ O
a DT DT O
statistically RB RB O
significant JJ JJ O
reduction NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
among IN IN O
women NNS NNS O
receiving VBG VBG O
tamoxifen NN NN B-CHEM
who WP WP O
also RB RB O
used VBN VBN O
hormone NN NN O
- - - O
replacement NN NN O
therapy NN NN O
during IN IN O
the DT DT O
trial NN NN O
: : : O
among IN IN O
390 CD CD O
women NNS NNS O
on IN IN O
such JJ JJ O
therapy NN NN O
and CC CC O
allocated VBD VBD O
to TO TO O
placebo NN NN O
, , , O
we PRP PRP O
found VBD VBD O
eight CD CD O
cases NNS NNS O
of IN IN O
breast JJ JJ O
cancer NN NN O
compared VBN VBN O
with IN IN O
one CD CD O
case NN NN O
among IN IN O
362 CD CD O
women NNS NNS O
allocated VBD VBD O
to TO TO O
tamoxifen VB VB B-CHEM
. . . O

Compared VBN VBN O
with IN IN O
the DT DT O
placebo NN NN O
group NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
significantly RB RB O
increased VBN VBN O
risk NN NN O
of IN IN O
vascular NN NN O
events NNS NNS O
and CC CC O
hypertriglyceridaemia NN NN O
among IN IN O
women NNS NNS O
on IN IN O
tamoxifen NN NN B-CHEM
. . . O

INTERPRETATION NN NN O
: : : O
Although IN IN O
this DT DT O
preliminary JJ JJ O
analysis NN NN O
has VBZ VBZ O
low JJ JJ O
power NN NN O
, , , O
in IN IN O
this DT DT O
cohort NN NN O
of IN IN O
women NNS NNS O
at IN IN O
low JJ JJ O
- - - O
to TO TO O
- - - O
normal JJ JJ O
risk NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
, , , O
the DT DT O
postulated JJ JJ O
protective JJ JJ O
effects NNS NNS O
of IN IN O
tamoxifen NN NN B-CHEM
are VBP VBP O
not RB RB O
yet RB RB O
apparent JJ JJ O
. . . O

Women NNP NNP O
using VBG VBG O
hormone NN NN O
- - - O
replacement NN NN O
therapy NN NN O
appear VB VB O
to TO TO O
have VB VB O
benefited VBN VBN O
from IN IN O
use NN NN O
of IN IN O
tamoxifen NN NN B-CHEM
. . . O

There EX EX O
were VBD VBD O
no DT DT O
deaths NNS NNS O
from IN IN O
breast NN NN O
cancer NN NN O
recorded VBN VBN O
in IN IN O
women NNS NNS O
in IN IN O
the DT DT O
study NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
essential JJ JJ O
to TO TO O
continue VB VB O
follow VB VB O
- - - O
up RP RP O
to TO TO O
quantify VB VB O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
risks NNS NNS O
and CC CC O
benefits NNS NNS O
of IN IN O
tamoxifen NN NN B-CHEM
therapy NN NN O
. . . O

Epileptogenic NNP NNP O
activity NN NN O
of IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
after IN IN O
drug NN NN O
induces NNS NNS O
SLE NNP NNP O
( ( ( O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
and CC CC O
epilepsy NN NN O
) ) ) O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
study VB VB O
the DT DT O
effect NN NN O
of IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
containing VBG VBG O
multivitamin NN NN O
supplementation NN NN O
in IN IN O
epileptic JJ JJ O
women NNS NNS O
before IN IN O
and CC CC O
during IN IN O
pregnancy NN NN O
in IN IN O
order NN NN O
to TO TO O
determine VB VB O
the DT DT O
rate NN NN O
of IN IN O
structural JJ JJ O
birth NN NN O
defects NNS NNS O
and CC CC O
epilepsy NN NN O
- - - O
related VBN VBN O
side NN NN O
effects NNS NNS O
. . . O

STUDY NNP NNP O
DESIGN NNP NNP O
: : : O
First CD CD O
a DT DT O
randomised VBN VBN O
trial NN NN O
, , , O
later RB RB O
periconception NN NN O
care NN NN O
including VBG VBG O
in IN IN O
total JJ JJ O
12225 CD CD O
females NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
60 CD CD O
epileptic JJ JJ O
women NNS NNS O
with IN IN O
periconceptional JJ JJ O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
0 CD CD O
. . . O
8 CD CD O
mg NN NN O
) ) ) O
- : : O
containing VBG VBG O
multivitamin NN NN O
supplementation NN NN O
, , , O
no DT DT O
one CD CD O
developed VBN VBN O
epilepsy NN NN O
- - - O
related VBN VBN O
side NN NN O
effects NNS NNS O
during IN IN O
the DT DT O
periconception NN NN O
period NN NN O
. . . O

One CD CD O
epileptic JJ JJ O
woman NN NN O
delivered VBD VBD O
a DT DT O
newborn JJ JJ O
with IN IN O
cleft NN NN O
lip NN NN O
and CC CC O
palate NN NN O
. . . O

Another DT DT O
patient NN NN O
exhibited VBN VBN O
with IN IN O
a DT DT O
cluster NN NN O
of IN IN O
seizures NNS NNS O
after IN IN O
the DT DT O
periconception NN NN O
period NN NN O
using VBG VBG O
another DT DT O
multivitamin NN NN O
. . . O

This DT DT O
22 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
epileptic JJ JJ O
woman NN NN O
was VBD VBD O
treated VBN VBN O
continuously RB RB O
by IN IN O
carbamazepine NN NN B-CHEM
and CC CC O
a DT DT O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
1 CD CD O
mg NN NN O
) ) ) O
- : : O
containing VBG VBG O
multivitamin NN NN O
from IN IN O
the DT DT O
20th JJ JJ O
week NN NN O
of IN IN O
gestation NN NN O
. . . O

She PRP PRP O
developed VBD VBD O
status NN NN O
epilepticus NN NN O
and CC CC O
later RB RB O
symptoms NNS NNS O
of IN IN O
systemic JJ JJ O
lupus NN NN O
erythematodes NNS NNS O
. . . O

Her PRP$ PRP$ O
pregnancy NN NN O
ended VBN VBN O
with IN IN O
stillbirth NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
epileptic JJ JJ O
pregnant JJ JJ O
patient NN NN O
' '' '' O
s VBZ VBZ O
autoimmune JJ JJ O
disease NN NN O
( ( ( O
probably RB RB O
drug NN NN O
- - - O
induced JJ JJ O
lupus NN NN O
) ) ) O
could MD MD O
damage VB VB O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
, , , O
therefore RB RB O
the DT DT O
therapeutic JJ JJ O
dose NN NN O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
1 CD CD O
mg NN NN O
) ) ) O
of IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
triggered VBD VBD O
a DT DT O
cluster NN NN O
of IN IN O
seizures NNS NNS O
. . . O

Physiological NNP NNP O
dose NN NN O
( ( ( O
< NN NN O
1 CD CD O
mg NN NN O
) ) ) O
of IN IN O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
both DT DT O
in IN IN O
healthy JJ JJ O
and CC CC O
60 CD CD O
epileptic JJ JJ O
women NNS NNS O
, , , O
all DT DT O
without IN IN O
any DT DT O
autoimmune JJ JJ O
disease NN NN O
, , , O
did VBD VBD O
not RB RB O
increase VB VB O
the DT DT O
risk NN NN O
for IN IN O
epileptic JJ JJ O
seizures NNS NNS O
. . . O

Stroke NNP NNP O
and CC CC O
cocaine NN NN B-CHEM
or CC CC O
amphetamine NN NN B-CHEM
use NN NN O
. . . O

The DT DT O
association NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
amphetamine NN NN B-CHEM
use NN NN O
with IN IN O
hemorrhagic JJ JJ O
and CC CC O
ischemic JJ JJ O
stroke NN NN O
is VBZ VBZ O
based VBN VBN O
almost RB RB O
solely RB RB O
on IN IN O
data NNS NNS O
from IN IN O
case NN NN O
series NN NN O
. . . O

The DT DT O
limited JJ JJ O
number NN NN O
of IN IN O
epidemiologic JJ JJ O
studies NNS NNS O
of IN IN O
stroke NN NN O
and CC CC O
use NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
amphetamine NN NN B-CHEM
have VBP VBP O
been VBN VBN O
done VBN VBN O
in IN IN O
settings NNS NNS O
that WDT WDT O
serve VBP VBP O
mostly RB RB O
the DT DT O
poor JJ JJ O
and CC CC O
/ NN NN O
or CC CC O
minorities NNS NNS O
. . . O

This DT DT O
case NN NN O
- : : O
control NN NN O
study NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
the DT DT O
defined JJ JJ O
population NN NN O
comprising VBG VBG O
members NNS NNS O
of IN IN O
Kaiser NNP NNP O
Permanente NNP NNP O
of IN IN O
Northern NNP NNP O
and CC CC O
Southern NNP NNP O
California NNP NNP O
. . . O

We PRP PRP O
attempted VBD VBD O
to TO TO O
identify VB VB O
all DT DT O
incident NN NN O
strokes NNS NNS O
in IN IN O
women NNS NNS O
ages NNS NNS O
15 CD CD O
- : : O
44 CD CD O
years NNS NNS O
during IN IN O
a DT DT O
3 CD CD O
- : : O
year NN NN O
period NN NN O
using VBG VBG O
hospital NN NN O
admission NN NN O
and CC CC O
discharge NN NN O
records NNS NNS O
, , , O
emergency NN NN O
department NN NN O
logs NNS NNS O
, , , O
and CC CC O
payment NN NN O
requests NNS NNS O
for IN IN O
out IN IN O
- - - O
of IN IN O
- - - O
plan NN NN O
hospitalizations NNS NNS O
. . . O

We PRP PRP O
selected VBD VBD O
controls NNS NNS O
, , , O
matched VBN VBN O
on IN IN O
age NN NN O
and CC CC O
facility NN NN O
of IN IN O
usual JJ JJ O
care NN NN O
, , , O
at IN IN O
random JJ JJ O
from IN IN O
healthy JJ JJ O
members NNS NNS O
of IN IN O
the DT DT O
health NN NN O
plan NN NN O
. . . O

We PRP PRP O
obtained VBD VBD O
information NN NN O
in IN IN O
face NN NN O
- - - O
to TO TO O
- - - O
face NN NN O
interviews NNS NNS O
. . . O

There EX EX O
were VBD VBD O
347 CD CD O
confirmed VBD VBD O
stroke NN NN O
cases NNS NNS O
and CC CC O
1 CD CD O
, , , O
021 CD CD O
controls NNS NNS O
. . . O

The DT DT O
univariate NN NN O
matched VBD VBD O
odds NNS NNS O
ratio NN NN O
for IN IN O
stroke NN NN O
in IN IN O
women NNS NNS O
who WP WP O
admitted VBD VBD O
to TO TO O
using VBG VBG O
cocaine NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
amphetamine NN NN B-CHEM
was VBD VBD O
8 CD CD O
. . . O
5 CD CD O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
= SYM SYM O
3 CD CD O
. . . O
6 CD CD O
- : : O
20 CD CD O
. . . O
0 CD CD O
) ) ) O
. . . O

After IN IN O
further JJ JJ O
adjustment NN NN O
for IN IN O
potential JJ JJ O
confounders NNS NNS O
, , , O
the DT DT O
odds NNS NNS O
ratio NN NN O
in IN IN O
women NNS NNS O
who WP WP O
reported VBD VBD O
using VBG VBG O
cocaine NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
amphetamine NN NN B-CHEM
was VBD VBD O
7 CD CD O
. . . O
0 CD CD O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
= SYM SYM O
2 CD CD O
. . . O
8 CD CD O
- : : O
17 CD CD O
. . . O
9 CD CD O
) ) ) O
. . . O

The DT DT O
use NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
amphetamine NN NN B-CHEM
is VBZ VBZ O
a DT DT O
strong JJ JJ O
risk NN NN O
factor NN NN O
for IN IN O
stroke NN NN O
in IN IN O
this DT DT O
socioeconomically RB RB O
heterogeneous JJ JJ O
, , , O
insured VBN VBN O
urban JJ JJ O
population NN NN O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
subsequent NN NN O
to TO TO O
the DT DT O
administration NN NN O
of IN IN O
rifampicin NN NN B-CHEM
. . . O

A DT DT O
follow VB VB O
- - - O
up RP RP O
study NN NN O
of IN IN O
cases NNS NNS O
reported VBD VBD O
earlier RBR RBR O
. . . O

A DT DT O
clinical JJ JJ O
presentation NN NN O
is VBZ VBZ O
made VBN VBN O
of IN IN O
a DT DT O
2 CD CD O
- : : O
3 CD CD O
year NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
six CD CD O
cases NNS NNS O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
that WDT WDT O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
earlier RBR RBR O
. . . O

The DT DT O
patients NNS NNS O
had VBD VBD O
developed VBN VBN O
transient NN NN O
renal JJ JJ O
failure NN NN O
after IN IN O
the DT DT O
intermittent JJ JJ O
administration NN NN O
of IN IN O
rifampicin NN NN B-CHEM
. . . O

The DT DT O
stage NN NN O
of IN IN O
olig NN NN O
- - - O
anuria NN NN O
lasted VBD VBD O
for IN IN O
1 CD CD O
- : : O
3 CD CD O
weeks NNS NNS O
, , , O
and CC CC O
five CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
treated VBN VBN O
by IN IN O
hemodialysis NN NN O
. . . O

Two CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
died VBD VBD O
due JJ JJ O
to TO TO O
unrelated JJ JJ O
causes NNS NNS O
during IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
. . . O

The DT DT O
four CD CD O
patients NNS NNS O
re NN NN O
- - - O
examined VBN VBN O
were VBD VBD O
clinically RB RB O
cured VBN VBN O
. . . O

Pathologic NNP NNP O
findings NNS NNS O
by IN IN O
light JJ JJ O
microscopy NN NN O
and CC CC O
immunofluorescence NN NN O
at IN IN O
biopsy NN NN O
were VBD VBD O
scarce JJ JJ O
. . . O

Nothing NN NN O
abnormal NN NN O
was VBD VBD O
seen VBN VBN O
by IN IN O
electron NN NN O
microscopy NN NN O
in IN IN O
two CD CD O
of IN IN O
the DT DT O
cases NNS NNS O
studied VBN VBN O
. . . O

Renal NNP NNP O
function NN NN O
was VBD VBD O
normal JJ JJ O
. . . O

In IN IN O
three CD CD O
cases NNS NNS O
the DT DT O
excretion NN NN O
at IN IN O
131I CD CD O
- : : O
hippuran NN NN O
renography NN NN O
was VBD VBD O
slightly RB RB O
slowed VBN VBN O
. . . O

Although IN IN O
in IN IN O
the DT DT O
acute JJ JJ O
stage NN NN O
the DT DT O
renal JJ JJ O
lesions NNS NNS O
histologically RB RB O
appeared VBD VBD O
toxic JJ JJ O
, , , O
evidence NN NN O
suggestive NN NN O
of IN IN O
an DT DT O
immunological JJ JJ O
mechanism NN NN O
cannot NN NN O
be VB VB O
excluded VBN VBN O
. . . O

Chronic NNP NNP O
effects NNS NNS O
of IN IN O
a DT DT O
novel NN NN O
synthetic JJ JJ O
anthracycline NN NN B-CHEM
derivative JJ JJ O
( ( ( O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
) ) ) O
on IN IN O
normal JJ JJ O
heart NN NN O
and CC CC O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
in IN IN O
beagle NN NN O
dogs NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
chronic JJ JJ O
cardiotoxic JJ JJ O
potential NN NN O
of IN IN O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
and CC CC O
a DT DT O
possible JJ JJ O
deteriorating VBG VBG O
effect NN NN O
of IN IN O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
on IN IN O
low JJ JJ O
- : : O
grade NN NN O
cardiotoxicity NN NN O
pre NN NN O
- - - O
induced VBN VBN O
by IN IN O
doxorubicin NN NN B-CHEM
in IN IN O
beagle NN NN O
dogs NNS NNS O
. . . O

In IN IN O
the DT DT O
chronic JJ JJ O
treatment NN NN O
, , , O
beagle NN NN O
dogs NNS NNS O
of IN IN O
each DT DT O
sex NN NN O
were VBD VBD O
given VBN VBN O
intravenously RB RB O
once RB RB O
every DT DT O
3 CD CD O
weeks NNS NNS O
, , , O
either CC CC O
a DT DT O
sublethal JJ JJ O
dose NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

The DT DT O
experiment NN NN O
was VBD VBD O
terminated VBN VBN O
3 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
ninth NN NN O
dosing VBG VBG O
. . . O

Animals NNS NNS O
which WDT WDT O
received VBD VBD O
over IN IN O
six CD CD O
courses NNS NNS O
of IN IN O
doxorubicin NN NN B-CHEM
demonstrated VBD VBD O
the DT DT O
electrocardiogram NN NN O
( ( ( O
ECG NNP NNP O
) ) ) O
changes NNS NNS O
, , , O
decrease NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
high JJ JJ O
- - - O
grade NN NN O
histopathological JJ JJ O
cardiomyopathy NN NN O
, , , O
while IN IN O
animals NNS NNS O
which WDT WDT O
were VBD VBD O
terminally RB RB O
sacrificed VBN VBN O
after IN IN O
the DT DT O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
administration NN NN O
did VBD VBD O
not RB RB O
show VB VB O
any DT DT O
changes NNS NNS O
in IN IN O
ECG NNP NNP O
, , , O
blood NN NN O
pressure NN NN O
and CC CC O
histopathological JJ JJ O
examinations NNS NNS O
. . . O

To TO TO O
examine VB VB O
a DT DT O
possibly RB RB O
deteriorating VBG VBG O
cardiotoxic JJ JJ O
effect NN NN O
of IN IN O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
, , , O
low JJ JJ O
- - - O
grade NN NN O
cardiomyopathy NN NN O
was VBD VBD O
induced VBN VBN O
in IN IN O
dogs NNS NNS O
by IN IN O
four CD CD O
courses NNS NNS O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

Nine CD CD O
weeks NNS NNS O
after IN IN O
pre NN NN O
- - - O
treatment NN NN O
, , , O
dogs NNS NNS O
were VBD VBD O
given VBN VBN O
four CD CD O
courses NNS NNS O
of IN IN O
either DT DT O
doxorubicin NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
once RB RB O
every DT DT O
3 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
low JJ JJ O
- - - O
grade NN NN O
cardiotoxic NN NN O
changes NNS NNS O
were VBD VBD O
enhanced VBN VBN O
by IN IN O
the DT DT O
additional JJ JJ O
doxorubicin NN NN B-CHEM
treatment NN NN O
. . . O

On IN IN O
the DT DT O
contrary NN NN O
, , , O
the DT DT O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
treatment NN NN O
did VBD VBD O
not RB RB O
progress VB VB O
the DT DT O
grade NN NN O
of IN IN O
cardiomyopathy NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
SM NNP NNP B-CHEM
- : : I-CHEM
5887 CD CD I-CHEM
does VBZ VBZ O
not RB RB O
have VB VB O
any DT DT O
potential NN NN O
of IN IN O
chronic JJ JJ O
cardiotoxicity NN NN O
and CC CC O
deteriorating VBG VBG O
effect NN NN O
on IN IN O
doxorubicin NN NN B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
in IN IN O
dogs NNS NNS O
. . . O

Risk NN NN O
for IN IN O
valvular JJ JJ O
heart NN NN O
disease NN NN O
among IN IN O
users NNS NNS O
of IN IN O
fenfluramine NN NN B-CHEM
and CC CC O
dexfenfluramine NN NN B-CHEM
who WP WP O
underwent JJ JJ O
echocardiography NN NN O
before IN IN O
use NN NN O
of IN IN O
medication NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Because IN IN O
uncontrolled JJ JJ O
echocardiographic JJ JJ O
surveys NNS NNS O
suggested VBD VBD O
that IN IN O
up IN IN O
to TO TO O
30 CD CD O
% NN NN O
to TO TO O
38 CD CD O
% NN NN O
of IN IN O
users NNS NNS O
of IN IN O
fenfluramine NN NN B-CHEM
and CC CC O
dexfenfluramine NN NN B-CHEM
had VBD VBD O
valvular JJ JJ O
disease NN NN O
, , , O
these DT DT O
drugs NNS NNS O
were VBD VBD O
withdrawn VBN VBN O
from IN IN O
the DT DT O
market NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
risk NN NN O
for IN IN O
new JJ JJ O
or CC CC O
worsening VBG VBG O
valvular JJ JJ O
abnormalities NNS NNS O
among IN IN O
users NNS NNS O
of IN IN O
fenfluramine NN NN B-CHEM
or CC CC O
dexfenfluramine NN NN B-CHEM
who WP WP O
underwent JJ JJ O
echocardiography NN NN O
before IN IN O
they PRP PRP O
began VBD VBD O
to TO TO O
take VB VB O
these DT DT O
medications NNS NNS O
. . . O

DESIGN NNP NNP O
: : : O
Cohort NNP NNP O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
Academic NNP NNP O
primary JJ JJ O
care NN NN O
practices NNS NNS O
. . . O

PATIENTS NNS NNS O
: : : O
46 CD CD O
patients NNS NNS O
who WP WP O
used VBD VBD O
fenfluramine NN NN B-CHEM
or CC CC O
dexfenfluramine NN NN B-CHEM
for IN IN O
14 CD CD O
days NNS NNS O
or CC CC O
more JJR JJR O
and CC CC O
had VBD VBD O
echocardiograms NNS NNS O
obtained VBN VBN O
before IN IN O
therapy NN NN O
. . . O

MEASUREMENTS NNP NNP O
: : : O
Follow VB VB O
- - - O
up RP RP O
echocardiography NN NN O
. . . O

The DT DT O
primary JJ JJ O
outcome NN NN O
was VBD VBD O
new JJ JJ O
or CC CC O
worsening VBG VBG O
valvulopathy NN NN O
, , , O
defined VBN VBN O
as IN IN O
progression NN NN O
of IN IN O
either DT DT O
aortic JJ JJ O
or CC CC O
mitral JJ JJ O
regurgitation NN NN O
by IN IN O
at IN IN O
least JJS JJS O
one CD CD O
degree NN NN O
of IN IN O
severity NN NN O
and CC CC O
disease NN NN O
that WDT WDT O
met VBD VBD O
U NNP NNP O
. . . O
S NNP NNP O
. . . O

Food NNP NNP O
and CC CC O
Drug NN NN O
Administration NNP NNP O
criteria NNS NNS O
( ( ( O
at IN IN O
least JJS JJS O
mild JJ JJ O
aortic JJ JJ O
regurgitation NN NN O
or CC CC O
moderate JJ JJ O
mitral NN NN O
regurgitation NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Two CD CD O
patients NNS NNS O
( ( ( O
4 CD CD O
. . . O
3 CD CD O
% NN NN O
[ NN NN O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
. . . O
6 CD CD O
% NN NN O
to TO TO O
14 CD CD O
. . . O
8 CD CD O
% NN NN O
] NN NN O
) ) ) O
receiving VBG VBG O
fenfluramine NN NN B-CHEM
- - - O
phentermine NN NN B-CHEM
developed VBN VBN O
valvular JJ JJ O
heart NN NN O
disease NN NN O
. . . O

One CD CD O
had VBD VBD O
baseline NN NN O
bicuspid NN NN O
aortic JJ JJ O
valve NN NN O
and CC CC O
mild JJ JJ O
aortic JJ JJ O
regurgitation NN NN O
that WDT WDT O
progressed VBD VBD O
to TO TO O
moderate VB VB O
regurgitation NN NN O
. . . O

The DT DT O
second JJ JJ O
patient NN NN O
developed VBN VBN O
new JJ JJ O
moderate JJ JJ O
aortic JJ JJ O
insufficiency NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Users NNS NNS O
of IN IN O
diet JJ JJ O
medications NNS NNS O
are VBP VBP O
at IN IN O
risk NN NN O
for IN IN O
valvular JJ JJ O
heart NN NN O
disease NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
incidence NN NN O
may MD MD O
be VB VB O
lower JJR JJR O
than IN IN O
that DT DT O
reported VBD VBD O
previously RB RB O
. . . O

Therapeutic NNP NNP O
drug NN NN O
monitoring NN NN O
of IN IN O
tobramycin NN NN B-CHEM
: : : O
once RB RB O
- - - O
daily JJ JJ O
versus CC CC O
twice RB RB O
- : : O
daily JJ JJ O
dosage NN NN O
schedules NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
effect NN NN O
of IN IN O
dosage NN NN O
regimen NNS NNS O
( ( ( O
once RB RB O
- : : O
daily JJ JJ O
vs NNS NNS O
. . . O
twice RB RB O
- : : O
daily JJ JJ O
) ) ) O
of IN IN O
tobramicyn NN NN B-CHEM
on IN IN O
steady JJ JJ O
- : : O
state NN NN O
serum NN NN O
concentrations NNS NNS O
and CC CC O
toxicity NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Patients NNS NNS O
undergoing VBG VBG O
treatment NN NN O
with IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
tobramycin NN NN B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
were VBD VBD O
randomised VBN VBN O
to TO TO O
two CD CD O
groups NNS NNS O
. . . O

Group NNP NNP O
OD NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
22 CD CD O
) ) ) O
received VBD VBD O
a DT DT O
once RB RB O
- - - O
daily JJ JJ O
dose NN NN O
of IN IN O
tobramycin NN NN B-CHEM
and CC CC O
group NN NN O
TD NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
21 CD CD O
) ) ) O
received VBD VBD O
the DT DT O
same JJ JJ O
dose NN NN O
divided VBN VBN O
into IN IN O
two CD CD O
doses NNS NNS O
daily RB RB O
. . . O

Tobramycin NNP NNP B-CHEM
serum NN NN O
concentrations NNS NNS O
( ( ( O
peak NN NN O
and CC CC O
trough NN NN O
) ) ) O
were VBD VBD O
measured VBN VBN O
by IN IN O
enzyme NN NN O
multiplied JJ JJ O
immunoassay NN NN O
. . . O

The DT DT O
renal NN NN O
and CC CC O
auditory JJ JJ O
functions NNS NNS O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
monitored VBN VBN O
before IN IN O
, , , O
during IN IN O
and CC CC O
immediately RB RB O
after IN IN O
treatment NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
two CD CD O
groups NNS NNS O
were VBD VBD O
comparable JJ JJ O
with IN IN O
respect NN NN O
to TO TO O
sex NN NN O
, , , O
age NN NN O
, , , O
body NN NN O
weight NN NN O
and CC CC O
renal JJ JJ O
function NN NN O
. . . O

No DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
mean NN NN O
daily JJ JJ O
dose NN NN O
, , , O
duration NN NN O
of IN IN O
treatment NN NN O
, , , O
or CC CC O
cumulative JJ JJ O
dose NN NN O
. . . O

Trough NNP NNP O
concentrations NNS NNS O
were VBD VBD O
< NN NN O
2 CD CD O
g SYM SYM O
/ NN NN O
ml NN NN O
in IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
( ( ( O
100 CD CD O
% NN NN O
) ) ) O
. . . O

Peak NNP NNP O
concentrations NNS NNS O
were VBD VBD O
> NN NN O
6 CD CD O
microg NN NN O
/ NN NN O
ml NN NN O
in IN IN O
100 CD CD O
% NN NN O
of IN IN O
the DT DT O
OD NNP NNP O
group NN NN O
and CC CC O
in IN IN O
67 CD CD O
% NN NN O
of IN IN O
the DT DT O
TD NNP NNP O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Mean VB VB O
peak NN NN O
concentrations NNS NNS O
were VBD VBD O
markedly RB RB O
different JJ JJ O
: : : O
11 CD CD O
. . . O
00 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
89 CD CD O
microg NN NN O
/ NN NN O
ml NN NN O
in IN IN O
OD NNP NNP O
vs NNS NNS O
. . . O
6 CD CD O
. . . O
53 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
45 CD CD O
microg NN NN O
/ NN NN O
ml NN NN O
in IN IN O
TD NNP NNP O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

The DT DT O
pharmacokinetics NNS NNS O
parameters NNS NNS O
were VBD VBD O
: : : O
Ke NNP NNP O
, , , O
( ( ( O
0 CD CD O
. . . O
15 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
03 CD CD O
/ NN NN O
h NN NN O
in IN IN O
OD NNP NNP O
vs NNS NNS O
. . . O
0 CD CD O
. . . O
24 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
06 CD CD O
/ NN NN O
h NN NN O
in IN IN O
TD NNP NNP O
) ) ) O
, , , O
t1 NN NN O
/ NN NN O
2 CD CD O
, , , O
( ( ( O
4 CD CD O
. . . O
95 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
41 CD CD O
h NN NN O
in IN IN O
OD NNP NNP O
vs NNS NNS O
. . . O
3 CD CD O
. . . O
07 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
71 CD CD O
h NN NN O
in IN IN O
TD NNP NNP O
) ) ) O
, , , O
Vd NNP NNP O
( ( ( O
0 CD CD O
. . . O
35 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
11 CD CD O
l NN NN O
/ NN NN O
kg NN NN O
in IN IN O
OD NNP NNP O
vs NNS NNS O
. . . O
0 CD CD O
. . . O
33 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
09 CD CD O
l NN NN O
/ NN NN O
kg NN NN O
in IN IN O
TD NNP NNP O
) ) ) O
, , , O
Cl NNP NNP O
( ( ( O
0 CD CD O
. . . O
86 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
29 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
/ NN NN O
kg NN NN O
in IN IN O
OD NNP NNP O
vs NNS NNS O
. . . O
1 CD CD O
. . . O
28 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
33 CD CD O
ml NN NN O
/ NN NN O
min NN NN O
/ NN NN O
kg NN NN O
in IN IN O
TD NNP NNP O
) ) ) O
. . . O

Increased NNP NNP O
serum NN NN O
creatinine NN NN B-CHEM
was VBD VBD O
observed VBN VBN O
in IN IN O
73 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
OD NNP NNP O
versus CC CC O
57 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
TD NNP NNP O
, , , O
without IN IN O
evidence NN NN O
of IN IN O
nephrotoxicity NN NN O
. . . O

In IN IN O
TD NNP NNP O
group NN NN O
, , , O
three CD CD O
patients NNS NNS O
developed VBN VBN O
decreased VBN VBN O
auditory JJ JJ O
function NN NN O
, , , O
of IN IN O
which WDT WDT O
one CD CD O
presented VBN VBN O
with IN IN O
an DT DT O
auditory NN NN O
loss NN NN O
of IN IN O
- - - O
30 CD CD O
dB NN NN O
, , , O
whereas IN IN O
in IN IN O
the DT DT O
OD NNP NNP O
group NN NN O
only RB RB O
one CD CD O
patient NN NN O
presented VBN VBN O
decreased VBD VBD O
auditory NN NN O
function NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
small JJ JJ O
study NN NN O
suggests VBZ VBZ O
that IN IN O
a DT DT O
once RB RB O
- - - O
daily JJ JJ O
dosing NN NN O
regimen NNS NNS O
of IN IN O
tobramycin NN NN B-CHEM
is VBZ VBZ O
at IN IN O
least JJS JJS O
as RB RB O
effective JJ JJ O
as IN IN O
and CC CC O
is VBZ VBZ O
no DT DT O
more JJR JJR O
and CC CC O
possibly RB RB O
less RBR RBR O
toxic JJ JJ O
than IN IN O
the DT DT O
twice RB RB O
- - - O
daily JJ JJ O
regimen NNS NNS O
. . . O

Using VBG VBG O
a DT DT O
single JJ JJ O
- - - O
dose NN NN O
therapy NN NN O
, , , O
peak NN NN O
concentration NN NN O
determination NN NN O
is VBZ VBZ O
not RB RB O
necessary JJ JJ O
, , , O
only RB RB O
trough JJ JJ O
samples NNS NNS O
should MD MD O
be VB VB O
monitored VBN VBN O
to TO TO O
ensure VB VB O
levels NNS NNS O
below IN IN O
2 CD CD O
microg NN NN O
/ NN NN O
ml NN NN O
. . . O

Enhanced NNP NNP O
bradycardia NN NN O
induced VBN VBN O
by IN IN O
beta NN NN O
- - - O
adrenoceptor NN NN O
antagonists NNS NNS O
in IN IN O
rats NNS NNS O
pretreated VBN VBN O
with IN IN O
isoniazid NN NN B-CHEM
. . . O

High NNP NNP O
doses NNS NNS O
of IN IN O
isoniazid NN NN B-CHEM
increase NN NN O
hypotension NN NN O
induced VBN VBN O
by IN IN O
vasodilators NNS NNS O
and CC CC O
change VB VB O
the DT DT O
accompanying VBG VBG O
reflex JJ JJ O
tachycardia NN NN O
to TO TO O
bradycardia NNS NNS O
, , , O
an DT DT O
interaction NN NN O
attributed VBD VBD O
to TO TO O
decreased VBD VBD O
synthesis NN NN O
of IN IN O
brain NN NN O
gamma NN NN B-CHEM
- : : I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
GABA NNP NNP B-CHEM
) ) ) O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
possible JJ JJ O
enhancement NN NN O
by IN IN O
isoniazid NN NN B-CHEM
of IN IN O
bradycardia NN NN O
induced VBN VBN O
by IN IN O
beta NN NN O
- - - O
adrenoceptor NN NN O
antagonists NNS NNS O
was VBD VBD O
determined VBN VBN O
in IN IN O
rats NNS NNS O
anaesthetised VBN VBN O
with IN IN O
chloralose NN NN B-CHEM
- - - O
urethane NN NN B-CHEM
. . . O

Isoniazid NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
bradycardia NNS NNS O
after IN IN O
propranolol NN NN B-CHEM
, , , O
pindolol NN NN B-CHEM
, , , O
labetalol NN NN B-CHEM
and CC CC O
atenolol NN NN B-CHEM
, , , O
as RB RB O
well RB RB O
as IN IN O
after IN IN O
clonidine NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
after IN IN O
hexamethonium NN NN B-CHEM
or CC CC O
carbachol NN NN B-CHEM
. . . O

Enhancement NNP NNP O
was VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
rats NNS NNS O
pretreated VBN VBN O
with IN IN O
methylatropine NN NN B-CHEM
or CC CC O
previously RB RB O
vagotomised VBN VBN O
. . . O

These DT DT O
results NNS NNS O
are VBP VBP O
compatible JJ JJ O
with IN IN O
interference NN NN O
by IN IN O
isoniazid NN NN B-CHEM
with IN IN O
GABAergic NNP NNP O
inhibition NN NN O
of IN IN O
cardiac JJ JJ O
parasympathetic JJ JJ O
tone NN NN O
. . . O

Such JJ JJ O
interference NN NN O
could MD MD O
be VB VB O
exerted VBN VBN O
centrally RB RB O
, , , O
possibly RB RB O
at IN IN O
the DT DT O
nucleus NN NN O
ambiguus NN NN O
, , , O
or CC CC O
peripherally RB RB O
at IN IN O
the DT DT O
sinus NN NN O
node NN NN O
. . . O

Structural NNP NNP O
and CC CC O
functional JJ JJ O
impairment NN NN O
of IN IN O
mitochondria NN NN O
in IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiomyopathy NN NN O
in IN IN O
mice NN NN O
: : : O
suppression NN NN O
of IN IN O
cytochrome JJ JJ O
c SYM SYM O
oxidase NN NN O
II NNP NNP O
gene NN NN O
expression NN NN O
. . . O

The DT DT O
use NN NN O
of IN IN O
adriamycin NN NN B-CHEM
( ( ( O
ADR NNP NNP B-CHEM
) ) ) O
in IN IN O
cancer NN NN O
chemotherapy NN NN O
has VBZ VBZ O
been VBN VBN O
limited JJ JJ O
due JJ JJ O
to TO TO O
its PRP$ PRP$ O
cumulative JJ JJ O
cardiovascular JJ JJ O
toxicity NN NN O
. . . O

Earlier RBR RBR O
observations NNS NNS O
that WDT WDT O
ADR NNP NNP B-CHEM
interacts VBZ VBZ O
with IN IN O
mitochondrial JJ JJ O
cytochrome NN NN O
c SYM SYM O
oxidase NN NN O
( ( ( O
COX NNP NNP O
) ) ) O
and CC CC O
suppresses VBZ VBZ O
its PRP$ PRP$ O
enzyme NN NN O
activity NN NN O
led VBD VBD O
us PRP PRP O
to TO TO O
investigate VB VB O
ADR NNP NNP B-CHEM
' POS POS O
s VBZ VBZ O
action NN NN O
on IN IN O
the DT DT O
cardiovascular JJ JJ O
functions NNS NNS O
and CC CC O
heart NN NN O
mitochondrial JJ JJ O
morphology NN NN O
in IN IN O
Balb NNP NNP O
- : : O
c SYM SYM O
mice NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
treated VBN VBN O
with IN IN O
ADR NNP NNP B-CHEM
for IN IN O
several JJ JJ O
weeks NNS NNS O
. . . O

At IN IN O
various JJ JJ O
times NNS NNS O
during IN IN O
treatment NN NN O
, , , O
the DT DT O
animals NNS NNS O
were VBD VBD O
assessed VBN VBN O
for IN IN O
cardiovascular JJ JJ O
functions NNS NNS O
by IN IN O
electrocardiography NN NN O
and CC CC O
for IN IN O
heart NN NN O
tissue NN NN O
damage NN NN O
by IN IN O
electron NN NN O
microscopy NN NN O
. . . O

In IN IN O
parallel JJ JJ O
, , , O
total JJ JJ O
RNA NNP NNP O
was VBD VBD O
extracted VBN VBN O
from IN IN O
samples NNS NNS O
of IN IN O
dissected JJ JJ O
heart NN NN O
and CC CC O
analyzed VBN VBN O
by IN IN O
Northern NNP NNP O
blot NN NN O
hybridization NN NN O
to TO TO O
determine VB VB O
the DT DT O
steady JJ JJ O
- - - O
state NN NN O
level NN NN O
of IN IN O
three CD CD O
RNA NNP NNP O
transcripts NNS NNS O
encoded VBN VBN O
by IN IN O
the DT DT O
COXII NNP NNP O
, , , O
COXIII NNP NNP O
, , , O
and CC CC O
COXIV NNP NNP O
genes NNS NNS O
. . . O

Similarly RB RB O
, , , O
samples NNS NNS O
obtained VBN VBN O
from IN IN O
the DT DT O
liver NN NN O
of IN IN O
the DT DT O
same JJ JJ O
animals NNS NNS O
were VBD VBD O
analyzed VBN VBN O
for IN IN O
comparative JJ JJ O
studies NNS NNS O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
indicated VBN VBN O
that IN IN O
1 CD CD O
) ) ) O
treatment NN NN O
of IN IN O
mice NNS NNS O
with IN IN O
ADR NNP NNP B-CHEM
caused VBD VBD O
cardiovascular JJ JJ O
arrhythmias NNS NNS O
characterized VBN VBN O
by IN IN O
bradycardia NN NN O
, , , O
extension NN NN O
of IN IN O
ventricular JJ JJ O
depolarization NN NN O
time NN NN O
( ( ( O
tQRS NN NN O
) ) ) O
, , , O
and CC CC O
failure NN NN O
of IN IN O
QRS NNP NNP O
at IN IN O
high JJ JJ O
concentrations NNS NNS O
( ( ( O
10 CD CD O
- : : O
14 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
cumulative JJ JJ O
dose NN NN O
) ) ) O
; : : O
2 CD CD O
) ) ) O
the DT DT O
heart NN NN O
mitochondria NN NN O
underwent JJ JJ O
swelling VBG VBG O
, , , O
fusion NN NN O
, , , O
dissolution NN NN O
, , , O
and CC CC O
/ NN NN O
or CC CC O
disruption NN NN O
of IN IN O
mitochondrial JJ JJ O
cristae NN NN O
after IN IN O
several JJ JJ O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

Such JJ JJ O
abnormalities NNS NNS O
were VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
the DT DT O
mitochondria NN NN O
of IN IN O
liver NN NN O
tissue NN NN O
; : : O
and CC CC O
3 CD CD O
) ) ) O
among IN IN O
the DT DT O
three CD CD O
genes NNS NNS O
of IN IN O
COX NNP NNP O
enzyme NN NN O
examined VBD VBD O
, , , O
only RB RB O
COXII NNP NNP O
gene NN NN O
expression NN NN O
was VBD VBD O
suppressed VBN VBN O
by IN IN O
ADR NNP NNP B-CHEM
treatment NN NN O
, , , O
mainly RB RB O
after IN IN O
8 CD CD O
weeks NNS NNS O
in IN IN O
both DT DT O
heart NN NN O
and CC CC O
liver NN NN O
. . . O

Knowing VBG VBG O
that IN IN O
heart NN NN O
mitochondria NN NN O
represent NN NN O
almost RB RB O
40 CD CD O
% NN NN O
of IN IN O
heart NN NN O
muscle NN NN O
by IN IN O
weight NN NN O
, , , O
we PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
deteriorating VBG VBG O
effects NNS NNS O
of IN IN O
ADR NNP NNP B-CHEM
on IN IN O
cardiovascular JJ JJ O
function NN NN O
involve CD CD O
mitochondrial JJ JJ O
structural JJ JJ O
and CC CC O
functional JJ JJ O
impairment NN NN O
. . . O


